<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="fedregister.xsl"?>
<FEDREG xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="FRMergedXML.xsd">
    <VOL>89</VOL>
    <NO>229</NO>
    <DATE>Wednesday, November 27, 2024</DATE>
    <UNITNAME>Contents</UNITNAME>
    <CNTNTS>
        <AGCY>
            <EAR>
                Administrative
                <PRTPAGE P="iii"/>
            </EAR>
            <HD>Administrative Conference of the United States</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Hearings, Meetings, Proceedings, etc., </DOC>
                    <PGS>93547</PGS>
                    <FRDOCBP>2024-27867</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Agency Health</EAR>
            <HD>Agency for Healthcare Research and Quality</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Supplemental Evidence and Data Request:</SJ>
                <SJDENT>
                    <SJDOC>Dietary Intake of Polyunsaturated Fatty Acids and Plasma Lipid and Cardiovascular Events, </SJDOC>
                    <PGS>93603-93606</PGS>
                    <FRDOCBP>2024-27798</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Agency</EAR>
            <HD>Agency for International Development</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Advisory Committee, </SJDOC>
                    <PGS>93547-93548</PGS>
                    <FRDOCBP>2024-27793</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Agriculture</EAR>
            <HD>Agriculture Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Federal Crop Insurance Corporation</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Food Safety and Inspection Service</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Forest Service</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>Centers Disease</EAR>
            <HD>Centers for Disease Control and Prevention</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Hearings, Meetings, Proceedings, etc., </DOC>
                    <PGS>93606-93607</PGS>
                    <FRDOCBP>2024-27856</FRDOCBP>
                      
                    <FRDOCBP>2024-27857</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Centers Medicare</EAR>
            <HD>Centers for Medicare &amp; Medicaid Services</HD>
            <CAT>
                <HD>RULES</HD>
                <SJ>Medicare and Medicaid Programs:</SJ>
                <SJDENT>
                    <SJDOC>Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs, including the Hospital Inpatient Quality Reporting Program, etc., </SJDOC>
                    <PGS>93912-94594</PGS>
                    <FRDOCBP>2024-25521</FRDOCBP>
                </SJDENT>
            </CAT>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Agency Information Collection Activities; Proposals, Submissions, and Approvals, </DOC>
                    <PGS>93607-93608</PGS>
                    <FRDOCBP>2024-27871</FRDOCBP>
                </DOCENT>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Medicare Program; Air Ambulance Quality and Patient Safety Advisory Committee, </SJDOC>
                    <PGS>93608-93609</PGS>
                    <FRDOCBP>2024-27740</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Children</EAR>
            <HD>Children and Families Administration</HD>
            <CAT>
                <HD>RULES</HD>
                <DOCENT>
                    <DOC>Investigations of Child Abuse and Neglect, </DOC>
                    <PGS>93498-93522</PGS>
                    <FRDOCBP>2024-27626</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Civil Rights</EAR>
            <HD>Civil Rights Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Colorado Advisory Committee, </SJDOC>
                    <PGS>93549-93550</PGS>
                    <FRDOCBP>2024-27736</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Puerto Rico Advisory Committee, </SJDOC>
                    <PGS>93550</PGS>
                    <FRDOCBP>2024-27852</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Utah Advisory Committee; Cancellation, </SJDOC>
                    <PGS>93550</PGS>
                    <FRDOCBP>2024-27738</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Coast Guard</EAR>
            <HD>Coast Guard</HD>
            <CAT>
                <HD>RULES</HD>
                <SJ>Safety Zone:</SJ>
                <SJDENT>
                    <SJDOC>City of Rockport, Rockport Tropical Christmas Festival Fireworks Display Show, </SJDOC>
                    <PGS>93476-93477</PGS>
                    <FRDOCBP>2024-27870</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Corpus Christi Bay, Corpus Christi, TX, </SJDOC>
                    <PGS>93474-93476</PGS>
                    <FRDOCBP>2024-27875</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Commerce</EAR>
            <HD>Commerce Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>International Trade Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>National Institute of Standards and Technology</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>National Oceanic and Atmospheric Administration</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>Comptroller</EAR>
            <HD>Comptroller of the Currency</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Computer-Security Incident Notification, </SJDOC>
                    <PGS>93827-93829</PGS>
                    <FRDOCBP>2024-27876</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Copyright Royalty Board</EAR>
            <HD>Copyright Royalty Board</HD>
            <CAT>
                <HD>RULES</HD>
                <SJ>Cost of Living Adjustment:</SJ>
                <SJDENT>
                    <SJDOC>Royalty Rates and Terms for Making and Distributing Phonorecords, </SJDOC>
                    <PGS>93477</PGS>
                    <FRDOCBP>2024-27819</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Defense Department</EAR>
            <HD>Defense Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Navy Department</P>
            </SEE>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Arms Sales, </DOC>
                    <PGS>93556-93566</PGS>
                    <FRDOCBP>2024-27773</FRDOCBP>
                      
                    <FRDOCBP>2024-27774</FRDOCBP>
                      
                    <FRDOCBP>2024-27775</FRDOCBP>
                      
                    <FRDOCBP>2024-27776</FRDOCBP>
                      
                    <FRDOCBP>2024-27778</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Education Department</EAR>
            <HD>Education Department</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>EDFacts Data Collection School Years 2025-26, 2026-27, and 2027-28, </SJDOC>
                    <PGS>93567</PGS>
                    <FRDOCBP>2024-27845</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>School Pulse Panel 2025-26 and 2026-27 Preliminary Field Activities, </SJDOC>
                    <PGS>93567-93568</PGS>
                    <FRDOCBP>2024-27846</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Energy Department</EAR>
            <HD>Energy Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Federal Energy Regulatory Commission</P>
            </SEE>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Supplemental Labor Management Office Driver Attestation, </SJDOC>
                    <PGS>93568-93569</PGS>
                    <FRDOCBP>2024-27835</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Environmental Protection</EAR>
            <HD>Environmental Protection Agency</HD>
            <CAT>
                <HD>PROPOSED RULES</HD>
                <SJ>West Virginia Underground Injection Control Program:</SJ>
                <SJDENT>
                    <SJDOC>Class VI Primacy, </SJDOC>
                    <PGS>93538-93545</PGS>
                    <FRDOCBP>2024-27638</FRDOCBP>
                </SJDENT>
            </CAT>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Annual Public Water Systems Compliance Report, </SJDOC>
                    <PGS>93573-93574</PGS>
                    <FRDOCBP>2024-27730</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Assessment of Environmental Performance Standards and Ecolabels for Federal Procurement, </SJDOC>
                    <PGS>93574-93575</PGS>
                    <FRDOCBP>2024-27816</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Background Checks for Contractor Employees, </SJDOC>
                    <PGS>93572-93573</PGS>
                    <FRDOCBP>2024-27731</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Exchange Network Grants Progress Reports, </SJDOC>
                    <PGS>93575-93576</PGS>
                    <FRDOCBP>2024-27729</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>NESHAP for Aerospace Manufacturing and Rework Facilities, </SJDOC>
                    <PGS>93580-93581</PGS>
                    <FRDOCBP>2024-27727</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Toxic Chemical Release Reporting, </SJDOC>
                    <PGS>93581-93582</PGS>
                    <FRDOCBP>2024-27824</FRDOCBP>
                </SJDENT>
                <SJ>Certain New Chemicals:</SJ>
                <SJDENT>
                    <SJDOC>Status Information for October 2024, </SJDOC>
                    <PGS>93576-93580</PGS>
                    <FRDOCBP>2024-27717</FRDOCBP>
                </SJDENT>
                <SJ>Clean Air Act Operating Permit Program:</SJ>
                <SJDENT>
                    <SJDOC>Order on Petitions for Objection to State Operating Permit for Flint Hills Resources Ingleside LLC, San Patricio County, TX, </SJDOC>
                    <PGS>93582-93583</PGS>
                    <FRDOCBP>2024-27732</FRDOCBP>
                </SJDENT>
                <SJ>Proposed Settlement Agreement, Stipulation, Order, and Judgment, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Bona Fide Prospective Purchaser, Miners Point Ventures, LLC, Central City, Clear Creek Superfund Site, CO, </SJDOC>
                    <PGS>93582</PGS>
                    <FRDOCBP>2024-27724</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>
                Federal Aviation
                <PRTPAGE P="iv"/>
            </EAR>
            <HD>Federal Aviation Administration</HD>
            <CAT>
                <HD>RULES</HD>
                <SJ>Airworthiness Directives:</SJ>
                <SJDENT>
                    <SJDOC>Embraer S.A. Airplanes, </SJDOC>
                    <PGS>93472-93474</PGS>
                    <FRDOCBP>2024-27709</FRDOCBP>
                </SJDENT>
            </CAT>
            <CAT>
                <HD>PROPOSED RULES</HD>
                <SJ>Airspace Designations and Reporting Points:</SJ>
                <SJDENT>
                    <SJDOC>Ahoskie, NC, </SJDOC>
                    <PGS>93530-93531</PGS>
                    <FRDOCBP>2024-27697</FRDOCBP>
                </SJDENT>
                <SJ>Airworthiness Directives:</SJ>
                <SJDENT>
                    <SJDOC>Bombardier, Inc., Airplanes, </SJDOC>
                    <PGS>93528-93530</PGS>
                    <FRDOCBP>2024-27784</FRDOCBP>
                </SJDENT>
            </CAT>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Environmental Assessments; Availability, etc.:</SJ>
                <SJDENT>
                    <SJDOC>SpaceX Starship/Super Heavy Vehicle Increased Cadence at the Boca Chica Launch Site in Cameron County, TX, </SJDOC>
                    <PGS>93820-93821</PGS>
                    <FRDOCBP>2024-27533</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Communications</EAR>
            <HD>Federal Communications Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Agency Information Collection Activities; Proposals, Submissions, and Approvals, </DOC>
                    <PGS>93583-93584</PGS>
                    <FRDOCBP>2024-27711</FRDOCBP>
                      
                    <FRDOCBP>2024-27855</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Crop</EAR>
            <HD>Federal Crop Insurance Corporation</HD>
            <CAT>
                <HD>RULES</HD>
                <DOCENT>
                    <DOC>Flax Revenue and Expanded Unit Options for Crop Insurance, </DOC>
                    <PGS>93463-93470</PGS>
                    <FRDOCBP>2024-27225</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Emergency</EAR>
            <HD>Federal Emergency Management Agency</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Flood Hazard Determinations, </DOC>
                    <PGS>93632-93634</PGS>
                    <FRDOCBP>2024-27725</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Energy</EAR>
            <HD>Federal Energy Regulatory Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Application:</SJ>
                <SJDENT>
                    <SJDOC>Brookfield White Pine Hydro, LLC, </SJDOC>
                    <PGS>93571</PGS>
                    <FRDOCBP>2024-27779</FRDOCBP>
                </SJDENT>
                <DOCENT>
                    <DOC>Combined Filings, </DOC>
                    <PGS>93571-93572</PGS>
                    <FRDOCBP>2024-27807</FRDOCBP>
                      
                    <FRDOCBP>2024-27808</FRDOCBP>
                </DOCENT>
                <SJ>Filing:</SJ>
                <SJDENT>
                    <SJDOC>Western Area Power Administration, </SJDOC>
                    <PGS>93570-93571</PGS>
                    <FRDOCBP>2024-27771</FRDOCBP>
                      
                    <FRDOCBP>2024-27772</FRDOCBP>
                </SJDENT>
                <SJ>Permits; Applications, Issuances, etc.:</SJ>
                <SJDENT>
                    <SJDOC>BOST1 Hydroelectric LLC, </SJDOC>
                    <PGS>93569</PGS>
                    <FRDOCBP>2024-27768</FRDOCBP>
                </SJDENT>
                <SJ>Request for Extension of Time:</SJ>
                <SJDENT>
                    <SJDOC>Driftwood Pipeline, LLC, </SJDOC>
                    <PGS>93569-93570</PGS>
                    <FRDOCBP>2024-27777</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Highway</EAR>
            <HD>Federal Highway Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Environmental Impact Statements; Availability, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Cameron, Hidalgo, and Willacy Counties, TX, </SJDOC>
                    <PGS>93822-93823</PGS>
                    <FRDOCBP>2024-27823</FRDOCBP>
                </SJDENT>
                <SJ>Final Federal Agency Action:</SJ>
                <SJDENT>
                    <SJDOC>Proposed Transportation Project in Florida, </SJDOC>
                    <PGS>93821-93822</PGS>
                    <FRDOCBP>2024-27817</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Railroad</EAR>
            <HD>Federal Railroad Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Request for Amendment</SJ>
                <SJDENT>
                    <SJDOC>National Railroad Passenger Corporation; Positive Train Control Safety Plan and Positive Train Control System, </SJDOC>
                    <PGS>93823-93824</PGS>
                    <FRDOCBP>2024-27818</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Reserve</EAR>
            <HD>Federal Reserve System</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Change in Bank Control:</SJ>
                <SJDENT>
                    <SJDOC>Acquisitions of Shares of a Bank or Bank Holding Company, </SJDOC>
                    <PGS>93584</PGS>
                    <FRDOCBP>2024-27847</FRDOCBP>
                </SJDENT>
                <DOCENT>
                    <DOC>Federal Reserve Bank Services, </DOC>
                    <PGS>93584-93602</PGS>
                    <FRDOCBP>2024-27831</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Trade</EAR>
            <HD>Federal Trade Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Agency Information Collection Activities; Proposals, Submissions, and Approvals; Correction, </DOC>
                    <PGS>93602-93603</PGS>
                    <FRDOCBP>2024-27794</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Federal Transit</EAR>
            <HD>Federal Transit Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Proposed Circular Updates, </DOC>
                    <PGS>93824-93827</PGS>
                    <FRDOCBP>2024-27645</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Food and Drug</EAR>
            <HD>Food and Drug Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Charter Amendments, Establishments, Renewals and Terminations:</SJ>
                <SJDENT>
                    <SJDOC>Oncologic Drugs Advisory Committee, </SJDOC>
                    <PGS>93609</PGS>
                    <FRDOCBP>2024-27797</FRDOCBP>
                </SJDENT>
                <SJ>Guidance:</SJ>
                <SJDENT>
                    <SJDOC>Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products, </SJDOC>
                    <PGS>93611-93612</PGS>
                    <FRDOCBP>2024-27804</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite to Support First-in-Human Clinical Trials with Healthy Subjects, </SJDOC>
                    <PGS>93610-93611</PGS>
                    <FRDOCBP>2024-27796</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Food Safety</EAR>
            <HD>Food Safety and Inspection Service</HD>
            <CAT>
                <HD>RULES</HD>
                <DOCENT>
                    <DOC>Uniform Compliance Date for Food Labeling Regulations, </DOC>
                    <PGS>93470-93471</PGS>
                    <FRDOCBP>2024-27864</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Foreign Assets</EAR>
            <HD>Foreign Assets Control Office</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Sanctions Action, </DOC>
                    <PGS>93829-93905</PGS>
                    <FRDOCBP>2024-27799</FRDOCBP>
                      
                    <FRDOCBP>2024-27801</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Forest</EAR>
            <HD>Forest Service</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Charter Amendments, Establishments, Renewals and Terminations:</SJ>
                <SJDENT>
                    <SJDOC>Northwest Forest Plan Area Advisory Committee, </SJDOC>
                    <PGS>93548-93549</PGS>
                    <FRDOCBP>2024-27781</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Health and Human</EAR>
            <HD>Health and Human Services Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Agency for Healthcare Research and Quality</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Centers for Disease Control and Prevention</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Centers for Medicare &amp; Medicaid Services</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Children and Families Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Food and Drug Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Inspector General Office, Health and Human Services Department</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>National Institutes of Health</P>
            </SEE>
            <CAT>
                <HD>RULES</HD>
                <SJ>Organ Procurement and Transplantation:</SJ>
                <SJDENT>
                    <SJDOC>Implementation of the HIV Organ Policy Equity Act, </SJDOC>
                    <PGS>93484-93498</PGS>
                    <FRDOCBP>2024-27410</FRDOCBP>
                </SJDENT>
            </CAT>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Agency Information Collection Activities; Proposals, Submissions, and Approvals, </DOC>
                    <PGS>93613-93616</PGS>
                    <FRDOCBP>2024-27714</FRDOCBP>
                      
                    <FRDOCBP>2024-27716</FRDOCBP>
                      
                    <FRDOCBP>2024-27721</FRDOCBP>
                      
                    <FRDOCBP>2024-27723</FRDOCBP>
                      
                    <FRDOCBP>2024-27806</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Homeland</EAR>
            <HD>Homeland Security Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Coast Guard</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Federal Emergency Management Agency</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>U.S. Citizenship and Immigration Services</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>U.S. Customs and Border Protection</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>U.S. Immigration and Customs Enforcement</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>Housing</EAR>
            <HD>Housing and Urban Development Department</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Manufactured Housing Survey, </SJDOC>
                    <PGS>93648-93649</PGS>
                    <FRDOCBP>2024-27789</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>
                Inspector General Health
                <PRTPAGE P="v"/>
            </EAR>
            <HD>Inspector General Office, Health and Human Services Department</HD>
            <CAT>
                <HD>PROPOSED RULES</HD>
                <SJ>Solicitation of Proposals:</SJ>
                <SJDENT>
                    <SJDOC>New and Modified Safe Harbors and Special Fraud Alerts, </SJDOC>
                    <PGS>93545-93546</PGS>
                    <FRDOCBP>2024-27710</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Interior</EAR>
            <HD>Interior Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Land Management Bureau</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>National Park Service</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>Internal Revenue</EAR>
            <HD>Internal Revenue Service</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Foreign Account Tax Compliance Act, </SJDOC>
                    <PGS>93905-93906</PGS>
                    <FRDOCBP>2024-27792</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>International Trade Adm</EAR>
            <HD>International Trade Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Export Trade Certificate of Review, </DOC>
                    <PGS>93551</PGS>
                    <FRDOCBP>2024-27866</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>International Trade Com</EAR>
            <HD>International Trade Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Antidumping or Countervailing Duty Investigations, Orders, or Reviews:</SJ>
                <SJDENT>
                    <SJDOC>Float Glass Products from China and Malaysia, </SJDOC>
                    <PGS>93651-93652</PGS>
                    <FRDOCBP>2024-27739</FRDOCBP>
                </SJDENT>
                <SJ>Investigations; Determinations, Modifications, and Rulings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Certain Movable Barrier Operator Systems and Components Thereof, </SJDOC>
                    <PGS>93653-93654</PGS>
                    <FRDOCBP>2024-27783</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Justice Department</EAR>
            <HD>Justice Department</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Census of Publicly Funded Forensic Crime Laboratories, </SJDOC>
                    <PGS>93663-93664</PGS>
                    <FRDOCBP>2024-27802</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Firearms Disabilities for Nonimmigrant Aliens, </SJDOC>
                    <PGS>93658-93659</PGS>
                    <FRDOCBP>2024-27821</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Identification Markings Placed on Firearms, </SJDOC>
                    <PGS>93661-93662</PGS>
                    <FRDOCBP>2024-27861</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Identification of Imported Explosives Materials, </SJDOC>
                    <PGS>93654-93655</PGS>
                    <FRDOCBP>2024-27860</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Law Enforcement Suicide Data Collection, </SJDOC>
                    <PGS>93662-93663</PGS>
                    <FRDOCBP>2024-27825</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>National Firearms Act Division and Firearms and Explosives Services Division Customer Service Survey, </SJDOC>
                    <PGS>93659-93660</PGS>
                    <FRDOCBP>2024-27862</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Private Industry Feedback Survey, </SJDOC>
                    <PGS>93660-93661</PGS>
                    <FRDOCBP>2024-27809</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Records of Acquisition and Disposition by Registered Importers of Arms, Ammunition, and Defense Articles on the U.S. Munitions Import List, </SJDOC>
                    <PGS>93655-93656</PGS>
                    <FRDOCBP>2024-27820</FRDOCBP>
                </SJDENT>
                <DOCENT>
                    <DOC>Privacy Act; Systems of Records, </DOC>
                    <PGS>93656-93658</PGS>
                    <FRDOCBP>2024-27570</FRDOCBP>
                </DOCENT>
                <SJ>Proposed Consent Decree:</SJ>
                <SJDENT>
                    <SJDOC>Clean Air Act, </SJDOC>
                    <PGS>93661</PGS>
                    <FRDOCBP>2024-27780</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Labor Department</EAR>
            <HD>Labor Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Occupational Safety and Health Administration</P>
            </SEE>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Davis-Bacon Certified Payroll, </SJDOC>
                    <PGS>93664-93665</PGS>
                    <FRDOCBP>2024-27720</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Unemployment Insurance Title XII Advances and Voluntary Repayment Process, </SJDOC>
                    <PGS>93665-93666</PGS>
                    <FRDOCBP>2024-27719</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Land</EAR>
            <HD>Land Management Bureau</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Alaska Native Claims Selection, </DOC>
                    <PGS>93649-93650</PGS>
                    <FRDOCBP>2024-27785</FRDOCBP>
                </DOCENT>
                <SJ>Record of Decision:</SJ>
                <SJDENT>
                    <SJDOC>Approved Resource Management Plan Amendment for the Buffalo Field Office, Wyoming, </SJDOC>
                    <PGS>93650</PGS>
                    <FRDOCBP>2024-27677</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Approved Resource Management Plan Amendment for the Miles City Field Office, Montana, </SJDOC>
                    <PGS>93650-93651</PGS>
                    <FRDOCBP>2024-27678</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Library</EAR>
            <HD>Library of Congress</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Copyright Royalty Board</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>National Institute</EAR>
            <HD>National Institute of Standards and Technology</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>National Council on Weights and Measures, </SJDOC>
                    <PGS>93551-93553</PGS>
                    <FRDOCBP>2024-27838</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>National Institute</EAR>
            <HD>National Institutes of Health</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Draft Revised Human Immunodeficiency Virus (HIV) Organ Policy Equity Act Safeguards and Research Criteria for Transplantation of Organs Infected with HIV, </DOC>
                    <PGS>93616-93623</PGS>
                    <FRDOCBP>2024-27733</FRDOCBP>
                </DOCENT>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Center for Scientific Review, </SJDOC>
                    <PGS>93625</PGS>
                    <FRDOCBP>2024-27879</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>National Cancer Institute, </SJDOC>
                    <PGS>93623-93624</PGS>
                    <FRDOCBP>2024-27877</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>National Heart, Lung, And Blood Institute, </SJDOC>
                    <PGS>93616</PGS>
                    <FRDOCBP>2024-27878</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>National Institute of Environmental Health Sciences, </SJDOC>
                    <PGS>93624-93625</PGS>
                    <FRDOCBP>2024-27715</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>National Institute of General Medical Sciences, </SJDOC>
                    <PGS>93625</PGS>
                    <FRDOCBP>2024-27873</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>National Oceanic</EAR>
            <HD>National Oceanic and Atmospheric Administration</HD>
            <CAT>
                <HD>RULES</HD>
                <SJ>Fisheries Off West Coast States:</SJ>
                <SJDENT>
                    <SJDOC>Coastal Pelagic Species Fisheries; Annual Specifications; 2024-2025 Annual Specifications and Management Measures for Pacific Sardine, </SJDOC>
                    <PGS>93522-93527</PGS>
                    <FRDOCBP>2024-27685</FRDOCBP>
                </SJDENT>
            </CAT>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Endangered and Threatened Species:</SJ>
                <SJDENT>
                    <SJDOC>Initiation of 5-Year Review of the Brazilian Guitarfish (Rhinobatos horkelii), </SJDOC>
                    <PGS>93554-93555</PGS>
                    <FRDOCBP>2024-27848</FRDOCBP>
                </SJDENT>
                <SJ>Fisheries of the South Atlantic:</SJ>
                <SJDENT>
                    <SJDOC>Southeast Data, Assessment, and Review, </SJDOC>
                    <PGS>93554</PGS>
                    <FRDOCBP>2024-27839</FRDOCBP>
                </SJDENT>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Gulf of Mexico Fishery Management Council, </SJDOC>
                    <PGS>93553-93554</PGS>
                    <FRDOCBP>2024-27770</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Mid-Atlantic Fishery Management Council, </SJDOC>
                    <PGS>93555</PGS>
                    <FRDOCBP>2024-27769</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>New England Fishery Management Council, </SJDOC>
                    <PGS>93555-93556</PGS>
                    <FRDOCBP>2024-27843</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>National Park</EAR>
            <HD>National Park Service</HD>
            <CAT>
                <HD>PROPOSED RULES</HD>
                <DOCENT>
                    <DOC>Hot Springs National Park; Use of Thermal Water and Commercial Passenger-Carrying Vehicles, </DOC>
                    <PGS>93531-93538</PGS>
                    <FRDOCBP>2024-27571</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Navy</EAR>
            <HD>Navy Department</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Science and Technology Board, </SJDOC>
                    <PGS>93566-93567</PGS>
                    <FRDOCBP>2024-27812</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Occupational Safety Health Adm</EAR>
            <HD>Occupational Safety and Health Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Recordkeeping and Reporting Occupational Injuries and Illnesses, </SJDOC>
                    <PGS>93666-93667</PGS>
                    <FRDOCBP>2024-27718</FRDOCBP>
                </SJDENT>
                <SJ>Requests for Nominations:</SJ>
                <SJDENT>
                    <SJDOC>Advisory Committee on Construction Safety and Health, </SJDOC>
                    <PGS>93667-93668</PGS>
                    <FRDOCBP>2024-27822</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Postal Regulatory</EAR>
            <HD>Postal Regulatory Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>New Postal Products, </DOC>
                    <PGS>93668-93671</PGS>
                    <FRDOCBP>2024-27726</FRDOCBP>
                      
                    <FRDOCBP>2024-27881</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>
                Postal Service
                <PRTPAGE P="vi"/>
            </EAR>
            <HD>Postal Service</HD>
            <CAT>
                <HD>RULES</HD>
                <DOCENT>
                    <DOC>Domestic Competitive Products Pricing and Mailing Standards Changes, </DOC>
                    <PGS>93477-93484</PGS>
                    <FRDOCBP>2024-27463</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Presidential Documents</EAR>
            <HD>Presidential Documents</HD>
            <CAT>
                <HD>PROCLAMATIONS</HD>
                <SJ>Special Observances:</SJ>
                <SJDENT>
                    <SJDOC>National Child's Day (Proc. 10862), </SJDOC>
                    <PGS>93461-93462</PGS>
                    <FRDOCBP>2024-28062</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Science Technology</EAR>
            <HD>Science and Technology Policy Office</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Request for Information:</SJ>
                <SJDENT>
                    <SJDOC>Downscaled Climate Projection Datasets Available to be Considered for Use in the Sixth National Climate Assessment, </SJDOC>
                    <PGS>93671-93672</PGS>
                    <FRDOCBP>2024-27858</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Securities</EAR>
            <HD>Securities and Exchange Commission</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Self-Regulatory Organizations; Proposed Rule Changes:</SJ>
                <SJDENT>
                    <SJDOC>Cboe BYX Exchange, Inc., </SJDOC>
                    <PGS>93683-93685</PGS>
                    <FRDOCBP>2024-27765</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Financial Industry Regulatory Authority, Inc., </SJDOC>
                    <PGS>93709-93731, 93750-93757</PGS>
                    <FRDOCBP>2024-27742</FRDOCBP>
                      
                    <FRDOCBP>2024-27764</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Fixed Income Clearing Corporation, </SJDOC>
                    <PGS>93735-93750, 93763-93780, 93784-93802</PGS>
                    <FRDOCBP>2024-27762</FRDOCBP>
                      
                    <FRDOCBP>2024-27763</FRDOCBP>
                      
                    <FRDOCBP>2024-27766</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>MIAX Exchange LLC, </SJDOC>
                    <PGS>93802-93810</PGS>
                    <FRDOCBP>2024-27741</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>MIAX PEARL, LLC, </SJDOC>
                    <PGS>93672-93678</PGS>
                    <FRDOCBP>2024-27743</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>MIAX Sapphire, LLC, </SJDOC>
                    <PGS>93757-93763</PGS>
                    <FRDOCBP>2024-27744</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Nasdaq BX, Inc., </SJDOC>
                    <PGS>93678-93681</PGS>
                    <FRDOCBP>2024-27758</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Nasdaq GEMX, LLC, </SJDOC>
                    <PGS>93810-93814</PGS>
                    <FRDOCBP>2024-27757</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Nasdaq ISE, LLC, </SJDOC>
                    <PGS>93780-93783</PGS>
                    <FRDOCBP>2024-27756</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Nasdaq MRX, LLC, </SJDOC>
                    <PGS>93685-93689</PGS>
                    <FRDOCBP>2024-27755</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Nasdaq PHLX LLC, </SJDOC>
                    <PGS>93697-93700</PGS>
                    <FRDOCBP>2024-27760</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>New York Stock Exchange LLC, </SJDOC>
                    <PGS>93700-93701</PGS>
                    <FRDOCBP>2024-27748</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>NYSE American LLC, </SJDOC>
                    <PGS>93703-93709</PGS>
                    <FRDOCBP>2024-27745</FRDOCBP>
                      
                    <FRDOCBP>2024-27747</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>NYSE Arca, Inc., </SJDOC>
                    <PGS>93694-93695, 93706-93707</PGS>
                    <FRDOCBP>2024-27750</FRDOCBP>
                      
                    <FRDOCBP>2024-27752</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>NYSE Chicago, Inc., </SJDOC>
                    <PGS>93681-93683</PGS>
                    <FRDOCBP>2024-27746</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>NYSE National, Inc., </SJDOC>
                    <PGS>93695-93697, 93701-93703</PGS>
                    <FRDOCBP>2024-27749</FRDOCBP>
                      
                    <FRDOCBP>2024-27751</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>The Depository Trust Co., </SJDOC>
                    <PGS>93689-93691</PGS>
                    <FRDOCBP>2024-27754</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>The Nasdaq Stock Market LLC, </SJDOC>
                    <PGS>93691-93693, 93731-93735</PGS>
                    <FRDOCBP>2024-27759</FRDOCBP>
                      
                    <FRDOCBP>2024-27761</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>The Options Clearing Corporation, </SJDOC>
                    <PGS>93693-93694</PGS>
                    <FRDOCBP>2024-27753</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Social</EAR>
            <HD>Social Security Administration</HD>
            <CAT>
                <HD>NOTICES</HD>
                <DOCENT>
                    <DOC>Agency Information Collection Activities; Proposals, Submissions, and Approvals, </DOC>
                    <PGS>93814-93815</PGS>
                    <FRDOCBP>2024-27811</FRDOCBP>
                </DOCENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>State Department</EAR>
            <HD>State Department</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Foreign Service Officer Test Registration Form, </SJDOC>
                    <PGS>93815-93816</PGS>
                    <FRDOCBP>2024-27735</FRDOCBP>
                </SJDENT>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Preparation for International Maritime Organization Session of the Sub-Committee on Ship Design and Construction, </SJDOC>
                    <PGS>93815</PGS>
                    <FRDOCBP>2024-27795</FRDOCBP>
                </SJDENT>
                <SJ>Request for Information:</SJ>
                <SJDENT>
                    <SJDOC>2025 Trafficking in Persons Report, </SJDOC>
                    <PGS>93816-93820</PGS>
                    <FRDOCBP>2024-27815</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Transportation Department</EAR>
            <HD>Transportation Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Federal Aviation Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Federal Highway Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Federal Railroad Administration</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Federal Transit Administration</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>Treasury</EAR>
            <HD>Treasury Department</HD>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Comptroller of the Currency</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Foreign Assets Control Office</P>
            </SEE>
            <SEE>
                <HD SOURCE="HED">See</HD>
                <P>Internal Revenue Service</P>
            </SEE>
        </AGCY>
        <AGCY>
            <EAR>U.S. Citizenship</EAR>
            <HD>U.S. Citizenship and Immigration Services</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Temporary Protected Status:</SJ>
                <SJDENT>
                    <SJDOC>Lebanon, </SJDOC>
                    <PGS>93641-93647</PGS>
                    <FRDOCBP>2024-27788</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Customs</EAR>
            <HD>U.S. Customs and Border Protection</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Application and Approval to Manipulate, Examine, Sample or Transfer Goods, </SJDOC>
                    <PGS>93630-93631</PGS>
                    <FRDOCBP>2024-27830</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Cost Submission, </SJDOC>
                    <PGS>93626</PGS>
                    <FRDOCBP>2024-27826</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Declaration of Ultimate Consignee That Articles Were Exported for Temporary Scientific or Educational Purposes, </SJDOC>
                    <PGS>93631-93632</PGS>
                    <FRDOCBP>2024-27828</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Declaration of Unaccompanied Articles, </SJDOC>
                    <PGS>93626-93627</PGS>
                    <FRDOCBP>2024-27829</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Documents Required Aboard Private Aircraft, </SJDOC>
                    <PGS>93627-93628</PGS>
                    <FRDOCBP>2024-27832</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Establishment of a Bonded Warehouse, </SJDOC>
                    <PGS>93628-93629</PGS>
                    <FRDOCBP>2024-27827</FRDOCBP>
                </SJDENT>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Commercial Customs Operations Advisory Committee, </SJDOC>
                    <PGS>93629-93630</PGS>
                    <FRDOCBP>2024-27805</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Immigration</EAR>
            <HD>U.S. Immigration and Customs Enforcement</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Employment Authorization:</SJ>
                <SJDENT>
                    <SJDOC>Lebanese F-1 Nonimmigrant Students Experiencing Severe Economic Hardship as a Direct Result of the Current Humanitarian Crisis in Lebanon, </SJDOC>
                    <PGS>93634-93641</PGS>
                    <FRDOCBP>2024-27787</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <AGCY>
            <EAR>Veteran Affairs</EAR>
            <HD>Veterans Affairs Department</HD>
            <CAT>
                <HD>NOTICES</HD>
                <SJ>Agency Information Collection Activities; Proposals, Submissions, and Approvals:</SJ>
                <SJDENT>
                    <SJDOC>Equipment Operation and Maintenance Manuals, </SJDOC>
                    <PGS>93907-93908</PGS>
                    <FRDOCBP>2024-27863</FRDOCBP>
                </SJDENT>
                <SJDENT>
                    <SJDOC>Nonprofit Research and Education Corporations—Annual Report, Remediation Plans and Assessment Questionnaires, </SJDOC>
                    <PGS>93906-93907</PGS>
                    <FRDOCBP>2024-27728</FRDOCBP>
                </SJDENT>
                <DOCENT>
                    <DOC>Assessment of Exposures and Conditions of Interest for Veterans who Served at Karshi-Khanabad Airs Base, </DOC>
                    <PGS>93908-93909</PGS>
                    <FRDOCBP>2024-27833</FRDOCBP>
                </DOCENT>
                <SJ>Hearings, Meetings, Proceedings, etc.:</SJ>
                <SJDENT>
                    <SJDOC>Veterans and Community Oversight and Engagement Board, </SJDOC>
                    <PGS>93906</PGS>
                    <FRDOCBP>2024-27868</FRDOCBP>
                </SJDENT>
            </CAT>
        </AGCY>
        <PTS>
            <HD SOURCE="HED">Separate Parts In This Issue</HD>
            <HD>Part II</HD>
            <DOCENT>
                <DOC>Health and Human Services Department, Centers for Medicare &amp; Medicaid Services, </DOC>
                <PGS>93912-94594</PGS>
                <FRDOCBP>2024-25521</FRDOCBP>
            </DOCENT>
        </PTS>
        <AIDS>
            <HD SOURCE="HED">Reader Aids</HD>
            <P>Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, and notice of recently enacted public laws.</P>
            <P>To subscribe to the Federal Register Table of Contents electronic mailing list, go to https://public.govdelivery.com/accounts/USGPOOFR/subscriber/new, enter your e-mail address, then follow the instructions to join, leave, or manage your subscription.</P>
        </AIDS>
    </CNTNTS>
    <VOL>89</VOL>
    <NO>229</NO>
    <DATE>Wednesday, November 27, 2024</DATE>
    <UNITNAME>Rules and Regulations</UNITNAME>
    <RULES>
        <RULE>
            <PREAMB>
                <PRTPAGE P="93463"/>
                <AGENCY TYPE="F">DEPARTMENT OF AGRICULTURE</AGENCY>
                <SUBAGY>Federal Crop Insurance Corporation</SUBAGY>
                <CFR>7 CFR Parts 407 and 457</CFR>
                <RIN>RIN 0563-AC86</RIN>
                <DEPDOC>[Docket ID FCIC-24-0005]</DEPDOC>
                <SUBJECT>Flax Revenue and Expanded Unit Options for Crop Insurance</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Crop Insurance Corporation, USDA.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule with request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Federal Crop Insurance Corporation (FCIC) is amending its regulations to allow revenue coverage for flax under the Small Grain Crop Insurance Provisions, to combine written agreement deadlines in the Dry Bean Crop Insurance Provisions to match other insurance policies, to expand the availability of enterprise and optional units for some specialty and perennial crops, and to make clarifications and corrections to the Area Risk Protection Insurance, Basic Provisions; Common Crop Insurance Policy, Basic Provisions; and several Crop Provisions. The changes will be effective for the 2025 and succeeding crop years for crops with a contract change date on or after November 30, 2024. For all other crops, the changes to the policies made in this rule are applicable for the 2026 and succeeding crop years.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        <E T="03">Effective date:</E>
                         This final rule is effective November 30, 2024.
                    </P>
                    <P>
                        <E T="03">Comment Date:</E>
                         We will consider comments that we receive by the close of business January 27, 2025. FCIC may consider the comments received and may conduct additional rulemaking based on the comments.
                    </P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>We invite you to submit comments on this rule. You may submit comments by going through the Federal eRulemaking Portal as follows:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                         Go to 
                        <E T="03">https://www.regulations.gov</E>
                         and search for Docket ID FCIC-24-0005. Follow the instructions for submitting comments.
                    </P>
                    <P>
                        All comments will be posted without change and will be publicly available on 
                        <E T="03">www.regulations.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Chandra Place; telephone (816) 926-3875; or email 
                        <E T="03">chandra.place@usda.gov.</E>
                         Persons with disabilities who require alternative means for communication should contact the USDA Target Center at (202) 720-2600 or (844) 433-2774 (toll-free nationwide).
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <HD SOURCE="HD1">Background</HD>
                <P>FCIC serves America's agricultural producers through effective, market-based risk management tools to strengthen the economic stability of agricultural producers and rural communities. FCIC is committed to increasing the availability and effectiveness of Federal crop insurance as a risk management tool. Approved Insurance Providers (AIPs) sell and service Federal crop insurance policies in every state through a public-private partnership. FCIC reinsures the AIPs who share the risks associated with catastrophic losses due to major weather events. FCIC's vision is to secure the future of agriculture by providing world class risk management tools to rural America.</P>
                <P>Federal crop insurance policies typically consist of the Basic Provisions, the Crop Provisions, the Special Provisions, the Commodity Exchange Price Provisions, if applicable, other applicable endorsements or options, the actuarial documents for the insured agricultural commodity, the Catastrophic Risk Protection Endorsement, if applicable, and the applicable regulations published in 7 CFR chapter IV. Throughout this rule, the terms “Crop Provisions,” “Special Provisions,” and “policy” are used as defined in the Common Crop Insurance Policy (CCIP) Basic Provisions in 7 CFR 457.8. Additional information and definitions related to Federal crop insurance policies are in 7 CFR 457.8.</P>
                <P>FCIC is amending the following regulations:</P>
                <P>• Area Risk Protection Insurance Basic Provisions (7 CFR part 407);</P>
                <P>• Common Crop Insurance Policy Basic Provisions (7 CFR 457.8);</P>
                <P>• Small grain crop insurance provisions (7 CFR 457.101);</P>
                <P>• Prune crop insurance provisions (7 CFR 457.133);</P>
                <P>• Green pea crop insurance provisions (7 CFR 457.137);</P>
                <P>• Northern potato crop insurance provisions (7 CFR 457.142);</P>
                <P>• Central and Southern potato crop insurance provisions (7 CFR 457.147);</P>
                <P>• Dry bean crop insurance provisions (7 CFR 457.150);</P>
                <P>• Processing sweet corn crop insurance provisions (7 CFR 457.154); and</P>
                <P>• Blueberry crop insurance provisions (7 CFR 457.166).</P>
                <P>The changes to the crop insurance policies resulting from the amendments in this rule are applicable for the 2025 and succeeding crop years for crops with a contract change date on or after November 30, 2024. For all other crops, the changes to the crop insurance policies resulting from the amendments in this rule are applicable for the 2026 and succeeding crop years.</P>
                <HD SOURCE="HD1">Flax Revenue Coverage</HD>
                <P>The Small Grain Crop Provisions previously offered actual production history (APH) coverage to buckwheat and flax; and offered yield protection (YP), revenue protection (RP), and revenue protection with harvest price exclusion (RP-HPE) to barley, oats, rye, and wheat. In this Final Rule, FCIC is expanding revenue protection (RP and RP-HPE) to flax, matching available coverage for barley, oats, rye, and wheat.</P>
                <P>The current APH coverage for flax is now converted to YP. For producers who wish to maintain yield coverage, the only difference in coverage is the price guarantee matches the projected price offered for revenue protection (established approximately two weeks prior to the sales closing date), instead of a price election established by the Risk Management Agency (RMA) (established prior to the contract change date).</P>
                <P>
                    With the availability of revenue protection for flax, the terms “price election” and “production guarantee” are no longer applicable. Instead, the terms “projected price,” “yield protection guarantee,” and “revenue protection guarantee” are applicable. These changes appear in the following sections of the Small Grain Crop Provisions: 3(a) and (b), 9(c), and 11(b) and (c).
                    <PRTPAGE P="93464"/>
                </P>
                <P>FCIC is revising section 3(a) to remove the references to flax. This provision previously stated that revenue protection is not available for flax or buckwheat. FCIC is removing flax from the list of crops because revenue coverage is now available for flax. FCIC is also revising section 3(b) to add references to flax. These provisions previously stated that revenue protection is available for barley, oats, rye, and wheat. FCIC is adding flax to the list of crops in the two places where the list occurs.</P>
                <P>FCIC is revising section 9(c)(2)(i) to remove the reference to flax and revise section 9(c)(2)(ii) to add a reference to flax. When a crop does not have yield or revenue protection available, the price used for determining coverage and any indemnity payments, including replanting payments, is called the price election. For crops for which yield and revenue protection are available, this price is called the projected price. In section 9(c)(2)(i), the provision previously stated that the replanting payment for flax will be determined by using the price election. Under this rule, revenue and yield protection plans of insurance are now available for flax; therefore, the price used is the projected price. FCIC is revising section 9(c)(2)(i) to remove the reference to flax. Section 9(c)(2)(ii) contains provisions applicable to the projected price. FCIC is revising section 9(c)(2)(ii) to include flax, as the projected price will now be used.</P>
                <P>For crops for which yield and revenue protection are available, the applicable terms for insurance coverage are yield protection guarantee and revenue protection guarantee. For crops for which yield and revenue protection are not available, the applicable term is production guarantee. FCIC is revising sections 11(b)(1)(i), (ii), and (iii). These sections refer to “yield protection guarantee,” “production guarantee,” and “revenue protection guarantee,” respectively. The references to flax in section 11(b)(1)(ii), which addresses production guarantee, were removed and added to sections 11(b)(1)(i) and (iii), which address yield protection guarantee and revenue protection guarantee.</P>
                <P>FCIC is also revising section 11(b)(3)(i) to add a reference to flax and revising section 11(b)(3)(ii) to remove the reference to flax. This change is consistent with the change in section 9(c)(2). Section 11(b)(3)(i) refers to computations using the projected price; section 11(b)(3)(ii) refers to computations using the price election. Flax was removed from section 11(b)(3)(ii) and added to section 11(b)(3)(i) to align with the proper terms for crops for which revenue protection is available.</P>
                <P>Section 11(c)(1)(i) explains what is included in appraised production. Previously, flax was contained in a list of crops with buckwheat. Those two crops had similar coverage and used the same crop insurance terminology under the Small Grain Crop Provisions when revenue coverage was not yet available for flax. Now, flax has been removed from the list of crops containing buckwheat and added to the list of crops containing barley, oats, rye, and wheat in two places because allowing revenue coverage for flax makes coverage and crop insurance terminology for that crop consistent with coverage and terminology for barley, oats, rye, and wheat.</P>
                <HD SOURCE="HD1">Dry Bean Written Agreement Deadlines</HD>
                <P>FCIC is combining written agreement deadlines to reduce confusion and administrative complexity when a producer requests a written agreement based on multiple criteria. Previously, the written agreement deadline to add an insurable practice or type was the acreage reporting date for new requests and the sales closing date for renewal requests; however, the deadline to add an insurable dry bean type that is not on the actuarial documents was the sales closing date. This created extra paperwork and confusion in instances where a producer wanted to insure a new dry bean type and under a practice that is not currently available in the county. FCIC is combining the deadline for all written agreements to match all other insurance policies with this type of request, so that for the first year of coverage, the deadline is the acreage reporting date and for subsequent years of coverage, the deadline is the sales closing date.</P>
                <HD SOURCE="HD1">Enterprise and Optional Units</HD>
                <P>The CCIP Basic Provisions allow enterprise units (EU) by organic farming practice, beginning with the June 30, 2024, contract change date. Unlike major row crops, optional units (OUs) by organic farming practice were not available for most specialty and perennial crops due to language in the Crop Provisions (CP) that superseded the standard OU definition in the CCIP Basic Provisions. In this rule, FCIC is removing limitations on OUs by organic farming practice and making clarifications and edits for consistency with the EU and OU choices provisions in the CCIP Basic Provisions in the following Crop Provisions:</P>
                <P>• Green pea crop insurance provisions (7 CFR 457.137); and</P>
                <P>• Processing sweet corn crop insurance provisions (7 CFR 457.154).</P>
                <P>These changes are responsive to organic growers and the Climate Smart Initiative.</P>
                <HD SOURCE="HD1">Clarifications and Corrections</HD>
                <P>FCIC is making the following corrections and clarifications in the Small Grain Crop Provisions (7 CFR 457.101):</P>
                <P>• Updating the effective crop year of the Crop Provisions;</P>
                <P>• Removing the hyphen in the phrase “initially-planted” in section 2(b) for consistency with the defined phrase in the Crop Provisions;</P>
                <P>• Making plain language clarifications in sections 5, 6, and 7;</P>
                <P>• Combining the two introductory paragraphs in section 8 into one introductory paragraph;</P>
                <P>• Replacing the word “and” with “or” in sections 11(d)(2)(i)(A) and 11(d)(2)(ii). Section 11(d) contains six subparagraphs for deficiencies in quality for the small grain crop. The list of deficiencies in quality varies by crop. In four of the six subparagraphs, the last item in the list is preceded by “or,” while in the other two paragraphs, the last item is preceded by “and.” FCIC is changing the word “and” to “or” for consistency among subparagraphs; and</P>
                <P>• Replacing the word “flaxseed” with “flax” in section 11(d)(2)(E). This is the only instance of “flaxseed,” whereas “flax” is used elsewhere.</P>
                <P>FCIC is making the following clarifications and corrections in the Green pea crop insurance provision (7 CFR 457.137):</P>
                <P>• Updating the effective crop year of the Crop Provisions;</P>
                <P>• Removing the paragraph immediately preceding section 1, which refers to the order of priority if a conflict exists among the policy provisions. This same provision is contained in the Basic Provisions. Therefore, the appearance here is duplicative and should be removed. FCIC is clarifying which Basic Provisions apply by replacing the aforementioned paragraph with an introductory sentence preceding the Crop Provisions;</P>
                <P>• Removing all instances of the phrase “the provisions of,” “the provisions contained in,” and “contained” where a policy reference follows;</P>
                <P>
                    • Revising the definition of “good farming practices” to clarify that the definition in the Crop Provisions expands upon the definition contained in the Basic Provisions because good farming practices include the cultural practices required by the processor contract;
                    <PRTPAGE P="93465"/>
                </P>
                <P>• Revising the definition of “practical to replant” to clarify that the definition in the Crop Provisions does not replace, but rather expands upon the definition in the Basic Provisions, and remove duplicative criteria that are already included in the definition in the Basic Provisions;</P>
                <P>• Revising the definition of “processor contract” to replace the phrase “a written agreement” with the phrase “a written contract.” The phrase “written agreement” is a specifically defined term in the Basic Provisions and is not applicable to a processor contract for green peas. This change is necessary to minimize confusion between a written contract and a written agreement, which is a document that alters designated terms of a policy as authorized under these Basic Provisions, the Crop Provisions, or the Special Provisions for the insured crop;</P>
                <P>• Removing the phrase “for determining indemnities” from the section heading for section 3. The section heading will now read “Insurance Guarantees, Coverage, Levels, and Prices.” The new section heading is more accurate because insurance guarantees, coverage levels, and prices are not exclusively used for determining indemnities. This change is also for consistency with section headings of the same name in other Crop Provisions;</P>
                <P>• Replacing the reference to Special Provisions with actuarial documents in section 3(a), since the price election information referred to in this section is displayed in the actuarial documents;</P>
                <P>• Replacing abbreviated months (“Feb” and “Mar”) with the full spelling for the months (“February” and “March”) in the cancellation and termination date table, in section 5;</P>
                <P>• Adding a hyphen to the adjective compound “15-day” as it describes a “15-day period” in section 11(c); and</P>
                <P>• Updating prices in the settlement of claim examples to be more reflective of current crop prices and potential indemnities, in section 12.</P>
                <P>FCIC is making the following clarifications and corrections in the Processing sweet corn crop insurance provisions (7 CFR 457.154):</P>
                <P>• Updating the effective crop year of the Crop Provisions;</P>
                <P>• Clarifying which Basic Provisions apply by adding an introductory sentence preceding the Crop Provisions; and</P>
                <P>• Adding a hyphen to the adjective compound “15-day” as it describes a “15-day period” in section 11(c).</P>
                <P>
                    In addition, the Common Crop Insurance Regulations in 7 CFR part 457 were revised by a final rule with request for comments published in the 
                    <E T="04">Federal Register</E>
                     on June 27, 2024 (89 FR 53822-53847). Changes were made in that rule to the Area Risk Protection Insurance Basic Provisions (7 CFR part 407), Common Crop Insurance Policy (Common Crop Insurance Policy (CCIP) Basic Provisions (7 CFR 457.8), the General Administrative Regulations in subpart J of part 400 (7 CFR 400.98), and 18 Crop Provisions. In reviewing the changes made, FCIC found some incorrect references, missing words, missing parentheses, incorrect paragraph designations, and an extra word. This rule will also make these corrections in the following provisions:
                </P>
                <P>• Area Risk Protection Insurance Basic Provisions (7 CFR part 407);</P>
                <P>• Common Crop Insurance Policy Basic Provisions (7 CFR 457.8);</P>
                <P>• Prune crop insurance provisions (7 CFR 457.133);</P>
                <P>• Northern potato crop insurance provisions (7 CFR 457.142);</P>
                <P>• Central and Southern potato crop insurance provisions (7 CFR 457.147); and</P>
                <P>• Blueberry crop insurance provisions (7 CFR 457.166).</P>
                <HD SOURCE="HD1">Effective Date, Notice and Comment, and Exemptions</HD>
                <P>The Administrative Procedure Act (APA, 5 U.S.C. 553) provides that the notice and comment and 30-day delay in the effective date provisions do not apply when the rule involves specified actions, including matters relating to contracts. This rule governs contracts for crop insurance policies and therefore falls within that exemption.</P>
                <P>This rule is exempt from the regulatory analysis requirements of the Regulatory Flexibility Act (5 U.S.C. 601-612), as amended by the Small Business Regulatory Enforcement Fairness Act of 1996.</P>
                <P>Subtitle E of the Small Business Regulatory Enforcement Fairness Act of 1996, (also known as the Congressional Review Act) requires a delay of the effective date of 60 days after publication to allow for Congressional review. The Office of Information and Regulatory Affairs has determined that this rule does not meet the criteria in 5 U.S.C. 804(2). Therefore, this final rule is effective on November 30, 2024. Although not required by APA or any other law, FCIC has chosen to request comments on this rule.</P>
                <HD SOURCE="HD1">Executive Orders 12866, 13563, and 14094</HD>
                <P>Executive Order 12866, “Regulatory Planning and Review,” was amended by and Executive Order 13563, “Improving Regulation and Regulatory Review,” and Executive Order 14094, “Modernizing Regulatory Review.” Executive Orders 12866 and 13563 direct agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). Executive Order 13563 emphasized the importance of quantifying both costs and benefits, of reducing costs, of harmonizing rules, and of promoting flexibility. The requirements in Executive Orders 12866 and 13563 for the analysis of costs and benefits apply to rules that are determined to be significant.</P>
                <P>The Office of Management and Budget (OMB) has designated this rule as not significant under Executive Order 12866, “Regulatory Planning and Review,” and therefore, OMB has not reviewed this rule and analysis of the costs and benefits is not required under either Executive Order 12866 or 13563.</P>
                <HD SOURCE="HD1">Clarity of the Regulation</HD>
                <P>Executive Order 12866, as supplemented by Executive Order 13563, requires each agency to write all rules in plain language. Executive Order 14094 requires Federal agencies to increase and improve public participation in the regulatory process. The Executive order's objective is to improve public trust in the regulatory process by reducing the risk or appearance of unequal or unfair influence in regulatory development. Under Executive Order 14904, agencies must, to the extent they can under law, seek out, assist with, and include your input in the regulatory process. We welcome comments from public (State, local, Tribal, and territorial) and private sector regulated entities; members of underserved communities; consumers; workers and labor organizations; businesses; and program beneficiaries, among others. In addition to your substantive comments on this rule, we invite your comments on how to make the rule easier to understand. For example:</P>
                <P>• Are the requirements in the rule clearly stated? Are the scope and intent of the rule clear?</P>
                <P>• Does the rule contain technical language or jargon that is not clear?</P>
                <P>• Is the material logically organized?</P>
                <P>• Would changing the grouping or order of sections or adding headings make the rule easier to understand?</P>
                <P>
                    • Could we improve clarity by adding tables, lists, or diagrams?
                    <PRTPAGE P="93466"/>
                </P>
                <P>• Would more, but shorter, sections be better? Are there specific sections that are too long or confusing?</P>
                <P>• What else could we do to make the rule easier to understand?</P>
                <HD SOURCE="HD1">Environmental Review</HD>
                <P>The environmental impacts of this final rule have been considered in a manner consistent with the provisions of the National Environmental Policy Act (NEPA, 42 U.S.C. 4321-4347), the regulations of the Council on Environmental Quality (40 CFR parts 1500-1508), and because USDA will be making the payments to producers, the USDA regulation for compliance with NEPA (7 CFR part 1b). As specified in 7 CFR 1b.4(b)(4), FCIC is categorically excluded from the preparation of an Environmental Analysis or Environmental Impact Statement unless the FCIC Manager (agency head) determines that an action may have a significant environmental effect. The FCIC Manager has determined this rule will not have a significant environmental effect. Therefore, FCIC will not prepare an environmental assessment or environmental impact statement for this action and this rule serves as documentation of the programmatic environmental compliance decision.</P>
                <HD SOURCE="HD1">Executive Order 12988</HD>
                <P>This rule has been reviewed under Executive Order 12988, “Civil Justice Reform.” This rule will not preempt State or local laws, regulations, or policies unless they represent an irreconcilable conflict with this rule. Before any judicial actions may be brought regarding the provisions of this rule, the administrative appeal provisions of 7 CFR part 11 are to be exhausted. For good farming practice determinations, the administrative appeal provisions under 7 CFR part 11 do not apply.</P>
                <HD SOURCE="HD1">Executive Order 13175</HD>
                <P>This rule has been reviewed in accordance with the requirements of Executive Order 13175, “Consultation and Coordination with Indian Tribal Governments.” Executive Order 13175 requires Federal agencies to consult and coordinate with Tribes on a government-to-government basis on policies that have Tribal implications, including regulations, legislative comments or proposed legislation, and other policy statements or actions that have substantial direct effects on one or more Indian Tribes, on the relationship between the Federal Government and Indian Tribes or on the distribution of power and responsibilities between the Federal Government and Indian Tribes.</P>
                <P>RMA has assessed the impact of this rule on Indian Tribes and determined that this rule does not, to our knowledge, have Tribal implications that require Tribal consultation under E.O. 13175. The regulation changes do not have Tribal implications that preempt Tribal law and are not expected have a substantial direct effect on one or more Indian Tribes. If a Tribe requests consultation, RMA will work with the USDA Office of Tribal Relations to ensure meaningful consultation is provided where changes, additions and modifications identified in this rule are not expressly mandated by Congress.</P>
                <HD SOURCE="HD1">The Unfunded Mandates Reform Act of 1995</HD>
                <P>Title II of the Unfunded Mandates Reform Act of 1995 (UMRA, Pub. L. 104-4) requires Federal agencies to assess the effects of their regulatory actions of State, local, and Tribal governments or the private sector. Agencies generally must prepare a written statement, including cost benefits analysis, for proposed and final rules with Federal mandates that may result in expenditures of $100 million or more in any 1 year for State, local or Tribal governments, in the aggregate, or to the private sector. UMRA generally requires agencies to consider alternatives and adopt the more cost effective or least burdensome alternative that achieves the objectives of the rule. This rule contains no Federal mandates, as defined in Title II of UMRA, for State, local, and Tribal governments or the private sector. Therefore, this rule is not subject to the requirements of sections 202 and 205 of UMRA.</P>
                <HD SOURCE="HD1">Federal Assistance Program</HD>
                <P>The title and number of the Assistance Listing, to which this rule applies is No. 10.450—Crop Insurance.</P>
                <HD SOURCE="HD1">Paperwork Reduction Act of 1995</HD>
                <P>In accordance with the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. chapter 35, subchapter I), the rule does not change the information collection approved by OMB under control numbers 0563-0053 and 0563-0083.</P>
                <HD SOURCE="HD1">USDA Non-Discrimination Policy</HD>
                <P>In accordance with Federal civil rights law and USDA civil rights regulations and policies, USDA, its Agencies, offices, and employees, and institutions participating in or administering USDA programs are prohibited from discriminating based on race, color, national origin, religion, sex, gender identity (including gender expression), sexual orientation, disability, age, marital status, family or parental status, income derived from a public assistance program, political beliefs, or reprisal or retaliation for prior civil rights activity, in any program or activity conducted or funded by USDA (not all bases apply to all programs). Remedies and complaint filing deadlines vary by program or incident.</P>
                <P>
                    Individuals who require alternative means of communication for program information (for example, braille, large print, audiotape, American Sign Language, etc.) should contact the responsible Agency or USDA TARGET Center at (202) 720-2600 (voice and text telephone (TTY)) or dial 711 for Telecommunications Relay Service (both voice and text telephone users can initiate this call from any telephone). Additionally, program information may be made available in languages other than English. To file a program discrimination complaint, complete the USDA Program Discrimination Complaint Form, AD-3027, found online at 
                    <E T="03">https://www.usda.gov/oascr/how-to-file-a-program-discrimination-complaint</E>
                     and at any USDA office or write a letter addressed to USDA and provide in the letter all the information requested in the form. To request a copy of the complaint form, call (866) 632-9992. Submit your completed form or letter to USDA by: (1) mail to: U.S. Department of Agriculture, Office of the Assistant Secretary for Civil Rights, 1400 Independence Avenue SW, Washington, DC 20250-9410; (2) fax: (202) 690-7442; or (3) email: 
                    <E T="03">program.intake@usda.gov.</E>
                </P>
                <P>USDA is an equal opportunity provider, employer, and lender.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects</HD>
                    <CFR>7 CFR Part 407</CFR>
                    <P>Acreage allotments, Administrative practice and procedure, Barley, Corn, Cotton, Crop insurance, Peanuts, Reporting and recordkeeping requirements, Sorghum, Soybeans, Wheat.</P>
                    <CFR>7 CFR Part 457</CFR>
                    <P>Acreage allotments, Crop insurance, Reporting and recordkeeping requirements.</P>
                </LSTSUB>
                <HD SOURCE="HD1">Final Rule</HD>
                <P>For the reasons discussed above, FCIC amends 7 CFR parts 407 and 457, effective for the 2025 and succeeding crop years for crops with a contract change date on or after November 30, 2024, and for the 2026 and succeeding crop years for all other crops, as follows:</P>
                <PART>
                    <PRTPAGE P="93467"/>
                    <HD SOURCE="HED">PART 407—AREA RISK PROTECTION INSURANCE REGULATIONS</HD>
                </PART>
                <REGTEXT TITLE="7" PART="407">
                    <AMDPAR>1. The authority citation for part 407 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P>7 U.S.C. 1506(l) and 1506(o).</P>
                    </AUTH>
                </REGTEXT>
                <REGTEXT TITLE="7" PART="407">
                    <AMDPAR>2. Amend § 407.9 as follows:</AMDPAR>
                    <AMDPAR>a. In section 5, in paragraph (c)(3), remove the words “stated in section 5(c)” and add “stated in section 5(c)(2)” in their place; and</AMDPAR>
                    <AMDPAR>b. In section 7, in paragraph (d)(2), remove “;” at the end of the paragraph and add in its place “; and”.</AMDPAR>
                </REGTEXT>
                <PART>
                    <HD SOURCE="HED">PART 457—COMMON CROP INSURANCE REGULATIONS</HD>
                </PART>
                <REGTEXT TITLE="7" PART="457">
                    <AMDPAR>3. The authority citation for 7 CFR part 457 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P>7 U.S.C. 1506(l), 1506(o).</P>
                    </AUTH>
                </REGTEXT>
                <REGTEXT TITLE="7" PART="457">
                    <AMDPAR>4. In § 457.8, in the “Common Crop Insurance Policy”, section 3, in paragraph (i) introductory text, remove the words “not applicable” and add “(not applicable” in their place.</AMDPAR>
                </REGTEXT>
                <REGTEXT TITLE="7" PART="457">
                    <AMDPAR>5. Amend § 457.101 as follows:</AMDPAR>
                    <AMDPAR>a. Revise the introductory text and the undesignated text at the beginning of the “Small Grain Crop Provisions”;</AMDPAR>
                    <AMDPAR>b. In section 2, in paragraph (b) remove the phrase “initially-planted” and add the phrase “initially planted” in its place;</AMDPAR>
                    <AMDPAR>c. In section 3, revise paragraphs (a), (b) introductory text, and (b)(1);</AMDPAR>
                    <AMDPAR>d. In section 5, in the table, remove the word “thereof” wherever it appears and add the words “of the named counties” in its place;</AMDPAR>
                    <AMDPAR>e. In section 6 in paragraph (c)(2), remove the phrase “set forth herein” and add the phrase “described in these Crop Provisions” in its place;</AMDPAR>
                    <AMDPAR>f. In section 7 in paragraph (a) introductory text, remove the word “thereof” and add the words “of a unit” in its place;</AMDPAR>
                    <AMDPAR>g. In section 9:</AMDPAR>
                    <AMDPAR>i. In paragraph (c)(2)(i), remove the phrase “flax or”; and</AMDPAR>
                    <AMDPAR>ii. In paragraph (c)(2)(ii), add the phrase “, flax” after the word “barley”;</AMDPAR>
                    <AMDPAR>h. In section 11:</AMDPAR>
                    <AMDPAR>i. In paragraph (b)(1)(i), add the phrase “, flax” after the word “barley”;</AMDPAR>
                    <AMDPAR>ii. In paragraph (b)(1)(ii), remove the phrase “flax or”;</AMDPAR>
                    <AMDPAR>iii. In paragraph (b)(1)(iii), add the phrase “, flax” after the word “barley”;</AMDPAR>
                    <AMDPAR>iv. In paragraph (b)(3)(i), add the phrase “, flax” after the word “barley”;</AMDPAR>
                    <AMDPAR>v. In paragraph (b)(3)(ii), remove the phrase “flax or”;</AMDPAR>
                    <AMDPAR>vi. Revise paragraph (c)(1)(i);</AMDPAR>
                    <AMDPAR>vii. In paragraph (d)(2)(i)(A), remove the phrase “smutty, and ergoty” and add the phrase “smutty, or ergoty” in its place;</AMDPAR>
                    <AMDPAR>viii. In paragraph (d)(2)(i)(E), remove the word “Flaxseed” and add the word “Flax” in its place; and</AMDPAR>
                    <AMDPAR>ix. In paragraph (d)(2)(ii), remove the phrase “smutty, and ergoty” and add the phrase “smutty, or ergoty” in its place.</AMDPAR>
                    <P>The revisions and additions read as follows:</P>
                    <SECTION>
                        <SECTNO>§ 457.101</SECTNO>
                        <SUBJECT>Small grain crop insurance provisions.</SUBJECT>
                        <P>The Small Grain Crop Insurance Provisions for the 2025 and succeeding crop years for crops with a contract change date on or after November 30, 2024, and for the 2026 and succeeding crop years with a contract change date prior to November 30, 2024, are as follows:</P>
                        <FP SOURCE="FP-1">United States Department of Agriculture</FP>
                        <FP SOURCE="FP-1">Federal Crop Insurance Corporation</FP>
                        <FP SOURCE="FP-1">Small Grain Crop Provisions</FP>
                        <P>In return for your payment of premium and administrative fee for coverage, these Small Grains Crop Provisions and corresponding Commodity Exchange Price Provisions will be attached to and made part of the Common Crop Insurance Policy, Basic Provisions (Basic Provisions) subject to the terms and conditions in your policy.</P>
                        <STARS/>
                        <HD SOURCE="HD3">3. Insurance Guarantees, Coverage Levels, and Prices</HD>
                        <P>(a) Revenue protection is not available for your buckwheat. Therefore, if you elect to insure such crop by the sales closing date, it will only be protected against a loss in yield.</P>
                        <P>(b) Revenue protection is available for barley, flax, oats, rye, and wheat. Therefore, if you elect to insure your barley, flax, oats, rye, or wheat:</P>
                        <P>(1) You must elect to insure your barley, flax, oats, rye, or wheat with either revenue protection or yield protection by the sales closing date; and</P>
                        <STARS/>
                        <HD SOURCE="HD3">11. Settlement of Claim</HD>
                        <STARS/>
                        <P>(c) * * *</P>
                        <P>(1) * * *</P>
                        <P>(i) For buckwheat, and for barley, flax, oats, rye, or wheat under yield protection, not less than the production guarantee (per acre), and for barley, flax, oats, rye, or wheat under revenue protection, not less than the amount of production that when multiplied by the harvest price equals the revenue protection guarantee (per acre) for acreage:</P>
                        <STARS/>
                    </SECTION>
                </REGTEXT>
                <REGTEXT TITLE="7" PART="457">
                    <AMDPAR>6. Amend § 457.133 as follows:</AMDPAR>
                    <AMDPAR>a. In the introductory text, remove the year “2025” and add the year “2026” in its place;</AMDPAR>
                    <AMDPAR>b. In section 1, revise the definition of “Standard prunes”.</AMDPAR>
                    <P>The revisions read as follows:</P>
                    <SECTION>
                        <SECTNO>§ 457.133</SECTNO>
                        <SUBJECT>Prune crop insurance provisions.</SUBJECT>
                        <STARS/>
                        <P>Definitions</P>
                        <STARS/>
                        <P>
                            <E T="03">Standard prunes.</E>
                             Any natural condition prunes:
                        </P>
                        <P>(1) That grade “C,” “U.S. Standard,” or better in accordance with the United States Standards for Grades of Dried Prunes; or</P>
                        <P>(2) That meet or exceed the grade standards in effect for the crop year if a Marketing Order for California Prunes has been established for the area in which the insured crop is grown.</P>
                        <STARS/>
                    </SECTION>
                </REGTEXT>
                <REGTEXT TITLE="7" PART="457">
                    <AMDPAR>7. Amend § 457.137 as follows:</AMDPAR>
                    <AMDPAR>a. Revise the introductory text and the undesignated text at the beginning of the “Green Pea Crop Provisions”;</AMDPAR>
                    <AMDPAR>b. In section 1:</AMDPAR>
                    <AMDPAR>i. Revise the definition of “Good farming practices”;</AMDPAR>
                    <AMDPAR>ii. In the definition of “Planted acreage,” remove the word “contained”;</AMDPAR>
                    <AMDPAR>iii. Revise the definitions of “Practical to replant” and “Price election”; and</AMDPAR>
                    <AMDPAR>iv. In the definition of “Processor contract,” remove the phrase “A written agreement” and add the phrase “A written contract” in its place;</AMDPAR>
                    <AMDPAR>c. In section 2:</AMDPAR>
                    <AMDPAR>i. In paragraph (a)(1), remove the word “contained”; and</AMDPAR>
                    <AMDPAR>ii. Revise paragraphs (a)(2) and (b);</AMDPAR>
                    <AMDPAR>d. In section 3:</AMDPAR>
                    <AMDPAR>i. Revise the section heading;</AMDPAR>
                    <AMDPAR>ii. In paragraph (a), remove the phrase “Special Provisions” and add the phrase “actuarial documents” in its place;</AMDPAR>
                    <AMDPAR>e. In section 5, in the table, replace the words “Feb.” and “Mar.” and add the words “February” and “March”, respectively, in their place;</AMDPAR>
                    <AMDPAR>f. In section 6, remove the phrase “the provisions of”;</AMDPAR>
                    <AMDPAR>g. In section 8, introductory paragraph, remove the phrase “the provisions of”;</AMDPAR>
                    <AMDPAR>h. In section 9, introductory paragraph, remove the phrase “the provisions contained in”;</AMDPAR>
                    <AMDPAR>i. In section 10:</AMDPAR>
                    <AMDPAR>i. In the introductory paragraph, remove the phrase “the provisions of”;</AMDPAR>
                    <AMDPAR>ii. In paragraph (a)(4), remove the word “contained”; and</AMDPAR>
                    <AMDPAR>iii. In paragraph (a)(8), remove the word “contained”;</AMDPAR>
                    <AMDPAR>
                        j. In section 11, in paragraph (c), remove the phrase “15 day period” and 
                        <PRTPAGE P="93468"/>
                        add the phrase “15-day period” in its place; and
                    </AMDPAR>
                    <AMDPAR>k. In section 12, revise paragraph (b)(7).</AMDPAR>
                    <P>The revisions and additions read as follows:</P>
                    <SECTION>
                        <SECTNO>§ 7 CFR 457.137</SECTNO>
                        <SUBJECT>Green pea crop insurance provisions.</SUBJECT>
                        <P>The Green Pea Crop Insurance Provisions for the 2025 and succeeding crop years are as follows:</P>
                        <FP SOURCE="FP-1">United States Department of Agriculture</FP>
                        <FP SOURCE="FP-1">Federal Crop Insurance Corporation.</FP>
                        <FP SOURCE="FP-1">Green Pea Crop Provisions</FP>
                        <P>In return for your payment of premium and administrative fee for the coverage, these Green Pea Crop Provisions will be attached to and made part of the Common Crop Insurance Policy, Basic Provisions (Basic Provisions) subject to the terms and conditions in your policy.</P>
                        <STARS/>
                        <P>1. Definitions</P>
                        <STARS/>
                        <P>
                            <E T="03">Good farming practices.</E>
                             In addition to the definition of “good farming practices” in the Basic Provisions, the cultural practices required by the processor contract.
                        </P>
                        <STARS/>
                        <P>
                            <E T="03">Practical to replant.</E>
                             In addition to the definition of “practical to replant” in the Basic Provisions, practical to replant is defined as our determination, after loss or damage to the insured crop, based on factors including, but not limited to, moisture availability, and marketing window, that replanting the insured crop will allow the crop to attain maturity prior to the calendar date for the end of the insurance period. It will not be considered practical to replant unless the replanted acreage can produce at least 75 percent of the approved yield, and the processor agrees in writing that it will accept the production from the replanted acreage.
                        </P>
                        <P>
                            <E T="03">Price election.</E>
                             In lieu of the definition of “price election” in the Basic Provisions, price election is defined as the price per pound stated in the processor contract (contracted price) for the tenderometer reading, grade factor, or sieve size contained in the Special Provisions.
                        </P>
                        <STARS/>
                        <HD SOURCE="HD3">Unit Division</HD>
                        <P>(a) * * *</P>
                        <P>(2) Optional units may be established by:</P>
                        <P>(i) Organic and non-organic farming practices as provided in Section 34(c)(3) of the Basic Provisions; or</P>
                        <P>(ii) Shell type and pod type for green peas if the shell type acreage does not continue into the pod type acreage in the same rows or planting pattern.</P>
                        <P>(b) For any processor contract that stipulates the number of acres to be planted, in addition to or instead of, establishing optional units as provided in Section 34(c) of the Basic Provisions, optional units may be established by the shell type and pod type for green peas if the shell type acreage does not continue into the pod type acreage in the same rows or planting pattern.</P>
                        <HD SOURCE="HD3">Insurance Guarantees, Coverage Levels, and Prices</HD>
                        <STARS/>
                        <HD SOURCE="HD3">12. Settlement of Claim</HD>
                        <STARS/>
                        <P>(b) * * *</P>
                        <P>(7) Multiplying the result of section 12(b)(6) by your share.</P>
                        <P>For example:</P>
                        <P>You have a 100 percent share in 100 acres of shell type green peas in the unit, with a guarantee of 4,000 pounds per acre and a price election of $0.15 per pound. You are only able to harvest 200,000 pounds. Your indemnity would be calculated as follows:</P>
                        <P>(1) 100 acres × 4,000 pounds = 400,000 pounds guarantee;</P>
                        <P>(2) 400,000 pounds × $0.15 price election = $60,000.00 value of guarantee;</P>
                        <P>(3) Not applicable;</P>
                        <P>(4) 200,000 pounds × $0.15 price election = $30,000.00 value of production to count;</P>
                        <P>(5) Not applicable;</P>
                        <P>(6) $60,000.00−$30,000.00 = $30,000.00 loss; and</P>
                        <P>(7) $30,000.00 × 100 percent = $30,000.00 indemnity payment.</P>
                        <P>You also have a 100 percent share in 100 acres of pod type green peas in the same unit, with a guarantee of 5,000 pounds per acre and a price election of $0.15 per pound. You are only able to harvest 450,000 pounds. Your total indemnity for both shell type and pod type green peas would be calculated as follows:</P>
                        <P>(1) 100 acres × 4,000 pounds = 400,000 pounds guarantee for the shell type, and 100 acres × 5,000 pounds = 500,000 pounds guarantee for the pod type;</P>
                        <P>(2) 400,000 pounds guarantee × $0.15 price election = $60,000.00 value of guarantee for the shell type, and 500,000 pounds guarantee × $0.15 price election = $75,000.00 value of guarantee for the pod type;</P>
                        <P>(3) $60,000.00 + $75,000.00 = $135,000.00 total value of guarantee;</P>
                        <P>(4) 200,000 pounds × $0.15 price election = $30,000.00 value of production to count for the shell type; and 450,000 pounds × $0.15 = $67,500.00 value of production to count for the pod type;</P>
                        <P>(5) $30,000.00 + $67,500.00 = $97,500.00 total value of production to count;</P>
                        <P>(6) $135,000.00—$97,500.00 = $37,500.00 loss; and</P>
                        <P>(7) $37,500.00 loss × 100 percent = $37,500.00 indemnity payment.</P>
                        <STARS/>
                    </SECTION>
                </REGTEXT>
                <REGTEXT TITLE="7" PART="457">
                    <AMDPAR>8. Amend § 457.142 as follows:</AMDPAR>
                    <AMDPAR>a. Revise the introductory text and the undesignated text at the beginning of the “Northern Potato Crop Provisions”;</AMDPAR>
                    <AMDPAR>b. In section 11, revise paragraph (e)(2).</AMDPAR>
                    <P>The revisions read as follows:</P>
                    <SECTION>
                        <SECTNO>§ 457.142</SECTNO>
                        <SUBJECT>Northern potato crop insurance provisions.</SUBJECT>
                        <P>The Northern Potato Crop Insurance Provisions for the 2025 and succeeding crop years in counties with a contract change date of November 30, and for the 2026 and succeeding crop years in counties with a contract change date of April 30, June 30, and September 30, are as follows:</P>
                        <FP SOURCE="FP-1">United States Department of Agriculture</FP>
                        <FP SOURCE="FP-1">Federal Crop Insurance Corporation</FP>
                        <FP SOURCE="FP-1">Northern Potato Crop Provisions</FP>
                        <P>In return for your payment of premium and administrative fee for the coverage, these Northern Potato Crop Provisions will be attached to and made part of the Common Crop Insurance Policy, Basic Provisions (Basic Provisions) subject to the terms and conditions in your policy.</P>
                        <P>These provisions will be applicable in: Alaska; Humboldt, Modoc, and Siskiyou Counties, California; Colorado; Connecticut; Idaho; Indiana; Iowa; Kansas; Maine; Massachusetts; Michigan; Minnesota; Montana; Nebraska; Nevada; San Juan County, New Mexico; New York; North Dakota; Ohio; Oregon; Pennsylvania; Rhode Island; South Dakota; Utah; Washington; Wisconsin; and Wyoming; and any other states or counties if allowed by the Special Provisions.</P>
                        <STARS/>
                        <HD SOURCE="HD3">11. Settlement of Claim</HD>
                        <STARS/>
                        <P>(e) * * *</P>
                        <P>(2) A grade inspection is completed no later than 21 days after the end of insurance period (if the Northern Potato Storage Coverage Endorsement is applicable, samples must be obtained within 60 days after the end of insurance period and quality (grade) determinations must be completed within 21 days of sampling; and</P>
                        <STARS/>
                    </SECTION>
                </REGTEXT>
                <REGTEXT TITLE="7" PART="457">
                    <PRTPAGE P="93469"/>
                    <AMDPAR>9. Amend § 457.147 as follows:</AMDPAR>
                    <AMDPAR>a. Revise the introductory text and the undesignated text at the beginning of the “Central and Southern Potato Crop Provisions”;</AMDPAR>
                    <AMDPAR>b. In section 12, revise the example after paragraph (b)(7) and before paragraph (c).</AMDPAR>
                    <P>The revision reads as follows:</P>
                    <SECTION>
                        <SECTNO>§ 457.147</SECTNO>
                        <SUBJECT>Central and Southern potato crop insurance provisions.</SUBJECT>
                        <P>The Central and Southern Potato Crop Insurance Provisions for the 2025 and succeeding crop years in counties with a contract change date of November 30, and for the 2026 and succeeding crop years in counties with a contract change date of April 30, June 30, and September 30, are as follows:</P>
                        <FP SOURCE="FP-1">United States Department of Agriculture</FP>
                        <FP SOURCE="FP-1">Federal Crop Insurance Corporation</FP>
                        <FP SOURCE="FP-1">Central and Southern Potato Crop Provisions</FP>
                        <P>In return for your payment of premium and administrative fee for the coverage, these Central and Southern Potato Crop Provisions will be attached to and made part of the Common Crop Insurance Policy, Basic Provisions (Basic Provisions) subject to the terms and conditions in your policy.</P>
                        <P>These provisions will be applicable in Alabama; Arizona; all California counties except Humboldt, Modoc, and Siskiyou; Delaware; Florida; Georgia; Maryland; Missouri; New Jersey; all New Mexico counties except San Juan; North Carolina; Oklahoma; Texas; and Virginia; and other states or counties if allowed by the Special Provisions.</P>
                        <STARS/>
                        <HD SOURCE="HD3">12. Settlement of Claim</HD>
                        <STARS/>
                        <P>(b) * * *</P>
                        <P>(7) * * *</P>
                        <P>For example: You have a 100 percent share in 100 harvested acres of potatoes in the unit, with a guarantee of 150 hundredweight per acre and a price election of $4.00 per hundredweight. You are only able to harvest 10,000 hundredweight. Your indemnity would be calculated as follows:</P>
                        <P>(1) 100 acres × 150 hundredweight = 15,000 hundredweight guarantee;</P>
                        <P>(2) 15,000 hundredweight × $4.00 price election = $60,000.00 value of guarantee;</P>
                        <P>(4) 10,000 hundredweight × $4.00 price election = $40,000.00 value of production to count;</P>
                        <P>(6) $60,000.00−$40,000.00 = $20,000.00 loss; and</P>
                        <P>(7) $20,000.00 × 100 percent = $20,000.00 indemnity payment.</P>
                        <P>You also have a 100 percent share in 100 unharvested acres of potatoes in the same unit, with a guarantee of 150 hundredweight per acre and a price election of $3.60 per hundredweight. (The price election for unharvested acreage is 90.0 percent of your elected price election ($4.00 × 0.90 = $3.60.)) This unharvested acreage was appraised at 35 hundredweight per acre for a total of 3,500 hundredweight as production to count. Your total indemnity for the harvested and unharvested acreage would be calculated as follows:</P>
                        <P>(1) 100 acres × 150 hundredweight = 15,000 hundredweight guarantee for the harvested acreage, and 100 acres × 150 hundredweight = 15,000 hundredweight guarantee for the unharvested acreage;</P>
                        <P>(2) 15,000 hundredweight guarantee × $4.00 price election = $60,000.00 value of guarantee for the harvested acreage, and 15,000 hundredweight guarantee × $3.60 price election = $54,000.00 value of guarantee for the unharvested acreage;</P>
                        <P>(3) $60,000.00 + $54,000.00 = $114,000.00 total value of guarantee;</P>
                        <P>(4) 10,000 hundredweight × $4.00 price election = $40,000.00 value of production to count for the harvested acreage, and 3,500 hundredweight × $3.60 = $12,600.00 value of production to count for the unharvested acreage;</P>
                        <P>(5) $40,000.00 + $12,600.00 = $52,600.00 total value of production to count;</P>
                        <P>(6) $114,000.00−$52,600.00 = $61,400.00 loss; and</P>
                        <P>(7) $61,400.00 loss × 100 percent = $61,400.00 indemnity payment.</P>
                        <STARS/>
                    </SECTION>
                </REGTEXT>
                <REGTEXT TITLE="7" PART="457">
                    <AMDPAR>10. In § 457.150, in the “Dry bean crop insurance provisions”, in section 7, revise paragraph (c) to read as follows:</AMDPAR>
                    <SECTION>
                        <SECTNO>§ 457.150</SECTNO>
                        <SUBJECT>Dry bean crop insurance provisions.</SUBJECT>
                        <STARS/>
                        <HD SOURCE="HD3">7. Insured Crop</HD>
                        <STARS/>
                        <P>(c) In addition to the types of dry beans designated in the Special Provisions, we will insure other types by written agreement if:</P>
                        <P>(1) The type you intend to plant has been demonstrated to be adapted to the area. Evidence of adaptability must include:</P>
                        <P>(i) Results of test plots for two years and recommendations by a university or seed company; or</P>
                        <P>(ii) Two years of production reports that indicate your experience producing the type in your production area;</P>
                        <P>(2) You submit your production reports and prices received, or the test plot results, and evidence of market potential, including the price buyers are willing to pay for the type; and</P>
                        <P>(3) Both parties (you and us) enter into a written agreement allowing insurance on the type in accordance with section 18 of the Basic Provisions.</P>
                        <STARS/>
                    </SECTION>
                </REGTEXT>
                <REGTEXT TITLE="7" PART="457">
                    <AMDPAR>11. Amend § 457.154 as follows:</AMDPAR>
                    <AMDPAR>a. Revise the introductory text and the undesignated text at the beginning of the “Processing Sweet Corn Crop Provisions”;</AMDPAR>
                    <AMDPAR>b. In section 2, revise paragraphs (a)(2) and (b); and</AMDPAR>
                    <AMDPAR>c. In section 11, in paragraph (c), remove the phrase “15 day period” and add the phrase “15-day period” in its place.</AMDPAR>
                    <P>The revisions read as follows:</P>
                    <SECTION>
                        <SECTNO>§ 457.154</SECTNO>
                        <SUBJECT>Processing sweet corn crop insurance provisions.</SUBJECT>
                        <P>The Processing Sweet Corn Crop Insurance Provisions for the 2025 and succeeding crop years are as follows:</P>
                        <FP SOURCE="FP-1">United States Department of Agriculture</FP>
                        <FP SOURCE="FP-1">Federal Crop Insurance Corporation.</FP>
                        <FP SOURCE="FP-1">Processing Sweet Corn Crop Provisions</FP>
                        <P>In return for your payment of premium and administrative fee for the coverage, these Processing Sweet Corn Crop Provisions will be attached to and made part of the Common Crop Insurance Policy, Basic Provisions (Basic Provisions) subject to the terms and conditions in your policy.</P>
                        <STARS/>
                        <HD SOURCE="HD3">2. Unit Division</HD>
                        <P>(a) * * *</P>
                        <P>(2) Section 34(c) of the Basic Provisions that allows optional units is not applicable.</P>
                        <P>(b) For processor contracts that stipulate the number of acres to be planted, optional units as provided in section 34(c) of the Basic Provisions will apply.</P>
                        <STARS/>
                    </SECTION>
                </REGTEXT>
                <REGTEXT TITLE="7" PART="457">
                    <AMDPAR>12. Amend § 457.166 as follows:</AMDPAR>
                    <AMDPAR>a. In the introductory text, remove the year “2025” and add the year “2026” in its place;</AMDPAR>
                    <AMDPAR>b. In section 1, revise the definition of “prune”.</AMDPAR>
                    <P>The revision reads as follows:</P>
                    <SECTION>
                        <SECTNO>§ 457.166</SECTNO>
                        <SUBJECT>Blueberry crop insurance provisions.</SUBJECT>
                        <STARS/>
                        <HD SOURCE="HD3">1. Definitions</HD>
                        <STARS/>
                        <P>
                            <E T="03">Prune.</E>
                             A cultural practice performed to increase blueberry production as follows:
                        </P>
                        <P>
                            (1) For lowbush blueberries, a process by which the acreage is either burned or mowed; and
                            <PRTPAGE P="93470"/>
                        </P>
                        <P>(2) For all other blueberries, a process by which parts of the bush are cut off or the bush is cut back.</P>
                        <STARS/>
                    </SECTION>
                </REGTEXT>
                <SIG>
                    <NAME>Marcia Bunger,</NAME>
                    <TITLE>Manager, Federal Crop Insurance Corporation.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27225 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3410-08-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF AGRICULTURE</AGENCY>
                <SUBAGY>Food Safety and Inspection Service</SUBAGY>
                <CFR>9 CFR Parts 317 and 381</CFR>
                <DEPDOC>[Docket No. FSIS-2022-0016]</DEPDOC>
                <RIN>RIN 0583-AD77</RIN>
                <SUBJECT>Uniform Compliance Date for Food Labeling Regulations</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food Safety and Inspection Service (FSIS), U.S. Department of Agriculture (USDA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final action.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>FSIS is establishing January 1, 2028, as the uniform compliance date for new meat and poultry product labeling regulations that will be issued between January 1, 2025, and December 31, 2026. FSIS periodically announces uniform compliance dates for new meat and poultry product labeling regulations to minimize the economic impact of label changes.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES: </HD>
                    <P>
                        <E T="03">Effective date:</E>
                         This action is effective November 27, 2024.
                    </P>
                    <P>
                        <E T="03">Compliance date:</E>
                         The uniform compliance date for new meat and poultry product labeling regulations that will be issued between January 1, 2025, and December 31, 2026, is January 1, 2028.
                    </P>
                    <P>
                        <E T="03">Comments due date:</E>
                         Comments on this final action must be received on or before December 27, 2024.
                    </P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>FSIS invites interested persons to submit comments on this rule. Comments may be submitted by one of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                         This website provides the ability to type short comments directly into the comment field on this web page or attach a file for lengthier comments. Go to 
                        <E T="03">https://www.regulations.gov.</E>
                         Follow the on-line instructions at that site for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail:</E>
                         Send to Docket Clerk, U.S. Department of Agriculture, Food Safety and Inspection Service, 1400 Independence Avenue SW, Mailstop 3758, Washington, DC 20250-3700.
                    </P>
                    <P>
                        • 
                        <E T="03">Hand- or Courier-Delivered Submittals:</E>
                         Deliver to 1400 Independence Avenue SW, Jamie L. Whitten Building, Room 350-E, Washington, DC 20250-3700.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All items submitted by mail or electronic mail must include the Agency name and docket number FSIS-2022-0016. Comments received in response to this docket will be made available for public inspection and posted without change, including any personal information, to 
                        <E T="03">https://www.regulations.gov.</E>
                    </P>
                    <P>
                        <E T="03">Docket:</E>
                         For access to background documents or comments received, call 202-720-5046 to schedule a time to visit the FSIS Docket Room at 1400 Independence Avenue SW, Washington, DC 20250-3700.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Contact Rosalyn Murphy-Jenkins, Director, Labeling and Program Delivery Staff, Office of Policy and Program Development, Food Safety and Inspection Service, U.S. Department of Agriculture, Telephone: (301) 504-0878.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>On December 14, 2004, FSIS issued a final rule establishing January 1, 2008, as the uniform compliance date for new meat and poultry labeling regulations issued between January 1, 2005, and December 31, 2006 (69 FR 74405). The 2004 final rule also provided that the Agency would set uniform compliance dates for new labeling regulations in 2-year increments and periodically issue final rules announcing and requesting comments on those dates. Consistent with the 2004 final rule, the Agency has since published nine rules establishing the uniform compliance dates of January 1, 2010, January 1, 2012, January 1, 2014, January 1, 2016, January 1, 2018, January 1, 2020, January 1, 2022, January 1, 2024, and January 1, 2026 (72 FR 9651, 73 FR 75564, 75 FR 71344, 77 FR 76824, 79 FR 71007, 81 FR 91670, 83 FR 63052, 85 FR 81339, and 87 FR 77707).</P>
                <HD SOURCE="HD1">The Final Rule</HD>
                <P>The new uniform compliance date will apply only to final FSIS regulations that require changes in the labeling of meat and poultry products and that are published after January 1, 2025, and before December 31, 2026. For each final rule that requires changes in labeling, FSIS will specifically identify January 1, 2028, as the compliance date. All meat and poultry food products that are subject to labeling regulations issued between January 1, 2025, and December 31, 2026, will be required to comply with these regulations on products introduced into commerce on or after January 1, 2028. If any food labeling regulation involves special circumstances that justify a compliance date other than January 1, 2028, the Agency will determine an appropriate compliance date and will publish that compliance date in the rulemaking.</P>
                <P>Two-year increments increase industry's ability to make orderly adjustments to new labeling requirements without exposing consumers to outdated labels. This approach allows meat and poultry producers to plan for the use of label inventories and to develop new labeling materials that meet the new requirements. It also serves to reduce the economic impact of changing labels on both producers and consumers.</P>
                <P>In the March 5, 2007, final rule, FSIS received only four comments on the announced uniform compliance dates, all in support. In the March 5, 2007, final rule, FSIS determined that further rulemaking for uniform compliance dates for labeling requirements is unnecessary (72 FR 9651). The Agency received no comments on the 2007 final rule, the comments FSIS received on the 2012 final rule were outside the scope (77 FR 76824), and FSIS received no comments on the 2014 final rule (79 FR 71007) or the 2016 final rule (81 FR 91670). The Agency received four comments on the 2018 final rule (83 FR 63052), all in support. The Agency received four comments on the 2020 final rule (85 FR 81339); one was outside the scope of the rulemaking and three were in support of the rule. The Agency received two comments on the 2022 final rule (87 FR 77707); one was in support of the rule, and one requested a 90-day extension because of potential supply chain issues for self-adhesive label materials. Because the commenter did not provide any additional information to support their claim about supply shortages and no other members of industry expressed concerns about a shortage, FSIS did not change the uniform compliance date.</P>
                <P>Consistent with its statement in 2007, FSIS finds that further rulemaking on this matter is unnecessary. However, FSIS is providing an opportunity for comment on the uniform compliance date established in this final rule.</P>
                <HD SOURCE="HD1">Executive Orders 12866 and 13563, and the Regulatory Flexibility Act</HD>
                <P>
                    Executive Orders (E.O.) 12866 (as amended by E.O. 14094) and 13563 direct agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, 
                    <PRTPAGE P="93471"/>
                    environmental, public health and safety effects, distributive impacts, and equity). E.O. 13563 emphasizes the importance of quantifying both costs and benefits, of reducing costs, of harmonizing rules, and of promoting flexibility. This final rule has been designated as a “non-significant” regulatory action under section 3(f) of E.O. 12866. Accordingly, the final rule has not been reviewed by the Office of Management and Budget (OMB) under E.O. 12866.
                </P>
                <P>This rule does not have a significant economic impact on a substantial number of small entities; consequently, a regulatory flexibility analysis is not required (5 U.S.C. 601-612).</P>
                <HD SOURCE="HD1">Paperwork Reduction Act</HD>
                <P>FSIS has reviewed this rule under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520) and has determined that there is no new information collection related to this final rule. Under this final rule, the Agency is establishing January 1, 2028, as the uniform compliance date for new meat and poultry product labeling regulations that will be issued between January 1, 2025, and December 31, 2026. The relevant information collection or record keeping requirements are covered under OMB approval number 0583-0092, Marking, Labeling, and Packaging.</P>
                <HD SOURCE="HD1">E-Government Act</HD>
                <P>
                    FSIS and USDA are committed to achieving the purposes of the E-Government Act (44 U.S.C. 3601, 
                    <E T="03">et seq.</E>
                    ) by, among other things, promoting the use of the internet and other information technologies and providing increased opportunities for citizen access to Government information and services, and for other purposes.
                </P>
                <HD SOURCE="HD1">Executive Order 12988, Civil Justice Reform</HD>
                <P>This final action has been reviewed under E.O. 12988, Civil Justice Reform. Under this rule: (1) All State and local laws and regulations that are inconsistent with this action will be preempted; (2) no retroactive effect will be given to this action; and (3) no administrative proceedings will be required before parties may file suit in court challenging this rule. However, parties may be required to exhaust their administrative remedies before challenging in court any specific agency action that is the subject of an appeal pursuant to this action.</P>
                <HD SOURCE="HD1">Executive Order 13175</HD>
                <P>This rule has been reviewed in accordance with the requirements of E.O. 13175, “Consultation and Coordination with Indian Tribal Governments.” E.O. 13175 requires Federal agencies to consult and coordinate with tribes on a government-to-government basis on policies that have tribal implications, including regulations, legislative comments or proposed legislation, and other policy statements or actions that have substantial direct effects on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes or on the distribution of power and responsibilities between the Federal Government and Indian tribes.</P>
                <P>FSIS has assessed the impact of this action on Indian tribes and determined that this rule does not, to our knowledge, have tribal implications that require tribal consultation under E.O. 13175. If a tribe requests consultation, FSIS will work with the Office of Tribal Relations to ensure meaningful consultation is provided where changes, additions, and modifications identified herein are not expressly mandated by Congress.</P>
                <HD SOURCE="HD1">Additional Public Notification</HD>
                <P>
                    Public awareness of all segments of rulemaking and policy development is important. Consequently, FSIS will announce this 
                    <E T="04">Federal Register</E>
                     publication on-line through the FSIS web page located at: 
                    <E T="03">https://www.fsis.usda.gov/federal-register.</E>
                </P>
                <P>
                    FSIS will also announce and provide a link to it through the FSIS 
                    <E T="03">Constituent Update,</E>
                     which is used to provide information regarding FSIS policies, procedures, regulations, 
                    <E T="04">Federal Register</E>
                     notices, FSIS public meetings, and other types of information that could affect or would be of interest to our constituents and stakeholders. The 
                    <E T="03">Constituent Update</E>
                     is available on the FSIS web page. Through the web page, FSIS is able to provide information to a much broader, more diverse audience. In addition, FSIS offers an email subscription service which provides automatic and customized access to selected food safety news and information. This service is available at: 
                    <E T="03">http://www.fsis.usda.gov/subscribe.</E>
                     Options range from recalls to export information, regulations, directives, and notices. Customers can add or delete subscriptions themselves and have the option to password protect their accounts.
                </P>
                <HD SOURCE="HD1">USDA's Non-Discrimination Statement</HD>
                <P>In accordance with Federal civil rights law and USDA civil rights regulations and policies, USDA, its Mission Areas, agencies, staff offices, employees, and institutions participating in or administering USDA programs are prohibited from discriminating based on race, color, national origin, religion, sex, gender identity (including gender expression), sexual orientation, disability, age, marital status, family/parental status, income derived from a public assistance program, political beliefs, or reprisal or retaliation for prior civil rights activity, in any program or activity conducted or funded by USDA (not all bases apply to all programs). Remedies and complaint filing deadlines vary by program or incident.</P>
                <P>
                    Program information may be made available in languages other than English. Persons with disabilities who require alternative means of communication to obtain program information (
                    <E T="03">e.g.,</E>
                     Braille, large print, audiotape, American Sign Language) should contact the responsible Mission Area, agency, or staff office; the USDA TARGET Center at (202) 720-2600 (voice and TTY); or the Federal Relay Service at (800) 877-8339.
                </P>
                <P>
                    To file a program discrimination complaint, a complainant should complete a Form AD-3027, USDA Program Discrimination Complaint Form, which can be obtained online at 
                    <E T="03">https://www.usda.gov/forms/electronic-forms,</E>
                     from any USDA office, by calling (866) 632-9992, or by writing a letter addressed to USDA. The letter must contain the complainant's name, address, telephone number, and a written description of the alleged discriminatory action in sufficient detail to inform the Assistant Secretary for Civil Rights about the nature and date of an alleged civil rights violation. The completed AD-3027 form or letter must be submitted to USDA by:
                </P>
                <P>
                    (1) 
                    <E T="03">Mail:</E>
                     U.S. Department of Agriculture, Office of the Assistant Secretary for Civil Rights, 1400 Independence Avenue SW, Washington, DC 20250-9410;
                </P>
                <P>
                    (2) 
                    <E T="03">Fax:</E>
                     (833) 256-1665 or (202) 690-7442; or
                </P>
                <P>
                    (3) 
                    <E T="03">Email: program.intake@usda.gov.</E>
                </P>
                <P>USDA is an equal opportunity provider, employer, and lender.</P>
                <SIG>
                    <P>Done in Washington, DC.</P>
                    <NAME>Paul Kiecker,</NAME>
                    <TITLE>Administrator.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27864 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3410-DM-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <PRTPAGE P="93472"/>
                <AGENCY TYPE="N">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2024-2020; Project Identifier MCAI-2024-00303-A; Amendment 39-22877; AD 2024-22-06]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; Embraer S.A. Airplanes</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The FAA is superseding Airworthiness Directive (AD) 2023-21-06 for certain Embraer S.A. (Embraer) Model EMB-505 airplanes. AD 2023-21-06 required installing structural reinforcements on certain monuments and replacing certain floor support rivets. Since the FAA issued AD 2023-21-06, the FAA determined that certain airplanes need to be re-assigned to a different group and certain re-identified floor support part numbers need to be corrected. This AD requires installing structural reinforcements on monuments and replacing fasteners on the floor support, as specified in an Agência Nacional de Aviação Civil (ANAC) AD, which is incorporated by reference. The FAA is issuing this AD to address the unsafe condition on these products.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This AD is effective January 2, 2025.</P>
                    <P>The Director of the Federal Register approved the incorporation by reference of a certain publication listed in this AD as of January 2, 2025.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2024-2020; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this final rule, the mandatory continuing airworthiness information (MCAI), any comments received, and other information. The address for Docket Operations is U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                    <P>
                        <E T="03">Material Incorporated by Reference:</E>
                    </P>
                    <P>
                        • For ANAC material identified in this AD, contact ANAC, Continuing Airworthiness Technical Branch (GTAC), Rua Doutor Orlando Feirabend Filho, 230—Centro Empresarial Aquarius—Torre B—Andares 14 a 18, Parque Residencial Aquarius, CEP 12.246-190—São José dos Campos—SP, Brazil; phone: 55 (12) 3203-6600; email: 
                        <E T="03">pac@anac.gov.br;</E>
                         website: 
                        <E T="03">anac.gov.br/en/.</E>
                         You may find this material on the ANAC website at 
                        <E T="03">sistemas.anac.gov.br/certificacao/DA/DAE.asp.</E>
                    </P>
                    <P>
                        • You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 901 Locust, Kansas City, MO 64106. For information on the availability of this material at the FAA, call (817) 222-5110. It is also available at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2024-2020.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Jim Rutherford, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (816) 329-4165; email: 
                        <E T="03">jim.rutherford@faa.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <P>The FAA issued a notice of proposed rulemaking (NPRM) to amend 14 CFR part 39 to supersede AD 2023-21-06, Amendment 39-22578 (88 FR 76114, November 6, 2023; corrected December 7, 2023 (88 FR 85093)) (AD 2023-21-06). AD 2023-21-06 applied to certain serial-numbered Embraer Model EMB-505 airplanes. AD 2023-21-06 was prompted by an MCAI originated by ANAC, which is the aviation authority for Brazil. ANAC issued ANAC AD 2023-05-03, effective June 2, 2023 (ANAC AD 2023-05-03) to correct an unsafe condition.</P>
                <P>AD 2023-21-06 required installing structural reinforcements on certain monuments and replacing certain floor support rivets. The FAA issued AD 2023-21-06 to address certain monuments (the right-hand refreshment center and left-hand forward cabinet) that might not withstand the loads expected for specific emergency landing conditions, which may cause the detachment of mass items and result in injuries to the airplane occupants.</P>
                <P>Since the FAA issued AD 2023-21-06, ANAC superseded ANAC AD 2023-05-03 and issued ANAC AD 2023-05-03R01, effective March 8, 2024 (ANAC AD 2023-05-03R01) for certain serial-numbered Embraer Model EMB-505 airplanes. ANAC AD 2023-05-03R01 stated it was issued to incorporate Embraer Service Bulletin SB505-25-0046, Revision 02, dated February 19, 2024, which updates effectivity information, compliance information, and part number information.</P>
                <P>ANAC superseded ANAC AD 2023-05-03R01 and issued ANAC AD 2023-05-03R02, effective May 17, 2024 (ANAC AD 2023-05-03R02) (also referred to as the MCAI) for certain serial-numbered Embraer Model EMB-505 airplanes. The MCAI states it was issued to incorporate Embraer Service Bulletin SB505-25-0046, Revision 03, dated May 6, 2024 (actual date May 7, 2024), which includes additional actions for certain airplane groups that had complied with the requirements of ANAC AD 2023-05-03R01 but had not yet installed part number 506-66837-001 and updates the effectivity information, compliance information, and part number information.</P>
                <P>
                    The NPRM published in the 
                    <E T="04">Federal Register</E>
                     on August 16, 2024 (89 FR 66642). The NPRM was prompted by ANAC AD 2023-05-03R02. In the NPRM, the FAA proposed to require installing structural reinforcements on monuments and replacing fasteners on the floor support, as specified in ANAC AD 2023-05-03R02.
                </P>
                <P>The FAA is issuing this AD to address certain monuments that might not withstand the loads expected for specific emergency landing conditions, which may cause the detachment of mass items and result in injuries to the airplane occupants.</P>
                <P>
                    You may examine the MCAI in the AD docket at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA-2024-2020.
                </P>
                <HD SOURCE="HD1">Discussion of Final Airworthiness Directive</HD>
                <HD SOURCE="HD1">Comments</HD>
                <P>The FAA received no comments on the NPRM or on the determination of the costs.</P>
                <HD SOURCE="HD1">Conclusion</HD>
                <P>These products have been approved by the aviation authority of another country and are approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, it has notified the FAA of the unsafe condition described in the MCAI referenced above. The FAA reviewed the relevant data and determined that air safety requires adopting this AD as proposed. Accordingly, the FAA is issuing this AD to address the unsafe condition on these products. This AD is adopted as proposed in the NPRM.</P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>The FAA reviewed ANAC AD 2023-05-03R02, which specifies procedures for installing structural reinforcements on certain monuments and replacing certain fasteners on the floor support.</P>
                <P>
                    This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in 
                    <E T="02">ADDRESSES</E>
                    .
                    <PRTPAGE P="93473"/>
                </P>
                <HD SOURCE="HD1">Differences Between This AD and the MCAI</HD>
                <P>The material specified in ANAC AD 2023-05-03R02 allows the use of alternative or similar parts in place of the ones specified in the kits, provided these alternative or similar parts are approved by Embraer, but this AD requires approval from either the Manager, International Validation Branch, FAA; ANAC; or ANAC's authorized Designee. If approved by the ANAC Designee, the approval must include the Designee's authorized signature.</P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>The FAA estimates that this AD affects 208 airplanes of U.S. registry.</P>
                <P>The FAA estimates the following costs to comply with this AD:</P>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s100,r50,10,8,xs100">
                    <TTITLE>Estimated Costs</TTITLE>
                    <BOXHD>
                        <CHED H="1">Action</CHED>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">
                            Cost per
                            <LI>product</LI>
                        </CHED>
                        <CHED H="1">Cost on U.S. operators</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Airplane groups 1 and 2—install structural reinforcements</ENT>
                        <ENT>22 work-hours × $85 per hour = $1,870</ENT>
                        <ENT>$1,600</ENT>
                        <ENT>$3,470</ENT>
                        <ENT>$242,900 (70 airplanes).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Airplane groups 3, 4, and 5—install structural reinforcements and replace floor fasteners</ENT>
                        <ENT>14 work-hours × $85 per hour = $1,190</ENT>
                        <ENT>600</ENT>
                        <ENT>1,790</ENT>
                        <ENT>$200,480 (112 airplanes).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Airplane groups 6 and 8—install structural reinforcements and replace floor fasteners</ENT>
                        <ENT>26 work-hours × $85 per hour = $2,210</ENT>
                        <ENT>2,000</ENT>
                        <ENT>4,210</ENT>
                        <ENT>$84,200 (20 airplanes).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Airplane group 7—install structural reinforcements</ENT>
                        <ENT>20 work-hours × $85 per hour = $1,700</ENT>
                        <ENT>1,600</ENT>
                        <ENT>3,300</ENT>
                        <ENT>$16,500 (5 airplanes).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Airplane group 9—install structural reinforcements</ENT>
                        <ENT>14 work-hours × $85 per hour = $1,190</ENT>
                        <ENT>1,600</ENT>
                        <ENT>2,790</ENT>
                        <ENT>$2,790 (1 airplane).</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The FAA estimates the following costs for the additional work that operators would be required to do for compliance with this AD if they completed the actions in the original version of Embraer Service Bulletin SB505-25-0046, dated March 31, 2021; Service Bulletin SB505-25-0046, Revision 01, dated May 8, 2023; or Service Bulletin SB505-25-0046, Revision 02, dated February 19, 2024. The agency has no way of determining the number of airplanes that might need these actions:</P>
                <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s100,r60,10,8">
                    <TTITLE>On-Condition Costs</TTITLE>
                    <BOXHD>
                        <CHED H="1">Action</CHED>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">Cost per product</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Inspect floor fasteners</ENT>
                        <ENT>9 work-hours × $85 per hour = $765</ENT>
                        <ENT>$50</ENT>
                        <ENT>$815</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Replace floor fasteners</ENT>
                        <ENT>1 work-hour × $85 per hour = $85</ENT>
                        <ENT>50</ENT>
                        <ENT>135</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Airplane groups 1 and 2 install reinforcement support on left-hand forward cabinet</ENT>
                        <ENT>2 work-hours × $85 per hour = $170</ENT>
                        <ENT>200</ENT>
                        <ENT>370</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The FAA has included all known costs in its cost estimate. According to the manufacturer, however, all of the costs of this AD may be covered under warranty, thereby reducing the cost impact on affected operators.</P>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII: Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>The FAA is issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.</P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>The FAA has determined that this AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify that this AD:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Will not affect intrastate aviation in Alaska, and</P>
                <P>(3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Amendment</HD>
                <P>Accordingly, under the authority delegated to me by the Administrator, the FAA amends 14 CFR part 39 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P> 49 U.S.C. 106(g), 40113, 44701.</P>
                    </AUTH>
                </REGTEXT>
                <SECTION>
                    <SECTNO>§ 39.13</SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <REGTEXT TITLE="14" PART="39">
                    <AMDPAR>2. The FAA amends § 39.13 by:</AMDPAR>
                    <AMDPAR>a. Removing Airworthiness Directive 2023-21-06, Amendment 39-22578 (88 FR 76114, November 6, 2023; corrected December 7, 2023 (88 FR 85093)); and</AMDPAR>
                    <AMDPAR>b. Adding the following new airworthiness directive:</AMDPAR>
                    <EXTRACT>
                        <PRTPAGE P="93474"/>
                        <FP SOURCE="FP-2">
                            <E T="04">2024-22-06 Embraer S.A.:</E>
                             Amendment 39-22877; Docket No. FAA-2024-2020; Project Identifier MCAI-2024-00303-A.
                        </FP>
                        <HD SOURCE="HD1">(a) Effective Date</HD>
                        <P>This airworthiness directive (AD) is effective January 2, 2025.</P>
                        <HD SOURCE="HD1">(b) Affected ADs</HD>
                        <P>This AD replaces AD 2023-21-06, Amendment 39-22578 (88 FR 76114, November 6, 2023; corrected December 7, 2023 (88 FR 85093)).</P>
                        <HD SOURCE="HD1">(c) Applicability</HD>
                        <P>This AD applies to Embraer S.A. Model EMB-505 airplanes, certificated in any category, as identified in Agência Nacional de Aviação Civil (ANAC) AD 2023-05-03R02, effective May 17, 2024 (ANAC AD 2023-05-03R02).</P>
                        <HD SOURCE="HD1">(d) Subject</HD>
                        <P>Joint Aircraft System Component (JASC) Code 2500, Cabin Equipment/Furnishings.</P>
                        <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                        <P>This AD was prompted by the analysis of certain monuments (the right-hand refreshment center and left-hand forward cabinet) that identified the need for installing structural reinforcements and replacing applicable floor support rivets. The FAA is issuing this AD to address the unsafe condition. The unsafe condition, if not addressed, could result in a monument not withstanding the loads expected for specific emergency landing conditions, which may cause the detachment of mass items and result in injuries to the airplane occupants.</P>
                        <HD SOURCE="HD1">(f) Compliance</HD>
                        <P>Comply with this AD within the compliance times specified, unless already done.</P>
                        <HD SOURCE="HD1">(g) Required Actions</HD>
                        <P>Except as specified in paragraphs (h) and (i) of this AD: Comply with all required actions and compliance times specified in, and in accordance with, ANAC AD 2023-05-03R02.</P>
                        <HD SOURCE="HD1">(h) Exceptions to ANAC AD 2023-05-03R02</HD>
                        <P>(1) Where ANAC AD 2023-05-03R02 refers to its effective date, this AD requires using the effective date of this AD.</P>
                        <P>(2) Where ANAC AD 2023-05-03R02 refers to Embraer Service Bulletin SB505-25-0046, Revision 03, as dated “May 6, 2024,” replace that text with “May 7, 2024.”</P>
                        <P>(3) Where paragraph (b) of ANAC AD 2023-05-03R02 refers to “June 2, 2023, the effective date of AD 2023-05-03, original revision,” replace that text with “December 11, 2023, the effective date of AD 2023-21-06.”</P>
                        <P>(4) Although the material referenced in ANAC AD 2023-05-03R02 allows the use of alternative or similar parts in place of the ones specified in the kits provided, this AD requires that alternative or similar parts be approved by the Manager, International Validation Branch, FAA; ANAC; or ANAC's authorized Designee. If approved by the ANAC Designee, the approval must include the Designee's authorized signature.</P>
                        <P>(5) Where the material referenced in ANAC AD 2023-05-03R02 specifies to “discard” certain parts, replace that text with “remove from service.”</P>
                        <P>(6) This AD does not adopt paragraph (d)(1) of ANAC AD 2023-05-03R02.</P>
                        <HD SOURCE="HD1">(i) No Reporting Requirement</HD>
                        <P>Although the material referenced in ANAC AD 2023-05-03R02 specifies to submit certain information to the manufacturer, this AD does not include that requirement.</P>
                        <HD SOURCE="HD1">(j) Alternative Methods of Compliance (AMOCs)</HD>
                        <P>
                            The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or local Flight Standards District Office, as appropriate. If sending information directly to the manager of the International Validation Branch, mail it to the address identified in paragraph (k) of this AD or email to: 
                            <E T="03">AMOC@faa.gov.</E>
                             If mailing information, also submit information by email. Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the local flight standards district office/certificate holding district office.
                        </P>
                        <HD SOURCE="HD1">(k) Additional Information</HD>
                        <P>
                            For more information about this AD, contact Jim Rutherford, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (816) 329-4165; email: 
                            <E T="03">jim.rutherford@faa.gov.</E>
                        </P>
                        <HD SOURCE="HD1">(l) Material Incorporated by Reference</HD>
                        <P>(1) The Director of the Federal Register approved the incorporation by reference (IBR) of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                        <P>(2) You must use this material as applicable to do the actions required by this AD, unless the AD specifies otherwise.</P>
                        <P>(i) Agência Nacional de Aviação Civil (ANAC) AD 2023-05-03R02, effective May 17, 2024.</P>
                        <P>(ii) [Reserved]</P>
                        <P>
                            (3) For ANAC material identified in this AD, contact ANAC, Continuing Airworthiness Technical Branch (GTAC), Rua Doutor Orlando Feirabend Filho, 230—Centro Empresarial Aquarius—Torre B—Andares 14 a 18, Parque Residencial Aquarius, CEP 12.246-190—São José dos Campos—SP, Brazil; phone: 55 (12) 3203-6600; email: 
                            <E T="03">pac@anac.gov.br;</E>
                             website: 
                            <E T="03">anac.gov.br/en/.</E>
                             You may find this material on the ANAC website at 
                            <E T="03">sistemas.anac.gov.br/certificacao/DA/DAE.asp.</E>
                        </P>
                        <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 901 Locust, Kansas City, MO 64106. For information on the availability of this material at the FAA, call (817) 222-5110.</P>
                        <P>
                            (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                            <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                             or email 
                            <E T="03">fr.inspection@nara.gov</E>
                            .
                        </P>
                    </EXTRACT>
                </REGTEXT>
                <SIG>
                    <DATED>Issued on October 24, 2024.</DATED>
                    <NAME>Victor Wicklund,</NAME>
                    <TITLE>Deputy Director, Compliance &amp; Airworthiness Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27709 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>Coast Guard</SUBAGY>
                <CFR>33 CFR Part 165</CFR>
                <DEPDOC>[Docket Number USCG-2024-1009]</DEPDOC>
                <RIN>RIN 1625-AA00</RIN>
                <SUBJECT>Safety Zone; Corpus Christi Bay, Corpus Christi, TX</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Coast Guard, DHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Temporary final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Coast Guard is establishing a temporary safety zone for certain navigable waters in the Laguna Madre, South Padre Island, Texas. The safety zone is needed to protect personnel, vessels, and the marine environment from potential hazards created by fireworks display launched from a barge in Laguna Madre, South Padre Island, Texas. Entry of vessels or persons into this zone is prohibited unless specifically authorized by the Captain of the Port, Sector Corpus Christi or a designated representative.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This rule is effective from 9:30 p.m. through 11:59 p.m. on December 7, 2024.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        To view documents mentioned in this preamble as being available in the docket, go to 
                        <E T="03">https://www.regulations.gov,</E>
                         type USCG-2024-1009 in the “SEARCH” box and click “SEARCH.” Click on Open Docket Folder on the line associated with this rule.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        If you have questions about this rule, call or email Lieutenant Timothy Cardenas, Sector Corpus Christi Waterways Management Division, U.S. Coast Guard; telephone 361-939-5130, email 
                        <E T="03">Timothy.J.Cardenas@uscg.mil.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <HD SOURCE="HD1">I. Table of Abbreviations</HD>
                <EXTRACT>
                    <FP SOURCE="FP-1">CFR Code of Federal Regulations</FP>
                    <FP SOURCE="FP-1">DHS Department of Homeland Security</FP>
                    <FP SOURCE="FP-1">FR Federal Register</FP>
                    <FP SOURCE="FP-1">NPRM Notice of proposed rulemaking</FP>
                    <FP SOURCE="FP-1">§ Section </FP>
                    <FP SOURCE="FP-1">U.S.C. United States Code</FP>
                </EXTRACT>
                <HD SOURCE="HD1">II. Background Information and Regulatory History</HD>
                <P>
                    The Coast Guard is issuing this temporary rule under authority in 5 
                    <PRTPAGE P="93475"/>
                    U.S.C. 553(b)(B). This statutory provision authorizes an agency to issue a rule without prior notice and opportunity to comment when the agency, for good cause, finds that those procedures are “impracticable, unnecessary, or contrary to the public interest.” Under 5 U.S.C. 553(b)(B), the Coast Guard finds that good cause exists for not publishing a notice of proposed rulemaking (NPRM) with respect to this rule because it is impracticable. The Coast Guard was notified of this event on October 30, 2024, and must establish this safety zone by December 7, 2024, to protect personnel, vessels, and the marine environment from potential hazards created by the fireworks display, and therefore lack sufficient time to provide a reasonable comment period and then a period to consider those comments before issuing the rule.
                </P>
                <P>
                    Under 5 U.S.C. 553(d)(3), the Coast Guard also finds that good cause exists for making this rule effective less than 30 days after publication in the 
                    <E T="04">Federal Register</E>
                    . Delaying the effective date of this rule would be contrary to the public interest because prompt action is needed to respond to the potential safety hazards associated with fireworks launched from a barge in the waters of the Laguna Madre.
                </P>
                <HD SOURCE="HD1">III. Legal Authority and Need for Rule</HD>
                <P>The Coast Guard is issuing this rule under authority in 46 U.S.C. 70034. The Captain of the Port, Sector Corpus Christi (COTP) has determined that potential hazards associated with the fireworks display, occurring from 9:30 p.m. through 11:59 p.m. on December 7, 2024, will be a safety concern for anyone within the waters of the Laguna Madre area within a 700-yard radius of the barge from which the display will be launched. This rule is needed to protect personnel, vessels, and the marine environment in the navigable waters within the safety zone while the fireworks display occurs in the Laguna Madre.</P>
                <HD SOURCE="HD1">IV. Discussion of the Rule</HD>
                <P>This rule establishes a temporary safety zone from 9:30 p.m. to 11:59 p.m. on the night of December 7, 2024. The safety zone will encompass all navigable waters of the Laguna Madre and is defined by a 700-yard radius from the launch platform. The regulated area encompasses a 700-yard radius of the following point: 26°06′02.1″ N, 97°10′17.7″ W. The fireworks display will take place in waters of the Laguna Madre. No vessel or person is permitted to enter the temporary safety zone during the effective period without obtaining permission from the COTP or a designated representative, who may be contacted on Channel 16 VHF-FM (156.8 MHz) or by telephone at 361-939-0450. The Coast Guard will issue Broadcast Notices to Mariners and Safety Marine Information Broadcasts.</P>
                <HD SOURCE="HD1">V. Regulatory Analyses</HD>
                <P>We developed this rule after considering numerous statutes and Executive orders related to rulemaking. Below we summarize our analyses based on a number of these statutes and Executive orders, and we discuss First Amendment rights of protestors.</P>
                <HD SOURCE="HD2">A. Regulatory Planning and Review</HD>
                <P>Executive Orders 12866 and 13563 direct agencies to assess the costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits. This rule has not been designated a “significant regulatory action,” under Executive Order 12866, as amended by Executive Order 14094 (Modernizing Regulatory Review). Accordingly, this rule has not been reviewed by the Office of Management and Budget (OMB).</P>
                <P>This regulatory action determination is based on the size, location, and duration of the safety zone. The temporary safety zone will be enforced for the short period of two and a half hours, on the night of December 7, 2024, when vessel traffic is normally low. The zone is limited to a 700-yard radius from the launching position in the navigable waters of the Laguna Madre. The rule does not completely restrict the traffic within a waterway and allows mariners to request permission to enter the zone.</P>
                <HD SOURCE="HD2">B. Impact on Small Entities</HD>
                <P>The Regulatory Flexibility Act of 1980, 5 U.S.C. 601-612, as amended, requires Federal agencies to consider the potential impact of regulations on small entities during rulemaking. The term “small entities” comprises small businesses, not-for-profit organizations that are independently owned and operated and are not dominant in their fields, and governmental jurisdictions with populations of less than 50,000. The Coast Guard certifies under 5 U.S.C. 605(b) that this rule will not have a significant economic impact on a substantial number of small entities.</P>
                <P>While some owners or operators of vessels intending to transit the safety zone may be small entities, for the reasons stated in section V.A above, this rule will not have a significant economic impact on any vessel owner or operator.</P>
                <P>
                    Under section 213(a) of the Small Business Regulatory Enforcement Fairness Act of 1996 (Pub. L. 104-121), we want to assist small entities in understanding this rule. If the rule would affect your small business, organization, or governmental jurisdiction and you have questions concerning its provisions or options for compliance, please call or email the person listed in the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section.
                </P>
                <P>Small businesses may send comments on the actions of Federal employees who enforce, or otherwise determine compliance with, Federal regulations to the Small Business and Agriculture Regulatory Enforcement Ombudsman and the Regional Small Business Regulatory Fairness Boards. The Ombudsman evaluates these actions annually and rates each agency's responsiveness to small business. If you wish to comment on actions by employees of the Coast Guard, call 1-888-REG-FAIR (1-888-734-3247). The Coast Guard will not retaliate against small entities that question or complain about this rule or any policy or action of the Coast Guard.</P>
                <HD SOURCE="HD2">C. Collection of Information</HD>
                <P>This rule will not call for a new collection of information under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520).</P>
                <HD SOURCE="HD2">D. Federalism and Indian Tribal Governments</HD>
                <P>A rule has implications for federalism under Executive Order 13132, Federalism, if it has a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government. We have analyzed this rule under that Order and have determined that it is consistent with the fundamental federalism principles and preemption requirements described in Executive Order 13132.</P>
                <P>
                    Also, this rule does not have tribal implications under Executive Order 13175, Consultation and Coordination with Indian Tribal Governments, because it does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes. If you believe this rule has implications for federalism or Indian tribes, please contact the person listed in the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section above.
                    <PRTPAGE P="93476"/>
                </P>
                <HD SOURCE="HD2">E. Unfunded Mandates Reform Act</HD>
                <P>The Unfunded Mandates Reform Act of 1995 (2 U.S.C. 1531-1538) requires Federal agencies to assess the effects of their discretionary regulatory actions. In particular, the Act addresses actions that may result in the expenditure by a State, local, or tribal government, in the aggregate, or by the private sector of $100,000,000 (adjusted for inflation) or more in any one year. Though this rule will not result in such an expenditure, we do discuss the effects of this rule elsewhere in this preamble.</P>
                <HD SOURCE="HD2">F. Environment</HD>
                <P>
                    We have analyzed this rule under Department of Homeland Security Directive 023-01, and Environmental Planning, COMDTINST 5090.1 (series), which guide the Coast Guard in complying with the National Environmental Policy Act of 1969 (42 U.S.C. 4321-4370f) and have determined that this action is one of a category of actions that do not individually or cumulatively have a significant effect on the human environment. This rule involves establishment of a temporary safety zone for navigable waters of the Laguna Madre in a zone defined by a 700-yard radius around the fireworks barge, located at the following point: 26°06′02.1″ N, 97°10′17.7″ W. It is categorically excluded from further review under paragraph L60(a) of Appendix A, Table 1 of DHS Instruction Manual 023-01-001-01, Rev. 1. A Record of Environmental Consideration supporting this determination is available in the docket. For instructions on locating the docket, see the 
                    <E T="02">ADDRESSES</E>
                     section of this preamble.
                </P>
                <HD SOURCE="HD2">G. Protest Activities</HD>
                <P>
                    The Coast Guard respects the First Amendment rights of protesters. Protesters are asked to contact the person listed in the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section to coordinate protest activities so that your message can be received without jeopardizing the safety or security of people, places or vessels.
                </P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 33 CFR Part 165</HD>
                    <P>Harbors, Marine safety, Navigation (water), Reporting and recordkeeping requirements, Security measures, Waterways.</P>
                </LSTSUB>
                <P>For the reasons discussed in the preamble, the Coast Guard amends 33 CFR part 165 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 165-REGULATED NAVIGATION AREAS AND LIMITED ACCESS AREAS</HD>
                </PART>
                <REGTEXT TITLE="33" PART="165">
                      
                    <AMDPAR>1. The authority citation for part 165 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P> 46 U.S.C. 70034, 70051, 70124; 33 CFR 1.05-1, 6.04-1, 6.04-6, and 160.5; Department of Homeland Security Delegation No. 00170.1, Revision No. 01.3.</P>
                    </AUTH>
                </REGTEXT>
                <REGTEXT TITLE="33" PART="165">
                    <AMDPAR>2. Add § 165.T08-1009 to read as follows:</AMDPAR>
                    <SECTION>
                        <SECTNO>§ 165.T08-1009</SECTNO>
                        <SUBJECT>Safety Zone; Corpus Christi Bay, Corpus Christi, TX.</SUBJECT>
                        <P>
                            (a) 
                            <E T="03">Location.</E>
                             The following area is a safety zone: all navigable waters of the Laguna Madre encompassed by a 700-yard radius around the fireworks barge, located at the following point: 26°06′02.1″ N, 97°10′17.7″ W.
                        </P>
                        <P>
                            (b) 
                            <E T="03">Enforcement period.</E>
                             This section is subject to enforcement from 9:30 p.m. through 11:59 p.m. on December 7, 2024.
                        </P>
                        <P>
                            (c) 
                            <E T="03">Regulations.</E>
                             (1) In accordance with the general regulations in subpart C of this part, entry into this temporary safety zone is prohibited unless authorized by the Captain of the Port Sector Corpus Christi (COTP) or a designated representative. They may be contacted on Channel 16 VHF-FM (156.8 MHz) or by telephone at 361-939-0450.
                        </P>
                        <P>(2) If permission is granted, all persons and vessels shall comply with the instructions of the COTP or designated representative.</P>
                        <P>
                            (d) 
                            <E T="03">Information broadcasts.</E>
                             The COTP or a designated representative will inform the public of the enforcement times and date for this safety zone through Broadcast Notices to Mariners and Safety Marine Information Broadcasts as appropriate.
                        </P>
                    </SECTION>
                </REGTEXT>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>T.H. Bertheau,</NAME>
                    <TITLE>Captain, U.S. Coast Guard, Captain of the Port, Sector Corpus Christi. </TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27875 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9110-04-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>Coast Guard</SUBAGY>
                <CFR>33 CFR Part 165</CFR>
                <DEPDOC>[Docket No. USCG-2024-1020]</DEPDOC>
                <SUBJECT>Safety Zone; City of Rockport, Rockport Tropical Christmas Festival Fireworks Display Show</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Coast Guard, DHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notification of enforcement of regulation.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Coast Guard will enforce the safety zone for the Rockport Tropical Christmas Festival Fireworks Display Show on December 6, 2024, or December 7, 2024, to provide for the safety of persons, vessels, and the marine environment on navigable waterways during this event. Our regulation for marine events within the Eighth Coast Guard District identifies the safety zone for this event in Rockport, TX. During the enforcement periods, entry into this zone is prohibited unless authorized by the Captain of the Port Sector Corpus Christi (COTP) or a designated representative.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The regulations in 33 CFR 165.801, Table 4, Line 11, will be enforced from 8 p.m. through 8:45 p.m. on December 6, 2024, unless the event is postponed because of adverse weather, in which case this rule will be enforced from 8 p.m. through 8:45 p.m. on December 7, 2024.</P>
                </EFFDATE>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        If you have questions about this notice of enforcement, call or email Lieutenant Timothy Cardenas, Sector Corpus Christi Waterways Management Division, U.S. Coast Guard; telephone 361-939-5130, email 
                        <E T="03">timothy.j.cardenas@uscg.mil.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The Coast Guard will enforce the safety zone in 33 CFR 165.801, Table 4, Line 11, for the Rockport Tropical Christmas Festival Fireworks Display Show from 8 p.m. through 8:45 p.m. on December 6, 2024, with a rain date set for December 7, 2024, from 8 p.m. through 8:45 p.m. This action is being taken to provide for the safety of persons, vessels, and the marine environment on navigable waterways during this event. Our regulation for marine events within the Eighth Coast Guard District, § 165.801, specifies the location of the safety zone for the Rockport Tropical Christmas Festival Fireworks Display Show, which encompasses portions of Little Bay in Rockport, TX. As reflected in § 165.23 and § 165.801(a), if you are the operator of a vessel in the regulated area you must comply with directions from the Captain of the Port Sector Corpus Christi (COTP) or any designated representative. Persons or vessels desiring to enter the zone must request permission from the COTP or a designated representative. They can be reached on VHF FM channel 16 or by telephone at (361) 939-0450.</P>
                <P>
                    If permission is granted, all persons and vessels shall comply with the instructions of the COTP or designated representative.
                    <PRTPAGE P="93477"/>
                </P>
                <P>
                    In addition to this notice of enforcement in the 
                    <E T="04">Federal Register</E>
                    , the COTP or a designated representative will inform the public through Broadcast Notice to Mariners (BNM) and Marine Safety Information Broadcasts (MSIBs) at least 24 hours in advance of each enforcement.
                </P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>T.H. Bertheau,</NAME>
                    <TITLE>Captain, U.S. Coast Guard, Captain of the Port, Sector Corpus Christi.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27870 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9110-04-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="N">LIBRARY OF CONGRESS</AGENCY>
                <SUBAGY>Copyright Royalty Board</SUBAGY>
                <CFR>37 CFR Part 385</CFR>
                <DEPDOC>[Docket No. Docket No. 24-CRB-0010-PR-COLA (2025)]</DEPDOC>
                <SUBJECT>Cost of Living Adjustment to Royalty Rates and Terms for Making and Distributing Phonorecords</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Copyright Royalty Board, Library of Congress.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule; cost of living adjustment.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Copyright Royalty Judges announce a cost of living adjustment (COLA) in the royalty rates for the statutory license for making and distributing phonorecords of nondramatic musical works regarding physical phonorecords and Permanent Downloads.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P/>
                    <P>
                        <E T="03">Effective date:</E>
                         November 27, 2024.
                    </P>
                    <P>
                        <E T="03">Applicability date:</E>
                         These rates and terms are applicable during the period from January 1, 2025, through December 31, 2025.
                    </P>
                </EFFDATE>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Anita Brown, Program Specialist, (202) 707-7658, 
                        <E T="03">crb@loc.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Section 115 of the Copyright Act, title 17 of the United States Code, creates a statutory license for making and distributing phonorecords of nondramatic musical works. On December 16, 2022, the Copyright Royalty Judges (Judges) adopted final regulations governing the rates and terms of copyright royalty payments under that license for the license period 2024-2027 for making and distributing phonorecords of nondramatic musical works. 
                    <E T="03">See</E>
                     87 FR 76942.
                </P>
                <P>
                    Pursuant to those regulations, at least 25 days before January 1 of each year, the Judges shall publish in the 
                    <E T="04">Federal Register</E>
                     notice of a cost of living adjustment (COLA) applicable to the royalty fees for making and distributing physical phonorecords and Permanent Downloads. 
                    <E T="03">See</E>
                     37 CFR 385.11.
                </P>
                <P>
                    The adjustment in the royalty fee shall be based on a calculation of the percentage increase in the Consumer Price Index for All Urban Consumers (CPI-U) published in November 2022 (298.012) 
                    <SU>1</SU>
                    <FTREF/>
                     (“base rate”) according to the following formulas: for the per-work rate, (1 + (Cy−298.012 
                    <SU>2</SU>
                    <FTREF/>
                    )/298.012) × 12¢, rounded to the nearest tenth of a cent; for the per-minute rate, (1 + (Cy−298.012)/298.012) × 2.31¢, rounded to the nearest hundredth of a cent; where Cy is the CPI-U published by the Secretary of Labor before December 1 of the preceding year. 37 CFR 385.11(a)(2). The CPI-U published by the Secretary of Labor from the most recent index published before December 1, 2024, is 315.664.
                    <SU>3</SU>
                    <FTREF/>
                     Applying the formulas in 37 CFR 385.11(a)(2) results in an increase in the rates for 2025.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         The CPI-U published in November 2022 is available at 
                        <E T="03">https://www.bls.gov/news.release/archives/cpi_11102022.htm</E>
                         at Table 1.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         Base rate.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The CPI-U announced on November13, 2024, by the Bureau of Labor Statistics in its 
                        <E T="03">Consumer Price Index News Release—Consumer Price Index,</E>
                         is available at 
                        <E T="03">https://www.bls.gov/news.release/archives/cpi_11142024.htm</E>
                         at Table 1.
                    </P>
                </FTNT>
                <P>The adjusted rates for 2025 are 12.7 cents for the per-work rate and 2.45 cents for the per-minute rate.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 37 CFR Part 385</HD>
                    <P>Copyright, Phonorecords, Recordings.</P>
                </LSTSUB>
                <HD SOURCE="HD1">Final Regulations</HD>
                <P>In consideration of the foregoing, the Judges amend part 385 of title 37 of the Code of Federal Regulations as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 385—RATES AND TERMS FOR USE OF NONDRAMATIC MUSICAL WORKS IN THE MAKING AND DISTRIBUTING OF PHYSICAL AND DIGITAL PHONORECORDS</HD>
                </PART>
                <REGTEXT TITLE="37" PART="385">
                    <AMDPAR>1. The authority citation for part 385 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P> 17 U.S.C. 115, 801(b)(1), 804(b)(4).</P>
                    </AUTH>
                </REGTEXT>
                <REGTEXT TITLE="37" PART="385">
                    <AMDPAR>2. Section 385.11 is amended by revising paragraph (a)(1) to read as follows:</AMDPAR>
                    <SECTION>
                        <SECTNO>§ 385.11</SECTNO>
                        <SUBJECT>Royalty fees for the public performance of sound recordings and the making of ephemeral recordings.</SUBJECT>
                        <P>(a) * * *</P>
                        <P>
                            (1) 
                            <E T="03">2025 rate.</E>
                             For the year 2025 for every physical phonorecord and Permanent Download the Licensee makes and distributes or authorizes to be made and distributed, the royalty rate payable for each work embodied in the phonorecord or Permanent Download shall be either 12.7 cents or 2.45 cents per minute of playing time or fraction thereof, whichever amount is larger.
                        </P>
                        <STARS/>
                    </SECTION>
                </REGTEXT>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>David P. Shaw,</NAME>
                    <TITLE>Chief Copyright Royalty Judge.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27819 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 1410-72-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="N">POSTAL SERVICE</AGENCY>
                <CFR>39 CFR Part 111</CFR>
                <SUBJECT>Domestic Competitive Products Pricing and Mailing Standards Changes</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>
                        Postal Service
                        <E T="51">TM</E>
                        .
                    </P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Postal Service is amending 
                        <E T="03">Mailing Standards of the United States Postal Service,</E>
                         Domestic Mail Manual (DMM®), to reflect changes to prices and mailing standards for competitive products.
                    </P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        <E T="03">Effective</E>
                         January 19, 2025.
                    </P>
                </EFFDATE>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Steven Jarboe at (202) 268-7690, Catherine Knox (202) 268-5636, or Garry Rodriguez at (202) 268-7281.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    This final rule describes new prices and product features for competitive products, by class of mail, established by the Governors of the United States Postal Service®. New prices are available under Docket Number CP2025-1 on the Postal Regulatory Commission PRC website at 
                    <E T="03">http://www.prc.gov,</E>
                     and on the Postal Explorer® website at 
                    <E T="03">http://pe.usps.com.</E>
                </P>
                <P>
                    The Postal Service will revise 
                    <E T="03">Mailing Standards of the United States Postal Service,</E>
                     Domestic Mail Manual (DMM), to reflect changes to certain prices and mailing standards for the following competitive products:
                </P>
                <P>• Priority Mail Express®.</P>
                <P>• Priority Mail®.</P>
                <P>• USPS Ground Advantage®.</P>
                <P>• Parcel Select®.</P>
                <P>• Extra Services.</P>
                <P>• Return Services.</P>
                <P>• Mailer Services.</P>
                <P>• Recipient Services.</P>
                <P>• Other.</P>
                <P>Competitive product prices and changes are identified by product as follows:</P>
                <HD SOURCE="HD1">Priority Mail Express</HD>
                <HD SOURCE="HD2">Prices</HD>
                <P>
                    Overall, Priority Mail Express prices will increase 3.2 percent. Priority Mail 
                    <PRTPAGE P="93478"/>
                    Express will continue to offer zoned and Flat Rate, Retail and Commercial pricing.
                </P>
                <P>Retail prices will increase an average of 3.2 percent. The Flat Rate Envelope price will increase to $31.40, the Legal Flat Rate Envelope will increase to $31.65, and the Padded Flat Rate Envelope will increase to $32.25.</P>
                <P>Commercial prices will increase an average of 3.2 percent.</P>
                <HD SOURCE="HD1">Priority Mail</HD>
                <HD SOURCE="HD2">Prices</HD>
                <P>Overall, Priority Mail prices will increase 3.2 percent. Priority Mail will continue to offer zoned and Flat Rate, Retail and Commercial pricing.</P>
                <P>Retail prices will increase an average of 3.2 percent. The Flat Rate Envelope price will increase to $10.10, the Legal Flat Rate Envelope will increase to $10.40, and the Padded Flat Rate Envelope will increase to $10.85. The Small Flat Rate Box price will increase to $10.65, and the Medium Flat Rate Boxes will increase to $19.15. The Large Flat Rate Box will increase to $26.30 and the APO/FPO/DPO Large Flat Rate Box will increase to $25.05.</P>
                <P>Commercial prices will increase an average of 3.2 percent.</P>
                <HD SOURCE="HD1">USPS Ground Advantage</HD>
                <HD SOURCE="HD2">Prices</HD>
                <P>Overall, USPS Ground Advantage prices will increase 3.9 percent.</P>
                <P>USPS Ground Advantage—Retail prices will increase 4.9 percent.</P>
                <P>USPS Ground Advantage—Commercial prices will increase 3.2 percent.</P>
                <HD SOURCE="HD1">Parcel Select</HD>
                <HD SOURCE="HD2">Prices</HD>
                <P>The prices for Parcel Select Destination Entry will increase an average of 9.2 percent.</P>
                <P>The prices for USPS Connect® Local will increase 5.4 percent.</P>
                <HD SOURCE="HD1">Extra Services</HD>
                <HD SOURCE="HD2">Adult Signature Service</HD>
                <P>Adult Signature Required and Adult Signature Restricted Delivery service prices are decreasing 10.2 and 10.4 percent respectively. The price for Adult Signature Required will decrease to $8.40 and Adult Signature Restricted Delivery will decrease to $8.65.</P>
                <HD SOURCE="HD1">Return Services</HD>
                <HD SOURCE="HD2">USPS Returns Service</HD>
                <P>There are no structural changes to USPS Returns Service.</P>
                <HD SOURCE="HD1">Mailer Services</HD>
                <HD SOURCE="HD2">Pickup on Demand Service</HD>
                <P>The Pickup on Demand® service fee will remain the same.</P>
                <HD SOURCE="HD2">USPS Tracking Plus Service</HD>
                <P>The USPS Tracking Plus® service prices will increase on average between 11.1 and 152.5 percent.</P>
                <HD SOURCE="HD2">USPS Label Delivery Service</HD>
                <P>
                    The USPS Label Delivery Service
                    <E T="51">TM</E>
                     prices will increase 24.0 percent to $1.55.
                </P>
                <HD SOURCE="HD1">Recipient Services</HD>
                <HD SOURCE="HD2">Post Office Box Service</HD>
                <P>
                    The competitive Post Office Box
                    <E T="51">TM</E>
                     service prices will increase an average of 5.7 percent within the updated price ranges.
                </P>
                <HD SOURCE="HD2">Premium Forwarding Service</HD>
                <P>Premium Forwarding Service® (PFS®) prices will increase between 2.5 and 6.1 percent depending on the specific price element. The enrollment fee paid at the retail counter for PFS-Residential will increase to $26.85 and the PFS-Residential, PFS-Commercial, and PFS-Local enrollment fee paid online will increase to $24.70 per application. The price of the weekly shipment charge for PFS-Residential and per container charge for PFS-Local will increase to $27.80.</P>
                <HD SOURCE="HD2">USPS Package Intercept</HD>
                <P>The USPS Package Intercept® fee will increase 4.9 percent to $18.35.</P>
                <HD SOURCE="HD1">Other</HD>
                <HD SOURCE="HD2">Address Enhancement Service</HD>
                <P>Address Enhancement Service competitive product prices will increase between 8.4 and 9.1 percent.</P>
                <HD SOURCE="HD2">IMpb Noncompliance Fee Renamed</HD>
                <P>To encompass all the compliance qualities included under the current IMpb Noncompliance Fee, the Postal Service is renaming the IMpb Noncompliance Fee the Package Quality Noncompliance Fee.</P>
                <HD SOURCE="HD2">Intelligent Mail Matrix Barcode</HD>
                <P>The Postal Service is requiring mailers to add a supplemental GS1-DataMatrix (2D) Intelligent Mail matrix barcode (IMmb) to domestic shipping labels to improve package visibility. The placement of the IMmb will be in the address block to the left of the delivery address. Optionally, a mailer may place a second IMmb in the lower right corner of the shipping label. The Postal Service recommends using the second IMmb on all labels. The addition of the IMmb barcode will provide the Postal Service with a greater opportunity for the package to be scanned providing customers with better visibility of their packages.</P>
                <P>The Postal Service will also update Publication 52, Hazardous, Restricted, and Perishable, Matter, for consistency in barcode application.</P>
                <HD SOURCE="HD2">Live Animal and Perishable Handling Fee</HD>
                <P>
                    The Postal Service is implementing a Live Animal and Perishable Handling fee. This fee will be assessed on all live animals and perishables (
                    <E T="03">e.g.</E>
                     fruit, meat), entered at retail and commercial Priority Mail Express, Priority Mail, and USPS Ground Advantage prices. The Live Animal and Perishable Handling fee is nonrefundable once the piece is entered in the network.
                </P>
                <P>The Live Animal and Perishable Handling fee is in addition to the current Live Animal Transportation fee provided in the Notice 123—Price List, when applicable.</P>
                <P>The Postal Service will also update Publication 52, Hazardous, Restricted, and Perishable, Matter, to provide detailed information on the fee requirement.</P>
                <HD SOURCE="HD2">Hazardous Materials Shipping Label Markings</HD>
                <P>The Postal Service is revising the current requirement to include the hazardous materials icon (“H”) in lieu of the service icon on a shipping address label when mailing eligible hazardous materials. Items containing mailable hazardous materials addressed to an APO/FPO/DPO, the USPS territories and possessions, and the Freely Associated States, are excluded from the requirement to include the hazardous materials icon in lieu of the service icon on a shipping address label.</P>
                <HD SOURCE="HD2">Overweight and Oversize Item Fee</HD>
                <P>The Postal Service is increasing the overweight and oversize item fee to $200.00, to continue to deter nonmailable volumes from being entered in the network.</P>
                <HD SOURCE="HD1">Resources</HD>
                <P>
                    The Postal Service provides additional resources to assist customers with this price change for competitive products. These tools include price lists, downloadable price files, and 
                    <E T="04">Federal Register</E>
                     Notices, which may be found on the Postal Explorer® website at 
                    <E T="03">http://pe.usps.com.</E>
                </P>
                <P>
                    The Postal Service adopts the described changes to 
                    <E T="03">Mailing Standards of the United States Postal Service,</E>
                     Domestic Mail Manual (DMM), 
                    <PRTPAGE P="93479"/>
                    incorporated by reference in the 
                    <E T="03">Code of Federal Regulations.</E>
                     We will publish an appropriate amendment to 39 CFR part 111 to reflect these changes.
                </P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 39 CFR Part 111</HD>
                    <P>Administrative practice and procedure, Postal Service.</P>
                </LSTSUB>
                <P>
                    Accordingly, the Postal Service amends 
                    <E T="03">Mailing Standards of the United States Postal Service,</E>
                     Domestic Mail Manual (DMM), incorporated by reference in the Code of Federal Regulations as follows (see 39 CFR part 111.1):
                </P>
                <PART>
                    <HD SOURCE="HED">PART 111—GENERAL INFORMATION ON POSTAL SERVICE</HD>
                </PART>
                <REGTEXT TITLE="39" PART="111">
                    <AMDPAR>1. The authority citation for 39 CFR part 111 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority:</HD>
                        <P> 5 U.S.C. 552(a); 13 U.S.C. 301-307; 18 U.S.C. 1692-1737; 39 U.S.C. 101, 401-404, 414, 416, 3001-3018, 3201-3220, 3401-3406, 3621, 3622, 3626, 3629, 3631-3633, 3641, 3681-3685, and 5001.</P>
                    </AUTH>
                </REGTEXT>
                <REGTEXT TITLE="39" PART="111">
                    <AMDPAR>
                        2. Revise 
                        <E T="03">Mailing Standards of the United States Postal Service,</E>
                         Domestic Mail Manual (DMM) as follows:
                    </AMDPAR>
                    <HD SOURCE="HD1">Mailing Standards of the United States Postal Service, Domestic Mail Manual (DMM)</HD>
                    <STARS/>
                    <HD SOURCE="HD1">100 Retail Mail Letters, Cards, Flats, and Parcels</HD>
                    <STARS/>
                    <HD SOURCE="HD1">110 Retail Mail Priority Mail Express</HD>
                    <HD SOURCE="HD1">113 Prices and Eligibility</HD>
                    <HD SOURCE="HD1">1.0 Prices and Fees</HD>
                    <STARS/>
                    <P>[Add new 1.7 to read as follows:]</P>
                    <HD SOURCE="HD1">1.7 Live Animal and Perishable Handling Fee</HD>
                    <P>
                        Priority Mail Express pieces containing live animals or perishables (
                        <E T="03">e.g.</E>
                         fruit, meat) are subject to the nonrefundable Live Animal and Perishable Handling fee (see Notice 123—Price List). This fee is in addition to the Live Animal Transportation fee provided in the Notice 123—Price List, when applicable. For additional information on the Live Animal and Perishable Handling fee see Publication 52, 
                        <E T="03">Hazardous, Restricted, and Perishable, Mail,</E>
                         (526).
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">115 Mail Preparation</HD>
                    <STARS/>
                    <HD SOURCE="HD1">2.0 Priority Mail Express 1-Day and 2-Day</HD>
                    <HD SOURCE="HD1">2.1 Mailing Label</HD>
                    <P>Priority Mail Express 1-Day and 2-Day items must be labeled as follows:</P>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the second sentence in item c to read as follows:]</E>
                    </P>
                    <P>c. * * * The Intelligent Mail package barcode (IMpb) and the Intelligent Mail matrix barcode (IMmb) on the shipping label must have the appropriate service-type code and banner text above the IMpb barcode used for cremated remains. * * *</P>
                    <STARS/>
                    <HD SOURCE="HD1">120 Retail Mail Priority Mail</HD>
                    <HD SOURCE="HD1">123 Prices and Eligibility</HD>
                    <HD SOURCE="HD1">1.0 Prices and Fees</HD>
                    <STARS/>
                    <P>
                        <E T="03">[Add new 1.7 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">1.7 Live Animal and Perishable Handling Fee</HD>
                    <P>
                        Priority Mail pieces containing live animals or perishables (
                        <E T="03">e.g.</E>
                         fruit, meat) are subject to the nonrefundable Live Animal and Perishable Handling fee (see Notice 123—Price List). This fee is in addition to the Live Animal Transportation fee provided in the Notice 123—Price List, when applicable. For additional information on the Live Animal and Perishable Handling fee see Publication 52, 
                        <E T="03">Hazardous, Restricted, and Perishable, Mail,</E>
                         (526).
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">130 Retail Mail First-Class Mail and USPS Ground Advantage—Retail</HD>
                    <HD SOURCE="HD1">133 Prices and Eligibility</HD>
                    <HD SOURCE="HD1">1.0 Prices and Fees</HD>
                    <STARS/>
                    <P>
                        <E T="03">[Add new 1.9 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">1.9 Live Animal and Perishable Handling Fee</HD>
                    <P>
                        USPS Ground advantage—Retail pieces containing live animals or perishables (
                        <E T="03">e.g.,</E>
                         fruit, meat) are subject to the nonrefundable Live Animal and Perishable Handling fee (see Notice 123—Price List). This fee is in addition to the Live Animal Transportation fee provided in the Notice 123—Price List, when applicable. For additional information on the Live Animal and Perishable Handling fee see Publication 52, 
                        <E T="03">Hazardous, Restricted, and Perishable, Mail,</E>
                         (526).
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">200 Commercial Letters, Cards, Flats, and Parcels</HD>
                    <STARS/>
                    <HD SOURCE="HD1">202 Elements on the Face of a Mailpiece</HD>
                    <STARS/>
                    <HD SOURCE="HD1">3.0 Placement and Content of Mail Markings</HD>
                    <STARS/>
                    <HD SOURCE="HD1">3.9 Shipping Address Label Markings</HD>
                    <HD SOURCE="HD1">3.9.1 General</HD>
                    <P>
                        <E T="03">[Revise the last sentence of 3.9.1 to read as follows:]</E>
                    </P>
                    <P>* * * Failure to comply may subject the piece to the Package Quality Noncompliance Fee.</P>
                    <HD SOURCE="HD1">3.9.2 Hazardous Materials</HD>
                    <P>
                        <E T="03">[Revise the text of 3.9.2 to read as follows:]</E>
                    </P>
                    <P>When a shipping address label is used on items containing mailable hazardous materials, except for items addressed to an APO/FPO/DPO, the USPS territories and possessions, and the Freely Associated States, it must include the hazardous materials icon in lieu of the service icon as provided in the Parcel Labeling Guide.</P>
                    <STARS/>
                    <HD SOURCE="HD1">6.0 Barcode Placement for Parcels</HD>
                    <STARS/>
                    <P>
                        <E T="03">[Delete 6.2 and 6.3 and add new 6.2 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">6.2 Intelligent Mail Matrix Barcode Location</HD>
                    <P>In addition to the placement of the IMpb and GS1-128 Routing Barcodes locations provided in 6.1, the Intelligent Mail matrix barcode (IMmb) must be placed in the address block to the left of the delivery address. Optionally, a mailer may place a second IMmb in the lower right corner of the shipping label.</P>
                    <STARS/>
                    <HD SOURCE="HD1">204 Barcode Standards</HD>
                    <STARS/>
                    <HD SOURCE="HD1">2.0 Standards for Package and Extra Service Barcodes</HD>
                    <P>
                        <E T="03">[Revise 2.1 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">2.1 Barcodes</HD>
                    <HD SOURCE="HD1">2.1.1 Definition</HD>
                    <P>The definition of an Intelligent Mail package barcode (IMpb) and an Intelligent Mail matrix barcode (IMmb) are as follows:</P>
                    <P>
                        a. IMpb—An IMpb is the USPS-developed barcode that can be read by automated parcel processing equipment and scanning devices and consists of a 
                        <PRTPAGE P="93480"/>
                        data string that generally follows the GS1-128 specification. These barcodes include a variable length format that is determined by the elements selected by the mailer, and supplies tracking and routing data for packages and extra service applications. Intelligent Mail package barcodes must be used on all commercial packages, and on other mailpieces of customers requesting extra services.
                    </P>
                    <P>b. IMmb—An IMmb is supplemental GS1-DataMatrix (2D) barcode to improve package visibility. The IMmb contains the same data as the IMpb barcode using a space-efficient barcode symbology.</P>
                    <HD SOURCE="HD1">2.1.2 Specification Resources</HD>
                    <P>
                        Detailed Specifications on an IMpb and IMmb can be found on PostalPro at 
                        <E T="03">https://postalpro.usps.com</E>
                         as follows:
                    </P>
                    <P>
                        a. Publication 199, 
                        <E T="03">Intelligent Mail Package Barcode (IMpb) Implementation Guide for Confirmation Services and Electronic Payment Systems.</E>
                    </P>
                    <P>b. Parcel Labeling Guide.</P>
                    <P>c. Intelligent Mail Package Barcode Technical Specifications.</P>
                    <P>d. Intelligent Mail Matrix Barcode Technical Specifications.</P>
                    <HD SOURCE="HD1">2.1.3 Barcode Location</HD>
                    <P>See 202.6.1 for barcode location standards.</P>
                    <HD SOURCE="HD1">2.1.4 Quality Assurance</HD>
                    <P>Mailers must perform routine inspections and testing of labels and barcodes to ensure quality.</P>
                    <HD SOURCE="HD1">2.1.5 Electronic File</HD>
                    <P>All mailers generating an IMpb and IMmb must transmit piece-level information to the USPS in an approved electronic file format (except for mailers generating barcodes for use on return services products, such as uninsured USPS Returns service packages).</P>
                    <HD SOURCE="HD1">2.1.6 Compliance Quality Thresholds</HD>
                    <P>All mailers who enter commercial parcels must meet the established thresholds for Compliance Quality outlined in Exhibit 2.1.6 to avoid payment of the Package Quality Noncompliance Fee. Failure to meet any compliance quality threshold in Exhibit 2.1.6 will result in the assessment of the Package Quality Noncompliance Fee.</P>
                    <HD SOURCE="HD1">Exhibit 2.1.6 Compliance Quality Thresholds</HD>
                    <NOTE>
                        <HD SOURCE="HED">Note:</HD>
                        <P>See Publication 199 for a list of validations for each Compliance Category (AQ, MQ, BQ).</P>
                    </NOTE>
                    <GPOTABLE COLS="3" OPTS="L2,nj,tp0,i1" CDEF="s100,xls54,10">
                        <TTITLE> </TTITLE>
                        <BOXHD>
                            <CHED H="1">Compliance categories</CHED>
                            <CHED H="1">
                                Compliance
                                <LI>codes</LI>
                            </CHED>
                            <CHED H="1">
                                Compliance
                                <LI>thresholds</LI>
                            </CHED>
                        </BOXHD>
                        <ROW>
                            <ENT I="01">Address Quality: Checks for a timely address that validates to a unique 11-Digit DPV or passes the critical validation criteria in Pub 199</ENT>
                            <ENT>AQ</ENT>
                            <ENT>90</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Manifest Quality (Shipping Services file): Checks for a timely manifest file that passes the critical validation criteria in Pub 199</ENT>
                            <ENT>MQ</ENT>
                            <ENT>94</ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">Barcode Quality: Checks the barcode in the manifest that passes the critical validation criteria in Pub 199</ENT>
                            <ENT>BQ</ENT>
                            <ENT>98</ENT>
                        </ROW>
                    </GPOTABLE>
                    <HD SOURCE="HD1">2.1.7 Alternate Approval</HD>
                    <P>Labels not meeting IMpb specifications or other label element standards, but still able to demonstrate acceptable functionality within USPS processes, may be allowed using an alternative approval process authorized by the vice president, Applied Engineering, (See 608.8.1 for contact information.).</P>
                    <STARS/>
                    <HD SOURCE="HD1">210 Commercial Mail Priority Mail Express</HD>
                    <HD SOURCE="HD1">213 Prices and Eligibility</HD>
                    <HD SOURCE="HD1">1.0 Prices and Fees</HD>
                    <STARS/>
                    <HD SOURCE="HD1">1.7 Unmanifested Fee</HD>
                    <P>
                        <E T="03">[Revise the text of 1.7 to read as follows:]</E>
                    </P>
                    <P>Eligible Priority Mail Express pieces omitted from the manifest are subject to the unmanifested fee (see Notice 123—Price List), unless the piece is subject to the Package Quality Noncompliance Fee as specified in 3.2.</P>
                    <STARS/>
                    <P>
                        <E T="03">[Add new 1.10 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">1.10 Live Animal and Perishable Handling Fee</HD>
                    <P>
                        Priority Mail Express pieces containing live animals or perishables (
                        <E T="03">e.g.</E>
                         fruit, meat) are subject to the nonrefundable Live Animal and Perishable Handling fee (see Notice 123—Price List). This fee is in addition to the Live Animal Transportation fee provided in the Notice 123—Price List, when applicable. For additional information on the Live Animal and Perishable Handling fee see Publication 52, 
                        <E T="03">Hazardous, Restricted, and Perishable, Mail,</E>
                         (526).
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">3.0 Basic Eligibility Standards for Priority Mail Express</HD>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the heading of 3.2 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.2 Barcode Standards</HD>
                    <P>
                        <E T="03">[Move the text from 3.2 under new heading 3.2.1 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.2.1 IMpb Standards</HD>
                    <P>
                        <E T="03">[Revise the renumbered text of 3.2.1 by deleting the second and last sentence.]</E>
                    </P>
                    <P>All Priority Mail Express pieces (outbound and returns) must bear an Intelligent Mail package barcode (IMpb) prepared under 204.2.0.</P>
                    <P>
                        <E T="03">[Add new 3.2.2 and 3.2.3 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.2.2 IMmb Standards</HD>
                    <P>In addition to the IMpb under 3.2.1, all Priority Mail Express pieces (outbound and returns) must bear an Intelligent Mail matrix barcode (IMmb) prepared under 204.2.0.</P>
                    <HD SOURCE="HD1">3.2.3 Package Quality Noncompliance Fee</HD>
                    <P>
                        Unless otherwise excepted, mailers of mailpieces not meeting the requirements for use of a unique IMpb, and IMmb as outlined in section 204.2.1.8 and Publication 199, Intelligent Mail Package Barcode (IMpb) Implementation Guide for: Confirmation Services and Electronic Payment Systems, will be assessed the Package Quality Noncompliance Fee (see Notice 123-Price List). For details see PostalPro at 
                        <E T="03">https://postalpro.usps.com.</E>
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">215 Mail Preparation</HD>
                    <STARS/>
                    <HD SOURCE="HD1">2.0 Priority Mail Express 1-Day and 2-Day</HD>
                    <HD SOURCE="HD1">2.1 Mailing Label</HD>
                    <P>Priority Mail Express 1-Day and 2-Day items must be labeled as follows:</P>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the second sentence in item c to read as follows:]</E>
                    </P>
                    <P>
                        c. * * * The Intelligent Mail package barcode (IMpb) and the Intelligent Mail matrix barcode (IMmb) on the shipping label must have the appropriate service-
                        <PRTPAGE P="93481"/>
                        type code and banner text above the IMpb barcode used for cremated remains. * * *
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">220 Commercial Mail Priority Mail</HD>
                    <HD SOURCE="HD1">223 Prices and Eligibility</HD>
                    <HD SOURCE="HD1">1.0 Prices and Fees</HD>
                    <STARS/>
                    <HD SOURCE="HD1">1.9 Unmanifested Fee</HD>
                    <P>
                        <E T="03">[Revise the text of 1.9 to read as follows:]</E>
                    </P>
                    <P>Eligible Priority Mail pieces omitted from the manifest are subject to the unmanifested piece fee (see Notice 123—Price List), unless the piece is subject to the Package Quality Noncompliance Fee as specified in 3.2.</P>
                    <STARS/>
                    <P>
                        <E T="03">[Add new 1.12 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">1.12 Live Animal and Perishable Handling Fee</HD>
                    <P>
                        Priority Mail pieces containing live animals or perishables (
                        <E T="03">e.g.,</E>
                         fruit, meat) are subject to the nonrefundable Live Animal and Perishable Handling fee (see Notice 123—Price List). This fee is in addition to the Live Animal Transportation fee provided in the Notice 123—Price List, when applicable. For additional information on the Live Animal and Perishable Handling fee see Publication 52, 
                        <E T="03">Hazardous, Restricted, and Perishable, Mail,</E>
                         (526).
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">3.0 Basic Eligibility Standards for Priority Mail</HD>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the heading of 3.2 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.2 Barcode Standards</HD>
                    <P>
                        <E T="03">[Move the text from 3.2 under new heading 3.2.1 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.2.1 IMpb Standards</HD>
                    <P>
                        <E T="03">[Revise the renumbered text of 3.2.1 by deleting the second and last sentence.]</E>
                    </P>
                    <P>
                        Unless the mailer is authorized to use a unique IMb on Priority Mail letters and flats prepared in high-speed environments, all Priority Mail pieces (outbound and returns) must bear an Intelligent Mail package barcode prepared under 204.2.0. To obtain information on how to acquire an authorization to use an IMb on Priority Mail letters and flats, mailers can contact USPS Shipping Information Systems at 
                        <E T="03">IMPB@usps.gov.</E>
                    </P>
                    <P>
                        <E T="03">[Add new 3.2.2 and 3.2.3 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.2.2 IMmb Standards</HD>
                    <P>In addition to the IMpb under 3.2.1, all Priority Mail pieces (outbound and returns) must bear an Intelligent Mail matrix barcode (IMmb) prepared under 204.2.0.</P>
                    <HD SOURCE="HD1">3.2.3 Package Quality Noncompliance Fee</HD>
                    <P>
                        Unless otherwise excepted, mailers of mailpieces not meeting the requirements for use of a unique IMpb and IMmb, as outlined in section 204.2.1.8 and Publication 199, Intelligent Mail Package Barcode (IMpb) Implementation Guide for: Confirmation Services and Electronic Payment Systems, will be assessed the Package Quality Noncompliance Fee (see Notice 123—Price List). For details see PostalPro at 
                        <E T="03">https://postalpro.usps.com.</E>
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">240 Commercial Mail USPS Marketing Mail</HD>
                    <HD SOURCE="HD1">243 Prices and Eligibility</HD>
                    <STARS/>
                    <HD SOURCE="HD1">3.0 Basic Eligibility Standards for USPS Marketing Mail</HD>
                    <STARS/>
                    <HD SOURCE="HD1">3.4 IMpb Standards</HD>
                    <P>
                        All USPS Marketing Mail parcels must bear an Intelligent Mail package barcode (IMpb) and an Intelligent Mail matrix barcode (IMmb) as outlined in section 204.2.0 and Publication 199, 
                        <E T="03">Intelligent Mail Package Barcode (IMpb) Implementation Guide for: Confirmation Services and Electronic Payment Systems.</E>
                         For details see PostalPro at 
                        <E T="03">https://postalpro.usps.com.</E>
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">250 Commercial Mail Parcel Select</HD>
                    <HD SOURCE="HD1">253 Prices and Eligibility</HD>
                    <HD SOURCE="HD1">1.0 Prices and Fees</HD>
                    <STARS/>
                    <HD SOURCE="HD1">1.4 Unmanifested Fee</HD>
                    <P>
                        <E T="03">[Revise the text of 1.4 to read as follows:]</E>
                    </P>
                    <P>Eligible Parcel Select pieces omitted from the manifest are subject to the unmanifested fee (see Notice 123—Price List), unless the piece is subject to the Package Quality Noncompliance Fee specified in 3.3.</P>
                    <STARS/>
                    <HD SOURCE="HD1">3.0 Basic Eligibility Standards for Parcel Select Parcels</HD>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the heading of 3.3 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.3 Barcode Standards</HD>
                    <P>
                        <E T="03">[Move the text from 3.3 under new heading 3.3.1 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.3.1 IMpb Standards</HD>
                    <P>
                        <E T="03">[Revise the renumbered text of 3.3.1 by deleting the second and last sentence.]</E>
                    </P>
                    <P>All Parcel Select mailpieces must bear an Intelligent Mail package barcode (IMpb) prepared under 204.2.0.</P>
                    <P>
                        <E T="03">[Add new 3.3.2 and 3.3.3 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.3.2 IMmb Standards</HD>
                    <P>In addition to the IMpb under 3.3.1, all Parcel Select pieces (outbound and returns) must bear an Intelligent Mail matrix barcode (IMmb) prepared under 204.2.0.</P>
                    <HD SOURCE="HD1">3.3.3 Package Quality Noncompliance Fee</HD>
                    <P>
                        Unless otherwise excepted, mailers of mailpieces not meeting the requirements for use of a unique IMpb and IMmb, as outlined in section 204.2.1.8 and Publication 199, 
                        <E T="03">Intelligent Mail Package Barcode (IMpb) Implementation Guide for: Confirmation Services and Electronic Payment Systems,</E>
                         will be assessed the Package Quality Noncompliance Fee (see Notice 123-Price List). For details see PostalPro at 
                        <E T="03">https://postalpro.usps.com.</E>
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">260 Commercial Mail Bound Printed Matter</HD>
                    <HD SOURCE="HD1">263 Prices and Eligibility</HD>
                    <STARS/>
                    <HD SOURCE="HD1">3.0 Basic Eligibility Standards for Bound Printed Matter</HD>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the heading and text of 3.5 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.5 Barcode Standards</HD>
                    <P>
                        Presorted priced BPM parcels must bear an Intelligent Mail package barcode (IMpb) and an Intelligent Mail matrix barcode (IMmb) as outlined in section 204.2.0 and Publication 199, 
                        <E T="03">Intelligent Mail Package Barcode (IMpb) Implementation Guide for: Confirmation Services and Electronic Payment Systems.</E>
                         For details see PostalPro at 
                        <E T="03">https://postalpro.usps.com.</E>
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">270 Commercial Mail Media Mail and Library Mail</HD>
                    <HD SOURCE="HD1">273 Prices and Eligibility</HD>
                    <STARS/>
                    <PRTPAGE P="93482"/>
                    <HD SOURCE="HD1">5.0 Basic Eligibility Standards for Media Mail and Library Mail</HD>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the heading and text of 5.5 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">5.5 Barcode Standards</HD>
                    <P>
                        All Media Mail and Library Mail parcels must bear an Intelligent Mail package barcode (IMpb) and an Intelligent Mail matrix barcode (IMmb) as outlined in section 204.2.0 and Publication 199, 
                        <E T="03">Intelligent Mail Package Barcode (IMpb) Implementation Guide for: Confirmation Services and Electronic Payment Systems.</E>
                         For details see PostalPro at 
                        <E T="03">https://postalpro.usps.com.</E>
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">280 Commercial Mail USPS Ground Advantage—Commercial</HD>
                    <HD SOURCE="HD1">283 Prices and Eligibility</HD>
                    <HD SOURCE="HD1">1.0 Prices and Fees</HD>
                    <STARS/>
                    <HD SOURCE="HD1">1.6 Unmanifested Fee</HD>
                    <P>
                        <E T="03">[Revise the text of 1.6 to read as follows:]</E>
                    </P>
                    <P>Eligible USPS Ground Advantage—Commercial pieces omitted from the manifest are subject to the unmanifested fee (see Notice 123-Price List), unless the piece is subject to the Package Quality Noncompliance Fee as specified in 3.4.</P>
                    <STARS/>
                    <P>
                        <E T="03">[Add new 1.9 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">1.9 Live Animal and Perishable Handling Fee</HD>
                    <P>
                        USPS Ground advantage—Commercial pieces containing live animals or perishables (
                        <E T="03">e.g.,</E>
                         fruit, meat) are subject to the nonrefundable Live Animal and Perishable Handling fee (see Notice 123—Price List). This fee is in addition to the Live Animal Transportation fee provided in the Notice 123—Price List, when applicable. For additional information on the Live Animal and Perishable Handling fee see Publication 52, 
                        <E T="03">Hazardous, Restricted, and Perishable, Mail,</E>
                         (526).
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">3.0 Basic Eligibility Standards for USPS Ground Advantage—Commercial</HD>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the heading of 3.4 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.4 Barcode Standards</HD>
                    <P>
                        <E T="03">[Move the text from 3.4 under new heading 3.4.1 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.4.1 IMpb Standards</HD>
                    <P>
                        <E T="03">[Revise the renumbered text of 3.4.1 by deleting the second and last sentence.]</E>
                    </P>
                    <P>All USPS Ground Advantage—Commercial parcels (outbound and returns) must bear an Intelligent Mail package barcode (IMpb) prepared under 204.2.0.</P>
                    <P>
                        <E T="03">[Add new 3.4.2 and 3.4.3 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">3.4.2 IMmb Standards</HD>
                    <P>In addition to the IMpb under 3.4.1, all USPS Ground Advantage pieces (outbound and returns) must bear an Intelligent Mail matrix barcode (IMmb) prepared under 204.2.0.</P>
                    <HD SOURCE="HD1">3.4.3 Package Quality Noncompliance Fee</HD>
                    <P>
                        Unless otherwise excepted, mailers of mailpieces not meeting the requirements for use of unique Intelligent Mail package barcodes or extra services barcodes, as outlined in section 204.2.1.8 and Publication 199, 
                        <E T="03">Intelligent Mail Package Barcode (IMpb) Implementation Guide for: Confirmation Services and Electronic Payment Systems,</E>
                         will be assessed the Package Quality Noncompliance Fee (see Notice 123—Price List). For details see PostalPro at 
                        <E T="03">https://postalpro.usps.com.</E>
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">500 Additional Mailing Services</HD>
                    <HD SOURCE="HD1">503 Extra Services</HD>
                    <HD SOURCE="HD1">1.0 Basic Standards for All Extra Services</HD>
                    <STARS/>
                    <HD SOURCE="HD1">1.7 Forms and Labels</HD>
                    <STARS/>
                    <HD SOURCE="HD1">1.7.2 Privately Printed Forms or Labels</HD>
                    <P>
                        <E T="03">[Revise the first and fourth sentence of 1.7.2 to read as follows:]</E>
                    </P>
                    <P>
                        Except for Certificate of Mailing service using privately printed forms (
                        <E T="03">i.e.,</E>
                         facsimiles) as provided under 5.0, if authorized, a mailer may use privately printed extra service forms and labels for domestic mail only, if the forms and labels are nearly identical in design elements and color to the USPS form, with an Intelligent Mail package barcode (IMpb) and human-readable numbers that meet USPS specifications, and an Intelligent Mail matrix barcode (IMmb), in 204.2.0.* * * * * * Mailers generating shipping labels bearing an IMpb and IMmb must also affix the appropriate colored non-barcoded color-coded label for Registered Mail (under 2.1.2) or Certified Mail (under 3.2.1).* * *
                    </P>
                    <P>
                        <E T="03">[Revise the heading and text of 1.7.3 to read as follows:]</E>
                    </P>
                    <HD SOURCE="HD1">1.7.3 Barcodes</HD>
                    <P>Items for which extra services are added must bear a correct Intelligent Mail package barcode (IMpb) and Intelligent Mail matrix barcode (IMmb).</P>
                    <STARS/>
                    <HD SOURCE="HD1">1.7.5 Legacy Extra-Service Forms</HD>
                    <P>
                        <E T="03">[Revise the last sentence in the introductory text of 1.7.5 to read as follows:]</E>
                    </P>
                    <P>* * * Mailers using noncompliant versions of the following extra-service forms will be subject to the Package Quality Noncompliance Fee (see Notice 123—Price List):</P>
                    <STARS/>
                    <HD SOURCE="HD1">2.0 Registered Mail</HD>
                    <HD SOURCE="HD1">2.1 Basic Standards</HD>
                    <STARS/>
                    <HD SOURCE="HD1">2.1.2 Label 200</HD>
                    <P>
                        <E T="03">[Revise the first sentence of 2.1.2 to read as follows:]</E>
                    </P>
                    <P>
                        Registered Mail must bear the barcoded red Label 200 (see forms at 
                        <E T="03">https://pe.usps.com/</E>
                        ), or a non-barcoded red Label 200-N when a mailer-generated shipping label bearing an IMpb and IMmb under 204.2.0 is also affixed on the same mailpiece.* * *
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">3.0 Certified Mail Services</HD>
                    <STARS/>
                    <HD SOURCE="HD1">3.2 Mailing</HD>
                    <HD SOURCE="HD1">3.2.1 PS Form 3800</HD>
                    <P>
                        <E T="03">[Revise the first sentence in the introductory text of 3.2.1 to read as follows:]</E>
                    </P>
                    <P>
                        Certified Mail must bear the barcoded green label part of the Form 3800 (see forms at 
                        <E T="03">https://pe.usps.com/</E>
                        ), or a non-barcoded green Label 3800-N when a mailer-generated shipping label bearing an IMpb and IMmb, under 204.2.0, is also affixed on the same mailpiece.* * *
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">4.0 Insured Mail</HD>
                    <STARS/>
                    <HD SOURCE="HD1">4.2 Insurance Coverage—Priority Mail, USPS Ground Advantage—Retail, and USPS Ground Advantage—Commercial</HD>
                    <P>
                        Priority Mail pieces (including Priority Mail Return service), USPS Ground Advantage—Retail, and USPS Ground Advantage—Commercial pieces (including USPS Ground Advantage Return service) are insured against loss, 
                        <PRTPAGE P="93483"/>
                        damage, or missing contents, for no more than $100.00 in coverage, subject to the following:
                    </P>
                    <P>
                        <E T="03">[Revise the text of item a to read as follows:]</E>
                    </P>
                    <P>a. Insurance coverage is provided against loss, damage, or missing contents and is limited to a maximum liability of $100.00 when the pieces bear an Intelligent Mail package barcode (IMpb) and an Intelligent Mail matrix barcode (IMmb) or USPS retail tracking barcode (see 4.3.4) and the mailer pays retail or commercial prices.</P>
                    <STARS/>
                    <HD SOURCE="HD1">4.3 Basic Standards</HD>
                    <STARS/>
                    <HD SOURCE="HD1">4.3.4 Markings and Forms</HD>
                    <P>The treatment of pieces is determined by the insurance amount as described in 4.3.1c and under the following conditions:</P>
                    <P>
                        <E T="03">[Revise the text of item a to read as follows:]</E>
                    </P>
                    <P>a. Retail Systems Software (RSS) sites—A label and a receipt will be provided at the retail counter. The label printed at the retail counter will include postage and an Intelligent Mail package barcode (IMpb) and an Intelligent Mail matrix barcode (IMmb) that contains the appropriate service type code for the product and extra service purchased.</P>
                    <STARS/>
                    <HD SOURCE="HD1">7.0 USPS Tracking</HD>
                    <STARS/>
                    <HD SOURCE="HD1">7.2 Labels</HD>
                    <HD SOURCE="HD1">7.2.1 Types of Labels</HD>
                    <P>* * * Mailers not printing their own privately printed labels must use one of the label options as follows:</P>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the second sentence of item b to read as follows:]</E>
                    </P>
                    <P>b. * * * The labels are populated with the product service type code and customer's Mailer Identification (MID) number in the Intelligent Mail package barcode (IMpb) and Intelligent Mail matrix barcode (IMmb).</P>
                    <STARS/>
                    <HD SOURCE="HD1">8.0 USPS Signature Services</HD>
                    <HD SOURCE="HD1">8.1 Basic Standards</HD>
                    <STARS/>
                    <HD SOURCE="HD1">8.1.2 Standards for Signature Confirmation</HD>
                    <P>For Signature Confirmation with Media Mail, Library Mail, Bound Printed Matter, or Parcel Select pieces meeting the physical standards under 201.7.0, the parcel must meet these additional requirements:</P>
                    <STARS/>
                    <P>d. Mailers must use one of the following labels:</P>
                    <P>
                        <E T="03">[Revise the second sentence of item d1 to read as follows:]</E>
                    </P>
                    <P>1. Retail Systems Software (RSS) sites—* * * The label printed at the retail counter will include postage and an Intelligent Mail package barcode (IMpb) and an Intelligent Mail matrix barcode (IMmb) that contains the appropriate service type code for the product and extra service purchased.</P>
                    <STARS/>
                    <HD SOURCE="HD1">505 Return Services</HD>
                    <STARS/>
                    <HD SOURCE="HD1">3.0 USPS Returns Service</HD>
                    <HD SOURCE="HD1">3.1 Basic Standards</HD>
                    <STARS/>
                    <HD SOURCE="HD1">3.1.3 Postage and Prices</HD>
                    <P>Postage and prices are subject to the following:</P>
                    <P>
                        <E T="03">[Revise the third and last sentence of item a to read as follows:]</E>
                    </P>
                    <P>a. * * * USPS Returns service packages are charged postage and fees based on the STC embedded in the IMpb and IMmb and as provided under 3.1.3c. If all or part of the barcodes are unreadable, or the package is unable to be priced based on the data collected, postage will be determined by the Postal Service based on historical data, or default data determined at time of enrollment.</P>
                    <STARS/>
                    <P>c. The account holder or mailer may obtain extra and additional services as follows:</P>
                    <P>
                        <E T="03">[Revise the third sentence of item c1 to read as follows:]</E>
                    </P>
                    <P>1. * * * Additional insurance for Priority Mail Return service and USPS Ground Advantage Return service is available to the account holder for a fee on packages that have the applicable STC embedded into the IMpb and IMmb on the label, and for which the account holder has provided electronic data that supports the value of the merchandise (see 503.4.1a).* * *</P>
                    <STARS/>
                    <HD SOURCE="HD1">3.1.4 Labels</HD>
                    <P>Distribution and preparation of labels are subject to the following:</P>
                    <STARS/>
                    <P>
                        b. 
                        <E T="03">Label Preparation.</E>
                         The following provisions apply:
                    </P>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the text of item b2 to read as follows:]</E>
                    </P>
                    <P>
                        2. The label must include an IMpb and IMmb (see 204.2.0), accommodate all required information, be legible, and be prepared in accordance with the standards in Publication 199, 
                        <E T="03">Intelligent Mail Package Barcode (IMpb) Implementation Guide for Confirmation Services and Electronic Payment Systems,</E>
                         available on the PostalPro website at 
                        <E T="03">https://postalpro.usps.com.</E>
                    </P>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the text of item b4 to read as follows:]</E>
                    </P>
                    <P>4. Except for USPS Returns service labels generated by the USPS API or MRA, all returns labels must have a properly constructed IMpb (C01, C05, N02, or N05, as applicable) and IMmb approved by the NCSC.</P>
                    <STARS/>
                    <HD SOURCE="HD1">3.1.5 Noncompliant Labels</HD>
                    <P>
                        <E T="03">[Revise the last sentence of 3.1.5 to read as follows:]</E>
                    </P>
                    <P>
                        * * * When noncompliant labels, including discontinued labels, are affixed to USPS Returns service packages, the permit holder may be assessed the Package Quality Noncompliance Fee (see Notice 123—Price List), or the appropriate USPS Returns class of mail retail price (
                        <E T="03">i.e.,</E>
                         permit holders of Priority Mail Express Returns service packages will be assessed the retail Priority Mail Express price) calculated from the package's initial entry point (first physical scan) in the USPS network to its delivery address.
                    </P>
                    <HD SOURCE="HD1">3.1.6 Enter and Deposit</HD>
                    <P>The following standards apply:</P>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the last sentence of item b to read as follows:]</E>
                    </P>
                    <P>b * * * Any such packages deposited in collection boxes may be returned to the sender for the extra service to be purchased appropriately, or it will be processed and the sender charged postage and fees based on the STC embedded in the IMpb and IMmb on the label and as provided under 3.1.4c.</P>
                    <STARS/>
                    <HD SOURCE="HD1">5.0 Bulk Parcel Return Service</HD>
                    <STARS/>
                    <HD SOURCE="HD1">5.4 Optional BPRS Label</HD>
                    <P>
                        <E T="03">[Revise the last sentence of 5.4 to read as follows:]</E>
                    </P>
                    <P>
                        * * * The label is prepared at the mailer's expense and must meet all format standards in the Parcel Labeling Guide available on PostalPro at 
                        <E T="03">https://postalpro.usps.com,</E>
                         including an IMpb 
                        <PRTPAGE P="93484"/>
                        and IMmb meeting the standards in 204.2.0.
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">507 Mailer Services</HD>
                    <STARS/>
                    <HD SOURCE="HD1">5.0 Package Intercept</HD>
                    <STARS/>
                    <HD SOURCE="HD1">5.3 Adding Extra Services</HD>
                    <P>
                        <E T="03">[Revise the third sentence in the introductory text of 5.3 to read as follows:]</E>
                    </P>
                    <P>* * * The relabeled item will be assigned a new barcode applicable to the extra service purchased.* * *</P>
                    <STARS/>
                    <HD SOURCE="HD1">600 Basic Standards for All Mailing Services</HD>
                    <HD SOURCE="HD1">601 Mailability</HD>
                    <HD SOURCE="HD1">1.0 General Standards</HD>
                    <STARS/>
                    <HD SOURCE="HD1">1.2 Overweight Items or Oversize Items</HD>
                    <STARS/>
                    <HD SOURCE="HD1">1.2.3 Fee</HD>
                    <P>
                        <E T="03">[Revise the text of 1.2.3 to read as follows:]</E>
                    </P>
                    <P>
                        Except for an overweight or oversize item discovered and picked up at the same facility where it was entered, the overweight/oversize item fee of $200 will be assessed and must be paid before release of the item. The $200 overweight or oversize item fee may be paid by any authorized retail payment method or through 
                        <E T="03">PostalOne!.</E>
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">604 Postage Payment Methods and Refunds</HD>
                    <STARS/>
                    <HD SOURCE="HD1">9.0 Exchanges and Refunds</HD>
                    <STARS/>
                    <HD SOURCE="HD1">9.2 Postage and Fee Refunds</HD>
                    <STARS/>
                    <HD SOURCE="HD1">9.2.4 Postage and Fee Refunds Not Available</HD>
                    <P>Refunds are not made for the following:</P>
                    <STARS/>
                    <P>
                        <E T="03">[Revise 9.2.4 by adding an item j to read as follows:]</E>
                    </P>
                    <P>j. For the Package Intercept per-piece fee once the USPS successfully intercepts the mailpiece (507.5.2) or the Live Animal and Perishable Handling fee once the piece is entered in the network.</P>
                    <STARS/>
                    <HD SOURCE="HD1">609 Filing Indemnity Claims for Loss or Damage</HD>
                    <HD SOURCE="HD1">1.0 General Filing Instructions</HD>
                    <STARS/>
                    <HD SOURCE="HD1">1.2.2 Eligibilty</HD>
                    <P>Eligibility for mailers to submit claims using the Bulk Indemnity Claims feature is based on the following:</P>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the text of item b to read as follows:]</E>
                    </P>
                    <P>b. IMpb and IMmb compliance history.</P>
                    <STARS/>
                    <HD SOURCE="HD1">1.3 Who May File</HD>
                    <P>A claim may be filed by:</P>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the text of item c to read as follows:]</E>
                    </P>
                    <P>c. Only the account holder, for USPS Returns packages that are insured as identified by the account holder's mailer identification (MID) and the applicable STC for insurance imbedded into the IMpb and IMmb on the label, and for which the account holder has provided electronic data that supports the value of the merchandise being returned (see 503.4.3.1a).</P>
                    <STARS/>
                    <HD SOURCE="HD1">700 Special Standards</HD>
                    <STARS/>
                    <HD SOURCE="HD1">705 Advanced Preparation and Special Postage Payment Systems</HD>
                    <STARS/>
                    <HD SOURCE="HD1">18.0 Priority Mail Express Open and Distribute and Priority Mail Open and Distribute</HD>
                    <STARS/>
                    <HD SOURCE="HD1">18.5 Preparation</HD>
                    <STARS/>
                    <HD SOURCE="HD1">18.5.7 Address Label Service Barcode Requirement</HD>
                    <P>
                        <E T="03">[Revise first and third through fifth sentences in the introductory text of 18.5.7 to read as follows:]</E>
                    </P>
                    <P>An electronic service barcode must include an Intelligent Mail package barcode (IMpb) and Intelligent Mail matrix barcode (IMmb) (eVS approved mailers) symbology for Priority Mail Express Open and Distribute, and the IMpb and IMmb symbology for Priority Mail Open and Distribute in the address label.* * * * * * Priority Mail Express Open and Distribute IMpb and IMmb labels must include service type code “723.” For Priority Mail Open and Distribute, the IMpb and IMmb must include service type code “123.” The human-readable text “USPS SCAN ON ARRIVAL” must appear above the IMpb barcode.* * *</P>
                    <STARS/>
                    <P>
                        <E T="03">[Add an IMmb in the address block to the left of the delivery address to the label graphics in Exhibits 18.5.8 through 18.5.12.]</E>
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">Index</HD>
                    <STARS/>
                    <HD SOURCE="HD1">I</HD>
                    <STARS/>
                    <HD SOURCE="HD1">Intelligent Mail</HD>
                    <STARS/>
                    <P>
                        <E T="03">[Revise the “Intelligent Mail” entry by alphabetically adding the following:]</E>
                         matrix barcode, 204.2.0
                    </P>
                    <STARS/>
                    <HD SOURCE="HD1">Notice 123 (Price List)</HD>
                    <P>
                        <E T="03">[Revise competitive prices as applicable.]</E>
                    </P>
                    <STARS/>
                </REGTEXT>
                <SIG>
                    <NAME>Colleen Hibbert-Kapler,</NAME>
                    <TITLE>Attorney, Ethics and Legal Compliance.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27463 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 7710-12-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <CFR>42 CFR Part 121</CFR>
                <RIN>RIN 0937-AA13</RIN>
                <SUBJECT>Organ Procurement and Transplantation: Implementation of the HIV Organ Policy Equity (HOPE) Act</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of the Assistant Secretary for Health (OASH) and Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Department of Health and Human Services (HHS) amends the regulations implementing the National Organ Transplant Act of 1984, as amended (NOTA), to remove clinical research and institutional review board (IRB) requirements (“research and IRB requirements”) for transplantation of kidneys and livers from donors with human immunodeficiency virus (HIV) to recipients with HIV. As allowed by the HIV Organ Policy Equity (HOPE) Act, the Secretary of HHS determines that participation in such clinical research should no longer be a requirement for transplantation of kidneys and livers from donors with HIV to recipients with HIV. This final rule serves as publication of the 
                        <PRTPAGE P="93485"/>
                        Secretary's determination and amends the regulations to reflect this determination. This final rule also serves as publication of the Secretary's direction to the Organ Procurement and Transplantation Network (OPTN) to adopt and use standards of quality with respect to kidneys and livers from donors with HIV to ensure that HOPE Act kidney and liver transplants are subject to OPTN policies that are consistent with NOTA, and in a way that ensures the revised requirements for transplantation of such organs will not reduce the safety of organ transplantation.
                    </P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This rule is effective November 27, 2024.</P>
                </EFFDATE>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Frank Holloman, Director, Division of Transplantation, Health Systems Bureau, HRSA, 5600 Fishers Lane, Room 08W63, Rockville, MD 20857; by email at 
                        <E T="03">donation@hrsa.gov;</E>
                         or by telephone (301) 443-7577.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Public Participation</HD>
                <P>
                    On September 12, 2024, HHS published a notice of proposed rulemaking (NPRM) in the 
                    <E T="04">Federal Register</E>
                     (89 FR 74174) proposing both that the Secretary of HHS determine that participation in clinical research should no longer be required for transplantation of kidneys and livers from donors with HIV to recipients with HIV, and that the HHS regulations at 42 CFR part 121 implementing the HOPE Act be amended consistent with this proposed determination. The NPRM provided for a 30-day comment period, and HHS received 56 comments raising a variety of issues. HHS has carefully considered all comments in developing this rule, as outlined in section III, below, and presents a summary of all significant comments and Departmental responses.
                </P>
                <HD SOURCE="HD1">II. Background</HD>
                <HD SOURCE="HD2">A. HHS Oversight of Organ Allocation and Transplantation</HD>
                <P>Within HHS, HRSA is responsible for overseeing the operation of the Nation's OPTN, including assisting in the equitable allocation of donor organs for transplantation. 42 U.S.C. 274(b)(2)(D). The allocation of organs is guided by the OPTN in accordance with NOTA and with the HHS regulations governing the operation of the OPTN in 42 CFR part 121. The OPTN is also charged with developing policies on many subjects related to organ donation, procurement, and transplantation, which include establishing standards of quality pertaining to organs procured for use in transplantation. 42 U.S.C. 274(b)(2)(E).</P>
                <HD SOURCE="HD2">B. HOPE Act Requirements and Implementation</HD>
                <P>The enactment of the HOPE Act in 2013, Public Law 113-51, amended NOTA to eliminate the prohibition in the United States on transplantation of organs from persons with HIV, allowing transplantation of these organs if certain requirements are satisfied. Under the HOPE Act, organs from donors with HIV may be transplanted only in recipients living with HIV prior to receiving such an organ. 42 U.S.C. 274(b)(3)(A). Further, the HOPE Act requires that transplants of HIV-positive organs occur only in recipients with HIV who are participating in IRB-approved research protocols that adhere to certain criteria, standards, and regulations. 42 U.S.C. 274(b)(3)(B)(i). However, the Secretary may lift the research and IRB requirements if the Secretary has determined that participation in such clinical research, as a requirement for such transplants, is no longer warranted. 42 U.S.C. 274(b)(3)(B)(ii).</P>
                <P>The HOPE Act outlines the process by which the Secretary may make such a determination under 42 U.S.C. 274(b)(3)(B)(ii). Specifically, the Secretary must routinely review the results of scientific research, in conjunction with the OPTN, to determine whether the results warrant revision of the OPTN standards of quality regarding organs from donors with HIV. If the Secretary determines that those standards of quality should be revised, the Secretary must direct the OPTN to revise the standards. 42 U.S.C. 274f-5(c)(2). The Secretary is also required to revise the regulatory provision implementing the HOPE Act, 42 CFR 121.6, upon determining that revisions to the OPTN standards of quality are warranted. 42 U.S.C. 274f-5(c)(3).</P>
                <P>
                    HRSA published a final rule implementing the HOPE Act on May 8, 2015. 80 FR 26464.
                    <SU>1</SU>
                    <FTREF/>
                     The 2015 rule amended 42 CFR 121.6 to permit transplants of organs from donors with HIV in accordance with the HOPE Act requirements.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="04">Federal Register</E>
                        . Organ Procurement and Transplantation: Implementation of the HIV Organ Policy Equity (HOPE) Act. 80 FR 26464 (May 8, 2015). 
                        <E T="03">https://www.federalregister.gov/documents/2015/05/08/2015-11048/organ-procurement-and-transplantation-implementation-of-the-hiv-organ-policy-equity-act.</E>
                    </P>
                </FTNT>
                <P>
                    The HOPE Act also directs the Secretary to develop and publish criteria for the conduct of research relating to transplantation of organs from donors with HIV into persons who are living with HIV before receiving an HIV-positive organ. 42 U.S.C. 274f-5(a). Subsequent to publication of the 2015 rule implementing the HOPE Act, the National Institutes of Health (NIH) published the 
                    <E T="03">Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV,</E>
                     on November 25, 2015. 80 FR 73785.
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         
                        <E T="04">Federal Register</E>
                        . Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV. 80 FR 73785 (Nov. 25, 2015). 
                        <E T="03">https://www.federalregister.gov/documents/2015/11/25/2015-30172/final-human-immunodeficiency-virus-hiv-organ-policy-equity-hope-act-safeguards-and-research-criteria.</E>
                    </P>
                </FTNT>
                <P>In general, the NIH Research Criteria include safeguards designed to protect both donors and recipients, as well as healthcare providers at Organ Procurement Organizations (OPOs) and transplant centers. Specifically, and in addition to the requirements in established OPTN transplant policies, donors with HIV must not have evidence of opportunistic infections and recipients must have a stable CD4+ T-cell count and established HIV suppression and control on effective antiretroviral therapy (ART). The study team must describe the anticipated effective HIV treatment plan and ART regimen for patients receiving an organ with a potentially different HIV strain. Antiretroviral drugs suppress viral replication; however, HIV may develop resistance to a specific drug necessitating a different medication regimen to maintain effectiveness. Transplant hospitals conducting HOPE Act operations are required to have expertise in transplants provided to recipients with HIV. OPOs are required to have procedures in place to address working with families of deceased donors who lived with HIV and a biohazard plan to address viral exposure and potential transmission. Finally, the Research Criteria establish uniform outcome measures that must be incorporated in the research design so that data on HOPE Act transplants can be analyzed consistently and data collection is harmonized to inform future implementation of the HOPE Act.</P>
                <P>
                    Publication of both the final rule implementing the HOPE Act and the NIH Research Criteria necessitated that the OPTN update its standards of quality for HIV-positive organ transplants and coordinate related OPTN policies. On November 21, 2015, the OPTN published an open variance (an experimental policy that tests 
                    <PRTPAGE P="93486"/>
                    methods of improving organ allocation) providing standards for transplant hospitals conducting HOPE Act transplants.
                    <SU>3</SU>
                    <FTREF/>
                     The OPTN expanded the variance in 2019 to include all solid organs,
                    <SU>4</SU>
                    <FTREF/>
                     and extended the variance through January 2026, to provide for the gathering of data and subsequent evaluation of the outcomes of HOPE Act transplants.
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         Organ Procurement and Transplantation Network. Policy Notice: Modifications to the Open Variance for the Recovery and Transplantation of Organs from HIV Positive Donors. 2016 Sep 1: 
                        <E T="03">https://optn.transplant.hrsa.gov/media/1872/dtac_policynotice_hope_201606.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Organ Procurement and Transplantation Network. Policy Notice: Modify HOPE Act Variance to Include Other Organs. 2019 Jun 10: 
                        <E T="03">https://optn.transplant.hrsa.gov/media/3000/dtac_policynotice_201906.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         Organ Procurement and Transplantation Network. Policy Notice: Extend HIV Organ Policy Equity (HOPE) Act Variance. 2021 Dec 6: 
                        <E T="03">https://optn.transplant.hrsa.gov/media/t1sdej22/policy-notice_dtac_hope_variance.pdf.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD2">C. Review of Research Results</HD>
                <P>The Secretary, in conjunction with the OPTN, reviewed the results of scientific research to determine whether the results warrant revision to the OPTN standards of quality with respect to organs from donors with HIV and the safety of transplanting an organ from a donor with a particular strain of HIV into a recipient with a different strain of HIV. 42 U.S.C. 274f-5(c)(1). This review allowed the Secretary to determine if the safety and efficacy of HOPE Act transplants are comparable to non-HOPE Act transplants and, if warranted, to further determine whether such transplants should be conducted outside of a research setting.</P>
                <HD SOURCE="HD3">1. OPTN Review and Recommendations</HD>
                <P>
                    In 2018, the OPTN initiated a review of research results and data relevant to HOPE Act transplants, forming a working group for this purpose.
                    <SU>6</SU>
                    <FTREF/>
                     The OPTN's assessment as to whether revision is warranted for the OPTN standards of quality applicable to HOPE Act transplants was based primarily on (1) the review of studies demonstrating the safety and outcomes of organ transplantation in recipients with HIV and (2) a recognition that the removal of the general research and IRB requirements for HOPE Act transplants could expand access to organ transplantation for all patients regardless of their HIV status. In this context, safety is measured by accidental or inadvertent transmission of HIV in the performance of HOPE Act transplants. (Of note, there were no recorded accidental or inadvertent transmission events in the data reviewed by the OPTN.) Outcomes are determined primarily by transplant recipient or graft survival, compared to non-HOPE Act transplants or transplant recipients without HIV. Measures (
                    <E T="03">e.g.,</E>
                     CD4+ T-cell counts, ART resistance, and detectable HIV viral loads) or variables such as opportunistic infections, HIV superinfection, malignancy, rejection, or graft failure may also factor into comparative outcomes in the short and long term.
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         Organ Procurement and Transplantation Network. Public Comment Proposal: Modify the HOPE Act Variance to Include Other Organs. 2019 Jan 22: 
                        <E T="03">https://optn.transplant.hrsa.gov/media/2800/dtac_publiccomment_20190122.pdf.</E>
                    </P>
                </FTNT>
                <P>The OPTN used three primary sources of data to assess HOPE Act transplants, each of which contributed to the recommendation the OPTN provided to the Secretary: (1) the research results of two pilot studies evaluating HOPE Act kidney transplants and liver transplants, and the progress of two ongoing NIH-funded clinical trials evaluating HOPE Act kidney transplants and liver transplants, (2) the research results of an older clinical trial analyzing safety and efficacy of kidney transplants in a small cohort of transplant recipients with HIV, and (3) OPTN data on the outcomes of all HOPE Act transplants.</P>
                <HD SOURCE="HD3">Pilot Studies</HD>
                <P>
                    A multicenter pilot study was launched in 2016 to determine safety and efficacy of HOPE Act kidney transplants. The HOPE In Action Consortium of 14 transplant centers conducting HOPE Act kidney transplants found no major differences between HOPE Act transplants of a kidney from a donor with HIV to a recipient with HIV and non-HOPE Act kidney transplants from a donor without HIV to a recipient with HIV.
                    <SU>7</SU>
                    <FTREF/>
                     Rates of opportunistic infections and infections requiring hospitalization post-transplant did not differ significantly across the study arms. Rejection was common for the study participants in the first year after transplant, occurring in 50 percent of recipients who received a kidney from a donor with HIV and 29 percent of recipients who received a kidney from a donor without HIV, but this result was not statistically significant. The insignificance of the result is due, in part, to the relatively small sample size. This finding is consistent with the earlier clinical trial of kidney transplantation in recipients with HIV, discussed in the next subsection of this preamble, which also found higher rejection rates in HIV allografts. The pilot study investigators noted that despite rejection rates, 1-year renal function was excellent for both study populations. Limitations of the pilot study include study size (75 transplants), which investigators attributed to the lower number of HOPE Act transplants conducted than the projected potential. In general, the study authors concluded that there is a survival benefit of transplantation for kidneys from donors with HIV to recipients with HIV, and that the availability of HOPE Act kidney transplants has the potential to mitigate disparities for a vulnerable population that faces lower access to transplant and higher waitlist mortality. The investigators further concluded that the observed trend toward higher rejection, albeit not statistically significant, for transplanted organs from donors with HIV merited further investigation.
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         Durand CM, Zhang W, Brown DM, Yu S, Desai N, Redd AD, Bagnasco SM, Naqvi FF, Seaman S, Doby BL, Ostrander D, Bowring MG, Eby Y, Fernandez RE, Friedman-Moraco R, Turgeon N, Stock P, Chin-Hong P, Mehta S, Stosor V, Small CB, Gupta G, Mehta SA, Wolfe CR, Husson J, Gilbert A, Cooper M, Adebiyi O, Agarwal A, Muller E, Quinn TC, Odim J, Huprikar S, Florman S, Massie AB, Tobian AAR, Segev DL; HOPE in Action Investigators. A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action. Am J Transplant. 2021 May;21(5):1754-1764.
                    </P>
                </FTNT>
                <P>
                    A separate pilot study conducted by HOPE In Action Consortium participants compared HOPE Act transplants of a liver from a donor with HIV to a recipient with HIV and non-HOPE Act liver transplants from a donor without HIV to a recipient with HIV, and found that there were no differences in one-year graft survival, rejections, HIV breakthrough or severe adverse events. While the recipients of HOPE Act liver transplants presented with more opportunistic infections, infectious hospitalizations, and cancer, compared to non-HOPE Act liver transplants, the investigators determined that these findings warrant further investigation and perhaps consideration of additional donor and recipient infection and malignancy monitoring. In general, the investigators concluded that the transplant outcomes were more favorable compared to historical data on liver transplantation in recipients with HIV, who are known to experience higher rates of opportunistic infections and other complications. In addition, it was noted that co-infections are more common among both donors and recipients with HIV and confound the results. (Results of non-HOPE Act transplants have confirmed that recipients with both HIV and a co-infection have lower survival rates. Therefore, the presence of co-infections could independently impact survival and other variables measured by studies on HOPE Act transplants.) 
                    <PRTPAGE P="93487"/>
                    This pilot study was the first multicenter prospective study reporting results of U.S. transplants of livers from donors with HIV to recipients with HIV and comparing outcomes according to donor HIV status in order to assess attributable risk. The investigators recognized as a limitation that the pilot study was relatively small (45 transplants), and noted that increases among HOPE Act liver transplant recipients in mortality, cytomegalovirus (CMV) viremia, infectious hospitalizations, and cancer, were observed. However, they note that these results should be considered in light of the relatively high rate of mortality for recipients awaiting liver transplant. For these patients, the benefit of undergoing a HOPE Act liver transplant may outweigh the risks of living with HIV and end stage liver disease.
                    <SU>8</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         Durand CM, Florman S, Motter JD, Brown D, Ostrander D, Yu S, Liang T, Werbel WA, Cameron A, Ottmann S, Hamilton JP, Redd AD, Bowring MG, Eby Y, Fernandez RE, Doby B, Labo N, Whitby D, Miley W, Friedman-Moraco R, Turgeon N, Price JC, Chin-Hong P, Stock P, Stosor V, Kirchner VA, Pruett T, Wojciechowski D, Elias N, Wolfe C, Quinn TC, Odim J, Morsheimer M, Mehta SA, Rana MM, Huprikar S, Massie A, Tobian AAR, Segev DL; HOPE in Action Investigators. HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV. Am J Transplant. 2022 Mar;22(3):853-864.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Ongoing Clinical Trials</HD>
                <P>
                    The OPTN further considered the progress of an NIH-funded study on HOPE Act kidney transplants that was ongoing at the time of the OPTN's analysis. The NIH-funded U01 HOPE Act kidney transplant clinical trial was designed to analyze rejection and long-term outcomes of kidney transplantation for recipients with HIV. While the study was subsequently expanded, at the time of the OPTN's consideration the study was designed to compare outcomes of 100 HOPE Act kidney transplant recipients to 100 kidney transplant recipients with HIV who received an HIV-negative organ at 15 transplant centers, adding to the cohort accrued from the pilot studies discussed in the immediately preceding section of this preamble.
                    <SU>9</SU>
                    <FTREF/>
                     The results from this clinical trial were published in October 2024 and are described in section 3, “Additional Research Results Published Subsequent to Issuance of the NPRM,” below. Of note, these investigators were awarded an expansion grant to evaluate longer-term outcomes in HOPE Act kidney transplants.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         National Institutes of Health RePORT. Kidney Transplantation from Donors with HIV: Impact on Rejection and Long-term Outcomes. Project No. 5U01AI177211-02. Accessed 21 May 2024. 
                        <E T="03">https://reporter.nih.gov/search/kcWJ0GeT8kigjO2_LU8R2g/project-details/10848468.</E>
                    </P>
                </FTNT>
                <P>
                    Similarly, the OPTN considered the progress of an ongoing U01 HOPE Act liver transplant clinical trial designed to compare outcomes between HOPE Act transplants and non-HOPE Act transplants of livers from donors without HIV. The study has enrolled 40 individuals in each group over 3 years at 16 transplant centers,
                    <SU>10</SU>
                    <FTREF/>
                     reaching target enrollment, and now is in the phase of patient follow-up. The final results are not yet published.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         National Institutes of Health RePORT. Hope In Action: A Clinical Trial of HIV-to-HIV Liver Transplantation. Project No. 5U01AI138897-05. Accessed 21 May 2024. 
                        <E T="03">https://reporter.nih.gov/project-details/10459319.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Other Research Results</HD>
                <P>
                    Prior to the initiation of the pilot studies and clinical trials discussed previously, a clinical trial examined outcomes of 150 kidney transplants in recipients with HIV conducted between November 2003 and June 2009. The investigators found both recipient and graft survival rates were high with no important increases in complications associated with HIV.
                    <SU>11</SU>
                    <FTREF/>
                     As noted in the description of the findings of the HOPE Act kidney transplant pilot study described in the immediately preceding subsection of this preamble, the investigators observed what they described as “unexpectedly higher” rejection rates in the transplant recipients with HIV participating in the study, compared with kidney transplant recipients who are not living with HIV. This higher rejection rate was blunted in transplant recipients that received anti-T-cell antibody medication at the time of transplantation. Studies of non-HOPE Act transplants have confirmed that such immunosuppressive regimens can reduce the risk of rejection for kidney transplant recipients with HIV.
                    <SU>12</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subramanian A, Millis JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stablein DM, Roland ME. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010 Nov 18;363(21):2004-14.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         Locke JE, James NT, Mannon RB, Mehta SG, Pappas PG, Baddley JW, Desai NM, Montgomery RA, Segev DL. Immunosuppression Regimen and the Risk of Acute Rejection in HIV-Infected Kidney Transplant Recipients. Transplantation. 2014 Feb 27;97(4):p 446-450.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">OPTN Data—HOPE Act Transplant Outcomes</HD>
                <P>Data from HOPE Act transplants is compiled by the OPTN on a quarterly basis, including waitlist registrations and counts of HOPE Act transplants, and is routinely reviewed. Prior to issuing its recommendation to the Secretary, the OPTN reviewed data on over 300 patients included in the HOPE Act research variance for which no case was halted, paused, or substantially amended to address safety concerns.</P>
                <HD SOURCE="HD3">OPTN Recommendations</HD>
                <P>
                    Based on the assessment of the above-described research results and data, in 2021 the OPTN recommended to the Secretary that the research and IRB requirements of the HOPE Act be removed for all organs.
                    <SU>13</SU>
                    <FTREF/>
                     The OPTN specifically noted that in its review of the data safety monitoring review board (DSMB) reports from five years of HOPE Act transplants, with over 300 persons with HIV receiving HOPE Act transplants, no DSMB identified patient safety concerns in HOPE Act research. Further, there have been no reports made to the OPTN of safety issues regarding HOPE Act transplants among OPO, hospital, or transplant center personnel or in patients, in donor hospitals, or transplant hospitals. The OPTN noted that it was the opinion of the OPTN Safety Review Group that the research and IRB requirements for HOPE Act transplants present a barrier to fully realizing the potential of organ transplantation from donors with HIV to recipients with HIV, as the research and IRB requirements limit access to such transplants.
                    <E T="51">14 15</E>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         Cooper M. “OPTN Letter to Secretary Becerra on the HOPE Act.” 2021 Oct 29. 
                        <E T="03">https://optn.transplant.hrsa.gov/media/ueyjdfnd/hope-act-letter.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         McCauley J. “Fifty Sixth ACBTSA Meeting, Written Public Comment—November 17, 2022 Meeting.” 2022 Nov 8. 
                        <E T="03">https://optn.transplant.hrsa.gov/media/hwgncda2/optn-executive-committee_acbtsa-letter.pdf.</E>
                    </P>
                    <P>
                        <SU>15</SU>
                         Chandran S, Stock PG, Roll GR. Expanding Access to Organ Transplant for People Living With HIV: Can Policy Catch Up to Outcomes Data? Transplantation. 2024 Apr 1;108(4):874-883.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Additional Research Results Published Subsequent to the OPTN Assessment</HD>
                <P>Prior to publication of the NPRM, the Secretary further considered additional research published providing more evidence for the safety of organ transplantation from donors with HIV to recipients with HIV. In general, this research demonstrates that the safety and outcomes of kidney and liver HOPE Act transplants are well established, with over 517 HOPE Act kidney and liver transplants conducted to date.</P>
                <P>
                    One prospective study published in 2022, examined 92 HOPE Act donors contributing 177 organs, which included 131 kidneys and 46 livers, to understand the characteristics of donors with HIV in terms of clinical, 
                    <PRTPAGE P="93488"/>
                    immunologic, and virologic profiles to ensure the safety of transplantation. Of these donors, 58 were donors with HIV and 34 were donors without HIV. For those donors with known HIV infection, 90 percent received ART treatment. The study concluded that although drug resistant mutations (DRMs) were common, DRMs that could compromise the effectiveness of certain ART were rare, reassuring the safety of using organs from donors with HIV in recipients with HIV. Further, the study also found that there were no major differences in comorbidities between recipient groups that received an organ from a donor with HIV compared to those that received an organ from a donor without HIV.
                    <SU>16</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         Werbel WA, Brown DM, Kusemiju OT, Doby BL, Seaman SM, Redd AD, Eby Y, Fernandez RE, Desai NM, Miller J, Bismut GA, Kirby CS, Schmidt HA, Clarke WA, Seisa M, Petropoulos CJ, Quinn TC, Florman SS, Huprikar S, Rana MM, Friedman-Moraco RJ, Mehta AK, Stock PG, Price JC, Stosor V, Mehta SG, Gilbert AJ, Elias N, Morris MI, Mehta SA, Small CB, Haidar G, Malinis M, Husson JS, Pereira MR, Gupta G, Hand J, Kirchner VA, Agarwal A, Aslam S, Blumberg EA, Wolfe CR, Myer K, Wood RP, Neidlinger N, Strell S, Shuck M, Wilkins H, Wadsworth M, Motter JD, Odim J, Segev DL, Durand CM, Tobian AAR; HOPE in Action Investigators. National Landscape of Human Immunodeficiency Virus-Positive Deceased Organ Donors in the United States. Clin Infect Dis. 2022 Jun 10;74(11):2010-2019.
                    </P>
                </FTNT>
                <P>
                    In a March 2024 analysis of the impact of the HOPE Act on access to kidney transplantation for recipients with HIV, the authors found 70 percent of HOPE Act recipients received a kidney transplant during the 4.5 year study period versus 43 percent of non-HOPE Act transplant candidates at the same center.
                    <SU>17</SU>
                    <FTREF/>
                     Furthermore, those who received transplants in HOPE Act trials had shorter estimated wait times (median 10.3 months versus 60.8 months), and after adjusting for relevant allocation factors including time on dialysis, kidney transplantation was 3.3-fold higher for those who received an organ from a donor with HIV.
                    <SU>18</SU>
                    <FTREF/>
                     These findings suggest that the availability of kidneys from donors with HIV increases access to transplantation among people with HIV. Given that people with HIV who are living with end stage renal disease (ESRD) have higher mortality than people with ESRD who are not also living with HIV,
                    <SU>19</SU>
                    <FTREF/>
                     in HHS's view, this data illustrates the benefit of HOPE Act kidney transplants for this vulnerable population.
                </P>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         Motter JD, Hussain S, Brown DM, Florman S, Rana MM, Friedman-Moraco R, Gilbert AJ, Stock P, Mehta S, Mehta SA, Stosor V, Elias N, Pereira MR, Haidar G, Malinis M, Morris MI, Hand J, Aslam S, Schaenman JM, Baddley J, Small CB, Wojciechowski D, Santos CAQ, Blumberg EA, Odim J, Apewokin SK, Giorgakis E, Bowring MG, Werbel WA, Desai NM, Tobian AAR, Segev DL, Massie AB, Durand CM; HOPE in Action Investigators. Wait Time Advantage for Transplant Candidates With HIV Who Accept Kidneys From Donors With HIV Under the HOPE Act. Transplantation. 2024 Mar 1;108(3):759-767.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         Motter JD, et al, on behalf of the HOPE in Action Investigators. Wait Time Advantage for Transplant Candidates With HIV Who Accept Kidneys From Donors With HIV Under the HOPE Act. Transplantation. 2024 Mar 1;108(3):759-767.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         Motter JD, et al., on behalf of the HOPE in Action Investigators. Wait Time Advantage for Transplant Candidates With HIV Who Accept Kidneys From Donors With HIV Under the HOPE Act. Transplantation. 2024 Mar 1;108(3):759-767.
                    </P>
                </FTNT>
                <P>
                    The HOPE in Action Consortium also has published information on the positive outcomes of living HOPE Act kidney donors. In a case series of three transplants, investigators reported that two of the three donors developed adverse events, but findings suggested these were medically managed and that HIV RNA copies and CD4+ T-cell counts were stable at two to four years post-transplant.
                    <SU>20</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         Durand CM, et al., on behalf of the HOPE in Action Investigators. Living Kidney Donors with HIV: Experience and Outcomes from a Case Series by the HOPE in Action Consortium. The Lancet Regional Health Americas. 2023 Jul;24:100553.
                    </P>
                </FTNT>
                <P>
                    There is significantly less data on non-kidney and non-liver HOPE Act transplants. Since 2019, when the OPTN's HOPE Act policy was expanded to include all solid organs, only three heart transplant programs have received approval to perform HOPE Act transplants. To date, just three heart transplants have been conducted, including one heart-kidney transplant.
                    <E T="51">21 22</E>
                    <FTREF/>
                     No HOPE Act transplants have been recorded among recipients in need of other organs. The lack of data makes it difficult to assess the safety and outcomes of HOPE Act transplants other than kidney and liver HOPE Act transplants.
                </P>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         Montefiore News Releases. World's First HIV-Positive to HIV-Positive Heart Transplant Performed at Montefiore Health System. 2022 Jul 22. 
                        <E T="03">https://www.montefiore.org/body.cfm?id=1738&amp;action=detail&amp;ref=2194.</E>
                    </P>
                    <P>
                        <SU>22</SU>
                         Hemmige V, Saeed O, Puius YA, Azzi Y, Colovai A, Borgi J, Goldstein DJ, Rahmanian M, Carlese A, Jorde UP, Patel S. HIV D+/R+ heart/kidney transplantation: First case report. J Heart Lung Transplant. 2023 Mar;42(3):406-408.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">3. Additional Research Results Published Subsequent to Issuance of the NPRM</HD>
                <P>
                    Since publication of the NPRM, results from a new, groundbreaking study were published in October 2024.
                    <SU>23</SU>
                    <FTREF/>
                     In the largest prospective, observational, multicenter study to date, researchers compared transplantation of kidneys at 26 U.S. centers from deceased donors with HIV and donors without HIV to recipients with HIV. The study enrolled 408 transplantation candidates, of whom 198 received a kidney from a deceased donor; 99 received a kidney from a donor with HIV and 99 from a donor without HIV. This study was larger than the HOPE Act pilot study, described above, and was designed to assess whether kidney transplantation from donors with HIV to recipients with HIV would be noninferior to transplantation from donors without HIV. The study further assessed safety and post-transplantation complications.
                </P>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         C.M. Durand, A. Massie, S. Florman, T. Liang, M.M. Rana, R. Friedman-Moraco, A. Gilbert, P. Stock, S.A. Mehta, S. Mehta, V. Stosor, M.R. Pereira, M.I. Morris, J. Hand, S. Aslam, M. Malinis, G. Haidar, C.B. Small, C.A.Q. Santos, J. Schaenman, J. Baddley, D. Wojciechowski, E.A. Blumberg, K. Ranganna, O. Adebiyi, N. Elias, J.A. Castillo-Lugo, E. Giorgakis, S. Apewokin, D. Brown, D. Ostrander, Y. Eby, N. Desai, F. Naqvi, S. Bagnasco, N. Watson, E. Brittain, J. Odim, A.D. Redd, A.A.R. Tobian, and D.L. Segev, for the HOPE in Action Investigators. Safety of Kidney Transplantation from Donors with HIV. New England Journal of Medicine. 2024 Oct 17; 391(15): 1390-1401.
                    </P>
                </FTNT>
                <P>The primary outcome assessed was a safety outcome (a composite of death from any cause, graft loss, serious adverse event, HIV breakthrough infection, persistent failure of HIV treatment, or opportunistic infection) for noninferiority (margin for the upper bound of the 95% confidence interval, 3.00). Researchers found an adjusted hazard ratio of 1.00 for the primary composite outcome, demonstrating noninferiority of kidney transplantation from donors with HIV as compared to kidney transplantation from donors without HIV.</P>
                <P>Secondary outcomes included overall survival, survival without graft loss, rejection, infection, cancer, and HIV superinfection. The following secondary outcomes were similar whether the donor had HIV or not: overall survival at 1 year (94% vs. 95%) and 3 years (85% vs. 87%), survival without graft loss at 1 year (93% vs. 90%) and 3 years (84% vs. 81%), and rejection at 1 year (13% vs. 21%) and 3 years (21% vs. 24%).</P>
                <P>
                    The incidence of serious adverse events, infections, and cancer was similar in all groups studied. Of note, the incidence of HIV breakthrough infection was approximately three times higher among HOPE Act transplants (incidence rate ratio, 3.14; 95% CI, 1.02 to 9.63), which the researchers attributed to non-adherence to antiretroviral therapy. In all participants with HIV breakthrough infection, viral suppression was regained. A single case of potential HIV superinfection or dual infection occurred among the 58 recipients in this group, without HIV breakthrough infection or clinical consequences.
                    <PRTPAGE P="93489"/>
                </P>
                <P>Among the acknowledged limitations of this study are the lack of true randomization, which the authors note was not possible due to the U.S. national organ allocation process. The authors further note that study participants were equally eligible for a kidney from a donor with or a donor without HIV, and that study group assignment was determined according to whichever organ was available first. The study group whose donors did not have HIV served as a control group and included 27 donors who were treated as having HIV during allocation but did not; in the authors' estimation, recipients of kidneys from these donors represent an ideal counterfactual control group. Immunosuppression and prophylaxis were heterogeneous; however, these factors were balanced between the two groups and reflect real-world practice, which the authors assert increases the generalizability of the study results.</P>
                <P>This study is an important addition to the evidence base for HOPE Act kidney transplants in that the finding that kidney transplantation from donors with HIV was noninferior to kidney transplantation from donors without HIV with respect to the primary safety outcome, and that the incidence of serious adverse events, infections, surgical or vascular complications, and cancer was similar in the two groups, supporting the safety of HOPE Act kidney transplants.</P>
                <HD SOURCE="HD3">4. HHS Advisory Committee on Blood and Tissue Safety and Availability Recommendations</HD>
                <P>
                    The Secretary also considered the HHS Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) recommendation that the Secretary eliminate research and IRB requirements for all HOPE Act transplants. The ACBTSA working group developing this recommendation considered the OPTN recommendation and the results of relevant scientific research. While the ACBTSA working group proposed that the full committee recommend that the Secretary eliminate research and IRB requirements for all HOPE Act transplants, the working group expressed concern about the elimination of research and IRB requirements for non-kidney and non-liver HOPE Act transplants,
                    <SU>24</SU>
                    <FTREF/>
                     and whether there was sufficient data collected on other organs to justify a full adoption of the OPTN's recommendation.
                </P>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         HHS Advisory Committee on Blood and Tissue Safety and Availability. 2022. Fifty-Sixth ACBTSA Meeting November 17, 2022—Meeting Summary. 
                        <E T="03">https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meeting-summary/2022-11-17/index.html.</E>
                    </P>
                </FTNT>
                <P>The ACBTSA subsequently recommended that the Secretary act to lift the statutory research and IRB requirements for all HOPE Act transplants and at the same time recommended that the Secretary direct the OPTN to adopt, for HOPE Act transplants of organs other than kidneys and livers, organ-specific policies imposing additional requirements for the conduct of these transplants, including collecting safety and outcomes data for transplant candidates and recipients of such transplants through an IRB-approved research protocol.</P>
                <P>These recommendations were later approved by the HHS Blood, Organ, and Tissue Senior Executive Council (BOTSEC), an advisory forum for senior leadership from HHS entities involved in blood, organ, and tissue safety and availability.</P>
                <P>Upon review of the OPTN, ACBTSA and BOTSEC recommendations, and in consideration of the results of relevant scientific research, the Secretary proposed to determine that the research and IRB requirements for kidney and liver HOPE Act transplants are no longer warranted. The NPRM incorporated this approach, publishing the Secretary's proposed determination for comment, and proposing regulatory changes to exempt HOPE Act kidney and liver transplants from research and IRB requirements. In an effort to avoid the use of stigmatizing language, the NPRM further proposed wording changes to references to persons, donors, and recipients with HIV, and organs from individuals with HIV.</P>
                <HD SOURCE="HD1">III. Discussion of Public Comment</HD>
                <P>HHS received 56 comments from individuals and organizations involved in healthcare, organ transplantation, HIV advocacy, health equity, LGTBQIA+ health, and HOPE Act clinical research. The comments received expressed overwhelming support for the finalization of this rule. A total of 55 of the 56 commenters expressed support for the proposed rule. One commenter did not support the proposed rule. Additional consideration was given to comments that were expressed by multiple individuals and entities. HHS has considered all of the comments, and, in response to comments regarding the use of non-stigmatizing language, made changes to the final rule as suggested by commenters.</P>
                <P>Themes identified in many comments include that the proposed rule, if finalized, could reduce morbidity and mortality for people with HIV, reduce barriers to organ transplantation, increase organ utilization, reduce wait times for people on organ transplant wait lists, and reduce stigma and discrimination associated with HIV. One commenter indicated that, given that only 31 of the 250 transplant centers in the U.S. currently participate in HOPE Act clinical trials, access to these vital transplants is geographically limited: the proposed rule would encourage more transplant centers to offer HOPE Act transplants, enabling more equitable access to life-saving care for people with HIV across the country and helping to generate additional clinical data to enhance understanding and inform best practices in transplant care for people with HIV. In addition, numerous commenters noted that research has sufficiently demonstrated that HOPE Act kidney and liver transplants are both safe and effective.</P>
                <P>The NPRM specifically invited public comment on the future Secretarial direction to the OPTN to revise the standards of quality concerning kidneys and livers from donors with HIV. Some commenters provided specific suggestions for the Secretary's direction, and other comments received appear relevant to HHS's consideration as to the content of the direction to the OPTN. These comments are noted below in both the subheading discussing the comments specifically provided on the content of the direction to the OPTN, and the subheadings relating to the subject matter of the comment. HHS has considered these comments in the development of the Secretary's direction to the OPTN, which is provided in section V, “Implementation Considerations,” below.</P>
                <P>Multiple commenters also provided specific suggestions for the content of the revised NIH Research Criteria, and other comments received appear relevant to the content of the Research Criteria. These comments are noted below in both the subheading discussing the comments specifically provided on the Research Criteria, as well as in the subheadings relating to the subject matter of the comment when the commenter did not specifically reference the Research Criteria. All comments relating to the content of the revised Research Criteria were provided to NIH for consideration in the development of the revised Research Criteria.</P>
                <P>
                    Detailed descriptions of comments on specific aspects of the NPRM preamble and the proposed regulation, and HHS's responses to these comments, are provided below.
                    <PRTPAGE P="93490"/>
                </P>
                <HD SOURCE="HD3">Removal of Research and IRB Requirements for All Organs</HD>
                <P>
                    Several commenters suggested that the Secretary should consider in this rule, or in a future rulemaking, the removal of research and IRB requirements for all HOPE Act organ transplants instead of removing research and IRB requirements only for kidney and liver transplants. Some of these commenters referenced the October 2021 letter from the OPTN to the Secretary providing that the OPTN had not identified any patient safety concerns involving HOPE Act transplants and that no research protocols applicable to HOPE Act transplants had been stopped, paused, or substantially altered due to patient safety concerns.
                    <SU>25</SU>
                    <FTREF/>
                     Many of these comments suggested that the available data was sufficient to prove the safety and efficacy of HOPE Act transplantation for all organ transplants, not only kidney and liver transplants. Others suggested that HHS should continue supporting research on HOPE Act transplants with the goal of generating sufficient evidence to make the case for a future Secretarial determination and rulemaking process that would remove the research and IRB requirements for all HOPE Act transplants.
                </P>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         Cooper M. “OPTN Letter to Secretary Becerra on the HOPE Act.” 2021 Oct 29. 
                        <E T="03">https://optn.transplant.hrsa.gov/media/ueyjdfnd/hope-act-letter.pdf.</E>
                    </P>
                </FTNT>
                <P>
                    <E T="03">HHS response:</E>
                     In the process leading up to the development of the NPRM, the Secretary considered whether to eliminate research and IRB requirements for all HOPE Act transplants. As a part of this process, the Secretary considered the October 2021 communication from the OPTN referenced by commenters, recommendations of advisory bodies, and research results and outcomes data on HOPE Act transplants. The vast majority of this data was generated from kidney and liver transplants, and, as discussed in the NPRM preamble, the Secretary notes the limited evidence demonstrating safety and efficacy of non-kidney and non-liver HOPE Act transplants. In order to lift the research and IRB requirements for HOPE Act transplants, the HOPE Act requires that the Secretary must determine that participation in clinical research is no longer warranted. 42 U.S.C. 274(b)(3)(B)(ii). In the absence of research results and robust outcomes data relevant to HOPE Act transplants of organs other than kidneys and livers, the Secretary does not have sufficient information about transplants of organs other than kidneys and livers on which to base the statutorily required determination. For this reason, the NPRM proposal to lift the research and IRB requirements only for HOPE Act kidney and liver transplants is incorporated in this final rule. As required by the HOPE Act, the Secretary will periodically review the results of additional scientific research relevant to transplants of organs other than kidneys and livers, and will reevaluate in the future whether the evidence is robust enough to demonstrate that other types of HOPE Act transplants need not be conducted in the research context. HHS makes no changes to the regulatory proposal in response to these comments.
                </P>
                <HD SOURCE="HD3">Language Regarding HIV</HD>
                <P>Many commenters expressed support for the proposed revisions to the regulatory language used when referencing people, donors, and recipients with HIV. In general, commenters suggested that the proposed changes are more respectful, reflect a person-centered approach, and help to combat stigma associated with HIV. Others noted that these wording changes help to create a more inclusive healthcare environment.</P>
                <P>One commenter requested that the proposed modification to 42 CFR 121.6 regarding references to donor organs be changed from “donor organ(s) with HIV” to “organ(s) from donors with HIV.” The commenter stated that, in their view, the term “organs from donors with HIV” is accurate and precise, stigma-reducing, and reflects a person-first approach in describing these donated organs.</P>
                <P>
                    <E T="03">HHS response:</E>
                     HHS appreciates this feedback, and includes the regulatory revisions in this final rule as proposed with regard to references to people, donors, and recipients with HIV. Further, HHS concurs with the suggested revision provided by the commenter with respect to the references to donor organs, and has incorporated this suggested revision and other similar revisions in the final rule at 42 CFR 121.6(b)(1)(ii)(B) introductory text, (b)(1)(ii)(B)(
                    <E T="03">1</E>
                    ) and (
                    <E T="03">2</E>
                    ), and (b)(2).
                </P>
                <HD SOURCE="HD3">Ongoing Data Monitoring</HD>
                <P>Multiple commenters expressed support for efforts to monitor outcomes of HOPE Act transplants, both for patient safety and to develop evidence for the safety and efficacy of HOPE Act transplants.</P>
                <P>Commenters addressing patient safety indicated that while the proposed rule may streamline the transplant process and increase the availability of organs, patient safety must be the top priority and rigorous safety standards must continue to apply. Several commenters noted that areas needing further attention, such as monitoring for rejection, malignancy, and infection, do not overshadow the overall favorable outcomes for HOPE Act kidney and liver transplants. Commenters emphasized the importance of continued monitoring of outcomes for these transplants by the OPTN, and that transparency and public communication of these outcomes are critical to maintaining trust and ensuring the ongoing success of HOPE Act transplant programs. Commenters indicated that application of the NIH Research Criteria has provided essential protections with regard to outcomes monitoring for HOPE Act kidney and liver transplants, and urged continued monitoring of HOPE Act transplants to ensure these protections are maintained.</P>
                <P>Other commenters expressed that data monitoring could help HOPE Act transplant recipients and HOPE Act living donors who may need to be monitored for the development of chronic or end-stage conditions. For example, one commenter noted that living kidney donors “are already at higher risk of kidney disease and will now only have one kidney.”</P>
                <P>Commenters addressing evidence development noted that monitoring and evaluation of HOPE Act transplants may help develop evidence that will inform future policy, including a potential future implementation of the HOPE Act to remove research and IRB requirements for all HOPE Act organ transplants.</P>
                <P>Several commenters indicated that current data monitoring requirements applicable to all organ transplants are sufficient. One commenter indicated that there is no reason to continue monitoring HOPE Act kidney and liver transplant outcomes above and beyond the baseline safety and outcomes monitoring for all organ transplants in the United States. One commenter indicated that the OPTN structure and outcome data collected are sufficient in their current state to provide oversight for all organs. Another commenter indicated comfort with appropriate oversight and data management by the organizations designated to oversee transplant services on a national level, which could include comprehensive reporting systems to track outcomes and address any issues promptly. The commenter further expressed an expectation that this information be made available to the public is a transparent manner.</P>
                <P>
                    <E T="03">HHS response:</E>
                     HHS notes that the final rule does not affect existing data 
                    <PRTPAGE P="93491"/>
                    monitoring or evaluation requirements for HOPE Act transplants, as these are determined by OPTN policy and the NIH Research Criteria. HHS agrees that patient safety remains a paramount concern and that appropriate safety standards apply to protect organ donors and transplant recipients. Further, HHS expects to utilize data on HOPE Act transplant outcomes in its ongoing evaluation of the HOPE Act. These comments were provided to the NIH working group for consideration in the development of revisions to the Research Criteria. Further, HHS considered these comments in developing the Secretary's direction to the OPTN to revise the OPTN standards of quality embodied in OPTN policy regarding organs from donors with HIV. HHS makes no changes to the regulatory proposal in response to these comments.
                </P>
                <HD SOURCE="HD3">Standards for Transplant Centers Performing HOPE Act Transplants</HD>
                <P>Several commenters provided suggestions for transplant centers that are seeking to participate in HOPE Act transplants. One commenter requested that HHS evaluate all outstanding requests by transplant centers to participate in HOPE Act transplants, and approve qualifying transplant centers as soon as possible to both expand access to care and to generate additional data on the HOPE Act transplants they perform. The commenter further requested that HHS explore providing grants designed to build the capacity at transplant centers such that more transplant centers will be able to meet the minimum requirements necessary to become HOPE Act transplant centers.</P>
                <P>
                    <E T="03">HHS response:</E>
                     Thank you for these suggestions. While no changes have been made to the regulatory proposal in response to these comments, HHS will consider these suggestions in the Department's ongoing approach to implementation of the HOPE Act.
                </P>
                <HD SOURCE="HD3">Informed Consent and Autonomy of Transplant Recipients</HD>
                <P>Some commenters expressed the desire that, if HHS finalizes the proposed rule, that HHS take steps to prioritize ethical considerations relevant to the autonomy of donors and recipients. In particular, commenters asked that transplant centers maintain meaningful processes to provide patients with the opportunity to provide informed consent, and that transplant candidates with HIV retain the option to elect a non-HOPE Act transplant instead of a HOPE Act transplant.</P>
                <P>
                    <E T="03">HHS response:</E>
                     This rule does not affect existing OPTN policies that require that informed consent is obtained from all transplant candidates, including HOPE Act transplant candidates,
                    <SU>26</SU>
                    <FTREF/>
                     or the informed consent policies or practices at hospitals providing clinical care to potential organ donors, OPOs, or individual transplant centers. HHS supports retaining the existing approach in OPTN policy that requires informed consent.
                </P>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         Organ Procurement and Transplantation Network. OPTN Policies. Updated October 31, 2024. 
                        <E T="03">https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf.</E>
                    </P>
                </FTNT>
                <P>
                    Further, existing OPTN policies do not prohibit transplant candidates eligible for a HOPE Act transplant to choose a non-HOPE Act transplant.
                    <SU>27</SU>
                    <FTREF/>
                     There are no revisions made in this rule that would force a transplant candidate to receive an organ from a donor with HIV. HHS supports retaining the existing approach in OPTN policy that permits transplant candidates eligible for a HOPE Act kidney or liver transplant to choose a non-HOPE Act kidney or liver transplant.
                </P>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         Organ Procurement and Transplantation Network. OPTN Policies. Updated October 31, 2024. 
                        <E T="03">https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf.</E>
                    </P>
                </FTNT>
                <P>HHS considered these comments in developing the Secretary's direction to the OPTN to revise the OPTN standards of quality embodied in OPTN policy regarding organs from donors with HIV, as provided below in this preamble in the discussion of implementation considerations. HHS makes no changes to the regulatory proposal in response to these comments.</P>
                <HD SOURCE="HD3">Education</HD>
                <P>Commenters expressed the desire for additional educational efforts regarding HOPE Act transplantation. Some commenters suggested that HRSA collaborate with the OPTN and work with OPOs to ensure that transplant centers are making compassionate efforts to seek authorization from potential kidney donors with HIV. Commenters further suggested that HRSA partner with the Centers for Medicare &amp; Medicaid Services (CMS) to ensure that donor hospitals recognize every opportunity for organ donation for patients with an HIV-positive diagnosis and make referrals to the local OPO for an organ donation evaluation as mandated by the CMS Conditions of Participation. Other commenters asked for educational efforts aimed at people with HIV, healthcare professionals, students of health sciences, transplant centers, OPOs, and the public at large to increase awareness of the HOPE Act and opportunities to elect organ donation regardless of HIV status.</P>
                <P>
                    <E T="03">HHS response:</E>
                     HHS is supportive of any and all efforts to increase awareness and education about HOPE Act transplants, opportunities for persons with HIV to participate as organ donors, and transplant candidates with HIV to receive a HOPE Act transplant. While HHS is not making any revisions to the regulatory proposal in response to these comments, HHS will consider additional educational efforts along the lines of those suggested by the commenters.
                </P>
                <HD SOURCE="HD3">NIH Research Criteria</HD>
                <P>Several commenters provided specific suggestions for the content and development of the revised NIH Research Criteria:</P>
                <P>• Commenters requested the elimination of the current requirement that a transplant team perform at least five transplants within a four-year period between any donor and a recipient with HIV for all organs, as, in the commenters' estimation, this requirement is not necessary for organs from donors with HIV to be used safely.</P>
                <P>• Commenters suggested that each transplant team should include infectious disease specialists with expertise in HIV care.</P>
                <P>• One commenter requested the elimination of the biopsy requirement.</P>
                <P>• One commenter noted that, in revising the Research Criteria, NIH should both maintain the strong patient safety record for HOPE Act transplants, while actively seeking to reduce burdens that may be slowing the establishment of non-kidney and non-liver HOPE Act transplant programs.</P>
                <P>• One commenter requested that NIH include people with HIV, HIV researchers, physicians, and healthcare providers in the process of developing revised Research Criteria, and indicated that these individuals can provide invaluable insights that can only come from lived experience.</P>
                <P>
                    <E T="03">HHS response:</E>
                     HHS appreciates these suggestions, and agrees that these comments are relevant to the content of the NIH Research Criteria. These comments were provided to the NIH working group for consideration in the development of revisions to the Research Criteria. HHS makes no changes to the regulatory proposal in response to these comments.
                </P>
                <HD SOURCE="HD3">Secretarial Direction to the OPTN</HD>
                <P>
                    While multiple commenters provided suggestions that appear relevant to the Secretary's future direction to the OPTN to revise the standards of quality concerning kidneys and livers from donors with HIV, only a few commenters specifically referenced the 
                    <PRTPAGE P="93492"/>
                    content of the Secretarial direction and provided recommendations. One commenter indicated that they defer to health care professionals as to the content of such direction, and further urged HHS to make sure that the final OPTN policies do not create additional barriers or lead to unintended consequences that make it more difficult for individuals to access these organs. One commenter requested that the direction to the OPTN require intensive and multi-disciplinary counseling and discussions to be conducted with the solid organ recipient, with ongoing care before, during, and after the transplant, to ensure that solid organ recipients understand the complexities of the transplant procedure while also receiving the emotional and physical care they need throughout the entirety of the process. The commenter further noted the opportunity for the OPTN to define transplant program collaboration on a more formal basis, recommending that the structure of the transplant team include nephrologists and/or hepatologists, infectious diseases experts, and transplant pharmacy members, and that requirements be instituted for providing counseling or any specific transplant training recommendations for infectious disease experts.
                </P>
                <P>The commenters who provided views and suggestions that are relevant to the Secretary's direction to the OPTN, while not specifically referencing the content of the Secretary's direction, generally indicated that the current requirements applicable to all organ transplants are sufficient to appropriately ensure the safety of HOPE Act kidney and liver transplants conducted outside of the research context. One commenter indicated that there is no reason to impose special monitoring requirements for HOPE Act kidney and liver transplant outcomes, as appropriately protective standards are already included in the baseline safety and outcomes monitoring for all organ transplants in the United States. One commenter indicated that the OPTN structure and outcome data collected are sufficient in their current state to provide appropriate oversight for all organ transplants, regardless of whether the transplant involves organs from donors with HIV to recipients with HIV. Another commenter indicated comfort with appropriate oversight and data management by the organizations designated to oversee transplant services on a national level, indicating that such oversight may include stringent medical protocols, regular follow-ups, and comprehensive reporting systems to track outcomes and address any issues promptly. The commenter further expressed an expectation that safety and outcomes information be made available to the public is a transparent manner.</P>
                <P>One commenter noted that HHS stated in the NPRM that scientific evidence demonstrates that transplants of kidneys and livers from donors with HIV to recipients with HIV are safe and effective. Given this view, the commenter opined that the current clinical standards of care for non-HOPE Act organ transplants are sufficient to apply to transplants of all kidneys and livers, of any HIV serostatus. The commenter further expressed that additional scrutiny of transplants of kidneys and livers from donors with HIV to recipients with HIV could be viewed as discrimination against recipients with HIV who are willing to accept offers of an organ from a donor with HIV, and infringes on patient autonomy. The commenter noted that the OPTN already is responsible for safety and outcomes monitoring for transplants that involve donors or recipients with viruses other than HIV, including cytomegalovirus, Epstein-Barr virus, hepatitis B and C viruses, and severe acute respiratory syndrome coronavirus 2.</P>
                <P>
                    <E T="03">HHS response:</E>
                     HHS appreciates all of the comments and suggestions regarding the content of the Secretary's direction to the OPTN. HHS has carefully considered these comments in developing the Secretary's direction to the OPTN to revise the OPTN standards of quality embodied in OPTN policy regarding organs from donors with HIV. As discussed below in section V, “Implementation Considerations,” through publication of this final rule, the Secretary directs the OPTN to adopt and use standards of quality with respect to kidneys and livers from donors with HIV to ensure that HOPE Act kidney and liver transplants are subject to OPTN policies that, from the OPTN's expertise, will not reduce the safety of HOPE Act kidney and liver transplants, provide appropriate oversight for these transplants, and require sufficient data collection and outcomes monitoring.
                </P>
                <HD SOURCE="HD3">Health Equity and Patient Experience</HD>
                <P>Many comments positively noted the health equity component of the proposed rule and the potential impact to populations that are disproportionately impacted by HIV and end-stage chronic diseases. Several commenters requested that HHS consider the insights and experiences of HOPE Act patients in this and future rulemaking efforts.</P>
                <P>
                    <E T="03">HHS response:</E>
                     We agree. HHS supports efforts to better address health equity in organ transplantation and believes this rule will help to increase access to care among populations that are disadvantaged. HHS also is supportive of efforts to incorporate patient experience into policy, and we have received, and considered, comments from HOPE Act patients during this rulemaking process, including a comment from a self-identified living donor of a kidney used in a HOPE Act transplant. HHS makes no changes to the regulatory proposal in response to these comments.
                </P>
                <HD SOURCE="HD3">Approach to Patient Care</HD>
                <P>Several commenters suggested changes to clinical care standards for HOPE Act transplant patients. One commenter requested that the Department encourage transplant centers to incorporate syndemic care approaches to address the complex needs of people with HIV. Syndemic care aims to provide more holistic service delivery to prevention and care, including by addressing the social determinants of health that allow for health conditions to cluster and interact. Several commenters requested that additional safety protocols be developed for transplant centers, such as post-operative care guidelines for HOPE Act transplant recipients.</P>
                <P>
                    <E T="03">HHS response:</E>
                     HHS is supportive of efforts to incorporate syndemic care approaches within the organ transplantation domain. Regarding the establishment of additional safety protocols for transplant centers, currently safety protocols beyond those included in the NIH Research Criteria are determined by individual transplant centers. These comments were provided to the NIH working group for consideration in the development of revisions to the Research Criteria. Further, HHS considered these comments in developing the Secretary's direction to the OPTN to revise the OPTN standards of quality embodied in OPTN policy regarding organs from donors with HIV, as provided below in the discussion of implementation considerations. HHS makes no changes to the regulatory proposal in response to these comments.
                </P>
                <HD SOURCE="HD3">Addressing Diverse Needs</HD>
                <P>
                    Several commenters requested that HHS consider the unique challenges of patients who are Black, Indigenous, and people of color and patients living in rural areas. A commenter indicated that post-transplant care is essential for 
                    <PRTPAGE P="93493"/>
                    positive patient outcomes and factors such as implicit bias in medical settings, socioeconomic disparities, and geographic limitations frequently hinder equitable access to post-transplant care, especially for people experiencing both geographic isolation and medical racism. Long travel distances to transplant centers and lacking local healthcare options can impede consistent follow-up care and medication compliance.
                </P>
                <P>
                    <E T="03">HHS response:</E>
                     HHS is supportive of efforts to improve health equity in organ transplantation and believes this rule will contribute to improving access to care for patients who are Black, Indigenous, and people of color and patients living in rural areas by allowing HOPE Act kidney and liver transplants to be conducted at any transplant center in the United States. HHS makes no changes to the regulatory proposal in response to this comment.
                </P>
                <HD SOURCE="HD3">Standards for Transplant Candidates</HD>
                <P>One commenter noted his opposition to lengthy sobriety requirements for liver transplant candidates.</P>
                <P>
                    <E T="03">HHS response:</E>
                     Currently, sobriety requirements for transplant candidates are determined by individual transplant centers. This comment was provided to the NIH working group for consideration in the development of revisions to the Research Criteria. Further, HHS considered this comment in developing the Secretary's direction to the OPTN to revise the OPTN standards of quality embodied in OPTN policy regarding organs from donors with HIV, as provided below in this preamble in the discussion of implementation considerations. HHS makes no changes to the regulatory proposal in response to this comment.
                </P>
                <HD SOURCE="HD3">Future Research on HOPE Act Transplants</HD>
                <P>Multiple commenters expressed support for additional research evaluating the safety and efficacy of HOPE Act transplants. One commenter suggested that the experience of HOPE Act transplant patients should help inform the direction of future research on HOPE Act transplants.</P>
                <P>
                    <E T="03">HHS response:</E>
                     HHS is supportive of additional research evaluating the safety and efficacy of HOPE Act transplants, and considering patient experiences in informing the direction of future research. While no changes are made to the regulatory proposal in response to these comments, HHS will consider these comments in further efforts to implement the HOPE Act.
                </P>
                <HD SOURCE="HD3">Beyond Scope</HD>
                <P>Some commenters provided comments or made suggestions that are beyond the scope of the proposed rule.</P>
                <P>One commenter requested that HHS establish a program to provide technical assistance to state, local, and tribal health departments with the goal of adopting policies to prevent health information from being used in a criminal, civil, or immigration legal proceeding.</P>
                <P>One commenter noted that none of the other comments provided on the NPRM highlight that there will be a conflict between a majority of expressly prohibitive or potentially permissive State laws and expressly permissive Federal law when this proposed rule is finalized. The commenter indicated that State laws that are silent on or prohibitive of organ transplantation between people diagnosed with HIV can and do preclude performance of HOPE Act transplants within a given jurisdiction regardless of permissive Federal laws, and despite Congress and Federal regulators having the authority to preempt state and local health laws.</P>
                <P>Multiple commenters noted that State criminal laws that prohibit persons with HIV for donating or attempting to donate organs, blood, tissue, and other bodily fluids are a legal barrier to implementation of the HOPE Act.</P>
                <P>
                    <E T="03">HHS response:</E>
                     As these comments are not within the scope of the proposed rule, these comments have not altered HHS's proposed approach to lifting the research and IRB requirements for HOPE Act kidney and liver transplants.
                </P>
                <HD SOURCE="HD3">Opposition</HD>
                <P>One commenter opposed the proposed rule, suggesting that organs from donors with HIV are not the same as organs from donors without HIV, and expressing concern regarding the transmission of HIV through organ transplantation to recipients without HIV.</P>
                <P>
                    <E T="03">HHS response:</E>
                     HHS notes that there have been no reported cases of inadvertent HIV transmission resulting from HOPE Act transplants. Further, under the requirements of the HOPE Act, transplantation of organs from donors with HIV to recipients without HIV is prohibited. HHS makes no changes to the regulatory proposal in response to this comment.
                </P>
                <HD SOURCE="HD1">IV. Secretarial Determination</HD>
                <P>The Secretary has reviewed the recommendations of the OPTN, the ACBTSA, and the BOTSEC on implementation of the HOPE Act, the results of research on HOPE Act transplants conducted to date as well as results of other relevant research on organ transplants in recipients with HIV, and public comment received on the NPRM. Pursuant to his authority under the HOPE Act, 42 U.S.C. 274(b)(3)(B)(ii), and consistent with the implementing regulations at 42 CFR 121.6, the Secretary determines that participation in clinical research, and therefore adherence to research and IRB requirements, as a requirement for transplants of kidneys and livers from persons with HIV, is no longer warranted. Through publication of this final rule, the Secretary is lifting the statutory research and IRB requirements for such transplants.</P>
                <P>
                    HHS anticipates that the Secretary's determination and publication of this final rule will increase access to kidney and liver transplants by allowing more transplant centers to perform HOPE Act kidney and liver transplants. Currently, only a limited number of centers can perform HOPE Act transplants, because there are specific requirements stipulated by the NIH Research Criteria for such transplant centers. These requirements include expertise in HIV infection management, minimum organ-specific transplant team experience of five transplants of organs from donors without HIV to recipients with HIV over four years and an independent advocate for both recipients with HIV and prospective living donors with HIV. The requirements for centers conducting HOPE Act transplants have been subject to critique and have been viewed by some as a barrier to participation in HOPE Act transplant programs, which may impact equity and access to organ transplantation throughout the United States.
                    <SU>28</SU>
                    <FTREF/>
                     By eliminating the requirement that HOPE Act kidney and liver transplants are conducted in the research context, HHS expects that a larger number of transplant centers will be able to conduct such transplants. This rule will enable more transplant centers to transplant kidneys and livers donated by both living and deceased donors with HIV, in recipients with HIV, thereby expanding opportunities for people with HIV and end-stage diseases.
                </P>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         Bowring, M.G., Ruck, J.M., Bryski, M.G., Werbel, W., Tobian, A.A.R., Massie, A.B., Segev, D.L., &amp; Durand, C.M. (2023). Impact of expanding HOPE Act experience criteria on program eligibility for transplantation from donors with human immunodeficiency virus to recipients with human immunodeficiency virus. American Journal of Transplantation, 23(6), 860-864.
                    </P>
                </FTNT>
                <P>
                    Further, HHS expects this rule will expand access to organ transplantation for all patients, regardless of their HIV status. When eligible for transplant, a 
                    <PRTPAGE P="93494"/>
                    person with HIV is added to the waiting list. That patient may elect to receive an organ from a donor with HIV, as a HOPE Act transplant, should it become available, or may choose to wait for an organ from a donor who did not have HIV. If the patient with HIV chooses the HOPE Act transplant, this will allow another patient on the waiting list to receive the next available organ from a donor who does not have HIV, which would reduce the time spent waiting for a transplant. Of note, patients who do not have HIV will not be offered an organ from a donor who has HIV, as such transplants are not allowed under Federal law.
                </P>
                <P>
                    As of February 16, 2024, more than 103,000 men, women, and children were on the national organ transplant waiting list.
                    <SU>29</SU>
                     Every 10 minutes another person is added to the waiting list, and nearly 20 people die every day while waiting for a transplant.
                    <SU>30</SU>
                     HHS expects that the Secretary's determination and publication of this rule will improve access to kidney and liver transplants both by increasing the number of kidneys and livers available for transplant, and by allowing more transplant centers to perform HOPE Act kidney and liver transplants. This anticipated positive result is consistent with the Department's commitment to reducing the number of persons on the organ transplant waiting list.
                </P>
                <HD SOURCE="HD1">V. Implementation Considerations</HD>
                <HD SOURCE="HD2">A. NIH Research Criteria</HD>
                <P>The HOPE Act provides the Secretary with the discretion to determine what research criteria should apply to HOPE Act transplants. 42 U.S.C. 274f-5(a). NIH, in consultation with HRSA and the OPTN, and including the input of other relevant Federal stakeholders, formed a working group to develop revised NIH Research Criteria. The NIH Research Criteria, as originally drafted, include a strong focus on HOPE Act kidney and liver transplants, as these are the most common types of HOPE Act transplants: as this rule removes HOPE Act kidney and liver transplants from the research context, it is necessary that the revised NIH Research Criteria appropriately address non-kidney and non-liver HOPE Act transplantation.</P>
                <P>Further, HHS recognizes the revised NIH Research Criteria should reflect advances in research in the time since HOPE Act transplants began, including the current needs of various entities involved in non-kidney and non-liver HOPE Act transplants in consideration of input from transplant centers, transplant surgeons, OPOs, HIV clinicians, donors, recipients, HIV advocates, the OPTN, and individuals affected by the HOPE Act.</P>
                <P>
                    HHS has considered the comments submitted in response to the NPRM that are relevant to the revised NIH Research Criteria, as summarized in the discussion of public comment in section III, 
                    <E T="03">supra.</E>
                     These comments have been provided to NIH for consideration in developing the revised NIH Research Criteria. HHS will publish updated Research Criteria in the 
                    <E T="04">Federal Register</E>
                     for public comment.
                </P>
                <HD SOURCE="HD2">B. Secretary's Direction To Revise OPTN Policies</HD>
                <P>As part of the implementation of the Secretary's determination that participation in clinical research as a requirement for transplants of kidneys and livers from persons with HIV is no longer warranted, the Secretary must direct the OPTN to update its policies to clarify that HOPE Act kidney and liver transplants may be conducted in a way consistent with the statutory requirements at 42 U.S.C. 274, and that ensures the revisions to the policies will not reduce the safety of organ transplantation. 42 U.S.C. 274f-5(c)(2); 42 CFR 121.6(b)(3).</P>
                <P>In the NPRM preceding publication of this final rule, HHS specifically sought public comment on the nature and content of the Secretary's direction to the OPTN, including the level of specificity in the direction and the extent of the OPTN's discretion in developing the revised policies; what factors should be considered in assessing whether the revised policies are consistent with 42 U.S.C. 274; and what factors should be considered in assessing whether the revisions to the OPTN policies will not reduce the safety of organ transplantation. HHS further welcomed comment on any other aspects relating to the Secretary's direction to the OPTN to revise its standards of quality as required by the HOPE Act.</P>
                <P>
                    As described in the discussion of public comment in section III, 
                    <E T="03">supra,</E>
                     HHS received multiple comments relating to HHS's consideration as to the direction to the OPTN. The vast majority of commenters agreed that scientific evidence clearly demonstrates that HOPE Act kidney and liver transplants are safe and effective. Many of those commenters indicated that the current requirements applicable to all organ transplants are sufficient to appropriately ensure the continued safety of HOPE Act kidney and liver transplants conducted outside of the research context. HHS has carefully considered all comments received in the development of the Secretary's direction to the OPTN.
                </P>
                <P>Through publication of this final rule, the Secretary directs the OPTN to adopt and use standards of quality with respect to kidneys and livers from donors with HIV to ensure that HOPE Act kidney and liver transplants are subject to OPTN policies that are consistent with 42 U.S.C. 274, and from the OPTN's expertise, will not reduce the safety of HOPE Act kidney and liver transplants, provide appropriate oversight for these transplants, and require sufficient data collection and outcomes monitoring.</P>
                <P>In consideration of the public comments received, HHS notes that it may be appropriate for the OPTN to determine that current OPTN policies that are generally applicable to kidney and liver transplants provide appropriate safety and oversight standards for HOPE Act kidney and liver transplants. Alternatively, the OPTN may choose to revise OPTN policies to provide additional standards for HOPE Act kidney and liver transplants.</P>
                <P>This rule provides the Secretary's determination that that participation in clinical research as a requirement for transplants of kidneys and livers from persons with HIV is no longer warranted; revises 42 CFR 121.6 to reflect the removal of the statutory research and IRB requirements for HOPE Act kidney and liver transplants; and directs the OPTN to revise its standards of quality with respect to kidneys and livers from donors with HIV consistent with 42 U.S.C. 274 and in a way that ensures the changes will not reduce the safety of organ transplantation policies as required by the HOPE Act. The final implementation step is for the OPTN to adopt and use standards of quality as directed by the Secretary to reflect that HOPE Act kidney and liver transplants no longer are subject to research and IRB requirements.</P>
                <P>
                    As was stated in the NPRM, HHS expects that the OPTN will solicit public comment on a proposed revision to relevant OPTN policies, and update the OPTN policies containing standards of quality with respect to kidneys and livers from donors with HIV, within 15 months from the publication of this final rule. As publication of this final rule has obviated current OPTN policies requiring HOPE Act kidney and liver transplants to be conducted in accordance with research and IRB requirements, HHS encourages the OPTN to act expeditiously to revise these policies. This will allow transplant centers that had not 
                    <PRTPAGE P="93495"/>
                    previously been performing HOPE Act kidney and liver transplants in the research context to begin performing HOPE Act kidney and liver transplants in accordance with the revised OPTN policies.
                </P>
                <HD SOURCE="HD1">VI. Final Rule Requirements</HD>
                <HD SOURCE="HD2">A. Removal of Research and IRB Requirements for HOPE Act Kidney and Liver Transplants</HD>
                <P>Consistent with the Secretary's determination under the HOPE Act, this rule revises 42 CFR 121.6 to reflect the removal of the statutory research and IRB requirements for kidney and liver HOPE Act transplants. Section 121.6(b)(1)(ii)(B) provides that participation in clinical research is no longer warranted for the following categories of transplants:</P>
                <P>• Transplant of a kidney from a donor with HIV; and</P>
                <P>• Transplant of a liver from a donor with HIV.</P>
                <P>In implementation, this means that HOPE Act kidney and liver transplants will no longer be required to be conducted as research, and instead will be conducted in accordance with OPTN policies applicable to HOPE Act kidney and liver transplants. As noted above, the OPTN may decide that OPTN policies that generally apply to kidney and liver transplants are appropriate to apply to HOPE Act kidney and liver transplants, or may create different policies for HOPE Act kidney and liver transplants.</P>
                <HD SOURCE="HD2">B. Revised Terminology: Persons With HIV</HD>
                <P>
                    HHS is aware that previous language used in enacting and implementing the HOPE Act contained vocabulary and phrases that some people find stigmatizing—namely, references to “infected with HIV” when the regulatory language encompasses both living and deceased donors with HIV, or recipients with HIV. For the references to both living and deceased donors with HIV, HHS revises all current references in 42 CFR 121.6(b) from “individuals infected with human immunodeficiency virus (HIV)” and “individuals infected with HIV” to “donors with HIV” or, when discussing organs donated, “organs from donors with HIV” and specifically “kidneys from donors with HIV” and “livers from donors with HIV.” Further, HHS revises the current reference in 42 CFR 121.6(b)(1)(i) describing the allowable recipients of HOPE Act transplants from individuals who are “infected with HIV before receiving such organ(s)” to instead refer to individuals who are “living with HIV before receiving such organ(s).” This is consistent with the Centers for Disease Control and Prevention's (CDC) Stigma Language Guide.
                    <SU>31</SU>
                    <FTREF/>
                     These changed regulatory references are to avoid stigmatizing language, and do not change the groups of people referenced in 42 CFR 121.6.
                </P>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         Centers for Disease Control and Prevention. Let's Stop HIV Together: Stigma Language Guide. 
                        <E T="03">https://www.cdc.gov/stophivtogether/hiv-stigma/ways-to-stop.html.</E>
                         Accessed 2/23/2024.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">VII. Effective Date</HD>
                <P>HHS finds that there is good cause for this rule to be effective upon publication in accordance with 5 U.S.C. 553(d)(3) of the Administrative Procedure Act and 5 U.S.C. 808(2) of the Congressional Review Act.</P>
                <P>
                    The waiting list for kidney transplant in the U.S. currently exceeds 88,700 candidates.
                    <SU>32</SU>
                    <FTREF/>
                     The 2022 OPTN/U.S. Scientific Registry of Transplant Recipients (SRTR) Annual Data Report indicated that over the course of a year more than 4,400 adults died while waiting for a kidney transplant, and an additional 4,500 persons were removed from the waiting list because they became too sick to receive a transplant.
                    <SU>33</SU>
                    <FTREF/>
                     Most transplant candidates wait years for a kidney transplant, often requiring dialysis or other interventions.
                </P>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         Organ Procurement and Transplantation Network. Dashboard and metrics. 
                        <E T="03">https://insights.unos.org/OPTN-metrics/.</E>
                         Accessed Feb 2024.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         Organ Procurement and Transplantation Network (OPTN)/Scientific Registry of Transplant Recipients (SRTR). 2022. “Annual Data Report.” Accessed November 2024. 
                        <E T="03">https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Liver&amp;year=2022.</E>
                    </P>
                </FTNT>
                <P>
                    In addition, thousands of Americans suffer from conditions requiring liver transplant. As of November 8, 2024, 13,170 candidates were added to the waiting list in 2024.
                    <SU>34</SU>
                    <FTREF/>
                     In 2022, more than 1,031 liver patients died while awaiting transplant, according to the OPTN/SRTR Annual Data Report.
                    <SU>35</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         Organ Procurement and Transplantation Network. Dashboard and metrics. 
                        <E T="03">https://optn.transplant.hrsa.gov/data/dashboards-metrics/.</E>
                         Accessed November 2024.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         Organ Procurement and Transplantation Network (OPTN)/Scientific Registry of Transplant Recipients (SRTR). 2021. “Annual Data Report.” Accessed February 2024. 
                        <E T="03">https://srtr.transplant.hrsa.gov/annual_reports/2021_ADR_Preview.aspx.</E>
                    </P>
                </FTNT>
                <P>
                    HHS expects that this final rule will have the effect of decreasing the time all candidates for kidney and liver transplants spend on the waiting list, regardless of their HIV status. As described in section IV, above, a transplant candidate with HIV may choose to receive a HOPE Act kidney or liver transplant if an organ from a donor with HIV becomes available, or may choose to wait for an organ from a donor without HIV. Research has demonstrated that candidates with HIV who accept a HOPE Act kidney transplant spend significantly less time awaiting transplant than candidates on the waiting list for an kidney from a donor without HIV. A 2023 study found that median wait time for a HOPE Act kidney transplant was 10.8 months compared to 60.8 months—a 3.3-fold higher rate of transplant compared to non-HOPE Act transplants.
                    <SU>36</SU>
                    <FTREF/>
                     When candidates with HIV choose a HOPE Act transplant, this data suggests that this will decrease the time they spent on the waiting list. Additionally, this will have the effect of allowing a candidate further down the waiting list to receive the next available organ from a donor who does not have HIV, both reducing the time that candidate spends waiting for a transplant and decreasing the time all other candidates spend on the waiting list.
                </P>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         Motter JD, et al; HOPE in Action Investigators. Wait Time Advantage for Transplant Candidates With HIV Who Accept Kidneys From Donors With HIV Under the HOPE Act. Transplantation. 2024 Mar 1;108(3):759-767.
                    </P>
                </FTNT>
                <P>Moreover, HHS expects that this final rule also will increase access to organ transplantation. Thirty-one transplant centers are qualified to perform HOPE Act kidney and liver transplants as research in conformance with the requirements of the NIH Research Criteria, while 250 transplant centers operate nationwide. As, pursuant to this rule, HOPE Act kidney and liver transplants no longer need to be conducted as research, it can be reasonably expected that more transplant centers than in the past will be able to offer HOPE Act kidney and liver transplants to appropriate candidates on the transplant center's waiting list. It also is reasonable to expect that if a greater number of transplant centers will be able to offer HOPE Act transplants, this will allow more candidates with HIV on the waiting list to receive HOPE Act kidney and liver transplants.</P>
                <P>
                    Lastly, HHS believes that a delayed effective date is unnecessary to afford affected parties a reasonable time to adjust practices in accordance with this rule. From the economic analysis of impacts, provided below in section IX, this final rule will have a minimal direct impact on affected entities with regard to preparing for implementation. The direct effect of this final rule on transplant centers is considered to be limited to the time spent by transplant centers to read and understand the final rule, educate their staff on the content of this final rule, and review and update 
                    <PRTPAGE P="93496"/>
                    internal policies. This rule does not impose obligations on transplant centers, and rather increases available flexibilities in that transplant centers are no longer required to conduct HOPE Act kidney and liver transplants in the research context. Further, as described above in section V(B), the final implementation step for HOPE Act kidney and liver transplants to begin occurring outside of the research context is for the OPTN to revise its policies to reflect that HOPE Act kidney and liver transplants no longer are subject to research and IRB requirements. HHS is encouraging the OPTN to act expeditiously to revise these policies, and it is likely that transplant centers will educate their staff and review and update internal policies relevant to the content of this final rule after the OPTN has published its revised policies for HOPE Act kidney and liver transplants. Transplant centers do not have any obligations stemming from this rule until the OPTN revises its policies. In light of this context, a delayed effective date for this rule is unnecessary for implementation purposes.
                </P>
                <P>Given that, and the expected positive effects on time candidates spend on the waiting list and the increase in access to HOPE Act transplants resulting from this rule, pursuant to 5 U.S.C. 553(d)(3) and 5 U.S.C. 808(2) HHS finds that there is good cause for this rule to be effective upon publication.</P>
                <HD SOURCE="HD1">VIII. Paperwork Reduction Act of 1995</HD>
                <P>This rule does not impose any additional information collection burden under the Paperwork Reduction Act and does not contain any information collection requirements beyond those already imposed by current regulations, which have been approved by the Office of Management and Budget (OMB). The current data collection requirements in the OPTN final rule approved by OMB under the Paperwork Reduction Act of 1995 are assigned control numbers OMB No. 0915-0157 (for organ donors, candidates, and recipients) and OMB No. 0915-0184 (for OPTN membership application data).</P>
                <HD SOURCE="HD1">IX. Final Economic Analysis of Impacts</HD>
                <P>We have examined the impacts of the final rule under Executive Order 12866, Executive Order 13563, Executive Order 14094, the Regulatory Flexibility Act (5 U.S.C. 601-612), the Congressional Review Act (5 U.S.C. 801, Pub. L. 104-121), and the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4).</P>
                <P>Executive Orders 12866, 13563, and 14094 direct us to assess all benefits, costs, and transfers of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety, and other advantages; distributive impacts; and equity). Rules are “significant” under Executive Order 12866, section 3(f)(1) (as amended by Executive Order 14094), if they have an annual effect on the economy of $200 million or more (adjusted every 3 years by the Administrator of the Office of Information and Regulatory Affairs (OIRA) for changes in gross domestic product); or adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, territorial, or tribal governments or communities. The regulatory impact analysis indicates, and OIRA has determined, that the final rule is a significant regulatory action under Executive Order 12866, section 3(f)(1), and that it meets the criteria set forth in 5 U.S.C. 804(2) under the Congressional Review Act.</P>
                <P>The Regulatory Flexibility Act (RFA) requires agencies to consider the impact of their regulatory proposals on small entities. Because the impacts on kidney and liver transplants are small relative to the number of transplants performed annually, and because the economic impacts on affected small entities are small relative to the average payroll of firms in the smallest enterprise size category, HHS certifies that the final rule will not have a significant economic impact on a substantial number of small entities.</P>
                <P>The Unfunded Mandates Reform Act of 1995 (UMRA) generally requires that each agency conduct a cost-benefit analysis; identify and consider a reasonable number of regulatory alternatives; and select the least costly, most cost-effective, or least burdensome alternative that achieves the objectives of the final rule before promulgating any proposed or final rule that includes a Federal mandate that may result in expenditures of more than $100 million (adjusted for inflation) in at least one year by State, local, and tribal governments, in the aggregate, or by the private sector. Each agency issuing a final rule with relevant effects over that threshold must also seek input from State, local, and tribal governments. The current threshold after adjustment for inflation using the Implicit Price Deflator for the Gross Domestic Product is $183 million, reported in 2023 dollars. The final rule will not result in an unfunded mandate in any year that meets or exceeds this amount.</P>
                <P>The final rule removes the current research and IRB requirements for the transplantation of kidneys and livers from donors with HIV. We have assessed the likely impacts of the final rule, and report in the regulatory impact analysis (RIA) several sources of monetized, quantified, and unquantified benefits, costs, or transfers. Most of the monetized or quantified impacts relate to the incremental increases in the number of kidney and liver transplants that will be performed annually as a result of the final rule.</P>
                <P>We report monetized benefits from increases in life expectancy for both kidney and liver transplant recipients; and for kidney transplant recipients, we also report monetized benefits from quality-of-life improvements and time savings from fewer kidney dialysis visits. We also anticipate quality-of-life improvements for liver transplant recipients, and quantify the number of people affected who might experience those benefits. We also identify several sources of unquantified benefits, which could potentially be quantified through additional research or data, including time savings for caregivers, and cost savings for transplant centers from removing the research and institutional review board requirements. We also identify difficult-to-quantify benefits associated with revising vocabulary and phrases that some people find stigmatizing through adoption of language that is intended be respectful of people living with HIV, and living and deceased donors with HIV. These changes may result in people living with HIV experiencing more inclusive interactions when accessing healthcare, generating additional benefits beyond the increases in life expectancy and improvements in quality of life from improved access to liver and kidney transplantation.</P>
                <P>We report monetized costs from increases in medical expenditures associated with organ transplantation; for kidney transplants, we report net costs that account for reductions in medical expenditures associated with kidney dialysis. We report this shift in expenditures from kidney dialysis to kidney transplantation as a monetized transfer. We also monetize the opportunity costs of the time spent by transplant centers reading and understanding the final rule, reviewing policies and procedures, and training staff.</P>
                <P>
                    Table 1 summarizes our estimates of the benefits, costs, and transfers of the final rule, annualizing impacts over a 10-year analytic time horizon covering 2025 through 2034 using a 2 percent real discount rate, and reporting all 
                    <PRTPAGE P="93497"/>
                    monetary estimates in constant 2023 dollars. Annualized benefits range from $381 million to $858 million, with a primary estimate of $612 million; costs range from $73 million to $92 million, with a primary estimate of $83 million; and transfers range from $24 million to $37 million, with a primary estimate of $30 million. Table 1 also reports our estimates of the annualized net benefits of the final rule, which range from $301 million to $772 million, with a primary estimate of $530 million. The RIA concludes that the monetized net benefits, combined with the quantified, but non-monetized, and unquantified impacts, indicate that the final rule is highly likely to generate net benefits to society. This finding is further supported through additional quantitative assessments of uncertainty and sensitivity analyses contained in the RIA. The full RIA is available in the docket for this final rule at 
                    <E T="03">https://www.regulations.gov/docket/HRSA-2024-0001/document.</E>
                </P>
                <GPOTABLE COLS="8" OPTS="L2,nj,p7,7/8,i1" CDEF="s30,10,10,10,xs60,10,10,r50">
                    <TTITLE>Table 1—Summary of Impacts of the Final Rule </TTITLE>
                    <TDESC>[Millions of constant 2023 dollars]</TDESC>
                    <BOXHD>
                        <CHED H="1">Category</CHED>
                        <CHED H="1">
                            Primary
                            <LI>estimate</LI>
                        </CHED>
                        <CHED H="1">
                            Low
                            <LI>estimate</LI>
                        </CHED>
                        <CHED H="1">
                            High
                            <LI>estimate</LI>
                        </CHED>
                        <CHED H="1">
                            Dollar
                            <LI>year or unit</LI>
                        </CHED>
                        <CHED H="1">
                            Discount
                            <LI>rate</LI>
                            <LI>(%)</LI>
                        </CHED>
                        <CHED H="1">
                            Time
                            <LI>horizon</LI>
                        </CHED>
                        <CHED H="1">Notes</CHED>
                    </BOXHD>
                    <ROW EXPSTB="07" RUL="s">
                        <ENT I="21">
                            <E T="02">BENEFITS</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">Annualized monetized benefits</ENT>
                        <ENT>$612</ENT>
                        <ENT>$381</ENT>
                        <ENT>$858</ENT>
                        <ENT>2023</ENT>
                        <ENT>2</ENT>
                        <ENT>2025-2034</ENT>
                        <ENT>Increased life expectancy for organ transplant recipients; improved quality of life for kidney transplant recipients; time savings from fewer kidney dialysis visits.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annualized quantified, but non-monetized, benefits</ENT>
                        <ENT>72</ENT>
                        <ENT>64</ENT>
                        <ENT>81</ENT>
                        <ENT>People affected</ENT>
                        <ENT>2</ENT>
                        <ENT>2025-2034</ENT>
                        <ENT>Improved quality of life for liver transplant recipients.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Unquantified benefits</ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT>2025-2034</ENT>
                        <ENT>Time savings for caregivers; cost savings for transplant centers from removing the research and institutional review board requirements; difficult-to-quantify benefits associated with stigma-reducing terminology.</ENT>
                    </ROW>
                    <ROW EXPSTB="07" RUL="s">
                        <ENT I="21">
                            <E T="02">COSTS</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00" RUL="s">
                        <ENT I="01">Annualized monetized costs</ENT>
                        <ENT>83</ENT>
                        <ENT>73</ENT>
                        <ENT>92</ENT>
                        <ENT>2023</ENT>
                        <ENT>2</ENT>
                        <ENT>2025-2034</ENT>
                        <ENT>Medical expenditures associated with transplantation; time spent by transplant centers to read and understand the final rule, review policies and procedures, and train staff.</ENT>
                    </ROW>
                    <ROW EXPSTB="07" RUL="s">
                        <ENT I="21">
                            <E T="02">TRANSFERS</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00" RUL="s">
                        <ENT I="01">Annualized monetized transfers</ENT>
                        <ENT>30</ENT>
                        <ENT>24</ENT>
                        <ENT>37</ENT>
                        <ENT>2023</ENT>
                        <ENT>2</ENT>
                        <ENT>2025-2034</ENT>
                        <ENT>Shift in expenditures from kidney dialysis to kidney transplantation.</ENT>
                    </ROW>
                    <ROW EXPSTB="07" RUL="s">
                        <ENT I="21">
                            <E T="02">NET BENEFITS</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">Annualized monetized net benefits</ENT>
                        <ENT>530</ENT>
                        <ENT>301</ENT>
                        <ENT>772</ENT>
                        <ENT>2023</ENT>
                        <ENT>2</ENT>
                        <ENT>2025-2034</ENT>
                    </ROW>
                    <TNOTE>
                        <E T="02">Note:</E>
                         primary, low, and high estimates correspond to the mean, 5th percentile, and 95th percentile of the outcomes of a Monte Carlo simulation.
                    </TNOTE>
                </GPOTABLE>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 42 CFR Part 121</HD>
                    <P>Health care, Hospitals, Organ transplantation, Reporting and recordkeeping requirements, Transplant centers.</P>
                </LSTSUB>
                <P>Accordingly, by the authority vested in me as the Secretary of Health and Human Services, and for the reasons set forth in the preamble, 42 CFR part 121 is amended as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 121—ORGAN PROCUREMENT AND TRANSPLANTATION NETWORK</HD>
                </PART>
                <REGTEXT TITLE="42" PART="121">
                    <AMDPAR>1. The authority citation for part 121 continues to read as follows:</AMDPAR>
                    <AUTH>
                        <HD SOURCE="HED">Authority: </HD>
                        <P> Sections 215, 371-377, and 377E of the PHS Act (42 U.S.C. 216, 273-274d, 274f-5); sections 1102, 1106, 1138 and 1871 of the Social Security Act (42 U.S.C. 1302, 1306, 1320b-8, and 1395hh); section 301 of the National Organ Transplant Act, as amended (42 U.S.C. 274e); and E.O. 13879, 84 FR 33817.</P>
                    </AUTH>
                </REGTEXT>
                <REGTEXT TITLE="42" PART="121">
                    <AMDPAR>2. In § 121.6, revise paragraph (b) to read as follows:</AMDPAR>
                    <SECTION>
                        <SECTNO>§ 121.6</SECTNO>
                        <SUBJECT>Organ procurement.</SUBJECT>
                        <STARS/>
                        <P>
                            (b) 
                            <E T="03">HIV.</E>
                             (1) Organs from donors with human immunodeficiency virus (HIV) may be transplanted only into individuals who—
                        </P>
                        <P>(i) Are living with HIV before receiving such organ(s); and</P>
                        <P>(ii)(A) Are participating in clinical research approved by an institutional review board, as defined in 45 CFR part 46, under the research criteria published by the Secretary under subsection (a) of section 377E of the Public Health Service Act, as amended; or</P>
                        <P>(B) The Secretary has published, through appropriate procedures, a determination under section 377E(c) of the Public Health Service Act, as amended, that participation in such clinical research, as a requirement for transplantation of organs from donors with HIV, is no longer warranted. The Secretary has determined that participation in such clinical research is no longer warranted for the following categories of transplants:</P>
                        <P>
                            (
                            <E T="03">1</E>
                            ) Transplant of a kidney from a donor with HIV; and
                        </P>
                        <P>
                            (
                            <E T="03">2</E>
                            ) Transplant of a liver from a donor with HIV.
                        </P>
                        <P>
                            (2) Except as provided in paragraph (b)(3) of this section, the OPTN shall adopt and use standards of quality with respect to organs from donors with HIV to the extent the Secretary determines necessary to allow the conduct of research in accordance with the criteria described in paragraph (b)(1)(ii)(A) of this section.
                            <PRTPAGE P="93498"/>
                        </P>
                        <P>(3) If the Secretary has determined under paragraph (b)(1)(ii)(B) of this section that participation in clinical research is no longer warranted as a requirement for transplantation of organs from donors with HIV, the OPTN shall adopt and use standards of quality with respect to organs from donors with HIV as directed by the Secretary, consistent with 42 U.S.C. 274, and in a way that ensures the changes will not reduce the safety of organ transplantation.</P>
                        <STARS/>
                    </SECTION>
                </REGTEXT>
                <SIG>
                    <DATED>Dated: November 19, 2024.</DATED>
                    <NAME>Xavier Becerra,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27410 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4150-41-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Administration for Children and Families</SUBAGY>
                <CFR>45 CFR Part 412</CFR>
                <RIN>RIN 0970-AD10</RIN>
                <SUBJECT>Investigations of Child Abuse and Neglect Rule</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Refugee Resettlement (ORR), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Interim final rule with comment period (IFR).</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>This IFR describes how ORR shall investigate and substantiate allegations of child abuse and neglect occurring in certain ORR care provider facilities, and maintain a registry of perpetrators relating to certain sustained allegations.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This IFR is effective December 27, 2024. Comments on this IFR must be received on or before January 27, 2025.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may send comments, identified by [docket number and/or Regulatory Information Number (RIN)], by any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal: http://www.regulations.gov.</E>
                         Follow the instructions for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Email: UCPolicy-RegulatoryAffairs@acf.hhs.gov.</E>
                         Include [docket number and/or RIN] in the subject line of the message.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All submissions received must include the agency name and docket number or RIN for this rulemaking. For detailed instructions on submitting comments and additional information on the rulemaking process, see the “Public Participation” heading of the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section of this document.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Toby Biswas, Director of Policy, Division of Unaccompanied Children Policy, Unaccompanied Children Bureau, Office of Refugee Resettlement, Administration for Children and Families, Department of Health and Human Services, Washington, DC, (202) 205-4440 or 
                        <E T="03">UCPolicy-RegulatoryAffairs@acf.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <HD SOURCE="HD1">Table of Contents</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">I. Public Participation</FP>
                    <FP SOURCE="FP1-2">A. Submitting Comments</FP>
                    <FP SOURCE="FP1-2">B. Viewing Comments and Documents</FP>
                    <FP SOURCE="FP1-2">C. Privacy Act</FP>
                    <FP SOURCE="FP-2">II. Table of Abbreviations</FP>
                    <FP SOURCE="FP-2">III. Executive Summary</FP>
                    <FP SOURCE="FP-2">IV. Background and Purpose</FP>
                    <FP SOURCE="FP1-2">A. Background and History</FP>
                    <FP SOURCE="FP1-2">B. Authority</FP>
                    <FP SOURCE="FP1-2">C. Basis and Scope of Regulatory Action</FP>
                    <FP SOURCE="FP1-2">D. Severability</FP>
                    <FP SOURCE="FP-2">V. Discussion of Elements of the Interim Final Rule</FP>
                    <FP SOURCE="FP-2">VI. Good Cause for Issuing This IFR</FP>
                    <FP SOURCE="FP-2">VII. Collection of Information Requirements</FP>
                    <FP SOURCE="FP-2">VIII. Regulatory Impact Analysis</FP>
                    <FP SOURCE="FP1-2">A. Economic Analysis</FP>
                    <FP SOURCE="FP1-2">B. Regulatory Flexibility Analysis</FP>
                    <FP SOURCE="FP1-2">C. Unfunded Mandates Reform Act</FP>
                    <FP SOURCE="FP1-2">D. Executive Order 13132: Federalism</FP>
                    <FP SOURCE="FP1-2">E. Executive Order 12988: Civil Justice Reform</FP>
                    <FP SOURCE="FP-2">IX. Assessment of Federal Regulation and Policies on Families</FP>
                </EXTRACT>
                <HD SOURCE="HD1">I. Public Participation</HD>
                <P>
                    ORR encourages all interested parties to participate in this rulemaking by submitting written comments, views, and data on any or all aspects of this interim final rule. ORR also invites comments that relate to the economic, environmental, or federalism effects that might result from this interim final rule. ORR will review all comments received, but ORR will only post comments that address the topic of the interim final rule. All comments ORR posts to 
                    <E T="03">https://www.regulations.gov</E>
                     will include any personal or commercial information you provide.
                </P>
                <HD SOURCE="HD2">A. Submitting Comments</HD>
                <P>
                    Comments that will provide the most assistance to ORR will reference a specific portion of the interim final rule, explain the reason for any recommended change, and include data, information, or authority that support such recommended change. If you submit comments, please indicate the specific section of this document to which each comment applies and provide a reason for each suggestion or recommendation. You may submit your comments and materials online or by email, but please use only one of these means. If you submit a comment online via 
                    <E T="03">https://www.regulations.gov,</E>
                     it will be considered received when it is received at the Docket Management Facility.
                </P>
                <P>
                    <E T="03">Instructions:</E>
                     To submit your comments online, go to 
                    <E T="03">https://www.regulations.gov</E>
                     and insert “XXXX-XXXX-XXXX” in the “Search” box. Click on the “Comment Now!” box and input your comment in the text box provided. Click the “Continue” box, and if you are satisfied with your comment, follow the prompts to submit it.
                </P>
                <P>
                    For additional information, please read the “Privacy and Security Notice” that is available via the link in the footer of 
                    <E T="03">https://www.regulations.gov.</E>
                </P>
                <P>ORR will consider all comments and materials received during the comment period and may change this rule based on your comments.</P>
                <HD SOURCE="HD2">B. Viewing Comments and Documents</HD>
                <P>
                    <E T="03">Docket:</E>
                     To view posted comments, as well as documents mentioned in this preamble as being available in the docket, go to 
                    <E T="03">https://www.regulations.gov</E>
                     and insert “XXXX-XXXX-XXXX” in the “Search” box. Click on the “Open Docket Folder,” and you can click on “View Comment” or “View All” under the “Comments” section of the page. Individuals without internet access can make alternate arrangements for viewing comments and documents related to this rulemaking by contacting ORR through the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section above. You may sign up for email alerts on the online docket to be notified when comments are posted, or a final rule is published.
                </P>
                <HD SOURCE="HD2">C. Privacy Act</HD>
                <P>As stated in the Submitting Comments section above, please be aware that anyone can search the electronic form of comments received into any dockets by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor union, etc.).</P>
                <HD SOURCE="HD1">II. Table of Abbreviations</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">ACF—Administration for Children and Families</FP>
                    <FP SOURCE="FP-2">ALJ—Administrative Law Judge</FP>
                    <FP SOURCE="FP-2">CAPTA—Child Abuse Prevention and Treatment Act</FP>
                    <FP SOURCE="FP-2">CWT—ORR's Child Welfare Team</FP>
                    <FP SOURCE="FP-2">DAB—HHS Departmental Appeals Board</FP>
                    <FP SOURCE="FP-2">DOJ—U.S. Department of Justice</FP>
                    <FP SOURCE="FP-2">EIF—Emergency or Influx Facility</FP>
                    <FP SOURCE="FP-2">FBI—Federal Bureau of Investigation</FP>
                    <FP SOURCE="FP-2">FSA—Flores Settlement Agreement</FP>
                    <FP SOURCE="FP-2">
                        HHS—U.S. Department of Health and Human Services
                        <PRTPAGE P="93499"/>
                    </FP>
                    <FP SOURCE="FP-2">HSA—Homeland Security Act of 2002</FP>
                    <FP SOURCE="FP-2">OIG—Office of the Inspector General</FP>
                    <FP SOURCE="FP-2">OMB—Office of Management and Budget</FP>
                    <FP SOURCE="FP-2">ORR—Office of Refugee Resettlement, U.S. Department of Health and Human Services</FP>
                    <FP SOURCE="FP-2">PCAN Team—ORR's Prevention of Child Abuse and Neglect Team</FP>
                    <FP SOURCE="FP-2">PSA IFR—Standards To Prevent, Detect, and Respond to Sexual Abuse and Sexual Harassment Involving Unaccompanied Children, Interim Final Rule</FP>
                    <FP SOURCE="FP-2">TVPRA—William Wilberforce Trafficking Victims Protection Reauthorization Act of 2008</FP>
                    <FP SOURCE="FP-2">UC Bureau—Unaccompanied Children Bureau</FP>
                    <FP SOURCE="FP-2">VCAA—Victims of Child Abuse Act</FP>
                </EXTRACT>
                <HD SOURCE="HD1">III. Executive Summary</HD>
                <P>
                    This interim final rule provides standards and processes for the Department of Health and Human Services (HHS), Administration for Children and Families (ACF), Office of Refugee Resettlement (ORR), to apply when it conducts investigations into allegations of child abuse and neglect that occur in certain care provider facilities funded by ORR to provide residential and other services for unaccompanied children; 
                    <SU>1</SU>
                    <FTREF/>
                     describes a process for appeal and review of substantiated allegations; and establishes an ORR Central Registry to list individuals with certain findings of child abuse and neglect that have been substantiated and sustained after exhausting the appeal and review process. This rule describes how and in what circumstances ORR may conduct investigations, and impose certain consequences with respect to sustained allegations of child abuse and neglect by care provider facility staff, contractors or sub-grantees of the care provider facility, care provider facility volunteers, and other individuals with access to unaccompanied children in ORR care through contracts or grants with ORR. Specifically, the investigations and required consequences described in this rule shall apply in two circumstances: (1) where the State or local authority that would otherwise be responsible for such investigations will not investigate allegations arising at ORR care provider facilities that care for or propose to care for unaccompanied children; and (2) at ORR emergency or influx facilities (EIFs).
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         An unaccompanied child is defined as a child who has no lawful immigration status in the United States; has not attained 18 years of age; and with respect to whom there is no parent or legal guardian in the United States, or no parent or legal guardian in the United States available to provide care and physical custody. 
                        <E T="03">See</E>
                         6 U.S.C. 279(g)(2).
                    </P>
                </FTNT>
                <P>Child abuse and neglect can have devastating lifelong mental and physical effects on an individual. ORR is committed to preventing and mitigating child abuse and neglect in its care provider facilities and seeks to ensure the safety, well-being, and security of all unaccompanied children in its care.</P>
                <HD SOURCE="HD1">IV. Background and Purpose</HD>
                <HD SOURCE="HD2">A. Background and History</HD>
                <P>
                    On March 1, 2003, section 462 of the Homeland Security Act of 2002 (HSA) transferred responsibilities for the care and placement of unaccompanied children from the Commissioner of the former Immigration and Naturalization Service to the Director of ORR. Since that time, ORR has provided for the day-to-day care of over 700,000 unaccompanied children in ORR care provider facilities that are currently administered through a nationwide network of providers (funded via cooperative agreements or contracts, or sub-awards thereof).
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         Unaccompanied Children Bureau Fact Sheet. (July 5, 2024). Retrieved from: 
                        <E T="03">https://www.acf.hhs.gov/orr/fact-sheet/programs/uc/fact-sheet.</E>
                    </P>
                </FTNT>
                <P>
                    As further detailed below in section IV.B., ORR oversees its care provider facilities through its Unaccompanied Children Bureau 
                    <SU>3</SU>
                    <FTREF/>
                     pursuant to its responsibilities under the HSA,
                    <SU>4</SU>
                    <FTREF/>
                     the Trafficking Victims Protection Reauthorization Act of 2008 (TVPRA),
                    <SU>5</SU>
                    <FTREF/>
                     the Unaccompanied Children (UC) Program Foundational Rule,
                    <SU>6</SU>
                    <FTREF/>
                     the 
                    <E T="03">Flores</E>
                     Settlement Agreement (FSA) as relevant,
                    <E T="51">7 8</E>
                    <FTREF/>
                     and ORR's regulatory Standards To Prevent, Detect, and Respond to Sexual Abuse and Sexual Harassment Involving Unaccompanied Children interim final rule (PSA IFR).
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Statement of Organization, Functions, and Delegations of Authority, 89 FR 49889 (Jun. 12, 2014) (redesignating the former “Unaccompanied Children Program” as the “Unaccompanied Children Bureau”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         6 U.S.C. 279.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         8 U.S.C. 1232.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         45 CFR part 410.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         Stipulated Settlement Agreement, 
                        <E T="03">Flores</E>
                         v. 
                        <E T="03">Reno,</E>
                         No. CV 85-4544-RJK(Px) (C.D. Cal. Jul. 17, 1997).
                    </P>
                    <P>
                        <SU>8</SU>
                         As of the publication of this rule, the 
                        <E T="03">Flores</E>
                         Settlement Agreement (FSA) has been partially and conditionally terminated as to ORR, as a result of the publication of the UC Program Foundational Rule. 
                        <E T="03">See</E>
                         Order Re Defendants' Motion to Terminate the 
                        <E T="03">Flores</E>
                         Settlement Agreement as to Defendant HHS, 
                        <E T="03">Flores</E>
                         v. 
                        <E T="03">Garland,</E>
                         No. 2:85-cv-04544 (C.D. Cal. Jun. 28, 2024), ECF No. 1447.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         45 CFR part 411.
                    </P>
                </FTNT>
                <P>
                    Consistent with the HSA and TVPRA, ORR is responsible for the care, custody, and placement of unaccompanied children who are in Federal custody by reason of their immigration status.
                    <SU>10</SU>
                    <FTREF/>
                     Any department or agency of the Federal government that has an unaccompanied child from a non-contiguous country in its custody is required to transfer custody of such child to HHS.
                    <SU>11</SU>
                    <FTREF/>
                     Typically, ORR places unaccompanied children in care provider facilities it funds to provide these children with residential and other services, until the children can be safely released to qualified and vetted sponsors (individuals or entities to whom ORR releases unaccompanied children out of ORR custody, in accordance with ORR's sponsor suitability assessment process and release procedures),
                    <SU>12</SU>
                    <FTREF/>
                     are repatriated to their home country, obtain legal status, or otherwise no longer meet the statutory definition of an unaccompanied child (
                    <E T="03">e.g.,</E>
                     turn 18 years old). In accordance with the UC Program Foundational Rule (and consistent with the FSA), ORR makes reasonable efforts to place unaccompanied children in State-licensed facilities in those geographical areas where the majority of children are apprehended 
                    <SU>13</SU>
                    <FTREF/>
                    —except in cases of emergency or influx, when ORR may utilize EIFs.
                    <SU>14</SU>
                    <FTREF/>
                     EIFs are Federally contracted facilities that ORR may need to stand up quickly to accommodate placements for children that exceed its standard capacity. Consistent with ORR's UC Program Foundational Rule (and the FSA), EIFs are not required to be State-licensed.
                    <SU>15</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         6 U.S.C. 279(b)(1)(A); 8 U.S.C. 1232(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         8 U.S.C. 1232(b)(3).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         45 CFR 410.1001.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         45 CFR 410.1103(e); 
                        <E T="03">see also</E>
                         FSA par. 6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See</E>
                         45 CFR part 410, subpart I; 
                        <E T="03">see also</E>
                         FSA Exhibit 3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See</E>
                         45 CFR 410.1001.
                    </P>
                </FTNT>
                <P>As of the publication date of this rulemaking, ORR has built a network of nearly 300 care provider facilities in 27 States, funded through cooperative agreements and grants between ORR and the care provider facilities. As discussed below, a significant number of ORR care provider facilities are in Texas, which has decided to no longer conduct investigations of reported abuse and neglect arising at ORR-funded care provider facilities housing unaccompanied children.</P>
                <P>
                    In addition, as of the publication date of this rulemaking, ORR oversees three influx care facilities, funded through contracts, that currently have no children in care but are ready to commence or resume operations within certain timeframes if needed.
                    <SU>16</SU>
                    <FTREF/>
                     ORR does not currently have formal written agreements with the relevant State or local authorities to investigate reports of 
                    <PRTPAGE P="93500"/>
                    child abuse and neglect at these facilities. If such agreements are executed, ORR may in its discretion elect not to exercise its investigative authority and instead rely on the relevant State or local authorities (consistent with its approach to sexual abuse as described at 45 CFR part 411).
                    <SU>17</SU>
                    <FTREF/>
                     Nevertheless, even in these circumstances, ORR retains statutory authority to conduct investigations at EIFs, and in these situations could do so consistent with this rule. If ORR were to conduct its own investigation concurrently with a State or local authority's investigation, ORR would cooperate with such authority and ORR's investigation would not conflict with such investigation. Further, ORR would conduct its investigation in such a manner as to minimize potential trauma to the alleged victim (
                    <E T="03">e.g.,</E>
                     by not interviewing a child where the State or local authority has already interviewed the child for the same information).
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         ORR Influx Care Facilities for Unaccompanied Children Fact Sheet. (July 29, 2024). Retrieved from: 
                        <E T="03">https://www.acf.hhs.gov/orr/fact-sheet/programs/uc/influx-care-facilities-fact-sheet.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         
                        <E T="03">See infra</E>
                         Section IV.B.
                    </P>
                </FTNT>
                <P>
                    To ensure that reports of child abuse and neglect at Texas care provider facilities and EIFs (as relevant) do not go uninvestigated, and pursuant to ORR's statutory responsibilities, on June 12, 2024, ORR established a Division of Unaccompanied Child Protection Investigations (DCPI) to, among other things, receive reports of alleged abuse or neglect involving unaccompanied children in ORR custody and investigate those claims where it has jurisdiction.
                    <SU>18</SU>
                    <FTREF/>
                     DCPI began conducting investigations of alleged child abuse and neglect in ORR-funded care provider facilities in Texas as of July 2024. This interim final rule describes the procedures DCPI uses when it performs child welfare investigations of alleged child abuse and neglect at ORR care provider facilities; and establishes employment consequences for care provider facility staff and volunteers based on ORR investigation dispositions, including relevant due process protections for alleged perpetrators of abuse and neglect.
                </P>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">See</E>
                         89 FR 49889, 49892.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Authority</HD>
                <P>
                    ORR's statutory authority enables it to perform investigations of alleged child abuse and neglect occurring at its care provider facilities, and to establish disciplinary consequences, including employment consequences, for individuals it determines to have perpetrated abuse or neglect. The HSA transferred to the Director of ORR functions under the immigration laws of the United States with respect to the care of unaccompanied children that were vested by statute in, or performed by, the Commissioner of the Immigration and Naturalization Service. Pursuant to such transfer, the ORR Director is “responsible for,” among other things, “ensuring that the interests of the child are considered in decisions and actions relating to the care and custody of an [unaccompanied child],” 
                    <SU>19</SU>
                    <FTREF/>
                     “implementing policies with respect to the care and placement of [unaccompanied children],” 
                    <SU>20</SU>
                    <FTREF/>
                     and “identifying a sufficient number of qualified individuals, entities, and facilities to house [unaccompanied children].” 
                    <SU>21</SU>
                    <FTREF/>
                     In addition, the HSA makes the ORR Director responsible for “overseeing the infrastructure and personnel of facilities in which [unaccompanied children] reside,” 
                    <SU>22</SU>
                    <FTREF/>
                     and “conducting investigations and inspections of facilities and other entities in which [unaccompanied children] reside, including regular follow-up visits to such facilities, placements, and other entities, to assess the continued suitability of such placements.” 
                    <SU>23</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         6 U.S.C. 279(b)(1)(B).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         6 U.S.C. 279(b)(1)(E).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         6 U.S.C. 279(b)(1)(F).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         6 U.S.C. 279(b)(1)(G).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         6 U.S.C. 279(b)(1)(L).
                    </P>
                </FTNT>
                <P>Necessarily, a fundamental aspect of ensuring that there are qualified individuals, entities, and care provider facilities to care for and house unaccompanied children is ensuring that care provider facility staff, contractors, or sub-grantees of the care provider facility, along with care provider facility volunteers and other individuals who have access to children in ORR care through contracts or grants with ORR, do not engage in abuse or neglect of children in ORR care; that such individuals who are alleged to have engaged in such abuse or neglect are reported and identified; that allegations of child abuse or neglect against such individuals are properly and thoroughly investigated; and that if the allegations are found to be substantiated and are sustained pursuant to an appeal and review process, actions are taken to ensure that such individuals are prohibited from working or volunteering in any way on ORR-funded grants or contracts and do not have contact with children in ORR custody. Thus, the rule described here is a crucial aspect of implementing ORR's statutory mandates under the HSA, which expressly delegates authority to the ORR Director to administer the UC Bureau.</P>
                <P>Pursuant to these authorities, this rule describes the circumstances in which ORR will investigate allegations of child abuse and neglect; the procedures for such investigations; and steps ORR may take in response to findings that individuals who work or volunteer at ORR-funded care provider facilities have perpetrated abuse or neglect against children in its custody, including due process requirements that would apply to such steps.</P>
                <P>
                    In addition to the HSA, ORR's Interim Final Rule regarding the Prevention of Sexual Abuse 
                    <SU>24</SU>
                    <FTREF/>
                     (PSA IFR), which ORR promulgated in 2014 pursuant to the Violence Against Women Reauthorization Act of 2013 (VAWA),
                    <SU>25</SU>
                    <FTREF/>
                     describes requirements concerning sexual abuse of unaccompanied children in ORR custody. Though the PSA IFR specifically applies to the prevention of 
                    <E T="03">sexual</E>
                     abuse of unaccompanied children, it describes requirements that inform this IFR regarding the prevention of abuse and neglect, including requirements for staff background checks; suspension of staff, contractors, and volunteers suspected of perpetrating sexual abuse or sexual harassment from all duties that would involve or allow access to unaccompanied children pending the outcome of an investigation; and requirements for restricting the employment of care provider facility staff against whom allegations of child abuse or neglect have been substantiated.
                    <SU>26</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         
                        <E T="03">Standards To Prevent, Detect, and Respond to Sexual Abuse and Sexual Harassment Involving Unaccompanied Children,</E>
                         79 FR 77768 (Dec. 24, 2014) (codified at 45 CFR part 411).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         
                        <E T="03">See</E>
                         Public Law 113-4,  1101(d), 127 Stat. 134, 135 (2013) (codified at 34 U.S.C. 30307(d)) (directing the Secretary of HHS to “publish a final rule adopting national standards for the detection, prevention, reduction, and punishment of rape and sexual assault in facilities that maintain custody of unaccompanied alien children (as defined in section 279(g) of Title 6)”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         
                        <E T="03">See generally</E>
                         Standards to Prevent, Detect, and Respond to Sexual Assault and Sexual Harassment Involving Unaccompanied Children, codified at 45 CFR part 411 (PSA IFR); 
                        <E T="03">see also</E>
                         the ORR Policy Guide at Section 4.3.
                    </P>
                </FTNT>
                <P>
                    The standards in the PSA IFR also require care provider facilities to refer allegations of sexual abuse and sexual harassment to proper investigating authorities (
                    <E T="03">i.e.,</E>
                     State and local law enforcement, child protective services, and licensing authorities), and to remain informed of ongoing investigations and fully cooperate with outside investigators as necessary.
                    <SU>27</SU>
                    <FTREF/>
                     ORR notes that nothing in this rule is intended to replace or prohibit investigations of sexual abuse and sexual harassment under other civil rights laws. The PSA IFR also states that ORR will refer allegations to the Department of Justice 
                    <PRTPAGE P="93501"/>
                    or other investigating authority for further investigation where such reporting is in accordance with its policies and procedures and any memoranda of understanding.
                    <SU>28</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         
                        <E T="03">See</E>
                         45 CFR 411.22(a); 411.71(c), (d).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         
                        <E T="03">See</E>
                         45 CFR 411.22(d).
                    </P>
                </FTNT>
                <P>At the time the PSA IFR was published, ORR assumed that all States or localities would maintain their historic practices of investigating alleged child abuse and neglect in ORR State-licensed care provider facilities. Accordingly, the PSA IFR only contemplates scenarios where a State or local authority is the investigating authority for allegations of sexual abuse and harassment occurring at ORR care provider facilities. This rule describes a new system of ORR investigations and actions to be taken based on investigation findings, which ORR would apply, as needed, at care provider facilities as described at § 412.100(c).</P>
                <P>
                    Finally, the Victims of Child Abuse Act (VCAA) and its implementing regulations 
                    <SU>29</SU>
                    <FTREF/>
                     impose reporting requirements on ORR-contracted facilities (
                    <E T="03">e.g.,</E>
                     EIFs). Under the VCAA, child abuse (as defined in the Act) occurring at Federally-operated or contracted facilities must be reported to local law enforcement or child protective services agencies with jurisdiction to investigate reports of child abuse or to protect child abuse victims in the land area or facility in question, “provided that such agencies, if non-federal, enter into formal written agreements to do so. . . .” 
                    <SU>30</SU>
                    <FTREF/>
                     If there is no such formal written agreement, the Federal Bureau of Investigation (FBI) is the agency designated to receive such reports.
                    <SU>31</SU>
                    <FTREF/>
                     However, ORR is advised that the FBI's jurisdiction is limited to Federal crimes (
                    <E T="03">i.e.,</E>
                     the FBI cannot investigate conduct that does not rise to the level of a Federal crime)—and many child abuse and neglect allegations that nonetheless warrant investigation do not constitute Federal crimes. Upon receipt of such reports of child abuse, agencies designated under the VCAA—which can include other federal agencies or non-federal agencies that are designated pursuant to a formal written agreement—may conduct investigations of the alleged abuse and neglect. This IFR does not conflict with any agency duties under the VCAA. If ORR executes formal written agreements with relevant local authorities to investigate child abuse and neglect at EIFs, it reserves discretion under its statutory authorities to conduct its own investigations as well. In such cases, ORR intends under this rule that any ORR investigation will not conflict with investigations performed by other authorities in connection with the VCAA.
                </P>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         
                        <E T="03">See</E>
                         34 U.S.C. 20341; 
                        <E T="03">see also</E>
                         28 CFR part 81.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         28 CFR 81.2
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         28 CFR 81.3.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">C. Basis and Scope of Regulatory Action</HD>
                <HD SOURCE="HD3">1. Discontinuation of Investigations of Child Abuse and Neglect at Care Provider Facilities That Care for Unaccompanied Children.</HD>
                <P>
                    For years, ORR has relied on States or localities both to license its care provider facilities and to investigate any allegations of child abuse and neglect.
                    <SU>32</SU>
                    <FTREF/>
                     Since 2021, however, three States—Texas, Florida, and South Carolina—have ceased licensing childcare facilities that serve or propose to serve unaccompanied children under grant or contract with ORR. As of publication of this rule, Florida and South Carolina continue to provide for State-based investigations of alleged child abuse and neglect in ORR-funded care provider facilities.
                    <SU>33</SU>
                    <FTREF/>
                     In contrast, in connection with the State's decision to end licensing of care provider facilities housing unaccompanied children, the Texas State agency that would otherwise be responsible for such investigations no longer conducts them at ORR care provider facilities (except foster care providers).
                </P>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         
                        <E T="03">See, e.g.,</E>
                         79 FR 77768, 77776 (“. . . ORR does not conduct investigations regarding the substance of an allegation. Instead, as stated in the previous paragraphs, ORR requires that all care provider facilities refer all allegations, regardless of how an allegation is made or who it comes from, to the proper investigating authorities.”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         ORR notes that Florida continues to investigate child abuse and neglect in care provider facilities housing unaccompanied children, and ORR only operates foster family home care settings in South Carolina. Foster care licensing has not been impacted by South Carolina's action to not license residential care.
                    </P>
                </FTNT>
                <P>
                    Pursuant to a proclamation by Texas's Governor Abbott,
                    <SU>34</SU>
                    <FTREF/>
                     on July 13, 2021, the Texas Health and Human Services Commission (HHSC) issued an emergency rule temporarily exempting Texas's childcare facilities that shelter unaccompanied children in Federal custody from Texas's licensing requirement.
                    <SU>35</SU>
                    <FTREF/>
                     The exemption went through a series of renewals until, on July 22, 2022, Texas amended the emergency rule to make the licensure exemption ongoing.
                    <SU>36</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         Proclamation by the Governor of the State of Texas. (May 31, 2021). Available at: 
                        <E T="03">https://gov.texas.gov/uploads/files/press/DISASTER_border_security_IMAGE_05-31-2021.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         46 Tex. Reg. 4407. (July 23, 2021). (Adopting on an emergency basis in Texas Administrative Code title 26 part 1, chapter 745, Licensing, new § 745.10301 and amended § 745.115). The emergency rule—and the exemption it provides—were only effective for 120 days and could only be renewed for an additional 60 days. Available at: 
                        <E T="03">https://texashistory.unt.edu/ark:/67531/metapth1362781/m2/1/high_res_d/0723is.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         Texas HHS Agenda Item. (May 19, 2022). Available at: 
                        <E T="03">https://www.hhs.texas.gov/sites/default/files/documents/may-2022-ec-agenda-item-2bvi.docx.</E>
                    </P>
                </FTNT>
                <P>
                    ORR understands that, pursuant to this change in Texas law, neither Texas HHSC nor the Texas Department of Family and Protective Services (DFPS) currently conducts child abuse and neglect investigations in facilities that house unaccompanied children due to their lack of jurisdiction over license-exempt childcare facilities. Because DFPS is not investigating, substantiating, or sustaining these allegations pursuant to administrative reviews as appropriate, DFPS does not list potential sustained perpetrators in the Texas child abuse and neglect registry,
                    <SU>37</SU>
                    <FTREF/>
                     and thus such perpetrators will not be identified as having committed abuse or neglect in a background check by an ORR-funded or other provider. State and local law enforcement continue to investigate reported child abuse and neglect that rises to the level of a crime, but in many instances, actions involving abuse or neglect constitute civil violations, but not criminal violations. Depending on circumstances, this may include physical abuse, verbal/emotional abuse, and sexual harassment.
                </P>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         Tex. Fam. Code § 261.002.
                    </P>
                </FTNT>
                <P>As discussed above, ORR has historically relied on State and local authorities to investigate allegations of child abuse and neglect arising at its care provider facilities. However, a significant gap in investigative capacity has resulted from Texas's decision to cease DFPS investigations at ORR care provider facilities. ORR was unable to immediately fill this gap by conducting its own investigations because such investigations necessitate the use of skilled and trained investigators, and historically ORR had not played this role.</P>
                <P>
                    However, ORR took immediate and ongoing steps after determining that Texas planned to cease its investigations into alleged child abuse and neglect at ORR-funded care provider facilities housing unaccompanied children. Soon after it became clear that Texas DFPS was not going to resume its long-standing child welfare and investigative functions when it extended its emergency declaration in 2022, ORR began examining the operational feasibility, capacity, and expertise that would be required to permanently absorb the investigative responsibilities once performed by Texas DFPS. Such an endeavor represented an unexpected 
                    <PRTPAGE P="93502"/>
                    and significant expansion of ORR's operations, as ORR had successfully relied on relevant state child welfare entities to fulfill that role for years up to this point. ORR's work over the past two years has included, but not been strictly limited to: communicating with Texas state officials to confirm their position regarding investigations into alleged child abuse and neglect at ORR care providers and attempt to reach a resolution with the state directly; consulting with other federal agencies to evaluate available options to address the lack of investigations and seek feedback on ORR's proposed approach; researching and planning how ORR would develop the necessary expertise and capacity to conduct investigations; developing policies and procedures to inform how investigations are conducted; obtaining administrative approval for new agency positions; creating of new comprehensive technical systems for recording and tracking investigations; and, eventually, the hiring, onboarding, and training of qualified investigative staff.
                </P>
                <P>In addition, while engaged in these efforts, ORR directed its care provider facilities in Texas to continue reporting abuse and neglect allegations to State child welfare agencies, State licensing agencies, State and local law enforcement, and where appropriate, the HHS Office of the Inspector General and the FBI. ORR also established a framework, utilizing its child welfare team or CWT (later becoming known as the ORR Prevention of Child Abuse and Neglect or PCAN Team) for conducting in-depth reviews of care provider facility responses to each individual allegation of abuse and neglect. In these reviews, ORR staff receive and review documentation concerning the allegation, assess whether proper interventions and reporting requirements under ORR policies and procedures were followed, and make recommendations for appropriate follow-up actions regarding the alleged victim's medical and mental health needs.</P>
                <P>
                    While ORR's in-depth reviews have played an important role in filling some of the investigations-related gaps like ensuring compliance with reporting requirements and following up on appropriate interventions for staff and children, there remained a need for a separate entity other than the care provider facilities themselves—that would ensure independent oversight and response—to investigate allegations of abuse and neglect that do not constitute criminal violations. Accordingly, pursuant to its statutory responsibilities to oversee the personnel and infrastructure of care provider facilities and to conduct investigations (see discussion under section IV.B. Authority), ORR established the Division of Unaccompanied Child Protection Investigations (DCPI) in June 2024.
                    <SU>38</SU>
                    <FTREF/>
                     DCPI began conducting investigations of alleged child abuse and neglect at care provider facilities in Texas in July 2024.
                </P>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         
                        <E T="03">See</E>
                         Statement of Organization, Functions, and Delegations of Authority, 89 FR 49889 (June 24, 2024).
                    </P>
                </FTNT>
                <P>However, investigations without more do not fully fill the gap left by Texas DFPS's decision not to investigate allegations of child abuse and neglect, including by substantiating and sustaining such allegations so that perpetrators may be identified and precluded from working with unaccompanied children in ORR's care. The statutory provisions authorizing ORR to establish its investigative division do not specify the particular procedures ORR should follow in conducting investigations and taking action to protect children from individuals with pending or sustained allegations of sexual abuse or neglect. Thus, ORR has determined that in order to fully address the protection of children in its custody, consistent with its statutory responsibility, it is important to establish a mechanism to ensure that individuals with sustained Tier I allegations (as defined in this rule) investigated by DCPI are terminated from employment in ORR-funded programs, prevented from having contact with children in ORR programs, and barred from employment in any ORR-funded program in the future. To accomplish this goal with appropriate due process protections, ORR has adopted this rule.</P>
                <HD SOURCE="HD3">2. Need for ORR To Investigate Child Abuse and Neglect at Emergency or Influx Facilities</HD>
                <P>
                    In addition, this rulemaking provides needed clarity with respect to investigations of child abuse and neglect at EIFs. Responsibility for investigating allegations of child abuse and neglect at EIFs is unique to each EIF based on a number of factors, including the willingness of States or local authorities to investigate child abuse and neglect at care provider facilities housing unaccompanied children or enter into a formal written agreement with ORR to do so; the unique size, capacity, and scope of EIFs; and the urgent timelines under which EIFs may be activated. Because EIFs are activated in times of influx, which arise based on unpredictable migration patterns, there may not be sufficient time to establish formal written agreements with local authorities to conduct child abuse and neglect investigations when ORR activates such facilities. For example, referrals of unaccompanied children to ORR increased dramatically from Federal fiscal year (FFY) 2020 (15,381 children) to FFY 2021 (122,731 children), continued to increase in FFY 2022 (128,904 children), but then decreased in FFY 2023 (118,938 children).
                    <SU>39</SU>
                    <FTREF/>
                     ORR believes, as a result, that it is appropriate to include EIFs within the scope of this rule—to ensure that reports of child abuse and neglect arising at EIFs are consistently investigated and that ORR may take actions to protect unaccompanied children from those with pending or sustained allegations.
                    <SU>40</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         ORR Unaccompanied Children Facts and Data. (July 5, 2024). Retrieved from: 
                        <E T="03">https://www.acf.hhs.gov/orr/about/ucs/facts-and-data.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         
                        <E T="03">See also infra</E>
                         Section VI (discussing good cause for issuing this IFR).
                    </P>
                </FTNT>
                <P>
                    ORR prefers that State and local authorities exercise their long-standing authority under State and local laws and regulations to investigate allegations of child abuse and neglect and will continue to seek to establish agreements with States and local authorities to investigate child abuse and neglect at EIFs. However, as noted above, as of the date of publication, ORR does not currently have written agreements with State or local authorities to conduct child welfare investigations at EIFs, and as noted above, FBI investigations are limited to allegations that potentially rise to the level of Federal crimes. Further, with DCPI investigations of alleged child abuse and neglect underway, there is also a need to maintain an ORR central registry to document substantiated abuse and neglect findings based on its own investigations. As in States that do not to provide an investigative infrastructure for ORR-funded facilities housing unaccompanied children, both investigations and the maintenance of a central registry are required at EIFs—particularly where no State or local investigative infrastructure is available (
                    <E T="03">e.g.,</E>
                     pursuant to a formal written agreement with ORR).
                </P>
                <P>
                    ORR notes that any ORR investigations into allegations of child abuse and neglect at EIFs under this rule would be separate from any other investigations that may occur by other authorities, whether pursuant to the VCAA or otherwise, and will not conflict with investigations by those other authorities.
                    <PRTPAGE P="93503"/>
                </P>
                <HD SOURCE="HD3">3. Scope of Rulemaking</HD>
                <P>This IFR describes the circumstances in which ORR will investigate and substantiate child abuse and neglect allegations. It also delineates further steps ORR may take upon conducting such investigations to protect unaccompanied children, such as ensuring that certain individuals against whom allegations of child abuse and neglect have been substantiated and upheld after an appeal and review process are prevented from working or volunteering in any way on ORR-funded grants or contracts, and that alleged perpetrators with pending allegations do not have continued access to children. As discussed below at section VI, considering ORR's recent establishment of the DCPI, there is good cause to issue an IFR both to describe the nature and scope of ORR investigations, and critically, to establish required consequences for certain investigative findings, with appropriate due process protections.</P>
                <P>This IFR:</P>
                <P>• Describes the responsibilities of ORR to conduct investigations into allegations of child abuse and neglect of unaccompanied children at (1) care provider facilities located in States where the State agency responsible for investigating child abuse and neglect allegations will not investigate such allegations in ORR-funded care provider facilities, and at (2) EIFs;</P>
                <P>• Defines the applicable burden of proof as a preponderance of the evidence and describes the investigation disposition types as substantiated-Tier I; substantiated-Tier II; not substantiated; unfounded; or administratively closed;</P>
                <P>• Describes notification requirements of the findings of investigations;</P>
                <P>• Describes an appeal and review process for individuals with substantiated allegations of child abuse and neglect at ORR care provider facilities in States that will not investigate allegations of abuse or neglect in facilities housing unaccompanied children and at emergency or influx facilities;</P>
                <P>• Creates an ORR Central Registry, and associated processes and sanctions, for individuals with sustained Tier I allegations of child abuse and neglect at EIFs and at ORR care provider facilities in States that will not investigate allegations of abuse or neglect in facilities housing unaccompanied children; and</P>
                <P>• Describes requirements for care provider facilities to cooperate with investigations.</P>
                <HD SOURCE="HD2">D. Severability</HD>
                <P>The different parts of this interim final rule address distinct aspects of investigations of child abuse and neglect. These include: the investigation of allegations of child abuse and neglect occurring at care provider facilities that do not conduct their own investigations, and investigations at EIFs (§ 412.100); interventions and discipline, including an ORR Central Registry of perpetrators relating to certain sustained allegations (§ 412.101); the appeal and review process (§ 412.102); and obligations of care provider facilities (§ 412.103) in cooperating with investigations. To the extent any section or subsection of the rule is declared invalid by a court, ORR intends for all remaining sections and subsections to remain in effect, as they would continue to function sensibly. As an illustration, ORR expects that if a court were to invalidate § 412.100(c)(2), which makes the requirements of § 412.100 relating to investigations into allegations of child abuse and neglect applicable to EIFs, the standards, requirements, and procedures under § 412.100 would continue to be applicable to care provider facilities housing unaccompanied children in States where the State agency responsible for investigating child abuse and neglect allegations will not investigate such allegations in ORR-funded care provider facilities, as provided in § 412.100(c)(1). Likewise, ORR expects that if a court were to declare that the ORR Central Registry as defined at § 412.001 and described at § 412.101(a) is invalid, the requirements of § 412.100 relating to investigations into allegations of child abuse and neglect at certain facilities, and the obligations of care facilities delineated at § 412.103 will remain in effect.</P>
                <HD SOURCE="HD1">V. Discussion of Elements of the Interim Final Rule</HD>
                <HD SOURCE="HD2">Section 412.001 Definitions</HD>
                <P>ORR, in § 412.001, is codifying the definitions of terms that apply to this part. Many terms used in this rule are defined in other authorities, including statutes and ORR regulations, and this rule uses these terms consistently with those definitions. For example, this rule uses the term “unaccompanied child” consistently with the definition provided in the UC Program Foundational Rule, at 45 CFR 410.1001 (which is further consistent with the definition of “unaccompanied alien child” found in the Homeland Security Act (HSA), at 6 U.S.C. 279(g)(2)). Below, ORR further explains its rationale for certain definitions applied in this rule.</P>
                <P>
                    The definition of “administrative closure” describes when ORR determines it will not make a finding regarding an allegation of child abuse or neglect. Administrative closure does not imply that ORR would have found an allegation of abuse or neglect to be substantiated or not substantiated. ORR may assign an intake report for administrative closure if ORR determines it is not appropriate for investigation. Reasons for administrative closure before an investigation may include, but are not limited to, lack of jurisdiction to conduct an investigation of the allegation (
                    <E T="03">e.g.,</E>
                     if the alleged abuse or neglect occurred in a State where the State agency responsible for investigating child abuse and neglect continues to investigate such reports of unaccompanied children in ORR care); transfer of the report to another jurisdiction or agency; an allegation not rising to the level of child abuse or neglect; duplication of an existing report; or an allegation is otherwise outside the scope of this rule, as described at § 412.100(c). ORR may also make a disposition of administrative closure after investigation. Reasons for administrative closure after an investigation may include, but are not limited to, inability to contact the child; insufficient information to proceed with the investigation; or transfer to another jurisdiction or agency. If ORR administratively closes an intake report or investigation, it may consider further investigation related to the initial allegation if new information becomes available.
                </P>
                <P>
                    The definition of “alleged perpetrator” means a person who is alleged to have abused or neglected a child within the scope of this part as described at § 412.100(a) and (c). The term encompasses individuals who are identified in an intake report, and subject to an investigation under this part, but does not include individuals who have been subject to an investigation which resulted in a not substantiated allegation, unfounded allegation, or administrative closure. Per the definition of child abuse and neglect set out at § 412.001, alleged perpetrators can include individuals who observed, permitted, or otherwise allowed a child to be mistreated and knowingly failed to act to protect the child. Alleged perpetrators do not become sustained perpetrators until all appropriate investigative steps have been completed and they have exhausted all administrative remedies, including waiving their right to appeal, as 
                    <PRTPAGE P="93504"/>
                    applicable and as specified in § 412.102(c).
                </P>
                <P>
                    The definition of “child abuse and neglect” in this IFR is based on ORR's review of Federal laws, consultation with the Administration on Children, Youth, and Families, including the Children's Bureau, and on its experience operating the UC Bureau. For example, ORR intends that this definition capture the types of behaviors identified at 22 U.S.C. 7102, 34 U.S.C. 20341, and 42 U.S.C. 5106g, Note § 3, to the extent they describe behaviors and situations that are relevant to unaccompanied children for purposes of this rule. At the same time, the definition of “child abuse and neglect” and related definitions (
                    <E T="03">e.g.,</E>
                     medical neglect, verbal or emotional abuse) in this rule provide additional granularity relevant to the UC Bureau. The definitions of sexual abuse and sexual harassment used in this rule are the same as the PSA IFR at 45 CFR 411.6. ORR developed other related definitions to appropriately capture incidents and circumstances that raise child welfare concerns, and also reflect how abuse or neglect has historically been identified within the UC Bureau (
                    <E T="03">e.g.,</E>
                     based on historical significant incident reporting to ORR, input from subject matter experts in child welfare including ORR's CWT, Prevention of Sexual Abuse Team, Division of Health for Unaccompanied Children, Federal field specialists, and Data Analytics and Information Management team). For example, this IFR provides separate definitions distinguishing neglect and medical neglect, and child abuse from child neglect, in contrast to 34 U.S.C. 20341, which groups these concepts together. Having separate definitions in this rule also enables ORR to have accurate data on specific kinds of abuse or neglect that may occur with respect to children in its care.
                </P>
                <P>The definition of “inappropriate sexual behavior” refers to inappropriate sexual, derogatory, or offensive conduct that does not rise to the level of sexual abuse or sexual harassment. ORR intends that this term, which is also used in current ORR policies, capture conduct that falls outside of other relevant definitions, but still merits reporting and response.</P>
                <P>The definition of “medical neglect” draws in part from ORR's review of other Federal authorities. For example, it is meant to include concerns described in the definition of “negligent treatment” from 34 U.S.C. 20341(c)(7), and the definition of “neglect” from 42 CFR 483.5. ORR found that these authorities described the types of issues from which it seeks to protect unaccompanied children in its custody, and, to that extent, these authorities informed the definition of “medical neglect” in this rule. ORR is providing a separate definition for medical neglect, distinct from other forms of neglect, based on its experience operating the UC Bureau, including knowledge of the forms of neglect historically reported within the context of the UC Bureau, and the importance of having sufficient granularity in data reporting and monitoring to appropriately capture and address the types of incidents and circumstances that raise child welfare concerns.</P>
                <P>“Multidisciplinary team” is defined as a group of individuals comprised of ORR staff, including subject matter experts. Multidisciplinary teams provide input to ORR's Child Welfare Investigators by assessing reported allegations of child abuse and neglect at care provider facilities and making recommendations regarding physical and behavioral healthcare needs of unaccompanied children potentially impacted by child abuse and neglect at these facilities. Notably, the multidisciplinary team may include, but is not limited to, child welfare experts, forensic interviewers, mental health practitioners, child development and disability practitioners, pediatricians and other medical experts as needed, policy advisors, Federal program analysts, Federal program management staff, or other subject matter experts. The multidisciplinary team will also focus on the physical and behavioral healthcare needs of unaccompanied children potentially impacted by, and during the course of, the investigation of child abuse or neglect. Importantly, this team is different from, and in addition to, the ORR Child Welfare Investigator. The ORR Child Welfare Investigator sits within the DCPI, which will have the option to consult with the separate multidisciplinary team as necessary and appropriate. ORR believes that this collaborative approach to the investigation will lead to a coordinated response, representing a variety of fields and disciplines to support unaccompanied children while also ensuring a more efficient and thorough investigation.</P>
                <P>The definition of “not substantiated allegation” means a disposition that there is not a preponderance of the evidence establishing that the alleged perpetrator committed child abuse or neglect (as defined in this section), but there is at least some evidence that the unaccompanied child was harmed or placed at risk of harm, whether or not by the alleged perpetrator. This term does not include administratively closed allegations. ORR notes that this definition differs from its definition of “unsubstantiated allegation” under the PSA IFR at 45 CFR 411.5 (“an allegation that was investigated and the investigation produced insufficient evidence to make a final determination as to whether or not the event occurred”). This investigation disposition, as well as the other defined dispositions, are further described in § 412.100.</P>
                <P>The definition of “physical abuse” in this IFR aligns with the types of behaviors identified at 34 U.S.C. 20341 and described at 42 U.S.C. 5106g, Note § 3, to the extent that those provisions describe behaviors and situations that are relevant to unaccompanied children for the purposes of this rule. Further, the definition of “physical abuse” provided in this rule includes specific non-exhaustive examples, based on ORR's experience operating the UC Bureau and the forms of physical abuse historically reported, as well as feedback from care provider facilities that definitions with greater specificity better support effective reporting and monitoring.</P>
                <P>The definition of “preponderance of the evidence” describes the burden of proof used to substantiate allegations of child abuse and neglect. ORR notes that this definition is based on 42 CFR 93.219, and that this definition means something is more likely than not to be true.</P>
                <P>The definition of “sexual abuse,” has the same meaning as that term is defined in 45 CFR 411.6.</P>
                <P>The definition of “sexual harassment,” has the same meaning as that term is defined in 45 CFR 411.6. ORR notes that this definition indicates that prohibited conduct “includes” repeated actions; however, the definition is not intended to be exhaustive, and a single instance may constitute sexual harassment.</P>
                <P>The definition of “sub-grantee” is based on the definition of the term “subrecipient” from 45 CFR 75.2. ORR is using the term sub-grantee instead of subrecipient for consistency with existing ORR policies and guidance.</P>
                <P>
                    The definition of “substantiated allegation-Tier I” means a disposition that there is a preponderance of the evidence establishing that the alleged perpetrator committed child abuse or neglect, and the investigation indicates one or more automatic Tier I substantiating circumstances have been found pursuant to § 412.100(e)(7) or substantiation at Tier I is warranted based on consideration of aggravating and mitigating factors pursuant to § 412.100(e)(8). ORR notes that this 
                    <PRTPAGE P="93505"/>
                    definition differs from its definition of “substantiated allegation” under the PSA IFR at 45 CFR 411.5 (“an allegation that was investigated and determined to have occurred”) to incorporate that ORR, as the investigating entity, is using the preponderance of evidence standard to establish a disposition of “substantiated” and to incorporate the consideration of automatic Tier I substantiating circumstances, aggravating factors, and mitigating factors.
                </P>
                <P>The definition of “substantiated allegation-Tier II” means a disposition that there is a preponderance of the evidence establishing that the alleged perpetrator committed child abuse or neglect, and that based on consideration of aggravating and mitigating factors pursuant to § 412.100(e)(8), the evidence does not warrant a finding of “Substantiated Allegation-Tier I.” ORR notes that this definition differs from its definition of “substantiated allegation” under the PSA IFR at 45 CFR 411.5 (“an allegation that was investigated and determined to have occurred”) to incorporate that ORR, as the investigating entity, is using the preponderance of the evidence standard to establish a disposition of “substantiated” and to incorporate the consideration of whether a disposition of substantiated allegation-Tier I is warranted, including in consideration of the aggravating and mitigating factors.</P>
                <P>The definition of “substantiated perpetrator” means a person against whom an allegation of child abuse or neglect has been substantiated by ORR at Tier I or Tier II, but who has not exhausted the applicable appeal and review process for such allegations. Substantiated perpetrators at both Tier I and Tier II may appeal the disposition made by ORR to an Administrative Law Judge (ALJ) of the HHS Departmental Appeals Board (DAB) pursuant to § 412.102(c) and subsequently to the HHS Assistant Secretary for Children and Families pursuant to § 412.102(e).</P>
                <P>The definition of “sustained allegation” means an allegation that was substantiated by ORR at Tier I or Tier II and that was upheld pursuant to the appeal and review process described in this rule or for which an appeal and review process was dismissed, including when the substantiated perpetrator waives their right to appeal by failing to make a timely request or by waiving those rights as specified in § 412.102(c).</P>
                <P>The definition of “sustained perpetrator” means a substantiated perpetrator at Tier I or Tier II whose child abuse or neglect finding was upheld in the appeal and review process or whose appeal and review process was dismissed, including due to the sustained perpetrator's waiver of their right to appeal by failing to timely request appeal, or by otherwise waiving those rights as specified at § 412.102(c). Tier I Sustained perpetrators shall be prohibited from working in any way in connection with ORR-funded grants or contracts, including working or volunteering at any ORR care provider facility; may not have access to or contact with any unaccompanied child in ORR custody; will be added to the ORR Central Registry; and will be referred to appropriate law enforcement agencies. Information concerning Tier II sustained perpetrators will be recorded and maintained in agency records.</P>
                <P>The definition of “unfounded allegation” means a disposition that there is not a preponderance of the evidence establishing that the alleged perpetrator committed child abuse or neglect, and the evidence indicates that the unaccompanied child was not harmed or placed at risk of harm. ORR notes that this definition differs from its definition of “unfounded allegation” under 45 CFR 411.5 (“an allegation that was investigated and determined not to have occurred”) to incorporate that ORR, as the investigating entity, is using the preponderance of evidence standard to establish a disposition of “unfounded allegation.” ORR also notes that records regarding unfounded allegations are maintained and disposed of in accordance with the applicable federal records management requirements.</P>
                <P>The definition of “verbal or emotional abuse” aligns with the definition of “mental injury” at 34 U.S.C. 20341 and described at 42 U.S.C. 5106g, Note § 3, to the extent that those authorities describe behaviors and situations that are relevant to unaccompanied children for the purposes of this rule. The definition also includes specific non-exhaustive examples, based on ORR's experience operating the UC Bureau and the forms of verbal and emotional abuse historically reported, as well as feedback from care provider facilities that definitions with greater specificity will better support effective reporting and monitoring.</P>
                <HD SOURCE="HD2">Section 412.100 Investigations Into Allegations of Child Abuse and Neglect</HD>
                <P>ORR describes the purpose of this IFR at § 412.100(a). This rule establishes the standards, requirements, and procedures for investigations by ORR of allegations of child abuse and neglect of unaccompanied children in ORR custody alleged to have been committed by care provider facility staff, contractors or sub-grantees of the care provider facility, care provider facility volunteers, or other individuals who have access to children in ORR care through contracts or grants with ORR, subject to § 412.100(c). ORR may also investigate individuals including those who are affiliated with legal service providers, child advocates, or other contractors engaged by ORR or the relevant care provider facility, to the extent allegations of abuse or neglect concern unaccompanied children who were in ORR custody at the time of the alleged incident. ORR believes these regulations will reduce the risk of child abuse and neglect of unaccompanied children in ORR care.</P>
                <P>Section 412.100(b) provides that the provisions of this part are separate and severable from one another and that if any provision is stayed or determined to be invalid in a final judgment by a court of law, the remaining provisions shall continue in effect. This provision is meant to be consistent with the discussion of severability provided in the preamble at section IV.D.</P>
                <P>
                    Section 412.100(c) states that this rule applies in two circumstances. First, it applies to care provider facilities located in States where the State agency otherwise responsible for investigating child abuse and neglect allegations will not, as a matter of policy, investigate allegations of abuse or neglect concerning unaccompanied children at ORR-funded care provider facilities.
                    <SU>41</SU>
                    <FTREF/>
                     Second, this rule applies to EIFs. ORR notes this regulation implements ORR's statutory authority to conduct investigations and inspections of care provider facilities and other entities in which unaccompanied children reside while in ORR custody, regardless of the alleged perpetrator's particular role or job at the care provider facility—
                    <E T="03">i.e.,</E>
                     regardless of whether they are employed directly by the care provider facility, are employed by a contractor or sub-grantee of the care provider facility, are caring for unaccompanied children through a cooperative agreement with ORR, or are volunteers at a care provider facility. Finally, this regulation provides ORR the authority to investigate any allegations of child abuse and neglect that occurred during a child's stay at an ORR care provider facility, even if the allegation is reported after the unaccompanied child has been released from ORR care and custody. In the event that a child is transferred to another care provider facility, ORR will continue to investigate any allegations of child abuse and neglect that occurred at the 
                    <PRTPAGE P="93506"/>
                    care provider facility for which the allegation was submitted.
                </P>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         As of the publication of this rule, the only such state is Texas.
                    </P>
                </FTNT>
                <P>
                    ORR believes that it is critical to ensure that allegations of child abuse and neglect are reported to ORR. For example, ORR's existing policies and procedures require care provider facilities to report all allegations of child abuse and neglect of an unaccompanied child in ORR custody to ORR and to Federal, State, and local authorities in accordance with any applicable Federal, State, and local reporting and licensing laws.
                    <SU>42</SU>
                    <FTREF/>
                     Further, 45 CFR 411.61 requires care provider facilities to report to ORR any allegation, suspicion, knowledge, or information regarding an incident of sexual abuse or sexual harassment occurring in ORR care, along with any retaliatory actions resulting from reporting such incidents. The UC Program Foundational Rule requires at 45 CFR 410.1303(g) that all care provider facilities report to ORR any emergency incident, significant incident, or program-level event, in accordance with any applicable Federal, State, and local reporting laws. These existing requirements apply to all ORR care provider facilities. The requirements outlined in this rule at § 412.100(d) further provide that any person may report an allegation of child abuse and neglect to ORR directly, to the care provider facility, or to a designated entity or office that is not part of the care provider facility. To ensure clarity and consistency, ORR believes it is important to outline these additional reporting requirements for care provider facilities subject to this rule.
                </P>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         
                        <E T="03">See,</E>
                         ORR Policy Guide Section 5.8.2 Significant Incidents.
                    </P>
                </FTNT>
                <P>
                    ORR believes that ensuring individuals can report allegations of child abuse and neglect without fear of retaliation is key to ensuring that such reports are made. Therefore, under § 412.100(d), care provider facilities to which this part applies must have written policies and procedures that allow children, care provider facility staff, contractors or sub-grantees of the care provider facility, care provider facility volunteers, families of unaccompanied children, legal service providers, child advocates, attorneys of record, and any other persons to report allegations of child abuse and neglect to ORR directly, to the care provider facility, or to a designated entity or office that is not part of the care provider facility. Under § 412.100(d), the written policies and procedures must minimally address three topics. First, under § 412.100(d)(1), the care provider facilities' policies and procedures must at minimum provide unaccompanied children and other individuals with methods for reporting and inform them of how they can report an allegation of child abuse and neglect to a designated entity or office that is not part of the care provider facility. Such entity or office must be able to receive allegations of child abuse and neglect and to immediately forward them to ORR, allowing unaccompanied children to remain anonymous upon request. Second, under § 412.100(d)(2), all the methods of reporting must be accessible to all unaccompanied children including those with disabilities and those with limited English proficiency. This can include, for example, ensuring unaccompanied children are aware of, and are able to call, ORR's National Call Center.
                    <SU>43</SU>
                    <FTREF/>
                     In order to be accessible to unaccompanied children with disabilities, the method of reporting must provide effective communication consistent with section 504 of the Rehabilitation Act of 1973. In addition, ORR notes that the requirements for language access for unaccompanied children with disabilities under the UC Program Foundational Rule must also be met, at 45 CFR 410.1306 and 45 CFR 410.1311 respectively. Third, under § 412.100(d)(3), the care provider facility policies and procedures must include protections to prevent retaliation against unaccompanied children and others who report allegations of child abuse and neglect.
                </P>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         
                        <E T="03">See</E>
                         ORR, Office of Refugee Resettlement National Call Center, 
                        <E T="03">https://www.acf.hhs.gov/orr/outreach-material/office-refugee-resettlement-national-call-center</E>
                         (date accessed Sept. 6, 2024).
                    </P>
                </FTNT>
                <P>At § 412.100(e), ORR is establishing requirements for the screening and intake of reports of allegations of child abuse and neglect, conducting investigations, assigning dispositions to the allegations, and documenting investigations. When receiving reports of allegations of child abuse and neglect and conducting investigations, ORR must ensure the health and safety of unaccompanied children while making every effort to reduce further trauma to the alleged victim(s).</P>
                <P>ORR is requiring at § 412.100(e)(1), that when it receives a report of alleged child abuse or neglect, ORR must generate an intake report and determine whether the report includes an allegation that, if found to be true, would meet the definition of child abuse and neglect in this part and is consistent with § 412.100(a) and (c). If so, ORR will assign the intake report for investigation. If not, ORR will assign the intake report for administrative closure. ORR will assign an intake report for investigation where the allegation meets the requirements of § 412.100(a) and (c); but ORR may in its discretion elect not to investigate an allegation at an EIF if it has a formal written agreement with the relevant State or local authority to perform such investigations. ORR may administratively close an intake report when it determines it is not appropriate for an investigation, which may include circumstances such as those described in the definition of administrative closure in § 412.001. ORR notes that it will assign an intake report for investigation in accordance with the requirements at § 412.100(e) even if the child is no longer in ORR care, as long as the alleged abuse or neglect occurred while the child was in ORR care. This could include, for example, instances in which an unaccompanied child reports an allegation of abuse or neglect to ORR after they have been released, or if the child has been transferred to another care provider facility. In the event that a child has been transferred to a new care provider facility in a State that conducts investigations, ORR will continue its investigation in the State in which the alleged child abuse or neglect occurred, as the alleged perpetrator may still pose a risk to other children in the care provider facility from which the child was transferred. ORR will document and assess the report to determine the timeline for assigning the report for investigation based on the level of risk of harm to the alleged victim and assign different response times based on the level of risk of harm. ORR will document and maintain a record of every allegation received at care provider facilities that fall under this IFR, whether it is ultimately assigned for investigation and a disposition rendered or assigned for administrative closure. ORR's decision and rationale about whether to classify the allegation as an intake report and assign it for investigation (or for administrative closure) will also be documented.</P>
                <P>
                    After an intake report is assigned for investigation, under § 412.100(e)(2), ORR shall assign an ORR Child Welfare Investigator to make a prompt and thorough investigation of the report to obtain sufficient information to determine whether the allegation is substantiated based on a preponderance of the evidence. The preponderance of the evidence standard for ORR investigations shall be applied in determining whether the alleged perpetrator committed child abuse or neglect. As such, the investigation prescribed in this section relates to the 
                    <PRTPAGE P="93507"/>
                    underlying allegation of abuse or neglect to a child, in addition to focusing on the individual perpetrator(s) involved. ORR will communicate its disposition to the alleged perpetrator, consistent with the requirements set forth at § 412.100(g), specifying whether the investigation determined that the alleged perpetrator committed abuse or neglect as defined in this rule. ORR emphasizes that this child-centered approach comports with common child welfare best practices seen across State systems.
                </P>
                <P>ORR is requiring, at § 412.100(e)(3), that ORR shall provide notification that an allegation of child abuse and neglect will be investigated by ORR. This notification shall be provided to the alleged perpetrator; care provider facility; alleged victim; alleged victim's attorney of record (if the child has an attorney of record); and the alleged victim's parent(s), legal guardian(s), or sponsor(s) (as appropriate), unless ORR has evidence showing the parents, legal guardians, or sponsors should not be notified. If the alleged victim is 14 years old or older and ORR has determined that the alleged victim is able to make an independent decision, the alleged victim can affirmatively consent to disclosure. ORR notes that this notification requirement to the alleged victim, their attorney of record, and their parents, legal guardians, or sponsors is consistent with ORR's existing subregulatory notification policies and the PSA IFR requirements at 45 CFR 411.61(e) that are specific to sexual abuse and sexual harassment. To be clear, ORR also notes that the requirements of 45 CFR 411.61(f) continue to apply with respect to allegations of sexual abuse and harassment.</P>
                <P>ORR is requiring, at § 412.100(e)(4), that the care provider facility must take immediate responsive measures to protect child welfare when notified that an investigation has been initiated, confirm the actions to ORR, and notify the alleged perpetrator, as appropriate. Such responsive measures may extend throughout the pendency of an investigation, and during the pendency of appeal and review processes, as necessary and applicable. ORR believes that this requirement is necessary to protect the safety and well-being of the unaccompanied children in ORR's care and custody until the allegation is either found to be not substantiated, unfounded, or is administratively closed. Additionally, ORR notes that care provider facility actions must be consistent with 45 CFR 411.66, which requires that any ORR and care provider facility staff, contractors, and volunteers suspected of perpetrating sexual abuse or sexual harassment must be suspended from all duties that would involve or allow access to unaccompanied children pending the outcome of an investigation.</P>
                <P>
                    At § 412.100(e)(5), ORR is establishing minimum standards that ORR shall follow when investigating allegations of child abuse and neglect. ORR investigations under this rule are not intended to replace investigations that may be performed by other relevant authorities, including State law enforcement or other Federal agencies, or entities designated under the VCAA to receive reports of child abuse. Accordingly, to the extent possible and appropriate, ORR is requiring at § 412.100(e)(5)(i) that it coordinate with any local or State law enforcement or other Federal agencies during its investigation. ORR may pause or resume an investigation at its discretion, with input from law enforcement partners or other relevant investigatory bodies, as necessary. Such coordination and cooperation with outside investigations is consistent with similar principles described in the PSA IFR.
                    <SU>44</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         
                        <E T="03">See, e.g.,</E>
                         79 FR 77768, 77793; 77797.
                    </P>
                </FTNT>
                <P>Additionally, under § 412.100(e)(5)(ii), ORR shall establish, as necessary, a multidisciplinary team comprised of ORR staff, which may include, but is not limited to, child welfare experts, forensic interviewers, mental health practitioners, child development and disability practitioners, pediatricians and other medical experts as needed, policy advisors, Federal program analysts, Federal program management staff, and subject matter experts to collaborate with the ORR Child Welfare Investigator. Although the ORR Child Welfare Investigator is responsible for rendering a final disposition based on their investigation, the multidisciplinary team will engage a range of ORR staff who are subject matter experts to provide input and an assessment of the reported allegation of child abuse or neglect to assist the ORR Child Welfare Investigator's investigation. The multidisciplinary team will also focus on the physical and behavioral healthcare needs of unaccompanied children potentially impacted by, and during the course of, the investigation of child abuse or neglect. This team is different from, and in addition to, the ORR Child Welfare Investigator and the DCPI will have the option to consult with the separate multidisciplinary team as necessary and appropriate. ORR believes that this collaborative approach to the investigation will lead to a coordinated response, representing a variety of fields and disciplines to support unaccompanied children while also ensuring a more efficient and thorough investigation.</P>
                <P>
                    Under § 412.100(e)(5)(iii), the Child Welfare Investigator is required to complete certain minimum actions during an investigation. The Investigator should demonstrate that they have thoroughly investigated the allegation to obtain sufficient information for ORR to make a disposition. Under § 412.100(e)(5)(iii)(A), ORR is requiring that upon receipt of the intake report, the ORR Child Welfare Investigator must review the intake report and the care provider facility's records on the alleged victim and alleged perpetrator, conduct a background check on the alleged perpetrator, interview the person who reported the allegation if this person was not interviewed during intake, immediately request preservation of any potential video and documentary evidence, and as needed, establish a plan for thoroughly investigating the allegation. ORR already requires background checks of care provider facility staff, contractors, and volunteers prior to hiring or before such individuals may have contact with unaccompanied children; 
                    <SU>45</SU>
                    <FTREF/>
                     but the intent of this requirement is to ensure that ORR has an updated background check regarding the alleged perpetrator. This may include an FBI fingerprint check of national and State criminal history repositories, a National Sex Offender Public website check, state child abuse and neglect registry checks, or other public records checks. Further, ORR recognizes the importance of avoiding the loss of any video and documentary evidence and therefore requires the ORR Child Welfare Investigator to immediately seek preservation of that evidence. At § 412.100(e)(5)(iii)(B), ORR is requiring the ORR Child Welfare Investigator to visit the care provider facility, as appropriate, to conduct a walkthrough of the facility and review video and documentary evidence. The intent of this requirement is to ensure the Investigator is able to review any video and documentary evidence in a timely way and record any observations that may be relevant to the investigation. Visits to the care provider facility may be unannounced, and the ORR Child Welfare Investigator may visit a care provider facility as often as necessary to complete an investigation.
                </P>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         
                        <E T="03">See</E>
                         45 CFR 411.16(c), (d).
                    </P>
                </FTNT>
                <P>
                    Under § 412.100(e)(5)(iii)(C), ORR is requiring the ORR Child Welfare Investigator to make reasonable efforts 
                    <PRTPAGE P="93508"/>
                    to interview all individuals who have information relevant to the report of child abuse or neglect, including, but not limited to, the alleged perpetrator, care provider facility staff, the alleged victim, sponsor(s), and the parent(s) or legal guardian(s) (as appropriate) of the alleged victim, and any other potential witnesses. ORR recognizes the importance of conducting investigations in a way that minimizes the number of times individual children, including the alleged victim and those who may have relevant information, are interviewed, so as to mitigate potential trauma during the investigation process and to promote reliability of the information collected. This includes taking into consideration when law enforcement or other Federal entities are conducting an investigation of the same allegation in alignment with § 412.100(e)(5)(i). ORR recognizes that some children, however, may require multiple interviews in order to feel more comfortable discussing allegations of child abuse and neglect, remember details, or overcome feelings of shame or guilt.
                    <SU>46</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>46</SU>
                         Child Welfare Information Gateway. (2023). 
                        <E T="03">Forensic interviewing: A primer for child welfare professionals.</E>
                         U.S. Department of Health and Human Services, Administration for Children and Families, Children's Bureau. Available at: 
                        <E T="03">https://www.childwelfare.gov/pubs/factsheets/forensicinterviewing/.</E>
                    </P>
                </FTNT>
                <P>Care provider facility staff will not be compelled to address questions about allegations regarding either themselves or other staff, under threat of disciplinary actions. ORR will not use threat of discharge to force an employee to be interviewed.</P>
                <P>
                    ORR notes that there may be circumstances where the ORR Child Welfare Investigator may not be able to interview all individuals who have information relevant to the report of child abuse or neglect. For example, the ORR Child Welfare Investigator may be unable to locate the individual after making reasonable efforts or the individual is unable to be interviewed due to the individual's parent, legal guardian, sponsor, or attorney representing the individual, refusing to permit the interview. ORR also notes that there may be situations in which it would not be appropriate for the parent, legal guardian, or sponsor to be interviewed (
                    <E T="03">e.g.,</E>
                     when a child 14 years old or older has not consented to disclosure). Additionally, the ORR Child Welfare Investigator may not be able to interview an alleged perpetrator if the perpetrator was arrested or is under investigation by a law enforcement agency and the interview would interfere with the investigation; or the alleged perpetrator is detained and the jail, prison, or other detention facility where the alleged perpetrator is detained will not permit the interview.
                </P>
                <P>At § 412.100(e)(5)(iii)(D), ORR is requiring the ORR Child Welfare Investigator ensure that interviews conducted as part of the investigation are accessible for all unaccompanied children, including those with disabilities and those with limited English proficiency and are properly documented either in writing or by audio or video recording. In order to be accessible for unaccompanied children with disabilities, the interviews must provide effective communication consistent with section 504 of the Rehabilitation Act of 1973. In addition, ORR notes that the requirements for language access and the requirements for unaccompanied children with disabilities under the UC Program Foundational Rule must also be met, at 45 CFR 410.1306 and 45 CFR 410.1311 respectively.</P>
                <P>At § 412.100(e)(5)(iii)(F), ORR is requiring that the ORR Child Welfare Investigator review any available evidence in DCPI's records relating to past conduct of an alleged perpetrator, except allegations that resulted in a finding of unfounded or administrative closure. ORR's intent in taking these steps is to ensure that it captures situations that reveal patterns of behavior warranting further scrutiny but protects the rights of the individual as relates to prior unfounded or administratively closed allegations.</P>
                <P>At § 412.100(e)(5)(iii)(F), ORR is requiring the ORR Child Welfare Investigator to gather relevant information as part of the investigation, including documents and audio or video evidence.</P>
                <P>Lastly, at § 412.100(e)(5)(iii)(G), ORR is requiring the ORR Child Welfare Investigator to assess any imminent or ongoing risk of child abuse or neglect to the unaccompanied children at the care provider facility and, as appropriate, request that the care provider facility implement a plan to mitigate the risk and ensure the safety of the children. ORR's intent, in addition to investigating the underlying allegation, is also to assess any imminent or ongoing risks to children at the care provider facility following an allegation and to ensure the care provider facility implements safeguards to mitigate any such risks and ensure the safety of the children. The ORR Child Welfare Investigator is responsible for identifying any immediate risks to child welfare during the initial care provider facility visit following an allegation. This is not the same as determining whether the allegation occurred, which is done through the described investigation process, but rather to gain additional insight on how the allegation may have occurred. As appropriate, the ORR Child Welfare Investigator may request that the care provider facility implement a plan to mitigate the risk of child abuse or neglect to ensure safety of the unaccompanied children in ORR care at the care provider facility.</P>
                <P>ORR is establishing at § 412.100(e)(6), that once the ORR Child Welfare Investigator's investigation is complete, ORR has the authority to render a disposition based on a preponderance of the evidence for each allegation. Possible dispositions include substantiated allegation-Tier I; substantiated allegation-Tier II; not substantiated allegation; unfounded; or administrative closure. If ORR determines the allegation is not substantiated, unfounded, or administratively closed, it may nevertheless consider further future investigation of the allegation if new information becomes available. ORR based its disposition types and definitions, including the relevant factors in § 412.100(e)(7) and (8), on a variety of existing State domestic child welfare systems and established best practices that balance children's needs and safety, the nuances that can exist in each allegation, and the due process rights of alleged perpetrators.</P>
                <P>
                    ORR notes that the first step in determining the disposition of an investigation is establishing whether child abuse or neglect, as defined under § 412.001, occurred based on the available information. If ORR finds, based on a preponderance of the evidence, that child abuse or neglect occurred, the allegation is considered substantiated as defined in § 412.001. ORR will determine whether each substantiated allegation is considered a substantiated allegation-Tier I or substantiated allegation-Tier II as to the substantiated perpetrator, based on the circumstances described at § 412.100(e)(7) and § 412.100(e)(8). ORR will make every reasonable effort to determine the perpetrator(s) responsible for each substantiated allegation of child abuse or neglect, and what role any other individuals involved in the abuse or neglect had, even if they did not perpetrate the act. An individual against whom an allegation of child abuse or neglect has been substantiated by ORR at Tier I or Tier II is considered a substantiated perpetrator, as defined in § 412.001. Under § 412.001, a substantiated perpetrator at Tier I or Tier II may appeal ORR's disposition pursuant to the established appeals process in § 412.102(d).
                    <PRTPAGE P="93509"/>
                </P>
                <P>ORR distinguishes an “unfounded” disposition from a “not substantiated” disposition based on whether there was evidence indicating that a child was harmed or placed at risk of harm. ORR believes that distinguishing these two categories in this way allows for a more child-centric approach to conducting investigations and rendering dispositions by ensuring that any situation in which a child is harmed or placed at risk of harm is specifically documented as such. While there are other existing mechanisms, including ORR's Significant Incident Reporting and monitoring systems, that may capture this information, these mechanisms do not specifically document ORR investigation dispositions.</P>
                <P>By distinguishing “unfounded” and “not substantiated” dispositions, ORR will be able to better monitor and track individuals, grantees, and contractors who may have repeated instances of allegations against them. Even where alleged child abuse and neglect is ultimately not substantiated, ORR believes documenting “not substantiated” is important for child welfare because over time such findings may reveal patterns of conduct requiring further scrutiny or action by ORR. Notably, ORR is also requiring at § 412.100(e)(5)(iii)(F) that any available evidence of past conduct in DCPI's records relating to the same alleged perpetrator be reviewed as part of the Child Welfare Investigator's investigative process, except for allegations that resulted in a finding of unfounded or administrative closure.</P>
                <P>
                    Under § 412.100(e)(7), a disposition of substantiated allegation-Tier I is automatically required where the allegation is (1) substantiated by a preponderance of the evidence, and (2) where certain enumerated factors are present. The factors warranting an automatic Tier I substantiated allegation are: (i) death or near death of a child as a result of child abuse or neglect; (ii) subjecting or exposing a child to sexual abuse or sexual harassment; (iii) inflicting an injury or creating a condition requiring a child to be hospitalized or to receive significant medical attention; (iv) repeated instances of physical abuse committed by the individual against any unaccompanied child in ORR care; (v) failure to take reasonable action to protect a child from sexual abuse or repeated instances of physical abuse under circumstances where the individual knew or should have known that such abuse was occurring; and (vi) depriving a child of necessary care (
                    <E T="03">e.g.,</E>
                     food, shelter, healthcare, supervision) which either caused serious harm or created a substantial risk of serious harm. ORR notes that “individual” in this case means the care provider facility staff, contractors or sub-grantees of the care provider facility, care provider facility volunteers, or other individuals who have access to children in ORR care through contracts or grants with ORR. Under § 410.100(e)(7)(iv), when repeated instances of physical abuse are committed by the individual, the finding of substantiated allegation-Tier I could apply to the first incident reported if evidence is found which indicates a pattern of abusive behavior, injuries to a child, or harm. Additionally, under § 410.100(e)(7)(v), the condition of an individual failing to take reasonable action to protect a child from sexual abuse or repeated instances of physical abuse would be met, for example, when another individual is aware of the abuse, and fails to take any action to stop it, and thus allows the perpetrator's abusive behavior to continue. Under § 410.100(e)(7)(vi), the condition of depriving a child of necessary care which either caused serious harm or a substantial risk of harm includes cases of willful abandonment, deprivation of food, withholding of vital healthcare, forced isolation, and other acts or omissions of similar severity.
                </P>
                <P>If no automatic Tier I substantiating circumstances, as described at § 412.100(e)(7), are present, § 412.100(e)(8) enumerates aggravating and mitigating factors which will be considered in determining if child abuse or neglect should be substantiated at Tier I or II. In the absence of automatic Tier I substantiating circumstances, where ORR finds under a preponderance of the evidence that child abuse or neglect occurred, ORR will make a determination as to whether the allegation should be substantiated as Tier I or Tier II by weighing aggravating and mitigating factors together. Consideration of aggravating and mitigating factors will be based on the totality of the circumstances and in the interest of protecting child welfare. ORR again notes that the “individual” means the care provider facility staff, contractors or sub-grantees of the care provider facility, care provider facility volunteers, or other individuals who have access to children in ORR care through contracts or grants with ORR. Aggravating factors include any of the following under § 412.100(e)(8)(i): (A) violations of ORR behavior management requirements pursuant to the UC Program Foundational Rule at 45 CFR 410.1304; (B) failure to comply with clearly established care provider facility policies, corrective action plans, or agreed-upon conditions; (C) the tender age, delayed developmental status or other vulnerability of the child; (D) any significant or lasting physical, psychological, or emotional harm to the child; (E) an attempt to inflict any significant or lasting physical, psychological, or emotional harm to the child; and (F) evidence suggesting a repetition or pattern of abuse or neglect, including multiple instances in which child abuse or neglect was substantiated at Tier I or Tier II, or not substantiated allegations if they demonstrate a pattern of abuse or neglect.</P>
                <P>
                    Under § 412.100(e)(8)(i)(A), violations of ORR behavior management requirements 
                    <SU>47</SU>
                    <FTREF/>
                     include, for example, the use of prone physical restraints, chemical restraints, or peer restraints for any reason in any care provider facility setting, especially considering the age and particular vulnerability of the child. ORR notes the factor under § 412.100(e)(8)(i)(C) includes tender age as defined in ORR's Policy Guide which means children 12 years of age or younger. It also includes the alleged victim's vulnerable status (including history of trauma), particularly if the child is under the age of five; the child's developmental stage; the child's individualized needs, the child's disabilities, if any; and other vulnerabilities of the child. ORR's consideration of an attempt to inflict any significant or lasting physical, psychological, or emotional harm on the child under § 412.100(e)(8)(i)(E) will include whether there was an attempt to harm the child, even if the child does not appear to have suffered actual harm. Finally, to understand whether there is a repetition or pattern of child abuse or neglect under § 412.100(e)(8)(i)(F), ORR will consider whether there have been multiple Tier I or Tier II allegations that have been sustained pursuant to this IFR, or determined to have occurred by other relevant authorities that indicate such a pattern. ORR will also consider whether there is evidence to indicate prior occurrences or ongoing incidents of child abuse or neglect even if it is the first incident investigated by ORR.
                </P>
                <FTNT>
                    <P>
                        <SU>47</SU>
                         
                        <E T="03">See</E>
                         45 CFR 410.1304.
                    </P>
                </FTNT>
                <P>
                    Under § 412.100(e)(8)(ii), mitigating factors shall be weighed together with any existing aggravating factors. ORR again notes that the “individual” means the care provider facility staff, contractors or sub-grantees of the care provider facility, volunteers, or other individuals who have access to children in ORR care through contracts or grants with ORR. Mitigating factors include 
                    <PRTPAGE P="93510"/>
                    any of the following: (A) remedial actions taken by the individual before the investigation was concluded; (B) extraordinary, situational, or temporary stressors that caused the individual to act in an uncharacteristically abusive or neglectful manner; (C) the isolated or aberrational nature of the child abuse or neglect; and (D) the limited, minor, or negligible physical, psychological, or emotional impact of the abuse or neglect on the child. Under § 412.100(e)(8)(ii)(C), ORR will consider the isolated nature of the child abuse or neglect and that there is no evidence of a pattern. If a subsequent report yields additional evidence of a historical pattern or behavior, however, this mitigating factor would be eliminated.
                </P>
                <P>
                    Under § 412.100(f), records created, and information gathered or obtained during the course of an investigation are for internal purposes only, will not be shared or made public unless otherwise required or authorized by law, and may not be disclosed without prior ORR approval. All records will be maintained in an appropriate recordkeeping system with protections for the privacy and security of the individuals identified in the records. This provision refers to the entire record gathered during the course of an investigation under this part, in contrast to § 412.101(d), which states ORR will refer names and other identifying information of sustained perpetrators to relevant State and local authorities and to relevant law enforcement agencies in the State in which the child abuse and neglect occurred. This provides ORR with discretion to disclose records, for example, to Federal, State, or local government authorities, or any agents of such authorities, that have a need for such information in order to carry out their responsibilities under law to protect children from child abuse and neglect. The provision also provides ORR with discretion to share relevant information with the HHS Office of the Inspector General (OIG) for purposes of conducting investigations in accordance with the Inspector General Act (IG Act) of 1978.
                    <SU>48</SU>
                    <FTREF/>
                     ORR notes that § 412.100(f) applies to all records and information gathered, whether they pertain to an alleged perpetrator, an unaccompanied child who is an alleged victim or any other unaccompanied child, an individual making an allegation to ORR, or any other individual associated with an allegation, intake report, or investigation under this part. Safeguarding and maintaining the confidentiality of an unaccompanied child's case file records is critical to carrying out ORR's responsibilities under the HSA and the TVPRA.
                    <SU>49</SU>
                    <FTREF/>
                     Additionally, requiring confidentiality is critical for promoting compliance with the requirement to report allegations of child abuse and neglect at § 412.100(d).
                    <SU>50</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>48</SU>
                         
                        <E T="03">See</E>
                         5 U.S.C. 6(a).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>49</SU>
                         
                        <E T="03">See</E>
                         89 FR 34384, 34494. 
                        <E T="03">See also</E>
                         81 FR 46682 (stating that ORR treats systems of records containing unaccompanied child information as subject to the provisions of the Privacy Act, 5 U.S.C. 552a).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>50</SU>
                         ORR further notes that it has finalized regulations relating to the confidentiality of case files of unaccompanied children in ORR care in the Unaccompanied Children Program Foundational Rule. 
                        <E T="03">See id.</E>
                         at 34599 (codified at 45 CFR 410.1303(h)).
                    </P>
                </FTNT>
                <P>ORR is establishing requirements pertaining to notification of dispositions at § 412.100(g). At § 412.100(g)(1), ORR must notify the alleged perpetrator of the disposition of an investigation in writing within five days of making the disposition. ORR must also notify in writing the alleged victim and their parent(s), legal guardian(s) (as appropriate), or sponsor(s), of the disposition within five days of making a disposition.</P>
                <P>Under § 412.100(g)(2), if the disposition is substantiated at Tier I, the notification must state: (i) the substantiated perpetrator will be considered a sustained perpetrator at Tier I and their name and other relevant information will be placed on the ORR Central Registry (unless they seek an appeal of the disposition pursuant to § 412.102) and that once identified in the Central Registry, they will be prohibited from working or volunteering in any way on ORR-funded grants or contracts, and may not have access to or contact with any unaccompanied child in ORR custody; (ii) the reasons for the Tier I substantiated perpetrator's placement on the ORR Central Registry in terms sufficient to put the perpetrator on notice of the conduct or incident(s) upon which it is based; (iii) the substantiated perpetrator may appeal ORR's disposition pursuant to § 412.102, but that if the Tier I substantiated perpetrator either fails to request such appeal in a timely manner, or upon conclusion of the appeal and subsequent review, if any, the disposition is upheld, the perpetrator will be added to the ORR Central Registry and the disposition will be reported to Federal, State, and local authorities as appropriate (such as notifying the State in which the allegation occurred when an allegation is sustained); and (iv) ORR's procedures for making the disposition. ORR believes these requirements are a key part in ensuring a Tier I substantiated perpetrator has adequate notification that they will be placed on the ORR Central Registry, the consequences of being placed on the Registry, and of the ability to request an appeal and subsequent review.</P>
                <P>Under § 412.100(g)(3), if the disposition is a Tier II substantiated allegation, the notification must inform the Tier II substantiated perpetrator that they may appeal ORR's disposition pursuant to § 412.102, but that if the Tier II substantiated perpetrator either fails to request such appeal in a timely manner, or upon the conclusion of the appeal and subsequent review, if any, the disposition is upheld, the Tier II substantiated perpetrator will be designated as a Tier II sustained perpetrator and ORR's disposition will be retained in ORR records. ORR may use these records for determining patterns of abuse and neglect and for informing future safety planning at care provider facilities. A Tier II sustained perpetrator will not be placed on the ORR Central Registry.</P>
                <HD SOURCE="HD2">Section 412.101 Interventions and Discipline</HD>
                <P>Under § 412.101, ORR is establishing mechanisms for interventions and discipline related to substantiated and sustained allegations of child abuse and neglect as determined by ORR under § 412.100. These intervention and discipline mechanisms include maintenance by ORR of a ORR Central Registry of individuals with Tier I sustained allegations of child abuse and neglect; prohibitions on hiring, employing, or permitting as volunteers individuals who are listed in the ORR Central Registry; required disciplinary sanctions by ORR care provider facilities; and provisions for ORR referrals of substantiated allegations of child abuse and neglect to other government and law enforcement agencies. ORR believes that these enforcement mechanisms and requirements are crucial to carrying out the purpose of this part, as specified and described under § 412.100(a) and (c) above.</P>
                <P>
                    Section 412.101(a) describes an ORR Central Registry to list Tier I sustained perpetrators under this rule. Under § 412.101(a)(1), for purposes consistent with § 412.100(a) and (c), ORR will create and maintain an ORR Central Registry of Tier I sustained perpetrators, including names and other identifying information, and details regarding the sustained allegations. Under § 412.101(a)(2), subject to legal requirements regarding disclosure of information (
                    <E T="03">e.g.,</E>
                     under Freedom of Information Act (FOIA), the Privacy Act, or the IG Act), the ORR Central Registry 
                    <PRTPAGE P="93511"/>
                    will not be public-facing, nor available to persons outside of ORR, since its purpose is to inform employment decisions by ORR care provider facilities, home study providers, and post-release service providers by providing the names and other identifying information of Tier I sustained perpetrators, and for ORR to use as part of the screening process by care provider facilities as described in § 412.101(b).
                </P>
                <P>
                    Section 412.101(b) sets out certain working and volunteering prohibitions for individuals listed in the ORR Central Registry, as well as requirements for checking the ORR Central Registry. ORR is requiring at § 412.101(b)(1) that the individuals listed in the ORR Central Registry shall be prohibited from working or volunteering in any way on ORR-funded grants or contracts, and may not have access to or contact with any unaccompanied child in ORR custody, unless ORR removes such individual from the Central Registry (
                    <E T="03">e.g.,</E>
                     circumstances contemplated under § 412.102(c)(2)(ii), addressing temporary removal of an individual from the Central Registry while an appeal is pending; § 412.102(e), addressing possible reversal of a DAB finding by second-level review, carried out by the Assistant Secretary for ACF). ORR-funded grants or contracts where individuals listed in the ORR Central Registry will be prohibited from working or volunteering may cover, for example, other care provider facilities, ORR home study and post-release service providers, or other ORR-funded services that may include access to unaccompanied children. At § 412.101(b)(2), ORR is requiring that, as part of the screening process for hiring decisions for staff, contractors or sub-grantees, or for screening volunteers, all care provider facilities, home study providers, and post-release service providers, whether or not located in States that investigate child abuse and neglect allegations at ORR care provider facilities, must check with ORR to confirm that an applicant is not listed in the ORR Central Registry.
                </P>
                <P>At § 412.101(b)(3), ORR sets out the requirement that all care provider facilities, home study providers, and post-release service providers, whether or not located in States that investigate child abuse and neglect allegations at ORR care provider facilities, must also check all of their personnel against the ORR Central Registry at least once annually. Checking applicants and current personnel against the ORR Central Registry is an especially important child safety measure for care provider facilities located in States that do not investigate allegations of child abuse and neglect, and thus whose registries will not include individuals alleged, or found through investigation, to have perpetrated abuse or neglect at ORR care provider facilities. ORR notes that the requirements at § 412.101(b) are supplementary to those in the PSA IFR at 45 CFR 411.16 and 45 CFR 411.81.</P>
                <P>Under § 412.101(c), care provider facilities must implement appropriate disciplinary or remedial measures where they or ORR find care provider facility staff, contractors or sub-grantees of the care provider facility, or care provider facility volunteers engaged in conduct that does not rise to the level of a Tier I substantiated allegation, as defined at § 412.001, but nevertheless raises child welfare concerns.</P>
                <P>
                    ORR believes that it is important to share information regarding sustained perpetrators with relevant State and local authorities such that they can take additional action as necessary to protect children in their jurisdictions in accordance with their legal obligations. This information sharing does not mean that information on the registry is public facing, such as other public criminal records databases. Rather, ORR will only share information directly with relevant entities and in accordance with applicable State and Federal information sharing, privacy, and due process protections. Accordingly, under § 412.101(d)(1), ORR will refer names and other identifying information of Tier I sustained perpetrators to relevant State and local authorities (
                    <E T="03">e.g.,</E>
                     child protective services) and to relevant law enforcement agencies in the State in which the sustained allegation of child abuse and neglect occurred. This requirement comports with existing requirements in the PSA IFR that all terminations for violations of ORR or care provider facility policies and procedures regarding sexual abuse and sexual harassment, or resignations by staff who would have been terminated if not for their resignation, must be reported to law enforcement agencies and to any relevant State or local licensing bodies.
                    <SU>51</SU>
                    <FTREF/>
                     Additionally, if requested by a relevant State or local authority or relevant law enforcement agency, including an authority or agency outside of the State in which the Tier I sustained allegation occurred, ORR will confirm whether a particular individual is on the ORR Central Registry. Furthermore, under § 412.101(d)(2), ORR will provide the names and other identifying information of Tier I sustained perpetrators to the Federal Bureau of Investigation, and HHS Office of the Inspector General (OIG), consistent with any applicable agreements. Finally, § 412.101(d)(3) requires that neither ORR nor care provider facilities shall interfere with another State, local, or Federal authority or agency's investigation into allegations of child abuse and neglect.
                </P>
                <FTNT>
                    <P>
                        <SU>51</SU>
                         
                        <E T="03">See</E>
                         45 CFR 411.81(c).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">Section 412.102 Appeal and Review Process</HD>
                <P>ORR is establishing guidelines and requirements regarding the availability of an appeal and review process of dispositions made by ORR at § 412.102.</P>
                <P>Under § 412.102(a), a substantiated perpetrator, whether at Tier I or Tier II, may appeal the disposition made by ORR to an Administrative Law Judge (ALJ) in the HHS Departmental Appeals Board (DAB) pursuant to § 412.102(c).</P>
                <P>
                    ORR is requiring, at § 412.102(b), that ORR shall notify substantiated perpetrators at Tier I or Tier II of their opportunity for an appeal. As stated above, all alleged perpetrators receive notice of the allegations against them pursuant to § 412.100(e)(3). Under § 412.102(b)(1), after completing an investigation and upon substantiation of any relevant allegations, ORR will send a written notice to the substantiated perpetrator at Tier I or Tier II, in accordance with § 412.100(g). The notice will state that the relevant allegations have been substantiated and that the Tier I substantiated perpetrator will be placed on the ORR Central Registry unless they appeal the disposition by ORR and that the Tier II substantiated perpetrator's information will be retained as a Tier II sustained perpetrator in agency records. Under § 412.102(b)(2), the written notice shall: (i) clearly describe the basis for ORR's disposition that substantiates the relevant allegations at Tier I or Tier II and shall explain the Tier I or Tier II substantiated perpetrator's right to appeal the disposition and the steps required to initiate the appeal; (ii) inform the substantiated perpetrator that they may appeal the disposition before an ALJ; (iii) provide the substantiated perpetrator at Tier I or Tier II and their attorney, if any, with written information and instructions describing the appeal process; and (iv) inform the substantiated perpetrator at Tier I or Tier II that if they do not appeal within 30 days of receiving the notice, the DAB will consider the substantiated perpetrator to have waived their opportunity for an appeal and any subsequent review. A Tier I substantiated perpetrator will be identified on the ORR Central Registry as a Tier I sustained perpetrator. A Tier II substantiated perpetrator's 
                    <PRTPAGE P="93512"/>
                    information will be retained as a Tier II sustained perpetrator in agency records.
                </P>
                <P>At § 412.102(c), ORR is establishing a process for substantiated perpetrators at Tier I or Tier II to appeal of ORR's disposition. Under § 412.102(c)(1)(i), and as further elaborated at § 412.102(c)(2), if the substantiated perpetrator elects to appeal ORR's disposition that a child abuse or neglect allegation is substantiated at Tier I or Tier II, they must file a written notice of appeal with the DAB within 30 days of receipt of the written notice of ORR's disposition. Under § 412.102(c)(1)(ii), within 30 days of receiving this written notice of appeal, ORR will provide all evidence it used in making its disposition to the DAB. Under § 412.102(c)(1)(iii), within 30 days of receiving this written notice of appeal, ORR will provide to the substantiated perpetrator at Tier I or Tier II, and their attorney, if any, all information used in making its disposition, except any information that ORR determines: (A) would compromise the safety and well-being of a child, the reporter, or any other person; (B) would reveal the identity of a child who furnished information with the understanding that their identity would be held in confidence; (C) would reveal the identity of any other alleged perpetrator(s) involved in the same case who has an unfounded disposition (to protect the privacy of the alleged perpetrator with an unfounded disposition); or (D) is otherwise prohibited by State or Federal law or regulation. In the case of information being withheld, the substantiated perpetrator at Tier I or Tier II will be advised of the general nature of the information and the reasons that it is being withheld. Neither the substantiated perpetrator at Tier I or Tier II nor the care provider facility are required to provide information unless they would like the ALJ to consider such information as part of the hearing or record review, and they will not be compelled to provide it.</P>
                <P>
                    Dismissal of appeals is covered in § 412.102(c)(2). Under § 412.102(c)(2)(i), the ALJ may dismiss an appeal when the ALJ determines that the substantiated perpetrator waived appeal by not submitting the notice of appeal in a timely manner (
                    <E T="03">i.e.,</E>
                     an appeal within 30 days of receiving written notice of ORR's disposition) and failed to demonstrate good cause for the untimely request, withdraws the appeal, abandons the appeal, or does not have a right to ALJ review (including, but not limited to, situations where the case does not involve a Tier I or Tier II substantiated allegation). If the appeal is dismissed, the Tier I substantiated perpetrator will be placed on the ORR Central Registry as a Tier I sustained perpetrator or ORR will retain the information regarding the Tier II substantiated perpetrator as a Tier II sustained perpetrator in agency records, as applicable. Notwithstanding such a dismissal, under § 412.102(c)(2)(ii) the DAB may in its discretion temporarily remove the designation of sustained perpetrator at Tier I or Tier II, which would result in ORR removing the individual who was designated as a Tier I sustained perpetrator from the ORR Central Registry, in situations where, for example, the ALJ determines that the sustained perpetrator at Tier I or Tier II has established good cause for exceeding the appeal timeframe. This rule contemplates that good cause may be established, for example, where a serious medical condition prevented timely filing of the notice of appeal.
                </P>
                <P>The appeal and review processes are described in § 412.102(d) and (e). Under § 412.102(d)(1), when a substantiated perpetrator at Tier I or Tier II appeals, ORR must transmit all of the evidence upon which ORR's disposition was based to the ALJ. Under § 412.102(d)(2), the evidentiary record must contain all documents and other materials, such as video or audio recordings, that were used by ORR in making its disposition. The ALJ may remand the case to ORR if the ALJ determines that the evidentiary record is insufficiently complete to determine whether ORR's disposition is supported by a preponderance of the evidence. Under § 412.102(d)(3), the substantiated perpetrator at Tier I or Tier II may be represented by an attorney. As described in § 412.102(d)(4), the substantiated perpetrator shall have the burden to show that, considering the totality of the evidence, there is not a preponderance of the evidence to support the substantiated allegation at Tier I or Tier II, and to dispute whether any automatic Tier I substantiating circumstances described at § 412.100(e)(7) existed (if applicable) or whether aggravating factors or mitigating factors described at § 412.100(e)(8) existed (if applicable). Both ORR and the substantiated perpetrator may present the testimony of witnesses, documents, factual data, arguments, or other submissions of proof. The testimony of care provider facility staff shall be voluntary and failure to provide such testimony will not subject the care provider staff member to disciplinary action. Under § 412.102(d)(5), if the substantiated perpetrator appeals and the appeal is not dismissed by the ALJ pursuant to § 412.102(d)(7), ORR must notify the alleged victim and the alleged victim's parent(s), legal guardian(s) (as appropriate), or sponsor(s) that an appeal of ORR's disposition will be conducted by an ALJ. The alleged victim, other child witness(es), and family members of the alleged victim shall not be required to testify. Refusal to testify shall have no bearing on a determination as to whether the alleged abuse or neglect did or did not take place.</P>
                <P>Under § 412.102(d)(6), both parties (ORR and the substantiated perpetrator) may cross examine witnesses and ask questions during a live hearing, as well as request additional information, either during a live hearing or pursuant to a record review. In order to mitigate the potential for re-traumatization of an alleged victim while still providing a substantiated perpetrator with the opportunity to respond to the allegations, a substantiated perpetrator may not personally cross examine the alleged victim. The parties will be given an opportunity to file briefs or other written statements of fact or law. Under § 412.102(d)(7), the ALJ must conduct a fair and impartial hearing under a de novo standard of review to determine whether the substantiated perpetrator met their burden of proving that, considering the totality of the evidence, there is not a preponderance of the evidence to support the substantiated allegation. The ALJ will issue a written decision upholding, modifying, or reversing the ORR's disposition. Under § 412.102(d)(8), the ALJ shall serve a copy of the decision upon the parties and the Assistant Secretary for ACF. The ALJ's decision shall provide the substantiated perpetrator at Tier I or Tier II and their attorney, if any, with instructions for filing a request for review with the Assistant Secretary for ACF. The ALJ also shall provide a copy of the decision to the alleged victim, and, as appropriate, the alleged victim's parent(s), legal guardian(s), or sponsor(s). The complete record upon which the decision is based shall be made available to the Assistant Secretary.</P>
                <P>
                    This rule provides another level of review under § 412.102(e). This subsection provides that the Assistant Secretary for ACF may review the ALJ's determination, either sua sponte or upon a request by the substantiated perpetrator. Under § 412.102(e)(1), a substantiated perpetrator at Tier I or Tier II may request review of the ALJ's decision within 30 days of receipt of the ALJ's decision, by filing a request for review with Office of the Assistant 
                    <PRTPAGE P="93513"/>
                    Secretary for ACF. Under § 412.102(e)(2), the Assistant Secretary has discretion, within 30 days after receiving a timely request for review of an ALJ's decision under § 412.102(e)(1), to review the ALJ's decision and to dismiss a request for review based on untimeliness or other procedural defects, or to affirm, modify, or reverse the ALJ's decision with regard to dismissal or ORR's disposition of the allegation. A review by the Assistant Secretary will determine whether the ALJ's decision was based on a material error of law or fact.
                </P>
                <P>Section 412.102(e)(3) provides that if the Assistant Secretary affirms the ALJ's decision, or does not modify or reverse the ALJ's decision, within 30 days after receiving a timely review request under § 412.102(e)(1), then the ALJ's decision becomes the final decision of the Assistant Secretary and is binding on both parties (ORR and the substantiated perpetrator). Likewise, under § 412.102(e)(4), if the Assistant Secretary modifies or reverses the ALJ's decision pursuant to § 412.102(e)(2), then the Assistant Secretary's decision is final and binding.</P>
                <P>Under § 412.102(e)(5), if at the end of the 30-day period in § 412.102(e)(1), no timely request for review has been made, the Assistant Secretary has 30 days from that point to exercise discretion to review the ALJ's decision. If the Assistant Secretary does not modify or reverse the ALJ's decision, then the ALJ's decision becomes the final decision of the Assistant Secretary and is binding on both parties. The intent of § 412.102(e)(5) is to make clear that the Assistant Secretary has discretion to review the ALJ's decision regardless of whether a timely request for review is made.</P>
                <P>Under § 412.102(e)(6), the Office of the Assistant Secretary for ACF shall notify the parties of the Assistant Secretary's final decision. The Office of the Assistant Secretary also shall provide a copy of the final decision to the alleged victim and the alleged victim's parent(s), legal guardian(s) (as appropriate), or sponsor(s), based on review of the ALJ's previous decision, under § 412.102(e).</P>
                <HD SOURCE="HD2">Section 412.103 Obligations of Care Provider Facilities</HD>
                <P>To ensure that ORR can obtain sufficient information to make fair, accurate, and impartial decisions regarding allegations of child abuse and neglect, at § 412.103, ORR is establishing obligations with which care provider facilities must comply during investigations.</P>
                <P>Under § 412.103(a)(1) through (3), during any investigation of child abuse and neglect by ORR, a care provider facility must permit ORR: (1) to have unrestricted access to the premises, any physical property on the premises, buildings, staff, and children in the physical custody of the care provider facility; (2) to conduct interviews with children residing at the care provider facility, and without care provider facility staff, contractors or sub-grantees of the care provider facility, or care provider facility volunteers, present; and (3) to observe the activities of care provider facility staff, contractors or sub-grantees of the care provider facility, care provider facility volunteers, or other individuals who have access to children in ORR care through contracts or grants with ORR. Under § 412.103(a)(4), care provider facilities must promptly preserve any potential video or documentary evidence. ORR notes that this requirement is aligned with the requirement at § 412.100(e)(5)(iii)(A), which states that upon receiving an intake report, the ORR Child Welfare Investigator must immediately request preservation of any potential video and documentary evidence. Additionally, under § 412.103(a)(5), care provider facilities must promptly provide and facilitate access to, upon request, all files, records, reports, data, video recordings, and other information, including copies of any such documents, requested by ORR either prior to or during the investigation. Care provider facilities subject to this rule must also promptly provide access to and contact information for staff, contractors, or sub-grantees of the care provider facility, its volunteers, or other individuals who have access to children in ORR care (§ 412.103(a)(6)); submit complete and accurate responses to any written questions in a timely manner (§ 412.103(a)(7)); and fully cooperate with ORR (§ 412.103(a)(8)). Finally, under § 412.103(a)(9) care provider facilities are required to fully cooperate with any investigation of the same allegation by other State, local, and Federal authorities, and relevant law enforcement agencies.</P>
                <P>Further, in alignment with existing ORR policy and 45 CFR 411.67, ORR is requiring at § 412.103(b) that care provider facility staff, contractors or sub-grantees of the care provider facility, and care provider facility volunteers must not retaliate against any person who in good faith reports or participates in an investigation of child abuse or neglect.</P>
                <P>
                    Under § 412.103(c), a care provider facility's obstruction, interference, delay of, or failure to permit or cooperate with any investigation under this part, including failure to protect unaccompanied children from retaliation pursuant to § 412.103(b), may result in ORR taking monitoring and enforcement measures. Such measures may include remote monitoring of the care provider facility (
                    <E T="03">i.e.,</E>
                     monitoring that does not occur on-site); on-site monitoring of the care provider facility; monitoring of the corporate offices to review internal policies and reporting structures, as well as supervisory responses to events (
                    <E T="03">e.g.,</E>
                     mitigation or future preventative measures); limiting or stopping new placements of unaccompanied children at the care provider facility; removing all children in ORR care and custody from the care provider facility and placing them into other care provider facilities; issuing corrective actions; terminating the contract or cooperative agreement with the care provider facility; or imposing other such remedies for noncompliance applicable to HHS grant recipients and contractors. ORR notes that the cooperation of care provider facilities is critical in investigations of child abuse and neglect, and that enforcement measures such as those described are appropriate to help ensure that ORR can obtain the information necessary to determine whether allegations are substantiated.
                </P>
                <P>
                    Under § 412.103(d), ORR requires care provider facilities, during the course of an investigation, to provide unaccompanied children confidential access to attorneys of record and other legal service providers, as well as their families and legal guardians, in a manner consistent with requirements established at 45 CFR 411.55 (as applicable) as well as 45 CFR 410.1309. Care provider facilities must provide unaccompanied children with access to their child advocates, in a manner consistent with the requirements of the TVPRA at 8 U.S.C. 1232(c)(6) and 45 CFR 410.1308. Finally, care provider facilities must also provide unaccompanied children access to health services (including specialists and mental health practitioners), individual counseling sessions, and crisis intervention (including access to outside victim services and rape crisis centers where appropriate) to most appropriately address unaccompanied children's needs, in a manner consistent with requirements established at 45 CFR 410.1302(c)(5), 45 CFR 410.1307, 45 CFR 410.1311, and 45 CFR 411.21 (as applicable).
                    <PRTPAGE P="93514"/>
                </P>
                <HD SOURCE="HD1">VI. Good Cause for Issuing This IFR</HD>
                <P>
                    When engaging in rulemaking, ORR ordinarily publishes a notice of proposed rulemaking (NPRM) in the 
                    <E T="04">Federal Register</E>
                     and invites public comment on the proposed rule. However, under the Administrative Procedure Act, 5 U.S.C. 553(b), an NPRM is not required when an agency, for good cause, finds that notice and public comment is impracticable, unnecessary, or contrary to the public interest, and incorporates a statement of the finding and the agency's reasons in the rule issued. With respect to this rulemaking, delaying implementation of the provisions of this regulation until a public notice and comment process is complete would risk serious and imminent harm to unaccompanied children in Texas care provider facilities (and in the future at EIFs, which ORR may need to open on short notice, before it can execute formal written agreements describing child welfare investigations of child abuse and neglect with relevant local authorities), and thus would be impracticable. As such, ORR believes that it has good cause to issue this rulemaking as an Interim Final Rule (IFR) rather than issuing an NPRM.
                </P>
                <P>
                    ORR has determined that this rulemaking is imminently necessary because ORR must have the ability to establish employment consequences at relevant care provider facilities for sustained perpetrators of abuse and neglect in order to fulfill its statutory responsibilities.
                    <SU>52</SU>
                    <FTREF/>
                     Critically, as mentioned earlier, ORR began taking immediate action soon after it became clear that Texas DFPS was not going to resume its historical child welfare and investigative functions when it extended its emergency declaration in 2022. Subsequently, ORR began consulting with other federal agencies, developing the necessary expertise and capacity to conduct investigations, drafting policies and procedures to inform how investigations are conducted, obtaining administrative approval for new agency positions, creating new comprehensive technical systems for recording and tracking investigations, and hiring, onboarding, and training qualified investigative staff. Most pertinently, as discussed at section IV.A, ORR's recently established Division of Unaccompanied Child Protective Investigations (DCPI) began its investigations of allegations of child abuse and neglect in ORR-funded care provider facilities in Texas as of July 2024.
                </P>
                <FTNT>
                    <P>
                        <SU>52</SU>
                         
                        <E T="03">See supra,</E>
                         Sec. IV.B (referencing various provisions of the HSA, including 6 U.S.C. 279(b)(1)(G) (making the ORR Director responsible for “overseeing the infrastructure and personnel of facilities in which unaccompanied alien children reside”) and 6 U.S.C. 279(b)(1)(L) (making the ORR Director responsible for “conducting investigations and inspections of facilities and other entities in which [unaccompanied children] reside. . .”)).
                    </P>
                </FTNT>
                <P>
                    In addition to investigating allegations of abuse and neglect at care provider facilities located in States that do not conduct investigations, and at EIFs, ORR needs to be able to direct its care provider facilities to prohibit individuals from working or volunteering on ORR-funded grants or contracts when there has been a sustained allegation of abuse or neglect at Tier I (as defined in this rule), and to ensure that perpetrators with such sustained allegations do not have access to or contact with children in ORR custody. To that end, this rulemaking establishes an ORR Central Registry listing Tier I sustained perpetrators, as described in this rule. Further, this rule establishes that Tier I sustained perpetrators listed on the ORR Central Registry are prohibited from working or volunteering in any way on ORR-funded grants or contracts, so as to prohibit them from having access to or contact with any unaccompanied child in ORR custody. Because such requirements potentially implicate alleged perpetrators' ability to work in their chosen profession (if the allegation is sustained at Tier I), ORR believes that substantive rulemaking is required to codify appeal and review procedures with appropriate due process protections for alleged perpetrators (
                    <E T="03">e.g.,</E>
                     notice and an opportunity to be heard).
                </P>
                <P>There is good cause to issue this rulemaking as an IFR because requiring notice and comment before implementing these provisions would risk serious and imminent harm to unaccompanied children. For example, even if DCPI concludes through an investigation that an individual perpetrated child abuse or neglect, without an ORR Central Registry, such a perpetrator could potentially pass a background check and be re-hired at any time at another ORR care provider facility, which would undermine the very purpose of the rule—to protect children from such perpetrators. As noted above, ORR understands that creation of the Central Registry requires rulemaking because adequate due process procedures need to be established in consideration of the employment interests at stake. In other words, ORR's DCPI can now investigate, substantiate, and sustain allegations of abuse and neglect of unaccompanied children in its custody against alleged perpetrators in accordance with existing statutory authority, but requiring notice and comment before this rule goes into effect would prevent ORR from using that critical information in the ORR Central Registry to keep children safe in the near and long term. Until ORR is able to begin operating the ORR Central Registry, unaccompanied children are at elevated risk of abuse or neglect—a risk that ORR seeks to prevent by using this IFR to prohibit the hiring of Tier I sustained perpetrators of child abuse and neglect.</P>
                <P>As discussed above, as of July 2024, ORR began investigative activities in relation to reported child abuse and neglect at care provider facilities in Texas. As a result, there is an urgent need to have the provisions of this rule in place to protect child welfare while also providing appropriate due process protections for alleged perpetrators of child abuse and neglect. Notice and comment rulemaking would prevent ORR from taking swift and appropriate action when it identifies an imminent threat to child safety and would allow perpetrators of child abuse and neglect to evade ORR's efforts, pursuant to statutory responsibilities, to protect unaccompanied children in its custody. Notice and comment rulemaking would increase the risk of serious potential harm to unaccompanied children—which ORR seeks to address through this IFR by prohibiting employment of individuals on the ORR Central Registry.</P>
                <P>ORR has therefore found good cause in the specific circumstances presented here—where ORR has recently established a new Division to conduct child welfare investigations at EIFs and in States that do not do so given that there is an immediate and ongoing risk to unaccompanied children in such States without the protections described in this rule. This rulemaking is urgently required now to establish required employment consequences for individuals found by ORR investigations to have perpetrated child abuse or neglect, and ORR has not delayed responding to the urgent need to establish such consequences because DCPI began initiating investigations as of July 2024.</P>
                <P>
                    Therefore, HHS finds good cause to waive the notice of proposed rulemaking and to issue this final rule on an interim basis. Finally, HHS is providing a 60-day public comment period and will carefully consider public comments received and may update the final rule, as appropriate. ORR plans to finalize the rule within one year of implementation.
                    <PRTPAGE P="93515"/>
                </P>
                <HD SOURCE="HD1">VII. Collection of Information Requirements</HD>
                <P>
                    Under the Paperwork Reduction Act of 1995 (PRA), HHS is required to provide 60-day notice in the 
                    <E T="04">Federal Register</E>
                     and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a control number assigned by OMB.
                </P>
                <P>
                    This interim final rule with comment requires information collections for which HHS plans to seek OMB approval at a later date. The information collection requirements associated with this interim final rule will not take effect until approved by OMB. HHS will issue future 
                    <E T="04">Federal Register</E>
                     notices to seek comments on its information collections within one month following finalization, as required by the PRA,
                    <SU>53</SU>
                    <FTREF/>
                     and will include a system of records notice related to the requirements in this rule.
                </P>
                <FTNT>
                    <P>
                        <SU>53</SU>
                         See 44 U.S.C. 3506(c)(2)(A).
                    </P>
                </FTNT>
                <P>
                    To estimate the costs associated with the information collection activities described in this interim final rule, ORR utilizes median hourly wage rates in accordance with the Bureau of Labor Statistics' (BLS) most recent update in April 2024 for Education and Childcare Administrators.
                    <SU>54</SU>
                    <FTREF/>
                     The median hourly wage rate is calculated to be $26.10 with fringe benefits at 100 percent, for a total hourly wage rate of $52.20 ($26.10 + $26.10).
                </P>
                <FTNT>
                    <P>
                        <SU>54</SU>
                         
                        <E T="03">https://www.bls.gov/oes/current/oes119031.htm.</E>
                         Accessed July 31, 2024.
                    </P>
                </FTNT>
                <P>Section 412.100(d) requires that care provider facility staff, contractors, sub-grantees, volunteers, and all ORR staff must report allegations of child abuse and neglect by care provider facility staff, contractors or sub-grantees of the care provider facility, care provider facility volunteers, or other individuals who have access to children in ORR care through contracts or grants with ORR in accordance with ORR policies and procedures to ORR, and to Federal, State, and local authorities in accordance with any applicable Federal, State, and local reporting and licensing laws. Because this reporting requirement would not require additional reporting above and beyond existing ORR policy, this requirement will not result in additional burden for care provider facilities.</P>
                <HD SOURCE="HD1">VIII. Regulatory Impact Analysis</HD>
                <HD SOURCE="HD2">A. Economic Analysis</HD>
                <P>Executive Orders 12866 and 13563 direct agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). Section 3(f) of Executive Order 12866, as amended by Executive Order 14094, defines a “significant regulatory action” as an action that is likely to result in a rule: (1) having an annual effect on the economy of $200 million or more (adjusted every 3 years for changes in gross domestic product), or adversely affecting in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, territorial, or tribal governments or communities; (2) creating a serious inconsistency or otherwise interfering with an action taken or planned by another agency; (3) materially altering the budgetary impact of entitlement grants, user fees, or loan programs or the rights and obligations of recipients thereof; or (4) raising legal or policy issues for which centralized review would meaningfully further the President's priorities or the principles set forth in the Executive Order. Executive Order 13563 emphasizes the importance of quantifying both costs and benefits, of reducing costs, of harmonizing rules, and of promoting flexibility. While there are some costs associated with these regulations, they do not exceed the monetary threshold for significance as defined under section 3(f)(1) of E.O. 12866, as amended. However, the regulation is significant and has been reviewed by OMB.</P>
                <P>As previously discussed, ORR has developed the child abuse and neglect investigation requirements for ORR care provider facilities with the intention of keeping the best interests of unaccompanied children at the forefront. Because the requirements in this IFR are in line with existing ORR policy, ORR anticipates that care provider facilities will need to make only minimal updates to their staffing, training, and/or policy in order to meet the requirements. Specifically, ORR anticipates that care provider facilities will need to make updates to meet requirements under § 412.101(c) and § 412.103. Typically, ORR care provider facilities spend up to approximately 5 hours to cooperate with a State-led investigation of alleged child abuse or neglect, which can vary widely depending on the circumstances of the specific allegation. ORR expects that its Texas care provider facilities will spend the same amount of time cooperating with investigations conducted by ORR. Because ACF lacks the ability to account for the specific details of every care provider facility and their ability to meet the requirements, ORR is only able to estimate costs associated with other remedies in general, rather than specific to each care provider facility.</P>
                <P>
                    To estimate the economic impacts associated with the policies promulgated in this interim final rule, ACF uses wage rate and annual salary data provided by BLS for Childcare Workers and First-Line Supervisors working in the Child Care Services industry.
                    <SU>55</SU>
                     
                    <SU>56</SU>
                    <FTREF/>
                     The median hourly wage rate for childcare workers is calculated to be $14.60. Assuming benefits and indirect costs of labor equal 100 percent of the hourly wage, the corresponding fully loaded cost of labor for childcare workers is $29.20 per hour. Additionally, the mean hourly wage rate for First-Line Supervisors working in the Child Care Services industry is calculated to be $22.45. Note that we do not use the median wage rate because BLS only provides mean wage rates for specific industries. Assuming benefits and indirect costs of labor equal 100 percent of the hourly wage, the corresponding fully loaded cost of labor for childcare supervisors is $44.90 per hour. ORR assumes that it will take between 0.25 and 0.5 hours at a cost between $7.30 ($29.20 × 0.25 hours) and $14.60 ($29.20 × 0.5 hours) for each childcare worker to receive the relevant policy update training and between $11.23 ($44.90 × 0.25 hours) and $22.45 ($44.90 × 0.5 hours) for each childcare supervisor to administer the training. This training would include administrative guidance related to how investigations will be conducted and due process under the interim final rule. ORR also assumes that it will take approximately 1 hour at a cost of $44.90 ($44.90 × 1 hour) for each childcare supervisor to update relevant policies.
                </P>
                <FTNT>
                    <P>
                        <SU>55</SU>
                         
                        <E T="03">https://www.bls.gov/oes/current/oes399011.htm.</E>
                         Accessed July 31, 2024.
                    </P>
                    <P>
                        <SU>56</SU>
                         
                        <E T="03">https://www.bls.gov/oes/current/oes391022.htm.</E>
                         Accessed July 31, 2024.
                    </P>
                </FTNT>
                <P>
                    In § 412.100(a) through (g) ORR discusses the establishment and operation of its investigations into alleged child abuse and neglect. Currently, based on FY 2024 levels of wages, benefits, and indirect labor costs, ORR estimates 24 full-time staff will be required at a cost of approximately $209,000 per staff member for a total of approximately $5 million ($209,000 × 
                    <PRTPAGE P="93516"/>
                    24 staff) per year. The ORR Child Welfare Investigators will receive allegations of child abuse and neglect as intake reports, assess the allegation to determine whether it meets applicable requirements and definitions, conduct all necessary interviews, review and preserve all relevant evidence, implement any necessary safety plans, coordinate with the multidisciplinary team as needed, and render a disposition. ORR expects no new costs or burdens on care provider facilities to cooperate with ORR's investigations.
                </P>
                <P>ORR also notes that all care provider facilities discussed in this interim final rule are ACF grantees and the costs of maintaining compliance with the requirements are allowable costs to grant awards under the Basic Considerations for cost provisions at 45 CFR 403 through 405, in that the costs are reasonable, necessary, ordinary, treated consistently, and are allocable to the award. Additional costs associated with the policies discussed in this interim final rule that were not budgeted, and cannot be absorbed within existing budgets, would be allowable for the grant recipient to submit a request for supplemental funds to cover the costs.</P>
                <HD SOURCE="HD2">B. Regulatory Flexibility Analysis</HD>
                <P>The Secretary certifies under 5 U.S.C. 605(b), as enacted by the Regulatory Flexibility Act (Pub. L. 96-354), that this rule will not result in a significant impact on a substantial number of small entities. This rule primarily affects the operations of the Federal Government and requires that ORR care provider facilities within the scope of this rule cooperate with Federal investigations of child abuse and neglect. As of publication of this rule, 66 of 284 (23 percent) ORR care provider facilities are located in Texas and would be impacted by the requirements in this interim final rule. While the affected percentage of small entities exceeds the threshold of 5 percent for this subcategory of care provider facilities within the U.S., ORR believes the burden associated with the requirements in this interim final rule are equal to or negligibly greater than the burden imposed by any State-based requirements to which the affected care provider facilities would otherwise be subjected. While this rule primarily affects the Federal Government, ORR assumes all of these care provider facilities qualify as small businesses as defined by the Small Business Administration (SBA), and ORR has therefore attempted to ensure the economic impact on individual care provider facilities is kept to a minimum.</P>
                <HD SOURCE="HD2">C. Unfunded Mandates Reform Act</HD>
                <P>The Unfunded Mandates Reform Act of 1995 (section 202(a)) requires ORR to prepare a written statement, which includes estimates of anticipated impacts, before proposing “any rule that includes any Federal mandate that may result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more (adjusted annually for inflation) in any one year.” The current threshold after adjustment for inflation is $177 million, using the most current (2022) Implicit Price Deflator for the Gross Domestic Product. This interim final rule would not likely result in unfunded expenditures that meet or exceed this amount.</P>
                <HD SOURCE="HD2">D. Executive Order 13132: Federalism</HD>
                <P>This interim final rule would not have substantial direct effects on the States, on the relationship between the Federal Government and the States, or on the distribution of power and responsibilities among the various levels of government. This interim final rule would implement ORR's explicit statutory authority to investigate child abuse and neglect allegations in ORR care provider facilities, and would enable it to make findings relevant to its responsibility for the care of unaccompanied children. In codifying these practices, ORR was mindful of its obligations to meet the requirements of Federal statutes while also minimizing conflicts between State law and Federal interests. At the same time, ORR is also mindful that its fundamental obligations are to ensure that it implements its statutory responsibilities pursuant to both the HSA and TVPRA, to protect the safety of unaccompanied children while in ORR care.</P>
                <P>Typically, ORR enters into cooperative agreements or contracts with non-profit and private organizations to provide shelter and care for unaccompanied children in a care provider facility licensed by the appropriate State or local licensing authority if the State licensing agency provides for licensing of care provider facilities that provide services to unaccompanied children. This regulation allows ORR to investigate allegations of child abuse and neglect only in instances where a State will not investigate allegations of child abuse and neglect in ORR care provider facilities, and at EIFs. ORR has designed its policies and regulations, as well as the terms of its cooperative agreements and contracts with the unaccompanied children care provider facilities, to complement applicable State and local licensing rules, not to supplant or replace the requirements. Because the applicability of this regulation is limited precisely to circumstances where a State does not investigate child abuse and neglect at ORR care provider facilities, and EIFs, it does not implicate federalism concerns or impose substantial direct compliance costs on State or local governments. Further, this regulation does not preempt State laws and regulations because it applies specifically where States have explicitly abdicated their investigatory responsibility in ORR care provider facilities housing unaccompanied children, and at EIFs where States may not have authority to conduct investigations. Where State or local authorities enter into formal written agreements with ORR to conduct investigations, ORR may still, pursuant to its statutory authority, carry out its own investigations, but any potential ORR investigation under this rule would not interfere with the State or local authority's investigation.</P>
                <P>Therefore, in accordance with section 6 of Executive Order 13132, it is determined that this interim final rule does not have sufficient federalism implications to warrant the preparation of a federalism summary impact statement.</P>
                <P>Notwithstanding the determination that the formal consultation process described in Executive Order 13132 is not required for this rule, ORR welcomes any comments from representatives of State and local juvenile or family residential facilities—among other individuals and groups—during this rulemaking.</P>
                <HD SOURCE="HD2">E. Executive Order 12988: Civil Justice Reform</HD>
                <P>This interim final rule meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.</P>
                <HD SOURCE="HD1">IX. Assessment of Federal Regulation and Policies on Families</HD>
                <P>
                    Section 654 of the Treasury and General Government Appropriations Act of 1999 requires Federal agencies to determine whether a policy or regulation may affect family well-being. If the agency's determination is affirmative, then the agency must prepare an impact assessment addressing criteria specified in the law. This regulation will not have an impact on family well-being as defined in this legislation, which asks agencies to assess policies with respect to whether the policy: strengthens or erodes family 
                    <PRTPAGE P="93517"/>
                    stability and the authority and rights of parents in the education, nurture, and supervision of their children; helps the family perform its functions; and increases or decreases disposable income.
                </P>
                <SIG>
                    <DATED>Dated: November 20, 2024.</DATED>
                    <NAME>Xavier Becerra,</NAME>
                    <TITLE>Secretary, Department of Health and Human Services.</TITLE>
                </SIG>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 45 CFR Part 412</HD>
                </LSTSUB>
                <P>For the reasons set forth in the preamble, the ORR adds 45 CFR part 412 to read as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 412—INVESTIGATIONS OF ALLEGATIONS OF CHILD ABUSE AND NEGLECT</HD>
                    <CONTENTS>
                        <SECHD>Sec.</SECHD>
                        <SECTNO>412.001</SECTNO>
                        <SUBJECT>Definitions</SUBJECT>
                        <SECTNO>412.100</SECTNO>
                        <SUBJECT>Investigations of allegations of child abuse and neglect</SUBJECT>
                        <SECTNO>412.101</SECTNO>
                        <SUBJECT>Interventions and discipline</SUBJECT>
                        <SECTNO>412.102</SECTNO>
                        <SUBJECT>Appeal and review process</SUBJECT>
                        <SECTNO>412.103</SECTNO>
                        <SUBJECT>Obligations of care provider facilities</SUBJECT>
                    </CONTENTS>
                </PART>
                <REGTEXT TITLE="45" PART="412">
                    <PART>
                        <HD SOURCE="HED">PART 412—INVESTIGATIONS OF ALLEGATIONS OF CHILD ABUSE AND NEGLECT</HD>
                        <SECTION>
                            <SECTNO>§ 412.001</SECTNO>
                            <SUBJECT>Definitions.</SUBJECT>
                            <P>
                                <E T="03">ACF</E>
                                 means the Administration for Children and Families, Department of Health and Human Services.
                            </P>
                            <P>
                                <E T="03">Administrative closure</E>
                                 means that ORR has determined that it will not make a finding regarding an allegation of child abuse or neglect. ORR may make a determination of administrative closure both before and after an investigation begins. Reasons for administrative closure of an intake report before investigation may include, but are not limited to, lack of jurisdiction to conduct an investigation of the allegation, transfer of the report to another jurisdiction or agency, duplication of an already existing report, an allegation not rising to the level of child abuse or neglect, or an allegation is otherwise outside the scope of this rule, as described at § 412.100(c). Reasons for a disposition of administrative closure after investigation may include, but are not limited to, inability to contact the child, insufficient information to proceed with the investigation, or transfer of the report to another jurisdiction or agency.
                            </P>
                            <P>
                                <E T="03">Allegation</E>
                                 means a written or oral report to ORR of suspected child abuse or neglect.
                            </P>
                            <P>
                                <E T="03">Alleged perpetrator</E>
                                 means a person who is alleged to have abused or neglected a child within the scope of this part as described at § 412.100(a) and (c).
                            </P>
                            <P>
                                <E T="03">Appeal and review process</E>
                                 means the appeal to an Administrative Law Judge (ALJ) of the HHS Departmental Appeal Board (DAB), and review by the Assistant Secretary for ACF of the disposition that an allegation of child abuse or neglect was substantiated at Tier I or Tier II.
                            </P>
                            <P>
                                <E T="03">Attorney of record</E>
                                 has the same definition as provided under 45 CFR 410.1001.
                            </P>
                            <P>
                                <E T="03">Care provider facility</E>
                                 has the same definition as provided under 45 CFR 410.1001.
                            </P>
                            <P>
                                <E T="03">Child abuse and neglect</E>
                                 means any act or failure to act which results in death, serious physical or emotional harm, sexual abuse, or exploitation of a child; or an act or failure to act which presents an imminent risk of serious harm to a child including but not limited to physical abuse, verbal or emotional abuse, sexual harassment, sexual abuse, inappropriate sexual behavior, neglect, and medical neglect.
                            </P>
                            <P>
                                <E T="03">Child advocates</E>
                                 has the same definition as provided under 45 CFR 410.1001.
                            </P>
                            <P>
                                <E T="03">Contractor</E>
                                 means an entity that receives a contract as provided under 45 CFR 75.2.
                            </P>
                            <P>
                                <E T="03">Days</E>
                                 means calendar days, unless otherwise stated.
                            </P>
                            <P>
                                <E T="03">Disposition</E>
                                 means a finding by ORR at the conclusion of an investigation that an allegation of abuse or neglect is substantiated at Tier I, substantiated at Tier II, not substantiated, unfounded, or administratively closed.
                            </P>
                            <P>
                                <E T="03">Emergency or influx facility (EIF)</E>
                                 has the same definition as provided under 45 CFR 410.1001.
                            </P>
                            <P>
                                <E T="03">HHS</E>
                                 means the U.S. Department of Health and Human Services.
                            </P>
                            <P>
                                <E T="03">Inappropriate sexual behavior</E>
                                 refers to inappropriate sexual, derogatory, or offensive conduct that does not rise to the level of sexual abuse or sexual harassment.
                            </P>
                            <P>
                                <E T="03">Intake report</E>
                                 means an allegation of child abuse or neglect identified by ORR as describing child abuse or neglect of an unaccompanied child by an alleged perpetrator.
                            </P>
                            <P>
                                <E T="03">Legal service provider (LSP)</E>
                                 has the same definition as provided under 45 CFR 410.1001.
                            </P>
                            <P>
                                <E T="03">Medical neglect</E>
                                 means any failure to provide medical care or access to medical services that endangers the health of the child.
                            </P>
                            <P>
                                <E T="03">Multidisciplinary team</E>
                                 is a group of individuals comprised of ORR staff that includes subject matter experts that provides input to ORR's Child Welfare Investigators by assessing reported allegations of child abuse and neglect at care provider facilities and making recommendations regarding the physical and behavioral healthcare needs of unaccompanied children potentially impacted by child abuse and neglect at these facilities.
                            </P>
                            <P>
                                <E T="03">Neglect</E>
                                 refers to any failure to provide adequate food, water, clothing, shelter, or other necessities; punitive, careless, or unnecessary denial of access to other basic services such as education, legal aid, exercise, recreation, bathroom usage, and communication or correspondence with families, sponsors, or attorneys.
                            </P>
                            <P>
                                <E T="03">Not substantiated allegation</E>
                                 means a disposition that there is not a preponderance of the evidence establishing that the alleged perpetrator committed child abuse or neglect, but there is at least some evidence that the unaccompanied child was harmed or placed at risk of harm, whether or not by the alleged perpetrator.
                            </P>
                            <P>
                                <E T="03">ORR</E>
                                 means the Office of Refugee Resettlement, Administration for Children and Families, U.S. Department of Health and Human Services.
                            </P>
                            <P>
                                <E T="03">ORR Central Registry</E>
                                 means a database maintained by ORR consisting of ORR findings of sustained perpetrators of child abuse and neglect at Tier I.
                            </P>
                            <P>
                                <E T="03">ORR Child Welfare Investigator</E>
                                 means an ORR staff member who investigates reports of alleged abuse or neglect of children, renders the investigative disposition, and issues corrective action on behalf of ORR and performs other related work for ORR.
                            </P>
                            <P>
                                <E T="03">Physical abuse</E>
                                 means physical harm to a child that includes, but is not limited to, bruises, cuts, sprains, welts, fractures, burns, lacerations, missing or broken teeth, muscle strains, or internal injuries; in addition to physical mistreatment such as whipping, punching, shoving, kicking, hitting, biting, shaking, dragging, throwing, stabbing, or choking a child, as well as the inappropriate use of restraints.
                            </P>
                            <P>
                                <E T="03">Preponderance of the evidence</E>
                                 means proof, after assessing the totality of available information, that leads to the conclusion that the fact at issue is more probably true than not.
                            </P>
                            <P>
                                <E T="03">Sexual abuse</E>
                                 has the same definition as provided under 45 CFR part 411.6.
                            </P>
                            <P>
                                <E T="03">Sexual harassment</E>
                                 has the same definition as provided under 45 CFR part 411.6.
                            </P>
                            <P>
                                <E T="03">Sub-grantee</E>
                                 means a person or entity that receives a subaward from a care provider facility to carry out activities and programs of ORR or the care provider facility pursuant to a grant or agreement with ORR or with a care provider facility (but does not include an individual that is a beneficiary of such program).
                                <PRTPAGE P="93518"/>
                            </P>
                            <P>
                                <E T="03">Substantiated allegation—Tier I</E>
                                 means a disposition that there is a preponderance of the evidence establishing that the alleged perpetrator committed child abuse or neglect, and the investigation indicates one or more Automatic Tier I substantiating circumstances are found pursuant to § 412.100(e)(7), or substantiation is warranted based on consideration of aggravating and mitigating factors pursuant to § 412.100(e)(8).
                            </P>
                            <P>
                                <E T="03">Substantiated allegation—Tier II</E>
                                 means a disposition that there is a preponderance of the evidence establishing that the alleged perpetrator committed child abuse or neglect, and that based on consideration of aggravating and mitigating factors pursuant to § 412.100(e)(8), the evidence does not warrant a finding of Substantiated Allegation—Tier I.
                            </P>
                            <P>
                                <E T="03">Substantiated perpetrator</E>
                                 means a person against whom an allegation of child abuse or neglect has been substantiated by ORR at Tier I or Tier II, but who has not exhausted all applicable appeal and review processes for such allegations.
                            </P>
                            <P>
                                <E T="03">Sustained allegation</E>
                                 means an allegation that was substantiated by ORR at Tier I or Tier II and:
                            </P>
                            <P>(1) That was upheld pursuant to appeal and review processes, as described at § 412.102; or</P>
                            <P>(2) For which the appeal was dismissed, including when the substantiated perpetrator waives their right to appeal by not making a timely request to the DAB ALJ or by waiving those rights as specified in § 412.102(c).</P>
                            <P>
                                <E T="03">Sustained perpetrator</E>
                                 means a substantiated perpetrator at Tier I or Tier II:
                            </P>
                            <P>(1) Whose child abuse or neglect finding was upheld in the appeal and review process; or</P>
                            <P>(2) Whose appeal and review process was dismissed, including due to waiving their right to appeal by not timely requesting an appeal to the DAB ALJ or by waiving those rights as specified in § 412.102(c).</P>
                            <P>
                                <E T="03">Unaccompanied child/children</E>
                                 has the same definition as provided under 45 CFR 410.1001.
                            </P>
                            <P>
                                <E T="03">Unfounded allegation</E>
                                 means a disposition that there is not a preponderance of the evidence establishing that the alleged perpetrator committed child abuse or neglect, and the evidence indicates that the unaccompanied child was not harmed or placed at risk of harm.
                            </P>
                            <P>
                                <E T="03">Verbal or emotional abuse</E>
                                 means any criticisms, comments, behaviors, or threats that cause harm to a child's psychological, intellectual, or emotional functioning or self-esteem, which may be exhibited by a child's anxiety, loneliness, fear, sadness, withdrawal, aggression, or loss of trust with staff.
                            </P>
                            <P>
                                <E T="03">Volunteer</E>
                                 has the same definition as provided under 45 CFR 411.
                            </P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 412.100</SECTNO>
                            <SUBJECT>Investigations into allegations of child abuse and neglect.</SUBJECT>
                            <P>
                                (a) 
                                <E T="03">Purpose.</E>
                                 This part establishes standards, requirements and procedures for investigations by ORR of allegations of child abuse and neglect of an unaccompanied child in ORR custody alleged to have been committed by care provider facility staff, contractors or sub-grantees of the care provider facility, care provider facility volunteers, or other individuals who have access to children in ORR care through contracts or grants with ORR, subject to § 412.100(c).
                            </P>
                            <P>
                                (b) 
                                <E T="03">Severability.</E>
                                 The provisions of this part are separate and severable from one another. If any provision is stayed or determined to be invalid by a court of law, the remaining provisions shall continue in effect.
                            </P>
                            <P>
                                (c) 
                                <E T="03">Applicability.</E>
                                 This part applies to:
                            </P>
                            <P>(1) Care provider facilities housing unaccompanied children in States where the State agency responsible for investigating child abuse and neglect allegations will not investigate such allegations in ORR-funded care provider facilities; and</P>
                            <P>(2) Emergency or influx facilities (EIFs).</P>
                            <P>
                                (d) 
                                <E T="03">Reporting.</E>
                                 Care provider facilities to whom this part applies must have written policies and procedures that allow unaccompanied children, care provider facility staff, contractors or sub-grantees of the care provider facility, care provider facility volunteers, families of unaccompanied children, legal service providers, child advocates, attorneys of record, and any other persons, to report allegations of child abuse and neglect to ORR directly, to the care provider facility, or to a designated entity or office that is not part of the care provider facility. The care provider facility written policies and procedures must:
                            </P>
                            <P>(1) Provide unaccompanied children and other individuals with methods for reporting and inform them of how they can report an allegation of child abuse and neglect to a designated entity or office that is not part of the care provider facility. Such entity or office must be able to receive allegations of child abuse and neglect and must immediately forward such allegations to ORR. The method for reporting must allow unaccompanied children to remain anonymous upon request.</P>
                            <P>(2) Ensure all the methods of reporting described at § 412.100(d)(1) are accessible for unaccompanied children with disabilities and with limited English proficiency.</P>
                            <P>(3) Ensure that unaccompanied children, staff, or others who report allegations of child abuse and neglect are protected against retaliation.</P>
                            <P>
                                (e) 
                                <E T="03">Investigations.</E>
                                 When receiving reports of allegations of child abuse and neglect and conducting investigations, ORR must ensure the health and safety of unaccompanied children while making every effort to reduce further trauma to the alleged victim(s).
                            </P>
                            <P>(1) If ORR receives a report of an allegation of child abuse or neglect, it must generate an intake report and determine whether the report includes an allegation that, if found to be true, would meet the definition of child abuse and neglect in this part and is consistent with § 412.100(a) and (c). If so, ORR will assign the intake report for investigation. If not, ORR will administratively close the report.</P>
                            <P>(2) If ORR determines that an intake report is appropriate for investigation, ORR shall assign an ORR Child Welfare Investigator to make a prompt and thorough investigation of the report to obtain sufficient information to determine whether the allegation of child abuse or neglect is substantiated, either at Tier I or II, based on a preponderance of the evidence.</P>
                            <P>(3) ORR shall provide notification that an allegation of child abuse and neglect will be investigated by ORR to the alleged perpetrator; care provider facility; alleged victim; alleged victim's attorney of record (if the child has an attorney of record); and the alleged victim's parent(s), legal guardian(s), or sponsor(s) (as appropriate), unless ORR has evidence showing the parents, legal guardians, or sponsors should not be notified or the victim is 14 years old or older. If the alleged victim is 14 years old or older and ORR has determined that the alleged victim is able to make an independent decision, the alleged victim can affirmatively consent to disclosure.</P>
                            <P>(4) Upon notification that an investigation has been initiated, the care provider facility must take immediate responsive measures, for the protection of child welfare, and notify the alleged perpetrator, as appropriate, and ORR of such measures. These measures may extend throughout the pendency of an investigation, and during the pendency of the appeal and review process, as necessary and applicable.</P>
                            <P>
                                (5) 
                                <E T="03">Investigations process.</E>
                                 (i) ORR shall coordinate with any local or State law enforcement agencies, or other Federal agencies, as appropriate, during its investigation. ORR may pause or 
                                <PRTPAGE P="93519"/>
                                resume an investigation at its discretion, with input from law enforcement partners or other relevant investigatory bodies, as necessary.
                            </P>
                            <P>(ii) A multidisciplinary team of ORR staff that includes subject matter experts, shall be established, as necessary, to provide input and an assessment of the reported allegation of child abuse or neglect to assist the ORR Child Welfare Investigator.</P>
                            <P>(iii) During the investigation, the ORR Child Welfare Investigator must complete, at a minimum, the following actions:</P>
                            <P>(A) Upon receiving an intake report, review the intake report and the care provider facility's records on the alleged victim and alleged perpetrator, conduct background checks on the alleged perpetrator, interview the person who reported the allegation if this person was not interviewed during intake, immediately request preservation of any potential video and documentary evidence, and as needed, establish a plan for thoroughly investigating the allegation;</P>
                            <P>(B) Visit the care provider facility, as appropriate, to conduct a walkthrough of the facility and review video and documentary evidence;</P>
                            <P>(C) Make reasonable efforts to interview all individuals who have information relevant to the allegation of child abuse or neglect, including, but not limited to, the alleged perpetrator (as appropriate), care provider facility staff, the alleged victim, sponsor(s), and the parent(s) or legal guardian(s) (as appropriate) of the alleged victim, and any other potential witnesses;</P>
                            <P>(D) Ensure that interviews conducted as part of the investigation are accessible for individuals with disabilities and with limited English proficiency and are properly documented either in writing or by audio or video recording;</P>
                            <P>(E) Gather all relevant information, including documents and audio or video evidence;</P>
                            <P>(F) Review any available evidence of past conduct contained in DCPI's records relating to the same alleged perpetrator, except for allegations that resulted in a finding of unfounded or administrative closure; and</P>
                            <P>(G) Assess the ongoing risk of child abuse or neglect to the unaccompanied children at the care provider facility and, as appropriate, request that the care provider facility implement a plan to mitigate the risk and ensure the safety of the children.</P>
                            <P>(6) After the investigation is complete, ORR may make any of the following dispositions based on the preponderance of the evidence for each reported allegation:</P>
                            <P>(i) Substantiated allegation—Tier I;</P>
                            <P>(ii) Substantiated allegation—Tier II;</P>
                            <P>(iii) Not substantiated allegation;</P>
                            <P>(iv) Unfounded allegation; or</P>
                            <P>(v) Administrative closure.</P>
                            <P>
                                (7) 
                                <E T="03">Automatic Tier I substantiating circumstances.</E>
                                 The existence of any one of the following circumstances in connection to a substantiated finding, by a preponderance of the evidence, of child abuse or neglect shall result in an automatic finding of Substantiated allegation—Tier I:
                            </P>
                            <P>(i) The death or near death of a child as a result of child abuse or neglect;</P>
                            <P>(ii) Subjecting or exposing a child to sexual abuse or sexual harassment;</P>
                            <P>(iii) The infliction of injury or creation of a condition requiring a child to be hospitalized or to receive significant medical attention;</P>
                            <P>(iv) Repeated instances of physical abuse committed by the individual against any unaccompanied child in ORR care;</P>
                            <P>(v) Failure to take reasonable action to protect a child from sexual abuse or repeated instances of physical abuse under circumstances where the individual knew or should have known that such abuse was occurring; and</P>
                            <P>(vi) Depriving a child of necessary care (food, shelter, healthcare, supervision) which either caused serious harm or created a substantial risk of serious harm.</P>
                            <P>
                                (8) 
                                <E T="03">Aggravating factors and mitigating factors.</E>
                                 If ORR determines that there are no automatic Tier I substantiating circumstances under § 412.100(e)(7), ORR shall consider the following aggravating and mitigating factors together in determining if child abuse or neglect should be substantiated at Tier I or II. Consideration of aggravating and mitigating factors will be based on the totality of the circumstances and the interest of protecting child welfare:
                            </P>
                            <P>
                                (i) 
                                <E T="03">Aggravating factors.</E>
                                 Aggravating factors shall be weighed together with any existing mitigating factors. Aggravating factors include any of the following:
                            </P>
                            <P>(A) Violations of ORR behavior management requirements pursuant to § 410.1304;</P>
                            <P>(B) The individual's failure to comply with clearly established care provider facility policies, corrective action plans, or agreed-upon conditions;</P>
                            <P>(C) The tender age, delayed developmental status or other vulnerability of the child;</P>
                            <P>(D) Any significant or lasting physical, psychological, or emotional harm to the child;</P>
                            <P>(E) An attempt to inflict any significant or lasting physical, psychological, or emotional harm to the child;</P>
                            <P>(F) Evidence suggesting a repetition or pattern of abuse or neglect, including multiple instances in which child abuse or neglect was substantiated at Tier I or Tier II and not substantiated allegations if they demonstrate a pattern of abuse or neglect or harm.</P>
                            <P>
                                (ii) 
                                <E T="03">Mitigating factors.</E>
                                 Mitigating factors shall be weighed together with any existing aggravating factors. Mitigating factors include any of the following:
                            </P>
                            <P>(A) Remedial actions taken by the individual before the investigation was concluded;</P>
                            <P>(B) Extraordinary, situational, or temporary stressors that caused the individual to act in an uncharacteristically abusive or neglectful manner;</P>
                            <P>(C) The isolated or aberrational nature of the child abuse or neglect; and</P>
                            <P>(D) The limited, minor, or negligible physical, psychological, or emotional impact of the abuse or neglect on the child.</P>
                            <P>
                                (f) 
                                <E T="03">Confidentiality.</E>
                                 Records created and information gathered or obtained during an investigation are for internal purposes only, will not be shared or made public unless otherwise required or authorized by law, and may not be disclosed without prior ORR approval. All records must be maintained in an appropriate recordkeeping system with protections for the privacy and security of the individuals identified in the records.
                            </P>
                            <P>
                                (g) 
                                <E T="03">Notifications of a Disposition.</E>
                                 (1) ORR must notify the alleged perpetrator of the disposition in writing within five days of making a disposition. ORR must also notify in writing the alleged victim, their parent(s) or legal guardian(s) (as appropriate), or sponsor(s), of the disposition within five days of making a disposition.
                            </P>
                            <P>(2) If the disposition is substantiated at Tier I, the notification must state:</P>
                            <P>(i) The substantiated perpetrator will be considered a Tier 1 sustained perpetrator and their name and other details related to the relevant abuse or neglect findings will be placed on the ORR Central Registry, unless they seek an appeal of the disposition pursuant to § 412.102, and that once identified in the ORR Central Registry they will be prohibited from working or volunteering in any way on ORR-funded grants or contracts, and may not have access to or contact with any unaccompanied child in ORR custody;</P>
                            <P>
                                (ii) The reasons for the Tier I substantiated perpetrator's placement on the ORR Central Registry in terms sufficient to put the perpetrator on 
                                <PRTPAGE P="93520"/>
                                notice of the conduct or incident(s) upon which it is based;
                            </P>
                            <P>(iii) The Tier I substantiated perpetrator may appeal ORR's disposition pursuant to § 412.102, but that if the Tier I substantiated perpetrator either fails to timely submit a notice of appeal, or upon conclusion of the appeal and subsequent review, if any, the disposition is upheld, the Tier I substantiated perpetrator will be added to the ORR Central Registry as a Tier I sustained perpetrator and the disposition will be reported to Federal, State, and local authorities, as appropriate; and</P>
                            <P>(iv) ORR's procedures for making the disposition.</P>
                            <P>(3) If the disposition is substantiated at Tier II, the notification must inform the Tier II substantiated perpetrator that they may appeal ORR's disposition pursuant to § 412.102, but that if they either fail to timely submit a notice of appeal, or upon the conclusion of the appeal and subsequent review, if any, the disposition is upheld, the Tier II substantiated perpetrator will be designated as a Tier II sustained perpetrator and ORR's disposition will be retained in ORR records. ORR may use these records to determine patterns of child abuse and neglect and to inform future safety planning at care provider facilities. A Tier II sustained perpetrator will not be placed on the ORR Central Registry.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 412.101</SECTNO>
                            <SUBJECT>Interventions and discipline.</SUBJECT>
                            <P>
                                (a) 
                                <E T="03">ORR Central Registry.</E>
                                 (1) ORR will maintain an ORR Central Registry consisting of the names of Tier I sustained perpetrators for purposes consistent with § 412.100(a) and (c). The ORR Central Registry will contain names and other identifying information for such persons, and details regarding any sustained allegations of child abuse and neglect against those persons.
                            </P>
                            <P>(2) Subject to legal requirements regarding disclosure of information, as well as information sharing obligations with relevant State, local, or Federal authorities, the ORR Central Registry will not be public-facing, nor available to persons outside of ORR. The ORR Central Registry will only be used by ORR to identify Tier I sustained perpetrators, as defined in this part, and for ORR to use as part of the screening process by care provider facilities as described in § 412.101(b).</P>
                            <P>
                                (b) 
                                <E T="03">Working and Volunteering Prohibitions and Mandatory ORR Central Registry Checks.</E>
                                 (1) The individuals listed in the ORR Central Registry shall be prohibited from working or volunteering in any way on ORR-funded grants or contracts and may not have access to or contact with any unaccompanied child in ORR custody unless ORR removes such individual from the ORR Central Registry.
                            </P>
                            <P>(2) As part of the screening process for hiring decisions for staff, contractors or sub-grantees, or for screening volunteers, all care provider facilities, home study providers, and post-release service providers, whether or not located in States that investigate child abuse and neglect allegations at ORR care provider facilities, must check with ORR to confirm that an applicant is not listed in the ORR Central Registry.</P>
                            <P>(3) All care provider facilities, home study providers, and post-release service providers, whether or not located in States that investigate child abuse and neglect allegations at ORR care provider facilities, must also check all of their personnel against the ORR Central Registry at least once annually.</P>
                            <P>
                                (c) 
                                <E T="03">Disciplinary Sanctions.</E>
                                 Care provider facilities must implement appropriate disciplinary or remedial measures where they or ORR find that care provider facility staff, contractors or sub-grantees of the care provider facility, or care provider facility volunteers whose conduct does not rise to the level of a Tier I substantiated allegation, as defined at § 412.001, but nevertheless raises child welfare concerns.
                            </P>
                            <P>
                                (d) 
                                <E T="03">Referrals to State, Local, and Other Federal Agencies.</E>
                                 (1) ORR shall refer the names and other identifying information of Tier I sustained perpetrators to relevant State and local authorities and to relevant law enforcement agencies in the State in which the sustained allegation of child abuse or neglect occurred. Additionally, if a State or local authority or relevant local law enforcement agency outside of the State in which the Tier I sustained allegation occurred requests information about the sustained perpetrator, ORR will confirm whether a particular individual is on the ORR Central Registry.
                            </P>
                            <P>(2) ORR will provide the names and other identifying information of Tier I sustained perpetrators to the Federal Bureau of Investigation and HHS Office of the Inspector General (OIG), consistent with any applicable agreements.</P>
                            <P>(3) ORR and care provider facilities shall not interfere with another State, local, or Federal authority or agency's investigation into allegations of child abuse and neglect.</P>
                        </SECTION>
                        <SECTION>
                            <SECTNO>§ 412.102</SECTNO>
                            <SUBJECT>Appeal and review process.</SUBJECT>
                            <P>(a) A substantiated perpetrator at Tier I or Tier II may appeal the disposition made by ORR to an Administrative Law Judge (ALJ) of the HHS Departmental Appeals Board (DAB) pursuant to § 412.102(c).</P>
                            <P>
                                (b) 
                                <E T="03">Notice of Opportunity for an Appeal.</E>
                                 (1) After ORR substantiates an allegation of child abuse and neglect at Tier I or Tier II, it will send a written notice to the substantiated perpetrator at Tier I or Tier II, in accordance with § 412.100(g), with notification that the allegation has been substantiated and that, unless they appeal the disposition by ORR, a Tier I substantiated perpetrator will be placed on the ORR Central Registry as a Tier I sustained perpetrator and a Tier II substantiated perpetrator's information will be retained as a Tier II sustained perpetrator in agency records.
                            </P>
                            <P>(2) The written notice shall:</P>
                            <P>(i) Clearly describe the basis for ORR's disposition that substantiates the relevant allegations at Tier I or Tier II and shall explain the Tier I or Tier II substantiated perpetrator's right to appeal the disposition and the steps required to initiate the appeal.</P>
                            <P>(ii) Inform the substantiated perpetrator that they may appeal the ORR disposition before an ALJ.</P>
                            <P>(iii) Provide the substantiated perpetrator at Tier I or Tier II and their attorney, if any, with written information and instructions describing the appeal process.</P>
                            <P>(iv) Inform the substantiated perpetrator at Tier I or Tier II that if they do not submit a notice of appeal within 30 days of receiving the notice of disposition, the DAB will consider the substantiated perpetrator to have waived their opportunity to appeal and any subsequent review. If the appeal is determined to be waived, a Tier I substantiated perpetrator will be identified as a Tier I sustained perpetrator on the ORR Central Registry and a Tier II substantiated perpetrator's information will be retained as a Tier II sustained perpetrator in agency records.</P>
                            <P>
                                (c) 
                                <E T="03">Notice of Appeal and Dismissal of an Appeal—</E>
                                (1) 
                                <E T="03">Notice of Appeal.</E>
                                 (i) If the substantiated perpetrator at Tier I or Tier II elects to appeal ORR's disposition that an allegation is substantiated at Tier I or Tier II, they must file a written notice of appeal with the DAB within 30 days of receipt of the written notice of ORR's disposition.
                            </P>
                            <P>(ii) Within 30 days of receipt of the notice of appeal, ORR shall provide all evidence it used in making its disposition to the DAB.</P>
                            <P>
                                (iii) ORR shall provide the substantiated perpetrator at Tier I or Tier II and their attorney, if any, all information used in making its disposition except any portion that ORR determines:
                                <PRTPAGE P="93521"/>
                            </P>
                            <P>(A) Would compromise the safety and well-being of a child, the reporter, or any other person;</P>
                            <P>(B) Would reveal the identity of a child who furnished information with the understanding that their identity would be held in confidence;</P>
                            <P>(C) Would reveal the identity of any alleged perpetrator(s) involved in the same case who has an unfounded disposition; or,</P>
                            <P>(D) Is otherwise prohibited by State or Federal law or regulation. In the case of information being withheld, the substantiated perpetrator at Tier I or Tier II shall be advised of the general nature of the information and the reasons that it is being withheld.</P>
                            <P>
                                (2) 
                                <E T="03">Dismissal of appeal.</E>
                                 (i) The ALJ shall dismiss an appeal when the substantiated perpetrator waives appeal by not submitting a notice of appeal within 30 days of receiving written notice of ORR's disposition, pursuant to § 410.102(b)(2)(iv), and does not demonstrate good cause for the untimely submission; or when the substantiated perpetrator withdraws the appeal, abandons the appeal, or does not have a right to ALJ review. If the appeal of a Tier I substantiated perpetrator is dismissed, they will be placed on the ORR Central Registry as a Tier I sustained perpetrator. If the appeal of a Tier II substantiated perpetrator is dismissed, ORR will retain the information regarding the Tier II substantiated perpetrator as a Tier II sustained perpetrator in agency records.
                            </P>
                            <P>(ii) Notwithstanding such dismissal, the DAB may in its discretion temporarily remove the designation of sustained perpetrator at Tier I or Tier II, which would result in ORR removing the individual who was designated as a sustained perpetrator at Tier I from the ORR Central Registry, for situations including, for example, where the ALJ determines that the sustained perpetrator at Tier I or Tier II has established good cause for exceeding the appeal timeframe.</P>
                            <P>
                                (d) 
                                <E T="03">Appeal of ORR's disposition.</E>
                                 (1) When a substantiated perpetrator at Tier I or Tier II appeals the ORR's disposition to an ALJ pursuant to § 412.102(c)(1)(i), ORR must transmit to the ALJ all of the evidence upon which the disposition was based.
                            </P>
                            <P>(2) The evidentiary record must contain all documents and other materials, such as video or audio recordings, that were used by ORR in making its disposition. The ALJ may remand the case to ORR if the ALJ determines that the evidentiary record is insufficiently complete to decide whether ORR's disposition is supported by a preponderance of the evidence.</P>
                            <P>(3) The substantiated perpetrator at Tier I or Tier II may be represented by an attorney and may present the testimony of witnesses, documents, factual data, arguments, or other submissions of proof.</P>
                            <P>(4) The substantiated perpetrator shall have the burden to show that, considering the totality of the evidence, there is not a preponderance of the evidence to support the substantiated allegation at Tier I or Tier II, and to dispute whether any automatic Tier I substantiating circumstances existed (if applicable) or whether any aggravating factors or mitigating factors existed (if applicable). Both ORR and the substantiated perpetrator may present the testimony of witnesses, documents, factual data, arguments, or other submissions of proof. The testimony of care provider facility staff shall be voluntary and failure to offer such testimony will not be subject to disciplinary action.</P>
                            <P>(5) If the substantiated perpetrator submits a notice of appeal and the appeal is not dismissed by the ALJ pursuant to § 412.102(d)(7), ORR must notify the alleged victim and the alleged victim's parent(s), legal guardian(s) (as appropriate), or sponsor(s) that that an appeal of ORR's disposition will be conducted by an ALJ. The alleged victim, other child witness(es), and family members of the alleged victim shall not be required to testify. Refusal to testify shall have no bearing on the determination as to whether abuse did or did not take place.</P>
                            <P>(6) The parties may direct and cross examine witnesses either during a live hearing or pursuant to a record review. The parties will be given an opportunity to file briefs or other written statements as to fact or law.</P>
                            <P>(7) The ALJ shall conduct a fair and impartial hearing and de novo review to determine whether the substantiated perpetrator proved their burden of showing that, considering the totality of the evidence, there is not a preponderance of the evidence to support the substantiated allegation. The ALJ may either dismiss the case for untimeliness, withdrawal of the appeal, abandonment of the appeal, or because the individual does not have the right to appeal or because of other procedural defects, or will issue a written decision to uphold, modify, or reverse ORR's disposition.</P>
                            <P>(8) The ALJ shall serve a copy of the decision upon the parties and the Assistant Secretary for ACF. The ALJ's decision shall provide the sustained perpetrator at Tier I or Tier II and their attorney, if any, with instructions for requesting review by the Assistant Secretary for ACF. The ALJ also shall provide a copy of the decision to alleged victim and the alleged victim's parent(s), legal guardian(s) (as appropriate), or sponsor(s). The complete record upon which the decision is based shall be made available to the Assistant Secretary.</P>
                            <P>
                                (e) 
                                <E T="03">Review of the ALJ's Decision.</E>
                                 (1) A substantiated perpetrator at Tier I or Tier II may request a review of the ALJ's decision within 30 days of receipt of the ALJ's decision, by filing a request for review with Office of the Assistant Secretary for ACF.
                            </P>
                            <P>(2) The Assistant Secretary for ACF has discretion, within 30 days after receiving a timely submission by a substantiated perpetrator of a request for review of an ALJ's decision under § 412.102(e)(1) to review the ALJ's decision to dismiss a case for untimeliness or other procedural defects, and to affirm, modify, or reverse the ALJ's decision with regard to dismissal or ORR's disposition of the allegation. A review by the Assistant Secretary will determine whether the ALJ's decision was based on a material error of law or fact.</P>
                            <P>(3) If the Assistant Secretary affirms the ALJ's decision or does not modify or reverse the ALJ's decision within 30 days after receiving a timely review request pursuant to § 412.102(e)(1), the ALJ's decision becomes the final decision of the Assistant Secretary and is binding on the parties.</P>
                            <P>(4) If the Assistant Secretary modifies or reverses the ALJ's decision pursuant to § 412.102(e)(2), the Assistant Secretary's decision is final and binding.</P>
                            <P>(5) If at the end of the 30-day period in § 412.102(e)(1), no timely request for review has been made, the Assistant Secretary has 30 days from that point to exercise discretion to review the ALJ's decision. If the Assistant Secretary does not modify or reverse the ALJ's decision, then the ALJ's decision becomes the final decision of the Assistant Secretary and is binding on both parties.</P>
                            <P>(6) The Office of the Assistant Secretary for ACF shall serve a copy of the final decision upon the parties involved. The Office of the Assistant Secretary for ACF also shall provide a copy of the final decision issued by the Assistant Secretary, based on review on the ALJ's decision under § 412.102(e), to the alleged victim and the alleged victim's parent(s), legal guardian(s) (as appropriate), or sponsor(s).</P>
                        </SECTION>
                        <SECTION>
                            <PRTPAGE P="93522"/>
                            <SECTNO>§ 412.103</SECTNO>
                            <SUBJECT>Obligations of care provider facilities.</SUBJECT>
                            <P>
                                (a) 
                                <E T="03">General requirements.</E>
                                 During any investigation by ORR, a care provider facility must:
                            </P>
                            <P>(1) Permit ORR unrestricted access to the premises, any physical property on the premises, buildings, staff, and children in the physical custody of the care provider facility;</P>
                            <P>(2) Permit ORR to conduct interviews with children residing at the care provider facility, and without care provider facility staff, contractors, or sub-grantees of the care provider facility, or care provider facility volunteers present;</P>
                            <P>(3) Permit ORR to observe the activities of care provider facility staff, contractors, or sub-grantees of the care provider facility, care provider facility volunteers, or other individuals who have access to children in ORR care through contracts or grants with ORR;</P>
                            <P>(4) Promptly preserve any potential video or documentary evidence;</P>
                            <P>(5) Promptly provide access to and, upon request, copies of all files, records, reports, data, video recordings, and other information to ORR, either prior to or during the investigation;</P>
                            <P>(6) Promptly provide access to and contact information for care provider facility staff, contractors, or sub-grantees of the care provider facility, care provider facility volunteers, or other individuals who have access to children in ORR care through other contracts or grants with ORR;</P>
                            <P>(7) Submit complete and accurate responses to any written questions in a timely manner;</P>
                            <P>(8) Fully cooperate with ORR;</P>
                            <P>(9) Fully cooperate with any investigation of the same allegation by State, local, and Federal authorities and relevant law enforcement agencies.</P>
                            <P>
                                (b) 
                                <E T="03">Protection against retaliation.</E>
                                 Care provider facility staff, contractors, or sub-grantees of the care provider facility, and care provider facility volunteers must not retaliate against any person who in good faith reports or participates in an investigation of child abuse or neglect.
                            </P>
                            <P>
                                (c) 
                                <E T="03">Obstruction, interference, delay of, or failure to permit an investigation.</E>
                                 Obstruction, interference, delay of, or failure of a care provider facility to permit or cooperate with any investigation under this part, including failure to protect unaccompanied children from retaliation pursuant to § 412.103(b), may result in ORR taking monitoring and enforcement measures including, but not limited to: remote monitoring of the care provider facility; on-site monitoring of the care provider facility; monitoring of the corporate offices to review internal policies and reporting structures, as well as supervisory response to events; limiting or stopping new placements of unaccompanied children at the care provider facility; removing all unaccompanied children from the care provider facility and placing them into other care provider facilities; issuing corrective actions; terminating the cooperative agreement or contract with the care provider facility; or imposing other such remedies for noncompliance applicable to HHS grant recipients and contractors.
                            </P>
                            <P>
                                (d) 
                                <E T="03">Rights to legal representation, familial supports, and other supports.</E>
                                 During the course of an investigation, care provider facilities must provide unaccompanied children confidential access to attorneys of record and other legal service providers, in a manner consistent with requirements established at 45 CFR 411.55 (as applicable) and 45 CFR 410.1309. Care provider facilities must provide unaccompanied children access to their families, including legal guardians, in a manner consistent with requirements established at 45 CFR 411.55 (as applicable) and 45 CFR 410.1309. Care provider facilities must provide unaccompanied children with access to their child advocates, in a manner consistent with the requirements at 8 U.S.C. 1232(c)(6) and 45 CFR 410.1308. Care provider facilities must also provide unaccompanied children access to health services (including specialists and mental health practitioners), individual counseling sessions, and crisis intervention (including access to outside victim services and rape crisis centers where appropriate) to most appropriately address unaccompanied children's needs, in a manner consistent with requirements established at 45 CFR 410.1307, 45 CFR 410.1311, 45 CFR 410.1302(c)(5), and 45 CFR 411.21 (as applicable).
                            </P>
                        </SECTION>
                    </PART>
                </REGTEXT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27626 Filed 11-25-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4184-45-P</BILCOD>
        </RULE>
        <RULE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>National Oceanic and Atmospheric Administration</SUBAGY>
                <CFR>50 CFR Part 660</CFR>
                <DEPDOC>[Docket No. 241120-0297]</DEPDOC>
                <RIN>RTID 0648-XD848</RIN>
                <SUBJECT>Fisheries Off West Coast States; Coastal Pelagic Species Fisheries; Annual Specifications; 2024-2025 Annual Specifications and Management Measures for Pacific Sardine</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Final rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>NMFS is implementing annual harvest specifications and management measures for the northern subpopulation of Pacific sardine (hereafter, Pacific sardine), for the fishing year from July 1, 2024, through June 30, 2025. This rule prohibits most directed commercial fishing for Pacific sardine off the coasts of Washington, Oregon, and California. Pacific sardine harvest is allowed only for use as live bait, in minor directed fisheries, as incidental catch in other fisheries, or as authorized under exempted fishing permits. The incidental harvest of Pacific sardine will be limited to 30 percent by weight of all fish per trip when caught with other stocks managed under the Coastal Pelagic Species (CPS) Fishery Management Plan (FMP), or up to 2 metric tons (mt) per trip when caught with non-coastal pelagic species stocks. The harvest specifications for 2024-2025 include an overfishing limit (OFL) of 8,312 mt, an acceptable biological catch (ABC) and annual catch limit (ACL) of 6,005 mt, and an annual catch target (ACT) of 5,500 mt. This final rule is intended to conserve, manage, and rebuild the Pacific sardine stock off the coasts of Washington, Oregon, and California.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Effective December 27, 2024.</P>
                </EFFDATE>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Katie Davis, West Coast Region, NMFS, (323) 372-2126, 
                        <E T="03">Katie.Davis@noaa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    NMFS manages the Pacific sardine fishery in the U.S. exclusive economic zone (EEZ) off the Pacific coast (
                    <E T="03">i.e.,</E>
                     off the U.S. West Coast states of California, Oregon, and Washington) in accordance with the CPS FMP. The CPS FMP and its implementing regulations require NMFS to set annual reference points and management measures for the Pacific 
                    <PRTPAGE P="93523"/>
                    sardine fishery based on the annual specification framework and control rules in the FMP. These control rules include the harvest guideline (HG) control rule, which, in conjunction with the OFL and ABC control rules in the FMP, are used to set required reference points, in accordance with the Magnuson-Stevens Fishery Conservation and Management Act (MSA) (16 U.S.C. 1801 
                    <E T="03">et seq.</E>
                    ). Additionally, the CPS FMP requires additional management measures, intended to restrict harvest, for the Pacific sardine fishery, such as catch restrictions.
                </P>
                <P>
                    NMFS publishes annual specifications in the 
                    <E T="04">Federal Register</E>
                     to establish these annual reference points (
                    <E T="03">e.g.,</E>
                     the OFL, ABC, and ACL) and management measures for each Pacific sardine fishing year. NMFS published proposed specifications and management measures on June 21, 2024 (89 FR 52005). Additionally, in response to a court order, and to avoid a lapse in regulations, NMFS published an interim final rule (89 FR 62668; August 1, 2024) that was effective July 29, 2024, and is in place until replaced by these 2024-2025 final specifications.
                </P>
                <HD SOURCE="HD1">Final Reference Points and Management Measures</HD>
                <P>Based on the 2024 benchmark stock assessment for Pacific sardine, the associated estimated age 1+ biomass of 58,614 mt, the control rule formulas in the FMP, and recent related Court orders, NMFS is implementing, as proposed, an OFL of 8,312 mt, an ABC of 6,005 mt, an ACL of 6,005 mt, and an ACT of 5,500 mt.</P>
                <P>The CPS FMP includes a prohibition of the primary directed fishery when the biomass is at or below 150,000 mt. The Pacific sardine primary directed fishery is therefore closed, and Pacific sardine catch during the 2024-2025 fishing season is prohibited unless it is harvested as part of the live bait, tribal, or minor directed fisheries, as incidental catch in other fisheries, or as part of exempted fishing permit (EFP) activities.</P>
                <P>The 2024-2025 fishing year specifications can be found in table 1, and management measures are listed after table 1.</P>
                <GPOTABLE COLS="6" OPTS="L2,i1" CDEF="s50,12C,12C,12C,12C,12C">
                    <TTITLE>Table 1—Harvest Specifications for the 2024-2025 Sardine Fishing Year, in Metric Tons</TTITLE>
                    <TDESC>[mt]</TDESC>
                    <BOXHD>
                        <CHED H="1">Biomass estimate</CHED>
                        <CHED H="1">OFL</CHED>
                        <CHED H="1">ABC</CHED>
                        <CHED H="1">HG</CHED>
                        <CHED H="1">ACL</CHED>
                        <CHED H="1">ACT</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">58,614</ENT>
                        <ENT>8,312</ENT>
                        <ENT>6,005</ENT>
                        <ENT>0</ENT>
                        <ENT>6,005</ENT>
                        <ENT>5,500</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The following are the additional management measures and in-season accountability measures for the 2024-2025 Pacific sardine fishing year:</P>
                <P>(1) If landings in the live bait fishery reach 3,000 mt of Pacific sardine, then a per-trip limit of 1 mt of Pacific sardine applies to the live bait fishery;</P>
                <P>
                    (2) An incidental per-landing limit of 30 percent (by weight) of Pacific sardine applies to other CPS primary directed fisheries (
                    <E T="03">e.g.,</E>
                     Pacific mackerel);
                </P>
                <P>
                    (3) If the ACT of 5,500 mt is attained, then a per-trip limit of 1 mt of Pacific sardine applies to all CPS fisheries (
                    <E T="03">i.e.,</E>
                     (1) and (2) will no longer apply); and
                </P>
                <P>(4) An incidental per-landing allowance of 2 mt of Pacific sardine applies to non-CPS fisheries until the ACL is reached.</P>
                <P>In addition to the management measures and in-season accountability measures listed in the previous paragraphs, Pacific sardine catch in the minor directed fishery for finfish remains limited to 1 mt per trip per day, and 1 trip per day by any vessel, per regulations at 50 CFR 660.511(d)(2).</P>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    At the April 2024 Pacific Fisheries Management Council (Council) meeting, the Council's Scientific and Statistical Committee (SSC) reviewed a Stock Assessment Review (STAR) panel report on the Southwest Fisheries Science Center's 2024 benchmark stock assessment, and also reviewed the benchmark stock assessment itself, titled “Assessment of the Pacific sardine resource (
                    <E T="03">Sardinops sagax</E>
                    ) in 2024 for U.S. management in 2024-2025.” The SSC concluded that the 2024 benchmark assessment for Pacific sardine is the best scientific information available for the management of Pacific sardine. During their review, the SSC noted major improvements in methodology from the 2020 benchmark assessment, including an updated habitat model for assigning fishery catch and survey biomass to the northern and southern subpopulations of Pacific sardine. However, the SSC applied a category 2d sigma uncertainty buffer which, compared to a category 1, equates to a larger allowance for scientific uncertainty, and therefore a lower ABC and a decreased risk of overfishing. During the discussion of the appropriate category, the SSC discussed potential uncertainty in the relationship between sardine productivity and ocean temperatures recently used to calculate the E
                    <E T="52">MSY</E>
                     parameter of the OFL and ABC control rules, as well as uncertainty in the strength of the 2023 year-class represented in the stock assessment, along with other uncertainties in the data used in the assessment.
                </P>
                <P>The CPS FMP control rules, as they apply to annual reference points, use the following formulas:</P>
                <FP SOURCE="FP-2">
                    OFL = Biomass * E
                    <E T="52">MSY</E>
                     * DISTRIBUTION
                </FP>
                <FP SOURCE="FP-2">
                    ABC = Biomass * BUFFER * E
                    <E T="52">MSY</E>
                     * DISTRIBUTION
                </FP>
                <P>
                    <E T="03">Biomass.</E>
                     The estimated stock biomass of Pacific sardine ages 1 and older, in metric tons.
                </P>
                <P>
                    <E T="03">E</E>
                    <E T="54">MSY</E>
                    . The exploitation rate for deterministic equilibrium maximum sustainable yield. Since 2014, based on annual recommendations by the Pacific Fishery Management Council's SSC, the E
                    <E T="52">MSY</E>
                     for Pacific sardine has most recently been based on a temperature-recruitment relationship based on a running 3-year average of the California Cooperative Oceanic Fisheries Investigations (CalCOFI) temperature index.
                </P>
                <P>
                    <E T="03">DISTRIBUTION.</E>
                     The average portion of the Pacific sardine biomass estimated to be in the U.S. EEZ off the Pacific coast. DISTRIBUTION is currently defined in the CPS FMP as 87 percent and is based on the average historical larval distribution obtained from scientific cruises and the distribution of the resource according to the logbooks of aerial fish-spotters.
                </P>
                <P>
                    <E T="03">BUFFER.</E>
                     The percentage reduction of the OFL as determined by the SSC's evaluation of scientific uncertainty (sigma) and the Council's risk policy (P*).
                </P>
                <HD SOURCE="HD1">Rebuilding Plan and Oceana, Inc., v. Raimondo, et al.</HD>
                <P>
                    During the 2019-2020 fishing year, the estimated biomass of sardine dropped below its minimum stock size threshold of 50,000 mt, which triggered an overfished determination process. NMFS accordingly declared the stock overfished on June 26, 2019 and notified the Council on July 9, 2019. NMFS worked with the Council to develop a rebuilding plan for Pacific sardine to 
                    <PRTPAGE P="93524"/>
                    implement within two years and finalized it on June 24, 2021 (86 FR 33142). The rebuilding plan maintained the status quo management for Pacific sardine, which includes a complete closure of the primary sardine fishery. Oceana, an environmental non-governmental organization, challenged this rebuilding plan and later included a challenge to the 2023-2024 annual specifications (“2023 Final Rule”; 88 FR 41040), in an action filed in the United States District Court for the Northern District of California: 
                    <E T="03">Oceana, Inc.,</E>
                     v. 
                    <E T="03">Raimondo, et al.,</E>
                     No. 5:21-cv-05407-VKD (N.D. Cal., filed July 14, 2021). In its rulings on the challenges, the Court partially vacated the rebuilding plan and held that NMFS failed to demonstrate that it relied on best available science to set the overfishing limits in using the CalCOFI temperature index to determine E
                    <E T="52">MSY</E>
                     for the 2023 Final Rule.
                </P>
                <HD SOURCE="HD1">Partially-Vacated Rebuilding Plan</HD>
                <P>The Court partially vacated the rebuilding plan on June 28, 2024. Accordingly, NMFS cannot rely on the vacated components of the rebuilding plan to guide these annual specifications. The harvest control rules in place before Amendment 18 to the CPS FMP implemented the now partially-vacated rebuilding plan are still applicable. None of the provisions of Amendment 18, whether vacated or not, changed the previously applicable harvest control rules.</P>
                <HD SOURCE="HD1">
                    E
                    <E T="0132">MSY</E>
                </HD>
                <P>
                    NMFS considered the recent order from the Court in making a determination that the harvest specifications and management measures in this action would prevent overfishing, rebuild the stock, and are supported by the best scientific information available. As they have in previous years, the SSC recommended an OFL and ABC for the 2024-2025 fishing year that were calculated, in part, by using an E
                    <E T="52">MSY</E>
                     based on a relationship with CalCOFI temperatures as best scientific information available for preventing overfishing. The CPS FMP does not mandate that E
                    <E T="52">MSY</E>
                     be based on this relationship. Under the MSA, the SSC provides scientific advice for NMFS' consideration in fishery management decisions, including ABC and preventing overfishing. Per National Standard 2 at 50 CFR 600.315(a)(2), scientific information that is used to inform decision making should include an evaluation of its uncertainty and management decisions should recognize the risks, such as those to overfishing, associated with the sources of uncertainty. The SSC discussed the potential uncertainty surrounding the use of the CalCOFI-based E
                    <E T="52">MSY</E>
                     when considering their choice of the appropriate sigma for the ABC. NMFS has determined that the use of a Category 2 sigma, as recommended by the SSC, appropriately accounts for any scientific uncertainty and gaps in scientific information that may exist, including any surrounding E
                    <E T="52">MSY</E>
                    , in the information used to calculate the recommended reference points.
                </P>
                <P>
                    In making the determination to approve the OFL and ABC recommended by the Council, NMFS took into account the fact that the SSC recommended that the analysis and assumptions surrounding a CalCOFI based E
                    <E T="52">MSY</E>
                     be revisited. This was one of several scientific recommendations made by the SSC in April 2024. Other recommendations included a potential reconsideration of the need for the precaution provided by the DISTRIBUTION term, noting that a substantial proportion of the U.S. catch in recent years is inferred to be from the southern subpopulation of Pacific sardine and that there has been a decline in the assumed catch of northern subpopulation by Mexico, as well as endorsement of the eight high-priority research recommendations for future sardine stock assessments in the 2024 sardine STAR panel report. All of these recommendations are typical of the scientific process to inform fishery management decisions such as determining an appropriate OFL and ABC to prevent overfishing and achieve optimum yield in the fishery.
                </P>
                <P>
                    NMFS also examined recent and past years' CalCOFI temperatures in relation to this year's calculated CalCOFI-based E
                    <E T="52">MSY</E>
                    . The calculated value for this year is 0.163 and represents the lowest E
                    <E T="52">MSY</E>
                     in 10 years, and falls in the lower range of expected values. The decline in E
                    <E T="52">MSY</E>
                     this year compared to the last 3 years is the result of a high temperature record year in 2020 falling out of the running 3-year average temperature used to calculate E
                    <E T="52">MSY</E>
                    . This effect was also observed between 2014 and 2017 when a very large marine heatwave off the Pacific coast caused unprecedented disruptions in the ocean environment, resulting in high CalCOFI temperatures. The highest CalCOFI temperature in 40 years was recorded in 2015. Such events increase the running 3-year average temperature used to calculate E
                    <E T="52">MSY</E>
                    . To reduce the risk of potentially excessive E
                    <E T="52">MSY</E>
                     values, the SSC recommended in 2014 that a CalCOFI-based E
                    <E T="52">MSY</E>
                     be restricted to a maximum of 0.25 (for reference, this equated to a temperature of 16.16 °C when the median temperature was 15.90 °C). This cap on E
                    <E T="52">MSY</E>
                     was applied to calculations of the reference points for the 2016-2017 and 2018-2019 fishing years.
                </P>
                <P>
                    Although the Court found that NMFS' rationale for exclusively using CalCOFI data to determine E
                    <E T="52">MSY</E>
                     in order to set the 2023-2024 specifications was inadequate, it explicitly declined to prohibit NMFS from employing the CalCOFI-based E
                    <E T="52">MSY</E>
                     in setting catch limits, and stated that the agency must reassess the rebuilding plan and determine how to meet the requirements of the MSA in view of the Court's order. In light of the Court's finding prior to the issuance of the 2024-2025 harvest specifications, and as part of a robust decision-making process, NMFS considered whether there was alternative scientific information, per 50 CFR 600.315(a)(2), that would warrant disapproving the Council's recommendation.
                </P>
                <P>
                    Although E
                    <E T="52">MSY</E>
                     is lower this year than any E
                    <E T="52">MSY</E>
                     used in the last 10 years, NMFS acknowledges there is still scientific uncertainty surrounding the predictive efficacy of the CalCOFI temperature index. However, as explained in both the proposed rule and this final rule, this uncertainty was considered by the SSC and the Council when recommending a 2,307 mt reduction from the OFL to the ABC (
                    <E T="03">i.e.,</E>
                     OFL is 8,312 mt but ABC and ACL are both 6,005 mt). Importantly, as discussed in the proposed rule and in the paragraphs that follow, in addition to accounting for any scientific uncertainty surrounding CalCOFI, NMFS also considered the only available alternative to its use, which resulted in a higher value than the CalCOFI-based E
                    <E T="52">MSY</E>
                    , and determined the lower value was appropriate to use in setting this year's specifications.
                </P>
                <P>
                    Currently, there are no other formulaic relationships between Pacific sardine recruitment and an environmental variable on which to base E
                    <E T="52">MSY</E>
                    . However, past analyses have calculated a stochastic (referenced as “static” in proposed rule) E
                    <E T="52">MSY</E>
                     of 0.18 when the effects of temperature on productivity are ignored.
                    <SU>1</SU>
                    <FTREF/>
                     This value for E
                    <E T="52">MSY</E>
                     was recommended by the SSC and utilized by NMFS as best scientific information available for management in 2012-2014 as an alternative to the default option of applying the temperature-stock relationship due to uncertainty surrounding the 
                    <PRTPAGE P="93525"/>
                    relationship at that time.
                    <SU>2</SU>
                    <FTREF/>
                     During the Council's April 2023 Pacific sardine harvest specification process, the SSC specifically compared this stochastic value to the CalCOFI-based 2023-2024 E
                    <E T="52">MSY</E>
                     of 0.22 in its discussion of an appropriate OFL buffer: “There was no support among SSC members for a category 1 designation, but there was some discussion of the merits of a category 2 versus a category 3 assessment. Although uncertainty in E
                    <E T="52">MSY</E>
                     would argue for increased uncertainty in the OFL, it was noted that the `nondynamic' harvest rate (estimated to maximize long-term yield in stochastic simulations), of 0.18, is not very different from 0.22 based on current SSTs, and that other CPS stocks have rates that are higher still (Pacific mackerel E
                    <E T="52">MSY</E>
                     is ~0.3).” 
                    <SU>3</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Hurtado-Ferro, F., and Punt, A.E. 2013. Revised analyses related to Pacific sardine harvest parameters. PFMC June 2013 Briefing Book. Agenda Item I.4.b Attachment 1.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         Prior to 2012, E
                        <E T="52">MSY</E>
                         was based on a relationship with sea surface temperature measured at the Scripps Institution of Oceanography (SIO) pier, in La Jolla, CA. A scientific paper was published calling into question this relationship, so while that was reviewed, 18 percent was used for E
                        <E T="52">MSY.</E>
                         The subsequent review of the SIO pier temperature and E
                        <E T="52">MSY</E>
                         relationship determined it was actually still correlated.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         Scientific and Statistical Committee Minutes. April 2023. PFMC. 
                        <E T="03">https://www.pcouncil.org/documents/2023/06/scientific-and-statistical-committee-draft-april-1-2-2023-minutes.pdf/.</E>
                    </P>
                </FTNT>
                <P>
                    NMFS considers this modeled stochastic E
                    <E T="52">MSY</E>
                     of 0.18 as the only available alternative that could have been considered in making OFL determinations for Pacific sardine without the use of the CalCOFI temperature index. However, the Council's SSC recommended to the Council an OFL that utilized the CalCOFI-based E
                    <E T="52">MSY</E>
                     as the best scientific information available. In making the decision to approve the OFL and ABC in this action, NMFS considered the stochastic E
                    <E T="52">MSY</E>
                     of 0.18. NMFS concluded that, at this time, it cannot make a determination that the stochastic E
                    <E T="52">MSY</E>
                     of 0.18 represents a better alternative to the CalCOFI-based E
                    <E T="52">MSY</E>
                     value the SSC recommended as the best scientific information available for determining this year's OFL. Since 2000, when the CPS FMP was adopted and harvest control rules were established for Pacific sardine, it has been determined that making efforts to include environmental information into the management of Pacific sardine is the preferred approach. And although the relatively recent running 3-year average CalCOFI temperatures have resulted in higher values than in previous years, likely as a result of anomalous, although becoming more frequent, oceanographic events, that may appear to contradict the original concept of the environmental E
                    <E T="52">MSY,</E>
                     this year's temperature and resulting E
                    <E T="52">MSY</E>
                     align with the concept as they are both in the lower range of values during a time of relatively low sardine recruitment. NMFS will continue, as it has each year, to evaluate whether the use of the CalCOFI-based E
                    <E T="52">MSY</E>
                     is the best scientific information available for future annual specifications.
                </P>
                <P>
                    As noted in the proposed rule, the Council's recommended OFL, calculated using an E
                    <E T="52">MSY</E>
                     of 0.163, is a lower OFL and therefore more precautionary than an OFL would have been based on the stochastic E
                    <E T="52">MSY</E>
                     of 0.18. Additionally, it has been previously suggested that one approach to set a precautionary proxy fishing mortality rate for small pelagic fish such as Pacific sardine is to use a value that equates to one half of the species natural mortality rate.
                    <SU>4</SU>
                    <FTREF/>
                     Based on the estimates of natural mortality from the 2024 Pacific sardine stock assessment, this formula would produce an E
                    <E T="52">MSY</E>
                     in the range of 0.25-0.30. By contrast, the E
                    <E T="52">MSY</E>
                     utilized to calculate the OFL implemented through this action is only 0.163. For these reasons, NMFS has determined that the reference points recommended by the Council are based on the best scientific information available and, therefore, NMFS has determined to implement them through this action.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Pikitch, E. et al. 2012. Little Fish, Big Impact: Managing a Crucial Link in Ocean Food Webs. Lenfest Ocean Program. Washington, DC. 108 pp.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Annual Catch Limit</HD>
                <P>Although this action implements an ACL equal to the ABC at 6,005 mt, as envisioned by the FMP, NMFS has determined that as a result of the closure of the directed fishery and additional management measures, landings of the northern subpopulation of Pacific sardine will remain very low and total U.S. sardine landings are highly unlikely to exceed 2,200 mt, similar to what has occurred since the 2015-2016 fishing year, when the directed fishery was closed (see table 2).</P>
                <GPOTABLE COLS="4" OPTS="L2,i1" CDEF="s50,10,21,22">
                    <TTITLE>Table 2—Landings Attributed in the 2024 Pacific Sardine Stock Assessment to Northern and Southern Subpopulations of Pacific Sardine (2014-2023), in Metric Tons</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fishing year</CHED>
                        <CHED H="1">ACL</CHED>
                        <CHED H="1">
                            Total landings of 
                            <LI>Pacific sardine </LI>
                            <LI>(combined catch of</LI>
                            <LI>northern and</LI>
                            <LI>southern </LI>
                            <LI>subpopulations)</LI>
                        </CHED>
                        <CHED H="1">
                            Assumed landings of 
                            <LI>northern subpopulation </LI>
                            <LI>of Pacific sardine</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">2014-2015</ENT>
                        <ENT>23,293</ENT>
                        <ENT>23,113</ENT>
                        <ENT>19,969</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2015-2016</ENT>
                        <ENT>7,000</ENT>
                        <ENT>1,919</ENT>
                        <ENT>75</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2016-2017</ENT>
                        <ENT>8,000</ENT>
                        <ENT>1,885</ENT>
                        <ENT>602</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2017-2018</ENT>
                        <ENT>8,000</ENT>
                        <ENT>1,775</ENT>
                        <ENT>351</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2018-2019</ENT>
                        <ENT>7,000</ENT>
                        <ENT>2,278</ENT>
                        <ENT>525</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2019-2020</ENT>
                        <ENT>4,000</ENT>
                        <ENT>2,062</ENT>
                        <ENT>627</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2020-2021</ENT>
                        <ENT>4,000</ENT>
                        <ENT>2,276</ENT>
                        <ENT>657</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2021-2022</ENT>
                        <ENT>3,000</ENT>
                        <ENT>1,772</ENT>
                        <ENT>298</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2022-2023</ENT>
                        <ENT>3,800</ENT>
                        <ENT>1,619</ENT>
                        <ENT>517</ENT>
                    </ROW>
                </GPOTABLE>
                <P>All sources of catch, including any EFP set-asides, the live bait fishery, and other minimal sources of harvest, such as incidental catch in CPS and non-CPS fisheries and minor directed fishing, will be accounted for against the ACT and ACL. Any Pacific sardine harvested between July 1, 2024, and the effective date of this final rule will count toward the 2024-2025 ACT and ACL.</P>
                <P>
                    At the April 2024 Council meeting, the Council recommended apportioning 670 mt of the ACL for two EFP proposals to support stock assessments for Pacific sardine. NMFS published a notice of receipt of EFP applications on June 26, 2024 (89 FR 53396). The comment period closed on July 26, 
                    <PRTPAGE P="93526"/>
                    2024, and NMFS received no comments. NMFS is deciding whether to issue the EFPs during the promulgation of this final rule. The NMFS West Coast Regional Administrator will publish a notice in the 
                    <E T="04">Federal Register</E>
                     to announce when catch reaches the incidental limits, as well as any changes to allowable incidental catch percentages or trip limits. Additionally, to ensure that the regulated community is informed of any closure, NMFS will make announcements through other means available, including emails to fishermen, processors, and state fishery management agencies.
                </P>
                <HD SOURCE="HD1">Comments and Responses</HD>
                <P>
                    On June 21, 2024, NMFS published a proposed rule for this action and solicited public comments through July 8, 2024 (89 FR 52005). NMFS received two public comment letters relevant to this action, one from the California Wetfish Producer's Association (CWPA) and one from the non-governmental conservation organization Oceana. After considering the public comments, NMFS made no changes from the proposed rule. The comment from CWPA supported this action. The comment letter from Oceana included multiple comments, some of which are beyond the scope of this action. Additionally, some of the comments and requests provided by Oceana were the subject of recent litigation. The U.S. District Court (N.D. Cal.) has ruled in this case, and NMFS notes that it must complete the remand of the Pacific sardine rebuilding plan by June 1, 2025 (
                    <E T="03">Oceana, Inc.,</E>
                     v. 
                    <E T="03">Raimondo, et al.</E>
                    ). NMFS summarizes and responds to those comments from Oceana below.
                </P>
                <P>
                    <E T="03">Comment 1:</E>
                     Oceana states that the E
                    <E T="52">MSY</E>
                     used to set the OFL, ABC, and ACL fails to prevent overfishing and is inconsistent with the best available science on sardine productivity. Oceana states that in NMFS' rationale for continuing to use the CalCOFI index for E
                    <E T="52">MSY</E>
                    , NMFS incorrectly asserts that the identified flaws in the CalCOFI index are due to uncertainty.
                </P>
                <P>
                    <E T="03">Response:</E>
                     NMFS has determined that the OFL and ABC implemented through this action will prevent overfishing and are supported by the best scientific information available. NMFS notes that this issue was the subject of recent court orders: on April 22, 2024, the Court issued an order stating that NMFS failed to demonstrate that it had relied on the best available science in setting the 2023-2024 OFL for Pacific sardine using an exclusively CalCOFI-derived E
                    <E T="52">MSY</E>
                    . As stated in this rule, NMFS took into account the Court's finding on this matter and has determined that reference points established by this action, specifically the OFL and ABC, will prevent overfishing, support the rebuilding of the stock, and are supported by the best scientific information available. In an attempt to address the Court's concern for these 2024-2025 harvest specifications, NMFS expressly considered what available information exists that would necessitate that NMFS disapprove the Council's recommended OFL. As stated above, NMFS considered the only alternative E
                    <E T="52">MSY</E>
                     value previously analyzed and used by the Council's SSC and NMFS, which was 18 percent. The use of the 18 percent E
                    <E T="52">MSY</E>
                     was previously supported by analyses conducted by Hurtado-Ferro and Punt (2013) developed to evaluate the performance of alternative candidate OFL and HG control rule variants. That analysis used a Pacific sardine specific model to calculate an E
                    <E T="52">MSY</E>
                     to examine constant exploitation rate harvest control rules (
                    <E T="03">i.e.,</E>
                     an E
                    <E T="52">MSY</E>
                     that does not account for an environmental effect), and is also the E
                    <E T="52">MSY</E>
                     value that was used to project the population in the rebuilding analysis for Pacific sardine.
                </P>
                <P>
                    For this year, the alternative of an 18 percent E
                    <E T="52">MSY</E>
                     would be higher than the CalCOFI-based E
                    <E T="52">MSY</E>
                     value, and would therefore result in a higher OFL than the OFL recommended by the SSC. As described in this rule, the CalCOFI-based E
                    <E T="52">MSY</E>
                     is among the lowest values produced by the CalCOFI (sea surface) temperature index in the past 10 years. The literature cited by the commenter (Zwolinski and Demer, 2019) re-evaluated the correlation between the sea surface temperature E
                    <E T="52">MSY</E>
                     values and recruitment success of the northern subpopulation of Pacific sardine over a specific period of years and suggested that the relationship was no longer statistically valid. However, the same journal article that called into question the validity of the CalCOFI temperature index in predicting the productivity of Pacific sardine stated that “. . . even a marginally statistically significant environment-dependent recruitment model may be useful. For example, if required by the HCR, it could be used to predict recruitment in the management year and forecast the stock biomass into the following year more precisely than a model without environmental influence.” 
                    <SU>5</SU>
                    <FTREF/>
                     While NMFS will continue to evaluate E
                    <E T="52">MSY</E>
                    , it has determined that use of the CalCOFI temperature index is the best scientific information available in setting the 2024-2025 Pacific sardine harvest specifications.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         Zwolinski, JP &amp; Demer, DA. 2019. Re-evaluation of the environmental dependence of Pacific sardine recruitment. Fisheries Research, 216, 120-125. 
                        <E T="03">https://doi.org/10.1016/j.fishres.2019.03.022.</E>
                    </P>
                </FTNT>
                <P>
                    <E T="03">Comment 2:</E>
                     Oceana argues that the stochastic E
                    <E T="52">MSY</E>
                     value of 18 percent is outdated and incorrect and that NMFS fails to analyze other available alternatives for setting the E
                    <E T="52">MSY</E>
                     value for the 2024-2025 specifications. Oceana suggests using an E
                    <E T="52">MSY</E>
                     value of 5 percent from Alternative 3 in Amendment 18 to the CPS FMP to set the OFL. Oceana states that NMFS could alternatively also readily produce an E
                    <E T="52">MSY</E>
                     from the 2024 stock assessment, as it did in the 2022 northern anchovy stock assessment, and use it to calculate the 2024-2025 annual catch specifications.
                </P>
                <P>
                    <E T="03">Response:</E>
                     As stated previously in this rule, in light of the Court's finding that NMFS' rationale for using the CalCOFI based E
                    <E T="52">MSY</E>
                     in the 2023-2024 specifications was inadequate, NMFS re-examined and reviewed the relevant information available to make a determination on approving the OFL and ABC implemented through this action. While Oceana states that the CalCOFI-based E
                    <E T="52">MSY</E>
                     and the stochastic 18 percent E
                    <E T="52">MSY</E>
                     are not consistent with the best scientific information available on sardine productivity, the comment did not offer alternative best scientific information available and NMFS has determined that none exists. Oceana suggests that NMFS consider a 5 percent E
                    <E T="52">MSY</E>
                    ; however, NMFS could not, through this action, implement an OFL utilizing a 5 percent E
                    <E T="52">MSY</E>
                     and additionally has no evidence that this would represent best scientific information available. NMFS recognizes that a harvest rate of 5 percent was considered as part of alternative 3 for Amendment 18, and this could remain a potential alternative under any future rebuilding plan; however, NMFS has determined it does not represent the best scientific information available for use as an E
                    <E T="52">MSY</E>
                     to calculate this year's OFL. NMFS has no basis to consider a 5 percent E
                    <E T="52">MSY</E>
                     as alternative best scientific information available. Unlike the stochastic 18 percent described above, 5 percent is not a result of modeling work explicitly designed to calculate E
                    <E T="52">MSY</E>
                    . The 5 percent value under alternative 3 represented a harvest level between status quo management and zero U.S. harvest, which was analyzed as a policy option to explore the differences in potential rebuilding timelines as a result of reduced harvest levels. Absent any support for an E
                    <E T="52">MSY</E>
                     of 5 percent as a basis for calculating the OFL, NMFS could not determine that it was the best scientific information available.
                    <PRTPAGE P="93527"/>
                </P>
                <P>
                    In addition, Oceana's suggestion that NMFS could “readily” produce an updated E
                    <E T="52">MSY</E>
                     from the 2024 stock assessment as was done for the central subpopulation of northern anchovy (CSNA) is misleading, because the 2024 sardine stock assessment did not produce an E
                    <E T="52">MSY</E>
                     that could be considered in this rulemaking. The management of Pacific sardine has never utilized an E
                    <E T="52">MSY</E>
                     derived from a stock assessment model. No such E
                    <E T="52">MSY</E>
                     is available because it has not been produced by scientists and peer reviewed, and thus an E
                    <E T="52">MSY</E>
                     derived from a stock assessment model would not be the best scientific information available as required under the MSA. Calculating E
                    <E T="52">MSY</E>
                     for CPS stocks from a stock assessment requires scientists to run multiple data analyses, including reassessments to address potential issues, and these results would then need to be packaged and written up. This is not a straightforward process that could be accomplished and appropriately reviewed in the time available to complete this rulemaking.
                </P>
                <P>
                    The complications of this process are highlighted by the CSNA E
                    <E T="52">MSY</E>
                     development. The most appropriate way to calculate the CSNA E
                    <E T="52">MSY</E>
                     was discussed at multiple meetings, including the STAR panel meeting for the 2022 CSNA assessment as well as a full SSC meeting. These discussions included scientifically technical deliberations on the parameters of the stock assessment that influence the E
                    <E T="52">MSY</E>
                     calculation. Ultimately the SSC recommended an E
                    <E T="52">MSY</E>
                     value resulting from the stock assessment model; however, at the time the SSC noted that uncertainty in that value remained: “The SSC endorses the E
                    <E T="52">MSY</E>
                     value (labeled F
                    <E T="52">MSY</E>
                     in the assessment) of 0.493 estimated within the assessment, where E is expressed as annual total catch divided by summary age-1+ biomass, while noting that the value of E
                    <E T="52">MSY</E>
                     remains a major uncertainty.” During the 2024 Pacific sardine stock assessment process an E
                    <E T="52">MSY</E>
                     was not developed. Furthermore, any sort of E
                    <E T="52">MSY</E>
                     from the assessment model for Pacific sardine would likely carry similar uncertainties as those associated with the CSNA value that would require a thorough review and would not be reliable for the 2024-25 specifications.
                </P>
                <P>
                    <E T="03">Comment 3:</E>
                     Oceana states that the proposed ACL would not allow rebuilding within the legally required timeline because it represents a harvest rate and overall catch level that NMFS's rebuilding analysis showed will not rebuild the Pacific sardine population. Oceana states that in contrast, NMFS's rebuilding analysis showed that a constant catch of 2,200 metric tons or a 5 percent harvest rate would rebuild the population.
                </P>
                <P>
                    <E T="03">Response:</E>
                     NMFS acknowledges that the Court's order vacated parts of the rebuilding plan that must be addressed by June 1, 2025, including that the plan failed to rebuild the stock within the statutory timeframe under the MSA. The Court has provided NMFS until June 1, 2025 to develop a new rebuilding plan that will specify a time period for rebuilding Pacific sardine that will be as short as possible, taking into account the status and biology of any overfished stocks of fish, the needs of fishing communities, recommendations by international organizations in which the United States participates, and the interaction of the overfished stock of fish within the marine ecosystem. The rebuilding plan will also include conservation and management measures consistent with achieving rebuilding within the specified time period. It is not required by the Court's order to implement this rebuilding plan in this rule.
                </P>
                <P>
                    <E T="03">Comment 4:</E>
                     Oceana states that given the uncertainties, evidence of previous overfishing, and the need to rebuild, Oceana recommended NMFS use a lower P-star parameter than the 0.4 recommended by the Council. Noting that P-star represents the risk of overfishing.
                </P>
                <P>
                    <E T="03">Response:</E>
                     The choice of P-star is only one factor in creating a buffer between the OFL and ABC to help ensure overfishing is prevented. The other factor used for Pacific sardine is the sigma value recommended by the SSC. This sigma value is intended to capture scientific uncertainty in the OFL estimate. The Council's P-star choice is then intended to capture other factors, such as management uncertainty, in preventing overfishing. There is extremely limited management uncertainty associated with tracking catch levels against the applicable catch reference points for Pacific sardine. NMFS is readily able to track fishing mortality across the various sectors in season to ensure landings do not exceed the ACL or ABC. NMFS therefore has determined that the ABC has been appropriately reduced from the OFL to prevent overfishing.
                </P>
                <P>
                    <E T="03">Comment 5:</E>
                     Oceana states that given the stock remains near the 50,000 mt minimum stock size threshold, the proposed incidental harvest rate of 30 percent is excessive.
                </P>
                <P>
                    <E T="03">Response:</E>
                     The CPS FMP dictates that if the estimated biomass is below 50,000 mt, then the incidental harvest rate is restricted to 20 percent landing by weight. The 2024 estimated biomass is 58,614 mt. Under the CPS FMP, at this value, the incidental rate could be up to 45 percent; therefore, 30 percent is in line with the allowances of the CPS FMP. Additionally, during the 2018-2019 fishing year, the last year that the stock's biomass was more than 50,000 mt, the incidental harvest allowance was 40 percent, and the incidental fishery harvested 272 mt. The following year, the incidental harvest allowance was restricted to 20 percent, and the incidental fishery harvested 249 mt. Increasing the incidental harvest allowance doesn't necessarily change the amount of Pacific sardine catch, but allows more flexibility for vessels to reduce unwanted discards when the catch ratio of sardine to other CPS is greater than 20 percent.
                </P>
                <HD SOURCE="HD1">Classification</HD>
                <P>Pursuant to section 304(b)(1)(A) of the MSA, the NMFS Assistant Administrator has determined that this final rule is consistent with the CPS FMP, other provisions of the MSA, and other applicable law.</P>
                <P>This final rule is exempt from review under Executive Order 12866 because it is a routine rule that would implement regulations for less than 1 year.</P>
                <P>The Chief Counsel for Regulation of the Department of Commerce certified to the Chief Counsel for Advocacy of the Small Business Administration during the proposed rule stage that this action would not have a significant economic impact on a substantial number of small entities for the purposes of the Regulatory Flexibility Act. The factual basis for the certification was published in the proposed rule (89 FR 52005, June 21, 2024) and is not repeated here. As a result, a final regulatory flexibility analysis was not required and none was prepared.</P>
                <P>Pursuant to Executive Order 13175, this proposed rule was developed after meaningful consultation and collaboration with the Council's tribal representative, who has agreed with the provisions that apply to tribal vessels.</P>
                <P>This action does not contain a collection-of-information requirement for purposes of the Paperwork Reduction Act. There are no relevant Federal rules that may duplicate, overlap, or conflict with the proposed action.</P>
                <AUTH>
                    <HD SOURCE="HED">Authority:</HD>
                    <P>
                        16 U.S.C. 1801 
                        <E T="03">et seq.</E>
                    </P>
                </AUTH>
                <SIG>
                    <DATED>Dated: November 20, 2024.</DATED>
                    <NAME>Samuel D. Rauch III,</NAME>
                    <TITLE>Deputy Assistant Administrator for Regulatory Programs, National Marine Fisheries Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27685 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-22-P</BILCOD>
        </RULE>
    </RULES>
    <VOL>89</VOL>
    <NO>229</NO>
    <DATE>Wednesday, November 27, 2024</DATE>
    <UNITNAME>Proposed Rules</UNITNAME>
    <PRORULES>
        <PRORULE>
            <PREAMB>
                <PRTPAGE P="93528"/>
                <AGENCY TYPE="F">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 39</CFR>
                <DEPDOC>[Docket No. FAA-2024-2543; Project Identifier MCAI-2024-00342-T]</DEPDOC>
                <RIN>RIN 2120-AA64</RIN>
                <SUBJECT>Airworthiness Directives; Bombardier, Inc., Airplanes</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of proposed rulemaking (NPRM).</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The FAA proposes to adopt a new airworthiness directive (AD) for all Bombardier, Inc., Model BD-700-2A12 airplanes. This proposed AD was prompted by the discovery that a partial loss of thrust after an engine failure during a required navigation performance authorization required (RNP-AR) approach under certain weight, altitude and temperature (WAT) conditions, may lead to a descent below the specified path guidance. This proposed AD would require a revision to the existing airplane flight manual (AFM), to incorporate updated WAT tables for RNP-AR approach operations. The FAA is proposing this AD to address the unsafe condition on these products.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The FAA must receive comments on this proposed AD by January 13, 2025.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may send comments, using the procedures found in 14 CFR 11.43 and 11.45, by any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal:</E>
                         Go to 
                        <E T="03">regulations.gov</E>
                        . Follow the instructions for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Fax:</E>
                         202-493-2251.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail:</E>
                         U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590.
                    </P>
                    <P>
                        • 
                        <E T="03">Hand Delivery:</E>
                         Deliver to Mail address above between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.
                    </P>
                    <P>
                        <E T="03">AD Docket:</E>
                         You may examine the AD docket at 
                        <E T="03">regulations.gov</E>
                         under Docket No. FAA-2024-2543; or in person at Docket Operations between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this NPRM, the mandatory continuing airworthiness information (MCAI), any comments received, and other information. The street address for Docket Operations is listed above.
                    </P>
                    <P>
                        <E T="03">Material Incorporated by Reference:</E>
                    </P>
                    <P>
                        • For Bombardier material identified in this proposed AD, contact Bombardier Business Aircraft Customer Response Center, 400 Côte-Vertu Road West, Dorval, Québec H4S 1Y9, Canada; telephone 514-855-2999; email 
                        <E T="03">ac.yul@aero.bombardier.com;</E>
                         website 
                        <E T="03">bombardier.com</E>
                        .
                    </P>
                    <P>• You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 2200 South 216th St., Des Moines, WA. For information on the availability of this material at the FAA, call 206-231-3195.</P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Joseph Catanzaro, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: 516-228-7300; email: 
                        <E T="03">9-avs-nyaco-cos@faa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <HD SOURCE="HD1">Comments Invited</HD>
                <P>
                    The FAA invites you to send any written relevant data, views, or arguments about this proposal. Send your comments to an address listed under the 
                    <E T="02">ADDRESSES</E>
                     section. Include “Docket No. FAA-2024-2543; Project Identifier MCAI-2024-00342-T” at the beginning of your comments. The most helpful comments reference a specific portion of the proposal, explain the reason for any recommended change, and include supporting data. The FAA will consider all comments received by the closing date and may amend the proposal because of those comments.
                </P>
                <P>
                    Except for Confidential Business Information (CBI) as described in the following paragraph, and other information as described in 14 CFR 11.35, the FAA will post all comments received, without change, to 
                    <E T="03">regulations.gov</E>
                    , including any personal information you provide. The agency will also post a report summarizing each substantive verbal contact received about this NPRM.
                </P>
                <HD SOURCE="HD1">Confidential Business Information</HD>
                <P>
                    CBI is commercial or financial information that is both customarily and actually treated as private by its owner. Under the Freedom of Information Act (FOIA) (5 U.S.C. 552), CBI is exempt from public disclosure. If your comments responsive to this NPRM contain commercial or financial information that is customarily treated as private, that you actually treat as private, and that is relevant or responsive to this NPRM, it is important that you clearly designate the submitted comments as CBI. Please mark each page of your submission containing CBI as “PROPIN.” The FAA will treat such marked submissions as confidential under the FOIA, and they will not be placed in the public docket of this NPRM. Submissions containing CBI should be sent to Joseph Catanzaro, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: 516-228-7300; email: 
                    <E T="03">9-avs-nyaco-cos@faa.gov.</E>
                     Any commentary that the FAA receives which is not specifically designated as CBI will be placed in the public docket for this rulemaking.
                </P>
                <HD SOURCE="HD1">Background</HD>
                <P>Transport Canada, which is the aviation authority for Canada, has issued Transport Canada AD CF-2024-22, dated June 13, 2024 (Transport Canada AD CF-2024-22) (also referred to after this as the MCAI), to correct an unsafe condition on all Bombardier, Inc., Model BD-700-2A12 airplanes. The MCAI states that it was discovered that a partial loss of thrust after an engine failure during an RNP-AR approach under certain WAT conditions, may lead to a descent below 75 foot of the path guidance, requiring a go-around. The resultant vertical deviation may exceed allowable approach containment for obstacle clearance and may largely reduce the safety margins in the missed approach.</P>
                <P>The FAA is proposing this AD to address the unsafe condition on these products.</P>
                <P>
                    You may examine the MCAI in the AD docket at 
                    <E T="03">regulations.gov</E>
                     under Docket No. FAA__.
                    <PRTPAGE P="93529"/>
                </P>
                <HD SOURCE="HD1">Material Incorporated by Reference Under 1 CFR Part 51</HD>
                <P>The FAA reviewed (Bombardier) Global 7500 Airplane Flight Manual Temporary Revision TR-58, dated March 21, 2024. This material specifies procedures to update WAT tables for RNP-AR approach operations to contain possible vertical deviations within the 75 foot requirement.</P>
                <P>
                    This material is reasonably available because the interested parties have access to it through their normal course of business or by the means identified in the 
                    <E T="02">ADDRESSES</E>
                     section.
                </P>
                <HD SOURCE="HD1">FAA's Determination</HD>
                <P>This product has been approved by the aviation authority of another country and is approved for operation in the United States. Pursuant to the FAA's bilateral agreement with this State of Design Authority, it has notified the FAA of the unsafe condition described in the MCAI and material referenced above. The FAA is issuing this NPRM after determining that the unsafe condition described previously is likely to exist or develop on other products of the same type design.</P>
                <HD SOURCE="HD1">Proposed AD Requirements in This NPRM</HD>
                <P>This proposed AD would require a revision to the existing AFM to incorporate updated WAT tables for RNP-AR approach operations that contain possible vertical deviations within the 75 foot requirement.</P>
                <HD SOURCE="HD1">Compliance With AFM Revisions</HD>
                <P>Transport Canada AD CF-2024-22 requires operators to “advise all flight crews” of revisions to the AFM, and thereafter to “operate the aeroplane accordingly.” However, this proposed AD would not specifically require those actions as those actions are already required by FAA regulations.</P>
                <P>FAA regulations require operators furnish to pilots any changes to the AFM (for example, 14 CFR 121.137), and to ensure the pilots are familiar with the AFM (for example, 14 CFR 91.505). As with any other flightcrew training requirement, training on the updated AFM content is tracked by the operators and recorded in each pilot's training record, which is available for the FAA to review. FAA regulations also require pilots to follow the procedures in the existing AFM including all updates. 14 CFR 91.9 requires that any person operating a civil aircraft must comply with the operating limitations specified in the AFM. Therefore, including a requirement in this proposed AD to operate the airplane according to the revised AFM would be redundant and unnecessary.</P>
                <HD SOURCE="HD1">Costs of Compliance</HD>
                <P>The FAA estimates that this AD, if adopted as proposed, would affect 70 airplanes of U.S. registry. The FAA estimates the following costs to comply with this proposed AD:</P>
                <GPOTABLE COLS="4" OPTS="L2,i1" CDEF="s100,12C,12C,12C">
                    <TTITLE>Estimated Costs for Required Actions</TTITLE>
                    <BOXHD>
                        <CHED H="1">Labor cost</CHED>
                        <CHED H="1">Parts cost</CHED>
                        <CHED H="1">
                            Cost per 
                            <LI>product</LI>
                        </CHED>
                        <CHED H="1">Cost on U.S. operators</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">1 work-hour × $85 per hour = $85</ENT>
                        <ENT>$0</ENT>
                        <ENT>$85</ENT>
                        <ENT>$5,950</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII: Aviation Programs, describes in more detail the scope of the Agency's authority.</P>
                <P>The FAA is issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701: General requirements. Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.</P>
                <HD SOURCE="HD1">Regulatory Findings</HD>
                <P>The FAA determined that this proposed AD would not have federalism implications under Executive Order 13132. This proposed AD would not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.</P>
                <P>For the reasons discussed above, I certify this proposed regulation:</P>
                <P>(1) Is not a “significant regulatory action” under Executive Order 12866,</P>
                <P>(2) Would not affect intrastate aviation in Alaska, and</P>
                <P>(3) Would not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 14 CFR Part 39</HD>
                    <P>Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Proposed Amendment</HD>
                <P>Accordingly, under the authority delegated to me by the Administrator, the FAA proposes to amend 14 CFR part 39 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 39—AIRWORTHINESS DIRECTIVES</HD>
                </PART>
                <AMDPAR>1. The authority citation for part 39 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority:</HD>
                    <P> 49 U.S.C. 106(g), 40113, 44701.</P>
                </AUTH>
                <SECTION>
                    <SECTNO>§ 39.13</SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <AMDPAR>2. The FAA amends § 39.13 by adding the following new airworthiness directive:</AMDPAR>
                <EXTRACT>
                    <FP SOURCE="FP-2">
                        <E T="04">Bombardier, Inc.:</E>
                         Docket No. FAA-2024-2543; Project Identifier MCAI-2024-00342-T.
                    </FP>
                    <HD SOURCE="HD1">(a) Comments Due Date</HD>
                    <P>The FAA must receive comments on this airworthiness directive (AD) by January 13, 2025.</P>
                    <HD SOURCE="HD1">(b) Affected ADs</HD>
                    <P>None.</P>
                    <HD SOURCE="HD1">(c) Applicability</HD>
                    <P>This AD applies to all Bombardier, Inc., Model BD-700-2A12 airplanes.</P>
                    <HD SOURCE="HD1">(d) Subject</HD>
                    <P>Air Transport Association (ATA) of America Code 34, Navigation.</P>
                    <HD SOURCE="HD1">(e) Unsafe Condition</HD>
                    <P>
                        This AD was prompted by the discovery that a partial loss of thrust after an engine failure during a required navigation performance authorization required (RNP-AR) approach under certain weight, altitude, and temperature (WAT) conditions, may lead to a descent below 75 feet of the path guidance, requiring a go-around. The resultant vertical deviation may exceed allowable approach containment for obstacle clearance and may reduce the safety margins in the missed approach.
                        <PRTPAGE P="93530"/>
                    </P>
                    <HD SOURCE="HD1">(f) Compliance</HD>
                    <P>Comply with this AD within the compliance times specified, unless already done.</P>
                    <HD SOURCE="HD1">(g) Revision of Existing Airplane Flight Manual (AFM)</HD>
                    <P>Within 30 days after the effective date of this AD, revise the existing AFM to include the information specified in (Bombardier) Global 7500 Airplane Flight Manual Temporary Revision TR-58, dated March 21, 2024.</P>
                    <HD SOURCE="HD1">(h) Additional AD Provisions</HD>
                    <P>The following provisions also apply to this AD:</P>
                    <P>
                        (1) 
                        <E T="03">Alternative Methods of Compliance (AMOCs):</E>
                         The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or responsible Flight Standards Office, as appropriate. If sending information directly to the manager of the International Validation Branch, send it to the attention of the person identified in paragraph (i) of this AD and email to: 
                        <E T="03">AMOC@faa.gov</E>
                        . Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the responsible Flight Standards Office.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Contacting the Manufacturer:</E>
                         For any requirement in this AD to obtain instructions from a manufacturer, the instructions must be accomplished using a method approved by the Manager, International Validation Branch, FAA; or Transport Canada; or Bombardier, Inc.'s, Transport Canada Design Approval Organization (DAO). If approved by the DAO, the approval must include the DAO-authorized signature.
                    </P>
                    <HD SOURCE="HD1">(i) Additional Information</HD>
                    <P>
                        For more information about this AD, contact Joseph Catanzaro, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: 516-228-7300; email: 
                        <E T="03">9-avs-nyaco-cos@faa.gov.</E>
                    </P>
                    <HD SOURCE="HD1">(j) Material Incorporated by Reference</HD>
                    <P>(1) The Director of the Federal Register approved the incorporation by reference of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.</P>
                    <P>(2) You must use this material as applicable to do the actions required by this AD, unless this AD specifies otherwise.</P>
                    <P>(i) (Bombardier) Global 7500 Airplane Flight Manual Temporary Revision TR-58, dated March 21, 2024.</P>
                    <P>(ii) Reserved</P>
                    <P>
                        (3) For material identified in this AD, contact Bombardier Business Aircraft Customer Response Center, 400 Côte-Vertu Road West, Dorval, Québec H4S 1Y9, Canada; telephone 514-855-2999; email 
                        <E T="03">ac.yul@aero.bombardier.com;</E>
                         website 
                        <E T="03">bombardier.com.</E>
                    </P>
                    <P>(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 2200 South 216th St., Des Moines, WA. For information on the availability of this material at the FAA, call 206-231-3195.</P>
                    <P>
                        (5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                        <E T="03">www.archives.gov/federal-register/cfr/ibr-locations</E>
                         or email 
                        <E T="03">fr.inspection@nara.gov.</E>
                    </P>
                </EXTRACT>
                <SIG>
                    <DATED>Issued on November 21, 2024.</DATED>
                    <NAME>Victor Wicklund,</NAME>
                    <TITLE>Deputy Director, Compliance &amp; Airworthiness Division, Aircraft Certification Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27784 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <CFR>14 CFR Part 71</CFR>
                <DEPDOC>[Docket No. FAA-2024-2530; Airspace Docket No. 24-ASO-33]</DEPDOC>
                <RIN>RIN 2120-AA66</RIN>
                <SUBJECT>Amendment of Class E Airspace; Ahoskie, NC</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of proposed rulemaking (NPRM).</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>This action proposes to amend Class E airspace extending upward from 700 feet above the surface for Ahoskie, NC, by adding airspace for ECU Health Roanoke Chowan Heliport, Ahoskie, NC. This action also proposes to amend the airport information for Tri-County at Henry Joyner Field Airport by updating the airport name and coordinates. Additionally, this action would bring the Ahoskie Class E airspace into compliance with FAA orders. Controlled airspace is necessary for the safety and management of instrument flight rules (IFR) operations at this airport.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be received on or before January 13, 2025.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>Send comments identified by FAA Docket No. FAA-2024-2530 and Airspace Docket No. 24-ASO-33 using any of the following methods:</P>
                    <P>
                        * 
                        <E T="03">Federal eRulemaking Portal:</E>
                         Go to 
                        <E T="03">www.regulations.gov</E>
                         and follow the online instructions for sending your comments electronically.
                    </P>
                    <P>
                        * 
                        <E T="03">Mail:</E>
                         Docket Operations, M-30; U.S. Department of Transportation, 1200 New Jersey Avenue SE, Room W12-140, West Building Ground Floor, Washington, DC 20590-0001.
                    </P>
                    <P>
                        * 
                        <E T="03">Hand Delivery or Courier:</E>
                         Take comments to Docket Operations in Room W12-140 of the West Building Ground Floor at 1200 New Jersey Avenue SE, Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except for Federal holidays.
                    </P>
                    <P>
                        * 
                        <E T="03">Fax:</E>
                         Fax comments to Docket Operations at (202) 493-2251.
                    </P>
                    <P>
                        <E T="03">Docket:</E>
                         Background documents or comments received may be read at 
                        <E T="03">www.regulations.gov</E>
                         at any time. Follow the online instructions for accessing the docket or go to the Docket Operations in Room W12-140 of the West Building Ground Floor at 1200 New Jersey Avenue SE, Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except for Federal holidays.
                    </P>
                    <P>
                        FAA Order JO 7400.11J Airspace Designations and Reporting Points and subsequent amendments can be viewed online at 
                        <E T="03">www.faa.gov/air_traffic/publications/.</E>
                         You may also contact the Rules and Regulations Group, Office of Policy, Federal Aviation Administration, 800 Independence Avenue SW, Washington, DC 20591; telephone: (202) 267-8783.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P> Marc Ellerbee, Operations Support Group, Eastern Service Center, Federal Aviation Administration, 1701 Columbia Avenue, College Park, GA 30337; Telephone: (404) 305-5589.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Authority for This Rulemaking</HD>
                <P>The FAA's authority to issue rules regarding aviation safety is found in Title 49 of the United States Code. Subtitle I, Section 106 describes the authority of the FAA Administrator. Subtitle VII, Aviation Programs, describes in more detail the scope of the agency's authority. This rulemaking is promulgated under the authority described in Subtitle VII, Part A, Subpart I, Section 40103. Under that section, the FAA is charged with prescribing regulations to assign the use of airspace necessary to ensure the safety of aircraft and the efficient use of airspace. This regulation is within the scope of that authority, as it would amend Class E airspace in Ahoskie, NC.</P>
                <HD SOURCE="HD1">Comments Invited</HD>
                <P>
                    The FAA invites interested persons to participate in this rulemaking by submitting written comments, data, or views. Comments are specifically invited on the overall regulatory, aeronautical, economic, environmental, and energy-related aspects of the proposal. The most helpful comments reference a specific portion of the proposal, explain the reason for any recommended change, and include supporting data. To ensure the docket does not contain duplicate comments, commenters should submit only one time if comments are filed electronically, or commenters should 
                    <PRTPAGE P="93531"/>
                    send only one copy of written comments if comments are filed in writing.
                </P>
                <P>The FAA will file in the docket all comments it receives, as well as a report summarizing each substantive public contact with FAA personnel concerning this proposed rulemaking. Before acting on this proposal, the FAA will consider all comments it receives on or before the closing date for comments. The FAA will consider comments filed after the comment period has closed if it is possible to do so without incurring expense or delay. The FAA may change this proposal in light of the comments it receives.</P>
                <P>
                    <E T="03">Privacy:</E>
                     In accordance with 5 U.S.C. 553(c), DOT solicits comments from the public to better inform its rulemaking process. DOT posts these comments, without edits, including any personal information the commenter provides, to 
                    <E T="03">www.regulations.gov,</E>
                     as described in the system of records notice (DOT/ALL-14 FDMS), which can be reviewed at 
                    <E T="03">www.dot.gov/privacy.</E>
                </P>
                <HD SOURCE="HD1">Availability of Rulemaking Documents</HD>
                <P>
                    An electronic copy of this document may be downloaded through the internet at 
                    <E T="03">www.regulations.gov.</E>
                     Recently published rulemaking documents can also be accessed through the FAA's web page at 
                    <E T="03">www.faa.gov/air_traffic/publications/airspace_amendments/.</E>
                </P>
                <P>
                    You may review the public docket containing the proposal, any comments received, and any final disposition in person in the Dockets Operations office (see 
                    <E T="02">ADDRESSES</E>
                     section for address, phone number, and hours of operations). An informal docket may also be examined during regular business hours at the office of the Eastern Service Center, Federal Aviation Administration, Room 210, 1701 Columbia Ave., College Park, GA 30337.
                </P>
                <HD SOURCE="HD1">Incorporation by Reference</HD>
                <P>
                    Class E airspace designations are published in Paragraph 6005 of FAA Order JO 7400.11, Airspace Designations and Reporting Points, which is incorporated by reference in 14 CFR 71.1 on an annual basis. This document proposes to amend the current version of that order, FAA Order JO 7400.11J, Airspace Designations and Reporting Points, dated July 31, 2024, and effective September 15, 2024. These updates will be published in the next update to FAA Order JO 7400.11. FAA Order JO 7400.11J is publicly available as listed in the 
                    <E T="02">ADDRESSES</E>
                     section of this document. FAA Order JO 7400.11J lists Class A, B, C, D, and E airspace areas, air traffic service routes, and reporting points.
                </P>
                <HD SOURCE="HD1">The Proposal</HD>
                <P>The FAA proposes an amendment to 14 CFR part 71 to amend Class E airspace by adding airspace extending upward from 700 feet above the surface within a 6-mile radius of ECU Health Roanoke Chowan Heliport, Ahoskie, NC. This action also proposes to correct the coordinates and airport name for Tri-County at Henry Joyner Field Airport. Additionally, this action would remove the city associated with the airport in the airspace legal description to comply with changes to FAA Order JO 7400.2P, Procedures for Handling Airspace Matters. Controlled airspace is necessary for the safety and management of instrument flight rules (IFR) operations in the area.</P>
                <HD SOURCE="HD1">Regulatory Notices and Analyses</HD>
                <P>The FAA has determined that this proposed regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. It, therefore, (1) is not a “significant regulatory action” under Executive Order 12866; (2) is not a “significant rule” under Department of Transportation (DOT) Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this proposed rule, when promulgated, will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.</P>
                <HD SOURCE="HD1">Environmental Review</HD>
                <P>This proposal will be subject to an environmental analysis in accordance with FAA Order 1050.1F, “Environmental Impacts: Policies and Procedures,” prior to any final regulatory action by the FAA.</P>
                <LSTSUB>
                    <HD SOURCE="HED">Lists of Subjects in 14 CFR Part 71</HD>
                    <P>Airspace, Incorporation by reference, Navigation (air).</P>
                </LSTSUB>
                <HD SOURCE="HD1">The Proposed Amendment</HD>
                <P>In consideration of the foregoing, the Federal Aviation Administration proposes to amend 14 CFR part 71 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 71—DESIGNATION OF CLASS A, B, C, D, AND E AIRSPACE AREAS; AIR TRAFFIC SERVICE ROUTES; AND REPORTING POINTS</HD>
                </PART>
                <AMDPAR>1. The authority citation for part 71 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority:</HD>
                    <P> 49 U.S.C. 106(f), 106(g); 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959-1963 Comp., p. 389.</P>
                </AUTH>
                <SECTION>
                    <SECTNO>§ 71.1</SECTNO>
                    <SUBJECT>[Amended]</SUBJECT>
                </SECTION>
                <AMDPAR>2. The incorporation by reference in 14 CFR 71.1 of FAA Order JO 7400.11J, Airspace Designations and Reporting Points, dated July 31, 2024, and effective September 15, 2024, is amended as follows: Paragraph 6005. Class E Airspace Areas Extending Upward from 700 feet or More Above the Surface of the Earth.</AMDPAR>
                <STARS/>
                <EXTRACT>
                    <HD SOURCE="HD1">ASO NC E5 Ahoskie, NC</HD>
                    <FP SOURCE="FP-2">Tri-County at Henry Joyner Field Airport, NC</FP>
                    <FP SOURCE="FP1-2">(Lat. 36°17′51″ N, long. 77°10′15″ W)</FP>
                    <FP SOURCE="FP-2">ECU Health Roanoke Chowan Heliport, NC</FP>
                    <FP SOURCE="FP1-2">(Lat. 36°17′5″ N, long. 76°59′44″ W)</FP>
                </EXTRACT>
                <P>That airspace extending upward from 700 feet above the surface within a 6.5-mile radius of Tri-County at Henry Joyner Field Airport and within a 6-mile radius of ECU Health Roanoke Chowan Heliport.</P>
                <STARS/>
                <SIG>
                    <DATED>Issued in College Park, Georgia, on November 21, 2024.</DATED>
                    <NAME>Patrick Young,</NAME>
                    <TITLE>Manager, Airspace &amp; Procedures Team North, Eastern Service Center, Air Traffic Organization.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27697 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF THE INTERIOR</AGENCY>
                <SUBAGY>National Park Service</SUBAGY>
                <CFR>36 CFR Parts 7 and 21</CFR>
                <DEPDOC>[NPS-HOSP-DTS38124; XXXP1039C6, PPMWHOSPM0, PRCRURUC6.U00000]</DEPDOC>
                <RIN>RIN 1024-AE86</RIN>
                <SUBJECT>Hot Springs National Park; Use of Thermal Water and Commercial Passenger-Carrying Vehicles</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Park Service, Interior.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Proposed rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The National Park Service (NPS) proposes to amend the special regulations for Hot Springs National Park to update regulations about the use of thermal water. The NPS also proposes to remove outdated regulations concerning commercial passenger-carrying motor vehicles.</P>
                </SUM>
                <EFFDATE>
                    <PRTPAGE P="93532"/>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments on the proposed rule must be received by 11:59 p.m. ET on January 27, 2025.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments, identified by Regulation Identifier Number (RIN) 1024-AE86, by either of the following methods:</P>
                    <P>
                        (1) 
                        <E T="03">Electronically:</E>
                         Go to the Federal eRulemaking Portal: 
                        <E T="03">https://www.regulations.gov/.</E>
                         Follow the instructions for submitting comments.
                    </P>
                    <P>
                        (2) 
                        <E T="03">By hard copy:</E>
                         Mail to: Superintendent, Hot Springs National Park, 101 Reserve Street, Hot Springs, Arkansas 71901.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         Comments will not be accepted by fax, email, or in any way other than those specified above. All submissions received must include the words “National Park Service” or “NPS” and must include the docket number or RIN (1024-AE86) for this rulemaking. Comments received may be posted without change to 
                        <E T="03">https://www.regulations.gov/,</E>
                         including any personal information provided.
                    </P>
                    <P>
                        <E T="03">Docket:</E>
                         For access to the docket to read comments received, go to 
                        <E T="03">https://www.regulations.gov/</E>
                         and search for “1024-AE86”
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Laura Miller, Superintendent, Hot Springs National Park; (501)-620-6735; 
                        <E T="03">laura_a_miller@nps.gov.</E>
                         Individuals in the United States who are deaf, deafblind, hard of hearing, or have a speech disability may dial 711 (TTY, TDD, or TeleBraille) to access telecommunications relay services. Individuals outside the United States should use the relay services offered within their country to make international calls to the point-of-contact in the United States. In compliance with the Providing Accountability Through Transparency Act of 2023, the plain language summary of the proposal is available on 
                        <E T="03">Regulations.gov</E>
                         in the docket for this rulemaking.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Background</HD>
                <HD SOURCE="HD2">Purpose and Significance of Hot Springs National Park</HD>
                <P>Hot Springs National Park is a 5,500-acre park in Hot Springs, Arkansas, located approximately 55 miles southwest of Little Rock, Arkansas. The U.S. Congress created the park in 1832 when it designated the land as Hot Springs Reservation. In 1921, the reservation name was changed to Hot Springs National Park. Today, the NPS administers the park as one of more than 400 units of the National Park System.</P>
                <P>The purpose of the park is to protect its unique geothermal spring water and associated lands for public health, wellness, and enjoyment. The park encompasses mostly forested mountains but includes a developed urban edge formed by Bathhouse Row, which was designated a national historic landmark in 1987. The NPS preserves and manages natural and cultural resources in the park for over 1.5 million annual visitors. Geothermal spring water originating within the park provides ample opportunities for public recreation, health, and wellness activities, including therapeutic bathing. The NPS collects and distributes thermal water to public fountains and to various entities (referred to collectively as bathhouses), including spas, a hotel, and a brewery, within and outside the park. The public uses and enjoys thermal water in bathhouses, by viewing display springs, and by collecting and drinking water free of charge from public fountains.</P>
                <HD SOURCE="HD2">Legal Framework for the Use of Thermal Water</HD>
                <P>Under the NPS Organic Act of 1916, the NPS has broad authority to regulate the use of the lands and waters within National Park System units. See 54 U.S.C. 100101; 100751(a). The enabling act that established Hot Springs National Park, now codified at 16 U.S.C. Subchapter XL, specifically authorizes the NPS to make all needful rules and regulations regarding the use of thermal water, including the use of thermal water by bathhouses. 16 U.S.C. 363. The park's enabling act authorizes specific uses and establishes conditions for the use of thermal water. 16 U.S.C. 361-363. In 1959, the NPS promulgated regulations, now codified at 36 CFR 7.18(b), prohibiting the removal of water from any source of supply within the park for the purpose of sale, or for any use other than personal drinking. In 1979, the NPS promulgated regulations, now codified at 36 CFR part 21, governing bathhouses that receive thermal water originating in the park and use it for purposes authorized by the superintendent. These regulations primarily address bathing in thermal water for medical treatment. They contain specific provisions about registration of prescribing physicians, health examinations for infectious or communicable diseases, and the control of persons with acute or infectious diseases and other maladies.</P>
                <P>Since 1979, the use of thermal water in bathhouses has evolved. Historical use of thermal water for medicinal purposes has been largely replaced by bathing for recreation or general health and wellness. The NPS receives requests for new uses of thermal water within and outside the park and the existing regulations do not clearly define procedures and standards for evaluating such requests. In particular, the existing regulations do not provide adequate notice about specific provisions in the park's enabling act about written instruments, priority users, surplus water, and rates and costs, none of which are addressed in the existing regulations.</P>
                <HD SOURCE="HD1">Proposed Rule</HD>
                <HD SOURCE="HD2">Summary of the Proposed Rule</HD>
                <P>The NPS proposes to update park regulations about the use of thermal water to reflect contemporary uses of water and provisions in the park's enabling act about the use of thermal water. For easier reference and improved transparency, all regulations addressing the use of thermal water would be located in paragraph (b) of § 7.18, rather than split between paragraph (b) of § 7.18 and part 21. This rule would remove part 21 in its entirety. This rule also would remove existing regulations in part 21 about registration of physicians (§ 21.4), requirements to have medical prescriptions before bathing (§ 21.5), control of persons with diseases and other maladies (§ 21.6), health examinations and infectious diseases (§ 21.7), solicitation by bathhouse employees for tips (§ 21.9), loss of personal valuables (§ 21.10), and the redemption and loss of bath tickets (§§ 21.11-21.12) as outdated and unnecessary because of changes in how the public uses thermal water and changes in how bathhouses operate.</P>
                <P>
                    In addition to updating regulations about the use of thermal water, this rule would revise existing paragraph (a) in § 7.18. This paragraph contains outdated permit and fee requirements for commercial passenger-carrying motor vehicles operating in the park. The NPS has a statutory authority to manage these services through commercial use authorizations (CUAs) that it did not have when paragraph (a) was promulgated. 54 U.S.C. 101925. Consistent with this authority, the NPS manages commercial passenger-carrying motor vehicles in the park through CUAs and applicable policy. In order to provide notice to the public, including affected service providers, this rule would replace the existing language in paragraph (a) with a statement that CUAs and fees for the operation of commercial passenger-carrying vehicles will be required in accordance with 54 U.S.C. 101925.
                    <PRTPAGE P="93533"/>
                </P>
                <P>Below is a paragraph-by-paragraph analysis of the proposed rule that explains changes to existing similar regulations, if any.</P>
                <HD SOURCE="HD1">Section-by-Section Analysis</HD>
                <HD SOURCE="HD2">Paragraph (b)(1)—Definitions</HD>
                <GPOTABLE COLS="2" OPTS="L2,tp0,i1" CDEF="s25,r25">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Proposed regulation</CHED>
                        <CHED H="1">Existing regulations</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">§ 7.18(b)(1) Definitions</ENT>
                        <ENT>• § 7.18(b) Use of water.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>• § 21.1 Definitions.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Existing regulations in § 21.1 define the terms “physician,” “registered physician,” “employee,” and “bathhouse”. The proposed rule would remove definitions for “physician” and “registered physician” because those terms would no longer be used in the regulations due to changes in how thermal water is used by the public. The existing definition of “employee” is any person licensed or certified by a State or territory in his or her specialty, or certified by the superintendent to perform special services in a bathhouse. The rule would remove the definition of “employee” as redundant with a provision in new paragraph (b)(3)(v) that would require bathhouses to ensure and maintain employee licenses and certifications where required by Federal or State law. The remainder of the existing definition of “employee” is outdated and unnecessary because the superintendent no longer issues such certifications.</P>
                <P>The proposed rule would simplify the definition of “bathhouse” by removing unnecessary references to individuals, trustees, partnerships, corporations, and business entities as potential operators, which is not relevant to the issue of authorized use of thermal water. Instead, the definition would simply state that bathhouse is a facility authorized to use thermal water for any purpose pursuant to a written instrument signed by the superintendent.</P>
                <P>The proposed rule would add a new definition of “bathing” to mean soaking in thermal water for health benefits. This definition is necessary to implement a distinction in the park's enabling act about rates charged to bathhouses for use of thermal water, explained below. The proposed rule would add a new definition of “thermal water” to mean water that emerges from springs, fountains, or other natural sources within the park. This language is similar to language in existing paragraph (b) of § 7.18 and serves to distinguish water that is subject to NPS administration, and water that is not. The rule would add a new definition of “use of thermal water” to mean heating, cooling, storing, removing from the park, combining with other substances, or otherwise altering thermal water in any manner. This definition is intentionally broad to include any possible use so that the NPS can effectively protect this resource through restrictions and conditions on the use of thermal water that appear elsewhere in the regulations. Finally, the rule would add a definition of “water treatment” to mean the introduction of any substance into thermal water, including chemicals, solutions, or other water. This type of use would be further defined because it requires specific approval by the NPS Office of Public Health (OPH), as explained below.</P>
                <HD SOURCE="HD2">Paragraph (b)(2)—Use of Thermal Water</HD>
                <GPOTABLE COLS="2" OPTS="L2,tp0,i1" CDEF="s25,r25">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Proposed regulation</CHED>
                        <CHED H="1">Existing regulations</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">§ 7.18(b)(2) Use of thermal water</ENT>
                        <ENT>• § 7.18(b) Use of water.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>• § 21.3 Use of thermal water.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Existing regulations in § 7.18(b) prohibit the carrying away of water, hot or cold, from any of the springs, fountains, or other sources of supply in the park for the purpose of sale, or for any use other than personal drinking. Existing regulations in § 21.3 prohibit the use of thermal waters for purposes other than those authorized by the superintendent. They further prohibit the heating, reheating, or otherwise increasing the temperature of thermal water, and the introduction of any substance, chemical, or other material or solution into thermal waters, except as may be prescribed by a physician for a bather or as may be directed by the superintendent.</P>
                <P>This rule would replace these existing regulations with new paragraph (b)(2) of § 7.18. In order to continue to protect the integrity of thermal water, new paragraph (b)(2)(i) would prohibit the use of thermal water except by individuals for personal consumption or as authorized in writing by the superintendent. As explained above, the new definition of “use of thermal water” would be broad enough to include any of the specific uses of water prohibited by the existing regulations.</P>
                <P>Under the rule, the superintendent's authority to allow use of thermal water would be limited to use that is consistent with the purposes of the park, including the protection of natural resource values. The park's Foundation Document (2022) states that the purpose of the park is to protect its geothermal spring water and associated lands for public health, wellness, and enjoyment. This regulatory provision, then, would allow the superintendent to authorize the use of thermal water for the general public welfare, to include, for example, use of thermal water for bathing, drinking, and relaxation, but not in a manner that is inconsistent with the mandate to protect the resource. The rule would more specifically prevent the superintendent from authorizing the removal of thermal water from the park for direct sale or use in products for sale. This would not prevent the superintendent from authorizing the use of thermal water by bathhouses that are commercial operations. Historic and contemporary bathhouses have and continue to operate as commercial businesses, such as spas, hotels, and (most recently) a brewery. This provision, similar to existing § 7.18(b), would prohibit the commercial exploitation of thermal water as a product that is created, packaged, and sold outside of the park or any bathhouse. These types of uses are too far removed from the establishment of the park as an in-situ reserve where the public can visit and benefit from thermal water originating in the park.</P>
                <P>The last sentence of new paragraph (b)(2)(i) would state that the superintendent, in addition to any other appropriate written instrument, may use lease agreements to authorize the use of thermal water, but only those lease agreements specifically authorized by the park's enabling legislation. The NPS intends this specific reference to the park's enabling legislation to clarify that lease agreements entered into by the NPS under its general leasing authority in 54 U.S.C. 102102, as implemented by NPS regulations in 36 CFR part 18, should not be used to authorize the use of thermal water.</P>
                <P>
                    New paragraph (b)(2)(ii) would require all water treatment to be approved by the OPH, and be limited to the minimum amount and type necessary for the maintenance of public health and safety, as determined by the OPH.
                    <SU>1</SU>
                    <FTREF/>
                     This provision would codify an additional level of protection for thermal water in NPS regulations. This is consistent with existing practice, as NPS staff at the park work closely with OPH officers to maintain the health and safety of thermal water. The rule would not include the allowance in existing § 7.18(b) that physicians can prescribe the introduction of substances into thermal water for a bather. Bathing for medicinal purposes is not a 
                    <PRTPAGE P="93534"/>
                    contemporary use of thermal water and the employees of the OPH are more appropriate subject matter experts than personal physicians to determine the potential impacts of water treatment on public health.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Water treatment also may be subject to approvals from local, county or State officials that have been delegated authority to enforce Federal statutes such as the Safe Drinking Water Act.
                    </P>
                </FTNT>
                <P>New paragraphs (b)(2)(iii)-(v) would codify in NPS regulations, for the first time, provisions in the park's enabling act that establish priority uses of thermal water by bathhouses located within and outside of the park. Restating these provisions in a more accessible format would benefit the NPS and existing and prospective bathhouses. Bathhouses would better understand how the park's enabling act prioritizes the use of thermal water among authorized users. Bathhouses also would better understand the requirement that there be a surplus of thermal water before the superintendent can authorize bathhouses located outside of the park, except for the Arlington Hotel, to use thermal water. New paragraph (b)(2)(iii) would restate the order of priority for using thermal water, consistent with 16 U.S.C. 362:</P>
                <P>1. Bathhouses located within the park, in the order in which they were authorized to use thermal water.</P>
                <P>2. Arlington Hotel.</P>
                <P>3. Bathhouses located outside of the park, in the order in which they were authorized to use thermal water, and only when the Superintendent has determined that there is a surplus of thermal water.</P>
                <P>The park's enabling act refers to the “Army and Navy hospital bathhouse” and the “public bathhouse” as having priority use before any of the bathhouses identified in the rule. These entities are not listed in the rule, however, because the Army and Navy hospital bathhouse ceased operation in 1959 and the public bathhouse, which referred to the Libbey Physical Medicine Center, ceased operation in 2005. In the future, if new bathhouses are established in either location, they would be categorized as bathhouses located within the park, and have priority use relative to other bathhouses within the park in the order in which they were authorized to use thermal water, but always before the Arlington Hotel and other bathhouses located outside of the park. The Arlington Hotel is located outside of the park and is specifically named in the park's enabling act as having priority use of thermal water in the order identified in the rule. Although it is located outside of the park, the superintendent is not required to determine there is a surplus of thermal water before authorizing the Arlington Hotel to use thermal water pursuant to a written instrument due to its specific mention in the enabling act. Currently, Levi Hospital is the only other bathhouse located outside of the park that is authorized to use thermal water. Levi Hospital is not named in the enabling act and its use of thermal water is conditioned upon the superintendent determining there is a surplus of thermal water. As long as it remains in continuous operation, its use of thermal water will have priority over other bathhouses located outside of the park that may be authorized to use thermal water in the future.</P>
                <P>
                    New paragraph (b)(2)(iv) would explain that a surplus of thermal water exists when, after accounting for all of the thermal water that bathhouses located within the park and the Arlington Hotel are authorized to use, the superintendent determines that additional thermal water may be used by other bathhouses located outside of the park in a manner that would not conflict with the requirements of applicable Federal laws and policies, including those that require the NPS to preserve the resources of the park. When the superintendent evaluates whether there is a surplus, the relevant value is the full amount of thermal water that may be used by bathhouses within the park and the Arlington Hotel, not the amount of thermal water actually used by those bathhouses at any time. The superintendent then must evaluate whether there is any remaining thermal water that could be used by other bathhouses, and whether such use would violate any applicable Federal laws (
                    <E T="03">e.g.,</E>
                     the park's enabling act and the NPS Organic Act) or any applicable Federal policies (
                    <E T="03">e.g.,</E>
                     NPS Management Policies 2006). This includes an evaluation of whether additional use of thermal water will cause impairment of park resources, including wildlife and other natural features in the park that use or depend on the water. The superintendent must determine there is a surplus of water before signing a written instrument authorizing the use of thermal water by a bathhouse located outside of the park.
                </P>
                <P>New paragraph (b)(2)(v) would require the NPS to provide adequate notice to bathhouses that have lower priority use authorizations before it authorizes a bathhouse higher in the order of priority to use thermal water. This paragraph would further require the NPS to provide adequate notice to bathhouses located outside of the park, other than the Arlington Hotel, if the superintendent's determination that there is a surplus of thermal water changes in a manner that will impact their authorizations to use thermal water. These provisions would help ensure that bathhouses have reasonable notice about potential decreases in the amount of thermal water they are authorized to use. This would allow them to adjust operations and notify customers about impacts to offered products and services. The superintendent may change the amount of thermal water bathhouses are authorized to use based upon determinations of surplus or determinations that use would be inconsistent with the purposes of the park, notwithstanding the terms and conditions of any written instrument authorizing use of thermal water.</P>
                <P>New paragraph (b)(2)(vi) would require bathhouses to have a thermal water management plan approved by the superintendent and the OPH, with an additional requirement that thermal water management plans for bathhouses located outside of the park also must be approved by the Arkansas Department of Health, as required by State law. Thermal water management plans are already required as a term and condition of all written instruments authorizing bathhouses to use thermal water. Including this requirement in the regulations would provide additional notice and transparency for bathhouses.</P>
                <P>The park's enabling act vests full power to the Secretary, acting through the NPS, to promulgate regulations that authorize the superintendent to examine and inspect at any time the manner of using thermal water in any bathtub. 16 U.S.C. 363. Consistent with this authority, new paragraph (b)(2)(vii) would give the superintendent (or someone with delegated authority) the right to examine and inspect the use of thermal water by a bathhouse at reasonable times to determine whether the bathhouse is being operated in accordance with the terms and conditions of the written instrument authorizing the use of thermal water, the approved thermal water management plan, and with the provisions of the regulations.</P>
                <HD SOURCE="HD2">Paragraph (b)(3)—Prohibited Acts</HD>
                <GPOTABLE COLS="2" OPTS="L2,tp0,i1" CDEF="s25,r25">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Proposed regulation</CHED>
                        <CHED H="1">Existing regulations</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">§ 7.18(b)(3) Prohibited acts</ENT>
                        <ENT>• § 21.1 Definitions.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>• § 21.2 Penalties</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>• § 21.8 Employee certification.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    The park's enabling act authorizes the Secretary, acting through the NPS, to provide penalties for the violation of any regulation as to the use of thermal water, including the cancellation of any lease for the use of such water. 16 U.S.C. 363. Consistent with this authorization, 
                    <PRTPAGE P="93535"/>
                    new paragraphs (b)(3)(i)-(v) would identify prohibited acts and state that they may result in the revocation or suspension of a written authorization to use thermal water. Prohibited acts would be failures to:
                </P>
                <P>• comply with a written instrument authorizing the use of thermal water;</P>
                <P>• comply with a provision of an approved water management plan;</P>
                <P>• make a required payment;</P>
                <P>• operate a pool or spa without appropriate certification, as determined by the OPH;</P>
                <P>• ensure and maintain employee licenses and certifications where required by Federal or State law; and</P>
                <P>• comply with any regulations addressing the use of thermal water.</P>
                <P>This list of prohibited acts would provide notice and transparency to bathhouses about the repercussions of certain actions. Existing regulations in § 21.1 and § 21.8 require persons performing special services in bathhouses, such as physical therapy, massage, and attending to baths, to be licensed or certified by a State or U.S. territory, or by the superintendent upon completion of examinations and (for bath attendants) an apprenticeship. Individuals who provide special services in bathhouses are already subject to licensing and certification requirements under applicable law. Rather than imposing those requirements again in NPS regulations, new paragraph (b)(3)(v) would instead hold bathhouses accountable for the services they offer their customers by requiring bathhouses to ensure and maintain employee licenses and certifications where required by Federal or State law. The superintendent no longer examines or certifies bathhouse employees. As a result, those provisions also would be removed.</P>
                <P>Existing regulations in § 21.2 state that any person convicted of violating any regulation in part 21 shall be punished by a fine not exceeding $100 and be adjudged to pay all costs of the proceedings. Existing regulations in 36 CFR 1.3 state that a person convicted of violating any regulation in parts 1 through 7, part 9 subpart B, and parts 12 and 13, shall be subject to the criminal penalties provided under 18 U.S.C. 1865. As a result of moving all regulations about the use of thermal water to § 7.18, a violation of any provision of the rule would result in criminal penalties under § 1.3. New paragraph (b)(3)(vi) would state this explicitly for additional notice and transparency.</P>
                <HD SOURCE="HD2">Paragraph (b)(4)—Rates and Cost Recovery</HD>
                <GPOTABLE COLS="2" OPTS="L2,tp0,i1" CDEF="s25,r25">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Proposed regulation</CHED>
                        <CHED H="1">Existing regulation</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">§ 7.18(b)(4) Rates and cost recovery</ENT>
                        <ENT>N/A.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The park's enabling act requires the NPS to charge bathhouses the same rates for thermal water that will be used for bathing, but allows the superintendent to charge bathhouses individual rates for thermal water that will not be used for bathing. 16 U.S.C. 362. The park's enabling act requires bathhouses located outside of the park that are authorized to use thermal water if there is a surplus, to pay all costs associated with connections for obtaining such thermal water. 16 U.S.C. 362. The park's enabling act requires the superintendent to readjust the terms and amounts of payment required under a written instrument authorizing the use of thermal water every five years during the term of the instrument. 16 U.S.C. 362. As stated above, the park's enabling act authorizes the NPS to make all needful rules and regulations regarding the use of thermal water, including the use of thermal water by bathhouses, and specifically states that such regulations can be made to prevent waste and be what the NPS deems best for the public interest. 16 U.S.C. 363.</P>
                <P>In order to provide additional notice and transparency to bathhouses, this rule would include regulations that address rates and cost recovery for the use of thermal water that are consistent with the statutory authorities discussed above. All of these proposed provisions reflect current practice by the NPS. New paragraph (b)(4)(i) would state that rates charged for thermal water will be specified in the written instrument authorizing the use of thermal water. New paragraph (b)(4)(ii) would state that rates for thermal water that will be used for bathing will be the same for all bathhouses, and that rates for thermal water that will not be used for bathing will be determined by the superintendent for each bathhouse. New paragraph (b)(4)(iii) would state that bathhouses located outside of the park that may be authorized to use thermal water if there is a surplus must pay all costs incurred by the NPS associated with connections for obtaining such thermal water. Connection costs include all costs incurred from activities that cause the connections to be made. These may include, but are not limited to, design and construction costs, and costs incurred to comply with applicable laws and policies, such as the National Environmental Policy Act and the National Historic Preservation Act. New paragraph (b)(4)(iv) would state that written instruments authorizing the use of thermal water may require bathhouses to reimburse the NPS for costs incurred from the distribution of thermal water and maintenance of the distribution system. The ability of the NPS to recover these costs, when appropriate, will help ensure that thermal water is distributed safely, efficiently, and without waste. Finally, new paragraph (b)(5)(v) would state that the NPS will readjust the terms and amounts of payments required under a written instrument authorizing the use of thermal water at least every five years during its term and upon the renewal of a written instrument at the end of its term.</P>
                <HD SOURCE="HD1">Compliance With Other Laws, Executive Orders and Department Policy</HD>
                <HD SOURCE="HD2">Regulatory Planning and Review (Executive Orders 12866 and 13563 and 14094)</HD>
                <P>Executive Order 12866, as amended by Executive Order 14094, provides that the Office of Information and Regulatory Affairs (OIRA) in the Office of Management and Budget will review all significant rules. OIRA has determined that the proposed rule is not significant.</P>
                <P>Executive Order 14094 amends Executive Order 12866 and reaffirms the principles of Executive Order 12866 and Executive Order 13563 and states that regulatory analysis should facilitate agency efforts to develop regulations that serve the public interest, advance statutory objectives, and be consistent with Executive Order 12866, Executive Order 13563, and the Presidential Memorandum of January 20, 2021 (Modernizing Regulatory Review). Regulatory analysis, as practicable and appropriate, shall recognize distributive impacts and equity, to the extent permitted by law.</P>
                <P>
                    Executive Order 13563 reaffirms the principles of Executive Order 12866 while calling for improvements in the nation's regulatory system to promote predictability, to reduce uncertainty, and to use the best, most innovative, and least burdensome tools for achieving regulatory ends. Executive Order 13563 directs agencies to consider regulatory approaches that reduce burdens and maintain flexibility and freedom of choice for the public where these approaches are relevant, feasible, and consistent with regulatory objectives. Executive Order 13563 emphasizes further that regulations must be based on the best available science and that the rulemaking process 
                    <PRTPAGE P="93536"/>
                    must allow for public participation and an open exchange of ideas. The NPS has developed this proposed rule in a manner consistent with these requirements.
                </P>
                <HD SOURCE="HD2">Regulatory Flexibility Act</HD>
                <P>
                    This proposed rule would not have a significant economic effect on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 
                    <E T="03">et seq.</E>
                    ). This certification is based on information contained in the economic analyses found in the report entitled ” Regulatory Analysis of the Use of Thermal Water and Commercial Passenger-Carrying Vehicles at Hot Springs National Park Proposed Rule.” The report may be viewed in the docket for this rulemaking action by visiting 
                    <E T="03">https://www.regulations.gov/</E>
                     and searching for “RIN 1024-AE86”.
                </P>
                <HD SOURCE="HD2">Congressional Review Act</HD>
                <P>This proposed rule is not a major rule under 5 U.S.C. 804(2). This proposed rule:</P>
                <P>(a) Does not have an annual effect on the economy of $100 million or more.</P>
                <P>(b) Will not cause a major increase in costs or prices for consumers, individual industries, Federal, State, or local government agencies, or geographic regions.</P>
                <P>(c) Does not have significant adverse effects on competition, employment, investment, productivity, innovation, or the ability of U.S.-based enterprises to compete with foreign-based enterprises.</P>
                <HD SOURCE="HD2">Unfunded Mandates Reform Act</HD>
                <P>
                    This proposed rule does not impose an unfunded mandate on State, local, or Tribal governments or the private sector of more than $100 million per year. The proposed rule does not have a significant or unique effect on State, local or Tribal governments or the private sector. It addresses public use of national park lands and imposes no requirements on other agencies or governments. A statement containing the information required by the Unfunded Mandates Reform Act (2 U.S.C. 1531 
                    <E T="03">et seq.</E>
                    ) is not required.
                </P>
                <HD SOURCE="HD2">Takings (Executive Order 12630)</HD>
                <P>This proposed rule does not effect a taking of private property or otherwise have takings implications under Executive Order 12630. A takings implication assessment is not required.</P>
                <HD SOURCE="HD2">Federalism (Executive Order 13132)</HD>
                <P>Under the criteria in section 1 of Executive Order 13132, the proposed rule does not have sufficient federalism implications to warrant the preparation of a Federalism summary impact statement. This proposed rule only affects use of federally administered lands and waters. It has no direct effects on other areas. A Federalism summary impact statement is not required.</P>
                <HD SOURCE="HD2">Civil Justice Reform (Executive Order 12988)</HD>
                <P>This proposed rule complies with the requirements of Executive Order 12988. This proposed rule:</P>
                <P>(a) Meets the criteria of section 3(a) requiring that all regulations be reviewed to eliminate errors and ambiguity and be written to minimize litigation; and</P>
                <P>(b) Meets the criteria of section 3(b)(2) requiring that all regulations be written in clear language and contain clear legal standards.</P>
                <HD SOURCE="HD2">Consultation With Indian Tribes (Executive Order 13175 and Department Policy)</HD>
                <P>The Department of the Interior strives to strengthen its government-to-government relationship with Indian Tribes through a commitment to consultation with Indian Tribes and recognition of their right to self-governance and Tribal sovereignty. The NPS has evaluated this proposed rule under the criteria in Executive Order 13175 and under the Department's Tribal consultation policy and has determined that Tribal consultation is not required because the proposed rule will have no substantial direct effect on federally recognized Indian Tribes. Nevertheless, in support of the Department of the Interior's and the NPS's commitment to government-to-government consultation, the NPS intends to coordinate with Indian Tribes that are traditionally associated with the land that is now part of the park, including the Caddo Nation, Quapaw Nation, Osage Nation, Shawnee Tribe, and Absentee Shawnee.</P>
                <HD SOURCE="HD2">Paperwork Reduction Act</HD>
                <P>
                    This proposed rule contains existing information collections. All information collections require approval under the Paperwork Reduction Act of 1995 (PRA; 44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    ). The NPS may not conduct or sponsor and you are not required to respond to a collection of information unless it displays a currently valid OMB control number. The OMB has reviewed and approved the information collection requirements associated with NPS Form 10-550 “Commercial Use Authorization Application” and assigned OMB control number 1024-0268 (currently under review for renewal; the Information Collection Request was submitted to OMB on 3/29/2023).
                </P>
                <HD SOURCE="HD2">National Environmental Policy Act</HD>
                <P>This proposed rule does not constitute a major Federal action significantly affecting the quality of the human environment. A detailed statement under the National Environmental Policy Act of 1969 (NEPA) is not required because the rule is covered by a categorical exclusion. NPS NEPA Handbook (2015) Section 3.3.A.8 allows for the following to be categorically excluded: Modifications or revisions to existing regulations or the promulgation of new regulations for NPS-administered areas, provided the modifications, revisions, or new regulations do not:</P>
                <P>a. Increase public use to the extent of compromising the nature and character of the area or causing physical damage to it,</P>
                <P>b. Introduce noncompatible uses that might compromise the nature and characteristics of the area or cause physical damage to it,</P>
                <P>c. Conflict with adjacent ownerships or land uses, or</P>
                <P>d. Cause a nuisance to adjacent owners or occupants.</P>
                <P>The NPS has also determined that the proposed rule does not involve any of the extraordinary circumstances listed in 43 CFR 46.215 that would require further analysis under NEPA.</P>
                <HD SOURCE="HD2">Effects on the Energy Supply (Executive Order 13211)</HD>
                <P>This proposed rule is not a significant energy action under the definition in Executive Order 13211; the proposed rule is not likely to have a significant adverse effect on the supply, distribution, or use of energy, and the rule has not otherwise been designated by the Administrator of OIRA as a significant energy action. A Statement of Energy Effects in not required.</P>
                <HD SOURCE="HD1">Clarity of This Rule</HD>
                <P>The NPS is required by Executive Orders 12866 (section 1(b)(12)) and 12988 (section 3(b)(1)(B)), and 13563 (section 1(a)), and by the Presidential Memorandum of June 1, 1998, to write all rules in plain language. This means that each rule the NPS publishes must:</P>
                <P>(a) Be logically organized;</P>
                <P>(b) Use the active voice to address readers directly;</P>
                <P>(c) Use common, everyday words and clear language rather than jargon;</P>
                <P>(d) Be divided into short sections and sentences; and</P>
                <P>(e) Use lists and tables wherever possible.</P>
                <P>
                    If you feel that the NPS has not met these requirements, send us comments by one of the methods listed in the 
                    <PRTPAGE P="93537"/>
                    <E T="02">ADDRESSES</E>
                     section. To better help the NPS revise the rule, your comments should be as specific as possible. For example, you should identify the numbers of the sections or paragraphs that you find unclear, which sections or sentences are too long, the sections where you feel lists or tables would be useful, etc.
                </P>
                <HD SOURCE="HD1">Public Participation</HD>
                <P>
                    It is the policy of the Department of the Interior, whenever practicable, to afford the public an opportunity to participate in the rulemaking process. Accordingly, interested persons may submit written comments regarding this proposed rule by one of the methods listed in the 
                    <E T="02">ADDRESSES</E>
                     section of this document.
                </P>
                <HD SOURCE="HD1">Public Availability of Comments</HD>
                <P>Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time.</P>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects</HD>
                    <CFR>36 CFR Part 7</CFR>
                    <P>National parks, Reporting and Recordkeeping requirements.</P>
                    <CFR>36 CFR Part 21</CFR>
                    <P>National parks.</P>
                </LSTSUB>
                <P>For the reasons stated in the preamble, and under the authority of 16 U.S.C. 363 and 54 U.S.C. 100751, the National Park Service proposes to amend 36 CFR chapter I, as set forth below:</P>
                <PART>
                    <HD SOURCE="HED">PART 7—SPECIAL REGULATIONS, AREAS OF THE NATIONAL PARK SYSTEM</HD>
                </PART>
                <AMDPAR>1. The authority citation for part 7 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority:</HD>
                    <P> 54 U.S.C. 100101, 100751, 320102; Sec. 7.96 also issued under DC Code 10-137 and DC Code 50-2201.07.</P>
                </AUTH>
                <AMDPAR>2. Amend § 7.18 by revising paragraphs (a) and (b) to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 7.18</SECTNO>
                    <SUBJECT>Hot Springs National Park.</SUBJECT>
                    <P>
                        (a) 
                        <E T="03">Commercial passenger-carrying vehicles.</E>
                         Commercial use authorizations and fees for the operation of commercial passenger-carrying vehicles carrying passengers for hire over park roads will be required in accordance with 54 U.S.C. 101925.
                    </P>
                    <P>
                        (b) 
                        <E T="03">Thermal water.</E>
                         The regulations contained in this paragraph (b) apply to the use of thermal water.
                    </P>
                    <P>
                        (1) 
                        <E T="03">Definitions.</E>
                         The following definitions apply to this paragraph (b):
                    </P>
                    <P>
                        <E T="03">Bathhouse</E>
                         means a facility authorized to use thermal water for any purpose pursuant to a written instrument signed by the Superintendent of Hot Springs National Park.
                    </P>
                    <P>
                        <E T="03">Bathing</E>
                         means soaking in thermal water for health benefits.
                    </P>
                    <P>
                        <E T="03">Thermal water</E>
                         means water that emerges from springs, fountains or other natural sources within Hot Springs National Park.
                    </P>
                    <P>
                        <E T="03">Use of thermal water</E>
                         means heating, cooling, storing, removing from Hot Springs National Park, combining with other substances, or otherwise altering thermal water in any manner.
                    </P>
                    <P>
                        <E T="03">Water treatment</E>
                         means the introduction of any substance into thermal water, including chemicals, solutions, or other water.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Use of thermal water.</E>
                         (i) The use of thermal water is prohibited except by individuals for personal consumption or as authorized in writing by the Superintendent provided that such use is consistent with the purposes of Hot Springs National Park, and provided further that under no circumstances may thermal water be removed from Hot Springs National Park for direct sale or use in products for sale. A written instrument authorizing the use of thermal water may be in the form of a lease agreement entered into under the specific authority of 16 U.S.C. 361 
                        <E T="03">et seq.,</E>
                         in addition to any other types of written instruments authorized by applicable law and policy.
                    </P>
                    <P>(ii) Water treatment must be approved by the NPS Office of Public Health and is limited to the minimum amount and type necessary for the maintenance of public health and safety, as determined by the NPS Office of Public Health.</P>
                    <P>(iii) Bathhouses may use thermal water in the order of priority identified below, consistent with 16 U.S.C. 362:</P>
                    <P>(A) Bathhouses located within Hot Springs National Park, in the order in which they were authorized to use thermal water.</P>
                    <P>(B) Arlington Hotel.</P>
                    <P>(C) Bathhouses located outside of Hot Springs National Park, in the order in which they were authorized to use thermal water, and only when the Superintendent has determined that there is a surplus of thermal water.</P>
                    <P>(iv) For purposes of paragraph (b)(2)(iii)(C), a surplus may exist when, after accounting for all of the thermal water that bathhouses referred to in paragraphs (b)(2)(iii)(A) and (b)(2)(iii)(B) are authorized to use, the Superintendent determines that additional thermal water may be used by other bathhouses located outside of Hot Springs National Park in a manner that would not conflict with the requirements of applicable Federal laws and policies, including those that require the NPS to preserve the resources of Hot Springs National Park.</P>
                    <P>(v) The NPS will provide adequate notice to bathhouses that have lower priority use authorizations before it authorizes a bathhouse higher in the order of priority to use thermal water. The NPS will provide adequate notice to bathhouses referred to in paragraph (b)(2)(iii)(C) if the Superintendent's determination that there is a surplus of thermal water changes in a manner that will impact their authorizations to use thermal water.</P>
                    <P>(vi) Bathhouses must have a thermal water management plan approved by the Superintendent and the NPS Office of Public Health. Thermal water management plans for bathhouses located outside of Hot Springs National Park also must be approved by the Arkansas Department of Health.</P>
                    <P>(vii) The Superintendent has the right to examine and inspect the use of thermal water by a bathhouse at reasonable times to determine whether the bathhouse is being operated in accordance with the terms and conditions of the written instrument authorizing the use of thermal water, an approved thermal water management plan, and with the provisions of this section.</P>
                    <P>
                        (3) 
                        <E T="03">Prohibited acts.</E>
                         The following acts are prohibited and may result in the revocation or suspension of a written authorization to use thermal water:
                    </P>
                    <P>(i) Failure to comply with terms and conditions of a written instrument authorizing the use of thermal water.</P>
                    <P>(ii) Failure to comply with any provision of an approved thermal water management plan.</P>
                    <P>(iii) Failure to make any payment required under this section.</P>
                    <P>(iv) Failure to operate a pool or spa without appropriate certification, as determined by the NPS Office of Public Health.</P>
                    <P>(v) Failure by bathhouses to ensure and maintain employee licenses and certifications where required by Federal or State law.</P>
                    <P>(vi) Failure to comply with any provision of this paragraph (b) of § 7.18, which also may result in applicable penalties under § 1.3 of this chapter.</P>
                    <P>
                        (4) 
                        <E T="03">Rates and cost recovery.</E>
                         (i) Rates charged for thermal water will be specified in the written instrument authorizing the use of thermal water.
                    </P>
                    <P>
                        (ii) Rates charged for thermal water that will be used for bathing will be the same for all bathhouses. Rates charged for thermal water that will not be used for bathing will be determined by the Superintendent for each bathhouse.
                        <PRTPAGE P="93538"/>
                    </P>
                    <P>(iii) Bathhouses referred to in paragraph (b)(2)(iii)(C) must pay all costs associated with connections for obtaining such thermal water.</P>
                    <P>(iv) Written instruments authorizing the use of the thermal water may require bathhouses to reimburse the NPS for costs incurred from the distribution of thermal water and maintenance of the distribution system.</P>
                    <P>(v) The NPS will readjust the terms and amounts of payments required under a written instrument authorizing the use of thermal water at least every five years during its term and upon the renewal of a written instrument at end of its term.</P>
                    <STARS/>
                </SECTION>
                <PART>
                    <HD SOURCE="HED">Part 21 [Removed]</HD>
                </PART>
                <AMDPAR>3. Remove part 21, consisting of §§ 21.1 through 21.12.</AMDPAR>
                <SIG>
                    <NAME>Shannon Estenoz,</NAME>
                    <TITLE>Assistant Secretary for Fish and Wildlife and Parks.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27571 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4312-52-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="N">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <CFR>40 CFR Part 147</CFR>
                <DEPDOC>[EPA-HQ-OW-2024-0357; FRL 12000-01-OW]</DEPDOC>
                <SUBJECT>West Virginia Underground Injection Control (UIC) Program; Class VI Primacy</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Proposed rule.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Environmental Protection Agency (EPA or the Agency) has received a complete Underground Injection Control (UIC) program revision package from the State of West Virginia (State), requesting approval of a revision to the State's Safe Drinking Water Act (SDWA) section 1422 UIC program to include Class VI injection well primary enforcement responsibility (primacy). The proposed revision would allow the West Virginia Department of Environmental Protection (WVDEP) to issue UIC permits for geologic carbon sequestration facilities as Class VI wells and ensure compliance of Class VI wells under the UIC program. The EPA proposes to issue a final rule approving West Virginia's application to implement the UIC program for Class VI injection wells located within the State, except those on Indian lands. The EPA proposes amendments to reflect this proposed approval of West Virginia's Class VI primacy application.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        Comments must be received on or before December 30, 2024.
                        <E T="03"> Public hearing:</E>
                         The EPA will hold a public hearing on December 30, 2024. Please refer to the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section for additional information on the public hearing.
                    </P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may send comments, identified by Docket ID No. EPA-HQ-OW-2024-0357 by any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal: https://www.regulations.gov/</E>
                         (our preferred method). Follow the online instructions for submitting comments.
                    </P>
                    <P>
                        • 
                        <E T="03">Mail:</E>
                         U.S. Environmental Protection Agency, EPA Docket Center, Water Docket, Mail Code 28221T, 1200 Pennsylvania Avenue NW, Washington, DC 20460.
                    </P>
                    <P>
                        • 
                        <E T="03">Hand Delivery or Courier:</E>
                         EPA Docket Center, WJC West Building, Room 3334, 1301 Constitution Avenue NW, Washington, DC 20004. The Docket Center's hours of operations are 8:30 a.m. to 4:30 p.m., Monday-Friday (except Federal Holidays).
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All submissions received must include the Docket ID No. for this rulemaking. Comments received may be posted without change to 
                        <E T="03">https://www.regulations.gov/,</E>
                         including personal information provided. For detailed instructions on sending comments and additional information on the rulemaking process, see the “Public Participation” heading of the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section of this document.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Colin Dyroff, Drinking Water Infrastructure Development Division, Office of Ground Water and Drinking Water (4606M), Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 564-3149; or Himanshu Vyas, Water Division, Source Water &amp; UIC Section (3WD22), Environmental Protection Agency, Region 3, Four Penn Center, 1600 JFK Boulevard, Philadelphia, PA 19103; telephone number: (215) 814-2112. Both can be reached by emailing 
                        <E T="03">WVClassVI@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <HD SOURCE="HD1">Table of Contents</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">I. Public Participation</FP>
                    <FP SOURCE="FP1-2">A. Written Comments</FP>
                    <FP SOURCE="FP1-2">B. Participation in Public Hearing</FP>
                    <FP SOURCE="FP1-2">C. Public Participation Activities Conducted by West Virginia</FP>
                    <FP SOURCE="FP-2">II. Introduction</FP>
                    <FP SOURCE="FP1-2">A. UIC Program and Primary Enforcement Authority (Primacy)</FP>
                    <FP SOURCE="FP1-2">B. Class VI Wells Under the UIC Program</FP>
                    <FP SOURCE="FP1-2">C. West Virginia UIC Program</FP>
                    <FP SOURCE="FP-2">III. Legal Authorities</FP>
                    <FP SOURCE="FP-2">IV. The EPA's Evaluation of West Virginia's Program Revision Application</FP>
                    <FP SOURCE="FP1-2">A. Background</FP>
                    <FP SOURCE="FP1-2">B. Environmental Justice in Class VI Permitting</FP>
                    <FP SOURCE="FP1-2">C. Summary of the EPA's Comprehensive Evaluation</FP>
                    <FP SOURCE="FP-2">V. The EPA's Proposed Action</FP>
                    <FP SOURCE="FP1-2">A. Incorporation by Reference</FP>
                    <FP SOURCE="FP1-2">B. Class I-V Codification—No Action</FP>
                    <FP SOURCE="FP-2">VI. Statutory and Executive Orders Reviews</FP>
                    <FP SOURCE="FP1-2">A. Executive Order 12866: Regulatory Planning and Review and Executive Order 14094: Modernizing Regulatory Review</FP>
                    <FP SOURCE="FP1-2">B. Paperwork Reduction Act (PRA)</FP>
                    <FP SOURCE="FP1-2">C. Regulatory Flexibility Act (RFA)</FP>
                    <FP SOURCE="FP1-2">D. Unfunded Mandates Reform Act (UMRA)</FP>
                    <FP SOURCE="FP1-2">E. Executive Order 13132: Federalism</FP>
                    <FP SOURCE="FP1-2">F. Executive Order 13175: Consultation and Coordination With Indian Tribal Governments</FP>
                    <FP SOURCE="FP1-2">G. Executive Order 13045: Protection of Children From Environmental Health and Safety Risks</FP>
                    <FP SOURCE="FP1-2">H. Executive Order 13211: Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use</FP>
                    <FP SOURCE="FP1-2">I. National Technology Transfer and Advancement Act (NTTAA)</FP>
                    <FP SOURCE="FP1-2">J. Executive Order 12898: Federal Actions To Address Environmental Justice in Minority Populations and Low-Income Populations and Executive Order 14096: Revitalizing Our Nation's Commitment to Environmental Justice for All</FP>
                    <FP SOURCE="FP-2">VII. References</FP>
                </EXTRACT>
                <HD SOURCE="HD1">I. Public Participation</HD>
                <HD SOURCE="HD2">A. Written Comments</HD>
                <P>
                    Submit your comments, identified by Docket ID No. EPA-HQ-OW-2024-0357, at 
                    <E T="03">https://www.regulations.gov</E>
                     (our preferred method), or the other methods identified in the 
                    <E T="02">ADDRESSES</E>
                     section. Once submitted, comments cannot be edited or removed from the docket. The EPA may publish any comment received to its public docket. Do not submit to the EPA's docket at 
                    <E T="03">https://www.regulations.gov</E>
                     any information you consider to be Confidential Business Information (CBI), Proprietary Business Information (PBI), or other information whose disclosure is restricted by statute. If you need to submit CBI, contact Himanshu Vyas with the contact information available in the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section. Multimedia submissions (audio, video, etc.) must be accompanied by a written comment. The written comment is considered the official comment and should include discussion of all points you wish to make. The EPA will generally not consider comments or comment contents located outside of the primary 
                    <PRTPAGE P="93539"/>
                    submission (
                    <E T="03">i.e.,</E>
                     on the web, cloud, or other file sharing system). Please visit 
                    <E T="03">https://www.epa.gov/dockets/commenting-epa-dockets</E>
                     for additional submission methods; the full EPA public comment policy; information about CBI, PBI, or multimedia submissions; and general guidance on making effective comments.
                </P>
                <HD SOURCE="HD2">B. Participation in Public Hearing</HD>
                <P>
                    A public hearing is anticipated to be held on December 30, 2024. The EPA expects to announce the location, time of the hearing, as well as any updates made to any aspect of the hearing online at 
                    <E T="03">https://www.epa.gov/aboutepa/epa-region-3-mid-atlantic#pn.</E>
                     The hearing can also be attended virtually at 
                    <E T="03">https://www.zoomgov.com/j/1600637199.</E>
                     While the EPA expects the hearing to go forward as set forth above, please monitor our website or contact Himanshu Vyas at (215) 814-2112 or 
                    <E T="03">WVClassVI@epa.gov</E>
                     to determine if there are any updates or for additional information regarding the public hearing. The EPA does not intend to publish a document in the 
                    <E T="04">Federal Register</E>
                     announcing updates.
                </P>
                <P>
                    The EPA will begin pre-registering speakers for the hearing upon publication of this document in the 
                    <E T="04">Federal Register</E>
                    . To register to speak at the hearing, please contact Himanshu Vyas at (215) 814-2112 or 
                    <E T="03">WVClassVI@epa.gov</E>
                     and indicate whether you will be attending in-person or virtually. The last day to pre-register to speak at the hearing will be December 23, 2024. Prior to the hearing, the EPA will post a general agenda for the hearing that will list pre-registered speakers in approximate order at: 
                    <E T="03">https://www.epa.gov/aboutepa/epa-region-3-mid-atlantic#pn.</E>
                </P>
                <P>The EPA will make every effort to follow the schedule as closely as possible on the day of the hearing; however, please plan for the hearings to run either ahead of schedule or behind schedule. Additionally, requests to speak will be taken the day of the hearing at the hearing registration desk. The EPA will make every effort to accommodate all speakers who arrive and register, although preferences on speaking times may not be able to be fulfilled.</P>
                <P>
                    The EPA encourages commenters to provide the EPA with a copy of their oral testimony electronically by emailing it to 
                    <E T="03">WVClassVI@epa.gov.</E>
                     The EPA also recommends submitting the text of your oral comments as written comments to the rulemaking docket.
                </P>
                <P>The EPA may ask clarifying questions during the oral presentations but will not respond to the presentations at that time. Written statements and supporting information submitted during the comment period will be considered with the same weight as oral comments and supporting information presented at the public hearing.</P>
                <P>The EPA will not provide audiovisual equipment for presentations unless we receive special requests in advance. Commenters should notify Himanshu Vyas when they pre-register to speak that they will need specific equipment. If you require the services of an interpreter or special accommodations such as audio description, please pre-register for the hearing with Himanshu Vyas and describe your needs by December 23, 2024. The EPA may not be able to arrange accommodations without advance notice.</P>
                <HD SOURCE="HD2">C. Public Participation Activities Conducted by West Virginia</HD>
                <P>On June 23, 2021, the WVDEP posted a notice of public comment period on their website for an action to revise West Virginia Code of State Rules 47CSR13 to add new regulations for Class VI wells and to update the State's existing Class I-V regulations. The WVDEP held a public comment period from June 23, 2021 to July 23, 2021 and held a virtual public hearing on July 23, 2021. The WVDEP received 55 comments, 19 of which commented on Class VI wells. These comments did not result in changes to the proposed regulatory revisions. The effective date for this rule revision was March 9, 2022.</P>
                <P>Then, on June 12, 2023, the WVDEP posted a notice of public comment period on their website for another action to make additional updates to the State's Class I-VI regulations in 47CSR13 of the West Virginia Code of State Rules. The WVDEP held a public comment period from June 12, 2023 to July 18, 2023 and held a public hearing on July 18, 2023 in Charleston, WV. The WVDEP received five comments, all of which related to Class VI wells. These comments did not result in changes to the proposed updates to the regulations. The effective date for this rule revision was April 5, 2024.</P>
                <P>Commenters on the WVDEP's proposed rulemakings shared concerns on various topics including applicant financial burden, fees, the area of review radius, post-injection site care, and seismic activity reviews. Commenters also expressed concern about whether the WVDEP has adequate staffing and technical expertise to properly manage a UIC Class VI program. Environmental justice (EJ) also appeared to be a major concern, with commenters asking about how EJ protections will be integrated into the program. The WVDEP responded to all public comments, provided various clarifications, and confirmed to commenters that EJ will be an important part of the agency's Class VI program. The WVDEP also added that the agency's Class VI team would be composed of technical specialists with expertise in geology, well construction, and UIC inspections. Additionally, the WVDEP stated that the rule revisions were adopted to be consistent with Federal requirements and that the agency's primary objective is to protect underground sources of drinking water, groundwater, and surface water. Documentation of West Virginia's public participation activities, including comments received and responses by the WVDEP, can be found in the EPA's Docket ID No. EPA-HQ-OW-2024-0357.</P>
                <HD SOURCE="HD1">II. Introduction</HD>
                <HD SOURCE="HD2">A. UIC Program and Primary Enforcement Authority (Primacy)</HD>
                <P>The SDWA protects public health by regulating the nation's public drinking water supply, including both surface and groundwater sources. The SDWA requires the EPA to develop minimum requirements for effective State and Tribal UIC programs to prevent underground injection of fluids (such as water, wastewater, brines from oil and gas production, and carbon dioxide) from endangering underground sources of drinking water (USDWs). In general, USDWs are aquifers or parts of aquifers that supply a public water system or contain enough groundwater to supply a public water system. See 40 CFR 144.3.</P>
                <P>The UIC program regulates various aspects of an injection well project. These include technical aspects throughout the lifetime of the project from site characterization, construction, operation, and testing and monitoring through site closure, as well as permitting, site inspections, and reporting to ensure well owners and operators comply with UIC regulations.</P>
                <P>
                    SDWA section 1421 directs the EPA to establish requirements that States, territories, and federally recognized Tribes (hereafter referred to as applicants) must meet to be granted primary enforcement responsibility or “primacy” for implementing a UIC program, including a Class VI program. An applicant seeking primacy under SDWA section 1422 for a Class VI program must demonstrate to the EPA that the applicant's Class VI program meets the Federal requirements and is protective of USDWs. An applicant agency must also demonstrate jurisdiction over underground injection 
                    <PRTPAGE P="93540"/>
                    and the administrative, civil, and criminal enforcement authorities required by EPA regulation. After the EPA approves a State for UIC primacy, the State's UIC program may be revised with EPA approval. See 40 CFR 145.32. When a State that already has primacy under SDWA section 1422 seeks to add Class VI primacy to its existing program, a subsequent primacy application and review process takes the form of a program revision.
                </P>
                <P>The EPA conducts a comprehensive technical and legal evaluation of each primacy application to assess and confirm that the proposed program meets Federal regulations and to evaluate the effectiveness of the State's proposed program. The EPA likewise conducts a comprehensive evaluation of a proposed revision to an existing UIC program, particularly a revision as substantial as adding Class VI primacy.</P>
                <HD SOURCE="HD2">B. Class VI Wells Under the UIC Program</HD>
                <P>Class VI wells are used to inject carbon dioxide into deep rock formations for the purpose of long-term underground storage, also known as geologic sequestration. The geologic sequestration of carbon dioxide in UIC Class VI wells is used in carbon capture and storage to prevent carbon dioxide emissions from industrial sources from reaching the atmosphere. Class VI injection wells are regulated under an existing, rigorous SDWA permitting framework that protects USDWs.</P>
                <P>The UIC Class VI program provides multiple safeguards that work together to protect USDWs and human health. Owners or operators that wish to inject carbon dioxide underground for the purpose of geologic sequestration must demonstrate that their injection well and injection activities will meet all regulatory requirements and receive a Class VI permit for each well. The UIC Class VI program requires applicants to meet strict technical, financial, and managerial requirements to obtain a Class VI permit, including:</P>
                <P>• Site characterization to ensure the geology in the project area will contain the carbon dioxide within the zone where it will be injected.</P>
                <P>• Modeling to delineate the predicted area influenced by injection activities through the lifetime of operation.</P>
                <P>• Evaluation of the delineated area to ensure all potential pathways for fluid movement have been identified and addressed through corrective action.</P>
                <P>• Well construction requirements that ensure the Class VI injection well will not leak carbon dioxide.</P>
                <P>
                    • Testing and monitoring throughout the life of the project, including after carbon dioxide injection has ended. Requirements include, for example, testing to ensure physical integrity of the well, monitoring for seismic activity near the injection site, monitoring of injection pressure and flow, chemical analysis of the carbon dioxide stream that is being injected, and monitoring the extent of the injected carbon dioxide plume and the surrounding area (
                    <E T="03">e.g.,</E>
                     ground water) to ensure the carbon dioxide is contained as predicted.
                </P>
                <P>• Operating requirements (for example, injection pressure limitations) to ensure the injection activity will not endanger USDWs or human health.</P>
                <P>• Financial assurance mechanisms sufficient to cover the costs for all phases of the geologic sequestration project including the post-injection site care period and until site closure has been approved by the permitting authority.</P>
                <P>• Emergency and remedial response plans.</P>
                <P>• Reporting of all testing and monitoring results to the permitting authority to ensure the well is operating in compliance with all permit and regulatory requirements.</P>
                <P>The permitting authority ensures that these protective requirements are included in each Class VI permit. A draft of each Class VI permit is made available to the public for comment before the decision is made whether to issue a final permit.</P>
                <HD SOURCE="HD2">C. West Virginia UIC Program</HD>
                <P>The State of West Virginia received primacy for Class I, III, IV, and V injection wells under SDWA section 1422 and Class II injection wells under SDWA section 1425 on December 9, 1983 (48 FR 55127). On May 1, 2024, West Virginia applied to the EPA under section 1422 of SDWA, 42 U.S.C. 300h-1, for primacy for Class VI injection wells located within the State, except those located on Indian lands.</P>
                <HD SOURCE="HD1">III. Legal Authorities</HD>
                <P>This regulation is proposed under authority of SDWA sections 1422 and 1450, 42 U.S.C. 300h-1 and 300j-9.</P>
                <P>Section 1421 of SDWA requires the Administrator of the EPA to promulgate Federal requirements for effective State UIC programs to prevent underground injection activities that endanger USDWs. Section 1422 of SDWA establishes requirements for States and Tribes seeking EPA approval of their UIC programs. It also requires that States and Tribes seeking approval demonstrate how the applicant (after public notice) will implement a UIC program which meets the requirements that the EPA promulgated under section 1421.</P>
                <P>For States and Tribes that seek approval for UIC programs under section 1422 of SDWA and those seeking EPA approval of revisions to existing State and Tribal UIC programs, the EPA has promulgated regulations setting forth the applicable procedures and substantive requirements codified in 40 CFR parts 144, 145 and 146. 40 CFR part 144 outlines general program requirements that each State must meet to obtain primary enforcement authority. 40 CFR part 145 specifies the procedures the EPA will follow in approving, revising, and withdrawing State programs and outlines the elements and provisions that a State must include in its application for primacy. 40 CFR part 145 also includes requirements for State permitting programs (by reference to certain provisions of 40 CFR parts 124 and 144), compliance evaluation programs, enforcement authority, and sharing of information between the EPA and the State. 40 CFR part 146 contains the technical criteria and standards applicable to each well class, including Class VI wells.</P>
                <HD SOURCE="HD1">IV. The EPA's Evaluation of West Virginia's Program Revision Application</HD>
                <HD SOURCE="HD2">A. Background</HD>
                <P>On May 1, 2024, West Virginia submitted to the EPA a program revision application to add Class VI wells to the State's SDWA section 1422 UIC program. The UIC program revision package from West Virginia includes a description of the State's UIC Class VI program, copies of all applicable rules and forms, a statement of legal authority, a summary and results of West Virginia's public participation activities, an amended addendum to the existing Memorandum of Agreement (MOA) between West Virginia and the EPA's Region 3 office, an interagency MOA between the WVDEP and the West Virginia Geologic and Economic Survey (WVGES), and an interagency MOA between the WVDEP and the West Virginia Department of Health. The EPA reviewed the application for completeness and performed a technical evaluation of the application materials.</P>
                <HD SOURCE="HD2">B. Environmental Justice in Class VI Permitting</HD>
                <P>
                    People across the country have shared with the EPA concerns that already environmentally overburdened communities may bear a disproportionate environmental burden associated with geologic sequestration. 
                    <PRTPAGE P="93541"/>
                    Executive Order 12898 (59 FR 7629, February 16, 1994) and Executive Order 14096 (88 FR 25251, April 21, 2023) direct Federal agencies, to the greatest extent practicable and permitted by law, to identify and address, as appropriate, disproportionate and adverse human health or environmental impacts on communities with EJ concerns. On August 17, 2023, the EPA released a guidance document titled 
                    <E T="03">Environmental Justice Guidance for UIC Class VI Permitting and Primacy.</E>
                     This guidance outlines expectations for the EPA to incorporate EJ considerations into Class VI activities. It is organized into five themes that address various aspects of EJ in UIC Class VI permitting, and strongly encourages States, Tribes, and Territories to implement their Class VI programs in a similar fashion.
                </P>
                <P>As part of developing this proposal, the EPA worked with the State of West Virginia to adopt the EJ approaches encouraged in the August 17, 2023 guidance document, which West Virginia has incorporated in its primacy application. The EPA reviewed West Virginia's EJ approach as described in the State's Class VI program description and amended MOA addendum and compared it to the EJ themes and actions in the guidance document. The EJ approach in the amended MOA addendum corresponds to the five themes in the EPA's August 17, 2023 guidance document, which include identifying communities with potential EJ concerns, implementing an augmented public participation process, conducting additional assessments for projects identified as having EJ concerns, ensuring the permitting process is transparent, and minimizing adverse effects to underground sources of drinking water and the communities they may serve. Furthermore, West Virginia's Class VI program description specifies that the WVDEP will require well owners or operators to conduct an EJ review as part of the Class VI permit application process. The EPA supports the WVDEP's agreement in its Class VI program description to evaluate project sites using the EPA's EJ Screen and to take additional steps if this initial screening identifies the presence of an EJ community or other risk factors in the area of review (AOR). West Virginia's Class VI program, as described in the WVDEP's primacy application, includes approaches to ensure equity and EJ will be appropriately considered in permit reviews, and in the WVDEP's UIC Class VI program as a whole.</P>
                <HD SOURCE="HD2">C. Summary of the EPA's Comprehensive Evaluation</HD>
                <P>The EPA conducted a comprehensive technical and legal evaluation of West Virginia's Class VI primacy application to assess and confirm that the State's UIC Class VI program is as stringent as the Federal regulations and evaluated the effectiveness of the State's Class VI program. To be approved for Class VI primacy under SDWA section 1422, a State or Tribe must have a UIC program that meets Federal requirements (40 CFR parts 124, 144, 145, and 146). The EPA evaluated West Virginia's Class VI UIC statutes and regulations against these Federal requirements. The EPA worked with West Virginia to address any stringency issues with their Class VI statutes and regulations prior to submittal of the Class VI primacy application. The Agency also evaluated for stringency and effectiveness West Virginia's Class VI program description, the Class VI Attorney General's statement, the amended Class VI addendum to the MOA between the EPA and West Virginia, the interagency MOA between the WVDEP and the West Virginia Geologic and Economic Survey, and the interagency MOA between the WVDEP and the West Virginia Department of Health.</P>
                <P>The EPA evaluated West Virginia's Class VI program description against 40 CFR 145.23, which lists all the information to be submitted as part of the program description. The EPA's evaluation of the Class VI program description included reviewing the scope, structure, coverage, processes, and organizational structure of the permitting authority. The EPA evaluated the WVDEP's permitting, administrative, and judicial review procedures, as well as the State's permit application, reporting, and manifest forms. The EPA also reviewed the State's compliance evaluation and enforcement mechanisms. The EPA evaluated the WVDEP's proposed schedule for issuing Class VI permits within the first two years after program approval. The EPA required West Virginia to demonstrate that the State's Class VI program will have adequate in-house staff or access to contractor support for technical areas including site characterization, modeling, well construction and testing, financial responsibility, and regulatory and risk analysis.</P>
                <P>The EPA evaluated West Virginia's Class VI Attorney General's statement against 40 CFR 145.24 to ensure it met Federal requirements. The Attorney General's statement is required to ensure that a State's top legal officer affirms that State statutes, regulations, and judicial decisions demonstrate adequate authority to administer the UIC program as described in the Class VI program description and consistent with the EPA's regulatory requirements for UIC programs. The EPA independently evaluates and confirms that the Attorney General's statement certifies that the State either does not have environmental audit privilege and/or immunity laws, or, if there are environmental audit privilege and/or immunity laws, that they will not affect the ability of the State to meet the enforcement and information gathering requirements under the SDWA.</P>
                <P>The EPA evaluated West Virginia's amended Class VI MOA addendum against 40 CFR 145.25 to ensure it met Federal requirements. The MOA is the central agreement setting the provisions and arrangements between the State and the EPA concerning the administration, implementation, and enforcement of the State UIC program. The EPA's evaluation includes ensuring that the MOA contains the necessary provisions pertaining to agreements on coordination, permitting, compliance monitoring, enforcement, and EPA oversight. For example, the amended MOA addendum specifies that the WVDEP and the EPA agree to maintain a high level of cooperation and coordination to assure successful and efficient administration of the UIC Class VI program.</P>
                <P>The EPA reviewed the WVDEP's interagency MOA with the West Virginia Geological and Economic Survey. The WVGES is a West Virginia agency with expertise to provide information to the WVDEP on local geologic characteristics in relation to proposed underground injection operations. The interagency MOA between the WVDEP and the WVGES establishes a coordinated relationship between the two state agencies to properly assess geological characteristics in a proposed work area to support permit determinations. The EPA also reviewed the WVDEP's interagency MOA with the West Virginia Department of Health (WVDOH). Under this interagency MOA, the WVDOH will conduct a review of the proposed area of work and permit application details and provide input to assist in permit determinations, among other provisions.</P>
                <P>
                    The EPA is aware that stakeholders have raised concern about geologic sequestration long term liability transfer provisions enacted in West Virginia and other States. The EPA reviewed the West Virginia statutory provision relating to long-term liability transfer 
                    <PRTPAGE P="93542"/>
                    (W. Va. Code § 22-11B-12) and determined that it does not undermine any protections under the Safe Drinking Water Act. Under the West Virginia long-term liability transfer provision, all Class VI regulatory and permit requirements must be met before liability transfer may occur.
                    <SU>1</SU>
                    <FTREF/>
                     Consistent with EPA regulations, West Virginia imposes extensive post-injection monitoring—a default of 50 years—and site closure requirements at the end of a Class VI well's life cycle to ensure that there will be no danger to USDWs. Only after all those requirements are met does West Virginia's long-term liability transfer provision allow a limited transfer of any future liability to a state-administered and industry-funded trust fund. Among other additional limitations, the provision is explicit that it does not: relieve any owner or operator from any liability that arises from noncompliance with UIC laws, regulations or permits; apply if the WVDEP determines that there is fluid migration for which the operator is responsible that threatens imminent and substantial endangerment to a USDW; or interfere with the EPA's emergency authority under SDWA section 1431.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Such requirements include the post closure deed notation and record retention requirements at 40 CFR 146.93 and 47CSR13.13.9, as specifically mentioned in the Class VI MOA amended addendum.
                    </P>
                </FTNT>
                <P>West Virginia has demonstrated that it has the legal authority to implement all permit requirements found in 40 CFR 145.11 for Class VI permits. West Virginia's UIC Class VI permitting provisions are as stringent as the EPA's regulations in 40 CFR parts 124 and 144. The State has incorporated necessary procedures, pursuant to 40 CFR 145.12 to support a robust Class VI compliance evaluation program. Additionally, West Virginia has the necessary administrative, civil, and criminal enforcement authorities pursuant to 40 CFR 145.13. West Virginia's Class VI regulations regarding permitting, inspection, operation, and monitoring meet Federal requirements found in 40 CFR parts 145 and 146. West Virginia's reporting and recordkeeping requirements meet Federal requirements found in 40 CFR 144.54 and 146.91 for Class VI wells.</P>
                <P>As a result of this comprehensive review, the EPA is proposing to approve West Virginia's application because the EPA has determined that the application meets all applicable requirements for approval under SDWA section 1422 and the State is capable of administering a UIC Class VI program in a manner consistent with the terms and purposes of SDWA and all applicable UIC regulations.</P>
                <HD SOURCE="HD1">V. The EPA's Proposed Action</HD>
                <HD SOURCE="HD2">A. Incorporation by Reference</HD>
                <P>The EPA is proposing to approve a revision to the State of West Virginia's UIC program for primacy for regulating Class VI injection wells in the State, except for those located on Indian lands. West Virginia's statutes and regulations that are proposed to be incorporated by reference are publicly available in the EPA's Docket No. EPA-HQ-OW-2024-0357. If finalized, this action would amend 40 CFR 147.2450 and incorporate by reference EPA-approved State statutes and regulations that contain standards, requirements, and procedures applicable to Class VI owners or operators. Any provisions incorporated by reference, as well as all permit conditions or permit denials issued pursuant to such provisions, are enforceable by the EPA pursuant to section 1423 of SDWA and 40 CFR 147.1(e). The EPA will continue to administer the UIC program for Class I, II, III, IV, V, and VI injection wells on Indian lands.</P>
                <P>
                    The EPA proposes to incorporate by reference the West Virginia statutes and regulations applicable to owners or operators of Class VI wells as a compilation titled “EPA-approved West Virginia SDWA section 1422 Underground Injection Control Program Statutes and Regulations for Well Class VI,” dated [date when the EPA compiles the notebook]. This compilation would be incorporated by reference into 40 CFR 147.2450 and is available at 
                    <E T="03">www.regulations.gov</E>
                     in the docket for this proposed rulemaking. The EPA also proposes to codify a table in 40 CFR 147.2450 listing the EPA-approved West Virginia Statutes and Regulations for Well Class VI included in the compilation that EPA would incorporate by reference. While the regulations in 47CSR13 contain requirements for all UIC well classes (
                    <E T="03">i.e.,</E>
                     Class I-VI), only the requirements applicable to owners or operators of Class VI wells would be incorporated by reference as part of this action.
                </P>
                <P>Upon approval, the EPA would oversee West Virginia's administration of its Class VI program and will continue to oversee West Virginia's administration of its programs for Class I, II, III, IV, and V wells. The EPA will require quarterly reports on non-compliance and annual UIC performance reports pursuant to 40 CFR 144.8. The amended MOA addendum between the EPA and West Virginia, signed by the Regional Administrator on October 9, 2024, articulates that the EPA will oversee the State's administration of the UIC Class VI program on a continuing basis to assure that such administration is consistent with the program MOAs, UIC grant agreements, and all applicable requirements embodied in current regulations and Federal law. In addition, the amended MOA addendum provides that the EPA may request specific information including permits and the accompanying EJ reviews.</P>
                <HD SOURCE="HD2">B. Class I-V Codification—No Action</HD>
                <P>
                    As referenced in section II.C of this preamble, the EPA approved West Virginia for Class I-V primacy in 1983. After notice and public comment, the EPA determined that West Virginia's UIC program met Federal requirements and published its decision to approve West Virginia's UIC program in the 
                    <E T="04">Federal Register</E>
                     (48 FR 55127, December 9, 1983). The Code of Federal Regulations (CFR) sets forth the applicable UIC program for each State (40 CFR 147.1) and, upon approving a State for UIC primacy, the EPA typically updates the CFR to reflect its approval. However, for reasons that current EPA staff were unable to ascertain, when the EPA approved West Virginia's UIC program in 1983, the CFR was not revised to reflect the EPA's approval, and the CFR currently does not reflect West Virginia's Class I-V primacy. While the EPA is not addressing this CFR discrepancy as part of this proposed action, the EPA expects to address it later as part of a separate action. The current proposal is confined to approving a revision to West Virginia's existing UIC primacy program to grant the State primacy over Class VI wells; it is not addressing other well classes.
                    <SU>2</SU>
                    <FTREF/>
                     Separately, the EPA is working with West Virginia to assess the State's current Class I-V program elements and expects to codify in the CFR the State's Class I-V program in 2025 as part of a separate action. An email from the WVDEP affirming the State's intention to submit a Class I-V program revision package in 2025 following the Class VI process can be found in the docket for this proposed rulemaking.
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         Even if this proposed action were not a revision to an existing UIC program, the UIC regulations at 40 CFR 145.1(i) allow States to apply for primary enforcement responsibility for Class VI wells independently of other injection well classes.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">VI. Statutory and Executive Orders Reviews</HD>
                <P>
                    Additional information about these statutes and Executive orders can be found at: 
                    <E T="03">https://www.epa.gov/laws-regulations/laws-and-executive-orders.</E>
                    <PRTPAGE P="93543"/>
                </P>
                <HD SOURCE="HD2">A. Executive Order 12866: Regulatory Planning and Review and Executive Order 14094: Modernizing Regulatory Review</HD>
                <P>This proposed action is exempt from review under Executive Order 12866, as amended by Executive Order 14094, because the Office of Management and Budget (OMB) has exempted, as a category, the approval of State UIC programs.</P>
                <HD SOURCE="HD2">B. Paperwork Reduction Act (PRA)</HD>
                <P>This proposed action will not impose any new information collection burden under the PRA. OMB has previously approved the information collection activities contained in the existing regulations and has assigned OMB control number 2040-0042. Reporting or recordkeeping requirements will be based on West Virginia's Class VI UIC Regulations, and the State of West Virginia is not subject to the PRA.</P>
                <HD SOURCE="HD2">C. Regulatory Flexibility Act (RFA)</HD>
                <P>I certify that this proposed action will not have a significant economic impact on a substantial number of small entities under the RFA. This proposed action would not impose any new requirements on small entities. It simply approves and codifies West Virginia's UIC Class VI program, which meets the same standard under SDWA section 1422 as is required for the EPA's regulations governing its direct implementation of a UIC Class VI program.</P>
                <HD SOURCE="HD2">D. Unfunded Mandates Reform Act (UMRA)</HD>
                <P>This proposed action does not contain an unfunded mandate as described in UMRA, 2 U.S.C. 1531-1538, and does not significantly or uniquely affect small governments. The proposed action imposes no enforceable duty on any state, local, or Tribal governments or the private sector. The EPA's proposed approval of West Virginia's Class VI program will not constitute a Federal mandate because there is no requirement that a state establish UIC regulatory programs and because the program is a state, rather than a Federal program.</P>
                <HD SOURCE="HD2">E. Executive Order 13132: Federalism</HD>
                <P>This proposed action does not have federalism implications. It will not have substantial direct effects on the states, on the relationship between the national government and the states, or on the distribution of power and responsibilities among the various levels of government.</P>
                <HD SOURCE="HD2">F. Executive Order 13175: Consultation and Coordination With Indian Tribal Governments</HD>
                <P>This proposed action does not have Tribal implications as specified in Executive Order 13175. This proposed action contains no Federal mandates for Tribal governments and does not impose any enforceable duties on Tribal governments. Thus, Executive Order 13175 does not apply to this proposed action.</P>
                <HD SOURCE="HD2">G. Executive Order 13045: Protection of Children From Environmental Health and Safety Risks</HD>
                <P>The EPA interprets Executive Order 13045 as applying only to those regulatory actions that concern environmental health or safety risks that the EPA has reason to believe may disproportionately affect children, per the definition of “covered regulatory action” in section 2-202 of the Executive Order. This proposed action is not subject to Executive Order 13045 because it approves a state program.</P>
                <HD SOURCE="HD2">H. Executive Order 13211: Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use</HD>
                <P>This proposed action is not subject to Executive Order 13211, because it is not a significant regulatory action under Executive Order 12866.</P>
                <HD SOURCE="HD2">I. National Technology Transfer and Advancement Act (NTTAA)</HD>
                <P>This proposed rulemaking does not involve technical standards.</P>
                <HD SOURCE="HD2">J. Executive Order 12898: Federal Actions To Address Environmental Justice in Minority Populations and Low-Income Populations and Executive Order 14096: Revitalizing Our Nation's Commitment to Environmental Justice for All</HD>
                <P>The EPA believes that it is not practicable to assess whether the human health or environmental conditions that exist prior to this proposed action result in disproportionate and adverse effects on communities with environmental justice concerns. There currently are no Class VI wells permitted in West Virginia and this proposed action would be a procedural action. The EPA has reviewed West Virginia's proposed approach to environmental justice, as outlined in the Class VI Program Description and Class VI MOA amended addendum, and described in section IV.B of this preamble. The EPA considers West Virginia's Class VI primacy application to integrate environmental justice and equity considerations into the State's UIC Class VI program, while ensuring protection of USDWs. This proposed action would provide West Virginia with primacy under SDWA section 1422 for a UIC Class VI program, pursuant to which West Virginia would implement a program that meets the EPA's requirements for UIC Class VI programs.</P>
                <HD SOURCE="HD1">VII. References</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">Attorney General's Statement “Attorney General's Statement to Accompany West Virginia's Underground Injection Program Class VI Primacy Application,” signed by the General Counsel of the West Virginia Department of Environmental Protection, April 29, 2024.</FP>
                    <FP SOURCE="FP-2">Class VI Underground Injection Control Program Description “WV Class 6 Program Description”, June 2024.</FP>
                    <FP SOURCE="FP-2">Email from West Virginia to EPA related to Class I-V program revision, April 22, 2024.</FP>
                    <FP SOURCE="FP-2">Letter from Governor of West Virginia to Regional Administrator, EPA Region III, April 25, 2024.</FP>
                    <FP SOURCE="FP-2">Memorandum of Agreement Amended Addendum 1 between the State of West Virginia and the EPA, Region III for the UIC Class VI Program, signed by the EPA Regional Administrator on October 9, 2024.</FP>
                    <FP SOURCE="FP-2">
                        <E T="04">Federal Register</E>
                         notice “West Virginia Department of Natural Resources; Underground Injection Control Program Approval”, EPA, 48 FR 55127-55128 (December 9, 1983).
                    </FP>
                    <FP SOURCE="FP-2">Memorandum of Agreement between the State of West Virginia and the EPA, Region III, signed by the EPA Regional Administrator on August 31, 1983.</FP>
                    <FP SOURCE="FP-2">Memorandum of Agreement Between The West Virginia Department of Environmental Protection and The West Virginia Department of Health, signed April 26, 2024.</FP>
                    <FP SOURCE="FP-2">Memorandum of Agreement Between The West Virginia Department of Environmental Protection and The West Virginia Geological and Economic Survey, signed April 29, 2024.</FP>
                    <FP SOURCE="FP-2">Program Description “Program Description for the West Virginia Underground Injection Control Program”, December 1983.</FP>
                    <FP SOURCE="FP-2">State of West Virginia. Notice of Action Taken by Legislative Rule-Making Review Committee, December 9, 2021.</FP>
                    <FP SOURCE="FP-2">State of West Virginia. Notice of Action Taken by Legislative Rule-Making Review Committee, September 13, 2023.</FP>
                    <FP SOURCE="FP-2">State of West Virginia. Notice of Public Comment Period and Hearing, June 12, 2023.</FP>
                    <FP SOURCE="FP-2">State of West Virginia. Notice of Public Comment Period and Hearing, June 23, 2021.</FP>
                    <FP SOURCE="FP-2">State of West Virginia. Public Comments and Responses, July 24, 2023.</FP>
                    <FP SOURCE="FP-2">State of West Virginia. Public Comments and Responses, July 30, 2021.</FP>
                    <FP SOURCE="FP-2">
                        State of West Virginia. Public Hearing Transcript (Public Hearing Date: July 23, 2021), July 31, 2021.
                        <PRTPAGE P="93544"/>
                    </FP>
                    <FP SOURCE="FP-2">State of West Virginia. Public Hearing Transcript (Public Hearing Date: July 18, 2023), August 12, 2023.</FP>
                    <FP SOURCE="FP-2">USEPA. 2023b. U.S. Environmental Protection Agency. Memorandum to Water Division Directors, Regions I-X, from Radhika Fox, Office of Water. Environmental Justice Guidance for UIC Class VI Permitting and Primacy (August 17, 2023).</FP>
                    <FP SOURCE="FP-2">West Virginia Code § 22-11. Water Pollution Control Act. May 13, 2024.</FP>
                    <FP SOURCE="FP-2">West Virginia Code § 22-11A. Carbon Dioxide Sequestration Pilot Program. May 20, 2022.</FP>
                    <FP SOURCE="FP-2">West Virginia Code § 22-11B. Underground Carbon Dioxide Sequestration and Storage. May 13, 2024.</FP>
                    <FP SOURCE="FP-2">West Virginia Code of State Rules § 47-13. Underground Injection Control. April 5, 2024.</FP>
                </EXTRACT>
                <LSTSUB>
                    <HD SOURCE="HED">List of Subjects in 40 CFR Part 147</HD>
                    <P>Environmental protection, Incorporation by reference, Indian lands, Intergovernmental relations, Reporting and recordkeeping requirements, Water supply.</P>
                </LSTSUB>
                <SIG>
                    <NAME>Michael S. Regan,</NAME>
                    <TITLE>Administrator.</TITLE>
                </SIG>
                <P>For the reasons set forth in the preamble, the EPA proposes to amend 40 CFR part 147 as follows:</P>
                <PART>
                    <HD SOURCE="HED">PART 147—STATE, TRIBAL, AND EPA-ADMINISTERED UNDERGROUND INJECTION CONTROL PROGRAMS</HD>
                </PART>
                <AMDPAR>1. The authority citation for part 147 continues to read as follows:</AMDPAR>
                <AUTH>
                    <HD SOURCE="HED">Authority:</HD>
                    <P>
                        42 U.S.C. 300f 
                        <E T="03">et seq.;</E>
                         and 42 U.S.C. 6901 
                        <E T="03">et seq.</E>
                    </P>
                </AUTH>
                <AMDPAR>2. Add § 147.2450 to read as follows:</AMDPAR>
                <SECTION>
                    <SECTNO>§ 147.2450</SECTNO>
                    <SUBJECT>State-administered program—Class VI Wells</SUBJECT>
                    <P>
                        The UIC program for Class VI wells in the State of West Virginia, except those on Indian lands, is the program administered by the West Virginia Department of Environmental Protection, approved by the EPA pursuant to SDWA section 1422. The effective date of this program is [DATE 30 DAYS AFTER FINAL RULE PUBLICATION IN THE 
                        <E T="04">FEDERAL REGISTER</E>
                        ]. The UIC program for Class VI wells in the State of West Virginia, except those located on Indian lands, consists of the following elements, as submitted to the EPA in the State's program revision application.
                    </P>
                    <P>
                        (a) 
                        <E T="03">Incorporation by reference.</E>
                         The requirements applicable to owners or operators of Class VI wells set forth in the State statutes and regulations approved by the EPA for including in “EPA-approved West Virginia SDWA § 1422 Underground Injection Control Program Statutes and Regulations for Well Class VI,” dated [date when the EPA compiles the notebook], and listed in table 1 to this paragraph (a), are hereby incorporated by reference and made a part of the applicable UIC program under the SDWA for the State of West Virginia. The Director of the Federal Register approves this incorporation by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies of the State of West Virginia's statutes and regulations that are incorporated by reference may be inspected at the U.S. Environmental Protection Agency, Region 3, Four Penn Center, 1600 JFK Blvd., Philadelphia, PA 19103 and the U.S. Environmental Protection Agency, Water Docket, EPA Docket Center (EPA/DC), EPA WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC 20004. If you wish to obtain materials from the EPA Regional Office, please call (215) 814-2816, or from the EPA Headquarters Library, please call the Water Docket at (202) 566-2426. You may also view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit 
                        <E T="03">www.archives.gov/federal-register/cfr/ibr-locations.html</E>
                         or email 
                        <E T="03">fr.inspections@nara.gov.</E>
                         You may also obtain the State of West Virginia's statutes and regulations that are incorporated by reference from: Room MB-27, Building 1, State Capitol Complex, Charleston, West Virginia 25305; phone: (304) 347-4836; website: 
                        <E T="03">www.wvlegislature.gov.</E>
                    </P>
                    <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s50,r50,r40,r75">
                        <TTITLE>
                            Table 1 to Paragraph (
                            <E T="01">a</E>
                            )—EPA-Approved West Virginia SDWA Sec. 1422 Underground Injection Control Program Statutes and Regulations for Well Class VI
                        </TTITLE>
                        <BOXHD>
                            <CHED H="1">State citation</CHED>
                            <CHED H="1">Title/subject</CHED>
                            <CHED H="1">State effective date</CHED>
                            <CHED H="1">EPA approval date</CHED>
                        </BOXHD>
                        <ROW>
                            <ENT I="01">West Virginia Code § 22-11</ENT>
                            <ENT>Water Pollution Control Act</ENT>
                            <ENT>May 13, 2024</ENT>
                            <ENT>
                                [DATE OF FINAL RULE PUBLICATION IN THE 
                                <E T="02">FEDERAL REGISTER</E>
                                .]
                            </ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">West Virginia Code § 22-11A</ENT>
                            <ENT>Carbon Dioxide Sequestration Pilot Program</ENT>
                            <ENT>May 30, 2022</ENT>
                            <ENT>
                                [DATE OF FINAL RULE PUBLICATION IN THE 
                                <E T="02">FEDERAL REGISTER</E>
                                .]
                            </ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">West Virginia Code § 22-11B</ENT>
                            <ENT>Underground Carbon Dioxide Sequestration and Storage</ENT>
                            <ENT>May 13, 2024</ENT>
                            <ENT>
                                [DATE OF FINAL RULE PUBLICATION IN THE 
                                <E T="02">FEDERAL REGISTER</E>
                                .]
                            </ENT>
                        </ROW>
                        <ROW>
                            <ENT I="01">West Virginia Code of State Rules § 47-13</ENT>
                            <ENT>Underground Injection Control</ENT>
                            <ENT>April 5, 2024</ENT>
                            <ENT>
                                [DATE OF FINAL RULE PUBLICATION IN THE 
                                <E T="02">FEDERAL REGISTER</E>
                                .]
                            </ENT>
                        </ROW>
                    </GPOTABLE>
                    <P>
                        (b) 
                        <E T="03">Memorandum of Agreement (MOA).</E>
                         (1) The Memorandum of Agreement between the State of West Virginia and the EPA, Region III, signed by the EPA Regional Administrator on August 31, 1983.
                    </P>
                    <P>(2) Memorandum of Agreement Amended Addendum 1 between the State of West Virginia and the EPA, Region III for the UIC Class VI Program, signed by the EPA Regional Administrator on October 9, 2024.</P>
                    <P>
                        (c) 
                        <E T="03">Letter from Governor.</E>
                         Letter from Governor of West Virginia to Regional Administrator, EPA Region III, April 25, 2024.
                    </P>
                    <P>
                        (d) 
                        <E T="03">West Virginia Memorandums of Agreement.</E>
                         (1) Memorandum of Agreement Between The West Virginia Department of Environmental Protection and The West Virginia Geological and Economic Survey, effective April 1, 2024.
                    </P>
                    <P>(2) Memorandum of Agreement Between The West Virginia Department of Environmental Protection and The West Virginia Department of Health, signed April 26, 2024.</P>
                    <P>
                        (e) 
                        <E T="03">Statement of legal authority.</E>
                         Attorney General's Statement, “Attorney General's Statement to Accompany West Virginia's Underground Injection Program Class VI Primacy Application”, signed by the Attorney General of West Virginia on April 29, 2024.
                    </P>
                    <P>
                        (f) 
                        <E T="03">Program Description.</E>
                         The Program Description, “Program Description for the West Virginia Underground Injection Control Program”, and any other materials submitted as part of the application or amendment thereto, and the Class VI Underground Injection Control Program Description, “WV Class 
                        <PRTPAGE P="93545"/>
                        6 Program Description”, and any other materials submitted as part of the program revision application or as amendment thereto.
                    </P>
                </SECTION>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27638 Filed 11-25-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </PRORULE>
        <PRORULE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Office of Inspector General</SUBAGY>
                <CFR>42 CFR Part 1001</CFR>
                <SUBJECT>Solicitation of Proposals for New and Modified Safe Harbors and Special Fraud Alerts</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Inspector General (OIG), Department of Health and Human Services (HHS or the Department).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notification of intent to develop regulations.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In accordance with section 205 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), this annual notification solicits proposals and recommendations for developing new, or modifying existing, safe harbor provisions under section 1128B(b) of the Social Security Act (the Act), the Federal anti-kickback statute, as well as developing new OIG Special Fraud Alerts.</P>
                </SUM>
                <EFFDATE>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>To ensure consideration, public comments must be received no later than 5 p.m. on January 27, 2025.</P>
                </EFFDATE>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        You may submit comments electronically at 
                        <E T="03">https://www.regulations.gov.</E>
                         Follow the “Submit a comment” instructions and refer to file code OIG-1124-N.
                    </P>
                    <P>
                        For information on viewing public comments, please see the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Benjamin Wallfisch, (202) 339-7980.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Inspection of Public Comments: All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following website as soon as possible after they have been received: 
                    <E T="03">https://www.regulations.gov.</E>
                </P>
                <HD SOURCE="HD1">I. Background</HD>
                <HD SOURCE="HD2">A. OIG Safe Harbor Provisions</HD>
                <P>Section 1128B(b) of the Act (42 U.S.C. 1320a-7b(b)), the Federal anti-kickback statute, provides for criminal penalties for whoever knowingly and willfully offers, pays, solicits, or receives remuneration to induce or reward, among other things, referrals for or purchases of items or services reimbursable under any of the Federal health care programs, as defined in section 1128B(f) of the Act (42 U.S.C. 1320a-7b(f)). The offense is classified as a felony and is punishable by a fine of up to $100,000 and imprisonment for up to 10 years. Violations of the Federal anti-kickback statute also may result in the imposition of civil monetary penalties under section 1128A(a)(7) of the Act (42 U.S.C. 1320a-7a(a)(7)), program exclusion under section 1128(b)(7) of the Act (42 U.S.C. 1320a-7(b)(7)), and liability under the False Claims Act (31 U.S.C. 3729-33).</P>
                <P>
                    Because of the broad reach of the statute, stakeholders expressed concern that some relatively innocuous business arrangements were covered by the statute and, therefore, potentially subject to criminal prosecution. In response, Congress enacted section 14 of the Medicare and Medicaid Patient and Program Protection Act of 1987, Public Law 100-93 (note to section 1128B of the Act; 42 U.S.C. 1320a-7b), which requires the development and promulgation of regulations, the so-called safe harbor provisions, that would specify various payment and business practices that would not be subject to sanctions under the Federal anti-kickback statute, even though they potentially may be capable of inducing referrals of business for which payment may be made under a Federal health care program. Since July 29, 1991, there has been a series of final regulations published in the 
                    <E T="04">Federal Register</E>
                     establishing safe harbors to protect various payment and business practices.
                    <SU>1</SU>
                    <FTREF/>
                     These safe harbor provisions have been developed “to limit the reach of the statute somewhat by permitting certain non-abusive arrangements, while encouraging beneficial and innocuous arrangements.” 
                    <SU>2</SU>
                    <FTREF/>
                     Health care providers and others may voluntarily seek to comply with the conditions of an applicable safe harbor so that they have the assurance that their payment or business practice will not be subject to sanctions under the Federal anti-kickback statute. The safe harbor regulations promulgated by OIG are found at 42 CFR part 1001.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See, e.g.,</E>
                         Medicare and State Health Care Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducements, 85 FR 77684 (Dec. 2, 2020).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         Medicare and State Health Care Programs: Fraud and Abuse; OIG Anti-Kickback Provisions, 56 FR 35952, 35958 (July 29, 1991).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. OIG Special Fraud Alerts</HD>
                <P>
                    OIG periodically issues Special Fraud Alerts to give continuing guidance to health care industry stakeholders about practices that OIG considers to be suspect or of particular concern.
                    <SU>3</SU>
                    <FTREF/>
                     Special Fraud Alerts encourage industry compliance by giving stakeholders guidance that can be applied to their own practices. OIG Special Fraud Alerts are published in the 
                    <E T="04">Federal Register</E>
                    , on OIG's website, or both, and are intended for extensive distribution.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See, e.g.,</E>
                         Special Fraud Alert: OIG Alerts Practitioners To Exercise Caution When Entering Into Arrangements With Purported Telemedicine Companies (July 20, 2022), 
                        <E T="03">https://oig.hhs.gov/documents/root/1045/sfa-telefraud.pdf.</E>
                    </P>
                </FTNT>
                <P>In developing Special Fraud Alerts, OIG relies on several sources and consults directly with experts in the subject field, including those within OIG, other agencies of HHS, other Federal and State agencies, and those in the health care industry.</P>
                <HD SOURCE="HD2">C. Section 205 of the Health Insurance Portability and Accountability Act of 1996</HD>
                <P>
                    Section 205 of HIPAA, Public Law 104-191, and section 1128D of the Act (42 U.S.C. 1320a-7d), requires the Department to develop and publish an annual notification in the 
                    <E T="04">Federal Register</E>
                     formally soliciting proposals for developing additional or modifying existing safe harbors to the Federal anti-kickback statute and for issuing Special Fraud Alerts.
                </P>
                <P>In developing or modifying safe harbors under the Federal anti-kickback statute, and in consultation with the Department of Justice, OIG thoroughly reviews the range of factual circumstances that may receive protection by the proposed or modified safe harbor. In doing so, OIG seeks to identify and develop safe harbors that protect beneficial and innocuous arrangements and safeguard Federal health care programs and their beneficiaries from the harms caused by fraud and abuse.</P>
                <HD SOURCE="HD1">II. Solicitation of New and Modified Safe Harbor Recommendations and Special Fraud Alert Proposals</HD>
                <P>
                    OIG seeks recommendations regarding the development of additional or modified safe harbor regulations and the issuance of new Special Fraud Alerts. A detailed explanation of justifications for, or empirical data supporting, a suggestion for a new or modified safe harbor or for the issuance of a new Special Fraud Alert would be helpful 
                    <PRTPAGE P="93546"/>
                    and should, if possible, be included in any response to this solicitation.
                </P>
                <HD SOURCE="HD2">A. Criteria for Modifying and Establishing Safe Harbor Provisions</HD>
                <P>In accordance with section 205 of HIPAA, we will consider various factors in reviewing proposals for additional or modified safe harbor provisions, such as the extent to which the proposals may result in an increase or decrease in:</P>
                <P>• access to health care services,</P>
                <P>• the quality of health care services,</P>
                <P>• patient freedom of choice among health care providers,</P>
                <P>• competition among health care providers,</P>
                <P>• the cost to Federal health care programs,</P>
                <P>• the potential overutilization of health care services, and</P>
                <P>• the ability of health care facilities to provide services in medically underserved areas or to medically underserved populations.</P>
                <P>In addition, we will consider other factors including, for example, the existence (or nonexistence) of any potential financial benefit to health care professionals or providers that may influence their decision whether to: (1) order a health care item or service or (2) arrange for a referral of health care items or services to a particular practitioner or provider.</P>
                <HD SOURCE="HD2">B. Criteria for Developing Special Fraud Alerts</HD>
                <P>In determining whether to issue additional Special Fraud Alerts, we will consider whether and to what extent the practices that would be identified in a new Special Fraud Alert may result in any of the consequences set forth above, as well as the volume and frequency of the conduct that would be identified in the Special Fraud Alert.</P>
                <SIG>
                    <NAME>Christi A. Grimm,</NAME>
                    <TITLE>Inspector General.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27710 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4152-01-P</BILCOD>
        </PRORULE>
    </PRORULES>
    <VOL>89</VOL>
    <NO>229</NO>
    <DATE>Wednesday, November 27, 2024</DATE>
    <UNITNAME>Notices</UNITNAME>
    <NOTICES>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="93547"/>
                <AGENCY TYPE="F">ADMINISTRATIVE CONFERENCE OF THE UNITED STATES</AGENCY>
                <SUBJECT>Notice of Public Meeting of the Assembly of the Administrative Conference of the United States</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Administrative Conference of the United States</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Assembly of the Administrative Conference of the United States (ACUS) will meet during a one-day hybrid plenary session to consider three proposed recommendations and to conduct other business. Written comments may be submitted in advance, and the meeting will be accessible to the public.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The meeting will take place on Thursday, December 12, 2024, from 9:30 a.m.-4 p.m. ET. The meeting may adjourn early if all business is concluded prior to the stated end time.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                         For those attending in person, the meeting will be held at The U.S. Small Business Administration Eisenhower Conference Room, 409 Third Street SW, Washington, DC 20416. There will be a virtual attendance option. Information on how the public can access the meeting will be available on the agency's website prior to the meeting at 
                        <E T="03">https://www.acus.gov/event/82nd-plenary-session.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Shawne McGibbon, General Counsel (Designated Federal Officer), Administrative Conference of the United States, Suite 706 South, 1120 20th Street NW, Washington, DC 20036; Telephone 202-480-2080; email 
                        <E T="03">smcgibbon@acus.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The Administrative Conference of the United States makes recommendations to federal agencies, the President, Congress, and the Judicial Conference of the United States regarding the improvement of administrative procedures (5 U.S.C. 594). ACUS's membership, when meeting in plenary session, constitutes the Assembly of the Conference (5 U.S.C. 595).</P>
                <P>
                    <E T="03">Agenda:</E>
                     Three proposed recommendations will be considered by the Assembly. In addition, there will be updates on past, current, and pending ACUS initiatives, as well as other business. Summaries of the recommendations appear below:
                </P>
                <P>
                    <E T="03">Using Algorithmic Tools in Regulatory Enforcement.</E>
                     This proposed recommendation provides best practices for using artificial intelligence, predictive analytics, and other algorithmic tools to support agencies' regulatory enforcement efforts. It addresses the potential benefits and risks of using algorithmic tools to detect, investigate, and prosecute noncompliance with the law and identifies policies, practices, and organizational structures that agencies can put in place to ensure they enforce the law fairly, accurately, and efficiently.
                </P>
                <P>
                    <E T="03">Public Engagement in Agency Rulemaking Under the Good Cause Exemption:</E>
                     This proposed recommendation provides best practices for public engagement when agencies find good cause to forgo notice-and-comment rulemaking procedures under the Administrative Procedure Act. It encourages agencies to use direct final rulemaking, interim final rulemaking, and alternative methods of public engagement to ensure robust public participation even when they rely properly on the good cause exemption.
                </P>
                <P>
                    <E T="03">Nonlawyer Assistance and Representation.</E>
                     This proposed recommendation provides best practices for agencies to increase the availability of nonlawyer representation and assistance to participants in their adjudicative systems. It provides guidance on the establishment of rules authorizing qualification or, as appropriate, accreditation of nonlawyer representatives; ways to make such processes accessible and transparent; and strategies for coordinating with other government agencies and nongovernmental organizations to increase the availability of representation and assistance.
                </P>
                <P>
                    Additional information about the proposals and the agenda, as well as any changes or updates to the same, can be found at the 82nd Plenary Session page on ACUS's website prior to the start of the meeting at: 
                    <E T="03">https://www.acus.gov/event/82nd-plenary-session.</E>
                </P>
                <P>
                    <E T="03">Public Participation:</E>
                     ACUS welcomes the virtual attendance of the public at the meeting. Members of the public wishing to view the meeting are asked to RSVP online at the 82nd Plenary Session web page shown above no later than two days before the meeting to ensure adequate bandwidth and accessibility. A link to a livestream of the meeting will be posted the morning of the meeting on the 82nd Plenary Session web page. A video recording of the meeting will be available on ACUS's website shortly after the conclusion of the event at 
                    <E T="03">https://youtube.com/channel/UC1Gu44Jq1U7XsGdC9Tfl_zA.</E>
                </P>
                <P>
                    <E T="03">Written Comments:</E>
                     Persons who wish to comment on any of the proposed recommendations may do so by submitting a written statement either by email to 
                    <E T="03">info@acus.gov</E>
                     with “December 2024 Plenary Session Comments” in the subject line of the email, or by U.S. Mail addressed to: December 2024 Plenary Session Comments, Administrative Conference of the United States, Suite 706 South, 1120 20th Street NW, Washington, DC 20036. Written submissions must be received no later than 10:00 a.m. (EDT), Friday, December 6, 2024, to ensure consideration by the Assembly.
                </P>
                <EXTRACT>
                    <FP>(Authority: 5 U.S.C. 595)</FP>
                </EXTRACT>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Shawne McGibbon,</NAME>
                    <TITLE>General Counsel.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27867 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6110-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">AGENCY FOR INTERNATIONAL DEVELOPMENT</AGENCY>
                <SUBJECT>Notice of Advisory Committee Public Meeting</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Agency for International Development (USAID).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of advisory committee public meeting and request for public comment.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Pursuant to the Federal Advisory Committee Act (FACA), notice is hereby given of Advisory Committee on Voluntary Foreign Aid (ACVFA) public meeting on Thursday, December 12, 2024.</P>
                </SUM>
                <ADD>
                    <PRTPAGE P="93548"/>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        To view additional information related to ACVFA please visit 
                        <E T="03">https://www.usaid.gov/organization/advisory-committee.</E>
                    </P>
                    <P>The meeting will feature remarks by the USAID Administrator and the ACVFA Chair, and two discussion panels featuring ACVFA members on (1) development and national security, and (2) ongoing challenges and opportunities for USAID policy and programming.</P>
                    <P>
                        You may submit comments regarding the work of ACVFA to 
                        <E T="03">acvfa@usaid.gov.</E>
                         Include “Public Comment, ACVFA Meeting, December 12, 2024” in the subject line. All public comments and questions will be included in the official record of the meeting and posted publicly on the USAID website.
                    </P>
                    <P>
                        American Sign Language interpretation will be provided during the public meeting. If you require a reasonable accommodation, please email 
                        <E T="03">reasonableaccommodations@usaid.gov.</E>
                         Include “Request for Reasonable Accommodation, ACVFA Meeting, December 12, 2024” in the subject line.
                    </P>
                    <P>
                        The entirety of this meeting is open to the public. You may register to watch the live public meeting at this link: 
                        <E T="03">https://usaid.zoomgov.com/webinar/register/WN_JQF23hAxRFmqPNJZLt1ZfQ.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Karen Vargas, Designated Federal Officer for ACVFA, at 
                        <E T="03">kvargas@usaid.gov</E>
                         or 202-705-5769.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>ACVFA is USAID's external advisory committee, bringing together representatives from private voluntary organizations, nongovernmental organizations, academia, civil society, and the private sector to foster understanding, communication, and cooperation in the area of foreign aid.</P>
                <P>Pursuant to its charter, ACVFA is holding an annual public meeting on December 12, 2024, from 10:30 a.m.-12 p.m. ET. This meeting is free and open to the public. The Committee welcomes public participation and comment via the web and/or email addresses provided above.</P>
                <SIG>
                    <NAME>Karen Vargas,</NAME>
                    <TITLE>ACVFA Designated Federal Officer.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27793 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6116-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF AGRICULTURE</AGENCY>
                <SUBAGY>Forest Service</SUBAGY>
                <SUBJECT>Intent To Renew the Northwest Forest Plan Area Advisory Committee</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Forest Service, United States Department of Agriculture (USDA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of intent to renew the Charter for the Northwest Forest Plan Area Advisory Committee.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In accordance with the Federal Advisory Committee Act (FACA), as amended, the United States Department of Agriculture announces its intent to renew the Charter for the Northwest Forest Plan Area Advisory Committee (Committee). The Charter for the Northwest Forest Plan Area Advisory Committee is being renewed so that the Committee may provide continued advice and recommendations on landscape management approaches and implementation of such approaches that promote sustainability, climate change adaptations, and wildfire resilience while providing for increasing use of and demands from National Forest System lands in the Northwest Forest Plan area. The Committee will be governed by the provisions of FACA. Duration of the Committee is for two years unless renewed by the Secretary of Agriculture.</P>
                </SUM>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        USDA Forest Service, 1220 Southwest 3rd Avenue, Ste. G015, Portland, OR 97204. Committee information can also be found on the Northwest Forest Plan Federal Advisory Committee website at 
                        <E T="03">https://www.fs.usda.gov/detail/r6/landmanagement/planning/?cid=fseprd1076013</E>
                         or by contacting the person listed under 
                        <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                        .
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Inquiries may be sent to Ann Eberhart Goode, U.S. Department of Agriculture, Forest Service, by phone at (707) 562-8738 or email at 
                        <E T="03">ann.goode@usda.gov</E>
                         or Delaney Caslow, U.S. Department of Agriculture, Forest Service, by phone at (503) 804-3545 or email at 
                        <E T="03">delaney.caslow@usda.gov.</E>
                         Individuals who use telecommunications devices for the hearing impaired may call 711 to reach the Telecommunications Relay Service, 24 hours a day, every day of the year, including holidays.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>In accordance with the provisions of the Federal Advisory Committee Act (FACA), as amended (5 U.S.C. app. 2), with the concurrence of the General Services Administration (GSA), and subject to the approval of the Secretary of Agriculture, the USDA Forest Service intends to renew the Federal Advisory Committee for sustainable, climate-adapted, wildfire-resilient landscapes across the Northwest Forest Plan (NWFP) area. The Committee will be a discretionary advisory committee. The Committee will operate under the provisions of the FACA and will report to the Secretary of Agriculture through the Chief of the Forest Service. The purpose of the Committee is to provide advice and recommendations on landscape management approaches and implementation of such approaches that promote sustainability, climate change adaptations, and wildfire resilience while providing for increasing use of and demands from National Forest System lands in the NWFP area. Accordingly, the Committee will be asked to perform the following duties or fulfill other requests made by the Secretary of Agriculture or the Chief of the Forest Service by offering recommendations on:</P>
                <P>1. Planning and implementation options that complement the national Wildfire Crisis Strategy to assist the USDA Forest Service to transition to greater proactive wildfire risk reduction and address key obstacles related to existing vegetation management.</P>
                <P>2. Approaches to address the dynamic nature of ecosystems, utilize adaptive management, monitoring, and integration of future uncertainty into land management planning.</P>
                <P>3. Application of the best available science regarding the following primary issues: (a) the ecological importance of old forests; (b) climate change, fire, and associated disturbance processes; (c) terrestrial and aquatic reserved land use allocations and the relationship between the two; (d) the climatic diversity of forests encompassed by the NWFP area; and (e) habitat connectivity at multiple scales in light of changed conditions.</P>
                <P>4. Incorporation of traditional ecological knowledge and indigenous perspectives and values into Federal forest planning and management.</P>
                <P>5. Communication tools and strategies to: (a) help provide greater understanding of landscape or programmatic level planning and implementation options and requirements and (b) enhance outreach efforts, public engagement, meaningful Tribal consultation and participation, targeted outreach to underserved communities, and stakeholder collaboration within the scope of the Committee.</P>
                <P>
                    6. Issue preliminary discrete recommendations in sequence with Forest Service NWFP planning and implementation timelines.
                    <PRTPAGE P="93549"/>
                </P>
                <P>All deliverables will be submitted to the Designated Federal Official (DFO) at USDA Forest Service, 1220 Southwest 3rd Avenue, Ste. G015, Portland, OR 97204.</P>
                <P>
                    The Committee will meet approximately four to six times annually or as often as necessary and at such times as designated by the DFO. Subcommittees may meet more frequently. Attendance may be in-person, by telephone, or by other electronic means. Meetings of the Committee whether in person, by telephone or electronic means shall be announced 15 calendar days in advance in the 
                    <E T="04">Federal Register</E>
                    . As required by the FACA, the Committee will hold open meetings unless the Secretary determines that a meeting or a portion of a meeting may be closed to the public in accordance with subsection C of section 522(b) of title 5, United States Code. All proceedings and relevant documents will be posted and made accessible to the public. No individual who is currently registered as a Federal lobbyist is eligible to serve as a member of the Committee.
                </P>
                <HD SOURCE="HD1">Overview and Membership</HD>
                <P>The Committee will be comprised of up to 23 members approved by the Secretary of Agriculture, and each will serve a two-year term. The Committee membership will be fairly balanced in terms of the points of view represented and functions to be performed. Members of the Committee will serve without compensation but may be reimbursed for travel expenses while performing duties on behalf of the Committee, subject to approval by the DFO and the Department. The Committee should represent to the extent possible, a balance across the three states covered by the NWFP (Oregon, Washington, and California) and reflect the demographic diversity of the NWFP area. The Committee shall include representation from experts in the following interest areas:</P>
                <P>
                    (1) 
                    <E T="03">Science:</E>
                     Up to 9 members who represent the scientific community, and have an understanding in the following disciplines and how they relate to the NWFP area:
                </P>
                <FP SOURCE="FP-1">(a) Forest ecology</FP>
                <FP SOURCE="FP-1">(b) Vegetation management</FP>
                <FP SOURCE="FP-1">(c) Fire ecology</FP>
                <FP SOURCE="FP-1">(d) Terrestrial wildlife ecology</FP>
                <FP SOURCE="FP-1">(e) Aquatic and riparian ecosystems and species</FP>
                <FP SOURCE="FP-1">(f) Climate change</FP>
                <FP SOURCE="FP-1">(g) Social science</FP>
                <FP SOURCE="FP-1">(h) Adaptive management and planning</FP>
                <FP SOURCE="FP-1">(i) Indigenous Traditional Ecological Knowledge (ITEK) practitioners</FP>
                <P>
                    (2) 
                    <E T="03">Organizations:</E>
                     Up to 8 members who represent a broad array of organizations with an interest in NWFP forests:
                </P>
                <FP SOURCE="FP-1">(a) National, regional, or local conservation organizations with staff and active programs in the Pacific Northwest</FP>
                <FP SOURCE="FP-1">(b) Forest products industry</FP>
                <FP SOURCE="FP-1">(c) Recreation organization</FP>
                <FP SOURCE="FP-1">(d) Organization involved in outreach with underserved communities</FP>
                <FP SOURCE="FP-1">(e) Forest collaborative groups</FP>
                <FP SOURCE="FP-1">(f) Wildlife organization</FP>
                <FP SOURCE="FP-1">(g) Watershed organization</FP>
                <P>
                    (3) 
                    <E T="03">Government and public:</E>
                     Up to 6 members who represent governmental entities or the public at large:
                </P>
                <FP SOURCE="FP-1">(a) Member of the affected public at large</FP>
                <FP SOURCE="FP-1">(b) Represent state governments</FP>
                <FP SOURCE="FP-1">(c) Represent counties</FP>
                <FP SOURCE="FP-1">(d) Represent American Indian Tribes</FP>
                <P>
                    Meeting locations will be compliant with the Americans with Disabilities Act, and the USDA provides reasonable accommodation to individuals with disabilities where appropriate. If you are a person requiring reasonable accommodation, please make requests in advance for sign language interpretation, assistive listening devices, or other reasonable accommodation to the person listed under the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section or contact USDA's TARGET Center at (202) 720-2600 (voice and TTY) or USDA through the Federal Relay Service at (800) 877-8339. Additionally, program information may be made available in languages other than English.
                </P>
                <P>USDA programs are prohibited from discriminating based on race, color, national origin, religion, sex, gender identity (including gender expression), sexual orientation, disability, age, marital status, family/parental status, income derived from a public assistance program, political beliefs, or reprisal or retaliation for prior civil rights activity, in any program or activity conducted or funded by USDA (not all bases apply to all programs). Remedies and complaint filing deadlines vary by program or incident.</P>
                <P>Equal opportunity practices in accordance with USDA policies shall be followed in all membership appointments to the Committee. To ensure that the recommendations of the Committee have taken into account the needs of the diverse groups served by USDA, membership shall include, to the extent practicable, individuals with demonstrated ability to represent the many communities, identities, races, ethnicities, backgrounds, abilities, cultures, and beliefs of the American people, including underserved communities. Persons with disabilities who require alternative means of communication for program information (Braille, large print, audiotape, American Sign Language, etc.) should contact the responsible agency or USDA's TARGET Center at (202) 720-2600 (voice and TTY) or contact USDA through the Federal Relay Service at (800) 877-8339. Additionally, program information may be made available in languages other than English. USDA is an equal opportunity provider, employer, and lender.</P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Cikena Reid,</NAME>
                    <TITLE>USDA Committee Management Officer.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27781 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3411-15-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">COMMISSION ON CIVIL RIGHTS</AGENCY>
                <SUBJECT>Notice of Public Meeting of the Colorado Advisory Committee to the U.S. Commission on Civil Rights</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Commission on Civil Rights.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of public meeting.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Notice is hereby given, pursuant to the provisions of the rules and regulations of the U.S. Commission on Civil Rights (Commission) and the Federal Advisory Committee Act that the Colorado Advisory Committee (Committee) to the U.S. Commission on Civil Rights will convene a monthly virtual business meeting on Wednesday, December 18, 2024, at 3:00 p.m. Mountain Time. The purpose of the meeting is to review the final version of its report on public school attendance zones in Colorado. The committee will vote on the report and discuss next steps.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Wednesday, December 18, 2024, at 3:00 p.m. Mountain Time.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>The meeting will be held via Zoom.</P>
                    <FP SOURCE="FP-1">
                        <E T="03">Meeting Link (Audio/Visual): https://tinyurl.com/279fjudv;</E>
                         password: USCCR-CO
                    </FP>
                    <FP SOURCE="FP-1">
                        <E T="03">Join by Phone (Audio Only):</E>
                         1-833-435-1820; Meeting ID: 160 614 2807#
                    </FP>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Barbara Delaviez, Designated Federal Official, at 
                        <E T="03">bdelaviez@usccr.gov.</E>
                         or by phone at 202-539-8246.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Any interested member of the public may attend the meeting via the link above. Before adjourning the meeting, the committee chair will announce that any member of the public may make a brief 
                    <PRTPAGE P="93550"/>
                    oral statement, as time allows. Per the Federal Advisory Committee Act, public minutes of the meeting will include a list of persons who are present at the meeting. If joining via phone, callers can expect to incur regular charges for calls they initiate over wireless lines, according to their wireless plan. The Commission will not refund any incurred charges. Callers will incur no charge for calls they initiate over land-line connections to the toll-free telephone number. Closed captioning is available by selecting “CC” in the meeting platform. To request additional accommodations, please email 
                    <E T="03">ebohor@usccr.gov</E>
                     at least 10 business days prior to each meeting.
                </P>
                <P>
                    Members of the public are entitled to submit written comments; the comments must be received in the regional office within 30 days following the scheduled meeting. Written comments may be emailed to Barbara Delaviez at 
                    <E T="03">bdelaviez@usccr.gov;</E>
                     please include Colorado Committee in the subject line of the transmitting email. Persons who desire additional information may contact the Regional Programs Coordination Unit at 1-312-353-8311.
                </P>
                <P>
                    Records generated from these meetings may be inspected and reproduced at the Regional Programs Coordination Unit Office, as they become available, both before and after the meetings. Records of the meeting will be available via 
                    <E T="03">www.facadatabase.gov</E>
                     under the Commission on Civil Rights, Colorado Advisory Committee link. Persons interested in the work of this Committee are directed to the Commission's website, 
                    <E T="03">http://www.usccr.gov,</E>
                     or may contact the Regional Programs Coordination Unit at 
                    <E T="03">ebohor@usccr.gov.</E>
                </P>
                <HD SOURCE="HD1">Agenda</HD>
                <FP SOURCE="FP-2">I. Welcome and Roll Call</FP>
                <FP SOURCE="FP-2">II. Report Stage: Discuss and Vote on Report—Public School Attendance Zones</FP>
                <FP SOURCE="FP-2">III. Discuss Next Steps</FP>
                <FP SOURCE="FP-2">IV. Public Comment</FP>
                <FP SOURCE="FP-2">V. Adjournment</FP>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>David Mussatt,</NAME>
                    <TITLE>Supervisory Chief, Regional Programs Unit.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27736 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6335-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">COMMISSION ON CIVIL RIGHTS</AGENCY>
                <SUBJECT>Notice of Public Meeting of the Utah Advisory Committee; Cancellation</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Commission on Civil Rights.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice; cancellation of meeting.</P>
                </ACT>
                <P>
                    The Commission on Civil Rights published a notice in the 
                    <E T="04">Federal Register</E>
                     concerning a meeting of the Utah Advisory Committee. The meeting, scheduled for Wednesday, November 20, 2024, at 3 p.m. MT, has been cancelled. The notice is in the 
                    <E T="04">Federal Register</E>
                     on Tuesday, November 19, 2024, in FR Document Number 2024-26723 at 89 FR 91319-91320.
                </P>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Liliana Schiller, Support Services Specialist, at 
                        <E T="03">lschiller@usccr.gov</E>
                         or (202) 770-1856.
                    </P>
                    <SIG>
                        <DATED>Dated: November 21, 2024.</DATED>
                        <NAME>David Mussatt,</NAME>
                        <TITLE>Supervisory Chief, Regional Programs Unit.</TITLE>
                    </SIG>
                </FURINF>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27738 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6335-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">COMMISSION ON CIVIL RIGHTS</AGENCY>
                <SUBJECT>Notice of Public Meeting of the Puerto Rico Advisory Committee to the U.S. Commission on Civil Rights</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Commission on Civil Rights.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Announcement of meeting.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Notice is hereby given, pursuant to the provisions of the rules and regulations of the U.S. Commission on Civil Rights (Commission), and the Federal Advisory Committee Act (FACA), that a meeting of the Puerto Rico Advisory Committee to the Commission will convene by virtual web conference on Wednesday, December 11, 2024, at 3:30 p.m. Atlantic Time/Eastern Time. The purpose is to continue discussion on their project on the civil rights impacts of the Insular Cases in Puerto Rico.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P> December 11, 2024, Wednesday, at 3:30 p.m. Atlantic Time (3:30 p.m. ET).</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P> Meeting will be held via Zoom.</P>
                    <P>
                        <E T="03">Registration Link (Audio/Visual): https://tinyurl.com/rbhrynke;</E>
                         Passcode, if needed: USCCR-PR.
                    </P>
                    <P>
                        <E T="03">Join by Phone (Audio Only):</E>
                         1-833-435-1820 USA Toll Free; Meeting ID: 161 027 9371 #.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Email Victoria Moreno, Designated Federal Officer at 
                        <E T="03">vmoreno@usccr.gov,</E>
                         or by phone at 434-515-0204.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    This meeting will take place in Spanish with English interpretation. This committee meeting is available to the public through the registration link above. Any interested member of the public may listen to the meeting. An open comment period will be provided to allow members of the public to make a statement as time allows. Per the Federal Advisory Committee Act, public minutes of the meeting will include a list of persons who are present at the meeting. If joining via phone, callers can expect to incur regular charges for calls they initiate over wireless lines, according to their wireless plan. The Commission will not refund any incurred charges. Callers will incur no charge for calls they initiate over land-line connections to the toll-free telephone number. Closed captioning will be available for individuals who are deaf, hard of hearing, or who have certain cognitive or learning impairments. To request additional accommodations, please email 
                    <E T="03">ebohor@usccr.gov</E>
                     at least 10 business days prior to the meeting.
                </P>
                <P>
                    Members of the public are entitled to submit written comments; the comments must be received in the regional office within 30 days following the meeting. Written comments may be emailed to Victoria Moreno at 
                    <E T="03">vmoreno@usccr.gov.</E>
                     Persons who desire additional information may contact the Regional Programs Coordination Unit at 1-312-353-8311.
                </P>
                <P>
                    Records generated from this meeting may be inspected and reproduced at the Regional Programs Coordination Unit Office, as they become available, both before and after the meeting. Records of the meetings will be available via 
                    <E T="03">www.facadatabase.gov</E>
                     under the Commission on Civil Rights, Puerto Rico Advisory Committee link. Persons interested in the work of this Committee are directed to the Commission's website, 
                    <E T="03">http://www.usccr.gov,</E>
                     or may contact the Regional Programs Coordination Unit at 
                    <E T="03">ebohor@usccr.gov.</E>
                </P>
                <HD SOURCE="HD1">Agenda</HD>
                <FP SOURCE="FP-2">1. Welcome &amp; Roll Call</FP>
                <FP SOURCE="FP-2">2. Committee Discussion on Project Regarding the Civil Rights Impacts of the Insular Cases in Puerto Rico</FP>
                <FP SOURCE="FP-2">3. Next Steps</FP>
                <FP SOURCE="FP-2">4. Public Comment</FP>
                <FP SOURCE="FP-2">5. Other Business</FP>
                <FP SOURCE="FP-2">6. Adjourn</FP>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>David Mussatt,</NAME>
                    <TITLE>Supervisory Chief, Regional Programs Unit.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27852 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="93551"/>
                <AGENCY TYPE="N">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>International Trade Administration</SUBAGY>
                <DEPDOC>[Application No. 19-5A001]</DEPDOC>
                <SUBJECT>Export Trade Certificate of Review</SUBJECT>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of application for an amended Export Trade Certificate of Review for National Pecan Shellers Association (NPSA), Application No. 19-5A001.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Secretary of Commerce, through the Office of Trade and Economic Analysis (OTEA) of the International Trade Administration, has received an application for an amended Export Trade Certificate of Review (Certificate). This notice summarizes the proposed application and seeks public comments on whether the Certificate should be issued.</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Amanda Reynolds, Acting Director, OTEA, International Trade Administration, (202) 482-5131 (this is not a toll-free number) or email at 
                        <E T="03">etca@trade.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Title III of the Export Trading Company Act of 1982 (15 U.S.C. 4011-21) authorizes the Secretary of Commerce to issue Export Trade Certificates of Review. An Export Trade Certificate of Review protects the holder and the members identified in the Certificate from State and Federal government antitrust actions and from private treble damage antitrust actions for the export conduct specified in the Certificate and carried out in compliance with its terms and conditions. The regulations implementing Title III are found at 15 CFR part 325. OTEA is issuing this notice pursuant to 15 CFR 325.6(a), which requires the Secretary of Commerce to publish a summary of the application in the 
                    <E T="04">Federal Register</E>
                    , identifying the applicant and each member and summarizing the proposed export conduct.
                </P>
                <HD SOURCE="HD1">Request for Public Comments</HD>
                <P>Interested parties may submit written comments relevant to the determination whether a Certificate should be issued. If the comments include any privileged or confidential business information, it must be clearly marked and a nonconfidential version of the comments (identified as such) should be included. Any comments not marked as privileged or confidential business information will be deemed to be nonconfidential.</P>
                <P>
                    Written comments should be sent to 
                    <E T="03">ETCA@trade.gov.</E>
                     An original and two (2) copies should also be submitted no later than 20 days after the date of this notice to: Office of Trade and Economic Analysis, International Trade Administration, U.S. Department of Commerce, Room 21028, Washington, DC 20230.
                </P>
                <P>Information submitted by any person is exempt from disclosure under the Freedom of Information Act (5 U.S.C. 552). However, nonconfidential versions of the comments will be made available to the applicant if necessary for determining whether or not to issue the Certificate. Comments should refer to this application as “Export Trade Certificate of Review, application number 19-5A001.”</P>
                <HD SOURCE="HD1">Summary of the Application</HD>
                <P>
                    <E T="03">Applicant:</E>
                     National Pecan Shellers Association, 4348 Carter Creek Pkwy Ste 101, Bryan, TX 77802.
                </P>
                <P>
                    <E T="03">Contact:</E>
                     Catherine Clark and Kelsey Wallis, Managing Staff at Texas Pecan Growers Association.
                </P>
                <P>
                    <E T="03">Application No.:</E>
                     19-5A001.
                </P>
                <P>
                    <E T="03">Date Deemed Submitted:</E>
                     November 13, 2024.
                </P>
                <P>
                    <E T="03">Proposed Amendment:</E>
                     National Pecan Shellers Association seeks to amend its Certificate as follows:
                </P>
                <P>1. Add the following entities as Exporting Members of the Certificate within the meaning of section 325.2(l) of the Regulations (15 CFR 325.2(l)):</P>
                <FP SOURCE="FP-1">• Pecaninis Inc., San Antonio, TX</FP>
                <FP SOURCE="FP-1">• Rancho Pecana, El Paso, TX</FP>
                <P>2. Remove the following companies as Members of the Certificate:</P>
                <FP SOURCE="FP-1">• Exporting Members</FP>
                <FP SOURCE="FP-1">○ Chase Pecan, LP, San Saba, TX</FP>
                <FP SOURCE="FP-1">○ John B. Sanfilippo &amp; Son, Inc., Elgin, IL</FP>
                <FP SOURCE="FP-1">○ Lamar Pecan Company, Hawkinsville, GA</FP>
                <FP SOURCE="FP-1">• Non-exporting Members</FP>
                <FP SOURCE="FP-1">○ The Kellen Company, Atlanta, GA (Independent Third Party)</FP>
                <P>3. Change the location of the following Non-exporting Member of the Certificate:</P>
                <FP SOURCE="FP-1">• Pecan Export Trade Council's location changes from Atlanta, GA to Bryan, TX</FP>
                <P>NPSA's proposed amendment of its Certificate would result in the following Membership list:</P>
                <HD SOURCE="HD2">Exporting Members</HD>
                <FP SOURCE="FP-1">• Arnco, Inc. dba Carter Pecan, Panama City Beach, FL</FP>
                <FP SOURCE="FP-1">• Diamond Foods LLC, Stockton, CA</FP>
                <FP SOURCE="FP-1">• Easterlin Pecan Co, Montezuma, GA</FP>
                <FP SOURCE="FP-1">• HNH Nut Company, Visalia, CA</FP>
                <FP SOURCE="FP-1">• Hudson Pecan Co., Inc., Ocilla, GA</FP>
                <FP SOURCE="FP-1">• Humphrey Pecan LLC, San Antonio, TX</FP>
                <FP SOURCE="FP-1">• La Nogalera USA Inc., El Paso, TX</FP>
                <FP SOURCE="FP-1">• Navarro Pecan Company, Corsicana, TX</FP>
                <FP SOURCE="FP-1">• Pecan Grove Farms, Dallas, TX</FP>
                <FP SOURCE="FP-1">• Pecan Star &amp; Nut Corp, San Antonio, TX</FP>
                <FP SOURCE="FP-1">• Pecaninis Inc., San Antonio, TX</FP>
                <FP SOURCE="FP-1">• Rancho Pecana, El Paso, TX</FP>
                <FP SOURCE="FP-1">• South Georgia Pecan Company, Valdosta, GA</FP>
                <FP SOURCE="FP-1">• Southern Roots Nut Company, LLC, Las Cruces, NM</FP>
                <HD SOURCE="HD2">Non-exporting Members</HD>
                <FP SOURCE="FP-1">• Pecan Export Trade Council, Bryan, TX</FP>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Amanda Reynolds,</NAME>
                    <TITLE>Acting Director, Office of Trade and Economic Analysis, International Trade Administration, U.S. Department of Commerce.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27866 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-DR-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>National Institute of Standards and Technology</SUBAGY>
                <SUBJECT>National Council on Weights and Measures 2025 Interim Meeting</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Institute of Standards and Technology, Commerce.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The 2025 Interim Meeting of the National Council on Weights and Measures (NCWM) will be held in-person at the Francis Marion Hotel, Charleston, South Carolina from Sunday, January 12, 2025, through Wednesday, January 15, 2025. This notice contains information about the most significant agenda items of the NCWM committees. As a result, the items are not consecutively numbered.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        The 2025 NCWM Interim Meeting will be held from Sunday, January 12, 2025, through Wednesday, January 15, 2025. The meeting schedule will be available on the NCWM website at 
                        <E T="03">www.ncwm.com.</E>
                    </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>This meeting will be held at the Francis Marion Hotel, with an address at 387 King Street, Charleston, South Carolina 29403.</P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Dr. Katrice Lippa, NIST, Office of Weights and Measures, 100 Bureau Drive, Stop 2600, Gaithersburg, MD 20899-2600. You may also contact Dr. Lippa at (301) 975-3116 or by email at 
                        <E T="03">katrice.lippa@nist.gov.</E>
                         The meeting is open to the public, but the payment of a registration fee is required. Please see the NCWM website (
                        <E T="03">www.ncwm.com</E>
                        ) to view the 
                        <PRTPAGE P="93552"/>
                        meeting agendas, registration forms, and hotel reservation information.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Publication of this notice on the NCWM's behalf is undertaken as a public service and does not itself constitute an endorsement by the National Institute of Standards and Technology (NIST) of the content of the notice. NIST participates in the NCWM as an NCWM member and pursuant to 15 U.S.C. 272(b)(10) and (c)(4) and in accordance with Federal policy (
                    <E T="03">e.g.,</E>
                     OMB Circular A-119 “Federal Participation in the Development and Use of Voluntary Consensus Standards”).
                </P>
                <P>The NCWM is an organization of weights and measures officials of the states, counties, and cities of the United States, and representatives from the private sector and federal agencies. These meetings bring together government officials and representatives of business, industry, trade associations, and consumer organizations on subjects related to the field of weights and measures technology, administration, and enforcement. NIST hosted the first meeting of the NCWM in 1905. Since then, the council has provided a model of cooperation between Federal, State, and local governments and the private sector. NIST participates in the NCWM to provide technical insights and expertise and encourage cooperation between the private sector, federal agencies, and the states in the development of legal metrology requirements. NIST also promotes uniformity in state laws, regulations, and testing procedures used in the regulatory control of commercial weighing and measuring devices, packaged goods, and for other trade and commerce issues.</P>
                <P>
                    The NCWM has established multiple committees, task groups, and other working bodies to address legal metrology issues of interest to, 
                    <E T="03">inter alia,</E>
                     regulatory officials, industry representatives, and consumers. Comments will be taken by the various NCWM committees on agenda items during the open hearing portions of the meeting identified in the meeting schedule. At this stage, the items are proposals. The open hearing sessions are accessible to all registered attendees of the meeting, including both NCWM members and non-members. The meeting also includes committee work sessions in which the committees may, 
                    <E T="03">inter alia,</E>
                     accept comments, withdraw or carryover agenda items that need additional maturation, and develop recommendations for the agenda items for consideration and possible adoption in July 2025 at the NCWM 110th Annual Meeting.
                </P>
                <P>These notices are intended to make interested parties aware of significant agenda items and alert them to the committees' intentions to share reports on the status of each at the 2025 NCWM Interim Meeting. The notices are also presented to invite the participation of manufacturers, experts, consumers, users, and others who may be interested in these efforts.</P>
                <P>
                    The following are brief descriptions of significant agenda items that will receive further consideration by the standing committees at the upcoming 2025 NCWM Interim Meeting. The full agenda of each standing committee is provided in NCWM Publication 15 (
                    <E T="03">ncwm.com/publication-15</E>
                    ). Comments will be taken on recommendations intended to amend NIST Handbook 44, “Specifications, Tolerances, and Other Technical Requirements for Weighing and Measuring Devices” (NIST HB 44), NIST Handbook 130, “Uniform Laws and Regulations in the Areas of Legal Metrology and Fuel Quality” (NIST HB 130), and NIST Handbook 133, “Checking the Net Contents of Packaged Goods” (NIST HB 133). The NIST Handbooks are regularly adopted by the states, either by reference or through administrative procedures.
                </P>
                <HD SOURCE="HD1">NCWM S&amp;T Committee</HD>
                <P>
                    The NCWM Specifications and Tolerances Committee (S&amp;T Committee) will consider proposed amendments to NIST HB 44, including those identified below. A detailed technical review by the NIST Office of Weights and Measures of the S&amp;T Committee agenda items will be made available prior to the 2025 NCWM Interim Meeting in the 2025 NIST OWM Interim Technical Analysis at 
                    <E T="03">https://www.nist.gov/pml/owm/publications/owm-technical-analysis.</E>
                </P>
                <HD SOURCE="HD1">SCL—Scales </HD>
                <HD SOURCE="HD2">SCL-25.1 S.5.2. Parameters for Accuracy Class, S.6. Marking Requirements, and UR.3. Use Requirements</HD>
                <P>The S&amp;T Committee will consider a new proposal submitted by NIST Office of Weights and Measures. The proposal is to amend the requirements to establish a minimum capacity for scales and require that information to be marked on new scales.</P>
                <HD SOURCE="HD2">SCL-25.3 UR.3.14. Zero-Balance Recorded Weight for Forklift Scales</HD>
                <P>The S&amp;T Committee will consider a new proposal submitted by the Pennsylvania Bureau of Ride and Measurement Standards. The proposal is to add a requirement for forklift scales that would require these devices to indicate and record a zero-balance condition prior to determining the weight of the load on the device.</P>
                <HD SOURCE="HD1">FMT—Farm Milk Tanks</HD>
                <HD SOURCE="HD2">FMT-25.1 UR.1. Installation</HD>
                <P>The S&amp;T Committee will consider a new proposal submitted by the USDA-AMS-Dairy Programs. The proposal amends the current section 4.42. Farm Milk Tanks Code paragraph UR.1. Installation to require the leveling legs on stationary farm milk tanks to be permanently attached to the floor by cement as a means to prevent any adjustment to the leveling legs after calibration. The proposal removes the option for defining the correct position of each leg on the floor for tanks that are not permanently mounted in the facility.</P>
                <HD SOURCE="HD1">Item Block 1 (B1)</HD>
                <HD SOURCE="HD2">TXI—Taximeters and TNS—Transportation Network Measurement Systems</HD>
                <HD SOURCE="HD2">
                    B1-TXI-25.1 5.54 
                    <E T="03">Transportation-For-Hire Systems</E>
                </HD>
                <P>The S&amp;T Committee will consider a new proposal submitted by the NCWM Transportation-for-Hire Systems Task Group. The proposal would revise section 5.54., currently titled “Taximeters,” and rename it “Transportation-For-Hire Systems.” The new revised section would combine the existing requirements for taximeters in section 5.54. with those that are currently in section 5.60. Transportation Network Measurement Systems to create a single section addressing both types of vehicle for hire applications.</P>
                <HD SOURCE="HD2">B1-TNS-25.1 Section 5.60. Transportation Network Measurement Systems—Tentative Code</HD>
                <P>The S&amp;T Committee will consider a new proposal submitted by the Transportation-for-Hire Systems Task Group. The proposal would consolidate section 5.60. Transportation Network Measurement Systems with section 5.54. Taximeters. Both sets of requirements would be incorporated into an updated and renamed section 5.54., and section 5.60. would be removed from NIST HB 44.</P>
                <HD SOURCE="HD1">OTH—Other Items</HD>
                <HD SOURCE="HD2">OTH-25.1 2.26. Weigh-in-Motion Systems Used for Vehicle Direct Enforcement</HD>
                <P>
                    The S&amp;T Committee will consider a proposal submitted by New York City 
                    <PRTPAGE P="93553"/>
                    Department of Transportation, NY State Department of Agriculture and Markets, NJ Office of Weights and Measures, Oregon Department of Agriculture, Washington DC Department of Transportation, C2SMART, and Kistler. The proposal is to include a new Section 2.26. Weigh-in-Motion Systems Used for Vehicle Direct Enforcement to NIST HB 44 that provides standards that can be used by local and State agencies to certify Weigh-In-Motion (WIM) systems used for automated enforcement of gross vehicle weight limits.
                </P>
                <HD SOURCE="HD1">NCWM L&amp;R Committee</HD>
                <P>
                    The NCWM Laws and Regulations Committee (L&amp;R Committee) will consider proposed amendments to NIST HB 130, including those identified below. A detailed technical review by the NIST Office of Weights and Measures of the L&amp;R Committee agenda items will be made available prior to the 2025 NCWM Interim Meeting in the 2025 NIST OWM Interim Analysis at 
                    <E T="03">https://www.nist.gov/pml/owm/publications/owm-technical-analysis.</E>
                </P>
                <HD SOURCE="HD1">MOS—NIST Handbook 130</HD>
                <HD SOURCE="HD2">NET-24.2. 2.16.3.1. Tare Weights; Part (c) Allowable difference</HD>
                <P>The L&amp;R Committee will further consider a proposal to clarify the existing language for the method of sale for stamped or stenciled tare weights of Liquefied Petroleum Gas cylinders. This will include changes to existing language within NIST HB 130 that references tolerances for cylinders. It is intended to resolve the discrepancy that exists between NIST Handbook 130 and Title 49 of the Code of Federal Regulations with respect to the allowable differences between the stamped tare weight and the actual tare weight of cylinders used for compressed or liquefied gases in refillable cylinders.</P>
                <HD SOURCE="HD1">OTH—NIST Handbook 130</HD>
                <HD SOURCE="HD2">OTH-24.1 X. Uniform Shipping Law</HD>
                <P>The L&amp;R Committee will further consider a proposal that has been designated as an “Assigned” item, meaning that further development will be done by the NCWM Uniform Shipping Law Task Group. This proposal provides model language for inclusion in NIST HB 130 that would establish Uniform Shipping Laws meant to ensure accurate shipment of goods. This regulation includes language authorizing the enforcement of these regulations, empowers the state to promulgate regulations as needed to carry out the provisions of the Act, and provides for civil and criminal penalties. The development of this item will include outreach to stakeholders, including federal agencies.</P>
                <HD SOURCE="HD1">FALS—Fuels and Lubricants Subcommittee</HD>
                <HD SOURCE="HD2">B2-FLR-24.1 3.12.1.X Identification of Grade &amp; 3.12.2.X. Identification of Grade</HD>
                <P>The L&amp;R Committee will further consider a proposal that has been designated as an “Assigned” item, meaning that the NCWM Fuels and Lubricants Subcommittee is being tasked to fully develop the proposal to ensure the applicable ASTM fuel grade designations are clearly identified for the marketplace. This proposal provides language for a new NIST HB 130 regulation that specifies labeling requirements that will properly identify the grade of natural gas (compressed and liquified to include blends of these products with hydrogen) when this product is dispensed and sold as a vehicle fuel. These standards will be applicable at the point fuel is dispensed into the vehicle.</P>
                <SIG>
                    <NAME>Alicia Chambers,</NAME>
                    <TITLE>NIST Executive Secretariat.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27838 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-13-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>National Oceanic and Atmospheric Administration</SUBAGY>
                <DEPDOC>[RTID 0648-XE497]</DEPDOC>
                <SUBJECT>Gulf of Mexico Fishery Management Council; Public Meeting</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of a public meeting.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Gulf of Mexico Fishery Management Council will hold a one-day in-person meeting of its Shrimp Advisory Panel (AP).</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        The meeting will convene Monday, December 16, 2024, from 8 a.m. to 1:30 p.m., EST. For agenda details, see 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                        .
                    </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The meeting will take place at the Gulf Council office. Registration information will be available on the Council's website by visiting 
                        <E T="03">www.gulfcouncil.org</E>
                         and clicking on the Shrimp AP meeting on the calendar.
                    </P>
                    <P>
                        <E T="03">Council address:</E>
                         Gulf of Mexico Fishery Management Council, 4107 W Spruce Street, Suite 200, Tampa, FL 33607; telephone: (813) 348-1630.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Dr. Matt Freeman, Economist, Gulf of Mexico Fishery Management Council; 
                        <E T="03">matt.freeman@gulfcouncil.org,</E>
                         telephone: (813) 348-1630.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The following items are on the agenda, though agenda items may be addressed out of order (changes will be noted on the Council's website when possible.)</P>
                <HD SOURCE="HD1">Monday, December 16, 2024; 8 a.m.-1:30 p.m., EST (7 a.m.-12:30 p.m. CST)</HD>
                <P>Meeting will begin with Introduction of Members, Election of Chair and Vice Chair, Adoption of Agenda and Approval of Summary from March 19-20, 2024 Meeting, and Scope of Work.</P>
                <P>
                    The AP will review and discuss Council Actions in Response to Motions from the March 2024 
                    <E T="03">Shrimp</E>
                     AP Meeting, discuss the Draft Shrimp Framework Action: Modification of the Vessel Position Data Collection Program for the Gulf of Mexico 
                    <E T="03">Shrimp</E>
                     Fishery, receive a presentation on Survey Design and Estimated Costs for Position-recording Devices in the Gulf of Mexico Shrimp Fleet, and receive an update on 
                    <E T="03">Shrimp</E>
                     Futures Program.
                </P>
                <P>Lastly, the AP will receive any public testimony and discuss other business items.</P>
                <FP>Meeting Adjourns—</FP>
                <P>
                    The in-person meeting will be broadcast via webinar. You may register by visiting 
                    <E T="03">www.gulfcouncil.org</E>
                     and clicking on the 
                    <E T="03">Shrimp</E>
                     Advisory Panel meeting on the calendar.
                </P>
                <P>
                    The Agenda is subject to change, and the latest version along with other meeting materials will be posted on 
                    <E T="03">www.gulfcouncil.org</E>
                     as they become available.
                </P>
                <P>Although other non-emergency issues not on the agenda may come before the Advisory Panel for discussion, in accordance with the Magnuson-Stevens Fishery Conservation and Management Act (Magnuson-Stevens Act), those issues may not be the subject of formal action during this meeting. Actions will be restricted to those issues specifically identified in this notice and any issues arising after publication of this notice that require emergency action under Section 305(c) of the Magnuson-Stevens Act, provided the public has been notified of the Council's intent to take-action to address the emergency at least 5 working days prior to the meeting.</P>
                <HD SOURCE="HD1">Special Accommodations</HD>
                <P>The meeting is physically accessible to people with disabilities. Requests for</P>
                <P>
                    sign language interpretation or other auxiliary aid or accommodations should be directed to Kathy Pereira, 
                    <PRTPAGE P="93554"/>
                    <E T="03">kathy.pereira@gulfcouncil.org,</E>
                     at least 5 days prior to the meeting date.
                </P>
                <P>
                    <E T="03">Authority</E>
                    : 16 U.S.C. 1801 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Rey Israel Marquez,</NAME>
                    <TITLE>Acting Deputy Director, Office of Sustainable Fisheries, National Marine Fisheries Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27770 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-22-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>National Oceanic and Atmospheric Administration</SUBAGY>
                <DEPDOC>[RTID 0648-XE471]</DEPDOC>
                <SUBJECT>Fisheries of the South Atlantic; Southeast Data, Assessment, and Review (SEDAR); Public Meeting</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of SEDAR 92 Atlantic Blueline Tilefish Life History Topical Working Group (LH-TWG) Webinar III.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The SEDAR 92 assessment of the Atlantic stock of blueline tilefish will consist of a series of assessment webinars. See 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                        .
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The SEDAR 92 Atlantic Blueline Tilefish LH-TWG Webinar III is scheduled for December 18, 2024, from 9 a.m. to 11 a.m., Eastern. The established times may be adjusted as necessary to accommodate the timely completion of discussion relevant to the assessment process. Such adjustments may result in the meeting being extended from or completed prior to the time established by this notice.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">Meeting address:</E>
                         The meeting will be held via webinar. The webinar is open to members of the public. Registration for the webinar is available by contacting the SEDAR coordinator via email at 
                        <E T="03">Julie.Neer@safmc.net.</E>
                    </P>
                    <P>
                        <E T="03">SEDAR address:</E>
                         South Atlantic Fishery Management Council, 4055 Faber Place Drive, Suite 201, N. Charleston, SC 29405. 
                        <E T="03">www.sedarweb.org.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Julie Neer, SEDAR Coordinator, 4055 Faber Place Drive, Suite 201, North Charleston, SC 29405; phone: (843) 571-4366; email: 
                        <E T="03">Julie.Neer@safmc.net.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The Gulf of Mexico, South Atlantic, and Caribbean Fishery Management Councils, in conjunction with NOAA Fisheries and the Atlantic and Gulf States Marine Fisheries Commissions, have implemented the Southeast Data, Assessment and Review (SEDAR) process, a multi-step method for determining the status of fish stocks in the Southeast Region. SEDAR is a three-step process including: (1) Data Workshop; (2) Assessment Process utilizing webinars; and (3) Review Workshop. The product of the Data Workshop is a data report which compiles and evaluates potential datasets and recommends which datasets are appropriate for assessment analyses. The product of the Assessment Process is a stock assessment report which describes the fisheries, evaluates the status of the stock, estimates biological benchmarks, projects future population conditions, and recommends research and monitoring needs. The assessment is independently peer reviewed at the Review Workshop. The product of the Review Workshop is a Summary documenting panel opinions regarding the strengths and weaknesses of the stock assessment and input data. Participants for SEDAR Workshops are appointed by the Gulf of Mexico, South Atlantic, and Caribbean Fishery Management Councils and NOAA Fisheries Southeast Regional Office, Highly Migratory Species Management Division, and Southeast Fisheries Science Center. Participants include: data collectors and database managers; stock assessment scientists, biologists, and researchers; constituency representatives including fishermen, environmentalists, and non-governmental organizations (NGOs); international experts; and staff of Councils, Commissions, and state and federal agencies.</P>
                <P>The items of discussion at the SEDAR 92 Atlantic Blueline Tilefish LH-TWG webinar III: The Group will discuss available life history data sources and make recommendation for their use in the assessment.</P>
                <P>Although non-emergency issues not contained in this agenda may come before this group for discussion, those issues may not be the subject of formal action during this meeting. Action will be restricted to those issues specifically identified in this notice and any issues arising after publication of this notice that require emergency action under section 305(c) of the Magnuson-Stevens Fishery Conservation and Management Act, provided the public has been notified of the intent to take final action to address the emergency.</P>
                <HD SOURCE="HD1">Special Accommodations</HD>
                <P>
                    This meeting is accessible to people with disabilities. Requests for auxiliary aids should be directed to the South Atlantic Fishery Management Council office (see 
                    <E T="02">ADDRESSES</E>
                    ) at least 10 business days prior to the meeting.
                </P>
                <NOTE>
                    <HD SOURCE="HED">Note:</HD>
                    <P> The times and sequence specified in this agenda are subject to change.</P>
                </NOTE>
                <P>
                    <E T="03">Authority:</E>
                     16 U.S.C. 1801 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Rey Israel Marquez,</NAME>
                    <TITLE>Acting Deputy Director, Office of Sustainable Fisheries, National Marine Fisheries Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27839 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-22-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>National Oceanic and Atmospheric Administration</SUBAGY>
                <DEPDOC>[RTID 0648-XE496]</DEPDOC>
                <SUBJECT>Endangered and Threatened Species; Initiation of 5-Year Review of the Brazilian Guitarfish (Rhinobatos horkelii)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice; request for information.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        We, NMFS, announce the initiation of a 5-year review of the endangered Brazilian guitarfish (
                        <E T="03">Rhinobatos horkelii</E>
                        ). The Endangered Species Act (ESA) requires us to conduct a review of listed species at least once every 5 years to determine whether a species should be removed from the list (
                        <E T="03">i.e.,</E>
                         delisted), reclassified from an endangered species to a threatened species (
                        <E T="03">i.e.,</E>
                         downlisted), or reclassified from a threatened species to an endangered species (
                        <E T="03">i.e.,</E>
                         uplisted). The determination must be based on the best scientific and commercial data available at the time of the review. Therefore, we request relevant information (
                        <E T="03">e.g.,</E>
                         biology, threats, and conservation efforts) that has become available since our previous review of the species.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>To allow us adequate time to conduct the 5-year review, we must receive your information no later than January 27, 2025. While we accept new information about any listed species at any time, information received after the date stated above may not be considered for the purposes of this review.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your information electronically via the Federal eRulemaking Portal. Go to 
                        <E T="03">https://www.regulations.gov</E>
                         and enter NOAA-NMFS-2024-0137 in the Search box. Click on the “Comment” icon, complete the required fields, and enter or attach your comments.
                        <PRTPAGE P="93555"/>
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         We may not consider comments or other information if sent by any other method, to any other address or individual, or received after the date stated above. All comments and information received are a part of the public record, and we will post the comments for public viewing on 
                        <E T="03">https://www.regulations.gov.</E>
                         All personal identifying information (
                        <E T="03">e.g.,</E>
                         name, address, 
                        <E T="03">etc.</E>
                        ) submitted voluntarily by the sender will be publicly accessible. Do not submit confidential business information, or otherwise sensitive or protected information. We will accept anonymous comments (enter “N/A” in the required fields if you wish to remain anonymous).
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Malcolm Mohead, NMFS Office of Protected Resources, (301) 427-8427, 
                        <E T="03">Malcolm.Mohead@noaa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    This notice announces our initiation of the Brazilian guitarfish (
                    <E T="03">Rhinobatos horkelii</E>
                    ) 5-year review. Section 4(c)(2) of the ESA requires us to conduct a review of listed species at least once every 5 years to determine whether species should be removed from the list, changed in status from an endangered species to a threatened species, or changed in status from a threatened species to an endangered species (16 U.S.C. 1533(c)(2)). Section 4(a)(1) of the ESA requires us to determine whether any species is an endangered or threatened species because of any of the following factors: (A) the present or threatened destruction, modification, or curtailment of its habitat or range; (B) overutilization for commercial, recreational, scientific, or educational purposes; (C) disease or predation; (D) the inadequacy of existing regulatory mechanisms; or (E) other natural or manmade factors affecting its continued existence (16 U.S.C. 1533(a)(1)). Section 4(b)(1)(A) of the ESA requires us to make the determination based solely on the best scientific and commercial data available at the time of the review and after taking into account efforts to protect the species (16 U.S.C. 1533(b)(1)(A)). Regulations in 50 CFR 424.21 require that we publish a notice in the 
                    <E T="04">Federal Register</E>
                     announcing species currently under active review. Based on such reviews, we determine whether a species should be delisted or reclassified (50 CFR 424.21). Any such change (
                    <E T="03">i.e.,</E>
                     delisting or reclassification) would require a separate rulemaking process.
                </P>
                <P>
                    We last performed a review of the Brazilian guitarfish in 2015. Background information on the species is available on the NMFS website at: 
                    <E T="03">https://www.fisheries.noaa.gov/species/brazilian-guitarfish/overview.</E>
                </P>
                <HD SOURCE="HD1">Public Solicitation of Relevant Information</HD>
                <P>To ensure that the 5-year review is based on the best scientific and commercial data available, we are soliciting information from the public, governmental agencies, Tribes, the scientific community, industry, environmental organizations, and any other interested parties. We request information that has become available since the previous review was published in 2015. Categories of requested information include: (1) species biology including, but not limited to, abundance, population trends, demographics, distribution, and diversity; (2) habitat conditions including, but not limited to, amount, distribution, suitability, and important features for conservation; (3) degree, nature, and trends of threats to the species and its habitats, especially those factors described in section 4(a)(1) of the ESA and listed above; (4) conservation efforts that have been implemented to benefit the species, including monitoring data demonstrating the effectiveness of such efforts; and (5) other information, data, or corrections including, but not limited to, taxonomic or nomenclatural changes and improved analytical methods for evaluating extinction risk.</P>
                <P>
                    If you wish to provide information for the review, please submit your information and materials electronically (see 
                    <E T="02">ADDRESSES</E>
                     section). We request that all information be accompanied by supporting documentation such as maps, bibliographic references, or reprints of pertinent publications.
                </P>
                <P>
                    <E T="03">Authority:</E>
                     16 U.S.C. 1531 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Lisa Manning,</NAME>
                    <TITLE>Acting Chief, Endangered Species Conservation Division, Office of Protected Resources, National Marine Fisheries Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27848 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-22-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>National Oceanic and Atmospheric Administration</SUBAGY>
                <DEPDOC>[RTID 0648-XE483]</DEPDOC>
                <SUBJECT>Mid-Atlantic Fishery Management Council (MAFMC); Public Meeting</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice; public meeting.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Mid-Atlantic and New England Fishery Management Councils (Councils) will hold a public meeting of their joint Northeast Trawl Advisory Panel (NTAP).</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        The meeting will be held on Friday, December 13, 2024, from 12 p.m. to  1:30 p.m. For agenda details, see 
                        <E T="02">SUPPLEMENTARY INFORMATION.</E>
                    </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The meeting will be held via webinar. Connection information will be posted to the calendar at 
                        <E T="03">www.mafmc.org</E>
                         prior to the meeting.
                    </P>
                    <P>
                        <E T="03">Council address:</E>
                         Mid-Atlantic Fishery Management Council, 800 N State Street, Suite 201, Dover, DE 19901; telephone: (302) 674-2331; 
                        <E T="03">www.mafmc.org.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Christopher M. Moore, Ph.D., Executive Director, Mid-Atlantic Fishery Management Council, telephone: (302) 526-5255.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The Councils' NTAP will meet to discuss the Operational Manual and Orientation Document. The intent of this meeting is to discuss NTAP in detail, including background, organization, purpose, and member expectation. This meeting will be an opportunity for new and existing NTAP members to discuss and learn about the goals and purposes of NTAP.</P>
                <HD SOURCE="HD1">Special Accommodations</HD>
                <P>The meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Shelley Spedden, (302) 526-5251 at least 5 days prior to the meeting date.</P>
                <P>
                    <E T="03">Authority:</E>
                     16 U.S.C. 1801 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Rey Israel Marquez,</NAME>
                    <TITLE>Acting Deputy Director, Office of Sustainable Fisheries, National Marine Fisheries Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27769 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-22-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF COMMERCE</AGENCY>
                <SUBAGY>National Oceanic and Atmospheric Administration</SUBAGY>
                <DEPDOC>[RTID 0648-XE469]</DEPDOC>
                <SUBJECT>Mid-Atlantic Fishery Management Council (MAFMC); New England Fishery Management Council (NEFMC) Public Meeting</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice; public meeting.</P>
                </ACT>
                <SUM>
                    <PRTPAGE P="93556"/>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Mid-Atlantic Fishery Management Council's Ecosystem and Ocean Planning Committee and New England Fishery Management Council's Habitat Committee will hold a joint public meeting.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        The meeting will be held on Wednesday, December 18, 2024, from 1 p.m. to 4 p.m. For agenda details, see 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                        .
                    </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The meeting will be held via webinar. Webinar connection, agenda items, and any additional information will be available at both 
                        <E T="03">www.mafmc.org/council-events</E>
                         and 
                        <E T="03">https://www.nefmc.org/calendar.</E>
                    </P>
                    <P>
                        <E T="03">Council addresses:</E>
                         Mid-Atlantic Fishery Management Council, 800 N. State Street, Suite 201, Dover, DE 19901; telephone: (302) 674-2331; 
                        <E T="03">www.mafmc.org.;</E>
                         New England Fishery Management Council, 50 Water Street, Mill 2, Newburyport, MA 01950; telephone: (978) 465-0492; 
                        <E T="03">www.nefmc.org.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Christopher M. Moore, Ph.D., Executive Director, Mid-Atlantic Fishery Management Council, telephone: (302) 526-5255 or Cate O'Keefe, Ph.D., Executive Director, New England Fishery Management Council; telephone: (978) 465-0492 (ext. 113).</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The purpose of this joint meeting is for the Ecosystem and Ocean Planning Committee and Habitat Committee to provide recommendations regarding the Councils' Essential Fish Habitat (EFH) reviews and the draft EFH Review Reports being prepared for the Council. Because many of the EFH Review work products apply to the entire Northeastern US, the Committees are being convened jointly for their review. The Committees will receive an overview of the NMFS EFH Review requirements (10 components of an EFH review), and will review components related to (a) Non-Magnuson-Stevens Act fishing activities that may adversely affect EFH, (b) Non-fishing related activities that may adversely affect EFH, (c) Prey species for federally-managed fish species, (d) EFH research needs, and (e) Methods related to the description and identification of EFH.</P>
                <HD SOURCE="HD1">Special Accommodations</HD>
                <P>The meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Shelley Spedden at the Council Office, (302) 526-5251, at least 5 days prior to the meeting date.</P>
                <P>
                    <E T="03">Authority:</E>
                     16 U.S.C. 1801 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Rey Israel Marquez,</NAME>
                    <TITLE>Acting Deputy Director, Office of Sustainable Fisheries, National Marine Fisheries Service.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27843 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3510-22-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF DEFENSE</AGENCY>
                <SUBAGY>Office of the Secretary</SUBAGY>
                <DEPDOC>[Transmittal No. 23-52]</DEPDOC>
                <SUBJECT>Arms Sales Notification</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Defense Security Cooperation Agency, Department of Defense (DoD).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Arms sales notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The DoD is publishing the unclassified text of an arms sales notification.</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Pamela Young at (703) 953-6092, 
                        <E T="03">pamela.a.young14.civ@mail.mil,</E>
                         or 
                        <E T="03">dsca.ncr.rsrcmgmt.list.cns-mbx@mail.mil.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This 36(b)(1) arms sales notification is published to fulfill the requirements of section 155 of Public Law 104-164 dated July 21, 1996. The following is a copy of a letter to the Speaker of the House of Representatives with attached Transmittal 23-52, Policy Justification, and Sensitivity of Technology.</P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Stephanie J. Bost,</NAME>
                    <TITLE>Alternate OSD Federal Register Liaison Officer, Department of Defense.</TITLE>
                </SIG>
                <BILCOD>BILLING CODE 6001-FR-P</BILCOD>
                <GPH SPAN="3" DEEP="555">
                    <PRTPAGE P="93557"/>
                    <GID>EN27NO24.293</GID>
                </GPH>
                <BILCOD>BILLING CODE 6001-FR-C</BILCOD>
                <HD SOURCE="HD3">Transmittal No. 23-52</HD>
                <HD SOURCE="HD3">Notice of Proposed Issuance of Letter of Offer Pursuant to Section 36(b)(1) of the Arms Export Control Act, as amended</HD>
                <P>
                    (i) 
                    <E T="03">Prospective Purchaser:</E>
                     Government of the United Arab Emirates
                </P>
                <P>
                    (ii) 
                    <E T="03">Total Estimated Value:</E>
                </P>
                <GPOTABLE COLS="2" OPTS="L0,tp0,p0,8/9,g1,t1,i1" CDEF="s30,xs56">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Major Defense Equipment *</ENT>
                        <ENT>$45 million</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">Other</ENT>
                        <ENT>$40 million</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="02">Total</ENT>
                        <ENT>$85 million</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Funding Source: National Funds.</P>
                <P>
                    (iii) 
                    <E T="03">Description and Quantity or Quantities of Articles or Services under Consideration for Purchase:</E>
                </P>
                <FP SOURCE="FP-2">
                    <E T="03">Major Defense Equipment (MDE):</E>
                </FP>
                <FP SOURCE="FP1-2">Eighteen (18) AN/TPQ-50 Radar Systems—Man Portable Version</FP>
                <FP SOURCE="FP-2">
                    <E T="03">Non-MDE:</E>
                </FP>
                <FP SOURCE="FP1-2">
                    Also included are 107mm High Explosive (HE) rockets (for CONUS testing only); Computer Digital Military Laptop Radar Control Display units; 5kW Advanced Medium Mobile Power Source (AMMPS) Trailer-Mounted, Diesel Engine Driven Power Unit PU-2001; spares; mission equipment; communication and navigation 
                    <PRTPAGE P="93558"/>
                    equipment; support equipment; repair parts; special tools and test equipment; technical data and publications; site survey; United States (U.S.) Government and contractor technical and logistics personnel services; and other related elements of logistics and program support.
                </FP>
                <P>
                    (iv) 
                    <E T="03">Military Department:</E>
                     Army (AE-B-ZVL).
                </P>
                <P>
                    (v) 
                    <E T="03">Prior Related Cases, if any:</E>
                     None.
                </P>
                <P>
                    (vi) 
                    <E T="03">Sales Commission, Fee, etc., Paid, Offered, or Agreed to be Paid:</E>
                     None.
                </P>
                <P>
                    (vii) 
                    <E T="03">Sensitivity of Technology Contained in the Defense Article or Defense Services Proposed to be Sold:</E>
                     See Attached Annex.
                </P>
                <P>
                    (viii) 
                    <E T="03">Date Report Delivered to Congress:</E>
                     December 4, 2023.
                </P>
                <P>* As defined in Section 47(6) of the Arms Export Control Act.</P>
                <HD SOURCE="HD2">POLICY JUSTIFICATION</HD>
                <HD SOURCE="HD2">United Arab Emirates—AN/TPQ-50 Radar</HD>
                <P>The Government of the United Arab Emirates (UAE) has requested to buy eighteen (18) AN/TPQ-50 Radar Systems—man portable version. Also included are 107mm High Explosive (HE) rockets (for CONUS testing only); Computer Digital Military Laptop Radar Control Display units; 5kW Advanced Medium Mobile Power Source (AMMPS) Trailer-Mounted, Diesel Engine Driven Power Unit PU-2001; spares; mission equipment; communication and navigation equipment; support equipment; repair parts; special tools and test equipment; technical data and publications; site survey; U.S. Government and contractor technical and logistics personnel services; and other related elements of logistics and program support. The estimated total cost is $85 million.</P>
                <P>This proposed sale will support the foreign policy and national security of the United States by helping to improve the security of an important regional partner. The UAE is a vital U.S. partner for political stability and economic progress in the Middle East.</P>
                <P>The proposed sale will support efforts to protect critical infrastructure and high value civilian assets, as well as military installations and forces from rocket, artillery, and mortar (RAM) and unmanned aerial system threats. It will also further enhance the United States—UAE relationship, both politically and militarily, while also increasing the UAE's effectiveness in executing military and civil defense operations that promote U.S. national interests. The UAE will use the TPQ-50 radars to recognize incoming threats from hostile nations or agents of adversary nations. The United Arab Emirates will have no difficulty absorbing this equipment and services into its armed forces.</P>
                <P>The proposed sale of this equipment and support will not alter the basic military balance in the region.</P>
                <P>The principal contractor will be SRC Inc, Syracuse, NY. There are no known offset agreements proposed in connection with this potential sale.</P>
                <P>Implementation of this proposed sale will not require the permanent assignment of any additional U.S. Government or contractor representatives to the UAE. Temporary periods of travel for two-week durations for both U.S. Government and contractor personnel will be necessary to conduct Operator/Maintainer training, as well as System Integration &amp; Check Out (SICO)/Quality Assurance and Testing (QUAT) activities.</P>
                <P>There will be no adverse impact on U.S. defense readiness as a result of this proposed sale.</P>
                <HD SOURCE="HD3">Transmittal No. 23-52</HD>
                <HD SOURCE="HD3">Notice of Proposed Issuance of Letter of Offer Pursuant to Section 36(b)(1) of the Arms Export Control Act</HD>
                <HD SOURCE="HD3">Annex</HD>
                <HD SOURCE="HD3">Item No. vii</HD>
                <P>
                    (vii) 
                    <E T="03">Sensitivity of Technology:</E>
                </P>
                <P>1. The AN/TPQ-50 Radar System—man portable version—provides continuous 360-degree surveillance and 3-D rocket, artillery, and mortar (RAM) locations using a L band non-rotating antenna with fixed elevation beams and which is electronically steered in azimuth only. Its full azimuth coverage allows it to simultaneously detect and track multiple rounds fired from separate locations within a 700 square kilometer surveillance area. The AN/TPQ 50 radar provides Point of Origin (POO) and Point of Impact (POI) locations for hostile RAM fire and tracking of air breathing targets (ABTs) in air surveillance (AS) and multi-mission radar (MMR) modes.</P>
                <P>2. The highest level of classification of defense articles, components, and services included in this potential sale is SECRET.</P>
                <P>3. If a technologically advanced adversary were to obtain knowledge of the specific hardware and software elements, the information could be used to develop countermeasures that might reduce weapon system effectiveness or be used in the development of a system with similar or advanced capabilities.</P>
                <P>4. A determination has been made that the United Arab Emirates can provide substantially the same degree of protection for the sensitive technology being released as the U.S. Government. This sale is necessary in furtherance of the U.S. foreign policy and national security objectives outlined in the Policy Justification.</P>
                <P>5. All defense articles and services listed in this transmittal have been authorized for release and export to the United Arab Emirates.</P>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27773 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6001-FR-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF DEFENSE</AGENCY>
                <SUBAGY>Office of the Secretary</SUBAGY>
                <DEPDOC>[Transmittal No. 23-88]</DEPDOC>
                <SUBJECT>Arms Sales Notification</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Defense Security Cooperation Agency, Department of Defense (DoD).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Arms sales notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The DoD is publishing the unclassified text of an arms sales notification.</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Pamela Young at (703) 953-6092, 
                        <E T="03">pamela.a.young14.civ@mail.mil,</E>
                         or 
                        <E T="03">dsca.ncr.rsrcmgmt.list.cns-mbx@mail.mil.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This 36(b)(1) arms sales notification is published to fulfill the requirements of section 155 of Public Law 104-164 dated July 21, 1996. The following is a copy of a letter to the Speaker of the House of Representatives with attached Transmittal 23-88, Policy Justification, and Sensitivity of Technology.</P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Stephanie J. Bost,</NAME>
                    <TITLE>Alternate OSD Federal Register Liaison Officer, Department of Defense.</TITLE>
                </SIG>
                <BILCOD>BILLING CODE 6001-FR-P</BILCOD>
                <GPH SPAN="3" DEEP="528">
                    <PRTPAGE P="93559"/>
                    <GID>EN27NO24.297</GID>
                </GPH>
                <BILCOD>BILLING CODE 6001-FR-C</BILCOD>
                <HD SOURCE="HD3">Transmittal No. 23-88</HD>
                <HD SOURCE="HD3">Notice of Proposed Issuance of Letter of Offer Pursuant to Section 36(b)(1) of the Arms Export Control Act, as amended</HD>
                <P>
                    (i) 
                    <E T="03">Prospective Purchaser:</E>
                     Government of Germany
                </P>
                <P>
                    (ii) 
                    <E T="03">Total Estimated Value:</E>
                </P>
                <GPOTABLE COLS="2" OPTS="L0,tp0,p0,8/9,g1,t1,i1" CDEF="s30,xs50">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Major Defense Equipment *</ENT>
                        <ENT>$158 million</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">Other</ENT>
                        <ENT>$142 million</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="02">Total</ENT>
                        <ENT>$300 million</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    (iii) 
                    <E T="03">Description and Quantity or Quantities of Articles or Services under Consideration for Purchase:</E>
                </P>
                <FP SOURCE="FP-2">
                    <E T="03">Major Defense Equipment (MDE):</E>
                </FP>
                <FP SOURCE="FP1-2">Up to eighty (80) MK 54 All Up Round Lightweight Torpedoes (LWT)</FP>
                <FP SOURCE="FP-2">
                    <E T="03">Non-MDE:</E>
                </FP>
                <FP SOURCE="FP1-2">Also included are MK 54 Mod 0 LWT spare parts; Recoverable Exercise Torpedoes (REXTORPs) with containers; handling shapes and containers; torpedo spare parts; tools for mounting and dismounting of Air Launch Accessories (ALAs); equipment for analysis of REXTORP exercise shots; REXTORP maintenance equipment; training; publications; support and test equipment; United States (U.S.) Government and contractor engineering, technical, and logistics support services; and other related elements of logistics and program support.</FP>
                <PRTPAGE P="93560"/>
                <P>
                    (iv) 
                    <E T="03">Military Department:</E>
                     Navy (GY-P-ALF)
                </P>
                <P>
                    (v) 
                    <E T="03">Prior Related Cases, if any:</E>
                     None
                </P>
                <P>
                    (vi) 
                    <E T="03">Sales Commission, Fee, etc., Paid, Offered, or Agreed to be Paid:</E>
                     None
                </P>
                <P>
                    (vii) 
                    <E T="03">Sensitivity of Technology Contained in the Defense Article or Defense Services Proposed to be Sold:</E>
                     See Attached Annex
                </P>
                <P>
                    (viii) 
                    <E T="03">Date Report Delivered to Congress:</E>
                     December 7, 2023
                </P>
                <P>* As defined in Section 47(6) of the Arms Export Control Act.</P>
                <HD SOURCE="HD2">POLICY JUSTIFICATION</HD>
                <HD SOURCE="HD2">Germany—MK 54 Lightweight Torpedoes</HD>
                <P>The Government of Germany has requested to buy up to eighty (80) MK 54 All Up Round Lightweight Torpedoes (LWT). Also included are MK 54 Mod 0 LWT spare parts; Recoverable Exercise Torpedoes (REXTORPs) with containers; handling shapes and containers; torpedo spare parts; tools for mounting and dismounting of Air Launch Accessories (ALAs); equipment for analysis of REXTORP exercise shots; REXTORP maintenance equipment; training; publications; support and test equipment; U.S. Government and contractor engineering, technical, and logistics support services; and other related elements of logistics and program support. The estimated total program cost is $300 million.</P>
                <P>This proposed sale will support the foreign policy and national security of the United States by improving the security of a NATO Ally that is an important force for political and economic stability in Europe.</P>
                <P>The proposed sale will improve Germany's capability to meet current and future threats by upgrading Anti-Submarine Warfare capabilities on its P-8A aircraft. Germany will have no difficulty absorbing this equipment into its armed forces.</P>
                <P>The proposed sale of this equipment and support will not alter the basic military balance in the region.</P>
                <P>The principal contractor will be Raytheon Integrated Defense Systems, Portsmouth, RI. There are no known offset agreements proposed in connection with this potential sale.</P>
                <P>Implementation of this proposed sale will not require the assignment of any additional U.S. Government or contractor representatives to Germany; however, U.S. Government Engineering and Technical Services may be required on an interim basis for training and technical assistance.</P>
                <P>There will be no adverse impact on U.S. defense readiness as a result of this proposed sale.</P>
                <HD SOURCE="HD3">Transmittal No. 23-88</HD>
                <HD SOURCE="HD3">Notice of Proposed Issuance of Letter of Offer Pursuant to Section 36(b)(1) of the Arms Export Control Act</HD>
                <HD SOURCE="HD3">Annex</HD>
                <HD SOURCE="HD3">Item No. vii</HD>
                <P>
                    (vii) 
                    <E T="03">Sensitivity of Technology:</E>
                </P>
                <P>1. The MK 54 Torpedo is a conventional torpedo that can be launched from surface ships, rotary and fixed wing aircraft. The MK 54 is an upgrade to the MK 46 Torpedo. The upgrade to the MK 54 entails replacement of the torpedo's sonar and guidance and control systems with modem technology. The new guidance and control system uses a mixture of commercial-off-the-shelf and custom-built electronics. The warhead, fuel tank, and propulsion system from the MK 46 torpedo are re-used in the MK 54 configuration with minor modifications.</P>
                <P>2. The highest level of classification of defense articles, components, and services included in this potential sale is SECRET.</P>
                <P>3. If a technologically advanced adversary were to obtain knowledge of the hardware and software elements, the information could be used to develop countermeasures or equivalent systems which might reduce system effectiveness or be used in the development of a system with similar or advanced capabilities.</P>
                <P>4. A determination has been made that Germany can provide substantially the same degree of protection for the sensitive technology being released as the U.S. Government. This sale is necessary in furtherance of the U.S. foreign policy and national security objectives outlined in the Policy Justification.</P>
                <P>5. All defense articles and services listed in this transmittal have been authorized for release and export to the Government of Germany.</P>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27778 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6001-FR-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF DEFENSE</AGENCY>
                <SUBAGY>Office of the Secretary</SUBAGY>
                <DEPDOC>[Transmittal No. 23-0U]</DEPDOC>
                <SUBJECT>Arms Sales Notification</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Defense Security Cooperation Agency, Department of Defense (DoD).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Arms sales notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The DoD is publishing the unclassified text of an arms sales notification.</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Pamela Young at (703) 953-6092, 
                        <E T="03">pamela.a.young14.civ@mail.mil,</E>
                         or 
                        <E T="03">dsca.ncr.rsrcmgmt.list.cns-mbx@mail.mil</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This 36(b)(5)(C) arms sales notification is published to fulfill the requirements of section 155 of Public Law 104-164 dated July 21, 1996. The following is a copy of a letter to the Speaker of the House of Representatives with attached Transmittal 23-0U.</P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Stephanie J. Bost,</NAME>
                    <TITLE>Alternate OSD Federal Register Liaison Officer, Department of Defense.</TITLE>
                </SIG>
                <BILCOD>BILLING CODE 6001-FR-P</BILCOD>
                <GPH SPAN="3" DEEP="452">
                    <PRTPAGE P="93561"/>
                    <GID>EN27NO24.296</GID>
                </GPH>
                <BILCOD>BILLING CODE 6001-FR-C</BILCOD>
                <HD SOURCE="HD3">Transmittal No. 23-0U</HD>
                <HD SOURCE="HD2">REPORT OF ENHANCEMENT OR UPGRADE OF SENSITIVITY OF TECHNOLOGY OR CAPABILITY (SEC. 36(B)(5)(C), AECA)</HD>
                <P>
                    (i) 
                    <E T="03">Purchaser:</E>
                     Government of Australia
                </P>
                <P>
                    (ii) 
                    <E T="03">Sec. 36(b)(1), AECA Transmittal No.:</E>
                     14-12
                </P>
                <P>Date: May 13, 2014</P>
                <P>Military Department: Navy</P>
                <P>
                    (iii) 
                    <E T="03">Description:</E>
                     On May 13, 2014, Congress was notified by Congressional certification transmittal number 14-12, of the possible sale, under Section 36(b)(l) of the Arms Export Control Act of up to 350 AIM-9X-2 Sidewinder Tactical Missiles; 35 AIM-9X Special Air Training Missiles (NATM); 95 AIM-9X-2 Captive Air Training Missiles (CATM); 22 AIM-9X-2 Tactical Guidance Units; 19 CATM-9X-2 Guidance Units; and 3 DATM-9X. Also included were containers, test sets and support equipment, spare and repair parts, publications and technical documents, personnel training and training equipment, United States (U.S.) Government and contractor technical assistance, and other related elements of logistics and program support. The estimated total cost was $534 million. Major Defense Equipment (MDE) constituted $476 million of this total.
                </P>
                <P>On January 9, 2018, Congress was notified by Congressional certification transmittal number 0W-17 of the change from 350 AIM-9X-2 Sidewinder Tactical Missiles to reflect 300 AIM-9X Sidewinder Block II+ Tactical Missiles and 50 AIM-9X-2 Sidewinder Tactical Missiles. Additionally, this transmittal reported the inclusion of 11 CATM-9X-2 Missile Guidance Units. The total notified cost of MDE remained $476 million. The total notified case value remained $534 million.</P>
                <P>On December 4, 2020, Congress was notified by Congressional certification transmittal number 0A-21 of the addition of four (4) AIM-9X Block II+ Tactical Missile Guidance Units. The total MDE value increase by $1 million to $477 million. The estimated total case value remained $534 million.</P>
                <P>
                    This transmittal notifies inclusion of the following MDE: an additional ten (10) AIM-9X Block II Sidewinder Tactical Guidance Units; thirty-two (32) AIM-9X Block II+ Sidewinder Tactical Guidance Units; and ninety (90) AIM-
                    <PRTPAGE P="93562"/>
                    9X Block II Sidewinder CATM Guidance Units. The estimated total value of the new items is $28 million. The net cost of MDE will increase by $28 million, resulting in a revised MDE value of $505 million. The estimated total case value will remain $534 million.
                </P>
                <P>
                    (iv) 
                    <E T="03">Significance:</E>
                     The proposed sale will improve Australia's capability to effectively maintain its current force projection and enhance interoperability with U.S. forces.
                </P>
                <P>
                    (v) 
                    <E T="03">Justification:</E>
                     This proposed sale will support the foreign policy and national security objectives of the U.S. Australia is one of our most important allies in the Western Pacific. The strategic location of this political and economic power contributes significantly to ensuring peace and economic stability in the region. It is vital to the U.S. national interest to assist our ally in developing and maintaining a strong and ready self-defense capability.
                </P>
                <P>
                    (vi) 
                    <E T="03">Sensitivity of Technology:</E>
                </P>
                <P>The AIM-9X Block II and Block II+ (Plus) SIDEWINDER Missile represents a substantial increase in missile acquisition and kinematics performance over the AIM-9M and replaces the AIM-9X Block I Missile configuration. The missile includes a high off-boresight seeker, enhanced countermeasure rejection capability, low drag/high angle of attack airframe, and the ability to integrate the Helmet Mounted Cueing System. The most current AIM-9X Block II/II+ Operational Flight Software developed for all international partner countries, which is authorized by U.S. Government export policy, provides fifth-generation infrared missile capabilities such as lock-on-after-launch, weapons data link, surface attack, and surface launch. No software source code or algorithms will be released.</P>
                <P>The Sensitivity of Technology Statement contained in the original notification applies to additional items reported here.</P>
                <P>The highest level of classification of defense articles, components, and services included in this potential sale is SECRET.</P>
                <P>
                    (vii) 
                    <E T="03">Date Report Delivered to Congress:</E>
                     December 5, 2023
                </P>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27776 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6001-FR-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF DEFENSE</AGENCY>
                <SUBAGY>Office of the Secretary</SUBAGY>
                <DEPDOC>[Transmittal No. 23-15]</DEPDOC>
                <SUBJECT>Arms Sales Notification</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Defense Security Cooperation Agency, Department of Defense (DoD).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Arms sales notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The DoD is publishing the unclassified text of an arms sales notification.</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Pamela Young at (703) 953-6092, 
                        <E T="03">pamela.a.young14.civ@mail.mil,</E>
                         or 
                        <E T="03">dsca.ncr.rsrcmgmt.list.cns-mbx@mail.mil.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This 36(b)(1) arms sales notification is published to fulfill the requirements of section 155 of Public Law 104-164 dated July 21, 1996. The following is a copy of a letter to the Speaker of the House of Representatives with attached Transmittal 23-15, Policy Justification, and Sensitivity of Technology.</P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Stephanie J. Bost,</NAME>
                    <TITLE>Alternate OSD Federal Register Liaison Officer, Department of Defense.</TITLE>
                </SIG>
                <BILCOD>BILLING CODE 6001-FR-P</BILCOD>
                <GPH SPAN="3" DEEP="551">
                    <PRTPAGE P="93563"/>
                    <GID>EN27NO24.294</GID>
                </GPH>
                <BILCOD>BILLING CODE 6001-FR-C</BILCOD>
                <HD SOURCE="HD3">Transmittal No. 23-15</HD>
                <HD SOURCE="HD3">Notice of Proposed Issuance of Letter of Offer Pursuant to Section 36(b)(1) of the Arms Export Control Act, as amended</HD>
                <P>
                    (i) 
                    <E T="03">Prospective Purchaser:</E>
                     Kingdom of Saudi Arabia
                </P>
                <P>
                    (ii) 
                    <E T="03">Total Estimated Value:</E>
                </P>
                <GPOTABLE COLS="2" OPTS="L0,tp0,p0,8/9,g1,t1,i1" CDEF="s30,xs56">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Major Defense Equipment *</ENT>
                        <ENT>$ 60 million</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">Other</ENT>
                        <ENT>$522 million</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="02">Total</ENT>
                        <ENT>$582 million</ENT>
                    </ROW>
                    <TNOTE>Funding Source: National Funds.</TNOTE>
                </GPOTABLE>
                <P>
                    (iii) 
                    <E T="03">Description and Quantity or Quantities of Articles or Services Under Consideration for Purchase:</E>
                     The Government of Saudi Arabia has requested to buy aircraft hardware and software modifications and support to replenish and modernize its RE-3A Tactical Airborne Surveillance System (TASS) aircraft, including:
                </P>
                <FP SOURCE="FP-2">
                    <E T="03">Major Defense Equipment (MDE):</E>
                </FP>
                <FP SOURCE="FP1-2">Seven (7) Embedded Global Positioning System/Inertial Navigation System (GPS/INS) (EGI) Security Devices, Airborne, with Selective Availability Anti-Spoofing Module (SAASM) or M-Code Capability</FP>
                <FP SOURCE="FP1-2">
                    Five (5) L3Harris BlackRock 
                    <PRTPAGE P="93564"/>
                    Communications Intelligence Sensor Suites
                </FP>
                <FP SOURCE="FP-2">
                    <E T="03">Non-MDE:</E>
                </FP>
                <FP SOURCE="FP1-2">Also included are KY-100M narrowband/wideband secure communications terminals; KIV-77 MODE 4/5 Identification Friend or Foe (IFF) cryptographic appliques; AN/PYQ-10 Simple Key Loaders; integrated electronic intelligence (ELINT)/signals intelligence (SIGINT) systems; L-3 Communication Systems-West (CSW) multiband receivers/transmitters; ARC-210 radios; high frequency (HF) radios; secure communications equipment; precision navigation and cryptographic devices; aircraft support and support equipment; test and integration support; equipment; spare and repair parts; consumables and accessories; repair and return support; United States (U.S.) Government and contractor engineering, technical, and logistics support services; studies and surveys; and other related elements of logistics and program support.</FP>
                <P>
                    (iv) 
                    <E T="03">Military Department:</E>
                     Air Force (SR-D-QDO)
                </P>
                <P>
                    (v) 
                    <E T="03">Prior Related Cases, if any:</E>
                     None
                </P>
                <P>
                    (vi) 
                    <E T="03">Sales Commission, Fee, etc., Paid, Offered, or Agreed to be Paid:</E>
                     None known at this time
                </P>
                <P>
                    (vii) 
                    <E T="03">Sensitivity of Technology Contained in the Defense Article or Defense Services Proposed to be Sold:</E>
                     See Attached Annex
                </P>
                <P>
                    (viii) 
                    <E T="03">Date Report Delivered to Congress:</E>
                     December 4, 2023
                </P>
                <P>* As defined in Section 47(6) of the Arms Export Control Act.</P>
                <HD SOURCE="HD2">POLICY JUSTIFICATION</HD>
                <HD SOURCE="HD2">Saudi Arabia—RE-3A Tactical Airborne Surveillance System Aircraft Modernization</HD>
                <P>The Kingdom of Saudi Arabia has requested to buy aircraft hardware and software modifications and support to replenish and modernize its RE-3A Tactical Airborne Surveillance System (TASS) aircraft, including: seven (7) Embedded Global Positioning System/Inertial Navigation System (GPS/INS) (EGI) security devices, Airborne, with Selective Availability Anti-Spoofing Module (SAASM) or M-Code capability, and five (5) L3Harris BlackRock Communications Intelligence Sensor Suites. Also included are KY-100M narrowband/wideband secure communications terminals; KIV-77 MODE 4/5 Identification Friend or Foe (IFF) cryptographic appliques; AN/PYQ-10 Simple Key Loaders; integrated electronic intelligence (ELINT)/signals intelligence (SIGINT) systems; L-3 Communication Systems-West (CSW) multiband receivers/transmitters; ARC-210 radios; high frequency (HF) radios; secure communications equipment; precision navigation and cryptographic devices; aircraft support and support equipment; test and integration support; equipment; spare and repair parts; consumables and accessories; repair and return support; U.S. Government and contractor engineering, technical, and logistics support services; studies and surveys; and other related elements of logistics and program support. The estimated total cost is $582 million.</P>
                <P>This proposed sale will support the foreign policy goals and national security objectives of the United States by improving the security of a partner country that is a force for political stability and economic progress in the Gulf Region.</P>
                <P>The proposed sale will improve Saudi Arabia's surveillance capability to counter current and future regional threats, strengthen its homeland defense, and improve interoperability with systems operated by U.S. forces and other Gulf Region partners. Saudi Arabia will have no difficulty absorbing these systems into its armed forces.</P>
                <P>The proposed sale of this equipment and support will not alter the basic military balance in the region.</P>
                <P>The principal contractor will be L3 Technologies, Greenville, TX. There are no known offset agreements proposed in connection with this potential sale.</P>
                <P>Implementation of this proposed sale will not require the assignment of any additional U.S. Government or contractor representatives to Saudi Arabia.</P>
                <P>There will be no adverse impact on U.S. defense readiness as a result of this proposed sale.</P>
                <HD SOURCE="HD3">Transmittal No. 23-15</HD>
                <HD SOURCE="HD3">Notice of Proposed Issuance of Letter of Offer Pursuant to Section 36(b)(1) of the Arms Export Control Act</HD>
                <HD SOURCE="HD3">Annex</HD>
                <HD SOURCE="HD3">Item No. vii</HD>
                <P>
                    (vii) 
                    <E T="03">Sensitivity of Technology:</E>
                </P>
                <P>1. The Embedded Global Positioning System/Inertial Navigation System (GPS/INS) (EGI) with Selective Availability Anti-Spoofing Module (SAASM)—or M-Code receiver when available—and Precise Positioning Service (PPS) is a self-contained navigation system that provides the following: acceleration, velocity, position, attitude, platform azimuth, magnetic and true heading, altitude, body angular rates, time tags, and coordinated universal time (UTC) synchronized time. SAASM or M-Code enables the GPS receiver access to the encrypted P(Y or M) signal, providing protection against active spoofing attacks.</P>
                <P>2. The L3Harris BlackRock is a communications intelligence (COMINT) system comprised of multiple Direction Finding (DF) antenna arrays, a Radio Frequency (RF) distribution system, software defined tuners, and a reconfigurable processing solution hosting the applications. The BlackRock provides COMINT processing of over 100 simultaneous signals for complete situational awareness of modern communications environments.</P>
                <P>3. The KY-100M is a lightweight terminal for secure voice and data communications. The KY-100M provides wideband/narrowband half-duplex communication. Operating in tactical ground, marine, and airborne applications, the KY-100M enables secure communication with a broad range of radio and satellite equipment.</P>
                <P>4 The Electronic Intelligence (ELINT) system is composed of Automatic (L3H Corvus) and Manual (SNC Small SwaP Digital SIGINT system) ELINT systems utilizing Left-Hand Side LHS) and Right-Hand Side (RHS) Interferometer arrays, signal tuners, processing/high speed data storage components, Radio Frequency (RF) distribution system, LHS and RHS steerable beam antennas and a 360-degree spin Direction Finding (DF) antennas.</P>
                <P>5. The AN/APQ-10C Simple Key Loader is a handheld fill device for securely receiving, storing, and transferring data between cryptographic and communications equipment.</P>
                <P>6. The L-3 Communication Systems-West (CSW) Multiband Receiver/Transmitter is a lightweight, handheld military radio that provides an integrated capability to receive and view battlefield video with advanced tactical voice and data communications.</P>
                <P>7. The ARC-210 UHF/VHF secure radio with HAVE QUICK II/SATURN is a voice communications radio system that can operate in either normal, secure, and/or jam-resistant modes.</P>
                <P>8. The highest level of classification of defense articles, components, and services included in this potential sale is SECRET.</P>
                <P>
                    9. If a technologically advanced adversary were to obtain knowledge of the hardware and software elements, the information could be used to develop countermeasures or equivalent systems which might reduce system effectiveness or be used in the development of a system with similar or advanced capabilities.
                    <PRTPAGE P="93565"/>
                </P>
                <P>10. A determination has been made that the Government of Saudi Arabia can provide substantially the same degree of protection for the sensitive technology being released as the U.S. Government. This sale is necessary in furtherance of the U.S. foreign policy and national security objectives outlined in the Policy Justification.</P>
                <P>11. All defense articles and services listed in this transmittal are authorized for release and export to Saudi Arabia.</P>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27774 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6001-FR-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF DEFENSE</AGENCY>
                <SUBAGY>Office of the Secretary</SUBAGY>
                <DEPDOC>[Transmittal No. 23-0X]</DEPDOC>
                <SUBJECT>Arms Sales Notification</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Defense Security Cooperation Agency, Department of Defense (DoD).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Arms sales notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The DoD is publishing the unclassified text of an arms sales notification.</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Pamela Young at (703) 953-6092, 
                        <E T="03">pamela.a.young14.civ@mail.mil,</E>
                         or 
                        <E T="03">dsca.ncr.rsrcmgmt.list.cns-mbx@mail.mil</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This 36(b)(5)(C) arms sales notification is published to fulfill the requirements of section 155 of Public Law 104-164 dated July 21, 1996. The following is a copy of a letter to the Speaker of the House of Representatives with attached Transmittal 23-0X.</P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Stephanie J. Bost,</NAME>
                    <TITLE>Alternate OSD Federal Register Liaison Officer, Department of Defense.</TITLE>
                </SIG>
                <BILCOD>BILLING CODE 6001-FR-P</BILCOD>
                <GPH SPAN="3" DEEP="474">
                    <GID>EN27NO24.295</GID>
                </GPH>
                <PRTPAGE P="93566"/>
                <BILCOD>BILLING CODE 6001-FR-P</BILCOD>
                <HD SOURCE="HD3">Transmittal No. 23-0X</HD>
                <HD SOURCE="HD2">REPORT OF ENHANCEMENT OR UPGRADE OF SENSITIVITY OF TECHNOLOGY OR CAPABILITY (SEC. 36(B)(5)(C), AECA)</HD>
                <P>
                    (i) 
                    <E T="03">Purchaser:</E>
                     Government of Spain
                </P>
                <P>
                    (ii) 
                    <E T="03">Sec. 36(b)(1), AECA Transmittal No.:</E>
                     20-57
                </P>
                <P>
                    <E T="03">Date:</E>
                     September 2, 2020
                </P>
                <P>
                    <E T="03">Implementing Agency:</E>
                     Air Force
                </P>
                <P>
                    (iii) 
                    <E T="03">Description:</E>
                     On September 2, 2020, Congress was notified by Congressional certification transmittal number 20-57, of the possible sale under Section 36(b)(1) of the Arms Export Control Act, of one hundred (100) AIM-120C-7/8 Advanced Medium Range Air-to-Air Missiles (AMRAAM) and one (1) AMRAAM Guidance Section (spare). Also included were KGV-135A encryption devices; containers; weapon support and support equipment; spare and repair parts; publications and technical documentation; United States (U.S.) Government and contractor engineering, technical, and logistics support services; and other related elements of logistical and program support. The estimated total cost was $248.5 million. Major Defense Equipment (MDE) constituted $237.0 million of this total.
                </P>
                <P>This transmittal notifies the addition of the following MDE items: six hundred fifty-five (655) AIM-120 C-8 Advanced Medium Range Air-to-Air Missiles (AMRAAM) or AIM-120 C-8 AMRAAM Extended Range Missiles (AMRAAM-ER); four (4) AIM-120C-8 AMRAAM Instrumented Test Vehicles (ITV); and thirteen (13) AIM-120 C-8 AMRAAM Guidance Sections (AMRAAM GS). Also included are AIM-120 Captive Air Training Missiles (CATM) and spare control sections; Common Munitions Built-in-Test (BIT)/Reprogramming Equipment (CMBRE); classified software delivery and support; transportation support; and studies and surveys. The estimated total value of the new items is $1.6835 billion. The estimated MDE value will increase by $1.5485 billion to a revised $1.7855 billion. The estimated non-MDE value will increase by $0.135 billion to a revised $0.1465 billion. The estimated total case value will increase to $1.932 billion.</P>
                <P>
                    (iv) 
                    <E T="03">Significance:</E>
                     This notification is being provided as the additional MDE items were not enumerated in the original notification. The inclusion of this MDE represents an increase in capability over what was previously notified. The proposed sale will improve Spain's capability to meet current and future threats by increasing its stocks of AMRAAMs for its fighter aircraft fleets and air defense in support of its national defense and will further strengthen interoperability with the U.S..
                </P>
                <P>
                    (v) 
                    <E T="03">Justification:</E>
                     This proposed sale will support the foreign policy and national security objectives of the United States by supporting the security and defense needs of a NATO Ally which is an important force for political stability and economic progress in Europe.
                </P>
                <P>
                    (vi) 
                    <E T="03">Sensitivity of Technology:</E>
                     The Advanced Medium Range Air-to-Air Missile-Extended Range (AMRAAM-ER) variant utilizes an AIM-120C-7 or C-8 seeker and warhead joined with a new control section and rocket rotor (for surface launch mode applications). This provides extended range and altitude as well as higher speed and maneuverability. Common Munitions Built-in-Test (BIT)/Reprogramming Equipment (CMBRE) is supporting equipment.
                </P>
                <P>The Instrumented Test Vehicle (ITV) is a captive carry test vehicle used primarily for flight test integration. The ITV verifies and assesses the aircraft's ability to safely support an AMRAAM launch through the aircraft interface mechanism and the aircraft datalink antenna.</P>
                <P>The Sensitivity of Technology Statement contained in the original notification applies to additional items reported here.</P>
                <P>The highest level of classification of defense articles, components, and services included in this potential sale is SECRET.</P>
                <P>
                    (vii) 
                    <E T="03">Date Report Delivered to Congress:</E>
                     December 5, 2023
                </P>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27775 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6001-FR-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF DEFENSE</AGENCY>
                <SUBAGY>Department of the Navy</SUBAGY>
                <SUBJECT>Department of the Navy Science and Technology Board; Notice of Federal Advisory Committee Meeting</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P> Department of the Navy (DoN), Department of Defense (DoD).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of Federal Advisory Committee meeting.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P> The DoD is publishing this notice to announce that the following Federal Advisory Committee meeting of the Department of the Navy Science and Technology Board (DoN S&amp;T Board) will take place. </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P> An open meeting will be held on Tuesday, December 3, 2024, from 10 a.m. to 10:30 a.m. Eastern Time Zone (ET).</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The Open session will be held virtually via video conference. Information for accessing the video conference will be provided after registering. (Pre-meeting registration is required. See guidance in 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         “Meeting Accessibility”.) 
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                         Ms. Maria Proestou, Designated Federal Officer (DFO), Office of the Assistant Secretary of the Navy (Research, Development &amp; Acquisition), Pentagon, Washington, DC 20350-1000, 703-692-8278, 
                        <E T="03">don-stb@us.navy.mil.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This meeting is being held under the provisions of chapter 10 of title 5 U.S.C. (commonly known as the Federal Advisory Committee Act (FACA), the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended), title 41 Code of Federal Regulations (CFR) 102-3.140 and 102-3.150. Due to circumstances beyond the control of the Designated Federal Officer, the DoN S&amp;T Board was unable to provide public notification required by 41 CFR 102-3.150(a) concerning its December 3, 2024 meeting. Accordingly, the Advisory Committee Management Officer for the Department of Defense, pursuant to 41 CFR 102-3.150(b), waives the 15-calendar day notification requirement.</P>
                <P>
                    <E T="03">Purpose of the Meeting:</E>
                     The purpose of the meeting will be for the Board to vote on two completed study topics, Electronic Warfare for Terminal Defense and Ship Maintenance.
                </P>
                <P>
                    <E T="03">Agenda:</E>
                     On December 3, 2024, the Chair of the Board will convene the open session in order to discuss and vote on forwarding two completed studies to the Board's sponsor, the Secretary of the Navy.
                </P>
                <P>
                    <E T="03">Availability of Materials for the Meeting:</E>
                     A copy of the agenda or any updates to the agenda for the meeting on December 3, 2024, as well as supporting documents, can be found on the website: 
                    <E T="03">https://www.secnav.navy.mil/rda/S&amp;TBoard/Pages/default.aspx</E>
                    .
                </P>
                <P>
                    <E T="03">Meeting Accessibility:</E>
                     The open session will be held by videoconference. All members of the public who wish to attend must register by contacting DON S&amp;T Board at 
                    <E T="03">don-stb@us.navy.mil.</E>
                     Once registered, the web address and/or audio number will be provided. If there are any questions or concerns, please send them to 
                    <E T="03">don-stb@us.navy.mil</E>
                     no later than November 26, 2024.
                </P>
                <P>
                    <E T="03">Written Statements:</E>
                     Pursuant to 41 CFR 102-3.105 and 102-3.140, and section 1009(a)(3) of title 5 U.S.C., 
                    <PRTPAGE P="93567"/>
                    written statements to the committee may be submitted at any time or in response to a stated planned meeting agenda by email to 
                    <E T="03">don-stb@us.navy.mil</E>
                     with the subject line, “Comments for DON S&amp;T Board Meeting.” 
                </P>
                <SIG>
                    <DATED>Dated: November 22, 2024</DATED>
                    <NAME>A.J. Gioiello,</NAME>
                    <TITLE>Lieutenant Commander, Judge Advocate General's Corps, U.S. Navy, Federal Register Liaison Officer.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27812 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3810-FF-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF EDUCATION</AGENCY>
                <DEPDOC>[Docket No.: ED-2024-SCC-0142]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Comment Request; EDFacts Data Collection School Years 2025-26, 2026-27, and 2027-28 (With 2024-25 Continuation)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Center for Education Statistics (IES), Department of Education (ED).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In accordance with the Paperwork Reduction Act (PRA) of 1995, the Department is proposing a revision of a currently approved information collection request (ICR).</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Interested persons are invited to submit comments on or before January 27, 2025.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        To access and review all the documents related to the information collection listed in this notice, please use 
                        <E T="03">http://www.regulations.gov</E>
                         by searching the Docket ID number ED-2024-SCC-0142. Comments submitted in response to this notice should be submitted electronically through the Federal eRulemaking Portal at 
                        <E T="03">http://www.regulations.gov</E>
                         by selecting the Docket ID number or via postal mail, commercial delivery, or hand delivery. If the regulations.gov site is not available to the public for any reason, the Department will temporarily accept comments at 
                        <E T="03">ICDocketMgr@ed.gov.</E>
                         Please include the docket ID number and the title of the information collection request when requesting documents or submitting comments. Please note that comments submitted after the comment period will not be accepted. Written requests for information or comments submitted by postal mail or delivery should be addressed to the Manager of the Strategic Collections and Clearance Governance and Strategy Division, U.S. Department of Education, 400 Maryland Ave. SW, LBJ, Room 4C210, Washington, DC 20202-1200.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>For specific questions related to collection activities, please contact Carrie Clarady, 202-245-6347.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The Department, in accordance with the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3506(c)(2)(A)), provides the general public and Federal agencies with an opportunity to comment on proposed, revised, and continuing collections of information. This helps the Department assess the impact of its information collection requirements and minimize the public's reporting burden. It also helps the public understand the Department's information collection requirements and provide the requested data in the desired format. The Department is soliciting comments on the proposed information collection request (ICR) that is described below. The Department is especially interested in public comment addressing the following issues: (1) is this collection necessary to the proper functions of the Department; (2) will this information be processed and used in a timely manner; (3) is the estimate of burden accurate; (4) how might the Department enhance the quality, utility, and clarity of the information to be collected; and (5) how might the Department minimize the burden of this collection on the respondents, including through the use of information technology. Please note that written comments received in response to this notice will be considered public records.</P>
                <FP SOURCE="FP-1">
                    <E T="03">Title of Collection:</E>
                     EDFacts Data Collection School Years 2025-26, 2026-27, and 2027-28 (with 2024-25 Continuation).
                </FP>
                <FP SOURCE="FP-1">
                    <E T="03">OMB Control Number:</E>
                     1850-0925.
                </FP>
                <FP SOURCE="FP-1">
                    <E T="03">Type of Review:</E>
                     A revision of a currently approved ICR.
                </FP>
                <FP SOURCE="FP-1">
                    <E T="03">Respondents/Affected Public:</E>
                     State, Local, and Tribal Governments. 
                </FP>
                <FP SOURCE="FP-1">
                    <E T="03">Total Estimated Number of Annual Responses:</E>
                     61.
                </FP>
                <FP SOURCE="FP-1">
                    <E T="03">Total Estimated Number of Annual Burden Hours:</E>
                     126,880.
                </FP>
                <P>
                    <E T="03">Abstract:</E>
                     EDFacts is a U.S. Department of Education (ED) initiative, conducted by the National Center for Education Statistics (NCES), to collect, analyze, report on, and promote the use of high-quality, pre-kindergarten through grade 12 (pre-K-12) performance data. By centralizing data provided by state education agencies about state level data, local education agencies, and schools, NCES uses the EDFacts data to report on students, schools, staff, services, and education outcomes at the state, district, and school levels. The centralized approach provides ED users with the ability to efficiently analyze and report on submitted data and has reduced the reporting burden for state and local data producers through the use of streamlined data collection, analysis, and reporting tools. EDFacts collects information on behalf of ED grant and program offices for approximately 170 data groups for all 50 states, Washington DC, Puerto Rico, and seven outlying areas and freely associated states (American Samoa, Federated States of Micronesia, Guam, Marshall Islands, Commonwealth of the Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands), the Department of Defense Education Activity (DoDEA), and the Bureau of Indian Education (BIE).
                </P>
                <P>This request is to collect EDFacts data for the 2025-26, 2026-27, and 2027-28 school years. This collection package will be available for public comment during two open periods, a 60-day and a 30-day, after which revisions will be made accordingly. As part of the public comment period review, ED requests that SEAs and other stakeholders respond to the directed questions found in Attachment D. Due to overlap in the timing of data collection activities between consecutive years of the EDFacts collection, we are carrying over in this submission the approved SY 2024-25 data collection, which is scheduled to end in February 2026.</P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Stephanie Valentine,</NAME>
                    <TITLE>PRA Coordinator, Strategic Collections and Clearance, Governance and Strategy Division, Office of Chief Data Officer, Office of Planning, Evaluation and Policy Development.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27845 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4000-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF EDUCATION</AGENCY>
                <DEPDOC>[Docket No.: ED-2024-SCC-0101]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; School Pulse Panel 2025-26 and 2026-27 (SPP 2025-26, SPP 2026-27) Preliminary Field Activities</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Center for Education Statistics (NCES), Department of Education (ED).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In accordance with the Paperwork Reduction Act (PRA) of 1995, the Department is proposing a revision of a currently approved information collection request (ICR).</P>
                </SUM>
                <DATES>
                    <PRTPAGE P="93568"/>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Interested persons are invited to submit comments on or before December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and recommendations for proposed information collection requests should be submitted within 30 days of publication of this notice. Click on this link 
                        <E T="03">www.reginfo.gov/public/do/PRAMain</E>
                         to access the site. Find this information collection request (ICR) by selecting “Department of Education” under “Currently Under Review,” then check the “Only Show ICR for Public Comment” checkbox. Reginfo.gov provides two links to view documents related to this information collection request. Information collection forms and instructions may be found by clicking on the “View Information Collection (IC) List” link. Supporting statements and other supporting documentation may be found by clicking on the “View Supporting Statement and Other Documents” link.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>For specific questions related to collection activities, please contact Carrie Clarady, 202-245-6347.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The Department is especially interested in public comment addressing the following issues: (1) is this collection necessary to the proper functions of the Department; (2) will this information be processed and used in a timely manner; (3) is the estimate of burden accurate; (4) how might the Department enhance the quality, utility, and clarity of the information to be collected; and (5) how might the Department minimize the burden of this collection on the respondents, including through the use of information technology. Please note that written comments received in response to this notice will be considered public records.</P>
                <P>
                    <E T="03">Title of Collection:</E>
                     School Pulse Panel 2025-26 and 2026-27 (SPP 2025-26, SPP 2026-27) Preliminary Field Activities.
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     1850-0975.
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     A revision of a currently approved ICR.
                </P>
                <P>
                    <E T="03">Respondents/Affected Public:</E>
                     State, Local, and Tribal Governments.
                </P>
                <P>
                    <E T="03">Total Estimated Number of Annual Responses:</E>
                     6,339.
                </P>
                <P>
                    <E T="03">Total Estimated Number of Annual Burden Hours:</E>
                     2,503.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The School Pulse Panel (SPP) is a data collection that was originally designed to collect voluntary responses from a nationally representative sample of public schools to better understand how schools, students, and educators were responding to the ongoing stressors of the coronavirus pandemic. The School Pulse Panel is conducted by the National Center for Education Statistics (NCES), part of the Institute of Education Sciences (IES), within the United States Department of Education. Initially, the purpose of the study was to collect extensive data on issues brought to light by the COVID-19 pandemic, as well as other important education-related issues that could inform data-driven policy decisions, in U.S. public schools. Due to the immediate need to collect pandemic-era information from schools as described in Executive Order 14000, an emergency clearance was issued to develop and field the first several monthly collections of the SPP in 2021 and a full review of the SPP data collection was performed in 2022 (OMB# 1850-0969). SPPs innovative design and timely dissemination of findings have been used and cited frequently among Department of Education senior leadership, the White House Domestic Policy Council, the USDAs Food and Nutrition Service, the Centers for Disease Control and Prevention, Congressional deliberations, and the media. The growing interest from stakeholders resulted in a request for funding to create an established NCES quick-turnaround data collection vehicle to become a mainstay for NCES. Funding for a mainstay collection was approved in late 2022, and NCES conducted a new collection during the 2023-24 school year (OMB# 1850-0975).
                </P>
                <P>The School Pulse Panel study is one of the few reliable, nationally representative, quick-turnaround studies that produces data on U.S. public schools. The sample design for the 2025-26 collection will roughly be the same as the 2024-25 collection with 4,000 public schools randomly selected to an initial sample and 4,000 in a reserve sample. It is expected these schools will come from roughly 3,000 districts. The goal is national representation from about 1,200 responding schools each month in order to report out national estimates. School staff will be asked to provide requested data monthly during the 2025-26 school year. This approach provides the ability to collect detailed information on various topics while also assessing changes over time for items that are repeated from year to year. Given the demand for data collection, the content of the survey is expected to change monthly. For the 2025-26 school year, the survey may ask school staff about a wide range of topics, including but not limited to staffing; learning recovery; absenteeism; usage of federal funds; and overall principal experiences.</P>
                <P>This package includes preliminary activities, including contacting and obtaining research approvals from public school districts with an established research approval process (special contact districts) where applicable; notifying sampled schools and districts of their selection for the survey; and inviting them to complete a short Screener Survey to establish points of contact. In spring of 2025, a clearance for main study data collection activities that will include instruments for the first quarter of collections will be submitted for 60-day and 30-day public comment. Subsequent quarterly content submissions will be submitted for 30-day public comment.</P>
                <P>This request is to conduct the SPP 2025-26 preliminary activities. Substantial edits and additional materials may be added to this package after the 60-day public comment period is complete, in time for the subsequent 30-day public comment period that will begin Fall 2024. Materials for SPP are cleared under two OMB Number sequences. Materials for SPP 2022 and SPP 2024-25 were cleared under OMB# 1850-0969, while SPP 2023-24 and now SPP 2025-26 are cleared under OMB# 1850-0975.</P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Stephanie Valentine,</NAME>
                    <TITLE>PRA Coordinator, Strategic Collections and Clearance, Governance and Strategy Division, Office of Chief Data Officer, Office of Planning, Evaluation and Policy Development.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27846 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4000-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF ENERGY</AGENCY>
                <SUBJECT>Proposed Agency Information Collection: Supplemental Labor Management Office (SLMO) Driver Attestation</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Department of Energy.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Department of Energy (DOE) invites public comment on a proposed collection of information that DOE is developing for submission to the Office of Management and Budget (OMB) pursuant to the Paperwork Reduction Act of 1995. The information collection requests a three-year approval of its collection, titled BPA Supplemental Labor Management Office (SLMO) Driver Authorization, OMB Control Number 1910-NEW. The proposed collection will ask contract personnel to certify they have 
                        <PRTPAGE P="93569"/>
                        completed the requirements to drive a government vehicle on behalf of BPA and presented credentials to their contract company that they are licensed for the type of license their role requires.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments regarding this collection must be received on or before December 27, 2024. If you anticipate that you will be submitting comments but find it difficult to do so within the period allowed by this notice, please advise the OMB Desk Officer of your intention to make a submission as soon as possible. The Desk Officer may be telephoned at 202-881-8585.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function. Written comments may be sent to Bonneville Power Administration, Attn: Stephanie Noell, Privacy Program, CGI-7, PO Box 3621, Portland, OR 97208-3621, or by email at 
                        <E T="03">privacy@bpa.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Requests for additional information or copies of the information collection instrument and instructions should be directed to Attn: Stephanie Noell, Privacy Program, by email at 
                        <E T="03">privacy@bpa.gov,</E>
                         or by phone at (503) 230-3881.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This information collection request contains:</P>
                <P>
                    (1) 
                    <E T="03">OMB No.:</E>
                     1910-NEW;
                </P>
                <P>
                    (2) 
                    <E T="03">Information Collection Request Title:</E>
                     BPA Supplemental Labor Management Office (SLMO) Driver Authorization;
                </P>
                <P>
                    (3) 
                    <E T="03">Type of Request:</E>
                     New;
                </P>
                <P>
                    (4) 
                    <E T="03">Purpose:</E>
                     The purpose of the Information Collection Request is to collect information from BPA contractors at Bonneville Power Administration (BPA) sites pertaining to authorization to operate BPA owned/leased/provided motor vehicles by contracted labor personnel;
                </P>
                <P>
                    (5) 
                    <E T="03">Annual Estimated Number of Respondents:</E>
                     250;
                </P>
                <P>
                    (6) 
                    <E T="03">Annual Estimated Number of Total Responses:</E>
                     250;
                </P>
                <P>
                    (7) 
                    <E T="03">Annual Estimated Number of Burden Hours:</E>
                     250;
                </P>
                <P>
                    (8) 
                    <E T="03">Annual Estimated Reporting and Recordkeeping Cost Burden:</E>
                     $17,150.
                </P>
                <P>
                    <E T="03">Statutory Authority:</E>
                     The Bonneville Project Act codified in 16 U.S.C. 832a, the Federal Columbia River Transmission System Act of 1974 codified in 16 U.S.C. 838 
                    <E T="03">et seq.,</E>
                     the Pacific Northwest Electric Power Planning and Conservation Act in 16 U.S.C. 839 
                    <E T="03">et seq.,</E>
                     Department of Energy Establishment Act 42 U.S.C. 7101 
                    <E T="03">et seq.,</E>
                     and 41 CFR 101-39.300 General Services Administration (GSA) Interagency Fleet Management System (IFMS).
                </P>
                <P>
                    <E T="03">Signing Authority:</E>
                     This document of the Department of Energy was signed on November 12, 2024, by Candice D. Palen, Information Collection Clearance Manager, pursuant to delegated authority from the Secretary of Energy. That document with the original signature and date is maintained by DOE. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DOE Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of the Department of Energy. This administrative process in no way alters the legal effect of this document upon publication in the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <SIG>
                    <P>Signed in Washington, DC on November 22, 2024.</P>
                    <NAME>Treena V. Garrett,</NAME>
                    <TITLE>Federal Register Liaison Officer, U.S. Department of Energy.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27835 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6450-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <DEPDOC>[Project No. 15300-001]</DEPDOC>
                <SUBJECT>BOST1 Hydroelectric LLC; Notice of Surrender of Preliminary Permit</SUBJECT>
                <P>
                    Take notice that BOST1 Hydroelectric LLC., permittee for the proposed Heard County Pumped Storage Project, has requested that its preliminary permit be terminated. The permit was issued on October 19, 2023,
                    <SU>1</SU>
                    <FTREF/>
                     and would have expired on September 30, 2027. The project would have been located approximately 1.8 miles west of the City of Enon Grove, Heard County, Georgia.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         185 FERC ¶ 61,041 (2023).
                    </P>
                </FTNT>
                <P>
                    The preliminary permit for Project No. 15300 will remain in effect until the close of business, December 20, 2024. But, if the Commission is closed on this day, then the permit remains in effect until the close of business on the next day in which the Commission is open.
                    <SU>2</SU>
                    <FTREF/>
                     New applications for this site may not be submitted until after the permit surrender is effective.
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         18 CFR 385.2007(a)(2) (2024).
                    </P>
                </FTNT>
                <SIG>
                    <DATED>Dated: November 20, 2024.</DATED>
                    <NAME>Debbie-Anne A. Reese,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27768 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <DEPDOC>[Docket No. CP21-465-004]</DEPDOC>
                <SUBJECT>Driftwood Pipeline, LLC; Notice of Request for Extension of Time</SUBJECT>
                <P>
                    Take notice that on November 13, 2024, Driftwood Pipeline, LLC (Driftwood Pipeline) requested that the Commission grant an extension of time, until October 21, 2027, to construct and place into service its Line 200 and Line 300 Project (Project), located in Beauregard and Calcasieu Parishes, Louisiana, as authorized in the April 21, 2023 Order Issuing Certificate (Order).
                    <SU>1</SU>
                    <FTREF/>
                     The Order required Driftwood Pipeline to complete construction of the Project and make it available for service within two years of the date of the Order, or by April 21, 2025.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">Driftwood Pipeline LLC,</E>
                         183 FERC ¶ 61,049 (2023), 
                        <E T="03">as amended, Driftwood Pipeline LLC,</E>
                         Errata Notice, Docket Nos. CP21-465-000, 
                        <E T="03">et al.</E>
                         (May 2, 2023).
                    </P>
                </FTNT>
                <P>Driftwood Pipeline states that it has experienced delays resulting from unforeseen circumstances, including litigation delays from an appeal of the Certificate Order in the United States Court of Appeals for the District of Columbia Circuit and uncertainty associated with impending changes in company leadership and other personnel related to a change in ownership of Driftwood Pipeline's parent company. Driftwood Pipeline states that these issues further complicated efforts to reach a final investment decision, and thus additional time is required for completing construction of the Project and placing it into service.</P>
                <P>
                    This notice establishes a 15-calendar day intervention and comment period deadline. Any person wishing to comment on Driftwood Pipeline's request for an extension of time may do so. No reply comments or answers will be considered. If you wish to obtain legal status by becoming a party to the proceedings for this request, you should, on or before the comment date stated below, file a motion to intervene in accordance with the requirements of the Commission's Rules of Practice and Procedure (18 CFR 385.214 or 385.211) and the Regulations under the Natural Gas Act (NGA) (18 CFR 157.10).
                    <PRTPAGE P="93570"/>
                </P>
                <P>
                    As a matter of practice, the Commission itself generally acts on requests for extensions of time to complete construction for NGA facilities when such requests are contested before order issuance. For those extension requests that are contested,
                    <SU>2</SU>
                    <FTREF/>
                     the Commission will aim to issue an order acting on the request within 45 days.
                    <SU>3</SU>
                    <FTREF/>
                     The Commission will address all arguments relating to whether the applicant has demonstrated there is good cause to grant the extension.
                    <SU>4</SU>
                    <FTREF/>
                     The Commission will not consider arguments that re-litigate the issuance of the certificate order, including whether the Commission properly found the project to be in the public convenience and necessity and whether the Commission's environmental analysis for the certificate complied with the National Environmental Policy Act.
                    <SU>5</SU>
                    <FTREF/>
                     At the time a pipeline requests an extension of time, orders on certificates of public convenience and necessity are final and the Commission will not re-litigate their issuance.
                    <SU>6</SU>
                    <FTREF/>
                     The Director of the Office of Energy Projects, or his or her designee, will act on all of those extension requests that are uncontested.
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         Contested proceedings are those where an intervenor disputes any material issue of the filing. 18 CFR 385.2201(c)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">Algonquin Gas Transmission, LLC,</E>
                         170 FERC ¶ 61,144, at P 40 (2020).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">Id.</E>
                         at P 40.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         Similarly, the Commission will not re-litigate the issuance of an NGA section 3 authorization, including whether a proposed project is not inconsistent with the public interest and whether the Commission's environmental analysis for the permit order complied with NEPA.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">Algonquin Gas Transmission, LLC,</E>
                         170 FERC ¶ 61,144, at P 40 (2020).
                    </P>
                </FTNT>
                <P>
                    In addition to publishing the full text of this document in the 
                    <E T="04">Federal Register</E>
                    , the Commission provides all interested persons an opportunity to view and/or print the contents of this document via the internet through the Commission's Home Page (
                    <E T="03">http://www.ferc.gov</E>
                    ). From the Commission's Home Page on the internet, this information is available on eLibrary. The full text of this document is available on eLibrary in PDF and Microsoft Word format for viewing, printing, and/or downloading. To access this document in eLibrary, type the docket number excluding the last three digits of this document in the docket number field.
                </P>
                <P>
                    User assistance is available for eLibrary and the Commission's website during normal business hours from FERC Online Support at (202) 502-6652 (toll free at 1-866-208-3676) or email at 
                    <E T="03">ferconlinesupport@ferc.gov,</E>
                     or the Public Reference Room at (202) 502-8371, TTY (202) 502-8659. Email the Public Reference Room at 
                    <E T="03">public.referenceroom@ferc.gov.</E>
                </P>
                <P>
                    The Commission strongly encourages electronic filings of comments in lieu of paper using the “eFile” link at 
                    <E T="03">http://www.ferc.gov.</E>
                     In lieu of electronic filing, you may submit a paper copy which must reference the Project docket number.
                </P>
                <FP SOURCE="FP-1">
                    <E T="03">To file via USPS:</E>
                     Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory Commission, 888 First Street NE, Washington, DC 20426.
                </FP>
                <FP SOURCE="FP-1">
                    <E T="03">To file via any other courier:</E>
                     Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory Commission, 12225 Wilkins Avenue, Rockville, Maryland 20852.
                </FP>
                <P>
                    The Commission's Office of Public Participation (OPP) supports meaningful public engagement and participation in Commission proceedings. OPP can help members of the public, including landowners, environmental justice communities, Tribal members and others, access publicly available information and navigate Commission processes. For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, the public is encouraged to contact OPP at (202) 502-6595 or 
                    <E T="03">OPP@ferc.gov.</E>
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. eastern time on December 5, 2024.
                </P>
                <SIG>
                    <DATED>Dated: November 20, 2024.</DATED>
                    <NAME>Debbie-Anne A. Reese,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27777 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <DEPDOC>[Docket No. EF25-2-000]</DEPDOC>
                <SUBJECT>Western Area Power Administration; Notice of Filing</SUBJECT>
                <P>Take notice that on November 15, 2024, Western Area Power Administration submitted a tariff filing per 300.10: UGP_PSMBP-ED_WAPA213-20240930 to be effective 1/1/2025.</P>
                <P>Any person desiring to intervene or to protest this filing must file in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211, 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a notice of intervention or motion to intervene, as appropriate. Such notices, motions, or protests must be filed on or before the comment date. On or before the comment date, it is not necessary to serve motions to intervene or protests on persons other than the Applicant.</P>
                <P>
                    The Commission strongly encourages electronic filings of comments, protests and interventions in lieu of paper using the “eFiling” link at 
                    <E T="03">https://www.ferc.gov.</E>
                     Persons unable to file electronically may mail similar pleadings to the Federal Energy Regulatory Commission, 888 First Street NE, Washington, DC 20426. Hand delivered submissions in docketed proceedings should be delivered to Health and Human Services, 12225 Wilkins Avenue, Rockville, Maryland 20852.
                </P>
                <P>
                    The Commission's Office of Public Participation (OPP) supports meaningful public engagement and participation in Commission proceedings. OPP can help members of the public, including landowners, environmental justice communities, Tribal members and others, access publicly available information and navigate Commission processes. For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, the public is encouraged to contact OPP at (202) 502-6595 or 
                    <E T="03">OPP@ferc.gov.</E>
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5:00 p.m. Eastern Time on December 15, 2024.
                </P>
                <SIG>
                    <DATED>Dated: November 20, 2024.</DATED>
                    <NAME>Debbie-Anne A. Reese,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27772 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <DEPDOC>[Docket No. EF25-1-000]</DEPDOC>
                <SUBJECT>Western Area Power Administration; Notice of Filing</SUBJECT>
                <P>Take notice that on November 15, 2024, Western Area Power Administration submitted a tariff filing per 300.10: RMR_LAP_WAPA212-20241115 to be effective January 1, 2025.</P>
                <P>
                    Any person desiring to intervene or to protest this filing must file in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211, 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken but will 
                    <PRTPAGE P="93571"/>
                    not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a notice of intervention or motion to intervene, as appropriate. Such notices, motions, or protests must be filed on or before the comment date. On or before the comment date, it is not necessary to serve motions to intervene or protests on persons other than the Applicant.
                </P>
                <P>
                    The Commission strongly encourages electronic filings of comments, protests and interventions in lieu of paper using the “eFiling” link at 
                    <E T="03">https://www.ferc.gov.</E>
                     Persons unable to file electronically may mail similar pleadings to the Federal Energy Regulatory Commission, 888 First Street NE, Washington, DC 20426. Hand delivered submissions in docketed proceedings should be delivered to Health and Human Services, 12225 Wilkins Avenue, Rockville, Maryland 20852.
                </P>
                <P>
                    The Commission's Office of Public Participation (OPP) supports meaningful public engagement and participation in Commission proceedings. OPP can help members of the public, including landowners, environmental justice communities, Tribal members and others, access publicly available information and navigate Commission processes. For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, the public is encouraged to contact OPP at (202) 502-6595 or 
                    <E T="03">OPP@ferc.gov.</E>
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. eastern time on December 15, 2024.
                </P>
                <SIG>
                    <DATED>Dated: November 20, 2024.</DATED>
                    <NAME>Debbie-Anne A. Reese,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27771 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <SUBJECT>Combined Notice of Filings</SUBJECT>
                <P>Take notice that the Commission has received the following Natural Gas Pipeline Rate and Refund Report filings:</P>
                <HD SOURCE="HD1">Filings Instituting Proceedings</HD>
                <P>
                    <E T="03">Docket Numbers:</E>
                     RP25-198-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Maritimes &amp; Northeast Pipeline, L.L.C.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Compliance filing: Joint Petition for Approval of Settlement Agreement to be effective N/A.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5001.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/3/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     RP25-199-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Kern River Gas Transmission Company.
                </P>
                <P>
                    <E T="03">Description:</E>
                     4(d) Rate Filing: 2024 Leap Year Reversal Filing to be effective 1/1/2025.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5047.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/3/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     RP25-200-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Southern Natural Gas Company, L.L.C.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Compliance filing: SNG Operational Transactions Filing 2024 to be effective N/A.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5053.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/3/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     RP25-201-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Transcontinental Gas Pipe Line Company, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     4(d) Rate Filing: List of Non-Conforming Service Agreements (SRE Interim) to be effective 12/22/2024.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5059.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/3/24.
                </P>
                <P>Any person desiring to intervene, to protest, or to answer a complaint in any of the above proceedings must file in accordance with Rules 211, 214, or 206 of the Commission's Regulations (18 CFR 385.211, 385.214, or 385.206) on or before 5:00 p.m. Eastern time on the specified comment date. Protests may be considered, but intervention is necessary to become a party to the proceeding.</P>
                <HD SOURCE="HD1">Filings in Existing Proceedings</HD>
                <P>
                    <E T="03">Docket Numbers:</E>
                     RP24-164-005.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Carolina Gas Transmission, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Compliance filing: CGT-RP24-164 Rate Case Settlement Compliance Filing to be effective 6/1/2024.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5025.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/3/24.
                </P>
                <P>Any person desiring to protest in any the above proceedings must file in accordance with Rule 211 of the Commission's Regulations (18 CFR 385.211) on or before 5:00 p.m. Eastern time on the specified comment date.</P>
                <P>
                    The filings are accessible in the Commission's eLibrary system (
                    <E T="03">https://elibrary.ferc.gov/idmws/search/fercgensearch.asp</E>
                    ) by querying the docket number.
                </P>
                <P>
                    eFiling is encouraged. More detailed information relating to filing requirements, interventions, protests, service, and qualifying facilities filings can be found at: 
                    <E T="03">http://www.ferc.gov/docs-filing/efiling/filing-req.pdf.</E>
                     For other information, call (866) 208-3676 (toll free). For TTY, call (202) 502-8659.
                </P>
                <P>The Commission's Office of Public Participation (OPP) supports meaningful public engagement and participation in Commission proceedings. OPP can help members of the public, including landowners, environmental justice communities, Tribal members and others, access publicly available information and navigate Commission processes.</P>
                <P>
                    For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, the public is encouraged to contact OPP at (202) 502-6595 or 
                    <E T="03">OPP@ferc.gov.</E>
                </P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Carlos D. Clay,</NAME>
                    <TITLE>Acting Deputy Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27808 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <DEPDOC>[Project No. 2322-069]</DEPDOC>
                <SUBJECT>Brookfield White Pine Hydro, LLC; Notice of Reasonable Period of Time for Water Quality Certification Application</SUBJECT>
                <P>
                    On November 8, 2024, Maine Department of Environmental Protection (Maine DEP) submitted to the Federal Energy Regulatory Commission (Commission) notice that it received a request for a Clean Water Act section 401(a)(1) water quality certification as defined in 40 CFR 121.5, from Brookfield White Pine Hydro, LLC, in conjunction with the above captioned project on October 21, 2024. Pursuant to section 5.23(b) of the Commission's regulations,
                    <SU>1</SU>
                    <FTREF/>
                     we hereby notify Maine DEP of the following:
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         18 CFR 5.23(b).
                    </P>
                </FTNT>
                <P>
                    <E T="03">Date of Receipt of the Certification Request:</E>
                     October 21, 2024.
                </P>
                <P>
                    <E T="03">Reasonable Period of Time to Act on the Certification Request:</E>
                     October 21, 2025.
                </P>
                <P>If Maine DEP fails or refuses to act on the water quality certification request on or before the above date, then the certifying authority is deemed waived pursuant to section 401(a)(1) of the Clean Water Act, 33 U.S.C. 1341(a)(1).</P>
                <SIG>
                    <DATED>Dated: November 20, 2024.</DATED>
                    <NAME>Debbie-Anne A. Reese,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27779 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="93572"/>
                <AGENCY TYPE="S">DEPARTMENT OF ENERGY</AGENCY>
                <SUBAGY>Federal Energy Regulatory Commission</SUBAGY>
                <SUBJECT>Combined Notice of Filings #1</SUBJECT>
                <P>Take notice that the Commission received the following exempt wholesale generator filings:</P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     EG25-34-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Enbridge Solar (Orange Grove), LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Enbridge Solar (Orange Grove), LLC submits Notice of Self-Certification of Exempt Wholesale Generator Status.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/5/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241105-5265.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 11/26/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     EG25-39-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Bluegrass Solar, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Bluegrass Solar, LLC submits Notice of Self-Certification of Exempt Wholesale Generator Status.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5100.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/12/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     EG25-40-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Burksol LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Burksol LLC submits Notice of Self-Certification of Exempt Wholesale Generator Status.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5148.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/12/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     EG25-41-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Desert Willow Energy Storage, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Desert Willow Energy Storage, LLC submits Notice of Self-Certification of Exempt Wholesale Generator Status.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5152.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/12/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     EG25-42-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Anole Energy Storage, LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Anole Energy Storage, LLC submits Notice of Self-Certification of Exempt Wholesale Generator Status.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5166.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/12/24.
                </P>
                <P>Take notice that the Commission received the following electric rate filings:</P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER25-500-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Scatter Wash Energy Storage LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Baseline eTariff Filing: Baseline new to be effective 11/21/2024.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/20/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241120-5176.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/11/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER25-501-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     PJM Interconnection, L.L.C.
                </P>
                <P>
                    <E T="03">Description:</E>
                     205(d) Rate Filing: Original GIA Service Agreement No. 7407; Project Identifier No. AF2-383 to be effective 10/23/2024.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5023.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/12/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER25-502-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     PJM Interconnection, L.L.C.
                </P>
                <P>
                    <E T="03">Description:</E>
                     205(d) Rate Filing: Rev to OA, Sch. 12 &amp; RAA, Sch. 17 RE 3Q 2024 Member Lists to be effective 9/30/2024.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5044.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/12/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER25-503-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Public Service Company of Colorado.
                </P>
                <P>
                    <E T="03">Description:</E>
                     205(d) Rate Filing: 2024-11-21-PSC-UPI-T-2024-8-Farren-SISA-853-0.0.0 to be effective 1/20/2025.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5062.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/12/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER25-504-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Midcontinent Independent System Operator, Inc.
                </P>
                <P>
                    <E T="03">Description:</E>
                     205(d) Rate Filing: 2024-11-21_SA 6522 MISO-Manitowoc Public Utilities Third SSR Agrmt Lakefront 9 to be effective 2/1/2025.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5071.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/12/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER25-505-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Nevada Gold Energy LLC.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Initial rate filing: Nevada Gold Energy Reactive Power Filing to be effective 1/21/2025.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5136.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/12/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER25-506-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Appalachian Power Company.
                </P>
                <P>
                    <E T="03">Description:</E>
                     205(d) Rate Filing: OATT—Revise Attachment K, AEP Texas Inc. Rate Update to be effective 12/31/9998.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5139.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/12/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER25-507-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     Midcontinent Independent System Operator, Inc.
                </P>
                <P>
                    <E T="03">Description:</E>
                     205(d) Rate Filing: 2024-11-21_Att X Queue Cap Proposal and Exemptions to Queue Cap Proposal to be effective 1/31/2025.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5143.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/12/24.
                </P>
                <P>
                    <E T="03">Docket Numbers:</E>
                     ER25-508-000.
                </P>
                <P>
                    <E T="03">Applicants:</E>
                     American Electric Power Service Corporation, PJM Interconnection, L.L.C.
                </P>
                <P>
                    <E T="03">Description:</E>
                     205(d) Rate Filing: American Electric Power Service Corporation submits tariff filing per 35.13(a)(2)(iii: AEP submits two Facilities Agreements re: ILDSA, SA No. 1336 to be effective 11/1/2024.
                </P>
                <P>
                    <E T="03">Filed Date:</E>
                     11/21/24.
                </P>
                <P>
                    <E T="03">Accession Number:</E>
                     20241121-5146.
                </P>
                <P>
                    <E T="03">Comment Date:</E>
                     5 p.m. ET 12/12/24.
                </P>
                <P>
                    The filings are accessible in the Commission's eLibrary system (
                    <E T="03">https://elibrary.ferc.gov/idmws/search/fercgensearch.asp</E>
                    ) by querying the docket number.
                </P>
                <P>Any person desiring to intervene, to protest, or to answer a complaint in any of the above proceedings must file in accordance with Rules 211, 214, or 206 of the Commission's Regulations (18 CFR 385.211, 385.214, or 385.206) on or before 5:00 p.m. Eastern time on the specified comment date. Protests may be considered, but intervention is necessary to become a party to the proceeding.</P>
                <P>
                    eFiling is encouraged. More detailed information relating to filing requirements, interventions, protests, service, and qualifying facilities filings can be found at: 
                    <E T="03">http://www.ferc.gov/docs-filing/efiling/filing-req.pdf.</E>
                     For other information, call (866) 208-3676 (toll free). For TTY, call (202) 502-8659.
                </P>
                <P>
                    The Commission's Office of Public Participation (OPP) supports meaningful public engagement and participation in Commission proceedings. OPP can help members of the public, including landowners, environmental justice communities, Tribal members and others, access publicly available information and navigate Commission processes. For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, the public is encouraged to contact OPP at (202) 502-6595 or 
                    <E T="03">OPP@ferc.gov.</E>
                </P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Carlos D. Clay,</NAME>
                    <TITLE>Acting Deputy Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27807 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6717-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OMS-2024-0127; FRL-12438-01-OMS]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Background Checks for Contractor Employees (Renewal)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <PRTPAGE P="93573"/>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) has submitted an information collection request (ICR), Background Checks for Contractor Employees (EPA ICR Number 2159.09, OMB Control Number 2030-0043) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act. This is a proposed extension of the ICR, which is currently approved through November 30, 2024. Public comments were previously requested via the 
                        <E T="04">Federal Register</E>
                         on May 29, 2024, during a 60-day comment period. This notice allows for 30 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be submitted on or before December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID Number EPA-HQ-OMS-2024-0127, to EPA online using 
                        <E T="03">www.regulations.gov</E>
                         (our preferred method), by email 
                        <E T="03">oei.docket@epa.gov,</E>
                         or by mail to: EPA Docket Center, Environmental Protection Agency, Mail Code 28221T, 1200 Pennsylvania Ave. NW, Washington, DC 20460.
                    </P>
                    <P>EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.</P>
                    <P>
                        Submit written comments and recommendations to OMB for the proposed information collection within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Brandon R. Hawkins, Policy and Oversite Branch, Office of Acquisition Solutions (3802R), Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: 202-250-8897; email address: 
                        <E T="03">Hawkins.Brandon.R@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a request for approval of a proposed extension of the ICR, which is currently approved through November 30, 2024. An agency may not conduct, or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    Public comments were previously requested via the 
                    <E T="04">Federal Register</E>
                     on May 29, 2024 during a 60-day comment period. This notice allows for an additional 30 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is 202-566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">https://www.epa.gov/dockets.</E>
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The EPA uses contractors to perform services throughout the nation with regard to environmental emergencies involving the release, or threatened release, of oil, radioactive materials, or hazardous chemicals that may potentially affect communities and the surrounding environment. The Agency may request contractors responding to any of these types of incidents to conduct background checks and apply Government-established suitability criteria in 5 CFR 731.104, 
                    <E T="03">Appointments Subject to Investigation;</E>
                     5 CFR 732.201, 
                    <E T="03">Sensitivity Level Designations and Investigative Requirements;</E>
                     and 5 CFR 736.102, 
                    <E T="03">Notice to Investigative Sources</E>
                     when determining whether employees are acceptable to perform on given sites or on specific projects. In addition to emergency response contractors, EPA may require background checks for contractor personnel working in sensitive sites or sensitive projects. The background checks and application of the Government's suitability criteria must be completed prior to contract employee performance. The contractor shall maintain records associated with all background checks. Background checks cover citizenship or valid visa status, criminal convictions, weapons offenses, felony convictions, and parties prohibited from receiving Federal contracts.
                </P>
                <P>
                    <E T="03">Form Numbers:</E>
                     None.
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Private Contractors.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Required to obtain a benefit per 5 CFR 731.104, 732.201, and 736.102.
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     1,000 (total).
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     Triennial.
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     1,000 hours (per year). Burden is defined at 5 CFR 1320.03(b). 
                    <E T="03">Total estimated cost:</E>
                     $208,720 (per year), which includes $0 annualized capital or operation &amp; maintenance costs.
                </P>
                <P>
                    <E T="03">Changes in the Estimates:</E>
                     There is no change in the hours in the total estimated respondent burden compared with the ICR currently approved by OMB.
                </P>
                <SIG>
                    <NAME>Courtney Kerwin, </NAME>
                    <TITLE>Director, Information Engagement Division.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27731 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OECA-2020-0020; FRL-12443-01-OMS]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Annual Public Water Systems Compliance Report (Renewal)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) has submitted an information collection request (ICR), Annual Public Water Systems Compliance Report (EPA ICR Number 1812.08, OMB Control Number 2020-0020) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act. This is a proposed extension of the ICR, which is currently approved through November 30, 2024. Public comments were previously requested via the 
                        <E T="04">Federal Register</E>
                         on March 13, 2024 during a 60-day comment period. This notice allows for an additional 30 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments may be submitted on or before December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID Number EPA-HQ-OECA-2020-0020, to EPA online using 
                        <E T="03">www.regulations.gov</E>
                         (our preferred method), by email to 
                        <E T="03">docket.oeca@epa.gov,</E>
                         or by mail to: EPA Docket Center, Environmental Protection Agency, Mail Code 28221T, 1200 Pennsylvania Ave. NW, Washington, DC 20460.
                    </P>
                    <P>EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.</P>
                    <P>
                        Submit written comments and recommendations to OMB for the 
                        <PRTPAGE P="93574"/>
                        proposed information collection within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Michael Chen, Monitoring, Assistance, and Media Programs Division, Office of Compliance, MC-2227A, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 564-3371; email address: 
                        <E T="03">chen.michael@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a proposed extension of the ICR, which is currently approved through November 30, 2024. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    Public comments were previously requested via the 
                    <E T="04">Federal Register</E>
                     on March 13, 2024 during a 60-day comment period (89 FR 18407). This notice allows for an additional 30 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is 202-566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">http://www.epa.gov/dockets.</E>
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     Section 1414(c)(3)(A) of the Safe Drinking Water Act requires that each state that has primary enforcement authority under the Act shall prepare, make readily available to the public, and submit to the Administrator of EPA, an annual report of violations of national primary drinking water regulations in the state. The states' reports are to include violations of maximum contaminant levels, treatment requirements, variances and exemptions, and monitoring requirements determined to be significant by the Administrator after consultation with the states. To minimize a state's burden in preparing its annual statutorily required report, EPA issued guidance that explains what Section 1414(c)(3)(A) requires and provides model language and reporting templates. EPA also annually makes available to the states a computer query that generates for each state (from information states are already separately required to submit to EPA's national database on a quarterly basis) the required violations information in a table consistent with the reporting template in EPAs guidance.
                </P>
                <P>
                    <E T="03">Form Numbers:</E>
                     None.
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Entities that are potentially affected by this action are states that have primacy enforcement authority and meet the definition of “state” under the SDWA.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Mandatory under Section 1414(c)(3)(A) of SDWA.
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     55 (total).
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     Annually.
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     4,400 hours (per year). Burden is defined at 5 CFR 1320.03(b).
                </P>
                <P>
                    <E T="03">Total estimated cost:</E>
                     $730,000 (per year), which includes $0 annualized capital or operation &amp; maintenance costs.
                </P>
                <P>
                    <E T="03">Changes in the Estimates:</E>
                     There is no change in burden hours from the most recently approved. This is due to two considerations. First, the requirements under SDWA have not changed over the past three years and are not anticipated to change over the next three years. Secondly, the number of states, territories or tribes with primacy has not changed, and is not anticipated to change over the next three years, so there is no significant change in the overall burden. The costs have increased solely due to increases in labor rates, see Tables 1 and 2 for further information.
                </P>
                <SIG>
                    <NAME>Courtney Kerwin, </NAME>
                    <TITLE>Director, Information Engagement Division.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27730 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OPPT-2014-0838; FRL-12379-01-OCSPP]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed Renewal of an Existing ICR Collection and Request for Comment; Assessment of Environmental Performance Standards and Ecolabels for Federal Procurement</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In compliance with the Paperwork Reduction Act (PRA), this document announces the availability of and solicits public comment on the following Information Collection Request (ICR) that EPA is planning to submit to the Office of Management and Budget (OMB): “Assessment of Environmental Performance Standards and Ecolabels for Federal Procurement,” identified by EPA ICR No. 2516.05 and OMB Control No. 2070-0199. This ICR represents a renewal of an existing ICR that is currently approved through September 30, 2025. Before submitting the ICR to OMB for review and approval under the PRA, EPA is soliciting comments on specific aspects of the information collection that is summarized in this document. The ICR and accompanying material are available in the docket for public review and comment.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be received on or before January 27, 2025.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, identified by docket identification (ID) number EPA-HQ-OPPT-2014-0838, through the Federal eRulemaking Portal at 
                        <E T="03">https://www.regulations.gov.</E>
                         Follow the online instructions for submitting comments. Do not submit electronically any information you consider to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Additional instructions on commenting or visiting the docket, along with more information about dockets generally, is available at 
                        <E T="03">https://www.epa.gov/dockets.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Carolyn Siu, Mission Support Division (7602M), Office of Program Support, Office of Chemical Safety and Pollution Prevention, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-0001; telephone number: (703) 719-1649; email address: 
                        <E T="03">siu.carolyn@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. What information is EPA particularly interested in?</HD>
                <P>Pursuant to PRA section 3506(c)(2)(A) (44 U.S.C. 3506(c)(2)(A)), EPA specifically solicits comments and information to enable it to:</P>
                <P>1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility.</P>
                <P>2. Evaluate the accuracy of the Agency's estimates of the burden of the proposed collection of information, including the validity of the methodology and assumptions used.</P>
                <P>3. Enhance the quality, utility, and clarity of the information to be collected.</P>
                <P>
                    4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated electronic, 
                    <PRTPAGE P="93575"/>
                    mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses. In particular, EPA is requesting comments from very small businesses (those that employ less than 25) on examples of specific additional efforts that EPA could make to reduce the paperwork burden for very small businesses affected by this collection.
                </P>
                <HD SOURCE="HD1">II. What information collection activity or ICR does this action apply to?</HD>
                <P>
                    <E T="03">Title:</E>
                     Assessment of Environmental Performance Standards and Ecolabels for Federal Procurement.
                </P>
                <P>
                    <E T="03">EPA ICR No.:</E>
                     2516.05.
                </P>
                <P>
                    <E T="03">OMB Control No.:</E>
                     2070-0199.
                </P>
                <P>
                    <E T="03">ICR status:</E>
                     This ICR is currently approved through September 30, 2025. Under the PRA, an agency may not conduct or sponsor, and a person is not required to respond to, a collection of information, unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations in title 40 of the Code of Federal Regulations (CFR), after appearing in the 
                    <E T="04">Federal Register</E>
                     when approved, are displayed either by publication in the 
                    <E T="04">Federal Register</E>
                     or by other appropriate means, such as on the related collection instrument or form, if applicable. The display of OMB control numbers for certain EPA regulations is consolidated in 40 CFR part 9.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     This ICR covers the information collection activities associated with the Agency's evaluation of private sector standards and ecolabels per EPA's Framework for the Assessment of Environmental Performance Standards and Ecolabels for Federal Purchasing (Framework), formerly referred to as the Guidelines. EPA's goal in developing this Framework is to create a transparent, fair, and consistent approach to selecting product environmental performance standards and ecolabels to support the Agency's mission and federal sustainable acquisition goals and mandates. The fundamental aim of this Framework is to establish a cross-sector approach to be used in recognizing private sector environmental performance standards (and consequently, environmentally preferable products and services meeting these standards) for use in federal purchasing.
                </P>
                <P>
                    <E T="03">Burden statement:</E>
                     The annual public reporting and recordkeeping burden for this collection of information is estimated to average 8.5 hours per response. Burden is defined in 5 CFR 1320.3(b).
                </P>
                <P>The ICR, which is available in the docket along with other related materials, provides a detailed explanation of the collection activities and the burden estimate that is only briefly summarized here:</P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Entities potentially affected are standard development organizations, ecolabel programs, and certification entities that manage product or service environmental performance standards and/or ecolabels that could be considered for use in United States federal sustainable procurement efforts.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Voluntary. See 15 U.S.C. 3701 and 42 U.S.C. 13103(b)(11).
                </P>
                <P>
                    <E T="03">Forms:</E>
                     EPA Form No. 9600-038.
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     On Occasion.
                </P>
                <P>
                    <E T="03">Total estimated number of potential respondents:</E>
                     100.
                </P>
                <P>
                    <E T="03">Total estimated average number of responses for each respondent:</E>
                     2.
                </P>
                <P>
                    <E T="03">Total estimated annual burden hours:</E>
                     613 hours.
                </P>
                <P>
                    <E T="03">Total estimated annual respondent costs:</E>
                     $49,284 which includes $0 for capital investment or maintenance and operational costs.
                </P>
                <HD SOURCE="HD1">III. Are there changes in the estimates from the last approval?</HD>
                <P>There is a decrease in burden of 94 hours. The burden decrease is a result of the decrease of respondents that were not previously assessed per EPA Framework. This change is an adjustment.</P>
                <HD SOURCE="HD1">IV. What is the next step in the process for this ICR?</HD>
                <P>
                    EPA will consider the comments received and amend the ICR as appropriate. The final ICR package will then be submitted to OMB for review and approval pursuant to 5 CFR 1320.12. EPA will issue another 
                    <E T="04">Federal Register</E>
                     document pursuant to 5 CFR 1320.5(a)(1)(iv) to announce the submission of the ICR to OMB and the opportunity to submit additional comments to OMB. If you have any questions about this ICR or the approval process, please contact the person listed under 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                    .
                </P>
                <P>
                    <E T="03">Authority:</E>
                     44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Michal Freedhoff,</NAME>
                    <TITLE>Assistant Administrator, Office of Chemical Safety and Pollution Prevention.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27816 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OEI-2006-0037; FRL-12444-01-OMS]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Exchange Network Grants Progress Reports (Renewal)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) has submitted an information collection request (ICR), Exchange Network Grants Program (EPA ICR Number 2207.09, OMB Control Number 2025-0006) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act. This is a proposed extension of the ICR, which is currently approved through November 30, 2024. Public comments were previously requested via the 
                        <E T="04">Federal Register</E>
                         on September 19, 2024 during a 60-day comment period. This notice allows for an additional 30 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments may be submitted on or before December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID Number EPA ICR Number 2207.09, OMB Control Number 2025-0006 to EPA online using 
                        <E T="03">www.regulations.gov</E>
                         (our preferred method), or by mail to: EPA Docket Center, Environmental Protection Agency, Mail Code 28221T, 1200 Pennsylvania Ave. NW, Washington, DC 20460. EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.
                    </P>
                    <P>
                        Submit written comments and recommendations to OMB for the proposed information collection within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Erin McGown, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; email address: 
                        <E T="03">mcgown.erin@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <PRTPAGE P="93576"/>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a proposed extension of the ICR, which is currently approved through November 30, 2024. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    Public comments were previously requested via the 
                    <E T="04">Federal Register</E>
                     on September 19, 2024 (89 FR 76826) during a 60-day comment period. This notice allows for an additional 30 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is 202-566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">http://www.epa.gov/dockets.</E>
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The Environmental Protection Agency's (EPA) Office of Mission Support provides funding via grants to EPA's Exchange Network partners (states, territories, and federally recognized Indian tribes) to support the development of the Exchange Network (EN). The EN facilitates the sharing of environmental data, especially through shared and reusable services; streamlines data collection and exchanges to improve timeliness for decision making; increases the quality and access to environmental data; reduces burden and costs for co-regulators and the regulated community; supports better decisions on environmental and health issues; and increases capacity for environmental data management for tribes and U.S. territories. As part of the terms and conditions of the EN grant program, recipients are required to submit the following forms: (i) Semi-Annual Progress Reports (EPA Form 5300-26) twice annually throughout the lifetime of the project, Final Progress Report (EPA Form 5300-26) within 120 calendar days after the period of performance end date, and the IT Component and Project Registration Form, at the time of grant close-out. The information gathered on items (i) and (ii) help EPA to ensure that projects are on schedule to meet identified project goals and produce high quality environmental outputs. The registration form (item iii) provides a detailed summary of the completed project and any developed/reused IT components; this information is made available to future applicants to inform the development of their proposed projects, promote the reuse of technologies, and connect to potential project partners and mentors.
                </P>
                <P>
                    <E T="03">Form Numbers:</E>
                     5300-26.
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Employees of state, tribal, or territorial environmental government offices.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Required to obtain or retain a benefit (2 CFR part 200, “Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards).
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     223 (149 semi-annually for the semi-annual progress report form; 38 annually for the IT Component and Project Registration Form, and 38 annually for the Final Progress Report Form).
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     EPA assumes that each grant recipient will submit two Semi-Annual Progress Report Forms each year the grant is active. In addition, the grantees will submit the Final Progress Report to RENC no later than 120 days after the grant performance period end date. At this time, the IT Component and Project Registration Form will likewise be submitted.
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     493 hours (per year). Burden is defined at 5 CFR 1320.03(b).
                </P>
                <P>
                    <E T="03">Total estimated cost:</E>
                     $29,530 (per year), includes $0 annualized capital or operation &amp; maintenance costs.
                </P>
                <P>
                    <E T="03">Changes in the Estimates:</E>
                     There is a slight decrease of 15 (493 hours in 2024 vs 508 hours in 2021) hours in the total estimated respondent burden as compared with the ICR currently approved by OMB. The number of open active grants each year was estimated at 149, which matches the 2021 estimate, as the number of new assistance agreements has remained consistent since 2021. Estimates for the Final Progress Reporting Form is also very similar to the 2021 estimate, with only a slight increase in the number of expected closed-out grants (from 36 in 2021 to 38 in 2024). This slight increase reflects an expectation for more EN assistance agreements to close out in the upcoming years, as projects which were initially delayed due to workplace changes associated with COVID-19 are now being completed. The slight decrease in burden hours for respondents can be attributed primarily to the retiring of the Quality Assurance Reporting Form, which was previously required within 90 days of each new assistance agreement. There was a new form added for this ICR, which was not present in the 2021 version. The IT Component and Project Registration Form is a fillable PDF form, that is submitted by the grantee to their Regional Exchange Network Coordinator (RENC) at the time of grant close-out. As this form is due at the time of grant close-out, the estimated number matches the estimated number of Final Progress Reports (38). This new form is estimated to take 2 hours to complete, which is a decrease of 0.6 compared to the retired Quality Assurance Reporting Form.
                </P>
                <SIG>
                    <NAME>Courtney Kerwin,</NAME>
                    <TITLE>Director, Regulatory Support Division.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27729 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OPPT-2024-0057; FRL-11683-10-OCSPP]</DEPDOC>
                <SUBJECT>Certain New Chemicals; Receipt and Status Information for October 2024</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        EPA is required under the Toxic Substances Control Act (TSCA), as amended by the Frank R. Lautenberg Chemical Safety for the 21st Century Act, to make information publicly available and to publish information in the 
                        <E T="04">Federal Register</E>
                         pertaining to submissions under TSCA section 5, including notice of receipt of a Premanufacture notice (PMN), Significant New Use Notice (SNUN) or Microbial Commercial Activity Notice (MCAN), including an amended notice or test information; an exemption application (Biotech exemption); an application for a test marketing exemption (TME), both pending and/or concluded; a notice of commencement (NOC) of manufacture (including import) for new chemical substances; and a periodic status report on new chemical substances that are currently under EPA review or have recently concluded review. This document covers the period from October 1, 2024 to October 31, 2024.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments identified by the specific case number provided in this document must be received on or before December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, identified by docket identification (ID) number EPA-HQ-OPPT-2024-0057, through the 
                        <E T="03">Federal eRulemaking Portal</E>
                         at 
                        <E T="03">https://www.regulations.gov.</E>
                         Follow the online instructions for submitting comments. Do not submit electronically any information you consider to be Confidential Business Information (CBI) 
                        <PRTPAGE P="93577"/>
                        or other information whose disclosure is restricted by statute. Additional instructions on commenting and visiting the docket, along with more information about dockets generally, is available at 
                        <E T="03">https://www.epa.gov/dockets.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        <E T="03">For technical information contact:</E>
                         Jim Rahai, Project Management and Operations Division (MC 7407M), Office of Pollution Prevention and Toxics, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-0001; telephone number: (202) 564-8593; email address: 
                        <E T="03">rahai.jim@epa.gov. For general information contact:</E>
                         The TSCA-Hotline, ABVI-Goodwill, 422 South Clinton Ave., Rochester, NY 14620; telephone number: (202) 554-1404; email address: 
                        <E T="03">TSCA-Hotline@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Executive Summary</HD>
                <HD SOURCE="HD2">A. What action is the Agency taking?</HD>
                <P>This document provides the receipt and status reports for the period from October 1, 2024 to October 31, 2024. The Agency is providing notice of receipt of PMNs, SNUNs, and MCANs (including amended notices and test information); an exemption application under 40 CFR part 725 (Biotech exemption); TMEs, both pending and/or concluded; NOCs to manufacture a new chemical substance; and a periodic status report on new chemical substances that are currently under EPA review or have recently concluded review.</P>
                <P>
                    EPA is also providing information on its website about cases reviewed under the amended TSCA, including the section 5 PMN/SNUN/MCAN and exemption notices received, the date of receipt, the final EPA determination on the notice, and the effective date of EPA's determination for PMN/SNUN/MCAN notices on its website at: 
                    <E T="03">https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca/status-pre-manufacture-notices.</E>
                     This information is updated on a weekly basis.
                </P>
                <HD SOURCE="HD2">B. What is the Agency's authority for taking this action?</HD>
                <P>
                    Under the Toxic Substances Control Act (TSCA), 15 U.S.C. 2601 
                    <E T="03">et seq.,</E>
                     a chemical substance may be either an “existing” chemical substance or a “new” chemical substance. Any chemical substance that is not on EPA's TSCA Inventory of Chemical Substances (TSCA Inventory) is classified as a “new chemical substance,” while a chemical substance that is listed on the TSCA Inventory is classified as an “existing chemical substance.” (See TSCA section 3(11).) For more information about the TSCA Inventory please go to: 
                    <E T="03">https://www.epa.gov/tsca-inventory.</E>
                </P>
                <P>Any person who intends to manufacture (including import) a new chemical substance for a non-exempt commercial purpose, or to manufacture or process a chemical substance in a non-exempt manner for a use that EPA has determined is a significant new use, is required by TSCA section 5 to provide EPA with a PMN, MCAN, or SNUN, as appropriate, before initiating the activity. EPA will review the notice, make a risk determination on the chemical substance or significant new use, and take appropriate action as described in TSCA section 5(a)(3).</P>
                <P>
                    TSCA section 5(h)(1) authorizes EPA to allow persons, upon application and under appropriate restrictions, to manufacture or process a new chemical substance, or a chemical substance subject to a significant new use rule (SNUR) issued under TSCA section 5(a)(2), for “test marketing” purposes, upon a showing that the manufacture, processing, distribution in commerce, use, and disposal of the chemical will not present an unreasonable risk of injury to health or the environment. This is referred to as a test marketing exemption, or TME. For more information about the requirements applicable to a new chemical go to: 
                    <E T="03">https://www.epa.gov/chemicals-under-tsca.</E>
                </P>
                <P>
                    Under TSCA sections 5 and 8 and EPA regulations, EPA is required to publish in the 
                    <E T="04">Federal Register</E>
                     certain information, including notice of receipt of a PMN/SNUN/MCAN (including amended notices and test information); an exemption application under 40 CFR part 725 (biotech exemption); an application for a TME, both pending and concluded; NOCs to manufacture a new chemical substance; and a periodic status report on the new chemical substances that are currently under EPA review or have recently concluded review.
                </P>
                <HD SOURCE="HD2">C. Does this action apply to me?</HD>
                <P>This action provides information that is directed to the public in general.</P>
                <HD SOURCE="HD2">D. Does this action have any incremental economic impacts or paperwork burdens?</HD>
                <P>No.</P>
                <HD SOURCE="HD2">E. What should I consider as I prepare my comments for EPA?</HD>
                <P>
                    1. 
                    <E T="03">Submitting confidential business information (CBI).</E>
                     Do not submit this information to EPA through 
                    <E T="03">regulations.gov</E>
                     or email. Clearly mark the part or all of the information that you claim to be CBI. For CBI information in a disk or CD-ROM that you mail to EPA, mark the outside of the disk or CD-ROM as CBI and then identify electronically within the disk or CD-ROM the specific information that is claimed as CBI. In addition to one complete version of the comment that includes information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public docket. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2.
                </P>
                <P>
                    2. 
                    <E T="03">Tips for preparing your comments.</E>
                     When preparing and submitting your comments, see the commenting tips at 
                    <E T="03">https://www.epa.gov/dockets/commenting-epa-dockets.</E>
                </P>
                <HD SOURCE="HD1">II. Status Reports</HD>
                <P>
                    In the past, EPA has published individual notices reflecting the status of TSCA section 5 filings received, pending, or concluded. In 1995, the Agency modified its approach and streamlined the information published in the 
                    <E T="04">Federal Register</E>
                     after providing notice of such changes to the public and an opportunity to comment (see the 
                    <E T="04">Federal Register</E>
                     of May 12, 1995 (60 FR 25798) (FRL-4942-7)). Since the passage of the Lautenberg amendments to TSCA in 2016, public interest in information on the status of section 5 cases under EPA review and, in particular, the final determination of such cases, has increased. In an effort to be responsive to the regulated community, the users of this information, and the general public, to comply with the requirements of TSCA, to conserve EPA resources and to streamline the process and make it more timely, EPA is providing information on its website about cases reviewed under the amended TSCA, including the section 5 PMN/SNUN/MCAN and exemption notices received, the date of receipt, the final EPA determination on the notice, and the effective date of EPA's determination for PMN/SNUN/MCAN notices on its website at: 
                    <E T="03">https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca/status-pre-manufacture-notices.</E>
                     This information is updated on a weekly basis.
                </P>
                <HD SOURCE="HD1">III. Receipt Reports</HD>
                <P>
                    For the PMN/SNUN/MCANs that have passed an initial screening by EPA during this period, Table I provides the following information (to the extent that such information is not subject to a CBI claim) on the notices screened by EPA 
                    <PRTPAGE P="93578"/>
                    during this period: The EPA case number assigned to the notice that indicates whether the submission is an initial submission, or an amendment, a notation of which version was received, the date the notice was received by EPA, the submitting manufacturer (
                    <E T="03">i.e.,</E>
                     domestic producer or importer), the potential uses identified by the manufacturer in the notice, and the chemical substance identity.
                </P>
                <P>
                    As used in each of the tables in this unit, (S) indicates that the information in the table is the specific information provided by the submitter, and (G) indicates that this information in the table is generic information because the specific information provided by the submitter was claimed as CBI. Submissions which are initial submissions will not have a letter following the case number. Submissions which are amendments to previous submissions will have a case number followed by the letter “A” (
                    <E T="03">e.g.</E>
                     P-18-1234A). The version column designates submissions in sequence as “1”, “2”, “3”, etc. Note that in some cases, an initial submission is not numbered as version 1; this is because earlier version(s) were rejected as incomplete or invalid submissions. Note also that future versions of the following tables may adjust slightly as the Agency works to automate population of the data in the tables.
                </P>
                <GPOTABLE COLS="6" OPTS="L2,nj,p7,7/8,i1" CDEF="xs60,7,10,r50,r65,r100">
                    <TTITLE>Table I—PMN/SNUN/MCANs Approved * from 10/01/2024 to 10/31/2024</TTITLE>
                    <BOXHD>
                        <CHED H="1">Case No.</CHED>
                        <CHED H="1">Version</CHED>
                        <CHED H="1">Received date</CHED>
                        <CHED H="1">Manufacturer</CHED>
                        <CHED H="1">Use</CHED>
                        <CHED H="1">Chemical substance</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">P-18-0127A</ENT>
                        <ENT>2</ENT>
                        <ENT>10/01/2024</ENT>
                        <ENT>Takasago</ENT>
                        <ENT>(S) Fragrance in fine fragrance, consumer products, household products (laundry detergent), shower gels and shampoos</ENT>
                        <ENT>(S) Heptane, 2-methoxy-2-methyl-.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-21-0007A</ENT>
                        <ENT>2</ENT>
                        <ENT>10/25/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) Catalyst</ENT>
                        <ENT>(G) Reaction products of Aluminoxanes, Me, Me group-terminated and (alkylcycloalkenyl) dialkylzirconium.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-21-0008A</ENT>
                        <ENT>2</ENT>
                        <ENT>10/25/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) Catalyst</ENT>
                        <ENT>(G) Reaction products of Aluminoxanes, Me, Me group-terminated and cycloalkylene dialkyl tetrahydro indenyl zirconium.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-22-0068A</ENT>
                        <ENT>4</ENT>
                        <ENT>10/04/2024</ENT>
                        <ENT>Aditya Birla Chemicals (USA), LLC</ENT>
                        <ENT>(S) An epoxy component used in a reaction with other components to produce an epoxy article</ENT>
                        <ENT>(S) 2-Propanamine, 1,1'-[(1-methylethylidene)bis(oxy)]bis-.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-23-0014A</ENT>
                        <ENT>2</ENT>
                        <ENT>10/25/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) Intermediate in production of fragrance</ENT>
                        <ENT>(G) [Polyalkyl-methylenepolyhydro-polycyclic] alkyl acetate.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-23-0086A</ENT>
                        <ENT>7</ENT>
                        <ENT>10/15/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) Additive for surfactant performance enhancement; intermediate used in the manufacturing of detergents</ENT>
                        <ENT>(S) 1,2-Benzisothiazole, 3-methyl-,1,1-dioxide.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-24-0006A</ENT>
                        <ENT>7</ENT>
                        <ENT>10/14/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(S) Oilfield Production Scale Inhibitor</ENT>
                        <ENT>(G) Propenoic acid, methyl- [phosphinicobis(oxy-ethanediyl)] ester, telomer with methyl -methyl-propenoate, (phosphonooxy) ethyl methyl-propenoate, propenoic acid, sodium methyl-[(oxo-propen-yl) amino]-propanesulfonate and sodium sulfite, sodium salt, peroxydisulfuric acid sodium salt -initiated.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-24-0160A</ENT>
                        <ENT>3</ENT>
                        <ENT>09/30/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) Photoacid generator use at customer sites</ENT>
                        <ENT>(G) Iodonium, bis (dialkyl carbomonocycle) salt with alkyl carbomonocycle hetero acid.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-24-0186A</ENT>
                        <ENT>4</ENT>
                        <ENT>10/21/2024</ENT>
                        <ENT>SGP Ventures, Inc.</ENT>
                        <ENT>(S) Epoxy used to fill holes in printed circuit boards</ENT>
                        <ENT>(S) 2-Oxiranemethanamine, N-[2-methyl-4-(2-oxiranylmethoxy) phenyl]-N-(2-oxiranylmethyl)-.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-24-0193A</ENT>
                        <ENT>2</ENT>
                        <ENT>10/10/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) Dispersive use</ENT>
                        <ENT>(G) Perfluorosulfonic acid polymer, with perfluoro dioxolane.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-24-0196</ENT>
                        <ENT>1</ENT>
                        <ENT>09/30/2024</ENT>
                        <ENT>Toray Resin Co.</ENT>
                        <ENT>(S) Additives for architectural paints (elongation improvers)</ENT>
                        <ENT>(S) 2-Pyrrolidinone, polymer with 2-oxepanone.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-24-0196A</ENT>
                        <ENT>2</ENT>
                        <ENT>10/15/2024</ENT>
                        <ENT>Toray Resin Co.</ENT>
                        <ENT>(S) Additives for architectural paints (elongation improvers)</ENT>
                        <ENT>(S) 2-Pyrrolidinone, polymer with 2-oxepanone.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-25-0001A</ENT>
                        <ENT>2</ENT>
                        <ENT>10/21/2024</ENT>
                        <ENT>Polyfil, Inc.</ENT>
                        <ENT>(G) UV initiated crosslinker</ENT>
                        <ENT>(G) Alkoxy benzophenone.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-25-0001A</ENT>
                        <ENT>3</ENT>
                        <ENT>10/28/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) UV crosslinker initiator</ENT>
                        <ENT>(G) Alkoxy benzophenone.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-25-0003</ENT>
                        <ENT>1</ENT>
                        <ENT>10/24/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) Contained use for microlithography for electronic device manufacturing</ENT>
                        <ENT>(G) Phenoxathiin ium, 10-phenyl-, tricycloalkylcarbomonocyclesulfonate (1:1).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-25-0004</ENT>
                        <ENT>1</ENT>
                        <ENT>10/25/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) Contained use for microlithography for electronic device manufacturing</ENT>
                        <ENT>(G) Sulfonium, triphenyl-, heteropolyclyclecarboxylate (1:1).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-25-0005</ENT>
                        <ENT>1</ENT>
                        <ENT>10/28/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) For use in coatings for metal parts</ENT>
                        <ENT>(G) Cashew, nutshell liq., polymer with [(aminoalkyl)imino] bis[alkanol], bisphenol and epichlorohydrin, reaction products with dialkanolamine, alkyl carboxylates (salts) alkanesulfonates (salts).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-25-0006</ENT>
                        <ENT>1</ENT>
                        <ENT>10/28/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) For use in coatings for metal parts</ENT>
                        <ENT>(G) Phenol, 4,4-(1-alkylidene) bis-, polymer with [(aminoalkyl)imino] bis[alkanol] and 2-(chloromethyl) oxirane, 3-alkyloxy-2-hydroxypropyl ethers, reaction products with dialkanolamine, alkyl carboxylates (salts). alkanesulfonates (salts).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-25-0007</ENT>
                        <ENT>1</ENT>
                        <ENT>10/28/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) For use in coatings for metal parts</ENT>
                        <ENT>(G) Phenol, 4,4-(1-alkylidene) bis-, polymer with [(aminoalkyl)imino] bis[alkanol] and 2-(chloromethyl) oxirane, 4-alkylphenyl ethers, reaction products with dialkanolamine, alkyl carboxylates (salts) alkanesulfonates (salts).</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="93579"/>
                        <ENT I="01">P-25-0008</ENT>
                        <ENT>1</ENT>
                        <ENT>10/28/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) For use in coatings for metal parts</ENT>
                        <ENT>(G) Benzenediol, polymer with [(aminoalkyl)imino] bis[alkanol], 2- (chloromethyl)oxirane and 4,4-(1-alkylidene) bis[phenol], 4-alkylphenyl ethers, reaction products with dialkanolamine, alkyl carboxylates (salts) alkanesulfonates (salts).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-25-0009</ENT>
                        <ENT>1</ENT>
                        <ENT>10/28/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) For use in coatings for metal parts</ENT>
                        <ENT>(G) Cashew, nutshell liq., polymer with [(aminoalkyl)imino] bis[alkanol], bisphenol, epichlorohydrin and benzenediol, reaction products with dialkanolamine, alkyl carboxylates (salts) alkanesulfonates (salts).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-25-0010</ENT>
                        <ENT>1</ENT>
                        <ENT>10/28/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(G) For use in coatings for metal parts</ENT>
                        <ENT>(G) Benzenediol, polymer with [(aminoalkyl)imino] bis[alkanol], 2- (chloromethyl)oxirane and 4,4-(1-alkylidene) bis[phenol], 3-alkyloxy-2-hydroxypropyl ethers, reaction products with dialkanolamine, alkyl carboxylates (salts) alkanesulfonates (salts).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-25-0012</ENT>
                        <ENT>1</ENT>
                        <ENT>10/30/2024</ENT>
                        <ENT>Bedoukian Research, Inc.</ENT>
                        <ENT>(G) Site limited chemical intermediate</ENT>
                        <ENT>(G) Alkanoic acid, 4-bromo-, ethyl ester.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">SN-22-0010A</ENT>
                        <ENT>4</ENT>
                        <ENT>10/24/2024</ENT>
                        <ENT>CBI</ENT>
                        <ENT>(S) Monomer chemical, reactive diluent in UV coating formulations (existing use, approved by PMN P-18-0392, additive in UV adhesive formulations (new use)</ENT>
                        <ENT>(S) 2-Oxazolidinone, 3-ethenyl-5-methyl-.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">SN-25-0001</ENT>
                        <ENT>1</ENT>
                        <ENT>10/16/2024</ENT>
                        <ENT>Ishihara Corporation (USA)</ENT>
                        <ENT>(S) Black pigment for architectural paint; Pigment used for non-spray applications (e.g., to make articles such as plastics, resins, fabrics, and textiles, use in adhesives)</ENT>
                        <ENT>(S) Calcium manganese titanium oxide.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    In Table II of this unit, EPA provides the following information (to the extent that such information is not claimed as CBI) on the NOCs that have passed an initial screening by EPA during this period: The EPA case number assigned to the NOC including whether the submission was an initial or amended submission, the date the NOC was received by EPA, the date of commencement provided by the submitter in the NOC, a notation of the type of amendment (
                    <E T="03">e.g.,</E>
                     amendment to generic name, specific name, technical contact information, etc.) and chemical substance identity.
                </P>
                <GPOTABLE COLS="5" OPTS="L2,nj,p7,7/8,i1" CDEF="s25,15,15,xs48,r150">
                    <TTITLE>Table II—NOCs Approved * From 10/01/2024 to 10/31/2024</TTITLE>
                    <BOXHD>
                        <CHED H="1">Case No.</CHED>
                        <CHED H="1">Received date</CHED>
                        <CHED H="1">Commencement date</CHED>
                        <CHED H="1">
                            If amendment, type of
                            <LI>amendment</LI>
                        </CHED>
                        <CHED H="1">Chemical substance</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">J-24-0016</ENT>
                        <ENT>10/16/2024</ENT>
                        <ENT>09/24/2024</ENT>
                        <ENT>N</ENT>
                        <ENT>(G) Chromosomally modified Saccharomyces cerevisiae.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">J-24-0017</ENT>
                        <ENT>10/16/2024</ENT>
                        <ENT>09/24/2024</ENT>
                        <ENT>N</ENT>
                        <ENT>(G) Chromosomally modified Saccharomyces cerevisiae.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">J-24-0018</ENT>
                        <ENT>10/16/2024</ENT>
                        <ENT>09/24/2024</ENT>
                        <ENT>N</ENT>
                        <ENT>(G) Chromosomally modified Saccharomyces cerevisiae.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">J-24-0019</ENT>
                        <ENT>10/16/2024</ENT>
                        <ENT>09/24/2024</ENT>
                        <ENT>N</ENT>
                        <ENT>(G) Chromosomally modified Saccharomyces cerevisiae.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-20-0183</ENT>
                        <ENT>10/29/2024</ENT>
                        <ENT>10/05/2024</ENT>
                        <ENT>N</ENT>
                        <ENT>(G) Aryl ether epoxide, homopolymer, ether with alkanolamine.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-21-0181</ENT>
                        <ENT>10/15/2024</ENT>
                        <ENT>09/17/2024</ENT>
                        <ENT>N</ENT>
                        <ENT>(S) 1,3-Benzenedicarboxamide, N1, N3-bis(3-methylphenyl)-5-[[(3-methylphenyl) amino] sulfonyl]-.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-22-0095</ENT>
                        <ENT>10/14/2024</ENT>
                        <ENT>10/13/2024</ENT>
                        <ENT>N</ENT>
                        <ENT>(G) Glycolipids.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-22-0155</ENT>
                        <ENT>10/23/2024</ENT>
                        <ENT>10/14/2024</ENT>
                        <ENT>N</ENT>
                        <ENT>(G) 2-alkyl-1,2-heteropolycycle-3-one.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-23-0094</ENT>
                        <ENT>10/08/2024</ENT>
                        <ENT>09/10/2024</ENT>
                        <ENT>N</ENT>
                        <ENT>(G) Polymer of benzenedicarboxylic acid, substituted-benzenedicarboxylic acid, branched-alkyldiol, alkyldiol and triisocyanato.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-23-0164</ENT>
                        <ENT>10/07/2024</ENT>
                        <ENT>10/06/2024</ENT>
                        <ENT>N</ENT>
                        <ENT>(S) Bismuth, 1,1′,1″,1″′-(1,2-ethanediyldinitrilo) tetrakis[2-propanol] 2-(2-ethoxyethoxy) ethanol neodecanoate polypropylene glycol complexes.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-23-0167</ENT>
                        <ENT>10/21/2024</ENT>
                        <ENT>09/22/2024</ENT>
                        <ENT>N</ENT>
                        <ENT>(G) Bisalkyldiacid fluorophosphate salt.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-24-0131</ENT>
                        <ENT>10/30/2024</ENT>
                        <ENT>10/28/2024</ENT>
                        <ENT>N</ENT>
                        <ENT>(S) Heptanoic acid, 2-octyldodecyl ester.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>In Table III of this unit, EPA provides the following information (to the extent such information is not subject to a CBI claim) on the test information that has been received during this time period: The EPA case number assigned to the test information; the date the test information was received by EPA, the type of test information submitted, and chemical substance identity.</P>
                <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s50,10,r100,r100">
                    <TTITLE>Table III—Test Information Received From 10/01/2024 to 10/31/2024</TTITLE>
                    <BOXHD>
                        <CHED H="1">Case No.</CHED>
                        <CHED H="1">Received date</CHED>
                        <CHED H="1">Type of test information</CHED>
                        <CHED H="1">Chemical substance</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">L-24-0191</ENT>
                        <ENT>10/16/2024</ENT>
                        <ENT>Final Report</ENT>
                        <ENT>(S) 1-Propene, 1-chloro-3,3,3-trifluoro-, (1Z).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-08-0200</ENT>
                        <ENT>10/29/2024</ENT>
                        <ENT>Required Annual Reporting per Consent Order</ENT>
                        <ENT>(G) Partially fluorinated amphiphilic condensation polymer.</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="93580"/>
                        <ENT I="01">P-08-0643</ENT>
                        <ENT>10/29/2024</ENT>
                        <ENT>Required Annual Reporting per Consent Order</ENT>
                        <ENT>(G) Fluorinated acrylic copolymer.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-08-0748</ENT>
                        <ENT>10/29/2024</ENT>
                        <ENT>Required Annual Reporting per Consent Order</ENT>
                        <ENT>(G) Fluorinated acrylic copolymer.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-09-0245</ENT>
                        <ENT>10/29/2024</ENT>
                        <ENT>Required Annual Reporting per Consent Order</ENT>
                        <ENT>(G) Partially fluorinated alcohol, reaction products with phosphorous oxide (P2O5), ammonium salts.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-10-0058</ENT>
                        <ENT>10/29/2024</ENT>
                        <ENT>Required Annual Reporting per Consent Order</ENT>
                        <ENT>(G) Partially fluorinated alcohol substituted glycol.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-11-0091</ENT>
                        <ENT>10/29/2024</ENT>
                        <ENT>Required Annual Reporting per Consent Order</ENT>
                        <ENT>(G) Fluorinated Acrylic Alkylamino Copolymer.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-11-0526</ENT>
                        <ENT>10/29/2024</ENT>
                        <ENT>Required Annual Reporting per Consent Order</ENT>
                        <ENT>(G) Amphoteric fluorinated surfactant.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-12-0450</ENT>
                        <ENT>10/29/2024</ENT>
                        <ENT>Required Annual Reporting per Consent Order</ENT>
                        <ENT>(G) Partially fluorinated alcohol, reaction products with phosphorus oxide (P2O5), amine salts.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-14-0712</ENT>
                        <ENT>10/08/2024</ENT>
                        <ENT>Quarterly Testing of Substance Using EPA Method 8290A</ENT>
                        <ENT>(S) Waste plastics, pyrolyzed, C5-55 fraction.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-14-0712</ENT>
                        <ENT>10/30/2024</ENT>
                        <ENT>Testing of Substance Described Using EPA Method 8290A</ENT>
                        <ENT>(S) Waste plastics, pyrolyzed, C5-55 fraction.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-16-0543</ENT>
                        <ENT>10/01/2024</ENT>
                        <ENT>Exposure Monitoring Data</ENT>
                        <ENT>(G) Halogenophosphoric acid metal salt.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-16-0543</ENT>
                        <ENT>10/22/2024</ENT>
                        <ENT>Exposure Monitoring Data</ENT>
                        <ENT>(G) Halogenophosphoric acid metal salt.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-22-0042</ENT>
                        <ENT>10/02/2024</ENT>
                        <ENT>Bacterial Reverse Mutation Test (OECD Test Guideline 471)</ENT>
                        <ENT>(G) Alkanedione, [[[(substituted)aryl] thio] aryl]-, 2-(O-acetyloxime).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-22-0042</ENT>
                        <ENT>10/16/2024</ENT>
                        <ENT>The summary of range finding study for OECD422 and protocol</ENT>
                        <ENT>(G) Alkanedione, [[[(substituted)aryl] thio] aryl]-, 2-(O-acetyloxime).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">P-22-0042</ENT>
                        <ENT>10/18/2024</ENT>
                        <ENT>Notice of test scheduling</ENT>
                        <ENT>(G) Alkanedione, [[[(substituted)aryl] thio] aryl]-, 2-(O-acetyloxime).</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    If you are interested in information that is not included in these tables, you may contact EPA's technical information contact or general information contact as described under 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     to access additional non-CBI information that may be available.
                </P>
                <P>
                    <E T="03">Authority:</E>
                     15 U.S.C. 2601 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Pamela Myrick,</NAME>
                    <TITLE>Director, Project Management and Operations Division, Office of Pollution Prevention and Toxics.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27717 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OAR-2023-0124; FRL-12445-OMS-01]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; NESHAP for Aerospace Manufacturing and Rework Facilities (Renewal)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) has submitted an information collection request (ICR), NESHAP for Aerospace Manufacturing and Rework Facilities (EPA ICR Number 1687.13, OMB Control Number 2060-0314) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act. This is a proposed extension of the ICR, which is currently approved through November 30, 2024. Public comments were previously requested via the 
                        <E T="04">Federal Register</E>
                         on May 18, 2023 during a 60-day comment period. This notice allows for an additional 30 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments may be submitted on or before December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID Number Docket ID Number EPA-HQ-OAR-2023-0124, to EPA online using 
                        <E T="03">www.regulations.gov</E>
                         (our preferred method), by email to 
                        <E T="03">a-and-r-docket@epa.gov,</E>
                         or by mail to: EPA Docket Center, Environmental Protection Agency, Mail Code 28221T, 1200 Pennsylvania Ave. NW, Washington, DC 20460.
                    </P>
                    <P>EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.</P>
                    <P>
                        Submit written comments and recommendations to OMB for the proposed information collection within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Muntasir Ali, Sector Policies and Program Division (D243-05), Office of Air Quality Planning and Standards, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711; telephone number: (919) 541-0833; email address: 
                        <E T="03">ali.muntasir@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a proposed extension of the ICR, which is currently approved through November 30, 2024. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    Public comments were previously requested via the 
                    <E T="04">Federal Register</E>
                     on May 18, 2023 during a 60-day comment period (88 FR 31748). This notice allows for an additional 30 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is 202-566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">https://www.epa.gov/dockets.</E>
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The National Emission Standards for Hazardous Air Pollutants (NESHAP) for the regulations published at 40 CFR part 63, subpart GG were proposed on June 6, 1994; promulgated on September 1, 1995; and amended on 
                    <PRTPAGE P="93581"/>
                    both December 7, 2015 and August 3, 2016. These regulations apply to existing and new aerospace manufacturing and rework facilities where the total hazardous air pollutants (HAP) emitted are greater than or equal to 10 tons per year of any combination of HAP, or where the total HAP emitted are greater than or equal to 25 tons per year of any combination of HAP. New facilities include those that commenced construction or reconstruction after the date of proposal. Operations covered include: cleaning, primer and top coat application, depainting, chemical milling maskant application, handling and storage of waste, and specialty coating operations. This information is being collected to assure compliance with 40 CFR part 63, subpart GG.
                </P>
                <P>In general, all NESHAP standards require initial notifications, performance tests, and periodic reports by the owners/operators of the affected facilities. They are also required to maintain records of the occurrence and duration of any startup, shutdown, or malfunction in the operation of an affected facility or any period during which the monitoring system is inoperative. These notifications, reports, and records are essential in determining compliance, and are required of all affected facilities subject to NESHAP.</P>
                <P>
                    <E T="03">Form Numbers:</E>
                     None.
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Aerospace manufacturing and rework facilities.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Mandatory (40 CFR part 63, subpart GG).
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     144 (total).
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     Initially, semiannually, annually.
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     154,000 total hours (per year). Burden is defined at 5 CFR 1320.3(b).
                </P>
                <P>
                    <E T="03">Total estimated cost:</E>
                     $16,800,000 (per year), includes $224,000 annualized capital or operation &amp; maintenance costs.
                </P>
                <P>
                    <E T="03">Changes in the Estimates:</E>
                     There is no significant change in burden from the most recently approved ICR as currently identified in the OMB Inventory of Approved Burdens. This is due to two considerations. First, the regulations have not changed over the past three years and are not anticipated to change over the next three years. Second, the growth rate for this industry is very low or non-existent, so there is no significant change in the overall burden. There is an increase in capital and operation &amp; maintenance costs due to an adjustment to increase from 2007 to 2022 $ using the CEPCI Equipment Cost Index.
                </P>
                <SIG>
                    <NAME>Courtney Kerwin, </NAME>
                    <TITLE>Director, Information Engagement Division.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27727 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-HQ-OPPT-2020-0078; FRL-12448-01-OMS]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities Submission to the Office of Management and Budget for Review and Approval; Comment Request; Toxic Chemical Release Reporting (Renewal)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) has submitted an information collection request (ICR), Toxic Chemical Release Reporting, (EPA ICR Number 2613.07, OMB Control Number 2070-0212) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act. This is a proposed extension of the ICR which is currently approved through June 30, 2025. Public comments were previously requested via the 
                        <E T="04">Federal Register</E>
                         on September 18, 2024, during a 60-day comment period. This notice allows for an additional 30 days for public comments.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments may be submitted on or before December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments, referencing Docket ID Number EPA-HQ-OPPT-2020-0078, to EPA online using 
                        <E T="03">www.regulations.gov</E>
                         (our preferred method) or by mail to: EPA Docket Center, Environmental Protection Agency, Mail Code 2821T, 1200 Pennsylvania Ave. NW, Washington, DC 20460. EPA's policy is that all comments received will be included in the public docket without change including any personal information provided, unless the comment includes profanity, threats, information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute.
                    </P>
                    <P>
                        Submit written comments and recommendations to OMB for the proposed information collection within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Katherine Sleasman, Office of Program Support (7602M), Office of Chemical Safety and Pollution Prevention, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 566-1206; email address: 
                        <E T="03">sleasman.katherine@epa.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This is a proposed extension of the ICR which is currently approved through June 30, 2025. An agency may not conduct, or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.</P>
                <P>
                    Public comments were previously requested via the 
                    <E T="04">Federal Register</E>
                     on September 18, 2024 during a 60-day comment period (89 FR 76470). This notice allows for an additional 30 days for public comments. Supporting documents, which explain in detail the information that the EPA will be collecting, are available in the public docket for this ICR. The docket can be viewed online at 
                    <E T="03">www.regulations.gov</E>
                     or in person at the EPA Docket Center, WJC West, Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone number for the Docket Center is 202-566-1744. For additional information about EPA's public docket, visit 
                    <E T="03">http://www.epa.gov/dockets.</E>
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     Pursuant to section 313 of the Emergency Planning and Community Right-to-Know Act (EPCRA), certain facilities that manufacture, process, or otherwise use specified toxic chemicals in amounts above reporting threshold levels as provided in 40 CFR 372.25 must submit annually to EPA and to their designated state or Indian country officials toxic chemical release forms containing information specified by EPA; (see 42 U.S.C. 11023). In addition, pursuant to section 6607 of the Pollution Prevention Act (PPA), facilities reporting under section 313 of EPCRA must also report pollution prevention and waste management data, including recycling information, for such chemicals; (see 42 U.S.C. 13106). EPA compiles and stores these reports in a publicly accessible database known as the Toxics Release Inventory (TRI). Regulations at 40 CFR part 372, subpart B, require facilities that meet the above criteria to report annually.
                </P>
                <P>
                    This ICR consolidates the following final rule ICRs titled: “Rule-Related ICR Amendment; Changes to Reporting Requirements for Per- and 
                    <PRTPAGE P="93582"/>
                    Polyfluoroalkyl Substances; Community Right-to-Know Toxic Chemical Release Reporting, Final Rule (RIN 2070-AK97)” (OMB Control Number 2070-0225; EPA ICR Number 2724.02), “Addition of Natural Gas Processing Facilities to the Toxics Release Inventory (TRI) (Final Rule)” (OMB Control Number 2070-0206; EPA ICR Number 2560.02); and “Parent Company Definition for TRI Reporting (Final Rule)” (OMB Control Number 2070-0216; EPA ICR Numer 2597.02) into this renewal ICR. Upon OMB approval of this ICR, EPA intends to discontinue OMB Control Numbers 2070-0225, 2070-0206, and 2070-0216.
                </P>
                <P>
                    <E T="03">Form numbers:</E>
                     9350-1, 9350-2, and 9350-3.
                </P>
                <P>
                    <E T="03">Respondents/affected entities:</E>
                     Entities potentially affected are those that apply to owners and operators of facilities covered under EPCRA section 313(a). EPCRA section 313(a) includes facilities that meet the following three criteria: have 10 or more full-time employee equivalents (
                    <E T="03">i.e.,</E>
                     a total of 20,000 hours worked per year or greater; see 40 CFR 372.3). The full list of potentially affected entities by North American Industry Classification System (NAICS) codes for facilities that must report to TRI (including exemptions and/or limitations), if all other reporting thresholds are met, can be found at 40 CFR 372.23.
                </P>
                <P>
                    <E T="03">Respondent's obligation to respond:</E>
                     Mandatory (40 CFR 372.23).
                </P>
                <P>
                    <E T="03">Estimated number of respondents:</E>
                     24,742 (total).
                </P>
                <P>
                    <E T="03">Frequency of response:</E>
                     Annual.
                </P>
                <P>
                    <E T="03">Total estimated burden:</E>
                     3,600,970 hours (per year). Burden is defined at 5 CFR 1320.3(b).
                </P>
                <P>
                    <E T="03">Total estimated cost:</E>
                     $285,304,888 (per year), which includes $0 annualized capital or operation &amp; maintenance costs.
                </P>
                <P>
                    <E T="03">Changes in the estimates:</E>
                     There is an overall average decrease of 698 Form Rs and an increase of 1600 Form As estimated to be submitted to EPA as a result of EPA's exercise of its discretionary authority to apply TRI reporting requirements to 2,990 particular facilities, for specified chemicals. There is a decrease of 15,858 burden hours. This is an adjustment to the estimates.
                </P>
                <SIG>
                    <NAME>Courtney Kerwin,</NAME>
                    <TITLE>Director, Information Engagement Division.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27824 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[EPA-R08-SFUND-2024-0475; FRL-12324-01-R8]</DEPDOC>
                <SUBJECT>Proposed Settlement With Bona Fide Prospective Purchaser, Miners Point Ventures, LLC, Central City, Clear Creek Superfund Site, Colorado</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of proposed settlement; request for public comment.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Notice is hereby given by the U.S. Environmental Protection Agency (EPA), Region 8, of an administrative settlement agreement for response action by bona fide prospective purchaser entered into voluntarily by the United States of America (“United States”) on behalf of the United States Environmental Protection Agency (“EPA”), the State of Colorado (“State”) and Miners Point Ventures, LLC (“Purchaser”) in connection with the Central City, Clear Creek Superfund Site in Idaho Springs, Clear Creek County, Colorado (“Site”). It is now subject to public comment, after which EPA may modify or withdraw its consent if comments received disclose facts or considerations that indicate that the proposed agreement is inappropriate, improper, or inadequate.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be submitted on or before December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The proposed agreement and additional background information relating to the agreement will be available upon request. Any comments or requests or for a copy of the proposed agreement should be addressed to Crystal Kotowski-Edmunds, Enforcement Specialist, Superfund and Emergency Management Division, Environmental Protection Agency, Region 8, Mail Code 8SEM-PAC, 1595 Wynkoop Street, Denver, Colorado 80202, telephone number: (303) 312-6124, email address: 
                        <E T="03">edmunds.crystal@epa.gov,</E>
                         and should reference the Central City, Clear Creek Site. You may also send comments, identified by Docket ID No. EPA-R08-SFUND-2024-0475, to 
                        <E T="03">https://www.regulations.gov.</E>
                         Follow the online instructions for submitting comments.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Amelia Piggott, Attorney, Office of Regional Counsel, Environmental Protection Agency, Region 8, Mail Code 8ORC-LEC, 1595 Wynkoop, Denver, Colorado 80202, telephone number:(303) 312-6410, email address: 
                        <E T="03">piggott.amelia@epa.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This settlement provides for the performance of a response action by Purchaser and the payment for certain response costs incurred by the United States and the State of Colorado at or in connection with property within the Site (“Property”). Uncovered mine waste containing lead and arsenic is located on the Property. EPA and the State previously installed engineering controls to a mine waste pile on the Property to ensure lead and aresenic-laden mine waste do not erode into Clear Creek. Uncovered mine waste remains on the Property. Purchaser anticipates developing the Property into a mining-related tourist attraction that will include operation of a gondola that will transport tourists to recreational hiking trails. In order to ensure the development will be protective of human health and the environment, the Purchaser will conduct risk assessment work.</P>
                <P>
                    For thirty (30) days following the date of publication of this document, EPA will receive electronic comments relating to the proposed agreement. EPA's response to any comments received will be available for public inspection by request. Please see the 
                    <E T="02">ADDRESSES</E>
                     section of this document for instructions.
                </P>
                <SIG>
                    <NAME>Aaron Urdiales,</NAME>
                    <TITLE>Division Director, Superfund and Emergency Management Division, Region 8.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27724 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">ENVIRONMENTAL PROTECTION AGENCY</AGENCY>
                <DEPDOC>[FRL-12428-01-R6]</DEPDOC>
                <SUBJECT>Clean Air Act Operating Permit Program: Order on Petitions for Objection to State Operating Permit for Flint Hills Resources Ingleside LLC, San Patricio County, Texas</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Environmental Protection Agency (EPA).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of final order on petition.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Environmental Protection Agency (EPA) Administrator signed an Order dated November 14, 2024, granting in part and denying in part two petitions dated July 10, 2024 (collectively the Petitions), from the Environmental Integrity Project, Ingleside on the Bay Coastal Watch Association, and TCHD Consulting LLC (the Petitioners). The Petitions requested that the EPA object to a Clean Air Act (CAA) title V operating permit issued by the Texas Commission on 
                        <PRTPAGE P="93583"/>
                        Environmental Quality (TCEQ) to Flint Hills Resources LLC, for its Ingleside Terminal located in San Patricio County, Texas.
                    </P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Jonathan Ehrhart, EPA Region 6 Office, Air Permits Section, (214) 665-2295, 
                        <E T="03">ehrhart.jonathan@epa.gov.</E>
                         The final order and petitions are available electronically at: 
                        <E T="03">https://www.epa.gov/title-v-operating-permits/title-v-petition-database.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The EPA received two petitions from Environmental Integrity Project, Ingleside on the Bay Coastal Watch Association, and TCHD Consulting LLC dated July 10, 2024, requesting that the EPA object to the issuance of operating permit No. O3454, issued by TCEQ to Flint Hills Resources LLC, for its Ingleside Terminal located in San Patricio County, Texas. On November 14, 2024, the EPA Administrator issued an Order granting in part and denying in part the petitions. The order itself explains the basis for the EPA's decision.</P>
                <P>Sections 307(b) and 505(b)(2) of the CAA provide that a petitioner may request judicial review of those portions of an order that deny issues in a petition. Any petition for review shall be filed in the United States Court of Appeals for the appropriate circuit no later than January 27, 2025.</P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>David Garcia,</NAME>
                    <TITLE>Director, Air and Radiation Division, Region 6.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27732 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6560-50-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">FEDERAL COMMUNICATIONS COMMISSION</AGENCY>
                <DEPDOC>[OMB 3060-1298; FR ID 264211]</DEPDOC>
                <SUBJECT>Information Collection Being Reviewed by the Federal Communications Commission</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Communications Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>As part of its continuing effort to reduce paperwork burdens, and as required by the Paperwork Reduction Act (PRA) of 1995, the Federal Communications Commission (FCC or the Commission) invites the general public and other Federal agencies to take this opportunity to comment on the following information collection. Comments are requested concerning: whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; the accuracy of the Commission's burden estimate; ways to enhance the quality, utility, and clarity of the information collected; ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology; and ways to further reduce the information collection burden on small business concerns with fewer than 25 employees.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Written PRA comments should be submitted on or before January 27, 2025. If you anticipate that you will be submitting comments, but find it difficult to do so within the period of time allowed by this notice, you should advise the contact listed below as soon as possible.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Direct all PRA comments to Nicole Ongele, FCC, via email 
                        <E T="03">PRA@fcc.gov</E>
                         and to 
                        <E T="03">nicole.ongele@fcc.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>For additional information about the information collection, contact Nicole Ongele, (202) 418-2991.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The FCC may not conduct or sponsor a collection of information unless it displays a currently valid control number. No person shall be subject to any penalty for failing to comply with a collection of information subject to the PRA that does not display a valid Office of Management and Budget (OMB) control number.</P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     3060-1298.
                </P>
                <P>
                    <E T="03">Title:</E>
                     Volunteer Service Agreement Form, FCC Form A-384.
                </P>
                <P>
                    <E T="03">Form No.:</E>
                     FCC Form A-384.
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Revision of a currently approved collection.
                </P>
                <P>
                    <E T="03">Respondents:</E>
                     Individuals or households.
                </P>
                <P>
                    <E T="03">Number of Respondents and Responses:</E>
                     140 respondents and 140 responses.
                </P>
                <P>
                    <E T="03">Estimated Time per Response:</E>
                     0.25 hours.
                </P>
                <P>
                    <E T="03">Frequency of Response:</E>
                     One-time reporting requirement.
                </P>
                <P>
                    <E T="03">Obligation to Respond:</E>
                     Mandatory. The statutory authority to collect this information derives from 5 U.S.C. 3111, Acceptance of volunteer service.
                </P>
                <P>
                    <E T="03">Total Annual Burden:</E>
                     35 hours.
                </P>
                <P>
                    <E T="03">Total Annual Cost:</E>
                     No Cost.
                </P>
                <P>
                    <E T="03">Needs and Uses:</E>
                     The Civil Service Reform Act of 1978 authorized Federal agencies to establish programs designed to provide educationally related work assignments for students in a non-pay status. The Act provides that heads of agencies may accept, subject to regulations issued by the Office of Personnel Management, volunteer service for the United States if the service (l) is performed by a student, with permission of the institution at which the student is enrolled; (2) is to be uncompensated; and (3) will not displace any employee. Form A-384 establishes the responsibility of students, their institutions, and the FCC as a precondition to accepting individuals as unpaid volunteers.
                </P>
                <SIG>
                    <FP>Federal Communications Commission.</FP>
                    <NAME>Marlene Dortch,</NAME>
                    <TITLE>Secretary. Office of the Secretary.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27855 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6712-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">FEDERAL COMMUNICATIONS COMMISSION</AGENCY>
                <DEPDOC>[OMB 3060-0706; FR ID 263015]</DEPDOC>
                <SUBJECT>Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Communications Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        As part of its continuing effort to reduce paperwork burdens, and as required by the Paperwork Reduction Act of 1995 (PRA), the Federal Communications Commission (FCC or Commission) invites the general public and other Federal agencies to take this opportunity to comment on the following information collection(s). Comments are requested concerning: whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; the accuracy of the Commission's burden estimate; ways to enhance the quality, utility, and clarity of the information collected; ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology; and ways to further reduce the information collection burden on small business concerns with fewer than 25 employees. The FCC may not conduct or sponsor a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. No person shall be subject to any penalty for failing to comply with 
                        <PRTPAGE P="93584"/>
                        a collection of information subject to the PRA that does not display a valid OMB control number.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Written comments should be submitted on or before January 27, 2025. If you anticipate that you will be submitting comments but find it difficult to do so within the period of time allowed by this notice, you should advise the contacts below as soon as possible.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Direct all PRA comments to Cathy Williams, FCC, via email to 
                        <E T="03">PRA@fcc.gov</E>
                         and to 
                        <E T="03">Cathy.Williams@fcc.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>For additional information about the information collection, contact Cathy Williams at (202) 418-2918.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <P>
                    <E T="03">OMB Control Number:</E>
                     3060-0706.
                </P>
                <P>
                    <E T="03">Title:</E>
                     Sections 76.952 and 76.990, Cable Act Reform.
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Extension a currently approved collection.
                </P>
                <P>
                    <E T="03">Respondents:</E>
                     Business or other for-profit entities; State, Local or Tribal Government.
                </P>
                <P>
                    <E T="03">Number of Respondents and Responses:</E>
                     70 respondents; 70 responses.
                </P>
                <P>
                    <E T="03">Estimated Time per Response:</E>
                     1-8 hours.
                </P>
                <P>
                    <E T="03">Frequency of Response:</E>
                     On occasion reporting requirement; Third party disclosure requirement.
                </P>
                <P>
                    <E T="03">Obligation to Respond:</E>
                     Required to obtain or retain benefits. The statutory authority for this collection of information is contained in the Telecommunications Act of 1996, Public Law 104-104, Sections 301 and 302, 110 Stat. 56, 114-124.
                </P>
                <P>
                    <E T="03">Total Annual Burden:</E>
                     210 hours.
                </P>
                <P>
                    <E T="03">Total Annual Cost:</E>
                     None.
                </P>
                <P>
                    <E T="03">Needs and Uses:</E>
                     The information collection requirements contained in 47 CFR 76.952 state that all cable operators must provide to the subscribers on monthly bills the name, mailing address and phone number of the franchising authority, unless the franchising authority in writing requests that the cable operator omits such information. The cable operator must also provide subscribers with the FCC community unit identifier for the cable system in their communities. 47 CFR 76.990(b)(1) requires that a small cable operator may certify in writing to its franchise authority at any time that it meets all criteria necessary to qualify as a small operator. Upon request of the local franchising authority, the operator shall identify in writing all of its affiliates that provide cable service, the total subscriber base of itself and each affiliate, and the aggregate gross revenues of its cable and non-cable affiliates. Within 90 days of receiving the original certification, the local franchising authority shall determine whether the operator qualifies for deregulation and shall notify the operator in writing of its decision, although this 90-day period shall be tolled for so long as it takes the operator to respond to a proper request for information by the local franchising authority. An operator may appeal to the Commission a local franchise authority's information request if the operator seeks to challenge the information request as unduly or unreasonably burdensome. If the local franchising authority finds that the operator does not qualify for deregulation, its notice shall state the grounds for that decision. The operator may appeal the local franchising authority's decision to the Commission within 30 days.
                </P>
                <SIG>
                    <FP>Federal Communications Commission.</FP>
                    <NAME>Marlene Dortch,</NAME>
                    <TITLE>Secretary, Office of the Secretary.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27711 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6712-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">FEDERAL RESERVE SYSTEM</AGENCY>
                <SUBJECT>Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company</SUBJECT>
                <P>The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).</P>
                <P>
                    The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at 
                    <E T="03">https://www.federalreserve.gov/foia/request.htm.</E>
                     Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.
                </P>
                <P>Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.</P>
                <P>Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than December 12, 2024.</P>
                <P>
                    <E T="03">A. Federal Reserve Bank of Atlanta</E>
                     (Erien O. Terry, Assistant Vice President) 1000 Peachtree Street NE, Atlanta, Georgia 30309. Comments can also be sent electronically to 
                    <E T="03">Applications.Comments@atl.frb.org:</E>
                </P>
                <P>
                    1. 
                    <E T="03">Nitin Shah and Mili N. Shah, both of Lawrenceville, Georgia;</E>
                     as a group acting in concert, to retain voting shares of Embassy Bancshares, Inc., and thereby indirectly retain voting shares of Embassy National Bank, both of Lawrenceville, Georgia.
                </P>
                <P>
                    <E T="03">B. Federal Reserve Bank of Kansas City</E>
                     (Jeffrey Imgarten, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri, 64198-0001. Comments can also be sent electronically to 
                    <E T="03">KCApplicationComments@kc.frb.org:</E>
                </P>
                <P>
                    1. 
                    <E T="03">Michael Scott Crowe, Sr., as co-trustee of the Robert E. Oliphant Trust, both of Kansas City, Missouri;</E>
                     to retain control of voting shares of Country Agencies &amp; Investments, Inc., and thereby indirectly retain control of voting shares of Bank of Odessa, both of Odessa, Missouri.
                </P>
                <P>The Robert E. Oliphant Trust has previously been permitted to control voting shares of Country Agencies &amp; Investments, Inc.</P>
                <SIG>
                    <P>Board of Governors of the Federal Reserve System.</P>
                    <NAME>Michele Taylor Fennell, </NAME>
                    <TITLE>Associate Secretary of the Board.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27847 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6210-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">FEDERAL RESERVE SYSTEM</AGENCY>
                <DEPDOC>[Docket No. OP-1862]</DEPDOC>
                <SUBJECT>Federal Reserve Bank Services</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Board of Governors of the Federal Reserve System.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Board of Governors of the Federal Reserve System (Board) has approved the private-sector adjustment factor (PSAF) for 2025 of $31.9 million and the 2025 fee schedules for Federal Reserve priced services and electronic access. These actions were taken in 
                        <PRTPAGE P="93585"/>
                        accordance with the Monetary Control Act of 1980, which requires that, over the long run, fees for Federal Reserve priced services be established based on all direct and indirect costs, including the PSAF.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The new fee schedules become effective January 1, 2025.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        For questions regarding the fee schedules: Ian Spear, Deputy Associate Director, (202) 452-3959; Anjana Ravi, Manager, (202) 530-6286; Division of Reserve Bank Operations and Payment Systems. For questions regarding the PSAF: Casey Clark, Associate Director, (202) 912-7978; Jamie Noonan, Assistant Director, (202) 530-6296; Grace Milbank, Lead Financial Institution Policy Analyst, (202) 263-4828; Division of Reserve Bank Operations and Payment Systems. For users of TTY-TRS, please call 711 from any telephone, anywhere in the United States. Copies of the 2025 fee schedules for Check Services are available from the Board, the Federal Reserve Banks, or the Federal Reserve Financial Services (FRFS) website at 
                        <E T="03">www.FRBservices.org.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Private-Sector Adjustment Factor, Priced Services Cost Recovery, and Overview of 2025 Price Changes</HD>
                <P>
                    A. 
                    <E T="03">Overview</E>
                    —Each year, as required by the Monetary Control Act of 1980 (MCA), the Reserve Banks set fees for priced services provided to financial institutions. These fees are set to recover, over the long run, all direct and indirect costs and imputed costs, including financing costs, taxes, and certain other expenses, as well as the return on equity (profit) that would have been earned if a private-sector business provided the services.
                    <SU>1</SU>
                    <FTREF/>
                     The imputed costs and imputed profit are collectively referred to as the private-sector adjustment factor (PSAF).
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See</E>
                         12 U.S.C. 248a. 
                        <E T="03">See also Principles for the Pricing of Federal Reserve Bank Services,</E>
                         46 FR 1338, 1339 (Jan. 6, 1981), 
                        <E T="03">available at https://www.federalreserve.gov/paymentsystems/pfs_principles.htm.</E>
                         Although the Monetary Control Act does not define “over the long run,” the Board has generally measured long-run cost recovery for mature services to be over a 10-year rolling time frame. The Board currently views a 10-year cost recovery expectation as appropriate for assessing mature services, which are those that have achieved a critical mass of customer participation and generally have stable and predictable volumes, costs, and revenues. The 10-year recovery rate is based on the pro forma income statements for Federal Reserve priced services published in the Board's 
                        <E T="03">Annual Report.</E>
                         In accordance with Accounting Standards Codification (ASC) 715 
                        <E T="03">Compensation—Retirement Benefits,</E>
                         the Reserve Banks recognized a $548.6 million cumulative reduction in equity related to the priced services' benefit plans through 2023. Including this cumulative reduction in equity from 2014 to 2023 results in cost recovery of 102.6 percent for the 10-year period. This measure of long-run cost recovery is also published in the Board's 
                        <E T="03">Annual Report.</E>
                    </P>
                </FTNT>
                <P>
                    From 2014 through 2023, the Reserve Banks recovered 102.6 percent of their total expenses (including imputed costs) and targeted after-tax profits or return on equity (ROE) for the mature services. During that period, Check Services, the Fedwire® Funds Service, the National Settlement Service (NSS), and the Fedwire® Securities Service achieved full cost recovery. The FedACH® Service achieved 99.0 percent cost recovery as a result of the Reserve Banks' development and implementation of a multiyear technology initiative to modernize the capabilities of the FedACH Service processing platform. Although the modernized platform was implemented in 2021, the Reserve Banks are continuing to invest in platform capabilities, as well as resiliency, as part of a broader enhancement strategy.
                    <SU>2</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         In alignment with the Board's 
                        <E T="03">Principles for the Pricing of Federal Reserve Bank Services,</E>
                         the Reserve Banks will continue to assess the tradeoffs between price stability for customers, investment in technology infrastructure to reflect desirable longer-run improvements in the ACH system, and the expectation of achieving full cost recovery for the FedACH Service over the long run.
                    </P>
                </FTNT>
                <P>
                    In its 2019 notice entitled 
                    <E T="03">Federal Reserve Actions to Support Interbank Settlement of Instant Payments</E>
                     (“2019 Notice”), the Board communicated that it expects the FedNow® Service to achieve its first instance of long-run cost recovery outside the 10-year time frame typically applied to mature services. New services like the FedNow Service are not expected to initially have stable volumes, costs, and revenues.
                    <SU>3</SU>
                    <FTREF/>
                     Thus, FedNow Service revenue and expenses are excluded from the overall performance projections. The FedNow Service is discussed in section G.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         Application of the 10-year rolling time frame used to evaluate mature services to the FedNow Service would result in prohibitively high or unnecessarily volatile pricing, negatively affecting the Federal Reserve's public policy objectives in providing the service. See 
                        <E T="03">Federal Reserve Actions to Support Interbank Settlement of Instant Payments, 84 FR 39297,</E>
                         (Aug. 9, 2019).
                    </P>
                </FTNT>
                <P>Table 1 summarizes 2023 actual, 2024 forecasted, and 2025 budgeted annual cost recovery rates for all mature priced services. Cost recovery is forecasted to be 108.8 percent in 2024 and budgeted to be 104.1 percent in 2025.</P>
                <GPOTABLE COLS="6" OPTS="L2(,0,)i1" CDEF="s50,12,12,12,12,14">
                    <TTITLE>
                        Table 1—Aggregate Mature Priced Services Pro Forma Cost and Revenue Performance 
                        <E T="0731">a</E>
                    </TTITLE>
                    <TDESC>[Dollars in millions]</TDESC>
                    <BOXHD>
                        <CHED H="1">Year</CHED>
                        <CHED H="1">Revenue</CHED>
                        <CHED H="1">Total expense</CHED>
                        <CHED H="1">
                            Net income
                            <LI>(ROE)</LI>
                        </CHED>
                        <CHED H="1">
                            Targeted
                            <LI>ROE</LI>
                        </CHED>
                        <CHED H="1">
                            Recovery rate
                            <LI>after targeted</LI>
                            <LI>ROE</LI>
                            <LI>(%)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW RUL="s">
                        <ENT I="25"> </ENT>
                        <ENT>
                            1 
                            <SU>b</SU>
                        </ENT>
                        <ENT>
                            2 
                            <SU>c</SU>
                        </ENT>
                        <ENT>3 [1−2]</ENT>
                        <ENT>
                            4 
                            <SU>d</SU>
                        </ENT>
                        <ENT>
                            5 
                            <SU>e</SU>
                             [1/(2 + 4)]
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2023 (actual)</ENT>
                        <ENT>507.3</ENT>
                        <ENT>467.1</ENT>
                        <ENT>40.1</ENT>
                        <ENT>8.4</ENT>
                        <ENT>106.7</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2024 (forecast)</ENT>
                        <ENT>520.9</ENT>
                        <ENT>468.9</ENT>
                        <ENT>52.0</ENT>
                        <ENT>9.7</ENT>
                        <ENT>108.8</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2025 (budget)</ENT>
                        <ENT>531.7</ENT>
                        <ENT>499.8</ENT>
                        <ENT>31.9</ENT>
                        <ENT>10.8</ENT>
                        <ENT>104.1</ENT>
                    </ROW>
                    <TNOTE>
                        <SU>a</SU>
                         Calculations in this table and subsequent pro forma cost and revenue tables may be affected by rounding. Excludes amounts related to the FedNow Service.
                    </TNOTE>
                    <TNOTE>
                        <SU>b</SU>
                         Revenue includes imputed income on investments when equity is imputed at a level that meets minimum capital requirements and, when combined with liabilities, exceeds total assets. For 2025, the budgeted revenue assumes implementation of the fee changes.
                    </TNOTE>
                    <TNOTE>
                        <SU>c</SU>
                         The calculation of total expense includes operating, imputed, and other expenses. Imputed and other expenses include taxes, Board of Governors priced services expenses, the cost of float, and interest on imputed debt, if any. Credits or debits related to the accounting for pension plans under ASC 715 are also included.
                    </TNOTE>
                    <TNOTE>
                        <SU>d</SU>
                         Targeted ROE is the after-tax ROE included in the PSAF.
                    </TNOTE>
                    <TNOTE>
                        <SU>e</SU>
                         The recovery rates in this and subsequent tables do not reflect the unamortized gains or losses that must be recognized in accordance with ASC 715. Future gains or losses, and their effect on cost recovery, cannot be projected.
                    </TNOTE>
                </GPOTABLE>
                <PRTPAGE P="93586"/>
                <P>Table 2 provides an overview of cost recovery budgets, forecasts, and performance for the 10-year period from 2014 to 2023, 2023 actual, 2024 budget, 2024 forecast, and 2025 budget by mature priced service.</P>
                <GPOTABLE COLS="6" OPTS="L2,i1" CDEF="s50,12,12,12,12,12">
                    <TTITLE>Table 2—Mature Priced Services Cost Recovery</TTITLE>
                    <TDESC>[Percent]</TDESC>
                    <BOXHD>
                        <CHED H="1">Priced service</CHED>
                        <CHED H="1">2014-2023</CHED>
                        <CHED H="1">2023 Actual</CHED>
                        <CHED H="1">
                            2024 Budget 
                            <SU>a</SU>
                        </CHED>
                        <CHED H="1">2024 Forecast</CHED>
                        <CHED H="1">
                            2025 Budget 
                            <SU>b</SU>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">All mature services</ENT>
                        <ENT>102.6</ENT>
                        <ENT>106.7</ENT>
                        <ENT>103.1</ENT>
                        <ENT>108.8</ENT>
                        <ENT>104.1</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Check</ENT>
                        <ENT>106.9</ENT>
                        <ENT>102.9</ENT>
                        <ENT>95.5</ENT>
                        <ENT>102.9</ENT>
                        <ENT>97.5</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">FedACH</ENT>
                        <ENT>99.0</ENT>
                        <ENT>108.8</ENT>
                        <ENT>106.0</ENT>
                        <ENT>109.4</ENT>
                        <ENT>106.0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fedwire Funds and NSS</ENT>
                        <ENT>101.9</ENT>
                        <ENT>103.1</ENT>
                        <ENT>103.2</ENT>
                        <ENT>108.3</ENT>
                        <ENT>103.2</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fedwire Securities</ENT>
                        <ENT>105.7</ENT>
                        <ENT>122.3</ENT>
                        <ENT>110.9</ENT>
                        <ENT>123.2</ENT>
                        <ENT>115.7</ENT>
                    </ROW>
                    <TNOTE>
                        <SU>a</SU>
                         The 2024 budget figures reflect the final budgets as approved by the Board in December 2023. 
                        <E T="03">See</E>
                         Board of Governors of the Federal Reserve System, 
                        <E T="03">2024 Federal Reserve Banks Budgets, https://www.federalreserve.gov/foia/files/2024ReserveBankBudgets.pdf.</E>
                    </TNOTE>
                    <TNOTE>
                        <SU>b</SU>
                         The 2025 budget figures reflect preliminary budget information from the Reserve Banks. The Reserve Banks will submit final budget data to the Board for consideration by December 2024.
                    </TNOTE>
                </GPOTABLE>
                <P>
                    1. 
                    <E T="03">2024 Forecasted Performance</E>
                    —The Reserve Banks forecast that they will recover 108.8 percent of the costs of providing mature priced services in 2024, including total expense and targeted ROE, compared with a 2024 budgeted recovery rate of 103.1 percent, as shown in Table 2. Overall, the Reserve Banks forecast that they will fully recover actual and imputed costs and earn net income of $52.0 million, compared with the targeted ROE of $9.7 million. The Reserve Banks forecast that all mature services will achieve full cost recovery in 2024.
                </P>
                <P>
                    2. 
                    <E T="03">2025 Private-Sector Adjustment Factor</E>
                    —The 2025 PSAF for Reserve Bank mature priced services is $31.9 million.
                    <SU>4</SU>
                    <FTREF/>
                     This amount represents an increase of $2.7 million from the 2024 PSAF of $29.2 million. This increase is attributable to a $2.1 million increase in the cost of capital primarily driven by higher short-term debt and higher return on equity and a $0.6 million increase in sales tax.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         The FedNow Service launched in July 2023. Inclusive of the FedNow Service, the PSAF increases to $42.3 million for 2025. Per its 2019 Notice, the Board has determined that it is most appropriate to report FedNow Service cost recovery independently of mature priced services until the service has relatively stable revenues and costs. Thus, FedNow Service revenue is excluded from overall performance projections for 2025.
                    </P>
                </FTNT>
                <P>
                    3. 
                    <E T="03">2025 Projected Performance</E>
                    —The Reserve Banks project a mature priced services cost recovery rate of 104.1 percent in 2025, with a net gain of $31.9 million and targeted ROE of $10.8 million. The Reserve Banks project that each of the individual mature service lines will achieve full cost recovery in 2025 except for Check Services. Check Services are expected to under recover primarily because of anticipated volume declines. The Reserve Banks' primary risks to current projections are unanticipated volume and revenue reductions and the potential for cost overruns from new and ongoing improvement initiatives.
                </P>
                <P>
                    4. 
                    <E T="03">2025 Pricing</E>
                    —The following summarizes the Reserve Banks' changes to fee schedules for priced services in 2025. For the mature services, these changes collectively are an average price increase of 2.8 percent. The price changes outlined below are in line with the Reserve Banks' strategy to offset rising costs, diversify revenue sources, and continue to reduce pricing volatility.
                </P>
                <HD SOURCE="HD2">Check Services</HD>
                <P>The Reserve Banks will increase participation fees, FedImage® fees, and certain forward paper and return paper fees. These changes will increase fixed fee revenue stability in light of declining check volumes.</P>
                <HD SOURCE="HD2">FedACH Service</HD>
                <P>The Reserve Banks will increase participation fees, origination and receipt minimum fees, and FedPayments Reporter® Service fees. These changes will help address ongoing operational costs, provide greater revenue stability, and account for the additional business value provided by the service enhancements over the last several years.</P>
                <HD SOURCE="HD2">Fedwire Funds Service</HD>
                <P>
                    The Reserve Banks will increase the Fedwire Funds participation fee, the transfer fee for all three tiers, and the FedPayments® Manager Import/Export fee. These increases will account for projected declining volume growth, coupled with ongoing technology enhancements and higher operating costs.
                    <SU>5</SU>
                    <FTREF/>
                     In addition, the Fedwire Funds Service will introduce a new fixed fee that will serve to better align fees with customer usage as well as address challenges associated with revenue volatility.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         Historically, Fedwire Funds volume has evolved in line with GDP forecasts.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">National Settlement Service</HD>
                <P>The Reserve Banks will increase the National Settlement Service per-file and per-entry fees. These changes will help address rising operational costs.</P>
                <HD SOURCE="HD2">Fedwire Securities Service</HD>
                <P>The Reserve Banks will maintain prices at existing levels for all Fedwire Securities priced services.</P>
                <HD SOURCE="HD2">FedNow Service</HD>
                <P>
                    The Reserve Banks will modify the Customer Credit Transfer, Customer Credit Transfer Return, and Request for Payment fee components of the FedNow Service to exclude “on-us” transactions sent from and received at the same financial institution.
                    <SU>6</SU>
                    <FTREF/>
                     This adjustment will both align with prevailing market practices and reduce inefficient off-network transaction activity. All other price points and discounts in the FedNow Service's fee schedule from the previous year will be maintained in 2025.
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         These fee modifications will take place at the parent financial institution level, as defined in the Reserve Banks' Global Customer Directory. “On-us” transactions include those made by the same financial institution, even if the financial institution uses multiple Routing Transit Numbers (RTNs).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">FedLine® Solutions </HD>
                <P>
                    The Reserve Banks will increase the monthly fees for the FedLine Direct® Solution, FedLine Command® Solution, and FedComplete® Packages. These price modifications account for enhancements to services and rising operational costs. The Reserve Banks are also discontinuing FedComplete Premier and FedLine Exchange® to streamline the FedLine product suite in response to a declining customer base and to simplify internal operating, servicing, and billing processes. Lastly, the Reserve Banks are preparing to 
                    <PRTPAGE P="93587"/>
                    implement a fee structure for services offered via Application Programming Interfaces (APIs) in 2025.
                </P>
                <P>
                    B. 
                    <E T="03">Private-Sector Adjustment Factor</E>
                    —The imputed debt financing costs, targeted ROE, and effective tax rate are based on a U.S. publicly traded market model.
                    <SU>7</SU>
                    <FTREF/>
                     The method for calculating the financing costs in the PSAF requires determining the appropriate imputed levels of debt and equity and then applying the applicable financing rates. In this process, a pro forma balance sheet using estimated assets and liabilities associated with the Reserve Banks' priced services is developed, and the remaining elements that would exist are imputed as if these priced services were provided by a private business firm. The same generally accepted accounting principles that apply to commercial-entity financial statements apply to the relevant elements in the priced services pro forma financial statements.
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         Data for U.S. publicly traded firms is from the Standard and Poor's Compustat® database. This database contains information on more than 6,000 U.S. publicly traded firms, which approximates information for the entirety of the U.S. market.
                    </P>
                </FTNT>
                <P>
                    The portion of Federal Reserve assets that will be used to provide priced services during the coming year is determined using information about actual assets and projected disposals and acquisitions. The priced portion of these assets is determined based on the allocation of depreciation and amortization expenses of each asset class. The priced portion of actual Federal Reserve liabilities consists of post-employment and post-retirement benefits, accounts payable, and other liabilities. The priced portion of the actual net pension asset or liability is also included on the balance sheet.
                    <SU>8</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         The pension assets are netted with the pension liabilities and reported as a net asset or net liability as required by ASC 715.
                    </P>
                </FTNT>
                <P>The equity financing rate is the targeted ROE produced by the capital asset pricing model (CAPM). In the CAPM, the required rate of return on a firm's equity is equal to the return on a risk-free asset plus a market risk premium. The risk-free rate is based on the three-month Treasury bill; the beta is assumed to be equal to 1.0, which approximates the risk of the market as a whole; and the market risk premium is based on the monthly returns in excess of the risk-free rate over the most recent 40 years. The resulting ROE reflects the return a shareholder would expect when investing in a private business firm.</P>
                <P>For simplicity, given that state income tax rates vary, and various credits and deductions can apply at the federal or state level, an actual income tax expense is not explicitly calculated for Reserve Bank priced services. Instead, the Board targets a pretax ROE that would provide sufficient income to fulfill the priced services' imputed income tax obligations. To the extent that performance results are greater or less than the targeted ROE, income taxes are adjusted using the effective tax rate.</P>
                <P>
                    <E T="03">Capital structure.</E>
                     The capital structure is imputed based on the imputed funding need (assets less liabilities), subject to minimum equity constraints. Short-term debt is imputed to fund the imputed short-term funding need. Long-term debt and equity are imputed to meet the priced services long-term funding need at a ratio based on the capital structure of the U.S. publicly traded market.
                    <SU>9</SU>
                    <FTREF/>
                     Any equity imputed that exceeds the amount needed to fund the priced services' assets and meet the minimum equity constraints is offset by a reduction in imputed long-term debt. When imputed equity is larger than what can be offset by imputed debt, the excess is imputed as investments in Treasury securities; income imputed on these investments reduces the PSAF.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         The FDIC rule requires that well-capitalized institutions meet or exceed the following standards: (1) total capital to risk-weighted assets ratio of at least 10 percent, (2) tier 1 capital to risk-weighted assets ratio of at least 8 percent, (3) common equity tier 1 capital to risk-weighted assets ratio of at least 6.5 percent, and (4) a leverage ratio (tier 1 capital to total assets) of at least 5 percent. Because all of the Federal Reserve priced services' equity on the pro forma balance sheet qualifies as tier 1 capital, only requirements 1 and 4 are binding. The FDIC rule can be located at 12 CFR 324.403(b).
                    </P>
                </FTNT>
                <P>
                    <E T="03">Application of the Federal Reserve Policy on Payment System Risk (PSR policy) to the Fedwire Funds Service.</E>
                     The Board's PSR policy incorporates the international standards for financial market infrastructures (FMIs) developed by the Committee on Payments and Market Infrastructures (CPMI) and the Technical Committee of the International Organization of Securities Commissions (IOSCO) known as the 
                    <E T="03">Principles for Financial Market Infrastructures.</E>
                    <SU>10</SU>
                    <FTREF/>
                     The Board recognizes the critical role the Fedwire Services, including the Fedwire Funds Service, play in the financial system and requires them to meet or exceed the risk-management standards in the PSR policy, consistent with relevant guidance and the requirements in the MCA.
                    <SU>11</SU>
                    <FTREF/>
                     Principle 15 states that an FMI should identify, monitor, and manage general business risk and hold sufficient liquid net assets funded by equity to cover potential general business losses so that it can continue operations and services as a going concern if those losses materialize. Further, liquid net assets should at all times be sufficient to ensure a recovery or orderly wind-down of critical operations and services. The Fedwire Funds Service does not face the risk that a business shock would cause the service to wind down in a disorderly manner and disrupt the stability of the financial system. To foster competition with private-sector FMIs, however, the Reserve Banks' priced services will hold an amount equivalent to six months of the Fedwire Funds Service's current operating expenses as liquid financial assets and equity on the pro forma balance sheet.
                    <SU>12</SU>
                    <FTREF/>
                     Current operating expenses are defined as normal business operating expenses on the income statement, less depreciation, amortization, taxes, and interest on debt. Using the Fedwire Funds Service's preliminary 2025 budget, six months of current operating expenses would be $71.7 million. In 2025, equity was sufficient to meet the FDIC capital requirements and $6.7 million of equity was imputed to meet the PSR policy requirement.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         Board of Governors of the Federal Reserve System, 
                        <E T="03">Federal Reserve Policy on Payment System Risk, https://www.federalreserve.gov/paymentsystems/files/psr_policy.pdf.</E>
                          
                        <E T="03">See also</E>
                         CPMI-IOSCO, 
                        <E T="03">Principles for Financial Market Infrastructures</E>
                         (April 2012), 
                        <E T="03">https://www.bis.org/cpmi/publ/d101a.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         Certain standards may require flexibility in the way they are applied to central bank-operated systems because of central banks' unique role in the financial markets and their public responsibilities. These principles include principle 2 on governance, principle 3 on the framework for the comprehensive management of risks, principle 4 on credit risk, principle 5 on collateral, principle 7 on liquidity risk, principle 13 on participant-default rules and procedures, principle 15 on general business risk, and principle 18 on access and participation requirements. 
                        <E T="03">See</E>
                         section I.B.1.a of the PSR policy.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         This requirement does not apply to the Fedwire Securities Service. There are no private-sector competitors to the Fedwire Securities Service that would be expected to meet such a requirement. Imposing such a requirement when pricing the securities services could artificially increase the cost of these services.
                    </P>
                </FTNT>
                <P>
                    <E T="03">Effective tax</E>
                     rate. Like the imputed capital structure, the effective tax rate is calculated based on data from U.S. publicly traded firms. The tax rate is the mean of the weighted average rates of the U.S. publicly traded market over the past five years.
                </P>
                <P>
                    <E T="03">Debt and equity financing.</E>
                     The imputed short- and long-term debt financing rates are derived from the nonfinancial commercial paper rates from the Federal Reserve Board's H.15 Selected Interest Rates release (AA and A2/P2) and the annual Merrill Lynch Corporate &amp; High Yield Index rate, respectively. The equity financing rate is described above. The rates for debt 
                    <PRTPAGE P="93588"/>
                    and equity financing are applied to the priced services' estimated imputed short-term debt, long-term debt, and equity needed to finance short- and long-term assets and meet equity requirements.
                </P>
                <P>The 2025 PSAF is $31.9 million, compared with $29.2 million in 2024. The increase of $2.7 million is attributable to a net $2.1 million increase in the cost of capital and a $0.6 million increase in sales tax. The net $2.1 million increase in cost of capital is primarily driven by a $1.3 million increase in ROE imputed to meet the PSR policy requirements and higher short-term debt resulting in a $0.5 million increase in cost of debt.</P>
                <P>The PSAF expense of $31.9 million, detailed in Table 5, includes $19.8 million for capital funding, $7.6 million for Board of Governors' expense, and $4.5 million in sales tax expense.</P>
                <P>As shown in Table 3, 2025 total assets of $890.3 million increased by $74.2 million from 2024. The net increase in total assets includes an additional $90.7 million in imputed investments and short-term assets partially offset by a $16.5 million decrease in long-term assets.</P>
                <P>
                    The net increase of $90.7 million primarily consists of a $80.8 million increase in the imputed investments and a $9.9 million increase driven by short-term assets, The imputed investment increase reflects a $74 million increase from float 
                    <SU>13</SU>
                    <FTREF/>
                     and a $6.7 million increase to comply with the PSR policy. The $9.9 million increase in short-term assets is driven by an increase in prepaid expenses.
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         Credit float, which represents the difference between items in process of collection and deferred credit items, occurs when the Reserve Banks debit the paying bank for transactions before providing credit to the depositing bank. Float is directly estimated at the service level.
                    </P>
                </FTNT>
                <P>The $16.5 million decrease in the long-term assets is primarily driven by a $38.0 million decrease in the net pension asset, partially offset by a $20.3 million increase in premises, furniture and equipment, and software and leasehold improvements.</P>
                <P>The capital structure of the 2025 pro forma balance sheet, provided in Table 4, is composed of equity of $71.7 million, or 12.6 percent of the 2025 risk-weighted assets detailed in Table 6, and long-term debt of $96.1 million. The 2025 capital structure aligns with that of 2024, which was composed of $68.5 million of equity and $100.3 million of long-term debt. As shown in Table 5, the 2025 initially imputed equity required to fund assets and meet the publicly traded firm model capital requirements is $65.0 million. As long-term assets are marginally greater than long-term liabilities, long-term debt of $96.1 million was imputed at the observed market ratio of 59.7 percent. The equity of $65.0 million was adequate to meet the FDIC capital requirements for a well-capitalized institution. Additional equity of $6.7 million was imputed to satisfy PSR policy requirements.</P>
                <P>The net accumulated other comprehensive loss is $563.3 million, compared with $551.0 million in 2024. The $12.3 million increase is primarily attributable to a lower discount rate. The net accumulated other comprehensive loss position does not reduce the total imputed equity required to fund priced services assets or fulfill the FDIC equity requirements for a well-capitalized institution.</P>
                <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s50,12,12,12">
                    <TTITLE>
                        Table 3—Comparison of Pro Forma Balance Sheets for Budgeted Federal Reserve Mature Priced Services 
                        <E T="0731">a</E>
                    </TTITLE>
                    <TDESC>[Millions of dollars—projected average for year]</TDESC>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">Change</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">Short-term assets:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Receivables</ENT>
                        <ENT>$ 44.3</ENT>
                        <ENT>$ 41.8</ENT>
                        <ENT>$ 2.5</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Inventory</ENT>
                        <ENT>0.4</ENT>
                        <ENT>0.2</ENT>
                        <ENT>0.2</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Prepaid expenses</ENT>
                        <ENT>34.2</ENT>
                        <ENT>24.0</ENT>
                        <ENT>10.2</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="03">
                            Items in process of collection 
                            <SU>13</SU>
                        </ENT>
                        <ENT>58.0</ENT>
                        <ENT>61.0</ENT>
                        <ENT>(3.0)</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Total short-term assets</ENT>
                        <ENT>136.9</ENT>
                        <ENT>127.0</ENT>
                        <ENT>9.9</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            Imputed investments: 
                            <SU>14</SU>
                        </ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Imputed investment in Treasury securities</ENT>
                        <ENT>6.8</ENT>
                        <ENT/>
                        <ENT>6.8</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="03">Imputed investment in Fed Funds</ENT>
                        <ENT>293.0</ENT>
                        <ENT>219.0</ENT>
                        <ENT>74.0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Total imputed investments</ENT>
                        <ENT>299.8</ENT>
                        <ENT>219.0</ENT>
                        <ENT>80.8</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Long-term assets:</ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Premises 
                            <SU>15</SU>
                             *
                        </ENT>
                        <ENT>105.3</ENT>
                        <ENT>99.4</ENT>
                        <ENT>5.9</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Furniture and equipment</ENT>
                        <ENT>60.8</ENT>
                        <ENT>53.9</ENT>
                        <ENT>6.9</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Software and leasehold improvements</ENT>
                        <ENT>74.5</ENT>
                        <ENT>67.0</ENT>
                        <ENT>7.5</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Net pension asset</ENT>
                        <ENT>82.4</ENT>
                        <ENT>120.4</ENT>
                        <ENT>(38.0)</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="03">Deferred tax asset</ENT>
                        <ENT>130.6</ENT>
                        <ENT>129.4</ENT>
                        <ENT>1.2</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="05">Total long-term assets</ENT>
                        <ENT>453.6</ENT>
                        <ENT>470.1</ENT>
                        <ENT>(16.5)</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">Total assets</ENT>
                        <ENT>890.3</ENT>
                        <ENT>816.1</ENT>
                        <ENT>74.2</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Short-term liabilities:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Deferred credit items</ENT>
                        <ENT>351.0</ENT>
                        <ENT>280.0</ENT>
                        <ENT>71.0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Short-term debt</ENT>
                        <ENT>42.2</ENT>
                        <ENT>32.7</ENT>
                        <ENT>9.5</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="03">Short-term payables</ENT>
                        <ENT>36.8</ENT>
                        <ENT>33.4</ENT>
                        <ENT>3.4</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Total short-term liabilities</ENT>
                        <ENT>430.0</ENT>
                        <ENT>346.0</ENT>
                        <ENT>84.0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Long-term liabilities:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Postemployment/postretirement benefits and net pension liabilities 
                            <SU>16</SU>
                        </ENT>
                        <ENT>292.5</ENT>
                        <ENT>301.2</ENT>
                        <ENT>(8.7)</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="03">Long term debt</ENT>
                        <ENT>96.1</ENT>
                        <ENT>100.3</ENT>
                        <ENT>(4.2)</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Total liabilities</ENT>
                        <ENT>818.6</ENT>
                        <ENT>747.6</ENT>
                        <ENT>71.0</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="05">
                            Equity 
                            <SU>17</SU>
                            *
                        </ENT>
                        <ENT>71.7</ENT>
                        <ENT>68.5</ENT>
                        <ENT>3.2</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="93589"/>
                        <ENT I="07">Total liabilities and equity</ENT>
                        <ENT>890.3</ENT>
                        <ENT>816.1</ENT>
                        <ENT>74.2</ENT>
                    </ROW>
                    <TNOTE>
                        <SU>a</SU>
                         Calculations in this table and subsequent PSAF tables may be affected by rounding. Excludes amounts related to the FedNow Service. * Premises, postemployment/postretirement benefits and net pension liabilities, and equity restated for 2024.
                    </TNOTE>
                </GPOTABLE>
                <GPOTABLE COLS="3" OPTS="L2,nj,i1" CDEF="s100,12,12">
                    <TTITLE>
                        Table 4—Imputed Funding for Mature Priced-Services Assets 
                        <E T="01">
                            <SU>a</SU>
                        </E>
                    </TTITLE>
                    <TDESC>[Millions of dollars]</TDESC>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">2024</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">
                            <E T="03">A. Short-term asset financing:</E>
                        </ENT>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Short-term assets to be financed:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Receivables</ENT>
                        <ENT>$ 44.3</ENT>
                        <ENT>$ 41.8</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Inventory</ENT>
                        <ENT>0.4</ENT>
                        <ENT>0.2</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="05">Prepaid expenses</ENT>
                        <ENT>34.2</ENT>
                        <ENT>24.0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">Total short-term assets to be financed</ENT>
                        <ENT>78.9</ENT>
                        <ENT>66.0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Short-term payables</ENT>
                        <ENT>36.8</ENT>
                        <ENT>33.4</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Net short-term assets to be financed</ENT>
                        <ENT>42.2</ENT>
                        <ENT>32.7</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Imputed short-term debt financing 
                            <SU>18</SU>
                        </ENT>
                        <ENT>42.2</ENT>
                        <ENT>32.7</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="03">B. Long-term asset financing:</E>
                        </ENT>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Long-term assets to be financed:</ENT>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">Premises *</ENT>
                        <ENT>105.3</ENT>
                        <ENT>99.4</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Furniture and equipment</ENT>
                        <ENT>60.8</ENT>
                        <ENT>53.9</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Software and leasehold improvements</ENT>
                        <ENT>74.5</ENT>
                        <ENT>67.0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Net pension asset</ENT>
                        <ENT>82.4</ENT>
                        <ENT>120.4</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="05">Deferred tax asset</ENT>
                        <ENT>130.6</ENT>
                        <ENT>129.4</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">Total long-term assets to be financed</ENT>
                        <ENT>453.6</ENT>
                        <ENT>470.1</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Postemployment/postretirement benefits and net pension liabilities *</ENT>
                        <ENT>292.5</ENT>
                        <ENT>301.2</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Net long-term assets to be financed *</ENT>
                        <ENT>161.1</ENT>
                        <ENT>168.9</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">
                            Imputed long-term debt 
                            <SU>21</SU>
                        </ENT>
                        <ENT>96.1</ENT>
                        <ENT>100.3</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="05">
                            Imputed equity 
                            <SU>21</SU>
                        </ENT>
                        <ENT>65.0</ENT>
                        <ENT>68.5</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">Total long-term financing *</ENT>
                        <ENT>161.1</ENT>
                        <ENT>168.9</ENT>
                    </ROW>
                    <TNOTE>
                        <SU>a</SU>
                         Excludes amounts related to the FedNow Service.
                    </TNOTE>
                    <TNOTE>* Premises and postemployment/postretirement benefits and net pension liabilities, net long-term assets to be financed and total long-term financing restated for 2024.</TNOTE>
                </GPOTABLE>
                <GPOTABLE COLS="5" OPTS="L2,nj,i1" CDEF="s50,14,12,14,12">
                    <TTITLE>
                        Table 5—Derivation of the PSAF for Mature Priced Services 
                        <E T="01">
                            <SU>a</SU>
                        </E>
                    </TTITLE>
                    <TDESC>[Dollars in millions]</TDESC>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="2">Debt</CHED>
                        <CHED H="2">Equity</CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="2">Debt</CHED>
                        <CHED H="2">Equity</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">
                            <E T="03">A. Imputed long-term debt and equity:</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Net long-term assets to finance</ENT>
                        <ENT>$ 161.1</ENT>
                        <ENT>$ 161.0</ENT>
                        <ENT>$ 168.9</ENT>
                        <ENT>$ 168.9</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Capital structure observed in market</ENT>
                        <ENT>59.7%</ENT>
                        <ENT>40.3%</ENT>
                        <ENT>59.4%</ENT>
                        <ENT>40.6%</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Pre-adjusted long-term debt and equity</ENT>
                        <ENT>$ 96.1</ENT>
                        <ENT>$ 65.0</ENT>
                        <ENT>$ 100.3</ENT>
                        <ENT>$ 68.5</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Equity adjustments: 
                            <SU>19</SU>
                        </ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Equity to meet capital requirements</ENT>
                        <ENT/>
                        <ENT>$ 65.0</ENT>
                        <ENT/>
                        <ENT>$ 68.5</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Adjustment to debt and equity funding given capital requirements 
                            <SU>20</SU>
                        </ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Adjusted equity balance</ENT>
                        <ENT/>
                        <ENT>$ 65.0</ENT>
                        <ENT/>
                        <ENT>$ 68.5</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            Equity to meet capital requirements 
                            <SU>21</SU>
                        </ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">Total imputed long-term debt and equity *</ENT>
                        <ENT>96.1</ENT>
                        <ENT>65.0</ENT>
                        <ENT>100.3</ENT>
                        <ENT>68.5</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            <E T="03">B. Cost of capital:</E>
                        </ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Elements of capital costs:</ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Short-term debt 
                            <SU>22</SU>
                        </ENT>
                        <ENT>$ 42.2 × 5.4%</ENT>
                        <ENT>= $ 2.3</ENT>
                        <ENT>$ 32.7 × 5.4%</ENT>
                        <ENT>= $ 1.8</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Long-term debt 
                            <SU>22</SU>
                        </ENT>
                        <ENT>$ 96.1 × 4.4%</ENT>
                        <ENT>= 4.2</ENT>
                        <ENT>$ 100.3 × 4.0%</ENT>
                        <ENT>= $ 4.0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Equity 
                            <SU>23</SU>
                        </ENT>
                        <ENT>$ 65.0 × 18.6%</ENT>
                        <ENT>= $ 12.1</ENT>
                        <ENT>$ 68.5 × 17.4%</ENT>
                        <ENT>= $ 11.9</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            <E T="03">C. Incremental cost of PSR policy:</E>
                        </ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Equity to meet policy</ENT>
                        <ENT>$ 6.7 × 18.6%</ENT>
                        <ENT>= $ 1.3</ENT>
                        <ENT>$ = × 17.4%</ENT>
                        <ENT>= $ =</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            <E T="03">D. Other required PSAF costs:</E>
                        </ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Sales taxes</ENT>
                        <ENT/>
                        <ENT>$ 4.5</ENT>
                        <ENT/>
                        <ENT>$ 3.9</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="03">Board of Governors expenses</ENT>
                        <ENT/>
                        <ENT>7.6</ENT>
                        <ENT/>
                        <ENT>7.6</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT/>
                        <ENT>$ 12.1</ENT>
                        <ENT/>
                        <ENT>$ 11.5</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            <E T="03">E. Total PSAF:</E>
                        </ENT>
                        <ENT/>
                        <ENT>$ 31.9</ENT>
                        <ENT/>
                        <ENT>$ 29.2</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="93590"/>
                        <ENT I="03">As a percent of assets</ENT>
                        <ENT/>
                        <ENT>3.6%</ENT>
                        <ENT/>
                        <ENT>3.6%</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">As a percent of expenses</ENT>
                        <ENT/>
                        <ENT>3.4%</ENT>
                        <ENT/>
                        <ENT>3.6%</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            <E T="03">F. Tax rates</E>
                        </ENT>
                        <ENT/>
                        <ENT>18.91%</ENT>
                        <ENT/>
                        <ENT>18.84%</ENT>
                    </ROW>
                    <TNOTE>
                        <SU>a</SU>
                         Excludes amounts related to the FedNow Service.
                    </TNOTE>
                    <TNOTE>* Total imputed long-term debt restated for 2024.</TNOTE>
                </GPOTABLE>
                <GPOTABLE COLS="4" OPTS="L2,nj,i1" CDEF="s50,12,12,12">
                    <TTITLE>
                        Table 6—Computation of 2025 Capital Adequacy for Federal Reserve Mature Priced Services 
                        <E T="01">
                            <SU>a</SU>
                        </E>
                    </TTITLE>
                    <TDESC>[Dollars in millions]</TDESC>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">Assets</CHED>
                        <CHED H="1">Risk weight</CHED>
                        <CHED H="1">
                            Weighted
                            <LI>assets</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">Imputed investments:</ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            1-Year Treasury securities 
                            <SU>24</SU>
                        </ENT>
                        <ENT>$ 6.7</ENT>
                        <ENT>0.0</ENT>
                        <ENT>$ =</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="03">
                            Federal funds 
                            <SU>25</SU>
                        </ENT>
                        <ENT>293.0</ENT>
                        <ENT>0.2</ENT>
                        <ENT>58.6</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Total imputed investments</ENT>
                        <ENT>299.8</ENT>
                        <ENT/>
                        <ENT>58.9</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Receivables</ENT>
                        <ENT>44.3</ENT>
                        <ENT>0.2</ENT>
                        <ENT>8.9</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Inventory</ENT>
                        <ENT>0.4</ENT>
                        <ENT>1.0</ENT>
                        <ENT>0.4</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Prepaid expenses</ENT>
                        <ENT>34.2</ENT>
                        <ENT>1.0</ENT>
                        <ENT>34.2</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Items in process of collection</ENT>
                        <ENT>58.0</ENT>
                        <ENT>0.2</ENT>
                        <ENT>11.6</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Premises</ENT>
                        <ENT>105.3</ENT>
                        <ENT>1.0</ENT>
                        <ENT>105.3</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Furniture and equipment</ENT>
                        <ENT>60.8</ENT>
                        <ENT>1.0</ENT>
                        <ENT>60.8</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Software and leasehold improvements</ENT>
                        <ENT>74.5</ENT>
                        <ENT>1.0</ENT>
                        <ENT>74.5</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Pension asset</ENT>
                        <ENT>82.4</ENT>
                        <ENT>1.0</ENT>
                        <ENT>82.4</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="03">Deferred tax asset</ENT>
                        <ENT>130.6</ENT>
                        <ENT>1.0</ENT>
                        <ENT>130.6</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Total</ENT>
                        <ENT>890.3</ENT>
                        <ENT/>
                        <ENT>567.6</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Imputed equity:</ENT>
                        <ENT/>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Capital to risk-weighted assets</ENT>
                        <ENT>12.6%</ENT>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Capital to total assets</ENT>
                        <ENT>8.1%</ENT>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <TNOTE>
                        <SU>a</SU>
                         Excludes amounts related to the FedNow Service.
                    </TNOTE>
                </GPOTABLE>
                <P>
                    C. 
                    <E T="03">Check Services</E>
                    —Table 7 shows the 2023 actual, 2024 forecasted, and 2025 budgeted cost-recovery performance for commercial check services.
                </P>
                <GPOTABLE COLS="6" OPTS="L2(,0,),i1" CDEF="s50,12,12,12,12,14">
                    <TTITLE>Table 7—Check Services Pro Forma Cost and Revenue Performance</TTITLE>
                    <TDESC>[Dollars in millions]</TDESC>
                    <BOXHD>
                        <CHED H="1">Year</CHED>
                        <CHED H="1">Revenue</CHED>
                        <CHED H="1">
                            Total
                            <LI>expense</LI>
                        </CHED>
                        <CHED H="1">
                            Net income
                            <LI>(ROE)</LI>
                        </CHED>
                        <CHED H="1">
                            Targeted
                            <LI>ROE</LI>
                        </CHED>
                        <CHED H="1">
                            Recovery rate
                            <LI>after targeted</LI>
                            <LI>ROE</LI>
                        </CHED>
                    </BOXHD>
                    <ROW RUL="n,s">
                        <ENT I="25"> </ENT>
                        <ENT>1</ENT>
                        <ENT>2</ENT>
                        <ENT>3 [1−2]</ENT>
                        <ENT>4</ENT>
                        <ENT>5 [1/(2 + 4)]</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2023 (actual)</ENT>
                        <ENT>111.8</ENT>
                        <ENT>107.4</ENT>
                        <ENT>4.4</ENT>
                        <ENT>1.3</ENT>
                        <ENT>102.9</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2024 (forecast)</ENT>
                        <ENT>110.2</ENT>
                        <ENT>105.0</ENT>
                        <ENT>5.2</ENT>
                        <ENT>2.1</ENT>
                        <ENT>102.9</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2025 (budget)</ENT>
                        <ENT>107.1</ENT>
                        <ENT>107.8</ENT>
                        <ENT>(0.7)</ENT>
                        <ENT>2.1</ENT>
                        <ENT>97.5</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    1. 
                    <E T="03">2024 Forecast</E>
                    —The Reserve Banks forecast that Check Services will recover 102.9 percent of total expenses and targeted ROE, compared with a 2024 budgeted recovery rate of 95.5 percent.
                </P>
                <P>Through August 2024, total commercial forward and total commercial return check volumes were 6.8 percent lower and 2.9 percent greater, respectively, than they were during the same period last year. For full-year 2024, the Reserve Banks estimate that their total forward check volume will decline 6.3 percent (compared with a budgeted decline of 8.0 percent), and their total return check volume will increase 1.6 percent (compared with a budgeted decline of 7.0 percent) from 2023 levels. The Reserve Banks expect that check volumes will continue to decline because of ongoing substitution away from checks to other payment instruments.</P>
                <P>
                    2. 
                    <E T="03">2025 Pricing</E>
                    —The Reserve Banks expect Check Services to recover 97.5 percent of total expenses and targeted ROE in 2025. The Reserve Banks project revenue to be $107.1 million, a decline of $3.1 million, or 2.8 percent from the 2024 forecast. Total expenses for Check Services are projected to be $107.8 million, an increase of $2.8 million, or 2.7 percent, from 2024 forecasted expenses.
                </P>
                <P>
                    As check volumes continue to decline, the pricing increases are intended to help stabilize check revenues, to shift the revenue mix 
                    <PRTPAGE P="93591"/>
                    toward fixed fees, and to continue a value-based pricing strategy for financial institutions that use the service. To that end, the Reserve Banks will increase the pricing tiers for the fixed monthly participation fees. For the participation fees, Tier 1 will increase by $125, Tier 2 will increase by $80, Tier 3 will increase by $50, and Tier 4 will increase by $10. These fee changes support the cost of maintaining FRFS Check Services infrastructure as fewer checks are written each year and follow the Check Services business line's pricing strategy to increase the share of revenue collected through fixed fees. Table 8 displayed below shows the 2025-tiered participation fees.
                </P>
                <GPOTABLE COLS="2" OPTS="L2,p7,7/8,i1" CDEF="s150,16">
                    <TTITLE>Table 8—Check 21 Participation Fee Structure</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            Tier 
                            <SU>26</SU>
                        </CHED>
                        <CHED H="1">Monthly fee</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">1</ENT>
                        <ENT>$550</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2</ENT>
                        <ENT>340</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">3</ENT>
                        <ENT>215</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">4</ENT>
                        <ENT>90</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    The Reserve
                    <FTREF/>
                     Banks will also increase the fees for each of the services in the FedImage suite by approximately 10% and merge the Back File Conversion and Electronic On-Us services with the FedImage Enhanced Truncation service into a single service at the new FedImage Enhanced Truncation price point. These changes will better reflect the value of services provided to customers and help simplify the services in the face of declining volumes. Table 9 below shows the 2025 FedImage services fees.
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         Consistent with the PSR policy, the Reserve Banks' priced services will hold an amount equivalent to six months of the Fedwire Funds Service's current operating expenses as liquid net financial assets and equity on the pro forma balance sheet. Six months of the Fedwire Funds Service's projected current operating expenses is $71.7 million. In 2025, $6.7 million of additional equity was imputed to meet PSR policy requirements.
                    </P>
                    <P>
                        <SU>15</SU>
                         Includes the allocation of Board of Governors assets to priced services of $5.2 million for 2025 and $3.5 million for 2024.
                    </P>
                    <P>
                        <SU>16</SU>
                         Includes the allocation of Board of Governors liabilities to priced services of $1.4 million for 2025 and $1.2 million for 2024.
                    </P>
                    <P>
                        <SU>17</SU>
                         Includes an accumulated other comprehensive loss of $563.3 million for 2025 and $551.0 million for 2024, which reflects the ongoing amortization of the accumulated loss in accordance with ASC 715. Future gains or losses, and their effects on the pro forma balance sheet, cannot be projected. See Table 5 for calculation of required imputed equity amount.
                    </P>
                    <P>
                        <SU>18</SU>
                         Imputed short-term debt financing is computed as the difference between short-term assets and short-term liabilities. As presented in Table 5, the financing costs of imputed short-term debt, imputed long-term debt and imputed equity are the elements of cost of capital, which contribute to the calculation of the PSAF.
                    </P>
                    <P>
                        <SU>19</SU>
                         If minimum equity constraints are not met after imputing equity based on the capital structure observed in the market, additional equity is imputed to meet these constraints. The long-term funding need was met by imputing long-term debt and equity based on the capital structure observed in the market (see Tables 4 and 6). In 2025, the amount of imputed equity met the minimum equity requirements for risk-weighted assets.
                    </P>
                    <P>
                        <SU>20</SU>
                         Equity adjustment offsets are due to a shift of long-term debt funding to equity in order to meet FDIC capital requirements for well-capitalized institutions.
                    </P>
                    <P>
                        <SU>21</SU>
                         Additional equity in excess of that needed to fund priced services assets is offset by an asset balance of imputed investments in Treasury securities.
                    </P>
                    <P>
                        <SU>22</SU>
                         Imputed short-term debt and long-term debt are computed in Table 4.
                    </P>
                    <P>
                        <SU>23</SU>
                         The 2025 ROE is equal to a risk-free rate plus a risk premium (beta * market risk premium). The 2025 after-tax CAPM ROE is calculated as 5.52% + (1.0 * 9.54%) = 15.06%. Using a tax rate of 18.9%, the after-tax ROE is converted into a pretax ROE, which results in a pretax ROE of (15.06%/(1-18.9%)) = 18.57%. Calculations may be affected by rounding.
                    </P>
                    <P>
                        <SU>24</SU>
                         If minimum equity constraints are not met after imputing equity based on all other financial statement components, additional equity is imputed to meet these constraints. Additional equity imputed to meet minimum equity requirements is invested solely in Treasury securities. The imputed investments are similar to those for which rates are available on the Federal Reserve's H.15 statistical release, available at 
                        <E T="03">https://www.federalreserve.gov/releases/h15/.</E>
                    </P>
                    <P>
                        <SU>25</SU>
                         The investments are imputed based on the amounts arising from the collection of items before providing credit according to established availability schedules.
                    </P>
                    <P>
                        <SU>26</SU>
                         This fee is charged to financial institutions that have received any Check 21 electronic or substitute check volume (forward or return) from the Reserve Banks during the month. The fee is applied at the parent financial institution level, as defined in the Reserve Banks' Global Customer Directory. Each financial institution's tier assignment is determined by the criteria described in the FedForward Standard Endpoint Tier Listing.
                    </P>
                    <P>
                        <SU>27</SU>
                         The 2025 fees are not listed for Back File Conversion and Electronic On-Us given their consolidation into a single service at the new FedImage Enhanced Truncation price point.
                    </P>
                </FTNT>
                <GPOTABLE COLS="5" OPTS="L2,p7,7/8,i1" CDEF="s50,12,12,12,12">
                    <TTITLE>
                        Table 9—2025 FedImage Services Fees 
                        <SU>27</SU>
                    </TTITLE>
                    <BOXHD>
                        <CHED H="1">FedImage Services</CHED>
                        <CHED H="1">2024 Fees</CHED>
                        <CHED H="2">Fixed/CL</CHED>
                        <CHED H="2">Item</CHED>
                        <CHED H="1">2025 Fees</CHED>
                        <CHED H="2">Fixed/CL</CHED>
                        <CHED H="2">Item</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">Image Archive:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">30 business day archive</ENT>
                        <ENT/>
                        <ENT>$ 0.0013</ENT>
                        <ENT/>
                        <ENT>$ 0.0014</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">60 business day archive</ENT>
                        <ENT/>
                        <ENT>0.0015</ENT>
                        <ENT/>
                        <ENT>0.0017</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">7 Year archive/11 year archive</ENT>
                        <ENT/>
                        <ENT>0.0024</ENT>
                        <ENT/>
                        <ENT>0.0026</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Extended RAID Storage:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">61 days to 6 months</ENT>
                        <ENT/>
                        <ENT>0.0012</ENT>
                        <ENT/>
                        <ENT>0.0013</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">61 days to 12 months</ENT>
                        <ENT/>
                        <ENT>0.0029</ENT>
                        <ENT/>
                        <ENT>0.0032</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">61 days to 24 months</ENT>
                        <ENT/>
                        <ENT>0.0074</ENT>
                        <ENT/>
                        <ENT>0.0081</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Image Retrievals:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Subscription Retrieval</ENT>
                        <ENT/>
                        <ENT>0.0032</ENT>
                        <ENT/>
                        <ENT>0.0035</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Manual FedImage Requests</ENT>
                        <ENT/>
                        <ENT>8.80</ENT>
                        <ENT/>
                        <ENT>10.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Back File Conversion</ENT>
                        <ENT>5.17</ENT>
                        <ENT>0.0146</ENT>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">Electronic On-Us Service</ENT>
                        <ENT>5.17</ENT>
                        <ENT>0.0146</ENT>
                        <ENT>8.80</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="22">Truncation:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">FedImage Enhanced Truncation</ENT>
                        <ENT>7.98</ENT>
                        <ENT>0.0132</ENT>
                        <ENT>8.80</ENT>
                        <ENT>0.0145</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Return Retrieval</ENT>
                        <ENT/>
                        <ENT>1.54</ENT>
                        <ENT/>
                        <ENT>1.70</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Custom Sort Fee</ENT>
                        <ENT>192.50</ENT>
                        <ENT/>
                        <ENT>212.00</ENT>
                        <ENT/>
                    </ROW>
                </GPOTABLE>
                <P>
                    Additionally, the Reserve Banks will increase certain forward paper fees. Specifically, the Reserve Banks will increase the Canadian cash letter fees for U.S. and Canadian funds by $2.00, the Canadian Amount Encoding per-
                    <PRTPAGE P="93592"/>
                    item fee by $0.50, and the Mixed Forward Products (domestic paper checks) cash letter fee by $2.00 and per-item fee by $0.50. Table 10 below shows the 2025 forward paper fees.
                </P>
                <GPOTABLE COLS="3" OPTS="L2,i1" CDEF="s100,12,12">
                    <TTITLE>Table 10—2025 Forward Paper Check Clearing Fees</TTITLE>
                    <BOXHD>
                        <CHED H="1">Forward paper check</CHED>
                        <CHED H="1">Fixed/CL</CHED>
                        <CHED H="1">Item</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Canadian—US Funds</ENT>
                        <ENT>$ 19.00</ENT>
                        <ENT>$ 6.50000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Canadian—Canadian Funds</ENT>
                        <ENT>19.00</ENT>
                        <ENT>6.50000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Canadian Amount Encoding</ENT>
                        <ENT/>
                        <ENT>2.50000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Mixed Paper Deposits</ENT>
                        <ENT>19.00</ENT>
                        <ENT>5.00000</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The Reserve Banks will increase certain return fees and will implement a new tiered fee structure for the Large Dollar Return Item Notification (LDRIN) via the FedLine Web® Solution. The fees for the new LDRIN via FedLine Web tiers will be $3.50 for Tier 1, for customers with greater than 5,000 monthly items, and $5.00 for Tier 2, for customers with less than 5,000 monthly items. Additionally, the Return Item Reclear cash letter fee will increase by $1.00 and the per-item fee will increase by $0.10. The Qualified and Unqualified Return Item cash letter fee will increase by $2.00 and the per-item fee will increase by $0.50. Lastly, the return Item Qualification per-item fee will increase by $1.00. Table 11 below shows the 2025 return fees and new LDRIN via FedLine Web tiers.</P>
                <GPOTABLE COLS="3" OPTS="L2,i1" CDEF="s100,12,12">
                    <TTITLE>Table 11—2025 Return Legacy/Paper Fees</TTITLE>
                    <BOXHD>
                        <CHED H="1">Return paper check</CHED>
                        <CHED H="1">Fixed/CL</CHED>
                        <CHED H="1">Item</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">LDRIN via FedLine for the Web:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Tier 1
                            <E T="03"> (Greater than 5,000 monthly)</E>
                        </ENT>
                        <ENT/>
                        <ENT>$ 3.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Tier 2 
                            <E T="03">(Less than 5,000 monthly)</E>
                        </ENT>
                        <ENT/>
                        <ENT>5.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Return Item Reclear:</ENT>
                        <ENT/>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Level 1
                            <E T="03"> (Items valued up to $100)</E>
                        </ENT>
                        <ENT>$12.00</ENT>
                        <ENT>0.85</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Level 2 
                            <E T="03">(Items valued up to $250)</E>
                        </ENT>
                        <ENT>12.00</ENT>
                        <ENT>0.95</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Level 3
                            <E T="03"> (Items valued up to $500)</E>
                        </ENT>
                        <ENT>12.00</ENT>
                        <ENT>1.05</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Level 4
                            <E T="03"> (Items valued up to $1,000)</E>
                        </ENT>
                        <ENT>12.00</ENT>
                        <ENT>1.15</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Qualified Return Items</ENT>
                        <ENT>19.00</ENT>
                        <ENT>8.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Unqualified Return Items</ENT>
                        <ENT>19.00</ENT>
                        <ENT>8.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Unencoded Qualification</ENT>
                        <ENT/>
                        <ENT>11.00</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The Reserve Banks' primary risk to current projections for Check Services is a greater than expected decline in check volume due to the general reduction in check writing, substitution away from checks to other payment instruments, and competition from correspondent banks, aggregators, and direct exchanges, which could result in lower than anticipated revenue. The Reserve Banks estimate these cumulative price changes will result in a 2.8 percent average increase for Check Services customers.</P>
                <P>
                    D. 
                    <E T="03">FedACH Services</E>
                    —Table 12 shows the 2023 actual, 2024 forecasted, and 2025 budgeted cost-recovery performance for commercial FedACH Services.
                </P>
                <GPOTABLE COLS="6" OPTS="L2(,0,),i1" CDEF="s25,12,12,12,12,14">
                    <TTITLE>Table 12—FedACH Services Pro Forma Cost and Revenue Performance</TTITLE>
                    <TDESC>[Dollars in millions]</TDESC>
                    <BOXHD>
                        <CHED H="1">Year</CHED>
                        <CHED H="1">Revenue</CHED>
                        <CHED H="1">Total expense</CHED>
                        <CHED H="1">
                            Net income
                            <LI>(ROE)</LI>
                        </CHED>
                        <CHED H="1">
                            Targeted
                            <LI>ROE</LI>
                        </CHED>
                        <CHED H="1">Recovery rate after targeted ROE</CHED>
                    </BOXHD>
                    <ROW RUL="s">
                        <ENT I="25"> </ENT>
                        <ENT>1</ENT>
                        <ENT>2</ENT>
                        <ENT>3 [1−2]</ENT>
                        <ENT>4</ENT>
                        <ENT>5 [1/(2 + 4)]</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2023 (actual)</ENT>
                        <ENT>183.8</ENT>
                        <ENT>166.5</ENT>
                        <ENT>17.1</ENT>
                        <ENT>2.3</ENT>
                        <ENT>108.8</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2024 (forecast)</ENT>
                        <ENT>189.0</ENT>
                        <ENT>169.0</ENT>
                        <ENT>20.0</ENT>
                        <ENT>3.7</ENT>
                        <ENT>109.4</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2025 (budget)</ENT>
                        <ENT>194.4</ENT>
                        <ENT>179.7</ENT>
                        <ENT>14.7</ENT>
                        <ENT>3.7</ENT>
                        <ENT>106.0</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    1. 
                    <E T="03">2024 Forecast</E>
                    —The Reserve Banks forecast that FedACH Services will recover 109.4 percent of total expenses and targeted ROE, compared with a 2024 budgeted recovery rate of 106.0 percent.
                </P>
                <P>Through August 2024, FedACH commercial origination and receipt volume were 7.7 percent higher and 5.3 percent higher, respectively, than they were during the same period last year. For full-year 2024, the Reserve Banks estimate that FedACH commercial origination and receipt volume will increase 6.7 percent and 4.7 percent, respectively, from 2023 levels, compared with a budgeted increase of 3.5 percent for both commercial origination and receipt.</P>
                <P>
                    2. 2025 
                    <E T="03">Pricing</E>
                    —The Reserve Banks expect FedACH Services to recover 106.0 percent of total expenses and targeted ROE in 2025. The Reserve Banks project revenue to be $194.4 million, an increase of $5.4 million, or 2.9 percent, from the 2024 forecast. Total expenses are projected to be $179.8 million, an increase of $10.8 
                    <PRTPAGE P="93593"/>
                    million, or 6.4 percent, from the 2024 forecast.
                </P>
                <P>
                    The Reserve Banks will increase the monthly ACH Participation fee from $75 to $80 per RTN. The Reserve Banks will also increase the monthly ACH Origination Minimum fee from $50 to $55 and Receipt Minimum fee from $40 to $45 per RTN.
                    <SU>28</SU>
                    <FTREF/>
                     The ACH Participation and Minimum Fee price changes are driven by ongoing operational costs and a continued focus on growing fixed fee revenue generation.
                </P>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         The FedACH Minimum Fee applies to any RTN that has originated or received a FedACH transaction during a calendar month. The customer is charged their normal item fees plus a variable amount that closes the gap to the minimum. For example, an RTN originating 10K items in a month pays $35 in item fees (10K items times $0.0035 per item) and $15 in minimum fees so that their total origination fees are $50. Another RTN paying $51 in item fees would be charged an effective minimum fee of $0. Only one minimum threshold applies in any given period, with RTNs subject to the Receipt Minimum fee only if they did not originate any items.
                    </P>
                </FTNT>
                <P>
                    In addition, the Reserve Banks will increase the FedACH FedPayments Reporter Service fees from 6 to 11 percent as shown in Table 13.
                    <SU>29</SU>
                    <FTREF/>
                     The FedPayments Reporter Service has continued to evolve and improve with enhanced features such as new intraday generation capabilities for select reports and the integration of an upgraded Electronic Data Interchange (EDI) parser. These efforts have increased both the costs of providing the FedPayments Reporter Service and the value it offers to customers.
                </P>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         The FedPayments Reporter Service for the FedACH Services provides financial institutions and their customers with reports of their ACH transactions processed by FedACH including valuable business information.
                    </P>
                </FTNT>
                <GPOTABLE COLS="2" OPTS="L2,i1" CDEF="s150,16">
                    <TTITLE>Table 13—FedACH FedPayments Reporter Service Fees</TTITLE>
                    <BOXHD>
                        <CHED H="1">Tiers</CHED>
                        <CHED H="1">2025 Monthly fee</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Tier 1—Up to 50 reports</ENT>
                        <ENT>$50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 2—From 51 to 150 reports</ENT>
                        <ENT>72</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 3—From 151 to 500 reports</ENT>
                        <ENT>133</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 4—From 501 to 1,000 reports</ENT>
                        <ENT>245</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 5—From 1,001 to 1,500 reports</ENT>
                        <ENT>355</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 6—From 1,501 to 2,500 reports</ENT>
                        <ENT>555</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 7—From 2,501 to 3,500 reports</ENT>
                        <ENT>775</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 8—From 3,501 to 4,500 reports</ENT>
                        <ENT>990</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 9—From 4,501 to 5,500 reports</ENT>
                        <ENT>1,200</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 10—From 5,501 to 7,000 reports</ENT>
                        <ENT>1,460</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 11—From 7,001 to 8,500 reports</ENT>
                        <ENT>1,700</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 12—From 8,501 to 10,000 reports</ENT>
                        <ENT>1,930</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 13—Over 10,000 reports</ENT>
                        <ENT>2,100</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The Reserve Banks estimate these cumulative price changes will result in a 1.4 percent average increase for FedACH customers.</P>
                <P>The Reserve Banks' primary risk to current projections for the FedACH Service are lower-than-projected volumes and growth due to potential customer attrition.</P>
                <P>
                    E. 
                    <E T="03">Fedwire Funds Service and National Settlement Service</E>
                    —Table 14 shows the 2023 actual, 2024 forecasted, and 2025 budgeted cost-recovery performance for the Fedwire Funds Service and the National Settlement Service.
                </P>
                <GPOTABLE COLS="6" OPTS="L2(,0,),i1" CDEF="s25,12,12,12,12,14">
                    <TTITLE>Table 14—Fedwire Funds Service and National Settlement Service Pro Forma Cost and Revenue Performance</TTITLE>
                    <TDESC>[Dollars in millions]</TDESC>
                    <BOXHD>
                        <CHED H="1">Year</CHED>
                        <CHED H="1">Revenue</CHED>
                        <CHED H="1">Total expense</CHED>
                        <CHED H="1">
                            Net income
                            <LI>(ROE)</LI>
                        </CHED>
                        <CHED H="1">
                            Targeted
                            <LI>ROE</LI>
                        </CHED>
                        <CHED H="1">
                            Recovery rate
                            <LI>after targeted</LI>
                            <LI>ROE</LI>
                        </CHED>
                    </BOXHD>
                    <ROW RUL="s">
                        <ENT I="25"> </ENT>
                        <ENT>1</ENT>
                        <ENT>2</ENT>
                        <ENT>3 [1−2]</ENT>
                        <ENT>4</ENT>
                        <ENT>5 [1/(2 + 4)]</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2023 (actual)</ENT>
                        <ENT>162.5</ENT>
                        <ENT>153.4</ENT>
                        <ENT>9.1</ENT>
                        <ENT>4.3</ENT>
                        <ENT>103.1</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2024 (forecast)</ENT>
                        <ENT>169.2</ENT>
                        <ENT>153.1</ENT>
                        <ENT>16.1</ENT>
                        <ENT>3.0</ENT>
                        <ENT>108.3</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2025 (budget)</ENT>
                        <ENT>174.4</ENT>
                        <ENT>164.9</ENT>
                        <ENT>9.5</ENT>
                        <ENT>4.1</ENT>
                        <ENT>103.2</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    1. 
                    <E T="03">2024 Forecast</E>
                    —The Reserve Banks forecast that the Fedwire Funds Service and the National Settlement Service will recover 108.3 percent of total expenses and targeted ROE, compared with a 2024 budgeted recovery rate of 103.2 percent.
                </P>
                <P>Through August 2024, Fedwire Funds Service online volume has been 5.9 percent higher than it was during the same period last year. The Reserve Banks expect volume to remain near this level through the remainder of 2024. Through August 2024, the National Settlement Service settlement file volume was 0.3 percent higher than it was during the same period last year, and settlement entry volume was 0.5 percent higher. For full-year 2024, the Reserve Banks estimate that settlement file volume will decrease 0.3 percent (compared with a budgeted decrease of 0.1 percent) and settlement entry volume will increase 0.4 percent (compared with a budgeted 0.4 percent increase) from 2023 levels.</P>
                <P>
                    2. 
                    <E T="03">2025 Pricing</E>
                    —The Reserve Banks expect the Fedwire Funds Service and the National Settlement Service to recover 103.2 percent of total expenses in 2025. The Reserve Banks project revenue to be $174.4 million, an increase of $5.2 million, or 3.1 percent from the 2024 forecast. The Reserve Banks project total expenses to be $164.9 million, an increase of 11.8 
                    <PRTPAGE P="93594"/>
                    million, or 7.7 percent, from the 2024 forecast. Rising costs are primarily driven by the Fedwire Funds Service's ongoing transition to the ISO® 20022 messaging format.
                    <SU>30</SU>
                    <FTREF/>
                     In addition, the National Settlement Service continues to incur higher costs because of the expansion of its operating hours in 2022.
                    <SU>31</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         In October 2021, the Board announced that the Federal Reserve Banks will adopt the ISO 20022 message format for the Fedwire Funds Service. 
                        <E T="03">See New Message Format for the Fedwire Funds Service,</E>
                         86 FR 55600 (Oct. 6, 2021).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         The National Settlement Service expanded its hours to 21.5 hours per day in 2022, with a new 9:00 p.m. ET open for the next business day.
                    </P>
                </FTNT>
                <P>The Reserve Banks will increase the Fedwire Funds Service participation fee from $115 to $120. In addition, all three of the gross origination and receipt tiered fees will be increased. The tier 1 fee will increase from $0.94 to $0.97, the tier 2 fee will increase from $0.29 to $0.30, and the tier 3 fee will increase from $0.19 to $0.195. Correspondingly, the volume-based incentive discount fee will increase for all three tiers. The tier 1 discount fee will increase from $0.188 to $0.194, the tier 2 discount fee will increase from $0.058 to $0.060, and the tier 3 discount fee will increase from $0.038 to $0.039. Finally, the FedPayments Manager Import/Export fee will increase from $60 to $65. The Reserve Banks will also change National Settlement Service fees for 2025. The per-file fee will increase from $35 to $40, and the per-entry fee will increase from $1.70 to $1.95.</P>
                <P>
                    In addition to these changes, the Reserve Banks will introduce a new volume-based fixed fee for the Fedwire Funds Service.
                    <SU>32</SU>
                    <FTREF/>
                     The introduction of this fee will serve to reconcile challenges associated with volatility stemming from variable revenues sources while ensuring a fee structure that is better aligned with customer usage. This fee is based on the volume tier thresholds.
                    <SU>33</SU>
                    <FTREF/>
                     The new volume-based fixed fee is one price point assessed at the parent level and is based on the highest volume tier of its associated affiliates.
                    <SU>34</SU>
                    <FTREF/>
                     This differs from the existing participation fee in that the participation fee is assessed at the sub-account level for any ABA with at least one origination or receipt transaction during the month.
                    <SU>35</SU>
                    <FTREF/>
                     The proposed price points for the volume-based fixed fees are as follows:
                </P>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         Volume-based pricing for Fedwire Funds was introduced in 1999. The analysis that led to volume-based pricing showed that Fedwire Funds can benefit from charging different prices to different areas of the market based on customer volume. When considering ways to increase fixed revenue, the Board re-examined this analysis and has concluded that establishing fixed revenue sources based on customer volume will benefit the Fedwire Funds service in a similar fashion to volume-based pricing for gross origination and receipt fees.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         Tiers are based on monthly total volume (send and receive) at the master account level: 0-14,000 messages (Tier 1); 14,001-90,000 (Tier 2), and all volume above 90,000 messages (Tier 3).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         For example, if a parent customer has affiliates in the Tier 2 and Tier 3 volume thresholds, the parent will be assessed the corresponding $500 Tier 3 monthly fee.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         The new Monthly Fixed Fee will not be applicable to customers in the Tier 1 volume level.
                    </P>
                </FTNT>
                <GPOTABLE COLS="3" OPTS="L2,i1" CDEF="s100,r100,12">
                    <TTITLE>Table 15—Fedwire Funds Service Volume-Based Fixed Fee Tiers</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fixed fee level</CHED>
                        <CHED H="1">Volume tier</CHED>
                        <CHED H="1">Monthly fee</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Tier 2</ENT>
                        <ENT>Tier 2</ENT>
                        <ENT>$250</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Tier 3</ENT>
                        <ENT>Tier 3</ENT>
                        <ENT>500</ENT>
                    </ROW>
                </GPOTABLE>
                <P>As noted above, this fee will serve to reconcile challenges associated with volatility stemming from variable revenues sources while ensuring a fee structure that is better aligned with customer usage. Fedwire Funds Service fee revenue has become increasingly dependent on variable sources and this growing exposure to uncertain fee fluctuations undermines annual revenue stability. This fee will address this uncertainty by increasing the percentage of fixed fee revenue. Further, the fee is intended to be commensurate with customer usage and structured so that smaller customers are not disproportionally impacted. In addition, this fee, alongside the other fee increases noted above, serves to help balance increases in ongoing operational costs incurred by the National Settlement Service for the period between 2014 and 2023, when fees did not increase.</P>
                <P>
                    The Reserve Banks' primary risk to current projections for these services is lower than-projected-volumes and growth due to the market and economic environment given that historically, Fedwire Funds Service volume has reflected market conditions.
                    <SU>36</SU>
                    <FTREF/>
                     The Reserve Banks estimate these cumulative price changes will result in a 5.7 percent average price increase for Fedwire Funds and National Settlement Service customers.
                </P>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         Fedwire Funds Service volume growth reflects economic growth. For example, its volume has grown every year except for 2008 and 2009, when it contracted 2.5 percent and 5.0 percent, respectively, during the Great Recession. For historical Fedwire Funds Service volume data, 
                        <E T="03">see FRBservices.org, Fedwire Funds Service—Annual Statistics, https://www.frbservices.org/resources/financial-services/wires/volume-value-stats/annual-stats.html.</E>
                    </P>
                </FTNT>
                <P>
                    F. 
                    <E T="03">Fedwire Securities Service</E>
                    —Table 16 shows the 2023 actual, 2024 forecast, and 2025 budgeted cost-recovery performance for the Fedwire Securities Service.
                    <SU>37</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         The Reserve Banks provide transfer services for securities issued by the U.S. Treasury, federal government agencies, government-sponsored enterprises, and certain international institutions. Prior to 2023, the priced component of this service consisted of revenues, expenses, and volumes associated with the transfer of all non-Treasury securities. Starting in 2023, the revenues, expenses, and volumes associated with the transfer of Treasury securities are also included in the priced component of this service.
                    </P>
                </FTNT>
                <GPOTABLE COLS="6" OPTS="L2(,0,),i1" CDEF="s25,12,12,12,12,14">
                    <TTITLE>Table 16—Fedwire Securities Service Pro Forma Cost and Revenue Performance</TTITLE>
                    <TDESC>[Dollars in millions]</TDESC>
                    <BOXHD>
                        <CHED H="1">Year</CHED>
                        <CHED H="1">Revenue</CHED>
                        <CHED H="1">
                            Total
                            <LI>expense</LI>
                        </CHED>
                        <CHED H="1">
                            Net income
                            <LI>(ROE)</LI>
                        </CHED>
                        <CHED H="1">
                            Targeted
                            <LI>ROE</LI>
                        </CHED>
                        <CHED H="1">
                            Recovery rate
                            <LI>after targeted</LI>
                            <LI>ROE</LI>
                        </CHED>
                    </BOXHD>
                    <ROW RUL="s">
                        <ENT I="25"> </ENT>
                        <ENT>1</ENT>
                        <ENT>2</ENT>
                        <ENT>3 [1−2]</ENT>
                        <ENT>4</ENT>
                        <ENT>5 [1/(2 + 4)]</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2023 (actual)</ENT>
                        <ENT>49.1</ENT>
                        <ENT>39.7</ENT>
                        <ENT>9.4</ENT>
                        <ENT>0.5</ENT>
                        <ENT>122.3</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2024 (forecast)</ENT>
                        <ENT>52.5</ENT>
                        <ENT>41.8</ENT>
                        <ENT>10.7</ENT>
                        <ENT>0.8</ENT>
                        <ENT>123.2</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">2025 (budget)</ENT>
                        <ENT>55.7</ENT>
                        <ENT>47.3</ENT>
                        <ENT>8.4</ENT>
                        <ENT>0.9</ENT>
                        <ENT>115.7</ENT>
                    </ROW>
                </GPOTABLE>
                <PRTPAGE P="93595"/>
                <P>
                    1. 
                    <E T="03">2024 Forecast</E>
                    —The Reserve Banks forecast that the Fedwire Securities Service will recover 123.2 percent of total expenses and targeted ROE, compared with a 2024 budgeted recovery rate of 110.9 percent.
                </P>
                <P>Through August 2024, Treasury security transfer volume was 15.9 percent higher than it was during the same period last year. For full-year 2024, the Reserve Banks estimate that Treasury security transfer volume will increase 4.0 percent from 2023 levels, compared with a budgeted decrease of 7.3 percent. Through August 2024, Agency security transfer volume was 3.8 percent lower than it was during the same period last year. For full-year 2024, the Reserve Banks estimate that Agency security transfer volume will decrease 2.6 percent from 2023 levels, compared with a budgeted increase of 1.3 percent.</P>
                <P>Through August 2024, account maintenance volume was 0.7 percent lower than it was during the same period last year. For full-year 2024, the Reserve Banks estimate that account maintenance volume will decline 1.0 percent from 2023 levels, compared with a budgeted decline of 2.6 percent. Through August 2024, the volume of Agency issues maintained was 0.5 percent lower than it was during the same period last year. For full-year 2024, the Reserve Banks estimate that the volume of Agency issues maintained will decrease 0.4 percent from 2023 levels, compared with a budgeted change of 0.0 percent.</P>
                <P>
                    2. 
                    <E T="03">2025 Pricing</E>
                    —The Reserve Banks expect the Fedwire Securities Service to recover 115.7 percent of total expenses and targeted ROE in 2025. Revenue is projected to be $55.7 million, an increase of $3.2 million, or 6.0 percent, from the 2024 revenue forecast. The Reserve Banks also project that 2025 expenses will be $47.3 million, an increase of $5.5 million, or 13.1 percent from the 2024 forecast.
                </P>
                <P>The Reserve Banks will leave fee schedules for Fedwire Securities priced services unchanged in 2025. This decision considers the benefits of maintaining consistent customer pricing in the face of rising costs and higher than expected volatility in transfer volumes.</P>
                <P>Regarding volumes, the Reserve Banks project that monthly maintenance products will maintain relatively stable volumes throughout 2025 with Issue Maintenance volume to increase slightly at 0.2 percent and Account Maintenance volume to decrease 0.6 percent in 2025. Treasury transfer volume is slated to continue its record growth trend with an anticipated 9.4 percent increase. Agency transfers are projected to increase by 0.5 percent in 2025.</P>
                <P>The Reserve Banks project that Agency transfer volume will increase moderately compared with previous years, as interest rates fall, encouraging home-buying and mortgage refinancing. As detailed in the figures above, the volume of Treasury security transfers is projected to continue its record growth trend due primarily to debt issuance by the Treasury. The volume of accounts maintained are expected to decrease 2.5 percent, consistent with recent trends and primarily driven by a reduction in joint custody accounts. The volume of Agency issues maintained is expected to remain relatively flat and claim adjustment volume is expected to remain relatively stable consistent with recent trends.</P>
                <P>The Reserve Banks' primary risks to current projections for the Fedwire Securities Service include variations in technology costs and product volume forecasts stemming from an uncertain macroeconomic outlook and market conditions.</P>
                <P>
                    G. 
                    <E T="03">FedNow Service—</E>
                </P>
                <P>
                    1. 
                    <E T="03">2024 Forecast</E>
                    —The Reserve Banks forecast that the FedNow Service will generate a total of $244.9 million in expenses in 2024.
                </P>
                <P>
                    The number of transactions processed by the FedNow Service in 2024 is modest and consistent with the Federal Reserve's expectations for a new service line. From January through August 2024, the transaction volume of the FedNow Service totaled 414,827 transactions, with the number of participants growing from 400 to just under 1,000 financial institutions during this time period. Broad adoption of the FedNow Service across an industry with more than 9,000 financial institutions will be a gradual journey, similar to other new payment services like FedACH in the 1970s and 1980s. As a result, the Board has adopted a long-term outlook in evaluating the development of the FedNow Service. The Board anticipates acceleration in volume over time as more financial institutions join the network and as the Reserve Banks release new service features on an ongoing basis.
                    <SU>38</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         For quarterly FedNow Service transaction data, see Board of Governors of the Federal Reserve System, 
                        <E T="03">FedNow Service, https://www.federalreserve.gov/paymentsystems/fednow_about.htm.</E>
                    </P>
                </FTNT>
                <P>
                    2. 
                    <E T="03">2025 Pricing</E>
                    —In 2025, the Reserve Banks project total operating expenses to be $245.5 million, which will be an increase of $0.6 million or 0.2 percent from the 2024 forecast.
                    <SU>39</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         During the time in 2023 when the FedNow Service was in production, expenses (including imputed costs) totaled $99.7 million.
                    </P>
                </FTNT>
                <P>
                    The Reserve Banks will modify the Customer Credit Transfer, Customer Credit Transfer Return, and Request for Payment fee components of the FedNow Service to exclude “on-us” transactions sent from and received at the same financial institution.
                    <SU>40</SU>
                    <FTREF/>
                     This adjustment will both align with prevailing market practices and reduce inefficient off-network transaction activity. All other components of the previous year's fee schedule, inclusive of discounts, will be maintained by the Reserve Banks in 2025.
                    <SU>41</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         The modifications will take place at the parent financial institution level, as defined in the Reserve Banks' Global Customer Directory. “On-us” transactions include those made by the same financial institution, even if the financial institution uses multiple RTNs.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         These maintained fees and discounts include the FedLine connectivity discount. The FedLine connectivity discount program consists of providing credits for upgrade fees from a FedMail or FedLine Web connection to FedLine Advantage and new FedLine Advantage connection fees for the FedNow Service to qualifying institutions. Credits will be for 12 months from FedLine Advantage billing eligibility. Customers that have received discounts throughout the 2024 program will see FedLine connectivity discounts roll off in 2025 following the completion of the 12-month term.
                    </P>
                </FTNT>
                <P>
                    <E T="03">H. FedLine Solutions</E>
                    —There are currently six FedLine Solutions channels through which customers can access the Reserve Banks' priced services: FedMail®, FedLine Exchange, FedLine Web, FedLine Advantage®, FedLine Command and FedLine Direct.
                    <SU>42</SU>
                    <FTREF/>
                     The Reserve Banks bundle these channels into 12 FedLine Solutions packages that are supplemented by a number of premium (or à la carte) access and accounting information options.
                </P>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         The Reserve Banks charge fees for the electronic connections that financial institutions use to access priced services and allocate the costs and revenues associated with this electronic access to the priced services. As a result, FedLine costs and revenue are allocated to the Reserve Banks' priced services on an expense ratio basis.
                    </P>
                </FTNT>
                <P>
                    The Reserve Banks also offer FedComplete® Packages, which are bundled offerings of FedLine connections and a fixed number of FedACH Services, Fedwire Funds Services, and Check 21-enabled transactions. In 2025, the Reserve Banks will increase the monthly fees for FedComplete 100A Plus from $900 to $1,150 and FedComplete 200A Plus from $1,425 to $1,725. The price increases reflect the rising fees and enhancements of the package's underlying services. To simplify the FedComplete Packages and create internal efficiencies, FedComplete 100A 
                    <PRTPAGE P="93596"/>
                    Premier and 200A Premier will be discontinued. Additionally, the Reserve Banks plan to discontinue the FedLine Exchange service to streamline FedLine Solution products and create internal efficiencies that simplify operating, servicing, and billing processes.
                    <SU>43</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         The FedLine Exchange service provides access to the E-Payments Routing Directory, which is also available to plus level customers across the FedLine channels. FedLine Solutions packages offer attended or unattended access to critical payment and information services. FedMail, FedLine Exchange, FedLine Web, and FedLine Advantage packages offer attended or manual access via a web-based interface.
                    </P>
                </FTNT>
                <P>
                    The Reserve Banks will increase the monthly fees for FedLine Command Plus from $1,035 to $1,185, FedLine Direct Plus from $5,500 to $5,750, and FedLine Direct Premier from $10,500 to $11,000 per month. Price changes for the FedLine Command and FedLine Direct packages are in response to enhancements for the FedNow Service and account for the price increases from the End-of-Day Financial Institution Reconcilement Date (FIRD) File and Statement of Account Spreadsheet File (SASF) offerings.
                    <SU>44</SU>
                    <FTREF/>
                     FedLine Direct had additional operational costs associated with a new network vendor and hardware upgrades that have contributed to these price increases.
                </P>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         FedLine Direct packages allow for unattended connections at multiple connection speeds to Check, FedACH, Fedwire Funds, and Fedwire Securities transactional and information services and to most accounting information services. The FedLine Command package offers a computer-to-computer, internet protocol-based interfaces that supports an unattended connection to FedACH, most accounting information services, and the FedNow Service.
                    </P>
                </FTNT>
                <P>
                    In 2025, the Reserve Banks are prepared to add API functionality for certain services and products.
                    <SU>45</SU>
                    <FTREF/>
                     The Reserve Banks are developing an initial pricing menu for priced APIs. Upon launch, each API would be assigned a core pricing scenario. Communication will be forthcoming on the timing, availability, and pricing scenarios for initial APIs.
                </P>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         APIs are a set of protocols for connecting software systems programmatically, enabling system-to-system interoperability.
                    </P>
                </FTNT>
                <P>The Reserve Banks estimate these cumulative price changes will result in a 4.8 percent average price increase for FedLine customers.</P>
                <HD SOURCE="HD1">II. Analysis of Competitive Effect</HD>
                <P>
                    All operational and legal changes considered by the Board that have a substantial effect on payment system participants are subject to the competitive impact analysis described in the Board's policy, 
                    <E T="03">The Federal Reserve in the Payments System.</E>
                     
                    <SU>46</SU>
                    <FTREF/>
                     Under this policy, the Board assesses whether changes would have a direct and material adverse effect on the ability of other service providers to compete effectively with the Federal Reserve in providing similar services due to differing legal powers or constraints or due to a dominant market position deriving from such legal differences. If any proposed changes create such an effect, the Board must further evaluate the changes to assess whether the benefits associated with the changes—such as contributions to payment system efficiency, payment system integrity, or other Board objectives—can be achieved while minimizing the adverse effect on competition.
                </P>
                <FTNT>
                    <P>
                        <SU>46</SU>
                         
                        <E T="03">See</E>
                         Board of Governors of the Federal Reserve System, 
                        <E T="03">Policies: The Federal Reserve in the Payments System, https://www.federalreserve.gov/paymentsystems/pfs_frpaysys.htm.</E>
                    </P>
                </FTNT>
                <P>The Board has conducted this analysis and concluded that the 2025 fees, fee structures, and changes in service will not have a direct and material adverse effect on the ability of other service providers to compete effectively with the Reserve Banks in providing similar services. When conducting the competitive effect analysis for the FedNow Service, the Board assessed whether its pricing strategy as a new service, including discounts, would have a material, adverse effect on the ability of other service providers to compete effectively with the Reserve Banks due to differing legal powers or a dominate market position as a result of such differing legal powers. The Board concluded that the pricing strategy, including discounts, followed general market practice for new services and could similarly be implemented by private sector providers unrelated to any differing legal powers. Therefore, the Reserve Banks' pricing does not have a material adverse effect on the ability of other service providers to compete effectively with the Reserve Banks in providing similar services.</P>
                <P>The Reserve Banks expect to continue to achieve aggregate long-run cost recovery across all mature priced services.</P>
                <HD SOURCE="HD1">III. 2025 Fee Schedules</HD>
                <GPOTABLE COLS="2" OPTS="L2,nj,p7,7/8,i1" CDEF="s150,xs84">
                    <TTITLE>FedACH Services 2025 Fee Schedule</TTITLE>
                    <TDESC>
                        [Effective January 1, 2025. 
                        <E T="02">Bold indicates changes from 2024 prices</E>
                        ]
                    </TDESC>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">Fee</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">
                            <E T="02">FedACH minimum monthly fee:</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">Originating depository financial institution (ODFI)</E>
                             
                            <SU>47</SU>
                        </ENT>
                        <ENT>
                            <E T="02">$55.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">Receiving depository financial institution (RDFI)</E>
                             
                            <SU>48</SU>
                        </ENT>
                        <ENT>
                            <E T="02">$45.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Origination (per item or record):</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Forward or return items</ENT>
                        <ENT>$0.0035.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            SameDay Service—forward item 
                            <SU>49</SU>
                        </ENT>
                        <ENT>$0.0010 surcharge.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Addenda record</ENT>
                        <ENT>$0.0015.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            FedLine Web-originated returns and notification of change (NOC) 
                            <SU>50</SU>
                        </ENT>
                        <ENT>$0.50.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Facsimile Exception Return/NOC 
                            <SU>51</SU>
                        </ENT>
                        <ENT>$45.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">SameDay Exception Return</ENT>
                        <ENT>$45.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Automated NOC</ENT>
                        <ENT>$0.20.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Volume discounts (based on monthly billed origination volume) 
                            <SU>52</SU>
                             per item when origination volume is
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">750,001 to 1,500,000 items per month discount</ENT>
                        <ENT>$0.0008.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">more than 1,500,000 items per month discount</ENT>
                        <ENT>$0.0010.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Volume discounts (based on monthly billed receipt volume) 
                            <SU>53</SU>
                             per item when receipt volume is
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">10,000,001 to 15,000,000 items per month discount</ENT>
                        <ENT>$0.0002.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">more than 15,000,000 items per month discount</ENT>
                        <ENT>$0.0003.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Receipt (per item or record):</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Forward Item</ENT>
                        <ENT>$0.0035.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Return Item</ENT>
                        <ENT>$0.0075.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Addenda record</ENT>
                        <ENT>$0.0015.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">Volume discounts:</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">
                            Non-Premium Receivers 
                            <SU>54</SU>
                             per item when volume is
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            750,001 to 12,500,000 items per month 
                            <SU>55</SU>
                        </ENT>
                        <ENT>$0.0017 discount.</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="93597"/>
                        <ENT I="07">
                            more than 12,500,000 items per month 
                            <SU>56</SU>
                        </ENT>
                        <ENT>$0.0019 discount.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">
                            Premium Receivers, Level One 
                            <SU>57</SU>
                             per item when volume is
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            750,001 to 1,500,000 items per month 
                            <SU>58</SU>
                        </ENT>
                        <ENT>$0.0017 discount.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            1,500,001 to 2,500,000 items per month 
                            <SU>59</SU>
                        </ENT>
                        <ENT>$0.0017 discount.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            2,500,001 to 12,500,000 items per month 
                            <SU>53</SU>
                        </ENT>
                        <ENT>$0.0018 discount.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            12,500,001 to 30,000,000 items per month 
                            <SU>53</SU>
                        </ENT>
                        <ENT>$0.0020 discount.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            more than 30,000,000 items per month 
                            <SU>53</SU>
                        </ENT>
                        <ENT>$0.0023 discount.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">
                            Premium Receivers, Level Two 
                            <SU>60</SU>
                             per item when volume is
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            750,001 to 1,500,000 items per month 
                            <SU>61</SU>
                        </ENT>
                        <ENT>$0.0017 discount.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            1,500,001 to 2,500,000 items per month 
                            <SU>62</SU>
                        </ENT>
                        <ENT>$0.0017 discount.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            2,500,001 to 12,500,000 items per month 
                            <SU>56</SU>
                        </ENT>
                        <ENT>$0.0019 discount.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            12,500,001 to 30,000,000 items per month 
                            <SU>56</SU>
                        </ENT>
                        <ENT>$0.0021 discount.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            more than 30,000,000 items per month 
                            <SU>56</SU>
                        </ENT>
                        <ENT>$0.0024 discount.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            FedACH Risk Management Services: 
                            <SU>63</SU>
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">Monthly Package Fee (a single fee based on total number of criteria sets):</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">For up to 5 criteria sets</ENT>
                        <ENT>$45.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">For 6 through 11 criteria sets</ENT>
                        <ENT>$85.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">For 12 through 23 criteria sets</ENT>
                        <ENT>$150.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">For 24 through 47 criteria sets</ENT>
                        <ENT>$180.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">For 48 through 95 criteria sets</ENT>
                        <ENT>$300.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">For 96 through 191 criteria sets</ENT>
                        <ENT>$510.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">For 192 through 383 criteria sets</ENT>
                        <ENT>$810.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">For 384 through 584 criteria sets</ENT>
                        <ENT>$1,025.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">For more than 584 criteria sets</ENT>
                        <ENT>$1,325.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">Batch/Item Monitoring (based on total monthly volume):</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">For 1 through 100,000 batches (per batch)</ENT>
                        <ENT>$0.007.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">For more than 100,000 batches (per batch)</ENT>
                        <ENT>$0.0035.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            FedPayments Insights Service: 
                            <SU>64</SU>
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">Monthly Fee (a single fee based on commercial receipt volume):</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">0-50,000 items per month</ENT>
                        <ENT>$75.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">50,001-100,000 items per month</ENT>
                        <ENT>$120.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">100,001-500,000 items per month</ENT>
                        <ENT>$180.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">500,001-1,000,000 items per month</ENT>
                        <ENT>$260.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">1,000,001-5,000,000 items per month</ENT>
                        <ENT>$340.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">5,000,001-10,000,000 items per month</ENT>
                        <ENT>$450.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">10,000,001-25,000,000 items per month</ENT>
                        <ENT>$550.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">25,000,001-60,000,000 items per month</ENT>
                        <ENT>$625.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Over 60,000,000 items per month</ENT>
                        <ENT>$700.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Monthly FedPayments Reporter Service:</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">FedPayments Reporter Service monthly package includes the following reports:</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Received Entries Detail—Customer and Depository Financial Institution</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Return Reason Report—Customer and Depository Financial Institution</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Originated Entries Detail—Customer and Depository Financial Institution</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Volume Summary by SEC Code—Customer</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Customer Transaction Activity</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Death Notification</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH International (IAT)</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Notification of Change</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Payment Data Information File</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Remittance Advice Detail</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Remittance Advice Summary</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Return Item Report and File</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Return Ratio</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Social Security Beneficiary</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Originator Setup</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">ACH Report Delivery via FedLine Solution</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">
                            On Demand Report Surcharge 
                            <SU>65</SU>
                        </ENT>
                        <ENT>$1.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            <E T="02">Monthly Package Fee (counts reflect reports generated as well as delivered via a FedLine Solution):</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For up to 50 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$50.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For 51 through 150 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$72.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For 151 through 500 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$133.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For 501 through 1,000 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$245.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For 1,001 through 1,500 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$355.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For 1,501 through 2,500 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$555.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For 2,501 through 3,500 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$775.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For 3,501 through 4,500 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$990.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For 4,501 through 5,500 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$1,200.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For 5,501 through 7,000 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$1,460.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For 7,001 through 8,500 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$1,700.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For 8,501 through 10,000 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$1,930.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">For more than 10,000 reports</E>
                        </ENT>
                        <ENT>
                            <E T="02">$2,100.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Premier reports (per report generated): 
                            <SU>66</SU>
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05" O="xl">ACH Volume Summary by SEC Code Report—Depository Financial Institution:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">For 1 through 5 reports</ENT>
                        <ENT>$10.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">For 6 through 10 reports</ENT>
                        <ENT>$6.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">For 11 or more reports</ENT>
                        <ENT>$1.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">On Demand Surcharge</ENT>
                        <ENT>$1.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05" O="xl">ACH Routing Number Activity Report:</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="07">For 1 through 5 reports</ENT>
                        <ENT>$10.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">For 6 through 10 reports</ENT>
                        <ENT>$6.00.</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="93598"/>
                        <ENT I="07">For 11 or more reports</ENT>
                        <ENT>$1.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">On Demand Surcharge</ENT>
                        <ENT>$1.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05" O="xl">ACH Originated Batch Report (monthly):</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="07">For 1 through 5 reports</ENT>
                        <ENT>$10.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">For 6 through 10 reports</ENT>
                        <ENT>$6.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">For 11 or more reports</ENT>
                        <ENT>$1.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">On Demand Surcharge</ENT>
                        <ENT>$1.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05" O="xl">ACH Originated Batch Report (daily):</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">Scheduled Report</ENT>
                        <ENT>$0.65.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">On Demand Surcharge</ENT>
                        <ENT>$1.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">On-us inclusion:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Participation (monthly fee per RTN)</ENT>
                        <ENT>$10.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Per-item</ENT>
                        <ENT>$0.0030.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Per-addenda</ENT>
                        <ENT>$0.0015.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Report delivery via encrypted email (per email)</ENT>
                        <ENT>$0.20.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Other Fees and Discounts:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">Monthly fee (per RTN):</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">
                            <E T="02">FedACH Participation Fee</E>
                             
                            <SU>67</SU>
                        </ENT>
                        <ENT>
                            <E T="02">$80.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">
                            Same Day Service Origination Participation Fee 
                            <SU>68</SU>
                        </ENT>
                        <ENT>$10.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            FedACH Settlement Fee 
                            <SU>69</SU>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Premium Receivers, Level One and Level Two</ENT>
                        <ENT>$60.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Non-Premium Receivers when volume is 1,500,000 items or less per month, Tier 2</ENT>
                        <ENT>$110.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Non-Premium Receivers when volume is more than 1,500,000 items per month, Tier 3</ENT>
                        <ENT>$250.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">FedACH Information File Extract Fee</ENT>
                        <ENT>$180.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">IAT Output File Sort Fee</ENT>
                        <ENT>$150.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Fixed Participation Fee—Automated NOCs 
                            <SU>70</SU>
                        </ENT>
                        <ENT>$5.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Non-Electronic Input/Output fee: 
                            <SU>71</SU>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">CD/DVD (CD or DVD)</ENT>
                        <ENT>$50.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Paper (file or report)</ENT>
                        <ENT>$50.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Fees and Credits Established by Nacha: 
                            <SU>72</SU>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Nacha Same-Day Entry fee (per item)</ENT>
                        <ENT>$0.052.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Nacha Same-Day Entry credit (per item)</ENT>
                        <ENT>$0.052 (credit).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Nacha Unauthorized Entry fee (per item)</ENT>
                        <ENT>$4.50.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Nacha Unauthorized Entry credit (per item)</ENT>
                        <ENT>$4.50 (credit).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Nacha Admin Network fee (monthly fee per RTN)</ENT>
                        <ENT>$30.50.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Nacha Admin Network fee (per entry)</ENT>
                        <ENT>$0.000185.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            FedGlobal® ACH Payments: 
                            <SU>73</SU>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Fixed Monthly Fee (per RTN): 
                            <SU>74</SU>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Monthly origination volume more than 500 items</ENT>
                        <ENT>$185.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Monthly origination volume between 161 and 500 items</ENT>
                        <ENT>$60.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Monthly origination volume less than 161 items</ENT>
                        <ENT>$20.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Per-item Origination Fee for Monthly Volume more than 500 Items (surcharge): 
                            <SU>75</SU>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Mexico service</ENT>
                        <ENT>$0.55.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Panama service</ENT>
                        <ENT>$0.60.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Per-item Origination Fee for Monthly Volume between 161 and 500 items (surcharge): 
                            <SU>79</SU>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Mexico service</ENT>
                        <ENT>$0.80.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Panama service</ENT>
                        <ENT>$0.85.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Per-item Origination Fee for Monthly Volume less than 161 items (surcharge): 
                            <SU>79</SU>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Mexico service</ENT>
                        <ENT>$1.05.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Panama service</ENT>
                        <ENT>$1.10.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">Other FedGlobal ACH Payments Fees:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05" O="xl">Mexico service:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            Return received from Mexico 
                            <SU>76</SU>
                        </ENT>
                        <ENT>$0.91 (surcharge).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            Item trace 
                            <SU>77</SU>
                        </ENT>
                        <ENT>$13.50.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            Foreign currency to foreign currency (F3X) item originated to Mexico 
                            <SU>79</SU>
                        </ENT>
                        <ENT>$0.67 (surcharge).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05" O="xl">Panama service:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            Return received from Panama 
                            <SU>71</SU>
                        </ENT>
                        <ENT>$1.00 (surcharge).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">
                            Item trace 
                            <SU>72</SU>
                        </ENT>
                        <ENT>$7.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="07">NOC</ENT>
                        <ENT>$0.72.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Exception Resolution Service:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Monthly Fees (applies to cases only at the parent RTN): 
                            <SU>78</SU>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Up to 5 cases</ENT>
                        <ENT>$20.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">6-25 cases</ENT>
                        <ENT>$40.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">26-50 cases</ENT>
                        <ENT>$60.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">51-100 cases</ENT>
                        <ENT>$100.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">101-1,000 cases</ENT>
                        <ENT>$250.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">1,001-5,000 cases</ENT>
                        <ENT>$400.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">5,001 cases and above</ENT>
                        <ENT>$500.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Offline Service Participant—Case Fees: 
                            <SU>79</SU>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Case Open Fee</ENT>
                        <ENT>$5.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Case Response Fee</ENT>
                        <ENT>$5.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            FedACH Receipt Discount Program Introduced in 2024: 
                            <SU>80</SU>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">Customers with more than 30 million FedACH receipt items per month:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Per-item discount on all forward receipt items received through FedACH for the full five-year length of the agreement</ENT>
                        <ENT>$0.0002.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Percentage discount on the FedACH FedPayments Reporter Service for two years at any point during participation in the program</ENT>
                        <ENT>50 percent.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Percentage discount on the FedACH Exception Resolution Service for two years at any point during their participation in the program</ENT>
                        <ENT>100 percent.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Percentage discount on the FedACH FedPayments® Insights Service for two years at any point during their participation in the program</ENT>
                        <ENT>100 percent.</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="93599"/>
                        <ENT I="03" O="xl">Customers with between 5 and 30 million FedACH receipt items per month:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Per-item discount on all forward receipt items received through FedACH for the full 5-year length of the agreement</ENT>
                        <ENT>$0.0001.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Percentage discount on the FedACH FedPayments Reporter Service for two years at any point during their participation in the program</ENT>
                        <ENT>25 percent.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Percentage discount on the FedACH Exception Resolution Service for two years at any point during their participation in the program</ENT>
                        <ENT>50 percent.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Percentage discount on the FedACH FedPayments Insights Service for two years at any point during their participation in the program</ENT>
                        <ENT>50 percent.</ENT>
                    </ROW>
                </GPOTABLE>
                <GPOTABLE COLS="2" OPTS="L2,nj,p7,7/8,i1" CDEF="s150,12">
                    <TTITLE>Fedwire Funds Service and National Settlement Service 2025 Fee Schedules</TTITLE>
                    <TDESC>
                        [Effective January 1, 2025. 
                        <E T="02">Bold indicates changes from 2024 prices</E>
                        .]
                    </TDESC>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">Fee</CHED>
                    </BOXHD>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Fedwire Funds Service</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">
                            <E T="02">Monthly Participation Fee</E>
                        </ENT>
                        <ENT>
                            <E T="02">$120.00</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            <E T="02">Basic volume-based pre-incentive transfer fee (originations and receipts)—per transfer for</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">Tier 1: The first 14,000 transfers per month</E>
                        </ENT>
                        <ENT>
                            <E T="02">0.970</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">Tier 2: Additional transfers up to 90,000 per month</E>
                        </ENT>
                        <ENT>
                            <E T="02">0.300</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">Tier 3: Every transfer over 90,000 per month</E>
                        </ENT>
                        <ENT>
                            <E T="02">0.195</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            <E T="02">Monthly Fixed Fee</E>
                            :
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">Tier 2 Monthly Fixed Fee</E>
                             
                            <SU>81</SU>
                        </ENT>
                        <ENT>
                            <E T="02">250.00</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">Tier 3 Monthly Fixed Fee</E>
                             
                            <SU>82</SU>
                        </ENT>
                        <ENT>
                            <E T="02">500.00</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            <E T="02">Volume-based transfer fee with the incentive discount (originations and receipts)—per eligible transfer for</E>
                             
                            <SU>83</SU>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">Tier 1: The first 14,000 transfers per month</E>
                        </ENT>
                        <ENT>
                            <E T="02">0.194</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">Tier 2: Additional transfers 14,001 to 90,000 per month</E>
                        </ENT>
                        <ENT>
                            <E T="02">0.060</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">Tier 3: Every transfer over 90,000 per month</E>
                        </ENT>
                        <ENT>
                            <E T="02">0.039</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Surcharge for Offline Transfers (Originations and Receipt) 
                            <SU>84</SU>
                        </ENT>
                        <ENT>75.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Surcharge for End-of-Day Transfer Originations 
                            <SU>85</SU>
                        </ENT>
                        <ENT>0.26</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="02">Monthly FedPayments Manager Import/Export fee</E>
                             
                            <SU>86</SU>
                        </ENT>
                        <ENT>
                            <E T="02">65.00</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Surcharge on transfers &gt;$10 million Origination and Receipt</ENT>
                        <ENT>0.14</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Surcharge on transfers &gt;$100 million Origination and Receipt</ENT>
                        <ENT>0.36</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Surcharge for Payment Notification:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Origination Surcharge 
                            <SU>87</SU>
                        </ENT>
                        <ENT>0.01</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Receipt Volume 
                            <SU>88</SU>
                        </ENT>
                        <ENT>N/A</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Delivery of Reports—Hard Copy Reports to On-Line Customers</ENT>
                        <ENT>50.00</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">
                            Special Settlement Arrangements (charge per settlement day) 
                            <SU>89</SU>
                        </ENT>
                        <ENT>150.00</ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">National Settlement Service</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="22">Basic:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">Settlement Entry Fee</E>
                        </ENT>
                        <ENT>
                            <E T="02">1.95</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="02">Settlement File Fee</E>
                        </ENT>
                        <ENT>
                            <E T="02">40.00</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Surcharge for Offline File Origination 
                            <SU>90</SU>
                        </ENT>
                        <ENT>45.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Minimum Monthly Fee 
                            <SU>91</SU>
                        </ENT>
                        <ENT>60.00</ENT>
                    </ROW>
                </GPOTABLE>
                <GPOTABLE COLS="2" OPTS="L2,nj,p7,7/8,i1" CDEF="s150,12">
                    <TTITLE>Fedwire Securities Service 2025 Fee Schedule</TTITLE>
                    <TDESC>
                        [Effective January 1, 2025. 
                        <E T="02">Bold indicates changes from 2024 prices.</E>
                        ]
                    </TDESC>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">Fee</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">
                            Basic Transfer Fee: 
                            <E T="0731">92 93</E>
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Agency Securities: Transfer or reversal originated or received</ENT>
                        <ENT>0.61</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Treasury Securities: Transfer or reversal originated or received</ENT>
                        <ENT>0.61</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            Surcharge: 
                            <SU>94</SU>
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Agency Securities: Offline origination &amp; receipt surcharge</ENT>
                        <ENT>80.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Treasury Securities: Offline origination &amp; receipt surcharge</ENT>
                        <ENT>80.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            Monthly Maintenance Fees: 
                            <SU>95</SU>
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Agency Securities: Account maintenance (per account) 
                            <SU>96</SU>
                        </ENT>
                        <ENT>57.50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Agency Securities: Issue maintenance (per issue/per account) 
                            <SU>97</SU>
                        </ENT>
                        <ENT>0.61</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Treasury Securities: Account maintenance (per account) 
                            <SU>98</SU>
                        </ENT>
                        <ENT>None</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Treasury Securities: Issue maintenance (per issue/per account) 
                            <SU>99</SU>
                        </ENT>
                        <ENT>None</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            ACAP Fees: 
                            <E T="51">100 101</E>
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Claims Adjustment Fee </ENT>
                        <ENT>$1.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Tracking Indicators Fee</ENT>
                        <ENT>0.10</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Position Maintenance Fee (per position maintained/per business day) 
                            <E T="0731">102 103</E>
                        </ENT>
                        <ENT>0.03</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            GNMA Serial Note Stripping or Reconstitution Fee 
                            <SU>104</SU>
                        </ENT>
                        <ENT>9.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Joint Custody Origination Surcharge 
                            <E T="0731">105 106</E>
                        </ENT>
                        <ENT>46.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Delivery of Reports—Hard Copy Reports to On-Line Customers 
                            <SU>107</SU>
                        </ENT>
                        <ENT>50.00</ENT>
                    </ROW>
                </GPOTABLE>
                <PRTPAGE P="93600"/>
                <GPOTABLE COLS="2" OPTS="L2,nj,p7,7/8,i1" CDEF="s150,r50">
                    <TTITLE>FedNow Service 2025 Fee Schedule</TTITLE>
                    <TDESC>
                        [Effective January 1, 2025. 
                        <E T="02">Bold indicates changes from 2024 prices.</E>
                        ]
                    </TDESC>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">Fee</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Customer Credit Transfer (per item) PACS.008 Origination</ENT>
                        <ENT>$0.045.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="02">PACS.008 Origination—On-Us</E>
                        </ENT>
                        <ENT>
                            <E T="02">$0.000.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Customer Credit Transfer Returns (per item) PACS.004 Origination</ENT>
                        <ENT>$0.045.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="02">PACS.004 Origination—On-Us</E>
                        </ENT>
                        <ENT>
                            <E T="02">$0.000.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Liquidity Management Transfer (LMT) (per-item) PACS.009 Origination</ENT>
                        <ENT>$1.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Request for Payment (RFP) (per-item) PAIN.013</ENT>
                        <ENT>$0.01.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="02">PAIN.013—On-Us</E>
                        </ENT>
                        <ENT>
                            <E T="02">$0.000.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">PACS.008 Origination Discount</ENT>
                        <ENT>−$0.045 per item for up to 2,500 customer credit transfers per month (in 2025).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Participation Fee—General (per month)</ENT>
                        <ENT>$25.00, discounted to $0.00 in 2025.</ENT>
                    </ROW>
                </GPOTABLE>
                <GPOTABLE COLS="2" OPTS="L2,nj,p7,7/8,i1" CDEF="s150,xs84">
                    <TTITLE>FedLine 2025 Fee Schedule</TTITLE>
                    <TDESC>
                        [Effective January 1, 2025. 
                        <E T="02">Bold indicates changes from 2024 prices.</E>
                        ]
                    </TDESC>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1">Fee</CHED>
                    </BOXHD>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            FedComplete Packages (monthly) 
                            <E T="0731">108 109</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">
                            <E T="02">FedComplete 100A Plus</E>
                             
                            <SU>110</SU>
                        </ENT>
                        <ENT>
                            <E T="02">$1,150.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="02">FedComplete 200A Plus</E>
                        </ENT>
                        <ENT>
                            <E T="02">$1,725.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            FedComplete Excess Volume and Receipt Surcharge: 
                            <SU>111</SU>
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            FedForward® 
                            <SU>112</SU>
                        </ENT>
                        <ENT>$0.03700/item.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">FedReturn®</ENT>
                        <ENT>$0.82000/item.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">FedReceipt</ENT>
                        <ENT>$0.00005/item.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Fedwire Funds Origination</ENT>
                        <ENT>$0.97000/item.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Fedwire Funds Receipt</ENT>
                        <ENT>$0.09700/item.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">FedACH Origination</ENT>
                        <ENT>$0.00350/item.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">FedACH Receipt</ENT>
                        <ENT>$0.00035/item.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">FedComplete credit adjustment</ENT>
                        <ENT>various.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">FedComplete debit adjustment</ENT>
                        <ENT>various.</ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">FedLine Solutions (monthly)</ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">
                            FedMail 
                            <SU>113</SU>
                        </ENT>
                        <ENT>$100.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            FedLine Web 
                            <SU>114</SU>
                        </ENT>
                        <ENT>$110.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            FedLine Web Plus 
                            <SU>106</SU>
                        </ENT>
                        <ENT>$160.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            FedLine Web Premier 
                            <SU>106</SU>
                        </ENT>
                        <ENT>$200.00</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Includes:</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Services included in the FedLine Web Plus package</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Check File Automation</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            FedLine Advantage 
                            <E T="0731">106 115</E>
                        </ENT>
                        <ENT>$415.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            FedLine Advantage Plus 
                            <E T="0731">106 107</E>
                        </ENT>
                        <ENT>$460.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            FedLine Advantage Premier 
                            <E T="0731">106 107</E>
                        </ENT>
                        <ENT>$570.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Includes:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">FedLine Advantage Plus package</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Two VPN devices</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Fedwire Funds FedPayments Manager Import/Export (more than 250 Fedwire transactions or more than one routing number in a given month)</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">FedTransaction Analyzer (more than 250 Fedwire transactions or more than one routing number per month)</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="02">FedLine Command Plus</E>
                             
                        </ENT>
                        <ENT>
                            <E T="02">$1,185.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="02">FedLine Direct Plus</E>
                             
                            <SU>116</SU>
                        </ENT>
                        <ENT>
                            <E T="02">$5,750.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="02">FedLine Direct Premier</E>
                             
                            <SU>108</SU>
                        </ENT>
                        <ENT>
                            <E T="02">$11,000.00.</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Includes:</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Services included in the FedLine Direct Plus package</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">Two 2 Mbps dedicated WAN Connections</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">One Network Diversity</ENT>
                        <ENT/>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="03">Two VPN devices</ENT>
                        <ENT/>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            A la carte options (monthly) 
                            <SU>117</SU>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="22">Electronic Access:</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">FedMail—Pack of 5</ENT>
                        <ENT>$25.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">FedLine Subscribers—Pack of 5</ENT>
                        <ENT>$100.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Additional VPNs 
                            <SU>118</SU>
                        </ENT>
                        <ENT>$100.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Additional 2 Mbps WAN connection 
                            <SU>108</SU>
                        </ENT>
                        <ENT>$3,000.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">WAN Connection Upgrade:</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">
                            10 Mbps 
                            <SU>119</SU>
                        </ENT>
                        <ENT>$1,700.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">
                            30 Mbps 
                            <SU>111</SU>
                        </ENT>
                        <ENT>$3,000.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">
                            50 Mbps 
                            <SU>120</SU>
                        </ENT>
                        <ENT>$4,000.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">
                            100 Mbps 
                            <SU>120</SU>
                        </ENT>
                        <ENT>$7,000.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">
                            200 Mbps 
                            <SU>120</SU>
                        </ENT>
                        <ENT>$11,000.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">FedLine International Setup (one-time fee)</ENT>
                        <ENT>$5,000.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            FedLine Custom Implementation Fee (one-time fee) 
                            <SU>120</SU>
                        </ENT>
                        <ENT>$2,500-$5,000.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Network Diversity</ENT>
                        <ENT>$2,500.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            FedMail Email (for customers with FedLine Web and above) 
                            <SU>121</SU>
                        </ENT>
                        <ENT>$100.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">VPN Device Modification (one-time fee)</ENT>
                        <ENT>$200.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">VPN Device Missed Activation Appointment (one-time fee)</ENT>
                        <ENT>$175.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">VPN Device Expedited Hardware Surcharge (one-time fee)</ENT>
                        <ENT>$100.00.</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="93601"/>
                        <ENT I="03">VPN Device Replacement or Move (one-time fee)</ENT>
                        <ENT>$300.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            E-Payments Automated Download Codes (Add'l Codes-Pack of 5) 
                            <SU>122</SU>
                        </ENT>
                        <ENT>$75.00/month.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            E-Payments Automated Download Codes (Add'l Codes-Pack of 20) 
                            <SU>114</SU>
                        </ENT>
                        <ENT>$150.00/month.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            E-Payments Automated Download Codes (Add'l Codes-Pack of 50) 
                            <SU>123</SU>
                        </ENT>
                        <ENT>$300.00/month.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            E-Payments Automated Download Codes (Add'l Codes-Pack of 100) 
                            <SU>123</SU>
                        </ENT>
                        <ENT>$500.00/month.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            E-Payments Automated Download Codes (Add'l Codes-Pack of 250) 
                            <SU>123</SU>
                        </ENT>
                        <ENT>$1,000.00/month.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            E-Payments Automated Download Codes (Add'l Codes- &gt;250) 
                            <SU>123</SU>
                        </ENT>
                        <ENT>$2,000.00/month.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">
                            Daily Statement of Account Activity and Monthly Statement of Service Charges (monthly): 
                            <E T="0731">123 124</E>
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03">End-of-Day Financial Institution Reconcilement Data (FIRD) File</ENT>
                        <ENT>$200.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Statement of Account Spreadsheet File (SASF)</ENT>
                        <ENT>$200.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Cash Management Service (CMS) Plus and Intra-day Service (monthly):</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Cash Management System (CMS) Plus—Own report—up to 12 files with: 
                            <SU>125</SU>
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">no OSRTN, respondent/sub-account activity</ENT>
                        <ENT>$75.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Up to nine OSRTNs, respondents and/or sub-accounts</ENT>
                        <ENT>$150.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">10-50 OSRTNs, respondents and/or sub-accounts</ENT>
                        <ENT>$300.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">51-100 OSRTNs, respondents and/or sub-accounts</ENT>
                        <ENT>$600.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">101-500 OSRTNs, respondents and/or sub-accounts</ENT>
                        <ENT>$900.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">&gt;500 OSRTNs, respondents and/or sub-accounts</ENT>
                        <ENT>$1,200.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            Intra-day Download Search Results in Spreadsheet Format (with AMI) 
                            <SU>126</SU>
                        </ENT>
                        <ENT>$200.00.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Other:</ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="03" O="xl">
                            Replacement Copies: 
                            <SU>127</SU>
                        </ENT>
                        <ENT/>
                    </ROW>
                    <ROW>
                        <ENT I="05">Daily Statement of Account</ENT>
                        <ENT>$10.00/copy</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="05">Monthly Statement of Service Charges</ENT>
                        <ENT>$10.00/copy</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Vendor Pass-Through Fee</ENT>
                        <ENT>various.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Electronic Access Credit Adjustment</ENT>
                        <ENT>various.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Electronic Access Debit Adjustment</ENT>
                        <ENT>various.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                     
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>47</SU>
                         Any ODFI incurring less than $55 for the following fees will be charged a variable amount to reach the minimum: Forward value and non-value item origination fees, and FedGlobal ACH origination surcharges.
                    </P>
                    <P>
                        <SU>48</SU>
                         Any RDFI not originating forward value and non-value items and incurring less than $45 in receipt fees will be charged a variable amount to reach the minimum. Any RDFI that originates forward value and non-value items incurring less than $55 in forward value and nonvalue item origination fees will only be charged a variable amount to reach the minimum monthly origination fee.
                    </P>
                    <P>
                        <SU>49</SU>
                         This surcharge is assessed on all forward items that qualify for same-day processing and settlement and is incremental to the standard origination item fee.
                    </P>
                    <P>
                        <SU>50</SU>
                         The fee includes the item and addenda fees in addition to the conversion fee.
                    </P>
                    <P>
                        <SU>51</SU>
                         The fee includes the item and addenda fees in addition to the conversion fee. Reserve Banks also assess a $45 fee for every government paper return/NOC they process.
                    </P>
                    <P>
                        <SU>52</SU>
                         Origination volumes at these levels qualify for a waterfall discount that includes all FedACH origination items.
                    </P>
                    <P>
                        <SU>53</SU>
                         Origination discounts based on monthly billed receipt volume apply only to those items received by FedACH receiving points and are available only to Premium Receivers.
                    </P>
                    <P>
                        <SU>54</SU>
                         RDFIs receiving through FedACH less than 90 percent of their FedACH-originated items.
                    </P>
                    <P>
                        <SU>55</SU>
                         This per-item discount is a reduction to the standard receipt fees listed in this fee schedule.
                    </P>
                    <P>
                        <SU>56</SU>
                         Receipt volumes at these levels qualify for a waterfall discount that includes all FedACH receipt items.
                    </P>
                    <P>
                        <SU>57</SU>
                         RDFIs receiving through FedACH at least 90 percent of their FedACH-originated items, but less than 90 percent of all of their ACH items originated through any operator.
                    </P>
                    <P>
                        <SU>58</SU>
                         This per-item discount is a reduction to the standard receipt fees listed in this fee schedule.
                    </P>
                    <P>
                        <SU>59</SU>
                         Receipt volumes at these levels qualify for a waterfall discount which includes all FedACH receipt items.
                    </P>
                    <P>
                        <SU>60</SU>
                         RDFIs receiving through FedACH at least 90 percent of all of their ACH items originated through any operator.
                    </P>
                    <P>
                        <SU>61</SU>
                         This per-item discount is a reduction to the standard receipt fees listed in this fee schedule.
                    </P>
                    <P>
                        <SU>62</SU>
                         Receipt volumes at these levels qualify for a waterfall discount which includes all FedACH receipt items.
                    </P>
                    <P>
                        <SU>63</SU>
                         Criteria may be set for both the Origination Monitoring Service and the RDFI Alert Service. Subscribers with no criteria set up will be assessed the $45 monthly package fee.
                    </P>
                    <P>
                        <SU>64</SU>
                         Monthly commercial receipt volume is calculated based on combined volume of subscribed RTNs in an account family.
                    </P>
                    <P>
                        <SU>65</SU>
                         Premier reports generated on demand are subject to the package/tiered fees plus a surcharge.
                    </P>
                    <P>
                        <SU>66</SU>
                         Premier reports generated on demand are subject to the package/tiered fees plus a surcharge.
                    </P>
                    <P>
                        <SU>67</SU>
                         The fee applies to RTNs that have received or originated FedACH transactions during a month. Institutions that receive only U.S. government transactions or that elect to use a private-sector operator exclusively are not assessed the fee.
                    </P>
                    <P>
                        <SU>68</SU>
                         This surcharge is assessed to any RTN that originates at least one item meeting the criteria for same-day processing and settlement in a given month.
                    </P>
                    <P>
                        <SU>69</SU>
                         The fee is applied to any RTN with activity during a month, including RTNs of institutions that elect to use a private-sector operator exclusively but also have items routed to or from customers that access the ACH network through FedACH. This fee does not apply to RTNs that use the Reserve Banks for only U.S. government transactions.
                    </P>
                    <P>
                        <SU>70</SU>
                         Fee will be assessed only when automated NOCs are generated.
                    </P>
                    <P>
                        <SU>71</SU>
                         Limited services are offered in contingency situations.
                    </P>
                    <P>
                        <SU>72</SU>
                         The fees and credits listed are collected from the ODFI and credited to Nacha (admin network) or to the RDFI (same-day entry and unauthorized entry) in accordance with the ACH Rules.
                    </P>
                    <P>
                        <SU>73</SU>
                         The international fees and surcharges vary from country to country as these are negotiated with each international gateway operator.
                    </P>
                    <P>
                        <SU>74</SU>
                         A single monthly fee based on total FedGlobal ACH Payments origination volume.
                    </P>
                    <P>
                        <SU>75</SU>
                         This per-item surcharge is in addition to the standard domestic origination fees listed in this fee schedule.
                    </P>
                    <P>
                        <SU>76</SU>
                         This per-item surcharge is in addition to the standard domestic receipt fees listed in this fee schedule.
                    </P>
                    <P>
                        <SU>77</SU>
                         U.S. ODFIs are responsible for any investigation fees should they be assessed by foreign RDFIs or downstream payment participants.
                    </P>
                    <P>
                        <SU>78</SU>
                         The monthly fee is rolled up to the parent DI level, such that a DI that opts into the FedACH Exception Resolution Service under two separate RTNs would pay a single monthly fee based on the total number of cases opened for their two RTNs combined.
                    </P>
                    <P>
                        <SU>79</SU>
                         A financial institution may enroll in the Service as an Offline Service Participant by designating the Reserve Bank to access and use the functionality of the application on behalf of the Offline Participant.
                    </P>
                    <P>
                        <SU>80</SU>
                         Federal Reserve Financial Services offers a five-year discount program to financial institutions that receive at least 5 million items per month through FedACH and meet the qualifications for Premium Receiver Level One or Level Two status. View code details and text on the FedACH Receipt Discount Program page.
                    </P>
                    <P>
                        <SU>81</SU>
                         This fee applies at the parent level to any bank which has at least 1 unit of volume in the Tier 2 Pre-Incentive Discount range and no volume in the Tier 3 Pre-Incentive Discount range.
                    </P>
                    <P>
                        <SU>82</SU>
                         This fee applies at the parent level to any bank which has at least 1 unit of volume in the Tier 3 Pre-Inventive Discount range.
                    </P>
                    <P>
                        <SU>83</SU>
                         The incentive discounts apply to the volume that exceeds 60 percent of a customer's historic benchmark volume. Historic benchmark volume is based on a customer's average daily activity over the previous five calendar years. If a customer has fewer than five full calendar years of previous activity, its historic benchmark volume is based on its daily activity for as many full calendar years of data as are available. If a customer has less than one year of past activity, then the customer qualifies automatically for incentive discounts for the year. The applicable incentive discounts are as follows: $0.752 for transfers up to 14,000; $0.232 for transfers 14,001 to 90,000; and $0.152 for transfers over 90,000.
                        <PRTPAGE/>
                    </P>
                    <P>
                        <SU>84</SU>
                         The offline service, which was originally scheduled to be discontinued as of December 31, 2024, will be extended to no later than February 2025 to accommodate financial institutions' readiness.
                    </P>
                    <P>
                        <SU>85</SU>
                         This surcharge applies to originators of transfers that are processed by the Reserve Banks after 5:00 p.m. ET.
                    </P>
                    <P>
                        <SU>86</SU>
                         This fee is charged to any Fedwire Funds participant that originates a transfer message via the FedPayments Manager Funds tool and has the import/export processing option setting active at any point during the month.
                    </P>
                    <P>
                        <SU>87</SU>
                         Payment Notification and End-of-Day Origination surcharges apply to each Fedwire funds transfer message.
                    </P>
                    <P>
                        <SU>88</SU>
                         Provided on billing statement for informational purposes only.
                    </P>
                    <P>
                        <SU>89</SU>
                         This charge is assessed to settlement arrangements that use the Fedwire Funds Service to affect the settlement of interbank obligations (as opposed to those that use the National Settlement Service). With respect to such special settlement arrangements, other charges may be assessed for each funds transfer into or out of the accounts used in connection with such arrangements.
                    </P>
                    <P>
                        <SU>90</SU>
                         An organization that is a settlement agent may be able to use the National Settlement Service offline service if it is experiencing an operational event that prevents the transmission of settlement files via its electronic connection to the Federal Reserve Banks. The Federal Reserve Banks have limited capacity to process offline settlement files. As a result, while the Federal Reserve Banks use best efforts to process offline settlement file submissions, there is no guarantee that an offline settlement file, in particular one that is submitted late in the operating day or that contains a large number of entries, will be accepted for processing. Only those persons identified as authorized individuals on the National Settlement Service 04 Agent Contact Form may submit offline settlement files. For questions related to the National Settlement Service offline service, please contact National Settlement Service Central Support Service Staff (CSSS) at 800-758-9403, or via email at 
                        <E T="03">csss.staff@ny.frb.org.</E>
                    </P>
                    <P>
                        <SU>91</SU>
                         Any settlement arrangement that accrues less than $60 during a calendar month will be assessed a variable amount to reach the minimum monthly fee.
                    </P>
                    <P>
                        <SU>92</SU>
                         Restricted Securities Accounts maintained by the Reserve Banks under the Loans and Discounts program and the 31 CFR part 202 program are not assessed for monthly account maintenance fees or fees for Transfers of Book-Entry Securities to or from such Restricted Securities Accounts. Restricted Securities Accounts maintained by the Reserve Banks under the 31 CFR part 225 program are subject to monthly account maintenance fees but not fees for Transfers of Book-Entry Securities to or from such Restricted Securities Accounts.
                    </P>
                    <P>
                        <SU>93</SU>
                         These fees are set by the Federal Reserve Banks.
                    </P>
                    <P>
                        <SU>94</SU>
                         This surcharge is set by the Federal Reserve Banks. It is in addition to any basic transfer or reversal fee.
                    </P>
                    <P>
                        <SU>95</SU>
                         Restricted Securities Accounts maintained by the Reserve Banks under the Loans and Discounts program and the 31 CFR. part 202 program are not assessed for monthly account maintenance fees or fees for Transfers of Book-Entry Securities to or from such Restricted Securities Accounts. Restricted Securities Accounts maintained by the Reserve Banks under the 31 CFR part 225 program are subject to monthly account maintenance fees but not fees for Transfers of Book-Entry Securities to or from such Restricted Securities Accounts.
                    </P>
                    <P>
                        <SU>96</SU>
                         These fees are set by the Federal Reserve Banks.
                    </P>
                    <P>
                        <SU>97</SU>
                         These fees are set by the Federal Reserve Banks.
                    </P>
                    <P>
                        <SU>98</SU>
                         The U.S. Department of the Treasury absorbs the cost of monthly account maintenance for securities accounts that contain only Treasury securities and reimburses the Federal Reserve Banks.
                    </P>
                    <P>
                        <SU>99</SU>
                         The U.S. Department of the Treasury absorbs the cost of monthly issue maintenance for custody holdings of Treasury securities and reimburses the Federal Reserve Banks.
                    </P>
                    <P>
                        <SU>100</SU>
                         These fees are set by the Federal Reserve Banks.
                    </P>
                    <P>
                        <SU>101</SU>
                         Automated Claim Adjustment Process (ACAP) fees apply to all ACAP-eligible security types. Phase 2 of the ACAP enhancement project will include expanding ACAP tracking to all coupon-paying securities issued over the Fedwire Securities Service and adding securities lending as a transaction type. For information about the ACAP enhancement project, please visit: 
                        <E T="03">https://www.frbservices.org/resources/financial-services/securities/acap.</E>
                    </P>
                    <P>
                        <SU>102</SU>
                         Participants are charged the Repo Position Maintenance Fee for both a Repo-Out balance and a Repo-In balance. These fees will be assessed every business day.
                    </P>
                    <P>
                        <SU>103</SU>
                         Participants are charged the Securities Lending Position Maintenance Fee for both a Securities Borrowed balance and a Securities Lent balance. These fees will be assessed every business day. Securities lending positions will be available when Phase 2 of the ACAP enhancement project is implemented. For information about the ACAP enhancement project, please visit: 
                        <E T="03">https://www.frbservices.org/resources/financial-services/securities/acap/</E>
                        .
                    </P>
                    <P>
                        <SU>104</SU>
                         This fee is set by and remitted to the Government National Mortgage Association (GNMA).
                    </P>
                    <P>
                        <SU>105</SU>
                         The Federal Reserve Banks charge participants a Joint Custody Origination Surcharge for both Agency and Treasury securities.
                    </P>
                    <P>
                        <SU>106</SU>
                         These fees are set by the Federal Reserve Banks.
                    </P>
                    <P>
                        <SU>107</SU>
                         These fees are set by the Federal Reserve Banks.
                    </P>
                </FTNT>
                <PRTPAGE P="93602"/>
                <P>
                     
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>108</SU>
                         FedComplete Packages are all-electronic service options that bundle payment services with an access solution for one monthly fee.
                    </P>
                    <P>
                        <SU>109</SU>
                         FedComplete customers that use the email service would be charged the FedMail Email a la carte fee and for all FedMail Subscriber 5-packs.
                    </P>
                    <P>
                        <SU>110</SU>
                         Packages with an “A” include the FedLine Advantage channel.
                    </P>
                    <P>
                        <SU>111</SU>
                         Per-item surcharges are in addition to the standard fees listed in the applicable priced services fee schedules.
                    </P>
                    <P>
                        <SU>112</SU>
                         FedComplete customers will be charged $4 for each FedForward cash letter over the monthly package threshold. This activity will appear under billing code 51998 in Service Area 1521 on a month-lagged basis.
                    </P>
                    <P>
                        <SU>113</SU>
                         FedMail package does not include user credentials, which are required to access priced services and certain informational services. Credentials are sold separately in packs of five via the FedMail Subscriber 5-pack.
                    </P>
                    <P>
                        <SU>114</SU>
                         FedLine Web and Advantage packages do not include user credentials, which are required to access priced services and certain informational services. Credentials are sold separately in packs of five via the FedLine Subscriber 5-pack.
                    </P>
                    <P>
                        <SU>115</SU>
                         Qualifying institutions who upgrade from FedMail or FedLine Web to FedLine Advantage or establish a new FedLine Advantage connection for the FedNow Service will receive 12 months of credits from FedLine Advantage billing eligibility.
                    </P>
                    <P>
                        <SU>116</SU>
                         Early termination fees and/or expedited order fees may apply to all FedLine Direct packages and FedLine Direct à la carte options.
                    </P>
                    <P>
                        <SU>117</SU>
                         These add-on services can be purchased only with a FedLine Solution.
                    </P>
                    <P>
                        <SU>118</SU>
                         Additional VPNs are available for FedLine Advantage, FedLine Command, and FedLine Direct packages only.
                    </P>
                    <P>
                        <SU>119</SU>
                         Fee is in addition to the FedLine Direct package fees or Additional 2Mbps WAN Connection fee.
                    </P>
                    <P>
                        <SU>120</SU>
                         The FedLine Custom Implementation Fee is $2,500 or $5,000 based on the complexity of the setup.
                    </P>
                    <P>
                        <SU>121</SU>
                         Available only to customers with a priced FedLine package and does not include user credentials, which are required to access priced services and certain informational services. Credentials are sold separately in packs of five via the FedMail Subscriber 5-pack.
                    </P>
                    <P>
                        <SU>122</SU>
                         Five download codes are included at no cost in all Plus and Premier packages.
                    </P>
                    <P>
                        <SU>123</SU>
                         Available for FedLine Web Plus, FedLine Web Premier, FedLine Advantage Plus, and FedLine Advantage Premier packages. It is also available for no extra fee in FedLine Command Plus and Direct packages.
                    </P>
                    <P>
                        <SU>124</SU>
                         The End of Day Financial Institution Reconcilement Data (FIRD) and Statement of Account Spreadsheet File (SASF) are available for Master accounts only.
                    </P>
                    <P>
                        <SU>125</SU>
                         Available with FedLine Plus and Premier packages.
                    </P>
                    <P>
                        <SU>126</SU>
                         Available for FedLine Web Plus and Premier packages. Available for no extra fee in FedLine Advantage and higher packages.
                    </P>
                    <P>
                        <SU>127</SU>
                         Charging the $10 Replacement Copy Fee is at the discretion of Reserve Banks.
                    </P>
                </FTNT>
                <SIG>
                    <P>By order of the Board of Governors of the Federal Reserve System.</P>
                    <NAME>Ann E. Misback,</NAME>
                    <TITLE>Secretary of the Board.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27831 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6210-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">FEDERAL TRADE COMMISSION</AGENCY>
                <DEPDOC>[File No. P085405]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed Collection; Comment Request; Extension; Correction</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Trade Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice; correction.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Federal Trade Commission (“Commission”) published a document in the 
                        <E T="04">Federal Register</E>
                         of November 4, 2024, concerning its proposal to extend for an additional three years the Office of Management and Budget (“OMB”) clearance for information collection requirements contained in the rules and regulations under the Pay-Per-Call Rule. Shortly after publication, Commission staff learned the document contained an incorrect date. The Commission issues this correction to reflect the corrected date. The current information collection clearance expires on January 31, 2025, not January 30, 2024.
                    </P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        P. Connell McNulty, Attorney, Division of Marketing Practices, Bureau of Consumer Protection, Federal Trade Commission, (202) 326-2061, 
                        <E T="03">pmcnulty@ftc.gov.</E>
                    </P>
                    <PRTPAGE P="93603"/>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The notice document submitted by Commission staff for publication contained a typographical error; specifically, the expiration date for the current OMB clearance was off by one year in the SUMMARY.</P>
                <HD SOURCE="HD1">Correction</HD>
                <P>
                    In notice FR Doc. 2024-25559 appearing at 89 FR 87575 in the 
                    <E T="04">Federal Register</E>
                     of Monday, November 4, 2024, make the following correction. On page 87576, in the last sentence of the 
                    <E T="02">SUMMARY</E>
                     section, the date of “January 30, 2024” is corrected to read “January 31, 2025”.
                </P>
                <SIG>
                    <DATED>Dated: November 20, 2024.</DATED>
                    <NAME>April J. Tabor,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27794 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 6750-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Agency for Healthcare Research and Quality</SUBAGY>
                <SUBJECT>Supplemental Evidence and Data Request on Dietary Intake of Polyunsaturated Fatty Acids and Plasma Lipid and Cardiovascular Events</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Agency for Healthcare Research and Quality (AHRQ), HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Request for supplemental evidence and data submission.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on 
                        <E T="03">Dietary Intake of Polyunsaturated Fatty Acids and Plasma Lipid and Cardiovascular Events,</E>
                         which is currently being conducted by the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        <E T="03">Submission Deadline</E>
                         on or before December 27, 2024.
                    </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">Email submissions: epc@ahrq.hhs.gov.</E>
                    </P>
                    <P>
                        <E T="03">Print submissions:</E>
                    </P>
                    <P>
                        <E T="03">Mailing Address:</E>
                    </P>
                    <FP SOURCE="FP-1">Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, Attn: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857</FP>
                    <P>
                        <E T="03">Shipping Address (FedEx, UPS, etc.):</E>
                    </P>
                    <FP SOURCE="FP-1">Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, Attn: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD 20857</FP>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Kelly Carper, Telephone: 301-427-1656 or Email: 
                        <E T="03">epc@ahrq.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The Agency for Healthcare Research and Quality has commissioned the Evidence-based Practice Centers (EPC) Program to complete a review of the evidence for 
                    <E T="03">Dietary Intake of Polyunsaturated Fatty Acids and Plasma Lipid and Cardiovascular Events.</E>
                     AHRQ is conducting this review pursuant to section 902 of the Public Health Service Act, 42 U.S.C. 299a.
                </P>
                <P>
                    The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for each of its reviews. In order to do so, we are supplementing the usual manual and electronic database searches of the literature by requesting information from the public (
                    <E T="03">e.g.,</E>
                     details of studies conducted). We are looking for studies that report on 
                    <E T="03">Dietary Intake of Polyunsaturated Fatty Acids and Plasma Lipid and Cardiovascular Events.</E>
                     The entire research protocol is available online at: 
                    <E T="03">https://effectivehealthcare.ahrq.gov/products/polyunsaturated-fatty/protocol.</E>
                </P>
                <P>
                    This is to notify the public that the EPC Program would find the following information on 
                    <E T="03">Dietary Intake of Polyunsaturated Fatty Acids and Plasma Lipid and Cardiovascular Events</E>
                     helpful:
                </P>
                <P>
                     A list of completed studies that your organization has sponsored for this topic. In the list, please 
                    <E T="03">indicate whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number.</E>
                </P>
                <P>
                      
                    <E T="03">For completed studies that do not have results on ClinicalTrials.gov</E>
                    , a summary, including the following elements, if relevant: study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/efficacy, and safety results.
                </P>
                <P>
                      
                    <E T="03">A list of ongoing studies that your organization has sponsored for this topic.</E>
                     In the list, please provide the 
                    <E T="03">ClinicalTrials.gov</E>
                     trial number or, if the trial is not registered, the protocol for the study including, if relevant, a study number, the study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes.
                </P>
                <P>
                     Description of whether the above studies constitute 
                    <E T="03">ALL Phase II and above clinical trials</E>
                     sponsored by your organization for this topic and an index outlining the relevant information in each submitted file.
                </P>
                <P>Your contribution is very beneficial to the Program. Materials submitted must be publicly available or able to be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on topics not included in the review cannot be used by the EPC Program. This is a voluntary request for information, and all costs for complying with this request must be borne by the submitter.</P>
                <P>
                    The draft of this review will be posted on AHRQ's EPC Program website and available for public comment for a period of 4 weeks. If you would like to be notified when the draft is posted, please sign up for the email list at: 
                    <E T="03">https://effectivehealthcare.ahrq.gov/email-updates.</E>
                </P>
                <P>
                    <E T="03">The review will answer the following questions. This information is provided as background. AHRQ is not requesting that the public provide answers to these questions.</E>
                </P>
                <HD SOURCE="HD1">Key Questions (KQ)</HD>
                <P>
                    <E T="03">KQ 1:</E>
                     What are the effects of different dietary polyunsaturated fatty acid intake on plasma lipid concentrations in the general population?
                </P>
                <P>
                    <E T="03">KQ 2:</E>
                     What are the effects of different dietary polyunsaturated fatty acid intake on cardiovascular events in the general population?
                </P>
                <GPOTABLE COLS="3" OPTS="L2,nj,i1" CDEF="s50,xl100,r100">
                    <TTITLE>PICOTS (Populations, Interventions, Comparators, Outcomes, Timing, and Setting)</TTITLE>
                    <TDESC>[Study eligibility criteria based on Population, Intervention, Comparator, Outcome (PICO), and other elements]</TDESC>
                    <BOXHD>
                        <CHED H="1">Element</CHED>
                        <CHED H="1">Inclusion criteria</CHED>
                        <CHED H="1">Exclusion criteria</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Population</ENT>
                        <ENT>
                            <E T="03">Both Key Questions:</E>
                        </ENT>
                        <ENT>
                            <E T="03">Both Key Questions:</E>
                        </ENT>
                    </ROW>
                    <ROW RUL="s">
                        <PRTPAGE P="93604"/>
                        <ENT I="22"> </ENT>
                        <ENT>
                            General population, without CVD, with or without modifiable CV risk factors, including
                            <LI O="oi3">○ Dyslipidemia (including if taking lipid-lowering medications) </LI>
                            <LI O="oi3">○ Overweight/obese</LI>
                            <LI O="oi3">○ Hyperglycemia and related conditions, including type 2 diabetes</LI>
                            <LI O="oi3">○ Hypertension/high blood pressure</LI>
                            <LI>
                                <E T="03">Key Question 1:</E>
                            </LI>
                            <LI>Children and adults</LI>
                            <LI>
                                <E T="03">Key Question 2:</E>
                            </LI>
                            <LI>Adults (≥18 years old)</LI>
                        </ENT>
                        <ENT>
                            • Participants with a health-related condition or taking medications that impact fat absorption, fat metabolism.
                            <LI>• Participants taking weight loss medications, including glucagon-like peptide-1 agonists.</LI>
                            <LI>• Undernourished, underweight, stunted, or wasted participants.</LI>
                            <LI>• Participants who are pre- or post-bariatric surgery.</LI>
                            <LI>
                                • Participants with other chronic diseases (
                                <E T="03">e.g.,</E>
                                 cancer, gastrointestinal disease, rheumatic disease, chronic kidney disease, neurologic diseases), including type 1 diabetes.
                            </LI>
                            <LI>
                                • Participants with clinical CVD (
                                <E T="03">e.g.,</E>
                                 history of myocardial infarction, angina, stroke, arrhythmia), including congenital heart diseases, or familial hypercholesterolemia.
                            </LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Interventions</ENT>
                        <ENT>
                            <E T="03">Both Key Questions:</E>
                        </ENT>
                        <ENT>
                            <E T="03">Both Key Questions:</E>
                        </ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="22"> </ENT>
                        <ENT>
                            Dietary intake of
                            <LI O="oi3">Total n-3 or total n-6 PUFA</LI>
                            <LI O="oi3">
                                Individual PUFA (
                                <E T="03">e.g.,</E>
                                 linoleic, ALA, EPA, DHA)
                            </LI>
                            <LI O="oi3">
                                Combination of long-chain PUFA (
                                <E T="03">e.g.,</E>
                                 EPA+DHA+DPA; DHA+ALA)
                            </LI>
                            <LI>PUFA intake must be defined or described prospectively</LI>
                            <LI>Studies must specify daily quantity of PUFA intake</LI>
                            <LI>
                                <E T="03">Key Question 1:</E>
                            </LI>
                            <LI>For studies in children,</LI>
                            <LI O="oi3">
                                ○ Include multicomponent interventions (
                                <E T="03">e.g.,</E>
                                 diet + exercise vs. exercise)
                            </LI>
                            <LI O="oi3">○ Infant formula</LI>
                        </ENT>
                        <ENT>
                            • Studies that do not quantify PUFA intake as either g/day or % of total energy intake from PUFA.
                            <LI>• Analyses with PUFA intake as a continuous variable.</LI>
                            <LI>• Fatty acid intake via infusion (not orally).</LI>
                            <LI>• Food products or dietary supplements not widely available to U.S. consumers.</LI>
                            <LI>
                                • Multi-component interventions (
                                <E T="03">e.g.,</E>
                                 exercise + diet vs. exercise or plant sterols + diet vs. plant sterols) that do not isolate the effect or association of PUFA.
                            </LI>
                            <LI>• Multi-component interventions of statins + diet where statins are being initiated. Dietary interventions among existing statin users will be included.</LI>
                            <LI>• Interventions designed to induce weight loss or treat overweight and obesity through energy restriction or hypocaloric diets.</LI>
                            <LI>• Interventions designed for the purposes of treating medical conditions other than modifiable CV risk factors.</LI>
                            <LI>• DHA and/or EPA n-3 FA dose &gt;4 g/d.</LI>
                            <LI>• Enteral feeding.</LI>
                        </ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Comparators</ENT>
                        <ENT>
                            <E T="03">Both Key Questions:</E>
                        </ENT>
                        <ENT>
                            <E T="03">Both Key Questions:</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>
                            Dietary intake of a different level of fatty acids relevant to the exposure
                            <LI>No added/supplement PUFA</LI>
                            <LI>Placebo supplements</LI>
                        </ENT>
                        <ENT>
                            Diets with a caloric intake that are significantly higher or lower than the intervention/exposure diet.
                            <LI>Diets or interventions that vary substantially in intake of macronutrients (or other factors) other than the intervention and comparator of interest.</LI>
                            <LI>
                                Different PUFA dietary exposure (
                                <E T="03">e.g.,</E>
                                 comparison of undefined quantiles).
                            </LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Outcomes</ENT>
                        <ENT>
                            <E T="03">Key Question 1:</E>
                        </ENT>
                        <ENT>
                            <E T="03">Key Question 1:</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>
                            • Plasma lipoprotein concentrations
                            <LI O="oi3">○ LDL cholesterol (LDL-c)</LI>
                            <LI O="oi3">○ HDL cholesterol (HDL-c)</LI>
                            <LI O="oi3">○ Non-HDL-cholesterol</LI>
                            <LI O="oi3">○ Triglycerides (triacylglycerol) (Tg)</LI>
                            <LI O="oi3">○ Lipoprotein(a)</LI>
                            <LI O="oi3">○ Apolipoprotein B (ApoB)</LI>
                        </ENT>
                        <ENT>
                            • Total cholesterol (TC).
                            <LI>• TC:HDL ratio.</LI>
                            <LI>• LDL:HDL ratio.</LI>
                            <LI>• Chylomicrons.</LI>
                            <LI>• VLDL-c.</LI>
                            <LI>• IDL-c.</LI>
                            <LI>• Other apolipoproteins.</LI>
                            <LI>• Lipoprotein profiles.</LI>
                            <LI>• Evaluations of fatty acid biomarker levels.</LI>
                        </ENT>
                    </ROW>
                    <ROW RUL="s">
                        <PRTPAGE P="93605"/>
                        <ENT I="22"> </ENT>
                        <ENT>
                            <E T="03">Key Question 2:</E>
                            <LI>• Cardiovascular events</LI>
                            <LI O="oi3">○ Atherosclerotic cardiovascular disease (total)</LI>
                            <LI O="oi3">○ Major adverse cardiac (or cerebral) events (MAC[C]E)</LI>
                            <LI O="oi3">○ Specific cardiovascular events</LI>
                            <LI O="oi6"> Myocardial infarction</LI>
                            <LI O="oi6"> Coronary heart/artery disease</LI>
                            <LI O="oi6"> Peripheral vascular/artery disease</LI>
                            <LI O="oi3">○ Revascularization (for studies published after 1995)</LI>
                            <LI O="oi3">○ Cardiovascular disease-related mortality</LI>
                            <LI O="oi3">○ Stroke</LI>
                            <LI O="oi3">○ Incident atrial fibrillation</LI>
                        </ENT>
                        <ENT>
                            <E T="03">Key Question 2:</E>
                            <LI>• Other cardiac or vascular related outcomes.</LI>
                            <LI>• Participant reported events.</LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Subgroups/effect modifiers of interest</ENT>
                        <ENT>
                            <E T="03">Both Key Questions:</E>
                        </ENT>
                        <ENT>None.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="22"> </ENT>
                        <ENT>
                            • Specific life stages
                            <LI O="oi3">○ Infants (for Key Question 1 only)</LI>
                            <LI O="oi3">○ Children and adolescents (for Key Question 1 only)</LI>
                            <LI O="oi3">○ Adults (19-64)</LI>
                            <LI O="oi3">○ Older adults (≥65)</LI>
                            <LI O="oi3">○ Pregnant or postpartum</LI>
                            <LI O="oi3">○ Menopausal status</LI>
                            <LI>• Other characteristics</LI>
                            <LI O="oi3">○ Sex (male, female)</LI>
                            <LI O="oi3">○ Socioeconomic status</LI>
                            <LI O="oi3">○ Social determinants of health</LI>
                            <LI O="oi3">○ Race/ethnicity</LI>
                            <LI O="oi3">○ Physical activity level</LI>
                            <LI O="oi3">○ Anthropometry</LI>
                            <LI O="oi3">○ Health status, including type 2 diabetes</LI>
                            <LI O="oi3">○ Percent of total energy intake replaced</LI>
                            <LI O="oi3">○ Dietary trans fatty acid intake</LI>
                            <LI O="oi3">○ Baseline lipid concentrations</LI>
                            <LI O="oi3">○ Dietary cholesterol intake</LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Design</ENT>
                        <ENT>
                            <E T="03">Key Question 1:</E>
                        </ENT>
                        <ENT>
                            <E T="03">Both Key Questions:</E>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>
                            • Studies of adults
                            <LI O="oi3">○ Parallel or cross-over randomized controlled trials (RCTs)</LI>
                            <LI O="oi6"> n ≥25/group *</LI>
                            <LI>• Studies of children</LI>
                            <LI O="oi3">○ Parallel or cross-over RCTs</LI>
                            <LI O="oi6"> n ≥25/group *</LI>
                            <LI O="oi3">○ Nonrandomized comparative studies</LI>
                            <LI O="oi6"> Must account for potential confounders</LI>
                            <LI O="oi6"> n ≥50/group *</LI>
                        </ENT>
                        <ENT>
                            • Observational studies that do not account for confounders.
                            <LI>
                                • Analyses of dietary fat as a continuous variable (
                                <E T="03">e.g.,</E>
                                 RR per g/day intake) without an analysis at a threshold (
                                <E T="03">e.g.,</E>
                                 RR for &gt; vs &lt; threshold).
                            </LI>
                            <LI>• All other study designs.</LI>
                        </ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="22"> </ENT>
                        <ENT>
                            <E T="03">Key Question 2:</E>
                            <LI>• Studies of adults</LI>
                            <LI O="oi3">○ Parallel or cross-over RCTs</LI>
                            <LI O="oi6"> n ≥25/group *</LI>
                            <LI O="oi3">○ Nonrandomized comparative studies</LI>
                            <LI O="oi6"> Must account for potential confounders</LI>
                            <LI O="oi6"> Dietary intake must be defined or described prospectively</LI>
                            <LI O="oi6">
                                 We will aim for a minimum of about 10 observational studies for each specific PUFA—CV event pair (
                                <E T="03">e.g.,</E>
                                 EPA and stroke). We will thus select the largest observational studies within each category.†
                            </LI>
                            <LI O="oi6"> n ≥100/group</LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Timing</ENT>
                        <ENT>
                            <E T="03">Key Question 1:</E>
                        </ENT>
                        <ENT>None.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>
                            • Minimum intervention length: 4 weeks
                            <LI>• In cross-over studies, any change in outcome measure must exclude data from the first week after end of any prior treatments</LI>
                        </ENT>
                    </ROW>
                    <ROW RUL="s">
                        <PRTPAGE P="93606"/>
                        <ENT I="22"> </ENT>
                        <ENT>
                            <E T="03">Key Question 2:</E>
                            <LI>• Minimum follow-up</LI>
                            <LI O="oi3">○ If population has no CV risk factors (or unselected general population): 10 years</LI>
                            <LI O="oi3">○ If population has one or more CV risk factors: 5 years</LI>
                        </ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Setting</ENT>
                        <ENT>• General community settings, including nursing homes, assisted living facilities, etc.</ENT>
                        <ENT>
                            • Hospital or other acute care settings.
                            <LI>
                                • Institutionalized, confined settings (
                                <E T="03">e.g.,</E>
                                 prisons).
                            </LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Publication</ENT>
                        <ENT>
                            • English language
                            <LI>• Published in peer-reviewed journals</LI>
                        </ENT>
                    </ROW>
                    <TNOTE>* Minimum sample size may be altered depending on the number of eligible studies found.</TNOTE>
                    <TNOTE>
                        † Applying this approach for the 2016 AHRQ report n-3 fatty acids and cardiovascular disease (
                        <E T="03">https://doi.org/10.23970/AHRQEPCERTA223</E>
                        ), we included: for cardiac event outcomes, observational studies with at least 10,000 participants; for stroke outcomes, at least 3000 participants; for arrhythmia outcomes, at least 2000 participants; congestive heart failure outcomes, at least 700 participants; and for peripheral vascular disease events and MACE outcomes, at least 500 participants. In all instances, if a study meets eligibility criteria for any outcome, we will extract all outcomes of interest from that study; therefore, there will be multiple instances of studies being included for an outcome even though the study might not have met study size criteria for that specific outcome.
                    </TNOTE>
                    <TNOTE>CV = cardiovascular; CVD = cardiovascular disease; PUFA = polyunsaturated fatty acids; ALA = alpha-linolenic acid; EPA = eicosapentaenoic aci; DHA= docosahexaenoic acid; DPA = docosapentaenoic acid; n-3 = Omega 3; n-6 = Omega 6; FA = fatty acid; c = cholesterol; LDL = low-density lipoprotein; IDL = intermediate-density lipoprotein; HDL high-density lipoprotein; TC—total cholesterol; Tg = Triglycerides/Triacylglycerols; apoA = apolipoprotein; MAC[C]E = Major adverse cardiac (or cerebro) events; BMI = body mass index; KQ = key question; N = number of participants.</TNOTE>
                </GPOTABLE>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Marquita Cullom,</NAME>
                    <TITLE>Associate Director.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27798 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4160-90-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Centers for Disease Control and Prevention</SUBAGY>
                <SUBJECT>Notice of Closed Meeting</SUBJECT>
                <P>Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.</P>
                <P>The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.</P>
                <P>
                    <E T="03">Name of Committee:</E>
                     Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—CE25-021, Research Grants for Preventing Violence and Violence Related Injury.
                </P>
                <P>
                    <E T="03">Dates:</E>
                     February 19-20, 2025.
                </P>
                <P>
                    <E T="03">Times:</E>
                     10 a.m.-5 p.m., EST.
                </P>
                <P>
                    <E T="03">Place:</E>
                     Web Conference.
                </P>
                <P>
                    <E T="03">Agenda:</E>
                     To review and evaluate grant applications.
                </P>
                <P>
                    <E T="03">For Further Information Contact:</E>
                     Carlisha Gentles, Pharm.D., B.C.P.S., C.D.C.E.S., Scientific Review Officer, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop S106-9, Atlanta, Georgia 30341. Telephone: (770) 488-1504; Email: 
                    <E T="03">CGentles@cdc.gov.</E>
                </P>
                <P>
                    The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign 
                    <E T="04">Federal Register</E>
                     notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
                </P>
                <SIG>
                    <NAME>Kalwant Smagh,</NAME>
                    <TITLE>Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27857 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4163-18-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Centers for Disease Control and Prevention</SUBAGY>
                <SUBJECT>Notice of Closed Meeting</SUBJECT>
                <P>Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.</P>
                <P>The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.</P>
                <P>
                    <E T="03">Name of Committee:</E>
                     Disease, Disability, and Injury Prevention and Control Special Emphasis Panel; (SEP)—CE25-025, Rigorous Evaluation of Community- and Societal-Level Primary Prevention Approaches to Prevent Adverse Childhood Experiences (ACEs): Expanding the Best Available Evidence.
                </P>
                <P>
                    <E T="03">Dates:</E>
                     February 25-26, 2025.
                </P>
                <P>
                    <E T="03">Times:</E>
                     10 a.m.-5 p.m., EST.
                </P>
                <P>
                    <E T="03">Place:</E>
                     Web Conference.
                </P>
                <P>
                    <E T="03">Agenda:</E>
                     To review and evaluate grant applications.
                    <PRTPAGE P="93607"/>
                </P>
                <P>
                    <E T="03">For Further Information Contact:</E>
                     Aisha L. Wilkes, M.P.H., Scientific Review Officer, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop S106-9, Atlanta, Georgia 30341. Telephone: (404) 639-6473; Email: 
                    <E T="03">AWilkes@cdc.gov.</E>
                </P>
                <P>
                    The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign 
                    <E T="04">Federal Register</E>
                     notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
                </P>
                <SIG>
                    <NAME>Kalwant Smagh,</NAME>
                    <TITLE>Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27856 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4163-18-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Centers for Medicare &amp; Medicaid Services</SUBAGY>
                <DEPDOC>[Document Identifier: CMS-10891]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities: Submission for OMB Review; Comment Request</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Centers for Medicare &amp; Medicaid Services, Health and Human Services (HHS).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Centers for Medicare &amp; Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the 
                        <E T="04">Federal Register</E>
                         concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, and to allow a second opportunity for public comment on the notice. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments on the collection(s) of information must be received by the OMB desk officer by December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                    <P>
                        To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, please access the CMS PRA website by copying and pasting the following web address into your web browser: 
                        <E T="03">https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>William Parham at (410) 786-4669.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term “collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires federal agencies to publish a 30-day notice in the 
                    <E T="04">Federal Register</E>
                     concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice that summarizes the following proposed collection(s) of information for public comment:
                </P>
                <P>
                    1. 
                    <E T="03">Type of Information Collection Request:</E>
                     New collection (Request for a new OMB control number); 
                    <E T="03">Title of Information Collection:</E>
                     Medicaid Program; Medicare Savings Program Application and Eligibility Determinations; 
                    <E T="03">Use:</E>
                     The provisions in this collection of information request are necessary for helping to enroll individuals into the Medicare Savings Programs (MSPs) as directed by the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA) and for implementing the September 21, 2023 (88 FR 65230) final rule entitled, “Streamlining Medicaid: Medicare Savings Program Eligibility Determination and Enrollment” (hereinafter “MSP final rule”) (CMS-2421-F; RIN 0938-AU00).
                </P>
                <P>CMS did not previously estimate several costs for implementing the provisions of MIPPA related to MSPs as well as costs related to MSPs that were longstanding costs inherent to the Medicaid program that predated MIPPA. To address that oversight, we estimate such burden in this collection of information request. We also estimate burden and savings associated with the provisions in the MSP final rule. Such burden was set out in the Regulatory Impact Analysis section of the final rule.</P>
                <P>The MSPs are essential to the health and well-being of those enrolled, promoting access to care and helping free up individuals' limited income for food, housing, and other life necessities. Through the MSPs, Medicaid pays Medicare Part B premiums each month for over 10 million individuals and Part A premiums for over 700,000 individuals. State Medicaid agencies receive applications and adjudicate eligibility for MSP coverage.</P>
                <P>MIPPA created new requirements for states to leverage the Medicare Part D Low-Income Subsidy (LIS) program to help enroll likely-eligible individuals in MSPs, and the MSP final rule expanded those requirements. States use information collected by the Social Security Administration on the LIS application (transmitted to states with the consent of an individual completing an application) to determine eligibility for the MSPs. Under the MSP final rule, the state Medicaid agency accepts and verifies the information provided on the LIS application (to the extent allowable under the MSP final rule); communicates with the applicant or the authorized representative about any additional information needed to make an MSP determination; makes the MSP eligibility determination; enrolls the individual in an MSP, if eligible; and informs the individual about the rights and responsibilities for applying for full Medicaid eligibility. Applicants include anyone who chooses to apply for LIS and provides consent for their application to be considered for MSPs.</P>
                <P>
                    In addition to building on MIPPA and strengthening the LIS pathway for enrolling in MSPs, the MSP final rule streamlined MSP eligibility and enrollment processes, reduced administrative burden on states and applicants, and increased enrollment and retention of eligible individuals.
                    <PRTPAGE P="93608"/>
                </P>
                <P>
                    <E T="03">Form Number:</E>
                     CMS-10891 (OMB control number: 0938-TBD); 
                    <E T="03">Frequency:</E>
                     Occasionally; 
                    <E T="03">Affected Public:</E>
                     State, Local and Tribal Governments and Individuals or households; 
                    <E T="03">Number of Respondents:</E>
                     3,460,750; 
                    <E T="03">Total Annual Responses:</E>
                     3,460,750; 
                    <E T="03">Total Annual Hours:</E>
                     5,517,157. (For policy questions regarding this collection contact: Melissa Heitt at 410-786-2484.)
                </P>
                <SIG>
                    <NAME>William N. Parham, III</NAME>
                    <TITLE>Director, Division of Information Collections and Regulatory Impacts, Office of Strategic Operations and Regulatory Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27871 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4120-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Centers for Medicare &amp; Medicaid Services</SUBAGY>
                <DEPDOC>[CMS-3471-N]</DEPDOC>
                <SUBJECT>Medicare Program; Public Meeting for Air Ambulance Quality &amp; Patient Safety Advisory Committee—December 12, 2024, February 18, 2025, and May 8, 2025</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Centers for Medicare &amp; Medicaid Services (CMS), HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of meeting.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>This notice announces virtual public meetings of the Air Ambulance Quality and Patient Safety (AAQPS) Advisory Committee. The AAQPS Advisory Committee will review options to establish quality, patient safety, and clinical capability standards for each clinical capability level of air ambulances.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        <E T="03">Virtual Meeting Dates:</E>
                         The AAQPS Advisory Committee will hold virtual meetings on December 12, 2024, February 18, 2025, and May 8, 2025, from 10:00 a.m. to 5:00 p.m., Eastern Time (E.T.).
                    </P>
                    <P>
                        <E T="03">Deadline for Submitting Requests for Special Accommodations:</E>
                         Requests for special accommodations must be received at least 2 weeks before each meeting.
                    </P>
                    <P>
                        <E T="03">Registration Link:</E>
                         The virtual meetings will be open to the public and held via the Zoom webinar platform. Virtual attendance information will be provided upon registration. To register for the virtual meeting, please visit: 
                        <E T="03">https://www.cms.gov/medicare/regulations-guidance/advisory-committees/advisory-committee-air-ambulance-quality-and-patient-safety.</E>
                         Attendance is open to the public subject to any technical or capacity limitations.
                    </P>
                    <P>
                        <E T="03">Deadline for Registration:</E>
                         All individuals who plan to attend the virtual public meeting must register to attend. Request to provide oral comments are due at least fourteen (14) calendar days prior to the meeting date. Interested parties are encouraged to register as far in advance of the meeting as possible.
                    </P>
                    <P>
                        A detailed agenda and materials will be available prior to the meeting on the AAQPS Advisory Committee website at: 
                        <E T="03">https://www.cms.gov/medicare/regulations-guidance/advisory-committees/advisory-committee-air-ambulance-quality-and-patient-safety.</E>
                    </P>
                    <P>A recording and a summary of the meeting will be made available on the AAQPS Advisory Committee website approximately 45 calendar days after the meeting.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        <E T="03">Virtual Meeting Location:</E>
                         All meetings are open to the public and instructions to view will be posted on the AAQPS Advisory Committee website, and upon registration. If you wish to provide oral comments during the meetings you must complete a registration form on the AAQPS Advisory Committee website at: 
                        <E T="03">https://www.cms.gov/medicare/regulations-guidance/advisory-committees/advisory-committee-air-ambulance-quality-and-patient-safety,</E>
                         and submit a written copy of your remarks to 
                        <E T="03">AAQPS@cms.hhs.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Ashley Spence, CMS, at (410) 786-2000 or via email at 
                        <E T="03">AAQPS@cms.hhs.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>The Secretary of the Department of Health and Human Services (HHS) and the Secretary of Transportation established the Air Ambulance Quality and Patient Safety (AAQPS) Advisory Committee on August 22, 2023, in response to section 106 of the No Surprises Act, enacted as part of the Consolidated Appropriations Act, 2021, div. BB, tit. I, Public Law 116-260 (December 27, 2020). The AAQPS Advisory Committee will be tasked with reviewing options to establish quality, patient safety, and clinical capability standards for each clinical capability level of air ambulances.</P>
                <P>The AAQPS Advisory Committee is governed by the provisions of the Federal Advisory Committee Act (FACA), Public Law 92-463 (Oct. 6, 1972), as amended by 5 U.S.C. app. 2.</P>
                <HD SOURCE="HD1">II. Advisory Committee Membership Roster</HD>
                <P>
                    On June 2, 2023, HHS published an Invitation for Member Nominations in the 
                    <E T="04">Federal Register</E>
                     for the AAQPS Advisory Committee (88 FR 37253). This notice also announces the members of the AAQPS Advisory Committee.
                </P>
                <P>• Jeff Richey—HHS Secretary's Designee/Representative.</P>
                <P>• Robert Reckert—DoT Secretary's Designee/Representative.</P>
                <P>• Ben Clayton—DoT Representative.</P>
                <P>• Colonel Steven L. Coffee—Patient Advocate.</P>
                <P>• Dr. Jordan Pritzker—Group Health Plans and Health Insurance Issuers.</P>
                <P>• Dr. Mark Gamber—HHS Representative.</P>
                <P>• Dr. William Hinckley—Healthcare Provider.</P>
                <P>• Eileen Frazer—Accrediting bodies.</P>
                <P>• Grace Arnold—State Insurance Regulator.</P>
                <P>• Jason Clark—HHS Representative.</P>
                <P>• Jason Quisling—DoT Representative.</P>
                <P>• Jeff Houser—DoT Representative.</P>
                <P>• Paul Julander—DoT Representative.</P>
                <P>• Thomas Judge—DoT Representative.</P>
                <HD SOURCE="HD1">III. Summary of the Agenda</HD>
                <P>
                    During the December 12, 2024, February 18, 2025, and May 8, 2025 meetings, the AAQPS Advisory Committee will review options to establish quality, patient safety, and clinical capability standards for each clinical capability level of air ambulances. A more detailed agenda and meeting materials will be made available 3 days before the meetings on the AAQPS Advisory Committee website at 
                    <E T="03">https://www.cms.gov/medicare/regulations-guidance/advisory-committees/advisory-committee-air-ambulance-quality-and-patient-safety.</E>
                </P>
                <HD SOURCE="HD1">IV. Public Participation</HD>
                <P>
                    The meetings will be open to the public for virtual attendance on a first-come, first-served basis, as there may be capacity or technical limitations. Please see the 
                    <E T="02">ADDRESSES</E>
                     section to view the meeting link.
                </P>
                <P>
                    The Department is committed to providing equal access to this meeting for all participants. If you need alternative formats or services because of a disability, such as sign language interpreter, please contact the person listed in the 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                     section no later than 2 weeks before each meeting.
                </P>
                <P>
                    The Department will accept oral comments, which must be limited to the objectives of the committee and limited to three (3) minutes per person. Individual members of the public who wish to present oral comments must register and provide a written copy of prepared remarks for inclusion in the meeting records and for circulation to 
                    <PRTPAGE P="93609"/>
                    AAQPS Advisory Committee members. All prepared remarks submitted on time will be considered as part of the meeting's record.
                </P>
                <HD SOURCE="HD1">V. Submitting Written Comments</HD>
                <P>
                    Members of the public may submit written comments for consideration by the Committee at any time via email to 
                    <E T="03">AAQPS@cms.hhs.gov.</E>
                     Additionally, members of the public will have the opportunity to submit comments during the December 12, 2024, February 18, 2025, and May 8, 2025, virtual meetings through the chat feature of the Zoom webinar platform. Members of the public are encouraged to submit lengthy written comments (more than three sentences) to the email address above. Advance submissions that become part of the committee deliberations will become part of the official record of the meeting.
                </P>
                <P>
                    The Administrator of CMS, Chiquita Brooks-LaSure, having reviewed and approved this document, authorizes Vanessa Garcia, who is the Federal Register Liaison, to electronically sign this document for purposes of publication in the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <SIG>
                    <NAME>Vanessa Garcia,</NAME>
                    <TITLE>Federal Register Liaison, Centers for Medicare &amp; Medicaid Services.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27740 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4120-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2018-N-3236]</DEPDOC>
                <SUBJECT>Advisory Committee; Oncologic Drugs Advisory Committee; Renewal</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice; renewal of Federal advisory committee.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Oncologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Oncologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the September 1, 2026, expiration date.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Authority for the Oncologic Drugs Advisory Committee will expire on September 1, 2026, unless the Commissioner formally determines that renewal is in the public interest.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Yvette Waples, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, 
                        <E T="03">ODAC@fda.hhs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Pursuant to 41 CFR 102-3.65 and approval by the Department of Health and Human Services and by the General Services Administration, FDA is announcing the renewal of the Oncologic Drugs Advisory Committee (the Committee). The Committee is a discretionary Federal advisory committee established to provide advice to the Commissioner. The Committee advises the Commissioner or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs for human use and, as required, any other product for which FDA has regulatory responsibility.</P>
                <P>The Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and makes appropriate recommendations to the Commissioner.</P>
                <P>Pursuant to its charter, the Committee shall consist of a core of 13 voting members, including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of general oncology, pediatric oncology, hematologic oncology, immunology oncology, biostatistics, and other related professions. Members will be invited to serve for overlapping terms of up to 4 years. Non-Federal members of this committee will serve as Special Government Employees or representatives. Federal members will serve as Regular Government Employees or Ex-Officios. The core of voting members may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. In addition to the voting members, the Committee may include one non-voting representative member who is identified with industry interests. There may also be an alternate industry representative.</P>
                <P>The Commissioner or designee shall have the authority to select members of other scientific and technical FDA advisory committees (normally not to exceed 10 members) to serve temporarily as voting members and to designate consultants to serve temporarily as voting members when: (1) expertise is required that is not available among current voting standing members of the Committee (when additional voting members are added to the Committee to provide needed expertise, a quorum will be based on the combined total of regular and added members) or (2) to comprise a quorum when, because of unforeseen circumstances, a quorum is or will be lacking. Because of the size of the Committee and the variety in the types of issues that it will consider, FDA may, in connection with a particular committee meeting, specify a quorum that is less than a majority of the current voting members. The Agency's regulations (21 CFR 14.22(d)) authorize a committee charter to specify quorum requirements.</P>
                <P>If functioning as a medical device panel, an additional non-voting representative member of consumer interests and an additional non-voting representative member of industry interests will be included in addition to the voting members.</P>
                <P>
                    Further information regarding the most recent charter and other information can be found at 
                    <E T="03">https://www.fda.gov/advisory-committees/oncologic-drugs-advisory-committee/oncologic-drugs-advisory-committee-roster</E>
                     or by contacting the Designated Federal Officer (see 
                    <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                    ). In light of the fact that no change has been made to the committee name or description of duties, no amendment will be made to 21 CFR 14.100.
                </P>
                <P>
                    This notice is issued under the Federal Advisory Committee Act as amended (5 U.S.C. 1001 
                    <E T="03">et seq.</E>
                    ). For general information related to FDA advisory committees, please visit us at 
                    <E T="03">http://www.fda.gov/AdvisoryCommittees/default.htm.</E>
                </P>
                <SIG>
                    <DATED>Dated: November 19, 2024.</DATED>
                    <NAME>P. Ritu Nalubola,</NAME>
                    <TITLE>Associate Commissioner for Policy.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27797 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="93610"/>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2024-D-4540]</DEPDOC>
                <SUBJECT>Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects; Draft Guidance for Industry; Availability</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of availability.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects.” This draft guidance makes recommendations on followup testing for Ames-positive active ingredients in circumstances when a sponsor decides to continue development. The guidance recommends a consistent process of followup testing and evaluation that first should be conducted for an Ames-positive active ingredient before proceeding with first-in-human (FIH) trials in healthy human subjects. These recommendations are intended to potentially help address and lower safety concerns before proceeding with FIH trials in healthy human subjects.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Submit either electronic or written comments on the draft guidance by February 25, 2025 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments on any guidance at any time as follows:</P>
                </ADD>
                <HD SOURCE="HD2">Electronic Submissions</HD>
                <P>Submit electronic comments in the following way:</P>
                <P>
                    • 
                    <E T="03">Federal eRulemaking Portal: https://www.regulations.gov.</E>
                     Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to 
                    <E T="03">https://www.regulations.gov</E>
                     will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on 
                    <E T="03">https://www.regulations.gov.</E>
                </P>
                <P>• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).</P>
                <HD SOURCE="HD2">Written/Paper Submissions</HD>
                <P>Submit written/paper submissions as follows:</P>
                <P>
                    • 
                    <E T="03">Mail/Hand Delivery/Courier (for written/paper submissions):</E>
                     Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
                </P>
                <P>• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”</P>
                <P>
                    <E T="03">Instructions:</E>
                     All submissions received must include the Docket No. FDA-2024-D-4540 for “Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at 
                    <E T="03">https://www.regulations.gov</E>
                     or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
                </P>
                <P>
                    • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on 
                    <E T="03">https://www.regulations.gov.</E>
                     Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: 
                    <E T="03">https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.</E>
                </P>
                <P>
                    <E T="03">Docket:</E>
                     For access to the docket to read background documents or the electronic and written/paper comments received, go to 
                    <E T="03">https://www.regulations.gov</E>
                     and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.
                </P>
                <P>You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).</P>
                <P>
                    Submit written requests for single copies of this draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the 
                    <E T="02">SUPPLEMENTARY INFORMATION</E>
                     section for information on electronic access to the draft guidance document.
                </P>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Timothy W. Robison, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 3328, Silver Spring, MD 20993, 301-796-1283.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>
                    FDA is announcing the availability of a draft guidance for industry entitled “Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects.” Positive results in the Ames test suggest potential DNA reactivity, indicating that followup testing and evaluation of an Ames-positive active ingredient are necessary to assess its in vivo mutagenic and carcinogenic potential.
                    <SU>1</SU>
                    <FTREF/>
                     Positive results in the Ames test are correlated with carcinogenic potential in rodents; however, this correlation is not perfect because mutations are only one of many 
                    <PRTPAGE P="93611"/>
                    stages in tumor development. In addition, the mutagenic response may be due to exceeding a detoxification threshold or the induction of oxidative damage to which bacterial cells may be more sensitive than mammalian cells in vitro or tissues in vivo.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         See the International Council for Harmonisation guidance for industry “S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use,” available at 
                        <E T="03">https://www.fda.gov/media/170461/download.</E>
                    </P>
                </FTNT>
                <P>This guidance makes recommendations on followup testing for Ames-positive active ingredients in those rare circumstances when a sponsor decides to continue development for potential approval by FDA. These recommendations are intended to potentially address and lower certain safety concerns before proceeding with FIH trials in healthy human subjects. Followup testing cannot entirely mitigate the concerns raised by an Ames-positive finding, and some residual risk remains in the absence of an adequate carcinogenicity assessment. Thus, Ames-positive active ingredients that are further developed should be those targeting serious or life-threatening diseases with unmet medical needs.</P>
                <P>
                    Consideration might be given to the administration of an investigational new drug containing an Ames-positive active ingredient to healthy human subjects only if the results of extensive followup testing conducted before clinical administration lowered the concern for cancer based on a weight-of-evidence (WoE) approach evaluating the potential for mutagenicity. A WoE evaluation, for instance, might find that followup testing in an in vitro mammalian cell mutation assay and in vivo mutation assay are both negative and that other considerations do not raise any other safety concerns. Positive findings in either the in vitro mammalian cell mutation assay or in vivo mutation assay would preclude testing in healthy human subjects. The sponsor also should provide a thoroughly considered rationale for why FIH trials should enroll healthy subjects in lieu of patients with the disease or condition the investigational drug product with the Ames-positive active ingredient is intended to treat. Alternatively, consideration should be given to enrolling patients with the disease or condition of interest and designing the trial in a manner that may offer a treatment benefit in addition to the usual aims of a phase 1 trial (
                    <E T="03">e.g.,</E>
                     pharmacokinetics, tolerability, etc.).
                </P>
                <P>
                    The guidance recommends that a consistent process of followup testing and evaluation should first be conducted for an Ames-positive active ingredient before FIH trials are commenced in healthy subjects. An Ames-positive metabolite observed at low levels (
                    <E T="03">e.g.,</E>
                     at the threshold of toxicological concern) would generally pose minimal safety concerns and may be managed differently. The recommendations explained in the guidance for followup testing are intended to inform both review staff and industry.
                </P>
                <P>This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on “Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects.” It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.</P>
                <HD SOURCE="HD1">II. Paperwork Reduction Act of 1995</HD>
                <P>While this guidance contains no collection of information, it does refer to previously approved FDA collections of information. The previously approved collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521). The collections of information in 21 CFR part 312 for investigational new drug applications have been approved under OMB control number 0910-0014. The collections of information found in 21 CFR parts 50 and 56 pertaining to protection of human subjects have been approved under OMB control number 0910-0130.</P>
                <HD SOURCE="HD1">III. Electronic Access</HD>
                <P>
                    Persons with access to the internet may obtain the draft guidance at 
                    <E T="03">https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/regulatory-information/search-fda-guidance-documents</E>
                    , or 
                    <E T="03">https://www.regulations.gov</E>
                    .
                </P>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>P. Ritu Nalubola,</NAME>
                    <TITLE>Associate Commissioner for Policy.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27796 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>Food and Drug Administration</SUBAGY>
                <DEPDOC>[Docket No. FDA-2024-D-4643]</DEPDOC>
                <SUBJECT>Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products; Draft Guidance for Industry; Availability</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Food and Drug Administration, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of availability.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products.” This draft guidance provides recommendations to sponsors regarding the measurement of ovarian toxicity using clinical measures and biomarkers of ovarian function in relevant cancer clinical trials that enroll premenopausal adults with ovaries. Assessment of ovarian toxicity in cancer trials helps ensure that patients and clinicians have information about the possible long-term impacts of treatment on ovarian function and thus facilitate informed decision-making regarding anti-cancer agents.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Submit either electronic or written comments on the draft guidance by January 27, 2025, to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may submit comments on any guidance at any time as follows:</P>
                </ADD>
                <HD SOURCE="HD2">Electronic Submissions</HD>
                <P>Submit electronic comments in the following way:</P>
                <P>
                    • 
                    <E T="03">Federal eRulemaking Portal:</E>
                      
                    <E T="03">https://www.regulations.gov.</E>
                     Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to 
                    <E T="03">https://www.regulations.gov</E>
                     will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your 
                    <PRTPAGE P="93612"/>
                    comments, that information will be posted on 
                    <E T="03">https://www.regulations.gov.</E>
                </P>
                <P>• If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).</P>
                <HD SOURCE="HD2">Written/Paper Submissions</HD>
                <P>Submit written/paper submissions as follows:</P>
                <P>
                    • 
                    <E T="03">Mail/Hand Delivery/Courier (for written/paper submissions):</E>
                     Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
                </P>
                <P>• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”</P>
                <P>
                    <E T="03">Instructions:</E>
                     All submissions received must include the Docket No. FDA-2024-D-4643 for “Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at 
                    <E T="03">https://www.regulations.gov</E>
                     or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
                </P>
                <P>
                    • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on 
                    <E T="03">https://www.regulations.gov.</E>
                     Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: 
                    <E T="03">https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.</E>
                </P>
                <P>
                    <E T="03">Docket:</E>
                     For access to the docket to read background documents or the electronic and written/paper comments received, go to 
                    <E T="03">https://www.regulations.gov</E>
                     and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.
                </P>
                <P>You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).</P>
                <P>
                    Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the 
                    <E T="02">SUPPLEMENTARY INFORMATION</E>
                     section for electronic access to the draft guidance document.
                </P>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Suparna Wedam, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 2112, Silver Spring, MD 20993, 301-796-1776, or James Myers, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993, 240-402-7911.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>FDA is announcing the availability of a draft guidance for industry entitled “Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products.” This draft guidance provides recommendations to sponsors regarding the measurement of ovarian toxicity using clinical measures and biomarkers of ovarian function in relevant cancer clinical trials that enroll premenopausal adults with ovaries. Loss of ovarian function is a potentially irreversible toxicity associated with systemic anti-cancer agents that may result in infertility and long-term morbidities related to early-onset menopause and estrogen deficiency, including vasomotor symptoms, sexual dysfunction, osteoporosis, cardiovascular disease, and cognitive dysfunction. Routine collection of ovarian toxicity data in cancer clinical trials of investigational agents is currently lacking. Assessment of ovarian toxicity in cancer trials is essential to ensure that patients and clinicians have information about the possible long-term impacts of treatment on ovarian function and thus facilitate informed decision-making regarding anti-cancer agents.</P>
                <P>This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on “Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products.” It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.</P>
                <HD SOURCE="HD1">II. Paperwork Reduction Act of 1995</HD>
                <P>While this guidance contains no collection of information, it does refer to previously approved FDA collections of information. The previously approved collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521). The collections of information in 21 CFR part 312 for investigational new drug applications have been approved under OMB control number 0910-0014. The collections of information in 21 CFR part 314 relating to new drug applications have been approved under OMB control number 0910-0001. The collections of information in 21 CFR part 601 relating to biologics license applications have been approved under OMB control number 0910-0338.</P>
                <HD SOURCE="HD1">III. Electronic Access</HD>
                <P>
                    Persons with access to the internet may obtain the draft guidance at 
                    <E T="03">https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/regulatory-information/search-fda-guidance-documents,</E>
                     or 
                    <E T="03">https://www.regulations.gov.</E>
                </P>
                <SIG>
                    <DATED>Dated: November 19, 2024.</DATED>
                    <NAME>P. Ritu Nalubola,</NAME>
                    <TITLE>Associate Commissioner for Policy.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27804 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4164-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="93613"/>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <DEPDOC>[Document Identifier: OS-4040-0012]</DEPDOC>
                <SUBJECT>Agency Information Collection Request; 60-Day Public Comment Request</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of the Secretary, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments on the ICR must be received on or before January 27, 2025.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments 
                        <E T="03">sagal.musa@hhs.gov</E>
                         or by calling (202) 205-2634.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        When submitting comments or requesting information, please include the document identifier 4040-0012-60D and project title for reference, to Sagal Musa, email: 
                        <E T="03">sagal.musa@hhs.gov,</E>
                         or call (202) 205-2634 the Reports Clearance Officer.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.</P>
                <P>
                    <E T="03">Title of the Collection:</E>
                     SF-270 Request for Advance or Reimbursement.
                </P>
                <P>
                    <E T="03">Type of Collection:</E>
                     Extension.
                </P>
                <P>
                    <E T="03">OMB No.</E>
                     4040-0012.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The SF-270 Request for Advance or Reimbursement is a federal form used by grant awardees to request funds either in advance or as reimbursement for project expenses. This IC expires on January 31, 2025. 
                    <E T="03">Grants.gov</E>
                     seeks a three-year clearance of these collections.
                </P>
                <GPOTABLE COLS="6" OPTS="L2,i1" CDEF="s50,r50,12,12,12,12">
                    <TTITLE>Annualized Burden Hour Table</TTITLE>
                    <BOXHD>
                        <CHED H="1">Forms (if necessary)</CHED>
                        <CHED H="1">Respondents (if necessary)</CHED>
                        <CHED H="1">
                            Number of
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Number of
                            <LI>responses per</LI>
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Average
                            <LI>burden per</LI>
                            <LI>response</LI>
                        </CHED>
                        <CHED H="1">Total burden hours</CHED>
                    </BOXHD>
                    <ROW RUL="n,n,s">
                        <ENT I="01">SF-270 Request for Advance or Reimbursement</ENT>
                        <ENT>Grant Applicants</ENT>
                        <ENT>100,000</ENT>
                        <ENT>1</ENT>
                        <ENT>1</ENT>
                        <ENT>100,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Total</ENT>
                        <ENT/>
                        <ENT>100,000</ENT>
                        <ENT>1</ENT>
                        <ENT>1</ENT>
                        <ENT>100,000</ENT>
                    </ROW>
                </GPOTABLE>
                <SIG>
                    <NAME>Sherrette A. Funn,</NAME>
                    <TITLE>Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27721 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4151-AE-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <DEPDOC>[Document Identifier: OS-4040-0014]</DEPDOC>
                <SUBJECT>Agency Information Collection Request. 60-Day Public Comment Request</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of the Secretary, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments on the ICR must be received on or before January 27, 2025.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments to 
                        <E T="03">sagal.musa@hhs.gov</E>
                         or by calling (202) 205-2634.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        When submitting comments or requesting information, please include the document identifier 4040-0014-60D and project title for reference, to Sagal Musa, email: 
                        <E T="03">sagal.musa@hhs.gov,</E>
                         or call (202) 205-2634 the Reports Clearance Officer.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.</P>
                <P>
                    <E T="03">Title of the Collection:</E>
                     Federal Financial Report (SF-425) and Federal Financial Report Attachment (SF-425A).
                </P>
                <P>
                    <E T="03">Type of Collection:</E>
                     Extension.
                </P>
                <P>
                    <E T="03">OMB No.</E>
                     4040-0014.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     Federal Financial Report (SF-425) and Federal Financial Report Attachment (SF-425A) are used by applicants to apply for Federal financial assistance. The Federal Financial Report (SF-425) and Federal Financial Report Attachment (SF-425A) forms allow the applicants to provide certain financial information as part of their grant proposals. These forms are evaluated by Federal agencies as part of the overall grant application. This IC expires on February 28, 2025. 
                    <E T="03">Grants.gov</E>
                     seeks a three-year clearance of these collections.
                </P>
                <P>
                    <E T="03">Type of Respondent:</E>
                     The Federal Financial Report (SF-425) and Federal Financial Report Attachment (SF-425A) forms are used by organizations to apply for Federal financial assistance in the form of grants. These forms are submitted to the Federal grant-making agencies for evaluation and review.
                    <PRTPAGE P="93614"/>
                </P>
                <GPOTABLE COLS="6" OPTS="L2,i1" CDEF="s50,r50,r50,12,12,r50">
                    <TTITLE>Annualized Burden Hour Table</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            Forms
                            <LI>(if necessary)</LI>
                        </CHED>
                        <CHED H="1">
                            Respondents
                            <LI>(if necessary)</LI>
                        </CHED>
                        <CHED H="1">
                            Number of 
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Number of 
                            <LI>responses per respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Average 
                            <LI>burden per </LI>
                            <LI>response</LI>
                        </CHED>
                        <CHED H="1">Total burden hours</CHED>
                    </BOXHD>
                    <ROW RUL="n,s">
                        <ENT I="01">Federal Financial Report (SF-425) and Federal Financial Report Attachment (SF-425A)</ENT>
                        <ENT>
                            Grant-seeking organizations
                            <LI>Grant-seeking organizations</LI>
                        </ENT>
                        <ENT>
                            100,000
                            <LI>100,000</LI>
                        </ENT>
                        <ENT>
                            1
                            <LI>1</LI>
                        </ENT>
                        <ENT>
                            1
                            <LI>1</LI>
                        </ENT>
                        <ENT>
                            100,000
                            <LI>100,000</LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Total</ENT>
                        <ENT/>
                        <ENT/>
                        <ENT>1</ENT>
                        <ENT/>
                        <ENT>200,000</ENT>
                    </ROW>
                </GPOTABLE>
                <SIG>
                    <NAME>Sherrette A. Funn,</NAME>
                    <TITLE>Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27716 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4151-AE-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <DEPDOC>[Document Identifier: OS-4040-0016]</DEPDOC>
                <SUBJECT>Agency Information Collection Request. 60-Day Public Comment Request</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of the Secretary, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments on the ICR must be received on or before January 27, 2025.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments to 
                        <E T="03">sagal.musa@hhs.gov</E>
                         or by calling (202) 205-2634.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        When submitting comments or requesting information, please include the document identifier 4040-0016-60D and project title for reference, to Sagal Musa, email: 
                        <E T="03">sagal.musa@hhs.gov,</E>
                         or call (202) 205-2634 the Reports Clearance Officer.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.</P>
                <P>Title of the Collection: SF-429-C Real Property Status Report ATTACHMENT C (Disposition or Encumbrance Request), SF-429-B Real Property Status Report ATTACHMENT B (Request to Acquire, Improve or Furnish), SF-429-A Real Property Status Report ATTACHMENT A (General Reporting), INSTRUCTIONS FOR THE SF-429 Real Property Status Report, and SF-429 Real Property Status Report (Cover Page).</P>
                <P>
                    <E T="03">Type of Collection:</E>
                     Extension.
                </P>
                <P>
                    <E T="03">OMB No.</E>
                     4040-0016.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     SF-429-C Real Property Status Report ATTACHMENT C (Disposition or Encumbrance Request), SF-429-B Real Property Status Report ATTACHMENT B (Request to Acquire, Improve or Furnish), SF-429-A Real Property Status Report ATTACHMENT A (General Reporting), INSTRUCTIONS FOR THE SF-429 Real Property Status Report, and SF-429 Real Property Status Report (Cover Page) forms allow the applicants to provide real property details as part of their grant proposals. These forms are evaluated by Federal agencies as part of the overall grant application. This IC expires on February 28, 2025. 
                    <E T="03">Grants.gov</E>
                     seeks a three-year clearance of these collections.
                </P>
                <P>
                    <E T="03">Type of Respondent:</E>
                     SF-429-C Real Property Status Report ATTACHMENT C (Disposition or Encumbrance Request), SF-429-B Real Property Status Report ATTACHMENT B (Request to Acquire, Improve or Furnish), SF-429-A Real Property Status Report ATTACHMENT A (General Reporting), INSTRUCTIONS FOR THE SF-429 Real Property Status Report, and SF-429 Real Property Status Report (Cover Page) forms are used by organizations to apply for Federal financial assistance in the form of grants. These forms are submitted to the Federal grant-making agencies for evaluation and review.
                </P>
                <GPOTABLE COLS="6" OPTS="L2,i1" CDEF="s50,r50,12,12,12,12">
                    <TTITLE>Annualized Burden Hour Table</TTITLE>
                    <BOXHD>
                        <CHED H="1">Forms (if necessary)</CHED>
                        <CHED H="1">Respondents (if necessary)</CHED>
                        <CHED H="1">
                            Number of
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Number of
                            <LI>responses per</LI>
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Average
                            <LI>burden per</LI>
                            <LI>response</LI>
                        </CHED>
                        <CHED H="1">
                            Total burden
                            <LI>hours</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">SF-429-C Real Property Status Report ATTACHMENT C (Disposition or Encumbrance Request)</ENT>
                        <ENT>Grant-seeking organizations</ENT>
                        <ENT>100,000</ENT>
                        <ENT>1</ENT>
                        <ENT>1</ENT>
                        <ENT>50,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">SF-429-B Real Property Status Report ATTACHMENT B (Request to Acquire, Improve or Furnish)</ENT>
                        <ENT>Grant-seeking organizations</ENT>
                        <ENT>100,000</ENT>
                        <ENT>1</ENT>
                        <ENT>1</ENT>
                        <ENT>100,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">SF-429-A Real Property Status Report ATTACHMENT A (General Reporting</ENT>
                        <ENT>Grant-seeking organizations</ENT>
                        <ENT>100,000</ENT>
                        <ENT>1</ENT>
                        <ENT>1</ENT>
                        <ENT>100,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">INSTRUCTIONS FOR THE SF-429 Real Property Status Report</ENT>
                        <ENT>Grant-seeking organizations</ENT>
                        <ENT>100,000</ENT>
                        <ENT>1</ENT>
                        <ENT>0.5</ENT>
                        <ENT>100,000</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">SF-429 Real Property Status Report (Cover Page)</ENT>
                        <ENT>Grant-seeking organizations</ENT>
                        <ENT>100,000</ENT>
                        <ENT>1</ENT>
                        <ENT>1</ENT>
                        <ENT>100,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Total</ENT>
                        <ENT/>
                        <ENT/>
                        <ENT>1</ENT>
                        <ENT/>
                        <ENT>450,000</ENT>
                    </ROW>
                </GPOTABLE>
                <SIG>
                    <PRTPAGE P="93615"/>
                    <NAME>Sherrette A. Funn,</NAME>
                    <TITLE>Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27723 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4151-AE-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <DEPDOC>[Document Identifier: OS-4040-0013]</DEPDOC>
                <SUBJECT>Agency Information Collection Request. 60-Day Public Comment Request</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of the Secretary, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments on the ICR must be received on or before January 27, 2025.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments to 
                        <E T="03">sagal.musa@hhs.gov</E>
                         or by calling (202) 205-2634.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        When submitting comments or requesting information, please include the document identifier 4040-0013-60D and project title for reference, to Sagal Musa, email: 
                        <E T="03">sagal.musa@hhs.gov,</E>
                         or call (202) 205-2634 the Reports Clearance Officer.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.</P>
                <P>
                    <E T="03">Title of the Collection:</E>
                     Disclosure of Lobbying Activities (SF-LLL) and Certification Regarding Lobbying.
                </P>
                <P>
                    <E T="03">Type of Collection:</E>
                     Extension.
                </P>
                <P>OMB No. 4040-0013.</P>
                <P>
                    <E T="03">Abstract:</E>
                     Disclosure of Lobbying Activities (SF-LLL) and Certification Regarding Lobbying are OMB-approved collections (4040-0013). These information collections are used by grant applicants. This IC expires on February 28, 2025. We are requesting a three-year clearance of these collections.
                </P>
                <P>
                    <E T="03">Type of respondent:</E>
                     The Disclosure of Lobbying Activities (SF-LLL) and Certification Regarding Lobbying forms are used by organizations to apply for Federal financial assistance in the form of grants. These forms are submitted to the Federal grant-making agencies for evaluation and review.
                </P>
                <GPOTABLE COLS="6" OPTS="L2,i1" CDEF="s50,r50,12,12,12,12">
                    <TTITLE>Annualized Burden Hour Table</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            Forms
                            <LI>(if necessary)</LI>
                        </CHED>
                        <CHED H="1">
                            Respondents
                            <LI>(if necessary)</LI>
                        </CHED>
                        <CHED H="1">
                            Number of 
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Number of 
                            <LI>responses per respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Average 
                            <LI>burden per </LI>
                            <LI>response</LI>
                        </CHED>
                        <CHED H="1">Total burden hours</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Disclosure of Lobbying Activities (SF-LLL)</ENT>
                        <ENT>Grant Applicants</ENT>
                        <ENT>12,675</ENT>
                        <ENT>1</ENT>
                        <ENT>1</ENT>
                        <ENT>12,675</ENT>
                    </ROW>
                    <ROW RUL="n,s">
                        <ENT I="01">Certification Regarding Lobbying</ENT>
                        <ENT>Grant Applicants</ENT>
                        <ENT>3,952</ENT>
                        <ENT>1</ENT>
                        <ENT>0.5</ENT>
                        <ENT>1,976</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Total</ENT>
                        <ENT/>
                        <ENT>12,675</ENT>
                        <ENT>1</ENT>
                        <ENT/>
                        <ENT>14,651</ENT>
                    </ROW>
                </GPOTABLE>
                <SIG>
                    <NAME>Sherrette A. Funn,</NAME>
                    <TITLE>Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27714 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4151-AE-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <DEPDOC>[Document Identifier: OS-0990-0434]</DEPDOC>
                <SUBJECT>Agency Information Collection Request. 60-Day Public Comment Request</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of the Secretary, HHS.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments on the ICR must be received on or before January 27, 2025.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit your comments to 
                        <E T="03">Sherrette.Funn@hhs.gov</E>
                         or by calling (202) 264-0041 and 
                        <E T="03">PRA@HHS.GOV.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        When submitting comments or requesting information, please include the document identifier 0990-0434-60D and project title for reference, to Sherrette A. Funn, email: 
                        <E T="03">Sherrette.Funn@hhs.gov, PRA@HHS.GOV</E>
                         or call (202) 264-0041 the Reports Clearance Officer.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.</P>
                <P>
                    <E T="03">Title of the Collection:</E>
                     Meetings, Conferences, and Seminars—Public Accommodations and Commercial Facilities—Funding and Sponsorship.
                </P>
                <P>
                    <E T="03">Type of Collection:</E>
                     Extension.
                </P>
                <P>OMB No. 0990-0434—Office of the Assistant Secretary for Financial Resources, Office of Acquisitions.</P>
                <P>
                    <E T="03">Abstract:</E>
                     Meetings, Conferences, and Seminars—Public Accommodations and Commercial Facilities—Funding and Sponsorship: Performance of HHS mission requires the support of contractors. In some circumstances, depending on the requirements of the specific contract, the contractor is tasked to conduct meetings, conferences, and seminars. HHSAR 311.7101(a) (Responsibilities) and the clause at HHSAR 352.211-1 (Accessibility of meetings, conferences, and seminars to persons with disabilities) require contractors to provide a plan describing the contractor's ability to meet the accessibility standards in 28 CFR part 36. HHSAR 311.7202(b) (Responsibilities) and the clause at HHSAR 352.211-2 (Conference sponsorship request and conference materials disclaimer) require contractors to provide funding disclosure and a content disclaimer statement on conference materials. As a result of these clauses, HHS contractors 
                    <PRTPAGE P="93616"/>
                    providing conference, meeting, or seminars services are required to provide specific information to HHS as stated in the HHS Acquisition Regulation.
                </P>
                <P>The Agency is requesting a 3-year extension to collect this information from public or private businesses.</P>
                <GPOTABLE COLS="6" OPTS="L2,i1" CDEF="s50,r50,12,12,12,12">
                    <TTITLE>Annualized Burden Hour Table</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            Forms
                            <LI>(if necessary)</LI>
                        </CHED>
                        <CHED H="1">
                            Respondents
                            <LI>(if necessary)</LI>
                        </CHED>
                        <CHED H="1">
                            Number of
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Number of
                            <LI>responses per</LI>
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Average
                            <LI>burden per</LI>
                            <LI>response</LI>
                        </CHED>
                        <CHED H="1">Total burden hours</CHED>
                    </BOXHD>
                    <ROW RUL="n,n,s">
                        <ENT I="22"> </ENT>
                        <ENT>Business (Contractor)</ENT>
                        <ENT>1,067</ENT>
                        <ENT>1</ENT>
                        <ENT>1</ENT>
                        <ENT>1,067</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Total</ENT>
                        <ENT/>
                        <ENT>1,067</ENT>
                        <ENT>1</ENT>
                        <ENT>1</ENT>
                        <ENT>1,067</ENT>
                    </ROW>
                </GPOTABLE>
                <SIG>
                    <NAME>Sherrette A. Funn,</NAME>
                    <TITLE>Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27806 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4150-24-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>National Institutes of Health</SUBAGY>
                <SUBJECT>National Heart, Lung, and Blood Institute, National Institutes of Health; Notice of Meeting</SUBJECT>
                <P>Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Sickle Cell Disease Advisory Committee.</P>
                <P>
                    The meeting will be held as a virtual meeting and open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH Videocast at the following link: 
                    <E T="03">https://videocast.nih.gov/watch=55419</E>
                    .
                </P>
                <EXTRACT>
                    <P>
                        <E T="03">Name of Committee:</E>
                         Sickle Cell Disease Advisory Committee.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         January 14, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         10:00 a.m. to 3:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         NHLBI Sickle Cell Disease Program Updates and Long Term Follow-up of Participants undergoing gene therapy for SCD.
                    </P>
                    <P>
                        <E T="03">Place:</E>
                         National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.
                    </P>
                    <P>
                        <E T="03">Contact Person: julie.panepinto@nih.gov</E>
                        .
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.</P>
                    <P>
                        Information is also available on the Institute's/Center's home page: 
                        <E T="03">https://www.nhlbi.nih.gov/advisory-and-peer-review-committees/nhlbi-sickle-cell-disease-advisory-committee</E>
                         where an agenda and any additional information for the meeting will be posted when available.
                    </P>
                    <FP>(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)</FP>
                </EXTRACT>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Bruce A. George, </NAME>
                    <TITLE>Program Analyst, Office of Federal Advisory Committee Policy.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27878 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4140-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>National Institutes of Health</SUBAGY>
                <SUBJECT>Draft Revised Human Immunodeficiency Virus (HIV) Organ Policy Equity Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>National Institutes of Health, Department of Health and Human Services.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The HOPE Act requires the Secretary of Health and Human Services (the Secretary) to develop and publish criteria for research involving the transplantation of organs from donors with HIV to recipients with HIV. In 2015, the National Institutes of Health (NIH), and the U.S. Department of Health and Human Services (HHS) published research criteria applicable to such transplants, which have been in effect for all transplants involving organs from donors with HIV as authorized by the HOPE Act. As amended in an HHS final rule published elsewhere in this issue of the 
                        <E T="04">Federal Register</E>
                        , the Secretary determined that participation in clinical research should no longer be a requirement for the transplantation of kidneys and livers from donors with HIV to recipients with HIV and amended the HHS regulations governing the operation of the Organ Procurement and Transplantation Network (OPTN) to reflect this determination. As a result, HOPE Act transplants involving kidneys and livers from donors with HIV no longer need to comply with the research criteria. Given this regulatory change, NIH proposes to delete aspects of the research criteria that are specific to kidney and liver transplantation. NIH proposes additional changes to the research criteria based on its review of scientific evidence and in consideration of prior public feedback concerning the criteria, including comments provided in the recent rulemaking procedure that modified the OPTN regulations. NIH invites the public to submit comments regarding the proposed changes to the research criteria.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>To ensure that comments will be considered, comments must be received no later than 5 p.m. on December 12, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>Comments may be submitted by any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Email: HOPEAct@mail.nih.gov.</E>
                    </P>
                    <P>
                        • 
                        <E T="03">Fax:</E>
                         301-451-5671.
                    </P>
                    <P>
                        • 
                        <E T="03">Regular Mail:</E>
                         Dr. Jonah Odim, 5601 Fishers Lane, Room 6B21, MSC 9827, Bethesda, MD 20892-9827.
                    </P>
                    <P>
                        • 
                        <E T="03">Hand Delivery, Overnight Mail, FedEx, and UPS:</E>
                         Dr. Jonah Odim, 5601 Fishers Lane, Room 6B21, MSC 9827, Rockville, MD 20852.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Dr. Jonah Odim, Chief Clinical Transplantation Section, Transplantation Branch, 5601 Fishers 
                        <PRTPAGE P="93617"/>
                        Lane, Room 6B21, MSC 9827, Rockville, MD 20892-9827; by email at 
                        <E T="03">odimj@niaid.nih.gov;</E>
                         by telephone at (301) 828-7220.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <HD SOURCE="HD2">A. HHS Oversight of Organ Allocation and Transplantation</HD>
                <P>HHS is responsible for overseeing the operation of the nation's OPTN, including assisting in the equitable allocation of donor organs for transplantation. 42 U.S.C. 274(b)(2)(D). The OPTN is a network of transplant centers, organ procurement organizations, and other providers who work collectively to develop, implement, and monitor organ allocation policy and performance of the organ transplant system. The OPTN is also charged with developing policies on many subjects related to organ donation and transplantation, which include establishing standards of quality pertaining to organs procured for use in transplantation. 42 U.S.C. 274(b)(2)(E).</P>
                <HD SOURCE="HD2">B. HOPE Act Requirements and Implementation</HD>
                <P>The enactment of the HOPE Act in 2013, Public Law 113-51, eliminated the prohibition in the United States on transplantation of organs from persons with HIV, allowing transplantation of these organs if certain requirements are satisfied. Under the HOPE Act, organs from donors with HIV may be transplanted only in recipients living with HIV prior to receiving such an organ. 42 U.S.C. 274(b)(3)(A). Further, the HOPE Act requires that transplants of HIV-positive organs occur only in recipients with HIV who are participating in institutional review board (IRB)-approved research protocols that adhere to certain criteria, standards, and regulations. 42 U.S.C. 274(b)(3)(B)(i). However, the Secretary may lift the research and IRB requirements if the Secretary has determined that participation in such clinical research, as a requirement for such transplants, is no longer warranted. 42 U.S.C. 274(b)(3)(B)(ii).</P>
                <P>The HOPE Act outlines the process by which the Secretary may make such a determination under 42 U.S.C. 274(b)(3)(B)(ii). Specifically, the Secretary must routinely review the results of scientific research, in conjunction with the OPTN, to determine whether the results warrant revision of the OPTN standards of quality regarding organs from donors with HIV. If the Secretary determines that those standards of quality should be revised, the Secretary must direct the OPTN to revise the standards. 42 U.S.C. 274f-5(c)(2). The Secretary is also required to revise the regulatory provision implementing the HOPE Act, 42 CFR 121.6, upon determining that revisions to the OPTN standards of quality are warranted. 42 U.S.C. 274f-5(c)(3).</P>
                <HD SOURCE="HD2">C. Research Criteria for HOPE Act Transplants</HD>
                <P>
                    In 2015, NIH published proposed research criteria for HOPE Act transplants in the 
                    <E T="04">Federal Register</E>
                     and solicited public comment. 80 FR 34912 (June 18, 2015). After consideration of public comments received, NIH published the “Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV” (“2015 Research Criteria”). 80 FR 73785 (November 25, 2015). The goals of the 2015 Research Criteria were to ensure that research using organs from donors with HIV was conducted under conditions protecting the safety of research participants and the public and that the results of this research provide a basis for evaluating the safety of transplants of organs from donors with HIV in recipients with HIV. 80 FR 73785.
                </P>
                <HD SOURCE="HD3">1. Proposed Changes to the 2015 Research Criteria</HD>
                <P>NIH is now proposing changes to the 2015 Research Criteria to reflect the Secretary's determination, published by regulation on November 27, 2024, that HOPE Act kidney and liver transplants are no longer required to be conducted as research subject to the 2015 Research Criteria and to continue to further the goals shared in 2015 with respect to HOPE Act transplants of other organs from donors with HIV that remain subject to the Research Criteria. NIH proposes to remove requirements from the Research Criteria applicable to HOPE Act kidney and liver transplants.</P>
                <P>
                    NIH also proposes other changes to the 2015 NIH Research Criteria for conducting HOPE Act transplants of organs other than kidneys and livers (primarily heart and lung transplants) in IRB-approved research. The proposed changes are intended to accelerate research, ensure research participant safety, and maintain stakeholder confidence in clinical research conducted under the HOPE Act. Notable revisions include the elimination of (i) the transplant program experience requirement of five organ-specific transplants of organs from a donor without HIV in a recipient with HIV conducted over 4 years; (ii) mandated pre-implant biopsies; and (iii) the requirement for HIV independent advocates for living donors with HIV and recipients with HIV. Other organs (including multi visceral organs such as small intestine, stomach, liver, pancreas and colon) and multi organ transplants (
                    <E T="03">e.g.,</E>
                     heart-kidney) must comply with the revised Research Criteria for inclusion of any non-kidney or non-liver organs from donors with HIV and subject to IRB approval.
                </P>
                <HD SOURCE="HD3">2. Consideration of Public Comment Received on the HOPE Act NPRM</HD>
                <P>In proposing these changes, NIH has considered the public participation in the HOPE Act rulemaking process through which the Secretary's determination was made. In response to the September 21, 2024, notice of proposed rulemaking that proposed the Secretary's determination with respect to HOPE Act kidney and liver transplants, 89 FR 74174, HHS received multiple comments that were relevant to the NIH Research Criteria, and some comments provided specific suggestions for the content of the revised NIH Research Criteria. All comments relating to the content of the revised Research Criteria were provided to NIH for consideration in the development of the proposed revised Research Criteria that appear later in this document. NIH has considered these comments and proposes changes to the Research Criteria responsive to specific comments received, as described here.</P>
                <P>
                    • Several commenters noted that referring to organs “infected with HIV” or “HIV positive organs” may be stigmatizing, and one commenter requested that references to “organs with HIV” be revised to “organ(s) from donors with HIV.” The commenters indicated a strong preference for the use of stigma-reducing, and person-first language. In response to these comments, NIH proposes to revise references in the Research Criteria to refer to donors with HIV, recipients with HIV, and organs from donors with HIV. This is consistent with the Centers for Disease Control and Prevention's (CDC) Stigma Language Guide 
                    <SU>1</SU>
                    <FTREF/>
                     and with language adopted in the final rule.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Centers for Disease Control and Prevention. Let's Stop HIV Together: Stigma Language Guide. 
                        <E T="03">https://www.cdc.gov/stophivtogether/hiv-stigma/ways-to-stop.html.</E>
                         Accessed 2/23/2024.
                    </P>
                </FTNT>
                <P>
                    • Commenters also requested the elimination of the current requirement that a transplant team perform at least five transplants within a four-year period between any donor and a recipient with HIV for all organs, as, in the commenters' estimation, this 
                    <PRTPAGE P="93618"/>
                    requirement is not necessary for organs from donors with HIV to be used safely. In response to these comments and based on its review of the evidence, NIH proposes to remove this requirement from the proposed revised Research Criteria.
                </P>
                <P>• Commenters suggested that each transplant team should include infectious disease specialists with expertise in HIV care. In response to these comments and based on its review of the evidence, NIH proposes that this requirement of the 2015 NIH Research Criteria be retained in the revised Research Criteria.</P>
                <P>• One commenter requested the elimination of the biopsy requirement. In response to this comment and based on its review of the evidence, NIH proposes to eliminate the requirement for a pre-implantation biopsy.</P>
                <P>• One commenter noted that, in revising the Research Criteria, NIH should maintain the strong patient safety record for HOPE Act transplants, while actively seeking to reduce burdens that may be slowing the establishment of non-kidney and non-liver HOPE Act transplant programs. In response to this comment and based on its review of the evidence, NIH believes that the proposed revisions to the Research Criteria appropriately strike this balance.</P>
                <P>NIH's rationale for these specific proposed revisions to the Research Criteria is provided in more detail in Section III, below.</P>
                <P>The Secretary delegated to the Director, NIH, the responsibility to revise the 2015 Research Criteria. The proposed revised Research Criteria proposed below were developed by NIH staff in collaboration with representatives of the Centers for Disease Control and Prevention, the Food and Drug Administration, the Health Resources and Services Administration, and the Office of the Assistant Secretary for Health.</P>
                <P>If adopted as proposed, it is anticipated that the revised Research Criteria would expand access to transplantation for recipients with HIV, provide benefits to organ donors; ensure safety of ongoing HOPE Act transplants of organs other than kidneys and livers; and provide for the systematic collection of safety and efficacy data related to transplants of hearts, lungs, and other organs from donors with HIV in recipients with HIV.</P>
                <HD SOURCE="HD3">3. Other Considerations</HD>
                <HD SOURCE="HD3">(a) Research Results—Heart and Lung Transplants in Recipients With HIV</HD>
                <P>As the Secretary has decided that HOPE Act transplants of organs other than kidneys and livers should remain subject to the Research Criteria until additional scientific research demonstrates the safety and efficacy of such transplants, NIH wishes to highlight the current state of the science with regard to transplantation of hearts and lungs from donors without HIV in recipients with HIV. The early outcomes data for such transplants may provide a foundation for future HOPE Act thoracic organ transplants (Koval 2018, 2019; Madan 2019). For example, in a retrospective analysis utilizing the OPTN database to compare outcomes of 75 heart transplant recipients with HIV to those of 29,848 heart transplant recipients without HIV, survival rates were similar across the comparator groups, while rejection rates were approximately 2-fold higher in recipients with HIV (38.7% vs. 17.7%, respectively) (Doberne 2021). Similar findings were reported in studies based on the International Society for Heart and Lung Transplantation (ISHLT) and Scientific Registry of Transplant Recipients (SRTR) databases (Wairmu 2021; Storm 2024; Madan 2019). Fewer transplants of lungs from donors without HIV in recipients with HIV have been reported (Koval 2019; Kern 2014; Rouzaud 2022).</P>
                <P>NIH recognizes that additional research in this area will advance the state of the relevant science, and the results of such research will increase the evidence basis needed to support any future determination by the Secretary that participation in clinical research is no longer a requirement for transplants of hearts or lungs from donors with HIV in recipients with HIV.</P>
                <HD SOURCE="HD3">(b) Education Regarding the HOPE Act</HD>
                <P>
                    While no related proposals are included in the proposed revision to the 2015 Research Criteria, NIH further notes that expanding awareness and continuing education of potential organ donors, transplant centers, organ procurement organizations (OPOs), healthcare providers, and people living with HIV will be important to fully realize the medical and societal benefits envisioned under the HOPE Act. Success in these endeavors will expand the supply of quality donor HIV organs, enhance transplant access, improve quality of life, and increase longevity for potential transplant recipients with HIV. Reducing longstanding stigma and increasing access to organ transplantation will be particularly important for communities disproportionately impacted by HIV (
                    <E T="03">https://www.hiv.gov/hiv-basics/overview/about-hiv-and-aids/who-is-at-risk-for-hiv</E>
                    ).
                </P>
                <HD SOURCE="HD3">(D) Secretary's Review of Research Results</HD>
                <P>As stated above, the HOPE Act requires that the Secretary, in conjunction with the OPTN, periodically review the results of scientific research to determine whether the results warrant revision to the OPTN standards of quality with respect to organs from donors with HIV and the safety of transplanting an organ from a donor with a particular strain of HIV into a recipient with a different strain of HIV. 42 U.S.C. 274f-5(c)(1). This review allows the Secretary to determine if the safety and efficacy of HOPE Act transplants are comparable to non-HOPE Act transplants and, if warranted, to further determine whether such transplants may be conducted outside of a research setting.</P>
                <P>
                    Past procedures for this review are described in detail in the final rule amending the OPTN regulation. Past reviews involved deliberations by bodies that provided recommendations to the Secretary, including the OPTN (which solicited and considered public comments) 
                    <E T="51">2 3</E>
                    <FTREF/>
                     the HHS Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) 
                    <SU>4</SU>
                    <FTREF/>
                     and the HHS Blood, Organ, and Tissue Senior Executive Council (BOTSEC) (an advisory forum for senior leadership from HHS entities involved in blood, organ, and tissue safety and availability. The recommendations of the OPTN, ASBTSA, and BOTSEC, as well as subsequent research results, were considered in the Secretary's decision as to whether participation in clinical research, as a requirement for certain types of transplants of organs from donors with HIV, is no longer warranted.
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         Organ Procurement and Transplantation Network. Public Comment Proposal: Modify the HOPE Act Variance to Include Other Organs. 2019 Jan 22: 
                        <E T="03">https://optn.transplant.hrsa.gov/media/2800/dtac_publiccomment_20190122.pdf.</E>
                    </P>
                    <P>
                        <SU>3</SU>
                         Cooper M. “OPTN Letter to Secretary Becerra on the HOPE Act.” 2021 Oct 29. 
                        <E T="03">https://optn.transplant.hrsa.gov/media/ueyjdfnd/hope-act-letter.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         HHS Advisory Committee on Blood and Tissue Safety and Availability. 2022. Fifty-Sixth ACBTSA Meeting November 17, 2022—Meeting Summary. 
                        <E T="03">https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meeting-summary/2022-11-17/index.html.</E>
                    </P>
                </FTNT>
                <P>
                    Although not incorporated into the 2015 Research Criteria or the proposed revised criteria, HHS intends to conduct a regular review of such scientific research to enable evidence-based recommendations, including any changes to the Research Criteria, and any determinations on transitioning additional HOPE Act organ transplants to medical practice and standard-of-care 
                    <PRTPAGE P="93619"/>
                    (
                    <E T="03">i.e.,</E>
                     removing the clinical research and IRB requirements for such transplants) if appropriate in the future. NIH seeks public comment on this approach, and on the procedures through which this review should be conducted.
                </P>
                <HD SOURCE="HD1">II. Instructions for Submitting Comments</HD>
                <P>Comments are invited on the proposed changes to the 2015 Research Criteria.</P>
                <P>
                    Please note that, during the rulemaking process resulting in the HHS final rule published elsewhere in this issue of the 
                    <E T="04">Federal Register</E>
                    , HHS received and considered public comments regarding whether HOPE Act kidney and liver transplants from donors with HIV should continue to be required to be conducted in accordance with the 2015 Research Criteria. After consideration of public comments received, the Secretary determined that participation in clinical research will no longer be a requirement for HOPE Act kidney and liver transplants from donors with HIV.
                </P>
                <P>
                    Further, in making the determination regarding HOPE Act kidney and liver transplants, the Secretary expressed the view in the notice of proposed rulemaking published on September 12, 2024, 89 FR 74174, that the current research and IRB requirements should be maintained for HOPE Act transplants of all other organs, considering the lack of data on outcomes for HOPE Act organ transplants other than kidney or liver transplants. This decision was affirmed in the HHS final rule published elsewhere in this issue of the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <P>Because the Secretary's determination regarding HOPE Act kidney and liver transplants, and the Secretary's decision that other HOPE Act organ transplants should remain subject to the Research Criteria, resulted from full notice and comment rulemaking procedures, NIH views comments concerning the Secretary's determination or decision to be outside the scope of this solicitation and such comments will not be considered. Specifically, related comments will not be considered with respect to these proposed changes to the 2015 Research Criteria: (1) eliminating the requirement that transplants involving kidneys and livers from donors with HIV comply with the NIH Research Criteria; (2) retaining the requirement that transplants involving all other organs (other than kidneys and livers) from donors with HIV comply with the NIH Research Criteria; and (3) removal of criteria specific to the transplantation of kidneys and livers.</P>
                <P>Do not include personal information in submitted comments that you do not want to be publicly disclosed.</P>
                <HD SOURCE="HD1">III. Proposed Revision to the 2015 Research Criteria</HD>
                <P>The proposed revision to the 2015 Research Criteria is as follows:</P>
                <HD SOURCE="HD3">Proposed Revised Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs From Donors With HIV</HD>
                <HD SOURCE="HD1">Table of Contents</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">Abbreviations</FP>
                    <FP SOURCE="FP-2">Definitions</FP>
                    <FP SOURCE="FP-2">Proposed Revised Hope Act Safeguards and Research Criteria</FP>
                    <FP SOURCE="FP-2">Table 1. Revised Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs With HIV</FP>
                    <FP SOURCE="FP-2">REFERENCES</FP>
                </EXTRACT>
                <GPOTABLE COLS="2" OPTS="L2,p1,7/8,i1" CDEF="s50,r150">
                    <TTITLE>Abbreviations</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">AIDS</ENT>
                        <ENT>Acquired Immunodeficiency Syndrome.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">ART</ENT>
                        <ENT>Antiretroviral Therapy.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">CD4</ENT>
                        <ENT>Cluster of Differentiation 4.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">D−</ENT>
                        <ENT>Donor Human Immunodeficiency Virus negative.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">D+</ENT>
                        <ENT>Donor Human Immunodeficiency Virus positive.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">HBV</ENT>
                        <ENT>Hepatitis B virus.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">HCT/Ps</ENT>
                        <ENT>Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">HCV</ENT>
                        <ENT>Hepatitis C virus.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">HIV</ENT>
                        <ENT>Human Immunodeficiency Virus.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">HIV−</ENT>
                        <ENT>Human Immunodeficiency Virus negative (using serology and/or nucleic acid testing using FDA-licensed, approved or cleared devices).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">HIV+</ENT>
                        <ENT>Human Immunodeficiency Virus positive (using serology and/or nucleic acid testing using FDA-licensed, approved or cleared devices).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">HOPE Act</ENT>
                        <ENT>HIV Organ Policy Equity Act.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">HRSA</ENT>
                        <ENT>Health Resources and Services Administration.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">IRB</ENT>
                        <ENT>Institutional review board.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">NIH</ENT>
                        <ENT>National Institutes of Health.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">NPRM</ENT>
                        <ENT>Notice of proposed rule making.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">OI</ENT>
                        <ENT>Opportunistic infection.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">OPO</ENT>
                        <ENT>Organ procurement organization.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">PML</ENT>
                        <ENT>Progressive multifocal leukoencephalopathy.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">R−</ENT>
                        <ENT>Recipient HIV negative.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">R+</ENT>
                        <ENT>Recipient HIV positive.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">RNA</ENT>
                        <ENT>Ribonucleic acid.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">SOPs</ENT>
                        <ENT>Standard operating procedures.</ENT>
                    </ROW>
                </GPOTABLE>
                <GPOTABLE COLS="2" OPTS="L2,p1,7/8,i1" CDEF="s50,r150">
                    <TTITLE>Definitions</TTITLE>
                    <BOXHD>
                        <CHED H="1"> </CHED>
                        <CHED H="1"> </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Antiretroviral therapy (ART) resistance</ENT>
                        <ENT>When an HIV strain develops drug resistance and/or genetic mutations associated with drug resistance.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">HIV superinfection</ENT>
                        <ENT>Systemic HIV superinfection is defined as the detection of HIV viral sequences that phylogenetically cluster with the donor's viral population at two or more time points in circulating blood cells, plasma, or recipient tissues other than the allograft.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Suppressed viral load</ENT>
                        <ENT>HIV RNA below 50 copies per mL with current technology at the time of publication of this research criteria document.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    The 2015 Research Criteria are outlined in six broad categories (Donor Eligibility, Recipient Eligibility, Transplant Hospital Criteria, Organ Procurement Organization (OPO) Responsibilities, Prevention of Inadvertent Transmission of HIV, and Study Design/Required Data Elements and Outcome Measures). Table 1 summarizes the proposed new HOPE Act Research Criteria in each category 
                    <PRTPAGE P="93620"/>
                    and compares them to the 2015 NIH Research Criteria.
                </P>
                <GPOTABLE COLS="3" OPTS="L2,nj,i1" CDEF="s75,r100,r100">
                    <TTITLE>
                        Table 1—Proposed Revised Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs From Donors With HIV 
                        <SU>1</SU>
                    </TTITLE>
                    <BOXHD>
                        <CHED H="1">Category</CHED>
                        <CHED H="1">Previous criteria</CHED>
                        <CHED H="1">
                            Proposed revised criteria
                            <LI>
                                (No longer pertains to kidney and liver transplants 
                                <SU>5</SU>
                                )
                            </LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="22">Donor Eligibility:</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="03">All deceased donors with HIV</E>
                        </ENT>
                        <ENT>No evidence of invasive opportunistic complications of HIV infection</ENT>
                        <ENT>No evidence of invasive opportunistic complications of HIV infection.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Pre-implant donor organ biopsy</ENT>
                        <ENT>There is no requirement for a pre-implantation biopsy.*</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Viral load: no requirement</ENT>
                        <ENT>Viral load: no requirement.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="03">Deceased donor with known history of HIV and prior antiretroviral therapy (ART)</E>
                        </ENT>
                        <ENT>The study team must describe the anticipated post-transplant antiretroviral regimen(s) to be prescribed for the recipient and justify its conclusion that the regimen will be safe, tolerable, and effective</ENT>
                        <ENT>The study team must describe the anticipated post-transplant antiretroviral regimen(s) to be prescribed for the recipient and justify its conclusion that the regimen will be safe, tolerable, and effective.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">
                            <E T="03">Living donor with HIV</E>
                        </ENT>
                        <ENT O="xl">
                            Well-controlled HIV infection defined as:
                            <LI O="xl">• Cluster of Differentiation 4 (CD4) + T-cell count ≥500/µL for the 6-month period before donation</LI>
                            <LI O="xl">• HIV-1 ribonucleic acid (RNA) &lt;50 copies/mL</LI>
                            <LI O="xl">• No evidence of invasive opportunistic complications of HIV infection</LI>
                            <LI O="xl">Pre-implant donor organ biopsy</LI>
                        </ENT>
                        <ENT>
                            <E T="03">Thoracic Organs Exception:</E>
                             The living donor standards are not relevant for thoracic organ transplant except in the rare instances of living donor lung transplant or “domino” heart transplant. In such circumstances, the deceased donor eligibility criteria should be followed.
                            <LI>
                                <E T="03">Other Organs:</E>
                                 If a living donor with HIV donates another type or organ (other than kidney and liver), the deceased donor eligibility criteria should be followed.*
                            </LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01" O="xl">Recipient Eligibility:</ENT>
                        <ENT>
                            CD4+ T-cell count ≥200/µL (kidney)
                            <LI>CD4+ T-cell count ≥100 µL (liver) within 16 weeks prior to transplant and no history of opportunistic infection (OI); or ≥200 µL if history of OI is present</LI>
                        </ENT>
                        <ENT>CD4+ T-cell count: no minimum threshold when all other recipient eligibility criteria are met.*</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>HIV-1 RNA &lt;50 copies/mL and on a stable antiretroviral regimen</ENT>
                        <ENT>HIV-1 RNA &lt;50 copies/mL and on a stable antiretroviral regimen.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>No evidence of active opportunistic complications of HIV infection</ENT>
                        <ENT>No evidence of active opportunistic complications of HIV infection.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>No history of primary central nervous system (CNS) lymphoma or progressive multifocal leukoencephalopathy (PML)</ENT>
                        <ENT>No history of primary central nervous system (CNS) lymphoma or progressive multifocal leukoencephalopathy (PML).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Transplant Hospital Criteria</ENT>
                        <ENT>Transplant hospital with established program for care of subjects with HIV</ENT>
                        <ENT>Transplant hospital with established program for care of patients with HIV.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>HIV program expertise on the transplant team</ENT>
                        <ENT>HIV program expertise on the transplant team.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Organ-specific experience with transplants of organs from donors without HIV to recipients with HIV (5 D-/R+ transplant cases over 4 years)</ENT>
                        <ENT>There is no longer a center specific case experience requirement with transplants of organs from donors without HIV to recipients with HIV.* Transplant patients with organs from donors with HIV must be managed with a multidisciplinary team before, during, and after transplant. The multidisciplinary team must include transplant surgeons, physicians, HIV specialists, nurses, social workers, and pharmacists capable of therapeutic drug monitoring to minimize drug-drug interactions.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Standard operating procedures (SOPs) and training for the organ procurement, implanting/operative, and postoperative care teams for handling subjects with HIV, and organs and tissues from individuals with HIV</ENT>
                        <ENT>Standard operating procedures (SOPs) and training for the organ procurement, implanting/operative, and postoperative care teams for handling HIV-infected subjects with HIV, and organs and tissues from individuals with HIV.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>IRB-approved research protocol for transplantation of organs from donors with HIV in recipients with HIV</ENT>
                        <ENT>IRB-approved research protocol for transplantation of organs from donors with HIV in recipients with HIV for the applicable organs.*</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Institutional biohazard plan outlining measures to prevent and manage inadvertent exposure to and/or transmission of HIV</ENT>
                        <ENT>Institutional biohazard plan outlining measures to prevent and manage inadvertent exposure to and/or transmission of HIV.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Provide each living donor with HIV and recipient with HIV with an “independent advocate”</ENT>
                        <ENT>There is no longer a requirement to provide an HIV independent advocate beyond standard site practices.*</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Policies and SOPs governing the necessary knowledge, experience, skills, and training for independent advocates</ENT>
                        <ENT>Policies and SOPs governing the necessary knowledge, experience, skills, and training for independent advocates.</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="93621"/>
                        <ENT I="01">OPO Responsibilities</ENT>
                        <ENT>SOPs and staff training procedures for working with deceased donors with HIV and their families in pertinent history taking; medical chart abstraction; the consent process; and handling blood, tissues, organs, and biospecimens</ENT>
                        <ENT>SOPs and staff training procedures for working with deceased donors with HIV and their families in pertinent history taking; medical chart abstraction; the consent process; and handling blood, tissues, organs, and biospecimens.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Biohazard plan to prevent and manage HIV exposure and/or transmission</ENT>
                        <ENT>Biohazard plan to prevent and manage HIV exposure and/or transmission.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Prevention of Inadvertent Transmission of HIV</ENT>
                        <ENT>Each participating Transplant Program and OPO shall develop an institutional biohazard plan for handling organs from HIV-positive donors that is designed to prevent and/or manage inadvertent transmission or exposure to HIV</ENT>
                        <ENT>Each participating Transplant Program and OPO shall develop an institutional biohazard plan for handling organs from HIV-positive donors that is designed to prevent and/or manage inadvertent transmission or exposure to HIV.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Procedures must be in place to ensure that human cells, tissues, and cellular and tissue-based products (HCT/Ps) are not recovered from donors with HIV for implantation, transplantation, infusion, or transfer into a human recipient; however, HCT/Ps from a donor determined to be ineligible may be made available for nonclinical purposes</ENT>
                        <ENT>Procedures must be in place to ensure that human cells, tissues, and cellular and tissue-based products (HCT/Ps) are not recovered from donors with HIV for implantation, transplantation, infusion, or transfer into a human recipient; however, HCT/Ps from a donor determined to be ineligible may be made available for nonclinical purposes.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22">Required Data Elements and Outcome Measures **</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="03">Wait List Candidates</E>
                        </ENT>
                        <ENT>HIV status</ENT>
                        <ENT>HIV status.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>CD4+ T-cell counts</ENT>
                        <ENT>CD4+ T-cell counts.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Co-infection (hepatitis C virus [HCV], hepatitis B virus [HBV])</ENT>
                        <ENT>
                            Co-infection:
                            <LI O="oi3">• Hepatitis C (HCV RNA).</LI>
                            <LI O="oi3">• Hepatitis B (HBV deoxyribonucleic acid, HBV antibody).</LI>
                            <LI O="oi3">• Cytomegalovirus (CMV immunoglobulin G [IgG]).*</LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>HIV viral load</ENT>
                        <ENT>HIV viral load.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>ART resistance</ENT>
                        <ENT>ART resistance.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Removal from wait list (death or other reason)</ENT>
                        <ENT>Removal from wait list (death or other reason).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Time on wait list</ENT>
                        <ENT>
                            Time on wait list.
                            <LI>Renal dysfunction.*</LI>
                            <LI>Liver dysfunction.*</LI>
                            <LI>Indication for transplant.*</LI>
                            <LI>Use of mechanical circulatory devices.*</LI>
                            <LI>Use of extracorporeal membrane oxygenation, intra-aortic balloon pump, ventricular assist device.*</LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="03">Donors (all)</E>
                        </ENT>
                        <ENT>Type (Living or deceased)</ENT>
                        <ENT>Type Donation after Brain Death vs. Donation after Circulatory Death vs. Living Donor.*</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>HIV status (new diagnosis of HIV, or known diagnosis of HIV)</ENT>
                        <ENT>HIV status (new diagnosis of HIV, or known diagnosis of HIV).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>CD4+ T-cell count</ENT>
                        <ENT>CD4+ T-cell count.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Co-infection (HCV, HBV)</ENT>
                        <ENT>Co-infection (HCV, HBV).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>HIV viral load</ENT>
                        <ENT>HIV viral load.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>ART resistance</ENT>
                        <ENT>ART resistance.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT O="xl"/>
                        <ENT>
                            Ex-vivo perfusion.*
                            <LI O="oi3">• Duration.</LI>
                            <LI O="oi3">• Warm and cold ischemia time.</LI>
                            <LI>Normothermic regional perfusion.*</LI>
                            <LI O="oi3">• Duration.</LI>
                            <LI O="oi3">• Warm and cold ischemia time.</LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="03">Living Donors</E>
                        </ENT>
                        <ENT>
                            Progression to renal insufficiency in kidney donors
                            <LI>Progression to hepatic insufficiency in liver donors</LI>
                        </ENT>
                        <ENT>These data elements no longer apply since kidney or liver donation from a living donor with HIV no longer falls under the Research Criteria except that these data elements apply to simultaneous multiple organ transplants.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Change in ART regimen as a result of organ dysfunction</ENT>
                        <ENT>Change in ART regimen as a result of organ dysfunction.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Progression to acquired immunodeficiency syndrome (AIDS)</ENT>
                        <ENT>Progression to AIDS.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Failure to suppress viral replication (persistent HIV viremia)</ENT>
                        <ENT>Failure to suppress viral replication (persistent HIV viremia).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Death</ENT>
                        <ENT>Death.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            <E T="03">Transplant Recipients</E>
                        </ENT>
                        <ENT>Rejection rate (annual up to 5 years)</ENT>
                        <ENT>Rejection rate (annual through 5 years).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Progression to AIDS</ENT>
                        <ENT>Progression to AIDS.</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="93622"/>
                        <ENT I="22"> </ENT>
                        <ENT>New OI</ENT>
                        <ENT>New OI.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Failure to suppress viral replication (persistent HIV viremia)</ENT>
                        <ENT>Failure to suppress viral replication (persistent HIV viremia).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>HIV-associated organ failure</ENT>
                        <ENT>HIV-associated organ failure.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Malignancy</ENT>
                        <ENT>Malignancy.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Graft failure</ENT>
                        <ENT>Graft failure.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Mismatched ART resistance versus donor</ENT>
                        <ENT>Mismatched ART resistance versus donor.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT>Death</ENT>
                        <ENT>Death.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT O="xl"/>
                        <ENT>Type of rejection (antibody mediated versus cellular rejection).*</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT O="xl"/>
                        <ENT>Chronic heart allograft vasculopathy.*</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT O="xl"/>
                        <ENT>Chronic lung allograft dysfunction.*</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT O="xl"/>
                        <ENT>Hospitalized infections.*</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT O="xl"/>
                        <ENT>Estimated glomerular filtration rate.*</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT O="xl"/>
                        <ENT>HIV superinfection.*</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT O="xl"/>
                        <ENT>Re-transplantation.*</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="22"> </ENT>
                        <ENT O="xl"/>
                        <ENT>Simultaneous multiple organ transplants.</ENT>
                    </ROW>
                    <TNOTE>* Denotes a revision of the 2015 Research Criteria.</TNOTE>
                    <TNOTE>** The previous category of outcome measures (from the original 2015 Research Criteria) is modified to also include data elements.</TNOTE>
                </GPOTABLE>
                <P>
                    A summary of the proposed revisions
                    <FTREF/>
                     in each category of the Research Criteria is provided below.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         Consistent with the final rule amending the OPTN regulations, transplants using kidneys and livers from donors with HIV no longer need to comply with the HOPE Act research criteria. When multiple organs from donors with HIV are implanted simultaneously (
                        <E T="03">e.g.,</E>
                         dual heart-kidney or dual lung-kidney), the Research Criteria apply to such multiple organ transplants if the transplant of any of the organs are subject to the revised Research Criteria. For example, while a kidney transplant from a donor with HIV no longer is required to be conducted in accordance with the Research Criteria, a dual heart-kidney or dual lung-kidney transplant with organs from donors with HIV is required to be conducted in accordance with the Research Criteria and in accordance with an IRB-approved research protocol. A dual liver-kidney transplant with from donors with HIV is not required to be conducted in accordance with the Research Criteria, as neither liver transplants nor kidney transplants from donors with HIV are required to be conducted as research.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Donor Eligibility</HD>
                <P>
                    The only change proposed by NIH to this category applies to all deceased donors with HIV. NIH proposes removing the requirement for a pre-implantation donor organ biopsy. Although pre-implantation biopsies for kidneys and livers have occurred regularly, pre-implant donor heart and lung biopsies are not routinely performed. Likewise, donor biopsies for other organs are not routine. Given that kidney and liver transplants are no longer subject to the NIH research criteria, NIH proposes removing the requirement for pre-implantation biopsies. Any pre-implant biopsies obtained, as part of future IRB-approved research protocols, should be stored in accordance with local institutional requirements and the federal regulations applicable to slides, tissues, and blocks, if applicable. 42 CFR 493.1105 (
                    <E T="03">https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493/subpart-J/section-493.1105</E>
                    ).
                </P>
                <P>With respect to living donors with HIV, the 2015 NIH Research Criteria defined a well-controlled HIV infection and required pre-implant donor organ biopsies. The last living lobar lung transplant procedure in the U.S. was performed in 2013. NIH proposes removing this element as not relevant for heart and lung transplantation except in the rare instances of living donor lung transplant or “domino” heart transplants. In such circumstances, NIH proposes that the deceased donor eligibility criteria apply. If another type of organ is donated by a living donor with HIV, NIH proposes that the deceased donor eligibility criteria apply.</P>
                <HD SOURCE="HD3">Recipient Eligibility</HD>
                <P>The only change proposed in this category concerns CD4+ T-cell counts. The 2015 NIH Research Criteria imposed requirements with respect to the CD4+ T-cell counts specific to livers and kidneys. Given that kidney and liver transplants are no longer required to comply with the research criteria, NIH proposes no minimum threshold CD4+ T-cell counts for other organs when all other eligibility criteria are met.</P>
                <HD SOURCE="HD3">Transplant Hospital</HD>
                <P>NIH proposes several changes to this category. The requirement for prior experience with transplantation of organs from donors without HIV in recipients with HIV. The 2015 NIH Research Criteria required experience with five transplants over the four preceding years involving organs from donors without HIV transplanted into recipients with HIV. NIH proposes removing this requirement, which was perceived by many as burdensome and a barrier to entry to transplant hospitals wishing to perform HOPE Act transplants. To maximize favorable outcomes and effectively prevent and manage adverse events, NIH proposes that all patients with transplants involving donors with HIV be managed by multidisciplinary teams before, during, and after transplantation. NIH proposes specific members of this multidisciplinary team.</P>
                <P>
                    NIH proposes removing the requirement that each living donor with HIV and each transplant recipient with HIV be provided with an HIV-independent advocate. NIH proposes instead that standard site practices apply. Based on a decade of HOPE Act clinical experience, stakeholder surveys have indicated that a requirement for an independent advocate is widely perceived as a redundant layer of consent and a potential barrier for some HIV patients who would otherwise benefit from an HIV donor transplant. The NIH notes that per current OPTN policy and guidance, all living donors, including those with HIV, have an independent advocate. NIH's proposed change to the 2015 Research Criteria will not alter that.
                    <PRTPAGE P="93623"/>
                </P>
                <HD SOURCE="HD3">Organ Procurement Organization (OPO) Responsibilities</HD>
                <P>NIH does not propose changes to this category.</P>
                <HD SOURCE="HD3">Prevention of Inadvertent Transmission of HIV</HD>
                <P>NIH does not propose changes to this category.</P>
                <HD SOURCE="HD3">Required Outcome Measures and Data Elements</HD>
                <P>The 2015 Research Criteria referenced required outcome measures. NIH proposes using the more precise “Required Data Elements and Outcome Measures.” NIH notes that data on these existing and proposed outcome measures is collected by the OPTN as specified by the Secretary. NIH does not intend to propose data collection requirements beyond those collected by the OPTN.</P>
                <P>
                    <E T="03">Waitlist Candidates:</E>
                     NIH proposes adding several data elements for waitlist candidates. NIH proposes adding cytomegalovirus (CMV immunoglobulin G [IgG]) as a required outcome measure for co-infection. NIH also proposes adding additional data elements and outcome measures: renal dysfunction, liver dysfunction, indication for transplant, use of mechanical circulatory devices, and use of extracorporeal membrane oxygenation, intra-aortic balloon pump, and ventricular assist device.
                </P>
                <P>
                    <E T="03">Donors (All):</E>
                     First, NIH proposes adding additional elements related to the type of deceased donation: after brain death (DBD) or after circulatory death (DCD) given the increasing use of the latter technique in the U.S. In addition, NIH proposes the following data elements for all donors (if applicable): 
                    <E T="03">ex-vivo</E>
                     perfusion and normothermic regional perfusion including durations of warm and cold ischemia.
                </P>
                <P>
                    <E T="03">Living Donors:</E>
                     The 2015 NIH Research Criteria included as required outcome measures progression to renal insufficiency in kidney living donors. Because kidney and liver transplants are no longer subject to the research criteria, NIH plans to retain these outcomes only where applicable (
                    <E T="03">e.g.,</E>
                     for deceased donor heart-living donor kidney transplants, deceased donor heart-living donor liver transplants, and for other organs subject to the research criteria).
                </P>
                <P>
                    <E T="03">Transplant Recipients:</E>
                     NIH proposes adding several additional data elements and outcome measures to those included for transplant recipients in the 2015 NIH Research Criteria. NIH proposes adding the following outcome measures: type of rejection (antibody-mediated versus cellular rejection), chronic allograft vasculopathy (heart), chronic lung allograft dysfunction (lung), hospital infections, estimated glomerular filtration rate (heart and lung), HIV superinfection, graft failure (heart and lung), re-transplantation, and simultaneous multiple organ transplants.
                </P>
                <P>
                    While not proposed as a requirement of the Research Criteria, NIH proposes to provide the following recommendation regarding patient management: NIH recommends that transplant programs and healthcare providers follow current and updated practice management guidelines. For specific guidance, transplant programs and healthcare providers should consult vaccination guidance (
                    <E T="03">https://www.cdc.gov/acip-recs/hcp/vaccine-specific/index.html</E>
                    ) and expert guidance for the management of patients with HIV pre-, during-, and post-transplant summarized in: Transplantation in people with HIV (
                    <E T="03">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new</E>
                    ).
                </P>
                <HD SOURCE="HD1">References</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">1. Department of Health and Human Services (DHHS). Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV. 80 FR 34912. June 18, 2015.</FP>
                    <FP SOURCE="FP-2">2. Doberne J.W., et al. (2021). Heart transplantation survival outcomes of HIV positive and negative recipients. Annals of Thoracic Surgery, 111:1465-71.</FP>
                    <FP SOURCE="FP-2">3. Durand C., et al. (2024). Safety of kidney transplantation from donors with HIV infection. N Engl J Med, 391:1390-401.</FP>
                    <FP SOURCE="FP-2">4. HIV Organ Policy Equity (HOPE) Act of 2013. Public Law 113-51.</FP>
                    <FP SOURCE="FP-2">5. Kern, R., Seethamraju, H., Blanc, P., Sinha, N., Loebe, M., Golden, J., et al. (2014). Lung Transplantation in HIV Seropositive Patients. Chest, 145(3 Suppl), 642A.</FP>
                    <FP SOURCE="FP-2">6. Koval C., et al. (2018). Heart and lung transplantation outcomes in HIV-positive recipients.</FP>
                    <FP SOURCE="FP-2">
                        7. Koval, C.E., Farr, M., Krisl, J., Haidar, G., Pereira, M.R., Shrestha, N., Malinis, M.F., Mueller, N.J., Hannan, M.M., Grossi, P., &amp; Huprikar, S. (2019). Heart or lung transplant outcomes in HIV-infected recipients. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation, 38(12), 1296-1305. 
                        <E T="03">https://doi.org/10.1016/j.healun.2019.09.011.</E>
                    </FP>
                    <FP SOURCE="FP-2">8. Madan S., et al, (2019). Outcomes of heart transplantation in patients with human immunodeficiency virus. Am J Transplant. 19:1529-35.</FP>
                    <FP SOURCE="FP-2">9. Rouzaud C., et al., (2022). Lung transplantation in HIV-positive patients: a European retrospective cohort study. Eur Respir J. 60(1):2200189.</FP>
                    <FP SOURCE="FP-2">
                        10. Storm, K., &amp; Durand, C.M. (2024). Overcoming barriers and stigma: new frontiers in solid organ transplantation for people with HIV. 
                        <E T="03">Clinical microbiology reviews, 37</E>
                        (1), e0011122. 
                        <E T="03">https://doi.org/10.1128/cmr.00111-22.</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        11. Wairimu, F., Ward, N.C., Liu, Y., &amp; Dwivedi, G. (2021). Cardiac Transplantation in HIV-Positive Patients: A Narrative Review. 
                        <E T="03">Journal of acquired immune deficiency syndromes (1999), 87</E>
                        (2), 763-768. 
                        <E T="03">https://doi.org/10.1097/QAI.0000000000002647.</E>
                    </FP>
                </EXTRACT>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Lawrence A. Tabak,</NAME>
                    <TITLE>Principal Deputy Director, National Institutes of Health.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27733 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4140-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>National Institutes of Health</SUBAGY>
                <SUBJECT>National Cancer Institute; Notice of Closed Meetings</SUBJECT>
                <P>Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.</P>
                <P>The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.</P>
                <EXTRACT>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Cancer Institute Special Emphasis Panel; Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE).
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         January 16, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         9:00 a.m. to 5:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W108, Rockville, Maryland 20850.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Clifford W. Schweinfest, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W108, Rockville, Maryland 20850, 240-276-6343, 
                        <E T="03">schweinfestcw@mail.nih.gov.</E>
                    </P>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Cancer Institute Special Emphasis Panel; Informatics Technologies for Cancer Research.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         January 29, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         10:00 a.m. to 6:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                        <PRTPAGE P="93624"/>
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W106, Rockville, Maryland 20850.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Eduardo Emilio Chufan, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W106, Rockville, Maryland 20850, 240-276-7975, 
                        <E T="03">chufanee@mail.nih.gov.</E>
                    </P>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Cancer Institute Special Emphasis Panel; NCI Review of Research Projects in Physical Sciences Oncology.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         January 31, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         11:00 a.m. to 4:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W640, Rockville, Maryland 20850.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Saejeong J. Kim, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W640, Rockville, Maryland 20850, 240-276-7684, 
                        <E T="03">saejeong.kim@nih.gov</E>
                        .
                    </P>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Cancer Institute Special Emphasis Panel; NCI Outstanding Investigator Award (R35).
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         February 6-7, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         9:00 a.m. to 5:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W104, Rockville, Maryland 20850.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         David G. Ransom, Ph.D., Chief, Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W104, Rockville, Maryland 20850, 240-276-6351, 
                        <E T="03">david.ransom@nih.gov</E>
                        .
                    </P>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Cancer Institute Special Emphasis Panel; SEP-3: NCI Clinical and Translational Cancer Research.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         February 6-7, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         9:30 a.m. to 2:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W612, Rockville, Maryland 20850.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Prashant Sharma, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W612, Rockville, Maryland 20850, 240-275-6351, 
                        <E T="03">prashant.sharma@nih.gov</E>
                        .
                    </P>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Cancer Institute Special Emphasis Panel; SEP-7: NCI Clinical and Translational Cancer Research.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         February 12, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         10:00 a.m. to 5:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W640, Rockville, Maryland 20850.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Saejeong J. Kim, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W640, Rockville, Maryland 20850, 240-276-7684, 
                        <E T="03">saejeong.kim@nih.gov</E>
                        .
                    </P>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Cancer Institute Special Emphasis Panel; NCI IMAT Biospecimen Special Emphasis Panel.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         February 13, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         10:00 a.m. to 4:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W236, Rockville, Maryland 20850.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Shuli Xia, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W236, Rockville, Maryland 20850, 240-276-5256, 
                        <E T="03">shuli.xia@nih.gov</E>
                        .
                    </P>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Cancer Institute Special Emphasis Panel; SEP-11: NCI Clinical and Translational Cancer Research.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         February 18, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         10:00 a.m. to 6:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W606, Rockville, Maryland 20850.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Bruce Daniel Hissong, Ph.D., Scientific Review Officer, Resource and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W606, Rockville, Maryland 20850, 240-276-7752, 
                        <E T="03">bruce.hissong@nih.gov</E>
                        .
                    </P>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Cancer Institute, Initial Review Group; Transition to Independence Study Section (I).
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         February 26-27, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         11:00 a.m. to 5:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address: Place:</E>
                         National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W602, Rockville, Maryland 20850.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Delia Tang, M.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W602,  Rockville, Maryland 20850, 240-276-6456, 
                        <E T="03">tangd@mail.nih.gov</E>
                        .
                    </P>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Cancer Institute Special Emphasis Panel; NCI Research specialist Award (R50).
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         February 27, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         10:00 a.m. to 6:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Zhiqiang Zou, M.D., Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850, 240-276-6372, 
                        <E T="03">zouzhiq@mail.nih.gov</E>
                        .
                    </P>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Cancer Institute Special Emphasis Panel; SEP-2: NCI Clinical and Translational Cancer Research.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         March 6, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         10:00 a.m. to 4:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Zhiqiang Zou, M.D., Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850, 240-276-6372, 
                        <E T="03">zouzhiq@mail.nih.gov.</E>
                    </P>
                    <FP>(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)</FP>
                </EXTRACT>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Miguelina Perez,</NAME>
                    <TITLE>Supervisory Program Analyst, Office of Federal Advisory Committee Policy.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27877 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4140-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>National Institutes of Health</SUBAGY>
                <SUBJECT>National Institute of Environmental Health Sciences; Notice of Meeting</SUBJECT>
                <P>Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Environmental Health Sciences Council.</P>
                <P>
                    The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIEHS Videocast at the following link: 
                    <E T="03">https://www.niehs.nih.gov/news/webcasts/index.cfm.</E>
                </P>
                <P>
                    The meeting will be closed to the public in accordance with the 
                    <PRTPAGE P="93625"/>
                    provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
                </P>
                <EXTRACT>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Advisory Environmental Health Sciences Council.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         February 18, 2025.
                    </P>
                    <P>
                        <E T="03">Open:</E>
                         10:30 a.m. to 3:45 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         Discussion of program policies and issues/Council Discussion.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         NIEHS/National Institutes of Health Building, 79 T.W. Alexander Drive, Research Triangle Park, NC 27709 Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Closed:</E>
                         4:00 p.m. to 6:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         NIEHS/National Institutes of Health Building, 79 T.W. Alexander Drive, Research Triangle Park, NC 27709 Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         David M. Balshaw, BA, Ph.D., Director Division of Extramural Research and Training National Institute of Environmental Health Sciences, P.O. Box 12233, MD EC-27, Research Triangle Park, NC 27709-2233, 984-287-3234, 
                        <E T="03">balshaw@niehs.nih.gov.</E>
                    </P>
                    <P>
                        Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has procedures at 
                        <E T="03">https://www.nih.gov/about-nih/visitor-information/campus-access-security</E>
                         for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.
                    </P>
                    <P>
                        Information is also available on the Institute's/Center's home page: 
                        <E T="03">www.niehs.nih.gov/dert/c-agenda.htm,</E>
                         where an agenda and any additional information for the meeting will be posted when available.
                    </P>
                    <FP>(Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS)</FP>
                </EXTRACT>
                <SIG>
                    <DATED>Dated: November 21, 2024.</DATED>
                    <NAME>Bruce A. George, </NAME>
                    <TITLE>Program Analyst, Office of Federal Advisory Committee Policy.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27715 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4140-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>National Institutes of Health</SUBAGY>
                <SUBJECT>National Institute of General Medical Sciences; Notice of Closed Meeting</SUBJECT>
                <P>Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.</P>
                <P>The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.</P>
                <EXTRACT>
                    <P>
                        <E T="03">Name of Committee:</E>
                         National Institute of General Medical Sciences Initial Review Group Training and Workforce Development Study Section—D.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         February 27-28, 2025.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         9:30 a.m. to 6:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Institutes of Health, National Institute of General Medical Sciences, Natcher Building, 45 Center Drive, Bethesda, Maryland 20892.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Marcienne Michele Wright, Scientific Review Officer, Office of Scientific Review, National Institutes of General Medical Sciences, National Institutes of Health, 45 Center Drive, Bethesda, Maryland 20892, 301-827-7635, 
                        <E T="03">marci.wright@nih.gov</E>
                    </P>
                    <FP>(Catalogue of Federal Domestic Assistance Program No. 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)</FP>
                </EXTRACT>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Miguelina Perez,</NAME>
                    <TITLE>Program Analyst, Office of Federal Advisory Committee Policy.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27873 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4140-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                <SUBAGY>National Institutes of Health</SUBAGY>
                <SUBJECT>Center for Scientific Review; Notice of Closed Meetings</SUBJECT>
                <P>Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.</P>
                <P>The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.</P>
                <EXTRACT>
                    <P>
                        <E T="03">Name of Committee:</E>
                         Center for Scientific Review Special Emphasis Panel; Neuromodulation and Imaging of Neuronal Circuits II.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         December 20, 2024.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         9:00 a.m. to 1:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Pablo M Blazquez Gamez, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435-1042, 
                        <E T="03">pablo.blazquezgamez@nih.gov.</E>
                    </P>
                    <P>
                        <E T="03">Name of Committee:</E>
                         Center for Scientific Review Special Emphasis Panel; Fellowships: Infectious Diseases and Immunology.
                    </P>
                    <P>
                        <E T="03">Date:</E>
                         December 20, 2024.
                    </P>
                    <P>
                        <E T="03">Time:</E>
                         10:30 a.m. to 12:00 p.m.
                    </P>
                    <P>
                        <E T="03">Agenda:</E>
                         To review and evaluate grant applications.
                    </P>
                    <P>
                        <E T="03">Address:</E>
                         National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.
                    </P>
                    <P>
                        <E T="03">Meeting Format:</E>
                         Virtual Meeting.
                    </P>
                    <P>
                        <E T="03">Contact Person:</E>
                         Maria Chiara G Monaco-Kushner, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 555-1212, 
                        <E T="03">monaco@csr.nih.gov.</E>
                    </P>
                    <FP>(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)</FP>
                </EXTRACT>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Miguelina Perez, </NAME>
                    <TITLE>Program Analyst, Office of Federal Advisory Committee Policy.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27879 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4140-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="93626"/>
                <AGENCY TYPE="N">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>U.S. Customs and Border Protection</SUBAGY>
                <DEPDOC>[OMB Control Number 1651-0028]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Extension; Cost Submission (Form 247)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Customs and Border Protection (CBP), Department of Homeland Security.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day Notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Department of Homeland Security, U.S. Customs and Border Protection (CBP) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). The information collection is published in the 
                        <E T="04">Federal Register</E>
                         to obtain comments from the public and affected agencies.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and must be submitted no later than December 27, 2024, to be assured of consideration.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and/or suggestions regarding the item(s) contained in this notice should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Please submit written comments and/or suggestions in English. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Requests for additional PRA information should be directed to Seth Renkema, Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection, Office of Trade, Regulations and Rulings, 90 K Street NE, 10th Floor, Washington, DC 20229-1177, Telephone number 202-325-0056 or via email 
                        <E T="03">CBP_PRA@cbp.dhs.gov.</E>
                         Please note that the contact information provided here is solely for questions regarding this notice. Individuals seeking information about other CBP programs should contact the CBP National Customer Service Center at 877-227-5511, (TTY) 1-800-877-8339, or CBP website at 
                        <E T="03">https://www.cbp.gov/.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    CBP invites the general public and other Federal agencies to comment on the proposed and/or continuing information collections pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    ). This proposed information collection was previously published in the 
                    <E T="04">Federal Register</E>
                     (89 FR 76864) on September 19, 2024, allowing for a 60-day comment period. This notice allows for an additional 30 days for public comments. This process is conducted in accordance with 5 CFR 1320.8. Written comments and suggestions from the public and affected agencies should address one or more of the following four points: (1) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) suggestions to enhance the quality, utility, and clarity of the information to be collected; and (4) suggestions to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses. The comments that are submitted will be summarized and included in the request for approval. All comments will become a matter of public record.
                </P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    <E T="03">Title:</E>
                     Cost Submission.
                </P>
                <P>
                    <E T="03">OMB Number:</E>
                     1651-0028.
                </P>
                <P>
                    <E T="03">Form Number:</E>
                     247.
                </P>
                <P>
                    <E T="03">Current Actions:</E>
                     CBP proposes to extend the expiration date of this information collection. There is no change to the burden hours or to the information collected.
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Extension (without change).
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Businesses.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The information collected on CBP Form 247, Cost Submission, is used by CBP to assist in correctly calculating the duty on imported merchandise. This form includes details on actual costs and helps CBP determine which costs are dutiable and which are not.
                </P>
                <P>This collection of information is provided for by subheadings 9801.00.10, 9802.00.40, 9802.00.50, 9802.00.60 and 9802.00.80 of the Harmonized Tariff Schedule of the United States (HTSUS), and by 19 U.S.C. 1508 through 1509, 19 CFR 10.11-10.24, 19 CFR 141.88 and 19 CFR 152.106.</P>
                <P>
                    <E T="03">CBP Form 247 can be found at: http://www.cbp.gov/xp/cgov/toolbox/forms/.</E>
                </P>
                <P>
                    <E T="03">Type of Information Collection:</E>
                     Form 247.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     1,000.
                </P>
                <P>
                    <E T="03">Estimated Number of Annual Responses per Respondent:</E>
                     1.
                </P>
                <P>
                    <E T="03">Estimated Number of Total Annual Responses:</E>
                     1,000.
                </P>
                <P>
                    <E T="03">Estimated Time per Response:</E>
                     50 hours.
                </P>
                <P>
                    <E T="03">Estimated Total Annual Burden Hours:</E>
                     50,000.
                </P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Seth D Renkema,</NAME>
                    <TITLE>Branch Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27826 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9111-14-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>U.S. Customs and Border Protection</SUBAGY>
                <DEPDOC>[OMB Control Number 1651-0030]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Extension; Declaration of Unaccompanied Articles (CBP Form 255)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Customs and Border Protection (CBP), Department of Homeland Security.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Department of Homeland Security, U.S. Customs and Border Protection (CBP) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). The information collection is published in the 
                        <E T="04">Federal Register</E>
                         to obtain comments from the public and affected agencies.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and must be submitted no later than December 27, 2024 to be assured of consideration.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and/or suggestions regarding the item(s) contained in this notice should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Please submit written comments and/or suggestions in English. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Requests for additional PRA information should be directed to Seth Renkema, Chief, Economic Impact Analysis 
                        <PRTPAGE P="93627"/>
                        Branch, U.S. Customs and Border Protection, Office of Trade, Regulations and Rulings, 90 K Street NE, 10th Floor, Washington, DC 20229-1177, Telephone number 202-325-0056 or via email 
                        <E T="03">CBP_PRA@cbp.dhs.gov.</E>
                         Please note that the contact information provided here is solely for questions regarding this notice. Individuals seeking information about other CBP programs should contact the CBP National Customer Service Center at 877-227-5511, (TTY) 1-800-877-8339, or CBP website at 
                        <E T="03">https://www.cbp.gov/.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    CBP invites the general public and other Federal agencies to comment on the proposed and/or continuing information collections pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    ). This proposed information collection was previously published in the 
                    <E T="04">Federal Register</E>
                     (89 FR 74281) on September 12, 2024, allowing for a 60-day comment period. This notice allows for an additional 30 days for public comments. This process is conducted in accordance with 5 CFR 1320.8. Written comments and suggestions from the public and affected agencies should address one or more of the following four points: (1) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) suggestions to enhance the quality, utility, and clarity of the information to be collected; and (4) suggestions to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses. The comments that are submitted will be summarized and included in the request for approval. All comments will become a matter of public record.
                </P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    <E T="03">Title:</E>
                     Declaration of Unaccompanied Articles (CBP Form 255).
                </P>
                <P>
                    <E T="03">OMB Number:</E>
                     1651-0030.
                </P>
                <P>
                    <E T="03">Form Number:</E>
                     255.
                </P>
                <P>
                    <E T="03">Current Actions:</E>
                     This submission will renew the expiration validity, without a change to the information requested or method of collection.
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Extension (without change).
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Individuals.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     CBP Form 255, Declaration of Unaccompanied Articles, is completed by travelers arriving in the United States either directly or indirectly from the U.S. Virgin Islands, American Samoa, Guam, and the Commonwealth of the Northern Mariana Islands who are declaring merchandise purchases while visiting these locations which are to be sent from these insular possessions at a later date. It is the only means whereby the CBP officer, when the traveler arrives, can apply the exemptions or 5 percent flat rate of duty to all of the traveler's purchases.
                </P>
                <P>
                    <E T="03">Type of Information Collection:</E>
                     CBP Form 255.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     7,500.
                </P>
                <P>
                    <E T="03">Estimated Number of Annual Responses per Respondent:</E>
                     2.
                </P>
                <P>
                    <E T="03">Estimated Number of Total Annual Responses:</E>
                     15,000.
                </P>
                <P>
                    <E T="03">Estimated Time per Response:</E>
                     5 minutes.
                </P>
                <P>
                    <E T="03">Estimated Total Annual Burden Hours:</E>
                     1,250.
                </P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Seth D. Renkema,</NAME>
                    <TITLE>Branch Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27829 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9111-14-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>U.S. Customs and Border Protection</SUBAGY>
                <DEPDOC>[OMB Control Number 1651-0058]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Extension; Documents Required Aboard Private Aircraft</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Customs and Border Protection (CBP), Department of Homeland Security.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day Notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Department of Homeland Security, U.S. Customs and Border Protection (CBP) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). The information collection is published in the 
                        <E T="04">Federal Register</E>
                         to obtain comments from the public and affected agencies.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and must be submitted (no later than December 27, 2024) to be assured of consideration.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and/or suggestions regarding the item(s) contained in this notice should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain</E>
                        . Please submit written comments and/or suggestions in English. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Requests for additional PRA information should be directed to Seth Renkema, Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection, Office of Trade, Regulations and Rulings, 90 K Street NE, 10th Floor, Washington, DC 20229-1177, Telephone number 202-325-0056 or via email 
                        <E T="03">CBP_PRA@cbp.dhs.gov.</E>
                         Please note that the contact information provided here is solely for questions regarding this notice. Individuals seeking information about other CBP programs should contact the CBP National Customer Service Center at 877-227-5511, (TTY) 1-800-877-8339, or CBP website at 
                        <E T="03">https://www.cbp.gov/.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    CBP invites the general public and other Federal agencies to comment on the proposed and/or continuing information collections pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    ). This proposed information collection was previously published in the 
                    <E T="04">Federal Register</E>
                     (89 FR 59921) on July 24, 2024, allowing for a 60-day comment period. This notice allows for an additional 30 days for public comments. This process is conducted in accordance with 5 CFR 1320.8. Written comments and suggestions from the public and affected agencies should address one or more of the following four points: (1) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) suggestions to enhance the quality, utility, and clarity of the information to be collected; and (4) suggestions to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting 
                    <PRTPAGE P="93628"/>
                    electronic submission of responses. The comments that are submitted will be summarized and included in the request for approval. All comments will become a matter of public record.
                </P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    <E T="03">Title:</E>
                     Documents Required Aboard Private Aircraft.
                </P>
                <P>
                    <E T="03">OMB Number:</E>
                     1651-0058.
                </P>
                <P>
                    <E T="03">Current Actions:</E>
                     CBP proposes to extend the expiration date of this information collection without a change to the burden hours or information collected.
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Extension (without change).
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Individuals.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     In accordance with 19 CFR 122.27(c), a commander of a private aircraft arriving in the U.S. must present several documents to CBP officers for inspection. These documents include: (1) a pilot certificate/license; (2) a medical certificate; and (3) a certificate of registration. CBP officers use the information on these documents as part of the inspection process for private aircraft arriving from a foreign country. This presentation of information is authorized by 19 U.S.C. 1433, as amended by Public Law 99-570.
                </P>
                <P>
                    <E T="03">Type of Information Collection:</E>
                     Documents aboard a private aircraft.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     120,000.
                </P>
                <P>
                    <E T="03">Estimated Number of Annual Responses per Respondent:</E>
                     1.
                </P>
                <P>
                    <E T="03">Estimated Number of Total Annual Responses:</E>
                     120,000.
                </P>
                <P>
                    <E T="03">Estimated Time per Response:</E>
                     .0166.
                </P>
                <P>
                    <E T="03">Estimated Total Annual Burden Hours:</E>
                     1,992.
                </P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Seth D Renkema,</NAME>
                    <TITLE>Branch Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27832 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9111-14-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>U.S. Customs and Border Protection</SUBAGY>
                <DEPDOC>[OMB Control Number 1651-0041]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Extension; Establishment of a Bonded Warehouse (Bonded Warehouse Regulations)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Customs and Border Protection (CBP), Department of Homeland Security.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day Notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Department of Homeland Security, U.S. Customs and Border Protection (CBP) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). The information collection is published in the 
                        <E T="04">Federal Register</E>
                         to obtain comments from the public and affected agencies.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and must be submitted no later than December 27, 2024 to be assured of consideration.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and/or suggestions regarding the item(s) contained in this notice should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain</E>
                        . Please submit written comments and/or suggestions in English. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Requests for additional PRA information should be directed to Seth Renkema, Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection, Office of Trade, Regulations and Rulings, 90 K Street NE, 10th Floor, Washington, DC 20229-1177, Telephone number 202-325-0056 or via email 
                        <E T="03">CBP_PRA@cbp.dhs.gov.</E>
                         Please note that the contact information provided here is solely for questions regarding this notice. Individuals seeking information about other CBP programs should contact the CBP National Customer Service Center at 877-227-5511, (TTY) 1-800-877-8339, or CBP website at 
                        <E T="03">https://www.cbp.gov/.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    CBP invites the general public and other Federal agencies to comment on the proposed and/or continuing information collections pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    ). This proposed information collection was previously published in the 
                    <E T="04">Federal Register</E>
                     (89 FR 74281) on September 12, 2024, allowing for a 60-day comment period. This notice allows for an additional 30 days for public comments. This process is conducted in accordance with 5 CFR 1320.8. Written comments and suggestions from the public and affected agencies should address one or more of the following four points: (1) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) suggestions to enhance the quality, utility, and clarity of the information to be collected; and (4) suggestions to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses. The comments that are submitted will be summarized and included in the request for approval. All comments will become a matter of public record.
                </P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    <E T="03">Title:</E>
                     Establishment of a Bonded Warehouse (Bonded Warehouse Regulations).
                </P>
                <P>
                    <E T="03">OMB Number:</E>
                     1651-0041.
                </P>
                <P>
                    <E T="03">Current Actions:</E>
                     This submission will extend the expiration date validity without a change to the information collected or method of collection.
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Extension (w/o change).
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Businesses.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     Owners or lessees desiring to establish a bonded warehouse must make written application to the U.S. Customs and Border Protection (CBP) port director of the port where the warehouse is located. The application must include the warehouse location, a description of the premises, and an indication of the class of bonded warehouse permit desired. Owners or lessees desiring to alter or to relocate a bonded warehouse may submit an application to the CBP port director of the port where the facility is located. The authority to establish and maintain a bonded warehouse is set forth in 19 U.S.C. 1555, and provided for by 19 CFR 19.2, 19 CFR 19.3, 19 CFR 19.6, 19 CFR 19.14, and 19 CFR 19.36.
                </P>
                <P>
                    <E T="03">Type of Information Collection:</E>
                     Bonded Warehouse Application.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     198.
                </P>
                <P>
                    <E T="03">Estimated Number of Annual Responses per Respondent:</E>
                     47.
                </P>
                <P>
                    <E T="03">Estimated Number of Total Annual Responses:</E>
                     9,306.
                </P>
                <P>
                    <E T="03">Estimated Time per Response:</E>
                     32 minutes.
                </P>
                <P>
                    <E T="03">Estimated Total Annual Burden Hours:</E>
                     4,963.
                </P>
                <SIG>
                    <PRTPAGE P="93629"/>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Seth D. Renkema</NAME>
                    <TITLE>Branch Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27827 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9111-14-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>U.S. Customs and Border Protection</SUBAGY>
                <DEPDOC>[Docket No. USCBP-2024-0027]</DEPDOC>
                <SUBJECT>Commercial Customs Operations Advisory Committee</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Customs and Border Protection (CBP), Department of Homeland Security (DHS).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Committee management; notice of open Federal Advisory Committee meeting.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Commercial Customs Operations Advisory Committee (COAC) will hold its quarterly meeting on Wednesday, December 11, 2024, in Washington, DC. The meeting will be open to the public via webinar only.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The COAC will meet on Wednesday, December 11, 2024, from 1:00 p.m. to 5:00 p.m. Eastern Standard Time (EST). Please note the meeting may close early if the committee has completed its business. Comments must be submitted in writing no later than December 6, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The meeting will be open to the public via webinar only. The webinar link will be posted by 5:00 p.m. EST on November 29, 2024, at 
                        <E T="03">https://www.cbp.gov/trade/stakeholder-engagement/coac/coac-public-meetings.</E>
                         For information or to request special assistance for the meeting, contact Mrs. Latoria Martin, Office of Trade Relations, U.S. Customs and Border Protection, at (202) 344-1440, as soon as possible.
                    </P>
                    <P>Comments may be submitted by one of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Federal eRulemaking Portal: http://www.regulations.gov.</E>
                         Search for Docket Number USCBP-2024-0027. To submit a comment, click the “Comment” button located on the top-left hand side of the docket page.
                    </P>
                    <P>
                        • 
                        <E T="03">Email: tradeevents@cbp.dhs.gov.</E>
                         Include Docket Number USCBP-2024-0027 in the subject line of the message.
                    </P>
                    <P>
                        Comments must be submitted in writing no later than December 6, 2024, and must be identified by Docket No. USCBP-2024-0027. All submissions received must also include the words “Department of Homeland Security.” All comments received will be posted without change to 
                        <E T="03">https://www.cbp.gov/trade/stakeholder-engagement/coac/coac-public-meetings</E>
                         and 
                        <E T="03">www.regulations.gov.</E>
                         Therefore, please refrain from including any personal information you do not wish to be posted. You may wish to view the Privacy and Security Notice, which is available via a link on 
                        <E T="03">www.regulations.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Mrs. Latoria Martin, Office of Trade Relations, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue NW, Room 3.5A, Washington, DC 20229, (202) 344-1440; or Ms. Felicia M. Pullam, Designated Federal Officer, at (202) 344-1440 or via email at 
                        <E T="03">tradeevents@cbp.dhs.gov</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Notice of this meeting is given under the authority of the Federal Advisory Committee Act, Title 5 U.S.C., ch. 10. The COAC provides advice to the Secretary of the Department of Homeland Security, the Secretary of the Department of the Treasury, and the Commissioner of U.S. Customs and Border Protection (CBP) on matters pertaining to the commercial operations of CBP and related functions within the Department of Homeland Security and the Department of the Treasury.</P>
                <P>The COAC is committed to ensuring all participants have equal access regardless of disability status. If you require a reasonable accommodation due to a disability to fully participate, please contact Mrs. Latoria Martin at (202) 344-1440 as soon as possible.</P>
                <P>Please feel free to share this information with other interested members of your organization or association.</P>
                <P>To facilitate public participation, we are inviting public comment on the issues the committee will consider prior to the formulation of recommendations as listed in the AGENDA section below.</P>
                <P>
                    There will be a public comment period after each subcommittee update during the meeting on December 11, 2024. During the meeting, comments may be submitted via the trade events mailbox at 
                    <E T="03">tradeevents@cbp.dhs.gov</E>
                     or through the Microsoft Teams chat feature. Please note the public comment period for speakers may end before the time indicated on the schedule that is posted on the CBP web page: 
                    <E T="03">http://www.cbp.gov/trade/stakeholder-engagement/coac.</E>
                </P>
                <HD SOURCE="HD1">Agenda</HD>
                <P>The COAC will hear from the current subcommittees on the topics listed below:</P>
                <P>1. The Intelligent Enforcement Subcommittee will provide updates on the work completed and topics discussed in its working groups as well as present proposed recommendations for the COAC's consideration. The Antidumping/Countervailing Duty (AD/CVD) Working Group will provide updates regarding its work and discussions on importer compliance with AD/CVD and other trade remedy measures and requirements. The Intellectual Property Rights (IPR) Process Modernization Working Group anticipates providing updates concerning progress associated with its proposed recommendations specific to IPR enforcement and facilitation. The Forced Labor Working Group (FLWG) will provide updates on continued discussions regarding trade outreach, clarification of requirements, and proposed recommendations. The FLWG reports that it will continue to provide CBP with input as CBP rolls out a case management portal. The Bond Working Group remained on hiatus status since the last public meeting.</P>
                <P>2. The Next Generation Facilitation Subcommittee will provide updates on all its existing working groups. The Automated Commercial Environment (ACE) 2.0 Working Group was focused on completing discussions on the Concept of Operations document regarding scenarios for Electronic Export Manifests (EEM) and a portal for infrequent importers, along with the status of previous recommendations proposed earlier this term. The Broker Modernization Working Group (BMWG) remains dedicated to the enhancement of the end user experience and improving the administration of the Customs Broker Licensing Exam (CBLE). This quarter, the Modernized Entry Processes Working Group (MEPWG) continues its National Customs Automation Program (NCAP) discussions and will provide updates on its efforts concerning the reconciliation test. The remaining working group, the Customs Interagency Industry Working Group (CIIWG), was not active this past quarter but will provide a report on topics that the working group will focus on in the coming quarter.</P>
                <P>
                    3. The Secure Trade Lanes Subcommittee will provide updates on its seven active working groups: the Centers Working Group, the Cross-Border Recognition Working Group, the De Minimis Working Group, the Export Modernization Working Group, the FTZ/Warehouse Working Group, the Pipeline Working Group, and the Trade Partnership and Engagement Working Group. The Centers Working Group consolidated its review of the Centers' communications functions into the Structure Sub-Working Group and the 
                    <PRTPAGE P="93630"/>
                    Operations Sub-Working Group. The Centers Working Group as a whole, through these two sub-working groups, continues to evaluate the structure and operations of the Centers to enhance their effectiveness, increase transparency, and build stronger communities within CBP and with the Trade. The Cross-Border Recognition Working Group is evaluating whether all deliverables outlined in the Statement of Work have been achieved to determine next steps. CBP has formed a Task Force to assist the De Minimis Working Group regarding the timeframe for submitting de minimis shipments. The De Minimis Working Group, via the Task Force, intends to present proposed recommendations at the December quarterly COAC meeting. The Export Modernization Working Group has continued its work on the Electronic Export Manifest Pilot Program and the effects of progressive filing by the shipper to continuously update export information on successive dates, rather than on a specific date. The Export Modernization Working Group is also working on previous proposed recommendations to determine if new proposed recommendations need to be made and is reviewing the status of proposed recommendations that have not been finalized. The Drawback Task Force, within the Export Modernization Working Group, has continued discussions around COAC-approved recommendations that are in the process of being implemented from last quarter. They are also conducting an analysis of program statistics in the areas of streamlining drawback ruling processes, reviewing compliance issues, and examining areas to maximize resources. The FTZ/Warehouse Working Group continues to review 19 CFR part 146, explore areas in which the Customs-Trade Partnership Against Terrorism (CTPAT) program can be expanded, and consider how to modernize ACE functionality for Foreign Trade Zones (FTZs), and it anticipates presenting proposed recommendations for the COAC's consideration at the December public meeting. The Pipeline Working Group has continued discussing the most appropriate commodities for and potential users of Distributed Ledger Technology to engage in the contemplated pilot for tracking pipeline-borne goods. The Global Interoperability Standard (GIS) Information Collection 
                    <E T="04">Federal Register</E>
                     Notice (FRN) was published on September 3, 2024 (89 FR 71381), and comments were accepted through November 4, 2024. The Pipeline Working Group has no proposed recommendations for this quarter.
                </P>
                <P>
                    Meeting materials will be available on December 2, 2024, at: 
                    <E T="03">http://www.cbp.gov/trade/stakeholder-engagement/coac/coac-public-meetings.</E>
                </P>
                <SIG>
                    <NAME>Felicia M. Pullam,</NAME>
                    <TITLE>Executive Director, Office of Trade Relations.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27805 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9111-14-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>U.S. Customs and Border Protection</SUBAGY>
                <DEPDOC>[OMB Control Number 1651-0006]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Extension; Application and Approval To Manipulate, Examine, Sample or Transfer Goods (CBP Form 3499)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Customs and Border Protection (CBP), Department of Homeland Security.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Department of Homeland Security, U.S. Customs and Border Protection (CBP) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). The information collection is published in the 
                        <E T="04">Federal Register</E>
                         to obtain comments from the public and affected agencies.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and must be submitted no later than December 27, 2024 to be assured of consideration.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and/or suggestions regarding the item(s) contained in this notice should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain</E>
                        . Please submit written comments and/or suggestions in English. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Requests for additional PRA information should be directed to Seth Renkema, Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection, Office of Trade, Regulations and Rulings, 90 K Street NE, 10th Floor, Washington, DC 20229-1177, Telephone number 202-325-0056 or via email 
                        <E T="03">CBP_PRA@cbp.dhs.gov.</E>
                         Please note that the contact information provided here is solely for questions regarding this notice. Individuals seeking information about other CBP programs should contact the CBP National Customer Service Center at 877-227-5511, (TTY) 1-800-877-8339, or CBP website at 
                        <E T="03">https://www.cbp.gov/.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    CBP invites the general public and other Federal agencies to comment on the proposed and/or continuing information collections pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    ). This proposed information collection was previously published in the 
                    <E T="04">Federal Register</E>
                     (89 FR 76866) on September 19, 2024, allowing for a 60-day comment period. This notice allows for an additional 30 days for public comments. This process is conducted in accordance with 5 CFR 1320.8. Written comments and suggestions from the public and affected agencies should address one or more of the following four points: (1) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) suggestions to enhance the quality, utility, and clarity of the information to be collected; and (4) suggestions to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses. The comments that are submitted will be summarized and included in the request for approval. All comments will become a matter of public record.
                </P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    <E T="03">Title:</E>
                     Application and Approval to Manipulate, Examine, Sample or Transfer Goods (CBP Form 3499).
                </P>
                <P>
                    <E T="03">OMB Number:</E>
                     1651-0006.
                </P>
                <P>
                    <E T="03">Form Number:</E>
                     3499.
                </P>
                <P>
                    <E T="03">Current Actions:</E>
                     This submission will renew the expiration date while updating the burden hours to reflect current usage. No change to information collected or method of collection.
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Extension (with change).
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Businesses.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     CBP Form 3499, “Application and Approval to 
                    <PRTPAGE P="93631"/>
                    Manipulate, Examine, Sample or Transfer Goods,” is used as an application to perform various operations on merchandise located at a Customs and Border Protection (CBP) approved bonded facility. This form is filed by importers, bonded warehouse proprietors, consignees, transferees, or owners of merchandise, and is subject to approval by the port director. The data requested on the form identifies the merchandise for which action is being sought and specifies the operation that is to be performed. The form may also be approved as a blanket application to manipulate goods for a period of up to one year for continuous or repetitive manipulation. CBP Form 3499 is provided for by 19 U.S.C. 1562, and 19 CFR 158.43, 19.8, 19.11 and is accessible at: 
                    <E T="03">https://www.cbp.gov/newsroom/publications/forms?title=3499&amp;=Apply.</E>
                </P>
                <P>
                    <E T="03">Type of Information Collection:</E>
                     Form 3499.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     4,200.
                </P>
                <P>
                    <E T="03">Estimated Number of Annual Responses per Respondent:</E>
                     60.
                </P>
                <P>
                    <E T="03">Estimated Number of Total Annual Responses:</E>
                     252,000.
                </P>
                <P>
                    <E T="03">Estimated Time per Response:</E>
                     6 minutes.
                </P>
                <P>
                    <E T="03">Estimated Total Annual Burden Hours:</E>
                     25,200.
                </P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Seth D. Renkema,</NAME>
                    <TITLE>Branch Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27830 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9111-14-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>U.S. Customs and Border Protection</SUBAGY>
                <DEPDOC>[OMB Control Number 1651-0036]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Extension; Declaration of Ultimate Consignee That Articles Were Exported for Temporary Scientific or Educational Purposes</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Customs and Border Protection (CBP), Department of Homeland Security.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Department of Homeland Security, U.S. Customs and Border Protection (CBP) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). The information collection is published in the 
                        <E T="04">Federal Register</E>
                         to obtain comments from the public and affected agencies.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and must be submitted (no later than December 27, 2024) to be assured of consideration.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and/or suggestions regarding the item(s) contained in this notice should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain</E>
                         . Please submit written comments and/or suggestions in English. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Requests for additional PRA information should be directed to Seth Renkema, Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection, Office of Trade, Regulations and Rulings, 90 K Street NE, 10th Floor, Washington, DC 20229-1177, Telephone number 202-325-0056 or via email 
                        <E T="03">CBP_PRA@cbp.dhs.gov.</E>
                         Please note that the contact information provided here is solely for questions regarding this notice. Individuals seeking information about other CBP programs should contact the CBP National Customer Service Center at 877-227-5511, (TTY) 1-800-877-8339, or CBP website at 
                        <E T="03">https://www.cbp.gov/.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    CBP invites the general public and other Federal agencies to comment on the proposed and/or continuing information collections pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    ). This proposed information collection was previously published in the 
                    <E T="04">Federal Register</E>
                     (89 FR 78325) on September 25, 2024, allowing for a 60-day comment period. This notice allows for an additional 30 days for public comments. This process is conducted in accordance with 5 CFR 1320.8. Written comments and suggestions from the public and affected agencies should address one or more of the following four points: (1) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) suggestions to enhance the quality, utility, and clarity of the information to be collected; and (4) suggestions to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses. The comments that are submitted will be summarized and included in the request for approval. All comments will become a matter of public record.
                </P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    <E T="03">Title:</E>
                     Declaration of Ultimate Consignee That Articles Were Exported for Temporary Scientific or Educational Purposes.
                </P>
                <P>
                    <E T="03">OMB Number:</E>
                     1651-0036.
                </P>
                <P>
                    <E T="03">Form Number:</E>
                     N/A.
                </P>
                <P>
                    <E T="03">Current Actions:</E>
                     CBP proposes to extend the expiration date of this information collection with no change to the burden hours or to the information collected.
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Extension (without change).
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Businesses.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The Declaration of the Ultimate Consignee that Articles were Exported for Temporary Scientific or Educational Purposes is used to document duty free entry under conditions when articles are temporarily exported solely for scientific or educational purposes. This declaration is provided for under 19 U.S.C. 1202, HTSUS Subheading 9801.00.40, and 19 CFR 10.67(a)(3) which requires a declaration from the ultimate consignee stating that the articles were sent from the United States solely for temporary scientific or educational use and for no other use abroad than for exhibition, examination, or experimentation; and that the articles are being returned without having been changed in condition in any manner, except by reason of their bona fide use as described in the declaration. This declaration is submitted to CBP by the importer or the agent of the importer and is used by CBP to determine whether the imported articles should be free of duty.
                </P>
                <P>
                    <E T="03">Type of Information Collection:</E>
                     Declaration that Articles were Exported for Temporary Scientific or Educational Purposes.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     55.
                </P>
                <P>
                    <E T="03">Estimated Number of Annual Responses per Respondent:</E>
                     3.
                </P>
                <P>
                    <E T="03">Estimated Number of Total Annual Responses:</E>
                     165.
                </P>
                <P>
                    <E T="03">Estimated Time per Response:</E>
                     10 minutes.
                    <PRTPAGE P="93632"/>
                </P>
                <P>
                    <E T="03">Estimated Total Annual Burden Hours:</E>
                     27.
                </P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Seth D Renkema,</NAME>
                    <TITLE>Branch Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27828 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9111-14-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>Federal Emergency Management Agency</SUBAGY>
                <DEPDOC>[Docket ID FEMA-2024-0002]</DEPDOC>
                <SUBJECT>Final Flood Hazard Determinations</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Emergency Management Agency, Department of Homeland Security.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Flood hazard determinations, which may include additions or modifications of Base Flood Elevations (BFEs), base flood depths, Special Flood Hazard Area (SFHA) boundaries or zone designations, or regulatory floodways on the Flood Insurance Rate Maps (FIRMs) and where applicable, in the supporting Flood Insurance Study (FIS) reports have been made final for the communities listed in the table below. The FIRM and FIS report are the basis of the floodplain management measures that a community is required either to adopt or to show evidence of having in effect in order to qualify or remain qualified for participation in the Federal Emergency Management Agency's (FEMA's) National Flood Insurance Program (NFIP).</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The date of March 25, 2025 has been established for the FIRM and, where applicable, the supporting FIS report showing the new or modified flood hazard information for each community.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The FIRM, and if applicable, the FIS report containing the final flood hazard information for each community is available for inspection at the respective Community Map Repository address listed in the tables below and will be available online through the FEMA Map Service Center at 
                        <E T="03">https://msc.fema.gov</E>
                         by the date indicated above.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Rick Sacbibit, Chief, Engineering Services Branch, Federal Insurance and Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472, (202) 646-7659, or (email) 
                        <E T="03">patrick.sacbibit@fema.dhs.gov;</E>
                         or visit the FEMA Mapping and Insurance eXchange (FMIX) online at 
                        <E T="03">https://www.floodmaps.fema.gov/fhm/fmx_main.html.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The Federal Emergency Management Agency (FEMA) makes the final determinations listed below for the new or modified flood hazard information for each community listed. Notification of these changes has been published in newspapers of local circulation and 90 days have elapsed since that publication. The Deputy Associate Administrator for Insurance and Mitigation has resolved any appeals resulting from this notification.</P>
                <P>This final notice is issued in accordance with section 110 of the Flood Disaster Protection Act of 1973, 42 U.S.C. 4104, and 44 CFR part 67. FEMA has developed criteria for floodplain management in floodprone areas in accordance with 44 CFR part 60.</P>
                <P>
                    Interested lessees and owners of real property are encouraged to review the new or revised FIRM and FIS report available at the address cited below for each community or online through the FEMA Map Service Center at 
                    <E T="03">https://msc.fema.gov.</E>
                </P>
                <P>The flood hazard determinations are made final in the watersheds and/or communities listed in the table below.</P>
                <EXTRACT>
                    <FP>(Catalog of Federal Domestic Assistance No. 97.022, “Flood Insurance.”)</FP>
                </EXTRACT>
                <SIG>
                    <NAME>Nicholas A. Shufro,</NAME>
                    <TITLE>Assistant Administrator (Acting) for Risk Management, Federal Emergency Management Agency, Department of Homeland Security.</TITLE>
                </SIG>
                <GPOTABLE COLS="2" OPTS="L2,nj,tp0,i1" CDEF="s100,r100">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Community</CHED>
                        <CHED H="1">Community map repository address</CHED>
                    </BOXHD>
                    <ROW EXPSTB="01">
                        <ENT I="21">
                            <E T="02">Barber County, Kansas and Incorporated Areas</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Docket No.: FEMA-B-2378</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">City of Hardtner</ENT>
                        <ENT>City Hall, 104 East Woodworth Avenue, Hardtner, KS 67057.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Hazelton</ENT>
                        <ENT>City Hall, 404 West Main Street, Hazelton, KS 67061.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Isabel</ENT>
                        <ENT>Barber County Courthouse, 120 East Washington Avenue, Medicine Lodge, KS 67104.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Kiowa</ENT>
                        <ENT>Barber County Courthouse, 120 East Washington Avenue, Medicine Lodge, KS 67104.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Medicine Lodge</ENT>
                        <ENT>City Hall, 114 West First Avenue, Medicine Lodge, KS 67104.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Sharon</ENT>
                        <ENT>Barber County Courthouse, 120 East Washington Avenue, Medicine Lodge, KS 67104.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Sun City</ENT>
                        <ENT>Barber County Courthouse, 120 East Washington Avenue, Medicine Lodge, KS 67104.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Unincorporated Areas of Barber County</ENT>
                        <ENT>Barber County Courthouse, 120 East Washington Avenue, Medicine Lodge, KS 67104.</ENT>
                    </ROW>
                    <ROW EXPSTB="01">
                        <ENT I="21">
                            <E T="02">Harper County, Kansas and Incorporated Areas</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Docket No.: FEMA-B-2374</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">City of Anthony</ENT>
                        <ENT>Harper County Courthouse, 201 North Jennings Avenue, Anthony, KS 67003.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Attica</ENT>
                        <ENT>Harper County Courthouse, 201 North Jennings Avenue, Anthony, KS 67003.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Bluff City</ENT>
                        <ENT>Harper County Courthouse, 201 North Jennings Avenue, Anthony, KS 67003.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Danville</ENT>
                        <ENT>Harper County Courthouse, 201 North Jennings Avenue, Anthony, KS 67003.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Harper</ENT>
                        <ENT>Harper County Courthouse, 201 North Jennings Avenue, Anthony, KS 67003.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Waldron</ENT>
                        <ENT>Harper County Courthouse, 201 North Jennings Avenue, Anthony, KS 67003.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <PRTPAGE P="93633"/>
                        <ENT I="01">Unincorporated Areas of Harper County</ENT>
                        <ENT>Harper County Courthouse, 201 North Jennings Avenue, Anthony, KS 67003.</ENT>
                    </ROW>
                    <ROW EXPSTB="01">
                        <ENT I="21">
                            <E T="02">St. Louis County, Minnesota and Incorporated Areas</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Docket No.: FEMA-B-2360</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">City of Aurora</ENT>
                        <ENT>City Hall, 16 West 2nd Avenue N, Aurora, MN 55705.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Babbitt</ENT>
                        <ENT>City Hall, 71 South Drive, Babbitt, MN 55706.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Biwabik</ENT>
                        <ENT>City Offices, 321 North Main Street, Biwabik, MN 55708.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Brookston</ENT>
                        <ENT>City Hall, 8757 1st Street S, Brookston, MN 55711.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Cook</ENT>
                        <ENT>City Hall, 127 South River Street, Cook, MN 55723.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Duluth</ENT>
                        <ENT>City Hall, 411 West 1st Street, Duluth, MN 55802.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Ely</ENT>
                        <ENT>City Hall, 209 East Chapman Street, Ely, MN 55731.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Floodwood</ENT>
                        <ENT>City Hall, 111 West 8th Avenue, Floodwood, MN 55736.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Hermantown</ENT>
                        <ENT>City Hall, 5105 Maple Grove Road, Hermantown, MN 55811.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Hibbing</ENT>
                        <ENT>City Hall, 401 East 21st Street, Hibbing, MN 55746.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Hoyt Lakes</ENT>
                        <ENT>Municipal Building, 206 Kennedy Memorial Drive, Hoyt Lakes, MN 55750.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Iron Junction</ENT>
                        <ENT>City Offices, 4141 Merrit Avenue, Iron Junction, MN 55751.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Meadowlands</ENT>
                        <ENT>Community Center, 7758 Western Avenue, Meadowlands, MN 55765.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Mountain Iron</ENT>
                        <ENT>City Hall, 8586 Enterprise Drive South, Mountain Iron, MN 55768.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Orr</ENT>
                        <ENT>City Hall, 4429 Highway 53, Orr, MN 55771.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Proctor</ENT>
                        <ENT>City Hall, 100 Pionk Drive, Proctor, MN 55810.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Rice Lake</ENT>
                        <ENT>Rice Lake City Hall, 4107 West Beyer Road, Duluth, MN 55803.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Tower</ENT>
                        <ENT>City Hall, 602 Main Street, Tower, MN 55790.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Virginia</ENT>
                        <ENT>City Hall, 327 South First Street, Virginia, MN 55792.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Winton</ENT>
                        <ENT>Community Center, 102 North Main Street, Winton, MN 55796.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Bois Forte Band of Chippewa</ENT>
                        <ENT>Boise Forte Band of Chippewa Tribal Government and Community Services Building, 5344 Lakeshore Drive, Nett Lake, MN 55772.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fond du Lac Band of Lake Superior Chippewa</ENT>
                        <ENT>Fond du Lac Band of Lake Superior Chippewa Tribal Center, 1720 Big Lake Road, Cloquet, MN 55720.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Township of Gnesen</ENT>
                        <ENT>Gnesen Community Center, 6356 Howard Gnesen Road, Duluth, MN 55803.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Township of Lakewood</ENT>
                        <ENT>Lakewood Town Hall, 3110 Strand Road, Duluth, MN 55803.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Township of Midway</ENT>
                        <ENT>Midway Town Hall, 3230 Midway Road, Duluth, MN 55810.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Unincorporated Areas of St. Louis County</ENT>
                        <ENT>St. Louis County Courthouse, 100 North 5th Avenue W, Duluth, MN 55802.</ENT>
                    </ROW>
                    <ROW EXPSTB="01">
                        <ENT I="21">
                            <E T="02">Douglas County, Nebraska and Incorporated Areas</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Docket No.: FEMA-B-2261</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">City of Bennington</ENT>
                        <ENT>City Hall, 15505 Warehouse Street, Bennington, NE 68007.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Omaha</ENT>
                        <ENT>Omaha-Douglas Civic Center, 1819 Farnam Street, Omaha, NE 68183.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Ralston</ENT>
                        <ENT>City Hall, 5500 South 77th Street, Ralston, NE 68127.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Valley</ENT>
                        <ENT>City Hall, 203 North Spruce Street, Valley, NE 68064.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Unincorporated Areas of Douglas County</ENT>
                        <ENT>Douglas County Environmental Services, 15335 West Maple Road, Suite 201, Omaha, NE 68116.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Village of Boys Town</ENT>
                        <ENT>Village Clerk, 14100 Crawford Street, Boys Town, NE 68010.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Village of Waterloo</ENT>
                        <ENT>Village Office, 509 South Front Street, Waterloo, NE 68069.</ENT>
                    </ROW>
                    <ROW EXPSTB="01">
                        <ENT I="21">
                            <E T="02">McIntosh County, North Dakota and Incorporated Areas</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Docket No.: FEMA-B-2222 and FEMA-B-2362</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">City of Ashley</ENT>
                        <ENT>McIntosh County Courthouse, 112 1st Street NE, Ashley, ND 54813.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Lehr</ENT>
                        <ENT>McIntosh County Courthouse, 112 1st Street NE, Ashley, ND 54813.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Venturia</ENT>
                        <ENT>McIntosh County Courthouse, 112 1st Street NE, Ashley, ND 54813.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Wishek</ENT>
                        <ENT>McIntosh County Courthouse, 112 1st Street NE, Ashley, ND 54813.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Zeeland</ENT>
                        <ENT>McIntosh County Courthouse, 112 1st Street NE, Ashley, ND 54813.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Unincorporated Areas of McIntosh County</ENT>
                        <ENT>McIntosh County Courthouse, 112 1st Street NE, Ashley, ND 54813.</ENT>
                    </ROW>
                    <ROW EXPSTB="01">
                        <ENT I="21">
                            <E T="02">Chesterfield County, South Carolina and Incorporated Areas</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Docket No.: FEMA-B-2371</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">Town of Cheraw</ENT>
                        <ENT>Town Hall, 200 Market Street, Cheraw, SC 29520.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Town of Chesterfield</ENT>
                        <ENT>Town Hall, 112 Main Street, Chesterfield, SC 29709.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Unincorporated Areas of Chesterfield County</ENT>
                        <ENT>Chesterfield County Administration Office, 178 Mill Street, Chesterfield, SC 29709.</ENT>
                    </ROW>
                    <ROW EXPSTB="01">
                        <ENT I="21">
                            <E T="02">Darlington County, South Carolina and Incorporated Areas</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Docket No.: FEMA-B-2371</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">City of Darlington</ENT>
                        <ENT>City Hall, 400 Pearl Street, Darlington, SC 29532.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Unincorporated Areas of Darlington County</ENT>
                        <ENT>Darlington County Courthouse, 1 Public Square, Room 303, Darlington, SC 29532.</ENT>
                    </ROW>
                    <ROW EXPSTB="01">
                        <PRTPAGE P="93634"/>
                        <ENT I="21">
                            <E T="02">Florence County, South Carolina and Incorporated Areas</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Docket No.: FEMA-B-2371</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">City of Florence</ENT>
                        <ENT>City Center, 324 West Evans Street, Florence, SC 29501.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Unincorporated Areas of Florence County</ENT>
                        <ENT>Florence County Planning and Building, 518 South Irby Street, Florence, SC 29501.</ENT>
                    </ROW>
                    <ROW EXPSTB="01">
                        <ENT I="21">
                            <E T="02">Spink County, South Dakota and Incorporated Areas</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Docket No.: FEMA-B-2380</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">City of Ashton</ENT>
                        <ENT>City Hall, 14 Main Street, Ashton, SD 57424.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Conde</ENT>
                        <ENT>City Hall, 343 Broadway Street, Conde, SD 57434.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Doland</ENT>
                        <ENT>City Hall, 106 North 2nd Street, Doland, SD 57436.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Frankfort</ENT>
                        <ENT>City Hall, 404 Maple Street, Frankfort, SD 57440.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">City of Redfield</ENT>
                        <ENT>City Hall, 626 Main Street, Redfield, SD 57469.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Town of Northville</ENT>
                        <ENT>Town Hall, 402 Thayer Street, Northville, SD 57465.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Town of Tulare</ENT>
                        <ENT>Community Hall, 112 Main Street, Tulare, SD 57476.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Town of Turton</ENT>
                        <ENT>Farmers State Bank, 123 East Center Street, Turton, SD 57477.</ENT>
                    </ROW>
                    <ROW RUL="s">
                        <ENT I="01">Unincorporated Areas of Spink County</ENT>
                        <ENT>Spink County Courthouse, 210 East 7th Avenue, Redfield, SD 57469.</ENT>
                    </ROW>
                    <ROW EXPSTB="01">
                        <ENT I="21">
                            <E T="02">Buckingham County, Virginia and Incorporated Areas</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="01" RUL="s">
                        <ENT I="21">
                            <E T="02">Docket No.: FEMA-B-2375</E>
                        </ENT>
                    </ROW>
                    <ROW EXPSTB="00">
                        <ENT I="01">Unincorporated Areas of Buckingham County</ENT>
                        <ENT>Buckingham County Administration Building, 13380 West James Anderson Highway, Buckingham, VA 23921.</ENT>
                    </ROW>
                </GPOTABLE>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27725 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9110-12-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>U.S. Immigration and Customs Enforcement</SUBAGY>
                <DEPDOC>[Docket No. ICEB-2024-0010]</DEPDOC>
                <RIN>RIN 1653-ZA54</RIN>
                <SUBJECT>Employment Authorization for Lebanese F-1 Nonimmigrant Students Experiencing Severe Economic Hardship as a Direct Result of the Current Crisis in Lebanon</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Immigration and Customs Enforcement; Department of Homeland Security.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of Homeland Security (DHS) is suspending certain regulatory requirements for F-1 nonimmigrant students from Lebanon who are experiencing severe economic hardship as a direct result of the current crisis in Lebanon. The Secretary is providing relief to these students who are in lawful F-1 nonimmigrant status, so the students may request employment authorization, work an increased number of hours while school is in session, and reduce their course load while continuing to maintain their F-1 nonimmigrant status.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>This action covers eligible Lebanese F-1 nonimmigrant students beginning on November 27, 2024, and ending on May 27, 2026.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Sharon Snyder, Unit Chief, Policy and Response Unit, Student and Exchange Visitor Program, MS 5600, U.S. Immigration and Customs Enforcement, 500 12th Street SW, Washington, DC 20536-5600; email: 
                        <E T="03">sevp@ice.dhs.gov,</E>
                         telephone: (703) 603-3400. This is not a toll-free number. Program information can be found at 
                        <E T="03">https://www.ice.gov/sevis/.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">What action is DHS taking under this notice?</HD>
                <P>
                    The Secretary is exercising authority under 8 CFR 214.2(f)(9) to temporarily suspend the applicability of certain requirements governing on-campus and off-campus employment for F-1 nonimmigrant students whose country of citizenship is Lebanon regardless of country of birth (or individuals having no nationality who last habitually resided in Lebanon), who are present in the United States in lawful F-1 nonimmigrant student status on the date of publication of this notice, and who are experiencing severe economic hardship as a direct result of the current crisis in Lebanon. Previously, DHS issued a notice which applied to F-1 nonimmigrant students from Lebanon who met certain criteria, including having been lawfully present in the United States in F-1 nonimmigrant status on July 26, 2024, that was effective through January 25, 2026. 
                    <E T="03">See</E>
                     89 FR 83897 (Oct. 18, 2024). While DHS's prior notice remains effective for eligible F-1 nonimmigrant students, effective with this publication, suspension of the employment limitations is also available through May 27, 2026, for those who are in lawful F-1 nonimmigrant status on the date of publication of this notice. DHS will deem an F-1 nonimmigrant student granted employment authorization through this Notice to be engaged in a “full course of study” for the duration of the employment authorization, if the student satisfies the minimum course load set forth in this notice.
                    <FTREF/>
                    <SU>1</SU>
                      
                    <E T="03">See</E>
                     8 CFR 214.2(f)(6)(i)(F).
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         Because the suspension of requirements under this notice applies throughout an academic term during which the suspension is in effect, DHS considers an F-1 nonimmigrant student who engages in a reduced course load or employment (or both) after this notice is effective to be engaging in a “full course of study,” 
                        <E T="03">see</E>
                         8 CFR 214.2(f)(6), and eligible for employment authorization, through the end of any academic term for which such student is matriculated as of May 27, 2026, provided the student satisfies the minimum course load requirements in this notice.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Who is covered by this notice?</HD>
                <P>This notice applies exclusively to F-1 nonimmigrant students who meet all of the following conditions:</P>
                <P>(1) Are a citizen of Lebanon regardless of country of birth (or an individual having no nationality who last habitually resided in Lebanon);</P>
                <P>(2) Were lawfully present in the United States on November 27, 2024, in F-1 nonimmigrant status under section 101(a)(15)(F)(i) of the Immigration and Nationality Act (INA), 8 U.S.C. 1101(a)(15)(F)(i);</P>
                <P>
                    (3) Are enrolled in an academic institution that is Student and Exchange Visitor Program (SEVP)-certified for 
                    <PRTPAGE P="93635"/>
                    enrollment for F-1 nonimmigrant students;
                </P>
                <P>(4) Are currently maintaining F-1 nonimmigrant status; and</P>
                <P>(5) Are experiencing severe economic hardship as a direct result of the current crisis in Lebanon.</P>
                <P>This notice applies to F-1 nonimmigrant students in an approved private school in kindergarten through grade 12, public school grades 9 through 12, and undergraduate and graduate education. An F-1 nonimmigrant student covered by this notice who transfers to another SEVP-certified academic institution remains eligible for the relief provided by means of this notice.</P>
                <HD SOURCE="HD1">Why is DHS taking this action?</HD>
                <P>DHS is taking action to provide relief to Lebanese F-1 nonimmigrant students experiencing severe economic hardship due to the current crisis in Lebanon. Based on its review of country conditions in Lebanon and input received from the U.S. Department of State (DOS), DHS is taking action to allow eligible F-1 nonimmigrant students from Lebanon to request employment authorization, work an increased number of hours while school is in session, and reduce their course load while continuing to maintain F-1 nonimmigrant student status.</P>
                <P>
                    Lebanon faces multiple and competing security threats, including political instability, civil unrest and violence, spill-over from the Syrian civil war, and increased border tension between Hezbollah 
                    <SU>2</SU>
                    <FTREF/>
                     and Israel.
                    <SU>3</SU>
                    <FTREF/>
                     Additionally, the deteriorating economic situation has led to alarming levels of poverty, food insecurity, and crumbling infrastructure.
                    <SU>4</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         Hezbollah (also spelled “Hizballah”) was designated as a foreign terrorist organization in 1997. 
                        <E T="03">See</E>
                         U.S. Dep't of State, Country Reports on Terrorism 2022, 276, Nov. 30, 2023, available at 
                        <E T="03">https://www.state.gov/wp-content/uploads/2023/11/Country_Reports_on_Terrorism_2022-v3.pdf</E>
                         (accessed Nov. 8, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         Instability in Lebanon, Global Conflict Tracker, Center for Preventive Action, Council on Foreign Relations, Oct. 28, 2024, available at 
                        <E T="03">https://www.cfr.org/global-conflict-tracker/conflict/political-instability-lebanon</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Famine Early Warning System, Escalating conflict leads to rising population in need of food assistance, Sept. 2024, available at 
                        <E T="03">https://fews.net/middle-east-and-asia/lebanon/key-message-update/september-2024</E>
                         (last visited Nov. 5, 2024); Mass displacement in Lebanon war revives spectre of sectarian strife, Reuters, Oct. 15, 2024, available at 
                        <E T="03">https://www.reuters.com/world/middle-east/mass-displacement-lebanon-war-revives-spectre-sectarian-strife-2024-10-15</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">Security Concerns</HD>
                <P>
                    Since October 7, 2023, there has been an escalation of hostilities across the Lebanon-Israel border between Israeli forces and Hezbollah.
                    <SU>5</SU>
                    <FTREF/>
                     As of early October 2024, the conflict between Israel and Hezbollah escalated significantly.
                    <SU>6</SU>
                    <FTREF/>
                     Increased Israeli airstrikes in Lebanon, including urban regions in and around Beirut, have resulted in civilian casualties and displacement.
                    <SU>7</SU>
                    <FTREF/>
                     According to Lebanese authorities, more than 2,300 people have been killed since October 2023 and 1.2 million people have been forced to flee their homes.
                    <SU>8</SU>
                    <FTREF/>
                     On September 30, 2024, Israel launched a ground invasion into southern Lebanon days after an Israeli air strike killed Hassan Nasrallah, the leader of Hezbollah.
                    <SU>9</SU>
                    <FTREF/>
                     Rising tensions between Israel and Hezbollah have resulted in the evacuation of both Israeli and Lebanese residents in communities along both sides of the shared border.
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         Instability in Lebanon, Global Conflict Tracker, Center for Preventive Action, Council on Foreign Relations, Oct. 28, 2024, available at 
                        <E T="03">https://www.cfr.org/global-conflict-tracker/conflict/political-instability-lebanon</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         ReliefWeb, Statement by the Humanitarian Coordinator for Lebanon, Imran Riza, on the One-Year Mark of Escalations in Lebanon, Oct. 9, 2024, available at 
                        <E T="03">https://reliefweb.int/report/lebanon/statement-humanitarian-coordinator-lebanon-imran-riza-one-year-mark-escalations-lebanon-9-october-2024-enar</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         Melanie Lidman, Bassam Hatoum, and Bassem Mroue, Israel expands its bombardment in Lebanon as thousands flee widening war, AP, Oct. 5, 2024, available at 
                        <E T="03">https://apnews.com/article/mideast-wars-lebanon-hezbollah-hamas-5-october-2024-a8b70daeccc57a86fc6d939c604f2caf</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         BBC, Israel-Hezbollah conflict in maps: Where is fighting happening in Lebanon, Oct. 17, 2024, available at 
                        <E T="03">https://www.bbc.com/news/articles/c9vp7dg3ml1o</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         NPR, Israel begins ground offensive in Lebanon, Oct. 1, 2024, available at 
                        <E T="03">https://www.npr.org/2024/10/01/g-s1-25657/israel-ground-offensive-lebanon</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">Economic Crisis</HD>
                <P>
                    The recent intensification of military conflict and population displacement has exacerbated an existing economic crisis in Lebanon. In 2021, the International Monetary Fund (IMF) estimated that Lebanon's economic collapse may be the third worst economic crisis in the world since the mid-nineteenth century.
                    <SU>11</SU>
                    <FTREF/>
                     Four years after the collapse, in September 2023, the IMF warned that “the small nation is still facing `enormous economic challenges,' with a collapsed banking sector, eroding public services, deteriorating infrastructure, inflation, and worsening poverty.” 
                    <SU>12</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         The World Bank, Lebanon Economic Monitor, Spring 2021: Lebanon Sinking (to the Top 3), available at 
                        <E T="03">https://www.worldbank.org/en/country/lebanon/publication/lebanon-economic-monitor-spring-2021-lebanon-sinking-to-the-top-3</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         Bassem Mroue, IMF warns Lebanon that the country is still facing enormous challenges, years after a meltdown began, Reuters, Sept. 15, 2023, available at 
                        <E T="03">https://apnews.com/article/lebanon-imf-central-bank-sayrafa-banks-meltdown-0d56ddea8dc9510d110959f794a06ed9</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <P>
                    Poverty in Lebanon has more than tripled over the past decade reaching 44 percent of the total population in 2022.
                    <SU>13</SU>
                    <FTREF/>
                     Families in Lebanon are described as multidimensionally poor, with “rising deprivation in the areas of health care, medicines, services, education employment, housing and assets.” 
                    <SU>14</SU>
                    <FTREF/>
                     Protective food subsidies have ended and living costs have risen dramatically, preventing families from accessing enough food and other basic needs each day.
                    <SU>15</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         World Bank, Lebanon Poverty and Equity Assessment 2024: Weathering a Protracted Crisis (English). Washington, D.C: World Bank Group, May 23, 2024, available at 
                        <E T="03">http://documents.worldbank.org/curated/en/099052224104516741/P1766511325da10a71ab6b1ae97816dd20c</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         United Nations Economic and Social Commission for Western Asia (ESCWA), Multidimensional poverty in Lebanon (2019-2021), available at 
                        <E T="03">https://www.unescwa.org/sites/default/files/news/docs/21-00634-_multidimentional_poverty_in_lebanon_-policy_brief_-_en.pdf</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         United Nations, Around 2 million facing food insecurity across Lebanon, Jan. 19, 2023, available at 
                        <E T="03">https://news.un.org/en/story/2023/01/1132642</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <P>
                    This economic crisis has caused Lebanon's Gross Domestic Product to “decrease from $54.9 billion in 2018 to $17.94 billion in 2023.” 
                    <SU>16</SU>
                    <FTREF/>
                     Additionally, Lebanon is grappling with hyperinflation, which is eroding the purchasing power of much of the Lebanese population.
                    <SU>17</SU>
                    <FTREF/>
                     Data from June 2023 indicates “that 59 percent of Lebanese households (and of these 86 percent of female headed households), excluding refugees, faced substantial challenges in meeting their needs, primarily driven by disrupted livelihoods.” 
                    <SU>18</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         Flash Appeal: Lebanon, October—December 2024, OCHA, October 2024, available at 
                        <E T="03">https://www.unocha.org/publications/report/lebanon/flash-appeal-lebanon-october-december-2024-october-2024</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD2">Political Crisis</HD>
                <P>
                    Since 2021, reports have implicated current and former Lebanese prime ministers in corruption cases.
                    <SU>19</SU>
                    <FTREF/>
                     More 
                    <PRTPAGE P="93636"/>
                    crucially, Lebanon has not had a President since 2022, when Michel Aoun stepped down a day before his presidential term expired.
                    <SU>20</SU>
                    <FTREF/>
                     The country's affairs are run by an unelected caretaker government; 
                    <SU>21</SU>
                    <FTREF/>
                     with no elected president, passage of new legislation and much needed economic reform is not occurring.
                    <SU>22</SU>
                    <FTREF/>
                     Moreover, since the hostilities increased between Israel and Hezbollah, tensions have also increased between Hezbollah and Sunni and Maronite factions in the government, making political agreements unlikely in the near-term.
                    <SU>23</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         The Washington Post, Pandora Papers: Leaks prompt investigations in some countries—and denial in others, Oct. 9, 2021, available at: 
                        <E T="03">https://www.washingtonpost.com/world/2021/10/09/russia-ukraine-jordan-lebanon-pandora-papers/</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         Lebanon's president leaves with no replacement amid political, economic crisis, PBS News Hour, Oct. 30, 2022, available at 
                        <E T="03">https://www.pbs.org/newshour/world/lebanons-president-leaves-with-no-replacement-amid-political-economic-crisis</E>
                         (last visited Nov. 5, 2024); Matt Bradley, Analysis: As was rages, some in Lebanon see opportunity in a weakened Hezbollah, NBC News, Oct. 4, 2024, available at 
                        <E T="03">https://www.nbcnews.com/news/world/israel-hezbollah-war-nasrallah-airstrikes-hamas-gaza-assassinations-rcna173851</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         Key Developments in 2023: Lebanon, Freedom House, 2023, available at 
                        <E T="03">https://freedomhouse.org/country/lebanon/freedom-world/2024</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         Matt Bradley, Analysis: As war rages, some in Lebanon see opportunity in a weakened Hezbollah, NBC News, Oct. 4, 2024, available at 
                        <E T="03">https://www.nbcnews.com/news/world/israel-hezbollah-war-nasrallah-airstrikes-hamas-gaza-assassinations-rcna173851</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         Instability in Lebanon, Global Conflict Tracker, Center for Preventive Action, Council on Foreign Relations, Oct. 28, 2024, available at 
                        <E T="03">https://www.cfr.org/global-conflict-tracker/conflict/political-instability-lebanon</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <P>
                    The inability to effectively govern in Lebanon has resulted in financial insolvency, crumbling infrastructure, and the inability to provide basic services including access to electricity and fuel.
                    <SU>24</SU>
                    <FTREF/>
                     Human Rights Watch reported that, “[o]n August 17, 2024, Lebanon's only operational power plant shut down after the state-run electricity company . . . ran out of fuel, resulting in a complete nationwide power outage.” 
                    <SU>25</SU>
                    <FTREF/>
                     This outage left residents of Lebanon and key state services like “the airport, water pump stations, sewage systems, and prisons, without state-provided electricity for more than 24 hours, and reliant on costly and highly polluting private diesel generators.” 
                    <SU>26</SU>
                    <FTREF/>
                     The Lebanese state is unable to provide the vast majority of residents with more than one to three hours of electricity per day.
                    <SU>27</SU>
                    <FTREF/>
                     This lack of access to electricity has adversely impacted Lebanese residents' access to education, health, water, sanitation, and a healthy environment.
                    <SU>28</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         International Organization for Migration, Lebanon Crisis Response Plan 2024, available at 
                        <E T="03">https://crisisresponse.iom.int/response/lebanon-crisis-response-plan-2024</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         Human Rights Watch, Lebanon: Nationwide Electricity Blackout, Aug. 29, 2024, available at 
                        <E T="03">https://www.hrw.org/news/2024/08/29/lebanon-nationwide-electricity-blackout</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         Human Rights Watch, “Cut Off From Life Itself” Lebanon's Failure on the Right to Electricity, Mar. 9, 2023, available at 
                        <E T="03">https://www.hrw.org/report/2023/03/09/cut-life-itself/lebanons-failure-right-electricity</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD2">Humanitarian Concerns</HD>
                <P>
                    The economic crisis, government failings, and increasingly escalating conflict have worsened an already fragile humanitarian situation in Lebanon.
                    <SU>29</SU>
                    <FTREF/>
                     Access to sufficient food, water, sanitation, hygiene, shelter, income, essential commodities, and healthcare have decreased.
                    <SU>30</SU>
                    <FTREF/>
                     Humanitarian needs continue to increase amid the escalating hostilities in Lebanon, exacerbated by the damage to vital infrastructure and the scale of internal and external displacement from conflict-affected areas of the country.
                    <SU>31</SU>
                    <FTREF/>
                     As of October 21, 2024, over 800,000 individuals were internally displaced in Lebanon.
                    <SU>32</SU>
                    <FTREF/>
                     More than 191,000 individuals have sought shelter in over 1,000 collective shelters, the vast majority of which are operating at full capacity.
                    <SU>33</SU>
                    <FTREF/>
                     Furthermore, the United Nations High Commissioner for Refugees estimates that approximately 425,000 people, including Syrians and Lebanese, have crossed from Lebanon into Syria since September, while more than 16,000 Lebanese have arrived in Iraq from Lebanon.
                    <SU>34</SU>
                    <FTREF/>
                     On October 4, 2024, the U.S. committed to providing nearly $157 million in new humanitarian assistance to support populations affected by conflict in Lebanon and the region.
                    <SU>35</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         United Nations Office for the Coordination of Humanitarian Affairs (OCHA), Today's top news: Israel and Occupied Palestinian Territory, Lebanon, Sudan, Oct. 7, 2024, available at 
                        <E T="03">https://www.unocha.org/news/todays-top-news-israel-and-occupied-palestinian-territory-lebanon-sudan</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         
                        <E T="03">Id;</E>
                         World Food Programme, Lebanon, available at 
                        <E T="03">https://www.wfp.org/countries/lebanon</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         OCHA, Lebanon Flash Update #37, Oct. 23, 2024, available at 
                        <E T="03">https://reliefweb.int/report/lebanon/lebanon-flash-update-37-escalation-hostilities-lebanon-21-october-2024</E>
                         (last visited Nov. 5, 2024)
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         OCHA, Lebanon Flash Update #37, Oct. 23, 2024, available at 
                        <E T="03">https://reliefweb.int/report/lebanon/lebanon-flash-update-37-escalation-hostilities-lebanon-21-october-2024</E>
                         (last visited Nov. 5, 2024)
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         The United Nations High Commissioner for Human Rights Syria Flash Update #17, Sept. 24-Oct 20, 2024, available at 
                        <E T="03">https://reporting.unhcr.org/syrian-arab-republic-response-displacement-lebanon-flash-update-17</E>
                         (last visited Nov. 5, 2024); OCHA, Lebanon Flash Update #37, Oct. 23, 2024, available at 
                        <E T="03">https://reliefweb.int/report/lebanon/lebanon-flash-update-37-escalation-hostilities-lebanon-21-october-2024</E>
                         (last visited Nov. 5, 2024); OCHA, Iraq Flash Update #14: Update on Displacement from Lebanon, Oct. 20, 2024, available at 
                        <E T="03">https://reliefweb.int/report/iraq/iraq-flash-update-14-update-displacement-lebanon-20-october-2024</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         U.S. Dep't of State, United States Provides Humanitarian Assistance in Response to the Escalating Crisis in Lebanon, Oct. 4, 2024, available at 
                        <E T="03">https://www.state.gov/united-states-provides-humanitarian-assistance-in-response-to-the-escalating-crisis-in-lebanon/</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <P>
                    Access to health care had been drastically reduced due to financial barriers and lack of medicine in Lebanon.
                    <SU>36</SU>
                    <FTREF/>
                     The current hostilities have aggravated the issues, with services struggling to respond to the needs of the displaced and conflict-affected,
                    <SU>37</SU>
                    <FTREF/>
                     and health care facilities have been either destroyed or closed due to the conflict.
                    <SU>38</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         European Commission, Lebanon, available at 
                        <E T="03">https://civil-protection-humanitarian-aid.ec.europa.eu/where/middle-east-and-northern-africa/lebanon_en</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         OCHA, Today's top news: Israel and Occupied Palestinian Territory, Lebanon, Sudan, Oct. 7, 2024, available at 
                        <E T="03">https://www.unocha.org/news/todays-top-news-israel-and-occupied-palestinian-territory-lebanon-sudan</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <P>
                    Access to food and potable water continue to be limited. As of October 2024, “at least 25 water facilities [were] damaged affecting more than 300,000 people.” 
                    <SU>39</SU>
                    <FTREF/>
                     According to the World Food Programme, 2.5 million people of the 5.3 million population need food assistance and 2.5 million, 47.5 percent, of people in Lebanon (including Lebanese nationals and refugees) are food insecure.
                    <SU>40</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         OCHA, Today's top news: Israel and Occupied Palestinian Territory, Lebanon, Sudan, Oct. 7, 2024, available at 
                        <E T="03">https://www.unocha.org/news/todays-top-news-israel-and-occupied-palestinian-territory-lebanon-sudan</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         World Food Programme, Lebanon, available at 
                        <E T="03">https://www.wfp.org/countries/lebanon</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <P>
                    Moreover, increasing levels of internal displacement are exacerbating the challenges facing Lebanon, including those related to hosting the substantial Syrian refugee population.
                    <SU>41</SU>
                    <FTREF/>
                     Children have also been impacted by the conflict. The start of the new school year has been postponed until November 4, 2024, as 75 percent of the country's public schools have been converted into shelters to accommodate the influx of internally displaced persons that have departed conflict-affected areas of 
                    <PRTPAGE P="93637"/>
                    Lebanon since the recent escalation.
                    <SU>42</SU>
                    <FTREF/>
                     According to the European Commission, “[m]ore than 10 percent of the 1.2 million school-aged Lebanese children are out of school, mainly due to economic vulnerabilities.” 
                    <SU>43</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         Flash Appeal: Lebanon, October-December 2024, OCHA, October 2024, available at 
                        <E T="03">https://www.unocha.org/publications/report/lebanon/flash-appeal-lebanon-october-december-2024-october-2024</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         ReliefWeb, Statement by the Humanitarian Coordinator for Lebanon, Imran Riza, on the One-Year Mark of Escalations in Lebanon, Oct. 9, 2024, available at 
                        <E T="03">https://reliefweb.int/report/lebanon/statement-humanitarian-coordinator-lebanon-imran-riza-one-year-mark-escalations-lebanon-9-october-2024-enar</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         European Commission, Lebanon, available at 
                        <E T="03">https://civil-protection-humanitarian-aid.ec.europa.eu/where/middle-east-and-northern-africa/lebanon_en</E>
                         (last visited Nov. 5, 2024).
                    </P>
                </FTNT>
                <P>As of November 7, 2024, 1,760 F-1 nonimmigrant students from Lebanon are enrolled at SEVP-certified academic institutions in the United States. Given the extent of the current crisis exacerbated by recent escalating violence, conflict and displacement in Lebanon, affected students whose primary means of financial support comes from Lebanon may need to be exempt from the normal student employment requirements to continue their studies in the United States. The current crisis has made it unfeasible for many students to safely return to Lebanon for the foreseeable future. Without employment authorization, these students may lack the means to meet basic living expenses.</P>
                <HD SOURCE="HD1">What is the minimum course load requirement to maintain valid F-1 nonimmigrant status under this notice?</HD>
                <P>
                    Undergraduate F-1 nonimmigrant students who receive on-campus or off-campus employment authorization under this notice must remain registered for a minimum of six semester or quarter hours of instruction per academic term. Undergraduate F-1 nonimmigrant students enrolled in a term of different duration must register for at least one half of the credit hours normally required under a “full course of study.” 
                    <E T="03">See</E>
                     8 CFR 214.2(f)(6)(i)(B) and (F). A graduate-level F-1 nonimmigrant student who receives on-campus or off-campus employment authorization under this notice must remain registered for a minimum of three semester or quarter hours of instruction per academic term. 
                    <E T="03">See</E>
                     8 CFR 214.2(f)(5)(v). Nothing in this notice affects the applicability of other minimum course load requirements set by the academic institution.
                </P>
                <P>
                    In addition, an F-1 nonimmigrant student (either undergraduate or graduate) granted on-campus or off-campus employment authorization under this notice may count up to the equivalent of one class or three credits per session, term, semester, trimester, or quarter of online or distance education toward satisfying this minimum course load requirement, unless their course of study is in an English language study program. 
                    <E T="03">See</E>
                     8 CFR 214.2(f)(6)(i)(G). An F-1 nonimmigrant student attending an approved private school in kindergarten through grade 12 or public school in grades 9 through 12 must maintain “class attendance for not less than the minimum number of hours a week prescribed by the school for normal progress toward graduation,” as required under 8 CFR 214.2(f)(6)(i)(E). Nothing in this notice affects the applicability of federal and state labor laws limiting the employment of minors.
                </P>
                <HD SOURCE="HD1">May an eligible F-1 nonimmigrant student who already has on-campus or off-campus employment authorization benefit from the suspension of regulatory requirements under this notice?</HD>
                <P>Yes. An F-1 nonimmigrant student who is a Lebanon citizen, regardless of country of birth (or an individual having no nationality who last habitually resided in Lebanon), who already has on-campus or off-campus employment authorization and is otherwise eligible may benefit under this notice, which suspends certain regulatory requirements relating to the minimum course load requirement under 8 CFR 214.2(f)(6)(i) and certain employment eligibility requirements under 8 CFR 214.2(f)(9). Such an eligible F-1 nonimmigrant student may benefit without having to apply for a new Form I-766, Employment Authorization Document (EAD). To benefit from this notice, the F-1 nonimmigrant student must request that their designated school official (DSO) enter the following statement in the remarks field of the student's Student and Exchange Visitor Information System (SEVIS) record, which the student's Form I-20, Certificate of Eligibility for Nonimmigrant (F-1) Student Status, will reflect:</P>
                <EXTRACT>
                    <P>
                        Approved for more than 20 hours per week of [DSO must insert “on-campus” or “off-campus,” depending upon the type of employment authorization the student already has] employment authorization and reduced course load under the Special Student Relief authorization from [DSO must insert the beginning date of the notice or the beginning date of the student's employment, whichever date is later] until [DSO must insert either the student's program end date, the current EAD expiration date (if the student is currently authorized for off-campus employment), or the end date of this notice, whichever date comes first].
                        <SU>44</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>44</SU>
                             Because the suspension of requirements under this notice applies throughout an academic term during which the suspension is in effect, DHS considers an F-1 nonimmigrant student who engages in a reduced course load or employment (or both) after this notice is effective to be engaging in a “full course of study,” 
                            <E T="03">see</E>
                             8 CFR 214.2(f)(6), and eligible for employment authorization, through the end of any academic term for which such student is matriculated as of May 27, 2026, provided the student satisfies the minimum course load requirements in this notice.
                        </P>
                    </FTNT>
                </EXTRACT>
                <HD SOURCE="HD1">Must the F-1 nonimmigrant student apply for reinstatement after expiration of this special employment authorization if the student reduces his or her “full course of study”?</HD>
                <P>
                    No. DHS will deem an F-1 nonimmigrant student who receives and comports with the employment authorization permitted under this notice to be engaged in a “full course of study” 
                    <SU>45</SU>
                    <FTREF/>
                     for the duration of the student's employment authorization, provided that a qualifying undergraduate level F-1 nonimmigrant student remains registered for a minimum of six semester or quarter hours of instruction per academic term, and a qualifying graduate level F-1 nonimmigrant student remains registered for a minimum of three semester or quarter hours of instruction per academic term. 
                    <E T="03">See</E>
                     8 CFR 214.2(f)(5)(v) and (f)(6)(i)(F). Undergraduate F-1 nonimmigrant students enrolled in a term of different duration must register for at least one half of the credit hours normally required under a “full course of study.” 
                    <E T="03">See</E>
                     8 CFR 214.2(f)(6)(i)(B) and (F). DHS will not require such students to apply for reinstatement under 8 CFR 214.2(f)(16) if they are otherwise maintaining F-1 nonimmigrant status.
                </P>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         
                        <E T="03">See</E>
                         8 CFR 214.2(f)(6).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Will an F-2 dependent (spouse or minor child) of an F-1 nonimmigrant student covered by this notice be eligible for employment authorization?</HD>
                <P>No. An F-2 spouse or minor child of an F-1 nonimmigrant student is not authorized to work in the United States and, therefore, may not accept employment while in F-2 nonimmigrant status, consistent with 8CFR 214.2(f)(15)(i).</P>
                <HD SOURCE="HD1">
                    Will the suspension of the applicability of the standard student employment requirements apply to an individual who receives an initial F-1 visa and makes an initial entry into the United States after the effective date of this notice in the 
                    <E T="04">Federal Register</E>
                    ?
                </HD>
                <P>
                    No. The suspension of the applicability of the standard regulatory 
                    <PRTPAGE P="93638"/>
                    requirements only applies to certain F-1 nonimmigrant students who meet the following conditions:
                </P>
                <P>(1) Are a citizen of Lebanon regardless of country of birth (or an individual having no nationality who last habitually resided in Lebanon);</P>
                <P>(2) Were lawfully present in the United States on November 27, 2024, in F-1 nonimmigrant status, under section 101(a)(15)(F)(i) of the INA, 8 U.S.C. 1101(a)(15)(F)(i);</P>
                <P>(3) Are enrolled in an academic institution that is SEVP-certified for enrollment of F-1 nonimmigrant students;</P>
                <P>(4) Are maintaining F-1 nonimmigrant status; and</P>
                <P>(5) Are experiencing severe economic hardship as a direct result of the current crisis in Lebanon.</P>
                <P>An F-1 nonimmigrant student who does not meet all these requirements is ineligible for the suspension of the applicability of the standard regulatory requirements (even if experiencing severe economic hardship as a direct result of the current crisis in Lebanon).</P>
                <HD SOURCE="HD1">
                    Does this notice apply to a continuing F-1 nonimmigrant student who departs the United States after the effective date of this notice in the 
                    <E T="04">Federal Register</E>
                     and who needs to obtain a new F-1 visa before returning to the United States to continue an educational program?
                </HD>
                <P>Yes. This notice applies to such an F-1 nonimmigrant student, but only if the DSO has properly notated the student's SEVIS record, which will then appear on the student's Form I-20. The normal rules for visa issuance remain applicable to a nonimmigrant who needs to apply for a new F-1 visa to continue an educational program in the United States.</P>
                <HD SOURCE="HD1">Does this notice apply to elementary school, middle school, and high school students in F-1 status?</HD>
                <P>Yes. However, this notice does not by itself reduce the required course load for F-1 nonimmigrant students from Lebanon enrolled in kindergarten through grade 12 at a private school, or grades 9 through 12 at a public high school. Such students must maintain the minimum number of hours of class attendance per week prescribed by the academic institution for normal progress toward graduation, as required under 8CFR214.2(f)(6)(i)(E). The suspension of certain regulatory requirements related to employment through this notice is applicable to all eligible F-1 nonimmigrant students regardless of educational level. Eligible F-1 nonimmigrant students from Lebanon enrolled in an elementary school, middle school, or high school may benefit from the suspension of the requirement in 8 CFR 214.2(f)(9)(i) that limits on-campus employment to 20 hours per week while school is in session.</P>
                <HD SOURCE="HD1">On-Campus Employment Authorization</HD>
                <HD SOURCE="HD1">Will an F-1 nonimmigrant student who receives on-campus employment authorization under this notice be authorized to work more than 20 hours per week while school is in session?</HD>
                <P>Yes. For an F-1 nonimmigrant student covered in this notice, the Secretary is suspending the applicability of the requirement in 8 CFR 214.2(f)(9)(i) that limits an F-1 nonimmigrant student's on-campus employment to 20 hours per week while school is in session. An eligible F-1 nonimmigrant student has authorization to work more than 20 hours per week while school is in session if the DSO has entered the following statement in the remarks field of the student's SEVIS record, which will be reflected on the student's Form I-20:</P>
                <EXTRACT>
                    <P>
                        Approved for more than 20 hours per week of on-campus employment and reduced course load, under the Special Student Relief authorization from [DSO must insert the beginning date of this notice or the beginning date of the student's employment, whichever date is later] until [DSO must insert the student's program end date or the end date of this notice, whichever date comes first].
                        <SU>46</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>46</SU>
                             Because the suspension of requirements under this notice applies throughout an academic term during which the suspension is in effect, DHS considers an F-1 nonimmigrant student who engages in a reduced course load or employment (or both) after this notice is effective to be engaging in a “full course of study,” 
                            <E T="03">see</E>
                             8 CFR 214.2(f)(6), and eligible for employment authorization, through the end of any academic term for which such student is matriculated as of May 27, 2026, provided the student satisfies the minimum course load requirements in this notice.
                        </P>
                    </FTNT>
                </EXTRACT>
                <P>To obtain on-campus employment authorization, the F-1 nonimmigrant student must demonstrate to the DSO that the employment is necessary to avoid severe economic hardship directly resulting from the current crisis in Lebanon. An F-1 nonimmigrant student authorized by the DSO to engage in on-campus employment by means of this notice does not need to file any applications with U.S. Citizenship and Immigration Services (USCIS). The standard rules permitting full-time on-campus employment when school is not in session or during school vacations apply, as described in 8 CFR 214.2(f)(9)(i).</P>
                <HD SOURCE="HD1">Will an F-1 nonimmigrant student who receives on-campus employment authorization under this notice have authorization to reduce the normal course load and still maintain his or her F-1 nonimmigrant student status?</HD>
                <P>
                    Yes. DHS will deem an F-1 nonimmigrant student who receives on-campus employment authorization under this notice to be engaged in a “full course of study” 
                    <SU>47</SU>
                    <FTREF/>
                     for the purpose of maintaining their F-1 nonimmigrant student status for the duration of the on-campus employment, if the student satisfies the minimum course load requirement described in this notice, consistent with 8 CFR 214.2(f)(6)(i)(F). However, the authorization to reduce the normal course load is solely for DHS purposes of determining valid F-1 nonimmigrant student status. Nothing in this notice mandates that school officials allow an F-1 nonimmigrant student to take a reduced course load if the reduction would not meet the academic institution's minimum course load requirement for continued enrollment.
                    <SU>48</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>47</SU>
                         
                        <E T="03">See</E>
                         8 CFR 214.2(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>48</SU>
                         Minimum course load requirement for enrollment in a school must be established in a publicly available document (
                        <E T="03">e.g.,</E>
                         catalog, website, or operating procedure), and it must be a standard applicable to all students (U.S. citizens and foreign students) enrolled at the school.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Off-Campus Employment Authorization</HD>
                <HD SOURCE="HD1">What regulatory requirements does this notice temporarily suspend relating to off-campus employment?</HD>
                <P>For an F-1 nonimmigrant student covered by this notice, as provided under 8 CFR 214.2(f)(9)(ii)(A), the Secretary is suspending the following regulatory requirements relating to off-campus employment:</P>
                <P>(a) The requirement that a student must have been in F-1 nonimmigrant student status for one full academic year to be eligible for off-campus employment;</P>
                <P>(b) The requirement that an F-1 nonimmigrant student must demonstrate that acceptance of employment will not interfere with the student's carrying a full course of study;</P>
                <P>(c) The requirement that limits an F-1 nonimmigrant student's employment authorization to no more than 20 hours per week of off-campus employment while the school is in session; and</P>
                <P>
                    (d) The requirement that the student demonstrate that employment under 8 CFR 214.2(f)(9)(i) is unavailable or otherwise insufficient to meet the needs that have arisen as a result of the unforeseen circumstances.
                    <PRTPAGE P="93639"/>
                </P>
                <HD SOURCE="HD1">Will an F-1 nonimmigrant student who receives off-campus employment authorization under this notice have authorization to reduce the normal course load and still maintain F-1 nonimmigrant status?</HD>
                <P>
                    Yes. DHS will deem an F-1 nonimmigrant student who receives off-campus employment authorization by means of this notice to be engaged in a “full course of study” 
                    <SU>49</SU>
                    <FTREF/>
                     for the purpose of maintaining F-1 nonimmigrant student status for the duration of the student's employment authorization if the student satisfies the minimum course load requirement described in this notice, consistent with 8 CFR 214.2(f)(6)(i)(F). The authorization for a reduced course load is solely for DHS purposes of determining valid F-1 nonimmigrant student status. Nothing in this notice mandates that school officials allow an F-1 nonimmigrant student to take a reduced course load if such reduced course load would not meet the school's minimum course load requirement.
                    <SU>50</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>49</SU>
                         
                        <E T="03">See</E>
                         8 CFR 214.2(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>50</SU>
                         Minimum course load requirement for enrollment in a school must be established in a publicly available document (
                        <E T="03">e.g.,</E>
                         catalog, website, or operating procedure), and it must be a standard applicable to all students (U.S. citizens and foreign students) enrolled at the school.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">How may an eligible F-1 nonimmigrant student obtain employment authorization for off-campus employment with a reduced course load under this notice?</HD>
                <P>
                    An F-1 nonimmigrant student must file a Form I-765, Application for Employment Authorization, with USCIS to apply for off-campus employment authorization based on severe economic hardship directly resulting from the current crisis in Lebanon.
                    <SU>51</SU>
                    <FTREF/>
                     Filing instructions are located at 
                    <E T="03">https://www.uscis.gov/i-765.</E>
                </P>
                <FTNT>
                    <P>
                        <SU>51</SU>
                         
                        <E T="03">See</E>
                         8 CFR 274a.12(c)(3)(iii).
                    </P>
                </FTNT>
                <P>
                    <E T="03">Fee considerations.</E>
                     Submission of a Form I-765 currently requires payment of a $520 fee. An applicant who is unable to pay the fee may submit a completed Form I-912, Request for Fee Waiver, along with the Form I-765, Application for Employment Authorization. 
                    <E T="03">See https://www.uscis.gov/i-912.</E>
                     The submission must include an explanation about why USCIS should grant the fee waiver and the reason(s) for the inability to pay, and any evidence to support the reason(s). 
                    <E T="03">See</E>
                     8 CFR 106.2 and 106.3.
                </P>
                <P>
                    <E T="03">Supporting documentation.</E>
                     An F-1 nonimmigrant student seeking off-campus employment authorization due to severe economic hardship must demonstrate the following to their DSO:
                </P>
                <P>(1) This employment is necessary to avoid severe economic hardship; and</P>
                <P>(2) The hardship is a direct result of the current crisis in Lebanon.</P>
                <P>If the DSO agrees that the F-1 nonimmigrant student is entitled to receive such employment authorization, the DSO must recommend application approval to USCIS by entering the following statement in the remarks field of the student's SEVIS record, which will then appear on that student's Form I-20:</P>
                <EXTRACT>
                    <P>
                        Recommended for off-campus employment authorization in excess of 20 hours per week and reduced course load under the Special Student Relief authorization from the date of the USCIS authorization noted on Form I-766 until [DSO must insert the program end date or the end date of this notice, whichever date comes first].
                        <SU>52</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>52</SU>
                             Because the suspension of requirements under this notice applies throughout an academic term during which the suspension is in effect, DHS considers an F-1 nonimmigrant student who engages in a reduced course load or employment (or both) after this notice is effective to be engaging in a “full course of study,” 
                            <E T="03">see</E>
                             8 CFR 214.2(f)(6), and eligible for employment authorization, through the end of any academic term for which such student is matriculated as of May 27, 2026, provided the student satisfies the minimum course load requirements in this notice.
                        </P>
                    </FTNT>
                </EXTRACT>
                <P>The F-1 nonimmigrant student must then file the properly endorsed Form I-20 and Form I-765 according to the instructions for the Form I-765. The F-1 nonimmigrant student may begin working off campus only upon receipt of the EAD from USCIS.</P>
                <P>
                    <E T="03">DSO recommendation.</E>
                     In making a recommendation that an F-1 nonimmigrant student be approved for Special Student Relief, the DSO certifies that:
                </P>
                <P>
                    (a) The F-1 nonimmigrant student is in good academic standing and is carrying a “full course of study” 
                    <SU>53</SU>
                    <FTREF/>
                     at the time of the request for employment authorization;
                </P>
                <FTNT>
                    <P>
                        <SU>53</SU>
                         
                        <E T="03">See</E>
                         8 CFR 214.2(f)(6).
                    </P>
                </FTNT>
                <P>(b) The F-1 nonimmigrant student is a citizen of Lebanon, regardless of country of birth (or an individual having no nationality who last habitually resided in Lebanon), and is experiencing severe economic hardship as a direct result of the current crisis in Lebanon, as documented on the Form I-20;</P>
                <P>
                    (c) The F-1 nonimmigrant student has confirmed that the student will comply with the reduced course load requirements of this notice and register for the duration of the authorized employment for a minimum of six semester or quarter hours of instruction per academic term if at the undergraduate level, or for a minimum of three semester or quarter hours of instruction per academic term if the student is at the graduate level; 
                    <SU>54</SU>
                    <FTREF/>
                     and
                </P>
                <FTNT>
                    <P>
                        <SU>54</SU>
                         8 CFR 214.2(f)(5)(v).
                    </P>
                </FTNT>
                <P>(d) The off-campus employment is necessary to alleviate severe economic hardship to the individual as a direct result of the current crisis in Lebanon.</P>
                <P>
                    <E T="03">Processing.</E>
                     To facilitate prompt adjudication of the student's application for off-campus employment authorization under 8 CFR 214.2(f)(9)(ii)(C), the F-1 nonimmigrant student should do both of the following:
                </P>
                <P>(a) Ensure that the application package includes the following documents:</P>
                <P>(1) A completed Form I-765 with all applicable supporting evidence;</P>
                <P>(2) The required fee or properly documented fee waiver request as defined in 8 CFR 106.2 and 106.3; and</P>
                <P>(3) A signed and dated copy of the student's Form I-20 with the appropriate DSO recommendation, as previously described in this notice; and</P>
                <P>
                    (b) Send the application in an envelope which is clearly marked on the front of the envelope, bottom right-hand side, with the phrase “SPECIAL STUDENT RELIEF.” 
                    <SU>55</SU>
                    <FTREF/>
                     Failure to include this notation may result in significant processing delays.
                </P>
                <FTNT>
                    <P>
                        <SU>55</SU>
                         Students who wish to apply for a Special Student Relief-related EAD under this notice should use the mailing address specifically designated for (C)(3)(iii) filings. The direct filing address is available at 
                        <E T="03">https://www.uscis.gov/i-765-addresses</E>
                         (last visited Sept. 12, 2024).
                    </P>
                </FTNT>
                <P>If USCIS approves the student's Form I-765, USCIS will send the student a Form I-766 EAD as evidence of employment authorization. The EAD will contain an expiration date that does not exceed the end of the granted temporary relief.</P>
                <HD SOURCE="HD1">Temporary Protected Status (TPS) Considerations</HD>
                <HD SOURCE="HD1">Can an F-1 nonimmigrant student apply for TPS and for benefits under this notice at the same time?</HD>
                <P>
                    Yes. An F-1 nonimmigrant student who has not yet applied for TPS or for other relief that reduces the student's course load per term and permits an increased number of work hours per week, such as Special Student Relief,
                    <SU>56</SU>
                    <FTREF/>
                     under this notice has two options.
                </P>
                <FTNT>
                    <P>
                        <SU>56</SU>
                         
                        <E T="03">See</E>
                         DHS Study in the States, Special Student Relief, available at 
                        <E T="03">https://studyinthestates.dhs.gov/students/special-student-relief</E>
                         (last visited Feb. 28, 2024).
                    </P>
                </FTNT>
                <P>
                    Under the first option, the F-1 nonimmigrant student may apply for TPS according to the instructions in the USCIS notice designating Lebanon for TPS elsewhere in this issue of the 
                    <E T="04">Federal Register</E>
                    . All TPS applicants must file a Form I-821, Application for 
                    <PRTPAGE P="93640"/>
                    Temporary Protected Status, with the appropriate fee (or request a fee waiver). Although not required to do so, if F-1 nonimmigrant students want to obtain a new TPS-related EAD that is valid through May 27, 2026, and to be eligible for automatic EAD extensions that may be available to certain EADs with an A-12 or C-19 category code, they must file Form I-765 and pay the Form I-765 fee (or request a fee waiver). After receiving the TPS-related EAD, an F-1 nonimmigrant student may request that their DSO make the required entry in SEVIS and issue an updated Form I-20, which notates that the nonimmigrant student has been authorized to carry a reduced course load, as described in this notice. As long as the F-1 nonimmigrant student maintains the minimum course load described in this notice, does not otherwise violate their nonimmigrant status, including as provided under 8 CFR 214.1(g), and maintains TPS, then the student maintains F-1 status and TPS concurrently.
                </P>
                <P>
                    Under the second option, the F-1 nonimmigrant student may apply for an EAD under Special Student Relief by filing Form I-765 with the location specified in the filing instructions. At the same time, the F-1 nonimmigrant student may file a separate TPS application but must submit the Form I-821 according to the instructions provided in the 
                    <E T="04">Federal Register</E>
                     notice designating Lebanon for TPS. If the F-1 nonimmigrant student has already applied for employment authorization under Special Student Relief, they are not required to submit the Form I-765 as part of the TPS application. However, some nonimmigrant students may wish to obtain a TPS-related EAD in light of certain extensions that may be available to EADs with an A-12 or C-19 category code that are not available to the C-3 category under which Special Student Relief falls. The F-1 nonimmigrant student should check the appropriate box when filling out Form I-821 to indicate whether a TPS-related EAD is being requested. Again, as long as the F-1 nonimmigrant student maintains the minimum course load described in this notice and does not otherwise violate the student's nonimmigrant status, included as provided under 8 CFR 214.1(g), the nonimmigrant will be able to maintain compliance requirements for F-1 nonimmigrant student status while having TPS.
                </P>
                <HD SOURCE="HD1">When a student applies simultaneously for TPS and benefits under this notice, what is the minimum course load requirement while an application for employment authorization is pending?</HD>
                <P>
                    The F-1 nonimmigrant student must maintain normal course load requirements for a “full course of study” 
                    <SU>57</SU>
                    <FTREF/>
                     unless or until the nonimmigrant student receives employment authorization under this notice. TPS-related employment authorization, by itself, does not authorize a nonimmigrant student to drop below twelve credit hours, or otherwise applicable minimum requirements (
                    <E T="03">e.g.,</E>
                     clock hours for non-traditional academic programs). Once approved for a TPS-related EAD and Special Student Relief employment authorization, as indicated by the DSO's required entry in SEVIS and issuance of an updated Form I-20, the F-1 nonimmigrant student may drop below twelve credit hours, or otherwise applicable minimum requirements (with a minimum of six semester or quarter hours of instruction per academic term if at the undergraduate level, or for a minimum of three semester or quarter hours of instruction per academic term if at the graduate level). 
                    <E T="03">See</E>
                     8 CFR 214.2(f)(5)(v), (f)(6), and (f)(9)(i) and (ii).
                </P>
                <FTNT>
                    <P>
                        <SU>57</SU>
                         
                        <E T="03">See</E>
                         8 CFR 214.2(f)(6).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">How does a student who has received a TPS-related EAD then apply for authorization to take a reduced course load under this notice?</HD>
                <P>There is no further application process with USCIS if a student has been approved for a TPS-related EAD. The F-1 nonimmigrant student must demonstrate and provide documentation to the DSO of the direct economic hardship resulting from the current crisis in Lebanon. The DSO will then verify and update the student's record in SEVIS to enable the F-1 nonimmigrant student with TPS to reduce the course load without any further action or application. No other EAD needs to be issued for the F-1 nonimmigrant student to have employment authorization.</P>
                <HD SOURCE="HD1">Can a noncitizen who has been granted TPS apply for reinstatement of F-1 nonimmigrant student status after the noncitizen's F-1 nonimmigrant student status has lapsed?</HD>
                <P>
                    Yes. Regulations permit certain students who fall out of F-1 nonimmigrant student status to apply for reinstatement. 
                    <E T="03">See</E>
                     8 CFR 214.2(f)(16). This provision may apply to students who worked on a TPS-related EAD or dropped their course load before publication of this notice, and therefore fell out of student status. These students must satisfy the criteria set forth in the F-1 nonimmigrant student status reinstatement regulations.
                </P>
                <HD SOURCE="HD1">Deferred Enforced Departure (DED) Considerations</HD>
                <HD SOURCE="HD1">Can an F-1 nonimmigrant student apply for a DED-related EAD and for benefits under this notice at the same time?</HD>
                <P>Yes. Although they are not required to apply for a DED-related EAD, an F-1 nonimmigrant student who meets the eligibility requirements under the applicable DED notice and wants to obtain such an EAD must file Form I-765 and pay the related fee (or request a fee waiver). The eligible F-1 student may also apply for Special Student Relief under this notice by requesting that the DSO notate on their Form I-20 in SEVIS that the student has been authorized to carry a reduced course load and is permitted to work an increased number of hours under Special Student Relief while school is in session. The DSO should also notate on the Form I-20 that the student is working pursuant to a DED-related EAD. As long as the F-1 nonimmigrant student maintains the minimum course load described in this notice, does not otherwise violate the student's nonimmigrant status, including as provided under 8 CFR 214.1(g), and remains covered under DED, then the student maintains F-1 nonimmigrant status and DED concurrently.</P>
                <HD SOURCE="HD1">When a student applies simultaneously for a DED-related EAD and benefits under this notice, what is the minimum course load requirement while an application for employment authorization is pending?</HD>
                <P>
                    The F-1 nonimmigrant student must maintain normal course load requirements for a “full course of study” 
                    <SU>58</SU>
                    <FTREF/>
                     unless or until the F-1 nonimmigrant student is granted employment authorization under this notice. DED-related employment authorization, by itself, does not authorize a nonimmigrant student to drop below twelve credit hours, or otherwise applicable minimum requirements (
                    <E T="03">e.g.,</E>
                     clock hours for non-traditional academic programs). Once approved for a DED-related EAD and Special Student Relief employment authorization, as indicated by the DSO's required entry in SEVIS and issuance of an updated Form I-20, the F-1 nonimmigrant student may drop below 
                    <PRTPAGE P="93641"/>
                    twelve credit hours, or otherwise applicable minimum requirements (with a minimum of six semester or quarter hours of instruction per academic term if the student is at the undergraduate level, or a minimum of three semester or quarter hours of instruction per academic term if the student is at the graduate level). 
                    <E T="03">See</E>
                     8 CFR 214.2(f)(5)(v), 214.2(f)(6), 214.2(f)(9)(i) and (ii).
                </P>
                <FTNT>
                    <P>
                        <SU>58</SU>
                         
                        <E T="03">See</E>
                         8 CFR 214.2(f)(6).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">How does an F-1 student who has received a DED-related EAD then apply for authorization to take a reduced course load under this notice?</HD>
                <P>There is no further application process with USCIS if a student has been approved for a DED-related EAD. However, the F-1 nonimmigrant student must demonstrate and provide documentation to the DSO of severe economic hardship as a direct result of the current humanitarian crisis in Lebanon. The DSO will then verify and update the student's SEVIS record to enable the F-1 nonimmigrant student with DED to reduce their course load without any further action or application. No other EAD needs to be issued for the F-1 nonimmigrant student to have employment authorization.</P>
                <HD SOURCE="HD1">Can a noncitizen who has been granted a DED-related EAD apply for reinstatement to F-1 nonimmigrant student status after the noncitizen's F-1 nonimmigrant student status has lapsed?</HD>
                <P>
                    Yes. Current regulations permit certain students who fall out of F-1 nonimmigrant student status to apply for reinstatement. 
                    <E T="03">See</E>
                     8 CFR 214.2(f)(16). This provision might apply to students who worked on a DED-related EAD or dropped their course load before July 26, 2024, and therefore fell out of F-1 nonimmigrant status. The student must satisfy the criteria set forth in the F-1 nonimmigrant student status reinstatement regulations.
                </P>
                <HD SOURCE="HD1">How long will this notice remain in effect?</HD>
                <P>
                    This notice grants temporary relief until May 27, 2026,
                    <SU>59</SU>
                    <FTREF/>
                     to eligible F-1 nonimmigrant students. DHS will continue to monitor the situation in Lebanon. Should the special provisions authorized by this notice need modification or extension, DHS will announce such changes in the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <FTNT>
                    <P>
                        <SU>59</SU>
                         Because the suspension of requirements under this notice applies throughout an academic term during which the suspension is in effect, DHS considers an F-1 nonimmigrant student who engages in a reduced course load or employment (or both) after this notice is effective to be engaging in a “full course of study,” 
                        <E T="03">see</E>
                         8 CFR 214.2(f)(6), and eligible for employment authorization, through the end of any academic term for which such student is matriculated as of May 27, 2026, provided the student satisfies the minimum course load requirements in this notice.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Paperwork Reduction Act (PRA)</HD>
                <P>An F-1 nonimmigrant student seeking off-campus employment authorization due to severe economic hardship resulting from the current crisis in Lebanon must demonstrate to the DSO that this employment is necessary to avoid severe economic hardship. A DSO who agrees that a nonimmigrant student should receive such employment authorization must recommend an application approval to USCIS by entering information in the remarks field of the student's SEVIS record. The authority to collect this information is in the SEVIS collection of information currently approved by the Office of Management and Budget (OMB) under OMB Control Number 1653-0038.</P>
                <P>This notice also allows an eligible F-1 nonimmigrant student to request employment authorization, work an increased number of hours while the academic institution is in session, and reduce their course load while continuing to maintain F-1 nonimmigrant student status.</P>
                <P>To apply for employment authorization, certain F-1 nonimmigrant students must complete and submit a currently approved Form I-765 according to the instructions on the form. OMB has previously approved the collection of information contained on the current Form I-765, consistent with the PRA (OMB Control Number 1615-0040). Although there will be a slight increase in the number of Form I-765 filings because of this notice, the number of filings currently contained in the OMB annual inventory for Form I-765 is sufficient to cover the additional filings. Accordingly, there is no further action required under the PRA.</P>
                <SIG>
                    <NAME>Alejandro Mayorkas,</NAME>
                    <TITLE>Secretary, U.S. Department of Homeland Security.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27787 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9111-CB-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF HOMELAND SECURITY</AGENCY>
                <SUBAGY>U.S. Citizenship and Immigration Services</SUBAGY>
                <DEPDOC>[CIS No. 2789-25; DHS Docket No. USCIS-2024-0015]</DEPDOC>
                <RIN>RIN 1615-ZC11</RIN>
                <SUBJECT>Designation of Lebanon for Temporary Protected Status</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. Citizenship and Immigration Services (USCIS), Department of Homeland Security (DHS).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of Temporary Protected Status (TPS) designation.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Through this notice, the Department of Homeland Security (DHS) announces that the Secretary of Homeland Security (Secretary) is designating Lebanon for Temporary Protected Status (TPS) for 18 months, beginning on November 27, 2024, and ending on May 27, 2026. This designation allows Lebanese nationals (and individuals having no nationality who last habitually resided in Lebanon) who have continuously resided in the United States since October 16, 2024, and who have been continuously physically present in the United States since November 27, 2024, to apply for TPS.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        <E T="03">Designation of Lebanon for TPS</E>
                         begins on November 27, 2024, and will remain in effect for 18 months. For registration instructions, see the Registration Information section below.
                    </P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P/>
                    <P>• You may contact Rená Cutlip-Mason, Chief, Humanitarian Affairs Division, Office of Policy and Strategy, U.S. Citizenship and Immigration Services, Department of Homeland Security, by mail at 5900 Capital Gateway Drive, Camp Springs, MD 20746, or by phone at 240-721-3000.</P>
                    <P>
                        • For further information on TPS, including guidance on the registration process and additional information on eligibility, please visit the USCIS TPS web page at 
                        <E T="03">https://uscis.gov/tps.</E>
                         You can find specific information about Lebanon's TPS designation by selecting “Lebanon” from the menu on the left side of the TPS web page.
                    </P>
                    <P>
                        • If you have additional questions about TPS, please visit 
                        <E T="03">https://uscis.gov/tools.</E>
                         Our online virtual assistant, Emma, can answer many of your questions and point you to additional information on our website. If you cannot find your answers there, you may also call our USCIS Contact Center at 800-375-5283 (TTY 800-767-1833).
                        <PRTPAGE P="93642"/>
                    </P>
                    <P>
                        • Applicants seeking information about the status of their individual cases may check Case Status Online, available on the USCIS website at 
                        <E T="03">uscis.gov</E>
                        , or visit the USCIS Contact Center at 
                        <E T="03">https://uscis.gov/contactcenter.</E>
                    </P>
                    <P>• You can also find more information at local USCIS offices after this notice is published.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <HD SOURCE="HD1">Table of Abbreviations</HD>
                <EXTRACT>
                    <FP SOURCE="FP-1">BIA—Board of Immigration Appeals</FP>
                    <FP SOURCE="FP-1">CFR—Code of Federal Regulations</FP>
                    <FP SOURCE="FP-1">DHS—U.S. Department of Homeland Security</FP>
                    <FP SOURCE="FP-1">DoS—U.S. Department of State</FP>
                    <FP SOURCE="FP-1">EAD—Employment Authorization Document</FP>
                    <FP SOURCE="FP-1">FNC—Final Nonconfirmation</FP>
                    <FP SOURCE="FP-1">Form I-131—Application for Travel Documents, Parole Documents, and Arrival/Departure Records</FP>
                    <FP SOURCE="FP-1">Form I-765—Application for Employment Authorization</FP>
                    <FP SOURCE="FP-1">Form I-797—Notice of Action (Approval Notice)</FP>
                    <FP SOURCE="FP-1">Form I-797C—Notice of Action (Receipt Notice)</FP>
                    <FP SOURCE="FP-1">Form I-821—Application for Temporary Protected Status</FP>
                    <FP SOURCE="FP-1">Form I-9—Employment Eligibility Verification</FP>
                    <FP SOURCE="FP-1">Form I-912—Request for Fee Waiver</FP>
                    <FP SOURCE="FP-1">Form I-94—Arrival/Departure Record</FP>
                    <FP SOURCE="FP-1">FR—Federal Register</FP>
                    <FP SOURCE="FP-1">Government—U.S. Government</FP>
                    <FP SOURCE="FP-1">IER—U.S. Department of Justice, Civil Rights Division, Immigrant and Employee Rights Section</FP>
                    <FP SOURCE="FP-1">IJ—Immigration Judge</FP>
                    <FP SOURCE="FP-1">INA—Immigration and Nationality Act</FP>
                    <FP SOURCE="FP-1">PDF—Portable Document Format</FP>
                    <FP SOURCE="FP-1">SAVE—USCIS Systematic Alien Verification for Entitlements Program</FP>
                    <FP SOURCE="FP-1">Secretary—Secretary of Homeland Security</FP>
                    <FP SOURCE="FP-1">TPS—Temporary Protected Status</FP>
                    <FP SOURCE="FP-1">TTY—Text Telephone</FP>
                    <FP SOURCE="FP-1">USCIS—U.S. Citizenship and Immigration Services</FP>
                    <FP SOURCE="FP-1">U.S.C.—United States Code</FP>
                </EXTRACT>
                <HD SOURCE="HD1">Registration Information</HD>
                <P>
                    <E T="03">Registration:</E>
                     The registration period for individuals to apply for TPS begins on November 27, 2024, and will remain in effect through May 27, 2026.
                </P>
                <HD SOURCE="HD1">Purpose of This Action (TPS)</HD>
                <P>
                    Through this notice, DHS sets forth procedures necessary for nationals of Lebanon (or individuals having no nationality who last habitually resided in Lebanon) to submit an initial registration application under the designation of Lebanon for TPS and apply for an Employment Authorization Document (EAD). Under the designation, individuals must submit an initial Application for Temporary Protected Status (Form I-821) for Lebanon, and they may also submit an Application for Employment Authorization (Form I-765), during the 18-month initial registration period that runs from November 27, 2024, through May 27, 2026. In addition to demonstrating continuous residence in the United States since October 16, 2024,
                    <SU>1</SU>
                    <FTREF/>
                     and meeting other eligibility criteria, initial applicants for TPS under this designation must demonstrate that they have been continuously physically present in the United States since November 27, 2024, the effective date of this designation of Lebanon, before USCIS may grant them TPS. DHS estimates that approximately 11,000 individuals are eligible to apply for TPS under the designation of Lebanon.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         The “continuous residence date” (CR) is any date established by the Secretary when a country is designated (or sometimes redesignated) for TPS. The “continuous physical presence date” (CPP) is the effective date of the most recent TPS designation of the country, which is either the publication date of the designation announcement in the 
                        <E T="04">Federal Register</E>
                         or a later date established by the Secretary. 
                        <E T="03">See</E>
                         INA sec. 244(b)(2)(A) (effective date of designation), (c)(1)(A)(i)-(ii) (discussing CR and CPP date requirements); 8 U.S.C. 1254a(b)(2)(A), (c)(1)(A)(i)-(ii).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">What is Temporary Protected Status (TPS)?</HD>
                <P>• TPS is a temporary immigration status granted to eligible nationals of a foreign state designated for TPS under the INA, or to eligible individuals without nationality who last habitually resided in the designated foreign state, regardless of their country of birth.</P>
                <P>• During the TPS designation period, TPS beneficiaries are eligible to remain in the United States, may not be removed, are authorized to work, and may obtain EADs if they continue to meet the requirements of TPS.</P>
                <P>• TPS beneficiaries may also apply for and be granted travel authorization as a matter of DHS discretion.</P>
                <P>• To qualify for TPS, beneficiaries must meet the eligibility standards at INA section 244(c)(1)-(2), 8 U.S.C. 1254a(c)(1)-(2).</P>
                <P>• When the Secretary terminates a foreign state's TPS designation, beneficiaries return to one of the following:</P>
                <P>○ The same immigration status or category that they maintained before TPS, if any (unless that status or category has since expired or terminated); or</P>
                <P>○ Any other lawfully obtained immigration status or category they received while registered for TPS, as long as it is still valid beyond the date TPS terminates.</P>
                <HD SOURCE="HD1">What authority does the Secretary have to designate Lebanon for TPS?</HD>
                <P>
                    Section 244(b)(1) of the INA, 8 U.S.C. 1254a(b)(1), authorizes the Secretary, after consultation with appropriate agencies of the U.S. Government, to designate a foreign state (or part thereof) for TPS if the Secretary determines that certain country conditions exist.
                    <SU>2</SU>
                    <FTREF/>
                     The Secretary may designate a country (or part of a country) for TPS on the basis of an “ongoing armed conflict” in the country if, due to such conflict, requiring the return of that country's nationals “would pose a serious threat to their personal safety.” 
                    <SU>3</SU>
                    <FTREF/>
                     The Secretary also may designate a country (or part thereof) for TPS if the Secretary finds “that there exist extraordinary and temporary conditions” in the country that prevent that country's nationals “from returning to the [country] in safety,” unless the Secretary finds that permitting such nationals “to remain temporarily in the United States is contrary to the national interest of the United States.” 
                    <SU>4</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         Although INA section 244(b)(1) ascribes this power to the Attorney General, Congress transferred this authority from the Attorney General to the Secretary of Homeland Security. 
                        <E T="03">See</E>
                         Homeland Security Act of 2002, Pub. L. 107-296, 116 Stat. 2135 (2002); 
                        <E T="03">see also</E>
                         8 U.S.C. 1103(a); 6 U.S.C. 557.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         INA sec. 244(b)(1)(A), 8 U.S.C. 1254a(b)(1)(A).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         INA sec. 244(b)(1)(C), 8 U.S.C. 1254a(b)(1)(C). In addition, the Secretary may designate a country (or part thereof) for TPS based on an environmental disaster if the country has officially requested such designation and certain other statutory requirements are met. INA sec. 244(b)(1)(B), 8 U.S.C. 1254a(b)(1)(B).
                    </P>
                </FTNT>
                <P>
                    The decision to designate any foreign state (or part thereof) is a discretionary decision, and there is no judicial review of any determination with respect to the designation, termination, or extension of a designation. 
                    <E T="03">See</E>
                     INA sec. 244(b)(5)(A), 8 U.S.C. 1254a(b)(5)(A). The Secretary, at their discretion, may then grant TPS to eligible nationals of that foreign state (or individuals having no nationality who last habitually resided in the designated foreign state). 
                    <E T="03">See</E>
                     INA sec. 244(a)(1)(A), 8 U.S.C. 1254a(a)(1)(A).
                </P>
                <P>
                    At least 60 days before the expiration of a foreign state's TPS designation or extension, the Secretary, after consultation with appropriate U.S. Government agencies, must review the conditions in the foreign state designated for TPS to determine whether they continue to meet the conditions for the TPS designation. 
                    <E T="03">See</E>
                     INA sec. 244(b)(3)(A), 8 U.S.C. 1254a(b)(3)(A). If the Secretary determines that the conditions in the foreign state continue to meet the conditions for TPS designation, the designation will be extended for an additional period of six months or, in the Secretary's discretion, 12 or 18 months. 
                    <E T="03">See</E>
                     INA sec. 244(b)(3)(A), (C), 8 U.S.C. 1254a(b)(3)(A), (C). If the Secretary determines that the foreign 
                    <PRTPAGE P="93643"/>
                    state no longer meets the conditions for TPS designation, the Secretary must terminate the designation. 
                    <E T="03">See</E>
                     INA sec. 244(b)(3)(B), 8 U.S.C. 1254a(b)(3)(B).
                </P>
                <HD SOURCE="HD1">Why was Lebanon designated for TPS?</HD>
                <P>
                    DHS has reviewed conditions in Lebanon. Based on this review, including input received from the Department of State (DoS) and other U.S. Government agencies, the Secretary has determined that an 18-month TPS designation is warranted because of armed conflict and extraordinary and temporary conditions described below.
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         This TPS designation for Lebanon is separate and apart from the President's July 26, 2024 memorandum providing for deferred enforced departure (DED) for certain Lebanese nationals in the United States. 
                        <E T="03">See Deferred Enforced Departure for Certain Lebanese Nationals,</E>
                         89 FR 61341 (July 26, 2024); 
                        <E T="03">see also Implementation of Employment Authorization for Individuals Covered by Deferred Enforced Departure for Lebanon,</E>
                         89 FR 83901 (Oct. 18, 2024).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">Overview</HD>
                <P>Long-standing humanitarian needs in Lebanon have been exacerbated by an escalation of armed conflict in the country, resulting in civilian casualties and massive numbers of displaced individuals. Lebanon was already grappling with profound socioeconomic and political crises, and the destruction and casualties caused by the ongoing armed conflict further threaten the safety of people in Lebanon and have significantly intensified the impact of the crises on people in Lebanon.</P>
                <HD SOURCE="HD2">Armed Conflict</HD>
                <P>
                    Since October 7, 2023, there has been an escalation of hostilities across the Lebanon-Israel border between Hezbollah 
                    <SU>6</SU>
                    <FTREF/>
                     and the Israel Defense Forces. By September 2024, the conflict between Israel and Hezbollah had significantly escalated, with Israel launching a ground invasion of southern Lebanon on September 30, 2024.
                    <SU>7</SU>
                    <FTREF/>
                     Israeli airstrikes targeting Hezbollah strongholds, including in urban regions in and around Beirut, caused civilian casualties and displacement.
                    <SU>8</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         Hezbollah (also spelled “Hizballah”) was designated as a foreign terrorist organization in 1997. 
                        <E T="03">See</E>
                         U.S. Dep't of State, Country Reports on Terrorism 2022, 276, Nov. 30, 2023, available at 
                        <E T="03">https://www.state.gov/wp-content/uploads/2023/11/Country_Reports_on_Terrorism_2022-v3.pdf</E>
                         (accessed Oct. 15, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         Israel-Hezbollah conflict in maps: Where is fighting happening in Lebanon, BBC, Oct. 9, 2024, available at: 
                        <E T="03">https://www.bbc.com/news/articles/c9vp7dg3ml1o</E>
                         (last visited Oct. 31, 2024); ReliefWeb, Statement By the Humanitarian Coordinator for Lebanon, Imran Riza, on the One-Year Mark of Escalations in Lebanon, 9 October 2024, available at: 
                        <E T="03">https://reliefweb.int/report/lebanon/statement-humanitarian-coordinator-lebanon-imran-riza-one-year-mark-escalations-lebanon-9-october-2024-enar</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         Melanie Lidman, Bassam Hatoum, and Bassem Mroue, Israel expands its bombardment in Lebanon as thousands flee widening war, AP, October 5, 2024, available at: 
                        <E T="03">https://apnews.com/article/mideast-wars-lebanon-hezbollah-hamas-5-october-2024-a8b70daeccc57a86fc6d939c604f2caf</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <P>
                    Since October 2023, more than 2,000 people in Lebanon have been killed and almost 10,000 injured, with approximately 1,100 people in Lebanon killed and 7,000 injured between September 17, 2024, and October 7, 2024 alone.
                    <SU>9</SU>
                    <FTREF/>
                     Approximately one million people have been impacted by the conflict, with estimates of between 541,000 and one million people being displaced in Lebanon, and over 200,000 people have fled to Syria.
                    <SU>10</SU>
                    <FTREF/>
                     The armed conflict has resulted in one of the deadliest periods in Lebanon's recent history.
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         9 Lebanon: Flash Update #33—Escalation of hostilities in Lebanon, United Nations Office for the Coordination of Humanitarian Affairs (OCHA), Oct. 9, 2024, available at: 
                        <E T="03">https://reliefweb.int/report/lebanon/lebanon-flash-update-33-escalation-hostilities-lebanon-7-october-2024</E>
                         (last visited Oct. 31, 2024); Lebanon: At a Glance—Escalation of hostilities in Lebanon, as of 07 October 2024, United Nations Office for the Coordination of Humanitarian Affairs (OCHA), Oct. 7, 2024, available at: 
                        <E T="03">https://reliefweb.int/report/lebanon/lebanon-glance-escalation-hostilities-lebanon-07-october-2024-assistance-provided-27-september-2024</E>
                         (last visited Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         OCHA, Today's top news: Lebanon, Occupied Palestinian Territory, Cameroon, Oct. 18, 2024, available at: 
                        <E T="03">https://www.unocha.org/news/todays-top-news-lebanon-occupied-palestinian-territory-cameroon</E>
                         (accessed Oct. 31, 2024); Displacement Tracking Matrix: Lebanon, Mobility Snapshot: Round 51, International Organization for Migration (IOM), Oct. 7, 2024, available at: 
                        <E T="03">https://dtm.iom.int/reports/lebanon-mobility-snapshot-round-51-07-10-2024</E>
                         (last visited Oct. 31, 2024). 
                        <E T="03">See</E>
                         also European Commission, Lebanon, available at: 
                        <E T="03">https://civil-protection-humanitarian-aid.ec.europa.eu/where/middle-east-and-northern-africa/lebanon_en#:~:text=People%20in%20Lebanon%2C%20including%20refugees,are%20dramatically%20exacerbating%20these%20vulnerabilities</E>
                         (accessed Oct. 31, 2024); United Nations High Commissioner for Refugees, Displaced families in Lebanon yearn for peace and a return home, Oct. 6, 2024, available at: 
                        <E T="03">https://www.unhcr.org/us/news/stories/displaced-families-lebanon-yearn-peace-and-return-home</E>
                         (accessed Nov. 4, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         ReliefWeb, Statement By the Humanitarian Coordinator for Lebanon, Imran Riza, on the One-Year Mark of Escalations in Lebanon, 9 October 2024, available at: 
                        <E T="03">https://reliefweb.int/report/lebanon/statement-humanitarian-coordinator-lebanon-imran-riza-one-year-mark-escalations-lebanon-9-october-2024-enar</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Economic Crisis</HD>
                <P>
                    Lebanon has been experiencing an economic crisis since 2019.
                    <SU>12</SU>
                    <FTREF/>
                     In October 2019, the Lebanese pound collapsed due to the nation's “unstable fixed exchange rate, large external and fiscal deficits, and mounting losses in the banking sector, which led to an abrupt reduction of capital inflows.” 
                    <SU>13</SU>
                    <FTREF/>
                     In March 2020, Lebanon defaulted on its government debt for the first time in its history.
                    <SU>14</SU>
                    <FTREF/>
                     Since the onset of the financial crisis in 2019, the Lebanese pound has lost more than 98% of its value.
                    <SU>15</SU>
                    <FTREF/>
                     In 2021, the International Monetary Fund (IMF) estimated that Lebanon's economic collapse may be the third worst economic crisis in the world since the mid-nineteenth century.
                    <SU>16</SU>
                    <FTREF/>
                     Almost four years after the collapse, in December 2023, the IMF warned that “the small nation is still facing `enormous economic challenges,' with a collapsed banking sector, eroding public services, deteriorating infrastructure and worsening poverty.” 
                    <SU>17</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         Georgetown Journal of International Affairs, The End Game to Lebanon's Woes: IMF Reform and Political Willingness, Nov. 10, 2023, available at: 
                        <E T="03">https://gjia.georgetown.edu/2023/11/10/the-end-game-to-lebanons-woes-imf-reform-and-political-willingness/</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         Georgetown Journal of International Affairs, The End Game to Lebanon's Woes: IMF Reform and Political Willingness, Nov. 10, 2023, available at: 
                        <E T="03">https://gjia.georgetown.edu/2023/11/10/the-end-game-to-lebanons-woes-imf-reform-and-political-willingness/</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         The Guardian, Lebanon to default on debt for first time amid financial crisis, Mar. 7, 2020, available at: 
                        <E T="03">https://www.theguardian.com/world/2020/mar/07/lebanon-to-default-on-debt-for-first-time-amid-financial-crisis</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         World Bank, Lebanon: New World Bank Project to Restore Basic Fiscal Management Functions in Support of Public Service Delivery, Feb. 15, 2024, available at: 
                        <E T="03">https://www.worldbank.org/en/news/press-release/2024/02/15/lebanon-new-world-bank-project-to-restore-basic-fiscal-management-functions-in-support-of-public-service-delivery#:~:text=Beirut%2C%20February%2015%2C%202024%20%E2%80%93,and%20use%20of%20public%20resources</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         The World Bank, Lebanon Economic Monitor, Spring 2021: Lebanon Sinking (to the Top 3), available at: 
                        <E T="03">https://www.worldbank.org/en/country/lebanon/publication/lebanon-economic-monitor-spring-2021-lebanon-sinking-to-the-top-3</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         Bassem Mroue, IMF warns Lebanon that the country is still facing enormous challenges, years after a meltdown began, Reuters, Sept. 15, 2023, available at: 
                        <E T="03">https://apnews.com/article/lebanon-imf-central-bank-sayrafa-banks-meltdown-0d56ddea8dc9510d110959f794a06ed9</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <P>
                    Poverty in Lebanon has more than tripled over the past decade reaching 44% of the total population.
                    <SU>18</SU>
                    <FTREF/>
                     Families in Lebanon are described as multidimensionally poor, with “rising deprivation in the areas of health care, medicines, services, education employment, housing and assets.
                    <FTREF/>
                    ” 
                    <SU>19</SU>
                      
                    <PRTPAGE P="93644"/>
                    Protective food subsidies have ended and living costs have risen dramatically, preventing families from accessing enough food and other basic needs each day.
                    <SU>20</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         World Bank, 
                        <E T="03">Lebanon Poverty and Equity Assessment 2024: Weathering a Protracted Crisis (English).</E>
                         Washington, DC: World Bank Group, May 23, 2024, available at: 
                        <E T="03">https://documents1.worldbank.org/curated/en/099052224104516741/pdf/P1766511325da10a71ab6b1ae97816dd20c.pdf</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         United Nations Economic and Social Commission for Western Asia (ESCWA), 
                        <PRTPAGE/>
                        Multidimensional poverty in Lebanon (2019-2021), available at: 
                        <E T="03">https://www.unescwa.org/sites/default/files/news/docs/21-00634-_multidimentional_poverty_in_lebanon_-policy_brief_-_en.pdf</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         IPC—Integrated Food Security Phase Classification, Lebanon: Acute Food Insecurity Projection Update for April-September 2023, May 30, 2024, available at: 
                        <E T="03">https://www.ipcinfo.org/ipc-country-analysis/details-map/en/c/1157035/?iso3=LBN</E>
                         (accessed Nov. 5, 2024).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Political Crisis</HD>
                <P>
                    Since 2022, reports have implicated current and former Lebanese prime ministers in corruption cases.
                    <SU>21</SU>
                    <FTREF/>
                     More crucially, Lebanon has not had a President since 2022, when Michel Aoun stepped down a day before his presidential term expired.
                    <SU>22</SU>
                    <FTREF/>
                     The country's affairs are run by an unelected caretaker government; with no elected president, passage of new legislation and much needed economic reform is not occurring.
                    <SU>23</SU>
                    <FTREF/>
                     Moreover, since the hostilities increased between Israel and Hezbollah, tensions have also increased between Hezbollah and Sunni and Maronite factions, making political agreements unlikely in the near-term.
                    <SU>24</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         The Washington Post, Pandora Papers: Leaks prompt investigations in some countries—and denial in others, Oct. 9, 2021, available at: 
                        <E T="03">https://www.washingtonpost.com/world/2021/10/09/russia-ukraine-jordan-lebanon-pandora-papers/</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         Lebanon's president leaves with no replacement amid political, economic crisis, PBS News Hour, Oct. 30, 2022, available at: 
                        <E T="03">https://www.pbs.org/newshour/world/lebanons-president-leaves-with-no-replacement-amid-political-economic-crisis</E>
                         (accessed Oct. 31, 2024); Matt Bradley, Analysis: As war rages, some in Lebanon see opportunity in a weakened Hezbollah, NBC News, Oct. 4, 2024, available at: 
                        <E T="03">https://www.nbcnews.com/news/world/israel-hezbollah-war-nasrallah-airstrikes-hamas-gaza-assassinations-rcna173851</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         Matt Bradley, Analysis: As war rages, some in Lebanon see opportunity in a weakened Hezbollah, NBC News, Oct. 4, 2024, available at: 
                        <E T="03">https://www.nbcnews.com/news/world/israel-hezbollah-war-nasrallah-airstrikes-hamas-gaza-assassinations-rcna173851</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         Instability in Lebanon, Global Conflict Tracker, Center for Preventive Action, Council on Foreign Relations, Feb. 13, 2024, available at: 
                        <E T="03">https://www.cfr.org/global-conflict-tracker/conflict/political-instability-lebanon</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <P>
                    The inability to effectively govern in Lebanon has resulted in financial insolvency, crumbling infrastructure, and the inability to provide basic services including access to electricity and fuel.
                    <SU>25</SU>
                    <FTREF/>
                     Problems with the electric utility are particularly severe, leading to shortages, including in August of this year when “Lebanon's only operational power plant shut down after the state-run electricity company . . . ran out of fuel, resulting in a complete nationwide power outage.” 
                    <SU>26</SU>
                    <FTREF/>
                     The blackout “left residents and key state institutions, such as the airport, water pump stations, sewage systems, and prisons, without state-provided electricity for more than 24 hours, and reliant on costly and highly polluting private diesel generators.” 
                    <SU>27</SU>
                    <FTREF/>
                     The Lebanese state is unable to provide the vast majority of citizens with more than one to three hours of electricity per day.
                    <SU>28</SU>
                    <FTREF/>
                     This lack of access to electricity has adversely impacted access to education, health, water, sanitation, and a healthy environment.
                    <SU>29</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         International Organization for Migration, Lebanon Crisis Response Plan 2024, available at: 
                        <E T="03">https://crisisresponse.iom.int/response/lebanon-crisis-response-plan-2024</E>
                         (accessed Oct. 31, 2024); Human Rights Watch, Cut Off From Life Itself: Lebanon's Failure on the Right to Electricity, Mar. 9, 2023, available at: 
                        <E T="03">https://www.hrw.org/report/2023/03/09/cut-life-itself/lebanons-failure-right-electricity</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         Human Rights Watch, Lebanon: Nationwide Electricity Blackout, Aug. 29, 2024, available at 
                        <E T="03">https://www.hrw.org/news/2024/08/29/lebanon-nationwide-electricity-blackout</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         Human Rights Watch, Lebanon: Nationwide Electricity Blackout, Aug. 29, 2024, available at 
                        <E T="03">https://www.hrw.org/news/2024/08/29/lebanon-nationwide-electricity-blackout</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         Human Rights Watch, “Cut Off From Life Itself” Lebanon's Failure on the Right to Electricity, Mar. 9, 2023, available at: 
                        <E T="03">https://www.hrw.org/report/2023/03/09/cut-life-itself/lebanons-failure-right-electricity</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD1">Humanitarian Crisis</HD>
                <P>
                    The economic crisis, government failings, and recent escalating conflict have worsened an already fragile humanitarian situation in Lebanon.
                    <SU>30</SU>
                    <FTREF/>
                     According to the United Nations Office for the Coordination of Humanitarian Affairs, “one year on from the escalation of hostilities across the country's southern border, Lebanon's humanitarian crisis is deteriorating at an alarming rate,” with Israeli airstrikes expanding beyond the border into civilian areas and greatly impacting vulnerable populations in Lebanon.
                    <SU>31</SU>
                    <FTREF/>
                     Access to sufficient food, water, and healthcare has decreased.
                    <SU>32</SU>
                    <FTREF/>
                     Humanitarian needs continue to increase amid the escalating hostilities in Lebanon, exacerbated by the damage to vital infrastructure.
                    <SU>33</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         OCHA, Today's top news: Israel and Occupied Palestinian Territory, Lebanon, Sudan, Oct. 7, 2024, available at: 
                        <E T="03">https://www.unocha.org/news/todays-top-news-israel-and-occupied-palestinian-territory-lebanon-sudan</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         Lebanon: Flash Update #33—Escalation of hostilities in Lebanon, United Nations Office for the Coordination of Humanitarian Affairs (OCHA), Oct. 9, 2024, available at: 
                        <E T="03">https://reliefweb.int/report/lebanon/lebanon-flash-update-33-escalation-hostilities-lebanon-7-october-2024</E>
                         (last visited Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         OCHA, Today's top news: Israel and Occupied Palestinian Territory, Lebanon, Sudan, Oct. 7, 2024, available at: 
                        <E T="03">https://www.unocha.org/news/todays-top-news-israel-and-occupied-palestinian-territory-lebanon-sudan</E>
                         (accessed Oct. 31, 2024); World Food Programme, Lebanon, available at: 
                        <E T="03">https://www.wfp.org/countries/lebanon</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         OCHA, Today's top news: Israel and Occupied Palestinian Territory, Lebanon, Sudan, Oct. 7, 2024, available at: 
                        <E T="03">https://www.unocha.org/news/todays-top-news-israel-and-occupied-palestinian-territory-lebanon-sudan</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <P>
                    Financial barriers and lack of medicine have significantly reduced access to health care in Lebanon.
                    <SU>34 </SU>
                    <FTREF/>
                     The ongoing hostilities have aggravated these issues, with services struggling to respond to the needs of the displaced and conflict-affected,
                    <SU>35</SU>
                    <FTREF/>
                     and health care facilities have been either destroyed or closed due to the conflict.
                    <SU>36</SU>
                    <FTREF/>
                     Access to food and potable water continue to be limited, as “[w]ater infrastructure is also affected with to date, at least 25 water facilities damaged affecting more than 300,000 people.” 
                    <SU>37</SU>
                    <FTREF/>
                     According to the World Food Programme, 2.5 million people of the 5.3 million population need food assistance and 47.5 percent of people in Lebanon (including Lebanese nationals and refugees) are food insecure.
                    <SU>38</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         European Commission, Lebanon, available at: 
                        <E T="03">https://civil-protection-humanitarian-aid.ec.europa.eu/where/middle-east-and-northern-africa/lebanon_en#:~:text=People%20in%20Lebanon%2C%20including%20refugees,are%20dramatically%20exacerbating%20these%20vulnerabilities</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         OCHA, Today's top news: Israel and Occupied Palestinian Territory, Lebanon, Sudan, Oct. 7, 2024, available at: 
                        <E T="03">https://www.unocha.org/news/todays-top-news-israel-and-occupied-palestinian-territory-lebanon-sudan</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         World Food Programme, Lebanon, available at: 
                        <E T="03">https://www.wfp.org/countries/lebanon</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <P>
                    Moreover, increasing levels of internal displacement are exacerbating the challenges facing Lebanon, including those related to hosting the substantial Syrian refugee population.
                    <SU>39</SU>
                    <FTREF/>
                     Children have also been impacted by the conflict. The start of the new school year has been postponed until November 4th as 75 percent of the country's public schools have been converted into shelters.
                    <SU>40</SU>
                    <FTREF/>
                     “More than 10% of the 1.2 
                    <PRTPAGE P="93645"/>
                    million school-aged Lebanese children are out of school, mainly due to economic vulnerabilities. Additionally, 54% of the 715,000 Syrian refugee children are out of formal education, with only 47,000 of them accessing some form of non-formal education.” 
                    <SU>41</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         OCHA, Today's top news: Lebanon, Occupied Palestinian Territory, Cameroon, Oct. 18, 2024, available at: 
                        <E T="03">https://www.unocha.org/news/todays-top-news-lebanon-occupied-palestinian-territory-cameroon</E>
                         (accessed Oct. 31, 2024); Human Rights Watch, Lebanon Events of 2022, available at: 
                        <E T="03">https://www.hrw.org/world-report/2023/country-chapters/lebanon</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         ReliefWeb, Statement by the Humanitarian Coordinator for Lebanon, Imran Riza, on the One-Year Mark of Escalations in Lebanon, 9 October 2024, available at: 
                        <E T="03">
                            https://reliefweb.int/report/lebanon/statement-humanitarian-coordinator-
                            <PRTPAGE/>
                            lebanon-imran-riza-one-year-mark-escalations-lebanon-9-october-2024-enar
                        </E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         European Commission, Lebanon, available at: 
                        <E T="03">https://civil-protection-humanitarian-aid.ec.europa.eu/where/middle-east-and-northern-africa/lebanon_en#:~:text=People%20in%20Lebanon%2C%20including%20refugees,are%20dramatically%20exacerbating%20these%20vulnerabilities</E>
                         (accessed Oct. 31, 2024).
                    </P>
                </FTNT>
                <P>In summary, based on the escalation of armed conflict and its resulting impacts on critical infrastructure, pre-existing economic and political crises, and further deteriorating humanitarian conditions, Lebanese nationals are unable to return safely to their homes.</P>
                <HD SOURCE="HD1">Notice of the Designation of Lebanon for TPS</HD>
                <P>
                    By the authority vested in me as Secretary under INA section 244, 8 U.S.C. 1254a, I have determined, after consultation with the appropriate U.S. Government agencies, the statutory conditions supporting Lebanon's designation for TPS on the basis of armed conflict and extraordinary and temporary conditions are met, and it is not contrary to the national interest of the United States to permit TPS Lebanon beneficiaries to remain in the United States temporarily. 
                    <E T="03">See</E>
                     INA sec. 244(b)(1)(A) and (C), 8 U.S.C. 1254a(b)(1)(A) and (C). I estimate approximately 11,000 individuals may be eligible for TPS under the designation of Lebanon. On the basis of this determination, I am designating Lebanon for TPS for 18 months, beginning on November 27, 2024, and ending on May 27, 2026. 
                    <E T="03">See</E>
                     INA sec. 244(b)(1) and (b)(2); 8 U.S.C. 1254a(b)(1), and (b)(2).
                </P>
                <SIG>
                    <NAME>Alejandro N. Mayorkas</NAME>
                    <TITLE>Secretary, U.S. Department of Homeland Security.</TITLE>
                </SIG>
                <HD SOURCE="HD1">Eligibility and Employment Authorization for TPS</HD>
                <HD SOURCE="HD1">Required Application Forms and Application Fees To Register for TPS</HD>
                <P>To register for TPS based on the designation of Lebanon, you must submit a Form I-821 and pay the filing fee (or request a fee waiver, which you may submit on Form I-912). You also need to pay a biometric services fee. If you cannot pay the biometric services fee, you may ask USCIS to waive the fee. Please see additional information under the “Biometric Services Fee” section of this notice.</P>
                <P>TPS beneficiaries are eligible for an EAD, which proves they are authorized to work in the United States. You do not need to submit Form I-765 or have an EAD to be granted TPS, but if you want an EAD to use as proof that you can work in the United States, see below for more information.</P>
                <P>
                    For more information on the application forms and fees for TPS, please visit the USCIS TPS web page at 
                    <E T="03">https://www.uscis.gov/tps.</E>
                     Fees for the Form I-821, the Form I-765, and biometric services are also described in 8 CFR 106.2 and the fee waiver-related regulations in 8 CFR 106.3. In addition, USCIS Form G-1055, Fee Schedule, provides the current fees required for the Form I-821 and Form I-765 for TPS applicants.
                </P>
                <HD SOURCE="HD1">How can TPS beneficiaries obtain an Employment Authorization Document (EAD)?</HD>
                <P>Everyone must provide their employer with documentation showing that they have the legal right to work in the United States. TPS beneficiaries are eligible to obtain an EAD, which proves their legal right to work. If you want to obtain an EAD, you must file Form I-765 and pay the Form I-765 fee (or request a fee waiver, which you may submit on Form I-912). TPS applicants may file this form along with their TPS application, or at a later date, if their TPS application is still pending or has been approved.</P>
                <HD SOURCE="HD1">Refiling an Initial TPS Registration Application After Receiving a Denial of a fee Waiver Request</HD>
                <P>If USCIS denies your fee waiver request, you can resubmit your TPS application. The fee waiver denial notice will contain specific instructions about resubmitting your application.</P>
                <HD SOURCE="HD1">Filing Information</HD>
                <P>
                    USCIS offers the option to applicants for TPS under Lebanon's designation to file Form I-821 and related requests for EADs online or by mail. However, if you file Form I-912, Request for Fee Waiver or a written fee waiver request for your Form I-821 or any applications filed together with your Form I-821, you must submit your applications by mail. When filing a TPS application, you can also request an EAD by submitting a completed Form I-765 with your Form I-821. Under certain circumstances, you may also upload a completed Form I-765 with a fee or fee waiver request, in Portable Document Format (PDF) through your USCIS online account. More information about filing your Form I-765 and fee waiver request through a PDF upload is available at 
                    <E T="03">https://www.uscis.gov/newsroom/stakeholder-messages/uscis-launches-online-pdf-filing-option.</E>
                </P>
                <P>
                    <E T="03">Online filing:</E>
                     Form I-821 and Form I-765 are available for concurrent filing online.
                    <SU>42</SU>
                    <FTREF/>
                     To file these forms online, you must first create a USCIS online account.
                    <SU>43</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         Find information about online filing at “Forms Available to File Online,” 
                        <E T="03">https://www.uscis.gov/file-online/forms-available-to-file-online.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         
                        <E T="03">https://myaccount.uscis.gov/users/sign_up.</E>
                    </P>
                </FTNT>
                <P>
                    <E T="03">PDF upload:</E>
                     Form I-765, if applicable, and Form I-912, if applicable, are available for PDF upload. To upload these documents, you must first create a USCIS online account.
                    <SU>44</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         
                        <E T="03">https://www.uscis.gov/newsroom/stakeholder-messages/uscis-launches-online-pdf-filing-option.</E>
                         Sign up to create a new USCIS online account at 
                        <E T="03">https://myaccount.uscis.gov/users/sign_up.</E>
                    </P>
                </FTNT>
                <P>
                    <E T="03">Mail filing:</E>
                     Mail your completed Form I-821; Form I-765, if applicable; Form I-912, if applicable; and supporting documentation to the proper address in Table 1—Mailing Addresses.
                </P>
                <GPOTABLE COLS="2" OPTS="L2,i1" CDEF="s25,r25">
                    <TTITLE>Table 1—Mailing Addresses</TTITLE>
                    <BOXHD>
                        <CHED H="1" O="L">If you send your paper application via:</CHED>
                        <CHED H="1" O="L">Then, mail your application to:</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01" O="xl">U.S. Postal Service USPS:</ENT>
                        <ENT>
                            USCIS 
                            <LI>Attn: TPS Lebanon, P.O. Box 6943, Chicago, IL 60680-6943.</LI>
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01" O="xl">FedEx, UPS, or DHL deliveries:</ENT>
                        <ENT>
                            USCIS 
                            <LI>Attn: TPS Lebanon (Box 6943), 131 S. Dearborn St. 3rd Floor, Chicago, IL 60603-5517.</LI>
                        </ENT>
                    </ROW>
                </GPOTABLE>
                <P>If you were granted TPS by an immigration judge (IJ) or the Board of Immigration Appeals (BIA) and you want to request an EAD, you may submit Form I-765 one of three ways: online, mail your Form I-765 to the appropriate address in table 1, or upload a completed PDF through your USCIS online account. If you file online, you must include the fee. If you file by mail, you must include the fee or fee waiver request. If you file by PDF upload, you must include the fee or a fee waiver request. When you request an EAD based on an IJ or BIA grant of TPS, include with your application a copy of the order from the IJ or BIA granting you TPS. This will help us verify your grant of TPS and process your application.</P>
                <HD SOURCE="HD1">Supporting Documents</HD>
                <P>
                    The filing instructions for Form I-821 list all the documents you need to establish eligibility for TPS. You may 
                    <PRTPAGE P="93646"/>
                    also find information on the acceptable documentation and other requirements for applying (also called registering) for TPS on the USCIS website at 
                    <E T="03">https://uscis.gov/tps</E>
                     under “Lebanon.”
                </P>
                <HD SOURCE="HD1">Travel</HD>
                <P>
                    TPS beneficiaries and TPS applicants with pending Form I-821 applications may also apply for travel authorization, which USCIS may grant as a matter of discretion. You must file for travel authorization if you wish to travel outside of the United States. If USCIS grants travel authorization, it gives you permission to leave the United States and return during a specific period. To request travel authorization, you must file Form I-131, available at 
                    <E T="03">https://www.uscis.gov/i-131.</E>
                     You may file Form I-131 together with your Form I-821 or separately.
                </P>
                <P>When you file Form I-131, a TPS beneficiary must:</P>
                <P>• Select Item Number 4 in Part 1 on the Form I-131; and</P>
                <P>• Submit the fee for Form I-131, or request a fee waiver, which you may submit on Form I-912.</P>
                <P>When you file Form I-131, a TPS applicant with a pending Form I-821 must:</P>
                <P>• Select Item Number 5C in Part 1 on the Form I-131; and</P>
                <P>• Submit the fee for Form I-131, or request a fee waiver, which you may submit on Form I-912.</P>
                <P>If you are filing Form I-131 together with Form I-821, send your forms to the address listed in table 1. If you are filing Form I-131 separately based on a pending or approved Form I-821, send your form to the address listed in table 2 and include a copy of Form I-797, Notice of Action, or Form I-797C, Notice of Action, indicating either approval or receipt of Form I-821. Form I-131 may not be filed by PDF upload.</P>
                <GPOTABLE COLS="2" OPTS="L2,i1" CDEF="s100,r100">
                    <TTITLE>Table 2—Mailing Addresses</TTITLE>
                    <BOXHD>
                        <CHED H="1" O="L">If you are . . .</CHED>
                        <CHED H="1" O="L">Mail to . . .</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Filing Form I-131 together with a Form I-821</ENT>
                        <ENT>The address provided in table 1.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01" O="xl">Filing Form I-131 based on a pending or approved Form I-821, and you are using the U.S. Postal Service (USPS): You must include a copy of the Notice of Action (Form I-797C or I-797) showing USCIS received or approved your Form I-821.</ENT>
                        <ENT>USCIS, Attn: I-131 TPS, P.O. Box 660167, Dallas, TX 75266-0867.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01" O="xl">
                            Filing Form I-131 based on a pending or approved Form I-821, and you are using FedEx, UPS, or DHL: 
                            <LI>You must include a copy of the Notice of Action (Form I-797C or Form I-797) showing USCIS received or approved your Form I-821</LI>
                        </ENT>
                        <ENT>USCIS, Attn: I-131 TPS, 2501 S. State Hwy. 121 Business, Ste. 400, Lewisville, TX 75067.</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">Biometric Services Fee for TPS</HD>
                <P>
                    Biometrics (such as fingerprints) are required for all applicants, in addition to a biometric services fee. As previously stated, if you cannot pay the biometric services fee, you may request a fee waiver, which you may submit on Form I-912. For more information on the application forms and fees for TPS, please visit the USCIS TPS web page at 
                    <E T="03">https://uscis.gov/tps.</E>
                     USCIS may require you to visit an Application Support Center to have your biometrics collected. For additional information on the USCIS biometric screening process, please see the USCIS Customer Profile Management Service Privacy Impact Assessment, available at 
                    <E T="03">https://www.dhs.gov/publication/dhsuscispia-060-customer-profile-management-service-cpms.</E>
                </P>
                <HD SOURCE="HD1">General Employment-Related Information for TPS Applicants and Their Employers</HD>
                <HD SOURCE="HD1">How can I obtain information on the status of my TPS application and EAD request?</HD>
                <P>
                    To get case status information about your TPS application, as well as the status of your TPS-based EAD request, you can check Case Status Online at uscis.gov or visit the USCIS Contact Center at 
                    <E T="03">https://uscis.gov/contactcenter.</E>
                     If you still need assistance, you may ask a question about your case online at 
                    <E T="03">https://egov.uscis.gov/e-request/Intro.do</E>
                     or call the USCIS Contact Center at 800-375-5283 (TTY 800-767-1833).
                </P>
                <HD SOURCE="HD1">When hired, what documentation may I show my employer as evidence of identity and employment authorization to complete Form I-9?</HD>
                <P>
                    You can find the Lists of Acceptable Documents on Form I-9, Employment Eligibility Verification, as well as on the Acceptable Documents web page at 
                    <E T="03">https://uscis.gov/i-9-central/acceptable-documents.</E>
                     Employers must complete Form I-9 to verify the identity and employment authorization of all new employees. Within three business days of hire, employees must present acceptable documents to their employers as evidence of identity and employment authorization to satisfy Form I-9 requirements.
                </P>
                <P>
                    You may present one selection from List A (which provides evidence of both identity and employment authorization) or one selection from List B (which provides evidence of your identity) together with one selection from List C (which provides evidence of employment authorization), or you may present an acceptable receipt as described in these lists. Employers may not reject a document based on a future expiration date. You can find additional information about Form I-9 on the I-9 Central web page at 
                    <E T="03">https://www.uscis.gov/I-9Central.</E>
                     An EAD is an acceptable document under List A.
                </P>
                <HD SOURCE="HD1">If I have an EAD based on another immigration status, can I obtain a new TPS-based EAD?</HD>
                <P>Yes, if you are eligible for TPS, you can obtain a new TPS-based EAD, even if you already have an EAD or work authorization based on another immigration status. If you want to obtain a new TPS-based EAD valid through May 27, 2026, you must file Form I-765 and pay the associated fee (unless USCIS grants your fee waiver request).</P>
                <HD SOURCE="HD1">Can my employer require that I provide any other documentation to complete Form I-9, such as evidence of my status, proof of my Lebanese citizenship, or a Form I-797 showing that I registered for TPS?</HD>
                <P>
                    No. When completing Form I-9, employers must accept any documentation you choose to present from the Form I-9 Lists of Acceptable Documents that reasonably appears to be genuine and that relates to you, or an acceptable List A, List B, or List C receipt. Employers may not request proof of Lebanese citizenship or proof of registration for TPS when completing Form I-9 for new hires or reverifying the employment authorization of current employees. Refer to the “Note to Employees” section of this 
                    <E T="04">
                        Federal 
                        <PRTPAGE P="93647"/>
                        Register
                    </E>
                     notice for important information about your rights if your employer rejects lawful documentation, requires additional documentation, or otherwise discriminates against you based on your citizenship or immigration status, or your national origin.
                </P>
                <HD SOURCE="HD1">Note to All Employers</HD>
                <P>
                    Employers are reminded that the laws requiring proper employment eligibility verification and prohibiting unfair immigration-related employment practices remain in full force. This 
                    <E T="04">Federal Register</E>
                     notice does not supersede or in any way limit applicable employment verification rules and policy guidance, including those rules setting forth reverification requirements. For general questions about the employment eligibility verification process, employers may call USCIS at 888-464-4218 (TTY 877-875-6028) or email USCIS at 
                    <E T="03">I9Central@uscis.dhs.gov.</E>
                     USCIS accepts calls and emails in English, Spanish and many other languages. For questions about avoiding discrimination during the employment eligibility verification process (Form I-9 and E-Verify), employers may call the U.S. Department of Justice, Civil Rights Division, Immigrant and Employee Rights Section (IER) Employer Hotline at 800-255-8155 (TTY 800-237-2515). IER offers language interpretation in many languages. Employers may also email IER at 
                    <E T="03">IER@usdoj.gov</E>
                     or get more information online at 
                    <E T="03">https://www.justice.gov/ier.</E>
                </P>
                <HD SOURCE="HD1">Note to Employees</HD>
                <P>
                    For general questions about the employment eligibility verification process, employees may call USCIS at 888-897-7781 (TTY 877-875-6028) or email USCIS at 
                    <E T="03">I-9Central@uscis.dhs.gov.</E>
                     USCIS accepts calls and emails in English, Spanish and many other languages. Employees or job applicants may also call the U.S. Department of Justice, Civil Rights Division, Immigrant and Employee Rights Section (IER) Worker Hotline at 800-255-7688 (TTY 800-237-2515) for information regarding employment discrimination based on citizenship, immigration status, or national origin, including discrimination related to Form I-9 and E-Verify. The IER Worker Hotline provides language interpretation in many languages.
                </P>
                <P>To comply with the law, employers must accept any document or combination of documents from the Lists of Acceptable Documents if the documentation reasonably appears to be genuine and to relate to the employee, or an acceptable List A, List B, or List C receipt as described in these lists. Employers may not require extra or additional documentation beyond what is required for Form I-9 completion. Further, employers participating in E-Verify who receive an E-Verify case result of “Tentative Nonconfirmation” (mismatch) must promptly inform employees of the mismatch and give such employees an opportunity to take action to contest the mismatch. A mismatch means that the information entered into E-Verify from Form I-9 differs from records available to DHS.</P>
                <P>
                    Employers may not terminate, suspend, delay training, withhold or lower pay, or take any adverse action against an employee because of a mismatch while the case is still pending with E-Verify. A Final Nonconfirmation (FNC) case result occurs if E-Verify cannot confirm an employee's employment eligibility. An employer may terminate employment based on a case result of FNC. Work-authorized employees who receive an FNC may call USCIS for assistance at 888-897-7781 (TTY 877-875-6028). For more information about E-Verify-related discrimination or to report an employer for discrimination in the E-Verify process based on citizenship, immigration status, or national origin, contact IER's Worker Hotline at 800-255-7688 (TTY 800-237-2515). Additional information about proper nondiscriminatory Form I-9 and E-Verify procedures is available on the IER website at 
                    <E T="03">https://www.justice.gov/ier</E>
                     and the USCIS and E-Verify websites at 
                    <E T="03">https://www.uscis.gov/i-9-central</E>
                     and 
                    <E T="03">https://www.e-verify.gov.</E>
                </P>
                <HD SOURCE="HD1">Note Regarding Federal, State, and Local Government Agencies (Such as Departments of Motor Vehicles)</HD>
                <P>For Federal purposes, individuals approved for TPS may show their Form I-797, Notice of Action, indicating approval of their Form I-821 application, or may show their EAD with category code of A12 or C19 to prove that they have TPS. However, while Federal Government agencies must follow the guidelines laid out by the Federal Government, State and local government agencies establish their own rules and guidelines when granting certain benefits. Each state may have different laws, requirements, and determinations about what documents you need to provide to prove eligibility for certain benefits. Whether you are applying for a Federal, State, or local government benefit, you may need to provide the government agency with documents that show you are a TPS beneficiary or applicant, show you are authorized to work based on TPS or other status, or that may be used by DHS to determine if you have TPS or another immigration status. Examples of such documents are:</P>
                <P>• Your new EAD with a TPS category code of A12 or C19, even if your country of birth noted on the EAD does not reflect the TPS-designated country of Lebanon;</P>
                <P>• Your Form I-94, Arrival/Departure Record;</P>
                <P>• Your Form I-797, Notice of Action, reflecting approval of your Form I-765; or</P>
                <P>• Your Form I-797 or Form I-797C, Notice of Action, reflecting approval or receipt of a current Form I-821, if you received one from USCIS.</P>
                <P>Check with the government agency requesting documentation about which documents the agency will accept.</P>
                <P>
                    Some state and local government agencies use SAVE, 
                    <E T="03">https://www.uscis.gov/save,</E>
                     to confirm the current immigration status of applicants for public benefits. SAVE can verify when an individual has TPS or a pending TPS application based on the documents above. In most cases, SAVE provides an automated electronic response to benefit-granting agencies within seconds, but occasionally verification can be delayed.
                </P>
                <P>
                    You can check the status of your SAVE verification by using CaseCheck at 
                    <E T="03">https://www.uscis.gov/save/save-casecheck.</E>
                     CaseCheck is a free service that lets you follow the progress of your SAVE verification case using your date of birth and one immigration identifier number (such as your A-Number, USCIS number, or Form I-94 number) or Verification Case Number. If an agency has denied your application based solely or in part on a SAVE response, the agency must allow you to appeal the decision in accordance with the agency's procedures. If the agency has received and acted on or will act on a SAVE verification and you do not believe the SAVE response is correct, the SAVE website, 
                    <E T="03">https://www.uscis.gov/save/for-benefit-applicants,</E>
                     has detailed information on how to correct or update your immigration record, make an appointment, or submit a written request to correct records.
                </P>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27788 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 9111-97-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="93648"/>
                <AGENCY TYPE="N"> DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT</AGENCY>
                <DEPDOC>[Docket No. FR-7090-N-09]</DEPDOC>
                <SUBJECT>60-Day Notice of Proposed Information Collection: Manufactured Housing Survey; OMB Control No.: 2528-0229</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Policy Development and Research, HUD.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>HUD is seeking approval from the Office of Management and Budget (OMB) for the information collection described below. In accordance with the Paperwork Reduction Act, HUD is requesting comment from all interested parties on the proposed collection of information. The purpose of this notice is to allow for 60 days of public comment.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments Due Date: January 27, 2025.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>Interested persons are invited to submit comments regarding this proposal.</P>
                    <P>
                        Written comments and recommendations for the proposed information collection can be submitted within 60 days of publication of this notice to 
                        <E T="03">www.regulations.gov.</E>
                         Interested persons are also invited to submit comments regarding this proposal by name and/or OMB Control Number and can be sent to: Anna Guido, Reports Management Officer, REE, Department of Housing and Urban Development, 451 7th Street SW, Room 8210, Washington, DC 20410-5000 or email at 
                        <E T="03">PaperworkReductionActOffice@hud.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Anna Guido, Reports Management Officer, Department of Housing and Urban Development, 451 7th Street SW, Washington, DC 20410; email; 
                        <E T="03">Anna.P.Guido@hud.gov;</E>
                         telephone (202) 402-5535 (this is not a toll-free number). HUD welcomes and is prepared to receive calls from individuals who are deaf or hard of hearing, as well as individuals with speech or communication disabilities. To learn more about how to make an accessible telephone call, please visit 
                        <E T="03">https://www.fcc.gov/consumers/guides/telecommunications-relay-service-trs.</E>
                    </P>
                    <P>Copies of available documents submitted to OMB may be obtained from Ms. Guido.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This notice informs the public that HUD is seeking approval from OMB for the information collection described in Section A.</P>
                <HD SOURCE="HD1">A. Overview of Information Collection</HD>
                <P>
                    <E T="03">Title of Information Collection:</E>
                     Manufactured Housing Survey.
                </P>
                <P>
                    <E T="03">OMB Approval Number:</E>
                     2528-0029.
                </P>
                <P>
                    <E T="03">Type of Request:</E>
                     Revision of a currently approved collection.
                </P>
                <P>
                    <E T="03">Form Number:</E>
                     C-MH-9A.
                </P>
                <P>
                    <E T="03">Description of the need for the information and proposed use:</E>
                     The Manufactured Housing Survey collects data on the characteristics of newly manufactured homes placed for residential use. Key data collected includes sales price and the number of units placed and sold within 4 months of shipment. Other selected housing characteristics collected include size, location, and titling. HUD is authorized to collect these statistics under the “Housing and Community Development Act of 1980,” Title 42 U.S.C. 5424 note (see Attachment 3), which provides the Secretary discretion to take necessary actions to ensure the public is aware of the distinctions between the types of factory-built housing. This allows HUD to collect and report manufactured home sales price information for the nation, Census Regions, States, and selected metropolitan statistical areas, and to monitor whether new manufactured homes are being placed on owned rather than rented lots. HUD also used these data to monitor total housing production and its affordability.
                </P>
                <P>
                    Furthermore, the Manufactured Housing Survey serves as a basis for HUD's mandated indexing of loan limits. Section 2145 (b) of the Housing and Economic Recovery Act (HERA) of 2008 requires HUD to develop a method of indexing to annually adjust Title I manufactured home loan limits. This index is partially based on manufactured housing price data collected by this survey. Section 2145 of the HERA of 2008 also amends the maximum loan limits for manufactured home loans insured under Title I. The Final Rule, entitled Indexing Methodology for Title I Manufactured Home Loan Limits, was published in the 
                    <E T="04">Federal Register</E>
                     on February 28, 2024. This Rule established separate indexing methodologies to annually calculate future loan limits for Manufactured Homes Loans, Manufactured Lot Loans and Manufactured Home and Lot Combination Loans for the Title I Manufactured Home Loan Program. Single- and double-section price data from this survey are used to determine maximum loan amounts for Title I Manufactured Home Loans. HUD implemented the revised loan limits, as shown below, for all manufactured home loans for which applications are received on or after March 29, 2024.
                </P>
                <GPOTABLE COLS="4" OPTS="L2,tp0,i1" CDEF="s50,r50,12,xs100">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Loan type</CHED>
                        <CHED H="1">Purpose</CHED>
                        <CHED H="1">Old loan limit</CHED>
                        <CHED H="1">New loan limit</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">MANUFACTURED HOME IMPROVEMENT LOAN</ENT>
                        <ENT>For financing alterations, repairs and improvements upon or in connection with existing manufactured homes</ENT>
                        <ENT>$25,090</ENT>
                        <ENT>$25,090.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">MANUFACTURED HOME UNIT(S)</ENT>
                        <ENT>To purchase or refinance a Manufactured Home unit (s)</ENT>
                        <ENT>69,678</ENT>
                        <ENT>Single-section: $105,532. Multi-section: $193,719.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">LOT LOAN</ENT>
                        <ENT>To purchase and develop a lot on which to place a manufactured home unit</ENT>
                        <ENT>23,226</ENT>
                        <ENT>$43,377.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">COMBINATION LOAN FOR LOT AND HOME</ENT>
                        <ENT>To purchase or refinance a manufactured home and lot on which to place the home</ENT>
                        <ENT>92,904</ENT>
                        <ENT>Single-section: $148,909. Multi-section: $237,096.</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD3">Method of Collection</HD>
                <P>The methodology for collecting information on new manufactured homes involves contacting dealers from a monthly sample of new manufactured homes shipped by manufacturers. The units are sampled from lists obtained from the Institute for Building Technology and Safety. Dealers that take shipment of the selected homes are mailed a survey form four months after shipment for recording the status of the manufactured home.</P>
                <P>
                    <E T="03">Respondents:</E>
                     Business firms or other for-profit institutions.
                </P>
                <P>
                    <E T="03">Respondent's Obligation:</E>
                     Voluntary.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     4,860.
                </P>
                <P>
                    <E T="03">Frequency of Response:</E>
                     Once.
                </P>
                <P>
                    <E T="03">Average Hours per Response:</E>
                     20 minutes per response (.33 hour).
                </P>
                <P>
                    <E T="03">Estimated Total Annual Burden Hours:</E>
                     1,620.
                </P>
                <P>
                    <E T="03">Estimated Total Annual Cost:</E>
                     $58,547. (We do not expect respondents to incur any costs other than that of their time to respond. The estimated hourly cost per response is $36.14, which is the hourly rate for typical 
                    <PRTPAGE P="93649"/>
                    respondent: Occupational code 41-4010: Sales Representatives, Wholesale and Manufacturing. The estimate total annual cost burden to respondents is $58,547, which is not a direct financial cost of respondents' time, but rather the associated cost burden of the respondents' voluntary responses.)
                </P>
                <GPOTABLE COLS="8" OPTS="L2,i1" CDEF="s20,12C,12C,12C,12C,12C,12C,12C">
                    <TTITLE>Total Estimated Burdens</TTITLE>
                    <BOXHD>
                        <CHED H="1">Information collection</CHED>
                        <CHED H="1">
                            Number of
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">Frequency of response</CHED>
                        <CHED H="1">Responses per annum</CHED>
                        <CHED H="1">Burden hour per response</CHED>
                        <CHED H="1">Annual burden hours</CHED>
                        <CHED H="1">Hourly cost per response</CHED>
                        <CHED H="1">Annual cost</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Manufactured Housing Survey</ENT>
                        <ENT>4,860</ENT>
                        <ENT>1</ENT>
                        <ENT>4,860</ENT>
                        <ENT>0.33</ENT>
                        <ENT>1,620</ENT>
                        <ENT>$36.14</ENT>
                        <ENT>$58,547</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD1">B. Solicitation of Public Comment</HD>
                <P>This notice is soliciting comments from members of the public and affected parties concerning the collection of information described in Section A on the following:</P>
                <P>(1) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;</P>
                <P>(2) The accuracy of the agency's estimate of the burden of the proposed collection of information;</P>
                <P>(3) Ways to enhance the quality, utility, and clarity of the information to be collected, and</P>
                <P>
                    (4) Ways to minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses.
                </P>
                <P>HUD encourages interested parties to submit comments in response to these questions.</P>
                <HD SOURCE="HD1">C. Authority</HD>
                <P>Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 3507.</P>
                <SIG>
                    <NAME>Todd M. Richardson,</NAME>
                    <TITLE>General Deputy Assistant Secretary for Policy Development and Research</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27789 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4210-67-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF THE INTERIOR</AGENCY>
                <SUBAGY>Bureau of Land Management</SUBAGY>
                <DEPDOC>[BLM_AK_FRN_MO4500183278; AA-8489-A]</DEPDOC>
                <SUBJECT>Alaska Native Claims Selection</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Bureau of Land Management, Interior.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of decision approving lands for conveyance.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Bureau of Land Management (BLM) hereby provides constructive notice that it will issue an appealable decision approving conveyance of the surface estate in certain lands to Chickaloon Moose Creek Native Association, Inc. for the Native village of Chickaloon, pursuant to the Alaska Native Claims Settlement Act of 1971 (ANCSA). The subsurface estate in the same lands will be conveyed to Cook Inlet Region, Inc. when the surface estate is conveyed to Chickaloon Moose Creek Native Association, Inc.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        Any party claiming a property interest in the lands affected by the decision may appeal the decision in accordance with the requirements of 43 CFR part 4 within the time limits set out in the 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section.
                    </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>You may obtain a copy of the decision from the Bureau of Land Management, Alaska State Office, 222 West Seventh Avenue, #13, Anchorage, AK 99513-7504.</P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Matthew R. Lux, Land Transfer Resolution Specialist, BLM Alaska State Office, 907-271-3176, or 
                        <E T="03">mlux@blm.gov.</E>
                         Individuals in the United States who are deaf, deafblind, hard of hearing, or have a speech disability may dial 711 (TTY, TDD, or TeleBraille) to access telecommunications relay services. Individuals outside the United States should use the relay services offered within their country to make international calls to the point of contact in the United States.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    As required by 43 CFR 2650.7(d), notice is hereby given that the BLM will issue an appealable decision to Chickaloon Moose Creek Native Association, Inc. The decision approves conveyance of the surface estate in certain lands pursuant to ANCSA (43 U.S.C. 1601, 
                    <E T="03">et seq.</E>
                    ). As provided by ANCSA, the subsurface estate in the same lands will be conveyed to Cook Inlet Region, Inc. when the surface estate is conveyed to Chickaloon Moose Creek Native Association, Inc. The lands are located in the vicinity of Chickaloon, Alaska, and are described as:
                </P>
                <EXTRACT>
                    <HD SOURCE="HD1">Seward Meridian, Alaska</HD>
                    <FP SOURCE="FP-2">T. 19 N., R. 3 E.,</FP>
                    <FP SOURCE="FP1-2">Secs. 25, 26, and 27;</FP>
                    <FP SOURCE="FP1-2">Secs. 32 to 36, inclusive.</FP>
                    <FP SOURCE="FP1-2">Containing approximately 2,691 acres.</FP>
                    <FP SOURCE="FP-2">T. 19 N., R. 4 E.,</FP>
                    <FP SOURCE="FP1-2">Secs. 12 and 19.</FP>
                    <FP SOURCE="FP1-2">Containing 113.28 acres.</FP>
                    <FP SOURCE="FP-2">T. 20 N., R. 5 E.,</FP>
                    <FP SOURCE="FP1-2">Tract A.</FP>
                    <FP SOURCE="FP1-2">Containing 4,414.29 acres.</FP>
                    <FP SOURCE="FP-2">T. 21 N., R. 5 E.,</FP>
                    <FP SOURCE="FP1-2">Sec. 3;</FP>
                    <FP SOURCE="FP1-2">Secs. 9 and 10;</FP>
                    <FP SOURCE="FP1-2">Secs. 16 and 17;</FP>
                    <FP SOURCE="FP1-2">Secs. 19 and 20;</FP>
                    <FP SOURCE="FP1-2">Secs. 30, and 31.</FP>
                    <FP SOURCE="FP1-2">Containing 5,735.68 acres.</FP>
                    <FP SOURCE="FP-2">T. 22 N., R. 5 E.,</FP>
                    <FP SOURCE="FP1-2">Secs. 25 and 26;</FP>
                    <FP SOURCE="FP1-2">Secs. 34, 35, and 36.</FP>
                    <FP SOURCE="FP1-2">Containing 3,200 acres.</FP>
                    <FP SOURCE="FP-2">T. 21 N., R. 6 E.,</FP>
                    <FP SOURCE="FP1-2">Secs. 2 and 3;</FP>
                    <FP SOURCE="FP1-2">Secs. 10 and 11;</FP>
                    <FP SOURCE="FP1-2">Secs. 14 and 15;</FP>
                    <FP SOURCE="FP1-2">Secs. 21 and 22;</FP>
                    <FP SOURCE="FP1-2">Secs. 28 and 29;</FP>
                    <FP SOURCE="FP1-2">Secs. 31, 32, and 33.</FP>
                    <FP SOURCE="FP1-2">Containing 8,323.92 acres.</FP>
                    <FP SOURCE="FP-2">T. 22 N., R. 6 E.,</FP>
                    <FP SOURCE="FP1-2">Sec. 1;</FP>
                    <FP SOURCE="FP1-2">Secs. 11 to 14, inclusive;</FP>
                    <FP SOURCE="FP1-2">Sec. 23;</FP>
                    <FP SOURCE="FP1-2">Sec. 26;</FP>
                    <FP SOURCE="FP1-2">Secs. 30 and 31;</FP>
                    <FP SOURCE="FP1-2">Sec. 35.</FP>
                    <FP SOURCE="FP1-2">Containing 5,894.64 acres.</FP>
                    <FP SOURCE="FP1-2">Aggregating approximately 30,373 acres.</FP>
                </EXTRACT>
                <P>The decision addresses public access easements, if any, to be reserved to the United States pursuant to sec. 17(b) of ANCSA (43 U.S.C. 1616(b)), in the lands described above.</P>
                <P>The BLM will also publish notice of the decision once a week for four consecutive weeks in the Anchorage Daily News newspaper.</P>
                <P>Any party claiming a property interest in the lands affected by the decision may appeal the decision in accordance with the requirements of 43 CFR part 4 within the following time limits:</P>
                <P>
                    1. Unknown parties, parties unable to be located after reasonable efforts have been expended to locate, parties who fail or refuse to sign their return receipt, and parties who receive a copy of the decision by regular mail which is not certified, return receipt requested, shall have until December 27, 2024 to file an appeal.
                    <PRTPAGE P="93650"/>
                </P>
                <P>2. Parties receiving service of the decision by certified mail shall have 30 days from the date of receipt to file an appeal.</P>
                <P>Parties who do not file an appeal in accordance with the requirements of 43 CFR part 4 shall be deemed to have waived their rights. Notices of appeal transmitted by facsimile will not be accepted as timely filed.</P>
                <SIG>
                    <NAME>Matthew R. Lux,</NAME>
                    <TITLE>Land Transfer Resolution Specialist, Resolution Group.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27785 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4331-10-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF THE INTERIOR</AGENCY>
                <SUBAGY>Bureau of Land Management</SUBAGY>
                <DEPDOC>[BLM_WY_FRN_MO4500183156]</DEPDOC>
                <SUBJECT>Notice of Availability of the Record of Decision and Approved Resource Management Plan Amendment for the Buffalo Field Office, Wyoming</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Bureau of Land Management, Interior.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of availability.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Bureau of Land Management (BLM) announces the availability of the Record of Decision (ROD) for the Approved Resource Management Plan (RMP) Amendment for the Buffalo Field Office located in Buffalo, Wyoming. The BLM Director signed the ROD on November 20, 2024, which constitutes the decision of the BLM and makes the Approved RMP Amendment effective immediately.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The BLM Director signed the ROD/Approved RMP Amendment on November 20, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The ROD/Approved RMP Amendment is available online at: 
                        <E T="03">https://eplanning.blm.gov/eplanning-ui/project/2021239/510.</E>
                         Printed copies of the ROD/Approved RMP Amendment are available for public inspection at the Buffalo Field Office or can be provided upon request by contacting Tom Bills, Project Manager, telephone (307) 684-1133; or at the address BLM Buffalo Field Office, 1425 Fort Street, Buffalo, WY 82834; email 
                        <E T="03">tbills@blm.gov.</E>
                    </P>
                    <P>
                        A copy of the Protest Resolution Report is available at: 
                        <E T="03">https://www.blm.gov/programs/planning-and-nepa/public-participation/protest-resolution-reports.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Thomas Bills, Project Manager, telephone (307) 684-1133; or at the address BLM Buffalo Field Office, 1425 Fort Street, Buffalo, WY 82834; email 
                        <E T="03">tbills@blm.gov.</E>
                         Individuals in the United States who are deaf, deafblind, hard of hearing, or have a speech disability may dial 711 (TTY, TDD, or TeleBraille) to access telecommunications relay services. Individuals outside the United States should use the relay services offered within their country to make international calls to the point-of-contact in the United States.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The Approved RMP Amendment addresses a United States District Court for the District of Montana order (
                    <E T="03">Western Organization of Resource Councils, et al.</E>
                     v. 
                    <E T="03">BLM</E>
                    ; CV 00076-GF-BMM; 8/3/2022). The Approved RMP Amendment changes the existing 2015 Buffalo Approved RMP.
                </P>
                <P>The RMP Amendment approved by the ROD includes land use allocations of areas acceptable for further consideration for coal leasing and those that are not. The Approved RMP Amendment is Alternative A (No Leasing) from the Final Supplemental Environmental Impact State (EIS), making no BLM administered coal acceptable and 413,250 acres unavailable for further consideration for coal leasing within the Buffalo Field Office planning area. The Approved RMP Amendment does not affect the area with coal development potential or the area determined to be suitable for surface coal mining. The Approved RMP Amendment includes the updated coal screens (43 CFR 3420.1-4(e)) using current data and evaluated the issues identified through internal and public scoping. Application of coal screen 1 (development potential) identified approximately 413,250 acres of BLM-administered coal as having development potential. The Approved RMP Amendment also addresses the NEPA deficiencies identified by the court order associated with the application of the multiple-use screen. Specifically, the application of a multiple-use climate change criterion that uses greenhouse gas emissions as a proxy for climate change. Reducing availability of BLM-administered coal for leasing consideration reduces the contribution of greenhouse gas emissions from the development and combustion of BLM-administered coal from the planning area.</P>
                <P>The BLM determined that additional leasing of BLM-administered coal is not necessary based on the current analysis in the Final Supplemental EIS. The analysis indicates that operating mines in the planning area collectively have existing leases with sufficient coal reserves to maintain projected mine production levels into 2041.</P>
                <P>
                    The BLM published a notice of availability for the Draft Supplemental EIS and Potential RMP Amendment in the 
                    <E T="04">Federal Register</E>
                     on May 8, 2023, which initiated a 90-day comment period (88 FR 29691). On May 31, 2023, the BLM hosted a public meeting in Gillette, Wyoming, to present the Draft Supplemental EIS/RMP Amendment to the public and solicit comments. The BLM also hosted an on-line public meeting on June 5, 2023. During the public comment period, the BLM received 25 unique written submissions containing 147 substantive comments. The Draft Supplemental EIS comments helped the BLM refine the Final Supplemental EIS and guided the development of the Proposed RMP Amendment.
                </P>
                <P>
                    The BLM provided the Proposed RMP Amendment for public protest on May 17, 2024 (89 FR 43431), for a 30-day protest period, and received five valid protests. The BLM Assistant Director for Planning and Resources resolved all protests. Responses to protest issues were compiled and documented in a Protest Resolution Report (see 
                    <E T="02">ADDRESSES</E>
                    ). No changes were made to the Approved RMP Amendment as a result of protest resolution.
                </P>
                <P>The BLM provided the Proposed RMP Amendment to the Governor of Wyoming for a 60-day Governor's consistency review. The State Director made no changes to the Proposed RMP Amendment as a result of the Governor's review. On September 13, 2024, the Governor submitted an appeal to the BLM Director on the State Director's response to the Governor's consistency review. In accordance with planning regulations (1610.3-2), the Director notified the Governor on November 6, 2024, of the reasons for the determination to reject the Governor's recommendations.</P>
                <EXTRACT>
                    <FP>(Authority: 40 CFR 1506.6; 43 CFR 1610.5-1)</FP>
                </EXTRACT>
                <SIG>
                    <NAME>Tracy Stone-Manning,</NAME>
                    <TITLE>BLM Director.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27677 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4331-26-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF THE INTERIOR</AGENCY>
                <SUBAGY>Bureau of Land Management</SUBAGY>
                <DEPDOC>[BLM_MT_FRN_MO4500182720]</DEPDOC>
                <SUBJECT>Notice of Availability of the Record of Decision and Approved Resource Management Plan Amendment for the Miles City Field Office, Montana</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Bureau of Land Management, Interior.</P>
                </AGY>
                <ACT>
                    <PRTPAGE P="93651"/>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of availability.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Bureau of Land Management (BLM) announces the availability of the Record of Decision (ROD) for the Approved Resource Management Plan (RMP) Amendment for the Miles City Field Office located in Miles City, Montana. The BLM Director signed the ROD on November 20, 2024, which constitutes the decision of the BLM and makes the Approved RMP Amendment effective immediately.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The BLM Director signed the ROD/Approved RMP Amendment on November 20, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The ROD/Approved RMP Amendment is available online 
                        <E T="03">https://eplanning.blm.gov/eplanning-ui/project/2021155/510.</E>
                         Printed copies of the ROD/Approved RMP Amendment are available for public inspection at the Miles City Field Office or can be provided upon request by contacting Irma Nansel, Project Manager, telephone (406) 233-3653; or at the address BLM Miles City Field Office, 111 Garryowen Road, Miles City, MT 59301; email 
                        <E T="03">inansel@blm.gov.</E>
                    </P>
                    <P>
                        A copy of the Protest Resolution Report is available at: 
                        <E T="03">https://www.blm.gov/programs/planning-and-nepa/public-participation/protest-resolution-reports.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Irma Nansel, Project Manager, telephone (406) 233-3653; or at the address BLM Miles City Field Office, 111 Garryowen Road, Miles City, MT 59301; email 
                        <E T="03">inansel@blm.gov.</E>
                         Individuals in the United States who are deaf, deafblind, hard of hearing, or have a speech disability may dial 711 (TTY, TDD, or TeleBraille) to access telecommunications relay services. Individuals outside the United States should use the relay services offered within their country to make international calls to the point-of-contact in the United States.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The Approved RMP Amendment addresses a United States District Court for the District of Montana order (
                    <E T="03">Western Organization of Resource Councils, et al.</E>
                     v. 
                    <E T="03">BLM</E>
                    ; CV 00076-GF-BMM; 8/3/2022). The Approved RMP Amendment changes the existing 2015 Miles City Approved RMP.
                </P>
                <P>The RMP Amendment approved by the ROD includes land use allocations of areas acceptable for further consideration for coal leasing and those that are not. The Approved RMP Amendment is Alternative D from the Final Supplemental EIS, which allocates zero acres of BLM administered coal as available, and 1,745,040 acres unavailable for further consideration for coal leasing within the Miles City Field Office planning area. The Approved RMP Amendment does not affect the area with coal development potential or the area determined to be suitable for surface coal mining.</P>
                <P>The Approved RMP Amendment includes the updated coal screens (43 CFR 3420.1-4(e)) using current data and evaluated the issues identified through internal and public scoping. Application of coal screen 1 (development potential) identified approximately 1,745,000 acres of BLM-administered coal as having development potential. The Approved RMP Amendment also addresses the NEPA deficiencies identified by the court order associated with the application of the multiple-use screen. Specifically, the application of a multiple-use climate change criterion that uses greenhouse gas emissions as a proxy for climate change. Reducing availability of BLM-administered coal for leasing consideration reduces the contribution of greenhouse gas emissions from the development and combustion of BLM-administered coal from the planning area.</P>
                <P>The BLM determined that additional leasing of BLM-administered coal is not necessary based on the current analysis in the Final Supplemental EIS. The analysis indicates that operating mines in the planning area have existing leases with sufficient coal reserves to maintain existing mine production levels until 2035 for Spring Creek Mine and 2060 for Rosebud Mine.</P>
                <P>
                    The BLM published a notice of availability for the Draft Supplemental EIS and Potential RMP Amendment in the 
                    <E T="04">Federal Register</E>
                     on May 8, 2023, which initiated a 90-day comment period (88 FR 29689). On June 6th, the BLM hosted a public meeting at the BLM Miles City Field Office in Miles City, Montana, to present the Draft Supplemental EIS and RMP Amendment to the public and solicit comments. The BLM also hosted an on-line public meeting on June 7, 2023. Eight members of the public attended the on-line meeting. During the public comment period, the BLM received 14 unique written submissions containing 167 substantive comments. The Draft Supplemental EIS comments helped the BLM refine the Final Supplemental EIS and guided the development of the Proposed RMP Amendment.
                </P>
                <P>
                    The BLM provided the Proposed RMP Amendment for public protest on May 17, 2024 (89 FR 43432), for a 30-day protest period, and received seven valid protests. The BLM Assistant Director for Planning and Resources resolved all protests. Responses to protest issues were compiled and documented in a Protest Resolution Report (see 
                    <E T="02">ADDRESSES</E>
                    ). No changes were made to the Approved RMP Amendment as a result of protest resolution.
                </P>
                <P>The BLM provided the Proposed RMP Amendment to the Governor of Montana for a 60-day Governor's consistency review. There were no inconsistencies with State or local plans, policies, or programs identified during the Governor's consistency review of the Proposed RMP Amendment. The State Director made no changes to the Proposed RMP Amendment as a result of the Governor's review. On September 18, 2024, the Governor submitted an appeal to the BLM Director on the State Director's response to the Governor's consistency review. In accordance with planning regulations (1610.3-2), the Director notified the Governor on November 6, 2024, of the reasons for the determination to reject the Governor's recommendations.</P>
                <EXTRACT>
                    <FP>(Authority: 40 CFR 1506.6; 43 CFR 1610.5-1)</FP>
                </EXTRACT>
                <SIG>
                    <NAME>Tracy Stone-Manning,</NAME>
                    <TITLE>BLM Director.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27678 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4331-20-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">INTERNATIONAL TRADE COMMISSION</AGENCY>
                <DEPDOC>[Investigation Nos. 701-TA-748-749 and 731-TA-1726-1727 (Preliminary)]</DEPDOC>
                <SUBJECT>Float Glass Products From China and Malaysia; Institution of Antidumping and Countervailing Duty Investigations and Scheduling of Preliminary Phase Investigations</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>United States International Trade Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Commission hereby gives notice of the institution of investigations and commencement of preliminary phase antidumping and countervailing duty investigation Nos. 701-TA-748-749 and 731-TA-1726-1727 (Preliminary) pursuant to the Tariff Act of 1930 (“the Act”) to determine whether there is a reasonable indication that an industry in the United States is materially injured or threatened with material injury, or the establishment of an industry in the United States is materially retarded, by reason of imports of float glass products from China and Malaysia, described in statistical reporting numbers 7005.10.8000, 7005.21.1010, 7005.21.1030, 7005.21.2000, 
                        <PRTPAGE P="93652"/>
                        7005.29.1810, 7005.29.1850, 7005.29.2500, 7007.29.0000, 7008.00.0000, 7009.91.5010, 7009.91.5095, 7009.92.5010, 7006.00.4010, 7006.00.4050, and 7007.19.0000 of the Harmonized Tariff Schedule of the United States, that are alleged to be sold in the United States at less than fair value and alleged to be subsidized by the Governments of China and Malaysia. Unless the Department of Commerce (“Commerce”) extends the time for initiation, the Commission must reach a preliminary determination in antidumping and countervailing duty investigations in 45 days, or in this case by January 6, 2025. The Commission's views must be transmitted to Commerce within five business days thereafter, or by January 13, 2025.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>November 21, 2024.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Kristina Lara (202-205-3386), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearing-impaired persons can obtain information on this matter by contacting the Commission's TDD terminal on 202-205-1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202-205-2000. General information concerning the Commission may also be obtained by accessing its internet server (
                        <E T="03">https://www.usitc.gov</E>
                        ). The public record for these investigations may be viewed on the Commission's electronic docket (EDIS) at 
                        <E T="03">https://edis.usitc.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    <E T="03">Background.</E>
                    —These investigations are being instituted, pursuant to sections 703(a) and 733(a) of the Tariff Act of 1930 (19 U.S.C. 1671b(a) and 1673b(a)), in response to petitions filed on November 21, 2024, by Vitro Flat Glass, LLC, Cheswick, Pennsylvania, and Vitro Meadville Flat Glass, LLC, Cochranton, Pennsylvania.
                </P>
                <P>For further information concerning the conduct of these investigations and rules of general application, consult the Commission's Rules of Practice and Procedure, part 201, subparts A and B (19 CFR part 201), and part 207, subparts A and B (19 CFR part 207).</P>
                <P>
                    <E T="03">Participation in the investigations and public service list.</E>
                    —Persons (other than petitioners) wishing to participate in the investigations as parties must file an entry of appearance with the Secretary to the Commission, as provided in §§ 201.11 and 207.10 of the Commission's rules, not later than seven days after publication of this notice in the 
                    <E T="04">Federal Register</E>
                    . Industrial users and (if the merchandise under investigation is sold at the retail level) representative consumer organizations have the right to appear as parties in Commission antidumping duty and countervailing duty investigations. The Secretary will prepare a public service list containing the names and addresses of all persons, or their representatives, who are parties to these investigations upon the expiration of the period for filing entries of appearance.
                </P>
                <P>
                    <E T="03">Limited disclosure of business proprietary information (BPI) under an administrative protective order (APO) and BPI service list.</E>
                    —Pursuant to § 207.7(a) of the Commission's rules, the Secretary will make BPI gathered in these investigations available to authorized applicants representing interested parties (as defined in 19 U.S.C. 1677(9)) who are parties to the investigations under the APO issued in the investigations, provided that the application is made not later than seven days after the publication of this notice in the 
                    <E T="04">Federal Register</E>
                    . A separate service list will be maintained by the Secretary for those parties authorized to receive BPI under the APO.
                </P>
                <P>
                    <E T="03">Conference.</E>
                    —The Office of Investigations will hold a staff conference in connection with the preliminary phase of these investigations beginning at 9:30 a.m. on Thursday, December 12, 2024. Requests to appear at the conference should be emailed to 
                    <E T="03">preliminaryconferences@usitc.gov</E>
                     (DO NOT FILE ON EDIS) on or before Tuesday, December 10, 2024. Please provide an email address for each conference participant in the email. Information on conference procedures, format, and participation, including guidance for requests to appear as a witness via videoconference, will be available on the Commission's Public Calendar (Calendar (USITC) | United States International Trade Commission). A nonparty who has testimony that may aid the Commission's deliberations may request permission to participate by submitting a short statement.
                </P>
                <P>
                    Please note the Secretary's Office will accept only electronic filings during this time. Filings must be made through the Commission's Electronic Document Information System (EDIS, 
                    <E T="03">https://edis.usitc.gov</E>
                    ). No in-person paper-based filings or paper copies of any electronic filings will be accepted until further notice.
                </P>
                <P>
                    <E T="03">Written submissions.</E>
                    —As provided in §§ 201.8 and 207.15 of the Commission's rules, any person may submit to the Commission on or before 5:15 p.m. on December 17, 2024, a written brief containing information and arguments pertinent to the subject matter of the investigations. Parties shall file written testimony and supplementary material in connection with their presentation at the conference no later than 4:00 p.m. on December 11, 2024. All written submissions must conform with the provisions of § 201.8 of the Commission's rules; any submissions that contain BPI must also conform with the requirements of §§ 201.6, 207.3, and 207.7 of the Commission's rules. The Commission's 
                    <E T="03">Handbook on Filing Procedures,</E>
                     available on the Commission's website at 
                    <E T="03">https://www.usitc.gov/documents/handbook_on_filing_procedures.pdf,</E>
                     elaborates upon the Commission's procedures with respect to filings.
                </P>
                <P>In accordance with §§ 201.16(c) and 207.3 of the rules, each document filed by a party to the investigations must be served on all other parties to the investigations (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.</P>
                <P>
                    <E T="03">Certification.</E>
                    —Pursuant to § 207.3 of the Commission's rules, any person submitting information to the Commission in connection with these investigations must certify that the information is accurate and complete to the best of the submitter's knowledge. In making the certification, the submitter will acknowledge that any information that it submits to the Commission during these investigations may be disclosed to and used: (i) by the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of these or related investigations or reviews, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. appendix 3; or (ii) by U.S. Government employees and contract personnel, solely for cybersecurity purposes. All contract personnel will sign appropriate nondisclosure agreements.
                </P>
                <P>
                    <E T="03">Authority:</E>
                     These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to § 207.12 of the Commission's rules.
                </P>
                <SIG>
                    <P>By order of the Commission.</P>
                    <DATED>Issued: November 21, 2024.</DATED>
                    <NAME>Lisa Barton,</NAME>
                    <TITLE>Secretary to the Commission.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27739 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 7020-02-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="93653"/>
                <AGENCY TYPE="S">INTERNATIONAL TRADE COMMISSION</AGENCY>
                <DEPDOC>[Investigation No. 337-TA-1118 (Remand)]</DEPDOC>
                <SUBJECT>Certain Movable Barrier Operator Systems and Components Thereof; Notice of a Final Determination Finding a Violation of Section 337 and Issuing a Limited Exclusion Order and Cease and Desist Orders; Termination of Investigation</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>U.S. International Trade Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Notice is hereby given that the U.S. International Trade Commission (“Commission”) has determined that respondents Nortek Security &amp; Control, LLC of Carlsbad, California (presently doing business as Nice North America LLC); Nortek, Inc. of Providence, Rhode Island; and GTO Access Systems, LLC of Tallahassee, Florida (collectively, “Nortek”) have violated section 337 of the Tariff Act of 1930, as amended, by importing, selling for importation, or selling in the United States after importation certain movable barrier operators (including garage door operators) and components thereof that infringe claim 11 of U.S. Patent No. 8,587,404 (“the '404 patent”). The Commission has determined that the appropriate remedies are a limited exclusion order (“LEO”) and cease and desist orders (“CDOs”) against Nortek. The Commission has also determined to set a bond in the amount of zero percent (0%) of the entered value of the excluded products imported during the period of Presidential review. This investigation is hereby terminated.</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Carl P. Bretscher, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205-2382. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket system (“EDIS”) at 
                        <E T="03">https://edis.usitc.gov.</E>
                         For help accessing EDIS, please email 
                        <E T="03">EDIS3Help@usitc.gov.</E>
                         General information concerning the Commission may also be obtained by accessing its internet server at 
                        <E T="03">https://www.usitc.gov.</E>
                         Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal, telephone (202) 205-1810.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The Commission instituted this investigation on June 11, 2018, based on a complaint, as supplemented, filed by The Chamberlain Group, Inc. (“Chamberlain”) of Oak Brook, Illinois. 83 FR 27020-21 (June 11, 2018). The complaint accuses Nortek of violating section 337 of the Tariff Act, as amended, 19 U.S.C. 1337 (“section 337”) by importing, selling for importation, or selling in the United States after importation certain movable barrier operator systems that infringe one or more of the asserted claims of the '404 patent and U.S. Patent Nos. 7,755,223 (“the '223 patent”) and 6,741,052 (“the '052 patent”). 
                    <E T="03">Id.</E>
                     The complaint also alleges the existence of a domestic industry. The Office of Unfair Import Investigations is not a party to the investigation.
                </P>
                <P>On November 25, 2019, the presiding administrative law judge (“ALJ”) issued two initial determinations (“IDs”). First, the ALJ issued Order No. 38, granting Chamberlain's motion for summary determination that it satisfied the economic prong of the domestic industry requirement (“DI economic prong”). Order No. 38 (Nov. 25, 2019). Second, the ALJ issued a final ID on violation, as well as a recommended determination (“RD”) on remedy and bond. The final ID finds no violation of section 337 because: (i) Nortek did not infringe claim 11 of the '404 patent; (ii) Nortek did not infringe the '223 patent and Chamberlain did not satisfy the technical prong of the domestic industry requirement (“DI technical prong”) for that patent; and (iii) asserted claim 1 of the '052 patent is invalid as obvious. The RD recommends issuing an LEO and CDOs against Nortek and setting the bond of 100 percent during the period of Presidential review.</P>
                <P>
                    On April 22, 2020, the Commission determined to review and, on review, to adopt the final ID's no-violation finding for the '404 patent, which was based on a narrow construction of the limitation “movable barrier operator” that excluded the wall station. Comm'n Notice at 3 (Apr. 22, 2020). The Commission took no position on the final ID's finding that Nortek failed to prove that claim 11 of the '404 patent is patent ineligible under 35 U.S.C. 101. The Commission also adopted the final ID's finding that there was no violation with respect to the '052 patent because the asserted claim is obvious. At the same time, the Commission vacated Order No. 38 and remanded the economic prong issue to the ALJ for further proceedings with respect to the '223 patent. 
                    <E T="03">Id.;</E>
                     Order Vacating and Remanding Order No. 38 (Apr. 22, 2020) (“First Remand Order”).
                </P>
                <P>The ALJ, after re-analyzing the domestic industry per the Commission's instructions, issued a Remand Initial Determination (“First RID”) on July 10, 2020. The First RID finds that Chamberlain made significant investments in plant and equipment as well as labor and capital, which satisfied the DI economic prong for the '223 patent under sections 337(a)(3)(A) and (B), respectively.</P>
                <P>On September 9, 2020, the Commission determined to review the First RID and requested additional briefing by the parties on issues relating to the DI economic prong and remedy, bond, and the public interest. 85 FR 57249-50 (Sept. 14, 2020).</P>
                <P>
                    On December 3, 2020, the Commission determined to adopt the First RID's findings that Chamberlain had satisfied the DI economic prong under subsections 337(a)(3)(A) and (B). 85 FR 79217-18 (Dec. 9, 2020). The Commission reversed the final ID's non-infringement finding for the '223 patent, finding instead that Nortek violated section 337 by infringing the '223 patent. 
                    <E T="03">Id.</E>
                     Finding that the public interest did not preclude relief, the Commission issued an LEO and CDOs against Nortek and set the bond at 100 percent of entered value. Comm'n Op. at 34-39, 41.
                </P>
                <P>On June 16, 2020, Chamberlain appealed the Commission's no-violation determinations for the '404 patent and '052 patent (which expired while the appeal was pending). On April 1, 2021, Nortek cross-appealed the Commission's violation determination for the '223 patent.</P>
                <P>
                    On April 27, 2023, the Federal Circuit issued its decision, in which it: (i) affirmed the Commission's violation determination for the '223 patent; (ii) for the '404 patent, reversed the Commission's construction of the term “movable barrier operator,” vacated its non-infringement, waiver, and no-violation determinations, and remanded with instructions to the Commission to re-evaluate infringement of the '404 patent using a proper claim construction; and (iii) vacated the Commission's determinations for the expired '052 patent and remanded with instructions to dismiss the infringement claim as moot. The 
                    <E T="03">Chamberlain Group, Inc.</E>
                     v. 
                    <E T="03">ITC,</E>
                     Appeal Nos. 20-1965, 21-1829, 2023 WL 3115579 at *1, *4-7 (Fed. Cir. Apr. 27, 2023).
                </P>
                <P>
                    On August 4, 2023, the Commission issued a notice asking the parties which issues needed to be resolved in view of the Federal Circuit's remand and whether additional proceedings were necessary. Comm'n Notice (Aug. 4, 2023). The parties filed responses identifying infringement of the '404 patent, patent-ineligibility of claim 11 of the '404 patent under section 101, and 
                    <PRTPAGE P="93654"/>
                    the economic prong of domestic industry with respect to the '404 patent as the violation issues that needed to be resolved. The parties agreed there was no need to reopen the evidentiary record, as it has already been fully developed.
                </P>
                <P>
                    On October 4, 2023, the Commission issued a second notice directing the parties to brief: (i) which, if any, of the accused products infringe claim 11 of the '404 patent under the Court's new construction of “movable barrier operator” and (ii) whether the ID properly finds that claim 11 is not patent-ineligible under 35 U.S.C. 101. Comm'n Notice at 3 (Oct. 4, 2023). The Commission determined not to reopen the evidentiary record. The Commission also remanded the investigation to the ALJ for the sole purpose of determining whether Chamberlain satisfied the DI economic prong for the '404 patent. 
                    <E T="03">See</E>
                     Remand Order (Oct. 4, 2023) (“Second Remand Order”).
                </P>
                <P>
                    On January 11, 2024, the presiding ALJ issued Order No. 46 directing the parties to provide supplemental information regarding the covered products allegedly protected by the '404 patent, the extent to which domestic investments relating to products covered by the '223 patent were applicable to products covered by the '404 patent, the domestic inventories of products covered by the '404 patent, and other issues relating to the DI economic prong analysis. 
                    <E T="03">See</E>
                     Order No. 46 (Jan. 11, 2024).
                </P>
                <P>
                    On May 8, 2024, the ALJ issued the Recommended [
                    <E T="03">sic,</E>
                     Remand] Initial Determination on Second Remand Order (“Second RID”) presently at issue. Order No. 50 (May 8, 2024). The Second RID finds that Chamberlain has satisfied the DI economic prong for the '404 patent under subsections 337(a)(3)(A), (B), and (C). The Second RID also makes subsidiary findings regarding infringement and the accused Nortek products. The Second RID also notes that the Commission previously found that Chamberlain's domestic industry products (the “'404 DI Products”) practice the '404 patent and Chamberlain thus satisfied the DI technical prong.
                </P>
                <P>On May 20, 2024, Nortek filed a petition for review of the Second RID. On May 28, 2024, Chamberlain filed its opposition to Nortek's petition for review.</P>
                <P>
                    On June 28, 2024, the Commission determined to review the Second RID. 89 FR 54038 (June 28, 2024). The Commission also requested briefing on remedy, bond, and the public interest. 
                    <E T="03">Id.</E>
                </P>
                <P>Upon review of the final ID, the Second RID, the Federal Circuit's decision on appeal, the parties' submissions, and the evidence of record, the Commission finds that Nortek has violated section 337 by importing into the United States, selling for importation, or selling in the United States after importation certain movable barrier operators and components thereof that infringe claim 11 of the '404 patent. As set forth in the accompanying Opinion, the Commission finds that Nortek has infringed claim 11 of the '404 patent, and that claim 11 is not abstract or patent-ineligible under 35 U.S.C. 101. The Commission also finds that Chamberlain has satisfied the DI economic prong per 19 U.S.C. 1337(a)(3)(A), (B), but takes no position on whether it has also satisfied the DI economic prong under section 337(a)(3)(C).</P>
                <P>The Commission has determined that the appropriate remedy is: (i) an LEO prohibiting the importation of certain movable barrier operator systems, including garage door operators, and components thereof that infringe claim 11 of the '404 patent; and (ii) a CDO against each Nortek respondents. The Commission has determined that the public interest factors do not preclude issuance of a remedy. The Commission has determined to set a bond in the amount of zero percent (0%) of the entered value of the infringing products imported during the period of Presidential review (19 U.S.C. 1337(j)).</P>
                <P>The Commission issues its opinion herewith setting forth its determinations on certain issues. This investigation is hereby terminated.</P>
                <P>The Commission's orders and opinion were delivered to the President and United States Trade Representative on the day of their issuance.</P>
                <P>The Commission vote for this determination took place on November 21, 2024.</P>
                <P>The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).</P>
                <SIG>
                    <P>By order of the Commission.</P>
                    <DATED>Issued: November 21, 2024.</DATED>
                    <NAME>Lisa Barton,</NAME>
                    <TITLE>Secretary to the Commission.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27783 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 7020-02-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF JUSTICE</AGENCY>
                <DEPDOC>[OMB 1140-0062]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed eCollection eComments Requested; Identification of Imported Explosives Materials</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Bureau of Alcohol, Tobacco, Firearms and Explosives, Department of Justice.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and will be accepted for 30 days until December 27, 2024.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: Michael O'Lena, Explosives Industry Programs Branch, by email at 
                        <E T="03">eipb-informationcollection@atf.gov</E>
                         or 
                        <E T="03">michael.olena@atf.gov,</E>
                         or telephone at (202) 648-7120.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The proposed information collection was previously published in the 
                    <E T="04">Federal Register</E>
                    , volume 89 page 80933, on Friday, October 4, 2024, allowing a 60-day comment period. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:
                </P>
                <FP SOURCE="FP-1">—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;</FP>
                <FP SOURCE="FP-1">—Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;</FP>
                <FP SOURCE="FP-1">—Enhance the quality, utility, and clarity of the information to be collected; and/or</FP>
                <FP SOURCE="FP-1">
                    —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms 
                    <PRTPAGE P="93655"/>
                    of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses.
                </FP>
                <P>
                    Written comments and recommendations for this information collection should be submitted within 30 days of the publication of this notice on the following website 
                    <E T="03">www.reginfo.gov/public/do/PRAMain</E>
                    . Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function and entering either the title of the information collection or the OMB Control Number 1140-0062. This information collection request may be viewed at 
                    <E T="03">www.reginfo.gov.</E>
                     Follow the instructions to view Department of Justice, information collections currently under review by OMB.
                </P>
                <P>DOJ seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years without renewal. The DOJ notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.</P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    1. 
                    <E T="03">Type of Information Collection:</E>
                     Extension of a previously approved collection.
                </P>
                <P>
                    2. 
                    <E T="03">Title of the Form/Collection:</E>
                     Identification of Imported Explosives Materials.
                </P>
                <P>
                    3. 
                    <E T="03">Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:</E>
                     None.
                </P>
                <P>
                    <E T="03">Component:</E>
                     Bureau of Alcohol, Tobacco, Firearms and Explosives, U.S. Department of Justice.
                </P>
                <P>
                    4. 
                    <E T="03">Affected public who will be asked or required to respond, as well as a brief abstract: Affected Public:</E>
                     Private Sector-for or not for profit institutions.
                </P>
                <P>
                    5. 
                    <E T="03">Obligation to Respond:</E>
                     The obligation to respond is mandatory per 27 CFR part 555.
                </P>
                <P>
                    6. 
                    <E T="03">Total Estimated Number of Respondents:</E>
                     51.
                </P>
                <P>
                    7. 
                    <E T="03">Estimated Time per Respondent:</E>
                     1 hour.
                </P>
                <P>
                    8. 
                    <E T="03">Frequency:</E>
                     3 times annually.
                </P>
                <P>
                    9. 
                    <E T="03">Total Estimated Annual Time Burden:</E>
                     51 hours.
                </P>
                <P>
                    10. 
                    <E T="03">Total Estimated Annual Other Costs Burden:</E>
                     $0.
                </P>
                <P>If additional information is required, contact: Darwin Arceo, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, United States Department of Justice, Two Constitution Square, 145 N Street NE, 4W-218, Washington, DC 20530.</P>
                <SIG>
                    <DATED>Dated: November 24, 2024.</DATED>
                    <NAME>Darwin Arceo,</NAME>
                    <TITLE>Department Clearance Officer for PRA, U.S. Department of Justice.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27860 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-FY-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF JUSTICE</AGENCY>
                <DEPDOC>[OMB 1140-0031]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed eCollection eComments Requested; Records of Acquisition and Disposition, Registered Importers of Arms, Ammunition &amp; Defense Articles on the U.S. Munitions Import List</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Bureau of Alcohol, Tobacco, Firearms and Explosives, Department of Justice.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and will be accepted for 30 days until December 27, 2024.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: Victoria Kenney, FESD/FEIB, by email at 
                        <E T="03">Victoria.Kenney@atf.gov,</E>
                         or telephone at 304-616-3376.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The proposed information collection was previously published in the 
                    <E T="04">Federal Register</E>
                    , volume 89 page 80931, on Friday, October 4, 2024, allowing a 60-day comment period. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:
                </P>
                <FP SOURCE="FP-1">—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;</FP>
                <FP SOURCE="FP-1">—Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;</FP>
                <FP SOURCE="FP-1">—Enhance the quality, utility, and clarity of the information to be collected; and/or</FP>
                <FP SOURCE="FP-1">
                    —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses.
                </FP>
                <P>
                    Written comments and recommendations for this information collection should be submitted within 30 days of the publication of this notice on the following website 
                    <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                     Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function and entering either the title of the information collection or the OMB Control Number 1140-0101. This information collection request may be viewed at 
                    <E T="03">www.reginfo.gov.</E>
                     Follow the instructions to view Department of Justice, information collections currently under review by OMB.
                </P>
                <P>DOJ seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years without renewal. The DOJ notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.</P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    1. 
                    <E T="03">Type of Information Collection:</E>
                     Revision of a previously approved collection.
                </P>
                <P>
                    2. 
                    <E T="03">Title of the Form/Collection:</E>
                     Records of Acquisition and Disposition, Registered Importers of Arms, Ammunition &amp; Defense Articles on the U.S. Munitions Import List.
                </P>
                <P>
                    3. 
                    <E T="03">Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:</E>
                     None.
                </P>
                <P>
                    <E T="03">Component:</E>
                     Bureau of Alcohol, Tobacco, Firearms and Explosives, U.S. Department of Justice.
                </P>
                <P>
                    4. 
                    <E T="03">Affected public who will be asked or required to respond, as well as a brief abstract:</E>
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Private Sector-for or not for profit institutions.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The records associated with this collection are defense articles other than firearms and ammunition enumerated on the U.S. Munitions Import List. Information Collection (IC) OMB 1140-0031 is being revised to 
                    <PRTPAGE P="93656"/>
                    change the title from `Records of Acquisition and Disposition, Registered Importers of Arms, Ammunition &amp; Implements of War on the U.S. Munitions Import List' to `Records of Acquisition and Disposition, Registered Importers of Arms, Ammunition &amp; Defense Articles on the U.S. Munitions Import List' to reflect a change in terminology.
                </P>
                <P>
                    5. 
                    <E T="03">Obligation to Respond:</E>
                     Mandatory. The statutory requirements are implemented in per aw 22 U.S.C. 2778 and regulations 27 CFR 447.54.
                </P>
                <P>
                    6. 
                    <E T="03">Total Estimated Number of Respondents:</E>
                     50 respondents.
                </P>
                <P>
                    7. 
                    <E T="03">Estimated Time per Respondent:</E>
                     5 hours.
                </P>
                <P>
                    8. 
                    <E T="03">Frequency:</E>
                     Once annually.
                </P>
                <P>
                    9. 
                    <E T="03">Total Estimated Annual Time Burden:</E>
                     250 hours.
                </P>
                <P>
                    10. 
                    <E T="03">Total Estimated Annual Other Costs Burden:</E>
                     $0.
                </P>
                <P>If additional information is required, contact: Darwin Arceo, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, United States Department of Justice, Two Constitution Square, 145 N Street NE, 4W-218 Washington, DC 20530.</P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Darwin Arceo,</NAME>
                    <TITLE>Department Clearance Officer for PRA, U.S. Department of Justice.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27820 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-FY-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF JUSTICE</AGENCY>
                <DEPDOC>[CPCLO Order No. 007-2024</DEPDOC>
                <SUBJECT>Privacy Act of 1974; System of Records</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Justice Programs, United States Department of Justice.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of a new system of records.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>Pursuant to the Privacy Act of 1974, Office of Management and Budget (OMB) Circular No. A-108, and Federal law, notice is hereby given that the DOJ's Office of Justice Programs (OJP) proposes a new system of records notice titled the Peer Review Management System (PRMS), JUSTICE/OJP-020. The DOJ uses the PRMS, a web-based tool, to manage the planning, selection, and assignment of peer reviewers as part of the merit review of DOJ's funding opportunities.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>In accordance with 5 U.S.C. 552a(e)(4) and (11), this system of records is effective upon publication, subject to a 30-day period in which to comment on the routine uses described below. Please submit any comments by December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The public, OMB, and Congress are invited to submit any comments by mail to the United States Department of Justice, Office of Privacy and Civil Liberties, ATTN: Privacy Analyst, 145 N St. NE, Suite 8W, Washington, DC 20002; by facsimile at 202-307-0693; or by email at 
                        <E T="03">privacy.compliance@usdoj.gov.</E>
                         To ensure proper handling, please reference the above CPCLO Order No. on your correspondence.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Bryce Mitchell, Division Director; Enterprise Application Development Division, Office of the Chief Information Officer, Office of Justice Programs; 999 North Capitol Street NE, Washington, DC 20002, 
                        <E T="03">Bryce.Mitchell@usdoj.gov,</E>
                         (202) 598-9418.
                    </P>
                    <P>
                        Jennifer Tyson, Deputy Director, Grants Management Division, Audit, Assessment, and Management, Office of Justice Programs; 999 North Capitol Street NE, Washington, DC 20002, 
                        <E T="03">Jennifer.Tyson@usdoj.gov,</E>
                         (202) 307-0750.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <P>
                    Potential peer reviewers, who may be members of the public or Federal Government personnel, use the PRMS online tool to enter their records via enrollment applications (
                    <E T="03">i.e.,</E>
                     profiles) to be considered for peer review assignments. Authorized DOJ users (
                    <E T="03">i.e.</E>
                     DOJ program office and contract staff) can search these profiles to nominate and invite a peer reviewer to review and score DOJ funding opportunity applications. Authorized users (
                    <E T="03">i.e.,</E>
                     those members of the public or Federal Government personnel invited by a DOJ program office staff to serve as peer reviewer) may log into PRMS to review their profiles and obtain access to assigned peer review tasks.
                </P>
                <P>In accordance with 5 U.S.C. 552a(r), the DOJ has provided a report to OMB and Congress on this new system of records.</P>
                <SIG>
                    <DATED>Dated: November 19, 2024</DATED>
                    <NAME>Peter A. Winn,</NAME>
                    <TITLE>Acting Chief Privacy and Civil Liberties Officer, United States Department of Justice.</TITLE>
                </SIG>
                <PRIACT>
                    <HD SOURCE="HD1">JUSTICE/OJP—020</HD>
                    <HD SOURCE="HD2">SYSTEM NAME AND NUMBER: \</HD>
                    <P>Peer Review Management System (PRMS), JUSTICE/OJP—020</P>
                    <HD SOURCE="HD2">SECURITY CLASSIFICATION:</HD>
                    <P>The system is unclassified.</P>
                    <HD SOURCE="HD2">SYSTEM LOCATION:</HD>
                    <P>
                        Records in this system are maintained at the following locations: Office of Justice Programs (OJP); 999 North Capitol Street NE, Washington, DC 20002; and cloud service providers at AWS GovCloud; 1200 12th Avenue; South Seattle, WA 98144. The cloud computing service providers and their location may change from time to time, and this document may not reflect the most current information available. To confirm information about the current cloud computing service provider, please contact OJP through the OJP service desk at email address 
                        <E T="03">OJP.ITservicedesk@ojp.usdoj.gov.</E>
                    </P>
                    <HD SOURCE="HD2">SYSTEM MANAGER(S):</HD>
                    <P>
                        Bryce Mitchell, Division Director, Enterprise Application Development Division, Office of the Chief Information Officer, Office of Justice Programs, 999 North Capitol Street NE, Washington, DC 20002, 
                        <E T="03">Bryce.Mitchell@usdoj.gov,</E>
                         (202) 514-2412.
                    </P>
                    <HD SOURCE="HD2">AUTHORITY FOR MAINTENANCE OF THE SYSTEM:</HD>
                    <P>28 U.S.C. 530C, Authority to use available funds; 34 U.S.C. 10226(b), Personnel and Administrative Authority</P>
                    <HD SOURCE="HD2">PURPOSE(S) OF THE SYSTEM:</HD>
                    <P>The Peer Review Management System (PRMS) supports DOJ's overall grantmaking and research efforts toward fair, equitable, and objective funding decisions by providing a centralized directory for DOJ staff to obtain peer reviewers. DOJ peer reviewers consist of Federal Government staff or members of the public, who offer their expertise in merit reviewing and scoring OJP funding opportunities. The system achieves this purpose through its two main components, the Peer Reviewer Database (PRD) and the Peer Review Support System (PRSS).</P>
                    <P>The PRD maintains and disseminates records of peer reviewers and potential peer reviewers, including their electronic enrollment information. This component collects records about potential peer reviewers who voluntarily complete a multi-step online application process to be assigned peer review as needed by DOJ. The PRD allows authorized DOJ users (DOJ program and contractor staff) to nominate and invite a potential peer reviewer for a peer review assignment. Authorized DOJ users can also review and evaluate work performed once a peer reviewer completes an assignment.</P>
                    <P>
                        The PRSS maintains details of the peer review process necessary for authorized DOJ users to manage the peer review process, including application review criteria from funding opportunities, application data, and peer reviewer assignments. The PRSS also converts raw peer review scores into normalized scores or tiers, which are uploaded into OJP's grants 
                        <PRTPAGE P="93657"/>
                        management system for programmatic review.
                    </P>
                    <HD SOURCE="HD2">CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM:</HD>
                    <P>Individuals applying to serve as peer reviewers and individuals selected by DOJ to serve as peer reviewers (including members of the public or Federal Government personnel); and DOJ personnel and DOJ contractors who have access to the system as permitted and authorized by the DOJ.</P>
                    <HD SOURCE="HD2">CATEGORIES OF RECORDS IN THE SYSTEM:</HD>
                    <P>
                        Records in the PRMS include an individual's name, mailing address, personal email address, telephone number, work-related information (
                        <E T="03">e.g.,</E>
                         current occupation, job title, work address, email address, work address, and work history), areas of expertise, and information on any relevant lived justice-involved experience. In addition, information regarding potential peer reviewers' education level, race, cultural or ethnic identity, education, sex or gender identity, Tribal affiliation, and former incarceration (as self-reported by the potential peer reviewers) may be provided.
                    </P>
                    <HD SOURCE="HD2">RECORD SOURCE CATEGORIES:</HD>
                    <P>The records in the system may obtained from, among other sources, individuals applying to serve as peer reviewers, individuals selected by DOJ to serve as peer reviewers, and OJP's grants management system, which provides grant application data.</P>
                    <HD SOURCE="HD2">ROUTINE USES OF RECORDS MAINTAINED IN THE SYSTEM, INCLUDING CATEGORIES OF USERS AND THE PURPOSES OF SUCH USES:</HD>
                    <P>In addition to those disclosures generally permitted under 5 U.S.C. 552a(b), all or a portion of the records contained in this system of records may be disclosed as a routine use pursuant to 5 U.S.C. 552a(b)(3) under the circumstances or for the purposes described below, to the extent such disclosures are compatible with the purposes for which the information was collected:</P>
                    <P>1. Where a record, either alone or in conjunction with other information, may be relevant to investigating a violation or potential violation of law—criminal, civil, or regulatory in nature—the relevant records may be referred to the appropriate Federal, State, local, territorial, Tribal, or foreign law enforcement authority or other appropriate entity charged with the responsibility for investigating or prosecuting such violation or charged with enforcing or implementing such law.</P>
                    <P>2. To appropriate officials and employees of a Federal agency or entity to the extent necessary for making decisions about peer review assignments, such as but not limited to knowledge and skills needed to evaluate DOJ funding opportunities.</P>
                    <P>3. To any person or entity that the DOJ has reason to believe possesses knowledge regarding matters pertaining to DOJ programs and activities, to the extent deemed to be necessary by the DOJ to elicit information about the potential peer reviewer for use in conferring the DOJ peer reviewer assignments.</P>
                    <P>4. To any person or entity that the DOJ has reason to believe possesses information regarding a matter within the jurisdiction of the DOJ, to the extent deemed to be necessary by the DOJ to elicit such information or cooperation from the recipient for use in the performance of an authorized activity.</P>
                    <P>5. In an appropriate proceeding before a court, grand jury, or administrative or adjudicative body, when the DOJ determines that the records are arguably relevant to the proceeding; or in an appropriate proceeding before an administrative or adjudicative body when the adjudicator determines the records to be relevant to the proceeding.</P>
                    <P>6. To the news media and the public, including but not limited to disclosures pursuant to 28 CFR 50.2, unless it is determined that release of the specific information in the context of a particular case or matter would constitute an unwarranted invasion of personal privacy. While disclosures under 28 CFR 50.2 are in connection with a civil or criminal proceeding, disclosures under this routine use may also pertain to administrative proceedings as well as investigations of Federal employee misconduct prejudicial to the interests of members of the public.</P>
                    <P>7. To contractors, recipients, experts, consultants, students, and others performing or working on a contract, service, grant, cooperative agreement, or other assignment for the Federal Government, when necessary to accomplish an agency function related to this system of records.</P>
                    <P>8. To a former employee of the DOJ for official purposes where the DOJ requires information and/or consultation assistance from the former employee regarding a matter within that person's former area of responsibility.</P>
                    <P>9. To a Member of Congress or staff acting upon the Member's behalf when the Member or staff requests the information on behalf of, and at the request of, the individual who is the subject of the record.</P>
                    <P>10. To the National Archives and Records Administration for purposes of records management inspections conducted under the authority of 44 U.S.C. 2904 and 2906.</P>
                    <P>11. To appropriate agencies, entities, and persons when (1) the DOJ suspects or has confirmed that there has been a breach of the system of records; (2) the DOJ has determined that as a result of the suspected or confirmed breach there is a risk of harm to individuals, the DOJ (including its information systems, programs, and operations), the Federal Government, or national security; and (3) the disclosure made to such agencies, entities, and persons is reasonably necessary to assist in connection with the DOJ's efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm.</P>
                    <P>12. To another Federal agency or Federal entity, when the DOJ determines that information from this system of records is reasonably necessary to assist the recipient agency or entity in (1) responding to a suspected or confirmed breach, or (2) preventing, minimizing, or remedying the risk of harm to individuals, the recipient agency or entity (including its information systems, programs, and operations), the Federal Government, or national security, resulting from a suspected or confirmed breach.</P>
                    <P>13. To any agency, organization, or individual for the purpose of performing authorized audit or oversight operations of DOJ and meeting related reporting requirements.</P>
                    <P>14. To such recipients and under such circumstances and procedures as are mandated by Federal statute or treaty.</P>
                    <HD SOURCE="HD2">POLICIES AND PRACTICES FOR STORAGE OF RECORDS:</HD>
                    <P>Records in the PRMS are stored in electronic format in the OJP cloud platforms. Records are stored securely in accordance with applicable Federal laws, regulations, Department directives, and guidance.</P>
                    <HD SOURCE="HD2">POLICIES AND PRACTICES FOR RETRIEVAL OF RECORDS:</HD>
                    <P>Records can be retrieved within PRMS by a peer reviewer's personal identifier to obtain profiles or other data matching the search criteria necessary for the merit review of DOJ funding opportunities.</P>
                    <P>
                        The records are retrievable by the peer reviewer's name, employee type (other Federal agency or other), education level, job category, race, cultural and ethnic identities, subject matter expertise, research expertise, business organization, organization unit, job title, 
                        <PRTPAGE P="93658"/>
                        phone number (home and business), address (home and business), and gender and sexual identities. The records are searchable and retrievable using those identifiers for diversifying the pool of reviewers needed to meet the objectives conducive to a full and fair evaluation of the relevant OJP funding opportunities.
                    </P>
                    <HD SOURCE="HD2">POLICIES AND PRACTICES FOR RETENTION AND DISPOSAL OF RECORDS:</HD>
                    <P>Records in this system are stored in electronic format and retained as well as disposed of in accordance with the National Archives and Records Administration, General Records Schedule 1.2, which covers grant and cooperative agreement records.</P>
                    <HD SOURCE="HD2">ADMINISTRATIVE, TECHNICAL, AND PHYSICAL SAFEGUARDS:</HD>
                    <P>This system meets all DOJ requirements for authorization to operate per DOJ Order 0904, Cybersecurity Program. Specifically, information in this system is maintained in accordance with applicable laws, rules, and policies on protecting individual privacy.</P>
                    <P>The system leverages cloud service providers that maintain an authority to operate in accordance with applicable laws, rules, and policies, including Federal Risk and Authorization Management Program (FedRAMP) requirements.</P>
                    <P>Backup information is maintained in accordance with a government contract that requires adherence to applicable laws, rules, and policies. Internet connections are protected by multiple firewalls. Security personnel conduct periodic vulnerability scans using DOJ-approved software to ensure security compliance and security logs are enabled for all computers to assist in troubleshooting and forensics analysis during incident investigations. Users of individual computers can only gain access to the data by a valid user's identification and authentication.</P>
                    <HD SOURCE="HD2">RECORD ACCESS PROCEDURES:</HD>
                    <P>All requests for access to records must be in writing and should be addressed to the relevant component:</P>
                    <P>OJP FOIA Officer; Office of Justice Programs; Office of the General Counsel; 999 North Capitol Street NE, Washington, DC 20002.</P>
                    <P>
                        The envelope and letter should be clearly marked “Privacy Act Access Request.” The request must describe the records sought in sufficient detail to enable DOJ personnel to locate them with a reasonable amount of effort. The request must include a general description of the records sought and must include the requester's full name, current address, and date and place of birth. The request must be signed and either notarized or submitted under penalty of perjury. Although no specific form is required, you may obtain forms for this purpose from the FOIA/Privacy Act Mail Referral Unit, United States Department of Justice, 950 Pennsylvania Avenue NW, Washington, DC 20530, or on the Department of Justice website at 
                        <E T="03">https://www.justice.gov/oip/oip-request.html.</E>
                    </P>
                    <P>More information regarding the DOJ's procedures for accessing records in accordance with the Privacy Act can be found at 28 CFR part 16 Subpart D, “Protection of Privacy and Access to Individual Records Under the Privacy Act of 1974.”</P>
                    <HD SOURCE="HD2">CONTESTING RECORD PROCEDURES:</HD>
                    <P>Individuals seeking to contest or amend records pertaining to them, maintained in this system of records, must direct their requests to the address indicated in the “RECORD ACCESS PROCEDURES” paragraph, above. All requests to contest or amend records must be in writing and the envelope and letter should be clearly marked “Privacy Act Amendment Request.” All requests must state clearly and concisely what record is being contested, the reasons for contesting it, and the proposed amendment to the record.</P>
                    <P>More information regarding the DOJ's procedures for amending or contesting records in accordance with the Privacy Act can be found at 28 CFR 16.46, “Requests for Amendment or Correction of Records.”</P>
                    <HD SOURCE="HD2">NOTIFICATION PROCEDURES:</HD>
                    <P>Individuals may request to be notified if a record in this system of records pertains to them by utilizing the same procedures as those identified in the “RECORD ACCESS PROCEDURES” paragraph, above.</P>
                    <HD SOURCE="HD2">EXEMPTIONS PROMULGATED FOR THE SYSTEM:</HD>
                    <P>None.</P>
                    <HD SOURCE="HD2">HISTORY:</HD>
                    <P>None.</P>
                </PRIACT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27570 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-18-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF JUSTICE</AGENCY>
                <DEPDOC>[OMB 1140-0060]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed eCollection eComments Requested; Firearms Disabilities for Nonimmigrant Aliens</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Bureau of Alcohol, Tobacco, Firearms and Explosives, Department of Justice.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and will be accepted for 30 days until December 27, 2024.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: Lindsay Babbie, EPS/FEID/FIPB, either by mail at Bureau of Alcohol, Tobacco, Firearms, and Explosives; 99 New York Ave. NE, Mail Stop 6N-518, Washington, DC 20226, by email at 
                        <E T="03">Lindsay.Babbie@atf.gov,</E>
                         or telephone at 202-648-7252.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The proposed information collection was previously published in the 
                    <E T="04">Federal Register</E>
                    , volume 89, page 80265, on Wednesday, October 2, 2024, allowing a 60-day comment period. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:
                </P>
                <FP SOURCE="FP-1">—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;</FP>
                <FP SOURCE="FP-1">—Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;</FP>
                <FP SOURCE="FP-1">—Enhance the quality, utility, and clarity of the information to be collected; and/or</FP>
                <FP SOURCE="FP-1">
                    —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, 
                    <PRTPAGE P="93659"/>
                    mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses.
                </FP>
                <P>
                    Written comments and recommendations for this information collection should be submitted within 30 days of the publication of this notice on the following website 
                    <E T="03">www.reginfo.gov/public/do/</E>
                    PRAMain. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function and entering either the title of the information collection or the OMB Control Number 1140-0060. This information collection request may be viewed at 
                    <E T="03">www.reginfo.gov.</E>
                     Follow the instructions to view Department of Justice, information collections currently under review by OMB.
                </P>
                <P>DOJ seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years without renewal. The DOJ notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.</P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    1. 
                    <E T="03">Type of Information Collection:</E>
                     Revision of a previously approved collection.
                </P>
                <P>
                    2. 
                    <E T="03">Title of the Form/Collection:</E>
                     Firearms Disabilities for Nonimmigrant Aliens.
                </P>
                <P>
                    3. 
                    <E T="03">Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:</E>
                     None.
                </P>
                <P>
                    <E T="03">Component:</E>
                     Bureau of Alcohol, Tobacco, Firearms and Explosives, U.S. Department of Justice.
                </P>
                <P>
                    4. 
                    <E T="03">Affected public who will be asked or required to respond, as well as a brief abstract:</E>
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Individuals or households, Private Sector-for or not for profit institutions.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The nonimmigrant alien information will be used to determine if a nonimmigrant alien is eligible to obtain a federal firearms license and purchase, obtain, possess, or import a firearm. Nonimmigrant aliens also must maintain the documents while in possession of firearms or ammunition in the United States for verification purposes. Information Collection (IC) OMB # 1140-0060 is being revised to reflect an increase in costs. The number of persons who annually submit ATF Form 6NIA has increased since this information collection was last renewed.
                </P>
                <P>
                    5. 
                    <E T="03">Obligation to Respond:</E>
                     As this is not a form, there is no obligation to respond.
                </P>
                <P>
                    6.
                    <E T="03"> Total Estimated Number of Respondents:</E>
                     2,531 respondents.
                </P>
                <P>
                    7. 
                    <E T="03">Estimated Time per Respondent:</E>
                     3 minutes and 59 seconds.
                </P>
                <P>
                    8. 
                    <E T="03">Frequency:</E>
                     Once annually.
                </P>
                <P>
                    9. 
                    <E T="03">Total Estimated Annual Time Burden:</E>
                     168 hours.
                </P>
                <P>
                    10. 
                    <E T="03">Total Estimated Annual Other Costs Burden:</E>
                     $3,864.
                </P>
                <P>If additional information is required, contact: Darwin Arceo, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, United States Department of Justice, Two Constitution Square, 145 N Street NE, 4W-218 Washington, DC 20530.</P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Darwin Arceo,</NAME>
                    <TITLE>Department Clearance Officer for PRA, U.S. Department of Justice.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27821 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-FY-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF JUSTICE</AGENCY>
                <DEPDOC>[OMB Number 1140-0101]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed eCollection eComments Requested; National Firearms Act Division and Firearms and Explosives Services Division Customer Service Survey</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Bureau of Alcohol, Tobacco, Firearms and Explosives, Department of Justice.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and will be accepted for 30 days until December 27, 2024.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: Paige Tisserand, National Firearms Division, either by email at 
                        <E T="03">NFAOMBCOMMENTS@ATF.GOV</E>
                         or 
                        <E T="03">meghan.tissserand@atf.gov,</E>
                         or telephone at 304-616-4500.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The proposed information collection was previously published in the 
                    <E T="04">Federal Register</E>
                    , volume 89 page 80935, on Friday, October 4, 2024, allowing a 60-day comment period. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:
                </P>
                <FP SOURCE="FP-1">—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;</FP>
                <FP SOURCE="FP-1">—Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;</FP>
                <FP SOURCE="FP-1">—Enhance the quality, utility, and clarity of the information to be collected; and/or</FP>
                <FP SOURCE="FP-1">
                    —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses.
                </FP>
                <P>
                    Written comments and recommendations for this information collection should be submitted within 30 days of the publication of this notice on the following website 
                    <E T="03">www.reginfo.gov/public/do/PRAMain</E>
                    . Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function and entering either the title of the information collection or the OMB Control Number 1140-0101. This information collection request may be viewed at 
                    <E T="03">www.reginfo.gov.</E>
                     Follow the instructions to view Department of Justice, information collections currently under review by OMB.
                </P>
                <P>DOJ seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years without renewal. The DOJ notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.</P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    1. 
                    <E T="03">Type of Information Collection:</E>
                     Revision of a previously approved collection.
                </P>
                <P>
                    2. 
                    <E T="03">Title of the Form/Collection:</E>
                     National Firearms Act Division and 
                    <PRTPAGE P="93660"/>
                    Firearms and Explosives Services Division Customer Service Survey.
                </P>
                <P>
                    3. 
                    <E T="03">Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:</E>
                     None.
                </P>
                <P>
                    <E T="03">Component:</E>
                     Bureau of Alcohol, Tobacco, Firearms and Explosives, U.S. Department of Justice.
                </P>
                <P>
                    4. 
                    <E T="03">Affected public who will be asked or required to respond, as well as a brief abstract:</E>
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     State, local and tribal governments, individuals or households, Federal Government.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The National Firearms Act Division and Firearms and Explosives Services Division Customer Service Survey is used to gather information about customer service provided to the firearms and explosives industry and government agencies to improve service delivery. Information Collection (IC) OMB 1140-0101 is being revised to include the NFA Division's newest branch: Information Compliance Branch.
                </P>
                <P>
                    5. 
                    <E T="03">Obligation to Respond:</E>
                     Voluntary.
                </P>
                <P>
                    6. 
                    <E T="03">Total Estimated Number of Respondents:</E>
                     100.
                </P>
                <P>
                    7. 
                    <E T="03">Estimated Time per Respondent:</E>
                     10 minutes.
                </P>
                <P>
                    8. 
                    <E T="03">Frequency:</E>
                     Once annually.
                </P>
                <P>
                    9. 
                    <E T="03">Total Estimated Annual Time Burden:</E>
                     17 hours.
                </P>
                <P>
                    10. 
                    <E T="03">Total Estimated Annual Other Costs Burden:</E>
                     $0.
                </P>
                <P>If additional information is required, contact: Darwin Arceo, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, United States Department of Justice, Two Constitution Square, 145 N Street NE, 4W-218, Washington, DC 20530.</P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Darwin Arceo,</NAME>
                    <TITLE>Department Clearance Officer for PRA, U.S. Department of Justice.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27862 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-FY-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF JUSTICE</AGENCY>
                <DEPDOC>[OMB Number 1110-0065]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Previously Approved Collection; Private Industry Feedback Survey</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Department of Justice, Federal Bureau of Investigation, Cyber Division.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>60-Day notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of Justice (DOJ), Federal Bureau of Investigation (FBI), Cyber Division (CyD) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and will be accepted for 60 days until January 27, 2025.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Lawrence Quigley, Unit Chief, FBI, CyD, 935 Pennsylvania Ave. NW, Washington, DC 20535; telephone: 304-367-3766, email: 
                        <E T="03">lwquigley@fbi.gov.</E>
                         Written comments and/or suggestions can also be sent to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted via email to 
                        <E T="03">OIRA_submissions@omb.eop.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:</P>
                <FP SOURCE="FP-1">—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Bureau of Justice Statistics, including whether the information will have practical utility;</FP>
                <FP SOURCE="FP-1">—Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;</FP>
                <FP SOURCE="FP-1">—Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and</FP>
                <FP SOURCE="FP-1">
                    —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses.
                </FP>
                <P>
                    <E T="03">Abstract:</E>
                     The FBI, Cyber Division, provides a voluntary “Feedback” Section on reports related to cyber trends and threats for private sector partners.
                </P>
                <P>
                    <E T="03">Overview of this information collection:</E>
                </P>
                <P>
                    1. 
                    <E T="03">Type of Information Collection:</E>
                     Extensions of a currently approved collection.
                </P>
                <P>
                    2. 
                    <E T="03">The Title of the Form/Collection:</E>
                     Private Industry Feedback Survey.
                </P>
                <P>
                    3. 
                    <E T="03">The agency form number, if any, and the applicable component of the Department sponsoring the collection:</E>
                     N/A.
                </P>
                <P>
                    4. 
                    <E T="03">Affected public who will be asked or required to respond, as well as the obligation to respond:</E>
                     The FBI, Cyber Division, produces reports that provide information related to cyber trends and threats for private sector partners. The reports are referred to as Private Industry Notifications (PINs) and FBI Liaison Alert Systems (FLASHs). In order to improve the PIN/FLASH reports, a “Feedback” Section has been added to the reports containing a URL that links to a voluntary online survey. The results of the survey are reviewed by CyD and used to improve future reports to better serve the FBI's private sector partners.
                </P>
                <P>
                    5. 
                    <E T="03">An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:</E>
                     An estimated 5,000 respondents will complete the survey. It is estimated that it takes each respondent 3 minutes to complete the survey.
                </P>
                <P>
                    6. 
                    <E T="03">An estimate of the total annual burden (in hours) associated with the collection:</E>
                     The estimated public burden associated with his collection is 250 hours.
                </P>
                <P>
                    7. 
                    <E T="03">An estimate of the total annual cost burden associated with the collection, if applicable:</E>
                     $0.
                    <PRTPAGE P="93661"/>
                </P>
                <GPOTABLE COLS="6" OPTS="L2,i1" CDEF="s50,12,12,12,12,12">
                    <TTITLE>Total Burden Hours</TTITLE>
                    <BOXHD>
                        <CHED H="1">Activity</CHED>
                        <CHED H="1">
                            Number of 
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">
                            Frequency
                            <LI>(annually)</LI>
                        </CHED>
                        <CHED H="1">Total annual responses</CHED>
                        <CHED H="1">
                            Time per 
                            <LI>response</LI>
                            <LI>(min)</LI>
                        </CHED>
                        <CHED H="1">
                            Total annual burden
                            <LI>(hours)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW RUL="n,s">
                        <ENT I="01">Ex: Survey</ENT>
                        <ENT>5,000</ENT>
                        <ENT/>
                        <ENT>5,000</ENT>
                        <ENT>3</ENT>
                        <ENT>250</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Unduplicated Totals</ENT>
                        <ENT>5,000</ENT>
                        <ENT/>
                        <ENT>5,000</ENT>
                        <ENT/>
                        <ENT>250 </ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    <E T="03">An estimate of the total annual burden (in hours) associated with the collection:</E>
                     The estimated public burden associated with this collection is 250 hours.
                </P>
                <P>
                    <E T="03">If additional information is required contact:</E>
                     Darwin Arceo, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE, 4W-218, Washington, DC.
                </P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Darwin Arceo,</NAME>
                    <TITLE>Department Clearance Officer for PRA, U.S. Department of Justice.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27809 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-02-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF JUSTICE</AGENCY>
                <SUBJECT>Notice of Lodging of Proposed Consent Decree Under the Clean Air Act</SUBJECT>
                <P>
                    On November 21, 2024, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the Western District of Pennsylvania in the lawsuit entitled 
                    <E T="03">United States and Commonwealth of Pennsylvania</E>
                     v. 
                    <E T="03">Hilcorp Energy Company,</E>
                     Civil Action No. 2:24-cv-01596 (W.D. Pa).
                </P>
                <P>The lawsuit seeks injunctive relief and civil penalties for violations of the Clean Air Act and its implementing regulations at oil and natural gas production facilities owned and operated by Hilcorp Energy Company (“Hilcorp”) in Lawrence and Mercer Counties, Pennsylvania. The violations relate to alleged failures to adequately design, operate, and maintain storage tank vapor control systems, resulting in emissions of volatile organic compounds (“VOC”) and other pollutants to the atmosphere.</P>
                <P>The proposed consent decree covers nine Hilcorp facilities in Pennsylvania. The proposed decree requires Hilcorp to perform injunctive relief, including conducting engineering evaluations of the vapor control systems at each of the controlled well pads to ensure that they are adequately sized and designed, and complete an environmental mitigation project. Hilcorp must also pay a $1,275,000 civil penalty. Entering into and fully complying with the proposed consent decree would release Hilcorp from past civil liability for violations of Clean Air Act regulations applicable to new and modified storage vessels and related state law at the facilities subject to the proposed consent decree.</P>
                <P>
                    The publication of this notice opens a period for public comment on the proposed Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to 
                    <E T="03">United States and Commonwealth of Pennsylvania</E>
                     v. 
                    <E T="03">Hilcorp Energy Company,</E>
                     D.J. Ref. No. 90-5-2-1-12372. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:
                </P>
                <GPOTABLE COLS="2" OPTS="L2,tp0,i1" CDEF="xs50,r50">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1" O="L">
                            <E T="03">To submit comments:</E>
                        </CHED>
                        <CHED H="1" O="L">
                            <E T="03">Send them to:</E>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">By email</ENT>
                        <ENT>
                            <E T="03">pubcomment-ees.enrd@usdoj.gov</E>
                            .
                        </ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">By mail</ENT>
                        <ENT>Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    During the public comment period, the proposed Consent Decree may be examined and downloaded at this Justice Department website: 
                    <E T="03">https://www.justice.gov/enrd/consent-decrees.</E>
                     If you require assistance accessing the proposed Consent Decree, you may request assistance by email or by mail to the addresses provided above for submitting comments.
                </P>
                <SIG>
                    <NAME>Jason A. Dunn,</NAME>
                    <TITLE>Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27780 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-15-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF JUSTICE</AGENCY>
                <DEPDOC>[OMB 1140-0050]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed eCollection eComments Requested; Identification Markings Placed on Firearms</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Bureau of Alcohol, Tobacco, Firearms and Explosives, Department of Justice.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and will be accepted for 30 days until December 27, 2024.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: Jennifer Scott, FIPB, 99 New York Avenue NE, Washington, DC 20226, either by email at 
                        <E T="03">fipb-informationcollection@atf.gov</E>
                         or 
                        <E T="03">jennifer.scott@atf.gov</E>
                         or telephone at 202-648-7190.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The proposed information collection was previously published in the 
                    <E T="04">Federal Register</E>
                    , volume 89, page 81111, on Monday, October 7, 2024, allowing a 60-day comment period. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:
                </P>
                <FP SOURCE="FP-1">—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;</FP>
                <FP SOURCE="FP-1">
                    —Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, 
                    <PRTPAGE P="93662"/>
                    including the validity of the methodology and assumptions used;
                </FP>
                <FP SOURCE="FP-1">—Enhance the quality, utility, and clarity of the information to be collected; and/or</FP>
                <FP SOURCE="FP-1">
                    —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses.
                </FP>
                <P>
                    Written comments and recommendations for this information collection should be submitted within 30 days of the publication of this notice on the following website 
                    <E T="03">www.reginfo.gov/public/do/</E>
                    PRAMain. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function and entering either the title of the information collection or the OMB Control Number 1140-0052. This information collection request may be viewed at 
                    <E T="03">www.reginfo.gov.</E>
                     Follow the instructions to view Department of Justice, information collections currently under review by OMB.
                </P>
                <P>DOJ seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years without renewal. The DOJ notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.</P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    1. 
                    <E T="03">Type of Information Collection:</E>
                     Revision of a previously approved collection.
                </P>
                <P>
                    2. 
                    <E T="03">Title of the Form/Collection:</E>
                     Identification Markings Placed on Firearms.
                </P>
                <P>
                    3. 
                    <E T="03">Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:</E>
                     None. 
                    <E T="03">Component:</E>
                     Bureau of Alcohol, Tobacco, Firearms and Explosives, U.S. Department of Justice.
                </P>
                <P>
                    4. 
                    <E T="03">Affected public who will be asked or required to respond, as well as a brief abstract:</E>
                      
                    <E T="03">Affected Public:</E>
                     Private Sector-for or not for profit institutions. 
                    <E T="03">Abstract:</E>
                     Each licensed firearms manufacturer and licensed firearms importer must legibly identify each firearm by engraving, casting, stamping (impressing), or otherwise conspicuously placing on the frame or receiver an individual serial number, any associated license number, and all other additional required information to a depth of at least .003 inch and in a print size no smaller than 
                    <FR>1/16</FR>
                     inch. Used to facilitate the investigations of the criminal use of firearms. Information Collection (IC) OMB #1140-0050 is being revised to reflect an increase in costs resulting from an increase in the number of respondents and firearms covered by the information collection, and from adding both a burden hour monetized value and start-up costs based on a rulemaking that occurred since the last time this collection was renewed.
                </P>
                <P>
                    5. 
                    <E T="03">Obligation to Respond:</E>
                     The obligation to respond is mandatory per 18 U.S.C. Chapter 44 and 26 U.S.C. § 5842.
                </P>
                <P>
                    6. 
                    <E T="03">Total Estimated Number of Respondents:</E>
                     22,662 total respondents.
                </P>
                <P>
                    7. 
                    <E T="03">Estimated Time per Respondent:</E>
                     1 minute.
                </P>
                <P>
                    8. 
                    <E T="03">Frequency:</E>
                     One per firearm.
                </P>
                <P>
                    9. 
                    <E T="03">Total Estimated Annual Time Burden:</E>
                     257,419,782 hours.
                </P>
                <P>
                    10. 
                    <E T="03">Total Estimated Annual Other Costs Burden:</E>
                     $45,598,278.00.
                </P>
                <P>If additional information is required, contact: Darwin Arceo, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, United States Department of Justice, Two Constitution Square, 145 N Street NE, 4W-218 Washington, DC 20530.</P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Darwin Arceo,</NAME>
                    <TITLE>Department Clearance Officer for PRA, U.S. Department of Justice.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27861 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-FY-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF JUSTICE</AGENCY>
                <DEPDOC>[OMB Number 1110-0082]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed eCollection eComments Requested; Law Enforcement Suicide Data Collection (LESDC)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Bureau of Investigation, Department of Justice.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>30-Day notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Federal Bureau of Investigation (FBI), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and will be accepted for 30 days until December 27, 2024.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: [Edward L. Abraham, Crime and Law Enforcement Statistics Unit Chief, FBI, CJIS Division, Module D-2, 1000 Custer Hollow Road, Clarksburg, West Virginia 26306; email: 
                        <E T="03">elabraham@fbi.gov</E>
                         or 
                        <E T="03">UCR@fbi.gov;</E>
                         telephone: 304-625-4830].
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The proposed information collection was previously published in the 
                    <E T="04">Federal Register</E>
                     on October 15, 2024 allowing a 60-day comment period. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:
                </P>
                <FP SOURCE="FP-1">—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;</FP>
                <FP SOURCE="FP-1">—Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;</FP>
                <FP SOURCE="FP-1">—Enhance the quality, utility, and clarity of the information to be collected; and/or</FP>
                <FP SOURCE="FP-1">
                    —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses.
                </FP>
                <P>
                    Written comments and recommendations for this information collection should be submitted within 30 days of the publication of this notice on the following website 
                    <E T="03">www.reginfo.gov/public/do/PRAMain</E>
                    . Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function and entering either the title of the information collection or the OMB Control Number 1110-0082. This information collection request may be viewed at 
                    <E T="03">www.reginfo.gov.</E>
                     Follow the instructions to view Department of Justice, information collections currently under review by OMB.
                </P>
                <P>
                    DOJ seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years 
                    <PRTPAGE P="93663"/>
                    without renewal. The DOJ notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.
                </P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    1. 
                    <E T="03">Type of Information Collection:</E>
                     Extension of a previously approved collection.
                </P>
                <P>
                    2. 
                    <E T="03">Title of the Form/Collection:</E>
                     Law Enforcement Suicide Data Collection.
                </P>
                <P>
                    3. 
                    <E T="03">Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:</E>
                     Criminal Justice Information Services (CJIS) Division, FBI.
                </P>
                <P>
                    4. 
                    <E T="03">Affected public who will be asked or required to respond, as well as a brief abstract</E>
                    :
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Law Enforcement Agencies.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     In response to the 
                    <E T="03">Law Enforcement Suicide Data Collection Act</E>
                     (Title 34, United States Code, Section 50701), the FBI's Uniform Crime Reporting Program established the LESDC which is designed to gather information on occurrences of suicide and attempted suicide within the law enforcement community. The data will be used to produce a report of information surrounding these incidents which will help promote the understanding of, and elicit further discussion within society about, law enforcement suicide and attempted suicide.
                </P>
                <P>
                    5. 
                    <E T="03">Obligation to Respond:</E>
                     Voluntary.
                </P>
                <P>
                    6. 
                    <E T="03">Total Estimated Number of Respondents:</E>
                     50 respondents.
                </P>
                <P>
                    7. 
                    <E T="03">Estimated Time per Respondent:</E>
                     15 minutes.
                </P>
                <P>
                    8. 
                    <E T="03">Frequency:</E>
                     Annually.
                </P>
                <P>
                    9. 
                    <E T="03">Total Estimated Annual Time Burden:</E>
                     15 minutes.
                </P>
                <P>
                    10. 
                    <E T="03">Total Estimated Annual Other Costs Burden:</E>
                     $0.
                </P>
                <P>If additional information is required, contact: Darwin Arceo, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, United States Department of Justice, Two Constitution Square, 145 N Street NE, 4W-218, Washington, DC 20530.</P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Darwin Arceo,</NAME>
                    <TITLE>Department Clearance Officer for PRA, U.S. Department of Justice.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27825 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-02-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF JUSTICE</AGENCY>
                <DEPDOC>[OMB Number 1121-0269]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities; Proposed eCollection eComments Requested; Reinstatement, With Change, of a Previously Approved Collection for Which Approval Has Expired: Census of Publicly Funded Forensic Crime Laboratories (CPFFCL)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Bureau of Justice Statistics, Department of Justice</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>60-Day notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Bureau of Justice Statistics, Department of Justice (DOJ) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments are encouraged and will be accepted for 60 days until January 27, 2025.</P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Matt Durose, Bureau of Justice Statistics, 999 North Capital Street NE, Washington, DC 20531 (email: 
                        <E T="03">Matt.Durose@usdoj.gov;</E>
                         telephone: 202-598-0295).
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:</P>
                <FP SOURCE="FP-1">—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Bureau of Justice Statistics, including whether the information will have practical utility;</FP>
                <FP SOURCE="FP-1">—Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;</FP>
                <FP SOURCE="FP-1">—Evaluate whether and if so, how the quality, utility, and clarity of the information to be collected can be enhanced; and</FP>
                <FP SOURCE="FP-1">
                    —Minimize the burden of the collection of information on those who are to respond, including using appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, 
                    <E T="03">e.g.,</E>
                     permitting electronic submission of responses.
                </FP>
                <P>
                    <E T="03">Abstract:</E>
                     Since 2002, the Bureau of Justice Statistics (BJS) has periodically conducted the Census of Publicly Funded Forensic Crime Laboratories (CPFFCL) through a survey that collects data on the staffing, budgets, workloads, resources, policies, and procedures among federal, state, and local crime labs. The 2024 CPFFCL will be the sixth administration. It will provide insight on emerging issues and challenges facing crime labs since the CPFFCL was last conducted in 2020. BJS uses the information gathered in CPFFCL in published reports and statistics. The reports will be made available to the U.S. Congress, Executive Office of the President, practitioners, researchers, students, the media, others interested in criminal justice statistics, and the general public via the BJS website.
                </P>
                <HD SOURCE="HD1">Overview of This Information Collection</HD>
                <P>
                    1. 
                    <E T="03">Type of Information Collection:</E>
                     Reinstatement, with changes, of a previously approved collection for which approval has expired.
                </P>
                <P>
                    2. 
                    <E T="03">Title of the Form/Collection:</E>
                     2024 Census of Publicly Funded Forensic Crime Laboratories (CPFFCL).
                </P>
                <P>
                    3. 
                    <E T="03">Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:</E>
                     The form number is CPFFCL-24. The applicable component within the Department of Justice is the Bureau of Justice Statistics (BJS), in the Office of Justice Programs.
                </P>
                <P>
                    4. 
                    <E T="03">Affected public who will be asked or required to respond, as well as the obligation to respond:</E>
                     Affected public are federal, state, and local government agencies. The 2024 CPFFCL is revised from the 2020 CPFFCL. BJS plans to field the 2024 CPFFCL from February through August 2025. Respondents will be the staff at the publicly funded forensic crime labs. The obligation to respond is voluntary.
                </P>
                <P>
                    5. 
                    <E T="03">An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:</E>
                     A projected 350 respondents from individual labs and multi-lab systems will take an average of 90 minutes (1.5 hours) each to complete form CPFFCL-24, including time to research or find information not readily available. In addition, an estimated 225 respondents will be contacted for data quality follow-up at 15 minutes (.25 hours) per respondent.
                </P>
                <P>
                    6. 
                    <E T="03">An estimate of the total public burden (in hours) associated with the collection:</E>
                     The total burden hours for this collection is 581 hours.
                    <PRTPAGE P="93664"/>
                </P>
                <P>
                    7. 
                    <E T="03">An estimate of the total annual cost burden associated with the collection, if applicable:</E>
                     $907,183.
                </P>
                <GPOTABLE COLS="6" OPTS="L2,nj,i1" CDEF="s50,12,12,12,xs25,12">
                    <TTITLE>Total Burden Hours</TTITLE>
                    <BOXHD>
                        <CHED H="1">Activity</CHED>
                        <CHED H="1">
                            Number of
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">Frequency</CHED>
                        <CHED H="1">
                            Total annual
                            <LI>responses</LI>
                        </CHED>
                        <CHED H="1">
                            Time per
                            <LI>response</LI>
                        </CHED>
                        <CHED H="1">
                            Total annual
                            <LI>burden</LI>
                            <LI>(hours)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Survey</ENT>
                        <ENT>350</ENT>
                        <ENT>1</ENT>
                        <ENT>350</ENT>
                        <ENT>90 min (1.5 hrs.)</ENT>
                        <ENT>525</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Data Quality Follow-Up</ENT>
                        <ENT>225</ENT>
                        <ENT>1</ENT>
                        <ENT>225</ENT>
                        <ENT>15 min (.25 hrs.)</ENT>
                        <ENT>56</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="03">Unduplicated Totals</ENT>
                        <ENT>350</ENT>
                        <ENT/>
                        <ENT>300</ENT>
                        <ENT/>
                        <ENT>581</ENT>
                    </ROW>
                </GPOTABLE>
                <P>If additional information is required, contact: Darwin Arceo, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE, 4W-218, Washington, DC.</P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Darwin Arceo,</NAME>
                    <TITLE>Department Clearance Officer for PRA, U.S. Department of Justice.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27802 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4410-18-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF LABOR</AGENCY>
                <SUBJECT>Agency Information Collection Activities; Submission for OMB Review; Comment Request; Davis-Bacon Certified Payroll</SUBJECT>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of availability; request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of Labor (DOL) is submitting this Wage and Hour Division (WHD)-sponsored information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). Public comments on the ICR are invited.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The OMB will consider all written comments that the agency receives on or before December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Nora Hernandez by telephone at 202-693-8633, or by email at 
                        <E T="03">DOL_PRA_PUBLIC@dol.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The Copeland Act requires contractors and subcontractors performing work on federally financed or assisted construction contracts to furnish weekly a statement on the wages paid each covered worker during the prior week. See 40 U.S.C. 3145; 29 CFR 3.3(b). This Copeland Act provision specifically requires the regulations to “include a provision that each contractor and subcontractor each week must furnish a statement on the wages paid each worker during the prior week.” This requirement is implemented by 29 CFR 3.3 and 3.4 and the standard Davis-Bacon contract clauses set forth at 29 CFR 5.5. The regulation at 29 CFR 5.5 (a)(3)(ii)(A) (“Frequency and method of submission”) requires contractors to submit weekly a copy of all payrolls to the federal agency contracting for or financing the construction project. If the agency is not a party to the contract, the contractor will submit the payrolls to the applicant, sponsor, or owner, as the case may be, for transmission to the contracting agency. This provision requires that the payrolls submitted shall set out accurately and completely information required to be maintained under 29 CFR 5.5(a)(3)(ii)(B) (“Information required”).</P>
                <P>
                    The information that must be included in the weekly transmittals includes the name of each covered worker; each worker's correct classification(s) of work actually performed; hourly rates of wages paid (including rates of contributions or costs anticipated for bona fide fringe benefits or cash equivalents thereof of the types described in 40 U.S.C. 3141(2)(B) of the Davis-Bacon Act); daily and weekly number of hours actually worked in total and on each covered contract; deductions made; and actual wages paid. 
                    <E T="03">See</E>
                     29 CFR 5.5(a)(3)(i)(B); 29 CFR 5.5(a)(3)(ii)(B). The weekly transmittals also must include an individually identifying number for each employee (
                    <E T="03">e.g.,</E>
                     the last four digits of the employee's Social Security number). 
                    <E T="03">See</E>
                     29 CFR 5.5(a)(3)(ii)(B).
                </P>
                <P>The provision at 29 CFR 5.5(a)(3)(ii)(B) also states what must not be included in the weekly transmittal. The weekly transmittal must not include workers' full social security numbers, last known addresses, telephone numbers, and email addresses. That information must be recorded and maintained by the contractors as part of the record-keeping provisions in the regulations at 29 CFR 5.5(a)(3)(i)(B), but it must not be included in the weekly transmittals.</P>
                <P>The regulations at 29 CFR 5.5(a)(3)(ii)(C) and 29 CFR 3.3(b) require each contractor to furnish weekly a signed “Statement of Compliance” accompanying the payroll indicating the payrolls are correct and complete and that each covered worker has been paid not less than the proper Davis-Bacon Act prevailing wage rate for the work performed.</P>
                <P>The required weekly payroll information may be submitted in any form desired. The information collection request that is the subject of this notice, Optional Form WH-347, is designed to include fields for all of the necessary information so as to satisfy the regulatory and contractual requirements. The weekly submission of a properly executed certification, with the prescribed language set forth on page 2 of Optional Form WH-347, satisfies the requirement for submission of the required “Statement of Compliance.” 29 CFR 5.5(a)(3)(ii)(C).</P>
                <P>
                    In addition to the weekly transmittal requirements, the regulations contain separate record retention requirements that require the retention of the weekly 
                    <PRTPAGE P="93665"/>
                    transmittals themselves as well as a broader subset of documents and information. Regulations 29 CFR 3.4(b) and 5.5(a)(3)(ii)(G) require contractors to maintain copies of these transmitted weekly certified payrolls for three years after all the work on the prime contract is completed. The record retention provision at 29 CFR 5.5(a)(3)(i) requires contractors performing work on projects subject to the Davis-Bacon and Related Acts (DBRA) to retain the address, telephone number, email address, and social security number of each covered worker, in addition to all of the worker-specific information that must be included on the weekly certified payroll. In addition, whenever a contractor seeks to provide a portion of its required fringe benefits though an unfunded plan (as described in 29 CFR 5.5(a)(1)(v)), the contractor must maintain records showing that the commitment to provide such benefits is enforceable, that the plan or program is financially responsible, that the plan or program has been communicated in writing to the laborers or mechanics affected, and the costs anticipated or the actual cost incurred in providing such benefits. See 29 CFR 5.5(a)(3)(i)(C). Contractors employing apprentices or trainees under approved programs also must maintain written evidence of the registration of apprenticeship programs and certification of trainee programs, the registration of the apprentices and trainees, and the ratios and wage rates prescribed in the applicable programs. Id. § 5.5(a)(3)(i)(D). 29 CFR 5.5(a)(3)(iii) provides that contractors and subcontractors must maintain copies of covered contracts, subcontracts, and related documents.
                </P>
                <P>
                    The Department periodically reviews its information collection requests to ensure that they are necessary and sufficient to effectively and efficiently fulfill the Department's statutory directive to oversee and enforce the Davis-Bacon Act. Substantive edits to the WH-347 form were last made in 2011. The Department reviewed the current form WH-347 and proposed several edits. For additional substantive information about this ICR, see the related notice published in the 
                    <E T="04">Federal Register</E>
                     on August 30, 2024 (89 FR 70670).
                </P>
                <P>
                    <E T="03">Comments are invited on:</E>
                     (1) whether the collection of information is necessary for the proper performance of the functions of the Department, including whether the information will have practical utility; (2) the accuracy of the agency's estimates of the burden and cost of the collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility and clarity of the information collection; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of automated collection techniques or other forms of information technology.
                </P>
                <P>
                    This information collection is subject to the PRA. A Federal agency generally cannot conduct or sponsor a collection of information, and the public is generally not required to respond to an information collection, unless the OMB approves it and displays a currently valid OMB Control Number. In addition, notwithstanding any other provisions of law, no person shall generally be subject to penalty for failing to comply with a collection of information that does not display a valid OMB Control Number. 
                    <E T="03">See</E>
                     5 CFR 1320.5(a) and 1320.6.
                </P>
                <P>DOL seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years without renewal. The DOL notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.</P>
                <P>
                    <E T="03">Agency:</E>
                     DOL-WHD.
                </P>
                <P>
                    <E T="03">Title of Collection:</E>
                     Davis-Bacon Certified Payroll.
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     1235-0008.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Businesses or other for-profits, Farms.
                </P>
                <P>
                    <E T="03">Total Estimated Number of Respondent:</E>
                     11,310,112.
                </P>
                <P>
                    <E T="03">Total Estimated Number of Responses:</E>
                     122,936.
                </P>
                <P>
                    <E T="03">Total Estimated Annual Time Burden:</E>
                     10,556,105 hours.
                </P>
                <P>
                    <E T="03">Total Estimated Annual Other Costs Burden:</E>
                     $0.
                </P>
                <EXTRACT>
                    <FP>(Authority: 44 U.S.C. 3507(a)(1)(D))</FP>
                </EXTRACT>
                <SIG>
                    <NAME>Nora Hernandez,</NAME>
                    <TITLE>PRA Department Clearance Officer.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27720 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4510-27-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF LABOR</AGENCY>
                <SUBJECT>Agency Information Collection Activities; Submission for OMB Review; Comment Request; Unemployment Insurance (UI) Title XII Advances and Voluntary Repayment Process</SUBJECT>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of availability; request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of Labor (DOL) is submitting this Employment and Training Administration (ETA)-sponsored information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). Public comments on the ICR are invited.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>The OMB will consider all written comments that the agency receives on or before December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Michael Howell by telephone at 202-693-6782, or by email at 
                        <E T="03">DOL_PRA_PUBLIC@dol.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    This information collection's purpose is to maintain a process for state governors for requesting advances and repaying advances through their correspondence with the Secretary of Labor. For additional substantive information about this ICR, see the related notice published in the 
                    <E T="04">Federal Register</E>
                     on May 9, 2024 (89 FR 39648).
                </P>
                <P>Comments are invited on: (1) whether the collection of information is necessary for the proper performance of the functions of the Department, including whether the information will have practical utility; (2) the accuracy of the agency's estimates of the burden and cost of the collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility and clarity of the information collection; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of automated collection techniques or other forms of information technology.</P>
                <P>
                    This information collection is subject to the PRA. A Federal agency generally cannot conduct or sponsor a collection of information, and the public is generally not required to respond to an information collection, unless the OMB approves it and displays a currently valid OMB Control Number. In addition, notwithstanding any other provisions of law, no person shall generally be subject to penalty for failing to comply with a collection of information that does not display a valid OMB Control Number. 
                    <E T="03">See</E>
                     5 CFR 1320.5(a) and 1320.6.
                </P>
                <P>
                    DOL seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years 
                    <PRTPAGE P="93666"/>
                    without renewal. The DOL notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.
                </P>
                <P>
                    <E T="03">Agency:</E>
                     DOL-ETA.
                </P>
                <P>
                    <E T="03">Title of Collection:</E>
                     Unemployment Insurance (UI) Title XII Advances and Voluntary Repayment Process.
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     1205-0199.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     State, Local and Tribal Governments.
                </P>
                <P>
                    <E T="03">Total Estimated Number of Respondents:</E>
                     4.
                </P>
                <P>
                    <E T="03">Total Estimated Number of Responses:</E>
                     12.
                </P>
                <P>
                    <E T="03">Total Estimated Annual Time Burden:</E>
                     12 hours.
                </P>
                <P>
                    <E T="03">Total Estimated Annual Other Costs Burden:</E>
                     $0.
                </P>
                <EXTRACT>
                    <FP>(Authority: 44 U.S.C. 3507(a)(1)(D))</FP>
                </EXTRACT>
                <SIG>
                    <NAME>Michael Howell,</NAME>
                    <TITLE>Senior Paperwork Reduction Act Analyst.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27719 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4510-FN-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF LABOR</AGENCY>
                <SUBAGY>Occupational Safety and Health Administration</SUBAGY>
                <DEPDOC>[Docket No. OSHA-2010-0055]</DEPDOC>
                <SUBJECT>Recordkeeping and Reporting Occupational Injuries and Illnesses; Revision of the Office of Management and Budget's (OMB) Approval of Information Collection (Paperwork) Requirements</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Occupational Safety and Health Administration (OSHA), Labor.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Request for public comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>OSHA solicits public comments concerning the proposed revision to combine two separate OMB approved Recordkeeping and Reporting Occupational Injuries and Illnesses Information Collections.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be submitted (postmarked, sent, or received) by January 27, 2025.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">Electronically:</E>
                         You may submit comments and attachments electronically at 
                        <E T="03">https://www.regulations.gov,</E>
                         which is the Federal eRulemaking Portal. Follow the instructions online for submitting comments.
                    </P>
                    <P>
                        <E T="03">Docket:</E>
                         To read or download comments or other material in the docket, go to 
                        <E T="03">https://www.regulations.gov.</E>
                         Documents in the docket are listed in the 
                        <E T="03">https://www.regulations.gov</E>
                         index; however, some information (
                        <E T="03">e.g.,</E>
                         copyrighted material) is not publicly available to read or download through the websites. All submissions, including copyrighted material, are available for inspection through the OSHA Docket Office. Contact the OSHA Docket Office at (202) 693-2350 (TTY (877) 889-5627) for assistance in locating docket submissions.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All submissions must include the agency name and OSHA docket number (OSHA-2010-0055) for the Information Collection Request (ICR). OSHA will place all comments, including any personal information, in the public docket, which may be made available online. Therefore, OSHA cautions interested parties about submitting personal information such as social security numbers and birthdates.
                    </P>
                    <P>
                        For further information on submitting comments, see the “Public Participation” heading in the section of this notice titled 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                        .
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Seleda Perryman, Directorate of Standards and Guidance, OSHA, U.S. Department of Labor; telephone (202) 693-2222.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">I. Background</HD>
                <P>
                    The Department of Labor, as part of the continuing effort to reduce paperwork and respondent (
                    <E T="03">i.e.,</E>
                     employer) burden, conducts a preclearance consultation program to provide the public with an opportunity to comment on proposed and continuing information collection requirements in accordance with the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3506(c)(2)(A)). This program ensures that information is in the desired format, reporting burden (time and costs) is minimal, the collection instruments are clearly understood, and OSHA's estimate of the information collection burden is accurate. The Occupational Safety and Health Act of 1970 (OSH Act) (29 U.S.C. 651 
                    <E T="03">et seq.</E>
                    ) authorizes information collection by employers as necessary or appropriate for enforcement of the OSH Act or for developing information regarding the causes and prevention of occupational injuries, illnesses, and accidents (29 U.S.C. 657). The OSH Act also requires that OSHA obtain such information with minimum burden upon employers, especially those operating small businesses, and to reduce to the maximum extent feasible unnecessary duplication of effort in obtaining information (29 U.S.C. 657).
                </P>
                <P>
                    The Agency requests a revision to incorporate the 
                    <E T="03">Improve Tracking of Workplace Injuries and Illnesses</E>
                     paperwork package, OMB Control Number 1218-0279, into the 
                    <E T="03">Recordkeeping and Reporting Occupational Injuries and Illnesses (29 CFR part 1904)</E>
                     paperwork package, OMB Control Number 1218-0176. While both paperwork packages contain information collections contained in the Recording and Reporting Occupational Injuries and Illnesses (29 CFR part 1904), a separate paperwork package for the Improve Tracking of Workplace Injuries and Illnesses rulemaking was necessary to ensure continued OMB approval of the existing information collections in the Recordkeeping and Reporting Occupational Injuries and Illnesses (29 CFR part 1904) paperwork package. The Occupational Safety and Health Act (OSH Act) and 29 CFR part 1904 prescribe that certain employers maintain records of job-related injuries and illnesses. Other employers with 100 or more employees in certain designated industries are required to submit electronically to OSHA information captured on their completed OSHA 300, 301, and 300A Forms. The injury and illness records are intended to have multiple purposes. One purpose is to provide data needed by OSHA to carry out enforcement and intervention activities to provide workers a safe and healthful work environment. Access to this data allows the Agency to more efficiently focus its enforcement and outreach resources toward establishments that are experiencing specific types of occupational injury and illness Expanded public access to establishment-specific, case-specific, injury and illness data will allow employers, employees, potential employees, employee representatives, customers, potential customers, researchers, and the general public to make informed decisions about the workplace safety and health at a given establishment, and this accessibility will ultimately result in the reduction of occupational injuries and illnesses.
                </P>
                <HD SOURCE="HD1">II. Special Issues for Comment</HD>
                <P>OSHA has a particular interest in comments on the following issues:</P>
                <P>• Whether the proposed information collection requirements are necessary for the proper performance of the agency's functions to protect workers, including whether the information is useful;</P>
                <P>• The accuracy of OSHA's estimate of the burden (time and costs) of the information collection requirements, including the validity of the methodology and assumptions used;</P>
                <P>
                    • The quality, utility, and clarity of the information collected; and
                    <PRTPAGE P="93667"/>
                </P>
                <P>• Ways to minimize the burden on employers who must comply; for example, by using automated or other technological information, and transmission techniques.</P>
                <HD SOURCE="HD1">III. Proposed Actions</HD>
                <P>OSHA is requesting a revision the currently approved collection of information requirements contained in the paperwork package for Recordkeeping and Reporting Occupational Injuries and Illnesses (29 CFR part 1904) by OMB. This revision is incorporating the collections of information contained in the paperwork package for Improve Tracking of Injuries and Illnesses, OMB Control Number 1218-0279, with the paperwork package for Recordkeeping and Reporting Occupational Injuries and Illnesses paperwork package, OMB Control Number 1218-0176. As a result, the agency is requesting a program change increase of 112,551 hours and an adjustment decrease of 5,934 hours the burden going from 2,167,111 to 2,161,177 hours.</P>
                <P>OSHA will summarize the comments submitted in response to this notice and will include this summary in the request to OMB to extend the approval of the information collection requirements.</P>
                <P>
                    <E T="03">Type of Review:</E>
                     Revision of a currently approved collection.
                </P>
                <P>
                    <E T="03">Title:</E>
                     Recordkeeping and Reporting Occupational Injuries and Illnesses (29 CFR part 1904).
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     1218-0176.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Business or other for-profits.
                </P>
                <P>
                    <E T="03">Number of Respondents:</E>
                     1,239,687.
                </P>
                <P>
                    <E T="03">Number of Responses:</E>
                     5,571,568.
                </P>
                <P>
                    <E T="03">Frequency of Responses:</E>
                     On occasion, Annual.
                </P>
                <P>
                    <E T="03">Average Time per Response:</E>
                     Varies.
                </P>
                <P>
                    <E T="03">Estimated Total Burden Hours:</E>
                     2,161,177.
                </P>
                <P>
                    <E T="03">Estimated Cost (Operation and Maintenance):</E>
                     $0.
                </P>
                <HD SOURCE="HD1">IV. Public Participation—Submission of Comments on This Notice and Internet Access to Comments and Submissions</HD>
                <P>
                    You may submit comments in response to this document as follows: (1) electronically at 
                    <E T="03">https://www.regulations.gov,</E>
                     which is the Federal eRulemaking Portal; or (2) by facsimile (fax), if your comments, including attachments, are not longer than 10 pages you may fax them to the OSHA Docket Office at (202) 693-1648. All comments, attachments, and other material must identify the agency name and the OSHA docket number for the ICR (Docket No. OSHA-2010-0055). You may supplement electronic submission by uploading document files electronically.
                </P>
                <P>
                    Comments and submissions are posted without change at 
                    <E T="03">https://www.regulations.gov.</E>
                     Therefore, OSHA cautions commenters about submitting personal information such as social security numbers and dates of birth. Although all submissions are listed in the 
                    <E T="03">https://www.regulations.gov</E>
                     index, some information (
                    <E T="03">e.g.,</E>
                     copyrighted material) is not publicly available to read or download from this website. All submission, including copyrighted material, are available for inspection and copying at the OSHA Docket Office. Information on using the 
                    <E T="03">https://www.regulations.gov</E>
                     website to submit comments and access the docket is available at the website's “User Tips” link.
                </P>
                <P>Contact the OSHA Docket Office at (202) 693-2350, (TTY (877) 889-5627) for information about materials not available from the website, and for assistance in using the internet to locate docket submissions.</P>
                <HD SOURCE="HD1">V. Authority and Signature</HD>
                <P>
                    James S. Frederick, Deputy Assistant Secretary of Labor for Occupational Safety and Health, directed the preparation of this notice. The authority for this notice is the Paperwork Reduction Act of 1995 (44 U.S.C. 3506 
                    <E T="03">et seq.</E>
                    ) and Secretary of Labor's Order No. 8-2020 (85 FR 58393).
                </P>
                <SIG>
                    <DATED>Signed at Washington, DC, on November 20, 2024.</DATED>
                    <NAME>James S. Frederick,</NAME>
                    <TITLE>Deputy Assistant Secretary of Labor for Occupational Safety and Health.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27718 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4510-26-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF LABOR</AGENCY>
                <SUBAGY>Occupational Safety and Health Administration</SUBAGY>
                <DEPDOC>[Docket No. OSHA-2024-0002]</DEPDOC>
                <SUBJECT>Advisory Committee on Construction Safety and Health (ACCSH)</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Occupational Safety and Health Administration (OSHA), Labor.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Request for Nominations.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Acting Secretary of Labor requests nominations for membership on the Advisory Committee for Construction Safety and Health (ACCSH).</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Submit nominations for ACCSH membership by January 2, 2025.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">Nominations:</E>
                         You must submit nominations and supporting materials, identified by Docket No. OSHA-2024-0002, electronically at 
                        <E T="03">https://www.regulations.gov,</E>
                         which is the Federal e-Rulemaking Portal. Follow the online instructions for submissions.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All submissions must include the agency name and the OSHA docket number for this 
                        <E T="04">Federal Register</E>
                         notice (Docket No. OSHA-2024-0002). OSHA will post all submissions, including personal information, in the public docket without change, which may be made available online at 
                        <E T="03">https://www.regulations.gov</E>
                        . Therefore, OSHA cautions interested parties about submitting information they do not want made available to the public or submitting materials that contain personal information (either about themselves or others), such as Social Security numbers and birthdates. For further information on submitting nominations, see the “Submission requirements” heading in the section of this notice titled 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                        .
                    </P>
                    <P>
                        <E T="03">Docket:</E>
                         To read or download nominations or other materials in the docket, go to 
                        <E T="03">https://www.regulations.gov</E>
                        . Documents in the docket are listed in the 
                        <E T="03">https://www.regulations.gov</E>
                         index; however, some information (
                        <E T="03">e.g.,</E>
                         copyrighted material) is not publicly available to read or download through the website. All submissions, including copyrighted material, are available for inspection through the OSHA Docket Office. Contact the OSHA Docket Office at (202) 693-2350 (TTY number: (877) 889-5627) for assistance in locating docket submissions.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P/>
                    <P>
                        <E T="03">For press inquiries:</E>
                         Mr. Frank Meilinger, Director, OSHA Office of Communications; telephone: (202) 693-1999; email: 
                        <E T="03">meilinger.francis2@dol.gov</E>
                        .
                    </P>
                    <P>
                        <E T="03">For general information about ACCSH and ACCSH membership:</E>
                         Mr. Jose Hererra, OSHA, Directorate of Construction; telephone: (202) 693-2020; email: 
                        <E T="03">herrera.jose.h@dol.gov</E>
                        .
                    </P>
                    <P>
                        <E T="03">Copies of this</E>
                          
                        <E T="7462">Federal Register</E>
                          
                        <E T="03">document:</E>
                         Electronic copies of this 
                        <E T="04">Federal Register</E>
                         document are available at 
                        <E T="03">https://www.regulations.gov</E>
                        . This document, as well as news releases and other relevant information are also available on the OSHA web page at 
                        <E T="03">https://www.osha.gov/</E>
                        .
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The Secretary of Labor invites interested persons to submit nominations for membership on ACCSH.</P>
                <HD SOURCE="HD1">A. Background</HD>
                <P>
                    ACCSH advises the Secretary of Labor and the Assistant Secretary of Labor for 
                    <PRTPAGE P="93668"/>
                    Occupational Safety and Health (Assistant Secretary) in the formulation of standards affecting the construction industry, and on policy matters arising in the administration of the safety and health provisions under the Contract Work Hours and Safety Standards Act (Construction Safety Act (CSA)) (40 U.S.C. 3701 
                    <E T="03">et seq.</E>
                    ) and the Occupational Safety and Health Act of 1970 (OSH Act) (29 U.S.C. 651 
                    <E T="03">et seq.</E>
                    ) (see also 29 CFR 1911.10 and 1912.3). In addition, the CSA and OSHA regulations require the Assistant Secretary to consult with ACCSH before the agency proposes occupational safety and health standards affecting construction activities (40 U.S.C. 3704; 29 CFR 1911.10).
                </P>
                <P>
                    ACCSH operates in accordance with the Federal Advisory Committee Act (FACA), as amended (5 U.S.C. 1001, 
                    <E T="03">et seq.</E>
                    ), and the implementing regulations (41 CFR 102-3 
                    <E T="03">et seq.</E>
                    ); and Department of Labor Manual Series Chapter 1-900 (3/25/2022). ACCSH generally meets two to four times a year.
                </P>
                <HD SOURCE="HD1">B. ACCSH Membership</HD>
                <P>ACCSH consists of 15 members whom the Secretary appoints. ACCSH members generally serve two-year terms, unless they resign, cease to be qualified, become unable to serve, or the Secretary removes them (29 CFR 1912.3(e)). The Secretary may appoint ACCSH members to successive terms. No member of ACCSH, other than members who represent employers or employees, shall have an economic interest in any proposed rule that affects the construction industry (29 CFR 1912.6).</P>
                <P>The categories of ACCSH membership are, and number of new members to be appointed to replace members whose terms will expire are:</P>
                <P>• Five members who are qualified by experience and affiliation to present the viewpoint of employers in the construction industry-five employer representatives will be appointed;</P>
                <P>• Five members who are similarly qualified to present the viewpoint of employees in the construction industry-five employee representatives will be appointed;</P>
                <P>• Two representatives of State safety and health agencies-two representatives from a State safety and health agency will be appointed;</P>
                <P>• Two public members, qualified by knowledge and experience to make a useful contribution to the work of ACCSH, such as those who have professional or technical experience and competence with occupational safety and health in the construction industry-two public representatives will be appointed; and</P>
                <P>• One representative designated by the Secretary of the Department of Health and Human Services and appointed by the Secretary-no new appointment will be made.</P>
                <P>Any interested person or organization may nominate one or more individuals for membership on ACCSH. Interested persons also are invited and encouraged to submit statements in support of nominees.</P>
                <HD SOURCE="HD1">C. Submission Requirements</HD>
                <P>Nominations must include the following information:</P>
                <P>• Nominee's contact information and current employment or position;</P>
                <P>• Nominee's résumé or curriculum vitae, including prior membership on ACCSH and other relevant organizations and associations;</P>
                <P>• Category of membership (employer, employee, public, State safety and health agency) that the nominee is qualified to represent;</P>
                <P>• A summary of the background, experience, and qualifications that addresses the nominee's suitability for each of the nominated membership categories;</P>
                <P>• Articles or other documents the nominee has authored that indicate the nominee's knowledge, experience, and expertise in occupational safety and health, particularly as it pertains to the construction industry; and</P>
                <P>• A statement that the nominee is aware of the nomination, is willing to regularly attend and participate in ACCSH meetings and has no conflicts of interest that would preclude membership on ACCSH.</P>
                <HD SOURCE="HD1">D. Member Selection</HD>
                <P>
                    The Department of Labor is committed to equal opportunity in the workplace and seeks broad-based and diverse ACCSH membership. To the extent permitted by FACA and other laws, ACCSH membership will be consistent with achieving the greatest impact, scope, and credibility among diverse stakeholders. The diversity in such membership includes, but is not limited to, race, sex, disability, sexual orientation, and gender identity. The Secretary will select the ACCSH members on the basis of their experience, knowledge, and competence in the field of occupational safety and health, particularly as it pertains to the construction industry. Information received through this nomination process, in addition to other relevant sources of information, will assist the Secretary in making these appointments to ACCSH. The Secretary will consider individuals nominated in response to this 
                    <E T="04">Federal Register</E>
                     document, as well as other qualified individuals, in selecting members to ACCSH. OSHA will publish a list of ACCSH members in the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <HD SOURCE="HD1">Authority and Signature</HD>
                <P>
                    James S. Frederick, Deputy Assistant Secretary of Labor for Occupational Safety and Health, authorized the preparation of this notice pursuant to 29 U.S.C. 655, 40 U.S.C. 3704, Secretary of Labor's Order No. 8-2020 (85 FR 58393), 5 U.S.C. 1001, 
                    <E T="03">et seq.,</E>
                     and 29 CFR part 1912.
                </P>
                <SIG>
                    <DATED>Signed at Washington, DC, on November 21, 2024.</DATED>
                    <NAME>James S. Frederick,</NAME>
                    <TITLE>Deputy Assistant Secretary of Labor for Occupational Safety and Health.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27822 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4510-26-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">POSTAL REGULATORY COMMISSION</AGENCY>
                <DEPDOC>[Docket Nos. MC2025-459 and K2025-456; MC2025-460 and K2025-457; MC2025-461 and K2025-458; MC2025-462 and K2025-459; MC2025-463 and K2025-460; MC2025-464 and K2025-461; MC2025-465 and K2025-462; MC2025-466 and K2025-463]</DEPDOC>
                <SUBJECT>New Postal Products</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Postal Regulatory Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Commission is noticing a recent Postal Service filing for the Commission's consideration concerning a negotiated service agreement. This notice informs the public of the filing, invites public comment, and takes other administrative steps.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        <E T="03">Comments are due:</E>
                         December 2, 2024.
                    </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit comments electronically via the Commission's Filing Online system at 
                        <E T="03">http://www.prc.gov.</E>
                         Those who cannot submit comments electronically should contact the person identified in the 
                        <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                         section by telephone for advice on filing alternatives.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>David A. Trissell, General Counsel, at 202-789-6820.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Table of Contents</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">I. Introduction</FP>
                    <FP SOURCE="FP-2">II. Public Proceeding(s)</FP>
                    <FP SOURCE="FP-2">III. Summary Proceeding(s) </FP>
                </EXTRACT>
                <HD SOURCE="HD1">I. Introduction</HD>
                <P>
                    Pursuant to 39 CFR 3041.405, the Commission gives notice that the Postal 
                    <PRTPAGE P="93669"/>
                    Service filed request(s) for the Commission to consider matters related to Competitive negotiated service agreement(s). The request(s) may propose the addition of a negotiated service agreement from the Competitive product list or the modification of an existing product currently appearing on the Competitive product list.
                </P>
                <P>
                    The public portions of the Postal Service's request(s) can be accessed via the Commission's website (
                    <E T="03">http://www.prc.gov</E>
                    ). Non-public portions of the Postal Service's request(s), if any, can be accessed through compliance with the requirements of 39 CFR 3011.301.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See</E>
                         Docket No. RM2018-3, Order Adopting Final Rules Relating to Non-Public Information, June 27, 2018, Attachment A at 19-22 (Order No. 4679).
                    </P>
                </FTNT>
                <P>Section II identifies the docket number(s) associated with each Postal Service request, if any, that will be reviewed in a public proceeding as defined by 39 CFR 3010.101(p), the title of each such request, the request's acceptance date, and the authority cited by the Postal Service for each request. For each such request, the Commission appoints an officer of the Commission to represent the interests of the general public in the proceeding, pursuant to 39 U.S.C. 505 and 39 CFR 3000.114 (Public Representative). Section II also establishes comment deadline(s) pertaining to each such request.</P>
                <P>The Commission invites comments on whether the Postal Service's request(s) identified in Section II, if any, are consistent with the policies of title 39. Applicable statutory and regulatory requirements include 39 U.S.C. 3632, 39 U.S.C. 3633, 39 U.S.C. 3642, 39 CFR part 3035, and 39 CFR part 3041. Comment deadline(s) for each such request, if any, appear in Section II.</P>
                <P>
                    Section III identifies the docket number(s) associated with each Postal Service request, if any, to add a standardized distinct product to the Competitive product list or to amend a standardized distinct product, the title of each such request, the request's acceptance date, and the authority cited by the Postal Service for each request. Standardized distinct products are negotiated service agreements that are variations of one or more Competitive products, and for which financial models, minimum rates, and classification criteria have undergone advance Commission review. 
                    <E T="03">See</E>
                     39 CFR 3041.110(n); 39 CFR 3041.205(a). Such requests are reviewed in summary proceedings pursuant to 39 CFR 3041.325(c)(2) and 39 CFR 3041.505(f)(1). Pursuant to 39 CFR 3041.405(c)-(d), the Commission does not appoint a Public Representative or request public comment in proceedings to review such requests.
                </P>
                <HD SOURCE="HD1">II. Public Proceeding(s)</HD>
                <P>
                    1. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-459 and K2025-456; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 766 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 20, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Kenneth Moeller; 
                    <E T="03">Comments Due:</E>
                     December 2, 2024.
                </P>
                <P>
                    2. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-460 and K2025-457; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail &amp; USPS Ground Advantage Contract 473 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 20, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Kenneth Moeller; 
                    <E T="03">Comments Due:</E>
                     December 2, 2024.
                </P>
                <P>
                    3. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-461 and K2025-458; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 767 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 20, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Kenneth Moeller; 
                    <E T="03">Comments Due:</E>
                     December 2, 2024.
                </P>
                <P>
                    4. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-462 and K2025-459; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 768 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 20, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Jana Slovinska; 
                    <E T="03">Comments Due:</E>
                     December 2, 2024.
                </P>
                <P>
                    5. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-463 and K2025-460; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 769 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 20, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Jana Slovinska; 
                    <E T="03">Comments Due:</E>
                     December 2, 2024.
                </P>
                <P>
                    6. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-464 and K2025-461; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 770 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 20, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Almaroof Agoro; 
                    <E T="03">Comments Due:</E>
                     December 2, 2024.
                </P>
                <P>
                    7. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-465 and K2025-462; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail &amp; USPS Ground Advantage Contract 474 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 20, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Almaroof Agoro; 
                    <E T="03">Comments Due:</E>
                     December 2, 2024.
                </P>
                <P>
                    8. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-466 and K2025-463; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 771 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 20, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Almaroof Agoro; 
                    <E T="03">Comments Due:</E>
                     December 2, 2024.
                </P>
                <HD SOURCE="HD1">III. Summary Proceeding(s)</HD>
                <P>
                    None. 
                    <E T="03">See</E>
                     Section II for public proceedings.
                </P>
                <P>
                    This Notice will be published in the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <SIG>
                    <NAME>Erica A. Barker,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27726 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 7710-FW-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">POSTAL REGULATORY COMMISSION</AGENCY>
                <DEPDOC>[Docket Nos. MC2025-467 and K2025-464; MC2025-468 and K2025-465; MC2025-469 and K2025-466; MC2025-470 and K2025-467; MC2025-471 and K2025-468; MC2025-472 and K2025-469; MC2025-473 and K2025-470; MC2025-474 and K2025-471; MC2025-475 and K2025-472; MC2025-476 and K2025-473; MC2025-478 and K2025-475; MC2025-479 and K2025-476; MC2025-480 and K2025-477; MC2025-481 and K2025-478; MC2025-482 and K2025-479]</DEPDOC>
                <SUBJECT>New Postal Products</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Postal Regulatory Commission.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Commission is noticing a recent Postal Service filing for the Commission's consideration concerning a negotiated service agreement. This notice informs the public of the filing, invites public comment, and takes other administrative steps.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        <E T="03">Comments are due:</E>
                         December 3, 2024.
                    </P>
                </DATES>
                <ADD>
                    <PRTPAGE P="93670"/>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submit comments electronically via the Commission's Filing Online system at 
                        <E T="03">http://www.prc.gov.</E>
                         Those who cannot submit comments electronically should contact the person identified in the 
                        <E T="02">FOR FURTHER INFORMATION CONTACT</E>
                         section by telephone for advice on filing alternatives.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>David A. Trissell, General Counsel, at 202-789-6820.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Table of Contents</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">I. Introduction</FP>
                    <FP SOURCE="FP-2">II. Public Proceeding(s)</FP>
                    <FP SOURCE="FP-2">III. Summary Proceeding(s)</FP>
                </EXTRACT>
                <HD SOURCE="HD1">I. Introduction</HD>
                <P>Pursuant to 39 CFR 3041.405, the Commission gives notice that the Postal Service filed request(s) for the Commission to consider matters related to Competitive negotiated service agreement(s). The request(s) may propose the addition of a negotiated service agreement from the Competitive product list or the modification of an existing product currently appearing on the Competitive product list.</P>
                <P>
                    The public portions of the Postal Service's request(s) can be accessed via the Commission's website (
                    <E T="03">http://www.prc.gov</E>
                    ). Non-public portions of the Postal Service's request(s), if any, can be accessed through compliance with the requirements of 39 CFR 3011.301.
                    <SU>1</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         
                        <E T="03">See</E>
                         Docket No. RM2018-3, Order Adopting Final Rules Relating to Non-Public Information, June 27, 2018, Attachment A at 19-22 (Order No. 4679).
                    </P>
                </FTNT>
                <P>Section II identifies the docket number(s) associated with each Postal Service request, if any, that will be reviewed in a public proceeding as defined by 39 CFR 3010.101(p), the title of each such request, the request's acceptance date, and the authority cited by the Postal Service for each request. For each such request, the Commission appoints an officer of the Commission to represent the interests of the general public in the proceeding, pursuant to 39 U.S.C. 505 and 39 CFR 3000.114 (Public Representative). Section II also establishes comment deadline(s) pertaining to each such request.</P>
                <P>The Commission invites comments on whether the Postal Service's request(s) identified in Section II, if any, are consistent with the policies of title 39. Applicable statutory and regulatory requirements include 39 U.S.C. 3632, 39 U.S.C. 3633, 39 U.S.C. 3642, 39 CFR part 3035, and 39 CFR part 3041. Comment deadline(s) for each such request, if any, appear in Section II.</P>
                <P>
                    Section III identifies the docket number(s) associated with each Postal Service request, if any, to add a standardized distinct product to the Competitive product list or to amend a standardized distinct product, the title of each such request, the request's acceptance date, and the authority cited by the Postal Service for each request. Standardized distinct products are negotiated service agreements that are variations of one or more Competitive products, and for which financial models, minimum rates, and classification criteria have undergone advance Commission review. 
                    <E T="03">See</E>
                     39 CFR 3041.110(n); 39 CFR 3041.205(a). Such requests are reviewed in summary proceedings pursuant to 39 CFR 3041.325(c)(2) and 39 CFR 3041.505(f)(1). Pursuant to 39 CFR 3041.405(c)-(d), the Commission does not appoint a Public Representative or request public comment in proceedings to review such requests.
                </P>
                <HD SOURCE="HD1">II. Public Proceeding(s)</HD>
                <P>
                    1. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-467 and K2025-464; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail &amp; USPS Ground Advantage Contract 475 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Gregory Stanton; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    2. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-468 and K2025-465; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail &amp; USPS Ground Advantage Contract 476 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Gregory Stanton; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    3. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-469 and K2025-466; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail &amp; USPS Ground Advantage Contract 477 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Gregory Stanton; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    4. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-470 and K2025-467; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 772 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Christopher Mohr; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    5. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-471 and K2025-468; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 773 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Christopher Mohr; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    6. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-472 and K2025-469; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 774 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Christopher Mohr; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    7. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-473 and K2025-470; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 775 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Katalin Clendenin; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    8. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-474 and K2025-471; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 776 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Almaroof Agoro; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    9. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-475 and K2025-472; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 777 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Almaroof Agoro; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    10. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-476 and K2025-473; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage 
                    <PRTPAGE P="93671"/>
                    Contract 778 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Almaroof Agoro; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    11. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-478 and K2025-475; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail &amp; USPS Ground Advantage Contract 479 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Jennaca Upperman; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    12. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-479 and K2025-476; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail &amp; USPS Ground Advantage Contract 480 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Jennaca Upperman; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    13. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-480 and K2025-477; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 779 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Maxine Bradley; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    14. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-481 and K2025-478; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 780 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Maxine Bradley; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <P>
                    15. 
                    <E T="03">Docket No(s).:</E>
                     MC2025-482 and K2025-479; 
                    <E T="03">Filing Title:</E>
                     USPS Request to Add Priority Mail Express, Priority Mail &amp; USPS Ground Advantage Contract 781 to the Competitive Product List and Notice of Filing Materials Under Seal; 
                    <E T="03">Filing Acceptance Date:</E>
                     November 21, 2024; 
                    <E T="03">Filing Authority:</E>
                     39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; 
                    <E T="03">Public Representative:</E>
                     Maxine Bradley; 
                    <E T="03">Comments Due:</E>
                     December 3, 2024.
                </P>
                <HD SOURCE="HD1">III. Summary Proceeding(s)</HD>
                <P>
                    None. 
                    <E T="03">See</E>
                     Section II for public proceedings.
                </P>
                <P>
                    This Notice will be published in the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <SIG>
                    <NAME>Erica A. Barker,</NAME>
                    <TITLE>Secretary.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27881 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 7710-FW-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">OFFICE OF SCIENCE AND TECHNOLOGY POLICY</AGENCY>
                <SUBJECT>Notice of Request for Information; Downscaled Climate Projection Datasets Available To Be Considered for Use in the Sixth National Climate Assessment</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Science and Technology Policy (OSTP).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Request for Information (RFI).</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>With this notice, the U.S. Global Change Research Program (USGCRP) is issuing a Request for Information (RFI) on downscaled climate projection datasets for possible use in the 6th National Climate Assessment (NCA6). USGCRP will use the information submitted in response to this RFI to identify downscaled datasets that may be used by NCA6 authors at their discretion and to develop an updated data atlas for NCA6.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments and nominations must be submitted to the web address specified below and received on or before January 17th, 2025.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Submitted information will be accepted electronically via the USGCRP Public Contribution System: 
                        <E T="03">https://contribute.globalchange.gov.</E>
                         Instructions for submitting comments are available on the website.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Aaron Grade (202) 419-3488, 
                        <E T="03">agrade@usgcrp.gov,</E>
                         U.S. Global Change Research Program.
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The Global Change Research Act (GCRA) of 1990 mandates that USGCRP deliver a National Climate Assessment to Congress and the President not less frequently than every four years that “(1) integrates, evaluates, and interprets the findings of the Program; (2) analyzes the effects of global change on the natural environment, agriculture, energy production and use, land and water resources, transportation, human health and welfare, human social systems, and biological diversity; and (3) analyzes current trends in global change, both human-induced and natural, and projects major trends for the subsequent 25 to 100 years.” One of the ways that projected changes across the United States are assessed is through the use of downscaled datasets, which are used by chapter author teams to support their understanding of the future impacts of climate change in each of the 50 states and in the U.S. territories so as to inform the assessment findings, narrative texts, and figures.</P>
                <P>
                    To date, five NCAs have been released. The most recent (NCA5) was released in November 2023, and can be found at 
                    <E T="03">https://nca2023.globalchange.gov.</E>
                     NCA6 is being developed in a way that maximizes transparency and inclusivity, offering opportunities for diverse public participation throughout the process. The production and review processes are designed to result in a report that is authoritative, timely, relevant, and policy-neutral; valued by authors and users; accessible to the widest possible audience; and fully compliant with the GCRA and federal Information Quality Act requirements.
                </P>
                <P>
                    A previous 
                    <E T="04">Federal Register</E>
                     Notice (
                    <E T="03">https://www.federalregister.gov/documents/2024/05/02/2024-09575/national-oceanic-and-atmospheric-administration-noaa-availability-for-public-comment-on-nca6-draft</E>
                    ) called for public input on themes, information for assessment, and volunteers to participate in the NCA6 development process. This RFI asks for input from the public on the availability of downscaled climate projection datasets that would advance NCA's efforts to inform decisions at more localized scales.
                </P>
                <P>This voluntary request for information is intended to support USGCRP's selection, processing, aggregation, and use of downscaled data in NCA6. NCA6 is currently under development, and it is projected to be publicly released between late 2027 and early 2028. USGCRP intends to use information from this RFI to plan for the appropriate volume and methods of data processing, aggregation, and data display techniques that reflect the expected increase in breadth of downscaled datasets that could be contributed to NCA6.</P>
                <P>
                    Information submitted through this form will be reviewed by a federal interagency group tasked with making recommendations to report leadership for appropriate downscaled datasets for use in NCA6. The USGCRP anticipates this process will require an ongoing dialogue with the groups that provide the selected downscaled datasets and has designed it to be as flexible as possible to be inclusive, while also mindful of NCA6 requirements as a Highly Influential Scientific Assessment. Responses to this request 
                    <PRTPAGE P="93672"/>
                    are strongly encouraged and will serve as a starting point for this dialogue.
                </P>
                <P>
                    Information submissions will be accepted electronically via the USGCRP Public Contribution System: 
                    <E T="03">https://contribute.globalchange.gov.</E>
                     Instructions for submitting technical inputs are available on the website. Submitters may enter text or upload files in response to this notice. See 
                    <E T="03">https://www.globalchange.gov/nca6</E>
                     for more information. While submissions to this RFI are not required, they are highly encouraged for consideration for inclusion in NCA6. If you wish to submit a downscaled data set to the NCA6 for consideration outside of this RFI, please contact Aaron Grade, 
                    <E T="03">agrade@usgcrp.gov</E>
                     no later than March 1, 2025.
                </P>
                <P>
                    Please note that submission in response to this RFI is entirely voluntary. More information, as well as information on asking questions beforehand, is available at 
                    <E T="03">https://www.globalchange.gov/nca6.</E>
                     Please also note that responses to this RFI may be made public as needed at USGCRP's discretion.
                </P>
                <P>
                    Via a questionnaire, submitters can provide the requested information on appropriate datasets that are either completed or in progress. Creation of these datasets may use statistical, dynamical, or other techniques, but are expected to be based on the latest generation of global climate models (GCMs) used in the Coupled Model Intercomparison Project—Phase 6 (CMIP6). NCA6 will prioritize the inclusion of datasets that fully encompass the entire conterminous United States and/or specialize in or incorporate U.S. regions outside of the conterminous United States (
                    <E T="03">i.e.,</E>
                     Alaska, Hawai'i, U.S.-Affiliated Pacific Islands, Puerto Rico, and/or the U.S. Virgin Islands) using a consistent and peer-reviewed technique. In addition to seeking details on dataset attributes, the USGCRP Public Contribution System (
                    <E T="03">https://contribute.globalchange.gov</E>
                    ) includes important requirements and considerations for the NCA timeline and project management.
                </P>
                <P>Given limited resources, considerations of overall fit for NCA priorities, and scientific rigor, NCA6 may not include all information submitted to through this RFI. Report leadership will make the final decision regarding datasets used in NCA6, including potentially combining information from multiple products. If a submission is identified as relevant for potential use, USGCRP will engage with the submitter to develop and format datasets and metadata for use. This process is expected to become a recurring opportunity that will accommodate the evolving science and the rapid expansion of downscaling approaches and products for future NCAs and other federal products.</P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Stacy Murphy,</NAME>
                    <TITLE>Deputy Chief Operations Officer/Security Officer.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27858 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 3270-F1-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101701; File No. SR-PEARL-2024-52]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; MIAX PEARL, LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend Exchange Rule 402, Criteria for Underlying Securities, Exchange To Allow the Exchange To List and Trade Options on the iShares Bitcoin Trust (the “Trust”)</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to the provisions of Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) 
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 18, 2024, MIAX PEARL, LLC (“MIAX Pearl” or “Exchange”) filed with the Securities and Exchange Commission (“Commission”) a proposed rule change as described in Items I and II below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>The Exchange is filing a proposal to amend Exchange Rule 402, Criteria for Underlying Securities.</P>
                <P>
                    The text of the proposed rule change is available on the Exchange's website at 
                    <E T="03">https://www.miaxglobal.com/markets/us-equities/pearl-equities/rule-filings,</E>
                     at MIAX Pearl's principal office, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    The Exchange proposes to amend Exchange Rule 402, Criteria for Underlying Securities,
                    <SU>3</SU>
                    <FTREF/>
                     to allow the Exchange to list and trade options on the iShares Bitcoin Trust (the “Trust”), designating the Trust as appropriate for options trading on the Exchange.
                    <SU>4</SU>
                    <FTREF/>
                     This is a competitive filing based on a similar proposal submitted by Nasdaq ISE, LLC (“ISE”) and approved by the Securities and Exchange Commission (“Commission”).
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The Exchange notes that its affiliate exchanges, MIAX Options and MIAX Sapphire, submitted substantively identical proposals. The Exchange notes that all the rules of Chapter III of the MIAX Options Exchange, including Rules 307 and 309, are incorporated by reference to MIAX Pearl and MIAX Sapphire. The Exchange also notes that all of the rules of Chapter III of the MIAX Options Exchange, including Rules 307 and 309, and the rules of Chapter IV of the MIAX Options Exchange, including Rule 402, are incorporated by reference to MIAX Emerald.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         On January 10, 2024, the Commission approved proposals by NYSE Arca, Inc., The Nasdaq Stock Market LLC, and Cboe BZX Exchange, Inc. to list and trade the shares of 11 bitcoin-based commodity-based trust shares and trust units, including the iShares Bitcoin Trust. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99306 (Jan. 10, 2024), 89 FR 3008 (Jan. 17, 2024) (order approving File Nos. SR-NYSEARCA-2021-90; SR-NYSEARCA-2023-44; SR-NYSEARCA-2023-58; SR-NASDAQ-2023-016; SR-NASDAQ-2023-019; SR-CboeBZX-2023-028; SR-CboeBZX-2023-038; SR-CboeBZX-2023-040; SR-CboeBZX-2023-042; SR-CboeBZX-2023-044; SR-CboeBZX-2023-072) (“Bitcoin ETP Order”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 101128 (September 20, 2024), 89 FR 78942 (September 26, 2024) (SR-ISE-2024-03) (Self-Regulatory Organizations; Nasdaq ISE, LLC; Notice of Filing of Amendment Nos. 4 and 5 and Order Granting Accelerated Approval of a Proposed Rule Change, as Modified by Amendment Nos. 1, 4, and 5, to Permit the Listing and Trading of Options on the iShares Bitcoin Trust).
                    </P>
                </FTNT>
                <P>
                    Current Exchange Rule 402(i)(4) provides that securities deemed appropriate for options trading include shares or other securities (“Exchange Traded Fund Shares”) that are traded on a national securities exchange and are defined as “NMS stock” under Rule 600 of Regulation NMS, and that meet specified criteria enumerated in the rule. Sub Section 4 of Exchange Rule 402(i) provides that such shares or other securities:
                    <PRTPAGE P="93673"/>
                </P>
                <P>(4) are issued by the SPDR® Gold Trust or the iShares COMEX Gold Trust or the iShares Silver Trust or the ETFS Silver Trust or the ETFS Gold Trust or the ETFS Palladium Trust or the ETFS Platinum Trust or the Sprott Physical Gold Trust; or</P>
                <P>In addition, the underlying securities and Exchange Rule 402i, including the commodity based trusts in Exchange Rule 402(i)(4), must meet the requirements of Exchange Rule 402(i), Sections i(5)(i)(A) or (B).</P>
                <HD SOURCE="HD3">Proposal</HD>
                <P>The Exchange proposes to amend Exchange Rule 402(i)(4) to expand the list of securities that are appropriate for options trading on the Exchange .</P>
                <HD SOURCE="HD3">
                    Description of the Trust 
                    <SU>6</SU>
                    <FTREF/>
                </HD>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99306 (Jan. 10, 2024), 89 FR 3008 (Jan. 17, 2024) (order approving File Nos. SR-NYSEARCA-2021-90; SR-NYSEARCA-2023-44; SR-NYSEARCA-2023-58; SR-NASDAQ-2023-016; SR-NASDAQ-2023-019; SR-CboeBZX-2023-028; SR-CboeBZX-2023-038; SR-CboeBZX-2023-040; SR-CboeBZX-2023-042; SR-CboeBZX-2023-044; SR-CboeBZX-2023-072)(Order Granting Accelerated Approval of Proposed Rule Changes, as Modified by Amendments Thereto, To List and Trade Bitcoin-Based Commodity-Based Trust Shares and Trust Units) for a complete description of the Trust.
                    </P>
                </FTNT>
                <P>The shares are issued by the Trust, a Delaware statutory trust. The Trust operates pursuant to a trust agreement (the “Trust Agreement”) between the Sponsor, BlackRock Fund Advisors (the “Trustee”) as the trustee of the Trust and Wilmington Trust, National Association, as Delaware trustee. The Trust issues shares representing fractional undivided beneficial interests in its net assets. The assets of the Trust consist only of bitcoin, held by a custodian on behalf of the Trust except under limited circumstances when transferred through the Trust's prime broker temporarily (described below), and cash. Coinbase Custody Trust Company, LLC (the “Bitcoin Custodian”) is the custodian for the Trust's bitcoin holdings, and maintains a custody account for the Trust (“Custody Account”); Coinbase, Inc. (the “Prime Execution Agent”), an affiliate of the Bitcoin Custodian, is the prime broker for the Trust and maintains a trading account for the Trust (“Trading Account”); and Bank of New York Mellon is the custodian for the Trust's cash holdings (the “Cash Custodian” and together with the Bitcoin Custodian, the “Custodians”) and the administrator of the Trust (the “Trust Administrator”). Under the Trust Agreement, the Trustee may delegate all or a portion of its duties to any agent, and has delegated the bulk of the day to day responsibilities to the Trust Administrator and certain other administrative and record-keeping functions to its affiliates and other agents. The Trust is not an investment company registered under the Investment Company Act of 1940, as amended.</P>
                <P>The investment objective of the Trust is to reflect generally the performance of the price of bitcoin. The Trust seeks to reflect such performance before payment of the Trust's expenses and liabilities. The shares are intended to constitute a simple means of making an investment similar to an investment in bitcoin through the public securities market rather than by acquiring, holding and trading bitcoin directly on a peer-to-peer or other basis or via a digital asset exchange. The shares have been designed to remove the obstacles represented by the complexities and operational burdens involved in a direct investment in bitcoin, while at the same time having an intrinsic value that reflects, at any given time, the investment exposure to the bitcoin owned by the Trust at such time, less the Trust's expenses and liabilities. Although the shares are not the exact equivalent of a direct investment in bitcoin, they provide investors with an alternative method of achieving investment exposure to bitcoin through the public securities market, which may be more familiar to them.</P>
                <HD SOURCE="HD3">Custody of the Trust's Bitcoin</HD>
                <P>
                    An investment in the shares is backed by bitcoin held by the Bitcoin Custodian on behalf of the Trust. All of the Trust's bitcoin will be held in the Custody Account, other than the Trust's bitcoin which is temporarily maintained in the Trading Account under limited circumstances, 
                    <E T="03">i.e.,</E>
                     in connection with creation and redemption Basket 
                    <SU>7</SU>
                    <FTREF/>
                     activity or sales of bitcoin deducted from the Trust's holdings in payment of Trust expenses or the Sponsor's fee (or, in extraordinary circumstances, upon liquidation of the Trust). The Custody Account includes all of the Trust's bitcoin held at the Bitcoin Custodian, but does not include the Trust's bitcoin temporarily maintained at the Prime Execution Agent in the Trading Account from time to time. The Bitcoin Custodian will keep all of the private keys associated with the Trust's bitcoin held in the Custody Account in “cold storage”.
                    <SU>8</SU>
                    <FTREF/>
                     The hardware, software, systems, and procedures of the Bitcoin Custodian may not be available or cost-effective for many investors to access directly.
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         The Trust issues and redeems Shares only in blocks of 40,000 or integral multiples thereof. A block of 40,000 Shares is called a “Basket.” These transactions take place in exchange for Bitcoin.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         The term “cold storage” refers to a safeguarding method by which the private keys corresponding to the Trust's bitcoins are generated and stored in an offline manner, subject to layers of procedures designed to enhance security. Private keys are generated by the Bitcoin Custodian in offline computers that are not connected to the internet so that they are more resistant to being hacked.
                    </P>
                </FTNT>
                <P>
                    The Exchange believes that offering options on the Trust will benefit investors by providing them with an additional, relatively lower cost investing tool to gain exposure to spot Bitcoin as well as a hedging vehicle to meet their investment needs in connection with Bitcoin products and positions. Similar to other commodity-based trusts on which options may be listed on the Exchange (
                    <E T="03">e.g.,</E>
                     SPDR® Gold Trust, the iShares COMEX Gold Trust, the iShares Silver Trust, or the ETFS Gold Trust),
                    <SU>9</SU>
                    <FTREF/>
                     the Trust essentially offers the same objectives and benefits to investors as do other commodity-based trusts on which options may be listed on the Exchange.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 402(i)(4).
                    </P>
                </FTNT>
                <P>Options on the Trust will trade in the same manner as options on other ETFs on the Exchange. Exchange Rules that currently apply to the listing and trading of all options on ETFs on the Exchange, including, for example, Rules that govern listing criteria, expirations, exercise prices, minimum increments, position and exercise limits (including as proposed in the filing submitted by Exchange's affiliate, MIAX Options filing), margin requirements, customer accounts and trading halt procedures, will apply to the listing and trading of options on the Trust on the Exchange. Today, these rules apply to options on the various commodities-based trusts deemed appropriate for options trading on the Exchange pursuant to Exchange Rule 402(i)(4).</P>
                <P>
                    The Exchange's initial listing standards for ETFs on which options may be listed and traded on the Exchange will apply to the Trust. Pursuant to Exchange Rule 402(a), a security (which includes ETFs) on which options may be listed and traded on the Exchange must be duly registered (with the Commission) and be an NMS stock (as defined in Rule 600 of Regulation NMS under the Act,) and be characterized by a substantial number of outstanding shares that are widely held and actively traded. Exchange Rule 402(i) requires that, in relevant part, ETFs must either (1) meet the criteria and standards set forth in Exchange Rule 402(a) or Exchange Rule 402(b), or (2) be available for creation or redemption each business day from or 
                    <PRTPAGE P="93674"/>
                    through the issuer in cash or in kind at a price related to net asset value, and the issuer must be obligated to issue ETFs in a specified aggregate number even if some or all of the investment assets required to be deposited have not been received by the issuer, subject to the condition that the person obligated to deposit the investments has undertaken to deliver the investment assets as soon as possible and such undertaking is secured by the delivery and maintenance of collateral consisting of cash or cash equivalents satisfactory to the issuer, as provided in the respective prospectus.
                </P>
                <P>Options on the Trust will also be subject to the Exchange's continued listing standards set forth in Exchange Rule 403(g), for ETFs deemed appropriate for options trading pursuant to Exchange Rule 402(i). Specifically, Exchange Rule 403(g) provides that ETFs that were initially approved for options trading pursuant to Exchange Rule 402(i) shall be deemed not to meet the requirements for continued approval, and the Exchange shall not open for trading any additional series of option contracts of the class covering that such ETFs, if the ETFs are delisted from trading pursuant to Exchange Rule 403(b)(4), are halted or suspended from trading in their primary market. Additionally, options on ETFs may be subject to the suspension of opening transactions in any of the following circumstances: (1) in the case of options covering ETFs approved for trading under Exchange Rule 402(i)(5)(i)(A), in accordance with the terms of paragraphs (b)(1), (2), and (3) of Exchange Rule 403; (2) in the case of options covering ETFs approved for trading under Exchange Rule 402(i)(5)(i)(B), following the initial twelve-month period beginning upon the commencement of trading in the ETFs on a national securities exchange and are defined as an NMS stock, there are fewer than 50 record and/or beneficial holders of such ETFs for 30 or more consecutive trading days; (3) the value of the index or portfolio of securities, non-U.S. currency, or portfolio of commodities including commodity futures contracts, options on commodity futures contracts, swaps, forward contracts and/or options on physical commodities and/or financial instruments and money market instruments on which the ETFs are based is no longer calculated or available; or (4) such other event shall occur or condition exist that in the opinion of the Exchange makes further dealing in such options on the Exchange inadvisable.</P>
                <P>
                    Options on the Trust would be physically settled contracts with American-style exercise.
                    <SU>10</SU>
                    <FTREF/>
                     Consistent with current Exchange Rule 404, which governs the opening of options series on a specific underlying security (including ETFs), the Exchange will open at least one expiration month for options on the Trust 
                    <SU>11</SU>
                    <FTREF/>
                     and may also list series of options on the Trust for trading on a weekly,
                    <SU>12</SU>
                    <FTREF/>
                     monthly,
                    <SU>13</SU>
                    <FTREF/>
                     or quarterly 
                    <SU>14</SU>
                    <FTREF/>
                     basis. The Exchange may also list long-term equity option series (“LEAPS”) that expire from 12 to 39 months from the time they are listed.
                    <SU>15</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 401, which provides that the rights and obligations of holders and writers are set forth in the Rules of the Options Clearing Corporation (“OCC”); 
                        <E T="03">see also</E>
                         OCC Rules, Chapters VIII (which governs exercise and assignment) and Chapter IX (which governs the discharge of delivery and payment obligations arising out of the exercise of physically settled stock option contracts).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404(b). The monthly expirations are subject to certain listing criteria for underlying securities described within Exchange Rule 404 and its Interpretations and Policies. Monthly listings expire the third Friday of the month. The term “expiration date” (unless separately defined elsewhere in the OCC By-Laws), when used in respect of an option contract (subject to certain exceptions), means the third Friday of the expiration month of such option contract, or if such Friday is a day on which the exchange on which such option is listed is not open for business, the preceding day on which such exchange is open for business. 
                        <E T="03">See</E>
                         OCC By-Laws Article I, Section 1. Pursuant to Exchange Rule 404(c), additional series of options of the same class may be opened for trading on the Exchange when the Exchange deems it necessary to maintain an orderly market, to meet customer demand or when the market price of the underlying stock moves more than five strike prices from the initial exercise price or prices. Pursuant to Exchange Rule 404(e), new series of options on an individual stock may be added until the beginning of the month in which the options contract will expire. Due to unusual market conditions, the Exchange, in its discretion, may add a new series of options on an individual stock until the close of trading on the business day prior to expiration.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretations and Policies .02.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretations and Policies .13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretations and Policies .03.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 406(a).
                    </P>
                </FTNT>
                <P>
                    Pursuant to Exchange Rule 404, Interpretation and Policy .06, which governs strike prices of series of options on ETFs, the interval between strike prices of series of options on ETFs approved for options trading pursuant to Exchange Rule 402(i) shall be fixed at a price per share which is reasonably close to the price per share at which the underlying security is traded in the primary market at or about the same time such series of options is first open for trading on the Exchange, or at such intervals as may have been established on another options exchange prior to the initiation of trading on the Exchange. With respect to the Short Term Options Series or Weekly Program, during the month prior to expiration of an option class that is selected for the Short Term Option Series Program, the strike price intervals for the related non-Short Term Option (“Related non-Short Term Option”) shall be the same as the strike price intervals for the Short Term Option.
                    <SU>16</SU>
                    <FTREF/>
                     Specifically, the Exchange may open for trading Short Term Option Series at strike price intervals of (i) $0.50 or greater where the strike price is less than $100, and $1 or greater where the strike price is between $100 and $150 for all option classes that participate in the Short Term Options Series Program; (ii) $0.50 for option classes that trade in one dollar increments and are in the Short Term Option Series Program; or (iii) $2.50 or greater where the strike price is above $150.
                    <SU>17</SU>
                    <FTREF/>
                     Additionally, the Exchange may list series of options pursuant to the $1 Strike Price Interval Program,
                    <SU>18</SU>
                    <FTREF/>
                     the $0.50 Strike Program,
                    <SU>19</SU>
                    <FTREF/>
                     and the $2.50 Strike Price Program.
                    <SU>20</SU>
                    <FTREF/>
                     Pursuant to Exchange Rule 510, where the price of a series of options for the Trust is less than $3.00, the minimum increment will be $0.05, and where the price is $3.00 or higher, the minimum increment will be $0.10 
                    <SU>21</SU>
                    <FTREF/>
                     consistent with the minimum increments for options on other ETFs listed on the Exchange. Any and all new series of Trust options that the Exchange lists will be consistent and comply with the expirations, strike prices, and minimum increments set forth in Rules 404 and 510, as applicable.
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretations and Policies .02(e).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretation and Policy .01.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretation and Policy .04.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404(f).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 510.
                    </P>
                </FTNT>
                <P>
                    Position and exercise limits for options on ETFs, including options on the Trust, are determined pursuant to the Exchange's affiliate MIAX Options Rules 307 and 309, respectively. Position and exercise limits for ETF options vary according to the number of outstanding shares and the trading volumes of the underlying ETF over the past six months, where the largest in capitalization and the most frequently traded ETFs have an option position and exercise limit of 250,000 contracts (with adjustments for splits, re-capitalizations, etc.) on the same side of the market; and smaller capitalization ETFs have position and exercise limits of 200,000, 75,000, 50,000 or 25,000 contracts (with adjustments for splits, re-capitalizations, etc.) on the same side of the market. The Exchange further notes that the Exchange's affiliate MIAX 
                    <PRTPAGE P="93675"/>
                    Options Rule 1502, which governs margin requirements applicable to trading on the Exchange, including options on ETFs, will also apply to the trading of the Trust options. Notwithstanding the position limits in the Exchange's affiliate MIAX Options Rule 307(d) and exercise limits in the Exchange's affiliate MIAX Options Rule 309, the Exchange proposes the position and exercise limits for the options on the Trust to be 25,000 contracts on the same side pursuant to proposed Supplementary Material .01 to the Exchange's affiliate MIAX Options Rule 307 and proposed Supplementary Material .01 to the Exchange's affiliate MIAX Options Rule 309.
                </P>
                <P>The Exchange represents that the same surveillance procedures applicable to all other options on other ETFs currently listed and traded on the Exchange will apply to options on the Trust. Also the Exchange represents that it has the necessary systems capacity to support the new option series. The Exchange believes that its existing surveillance and reporting safeguards are designed to deter and detect possible manipulative behavior which might potentially arise from listing and trading options on ETFs, including the proposed Trust options.</P>
                <P>
                    Today, the Exchange has an adequate surveillance program in place for options. The Exchange intends to apply those same program procedures to options on the Trust that it applies to the Exchange's other options products.
                    <SU>22</SU>
                    <FTREF/>
                     The Exchange's staff will have access to the surveillance programs conducted by its affiliate exchanges, MIAX Options and MIAX Sapphire with respect to trading in the shares of the underlying Trust when conducting surveillances for market abuse or manipulation in the options on the Trust. Additionally, the Exchange is a member of the Intermarket Surveillance Group (“ISG”) under the Intermarket Surveillance Group Agreement. ISG members work together to coordinate surveillance and investigative information sharing in the stock, options, and futures markets. In addition to obtaining surveillance data from MIAX Options and MIAX Sapphire, the Exchange will be able to obtain information regarding trading in the shares of the underlying Trust from Nasdaq, LLC and other markets through ISG. In addition, the Exchange has a Regulatory Services Agreement with the Financial Industry Regulatory Authority (“FINRA”). Pursuant to a multi-party 17d-2 joint plan, all options exchanges allocate regulatory responsibilities to FINRA to conduct certain options-related market surveillance that are common to rules of all options exchanges.
                    <SU>23</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         The surveillance program includes real-time patterns for price and volume movements and post-trade surveillance patterns (
                        <E T="03">e.g.,</E>
                         spoofing, marking the close, pinging, phishing).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         Section 19(g)(1) of the Act, among other things, requires every SRO registered as a national securities exchange or national securities association to comply with the Act, the rules and regulations thereunder, and the SRO's own rules, and, absent reasonable justification or excuse, enforce compliance by its members and persons associated with its members. See 15 U.S.C. 78q(d)(1) and 17 CFR 240.17d-2. Section 17(d)(1) of the Act allows the Commission to relieve an SRO of certain responsibilities with respect to members of the SRO who are also members of another SRO (“common members”). Specifically, Section 17(d)(1) allows the Commission to relieve an SRO of its responsibilities to: (i) receive regulatory reports from such members; (ii) examine such members for compliance with the Act and the rules and regulations thereunder, and the rules of the SRO; or (iii) carry out other specified regulatory responsibilities with respect to such members.
                    </P>
                </FTNT>
                <P>The underlying shares of spot bitcoin ETPs, including the Trust, are also subject to safeguards related to addressing market abuse and manipulation. As the Commission stated in Bitcoin ETP Order:</P>
                <P>
                    Each Exchange has a comprehensive surveillance-sharing agreement with the CME via their common membership in the Intermarket Surveillance Group. This facilitates the sharing of information that is available to the CME through its surveillance of its markets, including its surveillance of the CME bitcoin futures market.
                    <SU>24</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         
                        <E T="03">See supra</E>
                         note 4.
                    </P>
                </FTNT>
                <P>
                    The Exchange states that, given the consistently high correlation between the CME bitcoin futures market and the spot bitcoin market, as confirmed by the Commission through robust correlation analysis, the Commission was able to conclude that such surveillance sharing agreements could reasonably be “expected to assist in surveilling for fraudulent and manipulative acts and practices in the specific context of the [Bitcoin ETPs].” 
                    <SU>25</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         
                        <E T="03">See</E>
                         Bitcoin ETP Order, 89 FR at 3010-11.
                    </P>
                </FTNT>
                <P>
                    In light of surveillance measures related to both options and futures as well as the underlying Trust,
                    <SU>26</SU>
                    <FTREF/>
                     the Exchange believes that existing surveillance procedures are designed to deter and detect possible manipulative behavior which might potentially arise from listing and trading the proposed options on the Trust. Further, the Exchange represents that it will implement any new surveillance procedures it deems necessary to effectively monitor the trading of options on the Trust.
                </P>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99295 (January 8, 2024), 89 FR 2321, 2334-35 (January 12, 2024) (SR-NASDAQ-2023-016) (Notice of Filing of Amendment No. 1 to a Proposed Rule Change To List and Trade Shares of the iShares Bitcoin Trust Under Nasdaq Rule 5711(d)).
                    </P>
                </FTNT>
                <P>
                    The Exchange has also analyzed its capacity and represents that it believes the Exchange and Options Price Reporting Authority or “OPRA” have the necessary systems capacity to handle the additional traffic associated with the listing of new series that may result from the introduction of options on the Trust up to the number of expirations currently permissible under the Rules. Because the proposal is limited to one class, the Exchange believes any additional traffic that may be generated from the introduction of the Trust options will be manageable. Finally, the Exchange proposes a technical amendment to Exchange Rule 402(i)(4) to amend the name “ETFS Gold Trust” to “Aberdeen Standard Physical Gold Trust.” In 2018 ETFS Gold Trust was renamed.
                    <SU>27</SU>
                    <FTREF/>
                     At this time, the Exchange proposes to amend the name of the ETF to reflect its current name.
                </P>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         Effective October 1, 2018 ETFS Gold Trust was renamed Aberdeen Standard Gold ETF Trust. 
                        <E T="03">https://www.sec.gov/Archives/edgar/data/1450923/000138713118005292/ex10-2.htm.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The Exchange believes the proposed rule change is consistent with the Act and the rules and regulations thereunder applicable to the Exchange and, in particular, the requirements of Section 6(b) of the Act.
                    <SU>28</SU>
                    <FTREF/>
                     Specifically, the Exchange believes the proposed rule change is consistent with the Section 6(b)(5) 
                    <SU>29</SU>
                    <FTREF/>
                     requirements that the rules of an exchange be designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in regulating, clearing, settling, processing information with respect to, and facilitating transactions in securities, to remove impediments to and perfect the mechanism of a free and open market and a national market system, and, in general, to protect investors and the public interest. Additionally, the Exchange believes the proposed rule change is consistent with the Section (6)(b)(5) 
                    <SU>30</SU>
                    <FTREF/>
                     requirement that the rules of an exchange not be designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    In particular, the Exchange believes that the proposal to list and trade options on the Trust will remove impediments to and perfect the mechanism of a free and open market 
                    <PRTPAGE P="93676"/>
                    and a national market system and, in general, protect investors because offering options on the Trust will provide investors with a greater opportunity to realize the benefits of utilizing options on an ETF based on spot bitcoin, including cost efficiencies and increased hedging strategies. The Exchange believes that offering options on a competitively priced ETF based on spot bitcoin will benefit investors by providing them with an additional, relatively lower-cost risk management tool, allowing them to manage, more easily, their positions and associated risks in their portfolios in connection with exposure to spot bitcoin. Today, the Exchange lists options on other commodity ETFs structured as a trust, which essentially offer the same objectives and benefits to investors, and for which the Exchange has not identified any issues with the continued listing and trading of options on those ETFs.
                </P>
                <P>The Exchange also believes the proposal to permit options on the Trust will remove impediments to and perfect the mechanism of a free and open market and a national market system, because options on the Trust will comply with current Exchange Rules. Options on the Trust must satisfy the initial listing standards and continued listing standards currently in the Exchange Rules, applicable to options on all ETFs, including options on other commodity ETFs already deemed appropriate for options trading on the Exchange pursuant to Exchange Rule 402(i)(4). Further, Exchange Rules that currently govern the listing and trading of options on ETFs, including permissible expirations, strike prices, minimum increments, position and exercise limits (including as proposed in the filing submitted by Exchange's affiliate, MIAX Options), and margin requirements, will govern the listing and trading of options on the Trust. The proposed position and exercise limits for options on the Trust is 25,000 contracts. These position and exercise limits are the lowest position and exercise limits available in the options industry, are extremely conservative and more than appropriate given the Trust's market capitalization, average daily volume, and high number of outstanding shares. The proposed position limit, and exercise limit, is consistent with the Act as it addresses concerns related to manipulation and protection of investors because the position limit (and exercise limit) is extremely conservative and more than appropriate given the Trust is actively traded.</P>
                <P>
                    The Exchange represents that it has the necessary systems capacity to support options on the Trust. The Exchange believes that its existing surveillance and reporting safeguards are designed to deter and detect possible manipulative behavior which might arise from listing and trading options on ETFs, including the Trust options. Today, the Exchange has an adequate surveillance program in place for options. The Exchange intends to apply those same program procedures to options on the Trust that it applies to the Exchange's other options products.
                    <SU>31</SU>
                    <FTREF/>
                     The Exchange's staff will have access to the surveillance programs conducted by its affiliate exchanges, MIAX Options and MIAX Sapphire with respect to the underlying Trust when conducting surveillances for market abuse or manipulation in the options on the Trust. The Exchange will review activity in the underlying Trust when conducting surveillances for market abuse or manipulation in the options on the Trust. Additionally, the Exchange is a member of the ISG under the Intermarket Surveillance Group Agreement. ISG members work together to coordinate surveillance and investigative information sharing in the stock, options, and futures markets. In addition to obtaining surveillance data from MIAX Options and MIAX Sapphire, the Exchange will be able to obtain information from ISE and other markets through ISG. In addition, the Exchange has a Regulatory Services Agreement with FINRA. Pursuant to a multi-party 17d-2 joint plan, all options exchanges allocate regulatory responsibilities to FINRA to conduct certain options-related market surveillance that are common to rules of all options exchanges.
                    <SU>32</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         The surveillance program includes real-time patterns for price and volume movements and post-trade surveillance patterns (
                        <E T="03">e.g.,</E>
                         spoofing, marking the close, pinging, phishing).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         Section 19(g)(1) of the Act, among other things, requires every SRO registered as a national securities exchange or national securities association to comply with the Act, the rules and regulations thereunder, and the SRO's own rules, and, absent reasonable justification or excuse, enforce compliance by its members and persons associated with its members. See 15 U.S.C. 78q(d)(1) and 17 CFR 240.17d-2. Section 17(d)(1) of the Act allows the Commission to relieve an SRO of certain responsibilities with respect to members of the SRO who are also members of another SRO (“common members”). Specifically, Section 17(d)(1) allows the Commission to relieve an SRO of its responsibilities to: (i) receive regulatory reports from such members; (ii) examine such members for compliance with the Act and the rules and regulations thereunder, and the rules of the SRO; or (iii) carry out other specified regulatory responsibilities with respect to such members.
                    </P>
                </FTNT>
                <P>The underlying shares of spot bitcoin ETPs, including the Trust, are also subject to safeguards related to addressing market abuse and manipulation. As the Commission stated in Bitcoin ETP Order:</P>
                <P>
                    Each Exchange has a comprehensive surveillance-sharing agreement with the CME via their common membership in the Intermarket Surveillance Group. This facilitates the sharing of information that is available to the CME through its surveillance of its markets, including its surveillance of the CME bitcoin futures market.
                    <SU>33</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         
                        <E T="03">See supra</E>
                         note 4.
                    </P>
                </FTNT>
                <P>
                    The Exchange states that, given the consistently high correlation between the CME bitcoin futures market and the spot bitcoin market, as confirmed by the Commission through robust correlation analysis, the Commission was able to conclude that such surveillance sharing agreements could reasonably be “expected to assist in surveilling for fraudulent and manipulative acts and practices in the specific context of the [Bitcoin ETPs].” 
                    <SU>34</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         
                        <E T="03">See</E>
                         Bitcoin ETP Order, 89 FR at 3010-11.
                    </P>
                </FTNT>
                <P>
                    In light of surveillance measures related to both options and futures as well as the underlying Trust,
                    <SU>35</SU>
                    <FTREF/>
                     the Exchange believes that existing surveillance procedures are designed to deter and detect possible manipulative behavior which might potentially arise from listing and trading the proposed options on the Trust. Further, the Exchange represents that it will implement any new surveillance procedures it deems necessary to effectively monitor the trading of options on the Trust.
                </P>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99295 (January 8, 2024), 89 FR 2321, 2334-35 (January 12, 2024) (SR-NASDAQ-2023-016) (Notice of Filing of Amendment No. 1 to a Proposed Rule Change To List and Trade Shares of the iShares Bitcoin Trust Under Nasdaq Rule 5711(d)).
                    </P>
                </FTNT>
                <P>
                    Finally, the Commission has previously approved the listing and trading of options on other commodity ETFs structured as a trust, such as SPDR® Gold Trust,
                    <SU>36</SU>
                    <FTREF/>
                     the iShares COMEX Gold Trust 
                    <SU>37</SU>
                    <FTREF/>
                     the iShares Silver 
                    <PRTPAGE P="93677"/>
                    Trust,
                    <SU>38</SU>
                    <FTREF/>
                     the ETFS Gold Trust,
                    <SU>39</SU>
                    <FTREF/>
                     and the ETFS Silver Trust.
                    <SU>40</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 57897 (May 30, 2008), 73 FR 32061 (June 5, 2008) (SR-Amex-2008-15; SR-CBOE-2005-11; SR-ISE-2008-12; SR-NYSEArca-2008-52; and SRPhlx-2008-17) (Order Granting Approval of a Proposed Rule Change, as Modified, and Notice of Filing and Order Granting Accelerated Approval of Proposed Rule Changes, as Modified, Relating to Listing and Trading Options on the SPDR Gold Trust).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 59055 (December 4, 2008), 73 FR 75148 (December 10, 2008) (SR-Amex-2008-68; SR-BSE-2008-51; SR-CBOE-2008-72; SR-ISE-2008-58; SRNYSEArca-2008-66; and SR-Phlx-2008-58) (Notice of Filing and Order Granting Accelerated Approval of Proposed Rule Changes Relating to the Listing and Trading Options on Shares of the iShares COMEX Gold Trust and the iShares Silver Trust).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 61483 (February 3, 2010), 75 FR 6753 (February 10, 2010) (SR-CBOE-2010-007; SR-ISE-2009-106; SR-NYSEAmex-2009-86; and SR-NYSEArca-2009-110) (Order Granting Approval of Proposed Rule Changes and Notice of Filing and Order Granting Accelerated Approval of a Proposed Rule Change Relating to Listing and Trading Options on the ETFS Gold Trust and the ETFS Silver Trust).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>Further, the Exchange's proposal to amend the name “ETFS Gold Trust” to “Aberdeen Standard Physical Gold Trust” in Exchange Rule 402(i)(4) is consistent with the Act and the protection of investors as this amendment reflects the current name of this product.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>
                    The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. In this regard and as indicated above, the Exchange notes that the rule change is being proposed as a competitive response to filings submitted by ISE.
                    <SU>41</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         
                        <E T="03">See supra</E>
                         note 5.
                    </P>
                </FTNT>
                <P>The Exchange does not believe that the proposed rule change will impose any burden on intramarket competition that is not necessary or appropriate in furtherance of the purposes of the Act as options on the Trust will be subject to initial listing standards and continued listing standards the same as other options on ETFs listed on the Exchange. Further, options on the Trust will be subject to Exchange Rules that currently govern the listing and trading of options on ETFs, including permissible expirations, strike prices, minimum increments, position and exercise limits (including as proposed in the filing submitted by Exchange's affiliate, MIAX Options), and margin requirements. Options on the Trust will be equally available to all market participants who wish to trade such options. Also, and as stated above, the Exchange already lists options on other commodity ETFs structured as a trust.</P>
                <P>The Exchange does not believe that the proposal to list to list and trade options on the Trust will impose any burden on intermarket competition that is not necessary or appropriate in furtherance of the purposes of the Act. To the extent that permitting options on the Trust to trade on the Exchange may make the Exchange a more attractive marketplace to market participants, such market participants are free to elect to become market participants on the Exchange. Additionally, other options exchanges are free to amend their listing rules, as applicable, to permit them to list and trade options on the Trust. The Exchange believes that the proposed rule change may relieve any burden on, or otherwise promote, competition as it is designed to increase competition for order flow on the Exchange in a manner that is beneficial to investors by providing them with a lower-cost option to hedge their investment portfolios. The Exchange notes that it operates in a highly competitive market in which market participants can readily direct order flow to competing venues that offer similar products. Ultimately, the Exchange believes that offering options on the Trust for trading on the Exchange will promote competition by providing investors with an additional, relatively low-cost means to hedge their portfolios and meet their investment needs in connection with spot bitcoin prices and bitcoin related products and positions.</P>
                <P>Finally, the Exchange's proposal to amend the name “ETFS Gold Trust” to “Aberdeen Standard Physical Gold Trust” in Exchange Rule 402(i)(4) does not impose an undue burden on competition as this amendment reflects the current name of this product.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>Written comments were neither solicited nor received.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The Exchange has filed the proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>42</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6) thereunder.
                    <SU>43</SU>
                    <FTREF/>
                     Because the foregoing proposed rule change does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative for 30 days from the date on which it was filed, or such shorter time as the Commission may designate, it has become effective pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>44</SU>
                    <FTREF/>
                     and subparagraph (f)(6) of Rule 19b-4 thereunder.
                    <SU>45</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6)(iii) requires a self-regulatory organization to give the Commission written notice of its intent to file the proposed rule change, along with a brief description and text of the proposed rule change, at least five business days prior to the date of filing of the proposed rule change, or such shorter time as designated by the Commission. The Exchange has satisfied this requirement.
                    </P>
                </FTNT>
                <P>
                    A proposed rule change filed under Rule 19b-4(f)(6) 
                    <SU>46</SU>
                    <FTREF/>
                     under the Act does not normally become operative prior to 30 days after the date of the filing. However, pursuant to Rule 19b-4(f)(6)(iii),
                    <SU>47</SU>
                    <FTREF/>
                     the Commission may designate a shorter time if such action is consistent with the protection of investors and the public interest. The Exchange has requested that the Commission waive the 30-day operative delay so that the proposal may become operative immediately upon filing. The Commission previously approved the listing of options on iShares Bitcoin Trust.
                    <SU>48</SU>
                    <FTREF/>
                     The Exchange has provided information regarding the underlying iShares Bitcoin Trust, including, among other things, information regarding trading volume, the number of beneficial holders, and the market capitalization of the iShares Bitcoin Trust. The proposal also establishes position and exercise limits for options on the iShares Bitcoin Trust and provides information regarding the surveillance procedures that will apply to iShares Bitcoin Trust options. The Commission believes that waiver of the operative delay could benefit investors by providing an additional venue for trading iShares Bitcoin Trust options. Therefore, the Commission believes that waiver of the 30-day operative delay is consistent with the protection of investors and the public interest. Accordingly, the Commission hereby waives the 30-day operative delay and designates the proposed rule change as operative upon filing.
                    <SU>49</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>46</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>47</SU>
                         17 CFR 240.19b-4(f)(6)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>48</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 101128 (September 20, 2024), 89 FR 78942 (September 26, 2024) (SR-ISE-2024-03) (Self-Regulatory Organizations; Nasdaq ISE, LLC; Notice of Filing of Amendment Nos. 4 and 5 and Order Granting Accelerated Approval of a Proposed Rule Change, as Modified by Amendment Nos. 1, 4, and 5, to Permit the Listing and Trading of Options on the iShares Bitcoin Trust).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>49</SU>
                         For purposes only of waiving the 30-day operative delay, the Commission has also considered the proposed rule's impact on efficiency, competition, and capital formation. 
                        <E T="03">See</E>
                         15 U.S.C. 78c(f).
                    </P>
                </FTNT>
                <P>
                    At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings to determine whether the proposed rule should be approved or disapproved.
                    <PRTPAGE P="93678"/>
                </P>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-PEARL-2024-52 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-PEARL-2024-52. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-PEARL-2024-52 and should be submitted on or before December 18, 2024.
                    <FTREF/>
                </FP>
                <FTNT>
                    <P>
                        <SU>50</SU>
                         17 CFR 200.30-3(a)(12).
                    </P>
                </FTNT>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>50</SU>
                    </P>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27743 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101689; File No. SR-BX-2024-049]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; Nasdaq BX, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Its Fees for Connectivity and Co-Location Services</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”),
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 18, 2024, Nasdaq BX, Inc. (“BX” or “Exchange”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>The Exchange proposes to amend the Exchange's fees for connectivity and co-location services, as described further below.</P>
                <P>
                    The text of the proposed rule change is available on the Exchange's website at 
                    <E T="03">https://listingcenter.nasdaq.com/rulebook/bx/rules,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    The purpose of the proposed rule change is to amend the Exchange's fees relating to connectivity and co-location services.
                    <SU>3</SU>
                    <FTREF/>
                     Specifically, the Exchange proposes a one-time adjustment to raise its fees for connectivity and co-location services in General 8, fees assessed for remote multi-cast ITCH (“MITCH”) Wave Ports in Equity 7, Section 115, and certain fees related to Nasdaq Testing Facilities in Equity 7, Section 130 by 10%, with certain exceptions.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The Exchange initially filed the proposed pricing change on March 1, 2024 (SR-BX-2024-008). On April 29, 2024, the Exchange withdrew that filing and submitted SR-BX-2024-014. The Exchange withdrew BX-2024-14 and replaced it with SR-BX-2024-20. The Exchange withdrew SR-BX-2024-020 and replaced it with SR-BX-2024-033 on September 10, 2024. On October 11, 2024, the Exchange replaced SR-BX-2024-033 with SR-BX-2024-042. On November 08, 2024, the Exchange replaced SR-BX-2024-042 with SR-BX-2024-046. The instant filing replaces SR-BX-2024-046.
                    </P>
                </FTNT>
                <P>
                    General 8, Section 1 includes the Exchange's fees that relate to connectivity, including fees for cabinets, external telco/inter-cabinet connectivity fees, fees for connectivity to the Exchange, fees for connectivity to third party services, fees for market data connectivity, fees for cabinet power install, and fees for additional charges and services. General 8, Section 2 includes the Exchange's fees for direct connectivity services, including fees for direct circuit connection to the Exchange, fees for direct circuit connection to third party services, and fees for point of presence connectivity. With the exceptions of the Exchange's GPS Antenna fees and the Cabinet Proximity Option Fee for cabinets with power density &gt;10kW,
                    <SU>4</SU>
                    <FTREF/>
                     the Exchange proposes to increase its fees throughout General 8 by 10%.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         The Exchange proposes to exclude the GPS Antenna fees from the proposed fee increase because, unlike the other fees in General 8, the Exchange recently increased its GPS Antenna fees. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-99124 (December 8, 2023), 88 FR 86715 (December 14, 2023) (SR-BX-2023-033). The Exchange also proposes to exclude the Cabinet Proximity Option Fee for cabinets with power density &gt;10kW from the proposed fee increase because the Exchange recently established such fee. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-100195 (May 21, 2024), 89 FR 46180 (May 28, 2024) (SR-BX-2024-017). Similarly, the Exchange proposes to exclude from the proposed fee increase those fees that the Exchange recently established for services in its new NY11-4 expansion facility. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-101265 (October 7, 2024), 89 FR 82663 (October 11, 2024) (SR-BX-2024-037).
                    </P>
                </FTNT>
                <P>
                    In addition to increasing fees in General 8, the Exchange also proposes 
                    <PRTPAGE P="93679"/>
                    to increase certain fees in Equity 7. First, the Exchange proposes to increase the installation and recurring monthly fees assessed for remote MITCH Wave Ports 
                    <SU>5</SU>
                    <FTREF/>
                     in Equity 7, Section 115(g)(1) by 10%. In addition, the Exchange proposes to increase certain fees in Section 130(d), which relate to the Nasdaq Testing Facility. Equity 7, Section 130(d)(1)(C) provides that subscribers to the Nasdaq Testing Facility (“NTF”) located in Carteret, New Jersey shall pay a fee of $1,000 per hand-off, per month for connection to the NTF. The hand-off fee includes either a 1Gb or 10Gb switch port and a cross connect to the NTF. In addition, Equity 7, Section 130(d)(1)(C) provides that subscribers shall also pay a one-time installation fee of $1,000 per hand-off. The Exchange proposes to increase these aforementioned fees by 10% to require that subscribers to the NTF shall pay a fee of $1,100 per hand-off, per month for connection to the NTF and a one-time installation fee of $1,100 per hand-off.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         Remote MITCH Wave Ports are for clients co-located at other third-party data centers, through which NASDAQ TotalView ITCH market data is distributed after delivery to those data centers via wireless network.
                    </P>
                </FTNT>
                <P>The proposed increases in fees would enable the Exchange to maintain and improve its market technology and services to remain competitive with its peers. Over the years, customer demand for more sophisticated, higher-throughput, lower-latency, and higher-power connectivity solutions has increased. The Exchange continues to invest in maintaining, improving, and enhancing its connectivity and co-location products, services, and facilities—for the benefit and often at the behest of its customers. Such enhancements include refreshing hardware and expanding Nasdaq's existing co-location facility to offer customers additional space and power. Nevertheless, and with the exception of fees that were established as part of a new service in 2017 (and have remained unchanged since their adoption), the Exchange has not increased any of the fees included in the proposal since prior to 2017, and many of the fees date back to between 2010 and 2014. For each of the connectivity products and services that pre-date 2017, inflation (as measured using the “Data PPI” metric described below) has been between roughly 15-17%, and in no instance has such inflation been less than 10%. Nevertheless, the Exchange proposes to increase its fees only with respect to the 10% inflation that has occurred since 2017.</P>
                <P>As discussed below, the Exchange proposes to adjust its fees by an industry- and product-specific inflationary measure. It is reasonable and consistent with the Act for the Exchange to recoup its investments, at least in part, by adjusting its fees. Continuing to operate at fees frozen at 2010-2017 levels impacts the Exchange's ability to enhance its offerings and the interests of market participants and investors.</P>
                <P>
                    The fee increases the Exchange proposes are based on an industry-specific Producer Price Index (“PPI”), which is a tailored measure of inflation.
                    <SU>6</SU>
                    <FTREF/>
                     As a general matter, the Producer Price Index is a family of indexes that measures the average change over time in selling prices received by domestic producers of goods and services. PPI measures price change from the perspective of the seller. This contrasts with other metrics, such as the Consumer Price Index (“CPI”), that measure price change from the purchaser's perspective.
                    <SU>7</SU>
                    <FTREF/>
                     About 10,000 PPIs for individual products and groups of products are tracked and released each month.
                    <SU>8</SU>
                    <FTREF/>
                     PPIs are available for the output of nearly all industries in the goods-producing sectors of the U.S. economy—mining, manufacturing, agriculture, fishing, and forestry—as well as natural gas, electricity, and construction, among others. The PPI program covers approximately 69 percent of the service sector's output, as measured by revenue reported in the 2017 Economic Census.
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See https://fred.stlouisfed.org/series/PCU51825182#0.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See https://www.bls.gov/ppi/overview.htm.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See Id.</E>
                    </P>
                </FTNT>
                <P>For purposes of this proposal, the relevant industry-specific PPI is the Data Processing and Related Services PPI (“Data PPI”), which is an industry net-output PPI that measures the average change in selling prices received by companies that provide data processing services.</P>
                <P>
                    The Data PPI was introduced in January 2002 by the Bureau of Labor Statistics (“BLS”) as part of an ongoing effort to expand Producer Price Index coverage of the services sector of the U.S. economy and is identified as NAICS—518210 in the North American Industry Classification System.
                    <SU>9</SU>
                    <FTREF/>
                     According to the BLS “[t]he primary output of NAICS 518210 is the provision of electronic data processing services. In the broadest sense, computer services companies help their customers efficiently use technology. The processing services market consists of vendors who use their own computer systems—often utilizing proprietary software—to process customers' transactions and data. Companies that offer processing services collect, organize, and store a customer's transactions and other data for record-keeping purposes. Price movements for the NAICS 518210 index are based on changes in the revenue received by companies that provide data processing services. Each month, companies provide net transaction prices for a specified service. The transaction is an actual contract selected by probability, where the price-determining characteristics are held constant while the service is repriced. The prices used in index calculation are the actual prices billed for the selected service contract.” 
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">NAICS appears in table 5 of the PPI Detailed Report and is available at https://data.bls.gov/timeseries/PCU518210518210.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See https://www.bls.gov/ppi/factsheets/producer-price-index-for-the-data-processing-and-related-servicesindustry-naics-518210.htm.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange believes the Data PPI is an appropriate measure to be considered in the context of the proposed rule change to modify the fee for its connectivity products because the Exchange uses its “own computer systems” and “proprietary software,” 
                    <E T="03">i.e.,</E>
                     its own data center and proprietary matching engine software, respectively, to collect, organize, store and report customers' transactions in U.S. equity securities on the Exchange's proprietary trading platform. In other words, the Exchange is in the business of data processing and related services.
                </P>
                <P>For purposes of this proposed rule change, the Exchange examined the Data PPI value for the period from January 2017 to August 2024. The Data PPI had a starting value of 105.6 in January 2017 and an ending value of 116.022 in August 2024, a 10.422% increase. This indicates that companies who are also in the data storage and processing business have generally increased prices for a specified service covered under NAICS 518210 by an average of 10.422% during this period. Based on that percentage change, the Exchange proposes to make a one-time fee increase of only 10%, which reflects an increase covering roughly the entire period since the last price adjustments to these fees were made.</P>
                <P>
                    The Exchange further believes the Data PPI is an appropriate measure for purposes of the proposed rule change on the basis that it is a stable metric with limited volatility, unlike other consumer-side inflation metrics. In fact, the Data PPI has not experienced a greater than 2.16% increase for any one calendar year period since Data PPI was 
                    <PRTPAGE P="93680"/>
                    introduced into the PPI in January 2002. The average calendar year change from January 2002 to December 2023 was .62%, with a cumulative increase of 15.67% over this 21-year period. The Exchange believes the Data PPI is considerably less volatile than other inflation metrics such as CPI, which has had individual calendar-year increases of more than 6.5%, and a cumulative increase of over 73% over the same period.
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See https://www.usinflationcalculator.com/inflation/consumer-price-index-and-annual-percent-changesfrom-1913-to-2008/.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange believes the Data PPI, and significant investments into, and enhanced performance of, the Exchange support the reasonableness of the proposed fee increases.
                    <SU>12</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See supra</E>
                         discussion of connectivity product and facility improvements. Additionally, other exchanges have filed for increases in certain fees, based in part on comparisons to inflation. See, 
                        <E T="03">e.g.,</E>
                         Securities Exchange Act Release Nos. 34-100004 (April 22, 2024), 89 FR 32465 (April 26, 2024) (SR-CboeBYX-2024-012); and 34-100398 (June 21, 2024), 89 FR 53676 (June 27, 2024) (SR-BOX-2024-16)l; Securities Exchange Act Release No. 34-100994 (September 10, 2024), 89 FR 75612 (September 16, 2024) (SR-NYSEARCA-2024-79).
                    </P>
                </FTNT>
                <P>
                    These proposed fee increases will be immediately effective upon filing. However, going forward and until December 1, 2024, the Exchange will waive all fees set forth herein to the extent that such fees exceed the levels that would have been charged for the same products and services purchased during that time period, had such fees been calculated at the rates set forth in SR-BX-2024-033 (
                    <E T="03">i.e.,</E>
                     pricing reflective of a 5.5% increase from prior fee levels). This waiver is reasonable, equitable, and not unfairly discriminatory because it will afford all customers in excess of the 30-day prior notice period for fee changes set forth in the Exchange's service terms.
                </P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The Exchange believes that its proposal is consistent with Section 6(b) of the Act,
                    <SU>13</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Sections 6(b)(4) and 6(b)(5) of the Act,
                    <SU>14</SU>
                    <FTREF/>
                     in particular, in that it provides for the equitable allocation of reasonable dues, fees and other charges among members and issuers and other persons using any facility, and is not designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         15 U.S.C. 78f(b)(4) and (5).
                    </P>
                </FTNT>
                <P>This belief is based on two factors. First, the current fees do not properly reflect the quality of the services and products, as fees for the services and products in question have been static in nominal terms, and therefore falling in real terms due to inflation. Second, the Exchange believes that investments made in enhancing the capacity and speed of Exchange systems increase the performance of the services and products.</P>
                <HD SOURCE="HD3">The Proposed Rule Change Is Reasonable</HD>
                <P>
                    As noted above, the Exchange has not increased any of the fees included in the proposal since 2017 or earlier. However, in the years following the last fee increases, the Exchange has made significant investments in upgrades to its connectivity products, services, and facilities, enhancing the quality of its services. In other words, Exchange customers have greatly benefitted, while the Exchange's ability to recoup its investments has been hampered. Between 2017 and 2024, the inflation rate is 3.64% per year, on average, producing a cumulative inflation rate of 28.43%.
                    <SU>15</SU>
                    <FTREF/>
                     Using the more targeted inflation number of Data PPI, the cumulative inflation rate was 10.422%. The exchange believes the Data PPI is a reasonable metric to base this fee increase on because it is targeted to producer-side increases in the data processing industry.
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See https://www.officialdata.org/us/inflation/2017?amount=1.</E>
                    </P>
                </FTNT>
                <P>
                    Notwithstanding inflation, as noted above, the Exchange has not increased its fees at all for over seven years for the subject services. The proposed fee changes represent a modest increase from the current fees. The Exchange believes the proposed fee increase is reasonable in light of the Exchange's continued expenditure in maintaining a robust technology ecosystem. Furthermore, the Exchange continues to invest in maintaining and enhancing its connectivity products—for the benefit and often at the behest of its customers and global investors. Such enhancements include refreshing all aspects of the technology ecosystem including software, hardware, and network while introducing new and innovative products and expanded and modernized facilities.
                    <SU>16</SU>
                    <FTREF/>
                     The goal of the enhancements discussed above, among other things, is to provide faster, higher-capacity, and more modern connectivity products and services. Accordingly, the Exchange continues to expend resources to innovate and modernize technology so that it may benefit its members in offering its connectivity products and services.
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         
                        <E T="03">See, e.g.,</E>
                         Securities Exchange Act Release No. 34-101073 (September 18, 2024), 89 FR 77926 (September 24, 2024) (SR-BX-2024-035 (Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Expand [the Exchange's] Co-Location Services).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">The Proposed Fees Are Equitably Allocated and Not Unfairly Discriminatory</HD>
                <P>The Exchange believes that the proposed fee increases are equitably allocated and not unfairly discriminatory because they would apply to all market participants that choose to purchase connectivity products and services from the Exchange. Any participant that chooses to purchase the Exchange's connectivity products and services would be subject to the same Fee Schedule, regardless of what type of business they operate or the use they plan to make use of the products and services. Additionally, the fee increase would be applied uniformly to market participants without regard to Exchange membership status or the extent of any other business with the Exchange or affiliated entities. The Exchange also believes that the proposal represents an equitable allocation of reasonable dues, fees and other charges because Exchange fees have fallen in real terms during the relevant period. Finally, the Exchange believes that the proposed fee changes are not unfairly discriminatory because the fees would be assessed uniformly across all market participants, in the same manner they are today, that voluntarily purchase the Exchange's connectivity products and services, which would remain available for purchase by all market participants.</P>
                <P>
                    These proposed fee increases will be immediately effective upon filing. However, going forward and until December 1, 2024, the Exchange will waive all fees set forth herein to the extent that such fees exceed the levels that would have been charged for the same products and services purchased during that time period, had such fees been calculated at the rates set forth in SR-BX-2024-033 (
                    <E T="03">i.e.,</E>
                     pricing reflective of a 5.5% increase from prior fee levels). This waiver is reasonable, equitable, and not unfairly discriminatory because it will afford all customers in excess of the 30-day prior notice period for fee changes set forth in the Exchange's service terms.
                </P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed fees will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.</P>
                <HD SOURCE="HD3">Intramarket Competition</HD>
                <P>
                    The Exchange believes that the proposed fees do not put any market 
                    <PRTPAGE P="93681"/>
                    participants at a relative disadvantage compared to other market participants. As noted above, the fee schedule would continue to apply to all purchasers of the Exchange's connectivity products and services in the same manner as it does today albeit at inflation-adjusted rates for certain fees, and customers may choose whether to purchase these products and services at all. The Exchange also believes that the level of the proposed fees neither favor nor penalize one or more categories of market participants in a manner that would impose an undue burden on competition. Likewise, the proposed fee waiver described above will apply to all purchasers of the Exchange's connectivity products and services in the same manner and therefore will not burden competition among them.
                </P>
                <HD SOURCE="HD3">Intermarket Competition</HD>
                <P>The Exchange believes that the proposed fees do not impose a burden on competition or on other SROs that is not necessary or appropriate. In determining the proposed fees, the Exchange utilized an objective and stable metric with limited volatility. Utilizing Data PPI over a specified period of time is a reasonable means of recouping the Exchange's investment in maintaining and enhancing its connectivity products, services, and facilities. The Exchange believes utilizing Data PPI, a tailored measure of inflation, to increase certain fees for connectivity products and services to recoup the Exchange's investment in maintaining and enhancing such products, services, and its facilities would not impose a burden on competition.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were either solicited or received.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The foregoing rule change has become effective pursuant to Section 19(b)(3)(A)(ii) of the Act.
                    <SU>17</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         15 U.S.C. 78s(b)(3)(A)(ii).
                    </P>
                </FTNT>
                <P>At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is: (i) necessary or appropriate in the public interest; (ii) for the protection of investors; or (iii) otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings to determine whether the proposed rule should be approved or disapproved.</P>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-BX-2024-049 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-BX-2024-049. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-BX-2024-049 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>18</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>18</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27758 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101677; File No. SR-NYSECHX-2024-32]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; NYSE Chicago, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Rule 7.37</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) 
                    <SU>1</SU>
                    <FTREF/>
                     of the Securities Exchange Act of 1934 (the “Act”),
                    <SU>2</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>3</SU>
                    <FTREF/>
                     notice is hereby given that on November 7, 2024, the NYSE Chicago, Inc. (“NYSE Chicago” or the “Exchange”) filed with the Securities and Exchange Commission (the “Commission”) the proposed rule change as described in Items I and II below, which Items have been prepared by the self-regulatory organization. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         15 U.S.C. 78a.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>
                    The Exchange proposes to amend Rule 7.37 to specify the Exchange's source of data feeds from Investors' Exchange, LLC (“IEX”) for purposes of order handling, order execution, order routing, and regulatory compliance. The proposed rule change is available on the Exchange's website at 
                    <E T="03">www.nyse.com,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>
                    In its filing with the Commission, the self-regulatory organization included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of those statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, 
                    <PRTPAGE P="93682"/>
                    set forth in sections A, B, and C below, of the most significant parts of such statements.
                </P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>The Exchange proposes to update and amend the use of data feeds table in Rule 7.37(d), which sets forth on a market-by-market basis the specific securities information processor (“SIP”) and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks related to each of those functions. Specifically, the Exchange proposes to amend the table in Rule 7.37(d) to specify that, with respect to IEX, the Exchange will receive an IEX direct feed as its primary source of data for order handling, order execution, order routing, and regulatory compliance, and will use the SIP Data Feed as its secondary source for data from IEX.</P>
                <P>The Exchange proposes to make this change operative in the fourth quarter of 2024, and, in any event, before the end of the first quarter of 2025. The Exchange proposes to announce the implementation date of this change by Trader Update.</P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The proposed rule change is consistent with Section 6(b) of the Act,
                    <SU>4</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Section 6(b)(5),
                    <SU>5</SU>
                    <FTREF/>
                     in particular, because it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in facilitating transactions in securities, to remove impediments to, and perfect the mechanism of, a free and open market and a national market system and, in general, to protect investors and the public interest. Additionally, the Exchange believes that the proposed rule change is consistent with the Section 6(b)(5) requirement that the rules of an exchange not be designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <P>The Exchange believes its proposal to update the table in Rule 7.37(d) to include the IEX direct feed will ensure that the Rule correctly identifies and publicly states on a market-by-market basis all of the specific SIP and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks for each of those functions. The proposed rule change also removes impediments to and perfects the mechanism of a free and open market and protects investors and the public interest by providing additional specificity, clarity, and transparency in the Exchange's rules.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. Rather, the Exchange believes that the proposal will enhance competition because providing the public and market participants with up-to-date information about the data feeds the Exchange will use for the handling, execution, and routing of orders, as well as for regulatory compliance would enhance transparency and enable investors to better assess the quality of the Exchange's execution and routing services. The Exchange also believes the proposal would enhance competition because it would potentially enhance the performance of its order handling and execution of orders in equity securities by receiving market data directly from IEX. Finally, the proposed rule change would not impact competition between market participants because it will affect all market participants equally.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were solicited or received with respect to the proposed rule change.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The Exchange has filed the proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>6</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6) thereunder.
                    <SU>7</SU>
                    <FTREF/>
                     Because the proposed rule change does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative prior to 30 days from the date on which it was filed, or such shorter time as the Commission may designate, if consistent with the protection of investors and the public interest, the proposed rule change has become effective pursuant to Section 19(b)(3)(A) of the Act 
                    <SU>8</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6)(iii) thereunder.
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         15 U.S.C. 78s(b)(3)(A).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6) requires a self-regulatory organization to give the Commission written notice of its intent to file the proposed rule change, along with a brief description and text of the proposed rule change, at least five business days prior to the date of filing of the proposed rule change, or such shorter time as designated by the Commission. The Exchange has satisfied this requirement.
                    </P>
                </FTNT>
                <P>
                    At any time within 60 days of the filing of such proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings under Section 19(b)(2)(B) 
                    <SU>10</SU>
                    <FTREF/>
                     of the Act to determine whether the proposed rule change should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         15 U.S.C. 78s(b)(2)(B).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-NYSECHX-2024-32 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <P>
                    All submissions should refer to file number SR-NYSECHX-2024-32. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the 
                    <PRTPAGE P="93683"/>
                    Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-NYSECHX-2024-32 and should be submitted on or before December 18, 2024.
                </P>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>11</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>11</SU>
                             17 CFR 200.30-3(a)(12), (59).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27746 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101700; File No. SR-CboeBYX-2024-042]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; Cboe BYX Exchange, Inc.; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend Its Fee Schedule Relating to Routing Codes</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”),
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 14, 2024, Cboe BYX Exchange, Inc. (“Exchange” or “BYX”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>Cboe BYX Exchange, Inc. (the “Exchange” or “BYX”) proposes to amend its Fee Schedule. The text of the proposed rule change is provided in Exhibit 5.</P>
                <P>
                    The text of the proposed rule change is also available on the Exchange's website (
                    <E T="03">http://markets.cboe.com/us/equities/regulation/rule_filings/BYX/</E>
                    ), at the Exchange's Office of the Secretary, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    Effective November 1, 2024, the Exchange proposes to amend its BYX Fee Schedule applicable to its equities trading platform.
                    <SU>3</SU>
                    <FTREF/>
                     By implementing a remove fee (as opposed to a rebate) for fee code, AA, removing fee code, BJ, and adding EDGA to the list of venues to which orders appended with fee code, PL, are routed.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The Exchange initially filed the proposed fee change on November 1, 2024 (SR-CboeBYX-2024-040). On November 14, 2024, the Exchange withdrew that filing and submitted this filing.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Fee Codes</HD>
                <P>The Exchange proposes to implement a remove fee for fee code, AA. The proposed changes are as follows:</P>
                <P>
                    • For securities priced above $1.00,
                    <SU>4</SU>
                    <FTREF/>
                     fee code AA is appended to orders that are routed to EDGA using the ALLB 
                    <SU>5</SU>
                    <FTREF/>
                     routing strategy. Currently, orders appended with fee code AA receive a rebate of $0.0018.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         The Exchange notes for securities priced below $1.00, there is no fee or rebate for removing liquidity from EDGA using the ALLB routing strategy.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         ALLB is a routing option under which an order checks the System for available shares and is then sent to Cboe BZX Exchange, Inc., Cboe EDGA Exchange, Inc., and/or Cboe EDGX Exchange, Inc. in accordance with the System routing table. If shares remain unexecuted after routing, they are posted on the BYX Book, unless otherwise instructed by the User. 
                        <E T="03">See</E>
                         Rule 11.13(b)(3)(M).
                    </P>
                </FTNT>
                <P>The Exchange now proposes to amend fee code, AA, as follows:</P>
                <P>• For securities priced above $1.00, fee code AA will continue to be appended to orders that are routed to EDGA using the ALLB routing strategy. However, orders appended with fee code AA will now pay a fee of $0.0030. The Exchange does not propose to add a fee or rebate for removing liquidity for securities priced below $1.00.</P>
                <P>
                    The Exchange also proposes to remove fee code, BJ. For securities priced above $1.00,
                    <SU>6</SU>
                    <FTREF/>
                     fee code BJ is currently appended to orders that are routed to EDGA using the TRIM 
                    <SU>7</SU>
                    <FTREF/>
                     or SLIM 
                    <SU>8</SU>
                    <FTREF/>
                     routing strategies and receive a rebate of $0.0018. However, effective November 1, 2024,
                    <SU>9</SU>
                    <FTREF/>
                     EDGA transitioned from an inverted fee model 
                    <SU>10</SU>
                    <FTREF/>
                     to a maker-taker fee model.
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         There is no charge or rebate for securities priced below $1.00.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         TRIM is a routing strategy under which an order checks EDGA for available shares if so instructed by the entering User, and then is sent to destinations on the applicable System routing table. 
                        <E T="03">See generally</E>
                         Rule 11.13(b)(3)(G)(iv).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         SLIM is a routing strategy under which an order checks EDGA for available shares if so instructed by the entering User, and then is sent to destinations on the applicable System routing table. 
                        <E T="03">See generally</E>
                         Rule 11.13(b)(3)(G)(v).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See</E>
                         SR-CboeEDGA-2024-042; 
                        <E T="03">see also,</E>
                         SR-CboeEDGA-2024-045.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         The inverted As such, orders that remove liquidity from EDGA will pay a remove fee, rather than receive a rebate. Because Members typically utilize routing options TRIM and SLIM, and fee code BJ, to seek low-cost executions, it does not make sense to maintain fee code, BJ, as Members would not expect to pay a fee for removing liquidity from EDGA. Therefore, the Exchange proposes to discontinue this fee code, as it is no longer necessary, and BYX does not desire to charge such orders a fee for removing liquidity from EDGA.fee model is a pricing structure in which a market, such as an exchange, charges its participants a fee to provide liquidity in securities, and provides a rebate to participants that remove liquidity in securities. 
                        <E T="03">See</E>
                         SEC Market Structure Advisory Committee, Memorandum on “Maker-Taker Fees on Equities Exchanges,” October 20, 2015, available at: 
                        <E T="03">https://www.sec.gov/spotlight/emsac/memo-maker-taker-fees-on-equities-exchanges.pdf</E>
                        .
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         The maker-taker fee model is a pricing structure in which a market, such as an exchange, generally pays its members a per share rebate to provide (
                        <E T="03">i.e.,</E>
                         “make”) liquidity in securities and assesses on them a fee to remove (
                        <E T="03">i.e.,</E>
                         “take”) liquidity. 
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange also proposes to edit the description of fee code, PL. The BYX Fee Schedule currently describes PL, as a fee code appended to orders that are “[r]outed to BZX, EDGX, NYSE, NYSE Arca or Nasdaq using RMPL routing strategy.” The Exchange now proposes to move EDGA to the list of high-cost destinations for the RMPL routing 
                    <PRTPAGE P="93684"/>
                    strategy that are assigned the PL fee code, by amending the description in the Fee Schedule to read as follow: “Routed to BZX, EDGX, 
                    <E T="03">EDGA,</E>
                     NYSE, NYSE Arca or Nasdaq using RMPL routing strategy.” Previously, orders appended with fee code, PX, utilized routing option, RMPL, which is a midpoint liquidity seeking strategy that first targets low-cost executions at certain lower-cost venues, including EDGA. However, because EDGA is now transitioning to a maker-taker fee model, EDGA will now be assessing a full remove fee of $0.0030 for orders that remove liquidity from EDGA.
                    <SU>12</SU>
                    <FTREF/>
                     As such, the Exchange believes that current fee code, PL—which charges a $0.0030 for routing orders to other exchanges—is now the more appropriate fee code to be appended to midpoint liquidity seeking orders that are routed to other major exchanges. Similar to EDGA, the other exchanges targeted by RMPL—NYSE, NYSE Arca, and Nasdaq—also charge a high remove fee to liquidity removing orders.
                    <SU>13</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         SR-CboeEDGA-2024-045.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         NYSE Arca charges a removal fee of $0.0030. 
                        <E T="03">See</E>
                         Section III—Standard Rates—Transactions (applicable when Tier Rates do not apply), Removing Liquidity, pg. 3, available at: 
                        <E T="03">https://www.nyse.com/publicdocs/nyse/markets/nyse-arca/NYSE_Arca_Marketplace_Fees.pdf;</E>
                         NYSE charges a removal fee of $0.0030 for orders that remove midpoint liquidity. 
                        <E T="03">See</E>
                         NYSE Stock Exchange Price List, “Equity per Share Charge—per transaction—MPL orders that remove liquidity from the NYSE (Adding Tier Credits do not apply) and with no Retail Modifier, as defined in Rule 13 (“Retail Modifier”)), pg. 5, available at 
                        <E T="03">https://www.nyse.com/publicdocs/nyse/markets/nyse/NYSE_Price_List.pdf;</E>
                         Nasdaq charges a removal fee of $0.0030. 
                        <E T="03">See</E>
                         Fees to Remove Liquidity, Shares Executed at or above $1.00, available at: 
                        <E T="03">https://www.nasdaqtrader.com/Trader.aspx?id=PriceListTrading2.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The Exchange believes the proposed rule change is consistent with the Act and the rules and regulations thereunder applicable to the Exchange and, in particular, the requirements of Section 6(b) of the Act.
                    <SU>14</SU>
                    <FTREF/>
                     Specifically, the Exchange believes the proposed rule change is consistent with the Section 6(b)(5) 
                    <SU>15</SU>
                    <FTREF/>
                     requirements that the rules of an exchange be designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in regulating, clearing, settling, processing information with respect to, and facilitating transactions in securities, to remove impediments to and perfect the mechanism of a free and open market and a national market system, and, in general, to protect investors and the public interest. Additionally, the Exchange believes the proposed rule change is consistent with the Section 6(b)(5) 
                    <SU>16</SU>
                    <FTREF/>
                     requirement that the rules of an exchange not be designed to permit unfair discrimination between customers, issuers, brokers, or dealers as well as Section 6(b)(4) 
                    <SU>17</SU>
                    <FTREF/>
                     as it is designed to provide for the equitable allocation of reasonable dues, fees and other charges among its Members and other persons using its facilities.
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         15 U.S.C. 78f(b)(4).
                    </P>
                </FTNT>
                <P>
                    Adjusting fee code AA and removing fee code, BJ, is necessary to reflect the transition of EDGA to a maker-taker fee model, effective November 1, 2024. Prior to the November 1, 2024, orders entered onto BYX, that were appended with fee code, AA, and were routed to EDGA using routing option ALLB, received a rebate of $0.0018 for removing liquidity from the EDGA Book for securities priced at or above $1.00. However, given EDGA's transition to a maker-taker fee model, orders that remove liquidity will now need to pay a liquidity removal fee, rather than receive a rebate. Accordingly, removal of the current $0.00180 rebate associated with fee code, AA, and implementation of a $0.0030 remove fee is appropriate and consistent with the economics of a maker-taker model, as well as the expectations of Members that remove liquidity from EDGA (
                    <E T="03">i.e.,</E>
                     Members would expect to pay a fee to remove liquidity). Moreover, the proposed fee is not unfairly discriminatory because it applies to all Members equally, in that all Members will pay the same fee for orders routed to EDGA using the ALLB routing strategy, and appended with fee code, AA.
                </P>
                <P>The Exchange also believes that its removal of fee code, BJ, is reasonable, equitable, and not unfairly discriminatory as it does not change the fees or rebates assessed by the Exchange, but rather updates the BYX Fee Schedule to remove a fee code that the Exchange no longer desires to, nor is required to, offer to its Members. Therefore, the proposed rule change is reasonably designed to update the Fee Schedule to accurately reflect the Exchange's current product offerings and is designed to reduce any potential confusion regarding the routing of orders with fee code, BJ, from BYX to EDGA. Furthermore, as noted above, orders appended with fee code, BJ, entered onto BYX and routed to EDGA using the routing option TRIM or SLIM, previously received a rebate of $0.0018 for removing liquidity from the EDGA Book. However, effective November 1, 2024, EDGA transitioned from an inverted fee model to a maker-taker fee model. As such, orders that remove liquidity from EDGA will pay a remove fee, rather than receive a rebate. Because Members typically utilize routing options TRIM and SLIM, and fee code BJ, to seek low-cost executions, it does not make sense to maintain the BJ fee code, as Members utilizing this fee code would not expect to pay a fee for removing liquidity from EDGA. Therefore, the Exchange proposes to discontinue this fee code, as it is no longer necessary, and BYX does not desire to charge such orders a fee for removing liquidity from EDGA.</P>
                <P>Finally, the Exchange believes that moving EDGA to the list of high-cost destinations for the RMPL routing strategy that are assigned the PL fee code, and assessing such orders a fee of $0.0030, is necessary and appropriate. Members appending their orders with the PL fee code already expect to pay a remove fee for removing liquidity from exchanges accessed by RMPL, rather than receive a rebate for removing liquidity as they do with liquidity removing orders appended with the PX fee code. Additionally, the remove fee of $0.0030 per share represents an equitable allocation of reasonable dues, fees, and other charges. The proposed change would enable the Exchange to charge a rate reasonably related to the rate that Cboe Trading, Inc. (“Cboe Trading”), the Exchange's affiliated routing broker-dealer, would be charged for routing orders to destinations described in fee codes PL. As a result, when Cboe Trading is charged a fee when it routes an order which removes liquidity from a destination described in fee codes PL, Cboe Trading will pass through these rates to the Exchange and the Exchange, in turn, will charge the rate under fee codes PL. The proposed fee under fee code, PL, for orders routed pursuant to the RMPL routing strategy would enable the Exchange to equitably allocate its costs among all Members.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>
                    The Exchange does not believe that the proposed rule changes will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. Given EDGA's transition to a maker-taker fee model, orders that remove liquidity will now need to pay a liquidity removal fee, rather than receive a rebate. Accordingly, removing the current $0.0018 rebate associated with fee code, AA, and implementing a $0.0030 remove fee is appropriate and consistent 
                    <PRTPAGE P="93685"/>
                    with the economics of a maker-taker model, as well as the expectations of Members that remove liquidity from EDGA (
                    <E T="03">i.e.,</E>
                     Members would expect to pay a fee to remove liquidity).
                </P>
                <P>Moreover, moving EDGA to the list of high-cost destinations for the RMPL routing strategy that are assigned the PL fee code simply reflects the fact that orders routed to EDGA that remove liquidity will now—just as they do on other exchanges accessed with the PL fee code—pay a remove fee instead of receiving a rebate. In addition, the BJ fee code was typically appended to orders utilizing the TRIM or SLIM strategies, which are designed to seek low-cost executions. Given EDGA's transition to a maker-taker fee model, though, removers of liquidity will now pay a remove fee. As such, it is appropriate to remove the BJ fee code as Member's utilizing this fee code would expect to receive a rebate and not expect to pay a fee. Accordingly, these proposed changes are necessary and appropriate in order to align Members' expectations with the economics of EDGA's new maker-taker fee model and will not have any impact on competition.</P>
                <P>Additionally, moving EDGA from fee code, PX, to fee code is PL, will not have any impact on competition. Rather, it is necessary and appropriate given EDGA's transition to a maker-taker fee model. Users of the PL fee code already expect to pay fees for removing liquidity from exchanges, whereas users of the PX fee code would expect lower-cost executions for removing liquidity from exchanges, including EDGA.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>The Exchange neither solicited nor received comments on the proposed rule change.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The foregoing rule change has become effective pursuant to Section 19(b)(3)(A) of the Act 
                    <SU>18</SU>
                    <FTREF/>
                     and paragraph (f) of Rule 19b-4 
                    <SU>19</SU>
                    <FTREF/>
                     thereunder. At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission will institute proceedings to determine whether the proposed rule change should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         15 U.S.C. 78s(b)(3)(A).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         17 CFR 240.19b-4(f).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-CboeBYX-2024-042 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-CboeBYX-2024-042. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-CboeBYX-2024-042 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>20</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>20</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27765 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101686; File No. SR-MRX-2024-43]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; Nasdaq MRX, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend its Fees for Connectivity and Co-location Services</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”),
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 8, 2024, Nasdaq MRX, LLC (“MRX” or “Exchange”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>The Exchange proposes to amend the Exchange's fees for connectivity and co-location services, as described further below.</P>
                <P>
                    The text of the proposed rule change is available on the Exchange's website at 
                    <E T="03">https://listingcenter.nasdaq.com/rulebook/mrx/rules,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>
                    In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of 
                    <PRTPAGE P="93686"/>
                    the most significant aspects of such statements.
                </P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    The purpose of the proposed rule change is to amend the Exchange's fees relating to connectivity and co-location services.
                    <SU>3</SU>
                    <FTREF/>
                     Specifically, the Exchange proposes to raise its fees for connectivity and co-location services in General 8 as well as certain fees related to its Testing Facilities in Options 7, Section 7 by 10%, with certain exceptions.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The Exchange initially filed the proposed pricing change on March 1, 2024 (SR-MRX-2024-04). On April 29, 2024, the Exchange withdrew that filing and submitted SR-MRX-2024-10. On June 27, 2024, the Exchange withdrew SR-MRX-2024-10 and submitted SR-MRX-2024-18. The Exchange withdrew SR-MRX-2024-18 and replaced it with SR-MRX-2024-34 on September 10, 2024. On October 11, 2024, The Exchange replaced SR-MRX-2024-34 with SR-MRX-2024-41. This instant filing replaces SR-MRX-2024-41.
                    </P>
                </FTNT>
                <P>
                    General 8, Section 1 includes the Exchange's fees that relate to connectivity, including fees for cabinets, external telco/inter-cabinet connectivity fees, fees for connectivity to the Exchange, fees for connectivity to third party services, fees for market data connectivity, fees for cabinet power install, and fees for additional charges and services. General 8, Section 2 includes the Exchange's fees for direct connectivity services, including fees for direct circuit connection to the Exchange, fees for direct circuit connection to third party services, and fees for point of presence connectivity. With the exception of the Exchange's GPS Antenna fees and the Cabinet Proximity Option Fee for cabinets with power density &gt;10kW,
                    <SU>4</SU>
                    <FTREF/>
                     the Exchange proposes to increase its fees throughout General 8 by 10%.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         The Exchange proposes to exclude the GPS Antenna fees from the proposed fee increase because, unlike the other fees in General 8, the Exchange recently increased its GPS Antenna fees. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-99130 (December 11, 2023), 88 FR 87009 (December 15, 2023) (SR-MRX-2023-24). The Exchange also proposes to exclude the Cabinet Proximity Option Fee for cabinets with power density &gt;10kW from the proposed fee increase because the Exchange recently established such fee. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-100200 (May 21, 2024), 89 FR 46183 (May 28, 2024) (SR-MRX-2024-12). Similarly, the Exchange proposes to exclude from the proposed fee increase those fees that the Exchange recently established for services in its new NY11-4 expansion facility. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-101269 (October 7, 2024), 89 FR 82657 (October 11, 2024) (SR-MRX-2024-37).
                    </P>
                </FTNT>
                <P>In addition to increasing fees in General 8, the Exchange also proposes to increase certain fees in Options 7, Section 7, which relate to the Testing Facility. Options 7, Section 7 provides that subscribers to the Testing Facility located in Carteret, New Jersey shall pay a fee of $1,000 per hand-off, per month for connection to the Testing Facility. The hand-off fee includes either a 1Gb or 10Gb switch port and a cross connect to the Testing Facility. In addition, Options 7, Section 7 provides that subscribers shall also pay a one-time installation fee of $1,000 per hand-off. The Exchange proposes to increase these aforementioned fees by 10% to require that subscribers to the Testing Facility shall pay a fee of $1,100 per hand-off, per month for connection to the Testing Facility and a one-time installation fee of $1,100 per hand-off.</P>
                <P>The proposed increases in fees would enable the Exchange to maintain and improve its market technology and services to remain competitive with its peers. Over the years, customer demand for more sophisticated, higher-throughput, lower-latency, and higher-power connectivity solutions has increased. The Exchange continues to invest in maintaining, improving, and enhancing its connectivity and co-location products, services, and facilities—for the benefit and often at the behest of its customers. Such enhancements include refreshing hardware and expanding Nasdaq's existing co-location facility to offer customers additional space and power. Nevertheless, and with the exception of fees that were established as part of a new service in 2017 (and have remained unchanged since their adoption), the Exchange has not increased any of the fees included in the proposal since prior to 2017, and many of the fees date back to between 2010 and 2014. For each of the connectivity products and services that pre-date 2017, inflation (as measured using the “Data PPI” metric described below) has been between roughly 15-17%, and in no instance has such inflation been less than 10%. Nevertheless, the Exchange proposes to increase its fees only with respect to the 10% inflation that has occurred since 2017.</P>
                <P>As discussed below, the Exchange proposes to adjust its fees by an industry- and product-specific inflationary measure. It is reasonable and consistent with the Act for the Exchange to recoup its investments, at least in part, by adjusting its fees. Continuing to operate at fees frozen at 2010-2017 levels impacts the Exchange's ability to enhance its offerings and the interests of market participants and investors.</P>
                <P>
                    The fee increases the Exchange proposes are based on an industry-specific Producer Price Index (“PPI”), which is a tailored measure of inflation.
                    <SU>5</SU>
                    <FTREF/>
                     As a general matter, the Producer Price Index is a family of indexes that measures the average change over time in selling prices received by domestic producers of goods and services. PPI measures price change from the perspective of the seller. This contrasts with other metrics, such as the Consumer Price Index (“CPI”), that measure price change from the purchaser's perspective.
                    <SU>6</SU>
                    <FTREF/>
                     About 10,000 PPIs for individual products and groups of products are tracked and released each month.
                    <SU>7</SU>
                    <FTREF/>
                     PPIs are available for the output of nearly all industries in the goods-producing sectors of the U.S. economy—mining, manufacturing, agriculture, fishing, and forestry—as well as natural gas, electricity, and construction, among others. The PPI program covers approximately 69 percent of the service sector's output, as measured by revenue reported in the 2017 Economic Census.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See https://fred.stlouisfed.org/series/PCU51825182#0.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See https://www.bls.gov/ppi/overview.htm.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See Id.</E>
                    </P>
                </FTNT>
                <P>For purposes of this proposal, the relevant industry-specific PPI is the Data Processing and Related Services PPI (“Data PPI”), which is an industry net-output PPI that measures the average change in selling prices received by companies that provide data processing services.</P>
                <P>
                    The Data PPI was introduced in January 2002 by the Bureau of Labor Statistics (“BLS”) as part of an ongoing effort to expand Producer Price Index coverage of the services sector of the U.S. economy and is identified as NAICS—518210 in the North American Industry Classification System.
                    <SU>8</SU>
                    <FTREF/>
                     According to the BLS “[t]he primary output of NAICS 518210 is the provision of electronic data processing services. In the broadest sense, computer services companies help their customers efficiently use technology. The processing services market consists of vendors who use their own computer systems—often utilizing proprietary software—to process customers' transactions and data. Companies that offer processing services collect, organize, and store a customer's transactions and other data for record-keeping purposes. Price movements for the NAICS 518210 index are based on changes in the revenue received by companies that provide data processing 
                    <PRTPAGE P="93687"/>
                    services. Each month, companies provide net transaction prices for a specified service. The transaction is an actual contract selected by probability, where the price-determining characteristics are held constant while the service is repriced. The prices used in index calculation are the actual prices billed for the selected service contract.” 
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">NAICS appears in table 5 of the PPI Detailed Report and is available at https://data.bls.gov/timeseries/PCU518210518210.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See https://www.bls.gov/ppi/factsheets/producer-price-index-for-the-data-processing-and-related-servicesindustry-naics-518210.htm.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange believes the Data PPI is an appropriate measure to be considered in the context of the proposed rule change to modify the fee for its connectivity products because the Exchange uses its “own computer systems” and “proprietary software,” 
                    <E T="03">i.e.,</E>
                     its own data center and proprietary matching engine software, respectively, to collect, organize, store and report customers' transactions in U.S. equity securities on the Exchange's proprietary trading platform. In other words, the Exchange is in the business of data processing and related services.
                </P>
                <P>For purposes of this proposed rule change, the Exchange examined the Data PPI value for the period from January 2017 to August 2024. The Data PPI had a starting value of 105.6 in January 2017 and an ending value of 116.022 in August 2024, a 10.422% increase. This indicates that companies who are also in the data storage and processing business have generally increased prices for a specified service covered under NAICS 518210 by an average of 10.422% during this period. Based on that percentage change, the Exchange proposes to make a one-time fee increase of only 10%, which reflects an increase covering roughly the entire period since the last price adjustments to these fees were made.</P>
                <P>
                    The Exchange further believes the Data PPI is an appropriate measure for purposes of the proposed rule change on the basis that it is a stable metric with limited volatility, unlike other consumer-side inflation metrics. In fact, the Data PPI has not experienced a greater than 2.16% increase for any one calendar year period since Data PPI was introduced into the PPI in January 2002. The average calendar year change from January 2002 to December 2023 was .62%, with a cumulative increase of 15.67% over this 21-year period. The Exchange believes the Data PPI is considerably less volatile than other inflation metrics such as CPI, which has had individual calendar-year increases of more than 6.5%, and a cumulative increase of over 73% over the same period.
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See https://www.usinflationcalculator.com/inflation/consumer-price-index-and-annual-percent-changesfrom-1913-to-2008/.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange believes the Data PPI, and significant investments into, and enhanced performance of, the Exchange support the reasonableness of the proposed fee increases.
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See supra</E>
                         discussion of connectivity product and facility improvements. Additionally, other exchanges have filed for increases in certain fees, based in part on comparisons to inflation. See, 
                        <E T="03">e.g.,</E>
                         Securities Exchange Act Release Nos. 34-100004 (April 22, 2024), 89 FR 32465 (April 26, 2024) (SR-CboeBYX-2024-012); and 34-100398 (June 21, 2024), 89 FR 53676 (June 27, 2024) (SR-BOX-2024-16)l; Securities Exchange Act Release No. 34-100994 (September 10, 2024), 89 FR 75612 (September 16, 2024) (SR-NYSEARCA-2024-79).
                    </P>
                </FTNT>
                <P>
                    These proposed fee increases will be immediately effective upon filing. However, going forward and until December 1, 2024, the Exchange will waive all fees set forth herein to the extent that such fees exceed the levels that would have been charged for the same products and services purchased during that time period, had such fees been calculated at the rates set forth in SR-MRX-2024-34 (
                    <E T="03">i.e.,</E>
                     pricing reflective of a 5.5% increase from prior fee levels). This waiver is reasonable, equitable, and not unfairly discriminatory because it will afford all customers in excess of the 30-day prior notice period for fee changes set forth in the Exchange's service terms.
                </P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The Exchange believes that its proposal is consistent with Section 6(b) of the Act,
                    <SU>12</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Sections 6(b)(4) and 6(b)(5) of the Act,
                    <SU>13</SU>
                    <FTREF/>
                     in particular, in that it provides for the equitable allocation of reasonable dues, fees and other charges among members and issuers and other persons using any facility, and is not designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         15 U.S.C. 78f(b)(4) and (5).
                    </P>
                </FTNT>
                <P>This belief is based on two factors. First, the current fees do not properly reflect the quality of the services and products, as fees for the services and products in question have been static in nominal terms, and therefore falling in real terms due to inflation. Second, the Exchange believes that investments made in enhancing the capacity and speed of Exchange systems increase the performance of the services and products.</P>
                <HD SOURCE="HD3">The Proposed Rule Change Is Reasonable</HD>
                <P>
                    As noted above, the Exchange has not increased any of the fees included in the proposal since 2017 or earlier. However, in the years following the last fee increases, the Exchange has made significant investments in upgrades to its connectivity products, services, and facilities, enhancing the quality of its services. In other words, Exchange customers have greatly benefitted, while the Exchange's ability to recoup its investments has been hampered. Between 2017 and 2024, the inflation rate is 3.64% per year, on average, producing a cumulative inflation rate of 28.43%.
                    <SU>14</SU>
                    <FTREF/>
                     Using the more targeted inflation number of Data PPI, the cumulative inflation rate was 10.422%. The exchange believes the Data PPI is a reasonable metric to base this fee increase on because it is targeted to producer-side increases in the data processing industry.
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See https://www.officialdata.org/us/inflation/2017?amount=1.</E>
                    </P>
                </FTNT>
                <P>
                    Notwithstanding inflation, as noted above, the Exchange has not increased its fees at all for over seven years for the subject services. The proposed fee changes represent a modest increase from the current fees. The Exchange believes the proposed fee increase is reasonable in light of the Exchange's continued expenditure in maintaining a robust technology ecosystem. Furthermore, the Exchange continues to invest in maintaining and enhancing its connectivity products—for the benefit and often at the behest of its customers and global investors. Such enhancements include refreshing all aspects of the technology ecosystem including software, hardware, and network while introducing new and innovative products and expanded and modernized facilities.
                    <SU>15</SU>
                    <FTREF/>
                     The goal of the enhancements discussed above, among other things, is to provide faster, higher-capacity, and more modern connectivity products and services. Accordingly, the Exchange continues to expend resources to innovate and modernize technology so that it may benefit its members in offering its connectivity products and services.
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See, e.g.,</E>
                         Securities Exchange Act Release No. 34-101077 (September 18, 2024), 89 FR 77904 (September 24, 2024) (SR-MRX-2024-36 (Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Expand [the Exchange's] Co-Location Services)).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">The Proposed Fees Are Equitably Allocated and Not Unfairly Discriminatory</HD>
                <P>
                    The Exchange believes that the proposed fee increases are equitably 
                    <PRTPAGE P="93688"/>
                    allocated and not unfairly discriminatory because they would apply to all market participants that choose to purchase connectivity products and services from the Exchange. Any participant that chooses to purchase the Exchange's connectivity products and services would be subject to the same Fee Schedule, regardless of what type of business they operate or the use they plan to make use of the products and services. Additionally, the fee increase would be applied uniformly to market participants without regard to Exchange membership status or the extent of any other business with the Exchange or affiliated entities. The Exchange also believes that the proposal represents an equitable allocation of reasonable dues, fees and other charges because Exchange fees have fallen in real terms during the relevant period. Finally, the Exchange believes that the proposed fee changes are not unfairly discriminatory because the fees would be assessed uniformly across all market participants, in the same manner they are today, that voluntarily purchase the Exchange's connectivity products and services, which would remain available for purchase by all market participants.
                </P>
                <P>
                    These proposed fee increases will be immediately effective upon filing. However, going forward and until December 1, 2024, the Exchange will waive all fees set forth herein to the extent that such fees exceed the levels that would have been charged for the same products and services purchased during that time period, had such fees been calculated at the rates set forth in SR-MRX-2024-34 (
                    <E T="03">i.e.,</E>
                     pricing reflective of a 5.5% increase from prior fee levels). This waiver is reasonable, equitable, and not unfairly discriminatory because it will afford all customers in excess of the 30-day prior notice period for fee changes set forth in the Exchange's service terms.
                </P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed fees will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.</P>
                <HD SOURCE="HD3">Intramarket Competition</HD>
                <P>The Exchange believes that the proposed fees do not put any market participants at a relative disadvantage compared to other market participants. As noted above, the fee schedule would continue to apply to all purchasers of the Exchange's connectivity products and services in the same manner as it does today albeit at inflation-adjusted rates for certain fees, and customers may choose whether to purchase these products and services at all. The Exchange also believes that the level of the proposed fees neither favor nor penalize one or more categories of market participants in a manner that would impose an undue burden on competition. Likewise, the proposed fee waiver described above will apply to all purchasers of the Exchange's connectivity products and services in the same manner and therefore will not burden competition among them.</P>
                <HD SOURCE="HD3">Intermarket Competition</HD>
                <P>The Exchange believes that the proposed fees do not impose a burden on competition or on other SROs that is not necessary or appropriate. In determining the proposed fees, the Exchange utilized an objective and stable metric with limited volatility. Utilizing Data PPI over a specified period of time is a reasonable means of recouping the Exchange's investment in maintaining and enhancing its connectivity products, services, and facilities. The Exchange believes utilizing Data PPI, a tailored measure of inflation, to increase certain fees for connectivity products and services to recoup the Exchange's investment in maintaining and enhancing such products, services, and its facilities would not impose a burden on competition.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were either solicited or received.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The foregoing rule change has become effective pursuant to Section 19(b)(3)(A)(ii) of the Act.
                    <SU>16</SU>
                    <FTREF/>
                     At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is: (i) necessary or appropriate in the public interest; (ii) for the protection of investors; or (iii) otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings to determine whether the proposed rule should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         15 U.S.C. 78s(b)(3)(A)(ii).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-MRX-2024-43 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-MRX-2024-43. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright  protection. All submissions should refer to file number SR-MRX-2024-43 and should be submitted on or before December 18, 2024.
                    <FTREF/>
                </FP>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         17 CFR 200.30-3(a)(12).
                    </P>
                </FTNT>
                <SIG>
                    <PRTPAGE P="93689"/>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>17</SU>
                    </P>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27755 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101685; File Nos. SR-DTC-2024-003; SR-FICC-2024-006; SR-NSCC-2024-003]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; The Depository Trust Company; Fixed Income Clearing Corporation; National Securities Clearing Corporation; Order Approving Proposed Rule Change To Amend the Clearing Agency Risk Management Framework</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <HD SOURCE="HD1">I. Introduction</HD>
                <P>
                    On March 11, 2024, The Depository Trust Company (“DTC”), Fixed Income Clearing Corporation (“FICC”), and National Securities Clearing Corporation (“NSCC,” each a “Clearing Agency,” and collectively, the “Clearing Agencies”), filed with the Securities and Exchange Commission (“Commission”) proposed rule changes SR-DTC-2024-003, SR-FICC-2024-006, and SR-NSCC-2024-003, respectively, pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) 
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder (the “Proposed Rule Changes”).
                    <SU>2</SU>
                    <FTREF/>
                     The Proposed Rule Changes were published for comment in the 
                    <E T="04">Federal Register</E>
                     on March 26, 2024.
                    <SU>3</SU>
                    <FTREF/>
                     The Commission has received comments on the changes proposed.
                    <SU>4</SU>
                    <FTREF/>
                     For the reasons discussed below, the Commission is approving the Proposed Rule Changes.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99802 (Mar. 20, 2024), 89 FR 21118 (Mar. 26, 2024) (File No. SR-DTC-2024-003) (“DTC Notice of Filing”); Securities Exchange Act Release No. 99805 (Mar. 20, 2024), 89 FR 21068 (Mar. 26, 2024) (File No. SR-FICC-2024-006) (“FICC Notice of Filing”); Securities Exchange Act Release No. 99803 (Mar. 20, 2024), 89 FR 21091 (Mar. 26, 2024) (File No. SR-NSCC-2024-003) (“NSCC Notice of Filing”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Specifically, the Commission received comments on the FICC Notice of Filing, and the comments are available at 
                        <E T="03">https://www.sec.gov/comments/sr-ficc-2024-006/srficc2024006.htm.</E>
                         The comments generally relate to issues raised in other FICC proposed rule changes that are not relevant to the Notices of Filing. See, Securities Exchange Act Release Nos. 99817 (SR-FICC-2024-005) and 99844 (SR-FICC-2024-007). The Commission considers the relevant comments related to the FICC Notice of Filing in its analysis at Section IV 
                        <E T="03">infra.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD1">II. Background</HD>
                <P>
                    On December 13, 2023, the Commission adopted rules under the Act to amend the standards applicable to covered clearing agencies providing central counterparty services for transactions in U.S. Treasury securities to require policies and procedures be reasonably designed to ensure that the covered clearing agency has appropriate means to facilitate access to clearance and settlement services of all eligible secondary market transactions in U.S. Treasury securities, including those of indirect participants.
                    <SU>5</SU>
                    <FTREF/>
                     The adopted rules also require that these policies and procedures be reviewed annually by the board of directors of such covered clearing agencies for U.S. Treasury securities.
                    <SU>6</SU>
                    <FTREF/>
                     Currently, FICC is the only Clearing Agency providing clearance and settlement services to the U.S. Treasury securities market.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See</E>
                         Standards for Covered Clearing Agencies for U.S. Treasury Securities and Application of the Broker-Dealer Customer Protection Rule with Respect to U.S. Treasury Securities, Exchange Act Release No. 99149 (Feb. 15, 2023), 88 FR 13872 (Jan. 16, 2024) (S7-23-22) (“Treasury Clearing Adopting Release”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <P>
                    To address the new requirements, the Clearing Agencies propose to amend their Clearing Agency Risk Management Framework (“Framework).
                    <SU>7</SU>
                    <FTREF/>
                     Specifically, the Proposed Rule Changes would add a new section to the Framework regarding “Solicitation of Participant and Stakeholder Views”. This subsection would: (i) describe generally Clearing Agency participant and industry stakeholder outreach in the development and evaluation of new programs or risk management practices, and (ii) provide for the annual review of FICC's Government Securities Division (“GSD”) access models by FICC's Board of Directors. The proposal would also make other conforming and clean up changes to the text of the Framework, as described below.
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         The Framework provides an outline for, among other things, how each of the Clearing Agencies comprehensively manages the risks, including the legal, credit, liquidity, operational, general business, investment, custody, and other risks, that arise in or are borne by it.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">III. Description of the Proposed Rule Changes</HD>
                <HD SOURCE="HD2">A. Subsection 3.4.1 General Solicitation of Views</HD>
                <P>
                    The Clearing Agencies state that they routinely solicit their participants' and other industry stakeholders' views when developing and evaluating products, services, or risk management practices so they may best meet the industry's needs.
                    <SU>8</SU>
                    <FTREF/>
                     To codify this practice, the proposal would add a new subsection to the Framework (entitled “General Solicitation of Views”), which identifies several ways that the Clearing Agencies may seek the views of participants and stakeholders. Such methods would include targeted outreach to firms expected to be impacted by a proposal, widely distributed surveys, ad hoc forums, and standing advisory councils assembled to consider issues relevant to a proposal. This list of outreach methods is illustrative, not exhaustive.
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See</E>
                         DTC Notice of Filing, 
                        <E T="03">supra</E>
                         note 3, 89 FR at 21119; FICC Notice of Filing, 
                        <E T="03">supra</E>
                         note 3, 89 FR at 21069; and NSCC Notice of Filing, 
                        <E T="03">supra</E>
                         note 3, 89 FR at 21091.
                    </P>
                </FTNT>
                <P>
                    The subsection would also identify the industry stakeholders that may participate in such advisory councils, including for example, representatives from transfer agents, liquidity providers, market infrastructures, institutional and retail investors, customers of the Clearing Agencies' participants, securities issuers, and securities holders. The Clearing Agencies state that the proposed changes in subsection 3.4.1 do not create any obligation for the Clearing Agencies to conduct such outreach in any particular circumstances.
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See</E>
                         DTC Notice of Filing, 
                        <E T="03">supra</E>
                         note 3, 89 FR at 21119; FICC Notice of Filing, 
                        <E T="03">supra</E>
                         note 3, 89 FR at 21069; and NSCC Notice of Filing, 
                        <E T="03">supra</E>
                         note 3, 89 FR at 21092.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Subsection 3.4.2 Required Solicitation of Views—Annual Review of GSD Access Models</HD>
                <P>
                    The Clearing Agencies propose adding a new subsection to the Framework (entitled “Required Solicitation of Views—Annual Review of GSD Access Models”) in connection with the recently adopted requirement in Rule 17ad-22(e)(18)(iv)(C) that the board of directors of a covered clearing agency annually review the policies and procedures that the covered clearing agency uses to ensure that they have appropriate means to facilitate access to clearance and settlement services of all eligible secondary market transactions in U.S. Treasury securities, including those of indirect participants.
                    <SU>10</SU>
                    <FTREF/>
                     To assist the board in their review of GSD access models, the Proposed Rule Changes would establish an advisory council comprised of participants, their customers, and other industry stakeholders. This advisory council review of GSD's access models would be escalated to the FICC Board of Directors, or a committee thereof, with its annual review of GSD's access models, which 
                    <PRTPAGE P="93690"/>
                    would also be required by this new subsection.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <P>
                    FICC's goal in the annual review of FICC/GSD's access models is to determine whether the GSD Clearing Rules and any other written policies and procedures are reasonably designed to ensure appropriate and flexible means to facilitate access to clearance and settlement of all eligible secondary market transactions in U.S. Treasury securities, including those of indirect participants.
                    <SU>11</SU>
                    <FTREF/>
                     In furtherance of this goal, the new subsection would require that the annual review include the following: (1) document any instance in which FICC treats transactions differently based on either the identity of the submitting participant, the fact that an indirect participant is a party to the transaction, the method of execution, or any other way, and confirm that any variation in treatment is both necessary and appropriate to meet the minimum standards regarding, among other things, operations, governance, and risk management identified in the Standards for Covered Clearing Agencies; (2) consider whether to enable GSD's Netting Members, as defined in the GSD Rules,
                    <SU>12</SU>
                    <FTREF/>
                     to submit eligible transactions for clearance and settlement that have been executed by two indirect participants of FICC/GSD (“done-away”); (3) consider the volumes and proportion of the markets that are being centrally cleared through different access models in determining whether FICC/GSD's access models are meeting the needs of the market; and (4) consider whether it is appropriate to develop and propose an additional category or categories of Netting Members to the GSD Rules to reflect the types of legal entities that applied to be a Netting Member over the prior 12 months and did not fit into one of the existing Netting Member categories.
                    <SU>13</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         DTC Notice of Filing, 
                        <E T="03">supra</E>
                         note 3, 89 FR at 21119; FICC Notice of Filing, 
                        <E T="03">supra</E>
                         note 3, 89 FR at 21069; and NSCC Notice of Filing, 
                        <E T="03">supra</E>
                         note 3, 89 FR at 21092.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         Fixed Income Clearing Corporation Government Securities Division Rulebook, Rule 1 (defining Netting Member and associated terms), 
                        <E T="03">available at https://www.dtcc.com/~/media/files/downloads/legal/rules/ficc_gov_rules.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         In a separate proposed rule change, FICC proposed to add a framework to consider an applicant who does not meet the eligibility requirements of any existing categories. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99817 (Mar. 21, 2024), 89 FR 21362, 21373 (Mar. 27, 2024) (File No. SR-FICC-2024-005).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">C. Other Conforming and Clean Up Changes</HD>
                <P>The proposal would make other conforming and clean up changes to the Framework. The Clearing Agencies would amend Section 1 of the Framework to: (1) include the annual review of GSD's access models in the list of regulatory requirements that are addressed in the Framework, and (2) update the description of the contents of Section 3 of the Framework to include the solicitation of participant and stakeholder views and annual review of GSD's access models as part of the Clearing Agencies' management of risks.</P>
                <P>
                    The Clearing Agencies would also remove the defined term “Management Committee” wherever referenced and replace it with “senior management committee” while maintaining the current makeup and responsibilities of the current Management Committee, as described in the Framework. The Clearing Agencies state that the proposed change would allow the Framework to continue to be accurate notwithstanding any future name changes to the committee.
                    <SU>14</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See</E>
                         DTC Notice of Filing, 
                        <E T="03">supra</E>
                         note 3, 89 FR at 21120; FICC Notice of Filing, 
                        <E T="03">supra</E>
                         note 3, 89 FR at 21070; and NSCC Notice of Filing, 
                        <E T="03">supra</E>
                         note 3, at 3.
                    </P>
                </FTNT>
                <P>Other minor grammatical and clean up changes would also be made to the Framework.</P>
                <HD SOURCE="HD1">IV. Discussion and Commission Findings</HD>
                <P>
                    Section 19(b)(2)(C) of the Act 
                    <SU>15</SU>
                    <FTREF/>
                     directs the Commission to approve a proposed rule change of a self-regulatory organization if it finds that such proposed rule change is consistent with the requirements of the Act and rules and regulations thereunder applicable to such organization. After carefully considering the Proposed Rule Changes, the Commission finds that the Proposed Rule Changes are consistent with the requirements of the Act and the rules and regulations thereunder applicable to the Clearing Agencies. In particular, the Commission finds that the Proposed Rule Changes are consistent with Section 17A(b)(3)(F) 
                    <SU>16</SU>
                    <FTREF/>
                     of the Act and Rule 17Ad-22(e)(18)(iv)(C),
                    <SU>17</SU>
                    <FTREF/>
                     each promulgated under the Act.
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         15 U.S.C. 78s(b)(2)(C).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         15 U.S.C. 78q-1(b)(3)(F).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">A. Section 17A(b)(3)(F) of the Act</HD>
                <P>
                    Section 17A(b)(3)(F) of the Act requires, in part, that the rules of a registered clearing agency be designed to promote the prompt and accurate clearance and settlement of securities transactions and assure the safeguarding of securities and funds which are in their custody or control or for which they are responsible.
                    <SU>18</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">See supra</E>
                         note 13.
                    </P>
                </FTNT>
                <P>
                    As described above in Section III.A, the Clearing Agencies routinely solicit their participants' and other industry stakeholders' views. The Proposed Rule Changes would codify that the Clearing Agencies use this practice, which should help ensure that the Clearing Agencies have mechanisms in place to be informed of the views of their participants and other industry stakeholders. By allowing specifically for formal engagement and transparency on their risk management practices, the Proposed Rule Changes should continue to encourage communication and provide a formal mechanism to help the Clearing Agencies identify and evaluate any unintended consequences a proposal or practice may have on its direct and indirect participants and obtain recommendations on how to meet its goals through alternative approaches. In addition, as described in Section III.B, the Proposed Rule Changes would establish an annual advisory council for FICC's GSD to assist the FICC Board of Directors, or a committee thereof, in its required annual review of GSD access models, and the Proposed Rule Changes would also identify several things that the advisory council would have to do as part of its review. Adopting this advisory council and a plan for its work, as well as requiring annual review by the FICC Board of Directors, should help FICC work to meet its regulatory obligations to establish, implement, maintain and enforce written policies and procedures reasonably designed to ensure that it has appropriate means to facilitate access, including for indirect participants, to its clearance and settlement services by providing a method by which FICC can be informed by its participants and other industry stakeholders as to access issues. This change should help ensure that FICC solicits and considers such views when making decisions about how to structure its access models, which should, in turn, help further continued prompt and accurate clearance and settlement in the U.S. Treasury market, consistent with Section 17A(b)(3)(F) of the Act.
                    <SU>19</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         15 U.S.C. 78q-1(b)(3)(F).
                    </P>
                </FTNT>
                <P>
                    Finally, the proposed conforming and clean-up changes should help to ensure that the Framework is clear and accurate. The risk management functions described in the Framework allow the Clearing Agencies to continue their critical operations and services, and better understanding of the Framework should help promote the prompt and accurate clearance and settlement of securities transactions, 
                    <PRTPAGE P="93691"/>
                    consistent with Section 17A(b)(3)(F) of the Act.
                    <SU>20</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         15 U.S.C. 78q-1(b)(3)(F).
                    </P>
                </FTNT>
                <P>Accordingly, and for the reasons stated above, the Commission finds that the Proposed Rule Changes are consistent with Section 17A(b)(3)(F) of the Act.</P>
                <HD SOURCE="HD2">B. Section 17Ad-22(e)(18)(iv)(C) of the Act</HD>
                <P>
                    Section 17Ad-22(e)(18)(iv)(C) under the Act requires, among other things, that a covered clearing agency serving the U.S. Treasury market, like FICC, establish, implement, maintain, and enforce written policies and procedures reasonably designed to ensure that the covered clearing agency has appropriate means to facilitate access to clearance and settlement services of all eligible secondary market transactions in U.S. Treasury securities, including those of indirect participants, and that the board of directors for the covered clearing agency, like FICC, annually review such policies and procedures.
                    <SU>21</SU>
                    <FTREF/>
                     The Proposed Rule Changes, as described in Section III.B above, would establish an advisory council and framework for that council's work and would provide for annual review by the FICC Board of Directors as to FICC's policies and procedures regarding access to its clearance and settlement services.
                </P>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <P>
                    One commenter addressed certain aspects of this proposal. Specifically, the commenter states that FICC's rules “should provide that indirect participants will be allotted at least 50% of the representation on the council.” 
                    <SU>22</SU>
                    <FTREF/>
                     The Commission agrees that indirect participant representation on the proposed council is important. Under the Proposed Rule Changes, the advisory council would include representatives not only from FICC participants, but also their customers, that is, indirect participants who rely on FICC's services to access FICC's clearance and settlement services. Though not required, the use of an advisory council is consistent with Rule 17ad-22(e)(18)(iv)(C), and that rule does not mandate the particular composition of the advisory council that FICC has chosen to establish.
                </P>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         Letter from Jiri Krol, Deputy CEO, Global Head of Government Affairs, Alternative Investment Management Association, at 8 (Apr. 23, 2024), 
                        <E T="03">available at https://www.sec.gov/comments/sr-ficc-2024-006/srficc2024006.htm</E>
                         (“AIMA Letter”).
                    </P>
                </FTNT>
                <P>
                    The Commission recently adopted Rule 17ad-25(j) 
                    <SU>23</SU>
                    <FTREF/>
                     which requires each registered clearing agency to establish, implement, maintain, and enforce written policies and procedures reasonably designed to solicit, consider, and document its consideration of the views of participants and other relevant stakeholders. The Commission therefore has given clearing agencies discretion in the design and structure of stakeholder outreach.
                    <SU>24</SU>
                    <FTREF/>
                     The Commission also stated in the Rule 17ad-25(j) final rule release that such “other relevant stakeholders” generally would include investors, customers of clearing agency participants, and securities issuers.
                    <SU>25</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         17 CFR 240.17ad-25(j).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         Clearing Agency Governance and Conflicts of Interest, Securities Exchange Act Release No. 98959 (Nov. 16, 2023), 88 FR 84454, 84483 (Dec. 5, 2023).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>Pursuant to the Proposed Rule Changes, FICC would include indirect participants on its advisory council. The Commission supports the inclusion of indirect participants and encourages FICC to solicit views from a variety of indirect participants who may have differing needs.</P>
                <P>
                    The commenter further stated that FICC should, “explicitly describe how and to what extent the feedback and recommendations made by the indirect participant members on the council (or indirect participants at large) will be considered and/or incorporated into the review process and potential changes to the access models.” 
                    <SU>26</SU>
                    <FTREF/>
                     Within the Proposed Rule Changes, FICC has outlined specific points of consideration, and specific data to document and analyze in furtherance of the annual review by the Board of Directors, or a committee thereof, of GSD access models as noted in Section III.B above. In addition, pursuant to the Proposed Rule Changes, the advisory council's review would be escalated to the FICC Board of Directors, or a committee thereof, to assist in their annual review. Rule 17ad-22(e)(18)(iv)(C) does not require the use of an advisory council.
                </P>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         AIMA Letter, 
                        <E T="03">supra</E>
                         note 22, at 8.
                    </P>
                </FTNT>
                <P>
                    Accordingly, the Commission finds that the Proposed Rule Changes are consistent with the requirements of Rule 17ad-22(e)(18)(iv)(C).
                    <SU>27</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">V. Conclusion</HD>
                <P>
                    On the basis of the foregoing, the Commission finds that the Proposed Rule Change is consistent with the requirements of the Act and in particular with the requirements of Section 17A of the Act 
                    <SU>28</SU>
                    <FTREF/>
                     and the rules and regulations promulgated thereunder.
                </P>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         15 U.S.C. 78q-1.
                    </P>
                </FTNT>
                <P>
                    <E T="03">It is therefore ordered,</E>
                     pursuant to Section 19(b)(2) of the Act 
                    <SU>29</SU>
                    <FTREF/>
                     that proposed rule changes SR-DTC-2024-003, SR-FICC-2024-006, and SR-NSCC-2024-003 be, and hereby are, 
                    <E T="03">approved</E>
                    .
                    <SU>30</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         15 U.S.C. 78s(b)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         In approving the Proposed Rule Changes, the Commission considered their impact on efficiency, competition, and capital formation. 15 U.S.C. 78c(f).
                    </P>
                </FTNT>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>31</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>31</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27754 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101693; File No. SR-NASDAQ-2024-068]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; The Nasdaq Stock Market LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend the Deadline for a Listed Company To Notify Nasdaq of a Reverse Stock Split</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”),
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 8, 2024, The Nasdaq Stock Market LLC (“Nasdaq” or “Exchange”) filed with the Securities and Exchange Commission (“SEC” or “Commission”) the proposed rule change as described in Items I, II, and III, below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>The Exchange proposes to modify its listing standards related to notification and disclosure of reverse stock splits to the Exchange. The proposed rule change will become operative on January 30, 2025.</P>
                <P>
                    The text of the proposed rule change is available on the Exchange's website at 
                    <E T="03">https://listingcenter.nasdaq.com/rulebook/nasdaq/rules,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>
                    In its filing with the Commission, the Exchange included statements 
                    <PRTPAGE P="93692"/>
                    concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.
                </P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    On June 21, 2023, Nasdaq filed with the Commission a proposed rule change related to notification and disclosure of reverse stock splits.
                    <SU>3</SU>
                    <FTREF/>
                     On November 1, 2023, the Commission approved the proposed rule changes.
                    <SU>4</SU>
                    <FTREF/>
                     On March 1, 2024, Nasdaq adopted an additional change to the rule and Company Event Notification Form to further clarify the requirements.
                    <SU>5</SU>
                    <FTREF/>
                     Nasdaq is now proposing to amend the deadline for a company to notify Nasdaq of a reverse stock split from 5 business days to 10 calendar days in order to conform to the requirements of SEC Rule 10b-17 of the Act.
                    <SU>6</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 98014 (July 28, 2023), 88 FR 51376 (August 3, 2023) (proposing SR-Nasdaq-2023-025).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 98843 (November 1, 2023), 88 FR 76867 (November 7, 2023) (approving SR-Nasdaq-2023-025).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99734 (March 14, 2024), 89 FR 19905 (March 20, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         17 CFR 240.10b-17.
                    </P>
                </FTNT>
                <P>
                    Specifically, Rule 10b-17(a)(2) and (b) of the Act, require issuers to provide notice to FINRA (formerly the National Association of Securities Dealers, Inc.) no later than 10 calendar days prior to the date of record to participate in a stock split or reverse stock split, unless the impacted security is traded on a national securities exchange with a substantially comparable requirement to those set forth in Rule 10b-17(b)(1).
                    <SU>7</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         17 CFR 240.10b-17(a)(2), (b)(1) and (b)(3).
                    </P>
                </FTNT>
                <P>Currently, Rule 5250(e)(7) and IM-5250-3 require a company conducting a reverse stock split to notify Nasdaq about certain details of the reverse stock split by submitting a complete Company Event Notification Form and a draft of the disclosure required by Rule 5250(b)(4) at least 5 business days (no later than 12:00 p.m. ET) prior to the anticipated market effective date, which includes all the information required by Rule 10b-17 applicable to reverse stock splits.</P>
                <P>
                    It has come to Nasdaq's attention that Nasdaq's current rule may not be considered substantially comparable to the 10 calendar-day prior notice required in Rule 10b-17 of the Act. Accordingly, Nasdaq is proposing to amend the deadline for a company to notify Nasdaq of a reverse stock split from no later than 12:00 p.m. ET 5 business days to 10 calendar days prior to the anticipated market effective date of the reverse stock split to ensure that Rule 5250(e)(7) and IM-5250-3 are substantially comparable to Rule 10b-17 and, therefore, that companies are compliant with Rule 10b-17 when they give notice under those rules.
                    <SU>8</SU>
                    <FTREF/>
                     Nasdaq is not amending the requirement to provide public disclosure under Rule 5250(b)(4) at least 2 business days (no later than 12:00 p.m. ET) prior to the anticipated market effective date. Nasdaq still believes that this timeframe provides sufficient notice to the public about reverse stock splits.
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         For example, if a company desires to effect a reverse stock split with a market effective date of Monday, September 23, the company would have to provide Nasdaq with a draft of the disclosure required by proposed Rule 5250(b)(4) and a complete Company Event Notification Form by 12:00 p.m. ET on Friday, September 13, and provide the public disclosure by 12:00 p.m. ET by Thursday, September 19. Note that this example presumes that there are no holidays during these dates. If a company withdraws and re-submits a Company Event Notification Form, the 10 calendar day period would be measured from the date the company re-submitted the form (rather than the date of the first submission).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See supra</E>
                         note 3.
                    </P>
                </FTNT>
                <P>
                    Nasdaq is also submitting an updated Company Event Notification Form as 
                    <E T="03">Exhibit 3</E>
                     to the rule filing. Nasdaq is making conforming changes to the Form to reflect that the deadline for submission is 10 calendar days, rather than 5 business days.
                </P>
                <P>
                    In order to provide companies that have already planned action for a reverse stock split under the current rule's timeframe with the ability to effect their reverse stock split under that schedule, the proposed rule change will become operative on January 30, 2025.
                    <SU>10</SU>
                    <FTREF/>
                     Nasdaq believes that this delayed operative date will allow sufficient time for market participants to adjust to the new time frame. For example, a company may have already scheduled a shareholder meeting or submitted a preliminary or final proxy statement to the Commission with a view towards effecting a reverse stock split based on the currently required five-day notice period. Nasdaq believes this delayed operative date will reduce potential confusion for companies and investors about the transition and allow companies to appropriately plan for the change.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         For example, a company may have already scheduled a shareholder meeting or submitted a preliminary or final proxy statement to the Commission with a view towards effecting a reverse stock split during a compliance period under the Nasdaq Listing Rules. The additional time to provide 10 calendar days advance notice of the reverse stock split, instead of the currently required five business-day notice period, could prevent the company from regaining compliance during the compliance period.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The Exchange believes that its proposal is consistent with Section 6(b) of the Act,
                    <SU>11</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Section 6(b)(5) of the Act,
                    <SU>12</SU>
                    <FTREF/>
                     in particular, in that it is designed to promote just and equitable principles of trade, to remove impediments to and perfect the mechanism of a free and open market and a national market system, and, in general to protect investors and the public interest, by aligning its rules related to notification of reverse stock splits with the notification requirements of Rule 10b-17 of the Act.
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <P>The proposal amends Rule 5250(e)(7) and IM-5250-3 to require a company to submit a complete Company Event Notification Form and a draft of the disclosure required by Rule 5250(b)(4) at least 10 calendar days (no later than 12:00 p.m. ET) prior to the anticipated market effective date, rather than 5 business days, and provides conforming updates to the Company Event Notification Form. Nasdaq believes that this will align Nasdaq's rules with the requirements of Rule 10b-17 under the Act, and will thereby help promote clarity, transparency and consistency for market participants and companies. Nasdaq also believes that the delayed operative date of the proposed rule change is consistent with Section 6(b)(5) of the Act in that it will allow sufficient time for market participants to adjust to the new time frame and will thereby help to reduce potential confusion for companies and investors.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>
                    The Exchange does not believe that the proposed rule change will impose any burden on competition not necessary or appropriate in furtherance of the purposes of the Act. The proposed change is designed to align an existing rule and related Company Event Notification Form with the requirements of Rule 10b-17 of the Act and, therefore, Nasdaq believes that the proposed change will not impose a burden on competition.
                    <PRTPAGE P="93693"/>
                </P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were either solicited or received.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    Because the foregoing proposed rule change does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative for 30 days from the date on which it was filed, or such shorter time as the Commission may designate, it has become effective pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>13</SU>
                    <FTREF/>
                     and subparagraph (f)(6) of Rule 19b-4 thereunder.
                    <SU>14</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6) requires a self-regulatory organization to give the Commission written notice of its intent to file the proposed rule change at least five business days prior to the date of filing of the proposed rule change, or such shorter time as designated by the Commission. The Exchange has satisfied this requirement.
                    </P>
                </FTNT>
                <P>At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings to determine whether the proposed rule should be approved or disapproved.</P>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-NASDAQ-2024-068 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-NASDAQ-2024-068. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549 on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-NASDAQ-2024-068 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>15</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>15</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27761 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101684; File No. SR-OCC-2024-014]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; The Options Clearing Corporation; Notice of Designation of Longer Period for Commission Action on Proposed Rule Change, as Modified by Partial Amendment No. 1, by the Options Clearing Corporation Concerning Its Process for Adjusting Certain Parameters in Its Proprietary System for Calculating Margin Requirements During Periods When the Products It Clears and the Markets It Serves Experience High Volatility</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    On October 1, 2024, the Options Clearing Corporation (“OCC”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change SR-OCC-2024-014, pursuant to Section 19(b) of the Securities Exchange Act of 1934 (“Exchange Act”) 
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 
                    <SU>2</SU>
                    <FTREF/>
                     thereunder, to codify OCC's process for adjusting certain parameters in its proprietary system for calculating margin requirements during periods when the products OCC clears and the markets it serves experience high volatility.
                    <SU>3</SU>
                    <FTREF/>
                     The proposed rule change, as modified by Partial Amendment no. 1 (hereinafter, the “Proposed Rule Change”), was published for public comment in the 
                    <E T="04">Federal Register</E>
                     on October 9, 2024.
                    <SU>4</SU>
                    <FTREF/>
                     The Commission has received no comments regarding the Proposed Rule Change.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing 
                        <E T="03">infra</E>
                         note 4, at 89 FR 81958.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Securities Exchange Act Release No. 101246 (Oct. 3, 2024), 89 FR 81958 (Oct. 9, 2024) (File No. SR-OCC-2024-014) (“Notice of Filing”).
                    </P>
                </FTNT>
                <P>
                    Section 19(b)(2)(i) of the Exchange Act 
                    <SU>5</SU>
                    <FTREF/>
                     provides that, within 45 days of the publication of notice of the filing of a proposed rule change, the Commission shall either approve the proposed rule change, disapprove the proposed rule change, or institute proceedings to determine whether the proposed rule change should be disapproved unless the Commission extends the period within which it must act as provided in Section 19(b)(2)(ii) of the Exchange Act.
                    <SU>6</SU>
                    <FTREF/>
                     Section 19(b)(2)(ii) of the Exchange Act allows the Commission to designate a longer period for review (up to 90 days from the publication of notice of the filing of a proposed rule change) if the Commission finds such longer period to be appropriate and publishes 
                    <PRTPAGE P="93694"/>
                    its reasons for so finding, or as to which the self-regulatory organization consents.
                    <SU>7</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         15 U.S.C. 78s(b)(2)(i).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         15 U.S.C. 78 s(b)(2)(ii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>The 45th day after publication of the Notice of Filing is November 23, 2024. In order to provide the Commission with sufficient time to consider the Proposed Rule Change, the Commission finds that it is appropriate to designate a longer period within which to take action on the Proposed Rule Change and therefore is extending this 45-day time period.</P>
                <P>
                    Accordingly, the Commission, pursuant to Section 19(b)(2) of the Exchange Act,
                    <SU>8</SU>
                    <FTREF/>
                     designates January 7, 2025, as the date by which the Commission shall either approve, disapprove, or institute proceedings to determine whether to disapprove proposed rule change SR-OCC-2024-014.
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>9</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>9</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27753 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101683; File No. SR-NYSEARCA-2024-96]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; NYSE Arca, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Rule 7.37-E</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) 
                    <SU>1</SU>
                    <FTREF/>
                     of the Securities Exchange Act of 1934 (the “Act”),
                    <SU>2</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>3</SU>
                    <FTREF/>
                     notice is hereby given that on November 7, 2024, NYSE Arca, Inc. (“NYSE Arca” or the “Exchange”) filed with the Securities and Exchange Commission (the “Commission”) the proposed rule change as described in Items I and II below, which Items have been prepared by the self-regulatory organization. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         15 U.S.C. 78a.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>
                    The Exchange proposes to amend Rule 7.37-E to specify the Exchange's source of data feeds from Long-Term Stock Exchange, Inc. (“LTSE”) for purposes of order handling, order execution, order routing, and regulatory compliance. The proposed rule change is available on the Exchange's website at 
                    <E T="03">www.nyse.com,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the self-regulatory organization included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of those statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant parts of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>The Exchange proposes to update and amend the use of data feeds table in Rule 7.37-E(d), which sets forth on a market-by-market basis the specific securities information processor (“SIP”) and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks related to each of those functions. Specifically, the Exchange proposes to amend the table in Rule 7.37-E(d) to specify that, with respect to LTSE, the Exchange will receive a LTSE direct feed as its primary source of data for order handling, order execution, order routing, and regulatory compliance, and will use the SIP Data Feed as its secondary source for data from LTSE.</P>
                <P>The Exchange proposes to make this change operative in the fourth quarter of 2024, and, in any event, before the end of the first quarter of 2025. The Exchange proposes to announce the implementation date of this change by Trader Update.</P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The proposed rule change is consistent with Section 6(b) of the Act,
                    <SU>4</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Section 6(b)(5),
                    <SU>5</SU>
                    <FTREF/>
                     in particular, because it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in facilitating transactions in securities, to remove impediments to, and perfect the mechanism of, a free and open market and a national market system and, in general, to protect investors and the public interest. Additionally, the Exchange believes that the proposed rule change is consistent with the Section 6(b)(5) requirement that the rules of an exchange not be designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <P>The Exchange believes its proposal to update the table in Rule 7.37(e) to include the LTSE direct feed will ensure that the Rule correctly identifies and publicly states on a market-by-market basis all of the specific SIP and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks for each of those functions. The proposed rule change also removes impediments to and perfects the mechanism of a free and open market and protects investors and the public interest by providing additional specificity, clarity, and transparency in the Exchange's rules.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>
                    The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. Rather, the Exchange believes that the proposal will enhance competition because providing the public and market participants with up-to-date information about the data feeds the Exchange will use for the handling, execution, and routing of orders, as well as for regulatory compliance would enhance transparency and enable investors to better assess the quality of the Exchange's execution and routing services. The Exchange also believes the proposal would enhance competition because it would potentially enhance the performance of its order handling and execution of orders in equity securities by receiving market data directly from LTSE. Finally, the proposed rule change would not impact competition between market participants because it will affect all market participants equally.
                    <PRTPAGE P="93695"/>
                </P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were solicited or received with respect to the proposed rule change.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The Exchange has filed the proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>6</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6) thereunder.
                    <SU>7</SU>
                    <FTREF/>
                     Because the proposed rule change does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative prior to 30 days from the date on which it was filed, or such shorter time as the Commission may designate, if consistent with the protection of investors and the public interest, the proposed rule change has become effective pursuant to Section 19(b)(3)(A) of the Act 
                    <SU>8</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6)(iii) thereunder.
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         15 U.S.C. 78s(b)(3)(A).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6) requires a self-regulatory organization to give the Commission written notice of its intent to file the proposed rule change, along with a brief description and text of the proposed rule change, at least five business days prior to the date of filing of the proposed rule change, or such shorter time as designated by the Commission. The Exchange has satisfied this requirement.
                    </P>
                </FTNT>
                <P>
                    At any time within 60 days of the filing of such proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings under Section 19(b)(2)(B) 
                    <SU>10</SU>
                    <FTREF/>
                     of the Act to determine whether the proposed rule change should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         15 U.S.C. 78s(b)(2)(B).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-NYSEARCA-2024-96 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-NYSEARCA-2024-96. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-NYSEARCA-2024-96 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>11</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>11</SU>
                             17 CFR 200.30-3(a)(12), (59).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27752 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101682; File No. SR-NYSENat-2024-30]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; NYSE National, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Rule 7.37</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) 
                    <SU>1</SU>
                    <FTREF/>
                     of the Securities Exchange Act of 1934 (the “Act”),
                    <SU>2</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>3</SU>
                    <FTREF/>
                     notice is hereby given that on November 7, 2024, NYSE National, Inc. (“NYSE National” or the “Exchange”) filed with the Securities and Exchange Commission (the “Commission”) the proposed rule change as described in Items I and II below, which Items have been prepared by the self-regulatory organization. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         15 U.S.C. 78a.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>
                    The Exchange proposes to amend Rule 7.37 to specify the Exchange's source of data feeds from Long-Term Stock Exchange, Inc. (“LTSE”) for purposes of order handling, order execution, order routing, and regulatory compliance. The proposed rule change is available on the Exchange's website at 
                    <E T="03">www.nyse.com,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>
                    In its filing with the Commission, the self-regulatory organization included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of those statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant parts of such statements.
                    <PRTPAGE P="93696"/>
                </P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>The Exchange proposes to update and amend the use of data feeds table in Rule 7.37(d), which sets forth on a market-by-market basis the specific securities information processor (“SIP”) and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks related to each of those functions. Specifically, the Exchange proposes to amend the table in Rule 7.37(d) to specify that, with respect to LTSE, the Exchange will receive a LTSE direct feed as its primary source of data for order handling, order execution, order routing, and regulatory compliance, and will use the SIP Data Feed as its secondary source for data from LTSE.</P>
                <P>The Exchange proposes to make this change operative in the fourth quarter of 2024, and, in any event, before the end of the first quarter of 2025. The Exchange proposes to announce the implementation date of this change by Trader Update.</P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The proposed rule change is consistent with Section 6(b) of the Act,
                    <SU>4</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Section 6(b)(5),
                    <SU>5</SU>
                    <FTREF/>
                     in particular, because it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in facilitating transactions in securities, to remove impediments to, and perfect the mechanism of, a free and open market and a national market system and, in general, to protect investors and the public interest. Additionally, the Exchange believes that the proposed rule change is consistent with the Section 6(b)(5) requirement that the rules of an exchange not be designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <P>The Exchange believes its proposal to update the table in Rule 7.37(e) to include the LTSE direct feed will ensure that the Rule correctly identifies and publicly states on a market-by-market basis all of the specific SIP and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks for each of those functions. The proposed rule change also removes impediments to and perfects the mechanism of a free and open market and protects investors and the public interest by providing additional specificity, clarity, and transparency in the Exchange's rules.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. Rather, the Exchange believes that the proposal will enhance competition because providing the public and market participants with up-to-date information about the data feeds the Exchange will use for the handling, execution, and routing of orders, as well as for regulatory compliance would enhance transparency and enable investors to better assess the quality of the Exchange's execution and routing services. The Exchange also believes the proposal would enhance competition because it would potentially enhance the performance of its order handling and execution of orders in equity securities by receiving market data directly from LTSE. Finally, the proposed rule change would not impact competition between market participants because it will affect all market participants equally.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were solicited or received with respect to the proposed rule change.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The Exchange has filed the proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>6</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6) thereunder.
                    <SU>7</SU>
                    <FTREF/>
                     Because the proposed rule change does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative prior to 30 days from the date on which it was filed, or such shorter time as the Commission may designate, if consistent with the protection of investors and the public interest, the proposed rule change has become effective pursuant to Section 19(b)(3)(A) of the Act 
                    <SU>8</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6)(iii) thereunder.
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         15 U.S.C. 78s(b)(3)(A).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6) requires a self-regulatory organization to give the Commission written notice of its intent to file the proposed rule change, along with a brief description and text of the proposed rule change, at least five business days prior to the date of filing of the proposed rule change, or such shorter time as designated by the Commission. The Exchange has satisfied this requirement.
                    </P>
                </FTNT>
                <P>
                    At any time within 60 days of the filing of such proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings under Section 19(b)(2)(B) 
                    <SU>10</SU>
                    <FTREF/>
                     of the Act to determine whether the proposed rule change should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         15 U.S.C. 78s(b)(2)(B).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-NYSENat-2024-30 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-NYSENat-2024-30. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the 
                    <PRTPAGE P="93697"/>
                    public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-NYSENat-2024-30 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>11</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>11</SU>
                             17 CFR 200.30-3(a)(12), (59).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27751 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101691; File No. SR-Phlx-2024-57]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; Nasdaq PHLX LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Its Fees for Connectivity and Co-Location Services</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”),
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 8, 2024, Nasdaq PHLX LLC (“Phlx” or “Exchange”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>The Exchange proposes to amend the Exchange's fees for connectivity and co-location services, as described further below.</P>
                <P>
                    The text of the proposed rule change is available on the Exchange's website at 
                    <E T="03">https://listingcenter.nasdaq.com/rulebook/phlx/rules,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    The purpose of the proposed rule change is to amend the Exchange's fees relating to connectivity and co-location services.
                    <SU>3</SU>
                    <FTREF/>
                     Specifically, the Exchange proposes to raise its fees for connectivity and co-location services in General 8 as well as certain fees related to its Testing Facilities in Equity 7, Section 3 by 10%, with certain exceptions.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The Exchange initially filed the proposed pricing change on March 1, 2024 (SR-PHLX-2024-08). On April 29, 2024, the Exchange withdrew that filing and submitted SR-Phlx-2024-019. The Exchange withdrew SR-PHLX-2024-019 and replaced it with SR-PHLX-2024-27. The instant filing replaces SR-PHLX-2024-027, which was withdrawn on August 23, 2024. The Exchange withdrew SR-PHLX-2024-07 and replaced it with SR-PHLX-2024-45 on September 10, 2024. On October 11, 2024, the Exchange replaced SR-PHLX-2024-45 with SR-PHLX-2024-52. The instant filing replaces SR-PHLX-2024-52.
                    </P>
                </FTNT>
                <P>
                    General 8, Section 1 includes the Exchange's fees that relate to connectivity, including fees for cabinets, external telco/inter-cabinet connectivity fees, fees for connectivity to the Exchange, fees for connectivity to third party services, fees for market data connectivity, fees for cabinet power install, and fees for additional charges and services. General 8, Section 2 includes the Exchange's fees for direct connectivity services, including fees for direct circuit connection to the Exchange, fees for direct circuit connection to third party services, and fees for point of presence connectivity. With the exception of the Exchange's GPS Antenna fees and the Cabinet Proximity Option Fee for cabinets with power density &gt;10kW,
                    <SU>4</SU>
                    <FTREF/>
                     the Exchange proposes to increase its fees throughout General 8 by 10%.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         The Exchange proposes to exclude the GPS Antenna fees from the proposed fee increase because, unlike the other fees in General 8, the Exchange recently increased its GPS Antenna fees. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-99125 (December 8, 2023), 88 FR 86705 (December 14, 2023) (SR-Phlx-2023-53). The Exchange also proposes to exclude the Cabinet Proximity Option Fee for cabinets with power density &gt;10kW from the proposed fee increase because the Exchange recently established such fee. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-100197 (May 21, 2024), 89 FR 46185 (May 28, 2024) (SR-Phlx-2024-23). Similarly, the Exchange proposes to exclude from the proposed fee increase those fees that the Exchange recently established for services in its new NY11-4 expansion facility. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-101268 (October 7, 2024), 89 FR 82661 (October 11, 2024) (SR-PHLX-2024-49).
                    </P>
                </FTNT>
                <P>In addition to increasing fees in General 8, the Exchange also proposes to increase certain fees in Equity 7, Section 3, which relate to the Testing Facility. Equity 7, Section 3 provides that subscribers to the Testing Facility located in Carteret, New Jersey shall pay a fee of $1,000 per hand-off, per month for connection to the Testing Facility. The hand-off fee includes either a 1Gb or 10Gb switch port and a cross connect to the Testing Facility. In addition, Equity 7, Section 3 provides that subscribers shall also pay a one-time installation fee of $1,000 per hand-off. The Exchange proposes to increase these aforementioned fees by 10% to require that subscribers to the Testing Facility shall pay a fee of $1,100 per hand-off, per month for connection to the Testing Facility and a one-time installation fee of $1,100 per hand-off.</P>
                <P>
                    The proposed increases in fees would enable the Exchange to maintain and improve its market technology and services to remain competitive with its peers. Over the years, customer demand for more sophisticated, higher-throughput, lower-latency, and higher-power connectivity solutions has increased. The Exchange continues to invest in maintaining, improving, and enhancing its connectivity and co-location products, services, and facilities—for the benefit and often at the behest of its customers. Such enhancements include refreshing hardware and expanding Nasdaq's existing co-location facility to offer customers additional space and power. Nevertheless, and with the exception of fees that were established as part of a new service in 2017 (and have remained unchanged since their adoption), the Exchange has not increased any of the fees included in the proposal since prior to 2017, and many of the fees date back to between 2010 and 2014. For each of 
                    <PRTPAGE P="93698"/>
                    the connectivity products and services that pre-date 2017, inflation (as measured using the “Data PPI” metric described below) has been between roughly 15-17%, and in no instance has such inflation been less than 10%. Nevertheless, the Exchange proposes to increase its fees only with respect to the 10% inflation that has occurred since 2017.
                </P>
                <P>As discussed below, the Exchange proposes to adjust its fees by an industry- and product-specific inflationary measure. It is reasonable and consistent with the Act for the Exchange to recoup its investments, at least in part, by adjusting its fees. Continuing to operate at fees frozen at 2010-2017 levels impacts the Exchange's ability to enhance its offerings and the interests of market participants and investors.</P>
                <P>
                    The fee increases the Exchange proposes are based on an industry-specific Producer Price Index (“PPI”), which is a tailored measure of inflation.
                    <SU>5</SU>
                    <FTREF/>
                     As a general matter, the Producer Price Index is a family of indexes that measures the average change over time in selling prices received by domestic producers of goods and services. PPI measures price change from the perspective of the seller. This contrasts with other metrics, such as the Consumer Price Index (“CPI”), that measure price change from the purchaser's perspective.
                    <SU>6</SU>
                    <FTREF/>
                     About 10,000 PPIs for individual products and groups of products are tracked and released each month.
                    <SU>7</SU>
                    <FTREF/>
                     PPIs are available for the output of nearly all industries in the goods-producing sectors of the U.S. economy—mining, manufacturing, agriculture, fishing, and forestry—as well as natural gas, electricity, and construction, among others. The PPI program covers approximately 69 percent of the service sector's output, as measured by revenue reported in the 2017 Economic Census.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See https://fred.stlouisfed.org/series/PCU51825182#0.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See https://www.bls.gov/ppi/overview.htm.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See Id.</E>
                    </P>
                </FTNT>
                <P>For purposes of this proposal, the relevant industry-specific PPI is the Data Processing and Related Services PPI (“Data PPI”), which is an industry net-output PPI that measures the average change in selling prices received by companies that provide data processing services.</P>
                <P>
                    The Data PPI was introduced in January 2002 by the Bureau of Labor Statistics (“BLS”) as part of an ongoing effort to expand Producer Price Index coverage of the services sector of the U.S. economy and is identified as NAICS-518210 in the North American Industry Classification System.
                    <SU>8</SU>
                    <FTREF/>
                     According to the BLS “[t]he primary output of NAICS 518210 is the provision of electronic data processing services. In the broadest sense, computer services companies help their customers efficiently use technology. The processing services market consists of vendors who use their own computer systems—often utilizing proprietary software—to process customers' transactions and data. Companies that offer processing services collect, organize, and store a customer's transactions and other data for record-keeping purposes. Price movements for the NAICS 518210 index are based on changes in the revenue received by companies that provide data processing services. Each month, companies provide net transaction prices for a specified service. The transaction is an actual contract selected by probability, where the price-determining characteristics are held constant while the service is repriced. The prices used in index calculation are the actual prices billed for the selected service contract.” 
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">NAICS appears in table 5 of the PPI Detailed Report and is available at https://data.bls.gov/timeseries/PCU518210518210.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See https://www.bls.gov/ppi/factsheets/producer-price-index-for-the-data-processing-and-related-servicesindustry-naics-518210.htm.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange believes the Data PPI is an appropriate measure to be considered in the context of the proposed rule change to modify the fee for its connectivity products because the Exchange uses its “own computer systems” and “proprietary software,” 
                    <E T="03">i.e.,</E>
                     its own data center and proprietary matching engine software, respectively, to collect, organize, store and report customers' transactions in U.S. equity securities on the Exchange's proprietary trading platform. In other words, the Exchange is in the business of data processing and related services.
                </P>
                <P>For purposes of this proposed rule change, the Exchange examined the Data PPI value for the period from January 2017 to August 2024. The Data PPI had a starting value of 105.6 in January 2017 and an ending value of 116.022 in August 2024, a 10.422% increase. This indicates that companies who are also in the data storage and processing business have generally increased prices for a specified service covered under NAICS 518210 by an average of 10.422% during this period. Based on that percentage change, the Exchange proposes to make a one-time fee increase of only 10%, which reflects an increase covering roughly the entire period since the last price adjustments to these fees were made.</P>
                <P>
                    The Exchange further believes the Data PPI is an appropriate measure for purposes of the proposed rule change on the basis that it is a stable metric with limited volatility, unlike other consumer-side inflation metrics. In fact, the Data PPI has not experienced a greater than 2.16% increase for any one calendar year period since Data PPI was introduced into the PPI in January 2002. The average calendar year change from January 2002 to December 2023 was .62%, with a cumulative increase of 15.67% over this 21-year period. The Exchange believes the Data PPI is considerably less volatile than other inflation metrics such as CPI, which has had individual calendar-year increases of more than 6.5%, and a cumulative increase of over 73% over the same period.
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See https://www.usinflationcalculator.com/inflation/consumer-price-index-and-annual-percent-changesfrom-1913-to-2008/.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange believes the Data PPI, and significant investments into, and enhanced performance of, the Exchange support the reasonableness of the proposed fee increases.
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See supra</E>
                         discussion of connectivity product and facility improvements. Additionally, other exchanges have filed for increases in certain fees, based in part on comparisons to inflation. See, 
                        <E T="03">e.g.,</E>
                         Securities Exchange Act Release Nos. 34-100004 (April 22, 2024), 89 FR 32465 (April 26, 2024) (SR-CboeBYX-2024-012); and 34-100398 (June 21, 2024), 89 FR 53676 (June 27, 2024) (SR-BOX-2024-16)l; Securities Exchange Act Release No. 34-100994 (September 10, 2024), 89 FR 75612 (September 16, 2024) (SR-NYSEARCA-2024-79).
                    </P>
                </FTNT>
                <P>
                    These proposed fee increases will be immediately effective upon filing. However, going forward and until December 1, 2024, the Exchange will waive all fees set forth herein to the extent that such fees exceed the levels that would have been charged for the same products and services purchased during that time period, had such fees been calculated at the rates set forth in SR-PHLX-2024-45 (
                    <E T="03">i.e.,</E>
                     pricing reflective of a 5.5% increase from prior fee levels). This waiver is reasonable, equitable, and not unfairly discriminatory because it will afford all customers in excess of the 30-day prior notice period for fee changes set forth in the Exchange's service terms.
                </P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The Exchange believes that its proposal is consistent with Section 6(b) of the Act,
                    <SU>12</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Sections 6(b)(4) and 6(b)(5) of the Act,
                    <SU>13</SU>
                    <FTREF/>
                     in particular, in that it provides for the equitable allocation of reasonable dues, fees and other charges 
                    <PRTPAGE P="93699"/>
                    among members and issuers and other persons using any facility, and is not designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         15 U.S.C. 78f(b)(4) and (5).
                    </P>
                </FTNT>
                <P>This belief is based on two factors. First, the current fees do not properly reflect the quality of the services and products, as fees for the services and products in question have been static in nominal terms, and therefore falling in real terms due to inflation. Second, the Exchange believes that investments made in enhancing the capacity and speed of Exchange systems increase the performance of the services and products.</P>
                <HD SOURCE="HD3">The Proposed Rule Change Is Reasonable</HD>
                <P>
                    As noted above, the Exchange has not increased any of the fees included in the proposal since 2017 or earlier. However, in the years following the last fee increases, the Exchange has made significant investments in upgrades to its connectivity products, services, and facilities, enhancing the quality of its services. In other words, Exchange customers have greatly benefitted, while the Exchange's ability to recoup its investments has been hampered. Between 2017 and 2024, the inflation rate is 3.64% per year, on average, producing a cumulative inflation rate of 28.43%.
                    <SU>14</SU>
                    <FTREF/>
                     Using the more targeted inflation number of Data PPI, the cumulative inflation rate was 10.422%. The exchange believes the Data PPI is a reasonable metric to base this fee increase on because it is targeted to producer-side increases in the data processing industry.
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See https://www.officialdata.org/us/inflation/2017?amount=1.</E>
                    </P>
                </FTNT>
                <P>
                    Notwithstanding inflation, as noted above, the Exchange has not increased its fees at all for over seven years for the subject services. The proposed fee changes represent a modest increase from the current fees. The Exchange believes the proposed fee increase is reasonable in light of the Exchange's continued expenditure in maintaining a robust technology ecosystem. Furthermore, the Exchange continues to invest in maintaining and enhancing its connectivity products—for the benefit and often at the behest of its customers and global investors. Such enhancements include refreshing all aspects of the technology ecosystem including software, hardware, and network while introducing new and innovative products and expanded and modernized facilities.
                    <SU>15</SU>
                    <FTREF/>
                     The goal of the enhancements discussed above, among other things, is to provide faster, higher-capacity, and more modern connectivity products and services. Accordingly, the Exchange continues to expend resources to innovate and modernize technology so that it may benefit its members in offering its connectivity products and services.
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See, e.g.,</E>
                         Securities Exchange Act Release No.34-101079 (September 18, 2024), 89 FR 77931 (September 24, 2024) (SR-PHLX-2024-47 (Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Expand [the Exchange's] Co-Location Services).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">The Proposed Fees Are Equitably Allocated and Not Unfairly Discriminatory</HD>
                <P>The Exchange believes that the proposed fee increases are equitably allocated and not unfairly discriminatory because they would apply to all market participants that choose to purchase connectivity products and services from the Exchange. Any participant that chooses to purchase the Exchange's connectivity products and services would be subject to the same Fee Schedule, regardless of what type of business they operate or the use they plan to make use of the products and services. Additionally, the fee increase would be applied uniformly to market participants without regard to Exchange membership status or the extent of any other business with the Exchange or affiliated entities. The Exchange also believes that the proposal represents an equitable allocation of reasonable dues, fees and other charges because Exchange fees have fallen in real terms during the relevant period. Finally, the Exchange believes that the proposed fee changes are not unfairly discriminatory because the fees would be assessed uniformly across all market participants, in the same manner they are today, that voluntarily purchase the Exchange's connectivity products and services, which would remain available for purchase by all market participants.</P>
                <P>
                    These proposed fee increases will be immediately effective upon filing. However, going forward and until December 1, 2024, the Exchange will waive all fees set forth herein to the extent that such fees exceed the levels that would have been charged for the same products and services purchased during that time period, had such fees been calculated at the rates set forth in SR-PHLX-2024-45 (
                    <E T="03">i.e.,</E>
                     pricing reflective of a 5.5% increase from prior fee levels). This waiver is reasonable, equitable, and not unfairly discriminatory because it will afford all customers in excess of the 30-day prior notice period for fee changes set forth in the Exchange's service terms.
                </P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed fees will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.</P>
                <HD SOURCE="HD3">Intramarket Competition</HD>
                <P>The Exchange believes that the proposed fees do not put any market participants at a relative disadvantage compared to other market participants. As noted above, the fee schedule would continue to apply to all purchasers of the Exchange's connectivity products and services in the same manner as it does today albeit at inflation-adjusted rates for certain fees, and customers may choose whether to purchase these products and services at all. The Exchange also believes that the level of the proposed fees neither favor nor penalize one or more categories of market participants in a manner that would impose an undue burden on competition. Likewise, the proposed fee waiver described above will apply to all purchasers of the Exchange's connectivity products and services in the same manner and therefore will not burden competition among them.</P>
                <HD SOURCE="HD3">Intermarket Competition</HD>
                <P>The Exchange believes that the proposed fees do not impose a burden on competition or on other SROs that is not necessary or appropriate. In determining the proposed fees, the Exchange utilized an objective and stable metric with limited volatility. Utilizing Data PPI over a specified period of time is a reasonable means of recouping the Exchange's investment in maintaining and enhancing its connectivity products, services, and facilities. The Exchange believes utilizing Data PPI, a tailored measure of inflation, to increase certain fees for connectivity products and services to recoup the Exchange's investment in maintaining and enhancing such products, services, and its facilities would not impose a burden on competition.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>
                    No written comments were either solicited or received.
                    <PRTPAGE P="93700"/>
                </P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The foregoing rule change has become effective pursuant to Section 19(b)(3)(A)(ii) of the Act.
                    <SU>16</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         15 U.S.C. 78s(b)(3)(A)(ii).
                    </P>
                </FTNT>
                <P>At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is: (i) necessary or appropriate in the public interest; (ii) for the protection of investors; or (iii) otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings to determine whether the proposed rule should be approved or disapproved.</P>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-Phlx-2024-57 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-Phlx-2024-57. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-Phlx-2024-57 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>17</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>17</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27760 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101679; File No. SR-NYSE-2024-74]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; New York Stock Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Rule 7.37</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) 
                    <SU>1</SU>
                    <FTREF/>
                     of the Securities Exchange Act of 1934 (the “Act”),
                    <SU>2</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>3</SU>
                    <FTREF/>
                     notice is hereby given that on November 7, 2024, New York Stock Exchange LLC (“NYSE” or the “Exchange”) filed with the Securities and Exchange Commission (the “Commission”) the proposed rule change as described in Items I and II below, which Items have been prepared by the self-regulatory organization. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         15 U.S.C. 78a.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>
                    The Exchange proposes to amend Rule 7.37 to specify the Exchange's source of data feeds from Investors' Exchange, LLC (“IEX”) for purposes of order handling, order execution, order routing, and regulatory compliance. The proposed rule change is available on the Exchange's website at 
                    <E T="03">www.nyse.com,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the self-regulatory organization included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of those statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant parts of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>The Exchange proposes to update and amend the use of data feeds table in Rule 7.37(e), which sets forth on a market-by-market basis the specific securities information processor (“SIP”) and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks related to each of those functions. Specifically, the Exchange proposes to amend the table in Rule 7.37(e) to specify that, with respect to IEX, the Exchange will receive an IEX direct feed as its primary source of data for order handling, order execution, order routing, and regulatory compliance, and will use the SIP Data Feed as its secondary source for data from IEX.</P>
                <P>The Exchange proposes to make this change operative in the fourth quarter of 2024, and, in any event, before the end of the first quarter of 2025. The Exchange proposes to announce the implementation date of this change by Trader Update.</P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The proposed rule change is consistent with Section 6(b) of the Act,
                    <SU>4</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Section 6(b)(5),
                    <SU>5</SU>
                    <FTREF/>
                     in particular, because it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in facilitating transactions in securities, to 
                    <PRTPAGE P="93701"/>
                    remove impediments to, and perfect the mechanism of, a free and open market and a national market system and, in general, to protect investors and the public interest. Additionally, the Exchange believes that the proposed rule change is consistent with the Section 6(b)(5) requirement that the rules of an exchange not be designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <P>The Exchange believes its proposal to update the table in Rule 7.37(e) to include the IEX direct feed will ensure that the Rule correctly identifies and publicly states on a market-by-market basis all of the specific SIP and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks for each of those functions. The proposed rule change also removes impediments to and perfects the mechanism of a free and open market and protects investors and the public interest by providing additional specificity, clarity, and transparency in the Exchange's rules.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. Rather, the Exchange believes that the proposal will enhance competition because providing the public and market participants with up-to-date information about the data feeds the Exchange will use for the handling, execution, and routing of orders, as well as for regulatory compliance would enhance transparency and enable investors to better assess the quality of the Exchange's execution and routing services. The Exchange also believes the proposal would enhance competition because it would potentially enhance the performance of its order handling and execution of orders in equity securities by receiving market data directly from IEX. Finally, the proposed rule change would not impact competition between market participants because it will affect all market participants equally.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were solicited or received with respect to the proposed rule change.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The Exchange has filed the proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>6</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6) thereunder.
                    <SU>7</SU>
                    <FTREF/>
                     Because the proposed rule change does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative prior to 30 days from the date on which it was filed, or such shorter time as the Commission may designate, if consistent with the protection of investors and the public interest, the proposed rule change has become effective pursuant to Section 19(b)(3)(A) of the Act 
                    <SU>8</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6)(iii) thereunder.
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         15 U.S.C. 78s(b)(3)(A).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6) requires a self-regulatory organization to give the Commission written notice of its intent to file the proposed rule change, along with a brief description and text of the proposed rule change, at least five business days prior to the date of filing of the proposed rule change, or such shorter time as designated by the Commission. The Exchange has satisfied this requirement.
                    </P>
                </FTNT>
                <P>
                    At any time within 60 days of the filing of such proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings under Section 19(b)(2)(B) 
                    <SU>10</SU>
                    <FTREF/>
                     of the Act to determine whether the proposed rule change should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         15 U.S.C. 78s(b)(2)(B).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-NYSE-2024-74 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-NYSE-2024-74. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-NYSE-2024-74 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>11</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>11</SU>
                             17 CFR 200.30-3(a)(12), (59).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27748 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101680; File No. SR-NYSENAT-2024-29]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; NYSE National, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Rule 7.37</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) 
                    <SU>1</SU>
                    <FTREF/>
                     of the Securities Exchange Act of 1934 (the 
                    <PRTPAGE P="93702"/>
                    “Act”),
                    <SU>2</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>3</SU>
                    <FTREF/>
                     notice is hereby given that on November 7, 2024, NYSE National, Inc. (“NYSE National” or the “Exchange”) filed with the Securities and Exchange Commission (the “Commission”) the proposed rule change as described in Items I and II below, which Items have been prepared by the self-regulatory organization. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         15 U.S.C. 78a.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>
                    The Exchange proposes to amend Rule 7.37 to specify the Exchange's source of data feeds from Investors' Exchange, LLC (“IEX”) for purposes of order handling, order execution, order routing, and regulatory compliance. The proposed rule change is available on the Exchange's website at 
                    <E T="03">www.nyse.com,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the self-regulatory organization included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of those statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant parts of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>The Exchange proposes to update and amend the use of data feeds table in Rule 7.37(d), which sets forth on a market-by-market basis the specific securities information processor (“SIP”) and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks related to each of those functions. Specifically, the Exchange proposes to amend the table in Rule 7.37(d) to specify that, with respect to IEX, the Exchange will receive an IEX direct feed as its primary source of data for order handling, order execution, order routing, and regulatory compliance, and will use the SIP Data Feed as its secondary source for data from IEX.</P>
                <P>The Exchange proposes to make this change operative in the fourth quarter of 2024, and, in any event, before the end of the first quarter of 2025. The Exchange proposes to announce the implementation date of this change by Trader Update.</P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The proposed rule change is consistent with Section 6(b) of the Act,
                    <SU>4</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Section 6(b)(5),
                    <SU>5</SU>
                    <FTREF/>
                     in particular, because it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in facilitating transactions in securities, to remove impediments to, and perfect the mechanism of, a free and open market and a national market system and, in general, to protect investors and the public interest. Additionally, the Exchange believes that the proposed rule change is consistent with the Section 6(b)(5) requirement that the rules of an exchange not be designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <P>The Exchange believes its proposal to update the table in Rule 7.37(d) to include the IEX direct feed will ensure that the Rule correctly identifies and publicly states on a market-by-market basis all of the specific SIP and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks for each of those functions. The proposed rule change also removes impediments to and perfects the mechanism of a free and open market and protects investors and the public interest by providing additional specificity, clarity, and transparency in the Exchange's rules.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. Rather, the Exchange believes that the proposal will enhance competition because providing the public and market participants with up-to-date information about the data feeds the Exchange will use for the handling, execution, and routing of orders, as well as for regulatory compliance would enhance transparency and enable investors to better assess the quality of the Exchange's execution and routing services. The Exchange also believes the proposal would enhance competition because it would potentially enhance the performance of its order handling and execution of orders in equity securities by receiving market data directly from IEX. Finally, the proposed rule change would not impact competition between market participants because it will affect all market participants equally.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were solicited or received with respect to the proposed rule change.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The Exchange has filed the proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>6</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6) thereunder.
                    <SU>7</SU>
                    <FTREF/>
                     Because the proposed rule change does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative prior to 30 days from the date on which it was filed, or such shorter time as the Commission may designate, if consistent with the protection of investors and the public interest, the proposed rule change has become effective pursuant to Section 19(b)(3)(A) of the Act 
                    <SU>8</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6)(iii) thereunder.
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         15 U.S.C. 78s(b)(3)(A).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6) requires a self-regulatory organization to give the Commission written notice of its intent to file the proposed rule change, along with a brief description and text of the proposed rule change, at least five business days prior to the date of filing of the proposed rule change, or such shorter time as designated by the Commission. The Exchange has satisfied this requirement.
                    </P>
                </FTNT>
                <P>
                    At any time within 60 days of the filing of such proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings 
                    <PRTPAGE P="93703"/>
                    under Section 19(b)(2)(B) 
                    <SU>10</SU>
                    <FTREF/>
                     of the Act to determine whether the proposed rule change should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         15 U.S.C. 78s(b)(2)(B).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-NYSENAT-2024-29 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-NYSENAT-2024-29. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-NYSENAT-2024-29 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>11</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>11</SU>
                             17 CFR 200.30-3(a)(12), (59).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27749 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101676; File No. SR-NYSEAMER-2024-72]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; NYSE American LLC; Notice of Filing and Immediate Effectiveness of Proposed Change To Harmonize NYSE American Rule 4530</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) 
                    <SU>1</SU>
                    <FTREF/>
                     of the Securities Exchange Act of 1934 (“Act”) 
                    <SU>2</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>3</SU>
                    <FTREF/>
                     notice is hereby given that, on November 12, 2024, NYSE American LLC (“NYSE American” or the “Exchange”) filed with the Securities and Exchange Commission (the “Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the self-regulatory organization. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         15 U.S.C. 78a.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>
                    The Exchange proposes to harmonize NYSE American Rule 4530 (Reporting Requirements) with certain changes by the Financial Industry Regulatory Authority, Inc. (“FINRA”) to FINRA Rule 4530. The proposed rule change is available on the Exchange's website at 
                    <E T="03">www.nyse.com,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the self-regulatory organization included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of those statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant parts of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    The Exchange proposes to harmonize NYSE American Rule 4530 (Reporting Requirements) with certain changes by FINRA to FINRA Rule 4530.
                    <SU>4</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         This proposed change aligns with NYSE Rule 4530, which was recently updated to conform with FINRA 4530 regarding Reporting Requirements. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 100168 (May 17, 2024), 89 FR 45712 (May 23, 2024) (SR-NYSE-2024-28). 
                        <E T="03">See also</E>
                         NYSE Rule 4530.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Background and Proposed Rule Change</HD>
                <P>
                    NYSE American Rule 4530 requires member organizations to promptly report to the Exchange specified events, such as statutory disqualifications and quarterly statistical and summary information regarding written customer complaints. The Exchange adopted the text of FINRA Rule 4530 in 2011 to replace comparable provisions in its legacy reporting Rule 351.
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 64784 (June 30, 2011), 76 FR 39947 (July 7, 2011) (SR-NYSEAMEX-2011-42). FINRA Rule 4530, adopted in 2010, was modeled after NYSE American Rule 351(a)-(d) and NASD Rule 3070. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 63260 (November 5, 2010), 75 FR 69508 (November 12, 2010) (SR-FINRA-2010-034). 
                        <E T="03">See also</E>
                         Securities Exchange Act Release No. 64560 (May 27, 2011), 76 FR 32246 (June 3, 2011) (SR-FINRA-2011-024).
                    </P>
                </FTNT>
                <P>
                    In 2013, FINRA amended Rule 4530(e) to provide an exception from the reporting requirement for information disclosed on the Form U4 (Uniform Application for Securities Industry Registration or Transfer) in order to avoid duplicative reporting.
                    <SU>6</SU>
                    <FTREF/>
                     In addition, in 2013, FINRA added Supplementary Material .10 to FINRA Rule 4530 to provide that, for purposes of FINRA Rules 4530(a)(1)(A), (C) and (D) only, members are not required to report findings and actions by FINRA.
                    <SU>7</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 68701 (January 18, 2013), 78 FR 5532 (January 25, 2013) (SR-FINRA-2013-006) (Notice of Filing and Immediate Effectiveness of a Proposed Rule Change Relating to FINRA Rule 4530 (Reporting Requirements)).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See id.</E>
                         FINRA Rule 4530(a)(1)(A) requires a member to report external findings regarding the member or an associated person. FINRA Rules 4530(a)(1)(C) and (D) require a member to report regulatory actions against the member or an associated person. FINRA Rules 4530(a)(1)(A), (C) and (D) do not expressly exclude findings and actions by FINRA. 
                        <E T="03">See generally</E>
                          
                        <E T="03">id.</E>
                         NYSE American Rules 4530(a)(1)(A), (C) and (D) are virtually identical to the FINRA rules.
                    </P>
                </FTNT>
                <PRTPAGE P="93704"/>
                <P>
                    In 2015, FINRA again amended FINRA Rule 4530 to provide an exception from the reporting requirements of paragraph (a)(1)(H) of the rule for dealings with a member or associated person subject to statutory disqualification, if that member or associated person has been approved (or is otherwise permitted pursuant to FINRA rules and the federal securities laws) to be a member or to be associated with a member.
                    <SU>8</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 74953 (May 13, 2015), 80 FR 28740 (May 19, 2015) (SR-FINRA-2015-011) (Notice of Filing and Immediate Effectiveness of a Proposed Rule Change Relating to the Reporting Requirements of FINRA Rule 4530(a)(1)(H)).
                    </P>
                </FTNT>
                <P>The Exchange proposes to incorporate each of these amendments into NYSE American Rule 4530, as follows.</P>
                <HD SOURCE="HD3">NYSE American Rule 4530(a)(1)(H)</HD>
                <P>
                    NYSE American Rule 4530(a)(1)(H) requires member organizations to promptly report whenever the member organization or an associated person of the member organization is subject to a “statutory disqualification” as defined in the Act.
                    <SU>9</SU>
                    <FTREF/>
                     The rule also requires a member organization to report whenever the member organization or an associated person thereof is involved in the sale of any financial instrument, the provision of any investment advice or the financing of any such activities with any person that is subject to a “statutory disqualification” as defined in the Act. The report must include the name of the person subject to the statutory disqualification and details concerning the disqualification.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See</E>
                         15 U.S.C. 78c(a)(39).
                    </P>
                </FTNT>
                <P>The Exchange proposes, consistent with current FINRA Rule 4530(a)(1)(H), to exclude activities with a disqualified member or associated person that has been approved (or is otherwise permitted pursuant to FINRA rules and the federal securities laws) to be a member organization or associated with a member organization. To effectuate this change, the Exchange proposes to add the following deletions (bracketed) and additions (italicized) to NYSE American Rule 4530(a)(1)(H):</P>
                <EXTRACT>
                    <P>
                        (H) is 
                        <E T="03">(i) subject to a “statutory disqualification” as that term is defined in the Exchange Act</E>
                        [,] or [is]
                        <E T="03">(ii)</E>
                         involved in the sale of any financial instrument, the provision of any investment advice or the financing of any such activities with any person [who]
                        <E T="03">that</E>
                         is[,] subject to a “statutory disqualification” as that term is defined in the Exchange Act
                        <E T="03">, provided, however, that this requirement shall not apply to activities with a member organization or an associated person that has been approved (or is otherwise permitted pursuant to Exchange rules and the federal securities laws) to be a member organization or to be associated with a member organization.</E>
                         The report shall include the name of the person subject to the statutory disqualification and details concerning the disqualification; or
                    </P>
                </EXTRACT>
                <P>With the exception of conforming changes reflecting the Exchange's membership. the proposed text is identical to FINRA's counterpart rule.</P>
                <HD SOURCE="HD3">NYSE American Rule 4530(e)</HD>
                <P>NYSE American Rule 4530(e) currently provides that a member organization is not required to report a specified event under the rule if it reports that event on the Form U5 (Uniform Termination Notice for Securities Industry Registration), consistent with the requirements of that form. The exception does not extend to the reporting of quarterly statistical and summary customer complaint information under the rule. In order to eliminate duplicative reporting of information disclosed on a Form U4, and consistent with FINRA's current rule, the Exchange proposes to provide a similar exception for certain specified events reported on the Form U4. To effectuate this change, the Exchange proposes to add the following deletions (bracketed) and additions (italicized) to NYSE American Rule 4530(e):</P>
                <EXTRACT>
                    <P>
                        (e) Nothing contained in this Rule shall eliminate, reduce or otherwise abrogate the responsibilities of a member organization or person associated with a member organization to promptly disclose required information on the Forms BD, U4 or U5, as applicable, to make any other required filings or to respond to the Exchange with respect to any customer complaint, examination or inquiry. In addition, member organizations are required to comply with the reporting obligations under paragraphs (a), (b) and (d) of this Rule, regardless of whether the information is reported or disclosed pursuant to any other rule or requirement, including the requirements of the Form[s] BD [or U4]. However, a member organization need not report an event otherwise required to be reported under 
                        <E T="03">(1) paragraph (a)(1) of this Rule if the member organization discloses the event on the Form U4, consistent with the requirements of that form, and indicates, in such manner and format that the Exchange may require, that such disclosure satisfies the requirements of paragraph (a)(1) of this Rule, as applicable; or (2)</E>
                         paragraphs (a) or (b) of this Rule if the member organization discloses the event on the Form U5, consistent with the requirements of that form.
                    </P>
                </EXTRACT>
                <P>With the exception of conforming changes reflecting the Exchange's membership, the proposed text is identical to FINRA's counterpart rule.</P>
                <HD SOURCE="HD3">NYSE American Rule 4530, Supplementary Material .11</HD>
                <P>Finally, the Exchange proposes to adopt the text of FINRA Rule 4530, Supplementary Material .10, as new NYSE American Rule 4530, Supplementary Material .11.</P>
                <P>NYSE American Rule 4530(a)(1)(A) requires a member organization to report that the member organization or an associated person has been found to have violated any securities-, insurance-, commodities-, financial- or investment-related laws, rules, regulations or standards of conduct of any domestic or foreign regulatory body, self-regulatory organization or business or professional organization.</P>
                <P>NYSE American Rule 4530(a)(1)(C) requires a member organization to report that the member organization or an associated person thereof has been named as a defendant or respondent in any proceeding brought by a domestic or foreign regulatory body or self-regulatory organization alleging the violation of any provision of the Act, or of any other federal, state or foreign securities, insurance or commodities statute, or of any rule or regulation thereunder, or of any provision of the by-laws, rules or similar governing instruments of any securities, insurance or commodities domestic or foreign regulatory body or self-regulatory organization.</P>
                <P>Finally, NYSE American Rule 4530(a)(1)(D) requires a member organization to report that the member organization or associated person thereof has been denied registration or is expelled, enjoined, directed to cease and desist, suspended or otherwise disciplined by any securities, insurance or commodities industry domestic or foreign regulatory body or self-regulatory organization or is denied membership or continued membership in any such self-regulatory organization; or is barred from becoming associated with any member organization of any such self-regulatory organization.</P>
                <P>Since NYSE American Rules 4530(a)(1)(A), (C) and (D) do not expressly exclude findings and actions by the Exchange or FINRA, the Exchange proposes to add the following new Supplementary Material .11 to NYSE American Rule 4530 (additions italicized):</P>
                <EXTRACT>
                    <P>
                        <E T="03">.11 For purposes of paragraphs (a)(1)(A), (C) and (D) of this Rule only, member organizations are not required to report findings and actions by the Exchange or by FINRA.</E>
                    </P>
                </EXTRACT>
                <P>
                    With the exception of adding findings and actions by the Exchange, the proposed Supplementary Material .11 to NYSE American Rule 4530 is identical to FINRA Rule 4530.10.
                    <PRTPAGE P="93705"/>
                </P>
                <HD SOURCE="HD3">Statutory Basis</HD>
                <P>
                    The proposed rule change is consistent with Section 6(b) of the Act,
                    <SU>10</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Section 6(b)(5),
                    <SU>11</SU>
                    <FTREF/>
                     in particular, because it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in facilitating transactions in securities, to remove impediments to, and perfect the mechanism of, a free and open market and a national market system and, in general, to protect investors and the public interest.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <P>The Exchange believes that the proposed rule changes support the objectives of the Act by eliminating unnecessary reporting of information to the Exchange and allowing the Exchange to use its resources more efficiently. The Exchange believes that harmonizing Exchange rules modeled on FINRA's rules would result in less burdensome and more efficient regulatory compliance without compromising the regulatory information available to the Exchange. As previously noted, except for changes reflecting the Exchange's membership, the proposed additional text for NYSE American Rule 4530 is identical to the text in FINRA Rule 4530. As such, the proposed rule change would facilitate rule harmonization among self-regulatory organizations with respect to the reporting requirements, thereby fostering cooperation and coordination with persons engaged in facilitating transactions in securities and will remove impediments to and perfect the mechanism of a free and open market and a national market system.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. The proposed rule change is not intended to address competitive issues but rather would reduce potential compliance burdens on member organizations by eliminating potentially duplicative information under NYSE American Rule 4530. Specifically, the proposed rule change would reduce potential compliance burdens on firms by eliminating the requirements under NYSE American Rule 4530(a)(1)(H) to report to the Exchange each instance where a member organization or an associated person is involved in a financial activity with a disqualified member organization or associated person that has been approved or is otherwise permitted to be a member organization or associated with a member organization. Similarly, the proposed amendment to NYSE American Rule 4530(e) to provide an exception for information disclosed on the Form U4 will eliminate the burden on member organizations of having to report the same event twice. Finally, the addition of Supplementary Material .11 to NYSE American Rule 4530 eliminates the burden on member organizations of having to report findings and actions by the Exchange or by FINRA for purposes of NYSE American Rules 4530(a)(1)(A), (C) and (D).</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were solicited or received with respect to the proposed rule change.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The Exchange has filed the proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>12</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6) thereunder.
                    <SU>13</SU>
                    <FTREF/>
                     Because the proposed rule change does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative prior to 30 days from the date on which it was filed, or such shorter time as the Commission may designate, if consistent with the protection of investors and the public interest, the proposed rule change has become effective pursuant to Section 19(b)(3)(A) of the Act and Rule 19b-4(f)(6)(iii) thereunder.
                    <SU>14</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         Rule 19b-4(f)(6)(iii) requires a self-regulatory organization to give the Commission written notice of its intent to file the proposed rule change, along with a brief description and text of the proposed rule change, at least five business days prior to the date of filing of the proposed rule change, or such shorter time as designated by the Commission. The Exchange has satisfied this requirement.
                    </P>
                </FTNT>
                <P>
                    A proposed rule change filed under Rule 19b-4(f)(6) 
                    <SU>15</SU>
                    <FTREF/>
                     normally does not become operative prior to 30 days after the date of the filing. However, pursuant to Rule 19b-4(f)(6)(iii),
                    <SU>16</SU>
                    <FTREF/>
                     the Commission may designate a shorter time if such action is consistent with the protection of investors and the public interest.
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         17 CFR 240.19b-4(f)(6)(iii).
                    </P>
                </FTNT>
                <P>
                    At any time within 60 days of the filing of such proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings under Section 19(b)(2)(B) 
                    <SU>17</SU>
                    <FTREF/>
                     of the Act to determine whether the proposed rule change should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         15 U.S.C. 78s(b)(2)(B).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-NYSEAMER-2024-72 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-NYSEAMER-2024-72. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 
                    <PRTPAGE P="93706"/>
                    a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-NYSEAMER-2024-72 and should be submitted on or before December 18, 2024.
                    <FTREF/>
                </FP>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         17 CFR 200.30-3(a)(12).
                    </P>
                </FTNT>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>18</SU>
                    </P>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27745 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101681; File No. SR-NYSEARCA-2024-95]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; NYSE Arca, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Rule 7.37-E</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) 
                    <SU>1</SU>
                    <FTREF/>
                     of the Securities Exchange Act of 1934 (the “Act”),
                    <SU>2</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>3</SU>
                    <FTREF/>
                     notice is hereby given that on November 18, 2024, NYSE Arca, Inc. (“NYSE Arca” or the “Exchange”) filed with the Securities and Exchange Commission (the “Commission”) the proposed rule change as described in Items I and II below, which Items have been prepared by the self-regulatory organization. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         15 U.S.C. 78a.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>
                    The Exchange proposes to amend Rule 7.37-E to specify the Exchange's source of data feeds from Investors' Exchange, LLC (“IEX”) for purposes of order handling, order execution, order routing, and regulatory compliance. The proposed rule change is available on the Exchange's website at 
                    <E T="03">www.nyse.com,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the self-regulatory organization included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of those statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant parts of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>The Exchange proposes to update and amend the use of data feeds table in Rule 7.37-E(d), which sets forth on a market-by-market basis the specific securities information processor (“SIP”) and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks related to each of those functions. Specifically, the Exchange proposes to amend the table in Rule 7.37-E(d) to specify that, with respect to IEX, the Exchange will receive an IEX direct feed as its primary source of data for order handling, order execution, order routing, and regulatory compliance, and will use the SIP Data Feed as its secondary source for data from IEX.</P>
                <P>The Exchange proposes to make this change operative in the fourth quarter of 2024, and, in any event, before the end of the first quarter of 2025. The Exchange proposes to announce the implementation date of this change by Trader Update.</P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The proposed rule change is consistent with Section 6(b) of the Act,
                    <SU>4</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Section 6(b)(5),
                    <SU>5</SU>
                    <FTREF/>
                     in particular, because it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in facilitating transactions in securities, to remove impediments to, and perfect the mechanism of, a free and open market and a national market system and, in general, to protect investors and the public interest. Additionally, the Exchange believes that the proposed rule change is consistent with the Section 6(b)(5) requirement that the rules of an exchange not be designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <P>The Exchange believes its proposal to update the table in Rule 7.37-E(d) to include the IEX direct feed will ensure that the Rule correctly identifies and publicly states on a market-by-market basis all of the specific SIP and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks for each of those functions. The proposed rule change also removes impediments to and perfects the mechanism of a free and open market and protects investors and the public interest by providing additional specificity, clarity, and transparency in the Exchange's rules.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. Rather, the Exchange believes that the proposal will enhance competition because providing the public and market participants with up-to-date information about the data feeds the Exchange will use for the handling, execution, and routing of orders, as well as for regulatory compliance would enhance transparency and enable investors to better assess the quality of the Exchange's execution and routing services. The Exchange also believes the proposal would enhance competition because it would potentially enhance the performance of its order handling and execution of orders in equity securities by receiving market data directly from IEX. Finally, the proposed rule change would not impact competition between market participants because it will affect all market participants equally.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were solicited or received with respect to the proposed rule change.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The Exchange has filed the proposed rule change pursuant to Section 
                    <PRTPAGE P="93707"/>
                    19(b)(3)(A)(iii) of the Act 
                    <SU>6</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6) thereunder.
                    <SU>7</SU>
                    <FTREF/>
                     Because the proposed rule change does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative prior to 30 days from the date on which it was filed, or such shorter time as the Commission may designate, if consistent with the protection of investors and the public interest, the proposed rule change has become effective pursuant to Section 19(b)(3)(A) of the Act 
                    <SU>8</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6)(iii) thereunder.
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         15 U.S.C. 78s(b)(3)(A).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6) requires a self-regulatory organization to give the Commission written notice of its intent to file the proposed rule change, along with a brief description and text of the proposed rule change, at least five business days prior to the date of filing of the proposed rule change, or such shorter time as designated by the Commission. The Exchange has satisfied this requirement.
                    </P>
                </FTNT>
                <P>
                    At any time within 60 days of the filing of such proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings under Section 19(b)(2)(B) 
                    <SU>10</SU>
                    <FTREF/>
                     of the Act to determine whether the proposed rule change should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         15 U.S.C. 78s(b)(2)(B).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments:</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number
                </P>
                <P>SR-NYSEARCA-2024-95 on the subject line.</P>
                <HD SOURCE="HD2">Paper Comments:</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-NYSEARCA-2024-95. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-NYSEARCA-2024-95 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>11</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>11</SU>
                             17 CFR 200.30-3(a)(12), (59).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27750 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101678; File No. SR-NYSEAMER-2024-69]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; NYSE American LLC; Notice of Filing and Immediate Effectiveness of Proposed Change To Amend Rule 7.37E</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) 
                    <SU>1</SU>
                    <FTREF/>
                     of the Securities Exchange Act of 1934 (the “Act”),
                    <SU>2</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>3</SU>
                    <FTREF/>
                     notice is hereby given that on November 7, 2024, NYSE American LLC (“NYSE American” or the “Exchange”) filed with the Securities and Exchange Commission (the “Commission”) the proposed rule change as described in Items I and II below, which Items have been prepared by the self-regulatory organization. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         15 U.S.C. 78a.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>
                    The Exchange proposes to amend Rule 7.37E to specify the Exchange's source of data feeds from Investors' Exchange, LLC (“IEX”) for purposes of order handling, order execution, order routing, and regulatory compliance. The proposed rule change is available on the Exchange's website at 
                    <E T="03">www.nyse.com,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the self-regulatory organization included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of those statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant parts of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    The Exchange proposes to update and amend the use of data feeds table in Rule 7.37E(d), which sets forth on a market-by-market basis the specific securities information processor (“SIP”) and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks related to each of those functions. Specifically, the Exchange proposes to amend the table in Rule 7.37E(d) to specify that, with respect to IEX, the Exchange will receive an IEX direct feed as its primary source of data for order handling, order execution, order routing, and regulatory compliance, and will use the SIP Data Feed as its secondary source for data from IEX.
                    <PRTPAGE P="93708"/>
                </P>
                <P>The Exchange proposes to make this change operative in the fourth quarter of 2024, and, in any event, before the end of the first quarter of 2025. The Exchange proposes to announce the implementation date of this change by Trader Update.</P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The proposed rule change is consistent with Section 6(b) of the Act,
                    <SU>4</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Section 6(b)(5),
                    <SU>5</SU>
                    <FTREF/>
                     in particular, because it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in facilitating transactions in securities, to remove impediments to, and perfect the mechanism of, a free and open market and a national market system and, in general, to protect investors and the public interest. Additionally, the Exchange believes that the proposed rule change is consistent with the Section 6(b)(5) requirement that the rules of an exchange not be designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <P>The Exchange believes its proposal to update the table in Rule 7.37E(d) to include the IEX direct feed will ensure that the Rule correctly identifies and publicly states on a market-by-market basis all of the specific SIP and proprietary data feeds that the Exchange utilizes for the handling, execution, and routing of orders, and for performing the regulatory compliance checks for each of those functions. The proposed rule change also removes impediments to and perfects the mechanism of a free and open market and protects investors and the public interest by providing additional specificity, clarity, and transparency in the Exchange's rules.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. Rather, the Exchange believes that the proposal will enhance competition because providing the public and market participants with up-to-date information about the data feeds the Exchange will use for the handling, execution, and routing of orders, as well as for regulatory compliance would enhance transparency and enable investors to better assess the quality of the Exchange's execution and routing services. The Exchange also believes the proposal would enhance competition because it would potentially enhance the performance of its order handling and execution of orders in equity securities by receiving market data directly from IEX. Finally, the proposed rule change would not impact competition between market participants because it will affect all market participants equally.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were solicited or received with respect to the proposed rule change.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The Exchange has filed the proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>6</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6) thereunder.
                    <SU>7</SU>
                    <FTREF/>
                     Because the proposed rule change does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative prior to 30 days from the date on which it was filed, or such shorter time as the Commission may designate, if consistent with the protection of investors and the public interest, the proposed rule change has become effective pursuant to Section 19(b)(3)(A) of the Act 
                    <SU>8</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6)(iii) thereunder.
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         15 U.S.C. 78s(b)(3)(A).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6) requires a self-regulatory organization to give the Commission written notice of its intent to file the proposed rule change, along with a brief description and text of the proposed rule change, at least five business days prior to the date of filing of the proposed rule change, or such shorter time as designated by the Commission. The Exchange has satisfied this requirement.
                    </P>
                </FTNT>
                <P>
                    At any time within 60 days of the filing of such proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings under Section 19(b)(2)(B) 
                    <SU>10</SU>
                    <FTREF/>
                     of the Act to determine whether the proposed rule change should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         15 U.S.C. 78s(b)(2)(B).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-NYSEAMER-2024-69 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-NYSEAMER-2024-69. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-NYSEAMER-2024-69 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <PRTPAGE P="93709"/>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>11</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>11</SU>
                             17 CFR 200.30-3(a)(12), (59).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27747 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101696; File No. SR-FINRA-2024-019]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; Financial Industry Regulatory Authority, Inc.; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Adjust FINRA Fees To Provide Sustainable Funding for FINRA's Regulatory Mission</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) 
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 8, 2024, the Financial Industry Regulatory Authority, Inc. (“FINRA”) filed with the Securities and Exchange Commission (“SEC” or “Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by FINRA. FINRA has designated the proposed rule change as “establishing or changing a due, fee or other charge” under Section 19(b)(3)(A)(ii) of the Act 
                    <SU>3</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(2) thereunder,
                    <SU>4</SU>
                    <FTREF/>
                     which renders the proposal effective upon receipt of this filing by the Commission. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         15 U.S.C. 78s(b)(3)(A)(ii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         17 CFR 240.19b-4(f)(2).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>FINRA is proposing to adjust FINRA fees to provide sustainable funding for FINRA's regulatory mission.</P>
                <P>
                    The text of the proposed rule change is available on FINRA's website at 
                    <E T="03">http://www.finra.org,</E>
                     at the principal office of FINRA and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, FINRA included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. FINRA has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <HD SOURCE="HD3">Overview</HD>
                <P>FINRA is submitting this proposed rule change to increase the revenues that FINRA, as a not-for-profit self-regulatory organization (“SRO”), relies upon to fund its regulatory mission. Over the past year, FINRA has publicly stated many times its need to file a fee change this year to increase its fees. Over the past several years, FINRA has experienced significant expense growth resulting from rising technology costs related to capital investments seeking long-term efficiency gains for both FINRA and the industry, rising cloud hosting costs, ongoing disaster recovery and cybersecurity requirements, and elevated wage inflation and essential headcount increases necessitated by the growing breadth and complexity of FINRA's responsibilities.</P>
                <P>To sustain FINRA's regulatory capabilities, FINRA proposes to increase fees related to FINRA's core regulatory functions as well as select fees related to the use of FINRA programs and services. The proposal is designed to closely align FINRA's revenues with its costs while preserving the historical equitable allocation of fees among FINRA members. In parallel, FINRA continues to implement operational improvements to ensure FINRA's operations are effective and efficient.</P>
                <P>Implementation of the proposed rule change would take place over several years, with a minority of fees going into effect in 2025, most fees implemented in 2026 or later, and several fees phased in over several years between 2025 and 2029. </P>
                <FP>
                    Thus, under the proposed rule change, FINRA would aim to collect more than 90 percent of the revenue it seeks to raise in 2026 or later. FINRA is submitting the proposed rule change now to provide members with sufficient advance notice of the proposed fee changes for annual budgeting and financial planning purposes. The proposed rule change is intended to provide sustainable longer-term funding, in a manner consistent with FINRA's public Financial Guiding Principles (“Guiding Principles”),
                    <SU>5</SU>
                    <FTREF/>
                     to enable FINRA to continue fulfilling its regulatory mission.
                </FP>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See</E>
                         FINRA's Financial Guiding Principles, 
                        <E T="03">https://www.finra.org/sites/default/files/finra_financial_guiding_principles_0.pdf.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">FINRA's Current Fee Structure</HD>
                <P>
                    As a not-for-profit SRO, FINRA receives no taxpayer funding and instead relies on a mix of fees that are intended to cover the overall costs of FINRA's operations. The majority of FINRA's funding is derived from three regulatory fees: the Gross Income Assessment (GIA), Trading Activity Fee (TAF), and Personnel Assessment (PA). These fees, respectively, reflect one of the three critical components driving FINRA's regulatory costs with respect to a particular member: (1) the size of the firm measured by firm revenue, (2) the firm's trading activity, and (3) the number and role of persons registered with the firm. FINRA also employs use-based fees for specific services it provides to members and the public in support of its regulatory mission. Several use-based fees, including registration fees, qualification examination fees, and continuing education fees, among others, align with a critical component of FINRA's regulatory costs (
                    <E T="03">i.e.,</E>
                     the number and role of registered persons at a firm). As such, FINRA considers those use-based fees part of its “core” regulatory fees.
                </P>
                <P>
                    In addition, FINRA employs other use-based fees for certain services it provides to members and the public. Examples include fees associated with: reviewing public offering filings; reviewing communications with the public; and operating the FINRA Dispute Resolution Services (“DRS”) arbitration forum. As FINRA has explained previously,
                    <SU>6</SU>
                    <FTREF/>
                     when applying use-based fees, FINRA takes into account three associated types of costs: direct costs for the program associated with the use-based fee, such as program development and operating expenses, and reinvestments and enhancements; indirect costs for the program, including supporting services necessary for the program's associated regulatory activity; and a contribution to FINRA's overall regulatory operations, which promotes its mission of investor protection.
                    <SU>7</SU>
                    <FTREF/>
                     Thus, taken together, core regulatory 
                    <PRTPAGE P="93710"/>
                    fees and other use-based fees allow FINRA to fund its regulatory mission.
                    <SU>8</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 90176 (October 14, 2020), 85 FR 66592 (October 20, 2020) (Notice of Filing and Immediate Effectiveness of File No. SR-FINRA-2020-032).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See supra</E>
                         note 6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         In addition to the services FINRA provides in furtherance of its regulatory mission, FINRA also provides certain services on a contract basis to third parties. These contract service fees represent approximately 8% of FINRA's total revenues. Importantly, these revenues pay in full for the services rendered under the contracts, and FINRA's costs to perform these services are not funded with any of the regulatory revenue discussed in this filing.
                    </P>
                </FTNT>
                <P>
                    FINRA has explained that numerous operations and services must be funded by general revenue sources, which include both core regulatory and other use-based fees.
                    <SU>9</SU>
                    <FTREF/>
                     There are several reasons for this. For instance, it is not feasible to associate a direct affiliated revenue stream for each of FINRA's programs (
                    <E T="03">e.g.,</E>
                     examinations of members do not have an associated revenue stream). Similarly, there is no one consistent driver of costs of a particular regulatory program. Even where one cost driver may, at times, align with a particular revenue stream (
                    <E T="03">e.g.,</E>
                     as trading activity increases, certain Market Regulation costs may increase), the relationship may not hold at other times. For example, novel trading patterns in single or multiple securities may not be associated with significant volume but may require comparatively larger efforts in terms of regulatory oversight. Likewise, periods of intense market volatility may influence regulatory costs independent of the change in trading volume.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See supra</E>
                         note 6.
                    </P>
                </FTNT>
                <P>
                    Further, in light of FINRA's diverse membership of firms that vary greatly in size and business model, it is not feasible to develop a comprehensive pricing structure that precisely accounts for the particular costs associated with each member.
                    <SU>10</SU>
                    <FTREF/>
                     Rather, FINRA's current fee structure is designed to ensure sufficient funding to meet all of its regulatory obligations in a manner that equitably allocates fees among FINRA members, notwithstanding the fluctuations in different revenue streams and cost drivers that are naturally expected to occur over time. The Commission has historically agreed that this overall cost-based pricing structure “is reasonable in that it achieves a generally equitable impact across FINRA's membership and correlates the fees assessed to the regulatory services provided by FINRA.” 
                    <SU>11</SU>
                    <FTREF/>
                     FINRA continues to believe that this approved approach to overall pricing is the most reasonable and equitable way to provide sufficient funding to meet its regulatory obligations as a not-for-profit SRO with broad, diverse membership.
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See supra</E>
                         note 6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 61042 (November 20, 2009), 74 FR 62616, 62620 (November 30, 2009) (Order Approving File No. SR-FINRA-2009-057).
                    </P>
                </FTNT>
                <P>
                    As set out in the Guiding Principles, FINRA targets break-even cash flows as a means to appropriately fund its mission of protecting investors and promoting market integrity while facilitating vibrant capital markets. Careful expense management is another key element of the Guiding Principles. The Guiding Principles also explain the extent to which FINRA relies on its financial reserves—originally derived from the sale of Nasdaq—to help support its regulatory mission.
                    <SU>12</SU>
                    <FTREF/>
                     The Guiding Principles also describe how FINRA uses fine monies—which are not included in FINRA's operating budget—to promote compliance and improve markets.
                    <SU>13</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See supra</E>
                         note 5. Information about FINRA's financial reserves is provided each year in FINRA's published annual financial reports. 
                        <E T="03">See</E>
                         FINRA Financial Reports and Policies, available at 
                        <E T="03">https://www.finra.org/about/annual-reports.</E>
                         FINRA strives to maintain an appropriate level of reserves, which the FINRA Board of Governors has determined to be at least one year of expenditures.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         While fine monies are not included in FINRA's annual operating budget, they are included in cash flow projections. For purposes of its projections, FINRA assumed a conservative amount of fine money for future years based on historical fine money receipt. When FINRA imposes fines, the amounts are based on the facts and circumstances of the misconduct and are guided by the principles set forth in FINRA's Sanction Guidelines that are similar in nature—fines are not based on revenue considerations, and FINRA does not establish any minimum amount of fines that must be collected for purposes of the annual operating budget. Fines collected are accounted for separately, and the use of these monies is subject to special governance procedures and restrictions on use, as set forth in our Guiding Principles. 
                        <E T="03">See supra</E>
                         note 5. In accordance with the Guiding Principles, FINRA issues a separate annual report detailing use of fine monies as approved by the FINRA Board of Governors. 
                        <E T="03">See, e.g.,</E>
                         Report of Use of 2023 Fine Monies (June 14, 2024), available at 
                        <E T="03">https://www.finra.org/about/annual-reports/report-use-2023-fine-monies.</E>
                    </P>
                </FTNT>
                <P>
                    FINRA's most recent comprehensive fee increase included increases to core regulatory fees from 2022 through 2024.
                    <SU>14</SU>
                    <FTREF/>
                     Looking ahead, FINRA projects that its current fees will not keep pace with its projected future expenses in light of the continued growth in the breadth and complexity of FINRA's regulatory obligations, described in detail below. As FINRA noted recently in its 2024 Annual Budget Summary, based on the current fee structure (inclusive of the fee adjustments made from 2022 through 2024), FINRA projects it will recognize an operating loss in 2024, with a drawdown on its financial reserves of approximately $100 million.
                    <SU>15</SU>
                    <FTREF/>
                     FINRA estimates that, absent any action, its reserve balance will fall below its Board-approved target level of one-year of operating costs by 2027. As described in more detail below, FINRA has carefully managed its expenses; however, careful expense management cannot suffice as a sustainable financial strategy in the long term, particularly in the context of rising systemic costs and FINRA's increasing regulatory responsibilities.
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See supra</E>
                         note 6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See</E>
                         FINRA 2024 Annual Budget Summary, 
                        <E T="03">https://www.finra.org/sites/default/files/2024-06/FINRA-2024-Annual-Budget-Summary.pdf,</E>
                         at 2. This potential loss is in line with FINRA's previous multiyear strategic planning for financial sustainability, which contemplates a series of annual losses in order to reduce the size of FINRA's reserves. As discussed in the Guiding Principles, FINRA has relied on its financial reserves, which were originally derived from the sale of Nasdaq, to help support its regulatory mission. 
                        <E T="03">See also</E>
                         Funding FINRA's Mission, available at 
                        <E T="03">https://www.finra.org/media-center/blog/funding-finras-mission.</E>
                    </P>
                    <P>FINRA has made reasonably conservative assumptions using a variety of information points, including historical data and anticipated trends. If FINRA's structural financial deficit is materially reduced during this period, or if key assumptions change materially, FINRA would consider various modifications as appropriate. For example, FINRA has used rebates to support its commitment to reasonable, cost-based fee assessments in instances where revenues significantly exceed expenditures. These rebates are approved by the FINRA Board of Governors. A number of factors must be considered when determining whether to provide rebates, including the amount of excess revenue for the year, whether budget projections anticipate near-term revenue shortfalls, and the number of firms that would be eligible to receive rebates. FINRA makes information about these factors transparent to the public each year.</P>
                </FTNT>
                <HD SOURCE="HD3">Background</HD>
                <P>
                    Over the past several years, FINRA's regulatory and oversight responsibilities have grown significantly, and FINRA anticipates that they will continue to grow over the rest of this decade, requiring investments in technology and increased headcount. Simultaneously, FINRA has experienced substantial systemic expense growth resulting from, among other things, elevated wage inflation and increased operating costs related to technology.
                    <SU>16</SU>
                    <FTREF/>
                     Several factors have contributed to these areas of growth, including: continued increases in the volume and complexity of member activity; new investment products, services, and market participants under FINRA's purview; the continuing evolution of market structure and trading patterns; and the SEC's adoption of significant new rules that require implementation by FINRA and its expanded member oversight.
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         FINRA's technology costs, for example, have risen by approximately 11% per year over the last five years.
                    </P>
                </FTNT>
                <P>
                    For example, FINRA has made substantial investments to supervise or comply with new and amended SEC rules, such as amendments to Disclosure 
                    <PRTPAGE P="93711"/>
                    of Order Execution Information, Regulation M, Shortening the Securities Transaction Settlement Cycle, Regulation Best Interest, Market Data Infrastructure, and Minimum Pricing Increments, Access Fees, and Transparency of Better Priced Orders. FINRA must also be prepared to implement and supervise significant potential new and amended rules that the SEC has proposed, including Regulation S-P, Conflicts of Interest Associated with the Use of Predictive Data Analytics, Regulation Systems Compliance and Integrity, Cybersecurity Risk Management, Regulation Best Execution, and the Order Competition Rule. Furthermore, FINRA is investing in preparation for its expanded role in the oversight of a broader range of market participants under several SEC rulemakings. For example, the SEC has narrowed the exemption for certain exchange members under Exchange Act Rule 15b9-1, further defined “as part of a regular business” 
                    <SU>17</SU>
                    <FTREF/>
                     in the definitions of “dealer” and “government securities dealer” under the Exchange Act, and proposed to amend the definition of “exchange” under Exchange Act Rule 3b-16 and amend Regulation ATS.
                </P>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         The updated definition covers additional market participants engaged in liquidity-providing activities that generally would require SRO membership.
                    </P>
                </FTNT>
                <P>FINRA is also investing to enable continued effective oversight over evolving trading patterns, such as the significant growth in retail trading, growth in smaller and fractional share trading, and increased trading outside of regular trading hours. These and other market developments, together with the evolution of new and evolving products such as securities with crypto asset components and short-dated options products, require increased oversight by FINRA staff.</P>
                <P>
                    FINRA is committed to a culture of continuous improvement, with a rigorous focus on carefully managing costs and identifying new efficiency opportunities, where consistent with its mission. FINRA has exercised prudent expense control and managed costs through various initiatives and technology investments that have helped to enhance efficiency and effectiveness. Beginning with the FINRA360 
                    <SU>18</SU>
                    <FTREF/>
                     initiative, which launched a comprehensive self-evaluation and organizational improvement exercise in 2017 to ensure that FINRA was maximizing its effectiveness, FINRA has implemented a number of enhancements including: enforcement program consolidation; new external transparency tools; the launch of the Small Firm Helpline; increased examiner training; creation of an Innovation Outreach Initiative; and the development of a program to evaluate and integrate advances in data analytics.
                </P>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         Detailed information about the FINRA360 initiative is available at 
                        <E T="03">https://www.finra.org/about/finra-360.</E>
                    </P>
                </FTNT>
                <P>
                    FINRA continues to invest in technology to better serve its mission and to improve FINRA's ability to communicate with members. For example, FINRA completed a multi-year digital platform upgrade that improved system interfaces, including essential registration and disclosure systems used by members.
                    <SU>19</SU>
                    <FTREF/>
                     FINRA also continues to build on its early use of cloud computing in regulation, and invested in an Advanced Analytics Program that supports risk identification and other regulatory efforts. In the interest of regulatory efficiency, FINRA also recently discontinued a program requiring the reporting of prescribed data by certain members based on availability of data from alternative sources, resulting in millions of dollars in cost savings benefits to members.
                    <SU>20</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         Detailed information about FINRA's “Digital Experience Transformation” is available at
                        <E T="03"> https://www.finra.org/filing-reporting/dxt.</E>
                         FINRA built the capabilities of the Digital Experience Transformation initiative in consultation with the industry, and FINRA's investment is estimated to save the industry more than $200 million annually in time and direct costs.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See Regulatory Notice</E>
                         23-17 (October 2023).
                    </P>
                </FTNT>
                <P>Further, cost savings have been accomplished in recent years through supplementary expense reduction initiatives, including conducting a comprehensive efficiency review of FINRA's core business lines; establishing a framework for improving measurement of FINRA's key performance results; voluntary retirement/incentive programs in 2020 and 2024; and strategic reductions in FINRA's corporate real estate footprint.</P>
                <P>
                    Given this context, and despite the significant increase in the breadth and complexity of FINRA's regulatory responsibilities, FINRA's expense growth rate from 2013 through 2023 has been significantly lower than that of the broader financial services industry. Specifically, FINRA's costs increased by 41% cumulatively during this period compared with 129% for the industry.
                    <SU>21</SU>
                    <FTREF/>
                     Similarly, FINRA's total compensation costs rose by 31% on a cumulative basis during this period as compared with a 50% increase for the average U.S. financial services employee.
                    <SU>22</SU>
                    <FTREF/>
                     FINRA's restrained expense growth is the result of careful management of both compensation costs, the largest driver of FINRA's budget, and non-compensation costs, such as technology and real estate.
                </P>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         Based on FOCUS reporting.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         FINRA total compensation represents business compensation, excluding technology. Average U.S. employee wage growth represents Finance and Business Services wage growth supplied by the Bureau of Labor Statistics and Federal Reserve Bank of Atlanta. 
                        <E T="03">See</E>
                         Current Population Survey, Bureau of Labor Statistics, and Federal Reserve Bank of Atlanta Calculations at 
                        <E T="03">https://www.atlantafed.org/chcs/wage-growth-tracker.</E>
                    </P>
                </FTNT>
                <P>Notwithstanding these efforts, as discussed, FINRA projects that its current fees will not keep pace with its projected future expenses. FINRA therefore proposes to increase its fees as described below.</P>
                <HD SOURCE="HD3">Proposal</HD>
                <P>
                    The proposed rule change would raise FINRA's core regulatory fees 
                    <SU>23</SU>
                    <FTREF/>
                     as well as select use-based fees 
                    <SU>24</SU>
                    <FTREF/>
                     that fund various FINRA services and programs. Consistent with the Guiding Principles, the proposed rule change would more effectively allow FINRA to balance its cash flow sources, operating expenses and capital expenditures, and stabilize its financial reserves by 2029. As discussed above, a minority of proposed fee increases would go into effect in 2025, while most fees would be implemented in 2026 or later, and several fees would be phased in over several years between 2025 and 2029.
                    <SU>25</SU>
                    <FTREF/>
                     The following table summarizes the proposed timeline for implementing each fee increase: 
                    <SU>26</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         For ease of reference in this filing, FINRA refers to the following core regulatory fees: GIA; TAF; PA; Branch Office Fees; Registration; Qualification Examination; Continuing Education Regulatory Element Reporting; Late Disclosure; System Processing; and Renewal Late Fee.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         For ease of reference in this filing, FINRA refers to the following select use-based fees: Corporate Financing Private Placement Review; Corporate Financing Public Offering Review; Advertising Regulation Review; DRS Arbitration; and Regulation T and Exchange Act Rule 15c3-3(n) Requests for Extension of Time. The proposed fee increase will apply to filings or submissions related to these use-based services on or after the effective date.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         FINRA considered feedback from members of FINRA's advisory committees and other industry consultations that emphasized the importance of advance notice of fee increases to permit member firms to better plan for the proposed package of fee increases over multiple budget cycles. FINRA also considered stakeholder feedback that one-time increases for certain fees help reduce the administrative burdens on members.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         Fees listed in chronological order of initial implementation. Unless specified otherwise in the table above, the proposed fee increase would take effect on January 1 of the year stated. This table does not include proposed conforming amendments to two fees that impact funding portal members.
                    </P>
                </FTNT>
                <PRTPAGE P="93712"/>
                <GPOTABLE COLS="2" OPTS="L2,i1" CDEF="s100,xs60">
                    <TTITLE>Fee Implementation Schedule</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">
                            Implementation
                            <LI>schedule</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Advertising Regulation Review</ENT>
                        <ENT>2025.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">DRS Arbitration</ENT>
                        <ENT>2025.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Regulation T and Exchange Act Rule 15c3-3(n) Requests for Extension of Time</ENT>
                        <ENT>2025.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Corporate Financing Private Placement Review</ENT>
                        <ENT>2025 (Q3).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Corporate Financing Public Offering Review</ENT>
                        <ENT>2025 (Q3)-2029.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Branch Office Fees</ENT>
                        <ENT>2026, 2028.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Continuing Education Regulatory Element</ENT>
                        <ENT>2026.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Late Disclosure</ENT>
                        <ENT>2026.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Qualification Examination</ENT>
                        <ENT>2026.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">System Processing</ENT>
                        <ENT>2026, 2028.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">GIA</ENT>
                        <ENT>2026-2028.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">TAF</ENT>
                        <ENT>2026-2029.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">PA</ENT>
                        <ENT>2026-2029.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Registration</ENT>
                        <ENT>2028.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Renewal Late Fee</ENT>
                        <ENT>2028.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    Taken together, the proposed rule change is projected to generate additional revenue of between $40 million and $160 million each year compared to the previous year from 2025 through 2029. The amount of the increase varies each year due to the phased implementation schedule described above. Cumulatively, the proposed rule change would increase FINRA's annual fee revenues by an estimated $450 million (once fully implemented in 2029) as compared to the annual fee revenues that would have existed in the absence of the proposed rule change. As such, the proposed rule change is calibrated to cover FINRA's projected budget deficit and achieve a balanced budget by 2029.
                    <SU>27</SU>
                    <FTREF/>
                     This approach will retain FINRA's reserve balance at its target level based on FINRA's projected revenue and costs,
                    <SU>28</SU>
                    <FTREF/>
                     while providing members advance notice of fee increases, phasing some of the increases over multiple years, and maintaining an equitable allocation of fees among FINRA members. As discussed further below, under the proposed rule change, the current proportion of fees borne by FINRA members based on firm size and business model, respectively, would remain stable through 2029.
                    <SU>29</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         As discussed below, Chart 2, attached in Exhibit 3, available on FINRA's website at 
                        <E T="03">http://www.finra.org,</E>
                         demonstrates the difference between FINRA's projected cash flow sources and cash flow uses through 2029, absent the proposed rule change.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         Anticipated costs would not include potential costs associated with new services that may be initiated or approved in the future. FINRA may submit separate fee filings to cover program costs for new services. FINRA notes this proposed rule change does not include fees associated with the Consolidated Audit Trail (“CAT”) or the Securities Lending and Transparency Engine (“SLATE”), both of which are subject to separate proposed rule changes with the Commission. 
                        <E T="03">See, e.g.,</E>
                         Securities Exchange Act Release No. 100920 (September 4, 2024), 89 FR 73457 (September 10, 2024) (Notice of Filing and Immediate Effectiveness of File No. SR-FINRA-2024-011); Securities Exchange Act Release No. 100920 (September 4, 2024), 89 FR 73457 (September 10, 2024) (Notice of Filing and Immediate Effectiveness of File No. SR-FINRA-2024-012). Similarly, FINRA notes that program costs associated with the reporting of transactions in U.S. Treasury Securities (“Treasuries”) are not included in the targeted amount sought by this proposal; currently, Treasuries transactions are exempted from both TRACE transaction reporting fees and from the TAF. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 79116 (October 18, 2016), 81 FR 73167, 73176 (October 24, 2016) (Order Approving File No. SR-FINRA-2016-027).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         
                        <E T="03">See</E>
                         Exhibit 3, Charts 5 and 6.
                    </P>
                </FTNT>
                <P>
                    In total, the proposed fee changes will result in a compounded annualized growth rate (“CAGR”) of 5.3% across total FINRA fees between 2025 and 2029.
                    <SU>30</SU>
                    <FTREF/>
                     Excluding specific fees typically passed on by members,
                    <SU>31</SU>
                    <FTREF/>
                     the CAGR between 2025 and 2029 is projected to be 4.8% for FINRA members. Further, assuming that the majority, if not all, of TAF is also passed directly through to investors, the fee increase CAGR falls to the 3% to 4% range for FINRA members.
                    <SU>32</SU>
                    <FTREF/>
                     During the same period, FINRA reasonably anticipates that its future expenses will grow at a CAGR of 5.9%, with a portion of such expense growth covered by anticipated cash flow sources other than the proposed fee increases. FINRA's fees will continue to represent a small dollar proportion of industry revenues as reported in FOCUS reports. FINRA estimates that FINRA's total fees when the proposed fee increases are fully implemented would represent approximately 0.31% of recent industry revenues by 2029.
                    <SU>33</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         The CAGR provides a geometric average of the change in fees over the implementation period. It is particularly useful for comparing growth rates from various sets of data over the same multi-year period.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         Some of the fees discussed in this filing are or would be absorbed by non-members, including Corporate Financing review fees for public offerings and private placements, which are generally passed through to issuers, and a portion of DRS fees that are paid directly by customers.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         Many members identify that they pass through TAF to customers. Assuming 65% of TAF is passed to non-members, the fee increase CAGR to membership falls to 3.9%. If 100% of TAF is passed through, the fee increase CAGR to FINRA's membership falls to 3.1%.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         Industry revenue projections for 2029 are based on historical FOCUS revenue growth of 8.5% (2013-2023).
                    </P>
                </FTNT>
                <P>In sum, the proposed rule change is designed to collect the targeted revenue amount needed to address FINRA's projected budget deficit through a combination of core regulatory and select use-based fees that yield an equitable overall fee increase across member size and type. The proposed rule change is thus designed to preserve the same SEC-approved, equitable fee allocation across members that FINRA has maintained for years by minimizing the change to distribution of fees across members.</P>
                <P>Each specific fee in the proposed rule change is described below.</P>
                <HD SOURCE="HD3">Core Regulatory Fees</HD>
                <HD SOURCE="HD3">Gross Income Assessment</HD>
                <P>
                    The GIA is a core regulatory fee designed to correlate to one of the three critical components of FINRA's regulatory costs—the size of a firm (based on revenue). Accordingly, the GIA is based on a firm's annual gross revenue,
                    <SU>34</SU>
                    <FTREF/>
                     employing a graduated seven-tier rate structure that has applied since 2008.
                    <SU>35</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         Section 2 of Schedule A to the FINRA By-Laws defines gross revenue for assessment purposes as total income as reported on FOCUS form Part II or IIA, excluding commodities income.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         The applicable GIA rate applies on a marginal basis to annual gross revenues that exceed each applicable threshold. While the GIA rate structure has not changed since 2008, FINRA made modifications to the method of GIA calculation 
                        <PRTPAGE/>
                        under the structure in 2009 and 2014, and increased the GIA rate between 2022 and 2024. In 2009, the Commission approved a GIA calculation modification designed to mitigate year-to-year revenue volatility by assessing members the greater of a GIA calculated based on the firm's annual gross revenue from the preceding calendar year, or a GIA averaged over the prior three years. 
                        <E T="03">See</E>
                         Order Approving SR-FINRA-2009-057, 
                        <E T="03">supra</E>
                         note 11, 74 FR 62616, 62617. In 2014, FINRA refined the GIA calculation method to provide limited relief for smaller member firms from unintended effects of the 2009 calculation change; as a result of the 2014 change, firms that have annual gross revenue of $25 million or less pay the GIA based on preceding year revenue without looking to a three-year average. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 73632 (November 18, 2014), 79 FR 69937 (November 24, 2014) (Notice of Filing and Immediate Effectiveness of File No. SR-FINRA-2014-046). In 2020, FINRA proposed changes to the GIA tier rates, which went into effect between 2022 and 2024. 
                        <E T="03">See</E>
                         Order Approving SR-FINRA-2020-032, 
                        <E T="03">supra</E>
                         note 6, 85 FR 66592.
                    </P>
                </FTNT>
                <PRTPAGE P="93713"/>
                <P>Section 1(c) of Schedule A to the FINRA By-Laws sets forth the GIA. The current rates, which reflect the fee adjustments made from 2022 through 2024, are as follows:</P>
                <P>(1) $1,200.00 on annual gross revenue up to $1 million;</P>
                <P>(2) 0.1732% of annual gross revenue greater than $1 million up to $25 million;</P>
                <P>(3) 0.3705% of annual gross revenue greater than $25 million up to $50 million;</P>
                <P>(4) 0.0738% of annual gross revenue greater than $50 million up to $100 million;</P>
                <P>(5) 0.0520% of annual gross revenue greater than $100 million up to $5 billion;</P>
                <P>(6) 0.0566% of annual gross revenue greater than $5 billion up to $25 billion; and</P>
                <P>(7) 0.1219% of annual gross revenue greater than $25 billion.</P>
                <P>Thus, for example, under the current rates, for a member with annual gross revenue of $30 billion, the GIA would be calculated as follows: the first $1 million at the Tier 1 rate ($1,200), plus the next $24 million at the Tier 2 rate (0.1732%), plus the next $25 million at the Tier 3 rate (0.3705%), plus the next $50 million at the Tier 4 rate (0.0738%), plus the next $4.9 billion at the Tier 5 rate (0.0520%), plus the next $20 billion at the Tier 6 rate (0.0566%), plus the final $5 billion at the Tier 7 rate (0.1219%), for a total assessment of $20,135,293.</P>
                <P>
                    FINRA is proposing the following changes to its GIA tier rates from 2026 through 2028.
                    <SU>36</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         FINRA notes the Exhibit 5 to this proposed rule change, available on FINRA's website at 
                        <E T="03">http://www.finra.org,</E>
                         is marked to show the changes as they are proposed to take effect each year, as described in this filing. Specifically, Exhibit 5A and 5B shows the proposed changes that would take effect in 2025, Exhibit 5C shows the proposed changes that would take effect in 2026, Exhibit 5D shows the proposed changes that would take effect in 2027, Exhibit 5E shows the proposed changes that would take effect in 2028, and Exhibit 5F shows the proposed changes that would take effect in 2029.
                    </P>
                </FTNT>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s50,12,12,12,12,12,12">
                    <TTITLE>GIA—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            Tier
                            <LI>(revenue)</LI>
                        </CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">
                            2025
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">$0 to $1 million</ENT>
                        <ENT>$1,200</ENT>
                        <ENT>$1,200</ENT>
                        <ENT>$1,200</ENT>
                        <ENT>$1,200</ENT>
                        <ENT>$1,200</ENT>
                        <ENT>$1,200</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Greater than $1 million up to $25 million</ENT>
                        <ENT>0.1732%</ENT>
                        <ENT>0.1732%</ENT>
                        <ENT>0.1827%</ENT>
                        <ENT>0.2056%</ENT>
                        <ENT>0.2280%</ENT>
                        <ENT>0.2280%</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Greater than $25 million up to $50 million</ENT>
                        <ENT>0.3705%</ENT>
                        <ENT>0.3705%</ENT>
                        <ENT>0.3909%</ENT>
                        <ENT>0.4397%</ENT>
                        <ENT>0.4877%</ENT>
                        <ENT>0.4877%</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Greater than $50 million up to $100 million</ENT>
                        <ENT>0.0738%</ENT>
                        <ENT>0.0738%</ENT>
                        <ENT>0.0779%</ENT>
                        <ENT>0.0876%</ENT>
                        <ENT>0.0972%</ENT>
                        <ENT>0.0972%</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Greater than $100 million up to $5 billion</ENT>
                        <ENT>0.0520%</ENT>
                        <ENT>0.0520%</ENT>
                        <ENT>0.0549%</ENT>
                        <ENT>0.0618%</ENT>
                        <ENT>0.0685%</ENT>
                        <ENT>0.0685%</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Greater than $5 billion up to $25 billion</ENT>
                        <ENT>0.0566%</ENT>
                        <ENT>0.0566%</ENT>
                        <ENT>0.0597%</ENT>
                        <ENT>0.0672%</ENT>
                        <ENT>0.0745%</ENT>
                        <ENT>0.0745%</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Greater than $25 billion</ENT>
                        <ENT>0.1219%</ENT>
                        <ENT>0.1219%</ENT>
                        <ENT>0.1286%</ENT>
                        <ENT>0.1447%</ENT>
                        <ENT>0.1604%</ENT>
                        <ENT>0.1604%</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Thus, for example, under the new rates once fully implemented in 2029, for a member with annual gross revenue of $30 billion, the GIA would be calculated as follows: the first $1 million at the Tier 1 rate ($1,200), plus the next $24 million at the Tier 2 rate (0.2280%), plus the next $25 million at the Tier 3 rate (0.4877%), plus the next $50 million at the Tier 4 rate (0.0972%), plus the next $4.9 billion at the Tier 5 rate (0.0685%), plus the next $20 billion at the Tier 6 rate (0.0745%), plus the final $5 billion at the Tier 7 rate (0.1604%), for a total assessment of $26,502,945.</P>
                <P>When the proposed GIA rates are fully implemented, they are designed to generate an additional $80 million in annual revenue by 2029. The proposed GIA increase preserves the existing seven-tier structure and calculation method while raising each tier proportionately. With these proposed increases, the GIA structure would continue to reflect the costs associated with performing regulatory responsibilities across FINRA's diverse population of members. Notably, the proposed rule change would not increase the flat $1,200 fee for members with revenues of $1 million or less. Maintaining this fee level for the smallest members preserves FINRA's existing approach to cost distribution between members of varying sizes.</P>
                <P>Further, FINRA seeks to preserve the historical proportionality across fees associated with the three main components of FINRA's regulatory costs—the size of the firm measured by firm revenue, the firm's trading activity, and the number and role of persons registered with the firm—with the aim of collecting a generally comparable amount of revenue from fees associated with each of these components once the proposed rule change is fully implemented. To that end, the proposed rule change would increase the GIA at a reduced rate relative to the other core regulatory fees. This is because, for 2024, GIA revenues exceeded projections due to record aggregate industry revenues. As a result, FINRA has proposed to phase in the proposed increases to the GIA more gradually, and at a reduced rate, relative to the other core regulatory fees to help preserve historical proportionality across these fees and achieve a generally comparable revenue distribution. FINRA believes this proportional approach to fee increases will provide member firms a greater degree of certainty and predictability, as it seeks to maintain consistency with FINRA's existing equitable fee distribution. FINRA further believes its proportional approach reduces the potential for unintended impacts on the services provided by member firms, and the business models they adopt, that could arise from significant changes to fee distribution.</P>
                <HD SOURCE="HD3">Trading Activity Fee</HD>
                <P>
                    The TAF is a core regulatory fee designed to correlate to a critical component of FINRA's regulatory costs—the trading activity of a firm. 
                    <PRTPAGE P="93714"/>
                    FINRA initially adopted the TAF in 2002, modeled on the Commission's transaction-based Section 31 fee.
                    <SU>37</SU>
                    <FTREF/>
                     The TAF is generally assessed on the sale of all exchange-listed securities wherever executed (except debt securities that are not TRACE-Eligible Securities), over-the-counter equity securities, security futures, TRACE-Eligible Securities (provided that the transaction is a Reportable TRACE Transaction), and all municipal securities subject to Municipal Securities Rulemaking Board reporting requirements.
                    <SU>38</SU>
                    <FTREF/>
                     The current TAF rates, which reflect the fee adjustments made from 2022 through 2024, are:
                </P>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 46416 (August 23, 2002), 67 FR 55901 (August 30, 2002) (Notice of Filing and Immediate Effectiveness of File No. SR-NASD-2002-98).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         Certain types of transactions are excluded from the TAF (
                        <E T="03">e.g.,</E>
                         primary market transactions, proprietary transactions executed by a member on a national securities exchange in the member's capacity as an exchange specialist or market maker, transactions effected by a proprietary trading firm on an exchange of which such firm is a member, and transactions in U.S. Treasury Securities). 
                        <E T="03">See</E>
                         FINRA By-Laws, Schedule A, Section 1(b)(2) (providing full list of transactions exempt from the TAF). This proposed rule change would not change the scope of any current TAF exemptions.
                    </P>
                </FTNT>
                <P>(1) $0.000166 per share for each sale of a covered equity security, with a maximum charge of $8.30 per trade;</P>
                <P>(2) $0.00279 per contract for each sale of an option;</P>
                <P>(3) $0.00011 per contract for each round turn transaction of a security future, provided there is a minimum charge of $0.014 per round turn transaction;</P>
                <P>(4) $0.00105 per bond for each sale of a covered TRACE-Eligible Security (other than an Asset-Backed Security) and/or municipal security, with a maximum charge of $1.05 per trade; and</P>
                <P>
                    (5) $0.00000105 times the value, as reported to TRACE, of a sale of an Asset-Backed Security, with a maximum charge of $1.05 per trade.
                    <SU>39</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         If the execution price for a covered security is less than the TAF rate ($0.000166 for covered equity securities, $0.00279 for covered options contracts, or $0.014 for a security future) on a per share, per contract, or round turn transaction basis, then no fee is assessed.
                    </P>
                </FTNT>
                <P>FINRA is proposing the following changes to its TAF rates between 2026 and 2029:</P>
                <GPOTABLE COLS="7" OPTS="L2,nj,p7,7/8,i1" CDEF="s50,r50,r50,r50,r50,r50,r50">
                    <TTITLE>TAF—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">Security type</CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">
                            2025
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Covered Equity Security</ENT>
                        <ENT>$0.000166 per share (up to $8.30 max per trade)</ENT>
                        <ENT>$0.000166 per share (up to $8.30 max per trade)</ENT>
                        <ENT>$0.000195 per share (up to $9.79 max per trade)</ENT>
                        <ENT>$0.000232 per share (up to $11.61 max per trade)</ENT>
                        <ENT>$0.000240 per share (up to $12.05 max per trade)</ENT>
                        <ENT>$0.000249 per share (up to $12.50 max per trade).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Options</ENT>
                        <ENT>$0.00279 per contract</ENT>
                        <ENT>$0.00279 per contract</ENT>
                        <ENT>$0.00329 per contract</ENT>
                        <ENT>$0.00390 per contract</ENT>
                        <ENT>$0.00404 per contract</ENT>
                        <ENT>$0.00420 per contract.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Security Future</ENT>
                        <ENT>$0.00011 per contract (with $0.014 minimum per round turn transaction)</ENT>
                        <ENT>$0.00011 per contract (with $0.014 minimum per round turn transaction)</ENT>
                        <ENT>$0.000135 per contract (with $0.016 minimum per round turn transaction)</ENT>
                        <ENT>$0.00016 per contract (with $0.019 minimum per round turn transaction)</ENT>
                        <ENT>$0.000166 per contract (with $0.020 minimum per round turn transaction)</ENT>
                        <ENT>$0.000172 per contract (with $0.021 minimum per round turn transaction).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">TRACE-Eligible Security (Other than Asset-Backed Security) or municipal security</ENT>
                        <ENT>$0.00105 per bond (up to $1.05 max per trade)</ENT>
                        <ENT>$0.00105 per bond (up to $1.05 max per trade)</ENT>
                        <ENT>$0.00124 per bond (up to $1.24 max per trade)</ENT>
                        <ENT>$0.00147 per bond (up to $1.47 max per trade)</ENT>
                        <ENT>$0.00153 per bond (up to $1.53 max per trade)</ENT>
                        <ENT>$0.00158 per bond (up to $1.58 max per trade).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">TRACE-Eligible Asset-Backed Security</ENT>
                        <ENT>$0.00000105 times reported value (up to $1.05 max per trade)</ENT>
                        <ENT>$0.00000105 times reported value (up to $1.05 max per trade)</ENT>
                        <ENT>$0.00000124 times reported value (up to $1.24 max per trade)</ENT>
                        <ENT>$0.00000147 times reported value (up to $1.47 max per trade)</ENT>
                        <ENT>$0.00000153 times reported value (up to $1.53 max per trade)</ENT>
                        <ENT>$0.00000158 times reported value (up to $1.58 max per trade).</ENT>
                    </ROW>
                </GPOTABLE>
                <P>When the new TAF rates are fully implemented, they are designed to generate an additional $186 million in annual revenue by 2029. The proposed TAF changes reflect proportional increases in the amount raised for each security type—meaning there is no anticipated change in the percentage of overall TAF revenue collected from transactions in each security type—phased in incrementally over the delayed four-year implementation period. Accordingly, while TAF revenues are largely derived from transactions in equity securities, like the SEC's Section 31 fee, this proposed rule change is intended to preserve the current distribution of TAF fees among security types.</P>
                <P>The aggregate TAF increases would generate more revenue relative to the other core regulatory fees to preserve the historical proportionality among the core regulatory fees associated with firm trading activity and the other main components of FINRA's regulatory costs—the size of the firms measured by firm revenue and the number and role of persons registered with the firm—while seeking to collect a generally comparable amount of revenue from fees associated with each component. This is consistent with the proportional approach to fee increases discussed throughout this filing, which seeks to maintain consistency with FINRA's existing equitable fee distribution.</P>
                <HD SOURCE="HD3">Personnel Assessment</HD>
                <P>The PA is a core regulatory fee designed to correlate to the third critical component of FINRA's regulatory costs—the number and role of registered persons at a firm. The PA currently is assessed on a three-tiered rate structure: members with one to five registered representatives and principals are assessed $210 for each such registered person (“Reps” in the table below); there is a $200 charge for each of the next 20 registered persons (between 6 and 25); and a $190 charge for each additional registered person beyond 25 registered persons.</P>
                <P>
                    Section 1(e) of Schedule A to the FINRA By-Laws sets forth the PA. These rates last increased between 2022 and 2024.
                    <SU>40</SU>
                    <FTREF/>
                     FINRA is proposing the following increases to its PA tier rates between 2026 and 2029:
                </P>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         
                        <E T="03">See</E>
                         Order Approving SR-FINRA-2020-032, 
                        <E T="03">supra</E>
                         note 6, 85 FR 66592.
                    </P>
                </FTNT>
                <PRTPAGE P="93715"/>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s50,12,12,12,12,12,12">
                    <TTITLE>PA—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            Tier
                            <LI>(number of reps)</LI>
                        </CHED>
                        <CHED H="1">2024</CHED>
                        <CHED H="1">
                            2025
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Reps 0-5</ENT>
                        <ENT>$210</ENT>
                        <ENT>$210</ENT>
                        <ENT>$245</ENT>
                        <ENT>$260</ENT>
                        <ENT>$270</ENT>
                        <ENT>$295</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Reps 6-25</ENT>
                        <ENT>200</ENT>
                        <ENT>200</ENT>
                        <ENT>235</ENT>
                        <ENT>250</ENT>
                        <ENT>260</ENT>
                        <ENT>285</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Reps 26 and greater</ENT>
                        <ENT>190</ENT>
                        <ENT>190</ENT>
                        <ENT>225</ENT>
                        <ENT>240</ENT>
                        <ENT>250</ENT>
                        <ENT>275</ENT>
                    </ROW>
                </GPOTABLE>
                <P>When the proposed PA rates are fully implemented, they are designed to generate an additional $52 million in annual revenue by 2029. The proposed PA increases, together with the proposed increases to the use-based fees aligned with the number and role of registered persons at a firm discussed below, are calibrated to preserve the historical proportionality among the core regulatory fees associated with the three main components of FINRA's regulatory costs and collect a generally comparable amount of revenue from fees associated with each component. This is consistent with the proportional approach to fee increases discussed throughout this filing, which seeks to maintain consistency with FINRA's existing equitable fee distribution.</P>
                <HD SOURCE="HD3">Branch Office Fees</HD>
                <P>FINRA members are assessed regulatory fees for registered branch offices. These fees are related to firm size and structure. Section 4(a) of Schedule A to the FINRA By-Laws includes a branch office registration fee and a branch office system processing fee upon the initial registration of each branch office as defined in the By-Laws. The initial branch office registration fee is waived for the first branch office registered by a member. In addition, each member is assessed an annual registration fee for each branch office registered by the member. This fee has a tiered regressive rate structure that assesses a per branch office annual registration fee depending on the number of branch offices the firm has. Currently, each member is assessed an annual registration fee of: (1) $175, for each of the first 250 branch offices registered by the member; (2) $150, for each of branch offices 251 to 500 registered by the member; (3) $125, for each of branch offices 501 to 1,000 registered by the member; (4) $100, for each of branch offices 1,001 to 2,000 registered by the member; and (5) $75, for every branch office greater than 2,000 registered by the member. For one branch office per member per year, the annual branch office registration fee and annual branch office system processing fee is waived.</P>
                <P>
                    FINRA has not increased the branch office registration fee since 2013.
                    <SU>41</SU>
                    <FTREF/>
                     FINRA is proposing to retain the tiered regressive rate structure, but increase the branch office registration fee in 2026 as follows:
                </P>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         
                        <E T="03">See Regulatory Notice</E>
                         12-32 (June 2012).
                    </P>
                </FTNT>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s100,12,12,12,12,12,12">
                    <TTITLE>Branch Office Registration Fees—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">
                            2025
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">FINRA Branch Registration Fee</ENT>
                        <ENT>$75</ENT>
                        <ENT>$75</ENT>
                        <ENT>$105</ENT>
                        <ENT>$105</ENT>
                        <ENT>$105</ENT>
                        <ENT>$105</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Registration Fee 1-250 branch offices registered by the member</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                        <ENT>245</ENT>
                        <ENT>245</ENT>
                        <ENT>245</ENT>
                        <ENT>245</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Registration Fee 251-500 branch offices registered by the member</ENT>
                        <ENT>150</ENT>
                        <ENT>150</ENT>
                        <ENT>210</ENT>
                        <ENT>210</ENT>
                        <ENT>210</ENT>
                        <ENT>210</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Registration Fee 501-1000 branch offices registered by the member</ENT>
                        <ENT>125</ENT>
                        <ENT>125</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Registration Fee 1001-2000 branch offices registered by the member</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                        <ENT>140</ENT>
                        <ENT>140</ENT>
                        <ENT>140</ENT>
                        <ENT>140</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Annual Registration Fee 2001+ branch offices registered by the member</ENT>
                        <ENT>75</ENT>
                        <ENT>75</ENT>
                        <ENT>105</ENT>
                        <ENT>105</ENT>
                        <ENT>105</ENT>
                        <ENT>105</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    When the proposed branch office registration fee changes are fully implemented, they are designed to generate $7 million in annual revenue by 2029.
                    <SU>42</SU>
                    <FTREF/>
                     The proposed rule change would retain the same tiered regressive rate structure that assesses a per branch office annual registration fee depending on the number of branch offices of the firm, but would raise the fee associated with each range of branch office numbers. FINRA would continue to waive, for one branch office per member per year, payment of the annual registration fee, but increase the amount of the waiver from $175 to $245 to match the new rates.
                </P>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         The projected revenue from the proposed increased Branch Office Fees assumes that the number of branch offices will remain at 2024 levels through 2029. Due to the COVID-19 pandemic, FINRA had provided regulatory relief including a temporary suspension of the requirements to maintain updated Form U4 information regarding the office of employment address for registered persons who temporarily relocated due to the pandemic, and the requirement to submit branch office applications on Form BR for any newly opened temporary office locations or space-sharing arrangements. 
                        <E T="03">See Regulatory Notice</E>
                         20-08 (March 2020). In mid-2024, that relief ended and FINRA implemented new Rule 3110.19, which exempts from branch office registration a residential supervisory location (or RSL). An RSL is a private residence at which an associated person engages in specified supervisory activities, subject to certain safeguards and limitations. 
                        <E T="03">See Regulatory Notice</E>
                         24-02 (January 2024). FINRA believes its assumptions are reasonable given the recency of these changes. As noted, if key assumptions change materially, FINRA would consider various modifications as appropriate, including rebates, for example. 
                        <E T="03">See supra</E>
                         note 15.
                    </P>
                </FTNT>
                <P>
                    FINRA has not increased the branch office system processing fee since 2022.
                    <SU>43</SU>
                    <FTREF/>
                     FINRA is proposing to increase the branch office system processing fee in 2028 as follows:
                </P>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         
                        <E T="03">See supra</E>
                         note 6.
                    </P>
                </FTNT>
                <PRTPAGE P="93716"/>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s50,12C,12C,12C,12C,12C,12C">
                    <TTITLE>Branch Office System Processing Fee—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">
                            2025
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">
                            2026
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">
                            2027
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Branch Office System Processing Fee (initial and annual)</ENT>
                        <ENT>$75</ENT>
                        <ENT>$75</ENT>
                        <ENT>$75</ENT>
                        <ENT>$75</ENT>
                        <ENT>$105</ENT>
                        <ENT>$105</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    When the proposed branch office system processing fee change is fully implemented, it is designed to generate $4 million in annual revenue by 2029.
                    <SU>44</SU>
                    <FTREF/>
                     FINRA would continue to waive, for one branch office per member per year, payment of the annual branch office system processing fee, but increase the amount of the waiver from $75 to $105 to match the new rates. FINRA believes these proposed increases to the branch office fees, which relate to firm size and structure, are consistent with the proportional approach to fee increases discussed throughout this filing.
                </P>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         
                        <E T="03">See supra</E>
                         note 42.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Registration Fees</HD>
                <P>
                    Registration fees are registered person-level fees that, while use-based, also correlate to the third critical component of FINRA's regulatory costs—the number and role of registered persons at a firm. Section 4 of Schedule A to the FINRA By-Laws establishes fees connected to FINRA's operation of the Central Registration Depository (“Web CRD®” or “CRD system”), the central licensing and registration system that FINRA operates for the benefit of FINRA, the SEC, other SROs, state securities regulators, and broker-dealer firms. The CRD system contains the registration records of broker-dealer firms and their associated individuals including their qualification, employment, and disclosure histories; it also facilitates the processing of, among other things, form filings and facilitates the making of fingerprint results available to the appropriate authorized recipients.
                    <SU>45</SU>
                    <FTREF/>
                     The CRD system enables individuals and firms seeking registration with multiple states and SROs to do so by submitting a single form and fee payment.
                    <SU>46</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         Specified information reported to the CRD system is displayed in BrokerCheck®, an electronic system that provides the public with information on the professional background, business practices, and conduct of FINRA members and their associated persons. Investors use BrokerCheck to help make informed choices about the individuals and firms with which they currently conduct or are considering conducting business.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>46</SU>
                         FINRA outsources fingerprint processing to Sterling Identity (“Sterling”), an FBI-approved channeler that processes fingerprints for members on FINRA's behalf. This provides for a more efficient and streamlined process with fewer fingerprint rejections, secure electronic transmission of FBI results, and significantly reduced turn-around times. Sterling assesses and collects all fees for fingerprint collection and processing, including the FBI fee.
                    </P>
                </FTNT>
                <P>
                    FINRA last increased associated registration fees between 2022 and 2024.
                    <SU>47</SU>
                    <FTREF/>
                     FINRA has explained that these fees are important to fund activities that help ensure the integrity of information in the CRD system—information critical to FINRA and other regulators, as well as to investors through BrokerCheck—and to support FINRA's overall regulatory mission.
                    <SU>48</SU>
                    <FTREF/>
                     FINRA is proposing to increase certain registration fees 
                    <SU>49</SU>
                    <FTREF/>
                     in 2028 as follows:
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>47</SU>
                         
                        <E T="03">See</E>
                         Order Approving SR-FINRA-2020-032, 
                        <E T="03">supra</E>
                         note 6, 85 FR 66592.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>48</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 67247 (June 25, 2012), 77 FR 38866 (June 29, 2012) (Notice of Filing and Immediate Effectiveness of File No. SR-FINRA-2012-030).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>49</SU>
                         FINRA also proposes conforming changes to Section 15(g) of Schedule A to the FINRA By-Laws to align this proposed fee change with the same fees for Funding Portal members.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>50</SU>
                         This fee applies for each initial or transfer Uniform Application for Securities Industry Registration or Transfer (“Form U4”) filed by a member in the CRD system to register an individual. Section 4(b)(1) of Schedule A includes a discount in cases where a member is transferring the registrations of individuals in connection with the acquisition of all or part of another member's business. The discount ranges from 10 to 50 percent, based on the number of registered personnel being transferred. While FINRA is proposing to increase the registration fee, it is not proposing to make any changes to the discount schedule.
                    </P>
                    <P>
                        <SU>51</SU>
                         This fee applies for the additional processing of each initial or amended Form U4, Form U5, or Form BD that includes the initial reporting, amendment, or certification of one or more disclosure events or proceedings.
                    </P>
                    <P>
                        <SU>52</SU>
                         This fee applies for processing and posting to the CRD system each set of fingerprints submitted electronically by a member to FINRA, plus any other charge that may be imposed by the United States Department of Justice for processing each set of fingerprints.
                    </P>
                    <P>
                        <SU>53</SU>
                         In 2024, the fee for funding portal members that submit fingerprints electronically is $15. 
                        <E T="03">See</E>
                         Section 15(g) of Schedule A to FINRA By-Laws.
                    </P>
                    <P>
                        <SU>54</SU>
                         As discussed below, FINRA proposes a conforming change in 2025 to Section 15(g) of Schedule A to the FINRA By-Laws to align the fee for funding portal members that submit fingerprints electronically with the same fee charged to broker-dealer members.
                    </P>
                    <P>
                        <SU>55</SU>
                         This fee applies for processing and posting to the CRD system each set of fingerprints submitted in non-electronic format by a member to FINRA, plus any other charge that may be imposed by the United States Department of Justice for processing each set of fingerprints.
                    </P>
                </FTNT>
                <GPOTABLE COLS="7" OPTS="L2,nj,i1" CDEF="s50,r25,r25,r25,r25,r25,r25">
                    <TTITLE>Registration Fees—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">
                            2025
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">
                            2026
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">
                            2027
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">
                            Initial/Transfer Registration Form U4 filing 
                            <SU>50</SU>
                        </ENT>
                        <ENT>$125</ENT>
                        <ENT>$125</ENT>
                        <ENT>$125</ENT>
                        <ENT>$125</ENT>
                        <ENT>$175</ENT>
                        <ENT>$175.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Termination U5 filing</ENT>
                        <ENT>$50 (plus $100 if late filed)</ENT>
                        <ENT>$50 (plus $100 if late filed)</ENT>
                        <ENT>$50 (plus $100 if late filed)</ENT>
                        <ENT>$50 (plus $100 if late filed)</ENT>
                        <ENT>$70 (plus $140 if late filed)</ENT>
                        <ENT>$70 (plus $140 if late filed).</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Disclosure review 
                            <SU>51</SU>
                        </ENT>
                        <ENT>$155</ENT>
                        <ENT>$155</ENT>
                        <ENT>$155</ENT>
                        <ENT>$155</ENT>
                        <ENT>$215</ENT>
                        <ENT>$215.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Electronic Fingerprinting 
                            <SU>52</SU>
                        </ENT>
                        <ENT>
                            $20 
                            <SU>53</SU>
                        </ENT>
                        <ENT>
                            $20 
                            <SU>54</SU>
                        </ENT>
                        <ENT>$20</ENT>
                        <ENT>$20</ENT>
                        <ENT>$28</ENT>
                        <ENT>$28.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">
                            Non-Electronic Fingerprinting 
                            <SU>55</SU>
                        </ENT>
                        <ENT>$30</ENT>
                        <ENT>$30</ENT>
                        <ENT>$30</ENT>
                        <ENT>$30</ENT>
                        <ENT>$42</ENT>
                        <ENT>$42.</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Fingerprinting Processed Through Another SRO</ENT>
                        <ENT>$30</ENT>
                        <ENT>$30</ENT>
                        <ENT>$30</ENT>
                        <ENT>$30</ENT>
                        <ENT>$42</ENT>
                        <ENT>$42.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>When these proposed registration fee changes are fully implemented, they are designed to generate an additional $10 million in annual revenue by 2029.</P>
                <HD SOURCE="HD3">Renewal Late Fee</HD>
                <P>
                    Members renew their registrations with FINRA, other SROs and states/jurisdictions during the annual renewal program. Section 4(b)(8) of Schedule A to the FINRA By-Laws sets forth the renewal late fee, which applies if a member fails to timely pay the amount 
                    <PRTPAGE P="93717"/>
                    indicated on its preliminary annual renewal statement.
                    <SU>56</SU>
                    <FTREF/>
                     Where this late fee applies, FINRA includes it as part of the final statement. Currently, this fee is the greater of 10 percent of the member's final annual renewal assessment or $100, with a maximum charge of $5,000. FINRA has not increased the renewal late fee since it was established in 2002.
                    <SU>57</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>56</SU>
                         Members receive a preliminary annual renewal statement that reflects approved registrations at the time the statement is generated. The statement also includes a date by which members must make full payment available to FINRA.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>57</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 46466 (September 6, 2002), 67 FR 58092 (September 13, 2002) (Notice of Filing and Immediate Effectiveness of File No. SR-NASD-2002-100).
                    </P>
                </FTNT>
                <P>FINRA is proposing to increase the renewal late fee in 2028 as follows:</P>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s50,12,12,12,12,12,12">
                    <TTITLE>Renewal Late Fee—Proposed Implementation</TTITLE>
                    <TDESC>[The Renewal Late Fee is 10 percent of a member's cumulative final renewal statement with the following minimums and maximums]</TDESC>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">
                            2025
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">
                            2026
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">
                            2027
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">The minimum late fee FINRA will assess is</ENT>
                        <ENT>$100</ENT>
                        <ENT>$100</ENT>
                        <ENT>$100</ENT>
                        <ENT>$100</ENT>
                        <ENT>$140</ENT>
                        <ENT>$140</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">The maximum late fee FINRA will assess is</ENT>
                        <ENT>5,000</ENT>
                        <ENT>5,000</ENT>
                        <ENT>5,000</ENT>
                        <ENT>5,000</ENT>
                        <ENT>7,000</ENT>
                        <ENT>7,000</ENT>
                    </ROW>
                </GPOTABLE>
                <P>FINRA notes that it collects all applicable renewal fees on behalf of itself and participating regulators, which enables members to submit their total renewal payment to FINRA instead of to each regulator. Among other reasons noted, FINRA believes this proposed fee increase would further encourage members to submit such fees on time. When the proposed renewal late fee changes are fully implemented, they are designed to generate an additional $100,000 in annual revenue by 2029.</P>
                <HD SOURCE="HD3">Late Disclosure Fee</HD>
                <P>Related to the registration functions described above, FINRA charges a fee for each day that a new disclosure event or a change in the status of a previously reported disclosure event is not timely filed on an initial or amended Form U5 or an amended Form U4. Section 4(h) of Schedule A to the FINRA By-Laws sets forth the late disclosure fee. This fee is assessed starting on the day following the last date on which the event or change in status was required to be reported.</P>
                <P>Timely and complete reporting of all information required by the FINRA By-Laws and rules, as well as the federal securities laws, is critical to investor protection. The SEC, FINRA, other SROs and state securities regulators use the information to make licensing and registration decisions, among other things. FINRA also publishes information in FINRA BrokerCheck, which investors use for researching the professional backgrounds of firms and brokers.</P>
                <P>
                    FINRA has not increased the late disclosure fee since 2013.
                    <SU>58</SU>
                    <FTREF/>
                     Currently, disclosures filed more than 60 days following the last date on which the event was required to be reported under FINRA rules account for 50 percent of volume and 78 percent of revenues related to late filing fees.
                </P>
                <FTNT>
                    <P>
                        <SU>58</SU>
                         
                        <E T="03">See Regulatory Notice</E>
                         12-32, 
                        <E T="03">supra</E>
                         note 41.
                    </P>
                </FTNT>
                <P>
                    FINRA is proposing to increase the late disclosure fee 
                    <SU>59</SU>
                    <FTREF/>
                     in 2026 as follows:
                </P>
                <FTNT>
                    <P>
                        <SU>59</SU>
                         FINRA also proposes conforming changes to Section 15(e) of Schedule A to the FINRA By-Laws to align this proposed fee change with the same fee for Funding Portal members.
                    </P>
                </FTNT>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s50,12,12,12,12,12,12">
                    <TTITLE>Late Disclosure Fee—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">
                            2025
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">First Day</ENT>
                        <ENT>$100</ENT>
                        <ENT>$100</ENT>
                        <ENT>$100</ENT>
                        <ENT>$100</ENT>
                        <ENT>$100</ENT>
                        <ENT>$100</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Subsequent Days</ENT>
                        <ENT>25</ENT>
                        <ENT>25</ENT>
                        <ENT>40</ENT>
                        <ENT>40</ENT>
                        <ENT>40</ENT>
                        <ENT>40</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Maximum Fee</ENT>
                        <ENT>1,575</ENT>
                        <ENT>1,575</ENT>
                        <ENT>2,460</ENT>
                        <ENT>2,460</ENT>
                        <ENT>2,460</ENT>
                        <ENT>2,460</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    FINRA believes this proposed fee increase would further encourage firms to file timely and complete initial Forms U4 and U5 and amendments to these forms, while also generating additional revenue as part of the overall proposal to increase fees to fund FINRA's regulatory mission. When the proposed late disclosure fee changes are fully implemented, they are designed to generate an additional $3 million in annual revenue by 2029.
                    <SU>60</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>60</SU>
                         Projected revenue from the proposed increased Late Disclosure Fees assumes approximately 53% late filings based on the historical average (2018-2023) and is based on other reasonably conservative assumptions using a variety of information points, including historical data and anticipated trends. 
                        <E T="03">See supra</E>
                         note 15.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">System Processing Fee</HD>
                <P>
                    FINRA currently assesses an annual system processing fee for each of the member's registered persons. Like the registration fees described above, this fee correlates to the third critical component of FINRA's regulatory costs—the number and role of registered persons at a firm. Section 4(b)(7) of Schedule A to the FINRA By-Laws sets forth the system processing fee. Under the current fee structure, a flat $70 fee applies to each registered person of a member. Many registered persons are registered with one or more securities regulators (
                    <E T="03">i.e.,</E>
                     with jurisdictions as a broker-dealer agent and with SROs as a representative or principal).
                    <SU>61</SU>
                    <FTREF/>
                     The median number of other SROs and jurisdictions with which each registered person of a member is registered, in addition to their FINRA registration, is 11, with an average of 20.
                </P>
                <FTNT>
                    <P>
                        <SU>61</SU>
                         The term broker-dealer agent (or AG) is the designation used in Form U4 to identify a person who has been approved to sell securities in a particular jurisdiction.
                    </P>
                </FTNT>
                <P>
                    FINRA's costs and resources allocated to processing this information for members' registered persons depends, in part, on the number of securities regulators with which each registered person is registered (whether as a broker-dealer agent with one or more 
                    <PRTPAGE P="93718"/>
                    jurisdictions or as a representative or principal with one or more SROs). To account for this variability, FINRA proposes to replace the current flat fee structure with a tiered rate structure in 2026 as described below. In addition, FINRA proposes to increase the proposed tiers in 2028. These proposed changes are summarized as follows:
                </P>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s100,12,12,12,12,12,12">
                    <TTITLE>System Processing Fee—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">Number of securities regulators with which each registered person of a member is registered, excluding registration as an investment adviser representative</CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">
                            2025
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">
                            2027
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">
                            2029
                            <LI>(no change)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">1-5</ENT>
                        <ENT>$70</ENT>
                        <ENT>$70</ENT>
                        <ENT>$70</ENT>
                        <ENT>$70</ENT>
                        <ENT>$100</ENT>
                        <ENT>$100</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">6-20</ENT>
                        <ENT>70</ENT>
                        <ENT>70</ENT>
                        <ENT>95</ENT>
                        <ENT>95</ENT>
                        <ENT>125</ENT>
                        <ENT>125</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">21-40</ENT>
                        <ENT>70</ENT>
                        <ENT>70</ENT>
                        <ENT>110</ENT>
                        <ENT>110</ENT>
                        <ENT>140</ENT>
                        <ENT>140</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">41+</ENT>
                        <ENT>70</ENT>
                        <ENT>70</ENT>
                        <ENT>125</ENT>
                        <ENT>125</ENT>
                        <ENT>155</ENT>
                        <ENT>155</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The fee would be calculated based on the total number of securities regulators with which each registered person of a member is registered (whether as a broker-dealer agent with one or more jurisdictions or as a representative or principal with one or more SROs). A registered person's registration as an investment adviser representative would not be considered.</P>
                <P>FINRA believes this use-based fee will support FINRA's overall regulatory mission while reflecting the resources FINRA allocates to its securities licensing and registration operations for registered persons of members. Further, as noted above, this fee relates to the number and role of registered persons at a firm, which is one of the three critical components of FINRA's regulatory costs.</P>
                <P>FINRA proposes to implement the proposed tiered rate structure in 2026. To allow members additional time to adjust and plan, FINRA proposes to defer implementation of proposed increases to this fee until 2028. When this proposed rule change, including implementation of the tiered structure and the proposed increase are fully implemented, it is designed to generate an additional $31 million in annual revenue by 2029.</P>
                <HD SOURCE="HD3">Qualification Examination Fees</HD>
                <P>Like registration fees, qualification examination fees are registered person-level fees that, while use-based, also correlate to the third critical component of FINRA's regulatory costs—the number and role of registered persons at a firm. Section 4(c) of Schedule A to the FINRA By-Laws sets forth the fees associated with the qualification examinations that FINRA administers. Persons engaged in the investment banking or securities business of a FINRA member who function as principals or representatives are required to register with FINRA in each category of registration appropriate to their functions. Such individuals must pass an appropriate qualification examination or obtain a waiver before their registration can become effective. These qualification examinations cover a broad range of subjects regarding financial markets and products, individual responsibilities, securities industry rules, and regulatory structure.</P>
                <P>
                    FINRA develops, maintains, and delivers all qualification examinations for individuals who are registered or seeking registration with FINRA.
                    <FTREF/>
                    <SU>62</SU>
                     FINRA last increased its examination fees between 2022 and 2024.
                    <SU>63</SU>
                    <FTREF/>
                     FINRA is proposing to increase its examination fees in 2026 as follows:
                </P>
                <FTNT>
                    <P>
                        <SU>62</SU>
                         FINRA also administers and delivers examinations sponsored (
                        <E T="03">i.e.,</E>
                         developed) by the Municipal Securities Rulemaking Board (“MSRB”) and other SROs, the North American Securities Administrators Association, and the Federal Deposit Insurance Corporation. The fees charged for these examinations are set according to contracts with the examination sponsors, and FINRA is not proposing any changes to fees associated with those examinations at this time.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>63</SU>
                         
                        <E T="03">See</E>
                         Order Approving SR-FINRA-2020-032, 
                        <E T="03">supra</E>
                         note 6, 85 FR 66592.
                    </P>
                </FTNT>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s100,12,12,12,12,12,12">
                    <TTITLE>Qualification Examination Fees—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">Examination number and name</CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">
                            2025
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Securities Industry Essentials (SIE) Examination</ENT>
                        <ENT>$80</ENT>
                        <ENT>$80</ENT>
                        <ENT>$100</ENT>
                        <ENT>$100</ENT>
                        <ENT>$100</ENT>
                        <ENT>$100</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 4: Registered Options Principal Examination</ENT>
                        <ENT>155</ENT>
                        <ENT>155</ENT>
                        <ENT>200</ENT>
                        <ENT>200</ENT>
                        <ENT>200</ENT>
                        <ENT>200</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 6: Investment Company Products and Variable Contracts Representative Examination</ENT>
                        <ENT>75</ENT>
                        <ENT>75</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 7: General Securities Representative Examination</ENT>
                        <ENT>300</ENT>
                        <ENT>300</ENT>
                        <ENT>395</ENT>
                        <ENT>395</ENT>
                        <ENT>395</ENT>
                        <ENT>395</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 9: General Securities Sales Supervisor Examination—Options Module</ENT>
                        <ENT>130</ENT>
                        <ENT>130</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 10: General Securities Sales Supervisor Examination—General Module</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                        <ENT>235</ENT>
                        <ENT>235</ENT>
                        <ENT>235</ENT>
                        <ENT>235</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 14: Compliance Official Examination</ENT>
                        <ENT>350</ENT>
                        <ENT>350</ENT>
                        <ENT>450</ENT>
                        <ENT>450</ENT>
                        <ENT>450</ENT>
                        <ENT>450</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 16: Supervisory Analyst Examination</ENT>
                        <ENT>245</ENT>
                        <ENT>245</ENT>
                        <ENT>325</ENT>
                        <ENT>325</ENT>
                        <ENT>325</ENT>
                        <ENT>325</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 22: Direct Participation Programs Representative Examination</ENT>
                        <ENT>60</ENT>
                        <ENT>60</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 23: General Securities Principal Examination—Sales Supervisor Module</ENT>
                        <ENT>105</ENT>
                        <ENT>105</ENT>
                        <ENT>135</ENT>
                        <ENT>135</ENT>
                        <ENT>135</ENT>
                        <ENT>135</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="93719"/>
                        <ENT I="01">Series 24: General Securities Principal Examination</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                        <ENT>235</ENT>
                        <ENT>235</ENT>
                        <ENT>235</ENT>
                        <ENT>235</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 26: Investment Company Products and Variable Contracts Principal Examination</ENT>
                        <ENT>150</ENT>
                        <ENT>150</ENT>
                        <ENT>200</ENT>
                        <ENT>200</ENT>
                        <ENT>200</ENT>
                        <ENT>200</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 27: Financial and Operations Principal Examination</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                        <ENT>235</ENT>
                        <ENT>235</ENT>
                        <ENT>235</ENT>
                        <ENT>235</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 28: Introducing Broker-Dealer Financial and Operations Principal Examination</ENT>
                        <ENT>150</ENT>
                        <ENT>150</ENT>
                        <ENT>195</ENT>
                        <ENT>195</ENT>
                        <ENT>195</ENT>
                        <ENT>195</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 39: Direct Participation Programs Principal Examination</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                        <ENT>200</ENT>
                        <ENT>200</ENT>
                        <ENT>200</ENT>
                        <ENT>200</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 57: Securities Trader Examination</ENT>
                        <ENT>80</ENT>
                        <ENT>80</ENT>
                        <ENT>105</ENT>
                        <ENT>105</ENT>
                        <ENT>105</ENT>
                        <ENT>105</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 79: Investment Banking Representative Examination</ENT>
                        <ENT>300</ENT>
                        <ENT>300</ENT>
                        <ENT>395</ENT>
                        <ENT>395</ENT>
                        <ENT>395</ENT>
                        <ENT>395</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 82: Private Securities Offering Representative Examination</ENT>
                        <ENT>60</ENT>
                        <ENT>60</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 86: Research Analyst Examination—Analysis</ENT>
                        <ENT>225</ENT>
                        <ENT>225</ENT>
                        <ENT>295</ENT>
                        <ENT>295</ENT>
                        <ENT>295</ENT>
                        <ENT>295</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 87: Research Analyst Examination—Regulatory</ENT>
                        <ENT>150</ENT>
                        <ENT>150</ENT>
                        <ENT>195</ENT>
                        <ENT>195</ENT>
                        <ENT>195</ENT>
                        <ENT>195</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Series 99: Operations Professional Examination</ENT>
                        <ENT>60</ENT>
                        <ENT>60</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                        <ENT>100</ENT>
                    </ROW>
                </GPOTABLE>
                <P>FINRA is proposing a one-time fee increase across examinations in 2026 designed to generate an additional $14 million in revenue across all examinations by 2029. In addition, FINRA has determined the amount of each examination fee increase based on the frequency with which the examination is administered, as well as the average fee per hour of examination length. Examinations that are administered more frequently or are longer in duration typically require more effort and cost to develop, maintain, and update. As a result, FINRA is generally proposing greater increases for those examinations, and smaller increases for others to preserve the broad and equitable distribution of proposed fee increases, as discussed throughout this filing.</P>
                <HD SOURCE="HD3">Continuing Education Regulatory Element Fee</HD>
                <P>
                    Continuing education fees are also registered person-level fees that, while use-based, correlate to the third critical component of FINRA's regulatory costs—the number and role of registered persons at a firm. In conjunction with other SROs and the Securities Industry/Regulatory Council on Continuing Education, FINRA administers the continuing education (CE) program for the securities industry.
                    <SU>64</SU>
                    <FTREF/>
                     The Regulatory Element of the CE program provides training on significant rule changes and other regulatory developments relevant to each registration category. Registered persons must complete the Regulatory Element annually by December 31 for each registration that they hold.
                    <SU>65</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>64</SU>
                         
                        <E T="03">See</E>
                         FINRA Rule 1240.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>65</SU>
                         
                        <E T="03">See</E>
                         FINRA Rule 1240; 
                        <E T="03">see also</E>
                         Securities Exchange Act Release No. 93097 (September 21, 2021), 86 FR 53358 (September 27, 2021) (Order Approving File No. SR-FINRA-2021-015).
                    </P>
                </FTNT>
                <P>
                    Section 4(f) of Schedule A to the FINRA By-Laws sets forth the fees associated with the Regulatory Element requirement. FINRA has not increased the fee for the web-based delivery of the Regulatory Element since it was established in 2015.
                    <SU>66</SU>
                    <FTREF/>
                     FINRA is proposing to increase the Regulatory Element fee in 2026 as follows:
                </P>
                <FTNT>
                    <P>
                        <SU>66</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 75581 (July 31, 2015), 80 FR 47018 (August 6, 2015) (Order Approving File No. SR-FINRA-2015-015). After FINRA adopted amendments to require registered persons to complete the Regulatory Element of CE annually rather than every three years, FINRA revised the Regulatory Element fee from a $55 fee paid once every three years, to an $18 fee paid annually. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 93928 (January 7, 2022), 87 FR 2193, 2194 (January 13, 2022) (Notice of Filing and Immediate Effectiveness of File No. SR-FINRA-2021-034). Thus, the Regulatory Element fee has not substantially changed since 2015.
                    </P>
                </FTNT>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s50,12C,12C,12C,12C,12C,12C">
                    <TTITLE>Continuing Education Fee—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">
                            2025
                            <LI>(no change)</LI>
                        </CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Continuing Education</ENT>
                        <ENT>$18</ENT>
                        <ENT>$18</ENT>
                        <ENT>$25</ENT>
                        <ENT>$25</ENT>
                        <ENT>$25</ENT>
                        <ENT>$25</ENT>
                    </ROW>
                </GPOTABLE>
                <P>When the proposed regulatory element fee rate is fully implemented, it is designed to generate an additional $4 million in annual revenue by 2029.</P>
                <HD SOURCE="HD3">Select Use-Based Fees</HD>
                <HD SOURCE="HD3">Corporate Financing Private Placement Review Fee</HD>
                <P>
                    FINRA Rule 5122 (Private Placements of Securities Issued by Members) imposes requirements regarding disclosure, filing, and use of offering proceeds for members that sell a private placement of securities issued by a member or a control entity, subject to various exemptions. Pursuant to FINRA Rule 5122, members that offer or sell their own securities or those of a control 
                    <PRTPAGE P="93720"/>
                    entity must file with FINRA's Corporate Financing Department (“Corporate Financing”) a private placement memorandum, term sheet or other offering document and any retail communication that promotes or recommends the member private offering at or prior to the first time the documents are provided to any prospective investor.
                </P>
                <P>Its companion rule, FINRA Rule 5123 (Private Placement of Securities), requires members that sell any other type of private placement to file with Corporate Financing a copy of any private placement memorandum, term sheet or other offering document, and any retail communication that promotes or recommends the private placement. Such filing must occur within 15 calendar days of the first sale, subject to various exemptions.</P>
                <P>
                    FINRA has historically performed the review of such filings at no cost since the program was created approximately 15 years ago.
                    <SU>67</SU>
                    <FTREF/>
                     This program requires substantial resources, and the volume of filings has increased significantly in recent years.
                    <SU>68</SU>
                    <FTREF/>
                     FINRA thus proposes to establish the following fees related to private placement review in July 2025 as follows:
                </P>
                <FTNT>
                    <P>
                        <SU>67</SU>
                         FINRA Rule 5122 became effective on June 17, 2009; FINRA Rule 5123 became effective on December 3, 2012.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>68</SU>
                         
                        <E T="03">See Regulatory Notice</E>
                         23-08 (May 2023) (“In recent years, the unregistered offering market outpaced the public market. . . . In 2021, for example, members submitted over 3,800 unique filings for private placements pursuant to FINRA Rules 5122 and 5123, which require filings for private placements generally sold to individuals, in comparison to roughly 2,000 submissions in 2013.”).
                    </P>
                </FTNT>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s50,12,12,12,12,12,12">
                    <TTITLE>Corporate Financing Private Placement Review Fee—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">Private placements (offerings &gt;$25M)</CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">
                            2025
                            <LI>(effective</LI>
                            <LI>7/1/25)</LI>
                            <LI>(million)</LI>
                        </CHED>
                        <CHED H="1">
                            2026
                            <LI>(million)</LI>
                        </CHED>
                        <CHED H="1">
                            2027
                            <LI>(million)</LI>
                        </CHED>
                        <CHED H="1">
                            2028
                            <LI>(million)</LI>
                        </CHED>
                        <CHED H="1">
                            2029
                            <LI>(million)</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Flat Fee</ENT>
                        <ENT>$0</ENT>
                        <ENT>$300</ENT>
                        <ENT>$300</ENT>
                        <ENT>$300</ENT>
                        <ENT>$300</ENT>
                        <ENT>$300</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">% of Offering</ENT>
                        <ENT>0%</ENT>
                        <ENT>0.008%</ENT>
                        <ENT>0.008%</ENT>
                        <ENT>0.008%</ENT>
                        <ENT>0.008%</ENT>
                        <ENT>0.008%</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Offering Cap</ENT>
                        <ENT>$0</ENT>
                        <ENT>$500</ENT>
                        <ENT>$500</ENT>
                        <ENT>$500</ENT>
                        <ENT>$500</ENT>
                        <ENT>$500</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    The proposed fee is designed to be similar to the current fee for public offering reviews. Like the public offering review fee, this proposed fee would consist of both a flat fee and a percentage of the maximum offering proceeds. However, to reduce the impact on smaller issuers and broker-dealers, FINRA proposes to apply this fee only to private placement offerings of greater than $25 million and to cap the fee at $40,300 (0.008% of $500,000,000 offering + $300 flat fee). In general, FINRA believes that such fees would be paid for by, or passed through to, issuers.
                    <SU>69</SU>
                    <FTREF/>
                     This proposed new use-based fee is structured to take into account associated types of costs, including the substantial resources such reviews require.
                    <SU>70</SU>
                    <FTREF/>
                     When the proposed new fee for private placement review is fully implemented, it is designed to generate $6 million in annual revenue by 2029.
                </P>
                <FTNT>
                    <P>
                        <SU>69</SU>
                         FINRA's belief is informed by its experience with the public offering fee, described below, and based on discussions with FINRA advisory committees and other industry participants.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>70</SU>
                         As discussed above, when applying use-based fees, FINRA takes into account direct costs for the program, indirect costs for the program, and a contribution to FINRA's overall regulatory operations. 
                        <E T="03">See supra</E>
                         note 7 and accompanying text.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Corporate Financing Public Offering Review Fee</HD>
                <P>
                    Corporate Financing reviews the underwriting terms and arrangements of proposed public offerings of securities for compliance with the requirements of FINRA Rule 5110 (Corporate Financing Rule—Underwriting Terms and Arrangements). Pursuant to Rule 5110, no member firm or person associated with a member firm may participate in a public offering subject to the rule, or to FINRA Rules 5121 (Public Offerings of Securities With Conflicts of Interest) and 2310 (Direct Participation Programs), unless the documents and information specified in the rule have been filed with and reviewed by Corporate Financing. The documents Corporate Financing reviews include registration statements, underwriting agreements, engagement letters and other relevant supporting documentation for public offerings. Corporate Financing's review is complementary to the SEC's registration process, which covers a larger set of filings than FINRA's program.
                    <SU>71</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>71</SU>
                         The SEC's current filing fee rate for filings made pursuant to Sections 6(b) of the Securities Act of 1933 and Sections 13(e) and 14(g) of the Exchange Act is $147.60 per $1,000,000. 
                        <E T="03">See https://www.sec.gov/edgar/filer/filing-fees/filing-fee-rate.</E>
                    </P>
                </FTNT>
                <P>
                    Section 7 of Schedule A to the FINRA By-Laws sets forth the fees associated with filing documents pursuant to the Corporate Financing Rule. It currently provides for a flat fee of $500 plus .015% of the proposed maximum aggregate offering price or other applicable value of all securities registered on an SEC registration statement or included on any other type of offering document (where not filed with the SEC), with a cap of $225,500; or a fee of $225,500 for an offering of securities filed with the SEC and offered pursuant to Securities Act Rule 415 by a Well-Known Seasoned Issuer (“WKSI”) as defined in Securities Act Rule 405. The fee associated with any amendment or other change to the documents initially filed with Corporate Financing is also subject to the current $225,500 cap. FINRA has not raised the fee cap since 2012.
                    <SU>72</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>72</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 67241 (June 22, 2012), 77 FR 38698 (June 28, 2012) (Notice of Filing and Immediate Effectiveness of File No. SR-FINRA-2012-029); 
                        <E T="03">see also Regulatory Notice</E>
                         12-32 (June 2012).
                    </P>
                </FTNT>
                <P>
                    FINRA is proposing to increase and modify the fee cap beginning in July 2025 as follows:
                    <PRTPAGE P="93721"/>
                </P>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s50,12,12,12,12,12,12">
                    <TTITLE>Corporate Financing Public Offering Review Fee Cap—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">IPO</CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">
                            2025
                            <LI>(effective</LI>
                            <LI>7/1/25)</LI>
                        </CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Non-WKSI</ENT>
                        <ENT>$225,000</ENT>
                        <ENT>$1,125,000</ENT>
                        <ENT>$1,125,000</ENT>
                        <ENT>$1,125,000</ENT>
                        <ENT>$1,125,000</ENT>
                        <ENT>$1,125,000</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">WKSI</ENT>
                        <ENT>225,000</ENT>
                        <ENT>270,000</ENT>
                        <ENT>324,000</ENT>
                        <ENT>389,000</ENT>
                        <ENT>467,000</ENT>
                        <ENT>560,000</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    This proposed rule change would raise the fee cap to $1,125,000, which would account for the significant growth in the size of offerings since the cap was last raised in 2012. However, for WKSIs, the cap would be raised to $560,000 over a period of five years. FINRA notes that raising the caps would also create more consistency with the SEC IPO review fee, which has no cap.
                    <SU>73</SU>
                    <FTREF/>
                     FINRA projects that increasing the cap as proposed would capture 81% of the incremental revenues if there were no cap while bounding the impact on WKSIs whose offerings tend to be less resource intensive for Corporate Financing to review. FINRA believes such fees are and would continue to be paid for by, or passed through to, issuers.
                    <SU>74</SU>
                    <FTREF/>
                     When the proposed fee increase is fully implemented, it is designed to generate an additional $31 million in annual revenue by 2029.
                    <SU>75</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>73</SU>
                         
                        <E T="03">See supra</E>
                         note 71.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>74</SU>
                         
                        <E T="03">See supra</E>
                         note 69.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>75</SU>
                         The proposed rule change would remove the language “on an automatically effective Form S-3 or F-3 registration statement” because WKSIs may use other registration forms. 
                        <E T="03">See, e.g.,</E>
                         Securities Offering Reform for Closed-End Investment Companies, Investment Company Act Release No. 33836 (April 8, 2020), 85 FR 33290 (June 1, 2020).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Advertising Regulation Review Fee</HD>
                <P>
                    One way that FINRA protects investors is by having its Advertising Regulation Department review specified broker-dealers' communications for compliance with FINRA's communications with the public rules, and similar rules of 
                    <SU>76</SU>
                    <FTREF/>
                     the SEC, MSRB and Securities Investor Protection Corporation. FINRA rules require that member communications be based on principles of fair dealing and good faith, be fair and balanced, and provide a sound basis for evaluating the facts in regard to any particular security or type of security, industry or service. Among other things, FINRA rules prohibit member firm communications from including false, exaggerated, unwarranted or misleading statements or claims.
                </P>
                <FTNT>
                    <P>
                        <SU>76</SU>
                         
                        <E T="03">See generally</E>
                         FINRA Rule 2200 Series. FINRA also will review communications filed voluntarily.
                    </P>
                </FTNT>
                <P>
                    Section 13 of Schedule A to the FINRA By-Laws sets forth the fees associated with review of communications filed with FINRA. Despite rising costs to administer the Advertising Regulation Department review program, FINRA has not increased these fees since 2012.
                    <SU>77</SU>
                    <FTREF/>
                     FINRA is proposing an increase to the regular review charge in 2025 as follows:
                </P>
                <FTNT>
                    <P>
                        <SU>77</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 67239 (June 22, 2012), 77 FR 38692 (June 28, 2012) (Notice of Filing and Immediate Effectiveness of File No. SR-FINRA-2012-028).
                    </P>
                </FTNT>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s100,12C,12C,12C,12C,12C,12C">
                    <TTITLE>Advertising Regulation Review—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">Fee</CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Regular Review Charge (non-expedited)</ENT>
                        <ENT>$125</ENT>
                        <ENT>$300</ENT>
                        <ENT>$300</ENT>
                        <ENT>$300</ENT>
                        <ENT>$300</ENT>
                        <ENT>$300</ENT>
                    </ROW>
                </GPOTABLE>
                <P>
                    When the proposed fee increase is fully implemented, it is designed to generate an additional $11 million in annual revenue by 2029.
                    <SU>78</SU>
                    <FTREF/>
                     Under the proposed rule change, the $600 expedited fee would not change.
                </P>
                <FTNT>
                    <P>
                        <SU>78</SU>
                         FINRA currently charges a $10 fee for the review of each printed page or web page in excess of 10 pages, and for each minute of tape reviewed in excess of 10 minutes of video or audio media. This would not change under the proposed rule change.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Dispute Resolution Services Arbitration Fees</HD>
                <P>
                    DRS operates the largest securities arbitration forum in the United States, to assist in the resolution of disputes involving customers, members and associated persons. As discussed in turn below, FINRA proposes to raise the (1) hearing session fees, (2) filing fees, (3) member surcharge, and (4) member process fee, as set forth in the Code of Arbitration Procedure for Customer Disputes (“Customer Code”) and Code of Arbitration Procedure for Industry Disputes (“Industry Code”) (together, the “Codes”).
                    <SU>79</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>79</SU>
                         The Customer Code is the FINRA Rule 12000 Series; the Industry Code is the FINRA Rule 13000 Series. The proposed fee increases described, below, would be implemented in both Codes.
                    </P>
                </FTNT>
                <P>
                    FINRA believes that the cost of arbitration should be borne by the users of the forum, without imposing a significant barrier to public customers who bring arbitration claims to the forum. Thus, the current DRS arbitration fees are designed to be borne 85 percent by members and 15 percent by customers.
                    <SU>80</SU>
                    <FTREF/>
                     The proposed rule change would maintain that pricing structure. It would also maintain a sliding scale fee structure in which the member surcharge and process fees increase across the board, while the hearing session fees and filing fees increase more for higher value claims. Taken together, the proposed increase in DRS' arbitration fees would aim to partially recover increasing costs to operate the forum, without placing an undue burden on users of the forum, particularly customers or claimants with small claims. When the proposed DRS arbitration fee increases are fully implemented, they are designed to generate an additional $10 million in annual revenue by 2029.
                </P>
                <FTNT>
                    <P>
                        <SU>80</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 90227 (October 20, 2020), 85 FR 67794 (October 26, 2020) (Notice of Filing File No. SR-FINRA-2020-035).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Hearing Session Fees</HD>
                <P>
                    Under FINRA Rules 12902 and 13902, hearing session fees are charged for each hearing session based on the amount in dispute. In the award, the panel determines the amount of each hearing session fee that each party must pay. The arbitrators may apportion the fees in any manner, including assessing the entire amount against one party.
                    <SU>81</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>81</SU>
                         
                        <E T="03">See</E>
                         FINRA Rules 12902(a)(1) and 13902(a)(1).
                    </P>
                </FTNT>
                <P>
                    FINRA proposes to raise hearing session fees in 2025 as follows:
                    <PRTPAGE P="93722"/>
                </P>
                <GPOTABLE COLS="5" OPTS="L2,i1" CDEF="s50,12,12p,12,12">
                    <TTITLE>Hearing Session Fees—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            Amount of claim
                            <LI>(exclusive of interest and expenses)</LI>
                        </CHED>
                        <CHED H="1">2024 (current)</CHED>
                        <CHED H="2">
                            Hearing
                            <LI>session w/</LI>
                            <LI>one</LI>
                            <LI>arbitrator</LI>
                        </CHED>
                        <CHED H="2">
                            Hearing
                            <LI>session w/</LI>
                            <LI>three</LI>
                            <LI>arbitrators</LI>
                        </CHED>
                        <CHED H="1">2025-2029</CHED>
                        <CHED H="2">
                            Hearing
                            <LI>session w/</LI>
                            <LI>one</LI>
                            <LI>arbitrator</LI>
                        </CHED>
                        <CHED H="2">
                            Hearing
                            <LI>session w/</LI>
                            <LI>three</LI>
                            <LI>arbitrators</LI>
                        </CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Up to $2,500</ENT>
                        <ENT>$50</ENT>
                        <ENT>N/A</ENT>
                        <ENT>$50</ENT>
                        <ENT>N/A</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$2,500.01 to $5,000</ENT>
                        <ENT>125</ENT>
                        <ENT>N/A</ENT>
                        <ENT>125</ENT>
                        <ENT>N/A</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$5,000.01 to $10,000</ENT>
                        <ENT>250</ENT>
                        <ENT>N/A</ENT>
                        <ENT>250</ENT>
                        <ENT>N/A</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$10,000.01 to $25,000</ENT>
                        <ENT>450</ENT>
                        <ENT>N/A</ENT>
                        <ENT>450</ENT>
                        <ENT>N/A</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$25,000.01 to $50,000</ENT>
                        <ENT>450</ENT>
                        <ENT>$600</ENT>
                        <ENT>450</ENT>
                        <ENT>$600</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$50,000.01 to $100,000</ENT>
                        <ENT>450</ENT>
                        <ENT>750</ENT>
                        <ENT>450</ENT>
                        <ENT>750</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$100,000.01 to $500,000</ENT>
                        <ENT>450</ENT>
                        <ENT>1,125</ENT>
                        <ENT>675</ENT>
                        <ENT>1,690</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$500,000.01 to $1,000,000</ENT>
                        <ENT>450</ENT>
                        <ENT>1,325</ENT>
                        <ENT>675</ENT>
                        <ENT>1,990</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$1,000,000.01 to $5,000,000</ENT>
                        <ENT>450</ENT>
                        <ENT>1,435</ENT>
                        <ENT>675</ENT>
                        <ENT>2,160</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Over $5,000,000</ENT>
                        <ENT>450</ENT>
                        <ENT>1,575</ENT>
                        <ENT>675</ENT>
                        <ENT>2,370</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Non-Monetary/Not Specified</ENT>
                        <ENT>450</ENT>
                        <ENT>1,150</ENT>
                        <ENT>675</ENT>
                        <ENT>1,725</ENT>
                    </ROW>
                </GPOTABLE>
                <P>To minimize the impact of the proposed rule change on customers or claimants with small claims, the proposed fee increase would only apply to claims of more than $100,000 and claims for non-monetary or unspecified damages. The tiered structure of this fee would not change under the proposed rule change.</P>
                <P>
                    FINRA notes the hearing session fee may not be assessed under certain circumstances. For example, if the parties timely settle the arbitration, the parties will not be assessed hearing session fees.
                    <SU>82</SU>
                    <FTREF/>
                     During settlement negotiations, parties have the opportunity to determine how to share any hearing session fees, if hearings are held.
                    <SU>83</SU>
                    <FTREF/>
                     For cases that result in an award, the panel has discretion to assess hearing session fees as part of the award,
                    <SU>84</SU>
                    <FTREF/>
                     which allows them to consider numerous factors to determine each party's appropriate share and assign the costs accordingly. The proposed rule change would not change a party's ability to settle or arbitrators' discretion to assess the hearing session fees.
                </P>
                <FTNT>
                    <P>
                        <SU>82</SU>
                         
                        <E T="03">See</E>
                         FINRA Rules 12701 and 13701.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>83</SU>
                         
                        <E T="03">See</E>
                         FINRA Rules 12701(b) and 13701(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>84</SU>
                         
                        <E T="03">See</E>
                         FINRA Rules 12902(a)(1) and 13902(a)(1).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Filing Fees</HD>
                <HD SOURCE="HD3">Filing Fees Paid by Customers, Associated Persons or Other Non-Members</HD>
                <P>Filing fees are due when a claim is filed. FINRA Rule 12900(a) sets forth the filing fee schedule for customers, associated persons and other non-members who file a claim, counterclaim, cross claim or third party claim in a customer dispute. FINRA Rule 13900(a) sets forth the filing fee schedule for associated persons who file a claim, counterclaim, cross claim or third party claim in an industry dispute. The filing fee is based on the claim amount or type of damages requested.</P>
                <P>FINRA proposes to raise filing fees in 2025 as follows:</P>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s50,12,12,12,12,12,12">
                    <TTITLE>Filing Fee (Customers, Associated Persons, and other Non-Members)—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            Amount of claim
                            <LI>(exclusive of interest and expenses)</LI>
                        </CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">$.01 to $1,000</ENT>
                        <ENT>$50</ENT>
                        <ENT>$50</ENT>
                        <ENT>$50</ENT>
                        <ENT>$50</ENT>
                        <ENT>$50</ENT>
                        <ENT>$50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$1,000.01 to $2,500</ENT>
                        <ENT>75</ENT>
                        <ENT>75</ENT>
                        <ENT>75</ENT>
                        <ENT>75</ENT>
                        <ENT>75</ENT>
                        <ENT>75</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$2,500.01 to $5,000</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                        <ENT>175</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$5,000.01 to $10,000</ENT>
                        <ENT>325</ENT>
                        <ENT>325</ENT>
                        <ENT>325</ENT>
                        <ENT>325</ENT>
                        <ENT>325</ENT>
                        <ENT>325</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$10,000.01 to $25,000</ENT>
                        <ENT>425</ENT>
                        <ENT>425</ENT>
                        <ENT>425</ENT>
                        <ENT>425</ENT>
                        <ENT>425</ENT>
                        <ENT>425</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$25,000.01 to $50,000</ENT>
                        <ENT>600</ENT>
                        <ENT>600</ENT>
                        <ENT>600</ENT>
                        <ENT>600</ENT>
                        <ENT>600</ENT>
                        <ENT>600</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$50,000.01 to $100,000</ENT>
                        <ENT>975</ENT>
                        <ENT>975</ENT>
                        <ENT>975</ENT>
                        <ENT>975</ENT>
                        <ENT>975</ENT>
                        <ENT>975</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$100,000.01 to $500,000</ENT>
                        <ENT>1,425</ENT>
                        <ENT>1,790</ENT>
                        <ENT>1,790</ENT>
                        <ENT>1,790</ENT>
                        <ENT>1,790</ENT>
                        <ENT>1,790</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$500,000.01 to $1,000,000</ENT>
                        <ENT>1,740</ENT>
                        <ENT>2,175</ENT>
                        <ENT>2,175</ENT>
                        <ENT>2,175</ENT>
                        <ENT>2,175</ENT>
                        <ENT>2,175</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$1,000,000.01 to $5,000,000</ENT>
                        <ENT>2,025</ENT>
                        <ENT>2,540</ENT>
                        <ENT>2,540</ENT>
                        <ENT>2,540</ENT>
                        <ENT>2,540</ENT>
                        <ENT>2,540</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Over $5,000,000</ENT>
                        <ENT>2,300</ENT>
                        <ENT>2,875</ENT>
                        <ENT>2,875</ENT>
                        <ENT>2,875</ENT>
                        <ENT>2,875</ENT>
                        <ENT>2,875</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Non-Monetary/Not Specified</ENT>
                        <ENT>1,600</ENT>
                        <ENT>2,000</ENT>
                        <ENT>2,000</ENT>
                        <ENT>2,000</ENT>
                        <ENT>2,000</ENT>
                        <ENT>2,000</ENT>
                    </ROW>
                </GPOTABLE>
                <P>To minimize the impact of the proposed rule change on customers or claimants with small claims, and consistent with the current claim amount tier structure, the proposed fee increase would only apply to claims of more than $100,000 and claims for non-monetary or unspecified damages. The tiered structure of this fee would not change under the proposed rule change.</P>
                <HD SOURCE="HD3">Filing Fees Paid by Members</HD>
                <P>
                    FINRA Rules 12900(b) and 13900(b) set forth the filing fee schedule for members filing a claim, counterclaim, cross claim, or third party claim in customer and industry cases, respectively. FINRA proposes to increase the member filing fee in 2025 as follows:
                    <PRTPAGE P="93723"/>
                </P>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s100,12,12,12,12,12,12">
                    <TTITLE>Filing Fee (Members)—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            Amount of claim
                            <LI>(exclusive of interest and expenses)</LI>
                        </CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">$.01 to $1,000</ENT>
                        <ENT>$225</ENT>
                        <ENT>$225</ENT>
                        <ENT>$225</ENT>
                        <ENT>$225</ENT>
                        <ENT>$225</ENT>
                        <ENT>$225</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$1,000.01 to $2,500</ENT>
                        <ENT>350</ENT>
                        <ENT>350</ENT>
                        <ENT>350</ENT>
                        <ENT>350</ENT>
                        <ENT>350</ENT>
                        <ENT>350</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$2,500.01 to $5,000</ENT>
                        <ENT>525</ENT>
                        <ENT>525</ENT>
                        <ENT>525</ENT>
                        <ENT>525</ENT>
                        <ENT>525</ENT>
                        <ENT>525</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$5,000.01 to $10,000</ENT>
                        <ENT>750</ENT>
                        <ENT>750</ENT>
                        <ENT>750</ENT>
                        <ENT>750</ENT>
                        <ENT>750</ENT>
                        <ENT>750</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$10,000.01 to $25,000</ENT>
                        <ENT>1,050</ENT>
                        <ENT>1,050</ENT>
                        <ENT>1,050</ENT>
                        <ENT>1,050</ENT>
                        <ENT>1,050</ENT>
                        <ENT>1,050</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$25,000.01 to $50,000</ENT>
                        <ENT>1,450</ENT>
                        <ENT>1,450</ENT>
                        <ENT>1,450</ENT>
                        <ENT>1,450</ENT>
                        <ENT>1,450</ENT>
                        <ENT>1,450</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$50,000.01 to $100,000</ENT>
                        <ENT>1,750</ENT>
                        <ENT>1,750</ENT>
                        <ENT>1,750</ENT>
                        <ENT>1,750</ENT>
                        <ENT>1,750</ENT>
                        <ENT>1,750</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$100,000.01 to $500,000</ENT>
                        <ENT>2,125</ENT>
                        <ENT>2,660</ENT>
                        <ENT>2,660</ENT>
                        <ENT>2,660</ENT>
                        <ENT>2,660</ENT>
                        <ENT>2,660</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$500,000.01 to $1,000,000</ENT>
                        <ENT>2,650</ENT>
                        <ENT>3,320</ENT>
                        <ENT>3,320</ENT>
                        <ENT>3,320</ENT>
                        <ENT>3,320</ENT>
                        <ENT>3,320</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$1,000,000.01 to $5,000,000</ENT>
                        <ENT>3,550</ENT>
                        <ENT>4,440</ENT>
                        <ENT>4,440</ENT>
                        <ENT>4,440</ENT>
                        <ENT>4,440</ENT>
                        <ENT>4,440</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Over $5,000,000</ENT>
                        <ENT>4,200</ENT>
                        <ENT>5,250</ENT>
                        <ENT>5,250</ENT>
                        <ENT>5,250</ENT>
                        <ENT>5,250</ENT>
                        <ENT>5,250</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Non-Monetary/Not Specified</ENT>
                        <ENT>1,800</ENT>
                        <ENT>2,250</ENT>
                        <ENT>2,250</ENT>
                        <ENT>2,250</ENT>
                        <ENT>2,250</ENT>
                        <ENT>2,250</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD3">Partial Refund of Filing Fee</HD>
                <P>If a claim is settled or withdrawn more than 10 days before the date of the hearing on the merits, a party paying a filing fee will receive a partial refund of the filing fee in the amount specified under FINRA Rule 12900(c) for customer cases and FINRA Rule 13900(c) for industry cases. FINRA proposes to increase the partial filing fee refund in 2025 as follows:</P>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s100,12,12,12,12,12,12">
                    <TTITLE>Partial Filing Fee Refund—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            Amount of claim
                            <LI>(exclusive of interest and expenses)</LI>
                        </CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">$.01 to $1,000</ENT>
                        <ENT>$25</ENT>
                        <ENT>$25</ENT>
                        <ENT>$25</ENT>
                        <ENT>$25</ENT>
                        <ENT>$25</ENT>
                        <ENT>$25</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$1,000.01 to $2,500</ENT>
                        <ENT>50</ENT>
                        <ENT>50</ENT>
                        <ENT>50</ENT>
                        <ENT>50</ENT>
                        <ENT>50</ENT>
                        <ENT>50</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$2,500.01 to $5,000</ENT>
                        <ENT>125</ENT>
                        <ENT>125</ENT>
                        <ENT>125</ENT>
                        <ENT>125</ENT>
                        <ENT>125</ENT>
                        <ENT>125</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$5,000.01 to $10,000</ENT>
                        <ENT>250</ENT>
                        <ENT>250</ENT>
                        <ENT>250</ENT>
                        <ENT>250</ENT>
                        <ENT>250</ENT>
                        <ENT>250</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$10,000.01 to $25,000</ENT>
                        <ENT>300</ENT>
                        <ENT>300</ENT>
                        <ENT>300</ENT>
                        <ENT>300</ENT>
                        <ENT>300</ENT>
                        <ENT>300</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$25,000.01 to $50,000</ENT>
                        <ENT>450</ENT>
                        <ENT>450</ENT>
                        <ENT>450</ENT>
                        <ENT>450</ENT>
                        <ENT>450</ENT>
                        <ENT>450</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$50,000.01 to $100,000</ENT>
                        <ENT>750</ENT>
                        <ENT>750</ENT>
                        <ENT>750</ENT>
                        <ENT>750</ENT>
                        <ENT>750</ENT>
                        <ENT>750</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$100,000.01 to $500,000</ENT>
                        <ENT>1,125</ENT>
                        <ENT>1,410</ENT>
                        <ENT>1,410</ENT>
                        <ENT>1,410</ENT>
                        <ENT>1,410</ENT>
                        <ENT>1,410</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$500,000.01 to $1,000,000</ENT>
                        <ENT>1,300</ENT>
                        <ENT>1,625</ENT>
                        <ENT>1,625</ENT>
                        <ENT>1,625</ENT>
                        <ENT>1,625</ENT>
                        <ENT>1,625</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$1,000,000.01 to $5,000,000</ENT>
                        <ENT>1,400</ENT>
                        <ENT>1,750</ENT>
                        <ENT>1,750</ENT>
                        <ENT>1,750</ENT>
                        <ENT>1,750</ENT>
                        <ENT>1,750</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Over $5,000,000</ENT>
                        <ENT>1,500</ENT>
                        <ENT>1,875</ENT>
                        <ENT>1,875</ENT>
                        <ENT>1,875</ENT>
                        <ENT>1,875</ENT>
                        <ENT>1,875</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Non-Monetary/Not specified</ENT>
                        <ENT>1,200</ENT>
                        <ENT>1,500</ENT>
                        <ENT>1,500</ENT>
                        <ENT>1,500</ENT>
                        <ENT>1,500</ENT>
                        <ENT>1,500</ENT>
                    </ROW>
                </GPOTABLE>
                <HD SOURCE="HD3">Member Surcharge</HD>
                <P>FINRA assesses a surcharge against each member that (a) files a claim, counterclaim, cross claim or third party claim under the Codes; (b) is named as a respondent in a claim, counterclaim, cross claim, or third party claim filed and served under the Codes; or (c) employed, at the time the dispute arose, an associated person who is named as a respondent in a claim, counterclaim, cross claim, or third party claim filed and served under the Codes.</P>
                <P>
                    FINRA Rules 12901 and 13901 set forth the schedule of the member surcharge, which is assessed based on the amount of the claim, exclusive of interest and expenses. The member is assessed one surcharge per arbitration case.
                    <SU>85</SU>
                    <FTREF/>
                     Member surcharges are intended to allocate the costs of administering the arbitration case to the firms that are involved in those cases. Thus, each member is assessed a member surcharge, based on the aggregate claim amount, when it is brought into the case, whether through a claim, counterclaim, cross claim or third party claim. The member surcharge is the responsibility of the member party and cannot be allocated to any other party (“non-allocable”).
                </P>
                <FTNT>
                    <P>
                        <SU>85</SU>
                         
                        <E T="03">See</E>
                         FINRA Rules 12901(a)(6) and 13901(f).
                    </P>
                </FTNT>
                <P>FINRA proposes to increase the member surcharge in 2025 as follows:</P>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s100,12,12,12,12,12,12">
                    <TTITLE>Member Surcharge—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            Amount of claim
                            <LI>(exclusive of interest and expenses)</LI>
                        </CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">$.01 to $5,000</ENT>
                        <ENT>$150</ENT>
                        <ENT>$165</ENT>
                        <ENT>$165</ENT>
                        <ENT>$165</ENT>
                        <ENT>$165</ENT>
                        <ENT>$165</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$5,000.01-$10,000</ENT>
                        <ENT>325</ENT>
                        <ENT>360</ENT>
                        <ENT>360</ENT>
                        <ENT>360</ENT>
                        <ENT>360</ENT>
                        <ENT>360</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$10,000.01-$25,000</ENT>
                        <ENT>450</ENT>
                        <ENT>495</ENT>
                        <ENT>495</ENT>
                        <ENT>495</ENT>
                        <ENT>495</ENT>
                        <ENT>495</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$25,000.01-$50,000</ENT>
                        <ENT>750</ENT>
                        <ENT>975</ENT>
                        <ENT>975</ENT>
                        <ENT>975</ENT>
                        <ENT>975</ENT>
                        <ENT>975</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$50,000.01-$100,000</ENT>
                        <ENT>1,100</ENT>
                        <ENT>1,430</ENT>
                        <ENT>1,430</ENT>
                        <ENT>1,430</ENT>
                        <ENT>1,430</ENT>
                        <ENT>1,430</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$100,000.01-$250,000</ENT>
                        <ENT>1,700</ENT>
                        <ENT>2,210</ENT>
                        <ENT>2,210</ENT>
                        <ENT>2,210</ENT>
                        <ENT>2,210</ENT>
                        <ENT>2,210</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$250,000.01-$500,000</ENT>
                        <ENT>2,025</ENT>
                        <ENT>2,640</ENT>
                        <ENT>2,640</ENT>
                        <ENT>2,640</ENT>
                        <ENT>2,640</ENT>
                        <ENT>2,640</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$500,000.01-$1,000,000</ENT>
                        <ENT>2,625</ENT>
                        <ENT>3,420</ENT>
                        <ENT>3,420</ENT>
                        <ENT>3,420</ENT>
                        <ENT>3,420</ENT>
                        <ENT>3,420</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$1,000,000.01-$5,000,000</ENT>
                        <ENT>3,200</ENT>
                        <ENT>4,800</ENT>
                        <ENT>4,800</ENT>
                        <ENT>4,800</ENT>
                        <ENT>4,800</ENT>
                        <ENT>4,800</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$5,000,000.01-$10,000,000</ENT>
                        <ENT>3,850</ENT>
                        <ENT>5,775</ENT>
                        <ENT>5,775</ENT>
                        <ENT>5,775</ENT>
                        <ENT>5,775</ENT>
                        <ENT>5,775</ENT>
                    </ROW>
                    <ROW>
                        <PRTPAGE P="93724"/>
                        <ENT I="01">Over $10,000,000</ENT>
                        <ENT>4,325</ENT>
                        <ENT>6,490</ENT>
                        <ENT>6,490</ENT>
                        <ENT>6,490</ENT>
                        <ENT>6,490</ENT>
                        <ENT>6,490</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Non-Monetary/Not Specified</ENT>
                        <ENT>2,000</ENT>
                        <ENT>2,600</ENT>
                        <ENT>2,600</ENT>
                        <ENT>2,600</ENT>
                        <ENT>2,600</ENT>
                        <ENT>2,600</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The member surcharge would remain non-allocable under the proposed rule change and, therefore, would not result in any additional costs to other parties to the arbitration, including customers.</P>
                <HD SOURCE="HD3">Member Process Fee</HD>
                <P>
                    Under the Codes, each member that is a party to an arbitration or employed an associated person who is a party to an arbitration in which more than $25,000, exclusive of interest and expenses, is in dispute must pay a non-refundable process fee.
                    <SU>86</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>86</SU>
                         
                        <E T="03">See</E>
                         FINRA Rules 12903 and 13903. If a claim amount is $25,000 or less, the member would not be assessed any process fees.
                    </P>
                </FTNT>
                <P>
                    FINRA Rules 12903 and 13903 set forth the process fee schedule. FINRA assesses the member the applicable process fee when the parties are sent the arbitrator lists or notification of the hearing. Like the member surcharge, the process fee is non-allocable to other parties to the arbitration.
                    <SU>87</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>87</SU>
                         
                        <E T="03">See</E>
                         FINRA Rules 12903(d) and 13903(d). 
                        <E T="03">See also</E>
                         FINRA Rules 12701(b) and 13701(b).
                    </P>
                </FTNT>
                <P>FINRA proposes to increase the process fee in 2025 as follows:</P>
                <GPOTABLE COLS="7" OPTS="L2,i1" CDEF="s100,12,12,12,12,12,12">
                    <TTITLE>Member Process Fee—Proposed Implementation</TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            Amount of claim
                            <LI>(exclusive of interest and expenses)</LI>
                        </CHED>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">$.01-$25,000</ENT>
                        <ENT>$0</ENT>
                        <ENT>$0</ENT>
                        <ENT>$0</ENT>
                        <ENT>$0</ENT>
                        <ENT>$0</ENT>
                        <ENT>$0</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$25,000.01-$50,000</ENT>
                        <ENT>1,750</ENT>
                        <ENT>2,275</ENT>
                        <ENT>2,275</ENT>
                        <ENT>2,275</ENT>
                        <ENT>2,275</ENT>
                        <ENT>2,275</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$50,000.01-$100,000</ENT>
                        <ENT>2,250</ENT>
                        <ENT>2,925</ENT>
                        <ENT>2,925</ENT>
                        <ENT>2,925</ENT>
                        <ENT>2,925</ENT>
                        <ENT>2,925</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$100,000.01-$250,000</ENT>
                        <ENT>3,250</ENT>
                        <ENT>4,225</ENT>
                        <ENT>4,225</ENT>
                        <ENT>4,225</ENT>
                        <ENT>4,225</ENT>
                        <ENT>4,225</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$250,000.01-$500,000</ENT>
                        <ENT>3,875</ENT>
                        <ENT>5,040</ENT>
                        <ENT>5,040</ENT>
                        <ENT>5,040</ENT>
                        <ENT>5,040</ENT>
                        <ENT>5,040</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$500,000.01-$1,000,000</ENT>
                        <ENT>5,225</ENT>
                        <ENT>6,800</ENT>
                        <ENT>6,800</ENT>
                        <ENT>6,800</ENT>
                        <ENT>6,800</ENT>
                        <ENT>6,800</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$1,000,000.01-$5,000,000</ENT>
                        <ENT>6,375</ENT>
                        <ENT>9,570</ENT>
                        <ENT>9,570</ENT>
                        <ENT>9,570</ENT>
                        <ENT>9,570</ENT>
                        <ENT>9,570</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">$5,000,000.01-$10,000,000</ENT>
                        <ENT>7,050</ENT>
                        <ENT>10,575</ENT>
                        <ENT>10,575</ENT>
                        <ENT>10,575</ENT>
                        <ENT>10,575</ENT>
                        <ENT>10,575</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Over $10,000,000</ENT>
                        <ENT>7,300</ENT>
                        <ENT>10,950</ENT>
                        <ENT>10,950</ENT>
                        <ENT>10,950</ENT>
                        <ENT>10,950</ENT>
                        <ENT>10,950</ENT>
                    </ROW>
                    <ROW>
                        <ENT I="01">Non-Monetary/Not Specified</ENT>
                        <ENT>3,850</ENT>
                        <ENT>5,005</ENT>
                        <ENT>5,005</ENT>
                        <ENT>5,005</ENT>
                        <ENT>5,005</ENT>
                        <ENT>5,005</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The member process fee would remain non-allocable under the proposed rule change and, therefore, would not result in any additional costs to other parties to the arbitration, including customers.</P>
                <HD SOURCE="HD3">Regulation T and Exchange Act Rule 15c3-3(n) Requests for Extension of Time Fee</HD>
                <P>
                    Section 8 of Schedule A to the FINRA By-Laws governs the service charge for each extension of time request pursuant to Sections 220.4(c) and 220.8(d) of Regulation T 
                    <SU>88</SU>
                    <FTREF/>
                     of the Board of Governors of the Federal Reserve System (“Regulation T”) and Exchange Act Rule 15c3-3(n).
                    <SU>89</SU>
                    <FTREF/>
                     FINRA has not increased this fee since 2006.
                    <SU>90</SU>
                    <FTREF/>
                     FINRA proposes to raise the fee in 2025 as follows:
                </P>
                <FTNT>
                    <P>
                        <SU>88</SU>
                         12 CFR 220.4(c) and 220.8(d), respectively.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>89</SU>
                         17 CFR 240.15c3-3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>90</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 53982 (June 14, 2006), 71 FR 35720 (June 21, 2006) (Notice of Filing and Immediate Effectiveness of File No. SR-NASD-2006-063). 
                        <E T="03">See also Notice to Members</E>
                         06-30 (June 2006).
                    </P>
                </FTNT>
                <GPOTABLE COLS="6" OPTS="L2,i1" CDEF="xs75,xs75,xs75,xs75,xs75,xs75">
                    <TTITLE>
                        Regulation T and Exchange Act Rule 15
                        <E T="01">c</E>
                        3-3(
                        <E T="01">n</E>
                        ) Requests for Extension of Time—Proposed Implementation
                    </TTITLE>
                    <BOXHD>
                        <CHED H="1">
                            2024
                            <LI>(current)</LI>
                        </CHED>
                        <CHED H="1">2025</CHED>
                        <CHED H="1">2026</CHED>
                        <CHED H="1">2027</CHED>
                        <CHED H="1">2028</CHED>
                        <CHED H="1">2029</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">$4 per request</ENT>
                        <ENT>$8 per request</ENT>
                        <ENT>$8 per request</ENT>
                        <ENT>$8 per request</ENT>
                        <ENT>$8 per request</ENT>
                        <ENT>$8 per request.</ENT>
                    </ROW>
                </GPOTABLE>
                <P>Based on current annual extension filing volumes, the current fee does not cover the estimated personnel and technology costs necessary to process extension requests. The proposal to increase the fee would recover some of those costs. When the proposed service charge for Regulation T and Exchange Act Rule 15c3-3(n) requests for extension of time increases are fully implemented, they are designed to generate an additional $640,000 in annual revenue by 2029.</P>
                <P>Further, to streamline Section 8, FINRA proposes to eliminate current paragraph (a), which is not needed in light of the specific fee amount language set forth in paragraph (b) of that Section. The proposed rule change would also make minor technical corrections. As such, the proposed rule change would amend Section 8 to read: “The service charge for processing each initial extension of time request and for all subsequent extension of time requests (1) involving the same transaction under Regulation T or (2) involving an extension of time previously granted pursuant to SEA Rule 15c3-3(n) shall be $8.00 per request.”</P>
                <HD SOURCE="HD3">Proposed Conforming Changes To Select Funding Portal Member Fees</HD>
                <P>
                    Section 15 of Schedule A to the FINRA By-Laws sets forth the fees that 
                    <PRTPAGE P="93725"/>
                    govern funding portals that are FINRA members. These fees became effective in 2016. At the time they were proposed, the funding portal fees related to eligibility proceedings and fingerprint processing, among others, were “identical to those charged to broker-dealer members.” 
                    <SU>91</SU>
                    <FTREF/>
                     Though amendments to the fees charged to broker-dealer members related to eligibility proceedings and fingerprint processing have since occurred, those same fees for funding portal members have not been amended, and thus, are no longer aligned.
                </P>
                <FTNT>
                    <P>
                        <SU>91</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 76238 (October 22, 2015), 80 FR 66342 (October 28, 2015) (Notice of Filing and Immediate Effectiveness of File No. SR-FINRA-2015-041).
                    </P>
                </FTNT>
                <P>
                    This proposed rule change would amend Section 15(f)(1) and Section 15(g) to conform the fees for members that are funding portals with the same fees that are charged to broker-dealer members. Specifically, in 2025, the proposed rule change would raise the funding portal member fee for filing an application to initiate eligibility proceedings from $1,500 to $5,000 to conform with the same fee that currently applies to broker-dealer members. Also in 2025, the proposed rule change would raise the funding portal member fee for fingerprints submitted electronically from $15 to $20 to conform with the same fee that currently applies to broker-dealer members.
                    <SU>92</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>92</SU>
                         
                        <E T="03">See supra</E>
                         note 54.
                    </P>
                </FTNT>
                <P>FINRA has filed the proposed rule change for immediate effectiveness. Implementation of the proposed rule change will be phased in gradually over a five-year period beginning on January 1, 2025, with full implementation of all proposed fee changes by 2029.</P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    FINRA believes that the proposed rule change is consistent with the provisions of Section 15A(b)(5) of the Act,
                    <SU>93</SU>
                    <FTREF/>
                     which requires, among other things, that FINRA rules provide for the equitable allocation of reasonable dues, fees and other charges among members and issuers and other persons using any facility or system that FINRA operates or controls. FINRA further believes that the proposed rule change is consistent with the provisions of Section 15A(b)(6) of the Act, which requires, among other things, that FINRA rules are not designed to permit unfair discrimination between customers, issuers, brokers or dealers.
                    <SU>94</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>93</SU>
                         15 U.S.C. 78
                        <E T="03">o</E>
                        -3(b)(5).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>94</SU>
                         15 U.S.C. 78
                        <E T="03">o</E>
                        -3(b)(6).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Reasonableness of the Proposed Fees</HD>
                <P>As discussed above, FINRA's longstanding approach to funding employs a variety of fees designed to meet FINRA's overall costs. As a not-for-profit SRO with a diverse membership, FINRA designs its mix of fees to seek recovery of its overall regulatory costs in a manner that is fair, reasonable, and equitably allocated among FINRA's members and users of FINRA's services. As FINRA has explained in the past, it is not feasible to associate a direct affiliated revenue stream for each of its programs (for example, FINRA collects no revenues in connection with its examinations of members), and thus numerous operations and services must be funded by other revenue sources, which include both core regulatory fees and other use-based fees. FINRA continues to believe that its overall Commission-approved cost-based pricing structure is reasonable, achieves general equity across its membership, and correlates fees with those firm components that drive FINRA's regulatory costs to the extent feasible.</P>
                <P>The reasonableness of this proposal is reinforced by three key cost discipline mechanisms: oversight, transparency, and rebates.</P>
                <P>
                    First, FINRA's funding and operations are subject to several layers of oversight, including by the FINRA Board of Governors 
                    <SU>95</SU>
                    <FTREF/>
                     and the Commission. As discussed in FINRA's 2024 annual budget summary, FINRA's efforts to manage its expenses responsibly while appropriately funding its mission includes Board oversight of its annual budget, compensation, and capital initiatives. This oversight is spearheaded by key Board committees (such as its Finance, Operations and Technology Committee), and includes requirements for Board or relevant Committee approval with respect to various financial matters, such as the annual budget, the allocation and use of fine monies, the incurring of any expenses above certain pre-established thresholds, the amount of any annual merit or incentive compensation, and the compensation of certain key employees. The Board also relies on expert external consultants where appropriate. Notably, this Board oversight complements various staff level controls over routine costs, including expense policies that are enforced with systemic checks and escalating management approval requirements for expense requests, with the effectiveness of these policies further subject to review by FINRA's Internal Audit Department.
                </P>
                <FTNT>
                    <P>
                        <SU>95</SU>
                         The FINRA Board of Governors is composed of a mix of public and industry representatives and uses its diverse expertise to oversee management in the administration of FINRA's affairs and the promotion of FINRA's welfare, objectives, and its public service mission to protect investors and uphold the integrity of markets.
                    </P>
                </FTNT>
                <P>
                    FINRA is also extensively supervised by the Commission throughout the year. The SEC's Division of Examinations maintains dedicated staff as part of its FINRA and Securities Industry Oversight (“FSIO”) program who are devoted exclusively to overseeing FINRA and the MSRB—the two not-for-profit regulatory SROs—including with respect to FINRA's overall financial management and the adequacy of the resources devoted to its regulatory programs. In addition, rules or fees adopted by FINRA are subject to review by the Commission's Division of Trading and Markets. The Commission's oversight of FINRA, in turn, is itself subject to Congressional oversight and evaluation by the United States Government Accountability Office (“GAO”) every three years. By statute, the GAO evaluates ten specific aspects of the Commission's oversight of FINRA, including FINRA governance, executive compensation, and the use of funding to support FINRA's mission, including the methods and sufficiency of funding, how FINRA invests funds pending use, and the impact of these aspects on FINRA's regulatory enforcement. The GAO reports the results of its evaluation to Congress.
                    <SU>96</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>96</SU>
                         
                        <E T="03">See</E>
                         GAO Report to Congressional Committees (November 2023), available at 
                        <E T="03">https://www.gao.gov/assets/d24106578.pdf.</E>
                    </P>
                </FTNT>
                <P>
                    Second, FINRA's commitment to reasonable funding in support of its mission is further reinforced by the transparency it has committed to provide on an ongoing basis—pursuant to its Guiding Principles—regarding its financial performance. Each year, FINRA publishes an extensive Annual Financial Report regarding its operations, prepared in accordance with GAAP. In addition, FINRA publishes annual reports on its budget and its use of fine monies. FINRA's Board also reviews and affirms its Financial Guiding Principles bi-annually and re-publishes these as well. FINRA also files with the IRS the Form 990 mandated for all not-for-profit organizations. Collectively, these reports provide extensive and comprehensive information regarding FINRA's policies and operations with respect to its budgets, revenues, costs, financial reserves, use of fine monies, capital and strategic initiatives, and compensation of senior executives, among other information. FINRA maintains a dedicated web page that consolidates its 
                    <PRTPAGE P="93726"/>
                    annual reports in a readily accessible place.
                    <SU>97</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>97</SU>
                         
                        <E T="03">See</E>
                         FINRA Financial Reports and Policies, available at 
                        <E T="03">https://www.finra.org/about/annual-reports.</E>
                    </P>
                </FTNT>
                <P>Third, as a not-for-profit organization, FINRA is committed to aligning its revenues with its mission-driven costs. If revenues exceed costs on a sustained basis, and FINRA's reserves are sustained appropriately, FINRA will assess the merit of providing rebates. This approach helps ensure that the revenues from these proposed fee changes will not exceed FINRA's reasonable regulatory costs and reserve needs on an ongoing basis. As discussed above, FINRA will continue to be guided by its historical approach to rebates if its revenue in future years exceeds its costs and reserves needs by a material amount.</P>
                <P>Together, these mechanisms help ensure the ongoing reasonableness of FINRA's costs and the level of fees assessed to support those costs. The effectiveness of these mechanisms is demonstrated by FINRA's experience over the last decade, during which, FINRA was able to undertake expanding regulatory responsibilities while limiting cumulative cost growth to a rate that was lower than inflation and cost growth experienced by members.</P>
                <HD SOURCE="HD3">The Proposed Fees Are Equitable and Not Unfairly Discriminatory</HD>
                <P>As discussed throughout this filing, this proposed rule change is designed to increase the fees FINRA relies on to fund its regulatory mission in a manner that preserves an equitable and not unfairly discriminatory fee allocation among FINRA members and users of FINRA services. Notably, through this proposed rule change, FINRA is seeking to preserve the carefully calibrated mix of core regulatory fees and select use-based fees to fund its regulatory mission that the Commission previously approved as equitably allocated among its large and diverse membership. In addition, based on feedback from members of FINRA's advisory committees and other industry consultations that emphasized the importance of advance notice and clarity of any fee increases for budget planning, implementation of the proposed rule change would take place over several years, with some fees going into effect in 2025, others implemented in 2026 or later, and some phased in over several years between 2025 and 2029.</P>
                <P>
                    The fees included in this proposed rule change were selected to address the impending funding deficit by raising fees in a way that maintains proportionality across members with minimal distributional impacts across firm sizes and business models. FINRA projects an aggregate dispersion level for the rate of increase realized across members to be 2.3% once the proposal is fully implemented.
                    <SU>98</SU>
                    <FTREF/>
                     In other words, in choosing among options according to the principles described above, FINRA also sought to have minimal impact on the distribution of fee rate changes across members by firm size and business model, as measured by the standard deviation of the rate of the fee increases. Given this limited distributional impact, FINRA believes the proposed rule change will preserve the same equitable and not unfairly discriminatory fee allocation that has long served as the foundation for FINRA's funding model and has been approved by the Commission.
                </P>
                <FTNT>
                    <P>
                        <SU>98</SU>
                         
                        <E T="03">See generally</E>
                         Exhibit 3, Charts 7 through 10.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>FINRA does not believe that the proposed rule change will result in any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.</P>
                <HD SOURCE="HD3">Economic Impact Assessment</HD>
                <P>FINRA has undertaken an economic impact assessment, as set forth below, to analyze the regulatory need for the proposed rule change, its potential economic impacts, including anticipated costs, benefits, and distributional and competitive effects, relative to the current baseline, and the alternatives FINRA considered in assessing how best to meet FINRA's regulatory objectives.</P>
                <HD SOURCE="HD3">Regulatory Need</HD>
                <P>Based on an analysis of its funding sources, anticipated costs, and expanding responsibilities, FINRA has determined that it will require additional revenues to continue to effectively meet its regulatory obligations. FINRA anticipates that the absence of stable funding at the levels proposed here may have material negative impacts on its regulatory program, weakening investor protections. Specifically, FINRA may be unable to maintain its current capabilities at their current standards or respond to a significant market event requiring unanticipated funding. In the absence of a fee increase, eventually FINRA may not be able to hire and retain staff with the appropriate expertise to conduct its regulatory activities (including examinations, market surveillance and investigations, enforcement, regulatory policy and rulemaking, qualification examinations and credentialing, and providing transparency for markets, members and registered persons), or make the necessary investments in the technology needed to support these activities.</P>
                <HD SOURCE="HD3">Economic Baseline</HD>
                <P>The baseline for this proposed rule change includes FINRA's historical costs and revenues, the current schedule of fees assessed by FINRA, and the direct and indirect allocation of those fees across members, associated persons, third parties, and investors. The baseline also encompasses the scope of activities conducted by FINRA to meet its mission, and FINRA's current ability to address changing market activities and conditions through investment in staff, infrastructure, and technology.</P>
                <P>
                    As a not-for-profit organization, FINRA targets break-even cash flows that allow it to appropriately fund its regulatory mission, and maintains a reasonable financial reserve necessary to meet unanticipated circumstances. Between 2013 and 2023, FINRA's cost increase CAGR was 3.5%, or 41% over the entire period.
                    <SU>99</SU>
                    <FTREF/>
                     Over the same period, members' reported cost increase CAGR was 8.7%, or a total increase of 129%.
                    <SU>100</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>99</SU>
                         Based on figures drawn from FINRA's public Annual Financial Reports, which include FINRA subsidiaries.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>100</SU>
                         Based on FOCUS reports.
                    </P>
                </FTNT>
                <P>
                    At the same time, capital markets have grown in size, complexity, and retail investor participation, in part, through an increase in the number of self-directed accounts and rapid technological changes. Partly in response to these changes, FINRA's regulatory responsibilities have, and continue to, grow as described above. There have been substantial increases in equity and options trading volume (respectively, over 70% and 160% increases since 2013) and in corporate and agency bond trading volume (over 230% increase since 2013). There has also been growth in the complexity of the securities markets (the number of registered national securities exchanges significantly increased since 2013, from 14 to 24 
                    <SU>101</SU>
                    <FTREF/>
                    ) and trading of new and evolving products, such as security-based swaps and securities with crypto asset components, has increased. These changes have led to a more complex 
                    <PRTPAGE P="93727"/>
                    trading environment. This, in turn, has required enhancements to oversight by FINRA staff. In addition, as discussed above, FINRA has made substantial investments in its surveillance and examinations programs in response to new and amended SEC rules.
                </P>
                <FTNT>
                    <P>
                        <SU>101</SU>
                         
                        <E T="03">See https://www.sec.gov/fast-answers/divisionsmarketregmrexchangesshtml.</E>
                         Additional registered national securities exchanges may contribute to more complex order lifecycles and trade reporting scenarios.
                    </P>
                </FTNT>
                <P>
                    Over the past several years, FINRA has observed changes in the number of registered persons and members. Between 2013 and 2023, the number of registered persons was essentially unchanged (627,468 and 628,392, respectively).
                    <SU>102</SU>
                    <FTREF/>
                     In contrast, over the same period, the number of members decreased from 4,146 to 3,298, a decrease of approximately 20%.
                    <SU>103</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>102</SU>
                         
                        <E T="03">See</E>
                         Table 1.2.2 of the FINRA Industry Snapshot, available at 
                        <E T="03">https://www.finra.org/media-center/reports-studies/2024-industry-snapshot.</E>
                         As FINRA notes when it publishes industry snapshots, FINRA regularly updates historical data series due to data revisions by reporting firms.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>103</SU>
                         
                        <E T="03">See</E>
                         Table 2.2.3 of the FINRA Industry Snapshot.
                    </P>
                </FTNT>
                <P>
                    FINRA believes that the number of registered persons remained fairly constant because persons from exiting members migrated to other members, requiring FINRA regulatory resources to shift accordingly. FINRA staff's quarterly reviews of departing firms find that on average about 75% of their associated persons remain registered after their firm exits the securities business, either by remaining with an affiliate firm or moving to a new firm. In the last quarter of 2023, the retention rate was closer to 90%. The difference in the decline in the number of members versus registered persons is also related to the fact that most exiting firms are small,
                    <SU>104</SU>
                    <FTREF/>
                     such that their departure has relatively less impact on the total number of registered persons.
                </P>
                <FTNT>
                    <P>
                        <SU>104</SU>
                         FINRA By-laws define the size of a member firm by the number of associated registered representative as the following: small—150 or fewer registered representatives; mid-size—151 to 500 registered representatives; and large—more than 500 registered representatives. A subgroup of the small firms are known as micro firms, firms with 10 or fewer registered representatives.
                    </P>
                </FTNT>
                <P>
                    Despite its increased responsibilities and changes in FINRA's own oversight by the SEC, FINRA achieved relatively low expense growth through a variety of cost-saving mechanisms.
                    <SU>105</SU>
                    <FTREF/>
                     Staffing generates the majority of FINRA's expenses and was relatively flat until recent years, commensurate with increases in FINRA's responsibilities. As discussed above, since 2013, FINRA's total compensation costs rose by 31% on a cumulative basis as compared with a 50% increase for the average U.S. financial services employee.
                    <SU>106</SU>
                    <FTREF/>
                     In aggregate, since 2013, FINRA's expenses have grown less rapidly than those of members, with the ratio of member expenses to FINRA expenses gradually increasing over time. Chart 1, attached in Exhibit 3, presents these findings.
                    <SU>107</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>105</SU>
                         As discussed above, cost savings have been accomplished in recent years through expense reduction initiatives, including conducting a comprehensive efficiency review of FINRA's core business lines; establishing a framework for improving measurement of FINRA's key objectives and results; voluntary retirement/incentive programs in 2020 and 2024; and strategic reductions in FINRA's corporate real estate footprint.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>106</SU>
                         
                        <E T="03">See supra</E>
                         note 22.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>107</SU>
                         As with Chart 1, all of the charts discussed below are attached in Exhibit 3, available on FINRA's website at 
                        <E T="03">http://www.finra.org.</E>
                    </P>
                </FTNT>
                <P>Over the period between 2013 and 2023, FINRA's total regulatory and use-based fee CAGR was 3.9%. These revenues remained effectively flat from 2013 through 2019 due to a limited number of fee increases. A previously implemented fee increase was phased in between 2022 to 2024 and has resulted in increased levels of operating revenue. However, FINRA projects that increases in revenue will either remain flat or slightly decrease after 2024.</P>
                <P>
                    Chart 2 provides a view of actual revenues and expenses for 2013 to 2023 and anticipated revenue and expenses for 2024 to 2029 if no changes to the fee structure are made.
                    <SU>108</SU>
                    <FTREF/>
                     Chart 2 also includes historical and projected “excess reserves.” FINRA maintains a reserve fund as part of its funding framework, and excess reserves are reserves in excess of the minimum determined by the FINRA Board of Governors as appropriate, which is one year of expenditures.
                    <SU>109</SU>
                    <FTREF/>
                     FINRA has strategically relied on its reserves to help fund operating deficits in the past and will continue to strategically draw on its reserves where consistent with the Guiding Principles. Chart 2 illustrates, however, that without a fee increase, FINRA is projected to exhaust excess reserves and deplete its reserve balance below minimum target levels in the coming years.
                </P>
                <FTNT>
                    <P>
                        <SU>108</SU>
                         The revenues and expenses presented in Chart 2 in terms of Cash Flow Sources and Cash Flow Uses—both historical and projected—do not include subsidiaries other than FINRA Regulation and FINRA Dispute Resolution, which was merged into FINRA Regulation at the end of 2015. Cash Flow Sources includes Operating Revenues, Investment Returns and Fines. Cash Flow Uses includes Operating Expenses and Capital Initiatives.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>109</SU>
                         
                        <E T="03">See supra</E>
                         note 12.
                    </P>
                </FTNT>
                <P>
                    Although FINRA's revenues would remain near current levels without any changes in the fee structure, FINRA reasonably anticipates that its future expenses will continue to grow at a pace of 5.9% on average per year based on the compounding impact of annual wage inflation, technology costs, and future capital initiatives.
                    <SU>110</SU>
                    <FTREF/>
                     In this scenario, revenues would increasingly fall behind anticipated costs. While FINRA's reserves may continue to cover the shortfall in the near-term, the reserves will reach their minimum prudent level of one year of operating costs within three to four years based on current projections if no corrective action is taken.
                </P>
                <FTNT>
                    <P>
                        <SU>110</SU>
                         As discussed above, FINRA has made reasonably conservative assumptions using a variety of information points, including historical data and anticipated trends. 
                        <E T="03">See supra</E>
                         note 15. This estimate is based on the following assumptions for FINRA and excludes the independent budgeting of all of FINRA's active subsidiaries other than FINRA Regulation—specifically, FINRA CAT, LLC and the FINRA Investor Education Foundation: (1) wage inflation at an annual rate between 4% and 6%, consistent with the financial industry over the last five years; (2) technology expense growth: capital investments seeking long-term efficiency gains for both FINRA and the industry, rising cloud hosting costs driven by volume increases, maintaining technology labor competitiveness, and ongoing disaster recovery and cybersecurity requirements; and (3) rise in regulatory efforts and associated costs for FINRA's regulatory programs.
                    </P>
                </FTNT>
                <P>
                    As described above, FINRA funds its regulatory and other related activities through a combination of regulatory fees and use-based fees. GIA, TAF, PA and Branch Office Fees, taken together, represent approximately 69% of 2023 revenues, while use-based fees represent approximately 31% of 2023 revenues. The specific fees that would be increased under this proposal represent approximately 89% of 2023 revenues.
                    <SU>111</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>111</SU>
                         Following the implementation of the proposed rule change, GIA, TAF, PA and Branch Office Fees, together, would represent approximately 72% of revenues, while use-based fees would represent approximately 28%.
                    </P>
                </FTNT>
                <P>
                    All core regulatory and use-based fees mentioned above are assessed directly to members. FINRA understands that many members shift at least some of the fees to other parties. For instance, it is regular practice among clearing and trading firms to “pass-through” the TAF to the underlying firm executing the trade. Further, FINRA understands that the executing firms commonly pass the TAF directly on to their customers submitting orders. Typically, TAF fees are reflected on the confirmation statement received by customers.
                    <SU>112</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>112</SU>
                         FINRA conducted a study of a sample of members, which included approximately 25 retail investor focused broker-dealers and approximately 15 institutional investor focused broker-dealers, to better understand practices of TAF pass through. The research found that the majority of the retail focused firms did pass through the TAF to their customers. FINRA does not know the full extent of this practice across all members.
                    </P>
                </FTNT>
                <P>
                    Similarly, FINRA understands that many firms regularly pass-through to registered persons assessments such as the PA, registration fees, and qualification examination fees. FINRA understands that there may be 
                    <PRTPAGE P="93728"/>
                    differences in this practice across firms depending on each firms' business model. Competitive markets for the provision of brokerage and related financial intermediation services, along with difficulty in allocating certain fees to specific transactions, can limit the extent to which these fees can be passed-through.
                </P>
                <P>Core regulatory fees are calibrated so that larger, more active and more geographically dispersed members are assessed higher fees, reflecting regulatory resource allocation. Likewise, the use-based fees that are part of core regulatory fees are designed to capture some of the costs associated with core regulatory activities in addition to the direct and indirect costs of the associated services. For example, FINRA believes it is appropriate that registration and qualification examination fees help defray the costs of regulating registered persons because members employing more persons require more regulatory effort on FINRA's part. This approach is consistent with a structure where the fees paid increase with the size of the firm's revenues (GIA) and the amount of trading activity it conducts (TAF). In addition, core regulatory fees tend to be correlated with member size and structure. As such, core regulatory fees are designed cohesively and comprehensively such that they should be evaluated in aggregate and not on a fee-by-fee or service-by-service basis.</P>
                <P>The fee structure is also designed, purposefully, to account for diversity in firm size. Compliance and regulatory oversight naturally represent a larger relative cost to small firms. Because FINRA wants to prevent regulatory costs from either creating a barrier to entry for small firms, or over-burdening existing small firms, the current fee structure includes a level of cross-subsidization by larger firms.</P>
                <P>FINRA believes that this practice supports two objectives. First, it is important that retail investors have access to diverse types of financial services intermediaries, including members of varying size. For example, some investors may prefer to engage registered persons associated with smaller firms. Second, the extent to which firms benefit from well-regulated markets is relative to firm size. Under well-regulated markets, investors are more willing to trust financial intermediaries because they are confident that they are treated fairly in their access to securities markets and products. Greater participation in the financial markets by investors allows firms to grow larger and become more diversified, leading to cost savings and reduced risk through economies of scale and scope. The concentration in both retail and institutional investor activity at larger firms suggests that larger firms reap substantial benefits from strong regulation and should therefore provide a substantial portion of the fees that support this regulation. At the same time, the impact of widespread misconduct at a larger firm may impair investor confidence more broadly than similar misconduct at a smaller firm. This lends further support to the practice of assessing higher fees on larger firms.</P>
                <P>
                    Chart 3 presents the distribution in 2024 of FINRA's regulatory and use-based fee revenue and the proportion of FINRA's examination time, along with the proportion of firms and registered persons, by firm-size category as defined in the FINRA By-Laws.
                    <SU>113</SU>
                    <FTREF/>
                     Small firms, including micro firms, account for 89% of the firms in the industry, 10% of total registered persons, 57% of FINRA's total firm examination time, and 12% of FINRA's revenues. Large firms, conversely, represent less than 5% of firms, over 80% of registered persons, 32% of FINRA's firm examination effort, and approximately 67% of FINRA's revenues. The remaining portions of firm examination time and revenues are attributable to mid-size firms.
                </P>
                <FTNT>
                    <P>
                        <SU>113</SU>
                         The revenue in Charts 3-10 excludes Corporate Financing fees, which are generally passed through to issuers, and a portion of DRS fees that are paid directly by customers. 
                        <E T="03">See supra</E>
                         note 31. The revenue in these charts also excludes MAP fees, which are incurred irregularly. 
                        <E T="03">See also supra</E>
                         note 8 and accompanying text.
                    </P>
                </FTNT>
                <P>
                    Chart 4 presents the same measures as in Chart 3 by the business model category. The categories of capital markets and retail firms account for 80% of the firms in the industry, 72% of total registered persons, 55% of FINRA's total examination time, and 33% of FINRA's regulatory and use-based fee revenues.
                    <SU>114</SU>
                    <FTREF/>
                     The category of diversified firms, including most of the largest firms, accounts for approximately 5% of firms in the industry, almost 25% of total registered persons, over 27% of FINRA's total examination time, and 44% of FINRA's revenues. The remaining portions are attributable to the category of trading firms and the category of clearing firms.
                </P>
                <FTNT>
                    <P>
                        <SU>114</SU>
                         
                        <E T="03">See supra</E>
                         note 113. Here, business model represents the primary type of services provided by the member firm.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Economic Impact</HD>
                <P>FINRA's fee proposal is intended to ensure that FINRA can continue to meet its mission of promoting investor protection and market integrity in a manner that facilitates vibrant capital markets. This proposed rule change preserves FINRA's ability to be a robust and effective SRO, protecting investors from manipulation, exploitation, and other harms. Adequate funding allows FINRA to develop regulatory approaches that are effective and efficient, and to revise its rules through, among other ways, its robust retrospective review process. Through appropriate funding, FINRA will be better situated to adapt to changing markets, market behaviors, and expanding responsibilities. A stable and reliable funding model also permits members to better anticipate and plan for FINRA's fees. These benefits accrue to current and prospective investors, firms, issuers, and others participating in financial intermediation.</P>
                <P>
                    FINRA notes that academic literature has provided evidence of the linkage between strong regulation in securities markets and improved outcomes, including more trading, lower transaction costs, and greater investor participation in the markets.
                    <SU>115</SU>
                    <FTREF/>
                     Bruggemann, et al. [2018] study the impact of differences in state regulation on OTC stocks. They find that firms issuing in the OTC market subject to stricter regulation are more liquid and are subject to lower “crash risk.” Cazier, et al. [2023] examine the effect of the SEC's initiative to prevent fraud in OTC markets by suspending inactive shell companies that could be targeted by market manipulators. The authors find that these suspensions are associated with fraud deterrence among other OTC firms operating within the same regulatory jurisdiction as the suspended firm. Silvers [2016] studies the impact of SEC enforcement actions against foreign cross-listed issuers. He shows evidence that other cross-listed issuers (not cited by the SEC) experienced positive returns, suggesting that increased regulatory attention increases valuation. Silvers [2020] and Lang et al. 
                    <PRTPAGE P="93729"/>
                    [2020] further show that cross-border cooperation between securities regulators reduces the cost of liquidity provision and increases cross-border investment in the capital markets of participating countries. Finally, Christensen et al. [2019] and Aghanya et al. [2020] study the impact of the introduction of the European Union's Market Abuse Directive and MiFID. These studies conclude that these initiatives, designed to enhance investor protections, have led to higher household ownership of equities, higher liquidity, and higher stock price informativeness.
                </P>
                <FTNT>
                    <P>
                        <SU>115</SU>
                         
                        <E T="03">See, e.g.,</E>
                         U. Bruggemann, A. Kaul, C. Leuz &amp; I. Werner, The Twilight Zone: OTC Regulatory Regimes and Market Quality, 31(3) The Review of Financial Studies, 898-942 (2018); R. Cazier, J. Huang &amp; F. Zhou, Regulatory Spillover Effects in OTC Markets, Review of Accounting Studies, 1-33 (2023); Roger Silvers, The Valuation Impact of SEC Enforcement Actions on Nontarget Foreign Firms, 54 (1) Journal of Accounting Research, 187-234 (2016); Roger Silvers, Cross-Border Cooperation between Securities Regulators, 69 (2-3) Journal of Accounting and Economics, 101301 (2020); M. Lang, M. Maffett, J.D. Omartian &amp; R. Silvers, Regulatory Cooperation and Foreign Portfolio Investment, 138 (1) Journal of Financial Economics 138-158 (2020); H. Christensen, M. Maffett &amp; L. Vollon, Securities Regulation, Household Equity Ownership, and Trust in the Stock Market, 24 (3) Review of Accounting Studies, 824-859 (2019); and D. Aghanya, V. Agarwal &amp; S. Poshakwale. Market in Financial Instruments Directive (MiFID), Stock Price Informativeness and Liquidity, 113 Journal of Banking &amp; Finance, 105730 (2020).
                    </P>
                </FTNT>
                <P>
                    The proposed rule change would implement fee changes that would maintain the current distribution of total fees allocated across members by size and business model. Based on FINRA's projections of fee increases from 2024 to 2029, approximately 67% of the fee increases would be borne by large firms, 22% by mid-size firms, 9% by small firms, 1% by micro firms and the remaining 1% by non-members.
                    <SU>116</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>116</SU>
                         The firm size categories are defined above, 
                        <E T="03">see supra</E>
                         note 104.
                    </P>
                </FTNT>
                <P>
                    Chart 5 describes the proportion of regulatory and use-based fees anticipated to be collected under the proposed rule change across firm size categories during the period from 2024 through 2029.
                    <SU>117</SU>
                    <FTREF/>
                     In each year, 66%-68% of the fee is expected to be borne by large firms, 16%-17% by mid-size firms, 11%-12% by small firms, approximately 1% by micro firms, and 3-4% by non-members. Therefore, the overall allocation of fees by firm size is expected to remain relatively unchanged with the implementation of the increase in fees.
                </P>
                <FTNT>
                    <P>
                        <SU>117</SU>
                         
                        <E T="03">See supra</E>
                         note 113.
                    </P>
                </FTNT>
                <P>
                    Chart 6 describes the proportion of regulatory and use-based fees anticipated to be collected across firm business models during the period from 2024 through 2029.
                    <SU>118</SU>
                    <FTREF/>
                     In each year, approximately 70% of the fees are expected to be borne by diversified and retail firms, with the remaining fees distributed relatively evenly across trading, capital markets, and clearing firms. As with FINRA's analysis of the proposed fee increases by firm size, the chart demonstrates that the overall allocation by firm business models is expected to remain unchanged with the implementation of the increase in fees.
                </P>
                <FTNT>
                    <P>
                        <SU>118</SU>
                         
                        <E T="03">See supra</E>
                         note 113.
                    </P>
                </FTNT>
                <P>Taken together, these charts indicate that the proposed fee increases are designed to allocate the growth in fees in an equitable manner, all else held equal, by maintaining a similar allocation of fees across firm sizes and business models, both overall and year-by-year.</P>
                <P>
                    As discussed, while potentially material, FINRA fees represent a small dollar amount relative to industry activity. Since 2013, as a percentage of member revenue, FINRA's total fees have ranged between 0.2% and 0.4%, with an average of 0.30%. Under the assumption that members' revenues resume growth at a level commensurate with recent history,
                    <SU>119</SU>
                    <FTREF/>
                     FINRA's fees would be 0.31% percent by 2029.
                    <SU>120</SU>
                    <FTREF/>
                     This share of member revenue is close to the historical average of 0.30%.
                </P>
                <FTNT>
                    <P>
                        <SU>119</SU>
                         This 2029 industry revenue projection is based on historical FOCUS revenue growth of 8.5% (2013-2023).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>120</SU>
                         
                        <E T="03">See supra</E>
                         note 33 and accompanying text.
                    </P>
                </FTNT>
                <P>
                    The amount of the fee increase borne by members depends on the extent to which they shift the burden of these fees to their associated persons and customers. As discussed above, FINRA understands that of the fees addressed by this proposal, the fee most likely to be passed through to customers is TAF, which is directly tied to customer trading activities. Despite the pass-through, FINRA believes the proposed TAF increase would not significantly affect customer trading behavior as TAF represents a small proportion of the average value of customer transactions. In 2023, TAF per share traded was 0.031 basis points (0.00031%) of the average price of the traded shares. When the new rates are fully implemented in 2029, TAF per share traded would be approximately 0.058 basis points of the average price of traded shares.
                    <SU>121</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>121</SU>
                         The average share price estimate is based on the number of shares and dollar trading volume from CBOE. 
                        <E T="03">See https://www.cboe.com/data_and_access_solutions</E>
                         for details.
                    </P>
                </FTNT>
                <P>To better understand the impact of the proposed fee increases across members within each firm size category, FINRA analyzed the expected distribution of fee increases for all existing firms under the proposed fee structure, based on the expected rate of dispersion. Dispersion is a way to compare the anticipated growth rate in fees across a range of firms. Lower dispersion is associated with a higher degree of consistency in terms of the impact of the proposed fee increases and can be interpreted as more firms in a given group experiencing similar rates of growth. By seeking to limit dispersion, the proposal is effectively limiting the potential for inequitable treatment across members. This approach also reduces the potential for the proposed fee increase to create unintended impacts on the provision of financial services by members and the business models adopted by them.</P>
                <P>
                    FINRA's analysis examines the level of dispersion based on the CAGR of the expected fee increase. CAGR is measured in this analysis relative to FINRA's projection of total fees in 2024.
                    <SU>122</SU>
                    <FTREF/>
                     CAGR provides a standard metric to compare the relative impact of the fee increases within and across subgroups. Because the number of registered persons, trading and other business activities, and resulting aggregate fee dollar amounts vary significantly across firms and firm sizes, benchmarking to CAGR permits FINRA to closely compare the magnitude of the distribution across firms.
                </P>
                <FTNT>
                    <P>
                        <SU>122</SU>
                         We exclude firms that are not assessed GIA in the base year from CAGR distribution analysis. Since GIA in the base year drives the denominator of the CAGR formula, firms that are not assessed GIA would have inflated CAGRs by construction. Therefore, we exclude these firms to ensure that the tails of our distribution reflect a more accurate measure of fee growth.
                    </P>
                </FTNT>
                <P>As discussed, implementation of the proposed rule change would take place over several years, with a minority of fees going into effect in 2025, most fees implemented in 2026 or later, and several fees phased in over several years between 2025 and 2029. Due to the variability in when fees are implemented, and whether they are implemented at one time or phased in, FINRA believes that considering dispersion by firm size category over the five-year period is more useful than on an annual basis.</P>
                <P>Charts 7 through 10 provide a view on the distribution of fee increases within each firm size category. These charts also report the median increase in FINRA fees that are the subject of this proposal over the full period from 2025 through 2029 by firm size. Within the charts, each of the four central bars represents one standard deviation from the median, so that the two most central dark blue bars together would theoretically represent approximately 67% of all firms evaluated (plus or minus one standard deviation) and approximately 95% of firms evaluated should be represented under the four most central dark blue and mid-blue bars (plus or minus two standard deviations) presented in the charts.</P>
                <P>
                    While it is not feasible to eliminate the possibility that some members will experience a rate of fee growth that is outside of the two standard deviation range, FINRA sought to limit the number of firms falling into this category when structuring this proposal. These charts demonstrate that the proposal significantly limits the number of firms that fall beyond two standard deviations from the median increase. In particular, the proposal limits those 
                    <PRTPAGE P="93730"/>
                    firms that would be expected to experience a materially higher fee increase than the median (as defined by two standard deviations). When considering all the fees in this proposal, FINRA estimates that fewer than 2.5% of members would experience a fee increase greater than two standard deviations from the median. When only core regulatory fees are considered (
                    <E T="03">i.e.,</E>
                     excluding select use-based fees that only impact the users of those programs or services) fewer than 1% of firms would experience a fee increase greater than two standard deviations from the median.
                    <SU>123</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>123</SU>
                         As discussed above, the select use-based fees include Corporate Financing Private Placement Review; Corporate Financing Public Offering Review; Advertising Regulation Review; DRS Arbitration; and Regulation T and Exchange Act Rule 15c3-3(n) Requests for Extension of Time. 
                        <E T="03">See supra</E>
                         note 24.
                    </P>
                </FTNT>
                <P>Based on this analysis, FINRA concludes the following:</P>
                <P>• For micro firms, the median firm would anticipate an annual increase of 3.4%, translating to a dollar increase of $625. Approximately three-quarters of these firms would experience an annual increase between 1.4% and 5.4% between 2025 and 2029. Holding revenues constant at 2024 levels, total regulatory and use-based fees would increase from 0.26% to 0.31% of FOCUS reported revenues on average. This group includes 1,538 firms and represents 46.5% of all FINRA members.</P>
                <P>• For other small firms, the median firm would anticipate an annual increase of 3.9%, translating to a dollar increase of approximately $4,135. Approximately 80% of these firms would experience an annual increase in fees between 1.3% and 6.4% between 2025 and 2029. Holding revenues constant at 2024 levels, total regulatory and use-based fees would increase from 0.23% to 0.29% of FOCUS reported revenues on average. This group includes 1,414 firms and represents 42.8% of all FINRA members.</P>
                <P>• For mid-size firms, the median firm would anticipate a 5% annual increase, translating to a dollar increase of approximately $82,500. Approximately three-quarters of these firms would experience an annual increase between 2.9% and 7.1% between 2025 and 2029. Holding firm revenues constant at 2024 levels, total regulatory and use-based fees would increase from 0.26% to 0.36% of FOCUS reported revenues on average. This group includes 212 firms and represents 6.4% of all FINRA members.</P>
                <P>• For large firms, the median firm would anticipate a 5.4% annual increase, translating to a dollar increase of approximately $415,000. Approximately three-quarters of these firms would experience an annual increase between 4.0% and 6.9% between 2025 and 2029. Holding revenues constant at 2024 levels, total regulatory and use-based fees would increase from 0.18% to 0.23% of FOCUS reported revenues on average. This group includes 141 firms and represents 4.3% of all FINRA members.</P>
                <P>FINRA notes that 1.7% of micro firms would experience a fee increase greater than two standard deviations above the median. Because the median increase is relatively low ($625), small dollar increases in fees can result in a large change in CAGR and its distribution.</P>
                <P>FINRA also notes that the 2.5% of small firms that would experience a fee increase greater than two standard deviations are mostly firms that would incur new or increased use-based fees for FINRA services that are not core regulatory activities. If only core regulatory fees are considered, only 1.1% of small firms would experience a fee increase greater than two standard deviations from the median increase.</P>
                <P>The 2.4% of mid-size firms that would experience a fee increase greater than two standard deviations above the median are mostly firms that incur a significant increase in TAF. If TAF is excluded, only 1.4% of mid-size firms would experience a fee increase greater than two standard deviations from the median increase. As mentioned above, FINRA understands that the TAF is typically passed-through to customers.</P>
                <P>As part of its analysis, FINRA also considered the broad potential impacts on competition under this proposal. The analysis considers the impact across all FINRA members, across members based on size or business model, and between members and other financial services providers.</P>
                <P>FINRA does not anticipate that the proposal will materially impact competition among members. The proposal is designed to maintain the current funding model and the relative allocation of fees across its core regulatory fees and select use-based fees. In other words, each of the affected fees would increase commensurate with fees charged under the current framework; no individual fee would be raised such that it may create inordinate hardships for some firms and benefit others. Implementation of the proposed rule change would not require significant system or process changes by firms.</P>
                <P>Similarly, FINRA does not anticipate that the proposed rule change will materially impact competition across members of different sizes or business models. The analysis of distributions within firm size indicates that firms may anticipate some differences in fee increases based on the services they provide and the way they provide those services. Nevertheless, as designed, the proposal maintains the relative allocation of fees across firm size and business model, meaning the proposed rule change is designed to preserve a consistent rate of growth in fee increases across firm size and business model. As noted above, this approach is designed to limit the likelihood that any specific fee change may create hardships for some firms and benefit others. Further, this proposed rule change maintains the current approach for cross-subsidization of the cost of regulatory oversight of members of different sizes.</P>
                <P>
                    FINRA can identify two potential impacts of this proposal on the competition between its members and other providers of financial services. Although these increases are calibrated to limit the impact on individual members, at the margin, some members may find these increases material to their business. Further, where members may have the ability to provide similar services, or a subset of services, under an alternative business model that does not require FINRA membership, increased FINRA costs may increase the likelihood that these firms withdraw from FINRA in favor of the alternative business model. Based on the information available to it today, FINRA does not have an accurate measure of the number of members that may choose to withdraw registration as a FINRA member as a result of this proposed rule change.
                    <SU>124</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>124</SU>
                         FINRA notes that because of the time lapse between proposal, adoption and implementation of fee increases, combined with changing business environments over time, it is difficult to reliably estimate the number of firms that might have exited historically because of previous fee increases.
                    </P>
                </FTNT>
                <P>
                    The proposed rule change may have an additional impact on competition through funding FINRA's regulatory activities. As discussed above, strong and effective surveillance and regulation of securities markets has been shown to increase investor confidence in the fairness of the market. This has been measured by an increase in retail participation in the securities markets, greater liquidity, and higher securities valuations. Given the presence of substitutes to broker-dealers for retail clients—
                    <E T="03">e.g.,</E>
                     investment advisory services, issuers selling directly to the public, or certain market-linked insurance products—it may be reasonable to expect that effective regulation by FINRA would continue to 
                    <PRTPAGE P="93731"/>
                    be a positive externality to those competitors. That is, increased confidence by retail investors due to FINRA's activities may increase business opportunities and lower transaction costs in the securities industry as a whole. This would benefit non-FINRA member competitors, especially in instances where investors do not recognize these competitors are not regulated by FINRA.
                </P>
                <HD SOURCE="HD3">Alternatives Considered</HD>
                <P>In developing this proposal, FINRA considered several options. First, FINRA considered making all the fee changes effective in 2025. FINRA did not pursue this alternative because it believed that, where possible, members should be provided an extended time period to plan for the proposed fee increase. In light of uncertainty and volatility in the markets, FINRA believes that implementing the proposed fee increase at one time would impose a greater burden on members than phasing in the implementation of the fee increases, as proposed.</P>
                <P>
                    FINRA also considered making all of the fee changes effective in 2026, but decided against that approach for many of the same reasons noted above. However, FINRA believes that deferring implementation of all fees in this proposed rule change is unnecessary and would hinder FINRA's ability to support its regulatory mission. As discussed, the uncertainty in the markets, which creates challenges for members and investors, also impacts FINRA. For example, market volatility increases the risk that FINRA's reserve portfolio will fall below the appropriate minimum.
                    <SU>125</SU>
                    <FTREF/>
                     This limits FINRA's flexibility in relying on its reserves to cover funding gaps and indicates the need for stable funding as soon as practicable.
                </P>
                <FTNT>
                    <P>
                        <SU>125</SU>
                         
                        <E T="03">See supra</E>
                         note 12.
                    </P>
                </FTNT>
                <P>
                    Further, FINRA notes that consistent investor protection is of vital importance, particularly in times of uncertainty, where FINRA has seen an increase in customer complaints and alerts from its surveillance programs.
                    <SU>126</SU>
                    <FTREF/>
                     Financial limitations that constrain FINRA's ability to carry out its mission would have material negative implications for investors and the financial markets. Taking these concerns into account, FINRA believes that the most prudent course of action is to start increasing some fees in 2025, but to stagger the implementation over multiple years.
                </P>
                <FTNT>
                    <P>
                        <SU>126</SU>
                         In the first quarter of 2020, FINRA saw an increase in alerts generated through its market surveillance of over 250% compared to the same quarter in 2019.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>Written comments were neither solicited nor received.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The foregoing rule change has become effective pursuant to Section 19(b)(3)(A) of the Act 
                    <SU>127</SU>
                    <FTREF/>
                     and paragraph (f)(2) of Rule 19b-4 thereunder.
                    <SU>128</SU>
                    <FTREF/>
                     At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings to determine whether the proposed rule should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>127</SU>
                         15 U.S.C. 78s(b)(3)(A).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>128</SU>
                         17 CFR 240.19b-4(f)(2).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">http://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include File Number SR-FINRA-2024-019 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-FINRA-2024-019. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">http://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of FINRA. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection.
                </FP>
                <P>All submissions should refer to file number SR-FINRA-2024-019 and should be submitted on or before December 18, 2024.</P>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>129</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>129</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27764 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101690; File No. SR-NASDAQ-2024-067]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; The Nasdaq Stock Market LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Its Fees for Connectivity and Co-Location Services</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”),
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 8, 2024, The Nasdaq Stock Market LLC (“Nasdaq” or “Exchange”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <PRTPAGE P="93732"/>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>The Exchange proposes to amend the Exchange's fees for connectivity and co-location services, as described further below.</P>
                <P>
                    The text of the proposed rule change is available on the Exchange's website at 
                    <E T="03">https://listingcenter.nasdaq.com/rulebook/nasdaq/rules,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    The purpose of the proposed rule change is to amend the Exchange's fees relating to connectivity and co-location services.
                    <SU>3</SU>
                    <FTREF/>
                     Specifically, the Exchange proposes a one-time adjustment to raise its fees for connectivity and co-location services in General 8, fees assessed for remote multi-cast ITCH (“MITCH”) Wave Ports in Equity 7, Section 115, and certain fees related to Nasdaq Testing Facilities in Equity 7, Section 130 by 10%, with certain exceptions.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The Exchange initially filed the proposed pricing change on March 1, 2024 (SR-NASDAQ-2024-008). On April 29, 2024, the Exchange withdrew that filing and submitted SR-NASDAQ-2024-020. The Exchange withdrew SR-NASDAQ-2024-020 on June 27, 2024 and replaced it with SR-NASDAQ-2024-032. The Exchange withdrew SR-NASDAQ-2024-032 and replaced it with SR-NASDAQ-2024-053 on September 10, 2024. On October 11, 2024, the Exchange replaced SR-NASDAQ-2024-053 with SR-NASDAQ-2024-060. The instant filing replaces SR-NASDAQ-2024-060.
                    </P>
                </FTNT>
                <P>
                    General 8, Section 1 includes the Exchange's fees that relate to connectivity, including fees for cabinets, external telco/inter-cabinet connectivity fees, fees for connectivity to the Exchange, fees for connectivity to third party services, fees for market data connectivity, fees for cabinet power install, and fees for additional charges and services. General 8, Section 2 includes the Exchange's fees for direct connectivity services, including fees for direct circuit connection to the Exchange, fees for direct circuit connection to third party services, and fees for point of presence connectivity. With the exceptions of the Exchange's GPS Antenna fees and the Cabinet Proximity Option Fee for cabinets with power density &gt;10kW,
                    <SU>4</SU>
                    <FTREF/>
                     the Exchange proposes to increase its fees throughout General 8 by 10%.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         The Exchange proposes to exclude the GPS Antenna fees from the proposed fee increase because, unlike the other fees in General 8, the Exchange recently increased its GPS Antenna fees. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-99126 (December 8, 2023), 88 FR 86712 (December 14, 2023) (SR-NASDAQ-2023-052). The Exchange also proposes to exclude the Cabinet Proximity Option Fee for cabinets with power density &gt;10kW from the proposed fee increase because the Exchange recently established such fee. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-99796 (March 20, 2024), 89 FR 21088 (March 26, 2024) (SR-NASDAQ-2024-013). Similarly, the Exchange proposes to exclude from the proposed fee increase those fees that the Exchange recently established for services in its new NY11-4 expansion facility. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-101267 (October 7, 2024), 89 FR 82666 (October 11, 2024) (SR-NASDAQ-2024-056).
                    </P>
                </FTNT>
                <P>
                    In addition to increasing fees in General 8, the Exchange also proposes to increase certain fees in Equity 7. First, the Exchange proposes to increase the installation and recurring monthly fees assessed for remote MITCH Wave Ports 
                    <SU>5</SU>
                    <FTREF/>
                     in Equity 7, Section 115(g)(1) by 10%. In addition, the Exchange proposes to increase certain fees in Section 130(d), which relate to the Nasdaq Testing Facility. Equity 7, Section 130(d)(1)(C) provides that subscribers to the Nasdaq Testing Facility (“NTF”) located in Carteret, New Jersey shall pay a fee of $1,000 per hand-off, per month for connection to the NTF. The hand-off fee includes either a 1Gb or 10Gb switch port and a cross connect to the NTF. In addition, Equity 7, Section 130(d)(1)(C) provides that subscribers shall also pay a one-time installation fee of $1,000 per hand-off. The Exchange proposes to increase these aforementioned fees by 10% to require that subscribers to the NTF shall pay a fee of $1,100 per hand-off, per month for connection to the NTF and a one-time installation fee of $1,100 per hand-off.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         Remote MITCH Wave Ports are for clients co-located at other third-party data centers, through which NASDAQ TotalView ITCH market data is distributed after delivery to those data centers via wireless network.
                    </P>
                </FTNT>
                <P>The proposed increases in fees would enable the Exchange to maintain and improve its market technology and services to remain competitive with its peers. Over the years, customer demand for more sophisticated, higher-throughput, lower-latency, and higher-power connectivity solutions has increased. The Exchange continues to invest in maintaining, improving, and enhancing its connectivity and co-location products, services, and facilities—for the benefit and often at the behest of its customers. Such enhancements include refreshing hardware and expanding Nasdaq's existing co-location facility to offer customers additional space and power. Nevertheless, and with the exception of fees that were established as part of a new service in 2017 (and have remained unchanged since their adoption), the Exchange has not increased any of the fees included in the proposal since prior to 2017, and many of the fees date back to between 2010 and 2014. For each of the connectivity products and services that pre-date 2017, inflation (as measured using the “Data PPI” metric described below) has been between roughly 15-17%, and in no instance has such inflation been less than 10%. Nevertheless, the Exchange proposes to increase its fees only with respect to the 10% inflation that has occurred since 2017.</P>
                <P>As discussed below, the Exchange proposes to adjust its fees by an industry- and product-specific inflationary measure. It is reasonable and consistent with the Act for the Exchange to recoup its investments, at least in part, by adjusting its fees. Continuing to operate at fees frozen at 2010-2017 levels impacts the Exchange's ability to enhance its offerings and the interests of market participants and investors.</P>
                <P>
                    The fee increases the Exchange proposes are based on an industry-specific Producer Price Index (“PPI”), which is a tailored measure of inflation.
                    <SU>6</SU>
                    <FTREF/>
                     As a general matter, the Producer Price Index is a family of indexes that measures the average change over time in selling prices received by domestic producers of goods and services. PPI measures price change from the perspective of the seller. This contrasts with other metrics, such as the Consumer Price Index (“CPI”), that measure price change from the purchaser's perspective.
                    <SU>7</SU>
                    <FTREF/>
                     About 10,000 PPIs for individual products and groups of products are tracked and released each month.
                    <SU>8</SU>
                    <FTREF/>
                     PPIs are available for the output of nearly all industries in the goods-producing sectors of the U.S. economy—mining, manufacturing, 
                    <PRTPAGE P="93733"/>
                    agriculture, fishing, and forestry—as well as natural gas, electricity, and construction, among others. The PPI program covers approximately 69 percent of the service sector's output, as measured by revenue reported in the 2017 Economic Census.
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See https://fred.stlouisfed.org/series/PCU51825182#0.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See https://www.bls.gov/ppi/overview.htm.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See Id.</E>
                    </P>
                </FTNT>
                <P>For purposes of this proposal, the relevant industry-specific PPI is the Data Processing and Related Services PPI (“Data PPI”), which is an industry net-output PPI that measures the average change in selling prices received by companies that provide data processing services.</P>
                <P>
                    The Data PPI was introduced in January 2002 by the Bureau of Labor Statistics (“BLS”) as part of an ongoing effort to expand Producer Price Index coverage of the services sector of the U.S. economy and is identified as NAICS—518210 in the North American Industry Classification System.
                    <SU>9</SU>
                    <FTREF/>
                     According to the BLS “[t]he primary output of NAICS 518210 is the provision of electronic data processing services. In the broadest sense, computer services companies help their customers efficiently use technology. The processing services market consists of vendors who use their own computer systems—often utilizing proprietary software—to process customers' transactions and data. Companies that offer processing services collect, organize, and store a customer's transactions and other data for record-keeping purposes. Price movements for the NAICS 518210 index are based on changes in the revenue received by companies that provide data processing services. Each month, companies provide net transaction prices for a specified service. The transaction is an actual contract selected by probability, where the price-determining characteristics are held constant while the service is repriced. The prices used in index calculation are the actual prices billed for the selected service contract.” 
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">NAICS appears in table 5 of the PPI Detailed Report and is available at https://data.bls.gov/timeseries/PCU518210518210.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See https://www.bls.gov/ppi/factsheets/producer-price-index-for-the-data-processing-and-related-servicesindustry-naics-518210.htm.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange believes the Data PPI is an appropriate measure to be considered in the context of the proposed rule change to modify the fee for its connectivity products because the Exchange uses its “own computer systems” and “proprietary software,” 
                    <E T="03">i.e.,</E>
                     its own data center and proprietary matching engine software, respectively, to collect, organize, store and report customers' transactions in U.S. equity securities on the Exchange's proprietary trading platform. In other words, the Exchange is in the business of data processing and related services.
                </P>
                <P>For purposes of this proposed rule change, the Exchange examined the Data PPI value for the period from January 2017 to August 2024. The Data PPI had a starting value of 105.6 in January 2017 and an ending value of 116.022 in August 2024, a 10.422% increase. This indicates that companies who are also in the data storage and processing business have generally increased prices for a specified service covered under NAICS 518210 by an average of 10.422% during this period. Based on that percentage change, the Exchange proposes to make a one-time fee increase of only 10%, which reflects an increase covering roughly the entire period since the last price adjustments to these fees were made.</P>
                <P>
                    The Exchange further believes the Data PPI is an appropriate measure for purposes of the proposed rule change on the basis that it is a stable metric with limited volatility, unlike other consumer-side inflation metrics. In fact, the Data PPI has not experienced a greater than 2.16% increase for any one calendar year period since Data PPI was introduced into the PPI in January 2002. The average calendar year change from January 2002 to December 2023 was .62%, with a cumulative increase of 15.67% over this 21-year period. The Exchange believes the Data PPI is considerably less volatile than other inflation metrics such as CPI, which has had individual calendar-year increases of more than 6.5%, and a cumulative increase of over 73% over the same period.
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See https://www.usinflationcalculator.com/inflation/consumer-price-index-and-annual-percent-changesfrom-1913-to-2008/.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange believes the Data PPI, and significant investments into, and enhanced performance of, the Exchange support the reasonableness of the proposed fee increases.
                    <SU>12</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See supra</E>
                         discussion of connectivity product and facility improvements. Additionally, other exchanges have filed for increases in certain fees, based in part on comparisons to inflation. 
                        <E T="03">See, e.g.,</E>
                         Securities Exchange Act Release Nos. 34-100004 (April 22, 2024), 89 FR 32465 (April 26, 2024) (SR-CboeBYX-2024-012); and 34-100398 (June 21, 2024), 89 FR 53676 (June 27, 2024) (SR-BOX-2024-16); Securities Exchange Act Release No. 34-100994 (September 10, 2024), 89 FR 75612 (September 16, 2024) (SR-NYSEARCA-2024-79).
                    </P>
                </FTNT>
                <P>
                    These proposed fee increases will be immediately effective upon filing. However, going forward and until December 1, 2024, the Exchange will waive all fees set forth herein to the extent that such fees exceed the levels that would have been charged for the same products and services purchased during that time period, had such fees been calculated at the rates set forth in SR-NASDAQ-2024-053 (
                    <E T="03">i.e.,</E>
                     pricing reflective of a 5.5% increase from prior fee levels). This waiver is reasonable, equitable, and not unfairly discriminatory because it will afford all customers in excess of the 30-day prior notice period for fee changes set forth in the Exchange's service terms.
                </P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The Exchange believes that its proposal is consistent with Section 6(b) of the Act,
                    <SU>13</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Sections 6(b)(4) and 6(b)(5) of the Act,
                    <SU>14</SU>
                    <FTREF/>
                     in particular, in that it provides for the equitable allocation of reasonable dues, fees and other charges among members and issuers and other persons using any facility, and is not designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         15 U.S.C. 78f(b)(4) and (5).
                    </P>
                </FTNT>
                <P>This belief is based on two factors. First, the current fees do not properly reflect the quality of the services and products, as fees for the services and products in question have been static in nominal terms, and therefore falling in real terms due to inflation. Second, the Exchange believes that investments made in enhancing the capacity and speed of Exchange systems increase the performance of the services and products.</P>
                <HD SOURCE="HD3">The Proposed Rule Change Is Reasonable</HD>
                <P>
                    As noted above, the Exchange has not increased any of the fees included in the proposal since 2017 or earlier. However, in the years following the last fee increases, the Exchange has made significant investments in upgrades to its connectivity products, services, and facilities, enhancing the quality of its services. In other words, Exchange customers have greatly benefitted, while the Exchange's ability to recoup its investments has been hampered. Between 2017 and 2024, the inflation rate is 3.64% per year, on average, producing a cumulative inflation rate of 28.43%.
                    <SU>15</SU>
                    <FTREF/>
                     Using the more targeted inflation number of Data PPI, the cumulative inflation rate was 10.422%. The exchange believes the Data PPI is a reasonable metric to base this fee increase on because it is targeted to producer-side increases in the data processing industry.
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See https://www.officialdata.org/us/inflation/2017?amount=1.</E>
                    </P>
                </FTNT>
                <P>
                    Notwithstanding inflation, as noted above, the Exchange has not increased 
                    <PRTPAGE P="93734"/>
                    its fees at all for over seven years for the subject services. The proposed fee changes represent a modest increase from the current fees. The Exchange believes the proposed fee increase is reasonable in light of the Exchange's continued expenditure in maintaining a robust technology ecosystem. Furthermore, the Exchange continues to invest in maintaining and enhancing its connectivity products—for the benefit and often at the behest of its customers and global investors. Such enhancements include refreshing all aspects of the technology ecosystem including software, hardware, and network while introducing new and innovative products and expanded and modernized facilities.
                    <SU>16</SU>
                    <FTREF/>
                     The goal of the enhancements discussed above, among other things, is to provide faster, higher-capacity, and more modern connectivity products and services. Accordingly, the Exchange continues to expend resources to innovate and modernize technology so that it may benefit its members in offering its connectivity products and services.
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         
                        <E T="03">See, e.g.,</E>
                         Securities Exchange Act Release No. 34-101078 (September 18, 2024), 89 FR 77937 (September 2024, 2024) (SR-NASDAQ-2024-054 (Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Expand [the Exchange's] Co-Location Services).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">The Proposed Fees Are Equitably Allocated and Not Unfairly Discriminatory</HD>
                <P>The Exchange believes that the proposed fee increases are equitably allocated and not unfairly discriminatory because they would apply to all market participants that choose to purchase connectivity products and services from the Exchange. Any participant that chooses to purchase the Exchange's connectivity products and services would be subject to the same Fee Schedule, regardless of what type of business they operate or the use they plan to make use of the products and services. Additionally, the fee increase would be applied uniformly to market participants without regard to Exchange membership status or the extent of any other business with the Exchange or affiliated entities. The Exchange also believes that the proposal represents an equitable allocation of reasonable dues, fees and other charges because Exchange fees have fallen in real terms during the relevant period. Finally, the Exchange believes that the proposed fee changes are not unfairly discriminatory because the fees would be assessed uniformly across all market participants, in the same manner they are today, that voluntarily purchase the Exchange's connectivity products and services, which would remain available for purchase by all market participants.</P>
                <P>
                    These proposed fee increases will be immediately effective upon filing. However, going forward and until December 1, 2024, the Exchange will waive all fees set forth herein to the extent that such fees exceed the levels that would have been charged for the same products and services purchased during that time period, had such fees been calculated at the rates set forth in SR-NASDAQ-2024-053 (
                    <E T="03">i.e.,</E>
                     pricing reflective of a 5.5% increase from prior fee levels). This waiver is reasonable, equitable, and not unfairly discriminatory because it will afford all customers in excess of the 30-day prior notice period for fee changes set forth in the Exchange's service terms.
                </P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed fees will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.</P>
                <HD SOURCE="HD3">Intramarket Competition</HD>
                <P>The Exchange believes that the proposed fees do not put any market participants at a relative disadvantage compared to other market participants. As noted above, the fee schedule would continue to apply to all purchasers of the Exchange's connectivity products and services in the same manner as it does today albeit at inflation-adjusted rates for certain fees, and customers may choose whether to purchase these products and services at all. The Exchange also believes that the level of the proposed fees neither favor nor penalize one or more categories of market participants in a manner that would impose an undue burden on competition. Likewise, the proposed fee waiver described above will apply to all purchasers of the Exchange's connectivity products and services in the same manner and therefore will not burden competition among them.</P>
                <HD SOURCE="HD3">Intermarket Competition</HD>
                <P>The Exchange believes that the proposed fees do not impose a burden on competition or on other SROs that is not necessary or appropriate. In determining the proposed fees, the Exchange utilized an objective and stable metric with limited volatility. Utilizing Data PPI over a specified period of time is a reasonable means of recouping the Exchange's investment in maintaining and enhancing its connectivity products, services, and facilities. The Exchange believes utilizing Data PPI, a tailored measure of inflation, to increase certain fees for connectivity products and services to recoup the Exchange's investment in maintaining and enhancing such products, services, and its facilities would not impose a burden on competition.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were either solicited or received.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The foregoing rule change has become effective pursuant to Section 19(b)(3)(A)(ii) of the Act.
                    <SU>17</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         15 U.S.C. 78s(b)(3)(A)(ii).
                    </P>
                </FTNT>
                <P>At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is: (i) necessary or appropriate in the public interest; (ii) for the protection of investors; or (iii) otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings to determine whether the proposed rule should be approved or disapproved.</P>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-NASDAQ-2024-067 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-NASDAQ-2024-067. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the 
                    <PRTPAGE P="93735"/>
                    submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-NASDAQ-2024-067 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>18</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>18</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27759 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101675; File No. SR-FICC-2024-802]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; Fixed Income Clearing Corporation; Notice of No Objection To Advance Notice, as Modified by Partial Amendment No. 1, To Modify the GSD Rules (i) Regarding the Separate Calculation, Collection and Holding of Margin for Proprietary Transactions and That for Indirect Participant Transactions, and (ii) To Address the Conditions of Note H to Rule 15c3-3a</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    On March 14, 2024, Fixed Income Clearing Corporation (“FICC”) filed with the Securities and Exchange Commission (“Commission”) advance notice SR-FICC-2024-802 pursuant to Section 806(e)(1) of Title VIII of the Dodd-Frank Wall Street Reform and Consumer Protection Act entitled the Payment, Clearing, and Settlement Supervision Act of 2010 (“Clearing Supervision Act”) 
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4(n)(1)(i) under the Securities Exchange Act of 1934 (“Exchange Act”).
                    <SU>2</SU>
                    <FTREF/>
                     In the advance notice, FICC proposes to modify its Government Securities Division (“GSD”) Rulebook (“GSD Rules”) to calculate, collect, and hold margin for transactions that a direct GSD participant enters into for its own benefit (“proprietary transactions”) separately from margin a direct participant submits to FICC on behalf of indirect participants, and to address conditions of Note H to Rule 15c3-3a under the Exchange Act (“Advance Notice”).
                    <SU>3</SU>
                    <FTREF/>
                     The Advance Notice was published for public comment in the 
                    <E T="04">Federal Register</E>
                     on March 28, 2024.
                    <SU>4</SU>
                    <FTREF/>
                     Upon publication of notice of filing of the advance notice, the Commission extended the review period of the advance notice for an additional 60 days because the Commission determined that the advance notice raised novel and complex issues.
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         12 U.S.C. 5465(e)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4(n)(1)(i).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99149 (Dec. 13, 2023), 89 FR 2714 (Jan. 16, 2024) (S7-23-22) (“Adopting Release,” and the rules adopted therein as “Treasury Clearing Rules”). 
                        <E T="03">See also</E>
                         17 CFR 240.15c3-3a.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Securities Exchange Act Release No. 99845 (Mar. 22, 2024), 89 FR 21586 (Mar. 28, 2024) (File No. SR-FICC-2024-802) (“Notice of Filing”). On March 14, 2024, FICC filed the advance notice as a proposed rule change with the Commission pursuant to Section 19(b)(1) of the Exchange Act, 15 U.S.C. 78s(b)(1), and Rule 19b-4 thereunder, 17 CFR 240.19b-4. Securities Exchange Act Release No. 99844 (March 22, 2024), 89 FR 21603 (Mar. 28, 2024) (File No. SR-FICC-2024-007) (“Proposed Rule Change”). On April 24, 2024, the Commission designated a longer period within which to approve, disapprove, or institute proceedings to determine whether to approve or disapprove the proposed rule change, pursuant to section 19(b)(2) of the Exchange Act, 15 U.S.C. 78s(b)(2)(ii). Securities Exchange Act Release No. 100022 (Apr. 24, 2024), 89 FR 34289 (Apr. 30, 2024) (File No. SR-FICC-2024-007). On June 21, 2024, the Commission published in the 
                        <E T="04">Federal Register</E>
                         an Order Instituting Proceedings to determine whether to approve or disapprove the proposed rule change. Securities Exchange Act Release No. 100401 (Jun. 21, 2024), 89 FR 53690 (Jun. 27, 2024) (File No. SR-FICC-2024-007). On September 18, 2024, the Commission designated a longer period for Commission action on the proceedings to determine whether to disapprove the proposed rule change, until November 10, 2024. Securities Exchange Act Release No. 101082 (Sep. 18, 2024), 89 FR 77949 (Sep. 24, 2024) (File No. SR-FICC-2024-007). On October 25, 2024, FICC filed Partial Amendment No. 1 to the Proposed Rule Change. Securities Exchange Act Release No. 101454 (Oct. 28, 2024), 89 FR 87441 (Nov. 1, 2024) (File No. SR-FICC-2024-007).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         Pursuant to Section 806(e)(1)(H) of the Clearing Supervision Act, the Commission may extend the review period of an advance notice for an additional 60 days, if the changes proposed in the advance notice raise novel or complex issues, subject to the Commission providing the financial market utility (“FMU”) with prompt written notice of the extension.12 U.S.C. 5465(e)(1)(H); 
                        <E T="03">see supra</E>
                         note 4, at 21602 (explaining the Commission's rationale for determining that the proposed changes in the advance notice raise novel and complex issues).
                    </P>
                </FTNT>
                <P>
                    On April 24, 2024, the Commission requested additional information from FICC pursuant to Section 806(e)(1)(D) of the Clearing Supervision Act, which tolled the Commission's period of review of the advance notice until 120 days from the date the information requested by the Commission was received by the Commission.
                    <SU>6</SU>
                    <FTREF/>
                     On June 25, 2024, the Commission received FICC's response to the Commission's request for additional information.
                    <SU>7</SU>
                    <FTREF/>
                     On September 24, 2024, the Commission requested additional information from FICC pursuant to Section 806(e)(1)(D) of the Clearing Supervision Act, which tolled the Commission's period of review of the advance notice until 120 days from the date the information requested by the Commission was received by the Commission.
                    <SU>8</SU>
                    <FTREF/>
                     On October 21, 2024, the Commission received FICC's response to the Commission's September 24, 2024 request for additional information.
                    <SU>9</SU>
                    <FTREF/>
                     On October 25, 2024, FICC filed Partial Amendment No. 1 to the Advance Notice.
                    <SU>10</SU>
                    <FTREF/>
                     The Advance Notice, as modified by Partial Amendment No. 1, is referred to herein as the “Advance Notice.”
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         12 U.S.C. 5465(e)(1)(D). A memo regarding the Request for Additional Information and the tolled period of review is 
                        <E T="03">available at https://www.sec.gov/comments/sr-ficc-2024-802/srficc2024802-462751-1210414.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See</E>
                         12 U.S.C. 5465(e)(1)(E)(ii) and (G)(ii). A memo regarding receipt of FICC's response to the Request for Additional Information is 
                        <E T="03">available at https://www.sec.gov/comments/sr-ficc-2024-802/srficc2024802-494123-1433426.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">See</E>
                         12 U.S.C. 5465(e)(1)(D). A memo regarding the Request for Additional Information and the tolled period of review is 
                        <E T="03">available at https://www.sec.gov/comments/sr-ficc-2024-802/srficc2024802-524215-1504462.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See</E>
                         12 U.S.C. 5465(e)(1)(E)(ii) and (G)(ii). A memo regarding receipt of FICC's response to the Request for Additional Information is 
                        <E T="03">available at https://www.sec.gov/comments/sr-ficc-2024-802/srficc2024802-539295-1544222.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         Securities Exchange Act Release No. 101455 (Oct. 28, 2024), 89 FR 87449 (Nov. 1, 2024) (File No. SR-FICC-2024-802) (“Notice of Partial Amendment”).
                    </P>
                </FTNT>
                <P>
                    The Commission has received comments regarding the substance of the Advance Notice.
                    <SU>11</SU>
                    <FTREF/>
                     The Commission 
                    <PRTPAGE P="93736"/>
                    also received a letter from FICC responding to the comments.
                    <SU>12</SU>
                    <FTREF/>
                     This publication serves as notice of no objection to the Advance Notice.
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         Comments on the Advance Notice are 
                        <E T="03">available at https://www.sec.gov/comments/sr-ficc-2024-802/srficc2024802.htm.</E>
                         Comments on the Proposed Rule Change are 
                        <E T="03">available at https://www.sec.gov/comments/sr-ficc-2024-007/srficc2024007.htm.</E>
                         Because the proposals contained in the Proposed Rule Change and the Advance Notice are the same, the Commission considers all comments received on the proposal, regardless of whether the comments are submitted with respect to the Advance Notice or the Proposed Rule Change. The 
                        <PRTPAGE/>
                        comment letters to the Proposed Rule Change and Advance Notice also contained comments on the substance of another FICC proposed rule change, FICC-2024-005. The Commission will only be addressing comments relevant to this proposal and will address the comments on the other proposed rule change in a separate order.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         Letter from Laura Klimpel, Managing Director, Head of Fixed Income and Financing Solutions, Depository Trust &amp; Clearing Corporation, (Aug. 1, 2024) (“FICC Letter”).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Description of the Advance Notice</HD>
                <HD SOURCE="HD2">A. Background and Terminology</HD>
                <P>
                    FICC, through its GSD, is a central counterparty and provider of clearance and settlement services for the U.S. government securities markets. As a central counterparty in the U.S. government securities markets, FICC novates transactions between two counterparties, effectively becoming the buyer to every seller and the seller to every buyer, and guarantees the settlement of the novated transactions. This means that FICC is exposed to a number of risks arising from such transactions, including counterparty credit risk. FICC seeks to maintain sufficient resources (
                    <E T="03">i.e.,</E>
                     margin) to cover its credit exposures to its participants fully with a high degree of confidence and mitigate potential losses from a default of a direct GSD participant, which is generally referred to as a Netting Member under the GSD Rules 
                    <SU>13</SU>
                    <FTREF/>
                     (and in this Notice of No Objection).
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         The GSD Rules are 
                        <E T="03">available at https://www.dtcc.com/~/media/Files/Downloads/legal/rules/ficc_gov_rules.pdf.</E>
                         Terms not otherwise defined herein are defined in the GSD Rules.
                    </P>
                </FTNT>
                <P>
                    On December 13, 2023, the Commission adopted amendments to the standards applicable to covered clearing agencies that clear transactions in U.S. Treasury securities (“Treasury CCAs”), such as FICC.
                    <SU>14</SU>
                    <FTREF/>
                     These amendments require Treasury CCAs to establish, implement, maintain, and enforce written policies and procedures reasonably designed to, among other things, calculate, collect, and hold margin for direct participants' proprietary positions separately and independently from margin calculated, collected, and held for indirect participants that rely on the services provided by the direct participant to access the Treasury CCA's payment, clearing, or settlement facilities.
                    <SU>15</SU>
                    <FTREF/>
                     The Commission also amended its broker-dealer customer protection rule (“Rule 15c3-3”) 
                    <SU>16</SU>
                    <FTREF/>
                     and the customer and proprietary accounts of broker-dealer (“PAB”) reserve formulas thereunder (“Rule 15c3-3a”) 
                    <SU>17</SU>
                    <FTREF/>
                     to permit margin required and on deposit with Treasury CCAs to be included under certain conditions as a debit in the reserve formulas.
                    <SU>18</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See supra</E>
                         note 3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         17 CFR 240.17ad-22(e)(6)(i).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         17 CFR 240.15c3-3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         17 CFR 240.15c3-3a.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">See supra</E>
                         note 3.
                    </P>
                </FTNT>
                <P>
                    The GSD Rules describe how FICC provides clearance and settlement services to both direct participants and indirect participants, the latter of which rely on the services provided by direct participants to access FICC's clearance and settlement facilities. Currently, the GSD Rules allow indirect participants to access GSD's clearing services through a Netting Member (that is, a direct participant) via two models: the correspondent clearing/prime broker services 
                    <SU>19</SU>
                    <FTREF/>
                     and the Sponsored Service.
                    <SU>20</SU>
                    <FTREF/>
                     The primary difference between the two models is that an indirect participant who becomes a Sponsored Member via the Sponsored Service model must establish an indirect, limited purpose FICC membership, whereas the correspondent clearing/prime broker services do not require an indirect member to establish any relationship with FICC.
                    <SU>21</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 8, 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See generally</E>
                         GSD Rule 3A, 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99817 (Mar. 21, 2024), 89 FR 21362, at 21364 (Mar. 27, 2024) (File No. SR-FICC-2024-005).
                    </P>
                </FTNT>
                <P>
                    The correspondent clearing/prime broker services allow a Netting Member to submit eligible transactions to FICC on behalf of an indirect participant (referred to as the “Executing Firm”), record these transactions in the same account as the proprietary transactions that the Netting Member (referred to as a “Submitting Member”) enters into for its own benefit, and net the indirect participants' transactions against the Netting Member's proprietary transactions for purposes of calculating the Netting Member's margin requirements. Unlike the Sponsored Service, FICC has no relationship with the Executing Firm, and all obligations (
                    <E T="03">i.e.,</E>
                     margin and settlement) under the GSD Rules remain with the Submitting Member.
                    <SU>22</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         
                        <E T="03">Id.</E>
                         at 21365; 
                        <E T="03">see also</E>
                         GSD Rule 8, 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <P>
                    Under a proposed rule change being approved concurrently, FICC is renaming the prime broker/correspondent clearing model to be known as the Agent Clearing Service and providing further specificity around the operation of that service.
                    <SU>23</SU>
                    <FTREF/>
                     In that service, the Netting Member which serves as the direct participant to FICC would be referred to as the Agent Clearing Member, and the indirect participant would be referred to as an Executing Firm Customer. An Executing Firm Customer would have no direct relationship to FICC. This separate change would require that a Netting Member using the Agent Clearing Service submit transactions for Executing Firm Customers through an Agent Clearing Member Omnibus Account, to be recorded separately from its other clearing activity, including its proprietary activity. It would also add a definition for transactions eligible to be submitted by an Agent Clearing Member on behalf of its Executing Firm Customers (“Agent Clearing Transactions”).
                </P>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         
                        <E T="03">See</E>
                         Order, FICC-2024-005, 
                        <E T="03">available at https://www.sec.gov/rules-regulations/self-regulatory-organization-rulemaking/ficc.</E>
                    </P>
                </FTNT>
                <P>
                    In addition, in the Sponsored Service, both currently and in a concurrently approved proposed rule change,
                    <SU>24</SU>
                    <FTREF/>
                     Netting Members that are approved to be Sponsoring Members are able to sponsor certain indirect participants, referred to as Sponsored Members, into GSD membership and submit transactions on behalf of those Sponsored Members. A Sponsored Member is the legal counterparty to FICC for any submitted transactions.
                    <SU>25</SU>
                    <FTREF/>
                     However, the Sponsoring Member unconditionally guarantees to FICC the Sponsored Member's performance under a Sponsoring Member Guaranty, which guarantees to FICC the payment and performance of a Sponsored Member's obligations to FICC.
                    <SU>26</SU>
                    <FTREF/>
                     Therefore, reliance upon the Sponsoring Member Guaranty necessarily involves FICC's reliance upon the financial resources of the Sponsoring Member.
                </P>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 3A, section 7 (describing novation of Sponsored Member Trades) and 2 (identifying membership types), 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         
                        <E T="03">See</E>
                         GSD Rules 3A (describing the operation of the Sponsoring Member Guaranty) and 1 (defining the Sponsoring Member Guaranty), 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <P>
                    Unlike the correspondent clearing/prime broker services, transactions by the Sponsoring Member's Sponsored Members (“Sponsored Member Trades”) are not netted, for margining purposes, against transactions of the Sponsoring Member or another Sponsored Member. Instead, FICC records Sponsored Member Trades in a Sponsored Member Omnibus Account, and calculates margin requirements for each Sponsored Member individually on a gross basis (
                    <E T="03">i.e.,</E>
                     without netting their transactions against transactions of the Sponsoring 
                    <PRTPAGE P="93737"/>
                    Member or another Sponsored Member).
                    <SU>27</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 3A, Section 10(c), 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Proposed Changes</HD>
                <P>
                    In the Advance Notice, FICC seeks to address the Commission's new margin and account separation requirements and the conditions for including margin in the broker-dealer reserve formulas discussed in part I.A above.
                    <SU>28</SU>
                    <FTREF/>
                     As described in greater detail below, the Advance Notice would (1) provide for the separate and independent calculation, collection, and holding of margin for proprietary transactions of a Netting Member from margin submitted to FICC by a Netting Member to support the transactions of an indirect participant (
                    <E T="03">i.e.,</E>
                     either an Executing Firm Customer or a Sponsored Member); (2) establish segregated accounts for direct and indirect participants, including establishing a minimum $1 million cash margin requirement for each Segregated Indirect Participant; (3) consolidate the methodology for calculating the margin requirements, including definitions of relevant terms and components for calculating margin requirements from various sections of the current GSD Rules into a single margin component schedule (“Margin Component Schedule”), specify how the various components relate to different types of margin, and make certain changes to the margin methodology, including revising the Margin Liquidity Adjustment (“MLA Charge”) 
                    <SU>29</SU>
                    <FTREF/>
                     definition, providing a method for allocating net unsettled positions to individual indirect participants for calculating margin requirements, and revising and clarifying the calculation of the Excess Capital Premium (“ECP”) component 
                    <SU>30</SU>
                    <FTREF/>
                     of the Clearing Fund; and (4) modify the terms relating to transactions submitted by Inter-Dealer Broker Netting Members 
                    <SU>31</SU>
                    <FTREF/>
                     to FICC for clearance and settlement (“Brokered Transactions”).
                </P>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         
                        <E T="03">See supra</E>
                         note 3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         The MLA Charge is a margin component designed to address the market impact costs of liquidating a defaulted Netting Member's portfolio that may increase when that portfolio includes large net unsettled positions in a particular group of securities with a similar risk profile or in a particular asset type, thereby causing those costs to be higher than the amount collected for the Netting Member's volatility charge, which is designed to capture the market price risk associated with liquidating each Netting Member's portfolio at a 99th percentile level of confidence. 
                        <E T="03">See</E>
                         GSD Rule 1 (defining Margin Liquidity Adjustment Charge), 
                        <E T="03">supra</E>
                         note 13; 
                        <E T="03">see also</E>
                         Securities Exchange Act Release No. 89560 (Aug. 14, 2020), 85 FR 51503 (Aug. 20, 2020) (File No. SR-FICC-2020-09) (approving the MLA charge as a new component of the margin methodology); Securities Exchange Act Release No. 98558 (Sep. 27, 2023), 88 FR 68179 (Oct. 3, 2023) (File No. SR-FICC-2023-012) (approving revisions to ECP charge).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         The ECP is a margin component that allows FICC to collect additional margin if a member's exposure to FICC, based on its clearing activity, is out of proportion to its capital levels. It is designed to mitigate the heightened default risk a member could pose to FICC if it operates with lower capital levels relative to its margin requirements. 
                        <E T="03">See</E>
                         Margin Component Schedule (defining Excess Capital Premium), 
                        <E T="03">supra</E>
                         note 13; 
                        <E T="03">see also</E>
                         Securities Exchange Act Release No. 54457 (Sep. 15, 2006), 71 FR 55239 (Sep. 21, 2006) (File Nos. SR-FICC-2006-03 and SR-NSCC-2006-03) (approving the ECP charge as a new component of the margin methodology); Securities Exchange Act Release No. 96786 (Feb. 7, 2023), 88 FR 8013 (Feb. 7, 2023) (File No. SR-NSCC-2022-005) (approving revisions to ECP charge).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         An Inter-Dealer Broker is defined as a Person which is in the business of buying and selling securities as agent on behalf of dealers and is registered under Section 15 or Section 15C of the Exchange Act. GSD Rule 1 (defining Inter-Dealer Broker), 
                        <E T="03">supra</E>
                         note 13. An Inter-Dealer Broker Netting Member must meet that definition and certain applicable membership requirements. 
                        <E T="03">See id.</E>
                         and Rule 2A (setting forth membership requirements).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">1. Separate Calculation, Collection, and Holding of Margin</HD>
                <P>The Advance Notice would provide for the separate and independent calculation, collection, and holding of (i) margin deposited by a Netting Member to support its proprietary transactions, and (ii) margin deposited by a Netting Member to support the transactions of an indirect participant, that is, either an Executing Firm Customer or a Sponsored Member. To facilitate the separate and independent calculation, collection, and holding proprietary and indirect participant margin, FICC would establish proprietary accounts to record the proprietary transactions that the Netting Member enters into for its own benefit and separate indirect participant accounts to record transactions that the Netting Member submits on behalf of an indirect participant, which could be either a Sponsored Member or an Executing Firm Customer.</P>
                <P>
                    For proprietary transactions, the accounts would include Dealer Accounts, which would be available for all Netting Members, and Cash Broker Accounts and Repo Broker Accounts, which would only be available for Inter-Dealer Broker Netting Members.
                    <SU>32</SU>
                    <FTREF/>
                     Cash Broker Accounts would be available for recording an Inter-Dealer Broker Netting Member's Brokered Transactions (other than Brokered Repo Transactions), and Repo Broker Accounts would be for purposes of recording an Inter-Dealer Broker Netting Member's Brokered Repo Transactions.
                </P>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         Under the proposed changes, “Cash Broker Account” would be a proprietary account maintained by FICC for an Inter-Dealer Broker Netting Member to record Brokered Transactions, other than Brokered Repo Transactions, submitted to the Corporation by the Inter-Dealer Broker Netting Member. “Repo Broker Account” would be a proprietary account maintained by the FICC for an Inter-Dealer Broker Netting Member in its capacity as a Repo Broker to record Brokered Repo Transactions submitted to the Corporation by the Inter-Dealer Broker Netting Member.
                    </P>
                </FTNT>
                <P>
                    For indirect participant transactions, FICC would establish Indirect Participants Accounts to record transactions that a Netting Member submits to FICC on behalf of Sponsored Members and Executing Firm Customers. These Indirect Participants Accounts would include Sponsoring Member Omnibus Accounts for recording Sponsored Member Trades and Agent Clearing Member Omnibus Accounts for recording Agent Clearing Transactions submitted on behalf of Executing Firm Customers. In addition, the proposal would permit a Sponsoring Member or Agent Clearing Member to designate any of its Indirect Participants Accounts as a segregated customer account (a “Segregated Indirect Participants Account”). Such designation, as further described in part I.B.2 below, would give Netting Members a mechanism to direct FICC to calculate and segregate margin deposited in connection with the relevant Segregated Indirect Participants Account in accordance with the conditions described in Note H to Rule 15c3-3a.
                    <SU>33</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         17 CFR 240.15c3-3a.
                    </P>
                </FTNT>
                <P>
                    The proposal would require each Netting Member to deposit two forms of margin: the Required Fund Deposit and the Segregated Customer Margin Requirement. The Required Fund Deposit, which would be deposited to the Clearing Fund, would be the sum of each Netting Member's proprietary accounts (
                    <E T="03">e.g.,</E>
                     Dealer Accounts and Broker Accounts) and indirect participant accounts (
                    <E T="03">e.g.,</E>
                     Agent Clearing Omnibus Accounts and Sponsoring Member Omnibus Accounts) not designated as Segregated Indirect Participants Accounts. The Segregated Customer Margin Requirement, which would be excluded from the Clearing Fund, would be the sum of the Netting Member's Sponsoring Member Omnibus Accounts designated as Segregated Indirect Participants Accounts and Agent Clearing Member Omnibus Accounts designated as Segregated Indirect Participants Accounts.
                </P>
                <P>
                    FICC's proposal would also provide that a Netting Member's Margin Portfolio, which is utilized to determine a Netting Member's margin requirement, cannot include both proprietary and indirect participant accounts. As a result, the transactions a Netting 
                    <PRTPAGE P="93738"/>
                    Member submits to FICC on behalf of an indirect participant either as a Sponsoring Member or an Agent Clearing Member would no longer be netted against a Netting Member's proprietary transactions for calculating a Netting Member's margin requirements.
                    <SU>34</SU>
                    <FTREF/>
                     Since proprietary transactions and transactions submitted for indirect participants would not be recorded in the same type of account, these changes would result in margin for a Netting Member's proprietary transactions being calculated separately and independently from margin calculated for the transactions that the Netting Member submits on behalf of indirect participants.
                </P>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         The Advance Notice would also specify the types of accounts in which Netting Members may record transactions to identify the purpose and use of these accounts. FICC's “Accounts” are not custodial accounts in which FICC holds assets, but rather a mechanism for FICC to record and group transactions. These records are utilized by FICC in its calculation of a Netting Member's margining, settlement, and other obligations. Proprietary Accounts would include “Dealer Accounts,” which would be available for all Netting Members, and “Cash Broker Accounts” and “Repo Broker Accounts,” which would only be available for Inter-Dealer Broker Netting Members. Non-Proprietary Accounts would include, in the case of a Sponsoring Member, Sponsoring Member Omnibus Accounts for purposes of recording Sponsored Member Trades, and, in the case of an Agent Clearing Member, Agent Clearing Member Omnibus Accounts for purposes of recording Agent Clearing Transactions of its Executing Firm Customers.
                    </P>
                </FTNT>
                <P>To help ensure that margin for proprietary transactions is calculated, collected, and held separately and independently of margin for indirect participant transactions, FICC would require each Netting Member, at the time it submits a transaction to FICC for clearance and settlement, to designate the account in which the particular transaction should be recorded using a separate Deposit ID, which is an existing operational mechanism used by Netting Members to identify the type of account for which a margin deposit is being made. The use of these separate Deposit IDs would result in margin for each type of account being separately transferred to FICC and recorded on FICC's books as separate margin amounts for each account type. The proposal would also require FICC to report a Netting Member's Required Fund Deposit and Segregated Customer Margin Requirement twice daily and specify the amount of margin attributable to each Required Fund Deposit Portion or Segregated Indirect Participants Account so that the Netting Member can transfer the different margin amounts separately.</P>
                <P>
                    In addition, the proposal would eliminate the concept of a Permitted Margin Affiliate, which allows a Netting Member to include accounts of an affiliate that is also a Netting Member in the same Margin Portfolio as its accounts and net their transactions for margin calculation purposes. FICC states that no Netting Member currently has a Permitted Margin Affiliate, so keeping this option in the rules in conjunction with the proposed changes to establish separate and independent calculation, collection, and holding of margin would introduce unnecessary complexity in FICC's rules.
                    <SU>35</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 89 FR 21592.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Segregation of Customer Margin</HD>
                <P>
                    FICC is proposing several changes to allow for the segregation of customer margin in a manner that satisfies the conditions for recording a debit in the customer reserve formula under Note H to Exchange Act Rule 15c3-3a.
                    <SU>36</SU>
                    <FTREF/>
                     First, to satisfy Section (b)(2)(i) of Note H to Rule 15c3-3a,
                    <SU>37</SU>
                    <FTREF/>
                     FICC would calculate the margin requirements applicable to any segregated account on a gross basis (
                    <E T="03">i.e.,</E>
                     FICC would treat each indirect participant as if it were a separate Netting Member for margin calculations and would not net the transactions of one indirect participant against the transactions of another indirect participant). Second, to satisfy Section (b)(2)(iii) of Note H to Rule 15c3-3a,
                    <SU>38</SU>
                    <FTREF/>
                     FICC would establish Segregated Customer Margin Custody Accounts for eligible customers on its books and records. These accounts would segregate the margin deposited for transactions in that account from any margin for a Netting Member's proprietary positions, both on FICC's own books and records and at FICC's custodians. FICC would only be able to use such segregated margin to secure or satisfy the obligations of the customer for whom such margin is held, and it would not be considered part of the mutualized Clearing Fund. FICC would not be able to apply such margin to the proprietary obligations of the Netting Member that deposited it with FICC, to the obligations of any other Netting Member or indirect participant, or to any lien or claim against FICC.
                    <SU>39</SU>
                    <FTREF/>
                     FICC would provide written notice to any Netting Member that is a broker-dealer that any Segregated Customer Margin Custody Account is being held for the exclusive benefit of the customers and is being kept separate from any other accounts maintained by the broker-dealer or any other Netting Member at FICC, as required by Section (b)(2)(iii)(C) of Note H.
                    <SU>40</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         
                        <E T="03">See id.,</E>
                         at 21592 (citing 17 CFR 240.15c3-3a).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         
                        <E T="03">Id.</E>
                         at 21592-93.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         
                        <E T="03">Id.</E>
                         at 21593-94.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 35 (describing this as “an express prohibition on FICC using Segregated Customer Margin held in respect of one Segregated Indirect Participant for the obligations of any other person” and stating that, as a result, the default of one Segregated Indirect Participant should not generally cause another segregated Indirect participant to lose its margin).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         
                        <E T="03">Id.</E>
                         at 21594.
                    </P>
                </FTNT>
                <P>
                    Further, as amended, the proposal would clarify that any interest earned on Segregated Customer Margin consisting of cash must be paid to the Netting Member on behalf of, and as agent for, its Segregated Indirect Participant.
                    <SU>41</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         
                        <E T="03">See</E>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87450.
                    </P>
                </FTNT>
                <P>
                    Moreover, to comply with the custody requirements of (b)(2)(iv) of Note H,
                    <SU>42</SU>
                    <FTREF/>
                     FICC would require segregated margin accounts to be held at either a bank within the meaning of the Exchange Act that is insured by the Federal Deposit Insurance Corporation and is a qualified custodian under the 1940 Act, or the Federal Reserve Bank of New York.
                    <SU>43</SU>
                    <FTREF/>
                     FICC would require these accounts to be segregated from any other account of FICC and used exclusively to hold Segregated Customer Margin, in accordance with Section (b)(2)(iv)(A) of Note H. Moreover, each of these accounts would be subject to (i) a written notice of the bank or Federal Reserve Bank that the account is being held by the bank or Federal Reserve Bank pursuant to Rule 15c3-3 and is being kept separate from and not commingled with any other accounts maintained by FICC or any other person at the bank or Federal Reserve Bank and (ii) a written contract between FICC and the bank or Federal Reserve Bank which would provide that the Segregated Customer Margin in the account is subject to no right, charge, security interest, lien, or claim in favor of the bank or Federal Reserve Bank or any person claiming through the bank or Federal Reserve Bank, in accordance with Sections (b)(2)(iv)(B) and (C) of Note H.
                    <SU>44</SU>
                    <FTREF/>
                     FICC would also only allow Segregated Customer Margin consisting of cash to be invested in U.S. Treasury securities with a maturity of one year or less, in accordance with Section (b)(2)(ii) of Note H.
                    <SU>45</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21595-96.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         
                        <E T="03">See</E>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87450.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21594-95.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         
                        <E T="03">Id.</E>
                         at 21595.
                    </P>
                </FTNT>
                <P>
                    Finally, to satisfy Section (b)(2)(v) of Note H,
                    <SU>46</SU>
                    <FTREF/>
                     FICC would provide specific procedures to allow Netting Members to request the return of excess segregated 
                    <PRTPAGE P="93739"/>
                    margin. FICC notes that these changes would allow broker-dealer Netting Members to collect margin from customers and deposit it with FICC and to provide all customers, including those that access FICC through non-broker-dealers, the ability to segregate margin they deposit.
                    <SU>47</SU>
                    <FTREF/>
                     FICC would have the ability to retain some or all of the excess segregated customer margin if the Netting Member had an outstanding payment or margin obligation to FICC for transactions of any Segregated Indirect Participant. FICC could not retain the excess segregated customer margin for a Segregated Indirect Participant when FICC has determined, in its sole discretion, that such outstanding payment or margin obligation is unrelated to the transactions of that Segregated Indirect Participant.
                    <SU>48</SU>
                    <FTREF/>
                     FICC states that these aspects of the Advance Notice would allow for the segregation of certain customer margin in a manner that satisfies the conditions for a broker-dealer to record a debit in the customer reserve formula under Note H to Rule 15c3-3a.
                    <SU>49</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>46</SU>
                         
                        <E T="03">Id.</E>
                         at 21595-96.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>47</SU>
                         
                        <E T="03">Id.</E>
                         at 21590.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>48</SU>
                         
                        <E T="03">See</E>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87450.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>49</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21592.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">a. $1 Million Minimum Cash Margin Requirement</HD>
                <P>
                    FICC is also proposing a minimum $1 million cash margin requirement for each Segregated Indirect Participant Account, similar to the $1 million minimum cash margin requirement currently applicable to each Netting Member.
                    <SU>50</SU>
                    <FTREF/>
                     FICC conducts daily backtesting to evaluate whether each Netting Member's margin is sufficient to cover FICC's credit exposures to that member based on a simulated liquidation of the member's portfolio on that day. FICC's daily backtesting of the sufficiency of Clearing Fund deposits has shown a heightened risk of backtesting deficiencies (
                    <E T="03">i.e.,</E>
                     the projected liquidation losses to FICC due to a Netting Member's default would be greater than the member's margin) for members with lower deposits.
                    <SU>51</SU>
                    <FTREF/>
                     Because FICC is required to calculate the margin requirements for Segregated Indirect Participants on a gross basis, as if each Segregated Indirect Participant were a separate Margin Portfolio, and Segregated Customer Margin would not be available to address losses from other direct or indirect participants, FICC believes it is also appropriate to apply the same minimum cash requirement to each Segregated Indirect Participant that it applies to each Margin Portfolio.
                    <SU>52</SU>
                    <FTREF/>
                     Moreover, FICC believes that the $1 million cash requirement is the appropriate minimum amount to optimize the balance between financial impact of the requirement to participants and FICC's ability to continue to meet its regulatory obligation to maintain a backtesting performance coverage ratio above its 99 percent coverage target.
                    <SU>53</SU>
                    <FTREF/>
                     FICC states that the $1 million minimum is supported by its prior analyses of the appropriate minimum margin requirement for Netting Members.
                    <SU>54</SU>
                    <FTREF/>
                     FICC further describes this minimum requirement as critical to ensuring that the account segregation does not expose FICC and its participants to undue loss. FICC explains that the Segregated Customer Margin posted by an individual Segregated Indirect Participant needs to be enough, on its own, to address losses arising from the Segregated Indirect Participant's positions, and that, otherwise, such losses may be mutualized.
                    <SU>55</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>50</SU>
                         Like the current requirement for Netting Member Required Fund Deposits, the proposal would require that a minimum of 40 percent of the Segregated Customer Margin Requirement be satisfied with cash and/or Eligible Clearing Fund Treasury Securities.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>51</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21595.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>52</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>53</SU>
                         
                        <E T="03">Id.;</E>
                         FICC Letter at 28-29.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>54</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 28-29.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>55</SU>
                         
                        <E T="03">Id.</E>
                         at 29.
                    </P>
                </FTNT>
                <P>
                    However, FICC, in its sole discretion, would have the ability to adjust the amount of the minimum $1 million margin requirement if FICC determines that a different minimum charge would be appropriate and consistent with achieving its backtesting coverage target.
                    <SU>56</SU>
                    <FTREF/>
                     FICC would notify Netting Members of any such adjustment to the minimum margin requirement through an Important Notice.
                    <SU>57</SU>
                    <FTREF/>
                     In discussing this proposed ability, FICC states that it will review the $1 million floor for Segregated Customer Margin as part of ongoing internal surveillance and risk management monitoring procedures.
                    <SU>58</SU>
                    <FTREF/>
                     FICC further states that it would be prudent to have the ability to adjust the $1 million floor proactively to the extent that FICC identifies as part of these reviews that activity levels, margin performance observed through backtesting, and other measures indicate that FICC would be able to continue to manage the risks presented to it and meet its regulatory risk management obligations (including, for example, its 99% backtesting coverage target) with a lower minimum Segregated Customer Margin Requirement (that is, an amount below $1 million).
                    <SU>59</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>56</SU>
                         
                        <E T="03">See</E>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87451.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>57</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>58</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 30.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>59</SU>
                         
                        <E T="03">Id.</E>
                         at 31.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">3. Margin Component Schedule</HD>
                <P>
                    To improve the clarity and transparency of its margin components and Clearing Fund calculation methodology,
                    <SU>60</SU>
                    <FTREF/>
                     FICC would move the margin calculation methodology, including the relevant defined terms, into a new Margin Component Schedule. Currently, the terms and information concerning the margin calculation methodology, as well as the relevant definitions, appear in several different locations.
                    <SU>61</SU>
                    <FTREF/>
                     FICC states that its methodology and the included components would continue to be substantively the same as the methodology under the current Rules.
                    <SU>62</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>60</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21596.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>61</SU>
                         FICC would move the calculation methodology from Rule 4, Sections 1b, and 2a, Rule 3, Section 14, and Rule 3A, Section 10 to the new Margin Component Schedule. FICC would move the definitions from Rule 1 to Section 5 of the Margin Component Schedule.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>62</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21596.
                    </P>
                </FTNT>
                <P>
                    The new Margin Component Schedule would set out the methodology for calculating margin amounts. That Margin Component Schedule would provide for FICC to perform substantially the same calculation it currently performs when determining a Netting Member's Required Fund Deposit, except that (i) the calculation would be performed on a Segregated Indirect Participant-by-Segregated Indirect Participant basis as though each Segregated Indirect Participant represented a separate Margin Portfolio and (ii) FICC would not impose an ECP on Segregated Indirect Participant Accounts. Specifically, for Required Fund Deposit calculations, the margin amount shall equal the VaR Charge, plus or minus the Blackout Period Exposure Adjustment (as applicable), plus the Portfolio Differential Charge, with the following potential additional charges, as applicable: the Backtesting Charge, the Holiday Charge, the MLA Charge, the ECP, and the Intraday Supplemental Fund Deposit.
                    <SU>63</SU>
                    <FTREF/>
                     For Segregated Customer Margin Requirement calculations, the margin amount shall equal the VaR Charge, plus or minus the Blackout Period Exposure Adjustment (as applicable), plus the Portfolio Differential Charge, with the following potential additional charges, as 
                    <PRTPAGE P="93740"/>
                    applicable: the Backtesting Charge, the Holiday Charge, the MLA Charge, and the Intraday Supplemental Fund Deposit.
                </P>
                <FTNT>
                    <P>
                        <SU>63</SU>
                         This method does not represent a change from the current method of calculating Required Fund Deposits, but merely moves the description from current Rule 4 to the new Margin Component Schedule.
                    </P>
                </FTNT>
                <P>
                    For both types of calculations, the Margin Component Schedule addresses the applicable minimum cash margin requirements ($1 million for each Netting Member and Segregated Indirect Participant) 
                    <SU>64</SU>
                    <FTREF/>
                     and FICC's authority to require increased deposits as appropriate, including the use of a special charge. FICC would not add Segregated Customer Margin to Section 4 of the Margin Component Schedule, which describes FICC's ability to impose increased Required Fund Deposits under certain circumstances.
                    <SU>65</SU>
                    <FTREF/>
                     However, when determining whether to increase the Required Fund Deposit of a Netting Member under the circumstances described in Section 4, FICC would consider the risk presented by a Netting Member from the activity it submits to FICC, including activity of indirect participants.
                    <SU>66</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>64</SU>
                         
                        <E T="03">See supra</E>
                         Section I.B.2.a for a description of the proposed $1 million minimum cash margin requirement for each Segregated Indirect Participant Account.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>65</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21593.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>66</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">a. MLA Charge</HD>
                <P>
                    FICC would amend the definition of the MLA Charge to account for the use of Segregated Indirect Participant Accounts. Specifically, the definition would provide that, if a Segregated Indirect Participant clears through multiple Accounts 
                    <SU>67</SU>
                    <FTREF/>
                     (including Accounts of different Netting Members), then the MLA Charge for transactions in a Segregated Indirect Participants Account would be the greater of (i) an amount calculated for only the transactions maintained in that Account (
                    <E T="03">i.e.,</E>
                     excluding the other Accounts where the Segregated Indirect Participant's transactions are recorded) and (ii) an amount calculated on a consolidated portfolio basis (
                    <E T="03">i.e.,</E>
                     taking into account the transactions in each of the Accounts). This would be the same methodology currently used for Sponsored Members clearing through multiple Accounts.
                    <SU>68</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>67</SU>
                         FICC proposed to amend the definition of Account to be an account maintained by FICC for a Member to record transactions submitted by the member. FICC states that this change would clarify that Accounts are recordkeeping mechanisms for FICC to determine which transactions should be netted against each other, but are not custodial accounts through which FICC holds assets for a Netting Member. 
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21592.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>68</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 1 (defining MLA Charge, including for Sponsored Members sponsored by multiple Sponsoring Members), 
                        <E T="03">supra</E>
                         note 13; Securities Exchange Act Release No. 98558 (Sep. 27, 2024), 89 FR 68179 (Oct. 3, 2023) (File No. SR-FICC-2023-012).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">b. Allocation of Net Unsettled Positions</HD>
                <P>
                    The Advance Notice would also provide a method for allocating net unsettled positions to individual indirect participants for calculating margin requirements. Specifically, as amended, FICC would modify the definition of Current Net Settlement Positions in Rule 1 to provide that, for calculating margin requirements and not for purposes of calculating the Net Settlement Position under GSD Rule 11, positions that are not clearly allocable to an individual Sponsored Member or Segregated Indirect Participant (other than Sponsored GC Trades), because one or more transactions recorded for indirect participants did not settle on the original Scheduled Settlement Date, would be allocated 
                    <E T="03">pro rata</E>
                     to Sponsored Members or Segregated Indirect Participants that had positions in the same direction and CUSIP as the un-allocable Current Net Unsettled Positions at the end of the preceding business day. FICC states that this situation could arise if a transaction recorded in a Sponsoring Member Omnibus Account or Segregated Indirect Participants Account fails to settle and that such failure to settle would not occur with Sponsored GC Trades.
                    <SU>69</SU>
                    <FTREF/>
                     FICC believes this methodology facilitates a reasonable and fair allocation for purposes of calculating gross margin requirements.
                    <SU>70</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>69</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21596-97; Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87451.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>70</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21596-97.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">c. Calculation of Excess Capital Premium</HD>
                <P>
                    In addition, the Advance Notice would amend the terms related to the ECP component of the Clearing Fund, which is used to collect additional margin if a Netting Member's exposure to FICC through its clearing activity is out of proportion to its capital. Currently, the ECP applicable to a Netting Member equals the Netting Member's “Excess Capital Ratio” (
                    <E T="03">i.e.,</E>
                     its VaR Charge divided by its Netting Member Capital) multiplied by its “Excess Capital Differential” (
                    <E T="03">i.e.,</E>
                     the amount by which a Netting Member's VaR Charge exceeds its Netting Member Capital). However, FICC currently reserves the right to collect less than this amount or to return some or all of this amount.
                    <SU>71</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>71</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 1 (defining Excess Capital Ratio and Excess Capital Differential) and Rule 3, Section 14 (describing the Excess Capital Premium), 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <P>
                    The changes would seek to make the calculation of the ECP component clearer and more predictable by (i) capping the amount of the ECP at two times the amount by which a Netting Member's VaR Charge exceeds its Netting Capital,
                    <SU>72</SU>
                    <FTREF/>
                     (ii) specifying the Netting Member Capital amounts used to calculate the ECP (that is, the Net Capital amount from each Netting Member's most recent Form X-17-A-5 (Financial and Operational Combined Uniform Single Report (“FOCUS Report”)) or the Equity Capital amount on its most recent Consolidated Report of Condition and Income (“Call Report”)), (iii) providing that FICC may calculate the premium based on updated available information, and (iv) permitting FICC, in its discretion, to waive the amount of the ECP and setting forth a specific procedure for doing so. Regarding the waiver procedure, only a Managing Director in FICC's Group Chief Risk Office would be able to grant a waiver of an ECP in certain situations. These situations would be limited to exigent circumstances or other unexpected events. When deciding whether to grant a waiver, FICC would consider the degree to which a Netting Member's capital position and trading activity compare or correlate to the exigent circumstances and whether FICC can effectively manage the risk exposure from the Netting Member without collecting the ECP.
                    <SU>73</SU>
                    <FTREF/>
                     Any waiver would be documented in a written report made available to the Netting Member. FICC states that these changes are substantially similar to changes recently adopted by the National Securities Clearing Corporation (“NSCC”) and they would enhance the ability of Netting Members to identify what their ECP will be and to ensure such amount is accurately calibrated.
                    <SU>74</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>72</SU>
                         In addition, FICC would amend the definition of Netting Member Capital to refer to a Netting Member's Net Capital, Net Assets, or Equity Capital to link the calculation to the appropriate regulatory framework for each Netting Member and add the term Equity Capital to clarify that a Netting Member's most recent Call Report, or financial statements or equivalent reporting if a Netting Member is not required to file a Call Report, will be used for the calculation of the Excess Capital Premium.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>73</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21597.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>74</SU>
                         
                        <E T="03">Id. See</E>
                         Securities Exchange Act Release No. 96786 (Feb. 1, 2023), 88 FR 8013 (Feb. 7, 2023) (SR-NSCC-2022-005).
                    </P>
                </FTNT>
                <P>
                    In addition, the Advance Notice would revise the definitions of Excess Capital Ratio and Excess Capital Differential to exclude the VaR Charge for Segregated Indirect Participants. FICC is proposing this change because each indirect participant would be responsible for satisfying its own 
                    <PRTPAGE P="93741"/>
                    respective VaR Charge, not the Netting Member, and the Excess Margin Charge is designed to address the risk that a Netting Member with low capital relative to value-at-risk is not able to perform its obligations.
                    <SU>75</SU>
                    <FTREF/>
                     FICC states that including the VaR Charge that is calculated for an indirect participant and is satisfied by the capital of that indirect participant in the calculation of the Netting Member's ECP could result in assessing an ECP for that Netting Member that is greater than the amount required to mitigate the risk this margin component is designed to address.
                    <SU>76</SU>
                    <FTREF/>
                     FICC also states that this change is designed to ensure that the ECP does not result in differential treatment of Netting Members that act as intermediaries for Segregated Indirect Participants.
                </P>
                <FTNT>
                    <P>
                        <SU>75</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>76</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">4. Modification of Terms for Brokered Transactions</HD>
                <P>
                    The Advance Notice would modify the terms relating to Brokered Transactions. FICC's rules currently cap the amount of loss allocation that may be applied to Inter-Dealer Broker Netting Members and Non-IDB Repo Brokers submitting Brokered Transactions. FICC would revise the definition of Brokered Transactions to include only the side of the transactions submitted to FICC for novation by an Inter-Dealer Broker Netting Member and entered into on the Inter-Dealer Broker Netting Member's own trading platform.
                    <SU>77</SU>
                    <FTREF/>
                     As a result, the favorable loss allocation treatment for Brokered Transactions would apply only to the transactions that present limited risk since an Inter-Dealer Broker is standing between two counterparties in those transactions and is therefore completely flat (that is, subject to offsetting exposures).
                    <SU>78</SU>
                    <FTREF/>
                     Since FICC believes the favorable loss allocation treatment is appropriate only for Inter-Dealer Broker Netting Members submitting Brokered Transactions, it would delete the term “Non-IDB Repo Broker” from its rules.
                    <SU>79</SU>
                    <FTREF/>
                     FICC states that these changes would improve FICC's risk management and promote access by ensuring that its differential treatment of different parties and transactions has a sound risk management justification.
                    <SU>80</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>77</SU>
                         
                        <E T="03">See</E>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87451.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>78</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21598.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>79</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>80</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 89 FR 21588.
                    </P>
                </FTNT>
                <P>
                    In addition, the proposed changes would provide that transactions entered into on inter-dealer brokers and similar platforms may be cleared using the Sponsored Service or the Agent Clearing Service.
                    <SU>81</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>81</SU>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87451; 
                        <E T="03">see also</E>
                         FICC Letter at 22-23.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">II. Discussion and Commission Findings</HD>
                <P>
                    Although the Clearing Supervision Act does not specify a standard of review for an advance notice, the stated purpose of the Clearing Supervision Act is instructive: to mitigate systemic risk in the financial system and promote financial stability by, among other things, promoting uniform risk management standards for systemically important financial market utilities (SIFMUs) and strengthening the liquidity of SIFMUs.
                    <SU>82</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>82</SU>
                         
                        <E T="03">See</E>
                         12 U.S.C. 5461(b).
                    </P>
                </FTNT>
                <P>
                    Section 805(a)(2) of the Clearing Supervision Act authorizes the Commission to prescribe regulations containing risk management standards for the payment, clearing, and settlement activities of designated clearing entities engaged in designated activities for which the Commission is the supervisory agency.
                    <SU>83</SU>
                    <FTREF/>
                     Section 805(b) of the Clearing Supervision Act provides the following objectives and principles for the Commission's risk management standards prescribed under Section 805(a): 
                    <SU>84</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>83</SU>
                         12 U.S.C. 5464(a)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>84</SU>
                         12 U.S.C. 5464(b).
                    </P>
                </FTNT>
                <P>• to promote robust risk management;</P>
                <P>• to promote safety and soundness;</P>
                <P>• to reduce systemic risks; and</P>
                <P>• to support the stability of the broader financial system.</P>
                <P>
                    Section 805(c) provides, in addition, that the Commission's risk management standards may address risk management and default policies and procedures, among other areas.
                    <SU>85</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>85</SU>
                         12 U.S.C. 5464(c).
                    </P>
                </FTNT>
                <P>
                    The Commission has adopted risk management standards under Section 805(a)(2) of the Clearing Supervision Act and Section 17A of the Exchange Act (the “Clearing Agency Rules”).
                    <SU>86</SU>
                    <FTREF/>
                     The Clearing Agency Rules require, among other things, each covered clearing agency to establish, implement, maintain, and enforce written policies and procedures that are reasonably designed to meet certain minimum requirements for its operations and risk management practices on an ongoing basis.
                    <SU>87</SU>
                    <FTREF/>
                     As such, it is appropriate for the Commission to review advance notices against the Clearing Agency Rules and the objectives and principles of these risk management standards as described in Section 805(b) of the Clearing Supervision Act. As discussed below, the proposals in the Advance Notice are consistent with the objectives and principles described in Section 805(b) of the Clearing Supervision Act 
                    <SU>88</SU>
                    <FTREF/>
                     and in the Clearing Agency Rules, in particular Rules 17ad-22(e)(4)(i), (e)(6)(i), (e)(6)(iii), (e)(18)(ii), (e)(18)(iii), (e)(18)(iv)(C), (e)(19), and (e)(23)(ii) thereunder.
                    <SU>89</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>86</SU>
                         17 CFR 240.17ad-22. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 68080 (Oct. 22, 2012), 77 FR 66220 (Nov. 2, 2012) (S7-08-11). 
                        <E T="03">See also</E>
                         Securities Exchange Act Release No. 78961 (Sep. 28, 2016), 81 FR 70786 (Oct. 13, 2016) (S7-03-14). FICC is a “covered clearing agency” as defined in Rule 17ad-22(a)(5).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>87</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>88</SU>
                         12 U.S.C. 5464(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>89</SU>
                         17 CFR 240.17ad-22(e)(4)(i), (e)(6)(i), (e)(6)(iii), (e)(18)(ii), (e)(18)(iii), (e)(18)(iv)(C), (e)(19), and (e)(23)(ii).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">A. Consistency With Section 805(b) of the Clearing Supervision Act</HD>
                <P>
                    The proposals in the Advance Notice are consistent with the stated objectives and principles of Section 805(b) of the Clearing Supervision Act.
                    <SU>90</SU>
                    <FTREF/>
                     Specifically, the changes proposed in the Advance Notice are consistent with promoting robust risk management, promoting safety and soundness, reducing systemic risks, and supporting the broader financial system.
                    <SU>91</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>90</SU>
                         12 U.S.C. 5464(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>91</SU>
                         Several of the issues raised by the commenters are directed at issues specific to the proposed rule change and will be addressed in that context. These comments generally relate to the proposal's impact on competition and its consistency with the Exchange Act. 
                        <E T="03">See</E>
                         Letter from Jiří Król, Deputy CEO, Global Head of Government Affairs, Alternative Investment Management Association, at 6-7 (Apr. 23, 2024) (“AIMA Letter”); Letter from Joanna Mallers, Secretary, Futures Industry of America, Principal Traders Group (Oct. 11, 2024) (“FIA PTG Letter II”) at 2-3; Letter from Sarah A. Bessin, Deputy General Counsel and Nhan Nguyen, Associate General Counsel, Investment Company Institute, at 12 (Jun. 20, 2024) (“ICI Letter”); Letter from Katherine Darras, General Counsel, International Swaps and Derivatives Association, at 4 (Apr. 17, 2024) (“ISDA Letter I”); Letter from Jennifer W. Han, Executive Vice President, Chief Counsel and Head of Global Regulatory Affairs, Managed Funds Association, at 7 (Apr. 17, 2024) (“MFA Letter I”); Letter from Jennifer W. Han, Executive Vice President, Chief Counsel and Head of Global Regulatory Affairs, Managed Funds Association (Nov. 12, 2024) (“MFA Letter II”) at 7; Letter from William C. Thum, Managing Director and Assistant General Counsel, Securities Industry and Financial Markets Association, Asset Management Group, at 9 (May 24, 2024) (“SIFMA AMG Letter”) (commenting on the proposal's impact on competition). The Commission's evaluation of the Advance Notice is conducted under the Clearing Supervision Act and, as discussed above, generally considers whether the proposal would promote robust risk management, promote safety and soundness, reduce systemic risks, and support the broader financial system.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">1. Separate Calculation and Collection of Margin for Proprietary and Customer Accounts</HD>
                <P>
                    The proposed changes to require the separate and independent calculation 
                    <PRTPAGE P="93742"/>
                    and collection of margin for Netting Members' proprietary transactions and indirect participants' transactions, as described in Section I.B.1., should allow FICC to better identify and measure the unique risk profiles of each Netting Member and indirect participant. This proposed change would ensure that an indirect participant's positions are no longer netted against a Netting Member's positions, that margin is collected with respect to the indirect participant's positions specific to those transactions, and that interest on an indirect participant's cash margin would be paid to the Netting Member for the benefit of, and as agent for, the indirect participant. As discussed in more detail in Section II.C.1 below, this should enhance FICC's ability to calculate and collect the appropriate margin from each direct and indirect participant, which is consistent with promoting robust risk management.
                </P>
                <P>The separate and independent calculation and collection of margin for proprietary and indirect participants' transactions should allow FICC to better identify and measure the unique risk profiles of each Netting Member and indirect participant, enhancing FICC's ability to calculate and collect sufficient margin from each Netting Member and indirect participant to cover potential losses from a Netting Member or indirect participant default, thereby reducing the likelihood that any losses arising out of a default would exceed FICC's prefunded resources, as discussed in more detail in Section II.C.1 below, and threaten the safety and soundness of FICC's ongoing clearance and settlement services. Accordingly, the proposals are consistent with promoting safety and soundness at FICC.</P>
                <P>The separation of proprietary and customer margin discussed in Section I.B.1 above is consistent with reducing systemic risks and supporting the stability of the broader financial system. The separation of proprietary and customer accounts should also help avoid the risk of mutualizing loss among non-defaulting members as part of the close-out process and/or a disorderly default in the event of a direct participant default, in that FICC would be responsible for the central liquidation of the defaulting participant's trades and would be able to have a more holistic view of the market. These effects should, in turn, reduce the potential resultant effects on non-defaulting Netting Members, their customers, and the broader market, which is consistent with reducing systemic risks and supporting the stability of the broader financial system.</P>
                <HD SOURCE="HD3">2. $1 Million Minimum Cash Margin Requirement</HD>
                <P>For the reasons discussed below in more detail in Section II.B.2, the proposed $1 million minimum cash margin requirement for Segregated Indirect Participants, which could be adjusted by FICC if it determines that a different minimum amount would be appropriate and consistent with achieving its backtesting coverage target, should help ensure that each indirect participant provides sufficient margin to cover its potential obligations to FICC, thereby helping to allow FICC to meet its settlement obligations in the event of a default and to protect FICC, non-defaulting Netting Members, indirect participants, and the market from losses from an indirect participant default. Accordingly, the proposed $1 million minimum cash margin requirement is consistent with reducing systemic risks and supporting the stability of the broader financial system, as well as promoting safety and soundness.</P>
                <P>
                    In addition, as indicated by FICC's backtesting results, and discussed further in Section II.B.2 below, the $1 million minimum margin requirement should enhance FICC's ability to collect the appropriate margin from each indirect participant, which is consistent with robust risk management. FICC's flexibility to adjust the minimum margin amount if it determines that a different amount would be appropriate and consistent with achieving its backtesting coverage target is also consistent with robust risk management, because meeting backtesting coverage targets is essential to ensuring that the margin collected would be sufficient for FICC to cover its credit exposures to its Netting Members and indirect participants fully with a high degree of confidence, as required for a covered clearing agency such as FICC.
                    <SU>92</SU>
                    <FTREF/>
                     As defined in the Covered Clearing Agency Standards, backtesting is an ex-post comparison of actual outcomes with expected outcomes derived from the use of margin models,
                    <SU>93</SU>
                    <FTREF/>
                     and it is a key analytical mechanism for a CCP to consider the effectiveness of its margin model. FICC's ability to adjust the minimum margin amount would apply only where it would be appropriate and consistent with achieving its backtesting coverage target. This ability would, therefore, be limited to circumstances where its backtesting coverage target requirements are not being met or the amount of margin being collected exceeds the amount needed to cover the indirect participant's exposure to FICC.
                </P>
                <FTNT>
                    <P>
                        <SU>92</SU>
                         17 CFR 240.17ad-22(e)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>93</SU>
                         17 CFR 240.17ad-22(a).
                    </P>
                </FTNT>
                <P>
                    Based on FICC's representations, the Commission understands that FICC generally intends to use this ability to adjust the minimum margin requirement below $1 million if a lower minimum would suffice to reduce backtesting deficiencies comparably to the $1 million.
                    <SU>94</SU>
                    <FTREF/>
                     As part of its ongoing supervision of FICC, the Commission will continue to monitor the performance of the $1 million minimum margin requirement, including as its performance compares to backtesting, and will engage with FICC regarding any changes to that requirement and the supporting analysis for such changes, to help ensure that FICC is appropriately exercising that discretion consistent with the requirements imposed upon it by the rule (
                    <E T="03">i.e.,</E>
                     that it determines that any such adjustments would be appropriate and consistent with achieving its backtesting coverage target).
                    <SU>95</SU>
                    <FTREF/>
                     For example, not meeting backtesting coverage requirements would be an indication that the minimum margin amount is insufficient to cover FICC's credit exposure to its Netting Members and indirect participants, whereas, on the contrary, higher backtesting performance could indicate that the margin collected exceeds the exposure to FICC.
                </P>
                <FTNT>
                    <P>
                        <SU>94</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 3, 30-31.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>95</SU>
                         In addition, the requirements applicable to FICC as a self-regulatory organization under Section 19(b) of the Exchange Act and as a designated financial market utility under Title VIII of the Payment, Clearing, and Supervision Act (12 U.S.C. 5465(e)) would continue to apply. Thus, for example, if FICC were to amend the $1 million minimum margin requirement to an amount that would materially alter the level or nature of risk presented, FICC would be obligated to submit an advance notice of such change with the Commission.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">3. Margin Component Schedule</HD>
                <P>
                    The proposed changes in section I.B.3 regarding the calculation of margin for segregated and non-segregated accounts should help ensure that FICC collects margin sufficient to cover its exposures with respect to both direct and indirect participants. Requiring that the margin requirement for a Segregated Indirect Participant Account be calculated in generally the same manner as a Netting Member's requirement, which the Commission generally has reviewed and approved as part of FICC's rules,
                    <FTREF/>
                    <SU>96</SU>
                      
                    <PRTPAGE P="93743"/>
                    should help ensure that FICC collects margin sufficient to cover its exposures with respect to both direct and indirect participants, as discussed further in Sections II.B.3 and II.C.2 below, which is consistent with promoting robust risk management. In addition, by doing so, these proposed changes should help ensure that, in the event of such a default, FICC's operation of its critical clearance and settlement services would not be disrupted because of insufficient financial resources, which is consistent with safety and soundness at FICC. For the same reasons, these proposed changes should also help ensure that FICC is able to continue to meet its obligation in the event of a default, without accessing non-defaulting Netting Members' or indirect participants' margin deposits, which is consistent with reducing systemic risks and supporting the stability of the broader financial system.
                </P>
                <FTNT>
                    <P>
                        <SU>96</SU>
                         
                        <E T="03">See, e.g.,</E>
                         Self-Regulatory Organizations; Fixed Income Clearing Corporation; Notice of Filing of Amendment No. 1 and Order Granting Accelerated Approval of a Proposed Rule Change, as Modified by Amendment No. 1, To Implement Changes to the Required Fund Deposit Calculation in the Government Securities Division Rulebook, Exchange Act Release No. 83362 (June 1, 2018), 83 FR 26514 (June 7, 2018) (approving changes to how 
                        <PRTPAGE/>
                        FICC calculates the Value at Risk component of its margin methodology, addition of the new “Blackout Period Exposure adjustment” component to the margin methodology, eliminating certain existing components, and revising additional components).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">4. Allocation of Net Unsettled Positions</HD>
                <P>The proposed changes described in Section I.B.3.b. to adopt a method for allocating net unsettled positions to individual indirect participants for calculating margin requirements should reduce the potential exposure to FICC arising from indirect participant transactions that fail to settle by ensuring that FICC has a mechanism to collect margin for such transactions. Further, these proposed changes should make clear that such obligations are allocated only to participants that are outside the Sponsored GC service, since such fails to deliver do not occur in that service. By accounting for risks arising from net unsettled positions, the proposed changes are consistent with promoting robust risk management.</P>
                <HD SOURCE="HD3">5. Calculation of Excess Capital Premium</HD>
                <P>The proposed changes to the calculation of the ECP described in Section I.B.3.c. above are consistent with promoting robust risk management, because the changes should help ensure that FICC continues to collect margin sufficient to address the heightened default risk presented by a Netting Member operating with lower capital levels relative to its margin requirements. Based on its review of the Advance Notice, including the detailed impact analysis submitted as a confidential exhibit, FICC's margin coverage would not be impacted by this change and FICC would continue to collect sufficient margin to manage its potential exposure to its Netting Members.</P>
                <P>
                    In addition, the proposed changes to the calculation of the ECP should result in a simplified and more straight-forward method for calculating the ECP, based on understandable metrics with which FICC's Netting Members are familiar. Using a clearly defined source for determining Netting Member Capital in the calculation of the ECP would result in a more consistent calculation across different types of Netting Members. Moreover, capping the Excess Capital Ratio at 2.0 would provide transparency to Netting Members so they can understand how the ECP will be calculated, and it also would align FICC's cap with the recently approved changes to the ECP calculation at NSCC.
                    <SU>97</SU>
                    <FTREF/>
                     By improving the consistency and predictability of the ECP, the proposed enhancements would also improve FICC's ability to collect margin amounts that reflect the risks posed by its Netting Members such that, in the event of Netting Member default, FICC's operations would not be disrupted, and non-defaulting Netting Members and indirect participants would not be exposed to losses they cannot anticipate or control. In this way, this portion of the Advance Notice is consistent with promoting safety and soundness, as well as reducing systemic risks and supporting the stability of the broader financial system.
                </P>
                <FTNT>
                    <P>
                        <SU>97</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 96786 (Feb. 1, 2023), 88 FR 8013 (Feb. 7, 2023) (SR-NSCC-2022-005); 
                        <E T="03">see also id.</E>
                         (discussing the view that capping the ratio at 2.0 strikes an appropriate balance between addressing the heightened default risk without imposing overly burdensome Excess Capital Premium charges).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">6. Modification of Terms for Brokered Transactions</HD>
                <P>The proposed changes described in Section I.B.4. to revise the definition of Brokered Transactions to include only the side of the transactions submitted to FICC for novation by an Inter-Dealer Broker Netting Member and entered into on the Inter-Dealer Broker Netting Member's own trading platform should enhance FICC's risk management by providing favorable loss allocation treatment only to transactions that present limited risk to FICC. As a result, these changes should help ensure that FICC has sufficient prefunded financial resources to continue meeting its obligations in the event of a default, which is consistent with promoting safety and soundness at FICC, as well as reducing systemic risk and supporting the stability of the broader financial system.</P>
                <HD SOURCE="HD2">
                    A. 
                    <E T="03">Consistency With Rule 17ad-22(e)(4)(i)</E>
                </HD>
                <P>
                    Rule 17ad-22(e)(4)(i) requires that FICC establish, implement, maintain and enforce written policies and procedures reasonably designed to effectively identify, measure, monitor, and manage its credit exposures to participants and those arising from its payment, clearing, and settlement processes, including by maintaining sufficient financial resources to cover its credit exposure to each participant fully with a high degree of confidence.
                    <SU>98</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>98</SU>
                         17 CFR 240.17ad-22(e)(4)(i).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">1. Separate Calculation and Collection of Margin for Proprietary and Customer Accounts</HD>
                <P>
                    The proposed changes to require the separate and independent calculation and collection of margin for Netting Members' proprietary transactions and indirect participants' transactions, as described in Section I.B.1., are consistent with Rule 17ad-22(e)(4)(i).
                    <SU>99</SU>
                    <FTREF/>
                     The separate calculation and collection of margin from Netting Members and indirect participants should allow FICC to better identify and measure the unique risk profile of each participant, enhancing FICC's ability to calculate and collect the appropriate margin from each direct and indirect participant. As a result, the proposed changes should help ensure that FICC has sufficient margin to cover potential losses from a Netting Member or indirect participant default, thereby reducing the probability that FICC, non-defaulting Netting Members, or non-defaulting indirect participants would incur losses resulting from a default.
                </P>
                <FTNT>
                    <P>
                        <SU>99</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. $1 Million Minimum Cash Margin Requirement</HD>
                <P>
                    The proposed minimum $1 million cash margin requirement for each Segregated Indirect Participant Account, as described in Section I.B.2.a, is consistent with Rule 17ad-22(e)(4)(i). Several commenters state that FICC lacks a sufficient basis or justification for the required $1 million minimum margin amount.
                    <SU>100</SU>
                    <FTREF/>
                     Specifically, one commenter stated that using the amount applicable to Netting Members is not an appropriate basis for establishing a minimum for indirect participants, and also stated that the requirement lacks any support or analysis as to the level of margin attributable to a typical fund's positions in cleared Treasury repo, which is data FICC should have readily 
                    <PRTPAGE P="93744"/>
                    available.
                    <SU>101</SU>
                    <FTREF/>
                     An additional commenter stated the requirement seems arbitrary, and not practical or necessary, especially in the current done-with model, to force every segregated customer to be subject to the same minimum requirement as a Netting Member.
                    <SU>102</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>100</SU>
                         
                        <E T="03">See</E>
                         ISDA Letter I at 4; ICI Letter at 12; AIMA Letter at 6-7; MFA Letter II at 6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>101</SU>
                         ICI Letter at 12.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>102</SU>
                         AIMA Letter at 6. 
                        <E T="03">See also</E>
                         MFA Letter II at 7.
                    </P>
                </FTNT>
                <P>
                    In addition, commenters state that FICC should adopt a lower minimum requirement ($100,000 to $250,000), a dynamic minimum based on average exposure subject to a $250,000 cap, or a minimum set by the relevant Netting Member.
                    <SU>103</SU>
                    <FTREF/>
                     Commenters also state that FICC should determine a minimum deposit based on the individual client and the risk that such client presents to FICC and other market participants.
                    <SU>104</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>103</SU>
                         AIMA Letter at 7; MFA Letter I at 7; SIFMA AMG Letter at 9.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>104</SU>
                         ISDA I at 4; 
                        <E T="03">see also</E>
                         MFA Letter II at 7 (stating that the requirement should be determined based on a participant's particular risk profile, including its planned and historical clearing activity).
                    </P>
                </FTNT>
                <P>
                    In response, FICC states that the $1 million floor for Segregated Indirect Participants is the same floor FICC already has in place for its Netting Members.
                    <SU>105</SU>
                    <FTREF/>
                     FICC states that its impact study, conducted in 2022 when adopting the rule applicable to Netting Members, demonstrated that a $1 million floor would protect FICC and its participants from incurring a loss in the event of a Netting Member failure because the study indicated that a $1 million floor would provide an adequate buffer for additional repo activity due to increases in repo interest rates and would have mitigated 65 out of 396 backtesting deficiencies (16%) during the period from July 1, 2021 to June 30, 2022.
                    <SU>106</SU>
                    <FTREF/>
                     FICC further states that it analyzed alternative minimum margin amounts, such as $500,000, and, based on the results of its analysis, the $1 million floor provided the appropriate balance of improving backtesting performance and margin coverage while minimizing the impact on Netting Members.
                    <SU>107</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>105</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 28; Securities Exchange Act Release No. 96136 (Oct. 24, 2022), 87 FR 65268 (Oct. 28, 2022) (SR-FICC-2022-006) (“FICC-2022-006 Order”). The impact study contains an analysis of backtesting results on a member-by-member basis over a twelve-month period ending June 30, 2022, and it includes, for both the then-current rule and the proposed $1 million minimum rule, the number of backtesting deficiencies and the level of coverage obtained. It contains the same analysis for a $500,000 minimum as well, including the same data points on a member-by-member basis.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>106</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 28.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>107</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    FICC also states that the backtesting data from the period after the $1 million minimum floor was implemented indicated a “material reduction of backtesting deficiencies at FICC.” 
                    <SU>108</SU>
                    <FTREF/>
                     From December 5, 2022 to June 30, 2024, FICC states that the $1 million floor eliminated 24 backtesting deficiencies, a 12% reduction.
                    <SU>109</SU>
                    <FTREF/>
                     Further, during a period of 12-month period of moderate market volatility from July 1, 2023 to June 30, 2024, FICC states that the $1 million floor eliminated 15 backtesting deficiencies, a 22% reduction.
                    <SU>110</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>108</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 29.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>109</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>110</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    FICC further states that the $1 million floor is appropriate because the Segregated Customer Margin posted by each individual Segregated Indirect Participant needs to be sufficient on its own to address losses arising from the Segregated Indirect Participant's positions.
                    <SU>111</SU>
                    <FTREF/>
                     This is because Segregated Customer Margin is not subject to loss mutualization under the proposal, so FICC can only use Segregated Customer Margin posted by an individual Segregated Indirect Participant to satisfy that customer's obligations. As a result, each Segregated Indirect Participant's portfolio would present a risk to FICC that is equivalent to the risk of a proprietary portfolio of an individual Netting Member.
                    <SU>112</SU>
                    <FTREF/>
                     If the Segregated Customer Margin is insufficient, losses would need to be mutualized, with harm to FICC, its non-defaulting Netting Members, and, potentially, the market as a whole.
                    <SU>113</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>111</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>112</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>113</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    In addition, FICC stated that the risk cited by the Commission of inconsistent activity giving rise to dramatic changes in risk exposure, discussed by the Commission in the FICC-2022-006 Order,
                    <SU>114</SU>
                    <FTREF/>
                     is arguably more pronounced for indirect participants than for Netting Members.
                    <SU>115</SU>
                    <FTREF/>
                     First, indirect participants may clear through multiple Netting Members and shift their activity through different Netting Members, which can present risks to FICC since FICC cannot use the Segregated Customer Margin posted by the Segregated Indirect Participant through one Netting Member to address the Segregated Indirect Participant's transactions cleared by another Netting Member.
                    <SU>116</SU>
                    <FTREF/>
                     As a result, FICC states that, even if the Segregated Indirect Participant's overall activity remains steady, FICC could see dramatic shifts in its risk simply because the Segregated Indirect Participant shifts the Netting Members it uses as its intermediary at FICC.
                    <SU>117</SU>
                    <FTREF/>
                     Second, FICC states that it does not have the same general understanding of indirect participants' business that it has for its Netting Members, since it does not collect the same information on individual customers' business or finances that it does for its Netting Members.
                    <SU>118</SU>
                    <FTREF/>
                     As a result, FICC states that it is less likely to know when there may be significant swings in indirect participant risk exposures as it would for its Netting Members and, since indirect participants are likely to have a far more diverse array of business models and interest rate considerations than FICC's Netting Members, they could engage in inconsistent activity that could increase risk exposure to FICC.
                    <SU>119</SU>
                    <FTREF/>
                     According to FICC, the possibility of inconsistent activity among indirect participants is potentially greater.
                    <SU>120</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>114</SU>
                         FICC-2022-006 Order, 
                        <E T="03">supra</E>
                         note 105, at 65270.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>115</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 30.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>116</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>117</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>118</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>119</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>120</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>The Commission disagrees with commenters who stated that using the same minimum as Netting Members is not appropriate for Segregated Indirect Participants. As stated in Section I.A. above, FICC and non-defaulting Netting Members and indirect participants may be subject to losses should the Segregated Customer Margin of an indirect participant be insufficient to satisfy losses caused by the liquidation of that indirect participant's portfolio. This potential exposure both to FICC and non-defaulting Netting Members and indirect participants makes it essential that FICC determine margin amounts for Segregated Indirect Participant Accounts that are reasonably designed to ensure that FICC has sufficient margin to cover the losses of a defaulting Segregated Indirect Participant.</P>
                <P>
                    The analyses conducted by FICC both in connection with the 2022 change to the required minimum margin amount for Netting Members and after the implementation of that requirement, which the Commission has reviewed and analyzed, support the use of the $1 million margin requirement for Segregated Indirect Participant Accounts. The Commission agrees that these studies demonstrate that a $1 million margin floor has a material impact on reducing the number of backtesting deficiencies experienced by FICC's Netting Members, which would likely help FICC better manage its credit exposure to its Netting Members and indirect participants and credit 
                    <PRTPAGE P="93745"/>
                    exposures arising from its payment, clearing, and settlement processes.
                </P>
                <P>
                    Consideration of the appropriate Netting Member minimum is directly relevant to what is appropriate for Segregated Indirect Participant Accounts because FICC would treat such accounts the same as Netting Member accounts in the event of a default of that individual customer.
                    <SU>121</SU>
                    <FTREF/>
                     Even though a Segregated Indirect Participant would be the customer of a Sponsoring Member or an Agent Clearing Member, each Segregated Indirect Participant Account would need to provide sufficient margin to independently cover its losses in the event of a default. FICC will determine the appropriate margin for each Segregated Indirect Participant Account as if it were a separate Netting Member. As discussed above, indirect participants may increase risk by clearing through different Netting Members, which would provide FICC with less insight into their overall portfolio. Accordingly, it is appropriate for the minimum amount to be the same for both Netting Members and indirect participants.
                </P>
                <FTNT>
                    <P>
                        <SU>121</SU>
                         This also makes the 2022 impact study relevant to this determination because FICC would calculate margin requirements for each Segregated Indirect Participant in the same manner as margin requirements for each Netting Member. The Commission reviewed and analyzed that impact study when approving the current minimum applicable to Netting Members, and the same analysis should apply here as well.
                    </P>
                </FTNT>
                <P>
                    In response to commenters who proposed an alternative amount or approach, the Commission also has reviewed and analyzed the analysis of alternative minimum amounts that FICC conducted, which show that there would still be potential for higher amounts of backtesting deficiencies using a $500,000 alternative minimum, making the alternatives proposed by commenters ($100,000, $250,000 or a dynamic minimum with a $250,000 cap) not reasonably designed to allow FICC to collect sufficient margin to cover its exposures. As discussed above, FICC's backtesting data from December 5, 2022 to June 30, 2024 indicates that increasing the minimum margin amount from $100,000 to $1 million eliminated 24 Netting Member backtesting deficiencies, a 12% reduction.
                    <SU>122</SU>
                    <FTREF/>
                     Further, during a 12-month period of moderate market volatility from July 1, 2023 to June 30, 2024, the $1 million floor eliminated 15 backtesting deficiencies, a 22% reduction.
                    <SU>123</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>122</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 29.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>123</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    Because FICC is not able to predict how many indirect participants may elect to submit activity to FICC through a Segregated Indirect Participants Account or the size or volume of that activity, margin requirements for each Segregated Indirect Participant would be calculated in the same manner as for Netting Members.
                    <SU>124</SU>
                    <FTREF/>
                     FICC's impact studies of Netting Members provide a reasonable approximation of the risks FICC may face if the minimum margin amount is set below $1 million. Therefore, the proposed $1 million floor is appropriate to increase the probability that the margin amount collected by FICC is sufficient to cover FICC's credit exposure to Segregated Indirect Participants and protect non-defaulting parties from experiencing losses. However, as described above in Section I.B.2.a., if FICC determines that a different minimum charge would be appropriate and consistent with achieving its backtesting coverage target, FICC would have the ability to adjust the minimum charge of $1 million margin requirement. This added flexibility should allow FICC to continue to collect the appropriate amount of margin to cover its credit exposure to each participant fully with a high degree of confidence, as demonstrated by FICC's meeting its backtesting coverage targets, while minimizing the burden on indirect participants.
                </P>
                <FTNT>
                    <P>
                        <SU>124</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 89 FR 21595.
                    </P>
                </FTNT>
                <P>Moreover, the Commission disagrees that allowing the Netting Member to determine a minimum would be appropriate. It is unclear what basis a Netting Member would use to determine such a minimum in a way that would ensure that the amount is sufficient to meet FICC's regulatory obligations and minimize backtesting deficiencies because a Netting Member would not be able to replicate FICC's backtesting or calculate FICC's regulatory obligations.</P>
                <P>
                    The Commission disagrees that determining a minimum deposit on a case-by-case basis would be feasible for every Segregated Indirect Participant. FICC has stated that it does not know how many Segregated Indirect Participants will participate in FICC. At this time, there are over 2500 Sponsored Members at FICC,
                    <SU>125</SU>
                    <FTREF/>
                     and it is likely that additional indirect participants will want to access clearing going forward in light of the Treasury Clearing rules. Determining a minimum for even half the current Sponsored Members on a case-by-case basis would be extremely burdensome for FICC and would require the submission of detailed financial information by each Sponsored Member to inform FICC of its planned business activities, and it is unclear how or on what basis such a minimum would be adjusted over time. Establishment of a minimum requirement is appropriate to ensure that FICC can meet its obligations under Rule 17ad-22(e)(4)(i), and reliance upon the minimum for Netting Members is appropriate because, as discussed above, FICC has to treat each Segregated Indirect Participant as a stand-alone account for risk management purposes to segregate its margin appropriately.
                </P>
                <FTNT>
                    <P>
                        <SU>125</SU>
                         
                        <E T="03">See</E>
                         GSD Member Directories, 
                        <E T="03">available at https://www.dtcc.com/client-center/ficc-gov-directories.</E>
                    </P>
                </FTNT>
                <P>
                    For these reasons, the $1 million minimum margin requirement should help ensure that FICC has sufficient margin to cover potential losses from a Segregated Indirect Participant default, thereby reducing the probability that FICC, non-defaulting Netting Members, and non-defaulting indirect participants would incur losses resulting from a default. Moreover, as described above in Section I.B.2.a., FICC would have the ability to adjust the amount of the minimum $1 million margin requirement if FICC determines that a different minimum charge would be appropriate and consistent with achieving its backtesting coverage target. The Commission agrees with FICC that it should continue to assess the performance of this minimum requirement with respect to FICC's backtesting coverage requirements, as it provided in the Amendment to this filing, to ensure that FICC is not collecting more margin than is necessary to meet its regulatory obligations to cover its exposure to its participants.
                    <SU>126</SU>
                    <FTREF/>
                     Although the Commission recognizes that FICC could use this ability to increase the $1 million minimum to some greater amount, it would only be able to do so if determines that a different minimum charge would be appropriate and consistent with achieving its backtesting coverage target.
                </P>
                <FTNT>
                    <P>
                        <SU>126</SU>
                         One commenter states that FICC should not delay recalibration of the minimum margin requirement to a later date. MFA Letter II at 6-7. However, as the Commission discussed above, the minimum margin requirement is appropriate, based on the data available at this time. The Commission will continue to monitor implementation of this requirement going forward once more data regarding the use of segregated accounts is available.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">3. Margin Component Schedule</HD>
                <P>
                    The proposed changes in section I.B.3 regarding the calculation of margin for segregated and non-segregated accounts should ensure that FICC collects margin sufficient to cover its exposures with respect to both direct and indirect participants. Requiring that the margin 
                    <PRTPAGE P="93746"/>
                    requirement for a Segregated Indirect Participant Account be calculated in generally the same manner as a Netting Member's requirement, which the Commission has reviewed and approved as part of FICC's rules, should help ensure that FICC collects margin sufficient to cover its exposures with respect to both direct and indirect participants. By doing so, this portion of the Advance Notice should better ensure that, in the event of a Netting Member's or indirect participant's default, FICC has sufficient margin to cover potential losses from the default, thereby reducing the probability that FICC, non-defaulting Netting Members, and non-defaulting indirect participants would incur losses resulting from a default. Collecting the same margin components for a Segregated Indirect Participant Account as those used for a Netting Member Account is appropriate because FICC has to risk-manage each Segregated Indirect Participant Account individually, and application of the existing margin methodology would help ensure that FICC collects sufficient margin to cover its exposures to participants for all Accounts. FICC has, however, taken into account how the ECP should apply differently when determining a Segregated Customer Margin Requirement, which is appropriate for the reasons discussed in Section II.C.3 below, and the changes related to the ECP Charge would ensure that Segregated Indirect Participants are not required to post additional margin to account for the capital position of its Netting Member.
                </P>
                <P>
                    Accordingly, for the reasons discussed above, the Advance Notice is reasonably designed to enable FICC to effectively identify, measure, monitor, and manage its credit exposure to Netting Members and indirect participants, consistent with Rule 17ad-22(e)(4)(i).
                    <SU>127</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>127</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Consistency With Rule 17ad-22(e)(6)(i)</HD>
                <P>
                    Rule 17ad-22(e)(6)(i) requires FICC to establish, implement, maintain and enforce written policies and procedures reasonably designed to cover its credit exposures to its participants by establishing a risk-based margin system that, at a minimum, considers, and produces margin levels commensurate with, the risks and particular attributes of each relevant product, portfolio, and market, and, if the covered clearing agency provides central counterparty services for U.S. Treasury securities, calculates, collects, and holds margin amounts from a direct participant for its proprietary positions in Treasury securities separately and independently from margin calculated and collected from that direct participant in connection with U.S. Treasury securities transactions by an indirect participant that relies on the services provided by the direct participant to access the covered clearing agency's payment, clearing, or settlement facilities.
                    <SU>128</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>128</SU>
                         17 CFR 240.17ad-22(e)(6)(i).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">1. Separation of Proprietary and Customer Margin</HD>
                <P>
                    The proposed changes to separate proprietary and customer margin are consistent with Rule 17ad-22(e)(6)(i). First, to help ensure that proprietary transactions and transactions submitted to FICC on behalf of indirect participants are margined separately, FICC would require that each margin portfolio contain only transactions from the same account type and that Netting Members use separate Deposit IDs for different transaction types. Second, FICC would calculate each Segregated Indirect Participant's margin requirement separately on a gross basis as though each Segregated Indirect Participant were a separate Netting Member. Finally, FICC would create a separate “Segregated Customer Margin Custody Account” for each Netting Member that contains deposits of Segregated Customer Margin for indirect participants, with interest earned on cash margin paid to each Segregated Indirect Participant's Netting Member for the benefit of, and as an agent for, the Segregated Indirect Participant. Collectively, these proposed changes should ensure that a Netting Member's proprietary transactions are not netted with indirect participant transactions for margin calculations and that margin for indirect participant transactions is collected and held separately and independently from margin for a Netting Member's proprietary transactions. Moreover, by calculating each Segregated Indirect Participant's margin requirement separately from Netting Members and other Segregated Indirect Participants, the proposed changes should allow FICC to better isolate the risk profiles of individual indirect participants from Netting Members, which should help FICC better understand and monitor each individual participant's risk exposures.
                    <SU>129</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>129</SU>
                         Commenters requested clarification that FICC's funds-only settlement amounts are settlement payments rather than margin. 
                        <E T="03">See</E>
                         ISDA Letter at 6; Letter from Katherine Darras, General Counsel, International Swaps and Derivatives Association (July 18, 2024) (“ISDA Letter II”) at 6; SIFMA Letter at 4; Letter from Walt L. Lukken, President and Chief Executive Officer, Futures Industry of America (Apr. 18, 2024) (“FIA Letter”) at 11. The Advance Notice does not make any amendments to the funds-only settlement process at FICC. 
                        <E T="03">See</E>
                         GSD Rule 13. This aspect of FICC's rules is, therefore, not relevant to this Advance Notice. However, FICC clarified that it views such payments as constituting settlements that discharge outstanding payment obligations, rather than as margin or collateral. FICC Letter at 43. The Commission agrees with this clarification, based upon its knowledge of FICC's margin and payment flows and the applicable GSD Rules.
                    </P>
                </FTNT>
                <P>
                    One commenter expressed concern that the proposal would not fully eliminate fellow customer risk because it would allow for the 
                    <E T="03">pro rata</E>
                     allocation of Current Net Settlement positions among Segregated Indirect Participant positions held in the same Segregated Indirect Participants Account.
                    <SU>130</SU>
                    <FTREF/>
                     In response, FICC explained that, due to the requirement in the Treasury Clearing Rules that margin for customer positions be calculated separately from margin for a Netting Member's proprietary positions, FICC would not be able to allocate the margin obligations from Current Net Settlement Positions to a Netting Member's portfolio.
                    <SU>131</SU>
                    <FTREF/>
                     As a result, such margin must be allocated to customer positions and FICC states that, when it is not aware of the allocation of Current Net Settlement Positions among customers, it is most equitable to allocate such positions 
                    <E T="03">pro rata</E>
                     to customers who were long or short the relevant securities.
                    <SU>132</SU>
                    <FTREF/>
                     The Commission agrees that allocating the positions to the Netting Member's account would be inconsistent with Rule 17ad-22(e)(6)(i) because it would impermissibly net proprietary transactions against indirect participant transactions. The Commission further agrees that the positions must be allocated to ensure that FICC is able to appropriately risk-manage those positions (that is, to collect appropriate margin). The Commission further agrees with FICC's approach of limiting such 
                    <E T="03">pro rata</E>
                     allocations only to customers engaging in non-Sponsored GC Trades because settlement failures do not occur with respect to Sponsored GC Trades. Therefore, in the event that the positions are not allocated, a 
                    <E T="03">pro rata</E>
                     allocation among customers is appropriate.
                </P>
                <FTNT>
                    <P>
                        <SU>130</SU>
                         
                        <E T="03">See</E>
                         SIFMA AMG Letter at 10.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>131</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 36.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>132</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    Accordingly, the proposed changes in the Advance Notice would be consistent with Rule 17ad-22(e)(6)(i) because they should help ensure that FICC calculates, collects, and holds margin for a Netting Member's proprietary positions 
                    <PRTPAGE P="93747"/>
                    separately from the margin for positions the member clears for customers.
                    <SU>133</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>133</SU>
                         17 CFR 240.17ad-22(e)(6)(i).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">5. Margin Component Schedule</HD>
                <P>The proposed changes to establish a Margin Component Schedule, which would consolidate the terms and information relating to margin calculation throughout the Rules into a single schedule, are consistent with Rule 17ad-22(e)(6)(i). Under the proposed Margin Component Schedule, FICC would perform substantially the same calculation it currently performs when determining a Netting Member's Required Fund Deposit and include the methodology for calculating a Netting Member's Segregated Customer Margin Requirement. By including a methodology to calculate each Segregated Indirect Participant's margin requirement separately from Netting Members and other Segregated Indirect Participants, the proposed changes should help ensure that FICC calculates, collects, and holds margin for a Netting Member's proprietary positions separately from the margin for positions the member clears for customers. Moreover, calculating margin requirements for each Segregated Indirect Participant should allow FICC to better isolate the risk profiles of individual indirect participants from Netting Members, which should help FICC better understand and monitor each individual participant's risk exposures and thereby collect margin commensurate with the risks of each Netting Member and indirect participant portfolio.</P>
                <P>
                    A commenter states that FICC should confirm that segregation of margin for indirect participants does not magnify risk for Netting Members. Specifically, the commenter states that it is not clear whether the Required Fund Deposit to be posted by Netting Members incorporates any exposure associated with Segregated Indirect Participant Accounts and expresses concern as to whether FICC's rules allow FICC to collect additional margin to cover any enhanced risk that may arise relating to the Netting Member's obligations to FICC for its clients who are indirect participants generally or who choose segregation specifically.
                    <SU>134</SU>
                    <FTREF/>
                     However, FICC's proposed rules establish that the calculation of a Netting Member's Required Fund Deposit excludes the exposure of its Segregated Indirect Participants.
                    <SU>135</SU>
                    <FTREF/>
                     FICC's rules do permit FICC to collect increased Required Fund Deposits from Netting Members if “necessary to protect [FICC] and its Members from Legal Risk,” which, FICC states, would include the consideration of the Netting Members' indirect participants.
                    <SU>136</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>134</SU>
                         ISDA Letter I at 7; ISDA Letter II at 6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>135</SU>
                         
                        <E T="03">Compare</E>
                         proposed Margin Component Schedule section 2 (regarding Required Fund Deposits) 
                        <E T="03">with</E>
                         section 3 (regarding Segregated Customer Margin).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>136</SU>
                         
                        <E T="03">See</E>
                         proposed Margin Component Schedule section 4; 
                        <E T="03">see also</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21593.
                    </P>
                </FTNT>
                <P>
                    This commenter also states the fact that the ability to prefund margin for a customer is only temporary puts pressure on the Netting Member's own Required Fund Deposits, which “it seems would still cover the obligations of all its clients” and also on the Netting Member and the broader FICC membership, in the event of a failure by any Segregated Indirect Participant.
                    <SU>137</SU>
                    <FTREF/>
                     However, the Netting Member's Required Fund Deposits would not be calculated based on the obligations of its clients, and, in the event of the default of an indirect participant, FICC would use the Segregated Customer Margin for only that indirect participant. Therefore, the Commission disagrees that the inability to permanently prefund the customer's margin requirement puts additional pressure on the Netting Member's own Required Fund Deposits.
                </P>
                <FTNT>
                    <P>
                        <SU>137</SU>
                         
                        <E T="03">See</E>
                         ISDA Letter I at 7.
                    </P>
                </FTNT>
                <P>
                    Another commenter states that FICC should explain why it is appropriate to calculate a segregated customer's margin requirement as if it were a Netting Member, even though the margin calculation for FICC Netting Members covers both initial margin and guaranty fund contributions (and customers are not expected to be contributing to the guaranty fund).
                    <SU>138</SU>
                    <FTREF/>
                     However, FICC does not maintain a separate guaranty fund into which a Netting Member contributes for its customers. The Segregated Customer Margin Requirement must be sufficient to cover the exposures to FICC arising from that particular customer's activity because, under the segregation system proposed by the Advance Notice which would allow broker-dealers participating in FICC to comply with the conditions of Note H to Rule 15c3-3, FICC would not be able to use the margin collected from a Segregated Indirect Participant for any reason unrelated to the Segregated Indirect Participant. Therefore, calculating each Segregated Customer Margin Requirement in this manner is appropriate to ensure that FICC has appropriate resources to cover each customer's exposures. Therefore, this aspect of the Advance Notice is consistent with Rule 17ad-22(e)(6)(i) under the Exchange Act.
                </P>
                <FTNT>
                    <P>
                        <SU>138</SU>
                         
                        <E T="03">See</E>
                         Letter from Joanna Mallers, Secretary, Futures Industry of America, Principal Traders Group (Apr. 17, 2024) (“FIA PTG Letter I”) at 8.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">6. Excess Capital Premium</HD>
                <P>The proposed changes to the calculation of the ECP charge are consistent with Rule 17ad-22(e)(6)(i). FICC's margin deposits are made up of risk-based components (as margin) that are calculated and assessed daily to limit FICC's exposures to Netting Members. FICC's proposed changes to use clearly defined sources in the calculation of the ECP charge would collectively make the calculation clearer and more predictable to Netting Members, while continuing to apply an appropriate risk-based charge designed to mitigate the risks presented to FICC. Similarly, the proposal to cap the Excess Capital Ratio at 2.0 would allow FICC to appropriately address the risks it faces without imposing an overly burdensome ECP and would reduce the circumstances in which FICC may waive the charge, resulting in a more transparent margining methodology. Finally, the proposed rule change would clarify the exigent circumstances under which FICC may determine that it is appropriate to waive the ECP charge. Overall, these proposed changes would improve the effectiveness of the calculation of the ECP and, therefore, allow FICC to more effectively address the increased default risks presented by Netting Members that operate with lower capital levels relative to their margin requirements.</P>
                <P>In addition, FICC proposes to exclude VaR Charges for Segregated Indirect Participants Accounts when determining a Netting Member's Excess Capital Differential, in order to take into account the fact that each indirect participant would be responsible for satisfying its own respective VaR Charge. Not including these Segregated Indirect Participants Accounts when determining the Excess Capital Differential, and, therefore, the ECP Charge, is consistent with the purpose of the Excess Premium Charge. This charge is designed to address the risk that a Netting Member with low capital relative to its value-at-risk to FICC is not able to perform its obligations. Because the Netting Member's capital is not used to meet the indirect participant's obligation to FICC, excluding the indirect participant VaR Charges from the determination of the ECP should result in FICC collecting margin commensurate with the risks and particular attributes of each relevant portfolio.</P>
                <P>
                    Taken together, the proposed changes enhance the ability of the ECP to produce margin levels commensurate 
                    <PRTPAGE P="93748"/>
                    with the risks FICC faces related to its Netting Members' operating capital levels. Therefore, this aspect of the Advance Notice is consistent with Rule 17ad-22(e)(6)(i) under the Exchange Act.
                </P>
                <HD SOURCE="HD2">C. Consistency With Rule 17ad-22(e)(6)(iii)</HD>
                <P>
                    Rule 17ad-22(e)(6)(iii) requires that FICC establish, implement, maintain and enforce written policies and procedures reasonably designed to cover its credit exposures to its participants by establishing a risk-based margin system that, at a minimum, calculates margin sufficient to cover its potential future exposure to members in the interval between the last margin collection and the close out of positions following a member default.
                    <SU>139</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>139</SU>
                         17 CFR 240.17ad-22(e)(6)(iii).
                    </P>
                </FTNT>
                <P>
                    As summarized in Section I.B.3 above, FICC employs daily backtesting to determine the adequacy of each Netting Member's Required Fund Deposit, paying particular attention to members that have backtesting deficiencies below the 99% confidence target. Such backtesting deficiencies highlight exposure that could subject FICC to potential losses if a Netting Member defaults. As discussed in Section II.C.2, FICC's impact study during the period from July 1, 2021 to June 30, 2022 demonstrated that a $1 million floor would have protected FICC and its participants by reducing the possibility of incurring a loss in the event of a Netting Member failure by mitigating 16% of backtesting deficiencies.
                    <SU>140</SU>
                    <FTREF/>
                     Moreover, after the $1 million floor was implemented for Netting Members, FICC states that it eliminated 22% of backtesting deficiencies during a 12-month period of moderate market volatility from July 1, 2023 to June 30, 2024.
                    <SU>141</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>140</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 28.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>141</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    Therefore, adding the proposed $1 million minimum requirement for Segregated Customer Margin, and the ability to adjust the minimum million margin requirement to achieve FICC's backtesting coverage target, should better ensure that FICC maintains sufficient margin to cover its potential future exposure to its indirect participants in the interval between the last margin collection and the close out of positions following an indirect participant default. This should, thereby, reduce the likelihood FICC or non-defaulting Netting Members or indirect participants would incur losses as a result. Accordingly, FICC's proposed $1 million minimum requirement for Segregated Customer Margin would be consistent with Rule 17ad-22(e)(6)(iii).
                    <SU>142</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>142</SU>
                         17 CFR 240.17ad-22(e)(6)(iii).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">D. Consistency With Rule 17ad-22(e)(18)(ii)</HD>
                <P>
                    Rule 17ad-22(e)(18)(ii) requires that FICC establish, implement, maintain and enforce written policies and procedures reasonably designed to establish objective, risk-based, and publicly disclosed criteria for participation, which require participants to have sufficient financial resources and robust operational capacity to meet obligations arising from participation in the clearing agency.
                    <SU>143</SU>
                    <FTREF/>
                     The proposed changes to consolidate FICC's margin methodology in a single location, identify the particular Required Fund Deposit Portions and Segregated Customer Margin Requirements, and clarify the calculation of the Excess Capital Premium and circumstances in which FICC would waive the application of such premium should enhance FICC's public disclosure of the risk-based margin obligations that Netting Members and their indirect participants would have as a result of their participation in FICC's clearance and settlement services. This improved public disclosure should allow Netting Members and their indirect participants to better understand how their activity would impact margin calculations, which are designed to ensure that participants have sufficient financial resources and robust operational capacity to meet obligations to FICC. Accordingly, the proposed changes would be consistent with Rule 17ad-22(e)(18)(ii).
                    <SU>144</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>143</SU>
                         17 CFR 240.17ad-22(e)(4)(18)(ii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>144</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD2">E. Consistency With Rule 17ad-22(e)(18)(iii)</HD>
                <P>
                    Rule 17ad-22(e)(18)(iii) requires that FICC establish, implement, maintain and enforce written policies and procedures reasonably designed to establish objective, risk-based, and publicly disclosed criteria for participation, which monitor compliance with its participant requirements on an ongoing basis.
                    <SU>145</SU>
                    <FTREF/>
                     The proposed changes would require Netting Members to designate the specific account type when submitting transactions and to identify any Sponsored Member or Executing Firm Customer for whom the transaction is submitted. These changes should enhance FICC's ability to monitor which transactions are being entered into by which entities and assess the specific risks associated with those entities. This enhanced monitoring of participant activity should allow FICC to better monitor participants' compliance with FICC's Rules. Accordingly, the proposed changes would be consistent with Rule 17ad-22(e)(18)(iii) because they should enhance FICC's ability to monitor compliance with its participant requirements on an ongoing basis.
                    <SU>146</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>145</SU>
                         17 CFR 240.17ad-22(e)(18)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>146</SU>
                         17 CFR 240.17ad-22(e)(18)(iii).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">F. Consistency With Rule 17ad-22(e)(18)(iv)(C)</HD>
                <P>
                    Rule 17ad-22(e)(18)(iv)(C) requires that FICC establish, implement, maintain and enforce written policies and procedures reasonably designed to ensure that it has appropriate means to facilitate access to clearance and settlement services of all eligible secondary market transactions in U.S. Treasury securities, including those of indirect participants.
                    <SU>147</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>147</SU>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <P>As discussed above in Section II.B.3, by improving the transparency of FICC's account offerings and margin calculation methodology, the proposed changes should enhance market participants' understanding of how margin is calculated and their options for posting margin, thereby facilitating access to FICC's clearance and settlement services. In addition, the proposed changes should offer greater optionality to Netting Members and indirect participants, which should allow Netting Members and indirect participants to adopt a margining arrangement that aligns with their business objectives and regulatory, operational, and practical constraints. By enhancing transparency of FICC's margin framework and account options and offering greater optionality to participants concerning the type of account they transact in and how their margin is posted, the proposal should facilitate access to FICC's clearance and settlement systems.</P>
                <P>
                    Several commenters proposed that FICC should require Netting Members to offer account segregation to customers.
                    <SU>148</SU>
                    <FTREF/>
                     One such commenter 
                    <PRTPAGE P="93749"/>
                    specified that this should include bank Netting Members, who would not face the same restrictions on the use of customer margin as broker-dealer customers subject to Rule 15c3-3 and therefore may not be as incentivized to provide segregated account services.
                    <SU>149</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>148</SU>
                         Specifically, one commenter stated that for indirect participants, having a “right” to direct their Netting Member to segregate their margin is highly desirable because it would allow an indirect participant to have certainty that margin that it posts receives the protection afforded by segregation. SIFMA AMG Letter at 6. Another such commenter stated that, despite what a customer may desire with respect to margin and segregation, there could be incentives for direct participants to finance the margin for their customers' transactions (and thereby earn extra fees for doing so) instead of the customer financing or posting that margin, 
                        <PRTPAGE/>
                        and for the direct participant to accept the customer's margin without offering the option of segregation (and thereby avoid the additional operational and other costs associated with segregation), which would still be permissible if FICC were not to require its Netting Members to offer account segregation. MFA Letter I at 4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>149</SU>
                         SIFMA AMG Letter at 6.
                    </P>
                </FTNT>
                <P>
                    FICC did not propose a requirement that its Netting Members offer segregated accounts to their customers. Therefore, the Commission is not addressing any changes related to such a requirement in this Advance Notice. Nothing in the Treasury Clearing Rules or Rule 15c3-3 requires a covered clearing agency, like FICC, to require its Netting Members to provide certain services. Moreover, certain Netting Members may have regulatory or other reasons not to offer segregation, and, if required to offer such services, may choose to cease providing customer clearing services, which could, in turn, increase concentration in the market and reduce liquidity.
                    <SU>150</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>150</SU>
                         FICC Letter at 33.
                    </P>
                </FTNT>
                <P>
                    Additionally, a commenter urged FICC to allow indirect participants to post margin directly to FICC without intermediation from a Netting Member.
                    <SU>151</SU>
                    <FTREF/>
                     The Treasury Clearing Rules do not require FICC to provide this function, and FICC did not propose such a method for direct posting of margin.
                    <SU>152</SU>
                    <FTREF/>
                     Accordingly, the Commission is not addressing any changes related to such a requirement in this Advance Notice.
                </P>
                <FTNT>
                    <P>
                        <SU>151</SU>
                         
                        <E T="03">See</E>
                         ICI Letter at 13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>152</SU>
                         
                        <E T="03">See supra</E>
                         note 3 at 2751.
                    </P>
                </FTNT>
                <P>
                    One commenter sought clarification whether Netting Members other than broker-dealers can elect segregation for their customers.
                    <SU>153</SU>
                    <FTREF/>
                     Based on the Advance Notice, the Commission understands, and FICC confirmed,
                    <SU>154</SU>
                    <FTREF/>
                     that any Sponsoring Member or Agent Clearing Member, regardless of whether registered as broker-dealers, would be able to designate an account as a Segregated Indirect Participants Account.
                </P>
                <FTNT>
                    <P>
                        <SU>153</SU>
                         FIA-PTG Letter at 7-9.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>154</SU>
                         FICC Letter at 39.
                    </P>
                </FTNT>
                <P>
                    The same commenter also sought clarification whether a customer may segregate margin obtained through a margin financing arrangement.
                    <SU>155</SU>
                    <FTREF/>
                     Based on the Advance Notice, the Commission understands, and FICC confirmed,
                    <SU>156</SU>
                    <FTREF/>
                     that such segregation would be permissible under FICC's rules.
                </P>
                <FTNT>
                    <P>
                        <SU>155</SU>
                         FIA-PTG Letter at 7-9.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>156</SU>
                         FICC Letter at 40.
                    </P>
                </FTNT>
                <P>
                    This commenter also asked why excess margin would only be returned on request and states that an indirect participant should not have to request a return of its excess margin.
                    <SU>157</SU>
                    <FTREF/>
                     The Treasury Clearing Rules do not require FICC to provide this function, and FICC did not propose such a function. Accordingly, the Commission is not addressing any changes related to such a requirement in this Advance Notice. Moreover, when it adopted the amendments to Rule 15c3-3, the Commission declined to adopt a requirement to “push” excess margin to direct participants.
                    <SU>158</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>157</SU>
                         
                        <E T="03">See</E>
                         FIA PTG Letter I at 7-9.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>158</SU>
                         
                        <E T="03">See</E>
                         Treasury Clearing Adopting Release, 
                        <E T="03">supra</E>
                         note 3, at 2767 (removing, in response to commenters, the requirement that the covered clearing agency have procedures to return customer position margin to the broker-dealer that is no longer needed to meet a current margin requirement resulting from positions in U.S. Treasury securities of the broker-dealer's customers no later than the close of the next business day after the day the customer position margin is no longer needed for this purpose because such a requirement may add significant operational burdens to covered clearing agencies for U.S. Treasury securities and because the debit is limited to margin required and on deposit at the covered clearing agency and therefore does not include the excess margin).
                    </P>
                </FTNT>
                <P>
                    Another commenter suggested that FICC allow customer margin to be segregated, even when customers do not post the full amount of the margin needed to cover their positions.
                    <SU>159</SU>
                    <FTREF/>
                     FICC states that allowing customer margin to be segregated when customers do not post the full amount of margin would lead to disparities that would put broker-dealer Netting Members at competitive disadvantage to other Netting Members.
                    <SU>160</SU>
                    <FTREF/>
                     The Treasury Clearing Rules do not require FICC to provide this function, and FICC did not propose such a function. Any changes to FICC's rules to impose such a requirement would have to be filed with the Commission pursuant to Section 19(b) 
                    <SU>161</SU>
                    <FTREF/>
                     of the Exchange Act, as well as, potentially, in an advance notice filed pursuant to Section 806(e) of the Clearing Supervision Act.
                    <SU>162</SU>
                    <FTREF/>
                     Therefore, the Commission is not addressing any changes related to such a requirement in this Advance Notice.
                </P>
                <FTNT>
                    <P>
                        <SU>159</SU>
                         
                        <E T="03">See</E>
                         MFA Letter I at 6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>160</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 32. Specifically, FICC stated that the Treasury Clearing Rules, in particular the amendments to Exchange Act Rule 15c3-3a, provide that a broker-dealer may record a debit in the customer and PAB reserve formulas for margin it collects from customers and on-posts to FICC, but only if the broker-dealer collects from the customer the full amount of margin required for the customer's positions. Accordingly, a broker-dealer is effectively precluded from collecting from customers only a portion of the margin that their positions require and on-posting that amount to FICC. Were FICC to allow segregation of customer margin even if the customer did not fully fund its margin obligations, such segregation would effectively allow non-broker-dealer Netting Members to offer what broker-dealers cannot, 
                        <E T="03">i.e.,</E>
                         permitting their customers to post a portion of the margin required by FICC and on-post that margin to FICC. This ability would place such Netting Members at a competitive advantage relative to broker-dealer Netting Members.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>161</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>162</SU>
                         
                        <E T="03">See supra</E>
                         note 3 at 2751.
                    </P>
                </FTNT>
                <P>
                    Finally, one commenter urged FICC to address the cross-border implications of the proposal and provide a framework for compliance by non-U.S. Netting Members and indirect participants.
                    <SU>163</SU>
                    <FTREF/>
                     Specifically, this commenter was concerned that the U.S. Treasury clearing mandate will adversely impact foreign customers that are limited in their ability, or prohibited entirely, to post margin in connection with transactions involving U.S. Treasury securities.
                    <SU>164</SU>
                    <FTREF/>
                     However, nothing in the Advance Notice would require a particular market participant to post margin in connection with transactions involving U.S. Treasury securities. Indirect participants remain able to access FICC's central clearing services through access models that do not require the direct posting of margin to FICC (
                    <E T="03">e.g.,</E>
                     via the non-segregated versions of FICC's Sponsored and Agent Clearing Services), which should allow flexibility for market participants to determine the most effective way to access FICC indirectly regardless of potential regulatory or other constraints on the ability to post margin directly.
                </P>
                <FTNT>
                    <P>
                        <SU>163</SU>
                         
                        <E T="03">See</E>
                         SIFMA AMG Letter at 12-13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>164</SU>
                         
                        <E T="03">See id.</E>
                         (citing Article 15(2) of the European Union's Money Market Fund Regulation, which it describes as prohibiting European Money Market Mutual Funds from pledging any assets received under reverse repos and certain restrictions on Undertakings for Collective Investments in Transferable Securities and similar investment vehicles related to their ability to post margin that will be held on deposit at FICC).
                    </P>
                </FTNT>
                <P>
                    Accordingly, the proposed changes would be consistent with Rule 17ad-22(e)(18)(iv)(C).
                    <SU>165</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>165</SU>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">G. Consistency With Rule 17ad-22(e)(19)</HD>
                <P>
                    Rule 17ad-22(e)(19) requires that FICC establish, implement, maintain and enforce written policies and procedures reasonably designed to identify, monitor, and manage the material risks to the covered clearing agency arising from arrangements in which firms that are indirect participants in FICC rely on the services provided by direct participants to access FICC's clearance and settlement facilities.
                    <SU>166</SU>
                    <FTREF/>
                     The proposed changes 
                    <PRTPAGE P="93750"/>
                    described in Section I.B.1 would require that each margin portfolio contains only transactions from the same account type, Netting Members use separate Deposit IDs for different transaction types, each Segregated Indirect Participant's margin requirement be calculated separately on a gross basis as though each Segregated Indirect Participant were a separate Netting Member, and Segregated Customer Margin for each indirect participant be deposited into a separate interest-earning Segregated Customer Margin Custody Account. These changes should enhance FICC's ability to isolate the risk profiles of individual indirect participants from Netting Members, which should help FICC better understand and monitor each individual participant's risk exposures. In addition, the calculation and collection of Segregated Customer Margin on a gross basis, as described in Section I.B.1 and 1.B.2, and the establishment of a $1 million cash floor for Segregated Customer Margin, as described in Section I.B.2.a, should help ensure that FICC will have sufficient margin to manage the risk to FICC during an indirect participant default.
                </P>
                <FTNT>
                    <P>
                        <SU>166</SU>
                         17 CFR 240.17ad-22(e)(19).
                    </P>
                </FTNT>
                <P>
                    Accordingly, the proposed changes would be consistent with Rule 17ad-22(e)(19) because they should enhance FICC's ability to identify, monitor, and manage the material risks to FICC associated with indirect participants relying on Netting Members to access FICC's clearance and settlement services.
                    <SU>167</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>167</SU>
                         17 CFR 240.17ad-22(e)(19).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">H. Consistency With Rule 17ad-22(e)(23)(ii)</HD>
                <P>
                    Rule 17ad-22(e)(23)(ii) requires that FICC establish, implement, maintain and enforce written policies and procedures providing sufficient information to enable participants to identify and evaluate the risks, fees, and other material costs they incur by participating in FICC.
                    <SU>168</SU>
                    <FTREF/>
                     The proposed changes described in Section I.B.3 to consolidate and clarify FICC's margin calculation methodology in the proposed Margin Component Schedule, adopt a method for allocating net unsettled positions to individual indirect participants for purposes of calculating margin requirements and to clarify the calculation of the ECP should make it easier for both Netting Members and indirect participants to identify and price the potential margining costs associated with how each chooses to submit transactions to FICC for clearance and settlement.
                </P>
                <FTNT>
                    <P>
                        <SU>168</SU>
                         17 CFR 240.17ad-22(e)(23)(ii).
                    </P>
                </FTNT>
                <P>
                    Accordingly, the proposed changes would be consistent with Rule 17ad-22(e)(23)(ii) because they should enhance the ability of Netting Members and indirect participants to identify and evaluate the costs to access FICC's clearance and settlement services.
                    <SU>169</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>169</SU>
                         17 CFR 240.17ad-22(e)(23)(ii).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Conclusion</HD>
                <P>
                    <E T="03">It is therefore noticed,</E>
                     pursuant to Section 806(e)(1)(I) of the Clearing Supervision Act, that the Commission DOES NOT OBJECT to Advance Notice (SR-FICC-2024-802), as modified by Partial Amendment No. 1, and that FICC is AUTHORIZED to implement the proposed change as of the date of this notice or the date of an order by the Commission approving proposed rule change SR-FICC-2024-007, whichever is later.
                </P>
                <SIG>
                    <P>By the Commission.</P>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27766 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101697; File No. SR-FINRA-2024-020]</DEPDOC>
                <SUBJECT>
                    Self-Regulatory Organizations; Financial Industry Regulatory Authority, Inc.; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Adopt Fees in FINRA Rule 7720 (Securities Lending and Transparency Engine (SLATE
                    <E T="51">TM</E>
                    ))
                </SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) 
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 20, 2024, the Financial Industry Regulatory Authority, Inc. (“FINRA”) filed with the Securities and Exchange Commission (“SEC” or “Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by FINRA. FINRA has designated the proposed rule change as “establishing or changing a due, fee or other charge” under Section 19(b)(3)(A)(ii) of the Act 
                    <SU>3</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(2) thereunder,
                    <SU>4</SU>
                    <FTREF/>
                     which renders the proposal effective upon receipt of this filing by the Commission. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         15 U.S.C. 78s(b)(3)(A)(ii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         17 CFR 240.19b-4(f)(2).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>
                    FINRA is proposing to adopt new FINRA Rule 7720 (Securities Lending and Transparency Engine (SLATE
                    <E T="51">TM</E>
                    )) to establish securities loan reporting fees and securities loan data products with associated fees in connection with FINRA's separately proposed Rule 6500 Series (Securities Lending and Transparency Engine (SLATE)) establishing securities loan reporting and data dissemination requirements.
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See infra</E>
                         note 6.
                    </P>
                </FTNT>
                <P>
                    The text of the proposed rule change is available on FINRA's website at 
                    <E T="03">http://www.finra.org,</E>
                     at the principal office of FINRA and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, FINRA included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. FINRA has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <HD SOURCE="HD3">(i) Background</HD>
                <P>
                    On October 13, 2023, the Commission adopted new SEA Rule 10c-1a 
                    <SU>6</SU>
                    <FTREF/>
                     to require any “covered person” 
                    <SU>7</SU>
                    <FTREF/>
                     who agrees to a “covered securities loan” 
                    <SU>8</SU>
                    <FTREF/>
                     to 
                    <PRTPAGE P="93751"/>
                    provide specified information to a registered national securities association (“RNSA”).
                    <SU>9</SU>
                    <FTREF/>
                     The RNSA is then required to make publicly available information regarding reported securities loans, as described in SEA Rule 10c-1a.
                    <SU>10</SU>
                    <FTREF/>
                     In its Adopting Release, the Commission stated its belief that SEA Rule 10c-1a would increase transparency in the securities lending market, resulting in a reduction in the information disadvantage faced by end borrowers and beneficial owners, improve price discovery, increase competition among providers of securities lending analytics services, reduce costs associated with tracking market conditions for broker-dealers and lending programs, and improve decision-making by investors, beneficial owners, and other market participants.
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.10c-1a (“SEA Rule 10c-1a”); Securities Exchange Act Release No. 98737 (October 13, 2023), 88 FR 75644 (November 3, 2023) (Reporting of Securities Loans) (“Adopting Release”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         SEA Rule 10c-1a(j)(1) defines a “covered person” as (i) any person that agrees to a covered securities loan on behalf of a lender (“intermediary”) other than a clearing agency when providing only the functions of a central counterparty pursuant to Rule 17Ad-22(a)(2) of the Exchange Act or a central securities depository pursuant to Rule 17Ad-22(a)(3) of the Exchange Act; or (ii) any person that agrees to a covered securities loan as a lender when an intermediary is not used unless paragraph (j)(1)(iii) of this section applies; or (iii) a broker or dealer when borrowing fully paid or excess margin securities pursuant to Rule 15c3-3(b)(3) of the Exchange Act.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         SEA Rule 10c-1a(j)(2) defines a “covered securities loan” as a transaction in which any 
                        <PRTPAGE/>
                        person on behalf of itself or one or more other persons, lends a reportable security to another person, with exclusions for a position at a clearing agency that results from central counterparty services pursuant to Rule 17Ad-22(a)(2) of the Exchange Act or central securities depository services pursuant to Rule 17Ad-22(a)(3) of the Exchange Act, and the use of margin securities, as defined in Rule 15c3-3(a)(4) of the Exchange Act, by a broker or dealer. “Reportable security” is defined in SEA Rule 10c-1a(j)(3) as any security or class of an issuer's securities for which information is reported or required to be reported to the consolidated audit trail as required by § 242.613 of the Exchange Act and the CAT NMS Plan (“CAT”), the Financial Industry Regulatory Authority's Trade Reporting and Compliance Engine (“TRACE”), or the Municipal Securities Rulemaking Board's Real-Time Transaction Reporting System (“RTRS”), or any reporting system that replaces one of these systems.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         SEA Rule 10c-1a(j)(5) defines an “RNSA” as an association of brokers and dealers that is registered as a national securities association pursuant to 15 U.S.C. 78
                        <E T="03">o</E>
                        -3 of the Exchange Act. FINRA currently is the only RNSA.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         SEA Rule 10c-1a(g).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, 88 FR 75644, 75692.
                    </P>
                </FTNT>
                <P>
                    SEA Rule 10c-1a(f) requires an RNSA that is collecting the information required to be reported under the rule to implement rules regarding the format and manner of its collection of information described in paragraphs 10c-1a(c) through 10c-1a(e) of SEA Rule 10c-1a and make publicly available such information in accordance with rules promulgated by the RNSA pursuant to Section 19(b) of the Exchange Act and Rule 19b-4 thereunder. In accordance with this requirement, on May 1, 2024, FINRA filed with the Commission a proposed rule change to adopt the new FINRA Rule 6500 Series (Securities Lending and Transparency Engine (SLATE)) to establish reporting requirements for Covered Securities Loans 
                    <SU>12</SU>
                    <FTREF/>
                     and to provide for the public dissemination of loan information.
                    <SU>13</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         A “Covered Securities Loan” means a “covered securities loan” as defined in SEA Rule 10c1-a(j)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 100046 (May 1, 2024); 89 FR 38203 (May 7, 2024) (Notice of Filing of File No. SR-FINRA-2024-007) (Proposed Rule Change to Adopt the FINRA Rule 6500 Series (Securities Lending and Transparency Engine)) (“SLATE Proposal”).
                    </P>
                </FTNT>
                <P>
                    In its Adopting Release, the Commission recognized that an RNSA would incur costs to develop and maintain systems to comply with the covered securities loan reporting and data dissemination requirements of SEA Rule 10c-1a 
                    <SU>14</SU>
                    <FTREF/>
                     and expressly permitted an RNSA to establish and collect reasonable fees pursuant to rules established under Section 19(b) of the Exchange Act and Rule 19b-4 thereunder.
                    <SU>15</SU>
                    <FTREF/>
                     The purpose of this proposed rule change is to establish a SLATE fee structure to allow FINRA to recover reasonably estimated incremental direct ongoing costs associated with complying with SEA Rule 10c-1a.
                    <SU>16</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, 88 FR 75644, 75717.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, 88 FR 75644, 75648.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         FINRA does not have regulatory authority over Covered Persons or Reporting Agents that are non-FINRA members. As FINRA does today, FINRA would refer to the SEC potential violations of the federal securities laws and rules by non-members, including failures to comply with SEA Rule 10c-1a and FINRA rules adopted pursuant to SEA Rule 10c-1a (
                        <E T="03">e.g.,</E>
                         potential SLATE reporting violations or failures to pay when due any SLATE fees).
                    </P>
                </FTNT>
                <P>
                    Among other things, the SLATE Proposal would establish the requirements for reporting Initial Covered Securities Loans 
                    <SU>17</SU>
                    <FTREF/>
                     and Loan Modifications 
                    <SU>18</SU>
                    <FTREF/>
                     to SLATE and would require that such reports be submitted to FINRA timely, accurately, and completely.
                    <SU>19</SU>
                    <FTREF/>
                     In the SLATE Proposal, FINRA stated its intention to file separately a proposed rule change to establish covered securities loan reporting fees and to establish securities loan data products with associated fees.
                    <SU>20</SU>
                    <FTREF/>
                     The SLATE Proposal also provided that FINRA would make specified securities loan information available on its website free of charge for personal, non-commercial purposes only.
                    <SU>21</SU>
                    <FTREF/>
                     In the instant filing, FINRA proposes to establish such reporting fees and to establish SLATE data products with associated fees, as described below.
                </P>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         “Initial Covered Securities Loan” means a new Covered Securities Loan not previously reported to SLATE. 
                        <E T="03">See</E>
                         proposed Rule 6510(d).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         “Loan Modification” means a change to any Data Element with respect to a Covered Securities Loan (irrespective of whether such Covered Securities Loan was previously reported to SLATE). 
                        <E T="03">See</E>
                         proposed Rule 6510(e).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         
                        <E T="03">See</E>
                         proposed Rule 6530(c)(1); 
                        <E T="03">see also</E>
                         SLATE Proposal, 89 FR 38203, 38210.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See</E>
                         SLATE Proposal, 89 FR 38203, 38206.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         
                        <E T="03">See</E>
                         SLATE Proposal, 89 FR 38203, 38212 n.80. The SLATE data that FINRA will make available (pursuant to FINRA Rule 6540.02) will be displayed (viewable) free of charge on the FINRA website for personal, non-commercial purposes and will not be available in downloadable form through this means. Persons interested in receiving from FINRA downloadable files of SLATE data must subscribe to the appropriate data product made available pursuant to proposed Rule 7720.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">(ii) Proposed Rule Change</HD>
                <P>
                    FINRA is proposing to establish new Rule 7720 to provide for reporting fees for: (1) SLATE system connectivity; (2) Initial Covered Securities Loan reporting; (3) Loan Modification reporting; (4) late reporting; and (5) reporting cancellations, corrections, and deletions. Rule 7720 also establishes data products with associated fees for SLATE Loan-Level Data and Daily Loan Statistics; 
                    <SU>22</SU>
                    <FTREF/>
                     and Historic SLATE Data.
                    <SU>23</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         “SLATE Loan-Level Data and Daily Loan Statistics” means the data described in proposed Rule 6540(a) through (c).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         “Historic SLATE Data” means SLATE Loan-Level Data and Daily Loan Statistics from the beginning of SLATE data reporting through the end of the most recent calendar year.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">SLATE Reporting Fees</HD>
                <P>Previously proposed new Rule 6530(a) would establish the requirements relating to the reporting of Initial Covered Securities Loans to SLATE. Proposed Rule 7720(b)(1) provides that, for each such Initial Covered Securities Loan report, a SLATE Participant will be subject to a reporting fee of $0.07 per submission. Previously proposed new Rule 6530(b) would establish the requirements relating to the reporting of Covered Securities Loan Modifications to SLATE. Proposed Rule 7720(b)(2) provides that, for each such Loan Modification report, a SLATE Participant will be subject to a reporting fee of $0.03 per submission.</P>
                <P>
                    Proposed Rule 7720 also establishes fees for the reporting of cancellations, corrections, and deletions of previously submitted Covered Securities Loans and for the late submission of Initial Covered Securities Loan and Loan Modification reports, which is consistent with the requirement that Covered Persons report timely, accurately, and completely to SLATE,
                    <SU>24</SU>
                    <FTREF/>
                     and facilitates the dissemination of accurate and complete information to regulators and the public.
                    <SU>25</SU>
                    <FTREF/>
                     Specifically, 
                    <PRTPAGE P="93752"/>
                    pursuant to proposed Rule 7720(b)(3), a SLATE Participant will be charged a cancel,
                    <SU>26</SU>
                    <FTREF/>
                     correct,
                    <SU>27</SU>
                    <FTREF/>
                     or delete 
                    <SU>28</SU>
                    <FTREF/>
                     fee of $0.10 per canceled, corrected, or deleted Covered Securities Loan report. In addition, proposed Rule 7720(b)(4) establishes a late fee of $0.20 per Initial Covered Securities Loan report or Loan Modification report that is not timely reported to SLATE as required pursuant to the Rule 6500 Series.
                    <SU>29</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         
                        <E T="03">See</E>
                         proposed Rule 6530(c)(1). Proposed Rule 6530(c)(2) further provides that a member's pattern or practice of late reporting without exceptional circumstances may be considered conduct inconsistent with high standards of commercial honor and just and equitable principles of trade, in violation of FINRA Rule 2010. 
                        <E T="03">See</E>
                         SLATE Proposal, 89 FR 38203, 38210.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         “[SEA Rule 10c-1a] is designed to provide access to timely, comprehensive securities loan information to market participants, the public, and 
                        <PRTPAGE/>
                        regulators, which will help provide borrowers and lenders with better tools to assess the terms of their securities loans and enhance the ability of regulators to oversee the securities lending market.” Adopting Release, 88 FR 75644, 75648.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         A “cancellation” is used to remove a single event from the SLATE system. 
                        <E T="03">See</E>
                         Draft SLATE Participant Reporting Specifications, available at 
                        <E T="03">https://www.finra.org/filing-reporting/slate.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         A “correction” is used to replace fields in a prior reported event. 
                        <E T="03">See</E>
                         Draft SLATE Participant Reporting Specifications, available at 
                        <E T="03">https://www.finra.org/filing-reporting/slate.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         A “deletion” is used to remove an entire loan and all corresponding loan events (
                        <E T="03">i.e.,</E>
                         modifications, corrections, etc.). 
                        <E T="03">See</E>
                         Draft SLATE Participant Reporting Specifications, available at 
                        <E T="03">https://www.finra.org/filing-reporting/slate.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         While FINRA will seek to address late or inaccurate SLATE reporting through its customary means, FINRA believes it is appropriate to establish fees to promote timely and accurate reporting. 
                        <E T="03">See also</E>
                         SLATE Proposal, 89 FR 38203, 38206 n.17.
                    </P>
                </FTNT>
                <P>
                    Proposed Rule 7720 also sets forth the fees for connecting to SLATE. Specifically, proposed Rule 7720(a) provides that a SLATE Participant may choose to report Covered Securities Loans to FINRA pursuant to the Rule 6500 Series either via: (1) the SLATE web browser; or (2) a third-party reporting intermediary (and such third party must use the SLATE web browser). The fee for connecting to the SLATE web browser is $25 per month per user ID and will be assessed for connecting to SLATE through the browser, whether a Covered Person Reporting Agent, or other third party.
                    <SU>30</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         The $25 per month fee for connecting to the SLATE web browser is assessed per user (not per entity). Therefore, a single SLATE Participant will be charged $25 per month times the number of users that it determines to authorize for connecting to SLATE through the browser for SLATE reporting. This connectivity fee is not applicable to, or assessed on, SLATE data product subscribers for the purposes of receiving SLATE data.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">SLATE Loan-Level Data and Daily Loan Statistics</HD>
                <P>
                    FINRA is proposing Rule 7720(c) to establish the SLATE Loan-Level Data and Daily Loan Statistics data product with associated fees. As defined in Rule 7720(e)(2), “SLATE Loan-Level Data and Daily Loan Statistics” means the data described in proposed Rule 6540 (Dissemination of Loan Information) paragraph (a), which addresses next-day dissemination; 
                    <SU>31</SU>
                    <FTREF/>
                     paragraph (b), which addresses delayed dissemination; 
                    <SU>32</SU>
                    <FTREF/>
                     and paragraph (c), which addresses daily loan statistics (
                    <E T="03">i.e.,</E>
                     aggregate loan transaction activity 
                    <SU>33</SU>
                    <FTREF/>
                     and loan rate distribution data 
                    <SU>34</SU>
                    <FTREF/>
                    ). Proposed Rule 7720(c) sets forth the fees applicable to subscribers that are persons and organizations other than qualifying Tax-Exempt Organizations 
                    <SU>35</SU>
                    <FTREF/>
                     and subscribers that are qualifying Tax-Exempt Organizations. Recipients of the SLATE Loan-Level Data and Daily Loan Statistics product described herein will be required to execute appropriate agreements with FINRA to subscribe to SLATE Loan-Level Data and Daily Loan Statistics.
                </P>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         SLATE data that is subject to next day dissemination generally consists of the data set forth in Rule 6540(a): (1) the unique identifier assigned by FINRA to the loan; (2) the security identifier(s) specified in Rule 6530(a)(2)(A) or (B) that FINRA determines is appropriate to disseminate; (3)(a) for each Initial Covered Securities Loan, all other Data Elements reported to SLATE, except the amount of securities loaned and confidential data elements; (b) for each Loan Modification, the modified Data Elements reported to SLATE, except the amount of securities loaned and confidential data elements; or (c) for each Loan Modification to a Covered Securities Loan that was not previously required to be reported to SLATE, all other Data Elements reported to SLATE, except the amount of securities loaned and confidential data elements.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         SLATE data that is subject to delayed dissemination (20 business days after the date on which the Initial Covered Securities Loan was effected or the loan was modified) generally consists of the data set forth in Rule 6540(b): (1) the unique identifier assigned by FINRA to the Covered Securities Loan; (2) the security identifier(s) specified in Rule 6530(a)(2)(A) or (B) that FINRA determines is appropriate to disseminate; and (3) the amount of securities loaned reported to SLATE.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         Aggregate loan transaction activity data generally consists of the data set forth in Rule 6540(c)(1); specifically, the security identifier specified in Rule 6530(a)(2)(A) or (B) that FINRA determines is appropriate to disseminate and the aggregate volume of securities subject to an Initial Covered Securities Loan or modification to the amount of Reportable Securities loaned, reported on the prior business day.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         Loan rate distribution data generally consists of: (1) the security identifier specified in Rule 6530(a)(2)(A) or (B) that FINRA determines is appropriate to identify the relevant Reportable Security; (2) the highest rebate rate, lowest rebate rate, and volume weighted average of the rebate rates by U.S. currency and non-U.S. currency, as applicable, reported for Initial Covered Securities Loans collateralized by cash and for Loan Modifications collateralized by cash (where the Loan Modification involved a change to the rebate rate); and (3) the highest lending fee or rate, lowest lending fee or rate, and volume weighted average of the lending fees or rates reported for Initial Covered Securities Loans not collateralized by cash and for Loan Modifications not collateralized by cash (where the Loan Modification involved a change to the lending fee or rate).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         A “Tax-Exempt Organization” means an organization that is described in Section 501(c) of the Internal Revenue Code (26 U.S.C. 501(c)) and has received recognition of the exemption from federal income taxes from the Internal Revenue Service. 
                        <E T="03">See</E>
                         Proposed Rule 7720(e)(3).
                    </P>
                </FTNT>
                <P>
                    Under proposed Rule 7720(c)(1)(A), a fee of $3,000 per month will apply for daily receipt of the SLATE Loan-Level Data and Daily Loan Statistics, except for qualifying Tax-Exempt Organizations. The data is enabled for unlimited internal use through any number of display applications; separate fees and uses apply to qualifying Tax-Exempt Organizations (as discussed below). As further provided in proposed Rule 7720(c)(1)(A), the fee of $3,000 per month entitles subscribers to use SLATE Loan-Level Data and Daily Loan Statistics in one or more of the following ways: internal operational and processing systems, internal monitoring and surveillance systems, internal price validation, internal portfolio valuation services, internal analytical programs leading to purchase/sale or other trading decisions, and other related activities, and the repackaging of market data for delivery and dissemination outside the organization, such as indices or other derivative products. Bulk redistribution of SLATE Loan-Level Data and Daily Loan Statistics 
                    <SU>36</SU>
                    <FTREF/>
                     is not permitted under this subscription type, which is limited to internal use. In addition, any derivative products shall not permit end users to determine underlying SLATE Loan-Level Data and Daily Loan Statistics.
                </P>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         Bulk redistribution of SLATE data refers to the redistribution of the SLATE data files described in proposed Rule 7720. Bulk redistribution of SLATE data generally is not permitted, except for qualifying Tax-Exempt Organizations, subject to specified restrictions, as described in proposed Rule 7720(c)(2) and (d)(2).
                    </P>
                </FTNT>
                <P>Under proposed Rule 7720(c)(1)(B), a vendor display redistribution fee of $10,000 per month will apply for the display of SLATE Loan-Level Data and Daily Loan Statistics through any number of external display applications. However, bulk redistribution of SLATE Loan-Level Data and Daily Loan Statistics is not permitted. Therefore, any party wishing to receive a distribution of SLATE Loan-Level Data and Daily Loan Statistics files must subscribe directly with FINRA.</P>
                <P>
                    Proposed Rule 7720(c)(2) establishes a monthly fee of $1,500 applicable to qualifying Tax-Exempt Organizations for the daily receipt of SLATE Loan-Level Data and Daily Loan Statistics. FINRA is establishing a fee level for qualifying Tax-Exempt Organizations that is half of the fee that will be assessed on parties other than qualifying Tax-Exempt Organizations. The data is enabled for unlimited internal use. A Tax-Exempt Organization qualifies to receive SLATE Loan-Level Data and Daily Loan Statistics if it does not redistribute such data in bulk, or it redistributes such data in bulk or otherwise (
                    <E T="03">e.g.,</E>
                     unlimited external display) at no charge solely to other 
                    <PRTPAGE P="93753"/>
                    Tax-Exempt Organizations that agree to be subject to the same restrictions.
                </P>
                <HD SOURCE="HD3">Historic SLATE Data</HD>
                <P>
                    FINRA also is proposing Rule 7720(d) to establish the Historic SLATE Data product with associated fees. As defined in Rule 7720(e)(1), “Historic SLATE Data” means “SLATE Loan-Level Data and Daily Loan Statistics” from the beginning of SLATE data reporting (currently scheduled to commence on January 2, 2026) through the end of the most recent calendar year. Historic SLATE Data will be made available within one month of year-end (
                    <E T="03">e.g.,</E>
                     Historic SLATE Data for calendar year 2026 will be available by January 31, 2027; Historic SLATE Data for calendar year 2027 will be available by January 31, 2028, and so on). Proposed Rule 7720(d) sets forth the fees for Historic SLATE Data applicable to subscribers that are persons and organizations other than qualifying Tax-Exempt Organizations, and subscribers that are qualifying Tax-Exempt Organizations. Recipients of the Historic SLATE Data product described herein will be required to execute appropriate agreements with FINRA.
                </P>
                <P>Under proposed Rule 7720(d)(1)(A), a single fee of $2,000 will apply to persons or organizations other than qualifying Tax-Exempt Organizations for development and set-up to begin receiving Historic SLATE Data. The set-up fee is a one-time fee. Proposed Rule 7720(d)(1)(B) provides that a fee of $5,000 per calendar year will apply for receipt of Historic SLATE Data, except for qualifying Tax-Exempt Organizations. The data is enabled for unlimited internal use through any number of display applications. As further provided in proposed Rule 7720(d)(1)(B), the fee of $5,000 per calendar year entitles persons or organizations other than qualifying Tax-Exempt Organizations to use Historic SLATE Data in one or more of the following ways: internal operational and processing systems, internal monitoring and surveillance systems, internal price validation, internal portfolio valuation services, internal analytical programs leading to purchase/sale or other trading decisions, and other related activities, and the repackaging of market data for delivery and dissemination outside the organization, such as indices or other derivative products. Bulk redistribution of Historic SLATE Data is not permitted under this subscription type, which is limited to internal use. In addition, any derivative products shall not permit end users to determine underlying SLATE Loan-Level Data and Daily Loan Statistics.</P>
                <P>
                    Proposed Rule 7720(d)(2) establishes the fees applicable to qualifying Tax-Exempt Organizations for receipt of Historic SLATE Data. A Tax-Exempt Organization qualifies to receive Historic SLATE Data if it does not redistribute such data in bulk, or it redistributes such data in bulk or otherwise at no charge solely to other Tax-Exempt Organizations that agree to be subject to the same restrictions. Under proposed Rule 7720(d)(2)(A), a single fee of $1,000 will apply to any qualifying Tax-Exempt Organization for development and set-up to begin receiving Historic SLATE Data. The set-up fee is a one-time fee and was established to amount to half of the fee that would be assessed on parties other than qualifying Tax-Exempt Organizations for data set up. Proposed Rule 7720(d)(2)(B) provides that a fee of $2,500 per calendar year will apply to any qualifying Tax-Exempt Organization for receipt of Historic SLATE Data, which is half of the fee that would be assessed on parties other than qualifying Tax-Exempt Organizations for these data. Historic SLATE Data is enabled for unlimited internal use and may be redistributed by a qualifying Tax-Exempt Organization in bulk or otherwise (
                    <E T="03">e.g.,</E>
                     unlimited external display) subject to the restrictions in paragraph (d)(2) (
                    <E T="03">i.e.,</E>
                     redistributed at no charge solely to other Tax-Exempt Organizations that agree to be subject to the same restrictions prescribed in the rule).
                </P>
                <HD SOURCE="HD3">SLATE Cost Recovery</HD>
                <P>
                    As further discussed below in the Economic Impact Assessment, the proposed fees described herein are designed to permit FINRA to recover costs associated with the operation of the SLATE program, as expressly permitted for an RNSA under the Exchange Act and SEA Rule 10c-1a.
                    <SU>37</SU>
                    <FTREF/>
                     FINRA currently estimates an average of approximately $4.5 million in incremental direct ongoing costs per year from 2026 through 2028 (including the incremental direct ongoing costs incurred in 2024 and 2025 to be recovered over the 3-year period),
                    <SU>38</SU>
                    <FTREF/>
                     and approximately $4.4 million in annual incremental direct ongoing costs thereafter. In an effort to make SLATE financially self-sustaining on an ongoing basis, the proposed fees are designed to generate an amount of revenue that is calibrated to align with the estimated incremental direct ongoing costs associated with the SLATE program, to enable FINRA to meets its obligations pursuant to the SEA Rule 10c-1a mandate, as further described below.
                </P>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         
                        <E T="03">See</E>
                         10c-1a(i); 
                        <E T="03">see also</E>
                         Adopting Release 88 FR 75644, 75687.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         While SEA Rule 10c-1a does not require that securities loan reporting commence until January 2026 or that loan data dissemination commence until April 2026, FINRA has necessarily already begun making financial expenditures in response to the SEC's adoption of Rule 10c-1a so that FINRA will be positioned to comply with all of the obligations applicable to an RNSA under that rule.
                    </P>
                </FTNT>
                <P>
                    Specifically, FINRA's incremental direct costs associated with operating the SLATE program include costs for cloud resources (compute and storage), data validation, business rule processing, reference data, data dissemination, billing generation, technology operations monitoring and support, and alert escalation and remediation. Additional costs include staffing related to product management, application management, ongoing business and operational support for the user interface, and administration of participant information and applicable agreements.
                    <SU>39</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         To the extent possible, FINRA will leverage existing systems, personnel, and processes in connection with FINRA's SLATE program consistent with FINRA's structure as a not-for-profit self-regulatory organization.
                    </P>
                </FTNT>
                <P>FINRA intends to reassess the SLATE reporting fees and data products and associated fees after the commencement of SLATE reporting and dissemination and obtaining additional information regarding reporting volumes and subscription interest. To the extent that FINRA determines that a change to the SLATE fee structure would be appropriate to better align SLATE revenues with the incremental direct ongoing costs incurred in connection with the SLATE program, FINRA would file a proposed rule change with the Commission pursuant to Section 19(b) of the Exchange Act and Rule 19b-4 thereunder.</P>
                <P>
                    FINRA has filed the proposed rule change for immediate effectiveness. The Commission's release adopting SEA Rule 10c-1a specified the compliance dates applicable to securities loan reporting and data dissemination.
                    <SU>40</SU>
                    <FTREF/>
                     Accordingly, if the Commission approves FINRA's proposed rules establishing the reporting and dissemination requirements, unless an extension is provided pursuant to Commission order, the implementation date of the proposed FINRA rules establishing the securities loan reporting fees will correspond to the commencement of reporting to SLATE, and the implementation date of the proposed FINRA rules establishing the securities loan data products with associated fees will correspond to the commencement of SLATE data 
                    <PRTPAGE P="93754"/>
                    dissemination. If the SEC extends the compliance dates for SEA Rule 10c-1a's reporting or dissemination requirements, FINRA's proposed rules addressing covered securities loan reporting fees and securities loan data products with associated fees would become effective consistent with the SEC's extended timeframe for reporting and data dissemination, respectively.
                </P>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         
                        <E T="03">See supra</E>
                         note 6.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    FINRA believes that the proposed rule change is consistent with the provisions of Section 15A(b)(5) of the Act, which requires, among other things, that FINRA rules provide for the equitable allocation of reasonable dues, fees, and other charges among members and issuers and other persons using any facility or system that FINRA operates or controls.
                    <SU>41</SU>
                    <FTREF/>
                     FINRA also believes that the proposed rule change is consistent with the provisions of Section 15A(b)(6) of the Act, which requires, among other things, that FINRA rules are not designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                    <SU>42</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         15 U.S.C. 78
                        <E T="03">o</E>
                        -3(b)(5).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         15 U.S.C. 78
                        <E T="03">o</E>
                        -3(b)(6).
                    </P>
                </FTNT>
                <P>
                    Consistent with Section 984(b) of the Dodd-Frank Act, which mandates that the Commission increase the transparency of information available to brokers, dealers, and investors regarding securities loan activity, on October 13, 2023, the Commission adopted SEA Rule 10c-1a.
                    <SU>43</SU>
                    <FTREF/>
                     SEA Rule 10c-1a requires a Covered Person who agrees to a Covered Securities Loan to provide specified information to an RNSA.
                    <SU>44</SU>
                    <FTREF/>
                     The RNSA that is collecting the information required to be reported under the rule is then required to make publicly available information regarding reported securities loans, as described in SEA Rule 10c-1a.
                    <SU>45</SU>
                    <FTREF/>
                     Because FINRA is an RNSA, FINRA proposed to adopt the SLATE rules and is building a system (the proposed SLATE system) to which Covered Securities Loan information would be reported. SEA Rule 10c-1a sets forth other related requirements for an RNSA, as described in SEA Rule 10c-1a and the Adopting Release.
                    <SU>46</SU>
                    <FTREF/>
                     These mandates increase costs to FINRA, as an RNSA, that necessitate funding.
                </P>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         
                        <E T="03">See generally</E>
                         Adopting Release, 88 FR 75644. 
                        <E T="03">See also</E>
                         Public Law 111-203, 124 Stat. 1376 (2010).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         
                        <E T="03">See</E>
                         SEA Rule 10c1-a(a)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         
                        <E T="03">See</E>
                         SEA Rule 10c-1a(g).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>46</SU>
                         As noted above, SEA Rule 10c-1a anticipates that an RNSA will propose rules consistent with the Commission's mandate. 
                        <E T="03">See</E>
                         SEA Rule 10c-1a(i). Section 984(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act (“Dodd-Frank Act”) added section 10(c)(1) to the Exchange Act to provide the Commission with authority over securities lending. 
                        <E T="03">See</E>
                         15 U.S.C. 78j(c)(1). Section 984(b) of the Dodd-Frank Act mandates that the Commission increase the transparency of information available to brokers, dealers, and investors with respect to the loan or borrowing of securities. 
                        <E T="03">See</E>
                         Public Law 111-203, 124 Stat. 1376 (2010).
                    </P>
                </FTNT>
                <P>
                    Section 15A(b)(2) of the Act requires that an RNSA be “so organized and [have] the capacity to be able to carry out the purposes” of the Act and “to comply, and . . . to enforce compliance by its members and persons associated with its members,” with the provisions of the Exchange Act.
                    <SU>47</SU>
                    <FTREF/>
                     FINRA therefore believes it is consistent with the Act that FINRA impose reasonable fees that are designed to support FINRA with regard to expenditures to meet its regulatory obligations in connection with the securities loan reporting and transparency initiative. In addition, FINRA notes that SEA Rule 10c-1a itself explicitly provides that the RSNA may establish and collect reasonable fees, pursuant to rules that are promulgated pursuant to Section 19(b) and Rule 19b-4 of the Exchange Act.
                    <SU>48</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>47</SU>
                         15 U.S.C. 78
                        <E T="03">o</E>
                        -3(b)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>48</SU>
                         
                        <E T="03">See</E>
                         SEA Rule 10c-1a(i).
                    </P>
                </FTNT>
                <P>As discussed above, and further below in the Economic Impact Assessment, FINRA is establishing a fee structure to implement reasonable fees relating to the SLATE program; specifically: (1) SLATE system connectivity fees; (2) fees in connection with reporting Covered Securities Loan information to SLATE; and (3) SLATE data products and associated fees. The fees being proposed herein are reasonable, including because they are designed to generate an amount of revenue that is calibrated to align with the estimated incremental direct ongoing costs associated with the SLATE program and to enable FINRA to meet its regulatory obligations.</P>
                <P>
                    FINRA believes it is equitable, reasonable, and consistent with the Exchange Act that the proposed SLATE system connectivity and reporting fees be assessed directly on the parties that have been designated by the Commission as bearing the underlying regulatory responsibility for reporting securities loan information to an RNSA—
                    <E T="03">i.e.,</E>
                     Covered Persons that report to the SLATE system (and their agents).
                    <SU>49</SU>
                    <FTREF/>
                     In the Adopting Release, the Commission stated that “. . . RNSAs may establish and collect reasonable fees, pursuant to rules that are effective pursuant to section 19(b) of the Exchange Act and Rule 19b-4 thereunder, from each person who provides any data set forth in paragraphs (b) through (e) of this section directly to an RNSA.” 
                    <SU>50</SU>
                    <FTREF/>
                     The Adopting Release also stated that “[t]the final rule will also impose direct costs on an RNSA responsible for collecting, maintaining, and distributing the data, who may pass on these costs by imposing fees on entities that provide Rule 10c-1a information to an RNSA and/or consumers of Rule 10c-1a data.” 
                    <SU>51</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>49</SU>
                         “Under the Exchange Act, RNSAs are allowed to adopt rules that impose the equitable allocation of reasonable fees among members and issuers, and other persons that use an RNSA facility or system.” (citation omitted). 
                        <E T="03">See</E>
                         Adopting Release, 88 FR 75644, 75687.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>50</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, 88 FR 75644, 75687.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>51</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, 88 FR 75644, 75693.
                    </P>
                </FTNT>
                <P>
                    FINRA also believes that it is equitable, reasonable, and consistent with the Exchange Act to require that the parties reporting data to SLATE be directly responsible for paying SLATE fees because the reporting process is a primary driver of the costs that the proposed fees are intended to recover. Thus, assessing the SLATE system connectivity and reporting fees on Covered Persons (and their agents) aligns the direct responsibility for SLATE cost recovery with the parties generating the information collection costs.
                    <SU>52</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>52</SU>
                         FINRA understands that many members shift at least some of the regulatory fees incurred to other parties. For instance, it is regular practice among clearing and trading firms to “pass through” the Trading Activity Fee (“TAF”) to the underlying firm executing the trade. Further, FINRA understands that executing firms commonly pass the TAF directly on to their customers. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 90176 (October 14, 2020), 85 FR 66592, 66603 (October 20, 2020) (Notice of Filing and Immediate Effectiveness of File No. SR-FINRA-2020-032). “The entities that provide Rule 10c-1a information to an RNSA may absorb these costs in the form of lower profits or may pass them on to their customers in the form of increased fees for broker-dealer services or lending program services.” 
                        <E T="03">See</E>
                         Adopting Release 88 FR 75644, 75693.
                    </P>
                </FTNT>
                <P>
                    The proposed SLATE data products are offered on equal terms to similarly situated parties that choose to access the data products. Thus, FINRA believes that the proposed SLATE data fees are not designed to permit unfair discrimination between customers, issuers, brokers, or dealers, as provided for in Section 15A(b)(6).
                    <SU>53</SU>
                    <FTREF/>
                     Under the proposal, with one exception (qualifying Tax-Exempt Organizations), the content of the information in the data products and the data products' usage rights are offered on the same terms to interested parties. Thus, any party (except for a qualifying Tax-Exempt Organization) that seeks to access SLATE Loan-Level Data and Daily Loan Statistics will pay a fee depending upon whether such party seeks the right to use the data solely internally, as described in 
                    <PRTPAGE P="93755"/>
                    proposed Rule 7720(c)(1)(A) ($3,000 per month), or whether such party seeks the right to display the data externally, as described in proposed Rule 7720(c)(1)(B) ($10,000 per month).
                    <SU>54</SU>
                    <FTREF/>
                     The higher fee of $10,000 per month proposed in Rule 7720(c)(1)(B) is not unfairly discriminatory (as compared to the $3,000 per month fee for internal use only) given the significantly expanded usage rights authorized under proposed Rule 7720(c)(1)(B), which permits the display of SLATE Loan-Level Data and Daily Loan Statistics through any number of external display applications.
                    <SU>55</SU>
                    <FTREF/>
                     All interested parties (except qualifying Tax-Exempt Organizations) will be assessed the same fee, with the same usage rights, for Historic SLATE Data.
                </P>
                <FTNT>
                    <P>
                        <SU>53</SU>
                         15 U.S.C. 78
                        <E T="03">o</E>
                        -3(b)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>54</SU>
                         
                        <E T="03">See</E>
                         proposed Rule 7720(c)(1)(A)-(B).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>55</SU>
                         
                        <E T="03">See</E>
                         proposed Rule 7720(c)(1)(B).
                    </P>
                </FTNT>
                <P>
                    Proposed Rule 7720 would apply a lower fee to qualifying Tax-Exempt Organizations for both the SLATE Loan-Level Data and Daily Loan Statistics as well as the Historic SLATE Data. As is the case with other data products offered by FINRA, 
                    <E T="03">e.g.,</E>
                     TRACE,
                    <SU>56</SU>
                    <FTREF/>
                     FINRA offers data products at a reduced fee to qualifying Tax-Exempt Organizations that have received recognition of the exemption from federal income taxes from the Internal Revenue Service.
                    <SU>57</SU>
                    <FTREF/>
                     In the proposed rule change, FINRA has established the proposed fees applicable to qualifying Tax-Exempt Organizations as half of the amounts that will be assessed to parties other than qualifying Tax-Exempt Organizations. FINRA also notes that Tax-Exempt Organizations only qualify for the reduced fees offered under the rule if they do not redistribute the data in bulk, or redistribute the data in bulk or otherwise at no charge solely to other Tax-Exempt Organizations that agree to be subject to the same restrictions.
                    <SU>58</SU>
                    <FTREF/>
                     FINRA believes this aspect of the proposed rule change is appropriate given the not-for-profit nature of such organizations and therefore is not designed to permit unfair discrimination between customers, issuers, brokers, or dealers, as provided for in Section 15A(b)(6).
                    <SU>59</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>56</SU>
                         
                        <E T="03">See</E>
                         Rule 7730(d)(1)(B).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>57</SU>
                         
                        <E T="03">See</E>
                         supra note 35.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>58</SU>
                         
                        <E T="03">See</E>
                         proposed Rule 7720(c)(2) and (d)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>59</SU>
                         15 U.S.C. 78
                        <E T="03">o</E>
                        -3(b)(6).
                    </P>
                </FTNT>
                <P>
                    FINRA also believes that the amounts of the proposed SLATE fees are equitable, reasonable, and consistent with the Exchange Act. As further discussed in the Economic Impact Assessment, in developing reporting activity estimates, FINRA used data gathered through outreach to industry participants, including data vendors, agent lenders, prime brokers, retail brokers, and beneficial owners. FINRA believes that the proposed SLATE data subscription fees also are reasonable given the usage rights and the use cases for the data. Because the proposed SLATE data products are a new product offering, it is difficult to estimate subscription levels and associated revenue. In addition, based on FINRA's experience, subscribership to data products may be slower initially, with interest building over time. As a result, FINRA has initially sought to rely primarily on revenues through SLATE reporting to offset the costs that FINRA seeks to recover in connection with the SEA Rule 10c-1a mandate. As such, the proposed fees generally are consistent with FINRA's efforts to align its operating expenses with its operating revenues, target break-even cash flows, and continue to responsibly manage expenses driven by mandatory initiatives in a manner consistent with FINRA's public Financial Guiding Principles.
                    <SU>60</SU>
                    <FTREF/>
                     The proposed SLATE fees will be applied consistently to all similarly situated parties that are required to report Covered Securities Loans (and their agents) (
                    <E T="03">i.e.,</E>
                     SLATE Participants) and to those that choose to subscribe to SLATE data products.
                    <SU>61</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>60</SU>
                         
                        <E T="03">See</E>
                         FINRA's Financial Guiding Principles, 
                        <E T="03">https://www.finra.org/sites/default/files/finra_financial_guiding_principles_0.pdf.</E>
                         As discussed above, FINRA intends to reassess the SLATE reporting fees and data products and associated fees after gaining experience with the operation of SLATE and obtaining additional information regarding reporting volumes and subscription interest. To the extent that FINRA determines that a change to the SLATE fee structure would be appropriate to better align SLATE revenues with the incremental direct ongoing costs incurred in connection with the SLATE program, FINRA would file a proposed rule change with the Commission pursuant to Section 19(b) of the Exchange Act and Rule 19b-4 thereunder.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>61</SU>
                         The proposed data products will be offered on the same terms to any similarly situated party that seeks to subscribe.
                    </P>
                </FTNT>
                <P>
                    For the reasons discussed herein, FINRA believes that the proposed rule change is consistent with Section 15A(b)(5) of the Exchange Act, including that the proposal provides for the equitable allocation of reasonable dues, fees and other charges among members and issuers and other persons using any facility or system that FINRA operates or controls.
                    <SU>62</SU>
                    <FTREF/>
                     FINRA likewise believes that the proposed rule change is consistent with Section 15A(b)(6) of the Act, which requires, among other things, that FINRA rules are not designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                    <SU>63</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>62</SU>
                         15 U.S.C. 78
                        <E T="03">o</E>
                        -3(b)(5).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>63</SU>
                         15 U.S.C. 78
                        <E T="03">o</E>
                        -3(b)(6).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>
                    Section 15A(b)(9) of the Act requires that FINRA's rules not impose any burden on competition that is not necessary or appropriate in furtherance of the purpose of the Exchange Act.
                    <SU>64</SU>
                    <FTREF/>
                     FINRA does not believe that the proposed rule change will result in any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.
                </P>
                <FTNT>
                    <P>
                        <SU>64</SU>
                         15 U.S.C. 78
                        <E T="03">o</E>
                        -3(b)(9).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Economic Impact Assessment</HD>
                <P>FINRA has undertaken an economic impact assessment, as set forth below, to analyze the regulatory need for the proposed rule change, its potential economic impacts, including distributional and competitive effects, and the alternatives considered in assessing how to best meet FINRA's regulatory objectives. The regulatory need is discussed above.</P>
                <HD SOURCE="HD3">Economic Baseline</HD>
                <P>
                    In its Adopting Release, the SEC estimated that 609 Covered Persons and Reporting Agents would be affected by SEA Rule 10c-1a, of which 255 were Providing Covered Persons, 248 were Non-Providing Covered Persons, and 106 were Reporting Agents.
                    <SU>65</SU>
                    <FTREF/>
                     FINRA has estimated that approximately 125,000 Initial Covered Securities Loan reports and 200,000 Loan Modification reports per day may be reported to SLATE.
                    <SU>66</SU>
                    <FTREF/>
                     FINRA estimates that approximately 0.5% of Initial Covered Securities Loan reports and Loan Modification reports could result in corrections, cancellations, or deletions, and approximately 0.5% could be reported late.
                    <SU>67</SU>
                    <FTREF/>
                     FINRA anticipates that the volume of erroneous and late reports 
                    <PRTPAGE P="93756"/>
                    will decrease over time as Covered Persons gain experience with SLATE reporting.
                </P>
                <FTNT>
                    <P>
                        <SU>65</SU>
                         “Providing Covered Persons” would provide information directly to an RNSA while “Non-Providing Covered Persons” would use a reporting agent to provide information to an RNSA. 
                        <E T="03">See</E>
                         Adopting Release, 88 FR 75644, 75718. “Reporting Agent” is defined in SEA Rule 10c-1a(j)(4).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>66</SU>
                         The quantity of Loan Modification reports will be impacted by Covered Persons' reporting decisions, among other factors. For example, the extent to which Covered Persons choose to report rates as a spread to benchmark will affect the quantity of Loan Modification reports due to be reported, which in turn will impact fee revenues.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>67</SU>
                         This estimate is based on FINRA's experience with TRACE reporting. As of August 2024, the correction rate was approximately 0.8% for corporate bond reports and 0.68% for U.S. Treasury reports. The rate of late reports was 0.61% for corporate bonds and 0.42% for U.S. Treasury Securities. The correction and late reporting rates may be lower for SLATE reporting because proposed Rule 6530 generally provides a longer timeframe for reporting Covered Securities Loans to SLATE than is provided for corporates and U.S. Treasury Securities under the TRACE reporting regime.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Economic Impacts</HD>
                <P>The economic impact of the currently proposed reporting fees, data products and associated subscription fees are discussed below.</P>
                <HD SOURCE="HD3">SLATE Reporting Fees</HD>
                <P>As discussed above, Covered Persons will incur fees for reporting Initial Covered Securities Loans and Loan Modifications. Specifically, FINRA proposes that, for each Initial Covered Securities Loan report, a SLATE Participant will be subject to a fee of $0.07 per submission and for each Loan Modification report, a SLATE Participant will be subject to a fee of $0.03 per submission. FINRA also proposes that a SLATE Participant will be charged a cancel, correct, or delete fee of $0.10 per canceled, corrected, or deleted Covered Securities Loan report, and a late fee of $0.20 per Initial Covered Securities Loan or Loan Modification that is not reported timely to SLATE.</P>
                <P>Developing estimates for the anticipated number and type of SLATE reports is challenging due to the availability of only limited information upon which to base estimates. In developing estimates, FINRA used data gathered through outreach to industry participants, including data vendors, agent lenders, prime brokers, retail brokers, and beneficial owners. These estimates were used to develop the proposed fee structure, which is intended to align SLATE revenues with the incremental direct ongoing costs incurred in connection with the SLATE initiative.</P>
                <P>
                    Given the estimated number of reports and proposed reporting fees discussed above, FINRA approximates that annual revenues from reporting fees would be $2,205,000 for Initial Covered Securities Loan reports,
                    <SU>68</SU>
                    <FTREF/>
                     $1,512,000 for Loan Modification reports,
                    <SU>69</SU>
                    <FTREF/>
                     $40,950 for corrections, cancellations, and deletions,
                    <SU>70</SU>
                    <FTREF/>
                     and $81,900 for late reports.
                    <SU>71</SU>
                    <FTREF/>
                     SLATE Participants will incur a $25 fee per user per month for connecting to the SLATE web browser. Given the estimated number of Covered Persons and Reporting Agents from the SEC's Adopting Release,
                    <SU>72</SU>
                    <FTREF/>
                     FINRA estimates the total connection fees per year would be $365,400.
                    <SU>73</SU>
                    <FTREF/>
                     Together, FINRA estimates SLATE reporting fees would total $4,205,250 per year.
                    <SU>74</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>68</SU>
                         FINRA arrived at $2,205,000 by multiplying the estimated number of daily Initial Loan Reports (125,000) by the proposed fee rate of $0.07 by the number of business days per year (252 days).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>69</SU>
                         FINRA arrived at $1,512,000 by multiplying the estimated number of daily Loan Modification Reports (200,000) by the proposed fee rate of $0.03 by the number of business days per year (252 days).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>70</SU>
                         FINRA arrived at $40,950 by multiplying the sum of the estimated number of daily Initial Loan Reports (125,000) and the estimated number of daily Loan Modification Reports (200,000) by the estimated rate of reports requiring a correction, cancellation, or deletion (0.5%) by the proposed fee rate of $0.10 by the number of business days per year (252 days).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>71</SU>
                         FINRA arrived at $81,900 by multiplying the sum of the estimated number of daily Initial Loan Reports (125,000) and the estimated number of daily Loan Modification Reports (200,000) by the estimated rate of late reports (0.5%) by the proposed fee rate of $0.20 by the number of business days per year (252 days).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>72</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, 88 FR 75644, 75718.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>73</SU>
                         FINRA arrived at $365,400 by multiplying the estimated number of Covered Persons and Reporting Agents (609) by an assumed 2 user accounts per Covered Person by the proposed fee rate of $25 per month by 12 months per year.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>74</SU>
                         FINRA arrived at $4,205,250 by adding the estimated annual revenue from reporting fees for Initial Covered Securities Loan Reports ($2,205,000), the estimated annual revenue from reporting fees for Loan Modification Reports ($1,512,000), the estimated annual revenue from correction, cancellation, and deletion fees ($40,950), the estimated annual revenue from fees for late reports ($81,900), and the estimated annual revenue from connection fees ($365,400).
                    </P>
                </FTNT>
                <P>
                    FINRA considered the potential impact of the proposed SLATE reporting fee structure on securities lending activities. Covered Persons' securities lending activities will impact the amount of reporting fees that they would incur. Some types of Covered Persons, such as lending agents, may incur relatively larger reporting fees compared to other Covered Persons due to their function in the securities lending market (
                    <E T="03">e.g.,</E>
                     agent lenders generally transact as Covered Persons in higher volumes relative to other securities lending market participants). Lending agents may pass along fully or partially the reporting fees to beneficial owners, for instance, in the form of a direct charge or higher fees charged for lending services. The reporting fees also may affect how Covered Persons structure or conduct their securities lending business—
                    <E T="03">e.g.,</E>
                     how lending agents determine to structure pool or lending programs. However, Covered Persons' choices are also affected by other factors, including counterparty risk and business models.
                </P>
                <HD SOURCE="HD3">SLATE Data Products and Associated Fees</HD>
                <P>
                    As described above, FINRA is proposing to establish SLATE data products and associated fees.
                    <SU>75</SU>
                    <FTREF/>
                     Specifically, FINRA is proposing to make SLATE Loan-Level Data and Daily Loan Statistics available on a subscription basis to qualifying Tax-Exempt Organizations (for $1,500/month) as well as to persons and organizations other than qualifying Tax-Exempt Organizations (for $3,000/month). Also as described above, vendors may subscribe to display externally SLATE Loan-Level Data and Daily Loan Statistics (for $10,000/month). The proposed SLATE data products will enable a broader range of market participants to access comprehensive securities lending data than would otherwise be available in the absence of the proposed data products, which will further enhance market transparency and efficiency. As discussed in the Adopting Release, the broader availability of securities lending information may lead to increased competition for data analytics services as the barriers to entry for providing such services decline and new entrants compete to provide analytics services.
                    <SU>76</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>75</SU>
                         Separate from the SLATE data products and associated fees proposed herein, FINRA intends to make T+1 data, T+20 data, and daily loan statistics available on FINRA's website free of charge for personal, non-commercial purposes only. 
                        <E T="03">See supra</E>
                         note 21.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>76</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, 88 FR 75644, 75712.
                    </P>
                </FTNT>
                <P>
                    The proposed fees associated with the SLATE Loan-Level Data and Daily Loan Statistics product apply only to market participants that choose to subscribe. Market participants likely will assess the costs and benefits of having access to these data as compared to their existing sources of securities lending data.
                    <SU>77</SU>
                    <FTREF/>
                     Vendors externally displaying SLATE Loan-Level Data and Daily Loan Statistics may charge for access to SLATE data. If vendors use securities lending data obtained from FINRA to replace existing, more expensive sources of securities lending data, they may pass some or all of the savings on to their clients.
                </P>
                <FTNT>
                    <P>
                        <SU>77</SU>
                         For a discussion of the current state of transparency in securities lending, 
                        <E T="03">see</E>
                         Adopting Release, 88 FR 75644, 75696-75700.
                    </P>
                </FTNT>
                <P>
                    As described above, in addition to SLATE Loan-Level Data and Daily Loan Statistics, FINRA also will make Historic SLATE Data available: (1) to qualifying Tax-Exempt Organizations (for a $1,000 set-up fee and $2,500 per calendar year); and (2) to persons and organizations other than qualifying Tax-Exempt Organizations (for a $2,000 set-up fee and $5,000 per calendar year). Historic SLATE loan information would facilitate the availability of securities lending data to interested parties, such as academics, in connection with research efforts.
                    <SU>78</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>78</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, 88 FR 75644, 75705, 75717.
                    </P>
                </FTNT>
                <P>
                    Given the substantial uncertainty in future subscribership for new data products and the likelihood that interest may grow slowly over time, FINRA's 
                    <PRTPAGE P="93757"/>
                    best and conservative estimation of potential initial future revenues from data product subscriptions is $250,000. Together with the estimated reporting fee revenues discussed above, FINRA estimates approximately $4.2 million in annual revenue from reporting fees and $250,000 in revenue from data product subscriptions for total annual revenue of approximately $4.5 million. This aligns with FINRA's estimated incremental direct ongoing costs of approximately $4.5 million per year from 2026 through 2028, and approximately $4.4 million in incremental direct ongoing costs thereafter.
                </P>
                <HD SOURCE="HD3">Alternatives Considered</HD>
                <P>In developing the proposed rule change, FINRA considered various alternatives and the potential costs and benefits of those alternatives. Among other things, FINRA considered a volume-based reporting fee structure where reporting fees would vary depending on loan size. However, because loan size may not be proportional to the potential revenue from reportable securities loans, a volume-based reporting fee structure may create distortions in the market. For example, the ratio of lending revenue to loan volume for short-term financing or balance sheet management is generally lower than for securities lending transactions used for accessing hard-to-borrow securities. Volume-based reporting fees also could result in a substantial concentration of reporting fees on Covered Persons with a higher share of large-volume loans. Therefore, FINRA believes that a flat fee rate per report will distribute fees in a more equitable manner across market participants.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>Written comments were neither solicited nor received.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The foregoing rule change has become effective pursuant to Section 19(b)(3)(A) of the Act 
                    <SU>79</SU>
                    <FTREF/>
                     and paragraph (f)(2) of Rule 19b-4 thereunder.
                    <SU>80</SU>
                    <FTREF/>
                     At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings to determine whether the proposed rule should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>79</SU>
                         15 U.S.C. 78s(b)(3)(A).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>80</SU>
                         17 CFR 240.19b-4(f)(2).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-FINRA-2024-020 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-FINRA-2024-020. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of FINRA. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to File Number SR-FINRA-2024-020 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>81</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>81</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27742 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101699; File No. SR-SAPPHIRE-2024-36]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; MIAX Sapphire, LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend Exchange Rule 402, Criteria for Underlying Securities To List and Trade Options on the iShares Bitcoin Trust (the “Trust”)</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”) 
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 18, 2024, MIAX Sapphire, LLC (“Exchange”) filed with the Securities and Exchange Commission (“Commission”) a proposed rule change as described in Items I and II below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>
                    The Exchange proposes to amend Exchange Rule 402, Criteria for Underlying Securities. The text of the proposed rule change is available on the Exchange's website at 
                    <E T="03">https://www.miaxglobal.com/markets/us-options/miax-sapphire/rule-filings,</E>
                     at the Exchange's principal office, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>
                    In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these 
                    <PRTPAGE P="93758"/>
                    statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.
                </P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    The Exchange proposes to amend Exchange Rule 402, Criteria for Underlying Securities,
                    <SU>3</SU>
                    <FTREF/>
                     to allow the Exchange to list and trade options on the iShares Bitcoin Trust (the “Trust”), designating the Trust as appropriate for options trading on the Exchange.
                    <SU>4</SU>
                    <FTREF/>
                     This is a competitive filing based on a similar proposal submitted by Nasdaq ISE, LLC (“ISE”) and approved by the Securities and Exchange Commission (“Commission”).
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The Exchange notes that its affiliate exchanges, MIAX Options and MIAX Pearl, submitted substantively identical proposals. The Exchange notes that all the rules of Chapter III of the MIAX Options Exchange, including Rules 307 and 309, are incorporated by reference to MIAX Pearl and MIAX Sapphire. The Exchange also notes that all of the rules of Chapter III of the MIAX Options Exchange, including Rules 307 and 309, and the rules of Chapter IV of the MIAX Options Exchange, including Rule 402, are incorporated by reference to MIAX Emerald.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         On January 10, 2024, the Commission approved proposals by NYSE Arca, Inc., The Nasdaq Stock Market LLC, and Cboe BZX Exchange, Inc. to list and trade the shares of 11 bitcoin-based commodity-based trust shares and trust units, including the iShares Bitcoin Trust. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99306 (Jan. 10, 2024), 89 FR 3008 (Jan. 17, 2024) (order approving File Nos. SR-NYSEARCA-2021-90; SR-NYSEARCA-2023-44; SR-NYSEARCA-2023-58; SR-NASDAQ-2023-016; SR-NASDAQ-2023-019; SR-CboeBZX-2023-028; SR-CboeBZX-2023-038; SR-CboeBZX-2023-040; SR-CboeBZX-2023-042; SR-CboeBZX-2023-044; SR-CboeBZX-2023-072) (“Bitcoin ETP Order”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 101128 (September 20, 2024), 89 FR 78942 (September 26, 2024) (SR-ISE-2024-03) (Self-Regulatory Organizations; Nasdaq ISE, LLC; Notice of Filing of Amendment Nos. 4 and 5 and Order Granting Accelerated Approval of a Proposed Rule Change, as Modified by Amendment Nos. 1, 4, and 5, to Permit the Listing and Trading of Options on the iShares Bitcoin Trust).
                    </P>
                </FTNT>
                <P>Current Exchange Rule 402(i)(4) provides that securities deemed appropriate for options trading include shares or other securities (“Exchange Traded Fund Shares”) that are traded on a national securities exchange and are defined as “NMS stock” under Rule 600 of Regulation NMS, and that meet specified criteria enumerated in the rule. Sub Section 4 of Exchange Rule 402(i) provides that such shares or other securities:</P>
                <P>(4) are issued by the SPDR® Gold Trust or the iShares COMEX Gold Trust or the iShares Silver Trust or the ETFS Silver Trust or the ETFS Gold Trust or the ETFS Palladium Trust or the ETFS Platinum Trust or the Sprott Physical Gold Trust.</P>
                <P>In addition, the underlying securities and Exchange Rule 402i, including the commodity based trusts in Exchange Rule 402(i)(4), must meet the requirements of Exchange Rule 402(i), Sections i(5)(i)(A) or (B).</P>
                <HD SOURCE="HD3">Proposal</HD>
                <P>The Exchange proposes to amend Exchange Rule 402(i)(4) to expand the list of securities that are appropriate for options trading on the Exchange.</P>
                <HD SOURCE="HD3">
                    Description of the Trust 
                    <SU>6</SU>
                    <FTREF/>
                </HD>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99306 (Jan. 10, 2024), 89 FR 3008 (Jan. 17, 2024) (order approving File Nos. SR-NYSEARCA-2021-90; SR-NYSEARCA-2023-44; SR-NYSEARCA-2023-58; SR-NASDAQ-2023-016; SR-NASDAQ-2023-019; SR-CboeBZX-2023-028; SR-CboeBZX-2023-038; SR-CboeBZX-2023-040; SR-CboeBZX-2023-042; SR-CboeBZX-2023-044; SR-CboeBZX-2023-072)(Order Granting Accelerated Approval of Proposed Rule Changes, as Modified by Amendments Thereto, To List and Trade Bitcoin-Based Commodity-Based Trust Shares and Trust Units) for a complete description of the Trust.
                    </P>
                </FTNT>
                <P>The shares are issued by the Trust, a Delaware statutory trust. The Trust operates pursuant to a trust agreement (the “Trust Agreement”) between the Sponsor, BlackRock Fund Advisors (the “Trustee”) as the trustee of the Trust and Wilmington Trust, National Association, as Delaware trustee. The Trust issues shares representing fractional undivided beneficial interests in its net assets. The assets of the Trust consist only of bitcoin, held by a custodian on behalf of the Trust except under limited circumstances when transferred through the Trust's prime broker temporarily (described below), and cash. Coinbase Custody Trust Company, LLC (the “Bitcoin Custodian”) is the custodian for the Trust's bitcoin holdings, and maintains a custody account for the Trust (“Custody Account”); Coinbase, Inc. (the “Prime Execution Agent”), an affiliate of the Bitcoin Custodian, is the prime broker for the Trust and maintains a trading account for the Trust (“Trading Account”); and Bank of New York Mellon is the custodian for the Trust's cash holdings (the “Cash Custodian” and together with the Bitcoin Custodian, the “Custodians”) and the administrator of the Trust (the “Trust Administrator”). Under the Trust Agreement, the Trustee may delegate all or a portion of its duties to any agent, and has delegated the bulk of the day to day responsibilities to the Trust Administrator and certain other administrative and record-keeping functions to its affiliates and other agents. The Trust is not an investment company registered under the Investment Company Act of 1940, as amended.</P>
                <P>The investment objective of the Trust is to reflect generally the performance of the price of bitcoin. The Trust seeks to reflect such performance before payment of the Trust's expenses and liabilities. The shares are intended to constitute a simple means of making an investment similar to an investment in bitcoin through the public securities market rather than by acquiring, holding and trading bitcoin directly on a peer-to-peer or other basis or via a digital asset exchange. The shares have been designed to remove the obstacles represented by the complexities and operational burdens involved in a direct investment in bitcoin, while at the same time having an intrinsic value that reflects, at any given time, the investment exposure to the bitcoin owned by the Trust at such time, less the Trust's expenses and liabilities. Although the shares are not the exact equivalent of a direct investment in bitcoin, they provide investors with an alternative method of achieving investment exposure to bitcoin through the public securities market, which may be more familiar to them.</P>
                <HD SOURCE="HD3">Custody of the Trust's Bitcoin</HD>
                <P>
                    An investment in the shares is backed by bitcoin held by the Bitcoin Custodian on behalf of the Trust. All of the Trust's bitcoin will be held in the Custody Account, other than the Trust's bitcoin which is temporarily maintained in the Trading Account under limited circumstances, 
                    <E T="03">i.e.,</E>
                     in connection with creation and redemption Basket 
                    <SU>7</SU>
                    <FTREF/>
                     activity or sales of bitcoin deducted from the Trust's holdings in payment of Trust expenses or the Sponsor's fee (or, in extraordinary circumstances, upon liquidation of the Trust). The Custody Account includes all of the Trust's bitcoin held at the Bitcoin Custodian, but does not include the Trust's bitcoin temporarily maintained at the Prime Execution Agent in the Trading Account from time to time. The Bitcoin Custodian will keep all of the private keys associated with the Trust's bitcoin held in the Custody Account in “cold storage”.
                    <SU>8</SU>
                    <FTREF/>
                     The hardware, software, 
                    <PRTPAGE P="93759"/>
                    systems, and procedures of the Bitcoin Custodian may not be available or cost-effective for many investors to access directly.
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         The Trust issues and redeems Shares only in blocks of 40,000 or integral multiples thereof. A block of 40,000 Shares is called a “Basket.” These transactions take place in exchange for Bitcoin.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         The term “cold storage” refers to a safeguarding method by which the private keys corresponding to the Trust's bitcoins are generated and stored in an offline manner, subject to layers of procedures 
                        <PRTPAGE/>
                        designed to enhance security. Private keys are generated by the Bitcoin Custodian in offline computers that are not connected to the internet so that they are more resistant to being hacked.
                    </P>
                </FTNT>
                <P>
                    The Exchange believes that offering options on the Trust will benefit investors by providing them with an additional, relatively lower cost investing tool to gain exposure to spot Bitcoin as well as a hedging vehicle to meet their investment needs in connection with Bitcoin products and positions. Similar to other commodity-based trusts on which options may be listed on the Exchange (
                    <E T="03">e.g.,</E>
                     SPDR® Gold Trust, the iShares COMEX Gold Trust, the iShares Silver Trust, or the ETFS Gold Trust),
                    <SU>9</SU>
                    <FTREF/>
                     the Trust essentially offers the same objectives and benefits to investors as do other commodity-based trusts on which options may be listed on the Exchange.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 402(i)(4).
                    </P>
                </FTNT>
                <P>Options on the Trust will trade in the same manner as options on other ETFs on the Exchange. Exchange Rules that currently apply to the listing and trading of all options on ETFs on the Exchange, including, for example, Rules that govern listing criteria, expirations, exercise prices, minimum increments, position and exercise limits (including as proposed in the filing submitted by Exchange's affiliate, MIAX Options), margin requirements, customer accounts and trading halt procedures, will apply to the listing and trading of options on the Trust on the Exchange. Today, these rules apply to options on the various commodities-based trusts deemed appropriate for options trading on the Exchange pursuant to Exchange Rule 402(i)(4).</P>
                <P>The Exchange's initial listing standards for ETFs on which options may be listed and traded on the Exchange will apply to the Trust. Pursuant to Exchange Rule 402(a), a security (which includes ETFs) on which options may be listed and traded on the Exchange must be duly registered (with the Commission) and be an NMS stock (as defined in Rule 600 of Regulation NMS under the Act,) and be characterized by a substantial number of outstanding shares that are widely held and actively traded. Exchange Rule 402(i) requires that, in relevant part, ETFs must either (1) meet the criteria and standards set forth in Exchange Rule 402(a) or Exchange Rule 402(b), or (2) be available for creation or redemption each business day from or through the issuer in cash or in kind at a price related to net asset value, and the issuer must be obligated to issue ETFs in a specified aggregate number even if some or all of the investment assets required to be deposited have not been received by the issuer, subject to the condition that the person obligated to deposit the investments has undertaken to deliver the investment assets as soon as possible and such undertaking is secured by the delivery and maintenance of collateral consisting of cash or cash equivalents satisfactory to the issuer, as provided in the respective prospectus.</P>
                <P>Options on the Trust will also be subject to the Exchange's continued listing standards set forth in Exchange Rule 403(g), for ETFs deemed appropriate for options trading pursuant to Exchange Rule 402(i). Specifically, Exchange Rule 403(g) provides that ETFs that were initially approved for options trading pursuant to Exchange Rule 402(i) shall be deemed not to meet the requirements for continued approval, and the Exchange shall not open for trading any additional series of option contracts of the class covering that such ETFs, if the ETFs are delisted from trading pursuant to Exchange Rule 403(b)(4), are halted or suspended from trading in their primary market. Additionally, options on ETFs may be subject to the suspension of opening transactions in any of the following circumstances: (1) in the case of options covering ETFs approved for trading under Exchange Rule 402(i)(5)(i)(A), in accordance with the terms of paragraphs (b)(1), (2), and (3) of Exchange Rule 403; (2) in the case of options covering ETFs approved for trading under Exchange Rule 402(i)(5)(i)(B), following the initial twelve-month period beginning upon the commencement of trading in the ETFs on a national securities exchange and are defined as an NMS stock, there are fewer than 50 record and/or beneficial holders of such ETFs for 30 or more consecutive trading days; (3) the value of the index or portfolio of securities, non-U.S. currency, or portfolio of commodities including commodity futures contracts, options on commodity futures contracts, swaps, forward contracts and/or options on physical commodities and/or financial instruments and money market instruments on which the ETFs are based is no longer calculated or available; or (4) such other event shall occur or condition exist that in the opinion of the Exchange makes further dealing in such options on the Exchange inadvisable.</P>
                <P>
                    Options on the Trust would be physically settled contracts with American-style exercise.
                    <SU>10</SU>
                    <FTREF/>
                     Consistent with current Exchange Rule 404, which governs the opening of options series on a specific underlying security (including ETFs), the Exchange will open at least one expiration month for options on the Trust 
                    <SU>11</SU>
                    <FTREF/>
                     and may also list series of options on the Trust for trading on a weekly,
                    <SU>12</SU>
                    <FTREF/>
                     monthly,
                    <SU>13</SU>
                    <FTREF/>
                     or quarterly 
                    <SU>14</SU>
                    <FTREF/>
                     basis. The Exchange may also list long-term equity option series (“LEAPS”) that expire from 12 to 39 months from the time they are listed.
                    <SU>15</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 401, which provides that the rights and obligations of holders and writers are set forth in the Rules of the Options Clearing Corporation (“OCC”); 
                        <E T="03">see also</E>
                         OCC Rules, Chapters VIII (which governs exercise and assignment) and Chapter IX (which governs the discharge of delivery and payment obligations arising out of the exercise of physically settled stock option contracts).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404(b). The monthly expirations are subject to certain listing criteria for underlying securities described within Exchange Rule 404 and its Interpretations and Policies. Monthly listings expire the third Friday of the month. The term “expiration date” (unless separately defined elsewhere in the OCC By-Laws), when used in respect of an option contract (subject to certain exceptions), means the third Friday of the expiration month of such option contract, or if such Friday is a day on which the exchange on which such option is listed is not open for business, the preceding day on which such exchange is open for business. 
                        <E T="03">See</E>
                         OCC By-Laws Article I, Section 1. Pursuant to Exchange Rule 404(c), additional series of options of the same class may be opened for trading on the Exchange when the Exchange deems it necessary to maintain an orderly market, to meet customer demand or when the market price of the underlying stock moves more than five strike prices from the initial exercise price or prices. Pursuant to Exchange Rule 404(e), new series of options on an individual stock may be added until the beginning of the month in which the options contract will expire. Due to unusual market conditions, the Exchange, in its discretion, may add a new series of options on an individual stock until the close of trading on the business day prior to expiration.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretations and Policies .02.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretations and Policies .13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretations and Policies .03.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 406(a).
                    </P>
                </FTNT>
                <P>
                    Pursuant to Exchange Rule 404, Interpretation and Policy .06, which governs strike prices of series of options on ETFs, the interval between strike prices of series of options on ETFs approved for options trading pursuant to Exchange Rule 402(i) shall be fixed at a price per share which is reasonably close to the price per share at which the underlying security is traded in the primary market at or about the same time such series of options is first open for trading on the Exchange, or at such intervals as may have been established on another options exchange prior to the initiation of trading on the Exchange. With respect to the Short Term Options Series or Weekly Program, during the month prior to expiration of an option 
                    <PRTPAGE P="93760"/>
                    class that is selected for the Short Term Option Series Program, the strike price intervals for the related non-Short Term Option (“Related non-Short Term Option”) shall be the same as the strike price intervals for the Short Term Option.
                    <SU>16</SU>
                    <FTREF/>
                     Specifically, the Exchange may open for trading Short Term Option Series at strike price intervals of (i) $0.50 or greater where the strike price is less than $100, and $1 or greater where the strike price is between $100 and $150 for all option classes that participate in the Short Term Options Series Program; (ii) $0.50 for option classes that trade in one dollar increments and are in the Short Term Option Series Program; or (iii) $2.50 or greater where the strike price is above $150.
                    <SU>17</SU>
                    <FTREF/>
                     Additionally, the Exchange may list series of options pursuant to the $1 Strike Price Interval Program,
                    <SU>18</SU>
                    <FTREF/>
                     the $0.50 Strike Program,
                    <SU>19</SU>
                    <FTREF/>
                     and the $2.50 Strike Price Program.
                    <SU>20</SU>
                    <FTREF/>
                     Pursuant to Exchange Rule 510, where the price of a series of options for the Trust is less than $3.00, the minimum increment will be $0.05, and where the price is $3.00 or higher, the minimum increment will be $0.10 
                    <SU>21</SU>
                    <FTREF/>
                     consistent with the minimum increments for options on other ETFs listed on the Exchange. Any and all new series of Trust options that the Exchange lists will be consistent and comply with the expirations, strike prices, and minimum increments set forth in Rules 404 and 510, as applicable.
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretations and Policies .02(e).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretation and Policy .01.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretation and Policy .04.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404(f).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 510.
                    </P>
                </FTNT>
                <P>Position and exercise limits for options on ETFs, including options on the Trust, are determined pursuant to the Exchange's affiliate MIAX Options Rules 307 and 309, respectively. Position and exercise limits for ETF options vary according to the number of outstanding shares and the trading volumes of the underlying ETF over the past six months, where the largest in capitalization and the most frequently traded ETFs have an option position and exercise limit of 250,000 contracts (with adjustments for splits, re-capitalizations, etc.) on the same side of the market; and smaller capitalization ETFs have position and exercise limits of 200,000, 75,000, 50,000 or 25,000 contracts (with adjustments for splits, re-capitalizations, etc.) on the same side of the market. The Exchange further notes that the Exchange's affiliate MIAX Options Rule 1502, which governs margin requirements applicable to trading on the Exchange, including options on ETFs, will also apply to the trading of the Trust options. Notwithstanding the position limits in the Exchange's affiliate MIAX Options Rule 307(d) and exercise limits in the Exchange's affiliate MIAX Options Rule 309, the Exchange proposes the position and exercise limits for the options on the Trust to be 25,000 contracts on the same side pursuant to proposed Supplementary Material .01 to the Exchange's affiliate MIAX Options Rule 307 and proposed Supplementary Material .01 to the Exchange's affiliate MIAX Options Rule 309.</P>
                <P>The Exchange represents that the same surveillance procedures applicable to all other options on other ETFs currently listed and traded on the Exchange will apply to options on the Trust. Also the Exchange represents that it has the necessary systems capacity to support the new option series. The Exchange believes that its existing surveillance and reporting safeguards are designed to deter and detect possible manipulative behavior which might potentially arise from listing and trading options on ETFs, including the proposed Trust options.</P>
                <P>
                    Today, the Exchange has an adequate surveillance program in place for options. The Exchange intends to apply those same program procedures to options on the Trust that it applies to the Exchange's other options products.
                    <SU>22</SU>
                    <FTREF/>
                     The Exchange's staff will have access to the surveillance programs conducted by its affiliate exchanges, MIAX Options and MIAX Pearl with respect to trading in the shares of the underlying Trust when conducting surveillances for market abuse or manipulation in the options on the Trust. Additionally, the Exchange is a member of the Intermarket Surveillance Group (“ISG”) under the Intermarket Surveillance Group Agreement. ISG members work together to coordinate surveillance and investigative information sharing in the stock, options, and futures markets. In addition to obtaining surveillance data from MIAX Options and MIAX Sapphire, the Exchange will be able to obtain information regarding trading in the shares of the underlying Trust from Nasdaq, LLC and other markets through ISG. In addition, the Exchange has a Regulatory Services Agreement with the Financial Industry Regulatory Authority (“FINRA”). Pursuant to a multi-party 17d-2 joint plan, all options exchanges allocate regulatory responsibilities to FINRA to conduct certain options-related market surveillance that are common to rules of all options exchanges.
                    <SU>23</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         The surveillance program includes real-time patterns for price and volume movements and post-trade surveillance patterns (
                        <E T="03">e.g.,</E>
                         spoofing, marking the close, pinging, phishing).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         Section 19(g)(1) of the Act, among other things, requires every SRO registered as a national securities exchange or national securities association to comply with the Act, the rules and regulations thereunder, and the SRO's own rules, and, absent reasonable justification or excuse, enforce compliance by its members and persons associated with its members. See 15 U.S.C. 78q(d)(1) and 17 CFR 240.17d-2. Section 17(d)(1) of the Act allows the Commission to relieve an SRO of certain responsibilities with respect to members of the SRO who are also members of another SRO (“common members”). Specifically, Section 17(d)(1) allows the Commission to relieve an SRO of its responsibilities to: (i) receive regulatory reports from such members; (ii) examine such members for compliance with the Act and the rules and regulations thereunder, and the rules of the SRO; or (iii) carry out other specified regulatory responsibilities with respect to such members.
                    </P>
                </FTNT>
                <P>The underlying shares of spot bitcoin ETPs, including the Trust, are also subject to safeguards related to addressing market abuse and manipulation. As the Commission stated in Bitcoin ETP Order:</P>
                <P>
                    Each Exchange has a comprehensive surveillance-sharing agreement with the CME via their common membership in the Intermarket Surveillance Group. This facilitates the sharing of information that is available to the CME through its surveillance of its markets, including its surveillance of the CME bitcoin futures market.
                    <SU>24</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         
                        <E T="03">See supra</E>
                         note 4.
                    </P>
                </FTNT>
                <P>
                    The Exchange states that, given the consistently high correlation between the CME bitcoin futures market and the spot bitcoin market, as confirmed by the Commission through robust correlation analysis, the Commission was able to conclude that such surveillance sharing agreements could reasonably be “expected to assist in surveilling for fraudulent and manipulative acts and practices in the specific context of the [Bitcoin ETPs].” 
                    <SU>25</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         
                        <E T="03">See</E>
                         Bitcoin ETP Order, 89 FR at 3010-11.
                    </P>
                </FTNT>
                <P>
                    In light of surveillance measures related to both options and futures as well as the underlying Trust,
                    <SU>26</SU>
                    <FTREF/>
                     the Exchange believes that existing surveillance procedures are designed to deter and detect possible manipulative behavior which might potentially arise from listing and trading the proposed options on the Trust. Further, the Exchange represents that it will implement any new surveillance 
                    <PRTPAGE P="93761"/>
                    procedures it deems necessary to effectively monitor the trading of options on the Trust.
                </P>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99295 (January 8, 2024), 89 FR 2321, 2334-35 (January 12, 2024) (SR-NASDAQ-2023-016) (Notice of Filing of Amendment No. 1 to a Proposed Rule Change To List and Trade Shares of the iShares Bitcoin Trust Under Nasdaq Rule 5711(d)).
                    </P>
                </FTNT>
                <P>
                    The Exchange has also analyzed its capacity and represents that it believes the Exchange and Options Price Reporting Authority or “OPRA” have the necessary systems capacity to handle the additional traffic associated with the listing of new series that may result from the introduction of options on the Trust up to the number of expirations currently permissible under the Rules. Because the proposal is limited to one class, the Exchange believes any additional traffic that may be generated from the introduction of the Trust options will be manageable. Finally, the Exchange proposes a technical amendment to Exchange Rule 402(i)(4) to amend the name “ETFS Gold Trust” to “Aberdeen Standard Physical Gold Trust.” In 2018 ETFS Gold Trust was renamed.
                    <SU>27</SU>
                    <FTREF/>
                     At this time, the Exchange proposes to amend the name of the ETF to reflect its current name.
                </P>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         Effective October 1, 2018 ETFS Gold Trust was renamed Aberdeen Standard Gold ETF Trust. 
                        <E T="03">https://www.sec.gov/Archives/edgar/data/1450923/000138713118005292/ex10-2.htm</E>
                        .
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The Exchange believes the proposed rule change is consistent with the Act and the rules and regulations thereunder applicable to the Exchange and, in particular, the requirements of Section 6(b) of the Act.
                    <SU>28</SU>
                    <FTREF/>
                     Specifically, the Exchange believes the proposed rule change is consistent with the Section 6(b)(5) 
                    <SU>29</SU>
                    <FTREF/>
                     requirements that the rules of an exchange be designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in regulating, clearing, settling, processing information with respect to, and facilitating transactions in securities, to remove impediments to and perfect the mechanism of a free and open market and a national market system, and, in general, to protect investors and the public interest. Additionally, the Exchange believes the proposed rule change is consistent with the Section (6)(b)(5) 
                    <SU>30</SU>
                    <FTREF/>
                     requirement that the rules of an exchange not be designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>In particular, the Exchange believes that the proposal to list and trade options on the Trust will remove impediments to and perfect the mechanism of a free and open market and a national market system and, in general, protect investors because offering options on the Trust will provide investors with a greater opportunity to realize the benefits of utilizing options on an ETF based on spot bitcoin, including cost efficiencies and increased hedging strategies. The Exchange believes that offering options on a competitively priced ETF based on spot bitcoin will benefit investors by providing them with an additional, relatively lower-cost risk management tool, allowing them to manage, more easily, their positions and associated risks in their portfolios in connection with exposure to spot bitcoin. Today, the Exchange lists options on other commodity ETFs structured as a trust, which essentially offer the same objectives and benefits to investors, and for which the Exchange has not identified any issues with the continued listing and trading of options on those ETFs.</P>
                <P>The Exchange also believes the proposal to permit options on the Trust will remove impediments to and perfect the mechanism of a free and open market and a national market system, because options on the Trust will comply with current Exchange Rules. Options on the Trust must satisfy the initial listing standards and continued listing standards currently in the Exchange Rules, applicable to options on all ETFs, including options on other commodity ETFs already deemed appropriate for options trading on the Exchange pursuant to Exchange Rule 402(i)(4). Further, Exchange Rules that currently govern the listing and trading of options on ETFs, including permissible expirations, strike prices, minimum increments, position and exercise limits (including as proposed in the filing submitted by Exchange's affiliate, MIAX Options), and margin requirements, will govern the listing and trading of options on the Trust. The proposed position and exercise limits for options on the Trust is 25,000 contracts. These position and exercise limits are the lowest position and exercise limits available in the options industry, are extremely conservative and more than appropriate given the Trust's market capitalization, average daily volume, and high number of outstanding shares. The proposed position limit, and exercise limit, is consistent with the Act as it addresses concerns related to manipulation and protection of investors because the position limit (and exercise limit) is extremely conservative and more than appropriate given the Trust is actively traded.</P>
                <P>
                    The Exchange represents that it has the necessary systems capacity to support options on the Trust. The Exchange believes that its existing surveillance and reporting safeguards are designed to deter and detect possible manipulative behavior which might arise from listing and trading options on ETFs, including the Trust options. Today, the Exchange has an adequate surveillance program in place for options. The Exchange intends to apply those same program procedures to options on the Trust that it applies to the Exchange's other options products.
                    <SU>31</SU>
                    <FTREF/>
                     The Exchange's staff will have access to the surveillance programs conducted by its affiliate exchanges, MIAX Options and MIAX Sapphire with respect to the underlying Trust when conducting surveillances for market abuse or manipulation in the options on the Trust. The Exchange will review activity in the underlying Trust when conducting surveillances for market abuse or manipulation in the options on the Trust. Additionally, the Exchange is a member of the ISG under the Intermarket Surveillance Group Agreement. ISG members work together to coordinate surveillance and investigative information sharing in the stock, options, and futures markets. In addition to obtaining surveillance data from MIAX Options and MIAX Sapphire, the Exchange will be able to obtain information from ISE and other markets through ISG. In addition, the Exchange has a Regulatory Services Agreement with FINRA. Pursuant to a multi-party 17d-2 joint plan, all options exchanges allocate regulatory responsibilities to FINRA to conduct certain options-related market surveillance that are common to rules of all options exchanges.
                    <SU>32</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         The surveillance program includes real-time patterns for price and volume movements and post-trade surveillance patterns (
                        <E T="03">e.g.,</E>
                         spoofing, marking the close, pinging, phishing).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         Section 19(g)(1) of the Act, among other things, requires every SRO registered as a national securities exchange or national securities association to comply with the Act, the rules and regulations thereunder, and the SRO's own rules, and, absent reasonable justification or excuse, enforce compliance by its members and persons associated with its members. See 15 U.S.C. 78q(d)(1) and 17 CFR 240.17d-2. Section 17(d)(1) of the Act allows the Commission to relieve an SRO of certain responsibilities with respect to members of the SRO who are also members of another SRO (“common members”). Specifically, Section 17(d)(1) allows the Commission to relieve an SRO of its responsibilities to: (i) receive regulatory reports from such members; (ii) examine such members for compliance with the Act and the rules and regulations thereunder, and the rules of the SRO; or (iii) carry out other specified regulatory responsibilities with respect to such members.
                    </P>
                </FTNT>
                <P>
                    The underlying shares of spot bitcoin ETPs, including the Trust, are also 
                    <PRTPAGE P="93762"/>
                    subject to safeguards related to addressing market abuse and manipulation. As the Commission stated in Bitcoin ETP Order:
                </P>
                <P>
                    Each Exchange has a comprehensive surveillance-sharing agreement with the CME via their common membership in the Intermarket Surveillance Group. This facilitates the sharing of information that is available to the CME through its surveillance of its markets, including its surveillance of the CME bitcoin futures market.
                    <SU>33</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         
                        <E T="03">See supra</E>
                         note 4.
                    </P>
                </FTNT>
                <P>
                    The Exchange states that, given the consistently high correlation between the CME bitcoin futures market and the spot bitcoin market, as confirmed by the Commission through robust correlation analysis, the Commission was able to conclude that such surveillance sharing agreements could reasonably be “expected to assist in surveilling for fraudulent and manipulative acts and practices in the specific context of the [Bitcoin ETPs].” 
                    <SU>34</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         
                        <E T="03">See</E>
                         Bitcoin ETP Order, 89 FR at 3010-11.
                    </P>
                </FTNT>
                <P>
                    In light of surveillance measures related to both options and futures as well as the underlying Trust,
                    <SU>35</SU>
                    <FTREF/>
                     the Exchange believes that existing surveillance procedures are designed to deter and detect possible manipulative behavior which might potentially arise from listing and trading the proposed options on the Trust. Further, the Exchange represents that it will implement any new surveillance procedures it deems necessary to effectively monitor the trading of options on the Trust.
                </P>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99295 (January 8, 2024), 89 FR 2321, 2334-35 (January 12, 2024) (SR-NASDAQ-2023-016) (Notice of Filing of Amendment No. 1 to a Proposed Rule Change To List and Trade Shares of the iShares Bitcoin Trust Under Nasdaq Rule 5711(d)).
                    </P>
                </FTNT>
                <P>
                    Finally, the Commission has previously approved the listing and trading of options on other commodity ETFs structured as a trust, such as SPDR® Gold Trust,
                    <SU>36</SU>
                    <FTREF/>
                     the iShares COMEX Gold Trust 
                    <SU>37</SU>
                    <FTREF/>
                     the iShares Silver Trust,
                    <SU>38</SU>
                    <FTREF/>
                     the ETFS Gold Trust,
                    <SU>39</SU>
                    <FTREF/>
                     and the ETFS Silver Trust.
                    <SU>40</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 57897 (May 30, 2008), 73 FR 32061 (June 5, 2008) (SR-Amex-2008-15; SR-CBOE-2005-11; SR-ISE-2008-12; SR-NYSEArca-2008-52; and SRPhlx-2008-17) (Order Granting Approval of a Proposed Rule Change, as Modified, and Notice of Filing and Order Granting Accelerated Approval of Proposed Rule Changes, as Modified, Relating to Listing and Trading Options on the SPDR Gold Trust).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 59055 (December 4, 2008), 73 FR 75148 (December 10, 2008) (SR-Amex-2008-68; SR-BSE-2008-51; SR-CBOE-2008-72; SR-ISE-2008-58; SRNYSEArca-2008-66; and SR-Phlx-2008-58) (Notice of Filing and Order Granting Accelerated Approval of Proposed Rule Changes Relating to the Listing and Trading Options on Shares of the iShares COMEX Gold Trust and the iShares Silver Trust).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 61483 (February 3, 2010), 75 FR 6753 (February 10, 2010) (SR-CBOE-2010-007; SR-ISE-2009-106; SR-NYSEAmex-2009-86; and SR-NYSEArca-2009-110) (Order Granting Approval of Proposed Rule Changes and Notice of Filing and Order Granting Accelerated Approval of a Proposed Rule Change Relating to Listing and Trading Options on the ETFS Gold Trust and the ETFS Silver Trust).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>Further, the Exchange's proposal to amend the name “ETFS Gold Trust” to “Aberdeen Standard Physical Gold Trust” in Exchange Rule 402(i)(4) is consistent with the Act and the protection of investors as this amendment reflects the current name of this product.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>
                    The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. In this regard and as indicated above, the Exchange notes that the rule change is being proposed as a competitive response to filings submitted by ISE.
                    <SU>41</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         
                        <E T="03">See supra</E>
                         note 5.
                    </P>
                </FTNT>
                <P>The Exchange does not believe that the proposed rule change will impose any burden on intramarket competition that is not necessary or appropriate in furtherance of the purposes of the Act as options on the Trust will be subject to initial listing standards and continued listing standards the same as other options on ETFs listed on the Exchange. Further, options on the Trust will be subject to Exchange Rules that currently govern the listing and trading of options on ETFs, including permissible expirations, strike prices, minimum increments, position and exercise limits (including as proposed in the filing submitted by Exchange's affiliate, MIAX Options), and margin requirements. Options on the Trust will be equally available to all market participants who wish to trade such options. Also, and as stated above, the Exchange already lists options on other commodity ETFs structured as a trust.</P>
                <P>The Exchange does not believe that the proposal to list to list and trade options on the Trust will impose any burden on intermarket competition that is not necessary or appropriate in furtherance of the purposes of the Act. To the extent that permitting options on the Trust to trade on the Exchange may make the Exchange a more attractive marketplace to market participants, such market participants are free to elect to become market participants on the Exchange. Additionally, other options exchanges are free to amend their listing rules, as applicable, to permit them to list and trade options on the Trust. The Exchange believes that the proposed rule change may relieve any burden on, or otherwise promote, competition as it is designed to increase competition for order flow on the Exchange in a manner that is beneficial to investors by providing them with a lower-cost option to hedge their investment portfolios. The Exchange notes that it operates in a highly competitive market in which market participants can readily direct order flow to competing venues that offer similar products. Ultimately, the Exchange believes that offering options on the Trust for trading on the Exchange will promote competition by providing investors with an additional, relatively low-cost means to hedge their portfolios and meet their investment needs in connection with spot bitcoin prices and bitcoin related products and positions.</P>
                <P>Finally, the Exchange's proposal to amend the name “ETFS Gold Trust” to “Aberdeen Standard Physical Gold Trust” in Exchange Rule 402(i)(4) does not impose an undue burden on competition as this amendment reflects the current name of this product.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>Written comments were neither solicited nor received.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The Exchange has filed the proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>42</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6) thereunder.
                    <SU>43</SU>
                    <FTREF/>
                     Because the foregoing proposed rule change does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative for 30 days from the date on which it was filed, or such shorter time as the Commission may designate, it has become effective pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>44</SU>
                    <FTREF/>
                     and subparagraph (f)(6) of Rule 19b-4 thereunder.
                    <SU>45</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6)(iii) requires a self-regulatory organization to give the Commission written notice of its intent to file the proposed rule change, along with a brief description and text of the proposed rule change, at least five business days prior to the date of filing of the proposed rule change, or such shorter time 
                        <PRTPAGE/>
                        as designated by the Commission. The Exchange has satisfied this requirement.
                    </P>
                </FTNT>
                <PRTPAGE P="93763"/>
                <P>
                    A proposed rule change filed under Rule 19b-4(f)(6) 
                    <SU>46</SU>
                    <FTREF/>
                     under the Act does not normally become operative prior to 30 days after the date of the filing. However, pursuant to Rule 19b-4(f)(6)(iii),
                    <SU>47</SU>
                    <FTREF/>
                     the Commission may designate a shorter time if such action is consistent with the protection of investors and the public interest. The Exchange has requested that the Commission waive the 30-day operative delay so that the proposal may become operative immediately upon filing. The Commission previously approved the listing of options on iShares Bitcoin Trust.
                    <SU>48</SU>
                    <FTREF/>
                     The Exchange has provided information regarding the underlying iShares Bitcoin Trust, including, among other things, information regarding trading volume, the number of beneficial holders, and the market capitalization of the iShares Bitcoin Trust. The proposal also establishes position and exercise limits for options on the iShares Bitcoin Trust and provides information regarding the surveillance procedures that will apply to iShares Bitcoin Trust options. The Commission believes that waiver of the operative delay could benefit investors by providing an additional venue for trading iShares Bitcoin Trust options. Therefore, the Commission believes that waiver of the 30-day operative delay is consistent with the protection of investors and the public interest. Accordingly, the Commission hereby waives the 30-day operative delay and designates the proposed rule change as operative upon filing.
                    <SU>49</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>46</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>47</SU>
                         17 CFR 240.19b-4(f)(6)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>48</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 101128 (September 20, 2024), 89 FR 78942 (September 26, 2024) (SR-ISE-2024-03) (Self-Regulatory Organizations; Nasdaq ISE, LLC; Notice of Filing of Amendment Nos. 4 and 5 and Order Granting Accelerated Approval of a Proposed Rule Change, as Modified by Amendment Nos. 1, 4, and 5, to Permit the Listing and Trading of Options on the iShares Bitcoin Trust).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>49</SU>
                         For purposes only of waiving the 30-day operative delay, the Commission has also considered the proposed rule's impact on efficiency, competition, and capital formation. 
                        <E T="03">See</E>
                         15 U.S.C. 78c(f).
                    </P>
                </FTNT>
                <P>At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings to determine whether the proposed rule should be approved or disapproved.</P>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-SAPPHIRE-2024-36 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-SAPPHIRE-2024-36. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-SAPPHIRE-2024-36 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>50</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>50</SU>
                             17 CFR 200.30-3(a)(12), (59).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27744 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101695; File No. SR-FICC-2024-007]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; Fixed Income Clearing Corporation; Order Approving Proposed Rule Change, as Modified by Partial Amendment No. 1, To Modify the GSD Rules (i) Regarding the Separate Calculation, Collection and Holding of Margin for Proprietary Transactions and That for Indirect Participant Transactions, and (ii) To Address the Conditions of Note H to Rule 15c3-3a</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    On March 14, 2024, Fixed Income Clearing Corporation (“FICC”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change SR-FICC-2024-007 pursuant to Section 19(b) of the Securities Exchange Act of 1934 (“Exchange Act”) 
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 
                    <SU>2</SU>
                    <FTREF/>
                     thereunder to modify FICC's Government Securities Division (“GSD”) Rulebook (“GSD Rules”) to calculate, collect, and hold margin for transactions that a direct GSD participant enters into for its own benefit (“proprietary transactions”) separately from margin a direct participant submits to FICC on behalf of indirect participants and to address conditions of Note H to Rule 15c3-3a under the Exchange Act (the “Proposed Rule Change”).
                    <SU>3</SU>
                    <FTREF/>
                     The Proposed Rule Change was published for public comment in the 
                    <E T="04">Federal Register</E>
                     on March 28, 2024.
                    <SU>4</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99149 (Dec. 13, 2023), 89 FR 2714 (Jan. 16, 2024) (S7-23-22) (“Adopting Release,” and the rules adopted therein as “Treasury Clearing Rules”). 
                        <E T="03">See also</E>
                         17 CFR 240.15c3-3a.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Securities Exchange Act Release No. 99844 (March 22, 2024), 89 FR 21603 (Mar. 28, 2024) (File No. SR-FICC-2024-007) (“Notice of Filing”). FICC also filed a related Advance Notice with the Commission pursuant to Section 806(e)(1) of Title VIII of the Dodd-Frank Wall Street Reform and Consumer Protection Act, entitled the Payment, Clearing, and Settlement Supervision Act of 2010 and Rule 19b-4(n)(1)(i) under the Exchange Act. 12 U.S.C. 5465(e)(1). 15 U.S.C. 78s(b)(1) and 17 CFR 240.19b-4, respectively. The Advance Notice was 
                        <PRTPAGE/>
                        published in the 
                        <E T="04">Federal Register</E>
                         on March 28, 2024. Securities Exchange Act Release No. 99845 (Mar. 22, 2024), 89 FR 21586 (Mar. 28, 2024) (File No. SR-FICC-2024-802). Upon publication of notice of filing of the Advance Notice, the Commission extended the review period of the advance notice for an additional 60 days because the Commission determined that the advance notice raised novel and complex issues. On April 24, 2024, the Commission requested additional information from FICC pursuant to Section 806(e)(1)(D) of the Clearing Supervision Act, which tolled the Commission's period of review of the Advance Notice until 120 days from the date the information requested by the Commission was received by the Commission. 
                        <E T="03">See</E>
                         12 U.S.C. 5465(e)(1)(D). A memo regarding the Request for Additional Information and the tolled period of review is available at 
                        <E T="03">https://www.sec.gov/comments/sr-ficc-2024-802/srficc2024802-462751-1210414.pdf.</E>
                         On September 24, 2024, the Commission requested additional information from FICC pursuant to Section 806(e)(1)(D) of the Clearing Supervision Act, which tolled the Commission's period of review of the Advance Notice until 120 days from the date the information requested by the Commission was received by the Commission. On October 21, 2024, the Commission received FICC's response to the Commission's September 24, 2024 request for additional information. 
                        <E T="03">See</E>
                         12 U.S.C. 5465(e)(1)(E)(ii) and (G)(ii). A memo regarding receipt of FICC's response to the Request for Additional Information is available at 
                        <E T="03">https://www.sec.gov/comments/sr-ficc-2024-802/srficc2024802-539295-1544222.pdf.</E>
                    </P>
                </FTNT>
                <PRTPAGE P="93764"/>
                <P>
                    On April 24, 2024, pursuant to Section 19(b)(2) of the Exchange Act,
                    <SU>5</SU>
                    <FTREF/>
                     the Commission designated a longer period within which to approve, disapprove, or institute proceedings to determine whether to approve or disapprove the Proposed Rule Change.
                    <SU>6</SU>
                    <FTREF/>
                     On June 21, 2024, pursuant to Section 19(b)(2)(B) of the Exchange Act,
                    <SU>7</SU>
                    <FTREF/>
                     the Commission instituted proceedings to determine whether to approve or disapprove the Proposed Rule Change.
                    <SU>8</SU>
                    <FTREF/>
                     On September 18, 2024, the Commission extended the time period for Commission action on the proceedings to determine whether to disapprove the Proposed Rule Change.
                    <SU>9</SU>
                    <FTREF/>
                     On October 25, 2024, FICC filed Partial Amendment No. 1 to the Proposed Rule Change.
                    <SU>10</SU>
                    <FTREF/>
                     The Proposed Rule Change, as modified by Partial Amendment No. 1, is referred to herein as the “Proposed Rule Change.”
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         15 U.S.C. 78s(b)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         Securities Exchange Act Release No. 100022 (Apr. 24, 2024), 89 FR 34289 (Apr. 30, 2024) (File No. SR-FICC-2024-007).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         15 U.S.C. 78s(b)(2)(B).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         Securities Exchange Act Release No. 100401 (Jun. 21, 2024), 89 FR 53690 (Jun. 27, 2024) (File No. SR-FICC-2024-007).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         Securities Exchange Act Release No. 101082 (Sep. 18, 2024), 89 FR 77949 (Sep. 24, 2024) (File No. SR-FICC-2024-007).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         Securities Exchange Act Release No. 101454 (Oct. 28, 2024), 89 FR 87441 (Nov. 1, 2024) (File No. SR-FICC-2024-007) (“Notice of Partial Amendment”).
                    </P>
                </FTNT>
                <P>
                    The Commission has received comments regarding the substance of the Proposed Rule Change.
                    <SU>11</SU>
                    <FTREF/>
                     The Commission also received a letter from FICC responding to the comments.
                    <SU>12</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         Comments on the Proposed Rule Change are available at 
                        <E T="03">https://www.sec.gov/comments/sr-ficc-2024-007/srficc2024007.htm.</E>
                         Comments on the Advance Notice are available at 
                        <E T="03">https://www.sec.gov/comments/sr-ficc-2024-802/srficc2024802.htm.</E>
                         Because the proposals contained in the Proposed Rule Change and the Advance Notice are the same, the Commission considers all comments received on the proposal, regardless of whether the comments are submitted with respect to the Advance Notice or the Proposed Rule Change. The comment letters to the Proposed Rule Change and Advance Notice also contained comments on the substance of another FICC proposed rule change, FICC-2024-005. The Commission will only be addressing comments relevant to this proposal and will address the comments on the other proposed rule change in a separate order.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         Letter from Laura Klimpel, Managing Director, Head of Fixed Income and Financing Solutions, Depository Trust &amp; Clearing Corporation, (Aug. 1, 2024) (“FICC Letter”).
                    </P>
                </FTNT>
                <P>For the reasons discussed below, the Commission is approving the Proposed Rule Change.</P>
                <HD SOURCE="HD1">I. Description of the Proposed Rule Change</HD>
                <HD SOURCE="HD2">A. Background and Terminology</HD>
                <P>
                    FICC, through its GSD, is a central counterparty and provider of clearance and settlement services for the U.S. government securities markets. As a central counterparty in the U.S. government securities markets, FICC novates transactions between two counterparties, effectively becoming the buyer to every seller and the seller to every buyer, and guarantees the settlement of the novated transactions. This means that FICC is exposed to a number of risks arising from such transactions, including counterparty credit risk. FICC seeks to maintain sufficient resources (
                    <E T="03">i.e.,</E>
                     margin) to cover its credit exposures to its participants fully with a high degree of confidence and mitigate potential losses from a default of a direct GSD participant, which is generally referred to as a Netting Member under the GSD Rules 
                    <SU>13</SU>
                    <FTREF/>
                     (and in this Order).
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         The GSD Rules are available at 
                        <E T="03">https://www.dtcc.com/~/media/Files/Downloads/legal/rules/ficc_gov_rules.pdf.</E>
                         Terms not otherwise defined herein are defined in the GSD Rules.
                    </P>
                </FTNT>
                <P>
                    On December 13, 2023, the Commission adopted amendments to the standards applicable to covered clearing agencies that clear transactions in U.S. Treasury securities (“Treasury CCAs”), such as FICC.
                    <SU>14</SU>
                    <FTREF/>
                     These amendments require Treasury CCAs to establish, implement, maintain, and enforce written policies and procedures reasonably designed to, among other things, calculate, collect, and hold margin for direct participants' proprietary positions separately and independently from margin calculated, collected, and held for indirect participants that rely on the services provided by the direct participant to access the Treasury CCA's payment, clearing, or settlement facilities.
                    <SU>15</SU>
                    <FTREF/>
                     The Commission also amended its broker-dealer customer protection rule (“Rule 15c3-3”) 
                    <SU>16</SU>
                    <FTREF/>
                     and the customer and proprietary accounts of broker-dealer (“PAB” reserve formulas thereunder (“Rule 15c3-3a”) 
                    <SU>17</SU>
                    <FTREF/>
                     to permit margin required and on deposit with Treasury CCAs to be included under certain conditions as a debit in the reserve formulas.
                    <SU>18</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See supra</E>
                         note 3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         17 CFR 240.17ad-22(e)(6)(i).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         17 CFR 240.15c3-3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         17 CFR 240.15c3-3a.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">See supra</E>
                         note 3.
                    </P>
                </FTNT>
                <P>
                    The GSD Rules describe how FICC provides clearance and settlement services to both direct participants and indirect participants, the latter of which rely on the services provided by direct participants to access FICC's clearance and settlement facilities. Currently, the GSD Rules allow indirect participants to access GSD's clearing services through a Netting Member (that is, a direct participant) via two models: the correspondent clearing/prime broker services 
                    <SU>19</SU>
                    <FTREF/>
                     and the Sponsored Service.
                    <SU>20</SU>
                    <FTREF/>
                     The primary difference between the two models is that an indirect participant who becomes a Sponsored Member via the Sponsored Service model must establish an indirect, limited purpose FICC membership, whereas the correspondent clearing/prime broker services do not require an indirect member to establish any relationship with FICC.
                    <SU>21</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 8, 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See generally</E>
                         GSD Rule 3A, 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99817 (Mar. 21, 2024), 89 FR 21362, at 21364 (Mar. 27, 2024) (File No. SR-FICC-2024-005).
                    </P>
                </FTNT>
                <P>
                    The correspondent clearing/prime broker services allow a Netting Member to submit eligible transactions to FICC on behalf of an indirect participant (referred to as the “Executing Firm”), record these transactions in the same account as the proprietary transactions that the Netting Member (referred to as a “Submitting Member”) enters into for its own benefit, and net the indirect participants' transactions against the Netting Member's proprietary transactions for purposes of calculating the Netting Member's margin requirements. Unlike the Sponsored Service, FICC has no relationship with the Executing Firm, and all obligations (
                    <E T="03">i.e.,</E>
                     margin and settlement) under the GSD Rules remain with the Submitting Member.
                    <SU>22</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         
                        <E T="03">Id.</E>
                         at 21365; 
                        <E T="03">see also</E>
                         GSD Rule 8, 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <PRTPAGE P="93765"/>
                <P>
                    Under a proposed rule change being approved concurrently, FICC is renaming the prime broker/correspondent clearing model to be known as the Agent Clearing Service and providing further specificity around the operation of that service.
                    <SU>23</SU>
                    <FTREF/>
                     In that service, the Netting Member which serves as the direct participant to FICC would be referred to as the Agent Clearing Member, and the indirect participant would be referred to as an Executing Firm Customer. An Executing Firm Customer would have no direct relationship to FICC. This separate change would require that a Netting Member using the Agent Clearing Service submit transactions for Executing Firm Customers through an Agent Clearing Member Omnibus Account, to be recorded separately from its other clearing activity, including its proprietary activity. It would also add a definition for transactions eligible to be submitted by an Agent Clearing Member on behalf of its Executing Firm Customers (“Agent Clearing Transactions”).
                </P>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         
                        <E T="03">See</E>
                         Order, FICC-2024-005, 
                        <E T="03">available at https://www.sec.gov/rules-regulations/self-regulatory-organization-rulemaking/ficc.</E>
                    </P>
                </FTNT>
                <P>
                    In addition, in the Sponsored Service, both currently and in a concurrently approved proposed rule change,
                    <SU>24</SU>
                    <FTREF/>
                     Netting Members that are approved to be Sponsoring Members are able to sponsor certain indirect participants, referred to as Sponsored Members, into GSD membership and submit transactions on behalf of those Sponsored Members. A Sponsored Member is the legal counterparty to FICC for any submitted transactions.
                    <SU>25</SU>
                    <FTREF/>
                     However, the Sponsoring Member unconditionally guarantees to FICC the Sponsored Member's performance under a Sponsoring Member Guaranty, which guarantees to FICC the payment and performance of a Sponsored Member's obligations to FICC.
                    <SU>26</SU>
                    <FTREF/>
                     Therefore, reliance upon the Sponsoring Member Guaranty necessarily involves FICC's reliance upon the financial resources of the Sponsoring Member.
                </P>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 3A, section 7 (describing novation of Sponsored Member Trades) and 2 (identifying membership types), 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         
                        <E T="03">See</E>
                         GSD Rules 3A (describing the operation of the Sponsoring Member Guaranty) and 1 (defining the Sponsoring Member Guaranty), 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <P>
                    Unlike the correspondent clearing/prime broker services, transactions by the Sponsoring Member's Sponsored Members (“Sponsored Member Trades”) are not netted, for margining purposes, against transactions of the Sponsoring Member or another Sponsored Member. Instead, FICC records Sponsored Member Trades in a Sponsored Member Omnibus Account, and calculates margin requirements for each Sponsored Member individually on a gross basis (
                    <E T="03">i.e.,</E>
                     without netting their transactions against transactions of the Sponsoring Member or another Sponsored Member).
                    <SU>27</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 3A, Section 10(c), 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Proposed Changes</HD>
                <P>
                    In the Proposed Rule Change, FICC seeks to address the Commission's new margin and account separation requirements and the conditions for including margin in the broker-dealer reserve formulas discussed in part I.A above.
                    <SU>28</SU>
                    <FTREF/>
                     As described in greater detail below, the Proposed Rule Change would (1) provide for the separate and independent calculation, collection, and holding of margin for proprietary transactions of a Netting Member from margin submitted to FICC by a Netting Member to support the transactions of an indirect participant (
                    <E T="03">i.e.,</E>
                     either an Executing Firm Customer or a Sponsored Member); (2) establish segregated accounts for direct and indirect participants, including establishing a minimum $1 million cash margin requirement for each Segregated Indirect Participant; (3) consolidate the methodology for calculating the margin requirements, including definitions of relevant terms and components for calculating margin requirements from various sections of the current GSD Rules into a single margin component schedule (“Margin Component Schedule”), specify how the various components relate to different types of margin, and make certain changes to the margin methodology, including revising the Margin Liquidity Adjustment (“MLA Charge”) 
                    <SU>29</SU>
                    <FTREF/>
                     definition, providing a method for allocating net unsettled positions to individual indirect participants for calculating margin requirements, and revising and clarifying the calculation of the Excess Capital Premium (“ECP”) component 
                    <SU>30</SU>
                    <FTREF/>
                     of the Clearing Fund; and (4) modify the terms relating to transactions submitted by Inter-Dealer Broker Netting Members 
                    <SU>31</SU>
                    <FTREF/>
                     to FICC for clearance and settlement (“Brokered Transactions”).
                </P>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         
                        <E T="03">See supra</E>
                         note 3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         The MLA Charge is a margin component designed to address the market impact costs of liquidating a defaulted Netting Member's portfolio that may increase when that portfolio includes large net unsettled positions in a particular group of securities with a similar risk profile or in a particular asset type, thereby causing those costs to be higher than the amount collected for the Netting Member's volatility charge, which is designed to capture the market price risk associated with liquidating each Netting Member's portfolio at a 99th percentile level of confidence. 
                        <E T="03">See</E>
                         GSD Rule 1 (defining Margin Liquidity Adjustment Charge), 
                        <E T="03">supra</E>
                         note 13; 
                        <E T="03">see also</E>
                         Securities Exchange Act Release No. 89560 (Aug. 14, 2020), 85 FR 51503 (Aug. 20, 2020) (File No. SR-FICC-2020-09) (approving the MLA charge as a new component of the margin methodology); Securities Exchange Act Release No. 98558 (Sep. 27, 2023), 88 FR 68179 (Oct. 3, 2023) (File No. SR-FICC-2023-012) (approving revisions to ECP charge).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         The ECP is a margin component that allows FICC to collect additional margin if a member's exposure to FICC, based on its clearing activity, is out of proportion to its capital levels. It is designed to mitigate the heightened default risk a member could pose to FICC if it operates with lower capital levels relative to its margin requirements. 
                        <E T="03">See</E>
                         Margin Component Schedule (defining Excess Capital Premium), 
                        <E T="03">supra</E>
                         note 13; 
                        <E T="03">see also</E>
                         Securities Exchange Act Release No. 54457 (Sep. 15, 2006), 71 FR 55239 (Sep. 21, 2006) (File Nos. SR-FICC-2006-03 and SR-NSCC-2006-03) (approving the ECP charge as a new component of the margin methodology); Securities Exchange Act Release No. 96786 (Feb. 7, 2023), 88 FR 8013 (Feb. 7, 2023) (File No. SR-NSCC-2022-005) (approving revisions to ECP charge).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         An Inter-Dealer Broker is defined as a Person which is in the business of buying and selling securities as agent on behalf of dealers and is registered under Section 15 or Section 15C of the Exchange Act. GSD Rule 1 (defining Inter-Dealer Broker), 
                        <E T="03">supra</E>
                         note 13. An Inter-Dealer Broker Netting Member must meet that definition and certain applicable membership requirements. 
                        <E T="03">See id.</E>
                         and Rule 2A (setting forth membership requirements).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">1. Separate Calculation, Collection, and Holding of Margin</HD>
                <P>The Proposed Rule Change would provide for the separate and independent calculation, collection, and holding of (i) margin deposited by a Netting Member to support its proprietary transactions, and (ii) margin deposited by a Netting Member to support the transactions of an indirect participant, that is, either an Executing Firm Customer or a Sponsored Member. To facilitate the separate and independent calculation, collection, and holding proprietary and indirect participant margin, FICC would establish proprietary accounts to record the proprietary transactions that the Netting Member enters into for its own benefit and separate indirect participant accounts to record transactions that the Netting Member submits on behalf of an indirect participant, which could be either a Sponsored Member or an Executing Firm Customer.</P>
                <P>
                    For proprietary transactions, the accounts would include Dealer Accounts, which would be available for all Netting Members, and Cash Broker Accounts and Repo Broker Accounts, which would only be available for Inter-Dealer Broker Netting Members.
                    <SU>32</SU>
                    <FTREF/>
                     Cash 
                    <PRTPAGE P="93766"/>
                    Broker Accounts would be available for recording an Inter-Dealer Broker Netting Member's Brokered Transactions (other than Brokered Repo Transactions), and Repo Broker Accounts would be for purposes of recording an Inter-Dealer Broker Netting Member's Brokered Repo Transactions.
                </P>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         Under the proposed changes, “Cash Broker Account” would be a proprietary account maintained by FICC for an Inter-Dealer Broker Netting Member to record Brokered Transactions, other than Brokered Repo Transactions, submitted to the Corporation by the Inter-Dealer Broker 
                        <PRTPAGE/>
                        Netting Member. “Repo Broker Account” would be a proprietary account maintained by the FICC for an Inter-Dealer Broker Netting Member in its capacity as a Repo Broker to record Brokered Repo Transactions submitted to the Corporation by the Inter-Dealer Broker Netting Member.
                    </P>
                </FTNT>
                <P>
                    For indirect participant transactions, FICC would establish Indirect Participants Accounts to record transactions that a Netting Member submits to FICC on behalf of Sponsored Members and Executing Firm Customers. These Indirect Participants Accounts would include Sponsoring Member Omnibus Accounts for recording Sponsored Member Trades and Agent Clearing Member Omnibus Accounts for recording Agent Clearing Transactions submitted on behalf of Executing Firm Customers. In addition, the proposal would permit a Sponsoring Member or Agent Clearing Member to designate any of its Indirect Participants Accounts as a segregated customer account (a “Segregated Indirect Participants Account”). Such designation, as further described in part I.B.2 below, would give Netting Members a mechanism to direct FICC to calculate and segregate margin deposited in connection with the relevant Segregated Indirect Participants Account in accordance with the conditions described in Note H to Rule 15c3-3a.
                    <SU>33</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         17 CFR 240.15c3-3a.
                    </P>
                </FTNT>
                <P>
                    The proposal would require each Netting Member to deposit two forms of margin: the Required Fund Deposit and the Segregated Customer Margin Requirement. The Required Fund Deposit, which would be deposited to the Clearing Fund, would be the sum of each Netting Member's proprietary accounts (
                    <E T="03">e.g.,</E>
                     Dealer Accounts and Broker Accounts) and indirect participant accounts (
                    <E T="03">e.g.,</E>
                     Agent Clearing Omnibus Accounts and Sponsoring Member Omnibus Accounts) not designated as Segregated Indirect Participants Accounts. The Segregated Customer Margin Requirement, which would be excluded from the Clearing Fund, would be the sum of the Netting Member's Sponsoring Member Omnibus Accounts designated as Segregated Indirect Participants Accounts and Agent Clearing Member Omnibus Accounts designated as Segregated Indirect Participants Accounts.
                </P>
                <P>
                    FICC's proposal would also provide that a Netting Member's Margin Portfolio, which is utilized to determine a Netting Member's margin requirement, cannot include both proprietary and indirect participant accounts. As a result, the transactions a Netting Member submits to FICC on behalf of an indirect participant either as a Sponsoring Member or an Agent Clearing Member would no longer be netted against a Netting Member's proprietary transactions for calculating a Netting Member's margin requirements.
                    <SU>34</SU>
                    <FTREF/>
                     Since proprietary transactions and transactions submitted for indirect participants would not be recorded in the same type of account, these changes would result in margin for a Netting Member's proprietary transactions being calculated separately and independently from margin calculated for the transactions that the Netting Member submits on behalf of indirect participants.
                </P>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         The Proposed Rule Change would also specify the types of accounts in which Netting Members may record transactions to identify the purpose and use of these accounts. FICC's “Accounts” are not custodial accounts in which FICC holds assets, but rather a mechanism for FICC to record and group transactions. These records are utilized by FICC in its calculation of a Netting Member's margining, settlement, and other obligations. Proprietary Accounts would include “Dealer Accounts,” which would be available for all Netting Members, and “Cash Broker Accounts” and “Repo Broker Accounts,” which would only be available for Inter-Dealer Broker Netting Members. Non-Proprietary Accounts would include, in the case of a Sponsoring Member, Sponsoring Member Omnibus Accounts for purposes of recording Sponsored Member Trades, and, in the case of an Agent Clearing Member, Agent Clearing Member Omnibus Accounts for purposes of recording Agent Clearing Transactions of its Executing Firm Customers.
                    </P>
                </FTNT>
                <P>To help ensure that margin for proprietary transactions is calculated, collected, and held separately and independently of margin for indirect participant transactions, FICC would require each Netting Member, at the time it submits a transaction to FICC for clearance and settlement, to designate the account in which the particular transaction should be recorded using a separate Deposit ID, which is an existing operational mechanism used by Netting Members to identify the type of account for which a margin deposit is being made. The use of these separate Deposit IDs would result in margin for each type of account being separately transferred to FICC and recorded on FICC's books as separate margin amounts for each account type. The proposal would also require FICC to report a Netting Member's Required Fund Deposit and Segregated Customer Margin Requirement twice daily and specify the amount of margin attributable to each Required Fund Deposit Portion or Segregated Indirect Participants Account so that the Netting Member can transfer the different margin amounts separately.</P>
                <P>
                    In addition, the proposal would eliminate the concept of a Permitted Margin Affiliate, which allows a Netting Member to include accounts of an affiliate that is also a Netting Member in the same Margin Portfolio as its accounts and net their transactions for margin calculation purposes. FICC states that no Netting Member currently has a Permitted Margin Affiliate, so keeping this option in the rules in conjunction with the proposed changes to establish separate and independent calculation, collection, and holding of margin would introduce unnecessary complexity in FICC's rules.
                    <SU>35</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21608.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Segregation of Customer Margin</HD>
                <P>
                    FICC is proposing several changes to allow for the segregation of customer margin in a manner that satisfies the conditions for recording a debit in the customer reserve formula under Note H to Exchange Act Rule 15c3-3a.
                    <SU>36</SU>
                    <FTREF/>
                     First, to satisfy Section (b)(2)(i) of Note H to Rule 15c3-3a,
                    <SU>37</SU>
                    <FTREF/>
                     FICC would calculate the margin requirements applicable to any segregated account on a gross basis (
                    <E T="03">i.e.,</E>
                     FICC would treat each indirect participant as if it were a separate Netting Member for margin calculations and would not net the transactions of one indirect participant against the transactions of another indirect participant). Second, to satisfy Section (b)(2)(iii) of Note H to Rule 15c3-3a,
                    <SU>38</SU>
                    <FTREF/>
                     FICC would establish Segregated Customer Margin Custody Accounts for eligible customers on its books and records. These accounts would segregate the margin deposited for transactions in that account from any margin for a Netting Member's proprietary positions, both on FICC's own books and records and at FICC's custodians. FICC would only be able to use such segregated margin to secure or satisfy the obligations of the customer for whom such margin is held, and it would not be considered part of the mutualized Clearing Fund. FICC would not be able to apply such margin to the proprietary obligations of the Netting Member that deposited it with FICC, to the obligations of any other Netting Member or indirect participant, or to any lien or claim against FICC.
                    <SU>39</SU>
                    <FTREF/>
                     FICC would 
                    <PRTPAGE P="93767"/>
                    provide written notice to any Netting Member that is a broker-dealer that any Segregated Customer Margin Custody Account is being held for the exclusive benefit of the customers and is being kept separate from any other accounts maintained by the broker-dealer or any other Netting Member at FICC, as required by Section (b)(2)(iii)(C) of Note H.
                    <SU>40</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         
                        <E T="03">See id.,</E>
                         at 21608 (citing 17 CFR 240.15c3-3a).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         
                        <E T="03">Id.</E>
                         at 21608-09.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         
                        <E T="03">Id.</E>
                         at 21609.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 35 (describing this as “an express prohibition on FICC using Segregated Customer Margin held in respect of one Segregated Indirect Participant for the obligations of any other 
                        <PRTPAGE/>
                        person” and stating that, as a result, the default of one Segregated Indirect Participant should not generally cause another segregated Indirect participant to lose its margin).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         
                        <E T="03">Id.</E>
                         at 21610.
                    </P>
                </FTNT>
                <P>
                    Further, as amended, the proposal would clarify that any interest earned on Segregated Customer Margin consisting of cash must be paid to the Netting Member on behalf of, and as agent for, its Segregated Indirect Participant.
                    <SU>41</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         
                        <E T="03">See</E>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87443.
                    </P>
                </FTNT>
                <P>
                    Moreover, to comply with the custody requirements of (b)(2)(iv) of Note H,
                    <SU>42</SU>
                    <FTREF/>
                     FICC would require segregated margin accounts to be held at either a bank within the meaning of the Exchange Act that is insured by the Federal Deposit Insurance Corporation and is a qualified custodian under the 1940 Act, or the Federal Reserve Bank of New York.
                    <SU>43</SU>
                    <FTREF/>
                     FICC would require these accounts to be segregated from any other account of FICC and used exclusively to hold Segregated Customer Margin, in accordance with Section (b)(2)(iv)(A) of Note H. Moreover, each of these accounts would be subject to (i) a written notice of the bank or Federal Reserve Bank that the account is being held by the bank or Federal Reserve Bank pursuant to Rule 15c3-3 and is being kept separate from and not commingled with any other accounts maintained by FICC or any other person at the bank or Federal Reserve Bank and (ii) a written contract between FICC and the bank or Federal Reserve Bank which would provide that the Segregated Customer Margin in the account is subject to no right, charge, security interest, lien, or claim in favor of the bank or Federal Reserve Bank or any person claiming through the bank or Federal Reserve Bank, in accordance with Sections (b)(2)(iv)(B) and (C) of Note H.
                    <SU>44</SU>
                    <FTREF/>
                     FICC would also only allow Segregated Customer Margin consisting of cash to be invested in U.S. Treasury securities with a maturity of one year or less, in accordance with Section (b)(2)(ii) of Note H.
                    <SU>45</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21607.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         
                        <E T="03">See</E>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87443.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21607.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    Finally, to satisfy Section (b)(2)(v) of Note H,
                    <SU>46</SU>
                    <FTREF/>
                     FICC would provide specific procedures to allow Netting Members to request the return of excess segregated margin. FICC notes that these changes would allow broker-dealer Netting Members to collect margin from customers and deposit it with FICC and to provide all customers, including those that access FICC through non-broker-dealers, the ability to segregate margin they deposit.
                    <SU>47</SU>
                    <FTREF/>
                     FICC would have the ability to retain some or all of the excess segregated customer margin if the Netting Member had an outstanding payment or margin obligation to FICC for transactions of any Segregated Indirect Participant. FICC could not retain the excess segregated customer margin for a Segregated Indirect Participant when FICC has determined, in its sole discretion, that such outstanding payment or margin obligation is unrelated to the transactions of that Segregated Indirect Participant.
                    <SU>48</SU>
                    <FTREF/>
                     FICC states that these aspects of the Proposed Rule Change would allow for the segregation of certain customer margin in a manner that satisfies the conditions for a broker-dealer to record a debit in the customer reserve formula under Note H to Rule 15c3-3a.
                    <SU>49</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>46</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>47</SU>
                         
                        <E T="03">Id.</E>
                         at 21606.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>48</SU>
                         
                        <E T="03">See</E>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87443.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>49</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21606.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">a. $1 Million Minimum Cash Margin Requirement</HD>
                <P>
                    FICC is also proposing a minimum $1 million cash margin requirement for each Segregated Indirect Participant Account, similar to the $1 million minimum cash margin requirement currently applicable to each Netting Member.
                    <SU>50</SU>
                    <FTREF/>
                     FICC conducts daily backtesting to evaluate whether each Netting Member's margin is sufficient to cover FICC's credit exposures to that member based on a simulated liquidation of the member's portfolio on that day. FICC's daily backtesting of the sufficiency of Clearing Fund deposits has shown a heightened risk of backtesting deficiencies (
                    <E T="03">i.e.,</E>
                     the projected liquidation losses to FICC due to a Netting Member's default would be greater than the member's margin) for members with lower deposits.
                    <SU>51</SU>
                    <FTREF/>
                     Because FICC is required to calculate the margin requirements for Segregated Indirect Participants on a gross basis, as if each Segregated Indirect Participant were a separate Margin Portfolio, and Segregated Customer Margin would not be available to address losses from other direct or indirect participants, FICC believes it is also appropriate to apply the same minimum cash requirement to each Segregated Indirect Participant that it applies to each Margin Portfolio.
                    <SU>52</SU>
                    <FTREF/>
                     Moreover, FICC believes that the $1 million cash requirement is the appropriate minimum amount to optimize the balance between financial impact of the requirement to participants and FICC's ability to continue to meet its regulatory obligation to maintain a backtesting performance coverage ratio above its 99 percent coverage target.
                    <SU>53</SU>
                    <FTREF/>
                     FICC states that the $1 million minimum is supported by its prior analyses of the appropriate minimum margin requirement for Netting Members.
                    <SU>54</SU>
                    <FTREF/>
                     FICC further describes this minimum requirement as critical to ensuring that the account segregation does not expose FICC and its participants to undue loss. FICC explains that the Segregated Customer Margin posted by an individual Segregated Indirect Participant needs to be enough, on its own, to address losses arising from the Segregated Indirect Participant's positions, and that, otherwise, such losses may be mutualized.
                    <SU>55</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>50</SU>
                         Like the current requirement for Netting Member Required Fund Deposits, the proposal would require that a minimum of 40 percent of the Segregated Customer Margin Requirement be satisfied with cash and/or Eligible Clearing Fund Treasury Securities.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>51</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21611.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>52</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>53</SU>
                         
                        <E T="03">Id.;</E>
                         FICC Letter at 28-29.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>54</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 28-29.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>55</SU>
                         
                        <E T="03">Id.</E>
                         at 29.
                    </P>
                </FTNT>
                <P>
                    However, FICC, in its sole discretion, would have the ability to adjust the amount of the minimum $1 million margin requirement if FICC determines that a different minimum charge would be appropriate and consistent with achieving its backtesting coverage target.
                    <SU>56</SU>
                    <FTREF/>
                     FICC would notify Netting Members of any such adjustment to the minimum margin requirement through an Important Notice.
                    <SU>57</SU>
                    <FTREF/>
                     In discussing this proposed ability, FICC states that it will review the $1 million floor for Segregated Customer Margin as part of ongoing internal surveillance and risk management monitoring procedures.
                    <SU>58</SU>
                    <FTREF/>
                     FICC further states that it would be prudent to have the ability to adjust the $1 million floor proactively to the extent that FICC identifies as part of these reviews that activity levels, margin performance observed through backtesting, and other measures indicate that FICC would be able to continue to 
                    <PRTPAGE P="93768"/>
                    manage the risks presented to it and meet its regulatory risk management obligations (including, for example, its 99% backtesting coverage target) with a lower minimum Segregated Customer Margin Requirement (that is, an amount below $1 million).
                    <SU>59</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>56</SU>
                         
                        <E T="03">See</E>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87443.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>57</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>58</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 30.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>59</SU>
                         
                        <E T="03">Id.</E>
                         at 31.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">3. Margin Component Schedule</HD>
                <P>
                    To improve the clarity and transparency of its margin components and Clearing Fund calculation methodology,
                    <SU>60</SU>
                    <FTREF/>
                     FICC would move the margin calculation methodology, including the relevant defined terms, into a new Margin Component Schedule. Currently, the terms and information concerning the margin calculation methodology, as well as the relevant definitions, appear in several different locations.
                    <SU>61</SU>
                    <FTREF/>
                     FICC states that its methodology and the included components would continue to be substantively the same as the methodology under the current Rules.
                    <SU>62</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>60</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21612.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>61</SU>
                         FICC would move the calculation methodology from Rule 4, Sections 1b, and 2a, Rule 3, Section 14, and Rule 3A, Section 10 to the new Margin Component Schedule. FICC would move the definitions from Rule 1 to Section 5 of the Margin Component Schedule.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>62</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21612.
                    </P>
                </FTNT>
                <P>
                    The new Margin Component Schedule would set out the methodology for calculating margin amounts. That Margin Component Schedule would provide for FICC to perform substantially the same calculation it currently performs when determining a Netting Member's Required Fund Deposit, except that (i) the calculation would be performed on a Segregated Indirect Participant-by-Segregated Indirect Participant basis as though each Segregated Indirect Participant represented a separate Margin Portfolio and (ii) FICC would not impose an ECP on Segregated Indirect Participant Accounts. Specifically, for Required Fund Deposit calculations, the margin amount shall equal the VaR Charge, plus or minus the Blackout Period Exposure Adjustment (as applicable), plus the Portfolio Differential Charge, with the following potential additional charges, as applicable: the Backtesting Charge, the Holiday Charge, the MLA Charge, the ECP, and the Intraday Supplemental Fund Deposit.
                    <SU>63</SU>
                    <FTREF/>
                     For Segregated Customer Margin Requirement calculations, the margin amount shall equal the VaR Charge, plus or minus the Blackout Period Exposure Adjustment (as applicable), plus the Portfolio Differential Charge, with the following potential additional charges, as applicable: the Backtesting Charge, the Holiday Charge, the MLA Charge, and the Intraday Supplemental Fund Deposit.
                </P>
                <FTNT>
                    <P>
                        <SU>63</SU>
                         This method does not represent a change from the current method of calculating Required Fund Deposits, but merely moves the description from current Rule 4 to the new Margin Component Schedule.
                    </P>
                </FTNT>
                <P>
                    For both types of calculations, the Margin Component Schedule addresses the applicable minimum cash margin requirements ($1 million for each Netting Member and Segregated Indirect Participant) 
                    <SU>64</SU>
                    <FTREF/>
                     and FICC's authority to require increased deposits as appropriate, including the use of a special charge. FICC would not add Segregated Customer Margin to Section 4 of the Margin Component Schedule, which describes FICC's ability to impose increased Required Fund Deposits under certain circumstances.
                    <SU>65</SU>
                    <FTREF/>
                     However, when determining whether to increase the Required Fund Deposit of a Netting Member under the circumstances described in Section 4, FICC would consider the risk presented by a Netting Member from the activity it submits to FICC, including activity of indirect participants.
                    <SU>66</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>64</SU>
                         
                        <E T="03">See supra</E>
                         Section I.B.2.a for a description of the proposed $1 million minimum cash margin requirement for each Segregated Indirect Participant Account.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>65</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21609.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>66</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">a. MLA Charge</HD>
                <P>
                    FICC would amend the definition of the MLA Charge to account for the use of Segregated Indirect Participant Accounts. Specifically, the definition would provide that, if a Segregated Indirect Participant clears through multiple Accounts 
                    <SU>67</SU>
                    <FTREF/>
                     (including Accounts of different Netting Members), then the MLA Charge for transactions in a Segregated Indirect Participants Account would be the greater of (i) an amount calculated for only the transactions maintained in that Account (
                    <E T="03">i.e.,</E>
                     excluding the other Accounts where the Segregated Indirect Participant's transactions are recorded) and (ii) an amount calculated on a consolidated portfolio basis (
                    <E T="03">i.e.,</E>
                     taking into account the transactions in each of the Accounts). This would be the same methodology currently used for Sponsored Members clearing through multiple Accounts.
                    <SU>68</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>67</SU>
                         FICC proposed to amend the definition of Account to be an account maintained by FICC for a Member to record transactions submitted by the member. FICC states that this change would clarify that Accounts are recordkeeping mechanisms for FICC to determine which transactions should be netted against each other, but are not custodial accounts through which FICC holds assets for a Netting Member. 
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21608.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>68</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 1 (defining MLA Charge, including for Sponsored Members sponsored by multiple Sponsoring Members), 
                        <E T="03">supra</E>
                         note 13; Securities Exchange Act Release No. 98558 (Sep. 27, 2024), 89 FR 68179 (Oct. 3, 2023) (File No. SR-FICC-2023-012).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">b. Allocation of Net Unsettled Positions</HD>
                <P>
                    The Proposed Rule Change would also provide a method for allocating net unsettled positions to individual indirect participants for calculating margin requirements. Specifically, as amended, FICC would modify the definition of Current Net Settlement Positions in Rule 1 to provide that, for calculating margin requirements and not for purposes of calculating the Net Settlement Position under GSD Rule 11, positions that are not clearly allocable to an individual Sponsored Member or Segregated Indirect Participant (other than Sponsored GC Trades), because one or more transactions recorded for indirect participants did not settle on the original Scheduled Settlement Date, would be allocated 
                    <E T="03">pro rata</E>
                     to Sponsored Members or Segregated Indirect Participants that had positions in the same direction and CUSIP as the un-allocable Current Net Unsettled Positions at the end of the preceding business day. FICC states that this situation could arise if a transaction recorded in a Sponsoring Member Omnibus Account or Segregated Indirect Participants Account fails to settle and that such failure to settle would not occur with Sponsored GC Trades.
                    <SU>69</SU>
                    <FTREF/>
                     FICC believes this methodology facilitates a reasonable and fair allocation for purposes of calculating gross margin requirements.
                    <SU>70</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>69</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21612-13; Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87443.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>70</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21613.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">c. Calculation of Excess Capital Premium</HD>
                <P>
                    In addition, the Proposed Rule Change would amend the terms related to the ECP component of the Clearing Fund, which is used to collect additional margin if a Netting Member's exposure to FICC through its clearing activity is out of proportion to its capital. Currently, the ECP applicable to a Netting Member equals the Netting Member's “Excess Capital Ratio” (
                    <E T="03">i.e.,</E>
                     its VaR Charge divided by its Netting Member Capital) multiplied by its “Excess Capital Differential” (
                    <E T="03">i.e.,</E>
                     the amount by which a Netting Member's VaR Charge exceeds its Netting Member Capital). However, FICC currently reserves the right to collect less than 
                    <PRTPAGE P="93769"/>
                    this amount or to return some or all of this amount.
                    <SU>71</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>71</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 1 (defining Excess Capital Ratio and Excess Capital Differential) and Rule 3, Section 14 (describing the Excess Capital Premium), 
                        <E T="03">supra</E>
                         note 13.
                    </P>
                </FTNT>
                <P>
                    The changes would seek to make the calculation of the ECP component clearer and more predictable by (i) capping the amount of the ECP at two times the amount by which a Netting Member's VaR Charge exceeds its Netting Capital,
                    <SU>72</SU>
                    <FTREF/>
                     (ii) specifying the Netting Member Capital amounts used to calculate the ECP (that is, the Net Capital amount from each Netting Member's most recent Form X-17-A-5 (Financial and Operational Combined Uniform Single Report (“FOCUS Report”)) or the Equity Capital amount on its most recent Consolidated Report of Condition and Income (“Call Report”)), (iii) providing that FICC may calculate the premium based on updated available information, and (iv) permitting FICC, in its discretion, to waive the amount of the ECP and setting forth a specific procedure for doing so. Regarding the waiver procedure, only a Managing Director in FICC's Group Chief Risk Office would be able to grant a waiver of an ECP in certain situations. These situations would be limited to exigent circumstances or other unexpected events. When deciding whether to grant a waiver, FICC would consider the degree to which a Netting Member's capital position and trading activity compare or correlate to the exigent circumstances and whether FICC can effectively manage the risk exposure from the Netting Member without collecting the ECP.
                    <SU>73</SU>
                    <FTREF/>
                     Any waiver would be documented in a written report made available to the Netting Member. FICC states that these changes are substantially similar to changes recently adopted by the National Securities Clearing Corporation (“NSCC”) and they would enhance the ability of Netting Members to identify what their ECP will be and to ensure such amount is accurately calibrated.
                    <SU>74</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>72</SU>
                         In addition, FICC would amend the definition of Netting Member Capital to refer to a Netting Member's Net Capital, Net Assets, or Equity Capital to link the calculation to the appropriate regulatory framework for each Netting Member and add the term Equity Capital to clarify that a Netting Member's most recent Call Report, or financial statements or equivalent reporting if a Netting Member is not required to file a Call Report, will be used for the calculation of the Excess Capital Premium.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>73</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21613.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>74</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 96786 (Feb. 1, 2023), 88 FR 8013 (Feb. 7, 2023) (SR-NSCC-2022-005).
                    </P>
                </FTNT>
                <P>
                    In addition, the Proposed Rule Change would revise the definitions of Excess Capital Ratio and Excess Capital Differential to exclude the VaR Charge for Segregated Indirect Participants. FICC is proposing this change because each indirect participant would be responsible for satisfying its own respective VaR Charge, not the Netting Member, and the Excess Margin Charge is designed to address the risk that a Netting Member with low capital relative to value-at-risk is not able to perform its obligations.
                    <SU>75</SU>
                    <FTREF/>
                     FICC states that including the VaR Charge that is calculated for an indirect participant and is satisfied by the capital of that indirect participant in the calculation of the Netting Member's ECP could result in assessing an ECP for that Netting Member that is greater than the amount required to mitigate the risk this margin component is designed to address.
                    <SU>76</SU>
                    <FTREF/>
                     FICC also states that this change is designed to ensure that the ECP does not result in differential treatment of Netting Members that act as intermediaries for Segregated Indirect Participants.
                </P>
                <FTNT>
                    <P>
                        <SU>75</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>76</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">4. Modification of Terms for Brokered Transactions</HD>
                <P>
                    The Proposed Rule Change would modify the terms relating to Brokered Transactions. FICC's rules currently cap the amount of loss allocation that may be applied to Inter-Dealer Broker Netting Members and Non-IDB Repo Brokers submitting Brokered Transactions. FICC would revise the definition of Brokered Transactions to include only the side of the transactions submitted to FICC for novation by an Inter-Dealer Broker Netting Member and entered into on the Inter-Dealer Broker Netting Member's own trading platform.
                    <SU>77</SU>
                    <FTREF/>
                     As a result, the favorable loss allocation treatment for Brokered Transactions would apply only to the transactions that present limited risk since an Inter-Dealer Broker is standing between two counterparties in those transactions and is therefore completely flat (that is, subject to offsetting exposures).
                    <SU>78</SU>
                    <FTREF/>
                     Since FICC believes the favorable loss allocation treatment is appropriate only for Inter-Dealer Broker Netting Members submitting Brokered Transactions, it would delete the term “Non-IDB Repo Broker” from its rules.
                    <SU>79</SU>
                    <FTREF/>
                     FICC states that these changes would improve FICC's risk management and promote access by ensuring that its differential treatment of different parties and transactions has a sound risk management justification.
                    <SU>80</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>77</SU>
                         
                        <E T="03">See</E>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87444.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>78</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21614.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>79</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>80</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, 21604.
                    </P>
                </FTNT>
                <P>
                    In addition, the proposed changes would provide that transactions entered into on inter-dealer brokers and similar platforms may be cleared using the Sponsored Service or the Agent Clearing Service.
                    <SU>81</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>81</SU>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87444; 
                        <E T="03">see also</E>
                         FICC Letter at 22-23.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">II. Discussion and Commission Findings</HD>
                <P>
                    Section 19(b)(2)(C) of the Exchange Act 
                    <SU>82</SU>
                    <FTREF/>
                     directs the Commission to approve a proposed rule change of a self-regulatory organization if it finds that such proposed rule change is consistent with the requirements of the Exchange Act and rules and regulations thereunder applicable to such organization. After carefully considering the Proposed Rule Change, the Commission finds that the Proposed Rule Change is consistent with the requirements of the Exchange Act and the rules and regulations thereunder applicable to FICC. In particular, the Commission finds that the Proposed Rule Change is consistent with Sections 17A(b)(3)(F) and (b)(3)(I) of the Exchange Act 
                    <SU>83</SU>
                    <FTREF/>
                     and Rules 17ad-22(e)(4)(i), (e)(6)(i), (e)(6)(iii), (e)(18)(ii), (e)(18)(iii), (e)(18)(iv)(C), (e)(19), and (e)(23)(ii) thereunder.
                    <SU>84</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>82</SU>
                         15 U.S.C. 78s(b)(2)(C).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>83</SU>
                         15 U.S.C. 78q-1(b)(3)(F) and 15 U.S.C. 78q-1(b)(3)(I).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>84</SU>
                         17 CFR 240.17ad-22(e)(4)(i), (e)(6)(i), (e)(6)(iii), (e)(18)(ii), (e)(18)(iii), (e)(18)(iv)(C), (e)(19), and (e)(23)(ii).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">A. Consistency With Section 17A(b)(3)(F) of the Exchange Act</HD>
                <P>
                    Section 17A(b)(3)(F) of the Exchange Act 
                    <SU>85</SU>
                    <FTREF/>
                     requires the rules of a clearing agency to, among other things, promote the prompt and accurate clearance and settlement of securities transactions and assure the safeguarding of securities and funds which are in the custody or control of the clearing agency or for which it is responsible, and protect investors and promote the public interest.
                </P>
                <FTNT>
                    <P>
                        <SU>85</SU>
                         15 U.S.C. 78q-1(b)(3)(F).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">1. Separate Calculation and Collection of Margin for Proprietary and Customer Accounts</HD>
                <P>
                    The proposed changes to require the separate and independent calculation and collection of margin for Netting Members' proprietary transactions and indirect participants' transactions, as described in Section I.B.1., should allow FICC to better identify and measure the unique risk profiles of each Netting 
                    <PRTPAGE P="93770"/>
                    Member and indirect participant. This proposed change would ensure that an indirect participant's positions are no longer netted against a Netting Member's positions, that margin is collected with respect to the indirect participant's positions specific to those transactions, and that interest on an indirect participant's cash margin would be paid to the Netting Member for the benefit of, and as agent for, the indirect participant. As discussed in more detail in Section II.C.1 below, this should enhance FICC's ability to calculate and collect the appropriate margin from each direct and indirect participant and, therefore, meet its settlement obligations in the event of a Netting Member or indirect participant default. By doing so, the Proposed Rule Change should better ensure that, in the event of a default, FICC's operation of its critical clearance and settlement services would not be disrupted because of insufficient financial resources and, therefore, it would be able to continue providing prompt and accurate clearance and settlement of securities transactions, consistent with Section 17A(b)(3)(F).
                    <SU>86</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>86</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>The separate and independent calculation and collection of margin for proprietary and indirect participants' transactions should allow FICC to better identify and measure the unique risk profiles of each Netting Member and indirect participant, enhancing FICC's ability to calculate and collect sufficient margin from each Netting Member and indirect participant to cover potential losses from a Netting Member or indirect participant default, thereby reducing the likelihood that FICC, Netting Members, or indirect participants would incur losses resulting from a default. As a result, the proposed changes should limit FICC's risk to a Netting Member or indirect participant default and thereby enhance its ability to safeguard securities and funds in its control and for which it is responsible.</P>
                <HD SOURCE="HD3">2. $1 Million Minimum Cash Margin Requirement</HD>
                <P>For the reasons discussed below in more detail in Section II.C.2., the proposed $1 million minimum cash margin requirement for Segregated Indirect Participants, which could be adjusted by FICC if it determines that a different minimum amount would be appropriate and consistent with achieving its backtesting coverage target, should help ensure that each indirect participant provides sufficient margin to cover its potential obligations to FICC, thereby helping to allow FICC to meet its settlement obligations in the event of a default and to protect FICC, non-defaulting Netting Members, indirect participants, and the market from losses from an indirect participant default. Accordingly, the proposed $1 million minimum cash margin requirement should assure the safeguarding of securities and funds which are in the custody or control of FICC.</P>
                <P>
                    In addition, as indicated by FICC's backtesting results, and discussed further in Section II.C.2 below, the $1 million minimum margin requirement should enhance FICC's ability to collect the appropriate margin from each indirect participant and, therefore, meet its settlement obligations in the event of a default. FICC's flexibility to adjust the minimum margin amount if it determines that a different amount would be appropriate and consistent with achieving its backtesting coverage target is also consistent with ensuring that each indirect participant provides sufficient margin to cover its obligations to FICC. Achieving backtesting coverage targets is essential to ensuring that the margin collected would be sufficient for FICC to cover its credit exposures to its Netting Members and indirect participants fully with a high degree of confidence, as required for a covered clearing agency such as FICC.
                    <SU>87</SU>
                    <FTREF/>
                     As defined in the Covered Clearing Agency Standards, backtesting is an ex-post comparison of actual outcomes with expected outcomes derived from the use of margin models,
                    <SU>88</SU>
                    <FTREF/>
                     and it is a key analytical mechanism for a CCP to consider the effectiveness of its margin model. FICC's ability to adjust the minimum margin amount would apply only where it would be appropriate and consistent with achieving its backtesting coverage target. This ability would, therefore, be limited to circumstances where its backtesting coverage target requirements are not being met or the amount of margin being collected exceeds the amount needed to cover the indirect participant's exposure to FICC.
                </P>
                <FTNT>
                    <P>
                        <SU>87</SU>
                         17 CFR 240.17ad-22(e)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>88</SU>
                         17 CFR 240.17ad-22(a).
                    </P>
                </FTNT>
                <P>
                    Based on FICC's representations, the Commission understands that FICC generally intends to use this ability to adjust the minimum margin requirement below $1 million if a lower minimum would suffice to reduce backtesting deficiencies comparably to the $1 million.
                    <SU>89</SU>
                    <FTREF/>
                     As part of its ongoing supervision of FICC, the Commission will continue to monitor the performance of the $1 million minimum margin requirement, including as its performance compares to backtesting, and will engage with FICC regarding any changes to that requirement and the supporting analysis for such changes, to help ensure that FICC is appropriately exercising that discretion consistent with the requirements imposed upon it by the rule (
                    <E T="03">i.e.,</E>
                     that it determines that any such adjustments would be appropriate and consistent with achieving its backtesting coverage target).
                    <SU>90</SU>
                    <FTREF/>
                     For example, not meeting backtesting coverage requirements would be an indication that the minimum margin amount is insufficient to cover FICC's credit exposure to its Netting Members and indirect participants, whereas, on the contrary, higher backtesting performance could indicate that the margin collected exceeds the exposure to FICC.
                </P>
                <FTNT>
                    <P>
                        <SU>89</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 3, 30-31.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>90</SU>
                         In addition, the requirements applicable to FICC as a self-regulatory organization under Section 19(b) of the Exchange Act and as a designated financial market utility under Title VIII of the Payment, Clearing, and Supervision Act (12 U.S.C. 5465(e)) would continue to apply. Thus, for example, if FICC were to amend the $1 million minimum margin requirement to an amount that would materially alter the level or nature of risk presented, FICC would be obligated to submit an advance notice of such change with the Commission.
                    </P>
                </FTNT>
                <P>Therefore, the $1 million minimum margin requirement should help ensure that, in the event of a Segregated Indirect Participant default, FICC's operation of its critical clearance and settlement services would not be disrupted because of insufficient financial resources and it can continue providing prompt and accurate clearance and settlement of securities transactions.</P>
                <HD SOURCE="HD3">3. Margin Component Schedule</HD>
                <P>
                    The proposed changes in section I.B.3 regarding the calculation of margin for segregated and non-segregated accounts should help ensure that FICC collects margin sufficient to cover its exposures with respect to both direct and indirect participants. Requiring that the margin requirement for a Segregated Indirect Participant Account be calculated in generally the same manner as a Netting Member's requirement, which the Commission generally has reviewed and approved as part of FICC's rules,
                    <FTREF/>
                    <SU>91</SU>
                      
                    <PRTPAGE P="93771"/>
                    should help ensure that FICC collects margin sufficient to cover its exposures with respect to both direct and indirect participants, as discussed further in Sections II.C.3 and II.D.3 below. In addition, by doing so, these proposed changes should help ensure that, in the event of such a default, FICC's operation of its critical clearance and settlement services would not be disrupted because of insufficient financial resources and, therefore, it could continue providing prompt and accurate clearance and settlement of securities transactions, consistent with Section 17A(b)(3)(F).
                    <SU>92</SU>
                    <FTREF/>
                     For the same reasons, these proposed changes should also help ensure that FICC is able to continue to meet its obligation in the event of a default, without accessing non-defaulting Netting Members' or indirect participants' margin deposits, thereby helping FICC ensure that it can safeguard the funds and securities within its custody or control, consistent with Section 17A(b)(3)(F).
                    <SU>93</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>91</SU>
                         
                        <E T="03">See, e.g.,</E>
                         Self-Regulatory Organizations; Fixed Income Clearing Corporation; Notice of Filing of Amendment No. 1 and Order Granting Accelerated Approval of a Proposed Rule Change, as Modified by Amendment No. 1, To Implement Changes to the Required Fund Deposit Calculation in the Government Securities Division Rulebook, Exchange Act Release No. 83362 (June 1, 2018), 83 FR 26514 (June 7, 2018) (approving changes to how FICC calculates the Value at Risk component of its margin methodology, addition of the new “Blackout Period Exposure adjustment” component to the margin methodology, eliminating certain existing components, and revising additional components).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>92</SU>
                         15 U.S.C. 78q-1(b)(3)(F).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>93</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>In addition, the proposed changes described in Section I.B.4 to consolidate the terms relating to margin calculation into a single location and refine the description of FICC's margin methodology should help FICC's Netting Members and indirect participants better understand and anticipate their margin requirements. This improved understanding of the potential margin requirements should, in turn, facilitate prompt and accurate clearance and settlement by removing potential ambiguity or confusion about market participants' obligations to FICC. Similarly, the improved transparency provided by the proposed centralized margin component schedule and enhanced descriptions of FICC's margin components, such as the MLA Charge, should provide Netting Members, indirect participants, and the public with more clarity about the calculation and application of FICC's margin components and resolve potential ambiguity about when certain components would or would not apply, which is consistent with promoting the public interest.</P>
                <HD SOURCE="HD3">4. Allocation of Net Unsettled Positions</HD>
                <P>
                    The proposed changes described in Section I.B.3.b. to adopt a method for allocating net unsettled positions to individual indirect participants for calculating margin requirements should reduce the potential exposure to FICC arising from indirect participant transactions that fail to settle by ensuring that FICC has a mechanism to collect margin for such transactions. Further, these proposed changes should make clear that such obligations are allocated only to participants that are outside the Sponsored GC service, since such fails to deliver do not occur in that service. By accounting for risks arising from net unsettled positions, the proposed changes should enhance FICC's risk management and its ability to assure the safe return of funds and securities, consistent with Section 17A(b)(3)(F).
                    <SU>94</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>94</SU>
                         15 U.S.C. 78q-1(b)(3)(F).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">5. Calculation of Excess Capital Premium</HD>
                <P>The proposed changes to the calculation of the ECP described in Section I.B.3.c. above are consistent with promoting robust risk management, because the changes should help ensure that FICC continues to collect margin sufficient to address the heightened default risk presented by a Netting Member operating with lower capital levels relative to its margin requirements. Based on its review of the Proposed Rule Change, including the detailed impact analysis submitted as a confidential exhibit, FICC's margin coverage would not be impacted by this change and FICC would continue to collect sufficient margin to manage its potential exposure to its Netting Members.</P>
                <P>
                    In addition, the proposed changes to the calculation of the ECP should result in a simplified and more straight-forward method for calculating the ECP, based on understandable metrics with which FICC's Netting Members are familiar. Using a clearly defined source for determining Netting Member Capital in the calculation of the ECP would result in a more consistent calculation across different types of Netting Members. Moreover, capping the Excess Capital Ratio at 2.0 would provide transparency to Netting Members so they can understand how the ECP will be calculated, and it also would align FICC's cap with the recently approved changes to the ECP calculation at NSCC.
                    <SU>95</SU>
                    <FTREF/>
                     By improving the consistency and predictability of the ECP, the proposed enhancements would also improve FICC's ability to collect margin amounts that reflect the risks posed by its Netting Members such that, in the event of Netting Member default, FICC's operations would not be disrupted, and non-defaulting Netting Members and indirect participants would not be exposed to losses they cannot anticipate or control. In this way, the proposed rule change is designed to promote the prompt and accurate clearance and settlement of securities transactions and to assure the safeguarding of securities and funds which are in the custody or control of NSCC or for which it is responsible, consistent with Section 17A(b)(3)(F) of the Exchange Act.
                    <SU>96</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>95</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 96786 (Feb. 1, 2023), 88 FR 8013 (Feb. 7, 2023) (SR-NSCC-2022-005); 
                        <E T="03">see also id.</E>
                         (discussing the view that capping the ratio at 2.0 strikes an appropriate balance between addressing the heightened default risk without imposing overly burdensome Excess Capital Premium charges).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>96</SU>
                         15 U.S.C. 78q-1(b)(3)(F).
                    </P>
                </FTNT>
                <P>
                    The proposed changes set forth in section I.B.3.c should improve transparency and understanding of the FICC's governance and application of the ECP. For example, FICC's proposal would describe the exigent circumstances in which FICC may waive the ECP, describe what information FICC would consider when determining whether to waive the charge, and specify the approval necessary to waive the charge. Moreover, using commonly understood inputs as the determinants of the ECP (
                    <E T="03">i.e.,</E>
                     the FOCUS or Call Report) and capping the Excess Capital Ratio at 2.0 should help Netting Members better anticipate and plan for a potential ECP. These proposed changes should help FICC's members better anticipate their required margin because of the use of simplified inputs to the calculation of the ECP and the imposition of a cap on the applicable Excess Capital Ratio. This improved understanding of the potential margin requirements should, in turn, facilitate prompt and accurate clearance and settlement by removing potential ambiguity or confusion about a member's obligations to FICC.
                </P>
                <P>Similarly, the improved transparency provided by this Proposed Rule Change both with respect to a Netting Member's margin obligations and the process by which FICC would consider waiver of an ECP should provide Netting Members and the public with more clarity about the nature and application of the ECP and resolve potential ambiguity about when the ECP would or would not apply, which is consistent with promoting the public interest.</P>
                <HD SOURCE="HD3">6. Modification of Terms for Brokered Transactions</HD>
                <P>
                    The proposed changes described in Section I.B.4. to revise the definition of Brokered Transactions to include only the side of the transactions submitted to FICC for novation by an Inter-Dealer Broker Netting Member and entered into on the Inter-Dealer Broker Netting Member's own trading platform should enhance FICC's risk management by providing favorable loss allocation 
                    <PRTPAGE P="93772"/>
                    treatment only to transactions that present limited risk to FICC. As a result, these changes should help ensure that FICC has sufficient prefunded financial resources to continue meeting its obligations in the event of a default, which will facilitate the safeguarding of securities and funds which are in the custody or control of FICC, consistent with Section 17A(b)(3)(F).
                    <SU>97</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>97</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    For these reasons, the proposed changes are consistent with Section 17A(b)(3)(F) of the Exchange Act.
                    <SU>98</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>98</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Consistency With Section 17A(b)(3)(I) of the Exchange Act</HD>
                <P>
                    Section 17A(b)(3)(I) of the Exchange Act requires that the rules of a clearing agency, such as FICC, do not impose any burden on competition not necessary or appropriate in furtherance of the Exchange Act.
                    <SU>99</SU>
                    <FTREF/>
                     Section 17A(b)(3)(I) does not require the Commission to make a finding that FICC chose the option that imposes the least possible burden on competition. Rather, the Exchange Act requires that the Commission find that the Proposed Rule Change does not impose any burden on competition not necessary or appropriate in furtherance of the purposes of the Exchange Act, which involves balancing the competitive effects of the proposed rule change against all other relevant considerations under the Exchange Act.
                    <SU>100</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>99</SU>
                         15 U.S.C. 78q-1(b)(3)(I).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>100</SU>
                         
                        <E T="03">See</E>
                         Bradford National Clearing Corp., 590 F.2d 1085, 1105 (D.C. Cir. 1978).
                    </P>
                </FTNT>
                <P>
                    The Commission received comments regarding the impacts the Proposed Rule Change may have on competition. Several commenters state that the $1 million minimum Segregated Customer Margin Requirement for each Segregated Indirect Participant could discourage small firms from using the Segregated Indirect Participant Accounts.
                    <SU>101</SU>
                    <FTREF/>
                     Several commenters state that the requirement would increase costs for small firms and limit execution counterparties,
                    <SU>102</SU>
                    <FTREF/>
                     and several additional commenters state that FICC's proposed $1 million margin requirement is arbitrarily too high.
                    <SU>103</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>101</SU>
                         
                        <E T="03">See</E>
                         Letter from Katherine Darras, General Counsel, International Swaps and Derivatives Association (Apr. 17, 2024) (“ISDA Letter I”) at 4; Letter from Jennifer W. Han, Executive Vice President, Chief Counsel and Head of Global Regulatory Affairs, Managed Funds Association (Apr. 17, 2024) (“MFA Letter I”) at 6-7; Letter from Jennifer W. Han, Executive Vice President, Chief Counsel and Head of Global Regulatory Affairs, Managed Funds Association (Nov. 12, 2024) (“MFA Letter II”) at 7; Letter from Jiri Krol, Deputy Chief Executive Officer, Global Head of Government Affairs, Alternative Investment Management Association (Apr. 23, 2024) (“AIMA Letter”) at 6-7; Letter at 10; Letter from William C. Thum, Managing Director and Assistant General Counsel, Securities Industry and Financial Markets Association, Asset Management Group (May 24, 2024) (“SIFMA AMG Letter”) at 8; Letter from Joanna Mallers, Secretary, Futures Industry of America, Principal Traders Group (Oct. 11, 2024) (“FIA PTG Letter II”) at 2-3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>102</SU>
                         
                        <E T="03">See</E>
                         AIMA Letter at 6 (stating that the requirement will have myriad negative effects on customers and market liquidity generally, and that, for a customer with multiple clearing relationships and multiple segregated accounts, the need to maintain at $1 million cash in each account will increase costs for customers and prevent them from utilizing that capital in more productive ways); Letter from Joanna Mallers, Secretary, Futures Industry of America, Principal Traders Group (Apr. 17, 2024) (“FIA PTG Letter I”) at 7; FIA PTG Letter II at 2-3; SIFMA AMG Letter at 8-9. In addition, one commenter stated that, with the proposed deletion of the requirement to be a qualified institutional buyer (“QIB”) to be a Sponsored Member, these market participants may not be able to afford the $1 million cash requirement because QIBs, by definition, manage more than $100 million in securities on a discretionary basis, so it follows that the $1 million minimum could represent a sizable portion of a non-QIB's assets, potentially disincentivizing the non-QIB from pursuing indirect access to FICC. AIMA at 6-7.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>103</SU>
                         
                        <E T="03">See</E>
                         Letter from Sarah A. Bessin, Deputy General Counsel and Nhan Nguyen, Associate General Counsel, Investment Company Institute (Jun. 20, 2024) (“ICI Letter”) at 12; MFA Letter I at 6-7; MFA Letter II at 6-7.
                    </P>
                </FTNT>
                <P>
                    In response to concerns about increased costs to relatively small indirect participants, FICC states that the margin segregation regime under the proposal is entirely voluntary.
                    <SU>104</SU>
                    <FTREF/>
                     To the extent the $1 million floor is too costly for certain indirect participants, FICC states that they can choose to post margin to a Netting Member in a non-segregated account that could require them to post lower margin or no margin at all.
                    <SU>105</SU>
                    <FTREF/>
                     Further, FICC amended the Margin Segregation Proposal to provide that the minimum margin floor will be set at an amount of $1 million but could be adjusted by FICC if it determines that a different minimum amount would be appropriate and consistent with achieving its backtesting coverage target, and it would require that FICC's members would be notified of any such adjustment to the applicable minimum charge by an Important Notice.
                    <SU>106</SU>
                    <FTREF/>
                     Specifically, FICC states that it would review the $1 million floor for Segregated Customer Margin as part of ongoing internal surveillance and risk management monitoring procedures.
                    <SU>107</SU>
                    <FTREF/>
                     FICC also stated that it would be prudent to have the ability to adjust the $1 million floor proactively to the extent that FICC identifies, as part of these reviews, that activity levels, margin performance observed through backtesting, and other measures indicate that FICC would be able to continue to manage the risks presented to it and meet its regulatory risk management obligations (including, for example, its 99% backtesting coverage target) with a lower minimum Segregated Customer Margin Requirement.
                    <SU>108</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>104</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 30.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>105</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>106</SU>
                         
                        <E T="03">See</E>
                         Notice of Partial Amendment, 
                        <E T="03">supra</E>
                         note 10, at 87443.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>107</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 30.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>108</SU>
                         
                        <E T="03">Id.</E>
                         at 31.
                    </P>
                </FTNT>
                <P>
                    The Commission acknowledges the commenters' concerns that the $1 minimum margin requirement could result in increased costs for small firms that choose to utilize the proposed margin segregation regime, which may weaken those firms' competitive positions relative to others. In addition, the Commission acknowledges that FICC could, potentially, adjust the minimum margin requirement to an amount above $1 million; however, under the proposal, FICC would only be able to do so if it determines that a different amount would be appropriate and consistent with achieving its backtesting coverage target. As part of its ongoing supervision of FICC, the Commission will continue to monitor the performance of the $1 million minimum margin requirement, including as its performance compares to backtesting, and will engage with FICC regarding any changes to that requirement and the supporting analysis for such changes, to help ensure that FICC is appropriately exercising that discretion consistent with the requirements imposed upon it by the rule (
                    <E T="03">i.e.,</E>
                     that it determines that any such adjustments would be appropriate and consistent with achieving its backtesting coverage target). In addition, the Commission acknowledges that firms are not required to use a segregated account to participate at FICC and may choose to access FICC through a different type of account. Although some firms who choose to use segregated accounts could experience a burden on competition because of these potentially higher costs, the Commission concludes that any such burden to these firms is necessary and appropriate in furtherance of the Exchange Act 
                    <SU>109</SU>
                    <FTREF/>
                     for the following reasons.
                </P>
                <FTNT>
                    <P>
                        <SU>109</SU>
                         15 U.S.C. 78q 1(b)(3)(I). Specifically, as discussed in greater detail in Section II.C and II.H below, the Proposed Rule Change is necessary and appropriate to further the policy goals under Rule 17Ad 22(e)(4)(i) and (e)(19). 17 CFR 240.17Ad 22(e)(4)(i) and (e)(19).
                    </P>
                </FTNT>
                <P>
                    As discussed in Section I.A above, FICC seeks to maintain sufficient resources (
                    <E T="03">i.e.,</E>
                     margin) to cover its credit exposures to its Netting Members and indirect participants fully with a high degree of confidence and uses backtesting to determine when a Netting Member or indirect participant's margin 
                    <PRTPAGE P="93773"/>
                    would have been insufficient to cover FICC's credit exposure to that Netting Member or indirect participant. As described in Section II.C.2 below, the impact studies conducted by FICC prior to and after implementation of the $1 million Netting Member minimum margin requirement demonstrate that a $1 million margin floor has a material impact on reducing the number of backtesting deficiencies experienced by FICC's Netting Members, thereby increasing the number of Netting Members for which FICC maintained sufficient coverage at a confidence level of at least 99 percent. Since FICC would only be able to use Segregated Customer Margin posted by an individual Segregated Indirect Participant to satisfy that customer's obligations, the Segregated Customer Margin posted by each individual Segregated Indirect Participant would need to be sufficient on its own to address losses arising from the Segregated Indirect Participant's position. Therefore, adding the proposed $1 million floor for Segregated Customer Margin should enable FICC to better manage its credit exposure to a Segregated Indirect Participant by ensuring FICC holds sufficient collateral to cover that exposure, reducing the likelihood that FICC or non-defaulting parties would incur losses resulting from a Segregated Indirect Participant default. Moreover, if the $1 million floor is cost prohibitive for certain indirect participants, they can continue to access FICC's services by submitting activity through a Sponsoring Member Omnibus Account or Agent Clearing Member Omnibus Account that is not segregated, since the proposed margin segregation regime is entirely voluntary.
                </P>
                <P>
                    Therefore, the Commission concludes that any competitive burden imposed by the Proposed Rule Change is necessary and appropriate in furtherance of the Exchange Act. Accordingly, the Commission finds that the Proposed Rule Change is consistent with the requirements of Section 17A(b)(3)(I) of the Exchange Act.
                    <SU>110</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>110</SU>
                         15 U.S.C. 78q-1(b)(3)(I).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">A. Consistency With Rule 17ad-22(e)(4)(i)</HD>
                <P>
                    Rule 17ad-22(e)(4)(i) requires that FICC establish, implement, maintain and enforce written policies and procedures reasonably designed to effectively identify, measure, monitor, and manage its credit exposures to participants and those arising from its payment, clearing, and settlement processes, including by maintaining sufficient financial resources to cover its credit exposure to each participant fully with a high degree of confidence.
                    <SU>111</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>111</SU>
                         17 CFR 240.17ad-22(e)(4)(i).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">1. Separate Calculation and Collection of Margin for Proprietary and Customer Accounts</HD>
                <P>
                    The proposed changes to require the separate and independent calculation and collection of margin for Netting Members' proprietary transactions and indirect participants' transactions, as described in Section I.B.1., are consistent with Rule 17ad-22(e)(4)(i).
                    <SU>112</SU>
                    <FTREF/>
                     The separate calculation and collection of margin from Netting Members and indirect participants should allow FICC to better identify and measure the unique risk profile of each participant, enhancing FICC's ability to calculate and collect the appropriate margin from each direct and indirect participant. As a result, the proposed changes should help ensure that FICC has sufficient margin to cover potential losses from a Netting Member or indirect participant default, thereby reducing the probability that FICC, non-defaulting Netting Members, or non-defaulting indirect participants would incur losses resulting from a default.
                </P>
                <FTNT>
                    <P>
                        <SU>112</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. $1 Million Minimum Cash Margin Requirement</HD>
                <P>
                    The proposed minimum $1 million cash margin requirement for each Segregated Indirect Participant Account, as described in Section I.B.2.a, is consistent with Rule 17ad-22(e)(4)(i). Several commenters state that FICC lacks a sufficient basis or justification for the required $1 million minimum margin amount.
                    <SU>113</SU>
                    <FTREF/>
                     Specifically, one commenter stated that using the amount applicable to Netting Members is not an appropriate basis for establishing a minimum for indirect participants, and also stated that the requirement lacks any support or analysis as to the level of margin attributable to a typical fund's positions in cleared Treasury repo, which is data FICC should have readily available.
                    <SU>114</SU>
                    <FTREF/>
                     An additional commenter stated the requirement seems arbitrary, and not practical or necessary, especially in the current done-with model, to force every segregated customer to be subject to the same minimum requirement as a Netting Member.
                    <SU>115</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>113</SU>
                         
                        <E T="03">See</E>
                         ISDA Letter I at 4; ICI Letter at 12; AIMA Letter at 6-7; MFA Letter II at 6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>114</SU>
                         ICI Letter at 12.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>115</SU>
                         AIMA Letter at 6. 
                        <E T="03">See also</E>
                         MFA Letter II at 7.
                    </P>
                </FTNT>
                <P>
                    In addition, commenters state that FICC should adopt a lower minimum requirement ($100,000 to $250,000), a dynamic minimum based on average exposure subject to a $250,000 cap, or a minimum set by the relevant Netting Member.
                    <SU>116</SU>
                    <FTREF/>
                     Commenters also state that FICC should determine a minimum deposit based on the individual client and the risk that such client presents to FICC and other market participants.
                    <SU>117</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>116</SU>
                         AIMA Letter at 7; MFA Letter I at 7; SIFMA AMG Letter at 9.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>117</SU>
                         ISDA I at 4; 
                        <E T="03">see also</E>
                         MFA Letter II at 7 (stating that the requirement should be determined based on a participant's particular risk profile, including its planned and historical clearing activity).
                    </P>
                </FTNT>
                <P>
                    In response, FICC states that the $1 million floor for Segregated Indirect Participants is the same floor FICC already has in place for its Netting Members.
                    <SU>118</SU>
                    <FTREF/>
                     FICC states that its impact study, conducted in 2022 when adopting the rule applicable to Netting Members, demonstrated that a $1 million floor would protect FICC and its participants from incurring a loss in the event of a Netting Member failure because the study indicated that a $1 million floor would provide an adequate buffer for additional repo activity due to increases in repo interest rates and would have mitigated 65 out of 396 backtesting deficiencies (16%) during the period from July 1, 2021 to June 30, 2022.
                    <SU>119</SU>
                    <FTREF/>
                     FICC further states that it analyzed alternative minimum margin amounts, such as $500,000, and, based on the results of its analysis, the $1 million floor provided the appropriate balance of improving backtesting performance and margin coverage while minimizing the impact on Netting Members.
                    <SU>120</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>118</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 28; Securities Exchange Act Release No. 96136 (Oct. 24, 2022), 87 FR 65268 (Oct. 28, 2022) (SR-FICC-2022-006) (“FICC-2022-006 Order”). The impact study contains an analysis of backtesting results on a member-by-member basis over a twelve-month period ending June 30, 2022, and it includes, for both the then-current rule and the proposed $1 million minimum rule, the number of backtesting deficiencies and the level of coverage obtained. It contains the same analysis for a $500,000 minimum as well, including the same data points on a member-by-member basis.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>119</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 28.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>120</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    FICC also states that the backtesting data from the period after the $1 million minimum floor was implemented indicated a “material reduction of backtesting deficiencies at FICC.” 
                    <SU>121</SU>
                    <FTREF/>
                     From December 5, 2022 to June 30, 2024, FICC states that the $1 million floor eliminated 24 backtesting deficiencies, a 12% reduction.
                    <SU>122</SU>
                    <FTREF/>
                     Further, during a period of 12-month period of moderate market volatility from July 1, 2023 to June 30, 2024, FICC states that the $1 million floor 
                    <PRTPAGE P="93774"/>
                    eliminated 15 backtesting deficiencies, a 22% reduction.
                    <SU>123</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>121</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 29.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>122</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>123</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    FICC further states that the $1 million floor is appropriate because the Segregated Customer Margin posted by each individual Segregated Indirect Participant needs to be sufficient on its own to address losses arising from the Segregated Indirect Participant's positions.
                    <SU>124</SU>
                    <FTREF/>
                     This is because Segregated Customer Margin is not subject to loss mutualization under the proposal, so FICC can only use Segregated Customer Margin posted by an individual Segregated Indirect Participant to satisfy that customer's obligations. As a result, each Segregated Indirect Participant's portfolio would present a risk to FICC that is equivalent to the risk of a proprietary portfolio of an individual Netting Member.
                    <SU>125</SU>
                    <FTREF/>
                     If the Segregated Customer Margin is insufficient, losses would need to be mutualized, with harm to FICC, its non-defaulting Netting Members, and, potentially, the market as a whole.
                    <SU>126</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>124</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>125</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>126</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    In addition, FICC stated that the risk cited by the Commission of inconsistent activity giving rise to dramatic changes in risk exposure, discussed by the Commission in the FICC-2022-006 Order,
                    <SU>127</SU>
                    <FTREF/>
                     is arguably more pronounced for indirect participants than for Netting Members.
                    <SU>128</SU>
                    <FTREF/>
                     First, indirect participants may clear through multiple Netting Members and shift their activity through different Netting Members, which can present risks to FICC since FICC cannot use the Segregated Customer Margin posted by the Segregated Indirect Participant through one Netting Member to address the Segregated Indirect Participant's transactions cleared by another Netting Member.
                    <SU>129</SU>
                    <FTREF/>
                     As a result, FICC states that, even if the Segregated Indirect Participant's overall activity remains steady, FICC could see dramatic shifts in its risk simply because the Segregated Indirect Participant shifts the Netting Members it uses as its intermediary at FICC.
                    <SU>130</SU>
                    <FTREF/>
                     Second, FICC states that it does not have the same general understanding of indirect participants' business that it has for its Netting Members, since it does not collect the same information on individual customers' business or finances that it does for its Netting Members.
                    <SU>131</SU>
                    <FTREF/>
                     As a result, FICC states that it is less likely to know when there may be significant swings in indirect participant risk exposures as it would for its Netting Members and, since indirect participants are likely to have a far more diverse array of business models and interest rate considerations than FICC's Netting Members, they could engage in inconsistent activity that could increase risk exposure to FICC.
                    <SU>132</SU>
                    <FTREF/>
                     According to FICC, the possibility of inconsistent activity among indirect participants is potentially greater.
                    <SU>133</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>127</SU>
                         FICC-2022-006 Order, 
                        <E T="03">supra</E>
                         note 118, at 65270.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>128</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 30.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>129</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>130</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>131</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>132</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>133</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>The Commission disagrees with commenters who stated that using the same minimum as Netting Members is not appropriate for Segregated Indirect Participants. As stated in Section I.A. above, FICC and non-defaulting Netting Members and indirect participants may be subject to losses should the Segregated Customer Margin of an indirect participant be insufficient to satisfy losses caused by the liquidation of that indirect participant's portfolio. This potential exposure both to FICC and non-defaulting Netting Members and indirect participants makes it essential that FICC determine margin amounts for Segregated Indirect Participant Accounts that are reasonably designed to ensure that FICC has sufficient margin to cover the losses of a defaulting Segregated Indirect Participant.</P>
                <P>The analyses conducted by FICC both in connection with the 2022 change to the required minimum margin amount for Netting Members and after the implementation of that requirement, which the Commission has reviewed and analyzed, support the use of the $1 million margin requirement for Segregated Indirect Participant Accounts. The Commission agrees that these studies demonstrate that a $1 million margin floor has a material impact on reducing the number of backtesting deficiencies experienced by FICC's Netting Members, which would likely help FICC better manage its credit exposure to its Netting Members and indirect participants and credit exposures arising from its payment, clearing, and settlement processes.</P>
                <P>
                    Consideration of the appropriate Netting Member minimum is directly relevant to what is appropriate for Segregated Indirect Participant Accounts because FICC would treat such accounts the same as Netting Member accounts in the event of a default of that individual customer.
                    <SU>134</SU>
                    <FTREF/>
                     Even though a Segregated Indirect Participant would be the customer of a Sponsoring Member or an Agent Clearing Member, each Segregated Indirect Participant Account would need to provide sufficient margin to independently cover its losses in the event of a default. FICC will determine the appropriate margin for each Segregated Indirect Participant Account as if it were a separate Netting Member. As discussed above, indirect participants may increase risk by clearing through different Netting Members, which would provide FICC with less insight into their overall portfolio. Accordingly, it is appropriate for the minimum amount to be the same for both Netting Members and indirect participants.
                </P>
                <FTNT>
                    <P>
                        <SU>134</SU>
                         This also makes the 2022 impact study relevant to this determination because FICC would calculate margin requirements for each Segregated Indirect Participant in the same manner as margin requirements for each Netting Member. The Commission reviewed and analyzed that impact study when approving the current minimum applicable to Netting Members, and the same analysis should apply here as well.
                    </P>
                </FTNT>
                <P>
                    In response to commenters who proposed an alternative amount or approach, the Commission also has reviewed and analyzed the analysis of alternative minimum amounts that FICC conducted, which show that there would still be potential for higher amounts of backtesting deficiencies using a $500,000 alternative minimum, making the alternatives proposed by commenters ($100,000, $250,000 or a dynamic minimum with a $250,000 cap) not reasonably designed to allow FICC to collect sufficient margin to cover its exposures. As discussed above, FICC's backtesting data from December 5, 2022 to June 30, 2024 indicates that increasing the minimum margin amount from $100,000 to $1 million eliminated 24 Netting Member backtesting deficiencies, a 12% reduction.
                    <SU>135</SU>
                    <FTREF/>
                     Further, during a 12-month period of moderate market volatility from July 1, 2023 to June 30, 2024, the $1 million floor eliminated 15 backtesting deficiencies, a 22% reduction.
                    <SU>136</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>135</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 29.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>136</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    Because FICC is not able to predict how many indirect participants may elect to submit activity to FICC through a Segregated Indirect Participants Account or the size or volume of that activity, margin requirements for each Segregated Indirect Participant would be calculated in the same manner as for Netting Members.
                    <SU>137</SU>
                    <FTREF/>
                     FICC's impact studies of Netting Members provide a reasonable approximation of the risks FICC may face if the minimum margin amount is set below $1 million. 
                    <PRTPAGE P="93775"/>
                    Therefore, the proposed $1 million floor is appropriate to increase the probability that the margin amount collected by FICC is sufficient to cover FICC's credit exposure to Segregated Indirect Participants and protect non-defaulting parties from experiencing losses. However, as described above in Section I.B.2.a., if FICC determines that a different minimum charge would be appropriate and consistent with achieving its backtesting coverage target, FICC would have the ability to adjust the minimum charge of $1 million margin requirement. This added flexibility should allow FICC to continue to collect the appropriate amount of margin to cover its credit exposure to each participant fully with a high degree of confidence, as demonstrated by FICC's meeting its backtesting coverage targets, while minimizing the burden on indirect participants.
                </P>
                <FTNT>
                    <P>
                        <SU>137</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21595.
                    </P>
                </FTNT>
                <P>Moreover, the Commission disagrees that allowing the Netting Member to determine a minimum would be appropriate. It is unclear what basis a Netting Member would use to determine such a minimum in a way that would ensure that the amount is sufficient to meet FICC's regulatory obligations and minimize backtesting deficiencies because a Netting Member would not be able to replicate FICC's backtesting or calculate FICC's regulatory obligations.</P>
                <P>
                    The Commission disagrees that determining a minimum deposit on a case-by-case basis would be feasible for every Segregated Indirect Participant. FICC has stated that it does not know how many Segregated Indirect Participants will participate in FICC. At this time, there are over 2500 Sponsored Members at FICC,
                    <SU>138</SU>
                    <FTREF/>
                     and it is likely that additional indirect participants will want to access clearing going forward in light of the Treasury Clearing rules. Determining a minimum for even half the current Sponsored Members on a case-by-case basis would be extremely burdensome for FICC and would require the submission of detailed financial information by each Sponsored Member to inform FICC of its planned business activities, and it is unclear how or on what basis such a minimum would be adjusted over time. Establishment of a minimum requirement is appropriate to ensure that FICC can meet its obligations under Rule 17ad-22(e)(4)(i), and reliance upon the minimum for Netting Members is appropriate because, as discussed above, FICC has to treat each Segregated Indirect Participant as a stand-alone account for risk management purposes to segregate its margin appropriately.
                </P>
                <FTNT>
                    <P>
                        <SU>138</SU>
                         
                        <E T="03">See</E>
                         GSD Member Directories, 
                        <E T="03">available at https://www.dtcc.com/client-center/ficc-gov-directories.</E>
                    </P>
                </FTNT>
                <P>
                    For these reasons, the $1 million minimum margin requirement should help ensure that FICC has sufficient margin to cover potential losses from a Segregated Indirect Participant default, thereby reducing the probability that FICC, non-defaulting Netting Members, and non-defaulting indirect participants would incur losses resulting from a default. Moreover, as described above in Section I.B.2.a., FICC would have the ability to adjust the amount of the minimum $1 million margin requirement if FICC determines that a different minimum charge would be appropriate and consistent with achieving its backtesting coverage target. The Commission agrees with FICC that it should continue to assess the performance of this minimum requirement with respect to FICC's backtesting coverage requirements, as it provided in the Amendment to this filing, to ensure that FICC is not collecting more margin than is necessary to meet its regulatory obligations to cover its exposure to its participants.
                    <SU>139</SU>
                    <FTREF/>
                     Although the Commission recognizes that FICC could use this ability to increase the $1 million minimum to some greater amount, it would only be able to do so if determines that a different minimum charge would be appropriate and consistent with achieving its backtesting coverage target.
                </P>
                <FTNT>
                    <P>
                        <SU>139</SU>
                         One commenter states that FICC should not delay recalibration of the minimum margin requirement to a later date. MFA Letter II at 6-7. However, as the Commission discussed above, the minimum margin requirement is appropriate, based on the data available at this time. The Commission will continue to monitor implementation of this requirement going forward once more data regarding the use of segregated accounts is available.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">3. Margin Component Schedule</HD>
                <P>The proposed changes in section I.B.3 regarding the calculation of margin for segregated and non-segregated accounts should ensure that FICC collects margin sufficient to cover its exposures with respect to both direct and indirect participants. Requiring that the margin requirement for a Segregated Indirect Participant Account be calculated in generally the same manner as a Netting Member's requirement, which the Commission has reviewed and approved as part of FICC's rules, should help ensure that FICC collects margin sufficient to cover its exposures with respect to both direct and indirect participants. By doing so, this portion of the Advance Notice should better ensure that, in the event of a Netting Member's or indirect participant's default, FICC has sufficient margin to cover potential losses from the default, thereby reducing the probability that FICC, non-defaulting Netting Members, and non-defaulting indirect participants would incur losses resulting from a default. Collecting the same margin components for a Segregated Indirect Participant Account as those used for a Netting Member Account is appropriate because FICC has to risk-manage each Segregated Indirect Participant Account individually, and application of the existing margin methodology would help ensure that FICC collects sufficient margin to cover its exposures to participants for all Accounts. FICC has, however, taken into account how the ECP should apply differently when determining a Segregated Customer Margin Requirement, which is appropriate for the reasons discussed in Section II.C.3 below, and the changes related to the ECP Charge would ensure that Segregated Indirect Participants are not required to post additional margin to account for the capital position of its Netting Member.</P>
                <P>
                    Accordingly, for the reasons discussed above, the Proposed Rule Change is reasonably designed to enable FICC to effectively identify, measure, monitor, and manage its credit exposure to Netting Members and indirect participants, consistent with Rule 17ad-22(e)(4)(i).
                    <SU>140</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>140</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Consistency With Rule 17ad-22(e)(6)(i)</HD>
                <P>
                    Rule 17ad-22(e)(6)(i) requires FICC to establish, implement, maintain and enforce written policies and procedures reasonably designed to cover its credit exposures to its participants by establishing a risk-based margin system that, at a minimum, considers, and produces margin levels commensurate with, the risks and particular attributes of each relevant product, portfolio, and market, and, if the covered clearing agency provides central counterparty services for U.S. Treasury securities, calculates, collects, and holds margin amounts from a direct participant for its proprietary positions in Treasury securities separately and independently from margin calculated and collected from that direct participant in connection with U.S. Treasury securities transactions by an indirect participant that relies on the services provided by the direct participant to access the covered clearing agency's 
                    <PRTPAGE P="93776"/>
                    payment, clearing, or settlement facilities.
                    <SU>141</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>141</SU>
                         17 CFR 240.17ad-22(e)(6)(i).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">1. Separation of Proprietary and Customer Margin</HD>
                <P>
                    The proposed changes to separate proprietary and customer margin are consistent with Rule 17ad-22(e)(6)(i). First, to help ensure that proprietary transactions and transactions submitted to FICC on behalf of indirect participants are margined separately, FICC would require that each margin portfolio contain only transactions from the same account type and that Netting Members use separate Deposit IDs for different transaction types. Second, FICC would calculate each Segregated Indirect Participant's margin requirement separately on a gross basis as though each Segregated Indirect Participant were a separate Netting Member. Finally, FICC would create a separate “Segregated Customer Margin Custody Account” for each Netting Member that contains deposits of Segregated Customer Margin for indirect participants, with interest earned on cash margin paid to each Segregated Indirect Participant's Netting Member for the benefit of, and as an agent for, the Segregated Indirect Participant. Collectively, these proposed changes should ensure that a Netting Member's proprietary transactions are not netted with indirect participant transactions for margin calculations and that margin for indirect participant transactions is collected and held separately and independently from margin for a Netting Member's proprietary transactions. Moreover, by calculating each Segregated Indirect Participant's margin requirement separately from Netting Members and other Segregated Indirect Participants, the proposed changes should allow FICC to better isolate the risk profiles of individual indirect participants from Netting Members, which should help FICC better understand and monitor each individual participant's risk exposures.
                    <SU>142</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>142</SU>
                         Commenters requested clarification that FICC's funds-only settlement amounts are settlement payments rather than margin. 
                        <E T="03">See</E>
                         ISDA Letter at 6; Letter from Katherine Darras, General Counsel, International Swaps and Derivatives Association (July 18, 2024) (“ISDA Letter II”) at 6; SIFMA Letter at 4; Letter from Walt L. Lukken, President and Chief Executive Officer, Futures Industry of America (Apr. 18, 2024) (“FIA Letter”) at 11. The Proposed Rule Change does not make any amendments to the funds-only settlement process at FICC. 
                        <E T="03">See</E>
                         GSD Rule 13. This aspect of FICC's rules is, therefore, not relevant to this Proposed Rule Change. However, FICC clarified that it views such payments as constituting settlements that discharge outstanding payment obligations, rather than as margin or collateral. FICC Letter at 43. The Commission agrees with this clarification, based upon its knowledge of FICC's margin and payment flows and the applicable GSD Rules.
                    </P>
                </FTNT>
                <P>
                    One commenter expressed concern that the proposal would not fully eliminate fellow customer risk because it would allow for the 
                    <E T="03">pro rata</E>
                     allocation of Current Net Settlement positions among Segregated Indirect Participant positions held in the same Segregated Indirect Participants Account.
                    <SU>143</SU>
                    <FTREF/>
                     In response, FICC explained that, due to the requirement in the Treasury Clearing Rules that margin for customer positions be calculated separately from margin for a Netting Member's proprietary positions, FICC would not be able to allocate the margin obligations from Current Net Settlement Positions to a Netting Member's portfolio.
                    <SU>144</SU>
                    <FTREF/>
                     As a result, such margin must be allocated to customer positions and FICC states that, when it is not aware of the allocation of Current Net Settlement Positions among customers, it is most equitable to allocate such positions 
                    <E T="03">pro rata</E>
                     to customers who were long or short the relevant securities.
                    <SU>145</SU>
                    <FTREF/>
                     The Commission agrees that allocating the positions to the Netting Member's account would be inconsistent with Rule 17ad-22(e)(6)(i) because it would impermissibly net proprietary transactions against indirect participant transactions. The Commission further agrees that the positions must be allocated to ensure that FICC is able to appropriately risk-manage those positions (that is, to collect appropriate margin). The Commission further agrees with FICC's approach of limiting such 
                    <E T="03">pro rata</E>
                     allocations only to customers engaging in non-Sponsored GC Trades because settlement failures do not occur with respect to Sponsored GC Trades. Therefore, in the event that the positions are not allocated, a 
                    <E T="03">pro rata</E>
                     allocation among customers is appropriate.
                </P>
                <FTNT>
                    <P>
                        <SU>143</SU>
                         
                        <E T="03">See</E>
                         SIFMA AMG Letter at 10.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>144</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 36.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>145</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    Accordingly, the proposed changes in the Proposed Rule Change would be consistent with Rule 17ad-22(e)(6)(i) because they should help ensure that FICC calculates, collects, and holds margin for a Netting Member's proprietary positions separately from the margin for positions the member clears for customers.
                    <SU>146</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>146</SU>
                         17 CFR 240.17ad-22(e)(6)(i).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">5. Margin Component Schedule</HD>
                <P>The proposed changes to establish a Margin Component Schedule, which would consolidate the terms and information relating to margin calculation throughout the Rules into a single schedule, are consistent with Rule 17ad-22(e)(6)(i). Under the proposed Margin Component Schedule, FICC would perform substantially the same calculation it currently performs when determining a Netting Member's Required Fund Deposit and include the methodology for calculating a Netting Member's Segregated Customer Margin Requirement. By including a methodology to calculate each Segregated Indirect Participant's margin requirement separately from Netting Members and other Segregated Indirect Participants, the proposed changes should help ensure that FICC calculates, collects, and holds margin for a Netting Member's proprietary positions separately from the margin for positions the member clears for customers. Moreover, calculating margin requirements for each Segregated Indirect Participant should allow FICC to better isolate the risk profiles of individual indirect participants from Netting Members, which should help FICC better understand and monitor each individual participant's risk exposures and thereby collect margin commensurate with the risks of each Netting Member and indirect participant portfolio.</P>
                <P>
                    A commenter states that FICC should confirm that segregation of margin for indirect participants does not magnify risk for Netting Members. Specifically, the commenter states that it is not clear whether the Required Fund Deposit to be posted by Netting Members incorporates any exposure associated with Segregated Indirect Participant Accounts and expresses concern as to whether FICC's rules allow FICC to collect additional margin to cover any enhanced risk that may arise relating to the Netting Member's obligations to FICC for its clients who are indirect participants generally or who choose segregation specifically.
                    <SU>147</SU>
                    <FTREF/>
                     However, FICC's proposed rules establish that the calculation of a Netting Member's Required Fund Deposit excludes the exposure of its Segregated Indirect Participants.
                    <SU>148</SU>
                    <FTREF/>
                     FICC's rules do permit FICC to collect increased Required Fund Deposits from Netting Members if “necessary to protect [FICC] and its Members from Legal Risk,” which, FICC states, would include the consideration 
                    <PRTPAGE P="93777"/>
                    of the Netting Members' indirect participants.
                    <SU>149</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>147</SU>
                         ISDA Letter I at 7; ISDA Letter II at 6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>148</SU>
                         
                        <E T="03">Compare</E>
                         proposed Margin Component Schedule section 2 (regarding Required Fund Deposits) 
                        <E T="03">with</E>
                         section 3 (regarding Segregated Customer Margin).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>149</SU>
                         
                        <E T="03">See</E>
                         proposed Margin Component Schedule section 4; 
                        <E T="03">see also</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 4, at 21593.
                    </P>
                </FTNT>
                <P>
                    This commenter also states the fact that the ability to prefund margin for a customer is only temporary puts pressure on the Netting Member's own Required Fund Deposits, which “it seems would still cover the obligations of all its clients” and also on the Netting Member and the broader FICC membership, in the event of a failure by any Segregated Indirect Participant.
                    <SU>150</SU>
                    <FTREF/>
                     However, the Netting Member's Required Fund Deposits would not be calculated based on the obligations of its clients, and, in the event of the default of an indirect participant, FICC would use the Segregated Customer Margin for only that indirect participant. Therefore, the Commission disagrees that the inability to permanently prefund the customer's margin requirement puts additional pressure on the Netting Member's own Required Fund Deposits.
                </P>
                <FTNT>
                    <P>
                        <SU>150</SU>
                         
                        <E T="03">See</E>
                         ISDA Letter I at 7.
                    </P>
                </FTNT>
                <P>
                    Another commenter states that FICC should explain why it is appropriate to calculate a segregated customer's margin requirement as if it were a Netting Member, even though the margin calculation for FICC Netting Members covers both initial margin and guaranty fund contributions (and customers are not expected to be contributing to the guaranty fund).
                    <SU>151</SU>
                    <FTREF/>
                     However, FICC does not maintain a separate guaranty fund into which a Netting Member contributes for its customers. The Segregated Customer Margin Requirement must be sufficient to cover the exposures to FICC arising from that particular customer's activity because, under the segregation system proposed by the Proposed Rule Change which would allow broker-dealers participating in FICC to comply with the conditions of Note H to Rule 15c3-3, FICC would not be able to use the margin collected from a Segregated Indirect Participant for any reason unrelated to the Segregated Indirect Participant. Therefore, calculating each Segregated Customer Margin Requirement in this manner is appropriate to ensure that FICC has appropriate resources to cover each customer's exposures. Therefore, this aspect of the Proposed Rule Change is consistent with Rule 17ad-22(e)(6)(i) under the Exchange Act.
                </P>
                <FTNT>
                    <P>
                        <SU>151</SU>
                         
                        <E T="03">See</E>
                         Letter from Joanna Mallers, Secretary, Futures Industry of America, Principal Traders Group (Apr. 17, 2024) (“FIA PTG Letter I”) at 8.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">6. Excess Capital Premium</HD>
                <P>The proposed changes to the calculation of the ECP charge are consistent with Rule 17ad-22(e)(6)(i). FICC's margin deposits are made up of risk-based components (as margin) that are calculated and assessed daily to limit FICC's exposures to Netting Members. FICC's proposed changes to use clearly defined sources in the calculation of the ECP charge would collectively make the calculation clearer and more predictable to Netting Members, while continuing to apply an appropriate risk-based charge designed to mitigate the risks presented to FICC. Similarly, the proposal to cap the Excess Capital Ratio at 2.0 would allow FICC to appropriately address the risks it faces without imposing an overly burdensome ECP and would reduce the circumstances in which FICC may waive the charge, resulting in a more transparent margining methodology. Finally, the proposed rule change would clarify the exigent circumstances under which FICC may determine that it is appropriate to waive the ECP charge. Overall, these proposed changes would improve the effectiveness of the calculation of the ECP and, therefore, allow FICC to more effectively address the increased default risks presented by Netting Members that operate with lower capital levels relative to their margin requirements.</P>
                <P>In addition, FICC proposes to exclude VaR Charges for Segregated Indirect Participants Accounts when determining a Netting Member's Excess Capital Differential, in order to take into account the fact that each indirect participant would be responsible for satisfying its own respective VaR Charge. Not including these Segregated Indirect Participants Accounts when determining the Excess Capital Differential, and, therefore, the ECP Charge, is consistent with the purpose of the Excess Premium Charge. This charge is designed to address the risk that a Netting Member with low capital relative to its value-at-risk to FICC is not able to perform its obligations. Because the Netting Member's capital is not used to meet the indirect participant's obligation to FICC, excluding the indirect participant VaR Charges from the determination of the ECP should result in FICC collecting margin commensurate with the risks and particular attributes of each relevant portfolio.</P>
                <P>Taken together, the proposed changes enhance the ability of the ECP to produce margin levels commensurate with the risks FICC faces related to its Netting Members' operating capital levels. Therefore, this aspect of the Proposed Rule Change is consistent with Rule 17ad-22(e)(6)(i) under the Exchange Act.</P>
                <HD SOURCE="HD2">C. Consistency With Rule 17ad-22(e)(6)(iii)</HD>
                <P>
                    Rule 17ad-22(e)(6)(iii) requires that FICC establish, implement, maintain and enforce written policies and procedures reasonably designed to cover its credit exposures to its participants by establishing a risk-based margin system that, at a minimum, calculates margin sufficient to cover its potential future exposure to members in the interval between the last margin collection and the close out of positions following a member default.
                    <SU>152</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>152</SU>
                         17 CFR 240.17ad-22(e)(6)(iii).
                    </P>
                </FTNT>
                <P>
                    As summarized in Section I.B.3 above, FICC employs daily backtesting to determine the adequacy of each Netting Member's Required Fund Deposit, paying particular attention to members that have backtesting deficiencies below the 99% confidence target. Such backtesting deficiencies highlight exposure that could subject FICC to potential losses if a Netting Member defaults. As discussed in Section II.C.2, FICC's impact study during the period from July 1, 2021 to June 30, 2022 demonstrated that a $1 million floor would have protected FICC and its participants by reducing the possibility of incurring a loss in the event of a Netting Member failure by mitigating 16% of backtesting deficiencies.
                    <SU>153</SU>
                    <FTREF/>
                     Moreover, after the $1 million floor was implemented for Netting Members, FICC states that it eliminated 22% of backtesting deficiencies during a 12-month period of moderate market volatility from July 1, 2023 to June 30, 2024.
                    <SU>154</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>153</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 28.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>154</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    Therefore, adding the proposed $1 million minimum requirement for Segregated Customer Margin, and the ability to adjust the minimum million margin requirement to achieve FICC's backtesting coverage target, should better ensure that FICC maintains sufficient margin to cover its potential future exposure to its indirect participants in the interval between the last margin collection and the close out of positions following an indirect participant default. This should, thereby, reduce the likelihood FICC or non-defaulting Netting Members or indirect participants would incur losses as a result. Accordingly, FICC's proposed $1 million minimum requirement for Segregated Customer 
                    <PRTPAGE P="93778"/>
                    Margin would be consistent with Rule 17ad-22(e)(6)(iii).
                    <SU>155</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>155</SU>
                         17 CFR 240.17ad-22(e)(6)(iii).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">D. Consistency With Rule 17ad-22(e)(18)(ii)</HD>
                <P>
                    Rule 17ad-22(e)(18)(ii) requires that FICC establish, implement, maintain and enforce written policies and procedures reasonably designed to establish objective, risk-based, and publicly disclosed criteria for participation, which require participants to have sufficient financial resources and robust operational capacity to meet obligations arising from participation in the clearing agency.
                    <SU>156</SU>
                    <FTREF/>
                     The proposed changes to consolidate FICC's margin methodology in a single location, identify the particular Required Fund Deposit Portions and Segregated Customer Margin Requirements, and clarify the calculation of the Excess Capital Premium and circumstances in which FICC would waive the application of such premium should enhance FICC's public disclosure of the risk-based margin obligations that Netting Members and their indirect participants would have as a result of their participation in FICC's clearance and settlement services. This improved public disclosure should allow Netting Members and their indirect participants to better understand how their activity would impact margin calculations, which are designed to ensure that participants have sufficient financial resources and robust operational capacity to meet obligations to FICC. Accordingly, the proposed changes would be consistent with Rule 17ad-22(e)(18)(ii).
                    <SU>157</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>156</SU>
                         17 CFR 240.17ad-22(e)(4)(18)(ii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>157</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD2">E. Consistency With Rule 17ad-22(e)(18)(iii)</HD>
                <P>
                    Rule 17ad-22(e)(18)(iii) requires that FICC establish, implement, maintain and enforce written policies and procedures reasonably designed to establish objective, risk-based, and publicly disclosed criteria for participation, which monitor compliance with its participant requirements on an ongoing basis.
                    <SU>158</SU>
                    <FTREF/>
                     The proposed changes would require Netting Members to designate the specific account type when submitting transactions and to identify any Sponsored Member or Executing Firm Customer for whom the transaction is submitted. These changes should enhance FICC's ability to monitor which transactions are being entered into by which entities and assess the specific risks associated with those entities. This enhanced monitoring of participant activity should allow FICC to better monitor participants' compliance with FICC's Rules. Accordingly, the proposed changes would be consistent with Rule 17ad-22(e)(18)(iii) because they should enhance FICC's ability to monitor compliance with its participant requirements on an ongoing basis.
                    <SU>159</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>158</SU>
                         17 CFR 240.17ad-22(e)(18)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>159</SU>
                         17 CFR 240.17ad-22(e)(18)(iii).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">F. Consistency With Rule 17ad-22(e)(18)(iv)(C)</HD>
                <P>
                    Rule 17ad-22(e)(18)(iv)(C) requires that FICC establish, implement, maintain and enforce written policies and procedures reasonably designed to ensure that it has appropriate means to facilitate access to clearance and settlement services of all eligible secondary market transactions in U.S. Treasury securities, including those of indirect participants.
                    <SU>160</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>160</SU>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <P>As discussed above in Section II.B.3, by improving the transparency of FICC's account offerings and margin calculation methodology, the proposed changes should enhance market participants' understanding of how margin is calculated and their options for posting margin, thereby facilitating access to FICC's clearance and settlement services. In addition, the proposed changes should offer greater optionality to Netting Members and indirect participants, which should allow Netting Members and indirect participants to adopt a margining arrangement that aligns with their business objectives and regulatory, operational, and practical constraints. By enhancing transparency of FICC's margin framework and account options and offering greater optionality to participants concerning the type of account they transact in and how their margin is posted, the proposal should facilitate access to FICC's clearance and settlement systems.</P>
                <P>
                    Several commenters proposed that FICC should require Netting Members to offer account segregation to customers.
                    <SU>161</SU>
                    <FTREF/>
                     One such commenter specified that this should include bank Netting Members, who would not face the same restrictions on the use of customer margin as broker-dealer customers subject to Rule 15c3-3 and therefore may not be as incentivized to provide segregated account services.
                    <SU>162</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>161</SU>
                         Specifically, one commenter stated that for indirect participants, having a “right” to direct their Netting Member to segregate their margin is highly desirable because it would allow an indirect participant to have certainty that margin that it posts receives the protection afforded by segregation. SIFMA AMG Letter at 6. Another such commenter stated that, despite what a customer may desire with respect to margin and segregation, there could be incentives for direct participants to finance the margin for their customers' transactions (and thereby earn extra fees for doing so) instead of the customer financing or posting that margin, and for the direct participant to accept the customer's margin without offering the option of segregation (and thereby avoid the additional operational and other costs associated with segregation), which would still be permissible if FICC were not to require its Netting Members to offer account segregation. MFA Letter I at 4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>162</SU>
                         SIFMA AMG Letter at 6.
                    </P>
                </FTNT>
                <P>
                    FICC did not propose a requirement that its Netting Members offer segregated accounts to their customers. Therefore, the Commission is not addressing any changes related to such a requirement in this Proposed Rule Change. Nothing in the Treasury Clearing Rules or Rule 15c3-3 requires a covered clearing agency, like FICC, to require its Netting Members to provide certain services. Moreover, certain Netting Members may have regulatory or other reasons not to offer segregation, and, if required to offer such services, may choose to cease providing customer clearing services, which could, in turn, increase concentration in the market and reduce liquidity.
                    <SU>163</SU>
                    <FTREF/>
                     Any such requirement could constitute a burden on competition that would not be permissible under Section 17A(b)(3)(I) of the Exchange Act.
                </P>
                <FTNT>
                    <P>
                        <SU>163</SU>
                         FICC Letter at 33.
                    </P>
                </FTNT>
                <P>
                    Additionally, a commenter urged FICC to allow indirect participants to post margin directly to FICC without intermediation from a Netting Member.
                    <SU>164</SU>
                    <FTREF/>
                     The Treasury Clearing Rules do not require FICC to provide this function, and FICC did not propose such a method for direct posting of margin.
                    <SU>165</SU>
                    <FTREF/>
                     Accordingly, the Commission is not addressing any changes related to such a requirement in this Proposed Rule Change.
                </P>
                <FTNT>
                    <P>
                        <SU>164</SU>
                         
                        <E T="03">See</E>
                         ICI Letter at 13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>165</SU>
                         
                        <E T="03">See supra</E>
                         note 3 at 2751.
                    </P>
                </FTNT>
                <P>
                    One commenter sought clarification whether Netting Members other than broker-dealers can elect segregation for their customers.
                    <SU>166</SU>
                    <FTREF/>
                     Based on the Proposed Rule Change, the Commission understands, and FICC confirmed,
                    <SU>167</SU>
                    <FTREF/>
                     that any Sponsoring Member or Agent Clearing Member, regardless of whether registered as broker-dealers, would be able to designate an account as a Segregated Indirect Participants Account.
                </P>
                <FTNT>
                    <P>
                        <SU>166</SU>
                         FIA-PTG Letter at 7-9.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>167</SU>
                         FICC Letter at 39.
                    </P>
                </FTNT>
                <P>
                    The same commenter also sought clarification whether a customer may segregate margin obtained through a margin financing arrangement.
                    <SU>168</SU>
                    <FTREF/>
                     Based 
                    <PRTPAGE P="93779"/>
                    on the Proposed Rule Change, the Commission understands, and FICC confirmed,
                    <SU>169</SU>
                    <FTREF/>
                     that such segregation would be permissible under FICC's rules.
                </P>
                <FTNT>
                    <P>
                        <SU>168</SU>
                         FIA-PTG Letter at 7-9.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>169</SU>
                         FICC Letter at 40.
                    </P>
                </FTNT>
                <P>
                    This commenter also asked why excess margin would only be returned on request and states that an indirect participant should not have to request a return of its excess margin.
                    <SU>170</SU>
                    <FTREF/>
                     The Treasury Clearing Rules do not require FICC to provide this function, and FICC did not propose such a function. Accordingly, the Commission is not addressing any changes related to such a requirement in this Proposed Rule Change. Moreover, when it adopted the amendments to Rule 15c3-3, the Commission declined to adopt a requirement to “push” excess margin to direct participants.
                    <SU>171</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>170</SU>
                         
                        <E T="03">See</E>
                         FIA PTG Letter I at 7-9.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>171</SU>
                         
                        <E T="03">See</E>
                         Treasury Clearing Adopting Release, 
                        <E T="03">supra</E>
                         note 3, at 2767 (removing, in response to commenters, the requirement that the covered clearing agency have procedures to return customer position margin to the broker-dealer that is no longer needed to meet a current margin requirement resulting from positions in U.S. Treasury securities of the broker-dealer's customers no later than the close of the next business day after the day the customer position margin is no longer needed for this purpose because such a requirement may add significant operational burdens to covered clearing agencies for U.S. Treasury securities and because the debit is limited to margin required and on deposit at the covered clearing agency and therefore does not include the excess margin).
                    </P>
                </FTNT>
                <P>
                    Another commenter suggested that FICC allow customer margin to be segregated, even when customers do not post the full amount of the margin needed to cover their positions.
                    <SU>172</SU>
                    <FTREF/>
                     FICC states that allowing customer margin to be segregated when customers do not post the full amount of margin would lead to disparities that would put broker-dealer Netting Members at competitive disadvantage to other Netting Members.
                    <SU>173</SU>
                    <FTREF/>
                     The Treasury Clearing Rules do not require FICC to provide this function, and FICC did not propose such a function. Any changes to FICC's rules to impose such a requirement would have to be filed with the Commission pursuant to Section 19(b) 
                    <SU>174</SU>
                    <FTREF/>
                     of the Exchange Act, as well as, potentially, in an advance notice filed pursuant to Section 806(e) of the Clearing Supervision Act.
                    <SU>175</SU>
                    <FTREF/>
                     Therefore, the Commission is not addressing any changes related to such a requirement in this Proposed Rule Change.
                </P>
                <FTNT>
                    <P>
                        <SU>172</SU>
                         
                        <E T="03">See</E>
                         MFA Letter I at 6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>173</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 32. Specifically, FICC stated that the Treasury Clearing Rules, in particular the amendments to Exchange Act Rule 15c3-3a, provide that a broker-dealer may record a debit in the customer and PAB reserve formulas for margin it collects from customers and on-posts to FICC, but only if the broker-dealer collects from the customer the full amount of margin required for the customer's positions. Accordingly, a broker-dealer is effectively precluded from collecting from customers only a portion of the margin that their positions require and on-posting that amount to FICC. Were FICC to allow segregation of customer margin even if the customer did not fully fund its margin obligations, such segregation would effectively allow non-broker-dealer Netting Members to offer what broker-dealers cannot, 
                        <E T="03">i.e.,</E>
                         permitting their customers to post a portion of the margin required by FICC and on-post that margin to FICC. This ability would place such Netting Members at a competitive advantage relative to broker-dealer Netting Members.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>174</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>175</SU>
                         
                        <E T="03">See supra</E>
                         note 3 at 2751.
                    </P>
                </FTNT>
                <P>
                    Finally, one commenter urged FICC to address the cross-border implications of the proposal and provide a framework for compliance by non-U.S. Netting Members and indirect participants.
                    <SU>176</SU>
                    <FTREF/>
                     Specifically, this commenter was concerned that the U.S. Treasury clearing mandate will adversely impact foreign customers that are limited in their ability, or prohibited entirely, to post margin in connection with transactions involving U.S. Treasury securities.
                    <SU>177</SU>
                    <FTREF/>
                     However, nothing in the Proposed Rule Change would require a particular market participant to post margin in connection with transactions involving U.S. Treasury securities. Indirect participants remain able to access FICC's central clearing services through access models that do not require the direct posting of margin to FICC (
                    <E T="03">e.g.,</E>
                     via the non-segregated versions of FICC's Sponsored and Agent Clearing Services), which should allow flexibility for market participants to determine the most effective way to access FICC indirectly regardless of potential regulatory or other constraints on the ability to post margin directly.
                </P>
                <FTNT>
                    <P>
                        <SU>176</SU>
                         
                        <E T="03">See</E>
                         SIFMA AMG Letter at 12-13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>177</SU>
                         
                        <E T="03">See id.</E>
                         (citing Article 15(2) of the European Union's Money Market Fund Regulation, which it describes as prohibiting European Money Market Mutual Funds from pledging any assets received under reverse repos and certain restrictions on Undertakings for Collective Investments in Transferable Securities and similar investment vehicles related to their ability to post margin that will be held on deposit at FICC).
                    </P>
                </FTNT>
                <P>
                    Accordingly, the proposed changes would be consistent with Rule 17ad-22(e)(18)(iv)(C).
                    <SU>178</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>178</SU>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">G. Consistency With Rule 17ad-22(e)(19)</HD>
                <P>
                    Rule 17ad-22(e)(19) requires that FICC establish, implement, maintain and enforce written policies and procedures reasonably designed to identify, monitor, and manage the material risks to the covered clearing agency arising from arrangements in which firms that are indirect participants in FICC rely on the services provided by direct participants to access FICC's clearance and settlement facilities.
                    <SU>179</SU>
                    <FTREF/>
                     The proposed changes described in Section I.B.1 would require that each margin portfolio contains only transactions from the same account type, Netting Members use separate Deposit IDs for different transaction types, each Segregated Indirect Participant's margin requirement be calculated separately on a gross basis as though each Segregated Indirect Participant were a separate Netting Member, and Segregated Customer Margin for each indirect participant be deposited into a separate interest-earning Segregated Customer Margin Custody Account. These changes should enhance FICC's ability to isolate the risk profiles of individual indirect participants from Netting Members, which should help FICC better understand and monitor each individual participant's risk exposures. In addition, the calculation and collection of Segregated Customer Margin on a gross basis, as described in Section I.B.1 and 1.B.2, and the establishment of a $1 million cash floor for Segregated Customer Margin, as described in Section I.B.2.a, should help ensure that FICC will have sufficient margin to manage the risk to FICC during an indirect participant default.
                </P>
                <FTNT>
                    <P>
                        <SU>179</SU>
                         17 CFR 240.17ad-22(e)(19).
                    </P>
                </FTNT>
                <P>
                    Accordingly, the proposed changes would be consistent with Rule 17ad-22(e)(19) because they should enhance FICC's ability to identify, monitor, and manage the material risks to FICC associated with indirect participants relying on Netting Members to access FICC's clearance and settlement services.
                    <SU>180</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>180</SU>
                         17 CFR 240.17ad-22(e)(19).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">H. Consistency With Rule 17ad-22(e)(23)(ii)</HD>
                <P>
                    Rule 17ad-22(e)(23)(ii) requires that FICC establish, implement, maintain and enforce written policies and procedures providing sufficient information to enable participants to identify and evaluate the risks, fees, and other material costs they incur by participating in FICC.
                    <SU>181</SU>
                    <FTREF/>
                     The proposed changes described in Section I.B.3 to consolidate and clarify FICC's margin calculation methodology in the proposed Margin Component Schedule, adopt a method for allocating net unsettled positions to individual indirect participants for purposes of calculating margin requirements and to clarify the calculation of the ECP should make it easier for both Netting Members and indirect participants to identify and price the potential margining costs 
                    <PRTPAGE P="93780"/>
                    associated with how each chooses to submit transactions to FICC for clearance and settlement.
                </P>
                <FTNT>
                    <P>
                        <SU>181</SU>
                         17 CFR 240.17ad-22(e)(23)(ii).
                    </P>
                </FTNT>
                <P>
                    Accordingly, the proposed changes would be consistent with Rule 17ad-22(e)(23)(ii) because they should enhance the ability of Netting Members and indirect participants to identify and evaluate the costs to access FICC's clearance and settlement services.
                    <SU>182</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>182</SU>
                         17 CFR 240.17ad-22(e)(23)(ii).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">I. Other Comments Received</HD>
                <P>
                    Commenters submitted several comments that were not related to the Proposed Rule Change. Commenters stated that FICC should publish a roadmap and/or expedite their plans with the Chicago Mercantile Exchange (“CME”) for expanding their cross-margining framework.
                    <SU>183</SU>
                    <FTREF/>
                     The Proposed Rule Change does not address the cross-margining agreement between FICC and CME. The current cross-margining agreement between FICC and CME is part of FICC's rulebook, and therefore any changes to the agreement would have to be filed with the Commission pursuant to Section 19(b) 
                    <SU>184</SU>
                    <FTREF/>
                     of the Exchange Act.
                    <SU>185</SU>
                    <FTREF/>
                     Therefore, the Commission cannot approve or disapprove any changes related to the cross-margining agreement at this time. Cross-margining is not required by the recently adopted Treasury Clearing Rules.
                </P>
                <FTNT>
                    <P>
                        <SU>183</SU>
                         
                        <E T="03">See</E>
                         AIMA Letter at 5; FIA PTG Letter I at 15; MFA Letter I at 10; MFA Letter II at 5-6; SIFMA AMG Letter at 10.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>184</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>185</SU>
                         
                        <E T="03">See supra</E>
                         note 3 at 2751.
                    </P>
                </FTNT>
                <P>
                    However, the Commission historically has supported and approved cross-margining at clearing agencies and recognizes the potential benefits of cross-margining systems, which include freeing capital through reduced margin requirements, reducing clearing costs by integrating clearing functions, reducing clearing agency risk by centralizing asset management, and harmonizing liquidation procedures.
                    <SU>186</SU>
                    <FTREF/>
                     The Commission continues to believe that market participants can benefit from cross-margining arrangements and encourages U.S. Treasury CCAs to consider the potential of such benefits. FICC states, in its response letter regarding the Proposed Rule Change, that it is actively pursuing an end-user level cross-margining arrangement with CME. The Commission would consider any proposal arising from such pursuit in due course, if such a proposal were to be filed with the Commission.
                </P>
                <FTNT>
                    <P>
                        <SU>186</SU>
                         Treasury Clearing Adopting Release, at 2751 at n. 362 and accompanying text.
                    </P>
                </FTNT>
                <P>
                    Several commenters requested that FICC provide a legal analysis on the enforceability of the proposed changes, including the protection of segregated customer margin in the event of a Netting Member default.
                    <SU>187</SU>
                    <FTREF/>
                     In response, FICC states that it has prepared an analysis on the treatment of Segregated Customer Margin in the event of a FICC or Netting Member insolvency and that this analysis confirmed that, as long as customers and their Netting Members make clear that their relationship is a custodial one, Segregated Customer Margin would be reserved for customers and would not form part of FICC's or the Netting Member's general estate upon either institution's insolvency.
                    <SU>188</SU>
                    <FTREF/>
                     FICC states that it has made this analysis available to indirect participants upon request on a non-reliance basis.
                    <SU>189</SU>
                    <FTREF/>
                     This analysis addresses the commenters' request, and the Commission does not believe that any further action is necessary to respond to the commenters, who can use this analysis to inform their consideration whether to utilize a segregated account.
                </P>
                <FTNT>
                    <P>
                        <SU>187</SU>
                         
                        <E T="03">See</E>
                         AIMA Letter at 7; MFA Letter I at 8-9; SIFMA AMG Letter at 11.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>188</SU>
                         FICC Letter at 41.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>189</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Conclusion</HD>
                <P>
                    On the basis of the foregoing, the Commission finds that the Proposed Rule Change is consistent with the requirements of the Exchange Act and in particular with the requirements of Section 17A of the Exchange Act 
                    <SU>190</SU>
                    <FTREF/>
                     and the rules and regulations promulgated thereunder.
                </P>
                <FTNT>
                    <P>
                        <SU>190</SU>
                         15 U.S.C. 78q-1.
                    </P>
                </FTNT>
                <P>
                    <E T="03">It is therefore ordered</E>
                    , pursuant to Section 19(b)(2) of the Exchange Act 
                    <SU>191</SU>
                    <FTREF/>
                     that proposed rule change SR-FICC-2024-007, be, and hereby is, APPROVED.
                    <SU>192</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>191</SU>
                         15 U.S.C. 78s(b)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>192</SU>
                         In approving the Proposed Rule Change, the Commission considered its impact on efficiency, competition, and capital formation. 15 U.S.C. 78c(f).
                    </P>
                </FTNT>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>193</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>193</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27763 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101687; File No. SR-ISE-2024-52]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; Nasdaq ISE, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Its Fees for Connectivity and Co-Location Services</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”),
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 8, 2024, Nasdaq ISE, LLC (“ISE” or “Exchange”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>The Exchange proposes to amend the Exchange's fees for connectivity and co-location services, as described further below.</P>
                <P>
                    The text of the proposed rule change is available on the Exchange's website at 
                    <E T="03">https://listingcenter.nasdaq.com/rulebook/ise/rules,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    The purpose of the proposed rule change is to amend the Exchange's fees relating to connectivity and co-location 
                    <PRTPAGE P="93781"/>
                    services.
                    <SU>3</SU>
                    <FTREF/>
                     Specifically, the Exchange proposes to raise its fees for connectivity and co-location services in General 8 as well as certain fees related to its Testing Facilities in Options 7, Section 8 by 10%, with certain exceptions.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The Exchange initially filed the proposed pricing change on March 1, 2024 (SR-ISE-2024-09). On April 29, 2024, the Exchange withdrew that filing and submitted SR-ISE-2024-16. The Exchange withdrew that filing on June 27, 2024 and replaced it with SR-ISE-2024-23. The Exchange withdrew SR-ISE-2024-23 and replaced it with SR-ISE-2024-44 on September 10, 2024. On October 11, 2024, the Exchange replaced SR-ISE-2024-44 with SR-ISE-2024-50. The instant filing replaces SR-ISE-2024-50.
                    </P>
                </FTNT>
                <P>
                    General 8, Section 1 includes the Exchange's fees that relate to connectivity, including fees for cabinets, external telco/inter-cabinet connectivity fees, fees for connectivity to the Exchange, fees for connectivity to third party services, fees for market data connectivity, fees for cabinet power install, and fees for additional charges and services. General 8, Section 2 includes the Exchange's fees for direct connectivity services, including fees for direct circuit connection to the Exchange, fees for direct circuit connection to third party services, and fees for point of presence connectivity. With the exception of the Exchange's GPS Antenna fees and the Cabinet Proximity Option Fee for cabinets with power density &gt;10kW,
                    <SU>4</SU>
                    <FTREF/>
                     the Exchange proposes to increase its fees throughout General 8 by 10%.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         The Exchange proposes to exclude the GPS Antenna fees from the proposed fee increase because, unlike the other fees in General 8, the Exchange recently increased its GPS Antenna fees. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-99131 (December 11, 2023), 88 FR 86979 (December 15, 2023) (SR-ISE-2023-33). The Exchange also proposes to exclude the Cabinet Proximity Option Fee for cabinets with power density &gt;10kW from the proposed fee increase because the Exchange recently established such fee. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-100209 (May 22, 2024), 89 FR 46512 (May 29, 2024) (SR-ISE-2024-19). Similarly, the Exchange proposes to exclude from the proposed fee increase those fees that the Exchange recently established for services in its new NY11-4 expansion facility. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-101266 (October 7, 2024), 89 FR 82654 (October 11, 2024) (SR-ISE-2024-47).
                    </P>
                </FTNT>
                <P>In addition to increasing fees in General 8, the Exchange also proposes to increase certain fees in Options 7, Section 8, which relate to the Testing Facility. Options 7, Section 8(I) provides that subscribers to the Testing Facility located in Carteret, New Jersey shall pay a fee of $1,000 per hand-off, per month for connection to the Testing Facility. The hand-off fee includes either a 1Gb or 10Gb switch port and a cross connect to the Testing Facility. In addition, Options 7, Section 8(I) provides that subscribers shall also pay a one-time installation fee of $1,000 per hand-off. The Exchange proposes to increase these aforementioned fees by 10% to require that subscribers to the Testing Facility shall pay a fee of $1,100 per hand-off, per month for connection to the Testing Facility and a one-time installation fee of $1,100 per hand-off.</P>
                <P>The proposed increases in fees would enable the Exchange to maintain and improve its market technology and services to remain competitive with its peers. Over the years, customer demand for more sophisticated, higher-throughput, lower-latency, and higher-power connectivity solutions has increased. The Exchange continues to invest in maintaining, improving, and enhancing its connectivity and co-location products, services, and facilities—for the benefit and often at the behest of its customers. Such enhancements include refreshing hardware and expanding Nasdaq's existing co-location facility to offer customers additional space and power. Nevertheless, and with the exception of fees that were established as part of a new service in 2017 (and have remained unchanged since their adoption), the Exchange has not increased any of the fees included in the proposal since prior to 2017, and many of the fees date back to between 2010 and 2014. For each of the connectivity products and services that pre-date 2017, inflation (as measured using the “Data PPI” metric described below) has been between roughly 15-17%, and in no instance has such inflation been less than 10%. Nevertheless, the Exchange proposes to increase its fees only with respect to the 10% inflation that has occurred since 2017.</P>
                <P>As discussed below, the Exchange proposes to adjust its fees by an industry- and product-specific inflationary measure. It is reasonable and consistent with the Act for the Exchange to recoup its investments, at least in part, by adjusting its fees. Continuing to operate at fees frozen at 2010-2017 levels impacts the Exchange's ability to enhance its offerings and the interests of market participants and investors.</P>
                <P>
                    The fee increases the Exchange proposes are based on an industry-specific Producer Price Index (“PPI”), which is a tailored measure of inflation.
                    <SU>5</SU>
                    <FTREF/>
                     As a general matter, the Producer Price Index is a family of indexes that measures the average change over time in selling prices received by domestic producers of goods and services. PPI measures price change from the perspective of the seller. This contrasts with other metrics, such as the Consumer Price Index (“CPI”), that measure price change from the purchaser's perspective.
                    <SU>6</SU>
                    <FTREF/>
                     About 10,000 PPIs for individual products and groups of products are tracked and released each month.
                    <SU>7</SU>
                    <FTREF/>
                     PPIs are available for the output of nearly all industries in the goods-producing sectors of the U.S. economy—mining, manufacturing, agriculture, fishing, and forestry—as well as natural gas, electricity, and construction, among others. The PPI program covers approximately 69 percent of the service sector's output, as measured by revenue reported in the 2017 Economic Census.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See https://fred.stlouisfed.org/series/PCU51825182#0.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See https://www.bls.gov/ppi/overview.htm.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See Id.</E>
                    </P>
                </FTNT>
                <P>For purposes of this proposal, the relevant industry-specific PPI is the Data Processing and Related Services PPI (“Data PPI”), which is an industry net-output PPI that measures the average change in selling prices received by companies that provide data processing services.</P>
                <P>
                    The Data PPI was introduced in January 2002 by the Bureau of Labor Statistics (“BLS”) as part of an ongoing effort to expand Producer Price Index coverage of the services sector of the U.S. economy and is identified as NAICS—518210 in the North American Industry Classification System.
                    <SU>8</SU>
                    <FTREF/>
                     According to the BLS “[t]he primary output of NAICS 518210 is the provision of electronic data processing services. In the broadest sense, computer services companies help their customers efficiently use technology. The processing services market consists of vendors who use their own computer systems—often utilizing proprietary software—to process customers' transactions and data. Companies that offer processing services collect, organize, and store a customer's transactions and other data for record-keeping purposes. Price movements for the NAICS 518210 index are based on changes in the revenue received by companies that provide data processing services. Each month, companies provide net transaction prices for a specified service. The transaction is an actual contract selected by probability, where the price-determining characteristics are held constant while the service is repriced. The prices used in index calculation are the actual 
                    <PRTPAGE P="93782"/>
                    prices billed for the selected service contract.” 
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">NAICS appears in table 5 of the PPI Detailed Report and is available at https://data.bls.gov/timeseries/PCU518210518210.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See https://www.bls.gov/ppi/factsheets/producer-price-index-for-the-data-processing-and-related-servicesindustry-naics-518210.htm.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange believes the Data PPI is an appropriate measure to be considered in the context of the proposed rule change to modify the fee for its connectivity products because the Exchange uses its “own computer systems” and “proprietary software,” 
                    <E T="03">i.e.,</E>
                     its own data center and proprietary matching engine software, respectively, to collect, organize, store and report customers' transactions in U.S. equity securities on the Exchange's proprietary trading platform. In other words, the Exchange is in the business of data processing and related services.
                </P>
                <P>For purposes of this proposed rule change, the Exchange examined the Data PPI value for the period from January 2017 to August 2024. The Data PPI had a starting value of 105.6 in January 2017 and an ending value of 116.022 in August 2024, a 10.422% increase. This indicates that companies who are also in the data storage and processing business have generally increased prices for a specified service covered under NAICS 518210 by an average of 10.422% during this period. Based on that percentage change, the Exchange proposes to make a one-time fee increase of only 10%, which reflects an increase covering roughly the entire period since the last price adjustments to these fees were made.</P>
                <P>
                    The Exchange further believes the Data PPI is an appropriate measure for purposes of the proposed rule change on the basis that it is a stable metric with limited volatility, unlike other consumer-side inflation metrics. In fact, the Data PPI has not experienced a greater than 2.16% increase for any one calendar year period since Data PPI was introduced into the PPI in January 2002. The average calendar year change from January 2002 to December 2023 was .62%, with a cumulative increase of 15.67% over this 21-year period. The Exchange believes the Data PPI is considerably less volatile than other inflation metrics such as CPI, which has had individual calendar-year increases of more than 6.5%, and a cumulative increase of over 73% over the same period.
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See https://www.usinflationcalculator.com/inflation/consumer-price-index-and-annual-percent-changesfrom-1913-to-2008/.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange believes the Data PPI, and significant investments into, and enhanced performance of, the Exchange support the reasonableness of the proposed fee increases.
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See supra</E>
                         discussion of connectivity product and facility improvements. Additionally, other exchanges have filed for increases in certain fees, based in part on comparisons to inflation. See, 
                        <E T="03">e.g.,</E>
                         Securities Exchange Act Release Nos. 34-100004 (April 22, 2024), 89 FR 32465 (April 26, 2024) (SR-CboeBYX-2024-012); and 34-100398 (June 21, 2024), 89 FR 53676 (June 27, 2024) (SR-BOX-2024-16)l; Securities Exchange Act Release No. 34-100994 (September 10, 2024), 89 FR 75612 (September 16, 2024) (SR-NYSEARCA-2024-79).
                    </P>
                </FTNT>
                <P>
                    These proposed fee increases will be immediately effective upon filing. However, going forward and until December 1, 2024, the Exchange will waive all fees set forth herein to the extent that such fees exceed the levels that would have been charged for the same products and services purchased during that time period, had such fees been calculated at the rates set forth in SR-ISE-2024-44 (
                    <E T="03">i.e.,</E>
                     pricing reflective of a 5.5% increase from prior fee levels). This waiver is reasonable, equitable, and not unfairly discriminatory because it will afford all customers in excess of the 30-day prior notice period for fee changes set forth in the Exchange's service terms.
                </P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The Exchange believes that its proposal is consistent with Section 6(b) of the Act,
                    <SU>12</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Sections 6(b)(4) and 6(b)(5) of the Act,
                    <SU>13</SU>
                    <FTREF/>
                     in particular, in that it provides for the equitable allocation of reasonable dues, fees and other charges among members and issuers and other persons using any facility, and is not designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         15 U.S.C. 78f(b)(4) and (5).
                    </P>
                </FTNT>
                <P>This belief is based on two factors. First, the current fees do not properly reflect the quality of the services and products, as fees for the services and products in question have been static in nominal terms, and therefore falling in real terms due to inflation. Second, the Exchange believes that investments made in enhancing the capacity and speed of Exchange systems increase the performance of the services and products.</P>
                <HD SOURCE="HD3">The Proposed Rule Change Is Reasonable</HD>
                <P>
                    As noted above, the Exchange has not increased any of the fees included in the proposal since 2017 or earlier. However, in the years following the last fee increases, the Exchange has made significant investments in upgrades to its connectivity products, services, and facilities, enhancing the quality of its services. In other words, Exchange customers have greatly benefitted, while the Exchange's ability to recoup its investments has been hampered. Between 2017 and 2024, the inflation rate is 3.64% per year, on average, producing a cumulative inflation rate of 28.43%.
                    <SU>14</SU>
                    <FTREF/>
                     Using the more targeted inflation number of Data PPI, the cumulative inflation rate was 10.422%. The exchange believes the Data PPI is a reasonable metric to base this fee increase on because it is targeted to producer-side increases in the data processing industry.
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See https://www.officialdata.org/us/inflation/2017?amount=1.</E>
                    </P>
                </FTNT>
                <P>
                    Notwithstanding inflation, as noted above, the Exchange has not increased its fees at all for over seven years for the subject services. The proposed fee changes represent a modest increase from the current fees. The Exchange believes the proposed fee increase is reasonable in light of the Exchange's continued expenditure in maintaining a robust technology ecosystem. Furthermore, the Exchange continues to invest in maintaining and enhancing its connectivity products—for the benefit and often at the behest of its customers and global investors. Such enhancements include refreshing all aspects of the technology ecosystem including software, hardware, and network while introducing new and innovative products and expanded and modernized facilities.
                    <SU>15</SU>
                    <FTREF/>
                     The goal of the enhancements discussed above, among other things, is to provide faster, higher-capacity, and more modern connectivity products and services. Accordingly, the Exchange continues to expend resources to innovate and modernize technology so that it may benefit its members in offering its connectivity products and services.
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See, e.g.,</E>
                         Securities Exchange Act Release No.34-101076 (September 18, 2024), 89 FR 77951(September 24, 2024) (SR-ISE-2024-45 (Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Expand [the Exchange's] Co-Location Services).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">The Proposed Fees Are Equitably Allocated and Not Unfairly Discriminatory</HD>
                <P>
                    The Exchange believes that the proposed fee increases are equitably allocated and not unfairly discriminatory because they would apply to all market participants that choose to purchase connectivity products and services from the Exchange. Any participant that chooses to purchase the Exchange's connectivity products and services would be subject to the same Fee Schedule, regardless of what type of business they operate or 
                    <PRTPAGE P="93783"/>
                    the use they plan to make use of the products and services. Additionally, the fee increase would be applied uniformly to market participants without regard to Exchange membership status or the extent of any other business with the Exchange or affiliated entities. The Exchange also believes that the proposal represents an equitable allocation of reasonable dues, fees and other charges because Exchange fees have fallen in real terms during the relevant period. Finally, the Exchange believes that the proposed fee changes are not unfairly discriminatory because the fees would be assessed uniformly across all market participants, in the same manner they are today, that voluntarily purchase the Exchange's connectivity products and services, which would remain available for purchase by all market participants.
                </P>
                <P>
                    These proposed fee increases will be immediately effective upon filing. However, going forward and until December 1, 2024, the Exchange will waive all fees set forth herein to the extent that such fees exceed the levels that would have been charged for the same products and services purchased during that time period, had such fees been calculated at the rates set forth in SR-ISE-2024-44 (
                    <E T="03">i.e.,</E>
                     pricing reflective of a 5.5% increase from prior fee levels). This waiver is reasonable, equitable, and not unfairly discriminatory because it will afford all customers in excess of the 30-day prior notice period for fee changes set forth in the Exchange's service terms.
                </P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed fees will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.</P>
                <HD SOURCE="HD3">Intramarket Competition</HD>
                <P>The Exchange believes that the proposed fees do not put any market participants at a relative disadvantage compared to other market participants. As noted above, the fee schedule would continue to apply to all purchasers of the Exchange's connectivity products and services in the same manner as it does today albeit at inflation-adjusted rates for certain fees, and customers may choose whether to purchase these products and services at all. The Exchange also believes that the level of the proposed fees neither favor nor penalize one or more categories of market participants in a manner that would impose an undue burden on competition. Likewise, the proposed fee waiver described above will apply to all purchasers of the Exchange's connectivity products and services in the same manner and therefore will not burden competition among them.</P>
                <HD SOURCE="HD3">Intermarket Competition</HD>
                <P>The Exchange believes that the proposed fees do not impose a burden on competition or on other SROs that is not necessary or appropriate. In determining the proposed fees, the Exchange utilized an objective and stable metric with limited volatility. Utilizing Data PPI over a specified period of time is a reasonable means of recouping the Exchange's investment in maintaining and enhancing its connectivity products, services, and facilities. The Exchange believes utilizing Data PPI, a tailored measure of inflation, to increase certain fees for connectivity products and services to recoup the Exchange's investment in maintaining and enhancing such products, services, and its facilities would not impose a burden on competition.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were either solicited or received.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The foregoing rule change has become effective pursuant to Section 19(b)(3)(A)(ii) of the Act.
                    <SU>16</SU>
                    <FTREF/>
                     At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is: (i) necessary or appropriate in the public interest; (ii) for the protection of investors; or (iii) otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings to determine whether the proposed rule should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         15 U.S.C. 78s(b)(3)(A)(ii).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-ISE-2024-52 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-ISE-2024-52. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright  protection. All submissions should refer to file number SR-ISE-2024-52 and should be submitted on or before December 18, 2024.
                    <FTREF/>
                </FP>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         17 CFR 200.30-3(a)(12).
                    </P>
                </FTNT>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>17</SU>
                    </P>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27756 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <PRTPAGE P="93784"/>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101694; File No. SR-FICC-2024-005]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; Fixed Income Clearing Corporation; Order Approving a Proposed Rule Change, as Modified by Partial Amendment No. 1, To Modify the GSD Rules To Facilitate Access to Clearance and Settlement of All Eligible Secondary Market Transactions in U.S. Treasury Securities</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    On March 11, 2024, Fixed Income Clearing Corporation (“FICC”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change SR-FICC-2024-005 pursuant to Section 19(b) of the Securities Exchange Act of 1934 (“Exchange Act”) 
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 
                    <SU>2</SU>
                    <FTREF/>
                     thereunder to modify FICC's Government Securities Division (“GSD”) Rulebook (“GSD Rules”) with respect to facilitating access to GSD's clearance and settlement services for all eligible secondary market transactions in U.S. Treasury securities.
                    <SU>3</SU>
                    <FTREF/>
                     On March 19, 2024, FICC filed Partial Amendment No. 1 to make clarifications and corrections 
                    <SU>4</SU>
                    <FTREF/>
                     to the proposed rule change. The proposed rule change, as modified by Partial Amendment No. 1, is referred to herein as the “Proposed Rule Change.” The Proposed Rule Change was published for public comment in the 
                    <E T="04">Federal Register</E>
                     on March 27, 2024.
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">infra</E>
                         note 5, at 89 FR 21363.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         Partial Amendment No. 1 makes clarifications and corrections to the description of the proposed rule change and Exhibit 5. Specifically, as originally filed, the description of the proposed rule change made a reference to an incorrect section of the GSD Rulebook. Partial Amendment No. 1 corrects that reference. Additionally, as originally filed, the description of the proposed rule change and Exhibit 5 contained inconsistent references regarding whether FICC or its Board would be responsible for approving membership applications and related membership matters. Partial Amendment No. 1 clarifies and corrects those references.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         Securities Exchange Act Release No. 99817 (March 21, 2024), 89 FR 21362 (March 27, 2024) (File No. SR-FICC-2024-005) (“Notice of Filing”).
                    </P>
                </FTNT>
                <P>
                    On May 1, 2024, pursuant to Section 19(b)(2) of the Exchange Act,
                    <SU>6</SU>
                    <FTREF/>
                     the Commission designated a longer period within which to approve, disapprove, or institute proceedings to determine whether to approve or disapprove the Proposed Rule Change.
                    <SU>7</SU>
                    <FTREF/>
                     On June 27, 2024, the Commission instituted proceedings to determine whether to approve or disapprove the Proposed Rule Change.
                    <SU>8</SU>
                    <FTREF/>
                     On September 24, 2024, pursuant to Section 19(b)(2) of the Exchange Act,
                    <SU>9</SU>
                    <FTREF/>
                     the Commission extended the period for the conclusion of proceedings to determine whether to approve or disapprove the Proposed Rule Change.
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         15 U.S.C. 78s(b)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         Securities Exchange Act Release No. 100031 (Apr. 25, 2024), 89 FR 35269 (May 1, 2024) (File No. SR-FICC-2023-005).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         Securities Exchange Act Release No. 100399 (June 21, 2024), 89 FR 53681 (June 27, 2024) (SR-FICC-2024-005).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         15 U.S.C. 78s(b)(2)(B)(ii)(II).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         Securities Exchange Act Release No. 101081 (Sept. 18, 2024), 89 FR 77949 (Sept. 24, 2024) (SR-FICC-2024-005).
                    </P>
                </FTNT>
                <P>
                    The Commission received several comment letters on the Proposed Rule Change.
                    <SU>11</SU>
                    <FTREF/>
                     In addition, the Commission received a letter from FICC responding to the public comments.
                    <SU>12</SU>
                    <FTREF/>
                     For the reasons discussed below, the Commission is approving the Proposed Rule Change.
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         Comments on the Proposed Rule Change are available at 
                        <E T="03">https://www.sec.gov/comments/sr-ficc-2024-005/srficc2024005.htm.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         Letter from Laura Klimpel, Head of Fixed Income Financing Solutions, Depository Trust &amp; Clearing Corporation, (Aug. 1, 2024) (“FICC Letter”).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Description of the Proposed Rule Change</HD>
                <HD SOURCE="HD2">A. Background and Current Access Models</HD>
                <P>FICC, through GSD, serves as a central counterparty (“CCP”) and provides real-time trade matching, clearing, risk management and netting for cash purchases and sales of U.S. Treasury securities as well as repurchase and reverse repurchase transactions (“repos”) involving U.S. Treasury securities. Currently, FICC is the sole provider of clearance and settlement services for U.S. Treasury securities.</P>
                <P>
                    On December 13, 2023, the Commission adopted amendments to the standards applicable to covered clearing agencies, such as FICC,
                    <SU>13</SU>
                    <FTREF/>
                     requiring each such clearing agency for U.S. Treasury securities to have written policies and procedures reasonably designed to, among other things, ensure that it has appropriate means to facilitate access to clearance and settlement services of all eligible secondary market transactions in U.S. Treasury securities, including those of the clearing agency's indirect participants.
                    <SU>14</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         A “covered clearing agency” is, among other things, a registered clearing agency that provides the services of a CCP, and a CCP is a clearing agency that interposes itself between the counterparties to securities transactions, acting functionally as the buyer to every seller and the seller to every buyer. 17 CFR 240.17ad-22(a); 
                        <E T="03">see also</E>
                         15 U.S.C. 78c(a)(23) (defining a clearing agency). FICC is a clearing agency registered with the Commission under Section 17A of the Exchange Act (15 U.S.C. 78q-1), and it acts as a CCP.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         17 CFR 240.17ad-22(e)(18)(iv)(C). 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99149 (Dec. 13, 2023), 89 FR 2714 (Jan. 16, 2024) (“Adopting Release,” and the rules adopted therein referred to herein as “Treasury Clearing Rules”).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">1. Direct Participation at FICC</HD>
                <P>
                    GSD's CCP services are currently available directly to entities that are approved under the GSD Rules 
                    <SU>15</SU>
                    <FTREF/>
                     to be Netting Members.
                    <SU>16</SU>
                    <FTREF/>
                     Currently, there are different categories of Netting Member based upon the type of legal entity (
                    <E T="03">i.e.,</E>
                     Bank Netting Member, Dealer Netting Member, Inter-Dealer Broker Netting Member, 
                    <E T="03">etc.</E>
                    ) and whether an entity is incorporated in the United States or not (
                    <E T="03">i.e.,</E>
                     a Foreign Netting Member). Netting Member applicants must meet both financial and operational minimum eligibility requirements 
                    <SU>17</SU>
                    <FTREF/>
                     and, once admitted, Netting Members must adhere to ongoing minimum membership standards.
                    <SU>18</SU>
                    <FTREF/>
                     Furthermore, both the minimum eligibility requirements and ongoing standards vary depending on the relevant Netting Membership category. However, in general, all Netting Member categories may access the services available through GSD's Comparison System 
                    <SU>19</SU>
                    <FTREF/>
                     and Netting System.
                    <SU>20</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         The GSD Rules are 
                        <E T="03">available at https://www.dtcc.com/~/media/Files/Downloads/legal/rules/ficc_gov_rules.pdf.</E>
                         Terms not otherwise defined herein are defined in the GSD Rules.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 2, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 2A, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 3, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 5, 
                        <E T="03">supra</E>
                         note 15. The Comparison System includes the system of GSD services and operations in connection with the reporting, validating, and in some cases, matching of the long and short sides of a securities trade. GSD also has a limited membership that permits Comparison-Only Members to participate only in its Comparison System. FICC does not act as a CCP for activity processed through its Comparison System and the services offered through its Comparison System are not guaranteed by FICC.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 11, 
                        <E T="03">supra</E>
                         note 15. The Netting System includes the system of GSD services and operations in connection with aggregating and matching offsetting obligations resulting from securities trades submitted by or on behalf of Netting Members.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Indirect Participation at FICC</HD>
                <P>
                    Market participants may also access GSD's clearing services indirectly through a Netting Member. There are currently two indirect participation models to facilitate indirect participant access to GSD—the Sponsored Service 
                    <SU>21</SU>
                    <FTREF/>
                     and the correspondent clearing/prime broker services.
                    <SU>22</SU>
                    <FTREF/>
                     Each of these indirect participation models gives market participants different options to consider in accessing GSD's 
                    <PRTPAGE P="93785"/>
                    clearance and settlement services. The primary difference between the two models is that an indirect participant who becomes a Sponsored Member must establish an indirect, limited purpose GSD membership, whereas the correspondent clearing/prime broker services do not require an indirect member to establish any relationship with GSD.
                </P>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 3A, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 8, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <P>
                    The Sponsored Service permits Netting Members, approved under the GSD Rules as “Sponsoring Members,” to sponsor certain institutional firms, referred to as “Sponsored Members,” into GSD membership. The Sponsoring Member is permitted to submit to FICC for comparison, novation, and netting certain types of eligible transactions either between itself and its Sponsored Members (
                    <E T="03">i.e.,</E>
                     “done-with”), or between the Sponsored Members and other third-party Netting Members (
                    <E T="03">i.e.,</E>
                     “done-away”). For operational and administrative purposes, a Sponsored Member appoints its Sponsoring Member to act as processing agent with respect to the Sponsored Member's satisfaction of its securities and funds-only settlement obligations.
                    <SU>23</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 3A, 
                        <E T="03">supra</E>
                         note 15. An entity that chooses to become a Sponsoring Member retains its status as a Netting Member and can continue to submit any non-Sponsored Member activity to FICC as such.
                    </P>
                </FTNT>
                <P>
                    A Sponsored Member is a GSD Member and the legal counterparty to FICC for any submitted transactions.
                    <SU>24</SU>
                    <FTREF/>
                     However, the Sponsoring Member unconditionally guarantees to FICC the Sponsored Member's performance under a Sponsoring Member Guaranty, which guarantees to FICC the payment and performance of a Sponsored Member's obligations to FICC.
                    <SU>25</SU>
                    <FTREF/>
                     Therefore, FICC relies on the financial resources of the Sponsoring Member in relying upon the Sponsoring Member Guaranty. If a Sponsoring Member fails to perform under the Sponsoring Member Guaranty, FICC may cease to act for the Sponsoring Member both as a Sponsoring Member as well as a Netting Member.
                    <SU>26</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 3A, section 7 (describing novation of Sponsored Member Trades) and 2 (identifying membership types), 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 3A (describing the operation of the Sponsoring Member Guaranty) and 1 (defining the Sponsoring Member Guaranty), 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21365; 
                        <E T="03">see also</E>
                         GSD Rule 3A, Section 14; and GSD Rule 21, Sections 1(a), 1(b), 4(a) 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <P>
                    Netting Members may also submit to FICC eligible activity on behalf of their customers through the correspondent clearing/prime broker services.
                    <SU>27</SU>
                    <FTREF/>
                     Under the current GSD Rules, the Netting Member is referred to as the “Submitting Member” and the customer is referred to as the “Executing Firm.” 
                    <SU>28</SU>
                    <FTREF/>
                     Unlike the Sponsored Service, FICC has no relationship with the Executing Firm,
                    <SU>29</SU>
                    <FTREF/>
                     and all obligations (
                    <E T="03">i.e.,</E>
                     margin and settlement) under the GSD Rules remain with the Submitting Member.
                    <SU>30</SU>
                    <FTREF/>
                     Additionally, Submitting Members have the option of either netting Executing Firm activity with other activity they submit to FICC (
                    <E T="03">i.e.,</E>
                     Submitting Member proprietary activity) or segregating Executing Firm activity in separate accounts.
                    <SU>31</SU>
                    <FTREF/>
                     In all cases, however, the Submitting Member must identify the relevant Executing Firm(s) on the FICC transaction submission file.
                    <SU>32</SU>
                    <FTREF/>
                     The current GSD Rule does not address the qualifications of a Submitting Member (or how a Netting Member becomes a Submitting Member); does not specify the information that each Submitting Member must provide to FICC regarding the Executing Firms on whose behalf it submits transactions; does not require acknowledgments from Executing Firms; and does not set forth any rules regarding the processing of transactions through the correspondent clearing/prime broker service or how such transactions are treated in the event of a default.
                </P>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 8, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         
                        <E T="03">See id.</E>
                         There are no operational differences between the current correspondent clearing service and the prime broker service. The primary difference between the two services is that FICC provides a report to prime brokers that identifies margin calculation for their customers' transactions and does not provide such report to Members using the correspondent clearing service.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 1 (defining the term Executing Firm), 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 8, Section 4, and GSD Rule 15, Section 1, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 8, Section 2, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">
                    B. Proposed Changes 
                    <E T="51">33</E>
                    <FTREF/>
                </HD>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         For a detailed description of each proposed change, please refer generally to the Notice of Filing, 
                        <E T="03">supra</E>
                         note 5.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">1. Re-Naming the Correspondent Clearing/Prime Broker Services as the Agent Clearing Service and Providing Additional Specificity on the Agent Clearing Service</HD>
                <P>
                    FICC proposes to re-name, consolidate, and adopt additional provisions governing GSD's existing correspondent clearing/prime broker services. Moving forward, the correspondent clearing/prime broker services would be referred to as the “Agent Clearing Service,” Submitting Members would be referred to as “Agent Clearing Members,” and Executing Firms would be referred to as “Executing Firm Customers.” The Agent Clearing Service would continue to allow Netting Members to submit, on behalf of their customers, transactions to FICC for novation. These proposed changes would primarily amend GSD Rule 8,
                    <SU>34</SU>
                    <FTREF/>
                     which currently describes the correspondent clearing/prime broker services, to describe the Agent Clearing Service with greater specificity.
                </P>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 8, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <P>
                    FICC designed the proposed changes to the Agent Clearing Service to highlight the similarities between the Agent Clearing Service and other agent clearing models, such as those through which market participants in the cleared derivatives markets can execute commodity derivatives with third parties and then give them up to a futures commission merchant (“FCM”) for clearing.
                    <SU>35</SU>
                    <FTREF/>
                     FICC states that these proposed changes would enhance the ability of indirect participants to identify the Agent Clearing Service as a workable “done-away” model that allows indirect participants to access clearing through multiple direct participants.
                    <SU>36</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21365-66.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         
                        <E T="03">See id.</E>
                         FICC also states that these proposed changes would improve the transparency of the GSD Rules regarding the availability and operations of this service to both Netting Members and, indirectly, their customers. 
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    While the proposed changes would re-name certain terms in the GSD Rules and otherwise expand upon the description of how the correspondent clearing/prime broker access models operate, most of the proposed changes would not alter how Netting Members and their customers use this model to access GSD's services.
                    <SU>37</SU>
                    <FTREF/>
                     Like the correspondent clearing/prime broker models, the Agent Clearing Service would continue to facilitate agent-style trading by allowing an Agent Clearing Member to act as processing agent and credit intermediary for its Executing Firm Customers.
                </P>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21366.
                    </P>
                </FTNT>
                <P>
                    Specifically, the Proposed Rule Change would address various specific topics. First, the Proposed Rule Change would address Agent Clearing Member qualifications and the application process to become an Agent Clearing Member. A Netting Member, other than an Inter-Dealer Broker Netting Member, shall be eligible to become an Agent Clearing Member. An applicant to be an Agent Clearing Member would have to submit an application and provide additional information that FICC may request, and this application would include information about the applicant's customers, past and/or projected volumes of applicant customer activity, and the applicant's 
                    <PRTPAGE P="93786"/>
                    controls for monitoring and mitigating risks, including any risks posed by its customers.
                </P>
                <P>
                    Second, the Proposed Rule Change would require certain information regarding an Agent Clearing Member's Executing Firm Customer Relationships to be provided to FICC. The required information would include a Legal Entity Identifier (“LEI”) for each Executing Firm Customer,
                    <SU>38</SU>
                    <FTREF/>
                     and each Agent Clearing Member would be required to indemnify FICC for any losses, liabilities, expenses and legal actions that could arise related to the LEI requirement. Thus, an Agent Clearing Member would establish a relationship with one or more Executing Firm Customers and provide FICC with notice confirming the Executing Firm relationship with each such customer. FICC states that this information sharing would better enable FICC to identify and manage the risks posed by such indirect participants and would support FICC's compliance with the requirements of Rule 17ad-22(e)(18)(iii) under the Exchange Act to monitor compliance with its participation requirements on an ongoing basis.
                    <SU>39</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         In addition to the LEI, this information would include: the name and executing firm symbol of the Executing Firm Customer; written authorization from the Executing Firm Customer to act on its behalf; confirmation that the Executing Firm Customer and the Agent Clearing Member have entered into an agreement that binds the Executing Firm Customer to the applicable provisions of the GSD Rules, as would be required by Section 3, described below; and confirmation that the Executing Firm Customer understands, acknowledges and agrees to each of the Executing Firm Customer Acknowledgments set forth in, and as would be required by the GSD Rules.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21365; 17 CFR 240.17ad-22(e)(18)(iii).
                    </P>
                </FTNT>
                <P>In addition, the Proposed Rule Change would require that an agreement between the Agent Clearing Member and the Executing Firm Customer bind the customer to the applicable provisions of the GSD Rules. However, beyond this specific requirement the Proposed Rule Change would also acknowledge such an agreement may otherwise be on any terms and conditions mutually agreed to by the parties and confirm that the GSD Rules do not prohibit any reimbursement or other payments sharing arrangements that may be established between those parties, away from FICC.</P>
                <P>
                    Third, the Proposed Rule Change would define what transactions are eligible to be submitted through the Agent Clearing Service, which would remain the same as the transactions eligible for the correspondent/prime broker services and would continue to exclude Netting Eligible Auction Purchases, Brokered Transactions, GCF Repo Transactions, and CCIT Transactions.
                    <SU>40</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         FICC states that GCF Repo Transactions and CCIT Transactions are currently excluded due to system limitations, and Brokered Transactions are necessarily excluded because Inter-Dealer Broker Netting Members are not permitted to act as Agent Clearing Members, as discussed above. The exclusion of Netting Eligible Auction Purchases is driven by the specific processing rules applicable to auctions that are external to FICC and established by the U.S. Department of the Treasury. 
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21368.
                    </P>
                </FTNT>
                <P>
                    Fourth, the Proposed Rule Change would identify the rights and obligations of Agent Clearing Members. For example, it would define the role of the Agent Clearing Members as processing agents of Executing Firm Customers and establish that Agent Clearing Members are liable to FICC for all obligations arising in connection with their Agent Clearing Transactions in the same manner as if the Agent Clearing Member had executed those trades. It would also state that FICC has no liability or obligation to any Executing Firm Customer. It would also provide that FICC may request information or reports regarding Agent Clearing Transactions, which would allow FICC to continue to identify, monitor and manage the risks its Agent Clearing Members may present to it and the broader GSD membership.
                    <SU>41</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21368.
                    </P>
                </FTNT>
                <P>
                    Fifth, the Proposed Rule Change would include specific Executing Firm Customer acknowledgements with respect to their participation in the Agent Clearing Service.
                    <SU>42</SU>
                    <FTREF/>
                     Because Executing Firm Customers would continue to have no relationship to FICC, the Proposed Rule Change would provide that Agent Clearing Members are responsible for affirming that their Executing Firm Customers understand, acknowledge and agree to the provisions in the relevant section of the GSD Rules.
                </P>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         These acknowledgments would include that the Agent Clearing Service is governed by the GSD Rules, including Novation of Agent Clearing Transactions; that FICC is not obligated to deal directly with the Executing Firm Customer and may deal exclusively with the Agent Clearing Member; that FICC shall have no obligations to the Executing Firm Customer with respect to any Agent Clearing Transactions submitted by an Agent Clearing Member on behalf of the Executing Firm Customer, including with respect to any payment or delivery obligations; and that the Executing Firm Customer shall have no right to receive from FICC, or any right to assert a claim against FICC with respect to, nor shall FICC be liable to the Executing Firm Customer for, any payment or delivery obligation in connection with any Agent Clearing Transactions submitted by an Agent Clearing Member on behalf of the Executing Firm Customer, and FICC shall make any such payments or redeliveries solely to the Agent Clearing Member.
                    </P>
                </FTNT>
                <P>
                    Finally, the Proposed Rule Change would set forth rules regarding the processing of Agent Clearing Transactions. FICC would require Agent Clearing Members to process and record their customers' activity in separate “Agent Clearing Member Omnibus Accounts,” as opposed to the optional segregated submission approach provided for in the current GSD Rules, to facilitate FICC's ability to monitor and, ultimately, risk manage that activity appropriately.
                    <SU>43</SU>
                    <FTREF/>
                     It would also require that all Agent Clearing Transactions include an executing firm symbol that identifies the Executing Firm Customer. It would describe that Agent Clearing Transactions would continue to be processed in the same way that FICC processes other transactions through the GSD netting, clearing and settlement systems and would describe how Agent Clearing Transactions are processed when the optional field identifying the contra-party is either omitted or does not match on the transaction file. It would also address how a loss would be allocated within the Agent Clearing Service, that is, that the Agent Clearing Member, as principal, would be responsible for satisfying the loss allocation obligations that are calculated for its Executing Firm Customers.
                    <SU>44</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, 89 FR at 21368.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         The Proposed Rule Change would also provide that the Clearing Fund obligations applicable to an Agent Clearing Members' Agent Clearing Transactions would be calculated separately from the obligations calculated with respect to other activity of the Agent Clearing Member. However, FICC would have the right to apply any Clearing Fund deposits of an Agent Clearing Member to any obligations of that Member (including in their capacity as a Netting Member). As a substantive matter, the above two changes do not vary from how FICC calculates and applies loss allocation or Clearing Fund requirements under the correspondent clearing and prime broker services today. 
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, 89 FR at 21369.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Changes to the Sponsored Service</HD>
                <HD SOURCE="HD3">Eliminate Separate Categories of Sponsoring Members</HD>
                <P>
                    Under the current GSD Rules, there are two categories of Sponsoring Members—Category 1 Sponsoring Members are Bank Netting Members that meet the eligibility criteria described in Section 2(a) of Rule 3A, and Category 2 Sponsoring Members are all other eligible Netting Members.
                    <SU>45</SU>
                    <FTREF/>
                     While Bank Netting Members are currently subject to certain capitalization requirements as 
                    <PRTPAGE P="93787"/>
                    Sponsoring Member applicants,
                    <SU>46</SU>
                    <FTREF/>
                     Category 2 Sponsoring Member applicants are subject to financial requirements that are greater than the financial requirements applicable in their capacity as Netting Members.
                    <SU>47</SU>
                    <FTREF/>
                     Thus, the current tiered category structure creates differing applicant criteria based on the type of entity seeking Sponsoring Member status.
                </P>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 85470 (Mar. 29, 2019) 84 FR 13328 (Apr. 4, 2019) (SR-FICC-2018-013) (creating two categories of Netting Members to be eligible to be Sponsoring Members, expanding the eligibility of the service to other types of Netting Members in addition to Bank Netting Members). 
                        <E T="03">See also</E>
                         GSD Rule 3A, Section 2, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>46</SU>
                         Under Section 2(a) of GSD Rule 3A, Bank Netting Members applying to be a Sponsoring Member must (i) have equity capital of at least $5 billion, (ii) be “Well-Capitalized,” as such term is defined in the GSD Rules, and (iii) have a bank holding company that is registered under the Bank Holding Company Act of 1954, as amended and that such bank holding company also be “Well Capitalized.” “Well Capitalized” is defined in GSD Rule 1 to have the meaning given that term in the capital adequacy rules and regulations of the Federal Deposit Insurance Corporation. 
                        <E T="03">Supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>47</SU>
                         These increased financial requirements do not solely relate to an applicant's capitalization, but instead are based on the applicant's anticipated use of the Sponsoring Service in relation to their financial condition. 
                        <E T="03">See</E>
                         Section 2(b)(ii) of GSD Rule 3A, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <P>
                    Additionally, the ongoing Sponsoring Member requirements in the GSD Rules also apply a differentiated approach for Category 1 and Category 2 Sponsoring Members. For example, a Category 1 Sponsoring Member may be subject to an increase in its Required Fund Deposit if it fails to meet the applicable capitalization requirements.
                    <SU>48</SU>
                    <FTREF/>
                     Alternatively, a Category 2 Sponsoring Member may be subject to a limit on the activity it can submit through the Sponsoring Service if the Sponsoring Member's VaR Charges exceed its Netting Member Capital.
                    <SU>49</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>48</SU>
                         
                        <E T="03">See</E>
                         Section 2(h) of GSD Rule 3A, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>49</SU>
                         The “VaR Charge” is a component of the Required Fund Deposit and defined in GSD Rule 1; “Netting Member Capital” is defined in GSD Rule 1 to mean “Net Capital, net assets or equity capital as applicable, to a Netting Member based on its type of regulation.” 
                        <E T="03">Supra</E>
                         note 15.
                    </P>
                </FTNT>
                <P>
                    FICC proposes to eliminate the two categories of Sponsoring Members and make all Sponsoring Members subject to the same eligibility and ongoing requirements that are currently applicable to Category 2 Sponsoring Members. FICC states that these proposed changes would encourage additional Netting Members to become Sponsoring Members thus facilitating broader access to clearance and settlement services for eligible secondary market transactions in U.S. Treasury securities, including those of indirect participants who may seek to use the Sponsored Service as Sponsored Members.
                    <SU>50</SU>
                    <FTREF/>
                     The proposed changes would affect Bank Netting Members that are—or will apply to be—Sponsoring Members by removing the above-mentioned capitalization requirements and instead applying the activity limits and financial condition factors used under the current GSD Rules for Category 2 Sponsoring Members. The proposed changes would create parity among all Sponsoring Members (and applicants), which FICC states would encourage additional market participants to become Sponsoring Members, which in turn should give indirect participants a wider range of Sponsoring Members to consider should they choose to access GSD's central clearing services via the Sponsored Service.
                    <SU>51</SU>
                    <FTREF/>
                     FICC states that the activity limits and financial condition monitoring will allow FICC to continue to manage the risks that could be presented by any activity cleared through the Sponsored Service.
                    <SU>52</SU>
                    <FTREF/>
                     FICC does not believe the proposed changes would increase the risks presented to it by Bank Netting Members' participation in the Sponsored Service as Sponsoring Members because other existing risk management tools (
                    <E T="03">e.g.,</E>
                     FICC's ability to impose greater and additional financial requirements,
                    <SU>53</SU>
                    <FTREF/>
                     the Excess Capital Premium,
                    <SU>54</SU>
                    <FTREF/>
                     and activity limits 
                    <SU>55</SU>
                    <FTREF/>
                    ) would be available for FICC to continue to manage those risks.
                    <SU>56</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>50</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21370.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>51</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>52</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>53</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 3A, Section 2(b)(ii) (describing the factors that FICC may consider when determining whether to impose additional financial requirements on a Sponsoring Member), 
                        <E T="03">supra</E>
                         note 5. For the purposes of illustration only, such financial requirements could include, without limitation, additional reporting requirements, including reporting of parent company financials, or a higher minimum deposit to the Clearing Fund.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>54</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 3, Section 14 (the Excess Capital Premium is an additional Clearing Fund deposit that may be required if a Netting Member's capital levels drop below a threshold relative to its other margin requirements), 
                        <E T="03">supra</E>
                         note 5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>55</SU>
                         The activity limit, which currently only applies to Category 2 Sponsoring Members, restricts a Sponsoring Member from submitting additional activity into its Sponsoring Member Omnibus Account(s) if its capital levels exceed the sum of its VaR Charge component of the Clearing Fund. 
                        <E T="03">See</E>
                         GSD Rule 3A, Section 2(h), 
                        <E T="03">supra</E>
                         note 5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>56</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21370.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Remove the “Qualified Institutional Buyer” Requirements for Sponsored Members</HD>
                <P>
                    FICC proposes to remove the requirement that Sponsored Members either be “qualified institutional buyers,” as such term is defined by Rule 144A under the Securities Act of 1933,
                    <SU>57</SU>
                    <FTREF/>
                     or satisfy the financial requirements of such definition (“QIB Requirement”). This proposed change would make the Sponsored Service available to additional market participants, thereby providing such firms with access to GSD's clearing services. FICC states that expanding eligibility to become a Sponsored Member supports the goals of the Treasury Clearing Rules to facilitate increased central clearing of transactions involving U.S. Treasury securities.
                    <SU>58</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>57</SU>
                         17 CFR 230.144A.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>58</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21371; Adopting Release 
                        <E T="03">supra</E>
                         note 14, at 2716-17 (referring to the revisions to Rule 17ad-22(e)(18) as being designed to “bring the benefits of central clearing to more transactions involving U.S. Treasury securities, thereby reducing the overall systemic risk in the market”).
                    </P>
                </FTNT>
                <P>
                    FICC states that this change would not increase the relevant risks because FICC risk manages the Sponsored Service primarily at the Sponsoring Member level, not the Sponsored Member level.
                    <SU>59</SU>
                    <FTREF/>
                     For example, a Sponsoring Member is responsible for posting to FICC the Required Fund Deposit for its sponsored activity and, while Sponsored Members are principally liable to FICC for their settlement obligations, the Sponsoring Member is also required to provide a guaranty to FICC for such obligations.
                    <SU>60</SU>
                    <FTREF/>
                     In the event a Sponsored Member does not satisfy its settlement obligations, FICC is able to invoke the Sponsoring Member Guaranty.
                    <SU>61</SU>
                    <FTREF/>
                     Additionally, Sponsoring Members may be required to provide FICC with reports or other information that FICC may require, including, for example, responses to annual or ad hoc due diligence requests.
                    <SU>62</SU>
                    <FTREF/>
                     FICC utilizes such due diligence requests to identify, monitor and manage the risks Sponsoring Members and their Sponsored Members may present to it. As discussed above, where FICC identifies risks (whether via the due diligence process or otherwise), FICC can impose supplemental financial requirements on a Sponsoring Member, an Excess Capital Premium charge (where applicable), and activity limits.
                    <SU>63</SU>
                    <FTREF/>
                     Therefore, FICC states that that its existing risk management practices with respect to the Sponsored Service, which do not rely on the QIB Requirement, are sufficiently effective.
                    <SU>64</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>59</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21371.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>60</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 3A, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>61</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>62</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>63</SU>
                         
                        <E T="03">See supra</E>
                         notes 53, 54, and 55.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>64</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, 89 FR 21371.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">3. Clarify Eligibility Criteria for Non-U.S. and Other Applicants</HD>
                <HD SOURCE="HD3">Changes Regarding Non-U.S. Applicants</HD>
                <P>
                    Currently, a Foreign Person applying to be a Netting Member must meet the eligibility criteria for the distinct 
                    <PRTPAGE P="93788"/>
                    Netting Member category of “Foreign Netting Members.” 
                    <SU>65</SU>
                    <FTREF/>
                     In contrast with the eligibility criteria for other Netting Member categories, the eligibility criteria for Foreign Netting Members in Section 3(a)(v) of GSD Rule 2A do not specify or reference eligible types of legal entities.
                    <SU>66</SU>
                    <FTREF/>
                     Instead, Section 4(b)(ii)(E) of GSD Rule 2A provides FICC the authority to set minimum financial requirements for Foreign Netting Member applicants.
                    <SU>67</SU>
                    <FTREF/>
                     Additionally, Section 3(b) of GSD Rule 2A currently states that an entity can only be one category of Netting Member at a time.
                    <SU>68</SU>
                    <FTREF/>
                     Thus, a Foreign Person that is the foreign equivalent of, for example a Registered Investment Company, which is a legal entity recognized in the GSD Rules for U.S. entities, would apply to be a Foreign Netting Member, and would be subject to the eligibility criteria, other membership qualifications, and ongoing minimum membership standards applicable to Foreign Netting Members.
                    <SU>69</SU>
                    <FTREF/>
                     However, the GSD Rules also contain specific eligibility criteria, other membership qualifications, and ongoing minimum membership standards applicable to, in this example, Registered Investment Company Netting Members.
                    <SU>70</SU>
                    <FTREF/>
                     Therefore, in this example, the current GSD Rules are unclear as to whether the applicant entity would only be subject to the Foreign Netting Member standards or would also be subject to the Registered Investment Company Netting Member standards.
                    <SU>71</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>65</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 2A, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>66</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>67</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>68</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>69</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, 89 FR at 21372.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>70</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, 89 FR at 21372.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>71</SU>
                         
                        <E T="03">See id.</E>
                         FICC states that such ambiguity can have meaningful implications; for example, a Registered Investment Company Netting Member is excluded from certain requirements under the GSD Rules, and, therefore, if a Registered Investment Company that is a Foreign Person applied, and was approved, to be a Foreign Netting Member, it would not be clear if the applicable exclusions should apply to this Foreign Netting Member Applicant. 
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    To avoid this ambiguity, FICC proposes to eliminate the category of “Foreign Netting Member” and expand the qualifications for each category of Netting Member to include the foreign equivalent of the same legal entity types.
                    <SU>72</SU>
                    <FTREF/>
                     Foreign Persons that are eligible to apply to be a Netting Member would be subject to both the minimum membership standards of the applicable Netting Member category as well as the eligibility criteria currently applicable to Foreign Netting Members, currently set forth in Section 3(a)(v) of GSD Rule 2A.
                    <SU>73</SU>
                    <FTREF/>
                     In making the determination of whether a Foreign Person is an equivalent legal entity to the domestic legal entities that qualify for a category of Netting Member, FICC would consider, for example, the applicant's business model and its regulatory framework and designated examining authority. Therefore, the Proposed Rule Change would provide that a Foreign Person shall be eligible to become a Netting Member if either (1) it qualifies for one of the existing categories of Netting Member, or (2) FICC determines that the applicant may apply in the same way as an applicant that does not qualify under an existing category of Netting Member, as discussed with respect to “Changes Regarding Other Applicants” below.
                </P>
                <FTNT>
                    <P>
                        <SU>72</SU>
                         In making the determination of whether a Foreign Person is an equivalent legal entity to one of the domestic legal entities that qualify for a category of Netting Member, FICC would consider, for example, the applicant's business model and its regulatory framework and designated examining authority. 
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21372.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>73</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 2A, Section 3(a)(v) (providing that a person may be eligible to apply to be a Foreign Netting Member if it “(i) has a home country regulator that has entered into a memorandum of understanding with the SEC regarding the sharing or exchange of information, and (ii) maintains a presence in the United States, either directly or through a suitable agent, that both has available individuals fluent in English who are knowledgeable in the Foreign Person's business and can assist the Corporation's representatives as necessary, and ensures that the Foreign Person will be able to meet its data submission, settlement, and other obligations to the Corporation as a Member in a timely manner.”) and Section 4(b)(ii)(E) (specifying the minimum financial requirements for an applicant to be a Foreign Netting Member), 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <P>
                    Foreign Persons that are eligible to apply to be a Netting Member would be subject to both the minimum membership standards of the applicable Netting Member category and the eligibility criteria currently applicable to Foreign Netting Members, currently set forth in Section 3(a)(v) of Rule 2A. Where an applicable Netting Member category is subject to membership qualifications that are inconsistent with the qualifications applicable to a Foreign Person, then the standards applicable to a Foreign Person would apply. Although this could lead to an approach where a Foreign Person applicant remains subject to home jurisdiction requirements that are different than the requirements applicable to other Netting Members, FICC states that that this is acceptable because, as discussed further below, the GSD Rules would still provide that FICC will continue to apply the membership standards that were designed specifically to address the risks that may not be present when an applicant is not domiciled in the U.S. and whose primary regulator is not U.S.-based.
                    <SU>74</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>74</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, 89 FR at 21372.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">Changes Regarding Other Applicants</HD>
                <P>Additionally, FICC proposes to clarify the eligibility criteria for applicants that do not fit into one of the existing Netting Member categories. In light of the adoption of the Treasury Clearing Rules, additional market participants will need to access FICC's clearance and settlement services, either as direct Netting Members or as indirect participants. However, under the current GSD Rules, FICC does not have the authority to consider a Netting Member applicant that does not meet the eligibility criteria of one of the Netting Member categories enumerated in the GSD Rules. Therefore, FICC proposes amendments to the GSD Rules that would provide a framework for FICC to consider an applicant, including a Foreign Person, to be a Netting Member if that applicant does not meet the eligibility criteria of one of the existing Netting Member categories.</P>
                <P>Specifically, the Proposed Rule Change would first require that an applicant submit an application questionnaire and other initial application materials that demonstrate to FICC that the applicant's business and capabilities are such that it could reasonably expect material benefit from direct access to FICC's services. FICC proposes to establish minimum membership standards, including financial and other qualifications for membership, as it may determine are reasonable and appropriate based on information provided by or concerning such an applicant. FICC's determination of the minimum membership standards to apply to that applicant would be based on the risk profile of the applicant, as determined by FICC, and information related to (i) the applicant's business model, (ii) its regulatory framework and designated examining authority, (iii) its organizational structure and risk management framework, and (iv) its anticipated use of the Corporation's services.</P>
                <P>
                    FICC states that it cannot reliably predict which types of legal entities will apply for direct membership or predict the risk profiles of those entities.
                    <SU>75</SU>
                    <FTREF/>
                     The proposed changes would provide FICC with the necessary flexibility to consider any potential applicants, including legal entities that do not fit into its current Netting Member 
                    <PRTPAGE P="93789"/>
                    categories.
                    <SU>76</SU>
                    <FTREF/>
                     FICC states that these proposed changes would facilitate access to GSD's clearing services to a broader range of market participants.
                    <SU>77</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>75</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21373.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>76</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>77</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">4. Other Proposed Changes</HD>
                <P>
                    FICC proposes changes to the GSD Rules generally designed to describe the criteria and related requirements regarding direct and indirect access to GSD's clearance and settlement services. FICC states that these proposed changes should enhance the ability of market participants, and in particular indirect participants, to understand and evaluate the comparative tradeoffs of using GSD's central clearing services depending on the relevant access model.
                    <SU>78</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>78</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    Specifically, FICC proposes to include a “road map” in the GSD Rules describing the various GSD access models that allow for both direct and indirect access to GSD's clearance and settlement services. In addition, to simplify the description of eligibility requirements in GSD Rule 2A, FICC proposes to move the definitions of the Netting Member Categories from GSD Rule 2A to the defined terms in GSD Rule 1. FICC further proposes to remove definitions which are only used once in the GSD Rules and replace those uses with the defined terms, meaning that it would remove stand-alone definitions that are used only once and instead fold the one-time definition into broader context within the GSD Rules.
                    <SU>79</SU>
                    <FTREF/>
                     FICC proposes to clarify eligibility criteria for FCM Netting Members to require membership in the National Futures Association. Additionally, FICC proposes to make several grammatical and other non-substantive changes to the GSD Rules to streamline, clarify, and simplify the GSD access models, related definitions, and other relevant provisions.
                    <SU>80</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>79</SU>
                         For example, the GSD Rules currently contain a definition for Inter-Dealer Broker which is used only, in turn, to define an Inter-Dealer Broker Netting Member. The revisions would collapse the definition of an Inter-Dealer Broker into the description of an Inter-Dealer Broker Netting Member.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>80</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, 89 FR at 21374-75.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">II. Discussion and Commission Findings</HD>
                <P>
                    Section 19(b)(2)(C) of the Exchange Act 
                    <SU>81</SU>
                    <FTREF/>
                     directs the Commission to approve a proposed rule change of a self-regulatory organization if it finds that such proposed rule change is consistent with the requirements of the Exchange Act and rules and regulations thereunder applicable to such organization. After carefully considering the Proposed Rule Change,
                    <SU>82</SU>
                    <FTREF/>
                     the Commission finds that the Proposed Rule Change is consistent with the requirements of the Exchange Act and the rules and regulations thereunder applicable to FICC. In particular, the Commission finds that the Proposed Rule Change is consistent with Sections 17A(b)(3)(F) 
                    <SU>83</SU>
                    <FTREF/>
                     and (b)(3)(I) 
                    <SU>84</SU>
                    <FTREF/>
                     of the Exchange Act and Rules 17ad-22(e)(18)(iii), (e)(18)(iv)(C), (e)(19), and (e)(23)(ii) thereunder.
                    <SU>85</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>81</SU>
                         15 U.S.C. 78s(b)(2)(C).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>82</SU>
                         17 CFR 240.17ad-22(e)(18)(iii), (e)(18)(iv)(C), (e)(19), and (e)(23)(ii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>83</SU>
                         15 U.S.C. 78q-1(b)(3)(F).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>84</SU>
                         15 U.S.C. 78q-1(b)(3)(I).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>85</SU>
                         As part of the Commission's process of analyzing the Proposed Rule Change for consistency with the Exchange Act and rules and regulations thereunder, the Commission carefully considered the public comment letters. Many of the comment letters were submitted in response to both the Proposed Rule Change and a related set of proposed rule changes (
                        <E T="03">see</E>
                         Securities Exchange Act Release No. 99845 (Mar. 22, 2024), 89 FR 21603 (Mar. 28, 2024) (File No. SR-FICC-2024-802) and Securities Exchange Act Release No. 99844 (March 22, 2024), 89 FR 21586 (Mar. 28, 2024) (File No. SR-FICC-2024-007)). On October 25, 2024, FICC filed Partial Amendment No. 1 to the related set of proposed rule changes (
                        <E T="03">see</E>
                         Securities Exchange Act Release No. 101455 (Oct. 28, 2024), 89 FR 87449 (Nov. 1, 2024) (File No. SR-FICC-2024-802) and Securities Exchange Act Release No. 101454 (Oct. 28, 2024), 89 FR 87441 (Nov. 1, 2024) (File No. SR-FICC-2024-007) (together, the “Account Segregation Proposals”)). The comment letters generally did not specify which individual comments relate to the Proposed Rule Change as opposed to the Account Segregation Proposals. In the instant Order, the Commission addresses the comments related to the Proposed Rule Change. In a separate Order, the Commission addresses the comments related to the Account Segregation Proposals.
                    </P>
                </FTNT>
                <HD SOURCE="HD2">A. Consistency With Section 17A(b)(3)(F) of the Exchange Act</HD>
                <P>
                    Section 17A(b)(3)(F) of the Exchange Act 
                    <SU>86</SU>
                    <FTREF/>
                     requires that the rules of a clearing agency, such as FICC, be designed to, among other things, promote the prompt and accurate clearance and settlement of securities transactions, and protect investors and the public interest.
                </P>
                <FTNT>
                    <P>
                        <SU>86</SU>
                         15 U.S.C. 78q-1(b)(3)(F).
                    </P>
                </FTNT>
                <P>
                    As described above in Section I.B., FICC proposes changes to the GSD Rules that are designed to encourage and facilitate a greater number of market participants to utilize GSD's clearance and settlement services for transactions in U.S. Treasury securities, including for done-with and done-away transactions. Specifically, as described in Section I.B.1, FICC's consolidation of the correspondent clearing/prime broker services into the Agent Clearing Service and the substantially increased level of detail about how this service operates should allow for a better understanding of the availability of this model at FICC.
                    <SU>87</SU>
                    <FTREF/>
                     By updating and expanding the Agent Clearing Service to more closely resemble the nomenclature and functioning of an FCM-style model, the Proposed Rule Change should better present the Agent Clearing Service as a viable method for market participants to consider for clearing transactions in U.S. Treasury securities. The new terminology should help to show that the Agent Clearing Service operates similarly to agent clearing models in cleared derivatives markets, where market participants execute transactions with third parties and then give them up to their futures commission merchant for clearing.
                </P>
                <FTNT>
                    <P>
                        <SU>87</SU>
                         
                        <E T="03">See</E>
                         DTCC White Paper, Looking to the Horizon: Assessing a Potential Expansion of U.S. Treasury Central Clearing (Sept. 2023) (“2023 DTCC White Paper”) at 9, 
                        <E T="03">available at https://www.dtcc.com/-/media/Files/Downloads/WhitePapers/Accessing-Potential-Expansion-US-Treasury-Clearing-White-Paper.pdf.</E>
                    </P>
                </FTNT>
                <P>
                    Further, the increased specificity regarding the functioning of the Agent Clearing Service should help market participants better evaluate its fitness for their individual needs. The current GSD Rules do not describe a Submitting Member as an agent for an Executing Firm or as submitting given up transactions to FICC for clearing, and the current GSD Rules present only limited information about how the service functions. By contrast, the expanded rules regarding the Agent Clearing Service makes clear how the Agent Clearing Service would function. It addresses various topics, including the qualifications of Agent Clearing Members and the application process, what an Executing Firm Customer is and what information an Agent Clearing Member must provide to FICC regarding its Executing Firm Customers (including confirmation that there is an agreement binding the Executing Firm Customer to the applicable GSD Rules and that the Executing Firm Customer agrees to the specified Executing Firm Customer Acknowledgments, what transactions may be submitted through the service, the rights and obligations of the Agent Clearing Member, and how transactions are addressed in the event of a default or non-default loss event. These changes substantially expand the description of how this service functions beyond the limited and high-level information currently in the GSD Rules. The Commission understands that, based on a survey conducted by FICC, a significant number (28 percent) of Netting Member survey respondents have already indicated that they expect to facilitate clearing transactions in U.S. Treasury securities using their existing prime brokerage, agency clearing, or 
                    <PRTPAGE P="93790"/>
                    FCM business units currently used for clearing listed and over-the-counter derivatives.
                    <SU>88</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>88</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 5-6, 11 (citing DTCC White Paper, The U.S. Treasury Clearing Mandate: An Industry Pulse Check (July 2024) (“2024 DTCC White Paper”) at 6, 
                        <E T="03">available at https://www.dtcc.com/-/media/WhitePapers/Treasury-Clearing-Mandate.pdf</E>
                        ).
                    </P>
                </FTNT>
                <P>The changes regarding the Agent Clearing Service should help facilitate market participants' ability to access central clearing by providing more detail about how the service functions and, potentially, allowing market participants to leverage existing policies and practices used for other agent clearing models to clear other types of products. In addition, the changes would provide FICC with increased ability to risk manage and monitor the Agent Clearing Transactions because it would require additional information on Executing Firm Customers and the use of an Agent Clearing Omnibus Account. These changes should therefore help promote prompt and accurate clearance and settlement and protect investors and the public interest.</P>
                <P>Additionally, FICC's proposals to streamline and clarify certain aspects of its membership standards would remove entry barriers and make it easier for market participants to utilize the Sponsored Service. First, as described above in Section I.B.2., the Proposed Rule Change would enable additional market participants to become Sponsoring Members by removing capital requirements and eliminating other distinctions between the two existing categories of Sponsoring Members. Second, the Proposed Rule Change would enable additional market participants to become Sponsored Members by removing the QIB Requirement. These changes should allow FICC to streamline the Sponsored Service and improve its accessibility to potential Sponsoring and Sponsored Members, while still allowing FICC to appropriately risk manage transactions cleared through the Sponsored Service. Therefore, this aspect of the Proposed Rule Change should facilitate greater participation in the Sponsored Service and, therefore, in central clearing more generally, subject to appropriate risk management at FICC, which is consistent with both promoting prompt and accurate clearance and settlement and the protection of investors and the public interest.</P>
                <P>The Proposed Rule Change, as described in Section I.B.3, would also facilitate broader market participation in GSD by streamlining and clarifying the Netting Member eligibility criteria applicable to Foreign Persons and applicants that do not otherwise fit into one of the existing categories of Netting Member and would establish an application process for such entities that allows FICC to consider any applicant and the potential risk that it could bring to FICC. FICC's membership requirements are part of its overall risk management because membership requirements help to guard against defaults of any FICC member, as well as to protect FICC and the financial system as a whole from the risk that one member's default could cause others to default, potentially including FICC itself.</P>
                <P>Additionally, FICC's proposals to add new provisions to the GSD Rules that more clearly describe the various direct and indirect GSD access models, and otherwise clarify the GSD Rule provisions regarding the GSD access models, would provide greater transparency on those subjects to market participants, and thereby enable market participants to more accurately and efficiently evaluate which model best fits their business needs.</P>
                <P>Finally, as described above in Section I.B.4., FICC proposes to make several grammatical and other non-substantive changes to the GSD Rules to streamline, clarify, and simplify the GSD access models, related definitions, and other relevant provisions.</P>
                <P>
                    The Proposed Rule Change would encourage and facilitate greater participation in central clearing, while still providing sound risk management which would promote the prompt and accurate clearance and settlement of securities transactions, and would protect investors and the public interest. As the Commission explained when adopting the Treasury Clearing Rules, U.S. Treasury securities play a critical and unique role in the U.S. and global economy, serving as a significant investment instrument and hedging vehicle for investors, a risk-free benchmark for other financial instruments, and an important mechanism for the Federal Reserve's implementation of monetary policy.
                    <SU>89</SU>
                    <FTREF/>
                     Consequently, confidence in the U.S. Treasury market, and in its ability to function efficiently is critical to the stability of the global financial system. In central clearing, through novating transactions (
                    <E T="03">i.e.,</E>
                     becoming the counterparty to both sides of a transaction), a CCP addresses concerns about counterparty risk by substituting its own creditworthiness and liquidity for the creditworthiness and liquidity of the counterparties.
                    <SU>90</SU>
                    <FTREF/>
                     A CCP thereby enables market participants to effectively reduce costs, increase operational efficiency, and manage risks.
                    <SU>91</SU>
                    <FTREF/>
                     Moreover, a CCP provides a centralized system of default management that can mitigate the potential for a single market participant's failure to destabilize other market participants or the financial system more broadly.
                    <SU>92</SU>
                    <FTREF/>
                     The Commission adopted the Treasury Clearing Rules, in part, to help reduce contagion risk to the CCP and bring the benefits of central clearing to more transactions involving U.S. Treasury securities, thereby lowering overall systemic risk in the market.
                    <SU>93</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>89</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, 
                        <E T="03">supra</E>
                         note 14, 89 FR at 2715-17.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>90</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, supra note 14, 89 FR at 2716.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>91</SU>
                         
                        <E T="03">See id.</E>
                         (citing Covered Clearing Agency Standards Proposing Release, Exchange Act Release No. 71699 (Mar. 12, 2014), 79 FR 29507, 29587 (May 27, 2014) (“CCA Standards Proposing Release”)).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>92</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, 
                        <E T="03">supra</E>
                         note 14, 89 FR at 2716 (citing Order Granting Temporary Exemptions Under the Securities Exchange Act of 1934 in Connection with Request of Liffe Administration and Management and Lch.Clearnet Ltd. Related to Central Clearing of Credit Default Swaps, and Request for Comments, Exchange Act Release No. 59164 (Dec. 24, 2008), 74 FR 139, 140 (Jan. 2, 2009) (“Liffe Order”)).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>93</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, 
                        <E T="03">supra</E>
                         note 14, 89 FR at 2716 (citing Proposing Release, Standards for Covered Clearing Agencies for U.S. Treasury Securities and Application of the Broker-Dealer Customer Protection Rule With Respect to U.S. Treasury Securities, Exchange Act Release No. 95763 (Sept. 14, 2022), 87 FR 64610, 64614 (Oct. 25, 2022) (“Proposing Release”)).
                    </P>
                </FTNT>
                <P>CCP rules that are clear and comprehensible, increase operational efficiency, and more effectively manage risks, like the Proposed Rule Change, should encourage a broader scope of market participants to utilize the CCP's services, thereby promoting the prompt and accurate clearance and settlement of securities transactions, and protecting investors and the public interest, consistent with Section 17A(b)(3)(F) of the Exchange Act. The Proposed Rule Change is consistent with those objectives because it encourages and supports greater participation in GSD's central clearing services for different types of market participants and transactions. Accordingly, the Proposed Rule Change would promote the prompt and accurate clearance and settlement of securities transactions, and protect investors and the public interest, because by encouraging greater participation in central clearing, the proposals would extend the benefits of operational efficiency and risk management to a greater segment of the U.S. Treasury securities market.</P>
                <P>
                    For these reasons, the Proposed Rule Change is consistent with the 
                    <PRTPAGE P="93791"/>
                    requirements of Section 17A(b)(3)(F) of the Exchange Act.
                    <SU>94</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>94</SU>
                         15 U.S.C. 78q-1(b)(3)(F).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">B. Consistency With Section 17A(b)(3)(I) of the Exchange Act</HD>
                <P>
                    Section 17A(b)(3)(I) of the Exchange Act requires that the rules of a clearing agency, such as FICC, do not impose any burden on competition not necessary or appropriate in furtherance of the Exchange Act.
                    <SU>95</SU>
                    <FTREF/>
                     Section 17A(b)(3)(I) does not require the Commission to make a finding that FICC chose the option that imposes the least possible burden on competition. Rather, the Exchange Act requires that the Commission find that the Proposed Rule Change does not impose any burden on competition not necessary or appropriate in furtherance of the purposes of the Exchange Act, which involves balancing the competitive effects of the Proposed Rule Change against all other relevant considerations under the Exchange Act.
                    <SU>96</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>95</SU>
                         15 U.S.C. 78q-1(b)(3)(I).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>96</SU>
                         
                        <E T="03">See</E>
                         Bradford National Clearing Corp., 590 F.2d 1085, 1105 (D.C. Cir. 1978).
                    </P>
                </FTNT>
                <P>
                    Several commenters suggest that the Proposed Rule Change's failure to include a requirement that FICC's direct participants offer done-away clearing services would not sufficiently provide for a workable done-away model.
                    <SU>97</SU>
                    <FTREF/>
                     For example, one commenter states that it does not expect Netting Members to offer done-away trading via the Agent Clearing Model (which would effectively result in clearing members surrendering potentially lucrative commissions from trade execution to other brokers).
                    <SU>98</SU>
                    <FTREF/>
                     This commenter further states that the Proposed Rule Change does not address this or otherwise provide any other mechanism to properly align Netting Members' incentives with the goal of facilitating done-away trading.
                    <SU>99</SU>
                    <FTREF/>
                     Another commenter states that the Proposed Rule Change “ignores the current reality” in which the commenter is not aware of any clearing member currently offering done-away clearing to its customers for either cash or repo transactions and the Proposed Rule Change fails to explain why done-with and done-away transactions continue to be treated differently given that a clearing member should be agnostic about with whom a trade is executed, as the counterparty of a cleared trade is FICC (
                    <E T="03">i.e.,</E>
                     not the executing counterparty).
                    <SU>100</SU>
                    <FTREF/>
                     This commenter states that FICC has not explained the justification for treating done-with and done-away transactions differently and why it has elected to continue to permit its clearing members to require 
                    <E T="03">all</E>
                     customers to bundle execution and clearing in these models.
                    <SU>101</SU>
                    <FTREF/>
                     Another commenter states that there remain serious questions whether Netting Members view offering done-away services as practicable from a regulatory net capital perspective and whether a sufficient number of Netting Members will provide clearing services on a standalone basis, as opposed to bundling execution and clearing.
                    <SU>102</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>97</SU>
                         
                        <E T="03">See</E>
                         Letter from William C. Thum, Managing Director and Assistant General Counsel, Securities Industry and Financial Markets Association, Asset Management Group (May 24, 2024) (“SIFMA-AMG Letter”) at 5; Letter from Joanna Mallers, Secretary, Futures Industry of America, Principal Traders Group (April 17, 2024) (“FIA-PTG Letter I”) at 2-3, 6-7; Letter from Sarah A. Bessin, Deputy General Counsel and Nhan Nguyen, Associate General Counsel, Investment Company Institute (June 20, 2024) (“ICI Letter”) at 2, 4-5; Letter from Jennifer W. Han, Executive Vice President, Chief Counsel and Head of Global Regulatory Affairs, Managed Funds Association (April 17, 2024) (“MFA Letter I”) at 4-5, 7-8; Letter from Jennifer W. Han, Executive Vice President, Chief Counsel and Head of Global Regulatory Affairs, Managed Funds Association (Nov. 12, 2024) (“MFA Letter II”) at 3-4; 
                        <E T="03">see also</E>
                         Letter from Jiri Krol, Deputy Chief Executive Officer, Global Head of Government Affairs, Alternative Investment Management Association (April 23, 2024) (“AIMA Letter”) at 4-5 (stating that not addressing the done-away problem leaves a critical gap in access to clearing and settlement service and places significant competitive burdens on indirect participants).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>98</SU>
                         
                        <E T="03">See</E>
                         SIFMA-AMG Letter at 5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>99</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>100</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>101</SU>
                         
                        <E T="03">See id.; see also</E>
                         MFA Letter II at 3-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>102</SU>
                         
                        <E T="03">See</E>
                         ICI Letter at 4-5.
                    </P>
                </FTNT>
                <P>
                    As a solution to the foregoing concerns, the commenters state that FICC should require Netting Member intermediaries (
                    <E T="03">i.e.,</E>
                     Sponsoring Members and Agent Clearing Members) to offer done-away clearing to their customers.
                    <SU>103</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>103</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 3-4; MFA Letter I at 4-5, 7-8; AIMA Letter at 4-5; SIFMA-AMG Letter at 2; ICI Letter at 2, 4-5. Commenters also state that by not including a requirement on Netting Member intermediaries to offer done-away clearing to their customers, the Proposed Rule Change does not adequately facilitate access for such customers to FICC's clearance and settlement services, consistent with Rule 17ad-22(e)(18)(iv)(C). 
                        <E T="03">See</E>
                         17 CFR 240.17ad-22(e)(18)(iv)(C). The Commission addresses those comments below in Section II.D.
                    </P>
                </FTNT>
                <P>
                    In contrast to these commenters, one commenter states that a mandate from FICC is not a necessary condition for a viable done-away access model.
                    <SU>104</SU>
                    <FTREF/>
                     Instead, the commenter states that a Netting Member's decision to provide done-away services—or any services—to market participants is, and should remain, a commercial and risk decision of each member, and that such commercial arrangements should not be mandated by rule or otherwise.
                    <SU>105</SU>
                    <FTREF/>
                     The commenter further states that mandating the provision of done-away services could compromise the goals of the Treasury Clearing Rules by making the access models less attractive from a business perspective to Netting Members and cause Netting Members to limit the offerings they do make to customers if doing so would mandate other commercial arrangements or transactions that they may not wish to engage in.
                    <SU>106</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>104</SU>
                         
                        <E T="03">See</E>
                         Letter from Robert Toomey, Head of Capital Markets, Managing Director/Associate General Counsel, SIFMA, at 3-4 (July 31, 2024) (“SIFMA Letter II”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>105</SU>
                         
                        <E T="03">See</E>
                         SIFMA Letter II at 2.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>106</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    In response, FICC states that requiring Netting Member intermediaries to offer done-away clearing services to customers could expose FICC and its participants to additional risks and other challenges that could limit the commercial and risk management choices an intermediary could consider in offering clearing services, which in turn could reduce the number of market participants willing to provide such services.
                    <SU>107</SU>
                    <FTREF/>
                     FICC further states that such a contraction in the availability of direct participants providing clearing services would result in concentration of risk, increased costs, and reduced liquidity in the Treasury market.
                    <SU>108</SU>
                    <FTREF/>
                     Additionally, FICC states that unlike done-with clearing, done-away clearing presents unique liquidity risks to both FICC and Netting Member intermediaries.
                    <SU>109</SU>
                    <FTREF/>
                     For FICC, if a customer's Netting Member intermediary defaults, FICC would be obligated to perform the one-sided obligations of the done-away transactions of the customer and would need liquidity to do so.
                    <SU>110</SU>
                    <FTREF/>
                     For Netting Member intermediaries, done-away transactions would increase the maximum liquidity a Netting Member may be required to provide to FICC under the Capped Contingency 
                    <PRTPAGE P="93792"/>
                    Liquidity Facility (“CCLF”), increasing the cost of clearing done-away transactions.
                    <SU>111</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>107</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 11.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>108</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>109</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 11-14.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>110</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 11-12. FICC also states that, by contrast, in a done-with transaction, the customer enters into the transaction with its clearing member, and that, if the clearing member then defaults, the clearing agency has the option to close out both the obligations to the clearing member and those to the customer (
                        <E T="03">i.e.,</E>
                         “both sides of the trade”), with the sole resulting payment obligation being the mark-to-market value of the positions. 
                        <E T="03">See id.</E>
                         at 12. One commenter states that it is “inaccurate” that done-away transactions have greater liquidity risks, but the commenter does not disagree with FICC's description of these liquidity concerns, and instead states that this distinction highlights a deficiency of FICC's current default management framework. 
                        <E T="03">See</E>
                         Letter from Stephen Berger, Managing Director, Global Head of Government &amp; Regulatory Policy, Citadel and Citadel Securities, (Oct. 21, 2024) (“Citadel Letter”) at 5; 
                        <E T="03">see also</E>
                         MFA Letter II at 3-4. The concerns regarding the default management framework are discussed in Section II.D.6 
                        <E T="03">infra.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>111</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 12, 14. The CCLF is a member-funded, rules-based, committed liquidity resource, designed to enable FICC to meet its cash settlement obligations in the event of a default of the member (including affiliates) to which FICC has the largest exposure in extreme but plausible market conditions. FICC allocates $15 billion of the total size of the CCLF among all members. FICC allocates the remainder of the total size of the CCLF among members depending on the amount and frequency with which they generate liquidity needs above $15 billion. 
                        <E T="03">See</E>
                         GSD Rule 22A, Section 2a, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <P>
                    FICC also states that since done-away transactions are negotiated between a customer and its counterparty, the Netting Member intermediary must rely on external parties and/or processes to confirm that a transaction is consistent with the Netting Member's risk limits and regulatory requirements.
                    <SU>112</SU>
                    <FTREF/>
                     Therefore, FICC states that imposing a done-away mandate on Netting Members that lack the infrastructure to perform such confirmations could discourage market participants from providing clearing services to customers.
                    <SU>113</SU>
                    <FTREF/>
                     FICC also states that done-away clearing might subject Netting Member intermediaries to certain regulatory challenges (
                    <E T="03">e.g.,</E>
                     regarding trade reporting and confirmations) and/or increased capital requirements (since it may be difficult to conclude that they have a well-founded basis on which they can exercise close-out netting rights upon a customer default).
                    <SU>114</SU>
                    <FTREF/>
                     FICC states that in light of the foregoing risks and challenges, a done-away mandate could have the unintended consequence of discouraging Netting Member intermediaries from providing clearing services to customers, which would concentrate risk, increase costs, and reduce liquidity in the Treasury market.
                    <SU>115</SU>
                    <FTREF/>
                     Instead of a done-away mandate, FICC states that Netting Member intermediaries should be allowed to decide whether and how to provide clearing services to customers after evaluating the relevant risks.
                    <SU>116</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>112</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 12-13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>113</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>114</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 14.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>115</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 11.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>116</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 5-6, 11. FICC states that for Netting Members (both current and prospective) with business units already engaged in FCM-style derivatives clearing, the ability to leverage their existing systems should enable them to offer done-away clearing for transactions in U.S. Treasury securities. 
                        <E T="03">See also</E>
                         FICC Letter at 7, 9 (citing 2024 DTCC White Paper 
                        <E T="03">supra</E>
                         note 88 at 6 (noting a significant number (28 percent) of Netting Members indicated that they expect to facilitate clearing transactions in U.S. Treasury securities through business units already engaged in done-away clearing of other product types and citing statements from Netting Members and other market participants indicating an intent to utilize their existing FCM-style systems to offer done-away clearing for U.S. Treasury securities and citing statements from Netting Members and other market participants indicating an intent to utilize their existing FCM-style systems to offer done-away clearing for U.S. Treasury securities)).
                    </P>
                </FTNT>
                <P>
                    As proposed, the GSD access models, including the ability to bundle execution and clearing, do not constitute a burden on competition that is not necessary or appropriate in furtherance of the Exchange Act, because the models continue to offer optionality for different types of market participants to access central clearing in different ways. After proposing the Treasury Clearing Rules,
                    <SU>117</SU>
                    <FTREF/>
                     the Commission received similar comments regarding the impact that the absence of a done-away mandate would have on competition for GSD's indirect participants.
                    <SU>118</SU>
                    <FTREF/>
                     At that time, the Commission disagreed with those comments and declined to impose a done-away mandate and did not agree that FICC's current access models constituted a burden on competition that is not necessary or appropriate in furtherance of the Exchange Act.
                    <SU>119</SU>
                    <FTREF/>
                     Notably, the client clearing models that FICC has proposed allow for Netting Members to offer done-away services. Although the models have not been widely used for done-away services to date, market participants have indicated that they will provide such services going forward.
                    <SU>120</SU>
                    <FTREF/>
                     In addition, as the Commission stated in the Treasury Clearing Adopting Release, in order to encourage Netting Member intermediaries to provide services that enable customers to access central clearing, it is best not to remove the ability of such intermediaries to determine which risks to take with respect to guaranteeing transactions to a CCP.
                    <SU>121</SU>
                    <FTREF/>
                     As FICC and one commenter highlighted, providing done-away clearing services brings certain risks to the Netting Member, which the Netting Member must evaluate and manage. Finally, approving the Proposed Rule Change does not preclude further action by FICC to incentivize or facilitate done-away clearing services going forward.
                </P>
                <FTNT>
                    <P>
                        <SU>117</SU>
                         
                        <E T="03">See</E>
                         Covered Clearing Agency Standards Proposing Release, Securities Exchange Act Release No. 71699 (Mar. 12, 2014), 79 FR 29507 (May 27, 2014) (“Proposing Release”); Adopting Release at 2756-57, 
                        <E T="03">supra</E>
                         note 14 (regarding comments arguing that the Commission should require FICC obligate its members to accept done-away transactions to avoid an undue burden on competition).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>118</SU>
                         
                        <E T="03">See</E>
                         Adopting Release at 2756-57, 
                        <E T="03">supra</E>
                         note 14.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>119</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>120</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 8 (reporting survey results that 43 percent of Netting Members would likely clear indirect participant transactions through the Agent Clearing Service). 
                        <E T="03">See also, e.g.,</E>
                         Bernard Goyder, “BNY to Launch `Done Away' UST and Repo Clearing Service,” 
                        <E T="03">available at https://www.risk.net/markets/7960175/bny-to-launch-done-away-ust-and-repo-clearing-service</E>
                         (Oct. 21, 2024); Bernard Goyder, “RJ O'Brien Plots Expansion Into US Treasury Clearing,” 
                        <E T="03">available at https://www.risk.net/markets/7959638/rj-obrien-plots-expansion-into-us-treasury-clearing</E>
                         (July 1, 2024).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>121</SU>
                         
                        <E T="03">See</E>
                         Adopting Release at 2756-57, 
                        <E T="03">supra</E>
                         note 14.
                    </P>
                </FTNT>
                <P>
                    In addition, commenters state that the Proposed Rule Change should prohibit bundling of clearing and execution services. One commenter states that this prohibition need not include a done-away mandate, as it would simply prohibit Netting Members from requiring forced bundling, and the commenter also disagrees with FICC's legal arguments regarding whether FICC may impose such a prohibition.
                    <SU>122</SU>
                    <FTREF/>
                     An additional commenter states that there are economic incentives for direct participants to bundle their execution and clearing services by favoring done-with transactions.
                    <SU>123</SU>
                    <FTREF/>
                     This commenter cites certain prohibitions adopted by the Commodity Futures Trading Commission (“CFTC”) and states that FICC should adopt the same protections for the U.S. Treasury market, as necessary to ensure a robust done-away clearing market.
                    <SU>124</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>122</SU>
                         
                        <E T="03">See</E>
                         Citadel Letter at 8.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>123</SU>
                         
                        <E T="03">See</E>
                         MFA Letter I at 5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>124</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    In response to such comments, FICC states that such a prohibition would effectively mean that a Netting Member could not charge lower fees for done-with clearing because that would amount to tying executing to clearing, and, as a result, could be viewed as the clearing agency dictating pricing terms.
                    <SU>125</SU>
                    <FTREF/>
                     FICC further states that such setting of prices is not clearly consistent with Section 17A(b)(3)(E) of the Exchange Act, which provides that the rules of a clearing agency may not impose any schedule of prices, or fix rates or other fees, for services rendered by its participants.
                    <SU>126</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>125</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>126</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 15-16. One commenter states that FICC also relied upon Section 17A(b)(6) regarding a prohibition on bundling and execution. 
                        <E T="03">See</E>
                         Citadel Letter at 8. However, FICC's reference to that statutory provision relates to a comment that would require done-away clearing services to any customer that posts margin and not to the bundling of execution and clearing services.
                    </P>
                </FTNT>
                <P>
                    The Commission considered similar comments regarding a prohibition of bundling and clearing when it adopted the Treasury Clearing Rules.
                    <SU>127</SU>
                    <FTREF/>
                     Specifically, several commenters stated that the Commission should require 
                    <PRTPAGE P="93793"/>
                    U.S. Treasury securities central clearing agencies to obligate their members to accept done-away transactions and prohibit their members from requiring clients to bundle execution and clearing.
                    <SU>128</SU>
                    <FTREF/>
                     In response, the Commission stated that it disagrees that the failure to require the submission of done-away transactions necessarily constitutes “unfair discrimination,” as discussed in Section 17A(b)(3)(F).
                    <SU>129</SU>
                    <FTREF/>
                     In order to encourage market participants to provide services to enable indirect access to central clearing, the Commission stated that it believes it is best not to remove the ability of FICC's direct participants to determine what risks to take with respect to guaranteeing customer transactions. In addition, the Commission also did not agree that, at that time, the current access models offered by FICC constitute a burden on competition that is not necessary or appropriate, as discussed in Section 17A(b)(3)(I).
                    <SU>130</SU>
                    <FTREF/>
                     The Commission's analysis remains applicable to the commenters seeking such a prohibition from FICC.
                </P>
                <FTNT>
                    <P>
                        <SU>127</SU>
                         
                        <E T="03">See</E>
                         Treasury Clearing Adopting Release, 
                        <E T="03">supra</E>
                         note 14, 89 FR at 2756-77 (including n. 415 identifying such comments). More generally, the statutory authority for the CFTC provisions cited by one commenter differs significantly from the statutory authority applicable to the Commission for the U.S. Treasury market.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>128</SU>
                         
                        <E T="03">See</E>
                         Treasury Clearing Adopting Release, supra note 14, 89 FR at 2756.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>129</SU>
                         
                        <E T="03">See</E>
                         Treasury Clearing Adopting Release, supra note 14, 89 FR at 2757.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>130</SU>
                         
                        <E T="03">See</E>
                         Treasury Clearing Adopting Release, supra note 14, 89 FR at 2756-77.
                    </P>
                </FTNT>
                <P>
                    For these reasons, after considering the public comments and FICC's response, the access models in the Proposed Rule Change, which would not prevent a Netting Member from bundling execution and clearing and do not require a Netting Member to provide done-away clearing services would not impose a burden on competition not necessary or appropriate in furtherance of the Exchange Act.
                    <SU>131</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>131</SU>
                         15 U.S.C. 78q-1(b)(3)(I).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">C. Consistency With Rule 17ad-22(e)(18)(iii)</HD>
                <P>
                    Rule 17ad-22(e)(18)(iii) under the Exchange Act requires that a covered clearing agency, such as FICC, establish objective, risk-based, and publicly disclosed criteria for participation, which monitor compliance with such participation requirements on an ongoing basis.
                    <SU>132</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>132</SU>
                         17 CFR 240.17ad-22(e)(4)(18)(iii).
                    </P>
                </FTNT>
                <P>As described above in Section I.B.1., FICC proposes changes that would enable it to monitor activity submitted through the Agent Clearing Service. Specifically, FICC would require a Netting Member to submit an application to become an Agent Clearing Member and provide additional information regarding each Executing Firm Customer beyond that which is required for Executing Firms under the current GSD Rules, such as a Legal Entity Identifier (“LEI”). FICC would also require an Agent Clearing Member to submit activity on behalf of its Executing Firm Customer(s) through one or more separate Agent Clearing Member Omnibus Accounts, as opposed to the optional segregated submission approach provided for in the current GSD Rules. Finally, for both initial and ongoing membership purposes, FICC would require an Agent Clearing Member to provide FICC with information related to its use of the Agent Clearing Service. Adding these provisions to the GSD Rules should help FICC monitor the trading activity generated withing the Agent Clearing Service because they should allow FICC to better understand which transactions are attributable to which Executing Firm Customers submitting through an Agent Clearing Member, which should, in turn, provide better overall understanding of market participants' activity at FICC even across multiple Agent Clearing Members.</P>
                <P>
                    One commenter states that FICC should change its proposal regarding the requirement on Agent Clearing Members to indemnify FICC for any harm arising out of the Agent Clearing Member's failure to have the current LEIs of its Executing Firm Customers on file with FICC.
                    <SU>133</SU>
                    <FTREF/>
                     Specifically, the commenter states that FICC's proposal is overly broad insofar as it would ostensibly require an Agent Clearing Member to halt a customer's trading activity for minor lapses in LEI renewals and require the Agent Clearing Member to verify current LEIs on any number of LEI service provider websites.
                    <SU>134</SU>
                    <FTREF/>
                     The commenter states that FICC should not need to maintain such strict rules governing LEIs when other identifying information accompanies each trade.
                    <SU>135</SU>
                    <FTREF/>
                     Therefore, the commenter states that FICC should more narrowly tailor the indemnification provision to cover only relevant harms arising out of an Agent Clearing Member's gross negligence, willful misconduct, or fraudulent conduct.
                    <SU>136</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>133</SU>
                         
                        <E T="03">See</E>
                         Letter from Katherine Darras, General Counsel, International Swaps and Derivatives Association (April 17, 2024) (“ISDA Letter I”) at 5-6; Letter from Katherine Darras, General Counsel, International Swaps and Derivatives Association (July 18, 2024) (“ISDA Letter II”) at 5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>134</SU>
                         
                        <E T="03">See</E>
                         ISDA Letter II at 5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>135</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>136</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    In response, FICC states that, although the Agent Clearing Member has a contractual relationship with its customers, FICC does not.
                    <SU>137</SU>
                    <FTREF/>
                     Therefore, the Agent Clearing Member is able to include contract provisions that obligate its customers to maintain current LEI information and notify the Agent Clearing Member of any LEI renewals or changes.
                    <SU>138</SU>
                    <FTREF/>
                     FICC further states that although it does not generally expect the LEI indemnification provision to give rise to significant liability, neither FICC nor its other members should bear the costs of any such liability.
                    <SU>139</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>137</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 41.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>138</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>139</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    The Commission agrees with FICC on this point. The LEI portion of the Proposed Rule Change is consistent with FICC's existing rule regarding a Sponsoring Member's obligation to provide an LEI for its Sponsored Members.
                    <SU>140</SU>
                    <FTREF/>
                     Therefore, Sponsoring Members are already subject to such a requirement. An Agent Clearing Member, like a Sponsoring Member, should be able to contract with its Executing Firm Customers to ensure that it receives updated LEI information to provide to FICC. Neither FICC nor its other members should bear any liability arising out of an Agent Clearing Member's failure to have the current LEIs of its Executing Firm Customers on file with FICC.
                </P>
                <FTNT>
                    <P>
                        <SU>140</SU>
                         
                        <E T="03">See</E>
                         GSD Rules, Rule 3A, Section 2(d) (“Each Sponsoring Member shall submit the Legal Entity Identifier for each of its Sponsored Member applicants as part of the application of such Sponsored Member applicant. Each Sponsoring Member shall provide the Corporation with a Legal Entity Identifier for each of its Sponsored Members such that the Corporation shall have a current Legal Entity Identifier for each Sponsored Member at all times.”).
                    </P>
                </FTNT>
                <P>
                    Accordingly, the Proposed Rule Change would assist FICC in monitoring its participants' ongoing compliance with the Agent Clearing Service participation requirements, consistent with Rule 17ad-22(e)(18)(iii).
                    <SU>141</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>141</SU>
                         17 CFR 240.17ad-22(e)(18)(iii).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">D. Consistency With Rule 17ad-22(e)(18)(iv)(C)</HD>
                <P>
                    Rule 17ad-22(e)(18)(iv)(C) under the Exchange Act requires that a covered clearing agency, such as FICC, when providing CCP services for transactions in U.S Treasury securities, establish objective, risk-based, and publicly disclosed criteria for participation, which ensure that it has appropriate means to facilitate access to clearance and settlement services of all eligible secondary market transactions in U.S. Treasury securities, including those of indirect participants.
                    <SU>142</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>142</SU>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <P>
                    FICC states that the Proposed Rule Change is primarily designed to ensure that the access models in the GSD Rules comply with Rule 17ad-22(e)(18)(iv)(C) by constituting criteria for participation 
                    <PRTPAGE P="93794"/>
                    that facilitate access to GSD's clearance and settlement services, including for indirect participants.
                    <SU>143</SU>
                    <FTREF/>
                     Specifically, FICC developed the Proposed Rule Change following FICC's review of GSD's existing direct and indirect access models.
                    <SU>144</SU>
                    <FTREF/>
                     That review examined whether those models provide market participants with access to GSD's clearance and settlement services in as flexible a means as possible, consistent with FICC's responsibility to provide sound risk management and comply with its regulatory risk management obligations under Rule 17ad-22(e) and other parts of the Exchange Act.
                    <SU>145</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>143</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21363.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>144</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>145</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.17ad-22(e); Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21363.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">1. Changes to the Agent Clearing Service</HD>
                <P>As described above in Section I.B.1., FICC proposes to re-name GSD's existing correspondent clearing/prime broker services as the Agent Clearing Service. FICC also proposes to consolidate and adopt additional provisions governing the re-named Agent Clearing Service. The proposed changes to re-name, consolidate, and provide additional specificity regarding the operation of the Agent Clearing Service should improve transparency of the GSD Rules regarding the Agent Clearing Service and allow market participants to better evaluate and consider how the Agent Clearing Service operates, including how it compares to existing cleared derivatives systems and infrastructure. The refinement of the proposed Agent Clearing Service should help ensure that market participants are able to evaluate and, if they choose, use this service to access FICC, including for done-away transactions, as discussed above in Section I.A. Therefore, these proposed changes are consistent with Rule 17ad-22(e)(18)(iv)(C).</P>
                <P>
                    Several commenters request that FICC clarify that an Agent Clearing Member would be permitted to treat its customer transactions as off-balance sheet for accounting purposes, otherwise the Agent Clearing Service may be so capital intensive as to disincentivize use of the access model.
                    <SU>146</SU>
                    <FTREF/>
                     In response, FICC states that it is actively working with industry groups to determine the balance sheet impact of done-away transactions.
                    <SU>147</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>146</SU>
                         
                        <E T="03">See</E>
                         FIA Letter at 5, 10-11; Letter from Robert Toomey, Head of Capital Markets, Managing Director/Associate General Counsel, SIFMA, at 3-4 (May 22, 2024) (“SIFMA Letter I”) at 2, 5; SIFMA Letter II at 3. One commenter further states that if FICC can provide clarity on this matter, it would negate the need for a done-away clearing mandate in the GSD Rules. 
                        <E T="03">See</E>
                         SIFMA Letter I at 5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>147</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 14.
                    </P>
                </FTNT>
                <P>
                    It is ultimately the responsibility of each Netting Member to determine the accounting treatment of its own transactions. FICC need not opine on the balance sheet treatment for transactions within the Agent Clearing Service in order for the Commission to evaluate the Proposed Rule Change's consistency with Rule 17ad-22(e)(18)(iv)(C).
                    <SU>148</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>148</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <P>
                    Another commenter is concerned that the rights of Executing Firm Customers are too limited vis-à-vis FICC within the Agent Clearing Service.
                    <SU>149</SU>
                    <FTREF/>
                     For example, the commenter states that under the Proposed Rule Change, FICC would have no obligations to Executing Firm Customers; rather, FICC's obligations would be solely to the Agent Clearing Member.
                    <SU>150</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>149</SU>
                         
                        <E T="03">See</E>
                         ICI Letter at 4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>150</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    In the Notice of Filing, FICC states that within the current correspondent clearing/prime broker services, an indirect participant does not establish any relationship with FICC.
                    <SU>151</SU>
                    <FTREF/>
                     FICC's proposed changes regarding the Agent Clearing Service would not change that aspect of the access model. In contrast, within the Sponsored Service, a Sponsored Member must establish an indirect, limited purpose membership with FICC. FICC states that one of the factors that an indirect participant may wish to consider in choosing between GSD access models is whether the participant prefers to be in a direct contractual relationship with FICC.
                    <SU>152</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>151</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, 89 FR at 21364.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>152</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 50-51.
                    </P>
                </FTNT>
                <P>
                    In the Treasury Clearing Rules Adopting Release, the Commission also recognized that certain access models offered by FICC may not result in a contractual relationship or direct obligation between FICC and an indirect participant.
                    <SU>153</SU>
                    <FTREF/>
                     This generally would be the case in any agent clearing relationship in which an indirect participant relies upon a direct participant to submit transactions for clearing on its behalf.
                    <SU>154</SU>
                    <FTREF/>
                     The commenter's concern that within the Agent Clearing Service, indirect participants would not have a contractual relationship with FICC, does not render the Proposed Rule Change inconsistent with Rule 17ad-22(e)(18)(iv)(C).
                </P>
                <FTNT>
                    <P>
                        <SU>153</SU>
                         
                        <E T="03">See</E>
                         Adopting Release, supra note 14, 89 FR at 2758.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>154</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Comments Regarding Done-Away Clearing</HD>
                <P>
                    As discussed in more detail in Section II.B above, several commenters suggest that by not including a requirement on Netting Member intermediaries to provide done-away clearing services to customers, the Proposed Rule Change would fail to implement criteria for participation that facilitate access to GSD's clearance and settlement services for indirect participants.
                    <SU>155</SU>
                    <FTREF/>
                     Specifically, commenters state that if a customer is limited to done-with transactions, it would need to establish separate clearing relationships with each done-with counterparty with whom it wishes to transact, which would increase cost, complexity, operational risk, and limit the number of counterparties with whom to transact.
                    <SU>156</SU>
                    <FTREF/>
                     In addition, several commenters state that alternatively, these market participants may limit their cash and/or repo U.S. Treasury transactions, thereby negatively impacting market liquidity.
                    <SU>157</SU>
                    <FTREF/>
                     Commenters also state that FICC should prohibit the bundling of clearing and execution services to comply with Rule 17ad-22(e)(18)(iv)(C). As discussed further in Section II.B 
                    <E T="03">infra,</E>
                     these commenters state that such a prohibition is necessary to ensure that market participants will provide done-away clearing services.
                    <SU>158</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>155</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 3 (stating that the Proposed Rule Change “raises serious questions regarding whether [it] appropriately facilitate[s] access to clearing for indirect participants as required by” Rule 17ad-22(e)(18)(iv)(C)); MFA Letter I at 3 (stating that the Proposed Rule change “[does] not go far enough to satisfy” Rule 17ad-22(e)(18)(iv)(C)); AIMA Letter at 4-5 (stating that the changes in the Proposed Rule Change “are not sufficient to facilitate access to clearing for indirect participants”); SIFMA-AMG Letter at 4 (stating that FICC must ensure that the Proposed Rule Change facilitates done-away trading in a manner that fulfills the requirements of the Treasury Clearing Rules); ICI Letter at 4 (stating that “it is not clear that the [Proposed Rule Change] fully implements the requirements of” Rule 17ad-22(e)(18)(iv)(C)).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>156</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 3; MFA Letter I at 4-5; AIMA Letter at 4 (stating that without a done-away model, indirect participants will face new and unnecessary costs in having to bundle execution and clearing services or establish additional clearing relationships so that they can engage with multiple execution counterparties).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>157</SU>
                         
                        <E T="03">See</E>
                         AIMA Letter at 4; 
                        <E T="03">see also</E>
                         SIFMA-AMG-Letter at 4-5 (arguing that without changes to the GSD access models, many market participants may be shut out of the U.S. Treasury market, with significant negative effects on liquidity).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>158</SU>
                         
                        <E T="03">See</E>
                         Citadel Letter at 7-8; MFA Letter II at 4.
                    </P>
                </FTNT>
                <P>
                    Generally, these commenters state that FICC should impose a mandate on Netting Member intermediaries to provide done-away clearing services to customers and should prohibit the 
                    <PRTPAGE P="93795"/>
                    bundling of clearing and execution services to address these concerns.
                    <SU>159</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>159</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 2-3, 6-7; MFA Letter I at 4-5, 7-8; AIMA Letter at 4-5.
                    </P>
                </FTNT>
                <P>
                    As discussed in more detail in Section II.B above, in response, FICC states that the Proposed Rule Change would meaningfully facilitate done-away clearing, without imposing a done-away mandate or prohibiting the bundling of clearing and execution services.
                    <SU>160</SU>
                    <FTREF/>
                     FICC also states that a done-away mandate could expose both FICC and its participants to unique risks.
                    <SU>161</SU>
                    <FTREF/>
                     First, as discussed in Section II.B above, done-away transactions present liquidity risks that done-with transactions do not.
                    <SU>162</SU>
                    <FTREF/>
                     Because done-away transactions are entered into between a customer and a counterparty other than the customer's Netting Member intermediary, if the intermediary defaults, FICC would need to perform the one-sided obligations of the customer.
                    <SU>163</SU>
                    <FTREF/>
                     Second, because done-away transactions are negotiated between the customer and its counterparty, the Netting Member intermediary must depend on outside processes or parties to confirm that the transactions do not give rise to risk or regulatory issues (
                    <E T="03">e.g.,</E>
                     trade reporting and confirmation requirements, anti-money laundering and sanctions regulations, 
                    <E T="03">etc.</E>
                    ).
                    <SU>164</SU>
                    <FTREF/>
                     FICC states that its direct participants should independently determine whether they can assume the risks associated with providing done-away clearing services.
                    <SU>165</SU>
                    <FTREF/>
                     Otherwise, according to FICC, the increased risks and costs associated with a done-away mandate could stifle the ongoing and positive market developments toward done-away clearing by discouraging Netting Member intermediaries from providing clearing services altogether.
                    <SU>166</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>160</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 8.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>161</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 11-13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>162</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>163</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>164</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>165</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>166</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 13-15.
                    </P>
                </FTNT>
                <P>
                    FICC further states that a done-away mandate could be inconsistent with Section 17A(b)(3)(E) and/or Section 17A(b)(6) of the Exchange Act.
                    <SU>167</SU>
                    <FTREF/>
                     FICC states that for a done-away mandate to be effective, it would likely need to prohibit the bundling of execution and clearing (and thereby prevent a Netting Member intermediary from forcing its customers into done-with transactions through more favorable terms).
                    <SU>168</SU>
                    <FTREF/>
                     FICC states that, as a result, a done-away mandate could be viewed as FICC dictating pricing terms, which could violate Section 17A(b)(3)(E).
                    <SU>169</SU>
                    <FTREF/>
                     Additionally, Section 17A(b)(6) provides that a clearing agency may not “prohibit or limit access by any person to services offered by any participant therein.” 
                    <SU>170</SU>
                    <FTREF/>
                     FICC states that a requirement on Netting Member intermediaries to provide done-away clearing to customers that post margin could violate Section 17A(b)(6) because the service offered to customers who do not post margin could potentially be limited to done-with clearing.
                    <SU>171</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>167</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 15-16; 15 U.S.C. 78q-1(b)(3)(E); 15 U.S.C. 78q-1(b)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>168</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 15-16.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>169</SU>
                         
                        <E T="03">See</E>
                         15 U.S.C. 78q-1(b)(3)(E).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>170</SU>
                         15 U.S.C. 78q-1(b)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>171</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 16; 15 U.S.C. 78q-1(b)(6).
                    </P>
                </FTNT>
                <P>
                    In addition, as stated above in Section II.B., one commenter also states that FICC should not impose a done-away clearing mandate.
                    <SU>172</SU>
                    <FTREF/>
                     Rather, the commenter states that any decision to offer done-away services should be a commercial/business decision left to clearing members, driven by evaluations of risk.
                    <SU>173</SU>
                    <FTREF/>
                     The commenter states that FICC can implement an access model, without a done-away clearing mandate, that would be reasonably designed to ensure that FICC has appropriate means to facilitate access to its clearance and settlement services consistent with Rule 17ad-22(e)(18)(iv)(C).
                    <SU>174</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>172</SU>
                         
                        <E T="03">See</E>
                         SIFMA Letter II at 3-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>173</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>174</SU>
                         
                        <E T="03">See</E>
                         SIFMA Letter II at 4.
                    </P>
                </FTNT>
                <P>
                    The Proposed Rule Change does not include a requirement that FICC's participants offer done-away clearing or prohibit the bundling of clearing and execution services. The Commission shall approve a proposed rule change of a self-regulatory organization if it finds that it is consistent with the Exchange Act,
                    <SU>175</SU>
                    <FTREF/>
                     and the Proposed Rule Change is consistent with the Exchange Act and the rules thereunder, even in the absence of a done-away mandate or a prohibition on the bundling of clearing and execution services.
                </P>
                <FTNT>
                    <P>
                        <SU>175</SU>
                         
                        <E T="03">See</E>
                         15 U.S.C. 78s(b)(2)(C)(i).
                    </P>
                </FTNT>
                <P>
                    The Commission disagrees with the commenters arguing that FICC must impose a done-away clearing mandate on Netting Member intermediaries or prohibit the bundling of clearing and execution services to comply with Rule 17ad-22(e)(18)(iv)(C). As discussed in the Adopting Release, Rule 17ad-22(e)(18)(iv)(C) does not prescribe a particular access model, but it instead helps ensure that FICC, and any other covered clearing agency serving the U.S. Treasury market, review their indirect access models and ensure that they facilitate access to clearance and settlement services in a manner suited to the needs and regulatory requirements of market participants, including indirect participants.
                    <SU>176</SU>
                    <FTREF/>
                     Further, in the Adopting Release, the Commission stated that a requirement to accept done-away transactions would require a covered clearing agency to, in turn, require their direct participants to transact with their customers in specific ways and limit their ability to offer certain types of pricing services.
                    <SU>177</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>176</SU>
                         
                        <E T="03">See</E>
                         Treasury Clearing Adopting Release, 
                        <E T="03">supra</E>
                         note 14, 89 FR at 2755-56.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>177</SU>
                         
                        <E T="03">See</E>
                         Treasury Clearing Adopting Release, 
                        <E T="03">supra</E>
                         note 14, 89 FR at 2757.
                    </P>
                </FTNT>
                <P>
                    More generally, and as stated above in Section II.A., both the Sponsored Service and the Agent Clearing Service (including the prime broker/correspondent clearing service in place currently) allow (and are currently used) for done-away clearing.
                    <SU>178</SU>
                    <FTREF/>
                     As stated in the Adopting Release, in order to encourage Netting Member intermediaries to provide services that enable customers to access central clearing, it is best not to remove the ability of such intermediaries to determine which risks to take with respect to guaranteeing transactions to a CCP such as FICC.
                    <SU>179</SU>
                    <FTREF/>
                     This is also true with respect to providing done-away clearing services. The Commission agrees with the rationale articulated by both FICC and one commenter arguing that a done-away clearing mandate could be counterproductive and ultimately discourage Netting Member intermediaries from providing clearing services to customers.
                    <SU>180</SU>
                    <FTREF/>
                     Additionally, it is appropriate to allow the U.S. Treasury market to adjust to the implementation of the Treasury Clearing Rules (
                    <E T="03">e.g.,</E>
                     the Account Segregation Proposals) before determining that additional access models are needed.
                    <SU>181</SU>
                    <FTREF/>
                     For the foregoing reasons, FICC need not impose a done-away clearing mandate on Netting Member intermediaries in order to comply with Rule 17ad-22(e)(18)(iv)(C).
                    <SU>182</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>178</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 7, note 14 and accompanying text (highlighting that although the bulk of current done-away transactions are cash transactions cleared through the correspondent clearing/prime broker clearing models, nearly 10 percent of FICC's Sponsoring Members currently clear done-away repo transactions through the Sponsored Service).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>179</SU>
                         
                        <E T="03">See</E>
                         Adopting Release at 2756-57, 
                        <E T="03">supra</E>
                         note 14.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>180</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 11-15; SIFMA Letter II at 3-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>181</SU>
                         
                        <E T="03">See</E>
                         Adopting Release at 2756-57, 
                        <E T="03">supra</E>
                         note 14.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>182</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <P>
                    Several commenters state that FICC should explain how its proposal to re-brand the Agent Clearing Service would actually facilitate done-away 
                    <PRTPAGE P="93796"/>
                    clearing.
                    <SU>183</SU>
                    <FTREF/>
                     Two commenters state the re-branding and making conforming, technical amendments to the Agent Clearing Service are non-substantive and “superficial” and would not increase the availability of done-away trading.
                    <SU>184</SU>
                    <FTREF/>
                     One commenter states that there is not a significant amount of repo activity conducted through the current correspondent clearing/prime broker clearing services.
                    <SU>185</SU>
                    <FTREF/>
                     The commenter further questions why that would change after the services are re-branded as the Agent Clearing Service.
                    <SU>186</SU>
                    <FTREF/>
                     In response, FICC states that its survey results demonstrate that prior to publication of the Notice of Filing, 77 percent of market participants were not very familiar with the correspondent clearing/prime brokerage services, and that lack of familiarity is likely the reason for the relatively low level of use of those GSD access models.
                    <SU>187</SU>
                    <FTREF/>
                     FICC states that after publication of the Notice of Filing, its survey results indicate that 43 percent of Netting Members would likely clear indirect participant transactions through the Agent Clearing Service.
                    <SU>188</SU>
                    <FTREF/>
                     FICC attributes the shift among participants towards considering using the Agent Clearing Service is a result of the Proposed Rule Change's clarifications and consolidations regarding the Agent Clearing Service.
                    <SU>189</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>183</SU>
                         
                        <E T="03">See</E>
                         SIFMA-AMG Letter at 2, 4-5; ICI Letter at 2, 4-5; MFA Letter I at 3-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>184</SU>
                         
                        <E T="03">See</E>
                         SIFMA-AMG Letter at 2, 4-5; ICI Letter at 2, 4-5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>185</SU>
                         
                        <E T="03">See</E>
                         MFA Letter I at 3-4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>186</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>187</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 8.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>188</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>189</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    The Proposed Rule Change sufficiently explains how the Agent Clearing Service would work and how it could facilitate done-away clearing. Further explanation is unnecessary for purposes of considering the Proposed Rule Change, and each market participant has to determine which access model to use for its own business purposes. However, the Commission observes that FICC has engaged in market outreach to assist market participants in evaluating and understanding the operations and business case for each access model.
                    <SU>190</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>190</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 4; 
                        <E T="03">see generally</E>
                         FICC's U.S. Treasury Clearing information website, 
                        <E T="03">available at https://www.dtcc.com/ustclearing</E>
                         (
                        <E T="03">e.g.,</E>
                         the “Access Central Clearing” tab, which provides resources for direct and indirect participants to understand and evaluate each GSD access model, including explanations of recommended access models for specific types of market participants).
                    </P>
                </FTNT>
                <P>
                    Several commenters raise the concern that even if a Netting Member intermediary offers done-away clearing services, customers would be required to disclose the identity of their execution counterparties to the intermediary.
                    <SU>191</SU>
                    <FTREF/>
                     One commenter states that requiring the disclosure of execution counterparties to the Netting Member intermediary divulges confidential information regarding the customer's trading activities and could lead to limitations placed on those execution counterparties, directly undermining a key benefit of central clearing.
                    <SU>192</SU>
                    <FTREF/>
                     Another commenter states that in a cleared market, the identity of a customer's original execution counterparty should be irrelevant to a clearing member because the clearing member is not exposed to the creditworthiness of the execution counterparty, meaning that a clearing member should not be in a position to limit a customer's execution counterparties.
                    <SU>193</SU>
                    <FTREF/>
                     This commenter also states that this concern is why the Commodity Futures Trading Commission specifically prohibited “the type of trilateral execution agreement described by FICC.” 
                    <SU>194</SU>
                    <FTREF/>
                     Therefore, commenters state, FICC should enable customers to avoid disclosing the identity of their execution counterparties to their Netting Member intermediaries and prohibit the restriction of execution counterparties.
                    <SU>195</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>191</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 7-8; MFA Letter I at 4-5; FIA-PTG II at 3; Citadel Letter at 4-5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>192</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 7-8.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>193</SU>
                         
                        <E T="03">See</E>
                         Citadel Letter at 4-5; 
                        <E T="03">see also</E>
                         Letter from Joanna Mallers, Secretary, Futures Industry of America, Principal Traders Group (Oct. 11, 2024) (“FIA-PTG Letter II”) at 3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>194</SU>
                         
                        <E T="03">See</E>
                         Citadel Letter at 5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>195</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 7-8; MFA Letter I at 4-5.
                    </P>
                </FTNT>
                <P>
                    FICC states that it is currently not practically feasible to prohibit a direct participant from knowing the execution counterparty's identity because there is no mechanism in the U.S. Treasury market available for someone other than a direct participant to submit transactions and counterparty information to FICC.
                    <SU>196</SU>
                    <FTREF/>
                     Regarding the concerns that disclosure of the identity of a customer's execution counterparty could result in the Netting Member intermediary placing limitations on the execution counterparty, FICC states that Netting Member intermediaries may, in certain cases, have legitimate reasons to know or limit a customer's execution counterparties.
                    <SU>197</SU>
                    <FTREF/>
                     For example, FICC states that a Netting Member may need to confirm that a customer's proposed execution counterparty has an execution or similar agreement in place with the Netting Member and that the execution counterparty has performed any obligations set forth in that agreement.
                    <SU>198</SU>
                    <FTREF/>
                     FICC also states that Netting Members may also need to know the identity of a customer's execution counterparty to assess certain risks, such as potential CCLF requirements.
                    <SU>199</SU>
                    <FTREF/>
                     FICC states that whether and how a Netting Member intermediary may restrict execution counterparties are matters that should be commercially negotiated between the intermediary and its customers, rather than dictated by FICC in the GSD Rules.
                    <SU>200</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>196</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 16. FICC states that in other markets (
                        <E T="03">e.g.,</E>
                         the U.S. markets for equity securities and cleared derivatives), there are execution facilities or affirmation platforms that provide post-trade settlement market infrastructure with counterparty information. However, in the U.S. Treasury market, such facilities or platforms are not predominant or do not currently offer similar services. 
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>197</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 17.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>198</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>199</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>200</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    The Commission acknowledges that a customer may not wish to disclose the identity of its execution counterparty to its Netting Member intermediary. Although the commenters state that FICC should enable anonymous execution, such anonymous execution is not yet possible considering the current market infrastructure. Therefore, FICC need not require Netting Member intermediaries to provide for anonymous execution in order for the Proposed Rule Change to be consistent with Rule 17ad-22(e)(18)(iv)(C).
                    <SU>201</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>201</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <P>
                    In addition, regarding the concern that a Netting Member intermediary could restrict the execution counterparty, FICC's response that a Netting Member intermediary might have legitimate reasons to know the identity and restrict execution counterparties supports the suggestion that such matters should be negotiated bilaterally between customers and their Netting Members intermediaries.
                    <SU>202</SU>
                    <FTREF/>
                     However, regarding potential liquidity risk arising from done-away transactions, the Commission understands that the existence of exposure arising from a done-away transaction, and not necessarily the execution counterparty to that exposure, could have an effect on the Netting Member's liquidity obligations to FICC in the event of a member default. The Commission would not view the 
                    <PRTPAGE P="93797"/>
                    identity of the execution counterparty as relevant to the potential liquidity risk arising from that transaction. Moreover, the Commission disagrees that FICC's statements regarding confirming that a proposed execution counterparty has an execution or similar agreement in place with the Netting Member equates to the types of trilateral agreements prohibited by the CFTC.
                    <SU>203</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>202</SU>
                         In addition, the Commission understands that, to the extent that a market participant is transacting on an inter-dealer broker or similar platform, the execution counterparty to the transaction would be the inter-dealer broker or platform, not the other market participant that was brought together on the platform and also had a transaction with the inter-dealer broker or platform.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>203</SU>
                         Such agreements incorporated optional annexes that make the clearing member to one or both of the executing parties a party to the agreement. These trilateral agreements contain provisions that would permit a customer's FCM, in consultation with the swap dealer (“SD”) that is the customer's counterparty, to establish specific credit limits for the customer's swap transactions with the SD, and that the FCM will only accept for clearing those transactions that fall within these specific limits. The limits set for trades with the SD or MSP might be less than the overall limits set for the customer for all trades cleared through the FCM. CFTC, Customer Clearing Documentation, Timing of Acceptance for Clearing, and Clearing Member Risk Management, 77 FR 21278, 21279 (Apr. 9, 2012).
                    </P>
                </FTNT>
                <P>
                    One commenter asked why the Agent Clearing Service cannot be used for “brokered transactions” or GCF repo transactions.
                    <SU>204</SU>
                    <FTREF/>
                     The commenter also states that for Treasury cash transactions executed by inter-dealer brokers, there would appear to be no way to comply with the Treasury Clearing Rules via customer clearing, as the execution counterparty does not offer customer clearing services and therefore another clearing member must accept these trades via a done-away offering.
                    <SU>205</SU>
                    <FTREF/>
                     In response, FICC states that, with respect to general collateral repo transactions, FICC would not be able to clear such transactions through the proposed Agent Clearing Service, but it states that it is considering developing such capabilities based on feedback from market participants.
                    <SU>206</SU>
                    <FTREF/>
                     With respect to brokered transactions, FICC states that it would not be appropriate for transactions cleared through the proposed Agent Clearing Service to be treated as “Brokered Transactions” under the GSD Rules because Brokered Transactions are designed to capture certain transactions that present lower risk than other cleared transactions.
                    <SU>207</SU>
                    <FTREF/>
                     Moreover, the Account Segregation Proposals 
                    <SU>208</SU>
                    <FTREF/>
                     would modify the GSD Rules regarding Brokered Transactions, further clarifying the unique treatment of Brokered Transactions due to the limited risk they present to FICC.
                    <SU>209</SU>
                    <FTREF/>
                     The current GSD Rules cap the amount of loss allocation that may be applied to Inter-Dealer Broker Netting Members and Non-IDB Repo Brokers submitting Brokered Transactions.
                    <SU>210</SU>
                    <FTREF/>
                     The Account Segregation Proposals would revise the definition of Brokered Transactions to only include the side of the transactions submitted to FICC for novation by an Inter-Dealer Broker Netting Member and entered into on the Inter-Dealer Broker Netting Member's own trading platform.
                    <SU>211</SU>
                    <FTREF/>
                     As a result, the favorable loss allocation treatment for Brokered Transactions would only apply to the transactions that present limited risk since an Inter-Dealer Broker is standing in between two counterparties in those transactions and is therefore completely flat.
                    <SU>212</SU>
                    <FTREF/>
                     Since the favorable loss allocation treatment is only appropriate for Inter-Dealer Broker Netting Members submitting Brokered Transactions, the Account Segregation Proposals would delete the term “Non IDB Repo Broker” from the GSD Rules.
                    <SU>213</SU>
                    <FTREF/>
                     Additionally, the concurrently approved Account Segregation Proposals would provide that transactions entered into on an Inter-Dealer Broker Netting Member's trading platform or similar platform may be cleared using the Sponsored Service or the Agent Clearing Service, which addresses the commenter's concern.
                    <SU>214</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>204</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 7.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>205</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 3; FIA-PTG Letter II at 3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>206</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 22.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>207</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 22-23.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>208</SU>
                         
                        <E T="03">See</E>
                         Account Segregation Proposals, 
                        <E T="03">supra</E>
                         note 85.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>209</SU>
                         
                        <E T="03">See</E>
                         Account Segregation Proposals, 
                        <E T="03">supra</E>
                         note 85, 89 FR at 87451.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>210</SU>
                         
                        <E T="03">See</E>
                         GSD Rule 4, Section 6, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>211</SU>
                         
                        <E T="03">See</E>
                         Account Segregation Proposals, 
                        <E T="03">supra</E>
                         note 85, 89 FR at 87451.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>212</SU>
                         
                        <E T="03">See</E>
                         Account Segregation Proposals, 
                        <E T="03">supra</E>
                         note 85, 89 FR at 21598.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>213</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>214</SU>
                         
                        <E T="03">See</E>
                         Account Segregation Proposals, 
                        <E T="03">supra</E>
                         note 85, 89 FR at 87451; 
                        <E T="03">see also</E>
                         FICC Letter at 22-23.
                    </P>
                </FTNT>
                <P>
                    In response to the comments regarding transactions executed on an inter-dealer broker or similar platform, the Commission agrees that, as FICC represented,
                    <SU>215</SU>
                    <FTREF/>
                     such transactions could be submitted through the Agent Clearing Service.
                </P>
                <FTNT>
                    <P>
                        <SU>215</SU>
                         
                        <E T="03">See</E>
                         Account Segregation Proposals, 
                        <E T="03">supra</E>
                         note 85; FICC Letter at 23.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">3. Changes to the Sponsored Service</HD>
                <P>
                    As described above in Section I.B.2., FICC also proposes to update certain membership standards in the GSD Rules regarding the Sponsored Service. First, FICC proposes to eliminate the two categories of Sponsoring Members, and instead, make all Sponsoring Members subject to the same eligibility and ongoing requirements that are currently applicable to Category 2 Sponsoring Members. These proposed changes would remove the capitalization requirements on Bank Netting Members from the current GSD Rules, and instead apply the activity limits and financial condition factors used under the current GSD Rules for Category 2 Sponsoring Members. These proposed changes would create parity among all Sponsoring Members (and applicants), thereby encouraging additional market participants to become Sponsoring Members, which in turn should give indirect participants a wider range of Sponsoring Members to consider should they choose to access GSD's central clearing services via the Sponsored Service.
                    <SU>216</SU>
                    <FTREF/>
                     Second, FICC proposes to remove the QIB Requirement for Sponsored Members, which would make the Sponsored Service available to additional market participants (
                    <E T="03">i.e.,</E>
                     those unable to meet the QIB Requirement).
                    <SU>217</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>216</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, 89 FR at 21370.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>217</SU>
                         One commenter expressed support for FICC's proposal to eliminate the QIB Requirement. 
                        <E T="03">See</E>
                         ICI Letter at 5. No other commenter addressed this particular change or any other changes to the Sponsored Service.
                    </P>
                </FTNT>
                <P>
                    Therefore, the proposed changes to the GSD Rules to (1) consolidate the Sponsoring Member categories, and (2) eliminate the QIB Requirement for Sponsored Members, constitute criteria for participation that facilitate access to GSD's clearance and settlement services, including for indirect participants, are consistent with Rule 17ad-22(e)(18)(iv)(C), because the proposed changes would expand the availability of the Sponsored Service to a broader range of market participants.
                    <SU>218</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>218</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">4. Changes to Eligibility Criteria for Non-U.S. and Other Applicants</HD>
                <P>As described above in Section I.B.2., FICC proposes to clarify the eligibility criteria for non-U.S. Netting Member applicants. Whereas the current GSD Rules are unclear as to whether a non-U.S. applicant entity would only be subject to the Foreign Netting Member standards or would also be subject to the legal entity standards, FICC proposes to streamline the relevant membership categories by eliminating the category of “Foreign Netting Member” and expanding the qualifications for each category of Netting Member to include the foreign equivalent of the same legal entity types. Additionally, FICC proposes to clarify the eligibility criteria for applicants (including non-U.S. entities) that do not fit into one of the existing Netting Member categories.</P>
                <P>
                    Following the adoption of the Treasury Clearing Rules, additional market participants will need to access FICC's clearance and settlement services, either as direct Netting Members or as indirect participants. 
                    <PRTPAGE P="93798"/>
                    Whereas the current GSD Rules do not provide FICC with the authority to consider a Netting Member applicant that does not meet the eligibility criteria of one of the Netting Member categories enumerated in the GSD Rules, the proposed changes, as described in Section I.B.2, would provide a framework for FICC to consider such other applicants. FICC designed the proposed changes regarding non-U.S. and other applicants to facilitate access to GSD's clearing services to a broader range of market participants.
                    <SU>219</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>219</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, at 89 FR 21373.
                    </P>
                </FTNT>
                <P>
                    The proposed changes to the GSD Rules to clarify the eligibility criteria for non-U.S. Netting Member applicants and applicants that do not fit into one of the existing Netting Member categories, are consistent with Rule 17ad-22(e)(18)(iv)(C), because the proposed changes would expand the availability of GSD's clearing services to a broader range of market participants.
                    <SU>220</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>220</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">5. Changes To Clarify the GSD Access Models</HD>
                <P>
                    As described above in Section I.B.3., FICC proposes to include a “road map” in the GSD Rules describing the various GSD access models that allow for both direct and indirect access to GSD's clearance and settlement services. FICC also proposes to simplify the GSD Rule definitions regarding the different types of membership and other related definitions.
                    <SU>221</SU>
                    <FTREF/>
                     FICC states that these proposed changes would enhance the ability of market participants to better understand and evaluate the comparative tradeoffs between GSD's different access models.
                    <SU>222</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>221</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, 89 FR at 21374.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>222</SU>
                         
                        <E T="03">See</E>
                         Notice of Filing, 
                        <E T="03">supra</E>
                         note 5, 89 FR at 21373-74.
                    </P>
                </FTNT>
                <P>
                    Several commenters request that FICC provide further clarity regarding the GSD access models.
                    <SU>223</SU>
                    <FTREF/>
                     Specifically, commenters request that FICC explain the expected use cases for each of the GSD access models to enable market participants to better evaluate the relative benefits of each access model by understanding the substantive differences between them.
                    <SU>224</SU>
                    <FTREF/>
                     One commenter states that FICC should eliminate any access model that it cannot justify with a use case.
                    <SU>225</SU>
                    <FTREF/>
                     One commenter states that although the availability of multiple access models may provide flexibility to market participants, it could also introduce unnecessary complexity and confusion.
                    <SU>226</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>223</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 6-8; ISDA Letter I at 8; MFA Letter I at 6; AIMA Letter at 5-6; SIFMA-AMG Letter at 3, 11-12; ISDA Letter II at 2-3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>224</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>225</SU>
                         
                        <E T="03">See</E>
                         MFA Letter I at 7.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>226</SU>
                         
                        <E T="03">See</E>
                         MFA Letter I at 6; FIA-PTG Letter I at 4. For example, with a greater number of access models, a direct participant's service offerings and pricing might not be readily apparent to indirect participants. 
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    FICC states that it developed four indirect access models (
                    <E T="03">i.e.,</E>
                     the Sponsored Service and Agent Clearing Service, each with either segregated or non-segregated margin) after engagement with market participants to ensure a diverse array of models through which market participants can access central clearing.
                    <SU>227</SU>
                    <FTREF/>
                     In response to the comments requesting further clarity and challenging the need for each of the proposed access models, FICC describes some of the possible use cases and advantages of each of the four access models.
                    <SU>228</SU>
                    <FTREF/>
                     Specifically, FICC states that market participants might prefer the Agent Clearing Service due to its conceptual and operational similarity to an FCM-style cleared derivatives model, enabling market participants to leverage their existing legal analyses, structures, policies, and procedures to clear transactions in U.S. Treasury securities.
                    <SU>229</SU>
                    <FTREF/>
                     Additionally, due to the greater intermediation of the Agent Clearing Service, a Netting Member intermediary would be able to utilize a “financial asset” election to perfect its security interest in cleared transactions without having to file a Uniform Commercial Code financing statement, potentially reducing cost, risk, and publicity.
                    <SU>230</SU>
                    <FTREF/>
                     Moreover, in comparison to the Sponsored Service, the Agent Clearing Service would involve a simpler onboarding process, would not require privity of contract between indirect participants and FICC, and would not impose the same jurisdictional requirements on indirect participants.
                    <SU>231</SU>
                    <FTREF/>
                     On the other hand, FICC highlights potential advantages to the Sponsored Service, including being in a direct contractual relationship with FICC.
                    <SU>232</SU>
                    <FTREF/>
                     FICC also states that Netting Members have existing clearing agreements with many customers for the Sponsored Service without segregation and could continue to utilize their existing agreements.
                    <SU>233</SU>
                    <FTREF/>
                     Additionally, since the Sponsored Service has existed for nearly two decades, FICC states that market participants have achieved a certain level of confidence regarding the Sponsored Service's treatment for legal, regulatory, accounting, and other purposes.
                    <SU>234</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>227</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 18, 20.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>228</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 50-51.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>229</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 20, 50-51.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>230</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 19, 50-51.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>231</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 19-20, 50-51.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>232</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 50-51.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>233</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>234</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 20, 50-51.
                    </P>
                </FTNT>
                <P>
                    Publication of “use cases” or justifications are not required for a proposed rule change to be consistent with Rule 17ad-22(e)(18)(iv)(C), which requires only that a covered clearing agency have written policies and procedures reasonably designed to ensure appropriate access to its clearing and settlement services, including for indirect participants. Further, the decision of which access model to use is for each individual market participant to determine, as each market participant has different regulatory obligations, business strategies, ownership models, etc. Nevertheless, FICC's description of the reasons for each of its four access models is sound and clearly identifies potential advantages and disadvantages of each model for market participants to consider.
                    <SU>235</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>235</SU>
                         The Commission also understands that FICC has engaged in outreach and education efforts to further explain the different features of each model. 
                        <E T="03">See generally</E>
                         FICC's U.S. Treasury Clearing information website, 
                        <E T="03">available at https://www.dtcc.com/ustclearing</E>
                         (
                        <E T="03">e.g.,</E>
                         the “Access Central Clearing” tab, which provides resources for direct and indirect participants to understand and evaluate each GSD access model, including explanations of recommended access models for specific types of market participants).
                    </P>
                </FTNT>
                <P>
                    In addition, several commenters questioned the decision to offer both segregated and non-segregated accounts in both the Sponsored Service and Agent Clearing Service. Specifically, one commenter requests that FICC explain the benefits of the access models insofar as they allow for omnibus (
                    <E T="03">i.e.,</E>
                     non-segregated) margin submission.
                    <SU>236</SU>
                    <FTREF/>
                     Another commenter questioned whether both the Sponsored Service and Agent Clearing Service should offer segregated models.
                    <SU>237</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>236</SU>
                         
                        <E T="03">See</E>
                         SIFMA-AMG Letter at 11-12.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>237</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter at 4.
                    </P>
                </FTNT>
                <P>
                    In response, FICC explains potential advantages regarding margin segregation options (
                    <E T="03">i.e.,</E>
                     to explain why the GSD access models allow for both segregated and non-segregated, or omnibus, margin submission).
                    <SU>238</SU>
                    <FTREF/>
                     Specifically, within the Agent Clearing Service, if margin is not segregated, Clearing Fund requirements for customer transactions would be calculated on a net basis across all Executing Firm Customers whose transactions are recorded within the same account, resulting in aggregate margin obligations that are substantially lower than under the Sponsored 
                    <PRTPAGE P="93799"/>
                    Service.
                    <SU>239</SU>
                    <FTREF/>
                     If margin is segregated, Agent Clearing Members would not bear the costs of financing margin obligations for customer positions—a cost saving that could be passed on to customers without exposing customers to FICC, fellow customer, or Netting Member risk.
                    <SU>240</SU>
                    <FTREF/>
                     Regarding the Sponsored Service, FICC states that many customers have clearing agreements in place that already provide for non-segregated margin.
                    <SU>241</SU>
                    <FTREF/>
                     By continuing to allow non-segregated margin within the Sponsored Service, FICC would enable such customers to maintain their existing clearing agreements and associated processes.
                    <SU>242</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>238</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 50-51.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>239</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>240</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>241</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>242</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>FICC's explanation of the potential reasons why a customer may want to be able to pursue the various options of segregation within both models is sound. Each market participant will have to evaluate the advantages and drawbacks of each option and determine what works best for its own business. The existence of both segregated and omnibus options for both the Agent Clearing and Sponsored Services is consistent with Rule 17ad-22(e)(18)(iv)(C), which requires only that a covered clearing agency have written policies and procedures reasonably designed to ensure appropriate access to its clearing and settlement services, including for indirect participants.</P>
                <P>
                    For these reasons, FICC's proposals to include a “road map” describing the various GSD access models and to simplify the definitions regarding GSD membership would, among other things, provide clarity in the GSD Rules regarding the models that direct and indirect participants may use to access GSD's clearance and settlement services. The proposed changes would enable market participants to better understand and evaluate the various GSD access models for clearing transactions in U.S. Treasury securities. Therefore, the proposed changes would constitute criteria for participation that facilitate access to GSD's clearance and settlement services, including for indirect participants, consistent with Rule 17ad-22(e)(18)(iv)(C).
                    <SU>243</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>243</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <P>
                    Additionally, one commenter states that FICC should require Netting Member intermediaries to allow their customers to choose whether to access clearing through the Sponsored Service or the Agent Clearing Service.
                    <SU>244</SU>
                    <FTREF/>
                     The same commenter further states that that margin segregation should be automatic for any Sponsored Member that posts its own margin.
                    <SU>245</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>244</SU>
                         
                        <E T="03">See</E>
                         MFA Letter I at 7.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>245</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    In response, FICC states that the best way to facilitate access to clearing is to enable direct and indirect participants to select the access method and associated terms that are most consistent with their commercial, regulatory, risk, operational, and legal considerations. Moreover, FICC states that mandating that Netting Members offer a particular service or clearing model could be inconsistent with Section 17A(b)(3)(E) of the Exchange Act, which prohibits a clearing agency from imposing any schedule of prices, or fix rates or other fees for its participants' services.
                    <SU>246</SU>
                    <FTREF/>
                     In response to the comment regarding automatic margin segregation within the Sponsored Service, FICC states that margin segregation should not be automatic for Sponsored Members that post their own margin, because there are scenarios in which market participants may prefer the flexibility of choosing non-segregated margin even when a Sponsored Member posts its own margin.
                    <SU>247</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>246</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 32-33; 15 U.S.C. 78q-1(b)(3)(E).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>247</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 21-22.
                    </P>
                </FTNT>
                <P>
                    The Proposed Rule Change does not include a requirement that FICC's Netting Members offer their customers a choice of what access model to use. The Commission shall approve a proposed rule change of a self-regulatory organization if it finds that it is consistent with the Act,
                    <SU>248</SU>
                    <FTREF/>
                     and the lack of a requirement that each Netting Member give its customers the choice of which access model to use is not inconsistent with the Act.
                </P>
                <FTNT>
                    <P>
                        <SU>248</SU>
                         
                        <E T="03">See</E>
                         15 U.S.C. 78s(b)(2)(C)(i).
                    </P>
                </FTNT>
                <P>
                    One commenter raises concerns as to whether FICC has the operational capability to onboard and account for the large number of new accounts that would need to be established to support the increased volume of clearing activity that would arise from FICC's implementation of its requirements pursuant to the Treasury Clearing Rules.
                    <SU>249</SU>
                    <FTREF/>
                     Specifically, the commenter states that that FICC would need to establish and maintain a large number of new accounts because each Agent Clearing Member would need to set up an individual account at FICC for each indirect participant for which the Agent Clearing Member would segregate margin.
                    <SU>250</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>249</SU>
                         
                        <E T="03">See</E>
                         SIFMA-AMG Letter at 12.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>250</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    In response, FICC states it proposed each access model after confirming that FICC has the ability, from a legal, operational, risk, regulatory, and commercial perspective, to provide such a model.
                    <SU>251</SU>
                    <FTREF/>
                     Regarding individual accounts, FICC states that neither the Sponsored Service nor the Agent Clearing Service would necessitate individual accounts for each customer.
                    <SU>252</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>251</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 22.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>252</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    The Commission agrees that neither the Proposed Rule Change nor FICC's implementation of its other requirements pursuant to the Treasury Clearing Rules would require FICC to establish and maintain accounts for each indirect participant.
                    <SU>253</SU>
                    <FTREF/>
                     Moreover, in its supervisory capacity regarding FICC, the Commission routinely and regularly receives data, reports, and other information regarding FICC's clearance and settlement activities, including FICC's operational capabilities. Based on the Commission's supervisory knowledge, FICC has the requisite operational capacity to offer the access models that it has proposed.
                    <SU>254</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>253</SU>
                         
                        <E T="03">See https://www.dtcc.com/-/media/Files/Downloads/Microsites/Treasury-Clearing/FICC-Treasury-Clearing-Client-Impact-Roadmap.pdf.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>254</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <P>
                    One commenter raised concerns regarding the inability of FCMs to utilize the GSD access models.
                    <SU>255</SU>
                    <FTREF/>
                     Specifically, the commenter states that certain regulatory requirements to which FCMs are subject would conflict with FCMs participating in both the Sponsored Service and Agent Clearing Service.
                    <SU>256</SU>
                    <FTREF/>
                     The commenter urges FICC 
                    <PRTPAGE P="93800"/>
                    to allow Netting Members to maintain sub-accounts for futures customer funds, cleared swaps customer funds, and foreign futures customer funds that comply with CFTC requirements.
                    <SU>257</SU>
                    <FTREF/>
                     Additionally, the commenter states that FCMs are currently seeking relief from the CFTC to recognize FICC as an acceptable counterparty and otherwise align the GSD access models with CFTC requirements.
                    <SU>258</SU>
                    <FTREF/>
                     In the interim, the commenter requests that FICC apply to FCMs certain GSD Rules that would exempt a Netting Member's Covered Affiliate from submitting trades to FICC if the obligation to submit the trade would cause a violation of any applicable law, rule, or regulation.
                    <SU>259</SU>
                    <FTREF/>
                     The commenter further requests that FICC work with FCMs and the CFTC to develop alternative CFTC-compliant access models.
                    <SU>260</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>255</SU>
                         
                        <E T="03">See</E>
                         Letter from Walt L. Lukken, President and Chief Executive Officer, Futures Industry of America (April 18, 2024) (“FIA Letter”) at 2-12. On July 1, 2024, FICC filed a separate proposed rule change that would, among other things, require each Netting Member to submit for central clearing all eligible secondary market transactions in U.S. Treasury securities to which it is a counterparty. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 100417 (June 25, 2024), 89 FR 54602 (July 1, 2024) (SR-FICC-2024-009) (“Trade Submission Proposal”). The Commission notes that the FIA Letter includes a request for relief from the clearing requirement in the Trade Submission Proposal. 
                        <E T="03">See</E>
                         FIA Letter at 2-3. The commenter appropriately submitted a separate comment letter in response to the Trade Submission Proposal requesting similar relief, and the Commission will address the comment when adjudicating the Trade Submission Proposal. However, the commenter's request is outside the scope of the instant Proposed Rule Change.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>256</SU>
                         
                        <E T="03">See</E>
                         FIA Letter at 4, 7-8 (citing CFTC Regulations regarding acceptable FCM counterparties, delivery-versus-payment and payment-versus-delivery requirements, posting collateral as margin for repos entered into with customer funds, FCM bankruptcy management, FCM repos with affiliates, and FCMs holding customer assets in customer segregated accounts).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>257</SU>
                         
                        <E T="03">See</E>
                         FIA Letter at 8.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>258</SU>
                         
                        <E T="03">See</E>
                         FIA Letter at 2-3, 11.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>259</SU>
                         
                        <E T="03">See</E>
                         FIA Letter at 4-5; GSD Rule 11, Section 3 and GSD Rule 18, Section 2, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>260</SU>
                         
                        <E T="03">See</E>
                         FIA Letter at 5, 8-10.
                    </P>
                </FTNT>
                <P>
                    FICC states that it is open to considering additional access models if necessary to address market participants' regulatory or other needs.
                    <SU>261</SU>
                    <FTREF/>
                     In response to the commenter's request regarding sub-accounts, FICC states that the GSD Rules would allow Netting Members to instruct FICC to establish separate accounts for certain kinds of transactions and to have such accounts constitute separate margin portfolios.
                    <SU>262</SU>
                    <FTREF/>
                     Thus, a Netting Member that enters into transactions using futures, cleared swaps, or foreign futures customer funds could have those transactions recorded in an account that does not net with the Netting Member's other accounts for purposes of calculating margin or funds-only settlement amounts.
                    <SU>263</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>261</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 23.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>262</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>263</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    The commenter specifically seeks relief from the CFTC from certain CFTC regulations, which are not within the Commission's jurisdiction.
                    <SU>264</SU>
                    <FTREF/>
                     The commenter also requests that FICC continue to apply certain GSD Rule provisions that would exempt FCMs from the requirement to submit trades to FICC if such trade submission would cause the FCM to be in violation of any applicable rule, or regulation.
                    <SU>265</SU>
                    <FTREF/>
                     The Commission notes that the GSD Rule provisions cited by the commenter are currently the subject of the Trade Submission Proposal, a separate pending proposed rule change filed by FICC.
                    <SU>266</SU>
                    <FTREF/>
                     Because the commenter's request to be excluded from the trade submission requirement deals with GSD Rule provisions that are subject to change as part of a separate proposed rule change, the Commission is not addressing the comment in the instant Order. For the same reason, the Commission is not addressing the commenter's request to require FICC to apply those GSD Rule provisions that are subject to change as part of a separate proposed rule change.
                    <SU>267</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>264</SU>
                         
                        <E T="03">See</E>
                         FIA Letter at 4-5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>265</SU>
                         
                        <E T="03">See id.;</E>
                         GSD Rule 11, Section 3 and GSD Rule 18, Section 2, 
                        <E T="03">supra</E>
                         note 15.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>266</SU>
                         
                        <E T="03">See</E>
                         Trade Submission Proposal, 
                        <E T="03">supra</E>
                         note 257.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>267</SU>
                         
                        <E T="03">See</E>
                         FIA Letter at 11.
                    </P>
                </FTNT>
                <P>
                    Finally, the commenter requests that FICC work with FCMs and the CFTC to develop access models that are more suitable for FCMs than the Agent Clearing Service.
                    <SU>268</SU>
                    <FTREF/>
                     As mentioned above, FICC states that it is open to considering additional access models if necessary to address market participants' regulatory or other needs.
                    <SU>269</SU>
                    <FTREF/>
                     Additionally, FICC states that it continues to actively engage with the FCM community to resolve outstanding issues regarding the GSD access models.
                    <SU>270</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>268</SU>
                         
                        <E T="03">See</E>
                         FIA Letter at 4-5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>269</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 23.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>270</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 23-24.
                    </P>
                </FTNT>
                <P>
                    One commenter requests that FICC confirm that a bank's branches and Netting Member's affiliates can establish a separate margin portfolio within the Netting Member's account that would be separately netted and margined, such that they would not have to establish indirect access to FICC.
                    <SU>271</SU>
                    <FTREF/>
                     Because the commenter's request relates directly to GSD Rule provisions that are subject to change as part of the Trade Submission Proposal, a separate pending proposed rule change filed by FICC,
                    <SU>272</SU>
                    <FTREF/>
                     the Commission is not addressing the comment in the instant Order.
                </P>
                <FTNT>
                    <P>
                        <SU>271</SU>
                         
                        <E T="03">See</E>
                         ISDA Letter I at 6-7; ISDA Letter II at 5.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>272</SU>
                         
                        <E T="03">See</E>
                         Trade Submission Proposal, 
                        <E T="03">supra</E>
                         note 257, at 89 FR 54605.
                    </P>
                </FTNT>
                <HD SOURCE="HD3">6. Comments Regarding Default Within the Client Clearing Models</HD>
                <P>Commenters raised several issues related to how FICC should address certain aspects of default within the Agent Clearing and Sponsored Services.</P>
                <P>
                    One commenter states that FICC should allow indirect participants to close out their positions with a defaulting Sponsoring Member or Agent Clearing Member.
                    <SU>273</SU>
                    <FTREF/>
                     For example, the commenter states that under the current GSD Rules, the process for closing out indirect participants' trade positions under the Sponsored Service is driven entirely by FICC, with indirect participants having no “say” in whether their positions are closed out, meaning that the customer may need to continue to rely on an insolvent (or near insolvent) Netting Member to make or receive payments on its behalf.
                    <SU>274</SU>
                    <FTREF/>
                     This commenter also states that FICC should clearly address Executing Firm Customers close-out rights in the event of the default of their Agent Clearing Member.
                    <SU>275</SU>
                    <FTREF/>
                     Alternatively, the commenter states that in the event of such a default, customers should be able to elect to receive payment directly from FICC, with FICC using any customer funds held at FICC to satisfy such amounts owed.
                    <SU>276</SU>
                    <FTREF/>
                     Similarly, an additional commenter states that the GSD Rules should address the situation of a FICC default simultaneous with a Sponsoring Member default, suggesting that Sponsored Members should have the ability to promptly close out and manage its positions.
                    <SU>277</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>273</SU>
                         
                        <E T="03">See</E>
                         SIFMA-AMG Letter at 2, 6, 11.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>274</SU>
                         
                        <E T="03">See</E>
                         SIFMA-AMG Letter at 7.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>275</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>276</SU>
                         
                        <E T="03">See</E>
                         SIFMA-AMG Letter at 2, 6, 11.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>277</SU>
                         
                        <E T="03">See</E>
                         ICI Letter at 14.
                    </P>
                </FTNT>
                <P>
                    In response, FICC states that it was not aware of any such U.S. CCP that provides either for customers to have the ability to direct the CCP to terminate trades or to make payments directly to the customer, but that, instead, CCPs interface directly with clearing members, as agents for their customers consistent with the framework of an intermediated clearing arrangement.
                    <SU>278</SU>
                    <FTREF/>
                     FICC further states that, from a risk perspective, it important to FICC to interface with Netting Members as agents for their customers because Netting Members are subject to comprehensive operational requirements and testing that are designed to ensure that they have the capability to perform and to receive performance from FICC and that such performance will not expose FICC to operational risks (
                    <E T="03">e.g.,</E>
                     systems failures and viruses).
                    <SU>279</SU>
                    <FTREF/>
                     FICC states that because customers are not subject to such requirements, FICC cannot establish interoperability without exposing itself, its participants, and the broader market to significant operational risk.
                    <SU>280</SU>
                    <FTREF/>
                     FICC also states that imposition of operational standards to customers would be quite burdensome, if not infeasible, for many customers, and that such burdens would likely outweigh any benefits of establishing interoperability with customers, because in a Netting Member default scenario, FICC would generally 
                    <PRTPAGE P="93801"/>
                    close out trades or settle through the trustee or receiver of the defaulting member and applicable insolvency law would likely prohibit FICC from engaging directly with customers.
                    <SU>281</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>278</SU>
                         FICC Letter at 27.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>279</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>280</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>281</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    The Proposed Rule Change does not include these types of close-out provisions for indirect participants that the commenter seeks. The Commission shall approve a proposed rule change of a self-regulatory organization if it finds that it is consistent with the Act,
                    <SU>282</SU>
                    <FTREF/>
                     and the lack of such close-out provisions is not inconsistent with the Act.
                </P>
                <FTNT>
                    <P>
                        <SU>282</SU>
                         
                        <E T="03">See</E>
                         15 U.S.C. 78s(b)(2)(C)(i).
                    </P>
                </FTNT>
                <P>
                    One commenter requests that FICC clarify the differences in the GSD Rules between the Sponsored Service and Agent Clearing Service governing a default of the Sponsoring Member or Agent Clearing Member.
                    <SU>283</SU>
                    <FTREF/>
                     The commenter states that the Proposed Rule Change suggests that customer positions will always be closed-out under the Agent Clearing Service, whereas FICC may elect to continue to settle customer positions under the Sponsored Service in the event of a Netting Member default.
                    <SU>284</SU>
                    <FTREF/>
                     FICC agrees with the commenter's suggestion that FICC should have the opportunity to settle the outstanding cleared transactions that a defaulting Agent Clearing Member has cleared through the Agent Clearing Service.
                    <SU>285</SU>
                    <FTREF/>
                     FICC states that, as a general matter, settlement may in many instances be the most effective and customer-protective way to address a member default scenario, so long as the receiver or trustee of the defaulting member consents.
                    <SU>286</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>283</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter at 8.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>284</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter at 8; FIA-PTG Letter II at 3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>285</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 25-26.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>286</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 26. FICC further states that it is considering amendments to the Proposed Rule Change that would give FICC the option to effectuate such settlement, but that it would be more efficient to propose such changes after the Commission has considered the Proposed Rule Change, but at the very least before Dec. 31, 2025. 
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    The Proposed Rule Change does not include the ability for FICC to settle the transactions of a defaulting Agent Clearing Member's customers that the commenter seeks. The Commission shall approve a proposed rule change of a self-regulatory organization if it finds that it is consistent with the Act,
                    <SU>287</SU>
                    <FTREF/>
                     and the lack of such close-out provisions is not inconsistent with the Act.
                </P>
                <FTNT>
                    <P>
                        <SU>287</SU>
                         
                        <E T="03">See</E>
                         15 U.S.C. 78s(b)(2)(C)(i).
                    </P>
                </FTNT>
                <P>
                    Some commenters question why the proposed Agent Clearing Service does not include a close-out mechanism regarding a defaulted customer's open positions, which could pose unique risks to an Agent Clearing Member by forcing it to keep a defaulted customer's positions open until the default is resolved.
                    <SU>288</SU>
                    <FTREF/>
                     One commenter further states that FICC may have declined to provide a mechanism for liquidating customer trades because, in contrast to the Sponsored Service, Executing Firm Customers are not members of FICC and therefore a “close out amount” cannot be calculated as between the customer and FICC.
                    <SU>289</SU>
                    <FTREF/>
                     However, this commenter also states that FICC could amend its rulebook to explicitly allow Netting Members to liquidate positions with defaulting customers, with such close-out procedure then addressed in account documentation between the Agent Clearing Member and its Executing Firm Customer.
                    <SU>290</SU>
                    <FTREF/>
                     Several commenters also state that FICC should allow an Agent Clearing Member to liquidate the transactions of a defaulted customer by transferring the positions to its proprietary account or by transferring offsetting positions to its omnibus account.
                    <SU>291</SU>
                    <FTREF/>
                     In addition, one commenter states that FICC should include similar trade liquidation procedures for done-away transactions cleared through the Sponsored Service.
                    <SU>292</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>288</SU>
                         
                        <E T="03">See</E>
                         SIFMA Letter I at 2-3 (stating that FICC should revise the Agent Clearing Service to allow Netting Members to liquidate positions of defaulting indirect participants, consistent with what is available in the Sponsored Service); 
                        <E T="03">see also</E>
                         ISDA Letter I at 2-3 and ISDA Letter II at 4 (similarly discussing the need to close-out positions by transferring them to the proprietary/house account or by transferring offsetting positions to the omnibus account).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>289</SU>
                         
                        <E T="03">See</E>
                         SIFMA Letter I at 3.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>290</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>291</SU>
                         
                        <E T="03">See</E>
                         ISDA Letter I at 2-3 (stating that FICC should provide in the GSD Rules that an Agent Clearing Member may liquidate an Executing Firm Customer's positions by transferring the positions to its proprietary/house account or by transferring positions into the Agent Clearing Member Omnibus Account to flatten open positions of the Executing Firm Customer); ISDA Letter II at 4 (same); FIA Letter at 5, 10 (stating that FICC should incorporate a rule that authorizes an Agent Clearing Member, in connection with liquidating an Executing Firm Customer's open positions upon its default, to cause the Executing Firm Customer's open positions to be transferred from the applicable Agent Clearing Member Omnibus Account and/or transfer to the Agent Clearing Member Omnibus Account transactions that offset or flatten the Executing Firm Customer's open positions); SIFMA Letter I at 2-3 (stating that FICC's proposed rules should permit Netting Members to transfer a defaulting customer's positions to the Netting Member's Proprietary Account or Agent Clearing Member Omnibus Account to flatten open positions of the defaulting Executing Firm Customer).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>292</SU>
                         
                        <E T="03">See</E>
                         ISDA Letter II at 4.
                    </P>
                </FTNT>
                <P>
                    In response, FICC states that the Agent Clearing Service was designed to closely resemble the clearing model used in the futures and cleared swap market, and that such clearing models do not, to FICC's knowledge, prescribe a close-out mechanism for a clearing member to use to close out its customers' trades.
                    <SU>293</SU>
                    <FTREF/>
                     FICC further states that, instead, the clearing models generally leave it to the bilateral agreement between clearing members and their customers to address how such close-out should be effected. FICC also states that it is open to considering steps FICC can take to facilitate the ability of Netting Members to address a customer default situation and to promote legal certainty for both done-away and done-with transactions under the Agent Clearing and Sponsored Services.
                </P>
                <FTNT>
                    <P>
                        <SU>293</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 26.
                    </P>
                </FTNT>
                <P>
                    The Proposed Rule Change does not include these types of close-out provisions that the commenter seeks. However, the Commission shall approve a proposed rule change of a self-regulatory organization if it finds that it is consistent with the Act,
                    <SU>294</SU>
                    <FTREF/>
                     and the lack of such close-out provisions is not inconsistent with the Act.
                </P>
                <FTNT>
                    <P>
                        <SU>294</SU>
                         
                        <E T="03">See</E>
                         15 U.S.C. 78s(b)(2)(C)(i).
                    </P>
                </FTNT>
                <P>
                    Several commenters state that the GSD Rules should provide for a porting mechanism to enable a customer to transfer positions to another Netting Member intermediary for risk management or business-related reasons.
                    <SU>295</SU>
                    <FTREF/>
                     Some commenters highlight that porting mechanisms exist in the cleared futures market as an important risk management tool.
                    <SU>296</SU>
                    <FTREF/>
                     In addition, one commenter states that in the event of a clearing member default, 
                    <E T="03">all</E>
                     non-defaulting customers will want the option to avoid immediately having their positions closed-out by FICC (regardless of whether their original execution counterparty was the clearing member or a third party), through either continuing to settle open positions or porting them to another clearing member.
                    <SU>297</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>295</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 8; ISDA Letter I at 5; MFA Letter I at 6, 8; FIA Letter at 11; SIFMA Letter I at 2, 4; SIFMA-AMG Letter at 2-3; ISDA Letter II at 3-4; FIA-PTG Letter II at 2; MFA Letter II at 7.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>296</SU>
                         
                        <E T="03">See</E>
                         ISDA Letter I at 5 (stating that many cleared futures clients are accustomed to their porting rights and use them as an important risk management tool); ISDA Letter II at 3-4 (stating that the commenting association's members have already come to rely on this type of guardrail in the futures clearing model as an essential risk management tool); MFA Letter I at 6 (stating that porting is an important risk management tool that provides additional certainty to indirect participants, particularly during periods of market stress); SIFMA-AMG Letter at 8 (stating that the ability to port positions is an important feature of the cleared swaps and futures market.).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>297</SU>
                         
                        <E T="03">See</E>
                         Citadel Letter at 5.
                    </P>
                </FTNT>
                <P>
                    In response, FICC states that it intends to propose amendments to the GSD Rules that would add porting provisions similar to those adopted by other U.S. 
                    <PRTPAGE P="93802"/>
                    CCPs, to make clear that porting is possible for FICC-cleared trades.
                    <SU>298</SU>
                    <FTREF/>
                     FICC also states its belief that it will be more efficient to wait until the Commission decides whether to approve or disapprove the Proposed Rule Change before proposing a specific porting framework, and states that it will seek to facilitate porting before December 31, 2025.
                    <SU>299</SU>
                    <FTREF/>
                     FICC also states that any porting framework would need to take into consideration the fact that many FICC-cleared customer transactions are overnight, and that porting may not be practical for such transactions because they will generally settle before the porting can be completed.
                    <SU>300</SU>
                    <FTREF/>
                     FICC further states that the ability to settle (which is currently included in the GSD Rules governing the Sponsored Service) is therefore substantially more important than the ability to port.
                    <SU>301</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>298</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 25.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>299</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>300</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>301</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <P>
                    The Proposed Rule Change does not contain any provisions related to porting customer transactions at FICC. However, the Commission shall approve a proposed rule change of a self-regulatory organization if it finds that it is consistent with the Act,
                    <SU>302</SU>
                    <FTREF/>
                     and the lack of porting provisions is not inconsistent with the Act.
                </P>
                <FTNT>
                    <P>
                        <SU>302</SU>
                         
                        <E T="03">See</E>
                         15 U.S.C. 78s(b)(2)(C)(i).
                    </P>
                </FTNT>
                <P>
                    Accordingly, for the reasons above, the Proposed Rule Change is consistent with Rule 17ad-22(e)(18)(iv)(C).
                    <SU>303</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>303</SU>
                         
                        <E T="03">See</E>
                         17 CFR 240.17ad-22(e)(18)(iv)(C).
                    </P>
                </FTNT>
                <HD SOURCE="HD2">E. Consistency With Rule 17ad-22(e)(23)(ii)</HD>
                <P>
                    Rule 17ad-22(e)(23)(ii) under the Exchange Act requires a covered clearing agency, such as FICC, to establish, implement, maintain, and enforce written policies and procedures reasonably designed to provide sufficient information to enable participants to identify and evaluate the risks, fees, and other material costs they incur by participating in the covered clearing agency.
                    <SU>304</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>304</SU>
                         17 CFR 240.17ad-22(e)(23)(ii).
                    </P>
                </FTNT>
                <P>
                    Several commenters state that FICC should regularly publish statistics regarding the GSD access models, such as the volumes and proportion of transactions cleared through each access model and transactions executed on done-with and done-away bases.
                    <SU>305</SU>
                    <FTREF/>
                     The commenters suggest that FICC's publication of such data would enable market participants to better evaluate which access model best fits their business needs.
                    <SU>306</SU>
                    <FTREF/>
                     FICC responds that it intends to collect and publish information regarding the GSD access models, including the (1) number of Netting Members enabled to use each model, (2) number of Sponsoring Members enabled to offer done-away clearing, and (3) volumes of trading through each access model, including the number of transactions and total notional.
                    <SU>307</SU>
                    <FTREF/>
                     The Commission agrees that FICC's regular publication of the foregoing data should provide information that would better enable market participants to evaluate the GSD access models.
                </P>
                <FTNT>
                    <P>
                        <SU>305</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter I at 4; MFA Letter I at 8; AIMA Letter at 6.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>306</SU>
                         
                        <E T="03">See id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>307</SU>
                         
                        <E T="03">See</E>
                         FICC Letter at 20-21.
                    </P>
                </FTNT>
                <P>
                    One commenter states that in addition to regularly publishing the data referenced in the immediately preceding paragraph, FICC should also regularly publish the number of clearing members who are in fact clearing more than 
                    <E T="03">de minimis</E>
                     volumes pursuant to each such model, and clearly separate out done-with and done-away activity.
                    <SU>308</SU>
                    <FTREF/>
                     The Proposed Rule Change does not contain any provisions related to FICC's publication of the specific data requested by the commenter. The Commission shall approve a proposed rule change of a self-regulatory organization if it finds that it is consistent with the Act,
                    <SU>309</SU>
                    <FTREF/>
                     and the lack of provisions regarding FICC's regular publication of the data requested by the commenter is not inconsistent with the Act.
                </P>
                <FTNT>
                    <P>
                        <SU>308</SU>
                         
                        <E T="03">See</E>
                         FIA-PTG Letter II at 4.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>309</SU>
                         
                        <E T="03">See</E>
                         15 U.S.C. 78s(b)(2)(C)(i).
                    </P>
                </FTNT>
                <P>
                    For the reasons discussed above, the Proposed Rule Change would enable FICC to establish, implement, maintain, and enforce written policies and procedures reasonably designed to provide sufficient information to enable members to identify and evaluate the risks, fees, and other material costs they incur as FICC's members, consistent with Rule 17ad-22(e)(23)(ii).
                    <SU>310</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>310</SU>
                         17 CFR 240.17ad-22(e)(23)(ii).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">III. Conclusion</HD>
                <P>
                    On the basis of the foregoing, the Commission finds that the Proposed Rule Change is consistent with the requirements of the Exchange Act and in particular with the requirements of Section 17A of the Exchange Act 
                    <SU>311</SU>
                    <FTREF/>
                     and the rules and regulations promulgated thereunder.
                </P>
                <FTNT>
                    <P>
                        <SU>311</SU>
                         15 U.S.C. 78q-1.
                    </P>
                </FTNT>
                <P>
                    <E T="03">It is therefore ordered</E>
                    , pursuant to Section 19(b)(2) of the Exchange Act 
                    <SU>312</SU>
                    <FTREF/>
                     that proposed rule change SR-FICC-2024-005, be, and hereby is, Approved.
                    <SU>313</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>312</SU>
                         15 U.S.C. 78s(b)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>313</SU>
                         In approving the proposed rule change, the Commission considered the proposals' impact on efficiency, competition, and capital formation. 15 U.S.C. 78c(f).
                    </P>
                </FTNT>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>314</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>314</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27762 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION </AGENCY>
                <DEPDOC>[Release No. 34-101698; File No. SR-MIAX-2024-40]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; MIAX Exchange LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend Exchange Rule 402, Criteria for Underlying Securities, Exchange Rule 307, Position Limits, and Exchange Rule 309, Exercise Limits To Allow the Exchange To List and Trade Options on the iShares Bitcoin Trust (the “Trust”)</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”),
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 18, 2024, Miami International Securities Exchange, LLC (“MIAX” or “Exchange”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change as described in Items I and II below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>The Exchange proposes to amend Exchange Rule 402, Criteria for Underlying Securities, Exchange Rule 307, Position Limits, and Exchange Rule 309, Exercise Limits.</P>
                <P>
                    The text of the proposed rule change is available on the Exchange's website at 
                    <E T="03">https://www.miaxglobal.com/markets/us-options/miax-options/rule-filings,</E>
                     at MIAX's principal office, and at the Commission's Public Reference Room.
                    <PRTPAGE P="93803"/>
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.</P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    The Exchange proposes to amend Exchange Rule 402, Criteria for Underlying Securities, Exchange Rule 307, Position Limits, and Exchange Rule 309, Exercise Limits,
                    <SU>3</SU>
                    <FTREF/>
                     to allow the Exchange to list and trade options on the iShares Bitcoin Trust (the “Trust”), designating the Trust as appropriate for options trading on the Exchange.
                    <SU>4</SU>
                    <FTREF/>
                     This is a competitive filing based on a similar proposal submitted by Nasdaq ISE, LLC (“ISE”) and approved by the Securities and Exchange Commission (“Commission”).
                    <SU>5</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The Exchange notes that its affiliate exchanges, MIAX Pearl and MIAX Sapphire, submitted substantively identical proposals. The Exchange notes that all the rules of Chapter III of the MIAX Options Exchange, including Rules 307 and 309, are incorporated by reference to MIAX Pearl and MIAX Sapphire. The Exchange also notes that all of the rules of Chapter III of the MIAX Options Exchange, including Rules 307 and 309, and the rules of Chapter IV of the MIAX Options Exchange, including Rule 402, are incorporated by reference to MIAX Emerald.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         On January 10, 2024, the Commission approved proposals by NYSE Arca, Inc., The Nasdaq Stock Market LLC, and Cboe BZX Exchange, Inc. to list and trade the shares of 11 bitcoin-based commodity-based trust shares and trust units, including the iShares Bitcoin Trust. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99306 (Jan. 10, 2024), 89 FR 3008 (Jan. 17, 2024) (order approving File Nos. SR-NYSEARCA-2021-90; SR-NYSEARCA-2023-44; SR-NYSEARCA-2023-58; SR-NASDAQ-2023-016; SR-NASDAQ-2023-019; SR-CboeBZX-2023-028; SR-CboeBZX-2023-038; SR-CboeBZX-2023-040; SR-CboeBZX-2023-042; SR-CboeBZX-2023-044; SR-CboeBZX-2023-072) (“Bitcoin ETP Order”).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 101128 (September 20, 2024), 89 FR 78942 (September 26, 2024) (SR-ISE-2024-03) (Self-Regulatory Organizations; Nasdaq ISE, LLC; Notice of Filing of Amendment Nos. 4 and 5 and Order Granting Accelerated Approval of a Proposed Rule Change, as Modified by Amendment Nos. 1, 4, and 5, to Permit the Listing and Trading of Options on the iShares Bitcoin Trust).
                    </P>
                </FTNT>
                <P>Current Exchange Rule 402(i)(4) provides that securities deemed appropriate for options trading include shares or other securities (“Exchange Traded Fund Shares”) that are traded on a national securities exchange and are defined as “NMS stock” under Rule 600 of Regulation NMS, and that meet specified criteria enumerated in the rule. Sub Section 4 of Exchange Rule 402(i) provides that such shares or other securities:</P>
                <EXTRACT>
                    <P>(4) are issued by the SPDR® Gold Trust or the iShares COMEX Gold Trust or the iShares Silver Trust or the ETFS Silver Trust or the ETFS Gold Trust or the ETFS Palladium Trust or the ETFS Platinum Trust or the Sprott Physical Gold Trust; or</P>
                </EXTRACT>
                <P>In addition, the underlying securities and Exchange Rule 402i, including the commodity based trusts in Exchange Rule 402(i)(4), must meet the requirements of Exchange Rule 402(i), Sections (5)(i)(A) or (B).</P>
                <HD SOURCE="HD3">Proposal</HD>
                <P>The Exchange proposes to amend Exchange Rule 402(i)(4) to expand the list of securities that are appropriate for options trading on the Exchange.</P>
                <HD SOURCE="HD3">
                    Description of the Trust 
                    <E T="51">6</E>
                    <FTREF/>
                </HD>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99306 (Jan. 10, 2024), 89 FR 3008 (Jan. 17, 2024) (order approving File Nos. SR-NYSEARCA-2021-90; SR-NYSEARCA-2023-44; SR-NYSEARCA-2023-58; SR-NASDAQ-2023-016; SR-NASDAQ-2023-019; SR-CboeBZX-2023-028; SR-CboeBZX-2023-038; SR-CboeBZX-2023-040; SR-CboeBZX-2023-042; SR-CboeBZX-2023-044; SR-CboeBZX-2023-072) (Order Granting Accelerated Approval of Proposed Rule Changes, as Modified by Amendments Thereto, To List and Trade Bitcoin-Based Commodity-Based Trust Shares and Trust Units) for a complete description of the Trust.
                    </P>
                </FTNT>
                <P>The shares are issued by the Trust, a Delaware statutory trust. The Trust operates pursuant to a trust agreement (the “Trust Agreement”) between the Sponsor, BlackRock Fund Advisors (the “Trustee”) as the trustee of the Trust and Wilmington Trust, National Association, as Delaware trustee . The Trust issues shares representing fractional undivided beneficial interests in its net assets. The assets of the Trust consist only of bitcoin, held by a custodian on behalf of the Trust except under limited circumstances when transferred through the Trust's prime broker temporarily (described below), and cash. Coinbase Custody Trust Company, LLC (the “Bitcoin Custodian”) is the custodian for the Trust's bitcoin holdings, and maintains a custody account for the Trust (“Custody Account”); Coinbase, Inc. (the “Prime Execution Agent”), an affiliate of the Bitcoin Custodian, is the prime broker for the Trust and maintains a trading account for the Trust (“Trading Account”); and Bank of New York Mellon is the custodian for the Trust's cash holdings (the “Cash Custodian” and together with the Bitcoin Custodian, the “Custodians”) and the administrator of the Trust (the “Trust Administrator”). Under the Trust Agreement, the Trustee may delegate all or a portion of its duties to any agent, and has delegated the bulk of the day to day responsibilities to the Trust Administrator and certain other administrative and record-keeping functions to its affiliates and other agents. The Trust is not an investment company registered under the Investment Company Act of 1940, as amended.</P>
                <P>The investment objective of the Trust is to reflect generally the performance of the price of bitcoin. The Trust seeks to reflect such performance before payment of the Trust's expenses and liabilities. The shares are intended to constitute a simple means of making an investment similar to an investment in bitcoin through the public securities market rather than by acquiring, holding and trading bitcoin directly on a peer-to-peer or other basis or via a digital asset exchange. The shares have been designed to remove the obstacles represented by the complexities and operational burdens involved in a direct investment in bitcoin, while at the same time having an intrinsic value that reflects, at any given time, the investment exposure to the bitcoin owned by the Trust at such time, less the Trust's expenses and liabilities. Although the shares are not the exact equivalent of a direct investment in bitcoin, they provide investors with an alternative method of achieving investment exposure to bitcoin through the public securities market, which may be more familiar to them.</P>
                <HD SOURCE="HD3">Custody of the Trust's Bitcoin</HD>
                <P>
                    An investment in the shares is backed by bitcoin held by the Bitcoin Custodian on behalf of the Trust. All of the Trust's bitcoin will be held in the Custody Account, other than the Trust's bitcoin which is temporarily maintained in the Trading Account under limited circumstances, 
                    <E T="03">i.e.,</E>
                     in connection with creation and redemption Basket 
                    <SU>7</SU>
                    <FTREF/>
                     activity or sales of bitcoin deducted from the Trust's holdings in payment of Trust expenses or the Sponsor's fee (or, in extraordinary circumstances, upon liquidation of the Trust). The Custody Account includes all of the Trust's bitcoin held at the Bitcoin Custodian, 
                    <PRTPAGE P="93804"/>
                    but does not include the Trust's bitcoin temporarily maintained at the Prime Execution Agent in the Trading Account from time to time. The Bitcoin Custodian will keep all of the private keys associated with the Trust's bitcoin held in the Custody Account in “cold storage”.
                    <SU>8</SU>
                    <FTREF/>
                     The hardware, software, systems, and procedures of the Bitcoin Custodian may not be available or cost-effective for many investors to access directly.
                </P>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         The Trust issues and redeems Shares only in blocks of 40,000 or integral multiples thereof. A block of 40,000 Shares is called a “Basket.” These transactions take place in exchange for Bitcoin.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         The term “cold storage” refers to a safeguarding method by which the private keys corresponding to the Trust's bitcoins are generated and stored in an offline manner, subject to layers of procedures designed to enhance security. Private keys are generated by the Bitcoin Custodian in offline computers that are not connected to the internet so that they are more resistant to being hacked.
                    </P>
                </FTNT>
                <P>
                    The Exchange believes that offering options on the Trust will benefit investors by providing them with an additional, relatively lower cost investing tool to gain exposure to spot Bitcoin as well as a hedging vehicle to meet their investment needs in connection with Bitcoin products and positions. Similar to other commodity-based trusts on which options may be listed on the Exchange (
                    <E T="03">e.g.</E>
                     SPDR® Gold Trust, the iShares COMEX Gold Trust, the iShares Silver Trust, or the ETFS Gold Trust),
                    <SU>9</SU>
                    <FTREF/>
                     the Trust essentially offers the same objectives and benefits to investors as do other commodity-based trusts on which options may be listed on the Exchange.
                </P>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 402(i)(4).
                    </P>
                </FTNT>
                <P>Options on the Trust will trade in the same manner as options on other ETFs on the Exchange. Exchange Rules that currently apply to the listing and trading of all options on ETFs on the Exchange, including, for example, Rules that govern listing criteria, expirations, exercise prices, minimum increments, position and exercise limits (including as proposed herein), margin requirements, customer accounts and trading halt procedures, will apply to the listing and trading of options on the Trust on the Exchange. Today, these rules apply to options on the various commodities-based trusts deemed appropriate for options trading on the Exchange pursuant to Exchange Rule 402(i)(4).</P>
                <P>The Exchange's initial listing standards for ETFs on which options may be listed and traded on the Exchange will apply to the Trust. Pursuant to Exchange Rule 402(a), a security (which includes ETFs) on which options may be listed and traded on the Exchange must be registered (with the Commission) and be an NMS stock (as defined in Rule 600 of Regulation NMS under the Act,) and be characterized by a substantial number of outstanding shares that are widely held and actively traded. Exchange Rule 402(i) requires that, in relevant part, ETFs must either (1) meet the criteria and standards set forth in Exchange Rule 402(a) or Exchange Rule 402(b), or (2) be available for creation or redemption each business day from or through the issuer in cash or in kind at a price related to net asset value, and the issuer must be obligated to issue ETFs in a specified aggregate number even if some or all of the investment assets required to be deposited have not been received by the issuer, subject to the condition that the person obligated to deposit the investments has undertaken to deliver the investment assets as soon as possible and such undertaking is secured by the delivery and maintenance of collateral consisting of cash or cash equivalents satisfactory to the issuer, as provided in the respective prospectus.</P>
                <P>Options on the Trust will also be subject to the Exchange's continued listing standards set forth in Exchange Rule 403(g), for ETFs deemed appropriate for options trading pursuant to Exchange Rule 402(i). Specifically, Exchange Rule 403(g) provides that ETFs that were initially approved for options trading pursuant to Exchange Rule 402(i) shall be deemed not to meet the requirements for continued approval, and the Exchange shall not open for trading any additional series of option contracts of the class covering that such ETFs, if the ETFs are delisted from trading pursuant to Exchange Rule 403(b)(4), are halted or suspended from trading in their primary market. Additionally, options on ETFs may be subject to the suspension of opening transactions in any of the following circumstances: (1) in the case of options covering ETFs approved for trading under Exchange Rule 402(i)(5)(i)(A), in accordance with the terms of paragraphs (b)(1), (2), and (3) of Exchange Rule 403; (2) in the case of options covering ETFs approved for trading under Exchange Rule 402(i)(5)(i)(B), following the initial twelve-month period beginning upon the commencement of trading in the ETFs on a national securities exchange and are defined as an NMS stock, there are fewer than 50 record and/or beneficial holders of such ETFs for 30 or more consecutive trading days; (3) the value of the index or portfolio of securities, non-U.S. currency, or portfolio of commodities including commodity futures contracts, options on commodity futures contracts, swaps, forward contracts and/or options on physical commodities and/or financial instruments and money market instruments on which the ETFs are based is no longer calculated or available; or (4) such other event shall occur or condition exist that in the opinion of the Exchange makes further dealing in such options on the Exchange inadvisable.</P>
                <P>
                    Options on the Trust would be physically settled contracts with American-style exercise.
                    <SU>10</SU>
                    <FTREF/>
                     Consistent with current Exchange Rule 404, which governs the opening of options series on a specific underlying security (including ETFs), the Exchange will open at least one expiration month for options on the Trust 
                    <SU>11</SU>
                    <FTREF/>
                     and may also list series of options on the Trust for trading on a weekly,
                    <SU>12</SU>
                    <FTREF/>
                     monthly,
                    <SU>13</SU>
                    <FTREF/>
                     or quarterly 
                    <SU>14</SU>
                    <FTREF/>
                     basis. The Exchange may also list long-term equity option series (“LEAPS”) that expire from 12 to 39 months from the time they are listed.
                    <SU>15</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 401, which provides that the rights and obligations of holders and writers are set forth in the Rules of the Options Clearing Corporation (“OCC”); 
                        <E T="03">see also</E>
                         OCC Rules, Chapters VIII (which governs exercise and assignment) and Chapter IX (which governs the discharge of delivery and payment obligations arising out of the exercise of physically settled stock option contracts).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404(b). The monthly expirations are subject to certain listing criteria for underlying securities described within Exchange Rule 404 and its Interpretations and Policies. Monthly listings expire the third Friday of the month. The term “expiration date” (unless separately defined elsewhere in the OCC By-Laws), when used in respect of an option contract (subject to certain exceptions), means the third Friday of the expiration month of such option contract, or if such Friday is a day on which the exchange on which such option is listed is not open for business, the preceding day on which such exchange is open for business. 
                        <E T="03">See</E>
                         OCC By-Laws Article I, Section 1. Pursuant to Exchange Rule 404(c), additional series of options of the same class may be opened for trading on the Exchange when the Exchange deems it necessary to maintain an orderly market, to meet customer demand or when the market price of the underlying stock moves more than five strike prices from the initial exercise price or prices. Pursuant to Exchange Rule 404(e), new series of options on an individual stock may be added until the beginning of the month in which the options contract will expire. Due to unusual market conditions, the Exchange, in its discretion, may add a new series of options on an individual stock until the close of trading on the business day prior to expiration.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretations and Policies .02.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretations and Policies .13.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretations and Policies .03.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404(d).
                    </P>
                </FTNT>
                <P>
                    Pursuant to Exchange Rule 404, Interpretation and Policy .06, which governs strike prices of series of options on ETFs, the interval between strike prices of series of options on ETFs approved for options trading pursuant to Exchange Rule 402(i) shall be fixed at a price per share which is reasonably close to the price per share at which the 
                    <PRTPAGE P="93805"/>
                    underlying security is traded in the primary market at or about the same time such series of options is first open for trading on the Exchange, or at such intervals as may have been established on another options exchange prior to the initiation of trading on the Exchange. With respect to the Short Term Options Series or Weekly Program, during the month prior to expiration of an option class that is selected for the Short Term Option Series Program, the strike price intervals for the related non-Short Term Option (“Related non-Short Term Option”) shall be the same as the strike price intervals for the Short Term Option.
                    <SU>16</SU>
                    <FTREF/>
                     Specifically, the Exchange may open for trading Short Term Option Series at strike price intervals of (i) $0.50 or greater where the strike price is less than $100, and $1 or greater where the strike price is between $100 and $150 for all option classes that participate in the Short Term Options Series Program; (ii) $0.50 for option classes that trade in one dollar increments and are in the Short Term Option Series Program; or (iii) $2.50 or greater where the strike price is above $150.
                    <SU>17</SU>
                    <FTREF/>
                     Additionally, the Exchange may list series of options pursuant to the $1 Strike Price Interval Program,
                    <SU>18</SU>
                    <FTREF/>
                     the $0.50 Strike Program,
                    <SU>19</SU>
                    <FTREF/>
                     and the $2.50 Strike Price Program.
                    <SU>20</SU>
                    <FTREF/>
                     Pursuant to Exchange Rule 510, where the price of a series of options for the Trust is less than $3.00, the minimum increment will be $0.05, and where the price is $3.00 or higher, the minimum increment will be $0.10 
                    <SU>21</SU>
                    <FTREF/>
                     consistent with the minimum increments for options on other ETFs listed on the Exchange. Any and all new series of Trust options that the Exchange lists will be consistent and comply with the expirations, strike prices, and minimum increments set forth in Rules 404 and 510, as applicable.
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretations and Policies .02(e).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>17</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>18</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretation and Policy .01.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>19</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404, Interpretation and Policy .04.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>20</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 404(f).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>21</SU>
                         
                        <E T="03">See</E>
                         Exchange Rule 510.
                    </P>
                </FTNT>
                <P>Position and exercise limits for options on ETFs, including options on the Trust, are determined pursuant to Exchange Rules 307 and 309, respectively. Position and exercise limits for ETF options vary according to the number of outstanding shares and the trading volumes of the underlying ETF over the past six months, where the largest in capitalization and the most frequently traded ETFs have an option position and exercise limit of 250,000 contracts (with adjustments for splits, re-capitalizations, etc.) on the same side of the market; and smaller capitalization ETFs have position and exercise limits of 200,000, 75,000, 50,000 or 25,000 contracts (with adjustments for splits, re-capitalizations, etc.) on the same side of the market. The Exchange proposes to cap the position and exercise limits for the Trust at 25,000 contracts. Capping the position and exercise limits at 25,000 contracts, the lowest limits available in options, would address concerns related to manipulation and protection of investors as this number is extremely conservative for the Trust and is more than appropriate given its liquidity.</P>
                <P>
                    For purposes of addressing position and exercise limits, the Exchange applies position and exercise limits for options for each underlying security and does not aggregate position and exercise limits. In considering the appropriate position and exercise limits for the Trust, the Exchange reviewed the data presented by ISE in its filing, specifically in Exhibit 3 of the filing,
                    <SU>22</SU>
                    <FTREF/>
                     where ISE measured the Trust's market capitalization and ADV against other industry data as explained further below. The Commission should consider the position and exercise limits for options on the Trust exclusive of other options on bitcoin.
                </P>
                <FTNT>
                    <P>
                        <SU>22</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 101128 (September 20, 2024), 89 FR 78942 (September 26, 2024) (SR-ISE-2024-03) (Order Granting Accelerated Approval of a Proposed Rule Change, as Modified by Amendment Nos. 1, 4, and 5, to Permit the Listing and Trading of Options on the iShares Bitcoin Trust) (Exhibit 3) (“IBIT Approval Order”) (letter from Angela Dunn, Nasdaq ISE, LLC, to Vanessa Countryman, Secretary, Commission, dated August 21, 2024)(“ISE Letter”).
                    </P>
                </FTNT>
                <P>
                    In its filing, ISE considered the Trust's market capitalization and ADV, and prospective position limit in relation to other securities. In measuring the Trust against other securities, ISE aggregated market capitalization and volume data for securities that have defined position limits utilizing data from The Options Clearing Corporations (“OCC”).
                    <SU>23</SU>
                    <FTREF/>
                     This pool of data took into consideration 3,984 options on single stock securities, excluding broad based ETFs.
                    <SU>24</SU>
                    <FTREF/>
                     Next, ISE aggregated the data based on market capitalization and ADV and grouped option symbols by position limit utilizing statistical thresholds for ADV and market capitalization that were one standard deviation above the mean for each position limit category (
                    <E T="03">i.e.</E>
                     25,000, 50,000 to 65,000, 75,000, 100,000 to less than 250,000, 250,000 to 400,000, 450,000 to 1,000,000, and greater than or equal to 1,000,000)(sic).
                    <SU>25</SU>
                    <FTREF/>
                     Exchange Rule 307(d) sets out position limits for various contracts. For example, on the Exchange like on ISE, a 25,000 contract limit applies to those options having an underlying security that does not meet the requirements for a higher options contract limit. ISE performed an exercise to demonstrate the Trust's position limit relative to other options symbols in terms of market capitalization and ADV. For reference the market capitalization for the Trust was 19,789,068 billion 
                    <SU>26</SU>
                    <FTREF/>
                     with an ADV, for the preceding three months prior to August 7, 2024, of greater than 26 million shares.
                    <SU>27</SU>
                    <FTREF/>
                     Today, by comparison, other options symbols with similar market capitalization and ADV have a position limit in excess of 400,000.
                    <SU>28</SU>
                    <FTREF/>
                     Therefore, the proposed 25,000 same side position limit for options on the Trust is extremely conservative relative to these options symbols which are a full standard deviation above the mean in comparison.
                </P>
                <FTNT>
                    <P>
                        <SU>23</SU>
                         The computations are based on OCC data from August 6, 2024. Data displaying zero values in market capitalization or ADV were removed.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>24</SU>
                         The Trust has one asset and therefore is not comparable to a broad based ETF where there are typically multiple components.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>25</SU>
                         
                        <E T="03">See</E>
                         ISE Letter at 10.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>26</SU>
                         ISE acquired this figure as of August 13, 2024. 
                        <E T="03">See https://www.ishares.com/us/products/333011/ishares-bitcoin-trust.</E>
                         The global supply of bitcoin grows each day bitcoin are minted.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>27</SU>
                         
                        <E T="03">See</E>
                         ISE Letter at 10.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>28</SU>
                         
                        <E T="03">See, eg,.</E>
                         iShares® iBoxx® $ High Yield Corporate Bond ETF (“HYG”) with a market capitalization of 13,859,235,000 billion as of November 4, 2024. 
                        <E T="03">See https://www.ishares.com/us/products/239565/ishares-iboxx-high-yield-corporate-bond-etf.</E>
                         The Exchange notes that HYG has a position limit of 500,000 contracts.
                    </P>
                </FTNT>
                <P>
                    Second, ISE reviewed the Trust's data relative to the market capitalization of the entire bitcoin market in terms of exercise risk and availability of deliverables. Utilizing data as of August 3, 2024, there were 19,737,193 bitcoins in circulation.
                    <SU>29</SU>
                    <FTREF/>
                     ISE took a price of $57,000 that equates to a market capitalization of greater than 1.125 trillion US dollars, and applied that to a position limit of 400,000 for options on the Trust.
                    <SU>30</SU>
                    <FTREF/>
                     If a position limit of 400,000 options were considered (the position limit that would be typically assigned based upon data) the exercisable risk would represent only 6.6% of the outstanding shares of the Trust. The 25,000 position limit being sought only represents 0.4% of the outstanding shares of the Trust. Since the Trust has a creation and redemption process managed through the issuer, additionally it can be compared the position limit sought to the total market capitalization of the entire bitcoin market. In this case, the exercisable risk for options on the Trust would be less 
                    <PRTPAGE P="93806"/>
                    than 0.01% of the market capitalization of all outstanding bitcoin. Assuming a scenario where all options on the Trust's shares were exercised given the proposed 25,000 per same side position limit, this would have a virtually unnoticed impact on the entire bitcoin market. This analysis demonstrates that the proposed 25,000 per same side position limit is also extremely conservative and more than appropriate for options on the Trust.
                </P>
                <FTNT>
                    <P>
                        <SU>29</SU>
                         
                        <E T="03">See</E>
                         ISE Letter at 10.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>30</SU>
                         Id.
                    </P>
                </FTNT>
                <P>
                    Third, ISE reviewed the proposed position limit by comparing it to position limits for derivative products regulated by the Commodity Futures Trading Commission (“CFTC”). While the CFTC, through the relevant Designated Contract Markets, only regulates options positions based upon delta equivalents (creating a less stringent standard), ISE examined equivalent bitcoin futures position limits. In particular, ISE looked at the CME bitcoin futures contract 
                    <SU>31</SU>
                    <FTREF/>
                     that has a position limit of 2,000 futures.
                    <SU>32</SU>
                    <FTREF/>
                     On August 7, 2024, CME bitcoin futures settled at $55,000.
                    <SU>33</SU>
                    <FTREF/>
                     Taking the position limit of 2,000 futures at a $5 multiplier 
                    <SU>34</SU>
                    <FTREF/>
                     equates to $550 million of notional value for bitcoin futures. By way of comparison, on August 7, 2024, the Trust settled at $31.19 per share, which would equate to 17,633,857 shares of the Trust 
                    <SU>35</SU>
                    <FTREF/>
                     if the CME notional position limit were utilized. Since substantial portions of any distributed options portfolio are likely to be out of the money on expiration, an options position limit equivalent to the CME position limit for bitcoin futures (considering that all options deltas are ≤1.00) should be a bit higher than the CME implied 176,338 limit.
                </P>
                <FTNT>
                    <P>
                        <SU>31</SU>
                         CME Bitcoin Futures are described in Chapter 350 of CME's Rulebook.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>32</SU>
                         
                        <E T="03">See</E>
                         the Position Accountability and Reportable Level Table in the Interpretations &amp; Special Notices Section of Chapter 5 of CME's Rulebook.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>33</SU>
                         
                        <E T="03">See https://finance.yahoo.com/quote/BTC%3DF/history/?guccounter=1&amp;guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&amp;guce_referrer_sig=AQAAAM7ngaS6ZQS9c2Wzx7JW2IUe-_-_1FnLyr8T-Qw4jjkleHyCENfSMIEpPPt2hCzPDEryTVyB78NIwxkwFB5Fuw-jA-YiuSmYJHBriWbV6dYn91VQfzQNt3p0I2RkYLD3HhzXPwu4AP5as-_WzHNpEBon4sk5sUZXgkapMrZR—CS.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>34</SU>
                         Each bitcoin futures contract is valued at 5 bitcoins as defined by the CME CF Bitcoin Reference Rate (“BRR”). 
                        <E T="03">See</E>
                         CME Rule 35001.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>35</SU>
                         
                        <E T="03">See</E>
                         ISE Letter at 11.
                    </P>
                </FTNT>
                <P>
                    Of note, unlike options contracts, CME position limits are calculated on a net futures equivalent basis by contract and include contracts that aggregate into one or more base contract according to an aggregation ratio(s).
                    <SU>36</SU>
                    <FTREF/>
                     Therefore, if a portfolio includes positions in options on futures, CME would aggregate those positions into the underlying futures contracts in accordance with a table published by CME on a delta equivalent value for the relevant spot month, subsequent spot month, single month and all month position limits.
                    <SU>37</SU>
                    <FTREF/>
                     If a position exceeds position limits because of an option assignment, CME permits market participants to liquidate the excess position within one business day without being considered in violation of its rules. Additionally, if at the close of trading, a position that includes options exceeds position limits for futures contracts, when evaluated using the delta factors as of that day's close of trading, but does not exceed the limits when evaluated using the previous day's delta factors, then the position shall not constitute a position limit violation. Considering CME's position limits on futures for bitcoin, the Exchange believes that the proposed 25,000 per same side position limit is conservative and more than appropriate for options on the Trust.
                </P>
                <FTNT>
                    <P>
                        <SU>36</SU>
                         
                        <E T="03">See https://www.cmegroup.com/education/courses/market-regulation/position-limits/positionlimits-aggregation-of-contracts-and-table.htm.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>37</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>
                    In analyzing the proposed position limit for options on the Trust, ISE also considered the supply of bitcoin. Specifically, ISE examined the number of market participants with position limits that would need to exercise in unison to put the underlying asset under stress. In the case of options on the Trust, the proposed 25,000 same side position limit effectively restricts a market participant from holding positions that could be exercised in excess of 2,500,000 shares of the Trust. Utilizing data from August 12, 2024, the Trust had 611,040,000 shares outstanding, therefore 244 market participants would have to simultaneously exercise position limits in order to create a scenario that may put the underlying asset (the Trust) under stress.
                    <SU>38</SU>
                    <FTREF/>
                     The Exchange notes that historically, from observation only, it appears that no more than five market participants holding position limits in any security have exercised in unison in any option. As unlikely an occurrence as all market participants exercising their position limits in unison would be, if it were to occur, it should be noted that even such an occurrence would not likely put the Trust under stress as economic incentives, would induce the creation of more shares through the ETF creation and redemption process.
                </P>
                <FTNT>
                    <P>
                        <SU>38</SU>
                         
                        <E T="03">See https://www.ishares.com/us/products/333011/ishares-bitcoin-trust.</E>
                    </P>
                </FTNT>
                <P>
                    By way of example, given that the current global supply of bitcoin, the underlying asset of the Trust, is 19,789,068 
                    <SU>39</SU>
                    <FTREF/>
                     and that each bitcoin can currently be redeemed for 1,755 shares of the Trust, another 34,729,814,340 shares of the Trust could be created. To exhaust this supply of the Trust, 13,891 market participants would have to simultaneously exercise their position limit. Comparing the Trust to the SPDR Gold Shares (“GLD”) ETF or the iShares Silver Trust (“SLV”) ETF, which have position limits of 250,000 or ten times the proposed position limit for the Trust as well as lower shares outstanding in both products,
                    <SU>40</SU>
                    <FTREF/>
                     it is unjustified to mandate a different level of stringency with respect to a position limit for options on the Trust.
                </P>
                <FTNT>
                    <P>
                        <SU>39</SU>
                         This figure was acquired as of August 13, 2024. 
                        <E T="03">See https://www.ishares.com/us/products/333011/ishares-bitcoin-trust.</E>
                         The global supply of bitcoin grows each day bitcoin are minted.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>40</SU>
                         As of August 13, 2024, GLD had 294,000,000 shares outstanding and SLV had 510,200,000 shares outstanding. 
                        <E T="03">See https://www.ssga.com/us/en/intermediary/etfs/funds/spdr-gold-shares-gld</E>
                         and 
                        <E T="03">https://www.ishares.com/us/products/239855/ishares-silver-trust-fund.</E>
                    </P>
                </FTNT>
                <P>
                    The supply of bitcoin does have a limit, which will take years to fully mint.
                    <SU>41</SU>
                    <FTREF/>
                     The Exchange notes that bitcoin is a viable economic alternative to traditional assets. The price of goods denominated by bitcoin has actually declined. This dynamic not only makes a fixed supply desirable, but a necessary condition of the value added by this asset in the broader economy. Further, the Exchange notes that corporations have a limited number of outstanding shares. Corporations may authorize additional shares, repurchase shares or split their shares. Similarly, ETFs, like the Trust, may also create, redeem, or split shares to suit the demand of the marketplace.
                </P>
                <FTNT>
                    <P>
                        <SU>41</SU>
                         A recent article suggested that the remaining supply will take over 100 years to fully mint. 
                        <E T="03">See</E>
                         Sen, Vivek. “94% of Bitcoin's Supply Has Now Been Issued.” 
                        <E T="03">Bitcoin Magazine, https://bitcoinmagazine.com/business/94-of-bitcoins-supply-has-now-been-issued.</E>
                         August 19, 2024.
                    </P>
                </FTNT>
                <P>
                    Importantly, because the supply of bitcoin is much larger than the available supply of most securities and the proposed 25,000 contract position limit is so conservative, the Exchange believes that evaluating the available supply of bitcoin in establishing a position limit for options on the Trust would demonstrate that the proposed limit is safe for investors and the market.
                    <SU>42</SU>
                    <FTREF/>
                     The Trust constitutes less than 2% of the entire bitcoin supply. When comparing the market capitalization of bitcoin against the largest securities, bitcoin would rank 7th among those 
                    <PRTPAGE P="93807"/>
                    securities.
                    <SU>43</SU>
                    <FTREF/>
                     Further, the Exchange believes that its proposal to list options on the Trust with a position limit of 25,000 on the same side is a conservative position limit that does not lend itself to manipulation in the market given the ample market capitalization and liquidity in the Trust. If we look to the liquidity statistics of similar instruments and their concomitant position limits, we are able to extrapolate a reasonable standard for arriving at a position limit for a new product. In this case we can look to GLD, SLV, and the ProShares Bitcoin Strategy ETF (“BITO”). These products have volume statistics and “float” statistics, which gauge liquidity, which are in line, yet slightly lower than the Trust. All three of these reference products have position limits of 250,000 contracts. These reference products are remarkably similar in nature to the Trust; they are exchange-traded products (“ETPs”) holding one asset in a trust.
                </P>
                <FTNT>
                    <P>
                        <SU>42</SU>
                         A supply consideration would likely be valuable for an option symbol that had far less liquidity than the Trust.
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>43</SU>
                         
                        <E T="03">See https://companiesmarketcap.com/usa/largest-companies-in-the-usa-by-market-cap/.</E>
                    </P>
                </FTNT>
                <P>The Exchange further notes that Exchange Rule 1502, which governs margin requirements applicable to trading on the Exchange, including options on ETFs, will also apply to the trading of the Trust options. Notwithstanding the position limits in Exchange Rule 307(d) and exercise limits in Exchange Rule 309, the Exchange proposes the position and exercise limits for the options on the Trust to be 25,000 contracts on the same side pursuant to proposed Supplementary Material .01 to Exchange Rule 307 and proposed Supplementary Material .01 to Exchange Rule 309.</P>
                <P>The Exchange represents that the same surveillance procedures applicable to all other options on other ETFs currently listed and traded on the Exchange will apply to options on the Trust. Also the Exchange represents that it has the necessary systems capacity to support the new option series. The Exchange believes that its existing surveillance and reporting safeguards are designed to deter and detect possible manipulative behavior which might potentially arise from listing and trading options on ETFs, including the proposed Trust options.</P>
                <P>
                    Today, the Exchange has an adequate surveillance program in place for options. The Exchange intends to apply those same program procedures to options on the Trust that it applies to the Exchange's other options products.
                    <SU>44</SU>
                    <FTREF/>
                     The Exchange's staff will have access to the surveillance programs conducted by its affiliate exchanges, MIAX Pearl and MIAX Sapphire with respect to trading in the shares of the underlying Trust when conducting surveillances for market abuse or manipulation in the options on the Trust. Additionally, the Exchange is a member of the Intermarket Surveillance Group (“ISG”) under the Intermarket Surveillance Group Agreement. ISG members work together to coordinate surveillance and investigative information sharing in the stock, options, and futures markets. In addition to obtaining surveillance data from MIAX Pearl and MIAX Sapphire, the Exchange will be able to obtain information regarding trading in the shares of the underlying Trust from Nasdaq, LLC and other markets through ISG. In addition, the Exchange has a Regulatory Services Agreement with the Financial Industry Regulatory Authority (“FINRA”). Pursuant to a multi-party 17d-2 joint plan, all options exchanges allocate regulatory responsibilities to FINRA to conduct certain options-related market surveillance that are common to rules of all options exchanges.
                    <SU>45</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>44</SU>
                         The surveillance program includes real-time patterns for price and volume movements and post-trade surveillance patterns (
                        <E T="03">e.g.,</E>
                         spoofing, marking the close, pinging, phishing).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>45</SU>
                         Section 19(g)(1) of the Act, among other things, requires every SRO registered as a national securities exchange or national securities association to comply with the Act, the rules and regulations thereunder, and the SRO's own rules, and, absent reasonable justification or excuse, enforce compliance by its members and persons associated with its members. See 15 U.S.C. 78q(d)(1) and 17 CFR 240.17d-2. Section 17(d)(1) of the Act allows the Commission to relieve an SRO of certain responsibilities with respect to members of the SRO who are also members of another SRO (“common members”). Specifically, Section 17(d)(1) allows the Commission to relieve an SRO of its responsibilities to: (i) receive regulatory reports from such members; (ii) examine such members for compliance with the Act and the rules and regulations thereunder, and the rules of the SRO; or (iii) carry out other specified regulatory responsibilities with respect to such members.
                    </P>
                </FTNT>
                <P>The underlying shares of spot bitcoin ETPs, including the Trust, are also subject to safeguards related to addressing market abuse and manipulation. As the Commission stated in Bitcoin ETP Order:</P>
                <EXTRACT>
                    <P>
                        Each Exchange has a comprehensive surveillance-sharing agreement with the CME via their common membership in the Intermarket Surveillance Group. This facilitates the sharing of information that is available to the CME through its surveillance of its markets, including its surveillance of the CME bitcoin futures market.
                        <SU>46</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>46</SU>
                             
                            <E T="03">See</E>
                             Bitcoin ETP Order, 89 FR at 3010-11.
                        </P>
                    </FTNT>
                    <P>
                        The Exchange states that, given the consistently high correlation between the CME bitcoin futures market and the spot bitcoin market, as confirmed by the Commission through robust correlation analysis, the Commission was able to conclude that such surveillance sharing agreements could reasonably be “expected to assist in surveilling for fraudulent and manipulative acts and practices in the specific context of the [Bitcoin ETPs].” 
                        <SU>47</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>47</SU>
                             
                            <E T="03">See</E>
                             Bitcoin ETP Order, 89 FR at 3010-11.
                        </P>
                    </FTNT>
                </EXTRACT>
                <P>
                    In light of surveillance measures related to both options and futures as well as the underlying Trust,
                    <SU>48</SU>
                    <FTREF/>
                     the Exchange believes that existing surveillance procedures are designed to deter and detect possible manipulative behavior which might potentially arise from listing and trading the proposed options on the Trust. Further, the Exchange represents that it will implement any new surveillance procedures it deems necessary to effectively monitor the trading of options on the Trust.
                </P>
                <FTNT>
                    <P>
                        <SU>48</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99295 (January 8, 2024), 89 FR 2321, 2334-35 (January 12, 2024) (SR-NASDAQ-2023-016) (Notice of Filing of Amendment No. 1 to a Proposed Rule Change To List and Trade Shares of the iShares Bitcoin Trust Under Nasdaq Rule 5711(d)).
                    </P>
                </FTNT>
                <P>
                    The Exchange has also analyzed its capacity and represents that it believes the Exchange and Options Price Reporting Authority or “OPRA” have the necessary systems capacity to handle the additional traffic associated with the listing of new series that may result from the introduction of options on the Trust up to the number of expirations currently permissible under the Rules. Because the proposal is limited to one class, the Exchange believes any additional traffic that may be generated from the introduction of the Trust options will be manageable. Finally, the Exchange proposes a technical amendment to Exchange Rule 402(i)(4) to amend the name “ETFS Gold Trust” to “Aberdeen Standard Physical Gold Trust.” In 2018 ETFS Gold Trust was renamed.
                    <SU>49</SU>
                    <FTREF/>
                     At this time, the Exchange proposes to amend the name of the ETF to reflect its current name.
                </P>
                <FTNT>
                    <P>
                        <SU>49</SU>
                         Effective October 1, 2018 ETFS Gold Trust was renamed Aberdeen Standard Gold ETF Trust. 
                        <E T="03">https://www.sec.gov/Archives/edgar/data/1450923/000138713118005292/ex10-2.htm.</E>
                    </P>
                </FTNT>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The Exchange believes the proposed rule change is consistent with the Act and the rules and regulations thereunder applicable to the Exchange and, in particular, the requirements of Section 6(b) of the Act.
                    <SU>50</SU>
                    <FTREF/>
                     Specifically, the Exchange believes the proposed rule change is consistent with the Section 6(b)(5) 
                    <SU>51</SU>
                    <FTREF/>
                     requirements that the rules of an exchange be designed to prevent fraudulent and manipulative acts and 
                    <PRTPAGE P="93808"/>
                    practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in regulating, clearing, settling, processing information with respect to, and facilitating transactions in securities, to remove impediments to and perfect the mechanism of a free and open market and a national market system, and, in general, to protect investors and the public interest. Additionally, the Exchange believes the proposed rule change is consistent with the Section (6)(b)(5) 
                    <SU>52</SU>
                    <FTREF/>
                     requirement that the rules of an exchange not be designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>50</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>51</SU>
                         15 U.S.C. 78f(b)(5).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>52</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>In particular, the Exchange believes that the proposal to list and trade options on the Trust will remove impediments to and perfect the mechanism of a free and open market and a national market system and, in general, protect investors because offering options on the Trust will provide investors with a greater opportunity to realize the benefits of utilizing options on an ETF based on spot bitcoin, including cost efficiencies and increased hedging strategies. The Exchange believes that offering options on a competitively priced ETF based on spot bitcoin will benefit investors by providing them with an additional, relatively lower-cost risk management tool, allowing them to manage, more easily, their positions and associated risks in their portfolios in connection with exposure to spot bitcoin. Today, the Exchange lists options on other commodity ETFs structured as a trust, which essentially offer the same objectives and benefits to investors, and for which the Exchange has not identified any issues with the continued listing and trading of options on those ETFs.</P>
                <P>
                    The Exchange also believes the proposal to permit options on the Trust will remove impediments to and perfect the mechanism of a free and open market and a national market system, because options on the Trust will comply with current Exchange Rules. Options on the Trust must satisfy the initial listing standards and continued listing standards currently in the Exchange Rules, applicable to options on all ETFs, including options on other commodity ETFs already deemed appropriate for options trading on the Exchange pursuant to Exchange Rule 402(i)(4). Additionally, as demonstrated above, the Trust is characterized by a substantial number of shares that are widely held and actively traded. Further, Exchange Rules that currently govern the listing and trading of options on ETFs, including permissible expirations, strike prices, minimum increments, position and exercise limits (as proposed herein), and margin requirements, will govern the listing and trading of options on the Trust. The proposed position and exercise limits for options on the Trust is 25,000 contracts. These position and exercise limits are the lowest position and exercise limits available in the options industry, are extremely conservative and more than appropriate given the Trust's market capitalization, average daily volume, and high number of outstanding shares. The proposed position limit, and exercise limit, is consistent with the Act as it addresses concerns related to manipulation and protection of investors because, as demonstrated above, the position limit (and exercise limit) is extremely conservative and more than appropriate given the Trust is actively traded. In support of the proposed position and exercise limits for options on the Trust is 25,000 contracts, the Exchange is citing the in depth analysis ISE did in its filing. As noted above, in the IBIT Approval Order, ISE considered the: (i) Trust's market capitalization and ADV, and prospective position limit in relation to other securities; (ii) market capitalization of the entire bitcoin market in terms of exercise risk and availability of deliverables; (iii) proposed position limit by comparing it to position limits for derivative products regulated by the CFTC; and (iv) supply of bitcoin. Based on the Exchange's review of IBIT Approval Order, the Exchange believes that the setting position and exercise limits for options on the Trust is 25,000 contracts is more than appropriate for the Trust. The proposed position and exercise limits reasonably and appropriately balance the liquidity provisioning in the market against the prevention of manipulation. The Exchange believes these proposed limits are effectively designed to prevent an individual customer or entity from establishing options positions that could be used to manipulate the market of the underlying as well as the Bitcoin market.
                    <SU>53</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>53</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 39489 (December 24, 1997), 63 FR 276 (January 5, 1998) (SR-CBOE-1997-11).
                    </P>
                </FTNT>
                <P>
                    The Exchange represents that it has the necessary systems capacity to support options on the Trust. The Exchange believes that its existing surveillance and reporting safeguards are designed to deter and detect possible manipulative behavior which might arise from listing and trading options on ETFs, including the Trust options. Today, the Exchange has an adequate surveillance program in place for options. The Exchange intends to apply those same program procedures to options on the Trust that it applies to the Exchange's other options products.
                    <SU>54</SU>
                    <FTREF/>
                     The Exchange's staff will have access to the surveillance programs conducted by its affiliate exchanges, MIAX Pearl and MIAX Sapphire with respect to the underlying Trust when conducting surveillances for market abuse or manipulation in the options on the Trust. The Exchange will review activity in the underlying Trust when conducting surveillances for market abuse or manipulation in the options on the Trust. Additionally, the Exchange is a member of the ISG under the Intermarket Surveillance Group Agreement. ISG members work together to coordinate surveillance and investigative information sharing in the stock, options, and futures markets. In addition to obtaining surveillance data from MIAX Pearl and MIAX Sapphire, the Exchange will be able to obtain information from Nasdaq, LLC and other markets through ISG. In addition, the Exchange has a Regulatory Services Agreement with FINRA. Pursuant to a multi-party 17d-2 joint plan, all options exchanges allocate regulatory responsibilities to FINRA to conduct certain options-related market surveillance that are common to rules of all options exchanges.
                    <SU>55</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>54</SU>
                         The surveillance program includes real-time patterns for price and volume movements and post-trade surveillance patterns (
                        <E T="03">e.g.,</E>
                         spoofing, marking the close, pinging, phishing).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>55</SU>
                         Section 19(g)(1) of the Act, among other things, requires every SRO registered as a national securities exchange or national securities association to comply with the Act, the rules and regulations thereunder, and the SRO's own rules, and, absent reasonable justification or excuse, enforce compliance by its members and persons associated with its members. See 15 U.S.C. 78q(d)(1) and 17 CFR 240.17d-2. Section 17(d)(1) of the Act allows the Commission to relieve an SRO of certain responsibilities with respect to members of the SRO who are also members of another SRO (“common members”). Specifically, Section 17(d)(1) allows the Commission to relieve an SRO of its responsibilities to: (i) receive regulatory reports from such members; (ii) examine such members for compliance with the Act and the rules and regulations thereunder, and the rules of the SRO; or (iii) carry out other specified regulatory responsibilities with respect to such members.
                    </P>
                </FTNT>
                <P>The underlying shares of spot bitcoin ETPs, including the Trust, are also subject to safeguards related to addressing market abuse and manipulation. As the Commission stated in Bitcoin ETP Order:</P>
                <P>
                    Each Exchange has a comprehensive surveillance-sharing agreement with the CME via their common membership in the Intermarket Surveillance Group. 
                    <PRTPAGE P="93809"/>
                    This facilitates the sharing of information that is available to the CME through its surveillance of its markets, including its surveillance of the CME bitcoin futures market.
                    <SU>56</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>56</SU>
                         
                        <E T="03">See supra</E>
                         note 5.
                    </P>
                </FTNT>
                <P>
                    The Exchange states that, given the consistently high correlation between the CME bitcoin futures market and the spot bitcoin market, as confirmed by the Commission through robust correlation analysis, the Commission was able to conclude that such surveillance sharing agreements could reasonably be “expected to assist in surveilling for fraudulent and manipulative acts and practices in the specific context of the [Bitcoin ETPs].” 
                    <SU>57</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>57</SU>
                         
                        <E T="03">See</E>
                         Bitcoin ETP Order, 89 FR at 3010-11.
                    </P>
                </FTNT>
                <P>
                    In light of surveillance measures related to both options and futures as well as the underlying Trust,
                    <SU>58</SU>
                    <FTREF/>
                     the Exchange believes that existing surveillance procedures are designed to deter and detect possible manipulative behavior which might potentially arise from listing and trading the proposed options on the Trust. Further, the Exchange represents that it will implement any new surveillance procedures it deems necessary to effectively monitor the trading of options on the Trust.
                </P>
                <FTNT>
                    <P>
                        <SU>58</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 99295 (January 8, 2024), 89 FR 2321, 2334-35 (January 12, 2024) (SR-NASDAQ-2023-016) (Notice of Filing of Amendment No. 1 to a Proposed Rule Change To List and Trade Shares of the iShares Bitcoin Trust Under Nasdaq Rule 5711(d)).
                    </P>
                </FTNT>
                <P>
                    Finally, the Commission has previously approved the listing and trading of options on other commodity ETFs structured as a trust, such as SPDR® Gold Trust,
                    <SU>59</SU>
                    <FTREF/>
                     the iShares COMEX Gold Trust 
                    <SU>60</SU>
                    <FTREF/>
                     the iShares Silver Trust,
                    <SU>61</SU>
                    <FTREF/>
                     the ETFS Gold Trust,
                    <SU>62</SU>
                    <FTREF/>
                     and the ETFS Silver Trust.
                    <SU>63</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>59</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 57897 (May 30, 2008), 73 FR 32061 (June 5, 2008) (SR-Amex-2008-15; SR-CBOE-2005-11; SR-ISE-2008-12; SR-NYSEArca-2008-52; and SRPhlx-2008-17) (Order Granting Approval of a Proposed Rule Change, as Modified, and Notice of Filing and Order Granting Accelerated Approval of Proposed Rule Changes, as Modified, Relating to Listing and Trading Options on the SPDR Gold Trust).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>60</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 59055 (December 4, 2008), 73 FR 75148 (December 10, 2008) (SR-Amex-2008-68; SR-BSE-2008-51; SR-CBOE-2008-72; SR-ISE-2008-58; SRNYSEArca-2008-66; and SR-Phlx-2008-58) (Notice of Filing and Order Granting Accelerated Approval of Proposed Rule Changes Relating to the Listing and Trading Options on Shares of the iShares COMEX Gold Trust and the iShares Silver Trust).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>61</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>62</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 61483 (February 3, 2010), 75 FR 6753 (February 10, 2010) (SR-CBOE-2010-007; SR-ISE-2009-106; SR-NYSEAmex-2009-86; and SR-NYSEArca-2009-110) (Order Granting Approval of Proposed Rule Changes and Notice of Filing and Order Granting Accelerated Approval of a Proposed Rule Change Relating to Listing and Trading Options on the ETFS Gold Trust and the ETFS Silver Trust).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>63</SU>
                         
                        <E T="03">Id.</E>
                    </P>
                </FTNT>
                <P>Further, the Exchange's proposal to amend the name “ETFS Gold Trust” to “Aberdeen Standard Physical Gold Trust” in Exchange Rule 402(i)(4) is consistent with the Act and the protection of investors as this amendment reflects the current name of this product.</P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>
                    The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act. In this regard and as indicated above, the Exchange notes that the rule change is being proposed as a competitive response to filings submitted by ISE.
                    <SU>64</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>64</SU>
                         
                        <E T="03">See supra</E>
                         note 6.
                    </P>
                </FTNT>
                <P>The Exchange does not believe that the proposed rule change will impose any burden on intramarket competition that is not necessary or appropriate in furtherance of the purposes of the Act as options on the Trust will be subject to initial listing standards and continued listing standards the same as other options on ETFs listed on the Exchange. Further, options on the Trust will be subject to Exchange Rules that currently govern the listing and trading of options on ETFs, including permissible expirations, strike prices, minimum increments, position and exercise limits (including as proposed to modify herein), and margin requirements. Options on the Trust will be equally available to all market participants who wish to trade such options. Also, and as stated above, the Exchange already lists options on other commodity ETFs structured as a trust.</P>
                <P>The Exchange does not believe that the proposal to list to list and trade options on the Trust will impose any burden on intermarket competition that is not necessary or appropriate in furtherance of the purposes of the Act. To the extent that permitting options on the Trust to trade on the Exchange may make the Exchange a more attractive marketplace to market participants, such market participants are free to elect to become market participants on the Exchange. Additionally, other options exchanges are free to amend their listing rules, as applicable, to permit them to list and trade options on the Trust. The Exchange believes that the proposed rule change may relieve any burden on, or otherwise promote, competition as it is designed to increase competition for order flow on the Exchange in a manner that is beneficial to investors by providing them with a lower-cost option to hedge their investment portfolios. The Exchange notes that it operates in a highly competitive market in which market participants can readily direct order flow to competing venues that offer similar products. Ultimately, the Exchange believes that offering options on the Trust for trading on the Exchange will promote competition by providing investors with an additional, relatively low-cost means to hedge their portfolios and meet their investment needs in connection with spot bitcoin prices and bitcoin related products and positions.</P>
                <P>Finally, the Exchange's proposal to amend the name “ETFS Gold Trust” to “Aberdeen Standard Physical Gold Trust” in Exchange Rule 402(i)(4) does not impose an undue burden on competition as this amendment reflects the current name of this product.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>Written comments were neither solicited nor received.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The Exchange has filed the proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>65</SU>
                    <FTREF/>
                     and Rule 19b-4(f)(6) thereunder.
                    <SU>66</SU>
                    <FTREF/>
                     Because the foregoing proposed rule change does not: (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative for 30 days from the date on which it was filed, or such shorter time as the Commission may designate, it has become effective pursuant to Section 19(b)(3)(A)(iii) of the Act 
                    <SU>67</SU>
                    <FTREF/>
                     and subparagraph (f)(6) of Rule 19b-4 thereunder.
                    <SU>68</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>65</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>66</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>67</SU>
                         15 U.S.C. 78s(b)(3)(A)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>68</SU>
                         17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6)(iii) requires a self-regulatory organization to give the Commission written notice of its intent to file the proposed rule change, along with a brief description and text of the proposed rule change, at least five business days prior to the date of filing of the proposed rule change, or such shorter time 
                        <PRTPAGE/>
                        as designated by the Commission. The Exchange has satisfied this requirement.
                    </P>
                </FTNT>
                <PRTPAGE P="93810"/>
                <P>
                    A proposed rule change filed under Rule 19b-4(f)(6) 
                    <SU>69</SU>
                    <FTREF/>
                     under the Act does not normally become operative prior to 30 days after the date of the filing. However, pursuant to Rule 19b-4(f)(6)(iii),
                    <SU>70</SU>
                    <FTREF/>
                     the Commission may designate a shorter time if such action is consistent with the protection of investors and the public interest. The Exchange has requested that the Commission waive the 30-day operative delay so that the proposal may become operative immediately upon filing. The Commission previously approved the listing of options on iShares Bitcoin Trust.
                    <SU>71</SU>
                    <FTREF/>
                     The Exchange has provided information regarding the underlying iShares Bitcoin Trust, including, among other things, information regarding trading volume, the number of beneficial holders, and the market capitalization of the iShares Bitcoin Trust. The proposal also establishes position and exercise limits for options on the iShares Bitcoin Trust and provides information regarding the surveillance procedures that will apply to iShares Bitcoin Trust options. The Commission believes that waiver of the operative delay could benefit investors by providing an additional venue for trading iShares Bitcoin Trust options. Therefore, the Commission believes that waiver of the 30-day operative delay is consistent with the protection of investors and the public interest. Accordingly, the Commission hereby waives the 30-day operative delay and designates the proposed rule change as operative upon filing.
                    <SU>72</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>69</SU>
                         17 CFR 240.19b-4(f)(6).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>70</SU>
                         17 CFR 240.19b-4(f)(6)(iii).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>71</SU>
                         
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 101128 (September 20, 2024), 89 FR 78942 (September 26, 2024) (SR-ISE-2024-03) (Self-Regulatory Organizations; Nasdaq ISE, LLC; Notice of Filing of Amendment Nos. 4 and 5 and Order Granting Accelerated Approval of a Proposed Rule Change, as Modified by Amendment Nos. 1, 4, and 5, to Permit the Listing and Trading of Options on the iShares Bitcoin Trust).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>72</SU>
                         For purposes only of waiving the 30-day operative delay, the Commission has also considered the proposed rule's impact on efficiency, competition, and capital formation. 
                        <E T="03">See</E>
                         15 U.S.C. 78c(f).
                    </P>
                </FTNT>
                <P>At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings to determine whether the proposed rule should be approved or disapproved.</P>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-MIAX-2024-40 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-MIAX-2024-40. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright protection. All submissions should refer to file number SR-MIAX-2024-40 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>73</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>73</SU>
                             17 CFR 200.30-3(a)(12), (59).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27741 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">SECURITIES AND EXCHANGE COMMISSION</AGENCY>
                <DEPDOC>[Release No. 34-101688; File No. SR-GEMX-2024-40]</DEPDOC>
                <SUBJECT>Self-Regulatory Organizations; Nasdaq GEMX, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend Its Fees for Connectivity and Co-Location Services</SUBJECT>
                <DATE>November 21, 2024.</DATE>
                <P>
                    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”),
                    <SU>1</SU>
                    <FTREF/>
                     and Rule 19b-4 thereunder,
                    <SU>2</SU>
                    <FTREF/>
                     notice is hereby given that on November 8, 2024, Nasdaq GEMX, LLC (“GEMX” or “Exchange”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         15 U.S.C. 78s(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         17 CFR 240.19b-4.
                    </P>
                </FTNT>
                <HD SOURCE="HD1">I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change</HD>
                <P>The Exchange proposes to amend the Exchange's fees for connectivity and co-location services, as described further below.</P>
                <P>
                    The text of the proposed rule change is available on the Exchange's website at 
                    <E T="03">https://listingcenter.nasdaq.com/rulebook/gemx/rules,</E>
                     at the principal office of the Exchange, and at the Commission's Public Reference Room.
                </P>
                <HD SOURCE="HD1">II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <P>
                    In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of 
                    <PRTPAGE P="93811"/>
                    the most significant aspects of such statements.
                </P>
                <HD SOURCE="HD2">A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change</HD>
                <HD SOURCE="HD3">1. Purpose</HD>
                <P>
                    The purpose of the proposed rule change is to amend the Exchange's fees relating to connectivity and co-location services.
                    <SU>3</SU>
                    <FTREF/>
                     Specifically, the Exchange proposes to raise its fees for connectivity and co-location services in General 8 as well as certain fees related to its Testing Facilities in Options 7, Section 6 by 10%, with certain exceptions.
                </P>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         The Exchange initially filed the proposed pricing change on March 1, 2024 (SR-GEMX-2024-05). On April 29, 2024, the Exchange withdrew that filing and submitted SR-GEMX-2024-09. On June 27, 2024, the Exchange withdrew SR-GEMX-2024-09 and submitted SR-GEMX-2024-15. The Exchange withdrew SR-GEMX-2024-15 and replaced it with SR-GEMX-2024-33 on September 10, 2024. On October 11, 2024, the Exchange replaced SR-GEMX-2024-33 with SR-GEMX-2024-38. The instant filing replaces SR-GEMX-2024-38.
                    </P>
                </FTNT>
                <P>
                    General 8, Section 1 includes the Exchange's fees that relate to connectivity, including fees for cabinets, external telco/inter-cabinet connectivity fees, fees for connectivity to the Exchange, fees for connectivity to third party services, fees for market data connectivity, fees for cabinet power install, and fees for additional charges and services. General 8, Section 2 includes the Exchange's fees for direct connectivity services, including fees for direct circuit connection to the Exchange, fees for direct circuit connection to third party services, and fees for point of presence connectivity. With the exception of the Exchange's GPS Antenna fees and the Cabinet Proximity Option Fee for cabinets with power density &gt;10kW,
                    <SU>4</SU>
                    <FTREF/>
                     the Exchange proposes to increase its fees throughout General 8 by 10%.
                </P>
                <FTNT>
                    <P>
                        <SU>4</SU>
                         The Exchange proposes to exclude the GPS Antenna fees from the proposed fee increase because, unlike the other fees in General 8, the Exchange recently increased its GPS Antenna fees. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-99129 (December 11, 2023), 88 FR 87017 (December 15, 2023) (SR-GEMX-2023-17). The Exchange also proposes to exclude the Cabinet Proximity Option Fee for cabinets with power density &gt;10kW from the proposed fee increase because the Exchange recently established such fee. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-100210 (May 22, 2024), 89 FR 46476 (May 29, 2024) (SR-GEMX-2024-11). Similarly, the Exchange proposes to exclude from the proposed fee increase those fees that the Exchange recently established for services in its new NY11-4 expansion facility. 
                        <E T="03">See</E>
                         Securities Exchange Act Release No. 34-101262 (October 7, 2024), 89 FR 82649 (October 11, 2024) (SR-GEMX-2024-36).
                    </P>
                </FTNT>
                <P>In addition to increasing fees in General 8, the Exchange also proposes to increase certain fees in Options 7, Section 6, which relate to the Testing Facility. Options 7, Section 6(H) provides that subscribers to the Testing Facility located in Carteret, New Jersey shall pay a fee of $1,000 per hand-off, per month for connection to the Testing Facility. The hand-off fee includes either a 1Gb or 10Gb switch port and a cross connect to the Testing Facility. In addition, Options 7, Section 6(H) provides that subscribers shall also pay a one-time installation fee of $1,000 per hand-off. The Exchange proposes to increase these aforementioned fees by 10% to require that subscribers to the Testing Facility shall pay a fee of $1,100 per hand-off, per month for connection to the Testing Facility and a one-time installation fee of $1,100 per hand-off.</P>
                <P>The proposed increases in fees would enable the Exchange to maintain and improve its market technology and services to remain competitive with its peers. Over the years, customer demand for more sophisticated, higher-throughput, lower-latency, and higher-power connectivity solutions has increased. The Exchange continues to invest in maintaining, improving, and enhancing its connectivity and co-location products, services, and facilities—for the benefit and often at the behest of its customers. Such enhancements include refreshing hardware and expanding Nasdaq's existing co-location facility to offer customers additional space and power. Nevertheless, and with the exception of fees that were established as part of a new service in 2017 (and have remained unchanged since their adoption), the Exchange has not increased any of the fees included in the proposal since prior to 2017, and many of the fees date back to between 2010 and 2014. For each of the connectivity products and services that pre-date 2017, inflation (as measured using the “Data PPI” metric described below) has been between roughly 15-17%, and in no instance has such inflation been less than 10%. Nevertheless, the Exchange proposes to increase its fees only with respect to the 10% inflation that has occurred since 2017.</P>
                <P>As discussed below, the Exchange proposes to adjust its fees by an industry- and product-specific inflationary measure. It is reasonable and consistent with the Act for the Exchange to recoup its investments, at least in part, by adjusting its fees. Continuing to operate at fees frozen at 2010-2017 levels impacts the Exchange's ability to enhance its offerings and the interests of market participants and investors.</P>
                <P>
                    The fee increases the Exchange proposes are based on an industry-specific Producer Price Index (“PPI”), which is a tailored measure of inflation.
                    <SU>5</SU>
                    <FTREF/>
                     As a general matter, the Producer Price Index is a family of indexes that measures the average change over time in selling prices received by domestic producers of goods and services. PPI measures price change from the perspective of the seller. This contrasts with other metrics, such as the Consumer Price Index (“CPI”), that measure price change from the purchaser's perspective.
                    <SU>6</SU>
                    <FTREF/>
                     About 10,000 PPIs for individual products and groups of products are tracked and released each month.
                    <SU>7</SU>
                    <FTREF/>
                     PPIs are available for the output of nearly all industries in the goods-producing sectors of the U.S. economy—mining, manufacturing, agriculture, fishing, and forestry—as well as natural gas, electricity, and construction, among others. The PPI program covers approximately 69 percent of the service sector's output, as measured by revenue reported in the 2017 Economic Census.
                </P>
                <FTNT>
                    <P>
                        <SU>5</SU>
                         
                        <E T="03">See https://fred.stlouisfed.org/series/PCU51825182#0.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>6</SU>
                         
                        <E T="03">See https://www.bls.gov/ppi/overview.htm.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>7</SU>
                         
                        <E T="03">See Id.</E>
                    </P>
                </FTNT>
                <P>For purposes of this proposal, the relevant industry-specific PPI is the Data Processing and Related Services PPI (“Data PPI”), which is an industry net-output PPI that measures the average change in selling prices received by companies that provide data processing services.</P>
                <P>
                    The Data PPI was introduced in January 2002 by the Bureau of Labor Statistics (“BLS”) as part of an ongoing effort to expand Producer Price Index coverage of the services sector of the U.S. economy and is identified as NAICS-518210 in the North American Industry Classification System.
                    <SU>8</SU>
                    <FTREF/>
                     According to the BLS “[t]he primary output of NAICS 518210 is the provision of electronic data processing services. In the broadest sense, computer services companies help their customers efficiently use technology. The processing services market consists of vendors who use their own computer systems—often utilizing proprietary softwar—to process customers' transactions and data. Companies that offer processing services collect, organize, and store a customer's transactions and other data for record-keeping purposes. Price movements for the NAICS 518210 index are based on changes in the revenue received by companies that provide data processing 
                    <PRTPAGE P="93812"/>
                    services. Each month, companies provide net transaction prices for a specified service. The transaction is an actual contract selected by probability, where the price-determining characteristics are held constant while the service is repriced. The prices used in index calculation are the actual prices billed for the selected service contract.” 
                    <SU>9</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>8</SU>
                         
                        <E T="03">NAICS appears in table 5 of the PPI Detailed Report and is available at https://data.bls.gov/timeseries/PCU518210518210.</E>
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>9</SU>
                         
                        <E T="03">See https://www.bls.gov/ppi/factsheets/producer-price-index-for-the-data-processing-and-related-servicesindustry-naics-518210.htm.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange believes the Data PPI is an appropriate measure to be considered in the context of the proposed rule change to modify the fee for its connectivity products because the Exchange uses its “own computer systems” and “proprietary software,” 
                    <E T="03">i.e.,</E>
                     its own data center and proprietary matching engine software, respectively, to collect, organize, store and report customers' transactions in U.S. equity securities on the Exchange's proprietary trading platform. In other words, the Exchange is in the business of data processing and related services.
                </P>
                <P>For purposes of this proposed rule change, the Exchange examined the Data PPI value for the period from January 2017 to August 2024. The Data PPI had a starting value of 105.6 in January 2017 and an ending value of 116.022 in August 2024, a 10.422% increase. This indicates that companies who are also in the data storage and processing business have generally increased prices for a specified service covered under NAICS 518210 by an average of 10.422% during this period. Based on that percentage change, the Exchange proposes to make a one-time fee increase of only 10%, which reflects an increase covering roughly the entire period since the last price adjustments to these fees were made.</P>
                <P>
                    The Exchange further believes the Data PPI is an appropriate measure for purposes of the proposed rule change on the basis that it is a stable metric with limited volatility, unlike other consumer-side inflation metrics. In fact, the Data PPI has not experienced a greater than 2.16% increase for any one calendar year period since Data PPI was introduced into the PPI in January 2002. The average calendar year change from January 2002 to December 2023 was .62%, with a cumulative increase of 15.67% over this 21-year period. The Exchange believes the Data PPI is considerably less volatile than other inflation metrics such as CPI, which has had individual calendar-year increases of more than 6.5%, and a cumulative increase of over 73% over the same period.
                    <SU>10</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>10</SU>
                         
                        <E T="03">See https://www.usinflationcalculator.com/inflation/consumer-price-index-and-annual-percent-changesfrom-1913-to-2008/.</E>
                    </P>
                </FTNT>
                <P>
                    The Exchange believes the Data PPI, and significant investments into, and enhanced performance of, the Exchange support the reasonableness of the proposed fee increases.
                    <SU>11</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>11</SU>
                         
                        <E T="03">See supra</E>
                         discussion of connectivity product and facility improvements. Additionally, other exchanges have filed for increases in certain fees, based in part on comparisons to inflation. See, 
                        <E T="03">e.g.,</E>
                         Securities Exchange Act Release Nos. 34-100004 (April 22, 2024), 89 FR 32465 (April 26, 2024) (SR-CboeBYX-2024-012); and 34-100398 (June 21, 2024), 89 FR 53676 (June 27, 2024) (SR-BOX-2024-16)l; Securities Exchange Act Release No. 34-100994 (September 10, 2024), 89 FR 75612 (September 16, 2024) (SR-NYSEARCA-2024-79).
                    </P>
                </FTNT>
                <P>
                    These proposed fee increases will be immediately effective upon filing. However, going forward and until December 1, 2024, the Exchange will waive all fees set forth herein to the extent that such fees exceed the levels that would have been charged for the same products and services purchased during that time period, had such fees been calculated at the rates set forth in SR-GEMX-2024-33 (
                    <E T="03">i.e.,</E>
                     pricing reflective of a 5.5% increase from prior fee levels). This waiver is reasonable, equitable, and not unfairly discriminatory because it will afford all customers in excess of the 30-day prior notice period for fee changes set forth in the Exchange's service terms.
                </P>
                <HD SOURCE="HD3">2. Statutory Basis</HD>
                <P>
                    The Exchange believes that its proposal is consistent with Section 6(b) of the Act,
                    <SU>12</SU>
                    <FTREF/>
                     in general, and furthers the objectives of Sections 6(b)(4) and 6(b)(5) of the Act,
                    <SU>13</SU>
                    <FTREF/>
                     in particular, in that it provides for the equitable allocation of reasonable dues, fees and other charges among members and issuers and other persons using any facility, and is not designed to permit unfair discrimination between customers, issuers, brokers, or dealers.
                </P>
                <FTNT>
                    <P>
                        <SU>12</SU>
                         15 U.S.C. 78f(b).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>13</SU>
                         15 U.S.C. 78f(b)(4) and (5).
                    </P>
                </FTNT>
                <P>This belief is based on two factors. First, the current fees do not properly reflect the quality of the services and products, as fees for the services and products in question have been static in nominal terms, and therefore falling in real terms due to inflation. Second, the Exchange believes that investments made in enhancing the capacity and speed of Exchange systems increase the performance of the services and products.</P>
                <HD SOURCE="HD3">The Proposed Rule Change Is Reasonable</HD>
                <P>
                    As noted above, the Exchange has not increased any of the fees included in the proposal since 2017 or earlier. However, in the years following the last fee increases, the Exchange has made significant investments in upgrades to its connectivity products, services, and facilities, enhancing the quality of its services. In other words, Exchange customers have greatly benefitted, while the Exchange's ability to recoup its investments has been hampered. Between 2017 and 2024, the inflation rate is 3.64% per year, on average, producing a cumulative inflation rate of 28.43%.
                    <SU>14</SU>
                    <FTREF/>
                     Using the more targeted inflation number of Data PPI, the cumulative inflation rate was 10.422%. The exchange believes the Data PPI is a reasonable metric to base this fee increase on because it is targeted to producer-side increases in the data processing industry.
                </P>
                <FTNT>
                    <P>
                        <SU>14</SU>
                         
                        <E T="03">See https://www.officialdata.org/us/inflation/2017?amount=1.</E>
                    </P>
                </FTNT>
                <P>
                    Notwithstanding inflation, as noted above, the Exchange has not increased its fees at all for over seven years for the subject services. The proposed fee changes represent a modest increase from the current fees. The Exchange believes the proposed fee increase is reasonable in light of the Exchange's continued expenditure in maintaining a robust technology ecosystem. Furthermore, the Exchange continues to invest in maintaining and enhancing its connectivity products—for the benefit and often at the behest of its customers and global investors. Such enhancements include refreshing all aspects of the technology ecosystem including software, hardware, and network while introducing new and innovative products and expanded and modernized facilities.
                    <SU>15</SU>
                    <FTREF/>
                     The goal of the enhancements discussed above, among other things, is to provide faster, higher-capacity, and more modern connectivity products and services. Accordingly, the Exchange continues to expend resources to innovate and modernize technology so that it may benefit its members in offering its connectivity products and services.
                </P>
                <FTNT>
                    <P>
                        <SU>15</SU>
                         
                        <E T="03">See, e.g.,</E>
                         Securities Exchange Act Release No.34-101074 (September 18, 2024), 89 FR 77920 (September 24, 2024) (SR-GEMX-2024-34 (Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Expand [the Exchange's] Co-Location Services).
                    </P>
                </FTNT>
                <HD SOURCE="HD3">The Proposed Fees Are Equitably Allocated and Not Unfairly Discriminatory</HD>
                <P>
                    The Exchange believes that the proposed fee increases are equitably 
                    <PRTPAGE P="93813"/>
                    allocated and not unfairly discriminatory because they would apply to all market participants that choose to purchase connectivity products and services from the Exchange. Any participant that chooses to purchase the Exchange's connectivity products and services would be subject to the same Fee Schedule, regardless of what type of business they operate or the use they plan to make use of the products and services. Additionally, the fee increase would be applied uniformly to market participants without regard to Exchange membership status or the extent of any other business with the Exchange or affiliated entities. The Exchange also believes that the proposal represents an equitable allocation of reasonable dues, fees and other charges because Exchange fees have fallen in real terms during the relevant period. Finally, the Exchange believes that the proposed fee changes are not unfairly discriminatory because the fees would be assessed uniformly across all market participants, in the same manner they are today, that voluntarily purchase the Exchange's connectivity products and services, which would remain available for purchase by all market participants.
                </P>
                <P>
                    These proposed fee increases will be immediately effective upon filing. However, going forward and until December 1, 2024, the Exchange will waive all fees set forth herein to the extent that such fees exceed the levels that would have been charged for the same products and services purchased during that time period, had such fees been calculated at the rates set forth in SR-GEMX-2024-33 (
                    <E T="03">i.e.,</E>
                     pricing reflective of a 5.5% increase from prior fee levels). This waiver is reasonable, equitable, and not unfairly discriminatory because it will afford all customers in excess of the 30-day prior notice period for fee changes set forth in the Exchange's service terms.
                </P>
                <HD SOURCE="HD2">B. Self-Regulatory Organization's Statement on Burden on Competition</HD>
                <P>The Exchange does not believe that the proposed fees will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.</P>
                <HD SOURCE="HD3">Intramarket Competition</HD>
                <P>The Exchange believes that the proposed fees do not put any market participants at a relative disadvantage compared to other market participants. As noted above, the fee schedule would continue to apply to all purchasers of the Exchange's connectivity products and services in the same manner as it does today albeit at inflation-adjusted rates for certain fees, and customers may choose whether to purchase these products and services at all. The Exchange also believes that the level of the proposed fees neither favor nor penalize one or more categories of market participants in a manner that would impose an undue burden on competition. Likewise, the proposed fee waiver described above will apply to all purchasers of the Exchange's connectivity products and services in the same manner and therefore will not burden competition among them.</P>
                <HD SOURCE="HD3">Intermarket Competition</HD>
                <P>The Exchange believes that the proposed fees do not impose a burden on competition or on other SROs that is not necessary or appropriate. In determining the proposed fees, the Exchange utilized an objective and stable metric with limited volatility. Utilizing Data PPI over a specified period of time is a reasonable means of recouping the Exchange's investment in maintaining and enhancing its connectivity products, services, and facilities. The Exchange believes utilizing Data PPI, a tailored measure of inflation, to increase certain fees for connectivity products and services to recoup the Exchange's investment in maintaining and enhancing such products, services, and its facilities would not impose a burden on competition.</P>
                <HD SOURCE="HD2">C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others</HD>
                <P>No written comments were either solicited or received.</P>
                <HD SOURCE="HD1">III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action</HD>
                <P>
                    The foregoing rule change has become effective pursuant to Section 19(b)(3)(A)(ii) of the Act.
                    <SU>16</SU>
                    <FTREF/>
                     At any time within 60 days of the filing of the proposed rule change, the Commission summarily may temporarily suspend such rule change if it appears to the Commission that such action is: (i) necessary or appropriate in the public interest; (ii) for the protection of investors; or (iii) otherwise in furtherance of the purposes of the Act. If the Commission takes such action, the Commission shall institute proceedings to determine whether the proposed rule should be approved or disapproved.
                </P>
                <FTNT>
                    <P>
                        <SU>16</SU>
                         15 U.S.C. 78s(b)(3)(A)(ii).
                    </P>
                </FTNT>
                <HD SOURCE="HD1">IV. Solicitation of Comments</HD>
                <P>Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:</P>
                <HD SOURCE="HD2">Electronic Comments</HD>
                <P>
                    • Use the Commission's internet comment form (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ); or
                </P>
                <P>
                    • Send an email to 
                    <E T="03">rule-comments@sec.gov.</E>
                     Please include file number SR-GEMX-2024-40 on the subject line.
                </P>
                <HD SOURCE="HD2">Paper Comments</HD>
                <P>• Send paper comments in triplicate to Secretary, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549-1090.</P>
                <FP>
                    All submissions should refer to file number SR-GEMX-2024-40. This file number should be included on the subject line if email is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's internet website (
                    <E T="03">https://www.sec.gov/rules/sro.shtml</E>
                    ). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. Do not include personal identifiable information in submissions; you should submit only information that you wish to make available publicly. We may redact in part or withhold entirely from publication submitted material that is obscene or subject to copyright  protection. All submissions should refer to file number SR-GEMX-2024-40 and should be submitted on or before December 18, 2024.
                </FP>
                <SIG>
                    <PRTPAGE P="93814"/>
                    <P>
                        For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.
                        <SU>17</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>17</SU>
                             17 CFR 200.30-3(a)(12).
                        </P>
                    </FTNT>
                    <NAME>Sherry R. Haywood,</NAME>
                    <TITLE>Assistant Secretary.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27757 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8011-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">SOCIAL SECURITY ADMINISTRATION</AGENCY>
                <DEPDOC>[Docket No: SSA-2024-0050]</DEPDOC>
                <SUBJECT>Agency Information Collection Activities: Proposed Request and Comment Request</SUBJECT>
                <P>The Social Security Administration (SSA) publishes a list of information collection packages requiring clearance by the Office of Management and Budget (OMB) in compliance with Public Law 104-13, the Paperwork Reduction Act of 1995, effective October 1, 1995. This notice includes a revision of an OMB-approved information collection.</P>
                <P>SSA is soliciting comments on the accuracy of the agency's burden estimate; the need for the information; its practical utility; ways to enhance its quality, utility, and clarity; and ways to minimize burden on respondents, including the use of automated collection techniques or other forms of information technology. Mail, email, or fax your comments and recommendations on the information collection(s) to the OMB Desk Officer and SSA Reports Clearance Officer at the following addresses or fax numbers.</P>
                <FP SOURCE="FP-1">(OMB), Office of Management and Budget, Attn: Desk Officer for SSA</FP>
                <FP SOURCE="FP-1">
                    (SSA), Social Security Administration, OLCA, Attn: Reports Clearance Director, Mail Stop 3253 Altmeyer, 6401 Security Blvd., Baltimore, MD 21235, Fax: 833-410-1631, Email address: 
                    <E T="03">OR.Reports.Clearance@ssa.gov</E>
                </FP>
                <P>
                    Or you may submit your comments online through 
                    <E T="03">https://www.reginfo.gov/public/do/PRAmain</E>
                     by clicking on Currently under Review—Open for Public Comments and choosing to click on one of SSA's published items. Please reference Docket ID Number [SSA-2024-0050] in your submitted response.
                </P>
                <P>The information collection below is pending at SSA. SSA will submit it to OMB within 60 days from the date of this notice. To be sure we consider your comments, we must receive them no later than January 27, 2025. Individuals can obtain copies of the collection instruments by writing to the above email address.</P>
                <P>
                    <E T="03">Rules of Conduct and Standards of Responsibility for Appointed Representatives—20 CFR 404.1740(b)(5), 404.1740(b)(6), 404.1740(b)(9), 416.1540(b)(5), 416.1540(b)(6), and 416.1540(b)(9)—0960-0804.</E>
                     Section 205(a) of the Social Security Act (the Act) authorizes SSA's Commissioner to make rules and regulations and to establish procedures, not inconsistent with the provisions of this title, which are necessary or appropriate to carry out such provisions. Section 1631(d)(1) of the Act incorporates section 205(a) and applies it to Title XVI of the Act. Additionally, sections 206(a) and 1631(d)(2) of the Act provide that the Commissioner has the authority to establish rules and regulations governing the recognition of individuals who represent claimants before the Commissioner. Individuals appointed to represent claimants before SSA must report to SSA in writing whenever one of the following situations in our revised regulations occurs:
                </P>
                <P>
                    • 
                    <E T="03">20 CFR 404.1740(b)(5) and 416.1540(b)(5)</E>
                    —This regulatory section requires representatives to disclose to SSA in writing, at the time a medical or vocational opinion is submitted to SSA, or as soon as the representative is aware of the submission to us, if the representative's employee or any individual contracting with the representative drafted, prepared, or issued a medical or vocational opinion about a claimant's disability, or if the representative referred or suggested that the claimant seek an examination from, treatment by, or the assistance of the individual providing opinion evidence;
                </P>
                <P>
                    • 
                    <E T="03">20 CFR 404.1740(b)(6) and 416.1540(b)(6)</E>
                    —This regulatory section requires representatives to disclose to SSA immediately if the representative discovers that his or her services are or were used by the claimant to commit fraud against SSA;
                </P>
                <P>A representative's obligation to report these events is ongoing, and SSA requires representatives to report any time one or more of these events occurs. We consider this information essential to ensure the integrity of our administrative process and to safeguard the rights of all claimants. SSA requires representatives to notify SSA in writing, but there is no prescribed format for these reports. The respondents are individuals appointed to represent claimants before SSA.</P>
                <P>
                    <E T="03">Type of Request:</E>
                     Revision of an OMB-approved information collection.
                </P>
                <GPOTABLE COLS="7" OPTS="L2,nj,tp0,p7,7/8,i1" CDEF="s50,12C,12C,12C,12C,12C,12C">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Regulation citations</CHED>
                        <CHED H="1">
                            Number of
                            <LI>respondents</LI>
                        </CHED>
                        <CHED H="1">Frequency of response</CHED>
                        <CHED H="1">
                            Average 
                            <LI>burden per </LI>
                            <LI>response</LI>
                            <LI>(minutes)</LI>
                        </CHED>
                        <CHED H="1">
                            Estimated 
                            <LI>annual burden</LI>
                            <LI>(hours)</LI>
                        </CHED>
                        <CHED H="1">
                            Average 
                            <LI>theoretical hourly cost amount</LI>
                            <LI>(dollars) *</LI>
                        </CHED>
                        <CHED H="1">Total annual opportunity cost (dollars) **</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">404.1740(b)(5)&amp;(6)/416.1540(b)(5)&amp;(6)</ENT>
                        <ENT>43,600</ENT>
                        <ENT>1</ENT>
                        <ENT>5</ENT>
                        <ENT>3,633</ENT>
                        <ENT>$58.40</ENT>
                        <ENT>$212,149</ENT>
                    </ROW>
                    <TNOTE>
                        * We based this figure on average hourly wages for paralegals/legal assistants and lawyers 
                        <E T="03">https://www.bls.gov/oes/current/oes231011.htm</E>
                         as posted by the U.S. Bureau of Labor Statistics (
                        <E T="03">https://www.bls.gov/oes/current/oes_nat.htm</E>
                        ).
                    </TNOTE>
                    <TNOTE>** These figures do not represent actual costs that SSA is imposing on representatives to complete the required disclosures; rather, these are theoretical opportunity costs for the additional time representatives or their employees and associates will spend to complete the required disclosures. There is no actual charge to representatives to complete the required disclosures.</TNOTE>
                </GPOTABLE>
                <SIG>
                    <PRTPAGE P="93815"/>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Naomi Sipple,</NAME>
                    <TITLE>Reports Clearance Officer, Social Security Administration.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27811 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4191-02-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF STATE</AGENCY>
                <DEPDOC>[Public Notice: 12596]</DEPDOC>
                <SUBJECT>Notice of Public Meeting in Preparation for International Maritime Organization Eleventh Session of the Sub-Committee on Ship Design and Construction (SDC) Meeting</SUBJECT>
                <P>The Department of State will conduct a public meeting at 11 a.m. on Wednesday, January 8, 2025, both in-person at Coast Guard Headquarters in Washington, DC, and via teleconference. The primary purpose of the meeting is to prepare for the 11th session of the International Maritime Organization's (IMO) Sub-committee on Ship Design and Construction (SDC) to be held at IMO Headquarters in London, United Kingdom from Monday, January 13 to Friday, January 17, 2025.</P>
                <P>
                    Members of the public may participate up to the capacity of the teleconference phone line, which can handle 500 participants or up to the seating capacity of the room if attending in person. The meeting location will be the United States Coast Guard Headquarters, and the teleconference line will be provided to those who RSVP. To RSVP, participants should contact the meeting coordinator, LCDR Bryan Andrews, by email at 
                    <E T="03">bryan.j.andrews@uscg.mil.</E>
                     LCDR Andrews will provide access information for in-person and virtual attendance.
                </P>
                <P>The agenda items to be considered at SDC 11 include:</P>
                <FP SOURCE="FP-1">—Adoption of the agenda</FP>
                <FP SOURCE="FP-1">—Decisions of other IMO bodies</FP>
                <FP SOURCE="FP-1">—Development of Guidelines for emergency towing arrangements for ships other than tankers (2.20)</FP>
                <FP SOURCE="FP-1">—Further development of the IP Code and associated guidance (2.4)</FP>
                <FP SOURCE="FP-1">—Revision of the Interim explanatory notes for the assessment of passenger ship systems' capabilities after a fire or flooding casualty (MSC.1/Circ.1369) and related circulars (7.42)</FP>
                <FP SOURCE="FP-1">—Amendments to the 2011 ESP Code (7.21)</FP>
                <FP SOURCE="FP-1">—Amendments to the Guidelines for construction, installation, maintenance and inspection/survey of means of embarkation and disembarkation (MSC.1/Circ.1331) concerning the rigging of safety netting on accommodation ladders and gangways (7.35)</FP>
                <FP SOURCE="FP-1">—Revision of SOLAS chapters II-1 (part C) and V, and related instruments regarding steering and propulsion requirements, to address both traditional and non-traditional propulsion and steering systems. (2.9)</FP>
                <FP SOURCE="FP-1">—Amendment to regulation 25 of the 1988 Load Line Protocol regarding the requirement for setting of guard rails on the deck structure (7.25) Unified interpretation of provisions of IMO safety, security, environment, facilitation, liability and compensation-related conventions (7.1)</FP>
                <FP SOURCE="FP-1">—Guidelines for use of Fibre-Reinforced Plastics (FRP) within ship structures (2.6)</FP>
                <FP SOURCE="FP-1">—Review of the 2009 Code on Alerts and Indicators (7.47)</FP>
                <FP SOURCE="FP-1">—Biennial status report and provisional agenda for SDC 12</FP>
                <FP SOURCE="FP-1">—Election of Chair and Vice-Chair for 2026</FP>
                <FP SOURCE="FP-1">—Experience-building phase for the reduction of underwater radiated noise from shipping (1.16)</FP>
                <FP SOURCE="FP-1">—Any other business</FP>
                <FP SOURCE="FP-1">—Report to the Maritime Safety Committee</FP>
                <P>
                    <E T="03">Please note:</E>
                     The IMO may, on short notice, adjust the SDC 11 agenda to accommodate the constraints associated with the meeting format. Any changes to the agenda will be reported to those who RSVP.
                </P>
                <P>
                    Those who plan to participate should contact the meeting coordinator, LCDR Bryan Andrews, by email at 
                    <E T="03">bryan.j.andrews@uscg.mil,</E>
                     or in writing at 2703 Martin Luther King Jr. Ave. SE, Stop 7509, Washington, DC 20593-7509, by December 20, 2024. Please note that, due to security considerations, two valid, government issued photo identifications must be presented to gain entrance to the Douglas A. Munro Coast Guard Headquarters Building at St. Elizabeth's. This building is accessible by taxi, public transportation, and privately owned conveyance (upon request). Additionally, members of the public needing reasonable accommodation should advise the meeting coordinator not later than December 20, 2024. Requests made after that date will be considered but might not be possible to fulfill.
                </P>
                <P>
                    Additional information regarding this and other IMO public meetings may be found at: 
                    <E T="03">https://www.dco.uscg.mil/IMO</E>
                    .
                </P>
                <EXTRACT>
                    <FP>(Authority: 22 U.S.C. 2656 and 5 U.S.C. 552)</FP>
                </EXTRACT>
                <SIG>
                    <NAME>Leslie W. Hunt,</NAME>
                    <TITLE>Coast Guard Liaison Officer, Office of Ocean and Polar Affairs, Department of State.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27795 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4710-09-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF STATE</AGENCY>
                <DEPDOC>[Public Notice 12595]</DEPDOC>
                <SUBJECT>30-Day Notice of Proposed Information Collection: Foreign Service Officer Test Registration Form</SUBJECT>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of request for public comment and submission to OMB of proposed collection of information.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of State has submitted the information collection described below to the Office of Management and Budget (OMB) for approval. In accordance with the Paperwork Reduction Act of 1995 we are requesting comments on this collection from all interested individuals and organizations. The purpose of this Notice is to allow 30 days for public comment.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Submit comments up to December 18, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to 
                        <E T="03">www.reginfo.gov/public/do/PRAMain.</E>
                         Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Gailyn McClung, 771-205-1565. Direct requests for additional information regarding the collection listed in this notice, including requests for copies of the proposed collection instrument and supporting documents to Board of Examiners for the Foreign Service, Department of State SA-1, H-518. 2401 E Street NW, Washington, DC 20522.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <P>
                    • 
                    <E T="03">Title of Information Collection:</E>
                     Registration for the Foreign Service Officer Test.
                </P>
                <P>
                    • 
                    <E T="03">OMB Control Number:</E>
                     1405-0008.
                </P>
                <P>
                    • 
                    <E T="03">Type of Request:</E>
                     Extension of a Currently Approved Collection.
                </P>
                <P>
                    • 
                    <E T="03">Originating Office:</E>
                     Bureau of Human Resources, Board of Examiners.
                </P>
                <P>
                    • 
                    <E T="03">Form Number:</E>
                     DS-1998E.
                </P>
                <P>
                    • 
                    <E T="03">Respondents:</E>
                     Registrants for the Foreign Service Officer Test.
                </P>
                <P>
                    • 
                    <E T="03">Estimated Number of Respondents:</E>
                     7,000.
                </P>
                <P>
                    • 
                    <E T="03">Estimated Number of Responses:</E>
                     7,000.
                    <PRTPAGE P="93816"/>
                </P>
                <P>
                    • 
                    <E T="03">Average Time Per Response:</E>
                     2 hours.
                </P>
                <P>
                    • 
                    <E T="03">Total Estimated Burden Time:</E>
                     14,000 hours.
                </P>
                <P>
                    • 
                    <E T="03">Frequency:</E>
                     Annually.
                </P>
                <P>
                    • 
                    <E T="03">Obligation to Respond:</E>
                     Required to Obtain or Retain a Benefit.
                </P>
                <P>We are soliciting public comments to permit the Department to:</P>
                <P>• Evaluate whether the proposed information collection is necessary for the proper functions of the Department.</P>
                <P>• Evaluate the accuracy of our estimate of the time and cost burden for this proposed collection, including the validity of the methodology and assumptions used.</P>
                <P>• Enhance the quality, utility, and clarity of the information to be collected.</P>
                <P>• Minimize the reporting burden on those who are to respond, including the use of automated collection techniques or other forms of information technology.</P>
                <P>Please note that comments submitted in response to this Notice are public record. Before including any detailed personal information, you should be aware that your comments as submitted, including your personal information, will be available for public review.</P>
                <HD SOURCE="HD1">Abstract of Proposed Collection</HD>
                <P>Individuals registering for the Foreign Service Officer Test will complete a Registration Form, asking for their name, contact information, ethnicity, education and work history, and military experience. The information will be used to prepare and issue admission to the Foreign Service Officer Test, to provide data useful for improving future tests, and to conduct research studies based on the test results.</P>
                <HD SOURCE="HD1">Methodology</HD>
                <P>
                    The registration process, which includes concurrent application submission and seat selection, opens approximately four (4) weeks prior to each testing window. To register, individuals go to 
                    <E T="03">pearsonvue.com/fsot/</E>
                     during the four-week period prior to a specific testing window to create an account, submit completed eligibility verification and application forms, and select a location and seat for the specific test date.
                </P>
                <SIG>
                    <NAME>David J. Burger,</NAME>
                    <TITLE>Director, GTM/TAC/BEX, Department of State.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27735 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4710-15-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF STATE</AGENCY>
                <DEPDOC>[Public Notice: 12590]</DEPDOC>
                <SUBJECT>Request for Information for the 2025 Trafficking in Persons Report</SUBJECT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of State (“the Department”) requests written information to assist in reporting on the degree to which the United States and foreign governments meet the minimum standards for the elimination of trafficking in persons (“minimum standards”) that are prescribed by the Trafficking Victims Protection Act of 2000.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Submissions must be made in writing to the Office to Monitor and Combat Trafficking in Persons at the Department of State by 5 p.m. EST on February 3, 2025.</P>
                </DATES>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>This written information will assist in the preparation of the Trafficking in Persons Report (“TIP Report”) which the Department submits annually to the U.S. Congress on governments' concrete actions to meet the minimum standards for the elimination of trafficking in persons (“minimum standards”) that are prescribed by the Trafficking Victims Protection Act of 2000 (Div. A, Pub. L. 106-386), as amended (“TVPA”). Foreign governments that do not meet the minimum standards and are not making significant efforts to do so may be subject to restrictions on nonhumanitarian, nontrade-related foreign assistance from the United States, as defined by the TVPA. Please refer to the Information Sought Relevant to the Minimum Standards of this Notice for the questionnaire and to the Addresses, Scope of Interest, and Information Sought sections for additional instructions on submission requirements. Written submissions and supporting documentation may be submitted by the following method:</P>
                <P>
                    • 
                    <E T="03">Email: tipreport@state.gov</E>
                     for submissions related to foreign governments and 
                    <E T="03">tipreportUS@state.gov</E>
                     for submissions related to the United States.
                </P>
                <P>
                    <E T="03">Scope of Interest:</E>
                     The Department requests information relevant to assessing the United States' and foreign governments' concrete actions to meet the minimum standards for the elimination of trafficking in persons during the reporting period (April 1, 2024-March 31, 2025). The minimum standards are listed in the 
                    <E T="03">Background</E>
                     section. Submissions must include information relevant to efforts to meet the minimum standards and should include, but need not be limited to, answering the questions in the 
                    <E T="03">Information Sought</E>
                     section. Submissions need not include answers to all the questions; only those questions for which the submitter has direct professional experience should be answered, and that experience should be noted. For any critique or deficiency described, please provide a recommendation to remedy it. Note the country or countries that are the focus of the submission. Submissions may include written narratives answering the questions presented in this Notice, research, studies, statistics, fieldwork, training materials, evaluations, assessments, and other relevant evidence of local, state/provincial, and federal/central government efforts. To the extent possible, precise dates and numbers of officials or individuals affected should be included. Questions below seek to gather information and updates from the details provided and assessment on government efforts made in the 2024 TIP Report. Furthermore, we request information on the government's treatment of vulnerable populations and underserved communities, including how the government may have systemically denied opportunities to a community to participate in aspects of economic, social, and civic life that has led to heighted risk to human trafficking or how the government's anti-trafficking response may have treated certain groups differently. Written narratives providing factual information should provide citations of sources, and copies of and links to the source material should be provided. Please send electronic copies of the entire submission, including source material. If primary sources are used, such as research studies, interviews, direct observations, or other sources of quantitative or qualitative data, provide details on the research or data-gathering methodology and any supporting documentation. The Department only includes in the TIP Report information related to trafficking in persons as defined by the TVPA; it does not include, and is therefore not seeking, information on commercial sex, migrant smuggling, visa fraud, or child abuse, unless such crimes also involve the elements of sex trafficking or forced labor.
                </P>
                <P>
                    <E T="03">Confidentiality:</E>
                     Please provide the name, phone number, and email address of a single point of contact for any submission. It is Department practice not to identify in the TIP Report information concerning sources to safeguard those sources. Note, however, that any information submitted to the Department may be releasable pursuant to the provisions of the Freedom of 
                    <PRTPAGE P="93817"/>
                    Information Act or other applicable law. Submissions related to the United States will be shared with U.S. government agencies, as will submissions relevant to efforts by other U.S. government agencies.
                </P>
                <P>
                    <E T="03">Response:</E>
                     This is a request for information only; there will be no response to submissions. Remuneration for responses will not be provided. In order to expend appropriated funds, there must be specific authority to do so. The Department of State has no authority to expend funds for this purpose.
                </P>
                <HD SOURCE="HD1">Background</HD>
                <P>
                    <E T="03">Definitions:</E>
                     The TVPA defines “severe forms of trafficking in persons” as:
                </P>
                <P>• The recruitment, harboring, transportation, provision, obtaining, patronizing, or soliciting of a person for the purpose of a commercial sex act that is induced by force, fraud, or coercion, or in which the person induced to perform such act has not attained 18 years of age.</P>
                <P>○ Persons under age 18 in commercial sex are trafficking in persons victims regardless of whether force, fraud, or coercion were involved.</P>
                <P>• The recruitment, harboring, transportation, provision, or obtaining of a person for labor or services, through the use of force, fraud, or coercion, for the purpose of subjection to involuntary servitude, peonage, debt bondage, or slavery.</P>
                <P>
                    ○ Forced labor may take the form of domestic servitude, forced begging, forced criminal activity (
                    <E T="03">e.g.,</E>
                     drug smuggling), and prison labor that is not a consequence of a conviction in a court of law.
                </P>
                <P>• Children recruited or used as soldiers or for labor or services can be a severe form of human trafficking when the activity involves force, fraud, or coercion. Children may be victims regardless of gender.</P>
                <P>
                    <E T="03">The TIP Report:</E>
                     The TIP Report is the most comprehensive worldwide report assessing governments' efforts to combat trafficking in persons. It represents an annually updated global assessment of the nature and scope of trafficking in persons and the broad range of government actions to confront and eliminate it. The U.S. government uses the TIP Report to inform diplomacy, encourage partnership in creating and implementing laws and policies to combat trafficking, and target resources on prevention, protection, and prosecution programs. Worldwide, international organizations (IOs), foreign governments, and nongovernmental organizations (NGOs) use the TIP Report as a tool to examine where resources are most needed. Prosecuting traffickers, protecting victims, and preventing trafficking are the ultimate goals of the TIP Report and of the U.S government's anti-trafficking policy.
                </P>
                <P>The Department prepares the TIP Report with information from across the U.S. government, foreign government officials, nongovernmental and international organizations, survivors of trafficking in persons, published reports, and research related to every region. The TIP Report focuses on concrete actions made by governments to fight trafficking in persons, including prosecutions, convictions, and sentences for traffickers, as well as victim identification and protection measures and prevention efforts. Note that rankings only consider government actions to combat human trafficking, not NGOs' or IOs' activities. Each TIP Report narrative also includes prioritized recommendations for each country. These recommendations are used to assist the Department in measuring governments' progress from one year to the next and determining whether governments meet the minimum standards for the elimination of trafficking in persons or are making significant efforts to do so.</P>
                <P>
                    The TVPA creates a four-tier ranking system. Tier placement is based principally on the extent of concrete government action to combat trafficking. The Department first evaluates whether the government fully meets the TVPA's minimum standards for the elimination of trafficking, as set forth in Sec. 108 of the Trafficking Victims Protection Act, as amended (22 U.S.C. 7106). Governments that do so are placed on Tier 1. For other governments, the Department considers the extent of such efforts. Governments that are making significant efforts to meet the minimum standards are placed on Tier 2. Governments that do not fully meet the minimum standards and are not making significant efforts to do so are placed on Tier 3. Finally, the Department considers Watch List criteria and, when applicable, places countries on the Tier 2 Watch List. For more information, the 2024 TIP Report can be found at 
                    <E T="03">www.state.gov/reports/2024-trafficking-in-persons-report.</E>
                </P>
                <P>Since the inception of the TIP Report in 2001, the number of countries included and ranked has more than doubled; the 2024 TIP Report included 188 countries and territories. Around the world, the TIP Report and the promising practices reflected therein have inspired legislation, national action plans, policy implementation, program funding, protection mechanisms to complement prosecution efforts, and a stronger global understanding of this crime.</P>
                <P>Since 2003, the primary reporting on the United States' anti-trafficking activities has been through the annual Attorney General's Report to Congress and Assessment of U.S. Government Activities to Combat Human Trafficking mandated by section 105 of the TVPA (22 U.S.C. 7103(d)(7)). Since 2010, the TIP Report, through a collaborative interagency process, has included an assessment of U.S. government anti-trafficking efforts in light of the minimum standards to eliminate trafficking in persons set forth by the TVPA.</P>
                <HD SOURCE="HD1">Information Sought Relevant to the Minimum Standards</HD>
                <P>
                    Submissions should include, but need not be limited to, answers to relevant questions below for which the submitter has direct professional experience within the reporting period (April 1, 2024-March 31, 2025). Citations to source material should also be provided. Note the country or countries that are the focus of the submission. Please see the 
                    <E T="03">Scope of Interest</E>
                     section above for detailed information regarding submission requirements.
                </P>
                <HD SOURCE="HD1">Overview</HD>
                <P>
                    1. What were the government's major accomplishments in addressing human trafficking since April 1, 2024? In what significant ways have the government's efforts to combat trafficking in persons changed in the past year? How have new laws, regulations, policies, or implementation strategies (
                    <E T="03">e.g.,</E>
                     substantive criminal laws and procedures, mechanisms for civil remedies, and victim-witness programs, generally and in relation to court proceedings) affected its anti-trafficking response?
                </P>
                <P>2. Over the past year, what were the greatest deficiencies in the government's anti-trafficking efforts? What were the limitations on the government's ability to address human trafficking problems in practice?</P>
                <P>3. Provide additional information and/or recommendations to improve the government's anti-trafficking efforts overall.</P>
                <P>4. Highlight effective strategies and practices that other governments could consider adopting.</P>
                <HD SOURCE="HD1">Prosecution</HD>
                <P>
                    5. Provide observations regarding the implementation of existing laws, policies, and procedures. Are there gaps in anti-trafficking legislation that could be amended to improve the 
                    <PRTPAGE P="93818"/>
                    government's response? Are there any government policies that have undermined or otherwise negatively affected anti-trafficking efforts within that country?
                </P>
                <P>6. Do government officials understand the nature of all forms of trafficking? If not, provide examples of misconceptions or misunderstandings. Did the government effectively provide or support anti-trafficking trainings for officials including on enforcement of policies, and laws; and/or on victim identification measures or procedures? If not, how could it be improved?</P>
                <P>7. Provide observations on overall anti-trafficking law enforcement efforts and the efforts of police and prosecutors to investigate, prosecute, and convict traffickers. Is the government equally vigorous in pursuing forced labor and sex trafficking, domestic and transnational trafficking, and crimes that involve its own nationals or foreign citizens? Were anti-trafficking laws equitably enforced, or were certain communities disproportionately affected?</P>
                <P>8. Does law enforcement pursue trafficking cases seeking to hold criminally accountable private employers or corporations for forced labor in supply chains?</P>
                <P>9. Do judges appear appropriately knowledgeable and sensitized to trafficking cases? Do they implement and encourage trauma-informed practices in their courts?</P>
                <P>10. Describe any allegations of official complicity in trafficking crimes, including of state-sponsored forced labor. What measures did the government take to end such practices? What proactive measures did the government take to prevent official complicity in trafficking in persons crimes? How did the government respond to reports of complicity during the reporting period, including investigations, prosecutions, convictions, and sentencing of complicit officials? Were these efforts sufficient?</P>
                <P>11. Is there evidence nationals of the country deployed abroad as part of a diplomatic, peacekeeping, or other similar mission have engaged in or facilitated trafficking, including in domestic servitude? Has the government vigorously investigated, prosecuted, convicted, and sentenced nationals engaged in these activities?</P>
                <P>12. If the government has entered into a bilateral, multilateral, or regional anti-trafficking information-sharing and cooperation arrangements, is the agreement effective and has it resulted in concrete and measurable outcomes?</P>
                <HD SOURCE="HD1">Protection</HD>
                <P>13. Did the government make a coordinated, proactive effort to identify victims of all forms of trafficking? If there were any new (or changes to preexisting) formal/standard procedures for screening for trafficking, including of individuals in immigration detention or removal proceedings, and for victim referral to protection services, were those procedures sufficient and how did the government implement them?</P>
                <P>
                    14. If the government had written procedures to guide officials in referring potential trafficking victims to services (
                    <E T="03">e.g.,</E>
                     national referral mechanism, or a formal framework to complement victim identification procedures a government uses to ensure trafficking victims' referral and access to protection services), were front-line officials across government sectors and other responsible stakeholders aware of the procedures and how to use them? Did officials implement the referral procedures and was implementation equitable across all affected populations? Did officials effectively coordinate among one another and with relevant NGOs to conduct screenings and refer victims to care? Did the referral procedures require victims to interact with law enforcement before being referred to social service providers?
                </P>
                <P>15. Did government policy require a person to be formally identified as a trafficking victim to receive certain services or benefits? If yes, which services or benefits were limited to persons formally identified as trafficking victims? If applicable, which officials or entities did the government authorize to formally identify individuals as trafficking victims?</P>
                <P>16. If commercial sex is legalized or decriminalized in the country, how did health officials, labor inspectors, or police identify trafficking victims among persons involved in commercial sex? If commercial sex is illegal, did the government proactively identify trafficking victims during law enforcement operations or other encounters with commercial sex establishments?</P>
                <P>17. Were there any new (or changes to preexisting) services available for victims and survivors (legal, medical, food, shelter, interpretation, mental health care, employment, training, etc.)? If NGOs provide the services, does the government adequately support their work either financially or otherwise? Did all victims and survivors of both labor and sex trafficking—regardless of citizenship, gender identity, racial/ethnic identity, sexual orientation, religious affiliation, and physical ability—receive the same quality and level of access to services?</P>
                <P>18. What was the overall quality of victim care? How could victim services be improved? Are services victim-centered and trauma-informed? Were services linked to whether a victim assisted law enforcement or participated in a trial, or whether a trafficker was convicted? Were there populations that lacked access to care, including shelter and other services?</P>
                <P>
                    19. Where were child victims placed (
                    <E T="03">e.g.,</E>
                     in shelters, foster care, or juvenile justice detention centers), and what kind of specialized care did they receive?
                </P>
                <P>20. If the government operates or funds any trafficking-specific hotlines (including those run by NGOs), did calls to those hotlines lead to victim identification, victim referral to care, and/or criminal investigations?</P>
                <P>21. What is the level of cooperation, communication, and trust between service providers and law enforcement?</P>
                <P>22. Were there means by which victims could obtain restitution from defendants in criminal cases or file civil suits against traffickers for damages, and did this happen in practice? Did prosecutors request and/or courts order restitution in all cases where it was required, and if not, why?</P>
                <P>23. Please provide observations on trafficking victims and survivors' ability to access justice, as they define it, and the treatment of survivors throughout the criminal legal process. How did the government support victims who assisted in the investigation and prosecution of trafficking cases, and did it do so in a trauma-informed way? How did the government protect victims during the trial process and ensure victims were not re-traumatized during participation in the process? What, if any, alternatives were available to victims instead of speaking to law enforcement during investigations (for example, speaking to a victim-witness advocate, social worker, psychologist, etc.)? Did law enforcement allow a representative or advocate to accompany victims during interviews? In what ways could the government increase support for victims in prosecutions against traffickers?</P>
                <P>
                    24. Did the government provide, through a formal policy or otherwise, temporary or permanent residency status, or other relief from deportation, for foreign national victims of human trafficking who may face retribution or hardship in the countries to which they would be deported? Were foreign national victims given the opportunity to seek legal employment while in this 
                    <PRTPAGE P="93819"/>
                    temporary or permanent residency? Were such benefits linked to whether a victim assisted law enforcement, whether a victim participated in a trial, or whether there was a successful prosecution? Does the government repatriate victims who wish to return home or assist with third-country resettlement? Are victims awaiting repatriation or third-country resettlement offered services? Are victims indeed repatriated, or are they deported?
                </P>
                <P>25. Does the government effectively assist its nationals exploited abroad? Does the government work to ensure victims receive adequate assistance and support for their repatriation while in destination countries? Does the government provide adequate assistance to repatriated victims after their return to their countries of origin, and if so, what forms of assistance?</P>
                <P>
                    26. Were potential trafficking victims incarcerated, fined, or otherwise penalized solely for unlawful acts committed as a direct result of being trafficked (
                    <E T="03">e.g.,</E>
                     subject to commercial sex, drug-related, or other criminal charges, or subject to deportation/immigration enforcement or administrative penalties)? If so, do these victims disproportionately represent a certain gender, race, ethnicity, or other group or particular type of trafficking?
                </P>
                <HD SOURCE="HD1">Prevention</HD>
                <P>27. What efforts has the government made to prevent human trafficking? Did the government take new or ongoing steps to ensure policies did not further marginalize communities already overrepresented among trafficking victims, increasing their risk to human trafficking? If so, did it take efforts to implement those policies?</P>
                <P>28. If the government had a national action plan to address trafficking, how was it implemented in practice? Were NGOs and other relevant civil society stakeholders consulted in the development and implementation of the plan? Who will monitor its implementation and/or measure its impact?</P>
                <P>29. Please describe any government-funded anti-trafficking information or education campaigns or training, whether aimed at the public or at specific sectors or stakeholders/actors. What strategies did the campaigns employ to ensure messaging and images did not legitimize and/or perpetuate harmful or racialized narratives and/or stereotypes about victims, survivors, and perpetrators? Were campaign materials readily available, cost-free, and accessible in various languages, including braille? Does the government provide financial support to NGOs working to promote public awareness?</P>
                <P>30. Did the government seek and include the input of survivors in crafting or implementing anti-trafficking laws, regulations, policies, or programs? If so, did the government take steps to ensure input was received and incorporated from a diverse group of survivors?</P>
                <P>31. How did the government regulate, oversee, and screen for trafficking indicators in the labor recruitment process, including for both licensed and unlicensed recruitment and placement agencies, individual recruiters, and sub-brokers? Did the government prohibit (in any context) charging workers recruitment fees and prohibit the recruitment of workers through knowingly fraudulent job offers (including misrepresenting wages, working conditions, location, or nature of the job), contract switching, and confiscating or otherwise denying workers access to their identity documents? If there are laws or regulations on recruitment, did the government effectively enforce them? Did the government allow migrant workers to change employers in a timely manner without obtaining special permissions?</P>
                <P>
                    32. Did the government coordinate with other governments (
                    <E T="03">e.g.,</E>
                     via bilateral agreements with migrant labor sending or receiving countries) on safe and responsible labor recruitment including prevention measures to target known trafficking indicators? To what extent were these implemented? Are workers (both nationals of the country and foreign nationals) in all industries (
                    <E T="03">e.g.,</E>
                     domestic work, agriculture, etc.) equally and sufficiently protected under existing labor laws?
                </P>
                <P>33. Did government policies, regulations, or agreements relating to migration, labor, trade, and investment facilitate vulnerabilities to, or incidence of, forced labor or sex trafficking? If so, what actions did the government take to ensure that its policies, regulations, and agreements relating to migration, labor, trade, border security measures, and investment did not facilitate trafficking?</P>
                <P>34. Did the government take tangible action to prevent forced labor in domestic or global supply chains? Did the government make any efforts to prohibit and prevent trafficking in the supply chains of its own public procurement?</P>
                <P>35. Did the government provide assistance to other governments in combating trafficking in persons through trainings or other assistance programs?</P>
                <P>36. What measures has the government taken to reduce its nationals' or foreigners' participation in domestic and extraterritorial child sexual exploitation? Note: This was previously covered as “child sex tourism.”</P>
                <HD SOURCE="HD1">Territories and Semi-Autonomous Regions</HD>
                <P>37. Provide any information about trafficking trends and government anti-trafficking efforts in dependent territories and semi-autonomous regions to prosecute traffickers, identify and provide services to victims, and prevent trafficking.</P>
                <HD SOURCE="HD1">Trafficking Profile</HD>
                <P>38. Describe human trafficking trends, drivers, methods, source/destination dynamics, industries and sectors, impacted demographics, recruitment methods, etc.</P>
                <P>39. What groups, including vulnerable populations and underserved communities, are at particular risk of sex trafficking or forced labor? Vulnerable populations and underserved communities are populations sharing a particular characteristic, as well as geographic communities, that have been systematically denied a full opportunity to participate in aspects of economic, social, and civic life. This term may include, but is not limited to, women and girls, persons with disabilities, indigenous peoples, people of African descent, racial and ethnic minorities, refugees and internally displaced people, religious minorities, LGBTQI+ persons, rural residents, migrants, as well as those who are otherwise adversely affected by persistent poverty or inequality. Please also consider: adults arrested for engaging in commercial sex acts, undocumented migrants, asylum seekers, stateless persons, persons with severe mental illness, unhoused persons, children in welfare systems or aging out of such systems, previously incarcerated people, members of marginalized racial and ethnic communities, people in early or forced marriages, people living with HIV/AIDS, or individuals or communities living in conflict, crisis, or post-disaster settings.</P>
                <P>40. Are any Chinese, Cuban, or North Korean persons present in the country as part of government-to-government agreements and/or in foreign government-affiliated projects? If present, are these individuals subjected to or at high risk of forced labor?</P>
                <P>
                    41. Provide any information about trafficking trends, general numerical data on victims identified, or risk factors 
                    <PRTPAGE P="93820"/>
                    stemming from climate-related change or disasters, as well as any efforts to mitigate these vulnerabilities; emerging migration crises and associated vulnerabilities to human trafficking; the ongoing trafficking risk as a result of conflict; and the use of technology to recruit and exploit victims, including cyber or online scam operations involving indicators of trafficking.
                </P>
                <HD SOURCE="HD1">Child Soldiering</HD>
                <P>42. Using the definition of “child soldier” as defined by the Child Soldiers Prevention Act of 2008 (CSPA), describe instances, cases, and reports, including anecdotal reports, of:</P>
                <P>a. Use of any person under the age of 18 in direct hostilities as a member of governmental armed forces, police, or other security forces;</P>
                <P>b. Conscription or forced recruitment of persons under the age of 18 into governmental armed forces, police, or other security forces;</P>
                <P>c. Voluntary recruitment of any person under 15 years of age into governmental armed forces, police, or other security forces;</P>
                <P>d. Recruitment (forced or voluntary) or use in hostilities of persons under the age of 18 by armed groups distinct from the armed forces of a state.</P>
                <P>
                    e. Abuse of male and female children recruited by governmental armed forces, police, or other security forces, and government-supported armed groups (
                    <E T="03">e.g.,</E>
                     sexual abuse or use for forced labor). Describe the manner and age of conscription, noting differences in treatment or conscription patterns based on gender.
                </P>
                <P>
                    43. Did the government provide support to an armed group that recruits and/or uses child soldiers? What was the extent of the support (
                    <E T="03">e.g.,</E>
                     in-kind, financial, training, etc.)? Where did the provision of support occur (within the country or outside of the country)? In cases where the government was included on the CSPA list in 2024 based on its support to non-state armed groups that recruit and/or use child soldiers, describe whether the government took steps to pressure the group to cease its recruitment or use of child soldiers, publicly disavow the group's recruitment or use of child soldiers, or cease its support to that group.
                </P>
                <P>
                    44. Describe any government efforts to prevent or end child soldier recruitment or use, including efforts to disarm, demobilize, and reintegrate former child soldiers. (
                    <E T="03">i.e.,</E>
                     enacting any laws or regulations, implementing a United Nations Action Plan or Roadmap, specialized training for officials, procedures for age verification, etc.)
                </P>
                <SIG>
                    <NAME>Cynthia D. Dyer,</NAME>
                    <TITLE>Ambassador-at-Large, Office to Monitor and Combat Trafficking in Persons, Department of State.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27815 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4710-17-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Aviation Administration</SUBAGY>
                <SUBJECT>Notice of Availability, Notice of Public Comment Period, Notice of Public Meetings, and Request for Comment on the Revised Draft Tiered Environmental Assessment for SpaceX Starship/Super Heavy Vehicle Increased Cadence at the Boca Chica Launch Site in Cameron County, Texas</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Aviation Administration (FAA), Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of availability, notice of public comment period, notice of public meetings, and request for comment.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        In accordance with the National Environmental Policy Act of 1969, as amended (NEPA), Council on Environmental Quality NEPA-implementing regulations, and FAA Order 1050.1F, 
                        <E T="03">Environmental Impacts: Policies and Procedures,</E>
                         the FAA is announcing the availability of the Revised Draft Tiered Environmental Assessment for SpaceX's proposal to increase the number of launches and landings of its Starship/Super Heavy vehicle at the Boca Chica Launch Site in Cameron County, Texas (Revised Draft EA), and its intent to hold public meetings. The Revised Draft EA analyzes SpaceX's proposal to increase launch and landing cadence up to 25 annual Starship/Super Heavy orbital launches, including: up to 25 annual landings of Starship (Second stage), and up to 25 annual landings of Super Heavy (First stage). The Revised Draft EA also addresses vehicle upgrades.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>No registration is required for the four in-person public meetings that will be held at the following dates and times (Central):</P>
                    <P>• Tuesday, January 7, 2025; 1 p.m.-3 p.m. &amp; 5:30 p.m.-7:30 p.m. CT.</P>
                    <P>• Thursday, January 9, 2025; 1 p.m.-3 p.m. &amp; 5:30 p.m.-7:30 p.m. CT.</P>
                    <P>Registration is required for the virtual public meeting that will be held on Monday, January 13, 2025; 5:30 p.m.-7:30 p.m. CT.</P>
                    <P>The public comment period for the Revised Draft EA will close on January 17, 2025.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>The locations for the meetings are as follows:</P>
                    <P>• January 7, 2025; Texas Southmost College, Jacob Brown Auditorium, 600 International Boulevard, Brownsville, TX 78520.</P>
                    <P>• January 9, 2025; Port Isabel Event &amp; Cultural Center, Queen Isabella Room, 309 E Railroad Avenue, Port Isabel, TX 78578.</P>
                    <P>
                        • January 13, 2025; Registration Link: 
                        <E T="03">https://us02web.zoom.us/webinar/register/WN_6f5su5mtTne_vBr8MqJOLA,</E>
                         Dial-in phone number: 888-788-0099 (Toll Free), Webinar ID: 879 9253 6128, Passcode: 900729.
                    </P>
                    <P>
                        The Revised Draft EA is available for review at 
                        <E T="03">https://www.faa.gov/space/stakeholder_engagement/spacex_starship.</E>
                         The FAA invites interested parties to submit comments on the Revised Draft EA. Public comments can be submitted electronically to 
                        <E T="03">www.regulations.gov</E>
                         under Docket No. FAA-2024-2006, by postal mail to Ms. Amy Hanson, FAA Environmental Specialist, SpaceX EA, c/o ICF 1902 Reston Metro Plaza Reston, VA 20190, or delivered in written or verbal form during a public meeting. Instructions on how to submit comments can be found on the FAA web page at the address listed above.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Amy Hanson at 847-243-7609 or 
                        <E T="03">SpaceXBocaChica@icf.com.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    The FAA will provide a pre-recorded presentation during the first half hour of the public meetings. The public will also have an opportunity to submit comments during the meetings. English-Spanish translation services will be provided. Both English and Spanish versions of the presentation will be made available to the public on December 16, 2024, on this website listed above. More information on the public meetings can be found at: 
                    <E T="03">https://www.faa.gov/space/stakeholder_engagement/spacex_starship.</E>
                     If any accommodation for the public meetings is needed (such as additional translation services), please submit a request by December 16, 2024, to the project email address: 
                    <E T="03">SpaceXBocaChica@icf.com.</E>
                     For any media inquiries, please contact the FAA Press Office at 
                    <E T="03">pressoffice@faa.gov.</E>
                </P>
                <P>
                    Before including your address, phone number, email address, or other personal identifying information in your comment, be advised that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask the FAA in your comment to withhold from public review your personal identifying information, the 
                    <PRTPAGE P="93821"/>
                    FAA cannot guarantee that it will be able to do so. All comments received during the comment period will be given equal weight and be taken into consideration in the preparation of the Final EA.
                </P>
                <SIG>
                    <DATED>Issued in Washington, DC, on November 20, 2024.</DATED>
                    <NAME>Stacey Molinich Zee,</NAME>
                    <TITLE>Manager, Operations Support Branch.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27533 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-13-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Highway Administration</SUBAGY>
                <SUBJECT>Notice of Final Federal Agency Actions on Proposed Transportation Project in Florida</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Highway Administration (FHWA), DOT.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of Limitation on Claims for Judicial Review of Actions by Florida Department of Transportation (FDOT), pursuant to 23 U.S.C. 327, and other Federal Agencies.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The FHWA, on behalf of the FDOT, is issuing this notice to announce actions taken by FDOT and other Federal Agencies that are final agency actions. These actions relate to the proposed State Road (S.R.) 535/Vineland Road Project Development and Environment (PD&amp;E) Study (Financial Management Number 437174-2). The proposed S.R. 535/Vineland Road project will reduce congestion and improve safety from US 192 to World Center Drive (S.R. 536), a distance of approximately 2.35 miles. Improvements consist of widening the existing roadway from four to six lanes, improvements to intersections, and the construction of stormwater management facilities. These actions grant licenses, permits, or approvals for the project.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>By this notice, the FHWA, on behalf of FDOT, is advising the public of final agency actions subject to 23 U.S.C. 139(l)(1). A claim seeking judicial review of the Federal Agency actions on the listed highway project will be barred unless the claim is filed on or before April 28, 2025. If the Federal law that authorizes judicial review of a claim provides a time period of less than 150 days for filing such claim, then that shorter time period still applies.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        The Type 2 Categorical Exclusion and additional project documents can be viewed and downloaded from the project website at: 
                        <E T="03">https://www.cflroads.com/project/437174-2,</E>
                         or by contacting FDOT Office of Environmental Management, 605 Suwannee Street, MS 37, Tallahassee, Florida 32399, during normal business hours are 8:00 a.m. to 5:00 p.m. (Eastern Standard Time), Monday through Friday, except State holidays.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Jennifer Marshall, P.E., Director, FDOT Office of Environmental Management, FDOT; telephone (850) 414-4316; email: 
                        <E T="03">Jennifer.Marshall@dot.state.fl.us.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Effective December 14, 2016, and as subsequently renewed on May 26, 2022, the FHWA assigned, and the FDOT assumed, environmental responsibilities for this project pursuant to 23 U.S.C. 327. Notice is hereby given that FDOT and other Federal Agencies have taken final agency actions subject to 23 U.S.C. 139 (l)(1) by issuing licenses, permits, or approvals for the proposed highway improvement project. The actions by FDOT and other Federal Agencies on the project, and the laws under which such actions were taken are described in the Type II Categorical Exclusion approved on November 15, 2024, and in other project records for the listed project. The Type II Categorical Exclusion and other documents for the listed project are available by contacting FDOT at the address provided above. The project subject to this notice is:</P>
                <P>
                    <E T="03">Project Location:</E>
                     The project is located in Osceola and Orange Counties, Florida. The project limits are S.R. 535/Vineland Road from US 192 to north of World Center Drive (S.R. 536), a distance of approximately 2.35 miles.
                </P>
                <P>
                    <E T="03">Project Actions:</E>
                     This notice applies to the Type II Categorical Exclusion and all other Federal Agency licenses, permits, or approvals for the listed project as of the issuance date of this notice and all laws under which such actions were taken, including but not limited to:
                </P>
                <P>
                    1. 
                    <E T="03">General:</E>
                     National Environmental Policy Act (NEPA) [42 U.S.C. 4321
                    <E T="03">et seq.</E>
                    ]; Federal-Aid Highway Act (FAHA) [23 U.S.C. 109 and 23 U.S.C. 128]; 23 CFR part 771.
                </P>
                <P>
                    2. 
                    <E T="03">Air:</E>
                     Clean Air Act (CAA) [42 U.S.C. 7401-7671(q)], with the exception of project level conformity determinations [42 U.S.C. 7506].
                </P>
                <P>
                    3. 
                    <E T="03">Noise:</E>
                     Noise Control Act of 1972 [42 U.S.C. 4901-4918]; 23 CFR772.
                </P>
                <P>
                    4. 
                    <E T="03">Land:</E>
                     Section 4(f) of the Department of Transportation Act of 1966 [23 U.S.C. 138 and 49 U.S.C. 303]; 23 CFR part 774; Land and Water Conservation Fund (LWCF) [54 U.S.C. 200302-200310].
                </P>
                <P>
                    5. 
                    <E T="03">Wildlife:</E>
                     Endangered Species Act (ESA) [16 U.S.C. 1531-1544 and 1536]; Marine Mammal Protection Act [16 U.S.C. 1361-1423h], Anadromous Fish Conservation Act [16 U.S.C. 757(a)-757(f)]; Fish and Wildlife Coordination Act [16 U.S.C. 661-667(d)]; Migratory Bird Treaty Act (MBTA) [16 U.S.C. 703-712]; Magnuson-Stevenson Fishery Conservation and Management Act of 1976, as amended [16 U.S.C. 1801-1891d], with Essential Fish Habitat requirements [16 U.S.C. 1855(b)(2)].
                </P>
                <P>
                    6. 
                    <E T="03">Historic and Cultural Resources:</E>
                     Section 106 of the National Historic Preservation Act of 1966, as amended [54 U.S.C. 3006101 
                    <E T="03">et seq.</E>
                    ]; Archaeological Resources Protection Act of 1979 (ARPA) [16 U.S.C. 470(aa)-470(II)]; Preservation of Historical and Archaeological Data [54 U.S.C.312501-312508]; Native American Grave Protection and Repatriation Act (NAGPRA) [25 U.S.C. 3001-3013; 18 U.S.C. 1170].
                </P>
                <P>
                    7. 
                    <E T="03">Social and Economic:</E>
                     Civil Rights Act of 1964 [42 U.S.C. 2000 d-2000d-1]; American Indian Religious Freedom Act [42 U.S.C. 1996]; Farmland Protection Policy Act (FPPA) [7 U.S.C. 4201-4209].
                </P>
                <P>
                    8. 
                    <E T="03">Wetlands and Water Resources:</E>
                     Clean Water Act (Section 319, Section 401, Section 404) [33 U.S.C. 1251-1387]; Coastal Barriers Resources Act (CBRA) [16 U.S.C. 3501-3510]; Coastal Zone Management Act (CZMA) [16 U.S.C. 1451-1466];; Safe Drinking Water Act (SDWA) [42 U.S.C. 300f-300j—26]; Rivers and Harbors Act of 1899 [33 U.S.C. 401-406]; Wild and Scenic Rivers Act [16 U.S.C. 1271-1287]; Emergency Wetlands Resources Act [16 U.S.C. 3921, 3931]; Wetlands Mitigation, [23 U.S.C. 119(g) and 133(b)(3)]; Flood Disaster Protection Act [42 U.S.C. 4001-4130].
                </P>
                <P>
                    9. 
                    <E T="03">Hazardous Materials:</E>
                     Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601-9675]; Superfund Amendments and Reauthorization Act of 1986 (SARA); Resource Conservation and Recovery Act (RCRA) [42 U.S.C. 6901-6992(k)].
                </P>
                <P>
                    10. 
                    <E T="03">Executive Orders:</E>
                     E.O. 11990 Protection of Wetlands; E.O. 11988 Floodplain Management; E.O. 12898, Federal Actions to Address Environmental Justice in Minority Populations and Low Income Populations; E.O. 11593 Protection and Enhancement of Cultural Resources; E.O. 13007 Indian Sacred Sites; E.O. 13287 Preserve America; E.O. 11514 Protection and Enhancement of Environmental Quality; E.O. 13112 Invasive Species.
                </P>
                <EXTRACT>
                    <FP>
                        (Catalog of Federal Domestic Assistance Program Number 20.205, Highway Planning and Construction. The regulations implementing Executive Order 12372 regarding intergovernmental consultation on 
                        <PRTPAGE P="93822"/>
                        Federal programs and activities apply to this program.)
                    </FP>
                </EXTRACT>
                <P>
                    <E T="03">Authority:</E>
                     23 U.S.C. 139(l)(1).
                </P>
                <SIG>
                    <DATED>Issued on: November 21, 2024.</DATED>
                    <NAME>Karen M. Brunelle</NAME>
                    <TITLE>Director, Office of Project Development, Federal Highway Administration, Tallahassee, Florida.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27817 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-RY-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Highway Administration</SUBAGY>
                <SUBJECT>Environmental Impact Statement: Cameron, Hidalgo, And Willacy Counties, Texas</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Texas Department of Transportation (TxDOT), Federal Highway Administration (FHWA), Department of Transportation.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Federal notice of intent to prepare an Environmental Impact Statement (EIS).</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>FHWA, on behalf of TxDOT, is issuing this notice to advise the public that an EIS will be prepared for a proposed transportation project to study the effects of constructing a highway improvement project from Interstate Highway (I-) 69C/United States Highway (US) 281 to I-69E/US 77 in Hidalgo, Cameron, and Willacy Counties, Texas (CSJ: 0921-02-353). The proposed project will be referred to herein as I-69 Connector, or the I-69 Connector Project. The proposed project is approximately 25 miles in length.</P>
                </SUM>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Francisco Chapa, P.E., TxDOT Pharr District Project Manager, 600 West I-2, Pharr, Texas, 78577, (956) 702-6344, 
                        <E T="03">Francisco.chapa@txdot.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>The environmental review, consultation, and other actions required by applicable Federal environmental laws for this project are being, or have been, carried-out by TxDOT pursuant to 23 U.S.C. 327 and a Memorandum of Understanding dated December 9, 2019, and executed by FHWA and TxDOT.</P>
                <P>The purpose and need of the proposed I-69 Connector is to alleviate/reduce traffic congestion and improve regional mobility, to improve and increase transportation network connectivity, to address future population growth and travel demands, and to provide an east-west hurricane evacuation route.</P>
                <P>The proposed project would evaluate a new potential connection from I-69C/US 281 to I-69E/US 77 in Hidalgo, Cameron, and Willacy Counties, Texas (CSJ: 0921-02-353). The proposed project could potentially include constructing a highway on new location for approximately 25 miles with grade separations at intersections with major crossroads.</P>
                <P>The EIS will evaluate a range of build alternatives and a no-build alterative. Possible build alternatives include the four alternatives that were evaluated in the I-69 Connector Route Feasibility Study. Each alternative would be evaluated on the same right-of-way width and level of detail during the Alternative Analysis process.</P>
                <HD SOURCE="HD1">Alternative A</HD>
                <P>Alternative A starts on the western end at the intersection of I-69C/US 281 and State Highway (SH) 107. It follows SH 107 for approximately 3.2 miles to the east, where SH 107 curves north, before continuing on new location eastward for approximately 12.3 miles. After intersection with International Boundary and Water Commission (IBWC)'s North Floodway, the alignment follows SH 107 southeast for 2.2 miles before turning north at the intersection of Farm-to-Market (FM) 1425 for approximately 1.1 miles and continuing east for approximately 6.5 miles until the eastern end of the project at I-69E/US 77. Alternative A is on partial new location and approximately 25.5 miles long.</P>
                <HD SOURCE="HD1">Alternative B</HD>
                <P>Alternative B starts on new alignment at the western end at I-69C/US 281 and approximately 0.15 mile south of E. Richardson Road. This alignment continues east for approximately 3.4 miles, and curves slightly south at the intersection of SH 107 before continuing on new location for approximately 12.3 miles. After the alignment's intersection with the IBWC's North Floodway, the alignment moves slightly south until the intersection with FM 1425 for approximately 2.1 miles, then continues east for approximately 7 miles until the eastern end of the project at I-69E/US 77. Alternative B is on new location and approximately 24.8 miles long.</P>
                <HD SOURCE="HD1">Alternative C</HD>
                <P>Alternative C starts on new alignment at the western end at I-69C/US 281 and approximately 0.70 mile north of E. Richardson Road. The alignment continues east for approximately 9.7 miles until curving south after the intersection with FM 88. The alignment continues east for approximately 15.3 miles until the eastern end of the project at I-69E/US 77. Alternative C is on new location and approximately 25 miles long.</P>
                <HD SOURCE="HD1">Alternative D</HD>
                <P>Alternative D starts on new alignment at the western end at I-69C/US 281 and approximately 0.7 mile north of E. Richardson Road. The alignment continues east for approximately 9.3 miles until curving north 0.3 mile west of the intersection with FM 88. The alignment continues northeast for approximately 4.3 miles then continues east for approximately 9.6 miles until the intersection with I-69E/US 77. Alternative D is on new location and approximately 23 miles long.</P>
                <P>
                    <E T="03">Section 106 and Section 4(f) Historic Properties.</E>
                     The proposed build alternatives will be evaluated for potential adverse impacts to historic properties (
                    <E T="03">i.e.</E>
                     properties that are eligible for or listed in the National Register of Historic Places) within the study area.
                </P>
                <P>
                    <E T="03">Environmental Justice (EJ).</E>
                     The proposed build alternatives will be evaluated for potential adverse impacts to EJ communities due to anticipated relocations as well as other impacts such as access, noise, and visual aesthetics. Additional analysis and public involvement will be conducted during the National Environmental Policy Act process to assess if the project would result in any disproportionately high and adverse effects on low-income and minority communities.
                </P>
                <P>
                    <E T="03">Wildlife and threatened and endangered species.</E>
                     The proposed build alternatives will be evaluated for potential adverse impacts to wildlife and threatened and endangered species within the study area.
                </P>
                <P>
                    <E T="03">Floodplains.</E>
                     The proposed build alternatives will be evaluated for potential adverse impacts to floodplains within the study area.
                </P>
                <P>The EIS will evaluate the potential impacts and benefits to the resources/communities identified above as well as the following other subject areas: Limited English Proficiency communities, land use, right-of-way, social and community resources, traffic noise, air quality, water resources, hazardous materials sites, cultural resources, biological resources, protected lands 4(f) and 6(f), and visual resources.</P>
                <P>It is anticipated that the following would be required: Texas Antiquities Code permit and concurrence, Section 106 historic/archeological resources concurrence, Section 4(f) evaluation approval, Section 7 consultation with U.S. Fish and Wildlife, IBWC Permit, and U.S. Army Corp of Engineers Section 404 Nationwide Permit(s).</P>
                <P>
                    A Tentative Schedule is outlined below.
                    <PRTPAGE P="93823"/>
                </P>
                <P>The Agency Scoping Meeting was held July 29, 2024.</P>
                <P>Public Scoping Meeting: January 21 and 23, 2025.</P>
                <P>The FEIS/ROD is anticipated Summer 2027.</P>
                <P>In addition to the public scoping meeting, a public hearing will be held after the Draft EIS is prepared. Public notice will provide the time and place of the hearing. After the public hearing and end of Draft EIS comment period, issuance of the Final EIS/Record of Decision is anticipated. If a build alternative is selected, all permits and authorization decisions would occur before construction.</P>
                <P>The following entities have been invited to be cooperating agencies for this EIS: U.S. Environmental Protection Agency, U.S. Fish and Wildlife Service, U.S. Department of Agriculture, Natural Resource Conservation Service, National Park Service, U.S. Army Corp of Engineers, Federal Emergency Management Agency, Federal Transit Administration, Federal Railroad Administration, International Boundary and Water Commission, U.S. Customs and Border Protection, U.S. Department of Housing and Urban Development, Santa Ana National Wildlife Refuge, Lower Rio Grande Valley National Wildlife Refuge, Kiowa Tribe, Mescalero Apache Tribe, Tonkawa Tribe of Oklahoma, Apache Tribe of Oklahoma, and Comanche Nation of Oklahoma.</P>
                <P>The following entities have been invited to be participating agencies for this EIS: Texas Commission on Environmental Quality, McAllen Historic Preservation Council, Texas Division of Emergency Management, The Texas General Land Office, Texas Historical Commission/State Historic Preservation Officer, Texas Parks and Wildlife Department, Cameron County Regional Mobility Authority, Hidalgo County Regional Mobility Authority, Hidalgo County Planning and Development, Cameron County Planning and Development, Hidalgo County, Cameron County, Willacy County, Texas Department of Public Safety, City of Harlingen, City of Lyford, City of McAllen, City of Donna, City of Edinburg, City of Elsa, City of La Feria, City of La Villa, City of Alamo, City of San Juan, City of Weslaco, City of Mercedes, City of Palm Valley, City of Pharr, City of Raymondville, Town of Combes, Rio Grande Valley Metropolitan Planning Organization, Cameron County Historical Commission, Hidalgo County Historical Commission, Willacy County Historical Commission, Hidalgo County Drainage District No. 1, Cameron County Irrigation District No. 2, McAllen Economic Development Corporation (EDC), Harlingen EDC, Edinburg EDC, Alamo EDC, Donna EDC, Lyford EDC, Mercedes EDC, Pharr EDC, San Juan EDC, Weslaco EDC, Elsa EDC, and Combes EDC.</P>
                <P>TxDOT will issue a single Final Environmental Impact Statement and Record of Decision document pursuant to 23 U.S.C. 139(n)(2), unless TxDOT determines statutory criteria or practicability considerations preclude issuance of a combined document.</P>
                <P>In accordance with 23 U.S.C. 139, cooperating agencies, participating agencies, and the public will be given an opportunity for continued input on project development. A in-person public scoping meeting is planned for Tuesday, January 21, 2025, from 5 p.m. to 7 p.m. CST at J. Economedes High School 1414 N Alamo Rd, Edinburg, Texas 78541, and January 23, 2025, from 5 p.m. to 7 p.m. CST at Elma E. Barrera Elementary School, Hwy 107, Santa Rosa, Texas 78593. The public scoping meeting will provide an opportunity for the public to review and comment on the draft coordination plan and schedule, the project purpose and need, the range of alternatives, and methodologies and level of detail for analyzing alternatives. It will also allow the public an opportunity to provide input on any expected environmental impacts, anticipated permits or other authorizations, and any significant issues that should be analyzed in depth in the EIS. In addition to the public scoping meeting, a public hearing will be held after the draft EIS is prepared. Public notice will be given of the time and place of the meeting and hearing.</P>
                <P>The public meeting will be conducted in English. If you need an interpreter or document translator because English is not your primary language or you have difficulty communicating effectively in English, one will be provided to you. If you have a disability and need assistance, special arrangements can be made to accommodate most needs. If you need interpretation or translation services or you are a person with a disability who requires an accommodation to attend and participate in the public scoping meeting, please contact Norma Robledo, TxDOT Pharr District, at (956) 702-6161 no later than 4 p.m. CT, Thursday, January 16, 2025. Please be aware that advance notice is required as some services and accommodations may require time for the Texas Department of Transportation to arrange.</P>
                <P>
                    The public is requested to provide public comments on alternatives or impacts and on relevant information, studies, or analyses with respect to this proposed project. Comments may be provided in writing by mail to Francisco Chapa, TxDOT Project Manager at 600 West I-2, Pharr, Texas, 78577 or by email to 
                    <E T="03">Francisco.Chapa@txdot.gov</E>
                     or to 
                    <E T="03">PHR_I69_Connector@txdot.gov.</E>
                     Comments must be received by Friday, February 7, 2025.
                </P>
                <EXTRACT>
                    <FP>(Catalog of Federal Domestic Assistance Program Number 20.205, Highway Planning and Construction.)</FP>
                </EXTRACT>
                <SIG>
                    <NAME>Michael T. Leary,</NAME>
                    <TITLE>Director, Planning and Program Development, Federal Highway Administration.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27823 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-22-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Railroad Administration</SUBAGY>
                <DEPDOC>[Docket Number [FRA-2010-0029]</DEPDOC>
                <SUBJECT>The National Railroad Passenger Corporation's Request To Amend Its Positive Train Control Safety Plan and Positive Train Control System</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Railroad Administration (FRA), Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice of availability and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>This document provides the public with notice that, on November 14, 2024, the National Railroad Passenger Corporation (Amtrak) submitted a request for amendment (RFA) to its FRA-approved Positive Train Control Safety Plan (PTCSP) to provide supplemental information to its initial RFA, submitted November 7, 2024, to support updates to Amtrak's Onboard Computer (OBC) Serial platform and Fusion software release. As this RFA may involve a request for FRA's approval of proposed material modifications to an FRA-certified positive train control (PTC) system, FRA is publishing this notice and inviting public comment on Amtrak's RFA to its PTCSP.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>FRA will consider comments received by December 17, 2024. FRA may consider comments received after that date to the extent practicable and without delaying implementation of valuable or necessary modifications to a PTC system.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P/>
                    <P>
                        <E T="03">Comments:</E>
                         Comments may be submitted by going to 
                        <E T="03">https://www.regulations.gov</E>
                         and following the online instructions for submitting comments.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         All submissions must include the agency name and the 
                        <PRTPAGE P="93824"/>
                        applicable docket number. The relevant PTC docket number for this host railroad is Docket No. FRA-2010-0029. For convenience, all active PTC dockets are hyperlinked on FRA's website at 
                        <E T="03">https://railroads.dot.gov/research-development/program-areas/train-control/ptc/railroads-ptc-dockets.</E>
                         All comments received will be posted without change to 
                        <E T="03">https://www.regulations.gov;</E>
                         this includes any personal information.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Gabe Neal, Staff Director, Signal, Train Control, and Crossings Division, telephone: 816-516-7168, email: 
                        <E T="03">Gabe.Neal@dot.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>In general, Title 49 United States Code (U.S.C.) Section 20157(h) requires FRA to certify that a host railroad's PTC system complies with Title 49 Code of Federal Regulations (CFR) part 236, subpart I, before the technology may be operated in revenue service. Before making certain changes to an FRA-certified PTC system or the associated FRA-approved PTCSP, a host railroad must submit, and obtain FRA's approval of, an RFA to its PTCSP under 49 CFR 236.1021.</P>
                <P>
                    Under 49 CFR 236.1021(e), FRA's regulations provide that FRA will publish a notice in the 
                    <E T="04">Federal Register</E>
                     and invite public comment in accordance with 49 CFR part 211, if an RFA includes a request for approval of a material modification of a signal or train control system. Accordingly, this notice informs the public that, on November 14, 2024, Amtrak submitted an RFA to its PTCSP for its Advanced Civil Speed Enforcement System II (ACSES II), which seeks FRA's approval for updates to its OBC Serial platform and Fusion software release. That RFA is available in Docket No. FRA-2010-0029.
                </P>
                <P>
                    Interested parties are invited to comment on Amtrak's RFA to its PTCSP by submitting written comments or data. During FRA's review of Amtrak's RFA, FRA will consider any comments or data submitted within the timeline specified in this notice and to the extent practicable, without delaying implementation of valuable or necessary modifications to a PTC system. 
                    <E T="03">See</E>
                     49 CFR 236.1021; 
                    <E T="03">see also</E>
                     49 CFR 236.1011(e). Under 49 CFR 236.1021, FRA maintains the authority to approve, approve with conditions, or deny a railroad's RFA to its PTCSP at FRA's sole discretion.
                </P>
                <HD SOURCE="HD2">Privacy Act Notice</HD>
                <P>
                    In accordance with 49 CFR 211.3, FRA solicits comments from the public to better inform its decisions. DOT posts these comments, without edit, including any personal information the commenter provides, to 
                    <E T="03">https://www.regulations.gov,</E>
                     as described in the system of records notice (DOT/ALL-14 FDMS), which can be reviewed at 
                    <E T="03">https://www.transportation.gov/privacy.</E>
                     See 
                    <E T="03">https://www.regulations.gov/privacy-notice</E>
                     for the privacy notice of 
                    <E T="03">regulations.gov</E>
                    . To facilitate comment tracking, we encourage commenters to provide their name, or the name of their organization; however, submission of names is completely optional. If you wish to provide comments containing proprietary or confidential information, please contact FRA for alternate submission instructions.
                </P>
                <SIG>
                    <P>Issued in Washington, DC</P>
                    <NAME>Carolyn R. Hayward-Williams,</NAME>
                    <TITLE>Director, Office of Railroad Systems and Technology.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27818 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-06-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF TRANSPORTATION</AGENCY>
                <SUBAGY>Federal Transit Administration</SUBAGY>
                <DEPDOC>[Docket No. FTA-2024-0015]</DEPDOC>
                <SUBJECT>Notice of Availability of Proposed Circular Updates and Request for Comments</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Federal Transit Administration (FTA), Department of Transportation (DOT).</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice; request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The Federal Transit Administration (FTA) has placed in the docket and on its website proposed guidance in the form of an updated circular pertaining to procurements financed in whole or part with Federal assistance awarded by FTA through grants or cooperative agreements (
                        <E T="03">i.e.,</E>
                         “third party” procurements). This updated circular would cancel and replace Circular FTA C 4220.1F, most recently revised March 18, 2013. The proposed updates reflect statutory and regulatory changes that have occurred since the last update, as well as providing additional non-binding guidance. By this notice, FTA invites public comment on its proposed circular, “Third Party Contracting Guidance.”
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be submitted by December 27, 2024. Late-filed comments will be considered to the extent practicable.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Please submit your comments by only one of the following methods, identifying your submission by docket number FTA-2024-0015. All electronic submissions must be made to the U.S. Government electronic site at 
                        <E T="03">https://www.regulations.gov/.</E>
                    </P>
                    <P>
                        (1) 
                        <E T="03">Federal eRulemaking Portal:</E>
                         Go to 
                        <E T="03">https://www.regulations.gov/</E>
                         and follow the online instructions for submitting comments.
                    </P>
                    <P>
                        (2) 
                        <E T="03">Mail:</E>
                         Docket Management Facility: U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building, Ground Floor, Room W12-140, Washington, DC 20590-0001.
                    </P>
                    <P>
                        (3) 
                        <E T="03">Hand Delivery or Courier:</E>
                         West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, between 9 a.m. and 5 p.m. Eastern time, Monday through Friday, except Federal holidays.
                    </P>
                    <P>
                        (4) 
                        <E T="03">Fax:</E>
                         202-366-7951.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         You must include the agency name (Federal Transit Administration) and docket number (FTA-2024-0015) at the beginning of your comments. Submit two copies of your comments if you submit them by mail. For confirmation that FTA received your comments, include a self-addressed stamped postcard. Note that all comments received will be posted without change to 
                        <E T="03">https://www.regulations.gov/</E>
                         including any personal information provided and will be available to internet users. For information on DOT's compliance with the Privacy Act, please visit 
                        <E T="03">https://www.transportation.gov/privacy.</E>
                    </P>
                    <P>
                        <E T="03">Docket:</E>
                         For access to the docket to read background documents and comments received, go to 
                        <E T="03">https://www.regulations.gov/</E>
                         at any time or to the U.S. Department of Transportation, 1200 New Jersey Avenue SE, Docket Operations, M-30, West Building Ground Floor, Room W12-140, Washington, DC 20590 between 9 a.m. and 5 p.m. Eastern Time, Monday through Friday, except Federal holidays.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        For third party contracting questions, contact Tara Murphy, Division Chief, Office of Administration, Federal Transit Administration, 1200 New Jersey Ave. SE, Room E41-311, Washington, DC 20590, phone: (202) 366-5647 or email 
                        <E T="03">tara.murphy@dot.gov.</E>
                         For legal questions, Christopher Hall, Office of Chief Counsel, same address, Room E56-312, phone (202) 941-9595 or email 
                        <E T="03">christopher.hall@dot.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <HD SOURCE="HD1">Overview</HD>
                <P>
                    FTA proposes an update to its Third Party Contracting Guidance Circular, which would replace and cancel the current iteration dated March 18, 2013 (C 4220.1F). The proposed circular would update FTA's guidance for 
                    <PRTPAGE P="93825"/>
                    recipient procurements financed with FTA assistance (third party contracts) to reflect current statutory and regulatory text, including the Infrastructure Investment and Jobs Act (IIJA), Public Law 117-582, signed into law on November 15, 2021; the Fixing America's Surface Transportation (FAST) Act, Public Law 114-94, signed into law on December 4, 2015; and new or updated administrative requirements from 2 CFR parts 200 and 1201.
                </P>
                <P>
                    This notice does not include the proposed circular; electronic versions of the proposed circular may be found on the docket at 
                    <E T="03">https://www.regulations.gov,</E>
                     docket number FTA-2024-0015, or on FTA's website at 
                    <E T="03">https://www.transit.dot.gov.</E>
                </P>
                <HD SOURCE="HD1">Chapter-By-Chapter Summaries</HD>
                <P>Throughout the proposed circular, revisions are proposed that would clarify or reorganize sections for improved readability, without substantively altering guidance from the current Circular 4220.1F. The proposed circular also updates citations to authority and adds citations to improve transparency about the sources of requirements. Proposed changes that would not have a substantive effect are not necessarily called out in this notice.</P>
                <HD SOURCE="HD1">Chapter I</HD>
                <P>In Chapter I, FTA proposes to revise several key definitions, including “Approval, Authorization, Concurrence, Waiver,” “Best Value,” “Change Order,” “Common Grant Rules,” “Constructive Change,” “Contract,” “Design-Build Project,” “Governmental Recipient,” “Joint Procurement,” “Non-Governmental Recipient,” “Recipient,” “State or Local Government Purchasing Schedule or Purchasing Contract,” “Third Party Contract,” and “Value Engineering.” In most cases, revisions were to simplify definitions, or align definitions with existing statute or regulations. Additionally, this chapter would introduce new definitions, such as “Alternate Contracting Method (ACM),” “Progressive Design-Build (PDB),” and “Public-Private Partnership (P3).”</P>
                <P>FTA also proposes to update language in this chapter describing the Federal Transit Administration (FTA) and the roles of FTA's headquarters, regional, and metropolitan offices in supporting public transportation agencies.</P>
                <HD SOURCE="HD1">Chapter II</HD>
                <P>
                    FTA proposes to revise Chapter II to clarify the circular's effect and applicability, including by distinguishing between binding requirements (
                    <E T="03">e.g.,</E>
                     described using “must” or “shall”) and non-binding recommendations (
                    <E T="03">e.g.,</E>
                     described using “may” or “should”). Throughout the proposed circular, revisions would take care to distinguish between the mandatory and the advisory. The proposed revisions would specify how the circular applies to different entities, including States, Tribes, non-State recipients, and third party contractors, and would simplify the Project Types and Third Party Contracts sections under the Applicability of the Circular. Updates would consolidate or remove outdated and inapplicable sections from this Chapter, such as those on “Other Agreement” Assistance, Art, the Over the Road Bus Accessibility Program, and certain Operations and Preventive Maintenance contracts. These sections are redundant or otherwise no longer relevant due to program changes.
                </P>
                <P>Additionally, proposed changes would expand the descriptions of available project delivery options for recipients by adding Construction Manager/General Contractor (CM/GC), Full Delivery or Program Management, and Progressive Design-Build (PDB) to the list of project delivery systems. Proposed revisions to Chapter II would also add guidance on Alternative Contracting Methods (ACMs) regarding PDB and P3. Finally, the proposed updates would revise the Federal Laws and Regulations section and the State and Local Laws and Regulations section to update the description of the relationships among Federal and State laws, regulations, and the FTA grant agreements and Master Agreement.</P>
                <HD SOURCE="HD1">Chapter III</HD>
                <P>FTA proposes amendments to Chapter III that would update guidance on recipients' responsibilities, with particular emphasis on Written Standards of Conduct to address Gifts and Violations, along with new guidance on Organizational Conflicts, to reflect current Federal regulations. Similarly, the proposed changes would update guidance on Self-Certification and Third Party Contracting Capacity to clarify FTA's use of certifications and describe existing practice and procedures at FTA. Proposed revisions to Adequate Third Party Contract Provisions, Industry Contracts, Record Keeping, Procurement History, Procurement Method, Contract Type, and Contractor Selection would improve clarity, update citations, and bring them into alignment with current Federal regulations.</P>
                <P>Proposed revisions to Chapter III would also incorporate new guidance on Constructive Changes, update guidance on Access to Records, and remove Special Notification Requirements to align with current Federal regulations. Additionally, proposed changes would update guidance regarding Use of Technology/Electronic Commerce and Electronic Bidding and Reverse Auctions.</P>
                <P>To address the industry's growing need for control and access to data, as contracts increasingly involve data collection, new guidance would be added on Data Rights. This guidance would cover aspects such as data collection, ownership, and usage, with specific provisions on negotiating data rights to secure adequate licenses for federally funded data. It would also ensure the clear definition of data rights, negotiation of data access rights to meet Federal objectives, and inclusion of appropriate clauses.</P>
                <P>Proposed updates would update guidance on Audits to align with updated Federal regulations.</P>
                <P>To replace the current circular's description of protests and appeals to FTA (see below, under Chapter VII), Chapter III would include a new section describing FTA's role in the recipient's procurement disputes and FTA's interest in settlements impacting Federal funds.</P>
                <HD SOURCE="HD1">Chapter IV</HD>
                <P>In Chapter IV, FTA proposes to clarify the Determining the Recipient's Needs section, including guidance on Necessity, Unnecessary Reserves and Spare Ratios, Acquisition for Assignment Purposes (“piggybacking”), Changes in the Recipient's Needs, and Joint Procurements, as well as State or Local Government Purchasing Schedules or Purchasing Contracts, in accordance with current FTA guidance and purchasing authorities and to reduce duplication of other sections of the circular. Guidance on Joint Procurements would be clarified, while Small Procurements and Lease-versus-Purchase guidance would be updated to align with existing Federal regulation. New guidance to reflect innovative procurement flexibilities introduced by the FAST Act would be introduced on Leases of Rolling Stock and Related Equipment, Leases of Removable Power Sources, reporting requirements, and lease specifications.</P>
                <P>
                    Additional updates would clarify Federal requirements affecting recipient acquisitions. Guidance on Responsibility Requirements and DOT Debarment and Suspension would be updated, with references to the GSA Excluded Parties List replaced by the System for Award Management (SAM). Updates to Conflicts of Interest, and Lobbying Certification and Disclosure 
                    <PRTPAGE P="93826"/>
                    would improve clarity and reflect current Federal regulations and FTA policy.
                </P>
                <P>The Federal Civil Rights Laws and Regulations section would be renamed Civil Rights and moved and consolidated with other civil rights-related sections for better flow. Updates within Administrative Requirements would include minor clarifications for accuracy. Under Cost Principles, unnecessary guidance on Governmental Entities, Educational Institutions, Non-Profit Entities, and For-Profit Entities would be removed because these entities all apply the same cost principles under FTA's policy.</P>
                <P>The Payments Provision section would be updated with the latest FTA guidance on Advance Payments and Progress Payments.</P>
                <P>Wage and Hour Requirements under Socio-Economic Requirements would be renamed the Contract Work and Hours and Safety Standards Act, to be consistent with regulation, and the information therein would be updated to reflect the most current description in Federal regulation. Fair Labor Standards guidance would be similarly updated.</P>
                <P>Under Civil Rights, guidance would be reorganized for flow, and new guidance would address changes in the law regarding nondiscrimination on the basis of sexual orientation and gender since the last circular update.</P>
                <P>The Targeted Contracting section would be updated. The description of U.S. DOT's Disadvantaged Business Enterprise (DBE) rule would be updated to reflect changes to that rule that took effect in 2024. The section on Small and Disadvantaged Business Enterprises and HUBZones would be expanded in accordance with existing Federal regulation.</P>
                <P>Under Environmental Protection, guidance on the Clean Air Act, the Federal Water Pollution Control Act, and Recycled Products would be updated to reflect current Federal regulations. Energy Conservation would be updated to refer to current regulation. Preference for U.S. Property—Buy America would be updated to add reference to the Build America, Buy America Act that became law in 2021, the addition of construction materials to the list of products that must be manufactured in the United States on an FTA funded project, and reference to 2 CFR part 184, which implements the new requirement for construction materials. Guidance on Shipments by Ocean Vessel would be clarified.</P>
                <P>Under Technical Restrictions, updates would remove unnecessary Metric Measurements guidance, because 2 CFR part 200 does not require this.</P>
                <P>Under Rolling Stock—Special Requirements, guidance on Transit Vehicle Manufacturer Compliance with DBE Requirements would expand to include guidance on project-specific DBE participation goals. Updates on Minimum Useful Life and Spare Ratios would make clarifications and align with FTA's latest guidance. Outdated guidance on Air Pollution and Fuel Economy would be removed. Minor corrections and simplifications would be made to Preaward and Post Delivery Review, Bus Testing, In-State Dealers, and Rolling Stock Contract Options.</P>
                <P>The Art section would be substantially removed because art no longer is an eligible expense under FTA's statute.</P>
                <P>Guidance on Architectural and Engineering (A&amp;E) Services would include updates on Qualifications-Based Selection, renamed from Qualifications-Based Requirements, to reorganize and clarify without substantive changes. Related updates for Construction, Service Purposes, Equivalent State Law, and Indirect Cost Rates would enhance clarity.</P>
                <P>Under Construction—Special Requirements, guidance on Bonding, Bid Guarantees, Performance Bonds, Payment Bonds, Reduced Bonding, and Excessive Bonding would be updated to refer to current regulations and updated URLs without substantive change. Seismic Safety, Value Engineering, Equal Employment Opportunity, Davis-Bacon Wages, Anti-Kickback, Contract Work Hours and Safety Standards, and Labor Neutrality would receive non-substantive updates for clarity and regulatory alignment, and a new section on veterans' employment would be added in accordance with FTA's existing statute. The section on Preference for U.S. Property—Buy America would be consolidated earlier in the chapter. Accessibility guidance would also be relocated for clarity.</P>
                <P>The Research, Development, Demonstration, Deployment, and Special Studies—Special Requirements section would include updates to Patent Rights, Rights in Data, Export Control, Protection of Human Subjects, and Protection of Animals to cite to current Federal regulations and FTA's Master Agreement where appropriate.</P>
                <P>Finally, updates in Audit Services would align with current Federal regulations and dollar thresholds, with revisions to the Single Audit Act, Organizational Conflicts of Interest, Eligibility Costs, and verification processes. The section on Obtaining Indirect Cost Rates would be simplified and references to current Federal regulation would be added.</P>
                <HD SOURCE="HD1">Chapter V</HD>
                <P>Chapter V would update the Force Account and Shared Use sections for clarity to refer to FTA's latest guidance on the subjects. Under Joint Procurement, guidance would be clarified. Updates to the guidance on State or Local Government Purchasing Schedules or Purchasing Contracts would be clarified, and new guidance would be provided on Interstate Purchasing of Rolling Stock and Related Equipment to account for changes to rolling stock purchasing authorities. New guidance would be added on Interstate Purchasing Schedules and guidance on Intergovernmental Agreements would be updated to reflect new authorities introduced by the FAST Act for rolling stock procurements.</P>
                <P>New guidance on Cooperative Procurement of Rolling Stock and Related Equipment would be added to reflect new FAST Act authorities.</P>
                <P>Guidance on Competition and Price Reasonableness would be revised to align with current Federal regulations.</P>
                <P>The Existing Contracts (Assignments) section would be reorganized and streamlined for clarity. Information on Alternatives to Assigned Contract Rights, Joint Procurements, and Intergovernmental Procurements would be removed and consolidated with the sections elsewhere in the circular dealing with those topics. Guidance related to Impermissible Actions, Improper Contract Expansion and Improper Cardinal Changes would be updated to improve clarity. Sections on Tests, Rolling Stock, and Federal Procurement Standards would be removed from this section and consolidated with sections elsewhere in this circular dealing with those topics.</P>
                <HD SOURCE="HD1">Chapter VI</HD>
                <P>For Chapter VI, the Competition Required section would incorporate changes to more closely reflect existing Federal regulations. The subsection on Unsolicited Proposals would be reorganized for flow without substantive change. Prequalification guidance would be updated to match current regulation, adding Objective Factors and refining sections on Currentness (formerly Lists), Sources, and Qualification Periods.</P>
                <P>
                    Solicitation Requirements and Restrictions would also be updated to align with Federal regulations, including clarifications in the subsections What to Include and Brand Name or Equal. Prohibitions would be revised, with updates on Excessive Qualifications, Unnecessary Experience, Improper Prequalification, Retainer 
                    <PRTPAGE P="93827"/>
                    Contracts, Excessive Bonding, Brand Name Only, and Geographic Restrictions (formerly In-State or Local Geographic Restrictions). Regarding geographic restrictions, changes since the last circular update include authority in IIJA to apply local hiring targets to construction projects, and the removal of a former prohibition against geographic restrictions from 2 CFR part 200. A reference to Self-Dealing and Bid Rigging would be added to the list of prohibited restrictions on competition.
                </P>
                <P>The section on Organizational Conflicts of Interest would be revised to include new guidance on the Recipient's Conflicts in accordance with current regulation. Updates to Contractor's Conflicts would include expanded guidance on Biased Ground Rules in accordance with existing regulation.</P>
                <P>The Prohibited or Restricted Contract Types section would be simplified, with clarifications on Cost Plus a Percentage of Cost—Prohibited, Percentage of Construction Cost—Prohibited, and Time and Materials—Restricted. Subsections on When to Use and Firm Ceiling Price would be removed as unnecessary.</P>
                <P>Methods of Procurement would be revised to reflect updated Federal regulations, including a new section on Self-Certified Micro-Purchase Thresholds, which were introduced by a new provision in 2 CFR part 200 that took effect in 2024. Under the new provision, a recipient may set for itself a micro-purchase threshold that is higher than the Federal micro-purchase threshold. Procedures, including Distribution (formerly Competition) and Documentation, would be clarified, and the Small Purchases subsection would be renamed Simplified Acquisitions for accuracy, regulatory alignment, and to avoid confusion with FTA's unrelated “small purchases” Buy America waiver. The Simplified Acquisitions section would be updated to align with the current regulations, including updates to Competition and Documentation.</P>
                <P>Sealed Bids (Formal Advertising) would undergo updates to align with current Federal regulations and simplify guidance, with specific clarifications in When Appropriate, Fixed Price Contract, Discussions Unnecessary, and Procurement Procedures.</P>
                <P>Competitive Proposals (Request for Proposals) would be updated for regulatory consistency, with clarification in When Appropriate and Discussion Expected. Procurement Procedures would see updates in Notice (formerly Publicity), Written Procedures (formerly Evaluation Method), Price and Other Factors, and the absorption of Best Value into Price and Other Factors.</P>
                <P>The section on Two-Step Procurement Procedures would receive additional guidance and clarifications.</P>
                <P>Guidance on Architectural and Engineering (A&amp;E) Services and Other Services would be updated for clarity, and a new statement would be added to make clear that Multiple Award Indefinite-Delivery A&amp;E Contracts are permissible.</P>
                <P>Information on Design-Bid-Build (DBB) would be incorporated into a new section on Mixed A&amp;E-Construction Contracts, covering both DBB and Progressive Design-Build (PDB). The Procurement Method section would be updated, with Construction Predominant, Design Services Predominant, and Selection Processes sections absorbed into Procurement Method for streamlined guidance.</P>
                <P>The Other Than Full and Open Competition section would be revised to more closely follow Federal regulations. Guidance on Micro-Purchases, Sole Source, Unsolicited Proposals, and Restricted Data Rights would be updated for clarity. The Exigency or Emergency section would be clarified, with Unusual and Compelling Urgency absorbed under Exigency or Emergency. The significantly outdated paragraph about Associated Capital Maintenance Item Exception would be removed.</P>
                <P>Updates would clarify guidance on Cardinal Changes, including revised guidance on when cardinal changes impair competition and how to recognize cardinal changes that impair competition.</P>
                <P>Eligible Costs would be updated to align with the current Federal regulation and FTA policy in its Master Agreement. The section on Adjustments to Project Costs would be removed as unnecessary.</P>
                <P>Cost Analysis and Price Analysis would receive minor revisions for clarity and organization, and the sentence on Federal cost principles would be removed as redundant with the following subsection, Guidance on Cost and Price Analysis.</P>
                <P>Guidance on Evaluations and Contract Award would be updated with minor changes for clarity, and a new information on disqualifying offerors with recent Tax Liability or Felony Convictions.</P>
                <HD SOURCE="HD1">Chapter VII</HD>
                <P>Chapter VII in Circular 4220.1F deals with protests, changes, disputes, and appeals of the recipient's procurement decisions to FTA. The proposed circular would eliminate Chapter VII and replace it with a new paragraph in proposed Chapter III on Recipient Responsibilities and FTA's Role in Procurement Disputes. That paragraph would restate the current regulation, which commits procurement decisions to the discretion of the recipient and states that FTA will not substitute its judgment for that of the recipient unless the matter is primarily a Federal concern. It also would state FTA's interest in settlements of procurement disputes that would commit Federal funds or the proceeds of procurement disputes arising from federally funded procurements.</P>
                <HD SOURCE="HD1">Appendices</HD>
                <P>FTA proposes to revise the appendices of the circular to improve accuracy, accessibility, and ensure alignment with current best practices. Specifically, Appendix A, References, would be revised to reflect sources incorporated in this version. Appendix B, FTA Regional and Metropolitan Office Contact Information, and Appendix C, Third Party Contracting Checklist, would be removed to streamline the document and focus on core guidance. Additionally, Appendix D, Provisions, Certifications, Reports, Forms, and Other—Matrices, would be removed to enable more timely updates to this information on the FTA website.</P>
                <HD SOURCE="HD1">Closing</HD>
                <P>
                    After a review and consideration of the comments provided on the updates proposed, FTA will publish the updated Third Party Contracting Guidance Circular (C 4220.1G) on its website and will announce the availability of the updated circular and the response to comments in the 
                    <E T="04">Federal Register</E>
                    .
                </P>
                <SIG>
                    <NAME>Veronica Vanterpool,</NAME>
                    <TITLE>Deputy Administrator.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27645 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4910-57-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF THE TREASURY</AGENCY>
                <SUBAGY>Office of the Comptroller of the Currency</SUBAGY>
                <SUBJECT>Agency Information Collection Activities: Information Collection Renewal; Comment Request; Computer-Security Incident Notification </SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P> Office of the Comptroller of the Currency (OCC), Treasury. </P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P> Notice and request for comment.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        The OCC, as part of its continuing effort to reduce paperwork and respondent burden, invites 
                        <PRTPAGE P="93828"/>
                        comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995 (PRA). In accordance with the requirements of the PRA, the OCC may not conduct or sponsor, and the respondent is not required to respond to, an information collection unless it displays a currently valid Office of Management and Budget (OMB) control number. The OCC is soliciting comment concerning the renewal of its information collection titled, “Computer-Security Incident Notification.” 
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be received by January 27, 2025. </P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>Commenters are encouraged to submit comments by email, if possible. You may submit comments by any of the following methods:</P>
                    <P>
                        • 
                        <E T="03">Email: prainfo@occ.treas.gov.</E>
                    </P>
                    <P>
                        • 
                        <E T="03">Mail:</E>
                         Chief Counsel's Office, Attention: Comment Processing, Office of the Comptroller of the Currency, Attention: 1557-0350, 400 7th Street SW, Suite 3E-218, Washington, DC 20219.
                    </P>
                    <P>
                        • 
                        <E T="03">Hand Delivery/Courier:</E>
                         400 7th Street SW, Suite 3E-218, Washington, DC 20219.
                    </P>
                    <P>
                        • 
                        <E T="03">Fax:</E>
                         (571) 293-4835.
                    </P>
                    <P>
                        <E T="03">Instructions:</E>
                         You must include “OCC” as the agency name and “1557-0350” in your comment. In general, the OCC will publish comments on 
                        <E T="03">www.reginfo.gov</E>
                         without change, including any business or personal information provided, such as name and address information, email addresses, or phone numbers. Comments received, including attachments and other supporting materials, are part of the public record and subject to public disclosure. Do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure.
                    </P>
                    <P>Following the close of this notice's 60-day comment period, the OCC will publish a second notice with a 30-day comment period. You may review comments and other related materials that pertain to this information collection beginning on the date of publication of the second notice for this collection by the method set forth in the next bullet.</P>
                    <P>
                        • 
                        <E T="03">Viewing Comments Electronically:</E>
                         Go to 
                        <E T="03">www.reginfo.gov.</E>
                         Hover over the “Information Collection Review” tab and click on “Information Collection Review” from the drop-down menu. From the “Currently under Review” drop-down menu, select “Department of Treasury” and then click “submit.” This information collection can be located by searching OMB control number “1557-0350” or “Computer-Security Incident Notification.” Upon finding the appropriate information collection, click on the related “ICR Reference Number.” On the next screen, select “View Supporting Statement and Other Documents” and then click on the link to any comment listed at the bottom of the screen.
                    </P>
                    <P>
                        • For assistance in navigating 
                        <E T="03">www.reginfo.gov,</E>
                         please contact the Regulatory Information Service Center at (202) 482-7340.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Shaquita Merritt, Clearance Officer, (202) 649-5490, Chief Counsel's Office, Office of the Comptroller of the Currency, 400 7th Street SW, Washington, DC 20219. If you are deaf, hard of hearing, or have a speech disability, please dial 7-1-1 to access telecommunications relay services.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>
                    Under the PRA (44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                    ), Federal agencies must obtain approval from the OMB for each collection of information that they conduct or sponsor. “Collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) to include agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of title 44 generally requires Federal agencies to provide a 60-day notice in the 
                    <E T="04">Federal Register</E>
                     concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, the OCC is publishing notice of the renewal of this collection.
                </P>
                <P>
                    <E T="03">Title:</E>
                     Computer-Security Incident Notification.
                </P>
                <P>
                    <E T="03">OMB Control No.:</E>
                     1557-0350.
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Regular.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Businesses or other for-profit.
                </P>
                <P>
                    <E T="03">Description:</E>
                     Pursuant to 12 CFR part 53, the OCC has established certain computer-security incident notification requirements applicable to banking organizations 
                    <SU>1</SU>
                    <FTREF/>
                     and bank service providers.
                    <SU>2</SU>
                    <FTREF/>
                     Specifically, 12 CFR 53.3 requires a banking organization to notify the OCC about a “notification incident” as soon as possible but no later than 36 hours after the banking organization determines that a notification incident has occurred. The regulation defines a “notification incident” as “a computer-security incident that has materially disrupted or degraded, or is reasonably likely to materially disrupt or degrade, a banking organization's—(i) [a]bility to carry out banking operations, activities, or processes, or deliver banking products and services to a material portion of its customer base, in the ordinary course of business; (ii) [b]usiness line(s), including associated operations, services, functions, and support, that upon failure would result in a material loss of revenue, profit, or franchise value; or (iii) [o]perations, including associated services, functions and support, as applicable, the failure or discontinuance of which would pose a threat to the financial stability of the United States.” 
                    <SU>3</SU>
                    <FTREF/>
                </P>
                <FTNT>
                    <P>
                        <SU>1</SU>
                         A banking organization as “a national bank, Federal savings association, or Federal branch or agency of a foreign bank; provided, however, that no designated financial market utility shall be considered a banking organization.” 12 CFR 53.2(b)(1).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>2</SU>
                         A bank service provider is “a bank service company or other person that performs covered services; provided, however, that no designated financial market utility shall be considered a bank service provider.” 12 CFR 53.2(b)(2).
                    </P>
                </FTNT>
                <FTNT>
                    <P>
                        <SU>3</SU>
                         12 CFR 53.2(b)(7). A “computer-security incident” is “an occurrence that results in actual harm to the confidentiality, integrity, or availability of an information system or the information that the system processes, stores, or transmits.” 12 CFR 53.2(b)(4).
                    </P>
                </FTNT>
                <P>Additionally, a bank service provider must notify at least one bank-designated point of contact at each affected banking organization customer as soon as possible when the bank service provider determines that it has experienced a computer-security incident that has materially disrupted or degraded, or is reasonably likely to materially disrupt or degrade, covered services provided to such banking organization for four or more hours.</P>
                <P>
                    <E T="03">Estimated Burden:</E>
                </P>
                <P>
                    <E T="03">Estimated Frequency of Response:</E>
                     On occasion; event generated. 
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                </P>
                <P>
                    <E T="03">Reporting:</E>
                     100 Respondents.
                </P>
                <P>
                    <E T="03">Disclosure:</E>
                     832 Respondents.
                </P>
                <P>
                    <E T="03">Estimated Total Annual Burden:</E>
                     2,795 hours. 
                </P>
                <P>Comments submitted in response to this notice will be summarized and included in the request for OMB approval. All comments will become a matter of public record. Comments are invited on: </P>
                <P>(a) Whether the collection of information is necessary for the proper performance of the functions of the OCC, including whether the information has practical utility; </P>
                <P>(b) The accuracy of the OCC's estimate of the burden of the collection of information; </P>
                <P>(c) Ways to enhance the quality, utility, and clarity of the information to be collected; </P>
                <P>
                    (d) Ways to minimize the burden of the collection on respondents, including 
                    <PRTPAGE P="93829"/>
                    through the use of automated collection techniques or other forms of information technology; and 
                </P>
                <P>(e) Estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.</P>
                <SIG>
                    <NAME>Patrick T. Tierney,</NAME>
                    <TITLE>Assistant Director, Office of the Comptroller of the Currency.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27876 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4810-33-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF THE TREASURY</AGENCY>
                <SUBAGY>Office of Foreign Assets Control</SUBAGY>
                <SUBJECT>Notice of OFAC Sanctions Action</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Foreign Assets Control, Treasury.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of the Treasury's Office of Foreign Assets Control (OFAC) is publishing the names of one or more persons that have been placed on OFAC's Specially Designated Nationals and Blocked Persons List (SDN List) based on OFAC's determination that one or more applicable legal criteria were satisfied. All property and interests in property subject to U.S. jurisdiction of these persons are blocked, and U.S. persons are generally prohibited from engaging in transactions with them.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        This action was issued on October 30, 2024. See 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         for relevant dates.
                    </P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        OFAC: Associate Director for Global Targeting, 202-622-2420; or 
                        <E T="03">https://ofac.treasury.gov/contact-ofac.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Electronic Availability</HD>
                <P>
                    The SDN List and additional information concerning OFAC sanctions programs are available on OFAC's website: 
                    <E T="03">https://ofac.treasury.gov.</E>
                </P>
                <HD SOURCE="HD1">Notice of OFAC Action(s)</HD>
                <P>On October 30, 2024, OFAC determined that the property and interests in property subject to U.S. jurisdiction of the following persons are blocked under the relevant sanctions authorities listed below.</P>
                <BILCOD>BILLING CODE 4810-AL-P</BILCOD>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93830"/>
                    <GID>EN27NO24.323</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93831"/>
                    <GID>EN27NO24.324</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93832"/>
                    <GID>EN27NO24.325</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93833"/>
                    <GID>EN27NO24.326</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93834"/>
                    <GID>EN27NO24.327</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93835"/>
                    <GID>EN27NO24.328</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93836"/>
                    <GID>EN27NO24.329</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93837"/>
                    <GID>EN27NO24.330</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93838"/>
                    <GID>EN27NO24.331</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93839"/>
                    <GID>EN27NO24.332</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93840"/>
                    <GID>EN27NO24.333</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93841"/>
                    <GID>EN27NO24.334</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93842"/>
                    <GID>EN27NO24.335</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93843"/>
                    <GID>EN27NO24.336</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93844"/>
                    <GID>EN27NO24.337</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93845"/>
                    <GID>EN27NO24.338</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93846"/>
                    <GID>EN27NO24.339</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93847"/>
                    <GID>EN27NO24.340</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93848"/>
                    <GID>EN27NO24.341</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93849"/>
                    <GID>EN27NO24.342</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93850"/>
                    <GID>EN27NO24.343</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93851"/>
                    <GID>EN27NO24.344</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93852"/>
                    <GID>EN27NO24.345</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93853"/>
                    <GID>EN27NO24.346</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93854"/>
                    <GID>EN27NO24.347</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93855"/>
                    <GID>EN27NO24.348</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93856"/>
                    <GID>EN27NO24.349</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93857"/>
                    <GID>EN27NO24.350</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93858"/>
                    <GID>EN27NO24.351</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93859"/>
                    <GID>EN27NO24.352</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93860"/>
                    <GID>EN27NO24.353</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93861"/>
                    <GID>EN27NO24.354</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93862"/>
                    <GID>EN27NO24.355</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93863"/>
                    <GID>EN27NO24.356</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93864"/>
                    <GID>EN27NO24.357</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93865"/>
                    <GID>EN27NO24.358</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93866"/>
                    <GID>EN27NO24.359</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93867"/>
                    <GID>EN27NO24.360</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93868"/>
                    <GID>EN27NO24.361</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93869"/>
                    <GID>EN27NO24.362</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93870"/>
                    <GID>EN27NO24.363</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93871"/>
                    <GID>EN27NO24.364</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93872"/>
                    <GID>EN27NO24.365</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93873"/>
                    <GID>EN27NO24.366</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93874"/>
                    <GID>EN27NO24.367</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93875"/>
                    <GID>EN27NO24.368</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93876"/>
                    <GID>EN27NO24.369</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93877"/>
                    <GID>EN27NO24.370</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93878"/>
                    <GID>EN27NO24.371</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93879"/>
                    <GID>EN27NO24.372</GID>
                </GPH>
                <GPH SPAN="3" DEEP="190">
                    <PRTPAGE P="93880"/>
                    <GID>EN27NO24.373</GID>
                </GPH>
                <SIG>
                    <NAME>Lisa M. Palluconi,</NAME>
                    <TITLE>Acting Director, Office of Foreign Assets Control.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27799 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4810-AL-C</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF THE TREASURY</AGENCY>
                <SUBAGY>Office of Foreign Assets Control</SUBAGY>
                <SUBJECT>Notice of OFAC Sanctions Action</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Office of Foreign Assets Control, Treasury.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The U.S. Department of the Treasury's Office of Foreign Assets Control (OFAC) is publishing the names of one or more persons that have been placed on OFAC's Specially Designated Nationals and Blocked Persons List (SDN List) based on OFAC's determination that one or more applicable legal criteria were satisfied. All property and interests in property subject to U.S. jurisdiction of these persons are blocked, and U.S. persons are generally prohibited from engaging in transactions with them.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>
                        This action was issued on November 21, 2024. See 
                        <E T="02">SUPPLEMENTARY INFORMATION</E>
                         section for relevant dates.
                    </P>
                </DATES>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        OFAC: Associate Director for Global Targeting, 202-622-2420; or 
                        <E T="03">https://ofac.treasury.gov/contact-ofac.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <HD SOURCE="HD1">Electronic Availability</HD>
                <P>
                    The SDN List and additional information concerning OFAC sanctions programs are available on OFAC's website: 
                    <E T="03">https://ofac.treasury.gov.</E>
                </P>
                <HD SOURCE="HD1">Notice of OFAC Actions</HD>
                <P>On November 21, 2024, OFAC determined that the property and interests in property subject to U.S. jurisdiction of the following persons are blocked under the relevant sanctions authorities listed below.</P>
                <BILCOD>BILLING CODE 4180-AL-P</BILCOD>
                <GPH SPAN="3" DEEP="576">
                    <PRTPAGE P="93881"/>
                    <GID>EN27NO24.298</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93882"/>
                    <GID>EN27NO24.299</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93883"/>
                    <GID>EN27NO24.300</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93884"/>
                    <GID>EN27NO24.301</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93885"/>
                    <GID>EN27NO24.302</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93886"/>
                    <GID>EN27NO24.303</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93887"/>
                    <GID>EN27NO24.304</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93888"/>
                    <GID>EN27NO24.305</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93889"/>
                    <GID>EN27NO24.306</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93890"/>
                    <GID>EN27NO24.307</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93891"/>
                    <GID>EN27NO24.308</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93892"/>
                    <GID>EN27NO24.309</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93893"/>
                    <GID>EN27NO24.310</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93894"/>
                    <GID>EN27NO24.311</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93895"/>
                    <GID>EN27NO24.312</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93896"/>
                    <GID>EN27NO24.313</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93897"/>
                    <GID>EN27NO24.314</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93898"/>
                    <GID>EN27NO24.315</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93899"/>
                    <GID>EN27NO24.316</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93900"/>
                    <GID>EN27NO24.317</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93901"/>
                    <GID>EN27NO24.318</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93902"/>
                    <GID>EN27NO24.319</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93903"/>
                    <GID>EN27NO24.320</GID>
                </GPH>
                <GPH SPAN="3" DEEP="640">
                    <PRTPAGE P="93904"/>
                    <GID>EN27NO24.321</GID>
                </GPH>
                <GPH SPAN="3" DEEP="218">
                    <PRTPAGE P="93905"/>
                    <GID>EN27NO24.322</GID>
                </GPH>
                <SIG>
                    <NAME>Lisa M. Palluconi,</NAME>
                    <TITLE>Acting Director, Office of Foreign Assets Control.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27801 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4810-AL-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF THE TREASURY</AGENCY>
                <SUBAGY>Internal Revenue Service</SUBAGY>
                <SUBJECT>Proposed Collection; Comment Request for Foreign Account Tax Compliance Act Collections</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Internal Revenue Service (IRS), Treasury.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice and request for comments.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Internal Revenue Service, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on continuing information collections, as required by the Paperwork Reduction Act of 1995. The IRS is soliciting comments concerning the foreign account tax compliance act collection requirements.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Written comments should be received on or before January 27, 2025 to be assured of consideration.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Direct all written comments to Andres Garcia, Internal Revenue Service, Room 6526, 1111 Constitution Avenue NW, Washington, DC 20224 or by email to 
                        <E T="03">pra.comments@irs.gov.</E>
                         Include OMB Control number 1545-2246 or Forms: 8957, 8966, 8966-C, 8809-I, and 8508-I.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        Requests for additional information or copies of the form should be directed to Molly Stasko, at (202) 317-6206 or Internal Revenue Service, Room 6526, 1111 Constitution Avenue NW, Washington, DC 20224, or through the internet at 
                        <E T="03">Molly.J.Stasko@irs.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <P>
                    <E T="03">Title:</E>
                     Foreign Account Tax Compliance Act (FATCA).
                </P>
                <P>
                    <E T="03">OMB Number:</E>
                     1545-2246.
                </P>
                <P>
                    <E T="03">Form Numbers:</E>
                     8957, 8966, 8966-C, 8809-I, and 8508-I.
                </P>
                <P>
                    <E T="03">Regulation Project Numbers:</E>
                     IRS Notice 2023-11, IRS Notice 2024-78, and TD 9610.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     Internal Revenue Code (IRC) section 1471-1474 is part of the Foreign Account Tax Compliance Act (FATCA) legislative framework to obtain reporting from foreign financial institutions on the accounts held in their institutions by US persons. The IRS developed forms and regulations under these authorities of IRC. TD 9610 includes the regulations related to the reporting on the forms and the associated recordkeeping requirements.
                </P>
                <P>Form 8957, Foreign Account Tax Compliance Act (FATCA) Registration, information is to be used by a foreign financial institution to apply for status as a foreign financial institution (FFI) as defined in IRC 1471(b)(2). Form 8966, FATCA Report, is used by a responsible officer of a foreign institution to report information with respect to U.S. accounts or persons based on their IRC chapter 4 status. Form 8966-C is used to authenticate the paper-filed Forms 8966 and to ensure the ability to identify discrepancies between the number of forms received versus those claimed to have been sent by the filer. Taxpayers use Form 8508-I to request a waiver from filing Form 8966 electronically. Form 8809-I is used to request an initial or additional extension of time to file 8966 for the current year. IRS Notice 2023-11 and IRS Notice 2024-78 allow FFIs to obtain temporary relief from reporting missing required U.S. taxpayer identification numbers for certain preexisting accounts, when they comply with the procedures described within each notice. Publication 5124 provides directions on how Model 1 Intergovernmental Agreements report information directly to the IRS.</P>
                <P>
                    <E T="03">Current Actions:</E>
                     IRS is adding the Publication 5124, IRS Notice 2023-11 and 2024-78 to the OMB approval for 1545-2246. There are not changes to the requirements. This is an administrative change to count the burden within 1545-2246.
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Revision of a currently approved collection.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Business or other for-profit organizations.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     5,561,180.
                </P>
                <P>
                    <E T="03">Estimated Time per Response:</E>
                     7 minutes up to 8 hours, 7 minutes for the various collection requirements.
                </P>
                <P>
                    <E T="03">Estimated Total Annual Burden Hours:</E>
                     2,912,282.
                </P>
                <P>The following paragraph applies to all the collections of information covered by this notice.</P>
                <P>
                    An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection of information displays a valid OMB control number. Books or records relating to a collection of information must be retained if their contents may become material in the administration of any internal revenue law. Generally, tax returns and tax 
                    <PRTPAGE P="93906"/>
                    return information are confidential, as required by 26 U.S.C. 6103.
                </P>
                <P>
                    <E T="03">Request for Comments:</E>
                     Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval. All comments will become a matter of public record. Comments are invited on: (a) whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.
                </P>
                <SIG>
                    <DATED>Approved: November 21, 2024.</DATED>
                    <NAME>Molly J. Stasko,</NAME>
                    <TITLE>Senior Tax Analyst.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27792 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 4830-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="N">DEPARTMENT OF VETERANS AFFAIRS</AGENCY>
                <SUBJECT>Veterans and Community Oversight and Engagement Board, Notice of Meeting</SUBJECT>
                <P>The Department of Veterans Affairs (VA) gives notice under the Federal Advisory Committee Act (FACA), 5 U.S.C. ch. 10, that the Veterans and Community Oversight and Engagement Board will meet virtually on December 13, 2024. The meeting sessions will begin, and end as follows:</P>
                <GPOTABLE COLS="2" OPTS="L2,tp0,i1" CDEF="s100,r200">
                    <TTITLE> </TTITLE>
                    <BOXHD>
                        <CHED H="1">Date:</CHED>
                        <CHED H="1">Time:</CHED>
                    </BOXHD>
                    <ROW>
                        <ENT I="01">Friday, December 13, 2024</ENT>
                        <ENT>9:00 a.m. to 3:00 p.m. Pacific Standard Time (PST).</ENT>
                    </ROW>
                </GPOTABLE>
                <P>The meetings are open to the public and will be recorded.</P>
                <P>The Board was established by the West Los Angeles Leasing Act of 2016 on September 29, 2016. The purpose of the Board is to provide advice and make recommendations to the Secretary of Veterans Affairs on: identifying the goals of the community and Veteran partnership; improving services and outcomes for Veterans, members of the Armed Forces, and the families of such Veterans and members; and on the implementation of the Draft Master Plan approved by the Secretary on January 28, 2016, and on the creation and implementation of any successor master plans.</P>
                <P>On December 13, the agenda will include opening remarks from the Committee Chair and the Executive Sponsor. There will be a general update from VA Greater Los Angeles Healthcare System (VAGLAHS). The West Los Angeles Veterans Collective will provide a status briefing all activities since June 2024. The Urban Land Institute will present the results of their Implementation Technical Assistance Panel (ITAP) study. An update on the status and projected efforts related to Master Plan 2025, and an overview of the VA Survey on Veteran Preferences results will be presented by (VAGLAHS) staff. The Board's subcommittees on Outreach and Community Engagement with Services and Outcomes, and Master Plan with Services and Outcomes will report on activities since the last meeting. Subcommittee reports will be followed by an out brief to the full Board on any draft recommendations considered for forwarding to the Secretary.</P>
                <P>
                    Time will be allocated for receiving public comments on December 13, starting at 9:40 a.m. PST. Individuals wishing to make public comments are requested to submit a 1-2-page summary of their comments for inclusion in the official meeting record or would like to share information with the Committee should contact Mr. Chihung Szeto, Alternate Designated Federal Officer, at (562) 708-9959, at 
                    <E T="03">Chihung.Szeto@va.gov</E>
                     or 
                    <E T="03">VEOFACA@va.gov.</E>
                     Only those members of the public (first 6 public comment registrants) who have confirmed registrations to provide public comment will be allowed to provide public comment. In the interest of time, each speaker will be held to 5-minute time limit. The Committee will accept written comments from interested parties on issues outlined in the meeting agenda, from December 11, 2024 to December 15, 2024.
                </P>
                <P>Members of the public can attend the meeting via WEBEX by joining from the meeting link below. The link will be active from 8:45 a.m.-3:30 p.m. PST, December 13, 2024.</P>
                <HD SOURCE="HD1">Veteran and Community Oversight and Engagement Board (VCOEB)</HD>
                <P>Hosted by Walsh, Margaret K. (ERPI).</P>
                <P>https://veteransaffairs.webex.com/veteransaffairs/j.php?MTID=mef5d2ad406348e108778e341fcbbf891.</P>
                <P>Friday, December 13, 2024, 9:00 a.m. | 6 hours | Pacific Time (US &amp; Canada).</P>
                <P>
                    <E T="03">Meeting number:</E>
                     2831 720 3971.
                </P>
                <P>
                    <E T="03">Password:</E>
                     sJMpM2pJ*32.
                </P>
                <P>
                    Any member of the public seeking additional information should contact Mr. Eugene W. Skinner Jr. at (202) 631-7645 or at 
                    <E T="03">Eugene.Skinner@va.gov.</E>
                </P>
                <SIG>
                    <DATED>Dated: November 22, 2024.</DATED>
                    <NAME>Jelessa M. Burney,</NAME>
                    <TITLE>Federal Advisory Committee Management Officer.</TITLE>
                </SIG>
            </PREAMB>
            <FRDOC>[FR Doc. 2024-27868 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8320-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF VETERANS AFFAIRS</AGENCY>
                <DEPDOC>[OMB Control No. 2900-0783]</DEPDOC>
                <SUBJECT>Agency Information Collection Activity: Nonprofit Research and Education Corporations (NPCs)—Annual Report, Remediation Plans &amp; Assessment Questionnaires</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Veterans Health Administration, Department of Veterans Affairs.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        Veterans Health Administration (VHA), Department of Veterans Affairs (VA), is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act (PRA) of 1995, Federal agencies are required to publish notice in the 
                        <E T="04">Federal Register</E>
                         concerning each proposed collection of information, including each proposed extension of a currently approved collection, and allow 60 days for public comment in response to the notice.  DATES: Comments must be received on or before January 27, 2025.
                    </P>
                </SUM>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Comments must be submitted through 
                        <E T="03">www.regulations.gov.</E>
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P/>
                    <P>
                        <E T="03">Program-Specific information:</E>
                         Rebecca Mimnall, 202-695-9434, 
                        <E T="03">vhacopra@va.gov.</E>
                        <PRTPAGE P="93907"/>
                    </P>
                    <P>
                        <E T="03">VA PRA information:</E>
                         VA PRA Clearance Office, 202-461-8900, 
                        <E T="03">vacopaperworkreduact@va.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Under the PRA of 1995, Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. This request for comment is being made pursuant to section 3506(c)(2)(A) of the PRA.</P>
                <P>With respect to the following collection of information, VHA invites comments on: (1) whether the proposed collection of information is necessary for the proper performance of VHA's functions, including whether the information will have practical utility; (2) the accuracy of VHA's estimate of the burden of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or the use of other forms of information technology.</P>
                <P>
                    <E T="03">Title:</E>
                     Nonprofit Research and Education Corporations (NPCs)—Annual Report, Remediation Plans &amp; Assessment Questionnaires (VA Forms 10-10073, 10-10073A, 10-10073B, and 10-10073C).
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     2900-0783. 
                    <E T="03">https://www.reginfo.gov/public/do/PRASearch</E>
                     (Once at this link, you can enter the OMB Control Number to find the historical versions of this Information Collection).
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Revision of a currently approved collection.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     Federal law at 38 U.S.C. 7366, Accountability and Oversight, states “(b) each such corporation (NPC) shall submit to the Secretary (Department of Veterans Affairs (DVA)) an annual report providing a detailed statement of its operations, activities, and accomplishments during that year.” The individual NPC annual reports are combined into one NPC Annual Report to Congress. VA oversight of NPCs includes reviews, audits, self-assessments, and remediation plans. This information collection is used for oversight of NPCs and includes the following:
                </P>
                <FP SOURCE="FP-1">a. NPC Annual Report Template, VA Form 10-10073</FP>
                <FP SOURCE="FP-1">b. NPC Audit Actions Items Remediation Plans, VA Form 10-10073A</FP>
                <FP SOURCE="FP-1">c. NPPO Internal Control Questionnaire, VA Form 10-10073B</FP>
                <FP SOURCE="FP-1">d. NPPO Operations Oversight Questionnaire, VA Form 10-10073C</FP>
                <HD SOURCE="HD1">NPC Annual Report Template, VA Form 10-10073</HD>
                <P>Since 1988, when the enabling legislation for the NPCs was passed, annual reports have been obtained from each NPC and combined into an NPC Annual Report to Congress. Congress uses the combined NPC Annual Report to Congress to monitor the progress of the overall NPC program it created. The NPC Annual Report to Congress is also used by top-level VA executives to evaluate the program and to recommend changes where needed. VHA's Nonprofit Oversight Board and the Nonprofit Program Office (NPPO) use both the combined NPC Annual Report to Congress and the individual NPC Annual Report Templates to monitor and oversee the NPCs. Trend analyses and other financial information are analyzed for each NPC and judgments made about each NPC's progress, financial viability, stewardship of assets, and accomplishments.</P>
                <HD SOURCE="HD1">NPC Audit Actions Items Remediation Plans, VA Form 10-10073A</HD>
                <P>The NPC Audit Action Items Remediation Plans information collection is used to review the NPCs' remedies for audit deficiencies and recommendations. The major objective of the information collection is to help ensure proper corrective action. If any of the remediation plans submitted are inadequate, then the NPPO will make recommendations for sound, workable remedies.</P>
                <HD SOURCE="HD1">NPPO Internal Control Questionnaire, VA Form 10-10073B</HD>
                <P>The NPPO Internal Control Questionnaire, or portions of it, will be used in conducting reviews, audits, and investigations of the NPCs. The major objective of the questionnaire is to uncover weaknesses and lapses in internal controls. The NPPO will then make recommendations for improved internal controls wherever there are weaknesses or lapses. The questionnaire also may be used as a voluntary self-assessment by the NPCs.</P>
                <HD SOURCE="HD1">NPPO Operations Oversight Questionnaire, VA Form 10-10073C</HD>
                <P>The NPPO Operations Oversight Questionnaire, or portions of it, will be used in conducting operational reviews of the NPCs. The major objective of the questionnaire is to uncover operating problems and areas that need improvement. The NPPO will then make recommendations for operations improvements wherever problems or opportunities for improvement are found. The questionnaire also may be used as a voluntary self-assessment by the NPCs.</P>
                <P>VHA does not anticipate any changes to the annual number of responses or burden hours. However, there are some minor updates to the forms for clarification and to comply with current guidance on standard PRA language.</P>
                <P>
                    <E T="03">Total Annual Burden:</E>
                     858 hours.
                </P>
                <P>
                    <E T="03">Total Annual Responses:</E>
                     300.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Individuals or Households.
                </P>
                <P>
                    <E T="03">Estimated Annual Burden:</E>
                </P>
                <P>a. NPC Annual Report Template—301 hours.</P>
                <P>b. NPC Audit Actions Items Remediation Plans—84 hours.</P>
                <P>c. NPPO Internal Control Questionnaire—344 hours.</P>
                <P>d. NPPO Operations Oversight Questionnaire—129 hours.</P>
                <P>
                    <E T="03">Estimated Average Burden Per Respondent:</E>
                </P>
                <P>a. NPC Annual Report Template—210 minutes.</P>
                <P>b. NPC Audit Actions Items Remediation Plans—120 minutes.</P>
                <P>c. NPPO Internal Control Questionnaire—240 minutes.</P>
                <P>d. NPPO Operations Oversight Questionnaire—90 minutes.</P>
                <P>
                    <E T="03">Frequency of Response:</E>
                     Once annually.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                </P>
                <P>a. NPC Annual Report Template—86.</P>
                <P>b. NPC Audit Actions Items Remediation Plans—42.</P>
                <P>c. NPPO Internal Control Questionnaire—86.</P>
                <P>d. NPPO Operations Oversight Questionnaire—86.</P>
                <P>
                    <E T="03">Authority:</E>
                     44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <NAME>Maribel Aponte,</NAME>
                    <TITLE>VA PRA Clearance Officer, Office of Enterprise and Integration/Data Governance Analytics, Department of Veterans Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27728 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8320-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF VETERANS AFFAIRS</AGENCY>
                <DEPDOC>[OMB Control No. 2900-0587]</DEPDOC>
                <SUBJECT>Agency Information Collection Activity Under OMB Review: Equipment Operation and Maintenance Manuals</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Procurement Policy and Warrant Management Service (PPS), Office of Procurement Policy, Systems and Oversight, Office of Acquisition and Logistics, Department of Veterans Affairs.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>
                        In compliance with the Paperwork Reduction Act (PRA) of 
                        <PRTPAGE P="93908"/>
                        1995, this notice announces that the Procurement Policy and Warrant Management Service, Office of Procurement Policy, Systems and Oversight, Office of Acquisition and Logistics, Department of Veterans Affairs, will submit the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden, and it includes the actual data collection instrument.
                    </P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments and recommendations for the proposed information collection should be sent by December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        To submit comments and recommendations for the proposed information collection, please type the following link into your browser: 
                        <E T="03">www.reginfo.gov/public/do/PRAMain,</E>
                         select “Currently under Review—Open for Public Comments”, then search the list for the information collection by Title or “OMB Control No. 2900-0587.”
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>
                        VA PRA information: VA PRA Clearance Office, 202-461-8900, 
                        <E T="03">vacopaperworkreduact@va.gov.</E>
                    </P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P/>
                <P>
                    <E T="03">Title:</E>
                     VAAR Clause 852.211-70, Equipment Operation and Maintenance Manuals.
                </P>
                <P>
                    <E T="03">OMB Control Number:</E>
                     2900-0587 
                    <E T="03">https://www.reginfo.gov/public/do/PRASearch.</E>
                </P>
                <P>
                    <E T="03">Type of Review:</E>
                     Revision of a currently approved collection.
                </P>
                <P>
                    <E T="03">Abstract:</E>
                     The contracting officer shall insert the clause at 852.211-70, Equipment Operation and Maintenance Manuals, in solicitations and contracts for technical medical equipment, and other technical and mechanical equipment and devices where the requiring activity determines manuals are a necessary requirement for operation and maintenance of the equipment. Contractors are required to furnish both operation manuals and maintenance/repair manuals with the equipment provided to the Government. This clause sets forth those requirements and the minimum standards those manuals must meet to be acceptable. Generally, this is the same operation manual furnished with each piece of equipment sold to the general public and the same repair manual used by company technicians in repairing the company's equipment. The cost of the manuals is included in the contract price or listed as separately priced line items on the purchase order. The operation manual will be used by the individual actually operating the equipment to ensure proper operation and cleaning. The repair manual will be used by VA equipment repair staff to repair the equipment.
                </P>
                <P>
                    An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The 
                    <E T="04">Federal Register</E>
                     Notice with a 60-day comment period soliciting comments on this collection of information was published at 89FR76193, September 17, 2024.
                </P>
                <P>
                    <E T="03">Affected Public:</E>
                     Individuals or Households.
                </P>
                <P>
                    <E T="03">Estimated Annual Burden:</E>
                     745 hours.
                </P>
                <P>
                    <E T="03">Estimated Average Burden per Respondent:</E>
                     2 minutes.
                </P>
                <P>
                    <E T="03">Frequency of Response:</E>
                     On occasion.
                </P>
                <P>
                    <E T="03">Estimated Number of Respondents:</E>
                     22,337.
                </P>
                <P>
                    <E T="03">Authority:</E>
                     44 U.S.C. 3501 
                    <E T="03">et seq.</E>
                </P>
                <SIG>
                    <NAME>Maribel Aponte,</NAME>
                    <TITLE>VA PRA Clearance Officer, Office of Enterprise and Integration, Data Governance Analytics, Department of Veterans Affairs.</TITLE>
                </SIG>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27863 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8320-01-P</BILCOD>
        </NOTICE>
        <NOTICE>
            <PREAMB>
                <AGENCY TYPE="S">DEPARTMENT OF VETERANS AFFAIRS</AGENCY>
                <SUBJECT>Notice of Plans for Department of Veterans Affairs to Assess Exposures and Conditions of Interest for Veterans Who Served At Karshi-Khanabad Air Base and To Solicit Public Comment</SUBJECT>
                <AGY>
                    <HD SOURCE="HED">AGENCY:</HD>
                    <P>Department of Veterans Affairs.</P>
                </AGY>
                <ACT>
                    <HD SOURCE="HED">ACTION:</HD>
                    <P>Notice.</P>
                </ACT>
                <SUM>
                    <HD SOURCE="HED">SUMMARY:</HD>
                    <P>The Department of Veterans Affairs (VA) announces that it plans to conduct an assessment of scientific literature and historical claims data to determine whether there is an association between military environmental exposure to toxic substances related to military service at Camp Stronghold Freedom in Karshi-Khanabad (K2) in Uzbekistan from 2001 to 2005 and medical conditions. VA entered into an agreement with the Center for Disease Control and Prevention's Agency for Toxic Substances and Disease Registry and published a Report to Congress in 2022 that identified the known health consequences associated with the identified toxic substances, chemicals, and airborne hazards at K2. As part of a continuing effort to assess the health risks that may be associated with military service at K2, VA is soliciting public comment on environmental exposures at K2 and medical conditions developed by Veterans who served there. This notice provides an opportunity for Veterans, caregivers, survivors, and the public to share relevant information with VA to inform decisions regarding presumptive benefits that could impact the roughly 16,000 Veterans who served at K2.</P>
                </SUM>
                <DATES>
                    <HD SOURCE="HED">DATES:</HD>
                    <P>Comments must be received on or before December 27, 2024.</P>
                </DATES>
                <ADD>
                    <HD SOURCE="HED">ADDRESSES:</HD>
                    <P>
                        Comments must be submitted through 
                        <E T="03">www.regulations.gov.</E>
                         Except as provided below, comments received before the close of the comment period will be available as soon as possible after they have been received at 
                        <E T="03">www.regulations.gov</E>
                         for public viewing, inspection, or copying, including any personally identifiable or confidential business information that is included in a comment. VA will not post public comments that make threats to individuals or institutions or suggest that the commenter will take actions to harm an individual. VA encourages individuals not to submit duplicative comments. We will post comments from multiple unique commenters even if the content is identical or nearly identical to other comments. Any public comment received after the comment period's closing date is considered late and will not be considered in any potential future rulemaking.
                    </P>
                </ADD>
                <FURINF>
                    <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                    <P>Peter D. Rumm, M.D., MPH, Director of Policy, Health Outcomes Military Exposures, Veterans Health Administration, Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 20420, at 202-461-7297. This is not a toll-free number.</P>
                </FURINF>
            </PREAMB>
            <SUPLINF>
                <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                <P>Camp Stronghold Freedom was established at a former Soviet Air Base in K2 located in Southwest Uzbekistan in October 2001 and occupied by U.S. forces through the middle of 2005. During this period, several environmental site surveys were conducted by the Department of Defense (DOD) to assess contaminants that could impact the operational readiness of U.S. military operations and the safety of U.S. forces that deployed to K2. These surveys identified several contaminants, such as dust and particulate matter, underground jet fuel plumes, surface dirt with traces of asbestos, depleted uranium, benzene, chromium, and others. The Public Health website of the Defense Health Agency of the DOD lists contaminants of concern it identified at K2 [1].</P>
                <P>
                    Since 2021, VA has been assessing the potential health effects, including respiratory conditions and cancers, among K2 Veterans. Section 2010 of the Johnny Isakson and David P. Roe, M.D. 
                    <PRTPAGE P="93909"/>
                    Veterans Health Care and Benefits Improvement Act of 2020, Public Law 116-315 (the Isakson and Roe Act) [2], directed VA to engage the Center for Disease Control and Prevention's Agency for Toxic Substances and Disease Registry to describe the known health effects associated with the toxic substances, chemicals, airborne hazards, and other substances DOD identified at K2. This effort has been completed, and a report was submitted to Congress in January 2022, which documented the DOD identified contaminants of concern, medium of exposure, along with the potential cancer and noncancer health effects. The findings from this report can be found on VA's K2 website [3]. The Department of Defense has also studied the mortality among K2 Service members and found that a more in-depth study of health issues is necessary [4]. Section 2010 of the Isakson and Roe Act also directed VA to assess the health effects associated with deployment to K2, with a final report due to Congress no later than 2030 [2]. VA created a public health surveillance program to address this requirement. Analyses are underway and data are updated annually on all K2 Veterans to allow VA to address new information on adverse health outcomes and health concerns of veterans as they become known.
                </P>
                <P>The purpose of this Notice is to provide the K2 community (K2 Veterans, their caregivers, and their survivors) and the broader public the opportunity to share relevant information for VA to determine if VA should recognize the unique environmental exposures (individually and in combination) and medical conditions as presumptive based on a Veteran's service at K2. VA encourages the K2 community and broader public to submit thoughts, recommendations, and requests regarding the exposures and health conditions they feel are related to K2 service and warrant specific consideration by VA as a presumptive condition. VA also invites the public to submit information, evidence, and suggestions that may help VA assess potential exposures at K2 and health effects that may be associated with such exposures.</P>
                <P>In accordance with 38 U.S.C. 1172, as created by section 202 of the Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act of 2022 (PACT Act), VA is publishing this notice about its planned scientific assessment of the possibility of a relationship between all medical conditions and military environmental exposures related to service at Camp Stronghold Freedom in K2 from 2001 to 2005. Pursuant to section 202, the VA Secretary must determine whether to establish or remove presumptions for service connections based on military environmental exposure and the evaluation of adverse health outcomes. VA's procedure includes issuing a public notice regarding reviews, soliciting public comment, and recommendations for corrections to the Secretary from the working group subject matter experts to better reflect Veterans and dependents. Here, in recognition of the unique exposure environment at K2, Secretary McDonough directed a PACT Act presumptive process to formally solicit stakeholder input and demonstrate the rigor VA continues to apply to important questions concerning the contaminants present at K2 and the conditions that K2 Veterans developed following service there.</P>
                <P>In accordance with 38 U.S.C. 1119 and 1120, as created by the PACT Act, Uzbekistan is included as an eligible country covered under the PACT Act for certain presumptions of exposure and service connection. Thus, K2 Veterans are eligible for hundreds of individual presumptive conditions encompassed by the 23 disease categories designated under this landmark legislation [5]. Additionally, K2 Veterans are eligible to receive health care from the Veterans Health Administration, regardless of whether they have filed a claim for disability [6]. VA encourages all K2 Veterans to register for health care and encourages all K2 Veterans and their survivors to submit a claim for any adverse health outcome, even if not covered under the PACT Act, that they feel is related to their military service at K2 or elsewhere.</P>
                <HD SOURCE="HD1">Signing Authority</HD>
                <P>Denis McDonough, Secretary of Veterans Affairs, signed and approved this document on November 15, 2024, and authorized the undersigned to sign and submit the document to the Office of the Federal Register for publication electronically as an official document of the Department of Veterans Affairs.</P>
                <SIG>
                    <NAME>Jeffrey M. Martin,</NAME>
                    <TITLE>Assistant Director, Office of Regulation Policy &amp; Management, Office of General Counsel, Department of Veterans Affairs.</TITLE>
                </SIG>
                <HD SOURCE="HD1">References</HD>
                <EXTRACT>
                    <FP SOURCE="FP-2">
                        1. Karshi-Khanabad Airbase Exposures, (2024). 
                        <E T="03">https://ph.health.mil/topics/envirohealth/hrasm/Pages/K2-Airbase-Exposures.aspx</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        2. Johnny Isakson and David P. Roe, M.D. Veterans Health Care and Benefits Improvement Act of 2020, Public Law 116-315, § 2010. 
                        <E T="03">https://www.congress.gov/116/plaws/publ315/PLAW-116publ315.pdf</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        3. Karshi-Khanabad (K2) Air Base in Uzbekistan Potential Historical Contaminants of Concern (COCs) (2022). 
                        <E T="03">https://www.publichealth.va.gov/docs/exposures/K2_Contaminants.pdf#.</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        4. Environmental Hazards Study: Mortality Among U.S. Service Members Deployed to Karshi-Khanabad Air Base, Uzbekistan (2024). 
                        <E T="03">https://health.mil/Military-Health-Topics/Health-Readiness/Environmental-Exposures/Environmental-Hazards-Study-K2</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        5. Exposure to Burn Pits and Other Specific Environmental Hazards (2024). 
                        <E T="03">https://www.va.gov/disability/eligibility/hazardous-materials-exposure/specific-environmental-hazards/</E>
                    </FP>
                    <FP SOURCE="FP-2">6. Eligibility for VA Health Care (2024). Eligibility For VA Health Care | Veterans Affairs.</FP>
                </EXTRACT>
            </SUPLINF>
            <FRDOC>[FR Doc. 2024-27833 Filed 11-26-24; 8:45 am]</FRDOC>
            <BILCOD>BILLING CODE 8320-01-P</BILCOD>
        </NOTICE>
    </NOTICES>
    <VOL>89</VOL>
    <NO>229</NO>
    <DATE>Wednesday, November 27, 2024</DATE>
    <UNITNAME>Presidential Documents</UNITNAME>
    <PRESDOCS>
        <PRESDOCU>
            <PROCLA>
                <TITLE3>Title 3—</TITLE3>
                <PRES>
                    The President
                    <PRTPAGE P="93461"/>
                </PRES>
                <PROC>Proclamation 10862 of November 19, 2024</PROC>
                <HD SOURCE="HED">National Child's Day, 2024</HD>
                <PRES>By the President of the United States of America</PRES>
                <PROC>A Proclamation</PROC>
                <FP>This generation's young people are some of the most gifted, educated, and talented our Nation has ever known. They are the kite strings that keep our national ambitions aloft. On National Child's Day, we recommit to building a future worthy of their highest aspirations.</FP>
                <FP>So many of our Nation's children begin building their futures at our public schools—that is why I am proud that my Administration secured a historic $130 billion in funding for our Nation's K-12 schools through my American Rescue Plan. That law put more teachers in classrooms and more counselors, social workers, and other support staff in our schools. It also invested in high-quality tutoring and made historic expansions in summer and afterschool programs. My Bipartisan Infrastructure Law is expanding access to high-speed internet so students can access it regardless of their zip code. And my Administration has worked to advance a pathway to provide free, healthy school meals for all children as a part of our national strategy to end hunger and reduce diet-related diseases in America by 2030.</FP>
                <FP>My Administration has also worked hard to give families some well-deserved breathing room so that they can care for their children without worrying about how they are going to pay the bills. My American Rescue Plan expanded the Child Tax Credit, which helped reduce child poverty by nearly half across the Nation. That law also made our Nation's biggest investment in child care ever, helping hundreds of thousands of child care providers keep their doors open and continue providing care. I signed the Inflation Reduction Act, saving millions of families $800 per year on their health insurance premiums. My Administration also raised pay for early childhood educators across the country participating in the Head Start program. And my Administration modernized the Thrifty Food Plan for the first time in nearly five decades so that millions more families receiving Supplemental Nutrition Assistance Program benefits can afford nutritious foods.</FP>
                <FP>Securing the health and safety of children has always been a priority for my Administration. I signed the most significant gun safety law in nearly 30 years, working towards a future where no student or child has to live in fear of gun violence. That law also made the largest investment in youth mental health ever to help schools across the country train and hire new mental health counselors. At the same time, we made it easier for schools to leverage Medicaid to deliver health care. And we are working to support LGBTQI+ children and families by protecting their access to health care and preventing harmful practices, including the use of so-called conversion therapy.</FP>
                <FP>
                    My Administration has also been dedicated to addressing the existential threat of climate change—a critical task to secure our children's futures. My Inflation Reduction Act made the most significant investment in climate ever, which includes funding to get communities cleaner air and drinking water, and protect them from the harmful effects of pollution. My Bipartisan Infrastructure Law is working to replace every lead pipe in America, so that every family can turn on the faucet and drink clean, safe water. And my Administration has conserved more than 45 million acres of our Nation's 
                    <PRTPAGE P="93462"/>
                    lands and waters in an effort to ensure they can be enjoyed for generations to come.
                </FP>
                <FP>On National Child's Day, we recommit to ensuring that every child in America has the opportunity to pursue the limits of their talents and ambitions, and we uplift them as the leaders and doers of the future.</FP>
                <FP>NOW, THEREFORE, I, JOSEPH R. BIDEN JR., President of the United States of America, by virtue of the authority vested in me by the Constitution and the laws of the United States, do hereby proclaim November 20, 2024, as National Child's Day. I call upon all government officials, educators, volunteers, and all the people of the United States of America to observe this day with appropriate programs, ceremonies, and activities.</FP>
                <FP>IN WITNESS WHEREOF, I have hereunto set my hand this nineteenth day of November, in the year of our Lord two thousand twenty-four, and of the Independence of the United States of America the two hundred and forty-ninth.</FP>
                <GPH SPAN="1" DEEP="80" HTYPE="RIGHT">
                    <GID>BIDEN.EPS</GID>
                </GPH>
                <PSIG> </PSIG>
                <FRDOC>[FR Doc. 2024-28062</FRDOC>
                <FILED>Filed 11-26-24; 8:45 am]</FILED>
                <BILCOD>Billing code 3395-F4-P</BILCOD>
            </PROCLA>
        </PRESDOCU>
    </PRESDOCS>
    <VOL>89</VOL>
    <NO>229</NO>
    <DATE>Wednesday, November 27, 2024</DATE>
    <UNITNAME>Rules and Regulations</UNITNAME>
    <NEWPART>
        <PTITLE>
            <PRTPAGE P="93911"/>
            <PARTNO>Part II</PARTNO>
            <AGENCY TYPE="P">Department of Health and Human Services</AGENCY>
            <SUBAGY>Centers for Medicare &amp; Medicaid Services</SUBAGY>
            <HRULE/>
            <CFR>42 CFR Part 406, 407, 410, et al.</CFR>
            <TITLE>Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs, Including the Hospital Inpatient Quality Reporting Program; Health and Safety Standards for Obstetrical Services in Hospitals and Critical Access Hospitals; Prior Authorization; Requests for Information; Medicaid and CHIP Continuous Eligibility; Medicaid Clinic Services Four Walls Exceptions; Individuals Currently or Formerly in Custody of Penal Authorities; Revision to Medicare Special Enrollment Period for Formerly Incarcerated Individuals; and All-Inclusive Rate Add-On Payment for High-Cost Drugs Provided by Indian Health Service and Tribal Facilities; Final Rule</TITLE>
        </PTITLE>
        <RULES>
            <RULE>
                <PREAMB>
                    <PRTPAGE P="93912"/>
                    <AGENCY TYPE="S">DEPARTMENT OF HEALTH AND HUMAN SERVICES</AGENCY>
                    <SUBAGY>Centers for Medicare &amp; Medicaid Services</SUBAGY>
                    <CFR>42 CFR Parts 406, 407, 410, 411, 416, 419, 435, 440, 457, 482, and 485</CFR>
                    <DEPDOC>[CMS-1809-FC]</DEPDOC>
                    <RIN>RIN 0938-AV35</RIN>
                    <SUBJECT>Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs, Including the Hospital Inpatient Quality Reporting Program; Health and Safety Standards for Obstetrical Services in Hospitals and Critical Access Hospitals; Prior Authorization; Requests for Information; Medicaid and CHIP Continuous Eligibility; Medicaid Clinic Services Four Walls Exceptions; Individuals Currently or Formerly in Custody of Penal Authorities; Revision to Medicare Special Enrollment Period for Formerly Incarcerated Individuals; and All-Inclusive Rate Add-On Payment for High-Cost Drugs Provided by Indian Health Service and Tribal Facilities</SUBJECT>
                    <AGY>
                        <HD SOURCE="HED">AGENCY:</HD>
                        <P>Centers for Medicare &amp; Medicaid Services (CMS), Department of Health and Human Services (HHS).</P>
                    </AGY>
                    <ACT>
                        <HD SOURCE="HED">ACTION:</HD>
                        <P>Final rule with comment period.</P>
                    </ACT>
                    <SUM>
                        <HD SOURCE="HED">SUMMARY:</HD>
                        <P>This final rule with comment period revises the Medicare Hospital Outpatient Prospective Payment System (OPPS) and the Medicare Ambulatory Surgical Center (ASC) payment system for calendar year 2025 based on our continuing experience with these systems. We describe the changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment system. Also, this final rule updates the requirements for the Hospital Outpatient Quality Reporting Program, Rural Emergency Hospital Quality Reporting Program, Ambulatory Surgical Center Quality Reporting Program, and Hospital Inpatient Quality Reporting Program. We also summarize information received in response to a Request for Information on potential modifications to the Safety of Care measure group in the Overall Hospital Quality Star Rating methodology. In this final rule, we are also finalizing our proposal to narrow the description of “custody” in the Medicare payment exclusion rule and to revise the special enrollment period criteria for formerly incarcerated individuals. We are also finalizing our Medicaid and Children's Health Insurance Program (CHIP) continuous eligibility provisions. We are also finalizing the proposal to reduce the review timeframe for standard prior authorization requests for certain covered outpatient department services paid under the OPPS from 10-business days to 7-calendar days. Further, this rule finalizes updates to the Conditions of Participation (CoPs) for hospitals and critical access hospitals (CAHs) in an effort to advance the health and safety of pregnant, birthing, and postpartum women. This rule also finalizes our proposed policy to separately pay Indian Health Service (IHS) and Tribal hospitals for high-cost drugs furnished in hospital outpatient departments through an add-on payment in addition to the all-inclusive rate (AIR) under the authorities used to calculate the AIR starting January 1, 2025. Finally, we are finalizing exceptions to the Medicaid clinic services four walls requirement for IHS and Tribal clinics, and, at state option, for behavioral health clinics and clinics located in rural areas.</P>
                    </SUM>
                    <EFFDATE>
                        <HD SOURCE="HED">DATES:</HD>
                        <P/>
                        <P>
                            <E T="03">Effective date:</E>
                             The provisions of this rule are effective January 1, 2025.
                        </P>
                        <P>
                            <E T="03">Implementation date:</E>
                             Except as set forth in this section, the regulations at §§ 482.43(c), 482.55(c), and 485.618(e) must be implemented by July 1, 2025; the regulations at §§ 482.59(a) and (b) and 485.649(a) and (b) must be implemented by January 1, 2026; and the regulations at §§ 482.21(b)(4) and (e), 482.59(c), 485.641(d)(4) and (e)(2), and 485.649(c) must be implemented by January 1, 2027.
                        </P>
                        <P>
                            <E T="03">Comment period:</E>
                             To be assured consideration, comments must be received at one of the addresses provided below, by December 31, 2024.
                        </P>
                    </EFFDATE>
                    <ADD>
                        <HD SOURCE="HED">ADDRESSES:</HD>
                        <P>In commenting, please refer to file code CMS-1809-FC.</P>
                        <P>Comments, including mass comment submissions, must be submitted in one of the following three ways (please choose only one of the ways listed):</P>
                        <P>
                            1. 
                            <E T="03">Electronically.</E>
                             You may submit electronic comments on this regulation to 
                            <E T="03">https://www.regulations.gov</E>
                            . Follow the “Submit a comment” instructions.
                        </P>
                        <P>
                            2. 
                            <E T="03">By regular mail.</E>
                             You may mail written comments to the following address ONLY: Centers for Medicare &amp; Medicaid Services, Department of Health and Human Services, Attention: CMS-1809-FC, P.O. Box 8010, Baltimore, MD 21244-8010.
                        </P>
                        <P>Please allow sufficient time for mailed comments to be received before the close of the comment period.</P>
                        <P>
                            3. 
                            <E T="03">By express or overnight mail.</E>
                             You may send written comments to the following address ONLY: Centers for Medicare &amp; Medicaid Services, Department of Health and Human Services, Attention: CMS-1809-FC, Mail Stop C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850.
                        </P>
                        <P>
                            For information on viewing public comments, see the beginning of the 
                            <E T="02">SUPPLEMENTARY INFORMATION</E>
                             section.
                        </P>
                    </ADD>
                    <FURINF>
                        <HD SOURCE="HED">FOR FURTHER INFORMATION CONTACT:</HD>
                        <P>
                            Regulation coordination questions at 
                            <E T="03">OPPS-ASC-Rulemaking@cms.hhs.gov</E>
                             or Elise Barringer (410) 786, 9222.
                        </P>
                        <P>
                            Advisory Panel on Hospital Outpatient Payment (HOP Panel), contact the HOP Panel mailbox at 
                            <E T="03">APCPanel@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Ambulatory Surgical Center Quality Reporting (ASCQR) Program policies, contact Anita Bhatia via email at 
                            <E T="03">Anita.Bhatia@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Ambulatory Surgical Center Quality Reporting (ASCQR) Program measures, contact Marsha Hertzberg via email at 
                            <E T="03">Marsha.Hertzberg@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            All-Inclusive Rate (AIR) Add-On Payment for High-Cost Drugs Provided by Indian Health Service (IHS) and Tribal Facilities, contact Nate Vercauteren via email at 
                            <E T="03">Nathan.Vercauteren@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Blood and Blood Products, contact Au'Sha Washington via email at 
                            <E T="03">AuShaWashington@cms.hhs.gov</E>
                             or Nicole Marcos via email at 
                            <E T="03">Nicole.Marcos@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Cancer Hospital Payments, contact Scott Talaga via email at 
                            <E T="03">Scott.Talaga@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            CMS Web Posting of the OPPS and ASC Payment Files, contact Gil Ngan via email at 
                            <E T="03">Gil.Ngan@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Medicaid Clinic Services Four Walls Exceptions, contact Sheri Gaskins via email at 
                            <E T="03">Sheri.Gaskins@cms.hhs.gov</E>
                             or Ryan Tisdale via email at 
                            <E T="03">Ryan.Tisdale@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Composite APCs (Multiple Imaging and Mental Health) and Comprehensive APCs (C-APCs), via email at Elise Barringer via email at 
                            <E T="03">Elise.Barringer@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Device-Intensive Status and No Cost/Full Credit and Partial Credit Devices, contact Scott Talaga via email at 
                            <E T="03">Scott.Talaga@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Domestic Personal Protection Equipment RFI, contact Jesse Hawkins via email at 
                            <E T="03">jesse.hawkins@hhs.gov</E>
                        </P>
                        <P>
                            Health and Safety Standards for Obstetrical Services in Hospitals and Critical Access Hospitals, contact The Clinical Standards Group, 
                            <E T="03">HealthandSafetyInquiries@cms.hhs.gov</E>
                        </P>
                        <P>
                            Hospital Inpatient Quality Reporting (IQR) Program policies, contact Julia Venanzi via email at 
                            <E T="03">julia.venanzi@cms.hhs.gov</E>
                            .
                            <PRTPAGE P="93913"/>
                        </P>
                        <P>
                            Hospital Inpatient Quality Reporting (IQR) Program measures, contact Melissa Hager via email at 
                            <E T="03">melissa.hager@cms.hhs.gov</E>
                             or Ngozi Uzokwe via email at 
                            <E T="03">ngozi.uzokwe@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Hospital Outpatient Quality Reporting (OQR) Program policies, contact Kimberly Go via email at 
                            <E T="03">Kimberly.Go@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Hospital Outpatient Quality Reporting (OQR) Program measures, contact Janis Grady via email at 
                            <E T="03">Janis.Grady@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Hospital Outpatient Visits (Emergency Department Visits and Critical Care Visits), contact Elise Barringer via email at 
                            <E T="03">Elise.Barringer@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            IHS Outpatient Encounter Rate available to all American Indian and Alaska Native (AI/AN) Outpatient Programs Request for Information, contact Lisa Parker via email at 
                            <E T="03">Lisa.Parker1@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Inpatient Only (IPO) Procedures List, contact Abigail Cesnik via email at 
                            <E T="03">Abigail.Cesnik@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Medicaid and CHIP Continuous Eligibility Policy, contact Cassie Lagorio via email at 
                            <E T="03">Cassandra.Lagorio@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            New Technology Intraocular Lenses (NTIOLs), contact Scott Talaga via email at 
                            <E T="03">Scott.Talaga@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            No Legal Obligation to Pay Payment Exclusion, contact Frederick Grabau via email at 
                            <E T="03">Frederick.Grabau@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Non-Opioid Policy or Implementation of Section 4135 of the Consolidated Appropriations Act (CAA), 2023, contact Cory Duke via email at 
                            <E T="03">Cory.Duke@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            OPPS Brachytherapy, contact Cory Duke via email at 
                            <E T="03">Cory.Duke@cms.hhs.gov</E>
                             and Scott Talaga via email at 
                            <E T="03">Scott.Talaga@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            OPPS Data (APC Weights, Conversion Factor, Copayments, Cost-to-Charge Ratios (CCRs), Data Claims, Geometric Mean Calculation, Outlier Payments, and Wage Index), contact Erick Chuang via email at 
                            <E T="03">Erick.Chuang@cms.hhs.gov</E>
                             or Scott Talaga via email at 
                            <E T="03">Scott.Talaga@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            OPPS Dental Policy, contact Nicole Marcos via email at 
                            <E T="03">Nicole.Marcos@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            OPPS Drugs, Radiopharmaceuticals, Biologicals, and Biosimilar Products, contact Gil Ngan via email at 
                            <E T="03">Gil.Ngan@cms.hhs.gov</E>
                            , Cory Duke via email at 
                            <E T="03">Cory.Duke@cms.hhs.gov</E>
                            , or Tonya Gierke via email at 
                            <E T="03">Tonya.Gierke@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            OPPS New Technology Procedures/Services, contact the New Technology APC mailbox at 
                            <E T="03">NewTechAPCapplications@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            OPPS Packaged Items/Services, contact Cory Duke via email at 
                            <E T="03">Cory.Duke@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            OPPS Pass-Through Devices, contact the Device Pass-Through mailbox at 
                            <E T="03">DevicePTapplications@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            OPPS Status Indicators (SI) and Comment Indicators (CI), contact Marina Kushnirova via email at 
                            <E T="03">Marina.Kushnirova@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Outpatient Department Prior Authorization Process, contact Kelly Wojciechowski via email at 
                            <E T="03">Kelly.Wojciechowski@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Overall Hospital Quality Star Rating Request for Information, contact Tyson Nakashima Sr. via email at 
                            <E T="03">Tyson.Nakashima@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Partial Hospitalization Program (PHP), Intensive Outpatient (IOP), and Community Mental Health Center (CMHC) Issues, contact the PHP Payment Policy Mailbox at 
                            <E T="03">PHPPaymentPolicy@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Payment Policy for Devices in Category B Investigational Device Exemption Clinical Trials Policy and Drugs with a Medicare Coverage with Evidence Development (CED) Designation, contact Cory Duke via email at 
                            <E T="03">Cory.Duke@cms.hhs.gov</E>
                             and Nicole Marcos via email at 
                            <E T="03">Nicole.Marcos@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Remote Services, contact Elise Barringer via email at 
                            <E T="03">Elise.Barringer@cms.hhs.gov</E>
                             or Nate Vercauteren via email at 
                            <E T="03">Nathan.Vercauteren@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Rural Emergency Hospital Quality Reporting (REHQR) Program policies, contact Anita Bhatia via email at 
                            <E T="03">Anita.Bhatia@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Rural Emergency Hospital Quality Reporting (REHQR) Program measures, contact Melissa Hager via email at 
                            <E T="03">Melissa.Hager@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            Special Enrollment Period for Formerly Incarcerated Individuals, contact Steve Manning via email at 
                            <E T="03">Steve.Manning@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            All Other Issues Related to Hospital Outpatient Payments Not Previously Identified, contact the OPPS mailbox at 
                            <E T="03">OutpatientPPS@cms.hhs.gov</E>
                            .
                        </P>
                        <P>
                            All Other Issues Related to the Ambulatory Surgical Center Payments Not Previously Identified, contact the ASC mailbox at 
                            <E T="03">ASCPPS@cms.hhs.gov</E>
                            .
                        </P>
                    </FURINF>
                </PREAMB>
                <SUPLINF>
                    <HD SOURCE="HED">SUPPLEMENTARY INFORMATION:</HD>
                    <P/>
                    <P>
                        <E T="03">Inspection of Public Comments:</E>
                         All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following website as soon as possible after they have been received: 
                        <E T="03">https://www.regulations.gov</E>
                        . Follow the search instructions on that website to view public comments. CMS will not post on 
                        <E T="03">Regulations.gov</E>
                         public comments that make threats to individuals or institutions or suggest that the individual will take actions to harm the individual. CMS continues to encourage individuals not to submit duplicative comments. We will post acceptable comments from multiple unique commenters even if the content is identical or nearly identical to other comments.
                    </P>
                    <P>
                        <E T="03">Plain Language Summary:</E>
                         In accordance with 5 U.S.C. 553(b)(4), a plain language summary of this rule may be found at 
                        <E T="03">https://www.regulations.gov/</E>
                        .
                    </P>
                    <P>
                        <E T="03">Severability of Provisions:</E>
                         We are clarifying and emphasizing our intent that if any provision of this final rule is held to be invalid or unenforceable by its terms, or as applied to any person or circumstance, or stayed pending further action, it shall be severable from other parts of this final rule, and from rules and regulations currently in effect, and not affect the remainder thereof or the application of the provision to other persons not similarly situated or to other, dissimilar circumstances. If any provision is held to be invalid or unenforceable, the remaining provisions which could function independently should take effect and be given the maximum effect permitted by law. Through this rule, we adopt provisions that are intended to and will operate independently of each other, even if each serves the same general purpose or policy goal. Where a provision is necessarily dependent on another, the context generally makes that clear.
                    </P>
                    <HD SOURCE="HD1">Addenda Available Only Through the Internet on the CMS Website</HD>
                    <P>
                        In the past, a majority of the Addenda referred to in our OPPS/ASC proposed and final rules were published in the 
                        <E T="04">Federal Register</E>
                         as part of the annual rulemakings. However, beginning with the calendar year (CY) 2012 OPPS/ASC proposed rule, all of the Addenda no longer appear in the 
                        <E T="04">Federal Register</E>
                         as part of the annual OPPS/ASC proposed and final rules to decrease administrative burden and reduce costs associated with publishing lengthy tables. Instead, these Addenda are published and available only on the CMS website. The Addenda relating to the OPPS are available at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        . The Addenda relating to the ASC payment 
                        <PRTPAGE P="93914"/>
                        system are available at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/ambulatory-surgical-center-asc/asc-regulations-and-notices</E>
                        .
                    </P>
                    <HD SOURCE="HD1">Current Procedural Terminology (CPT) Copyright Notice</HD>
                    <P>Throughout this final rule with comment period, we use CPT codes and descriptions to refer to a variety of services. We note that CPT codes and descriptions are copyright 2024 American Medical Association (AMA). All Rights Reserved. CPT is a registered trademark of the AMA. Applicable Federal Acquisition Regulations and Defense Federal Acquisition Regulations apply.</P>
                    <HD SOURCE="HD1">Table of Contents</HD>
                    <EXTRACT>
                        <FP SOURCE="FP-2">I. Summary and Background</FP>
                        <FP SOURCE="FP1-2">A. Executive Summary of This Document</FP>
                        <FP SOURCE="FP1-2">B. Legislative and Regulatory Authority for the Hospital OPPS</FP>
                        <FP SOURCE="FP1-2">C. Excluded OPPS Services and Hospitals</FP>
                        <FP SOURCE="FP1-2">D. Prior Rulemaking</FP>
                        <FP SOURCE="FP1-2">E. Advisory Panel on Hospital Outpatient Payment (the HOP Panel or the Panel)</FP>
                        <FP SOURCE="FP1-2">F. Public Comments Received on the CY 2024 Proposed Rule</FP>
                        <FP SOURCE="FP1-2">G. Public Comments Received on the CY 2024 OPPS/ASC Final Rule With Comment Period</FP>
                        <FP SOURCE="FP-2">II. Updates Affecting OPPS Payments</FP>
                        <FP SOURCE="FP1-2">A. Recalibration of APC Relative Payment Weights</FP>
                        <FP SOURCE="FP1-2">B. Conversion Factor Update</FP>
                        <FP SOURCE="FP1-2">C. Wage Index Changes</FP>
                        <FP SOURCE="FP1-2">D. Statewide Average Default Cost-to-Charge Ratios (CCRs)</FP>
                        <FP SOURCE="FP1-2">E. Adjustment for Rural Sole Community Hospitals (SCHs) and Essential Access Community Hospitals (EACHs) Under Section 1833(t)(13)(B) of the Act for CY 2025</FP>
                        <FP SOURCE="FP1-2">F. Payment Adjustment for Certain Cancer Hospitals for CY 2025</FP>
                        <FP SOURCE="FP1-2">G. Hospital Outpatient Outlier Payments</FP>
                        <FP SOURCE="FP1-2">H. Calculation of an Adjusted Medicare Payment From the National Unadjusted</FP>
                        <FP SOURCE="FP1-2">Medicare Payment</FP>
                        <FP SOURCE="FP1-2">I. Beneficiary Copayments</FP>
                        <FP SOURCE="FP-2">III. OPPS Ambulatory Payment Classification (APC) Group Policies</FP>
                        <FP SOURCE="FP1-2">A. OPPS Treatment of New and Revised HCPCS Codes</FP>
                        <FP SOURCE="FP1-2">B. OPPS Changes—Variations Within APCs</FP>
                        <FP SOURCE="FP1-2">C. New Technology APCs</FP>
                        <FP SOURCE="FP1-2">D. Universal Low Volume APC Policy for Clinical and Brachytherapy APCs</FP>
                        <FP SOURCE="FP1-2">E. APC-Specific Policies</FP>
                        <FP SOURCE="FP-2">IV. OPPS Payment for Devices</FP>
                        <FP SOURCE="FP1-2">A. Pass-Through Payment for Devices</FP>
                        <FP SOURCE="FP1-2">B. Device-Intensive Procedures</FP>
                        <FP SOURCE="FP-2">V. OPPS Payment for Drugs, Biologicals, and Radiopharmaceuticals</FP>
                        <FP SOURCE="FP1-2">A. OPPS Transitional Pass-Through Payment for Additional Costs of Drugs, Biologicals, and Radiopharmaceuticals</FP>
                        <FP SOURCE="FP1-2">B. OPPS Payment for Drugs, Biologicals, and Radiopharmaceuticals Without Pass-Through Payment Status</FP>
                        <FP SOURCE="FP-2">VI. Estimate of OPPS Transitional Pass-Through Spending for Drugs, Biologicals, Radiopharmaceuticals, and Devices</FP>
                        <FP SOURCE="FP1-2">A. Amount of Additional Payment and Limit on Aggregate Annual Adjustment</FP>
                        <FP SOURCE="FP1-2">B. Final Estimate of Pass-Through Spending for CY 2025</FP>
                        <FP SOURCE="FP-2">VII. OPPS Payment for Hospital Outpatient Visits and Critical Care Services</FP>
                        <FP SOURCE="FP-2">VIII. Payment for Partial Hospitalization and Intensive Outpatient Services</FP>
                        <FP SOURCE="FP1-2">A. Background</FP>
                        <FP SOURCE="FP1-2">B. Coding and Billing for PHP and IOP Services Under the OPPS</FP>
                        <FP SOURCE="FP1-2">C. CY 2025 Payment Rates for PHP and IOP</FP>
                        <FP SOURCE="FP1-2">D. Outlier Policy for CMHCs</FP>
                        <FP SOURCE="FP-2">IX. Services That Will Be Paid Only as Inpatient Services</FP>
                        <FP SOURCE="FP1-2">A. Background</FP>
                        <FP SOURCE="FP1-2">B. Changes to the Inpatient Only (IPO) List</FP>
                        <FP SOURCE="FP-2">X. Nonrecurring Policy Changes</FP>
                        <FP SOURCE="FP1-2">A. Remote Services</FP>
                        <FP SOURCE="FP1-2">B. Virtual Direct Supervision of Cardiac Rehabilitation (CR), Intensive Cardiac Rehabilitation (ICR), Pulmonary Rehabilitation (PR) Services and Diagnostic Services Furnished to Hospital Outpatients</FP>
                        <FP SOURCE="FP1-2">C. All-Inclusive Rate (AIR) Add-On Payment for High-Cost Drugs Provided by Indian Health Service and Tribal Facilities</FP>
                        <FP SOURCE="FP1-2">D. Coverage Changes for Colorectal Cancer (CRC) Screening Services</FP>
                        <FP SOURCE="FP1-2">E. Request for Comment on Payment Adjustments under the IPPS and OPPS for Domestic Personal Protective Equipment</FP>
                        <FP SOURCE="FP1-2">F. Payment for HIV Pre-Exposure Prophylaxis (PrEP) in Hospital Outpatient Departments</FP>
                        <FP SOURCE="FP1-2">G. Payment Policy for Devices in Category B Investigational Device Exemption (IDE) Clinical Trials Policy and Drugs/Devices With a Medicare Coverage With Evidence Development (CED) Designation</FP>
                        <FP SOURCE="FP-2">XI. CY 2025 OPPS Payment Status and Comment Indicators</FP>
                        <FP SOURCE="FP1-2">A. CY 2025 OPPS Payment Status Indicator Definitions</FP>
                        <FP SOURCE="FP1-2">B. CY 2025 Comment Indicator Definitions</FP>
                        <FP SOURCE="FP-2">XII. MedPAC Recommendations</FP>
                        <FP SOURCE="FP1-2">A. OPPS Payment Rates Update</FP>
                        <FP SOURCE="FP1-2">B. Medicare Safety Net Index</FP>
                        <FP SOURCE="FP1-2">C. ASC Cost Data</FP>
                        <FP SOURCE="FP-2">XIII. Updates to the Ambulatory Surgical Center (ASC) Payment System</FP>
                        <FP SOURCE="FP1-2">A. Background, Legislative History, Statutory Authority, and Prior Rulemaking for the ASC Payment System</FP>
                        <FP SOURCE="FP1-2">B. ASC Treatment of New and Revised Codes</FP>
                        <FP SOURCE="FP1-2">C. Payment Policies Under the ASC Payment System</FP>
                        <FP SOURCE="FP1-2">D. Additions to ASC Covered Surgical Procedures and Covered Ancillary Services Lists</FP>
                        <FP SOURCE="FP1-2">E. ASC Payment Policy for Non-Opioid Post-Surgery Pain Management Drugs, Biologicals, and Devices</FP>
                        <FP SOURCE="FP1-2">F. Final CY 2025 Non-Opioid Policy for Pain Relief Under the OPPS and ASC Payment System</FP>
                        <FP SOURCE="FP1-2">G. New Technology Intraocular Lenses (NTIOLs)</FP>
                        <FP SOURCE="FP1-2">H. Calculation of the ASC Payment Rates and the ASC Conversion Factor</FP>
                        <FP SOURCE="FP-2">XIV. Cross-Program Measures for the Hospital Outpatient Quality Reporting (OQR), Rural Emergency Hospital Quality Reporting (REHQR), and Ambulatory Surgical Center Quality Reporting (ASCQR) Programs</FP>
                        <FP SOURCE="FP1-2">A. Background</FP>
                        <FP SOURCE="FP1-2">B. CMS Commitment To Advancing Health Equity Using Quality Measurement</FP>
                        <FP SOURCE="FP1-2">C. Modification of the Immediate Measure Removal Policy for the Hospital Outpatient Quality Reporting (OQR) and Ambulatory Surgical Center Quality Reporting (ASCQR) Programs Beginning With CY 2025</FP>
                        <FP SOURCE="FP-2">XV. Hospital Outpatient Quality Reporting (OQR) Program</FP>
                        <FP SOURCE="FP1-2">A. Background and Statutory Authority</FP>
                        <FP SOURCE="FP1-2">B. Program Measure Set Policies</FP>
                        <FP SOURCE="FP1-2">C. Program Measure Updates</FP>
                        <FP SOURCE="FP1-2">D. Administrative Requirements</FP>
                        <FP SOURCE="FP1-2">E. Form, Manner, and Timing of Data Submission</FP>
                        <FP SOURCE="FP1-2">F. Public Reporting of Measure Data</FP>
                        <FP SOURCE="FP1-2">G. Payment Reduction for Hospitals That Fail To Meet the Hospital OQR Program Requirements for the CY 2025 Payment Determination</FP>
                        <FP SOURCE="FP-2">XVI. Rural Emergency Hospital Quality Reporting (REHQR) Program</FP>
                        <FP SOURCE="FP1-2">A. Background and Statutory Authority</FP>
                        <FP SOURCE="FP1-2">B. Program Measure Set Policies</FP>
                        <FP SOURCE="FP1-2">C. Program Measure Updates</FP>
                        <FP SOURCE="FP1-2">D. Administrative Requirements</FP>
                        <FP SOURCE="FP1-2">E. Form, Manner, and Timing of Data Submission</FP>
                        <FP SOURCE="FP1-2">F. Public Reporting of Measure Data</FP>
                        <FP SOURCE="FP-2">XVII. Ambulatory Surgical Center Quality Reporting (ASCQR) Program</FP>
                        <FP SOURCE="FP1-2">A. Background and Statutory Authority</FP>
                        <FP SOURCE="FP1-2">B. Program Measure Set Policies</FP>
                        <FP SOURCE="FP1-2">C. Program Measure Updates</FP>
                        <FP SOURCE="FP1-2">D. Administrative Requirements</FP>
                        <FP SOURCE="FP1-2">E. Form, Manner, and Timing of Data Submission</FP>
                        <FP SOURCE="FP1-2">F. Public Reporting of Measure Data</FP>
                        <FP SOURCE="FP1-2">G. Request for Information (RFI)—Development of Frameworks for Specialty Focused Reporting and Minimum Case Number for Required Reporting</FP>
                        <FP SOURCE="FP1-2">H. Payment Reduction for ASCs That Fail To Meet the ASCQR Program Requirements</FP>
                        <FP SOURCE="FP-2">XVIII. Medicaid Clinic Services Four Walls Exceptions</FP>
                        <FP SOURCE="FP1-2">A. Background</FP>
                        <FP SOURCE="FP1-2">B. Summary of the Medicaid Clinic Services Four Walls Exceptions Proposed Provisions, Public Comments and Responses to Comments</FP>
                        <FP SOURCE="FP-2">XIX. Changes to the Review Timeframes for the Hospital Outpatient Department (OPD) Prior Authorization Process</FP>
                        <FP SOURCE="FP-2">XX. Provisions Related to Medicaid and the Children's Health Insurance Program (CHIP)</FP>
                        <FP SOURCE="FP1-2">A. Continuous Eligibility in Medicaid and CHIP (42 CFR 435.926 and 457.342)</FP>
                        <FP SOURCE="FP1-2">
                            B. Summary of the Proposed Provisions, Public Comments and Responses to Comments on Medicaid and CHIP Continuous Eligibility
                            <PRTPAGE P="93915"/>
                        </FP>
                        <FP SOURCE="FP-2">XXI. Health and Safety Standards for Obstetrical Services in Hospitals and Critical Access Hospitals</FP>
                        <FP SOURCE="FP1-2">A. Background and Statutory Authority</FP>
                        <FP SOURCE="FP1-2">B. The U.S. Maternal Health Crisis</FP>
                        <FP SOURCE="FP1-2">C. Summary of the Proposed Provisions, Public Comments and Responses to Comments on Health and Safety Standards for Obstetrical Services in Hospitals and Critical Access Hospitals</FP>
                        <FP SOURCE="FP-2">XXII. Hospital-Wide All-Cause Risk Standardized Mortality Measures in the Hospital Inpatient Quality Reporting Program</FP>
                        <FP SOURCE="FP1-2">A. Background</FP>
                        <FP SOURCE="FP1-2">B. Updates to the Form, Time, and Manner Requirements for the Hybrid Hospital-Wide All-Cause Readmission (HWR) and Hybrid Hospital-Wide All-Cause Risk Standardized Mortality (HWM) Measures for the FY 2026 and the FY 2027 Payment Determinations</FP>
                        <FP SOURCE="FP-2">XXIII. Individuals Currently or Formerly in the Custody of Penal Authorities</FP>
                        <FP SOURCE="FP1-2">A. Medicare FFS No Legal Obligation to Pay Payment Exclusion and Incarceration (revisions to 42 CFR 411.4)</FP>
                        <FP SOURCE="FP1-2">B. Revision to Medicare Special Enrollment Period for Formerly Incarcerated Individuals</FP>
                        <FP SOURCE="FP-2">XXIV. Overall Hospital Quality Star Rating Modification To Emphasize the Safety of Care Measure Group: Request for Information (RFI)</FP>
                        <FP SOURCE="FP1-2">A. Summary</FP>
                        <FP SOURCE="FP1-2">B. Background</FP>
                        <FP SOURCE="FP1-2">C. Current Overall Hospital Quality Star Rating Methodology</FP>
                        <FP SOURCE="FP1-2">D. Safety of Care in Star Ratings</FP>
                        <FP SOURCE="FP1-2">E. Potential Future Options To Greater Emphasize Patient Safety in the Overall Hospital Quality Star Rating</FP>
                        <FP SOURCE="FP1-2">F. Solicitation of Public Comment</FP>
                        <FP SOURCE="FP-2">XXV. Files Available to the Public via the Internet</FP>
                        <FP SOURCE="FP-2">XXVI. Collection of Information Requirements</FP>
                        <FP SOURCE="FP1-2">A. ICRs for the Hospital Outpatient Quality Reporting (OQR) Program</FP>
                        <FP SOURCE="FP1-2">B. ICRs for the Rural Emergency Hospitals Quality Reporting (REHQR) Program</FP>
                        <FP SOURCE="FP1-2">C. ICRs for the Ambulatory Surgical Center Quality Reporting (ASCQR) Program</FP>
                        <FP SOURCE="FP1-2">D. ICRs Related to Medicaid Clinic Services Four Walls Exceptions</FP>
                        <FP SOURCE="FP1-2">E. ICRs for Changes to the Review Timeframes for Hospital Outpatient Department (OPD) Prior Authorization Process</FP>
                        <FP SOURCE="FP1-2">F. ICRs for the Hospital Inpatient Quality Reporting (IQR) Program</FP>
                        <FP SOURCE="FP1-2">G. ICRs for Continuous Eligibility (42 CFR 435.926 and 457.342)</FP>
                        <FP SOURCE="FP1-2">H. ICRs Regarding Organization, Staffing and Delivery of Services for Hospitals (§ 482.59(a) and (b)) and CAHs (§ 485.649(a) and (b))</FP>
                        <FP SOURCE="FP1-2">I. ICRs Regarding OB Staff Training for Hospitals (§ 482.59(c) and CAHs (§ 485.649(c))</FP>
                        <FP SOURCE="FP1-2">J. ICRs Regarding Revisions to QAPI (§ 482.21) Standards for OB Services</FP>
                        <FP SOURCE="FP1-2">K. ICRS Regarding Emergency Services Readiness in Emergency Services (§ 482.55) for Hospitals</FP>
                        <FP SOURCE="FP1-2">L. Transfer Protocols in Discharge Planning (§ 482.43) for Hospitals</FP>
                        <FP SOURCE="FP1-2">M. Total Costs for all ICRs Related to Maternal Health</FP>
                        <FP SOURCE="FP-2">XXVII. Response to Comments</FP>
                        <FP SOURCE="FP-2">XXVIII. Economic Analyses</FP>
                        <FP SOURCE="FP1-2">A. Statement of Need</FP>
                        <FP SOURCE="FP1-2">B. Overall Impact of Provisions of This Final Rule With Comment Period</FP>
                        <FP SOURCE="FP1-2">C. Detailed Economic Analyses</FP>
                        <FP SOURCE="FP1-2">D. Regulatory Review Cost Estimation</FP>
                        <FP SOURCE="FP1-2">E. Regulatory Flexibility Act (RFA) Analysis</FP>
                        <FP SOURCE="FP1-2">F. Unfunded Mandates Reform Act Analysis</FP>
                        <FP SOURCE="FP1-2">G. Federalism</FP>
                        <FP SOURCE="FP1-2">H. Conclusion</FP>
                        <FP SOURCE="FP1-2">I. Waiver Fiscal Responsibility Act Requirements</FP>
                    </EXTRACT>
                    <HD SOURCE="HD1">I. Summary and Background</HD>
                    <HD SOURCE="HD2">A. Executive Summary of This Document</HD>
                    <HD SOURCE="HD3">1. Purpose</HD>
                    <P>We are updating the payment policies and payment rates for services furnished to Medicare beneficiaries in hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs), beginning January 1, 2025. Section 1833(t) of the Social Security Act (the Act) requires us to annually review and update the payment rates for services payable under the Hospital Outpatient Prospective Payment System (OPPS). Specifically, section 1833(t)(9)(A) of the Act requires the Secretary of the Department of Health and Human Services (the Secretary) to review certain components of the OPPS not less often than annually, and to revise the groups, the relative payment weights, and the wage and other adjustments to take into account changes in medical practice, changes in technology, and the addition of new services, new cost data, and other relevant information and factors. In addition, under section 1833(i)(D)(v) of the Act, we annually review and update the ASC payment rates. This final rule with comment period also includes additional policy changes made in accordance with our experience with the OPPS and the ASC payment system and recent changes in our statutory authority. We describe these and various other statutory authorities in the relevant sections of this final rule with comment period. Also, this final rule with comment period updates the requirements for the Hospital Outpatient Quality Reporting (OQR) Program, the Rural Emergency Hospital Quality Reporting (REHQR) Program, the Ambulatory Surgical Center Quality Reporting (ASCQR) Program, and the Hospital Inpatient Quality Reporting (IQR) Program. We summarize information received in response to a Request for Information on potential modifications of the Safety of Care measure group in the Overall Hospital Quality Star Rating methodology. Given that the maternal health crisis in the United States is among the highest in high-income countries and also disproportionately impacts racial and ethnic minorities, we are finalizing updates to the CoPs for hospitals and CAHs in an effort to advance the health and safety of pregnant, birthing, and post-partum women. We are also finalizing an implementation approach in phases that allows additional time for hospitals and CAHs to comply with the requirements of the rule. In addition, we are narrowing the description of “custody” for the purposes of Medicare's no legal obligation to pay payment exclusion at § 411.4(b), providing an illustrative list of individuals who are not considered to be in custody, adding a definition of “penal authority,” reorganizing the regulation, and making certain technical edits. This rule also revises the eligibility requirements in the special enrollment period (SEP) for formerly incarcerated individuals at §§ 406.27(d) (Premium Part A) and 407.23(d) (Part B) to tie the eligibility for this SEP to the determination made by the Social Security Administration (SSA) that they are no longer incarcerated for releases beginning on January 1, 2025, and limit the current eligibility criteria for the SEP, with reference to “custody” associated with § 411.4(b) to releases between January 1, 2023, and December 31, 2024. Additionally, we are finalizing our proposed revisions to Medicaid and CHIP regulations to codify the requirement within the CAA, 2023 to require States to provide 12 months of continuous eligibility to children under the age of 19 in Medicaid and CHIP, with limited exceptions.</P>
                    <P>
                        Finally, we are finalizing our proposed exceptions to the Medicaid clinic services benefit four walls requirement, to authorize Medicaid payment for clinic services provided outside the four walls of the clinic for IHS/Tribal clinics, and at State option, behavioral health clinics and clinics located in rural areas. Our current regulation at 42 CFR 440.90(b) includes an exception to the four walls requirement under the Medicaid clinic services benefit only for clinic services furnished to individuals who are unhoused. We believe finalizing these additional exceptions will help maintain and improve access for the populations served by IHS/Tribal clinics, behavioral health clinics, and clinics located in rural areas.
                        <PRTPAGE P="93916"/>
                    </P>
                    <HD SOURCE="HD3">2. Summary of the Major Provisions</HD>
                    <P>
                        • 
                        <E T="03">OPPS Update:</E>
                         For CY 2025, we are increasing the payment rates under the OPPS by an Outpatient Department (OPD) fee schedule increase factor of 2.9 percent. This increase factor is based on the final inpatient hospital market basket percentage increase of 3.4 percent for inpatient services paid under the hospital inpatient prospective payment system (IPPS) reduced by a final productivity adjustment of 0.5 percentage point. Based on this update, we estimate that total payments to OPPS providers (including beneficiary cost sharing and estimated changes in enrollment, utilization, and case mix) for calendar year (CY) 2025 will be approximately $87.7 billion, an increase of approximately $4.7 billion compared to estimated CY 2024 OPPS payments. We are continuing to implement the statutory 2.0 percentage point reduction in payments for hospitals that fail to meet the hospital outpatient quality reporting requirements by applying a reporting factor of 0.9806 to the OPPS payments and copayments for all applicable services.
                    </P>
                    <P>
                        • 
                        <E T="03">ASC Payment Update:</E>
                         For CYs 2019 through 2023, we adopted a policy to update the ASC payment system using the hospital market basket update. In light of the impact of the COVID-19 public health emergency (PHE) on healthcare utilization, we extended our policy to update the ASC payment system using the hospital market basket update an additional 2 years—through CYs 2024 and 2025. Using the hospital market basket methodology, for CY 2025, we increased payment rates under the ASC payment system by 2.9 percent for ASCs that meet the quality reporting requirements under the ASCQR Program. This increase is based on a final hospital market basket percentage increase of 3.4 percent reduced by a productivity adjustment of 0.5 percentage point. Based on this final update, we estimate that total payments to ASCs (including beneficiary cost sharing and estimated changes in enrollment, utilization, and case-mix) for CY 2025 will be approximately $7.4 billion, an increase of approximately $308 million compared to estimated CY 2024 Medicare payments.
                    </P>
                    <P>
                        • 
                        <E T="03">Device Pass-Through Payment Applications:</E>
                         For CY 2025, we received 14 complete applications for device pass-through payments. We sought public comment on these applications and make final determinations on these applications in this final rule with comment period.
                    </P>
                    <P>
                        • 
                        <E T="03">Changes to the List of ASC Covered Surgical Procedures and Ancillary Services Lists:</E>
                         For CY 2025, we are adding 21 medical and dental procedures to the ASC covered procedures list (CPL) and ancillary services lists, based upon existing criteria at § 416.166.
                    </P>
                    <P>
                        • 
                        <E T="03">Changes to the Inpatient Only (IPO) List:</E>
                         For CY 2025, we are finalizing adding three liver allograft services for which codes were newly created by the AMA CPT Editorial Panel for CY 2025 to the IPO list. Additionally, we are finalizing removing a pelvic fixation code (CPT code 22848) from the IPO list for CY 2025.
                    </P>
                    <P>
                        • 
                        <E T="03">Remote Services:</E>
                         For CY 2025, we are clarifying our policies for remotely furnished outpatient therapy services, Diabetes Self-Management Training and Medical Nutrition Therapy services and mental health services furnished remotely to beneficiaries in their homes by hospital staff to maintain alignment across payment systems.
                    </P>
                    <P>
                        • 
                        <E T="03">Payment for High-Cost Drugs Provided by Indian Health Service and Tribal Hospitals:</E>
                         For CY 2025, we are finalizing our policy to separately pay IHS and tribal hospitals for high-cost drugs furnished in hospital outpatient departments through an add-on payment in addition to the AIR under the authorities used to calculate the AIR.
                    </P>
                    <P>
                        • 
                        <E T="03">Clinical Trials Coding and Payment:</E>
                         We are finalizing a clarification to our Category B clinical trials coding and payment policy for devices and procedures to specify that our policy applies only to IDE studies with a control arm and where a payment adjustment is necessary to preserve the scientific validity of such a study. We are not finalizing our proposal to extend our coding and payment policy to drugs and devices that are being studied in clinical trials under a Coverage with Evidence Development (CED) National Coverage Determination (NCD),
                        <SU>1</SU>
                        <FTREF/>
                         for which the trial includes a treatment and control arm for CY 2025. We are taking additional time to consider the broad implications of a payment methodology for clinical trials for CED drugs and devices.
                    </P>
                    <FTNT>
                        <P>
                            <SU>1</SU>
                             
                            <E T="03">https://www.cms.gov/medicare/coverage/evidence.</E>
                        </P>
                    </FTNT>
                    <P>
                        • 
                        <E T="03">Payment for HIV Pre-Exposure Prophylaxis (PrEP) in Hospital Outpatient Departments:</E>
                         For CY 2025, we are finalizing paying for HIV PrEP drugs covered as an additional preventive service and related services under the OPPS. We are finalizing a site neutral policy where products are generally paid similar rates under the OPPS and Physician Fee Schedule.
                    </P>
                    <P>
                        • 
                        <E T="03">Diagnostic Radiopharmaceuticals Separate Payment:</E>
                         We are finalizing a policy to pay separately for diagnostic radiopharmaceuticals with per day costs above a threshold of $630, which is approximately two times the volume weighted average cost amount currently associated with diagnostic radiopharmaceuticals in the Nuclear Medicine APCs. We also are finalizing updating the $630 threshold in CY 2026 and subsequent years by the Producer Price Index (PPI) for Pharmaceutical Preparations. Finally, we are finalizing payment for separately payable diagnostic radiopharmaceuticals based on their Mean Unit Cost (MUC) derived from OPPS claims for CY 2025.
                    </P>
                    <P>
                        • 
                        <E T="03">Exclusion of Cell and Gene Therapies from Comprehensive Ambulatory Payment Classification (C-APC) Packaging:</E>
                         We are finalizing a policy to exclude qualifying cell and gene therapies from C-APC packaging.
                    </P>
                    <P>
                        • 
                        <E T="03">Add-on Payment for Radiopharmaceutical Technetium-99m (Tc-99m) Derived from Domestically Produced Mo-99:</E>
                         For CY 2025, an add-on payment applies to radiopharmaceuticals that use Tc-99m produced without use of highly enriched uranium (HEU). For CY 2026, we are finalizing replacing the add-on payment for radiopharmaceuticals produced without the use of Tc-99m derived from non-HEU sources with an add-on payment for radiopharmaceuticals that use Tc-99m derived from domestically produced Mo-99.
                    </P>
                    <P>
                        • 
                        <E T="03">Changes to the Review Timeframes for the Hospital Outpatient Department (OPD) Prior Authorization Process:</E>
                         We are changing the current review timeframe for prior authorization requests for OPD services from 10-business days to 7-calendar days for standard reviews.
                    </P>
                    <P>
                        • 
                        <E T="03">Health Equity Measures for the Hospital Outpatient Quality Reporting (OQR), Rural Emergency Hospital Quality Reporting (REHQR), and Ambulatory Surgical Center Quality Reporting (ASCQR) Programs:</E>
                         We are finalizing: (1) adoption of the Hospital Commitment to Health Equity (HCHE) measure in the Hospital OQR and the REHQR Programs, and adoption of the Facility Commitment to Health Equity (FCHE) measure in the ASCQR Program, beginning with the CY 2025 reporting period/CY 2027 payment or program determinations; (2) adoption of the Screening for Social Drivers of Health (SDOH) measure in all three programs beginning with voluntary reporting for the CY 2025 reporting period followed by mandatory reporting beginning with the CY 2026 reporting period/CY 2028 
                        <PRTPAGE P="93917"/>
                        payment or program determinations; and (3) adoption of the Screen Positive Rate for SDOH measure in all three programs beginning with voluntary reporting for the CY 2025 reporting period followed by mandatory reporting beginning with the CY 2026 reporting period/CY 2028 payment or program determinations.
                    </P>
                    <P>
                        • 
                        <E T="03">Modification of the Immediate Measure Removal Policy for the Hospital OQR and ASCQR Programs:</E>
                         We are finalizing modification of the immediate measure removal policy to an immediate measure suspension policy to increase transparency regarding the process for removing adopted measures in the Hospital OQR and ASCQR Programs beginning with CY 2025.
                    </P>
                    <P>
                        • 
                        <E T="03">Hospital Outpatient Quality Reporting (OQR) Program:</E>
                         In addition to the cross-program measures and policies, we are finalizing: (1) adoption of the Patient Understanding of Key Information Related to Recovery After a Facility-Based Outpatient Procedure or Surgery, Patient Reported Outcome-Based Performance Measure (Information Transfer PRO-PM) beginning with voluntary reporting for the CY 2026 reporting period followed by mandatory reporting beginning with the CY 2027 reporting period/CY 2029 payment determination; (2) removal of the MRI Lumbar Spine for Low Back Pain measure beginning with the CY 2025 reporting period/CY 2027 payment determination; (3) removal of the Cardiac Imaging for Preoperative Risk Assessment for Non-Cardiac, Low-Risk Surgery measure beginning with the CY 2025 reporting period/CY 2027 payment determination; (4) the requirement that electronic health record (EHR) technology be certified to all electronic clinical quality measures (eCQMs) available to report beginning with the CY 2025 reporting period/CY 2027 payment determination; and (5) public reporting of the Median Time from Emergency Department (ED) Arrival to ED Departure for Discharged ED Patients measure—Psychiatric/Mental Health Patients stratification on Care Compare beginning with CY 2025.
                    </P>
                    <P>
                        • 
                        <E T="03">Rural Emergency Hospital Quality Reporting (REHQR) Program:</E>
                         In addition to the cross-program measures, we are finalizing: (1) extension of the reporting period for the Risk-Standardized Hospital Visits Within 7 Days After Hospital Outpatient Surgery measure from 1 year to 2 years beginning with the CY 2027 program determination; and (2) when, after status conversion, REHs are required to report data under the REHQR Program.
                    </P>
                    <P>
                        • 
                        <E T="03">Ambulatory Surgical Center Quality Reporting (ASCQR) Program:</E>
                         In addition to finalizing the cross-program measures and policies, we summarize comments received on the potential development of frameworks for specialty focused reporting and minimum case number for required reporting under the ASCQR Program.
                    </P>
                    <P>
                        • 
                        <E T="03">Hospital Inpatient Quality Reporting (IQR) Program:</E>
                         We are finalizing the voluntary reporting of the core clinical data elements (CCDEs) and linking variables for both the Hybrid Hospital-Wide Readmission (HWR) and Hybrid Hospital-Wide Standardized Mortality (HWM) measures, for the performance period of July 1, 2023, through June 30, 2024, impacting the FY 2026 payment determination for the Hospital IQR Program. Additionally, we are extending voluntary reporting of CCDEs and linking variables for an additional year for the performance period of July 1, 2024, through June 30, 2025, impacting the FY 2027 payment determination for the Hospital IQR Program.
                    </P>
                    <P>
                        • 
                        <E T="03">Overall Hospital Quality Star Rating:</E>
                         We summarize comments received on potential modifications to the Safety of Care measure group in the Overall Hospital Quality Star Rating methodology.
                    </P>
                    <P>
                        • 
                        <E T="03">Medicare FFS No Legal Obligation to Pay Payment Exclusion and Incarceration:</E>
                         We are narrowing the description of “custody” for purposes of Medicare's no legal obligation to pay payment exclusion at § 411.4(b), stating explicitly in regulatory text that individuals who are released to the community pending trial (including those in pretrial community supervision and those released pursuant to cash bail), on parole, probation, or home detention, or required to reside in halfway houses are not considered to be in “custody” for purposes of the payment exclusion, adding a definition of “penal authority,” reorganizing the regulation, and making certain technical edits.
                    </P>
                    <P>
                        • 
                        <E T="03">Revision to Medicare Special Enrollment Period for Formerly Incarcerated Individuals:</E>
                         We are finalizing the eligibility requirements in the special enrollment period (SEP) for formerly incarcerated individuals at §§ 406.27(d) and 407.23(d) to remove the reference to “custody” associated with § 411.4(b) and instead tie the eligibility for this SEP to the determination made by SSA that they are no longer incarcerated. We are also expanding the SEP eligibility criteria to include individuals released from confinement to residency in halfway houses.
                    </P>
                    <P>
                        • 
                        <E T="03">Continuous Eligibility in Medicaid and CHIP:</E>
                         We are finalizing our proposed revisions to Medicaid and CHIP regulations to codify the requirement within the CAA, 2023 for States to provide 12 months of continuous eligibility to children under the age of 19 in Medicaid and CHIP, with limited exceptions. Specifically, we are finalizing the removal of the option to provide continuous eligibility to a subgroup of Medicaid and CHIP enrollees and for a time period of less than 12 months. For CHIP, we are finalizing the removal of the option to disenroll children from CHIP during a continuous eligibility period for failure to pay premiums.
                    </P>
                    <P>
                        • 
                        <E T="03">Medicaid Clinic Services Four Walls Exceptions:</E>
                         We are finalizing three exceptions to the Medicaid clinic services benefit four walls requirement at 42 CFR 440.90. Our current regulation at 42 CFR 440.90(b) allows for Medicaid payment for clinic services furnished outside of the four walls of the clinic only to individuals who are unhoused. Our final rule adds a mandatory exception to the four walls requirement for IHS/Tribal clinics at 42 CFR 440.90(c) and optional exceptions for behavioral health clinics and clinics located in rural areas at 42 CFR 440.90(d) and (e), respectively.
                    </P>
                    <P>
                        • 
                        <E T="03">Health and Safety Standards for Obstetrical Services in Hospitals and Critical Access Hospitals:</E>
                         We are finalizing new Conditions of Participation (CoPs) for hospitals and CAHs for obstetrical services, including new requirements for maternal quality assessment and performance improvement (QAPI), as well as baseline standards for the organization, staffing, and delivery of care within obstetrical units, and staff training on evidence-based best practices every 2 years. We are finalizing revisions to the emergency services CoP related to emergency readiness for hospitals and CAHs that provide emergency services. In addition, we are finalizing revisions to the Discharge Planning CoP for all hospitals related to transfer protocols. Further, we are finalizing a phased-in implementation to provide hospitals and CAHs with additional time to come into compliance with the requirements. Lastly, we sought comments in the proposed rule on whether these requirements should also apply to rural emergency hospitals (REHs), which we discuss below.
                    </P>
                    <HD SOURCE="HD3">3. Summary of Costs and Benefits</HD>
                    <P>
                        In section XXVIII of this final rule with comment period, we set forth a detailed analysis of the regulatory and federalism impacts that the proposed 
                        <PRTPAGE P="93918"/>
                        changes would have on affected entities and beneficiaries. Key estimated impacts are described below.
                    </P>
                    <HD SOURCE="HD3">a. Impacts of All OPPS Changes</HD>
                    <P>Table 201 in section XXVIII.C of this final rule with comment period displays the distributional impact of all the OPPS changes on various groups of hospitals and CMHCs for CY 2025 compared to all estimated OPPS payments in CY 2024. We estimate that the final policies in this final rule with comment period would result in a 3.0 percent overall increase in OPPS payments to providers. We estimate that total OPPS payments for CY 2025, including beneficiary cost-sharing, to the approximately 3,500 facilities paid under the OPPS (including general acute care hospitals, children's hospitals, cancer hospitals, and CMHCs) would increase by approximately $1.98 billion compared to CY 2024 payments, excluding our estimated changes in enrollment, utilization, and case-mix.</P>
                    <P>We estimated the isolated impact of our OPPS policies on CMHCs because CMHCs have historically only been paid for partial hospitalization services under the OPPS. Beginning CY 2024, they are also paid for intensive outpatient program (IOP) services under the OPPS. Continuing the provider-specific structure we adopted beginning in CY 2011, and basing payment fully on the type of provider furnishing the service, we estimate a 11.9 percent increase in CY 2025 payments to CMHCs relative to their CY 2024 payments.</P>
                    <HD SOURCE="HD3">b. Impacts of the Updated Wage Indexes</HD>
                    <P>We estimate that our update of the wage indexes based on the fiscal year (FY) 2025 IPPS final rule wage indexes will result in a 0.1 percent increase for urban hospitals under the OPPS and a 0.9 percent increase for rural hospitals. These wage indexes include continued implementation of the Office of Management and Budget (OMB) labor market area delineations based on 2020 Decennial Census data, with updates, as discussed in section II.C of this final rule with comment period.</P>
                    <HD SOURCE="HD3">c. Impacts of the Rural Adjustment and the Cancer Hospital Payment Adjustment</HD>
                    <P>For CY 2025, we are continuing to provide additional payments to cancer hospitals so that a cancer hospital's payment-to-cost ratio (PCR) after the additional payments is equal to the weighted average PCR for the other OPPS hospitals using the most recently submitted or settled cost report data. Section 16002(b) of the 21st Century Cures Act requires that this weighted average PCR be reduced by 1.0 percentage point. In light of the COVID-19 PHE impact on claims and cost data used to calculate the target PCR, we had maintained the CY 2021 target PCR of 0.89 through CYs 2022 and 2023. However, in CY 2024, we finalized a policy to reduce the target PCR by 1.0 percentage point each calendar year until the target PCR equals the PCR of non-cancer hospitals using the most recently submitted or settled cost report data. For CY 2024, we finalized a target PCR of 0.88. For CY 2025, we are finalizing a target PCR of 0.87 to determine the CY 2025 cancer hospital payment adjustment to be paid at cost report settlement. That is, the payment adjustments would be the additional payments needed to result in a PCR equal to 0.87 for each cancer hospital.</P>
                    <HD SOURCE="HD3">d. Impacts of the OPD Fee Schedule Increase Factor</HD>
                    <P>For the CY 2025 OPPS/ASC, we are establishing an OPD fee schedule increase factor of 2.9 percent and applying that increase factor to the conversion factor for CY 2025. As a result of the OPD fee schedule increase factor and other budget neutrality adjustments, we estimate that urban hospitals will experience an increase in payments of approximately 3.2 percent and that rural hospitals will experience an increase in payments of 3.2 percent. Classifying hospitals by teaching status, we estimate non-teaching hospitals will experience an increase in payments of 3.3 percent, minor teaching hospitals will experience an increase in payments of 3.5 percent, and major teaching hospitals will experience an increase in payments of 2.7 percent. We also classified hospitals by the type of ownership. We estimate that hospitals with voluntary ownership will experience an increase of 3.1 percent in payments, while hospitals with government ownership will experience an increase of 2.6 percent in payments. We estimate that hospitals with proprietary ownership will experience an increase of 4.9 percent in payments.</P>
                    <HD SOURCE="HD3">e. Impacts of the ASC Payment Update</HD>
                    <P>For impact purposes, the surgical procedures on the ASC covered surgical procedure list are aggregated into surgical specialty groups using CPT and HCPCS code range definitions. The percentage change in estimated total payments by specialty groups under the CY 2025 payment rates, compared to estimated CY 2024 payment rates, generally ranges between an increase of 3 percent and an increase of 4 percent, depending on the service, with some exceptions. We estimate the impact of applying the inpatient hospital market basket update to ASC payment rates will increase payments by $193 million under the ASC payment system in CY 2025.</P>
                    <HD SOURCE="HD3">f. Impacts of Medicaid Clinic Services Four Walls Exceptions</HD>
                    <P>We estimate that the finalized exceptions to the four walls requirement under the Medicaid clinic services benefit for IHS/Tribal clinics, behavioral health clinics, and clinics located in rural areas will increase total expenditures by $1.18 billion from FY 2025 through 2029. Our estimate includes a Federal impact of $1.15 billion and impact to States of $30 million. These estimates are discussed in more detail in section XXVIII of this final rule.</P>
                    <HD SOURCE="HD3">g. Impacts of Health and Safety Standards for Obstetrical Services in Hospitals and Critical Access Hospitals</HD>
                    <P>We are finalizing maternal health focused revisions to the CoPs for hospitals and CAHs, which are estimated to increase burden on hospitals and CAHs by $423 million annually with total costs estimated at $4.23 billion over 10 years. We expect an average annual cost of $67,103 per hospital and CAH. As discussed in detail in section XXVIII of this final rule with comment period, we expect the benefits of these policies to include reduced maternal morbidity and mortality, leading to financial benefits for patients, their families, and payors. We also expect that the policies are likely to reduce inequality in maternal health outcomes among pregnant and postpartum women from different groups and lead to overall improvements in patient care.</P>
                    <HD SOURCE="HD3">h. Impacts of the Medicaid and CHIP Continuous Eligibility Requirements</HD>
                    <P>
                        We are finalizing our proposed revisions to Medicaid and CHIP regulations to codify the requirement within the CAA, 2023 for States to provide 12 months of continuous eligibility to children under the age of 19 in Medicaid and CHIP, with limited exceptions. For CHIP, we are finalizing the removal of the option to disenroll children from CHIP during a continuous eligibility period for failure to pay premiums. Requiring 12months of continuous eligibility in Medicaid and CHIP is estimated to increase annual average enrollment in Medicaid and CHIP by approximately 124,000 by 2028 (75,000 in Medicaid and 49,000 in CHIP). The total estimated impact of this requirement over 5 years is $2,466 million, including Federal impact of 
                        <PRTPAGE P="93919"/>
                        $1,592 million and State impact of $874 million.
                    </P>
                    <HD SOURCE="HD2">B. Legislative and Regulatory Authority for the Hospital OPPS</HD>
                    <P>When Title XVIII of the Act was enacted, Medicare payment for hospital outpatient services was based on hospital-specific costs. In an effort to ensure that Medicare and its beneficiaries pay appropriately for services and to encourage more efficient delivery of care, the Congress mandated replacement of the reasonable cost-based payment methodology with a prospective payment system (PPS). The Balanced Budget Act of 1997 (BBA) (Pub. L. 105-33) added section 1833(t) to the Act, authorizing implementation of a PPS for hospital outpatient services. The OPPS was first implemented for services furnished on or after August 1, 2000. Implementing regulations for the OPPS are located at 42 CFR parts 410 and 419.</P>
                    <P>The Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106-113) made major changes in the hospital OPPS. The following Acts made additional changes to the OPPS: the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA) (Pub. L. 106-554); the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. 108-173); the Deficit Reduction Act of 2005 (DRA) (Pub. L. 109-171), enacted on February 8, 2006; the Medicare Improvements and Extension Act under Division B of Title I of the Tax Relief and Health Care Act of 2006 (MIEA-TRHCA) (Pub. L. 109-432), enacted on December 20, 2006; the Medicare, Medicaid, and SCHIP Extension Act of 2007 (MMSEA) (Pub. L. 110-173), enacted on December 29, 2007; the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA) (Pub. L. 110-275), enacted on July 15, 2008; the Patient Protection and Affordable Care Act (Pub. L. 111-148), enacted on March 23, 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (HCERA, Pub. L. 111-152), enacted on March 30, 2010 (these two public laws are collectively known as the Affordable Care Act); the Medicare and Medicaid Extenders Act of 2010 (MMEA, Pub. L. 111-309); the Temporary Payroll Tax Cut Continuation Act of 2011 (TPTCCA, Pub. L. 112-78), enacted on December 23, 2011; the Middle Class Tax Relief and Job Creation Act of 2012 (MCTRJCA, Pub. L. 112-96), enacted on February 22, 2012; the American Taxpayer Relief Act of 2012 (Pub. L. 112-240), enacted January 2, 2013; the Pathway for SGR Reform Act of 2013 (Pub. L. 113-67) enacted on December 26, 2013; the Protecting Access to Medicare Act of 2014 (PAMA, Pub. L. 113-93), enacted on March 27, 2014; the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 (Pub. L. 114-10), enacted April 16, 2015; the Bipartisan Budget Act of 2015 (Pub. L. 114-74), enacted November 2, 2015; the Consolidated Appropriations Act, 2016 (Pub. L. 114-113), enacted on December 18, 2015, the 21st Century Cures Act (Pub. L. 114-255), enacted on December 13, 2016; the Consolidated Appropriations Act, 2018 (Pub. L. 115-141), enacted on March 23, 2018; the Substance Use Disorder—Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (Pub. L. 115-271), enacted on October 24, 2018; the Further Consolidated Appropriations Act, 2020 (Pub. L. 116-94), enacted on December 20, 2019; the Coronavirus Aid, Relief, and Economic Security Act (Pub. L. 116-136), enacted on March 27, 2020; the Consolidated Appropriations Act, 2021 (Pub. L. 116-260), enacted on December 27, 2020; the Inflation Reduction Act, 2022 (Pub. L. 117-169), enacted on August 16, 2022; and the Consolidated Appropriations Act (CAA), 2023 (Pub. L. 117-238), enacted December 29, 2022.</P>
                    <P>Under the OPPS, we generally pay for hospital Part B services on a rate-per-service basis that varies according to the APC group to which the service is assigned. We use the Healthcare Common Procedure Coding System (HCPCS) (which includes certain Current Procedural Terminology (CPT) codes) to identify and group the services within each APC. The OPPS includes payment for most hospital outpatient services, except those identified in section I.C of this final rule with comment period. Section 1833(t)(1)(B) of the Act provides for payment under the OPPS for hospital outpatient services designated by the Secretary (which includes partial hospitalization services furnished by CMHCs), and certain inpatient hospital services that are paid under Medicare Part B.</P>
                    <P>The OPPS rate is an unadjusted national payment amount that includes the Medicare payment and the beneficiary copayment. This rate is divided into a labor-related amount and a nonlabor-related amount. The labor-related amount is adjusted for area wage differences using the hospital inpatient wage index value for the locality in which the hospital or CMHC is located.</P>
                    <P>All services and items within an APC group are comparable clinically and with respect to resource use, as required by section 1833(t)(2)(B) of the Act. In accordance with section 1833(t)(2)(B) of the Act, subject to certain exceptions, items and services within an APC group cannot be considered comparable with respect to the use of resources if the highest median cost (or mean cost, if elected by the Secretary) for an item or service in the APC group is more than 2 times greater than the lowest median cost (or mean cost, if elected by the Secretary) for an item or service within the same APC group (referred to as the “2 times rule”). In implementing this provision, we generally use the cost of the item or service assigned to an APC group.</P>
                    <P>For new technology items and services, special payments under the OPPS may be made in one of two ways. Section 1833(t)(6) of the Act provides for temporary additional payments, which we refer to as “transitional pass-through payments,” for at least 2 but not more than 3 years for certain drugs, biological agents, brachytherapy devices used for the treatment of cancer, and categories of other medical devices. For new technology services that are not eligible for transitional pass-through payments, and for which we lack sufficient clinical information and cost data to appropriately assign them to a clinical APC group, we have established special APC groups based on costs, which we refer to as New Technology APCs. These New Technology APCs are designated by cost bands which allow us to provide appropriate and consistent payment for designated new procedures that are not yet reflected in our claims data. Similar to pass-through payments, an assignment to a New Technology APC is temporary; that is, we retain a service within a New Technology APC until we acquire sufficient data to assign it to a clinically appropriate APC group.</P>
                    <HD SOURCE="HD2">C. Excluded OPPS Services and Hospitals</HD>
                    <P>
                        Section 1833(t)(1)(B)(i) of the Act authorizes the Secretary to designate the hospital outpatient services that are paid under the OPPS. While most hospital outpatient services are payable under the OPPS, section 1833(t)(1)(B)(iv) of the Act excludes payment for ambulance, physical and occupational therapy, and speech-language pathology services, for which payment is made under a fee schedule. It also excludes screening mammography, diagnostic mammography, and effective January 1, 2011, an annual wellness visit providing personalized prevention plan services. The Secretary exercises the authority granted under the statute to also exclude from the OPPS certain services that are 
                        <PRTPAGE P="93920"/>
                        paid under fee schedules or other payment systems. Such excluded services include, for example, the professional services of physicians and nonphysician practitioners paid under the Medicare Physician Fee Schedule (MPFS); certain laboratory services paid under the Clinical Laboratory Fee Schedule (CLFS); services for beneficiaries with end-stage renal disease (ESRD) that are paid under the ESRD prospective payment system; and services and procedures that require an inpatient stay that are paid under the hospital IPPS. In addition, section 1833(t)(1)(B)(v) of the Act does not include applicable items and services (as defined in subparagraph (A) of paragraph (21)) that are furnished on or after January 1, 2017, by an off-campus outpatient department of a provider (as defined in subparagraph (B) of paragraph (21)). We set forth the services that are excluded from payment under the OPPS in regulations at 42 CFR 419.22.
                    </P>
                    <P>Under § 419.20(b) of the regulations, we specify the types of hospitals that are excluded from payment under the OPPS. These excluded hospitals are:</P>
                    <P>• Critical access hospitals (CAHs);</P>
                    <P>• Hospitals located in Maryland and paid under Maryland's All-Payer or Total Cost of Care Model;</P>
                    <P>• Hospitals located outside of the 50 States, the District of Columbia, and Puerto Rico;</P>
                    <P>• Indian Health Service (IHS) hospitals; and</P>
                    <P>• Rural emergency hospitals (REH).</P>
                    <HD SOURCE="HD2">D. Prior Rulemaking</HD>
                    <P>
                        On April 7, 2000, we published in the 
                        <E T="04">Federal Register</E>
                         a final rule with comment period (65 FR 18434) to implement a prospective payment system for hospital outpatient services. The hospital OPPS was first implemented for services furnished on or after August 1, 2000. Section 1833(t)(9)(A) of the Act requires the Secretary to review certain components of the OPPS, not less often than annually, and to revise the groups, the relative payment weights, and the wage and other adjustments to take into account changes in medical practices, changes in technology, the addition of new services, new cost data, and other relevant information and factors.
                    </P>
                    <P>
                        Since initially implementing the OPPS, we have published final rules in the 
                        <E T="04">Federal Register</E>
                         annually to implement statutory requirements and changes arising from our continuing experience with this system. These rules can be viewed on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        .
                    </P>
                    <HD SOURCE="HD2">E. Advisory Panel on Hospital Outpatient Payment (the HOP Panel or the Panel)</HD>
                    <HD SOURCE="HD3">1. Authority of the Panel</HD>
                    <P>Section 1833(t)(9)(A) of the Act, as amended by section 201(h) of Public Law 106-113, and redesignated by section 202(a)(2) of Public Law 106-113, requires that we consult with an expert outside advisory panel composed of an appropriate selection of representatives of providers to annually review (and advise the Secretary concerning) the clinical integrity of the payment groups and their weights under the OPPS. In CY 2000, based on section 1833(t)(9)(A) of the Act, the Secretary established the Advisory Panel on Ambulatory Payment Classification Groups (APC Panel) to fulfill this requirement. In CY 2011, based on section 222 of the Public Health Service Act (the PHS Act), which gives discretionary authority to the Secretary to convene advisory councils and committees, the Secretary expanded the panel's scope to include the supervision of hospital outpatient therapeutic services in addition to the APC groups and weights. To reflect this new role of the panel, the Secretary changed the panel's name to the Advisory Panel on Hospital Outpatient Payment (the HOP Panel). The HOP Panel is not restricted to using data compiled by CMS, and in conducting its review, it may use data collected or developed by organizations outside the Department.</P>
                    <HD SOURCE="HD3">2. Establishment of the Panel</HD>
                    <P>On November 21, 2000, the Secretary signed the initial charter establishing the Panel, and, at that time, named the APC Panel. This expert panel is composed of appropriate representatives of providers (currently employed full-time, not as consultants, in their respective areas of expertise) who review clinical data and advise CMS about the clinical integrity of the APC groups and their payment weights. Since CY 2012, the Panel also is charged with advising the Secretary on the appropriate level of supervision for individual hospital outpatient therapeutic services. The Panel is technical in nature, and it is governed by the provisions of the Federal Advisory Committee Act (FACA). The current charter specifies, among other requirements, that the Panel—</P>
                    <P>• May advise on the clinical integrity of Ambulatory Payment Classification (APC) groups and their associated weights;</P>
                    <P>• May advise on the appropriate supervision level for hospital outpatient services;</P>
                    <P>• May advise on OPPS APC rates for ASC covered surgical procedures;</P>
                    <P>• Continues to be technical in nature;</P>
                    <P>• Is governed by the provisions of the FACA;</P>
                    <P>• Has a Designated Federal Official (DFO); and</P>
                    <P>• Is chaired by a Federal Official designated by the Secretary.</P>
                    <P>The Panel's charter was amended on November 15, 2011, renaming the Panel and expanding the Panel's authority to include supervision of hospital outpatient therapeutic services and to add critical access hospital (CAH) representation to its membership. The Panel's charter was also amended on November 6, 2014 (80 FR 23009), and the number of members was revised from up to 19 to up to 15 members. The Panel's current charter was approved on November 21, 2022, for a 2-year period.</P>
                    <P>
                        The current Panel membership and other information pertaining to the Panel, including its charter, 
                        <E T="04">Federal Register</E>
                         notices, membership, meeting dates, agenda topics, and meeting reports, can be viewed on the CMS website at: 
                        <E T="03">https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonAmbulatoryPaymentClassificationGroups.html</E>
                        .
                    </P>
                    <HD SOURCE="HD3">3. Panel Meetings and Organizational Structure</HD>
                    <P>
                        The Panel has held many meetings, with the last meeting taking place on August 26, 2024. The recommendations of the Panel for the most recent meeting are available on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/regulations-guidance/advisory-committees/hospital-outpatient-payment</E>
                        . Prior to each meeting, we publish a notice in the 
                        <E T="04">Federal Register</E>
                         to announce the meeting, new members, and any other changes of which the public should be aware. Beginning in CY 2017, we have transitioned to one meeting per year (81 FR 31941). In CY 2022, we published a 
                        <E T="04">Federal Register</E>
                         notice requesting nominations to fill vacancies on the Panel (87 FR 68499). CMS is currently accepting nominations at: 
                        <E T="03">https://mearis.cms.gov</E>
                        .
                    </P>
                    <P>In addition, the Panel has established an administrative structure that, in part, currently includes the use of three subcommittee workgroups to provide preparatory meeting and subject support to the larger panel. The three current subcommittees include the following:</P>
                    <P>
                        • APC Groups and Status Indicator Assignments Subcommittee, which advises and provides recommendations to the Panel on the appropriate status 
                        <PRTPAGE P="93921"/>
                        indicators to be assigned to HCPCS codes, including but not limited to whether a HCPCS code or a category of codes should be packaged or separately paid, as well as the appropriate APC assignment of HCPCS codes regarding services for which separate payment is made;
                    </P>
                    <P>• Data Subcommittee, which is responsible for studying the data issues confronting the Panel and for recommending options for resolving them; and</P>
                    <P>• Visits and Observation Subcommittee, which reviews and makes recommendations to the Panel on all technical issues pertaining to observation services and hospital outpatient visits paid under the OPPS.</P>
                    <P>Each of these workgroup subcommittees was established by a majority vote from the full Panel during a scheduled Panel meeting, and the Panel recommended at the August 21, 2023, meeting that the subcommittees continue. We accepted this recommendation.</P>
                    <P>
                        For discussions of earlier Panel meetings and recommendations, we refer readers to previously published OPPS/ASC proposed and final rules, the CMS website mentioned earlier in this section, and the FACA database at 
                        <E T="03">https://facadatabase.gov.</E>
                    </P>
                    <HD SOURCE="HD2">F. Public Comments Received on the CY 2025 Proposed Rule</HD>
                    <P>
                        We received approximately 3,500 timely pieces of correspondence on the CY 2025 OPPS/ASC proposed rule that appeared in the 
                        <E T="04">Federal Register</E>
                         on July 22, 2024 (89 FR 59186). We received comments from elected officials, providers and suppliers, practitioners, and advocacy groups. We provide summaries of the public comments, and our responses are set forth in the various sections of this final rule with comment period under the appropriate headings. We note that we received some public comments that were outside the scope of the CY 2025 OPPS/ASC proposed rule. Out-of-scope-public comments are not addressed in this CY 2025 OPPS/ASC final rule with comment period.
                    </P>
                    <HD SOURCE="HD2">G. Public Comments Received on the CY 2024 OPPS/ASC Final Rule With Comment Period</HD>
                    <P>
                        We received approximately 180 timely pieces of correspondence on the CY 2024 OPPS/ASC final rule with comment period that appeared in the 
                        <E T="04">Federal Register</E>
                         on November 22, 2023 (88 FR 81540).
                    </P>
                    <HD SOURCE="HD1">II. Updates Affecting OPPS Payments</HD>
                    <HD SOURCE="HD2">A. Recalibration of APC Relative Payment Weights</HD>
                    <HD SOURCE="HD3">1. Database Construction</HD>
                    <HD SOURCE="HD3">a. Database Source and Methodology</HD>
                    <P>Section 1833(t)(9)(A) of the Act requires that the Secretary review not less often than annually and revise the relative payment weights for Ambulatory Payment Classifications (APCs). In the April 7, 2000, OPPS final rule with comment period (65 FR 18482), we explained in detail how we calculated the relative payment weights that were implemented on August 1, 2000, for each APC group.</P>
                    <P>For the CY 2025 OPPS, we proposed to recalibrate the APC relative payment weights for services furnished on or after January 1, 2025, and before January 1, 2026 (CY 2025), using the same basic methodology that we described in the CY 2024 OPPS/ASC final rule with comment period (88 FR 81549 through 81552), using CY 2023 claims data. That is, we proposed to recalibrate the relative payment weights for each APC based on claims and cost report data for hospital outpatient department (HOPD) services to construct a database for calculating APC group weights.</P>
                    <P>
                        For the purpose of recalibrating the proposed APC relative payment weights for CY 2025, we began with approximately 145 million final action claims (claims for which all disputes and adjustments have been resolved and payment has been made) for HOPD services furnished on or after January 1, 2023, and before January 1, 2024, before applying our exclusionary criteria and other methodological adjustments. After the application of those data processing changes, we used approximately 73 million final action claims to develop the proposed CY 2025 OPPS payment weights. For exact numbers of claims used and additional details on the claims accounting process, we refer readers to the claims accounting narrative under supporting documentation for the CY 2025 OPPS/ASC proposed rule on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient</E>
                        .
                    </P>
                    <P>
                        Addendum N to the CY 2025 OPPS/ASC proposed rule (which is available via the internet on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        ) includes the proposed list of bypass codes for CY 2025. The proposed list of bypass codes contains codes that are reported on claims for services in CY 2023 and, therefore, includes codes that were in effect in CY 2023 and used for billing. We proposed to retain these deleted bypass codes on the proposed CY 2025 bypass list because these codes existed in CY 2023 and were covered OPD services in that period, and CY 2023 claims data were used to calculate proposed CY 2025 payment rates. Keeping these deleted bypass codes on the bypass list potentially allows us to create more “pseudo” single procedure claims for ratesetting purposes. “Overlap bypass codes” that are members of the proposed multiple imaging composite APCs are identified by asterisks (*) in the third column of Addendum N to the CY 2025 OPPS/ASC proposed rule. HCPCS codes that we proposed to add for CY 2025 are identified by asterisks (*) in the fourth column of Addendum N.
                    </P>
                    <P>
                        We did not receive any public comments on our general proposal to recalibrate the relative payment weights for each APC based on claims and cost report data for HOPD services or on our proposed bypass code process. We are finalizing as proposed the “pseudo” single claims process and the final CY 2025 list of bypass codes, as displayed in Addendum N to this final rule with comment period (which is available via the internet on the CMS website). For this final rule with comment period, for the purpose of recalibrating the final APC relative payment weights for CY 2025, we used approximately 78 million final action claims (claims for which all disputes and adjustments have been resolved and payment has been made) for HOPD services furnished on or after January 1, 2023, and before January 1, 2024. For the exact numbers of claims used and additional details on the claims accounting process, we refer readers to the claims accounting narrative under supporting documentation for this final rule with comment period on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient</E>
                        .
                    </P>
                    <HD SOURCE="HD3">b. Calculation and Use of Cost-to-Charge Ratios (CCRs)</HD>
                    <P>
                        For CY 2025, we proposed to continue to use the hospital-specific overall ancillary and departmental cost-to-charge ratios (CCRs) to convert charges to estimated costs through application of a revenue code-to-cost center crosswalk. To calculate the APC costs on which the proposed CY 2025 APC payment rates are based, we calculated hospital-specific departmental CCRs for each hospital for which we had CY 2023 claims data by comparing these claims data to the most recently available hospital cost reports, which, in most 
                        <PRTPAGE P="93922"/>
                        cases, are from CY 2022. For the proposed CY 2025 OPPS payment rates, we used the set of claims processed during CY 2023. We applied the hospital-specific CCR to the hospital's charges at the most detailed level possible, based on a revenue code-to-cost center crosswalk that contains a hierarchy of CCRs used to estimate costs from charges for each revenue code. To ensure the completeness of the revenue code-to-cost center crosswalk, we reviewed changes to the list of revenue codes for CY 2023 (the year of claims data we used to calculate the proposed CY 2025 OPPS payment rates) and updates to the National Uniform Billing Committee (NUBC) 2023 Data specifications Manual. That crosswalk is available for review and continuous comment on the CMS website at 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient</E>
                        .
                    </P>
                    <P>In accordance with our longstanding policy, similar to our finalized policy for CY 2024 OPPS ratesetting, we proposed to calculate CCRs for the standard cost centers—cost centers with a predefined label—and nonstandard cost centers—cost centers defined by a hospital—accepted by the electronic cost report database. In general, the most detailed level at which we calculate CCRs is the hospital-specific departmental level.</P>
                    <P>While we generally view the use of additional cost data as improving our OPPS ratesetting process, we have historically not included cost report lines for certain nonstandard cost centers in the OPPS ratesetting database construction when hospitals have reported these nonstandard cost centers on cost report lines that do not correspond to the cost center number. We believe it is important to further investigate the accuracy of these cost report data before including such data in the ratesetting process. Further, we believe it is appropriate to gather additional information from the public as well before including them in OPPS ratesetting. For CY 2025, we proposed not to include the nonstandard cost centers reported in this way in the OPPS ratesetting database construction.</P>
                    <P>We did not receive any public comments on the general CCR process and therefore, we are finalizing our proposal for CY 2025 to use the hospital-specific overall ancillary and departmental CRs to convert charges to estimated costs through application of a revenue code-to-cost center crosswalk and the proposed methodology.</P>
                    <HD SOURCE="HD3">2. Final Data Development and Calculation of Costs Used for Ratesetting</HD>
                    <P>
                        In this section of this final rule with comment period, we discuss the use of claims to calculate the OPPS payment rates for CY 2025. The Hospital OPPS page on the CMS website on which this final rule with comment period is posted (
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient</E>
                        ) provides an accounting of claims used in the development of the proposed payment rates. That accounting provides additional detail regarding the number of claims derived at each stage of the process. In addition, later in this section we discuss the file of claims that comprises the data set that is available upon payment of an administrative fee under a CMS data use agreement. The CMS website, 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient</E>
                        , includes information about obtaining the “OPPS Limited Data Set,” which now includes the additional variables previously available only in the OPPS Identifiable Data Set, including International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes and revenue code payment amounts. This file is derived from the CY 2023 claims that are used to calculate the proposed payment rates for the CY 2025 OPPS/ASC proposed rule.
                    </P>
                    <P>Previously, the OPPS established the scaled relative weights on which payments are based using APC median costs, a process described in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74188). However, as discussed in more detail in section II.A.2.f of the CY 2013 OPPS/ASC final rule with comment period (77 FR 68259 through 68271), we finalized the use of geometric mean costs to calculate the relative weights on which the CY 2013 OPPS payment rates were based. While this policy changed the cost metric on which the relative payments are based, the data process in general remained the same under the methodologies that we used to obtain appropriate claims data and accurate cost information in determining estimated service cost.</P>
                    <P>
                        We used the methodology described in sections II.A.2.a through II.A.2.c of this final rule with comment period to calculate the costs we used to establish the proposed relative payment weights used in calculating the OPPS payment rates for CY 2025 shown in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        ). We refer readers to section II.A.4 of this final rule with comment period for a discussion of the conversion of APC costs to scaled payment weights.
                    </P>
                    <P>We note that under the OPPS, CY 2019 was the first year in which the claims data used for setting payment rates (CY 2017 data) contained lines with the modifier “PN,” which indicates nonexcepted items and services furnished and billed by off-campus provider-based departments (PBDs) of hospitals. Because nonexcepted items and services are not paid under the OPPS, in the CY 2019 OPPS/ASC final rule with comment period (83 FR 58832), we finalized a policy to remove those claim lines reported with modifier “PN” from the claims data used in ratesetting for the CY 2019 OPPS and subsequent years. For the CY 2025 OPPS, we proposed to continue to remove claim lines with modifier “PN” from the ratesetting process.</P>
                    <P>We did not receive any public comments on our proposal and are finalizing our proposal to continue to remove claim lines reported with modifier “PN” from the ratesetting process.</P>
                    <P>
                        For details of the claims accounting process used in this CY 2025 OPPS/ASC final rule with comment period, we refer readers to the claims accounting narrative under supporting documentation for this final rule with comment period on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient</E>
                        .
                    </P>
                    <HD SOURCE="HD3">a. Calculation of Single Procedure APC Criteria-Based Costs</HD>
                    <HD SOURCE="HD3">(1) Blood and Blood Products</HD>
                    <HD SOURCE="HD3">(a) Methodology</HD>
                    <P>Since the implementation of the OPPS in August 2000, we have made separate payments for blood and blood products through APCs rather than packaging payment for them into payments for the procedures with which they are administered. Hospital payments for the costs of blood and blood products, as well as for the costs of collecting, processing, and storing blood and blood products, are made through the OPPS payments for specific blood product APCs.</P>
                    <P>
                        In the CY 2025 OPPS/ASC proposed rule, we proposed to continue to establish payment rates for blood and blood products using our blood-specific CCR methodology (88 FR 49562), which utilizes actual or simulated CCRs from 
                        <PRTPAGE P="93923"/>
                        the most recently available hospital cost reports to convert hospital charges for blood and blood products to costs. This methodology has been our standard ratesetting methodology for blood and blood products since CY 2005. It was developed in response to data analysis indicating that there was a significant difference in CCRs for those hospitals with and without blood-specific cost centers and past public comments indicating that the former OPPS policy of defaulting to the overall hospital CCR for hospitals not reporting a blood-specific cost center often resulted in an underestimation of the true hospital costs for blood and blood products. To address the differences in CCRs and to better reflect hospitals' costs, our methodology simulates blood CCRs for each hospital that does not report a blood cost center by calculating the ratio of the blood-specific CCRs to hospitals' overall CCRs for those hospitals that do report costs and charges for blood cost centers and applies this mean ratio to the overall CCRs of hospitals not reporting costs and charges for blood cost centers on their cost reports. We propose to calculate the costs upon which the proposed payment rates for blood and blood products are based using the actual blood-specific CCR for hospitals that reported costs and charges for a blood cost center and a hospital-specific, simulated, blood-specific CCR for hospitals that did not report costs and charges for a blood cost center.
                    </P>
                    <P>We stated in the CY 2025 OPPS/ASC proposed rule that we continue to believe that the hospital-specific, simulated, blood-specific CCR methodology takes into account the unique charging and cost accounting structure of each hospital, as it better responds to the absence of a blood-specific CCR for a hospital than alternative methodologies, such as defaulting to the overall hospital CCR or applying an average blood-specific CCR across hospitals. This methodology also yields more accurate estimated costs for these products and results in payment rates for blood and blood products that appropriately reflect the relative estimated costs of these products for hospitals without blood cost centers and for these blood products in general.</P>
                    <P>
                        We refer readers to Addendum B to this final rule with comment period (which is available via the internet on the CMS website at 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        ) for the final CY 2025 payment rates for blood and blood products (which are generally identified with status indicator “R”).
                    </P>
                    <P>For a more detailed discussion of payments for blood and blood products through APCs, we refer readers to:</P>
                    <P>• the CY 2005 OPPS proposed rule (69 FR 50524 and 50525) for a more comprehensive discussion of the blood-specific CCR methodology;</P>
                    <P>• the CY 2008 OPPS/ASC final rule with comment period (72 FR 66807 through 66810) for a detailed history of the OPPS payment for blood and blood products; and</P>
                    <P>• the CY 2015 OPPS/ASC final rule with comment period (79 FR 66795 and 66796) for additional discussion of our policy not to make separate payments for blood and blood products when they appear on the same claims as services assigned to a C-APC.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment regarding the cost calculations for blood and blood products. The commenter stated that current payment rates do not always cover the cost to process, store, and transport the unit of blood. The commenter recommended that CMS utilize the average wholesale price (AWP) as the payment rate for blood products, in addition to basing payment rates on the hospital CCRs, as they believed using AWP would help eliminate outliers and produce more accurate payment calculations. The commenter explained that cost reporting methodologies may vary among hospitals. For example, some cost centers may combine blood products with blood bank testing which could skew the CCRs for that cost center, which would then impact the payment rates.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input and will keep it in mind for future rulemaking. However, we note that reflecting the range and variation of billing patterns across hospitals, as reflected in their claims, is part of establishing prospective payment rates. Additionally, we do not believe at this time that using AWP to set the payment rate for blood products would necessarily result in more accurate payment calculations, because AWP does not factor in volume discounts or rebates and, therefore, may not reflect the true cost of the product.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter supported our proposal to continue to pay separately for blood and blood products.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their support.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposals for blood and blood products using our blood-specific CCR methodology without modification. Please refer to Addendum B to this final rule with comment period, which is available on the CMS website, for the final CY 2025 payment rates for blood and blood products.</P>
                    <HD SOURCE="HD3">(b) New HCPCS Code for Red Blood Cell Product (HCPCS Code P9027)</HD>
                    <P>Effective October 1, 2024, the HCPCS workgroup created HCPCS code P9027 (Red blood cells, leukocytes reduced, oxygen/carbon dioxide reduced, each unit). HCPCS code P9027 may be used to bill for a blood product that utilizes a two-stage process to remove oxygen and maintain a deoxygenated state throughout its storage period, thereby preventing oxidative damage to red blood cells. We note that because HCPCS code P9027 was created after the CY 2025 OPPS/ASC proposed rule was issued, we did not include a proposal regarding the APC assignment for HCPCS code P9027 in the CY 2025 OPPS/ASC proposed rule. Due to its effective date, we assigned HCPCS code P9027 to APC 9541 with an SI = R (Blood and Blood Products) in Change Request 13784. The payment rate for HCPCS code P9027, effective October 1, 2024, is $252.48.</P>
                    <P>While we usually calculate payment rates for blood and blood products using our blood-specific CCR methodology, when there is no claims data on the charges and costs for blood products upon which to apply our blood-specific CCR methodology, we establish a payment rate for the new blood product based on a crosswalk to an existing blood product HCPCS code that we believe provides the best proxy for the costs of the new blood product. Because we did not have any claims data on HCPCS code P9027 ahead of its October 1, 2024, effective date, we used a crosswalk code to assign a payment rate for HCPCS code P9027. Specifically, we found that HCPCS code P9040 (Red blood cells, leukocytes reduced, irradiated, each unit) with a CY 2024 payment rate of $252.48 was sufficiently similar to P9027 to serve as a crosswalk for purposes of a payment rate assignment.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received a comment from the manufacturer of the blood product described by P9027. HCPCS code P9027 may be used to bill for the blood product involving the Hemanext ONE System. The commenter provided estimated cost information regarding the blood product, including an expected average per-unit anticipated hospital cost of $510. The manufacturer provided the estimated costs based on total blood establishment manufacturing costs, including the costs to manufacture a single unit of the starting materials, the sales price for the Hemanext ONE System, and the blood establishment labor, overhead, 
                        <PRTPAGE P="93924"/>
                        administrative, and shipping costs. The commenter noted that they believe their red blood cell product is potentially transformative and would provide improved health outcomes. The commenter stated that they believe the product whose CY 2024 Medicare payment rate reasonably approximates the projected average hospital acquisition cost for HCPCS P9027 is HCPCS code P9057 (Red blood cells, frozen/deglycerolized/washed/leukocytes reduced, irradiated, each unit), with a CY 2024 payment rate of $493.21 per unit. As such, the commenter recommends that CMS crosswalk the payment rate for HCPCS P9057 to HCPCS P9027. The commenter believes that a crosswalk to any other red blood cell product will result in a payment rate that does not cover the acquisition cost for HCPCS P9027 and creates patient access barriers.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their comment. Based on the additional cost information provided by the manufacturer, we believe that HCPCS code P9040 is not the best proxy for the costs of the blood product described by HCPCS code P9027. However, we disagree with the commenter that HCPCS code P9057 is the most appropriate crosswalk for new HCPCS code P9027 because the payment rate for HCPCS code P9057 reflects additional processes that are not reflected in the code descriptor for HCPCS code P9027. Given this difference in process, and the associated differences in estimated costs, we believe HCPCS code P9035 is a more appropriate proxy for the costs associated with HCPCS code P9027. Therefore, we are establishing an interim payment rate for HCPCS code P9027 based on a crosswalk to existing blood product HCPCS code P9035. Table 1 lists the new HCPCS code P9027 and its payment crosswalk.
                    </P>
                    <GPH SPAN="3" DEEP="150">
                        <GID>ER27NO24.000</GID>
                    </GPH>
                    <P>The interim payment rate for HCPCS code P9027 is open for public comment in this CY 2025 final rule with comment period. Specifically, HCPCS code P9027 is flagged with comment indicator “NI” in Addendum B to this final rule with comment period to indicate that we have assigned the codes an interim OPPS payment status for CY 2025 and are seeking public comments on the APC and status indicator assignments. Once we have claims data for this new HCPCS P-code, we will calculate a payment rate using the claims data that should be available for these new codes beginning in CY 2027, which is our practice for other blood products for which claims data have been available for 2 years.</P>
                    <HD SOURCE="HD3">(2) Brachytherapy Sources</HD>
                    <P>Section 1833(t)(2)(H) of the Act mandates the creation of additional groups of covered OPD services that classify devices of brachytherapy—cancer treatment through solid source radioactive implants—consisting of a seed or seeds (or radioactive source) (“brachytherapy sources”) separately from other services or groups of services. The statute provides certain criteria for the additional groups. For the history of OPPS payment for brachytherapy sources, we refer readers to prior OPPS final rules, such as the CY 2012 OPPS/ASC final rule with comment period (77 FR 68240 and 68241). As we have stated in prior OPPS updates, we believe that adopting the general OPPS prospective payment methodology for brachytherapy sources is appropriate for a number of reasons (77 FR 68240). The general OPPS methodology uses costs based on claims data to set the relative payment weights for hospital outpatient services. This payment methodology results in more consistent, predictable, and equitable payment amounts per source across hospitals by averaging the extremely high and low values, in contrast to payment based on hospitals' charges adjusted to costs. We believe that the OPPS methodology, as opposed to payment based on hospitals' charges adjusted to cost, also would provide hospitals with incentives for efficiency in the provision of brachytherapy services to Medicare beneficiaries. Moreover, this approach is consistent with our payment methodology for the vast majority of items and services paid under the OPPS. We refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70323 through 70325) for further discussion of the history of OPPS payment for brachytherapy sources.</P>
                    <P>
                        For CY 2025, except where otherwise indicated, we proposed to continue our policy and use the costs derived from CY 2023 claims data to set the proposed CY 2025 payment rates for brachytherapy sources because CY 2023 is the year of data we proposed to use to set the proposed payment rates for most other items and services that would be paid under the CY 2025 OPPS. With the exception of the proposed payment rate for brachytherapy source C2645 (Brachytherapy planar source, palladium-103, per square millimeter) and the proposed payment rates for low-volume brachytherapy APCs discussed in section III.D of the CY 2025 OPPS/ASC proposed rule, we proposed to base the payment rates for brachytherapy sources on the geometric mean unit costs for each source, consistent with the methodology that we proposed for other items and services paid under the OPPS, as discussed in section II.A.2 of the CY 2025 OPPS/ASC proposed rule. We also proposed for CY 2025 and subsequent years to continue the other payment policies for brachytherapy sources that we finalized and first implemented in the CY 2010 OPPS/ASC final rule with comment period (74 FR 
                        <PRTPAGE P="93925"/>
                        60537). For CY 2025 and subsequent years, we proposed to pay for the stranded and nonstranded not otherwise specified (NOS) codes, HCPCS codes C2698 (Brachytherapy source, stranded, not otherwise specified, per source) and C2699 (Brachytherapy source, non-stranded, not otherwise specified, per source), at a rate equal to the lowest stranded or nonstranded prospective payment rate for such sources, respectively, on a per-source basis (as opposed to, for example, per mCi), which is based on the policy we established in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66785). For CY 2025 and subsequent years, we also proposed to continue the policy we first implemented in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60537) regarding payment for new brachytherapy sources for which we have no claims data, based on the same reasons we discussed in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66786; which was delayed until January 1, 2010, by section 142 of Pub. L. 110-275). Specifically, this policy is intended to enable us to assign new HCPCS codes for new brachytherapy sources to their own APCs, with prospective payment rates set based on our consideration of external data and other relevant information regarding the expected costs of the sources to hospitals. The proposed CY 2025 payment rates for brachytherapy sources are included on Addendum B to the CY 2025 OPPS/ASC proposed rule (which is available via the internet on the CMS website) and identified with status indicator “U.”
                    </P>
                    <P>
                        For CY 2018, we assigned status indicator “U” (Brachytherapy Sources, Paid under OPPS; separate APC payment) to HCPCS code C2645 (Brachytherapy planar source, palladium-103, per square millimeter) in the absence of claims data and established a payment rate using external data (invoice price) at $4.69 per mm
                        <SU>2</SU>
                         for the brachytherapy source's APC-APC 2648 (Brachytx planar, p-103). For CY 2019, in the absence of sufficient claims data, we continued to establish a payment rate for C2645 at $4.69 per mm
                        <SU>2</SU>
                         for APC 2648 (Brachytx planar, p103). Our CY 2018 claims data available for the CY 2020 OPPS/ASC final rule with comment period (84 FR 61142) included two claims with a geometric mean cost for HCPCS code C2645 of $1.02 per mm
                        <SU>2</SU>
                        . In response to comments from interested parties, we agreed that, given the limited claims data available and a new outpatient indication for C2645, a payment rate for HCPCS code C2645 based on the geometric mean cost of $1.02 per mm
                        <SU>2</SU>
                         may not adequately reflect the cost of HCPCS code C2645. In the CY 2020 OPPS/ASC final rule with comment period, we finalized our policy to use our equitable adjustment authority under section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments, to maintain the CY 2019 payment rate of $4.69 per mm
                        <SU>2</SU>
                         for HCPCS code C2645 for CY 2020. Similarly, in the absence of sufficient claims data to establish an APC payment rate, in the CY 2021, CY 2022, CY 2023, and CY 2024 OPPS/ASC final rules with comment period (85 FR 85879 through 85880, 86 FR 63469, 87 FR 71760-71761, and 88 FR 81553), we finalized our policy to use our equitable adjustment authority under section 1833(t)(2)(E) of the Act to maintain the CY 2019 payment rate of $4.69 per mm
                        <SU>2</SU>
                         for HCPCS code C2645 for CYs 2021 through 2024.
                    </P>
                    <P>
                        There were no CY 2023 claims available that reported HCPCS code C2645 for the CY 2025 OPPS/ASC proposed rule. Therefore, in the absence of claims data, we proposed to continue to use our equitable adjustment authority under section 1833(t)(2)(E) of the Act to maintain the CY 2024 payment rate of $4.69 per mm
                        <SU>2</SU>
                         for HCPCS code C2645, which we proposed to be assigned to APC 2648 (Brachytx planar, p-103), for CY 2025.
                    </P>
                    <P>Additionally, for CY 2022 and subsequent calendar years, we adopted a Universal Low Volume APC policy for clinical and brachytherapy APCs. As discussed in further detail in section X.C of the CY 2022 OPPS/ASC final rule with comment period (86 FR 63743 through 63747), we adopted this policy to mitigate wide variation in payment rates that occur from year to year for APCs with low utilization. Such volatility in payment rates from year to year can result in even lower utilization and potential barriers to access. Brachytherapy APCs that have fewer than 100 single claims used for ratesetting purposes are designated as Low Volume APCs unless an alternative payment rate is applied, such as the use of our equitable adjustment authority under section 1833(t)(2)(E) of the Act in the case of APC 2648 (Brachytx planar, p-103), for which HCPCS code C2645 (Brachytherapy planar source, palladium-103, per square millimeter) is the only code assigned as discussed previously in this section.</P>
                    <P>For CY 2025, we proposed to designate six brachytherapy APCs as Low Volume APCs as these APCs meet our criteria to be designated as Low Volume APCs. For more information on the brachytherapy APCs we proposed to designate as Low Volume APCs, see section III.D of the CY 2025 OPPS/ASC proposed rule.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received support from commenters for our proposal to use our equitable adjustment authority under section 1833(t)(2)(E) of the Act to maintain the CY 2024 payment rate of $4.69 per mm
                        <SU>2</SU>
                         for HCPCS code C2645, which we proposed to assign to APC 2648 (Brachytx planar, p-103) for CY 2025.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their support.
                    </P>
                    <P>
                        After consideration of the public comment we received, we are finalizing, without modification, that we will use our equitable adjustment authority under section 1833(t)(2)(E) of the Act to maintain the CY 2024 payment rate of $4.69 per mm
                        <SU>2</SU>
                         for HCPCS code C2645, which we are assigning to APC 2648 (Brachytx planar, p-103), for CY 2025.
                    </P>
                    <P>
                        The final CY 2025 payment rates for brachytherapy sources are included in Addendum B to this final rule with comment period (which is available via the internet on the CMS website) and are identified with status indicator “U.” We continue to invite interested parties to submit recommendations for new codes to describe new brachytherapy sources. Such recommendations should be directed via email to 
                        <E T="03">outpatientpps@cms.hhs.gov</E>
                         or by mail to the Division of Outpatient Care, Mail Stop C4-01-26, Centers for Medicare and Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244. We will continue to add new brachytherapy source codes and descriptors to our systems for payment on a quarterly basis.
                    </P>
                    <HD SOURCE="HD3">b. Comprehensive APCs (C-APCs) for CY 2025</HD>
                    <HD SOURCE="HD3">(1) Background</HD>
                    <P>
                        In the CY 2014 OPPS/ASC final rule with comment period (78 FR 74861 through 74910), we finalized a comprehensive payment policy that packages payment for adjunctive and secondary items, services, and procedures into the most costly primary procedure under the OPPS at the claim level. The policy was finalized in CY 2014, but the effective date was delayed until January 1, 2015, to allow additional time for further analysis, opportunity for public comment, and systems preparation. The comprehensive APC (C-APC) policy was implemented effective January 1, 2015, with modifications and clarifications in response to public 
                        <PRTPAGE P="93926"/>
                        comments received regarding specific provisions of the C-APC policy (79 FR 66798 through 66810).
                    </P>
                    <P>A C-APC is defined as a classification for the provision of a primary service and all adjunctive services provided to support the delivery of the primary service. We established C-APCs as a category broadly for OPPS payment and implemented 25 C-APCs beginning in CY 2015 (79 FR 66809 and 66810). We have gradually added new C-APCs since the policy was implemented beginning in CY 2015, with the number of C-APCs now totaling 72 (80 FR 70332; 81 FR 79584 and 79585; 83 FR 58844 through 58846; 84 FR 61158 through 61166; 85 FR 85885; 86 FR 63474; 87 FR 71769; and 88 FR 81562).</P>
                    <P>Under our C-APC policy, we designate a service described by a HCPCS code assigned to a C-APC as the primary service when the service is identified by OPPS status indicator “J1.” When such a primary service is reported on a hospital outpatient claim, taking into consideration the few exceptions that are discussed below, we make payment for all other items and services reported on the hospital outpatient claim as being integral, ancillary, supportive, dependent, and adjunctive to the primary service (hereinafter collectively referred to as “adjunctive services”) and representing components of a complete comprehensive service (78 FR 74865 and 79 FR 66799). Payments for adjunctive services are packaged into the payments for the primary services. This results in a single prospective payment for each of the primary, comprehensive services based on the costs of all reported services at the claim level. One example of a primary service would be a partial mastectomy and an example of a secondary service packaged into that primary service would be a radiation therapy procedure.</P>
                    <P>
                        Services excluded from the C-APC policy under the OPPS include services that are not covered OPD services, services that cannot by statute be paid for under the OPPS, and services that are required by statute to be separately paid. This includes certain mammography and ambulance services that are not covered OPD services in accordance with section 1833(t)(1)(B)(iv) of the Act; brachytherapy seeds, which also are required by statute to receive separate payment under section 1833(t)(2)(H) of the Act; pass-through payment drugs and devices, which also require separate payment under section 1833(t)(6) of the Act; self-administered drugs (SADs) that are not otherwise packaged as supplies because they are not covered under Medicare Part B under section 1861(s)(2)(B) of the Act; and certain preventive services (78 FR 74865 and 79 FR 66800 and 66801). A list of services excluded from the C-APC policy is included in Addendum J to this final rule (which is available via the internet on the CMS website at 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        ). If a service does not appear on this list of excluded services, payment for it will be packaged into the payment for the primary C-APC service when it appears on an outpatient claim with a primary C-APC service.
                    </P>
                    <P>The C-APC policy payment methodology set forth in the CY 2014 OPPS/ASC final rule with comment period and modified and implemented beginning in CY 2015 is summarized as follows (78 FR 74887 and 79 FR 66800):</P>
                    <P>
                        <E T="03">Basic Methodology.</E>
                         As stated in the CY 2015 OPPS/ASC final rule with comment period, we define the C-APC payment policy as including all covered OPD services on a hospital outpatient claim reporting a primary service that is assigned to status indicator “J1,” 
                        <SU>2</SU>
                        <FTREF/>
                         excluding services that are not covered OPD services or that cannot by statute be paid for under the OPPS. Services and procedures described by HCPCS codes assigned to status indicator “J1” are assigned to C-APCs based on our usual APC assignment methodology by evaluating the geometric mean costs of the primary service claims to establish resource similarity and the clinical characteristics of each procedure to establish clinical similarity within each APC.
                    </P>
                    <FTNT>
                        <P>
                            <SU>2</SU>
                             Status indicator “J1” denotes Hospital Part B Services Paid Through a Comprehensive APC. Further information can be found in CY 2025 Addendum D1.
                        </P>
                    </FTNT>
                    <P>
                        In the CY 2016 OPPS/ASC final rule with comment period, we expanded the C-APC payment methodology to qualifying extended assessment and management encounters through the “Comprehensive Observation Services” C-APC (C-APC 8011). Services within this APC are assigned status indicator “J2.” 
                        <SU>3</SU>
                        <FTREF/>
                         Specifically, we make a payment through C-APC 8011 for a claim that:
                    </P>
                    <FTNT>
                        <P>
                            <SU>3</SU>
                             Status indicator “J2” denotes Hospital Part B Services That May Be Paid Through a Comprehensive APC. Further information can be found in CY 2025 Addendum D1.
                        </P>
                    </FTNT>
                    <P>• Does not contain a procedure described by a HCPCS code to which we have assigned status indicator “T;”</P>
                    <P>• Contains 8 or more units of services described by HCPCS code G0378 (Hospital observation services, per hour);</P>
                    <P>• Contains services provided on the same date of service or one day before the date of service for HCPCS code G0378 that are described by one of the following codes: HCPCS code G0379 (Direct admission of patient for hospital observation care) on the same date of service as HCPCS code G0378; CPT code 99281 (Emergency department visit for the evaluation and management of a patient (Level 1)); CPT code 99282 (Emergency department visit for the evaluation and management of a patient (Level 2)); CPT code 99283 (Emergency department visit for the evaluation and management of a patient (Level 3)); CPT code 99284 (Emergency department visit for the evaluation and management of a patient (Level 4)); CPT code 99285 (Emergency department visit for the evaluation and management of a patient (Level 5)) or HCPCS code G0380 (Type B emergency department visit (Level 1)); HCPCS code G0381 (Type B emergency department visit (Level 2)); HCPCS code G0382 (Type B emergency department visit (Level 3)); HCPCS code G0383 (Type B emergency department visit (Level 4)); HCPCS code G0384 (Type B emergency department visit (Level 5)); CPT code 99291 (Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes); or HCPCS code G0463 (Hospital outpatient clinic visit for assessment and management of a patient); and</P>
                    <P>• Does not contain services described by a HCPCS code to which we have assigned status indicator “J1.”</P>
                    <P>The assignment of status indicator “J2” to a specific set of services performed in combination with each other allows for all other OPPS payable services and items reported on the claim (excluding services that are not covered OPD services or that cannot by statute be paid for under the OPPS) to be deemed adjunctive services representing components of a comprehensive service and resulting in a single prospective payment for the comprehensive service based on the costs of all reported services on the claim (80 FR 70333 through 70336).</P>
                    <P>
                        Services included under the C-APC payment packaging policy, that is, services that are typically adjunctive to the primary service and provided during the delivery of the comprehensive service, include diagnostic procedures, laboratory tests, and other diagnostic tests and treatments that assist in the delivery of the primary procedure; visits and evaluations performed in association with the procedure; uncoded services and supplies used during the service; durable medical equipment as well as prosthetic and 
                        <PRTPAGE P="93927"/>
                        orthotic items and supplies when provided as part of the outpatient service; and any other components reported by HCPCS codes that represent services that are provided during the complete comprehensive service (78 FR 74865 and 79 FR 66800).
                    </P>
                    <P>In addition, payment for hospital outpatient department services that are similar to therapy services, such as speech language pathology, and delivered either by therapists or nontherapists is included as part of the payment for the packaged complete comprehensive service. These services that are provided during the perioperative period are adjunctive services and are deemed not to be therapy services as described in section 1834(k) of the Act, regardless of whether the services are delivered by therapists or other nontherapist health care workers. We have previously noted that therapy services are those provided by therapists under a plan of care in accordance with section 1835(a)(2)(C) and section 1835(a)(2)(D) of the Act and are paid for under section 1834(k) of the Act, subject to annual therapy caps as applicable (78 FR 74867 and 79 FR 66800). However, certain other services similar to therapy services are considered and paid for as hospital outpatient department services. Payment for these nontherapy outpatient department services that are reported with therapy codes and provided with a comprehensive service is included in the payment for the packaged complete comprehensive service. We note that these services, even though they are reported with therapy codes, are hospital outpatient department services and not therapy services. We refer readers to the July 2016 OPPS Change Request 9658 (Transmittal 3523) for further instructions on reporting these services in the context of a C-APC service.</P>
                    <P>
                        Items included in the packaged payment provided in conjunction with the primary service also include all drugs, biologicals, and radiopharmaceuticals, regardless of cost, except those drugs with pass-through payment status and SADs, unless they function as packaged supplies (78 FR 74868, 74869, and 74909 and 79 FR 66800). We refer readers to Section 50.2M, Chapter 15, of the Medicare Benefit Policy Manual for a description of our policy on SADs treated as hospital outpatient supplies, including lists of SADs that function as supplies and those that do not function as supplies.
                        <SU>4</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>4</SU>
                             
                            <E T="03">https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf</E>
                            .
                        </P>
                    </FTNT>
                    <P>We define each hospital outpatient claim reporting a single unit of a single primary service assigned to status indicator “J1” as a single “J1” unit procedure claim (78 FR 74871 and 79 FR 66801). Line-item charges for services included on the C-APC claim are converted to line-item costs, which are then summed to develop the estimated APC costs. These claims are then assigned one unit of the service with status indicator “J1” and later used to develop the geometric mean costs for the C-APC relative payment weights. (We note that we use the term “comprehensive” to describe the geometric mean cost of a claim reporting “J1” service(s) or the geometric mean cost of a C-APC, inclusive of all the items and services included in the C-APC service payment bundle.) Charges for services that would otherwise be separately payable are added to the charges for the primary service. This process differs from our traditional cost accounting methodology only in that all such services on the claim are packaged (except certain services as described above). We apply our standard data trims, which exclude claims with extremely high primary units or extreme costs.</P>
                    <P>The comprehensive geometric mean costs are used to establish resource similarity and, along with clinical similarity, dictate the assignment of the primary services to the C-APCs. We establish a ranking of each primary service (single unit only) to be assigned to status indicator “J1” according to its comprehensive geometric mean costs. For the minority of claims reporting more than one primary service assigned to status indicator “J1” or units thereof, we identify one “J1” service as the primary service for the claim based on our cost-based ranking of primary services. We then assign these multiple “J1” procedure claims to the C-APC to which the service designated as the primary service is assigned. If the reported “J1” services on a claim map to different C-APCs, we designate the “J1” service assigned to the C-APC with the highest comprehensive geometric mean cost as the primary service for that claim. If the reported multiple “J1” services on a claim map to the same C-APC, we designate the most costly service (at the HCPCS code level) as the primary service for that claim. This process results in initial assignments of claims for the primary services assigned to status indicator “J1” to the most appropriate C-APCs based on both single and multiple procedure claims reporting these services and clinical and resource homogeneity.</P>
                    <P>
                        <E T="03">Complexity Adjustments.</E>
                         We use complexity adjustments to provide increased payment for certain comprehensive services. We apply a complexity adjustment by promoting qualifying paired “J1” service code combinations or paired code combinations of “J1” services and certain add-on codes (as described further below) from the originating C-APC (the C-APC to which the designated primary service is first assigned) to the next higher paying C-APC in the same clinical family of C-APCs. We apply this type of complexity adjustment when the paired code combination represents a complex, costly form or version of the primary service according to the following criteria:
                    </P>
                    <P>• Frequency of 25 or more claims reporting the code combination (frequency threshold); and</P>
                    <P>• Violation of the 2 times rule, as stated in section 1833(t)(2) of the Act and section III.B.2 of this final rule with comment period, in the originating C-APC (cost threshold).</P>
                    <P>These criteria identify paired code combinations that occur commonly and exhibit materially greater resource requirements than the primary service. The CY 2017 OPPS/ASC final rule with comment period (81 FR 79582) included a revision to the complexity adjustment eligibility criteria. Specifically, we finalized a policy to discontinue the requirement that a code combination (that qualifies for a complexity adjustment by satisfying the frequency and cost criteria thresholds described above) also not create a 2 times rule violation in the higher level or receiving APC.</P>
                    <P>After designating a single primary service for a claim, we evaluate that service in combination with each of the other procedure codes reported on the claim assigned to status indicator “J1” (or certain add-on codes) to determine if there are paired code combinations that meet the complexity adjustment criteria. For a new HCPCS code, we determine initial C-APC assignment and qualification for a complexity adjustment using the best available information, crosswalking the new HCPCS code to a predecessor code(s) when appropriate.</P>
                    <P>
                        Once we have determined that a particular code combination of “J1” services (or combinations of “J1” services reported in conjunction with certain add-on codes) represents a 
                        <PRTPAGE P="93928"/>
                        complex version of the primary service because it is sufficiently costly, frequent, and a subset of the primary comprehensive service overall according to the criteria described above, we promote the claim including the complex version of the primary service as described by the code combination to the next higher cost C-APC within the clinical family, unless the primary service is already assigned to the highest cost APC within the C-APC clinical family or assigned to the only C-APC in a clinical family. We do not create new APCs with a comprehensive geometric mean cost that is higher than the highest geometric mean cost (or only) C-APC in a clinical family just to accommodate potential complexity adjustments. Therefore, the highest payment for any claim including a code combination for services assigned to a C-APC would be the highest paying C-APC in the clinical family (79 FR 66802).
                    </P>
                    <P>We package payment for all add-on codes into the payment for the C-APC. However, certain primary service add-on combinations may qualify for a complexity adjustment. As noted in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70331), all add-on codes that can be appropriately reported in combination with a base code that describes a primary “J1” service are evaluated for a complexity adjustment.</P>
                    <P>
                        To determine which combinations of primary service codes reported in conjunction with an add-on code may qualify for a complexity adjustment for CY 2025, we apply the frequency and cost criteria thresholds discussed above, testing claims reporting one unit of a single primary service assigned to status indicator “J1” and any number of units of a single add-on code for the primary “J1” service. If the frequency and cost criteria thresholds for a complexity adjustment are met and reassignment to the next higher cost APC in the clinical family is appropriate (based on meeting the criteria outlined above), we make a complexity adjustment for the code combination; that is, we reassign the primary service code reported in conjunction with the add-on code to the next higher cost C-APC within the same clinical family of C-APCs. As previously stated, we package payment for add-on codes into the C-APC payment rate. If any add-on code reported in conjunction with the “J1” primary service code does not qualify for a complexity adjustment, payment for the add-on service continues to be packaged into the payment for the primary service and is not reassigned to the next higher cost C-APC. We list the complexity adjustments for “J1” and add-on code combinations for CY 2025, along with all the other final complexity adjustments, in Addendum J to this final rule with comment period (which is available via the internet on the CMS website at 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        ).
                    </P>
                    <P>Addendum J to this final rule with comment period includes the cost statistics for each code combination that would qualify for a complexity adjustment (including primary code and add-on code combinations). Addendum J to this final rule with comment period also contains summary cost statistics for each of the paired code combinations that describe a complex code combination that would qualify for a complexity adjustment and be reassigned to the next higher cost C-APC within the clinical family. The combined statistics for all proposed reassigned complex code combinations are represented by an alphanumeric code with the first four digits of the designated primary service followed by a letter. For example, the proposed geometric mean cost listed in Addendum J for the code combination described by complexity adjustment assignment 3320R, which is assigned to C-APC 5224 (Level 4 Pacemaker and Similar Procedures), includes all paired code combinations that will be reassigned to C-APC 5224 when CPT code 33208 is the primary code. Providing the information contained in Addendum J to this final rule with comment period allows interested parties the opportunity to better assess the impact associated with the assignment of claims with each of the paired code combinations eligible for a complexity adjustment.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received support from commenters for a variety of existing and proposed complexity adjustments.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their support.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Multiple commenters requested that CMS apply a complexity adjustment to additional code combinations. The specific C-APC complexity adjustment code combinations requested by the commenters for CY 2025 are listed in Table 2.
                    </P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="93929"/>
                        <GID>ER27NO24.001</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="93930"/>
                        <GID>ER27NO24.002</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <P>
                        <E T="03">Response:</E>
                         We reviewed each of the requested code combinations suggested by commenters, listed in Table 2, against our complexity adjustment 
                        <PRTPAGE P="93931"/>
                        criteria. The code combination for primary HCPCS code 28296 with secondary HCPCS code 28270 meets our cost and frequency criteria, qualifying for a complexity adjustment for CY 2025. All the remaining code combinations listed failed to meet our cost or frequency criteria and do not qualify for complexity adjustments for CY 2025. Addendum J to this final rule with comment period includes the cost statistics for each code combination that was evaluated for a complexity adjustment.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters requested that CMS modify, waive, or eliminate the established C-APC complexity adjustment eligibility criteria of 25 or more claims reporting the code combination (frequency) and a violation of the 2 times rule in the originating C-APC (cost) to allow additional code combinations to qualify for complexity adjustments. These commenters were concerned that C-APC packaging and a lack of complexity adjustment would limit access to procedures. Specifically, some commenters expressed concern that CMS's methodology for determining complexity adjustments is unnecessarily restrictive, particularly the 25-claim threshold, and suggested that CMS eliminate the 25-claim threshold and implement a complexity adjustment whenever a code pair exceeds the cost threshold.
                    </P>
                    <P>Some commenters were concerned that when multiple “J1” primary services are reported on a claim, along with an add-on service, the add-on service is not evaluated for a complexity adjustment. Commenters cited examples where significant claims volume from add-on services may not be incorporated into the complexity adjustment evaluation. Commenters also reiterated requests to broaden the complexity adjustment policy and allow clusters of procedures, consisting of a “J1” code pair and multiple other associated add-on codes used in combination with that “J1” code pair, to qualify for complexity adjustments. Commenters stated that there are certain complex procedures that include numerous add-on codes and this approach would allow more accurate reflection of the cost of medical practice when multiple procedures are performed together. They noted that lack of additional payment for these code combinations can present a financial challenge for the providers who perform these more resource intensive services.</P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate these comments. At this time, we do not believe changes to the C-APC complexity adjustment criteria are necessary or that we should make exceptions to the criteria to allow claims with the code combinations suggested by the commenters to receive complexity adjustments. As we stated in the CY 2017 OPPS/ASC final rule (81 FR 79582), we believe that the complexity adjustment criteria, which require a frequency of 25 or more claims reporting a code combination and a violation of the 2 times rule in the originating C-APC, are appropriate to determine if a combination of procedures represents a complex, costly subset of the primary service that should qualify for the adjustment and be paid at the next higher paying C-APC in the clinical family. As we also previously stated in the CY 2020 OPPS/ASC final rule with comment period (84 FR 61161), a minimum of 25 claims is already a very low threshold for a national payment system. Lowering the minimum of 25 claims further could lead to unnecessary complexity adjustments for service combinations that are rarely performed.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A few commenters suggested that to help maintain better stability and predictability of payments associated with complex procedures, CMS should revise the complexity adjustment policy by allowing qualifying codes to maintain the complexity adjusted payment for three calendar years before they are required to go through the eligibility review. For codes that do not qualify in a given year, they could be evaluated in the next calendar year. Commenters asserted that the updated cadence would allow more time for providers and coders to be educated on new code pairs that qualify for complexity adjustments and it would help promote payment stability and predictability for these complex procedures.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         For the OPPS ratesetting process, our goal is to use the best available data for ratesetting to accurately estimate the costs associated with furnishing outpatient services and to set appropriate payment rates. We evaluate code combinations each year against our complexity adjustment criteria using the latest available data. Potentially maintaining complexity adjustments that are not supported by the latest data could undermine our goals for the ratesetting process.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A few commenters requested that CMS provide additional information on the rationale for not counting claims that reflect code combinations of services that would otherwise meet the frequency criteria needed to receive a complexity adjustment. Commenters conducted their own data modeling using data reflecting all code combinations that met the frequency criteria needed to receive a complexity adjustment. Commenters asked for greater transparency on the methodology CMS used to evaluate the complexity adjustment frequency criteria for code combinations.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We refer commenters to the claims accounting narrative under supporting documentation for this CY 2025 OPPS/ASC final rule on the CMS website at: 
                        <E T="03">https://www.cms.gov/files/document/2025-nprm-opps-claims-accounting.pdf</E>
                        . The claims accounting narrative provides a detailed overview of how CMS processes the CY 2023 claims data to produce the proposed prospective CY 2025 OPPS payment rates. We are updating the section on Comprehensive APCs in order to provide additional clarity on the claims accounting process used for determining complexity adjustments.
                    </P>
                    <P>
                        After consideration of the public comments we received, we are finalizing the C-APC complexity adjustment policy for CY 2025 as proposed. We are also finalizing the proposed complexity adjustments, with the addition of one new code combination (
                        <E T="03">i.e.,</E>
                         primary HCPCS code 28296 with secondary HCPCS code 28270) suggested by commenters that meets our complexity adjustment criteria.
                    </P>
                    <HD SOURCE="HD3">(2) Exclusion of Procedures Assigned to New Technology APCs From the C-APC Policy</HD>
                    <P>Services that are assigned to New Technology APCs are typically new procedures that do not have sufficient claims history to establish an accurate payment for them. Beginning in CY 2002, we retain services within New Technology APC groups until we gather sufficient claims data to enable us to assign the service to an appropriate clinical APC. This policy allows us to move a service from a New Technology APC in less than 2 years if sufficient data are available. It also allows us to retain a service in a New Technology APC for more than 2 years if sufficient data upon which to base a decision for reassignment have not been collected (82 FR 59277).</P>
                    <P>
                        The C-APC payment policy packages payment for adjunctive and secondary items, services, and procedures into the most costly primary procedure under the OPPS at the claim level. Prior to CY 2019, when a procedure assigned to a New Technology APC was included on the claim with a primary procedure, identified by OPPS status indicator “J1,” payment for the new technology service was typically packaged into the payment for the primary procedure. 
                        <PRTPAGE P="93932"/>
                        Because the new technology service was not separately paid in this scenario, the overall number of single claims available to determine an appropriate clinical APC for the new service was reduced. This was contrary to the objective of the New Technology APC payment policy, which is to gather sufficient claims data to enable us to assign the service to an appropriate clinical APC.
                    </P>
                    <P>To address this issue and ensure that there are sufficient claims data for services assigned to New Technology APCs, in the CY 2019 OPPS/ASC final rule with comment period (83 FR 58847), we finalized excluding payment for any procedure that is assigned to a New Technology APC (APCs 1491 through 1599 and APCs 1901 through 1908) from being packaged when included on a claim with a “J1” service assigned to a C-APC. In the CY 2020 OPPS/ASC final rule with comment period, we finalized that beginning in CY 2020, payment for services assigned to a New Technology APC would be excluded from being packaged into the payment for comprehensive observation services assigned status indicator “J2” when they are included on a claim with a “J2” service (84 FR 61167).</P>
                    <HD SOURCE="HD3">(3) Exclusion of Drugs and Biologicals Described by HCPCS Code C9399 (Unclassified Drugs or Biologicals) From the C-APC Policy</HD>
                    <P>Section 1833(t)(15) of the Act, as added by section 621(a)(1) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. 108-173), provides for payment under the OPPS for new drugs and biologicals until HCPCS codes are assigned. Under this provision, we are required to make payment for a covered outpatient drug or biological that is furnished as part of covered outpatient department services but for which a HCPCS code has not yet been assigned in an amount equal to 95 percent of average wholesale price (AWP) for the drug or biological.</P>
                    <P>In the CY 2005 OPPS/ASC final rule with comment period (69 FR 65805), we implemented section 1833(t)(15) of the Act by instructing hospitals to bill for a drug or biological that is newly approved by the Food and Drug Administration (FDA) and that does not yet have a HCPCS code by reporting the National Drug Code (NDC) for the product along with the newly created HCPCS code C9399 (Unclassified drugs or biologicals). We explained that when HCPCS code C9399 appears on a claim, the Outpatient Code Editor (OCE) suspends the claim for manual pricing by the Medicare Administrative Contractor (MAC). The MAC prices the claim at 95 percent of the drug or biological's AWP, using Red Book or an equivalent recognized compendium, and processes the claim for payment. We emphasized that this approach enables hospitals to bill and receive payment for a new drug or biological concurrent with its approval by the FDA. The hospital does not have to wait for the next quarterly release or for approval of a product specific HCPCS code to receive payment for a newly approved drug or biological or to resubmit claims for adjustment. We instructed that hospitals would discontinue billing HCPCS code C9399 and the NDC upon implementation of a product specific HCPCS code, status indicator, and appropriate payment amount with the next quarterly update. We also note that HCPCS code C9399 is paid in a similar manner in the ASC setting, as 42 CFR 416.171(b) outlines that certain drugs and biologicals for which separate payment is allowed under the OPPS are considered covered ancillary services for which the OPPS payment rate, which is 95 percent of AWP for HCPCS code C9399, applies. Since the implementation of the C-APC policy in 2015, payment for drugs and biologicals described by HCPCS code C9399 had been included in the C-APC payment when these products appear on a claim with a primary C-APC service. Packaging payment for these drugs and biologicals that appear on a hospital outpatient claim with a primary C-APC service is consistent with our C-APC packaging policy under which we make payment for all items and services, including all non-pass-through drugs, reported on the hospital outpatient claim as being integral, ancillary, supportive, dependent, and adjunctive to the primary service and representing components of a complete comprehensive service, with certain limited exceptions (78 FR 74869). It was our position that the total payment for the C-APC with which payment for a drug or biological described by HCPCS code C9399 is packaged includes payment for the drug or biological at 95 percent of its AWP.</P>
                    <P>However, we determined that in certain instances, drugs and biologicals described by HCPCS code C9399 are not being paid at 95 percent of their AWPs when payment for them is packaged with payment for a primary C-APC service. In order to ensure payment for new drugs, biologicals, and radiopharmaceuticals described by HCPCS code C9399 at 95 percent of their AWP, for CY 2023 and subsequent years, we finalized our proposal to exclude any drug, biological, or radiopharmaceutical described by HCPCS code C9399 from packaging when the drug, biological, or radiopharmaceutical is included on a claim with a “J1” service, which is the status indicator assigned to a C-APC, and a claim with a “J2” service, which is the status indicator assigned to comprehensive observation services. See Addendum J for the CY 2025 C-APC payment policy exclusions.</P>
                    <P>In the CY 2023 OPPS/ASC final rule with comment period, we finalized the proposal in section XI “CY 2023 OPPS Payment Status and Comment Indicators” to add a new definition to status indicator “A” to include unclassified drugs and biologicals that are reportable with HCPCS code C9399 (87 FR 72051). The definition, found in Addendum D1, would ensure the MAC prices claims for drugs, biologicals, or radiopharmaceuticals billed with HCPCS code C9399 at 95 percent of the drug or biological's AWP and pays separately for the drug, biological, or radiopharmaceutical under the OPPS when it appears on the same claim as a primary C-APC service.</P>
                    <HD SOURCE="HD3">(4) Exclusion of Cell and Gene Therapies From the C-APC Policy</HD>
                    <P>As previously discussed in this section, and in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74865), the C-APC policy packages payment for items and services that are typically integral, ancillary, supportive, dependent, or adjunctive to the primary service and provided during the delivery of the comprehensive service, including diagnostic procedures, laboratory tests and other diagnostic tests and treatments that assist in the delivery of the primary procedure. In the CY 2014 OPPS/ASC final rule (78 FR 74861), we finalized defining a comprehensive APC as a classification for the provision of a primary service and all adjunctive services provided to support the delivery of the primary service. Because a comprehensive APC treats all individually reported codes as representing components of the comprehensive service, we make a single prospective payment based on the cost of all individually reported codes that represent the provision of a primary service and all adjunctive services provided to support that delivery of the primary service.</P>
                    <P>
                        As discussed in the CY 2025 OPPS/ASC proposed rule (89 FR 59201 through 59204), we generally treat all items and services reported on a C-APC claim as integral, ancillary, supportive, dependent, and adjunctive to the primary service and representing 
                        <PRTPAGE P="93933"/>
                        components of a comprehensive service. Historically, items packaged for payment provided in conjunction with the primary C-APC service also include all drugs, biologicals, and radiopharmaceuticals, regardless of cost, except those drugs with pass-through payment status and those drugs that are usually self-administered (SADs), unless they function as supplies (78 FR 74868 through 74869 and 74909).
                    </P>
                    <P>
                        Our intent has been to make a single prospective payment based on the cost of all individually reported codes that appear on a claim with the primary C-APC service, which we believe represent the provision of a primary service and all adjunctive services provided to support that delivery of the primary service. We discussed in the CY 2025 OPPS/ASC proposed rule (89 FR 59201 through 59204), there are rare instances where the cell and gene therapies listed in Table 3, which are usually separately payable under the OPPS, appear on the same claim as a primary C-APC service and therefore, have their payment packaged with payment for the primary C-APC service. The therapies in Table 3 are usually separately paid and priced using the ASP methodology when not on a C-APC claim. Given the unique nature of these therapies, we do not believe they function as integral, ancillary, supportive, dependent, or adjunctive to any of the current C-APCs primary services. The cell therapies described in Table 3 are primarily for the treatment of specific cancers and are administered through an intravenous infusion. The gene therapies listed in Table 3 are generally for the treatment of certain rare ocular or spinal conditions caused by specific genetic mutations and are also either intravenously infused or administered through a subretinal injection. When these products are administered, they are the primary treatment being administered to a patient and thus, are not integral, ancillary, supportive, dependent, or adjunctive to any primary C-APC services. Additionally, the current primary C-APC services describe common surgical procedures, such as breast/lymphatic surgery and musculoskeletal procedures. The cell and gene therapies listed in Table 3 are intended to treat a specific condition and would not be used to support the outcome of any primary C-APC procedure. For example, HCPCS code J3399 (Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10‸15 vector genomes) may be used to describe the gene therapy Zolgensma. This product is FDA-approved as an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. The specified mechanism of onasemnogene abeparvovec is a recombinant AAV9-based gene therapy designed to deliver a copy of the gene encoding the human SMN protein.
                        <SU>5</SU>
                        <FTREF/>
                         The function of a product such as Zolgensma, is not intended to be integral, ancillary, supportive, dependent, and adjunctive to any C-APC as the gene therapy itself is an independent treatment.
                    </P>
                    <FTNT>
                        <P>
                            <SU>5</SU>
                             Zolgensma. FDA Package Insert. October 2023. 
                            <E T="03">https://www.fda.gov/media/126109/download?attachment.</E>
                        </P>
                    </FTNT>
                    <P>
                        Yescarta (HCPCS code Q2041) is an example of a cell therapy that functions as an independent treatment. Based on its FDA-approved indication,
                        <SU>6</SU>
                        <FTREF/>
                         this product's intended clinical use would not be integral, ancillary, supportive, dependent, or adjunctive to any current C-APC primary service. Yescarta is indicated as a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy and adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Yescarta is the primary treatment being performed when administered for these FDA-approved indications and should not be packaged as supportive of any C-APC primary service even if the two services appear on the same claim.
                    </P>
                    <FTNT>
                        <P>
                            <SU>6</SU>
                             FDA Package Insert. Yescarta. April 2024. 
                            <E T="03">https://www.fda.gov/media/108377/download?attachment.</E>
                        </P>
                    </FTNT>
                    <P>We explained in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74868) that intravenous drugs, for example, are OPPS services that are considered adjunctive to the primary procedure because the correct administration of the drug either promotes a beneficial outcome, such as the use of intravenous pain medications, or prevents possible complications, such as the use of intravenous blood pressure medications to temporarily replace oral blood pressure medications and reduce the risk of a sudden rise in blood pressure when a normal daily medication is stopped. In the case of the cell and gene therapies described in Table 3, however, we do not believe the therapies “promote a beneficial outcome” or “prevent possible complications” of any of the procedures currently designated as primary C-APC services. While the cell and gene therapies in Table 3 may “promote a beneficial outcome” for the patient in general, we do not believe the provision of cell and gene therapies are “promoting a beneficial outcome” for any of the primary C-APC services themselves, as the cell and gene therapies are serving as independent therapies. These are distinguishable from the previous examples of intravenous pain medications that are directly related to the primary C-APC service and promote a beneficial outcome for that procedure. Further, in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74865), we stated that we proposed to package into C-APCs all of these integral, ancillary, supportive, dependent, and adjunctive services, hereinafter collectively referred to as “adjunctive services,” provided during the delivery of the comprehensive service. This includes the diagnostic procedures, laboratory tests and other diagnostic tests, and treatments that assist in the delivery of the primary procedure. In the CY 2025 OPPS/ASC proposed rule (89 FR 59201 through 59204), we stated we did not believe that the cell and gene therapies listed in Table 3 are assisting in the delivery of any primary procedure currently assigned to a C-APC.</P>
                    <P>Therefore, for CY 2025 only, we proposed not to package payment for the cell and gene therapies listed in Table 3 into the payment for the primary C-APC service when they appear on the same claim as primary C-APCs services. We proposed this policy for one year only in order to gather more information from interested parties as to whether the proposed policy appropriately captures all of the unique therapies, such as the cell and gene therapies listed in Table 3, that function as primary treatments and do not support C-APC primary services. As discussed later in this section, we welcomed comments from readers on the proposal and the potential need for a different, modified, expanded, or supplemental policy for future rulemaking. We stated we will assess whether to continue this policy, or a modified version of this policy, beyond one year in future rulemaking, taking into consideration the comments received.</P>
                    <P>
                        We did not propose to include therapies that are on drug pass-through status for all of CY 2025 in Table 3 
                        <PRTPAGE P="93934"/>
                        because pass-through drugs are already excluded from C-APC packaging. We proposed that products for which pass-through status is expiring in CY 2025 would be excluded from C-APC packaging after their pass-through status expires. For example, the product described by HCPCS code Q2056 has pass-through status expiring June 30, 2025. Until its pass-through status expires, the product will be excluded from C-APC packaging due to the pass-through C-APC exclusion policy, but after its pass-through status expires, we propose that the therapy would continue to be excluded from C-APC packaging under our proposed exclusion for cell and gene therapies. For more information on drug pass-through status, including expiring and continuing pass-through status, please see section V.A of this final rule with comment period.
                    </P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="559">
                        <GID>ER27NO24.003</GID>
                    </GPH>
                    <PRTPAGE P="93935"/>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <P>We proposed to exclude the therapies listed in Table 3 from C-APC packaging. We invited comment on the proposal, and we invited comment on whether there are any additional cell and gene therapies that may be appropriate to exclude from C-APC packaging for CY 2025. We asked commenters to explain why any additional cell and gene therapies that they believe should be excluded from C-APC packaging were not integral, ancillary, supportive, dependent, or adjunctive to any C-APC primary service. We invited comment on whether the proposal should be extended beyond 1 year or if a different, expanded, or supplemental policy approach may be warranted in future rulemaking. For example, we were interested in comments on whether there are other classes of drugs, biologicals, or other products that are not clearly integral, ancillary, adjunctive, or supportive of a primary C-APC service but could appear on the same claim as the C-APC for that primary service and for which payment would be packaged into the C-APC payment under our current policy. We stated that we would expect clinical evidence supporting commenters' assertion that other identified classes of drugs, biologicals, medical devices, or other products are not clearly supportive of a primary C-APC service but may nonetheless appear on the same claim as a primary C-APC procedure. Similarly, we invited comment on whether interested parties believe it is appropriate for these other classes of drugs, biologicals, or medical devices to be excluded from packaging with all C-APCs or only specific C-APCs, such as the Comprehensive Observation Services C-APC (SI = “J2”).</P>
                    <P>Finally, we invited comment on the following:</P>
                    <P>• Because the cell and gene therapies listed in Table 3 are not integral, ancillary, supportive, dependent, or adjunctive to any current C-APC procedure, how could CMS structure a new C-APC, or similar packaged payment policy, for the service to administer cell or gene therapies, such by creating as a Chimeric Antigen Receptor (CAR) T-cell therapy administration C-APC, with which the CAR-T or gene therapy would be integral, ancillary, supportive, dependent, or adjunctive to the primary C-APC service? What integral, ancillary, supportive, dependent, or adjunctive items and services are routinely provided as part of the administration of cell and gene therapies or in conjunction with cell and gene therapies generally?</P>
                    <P>We recognized that currently, for CY 2024, the following HCPCS codes are associated with CAR-T therapy: HCPCS code 0537T (Chimeric antigen receptor t-cell (car-t) therapy; harvesting of blood-derived t lymphocytes for development of genetically modified autologous car-t cells, per day), 0538T (Chimeric antigen receptor t-cell (car-t) therapy; preparation of blood-derived t lymphocytes for transportation (eg, cryopreservation, storage)), 0539T (Chimeric antigen receptor t-cell (car-t) therapy; receipt and preparation of car-t cells for administration), and 0540T (Chimeric antigen receptor t-cell (car-t) therapy; car-t cell administration, autologous) as discussed in previous OPPS rulemaking, including the CY 2022 OPPS/ASC final rule with comment period (86 FR 63550 through 63552).</P>
                    <P>
                        Separately, we also invited comment on whether policy revisions to the C-APC policy may be appropriate in future rulemaking, such as a modified outlier payment policy specific to C-APCs to address related situations in the future. We listed all proposed C-APC exclusion categories for CY 2025 in Addendum J to the CY 2025 OPPS/ASC proposed rule (which is available via the internet on the CMS website at 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        ).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters were generally very supportive of the proposal and thought this agency action was a positive step forward to ensure access to these new classes of drugs. They agreed with CMS's assessment that the cell and gene therapies listed in the CY 2025 OPPS/ASC proposed rule did not function as integral, ancillary, supportive, dependent, or adjunctive to any of the current C-APCs primary services. Commenters noted that they agreed that these treatments acted as independent therapies and were the reason for a Medicare beneficiary's visit to a hospital outpatient department. Additionally, commenters believed that this policy was necessary and important given the large number of cell and gene therapy products currently being researched that may ultimately be approved and available to Medicare beneficiaries in the coming years.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their support of our proposal and rationale.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Many commenters recommended CMS make this policy permanent as soon as possible. They noted that they agreed with CMS's assessment that it would be inappropriate to package cell and gene therapies into C-APCs for CY 2025 only, but that the same reasons that C-APC packaging would be inappropriate for CY 2025 would also apply to subsequent years. Other commenters recommended that CMS make this policy effective for an extended period of time, such as three years, in order to better understand how the policy is working.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their feedback. Based on the comments received, we are persuaded that the reasoning for excluding these cell and gene therapy products from C-APC packaging in CY 2025 would also apply to subsequent years. As such, we will be finalizing our proposal as later discussed in this section for CY 2025 and subsequent years.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter recommended that its cell therapy be added to the list of qualifying exceptions to C-APC packaging as their product received FDA approval on August 1, 2024, during the public comment period. A few commenters recommended CMS apply this packaging exception to other categories of drugs that they believed fell into a similar clinical category as cell and gene therapies. For example, one commenter suggested that its drug product is one of a growing number of innovative drugs that are administered using surgical procedures that are mapped to a C-APC, resulting in packaging of that product. The commenter stated that the product was the primary treatment being delivered to the patient, and not the C-APC procedure. Another commenter stated they have a product in the pipeline that, according to guidance from a specialty society, requires a procedure corresponding to CPT code 51720 (bladder instillation of anticarcinogenic agent), which is assigned to C-APC 5372, in order to insert the investigational product into the bladder. This commenter believed their product is the primary treatment being administered to a patient and is not supportive to any primary C-APC services. Therefore, they requested this product not be packaged into a C-APC and believed C-APC packaging would be inappropriate. This commenter also requested that in order to prevent C-APC packaging, one option would be for CMS to reassign the code used to describe the administration of its product to a drug administration APC rather than a C-APC. Specifically, they recommended CMS reassign CPT code 51720, which corresponds to the procedure used to administer the investigational product, to a non C-APC, such as a drug administration APC.
                        <PRTPAGE P="93936"/>
                    </P>
                    <P>Some commenters recommended that CMS extend the proposed policy to cell and gene therapies assigned to status indicator “G”, which correlates to pass-through status. Similarly, commenters recommend CMS exclude a variety of products from C-APC packaging, such as Casgevy, Lyfgenia, Amtagvi, Omisurge, Zynteglo, Obe-cel, Hemgenix, Beqvez, Roctavian, Spinraza and Elevidys. A few commenters suggested CMS should review and identify any other products that may be administered as independent therapies in the hospital outpatient setting and stated that such products should be separately paid.</P>
                    <P>
                        <E T="03">Response:</E>
                         We greatly thank commenters for their detailed comments. For new cell and gene therapy products that are not integral, ancillary, supportive, dependent, or adjunctive to any C-APC primary service that were approved during CY 2024 and that continue to be approved, CMS will add their product specific HCPCS codes, when created, to the C-APC exclusion list. For example, HCPCS code J3392 (Injection, exagamglogene autotemcel, per treatment) effective October 1, 2024, which may be used to describe the product Casgevy, was added to the list of qualifying products. We also thank commenters for their suggestions to add additional drugs and classes of drugs to this C-APC exclusion policy as well as those drugs that are administered during a C-APC procedure. Additionally, we thank the commenter for its suggestion to move some codes that describe the administration of a product from a C-APC to a drug administration APC. We will take this feedback into consideration for future rulemaking. As we stated in the proposed rule, we welcomed comments from readers on the proposal and the potential need for a different, modified, expanded, or supplemental policy for future rulemaking. We believe that cell and gene therapies are a unique class of products, but we believe we need additional evidence and engagement from interested parties concerning whether other identified classes of drugs, biologicals, medical devices, or other products are not supportive of a primary C-APC service but may nonetheless appear on the same claim as a primary C-APC procedure. We strongly believe in the principles of our prospective payment system and the C-APC policy; therefore, we want to ensure than any potential future changes to our C-APC packaging policy maintain these principles.
                    </P>
                    <P>Commenters suggested that we exclude several additional products from C-APC packaging, such as Lyfgenia, Zynteglo, Hemgenix, Beqvez, Roctavian, and Elevidys. We note that these products are currently on OPPS pass-through status for the duration of CY 2025, and therefore will be excluded from C-APC packaging under that policy. Similarly, in response to commenters suggestion that we apply this policy to cell and gene therapy products assigned to status indicator “G”, we note that we specifically did not propose to include therapies that are on drug pass-through status, represented by status indicator “G” for all of CY 2025 because pass-through drugs are already excluded from C-APC packaging. Please see section V.A of this final rule with comment period for additional information on OPPS drug pass-through status.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters recommended that CMS unpackage all status indicator “K” drugs from C-APC packaging, which aligned with the 2024 Advisory Panel on Hospital Outpatient Payment recommendation to no longer package drugs with a status indicator of “K” into any C-APC and, instead, they recommended CMS provide separate payment for all drugs and biologicals above the drug packaging threshold. Commenters said these status indicator “K” drugs should be paid based on 1847A of the Social Security Act and reimbursed at Average Sales Price plus 6 percent rather than packaged. Similarly, a commenter suggested that since drugs on pass-through status are paid separately when billed with a C-APC, that CMS should continue that separately payable status after passthrough status expiration and the transition of that code's status indicator from “G” to “K.”
                    </P>
                    <P>Commenters suggested that the proportion of status indicator “K” drug charges relative to all other charges appearing on C-APCs claims was less than 2.5 percent across all C-APCs. Meaning, in commenters' views, that C-APCs do not inherently involve the provision of status indicator “K” drugs. Another commenter recommended that CMS exclude high-cost primary therapy drugs across drug classes and not only to cell and gene therapies, apply the C-APC exclusion to primary therapy drugs that clinically align to C-APCs, and they included specific examples they researched that serve as the primary therapy drugs similar to cell and gene therapies.</P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the information submitted by commenters, but respectfully disagree with their conclusions. The C-APC policy aims to package payment for items and services that are typically integral, ancillary, supportive, dependent, or adjunctive to the primary service and provided during the delivery of the comprehensive service, including diagnostic procedures, laboratory tests and other diagnostic tests and treatments that assist in the delivery of the primary procedure. We believe it is appropriate for most drugs and biologicals to be packaged into C-APCs as we believe they function to “promote a beneficial outcome” or “prevent possible complications” of C-APC services. We explained in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74868) that intravenous drugs, for example, are OPPS services that are considered adjunctive to the primary procedure because the correct administration of the drug either promotes a beneficial outcome, such as the use of intravenous pain medications, or prevents possible complications, such as the use of intravenous blood pressure medications to temporarily replace oral blood pressure medications and reduce the risk of a sudden rise in blood pressure when a normal daily medication is stopped. We are therefore not excluding all status indicator “K” drugs above the drug packaging threshold from C-APC packaging. Our packaging policies are a fundamental component of the OPPS and they support our strategic goal of using larger payment bundles in the OPPS to maximize hospitals' incentives to provide care in the most efficient manner. Additionally, we do not believe at this time that cost alone is a reason to exclude a product from packaging.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Many commenters responded to several of our requests for comment associated with the proposal. Commenters recommended no significant overall changes to the general methodology CMS proposed to exclude products from all C-APC packaging and pay separately based on the individual product's average sales price plus 6 percent. Specifically, commenters strongly conveyed that they did not see an appropriate reason for CMS to structure a new C-APC, or similar packaged payment policy, for the service to administer cell or gene therapies, such as by creating a CAR T-cell therapy administration C-APC. Commenters believed that there is no accurate way to create a bundled payment for a whole group of cell and gene therapies as the costs and resources required are unique and novel between each of the therapies, which also makes it difficult to determine appropriate items and services associated with each therapy for inclusion in C-APC packaging. Commenters broadly believed no 
                        <PRTPAGE P="93937"/>
                        different or supplemental policy was warranted given the numerous challenges providers face related to cell and gene therapies currently. They saw any additional change to move towards a packaged payment policy as an additional challenge for the hospitals providing the therapies.
                    </P>
                    <P>Similarly, commenters cautioned CMS against creating C-APCs for cell and gene therapies as this may cause inadequate Medicare reimbursement to hospitals, which, in their view, has the potential to jeopardize beneficiary access to CAR T-cell therapy and other high-cost therapies as commenters communicated that institutions weigh reimbursement challenges with their ability to provide this costly care. Commenters were concerned that creating a new packaged payment policy could lead to a financial loss and decrease the number of facilities offering high-cost cell and gene therapies in the hospital outpatient department.</P>
                    <P>Commenters emphasized that these therapies involve highly specialized procedures, intensive monitoring, and multidisciplinary care teams, all of which contribute to their substantial costs. Commenters were concerned by the fact that the administration of cell and gene therapies are multi-step processes that can take weeks if not months and entail multiple services that would not appear on the same claim. Additional commenters reiterated that all of the various and distinct clinical services for CAR T-cell therapy are furnished over multiple encounters on different dates—making CAR T-cell therapy inappropriate for C-APCs, which are typically specific to a single encounter in their view. Commenters believed a CAR T-cell therapy C-APC, or similar packaged payment policy, would be unprecedented and a huge policy departure for CMS and recommended CMS not pursue the idea any further.</P>
                    <P>Many commenters believed that separate payment based on average sales price plus 6 percent is the most appropriate payment methodology for cell and gene therapies due to its transparency, uniformity and predictability. A few commenters pointed out that current hospital cost data is lower than ASP for CAR T-cell therapy products, potentially leaving products underpaid if paid based on C-APC principles. Commenters similarly took the position that there is no appropriate method in which CMS could modify its outlier payment policy with respect to C-APCs to better pay for these types of products.</P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the insights provided by commenters and will take them into consideration for future rulemaking. At this time, we are not considering the creation of a new C-APC, similar packaged payment policy, or modified outlier policy, for services to administer cell or gene therapies.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our policy proposal with a modification with respect to how long this policy will apply. For CY 2025 and subsequent years, we are finalizing a policy not to package payment for cell and gene therapies into C-APCs, when those cell and gene therapies are not functioning as integral, ancillary, supportive, dependent, or adjunctive to the primary C-APC service. For new cell and gene therapy products that are not integral, ancillary, supportive, dependent, or adjunctive to any C-APC primary service, we will continue to add their product specific HCPCS codes, when created, to the C-APC exclusion list. The current list of qualifying products can be found in Table 4. We are not adding any additional drug classes to this policy exclusion at this time, and we are not currently considering any additional modifications to our policy, but will continue to consider additional refinements for future rulemaking.</P>
                    <P>
                        We list all final C-APC exclusion categories for CY 2025 in Addendum J to this final rule (which is available via the internet on the CMS website at 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        ).
                    </P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="585">
                        <PRTPAGE P="93938"/>
                        <GID>ER27NO24.004</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <HD SOURCE="HD3">(5) Exclusion of Non-Opioid Products for Pain Relief Under Section 4135 of the Consolidated Appropriations Act, 2023 From the C-APC Policy</HD>
                    <P>
                        The Consolidated Appropriations Act (CAA), 2023 (Pub. L. 117-328), was signed into law on December 29, 2022. Section 4135(a) and (b) of the CAA, 2023, titled “Access to Non-Opioid Treatments for Pain Relief,” amended section 1833(t)(16) and section 1833(i) of the Social Security Act, respectively, to provide for temporary additional payments for non-opioid treatments for pain relief (as that term is defined in section 1833(t)(16)(G)(i) of the Act). In particular, section 1833(t)(16)(G) provides that with respect to a non-opioid treatment for pain relief furnished on or after January 1, 2025, 
                        <PRTPAGE P="93939"/>
                        and before January 1, 2028, the Secretary shall not package payment for the non-opioid treatment for pain relief into payment for a covered OPD service (or group of services) and shall make an additional payment for the non-opioid treatment for pain relief as specified in clause (ii) of that section. Clauses (ii) and (iii) of section 1833(t)(16)(G) of the Act provide for the amount of additional payment and set a limitation on that amount. As stated earlier in this section, our current policy is to exclude from the packaged C-APC payment those items and services that are required by statute to be separately paid.
                    </P>
                    <P>Accordingly, we proposed to exclude the non-opioid treatments for pain relief identified as satisfying the required criteria for payment under section 4135 of the CAA, 2023 from the C-APC policy to ensure payment is not packaged into any C-APC and that separate payment is made in accordance with the statute.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters were generally supportive of our proposal not to package payment and to pay separately for qualifying drugs, biologicals, and medical devices that met the criteria for payment under section 4135 of the CAA, 2023. A commenter mentioned its support of CMS packaging policies, and noted reservations about paying separately, and not packaging, non-opioid treatments for pain relief; however, they ultimately conceded that CMS must implement section 4135 of the CAA, 2023, which requires separately payable status, and supported CMS's implementation methodology.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their support.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our policy as proposed, and will exclude the non-opioid treatments for pain relief identified as satisfying the required criteria for payment under section 4135 of the CAA, 2023 from the C-APC policy to ensure payment is not packaged into any C-APC and that separate payment is made in accordance with the statute. Please see section XIII.F of this final rule with comment period for a list of the products that we are finalizing would qualify for payment under the new payment policy for non-opioid drugs, biologicals, and devices for pain relief.</P>
                    <HD SOURCE="HD3">(6) C-APCs for CY 2025</HD>
                    <P>For CY 2025 and subsequent years, we proposed to continue to apply the C-APC payment policy methodology. We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79583) for a discussion of the C-APC payment policy methodology and revisions.</P>
                    <P>Each year, in accordance with section 1833(t)(9)(A) of the Act, we review and revise the services within each APC group and the APC assignments under the OPPS. As a result of our annual review of the services and the APC assignments under the OPPS, we did not propose to convert any standard APCs to C-APCs in CY 2025; thus, we proposed that the number of C-APCs for CY 2025 would be the same as the number for CY 2024, which is 72 C-APCs.</P>
                    <P>
                        <E T="03">Comment:</E>
                         A few commenters requested that CMS reconsider our packaging policies for C-APC 8011 (Comprehensive Observation Services). They requested that CMS remove the rule that the presence of a SI “T” procedure on a claim excludes payment of C-APC 8011 and instead package the payment of the SI “T” procedure into C-APC 8011, as is already done with SI “Q” procedures. Commenters stated that this requirement violates the basic tenet of the packaging concept in that when observation services are ordered and furnished, the observation services become the primary service provided to such patients and the SI “T” procedure is provided ancillary to that primary service. Commenters cited scenarios in which hospitals provide significant, resource-intensive services to a patient but are paid significantly less than if a SI “T” procedure was not done.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for bringing this to our attention. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70334-70336), in response to commenters' concerns regarding packaging payment for potentially high-cost surgical procedures into the payment for an observation C-APC, we finalized a policy that claims reporting procedures assigned status indicator “T” do not qualify for payment through C-APC 8011, regardless of whether the procedure assigned status indicator “T” was furnished before or after observation services (described by HCPCS code G0378) were provided. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79562), we stated that services that would otherwise qualify for C-APC 8011 are not considered to be observation services when they are associated with a surgical procedure (assigned to status indicator “T”). Instead, they are considered to be perioperative recovery, which is always packaged in with the surgical procedure. We will continue to review the impacts of this issue and may revisit it in future rulemaking.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Two commenters expressed concerns with the C-APC methodology for surgical insertion codes for brachytherapy treatment, stating that these concerns impact beneficiary access to brachytherapy in the HOPD setting. These commenters stated that the C-APC methodology lacks the appropriate charge capture mechanisms to accurately reflect the services associated with the C-APC, that there are significant variations in the clinical practice and billing patterns in the hospital claims data used for ratesetting, and that the C-APC rates do not accurately or fully reflect the services and costs associated with the primary procedure. Commenters urged the agency to explore alternatives, including that CMS discontinue the C-APC policy for all brachytherapy insertion codes. Alternatively, one commenter suggested that CMS could continue to pay for “J1” brachytherapy insertion codes under the C-APC payment methodology but exclude and make separate payment for designated preparation and planning services in addition to the C-APC payment. Another commenter called for education on whether services, like brachytherapy, that are assigned to a J1 indicators and delivered over multiple patient encounters may be reported per encounter.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the comments on the C-APC methodology. However, we believe that the current C-APC methodology is appropriately applied to surgical insertion for brachytherapy treatment procedures and is accurately capturing costs, particularly as the brachytherapy sources used for these procedures are excluded from C-APC packaging and are separately payable. We will evaluate if provider education may be appropriate in this circumstance. We will continue to examine these concerns and will determine if any modifications on this policy are warranted in future rulemaking.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing the C-APCs as proposed. Table 5 lists the final C-APCs for CY 2025. All C-APCs are displayed in Addendum J to this CY 2025 OPPS/ASC final rule with comment period (which is available via the internet on the CMS website). Addendum J to this final rule with comment period also contains all of the data related to the C-APC payment policy methodology, including the list of complexity adjustments and other information for CY 2025.</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="638">
                        <PRTPAGE P="93940"/>
                        <GID>ER27NO24.005</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="585">
                        <PRTPAGE P="93941"/>
                        <GID>ER27NO24.006</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <EXTRACT>
                        <P>
                            <E T="03">C-APC Clinical Family Descriptor Key:</E>
                        </P>
                        <FP SOURCE="FP-2">AENDO = Airway Endoscopy</FP>
                        <FP SOURCE="FP-2">AICDP = Automatic Implantable Cardiac Defibrillators, Pacemakers, and Related Devices.</FP>
                        <FP SOURCE="FP-2">BREAS = Breast Surgery</FP>
                        <FP SOURCE="FP-2">COCHL = Cochlear Implant</FP>
                        <FP SOURCE="FP-2">EBIDX = Excision/Biopsy/Incision and Drainage</FP>
                        <FP SOURCE="FP-2">ENTXX = ENT Procedures</FP>
                        <FP SOURCE="FP-2">EPHYS = Cardiac Electrophysiology/</FP>
                        <FP SOURCE="FP-2">EVASC = Endovascular Procedures</FP>
                        <FP SOURCE="FP-2">EXEYE = Extraocular Ophthalmic Surgery</FP>
                        <FP SOURCE="FP-2">GIXXX = Gastrointestinal Procedures</FP>
                        <FP SOURCE="FP-2">GYNXX = Gynecologic Procedures</FP>
                        <FP SOURCE="FP-2">INEYE = Intraocular Surgery</FP>
                        <FP SOURCE="FP-2">LAPXX = Laparoscopic Procedures</FP>
                        <FP SOURCE="FP-2">NERVE = Nerve Procedures</FP>
                        <FP SOURCE="FP-2">NSTIM = Neurostimulators</FP>
                        <FP SOURCE="FP-2">ORTHO = Orthopedic Surgery</FP>
                        <FP SOURCE="FP-2">PUMPS = Implantable Drug Delivery Systems</FP>
                        <FP SOURCE="FP-2">RADTX = Radiation Oncology</FP>
                        <FP SOURCE="FP-2">
                            SCTXX = Stem Cell Transplant
                            <PRTPAGE P="93942"/>
                        </FP>
                        <FP SOURCE="FP-2">UROXX = Urologic Procedures</FP>
                        <FP SOURCE="FP-2">VASCX = Vascular Procedures</FP>
                        <FP SOURCE="FP-2">WPMXX = Wireless PA Pressure Monitor</FP>
                    </EXTRACT>
                    <HD SOURCE="HD3">c. Calculation of Composite APC Criteria-Based Costs</HD>
                    <P>As discussed in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66613), we believe it is important that the OPPS enhance incentives for hospitals to provide necessary, high-quality care as efficiently as possible. For CY 2008, we developed composite APCs to provide a single payment for groups of services that are typically performed together during a single clinical encounter and that result in the provision of a complete service. Combining payment for multiple, independent services into a single OPPS payment in this way enables hospitals to manage their resources with maximum flexibility by monitoring and adjusting the volume and efficiency of services themselves. An additional advantage to the composite APC model is that we can use data from correctly coded multiple procedure claims to calculate payment rates for the specified combinations of services, rather than relying upon single procedure claims which may be low in volume and/or incorrectly coded. Under the OPPS, we currently have composite policies for mental health services and multiple imaging services. We refer readers to the CY 2008 OPPS/ASC final rule with comment period (72 FR 66611 through 66614 and 66650 through 66652) for a full discussion of the development of the composite APC methodology, and the CY 2012 OPPS/ASC final rule with comment period (76 FR 74163) and the CY 2018 OPPS/ASC final rule with comment period (82 FR 59241, 59242, and 59246 through 52950) for more recent background.</P>
                    <HD SOURCE="HD3">(1) Mental Health Services Composite APC</HD>
                    <P>For CY 2025, we proposed to continue our longstanding policy of limiting the aggregate payment for specified less resource-intensive mental health services furnished on the same date to the payment for a day of partial hospitalization services provided by a hospital, which we consider to be the most resource-intensive of all outpatient mental health services (88 FR 49572). We refer readers to the April 7, 2000, OPPS final rule with comment period (65 FR 18452 through 18455) for the initial discussion of this longstanding policy and the CY 2012 OPPS/ASC final rule with comment period (76 FR 74168) for more recent background.</P>
                    <P>In the CY 2018 OPPS/ASC proposed rule and final rule with comment period (82 FR 33580 and 33581 and 82 FR 59246 and 59247), we proposed and finalized the policy for CY 2018 and subsequent years that, when the aggregate payment for specified mental health services provided by one hospital to a single beneficiary on a single date of service, based on the payment rates associated with the APCs for the individual services, exceeds the maximum per diem payment rate for partial hospitalization services provided by a hospital, those specified mental health services will be paid through composite APC 8010 (Mental Health Services Composite). In addition, we set the payment rate for composite APC 8010 for CY 2018 at the same payment rate for APC 5863, which was the maximum partial hospitalization per diem payment rate for a hospital, and finalized a policy that the hospital would continue to be paid the payment rate for composite APC 8010. This policy applied in CYs 2018 through 2023.</P>
                    <P>In the CY 2024 OPPS/ASC proposed rule, we stated that APC 5863 was no longer the maximum partial hospitalization per diem payment rate for a hospital due to the creation of APC 5864, which is four or more hospital-based PHP services per day (88 FR 49572). We solicited comment on whether APC 5864 would be appropriate to use as the daily mental health cap, as we have historically set the daily mental health cap for composite APC 8010 at the maximum partial hospitalization per diem payment rate for a hospital (88 FR 49572). Based on public comments received and our longstanding policy, in CY 2024 OPPS/ASC final rule, we finalized APC 5864, four hospital-based PHP services per day, as the daily mental health cap (88 FR 81566).</P>
                    <P>We continue to believe that the costs associated with administering a partial hospitalization program represent the most resource intensive of all outpatient mental health services. For CY 2025 and subsequent years, we proposed to continue this policy that when the aggregate payment for specified mental health services provided by one hospital to a single beneficiary on a single date of service, based on the payment rates associated with the APCs for the individual services, exceeds the per diem payment rate for 4 partial hospitalization services provided in a day by a hospital (the payment amount for APC 5864), those specified mental health services would be paid through composite APC 8010. In addition, we proposed to continue to set the payment rate for composite APC 8010 at the same payment rate that we propose for APC 5864, which is a partial hospitalization per diem payment rate for 4 partial hospitalization services furnished in a day by a hospital.</P>
                    <P>Under the proposed policy, the Integrated OCE (I/OCE) would continue to determine whether to pay for these specified mental health services individually, or to make a single payment at the same payment rate established for APC 5864 for all the specified mental health services furnished by the hospital on that single date of service by paying for the services through composite APC 5863.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter recommended that CMS change the status indicator for two neuropsychological testing codes (HCPCS codes 96133 and 96137) from SI = N to SI = Q3 to allow separate payment for additional hours of testing or increase the payment rate for the primary testing procedure codes. Noting the multiple day structure of neuropsychological testing, they requested a daily payment for each date of service. The commenters noted that the payment rate for Composite APC 8010, which is capped at the maximum per diem partial hospitalization rate, is lower than the individual HCPCS code APC payment rates and does not provide sufficient payment for these procedures.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         After reviewing this issue, we believe the Composite APC methodology is being appropriately applied in this case. Composite APCs provide a single payment for groups of services that are typically performed together during a single clinical encounter and that result in the provision of a complete service.
                    </P>
                    <P>
                        The words “list separately in addition to code for primary procedure” are included in the long descriptors for HCPCS codes 96133 and 96137 to indicate that that the codes are considered “add-ons” to another primary code that cannot be reported independently. Specifically, add-on codes must always be reported with another primary code on the same day. The AMA states in the CPT 2024 Professional Edition (page xviii) that “add-on codes are always performed in addition to the primary service or procedure and must never be reported as a stand-alone code.” In most cases, add-on codes are typically ancillary and supportive to a primary diagnostic or therapeutic modality and are an integral part of the primary service they support. As specified under 42 CFR 419.2(b)(18), certain services described by add-on codes are generally packaged under the OPPS, and payments for the codes are bundled with the primary codes. 
                        <PRTPAGE P="93943"/>
                        Consequently, HCPCS codes 96133 and 96137 are not paid separately under the OPPS, but instead, their payment is packaged into the primary code.
                    </P>
                    <P>In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59246 through 59247), we stated that the costs associated with administering a partial hospitalization program at a hospital represent the most resource intensive of all outpatient mental health services. We continue to believe that the Composite APC methodology, which limits the aggregate payment for specified mental health services provided by one hospital to a single beneficiary on a single date of service, based on the payment rates associated with the APCs for the individual services, to the per diem payment rate for four partial hospitalization services provided in a day by a hospital (the payment amount for APC 5864), is appropriate.</P>
                    <P>We will continue to examine these concerns and will determine if any modifications to this policy are warranted in future rulemaking.</P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal, without modification, that when the aggregate payment for specified mental health services provided by one hospital to a single beneficiary on a single date of service, based on the payment rates associated with the APCs for the individual services, exceeds the maximum per diem payment rate for four partial hospitalization services provided in a day by a hospital (the payment amount for APC 5864), those specified mental health services would be paid through composite APC 8010 for CY 2025. In addition, we are finalizing setting the payment rate for composite APC 8010 for CY 2025 at the same payment rate that we set for APC 5864, which is the maximum partial hospitalization per diem payment rate for a hospital.</P>
                    <HD SOURCE="HD3">(2) Multiple Imaging Composite APCs (APCs 8004, 8005, 8006, 8007, and 8008)</HD>
                    <P>Effective January 1, 2009, we provide a single payment each time a hospital submits a claim for more than one imaging procedure within an imaging family on the same date of service, to reflect and promote the efficiencies hospitals can achieve when performing multiple imaging procedures during a single session (73 FR 41448 through 41450). We utilize three imaging families based on imaging modality for purposes of this methodology: (1) ultrasound; (2) computed tomography (CT) and computed tomographic angiography (CTA); and (3) magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA). The HCPCS codes subject to the multiple imaging composite policy and their respective families are listed in Table 6.</P>
                    <P>While there are three imaging families, there are five multiple imaging composite APCs due to the statutory requirement under section 1833(t)(2)(G) of the Act that we differentiate payment for OPPS imaging services provided with and without contrast. While the ultrasound procedures included under the policy do not involve contrast, both CT/CTA and MRI/MRA scans can be provided either with or without contrast. The five multiple imaging composite APCs established in CY 2009 are:</P>
                    <P>• APC 8004 (Ultrasound Composite);</P>
                    <P>• APC 8005 (CT and CTA without Contrast Composite);</P>
                    <P>• APC 8006 (CT and CTA with Contrast Composite);</P>
                    <P>• APC 8007 (MRI and MRA without Contrast Composite); and</P>
                    <P>• APC 8008 (MRI and MRA with Contrast Composite).</P>
                    <P>We define the single imaging session for the “with contrast” composite APCs as having at least one or more imaging procedures from the same family performed with contrast on the same date of service. For example, if the hospital performs an MRI without contrast during the same session as at least one other MRI with contrast, the hospital will receive payment based on the payment rate for APC 8008, the “with contrast” composite APC.</P>
                    <P>We make a single payment for those imaging procedures that qualify for payment based on the composite APC payment rate, which includes any packaged services furnished on the same date of service. The standard (noncomposite) APC assignments continue to apply for single imaging procedures and multiple imaging procedures performed across families. For a full discussion of the development of the multiple imaging composite APC methodology, we refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68559 through 68569).</P>
                    <P>For CY 2025, we proposed to continue to pay for all multiple imaging procedures within an imaging family performed on the same date of service using the multiple imaging composite APC payment methodology. We continue to believe that this policy would reflect and promote the efficiencies hospitals can achieve when performing multiple imaging procedures during a single session.</P>
                    <P>For CY 2025, except where otherwise indicated, we proposed to use the costs derived from CY 2023 claims data to set the proposed CY 2025 payment rates. Therefore, for CY 2025, the proposed payment rates for the five multiple imaging composite APCs (APCs 8004, 8005, 8006, 8007, and 8008) were based on proposed geometric mean costs calculated from CY 2023 claims available for the CY 2025 OPPS/ASC proposed rule that qualify for composite payment under the current policy (that is, those claims reporting more than one procedure within the same family on a single date of service). To calculate the proposed geometric mean costs, we used the same methodology that we used to calculate the geometric mean costs for these composite APCs since CY 2014, as described in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74918). The imaging HCPCS codes referred to as “overlap bypass codes” that we removed from the bypass list for purposes of calculating the proposed multiple imaging composite APC geometric mean costs, in accordance with our established methodology as stated in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74918), are identified by asterisks in Addendum N to this final rule with comment period (which is available via the internet on the CMS website) and are discussed in more detail in section II.A.1.a of the this final rule with comment period.</P>
                    <P>For this final rule with comment period, we were able to identify approximately 0.95 million “single session” claims out of an estimated 2.1 million potential claims for payment through composite APCs from our ratesetting claims data, which represents approximately 45.0 percent of all eligible claims, to calculate the final CY 2025 geometric mean costs for the multiple imaging composite APCs. Table 6 lists the final HCPCS codes that would be subject to the multiple imaging composite APC policy and their respective families and approximate composite APC final geometric mean costs for CY 2025.</P>
                    <P>We did not receive any public comments on this policy. We are finalizing without modification our proposal to continue the use of multiple imaging composite APCs to pay for the provision of more than one imaging procedure from the same imaging family on the same date. Table 6 lists the HCPCS codes that will be subject to the multiple imaging composite APC policy and their respective imaging families and approximate composite APC final geometric mean costs for CY 2025.</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="93944"/>
                        <GID>ER27NO24.007</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="93945"/>
                        <GID>ER27NO24.008</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="93946"/>
                        <GID>ER27NO24.009</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="592">
                        <PRTPAGE P="93947"/>
                        <GID>ER27NO24.010</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <HD SOURCE="HD3">3. Changes to Packaged Items and Services</HD>
                    <HD SOURCE="HD3">a. Background and Rationale for Packaging in the OPPS</HD>
                    <P>
                        Like other prospective payment systems, the OPPS relies on the concept of averaging to establish a payment rate for services. The payment may be more or less than the estimated cost of providing a specific service or a bundle of specific services for a particular beneficiary. The OPPS packages payments for multiple interrelated items 
                        <PRTPAGE P="93948"/>
                        and services into a single payment to create incentives for hospitals to furnish services most efficiently and to manage their resources with maximum flexibility. Our packaging policies support our strategic goal of using larger payment bundles in the OPPS to maximize hospitals' incentives to provide care in the most efficient manner. For example, where there are a variety of devices, drugs, items, and supplies that could be used to furnish a service, some of which are more costly than others, packaging encourages hospitals to use the most cost-efficient item that meets the patient's needs, rather than to routinely use a more expensive item, which may occur if separate payment is provided for the item.
                    </P>
                    <P>Packaging also encourages hospitals to effectively negotiate with manufacturers and suppliers to reduce the purchase price of items and services or to explore alternative group purchasing arrangements, thereby encouraging the most economical health care delivery. Similarly, packaging encourages hospitals to establish protocols that ensure that necessary services are furnished, while scrutinizing the services ordered by practitioners to maximize the efficient use of hospital resources. Packaging payments into larger payment bundles promotes the predictability and accuracy of payment for services over time. Finally, packaging may reduce the importance of refining service-specific payments because packaged payments include costs associated with higher cost cases requiring many ancillary items and services and lower cost cases requiring fewer ancillary items and services. Packaging encourages efficiency and is an essential component of a prospective payment system, therefore packaging payments for items and services that are typically integral, ancillary, supportive, dependent, or adjunctive to a primary service has been a fundamental part of the OPPS since its implementation in August 2000. As we continue to develop larger payment groups that more broadly reflect services provided in an encounter or episode of care, we have expanded the OPPS packaging policies. Most, but not necessarily all, categories of items and services currently packaged in the OPPS are listed in 42 CFR 419.2(b). Our overarching goal is to make payments for all services under the OPPS more consistent with those of a prospective payment system and less like those of a per-service fee schedule, which pays separately for each coded item. As a part of this effort, we have continued to examine the payment for items and services provided under the OPPS to determine which OPPS services can be packaged to further achieve the objective of advancing the OPPS toward a more prospective payment system.</P>
                    <HD SOURCE="HD3">b. Final CY 2025 Policy on Packaged Items and Services</HD>
                    <P>For CY 2025, we examined the items and services currently provided under the OPPS, reviewing categories of integral, ancillary, supportive, dependent, or adjunctive items and services for which we believe payment would be appropriately packaged into payment for the primary service that they support. Specifically, we examined the HCPCS code definitions (including CPT code descriptors) and hospital outpatient department billing patterns to determine whether there were categories of codes for which packaging would be appropriate according to existing OPPS packaging policies or a logical expansion of those existing OPPS packaging policies.</P>
                    <P>For CY 2025, we did not propose any changes to the overall packaging policy discussed. We proposed to continue to conditionally package the costs of selected newly identified ancillary services into payment for a primary service where we believe that the packaged item or service is integral, ancillary, supportive, dependent, or adjunctive to the provision of care that was reported by the primary service HCPCS code.</P>
                    <P>While we did not propose any changes to the overall packaging policy, we proposed potential modifications to our packaging policy as described in the following sections.</P>
                    <P>We did not receive any public comments on our overall packaging policy proposal and therefore, we are finalizing our proposal to continue to conditionally package the costs of selected newly identified ancillary services into payment for a primary service where we believe that the packaged item or service is integral, ancillary, supportive, dependent, or adjunctive to the provision of care that was reported by the primary service HCPCS code, as proposed for CY 2025.</P>
                    <P>We did receive specific recommendations regarding C-APC packaging of Cell and Gene Therapies and associated products, which are addressed in section II.b.4 of this final rule with comment period, and the packaging of non-opioid treatments for pain relief, which are addressed in section XIII.E of this final rule with comment period. Additionally, commenters made recommendations on our packaging policies in the context of our diagnostic radiopharmaceutical proposal, which is discussed in the next section.</P>
                    <HD SOURCE="HD3">c. Payment for Diagnostic Radiopharmaceuticals</HD>
                    <HD SOURCE="HD3">(1) Background on OPPS Packaging Policy for Diagnostic Radiopharmaceuticals</HD>
                    <P>Under the OPPS, we package several categories of nonpass-through drugs, biologicals, and radiopharmaceuticals, regardless of the cost of the products. Because the products are packaged according to the policies in § 419.2(b), we refer to them as “policy-packaged” drugs, biologicals, and radiopharmaceuticals. In particular, under § 419.2(b)(15), payment for drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test or procedure is packaged with the payment for the related procedure or service. Packaging costs into a single aggregate payment for a service, encounter, or episode of care is a fundamental principle that distinguishes a prospective payment system from a fee schedule. In general, packaging the costs of supportive items and services into the payment for the primary procedure or service with which they are associated encourages hospital efficiencies and enables hospitals to manage their resources with maximum flexibility.</P>
                    <P>
                        In the CY 2008 OPPS/ASC final rule with comment period we finalized the packaging status of diagnostic radiopharmaceuticals as part of our overall enhanced packaging approach for the CY 2008 OPPS and subsequent years (72 FR 66635 through 66641). Importantly, we believed diagnostic radiopharmaceuticals are always intended to be used with a diagnostic nuclear medicine procedure and function as supplies when used in a diagnostic test or procedure, making it appropriate to package the payment for the diagnostic radiopharmaceutical into the payment for the related nuclear medicine procedure. Diagnostic radiopharmaceuticals are one specific type of product that is policy packaged under the category described by § 419.2(b)(15). Since we implemented this policy in CY 2008, interested parties have raised concerns regarding policy packaging of diagnostic radiopharmaceuticals. In previous rulemaking (87 FR 71962 and 71963), commenters recommended that CMS always pay separately under the OPPS for diagnostic radiopharmaceuticals, not just when the products have pass-through payment status. Many of these commenters mentioned that pass-
                        <PRTPAGE P="93949"/>
                        through payment status helps the diffusion of new diagnostic radiopharmaceuticals into the market. However, commenters believe the packaged payment rate is often inadequate after pass-through status expires, especially in cases where the diagnostic radiopharmaceutical is high-cost and has low utilization.
                    </P>
                    <P>We have heard from interested parties regarding alternative payment methodologies, such as subjecting diagnostic radiopharmaceuticals to the drug packaging threshold and creating separate APC payments for diagnostic radiopharmaceuticals with a per-day cost greater than $500. Interested parties have also recommended that we analyze our nuclear medicine APC structure and consider establishing additional nuclear medicine APCs to reflect the costs of diagnostic radiopharmaceuticals more accurately. Historically, commenters opposed incorporating the cost of diagnostic radiopharmaceuticals into the associated nuclear medicine APC as the nuclear medicine APCs are sometimes paid at a lower rate than the payment rate for the diagnostic radiopharmaceutical itself when it has pass-through payment status (87 FR 71962 and 71963).</P>
                    <P>Importantly, commenters historically have also been concerned that packaging payment for precision diagnostic radiopharmaceuticals in the outpatient hospital setting creates barriers to beneficiary access for safety net hospitals serving a high proportion of Medicare beneficiaries and hospitals serving underserved communities (87 FR 71962 and 71963). Commenters specified that certain populations, such as those with Alzheimer's disease, depend on the use of certain high-cost diagnostic radiopharmaceuticals. Commenters discussed difficulties enrolling hospitals in clinical studies due to OPPS packaging policies and suggested that we pay separately under the OPPS specifically for radiopharmaceuticals that are used for Alzheimer's disease. Additionally, commenters have recommended that CMS continue to apply radiolabeled product edits to the nuclear medicine procedures to ensure that all packaged costs are included on nuclear medicine claims to establish appropriate payment rates in the future. Beginning January 1, 2008, CMS implemented OPPS edits that require hospitals to include a HCPCS code for a radiolabeled product when a separately payable nuclear medicine procedure is present on a claim. This policy to require hospitals to include a HCPCS code for a radiolabeled product for a separately payable nuclear medicine procedure ended in CY 2014 (78 FR 75033 through 75034).</P>
                    <P>Many of these comments and our responses have been discussed in rulemaking since the policy to package diagnostic radiopharmaceuticals was adopted, and they prompted us to solicit comment on payment for diagnostic radiopharmaceuticals in the CY 2024 OPPS/ASC proposed rule (88 FR 49577). In that proposed rule, we stated we continue to believe that diagnostic radiopharmaceuticals are an integral component of many nuclear medicine and imaging procedures and charges associated with them should be reported on hospital claims to the extent they are used. Accordingly, we reiterated our belief that the payment for the diagnostic radiopharmaceutical should be reflected within the payment for the primary procedure with which it is used. We noted that ratesetting uses the geometric mean of reported procedure costs, which in the example of nuclear medicine procedures includes the costs of the reported diagnostic radiopharmaceutical, based on data submitted to CMS from all hospitals paid under the OPPS to set the payment rate for the service. The costs that are calculated by Medicare reflect the average costs of items and services that are packaged into a primary procedure and will not necessarily equal the sum of the cost of the primary procedure and the Average Sales Price (ASP) of the specific items and services used in the procedure in each case. Furthermore, we explained that the costs are based on the reported costs submitted to Medicare by the hospitals and not the list price established by the manufacturer. Claims data that include the diagnostic radiopharmaceutical packaged with the associated procedure should reflect the combined cost of the procedure and the radiopharmaceutical used in the procedure.</P>
                    <P>As we have reiterated over the years, we believe packaging policies are inherent principles of the OPPS and are essential to a prospective payment system. At the same time, we have explained that we are committed to ensuring beneficiary access to diagnostic radiopharmaceuticals while also ensuring the availability of new and innovative diagnostic tools for Medicare beneficiaries. Therefore, we sought public comments on potential modifications to our packaging policy for diagnostic radiopharmaceuticals to ensure equitable payment and continued beneficiary access.</P>
                    <P>As described in the CY 2024 OPPS/ASC proposed rule (88 FR 49578), we solicited comment on how the OPPS packaging policy for diagnostic radiopharmaceuticals has impacted beneficiary access, including whether there are specific patient populations or clinical disease states for whom this issue is especially critical.</P>
                    <P>In addition, we solicited comment on the following potential approaches that would enhance beneficiary access, while also maintaining the principles of the outpatient prospective payment system. These approaches included: (1) paying separately for diagnostic radiopharmaceuticals with per-day costs above the OPPS drug packaging threshold of $140; (2) establishing a specific per-day cost threshold that may be greater or less than the OPPS drug packaging threshold; (3) restructuring APCs, including by adding nuclear medicine APCs for services that utilize high-cost diagnostic radiopharmaceuticals; (4) creating specific payment policies for diagnostic radiopharmaceuticals used in clinical trials; and (5) adopting codes that incorporate the disease state being diagnosed or a diagnostic indication of a particular class of diagnostic radiopharmaceuticals.</P>
                    <P>Finally, we were interested in hearing from stakeholders how the suggested policy modifications might impact our overarching goal of utilizing packaging policies to better align OPPS policies with those of a prospective payment system rather than a fee schedule. We stated we would also like to know if making any of the suggested policy changes could have negative consequences for beneficiaries, such as unintentionally influencing clinical practice decisions, increasing beneficiary cost-sharing obligations, or inadvertently encouraging the use of higher-cost diagnostic radiopharmaceuticals over lower cost, but equally effective, diagnostic options.</P>
                    <P>
                        We received a significant number of comments in response to the comment solicitation on potential issues caused by our current payment policy for diagnostic radiopharmaceuticals under the OPPS and on new approaches to payment for these products. Commenters expressed concerns regarding the CMS policy to package diagnostic radiopharmaceuticals and the financial implications this policy has for facilities. Commenters believe that, for newer, more innovative radiopharmaceuticals, the current OPPS packaging policy has led to a lack of patient access to the technologies after the radiopharmaceutical's pass-through status expires, especially if there is no clinical alternative to the radiopharmaceutical. Most commenters requested that CMS provide separate payment for diagnostic 
                        <PRTPAGE P="93950"/>
                        radiopharmaceuticals. Some commenters believed paying separately for all diagnostic radiopharmaceuticals regardless of their per-day cost was the best methodology to avoid encouraging price inflation for diagnostic radiopharmaceuticals to reach a certain threshold. Other commenters thought that applying the existing OPPS per-day cost threshold ($135 for CY 2024) to the payment of diagnostic radiopharmaceuticals would be an adequate solution. Others supported a $500 threshold, and many cited the Facilitating Innovative Nuclear Diagnostics Act (FIND Act) of 2023 as their rationale for that number and recognized that the $500 threshold number may be a more targeted approach relative to the OPPS drug packaging threshold as the higher cost diagnostic radiopharmaceuticals are the most disadvantaged by the OPPS packaging policy in their view. For the full discussion on the comment solicitation summarized here, refer to the CY 2024 OPPS/ASC final rule with comment period (88 FR 81573 through 81577).
                    </P>
                    <HD SOURCE="HD3">(2) Packaging Threshold for Diagnostic Radiopharmaceuticals</HD>
                    <P>As stated in the CY 2024 OPPS final rule with comment period (88 FR 81577), we agree with commenters that payment for diagnostic radiopharmaceuticals is a complex and important issue. We explained that we intended to further consider these points and take them into consideration for future notice and comment rulemaking. As described in the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222), after significant consideration and ongoing engagement from interested parties, we proposed a change to our current policy that packages diagnostic radiopharmaceuticals regardless of their cost.</P>
                    <P>We continue to believe diagnostic radiopharmaceuticals are always intended to be used with a diagnostic nuclear medicine procedure and function as supplies when used in a diagnostic test or procedure, generally making it appropriate to package payment for them with payment for the related nuclear medicine procedure. In the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222), we stated that while we continue to believe that this should be the policy for most diagnostic radiopharmaceuticals, we believe there are certain situations in which the packaged payment amount attributed to the diagnostic radiopharmaceutical used in an imaging procedure assigned to a nuclear medicine APC may not adequately account for the cost of a diagnostic radiopharmaceutical that has a significantly higher cost, but lower utilization relative to the other diagnostic radiopharmaceuticals that may be used with the procedure. In situations where a hospital may have to pay significantly more to purchase a diagnostic radiopharmaceutical than Medicare pays, a hospital may decide not to provide that specific diagnostic radiopharmaceutical imaging agent to Medicare beneficiaries. This could potentially deny access to diagnostic tools for which there is no clinical alternative. To ensure Medicare payment policy is not providing a financial disincentive to using high cost, low utilization diagnostic radiopharmaceuticals, especially when those agents may be the most clinically appropriate, and to ensure appropriate beneficiary access, we believe a subset of diagnostic radiopharmaceuticals with higher per day costs should be paid separately and not packaged into the diagnostic procedure with which the diagnostic radiopharmaceutical is used.</P>
                    <P>To address these concerns, we proposed to pay separately for any diagnostic radiopharmaceutical with a per day cost greater than $630. Any diagnostic radiopharmaceutical with a per day cost below that threshold would continue to be policy packaged under the current policy at § 419.2(b)(15). We discuss our proposed methodology for determining the proposed per day cost threshold of $630 in further detail in this section.</P>
                    <P>To determine an appropriate threshold for our proposal, we estimated the approximate payment that would typically be attributable to diagnostic radiopharmaceutical payment within each nuclear medicine APC (APCs 5591, 5592, 5593, and 5594). We did this by assessing the offsets associated with these APCs that were directly attributable to “policy packaged” drugs. The offset amounts used are correlated with the approximate portion of APC payment associated with these “policy packaged” drugs. For nuclear medicine APCs, the primary “policy packaged” drugs are diagnostic radiopharmaceuticals. To calculate this threshold, we calculated a volume weighted average of the offset dollar amount of each nuclear medicine APC. This involved taking the offset percentage for “policy packaged” drugs, multiplying it by the APC geometric mean to get an offset dollar amount, and then multiplying that offset amount by the number of single claims to get the total offset amount for each nuclear medicine APC level. We then calculated the sum of the total offset amount for all 4 of the nuclear medicine APCs. We divided this number by the total number of single claims for all 4 nuclear medicine APCs, resulting in $314.28, which represents the volume weighted average policy packaged offset amount for the nuclear medicine APC series. We then took that number and multiplied it by 2, and rounded it to the nearest $5 increment, which resulted in $630. See Table 7 for the values used to calculate this threshold amount. We noted that the data values in Table 7 were collected without unpackaging the set of diagnostic radiopharmaceuticals listed in Table 8. We noted that if we finalized our proposal and those diagnostic radiopharmaceuticals were unpackaged, it would change the APC geometric mean unit costs (MUCs) as well as the offset percentages. This is why the APC geometric mean cost values listed below are not the same as in the addenda to this rule.</P>
                    <GPH SPAN="3" DEEP="217">
                        <PRTPAGE P="93951"/>
                        <GID>ER27NO24.011</GID>
                    </GPH>
                    <P>
                        The offset percentages used were updated based on the available data for the CY 2025 proposed rule and these offset percentages are usually the offsets that are published in the final rule. However, we included the data in Table 7 to illustrate how we arrived at the proposed $630 threshold. Additionally, the file and corresponding offset percentages used for the $630 threshold are similar to and consistent with the ones that can be found in the CY 2024 NFRM APC Offset File. These files are available via the internet on the CMS OPPS website.
                        <SU>7</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>7</SU>
                             
                            <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/annual-policy-files</E>
                            .
                        </P>
                    </FTNT>
                    <P>We proposed to multiply by two the volume weighted average amount of the offset to establish the threshold triggering separate payment because this amount would ensure that separate payment would apply only to diagnostic radiopharmaceuticals whose costs significantly exceed the approximate amount of payment already attributed to the product in the nuclear medicine APC payment. This is consistent with the principles of a prospective payment system where some payments are lower than hospitals' costs while other payments are greater than a hospitals' costs. However, diagnostic radiopharmaceuticals with costs more than double the volume weighted average amount of the offset could present a hospital with a significant financial loss. This is why the OPPS has several payment provisions that rely on a multiplier of costs as a threshold for modifying payment.</P>
                    <P>Our proposed approach to multiply the average offset amount by two is consistent with the two-times rule the OPPS uses to determine Ambulatory Payment Classification (APC) levels, where a significant service that has a cost greater than two times the lowest cost significant service in an APC is generally moved to a higher level APC in the series. The two-times rule requires that the highest calculated cost of an individual procedure categorized to any given APC cannot exceed two times the calculated cost of the lowest cost procedure categorized to that same APC. We note that the two-times rule does not apply to diagnostic radiopharmaceuticals themselves, but only to the procedures in which they are used, which is why we are proposing a diagnostic radiopharmaceutical packaging threshold utilizing a similar two-times methodology.</P>
                    <P>As described in the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222), our proposed approach to multiply the average offset amount by two is also generally consistent with the OPPS outlier policy applicable to certain high-cost procedures, where costs greater than 1.75 times the APC payment trigger an additional outlier payment. The OPPS provides outlier payments to hospitals to help mitigate the financial risk associated with high-cost and complex procedures, where a very costly service could present a hospital with significant financial loss. Outlier payments are provided on a service basis when the cost of a service exceeds the APC payment amount multiplier threshold (1.75) as well as the APC payment amount plus a fixed-dollar amount threshold. The proposed diagnostic radiopharmaceutical packaging threshold would serve a similar purpose as the outlier policy, in that it would provide payments to hospitals to help mitigate the financial risk associated with high-cost diagnostic radiopharmaceuticals, where a very costly diagnostic radiopharmaceutical could present a hospital with significant financial loss.</P>
                    <P>
                        We proposed a multiplier of two and explained that we believe two is the most appropriate number for the multiplier for the volume weighted average amount of the offset, but we sought comment on the alternatives of using 1.75 times the volume weighted average amount of the offset as the threshold amount for triggering separate payment, or another appropriate multiplier amount. We stated that, for example, an interested party could present data that a financial disincentive to use diagnostic radiopharmaceuticals exists when costs are 1.75 times, or three times or five times, the volume weighted average offset amount. Since the hospital outpatient outlier payment policy is a longstanding policy familiar to most hospitals, we sought comment on utilizing elements of that policy for purposes of our proposed diagnostic radiopharmaceutical packaging policy in order to help hospitals mitigate the financial risk that may be associated with furnishing high-cost and complex diagnostic radiopharmaceuticals. As previously mentioned, we sought comment on the use of 1.75 times as the multiplier threshold rather than 2. Although the outlier policy uses both a 1.75 multiplier threshold and a fixed-dollar threshold, we sought comment regarding the use of 1.75 as the multiplier to set a fixed dollar threshold for the volume weighted average amount of the offset as the goals of the 
                        <PRTPAGE P="93952"/>
                        outlier policy and the proposed diagnostic radiopharmaceutical policy are similar.
                    </P>
                    <P>We also solicited comment on the alternative of using the standard drug packaging threshold, which was proposed to be $140 for CY 2025 and is being finalized as $140 for CY 2025 in section V.B of this final rule with comment period, as the threshold for separate payment for diagnostic radiopharmaceuticals. We believe that diagnostic radiopharmaceuticals are functioning as supplies to the nuclear medicine procedure in which they are used. Because diagnostic radiopharmaceuticals function as supplies in the diagnostic procedures in which they are used, they are serving as an item that is integral, ancillary, supportive, dependent, or adjunctive to the primary diagnostic service. This is in contrast to therapeutic drugs, biologicals, and therapeutic radiopharmaceuticals that are typically packaged under the standard drug packaging threshold. These products could be the only therapeutic modality provided to a patient during an encounter and may not serve as an item that is integral, ancillary, supportive, dependent, or adjunctive to the primary service. Due to this clinical difference, we did not believe that using the standard drug packaging threshold was appropriate for diagnostic radiopharmaceuticals, and therefore we proposed a threshold specific to diagnostic radiopharmaceuticals. As stated in the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222), we were interested to hear from commenters whether they agreed or disagreed with this assessment.</P>
                    <P>
                        <E T="03">Comment:</E>
                         A significant portion of commenters provided broad support for CMS's overall proposal regarding payment for diagnostic radiopharmaceuticals, stating that this policy will ensure access for Medicare beneficiaries, empower clinicians to make the best treatment decisions, and encourage innovation from industry. Commenters frequently stated that this policy will ensure access for underrepresented populations, which often have higher rates of disease but lower rates of detection.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their support.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Many commenters were supportive of CMS's proposal regarding separate payment for diagnostic radiopharmaceuticals, including the packaging threshold of $630. Commenters appreciated that CMS was targeting those products with costs that significantly exceeded the amount of the current packaged payment. These commenters supported the overall methodology and rationale for the calculation of the threshold, which was based on the approximate payment that would typically be attributable to diagnostic radiopharmaceuticals within each nuclear medicine APC by assessing the offsets associated with these APCs that were directly attributable to “policy packaged” drugs. Commenters generally agreed with using two times this amount to establish the threshold as they agreed it correlated with the statutory OPPS two times rule.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their support of our proposal to create a $630 threshold and the associated methodology used to calculate that threshold.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         While many commenters were supportive of CMS's proposed $630 using the two times threshold multiplier, several said they also would not be opposed to a 1.75 multiplier, which would result in a $550 threshold. Other commenters advocated solely for a 1.75 multiplier citing consistency with the OPPS outlier policy, which they believed is a more appropriate comparator policy than the OPPS two times rule.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         The OPPS provides outlier payments to hospitals to help mitigate the financial risk associated with high-cost and complex procedures, where a very costly service could present a hospital with significant financial loss. Outlier payments are provided on a service basis when the cost of a service exceeds the APC payment amount multiplier threshold (1.75) as well as the APC payment amount plus a fixed-dollar amount threshold. An outlier payment is triggered when the cost of a service exceeds two different thresholds, a fixed dollar threshold and a multiplier threshold. A 1.75 multiplier is appropriate for the outlier payment policy as it is combined with a secondary fixed-dollar threshold, which is appropriate for the broader OPPS outlier policy which can apply to a large number of services with vastly different costs and payment amounts. For the OPPS outlier policy, two separate thresholds must be surpassed in order for separate payment to be made. We believe the lower 1.75 multiplier is appropriate for the outlier policy as there is also a secondary threshold that must be met to trigger outlier payments. The single threshold for separate payment for diagnostic radiopharmaceuticals would apply to a much narrower range of products; therefore, we do not believe the same two-threshold system used for OPPS outlier payments is practical. This makes a single threshold more appropriate, and because we are using a single threshold, we believe the higher two times multiplier is more appropriate, as there is not a secondary threshold that must also be surpassed. We believe our proposed approach to multiply the average offset amount by two to set the threshold is the most appropriate approach to determining this threshold, as this results in only those products whose costs significantly exceed, by two-times, the approximate amount of payment already attributed to the product in the nuclear medicine APC payment. This multiplier is consistent with the two-times rule the OPPS uses to determine Ambulatory Payment Classification (APC) levels, which also uses a single two times multiplier, rather than a two-threshold system like the OPPS outlier policy. The OPPS two times rule instructs that a significant service that has a cost greater than two times the lowest cost significant service in an APC is generally moved to a higher-level APC in the series. The two-times rule requires that the highest calculated cost of an individual procedure categorized to any given APC cannot exceed two times the calculated cost of the lowest cost procedure assigned to that same APC. A two times multiplier ensures that separate payment would apply only to diagnostic radiopharmaceuticals whose costs significantly exceed the approximate amount of payment already attributed to the product in the nuclear medicine APC payment.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A few commenters suggested other thresholds, such as the OPPS drug packaging threshold, in order to treat diagnostic radiopharmaceuticals in a similar manner as other drugs, biologicals, and therapeutic radiopharmaceuticals paid under the OPPS. Commenters also believed that using a lower threshold actually decreased the likelihood that a provider would be financially incentivized to use a product above the threshold, as more products would be paid separately using a lower threshold. They believed a lower threshold decreased the likelihood of a non-clinical financial incentive to use a higher cost radiopharmaceutical. Other commenters believed using a $500 threshold would be appropriate as it coincided with the figure used for separate payment for diagnostic radiopharmaceuticals in draft legislation, titled the Facilitating Innovative Nuclear Diagnostics (FIND) Act. Commenters also suggested using an alternative threshold multiplier, such as 1.51, 1.50, or 1.25. These commenters thought these lower thresholds would 
                        <PRTPAGE P="93953"/>
                        allow for more products to be paid separately and argued a cost for a diagnostic radiopharmaceutical even 25 percent higher than the average diagnostic radiopharmaceutical cost could be considered significant and warrant separate payment. Two commenters suggested reassessing the threshold based on the changing costs of products over time or assessing which products are driving the APC payments and then setting the threshold higher than the cost of those high-volume products.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their comments; however, we believe the commenters' suggested thresholds are inconsistent with our OPPS two-times rule as described, which we believe is a longstanding and reasonable proxy for determining when costs exceed payment to a degree that warrants payment modification. The two-times rule utilizes a two times multiplier to determine APC levels, where a significant service that has a cost greater than two times the lowest cost significant service in an APC is generally moved to a higher-level APC in the series. The lower thresholds suggested by commenters would not follow this principle, and therefore, would not exclusively identify diagnostic radiopharmaceuticals whose costs significantly exceed the approximate amount of payment already attributed to the product in the nuclear medicine APC payment. We believe diagnostic radiopharmaceuticals are unique and therefore warrant their own specific threshold that is distinct from the broader drug packaging threshold used for therapeutic drugs, biologicals, and radiopharmaceuticals. This is because diagnostic radiopharmaceuticals are functioning as supplies to the nuclear medicine procedure in which they are used and are serving as an item that is integral, ancillary, supportive, dependent, or adjunctive to the primary diagnostic service. This is in contrast to therapeutic drugs, biologicals, and therapeutic radiopharmaceuticals that are typically packaged under the standard drug packaging threshold. These products could be the only therapeutic modality provided to a patient during an encounter and may not serve as an item that is integral, ancillary, supportive, dependent, or adjunctive to the primary service. Due to these differences, we believe a threshold specific to diagnostic radiopharmaceuticals is appropriate.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Some commenters advocated that CMS use a threshold of at least $630. Several commenters believed that focusing separate payment on those radiopharmaceuticals whose costs significantly exceed the payment already attributable to the product will help concentrate the effects of unbundling on only those products that are most likely to create access issues for beneficiaries while reducing the broader effects on the nuclear medicine APCs. One commenter stated that unpackaging radiopharmaceuticals with per day costs greater than $630 would decrease the nuclear medicine APC procedure payment rates, but that decrease would be exacerbated if CMS used a lower threshold.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their support. We agree a $630 threshold would appropriately identify only those diagnostic radiopharmaceuticals whose costs significantly exceed the approximate amount of payment already attributed to the product in the nuclear medicine APC payment.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters requested that CMS clarify that the proposal does not alter the qualifications for pass-through payment status or the pass-through payment methodology for those diagnostic radiopharmaceuticals that apply for pass-through status under the OPPS.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         That is correct. This policy is distinct from the policies described in section V.A of this final rule with comment period, which describe the qualifications and payment methodology for those products that qualify for OPPS pass-through status.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A few commenters recommended CMS monitor the effects of this policy if finalized. For example, one commenter supported the proposal, but suggested CMS carefully monitor the affected nuclear medicine APCs and address any larger than expected alterations to their reimbursement or other unintended consequences. An additional commenter encouraged CMS to continue to evaluate this methodology as new products enter the market. This commenter recommended CMS ensure no unintended consequences of this policy occur, such as manufacturers purposefully pricing their products just above the payment threshold.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their support. We will monitor the effects of this policy and will consider proposing modifications in future rulemaking if appropriate.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter sought clarification from CMS that, if finalized, its proposal to provide separate payment for diagnostic radiopharmaceutical products would be implemented in a budget neutral manner.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         Yes. This policy will be implemented in a budget neutral manner.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing this aspect of our proposal without modification and will pay separately for any diagnostic radiopharmaceutical with a per day cost greater than $630 for CY 2025. Any diagnostic radiopharmaceutical with a per day cost at or below that threshold will continue to be policy packaged under the current policy at § 419.2(b)(15).</P>
                    <HD SOURCE="HD3">(3) Calculating the Per Day Cost of Diagnostic Radiopharmaceuticals</HD>
                    <P>We proposed to calculate the per day costs for diagnostic radiopharmaceuticals using a methodology similar to the one we use for determining the per day costs of drugs and biologicals for comparison to the OPPS drug packaging threshold, proposed to be $140 for CY 2025.</P>
                    <P>We proposed to calculate the per day cost based on the methodology described in section V.B.1.b of the CY 2025 OPPS/ASC proposed rule, which relies on the methodology in the CY 2006 OPPS/ASC proposed rule (70 FR 42723 and 42724) and finalized in the CY 2006 OPPS final rule with comment period (70 FR 68636 through 68638). Though the clinical use of the drugs, biologicals, and therapeutic radiopharmaceuticals differs from diagnostic radiopharmaceuticals, we believe the method of determining how much of that item is used per day should be similar. Therefore, we proposed to use a similar methodology for determining the per day costs of diagnostic radiopharmaceuticals, as we do drugs, biologicals, and therapeutic radiopharmaceuticals. This methodology consists of nine steps:</P>
                    <P>
                        <E T="03">Step 1.</E>
                         After application of the CCRs, we aggregated all line-items for a single date of service on a single claim for each product. This resulted in creation of a single line-item with the total number of units and the total cost of a diagnostic radiopharmaceutical given to a patient in a single day.
                    </P>
                    <P>
                        <E T="03">Step 2.</E>
                         We then created a separate record for each diagnostic radiopharmaceutical by date of service, regardless of the number of lines on which the diagnostic radiopharmaceutical was billed on each claim. For example, “diagnostic radiopharmaceutical X” is billed on a claim with two different dates of service, and for each date of service, the diagnostic radiopharmaceutical is billed on two line-items with a cost of $10 and 5 units for each line-item. In this case, 
                        <PRTPAGE P="93954"/>
                        the computer program would create two records for this diagnostic radiopharmaceutical, and each record would have a total cost of $20 and 10 units of the product.
                    </P>
                    <P>
                        <E T="03">Step 3.</E>
                         We trimmed records with unit counts per day greater or less than 3 standard deviations from the geometric mean.
                    </P>
                    <P>
                        <E T="03">Step 4.</E>
                         For each remaining record for a diagnostic radiopharmaceutical, we calculated the cost per unit of the diagnostic radiopharmaceutical. If the HCPCS descriptor for “diagnostic radiopharmaceutical X” is “per 1 millicurie” and one record was created for a total of 10 millicurie (as indicated by the total number of units for the diagnostic radiopharmaceutical on the claim for each unique date of service), the computer program divided the total cost for the record by 10 to give a per unit cost. We then weighted this unit cost by the total number of units in the record. We did this by generating a number of line-items equivalent to the number of units in that particular claim. Thus, a claim with 100 units of “diagnostic radiopharmaceutical X” and a total cost of $200 would be given 100 line-items, each with a cost of $2, while a claim of 50 units with a cost of $50 would be given 50 line items, each with a cost of $1.
                    </P>
                    <P>
                        <E T="03">Step 5.</E>
                         We trimmed the unit records with cost per unit greater or less than 3 standard deviations from the geometric mean.
                    </P>
                    <P>
                        <E T="03">Step 6.</E>
                         We aggregated the remaining unit records to determine the mean cost per unit of the diagnostic radiopharmaceutical.
                    </P>
                    <P>
                        <E T="03">Step 7.</E>
                         Using only the records that remained after records with unit counts per day greater or less than 3 standard deviations from the geometric mean were trimmed (step 3), we determined the total number of units billed for each item and the total number of unique per-day records for each item. We divided the count of the total number of units by the total number of unique per day records for each item to calculate an average number of units per day.
                    </P>
                    <P>
                        <E T="03">Step 8.</E>
                         We used the payment rate (the mean unit cost (MUC) derived from the CY 2023 hospital claims data) for each diagnostic radiopharmaceutical and multiplied the payment rate by the average number of units per day for each diagnostic radiopharmaceutical to arrive at its per day cost.
                    </P>
                    <P>
                        <E T="03">Step 9.</E>
                         We packaged the items with per day costs less than or equal to $630 and designated items with per day costs greater than $630 as separately payable.
                    </P>
                    <P>As just described, to determine the proposed CY 2025 packaging status for all nonpass-through diagnostic radiopharmaceuticals, we proposed to use the per day cost, calculated on a HCPCS code-specific basis, of each diagnostic radiopharmaceutical that had a HCPCS code in CY 2023 and was paid (via packaged or separate payment) under the OPPS. We used data from CY 2023 claims processed through December 31, 2023, for this calculation.</P>
                    <P>We proposed to continue to package payment for diagnostic radiopharmaceuticals with per day costs less than or equal to $630 under our existing packaging policy for diagnostic radiopharmaceuticals that function as surgical supplies under § 419.2(b)(15). Similar to our policy for the drug packaging threshold, we proposed to use updated claims data to make final determinations of the packaging status of HCPCS codes for diagnostic radiopharmaceuticals for each OPPS/ASC final rule with comment period. We proposed to make an annual packaging determination for each diagnostic radiopharmaceutical HCPCS code only when we develop the OPPS/ASC final rule with comment period for the update year. We proposed that only diagnostic radiopharmaceutical HCPCS codes that are identified as separately payable in this final rule with comment period would be subject to quarterly updates.</P>
                    <P>Consequently, the packaging status of some HCPCS codes for diagnostic radiopharmaceuticals in the OPPS/ASC proposed rule may differ from the same HCPCS codes' packaging status determined based on the data used for the final rule with comment period. Under these circumstances, we proposed to follow the established policies for the OPPS drug packaging threshold, which were initially adopted for the CY 2005 OPPS (69 FR 65780), to more equitably pay for those diagnostic radiopharmaceuticals whose costs fluctuate relative to the proposed CY 2025 OPPS diagnostic radiopharmaceutical packaging threshold in a way that affects the product's payment status (packaged or separately payable). Our policy for the OPPS drug packaging threshold has not changed for many years and is the same as described in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70434). We believe these same policies should apply to diagnostic radiopharmaceuticals in order to ensure payment consistency for those diagnostic radiopharmaceuticals whose costs fluctuate relative to the proposed CY 2025 OPPS diagnostic radiopharmaceutical packaging threshold. For CY 2025, similar to our historical practice for the drug packaging threshold, we proposed to apply the following policies to those HCPCS codes for diagnostic radiopharmaceuticals whose relationship to the diagnostic radiopharmaceutical packaging threshold changes based on the final updated data: HCPCS codes for diagnostic radiopharmaceuticals that are proposed for separate payment in CY 2025, and that then have per day costs equal to or less than the CY 2025 final rule diagnostic radiopharmaceutical packaging threshold, based on the updated hospital claims data used for the CY 2025 final rule, would remain packaged in CY 2025. HCPCS codes for diagnostic radiopharmaceuticals for which we proposed packaged payment in CY 2025 but that then have per-day costs greater than the CY 2025 final rule drug packaging threshold, based on updated hospital claims data used for the CY 2025 final rule, would receive separate payment in CY 2025.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Most commenters were supportive of the methodology used to calculate the per day costs, and many commenters were able to analyze the cost data published with the proposed rule and calculate the same list of products with per day costs exceeding $630.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their support of our proposal, and for their agreement with our calculations of the per day costs.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A few commenters recommended CMS consider alternative methods of calculating per day costs and make refinements in the future as we gain more experience with this policy.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their input. Our methods for calculating per day cost are consistent with our longstanding policies for calculating per day costs for purposes of the OPPS drug packaging threshold and we believe they should be finalized for CY 2025 and subsequent years. We could address this methodology in future rulemaking if the need arises; however, this methodology has worked effectively for calculating per day costs of drugs, biologicals and radiopharmaceuticals for purposes of the OPPS drug packaging threshold, and we believe this well-known process will work equally well for diagnostic radiopharmaceuticals to create a trimmed data set from which from per day costs can be calculated.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Many commenters recommended that CMS not apply the proposed packaging rules in 2025 and pay separately for any product that was proposed for separate payment or that exceeds the cost threshold in the final rule data. Commenters stated that CMS 
                        <PRTPAGE P="93955"/>
                        should only consider applying its proposed methodology after the separate payment threshold has been in effect for a reasonable period of time. Specifically, commenters recommended that HCPCS codes for diagnostic radiopharmaceuticals that are proposed for separate payment in CY 2025, and that then have per day costs equal to or less than the threshold for the final rule, be separately paid. Similarly, commenters believed HCPCS codes for diagnostic radiopharmaceuticals for which CMS proposed packaged payment in CY 2025 but that then have per-day costs greater than the CY 2025 final rule drug packaging threshold, based on updated hospital claims data used for the CY 2025 final rule, receive separate payment in CY 2025.
                    </P>
                    <P>Commenters stated that the claims data and the cost report data are updated between the proposed and final rule. Specifically, commenters noted that the determination of whether a diagnostic radiopharmaceutical will qualify for separate payment uses both units and mean cost calculated from Medicare claims data to determine the per day cost. As the mean cost estimate relies on cost-to-charge ratios, in the commenter's view, the diagnostic radiopharmaceutical packaging determination is susceptible to fluctuations in the mean cost estimate and those fluctuations are not necessarily driven by variation in the actual price of the product. The commenter stated that this is in contrast to ASP based payment rates, as ASP is an external estimate of product cost.</P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their comments and understand their concerns about potential cost data fluctuations changing packaging determinations between the proposed and final rule. However, based on updated data for the final rule, the diagnostic radiopharmaceuticals that have per day costs that exceed $630 are the same 26 diagnostic radiopharmaceuticals that exceeded the $630 threshold using proposed rule data, meaning, for purposes of determining whether a product's per day cost exceeded $630, the updated data for the final rule did not change the list of qualifying products.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal regarding the calculation of per day costs of diagnostic radiopharmaceuticals without modification. Specifically, we are finalizing a policy to calculate the per day costs for diagnostic radiopharmaceuticals for purposes of determining whether a diagnostic radiopharmaceutical qualifies for separate payment using a methodology similar to the one we use for determining the per day costs of drugs and biologicals for comparison to the OPPS drug packaging threshold. We calculated the per day cost based on the methodology described in section V.B.1.b of this final rule with comment period, which relies on the methodology in the CY 2006 OPPS/ASC proposed rule (70 FR 42723 and 42724) and finalized in the CY 2006 OPPS final rule with comment period (70 FR 68636 through 68638).</P>
                    <HD SOURCE="HD3">(4) Updating the Diagnostic Radiopharmaceutical Packaging Threshold in CY 2026</HD>
                    <P>Starting in CY 2026 and subsequent years, we proposed to update the proposed threshold amount of $630 by the PPI for Pharmaceuticals for Human Use (Prescription) (Bureau of Labor Statistics series code WPUSI07003) from IHS Global, Inc (IGI). IGI is a nationally recognized economic and financial forecasting firm with which CMS contracts to forecast the various price indexes including the Producer Price Index (PPI) Pharmaceuticals for Human Use (Prescription). This is the same as the update factor used for the OPPS drug packaging threshold, where we originally used the four-quarter moving average PPI levels for Pharmaceutical Preparations (Prescription) to trend the $50 threshold forward from the third quarter of CY 2005 (when the Pub. L. 108-173 mandated threshold became effective) to the third quarter of the applicable calendar year. We believe it is appropriate to use the same PPI for Pharmaceuticals for Human Use (Prescription) for the diagnostic radiopharmaceutical packaging threshold, as diagnostic radiopharmaceuticals are also prescription pharmaceuticals for human use. We proposed that starting for CY 2026, we would use the most recently available four quarter moving average PPI levels to trend the final CY 2025 threshold forward from the third quarter of CY 2024 to the third quarter of CY 2025 and round the resulting dollar amount to the nearest $5 increment. We explained that the proposal to update the diagnostic radiopharmaceutical packaging threshold would maintain consistency with our longstanding methodology for updating the OPPS drug packaging threshold, which is discussed in more detail in section V.B.1.a. of this final rule with comment period and also in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68085 and 68086).</P>
                    <P>
                        <E T="03">Comment:</E>
                         The majority of commenters supported our proposal to update the final threshold by the PPI for Pharmaceuticals for Human Use (Prescription) in CY 2026 and future years. They stated this was appropriate to reflect the increasing cost of diagnostic radiopharmaceuticals annually.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their support.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A small number of commenters were not in favor of our proposal to update the threshold by the PPI for Pharmaceuticals for Human Use (Prescription). One commenter believed CMS should take a broader approach and comprehensively review the appropriateness of the threshold amount yearly based on data for that year.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their insights; however, we continue to believe it is appropriate to subject the diagnostic radiopharmaceutical packaging threshold to the same update factor that is used for the OPPS drug packaging threshold as supported by the majority of commenters. Updating the finalized threshold by the PPI for Pharmaceuticals for Human Use (Prescription) is consistent with our longstanding policy to update the OPPS drug packaging threshold annually. This PPI update factor provides aggregate changes in the selling prices of pharmaceuticals, which makes it an appropriate factor with which to update the diagnostic radiopharmaceutical packaging threshold to ensure that as diagnostic radiopharmaceuticals' costs change over time, the threshold continues to identify products with costs that significantly exceed the otherwise applicable APC payment amounts as determined in this rule and that therefore should be eligible for separate payment.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal to update the finalized packaging threshold without modification. Specifically, starting in CY 2026 and for subsequent years, we will update the threshold amount of $630 by the PPI for Pharmaceuticals for Human Use (Prescription) (Bureau of Labor Statistics series code WPUSI07003) from IHS Global, Inc (IGI).</P>
                    <HD SOURCE="HD3">(5) Amount of Separate Payment for Diagnostic Radiopharmaceuticals Exceeding the Threshold</HD>
                    <P>
                        As discussed in the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222), once we determine that the per day cost of a nonpass-through diagnostic radiopharmaceutical exceeds the cost threshold of $630 per day for CY 2025, we then proposed to assign that radiopharmaceutical to an APC, 
                        <PRTPAGE P="93956"/>
                        making it a specified covered outpatient drug (SCOD) per section 1833(t)(14)(B) of the Act. Accordingly, we proposed to pay for those nonpass-through, separately payable diagnostic radiopharmaceuticals based on our authority under section 1833(t)(14)(A)(iii)(II) of the Act. While under this authority we would ordinarily use the ASP methodology under section 1847A of the Act, we find that the ASP data we have is not usable for payment purposes. As previously mentioned, radiopharmaceuticals are not required to report ASP under section 1847A of the Act, and as such, there are very few manufacturers reporting ASP for their products currently. As discussed in the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222), of those few manufacturers reporting ASP, the ASP values that we do have generally do not align with the ASP we would expect based on the cost and Mean Unit Cost (MUC) data submitted to CMS by hospitals. For example, a frequently used diagnostic radiopharmaceutical had a reported ASP that is over 23,000 percent higher than the MUC derived from claims data. As manufacturers of diagnostic radiopharmaceuticals may be unaware of the correct reporting requirements, we explained that we believe it would be inappropriate to propose to pay for separately payable diagnostic radiopharmaceuticals based on their ASPs as currently reported, without giving manufacturers the opportunity to submit, certify, or restate the ASPs of their products. We believed MUC would be an appropriate proxy for the average price for a diagnostic radiopharmaceutical for a given year, as it is calculated based on the average costs for a particular year and is directly reflective of the actual cost data that hospitals submit to CMS.
                    </P>
                    <P>In the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222), we stated that under our policy for therapeutic radiopharmaceuticals (74 FR 60520), there are several requirements for reporting ASP. For example, ASP data submitted would need to be provided for a patient-specific dose, or patient-ready form, of the radiopharmaceutical in order to properly calculate the ASP amount for a given HCPCS code if that HCPCS code dose descriptor was per study dose or similar. ASP data submitted should align with the code's dose descriptor and billing unit. We stated we would expect that the ASP data reported by a manufacturer would be representative of the item(s) sold by the manufacturer. We used the term “patient-ready” in that rule to ensure that ASP data submitted for OPPS payment purposes for separately payable radiopharmaceuticals reflect the costs of all the component materials of the finished radiopharmaceutical product. We expected that the ASP data would represent the sales price of all of the component materials of the finished radiopharmaceutical product sold by the manufacturer in terms that reflect the applicable HCPCS code descriptor such as “per study dose”, “per millicurie” and “up to XX millicuries.” For the few manufacturers that reported ASP data for their diagnostic radiopharmaceuticals, we believed it may be possible that they are not aware of the reporting requirements or are unaware of how to properly report ASP for their product, as CMS has not used ASP as the basis of payment for nonpass-through diagnostic radiopharmaceuticals before. Therefore, we explained that we believe a reasonable alternative for CY 2025 for separate payment of diagnostic radiopharmaceuticals that exceed the per day cost threshold is to use of their mean unit cost from claims data. This is consistent with our current practice for therapeutic radiopharmaceuticals when ASP data is not available. For diagnostic radiopharmaceuticals, we believe that ASP data is effectively not available for purposes of determining a payment amount and, therefore, payment based on MUC is a reasonable alternative.</P>
                    <P>We previously acknowledged (74 FR 35335), and continue to acknowledge, the complexities associated with reporting ASP for radiopharmaceuticals. We encourage manufacturers to submit ASP information for diagnostic radiopharmaceuticals, if possible. While we proposed to use MUC to pay for separately payable diagnostic radiopharmaceuticals in CY 2025, manufacturers can begin, or continue, to report ASP data for potential future use in paying for diagnostic radiopharmaceuticals. For CY 2025, ASP reporting is voluntary for diagnostic radiopharmaceuticals paid under the OPPS. We encouraged interested parties to submit comments regarding potential issues that may arise that prevent appropriate ASP reporting for diagnostic radiopharmaceuticals. If manufacturers choose to report ASP data, the data must meet reporting requirements to be used for payment under the OPPS.</P>
                    <P>As discussed in the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222), manufacturers that choose to report ASP data for their diagnostic radiopharmaceuticals would need to provide comprehensive data for CMS to calculate an ASP amount for a given HCPCS code. In instances where there is more than one manufacturer of a particular diagnostic radiopharmaceutical, we proposed that all manufacturers would need to submit ASP information for payment to be made based on ASP. This is because it would be inappropriate for Medicare payment for a HCPCS code to be based on the payment information submitted by one manufacturer, if that payment is used for a product made by different manufacturers. This is because the ASP information reported by one manufacturer might not reflect the ASP of the same product made by other manufacturers.</P>
                    <P>We note that ASP submissions for radiopharmaceutical payment under the OPPS would need to meet all of the existing regulatory and subregulatory requirements of the ASP reporting process under sections 1847A and 1927(b)(3) of the Act.</P>
                    <P>
                        Specifically, we reiterated our ASP reporting requirements outlined in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60520) for products for which we are encouraging the reporting of ASP, but for which reporting is not statutorily required. The ASP data submitted would need to be provided for a patient-specific dose, or patient-ready form, of the diagnostic radiopharmaceutical in order to properly calculate the ASP amount that aligns with the dose descriptor for a given HCPCS code. When reporting an ASP for a separately payable radiopharmaceutical, we expect that the ASP data reported by a manufacturer would be representative of the item(s) sold by the manufacturer. In the CY 2010 OPPS/ASC final rule with comment period (74 FR 60520), we used the term “patient-ready” to ensure that ASP data submitted for OPPS payment purposes for separately payable radiopharmaceuticals reflect the costs of all the component materials of the finished radiopharmaceutical product. We expect that the ASP data would represent the sales price of all of the component materials of the finished radiopharmaceutical product sold by the manufacturer in terms that reflect the applicable HCPCS code descriptor, such as “per study dose” or “millicurie.” We defined a “patient-ready” dose for OPPS purposes as including all component materials of the radiopharmaceutical, at a minimum, and any other processing the manufacturer requires to produce the radiopharmaceutical that it sells that are reflected in the sales price, including radiolabeling, as long as any fees paid for such processing done on behalf of 
                        <PRTPAGE P="93957"/>
                        the manufacturer meet the definition of “bona fide service fees” under § 414.802 (74 FR 60525).
                    </P>
                    <P>As discussed in the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222), we understand that manufacturers of separately payable radiopharmaceuticals produce radiopharmaceuticals that require a variety of processing steps in order to prepare the product for administration to a beneficiary. To be used for separate OPPS radiopharmaceutical payment, the ASP data reported by a manufacturer must represent sales of all of the component materials associated with the radiopharmaceutical. For our full policy on which factors to incorporate into ASP pricing, please see the CY 2010 OPPS/ASC final rule with comment period (74 FR 60520 through 60521).</P>
                    <P>In order to be used for payment under the OPPS, all radiopharmaceutical ASP submissions should meet the existing regulatory and subregulatory requirements of the ASP submission process under sections 1847A and 1927(b)(3) of the Act. In particular, we explained that we believe the “bona fide service fee” test in the ASP regulations is instructive here, and we refer readers to the CY 2010 OPPS/ASC final rule with comment period for our discussion on radiopharmaceutical ASP reporting (74 FR 60521).</P>
                    <P>
                        To summarize our CY 2010 policy for ASP reporting on radiopharmaceuticals for OPPS payment purposes (74 FR 60521), a patient-specific dose or patient-ready form in the context of OPPS ASP submission for radiopharmaceutical payment means that the ASP reflecting manufacturer sales must represent sales of all of the component materials for the radiopharmaceutical, including a minimum of a cold kit and a radioisotope, and be reported in terms that reflect the applicable HCPCS code descriptor, such as “treatment dose” or “millicurie.” The ASP would not necessarily take into account the preparation of the final form of the radiopharmaceutical for patient administration, including radiolabeling, which may be conducted by the manufacturer, freestanding radiopharmacy, hospital pharmacy, or other entity. With respect to the latter, fees paid by the manufacturer for these services would be excluded from the ASP calculation (that is, would not be considered price concessions that reduce the ASP) only if they are “bona fide service fees” as defined in the regulations governing ASP. Thus, if the manufacturer pays a “bona fide service fee” for the services of the freestanding radiopharmacy, hospital pharmacy, or other entity, and reflects that fee in its price for the radiopharmaceutical, the amount of the “bona fide service fee” would be taken into account in the reported ASP data. However, manufacturers are not required to pay for the preparation of a radiopharmaceutical (including radiolabeling) in a freestanding radiopharmacy, hospital pharmacy, or other entity after sale of all of the component materials, and in that case, the cost of those services would not be reflected in the ASP data submitted to CMS. Manufacturers should submit ASP data for a separately payable radiopharmaceutical that incorporates prices for sales of all of the component materials by the manufacturer. We sought comment on these ASP reporting requirements outlined in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60521) and previous CMS guidance on the guidelines for the Submission of OPPS ASP Data for Nonpass-Through Separately Payable Therapeutic Radiopharmaceuticals and Radiopharmaceuticals with Pass-Through Status.
                        <SU>8</SU>
                        <FTREF/>
                         We continue to believe that these ASP reporting practices should be applicable to radiopharmaceuticals, including both therapeutic and diagnostic radiopharmaceuticals, but sought comment from interested parties in this space to ensure that these reporting guidelines are clear and reflective of clinical practice today.
                    </P>
                    <FTNT>
                        <P>
                            <SU>8</SU>
                             
                            <E T="03">https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/opps_asp_radiopharm_guidance10302009.pdf.</E>
                        </P>
                    </FTNT>
                    <P>We mentioned in the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222) that we still see the potential value in the use of ASP data for payment purposes for diagnostic radiopharmaceuticals when reported correctly and by all manufacturers who manufacture a product that is described by a given HCPCS code. We stated that we believe that the use of ASP information for OPPS payment could provide an opportunity to improve payment accuracy for separately payable diagnostic radiopharmaceuticals by applying an established methodology that has already been successfully implemented under the OPPS for other separately payable drugs and biologicals, as well as therapeutic radiopharmaceuticals. Because the per day cost calculations determine whether a diagnostic radiopharmaceutical qualifies for separate payment, using the most accurate pricing information is paramount. The use of ASP information could provide an opportunity to further improve the accuracy of the per day cost calculations and the separate payment amounts for diagnostic radiopharmaceuticals. As previously mentioned, we do not believe that the limited amount of ASP information submitted currently is adequate for the purpose of determining separate payment for those few products that currently do report ASP, which is why we proposed to pay diagnostic radiopharmaceuticals with per day costs above the $630 threshold at each diagnostic radiopharmaceutical's mean unit cost. However, we were still interested in the potential to use ASP for the purpose of determining a diagnostic radiopharmaceutical's per day cost and payment amount in the future. Therefore, we wanted to engage with interested parties to learn about the unique aspects and challenges that may be associated with reporting ASP for diagnostic radiopharmaceuticals, and radiopharmaceuticals in general. We specifically sought comment as to whether interested parties believe CMS should require payment for diagnostic radiopharmaceuticals to be based on ASP in the future, such as in CY 2026 rulemaking, if interested parties are confident in their reporting ability.</P>
                    <P>
                        We discussed in the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222) that we do believe that there could be situations in which it is appropriate to use ASP currently. For example, in section V.A.4 of the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222), we proposed to utilize ASP in payment for diagnostic radiopharmaceuticals on OPPS transitional pass-through status. In this situation, we believed the use of ASP is appropriate as the manufacturer of that diagnostic radiopharmaceutical is actively involved in the radiopharmaceutical's pass-through application, and CMS can ensure that pricing is reported appropriately for purposes of the drug pass-through cost significance tests and for purposes of payment if the pass-through status is approved. Typically, there is only one manufacturer for a diagnostic radiopharmaceutical applying for pass-through status, so CMS does not have to ensure all manufacturers are reporting ASP for that particular HCPCS code prior to establishing a separate payment amount based on ASP. Additionally, as discussed in section V.B.5 of the CY 2025 OPPS/ASC proposed rule (Proposed Payment for Nonpass-Through Drugs, Biologicals, and Radiopharmaceuticals with HCPCS Codes but Without OPPS Hospital 
                        <PRTPAGE P="93958"/>
                        Claims Data), we proposed to base the initial payment for new diagnostic radiopharmaceuticals with HCPCS codes, but which do not have pass-through status and are without claims data, on ASP, and on WAC if ASP data for these diagnostic radiopharmaceuticals are not available. If the WAC also is unavailable, we proposed to make payment for new diagnostic radiopharmaceuticals at 95 percent of the products' most recent AWP. We believe the volume of products in this category will typically be very low; however, in these rare situations, we believe it would be appropriate to use ASP until a MUC is available. Similar to drugs applying for pass-through status, there is typically only one manufacturer for a diagnostic radiopharmaceutical that is new and described by a HCPCS code, but without claims data, so CMS does not have to ensure all manufacturers are reporting ASP for that particular HCPCS code prior to establishing a separate payment amount based on ASP. Additionally, although reporting of ASP is not a condition of CMS approving a HCPCS application, CMS has the opportunity to actively engage with the manufacturer, or sponsor of a HCPCS application, during the HCPCS application process. This allows for ongoing dialogue and education regarding the unique ASP reporting requirements that may be associated with a particular product, including how to ensure the reported ASP aligns with the dose descriptor for the newly assigned HCPCS code.
                    </P>
                    <P>We sought comments on additional unique situations in which it still may be appropriate for CMS to use ASP information to assess per day costs and payment amounts for diagnostic radiopharmaceuticals for CY 2025. For example, we stated that one such unique situation could be continuing the use of ASP for a particular HCPCS code once its pass-through status has ended, if the HCPCS code was actively being paid based on ASP while on pass-through status. Under our proposal, payment for a diagnostic radiopharmaceutical would be based on MUC once its pass-through status ends. We sought comment on this potential unique situation, as well as others of which readers may be aware. We stated that we may finalize utilizing ASP in additional situations that commenters bring to our attention in the final rule as policies for CY 2025 depending on comments received.</P>
                    <P>As discussed, we proposed to base the payment rate for diagnostic radiopharmaceuticals on mean unit cost data derived from hospital claims. We did not propose to use ASP data for determining payment rates of nonpass-through diagnostic radiopharmaceuticals with claims data but are seeking comment on its use for determining the per day cost and setting the payment rate for diagnostic radiopharmaceuticals in the future. Additionally, we did not propose to use WAC or AWP as a basis for payment for diagnostic radiopharmaceuticals. Similar to our reasoning for payment of therapeutic radiopharmaceuticals in the CY 2012 OPPS/ASC final rule with comment period (77 FR 68390), we believe that paying for diagnostic radiopharmaceuticals using mean unit cost would appropriately pay for the average price of nonpass-through separately payable diagnostic radiopharmaceuticals for the applicable year. We believe MUC is an appropriate proxy for the average price for a diagnostic radiopharmaceutical for a given year, as it is calculated based on the average costs for a particular year and is directly reflective of the actual cost data that hospitals submit to CMS.</P>
                    <P>As we stated in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60523), we believe that WAC or AWP is not an appropriate proxy to provide OPPS payment for average therapeutic radiopharmaceutical acquisition cost and associated handling costs when manufacturers are not required to submit ASP data because payment based on WAC or AWP for separately payable drugs and biologicals is usually temporary for a calendar quarter until a manufacturer is able to submit the required ASP data in accordance with the quarterly ASP submission timeframes for reporting under section 1847A of the Act. However, WAC and AWP reported to compendia may not be reflective of a patient ready dose. We are additionally concerned about the use of WAC and AWP since ASP reporting for OPPS payment of separately payable diagnostic radiopharmaceuticals would not be required for CY 2025. The absence of appropriate ASP reporting could result in payment for a separately payable diagnostic radiopharmaceutical based on WAC or AWP indefinitely, a result which we believe would be inappropriate, as these pricing metrics do not capture all of the pricing discounts that may be reflected in the ASP. In the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222), we stated that given all of the concerns we had with other pricing methodologies for diagnostic radiopharmaceuticals, we proposed to rely on CY 2023 mean unit cost data derived from hospital claims data for payment rates for diagnostic radiopharmaceuticals for CY 2025.</P>
                    <P>Our proposed payment methodology for diagnostic radiopharmaceuticals that have costs above a $630 threshold would be similar, but not the same, as the methodology adopted for therapeutic radiopharmaceuticals as described in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60518). Although therapeutic radiopharmaceuticals are generally targeted at treating a certain disease or condition, and diagnostic radiopharmaceuticals are generally targeted at diagnosing a certain disease or condition, we believe they are clinically very similar products, manufactured in a similar manner, and should generally be paid using a similar payment methodology when paid separately. As such, we stated that we believe the same payment method as is used for therapeutic radiopharmaceuticals should apply to diagnostic radiopharmaceuticals above the cost threshold. However, as previously discussed, given our concerns with current ASP reporting patterns, we proposed to use MUC as the basis of payment for nonpass-through diagnostic radiopharmaceuticals for CY 2025. Therefore, we explained that we believe it is appropriate for the methodology to determine the proposed payment amounts to differ between diagnostic and therapeutic radiopharmaceuticals, at least for CY 2025. We stated that we will consider aligning the payment methodologies between therapeutic and diagnostic radiopharmaceuticals, either based on ASP or MUC, in future rulemaking.</P>
                    <P>We explained that we believe that mean unit cost data is an appropriate and adequate proxy for the average price for diagnostic radiopharmaceuticals and associated handling costs for these products. Mean unit cost data is reflective of the actual cost data that hospitals submit to CMS. The MUC payment methodology is consistent with our payment policy for therapeutic radiopharmaceuticals as stated in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60523) and is currently the basis of payment for many therapeutic radiopharmaceuticals when ASP is unavailable.</P>
                    <P>
                        As previously discussed, we find that the ASP data we have is not usable for the purpose of paying for diagnostic radiopharmaceuticals and, therefore, we proposed to pay for qualifying nonpass-through diagnostic radiopharmaceuticals with claims data based on MUC. However, we also sought comment on how we could 
                        <PRTPAGE P="93959"/>
                        potentially use our equitable adjustment authority at section 1833(t)(2)(E) of the Act to make an adjustment to the ASP data that has been reported in order to make it usable for the purpose of paying equitably for these products. For example, we sought comment as to whether CMS could use its equitable adjustment authority to adjust payment for diagnostic radiopharmaceuticals based on an adjusted ASP value when the ASP amounts reported to CMS deviate by a given threshold, such as two times the MUC calculated for the diagnostic radiopharmaceutical using claims data. Alternatively, the adjusted payment rate could be an average of the reported ASP and MUC, or other methodologies suggested by commenters. We broadly sought comment on this potential use of equitable adjustment authority to make the limited ASP data reported for diagnostic radiopharmaceuticals usable for purposes of setting payment rates for qualifying products.
                    </P>
                    <P>We note, if readers do not believe it is appropriate for CMS to base the payment amount for diagnostic radiopharmaceuticals on MUC for CY 2025, we proposed in the alternative to maintain our current policy of unconditionally policy packaging all diagnostic radiopharmaceuticals regardless of their cost until an appropriate payment methodology can be established to determine a separate payment amount for diagnostic radiopharmaceuticals.</P>
                    <P>We stated that HCPCS codes that describe diagnostic radiopharmaceuticals with per day costs that meet or exceed the proposed diagnostic radiopharmaceutical packaging threshold would be assigned to a status indicator of “K”, indicating separate payment. An APC and a payment rate would be assigned as shown in Addendum B to the proposed rule. HCPCS codes that describe diagnostic radiopharmaceuticals with per day costs that are at or below the proposed diagnostic radiopharmaceutical packaging threshold would continue to be assigned to a status indicator of “N”, indicating packaged payment. We welcomed comment on these determinations. The proposed list of diagnostic radiopharmaceuticals that we calculated as having per day costs that exceed $630 and their proposed status indicators can be found in Table 8.</P>
                    <GPH SPAN="3" DEEP="480">
                        <PRTPAGE P="93960"/>
                        <GID>ER27NO24.012</GID>
                    </GPH>
                    <P>Proposed definitions of status indicators were included in Addendum D1 to the CY 2025 OPPS/ASC proposed rule (89 FR 59213 through 59222). Addenda to that proposed rule can be found on the CMS OPPS web page.</P>
                    <P>We proposed corresponding regulation text edits at § 419.2(b)(15) to only package diagnostic radiopharmaceuticals when their per day cost is at or below the per day diagnostic radiopharmaceutical packaging threshold for the applicable year. Specifically, we proposed to add the text “at or below the per-day diagnostic radiopharmaceutical packaging threshold for the applicable year” to qualify the packaging of diagnostic radiopharmaceuticals. We also proposed corresponding regulation text edits at § 419.41 (Calculation of national beneficiary copayment amounts and national Medicare program payment amounts) to codify our proposed payment policy for diagnostic radiopharmaceuticals and our existing policy for therapeutic radiopharmaceuticals.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters were largely supportive of CMS's proposal to pay diagnostic radiopharmaceuticals based on their mean unit cost for CY 2025. Commenters applauded CMS for recognizing that the uniqueness of diagnostic radiopharmaceuticals could lead to some difficulty or uncertainty around reporting other pricing data, such as Average Sales Price (ASP), for these products. Additionally, commenters generally seemed to understand CMS's concerns with using ASP as a basis for payment broadly for CY 2025 given the limited information available.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their support of our proposal.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Although the majority of commenters were generally supportive of using mean unit cost as the basis for diagnostic radiopharmaceutical payment for CY 2025, many of these commenters saw the use of MUC as a transitional step, and recommended CMS consider Average Sales Price as the 
                        <PRTPAGE P="93961"/>
                        methodology to determine the payment amount as soon as possible. Other commenters suggested specific unique situations in which they believed it would be appropriate for CMS to use ASP, such as when a product's OPPS pass-through status expires if the product was being paid based on ASP while on OPPS pass-through status. Similarly, some commenters expressed some drawbacks to using MUC as a payment amount rather than ASP, such as that mean unit cost depends on hospital cost to charge ratios and uses cost data from prior years, rather than from the current payment year. Similarly, a commenter communicated that the MUC methodology underestimates the actual costs to hospitals for higher priced technologies due to charge compression which, in their view, may result in an inaccurate payment rate for a product compared to the actual acquisition cost for a product by a given hospital.
                    </P>
                    <P>Commenters stated that using ASP information was consistent with payment for drugs under the OPPS, and they also stated that ASP information was an established methodology that could provide an opportunity to improve payment accuracy.</P>
                    <P>Commenters believed there was value in using ASP as the basis of payment, and although they acknowledged CMS may not have access to ASP data for patient ready doses for all diagnostic radiopharmaceuticals, commenters recommended we transition to an ASP-based payment.</P>
                    <P>Some commenters stated their belief that separate payment will incentivize reporting of ASP data. CMS was urged to work with manufacturers to obtain ASP data and only consider basing payment on ASP when such data are determined to be reliable. Commenters also recommended that CMS provide at least one year notice of its intent to base payment on ASP to facilitate the most complete reporting and consistent payment methodologies across products.</P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their feedback and considerations on our proposal. Our concerns from the proposed rule remain for the final rule, in that there are very few manufacturers reporting ASP for their products currently, and of those few manufacturers reporting ASP, the ASP values that we do have generally do not align with the ASP we would expect based on the cost data submitted to CMS by hospitals. While a small number of manufacturers may be reporting ASP correctly, such as those recently on OPPS pass-through status, we believe a consistent payment methodology is most appropriate for nonpass-through diagnostic radiopharmaceuticals with per day costs above the threshold. We do agree that there could be some value in the use of ASP for determining a payment amount in the future; however, if we were to use the ASP methodology, we believe there must be more consistent, validated, and universal reporting in order for ASP to be a viable payment methodology. To maintain a consistent payment methodology for CY 2025, we believe it is appropriate to treat all nonpass-through diagnostic radiopharmaceuticals with claims data the same and pay using MUC without exception, such as for products with recent pass-through expiration.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters expressed a broad interest in using ASP data and learning how to report that data appropriately to CMS, including regarding topics such as “bona fide service fees.” Commenters indicated a desire to learn more about how they could report ASP for their specific products. Many manufacturers expressed their intent to initiate discussions with CMS in order to potentially begin to report ASP data.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for expressing their interest in use of ASP data and appropriate ASP reporting. As we have previously stated, and as commenters have noted, we recognize the complexities associated with reporting ASP for radiopharmaceuticals. We encourage ongoing engagement with CMS in order for manufacturers to provide information regarding their products' unique reporting complexities.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Some commenters recommended CMS continue to consider the appropriateness of other sources of cost data for future years, such as wholesale acquisition cost (WAC).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We continue to believe that neither WAC nor AWP is an appropriate proxy to provide OPPS payment for average radiopharmaceutical acquisition costs and associated handling costs when manufacturers are not required to submit ASP data. This is because payment based on WAC or AWP for separately payable drugs and biologicals is usually temporary for a calendar quarter until a manufacturer is able to submit the required ASP data in accordance with the quarterly ASP submission timeframes for reporting under section 1847A of the Act. WAC and AWP reported to compendia may not be reflective of a patient ready dose. The absence of an ASP reporting requirement and inappropriate or no reporting of ASP could result in payment for a separately payable diagnostic radiopharmaceutical based on WAC or AWP indefinitely, a result which we believe would be inappropriate, as these pricing metrics do not capture all of the pricing discounts that may be reflected in the ASP.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Some commenters were concerned about potential fluctuations in MUC data and the effect on payment for separately payable diagnostic radiopharmaceuticals. Several commenters recommend CMS apply its low volume APC policy to diagnostic radiopharmaceutical APCs, stating that CMS's policy for setting payment rates for low volume APCs, defined as those with fewer than 100 claims, by using up to four years of claims data and basing the rate on the highest value among the arithmetic mean, geometric mean, or median improves payment rate stability for low volume APCs.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their recommendations. We did not propose to subject low volume diagnostic radiopharmaceutical APCs to the broader OPPS low volume policy, and we note that the low volume APC policy does not apply to APCs to which single drugs, biologicals, or radiopharmaceuticals are assigned, even if there is a low volume of claims for these items. We understand the commenter's concerns; however, we do not believe it would be appropriate to finalize this policy modification without further engagement from interested parties. While we agree this suggested policy modification could result in greater payment stability, we want to ensure that there are no unintended consequences of such a policy, such as an unintended decrease in the overall MUC payment rate as a result of using 4 years of cost data. We encourage additional engagement on this issue.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A commenter noted that we proposed that only diagnostic radiopharmaceutical HCPCS codes that are identified as separately payable in the final rule with a comment period would be subject to quarterly updates. The commenter was unsure why quarterly updates would be necessary for MUC-based payment, which they expect would be established annually as part of the rulemaking process and thus not be subject to quarterly updates.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for this comment and confirm that their understanding is correct. MUC will be calculated on an annual basis for the payment of nonpass-through diagnostic radiopharmaceuticals with per day costs exceeding $630. Because we are not adopting an ASP-based payment approach at this time, there is no need to update the payment amounts 
                        <PRTPAGE P="93962"/>
                        quarterly as the MUC will be set in this final rule for the entire calendar year.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A few commenters believed that the product Magtrace, which may be described by HCPCS code A9697 (Injection, carboxydextran-coated superparamagnetic iron oxide, per study dose), was inappropriately assigned to a packaged payment status for the proposed rule and should be subject to this policy and designated for separate payment in the final rule. One commenter stated that the product is a magnetic tracer indicated to assist in localizing lymph nodes draining a tumor site, as part of a sentinel lymph node biopsy procedure in patients with breast cancer undergoing mastectomy or lumpectomy. The commenter stated that when HCPCS code A9697 was first incorporated in the October 2023 OPPS Update Transmittal, it was in a table titled “Table 15.—Newly Established HCPCS Codes for Drugs, Biologicals, and Radiopharmaceuticals as of October 1, 2023” and that Medicare Administrative Contractors (MACs) have indicated that HCPCS codes in the A9500-A9700 range, which the Magtrace code falls within, are for radiopharmaceuticals.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We note that this product is not radioactive 
                        <E T="51">9 10</E>
                        <FTREF/>
                         and is regulated by the FDA as a medical device under the product name “Magtrace and Sentimag Magnetic Localization System” with a premarket approval.
                        <SU>11</SU>
                        <FTREF/>
                         Accordingly, we do not believe that this product qualifies as a diagnostic radiopharmaceutical, and do not believe that it should be paid separately under this policy. We believe this product functions as a supply when used in a diagnostic test or procedure and should continue to be packaged under 42 CFR 419.2(b)(15). Please see section V.A. of this final rule with comment period for the payment status of HCPCS code A9697 for CY 2025.
                    </P>
                    <FTNT>
                        <P>
                            <SU>9</SU>
                             Per the manufacturer's website: “Is Magtrace Radioactive? No. Magtrace is the world's first non-radioactive tracer to offer dual identification. This not only facilitates the eradication of radioactive products from the OR, but provides psychological benefits for the patient.” 
                            <E T="03">https://www.endomag.com/resources/faqs/magtrace/?product=magtrace</E>
                            .
                        </P>
                        <P>
                            <SU>10</SU>
                             Per the manufacturer's website: “Magtrace® is a uniquely designed non-radioactive liquid tracer used to map the potential spread of cancer to the axilla in sentinel lymph node biopsy procedures. The liquid is made up of tiny particles of iron oxide, coated in sugar and suspended in saline.” 
                            <E T="03">https://www.endomag.com/resources/faqs/magtrace/.</E>
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>11</SU>
                             
                            <E T="03">https://www.fda.gov/medical-devices/recently-approved-devices/magtrace-and-sentimag-magnetic-localization-system-p160053s002.</E>
                        </P>
                    </FTNT>
                    <P>
                        <E T="03">Comment:</E>
                         Broadly, commenters suggested that CMS subject additional classes of drugs, such as contrast agents to this policy. For example, a commenter discussed one such product, Cysview, which may be described by HCPCS code A9589 (Instillation, hexaminolevulinate hydrochloride, 100 mg), and believed CMS's reasoning in the proposed rule for unpackaging and paying separately for diagnostic radiopharmaceuticals applies equally to their product. The commenter believed lack of separate payment was a barrier to beneficiary access and recommended CMS pay for products like theirs when the products' costs exceeded a certain threshold.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their feedback. We continue to believe that our packaging policies are a fundamental principle that distinguishes a prospective payment system from a fee schedule. In general, packaging the costs of supportive items and services into the payment for the primary procedure or service with which they are associated encourages hospital efficiencies and enables hospitals to manage their resources with maximum flexibility. We will take the information commenters provided into consideration as appropriate for possible future rulemaking.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal without modification. In summary, for CY 2025 we are paying separately for any diagnostic radiopharmaceutical with a per day cost greater than $630 using the methodology described. Any diagnostic radiopharmaceutical with a per day cost at or below that threshold would continue to be policy packaged under our longstanding policy at § 419.2(b)(15). We are finalizing our proposal regarding updating the selected packaging threshold without modification. Specifically, starting in CY 2026 and for subsequent years, we will update the threshold amount of $630 by the PPI for Pharmaceuticals for Human Use (Prescription) (Bureau of Labor Statistics series code WPUSI07003) from IHS Global, Inc (IGI). We are finalizing our proposal to pay for those nonpass-through, separately payable diagnostic radiopharmaceuticals based on our authority under section 1833(t)(14)(A)(iii)(II) of the Act, and as we find that the ASP data we have is not usable for the purpose of paying for diagnostic radiopharmaceuticals, we are paying for qualifying nonpass-through diagnostic radiopharmaceuticals with claims data based on mean unit cost data derived from hospital claims. We believe that paying for diagnostic radiopharmaceuticals using mean unit cost would appropriately pay for the average price of nonpass-through separately payable diagnostic radiopharmaceuticals for the applicable year. We believe MUC is an appropriate proxy for the average price for a diagnostic radiopharmaceutical for a given year, as it is calculated based on the average costs for a particular year and is directly reflective of the actual cost data that hospitals submit to CMS.</P>
                    <P>The finalized list of diagnostic radiopharmaceuticals that have calculated per day costs that exceed $630 and their status indicators can be found in Table 9.</P>
                    <GPH SPAN="3" DEEP="494">
                        <PRTPAGE P="93963"/>
                        <GID>ER27NO24.013</GID>
                    </GPH>
                    <P>Definitions of status indicators can be found in Addendum D1 to this final rule with comment period. Addenda to this final rule with comment period can be found on the CMS OPPS web page.</P>
                    <P>
                        Additionally, we are finalizing with slight modification corresponding regulation text edits at § 419.2(b)(15) to only package diagnostic radiopharmaceuticals when their per day cost is at or below the per day diagnostic radiopharmaceutical packaging threshold for the applicable year. We are adding the language “with per-day costs at or” to the regulation text as a technical change to conform with our final policy as the prior text did not make it clear that the per day cost of a diagnostic radiopharmaceutical must be at or below the per-day diagnostic radiopharmaceutical packaging threshold in order for the product to be packaged. Overall, this regulation text is changed by adding the text “with per-day costs at or below the per-day diagnostic radiopharmaceutical packaging threshold for the applicable year” rather than only “below the per-day diagnostic radiopharmaceutical packaging threshold for the applicable year” to qualify the packaging of diagnostic radiopharmaceuticals. Aside from those changes described in V.B.5 of this CY 2025 OPPS/ASC final rule with comment period to conform with our payment policy for nonpass-through diagnostic radiopharmaceuticals in situations in which claims data are not available, we are finalizing without modification corresponding regulation text edits at § 419.41 (Calculation of national beneficiary copayment amounts and national Medicare program payment amounts) to codify our proposed payment policy for diagnostic radiopharmaceuticals and our existing policy for therapeutic radiopharmaceuticals.
                        <PRTPAGE P="93964"/>
                    </P>
                    <HD SOURCE="HD3">4. Implementation of Section 4135 of the Consolidated Appropriations Act (CAA)</HD>
                    <P>The Consolidated Appropriations Act (CAA), 2023 (Pub. L. 117-328), was signed into law on December 29, 2022. Section 4135(a) and (b) of the CAA, 2023, titled Access to Non-Opioid Treatments for Pain Relief, amended sections 1833(t)(16) and 1833(i) of the Act, respectively, to provide for temporary additional payments for non-opioid treatments for pain relief (as that term is defined in section 1833(t)(16)(G)(i) of the Act). In particular, section 1833(t)(16)(G) of the Act provides that with respect to a non-opioid treatment for pain relief furnished on or after January 1, 2025, and before January 1, 2028, the Secretary shall not package payment for the non-opioid treatment for pain relief into payment for a covered OPD service (or group of services) and shall make an additional payment for the non-opioid treatment for pain relief as specified in clause (ii) of that section. Clauses (ii) and (iii) of section 1833(t)(16)(G) of the Act provide for the amount of additional payment and set a limitation on that amount, respectively.</P>
                    <P>As the additional payments are required to begin on January 1, 2025, we proposed and are finalizing a policy to implement the CAA, 2023 section 4135 amendments in this final rule with comment period. Our finalized policy to implement section 4135 of CAA, 2023 can be found in section XIII.E of this final rule with comment period. </P>
                    <HD SOURCE="HD3">5. Calculation of OPPS Scaled Payment Weights</HD>
                    <P>We established a policy in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68283) of using geometric mean-based APC costs to calculate relative payment weights under the OPPS. In the CY 2024 OPPS/ASC final rule with comment period (88 FR 81577 through 81578), we applied this policy and calculated the relative payment weights for each APC for CY 2024 that were shown in Addenda A and B of the CY 2024 OPPS/ASC final rule with comment period (which were made available via the internet on the CMS website) using the APC costs discussed in sections II.A.1 and II.A.2 of the CY 2024 OPPS/ASC final rule with comment period (88 FR 81549 through 81572). For CY 2025, as we did for CY 2024, we proposed to continue to apply the policy established in CY 2013 and calculate relative payment weights for each APC for CY 2025 using geometric mean-based APC costs.</P>
                    <P>For CY 2012 and CY 2013, outpatient clinic visits were assigned to one of five levels of clinic visit APCs, with APC 0606 representing a mid-level clinic visit. In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75036 through 75043), we finalized a policy that created alphanumeric HCPCS code G0463 (Hospital outpatient clinic visit for assessment and management of a patient), representing all clinic visits under the OPPS. HCPCS code G0463 was assigned to APC 0634 (Hospital Clinic Visits). We also finalized a policy to use CY 2012 claims data to develop the CY 2014 OPPS payment rates for HCPCS code G0463 based on the total geometric mean cost of the levels one through five CPT Evaluation or Assessment and Management (E/M) codes for clinic visits previously recognized under the OPPS (CPT codes 99201 through 99205 and 99211 through 99215). In addition, we finalized a policy to no longer recognize a distinction between new and established patient clinic visits.</P>
                    <P>For CY 2016, we deleted APC 0634 and reassigned the outpatient clinic visit HCPCS code G0463 to APC 5012 (Level 2 Examinations and Related Services) (80 FR 70372). For CY 2025, as we did for CY 2024, we proposed to continue to standardize all of the relative payment weights to APC 5012. We believe that standardizing relative payment weights to the geometric mean of the APC to which HCPCS code G0463 is assigned maintains consistency in calculating unscaled weights that represent the cost of some of the most frequently provided OPPS services. For CY 2025, as we did for CY 2024, we proposed to assign APC 5012 a relative payment weight of 1.00 and to divide the geometric mean cost of each APC by the geometric mean cost for APC 5012 to derive the unscaled relative payment weight for each APC. The choice of the APC on which to standardize the relative payment weights does not affect payments made under the OPPS because we scale the weights for budget neutrality.</P>
                    <P>Section 1833(t)(9)(B) of the Act requires that APC reclassification and recalibration changes, wage index changes, and other adjustments be made in a budget neutral manner. Budget neutrality ensures that the estimated aggregate weight under the OPPS for CY 2025 is neither greater than nor less than the estimated aggregate weight that would have been calculated without the changes. To comply with this requirement concerning the APC changes, we proposed to compare the estimated aggregate weight using the CY 2024 scaled relative payment weights to the estimated aggregate weight using the proposed CY 2025 unscaled relative payment weights.</P>
                    <P>For CY 2024, we multiplied the CY 2024 scaled APC relative payment weight applicable to a service paid under the OPPS by the volume of that service from CY 2023 claims to calculate the total relative payment weight for each service. We then added together the total relative payment weight for each of these services in order to calculate an estimated aggregate weight for the year. For CY 2025, we proposed to apply the same process using the estimated CY 2025 unscaled relative payment weights rather than scaled relative payment weights. We proposed to calculate the weight scalar by dividing the CY 2024 estimated aggregate weight by the unscaled CY 2025 estimated aggregate weight.</P>
                    <P>
                        For a detailed discussion of the weight scalar calculation, we refer readers to the OPPS claims accounting document available on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        . Click on the link labeled “Hospital Outpatient Prospective Payment—Notice of Proposed Rulemaking with Comment Period (NPRM)” for 2025, which can be found under the heading “Hospital Outpatient Regulations and Notices” and open the claims accounting document link, which is labeled “2025 NPRM OPPS Claims Accounting (PDF).”
                    </P>
                    <P>We proposed to compare the estimated unscaled relative payment weights in CY 2025 to the estimated total relative payment weights in CY 2024 using CY 2023 claims data, holding all other components of the payment system constant to isolate changes in total weight. Based on this comparison, we proposed to adjust the calculated CY 2025 unscaled relative payment weights for purposes of budget neutrality. We proposed to adjust the estimated CY 2025 unscaled relative payment weights by multiplying them by a proposed weight scalar of 1.4452 to ensure that the proposed CY 2025 relative payment weights are scaled to be budget neutral. The proposed CY 2025 relative payment weights listed in Addenda A and B to the proposed rule (which are available via the internet on the CMS website) are scaled and incorporate the recalibration adjustments discussed in sections II.A.1 and II.A.2 of this final rule with comment period.</P>
                    <P>
                        Section 1833(t)(14) of the Act provides the payment rates for certain specified covered outpatient drugs (SCODs). Section 1833(t)(14)(H) of the 
                        <PRTPAGE P="93965"/>
                        Act provides that additional expenditures resulting from this paragraph shall not be taken into account in establishing the conversion factor, weighting, and other adjustment factors for 2004 and 2005 under paragraph (9) but shall be taken into account for subsequent years. Therefore, the cost of those SCODs (as discussed in section V.B.2 of this final rule with comment period) is included in the budget neutrality calculations for the CY 2025 OPPS.
                    </P>
                    <P>We did not receive any public comments on the proposed weight scalar calculation, and we are finalizing our proposal to use the calculation process described in the CY 2025 OPPS/ASC proposed rule, without modification, for CY 2025. For CY 2025, as we did for CY 2024, we will continue to apply the policy established in CY 2013 and calculate relative payment weights for each APC for CY 2025 using geometric mean-based APC costs. For CY 2025, as we did for CY 2024, we will assign APC 5012 a relative payment weight of 1.00; and we will divide the geometric mean cost of each APC by the geometric mean cost for APC 5012 to derive the unscaled relative payment weight for each APC. To comply with this requirement concerning the APC changes, we will compare the estimated aggregate weight using the CY 2024 scaled relative payment weights to the estimated aggregate weight using the CY 2025 unscaled relative payment weights.</P>
                    <P>Using updated final rule claims data, we are updating the estimated CY 2025 unscaled relative payment weights by multiplying them by a weight scalar of 1.4452 to ensure that the final CY 2025 relative payment weights are scaled to be budget neutral. The final CY 2025 relative payments weights listed in Addenda A and B of this final rule with comment period (available via the internet on the CMS website) were scaled and incorporate the recalibration adjustments discussed in sections II.A.1 and II.A.2 of this final rule with comment period.</P>
                    <HD SOURCE="HD2">B. Conversion Factor Update</HD>
                    <HD SOURCE="HD3">1. OPD Fee Schedule Increase Factor</HD>
                    <P>Section 1833(t)(3)(C)(ii) of the Act requires the Secretary to update the conversion factor used to determine the payment rates under the OPPS on an annual basis by applying the OPD fee schedule increase factor. For purposes of section 1833(t)(3)(C)(iv) of the Act, subject to sections 1833(t)(17) and 1833(t)(3)(F) of the Act, the OPD fee schedule increase factor is equal to the hospital inpatient market basket percentage increase applicable to hospital discharges under section 1886(b)(3)(B)(iii) of the Act. In the FY 2025 IPPS/Long Term Care Hospital (LTCH) PPS proposed rule (89 FR 36204), consistent with current law, based on IHS Global, Inc.'s fourth quarter 2023 forecast, the proposed FY 2025 IPPS market basket percentage increase was 3.0 percent. In the CY 2025 OPPS/ASC proposed rule, we noted that under our regular process for the CY 2025 OPPS/ASC final rule with comment period, we would use the market basket update for the FY 2025 IPPS/LTCH PPS final rule (89 FR 68986). We explained that if that forecast is different than the IPPS market basket percentage increase used for the proposed rule, the CY 2025 OPPS/ASC final rule with comment period OPD fee schedule increase factor would reflect that updated forecast of the market basket percentage increase.</P>
                    <P>For CY 2025, we proposed to use the estimate of the hospital inpatient market basket percentage increase of 3.0 percent as one component to calculate the OPD fee schedule increase factor.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Two commenters expressed their support for the proposed hospital inpatient market basket increase of 3.0 percent.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the support of the commenters.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters expressed concerns that the proposed CY 2025 market basket update does not adequately reflect the rising inflation and costs that hospitals have faced over the last few years. Commenters stated that economy-wide inflation grew by 12.4 percent from 2021 through 2023 (as measured by the Consumer Price Index (CPI)), more than two times faster than Medicare reimbursement for hospital outpatient services, which increased by 5.9 percent during the same time. A commenter noted that the US Health Care Inflation Rate (USHCIR) for June 2024 was 3.3 percent and long-term USHCIR was 5.1 percent. Another commenter noted that inflation for hospital services in July 2024 was 6.1 percent. The commenters observed these rates are substantially higher that the proposed market basket increase.
                    </P>
                    <P>Many commenters stated that rapid and sustained growth in labor costs have put persistent cost pressure on hospitals. They also noted increases in drug prices, citing a recent study and a report by the Health and Human Services (HHS) Assistant Secretary for Planning and Evaluation which found that in 2022 and 2023, prices for nearly 2,000 drugs increased faster than the rate of general inflation, with an average price increase of 15.2 percent. Several commenters also stated that hospitals have seen significant growth in administrative costs due to what they described as inappropriate practices by large commercial health insurers, including Medicare Advantage and Medicaid managed care plans, such as automatic claim denials and onerous prior authorization requirements. Commenters also discussed the continued costs of addressing past and preventing future cyberattacks and a commenter stated they have seen significant increases in capital costs, particularly since the pandemic. Some commenters stated that hospitals will continue to face increased costs due to the Change Healthcare cyberattack, such as interest costs on loan payments for loans acquired during the cyberattack, expected denials that will require additional administrative costs, and manual processing of claims. Commenters also urged CMS to consider the changing health care environment, which they state is putting enormous financial strain on hospitals and health systems and is expected to continue through 2025.</P>
                    <P>Several commenters proposed CMS apply a payment increase of at least 4.1 percent which is aligned with MedPAC's March 2024 Report to Congress, which recommended a 1.5 percentage points increase over the FY 2025 payment update. These commenters noted that this was the second year that MedPAC made a recommendation of increasing the market basket update. Several commenters suggested various higher market basket increases, which they believe better reflects hospitals' input prices and the contract labor staffing challenge. A commenter encouraged CMS to consider, at a minimum, matching the 3.7 percent increase that the commenter stated Medicare Advantage will receive.</P>
                    <P>Several commenters recommended CMS look to alternative data sources that they asserted better reflect true labor and input cost increases in a timely manner. The commenters stated that the proposed payment update does not recognize these challenges, nor does it factor in the realities of inflation impacting operating costs. Commenters also stated CMS must use data that better reflects the input price inflation that hospitals have experienced and are projected to experience in CY 2025. Multiple commenters recommended CMS use more recent data to update adjustments to 2025 OPPS rates.</P>
                    <P>
                        Many commenters noted their financial pressures due to the PHE, aging, more complex patients, negative Medicare margins of −12.7 percent as 
                        <PRTPAGE P="93966"/>
                        estimated by MedPAC, and reliance on public payers. Several commenters urged CMS to consider and assess the financial position of hospitals, particularly those with low margins. Multiple commenters asked for CMS to increase rates to cover the cost of care for Medicaid patients. Many commenters noted financial hardships, particularly in 2022, with high inflation and workforce shortages. They noted that MedPAC found that all-payment operating and overall Medicare margins both fell to record lows, estimating Medicare hospital margins of negative 12.7 percent for FY 2022. MedPAC's FY 2024 recommendation was to increase the market basket update by one percentage point and, for FY 2025, that Congress increase the acute hospital market basket by 1.5 percentage points over current law.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We acknowledge commenters' concerns, however, as we stated in the CY 2025 OPPS/ASC proposed rule, section 1833(t)(3)(C)(iv) of the Act requires the OPD fee schedule increase factor for a year to equal the IPPS market basket percentage increase factor applicable under section 1886(b)(3)(B)(iii) to hospital discharges in the fiscal year ending in such year. Accordingly, we are unable to adopt a final OPD fee schedule increase factor different than the IPPS market basket percentage increase factor finalized in the FY 2025 IPPS/LTCH PPS final rule. We refer commenters to that final rule for responses regarding the issues commenters raised (89 FR 69340).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Many commenters expressed concerns with the Employment Cost Index (ECI) used to measure changes in labor compensation in the market basket, which they state may no longer accurately capture the changing composition and cost structure of the hospital labor market given the large increases in short-term contract labor use and its growing costs. The commenters stated labor costs have increased by more than 18 percent from CY 2020 to CY 2023. They attributed this increase to expensive contract labor costs (as a result of higher utilization rates and higher costs per hour) and faster growth in salaries for employed workers (reflecting sign-on and retention bonuses). They further stated that while salaries for contract nurses have decreased some from a peak in certain geographical areas, they still remained nearly 60 percent higher at the end of FY 2023 compared to the start of FY 2020. They further stated that CMS recognizes that the ECI does not capture shifts in composition of labor, and the commenters stated that by design, the ECI is not capturing the shifts that have occurred as hospitals have had to turn to contract labor to meet patient demand. Several commenters recommended that CMS use its exceptions and adjustments authority to adopt new or supplemental data sources, to ensure labor costs are adequately reflected in the payment update in the final rule. They further requested CMS utilize supplemental data sources to evaluate the accuracy of the ECI proxy and to modify methodologies, including adopting new or supplemental data, to calculate the payment update if its analysis determines that the ECI is not adequately capturing labor costs.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We refer commenters to the FY 2025 IPPS/LTCH PPS final rule, where we responded to similar comments regarding the use of the ECI and related issues raised by commenters (89 FR 69340 through 69341). We further note that, as we stated in the CY 2025 OPPS/ASC proposed rule, section 1833(t)(3)(C)(iv) of the Act requires the OPD fee schedule increase factor for a year to equal the IPPS market basket percentage increase factor applicable under section 1886(b)(3)(B)(iii) to hospital discharges in the fiscal year ending in such year. Accordingly, we are unable to adopt a final OPD fee schedule increase factor different than the IPPS market basket percentage increase factor finalized in the FY 2025 IPPS/LTCH PPS final rule, which would occur if we used a different methodology to measure changes in labor compensation in the OPPS market basket.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters recommended that CMS reevaluate the data sources it uses for rebasing its market basket and calculating the annual market basket update, including labor costs. They strongly encouraged CMS to adopt new or supplemental data sources in future rulemaking that more accurately reflect the costs to hospitals, such as through use of more real time data from the hospital community. They stated that they believe that the current market basket does not account for the higher costs of contract labor, which has become more common in hospitals in an era of clinical labor shortages. A commenter requested that CMS rebase the market baskets more frequently and at least every 3 years to ensure the market basket reflects the appropriate mix of services provided to Medicare beneficiaries.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We refer commenters to the FY 2025 IPPS/LTCH PPS final rule, where we responded to similar comments (89 FR 69341). As we stated in the CY 2025 OPPS/ASC proposed rule, section 1833(t)(3)(C)(iv) of the Act requires the OPD fee schedule increase factor for a year to equal the IPPS market basket percentage increase factor applicable under section 1886(b)(3)(B)(iii) to hospital discharges in the fiscal year ending in such year. Accordingly, we are unable to adopt a final OPD fee schedule increase factor different than the IPPS market basket percentage increase factor finalized in the FY 2025 IPPS/LTCH PPS final rule.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters stated that since the COVID-19 PHE, IHS Global, Inc (IGI) has shown a consistent 3-year trend of under-forecasting the market basket growth and expressed concern this may indicate a more systematic issue with IGI's forecasting. They stated that these missed forecasts are permanently established in the standard payment rate for IPPS and will continue to compound, which they estimate to be $4 billion. Several commenters, including many associations, urged CMS to use its special exceptions and adjustments authority under section 1886(d)(5)(i) of the Act to implement a retrospective one-time adjustment for CY 2025 to account for the underestimation of the market basket updates over the last several years. Commenters recommended that CMS implement various one-time adjustments to account for underpayments in one or more years between CY 2021 and CY 2023 as well as for forecasted underpayments for CY 2024. The commenters stated the underestimation is, in large part, because the market basket is a time-lagged estimate that cannot fully account for unexpected changes that occur, such as historic inflation and increased labor and supply costs. They stated this is exactly what occurred at the end of the CY 2021 into CY 2022, which resulted in a large forecast error in the CY 2022 market basket update.
                    </P>
                    <P>
                        Several commenters noted that CMS currently implements a capital IPPS market basket forecast error adjustment as well as SNF PPS market basket forecast error adjustment policy, which resulted in FY 2024 and FY 2025 SNF forecast error adjustments of 3.6 percentage points and 1.7 percentage points, respectively. They stated while CMS has not developed an analogous policy for the OPPS operating update, they believe such a forecast error adjustment to the CY 2025 OPPS operating update could be adopted under CMS' existing authority. They noted the forecast errors for CY 2021 through CY 2023 for OPPS exceeded the 0.5 percentage point threshold that is used for the SNF forecast error adjustment policy. A commenter recommended CMS establish a forecast 
                        <PRTPAGE P="93967"/>
                        error threshold of 1.5 percentage points, and retroactively adjust payments for that year.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We refer commenters to the FY 2025 IPPS/LTCH PPS final rule, where we responded to similar comments (89 FR 69342). As we stated in the CY 2025 OPPS/ASC proposed rule, section 1833(t)(3)(C)(iv) of the Act requires the OPD fee schedule increase factor for a year to equal the IPPS market basket percentage increase factor applicable under section 1886(b)(3)(B)(iii) to hospital discharges in the fiscal year ending in such year. Accordingly, we are unable to adopt a final OPD fee schedule increase factor different than the IPPS market basket percentage increase factor finalized in the FY 2025 IPPS/LTCH PPS final rule.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Multiple commenters supported the proposed 3.0 percent market basket increase believing the market basket increase would help rural hospitals. However, the commenters believe inflation for outpatient hospital services is substantially higher than the market basket increase, and they would prefer a higher market basket increase to help rural providers. The commenters stated that the operating margin for independent rural hospitals is -2.2 percent and that the operating margins for system-affiliated rural hospitals is 1.7 percent. Other commenters believe the low market basket increases lead to challenges for rural providers. Those commenters noted that the operating margins for rural hospitals are not sustainable, and they noted that eleven hospitals in rural and underserved areas have closed in the past two years even with the establishment of a new Medicare provider type that allows such hospitals to become rural emergency hospitals. The commenters believe a higher market basket increase would help rural hospitals stay open and provide access to quality care especially maternal care in the areas that they serve.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the support of the commenters of the proposed market basket increase, and we appreciate the commenters' raising their concerns regarding rural hospitals. As we stated in the CY 2025 OPPS/ASC proposed rule, section 1833(t)(3)(C)(iv) of the Act requires the OPD fee schedule increase factor for a year to equal the IPPS market basket percentage increase factor applicable under section 1886(b)(3)(B)(iii) to hospital discharges in the fiscal year ending in such year. Accordingly, we are unable to adopt a final OPD fee schedule increase factor different than the IPPS market basket percentage increase factor finalized in the FY 2025 IPPS/LTCH PPS final rule.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Multiple commenters claim that section 1833(t)(3)(C)(iv) of the Act, which defines the outpatient hospital department market basket increase factor, has provisions that give CMS flexibility to use a different market basket increase factor for outpatient hospital services than the market basket increase factor used for inpatient hospital services. The commenters requested that CMS take advantage of section 1833(t)(3)(C)(iv) to establish a market basket increase for CY 2025 for the OPPS that would be larger than the market basket increase that was finalized for FY 2025 for the IPPS.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         Section 1833(t)(3)(C)(iv) of the Act permits the Secretary to substitute for the market basket percentage increase an annual percentage increase that is computed and applied with respect to covered OPD services furnished in a year in the same manner as the market basket percentage increase is determined and applied to inpatient hospital services for discharges occurring in a fiscal year. We would only anticipate utilizing a specific outpatient hospital market basket factor if the rate of change in the cost of covered OPD services was substantially different than the rate of change in the cost of inpatient hospital services for the previous fiscal year. We did not find evidence that the rate of change for covered OPD services was substantially different that the rate of changes for inpatient hospital services. Therefore, we are adopting an OPD fee schedule increase factor for CY 2025 equal to the IPPS market basket percentage increase factor applicable under section 1886(b)(3)(B)(iii) to hospital discharges in the fiscal year ending in such year, as required by section 1833(t)(3)(C)(iv) of the Act. We decline to adopt a final OPD fee schedule increase factor different than the IPPS market basket percentage increase factor finalized in the FY 2025 IPPS/LTCH PPS final rule.
                    </P>
                    <HD SOURCE="HD3">2. Productivity Adjustment</HD>
                    <P>
                        Section 1833(t)(3)(F)(i) of the Act requires that, for 2012 and subsequent years, the OPD fee schedule increase factor under subparagraph (C)(iv) be reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act. Section 1886(b)(3)(B)(xi)(II) of the Act defines the productivity adjustment as equal to the 10-year moving average of changes in annual economy-wide, private nonfarm business multifactor productivity (MFP) (as projected by the Secretary for the 10-year period ending with the applicable fiscal year, year, cost reporting period, or other annual period) (the “productivity adjustment”). In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51689 through 51692), we finalized our methodology for calculating and applying the productivity adjustment. The U.S. Department of Labor's Bureau of Labor Statistics (BLS) publishes the official measures of private nonfarm business productivity for the U.S. economy. We note that previously the productivity measure referenced in section 1886(b)(3)(B)(xi)(II) of the Act was published by BLS as private nonfarm business multifactor productivity. Beginning with the November 18, 2021, release of productivity data, BLS replaced the term multifactor productivity (MFP) with total factor productivity (TFP). BLS noted that this is a change in terminology only and will not affect the data or methodology. As a result of the BLS name change, the productivity measure referenced in section 1886(b)(3)(B)(xi)(II) of the Act is now published by BLS as private nonfarm business total factor productivity. However, as mentioned, the data and methods are unchanged. Please see 
                        <E T="03">www.bls.gov</E>
                         for the BLS historical published TFP data. A complete description of IHS Global, Inc.'s (IGI) TFP projection methodology is available on the CMS website at 
                        <E T="03">https://www.cms.gov/data-research/statistics-trends-and-reports/medicare-program-rates-statistics/market-basket-research-and-information</E>
                        . In addition, we note that beginning with the FY 2022 IPPS/LTCH PPS final rule, we refer to this adjustment as the productivity adjustment rather than the MFP adjustment to more closely track the statutory language in section 1886(b)(3)(B)(xi)(II) of the Act. We note that the adjustment continues to rely on the same underlying data and methodology. In the FY 2025 IPPS/LTCH PPS proposed rule (89 FR 36204), the proposed productivity adjustment for FY 2025 was 0.4 percentage point.
                    </P>
                    <P>
                        Therefore, we proposed that the productivity adjustment for the CY 2025 OPPS/ASC would be 0.4 percentage point. We also proposed that if more recent data subsequently became available after the publication of the CY 2025 OPPS/ASC proposed rule (for example, a more recent estimate of the market basket percentage increase and/or the productivity adjustment), we would use such updated data, if appropriate, to determine the CY 2025 hospital inpatient market basket update and the productivity adjustment, which are components in calculating the OPD fee schedule increase factor under 
                        <PRTPAGE P="93968"/>
                        sections 1833(t)(3)(C)(iv) and 1833(t)(3)(F) of the Act.
                    </P>
                    <P>We note that section 1833(t)(3)(F) of the Act provides that application of this subparagraph may result in the OPD fee schedule increase factor under section 1833(t)(3)(C)(iv) of the Act being less than 0.0 percent for a year and may result in OPPS payment rates being less than rates for the preceding year. As described in further detail below, we proposed for CY 2025 an OPD fee schedule increase factor of 2.6 percent for the CY 2025 OPPS/ASC (which is the proposed estimate of the hospital inpatient market basket percentage increase of 3.0 percent, less the proposed 0.4 percentage point productivity adjustment).</P>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters expressed concerns about the application of the productivity adjustment, particularly given the extreme pressures in which hospital and health systems operate. They stated the use of the private nonfarm business TFP is meant to capture gains from new technologies, economies of scale, business acumen, managerial skills and changes in productions. Thus, they stated this measure effectively assumes the hospital sector can mirror productivity gains from the private nonfarm business sector. They stated, however, in an economy marked by great uncertainty due to the PHE and labor and other productivity shocks, this assumption is significantly flawed. Other commenters requested that productivity adjustment be eliminated for CY 2025 without any additional reasons. A commenter also requested that CMS use its “special exceptions and adjustments” authority to reduce the productivity adjustment for CY 2025. Another commenter asked that the productivity adjustment not apply to small rural and sole community hospitals for CY 2025.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         Section 1833(t)(3)(F)(i) requires that after determining the OPD fee schedule increase factor under subparagraph (C)(iv), the Secretary shall reduce such increase factor by the productivity adjustment described in section 1886(b)(3)(B)(xi) of the Act. As required by statute, the FY 2025 productivity adjustment is derived based on the 10-year moving average growth in economy-wide productivity for the period ending FY 2025.
                    </P>
                    <P>We thank the commenters for their comments. After consideration of the comments received and consistent with our proposal, we are finalizing an OPD fee schedule increase factor of 2.9 percent for CY 2025, which consists of the IPPS market basket increase factor of 3.4 percent less a 0.5 percentage point productivity adjustment.</P>
                    <HD SOURCE="HD3">3. Other Conversion Factor Adjustments</HD>
                    <P>To set the OPPS conversion factor for 2025, we proposed to increase the CY 2024 conversion factor of $87.382 by 2.6 percent. In accordance with section 1833(t)(9)(B) of the Act, we proposed further to adjust the conversion factor for CY 2025 to ensure that any revisions made to the wage index and rural adjustment are made on a budget neutral basis. We proposed to calculate an overall budget neutrality factor of 1.0026 for wage index changes by comparing proposed total estimated payments from our simulation model using the proposed FY 2025 IPPS wage indexes to those payments using the FY 2024 IPPS wage indexes, as adopted on a calendar year basis for the OPPS. We further proposed to calculate an additional budget neutrality factor of 0.9982 to account for our proposed policy to cap wage index reductions for hospitals at 5 percent on an annual basis.</P>
                    <P>For CY 2025, we proposed to maintain the current rural adjustment policy, as discussed in section II.E of this final rule with comment period. Therefore, the proposed budget neutrality factor for the rural adjustment was 1.0000.</P>
                    <P>We proposed to calculate a CY 2025 budget neutrality adjustment factor for the cancer hospital payment adjustment by transitioning from the target PCR of 0.89 we finalized for CYs 2020 through 2023 (which included the 1.0 percentage point reduction as required by section 16002(b) of the 21st Century Cures Act) and incrementally reducing the target PCR by an additional 1.0 percentage point for each calendar year, beginning with CY 2024, until the target PCR equals the PCR of non-cancer hospitals calculated using the most recent data minus 1.0 percentage point as required by section 16002(b) of the 21st Century Cures Act. Therefore, we proposed to apply a budget neutrality adjustment factor of 1.0006 to the conversion factor for the cancer hospital payment adjustment. In accordance with section 1833(t)(18)(C) of the Act, as added by section 16002(b) of the 21st Century Cures Act (Pub. L. 114-255), we reduce the target PCR by 0.01, which brings the proposed target PCR to 0.87. This is 0.02 less than the target PCR of 0.89 from CY 2021 through CY 2023, which was held at the pre-PHE target.</P>
                    <P>For the CY 2025 OPPS/ASC proposed rule, we estimated that proposed pass-through spending for drugs, biologicals, and devices for CY 2025 would equal approximately $625 million, which represented 0.71 percent of total projected CY 2025 OPPS spending. Therefore, we stated that the proposed conversion factor would be adjusted by the difference between the 0.27 percent estimate of pass-through spending for CY 2024 and the 0.71 percent estimate of proposed pass-through spending for CY 2025, resulting in a proposed decrease to the conversion factor for CY 2025 of 0.44 percent.</P>
                    <P>We proposed that estimated payments for outliers would remain at 1.0 percent of total OPPS payments for CY 2025. We estimated for the proposed rule that outlier payments would be approximately 0.85 percent of total OPPS payments in CY 2024; the 1.00 percent for proposed outlier payments in CY 2025 would constitute a 0.15 percent increase in payment in CY 2025 relative to CY 2024.</P>
                    <P>For CY 2025, we proposed to use a conversion factor of $87.382 in the calculation of the national unadjusted payment rates for those items and services for which payment rates are calculated using geometric mean costs; that is, the proposed OPD fee schedule increase factor of 2.6 percent for CY 2025, the required proposed wage index budget neutrality adjustment of approximately 1.0026, the proposed 5 percent annual cap for individual hospital wage index reductions adjustment of approximately 0.9982, the proposed cancer hospital payment adjustment of 1.0006, and the proposed adjustment of a decrease of 0.44 percentage point of projected OPPS spending for the difference in pass-through spending, which resulted in a proposed conversion factor for CY 2025 of $89.379.</P>
                    <P>
                        For CY 2025, we also proposed that hospitals that fail to meet the reporting requirements of the Hospital OQR Program would continue to be subject to a further reduction of 2.0 percentage points to the OPD fee schedule increase factor. For hospitals that fail to meet the requirements of the Hospital OQR Program, we proposed to make all other adjustments discussed above, but use a reduced OPD fee schedule update factor of 0.6 percent (that is, the proposed OPD fee schedule increase factor of 2.6 percent further reduced by 2.0 percentage points). This would result in a proposed reduced conversion factor for CY 2025 of $87.636 for hospitals that fail to meet the Hospital OQR Program requirements (a difference of −1.743 in the conversion factor relative to hospitals that met the requirements). For further discussion of the Hospital OQR Program, we refer readers to section XV of this final rule with comment period. For 2025, we proposed 
                        <PRTPAGE P="93969"/>
                        to use a reduced conversion factor of $87.636 in the calculation of payments for hospitals that fail to meet the Hospital OQR Program requirements (a difference of −1.743 in the conversion factor relative to hospitals that met the requirements).
                    </P>
                    <P>We received no comments on our proposed adjustments to the conversion factor for CY 2025. For this CY 2025 OPPS/ASC final rule with comment period, based on more recent data available, the OPD fee schedule increase factor for the CY 2025 OPPS is 2.9 percent (which reflects the 3.4 percent final estimate of the hospital inpatient market basket percentage increase reduced by a 0.5 percentage point productivity adjustment). For CY 2025, we are using a conversion factor of $89.169 in the calculation of the national unadjusted payment rates for those items and services for which payment rates are calculated using geometric mean costs; that is, the OPD fee schedule increase factor of 2.9 percent for CY 2025, the required wage index budget neutrality adjustment of 0.9927, the 5 percent annual cap for individual hospital wage index reductions of 0.9995, the cancer hospital payment adjustment of 1.0005, and the adjustment of 0.10 (or 0.37 less 0.27) percentage point of projected OPPS spending for the difference in pass-through spending that results in a conversion factor for CY 2024 of $89.169. We are also finalizing a reduced conversion factor of $87.439 in the calculation of payments for hospitals that fail to meet the Hospital OQR Program requirements (a difference of −1.730 in the conversion factor relative to hospitals that met the requirements).</P>
                    <P>The calculations we performed to determine the CY 2025 final conversion factor are shown in Table 10.</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="539">
                        <PRTPAGE P="93970"/>
                        <GID>ER27NO24.014</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="390">
                        <PRTPAGE P="93971"/>
                        <GID>ER27NO24.015</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <HD SOURCE="HD2">C. Wage Index Changes</HD>
                    <P>Section 1833(t)(2)(D) of the Act requires the Secretary to determine a wage adjustment factor to adjust the portion of payment and coinsurance attributable to labor-related costs for relative differences in labor and labor-related costs across geographic regions in a budget neutral manner (codified at 42 CFR 419.43(a)). This portion of the OPPS payment rate is called the OPPS labor-related share. Budget neutrality is discussed in section II.A.5 of this final rule with comment period.</P>
                    <P>The OPPS labor-related share is 60 percent of the national OPPS payment. This labor-related share is based on a regression analysis that determined that, for all hospitals, approximately 60 percent of the costs of services paid under the OPPS were attributable to wage costs. We confirmed that this labor-related share for outpatient services is appropriate during- our regression analysis for the payment adjustment for rural hospitals in the CY 2006 OPPS final rule with comment period (70 FR 68553). We proposed to continue this policy for the CY 2025 OPPS/ASC. We refer readers to section II.C of this final rule with comment period for a description and an example of how the wage index for a particular hospital is used to determine payment for the hospital.</P>
                    <P>We did not receive any public comments on our proposed labor-related share, and we are finalizing our proposal without modification.</P>
                    <P>
                        As discussed in the claims accounting narrative included with the supporting documentation for this final rule with comment period (which is available via the internet on the CMS website (
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        )), for estimating APC costs, we would standardize 60 percent of estimated claims costs for geographic area wage variation using the same FY 2025 pre-reclassified wage index that we use under the IPPS to standardize costs. This standardization process removes the effects of differences in area wage levels from the determination of a national unadjusted OPPS payment rate and copayment amount.
                    </P>
                    <P>
                        Under 42 CFR 419.41(c)(1) and 419.43(c) (published in the OPPS April 7, 2000, final rule with comment period (65 FR 18495 and 18545)), the OPPS adopted the final fiscal year IPPS post-reclassified wage index as the calendar year wage index for adjusting the OPPS standard payment amounts for labor market differences. Therefore, in general, the wage index that applies to a particular acute care, short-stay hospital under the IPPS has also applied to that hospital under the OPPS. As initially explained in the September 8, 1998, OPPS/ASC proposed rule (63 FR 47576), we believe that using the IPPS wage index as the source of an adjustment factor for the OPPS is reasonable and logical, given the inseparable, subordinate status of the HOPD within the hospital overall. In accordance with section 1886(d)(3)(E) of 
                        <PRTPAGE P="93972"/>
                        the Act, the IPPS wage index is updated annually.
                    </P>
                    <P>The Affordable Care Act contained several provisions affecting the wage index. These provisions were discussed in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74191). Section 10324 of the Affordable Care Act added section 1886(d)(3)(E)(iii)(II) to the Act, which defines a frontier State and amended section 1833(t) of the Act to add paragraph (19), which requires a frontier State wage index floor of 1.00 in certain cases, and states that the frontier State floor shall not be applied in a budget neutral manner. We codified these requirements at § 419.43(c)(2) and (3) of our regulations. For CY 2025 we proposed to implement this provision in the same manner as we have since CY 2011. Under this policy, the frontier State hospitals would receive a wage index of 1.00 if the otherwise applicable wage index (including reclassification, the rural floor, and rural floor budget neutrality) is less than 1.00. Because the HOPD receives a wage index based on the geographic location of the specific inpatient hospital with which it is associated, the frontier State wage index adjustment applicable for the inpatient hospital also would apply for any associated HOPD. We refer readers to the FY 2011 through FY 2024 IPPS/LTCH PPS final rules for discussions regarding this provision, including our methodology for identifying which areas meet the definition of “frontier States” as provided for in section 1886(d)(3)(E)(iii)(II) of the Act: for FY 2011, 75 FR 50160 through 50161; for FY 2012, 76 FR 51793, 51795, and 51825; for FY 2013, 77 FR 53369 and 53370; for FY 2014, 78 FR 50590 and 50591; for FY 2015, 79 FR 49971; for FY 2016, 80 FR 49498; for FY 2017, 81 FR 56922; for FY 2018, 82 FR 38142; for FY 2019, 83 FR 41380; for FY 2020, 84 FR 42312; for FY 2021, 85 FR 58765; for FY 2022, 86 FR 45178; FY 2023, 87 FR 49006; and for FY 2024, 88 FR 58977.</P>
                    <P>In addition to the changes required by the Affordable Care Act, we note that the proposed FY 2025 IPPS wage indexes continue to reflect a number of adjustments implemented in past years, including, but not limited to, reclassification of hospitals to different geographic areas, the rural floor provisions, the imputed floor wage index adjustment in all-urban states, an adjustment for occupational mix, an adjustment to the wage index based on commuting patterns of employees (the out-migration adjustment), and the permanent 5-percent cap on any decrease to a hospital's wage index from its wage index in a prior FY. Beginning with FY 2024, we include hospitals with § 412.103 reclassification along with geographically rural hospitals in all rural wage index calculations, and exclude “dual reclass” hospitals (hospitals with simultaneous § 412.103 and Medicare Geographic Classification Review Board (MGCRB) reclassifications) implicated by the hold harmless provision at section 1886(d)(8)(C)(ii) of the Act (88 FR 58971 through 58973). We also proposed to continue the low wage index hospital policy, under which we increase the wage index for hospitals with a wage index value below the 25th percentile wage index value for a fiscal year by half the difference between the otherwise applicable final wage index value for a year for that hospital and the 25th percentile wage index value for that year across all hospitals. We refer readers to the FY 2025 IPPS/LTCH PPS proposed rule (89 FR 36181 through 36186) for a detailed discussion of all proposed changes to the FY 2025 IPPS wage indexes.</P>
                    <P>We note that in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49018 through 49021), we finalized a permanent approach to smooth year-to-year decreases in hospitals' wage indexes. Specifically, for FY 2023 and subsequent years, we apply a 5-percent cap on any decrease to a hospital's wage index from its wage index in the prior FY, regardless of the circumstances causing the decline. That is, a hospital's wage index for FY 2025 would not be less than 95 percent of its final wage index for FY 2024. Except for newly opened hospitals, we apply the cap for a fiscal year using the final wage index applicable to the hospital on the last day of the prior fiscal year. A newly opened hospital would be paid the wage index for the area in which it is geographically located for its first full or partial fiscal year (subject to any reclassification), and it would not receive a cap for that first year, because it would not have been assigned a wage index in the prior year (in accordance with 42 CFR 419.41(c)(1) and 419.43(c), as noted previously).</P>
                    <P>
                        We delineate hospital labor market areas based on Core-Based Statistical Areas (CBSAs) established by the Office of Management and Budget (OMB). As discussed in the FY 2025 IPPS/LTCH PPS proposed rule (89 FR 36139 through 36174), OMB issued revisions to the current labor market area delineations on July 21, 2023, that included a number of significant changes such as new CBSAs, urban counties that become rural, rural counties that become urban, and existing CBSAs that are split apart (OMB Bulletin 23-01). This bulletin can be found at: 
                        <E T="03">https://www.whitehouse.gov/wp-content/uploads/2023/07/OMB-Bulletin-23-01.pdf</E>
                        . The proposed changes to the IPPS wage index based on the newest CBSA delineations are available in the FY 2025 IPPS/LTCH PPS proposed rule. We proposed that corresponding changes would be adopted in the OPPS, which uses the IPPS wage index, based on the new OMB delineations in the CY 2025 OPPS/ASC proposed rule, consistent with any proposals in the FY 2025 IPPS/LTCH PPS proposed rule. We believe that using the revised delineations based on OMB Bulletin No. 23-01 will increase the integrity of the OPPS wage index system by creating a more accurate representation of current geographic variations in wage levels. We refer readers to proposed changes based on the new OMB delineations in the FY 2025 IPPS/LTCH PPS proposed rule at 89 FR 36139 through 36174, which includes a discussion of the effects of implementation of the proposal to adopt the revised OMB labor market area delineations on reclassified hospitals.
                    </P>
                    <P>
                        CBSAs are made up of one or more constituent counties. Each CBSA and constituent county has its own unique identifying codes. The FY 2018 IPPS/LTCH PPS final rule (82 FR 38130) discussed the two different lists of codes to identify counties: Social Security Administration (SSA) codes and Federal Information Processing Standard (FIPS) codes. Historically, CMS listed and used SSA and FIPS county codes to identify and crosswalk counties to CBSA codes for purposes of the IPPS and OPPS wage indexes. However, the SSA county codes are no longer being maintained and updated, although the FIPS codes continue to be maintained by the U.S. Census Bureau. The Census Bureau's most current statistical area information is derived from ongoing census data from 2020. The Census Bureau maintains a complete list of changes to counties or county equivalent entities on the website at: 
                        <E T="03">https://www.census.gov/geo/reference/county-changes.html</E>
                         (which, as of May 6, 2019, migrated to: 
                        <E T="03">https://www.census.gov/programs-surveys/geography.html</E>
                        ). In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38130), for purposes of cross walking counties to CBSAs for the IPPS wage index, we finalized our proposal to discontinue the use of the SSA county codes and begin using only the FIPS county codes. Similarly, for the purposes of cross walking counties to CBSAs for the OPPS wage index, in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59260), we finalized our proposal to discontinue 
                        <PRTPAGE P="93973"/>
                        the use of SSA county codes and begin using only the FIPS county codes. For CY 2025, under the OPPS, we are continuing to use only the FIPS county codes for purposes of cross walking counties to CBSAs.
                    </P>
                    <P>
                        We proposed to use the FY 2025 IPPS post-reclassified wage index for urban and rural areas as the wage index for the OPPS to determine the wage adjustments for both the OPPS payment rate and the copayment rate for CY 2025. We note that the proposed FY 2025 IPPS wage indexes reflect several proposed changes as a result of the revised OMB delineations, including proposed policies to accommodate changes in rural or urban status for existing counties, as well as addition or removal of certain individual CBSAs compared to the previous delineations. Therefore, policies and adjustments that were finalized for the FY 2025 IPPS post-reclassified wage index would be reflected in the final CY 2025 OPPS wage index beginning on January 1, 2025, if appropriate. We refer readers to the FY 2025 IPPS/LTCH PPS proposed rule (89 FR 36181 through 36186) and the proposed FY 2025 hospital wage index files posted on the CMS website at 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/fy-2025-ipps-proposed-rule-home-page</E>
                        . Regarding budget neutrality for the CY 2025 OPPS wage index, we refer readers to section II.C of this final rule with comment period.
                    </P>
                    <P>
                        As a general matter, we continue to believe that using the IPPS post-reclassified wage index as the source of an adjustment factor for the OPPS is reasonable and logical, given the inseparable, subordinate status of the HOPD within the hospital overall. We acknowledge, however, that an interim final action with comment period (IFC) entitled Changes to the Fiscal Year 2025 Hospital Inpatient Prospective Payment System (IPPS) Rates Due to Court Decision appeared in the October 3, 2024 
                        <E T="04">Federal Register</E>
                         (89 FR 80405), which makes certain changes to the FY 2025 IPPS post-reclassified wage index for some hospitals that were not and could not have been anticipated or accounted for in the OPPS proposed rule. For reasons discussed in detail later in this section, we believe it is more appropriate and consistent with CMS' authority to use the post-reclassified wage index established in the FY 2025 IPPS final rule (89 FR 68986) as corrected in the FY 2025 IPPS final rule correction (89 FR 80098) for purposes of the CY 2025 OPPS wage index than it would be to incorporate the exceptional changes implemented by the IFC.
                    </P>
                    <P>Hospitals that are paid under the OPPS, but not under the IPPS, do not have an assigned hospital wage index under the IPPS. Therefore, for non-IPPS hospitals paid under the OPPS, it is our longstanding policy to assign the wage index that would be applicable if the hospital was paid under the IPPS, based on its geographic location and any applicable wage index policies and adjustments. We proposed to continue this policy for CY 2025. We refer readers to the FY 2025 IPPS/LTCH PPS proposed rule (89 FR 36181 through 36186) for a detailed discussion of the proposed changes to the FY 2025 IPPS wage indexes.</P>
                    <P>It has been our longstanding policy to allow non-IPPS hospitals paid under the OPPS to qualify for the out-migration adjustment if they are located in a section 505 out-migration county (section 505 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA)) (Pub. L. 108-173). Applying this adjustment is consistent with our general approach to adopt IPPS wage index policies for hospitals paid under the OPPS. We note that, because non-IPPS hospitals cannot reclassify, they are eligible for the out-migration wage index adjustment if they are located in a section 505 out-migration county. This is the same out-migration adjustment policy that would apply if the hospital were paid under the IPPS. For CY 2025, we proposed to continue our policy of allowing non-IPPS hospitals paid under the OPPS to qualify for the outmigration adjustment if they are located in a section 505 out-migration county (section 505 of the MMA) (88 FR 49585 and 49586). Furthermore, we proposed that the wage index that would apply for CY 2025 to non-IPPS hospitals paid under the OPPS would continue to include the rural floor adjustment and any policies and adjustments applied to the IPPS wage index to address wage index disparities. In addition, we proposed that the wage index that would apply to non-IPPS hospitals paid under the OPPS would include the 5-percent cap on wage index decreases.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter supported CMS's decision to utilize the updated OMB delineations and agreed with the CBSA assignments made in Connecticut based on the regional planning areas.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's support.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A commenter did not agree with CMS's adoption of OMB's CBSA delineation revisions. The commenter stated that OMB cautions that CBSAs are not intended for any non-statistical uses and should only be used for other purposes with full consideration of the effects of using the delineations for such purposes. Further, the commenter stated that the Metropolitan Areas Protection and Standardization Act (MAPS Act) bars the automatic propagation of OMB revisions in CBSA delineations to geographic area determinations in nonstatistical Federal programs, and stated that any change to the standards of CBSA delineations shall propagate for any non-statistical use by any domestic assistance program only if the relevant agency determines that such a propagation supports the purposes of the program, is in the public interest, and adopts the change through notice-and-comment rulemaking. The commenter contends that if CMS chooses to adopt new OMB delineations, CMS must fully explain why reliance on the updated CBSAs as set forth by OMB is appropriate for purposes of the FY 2025 hospital wage index adjustments. The commenter stated that CMS has not provided an appropriate rationale for relying on the updated CBSAs and proposed to adopt the revised CBSAs by default. The commenter contends that CMS must make a fact-specific determination of those CBSAs' suitability for Medicare reimbursement purposes, including whether it would be appropriate to use additional data to modify OMB's delineations to ensure that such changes are appropriate for purposes of defining regional labor markets for hospital workers.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         CMS acknowledges that the CBSA definitions and delineations were not specifically created for the purpose of determining a hospital wage index. However, based on the reasons stated in prior rulemaking, we continue to believe that these definitions and delineations, which are regularly reviewed and updated by OMB, are the best proxy for CMS to use to adjust hospital payment rates based on geographic variations in labor costs in accordance with the statute. We note that the OPPS wage index has historically adopted the IPPS wage index on a calendar year basis, and thus the same structure for organizing geographic areas applied to the IPPS through CBSAs has applied in the OPPS.
                    </P>
                    <P>
                        Section 1886(d)(3)(E) of the Act requires that, as part of the methodology for determining prospective payments to hospitals through the IPPS, the Secretary must adjust the standardized amounts “for area differences in hospital wage levels by a factor (established by the Secretary) reflecting the relative hospital wage level in the 
                        <PRTPAGE P="93974"/>
                        geographic area of the hospital compared to the national average hospital wage level.” Section 1833(t)(2)(D) of the Act provides that for the OPPS, “the Secretary shall determine a wage adjustment factor to adjust the portion of payment and coinsurance attributable to labor-related costs for relative differences in labor and labor-related costs across geographic regions in a budget neutral manner.” We refer readers to the FY 1985 IPPS final rule (50 FR 24375 through 24377) and the FY 1995 IPPS final rule (60 FR 29218 through 29220) for a history of the outreach, consultation, and discussion of the challenges faced in defining appropriate labor market areas for purposes of the wage index methodology. As with any classification system in which boundaries must be established, it is impossible to designate boundaries that will be completely satisfactory to all concerned. There was no consensus among the interested parties on a choice for new labor market areas, and CMS concluded the adoption and continuation of an MSA-based framework was the most prudent course of action. We also refer readers to the FY 2005 rule (69 FR 49027 through 49028) for further discussion regarding the process and outreach CMS undertook before initially adopting OMB CBSAs as the basis for the wage index methodology. We found that the CBSA framework offered a useful proxy for labor market area delineations and that none of the alternative labor market areas that were studied provided a distinct improvement over the use of MSAs.
                    </P>
                    <P>
                        As stated previously, CMS continued to evaluate other potential methods to calculate variations in geographic labor markets in a manner that maintains or improves consistency and equity in hospital payments in response to recommendations from MedPAC. However, as stated in the 2012 Report to Congress: Plan to Reform the Medicare Wage Index (on the web at 
                        <E T="03">https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-IndexReform</E>
                        ), CMS has concluded that implementing any of the recommended revisions to wage index methodologies would require Congressional action. The commenter did not suggest any alternative method for defining geographic labor market areas and, given our decades long history of using OMB CBSA (and the prior Primary MSA) definitions and delineations for wage index purposes, we continue to believe adopting OMB revisions in a timely manner is essential to the wage index by creating a more accurate representation of geographic variations in wage levels. CMS is aware of the MAPS Act requirements for the adoption of CBSA definitions for nonstatistical use and believes that we have provided an adequate rationale to support our proposed adoption through notice and comment rulemaking. As we stated in the proposed rule (89 FR 36140), we believe that using the revised delineations based on OMB Bulletin No. 23-01 will increase the integrity of the wage index by creating a more accurate representation of current geographic variations in wage levels. While the adoption of the revised delineations will have both positive and negative impacts on specific hospitals and labor markets, we believe that periodically updating the labor market delineations using objective criteria and based on the most recently available commuting data will serve the public's interest in ensuring accurate Medicare payments to hospitals under the OPPS by more accurately reflecting current geographic variations in labor costs in the hospital payment methodology. While some CBSAs would be modified in significant ways, the criteria for MSA, Micropolitan Statistical Area, and Metropolitan Division definitions finalized by OMB are generally consistent with past updates, and we do not find that the adoption of these delineations will create extreme variations in payments to hospitals, especially when considering the impact of the policy to cap annual wage index reductions at 5 percent. On this basis, and for the reasons we stated in prior rulemaking, we have determined that their use supports the purpose of adjusting hospital payment rates based on geographic variations in labor costs in accordance with the statute. We have reviewed our findings and impacts relating to the new OMB delineations and find no compelling reason to delay implementation. Therefore, we are finalizing the proposed policies implementing the revised OMB delineations, including the policy for the treatment of Micropolitan Statistical areas, Metropolitan divisions, and the change to county-equivalent definitions for the State of Connecticut.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A commenter requested that in addition to the permanent cap policy, CMS implement a 3-year wage index transition period consistent with prior updates to the CBSA categorizations made due to OMB updates.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We note that when we previously adopted revised OMB delineations, the majority of negatively impacted hospitals received a wage index adjustment for only one fiscal year via a 50/50 blend of wage index values using the then-current and newly adopted delineations (79 FR 66827). Hospitals that were reassigned from an urban to rural area as a result of our adoption of the revised OMB delineations received a 3-year transition period from their previous urban area wage index, as long as they did not obtain a new MGCRB reclassification during that time period. As discussed in the FY 2023 IPPS/LTCH PPS final rule (87 FR 49018 through 49021), the 5 percent cap on annual wage index reductions was intended to make unnecessary any future transitions in connection with wage index policy implementations, including the adoption of revised labor market area definitions. Based on our analysis of wage index differences between FY 2024 and FY 2025, we estimate that only 136 hospitals (less that 4 percent) will receive a wage index cap that did not receive the cap in FY 2024. This indicates any impact on overall wage index values that could be caused by the adoption of the revised delineations would be relatively small. Furthermore, given the iterative and interactive effects of different reclassification and wage index hold-harmless policies, it is difficult to isolate the effects on wage index values (both positive and negative) that are due solely to the adoption of the revised delineations. That is, hospitals may make different reclassification decisions based on the transition policy, rather than the actual impacts of the revised delineations. We believe that any attempt to tailor a transition policy specifically to the impacts of adopting revised labor market delineations is not likely to yield results that more accurately reflect current differences in area wages than the 5 percent cap policy. We believe the 5 percent cap policy ensures that hospitals will not experience large payment reductions as a result of annual changes in their wage index value, allows adequate time for hospitals to evaluate reclassification options, and provides consistency and predictability in wage index values. Largely due to the modification of the rural wage index calculation finalized in FY 2024 IPPS/LTCH PPS final rule (88 FR 58971 through 58977), a much larger number of urban and rural hospitals within the same state (nearly 60 percent) receive identical wage index values (prior to the application of other policies, such as the outmigration adjustment, 5 percent cap on annual wage index decreases, and low-wage index hospital policy). This 
                        <PRTPAGE P="93975"/>
                        fact suggests that there is even less need for separate transition policies for urban and rural hospitals in response to changes in geographic delineations than there was previously. Furthermore, we did not receive a comment from any hospital (urban or rural) citing specific negative impacts due solely or primarily to the proposed adoption of the revised OMB delineations. For these reasons, we do not believe it is necessary to implement any additional or alternative transition policy to the 5 percent cap on wage index decrease policy.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A commenter supported our policy to treat urban hospitals reclassified as rural hospitals under § 412.103 as rural hospitals for purposes of the rural wage indexes and the rural floor.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's support of our policy.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Multiple commenters supported our proposed low-wage index policy, which, for hospitals with a wage index value below the 25th percentile, increases the hospital's wage index by half the difference between the otherwise applicable wage index value for that hospital and the 25th percentile wage index value for all hospitals. Some commenters stated that the policy helps to address unjustified disparities in Medicare reimbursement. One commenter supported the continuation of this policy and noted the court decision in 
                        <E T="03">Bridgeport Hospital</E>
                         v. 
                        <E T="03">Becerra,</E>
                         108 F.4th 882 (D.C. Cir. 2024) that determined that CMS lacked the statutory authority to adopt this policy in the IPPS.
                    </P>
                    <P>
                        One commenter opposed the proposed low wage index hospital policy. They believe that it has the effect of harming hospitals in high wage areas while having unclear impacts on the hospitals in low wage areas that receive higher payments. The commenter further noted the recent court decision in 
                        <E T="03">Bridgeport Hospital</E>
                         v. 
                        <E T="03">Becerra.</E>
                         As a result, they urged CMS to discontinue the low wage index policy in the OPPS, but advocated that if CMS maintained the policy, it do so in a non-budget neutral manner.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate these comments.
                    </P>
                    <P>Since the establishment of the OPPS, we have adopted the IPPS wage index on a calendar year basis in the OPPS. As we have noted across the years and earlier in this section, using the IPPS wage index as the source of an adjustment factor for the OPPS is reasonable and logical, given the inseparable, subordinate status of the HOPD within the hospital overall. In cases where CMS has had statutory authority to implement certain policies under the IPPS in a non-budget neutral manner, to apply the same wage index values in the OPPS we have budget neutralized those adjustments in accordance with section 1833(t)(2)(D) of the Act, such as with the outmigration adjustment (69 FR 65842 through 65844).</P>
                    <P>
                        On July 23, 2024, the Court of Appeals for the D.C. Circuit held that the Secretary lacked authority under section 1886(d)(3)(E) of the Act or under the “adjustments” language of section 1886(d)(5)(I)(i) of the Act to adopt the low wage index hospital policy for FY 2020 for the IPPS, and that the policy and related budget neutrality adjustment in the IPPS must be vacated. 
                        <E T="03">Bridgeport Hosp.</E>
                         v. 
                        <E T="03">Becerra,</E>
                         108 F.4th 882, 887-91 &amp; n.6 (D.C. Cir. 2024). In consideration of the court decision, CMS subsequently issued the interim final action with comment period (IFC) entitled Changes to the Fiscal Year 2025 Hospital Inpatient Prospective Payment System (IPPS) Rates Due to Court Decision (CMS-1808-IFC) to remove the low wage index hospital policy for FY 2025 IPPS purposes. At the same time, the IFC included a payment exception under section 1886(d)(5)(I)(i) of the Act that corresponded mathematically to a 5 percent cap on wage index reductions from FY 2024 for certain low wage index hospitals most significantly impacted by the removal of the low wage index policy.
                    </P>
                    <P>
                        We note that we proposed to include the low wage index hospital policy as part of the CY 2025 OPPS wage index and believe that the statutory authority provided under section 1833(t)(2)(D) of the Act allows us to finalize a similar policy for the CY 2025 OPPS, as we have done each year beginning in CY 2020. Specifically, section 1886(d)(3)(E) of the Act requires that CMS base the IPPS wage index on a comparison of “the relative hospital wage level in the geographic area of the hospital compared to the national average hospital wage level,” and on “a survey conducted by the Secretary (and updated as appropriate) of the wages and wage-related costs of subsection (d) hospitals in the United States,” whereas section 1833(t)(2)(D) contains no such prescriptions for the manner of determining the OPPS wage index. (We continue to effectuate relevant prescriptions, such as the requirement in sections 1833(t)(2)(D) and 1833(t)(9) of the Act that OPPS wage index policies are generally budget neutral.) In addition, CMS has authority to apply the low wage index hospital policy to the OPPS wage index under section 1833(t)(2)(E) of the Act, which allows the Secretary to “establish, in budget neutral manner, . . . other adjustments as determined to be necessary to ensure equitable payments, such as adjustments for certain classes of hospitals. We believe implementing the low wage index hospital policy is a valid exercise of the Secretary's authority to adopt “adjustments” to OPPS payments under the OPPS statute, where the provision regarding calculation of the OPPS wage adjustment factor does not contain the same language that the D.C. Circuit found to be prescriptive for the calculation of the IPPS wage index found at section 1886(d)(3)(E) of the Act. Additionally, section 1833(t)(2)(E) of the Act—unlike the adjustment authority at section 1886(d)(5)(I)—authorizes us to make adjustments to “ensure equitable payments.” In light of the unique circumstances presented by the timing of D.C. Circuit's decision, application of the low wage-index-hospital policy under the OPPS for CY 2025 avoids unexpected and arguably unfair payment consequences for hospitals that were not plaintiffs in the 
                        <E T="03">Bridgeport</E>
                         case and so falls within our equitable adjustment authority.
                    </P>
                    <P>
                        While this would create a divergence between the OPPS wage index values in CY 2025 and the ultimate, effective FY 2025 IPPS wage index values for some hospitals, we continue to believe that the concerns related to the wage index that led to the application of this policy to the OPPS wage index in previous years continue to apply, and that the OPPS authority for wage adjustment factors continues to give CMS the authority to implement a budget neutral low wage index hospital policy. Additionally, we believe that the same reasons underlying adoption of the IFC policies for the FY 2025 IPPS wage index weigh against incorporating those policies for purposes of the CY 2025 OPPS wage index. Specifically, we noted in the IFC that the intention of the policies implemented therein is to “promote certainty regarding. . .payments” and “provide for payment stability and promote predictability,” in light of the court's decision in the 
                        <E T="03">Bridgeport Hospital</E>
                         case (89 FR 80408). Given the differences noted in the previous paragraph between the IPPS and OPPS in CMS's statutory authorities related to the wage index, those interests are better served by finalizing the OPPS wage index methodology as proposed, including the low wage index hospital policy.
                    </P>
                    <P>
                        Finally, we acknowledge that in the IFC, we implemented under section 1886(d)(5)(I)(i) of the Act a transitional payment exception for hospitals that benefitted from the FY 2024 low wage 
                        <PRTPAGE P="93976"/>
                        index hospital policy in the IPPS without budget neutralizing that exception. But that payment exception serves a different purpose from that of the low wage index hospital policy. And, in any event, unlike the statute authorizing the transitional payment exception, CMS's authority to implement a low wage index hospital policy in the OPPS requires it to budget neutralize that policy. That is, while section 1886(d)(5)(I)(i) contains no budget neutrality requirement, both section 1833(t)(2)(D) and (t)(2)(E) do. Thus, in the context of the OPPS, we will continue to budget neutralize the low wage index hospital policy. For these reasons, and those discussed above, we are finalizing in the CY 2025 OPPS the low wage index hospital policy as we had proposed in the CY 2025 OPPS/ASC proposed rule (89 FR 59227).
                    </P>
                    <P>
                        We recognize that creating different effective wage index values for a hospital under the OPPS than the wage index value for the hospital under the IPPS for CY 2025 differs in some respects from how we have implemented the OPPS wage index previously, where we have used the IPPS wage index value in effect throughout the FY as the OPPS wage index value for all hospitals. However, we believe this is the appropriate approach for the CY 2025 OPPS given the unusual circumstances wherein an appellate court ruled that CMS lacked authority under the IPPS statute for a policy under the FY 2020 IPPS wage index that the OPPS proposed rule had already proposed to include in the OPPS wage index. We further believe the approach in this final rule is consistent with § 419.43(c), which states: “CMS uses the hospital inpatient prospective payment system wage index established in accordance with Part 412 of this chapter to make the adjustment specified under paragraph (a) of this section.” The OPPS wage index values will match the IPPS wage index values in the FY 2025 IPPS final rule, as corrected in the FY 2025 IPPS final rule correction (89 FR 80098), which were “established in accordance with Part 412”; we are merely declining to incorporate certain modifications to those values made in the IFC, which reflect extraordinary steps taken due to the timing of the court's decision in 
                        <E T="03">Bridgeport Hospital.</E>
                    </P>
                    <P>CMS will explore options for realigning the IPPS and OPPS wage index values through future rulemaking.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Multiple commenters supported our policy to apply a 5 percent cap on any decrease to a hospital's wage index from its wage index in the prior FY. Commenters also requested that the proposed 5-percent cap policy be applied in a non-budget neutral manner, which the commenter stated would allow the cap to be applied while avoiding decreases to the wage index in areas with high wage indexes.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' support of our policy to apply a 5-percent cap on any decrease to a hospital's wage index from its wage index in the prior FY. For the OPPS, section 1833(t)(2)(D) of the Act requires the Secretary to determine a wage adjustment factor to adjust the portion of payment and coinsurance attributable to labor-related costs for relative differences in labor and labor-related costs across geographic regions in a budget neutral manner, which is inconsistent with the commenters' request to exclude the wage index cap policy from budget neutrality.
                    </P>
                    <P>
                        After consideration of the public comments we received, we are finalizing our proposal without modification to use the FY 2025 IPPS post-reclassified wage index for urban and rural areas as finalized in the FY 2025 IPPS final rule and corrected in the FY 2025 IPPS final rule correction as the wage index for the OPPS, which includes the OPPS low wage index hospital policy, to determine the wage adjustments for both the OPPS payment rate and the copayment rate for CY 2025. In addition to the low wage index hospital policy, which will only apply in the OPPS in CY 2025, certain FY 2025 post-reclassified wage index policies will be reflected in the final CY 2025 OPPS wage index beginning on January 1, 2025, including, but not limited to, reclassification of hospitals to different geographic areas, the rural floor provisions, the imputed floor wage index adjustment in all-urban states, an adjustment for occupational mix, an adjustment to the wage index based on commuting patterns of employees (the out-migration adjustment), and a 5-percent cap on any decrease to a hospital's wage index from its wage index in the prior FY. We refer readers to the FY 2025 IPPS/LTCH PPS final rule (89 FR 69252 through 69310) and the FY 2025 hospital wage index files posted on the CMS website at 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/fy-2025-ipps-final-rule-home-page</E>
                        . Regarding budget neutrality for the CY 2025 OPPS wage index, we refer readers to section II.B. of this final rule with comment period.
                    </P>
                    <P>For CMHCs, for CY 2025, we proposed to continue to calculate the wage index by using the post-reclassification IPPS wage index based on the CBSA where the CMHC is located. Furthermore, we proposed that the wage index that would apply to a CMHC for CY 2025 would continue to include the rural floor adjustment and any policies and adjustments applied to the IPPS wage index to address wage index disparities. In addition, the wage index that would apply to CMHCs would include the 5-percent cap on wage index decreases. Also, we proposed that the wage index that would apply to CMHCs would not include the outmigration adjustment because that adjustment only applies to hospitals.</P>
                    <P>We did not receive any public comments on our proposals, and we are finalizing our proposals regarding CMHC wage index calculations without modification.</P>
                    <P>
                        Table 4A associated with the FY 2025 IPPS/LTCH PPS final rule (available via the internet on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/fy-2025-ipps-final-rule-home-page</E>
                        ) identifies counties that would be eligible for the out-migration adjustment. Table 2 associated with the FY 2025 IPPS/LTCH PPS final rule as corrected by the FY 2025 IPPS final rule correction identifies IPPS hospitals that would receive the out-migration adjustment for FY 2025. We are including the outmigration adjustment information from Table 2 associated with the FY 2025 IPPS/LTCH PPS final rule as Addendum L to this final rule with comment period, with the addition of non-IPPS hospitals that would receive the section 505 outmigration adjustment under this final rule. Addendum L is available via the internet on the CMS website. We refer readers to the CMS website for the OPPS at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        . At this link, readers will find a link to the FY 2025 IPPS final rule wage index tables and the CY 2025 OPPS final rule Addendum L.
                    </P>
                    <HD SOURCE="HD2">D. Statewide Average Default Cost-to-Charge Ratios (CCRs)</HD>
                    <P>
                        In addition to using CCRs to estimate costs from charges on claims for ratesetting, we use overall hospital-specific CCRs calculated from the hospital's most recent cost report (OMB control number: 0938-0050 for Form CMS-2552-10) to determine outlier payments, payments for pass-through devices, and monthly interim transitional corridor payments under the OPPS during the PPS year. For certain hospitals, under the regulations at 42 CFR 419.43(d)(5)(iii), we use the 
                        <PRTPAGE P="93977"/>
                        statewide average default CCRs to determine the payments mentioned earlier if it is not possible to determine an accurate CCR for a hospital in certain circumstances. This includes hospitals that are new, hospitals that have not accepted assignment of an existing hospital's provider agreement, and hospitals that have not yet submitted a cost report. We also use the statewide average default CCRs to determine payments for hospitals whose CCR falls outside the predetermined ceiling threshold for a valid CCR or for hospitals in which the most recent cost report reflects an all-inclusive rate status (Medicare Claims Processing Manual (Pub. L. 100-04), Chapter 4, Section 10.11).
                    </P>
                    <P>We discussed our policy for using default CCRs, including setting the ceiling threshold for a valid CCR, in the CY 2009 OPPS/ASC final rule with comment period (73 FR 68594 through 68599) in the context of our adoption of an outlier reconciliation policy for cost reports beginning on or after January 1, 2009. For details on our process for calculating the statewide average CCRs, we refer readers to the Claims Accounting Narrative for this final rule with comment period, which is posted on our website. We proposed to calculate the default ratios for CY 2025 using the most recent cost report data.</P>
                    <P>We did not receive any public comments on our proposal, and we are finalizing our proposal without modification to calculate the default ratios for CY 2025 using the most recent cost report data, which are from a June 2024 HCRIS cost report extract.</P>
                    <P>
                        We no longer publish a table in the 
                        <E T="04">Federal Register</E>
                         containing the statewide average CCRs in the annual OPPS/ASC proposed rule and final rule with comment period. These CCRs and the upper limit CCR value at which we would apply statewide CCRs will be available for download with each OPPS/ASC CY proposed rule and final rule on the CMS website. We refer readers to our website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices;</E>
                         click on the link on the left of the page titled “Annual Policy Files” and then select the relevant year to download the statewide CCRs and upper limit in the “Downloads” section of the web page.
                    </P>
                    <HD SOURCE="HD2">E. Adjustment for Rural Sole Community Hospitals (SCHs) and Essential Access Community Hospitals (EACHs) Under Section 1833(t)(13)(B) of the Act for CY 2025</HD>
                    <P>In the CY 2006 OPPS final rule with comment period (70 FR 68556), we finalized a payment increase for rural sole community hospitals (SCHs) of 7.1 percent for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, brachytherapy sources, items paid at charges reduced to costs, and devices paid under the pass-through payment policy, in accordance with section 1833(t)(13)(B) of the Act, as added by section 411 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. 108-173). Section 1833(t)(13) of the Act provides the Secretary the authority to make an adjustment to OPPS payments for rural hospitals, effective January 1, 2006, if justified by a study of the difference in costs by APC between hospitals in rural areas and hospitals in urban areas. Our analysis showed a difference in costs for rural SCHs. Therefore, for the CY 2006 OPPS, we finalized a payment adjustment for rural SCHs of 7.1 percent for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, brachytherapy sources, items paid at charges reduced to costs, and devices paid under the pass-through payment policy, in accordance with section 1833(t)(13)(B) of the Act.</P>
                    <P>In the CY 2007 OPPS/ASC final rule with comment period (71 FR 68010 and 68227), for purposes of receiving this rural adjustment, we revised our regulations at § 419.43(g) to clarify that essential access community hospitals (EACHs) are also eligible to receive the rural SCH adjustment, assuming these entities otherwise meet the rural adjustment criteria. Currently, two hospitals are classified as EACHs, and as of CY 1998, under section 4201(c) of the Balanced Budget Act of 1997 (BBA) (Pub. L. 105-33), a hospital can no longer become newly classified as an EACH.</P>
                    <P>This adjustment for rural SCHs is budget neutral and applied before calculating outlier payments and copayments. We stated in the CY 2006 OPPS final rule with comment period (70 FR 68560) that we would not reestablish the adjustment amount on an annual basis, but we may review the adjustment in the future and, if appropriate, would revise the adjustment. We provided the same 7.1 percent adjustment to rural SCHs, including EACHs, again in CYs 2008 through 2024.</P>
                    <P>For CY 2025, we proposed to continue the current policy of a 7.1 percent payment adjustment for rural SCHs, including EACHs, for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, brachytherapy sources, items paid at charges reduced to costs, and devices paid under the pass-through payment policy, applied in a budget neutral manner.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Many commenters supported our policy to continue the 7.1 percent payment adjustment for rural SCHs and EACHs.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their support of our policy.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Multiple commenters stated that the 7.1 percent payment adjustment should be extended to urban SCHs and Medicare dependent hospitals (MDHs). The commenters suggested CMS perform another study to look at the costs that MDHs incur and that CMS has the authority to extend the adjustment to MDHs and urban SCHs without legislation.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We reiterate that our study of the cost difference by APC's between hospitals in rural areas and urban areas only showed a significant difference in costs for rural SCHs. CMS results did not identify significant cost differences between hospitals in urban areas and MDHs. In addition, our authority under section 1833(t)(13) of the Act only extends to rural hospitals. Therefore, we are not expanding the types of hospitals eligible for the 7.1 percent payment adjustment at this time.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal, without modification, to continue our current policy of utilizing a budget neutral 7.1 percent payment adjustment for rural SCHs, including EACHs, for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, devices paid under the pass-through payment policy, and items paid at charges reduced to costs.</P>
                    <HD SOURCE="HD2">F. Payment Adjustment for Certain Cancer Hospitals for CY 2025</HD>
                    <HD SOURCE="HD3">1. Background</HD>
                    <P>
                        Since the inception of the OPPS, which was authorized by the Balanced Budget Act of 1997 (BBA) (Pub. L. 105-33), Medicare has paid the 11 hospitals that meet the criteria for cancer hospitals identified in section 1886(d)(1)(B)(v) of the Act under the OPPS for covered outpatient department services. These cancer hospitals are exempted from payment under the IPPS. With the Medicare, Medicaid and SCHIP Balanced Budget Refinement Act of 1999 (Pub. L. 106-113), the Congress added section 1833(t)(7), “Transitional Adjustment to Limit Decline in Payment,” to the Act, which requires the Secretary to determine OPPS payments to cancer and children's hospitals based on their pre-BBA 
                        <PRTPAGE P="93978"/>
                        payment amount (these hospitals are often referred to under this policy as “held harmless” and their payments are often referred to as “hold harmless” payments).
                    </P>
                    <P>As required under section 1833(t)(7)(D)(ii) of the Act, a cancer hospital receives the full amount of the difference between payments for covered outpatient department services under the OPPS and a “pre-BBA amount.” That is, cancer hospitals are permanently held harmless to their “pre-BBA amount,” and they receive transitional outpatient payments (TOPs) or hold harmless payments to ensure that they do not receive a payment that is lower in amount under the OPPS than the payment amount they would have received before implementation of the OPPS, as set forth in section 1833(t)(7)(F) of the Act. The “pre-BBA amount” is the product of the hospital's reasonable costs for covered outpatient department services occurring in the current year and the base payment-to-cost ratio (PCR) for the hospital defined in section 1833(t)(7)(F)(ii) of the Act. The “pre-BBA amount” and the determination of the base PCR are defined at § 419.70(f). TOPs are calculated on Worksheet E, Part B, of the Hospital Cost Report or the Hospital Health Care Complex Cost Report (Form CMS-2552-96 or Form CMS-2552-10 (OMB NO: 0938-0050), respectively), as applicable each year. Section 1833(t)(7)(I) of the Act exempts TOPs from budget neutrality calculations.</P>
                    <P>Section 3138 of the Affordable Care Act (Pub. L. 111-148) amended section 1833(t) of the Act by adding a new paragraph (18), which instructs the Secretary to conduct a study to determine if, under the OPPS, outpatient costs incurred by cancer hospitals described in section 1886(d)(1)(B)(v) of the Act with respect to APC groups exceed outpatient costs incurred by other hospitals furnishing services under section 1833(t) of the Act, as determined appropriate by the Secretary. Section 1833(t)(18)(A) of the Act requires the Secretary to take into consideration the cost of drugs and biologicals incurred by cancer hospitals and other hospitals. Section 1833(t)(18)(B) of the Act provides that, if the Secretary determines that cancer hospitals' costs are higher than those of other hospitals, the Secretary shall provide an appropriate adjustment under section 1833(t)(2)(E) of the Act to reflect these higher costs. In 2011, after conducting the study required by section 1833(t)(18)(A) of the Act, we determined that outpatient costs incurred by the 11 specified cancer hospitals were greater than the costs incurred by other OPPS hospitals. For a complete discussion regarding the cancer hospital cost study, we refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74200 and 74201).</P>
                    <P>Based on these findings, we finalized a policy to provide a payment adjustment to the 11 specified cancer hospitals that reflects their higher outpatient costs, as discussed in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74202 through 74206). Specifically, we adopted a policy to provide additional payments to the cancer hospitals so that each cancer hospital's final PCR for services provided in a given calendar year is equal to the weighted average PCR (which we refer to as the “target PCR”) for other hospitals paid under the OPPS. The target PCR is set in advance of the calendar year and is calculated using the most recently submitted or settled cost report data that are available at the time of final rulemaking for the calendar year. The amount of the payment adjustment is made on an aggregate basis at cost report settlement. We note that the changes made by section 1833(t)(18) of the Act do not affect the existing statutory provisions that provide for TOPs for cancer hospitals. The TOPs are assessed, as usual, after all payments, including the cancer hospital payment adjustment, have been made for a cost reporting period. Table 11 displays the target PCR for purposes of the cancer hospital adjustment for CY 2012 through CY 2024.</P>
                    <GPH SPAN="3" DEEP="239">
                        <GID>ER27NO24.016</GID>
                    </GPH>
                    <HD SOURCE="HD3">2. Policy for CY 2025</HD>
                    <P>
                        Section 16002(b) of the 21st Century Cures Act (Pub. L. 114-255) amended section 1833(t)(18) of the Act by adding subparagraph (C), which requires that in applying § 419.43(i) (that is, the payment adjustment for certain cancer hospitals) for services furnished on or after January 1, 2018, the target PCR adjustment be reduced by 1.0 percentage point less than what would 
                        <PRTPAGE P="93979"/>
                        otherwise apply. Section 16002(b) also provides that, in addition to the percentage reduction, the Secretary may consider making an additional percentage point reduction to the target PCR that takes into account payment rates for applicable items and services described under section 1833(t)(21)(C) of the Act for hospitals that are not cancer hospitals described under section 1886(d)(1)(B)(v) of the Act. Further, in making any budget neutrality adjustment under section 1833(t) of the Act, the Secretary shall not take into account the reduced expenditures that result from application of section 1833(t)(18)(C) of the Act.
                    </P>
                    <P>We proposed to provide additional payments to the 11 specified cancer hospitals so that each cancer hospital's proposed PCR is equal to the weighted average PCR (or “target PCR”) for the other OPPS hospitals, generally using the most recent submitted or settled cost report data that are available, reduced by 1.0 percentage point, to comply with section 16002(b) of the 21st Century Cures Act, and adjusted by the proposed post-Public Health Emergency (PHE) transition as described later in this section. We are not proposing an additional reduction beyond the 1.0 percentage point reduction required by section 16002(b) of the 21st Century Cures Act for CY 2025.</P>
                    <P>To calculate the proposed CY 2025 target PCR, we proposed to use the same extract of cost report data from HCRIS used to estimate costs for the CY 2025 OPPS which, in most cases, would be the most recently available hospital cost reports. Using these cost report data, we included data from Worksheet E, Part B, for each hospital, using data from each hospital's most recent cost report, whether as submitted or settled.</P>
                    <P>We then limited the dataset to the hospitals with CY 2023 claims data that we used to model the impact of the proposed CY 2025 APC relative payment weights (3,448 hospitals) because it is appropriate to use the same set of hospitals that are being used to calibrate the modeled CY 2025 OPPS. The cost report data for the hospitals in this dataset were from cost report periods with fiscal year ends ranging from 2019 to 2023; however, the cost reporting periods were predominantly from fiscal years ending in 2022 and 2023. We then removed the cost report data of the 49 hospitals located in Puerto Rico from our dataset because we did not believe their cost structure reflected the costs of most hospitals paid under the OPPS, and, therefore, their inclusion may bias the calculation of hospital-weighted statistics. We also removed the cost report data of 16 hospitals because these hospitals had cost report data that were not complete (missing aggregate OPPS payments, missing aggregate cost data, or missing both), so that all cost reports in the study would have both the payment and cost data necessary to calculate a PCR for each hospital, leading to a proposed analytic file of 3,421 hospitals with cost report data.</P>
                    <P>Using this smaller dataset of cost report data, we estimated that, on average, the OPPS payments to other hospitals furnishing services under the OPPS were approximately 87 percent of reasonable cost (weighted average PCR of 0.87). Therefore, after applying the 1.0 percentage point reduction, as required by section 16002(b) of the 21st Century Cures Act, using our standard process the payment amount associated with the cancer hospital payment adjustment to be determined at cost report settlement would be the additional payment needed to result in a target PCR equal to 0.86 for each cancer hospital.</P>
                    <P>In the CY 2024 OPPS/ASC final rule with comment period (88 FR 81586 through 81589), we explained that we believe we should begin to take into consideration the PCR of non-cancer hospitals based on the most recently available data for calculating the target PCR. We noted that we do not know if the changes in the data that have yielded lower PCRs for non-cancer hospitals are likely to continue in future years or if, when data from after the PHE is available, we will see the target PCR increase toward its historical norm. Therefore, in the CY 2024 OPPS/ASC final rule with comment period, we finalized our proposal to transition from the target PCR of 0.89 we finalized for CYs 2020 through 2024 (which included the 1.0 percentage point reduction as required by section 16002(b) of the 21st Century Cures Act) and incrementally reduce the target PCR by an additional 1.0 percentage point for each calendar year, beginning with CY 2024, until the target PCR equals the PCR of non-cancer hospitals calculated using the most recent data minus 1.0 percentage point as required by section 16002(b) of the 21st Century Cures Act. Therefore, utilizing this methodology for the CY 2025 OPPS/ASC proposed rule, since the target PCR that would otherwise apply under our standard process would be a target PCR of 0.86, we proposed to reduce the CY 2024 target PCR of 0.88 by 1 percentage point and proposed a cancer hospital target PCR of 0.87 for CY 2025.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters supported the proposed target PCR of 0.87 for CY 2025. One commenter requested that CMS ensure that repayments to 340B hospitals are appropriately reflected in the final 2025 PCR calculation.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their support. With respect to the commenter's request that the final 2025 PCR calculation include repayments to 340B hospitals, we refer to our response to that same comment in the CY 2024 OPPS/ASC final rule with comment period (88 FR 81588).
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing without modification our proposal to reduce the CY 2024 target PCR by 1 percentage point and apply a target PCR of 0.87 to the 11 specified cancer hospitals for CY 2025.</P>
                    <P>Table 12 shows the estimated percentage increase in OPPS payments to each cancer hospital for CY 2025, due to the cancer hospital payment adjustment policy. The actual, final amount of the CY 2025 cancer hospital payment adjustment for each cancer hospital will be determined at cost report settlement and will depend on each hospital's CY 2025 payments and costs from the settled CY 2025 cost report. We note that the requirements contained in section 1833(t)(18) of the Act do not affect the existing statutory provisions that provide for TOPs for cancer hospitals. The TOPs will be assessed, as usual, after all payments, including the cancer hospital payment adjustment, have been made for a cost reporting period.</P>
                    <GPH SPAN="3" DEEP="339">
                        <PRTPAGE P="93980"/>
                        <GID>ER27NO24.017</GID>
                    </GPH>
                    <HD SOURCE="HD2">G. Hospital Outpatient Outlier Payments</HD>
                    <HD SOURCE="HD3">1. Background</HD>
                    <P>The OPPS provides outlier payments to hospitals to help mitigate the financial risk associated with high-cost and complex procedures, where a very costly service could present a hospital with significant financial loss. As explained in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66832 through 66834), we set our projected target for aggregate outlier payments at 1.0 percent of the estimated aggregate total payments under the OPPS for the prospective year. Outlier payments are provided on a service-by-service basis when the cost of a service exceeds the APC payment amount multiplier threshold (the APC payment amount multiplied by a certain amount) as well as the APC payment amount plus a fixed-dollar amount threshold (the APC payment plus a certain dollar amount). In CY 2024, the outlier threshold was met when the hospital's cost of furnishing a service exceeded 1.75 times the APC payment amount (the multiplier threshold) and exceeded the APC payment amount plus $7,750 (the fixed-dollar amount threshold) (88 FR 81589 through 81591). If the hospital's cost of furnishing a service exceeds both the multiplier threshold and the fixed-dollar threshold, the outlier payment is calculated as 50 percent of the amount by which the hospital's cost of furnishing the service exceeds 1.75 times the APC payment amount. Beginning with CY 2009 payments, outlier payments are subject to a reconciliation process similar to the IPPS outlier reconciliation process for cost reports, as discussed in the CY 2009 OPPS/ASC final rule with comment period (73 FR 68594 through 68599).</P>
                    <P>It has been our policy to report the actual amount of outlier payments as a percent of total spending in the claims being used to model the OPPS. Our estimate of total outlier payments as a percent of total CY 2023 OPPS payments, using CY 2023 claims available for this CY 2025 OPPS/ASC final rule with comment period, is approximately 0.65 percent. Therefore, for CY 2023, we estimate that we did not meet the outlier target by 0.35 percent of total aggregated OPPS payments.</P>
                    <P>
                        For this CY 2025 OPPS/ASC final rule with comment period, using CY 2023 claims data and CY 2024 payment rates, we estimate that the aggregate outlier payments for CY 2024 would be approximately 0.83 percent of the total CY 2024 OPPS payments. We provide estimated CY 2025 outlier payments for hospitals and CMHCs with claims included in the claims data that we used to model impacts in the Hospital-Specific Impacts—Provider-Specific Data file on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient</E>
                        .
                    </P>
                    <HD SOURCE="HD3">2. Outlier Calculation for CY 2025</HD>
                    <P>
                        For CY 2025, we proposed to continue our policy of estimating outlier payments to be 1.0 percent of the estimated aggregate total payments under the OPPS. We proposed that a portion of that 1.0 percent, an amount equal to less than 0.01 percent of outlier payments (or 0.0001 percent of total OPPS payments), would be allocated to CMHCs for partial hospitalization program (PHP) and intensive outpatient program (IOP) outlier payments. This is the amount of estimated outlier payments that would result from the proposed CMHC outlier threshold as a proportion of total estimated OPPS 
                        <PRTPAGE P="93981"/>
                        outlier payments. We proposed to continue our outlier policy that if a CMHC's cost for PHP and IOP services exceeds 3.40 times the APC payment rate, the outlier payment would be calculated as 50 percent of the amount by which the cost exceeds 3.40 times the proposed APC payment rate.
                    </P>
                    <P>For further discussion of CMHC outlier payments, we refer readers to section VIII.C of this final rule with comment period.</P>
                    <P>To ensure that the estimated CY 2025 aggregate outlier payments would equal 1.0 percent of estimated aggregate total payments under the OPPS, we proposed that the hospital outlier threshold be set so that outlier payments would be triggered when a hospital's cost of furnishing a service exceeds 1.75 times the APC payment amount and exceeds the APC payment amount plus the fixed-dollar threshold.</P>
                    <P>We calculated the proposed fixed-dollar threshold using the standard methodology most recently used for CY 2024 (88 FR 81589 through 81591). For purposes of estimating outlier payments for CY 2025, we use the hospital-specific overall ancillary CCRs available in the April 2024 update to the Outpatient Provider-Specific File (OPSF). The OPSF contains provider-specific data, such as the most current CCRs, which are maintained by the MACs and used by the OPPS Pricer to pay claims. The claims that we generally use to model each OPPS update lag by 2 years.</P>
                    <P>In order to estimate the CY 2025 hospital outlier payments, we inflated the charges on the CY 2023 claims using the same proposed charge inflation factor of 1.084555 that we used to estimate the IPPS fixed-loss cost threshold for the FY 2025 IPPS/LTCH PPS proposed rule (89 FR 36572). We used an inflation factor of 1.04142 to estimate CY 2024 charges from the CY 2023 charges reported on CY 2023 claims before applying CY 2024 CCRs to estimate the percent of outliers paid in CY 2024. The proposed methodology for determining these charge inflation factors is discussed in the FY 2025 IPPS/LTCH PPS proposed rule (89 FR 36572). As we stated in the CY 2005 OPPS final rule with comment period (69 FR 65844 through 65846), we believe that the use of the same charge inflation factors is appropriate for the OPPS because, with the exception of the inpatient routine service cost centers, hospitals use the same ancillary and cost centers to capture costs and charges for inpatient and outpatient services.</P>
                    <P>As noted in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68011), we are concerned that we could systematically overestimate the OPPS hospital outlier threshold if we did not apply a CCR inflation adjustment factor. Therefore, we proposed to apply the same CCR adjustment factor that we proposed to apply for the FY 2025 IPPS outlier calculation to the CCRs used to simulate the proposed CY 2025 OPPS outlier payments to determine the fixed-dollar threshold. Specifically, for CY 2025, we proposed to apply an adjustment factor of 1.03331 to the CCRs that were in the April 2024 OPSF to trend them forward from CY 2024 to CY 2025. The methodology for calculating the proposed CCR adjustment factor is discussed in the FY 2025 IPPS/LTCH PPS proposed rule (89 FR 36572 through 36573).</P>
                    <P>To model hospital outlier payments for the CY 2025 proposed rule, we applied the overall CCRs from the April 2024 OPSF after adjustment (using the proposed CCR inflation adjustment factor of 1.03331 to approximate CY 2025 CCRs) to charges on CY 2023 claims that were adjusted (using the proposed charge inflation factor of 1.084555 to approximate CY 2025 charges). We simulated aggregated CY 2023 hospital outlier payments using these costs for several different fixed-dollar thresholds, holding the 1.75 multiplier threshold constant and assuming that outlier payments would continue to be made at 50 percent of the amount by which the cost of furnishing the service would exceed 1.75 times the APC payment amount, until the total outlier payments equaled 1.0 percent of aggregated estimated total CY 2025 OPPS payments. We estimated that a proposed fixed-dollar threshold of $8,000, combined with the proposed multiplier threshold of 1.75 times the APC payment rate, would allocate 1.0 percent of aggregated total OPPS payments to outlier payments. For CMHCs, we proposed that, if a CMHC's cost for partial hospitalization or intensive outpatient services exceeds 3.40 times the APC payment rate, the outlier payment would be calculated as 50 percent of the amount by which the cost exceeds 3.40 times the APC payment rate.</P>
                    <P>Section 1833(t)(17)(A) of the Act, which applies to hospitals, as defined under section 1886(d)(1)(B) of the Act, requires that hospitals that fail to report data required for the quality measures selected by the Secretary, in the form and manner required by the Secretary under section 1833(t)(17)(B) of the Act, incur a 2.0 percentage point reduction to their OPD fee schedule increase factor; that is, the annual payment update factor. The application of a reduced OPD fee schedule increase factor results in reduced national unadjusted payment rates that would apply to certain outpatient items and services furnished by hospitals that are required to report outpatient quality data and that fail to meet the Hospital Outpatient Quality Reporting (OQR) Program requirements. For hospitals that fail to meet the Hospital OQR Program requirements, we proposed to continue the policy that we implemented in CY 2010 that the hospitals' costs would be compared to the reduced payments for purposes of outlier eligibility and payment calculation. For more information on the Hospital OQR Program, we refer readers to section XV of this final rule with comment period.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter noted that they believe the CCR adjustment factors used for the IPPS and OPPS proposed rules overstate the effect of cost increases that took place from 2022 to 2023. The commenter argues that the CCR adjustment factor used in each final rule has been below 1.0; however, we proposed a CCR adjustment factor of 1.03331. The commenter recommended that we substitute a different CCR adjustment factor or cap the CCR adjustment factor at 1.0.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         As discussed in greater detail in the FY 2025 IPPS/LTCH PPS final rule (89 FR 69955 through 69962), consistent with our usual practice, we are using more recent CCR data for this final rule with comment period which yields a CCR adjustment factor of 1.015123. We do not believe it is necessary to deviate from our usual practice of using the CCR adjustment factor for our calculation, which was finalized under the IPPS for FY 2025. Therefore, we are also not accepting this recommendation under the OPPS.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal, without modification, to continue our policy of estimating outlier payments to be 1.0 percent of the estimated aggregate total payments under the OPPS and to use our established methodology to set the OPPS outlier fixed-dollar loss threshold for CY 2025.</P>
                    <HD SOURCE="HD3">3. Final Outlier Calculation</HD>
                    <P>
                        Consistent with historical practice, we used updated data for this final rule with comment period for outlier calculations. For CY 2025, we are applying the overall ancillary CCRs from the July 2024 OPSF file after adjustment (using the CCR adjustment factor of 1.015123 to approximate CY 2025 CCRs) to charges on CY 2023 claims that were adjusted using a charge inflation factor of 1.08406 to 
                        <PRTPAGE P="93982"/>
                        approximate CY 2025 charges. These are the same CCR adjustment and charge inflation factors that were used to set the IPPS fixed-dollar thresholds for the FY 2025 IPPS/LTCH PPS final rule (89 FR 69955 through 69962). We simulated aggregated CY 2025 hospital outlier payments using these costs for several different fixed-dollar thresholds, holding the 1.75 multiple-threshold constant and assuming that outlier payments will continue to be made at 50 percent of the amount by which the cost of furnishing the service would exceed 1.75 times the APC payment amount, until the total outlier payment equaled 1.0 percent of aggregated estimated total CY 2025 OPPS payments. We estimate that a fixed-dollar threshold of $7,175 combined with the multiple threshold of 1.75 times the APC payment rate, will allocate the 1.0 percent of aggregated total OPPS payments to outlier payments.
                    </P>
                    <P>For CMHCs, if a CMHC's cost for partial hospitalization or intensive outpatient services exceeds 3.40 times the APC payment rate, the outlier payment will be calculated as 50 percent of the amount by which the cost exceeds the 3.40 times the ACP payment rate.</P>
                    <HD SOURCE="HD2">H. Calculation of an Adjusted Medicare Payment From the National Unadjusted Medicare Payment</HD>
                    <P>
                        The national unadjusted payment rate is the payment rate for most APCs before accounting for the wage index adjustment or any applicable adjustments. The basic methodology for determining prospective payment rates for HOPD services under the OPPS is set forth in existing regulations at 42 CFR part 419, subparts C and D. For this CY 2025 OPPS/ASC final rule with comment period, the payment rate for most services and procedures for which payment is made under the OPPS is the product of the conversion factor calculated in accordance with section II.B of this final rule with comment period and the relative payment weight described in section II.A of this final rule with comment period. The national unadjusted payment rate for most APCs contained in Addendum A to this final rule with comment period (which is available via the CMS website 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/addendum-a-b-updates</E>
                        ) and for most HCPCS codes to which separate payment under the OPPS has been assigned in Addendum B to this final rule with comment period (which is available on the CMS website link above) is calculated by multiplying the final CY 2025 scaled weight for the APC by the CY 2025 conversion factor.
                    </P>
                    <P>We note that section 1833(t)(17) of the Act, which applies to hospitals, as defined under section 1886(d)(1)(B) of the Act, requires that hospitals that fail to submit data required to be submitted on quality measures selected by the Secretary, in the form and manner and at a time specified by the Secretary, incur a reduction of 2.0 percentage points to their OPD fee schedule increase factor, that is, the annual payment update factor. The application of a reduced OPD fee schedule increase factor results in reduced national unadjusted payment rates that apply to certain outpatient items and services provided by hospitals that are required to report outpatient quality data and that fail to meet the Hospital OQR Program requirements. For further discussion of the payment reduction for hospitals that fail to meet the requirements of the Hospital OQR Program, we refer readers to section XIV of this final rule with comment period.</P>
                    <P>Below we demonstrate the steps used to determine the APC payments that will be made in a CY under the OPPS to a hospital that fulfills the Hospital OQR Program requirements and to a hospital that fails to meet the Hospital OQR Program requirements for a service that has any of the following status indicator assignments: “J1,” “J2,” “P,” “Q1,” “Q2,” “Q3,” “Q4,” “R,” “S,” “T,” “U,” or “V” (as defined in Addendum D1 to this final rule with comment period, which is available via the internet on the CMS website), in a circumstance in which the multiple procedure discount does not apply, the procedure is not bilateral, and conditionally packaged services (status indicator of “Q1” and “Q2”) qualify for separate payment. We note that, although blood and blood products with status indicator “R” and brachytherapy sources with status indicator “U” are not subject to wage adjustment, they are subject to reduced payments when a hospital fails to meet the Hospital OQR Program requirements.</P>
                    <P>Individual providers interested in calculating the payment amount that they would receive for a specific service from the national unadjusted payment rates presented in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website) should follow the formulas presented in the following steps. For purposes of the payment calculations below, we refer to the national unadjusted payment rate for hospitals that meet the requirements of the Hospital OQR Program as the “full” national unadjusted payment rate. We refer to the national unadjusted payment rate for hospitals that fail to meet the requirements of the Hospital OQR Program as the “reduced” national unadjusted payment rate. The reduced national unadjusted payment rate is calculated by multiplying the reporting ratio of 0.9806 times the “full” national unadjusted payment rate. The national unadjusted payment rate used in the calculations below is either the full national unadjusted payment rate or the reduced national unadjusted payment rate, depending on whether the hospital met its Hospital OQR Program requirements to receive the full CY 2025 OPPS fee schedule increase factor.</P>
                    <P>
                        <E T="03">Step 1.</E>
                         Calculate 60 percent (the labor-related portion) of the national unadjusted payment rate. Since the initial implementation of the OPPS, we have used 60 percent to represent our estimate of that portion of costs attributable, on average, to labor. We refer readers to the April 7, 2000 OPPS/ASC final rule with comment period (65 FR 18496 through 18497) for a detailed discussion of how we derived this percentage. During our regression analysis for the payment adjustment for rural hospitals in the CY 2006 OPPS final rule with comment period (70 FR 68553), we confirmed that this labor-related share for hospital outpatient services is appropriate.
                    </P>
                    <P>The formula below is a mathematical representation of Step 1 and identifies the labor-related portion of a specific payment rate for a specific service.</P>
                    <FP SOURCE="FP-2">
                        <E T="03">X is the labor-related portion of the national unadjusted payment rate.</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">X</E>
                         = .60 * (national unadjusted payment rate).
                    </FP>
                    <P>
                        <E T="03">Step 2.</E>
                         Determine the wage index area in which the hospital is located and identify the wage index level that applies to the specific hospital. The wage index values assigned to each area would reflect the geographic statistical areas (which are based upon OMB standards) to which hospitals are assigned for FY 2025 in the FY 2025 IPPS, as corrected in the FY 2025 IPPS final rule correction (89 FR 80098), reclassifications through the Medicare Geographic Classification Review Board (MGCRB), section 1886(d)(8)(B) “Lugar” hospitals, and reclassifications under section 1886(d)(8)(E) of the Act, as implemented in § 412.103 of the regulations. We are continuing to apply for the CY 2025 OPPS wage index any adjustments for the FY 2025 IPPS final rule post-reclassified wage index, including, but not limited to, the rural floor adjustment and a wage index floor of 1.00 in frontier states, in accordance with section 10324 of the Affordable 
                        <PRTPAGE P="93983"/>
                        Care Act of 2010. We are also including the low wage index hospital policy as part of the CY 2025 OPPS wage index. The adoption of this policy for CY 2025 for the OPPS wage index will create different effective wage index values for hospitals that benefit from the policy under the OPPS than the wage index value for those hospitals under the IPPS for FY 2025 as modified by the interim final action with comment period “Changes to the Fiscal Year 2025 Hospital Inpatient Prospective Payment System (IPPS) Rates Due to Court Decision” (89 FR 80405). For further discussion of the wage index we are applying for the CY 2025 OPPS, including the low wage index hospital policy, we refer readers to section II.C of this final rule with comment period.
                    </P>
                    <P>
                        <E T="03">Step 3.</E>
                         Adjust the wage index of hospitals located in certain qualifying counties that have a relatively high percentage of hospital employees who reside in the county, but who work in a different county with a higher wage index, in accordance with section 505 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. 108-173). Addendum L to this final rule with comment period (which is available via the internet on the CMS website) contains the qualifying counties and the associated wage index increase developed for the final FY 2025 IPPS wage index, which are listed in Table 3 associated with the FY 2025 IPPS final rule and available via the internet on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps</E>
                        . (Click on the link on the left side of the screen titled “FY 2025 IPPS Final Rule Home Page” and select “FY 2025 Final Rule Tables.”) This step is to be followed only if the hospital is not reclassified or redesignated under section 1886(d)(8) or section 1886(d)(10) of the Act.
                    </P>
                    <P>
                        <E T="03">Step 4.</E>
                         Multiply the applicable wage index determined under Steps 2 and 3 by the amount determined under Step 1 that represents the labor-related portion of the national unadjusted payment rate.
                    </P>
                    <P>The formula below is a mathematical representation of Step 4 and adjusts the labor-related portion of the national unadjusted payment rate for the specific service by the wage index.</P>
                    <FP SOURCE="FP-2">
                        <E T="03">X</E>
                        <E T="54">a</E>
                          
                        <E T="03">is the labor-related portion of the national unadjusted payment rate (wage adjusted).</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">X</E>
                        <E T="52">a</E>
                         = labor-portion of the national unadjusted payment rate * applicable wage index.
                    </FP>
                    <P>
                        <E T="03">Step 5.</E>
                         Calculate 40 percent (the nonlabor-related portion) of the national unadjusted payment rate and add that amount to the resulting product of Step 4. The result is the wage index adjusted payment rate for the relevant wage index area.
                    </P>
                    <P>The formula below is a mathematical representation of Step 5 and calculates the remaining portion of the national payment rate, the amount not attributable to labor, and the adjusted payment for the specific service.</P>
                    <FP SOURCE="FP-2">
                        <E T="03">Y is the nonlabor-related portion of the national unadjusted payment rate.</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Y</E>
                         = 0.40 * (national unadjusted payment rate).
                    </FP>
                    <P>
                        <E T="03">Step 6.</E>
                         If a provider is an SCH, as set forth in the regulations at § 412.92, or an EACH, which is considered to be an SCH under section 1886(d)(5)(D)(iii)(III) of the Act, and located in a rural area, as defined in § 412.64(b), or is treated as being located in a rural area under § 412.103, multiply the wage index adjusted payment rate by 1.071 to calculate the total payment.
                    </P>
                    <P>The formula below is a mathematical representation of Step 6 and applies the rural adjustment for rural SCHs.</P>
                    <FP SOURCE="FP-2">Adjusted Medicare Payment (SCH or EACH) = Adjusted Medicare Payment * 1.071.</FP>
                    <P>
                        <E T="03">Step 7.</E>
                         The adjusted payment rate is the sum of the wage adjusted labor-related portion of the national unadjusted payment rate and the nonlabor-related portion of the national unadjusted payment rate.
                    </P>
                    <FP SOURCE="FP-2">
                        <E T="03">X</E>
                        <E T="54">a</E>
                        <E T="03">is the labor-related portion of the national unadjusted payment rate (wage adjusted).</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">Y is the nonlabor-related portion of the national unadjusted payment rate.</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        Adjusted Medicare Payment = 
                        <E T="03">X</E>
                        <E T="54">a</E>
                         + 
                        <E T="03">Y</E>
                    </FP>
                    <P>We are providing examples below of the calculation of both the full and reduced national unadjusted payment rates that would apply to certain outpatient items and services performed by hospitals that meet and that fail to meet the Hospital OQR Program requirements, using the steps outlined previously. For purposes of this example, we are using a provider that is located in Brooklyn, New York that is assigned to CBSA 35614. This provider bills one service that is assigned to APC 5071 (Level 1 Excision/Biopsy/Incision and Drainage). The final CY 2025 full national unadjusted payment rate for APC 5071 is $703.59. The final reduced national adjusted payment rate for APC 5071 for a hospital that fails to meet the Hospital OQR Program requirements is $689.94. This reduced rate is calculated by multiplying the reporting ratio of 0.9806 by the full unadjusted payment rate for APC 5071.</P>
                    <P>
                        <E T="03">Step 1.</E>
                         The labor-related portion of the final full national unadjusted payment is approximately $422.15 (0.60 * $703.59). The labor-related portion of the final reduced national adjusted payment is approximately $413.96 (0.60 * $689.94).
                    </P>
                    <P>
                        <E T="03">Step 2 &amp; 3.</E>
                         The FY 2025 wage index for a provider located in CBSA 35614 in New York, which includes the adoption of the final IPPS 2025 wage index policies, is 1.3056.
                    </P>
                    <P>
                        <E T="03">Step 4.</E>
                         The wage adjusted labor-related portion of the final full national unadjusted payment is approximately $551.16 ($422.15 * 1.3056). The wage adjusted labor-related portion of the final reduced national adjusted payment is approximately $540.47 ($413.96 * 1.3056).
                    </P>
                    <P>
                        <E T="03">Step 5.</E>
                         The nonlabor-related portion of the final full national unadjusted payment is approximately $281.44 (0.40 * $703.59). The nonlabor-related portion of the final reduced national adjusted payment is approximately $275.98 (0.40 * $689.94).
                    </P>
                    <P>
                        <E T="03">Step 6.</E>
                         For this example of a provider located in Brooklyn, New York, the rural adjustment for rural SCHs does not apply.
                    </P>
                    <P>
                        <E T="03">Step 7.</E>
                         The sum of the labor-related and nonlabor-related portions of the final full national unadjusted payment is approximately $832.60 ($551.16 + $281.44). The sum of the portions of the final reduced national adjusted payment is approximately $816.45 ($540.47 + $275.98) as shown in Table 13.
                    </P>
                    <GPH SPAN="3" DEEP="93">
                        <PRTPAGE P="93984"/>
                        <GID>ER27NO24.018</GID>
                    </GPH>
                    <P>We did not receive any public comments on these steps under the methodology that we included in the proposed rule to determine the APC payments for CY 2025. Therefore, we are using the steps in the methodology specified above to demonstrate the calculation of the final CY 2025 OPPS payments using the same parameters.</P>
                    <HD SOURCE="HD2">I. Beneficiary Copayments</HD>
                    <HD SOURCE="HD3">1. Background</HD>
                    <P>Section 1833(t)(3)(B) of the Act requires the Secretary to set rules for determining the unadjusted copayment amounts to be paid by beneficiaries for covered OPD services. Section 1833(t)(8)(C)(ii) of the Act specifies that the Secretary must reduce the national unadjusted copayment amount for a covered OPD service (or group of such services) furnished in a year in a manner so that the effective copayment rate (determined on a national unadjusted basis) for that service in the year does not exceed a specified percentage. As specified in section 1833(t)(8)(C)(ii)(V) of the Act, the effective copayment rate for a covered OPD service paid under the OPPS in CY 2006, and in CYs thereafter, shall not exceed 40 percent of the APC payment rate.</P>
                    <P>Section 1833(t)(3)(B)(ii) of the Act provides that, for a covered OPD service (or group of such services) furnished in a year, the national unadjusted copayment amount cannot be less than 20 percent of the OPD fee schedule amount. However, section 1833(t)(8)(C)(i) of the Act limits the amount of beneficiary copayment that may be collected for a procedure (including items such as drugs and biologicals) performed in a year to the amount of the inpatient hospital deductible for that year.</P>
                    <P>Section 4104 of the Affordable Care Act eliminated the Medicare Part B coinsurance for preventive services furnished on and after January 1, 2011, that meet certain requirements, including flexible sigmoidoscopies and screening colonoscopies, and waived the Part B deductible for screening colonoscopies that become diagnostic during the procedure. For a discussion of the changes made by the Affordable Care Act with regard to copayments for preventive services furnished on and after January 1, 2011, we refer readers to section XII.B of the CY 2011 OPPS/ASC final rule with comment period (75 FR 72013).</P>
                    <P>Section 122 of the Consolidated Appropriations Act (CAA) of 2021 (Pub. L. 116-260), Waiving Medicare Coinsurance for Certain Colorectal Cancer Screening Tests, amended section 1833(a) of the Act to offer a special coinsurance rule for screening flexible sigmoidoscopies and screening colonoscopies, regardless of the code that is billed for the establishment of a diagnosis as a result of the test, or for the removal of tissue or other matter or other procedure, that is furnished in connection with, as a result of, and in the same clinical encounter as the colorectal cancer screening test. We refer readers to section X.B, “Changes to Beneficiary Coinsurance for Certain Colorectal Cancer Screening Tests,” of the CY 2022 OPPS/ASC final rule with comment period for the full discussion of this policy (86 FR 63740 through 63743). Under the regulation at 42 CFR 410.152(l)(5)(i)(B), the Medicare Part B payment percentage for colorectal cancer screening tests described in the regulation at § 410.37(j) that are furnished in CY 2023 through CY 2026 is 85 percent, with beneficiary coinsurance equal to 15 percent.</P>
                    <P>
                        On August 16, 2022, the Inflation Reduction Act of 2022 (IRA) (Pub. L. 117-169) was signed into law. Section 11101(a) of the IRA amended section 1847A of the Act by adding a new subsection (i), which requires the payment of rebates into the Supplementary Medical Insurance Trust Fund for Part B rebatable drugs if the payment limit amount exceeds the inflation-adjusted payment amount, which is calculated as set forth in section 1847A(i)(3)(C) of the Act. The provisions of section 11101 of the IRA thus far have primarily been implemented through program instruction, as permitted under section 1847A(c)(5)(C) of the Act. As such, we issued guidance for the computation of inflation-adjusted beneficiary coinsurance under section 1847A(i)(5) of the Act and amounts paid under section 1833(a)(1)(EE) of the Act on February 9, 2023.
                        <E T="51">12 13</E>
                        <FTREF/>
                         For additional information regarding implementation of section 11101 of the IRA, please see the inflation rebates resources page at 
                        <E T="03">https://www.cms.gov/inflation-reduction-act-and-medicare/inflation-rebates-medicare</E>
                        .
                    </P>
                    <FTNT>
                        <P>
                            <SU>12</SU>
                             
                            <E T="03">https://www.cms.gov/files/document/medicare-part-b-inflation-rebate-program-initial-guidance.pdf</E>
                            .
                        </P>
                        <P>
                            <SU>13</SU>
                             In addition, beginning with the April 2023 ASP Drug Pricing file, the file includes the coinsurance percentage for each drug and specifies “inflation-adjusted coinsurance” in the “Notes” column if the coinsurance for a drug is less than 20 percent of the Medicare Part B payment amount. Drug pricing files are available at 
                            <E T="03">https://www.cms.gov/medicare/medicare-fee-for-service-part-b-drugs/mcrpartbdrugavgsalesprice</E>
                            .
                        </P>
                    </FTNT>
                    <P>
                        Section 11101(b) of the IRA amended sections 1833(i) and 1833(t)(8) of the Act by adding a new paragraph (9) and subparagraph (F), respectively. Section 1833(i)(9) requires under the ASC payment system that, in the case of a Part B rebatable drug, in lieu of calculation of coinsurance that would otherwise apply under the ASC payment system, the provisions of section 1847A(i)(5) of the Act shall, as determined appropriate by the Secretary, apply for calculation of beneficiary coinsurance in the same manner as the provisions of section 1847A(i)(5) of the Act apply under that section. Similarly, section 1833(t)(8)(F) of the Act requires under the OPPS that in the case of a Part B rebatable drug (except for a drug that has no copayment applied under subparagraph (E) of such section or for which payment is packaged into the payment for a covered OPD service or group of services), in lieu of the calculation of the copayment amount that would otherwise apply under the OPPS, the provisions of section 1847A(i)(5) of the Act shall, as determined appropriate by the Secretary, apply in the same manner as the provisions of section 1847A(i)(5) of the Act apply under that section. Section 1847A(i)(5) of the Act requires that for Part B rebatable drugs, as defined in section 1847A(i)(2)(A) of the Act, furnished on or after April 1, 2023, in quarters in which the payment 
                        <PRTPAGE P="93985"/>
                        amount described in section 1847A(i)(3)(A)(ii)(I) of the Act (or, in the case of selected drugs described under section 1192(c) of the Act, the payment amount described in section 1847A(b)(1)(B) of the Act), exceeds the inflation-adjusted payment amount determined in accordance with section 1847A(i)(3)(C) of the Act, the coinsurance will be 20 percent of the inflation-adjusted payment amount for such quarter (hereafter, the inflation-adjusted coinsurance amount). This inflation-adjusted coinsurance amount is applied as a percent, as determined by the Secretary, to the payment amount that would otherwise apply for such calendar quarter in accordance with section 1847A(b)(1)(B) or (C) of the Act, as applicable, including in the case of a selected drug.
                    </P>
                    <P>Paragraph (9) of section 1833(i) of the Act and subparagraph (F) of section 1833(t)(8) of the Act, as added by section 11101(b) of the IRA, also provide that in lieu of the amounts of payment otherwise applicable under the ASC payment system and the OPPS, the provisions of paragraph (1)(EE) of subsection (a) of section 1833 of the Act shall apply, as determined appropriate by the Secretary. Section 11101(b) of the IRA amended section 1833(a)(1) of the Act by adding a new subparagraph (EE), which requires that if the payment amount under section 1847A(i)(3)(A)(ii)(I) of the Act or, in the case of a selected drug, the payment amount described in section 1847A(b)(1)(B) of the Act, for that drug exceeds the inflation-adjusted payment amount for a Part B rebatable drug, the Part B payment amount would, subject to the Part B deductible and sequestration, equal the difference between such payment amount and the inflation-adjusted coinsurance amount. Consistent with the policy adopted in section 40 of the revised Medicare Part B Drug Inflation Rebate Guidance, the calculation to determine the applicable beneficiary coinsurance amount would not be adjusted for sequestration. CMS codified the Medicare payment for Part B rebatable drugs in the CY 2024 PFS final rule by adding new paragraph (m) to § 410.152.</P>
                    <P>In the CY 2024 OPPS/ASC final rule with comment period (88 FR 81594), we codified the OPPS program payment and cost sharing amounts for Part B rebatable drugs as required by section 1833(t)(8)(F) by adding a new paragraph (e) to § 419.41, which cross-references the regulations adopted in the CY 2024 PFS final rule (§§ 410.152(m) and 489.30(b)(6)). We also amended the regulation text to reflect our longstanding policies for calculating the Medicare program payment and cost sharing amounts for separately payable drugs and biologicals by adding a new paragraph (d) to § 419.41. Similarly, we codified the ASC cost sharing amounts for Part B rebatable drugs as required by section 1833(i)(9) of the Act by revising § 416.172(d) to include a cross-reference to 42 CFR 489.30(b)(6), which codified the cost sharing amounts for Part B rebatable drugs with prices increasing at a rate faster than inflation.</P>
                    <P>In the CY 2025 PFS proposed rule (89 FR 61956), CMS proposed to adopt new provisions at §§ 427.200 and 427.201 to codify the policies regarding the computation of the inflation-adjusted beneficiary coinsurance, defined in § 427.200, for Part B rebatable drugs as required by section 1847A(i)(5) of the Act. The proposed new provision at § 427.201 includes references to the existing provisions at §§ 410.152(m), 419.41(e), and 489.30(b)(6). CMS further proposed at § 427.201(c) that any category of products that is excluded from the identification of Part B rebatable drugs at § 427.101(b) is not subject to the inflation-adjusted beneficiary coinsurance. Examples of these excluded products include separately payable radiopharmaceuticals, skin substitute products, and qualifying biosimilar biological products.</P>
                    <P>
                        Additionally, CMS proposed at § 427.201(b) that CMS would use the published payment amount in quarterly pricing files 
                        <E T="51">14 15 16</E>
                        <FTREF/>
                         to determine if a Part B rebatable drug should have an adjusted beneficiary coinsurance equal to 20 percent of the inflation-adjusted payment amount as described in section 1847A(i)(3)(C) for a calendar quarter. The proposed approach deviates from the rebate calculation approach proposed in § 427.302, which relies on the specified amount defined at § 427.20 even when the specified amount and the published payment amount in quarterly pricing files differ. The approach proposed at § 427.201(b) will be used only to determine whether there should be a coinsurance adjustment and will not impact the applicability or calculation of inflation rebates. CMS believes this approach is consistent with the statutory language and appropriately reflects the differences in the statutory text of section 1847A(i)(5) of the Act, which sets forth the payment amount that is used to determine whether coinsurance should be adjusted, and section 1847A(i)(3)(A) of the Act, which sets forth the “specified amount” used to determine rebate amounts.
                    </P>
                    <FTNT>
                        <P>
                            <SU>14</SU>
                             See: 
                            <E T="03">https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files</E>
                            .
                        </P>
                        <P>
                            <SU>15</SU>
                             See: 
                            <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/addendum-a-b-updates</E>
                            .
                        </P>
                        <P>
                            <SU>16</SU>
                             See: 
                            <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/ambulatory-surgical-center-asc/asc-payment-rates-addenda</E>
                            .
                        </P>
                    </FTNT>
                    <P>We did not receive any public comments related to inflation-adjusted beneficiary coinsurance or program payment amounts.</P>
                    <HD SOURCE="HD3">2. OPPS Copayment Policy</HD>
                    <P>For CY 2025, we proposed to determine copayment amounts for new and revised APCs using the same methodology that we implemented beginning in CY 2004. We refer readers to the November 7, 2003 OPPS final rule with comment period for a discussion of that methodology (68 FR 63458). In addition, we proposed to use the same standard rounding principles that we have historically used in instances where the application of our standard copayment methodology would result in a copayment amount that is less than 20 percent and cannot be rounded, under standard rounding principles, to 20 percent. We refer readers to the CY 2008 OPPS/ASC final rule with comment period (72 FR 66687) in which we discuss our rationale for applying these rounding principles. The final national unadjusted copayment amounts for services payable under the OPPS that will be effective January 1, 2025, are included in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website).</P>
                    <P>As discussed in section XIV.E of this final rule with comment period, for CY 2025, the Medicare beneficiary's minimum unadjusted copayment and national unadjusted copayment for a service to which a reduced national unadjusted payment rate applies will equal the product of the reporting ratio and the national unadjusted copayment, or the product of the reporting ratio and the minimum unadjusted copayment, respectively, for the service.</P>
                    <P>We note that OPPS copayments may increase or decrease each year based on changes in the calculated APC payment rates, due to updated cost report and claims data, and any changes to the OPPS cost modeling process. However, as described in the CY 2004 OPPS final rule with comment period, the development of the copayment methodology generally moves beneficiary copayments closer to 20 percent of OPPS APC payments (68 FR 63458 through 63459).</P>
                    <P>
                        In the CY 2004 OPPS final rule with comment period (68 FR 63459), we adopted a new methodology to calculate unadjusted copayment amounts in situations including reorganizing APCs, 
                        <PRTPAGE P="93986"/>
                        and we finalized the following rules to determine copayment amounts in CY 2004 and subsequent years.
                    </P>
                    <P>• When an APC group consists solely of HCPCS codes that were not paid under the OPPS the prior year because they were packaged or excluded or are new codes, the unadjusted copayment amount would be 20 percent of the APC payment rate.</P>
                    <P>• If a new APC that did not exist during the prior year is created and consists of HCPCS codes previously assigned to other APCs, the copayment amount is calculated as the product of the APC payment rate and the lowest coinsurance percentage of the codes comprising the new APC.</P>
                    <P>
                        • If no codes are added to or removed from an APC and, after recalibration of its relative payment weight, the new payment rate is equal to or 
                        <E T="03">greater than</E>
                         the prior year's rate, the copayment amount remains constant (unless the resulting coinsurance percentage is less than 20 percent).
                    </P>
                    <P>
                        • If no codes are added to or removed from an APC and, after recalibration of its relative payment weight, the new payment rate is 
                        <E T="03">less than</E>
                         the prior year's rate, the copayment amount is calculated as the product of the new payment rate and the prior year's coinsurance percentage.
                    </P>
                    <P>• If HCPCS codes are added to or deleted from an APC and, after recalibrating its relative payment weight, holding its unadjusted copayment amount constant results in a decrease in the coinsurance percentage for the reconfigured APC, the copayment amount would not change (unless retaining the copayment amount would result in a coinsurance rate less than 20 percent).</P>
                    <P>• If HCPCS codes are added to an APC and, after recalibrating its relative payment weight, holding its unadjusted copayment amount constant results in an increase in the coinsurance percentage for the reconfigured APC, the copayment amount would be calculated as the product of the payment rate of the reconfigured APC and the lowest coinsurance percentage of the codes being added to the reconfigured APC.</P>
                    <P>We noted in the CY 2004 OPPS final rule with comment period that we would seek to lower the copayment percentage for a service in an APC from the prior year if the copayment percentage was greater than 20 percent. We noted that this principle was consistent with section 1833(t)(8)(C)(ii) of the Act, which accelerates the reduction in the national unadjusted coinsurance rate so that beneficiary liability will eventually equal 20 percent of the OPPS payment rate for all OPPS services to which a copayment applies, and with section 1833(t)(3)(B) of the Act, which achieves a 20-percent copayment percentage when fully phased in and gives the Secretary the authority to set rules for determining copayment amounts for new services. We further noted that the use of this methodology would, in general, reduce the beneficiary coinsurance rate and copayment amount for APCs for which the payment rate changes as the result of the reconfiguration of APCs and/or recalibration of relative payment weights (68 FR 63459).</P>
                    <P>We did not receive any public comments on our proposal and we are finalizing our proposal to determine copayment amounts for new and revised APCs using the same methodology that we implemented beginning in CY 2004. The finalized national unadjusted copayment amounts for services payable under the OPPS that will be effective January 1, 2025, are included in Addenda A and B to the CY 2025 OPPS/ASC final rule (which are available on the CMS website).</P>
                    <HD SOURCE="HD3">3. Calculation of an Adjusted Copayment Amount for an APC Group</HD>
                    <P>Individuals interested in calculating the national copayment liability for a Medicare beneficiary for a given service provided by a hospital that met or failed to meet its Hospital OQR Program requirements should follow the formulas presented in the following steps.</P>
                    <P>
                        <E T="03">Step 1.</E>
                         Calculate the beneficiary payment percentage for the APC by dividing the APC's national unadjusted copayment by its proposed payment rate. For example, using APC 5071, $140.72 is approximately 20 percent of the full national unadjusted payment rate of $703.59. For APCs with only a minimum unadjusted copayment in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website), the beneficiary payment percentage is 20 percent.
                    </P>
                    <P>The formula below is a mathematical representation of Step 1 and calculates the national copayment as a percentage of national payment for a given service.</P>
                    <FP SOURCE="FP-2">
                        <E T="03">B is the beneficiary payment percentage.</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        <E T="03">B</E>
                         = National unadjusted copayment for APC/national unadjusted payment rate for APC.
                    </FP>
                    <P>
                        <E T="03">Step 2.</E>
                         Calculate the appropriate wage-adjusted payment rate for the APC for the provider in question, as indicated in Steps 2 through 4 under section II.H of this final rule with comment period. Calculate the rural adjustment for eligible providers, as indicated in Step 6 under section II.H of this final rule with comment period.
                    </P>
                    <P>
                        <E T="03">Step 3.</E>
                         Multiply the percentage calculated in Step 1 by the payment rate calculated in Step 2. The result is the wage-adjusted copayment amount for the APC.
                    </P>
                    <P>The formula below is a mathematical representation of Step 3 and applies the beneficiary payment percentage to the adjusted payment rate for a service calculated under section II.H of this final rule with comment period, with and without the rural adjustment, to calculate the adjusted beneficiary copayment for a given service.</P>
                    <FP SOURCE="FP-2">
                        Wage-adjusted copayment amount for the APC = Adjusted Medicare Payment * 
                        <E T="03">B.</E>
                    </FP>
                    <FP SOURCE="FP-2">
                        Wage-adjusted copayment amount for the APC (SCH or EACH) = (Adjusted Medicare Payment * 1.071) * 
                        <E T="03">B.</E>
                    </FP>
                    <P>
                        <E T="03">Step 4.</E>
                         For a hospital that failed to meet its Hospital OQR Program requirements, multiply the copayment calculated in Step 3 by the reporting ratio of 0.9806.
                    </P>
                    <P>The unadjusted copayments for services payable under the OPPS that will be effective January 1, 2025, are shown in Addenda A and B to this final rule with comment period (which are available via the CMS website). We note that the final national unadjusted payment rates and copayment rates shown in Addenda A and B to this final rule with comment period reflect the CY 2025 OPD fee schedule increase factor discussed in section II.B of this final rule with comment period.</P>
                    <P>In addition, as noted earlier, section 1833(t)(8)(C)(i) of the Act limits the amount of beneficiary copayment that may be collected for a procedure performed in a year to the amount of the inpatient hospital deductible for that year.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter suggested beneficiaries should not be responsible for drug pricing increases and that CMS should limit or eliminate cost-sharing for beneficiaries. The commenter also stated that cost-sharing has unintended consequences and negative effects on access to health care and health outcomes, including increased use of emergency rooms. The commenter also acknowledged that CMS is limited by statute and that our copayment methodologies ensure that copayments are minimal.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for the input. We note that the beneficiary copayment is established by section 1833(t)(3)(B) of the Act and § 419.41(d). Section 1847A(i)(5) of the Act provides for an adjustment to the 
                        <PRTPAGE P="93987"/>
                        beneficiary coinsurance for Part B rebatable drugs with prices that have increased faster than the rate of inflation beginning April 1, 2023. In the CY 2024 OPPS/ASC OPPS final rule and the CY 2024 Physician Fee Schedule final rule, CMS codified this inflation-adjusted coinsurance amount at §§ 419.41(e), 410.152(m), and 489.30(b)(6), respectively. For these drugs and biologicals, the beneficiary coinsurance is 20 percent of the inflation-adjusted payment amount, which is less than what the beneficiary would pay in coinsurance otherwise. Therefore, beneficiaries are insulated from coinsurance amounts calculated based on drug prices that outpace inflation. More information about the beneficiary coinsurance adjustment and the Medicare Part B Inflation Rebate Program is available at 
                        <E T="03">https://www.cms.gov/inflation-reduction-act-and-medicare/inflation-rebates-medicare</E>
                        .
                    </P>
                    <HD SOURCE="HD1">III. OPPS Ambulatory Payment Classification (APC) Group Policies</HD>
                    <HD SOURCE="HD2">A. OPPS Treatment of New and Revised HCPCS Codes</HD>
                    <P>Payments for OPPS procedures, services, and items are generally based on medical billing codes, specifically, Healthcare Common Procedure Coding System (HCPCS) codes, that are reported on hospital outpatient department (HOPD) claims. HCPCS codes are used to report surgical procedures, medical services, items, and supplies under the hospital OPPS. The HCPCS is divided into two principal subsystems, referred to as Level I and Level II of the HCPCS. Level I is comprised of CPT (Current Procedural Terminology) codes, a numeric and alphanumeric coding system that is established and maintained by the American Medical Association (AMA), and consists of Category I, II, III, MAAA, and PLA CPT codes. Level II, which is established and maintained by CMS, is a standardized coding system that is used primarily to identify products, supplies, and services not included in the CPT codes. Together, Level I and II HCPCS codes are used to report procedures, services, items, and supplies under the OPPS payment system. Specifically, we recognize the following codes on OPPS claims:</P>
                    <P>• Category I CPT codes, which describe surgical procedures, diagnostic and therapeutic services, and vaccine codes;</P>
                    <P>• Category III CPT codes, which describe new and emerging technologies, services, and procedures;</P>
                    <P>• MAAA CPT codes, which describe laboratory multianalyte assays with algorithmic analyses (MAA);</P>
                    <P>• PLA CPT codes, which describe proprietary laboratory analyses (PLA) services; and</P>
                    <P>• Level II HCPCS codes (also known as alpha-numeric codes), which are used primarily to identify drugs, devices, supplies, temporary procedures, and services not described by CPT codes.</P>
                    <P>The codes are updated and changed throughout the year. CPT and Level II HCPCS code changes that affect the OPPS are published through the annual rulemaking cycle and through the OPPS quarterly update Change Requests (CRs). Generally, these code changes are effective January 1, April 1, July 1, or October 1. CPT code changes are released by the AMA (via their website) while Level II HCPCS code changes are released to the public via the CMS HCPCS website. CMS recognizes the release of new CPT and Level II HCPCS codes outside of the formal rulemaking process via OPPS quarterly update CRs. Based on our review, we assign the new codes to interim status indicators (SIs) and APCs. These interim assignments are finalized in the OPPS/ASC final rules. This quarterly process offers hospitals access to codes that more accurately describe the items or services furnished and provides payment for these items or services in a timelier manner than if we waited for the annual rulemaking process. We solicit public comments on the new CPT and Level II HCPCS codes, status indicators, and APC assignments through our annual rulemaking process.</P>
                    <P>We note that, under the OPPS, the APC assignment determines the payment rate for an item, procedure, or service. The items, procedures, or services not exclusively paid separately under the hospital OPPS are assigned to appropriate status indicators. Certain payment status indicators provide separate payment while other payment status indicators do not. In section XI (CY 2025 Payment Status and Comment Indicators) of this final rule with comment period, we discuss the various status indicators and comment indicators used under the OPPS. We also provide a complete list of the status indicators and their definitions in Addendum D1 to this final rule with comment period.</P>
                    <HD SOURCE="HD3">1. April 2024 HCPCS Codes Proposed Rule Comment Solicitation</HD>
                    <P>For the April 2024 update, 73 new HCPCS codes were established and made effective on April 1, 2024. Through the April 2024 OPPS quarterly update CR (Transmittal 12552, Change Request 13568, dated March 21, 2024), we recognized several new HCPCS codes for payment under the OPPS. We solicited public comments on the proposed APC and status indicator assignments for the codes listed in Table 10 (New HCPCS Codes Effective April 1, 2024) of the CY 2025 OPPS/ASC proposed rule (89 FR 59239 through 59241, which are also displayed in Table 14.</P>
                    <P>We received some public comments on the proposed OPPS APC and SI assignments for the new Level II HCPCS codes that were effective on April 1, 2024. The comments and our responses are addressed in the applicable sections of this final rule with comment period, which include, but are not limited to: sections III.C. (New Technology APCs); III.E. (OPPS APC-Specific Policies); and IV. (OPPS Payment for Devices). For those April 2024 codes for which we received no comments, we are finalizing the proposed APC and status indicator assignments as proposed. We note that several of the HCPCS C-codes have been replaced with HCPCS J-codes, effective January 1, 2025. Their replacement codes are listed in Table 14. In addition, in prior years we included the final OPPS status indicators and APC assignments in the coding preamble tables, however, because the same information can be found in Addendum B, we are no longer including them in Table 14. Therefore, readers are advised to refer to the OPPS Addendum B for the final OPPS status indicators, APC assignments, and payment rates for all codes reportable under the hospital OPPS. These new codes that were effective April 1, 2024, were assigned to comment indicator “NP” in Addendum B to the CY 2025 OPPS/APC proposed rule to indicate that the codes are assigned to an interim APC assignment and comments would be accepted on their interim APC assignments. The complete list of status indicators and definitions used under the OPPS can be found in Addendum D1 to this final rule with comment period, while the complete list comment indicators and definitions can be found in Addendum D2 to this final rule with comment period. We note that OPPS Addendum B (OPPS payment file by HCPCS code), Addendum D1 (OPPS Status Indicators), and Addendum D2 (OPPS Comment Indicators) are available via the internet on the CMS website.</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="93988"/>
                        <GID>ER27NO24.019</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="93989"/>
                        <GID>ER27NO24.020</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="93990"/>
                        <GID>ER27NO24.021</GID>
                    </GPH>
                    <PRTPAGE P="93991"/>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <HD SOURCE="HD3">2. July 2024 HCPCS Codes Proposed Rule Comment Solicitation</HD>
                    <P>For the July 2024 update, 130 new codes were established and made effective July 1, 2024. Through the July 2024 OPPS quarterly update CR (Transmittal 12665, Change Request 13632, dated May 31, 2024), we recognized several new codes for payment and assigned them to appropriate interim OPPS status indicators and APCs. We solicited public comments on the proposed APC and status indicator assignments for the codes listed in Table 11 (New HCPCS Codes Effective July 1, 2024) of the CY 2025 OPPS/ASC proposed rule (89 FR 59242 through 59249), which are also listed in Table 15.</P>
                    <P>We received some public comments on the proposed OPPS APC and SI assignments for the new Level II HCPCS codes implemented on July 1, 2024. The comments and our responses are addressed in pertinent sections of this final rule with comment period, which include, but are not limited to: sections III.C (New Technology APCs); III.E (OPPS APC-Specific Policies); and IV (OPPS Payment for Devices). For those July 1, 2024, codes for which we received no comments, we are finalizing the proposed APC and status indicator assignments. Additionally, we note that in prior years we included the final OPPS status indicators and APC assignments in the coding preamble tables, however, because the same information can be found in Addendum B, we are no longer including them in Table 15. Therefore, readers are advised to refer to the OPPS Addendum B for the final OPPS status indicators, APC assignments, and payment rates for all codes reportable under the hospital OPPS. These new codes that were effective July 1, 2024, were assigned to comment indicator “NP” in Addendum B to the CY 2025 OPPS/ASC proposed rule to indicate that the codes are assigned to an interim APC assignment and comments would be accepted on their interim APC assignments. The complete list of status indicators and definitions used under the OPPS can be found in Addendum D1 to this final rule with comment period, while the complete list of comment indicators and definitions can be found in Addendum D2 to this final rule with comment period. We note that OPPS Addendum B (OPPS payment file by HCPCS code), Addendum D1 (OPPS Status Indicators), and Addendum D2 (OPPS Comment Indicators) are available via the internet on the CMS website.</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="636">
                        <PRTPAGE P="93992"/>
                        <GID>ER27NO24.022</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="631">
                        <PRTPAGE P="93993"/>
                        <GID>ER27NO24.023</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="93994"/>
                        <GID>ER27NO24.024</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="629">
                        <PRTPAGE P="93995"/>
                        <GID>ER27NO24.025</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="641">
                        <PRTPAGE P="93996"/>
                        <GID>ER27NO24.026</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="627">
                        <PRTPAGE P="93997"/>
                        <GID>ER27NO24.027</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="93998"/>
                        <GID>ER27NO24.028</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="613">
                        <PRTPAGE P="93999"/>
                        <GID>ER27NO24.029</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94000"/>
                        <GID>ER27NO24.030</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="515">
                        <PRTPAGE P="94001"/>
                        <GID>ER27NO24.031</GID>
                    </GPH>
                    <HD SOURCE="HD3">3. October 2024 HCPCS Codes Final Rule Comment Solicitation</HD>
                    <P>For the October 2024 update, 107 codes were established and made effective October 1, 2024. Through the October 2024 OPPS quarterly update CR (Transmittal 12816, Change Request 13784, dated August 29, 2024), we recognized several new codes for separate payment and assigned them to appropriate interim OPPS status indicators and APCs. For CY 2025, consistent with our established policy, we proposed in the CY 2025 OPPS/ASC proposed rule (89 FR 59250) that the HCPCS codes that would be effective October 1, 2024, would be flagged with comment indicator “NI” in Addendum B to the CY 2025 OPPS/ASC final rule with comment period to indicate that we have assigned the codes to interim OPPS status indicators for CY 2025. Table 16 lists the codes that were effective October 1, 2024. We note that one of the temporary C-codes has been replaced with a permanent J-code effective January 1, 2025. We are inviting public comments in this final rule with comment period on the interim payment indicators, which will be finalized in the CY 2026 OPPS/ASC final rule with comment period. We note the proposed APC assignments and status indicators for these same codes will be subject to comment in the CY 2026 OPPS/ASC proposed rule with comment period, and will be finalized in the CY 2026 OPPS/ASC final rule with comment period.</P>
                    <GPH SPAN="3" DEEP="444">
                        <PRTPAGE P="94002"/>
                        <GID>ER27NO24.032</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94003"/>
                        <GID>ER27NO24.033</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94004"/>
                        <GID>ER27NO24.034</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94005"/>
                        <GID>ER27NO24.035</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94006"/>
                        <GID>ER27NO24.036</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94007"/>
                        <GID>ER27NO24.037</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94008"/>
                        <GID>ER27NO24.038</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="394">
                        <PRTPAGE P="94009"/>
                        <GID>ER27NO24.039</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <P>4. January 2025 HCPCS Codes</P>
                    <P>a. New Level II HCPCS Codes Final Rule Comment Solicitation</P>
                    <P>Consistent with past practice, we are soliciting comments on the new Level II HCPCS codes that will be effective January 1, 2025, in this CY 2025 OPPS/ASC final rule with comment period, thereby allowing us to finalize the status indicators and APC assignments for the codes in the CY 2026 OPPS/ASC final rule with comment period. Unlike the CPT codes that are effective January 1 and are included in the OPPS/ASC proposed rules, and except for the proposed new C-codes and G-codes listed in Addendum O of the CY 2025 OPPS/ASC proposed rule, most Level II HCPCS codes are not released until sometime around November to be effective January 1. Because these codes are not available until November, we are unable to include them in the OPPS/ASC proposed rules. Consequently, for CY 2025, we propose to include the new Level II HCPCS codes that will be effective January 1, 2025 (that would be incorporated in the January 2025 OPPS quarterly update CR), in Addendum B to the CY 2025 OPPS/ASC final rule with comment period. Specifically, for CY 2025, we propose to continue our established policy of assigning comment indicator “NI” in Addendum B to the OPPS/ASC final rule with comment period to the new HCPCS codes that will be effective January 1, 2025, to indicate that we are assigning them an interim status indicator, which is subject to public comment. We are inviting public comments in this final rule with comment period on the status indicators and APC assignments, which would then be finalized in the CY 2026 OPPS/ASC final rule with comment period. Similar to the codes effective October 1, 2024, the proposed APC assignments and status indicators for these new Level II HCPCS codes that will be effective January 1, 2025, will also be subject to comment in the CY 2026 OPPS/ASC proposed rule with comment period, and will be finalized in the CY 2026 OPPS/ASC final rule with comment period.</P>
                    <HD SOURCE="HD3">b. New CPT Codes Proposed Rule Comment Solicitation</HD>
                    <P>
                        In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66841 through 66844), we finalized a revised process of assigning APCs and status indicators for new and revised Category I and III CPT codes that would be effective January 1. Specifically, for the new/revised CPT codes that we receive in a timely manner from the AMA's CPT Editorial Panel, we finalized our proposal to include the codes that would be effective January 1 in the OPPS/ASC proposed rules, along with proposed APC and status indicator assignments for them, and to finalize the APC and status indicator assignments in the OPPS/ASC final rules beginning with the CY 2016 OPPS update. For those new/revised CPT codes that were received too late for inclusion in the OPPS/ASC proposed rule, we finalized our proposal to establish and use 
                        <PRTPAGE P="94010"/>
                        HCPCS G-codes that mirror the predecessor CPT codes and retain the current APC and status indicator assignments for a year until we can propose APC and status indicator assignments in the following year's rulemaking cycle. We note that even if we find that we need to create HCPCS G-codes in place of certain CPT codes for the PFS proposed rule, we do not anticipate that these HCPCS G-codes will always be necessary for OPPS purposes. We will make every effort to include proposed APC and status indicator assignments for all new and revised CPT codes that the AMA makes publicly available in time for us to include them in the proposed rule, and to avoid resorting to use of HCPCS G-codes and the resulting delay in utilization of the most current CPT codes. Also, we finalized our proposal to make interim APC and status indicator assignments for CPT codes that are not available in time for the proposed rule and that describe wholly new services (such as new technologies or new surgical procedures), to solicit public comments in the final rule, and to finalize the specific APC and status indicator assignments for those codes in the following year's final rule.
                    </P>
                    <P>For the CY 2025 OPPS update, we received the CPT codes that will be effective January 1, 2025, from the AMA in time to be included in the CY 2025 OPPS/ASC proposed rule. The new, revised, and deleted CPT codes were included in Addendum B to the proposed rule (which is available via the internet on the CMS website). We note that the new and revised CPT codes were assigned to comment indicator “NP” in Addendum B of the proposed rule to indicate that the code is new for the next calendar year or the code is an existing code with substantial revision to its code descriptor in the next calendar year as compared to the current calendar year with a proposed APC assignment, and that comments would be accepted on the proposed APC assignment and status indicator.</P>
                    <P>Further, we noted that the CPT code descriptors that appeared in Addendum B were short descriptors and did not accurately describe the complete procedure, service, or item described by the CPT code. Therefore, we included the 5-digit placeholder codes and the long descriptors for the new and revised CY 2025 CPT codes in Addendum O to the proposed rule (which is available via the internet on the CMS website) so that the public could adequately comment on the proposed APCs and SI assignments. The 5-digit placeholder codes were included in Addendum O to the proposed rule, specifically under the column labeled “CY 2025 OPPS/ASC Proposed Rule 5- Digit AMA Placeholder Code”. We noted that the final CPT code numbers would be included in this CY 2025 OPPS/ASC final rule with comment period. We also noted that not every code listed in Addendum O is subject to public comment. For the new and revised Category I and III CPT codes, we requested public comments on only those codes that are assigned comment indicator “NP.”</P>
                    <P>In summary, in the CY 2025 OPPS/ASC proposed rule, we solicited public comments on the proposed CY 2025 SI and APC assignments for the new and revised Category I and III CPT codes that would be effective January 1, 2025. The CPT codes were listed in Addendum B to the proposed rule with short descriptors only. We listed them again, with long descriptors, in Addendum O to the proposed rule. We also proposed to finalize the SI and APC assignments for these codes (with their final CPT code numbers) in the CY 2025 OPPS/ASC final rule with comment period. The proposed SI and APC assignments for these codes were included in Addendum B to the proposed rule (which is available via the internet on the CMS website). We received comments on several of the new CPT codes that were assigned to comment indicator “NP” in Addendum B to the CY 2025 OPPS/ASC proposed rule. We have responded to those public comments in sections III.C, III.E, and IV of this CY 2025 OPPS/ASC final rule with comment period.</P>
                    <P>The final SIs, APC assignments, and payment rates for the new CPT codes that are effective January 1, 2025, can be found in Addendum B to this final rule with comment period. In addition, the SI definitions can be found in Addendum D1 (OPPS Payment Status Indicators for CY 2024) to this final rule with comment period. Addenda B and D1 are available via the internet on the CMS website.</P>
                    <P>Finally, Table 17, which is a reprint of Table 12 from the CY 2025 OPPS/ASC proposed rule (89 FR 59251), shows the comment timeframe for new and revised HCPCS codes. The table provides information on our current process for updating codes through our OPPS quarterly update CRs, seeking public comments, and finalizing the treatment of these codes under the OPPS.</P>
                    <GPH SPAN="3" DEEP="401">
                        <PRTPAGE P="94011"/>
                        <GID>ER27NO24.040</GID>
                    </GPH>
                    <HD SOURCE="HD2">B. OPPS Changes—Variations Within APCs</HD>
                    <HD SOURCE="HD3">1. Background</HD>
                    <P>Section 1833(t)(2)(A) of the Act requires the Secretary to develop a classification system for covered hospital outpatient department services. In addition, section 1833(t)(2)(B) of the Act provides that the Secretary may establish groups of covered OPD services within this classification system, so that services classified within each group are comparable clinically and with respect to the use of resources. In accordance with these provisions, we developed a grouping classification system, referred to as Ambulatory Payment Classifications (APCs), as set forth in the regulation at 42 CFR 419.31. We use Level I (also known as CPT codes) and Level II HCPCS codes (also known as alphanumeric codes) to identify and group the services within each APC. The APCs are organized such that each group is homogeneous both clinically and in terms of resource use. Using this classification system, we have established distinct groups of similar services. We also have developed separate APC groups for certain medical devices, drugs, biologicals, therapeutic radiopharmaceuticals, and brachytherapy devices that are not packaged into the payment for the procedure.</P>
                    <P>We have packaged into the payment for each procedure or service within an APC group, the costs associated with those items and services that are typically ancillary and supportive to a primary diagnostic or therapeutic modality and, in those cases, are an integral part of the primary service they support. Therefore, we do not make separate payment for these packaged items or services. In general, packaged items and services include, but are not limited to, the items and services listed in the regulation at 42 CFR 419.2(b). A further discussion of packaged services is included in section II.A.3 of this final rule with comment period.</P>
                    <P>Under the OPPS, we generally pay for covered hospital outpatient services on a rate-per-service basis, where the service may be reported with one or more HCPCS codes. Payment varies according to the APC group to which the independent service or combination of services is assigned. For CY 2025, we proposed that each APC relative payment weight represents the hospital cost of the services included in that APC, relative to the hospital cost of the services included in APC 5012 (Clinic Visits and Related Services). The APC relative payment weights are scaled to APC 5012 because it is the hospital clinic visit APC and clinic visits are among the most frequently furnished services in the hospital outpatient setting.</P>
                    <HD SOURCE="HD3">2. Application of the 2 Times Rule</HD>
                    <P>
                        Section 1833(t)(9)(A) of the Act requires the Secretary to review, not less 
                        <PRTPAGE P="94012"/>
                        often than annually, and revise the APC groups, the relative payment weights, and the wage and other adjustments described in paragraph (2) to consider changes in medical practice, changes in technology, the addition of new services, new cost data, and other relevant information and factors. Section 1833(t)(9)(A) of the Act also requires the Secretary to consult with an expert outside advisory panel composed of an appropriate selection of representatives of providers to review (and advise the Secretary concerning) the clinical integrity of the APC groups and the relative payment weights. We note that the Advisory Panel on Hospital Outpatient Payment (also known as the HOP Panel or the Panel) recommendations for specific services for the CY 2025 OPPS update will be discussed in the relevant specific sections throughout this CY 2025 OPPS/ASC final rule with comment period.
                    </P>
                    <P>In addition, section 1833(t)(2) of the Act provides that, subject to certain exceptions, the items and services within an APC group cannot be considered comparable regarding the use of resources if the highest cost for an item or service in the group is more than 2 times greater than the lowest cost for an item or service within the same group (referred to as the “2 times rule”). The statute authorizes the Secretary to make exceptions to the 2 times rule in unusual cases, such as for low-volume items and services (but the Secretary may not make such an exception in the case of a drug or biological that has been designated as an orphan drug under section 526 of the Federal Food, Drug, and Cosmetic Act). In determining the APCs with a 2 times rule violation, we consider only those HCPCS codes that are significant based on the number of claims. We note that, for purposes of identifying significant procedure codes for examination under the 2 times rule, we consider procedure codes that have more than 1,000 single major claims or procedure codes that both have more than 99 single major claims and contribute at least 2 percent of the single major claims used to establish the APC cost to be significant (75 FR 71832). This longstanding definition of when a procedure code is significant for purposes of the 2 times rule was selected because we believe that a subset of 1,000 or fewer claims is negligible within the set of approximately 100 million single procedure or single session claims we use for establishing costs. Similarly, a procedure code for which there are fewer than 99 single claims and that comprises less than 2 percent of the single major claims within an APC will have a negligible impact on the APC cost (75 FR 71832). In the CY 2025 OPPS/ASC proposed rule, for CY 2025, we proposed to make exceptions to this limit on the variation of costs within each APC group in unusual cases, such as for certain low-volume items and services.</P>
                    <P>
                        For the CY 2025 OPPS update, we identified the APCs with violations of the 2 times rule, and we proposed changes to the procedure codes assigned to these APCs (with the exception of those APCs for which we proposed a 2 times rule exception) in Addendum B to CY 2025 OPPS/ASC proposed rule. We note that Addendum B does not appear in the printed version of the 
                        <E T="04">Federal Register</E>
                         as part of this final rule with comment period. Rather, it is published and made available via the internet on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        .
                    </P>
                    <P>
                        To eliminate a violation of the 2 times rule and improve clinical and resource homogeneity in the APCs for which we did not propose a 2 times rule exception, we proposed to reassign these procedure codes to new APCs that contain services that are similar with regard to both their clinical and resource characteristics. In many cases, the proposed procedure code reassignments and associated APC reconfigurations for CY 2025 included in the CY 2025 OPPS/ASC proposed rule are related to changes in costs of services that were observed in the CY 2023 claims data available for CY 2025 ratesetting. Addendum B to the CY 2025 OPPS/ASC proposed rule identifies with a comment indicator “CH” those procedure codes for which we proposed a change to the APC assignment or status indicator, or both, that were initially assigned in the July 1, 2024, OPPS Addendum B Update, which is available via the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/addendum-a-b-updates</E>
                        .
                    </P>
                    <HD SOURCE="HD3">3. APC Exceptions to the 2 Times Rule</HD>
                    <P>While considering the APC changes that we proposed for CY 2025, we reviewed all of the APCs for which we identified 2 times rule violations to determine whether any of the APCs would qualify for an exception. We used the following criteria to evaluate whether to propose exceptions to the 2 times rule for affected APCs:</P>
                    <P>• Resource homogeneity;</P>
                    <P>• Clinical homogeneity;</P>
                    <P>• Hospital outpatient setting utilization;</P>
                    <P>• Frequency of service (volume); and</P>
                    <P>• Opportunity for upcoding and code fragments.</P>
                    <P>For a detailed discussion of these criteria, we refer readers to the April 7, 2000 final rule (65 FR 18457 and 18458).</P>
                    <P>Based on the CY 2023 claims data available for the CY 2025 OPPS/ASC proposed rule, we found 23 APCs with violations of the 2 times rule. We applied the criteria as described above to identify the APCs for which we proposed to make exceptions under the 2 times rule for CY 2025 and found that all of the 23 APCs we identified met the criteria for an exception to the 2 times rule based on the CY 2023 claims data available for the CY 2025 OPPS/APC proposed rule. We note that, on an annual basis, based on our analysis of the latest claims data, we identify violations to the 2 times rule and propose changes when appropriate. Those APCs that violate the 2 times rule are identified and appear in Table 18. In addition, we did not include in that determination those APCs where a 2 times rule violation was not a relevant concept, such as APC 5401 (Dialysis), which only has two HCPCS codes assigned to it that have similar geometric mean costs and do not create a 2 times rule violation. Therefore, we have only identified those APCs, including those with criteria-based costs, such as device-dependent CPT/HCPCS codes, with violations of the 2 times rule, where a 2 times rule violation is a relevant concept.</P>
                    <P>
                        Table 13 of the CY 2025 OPPS/ASC proposed rule (89 FR 59253) listed the 23 APCs for which we proposed to make an exception under the 2 times rule for CY 2025 based on the criteria cited above and claims data submitted between January 1, 2023, and December 31, 2023, and CCRs, if available. The proposed geometric mean costs for covered hospital outpatient services for these and all other APCs that were used in the development of the proposed rule can be found on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        .
                    </P>
                    <P>
                        Based on the updated final rule CY 2023 claims data used for this CY 2025 final rule with comment period, we found a total of 28 APCs with violations of the 2 times rule. Of these 28 total APCs, 23 were identified in the proposed rule and five are newly identified in this final rule with comment period. The following two APCs appeared in Table 13 of the CY 2025 OPPS/ASC proposed rule (89 FR 
                        <PRTPAGE P="94013"/>
                        59253) as violating the 2 times rule, however, after conducting our data analysis for this final rule with comment period, we found that the APCs no longer violate the 2 times rule:
                    </P>
                    <FP SOURCE="FP-1">• APC 5303 (Level 3 Upper GI Procedures)</FP>
                    <FP SOURCE="FP-1">• APC 5822 (Health and Behavior Services)</FP>
                    <FP SOURCE="FP-1">• In addition, the following five APCs are newly identified with 2 times rule violations using updated data for this final rule with comment period: APC 5024 (Level 4 Type A ED Visits)</FP>
                    <FP SOURCE="FP-1">• APC 5501 (Level 1 Extraocular, Repair, and Plastic Eye Procedures)</FP>
                    <FP SOURCE="FP-1">• APC 5613 (Level 3 Therapeutic Radiation Treatment Preparation)</FP>
                    <FP SOURCE="FP-1">• APC 5674 (Level 4 Pathology)</FP>
                    <FP SOURCE="FP-1">• APC 5722 (Level 2 Diagnostic Tests and Related Services)</FP>
                    <P>Although we did not receive any comments on Table 13 of the CY OPPS/ASC proposed rule, we did receive comments on APC assignments for specific HCPCS codes. The comments, and our responses, can be found in section III.E. of this final rule with comment period.</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94014"/>
                        <GID>ER27NO24.041</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <PRTPAGE P="94015"/>
                    <P>We did not receive any public comments on our proposal. Based on our analysis of the CY 2023 costs from hospital claims and cost report data available for this CY 2025 final rule with comment period, we are finalizing our proposals with some modifications. Specifically, we are finalizing our proposal to except the 23 proposed APCs that continue to have 2 times violations in the final rule data from the 2 times rule for CY 2023 claims data and also excepting five additional APCs (APCs 5024, 5501, 5613, 5674, 5722) that did not violate the 2 times rule in the proposed rule data, but do violate the 2 times rule in the final rule data, for a total of 28 APCs for which we identified 2 times rule violations but that qualify for exceptions.</P>
                    <P>
                        In summary, Table 18 lists the 28 APCs that we are excepting from the 2 times rule for CY 2025 based on the criteria described earlier and a review of updated claims data for dates of service between January 1, 2023, and December 31, 2023, that were processed on or before June 30, 2024, and updated CCRs, if available. We note that, for cases in which a recommendation by the HOP Panel appears to result in or allow a violation of the 2 times rule, we generally accept the HOP Panel's recommendation because those recommendations are based on explicit consideration of resource use, clinical homogeneity, site of service, and the quality of the claims data used to determine the APC payment rates. The geometric mean costs for hospital outpatient services for these and all other APCs that were used in the development of this final rule with comment period can be found on the CMS website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        .
                    </P>
                    <HD SOURCE="HD2">C. New Technology APCs</HD>
                    <HD SOURCE="HD3">1. Background</HD>
                    <P>In the CY 2002 OPPS final rule (66 FR 59903), we finalized changes to the time period in which a service can be eligible for payment under a New Technology APC. Beginning in CY 2002, we retain services within New Technology APC groups until we gather sufficient claims data to enable us to assign the service to an appropriate clinical APC. This policy allows us to move a service from a New Technology APC in less than 2 years if sufficient data are available. It also allows us to retain a service in a New Technology APC for more than 2 years if sufficient data upon which to base a decision for reassignment have not been collected.</P>
                    <P>
                        We also adopted in the CY 2002 OPPS final rule the following criteria for assigning a complete or comprehensive service to a New Technology APC: (1) the service must be truly new, meaning it cannot be appropriately reported by an existing HCPCS code assigned to a clinical APC and does not appropriately fit within an existing clinical APC; (2) the service is not eligible for transitional pass-through payment (however, a truly new, comprehensive service could qualify for assignment to a new technology APC even if it involves a device or drug that could, on its own, qualify for pass-through payment); and (3) the service falls within the scope of Medicare benefits under section 1832(a) of the Act and is reasonable and necessary in accordance with section 1862(a)(1)(A) of the Act (66 FR 59898 through 59903). For additional information about our New Technology APC policy, we refer readers to 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/pass-through-payment-status-new-technology-ambulatory-payment-classification-apc</E>
                         on the CMS website and then follow the instructions to access the MEARIS
                        <SU>TM</SU>
                         system for OPPS New Technology APC applications.
                        <SU>17</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>17</SU>
                             Currently approved under OMB control number 0938-0860; expires 07/31/2024.
                        </P>
                    </FTNT>
                    <P>In the CY 2004 OPPS final rule with comment period (68 FR 63416), we restructured the New Technology APCs to make the cost intervals more consistent across payment levels and refined the cost bands for these APCs to retain two parallel sets of New Technology APCs: one set with a status indicator of “S” (Significant Procedures, Not Discounted when Multiple. Paid under OPPS; separate APC payment) and the other set with a status indicator of “T” (Significant Procedure, Multiple Reduction Applies. Paid under OPPS; separate APC payment). These current New Technology APC configurations allow us to price new technology services more appropriately and consistently.</P>
                    <P>For CY 2024, there were 52 New Technology APC levels, ranging from the lowest cost band assigned to APC 1491 (New Technology—Level 1A ($0-$10)) to the highest cost band assigned to APC 1908 (New Technology—Level 52 ($145,001-$160,000)). We note that the cost bands for the New Technology APCs, specifically, APCs 1491 through 1599 and 1901 through 1908, vary with increments ranging from $10 to $14,999. These cost bands identify the APCs to which new technology procedures and services with estimated service costs that fall within those cost bands are assigned under the OPPS. Payment for each APC is made at the mid-point of the APC's assigned cost band. For example, payment for New Technology APC 1507 (New Technology—Level 7 ($501-$600)) is made at $550.50.</P>
                    <P>Under the OPPS, one of our goals is to make payments that are appropriate for the services that are necessary for the treatment of Medicare beneficiaries. The OPPS, like other Medicare payment systems, is budget neutral and increases are limited to the annual hospital market basket increase reduced by the productivity adjustment. We believe that our payment rates reflect the costs that are associated with providing care to Medicare beneficiaries and are adequate to ensure access to services (80 FR 70374). For many emerging technologies, there is a transitional period during which utilization may be low, often because providers are first learning about the technologies and their clinical utility. Quite often, parties request that Medicare make higher payments under the New Technology APCs for new procedures in that transitional phase. These requests, and their accompanying estimates for expected total patient utilization, often reflect very low rates of patient use of expensive equipment, resulting in high per-use costs for which requesters believe Medicare should make full payment. Medicare does not, and we believe should not, assume responsibility for more than its share of the costs of procedures based on projected utilization for Medicare beneficiaries and does not set its payment rates based on initial projections of low utilization for services that require expensive capital equipment. For the OPPS, we rely on hospitals to make informed business decisions regarding the acquisition of high-cost capital equipment, taking into consideration their knowledge about their entire patient base (Medicare beneficiaries included) and an understanding of Medicare's and other payers' payment policies. We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68314) for further discussion regarding this payment policy.</P>
                    <P>
                        Some services assigned to New Technology APCs have low annual volume, which we consider to be fewer than 100 claims in the year of claims data used for ratesetting (86 FR 63528). Where utilization of services assigned to a New Technology APC is low, it can lead to wide variation in payment rates from year to year, resulting in even lower utilization and potential barriers to access to new technologies, which 
                        <PRTPAGE P="94016"/>
                        ultimately limits our ability to assign the service to the appropriate clinical APC. To mitigate these issues, we finalized a policy in the CY 2019 OPPS/ASC final rule with comment period to utilize our equitable adjustment authority at section 1833(t)(2)(E) of the Act to adjust how we determine the costs for low-volume services assigned to New Technology APCs (83 FR 58892 through 58893). Specifically, in the CY 2019 OPPS/ASC final rule with comment period (83 FR 58893), we established that, in each of our annual rulemakings, we would calculate and present the result of each statistical methodology (arithmetic mean, geometric mean, and median) based on up to 4 years of claims data and solicit public comment on which methodology should be used to establish the payment rate for the low-volume new technology service. In the CY 2022 OPPS/ASC final rule (86 FR 63529), we replaced the New Technology APC low volume policy with the universal low volume APC policy. Unlike the New Technology APC low volume policy, the universal low volume APC policy applies to clinical APCs and brachytherapy APCs, in addition to procedures assigned to New Technology APCs, and uses the highest of the geometric mean, arithmetic mean, or median based on up to 4 years of claims data to set the payment rate for the APC. We refer readers to the CY 2022 OPPS/ASC final rule with comment period (86 FR 63529) for further discussion regarding this policy.
                    </P>
                    <P>
                        Finally, we note that, in a budget-neutral system, payments may not fully cover hospitals' costs in a particular circumstance, including those for the purchase and maintenance of capital equipment. We rely on hospitals to make their decisions regarding the acquisition of high-cost equipment with the understanding that the Medicare program must be careful to establish its initial payment rates, including those made through New Technology APCs, for new services that lack hospital claims data based on realistic utilization projections for all such services delivered in cost-efficient hospital outpatient settings. As the OPPS acquires claims data regarding hospital costs associated with new procedures, we regularly examine the claims data and any available new information regarding the clinical aspects of new procedures to confirm that our OPPS payments remain appropriate for procedures as they transition into mainstream medical practice (77 FR 68314). For CY 2025, we included the proposed payment rates for New Technology APCs 1491 to 1599 and 1901 through 1908 in Addendum A to the proposed rule (which is available on the CMS website at 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        ).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received a comment requesting that CMS revise the New Technology APC criteria to accommodate for forms of algorithm-based healthcare services (ABHS). The commenter explained that certain ABHS, that provide new clinical outputs that can impact the diagnosis or treatment of a patient's disease, and represent additional costs to hospitals not currently accounted for in the provision of an underlying service, would most likely not meet the New Technology APC criteria because the service provided by the technology is occurring at the same time as the performance of an underlying service. The commenter also requested that the New Technology APC process allow for the creation of new procedural C-codes when needed.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their comment. As part of the existing New Technology APC process, CMS creates C-codes when we find that there is no existing code that can appropriately describe a service. CMS will assign a service to a New Technology APC when certain criteria are met, including the criterion that the service is truly new, meaning that it cannot be appropriately reported by an existing HCPCS code assigned to a clinical APC and does not appropriately fit within an existing clinical APC. In the past, we have found that several SaaS procedures, including those that are algorithm-based, meet the existing New Technology APC criteria. For CY 2025, we proposed to assign several SaaS procedures that meet our criteria to New Technology APCs, many of which have been assigned to New Technology APCs for several years. However, we recognize that software-based technologies are rapidly evolving and, therefore, we are considering for future rulemaking whether specific adjustments to payment policies, including our New Technology APC policies, are needed to more accurately and appropriately pay for these products and services across settings of care.
                    </P>
                    <P>For CY 2025, we did not propose to make any changes to the existing New Technology APC criteria. After consideration of the public comments we received, we are not finalizing any changes to the New Technology APC criterion at this time.</P>
                    <HD SOURCE="HD3">2. Policy To Exempt Services With Very Low Claims Volume From APC Reassignment Based on the Universal Low Volume Policy</HD>
                    <P>We continue to be concerned about payment stability for services assigned to New Technology APCs, specifically services with very low claims volume of fewer than 10 claims in the 4-year lookback period used under the universal low volume APC policy. Historically, we have used our equitable adjustment authority at section 1833(t)(2)(E) of the Act to exempt a number of services with very low claims volume from the universal low volume APC policy in instances where application of the universal low volume policy would lead to significant fluctuations in payment. Given the frequency with which we have needed to utilize our equitable adjustment authority to address significant fluctuations in payment for very low volume services, we noted in the proposed rule that we believed that refinements to our universal low volume policy for services assigned to New Technology APCs may be necessary. We also recognized that determining initial cost estimates for these services may be particularly challenging, given the lack of cost information for new and innovative technologies.</P>
                    <P>
                        To allow time for us to consider these issues, we proposed for CY 2025 to exempt services assigned to New Technology APCs with fewer than 10 claims over the 4-year lookback period used for the universal low volume policy. Instead of assigning these services to a different New Technology APC based on the very few claims available, we proposed that we would maintain the New Technology APC assignment for each service from the prior year, which in this case would be the New Technology APC assignment for CY 2024. We explained that we believed it was appropriate to apply this policy to New Technology APCs because services assigned to New Technology APCs represent new technologies for which it may be more challenging to determine an appropriate cost than for other, more established services. We believed 10 claims was an appropriate ceiling for exempting services from reassignment based on the universal low volume policy because we believed that at 10 claims a rough standard distribution begins to appear. We also believed that services with so few claims over the 4-year lookback period would be especially vulnerable to large changes in payment rates year-to-year as a result of one or two new 
                        <PRTPAGE P="94017"/>
                        claims being available or one or two claims from what was previously the fourth year of the lookback period no longer being included in that period.
                    </P>
                    <P>Consistent with our overall policy regarding use of updated claims data in the final rule, we proposed to perform a similar analysis for the final rule using updated claims data, including determining whether specific HCPCS codes continue to meet the criteria for our universal low volume APC policy or our proposal to exempt services with fewer than 10 claims in the 4-year lookback period from the universal low volume APC policy and maintain their CY 2024 New Technology APC assignment. We noted we would update the APC placement as needed in the final rule.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters agreed with our concerns that the application of the universal low volume APC policy may result in payment instability for certain services assigned to New Technology APCs, but offered different perspectives on how to address the issue. One commenter, representing artificial intelligence companies, supported our proposal to exempt certain services from the universal low volume APC policy and recommended that we utilize 25 claims, rather than 10 claims when determining whether to maintain a service's New Technology APC assignment from the previous year. Another commenter, representing manufacturers of medical imaging equipment, did not believe that the proposal sufficiently addressed the policy concern of payment stability for services assigned to New Technology APCs. This commenter also believed that the proposal would create a disincentive for hospitals to furnish the service and, therefore, discourage claims utilization where it would be more prudent to have no claims than to risk being assigned to a lower paying New Technology APC in future years by exceeding the 10-claim threshold.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We agree with the commenters' concerns that applying the universal low volume APC policy can result in payment fluctuations from year-to-year. We also recognize that major payment fluctuations that do not reflect the actual cost of the service can have the effect of discouraging usage and keeping claims volume low, which prevents CMS from gathering sufficient claims data upon which to transition the service from a New Technology APC to an appropriate clinical APC. We disagree with one commenter's assertion that our proposal to maintain the New Technology APC placement of a service with extremely low claims volume would disincentivize usage of the service. By maintaining the APC placement for services with fewer than 10 claims in the four-year lookback period, we are removing the potential for a major payment change based on a handful of claims over multiple years, that may not reflect the actual cost of the service. We believe that this policy is an incremental step towards more stable and predictable payments while providers learn about these new technology services, which should have the effect of encouraging utilization in the long-term. We also disagree with the commenter's suggestion to increase the claims threshold from 10 to 25 claims. We proposed to exempt less than 10 claims from the universal low volume APC policy because at 10 claims a rough standard distribution begins to appear, and services with an extremely low number of claims are most vulnerable to significant payment fluctuations.
                    </P>
                    <P>Our proposal is meant to serve as a first step to addressing the issue of payment stability for services assigned to New Technology APCs. As we stated in the proposed rule, we continue to believe that refinements to the universal low volume APC policy with respect to its application to services in New Technology APCs may be necessary. We are finalizing our policy as proposed for CY 2025 and will consider additional changes in future years.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter expressed support for the universal low volume APC policy.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal to exempt services assigned to New Technology APCs with fewer than 10 claims in the four-year lookback period from the universal low volume APC policy and maintain their CY 2024 New Technology APC assignment as proposed.</P>
                    <HD SOURCE="HD3">3. Procedures Assigned to New Technology APCs for CY 2025</HD>
                    <P>As we described in the CY 2002 OPPS final rule (66 FR 59902), we generally retain a procedure in the New Technology APC to which it is initially assigned until we have obtained sufficient claims data to justify reassignment of the procedure to a clinically appropriate APC. In addition, in cases where we find that our initial New Technology APC assignment was based on inaccurate or inadequate information (although it was the best information available at the time), where we obtain new information that was not available at the time of our initial New Technology APC assignment, or where the New Technology APCs are restructured, we may, based on more recent resource utilization information (including claims data) or the availability of refined New Technology APC cost bands, reassign the procedure or service to a different New Technology APC that more appropriately reflects its cost (66 FR 59903).</P>
                    <P>Consistent with our current policy, for CY 2025, we proposed to retain services within New Technology APC groups until we obtain sufficient claims data to justify reassignment of the service to an appropriate clinical APC. The flexibility associated with this policy allows us to reassign a service from a New Technology APC in less than 2 years if we have obtained sufficient claims data. It also allows us to retain a service in a New Technology APC for more than 2 years if we have not obtained sufficient claims data upon which to base a reassignment decision (66 FR 59902).</P>
                    <HD SOURCE="HD3">a. Administration of Subretinal Therapies Requiring Vitrectomy (APC 1563)</HD>
                    <P>Effective January 1, 2021, CMS established HCPCS code C9770 (Vitrectomy, mechanical, pars plana approach, with subretinal injection of pharmacologic/biologic agent) and assigned it to a New Technology APC based on the geometric mean cost of CPT code 67036 (Vitrectomy, mechanical, pars plana approach) due to similar resource utilization. For CY 2021, HCPCS code C9770 was assigned to APC 1561 (New Technology—Level 24 ($3001-$3500)). This code may be used to describe the administration of HCPCS code J3398 (Injection, voretigene neparvovec-rzyl, 1 billion vector genomes). This procedure was previously discussed in depth in the CY 2021 OPPS/ASC final rule with comment period (85 FR 85939 through 85940). For CY 2022, we maintained the APC assignment of APC 1561 (New Technology—Level 24 ($3001-$3500)) for HCPCS code C9770 (86 FR 63531 through 63532).</P>
                    <PRTPAGE P="94018"/>
                    <P>
                        HCPCS code
                        <FTREF/>
                         J3398 (Injection, voretigene neparvovec-rzyl, 1 billion vector genomes) is for a gene therapy product indicated for a rare mutation-associated retinal dystrophy. Voretigene neparvovec-rzyl (Luxturna®) was approved by FDA in December of 2017 and is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.
                        <SU>18</SU>
                         This therapy is administered through a subretinal injection, which interested parties describe as an extremely delicate and sensitive surgical procedure. The FDA-approved package insert describes one of the steps for administering Luxturna as, “after completing a vitrectomy, identify the intended site of administration. The subretinal injection can be introduced via pars plana.”
                    </P>
                    <FTNT>
                        <P>
                            <SU>18</SU>
                             Luxturna. FDA Package Insert. Available: 
                            <E T="03">https://www.fda.gov/media/109906/download</E>
                            .
                        </P>
                    </FTNT>
                    <P>
                        Interested parties, including the manufacturer of Luxturna®, recommended CPT code 67036 (Vitrectomy, mechanical, pars plana approach) for the administration of the gene therapy.
                        <SU>19</SU>
                        <FTREF/>
                         However, the manufacturer previously contended the administration was not accurately described by any existing codes as CPT code 67036 (Vitrectomy, mechanical, pars plana approach) does not account for the administration itself.
                    </P>
                    <FTNT>
                        <P>
                            <SU>19</SU>
                             LUXTURNA REIMBURSEMENT GUIDE FOR TREATMENT CENTERS. 
                            <E T="03">https://mysparkgeneration.com/uploads/2022/09/LUXTURNA-Reimbursement-Guide-for-Treatment-Centers-ISI-Update-April-2022-P-RPE65-US-320025.pdf.</E>
                        </P>
                    </FTNT>
                    <P>CMS recognized the need to accurately describe the unique procedure that is required to administer the therapy described by HCPCS code J3398. Therefore, in the CY 2021 OPPS/ASC proposed rule (85 FR 48832), we proposed to establish a new HCPCS code, C97X1 (Vitrectomy, mechanical, pars plana approach, with subretinal injection of pharmacologic/biologic agent) to describe this process. We stated that we believed this new HCPCS code accurately described the unique service associated with intraocular administration of HCPCS code J3398. We recognized that CPT code 67036 represents a clinically similar procedure and process that approximates similar resource utilization to C97X1. However, we also recognized that it is not prudent for the code that describes the administration of this unique gene therapy, C97X1, to be assigned to the same C-APC to which CPT code 67036 is assigned, as this would package the primary therapy, HCPCS code J3398, into the code that represents the process to administer the gene therapy.</P>
                    <P>Therefore, for CY 2021, we proposed to assign the services described by C97X1 to a New Technology APC with a cost band that contains the geometric mean cost for CPT code 67036. The placeholder code C97X1 was replaced by HCPCS code C9770. For CY 2021, we finalized our proposal to create HCPCS code C9770 (Vitrectomy, mechanical, pars plana approach, with subretinal injection of pharmacologic/biologic agent), and we assigned this code to APC 1561 (New Technology—Level 24 ($3001-$3500)) using the geometric mean cost of CPT code 67036. For CY 2022, we continued to assign HCPCS code C9770 to APC 1561 (New Technology—Level 24 ($3001-$3500)) using the geometric mean cost of CPT code 67036.</P>
                    <P>CY 2023 was the first year that claims data were available for HCPCS code C9770; therefore, we proposed and finalized a policy to base the payment rate of HCPCS code C9770 on claims data for that code rather than on the geometric mean cost of CPT code 67036. Given the low number of claims for this procedure, we designated HCPCS code C9770 as a low volume procedure under our universal low volume APC policy and used the greater of the geometric mean, arithmetic mean, or median cost calculated based on the available claims data to calculate an appropriate payment rate for purposes of assigning HCPCS code C9770 to a New Technology APC.</P>
                    <P>Based on the claims data available for the CY 2023 OPPS/ASC final rule with comment period, we found the median was the statistical methodology that estimated the highest cost for the service. The payment rate calculated using this methodology fell within the cost band for New Technology APC 1562 (New Technology—Level 25 ($3501-$4000)). Therefore, we finalized our proposal to assign HCPCS code C9770 to APC 1562 for CY 2023.</P>
                    <P>For CY 2024, we proposed and finalized that we would delete HCPCS code C9770 effective December 31, 2023, and recognize CPT code 0810T (Subretinal injection of a pharmacologic agent, including vitrectomy and 1 or more retinotomies) starting January 1, 2024 (88 FR 81617 through 81619). We determined the payment rate for CPT code 0810T using the claims data for HCPCS code C9770 and designated CPT code 0810T as a low volume procedure under our universal low volume APC policy and used the greater of the geometric mean, arithmetic mean, or median cost calculated based on the available claims data for HCPCS code C9770 to calculate an appropriate payment rate for purposes of assigning CPT code 0810T to a New Technology APC. For CY 2024, we finalized assignment of CPT code 0810T to APC 1563 (New Technology—Level 26 ($4001-$4500)) (88 FR 81617 through 81619).</P>
                    <P>Since CMS recognized CPT code 0810T starting January 1, 2024, we do not have claims data for CPT code 0810T available for CY 2025 rulemaking. However, as HCPCS code C9770 was still in use until December 31, 2023, we proposed to determine the payment rate for CPT code 0810T using the claims data for HCPCS code C9770. This is similar to the policy we finalized for CY 2024. For CY 2025, we proposed to designate CPT code 0810T as a low volume procedure under our universal low volume APC policy, given that there were only 34 claims available for HCPCS code C9770 and none for CPT code 0810T. This is below the threshold of 100 claims for a service within a year required to designate a service as a low volume service and apply our universal low volume APC policy. Therefore, we proposed to use the greater of the geometric mean, arithmetic mean, or median cost calculated based on the available claims data for HCPCS code C9770 to calculate an appropriate payment rate for purposes of assigning CPT code 0810T to a New Technology APC.</P>
                    <P>Using all available claims from the 4-year lookback period, which was 34 claims, we determined the geometric mean cost to be $3,934, the arithmetic mean cost to be $4,173, and the median cost to be $4,103. Because the arithmetic mean is the statistical methodology that estimated the highest cost for the service, we proposed to use this cost to determine the New Technology APC placement. The arithmetic mean of $4,173 falls within the cost band for New Technology APC 1563 (New Technology—Level 26 ($4001-$4500)). Therefore, we proposed to assign CPT code 0810T to APC 1563 for CY 2025. Additionally, we proposed to perform a similar analysis using updated claims data in this final rule with comment period, including determining if CPT code 0810T continues to meet the criteria for our universal low volume APC policy, and update the APC assignment as needed.</P>
                    <P>Please refer to Table 19 below for the final CY 2024 and proposed CY 2025 OPPS New Technology APC and status indicator assignments for CPT code 0810T. The proposed CY 2025 payment rates can be found in Addendum B to the CY 2025 OPPS/ASC proposed rule via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="181">
                        <PRTPAGE P="94019"/>
                        <GID>ER27NO24.042</GID>
                    </GPH>
                    <P>We did not receive any public comments on our proposal to continue to assign HCPCS code 0810T to APC 1563 for CY 2025.</P>
                    <P>Additional claims for CY 2023 have been processed since the proposed rule. Our analysis of the updated claims data found that the greater of the geometric mean, arithmetic mean, or median cost calculated for HCPCS code C9770 is approximately $4,240. This continues to fall into the cost band of New Technology APC 1563. Therefore, we are finalizing our proposal without modification to continue to assign HCPCS code 0810T to APC 1563. Please refer to Table 20 for the final OPPS New Technology APC and status indicator assignment for HCPCS codes 0810T for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="181">
                        <GID>ER27NO24.043</GID>
                    </GPH>
                    <HD SOURCE="HD3">b. BgRT (APCs 1521 and 1525)</HD>
                    <P>
                        Biology Guided Radiation Therapy (BgRT) uses positron-emitting radiopharmaceuticals to control delivery of radiation therapy to treat primary and metastatic lung or bone tumors. During radiation treatment delivery, the same system applies these firing filters to the real-time positron emission tomography (PET) data collected by the radiation treatment delivery machine. Effective January 1, 2024, CMS created HCPCS codes C9794 (Therapeutic radiology simulation-aided field setting; complex, including acquisition of PET and CT imaging data required for radiopharmaceutical-directed radiation therapy treatment planning (
                        <E T="03">i.e.,</E>
                         modeling) and C9795 (Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions) to describe the modeling and treatment delivery portions of the BgRT service. We assigned HCPCS code C9794 to APC 1521 (New Technology—Level 21 ($1901-$2000)) and HCPCS code C9795 to APC 1525 (New Technology—Level 25 ($3501-$4000)) for CY 2024.
                    </P>
                    <P>
                        For CY 2025, the OPPS payment rates were proposed based on available CY 2023 claims data. As HCPCS codes C9794 and C9795 were effective January 1, 2024, we do not have any claims data for the service. Therefore, for CY 2025, we proposed to continue to assign HCPCS code C9794 to APC 1521 (New Technology—Level 21 ($1901-$2000)) with a payment rate of $1,950.50 and HCPCS code C9795 to APC 1525 (New Technology—Level 25 ($3501-$4000)) with a payment rate of $3,750.50. Please refer to Table 21 below for the proposed 
                        <PRTPAGE P="94020"/>
                        OPPS New Technology APC and status indicator assignment for HCPCS codes C9794 and C9795 for CY 2025. The proposed CY 2025 payment rates can be found in Addendum B to the CY 2025 OPPS/ASC proposed rule via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.
                    </P>
                    <GPH SPAN="3" DEEP="228">
                        <GID>ER27NO24.044</GID>
                    </GPH>
                    <P>
                        <E T="03">Comment:</E>
                         We received several comments supporting our proposal to maintain the APC assignments for HCPCS code C9794 and C9795 until claims data are received.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their support.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal without modification. Specifically, for CY 2025 we are finalizing our proposal to assign C9794 and C9795 to APCs 1521 (New Technology—Level 21 ($1901-$2000)) and 1525 (New Technology—Level 25 ($3501-$4000)), respectively.</P>
                    <P>We note that, effective January 1, 2025, two new G-codes are replacing HCPCS codes C9794 and C9795. Specifically, effective January 1, 2025, HCPCS codes C9794 and C9795 are being deleted and replaced by G0562 and G0563, respectively, to allow for payment in settings other than hospital outpatient departments for CY 2025. The descriptors for the new G-codes are the same as existing HCPCS codes C9794 and C9795.</P>
                    <P>Please refer to Table 22 for the final OPPS New Technology APC and status indicator assignments for HCPCS codes G0562 and G0563 for CY 2025. The CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="214">
                        <PRTPAGE P="94021"/>
                        <GID>ER27NO24.045</GID>
                    </GPH>
                    <HD SOURCE="HD3">c. Blinded Procedure for NYHA Class III/IV Heart Failure (APC 1590)</HD>
                    <P>A randomized, double-blinded, controlled IDE study is currently in progress for the V-Wave interatrial shunt. The V-Wave interatrial shunt is for patients with severe symptomatic heart failure and is designed to regulate left atrial pressure in the heart. All participants who passed initial screening for the study receive a right heart catheterization procedure described by CPT code 93451 (Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed). Participants assigned to the experimental group also receive the V-Wave interatrial shunt procedure while participants assigned to the control group only receive right heart catheterization. The developer of V-Wave was concerned that the current coding of these services by Medicare would reveal to the study participants whether they had received the interatrial shunt because an additional procedure code, CPT code 93799 (Unlisted cardiovascular service or procedure), would be included on the claims for participants receiving the interatrial shunt. Therefore, for CY 2020, we created a temporary HCPCS code to describe the V-Wave interatrial shunt procedure for both the experimental group and the control group in the study. Specifically, we established HCPCS code C9758 (Blinded procedure for NYHA class III/IV heart failure; transcatheter implantation of interatrial shunt or placebo control, including right heart catheterization, trans-esophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (for example, ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study) to describe the service, and we assigned the service to New Technology APC 1589 (New Technology—Level 38 ($10,001-$15,000)) with a payment rate of $12,500.50.</P>
                    <P>In the CY 2021 OPPS/ASC final rule with comment period (85 FR 85946), we stated that we believe similar resources and device costs are involved with the V-Wave interatrial shunt procedure and the Corvia Medical interatrial shunt procedure (HCPCS code C9760), except that payment for HCPCS codes C9758 and C9760 differs based on how often the interatrial shunt is implanted when each code is billed. An interatrial shunt is implanted one-half of the time HCPCS code C9758 is billed, whereas an interatrial shunt is implanted every time HCPCS code C9760 is billed. Accordingly, for CY 2021, we reassigned HCPCS code C9758 to New Technology APC 1590 (New Technology—Level 39 ($15,001-$20,000)), which reflects the cost of furnishing the interatrial shunt one-half of the time the procedure is performed.</P>
                    <P>For CY 2022, we used the same claims data from CY 2019 that we did for the CY 2021 OPPS/ASC final rule with comment period. Because there were no claims reporting HCPCS code C9758, we continued to assign HCPCS code C9758 to New Technology APC 1590 with a payment rate of $17,500.50 for CY 2022. For CY 2023 we used claims data from CY 2019 through CY 2022. Because there were no claims reporting HCPCS code C9758 in CY 2023 or CY 2024, we continued to assign HCPCS code C9758 to New Technology APC 1590 with a payment rate of $17,500.50 for CY 2023 and 2024.</P>
                    <P>For CY 2025, the OPPS payment rates were proposed based on available CY 2023 claims data. There were only three claims for HCPCS code C9758 within this time period. As this is below the threshold of 100 claims for a service within a year, we would designate C9758 as a low volume service and apply our universal low volume APC policy. Under this policy, we would use the highest of the geometric mean cost, arithmetic mean cost, or median cost based on up to 4 years of claims data to assign HCPCS code C9758 to the appropriate New Technology APC. Given our proposal, which we are finalizing, to maintain current New Technology APC assignments for CY 2025 for New Technology APC services with fewer than 10 claims in the 4-year lookback period applicable for the universal low volume APC policy, we proposed to continue assigning HCPCS code C9758 to New Technology APC 1590 with a proposed payment rate of $17,500.50.</P>
                    <P>Please refer to Table 23 for the proposed OPPS New Technology APC and status indicator assignments for HCPCS code C9758 for CY 2025.</P>
                    <GPH SPAN="3" DEEP="206">
                        <PRTPAGE P="94022"/>
                        <GID>ER27NO24.046</GID>
                    </GPH>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment supporting our proposal to continue to assign HCPCS code C9758 to New Technology APC 1590.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their support. Our updated claims data for the 4-year lookback period for the universal low volume APC policy continues to show only 3 claims for HCPCS code C9758. Therefore, we are finalizing our proposal without modification to continue assigning HCPCS code C9758 to New Technology APC 1590. Please refer to Table 24 for the final OPPS New Technology APC and status indicator assignment for HCPCS code C9758 for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.
                    </P>
                    <GPH SPAN="3" DEEP="178">
                        <GID>ER27NO24.047</GID>
                    </GPH>
                    <HD SOURCE="HD3">d. Bronchoscopy With Transbronchial Ablation of Lesion(s) by Microwave Energy (APC 1562)</HD>
                    <P>
                        Effective January 1, 2019, CMS established HCPCS code C9751 (Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (
                        <E T="03">e.g.,</E>
                         aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)). This microwave ablation procedure utilizes a flexible catheter to access the lung tumor via a working channel and may be used as an alternative procedure to a percutaneous microwave approach. Based on our review of the New Technology APC application for this service and the service's clinical similarity to existing services paid under the OPPS, we estimated the likely cost of the procedure would be between $8,001 and $8,500. We assigned the procedure to New Technology APC 1571 (New Technology—Level 34 ($8001-$8500)) for CY 2019.
                    </P>
                    <P>
                        In claims data available from CY 2019 for the CY 2021 OPPS/ASC final rule with comment period, there were four claims reported for bronchoscopy with transbronchial ablation of lesions by microwave energy. Given the low volume of claims for the service, we proposed for CY 2021 to apply the universal low volume APC policy we adopted in CY 2019, under which we utilize our equitable adjustment 
                        <PRTPAGE P="94023"/>
                        authority under section 1833(t)(2)(E) of the Act to calculate the geometric mean, arithmetic mean, and median costs to determine an appropriate payment rate for purposes of assigning bronchoscopy with transbronchial ablation of lesions by microwave energy to a New Technology APC. We found the geometric mean cost for the service to be approximately $2,693, the arithmetic mean cost to be approximately $3,086, and the median cost to be approximately $3,708. The median was the statistical methodology that estimated the highest cost for the service. The payment rate calculated using this methodology fell within the cost band for New Technology APC 1562 (New Technology—Level 25 ($3501-$4000)). Therefore, we assigned HCPCS code C9751 to APC 1562 for CY 2021.
                    </P>
                    <P>In CY 2022, we again used the claims data from CY 2019 for HCPCS code C9751. Because the claims data was unchanged from when it was used in CY 2021, the values for the geometric mean cost ($2,693), the arithmetic mean cost ($3,086), and the median cost ($3,708) for the service described by HCPCS code C9751 remained the same. The highest cost metric using these methodologies was again the median and within the cost band for New Technology APC 1562 (New Technology—Level 25 ($3,501-$4,000)). Therefore, we continued to assign HCPCS code C9751 to APC 1562 (New Technology—Level 25 ($3501-$4000)), with a payment rate of $3,750.50 for CY 2022.</P>
                    <P>There were no new claims for HCPCS code C9751 for the CY 2024 OPPS/ASC final rule with comment period. Therefore, we continued to use claims from CY 2019 to determine the payment rate for the service; and continued to assign HCPCS code C9751 to APC 1562 (New Technology—Level 25 ($3501-$4000)), with a payment rate of $3,750.50.</P>
                    <P>There continue to be no separately payable claims for HCPCS code C9751 since 2019. Consistent with our proposal to maintain current New Technology APC assignments for CY 2025 for New Technology APC services with fewer than 10 claims in the 4-year lookback period applicable for the universal low volume APC policy, we proposed, for CY 2025, to continue to assign HCPCS code C9751 to APC 1562 (New Technology—Level 25 ($3501-$4000)), with a payment rate of $3,750.50.</P>
                    <P>Please refer to Table 25 for the proposed OPPS New Technology APC and status indicator assignments for HCPCS code C9751 for CY 2025.</P>
                    <GPH SPAN="3" DEEP="199">
                        <GID>ER27NO24.048</GID>
                    </GPH>
                    <P>We did not receive any public comments on our proposal to continue to assign HCPCS code C9751 to APC 1562 (New Technology—Level 25 ($3501-$4000)). Additionally, our updated claims data continues to show that there are no new claims for C9751 for CY 2025. Therefore, we are finalizing our proposal without modification to continue to assign HCPCS code C9751 to APC 1562. Please refer to Table 26 for the final OPPS New Technology APC and status indicator assignment for HCPCS codes C9751 for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="213">
                        <PRTPAGE P="94024"/>
                        <GID>ER27NO24.049</GID>
                    </GPH>
                    <HD SOURCE="HD3">e. Cardiac Positron Emission Tomography (PET)/Computed Tomography (CT) Studies (APCs 1520 and 1522)</HD>
                    <P>For CY 2025, the OPPS payment rates for the service described by CPT codes 78431, 78432, and 78433 were proposed to be based on available CY 2023 claims data. CPT code 78431 had over 26,000 single frequency claims in CY 2023. The geometric mean cost for CPT code 78431 was approximately $2,350. The geometric mean falls within APC 1522 (New Technology—Level 22 ($2001-$2500)) with a payment rate of $2,250.50, which is the current APC assignment for this service. Therefore, we proposed, for CY 2025, to continue to assign CPT code 78431 to APC 1522 (New Technology—Level 22 ($2001-$2500)) with a payment rate of $2,250.50.</P>
                    <P>There were only 19 single frequency claims in CY 2023 for CPT code 78432. As this is below the threshold of 100 claims for a service within a year, we proposed to apply our universal low volume New Technology APC policy and used the highest of the geometric mean cost, arithmetic mean cost, or median cost based on up to 4 years of claims data to assign CPT code 78432 to the appropriate New Technology APC. Using available claims data from CY 2021, CY 2022, and CY 2023, our analysis found the geometric mean cost of the service was approximately $1,760, the arithmetic mean cost of the service was approximately $1,920, and the median cost of the service was approximately $1,540. The arithmetic mean was the statistical methodology that estimated the highest cost for the service. The arithmetic mean cost of $1,923, is an amount that is above the cost band for APC 1520 (New Technology—Level 20 ($1801-$1900)), where the procedure is currently assigned for CY 2024. Therefore, we proposed, for CY 2025, to assign CPT code 78432 to APC 1521 (New Technology—Level 21 ($1901-$2000)) with a payment rate of $1950.50.</P>
                    <P>There were over 1,400 single frequency claims for CPT code 78433 in CY 2023. The geometric mean cost for CPT code 78433 was approximately $2,010, which is an amount that is above the current New Technology APC cost band for APC 1521 (New Technology—Level 21 ($1901-$2000)) to which it is assigned for CY 2024. Therefore, for CY 2025, we proposed to reassign CPT code 78433 to APC 1522 (New Technology—Level 22 ($2001-$2500)) with a payment rate of $2,250.50.</P>
                    <P>Please refer to Table 27 below for the proposed OPPS New Technology APC and status indicator assignments for CPT codes 78431, 78432, and 78433 for CY 2025. The proposed CY 2025 payment rates can be found in Addendum B to the CY 2025 OPPS/ASC proposed rule via the internet on the CMS website.</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="486">
                        <PRTPAGE P="94025"/>
                        <GID>ER27NO24.050</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <P>
                        <E T="03">Comment:</E>
                         We received comments supporting our proposals to assign CPT codes 78431 and 78433 to APC 1522 (New Technology—Level 22 ($2001-$2500)) and to assign CPT code 78432 to APC 1521 (New Technology—Level 21 ($1901-$2000)). One commenter noted that the geometric mean costs and hospital reporting for PET/CT services is stabilizing and that the claims data will support stable payment rates in future years.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their support. We agree that the claims data for these services have been stabilizing in recent years, and any payment adjustments have been, generally, minor. As we have begun to gather adequate claims data, we will consider whether to assign CPT codes 78431 and 78433 to clinical APCs in future rulemaking.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter supported our proposals to assign CPT codes 78431 and 78433 to APC 1522 but did not support our proposal to assign CPT code 78432 to APC 1521. The commenter explained that CPT code 78431 should be assigned to APC 1522 or higher because, from a clinical workflow perspective, CPT code 78432 requires more resources than CPT code 78431. The commenter explained that they believe the low claims volume is responsible for the lower payment rate for CPT codes 78432.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input. We note that New Technology APCs are cost bands rather than clinical groupings. Unlike when we assign a service to a clinical APC and consider resource and clinical similarities to other services in a clinical APC, we assign services to New Technology APCs based on cost. While we appreciate the commenter's information regarding the clinical differences between CPT codes 78431 and 78432, we adjust New Technology APC assignments based on the claims 
                        <PRTPAGE P="94026"/>
                        data available rather than clinical characteristics of a service.
                    </P>
                    <P>We note that additional claims for CPT codes 78431 through 78433 have been processed since the proposed rule. Based on updated claims data, CPT code 78431 has an updated geometric mean cost of approximately $2,300. Because the geometric mean cost of CPT code 78431 is still within the range for APC 1522, the proposed APC assignment for CPT code 78431 for CY 2025, we are finalizing the proposed APC assignment of CPT code 78431 without modification.</P>
                    <P>There were close to 15 additional single frequency claims for CY 2023 processed for CPT code 78432 since the proposed rule, bringing the total number of single frequency claims to approximately 33 for CPT code 78432 for CY 2023. Based on the updated claims data for CPT code 78432, the geometric mean cost is approximately $1,750; the arithmetic mean cost is approximately $1,890; and the median cost is approximately $1,590. Of these, the highest statistical methodology is the arithmetic mean cost of $1,890. Since the updated arithmetic mean cost for CPT code 78432 is outside of the cost band for APC 1521 (New Technology—Level 21 ($1901-$2000), we are not finalizing our proposal to assign CPT code 78432 to APC 1521 for CY 2025. Based on the updated statistical methodologies, we are assigning CPT code 78432 to APC 1520 for CY 2025 (New Technology—Level 20 ($1801-$1900)) with a payment rate of $1,850.50.</P>
                    <P>For CPT code 78433, the geometric mean cost based on the updated claims data has changed to approximately $1964, down from approximately $2010 at the time of the proposed rule. Therefore, we are not finalizing the assignment of CPT code 78433 to APC 1522 as proposed because the geometric mean cost falls outside of the cost band for proposed APC 1522 (New Technology—Level 22 ($2001-$2500)). We are assigning CPT code 78433 to APC 1521 (New Technology—Level 21 ($1901-$2000)) for CY 2025, which is the same New Technology APC to which it is currently assigned for CY 2024.</P>
                    <P>Please refer to Table 28 for the final OPPS New Technology APC and status indicator assignments for CPT codes 7843, 78432, and 78433 for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="486">
                        <PRTPAGE P="94027"/>
                        <GID>ER27NO24.051</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <HD SOURCE="HD3">f. CardiAMP (APC 1590)</HD>
                    <P>
                        The CardiAMP cell therapy IDE studies are two randomized, double-blinded, controlled IDE studies: the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial 
                        <SU>20</SU>
                        <FTREF/>
                         and the CardiAMP Cell Therapy Heart Failure Trial.
                        <SU>21</SU>
                        <FTREF/>
                         The two trials are designed to investigate the safety and efficacy of autologous bone marrow mononuclear cell treatment for the following: (1) patients with medically refractory and symptomatic ischemic cardiomyopathy; and (2) patients with refractory angina pectoris and chronic myocardial ischemia. On April 1, 2022, we established HCPCS code C9782 to describe the CardiAMP cell therapy IDE studies and assigned HCPCS code C9782 to APC 1574 (New Technology—Level 37 ($9,501-$10,000)) with the status indicator “T.” We subsequently revised the descriptor for HCPCS code C9782 to: (Blinded procedure for New York Heart Association (NYHA) Class II or III heart failure, or Canadian Cardiovascular Society (CCS) Class III or IV chronic refractory angina; transcatheter intramyocardial transplantation of autologous bone marrow cells (
                        <E T="03">e.g.,</E>
                         mononuclear) or placebo control, autologous bone marrow harvesting and preparation for transplantation, left heart catheterization including ventriculography, all laboratory services, and all imaging with or without guidance (
                        <E T="03">e.g.,</E>
                         transthoracic 
                        <PRTPAGE P="94028"/>
                        echocardiography, ultrasound, fluoroscopy), all device(s), performed in an approved Investigational Device Exemption (IDE) study) to clarify the inclusion of the Helix trans endocardial injection catheter device in the descriptor. Additionally, we determined that APC 1590 (New Technology—Level 39 ($15,001-$20,000)) most accurately accounted for the resources associated with furnishing the procedure described by HCPCS code C9782.
                    </P>
                    <FTNT>
                        <P>
                            <SU>20</SU>
                             
                            <E T="03">ClinicalTrials.gov.</E>
                             “Randomized Controlled Pivotal Trial of Autologous Bone Marrow Cells Using the CardiAMP Cell Therapy System in Patients With Refractory Angina Pectoris and Chronic Myocardial Ischemia.” Accessed May 10, 2022. 
                            <E T="03">https://clinicaltrials.gov/ct2/show/NCT03455725?term=NCT03455725&amp;rank=1</E>
                            .
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>21</SU>
                             
                            <E T="03">ClinicalTrials.gov.</E>
                             “Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients With Post Myocardial Infarction Heart Failure.” Accessed May 10, 2022. 
                            <E T="03">https://clinicaltrials.gov/ct2/show/NCT02438306</E>
                            .
                        </P>
                    </FTNT>
                    <P>For CY 2025, the proposed OPPS payment rates were based on available CY 2023 claims data. We identified three single frequency paid claims for C9782 for ratesetting for CY 2025. As this is below the threshold of 100 claims for a service within a year, we would designate C9782 as a low volume service and apply our universal low volume APC policy. Under this policy, we would use the highest of the geometric mean cost, arithmetic mean cost, or median cost based on up to 4 years of claims data to assign CPT codes C9782 to the appropriate New Technology APC. Our analysis of the data found the geometric mean cost of the service is approximately $18,045, the arithmetic mean cost of the service is approximately $18,332, and the median cost of the service is approximately $20,394. The median was the statistical methodology that estimated the highest cost for the service. However, because there are only three claims for HCPCS code C9782 from the CY 2023 claims data, we had concerns that the universal low volume APC policy calculations would not accurately capture the cost of the service. Given our proposal to maintain current New Technology APC assignments for CY 2025 for New Technology APC services with fewer than 10 claims in the 4-year lookback period applicable for the universal low-volume APC policy, we proposed to continue to assign HCPCS code C9782 to New Technology APC 1590 with a payment rate of $17,050.50.</P>
                    <P>Please refer to Table 29 below for the proposed OPPS New Technology APC and status indicator assignments for HCPCS code C9782 for CY 2025. The proposed CY 2025 payment rates can be found in Addendum B to the CY 2025 OPPS/ASC proposed rule via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="261">
                        <GID>ER27NO24.052</GID>
                    </GPH>
                    <P>We did not receive any public comments on our proposal and are finalizing it without modification. HCPCS code C9782 will be assigned to New Technology APC 1590 with a status indication of “T” for CY 2025. Please refer to Table 30 for the final OPPS New Technology APC and status indicator assignment for CPT code C9782. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="301">
                        <PRTPAGE P="94029"/>
                        <GID>ER27NO24.053</GID>
                    </GPH>
                    <HD SOURCE="HD3">g. Atherosclerosis Imaging-Quantitative Computer Tomography (AI-QCT) (APC 1511)</HD>
                    <P>Atherosclerosis Imaging-Quantitative Computer Tomography (AI-QCT) is a Software as a Service (SaaS) that assesses the extent of coronary artery disease severity. This procedure is performed to quantify the extent of coronary plaque and stenosis in patients who have undergone coronary computed tomography analysis (CCTA). The AMA CPT Editorial Panel established the following four codes associated with this service, effective January 1, 2021:</P>
                    <P>
                        <E T="03">0623T:</E>
                         Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation, and report.
                    </P>
                    <P>
                        <E T="03">0624T:</E>
                         Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission.
                    </P>
                    <P>
                        <E T="03">0625T:</E>
                         Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography.
                    </P>
                    <P>
                        <E T="03">0626T:</E>
                         Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report.
                    </P>
                    <P>Of these four CPT codes, only CPT code 0625T was determined to be separately payable in the OPPS and was assigned to status indicator = “S” (Procedure or Service, Not Discounted When Multiple) starting October 1, 2022. We assigned CPT code 0625T to a separately payable status indicator based on the technology and its potential utilization in the HOPD setting, our evaluation of the service, as well as input from our medical advisors. The procedure was assigned to APC 1511 (New Technology—Level 11 ($900-$1000)) with a payment rate of $950.50.</P>
                    <P>
                        For CY 2024, the OPPS payment rates were proposed to be based on available CY 2022 claims data. There were 37 claims for CPT code 0625T during this time period. As this was below the threshold of 100 claims for a service within a year, we explained that we could propose to designate CPT code 0625T as a low volume service under our universal low volume New Technology APC policy and use the highest of the geometric mean cost, arithmetic mean cost, or median cost based on up to 4 years of claims data to assign code 0625T to the appropriate New Technology APC. We found the geometric mean cost for the service to be approximately $3.70, the arithmetic mean cost to be approximately $4.10, and the median cost to be approximately $3.50. Under our universal low volume New Technology APC policy, we would use the greatest of the statistical methodologies, the arithmetic mean, to assign CPT code 0625T to New Technology 1491 (New Technology Level 1A—(0-$10)) with a payment rate of $5.00. However, we acknowledged that, because CPT code 0625T was only made separately payable as part of the OPPS in October 2022, and, therefore, the claims available only reflect two months of data, we were concerned that we did not have sufficient claims data to justify reassignment to another New Technology APC (66 FR 69902). Therefore, consistent with our current policy to retain services within New Technology APC groups until we obtain sufficient claims data to justify reassignment (66 FR 59902), for CY 2024 we adopted as final our proposal 
                        <PRTPAGE P="94030"/>
                        to maintain CPT code 0625T's current assignment to APC 1511 (New Technology—Level 11 ($901-$1000) with a payment rate of $950.50.
                    </P>
                    <P>For setting CY 2025 payment rates, there were only three separately payable claims in the CY 2023 data reported for CPT code 0625T indicating a geometric mean cost of approximately $180, which is substantially lower than the code's current payment rate of $950.50. Additionally, in CY 2022 and CY 2023, there were a total of 40 separately payable claims reported for CPT code 0625T, but it is unlikely that a service with a current payment rate of $950.50 would have a geometric mean of $4.20, an arithmetic mean of $6.60, and a median of $3.52. These findings lead to uncertainty about the appropriate payment rate for the service described by CPT code 0625T. A review of the evidence submitted by the developer of the procedure when this procedure was originally assigned to a New Technology APC, and before any claims data were available, indicated the procedure had a cost between $901 and $1,000. Claims for CPT code 0625T from CY 2021 and CY 2022 indicate that the cost of the procedure is less than $10, which would not appear to cover the basic cost of this procedure, including computing time, generating a report, and having medical personnel interpret the report. For CY 2023, the geometric mean cost of approximately $180 based on three claims may better reflect the cost of the procedure described by CPT code 0625T, but there were not enough claims to be confident about the result. Therefore, we proposed to use our authority under section 1833(t)(2)(E) for CY 2025 to continue to assign CPT code 0625T to APC 1511 (New Technology—Level 11 ($901-$1000) with a payment rate of $950.50 based on the data currently available to us, which we believe best reflects the cost of the service as described by the New Technology APC application.</P>
                    <P>Refer to Table 31 for the proposed OPPS New Technology APC and status indicator assignments for CPT code 0625T for CY 2025.</P>
                    <GPH SPAN="3" DEEP="205">
                        <GID>ER27NO24.054</GID>
                    </GPH>
                    <P>
                        <E T="03">Comment:</E>
                         We received several comments supporting the assignment of CPT code 0625T to APC 1511 (New Technology—Level 11 ($901-$1000) for CY 2025.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their support. We note that since the CY 2025 OPPS/ASC proposed rule was issued, two additional claims for CPT code 0625T have been processed, with the updated geometric mean cost increasing to approximately $498. Although we have two additional claims, we are not certain that we have enough claims data to be confident in the calculated geometric mean cost for CPT code 0625T. Therefore, we are finalizing our proposal, without modification, to continue to assign CPT code 0625T to APC 1511 (New Technology—Level 11 ($901-$1000). Please refer to Table 32 for the final OPPS New Technology APC and status indicator assignment for CPT code 0625T. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website.
                    </P>
                    <GPH SPAN="3" DEEP="205">
                        <PRTPAGE P="94031"/>
                        <GID>ER27NO24.055</GID>
                    </GPH>
                    <HD SOURCE="HD3">h. Corvia Medical Interatrial Shunt Procedure (APC 1592)</HD>
                    <P>On July 1, 2020, we established HCPCS code C9760 (Non-randomized, non-blinded procedure for nyha class ii, iii, iv heart failure; transcatheter implantation of interatrial shunt, including right and left heart catheterization, transeptal puncture, trans-esophageal echocardiography (tee)/intracardiac echocardiography (ice), and all imaging with or without guidance (for example, ultrasound, fluoroscopy) performed in an approved investigational device exemption (ide) study, performed in an approved investigational device exemption (ide) study) to facilitate payment for the implantation of the Corvia Medical interatrial shunt.</P>
                    <P>As we stated in the CY 2021 OPPS final rule with comment period (85 FR 85947), we believe that similar resources and device costs are involved with the Corvia Medical interatrial shunt procedure and the V-Wave interatrial shunt procedure. Unlike the V-Wave interatrial shunt, which is implanted half the time the associated interatrial shunt procedure described by HCPCS code C9758 is billed, the Corvia Medical interatrial shunt is implanted every time the associated interatrial shunt procedure (HCPCS code C9760) is billed. Therefore, for CY 2021, we assigned HCPCS code C9760 to New Technology APC 1592 (New Technology—Level 41 ($25,001-$30,000)) with a payment rate of $27,500.50. We also modified the code descriptor for HCPCS code C9760 to remove the phrase “or placebo control,” from the descriptor. In CY 2022, we generally used the same claims data as was used in the CY 2021 OPPS final rule to set the payment rates for that year. Accordingly, because there were no claims for this service in CY 2019, we continued to assign HCPCS code C9760 to New Technology APC 1592 in CY 2022. There continued to be no claims data for this service in CY 2021, so we continued to assign HCPCS code C9760 to New Technology APC 1592 in CY 2023, the year for which we used CY 2021 data for ratesetting. While there was one claim in CY 2022, we continued to assign HCPCS code C9760 to New Technology APC 1592 for CY 2024 due to the extremely limited claims data available.</P>
                    <P>For CY 2025, the OPPS payment rates were proposed to be based on available CY 2023 claims data. There were no claims for HCPCS code C9760 in CY 2023. Therefore, we proposed to continue assigning HCPCS code C9760 to New Technology APC 1592.</P>
                    <P>Please refer to Table 33 for the proposed OPPS New Technology APC and status indicator assignments for HCPCS code C9760. The proposed CY 2025 payment rates can be found in Addendum B to the CY 2025 OPPS/ASC proposed rule via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="227">
                        <PRTPAGE P="94032"/>
                        <GID>ER27NO24.056</GID>
                    </GPH>
                    <P>We did not receive any public comments on our proposal, and we still do not have any claims for the service. Therefore, for CY 2025, we are finalizing our proposal without modification. Specifically for CY 2025, we are assigning HCPCS code C9760 to APC 1592 (New Technology—Level 41 ($25,001-$30,000)) with a payment rate of $27,500.50.</P>
                    <P>Please refer to Table 34 below for the final OPPS New Technology APC and status indicator assignments for HCPCS code C9760 for CY 2025. The CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="213">
                        <GID>ER27NO24.057</GID>
                    </GPH>
                    <HD SOURCE="HD3">i. DARI Motion Procedure (APC 1505)</HD>
                    <P>
                        Effective January 1, 2022, CPT code 0693T (Comprehensive full body computer-based markerless 3D kinematic and kinetic motion analysis and report) is associated with the DARI Motion Procedure, a service that provides human motion analysis to aid clinicians in pre- and post-operative surgical intervention and in making other treatment decisions, including selecting the best course of physical therapy and rehabilitation. The technology consists of eight cameras that surround a patient, which send live video to a computer workstation that analyzes the video to create a 3D reconstruction of the patient without the need for special clothing, markers, or devices attached to the patient's clothing or skin. For CY 2022, we assigned CPT code 0693T to New Technology APC 1505 (New Technology—Level 5 ($301-$400)). For CY 2023, the OPPS payment rates were based on claims submitted between January 1, 2021, and December 31, 2021, processed through June 30, 2022. Due to its effective date of January 1, 2022, there were no claims available for CPT 
                        <PRTPAGE P="94033"/>
                        code 0693T for rate setting in CY 2023. Therefore, in CY 2023, we continued to assign CPT code 0693T to New Technology APC 1505. For CY 2024, there were no claims available, so we again continued to assign CPT code 0693T to New Technology APC 1505.
                    </P>
                    <P>For CY 2025, the OPPS payment rates were proposed based on available CY 2023 claims data. Although CPT code 0693T was effective January 1, 2022, we have no claims data at this time. Because we have no claims data, for CY 2025, we proposed to continue to assign CPT code 0693T to APC 1505 with a proposed payment rate of $350.50.</P>
                    <P>Refer to Table 35 for the proposed OPPS New Technology APC and status indicator assignments for CPT code 0693T for CY 2025. The proposed CY 2025 payment rates can be found in Addendum B to the CY 2025 OPPS/ASC proposed rule via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="132">
                        <GID>ER27NO24.058</GID>
                    </GPH>
                    <P>We did not receive any public comments on our proposal, and we still do not have any claims for the service. Therefore, for CY 2025, we are finalizing our proposal without modification. Specifically, for CY 2025, we are assigning CPT code 0693T to APC 1505 with a status indicator of “S”. The final New Technology APC and status indicator assignments for CPT code 0693T for CY 2025 are found in Table 36. The CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="185">
                        <GID>ER27NO24.059</GID>
                    </GPH>
                    <HD SOURCE="HD3">j. Instillation of Anti-Neoplastic Pharmacologic/Biologic Agent Into Renal Pelvis (APC 1558)</HD>
                    <P>Effective October 1, 2023, CMS established HCPCS code C9789 (Instillation of anti-neoplastic pharmacologic/biologic agent into renal pelvis, any method, including all imaging guidance, including volumetric measurement if performed) and assigned it to New Technology APC 1559 (New Technology—Level 22 ($2001-$2500)), with a payment rate of $2,250.50 based on our review of the clinical and resource characteristics of this service.</P>
                    <P>
                        This code may be used to describe the unique procedure associated with the administration of the drug described by HCPCS code J9281 (Mitomycin pyelocalyceal instillation, 1 mg) or similar products. HCPCS code J9281 may be used to describe the product, Jelmyto (mitomycin for pyelocalyceal solution). The FDA approved Jelmyto in 2020, and the FDA approved indication and usage for Jelmyto is as an alkylating drug indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUS).
                        <SU>22</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>22</SU>
                             Jelmyto Package Insert. 01/14/2021. 
                            <E T="03">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211728s002lbl.pdf.</E>
                        </P>
                    </FTNT>
                    <P>
                        Because we created HCPCS code C9789 effective October 1, 2023, we have limited claims data from CY 2023 available for CY 2025 rulemaking. Specifically, we only had 6 claims available. Given our proposal to 
                        <PRTPAGE P="94034"/>
                        maintain current New Technology APC assignments for CY 2025 for New Technology APC services with fewer than 10 claims in the 4-year lookback period applicable for the universal low-volume APC policy, we proposed to continue to assign HCPCS code C9789 to New Technology APC 1559 (New Technology—Level 22 ($2001-$2500)).
                    </P>
                    <P>Please refer to Table 37 for the proposed OPPS New Technology APC and status indicator assignments for CPT code C9789 for CY 2025.</P>
                    <GPH SPAN="3" DEEP="211">
                        <GID>ER27NO24.060</GID>
                    </GPH>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment in support of our proposal.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their support.
                    </P>
                    <P>Our updated claims data during the 4-year lookback period applicable for the universal low-volume APC policy continues to show only 6 claims for HCPCS code C9789. Therefore, we are finalizing our proposal without modification to continue assigning HCPCS code C9758 to New Technology APC 1559 (New Technology—Level 22 ($2001-$2500)). Please refer to Table 38 below for the final OPPS New Technology APC and status indicator assignment for HCPCS code C9789 for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="197">
                        <GID>ER27NO24.061</GID>
                    </GPH>
                    <HD SOURCE="HD3">k. LimFlow TADV Procedure CPT Code 0620T (APC 1579)</HD>
                    <P>
                        The LimFlow TADV procedure, which is described by CPT code 0620T (Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed), is an endovascular procedure that is used 
                        <PRTPAGE P="94035"/>
                        to treat patients with chronic limb-threatening ischemia. According to the developer, these patients are no longer eligible for conventional endovascular or open bypass surgery to treat their artery blockage, and without this procedure, they are likely to face limb amputation.
                    </P>
                    <P>CPT code 0620T was established in January 2021 and was assigned to APC 5194 (Level 4 Endovascular Procedures) with a payment rate of approximately $17,400, which is the highest-paying APC for endovascular procedures. While we proposed to continue to assign CPT code 0620T to APC 5194 for CY 2024, we finalized a reassignment from a clinical APC to a New Technology APC with a higher payment rate based on comments received expressing concern that the low payment rate of the procedure would discourage providers from performing the procedure and deny access to the procedure. To determine the appropriate New Technology APC assignment for CY 2024, we looked at the available cost information. There were only 15 claims for the procedure for CY 2021 and CY 2022, so the LimFlow TADV procedure was subject to our new technology procedure low volume APC policy. An analysis of the median, arithmetic mean, and geometric mean of CPT code 0620T for CY 2024 rulemaking found that the median was approximately $25,800, the arithmetic mean was approximately $28,600, and the geometric mean was approximately $26,700. Because the arithmetic mean had the highest value of the three cost statistics, for CY 2024, we assigned CPT code 0620T to New Technology APC 1578 (New Technology—Level 41 ($25,001-$30,000)) with a payment rate of $27,500.50.</P>
                    <P>For CY 2025, the OPPS payment rates were proposed to be based on available CY 2023 claims data. We identified only six single frequency claims for CPT code 0620T in the CY 2023 claims data. As this is below the threshold of 100 claims for a service within a year, we proposed to again apply our universal low volume APC policy and use the highest of the geometric mean cost, arithmetic mean cost, or median cost based on up to 4 years of claims data to assign the service to the appropriate New Technology APC. Based on our review of the available claims, we determined that the arithmetic mean was approximately $35,000; the median was approximately $36,000; and the geometric mean cost was approximately $33,000. Of these, the median was the statistical methodology that estimated the highest cost for the service. The payment rate calculated using this methodology fell within the cost band for New Technology APC 1579 (New Technology—Level 42 ($30,001-$40,000)) with a payment rate of $35,000.50. Therefore, for CY 2025, we proposed to designate this service as a low volume service under our universal low volume APC policy and to assign HCPCS code 0620T to New Technology APC 1579.</P>
                    <GPH SPAN="3" DEEP="235">
                        <GID>ER27NO24.062</GID>
                    </GPH>
                    <P>
                        <E T="03">Comment:</E>
                         We received a comment from the manufacturer supporting our proposal to designate CPT code 0620T as a low volume service under the universal low volume APC policy and assign the service to New Technology APC 1579 for CY 2025, as they believe the proposed assignment more accurately reflects the resources used in the procedure.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their support.
                    </P>
                    <P>We note that there are an additional five claims for CPT code 0620T for CY 2023 that have been processed since the proposed rule. Based on the 11 single frequency claims available for CY 2023, in addition to the other 26 claims in the 4-year lookback period, we determined that the arithmetic mean is $35,700; the median is $36,400; and the geometric mean cost is $33,900. Since the total number of claims for CPT code 0620T for CY 2023 is still below the 100-claim threshold, we are finalizing our proposal to designate 0620T as a low volume service under the universal low volume APC policy. The payment rate calculated using the highest of these methodologies, the median, continues to fall within the cost band for New Technology APC 1579 (New Technology—Level 42 ($30,001-$40,000)) with a payment rate of $35,000.50. Therefore, we are also finalizing our proposal without modification to assign CPT code 0620T to New Technology APC 1579 for CY 2025.</P>
                    <P>
                        Please refer to Table 40 for the final OPPS New Technology APC and status indicator assignments for CPT code 
                        <PRTPAGE P="94036"/>
                        0662T for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.
                    </P>
                    <GPH SPAN="3" DEEP="235">
                        <GID>ER27NO24.063</GID>
                    </GPH>
                    <HD SOURCE="HD3">l. Liver Histotripsy Service (APC 1576)</HD>
                    <P>
                        CPT code 0686T (Histotripsy (
                        <E T="03">i.e.,</E>
                         non-thermal ablation via acoustic energy delivery) of malignant hepatocellular tissue, including image guidance) was first effective July 1, 2021, and describes the histotripsy service associated with the use of the HistoSonics system. Histotripsy is a non-invasive, non-thermal, mechanical process that uses a focused beam of sonic energy to destroy cancerous liver tumors and is currently in a non-randomized, prospective clinical trial to evaluate the efficacy and safety of the device for the treatment of primary or metastatic tumors located in the liver.
                        <SU>23</SU>
                        <FTREF/>
                         When HCPCS code 0686T was first effective, the histotripsy procedure was designated as a Category A IDE clinical study (NCT04573881). Since devices in Category A IDE studies are excluded from Medicare payment, payment for CPT code 0686T only reflected the cost of the service that is performed (absent the cost of the device) each time it is reported on a claim. On March 2, 2023, the histotripsy IDE clinical study was re-designated as a Category B (Non-experimental/Investigational) IDE study. Due to this new designation, payment for CPT code 0686T in CY 2024 reflects payment for both the service that is performed and the device used each time it is reported on a claim. For CY 2024, we assigned CPT code 0686T to New Technology APC 1576 (New Technology—Level 39 ($15,001-$20,000)) with a payment rate of $17,500.50.
                    </P>
                    <FTNT>
                        <P>
                            <SU>23</SU>
                             
                            <E T="03">ClinicalTrials.gov.</E>
                             “The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER) (#HOPE4LIVER).” Accessed May 10, 2022. 
                            <E T="03">https://clinicaltrials.gov/ct2/show/study/NCT04573881</E>
                            .
                        </P>
                    </FTNT>
                    <P>For CY 2025, proposed OPPS payment rates were based on available CY 2023 claims data. We have identified one claim for CPT code 0686T within the CY 2023 claims data. As the available claims data is below the threshold of 100 claims for a service within a year, we would propose to designate CPT code 0686T as a low volume service under our universal low volume APC policy, and use the highest of the geometric mean cost, arithmetic mean cost, or median cost to assign CPT code 0686T to the appropriate New Technology APC. However, because there is only a single claim in the CY 2023 data, we have concerns that the universal low volume APC policy calculations do not accurately capture the cost of the service.</P>
                    <P>Given our proposal to maintain current New Technology APC assignments for CY 2025 for New Technology APC services with fewer than 10 claims in the 4-year lookback period applicable for the universal low volume APC policy, and based on the fact that there have only been 3 claims for CPT code 0686T in the prior 4-year period, we proposed to continue to assign CPT code 0686T to APC 1576 (New Technology—Level 39 ($15,001-$20,000)) with a payment rate of $17,500.50 as shown in Table 25.</P>
                    <P>Please refer to Table 41 for the proposed OPPS New Technology APC and status indicator assignments for CPT code 0686T for CY 2025. The proposed CY 2025 payment rates can be found in Addendum B to the CY 2025 OPPS/ASC proposed rule.</P>
                    <GPH SPAN="3" DEEP="192">
                        <PRTPAGE P="94037"/>
                        <GID>ER27NO24.064</GID>
                    </GPH>
                    <P>We did not receive any public comments on our proposal and are finalizing it without modification. HCPCS code 0686T will be assigned to New Technology APC 1576 with a status indication of “S” for CY 2025. Please refer to Table 42 below for the final OPPS New Technology APC and status indicator assignment for CPT code 0686T. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="152">
                        <GID>ER27NO24.065</GID>
                    </GPH>
                    <HD SOURCE="HD3">m. LiverMultiScan Service (APC 1511)</HD>
                    <P>
                        Effective July 1, 2021, CPT codes 0648T (Quantitative magnetic resonance for analysis of tissue composition (
                        <E T="03">e.g.,</E>
                         fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic mri examination of the same anatomy (
                        <E T="03">e.g.,</E>
                         organ, gland, tissue, target structure) during the same session; single organ) and 0649T (Quantitative magnetic resonance for analysis of tissue composition (
                        <E T="03">e.g.,</E>
                         fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic mri examination of the same anatomy (
                        <E T="03">e.g.,</E>
                         organ, gland, tissue, target structure); single organ (list separately in addition to code for primary procedure)) are associated with the LiverMultiScan service. LiverMultiScan is a Software as a medical Service (SaaS) that is intended to aid the diagnosis and management of chronic liver disease, the most prevalent of which is Non-Alcoholic Fatty Liver Disease (NAFLD). It provides standardized, quantitative imaging biomarkers for the characterization and assessment of inflammation, hepatocyte ballooning, and fibrosis, as well as steatosis, and iron accumulation. LiverMultiScan receives MR images acquired from patients' providers and analyzes the images using their proprietary Artificial Intelligence (AI) algorithms. It then sends the providers a quantitative metric report of the patient's liver fibrosis and inflammation. In accordance with our SaaS add-on codes policy (87 FR 72032 to 72033), SaaS CPT add-on codes are assigned to the same APCs and status indicators as their standalone codes. Thus, CPT code 0649T, the add-on code for LiverMultiScan, is assigned to the identical APC and status indicator as CPT code 0648T, the standalone code for the same service. For CY 2024, we assigned CPT codes 0648T and 0649T to New Technology APC 1511 (New Technology—Level 11 ($901-$1,000) with a payment rate of $950.50.
                    </P>
                    <P>
                        For CY 2025, the OPPS payment rates were proposed to be based on available CY 2023 claims data. We identified 71 claims for CPT code 0648T and 72 claims for CPT code 0649T for CY 2023. As this is below the threshold of 100 claims for each code within a year, we 
                        <PRTPAGE P="94038"/>
                        proposed to utilize our universal low volume APC policy and use the highest of the geometric mean cost, arithmetic mean cost, or median cost based on up to 4 years of claims data to assign CPT codes 0648T and 0649T to the appropriate New Technology APC. There are available claims data from CY 2021 and CY 2022 for CPT codes 0648T and 0649T. Our analysis of the combined data, 114 claims for CPT code 0648T and 115 claims for CPT code 0649T, yielded a geometric mean cost of approximately $180, an arithmetic mean cost of approximately $234, and a median cost of approximately $197. We explained that we believed it was appropriate to utilize our universal low volume APC policy to assign the LiverMultiScan service to a New Technology APC because we stated that we believed that the combined claims data from CY 2021 to CY 2023 provided sufficient claims to capture the cost of the service. The arithmetic mean was the statistical methodology that estimated the highest cost for CPT codes 0648T and 0649T. Therefore, we proposed to reassign CPT codes 0648T and 0649T to New Technology APC 1504 (New Technology—Level 4 ($201-$300)) with a payment rate of $250.50 as shown in Table 43.
                    </P>
                    <GPH SPAN="3" DEEP="324">
                        <GID>ER27NO24.066</GID>
                    </GPH>
                    <P>
                        <E T="03">Comment:</E>
                         We received several comments, including a comment from the manufacturer, requesting that we maintain the APC assignment for the CPT codes 0648T and 0649T at APC 1511. Many commenters stated that the cost of each of the services is at least $950, and that the proposed payment rate of $250 would be inadequate to ensure patient access. Commenters noted that the claims data used to determine the CY 2025 OPPS proposed APC assignment for this service represent an insufficient number of claims to estimate the cost for this service. One commenter expressed concern about the wide data variability present in the claims data for CPT codes 0648T and 0649T. One commenter requested that we develop a payment policy for SaaS like CPT codes 0648T and 0649T that results in appropriate and consistent payment for innovative new services. We also received one comment signed by ten radiologists stating that the current payment rate for the procedures was too high.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We recognize that software-based technologies, like those described by CPT codes 0648T and 0649T, are rapidly evolving and, therefore, we are considering for future rulemaking whether specific adjustments to payment policies, including our New Technology APC policies, are needed to more accurately and appropriately pay for these products and services across settings of care. For CY 2025, we recognize that the few claims available for CPT codes 0648T and 0649T may not truly represent the cost of this service. While we received a comment expressing concern over the potential overpayment of the service, we do not believe we have sufficient claims to justify a reassignment at this time. Therefore, we agree with the commenters that, for both CPT codes 0648T and 0649T, we should maintain the payment rates for CY 2025 until we have additional claims data.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter supported the proposed reassignment of CPT codes 0648T and 0649T to New Technology APC 1504. The commenter stated that the payment rate of $950 created a paradigm where the third-party automated quantitative analytic service was valued greater than the MRI procedure that included technologist staffing, professional interpretation and liability. The commenter believed that the payment of the service should be 
                        <PRTPAGE P="94039"/>
                        based on the true cost of these automated digital quantitative services at New Technology APC 1504.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for its support of our proposal. We reiterate that the few claims for CPT codes 0648T and 0649T may not truly represent the cost of this service or justify a reassignment at this time.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal with modifications. We are using our equitable adjustment authority under section 1833(t)(2)(E) to continue to assign CPT codes 0648T and 0649T to New Technology APC 1511 (New Technology—Level 11 ($901-$1,000) with a payment rate of $950.50 for CY 2025. Please refer to Table 44 below for the final OPPS New Technology APC and status indicator assignments for CPT codes 0648T and 0649T for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="324">
                        <GID>ER27NO24.067</GID>
                    </GPH>
                    <HD SOURCE="HD3">n. Optellum Lung Cancer Prediction (LCP) (APC 1508)</HD>
                    <P>CPT codes 0721T (Quantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging) and 0722T (Quantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained with concurrent CT examination of any structure contained in the concurrently acquired diagnostic imaging dataset (list separately in addition to code for primary procedure)) became effective July 1, 2022, and are associated with the Optellum LCP technology. The Optellum LCP applies an algorithm to a patient's CT scan to produce a raw risk score for a patient's pulmonary nodule. The physician uses the risk score to quantify the risk of lung cancer and to determine what the next management step should be for the patient (for example, CT surveillance versus invasive procedure). In accordance with our SaaS add-on codes policy (87 FR 72032 and 72033), SaaS CPT add-on codes are assigned to the same APCs and status indicators as their standalone codes. Thus, CPT code 0722T, the add-on code for the Optellum LCP service, is assigned to the identical APC and status indicator as CPT code 0721T, the standalone code for the same service. For CY 2024, we assigned CPT codes 0721T and 0722T to APC New Technology 1508 (New Technology—Level 8 ($601-$700)).</P>
                    <P>
                        For CY 2025, the OPPS payment rates were proposed based on available CY 2023 claims data. We identified three claims for CPT codes 0721T and 0722T for ratesetting for CY 2025. As this is below the threshold of 100 claims for a service within a year, we would usually propose to apply our universal low volume APC policy and use the highest of the geometric mean cost, arithmetic mean cost, or median cost based on up to 4 years of claims data to assign CPT codes 0721T and 0722T to the appropriate New Technology APC. There are available claims data only from CY 2023 for CPT codes 0721T and 0722T. Our analysis of the data for CPT code 0721T found the geometric mean cost of the service is approximately $84, the arithmetic mean cost of the service is approximately $98, and the median 
                        <PRTPAGE P="94040"/>
                        cost of the service is approximately $130. We did not identify any reported claims for CPT code 0722T. However, because there were only three claims for the Optellum LCP service and these claims show a much lower cost than would be expected based on the current APC assignment of this service, we have concerns that the universal low volume APC policy calculations do not accurately capture the cost of the service. Given our proposal to maintain current New Technology APC assignments for CY 2025 for New Technology APC services with fewer than 10 claims in the 4-year lookback period applicable for the universal low-volume APC policy, we proposed to continue to assign CPT codes 0721T and 0722T to New Technology APC 1508 (New Technology—Level 8 ($601-$700)) with a proposed payment rate of $650.50.
                    </P>
                    <P>Please refer to Table 45 below for the proposed OPPS New Technology APC and status indicator assignments for HCPCS codes 0721T and 0722T for CY 2025. The proposed CY 2025 payment rates can be found in Addendum B to the CY 2025 OPPS/ASC proposed rule via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="294">
                        <GID>ER27NO24.068</GID>
                    </GPH>
                    <P>We did not receive any public comments on our proposal, and we are finalizing our proposal without modification. We are assigning HCPCS codes 0721T and 0722T to New Technology APC 1508 with a status indication of “S” for CY 2025. Please refer to Table 46 below for the final OPPS New Technology APC and status indicator assignment for CPT codes 0721T and 0722T. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="288">
                        <PRTPAGE P="94041"/>
                        <GID>ER27NO24.069</GID>
                    </GPH>
                    <HD SOURCE="HD3">o. Quantitative Magnetic Resonance (QMR) for Analysis of Tissue Composition (APC 1511)</HD>
                    <P>
                        Effective January 1, 2022, CPT codes 0697T (Quantitative magnetic resonance for analysis of tissue composition (
                        <E T="03">e.g.,</E>
                         fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic mri examination of the same anatomy (
                        <E T="03">e.g.,</E>
                         organ, gland, tissue, target structure) during the same session; multiple organs) and 0698T (Quantitative magnetic resonance for analysis of tissue composition (
                        <E T="03">e.g.,</E>
                         fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic mri examination of the same anatomy (
                        <E T="03">e.g.,</E>
                         organ, gland, tissue, target structure); multiple organs (list separately in addition to code for primary procedure)) are associated with the CoverScan Software as a medical Service (SaaS). This service is a medical image management and processing software package that analyzes MR data and provides quantified metrics of multiple organs such as the heart, lungs, liver, spleen, pancreas, and kidney. In accordance with our SaaS add-on codes policy (87 FR 72032 to 72033), SaaS CPT add-on codes are assigned to the same APCs and status indicators as their standalone codes. Thus, CPT code 0698T, the add-on code for CoverScan is be assigned to the same APC and status indicator as CPT code 0697T, the standalone code for the same service. For CY 2024, we assigned CPT codes 0697T and 0698T to New Technology APC 1511 (New Technology—Level 11 ($900-$1,000)).
                    </P>
                    <P>For CY 2025, the proposed OPPS payment rates were based on available CY 2023 claims data. We identified 48 claims for CPT code 0698T and no claims for CPT code 0697T in CY 2023. As this is below the threshold of 100 claims for a service within a year, we proposed to apply our universal low volume APC policy and use the highest of the geometric mean cost, arithmetic mean cost, or median cost based on up to 4 years of claims data to assign CPT codes 0697T and 0698T to the appropriate New Technology APC. There are also available claims data from CY 2022 for CPT code 0698T. Our analysis of the combined data, approximately 80 claims, yielded a geometric mean cost of approximately $444, an arithmetic mean cost of approximately $622, and a median cost of approximately $786. The median cost is the statistical methodology that estimates the highest cost for CPT codes 0697T and 0698T. Therefore, we proposed, for CY 2025, to reassign CPT codes 0697T and 0698T to APC 1509 (New Technology—Level 9 ($701-$800)) with a payment rate of $750.50.</P>
                    <P>Refer to Table 47 below for the proposed OPPS New Technology APC and status indicator assignments for CPT codes 0697T and 0698T for CY 2025. The proposed CY 2025 payment rates can be found in Addendum B to the CY 2025 OPPS/ASC proposed rule via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="339">
                        <PRTPAGE P="94042"/>
                        <GID>ER27NO24.070</GID>
                    </GPH>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters requested that we maintain the APC assignment for the CPT codes 0697T and 0698T at APC 1511 for CY 2025. Many commenters stated that the cost of each of the services is at least $950, and that the proposed payment rate of $750 does not cover the cost of this service. One commenter noted that the claims data used to determine the CY 2025 OPPS proposed rate for this service represent an insufficient number of claims to estimate the cost for this service. Additionally, the commenter stated that wide variability in claims data distorts the applicability of the universal low volume APC policy and skews the arithmetic mean value. Commenters were concerned that the proposed payment rate would hinder patient access to these services.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We recognize that software-based technologies, like those described by CPT codes 0697T and 0698T, are rapidly evolving and, therefore, we are considering for future rulemaking whether specific adjustments to payment policies, including our New Technology APC policies, are needed to more accurately and appropriately pay for these products and services across settings of care. For CY 2025, we recognize that the few claims available for CPT codes 0697T and 0698T may not truly represent the cost of this service. We agree with the commenters that, for both CPT codes 0697T and 0698T, we should maintain the payment rates for CY 2025 until we have additional claims data.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal with modifications. We will use our equitable adjustment authority under section 1833(t)(2)(E) to continue to assign CPT codes 0697T and 0698T to New Technology APC 1511 (New Technology—Level 11 ($901-$1,000) with a payment rate of $950.50 for CY 2025. Please refer to Table 48 below for the final OPPS New Technology APC and status indicator assignments for CPT codes 0697T and 0698T for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="354">
                        <PRTPAGE P="94043"/>
                        <GID>ER27NO24.070</GID>
                    </GPH>
                    <HD SOURCE="HD3">p. Quantitative Magnetic Resonance Cholangiopancreatography (QMRCP) (APC 1511)</HD>
                    <P>
                        Effective July 1, 2022, CPT codes 0723T (Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained without diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (
                        <E T="03">e.g.,</E>
                         organ, gland, tissue, target structure) during the same session) and 0724T (Quantitative magnetic resonance cholangiopancreatography (QMRCP), including data preparation and transmission, interpretation and report, obtained with diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (
                        <E T="03">e.g.,</E>
                         organ, gland, tissue, target structure) (list separately in addition to code for primary procedure)) are associated with the QMRCP Software as a medical Service (SaaS). The service performs quantitative assessment of the biliary tree and gallbladder. It uses a proprietary algorithm that produces a three-dimensional reconstruction of the biliary tree and pancreatic duct and also provides precise quantitative information of biliary tree volume and duct metrics. In accordance with our SaaS add-on codes policy (87 FR 72032 and 72033), SaaS CPT add-on codes are assigned to the same APCs and status indicators as their standalone codes. Consistent with our SaaS add-on codes policy, CPT code 0724T, the add-on code for QMRCP is assigned to the identical APC and status indicator as CPT code 0723T, the standalone code for the same service. For CY 2024, we assigned CPT codes 0723T and 0724T to New Technology APC 1511 (New Technology—Level 11 ($900-$1,000)).
                    </P>
                    <P>For CY 2025, the proposed OPPS payment rates were based on available CY 2023 claims data. We identified 3 claims for CPT code 0724T and no claims for CPT code 0723T in CY 2023. As this is below the threshold of 100 claims for a service within a year, we would usually propose to apply our universal low volume APC policy and use the highest of the geometric mean cost, arithmetic mean cost, or median cost based on up to 4 years of claims data to assign CPT codes 0723T and 0724T to the appropriate New Technology APC. There is only one single claim from CY 2022 for CPT code 0724T and no claims for CPT code 0723T. For CY 2023, we received 3 claims for CPT code for CPT 0724T and no claims for CPT code 0723T. Our analysis of the combined CY 2022 and CY 2023 data for CPT code 0723T and 0724T found the geometric mean cost of the service is approximately $26, the arithmetic mean cost of the service is approximately $26, and the median cost of the service is approximately $27. Given our proposal to maintain current New Technology APC assignments for CY 2025 for New Technology APC services with fewer than 10 claims in the 4-year lookback period applicable for the universal low volume APC policy, we proposed to continue to assign the CPT codes 0723T and 0724T to New Technology APC 1511 (New Technology—Level 11 ($901-$1,000)) with a payment rate of $950.50.</P>
                    <P>Refer to Table 49 for the proposed OPPS New Technology APC and status indicator assignments for CPT codes 0723T and 0724T for CY 2025.</P>
                    <GPH SPAN="3" DEEP="324">
                        <PRTPAGE P="94044"/>
                        <GID>ER27NO24.072</GID>
                    </GPH>
                    <P>We did not receive any public comments on our proposal to continue to assign the CPT codes 0723T and 0724T to New Technology APC 1511 (New Technology—Level 11 ($901-$1,000)). Our updated claims data did not show any additional claims for CY 2023 for CPT codes 0723T and 0724T. Therefore, we are finalizing our proposal without modification to continue to assign CPT codes 0723T and 0724T to APC 1511. Please refer to Table 50 for the final OPPS New Technology APC and status indicator assignment for CPT codes 0723T and 0724T for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="324">
                        <PRTPAGE P="94045"/>
                        <GID>ER27NO24.073</GID>
                    </GPH>
                    <HD SOURCE="HD3">q. Scalp Cooling (APC 1519)</HD>
                    <P>CPT code 0662T (Scalp cooling, mechanical; initial measurement and calibration of cap) became effective on July 1, 2021, to describe initial measurement and calibration of a scalp cooling device for use during chemotherapy administration to prevent hair loss. According to Medicare's National Coverage Determination (NCD) policy, specifically, NCD 110.6 (Scalp Hypothermia During Chemotherapy to Prevent Hair Loss), the scalp cooling cap itself is classified as an incident to supply to a physician service, and would not be paid under the OPPS; however, interested parties have indicated that there are substantial resource costs of around $1,900 to $2,400 associated with calibrating and fitting the cap. CPT guidance states that CPT code 0662T should be billed once per chemotherapy session, which we interpret to mean once per course of chemotherapy. Therefore, if a course of chemotherapy involves, for example, 6 or 18 sessions, HOPDs should report CPT 0662T only once for that 6 or 18 therapy sessions.</P>
                    <P>For CY 2022, we assigned CPT code 0662T to APC New Technology 1520 (New Technology—Level 20 ($1,801-$1,900)) with a payment rate of $1,850.50. For CY 2023, we did not have any claims data, so we continued to assign CPT code 0662T to APC 1520. For CY 2024 we finalized reassignment of CPT code 0662T to APC 1514 (New Technology—Level 14 ($1,201-$1,300)) with a payment rate of $1,250.50 based on 11 single frequency claims.</P>
                    <P>For CY 2025, the OPPS payment rates were proposed to be based on available CY 2023 claims data. The Scalp Cooling service became effective in the OPPS in CY 2022, and we identified 38 single frequency paid claims for CPT code 0662T for CY 2023. As this is below the threshold of 100 claims for a service within a year, we proposed to designate CPT code 0662T as a low volume service under our universal low volume APC policy and to use the highest of the geometric mean cost, arithmetic mean cost, or median cost based on up to 4 years of claims data to assign the service to the appropriate New Technology APC. Based on our review of the available claims, we determined that the geometric mean cost for CPT code 0662T was approximately $841; the median was approximately $1,351; and the arithmetic mean was approximately $1,361. Therefore, for CY 2025, we proposed to designate this service as a low volume service under our universal low volume APC policy and to reassign CPT code 0662T to APC 1515 (New Technology—Level 15 ($1301-$1400)) with a payment rate of $1,350.50 for CY 2025 based on the arithmetic mean of approximately $1,361.Please refer to Table 51 below for the proposed OPPS New Technology APC and status indicator assignment for CPT code 0662T. The proposed CY 2025 payment rates can be found in Addendum B CY 2025 OPPS/ASC proposed rule via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="103">
                        <PRTPAGE P="94046"/>
                        <GID>ER27NO24.074</GID>
                    </GPH>
                    <P>We did not receive any public comments on our proposal. We note that additional claims for CPT code 0662T have been processed since the proposed rule. Specifically, there are 50 single frequency claims for CPT code 0662T for CY 2023. Since this is below the threshold of 100 claims, we are finalizing our proposal to designate CPT code 0662T as a low volume service under our universal low volume APC policy and use the greater of the geometric mean, arithmetic mean, or median cost based on the available claims data for CPT code 0662T to calculate an appropriate payment rate for purposes of assigning CPT code 0662T to a New Technology APC. Based on the updated claims data available for this final rule, we found the geometric mean cost to be approximately $1,110, the median to be $1,750, and the arithmetic mean to be $1,420. The median was the statistical methodology that estimated the highest cost for the service. The payment rate calculated using this methodology falls within the cost band for New Technology APC 1519 (New Technology—Level 19 ($1701-$1800)). Therefore, we are assigning CPT code 0662T to APC 1519 for CY 2025.</P>
                    <P>Please refer to Table 52 for the final OPPS New Technology APC and status indicator assignments for CPT code 0662T for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="186">
                        <GID>ER27NO24.075</GID>
                    </GPH>
                    <HD SOURCE="HD3">r. Supervised Visits for Esketamine Self-Administration (APCs 1513 and 1518)</HD>
                    <P>
                        On March 5, 2019, FDA approved Spravato
                        <E T="51">TM</E>
                         (esketamine) nasal spray, used in conjunction with an oral antidepressant, for treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression (TRD)). This is the first FDA approval of esketamine for any use.
                    </P>
                    <P>Esketamine is a noncompetitive N-methyl D-aspartate (NMDA) receptor antagonist. It is a nasal spray supplied as an aqueous solution of esketamine hydrochloride in a vial with a nasal spray device. Each device delivers two sprays containing a total of 28 mg of esketamine. Patients would require either two (2) devices (for a 56 mg dose) or three (3) devices (for an 84 mg dose) per treatment.</P>
                    <P>
                        Because of the risk of serious adverse outcomes resulting from sedation and dissociation caused by esketamine nasal spray administration, and the potential for misuse of the product, it is only available through a restricted distribution system under a Risk Evaluation and Mitigation Strategy (REMS). A REMS is a drug safety program that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. The Spravato
                        <E T="51">TM</E>
                         REMS program requires the esketamine nasal spray to be dispensed and administered to enrolled patients in health care settings that are certified in the REMS. See 
                        <E T="03">www.fda.gov</E>
                         for more information regarding the Spravato
                        <E T="51">TM</E>
                         REMS program compliance requirements.
                    </P>
                    <P>
                        A treatment session of esketamine consists of instructed nasal self-administration by the patient followed by a period of at least 2 hours post-administration observation of the patient under direct supervision of a health care professional in the certified health care setting. Refer to the CY 2020 PFS final rule and interim final rule for 
                        <PRTPAGE P="94047"/>
                        more information about supervised visits for esketamine nasal spray self-administration (84 FR 63102 through 63105).
                    </P>
                    <P>To facilitate prompt beneficiary access to the new, potentially life-saving treatment for TRD using esketamine, we created two new HCPCS G codes, G2082 and G2083, effective January 1, 2020. HCPCS code G2082 is for an outpatient visit for the evaluation and management of an established patient who requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine through nasal self-administration and includes 2 hours of post-administration observation. For CY 2020, HCPCS code G2082 was assigned to New Technology APC 1508 (New Technology—Level 8 ($601-$700)) with a payment rate of $650.50. HCPCS code G2083 describes a similar service to HCPCS code G2082 but involves the administration of more than 56 mg of esketamine. For CY 2020, HCPCS code G2083 was assigned to New Technology APC 1511 (New Technology—Level 11 ($901-$1000)) with a payment rate of $950.50. Updates to the APC assignments for G2082 and G2083 have been made in past rules. See the CY 2021 OPPS/ASC final rule with comment period (85 FR 85948), CY 2022 OPPS/ASC final rule with comment period (86 FR 63538), CY 2023 OPPS/ASC final rule with comment period (87 FR 71816-71817), and CY 2024 OPPS/ASC final rule with comment period (88 FR 81628—81630) for these updates.</P>
                    <P>For CY 2025, the OPPS payment rates were proposed based on available CY 2023 claims data as the available single frequency claims exceed the 100 claims threshold generally used for our universal low volume policy. Therefore, for CY 2025, we proposed to assign HCPCS codes G2082 and G2083 to New Technology APCs based on the codes' geometric mean costs. Specifically, we proposed to assign HCPCS code G2082 to New Technology APC 1512 (New Technology—Level 12 ($1001-$1100)) with a payment rate of $1,050.50 based on its geometric mean cost of $1,087, which was calculated using the available 424 single frequency claims from CY 2023 claims data. We also proposed to assign HCPCS code G2083 to New Technology APC 1518 (New Technology—Level 18 ($1601-$1700)) with a payment rate of $1,650.50 based on its geometric mean cost of $1,643, which was calculated using the available 2,482 single frequency claims from CY 2023 claims data.</P>
                    <P>Refer to Table 53 for the New Technology APC and status indicator assignments for HCPCS codes G2082 and G2083. The proposed CY 2025 payment rates for these HCPCS codes can be found in Addendum B to the CY 2025 OPPS/ASC proposed rule.</P>
                    <GPH SPAN="3" DEEP="427">
                        <PRTPAGE P="94048"/>
                        <GID>ER27NO24.076</GID>
                    </GPH>
                    <P>We did not receive any public comments on our proposal. We note however that the geometric mean costs for both HCPCS code G2082 and HCPCS code G2083 have changed since the proposed rule. Based on the updated claims data available for this final rule, the geometric mean cost for HCPCS code G2082 is $1,104.71 and the geometric mean cost for G2083 is $1,448.83. Based on updated claims data available for this final rule with comment period, we are finalizing a New Technology APC assignment for HCPCS code G2082 to APC 1513 (New Technology—Level 13 ($1101-$1200)) with a payment of $1150.50 and we are finalizing a New Technology APC assignment for HCPCS code G2083 to APC 1516 (New Technology—Level 16 ($1401-$1500)) with a payment of $1450.50.</P>
                    <P>Please refer to Table 54 for the CY 2025 proposed and final APC and SI assignments for HCPCS codes G2082 and G2083. The CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website.</P>
                    <P>Finally, we note that because we have gathered additional claims data and seen increases in claims volume, we are considering placing HCPCS codes G2082 and G2083 into clinical APCs through future rulemaking.</P>
                    <GPH SPAN="3" DEEP="372">
                        <PRTPAGE P="94049"/>
                        <GID>ER27NO24.077</GID>
                    </GPH>
                    <HD SOURCE="HD3">s. Surfacer® Inside-Out® Access Catheter System (APC 1534)</HD>
                    <P>
                        HCPCS code C9780 (Insertion of central venous catheter through central venous occlusion via inferior and superior approaches (
                        <E T="03">e.g.,</E>
                         inside-out technique), including imaging guidance) describes the procedure associated with the use of the Surfacer® Inside-Out® Access Catheter System that is designed to address central venous occlusion. HCPCS code C9780 was established on October 1, 2021, and since its establishment the code has been assigned to New Technology APC 1534 (New Technology—Level 34 ($8001-$8500)).
                    </P>
                    <P>For CY 2025, there were only 3 single frequency claims in CY 2023 for HCPCS code C9780. There were no available claims from CY 2021 or CY 2022. Given our proposal to maintain current New Technology APC assignments for CY 2025 for New Technology APC services with fewer than 10 claims in the 4-year lookback period applicable for the universal low volume APC policy, we proposed to continue to assign HCPCS code C9780 to APC 1534 (New Technology—Level 34 ($8001-$8500)) with a payment rate of $8,250.50. Refer to Table 55 for the proposed New Technology APC and status indicator assignments for HCPCS code C9780.</P>
                    <GPH SPAN="3" DEEP="170">
                        <PRTPAGE P="94050"/>
                        <GID>ER27NO24.078</GID>
                    </GPH>
                    <P>We did not receive any public comments on our proposal to continue to assign CPT code C9870 to APC 1534 (New Technology—Level 34 ($8001-$8500)). We note that there was one additional claim in our updated claims data, however, the total number of claims for CY 2023 is still under 10. Therefore, given our new policy to maintain current New Technology APC assignments for CY 2025 for New Technology APC services with fewer than 10 claims in the 4-year lookback period applicable for the universal low volume APC policy, we are finalizing as proposed to continue to assign CPT code C9870 to APC 1534. Please refer to Table 56 below for the final OPPS New Technology APC and status indicator assignment for HCPCS code C9780. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="169">
                        <GID>ER27NO24.079</GID>
                    </GPH>
                    <HD SOURCE="HD3">t. TASS (APC 1537)</HD>
                    <P>
                        The Transcatheter Atrial Shunt System (TASS) is a nitinol self-expanding cardiovascular implant consisting of four arms including two left atrial (LA) arms and two coronary sinus (CS) arms placed between the left atrium and coronary sinus to create a 7mm flow diameter channel for blood to flow from the high pressure region of the left atrium to the lower pressure region of the right atrium via the coronary sinus. TASS is currently in a Category B IDE clinical trial. Effective October 1, 2023 CMS created HCPCS code C9792 (Blinded or nonblinded procedure for symptomatic New York Heart Association (NYHA) Class II, III, IV a heart failure; transcatheter implantation of left atrial to coronary sinus shunt using jugular vein access, including all imaging necessary to intra procedurally map the coronary sinus for optimal shunt placement (
                        <E T="03">e.g.,</E>
                         TEE or ICE ultrasound, fluoroscopy), performed under general anesthesia in an approved investigational device exemption (IDE) study) to describe the TASS service and assigned it to APC 1537 (New Technology—Level 37 ($9501-$10000)) with a payment rate of $9,750.50.
                    </P>
                    <P>For CY 2025, the proposed OPPS payment rates were based on available CY 2023 claims data. Due to the effective date of the code of October 1, 2023, there were no claims available for HCPCS code C9792 for rate setting in CY 2024. Therefore, in CY 2025, we proposed to continue to assign HCPCS code C9792 to APC 1537.</P>
                    <P>Please refer to Table 57 below for the current and proposed OPPS New Technology APC and status indicator assignments for HCPCS code C9792. The proposed CY 2025 payment rates can be found in Addendum B to the proposed rule via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="227">
                        <PRTPAGE P="94051"/>
                        <GID>ER27NO24.080</GID>
                    </GPH>
                    <P>
                        <E T="03">Comment:</E>
                         We received a comment supporting our proposal to continue to assign HCPCS code C9792 to APC 1537.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's support for our proposal.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal without modification to assign CPT code C9792 to APC 1537 (New Technology—Level 37 ($9501-$10000)) with a payment rate of $9,750.50 for CY 2025. Please refer to Table 58 for the final OPPS New Technology APC and status indicator assignment for HCPCS code C9792. The final CY 2024 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="213">
                        <GID>ER27NO24.081</GID>
                    </GPH>
                    <HD SOURCE="HD3">u. Magnetic Resonance Imaging With Inhaled Hyperpolarized Xenon-129 Contrast Agent (APC 1551)</HD>
                    <P>HCPCS code C9791 (Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent) was established on October 1, 2023. For CY 2023, we assigned HCPCS code C9791 to New Technology APC 1551 (New Technology—Level 14 ($1201-$1300)). For CY 2024, the OPPS payment rates were based on claims submitted between January 1, 2022, and December 31, 2022, processed through June 30, 2023. Due to the effective date of the service of October 1, 2023, there were no claims available for HCPCS code C9791 for rate setting in CY 2024. Therefore, in CY 2024, we continued to assign HCPCS code C9791 to New Technology APC 1551.</P>
                    <P>
                        For CY 2025, the proposed OPPS payment rates were based on available CY 2023 claims data. Although HCPCS code C9791 was effective October 1, 2023, we did not have any claims data for the service for the proposed rule. Therefore, for CY 2025, we proposed to continue to assign HCPCS code C9791 to New Technology APC 1551 (New Technology—Level 14) with a proposed payment rate of $1,250.50.
                        <PRTPAGE P="94052"/>
                    </P>
                    <P>Please refer to Table 59 for the proposed OPPS New Technology APC and status indicator assignment for HCPCS code C9791 for CY 2025.</P>
                    <GPH SPAN="3" DEEP="177">
                        <GID>ER27NO24.082</GID>
                    </GPH>
                    <P>We did not receive any public comments on our proposal, and we still do not have any claims for the service. Therefore, for CY 2025, we are finalizing our proposal without modification to assign HCPCS code C9791 to New Technology APC 1551 (New Technology—Level 14 ($1201-$1300)) and SI “T”. The final New Technology APC and status indicator assignments for HCPCS code C9791 for CY 2025 are found in Table 60. The CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="177">
                        <GID>ER27NO24.083</GID>
                    </GPH>
                    <HD SOURCE="HD3">v. SAINT Neuromodulation System</HD>
                    <P>The SAINT Neuromodulation System is a non-invasive repetitive transcranial magnetic stimulation (rTMS) system that identifies an individualized target and delivers navigationally directed repetitive magnetic pulses to that individualized target located within the left dorsolateral prefrontal cortex to treat major depressive disorder (MDD). The patient first receives structural MRI and functional MRI scans that are analyzed by the provider to identify and localize the personalized stimulation target in the patient's dorsolateral prefrontal cortex. Once the areas targeted for treatment are identified, the patient receives non-invasive magnetic stimulation in the targeted area. The patient has 10 treatment sessions per day with each treatment session lasting 10 minutes followed by 50 minutes of rest before another treatment session occurs. The treatment is administered over five days for a total of 50 sessions of non-invasive magnetic stimulation therapy. There are four CPT codes listed in Table 61 that describe the MRI scans that are used to target the treatment and describe the administration of the non-invasive magnetic stimulation therapy.</P>
                    <GPH SPAN="3" DEEP="347">
                        <PRTPAGE P="94053"/>
                        <GID>ER27NO24.084</GID>
                    </GPH>
                    <P>For CY 2025, the OPPS payment rates were proposed based on available CY 2023 claims data. However, CPT codes 0889T, 0890T, 0891T, and 0892T did not become effective until July 1, 2024, which means there was no claims data for the procedures described these CPT codes. We assigned our proposed rates for these services based on our evaluation of the resources needed to perform these services. Table 62 lists CPT codes 0889T, 0890T, 0891T, and 0892T and our proposed status indicator and APC assignment for CY 2025.</P>
                    <GPH SPAN="3" DEEP="462">
                        <PRTPAGE P="94054"/>
                        <GID>ER27NO24.085</GID>
                    </GPH>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters, including clinicians and other interested parties, believe that the payment rate of $2,250.50 for the proposed APC assignment to New Technology APC 1522 (New Technology—Level 22 ($2001-$2500)) for CPT codes 0890T, 0891T, and 0892T that describes the administration of the non-invasive magnetic stimulation therapy is too low. The commenters are concerned that the proposed payment rate will discourage providers from using the SAINT neuromodulation system to treat MDD. The commenters supported assigning CPT codes 0890T, 0891T, and 0892T to New Technology APC 1528 (New Technology—Level 28 ($5001-$5500)) with a payment rate of $5,250.50 to better reflect the resource cost of each of these three services. Multiple commenters also felt that the IPPS new technology add-on payment amount for the SAINT neuromodulation system acknowledged the cost of the SAINT system.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We do not have any claims data to directly determine the cost of the procedures described by CPT codes 0890T, 0891T, and 0892T. Therefore, we make our assessment of the resource costs to perform the procedure based on our judgment of the clinical and resource information presented to us about the SAINT neuromodulation system and the treatment approach in the manufacturer's OPPS New Technology APC application and through comments on the proposed rule. We agree with the commenters that the cost per case used for purposes of determining the IPPS maximum new technology add-on payment amount (88 FR 58938) was a more appropriate estimate of the cost of the SAINT neuromodulation system than our original cost estimate for the procedure in the CY 2025 OPPS proposed rule. For purposes of determining the new technology add-on payment amount, the cost estimate for the entire SAINT course of treatment, which included fifty sessions over five days of the non-invasive magnetic stimulation therapy and related operating costs, was $19,500.
                    </P>
                    <P>
                        Our review has determined that the cost estimate of the procedure described by CPT code 0899T should remain the same and CPT code 0899T should 
                        <PRTPAGE P="94055"/>
                        continue to be assigned to New Technology APC 1511 (New Technology—Level 11 ($901-$1000)) with a payment rate of $950.50. However, we now have determined that the per day cost of the services described by CPT codes 0890T, 0891T, and 0892T is around $3,710 instead of our proposed estimate of around $2,250. We are changing the APC assignment for CPT codes 0890T, 0891T, and 0892T to New Technology APC 1525 (New Technology—Level 25 ($3501-$4000)) with a payment rate of $3,750.50.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters described their experiences with MDD and receiving treatment for their MDD using the SAINT neuromodulation system. All of these commenters claimed that the SAINT therapy was beneficial to them and helped to reduce the symptoms of MDD, which substantially improved their mental health. Many of these commenters were able to receive SAINT because they participated in clinical trials for the therapy or were able to afford the treatment even if it was not covered by health insurance. The commenters want us to ensure that SAINT will be affordable to patients who receive treatment, and that SAINT will be widely available throughout the United States, so those who have MDD are able to access this therapy.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their input, and we are committed to establishing appropriate payment for the services described by CPT codes 0890T, 0891T, and 0892T.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal with modification for CY 2025 to assign CPT code 0899T to New Technology APC 1511 (New Technology—Level 11 ($901-$1000)) and SI of “S” and to assign CPT codes 0890T, 0891T and 0892T to New Technology APC 1525 (New Technology—Level 25 ($3501-$4000)) and SI of “S”. The final New Technology APC and status indicator assignments for CPT codes 0889T, 0890T, 0891T, and 0892T for CY 2025 are found in Table 63. The CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addendum D1 can also be found via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="462">
                        <PRTPAGE P="94056"/>
                        <GID>ER27NO24.086</GID>
                    </GPH>
                    <HD SOURCE="HD2">D. Universal Low Volume APC Policy for Clinical and Brachytherapy APCs</HD>
                    <P>In the CY 2022 OPPS/ASC final rule with comment period (86 FR 63743 through 63747), we adopted a policy to designate clinical and brachytherapy APCs as low volume APCs if they have fewer than 100 single claims that can be used for ratesetting purposes in the claims year used for ratesetting for the prospective year. For the CY 2025 OPPS/ASC proposed rule, CY 2023 claims are generally the claims used for ratesetting; and clinical and brachytherapy APCs with fewer than 100 single claims from CY 2023 that can be used for ratesetting would be low volume APCs subject to our universal low volume APC policy. As we stated in the CY 2022 OPPS/ASC final rule with comment period, we adopted this policy to reduce the volatility in the payment rate for those APCs with fewer than 100 single claims. Where a clinical or brachytherapy APC has fewer than 100 single claims that can be used for ratesetting, under our low volume APC payment adjustment policy, we determine the APC cost as the greatest of the geometric mean cost, arithmetic mean cost, or median cost based on up to 4 years of claims data. We excluded APC 5853 (Partial Hospitalization for CMHCs) and APC 5863 (Partial Hospitalization for Hospital-based PHPs) from our universal low volume APC policy given the different nature of policies that affect the partial hospitalization program. We also excluded APC 2698 (Brachytx, stranded, nos) and APC 2699 (Brachytx, non-stranded, nos) as our current methodology for determining payment rates for non-specified brachytherapy sources is appropriate.</P>
                    <P>
                        Based on claims data available for the CY 2025 OPPS/ASC proposed rule, we proposed to designate six brachytherapy APCs and five clinical APCs as low volume APCs under the OPPS. The six brachytherapy APCs and five clinical APCs meet our criteria of having fewer than 100 single claims in the claims' year used for ratesetting (CY 2023 for the CY 2025 OPPS/ASC proposed rule). Nine of the 11 APCs were designated as low volume APCs in CY 2024. Based on data for the CY 2025 OPPS/ASC proposed rule, APC 2645 (Brachytx, 
                        <PRTPAGE P="94057"/>
                        non-stranded, gold-198) and APC 5881 (Ancillary Outpatient Services When Patient Dies) met our criteria to be designated a Low Volume APCs; and we proposed to designate those APCs as such for CY 2025.
                    </P>
                    <P>
                        We did not receive any public comments on our proposal. Based on CY 2023 claims data available for this final rule with comment period, we are finalizing our proposal to designate six brachytherapy APCs and five clinical APCs as low volume APCs under the OPPS. Table 64 includes the CY 2023 claims available for ratesetting for each of the APCs we are designating as Low Volume APCs for CY 2025. The final cost statistics for our CY 2025 Low Volume APCs, such as the median, arithmetic mean, and geometric mean cost are available for download with this final rule with comment period on the CMS website. We refer readers to our website at: 
                        <E T="03">https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices</E>
                        ; click on the relevant regulation to download the low volume APC cost statistics under the comprehensive (OPPS) ratesetting methodology in the downloads section of the web page.
                    </P>
                    <GPH SPAN="3" DEEP="266">
                        <GID>ER27NO24.087</GID>
                    </GPH>
                    <HD SOURCE="HD2">E. APC-Specific Policies</HD>
                    <HD SOURCE="HD3">1. Cardiac CT Services, CPT Codes 75572, 75573, and 75574 (APC 5572)</HD>
                    <P>For the 2006 coding update, the AMA's CPT Editorial Panel established six Category III CPT codes to describe cardiac computed tomography angiography with contrast materials (cardiac CT services) effective January 1, 2006. The codes were active and separately payable under the OPPS between January 1, 2006, and December 31, 2009. The CPT Editorial Panel deleted the Category III CPT codes and replaced them with Category I CPT codes 75572 through 75574 effective January 1, 2010. With the deletion of the Category III CPT codes on December 31, 2009, we crosswalked the APC assignments from the Category III CPT codes (predecessor codes) to the new Category I CPT codes effective January 1, 2010. Since 2010, the Category I CPT codes describing cardiac CT services are CPT codes 75572, 75573, and 75574. The codes and their long descriptors are listed below.</P>
                    <P>• 75572: Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed).</P>
                    <P>• 75573: Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of left ventricular (LV) cardiac function, right ventricular (RV) structure and function and evaluation of vascular structures, if performed).</P>
                    <P>• 75574: Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed).</P>
                    <P>Like the predecessor codes, CPT codes 75572, 75573, and 75574 have been paid separately under the OPPS since 2010. From CY 2015 through CY 2024, the OPPS payment rate, based on the geometric mean cost for the cardiac CT codes, has ranged between $175 and $265 for these codes, as listed in Table 65 below.</P>
                    <GPH SPAN="3" DEEP="89">
                        <PRTPAGE P="94058"/>
                        <GID>ER27NO24.088</GID>
                    </GPH>
                    <P>We note that the OPPS payment rate applies only to the hospital outpatient facility and does not include the physician service payment. Physician services are paid under Medicare's Physician Fee Schedule (PFS).</P>
                    <P>We update the OPPS payment rates on an annual basis consistent with the requirements set forth in section 1833(t)(9)(A) of the Act, which requires the HHS Secretary to review, not less often than annually, and revise the APC groups, the relative payment weights, and the wage and other adjustments to take into account changes in medical practice, changes in technology, the addition of new services, new cost data, and other relevant information and factors. Because of the annual updates, OPPS payment rates for services may fluctuate from year to year. We note that we generally use the latest claims data available to set the annual payment rates. Payment rates for this CY 2025 OPPS/ASC final rule with comment period are based on claims with dates of service between January 1, 2023, and December 31, 2023, processed through June 30, 2024.</P>
                    <P>Over the years we have received comments noting that the payment for these codes has declined since 2017. Comments on previous OPPS proposed rules have indicated that the payment amount is insufficient to cover the cost of providing the service and have stated that the payment amount does not consider the hospital resources required to perform these services, including the use of the equipment, medication administration, staff time, and scanner time. We have maintained over the years that an analysis of our claims data for these three codes have shown geometric mean costs consistent with the geometric mean cost for APC 5571 (Level 1 Imaging with Contrast), the APC to which the cardiac CT codes have been assigned since 2015.</P>
                    <P>We have also received comments in the past urging CMS to allow hospitals the flexibility to submit charges for cardiac CT services with a revenue code other than CT scan (035X) and Radiology Diagnostic (032X) revenue codes, implying that MACs had applied edits to the cardiac CT codes that prevented hospitals from reporting a cardiology (048X) revenue code when appropriate. It is longstanding CMS policy that hospital outpatient facilities are responsible for reporting the appropriate cost centers and revenue codes on claims. As stated in section 20.5 in Chapter 4 (Part B Hospital) of the Medicare Claims Processing Manual, CMS “does not instruct hospitals on the assignment of HCPCS codes to revenue codes for services provided under OPPS since hospitals' assignments of cost vary. Where explicit instructions are not provided, HOPDs should report their charges under the revenue code that will result in the charges being assigned to the same cost center to which the cost of those services are assigned in the cost report.” We have consistently stated that hospital outpatient facilities must determine the most appropriate cost center and revenue code for the cardiac CT codes (87 FR 71849, 88 FR 81664).</P>
                    <P>After we issued the CY 2024 OPPS/ASC final rule, interested parties notified us of a specific claims edit that may have limited the revenue codes reported with the cardiac CT codes in prior years' claims data. CMS removed the revenue code edit in early December 2023 to allow for the cardiac CT codes to be billed with any appropriate revenue code. We informed the public of our findings and the changes that we made in the January 2024 OPPS Update (Transmittal 12421, Change Request 13488), dated December 21, 2023. We believe the edit may have prevented some providers from reporting the cardiology revenue code (048X), which maps to the cardiology cost center (03140), when billing for cardiac CT services. In the past, commenters have indicated that the cardiology cost center has a higher cost-to-charge ratio (CCR) than the imaging cost centers, and they believe the inability to report the cardiology revenue code has resulted in a lower payment rate for cardiac CT services. Since the OPPS ratesetting process utilizes the applicable cost center's CCR to reduce the charges on the claim to estimated cost, utilizing cost centers with lower CCRs results in a lower OPPS payment compared to utilizing cost centers with higher CCRs. With the edit no longer in place, hospitals may bill for cardiac CT services with whichever revenue code they believe appropriate for CY 2024, including cardiology revenue code 048X, and the CY 2026 OPPS payment rates (which most likely will be based on CY 2024 claims) will reflect those updated revenue code billing patterns. We note that for CY 2025, based on our standard ratesetting methodology using claims submitted during CY 2023, our analysis reveals that the angiocardiography and CT scan revenue codes were reported with CPT codes 75572 through 75574, which were mapped to angiography and CT scan cost centers, as shown in Table 66.</P>
                    <GPH SPAN="3" DEEP="257">
                        <PRTPAGE P="94059"/>
                        <GID>ER27NO24.089</GID>
                    </GPH>
                    <P>Because we wanted to determine whether the revenue edit could have affected the geometric mean costs for CPT codes 75572 through 75574, we conducted studies prior to the CY 2025 proposed rule and during the comment period to calculate HCPCS geometric mean costs for these codes based on a simulation that assumed that differing numbers of HOPDs (specifically 25 percent, 50 percent, and 75 percent of the total number of HOPDs billing for these services) would have assigned these services to the cardiology revenue code (048X) and cardiology cost center (03140). Based upon the results of the studies, we found that if 50 percent or more of HOPDs had billed these services with the cardiology revenue code (048X) and cardiology cost center (03140), the geometric mean cost for these codes would have increased and would have resulted in a revised APC assignment from APC 5571 (Level 1 Imaging with Contrast) to APC 5572 (Level 2 Imaging with Contrast). As noted in Table 67, under our standard ratesetting methodology, the geometric mean cost for the cardiac CT codes would be approximately $182, which maps to APC 5571, while an assumption that 50 percent of HOPDs billed with the cardiology revenue code (048X) and cardiology cost center (03140) on CY 2023 claims would result in a geometric mean cost of about $386, which maps to APC 5572.</P>
                    <P>We also reviewed the limited CY 2024 claims data for cardiac CT services available to determine the percentage of HOPDs that are utilizing the cardiology revenue code (048X) and cardiology cost center (03140) with the understanding that many HOPDs may still be updating their current billing practices. We did not find any appreciable change in current billing practices.</P>
                    <GPH SPAN="3" DEEP="201">
                        <GID>ER27NO24.090</GID>
                    </GPH>
                    <PRTPAGE P="94060"/>
                    <P>Because the RTP edit associated with the cardiac CT codes may have affected the CY 2023 data we have available to establish the CY 2025 OPPS payment rates for these services, in the CY 2025 OPPS/ASC proposed rule, we requested information on the following topics regarding hospitals' billing practices for cardiac CT services:</P>
                    <P>(1) Where are cardiac CT services performed in a hospital? Are cardiac CT services performed in a dedicated cardiology department, radiology department, or some other hospital outpatient department?</P>
                    <P>
                        (2) What factors determine the revenue code assignment for cardiac CT services (
                        <E T="03">i.e.,</E>
                         the department in which the service is performed, the type of service that is performed, or some other factor)?
                    </P>
                    <P>(3) What revenue codes are HOPDs reporting for these services in CY 2024? Are HOPDs using the cardiology revenue code on claims for cardiac CT services now that they are no longer restricted from using this revenue code?</P>
                    <P>We stated in the CY 2025 OPPS/ASC proposed rule that we would use the comments received and the information from the CY 2024 claims data to help us identify whether the current OPPS payment is appropriate for the cardiac CT codes, or whether we should revise the payment methodology for the CY 2025 OPPS. We received a significant number of comments in response to our Request for Information. While a major portion of the comments were part of a large write-in campaign, commenters provided information specific to their experiences in their facilities. We appreciate all the feedback and address the comments below.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received a significant number of comments in response to our Request for Information about cardiac CT services and the billing practices for these services. Commenters ranged from specialty societies to healthcare providers who practice in a variety of settings of different sizes and in various locations throughout the United States.
                    </P>
                    <P>In terms of where cardiac CT services are performed, commenters shared that cardiac CT services may be performed in a radiology department, an interventional radiology department, a cardiology department, or a clinic setting. Resources to furnish the services, such as staff, are utilized from both the cardiology and radiology departments. Many commenters described the test being performed in radiology departments utilizing cardiology nursing staff to prepare the patient, administer medications (such as IV beta blockers and nitroglycerin), and monitor the patient during and after the procedure.</P>
                    <P>In terms of the factors that determine the revenue code assignment for cardiac CT services, most commenters stated that the resources used for these services are very similar to other cardiac procedures such as cardiac stress tests or even cardiac catheterizations, which are assigned to the cardiology revenue code. Commenters described cardiac CT services as resource intensive, stating that the cross-department coordination between cardiology and radiology, the skill level of staff (technicians, nurses, and physicians), the expense of up-to-date CT equipment, and the amount of testing time involved is comparable to other more expensive and invasive cardiac tests.</P>
                    <P>In response to our request for the revenue codes hospital outpatient departments are reporting with cardiac CT services now that there is not an edit in place prohibiting them from using the cardiology revenue code, commenters stated that they want to use the cardiology revenue code when billing cardiac CT services, but they are unable to due to third-party edits (billing and payer) in place from clearinghouses, billing companies, or billing software companies. Some stated that they have continued to use the radiology revenue codes to prevent receiving claims denials. Another commenter stated their coding staff expressed compliance concerns with assigning cardiac CT services to a cardiology revenue code versus the CT revenue code. Commenters requested that CMS provide education about revenue code use for providers, healthcare facilities, clearinghouses, and health plans and indicated that explicit education would facilitate use of the cardiac revenue code with cardiac CT services.</P>
                    <P>Many commenters shared how many cardiac CT services are completed per year at their facilities. They expressed concern about the declining payment for such a complex, resource-intensive test that is used to accurately diagnose and manage coronary artery disease and the impact that insufficient payment could have on beneficiary access. Commenters noted that cardiac CT has been identified by the American College of Cardiology as a first line approach to manage patients with chest pain and asserted that cardiac CT is more clinically useful than more expensive, invasive tests such as cardiac catheterizations.</P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their feedback regarding the clinical value cardiac CT services provide for clinicians diagnosing and managing patients with chest pain and coronary artery disease. We also thank commenters for describing the process of cardiac CT tests and all the resources used in providing those services and sharing information about selection of revenue code assignment when billing for CT services.
                    </P>
                    <P>We acknowledge commenters' concerns that, even with the revenue code edit removed for CY 2024, there are a number of procedural and logistical hurdles to providers billing with the cardiology revenue codes in CY 2024 and that it would not be realistic to expect a majority of providers to be billing with the cardiology revenue codes at this point due to those issues. We acknowledge that process changes often happen slowly and that it may take time for facilities to update their billing practices, even if the majority of providers would prefer to bill these codes with the cardiology revenue code.</P>
                    <P>
                        We appreciate commenters sharing their concerns about third-party edits that are still affecting the billing process and understand their request for additional guidance from CMS. We remind readers that we informed the public of our findings and the changes that we made in the January 2024 OPPS Update (Transmittal 12421, Change Request 13488), dated December 21, 2023. Specifically, we stated the following: “We recently identified an outdated return-to-provider (RTP) Healthcare Common Procedure Coding System-to-revenue code edit that resulted in certain claims submissions being limited to specific revenue codes for CPT codes 75572, 75573, and 75574. These claims were returned to the providers for resubmission. The outdated edit has been removed; and providers, when appropriate, may begin billing these codes with any appropriate revenue code.” We have also stated in section 20.5 in Chapter 4 (Part B Hospital) of the Medicare Claims Processing Manual, CMS “does not instruct hospitals on the assignment of HCPCS codes to revenue codes for services provided under OPPS since hospitals' assignments of cost vary. Where explicit instructions are not provided, HOPDs should report their charges under the revenue code that will result in the charges being assigned to the same cost center to which the cost of those services are assigned in the cost report.” We have consistently stated that hospital outpatient facilities must determine the most appropriate cost center and revenue code for the cardiac CT codes (87 FR 71849, 88 FR 81664). While we believe that this information should suffice for education to third parties who may have edits in place that affect the selection of a cardiology 
                        <PRTPAGE P="94061"/>
                        revenue code when billing for cardiac CT services and for other interested parties who have compliance concerns, we will be providing public education and instruction through the CMS Medicare Learning Network (MLN).
                    </P>
                    <P>We are persuaded after a review of the comments submitted that a majority of providers who bill these codes would prefer to bill them with the cardiology revenue code but have not been able to do so due to the prior revenue code edit and remaining procedural hurdles that flow from the prior revenue code edit. As stated above, if there had not been a systems edit in place preventing providers from choosing the cardiology revenue code (048X) and cardiology cost center (03140) and 50 percent or more of HOPDs had billed these services with the cardiology revenue code and cardiology cost center, the geometric mean cost for these codes would have increased and would have resulted in a revised APC assignment from APC 5571 (Level 1 Imaging with Contrast) to APC 5572 (Level 2 Imaging with Contrast). Therefore, for CY 2025, we are using our equitable adjustment authority under section 1833(t)(2)(E) of the Act to utilize an alternative methodology to calculate the payment for the cardiac CT services in CY 2025 and subsequent years. Specifically, we are finalizing a temporary reassignment of the cardiac CT codes (CPT code 75572 through 75574) to APC 5572 (Level 2 Imaging with Contrast). See Table 68 for the CY 2025 Proposed and Final OPPS SI and APC assignments for CPT codes 75572 through 75574. We anticipate that it may take 3 to 4 years to see an impact from changes in billing practices from providers based on the comments we received on the proposed rule. If we do not see a significant change in the geometric mean costs after several years, we would revert payment for these services to the standard OPPS payment methodology and assign the cardiac CT codes to appropriate APCs based on their geometric mean costs. We note that this APC reassignment will not involve reprocessing of claims with dates prior to January 1, 2025.</P>
                    <GPH SPAN="3" DEEP="510">
                        <PRTPAGE P="94062"/>
                        <GID>ER27NO24.091</GID>
                    </GPH>
                    <P>The final CY 2025 payment with rates for the cardiac CT CPT codes can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the SI definitions for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">2. Neurostimulator and Related Procedures (APCs 5461 Through 5465)</HD>
                    <P>In the CY 2021 OPPS/ASC final rule with comment period, we finalized a five-level APC structure for the Neurostimulator and Related Procedures series (85 FR 85968 through 85970). For a detailed discussion of the history of neurostimulators policy, we refer readers to the CY 2015, CY 2020, CY 2021, CY 2023, and CY 2024 OPPS/ASC final rules with comment period (79 FR 66807 through 66808; 84 FR 61162 through 6116, 85 FR 85968 through 85970; 87 FR 71869; 88 FR 81645 through 81658).</P>
                    <P>
                        In the CY 2024 OPPS/ASC final rule with comment period, we did not make any changes to the 5 level APC structure for the Neurostimulator and Related Procedures series. However, we made temporary changes to services previously assigned to the neurostimulator APCS: reassigning HCPCS code 33276 (Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed), with predecessor code 0424T, and 33287 (Removal and replacement of phrenic nerve stimulator, including vessel 
                        <PRTPAGE P="94063"/>
                        catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator), from New Technology APC 1581 to New Technology APC 1580 (88 FR 81645 through 81647) and assigning HCPCS code 0266T (Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)) to New Tech APC 1580 (88 FR 81658).
                    </P>
                    <P>For the CY 2025 OPPS/ASC proposed rule, we proposed to maintain the 5 level APC structure for the Neurostimulator series. We proposed to assign HCPCS codes 0266T and 33276 to the APC 5465 (Level 5 Neurostimulator and Related Procedures), given the cost and coding changes associated with those codes. We noted that while we have claims data available for HCPCS codes in the neurostimulator APC series that are no longer active, there would also be cost and coding changes associated with new CPT codes as their claims data become available.</P>
                    <P>While we continued to believe that a five-level structure for the Neurostimulator and Related Procedures APC series remained appropriate, we also solicited comments from interested parties in CY 2025 OPPS/ASC proposed rule on the need for a Level 6 APC, given the clinical and estimated cost characteristics of the services currently assigned to APC 5465 (Level 5 Neurostimulator and Related Procedures).</P>
                    <P>In summary, for the CY 2025 OPPS, we proposed to maintain the current 5-level structure for the Neurostimulator and Related Procedure APC series, assign HCPCS codes 0266T and 33276 to APC 5465, and solicited comment creating an additional Level 6 Neurostimulator APC.</P>
                    <P>See Table 69 for the services that we proposed to reassign to the Level 5 APC and Table 70 below for the proposed CY 2025 Neurostimulator and Related Procedures APCs.</P>
                    <GPH SPAN="3" DEEP="347">
                        <GID>ER27NO24.092</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="238">
                        <PRTPAGE P="94064"/>
                        <GID>ER27NO24.093</GID>
                    </GPH>
                    <P>
                        At the August 26, 2024, HOP Panel Meeting, several presenters provided information to the Panel regarding HCPCS codes 33276 (Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed), 64568 (Open implantation of cranial nerve (
                        <E T="03">e.g.,</E>
                         vagus nerve) neurostimulator electrode array and pulse generator), and 0266T (Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)). The presenters advised the Panel to request that CMS either create a new Level 6 Neurostimulator and Related Procedures APC and consider including the three codes mentioned above in the Level 6 Neurostimulator APC, or alternatively assign the three codes mentioned above to New Technology APC 1580 (New Technology—Level 43 ($40,001-$50,000)). The HOP Panel agreed with the presenter and made that recommendation.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Many commenters requested the creation of a Level 6 Neurostimulator and Related Procedures APC, noting that creating an additional APC would align payment more closely with costs incurred while maintaining access to services assigned to that APC. Many of these commenters requested that if a Level 6 APC could not be created, that HCPCS code 0266T be maintained in New Technology APC 1580 for an additional year. Other commenters asked that CMS reconsider the proposed assignment of HCPCS code 33276 to APC 5465 and place the code in an APC consistent with the resources required for the procedure. One of those commenters specifically requested an APC assignment to New Technology APC 1580 until a more permanent solution to address disparity between payment and resource costs could be determined. Some commenters requested that HCPCS code 64568 be moved from APC 5465 (Level 5 Neurostimulator and Related Procedures) to New Technology APC 1580. Two commenters supported maintaining the current 5 level APC structure for the Neurostimulator series. One of those commenters recommended that HCPCS codes 33276 and 0266T continue to be assigned to New Technology APC 1580 to maintain beneficiary access while additional claims data are collected, while the other recommended more broadly that New Technology APCs be used for similar scenarios where codes had high cost but low volume. One commenter believed that HCPCS code 64568 should remain assigned to APC 5465 (Level 5 Neurostimulator and Related Procedures) since it is a long-established procedure and would not be expected to have changes in cost or volume the way “new” technologies would.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the thoughtful responses commenters have provided with regard to the proposed policy and our requests for comments. While we understand the concerns and issues commenters have raised, we believe that the 5 level APC structure for the series continues to remain appropriate in grouping together procedures with similar cost and clinical characteristics. Therefore, we are finalizing the 5 level APC structure for the Neurostimulator and Related Procedures APCs.
                    </P>
                    <P>However, we also recognize the concerns commenters have raised regarding HCPCS codes 0266T and 33276 and in particular, the request that we return those codes to their current New Technology APC placements should we establish a final policy of not creating an additional APC level. Thus, we are assigning these codes to New Tech APC 1580, the same APC these codes were assigned to in CY 2024, in this CY 2025 OPPS/ASC final rule with comment period.</P>
                    <P>For HCPCS code 64568, we believe its current assignment to the Level 5 APC remains appropriate. The code has been assigned to the Neurostimulator and Related Procedures APC series for many years and the claims volume we have for the procedure allow for an estimate of the associated resource costs. Therefore, we do not believe a New Tech APC assignment is appropriate at this time, as New Technology APC placements are typically used when insufficient cost and claims data are available to make appropriate clinical APC assignments. We will continue to monitor the data as additional claims become available for these codes.</P>
                    <P>
                        After consideration of the public comments we received, we are finalizing our proposal with modification. We are finalizing the 
                        <PRTPAGE P="94065"/>
                        proposed 5 level APC structure for the Neurostimulator and Related Procedures APC series. However, we are continuing to assign HCPCS codes 33276 and 0266T to New Technology APC 1580 (New Technology—Level 43 ($40,001-$50,000)) in CY 2025 rather than finalizing our proposal to assign them to APC 5465. See Table 71 for the status indicators and APC assignments for HCPCS codes 0266T and 33276. We note that we have previously discussed the placement of these codes in New Technology APCs until such time that sufficient claims data were available to assign those codes to clinical APCs (87 FR 81769, 88 FR 81645 through 81647, 88 FR 81658). We will continue to monitor the data as more claims for these codes become available. Finally, we are maintaining the APC assignment of HCPCS code 64568 to APC 5465 (Level 5 Neurostimulator and Related Procedures). Please see Table 74 for the final CY 2025 OPPS APC and SI assignments for HCPCS codes 0266T and 33276.
                    </P>
                    <GPH SPAN="3" DEEP="278">
                        <GID>ER27NO24.094</GID>
                    </GPH>
                    <HD SOURCE="HD3">3. Focal Laser Ablation, CPT Code 0655T (APC 5375)</HD>
                    <P>Focal laser ablation is an MRI directed and image guided, minimally invasive procedure that targets prostate cancer tissue. The focal laser ablation procedure, represented by CPT code 0655T (Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with mr-fused images or other enhanced ultrasound imaging), became effective July 1, 2021, and describes the destruction of localized prostate cancer tissue with the high energy source of focal laser radiation. The procedure utilizes real-time intraoperative prostate ultrasound fused with MRI guidance to allow the surgeon to plan the ablation and guide the laser targeting as well as providing real-time feedback to minimize changes to the tissues outside of the targeted ablation zone. This procedure offers another therapy option for select patients with localized intermediate risk prostate cancer.</P>
                    <P>For the CY 2025 OPPS/ASC proposed rule, we reviewed the CY 2023 claims submitted between January 1, 2023, through December 31, 2023, that were processed on or before December 31, 2023, for CPT code 0655T and found seven single frequency claims available for ratesetting, with a resulting geometric mean cost of $12,777. Additionally, for the CY 2025 OPPS/ASC proposed rule, we examined the procedures assigned to the Urology Procedures APCs. Based on our examination of the procedures assigned to Urology and Related Procedures APCs and the available CY 2023 claims data, we stated that we believe it is appropriate to move CPT code 0655T to APC 5375 (Level 5 Urology and Related Services) from APC 5374 (Level 4 Urology and Related Services) because 0655T shares more resource cost and clinical homogeneity with procedures in APC 5375. Specifically, we explained that we believe CPT code 0655T shares resources and is clinical homogeneous with CPT code 0714T (Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance), and CPT code 52648 (Laser vaporization of prostate, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, internal urethrotomy and transurethral resection of prostate are included if performed)). We noted that the seven available CY 2023 single frequency claims for CPT code 0655T would not significantly impact the geometric mean cost calculations for APC 5374 and APC 5375. Therefore, for CY 2025, we proposed to reassign CPT code 0655T from APC 5374 (Level 4 Urology and Related Services) to APC 5375 (Level 5 Urology and Related Services).</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter supported our proposal to reassign CPT code 0655T from APC 5374 (Level 4 Urology and Related Services) to APC 5375 (Level 5 Urology and Related Services), citing the clinical and resource homogeneity with CPT codes 52648 and 0714T. Furthermore, the commenter suggested we monitor the impact of the 
                        <PRTPAGE P="94066"/>
                        reassignment on the geometric mean cost for APCs 5374 and 5375 to ensure payment stability.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for the support. Based on evaluation of their clinical and resource similarities, and taking into account updated claims data for this final rule with comment period, we continue to believe it is appropriate to reassign CPT code 0655T to APC 5375.
                    </P>
                    <P>After consideration of the public comment we received, we are finalizing our policy without modification for CPT code 0655T. Please refer to Table 72 below for the final OPPS APC and status indicator assignments for HCPCS code 0655T for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="190">
                        <GID>ER27NO24.095</GID>
                    </GPH>
                    <HD SOURCE="HD3">4. Bone Mass Measurement: Biomechanical Computed Tomography (BCT) Analysis With and Without Vertebral Fracture Assessment, CPT Codes 0554T-0558T, 0743T (APCs 5521, 5523, and 5731)</HD>
                    <P>CPT code 0743T (Bone strength and fracture risk using finite element analysis of functional data and bone mineral density (BMD), with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and BMD and classification of any vertebral fractures, with overall fracture-risk assessment, interpretation and report) became effective January 1, 2023. This code describes the service associated with biomechanical computed tomography (BCT) analysis with concurrent vertebral fracture assessment (VFA).</P>
                    <P>In the CY 2023 OPPS/ASC final rule (87 FR71844 through 71846), we stated that, based on our review and understanding of the service, BCT analysis does not meet Medicare's definition of bone mass measurement, as specified in § 410.31(a), which specifies the coverage of, and payment for, bone mass measurements for Medicare beneficiaries. Therefore, we assigned the BCT codes (CPT codes 0554T-0558T) and CPT code 0743T to status indicator “E1” to indicate that these codes are not covered by Medicare, and not paid by Medicare when submitted on outpatient claims (any outpatient bill type). The complete long descriptors for the codes can be found below:</P>
                    <P>
                        <E T="03">0554T:</E>
                         Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone-mineral density, interpretation and report.
                    </P>
                    <P>
                        <E T="03">0555T:</E>
                         Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan; retrieval and transmission of the scan data.
                    </P>
                    <P>
                        <E T="03">0556T:</E>
                         Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan; assessment of bone strength and fracture risk and bone mineral density.
                    </P>
                    <P>
                        <E T="03">0557T:</E>
                         Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan; interpretation and report.
                    </P>
                    <P>
                        <E T="03">0558T:</E>
                         Computed tomography scan taken for the purpose of biomechanical computed tomography analysis.
                    </P>
                    <P>In the CY 2024 OPPS/ASC proposed rule, we proposed to continue to assign the codes to status indicator “E1” to indicate non-coverage and non-payment for the services. (See Addendum B for CY 2024/ASC proposed rule via the internet on the CMS website.) However, as discussed in the CY 2024 OPPS/ASC final rule with comment period (88 FR 81660 through 81661), based on comments received and further review of the issue, we did not finalize our proposal. We instead assigned CPT code 0555T to APC 5731 (Level 1 Minor Procedures) and SI of “S,” (Procedure or Service, Not Discounted When Multiple; Paid under OPPS; separate APC payment), CPT code 0556T to APC 5523 (Level 3 Imaging without Contrast) and SI of “S,” and CPT code 0558T to APC 5521 (Level 1 Imaging without Contrast) with SI of “S,” which were the same APC assignments for the codes between CY 2019 and CY 2022. In addition, we assigned CPT codes 0554T, 0557T, and 0743T to SI of “M” (Items and Services Not Billable to the MAC. Not paid under OPPS) to indicate that these codes are not payable under the OPPS because they describe physician-only services. The final payment rates for these codes were listed in the OPPS Addendum B that was released with the CY 2024 OPPS/ASC final rule via the internet on the CMS website.</P>
                    <P>
                        For the CY 2025 OPPS/ASC proposed rule, we proposed to assign CPT codes 0554T and 0557T to status indicator of “M” as the codes include or describe a professional component of the service 
                        <PRTPAGE P="94067"/>
                        that is provided by a physician as evidenced by “interpretation and report” in the descriptor. It is important to note that CPT code 0554T is a comprehensive code (or “parent code”) that includes both technical and professional components. Because there are additional CPT codes (“child codes”) that facilities can use to describe the technical components of BCT analysis, we explained that we believed it was appropriate for the comprehensive code that includes the professional component to be assigned a SI of “M”. In addition, we proposed to assign CPT code 0555T to APC 5731 (Level 1 Minor Procedures) and a SI of “S,” CPT code 0556T to APC 5523 (Level 3 Imaging without Contrast) and a SI of “S,” and CPT code 0558T to APC 5521 (Level 1 Imaging without Contrast) with a SI of “S.”
                    </P>
                    <P>For the CY 2025 OPPS/ASC proposed rule, we explained that we believe the service described by CPT code 0743T is a comprehensive code and involves both a technical component and a professional component that are performed by hospital outpatient facilities. Unlike CPT 0554T, there are no additional codes to describe the technical component(s) of this service (BCT analysis and VFA) and there is a parenthetical note instructing facilities to not report the BCT analysis codes (0554T-0557T) with CPT code 0743T. Consequently, we proposed to assign CPT code 0743T to APC 5523 (Level 3 Imaging without Contrast) and we proposed to change the status indicator for 0743T from “M” to “S” (Procedure or Service, Not Discounted When Multiple; Paid under OPPS; separate APC payment) for CY 2025. See Table 73 below.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received several comments describing support for the use of BCT services to assess bone strength, bone mineral density, and fracture risk indicating that these services were cost-effective and provided valuable clinical information. Commenters noted the significant impact that osteoporosis has on Medicare beneficiaries, especially women. They shared that BCT is effective in clinical practice when determining use and approval of anti-osteoporotic medications that are dependent on bone density assessments. They also noted that DXA (dual-energy X-ray absorptiometry) scans (most common test used to measure bone mineral density) may be difficult to do when patients have scoliosis or extensive degenerative diseases and thus prefer to use BCT.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the feedback supporting BCT services.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment requesting that we assign payable status indicators for CPT codes 0554T and 0557T.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their request. As stated above, we proposed to continue to assign CPT codes 0554T and 0557T a status indicator of “M” as the codes include or describe a professional component of the service that is provided by a physician as evidenced by “interpretation and report” in the descriptor. CPT code 0554T is a comprehensive code (or “parent code”) that includes both technical and professional components. Because there are additional CPT codes (“child codes”) that facilities can use to describe the technical components of BCT analysis, it is appropriate for the comprehensive code that includes the professional component to be assigned a SI of “M”. CPT code 0557T describes only the professional component of the BCT analysis code and therefore, is appropriately assigned a SI of “M”.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received several comments expressing support for the proposed APC and status indicator assignments.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their support.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters believe that Medicare has limited access to some BCT services in the hospital outpatient setting by assigning non-payable status indicators. Consequently, they are requesting that the pertinent codes be allowed through national coverage.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate these comments. In Transmittal 2362 dated September 19, 2019, we note the BCT codes, specifically CPT codes 0554T, 0555T, 0556T, 0557T, and 0558T were listed as covered effective July 1, 2019 under NCD 150.3 Bone Mineral Density Studies. These services were added in error and were retracted due to “added in error” in Transmittal 11952 dated April 12, 2023. We apologize for the confusion this has caused and the mistaken belief that “coverage was revoked” when in fact these services had not been approved for national coverage.
                    </P>
                    <P>While CMS further considers the issue of national coverage, we will finalize our proposed status indicator and (if applicable) APC assignments for CPT codes 0554T-0558T and CPT code 0743T as listed in Table G42 below.</P>
                    <P>The regulation at 42 CFR 410.31(f) (Bone mass measurement: Conditions for coverage and frequency standards) recognizes that CMS may use the Medicare National Coverage Determination (NCD) process to examine additional BMM systems for coverage. The public may request an NCD for a particular item or service by following the procedures established at 78 FR 48164 (August7, 2013). The commenter may request a new NCD (or seek reconsideration of an existing NCD). As a reminder to our readers, National Coverage Determinations do not include coding and payment decisions.</P>
                    <P>In summary, after consideration of the public comments, we are finalizing our proposed status indicator and (if applicable) APC assignments for CPT codes 0554T-0558T and CPT code 0743T without modification. The final payment rates for the separately payable codes can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator (SI) meanings for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94068"/>
                        <GID>ER27NO24.096</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="166">
                        <PRTPAGE P="94069"/>
                        <GID>ER27NO24.097</GID>
                    </GPH>
                    <HD SOURCE="HD3">5. 3D Contour Simulation, CPT Code 0944T (APC 5523)</HD>
                    <P>CAS-One® IR is Software as a Service (SaaS) that assists a physician or other qualified health care professional during percutaneous liver ablation treatments by providing 3D images that allow the physician to visualize the liver lesions, as well as define suitable margins and pathways to perform the ablation procedure. The AMA CPT Editorial Panel established CPT code 0944T effective January 1, 2025:</P>
                    <P>The long descriptor for CPT code 0944T is as follows: 3D contour simulation of target liver lesion(s) and margin(s) for image-guided percutaneous microwave ablation.</P>
                    <P>In the CY 2025 OPPS/ASC proposed rule with comment period, we proposed to assign 0944T to status indicator “E1” to indicate that the code is not payable by Medicare when submitted on outpatient claims because the service had not received FDA clearance at the time of the assignment.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment from the manufacturer. The commenter states that the 3D simulation is always performed with CPT code 47382 (Ablation, 1 or more liver tumor(s), percutaneous, radiofrequency) which is assigned to APC 5361 (Level 1 Laparoscopy and Related Services) and has a payment rate of approximately $5,800. The manufacturer asserts the costs for the 3D simulation service are approximately $3,000 which include a CT of the abdomen with contrast, utilization of the CAS-One® system, sterile accessories (patient markers, instrument markers, drapes, and marker templates), and annual services for the system (including maintenance, warranty, software subscription, and clinical support). They have requested that we reassign CPT code 0944T to APC 5362 (Level 2 Laparoscopy and Related Service) with a payment rate of approximately $10,400 and a status indicator of J1, representing a comprehensive service that includes both the ablation procedure (CPT code 47382) and the 3D simulation service (CPT code 0944T).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input. We disagree that we should consider adding the costs of both the ablation procedure (CPT code 47382) and the 3D simulation service (CPT code 0944T) to determine the appropriate payment for the 3D simulation service. The ablation procedure (CPT code 47382) is a primary service as identified by the OPPS status indicator “J1” (Hospital Part B Services Paid Through a Comprehensive APC; Paid under OPPS). The ablation procedure can be done with or without 3D simulation services, but 3D simulation services are never provided without the primary ablation services. Under our C-APC policy, we designate a service described by a HCPCS code assigned to a C-APC as the primary service when the service is identified by OPPS status indicator “J1”. Because the 3D simulation service is always performed with the ablation service, we believe the 3D simulation could be considered an adjunctive service. (See 78 FR 74865 and 79 FR 66799.) Payments for adjunctive services are generally packaged into the payments for the primary services.
                    </P>
                    <P>After review of the procedure description for 3D simulation and input from our CMS medical officers, we do not believe it would be appropriate to always package the costs of the 3D simulation procedure into the ablation procedure. Based on the technology and its potential use in the HOPD setting, we used CPT code 75557 (Cardiac magnetic resonance imaging for morphology and function without contrast material) as a comparator code to determine an APC and status indicator assignment for CPT 0944T. While we realize that there are significant differences between these two codes, we believe that both codes use a type of imaging service to provide valuable information for the clinician to assist in further diagnosing and treating patients. CPT code 75557 is assigned to APC 5523 (Level 3 Imaging without Contrast) and a status indicator of “Q1” (STV-Packaged Codes; Paid under OPPS). We also note that the CAS-One® IR has received 510(k) Premarket Notification from the FDA and should no longer be assigned status indicator “E1”.</P>
                    <P>In summary, we are revising the status indicator for CPT code 0944T from status indicator “E1” to status indicator “Q1” (STV-Packaged Codes; Paid under OPPS), indicating a conditionally packaged procedure. CPT code 0944T will be packaged when it is provided with a significant procedure but will be separately paid when the service appears on the claim without a significant procedure (see Table 74). We are assigning CPT code 0944T to APC 5523 (Level 3 Imaging without Contrast) with a final payment rate of around $240.00. Please refer to Table G43 for the code descriptor, APC assignment, and status indicator assignment for CPT code 0944T for CY 2025. The final payment rate for 0944T can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator (SI) meanings for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="158">
                        <PRTPAGE P="94070"/>
                        <GID>ER27NO24.098</GID>
                    </GPH>
                    <HD SOURCE="HD3">6. Administration of Lacrimal Ophthalmic Insert Into Lacrimal Canaliculus, CPT Code 68841(APC 5503)</HD>
                    <P>
                        Dextenza, which is described by HCPCS code J1096 (Dexamethasone, lacrimal ophthalmic insert, 0.1 mg), is a drug indicated for “the treatment of ocular inflammation and pain following ophthalmic surgery” and for “the treatment of ocular itching associated with allergic conjunctivitis.” 
                        <SU>24</SU>
                        <FTREF/>
                         The drug manufacturer previously asserted that this drug is administered and described by CPT code 0356T (Insertion of drug-eluting implant (including punctal dilation and implant removal when performed) into lacrimal canaliculus, each). Interested parties also previously stated that Dextenza is inserted in a natural opening in the eyelid (called the punctum) and that the drug is designed to deliver a tapered dose of dexamethasone to the ocular surface for up to 30 days. CPT code 0356T was deleted December 31, 2021, and replaced with CPT code 68841 (Insertion of drug-eluting implant, including punctal dilation when performed, into lacrimal canaliculus, each), effective January 1, 2022.
                    </P>
                    <FTNT>
                        <P>
                            <SU>24</SU>
                             FDA Package Insert. 
                            <E T="03">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208742s007lbl.pdf</E>
                            .
                        </P>
                    </FTNT>
                    <P>Interested parties currently assert that the drug, Dextenza, is administered and described by CPT code 68841. We refer readers to the CY 2023 OPPS/ASC final rule with comment period for a detailed history of CMS payment assignments for CPT code 0356T and CPT code 68841 (87 FR 71840). See section XIII.F. of this final rule with comment period for the CY 2025 payment status of the drug, Dextenza, which may be described by HCPCS code J1096.</P>
                    <P>In the CY 2024 OPPS/ASC final rule with comment period (88 FR 81651 through 81653), we stated that based on the claims data available at the time, we continued to believe that the assignment of CPT code 68841 to APC 5503 (Level 3 Extraocular, Repair, and Plastic Eye Procedures) was appropriate based on the geometric mean costs. We also reiterated our reasoning that CPT code 68841 was appropriately assigned to an OPPS status indicator of “Q1” and ASC payment indicator of “N1.” We continued to believe that CPT code 68841 is mostly performed during ophthalmic surgeries, such as cataract surgeries. A status indicator “Q1,” indicating a conditionally packaged procedure, describes a HCPCS code where the payment is packaged when it is provided with a significant procedure but is separately paid when the service appears on the claim without a significant procedure. Because ASC services always include a surgical procedure, HCPCS codes that are conditionally packaged under the OPPS are generally packaged (payment indictor “N1”) under the ASC payment system. Although stakeholders stated this is an independent surgical procedure and should not be packaged into the primary ophthalmic procedure in which the drug and drug administration are associated, we did not agree based on observed clinical patterns of how the drug is used. Based on CY 2024 claims data, out of over 7,000 total frequency claims, CPT code 68841 was used independently only about 2 percent of the time, meaning that the other 98 percent of the time CPT code 68841 had its payment packaged into the primary procedure with which it is associated.</P>
                    <P>These data reinforced our belief that Dextenza and CPT code 68841 are not furnished independently of a surgical procedure and should be packaged into the primary ophthalmic procedure with which the drug and drug administration are associated. While we recognized that there are some claims that may only include CPT code 68841 without a primary ophthalmic surgery on the claim, we did not believe that this is a frequent occurrence based on our claims data and clinical use patterns; as previously mentioned, our claims data showed that only 2 percent of claims are performed independently of another primary procedure.</P>
                    <P>For CY 2025, we proposed to continue to assign CPT code 68841 to APC 5503 (Level 3 Extraocular, Repair, and Plastic Eye Procedures). We also proposed to continue to assign CPT code 68841 to OPPS status indicator “Q1” and an ASC payment indicator of “N1.” The issue of payment for CPT code 68841 was brought to the Advisory Panel on Hospital Outpatient Payment (also known as HOP Panel) in 2024 for CY 2025 rulemaking. At the August 2024 meeting, based on the information presented, the Panel made no recommendation to CMS regarding changing the proposed status indicator assignment, Q1, for HCPCS code 68841 for CY 2025.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received input from several interested parties contending that increased and separate payment for CPT code 68841, the code that can be used to describe the administration of the drug Dextenza, is required to ensure continued beneficiary access to Dextenza (HCPCS code J1096) in both the HOPD and ASC settings. Commenters emphasized that the lack of payment disproportionately and negatively affects the ASC setting. Several commenters pointed to the clinical importance of providing Dextenza to patients, noting that it reduces ocular pain and inflammation and reduces the burden of topical eyedrop application. Additionally, commenters stated that they usually perform the procedure to administer Dextenza in conjunction with ophthalmic surgeries.
                    </P>
                    <P>
                        Commenters generally did not disagree with the proposed APC assignment, but rather recommended CMS pay separately for the procedure. 
                        <PRTPAGE P="94071"/>
                        Many of these commenters recommended CMS assign CPT code 68841 to a status indicator of “J1,” indicating a comprehensive APC procedure. Commenters believed that “J1” would be the most accurate status indicator assignment and would generate consistency within APC 5503 (Level 3 Extraocular, Repair, and Plastic Eye Procedures), as all other codes in APC 5503 are assigned to status indicator “J1.” Commenters stated that CPT code 68841 required an additional 5 minutes of operating time and the assistance of an ophthalmic technician, and without payment for those costs, it was difficult to provide the drug to Medicare beneficiaries.
                    </P>
                    <P>Commenters did not agree with CMS that the fact that CPT code 68841 was performed as a standalone procedure only two percent of the time was an adequate justification for assigning a “Q1” status indicator. They believed, and provided examples, that there are many other procedures that are performed independently at that frequency or a lower percentage of the time, that are assigned to a payable status indicator for hospital outpatient purposes and thus also are paid separately in the ASC setting. For example, commenters mentioned CPT code 64415 (Injection(s), anesthetic agent(s) and/or steroid; brachial plexus, including imaging guidance when performed) as an example of a procedure with a lower percentage of single frequency claims and that is assigned to a payable status indicator; a status indicator of “T” in this example. Commenters also believed that CPT code 68841 was similar to other procedures for introducing a product to the eye, such as CPT code 66020 (Injection, anterior chamber of eye (separate procedure); air or liquid) and should be paid in a similar manner. Commenters believed the procedure described by CPT code 68841 is a distinct surgical procedure that requires additional operating room time and resources. These commenters believed that the cataract surgery is conducted and concluded, and then the procedure described by CPT code 68841 begins.</P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their feedback. We have long maintained that Dextenza is a drug that functions as a surgical supply and should be packaged under our packaging policy at 42 CFR 419.2(b), which lists the types of items and services for which payment is packaged under the OPPS. Specifically, § 419.2(b)(16) includes drugs and biologicals that function as supplies when used in a surgical procedure as packaged costs. Historically, we have stated that we consider all items related to the surgical outcome and provided during the hospital stay in which the surgery is performed, including postsurgical pain management drugs, to be part of the surgery for purposes of our drug and biological surgical supply packaging policy (79 FR 66875). As such, the drug administration procedure, CPT code 68841, is also supporting the main ocular procedure being performed. CPT code 68841 should, therefore, be packaged as an intraoperative service under § 419.2(b)(14).
                    </P>
                    <P>Based on the rationale provided in the CY 2024 OPPS/ASC final rule with comment period, (88 FR 81651 through 81653), the procedure described by CPT code 68841 had its payment packaged into another procedure 98 percent of the time, meaning that it is not an independent surgical procedure as commenters assert. Rather, CPT code 68841 is used to support the primary procedure being performed and is a supportive intraoperative service that is a part of that primary procedure. We reiterate that both Dextenza and its administration impact the surgical outcome of the primary procedure and are provided during the hospital stay in which the surgery is performed, which we consider to be part of the surgery for purposes of our drug and biological surgical supply packaging policy. Although interested parties state this is an independent surgical procedure and should not be packaged into the primary ophthalmic procedure in which the drug and drug administration are associated, based on expected and observed clinical patterns as to how the drug is used, we do not agree.</P>
                    <P>When revaluating the claims data available for CY 2025, CPT code 68841 has 94 single frequency claims in the OPPS out of over 4200 total frequency claims, meaning that 98 percent of the time CPT code 68841 was furnished with another primary procedure into which CPT code 68841's payment was packaged. This confirms our belief that CPT code 68841 is a component of another primary procedure, supportive of that procedure, and should have its payment packaged into that procedure.</P>
                    <P>Additionally, as commenters were most concerned about a financial disincentive, we note that utilization has been increasing year over year based on utilization patterns of Dextenza in the ASC setting. For example, from claims year CY 2022 to claims year CY 2023, the number of units of Dextenza billed increased from approximately 260,000 to approximately 320,000 units, which reflects a nearly 20 percent year over year increase in utilization. Therefore, we do not believe that our packaging policies are hindering appropriate utilization as suggested by commenters. We note that HCPCS code J1096, which may be used to describe the drug, Dextenza, is a qualifying product for separate payment in both the OPPS and ASC under our policy to implement section 4135 of the CAA, 2023. Please see section XIII.F. of this final rule with comment period, for additional information.</P>
                    <P>For the reasons discussed, we continue to believe that it is appropriate to assign CPT code 68841 to a status indicator “Q1,” indicating a conditionally packaged procedure, which describes a HCPCS code where the payment is packaged when it is provided with a significant procedure but is separately paid when the service appears on the claim without a significant procedure. Because ASC services always include a surgical procedure, HCPCS codes that are conditionally packaged under the OPPS are generally packaged (payment indictor “N1”) under the ASC payment system. We do not believe the HCPCS codes suggested by commenters that are not conditionally packaged are analogous to CPT code 68841. Therefore, our analysis was based on claims data specific to CPT code 68841 in order to confirm the appropriateness of the assignment to an OPP SI = “Q1” and ASC PI = “N1.”</P>
                    <P>After consideration of the public comments, we are finalizing our proposal, without modification, to assign CPT code 68841 to APC 5503 with OPPS status indicator “Q1” (STV Packaged Codes) for CY 2025, which typically means there will be a packaged APC payment if this code is billed on the same claims as a HCPCS code assigned to status indictor “S,” “T,” or “V” (Clinic or Emergency Department Visit). In addition, based on the OPPS assignments, we are finalizing an ASC payment indicator of “N1” (Packaged service/item; no separate payment made) for CPT code 68841 for CY 2025.</P>
                    <P>
                        For the final CY 2025 OPPS payment rates, we refer readers to OPPS Addendum B to this final rule with comment period. In addition, we refer readers to OPPS Addendum D1 to this final rule with comment period for the status indicator definitions for all codes reported under the OPPS. For the final CY 2025 ASC payment rates and payment indicators, we refer readers to Addendum AA and Addendum BB for the ASC payment rates, and Addendum DD1 for the ASC payment indicator and their definitions. The OPPS Addenda B and D1 and ASC Addenda AA, BB, and 
                        <PRTPAGE P="94072"/>
                        DD1 are available via the internet on the CMS website.
                    </P>
                    <P>Please refer to Table 75 for the code descriptor, APC assignment, status indicator assignment, and payment indicator assignment for CPT code 68841 for CY 2025.</P>
                    <GPH SPAN="3" DEEP="164">
                        <GID>ER27NO24.099</GID>
                    </GPH>
                    <HD SOURCE="HD3">7. Application of Rigid Total Contact Leg Cast, CPT Code 29445 (APC 5102)</HD>
                    <P>CPT code 29445 describes the procedure of applying a rigid leg cast. This code specifically refers to the process of immobilizing a leg fracture or injury by encasing the affected area in a hard cast, which helps to stabilize the bone and promote healing.</P>
                    <P>In the CY 2025 OPPS/ASC proposed rule, we proposed to continue to assign CPT code 29445 to APC 5102 (Level 2 Strapping and Cast Application) with status indicator “T” (Procedure or service, multiple procedure reduction applies; with a separate APC payment under OPPS) and proposed payment rate of $266.86.</P>
                    <P>Payment for CPT code 29445 was brought to the Advisory Panel on Hospital Outpatient Payment (also known as HOP Panel) at the August 2024 meeting. Based on the information presented, the HOP Panel recommended that “CMS consider HCPCS code 29445, (Application of rigid total contact leg cast), a separately payable code when performed concurrently on the same date of service as any of the following: HCPCS codes 11402, 11403,11404, 11405, 11406, 11407, 97597, 97598, 15271, 15272, 15273, 15274, 15275, 15276, 15277, 15278.”</P>
                    <P>We received two public comments endorsing the recommendation of the HOP Panel.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter requested that CMS ensure that hospital outpatient departments are able to receive separate payment for the CPT code 29445 when a debridement or graft is performed on the same date of service, which they are currently are unable to do because of a National Correct Coding Initiative (NCCI) edit that has been put in place.
                    </P>
                    <P>Another commenter stated that if a wound debridement is performed (codes 11042-11047, 97597-97598), any primary or secondary dressing materials used to cover the wound would be included in the debridement and would not be separately reported. However, a TCC is not considered a wound dressing and is not included in the debridement procedure. Therefore, the commenter believed the cast application should be reported in addition to the code for the appropriate level of debridement, if performed, and should be mapped to APC 5102.</P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for providing this information related to CPT code 29445. We will take commenters' suggestions into consideration for the future rulemaking.
                    </P>
                    <HD SOURCE="HD3">8. Aquabeam Waterjet Ablation Procedure, CPT Code 0421T (APC 5376)</HD>
                    <P>CPT code 0421T (Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed) describes the Aquabeam waterjet ablation procedure. According to the manufacturer, Aquabeam is for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) by using a high-velocity water stream to ablate and remove tissue from enlarged prostates.</P>
                    <P>For the CY 2025 proposed rule, we estimated the geometric mean cost for CPT code 0421T to be $10,438 based on 4,743 single claims and proposed to assign the service to APC 5376 (Level 6 Urology and Related Services), which has a geometric mean cost of $9,356.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter supported our proposal to assign CPT code 0421T to APC 5376 due to the clinical and resource similarities to other procedures assigned to APC 5376.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's feedback on CPT code 0421T and we agree with the commenter's recommendation to finalize the APC assignment.
                    </P>
                    <P>After consideration of the public comment we received, we are finalizing our proposal without modification to assign CPT code 0421T to APC 5376. Please refer to Table 76 below for the final OPPS APC and status indicator assignment for HCPCS code 0421T for CY 2025. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="161">
                        <PRTPAGE P="94073"/>
                        <GID>ER27NO24.100</GID>
                    </GPH>
                    <HD SOURCE="HD3">9. Aqueous Shunt to Extraocular Plate Reservoir Procedure, CPT Code 66180 (APC 5493)</HD>
                    <P>For CY 2024, we assigned CPT code 66180 (Aqueous shunt to extraocular equatorial plate reservoir, external approach; with graft) to APC 5492 (Level 2 Intraocular Procedures). For CY 2025, as shown in OPPS Addendum B that was released with the CY 2025 OPPS/ASC proposed rule with comment period, we proposed to maintain the APC assignment to APC 5492 with a payment rate of $3,873.90 for CPT code 66180.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received two comments requesting that we reassign CPT code 66180 to APC 5493 (Level 3 Intraocular Procedures) due to the code's similarity to CPT code 66179 (Aqueous shunt to extraocular equatorial plate reservoir, external approach; without graft), which we proposed to assign to APC 5493 for CY 2025. The commenters explained that the procedures are the same except that CPT code 66180 requires additional clinical work, time, and resources, associated with suturing a patch graft to the eye. The commenters also explained that the available claims data from the CY 2025 OPPS/ASC proposed rule support assigning CPT code 66180 to APC 5493. For example, per the commenters, the geometric mean cost for CPT code 66180 ($5,026.75) is closer to the geometric mean cost of APC 5493 ($5,298.63) than the geometric mean cost of APC 5492 ($4,159.32).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We agree with the commenters that APC 5493 is a more appropriate placement for CPT code 66180 due to the additional clinical work and resources utilized to furnish the service due to its similarity to CPT code 66179. We also agree with the commenters that the geometric mean cost of CPT code 66180 confirms that the resources necessary to furnish the service more closely match the geometric mean cost of APC 5493 than APC 5492.
                    </P>
                    <P>After consideration of the public comments received, we are finalizing an APC assignment for CPT code 66180 to APC 5493 for CY 2025. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">10. Arteriovenous Fistula (AVF) Creation Procedures, CPT Codes 36836 and 36837 (APC 5194)</HD>
                    <P>
                        CPT codes 36836 (Percutaneous arteriovenous fistula creation, upper extremity, single access of both the peripheral artery and peripheral vein, including fistula maturation procedures (
                        <E T="03">e.g.,</E>
                         transluminal balloon angioplasty, coil embolization) when performed, including all vascular access, imaging guidance and radiologic supervision and interpretation) and 36837 (Percutaneous arteriovenous fistula creation, upper extremity, separate access sites of the peripheral artery and peripheral vein, including fistula maturation procedures (
                        <E T="03">e.g.,</E>
                         transluminal balloon angioplasty, coil embolization) when performed, including all vascular access, imaging guidance and radiologic supervision and interpretation) describe a percutaneous arteriovenous fistula creation of an upper extremity. CPT code 36836 replaced HCPCS codes C9754 and G2170, while CPT code 36837 replaced HCPCS codes C9755 and G2171.
                    </P>
                    <P>In the CY 2020 OPPS/ASC final rule with comment period (84 FR 61246 through 61247), in response to public comment, input from our medical advisors, and the available claims data, we reassigned C9754 and C9755 from APC 5193 to APC 5194. In the CY 2021 OPPS/ASC final rule with comment period (85 FR 85954 through 95955), we used our equitable adjustment authority to maintain the assignment of HCPCS codes G2170 and G2171 to APC 5194 (Level 4 Endovascular Procedures), given that both procedures are for ESRD patients that need dialysis, the predecessor codes had very similar median costs, and there were low claims data available. We continued the assignment of CPT codes 36836 and 36837 to APC 5194, with commenter support, for CY 2022.</P>
                    <P>
                        In the CY 2023 OPPS/ASC final rule with comment period (87 FR 71863 through 71864), we assigned the newly established 
                        <SU>25</SU>
                        <FTREF/>
                         CPT codes 36836 and 36837 to APC 5194 based on our assessment of the CY 2023 geometric mean cost of predecessor codes HCPCS codes G2170 ($12,055.90) and G2171 ($13,486.08) and their APC assignment. For CY 2024, we continued assignment to APC 5194 for HCPCS codes G2170 and G2171, with commenter support.
                    </P>
                    <FTNT>
                        <P>
                            <SU>25</SU>
                             The AMA's CPT Editorial Panel established CPT codes 36836 and 36837 during the January 2023 update and CMS deleted HCPCS codes G2170 and G2171, effective January 1, 2023.
                        </P>
                    </FTNT>
                    <P>For CY 2025, we proposed to continue assignment of both CPT codes 36836 and 36837 to APC 5194 (Level 4 Endovascular) with a proposed payment rate of around $17,956. For the CY 2025 proposed rule, CPT code 36836 had227 single claims for ratesetting, a geometric mean cost (GMC) of around $11,234, and CPT code 36837 had 121 single claims for ratesetting and a GMC of around $16,770.</P>
                    <P>
                        <E T="03">Comment:</E>
                         A few commenters supported our assignment of CPT code 36837 to APC 5194.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their support.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters requested that we avoid a proposed payment reduction for CPT code 36837 by maintaining its CY 2024 APC assignment.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We note that for CY 2025 we proposed to maintain the assignment 
                        <PRTPAGE P="94074"/>
                        of CPT code 36837 to APC 5194 and did not propose to reassign CPT code 36837 to a lower-paying APC.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters indicated that CPT codes 36836 and 36837 do not have similar resource costs and that CPT code 36836 would be more appropriately assigned to APC 5193, which had a proposed payment rate of $11,478.26, as opposed to continuing to assign the code to APC 5194, which had a proposed payment rate of $18,167.36. A commenter further suggested that the volume of current claims data is sufficient to support reassigning CPT code 36836 to APC 5193. The commenter believed that the proposed rule geometric mean cost data illustrated distinct differences in required resources to perform the procedures described CPT code 36836 (GMC: $10,123.79) and CPT code 36837 (GMC: $16,849.60) and that CPT code 36836 is significantly overpaid in APC 5194 and would be overpaid in APC 5193, but to a lesser degree.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their comments. We reiterate that we review, on an annual basis, the APC assignments for all services and items paid under the OPPS based on our analysis of the latest claims data and review of the clinical characteristics of the procedure. After further clinical review, we continue to believe that CPT code 36836 is more similar clinically to services in APC 5194, which includes more complex endovascular procedures, than those in APC 5193, which primarily contains less complex revascularization and embolization procedures. Further, while CPT code 36836 does have more available claims than what was available for the initial assignment of CPT code 36836 to APC 5194, we believe additional claims and clinical data would be useful before proposing to move this code to a different APC.
                    </P>
                    <P>However, we note that we review the APC assignments for all items and services paid under the OPPS on an annual basis. We will reevaluate the APC assignment for CPT code 36836 in the next rulemaking cycle.</P>
                    <P>In summary, after consideration of the public comments we received, we are finalizing our proposal, without modification, to continue to assign CPT code 36836 and CPT code 36837 to APC 5194 for CY 2025. We refer readers to Addendum B of this final rule with comment period for the payment rate for all codes paid under the OPPS.</P>
                    <HD SOURCE="HD3">11. Arthroscopic Subacromial Balloon Implant, HCPCS Code C9781 (APC 5115)</HD>
                    <P>HCPCS code C9781 describes the implantation of a subacromial spacer, such as a balloon, in the shoulder to treat a torn rotator cuff. The procedure may also include debridement, acromioplasty, subacromial decompression, and biceps tenodesis.</P>
                    <P>
                        In the CY 2025 OPPS/ASC proposed rule, we proposed to continue to assign HCPCS code C9781 (Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (
                        <E T="03">e.g.,</E>
                         balloon), includes debridement (
                        <E T="03">e.g.,</E>
                         limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed) to APC 5115 (Level 5 Musculoskeletal Procedures) with a proposed payment rate of $12,755.58.
                    </P>
                    <P>We received two comments in support of our proposal.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Both commenters endorsed our proposal to assign HCPCS code C9781, which describes InSpace
                        <E T="51">TM</E>
                         Subacromial Tissue Spacer System, to APC 5115 for CY 2025. They encouraged CMS to maintain this assignment in the final rule.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         Based on our analysis of the latest CY 2023 claims data available for CY 2025 OPPS ratesetting, the geometric mean cost associated with HCPCS code C9781 is $12,757.71based on 493 single claims, which is consistent with the geometric mean cost of $13,022.88for APC 5115.
                    </P>
                    <P>In summary, after consideration of the public comments we received, we are finalizing our proposal to assign HCPCS code C9781 to APC 5115 without modification. The final CY 2025 OPPS payment rate for this code can be found in Addendum B to this final rule with comment period.</P>
                    <HD SOURCE="HD3">12. Artificial Iris Insertion Procedures, CPT Code 66683 (APC 5496)</HD>
                    <P>For the CY 2025 OPPS proposed rule, we proposed to assign placeholder CPT code 6X004 (Implantation of iris prosthesis, including suture fixation and repair or removal of iris, when performed) to APC 5496 (Level 6 Intraocular Procedures) with a payment rate of around $16,416. CPT code 66683 is the final code for 6X004 and will replace CPT code 0616T (Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; without removal of crystalline lens or intraocular lens, without insertion of intraocular lens); CPT code 0617T (Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with removal of crystalline lens and insertion of intraocular lens); and CPT code 0618T (Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with secondary intraocular lens placement or intraocular lens exchange).</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter supported our proposal to assign placeholder CPT code 6X004 (CPT code 66683) to APC 5496.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the support of the commenter for our proposal.
                    </P>
                    <P>After consideration of the public comments we received, we are implementing our proposal without modification to assign CPT code 66683 to APC 5496 (Level 6 Intraocular Procedures). Table 77 shows the finalized status indicator and APC assignment for CPT code 66683. We refer readers to Addendum B of this final rule for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="152">
                        <PRTPAGE P="94075"/>
                        <GID>ER27NO24.101</GID>
                    </GPH>
                    <HD SOURCE="HD3">13. Bronchoscopy With Needle Biopsy, CPT Code 31629 (APC 5154)</HD>
                    <P>CPT code 31629 describes the use of diagnostic rigid or flexible bronchoscope to obtain one or more biopsies from the trachea, main stem, and/or lobar bronchus using a transbronchial needle aspiration technique. In the CY 2025 OPPS/ASC proposed rule, we proposed to continue to assign CPT code 31629 to APC 5154 (Level 4 Airway Endoscopy) with a proposed payment rate of $3,681.38.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one public comment that requested CMS reassign CPT code 31629 from APC 5154 (Level 4 Airway Endoscopy) to APC 5155 (Level 5 Airway Endoscopy) in the CY 2025 ASC/OPPS final rule. The commenter stated that CPT code 31629 is the highest cost significant procedure in APC 5154 with a geometric mean cost of $5,123.33. The geometric mean cost of CPT code 31629 exceeds the geometric mean cost of the lowest cost significant procedure in APC 5155, CPT code 31267 with a geometric mean cost of $5,031.74.
                    </P>
                    <P>According to the commenter, given the intraoperative service time and physician skill level required for the procedure, this procedure is aligned with procedures already assigned to APC 5155 including balloon dilation and stenting procedures. The commenter stated that the reassignment of CPT code 31629 from APC 5154 to APC 5155 would better support resource homogeneity within the Airway Endoscopy Procedures APC series.</P>
                    <P>
                        <E T="03">Response:</E>
                         Although the geometric mean cost of the CPT code 31629 is $1,300 higher than the geometric mean cost of APC 5154, it is $1,974 lower than the geometric mean cost of APC 5155. CPT code 31629 also does not violate the 2 times rule in its current assignment in APC 5154. In addition, we believe that CPT code 31629 fits appropriately in APC 5154 based on clinical similarity and resource homogeneity with the procedures in that APC.
                    </P>
                    <P>Therefore, after consideration of the public comment we received, we are finalizing our proposal without modification, to assign CPT code 31629 to APC 5154 for CY 2025. We refer readers to Addendum B of this final rule with comment period for the CY 2025 final payment rate for this code. Addendum B is available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">14. CADScor System, CPT Code 0716T (APC 5733)</HD>
                    <P>The CADScor System is intended as a diagnostic aid in symptomatic patients suspected of stable coronary artery disease (CAD) and is designed to help reduce invasive and costly diagnostic procedures. The CADScor System is a diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out obstructive CAD. CPT code 0716T describes the service that utilizes the CADScor System: Cardiac acoustic waveform recording with automated analysis and generation of coronary artery disease risk score. For CY 2025, we proposed to assign CPT 0716T to APC 5733—Level 3 Minor Procedures, with a payment rate of $59.07 and a status indicator of “Q1” (conditionally packaged).</P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters disagreed with our proposal to assign CPT code 0716T to APC 5733 with a status indicator of “Q1.” Commenters suggested that CPT code 0716T should be assigned to APC 5722 based on clinical and resource homogeneity with other services assigned to APC 5722. Commenters also expressed that status indicator “S” (separately payable) would be most appropriate for CPT code 0716T. They contended that status indicator “Q1” essentially unconditionally packages the code because CPT code 0716T is never furnished without an emergency department visit.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         Although CPT code 0716T was effective July 1, 2022, we have no claims data for the code. The OPPS payment rates are proposed based on available CY 2023 claims data. Because we have no claims data, we believe that we should continue to assign CPT code 0716T to APC 5733 for CY 2024. We review, on an annual basis, the APC assignments for all services and items paid under the OPPS. As a result, we will reevaluate the APC assignment for CPT code 0716T for the next rulemaking cycle.
                    </P>
                    <P>In addition, as listed in OPPS Addendum D1 of the CY 2025 OPPS/ASC proposed rule, codes assigned to status indicator “Q1” may be packaged, assigned to a composite APC, or paid separately under the OPPS. Specifically, a “Q1” status indicator may indicate a:</P>
                    <P>• Packaged APC payment if billed on the same claim as a HCPCS code assigned status indicator “S”, “T”, or “V”; or</P>
                    <P>• Composite APC payment if billed with specific combinations of services based on OPPS composite-specific payment criteria. Payment is packaged into a single payment for specific combinations of services; or</P>
                    <P>• In other circumstances, payment is made through a separate APC payment</P>
                    <P>After reviewing the public comments, we believe that it is appropriate for the procedure described by CPT code 0716T to be paid separately. We agree with commenters that it is unlikely that CPT code 0716T would be furnished without an emergency department (ED) visit and should not be always be packaged with an ED visit. Therefore, we are revising the status indicator for the code from “Q1” (conditionally packaged) to “S” (Procedure or Service, Not Discounted When Multiple) to indicate that the service is paid separately.</P>
                    <P>
                        In summary, after consideration of the public comments, we are finalizing the APC and status indicator assignment for 
                        <PRTPAGE P="94076"/>
                        CPT code 0716T with modification. Specifically, we are finalizing the assignment of CPT code 0716T to APC 5733 and we are revising the status indicator assignment for CPT code 0716T to “S” (separately payable). Please refer to Table 78 for the code descriptor, APC assignment, status indicator assignment, and payment indicator assignment for CPT code 0716T for CY 2025.
                    </P>
                    <GPH SPAN="3" DEEP="177">
                        <GID>ER27NO24.102</GID>
                    </GPH>
                    <HD SOURCE="HD3">15. Cardiac Magnetic Resonance Imaging Procedures, CPT Codes 75561 and 75563 (APCs 5572 and 5573)</HD>
                    <P>CPT code 75561 (Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences) and CPT code 75563 (Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences; with stress imaging) both describe cardiac MRI procedures.</P>
                    <P>For CY 2024, we assigned CPT code 75561 to APC 5572 (Level 2 Imaging with Contrast), and CPT code 75563 to APC 5573 (Level 3 Imaging with Contrast). For the CY 2025 OPPS/ASC proposed rule, we proposed to maintain the current APC assignments for both cardiac MRI codes.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment requesting that we reassign CPT code 75561 to APC 5573 (Level 3 Imaging with Contrast). The commenter indicated that the other services in APC 5572 (Level 2 Imaging with Contrast) are not clinically similar or similar in resource use to the service described by CPT code 75561.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input. The OPPS payment rates are proposed based on available CY 2023 claims data. Our claims data show a geometric mean cost of about $450 for CPT code 75561 based on 27,543 single claims. We believe that the geometric mean cost of about $450 for CPT code 75561 is more consistent with the geometric mean cost of approximately $361 for APC 5572, than the geometric mean cost of approximately $800 for APC 5573. We continue to believe that the clinical and resource characteristics of CPT code 75561 are sufficiently like other procedures assigned to APC 5572 and should continue to be assigned to APC 5572.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The same commenter requested that CPT code 75563 (Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences; with stress imaging) be reassigned to APC 5593 (Level 3 Nuclear Medicine and Related Services) because of lack of clinical homogeneity and resource utilization with other services currently assigned to APC 5573. The commenter notes that CPT code 75563 was previously assigned to the Nuclear Medicine APC family until the imaging services were restructured during a comprehensive review of the APC series that took place in CY 2016. The purpose of the restructuring of the OPPS APC groupings for imaging services was to improve the clinical and resource homogeneity of the services classified within the imaging APCs (80 FR 70392 and 81 FR 7928).
                    </P>
                    <P>The commenter cites the following reasons to support the reassignment of 75563 to APC 5593:</P>
                    <P>(1) the clinical labor and resources (acquisition time, staffing, medications, and perfusion agents) are very similar to CPT code 78452 which describes myocardial perfusion imaging;</P>
                    <P>(2) both tests are indicated for patients with cardiac angina or coronary artery disease; and</P>
                    <P>(3) both tests provide the same clinical information.</P>
                    <P>We disagreed with a similar argument in the past (81 FR 79630) where commenters asserted that cardiac MRI with stress imaging is very similar to myocardial perfusion imaging because both tests are performed under a stress protocol and therefore should be assigned to APC 5593. APC 5593 contains procedures that describe nuclear medicine tests, and CPT code 75563 is a specific type of MRI and not a nuclear medicine test. Additionally, the geometric mean cost of CPT code 75563 is approximately $887 and the geometric mean cost of the APC to which it is assigned, APC 5573, is approximately $800. These geometric mean costs are very similar. However, the geometric mean cost of APC 5593 is approximately $1,321, which is significantly higher than the geometric mean cost of CPT code 75563. Therefore, assigning CPT code 75563 to APC 5593 would assign the procedure to an APC with clinically dissimilar nuclear medicine tests that have a geometric mean cost of $1,321 (as compared to the $887 geometric mean cost of CPT code 75563).</P>
                    <P>
                        In summary, after consideration of the public comment, we are finalizing our proposal without modification to assign CPT code 75561 to APC 5572 and CPT code 75563 to APC 5573 for CY 2025. The final CY 2025 payment rates for the codes can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the SI definitions for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.
                        <PRTPAGE P="94077"/>
                    </P>
                    <HD SOURCE="HD3">16. CardioMEMS, HCPCS Code GMEM1, CPT Code 93264 (APCs 5724 and 5741)</HD>
                    <P>The CardioMEMS Heart Failure System allows practitioners treating heart failure patients to wirelessly monitor and measure pulmonary artery pressure and heart rate in patients with heart failure and transmit the information to the physician to inform the treatment plan for the patient. The system includes two critical components: first, a miniaturized, wireless monitor, which is implanted into a patient's pulmonary artery, and second, a smart pillow (the CardioMEMS Patient Electronics System), which captures and transmits readings via safe radio frequency from the patient's implanted CardioMEMS Heart Failure System. The CardioMEMS Heart Failure System enables patients to transmit critical heart failure status information to clinicians regularly, potentially eliminating the need for frequent clinic or hospital visits. The CardioMEMS Heart Failure System is described by CPT code 33289 (Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed).</P>
                    <P>Interested parties have met with CMS and highlighted the critical importance of the device for heart failure patients who require close monitoring of weight and blood pressure to prevent fluid buildup around the heart and have requested that CMS establish coding to describe when practitioners and hospitals incur costs during clinical scenarios when crucial components of the system require replacement. Given that these components are crucial for system functionality and there is no existing coding framework to address their replacement, we believe that establishing appropriate coding and payment mechanisms can facilitate the provision of these services more effectively in the office and hospital settings. In the CY 2025 Physician Fee Schedule (PFS) proposed rule, we proposed a new code, HCPCS code GMEM1 (Provision of replacement patient electronics system (for example, system pillow) for home pulmonary artery pressure monitoring including provision of materials for use in the home and reporting of test results to physician or qualified health care professional). The CY 2025 PFS proposed rule (89 FR 61956) sought comment from interested parties regarding direct costs from invoices for the replacement component referenced above, utilization estimates, and potential indicators.</P>
                    <P>CPT Code 93264 (Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional) can be used by hospitals to bill for the ongoing analysis and monitoring performed with CardioMEMS.</P>
                    <P>While we did not discuss the GMEM1 code in the CY 2025 OPPS proposed rule preamble it was included in Addendum B with an assignment to APC 5741 (Level 1 Electronic Analysis of Devices) with a payment rate of $36.90 and assigned a status indicator of Q1. CPT code 93264 was included in Addendum B with a status indicator of “M” to indicate that this code is not payable under the OPPS.</P>
                    <P>The issue of payment for GMEM1 was brought to the Advisory Panel on Hospital Outpatient Payment (also known as HOP Panel) in 2024 for CY 2025 rulemaking. At the August 2024 meeting, based on the information presented, the Panel did not make any recommendations on GMEM1.</P>
                    <P>We note that HCPCS code G0555 is replacing the placeholder code GMEM1.</P>
                    <P>
                        <E T="03">Comment:</E>
                         In their comment letters on the CY 2025 OPPS proposed rule, commenters indicated that the G0555 (placeholder codeGMEM1) code descriptor proposed in the CY 2025 PFS proposed rule introduces confusion by also referencing reporting test results to the physician, which is a separate function furnished by a different party than the replacement Patient Electronics System (PES). Commenters requested that CMS revise the proposed code descriptor for G0555 (placeholder code GMEM1) to clarify that it is for the replacement PES only and remove the following language from the descriptor: “and reporting of test results to physician or qualified health care professional”). Commenters requested that if the code is finalized under OPPS (and PFS) with the revised descriptor, that CMS assign it to APC 1528, New Technology—Level 28 ($5001-$5500), which they believe is reflective of the cost of the replacement PES.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We agree that assignment to APC 5741 is likely not reflective of the cost of the replacement PES. However, assignment to New Technology APCs usually occurs when there is no existing clinical APC that is appropriate in terms of clinical similarity or resources. Based on the nature of the procedure, we believe that the service associated with GMEM1 is more appropriately in APC 5724 (Level 4 Diagnostic Tests and Related Services). We believe that the service described by HCPCS code G0555 (placeholder code GMEM1) shares similar resource costs and clinical characteristics with services included in APC 5724. Assignment to APC 5741 may not have sufficiently covered the cost of the replacement of the PES. Therefore, for CY 2025, we are revising the assignment for HCPCS code G0555 (placeholder code GMEM1) to APC 5724, with a status indicator of “S”.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters recommend that CMS revise the OPPS status indicator for CPT 93264, which CMS proposed to designate as “M” (not payable under the OPPS). They argued that this classification is contrary to CMS's treatment of similar monitoring procedures (
                        <E T="03">e.g.,</E>
                         CPT codes 93297 and 93298), which have status indicator “Q1” and are assigned to APC 5741 (Level 1 Electronic Analysis of Devices).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         As listed in OPPS Addendum D1 of the CY 2025 OPPS/ASC proposed rule, codes assigned to status indicator “Q1” may be packaged, assigned to a composite APC, or paid separately under the OPPS. Specifically, a “Q1” status indicator may indicate a:
                    </P>
                    <P>• Packaged APC payment if billed on the same claim as a HCPCS code assigned status indicator “S”, “T”, or “V”; or</P>
                    <P>• Composite APC payment if billed with specific combinations of services based on OPPS composite-specific payment criteria. Payment is packaged into a single payment for specific combinations of services; or</P>
                    <P>• In other circumstances, payment is made through a separate APC payment</P>
                    <P>
                        After reviewing the public comments, we agree with commenters that it is appropriate for the procedure described by CPT code 93264 to be assigned to status indicator Q1(conditionally packaged). Therefore, we are revising the status indicator for the code from “M” (not payable under the OPPS”) to “Q1” (conditionally packaged). The conditional packaging of this code supports our overarching goal to make payments for all services paid under the OPPS and ASC payment system more consistent with those of a prospective payment system and less like those of a per-service fee schedule. We believe that packaging encourages efficiency and is an essential component of a prospective payment system, and that packaging payments for items and services that are typically integral, ancillary, supportive, dependent, or adjunctive to a primary service is a 
                        <PRTPAGE P="94078"/>
                        fundamental part of the OPPS. We therefore believe packaging of CPT code 93264 is appropriate.
                    </P>
                    <P>Because CPT code 93264 was assigned status indicator “M” (not payable under the OPPS) we have no claims data to use for making an APC assignment for CPT code 93264 in CY 2025. We agree with commenters that the code is similar in clinical and resource use to CPT codes 93297 and 93298. Therefore, we will be assigning CPT code 93264 to APC 5741 (Level 1 Electronic Analysis of Devices) for CY 2025.</P>
                    <P>In summary, after consideration of the public comment, we are finalizing the APC assignment for HCPCS code G0555 (placeholder code GMEM1) with modification. Specifically, we are revising the APC assignment for HCPCS code G0555 (placeholder code GMEM1) to APC 5724 and assigning the code to status indicator “S” for CY 2025. We are revising the status indicator for CPT 93264 and assigning a status indicator of “Q1” for CY 2025. Lastly, we are assigning CPT 93264 to APC 5741 for CY 2025. The final CY 2025 OPPS payment rate for this code can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the SI meanings for all codes reported under the OPPS. Addendum D1 is available via the internet on the CMS website.</P>
                    <P>We refer readers to Table 79 for the code descriptor, APC assignment, status indicator assignment, and payment indicator assignment for CPT codes G0555 (placeholder code GMEM1) and 93264 for CY 2025.</P>
                    <GPH SPAN="3" DEEP="322">
                        <GID>ER27NO24.103</GID>
                    </GPH>
                    <HD SOURCE="HD3">17. Caregiver Training Services, HCPCS Codes GCTD1, GCTD2, and GCTD3 (APC 5731)</HD>
                    <P>
                        The CY 2025 Physician Fee Schedule (PFS) proposed rule (89 FR 61956) proposed to establish new coding and payment for caregiver training for direct care services and supports. The topics of training could include, but would not be limited to, techniques to prevent decubitus ulcer formation, wound dressing changes, and infection control. Unlike other caregiver training codes that are currently paid under the PFS, the caregiver training codes for direct care services and supports focus on specific clinical skills aimed at the caregiver effectuating hands-on treatment, reducing complications, and monitoring the patient when the patient is not capable to do so themselves. Three new HCPCS codes were proposed: GCTD1 (
                        <E T="03">Caregiver training in direct care strategies and techniques to support care for patients with an ongoing condition or illness and to reduce complications (including, but not limited to, techniques to prevent decubitus ulcer formation, wound dressing changes, and infection control) (without the patient present), face-to-face; initial 30 minutes</E>
                        ), GCTD2 (
                        <E T="03">Caregiver training in direct care strategies and techniques to support care for patients with an ongoing condition or illness and to reduce complications (including, but not limited to, techniques to prevent decubitus ulcer formation, wound dressing changes, and infection control) (without the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service) (Use GCTD2 in conjunction with GCTD1)</E>
                        ), and GCTD3 (
                        <E T="03">
                            Group caregiver training in direct care strategies and techniques to support care for patients with an ongoing condition or illness and to reduce complications (including, but not limited to, techniques to prevent 
                            <PRTPAGE P="94079"/>
                            decubitus ulcer formation, wound dressing changes, and infection control) (without the patient present), face-to-face with multiple sets of caregivers)
                        </E>
                        ). We did not propose APC or status indicator assignments for these G codes in the CY 2025 OPPS proposed rule (89 FR 59186).
                    </P>
                    <P>We note that the HCPCS codes G0541, G0542, and G0543 are replacing their respective placeholder codes GCTD1, GCDT2, and GCTD3.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received several comments related to the CY 2025 Physician Fee Schedule (PFS) proposal suggesting that we begin providing payment for Caregiver Training Services (CTS) G0541, G0542, and G0543placeholder codes GCTD1, GCTD2, and GCTD3) under the OPPS. Commenters asked for clarification on whether these codes would be given the OPPS status indicator “A,” which would limit their use for outpatient hospital payment purposes to therapists only, or whether CMS will assign separately payable status indicators to those codes. Commenters stated that assigning separately payable status would recognize the different types of hospital staff that can render appropriate CTS. Commenters requested that CMS make the newly proposed CTS codes G0541, G0542, and G0543 (placeholder codes GCTD1, GCTD2, and GCTD3) payable under the OPPS.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         HCPCS codes G0541, G0542, and G0543 (placeholder codes GCTD1, GCTD2, and GCTD3) will be effective on January 1, 2025. Based on our evaluation of these new codes, we are proposing an interim assignment of HCPCS codes G0541, G0542, and G0543 (placeholder codes GCTD1, GCTD2, and GCTD3) to status indicator “A” to indicate that these codes are payable under a fee schedule or payment system other than the OPPS. These services are covered Medicare services and will be assigned payable indicators under the Physician Fee Schedule (PFS). While these services are not payable under the OPPS, they are payable under the PFS; therefore, we are proposing to assign them status indicator of “A.” Sections 1834(k) and 1833(a)(8) of the Act require that payment be made for outpatient therapy services (physical therapy, speech language pathology, and occupational therapy) furnished by providers of therapy services, including a hospital (to its outpatients and inpatients not under a Part A stay), be made under the PFS.
                    </P>
                    <P>In summary, we are proposing an interim assignment of HCPCS codes G0541, G0542, and G0543 (placeholder codes GCTD1, GCTD2, and GCTD3) to status indictor “A” to indicate that the code is payable under a fee schedule or payment system other than the OPPS. Because we were not able to propose APC and status indicator assignments in the CY 2025 OPPS proposed rule, we will be assigning HCPCS codes G0541, G0542, and G0543 (placeholder codes GCTD1, GCTD2, and GCTD3) comment indicator “NI” in Addendum B of this final rule. This comment indicator is for new HCPCS codes that will be effective January 1, 2025, to indicate that we are assigning them an interim status indicator and APC assignment, which is subject to public comment. We invite public comment on the interim proposed status indicators for HCPCS codes G0541, G0542, and G0543 (placeholder codes GCTD1, GCTD2, and GCTD3), which will then be finalized in the CY 2026 OPPS/ASC final rule with comment period.</P>
                    <P>Please refer to Table 80 below for the proposed interim status indicator assignments for HCPCS codes G0541, G0542, and G0543 (placeholder codes GCTD1, GCTD2, and GCTD3) for CY 2025.</P>
                    <GPH SPAN="3" DEEP="481">
                        <PRTPAGE P="94080"/>
                        <GID>ER27NO24.104</GID>
                    </GPH>
                    <HD SOURCE="HD3">18. Chimeric Antigen Receptor Therapy (CAR-T), CPT Codes 0537T, 0538T, 0539T, and 0540T (APC 5694)</HD>
                    <P>
                        Chimeric Antigen Receptor T-Cell (CAR T-cell) therapy is a cell-based gene therapy in which T-cells are collected and genetically engineered to express a chimeric antigen receptor that will bind to a certain protein on a patient's cancerous cells. The CAR T-cells are then administered to the patient to attack certain cancerous cells, and the individual is observed for potential serious side effects that would require medical intervention. We refer readers to previous discussions in the OPPS/ASC final rules with comment period for background regarding the specific CAR T-cell products, in both the CY 2020 OPPS/ASC final rule with comment period (84 FR 61231 through 61234) and the CY 2019 OPPS/ASC final rule with comment period (83 FR 58904 through 58908). In addition, for discussion about CY 2022 OPPS payment policies for separately paid drugs with pass-through status expiring or continuing in CY 2022, please see sections V.A.4 and V.A.5 of this final rule with comment period. The AMA created four Category III CPT codes that are related to CAR T-cell therapy, effective January 1, 2019. As discussed in the CY 2019 OPPS/ASC final rule with comment period (83 FR 58904 through 58908), the CY 2020 OPPS/ASC final rule with comment period (84 FR 61231 through 61234), and the CY 2021 OPPS/ASC final rule with comment period (85 FR 85949 through 85951) we finalized our proposal to assign procedures described by CPT codes 0537T, 0538T, and 0539T to status indicator “B” (Codes that are not recognized by OPPS when submitted on an outpatient hospital Part B bill type (12x and 13x)) to indicate that the services are not paid under the OPPS. The procedures described by CPT codes 0537T, 0538T, and 0539T describe the various steps required to collect and prepare the genetically modified T-cells, and Medicare does not generally pay separately for each step used to 
                        <PRTPAGE P="94081"/>
                        manufacture a drug or biological. We also finalized that the procedures described by CPT code 0540T would be assigned status indicator “S” (Procedure or Service, Not Discounted when Multiple) and APC 5694 (Level 4 Drug Administration) for CY 2019 through CY 2024 and made no proposal to change the assignment for CY 2025. Additionally, the National Uniform Billing Committee (NUBC) established CAR T-cell-related revenue codes and a value code to be reportable on Hospital Outpatient Department (HOPD) claims effective for claims received on or after April 1, 2019.
                    </P>
                    <P>Category III CPT codes 0537T, 0538T, 0539T, and 0540T are being replaced by Category I CPT codes 38225, 38226, 38227, and 38228, which were previously represented by placeholder codes 3X018, 3X019, 3X020, and 3X021. As such, we made no specific proposal related to the CAR T-cell preparation codes but proposed to apply the existing APC and status indicator assignments for the predecessor Category III CPT codes to the replacement Category I CPT codes.</P>
                    <P>As listed in Addendum B of the CY 2025 OPPS/ASC proposed rule, we proposed to continue to assign procedures described by these CPT codes, 3X018, 3X019, and 3X020, to status indicator “B” (Codes that are not recognized by OPPS when submitted on an outpatient hospital Part B bill type (12x and 13x)) to indicate that the services are not paid under the OPPS. We proposed to continue to assign CPT code 3X021 to status indicator “S” (Procedure or Service, Not Discounted when Multiple) and APC 5694 (Level IV Drug Administration).</P>
                    <P>
                        <E T="03">Comment:</E>
                         Some commenters provided input on the proposed policies in the physician office setting regarding the dose preparation procedures associated with CAR T-cell therapy and other billing topics in the office setting, such as the expansion of digits on MAC claims processing screens for physician office claims.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         Comments related to the CY 2025 PFS payment policies are out of scope.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters opposed our proposal to continue to assign status indicator “B” to CPT codes 38225, 38226, and 38227, for CY 2025. Many commenters provided alternate status indicator assignment recommendations, such as “S”, as well as APC assignment recommendations. Commenters stated that by allowing these codes to be billable and paid, CMS could use claims data collected to assign the codes to more accurate APCs. Some commenters explained that CMS's overall practice and billing process should be reevaluated, with some recommending revisions to, or the retirement of, MLN Matters Number SE19009 
                        <SU>26</SU>
                        <FTREF/>
                         which they believed caused confusion, raised numerous program integrity concerns, including confusion regarding what can be included in ASP reporting, increased inconsistencies with Medicare requirements for under arrangement services and with charges reported and hospital billing, and commenters believed the elimination of this guidance, including separate payment of 38225, 38226, and 38227, would reduce hospital burden. One commenter raised the concern that some manufacturers will pay hospitals for the dose preparation services, while other manufacturers will not. In their view, this raises potential program integrity concerns and could influence medical decision making.
                    </P>
                    <FTNT>
                        <P>
                            <SU>26</SU>
                             
                            <E T="03">https://www.cms.gov/regulations-and-guidance/guidance/transmittals/2019-transmittals-items/se19009.</E>
                        </P>
                    </FTNT>
                    <P>Commenters stated that the cell collection required as part of the CAR T-cell therapy process is done by leukapheresis, a costly and labor-intensive procedure in commenters' view. Commenters also communicated that the hospital in which the preparation procedure occurs is not always the same facility in which the final infusion of the therapy occurs. In their view, this could disincentivize hospitals from providing the preparation procedures if they are not the hospital ultimately providing the final product. A few commenters emphasized that manufacturers do not provide these services, hospitals do. Commenters believed “under-arrangements” made between hospitals were infeasible long term given the likely growth in the volume of these therapies and the costs incurred. Commenters also discussed that the preparation procedures could occur months apart from the final administration of the product.</P>
                    <P>Many of these commenters also stated that 10-15 percent of the time a finalized CAR T-cell therapy product is never administered to a beneficiary, which could occur for a multitude of reasons, such as a manufacturing failure, or disease progression potentially resulting in death or ineligibility for treatment while the CAR T-cell therapy product is being manufactured.</P>
                    <P>Commenters also recommended CMS revise the product specific Q-codes to remove “leukapheresis and dose preparation procedures” and they believe it is inappropriate for these services to be described by the HCPCS Level II codes when they can be described by Level I HCPCS codes. Additional commenters recommended CMS transition the product specific Q-codes to permanent J-codes.</P>
                    <P>Several commenters discussed other therapies, such as stem cell transplant, and therapies such as those described by HCPCS codes J3394 (Injection, lovotibeglogene autotemcel, per treatment) and J3393 (Injection, betibeglogene autotemcel, per treatment), which in commenter's view is similar to CAR T-cell therapy and requires similar dose preparation procedures.</P>
                    <P>
                        Commenters supported the 2024 Advisory Panel on Hospital Outpatient Payment recommendation to assign CPT code 38225/3X018, 
                        <E T="03">Chimeric antigen receptor T-cell therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day,</E>
                         an SI of S and place the code in APC 5242, 
                        <E T="03">Level 2 Blood Product Exchange and Related Services.</E>
                         The Panel further recommended that CMS assign CPT code 38226/3X019, 
                        <E T="03">Chimeric antigen receptor T-cell therapy; preparation of blood-derived T lymphocytes for transportation (e.g., cryopreservation, storage);</E>
                         and CPT code 38227/3X020, 
                        <E T="03">Chimeric antigen receptor T-cell therapy; receipt and preparation of CAR-T cells for administration;</E>
                         an SI of S and place these codes in APC 5241, 
                        <E T="03">Level 1 Blood Product Exchange and Related Services.</E>
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their feedback. CMS continues to believe that the procedures described by CPT codes 0537T, 0538T, and 0539T and replacement CPT codes 38225, 38226, and 38227, describe the various steps required to collect and prepare the genetically modified T-cells, and Medicare does not generally pay separately for each step used to manufacture a drug or biological product. Therefore, CMS does not believe that separate or packaged payment under the OPPS is necessary for the procedures described by CPT codes 38225, 38226, and 38227, for CY 2025. However, we thank commenters for providing their unique perspectives and experiences in situations where the manufacturing process does not result in a final product being administered to a beneficiary.
                    </P>
                    <P>
                        We note that the current HCPCS coding for the currently approved CAR T-cell therapies include leukapheresis and dose preparation procedures, as these services are included in the manufacturing of these biologicals. Therefore, payment for these services is 
                        <PRTPAGE P="94082"/>
                        incorporated into the drug codes. CMS is not revising the descriptors for the Q-codes to remove leukapheresis and dose preparation procedures nor are we transitioning the Q-codes to J-codes at this time.
                    </P>
                    <P>We note that, although there is no payment associated with CPT codes 38225, 38226, and 38227, for reasons stated previously, these codes can still be reported to CMS for tracking purposes. We thank commenters for their feedback and for raising concerns related to our guidance contained in MLN Matters Article SE19009. We are not revising this document at this time as we believe these instructions are consistent with our longstanding policies, but we understand the feedback provided. Accordingly, we are not accepting the recommendations at this time to revise the status indicators for procedures described by CPT codes 38225, 38226, and 38227. We will continue to evaluate and monitor payment for CAR T-cell therapies. In summary, after consideration of the public comments we received, we are finalizing our proposal to assign status indicator “B” to CPT codes 38225, 38226, and 38227 for CY 2025 without modification.</P>
                    <P>Additionally, we are continuing our policy from CY 2019 to assign status indicator “S” to CPT code 38228 for CY 2025. Table 81 shows the final SI and APC assignments for HCPCS codes 38225, 38226, 38227, and 38228 for CY 2025. For more information on CY 2025 OPPS final status indicators, APC assignments, and payment rates for HCPCS codes, including the CAR T-cell drug codes, we refer readers to Addendum B to this final rule with comment period. In addition, the status indicator definitions can be found in Addendum D1 (OPPS Payment Status Indicators for CY 2025) to this final rule with comment period. Both Addendum B and D1 are available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="430">
                        <GID>ER27NO24.105</GID>
                    </GPH>
                    <HD SOURCE="HD3">19. Complex Bunion Correction Procedure CPT Code 28297 (APC 5115)</HD>
                    <P>CPT code 28297 describes a surgical procedure to correct a bunion, or hallux valgus, in the foot. The procedure involves:</P>
                    <FP SOURCE="FP-1">• Removing the bunion</FP>
                    <FP SOURCE="FP-1">• Realigning the big toe</FP>
                    <FP SOURCE="FP-1">
                        • Correcting the bony prominence at the base of the toe
                        <PRTPAGE P="94083"/>
                    </FP>
                    <FP SOURCE="FP-1">• Fusing the joint between the first metatarsal bone and the medial cuneiform bone</FP>
                    <FP SOURCE="FP-1">• Removing the sesamoid bones, which are pea-shaped bones under the big toe joint</FP>
                    <P>In the CY 2025 OPPS/ASC proposed rule, we proposed to move CPT code 28297 (Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method) from APC 5114 (Level 4 Musculoskeletal Procedures) to APC 5115 (Level 5 Musculoskeletal Procedures) with the proposed payment rate of $12,755.58.</P>
                    <P>We received several comments supporting the proposed reassignment of CPT code 28297 from APC 5114 (Level 4 Musculoskeletal Procedures) to APC 5115 (Level 5 Musculoskeletal Procedures).</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter stated that CPT code 28297 clearly meets the criteria for reassignment. The total frequency of CPT code 28297 exceeded the significance threshold of 1,000 procedures. The geometric mean cost of CPT code 28297 exceeded two times the geometric mean cost of the lowest significant procedure in APC 5114 (Level 4 Musculoskeletal Procedures). Furthermore, the geometric mean cost of CPT code 28297 was nearly equal to the geometric mean cost of APC 5115 (Level 5 Musculoskeletal Procedures). Several other commenters also supported assigning CPT code 28297 to APC 5114 ((Level 5 Musculoskeletal Procedures).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We agree with the commenters, and we thank them for their support. In summary, after consideration of the public comments that we received, we are finalizing our proposal without modification and are assigning CPT code 28297 to APC 5115 (Level 5 Musculoskeletal Procedures) for CY 2025. The final CY 2025 payment rate for this code can be found in Addendum B of this final rule with comment period.
                    </P>
                    <HD SOURCE="HD3">20. Computational Electrocardiogram (ECG) Analysis System (vMap), CPT Code 0897T (APC 5724)</HD>
                    <P>CPT code 0897T (Noninvasive augmentative arrhythmia analysis derived from quantitative computational cardiac arrhythmia simulations, based on selected intervals of interest from 12-lead electrocardiogram and uploaded clinical parameters, including uploading clinical parameters with interpretation and report) utilizes ECG data to identify potential arrhythmia focal points for patients. The vMap provides augmented information which enables physicians to characterize arrhythmia and assists in triage and treatment of abnormal rhythm. CPT code 0897T became effective July 1, 2024 and since its establishment, the code has been assigned to APC 5724 (Level 4 Diagnostic Tests and Related Services) for CY 2024. Because this is a new code for CY 2024, there are no claims available. For CY 2025, we proposed to maintain the assignment to APC 5724, with a payment rate of $1,012.27.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter supported our proposal to assign CPT code 0897T to APC 5724, due to the resource similarity of this technology to other procedures assigned to APC 5724.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's feedback on CPT code 0897T and we agree with the commenter's recommendation to finalize the APC assignment.
                    </P>
                    <P>After consideration of the public comment we received, we are finalizing our proposal without modification for CPT code 0897T. Please refer to Table 82 below for the final OPPS APC and status indicator assignment for HCPCS code 0897T for CY 2025. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="175">
                        <GID>ER27NO24.106</GID>
                    </GPH>
                    <HD SOURCE="HD3">21. Computed Tomographic Colonography, CPT Code 74263 (APC 5523)</HD>
                    <P>For CY 2024, we assigned CPT code 74263 (Computed tomographic (CT) colonography, screening, including image postprocessing) to status indicator “E1” indicating that the service was not covered and not payable by Medicare under the OPPS. For the CY 2025 OPPS/ASC proposed rule, we proposed to assign CPT code 74263 to APC 5522 (Level 2 Imaging without Contrast) and a status indicator of “S” (Procedure or Service, Not Discounted When Multiple. Paid under OPPS; separate APC payment) to indicate that the code is separately payable under OPPS based on the proposed coverage changes for the colorectal cancer screening. (We refer our readers to section X.E. of this final rule with comment period for a full discussion of the coverage changes for colorectal cancer screening services.)</P>
                    <P>
                        For the CY 2025 OPPS/ASC proposed rule, we believed the time and resources associated with performing a screening virtual colonoscopy is similar to those necessary to furnish a diagnostic virtual colonoscopy, which is described by CPT code 74261 (Computed tomographic (ct) colonography, diagnostic, including image postprocessing; without contrast material). Consequently, we proposed to 
                        <PRTPAGE P="94084"/>
                        assign CPT code 74263 to APC 5522 (Level 2 Imaging without Contrast) based on its clinical and resource homogeneity to CPT code 74261, which is assigned to the same clinical APC.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment requesting to reassign CPT code 74263 to APC 5571 (Level 1 Imaging with Contrast). The commenter is concerned that the proposed payment for the screening CT colonography is insufficient to cover the costs of providing the service. The commenter believed that other services within that APC family such as CT abdomen with contrast have greater clinical homogeneity with CPT code 74263.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input. We disagree with the commenter that CPT code 74263 should be placed in APC 5571 (Level 1 Imaging with Contrast) as it is a procedure that is completed without contrast. However, we do believe that this newly covered screening test for colorectal cancer should be assigned to an APC where payment is more comparable to the purported resource costs. Given that any claims data in CY 2023 would be from before the service was payable in the OPPS, it would be difficult to rely on the claims data to determine the APC assignment for this code. Based on our review of the service (CT colonography) compared to other services assigned to the Imaging without Contrast APC series, we believe CPT code 74176 (Computed tomography, abdomen and pelvis; without contrast material) is an appropriate crosswalk code for CPT code 74263.
                    </P>
                    <P>In summary, after consideration of the public comment, we are finalizing our proposal with modification to assign CPT code 74263 to APC 5523 (Level 3 Imaging without Contrast) and a status indicator of “S” for CY 2025. The final CY 2025 payment with rates for this code can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the SI definitions for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">22. Concurrent Optical and Magnetic Stimulation (COMS) Therapy, CPT Codes 0906T and 0907T (APC 5051)</HD>
                    <P>
                        On June 20, 2023, CMS approved for Medicare coverage the Category B Investigational Device Exemption (IDE) study associated with concurrent optical and magnetic stimulation (Study Title: 
                        <SU>27</SU>
                        <FTREF/>
                         Concurrent Optical and Magnetic Stimulation (COMS) for Treatment of Refractory Diabetic Foot Ulcer; a Prospective Randomized, Sham-controlled, Double-blinded, Pivotal Clinical Trial; NCT number NCT05758545; IDE number G220277 
                        <SU>28</SU>
                        <FTREF/>
                        ). For the July 2024 update, the AMA CPT Editorial Panel established 0906T (placeholder code XX18T) (Concurrent optical and magnetic stimulation therapy, wound assessment and dressing care; first application, total wound(s) surface area less than or equal to 50 sq cm) and 0907T (placeholder code XX37T) (Concurrent optical and magnetic stimulation (COMS) therapy, wound assessment and dressing care; each additional application, total wound(s) surface area less than or equal to 50 sq cm (List separately in addition to code for primary procedure)) for COMS, effective January 1, 2025.
                    </P>
                    <FTNT>
                        <P>
                            <SU>27</SU>
                             
                            <E T="03">ClinicalTrials.gov.</E>
                             “Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers (Mavericks).” Accessed September 24, 2024. 
                            <E T="03">https://clinicaltrials.gov/study/NCT05758545</E>
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>28</SU>
                             Approved IDE Studies- “G220277-NCT05758545.” Accessed September 24, 2024. 
                            <E T="03">https://www.cms.gov/medicare/coverage/ide/approved-ide-studies/683545095/g220277-nct05758545</E>
                        </P>
                    </FTNT>
                    <P>For the CY 2025 OPPS/ASC proposed rule, CMS proposed to assign the SIs and APCs listed in Table 83 below for the new codes based on the clinical characteristics of the procedures.</P>
                    <GPH SPAN="3" DEEP="259">
                        <GID>ER27NO24.107</GID>
                    </GPH>
                    <P>
                        We note that at the August 28, 2024, HOP Panel Meeting, a presentation was made requesting the reassignment to APC 5053 for CPT code 0906T (placeholder code XX18T). Based on the information presented at the meeting, the Panel made no recommendation on the APC assignment for the code.
                        <PRTPAGE P="94085"/>
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received a comment from the manufacturer of COMS on our proposed assignments for the codes listed in Table 83. The commenter stated that the COMS procedures include extensive wound examination, wound bed preparation, and dressing management. With the inclusion of standard wound care administered before and after each active COMS device treatment, the commenter estimates that the total time required for a COMS procedure is 35-50 minutes, during which considerable medical supplies and facility resources are utilized. The manufacturer suggested that the total resource code for CPT code 0906T is $627, with $392 in hospital facility resource costs and $235 specifically for the COMS device-associated costs. The commenter maintains that the assignment to APC 5051, which has a proposed CY 2025 payment rate of $201.14, does not cover the costs of the procedure.
                    </P>
                    <P>The commenter claims that CPT code 0906T is sufficiently similar in terms of resources and time to CPT codes 11043 (Debridement, muscle and/or fascia (includes epidermis, dermis, and subcutaneous tissue, if performed); first 20 sq cm or less) and 12044 (Repair, intermediate, wounds of neck, hands, feet and/or external genitalia; 7.6 cm to 12.5 cm), both assigned to APC 5053 ((Level 3 Skin Procedures, proposed CY 2025 payment rate of $619.63), to warrant the reassignment of CPT code 0906T to APC 5053. The commenter further stated that assigning these procedures to APC 5053 would align with other wound care procedures with similar resource costs and procedural time.</P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input. We have no claims data for CPT code 0906T available for this final rule. However, based on this code's similarity to CPT code 0521T (Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; initial wound) and CPT code 97610 (Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day) which are both assigned to APC 5051, we continue to believe CPT code 0906T has clinical and resource similarities to procedures assigned to APC 5051. Therefore, for CY 2025, we are finalizing our proposal without modification and assigning CPT code 0906T to APC 5051. Table 84 lists the final CY 2025 OPPS payment rate for 0906T and 0907T.
                    </P>
                    <P>In summary, after consideration of the public comment that we received, we are finalizing the APC and SI assignments for CPT codes 0906T to APC 5051. As we do every year, we will reevaluate the APC assignments for these codes in the next rulemaking cycle. We remind hospitals that we review, on an annual basis, the APC assignments for all items and services paid under the OPPS. The final payment rates for the codes can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Both Addendum B and D1 are available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="301">
                        <GID>ER27NO24.108</GID>
                    </GPH>
                    <PRTPAGE P="94086"/>
                    <HD SOURCE="HD3">23. Cystourethroscopy With Temporarily Implanted Nitinol Device Procedure, HCPCS Code C9769 (APC 5376)</HD>
                    <P>Cystourethroscopy temporarily implanted nitinol device (iTIND) is a minimally invasive surgery to treat bothersome lower urinary tract symptoms (LUTS) caused by benign prostate enlargement. The iTIND serves to re-model the bladder neck and the prostatic urethra. The HCPCS Code C9769 (Cystourethroscopy, with insertion of temporary prostatic implant/stent with fixation/anchor and incisional struts) became effective October 1, 2020.</P>
                    <P>For CY 2025, the proposed OPPS payment rates are based on available CY 2023 claims data. For CY 2025, based on our analysis of claims data, we found a total of 96 single frequency claims and a geometric mean cost of approximately $4,902 for HCPCS code C9769. For CY 2025, we proposed to continue to assign HCPCS code C9769 to APC 5376 (Level 6 Urology and Related Services) with a proposed payment rate of approximately $9,209.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter pointed out that the AMA CPT created a new code, CPT code 5XX05 effective January 1, 2025, to describe the cystourethroscopy with iTIND service represented by HCPCS code C9769. CPT code 5XX05 (Cystourethroscopy with insertion of temporary device for ischemic remodeling (
                        <E T="03">i.e.,</E>
                         pressure necrosis) of bladder neck and prostate) becomes effective January 1, 2025. The commenter stated that CMS may either sunset HCPCS code C9769 and reassign the underlying claims to CPT code 5XX05 or maintain HCPCS code C9769 active and assign CPT code 5XX05 to a non-payable status in the OPPS.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for pointing out that CPT code 5XX05 (53865) will become effective January 1, 2025. We note that we will replace HCPCS code C9769 with CPT code 5XX05 (53865) effective January 1, 2025, as well as assign the underlying claims associated with HCPCS code C9769 to CPT code 5XX05 (53865). Therefore, for CY 2025, we are reassigning CPT code 5XX05 (53865) to Level 6 Urology and Related Services (APC 5376). We note that we will continue to evaluate and monitor the cost for CPT code 5XX05 (53865) for future rulemaking.
                    </P>
                    <P>After consideration of the public comment we received, we are finalizing our policy to assign CPT code 5XX05 (53865) to APC 5376 (Level 6 Urology and Related Services) and we will be sunsetting HCPCS code C9769. Please refer to Table 85 for the final OPPS APC and status indicator assignment for CPT code 5XX05 (53865) for CY 2025. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="134">
                        <GID>ER27NO24.109</GID>
                    </GPH>
                    <HD SOURCE="HD3">24. Dental Alveoloplasty and Exostosis Removal Procedures, CDT Codes D7320, D7321, and D7471 (APCs 5163, 5164)</HD>
                    <P>Effective January 1, 2024, we made 229 additional dental codes payable under the OPPS when payment and coverage requirements are met, as provided in the relevant PFS payment rules regarding Medicare Part B payment for dental services (88 FR 81540-82185). For CY 2025, we did not propose to make additional dental codes payable under the OPPS. As a result, we proposed to continue to assign many dental services to non-payable status indicators, including CDT codes D7320 (Alveoloplasty not in conjunction with extractions—four or more teeth or tooth spaces, per quadrant), D7321(Alveoloplasty not in conjunction with extractions—one to three teeth or tooth spaces, per quadrant), and D7471 (Removal of lateral exostosis (maxilla or mandible), which we proposed to assign to status indicator “B,” indicating the service is not paid under OPPS, for CY 2025.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received a comment from an association representing oral and maxillofacial surgeons requesting that we make CDT codes D7320, D7321, and D7471 payable under the OPPS. The commenter stated that these codes may contribute to the elimination of an oral or dental infection. The commenter explained that alveoloplasty and the removal of lateral exostosis are often necessary procedures for medically compromised patients undergoing tooth removal prior to radiation treatment. Failure to perform these procedures, per the commenter, can put patients at risk for osteoradionecrosis following radiation therapy. In addition, the commenter explained that not performing an alveoloplasty or removing the exostosis when clinically indicated may impede the patient's ability to receive a removable prosthesis due to the risk of tissue trauma. The procedures may also be required to address common sequelae following dental extractions. Per the commenters, excluding the services described by CDT codes D7320, D7321, and D7471 from OPPS payment places patients at considerable risk and diminishes the effectiveness of initial treatments aimed at eliminating oral or dental infections. Finally, the commenters stated that there are existing CPT codes that describe these procedures. Specifically, per the commenters, CPT code 41874 (Alveoloplasty, each quadrant (specify)) may describe alveoloplasty procedures and CPT code 41823 (Excision of osseous tuberosities, dentoalveolar structures) may describe the removal of exostosis.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's input. We note that the commenter submitted a similar public comment to the CY 2024 OPPS/ASC final rule to assign several codes, including CDT codes D7320, D7321, and 
                        <PRTPAGE P="94087"/>
                        D7471, to APCs for CY 2024. In the CY 2024 OPPS/ASC final rule, we agreed to assign to clinical APCs the codes for which we agreed with the commenter may be considered medically necessary diagnostic and treatment services immediately necessary to eliminate or eradicate an oral or dental infection prior to, or contemporaneously with certain Medicare-covered medical services specified in the CY 2023 PFS final rule (42 CFR 411.15). We also specified we needed more information on how certain codes the commenter recommended for APC assignment, including CDT codes D7320, D7321, and D7471, were consistent with existing dental payment polices.
                    </P>
                    <P>The comment to the CY 2025 OPPS/ASC proposed rule provided additional information regarding how dental surgical procedures including surgical interventions to facilitate tooth eruption, alveoloplasty or ridge preparation and removal of lateral exostosis of the jaw may contribute to the elimination of an oral or dental infection. Based on the additional information provided, we agree with the commenter that t CDT codes D7320, D7321 and D7471 should be assigned to clinical APCs for CY 2025 as we believe there may be instances where these services may be considered medically necessary diagnostic and treatment services immediately necessary to eliminate or eradicate an oral or dental infection prior to, or contemporaneously with, certain Medicare-covered medical services specified in the CY 2023 and CY 2024 PFS final rules. For CY 2025, we are assigning CDT codes D7320 and D7321 to APC 5163 (Level 3 ENT Procedures), based on clinical and resource similarities to other alveoloplasty codes currently assigned to the same clinical APC, specifically CDT codes D7310 (Alveoloplasty in conjunction with extractions—four or more teeth or tooth spaces, per quadrant) and D7311 (Alveoloplasty in conjunction with extractions—one to three teeth or tooth spaces, per quadrant). We are also assigning CDT code D7471 to APC 5164 (Level 4 ENT Procedures) based on clinical and resource similarities to other exostosis services assigned to the same clinical APC, specifically CPT codes 21031 (Remove exostosis mandible) and 21032 (Remove exostosis maxilla).</P>
                    <P>
                        We note that Medicare Part B does not pay for removable prostheses, such as dentures. While we understand that services like alveoloplasty and the removal of the exostosis can improve the fit and stability of dentures and other dental prosthetics as the commenter explained, we are not finalizing APC assignments for CPT codes D7320, D7321 and D7471 so that these services may be furnished in preparation for a patient's denture or dental implant, and billing Medicare for that purpose would not meet our payment and coverage requirements. As we have consistently stated in past rules (87 FR 71879) and quarterly change requests to assign new codes to APCs (see, 
                        <E T="03">e.g.,</E>
                         Pub 100-04 Medicare Claims Processing, Transmittal 11937), the fact that a drug, device, procedure or service is assigned a HCPCS code and a payment rate under the OPPS does not imply coverage by the Medicare program, but indicates only how the product, procedure, or service may be paid if covered by the program. Medicare Administrative Contractors (MACs) determine whether a drug, device, procedure, or other service meets all program requirements and conditions for coverage and payment. Accordingly, we emphasize that HOPDs would only receive payment for a dental service assigned to an APC when the appropriate MAC determines that the service meets the relevant conditions for coverage and payment.
                    </P>
                    <P>After consideration of the public comment received, for CY 2025, we are finalizing clinical APC assignments for CDT codes D7320, D7321, and D7471. Please refer to Table 86for the final APC assignments and status indicators for CDT codes D7320, D7321, and D7471. We refer readers to Addendum D1 to this final rule with comment period for a complete list of status indicators and their definitions. Addendum D1 is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="190">
                        <GID>ER27NO24.110</GID>
                    </GPH>
                    <HD SOURCE="HD3">25. Digital Mental Health Treatment Devices, HCPCS Codes GMBT1, GMBT2, and GMBT3 (APC 5012)</HD>
                    <P>
                        In CY 2025 Medicare Physician Fee Schedule proposed rule (89 FR 61956) we stated that we recognize that digital therapeutics may offer innovative means to access certain behavioral health care services. We noted that given nationwide behavioral health workforce shortages combined with increasing demand for behavioral health care services, some Medicare beneficiaries may have limited access to these services. To that end, we proposed to create three new HCPCS codes for Digital Mental Health Treatment Devices (DHMT): GMBT1 (
                        <E T="03">Supply of digital mental health treatment device and initial education and onboarding, per course of treatment that augments a behavioral therapy plan</E>
                        ) for furnishing a DMHT device; GMBT2 (
                        <E T="03">
                            First 20 
                            <PRTPAGE P="94088"/>
                            minutes of monthly treatment management services directly related to the patient's therapeutic use of the digital mental health treatment (DMHT) device that augments a behavioral therapy plan, physician/other qualified health care professional time reviewing data generated from the DMHT device from patient observations and patient specific inputs in a calendar month and requiring at least one interactive communication with the patient/caregiver during the calendar month
                        </E>
                        ) and GMBT3 (
                        <E T="03">Each additional 20 minutes of monthly treatment management services directly related to the patient's therapeutic use of the digital mental health treatment (DMHT) device that augments a behavioral therapy plan, physician/other qualified health care professional time reviewing data generated from the DMHT device from patient observations and patient specific inputs in a calendar month and requiring at least one interactive communication with the patient/caregiver during the calendar month</E>
                        ). We did not address the new proposed DMHT device G-codes or propose APC or Status Indicator assignments in the CY 2025 OPPS proposed rule (89 FR 59186).
                    </P>
                    <P>The HCPCS codes G0552, G0553, and G0554 are replacing the respective placeholder codes GMBT1, GMBT2, and GMBT3.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received several comments on the DHMT codes with different suggestions on how these codes be treated in the OPPS. One commenter recommended that CMS assign code G0552 (placeholder code GMBT1) to APC 1511—New Technology Level 11—with a CY 2025 proposed payment rate of $950.50. This commenter went on to say that CMS could then update the applicable APC assignment for DMHT devices over time after it obtains hospital claims data. Commenters who suggested CMS assign HCPCS code G0552 (placeholder code GMBT1) to a New Technology APC explained that this approach is similar to ones the agency has taken in the past—most notably for reimbursing for the technical/facility components of remote therapeutic monitoring (RTM) and remote physiological monitoring (RPM) codes. One commenter supported contractor pricing for HCPCS code G0552 (placeholder code GMBT1). Commenters urged CMS to establish a payment for the DMHT device supply in the hospital outpatient setting in the CY 2025 OPPS final rule.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         HCPCS codes G0552, G0553, and G0554 (placeholder codes GMBT1, GMBT2, and GMBT3) will be effective on January 1, 2025. Based on our evaluation of these new codes and in response to commenters' requests, we are proposing an interim assignment of HCPCS code G0552 (placeholder code GMBT1) to status indicator “V” (Clinic or Emergency Department Visit; Paid under OPPS; separate APC payment) and APC 5012 (Clinic Visits and Related Services). We are proposing an interim assignment of HCPCS code G0553 (placeholder code GMBT2) to status indicator “V” (Clinic or Emergency Department Visit; Paid under OPPS; separate APC payment) and APC 5012 (Clinic Visits and Related Services). Finally, we are proposing an interim assignment of HCPCS code G0554 (placeholder code GMBT3) to status indictor “N” to indicate that the code is packaged since it is an add-on service to the primary code, and payment for add-on codes is always packaged with their associated primary service codes under regulation at 419.2(b)(18).
                    </P>
                    <P>Because we were not able to propose APC and status indicator assignments in the CY 2025 OPPS proposed rule, we will be assigning HCPCS codes G0552, G0553, and G0554 (placeholder codes GMBT1, GMBT2, and GMBT3) comment indicator “NI” in Addendum B of this final rule. This comment indicator is for new HCPCS codes that will be effective January 1, 2025, to indicate that we are assigning them an interim status indicator and APC assignment, which is subject to public comment. We invite public comment on the interim proposed status indicators and APC assignments for HCPCS codes G0552, G0553, and G0554 (placeholder codes GMBT1, GMBT2, and GMBT3), which will then be finalized in the CY 2026 OPPS/ASC final rule with comment period.</P>
                    <P>Please refer to Table 87 for the proposed interim APC and status indicator assignments for HCPCs codes G0552, G0553, and G0554 (placeholder codes GMBT1, GMBT2, and GMBT3) for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period.</P>
                    <GPH SPAN="3" DEEP="300">
                        <PRTPAGE P="94089"/>
                        <GID>ER27NO24.111</GID>
                    </GPH>
                    <HD SOURCE="HD3">26. Drug-Coated Balloon for Esophageal and Bowel Strictures, CPT Codes 0884T, 0885T, and 0886T (APC 5331)</HD>
                    <P>
                        ProTractX3
                        <SU>TM</SU>
                         TTS is a drug-coated balloon that is used to treat strictures in the esophagus, small intestine, and large intestine. For the CY 2025 OPPS proposed rule, we proposed to assign CPT code 0884T (Esophagoscopy, flexible, transoral, with initial transendoscopic mechanical dilation (
                        <E T="03">e.g.,</E>
                         nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for esophageal stricture, including fluoroscopic guidance, when performed) with no claims data for CY 2025 to APC 5303 (Level 3 Upper GI Procedures) with a payment rate of around $3,805804. In addition, we proposed to assign both CPT code 0885T (Colonoscopy, flexible, with initial transendoscopic mechanical dilation (
                        <E T="03">e.g.,</E>
                         nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed) and CPT code 0886T (Sigmoidoscopy, flexible, with initial transendoscopic mechanical dilation (
                        <E T="03">e.g.,</E>
                         nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed) with no claims data for CY 2025 to APC 5313 (Level 3 Lower GI Procedures) with a payment rate of around $2,742.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter, the manufacturer of the ProTractX3
                        <SU>TM</SU>
                         TTS, requested that the procedures described CPT codes 0884T-0886T be reassigned to APC 5331 (Complex GI Procedures) with a payment rate of around $5,953. The commenter stated that the cost of the ProTractX3
                        <SU>TM</SU>
                         TTS is $3,100. The commenter based their cost estimate for the ProTractX3
                        <SU>TM</SU>
                         TTS on similar drug-coated balloons used for other medical procedures. The commenter believes the cost of ProTractX3
                        <SU>TM</SU>
                         TTS should be added to the geometric mean cost of the existing procedures that correspond to the procedures described by CPT codes 0884T-0886T, but do not describe the use of a drug-coated balloon with the procedures. These procedures are CPT code 43220 (Esophagoscopy, flexible, transoral; with transendoscopic balloon dilation (less than 30 mm diameter) with a geometric mean cost of around $2,175 that corresponds to procedure described by CPT code 0884T; CPT code 45386 (Colonoscopy, flexible; with transendoscopic balloon dilation) with a geometric mean cost of around $1,662 that corresponds to the procedure described by CPT code 0885T; and CPT code 45340 (Sigmoidoscopy, flexible; with transendoscopic balloon dilation) with a geometric mean cost of around $1,518 that corresponds to the procedure described by CPT code 0886T. The commenter also noted that additional operating room time needed to use the drug-coated balloon adds another $806 to the cost of each of these procedures.
                    </P>
                    <P>
                        According to the commenter, when the cost of ProTractX3
                        <SU>TM</SU>
                         TTS drug-coated balloon and the cost of the additional operating room time to use the drug-coated balloon is added to the geometric cost of CPT code 43220, the estimated cost of CPT code 0884T is $6,081. The commenter performed similar calculations for CPT code 0885T reporting an estimated procedure cost of $5,568, and for CPT code 0886T, the commenter reported an estimated procedure cost is $5,424. The commenter made the case that these procedure costs are much closer to the payment rate of APC 5331 of $5,953, than the payment rate of $3,805 for APC 5303 where we proposed to assign CPT code 0884T. Likewise, the commenter showed that the procedure costs for CPT codes 0885T and 0886T are much closer to the payment rate of APC 5331 of $5,953, than the payment rate of APC 5313 of $2,742 where we had proposed to assign those CPT codes.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the detailed analysis by the commenter which demonstrated the additional costs of the ProTractX3
                        <SU>TM</SU>
                         TTS drug-coated balloon, as well as the use of the drug-coated 
                        <PRTPAGE P="94090"/>
                        balloon when compared to the corresponding procedures where no drug-coated balloon is used. Based on the additional cost data provided by the commenter, we agree with the commenter that CPT codes 0884T-0886T should be assigned to APC 5331.
                    </P>
                    <P>After consideration of the public comments we received, we are implementing our proposal with modification to assign CPT codes 0884T, 0885T, and 0886T to APC 5331 (Complex GI Procedures). Table 88 shows the finalized status indicator and APC assignment for all of the procedure codes. We refer readers to Addendum B of this final rule for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="431">
                        <GID>ER27NO24.112</GID>
                    </GPH>
                    <HD SOURCE="HD3">27. EchoGo Echocardiography Image Processing Service, HCPCS Code C9786 (APC 5743)</HD>
                    <P>Effective July 1, 2023, based on a New Technology application received by CMS for an echocardiography image processing service, CMS established HCPCS code C9786 (Echocardiography image post processing for computer aided detection of heart failure with preserved ejection fraction, including interpretation and report) and assigned it to APC 5742 (Level 2 Electronic Analysis of Devices). In CY 2024, CMS reassigned HCPCS code C9786 to APC 5743 (Level 3 Electronic Analysis of Devices).</P>
                    <P>For CY 2025, CMS is deleting HCPCS code C9786 because the CPT Editorial Panel established new Category III CPT code, specifically, 0932T (Noninvasive detection of heart failure derived from augmentative analysis of an echocardiogram that demonstrated preserved ejection fraction, with interpretation and report by a physician or other qualified health care professional) to describe the same service, which will be effective January 1, 2025. Because the final CY 2025 CPT code number was not available when we published the CY 2025 OPPS/ASC proposed rule, the code was listed as placeholder code XX68T in the OPPS Addendum B of the CY 2025 OPPS/ASC proposed rule.</P>
                    <P>
                        In the CY 2025 OPPS/ASC proposed rule, we proposed to assign CPT code XX68T (Noninvasive detection of heart failure derived from augmentative analysis of an echocardiogram that demonstrated preserved ejection 
                        <PRTPAGE P="94091"/>
                        fraction, with interpretation and report by a physician or other qualified health care professional) to APC 5743 (Level 3 Electronic Analysis of Devices), the same APC to which HCPCS code C9786 is assigned.
                    </P>
                    <P>We note that because both HCPCS code C9786 and CPT code 0932T describe the same service, effective January 1, 2025, CMS will delete HCPCS code C9786 and only CPT code 0932T will be used to bill for the service. We received one public comment in support of our proposal.</P>
                    <P>
                        <E T="03">Comment:</E>
                         The commenter noted that the assignment of XX68T to APC 5743 appropriately reflects the resources required to perform this advanced artificial intelligence (AI) analysis, as well as the clinical value it provides. and stated that this APC assignment would help ensure adequate reimbursement for hospitals, supporting broader access to this important diagnostic tool for Medicare beneficiaries. The commenter appreciated CMS's consideration of this new technology and its potential impact on patient care.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for the support.
                    </P>
                    <P>In summary, after consideration of the public comment we received, we are finalizing our proposal, without modification, to assign CPT code 0932T to APC 5743 for CY 2025. We note that the final CY 2025 payment rate for the code can be found in Addendum B of this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the SI meanings for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">28. Endoscopic Submucosal Dissection (ESD) Procedure, HCPCS Code C9779 (APC 5303)</HD>
                    <P>CMS established HCPCS code C9779 (Endoscopic submucosal dissection (ESD), including endoscopy or colonoscopy, mucosal closure, when performed) effective October 1, 2021, to describe the endoscopic submucosal dissection (ESD) performed during an endoscopy or colonoscopy. HCPCS code C9779 was established based on a New Technology application that was submitted to CMS for New Technology consideration under the OPPS. Based on our assessment, we assigned the code to APC 5313 (Level 3 Lower GI Procedures) because we believed the ESD procedure had similar clinical characteristics and resource costs as the surgical procedures assigned to APC 5313. We announced the assignment to APC 5313 in the October 2021 OPPS quarterly update CR (Transmittal 10997, Change Request 12436, dated September 16, 2021). In CY 2022, we continued to assign the code to APC 5313.</P>
                    <P>
                        For CY 2023, we assigned HCPCS code C9779 to APC 5303 (Level 3 Upper GI Procedures) after receiving public comments that stated that the ESD procedure's resource requirements and geometric mean cost were more similar to the resource requirements and geometric mean costs of procedures found in APC 5303. Further, commenters noted that the ESD procedure is technically more demanding, requires advanced skills to perform, and is clinically similar to CPT code 43497 (Lower esophageal myotomy, transoral (
                        <E T="03">i.e.,</E>
                         peroral endoscopic myotomy [POEM])), which was assigned to APC 5303. For CY 2025, we proposed to maintain HCPCS code C9779 (with a geometric mean cost (GMC) of around $5,093) in APC 5303 (Level 3 Upper GI Procedures).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment requesting that we reassign HCPCS code C9779 from APC 5303 (Level 3 Upper GI Procedures) to APC 5361 (Level 1 Laparoscopy and Related Procedures). The commenter states that resource requirements for HCPCS code C9779 are well-aligned with other procedures in APC 5361, noting that the geometric mean cost of HCPCS code C9779 is higher than 4 procedures with significant volume assigned to APC 5361. The commenter believes that based on resource cost and clinical homogeneity, HCPCS code C9779 should be reassigned to APC 5361.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input. We disagree with the commenter that HCPCS code C9779 should be assigned to APC 5361. Specifically, we do not believe that endoscopic submucosal dissection is a laparoscopic procedure and should not be assigned to a laparoscopic APC family. Additionally, we believe HCPCS code C9779 is appropriately assigned, based on both clinical similarity and resource costs, to APC 5303 (Level 3 Upper GI Procedures).
                    </P>
                    <P>In summary, after consideration of the public comment, we are finalizing our proposal without modification to assign HCPCS code C9779 to APC 5303 (Level 3 Upper GI Procedures). We note that we review, on an annual basis, the APC assignments for all services and items paid under the OPPS based on our analysis of the latest claims data. The final CY 2025 OPPS payment rate for the code can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator (SI) meanings for all codes reported under the OPPS. Both Addendum B and D1 are available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">29. Esophageal Balloon Distention Study, CPT Code 91040 (APC 5723)</HD>
                    <P>Esophageal balloon distension studies are used to diagnose conditions of the esophagus and may be used to determine the source of certain types of pain, such as chest pain. The esophageal balloon study is often performed in conjunction with esophagogastroduodenoscopy procedures. For CY 2025, we proposed to assigned CPT code 91040 (Esophageal balloon distension study, diagnostic, with provocation when performed) to APC 5723 (Level 3 Diagnostic Tests and Related Services) with a proposed payment rate of around $530.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one public comment requesting that CPT code 91040 be reassigned from APC 5723 (Level 3 Diagnostic Tests and Related Services) to APC 5724 (Level 4 Diagnostic Tests and Related Services), stating that the costs of this procedure significantly exceed the APC 5723 assignment. The commenter suggested that a higher payment would more closely align with the costs of the resources utilized to perform this test.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input. We note that the geometric mean cost (GMC) for CPT code 91040 is around $1,500, and the GMC for APC 5723 is around $537. While this is a significant difference, our claims data show that approximately 70 percent of the costs for this procedure are made up of higher cost items (equipment, drugs, and supplies) that are packaged with the procedure costs.
                    </P>
                    <P>In addition, claims data for CY 2025, show that out of all the claims billed with CPT code 91040 (3,429 total frequency), only 2.7 percent (approximately 95) of those claims were billed with only CPT code 91040. We believe that in addition to the higher costs of the items that are packaged, the costs from the other procedures that are performed with CPT code 91040 have driven up the GMC of CPT code 91040.</P>
                    <P>
                        Based on review of the service and other services in the same APC family, input from CMS medical advisors, and the claims data, we believe that the clinical and resource characteristics of CPT code 91040 are sufficiently like other procedures assigned to APC 5723 and should continue to be assigned to APC 5723. For CY 2025, based on our evaluation, we are finalizing our proposal, without modification, to assign CPT code 91040 to APC 5723. 
                        <PRTPAGE P="94092"/>
                        The final CY 2025 payment rate for the code can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the SI meanings for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.
                    </P>
                    <HD SOURCE="HD3">30. Esophagogastroduodenoscopy With Optical Endomicroscopy, CPT Code 43252 (APC 5302)</HD>
                    <P>An esophagogastroduodenoscopy is a procedure to view the esophagus, stomach, and duodenum by means of a flexible endoscope passed through the mouth. The provider uses an endomicroscopy system to evaluate the structures during this procedure. This procedure is reported with CPT code 43252 (Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy).</P>
                    <P>In the CY 2024 OPPS/ASC final rule with comment period (88 FR 81685), we reassigned CPT code 43252 from APC 5303 (Level 3 Upper GI Procedures) to APC 5302 (Level 2 Upper GI Procedures). In the 2025 OPPS/ASC proposed rule, we proposed to continue to assign this code to APC 5302 with a proposed payment rate of $1,884.11. We received two public comments that disagreed with our proposal.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Both commenters noted that the significant payment reduction for this service could impede access to this service for beneficiaries. One commenter noted that just a few hospital outpatient facilities are offering this procedure and that over 70 percent of cases are performed in ASCs.
                    </P>
                    <P>One commenter stated that CPT code 43252 is similar in clinical intensity, resource utilization and costs to CPT code 0654T (Esophagogastroduodenoscopy, flexible, transnasal; with insertion of intraluminal tube or catheter) which is assigned to APC 5303. This commenter also claimed that some hospitals are underreporting their costs for CPT code 43252. Both commenters requested that CMS reassign CPT code 43252 to APC 5303.</P>
                    <P>
                        <E T="03">Response:</E>
                         We note that the CY 2025 OPPS payment rates are proposed based on available CY 2023 claims data. Based on our latest review of the claims data, we found the geometric mean cost of approximately $1,839.38for CPT code 43252 based on 246 single claims, is consistent with the geometric mean cost of about $1,920.00for APC 5302. We note that the geometric mean cost of APC 5303 is approximately $3,850.67which is about $2,011 more than the geometric mean cost of CPT code 43252.
                    </P>
                    <P>In summary, we are finalizing without modification our proposal to assign CPT code 43252 to APC 5302 for CY 2025. The CY 2025 final payment rate for this code can be found in Addendum B of this final rule with comment period.</P>
                    <HD SOURCE="HD3">31. Extracorporeal Shock Wave Lithotripsy (SWL), CPT Code 50590 (APC 5374)</HD>
                    <P>Extracorporeal shock wave lithotripsy is a procedure used to break up stone in the urinary tract using directed shock wave therapy. Shock waves are generated by a lithotripter which is a machine and capital equipment for the provider. The procedure is described by CPT code 50590 (Lithotripsy, extracorporeal shock wave).</P>
                    <P>For CY 2025, the OPPS payment rates are proposed based on available CY 2023 claims data. For the CY 2025 OPPS/ASC proposed rule, we found a total of 26,669 single frequency claims and a geometric mean cost of approximately $3,536 for CPT code 50590. For CY 2025, we proposed to continue to assign CPT code 50590 to APC 5374 (Level 4 Urology and Related Services) with a proposed payment rate of approximately $3,438.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter disagreed with our APC assignment of CPT code 50590 to APC 5374 (Level 4 Urology and Related Services) and suggested that CPT code 50590 should be assigned to APC 5375 (Level 5 Urology and Related Services) like CPT code 52353 (Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with lithotripsy (ureteral catheterization is included)) and CPT code 52356 (Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with lithotripsy including insertion of indwelling ureteral stent (
                        <E T="03">e.g.,</E>
                         gibbons or double-j type)). The commenter stated that higher payment for CPT codes 52353 and 52356 has driven service volume toward those codes and away from CPT code 50590.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for the input. We note that, with over 25,000 single claims in CY 2025, the geometric mean cost of CPT code 50590 very closely aligns with the geometric mean cost of the APC to which it is assigned, APC 5374. Furthermore, CPT code's geometric mean cost is well below that of CPT code 52356, which is the primary driver of the geometric mean cost of APC 5375.
                    </P>
                    <P>After consideration of the public comment we received, we are finalizing our proposal without modification for CPT code 50590. Please refer to Table 89 for the final OPPS APC and status indicator assignment for CPT code 50590 for CY 2025. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="118">
                        <GID>ER27NO24.113</GID>
                    </GPH>
                    <PRTPAGE P="94093"/>
                    <HD SOURCE="HD3">32. Female Intraurethral Valve-Pump, Insertion and Replacement, CPT Codes 0596T and 0597T (APC 5372)</HD>
                    <P>
                        For CY 2025, we proposed to assign CPT codes 0596T (Temporary female intraurethral valve-pump (
                        <E T="03">i.e.,</E>
                         voiding prosthesis); initial insertion, including urethral measurement) and 0597T (Temporary female intraurethral valve-pump (
                        <E T="03">i.e.,</E>
                         voiding prosthesis); replacement) to status indicator “J1”, APC 5372 (Level 2 Urology and Related Services) with a proposed payment rate of $675.64.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters shared support for the proposal to assign CPT code 0597T to APC 5372 and agreed that the proposed assignment to APC 5372 aligns with costs incurred by hospitals to perform this service.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their support.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters, the manufacturer and a trade association, expressed concerns that the proposed assignment of CPT code 0597T to APC 5372 does not sufficiently consider the targeted device cost of $1,885 and is not appropriate from a resource perspective, which the commenters feel may limit access to the procedures. The commenters requested reassignment of CPT code 0596T to APC 5373 (Level 3 Urology and Related Services) with a proposed payment rate of $2,074.53 as they believe that APC 5373 would be appropriate from a clinical and resource perspective and would more appropriately reflect the device costs to hospitals to furnish the service.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their comment. For this final rule with comment period, we have no claims data for CPT code 0596T for OPPS ratesetting purposes. We continue to believe that CPT code 0596T shares similar clinical characteristics and resource costs to the services assigned to APC 5372.
                    </P>
                    <P>In summary, after consideration of the public comments we received, we are finalizing our proposal, without modification, to continue to assign CPT codes 0596T and 0597T to APC 5372 for CY 2025. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reported under the OPPS. In addition, we refer readers to Addendum A of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Both Addendum A and Addendum B are available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">33. Fractional Flow Reserve (FFR) With 3D Coronary Mapping, CPT Code 0523T</HD>
                    <P>The fractional flow reserve (FFR) with 3D coronary mapping procedure is described by CPT code 0523T (Intraprocedural coronary fractional flow reserve (ffr) with 3d functional mapping of color-coded ffr values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention (list separately in addition to code for primary procedure)). CPT code 0523T became effective January 1, 2019. For CY 2024, CPT code 0523T was assigned the status indicator “N” (packaged).</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter requested that the packaging exemption for SaaS add-on codes policy should be applied to CPT code 0523T. The commenter further requested that CPT code 0523T be assigned to status indicator “J1” (Comprehensive APC) and assigned to APC 5191 (Level 1 Endovascular Procedures) for CY 2025.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We note that CPT code 0523T is an add-on code. Add-on codes represent services that are always performed in addition to the primary service or procedure and must never be reported as a stand-alone code. As specified under 42 CFR 419.2(b)(18), add-on codes are generally packaged under the OPPS, and payment for the codes are bundled with the primary codes. Consequently, CPT code 0523T is not paid separately under the OPPS, but instead, has its payment packaged into the payment for the primary code.
                    </P>
                    <P>Under the packaging exemption for SaaS add-on codes (87 FR 72027 to 72035), we adopted a policy that services represented by SaaS add-on codes are not among the “certain services described by add-on codes” for which we package payment with the related procedures or services under the regulation at 42 CFR 419.2(b)(18). Specifically, the SaaS CPT add-on codes will be assigned to identical APCs and have the same status indicator assignments as their standalone SaaS codes. As such, the policy exempts SaaS add-on codes for which a standalone SaaS code is separately payable under the OPPS for the identical SaaS service furnished without concurrent imaging and described by the standalone CPT code. In summary, the packaging exemption for SaaS add-on codes policy only exempts SaaS add-on codes when the identical SaaS procedure is also represented by a standalone SaaS code and payable under the OPPS because the procedure requires the same resources regardless of whether it is furnished with or without the imaging service.</P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal without modification for CPT codes 0523T. Please refer to Table 90 below for the final OPPS APC and status indicator assignment for CPT codes 0523T for CY 2025. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="175">
                        <PRTPAGE P="94094"/>
                        <GID>ER27NO24.114</GID>
                    </GPH>
                    <HD SOURCE="HD3">34. Fractional Flow Reserve Derived From Computed Tomography (FFRCT), CPT Code 75580 (APC 5724)</HD>
                    <P>Fractional Flow Reserve Derived from Computed Tomography (FFRCT), also known by the trade name HeartFlow®, is a noninvasive diagnostic service that allows physicians to measure coronary artery disease in a patient through the use of coronary CT scans. The HeartFlow® service is indicated for clinically stable symptomatic patients with coronary artery disease, and, in many cases, may avoid the need for an invasive coronary angiogram procedure. HeartFlow® uses a proprietary data analysis process performed at a central facility to develop a three-dimensional image of a patient's coronary arteries, which allows physicians to identify the fractional flow reserve to assess whether patients should undergo further invasive testing (that is, a coronary angiogram).</P>
                    <P>HeartFlow® is currently described by CPT code 75580 (Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified health care professional). On January 1, 2024, CPT code 75580 replaced CPT code 0503T ((Noninvasive estimated coronary fractional flow reserve (ffr) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; analysis of fluid dynamics and simulated maximal coronary hyperemia, and generation of estimated ffr model).</P>
                    <P>HeartFlow® was assigned to APC 5724 (Level 4 Diagnostic Tests and Related Services) for CY 2024, and we proposed for CY 2025 to continue to assign HeartFlow® (CPT code 75580) to APC 5724.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment stating that several of the Medicare Administrative Contractors (MACs) have an edit in place that prohibits the use of the cardiology revenue code (0480) when billing CPT code 75580 as evidenced by claims denials with “Invalid Revenue Code” errors. The commenter asked that we provide guidance that explicitly allows CPT code 75580 to be billed with any appropriate revenue code just as we did for cardiac CT services. (See January 2024 Update (Transmittal 12421, Change Request 13488, dated December 21, 2023.)
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         Based on the information the commenter provided, we were able to identify the outdated edit and remove it. Facilities may bill CPT 75580 with any appropriate revenue code. As a reminder, it is longstanding CMS policy that hospital outpatient facilities are responsible for reporting the appropriate cost centers and revenue codes on claims. As stated in section 20.5 in Chapter 4 (Part B Hospital) of the Medicare Claims Processing Manual, CMS “does not instruct hospitals on the assignment of HCPCS codes to revenue codes for services provided under OPPS since hospitals' assignment of cost vary. Where explicit instructions are not provided, HOPDs should report their charges under the revenue code that will result in the charges being assigned to the same cost center to which the cost of those services are assigned in the cost report.” In addition to referring readers to the Medicare Claims Processing Manual, we will be providing public education and instruction through the CMS Medicare Learning Network (MLN).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Multiple commenters supported our proposal to continue to assign CPT code 75580 to APC 5724 for CY 2025.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their input and for their support of our policy.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal without modification. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">35. Gastric Electrophysiology Mapping With Simultaneously Validated Patient System Profiling (GEMS) Service, CPT Code 0868T (APC 5723)</HD>
                    <P>Effective July 1, 2023, based on a New Technology application received by CMS for the GEMS service, CMS established HCPCS code C9787 (Gastric electrophysiology mapping with simultaneous patient symptom profiling) and assigned it to APC 5723 (Level 3 Diagnostic Tests and Related Services). Effective July 1, 2024, HCPCS code C9787 was deleted and replaced by CPT code 0868T (High-resolution gastric electrophysiology mapping with simultaneous patient symptom profiling, with interpretation and report). CMS assigned CPT code 0868T to APC 5723, the same APC to which its predecessor code, HCPCS code C9787, was assigned. For CY 2025, CMS proposed to continue to assign CPT code 0868T to APC 5723 with a proposed payment rate of $527.44 for CY 2025.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received several comments, including a comment from the manufacturer, requesting that we reassign CPT code 0868T from APC 5723 to APC 1520 (New Technology—Level 20 ($1801-$1900)) with a payment rate of $1850.50, based on the purported cost of the technology and the 
                        <PRTPAGE P="94095"/>
                        fact that it is a new service with a low volume of claims. The commenters explained that the proposed payment rate for CPT code 0868T would not cover the costs of the device, supplies, and clinical staff expenses. One commenter explained that the available claims data supports the conclusion that the proposed APC placement is inadequate. Specifically, the commenter pointed to one single frequency claim that shows a geometric mean cost of approximately $1,800 to demonstrate that CPT code 0868T should be assigned to APC 1520. The commenters suggested that if CMS did not agree to finalize an assignment to APC 1520, they would then suggest that CPT code 0868T be assigned to APC 5724 (Level 4 Diagnostic Tests and Related Services) with a proposed payment rate of approximately $1,000 or APC 5302 (Level 2 Upper GI Procedures) with a proposed payment rate of approximately $1,800 for CY 2025. Finally, one commenter drew differences between the clinical characteristics of CPT code 0868T and the other services assigned to APC 5723, including CPT code 0799T. For example, the commenter stated that CPT code 0799T involves a low-resolution electrode patch generating data comparable to traditional legacy electrogastrography, whereas C9787/0868T uses a high-resolution 64-lead array and sophisticated software to provide detailed multimodal diagnostic data.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' input. We disagree with the APC assignments recommended by commenters based on the purported costs of the service. Since we issued the proposed rule, additional claims data have been processed which, we believe, confirm that the proposed APC assignment is appropriate for HCPCS code C9787/CPT code 0868T for CY 2025. Our analysis of the available claims data demonstrates that the geometric mean cost for HCPCS code C9787 is approximately $310 based on 5 single frequency claims, which is below the geometric mean cost of $530 for APC 5723, but within the range of geometric mean costs of services assigned to APC 5723 which vary from approximately $150 to $2000. We note that given the effective date of payment, we have only one year of claims data for HCPCS code C9787/CPT code 0868T with an extremely low level of single frequency claims.
                    </P>
                    <P>We will continue to monitor the claims data and adjust the APC placement for CPT code 0868T, based on the claims data in future rulemaking. Additionally, based on our review of the technology used as part of the service, input from CMS medical advisors, and review of all other information available to us, we continue to believe that CPT code 0868T is similar to services assigned to APC 5723. Based on the resource and clinical similarities to other services assigned to APC 5723, including CPT code 0779T (Gi myoelectrical actv study), as well as the available claims data, we believe that our proposal to assign CPT code 0868T is appropriate for CY 2025.</P>
                    <P>After consideration of the public comments, we are finalizing our proposal without modification to continue to assign CPT code 0868T to APC 5723. The final CY 2025 payment rate for the code can be found in Addendum B to this final rule with comment period. We also refer readers to Addendum D1 of this final rule with comment period for the SI meanings for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">36. Hernia Repair Procedures, CPT Codes 49593, 49595, and 49615 (APCs 5342 and 5361)</HD>
                    <P>
                        Effective January 1, 2023, the AMA created new abdominal hernia repair CPT codes 49593 (Repair of anterior abdominal hernia(s) (
                        <E T="03">i.e.,</E>
                         epigastric, incisional, ventral, umbilical, spigelian), any approach (
                        <E T="03">i.e.,</E>
                         open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); 3 cm to 10 cm, reducible), 49595 (Repair of anterior abdominal hernia(s) (
                        <E T="03">i.e.,</E>
                         epigastric, incisional, ventral, umbilical, spigelian), any approach (
                        <E T="03">i.e.,</E>
                         open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); greater than 10 cm, reducible), and 49615 (Repair of anterior abdominal hernia(s) (
                        <E T="03">i.e.,</E>
                         epigastric, incisional, ventral, umbilical, spigelian), any approach (
                        <E T="03">i.e.,</E>
                         open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); 3 cm to 10 cm, reducible). For CY 2023, we assigned these codes to APC 5341 (Level 1 Abdominal/Peritoneal/Biliary and Related Procedures). For CY 2025, we proposed to reassign these codes to APC 5342 (Level 2 Abdominal/Peritoneal/Biliary and Related Procedures) to resolve a 2-times violation for APC 5341.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received two comments supporting the reassignment of CPT codes 49593, 49595, and 49615 to APC 5342 for CY 2025.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their support.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The two commenters recommended that we also reassign CPT codes 49650 (Laparoscopy, surgical; repair initial inguinal hernia) and 49651 (Laparoscopy, surgical; repair recurrent inguinal hernia) from APC 5361 (Level 1 Laparoscopy and Related Services) to APC 5342. The commenters noted that with the addition of the three ventral hernia procedures, APC 5342 would now contain both open and laparoscopic surgical procedures.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their suggestions. After further clinical review, we continue to believe that CPT codes 49650 and 49651 are still appropriately assigned to APC 5361 based on clinical and resource homogeneity to the procedures in the APC 5361.
                    </P>
                    <P>After consideration of the public comment we received, we are finalizing our proposal without modification to reassign CPT codes 49593, 49595 and 49615 to APC 5342 (Level 2 Abdominal/Peritoneal/Biliary and Related Procedures). We are also finalizing our proposal without modification to continue to assign CPT codes 49650 and 49651 to APC 5361 (Level 1 Laparoscopy and Related Services). Table 91 shows the finalized status indicator and APC assignment for the procedure code. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="370">
                        <PRTPAGE P="94096"/>
                        <GID>ER27NO24.115</GID>
                    </GPH>
                    <HD SOURCE="HD3">37. Imaging of Retina for Detection or Monitoring of Disease, CPT Code 92229 (APC 5733)</HD>
                    <P>CPT code 92229 (Imaging of retina for detection or monitoring of disease; point-of-care autonomous analysis and report, unilateral or bilateral) is performed to screen patients with diabetes for signs of diabetic retinopathy and other eye diseases. The code was established on January 1, 2021 and assigned to APC 5733 (Level 3 Minor Procedures). The code was assigned to Level 3 Minor Procedures because the service had clinical and resource similarity to long-established CPT code 92227 (Imaging of retina for detection or monitoring of disease; with remote clinical staff review and report, unilateral or bilateral) which also is assigned to APC 5733 (Level 3 Minor Procedures).</P>
                    <P>In the CY 2023 claims data, there were 370 (single frequency) claims for CPT code 92229 and the geometric mean for the service was $28.53. For CY 2025, we proposed to maintain CPT code 92229 in APC 5733 (Level 3 Minor Procedures) and wait for more claims data to be available before adjusting the payment rates for this service.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received several comments supporting our decision to maintain CPT 92229 in APC 5733 (Level 3 Minor Procedures). Commenters noted that this service provides potentially sight saving technology to beneficiaries with diabetes in rural and underserved communities.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their input.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment requesting that CPT code 92229 be removed from the Deficit Reduction Act (DRA) cap.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input, but we note that this comment is out of scope for purposes of this CY 2025 OPPS/ASC final rule with comment period.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal without modification to assign CPT code 92229 to APC 5733. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">38. Implantable Cardiac Alert System, CPT Codes 0525T and 0527T (APCs 5224 and 5222)</HD>
                    <P>The implantable cardiac alert system is a cardiac monitoring and alerting device to detect acute coronary syndrome (ACS) events and alerts the patient to seek urgent medical attention. The CPT codes 0525T (Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)) and 0527T (Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only) became effective January 1, 2019.</P>
                    <P>
                        For CY 2025, the OPPS payment rates are proposed based on available CY 2023 claims data. For the CY 2025 OPPS/ASC proposed rule, based on our 
                        <PRTPAGE P="94097"/>
                        analysis of claims data, we found a total of 15 single frequency claims and an estimated geometric mean cost of $3,244 for CPT code 0525T and a total of three single frequency claims and an estimated geometric mean cost of $3,433 for CPT code 0527T. For CY 2025, we proposed to continue to assign CPT code 0525T to Level 3 Pacemaker and Similar Procedures (APC 5223) and CPT code 0527T to Level 2 Pacemaker and Similar Procedures (APC 5222).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         One Commenter disagreed with our APC's assignments of CPT codes 0525T and 0527T, suggesting that we did not account for the cost of the device represented by HCPCS code C1833 in the proposed rule. The commenter also stated that we erroneously assigned the status indicator of “H” to HCPCS code C1833 in the CY 2025 OPPS/ASC proposed rule. The commenter noted the Transitional Pass-Through period for C1833 expires December 31, 2024, and that HCPCS code C1833 should have been assigned the status indicator of “N” for CY 2025.
                    </P>
                    <P>Additionally, the commenter argued that the proposed payment rates for CPT codes 0525T and 0527T are insufficient to cover the procedures' cost because we did not account for the device cost in the proposed CY 2025 payment rates. They claimed that the procedures represented by 0525T and 0527T are similar procedures and should both be assigned to APC 5231 (Level 1 ICD and Similar Procedures).</P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter pointing out that HCPCS code C1833's Transitional Pass-through Status expires December 31, 2024. Therefore, we are revising the HCPCS code C1833's status indicator to “N” (packaged) for CY 2025.
                    </P>
                    <P>We agree with the commenter the CY 2025 proposed APC assignments for 0525T and 0527T erroneously omitted the device cost (HCPCS code C1833) associated with these procedures. With the updated final rule data including the HCPCS code C1833 device cost, the revised geometric mean cost for CPT code 0525T is approximately $15,167 and the geometric mean cost for 0527T is approximately $7,242. Therefore, we believe an appropriate APC assignment for CPT code 0525T would be APC 5224 (Level 4 Pacemaker and Similar Procedures); and an appropriate assignment for CPT code 0527T would be APC 5222 (Level 2 Pacemaker and Similar Procedures).</P>
                    <P>We disagree with the commenter that CPT code 0525T is similar clinically and in resource costs to CPT code 0527T. We note that CPT code 0525T is for insertion of the complete system while CPT code 0527T is for insertion of the implantable monitor only.</P>
                    <P>After consideration of the public comments we received, we are finalizing a revision to our proposed APC assignment for CPT code 0525T and assigning this code to APC 5224 (Level 4 Pacemaker and Similar Procedures). We are finalizing the assignment of CPT code 0527T to APC 5222 (Level 2 Pacemaker and Similar Procedures) as proposed. Please refer to Table 92 for the final OPPS APC and status indicator assignment for CPT codes 0525T, 0527T and C1833 for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="373">
                        <PRTPAGE P="94098"/>
                        <GID>ER27NO24.116</GID>
                    </GPH>
                    <HD SOURCE="HD3">39. Implantable Glucose Monitoring System, CPT Codes 0446T and 0448T (APC 5054)</HD>
                    <P>In 2017, the AMA CPT Editorial Panel established CPT codes 0446T and 0448T. CPT code 0446T (Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training) and CPT code 0448T (Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation) describe an implantable glucose sensor for diabetic patients. The current codes are used to describe both 90-day and 180-day sensors. The FDA recently approved a 365-day sensor that is not currently on the market.</P>
                    <P>For CY 2025, we proposed to maintain both CPT codes in APC 5054 (Level 4 Skin Procedures) with a status indicator of “T” (Procedure or Service, Multiple Procedure Reduction Applies; Paid under OPPS; separate APC payment.).</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment from the manufacturer requesting that we reassign CPT codes 0446T and 0448T from APC 5054 (Level 4 Skin Procedures) to APC 1531 (New Technology—Level 31 ($6501-$7000)) with a payment of $6,750.50 to reflect the increased expense of the implantable sensor that has quadrupled the life of the 90-day sensor. The manufacturer reiterated the value of the longer sensor duration, including fewer insertion and removal procedures and increased adherence to therapy.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the request of the commenter and understand the implicated value that a longer life sensor brings to Medicare beneficiaries. Because the current CPT codes do not designate the increased battery life of the sensor, we believe it is more appropriate to create 2 new HCPCS G codes effective January 1, 2025 to describe the implantable interstitial glucose sensor with a 365-day battery life than to make APC reassignments and potentially overpay for the current codes that could be used to describe the 90-day, 180-day, or 365-day sensor. Specifically, we created the following G codes to describe the 365-day sensor:
                    </P>
                    <P>• G0564 (Creation of subcutaneous pocket with insertion of 365 day implantable interstitial glucose sensor, including system activation and patient training); and</P>
                    <P>• G0565 (Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new 365 day implantable sensor, including system activation).</P>
                    <P>The manufacturer asserts the supply costs of the 365-day system will be equivalent to two 180-day systems or four 90-day systems. While we agree that there would be inherently increased costs to the new technology of a 365-day system, we do not agree that those costs would be 4 times more than the 90-day system.</P>
                    <P>
                        After reviewing the device and procedure and obtaining input from our medical officers, we are assigning HCPCS codes G0564 and G0565 to APC 1561 (New Technology—Level 24 ($3001-$3500)) with a payment rate of $3,250.50.
                        <PRTPAGE P="94099"/>
                    </P>
                    <P>We currently have very little claims information available for CPT codes 0446T and 0448T as there has only been 1 single frequency claim for CPT 0448T (with a geometric mean cost of around $1,320) and no single frequency claims for 0446T. The geometric mean cost for APC 5054 (Level 4 Skin Procedures) is around $1,850 so we believe APC 5054 is an appropriate assignment. We will continue to monitor these codes as we gather adequate claim information and other relevant clinical information that would be useful in determining appropriate APC assignments.</P>
                    <P>In summary, after consideration of the public comment, we are finalizing our proposal, without modification, to assign CPT code 0446T and 0448T to APC 5054 (Level 4 Skin Procedures) for CY 2025 and finalizing APC assignments for G0564 and G0565. The final CY 2025 payment rate for these codes can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the SI meanings for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">40. Integrated Sacral Neurostimulators, CPT Code 0786T</HD>
                    <P>
                        Effective January 1, 2024, the CPT Editorial Panel separated integrated from non-integrated (
                        <E T="03">i.e.,</E>
                         traditional) sacral neurostimulator procedure by establishing new CPT code, 0786T to report procedures using integrated sacral neurostimulator devices, while CPT code 64590 was updated to reflect the use of traditional technology:
                    </P>
                    <P>
                        • 
                        <E T="03">0786T:</E>
                         Insertion or replacement of percutaneous electrode array, sacral, with integrated neurostimulator, including imaging guidance, when performed.
                    </P>
                    <P>
                        • 
                        <E T="03">64590:</E>
                         Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver
                    </P>
                    <P>In the CY 2025 OPPS/ASC proposed rule Addendum B, we proposed to continue to assign CPT code 0786T to APC 5463 (Level 3 Neurostimulator and Related Procedures) with a proposed payment rate of $13,029.81. We received several comments related to the proposal.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter disagreed with our proposal. The commenter stated that the proposed assignment for this technology would reduce reimbursement and limit access for Medicare and Medicaid patients seeking care in the outpatient surgery setting. The commenter thought that this decision may have been based on the concept that the Neuspera system is an integrated system, requiring no intra-operative connection. Although physical connections are not required, they stated a considerable amount of time and effort is expended on creating wireless connections and re-positioning the device once partially deployed.
                    </P>
                    <P>One commenter asserted that the integrated sacral neuromodulation system (SNM) represents a disruptive technology that should improve patient satisfaction, with similar efficacy, lower risk, and as a “one and done” procedure that will reduce the need for 2-3 devices per patient to only one Neuspera devices per patient. The commenter stated the lead placement takes the majority of the procedure time, while the implantable pulse generator (IPG) placement requires very little time and expertise. Given their claim that the integrated system is nearly identical to the current non-integrated systems, they requested it should be paid on par with the current non-integrated system.</P>
                    <P>Other commenters maintained that the integrated SNM system anticipated to reach the market in 2025 has time and resources substantially equivalent to those for traditional SNM systems. Given this, they noted keeping CPT code 0786T in a lower APC with a lower device-intensive designation than traditional SNM systems will create an economic barrier and restrict hospitals and ASCs from offering this new less invasive form of SNM to patients.</P>
                    <P>Several commenters urged CMS to reassign CPT code 0786T to APC 5464 (Level 4 Neurostimulator and Related Procedures) to reflect the most accurate procedure and cost information related to this novel sacral neuromodulation system. They stated that there is a high degree of parity and similarity in time, work, staffing, costs, and resources required for the Neuspera procedure, compared to traditional sacral neuromodulation systems, which are currently assigned to APC 5464. The commenters also pointed out that if CMS is not willing to reassign CPT code 0786T to APC 5464, status indicator “E1” may provide CMS the ability to postpone APC assignment until there is FDA cleared technology to make a decision. Currently no FDA approved “integrated” sacral neuromodulation system exists.</P>
                    <P>
                        <E T="03">Response:</E>
                         We proposed to continue to assign CPT code 0786T to APC 5463 for CY 2025, based on input from our clinicians and based on our evaluation of the code. We inadvertently listed Neuspera integrated sacral nerve stimulation system as receiving FDA-approval. However, it is still pending FDA approval and therefore, we agree with most of the commenters who recommended to reassign CPT code 0786T to status indicator “E1” until FDA approval has been received.
                    </P>
                    <P>In summary, after consideration of the public comments that we received, we are finalizing our proposal with modification and are reassigning CPT code 0786T from APC 5463 to status indicator “E1” (Not covered by any Medicare outpatient benefit category; Statutorily excluded by Medicare; Not reasonable and necessary; Not paid by Medicare when submitted on outpatient claims (any outpatient bill type)) for CY 2025 because this service is not yet FDA approved.</P>
                    <P>We refer readers to Addendum D1 of this final rule with comment period for the status indicator (SI) meanings for all codes reported under the OPPS. Addendum D1 is available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">41. Laparoscopic Appendectomy, CPT Code 44970 (APC 5361)</HD>
                    <P>CPT code 44970 (Laparoscopy, surgical, appendectomy) describes the procedure for laparoscopic appendectomy. Using CY 2023 claims data, CPT code 44970 had a geometric mean cost of $6,499.86 in the CY 2025 OPPS/ASC proposed rule. For CY 2025, we believed this was still appropriately assigned to APC 5361 (Level 1 Laparoscopy and Related Services), which had a proposed payment rate of $5,798.13. Therefore, we proposed to continue assigning CPT code 44970 to APC 5361.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment requesting that we reassign CPT code 44970 to APC 5342 (Level 2 Abdominal/Peritoneal/Biliary and Related Procedures). The commenter argued that CPT code 44970 had clinical homogeneity and resource utilization similar to CPT code 44950 (Appendectomy), which is currently assigned to APC 5342.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input. CPT code 44970 has an updated GMC of $6,404.30 in the final rule data. While this is closer to the payment rate for APC 5342, after clinical review of this procedure, we did not find APC 5342 to be the clinically appropriate APC family for CPT code 44970. We continue to believe that this procedure belongs in the Laparoscopy and Related Procedures family.
                    </P>
                    <P>
                        After consideration of the public comment we received, we are finalizing our proposal without modification to continue to assign CPT code 44970 to APC 5361 (Level 1 Laparoscopy and Related Services). Table 93 shows the 
                        <PRTPAGE P="94100"/>
                        finalized status indicator and APC assignment for the procedure code. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.
                    </P>
                    <GPH SPAN="3" DEEP="92">
                        <GID>ER27NO24.117</GID>
                    </GPH>
                    <HD SOURCE="HD3">42. Litholapaxy Procedure, CPT Code 52318 (APC 5374)</HD>
                    <P>Litholapaxy is a procedure that involves crushing bladder stones and extracting the fragmented stones. CPT code 52318 (Litholapaxy: crushing or fragmentation of calculus by any means in bladder and removal of fragments; complicated or large (over 2.5 cm)) became effective January 1, 1985.</P>
                    <P>For CY 2025, OPPS payment rates are proposed based on available CY 2023 claims data. For CY 2025, based on our analysis of claims data, we found a total of 4,215 single frequency claims and a geometric mean cost of approximately $4,298 for CPT code 52318. For CY 2025, we proposed to continue to assign CPT code 52318 to Level 4 Urology and Related Services (APC 5374) with a proposed payment rate of approximately $3,438.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter requested the APC assignment of CPT code 52318 to Level 5 Urology and Related Services (APC 5375). The commenter stated that the complexity and resources required for CPT code 52318 is comparable to CPT code 52601 (Transurethral electrosurgical resection of prostate, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included)), which is assigned to APC 5375. Moreover, the commenter alleged that CPT code 52318 is two times greater than the lowest geometric mean of CPT code 54670 (Suture or repair of testicular injury) in APC 5375, which is a two times rule violation.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's recommendation regarding the APC assignment of CPT code 52318, but we disagree that the complexity and resources required for CPT code 52318 are comparable to CPT code 52601. Based on the claims data, we believe that CPT code 52318 fits more appropriately in APC 5374, rather than in APC 5375, based on resource cost and clinical similarity to the procedures in APC 5374.
                    </P>
                    <P>Furthermore, CPT codes 52318 and 54670 are currently assigned to APC 5374 (Level 4 Urology and Related Services). We note that APC 5374 does not currently have a 2 times rule violation in the final rule data. In addition, both CPT codes 52318 and 54670 do not meet the requirements for cost significance for 2 times rule violation purposes, under the requirements described in section III.B.2. of this final rule with comment period. We have reviewed the codes' geometric mean cost based on the available CY 2023 claims data within APC 5374 and believe that their current APC assignment continues to be appropriate.</P>
                    <P>After consideration of the public comment we received, we are finalizing our proposal without modification for CPT code 52318 to be reassigned to APC 5374 (Level 4 Urology and Related Services). Please refer to Table 94 for the final OPPS APC and status indicator assignment for CPT code 52318 for CY 2025. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="134">
                        <GID>ER27NO24.118</GID>
                    </GPH>
                    <HD SOURCE="HD3">43. LIXELLE® Apheresis</HD>
                    <P>
                        LIXELLE® β2-microglobulin Apheresis Column is indicated for use in the treatment of dialysis-related amyloidosis (DRA), a disease that affects people with end-stage renal disease (ESRD). DRA is a metabolic disorder from the failure of the kidney to filter and remove β2-microglobulin, typically from chronic hemodialysis (typically 5 years or longer). The LIXELLE® device is used in an apheresis procedure that selectively removes β2-microglobulin from circulating blood and is used pursuant to a physician prescription in conjunction with hemodialysis. It is intended to be used at each hemodialysis session (that is, frequency 
                        <PRTPAGE P="94101"/>
                        of treatment is expected to be 3 times per week). In March 2015, FDA approved LIXELLE® as a Class III Humanitarian Use Device (HUD) with an approved Humanitarian Device Exemption (HDE). For CY 2025, there are currently no specific HCPCS or CPT codes that represent the LIXELLE® apheresis service.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment, from the manufacturer, requesting CMS provide reimbursement for LIXELLE® apheresis procedure under the ESRD payment system or the OPPS to benefit patients with DRA. Specifically, the commenter requested that CMS provide separate payment under the OPPS for the procedure, and offered the following options:
                    </P>
                    <P>(1) establish a new HCPCS C code or G code for the LIXELLE® apheresis procedure and assign the code to APC 5242 (Level 2 Blood Product Exchange and Related Services); or</P>
                    <P>(2) pay separately for the apheresis procedure used with the LIXELLE® device through CPT code 36516 (Therapeutic apheresis with extracorporeal immunoadsorption, selective adsorption or selective filtration and plasma reinfusion), assigned to APC 5243 (Level 3 Blood Product Exchange and Related Services) for CY 2025, and require the use of a modifier or add-on code when the LIXELLE® apheresis procedure is billed to reduce the procedure payment APC 5242 (Level 2 Blood Product Exchange and Related Services) payment rate; or</P>
                    <P>(3) allow separate payment for the dialysis performed as part of LIXELLE® apheresis procedure through HCPCS code G0257 (Unscheduled or emergency dialysis treatment for an ESRD patient in a hospital outpatient department that is not certified as an ESRD facility), which is assigned to APC 5401 (Dialysis) for CY 2025 and require the use of a modifier or add-on code to provide additional payment beyond that provided for APC 5401; or</P>
                    <P>
                        (4) assign CPT 90947 (Dialysis procedure other than hemodialysis (
                        <E T="03">e.g.,</E>
                         peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated evaluations by a physician or other qualified health care professional, with or without substantial revision of dialysis prescription) to APC 5242 (Level 2 Blood Product Exchange and Related Services).
                    </P>
                    <P>The commenter also noted the FDA has approved a clarification to the Instructions for Use (IFU) since last year's comment and rulemaking. The IFU for LIXELLE® expands the list of personnel who can supervise the patient while connected to the extracorporeal system to include not only a physician, but a qualified health care professional such as a physician assistant, nurse practitioner, or registered nurse who is qualified to supervise hemodialysis procedures.</P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the thoughtful recommendations and will consider them for future rulemaking. We note this complex, ongoing issue is still under consideration and continues to merit a thorough evaluation to ensure an appropriate Medicare benefit category and payment pathway for the service is determined.
                    </P>
                    <HD SOURCE="HD3">44. Low Ejection Fraction AI-ECG Service, CPT Codes 0764T and 0765T (APC 5734)</HD>
                    <P>
                        The low ejection fraction AI-ECG Service is intended to aid in screening for Left Ventricular Ejection Fraction (LVEF) less than or equal to 40 percent in adults at risk for heart failure. The low ejection fraction AI-ECG Service is an algorithmic SaaS service that aims to detect hidden diseases using algorithms to enhance and improve interventional procedures through real-time AI insights. CPT codes 0764T (Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (
                        <E T="03">e.g.,</E>
                         low ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently performed electrocardiogram (List separately in addition to code for primary procedure)) and 0765T (Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (
                        <E T="03">e.g.,</E>
                         low ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram) became effective January 1, 2023 and were assigned to status indicator “E1” (Not paid by Medicare when submitted on outpatient claims). For CY 2025, we proposed that CPT codes 0764T and 0765T continue to be assigned to status indicator E1.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         One Commenter provided documentation that AI-ECG has been FDA approved on September 28, 2023. The commenter requested separate payment for the low ejection fraction AI-ECG service for CY 2025. In addition, the commenter referenced our CY 2023 packaging exemption for SaaS add-on codes policy and requested separate payment for the add-on CPT code 0764T.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter providing the FDA documentation for the AI-ECG approval. We agree that CPT code 0765T should be payable for CY 2025. Consistent with our SaaS Add-on Codes policy, CPT code 0764T, the add-on code for the low ejection fraction AI-ECG service would be assigned to the identical APC and status indicator to CPT code 0765T, the standalone code for the same service.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing revised status indicator and APC assignments for CPT codes 0764T and 0765T. Please refer to Table 95 for the final OPPS APC and status indicator assignment for HCPCS codes 0764T and 0765T for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="303">
                        <PRTPAGE P="94102"/>
                        <GID>ER27NO24.119</GID>
                    </GPH>
                    <HD SOURCE="HD3">45. Lower Esophageal Myotomy (POEM), CPT 43497 (APC 5331)</HD>
                    <P>
                        CPT code 43497 (Lower esophageal myotomy, transoral (
                        <E T="03">i.e.,</E>
                         peroral endoscopic myotomy [POEM]) describes a minimally invasive endoscopic procedure that treats swallowing disorders caused by muscle problems in the esophagus.
                    </P>
                    <P>For CY 2025, we proposed to assign CPT code 43497 to APC 5331 (Complex GI Procedures) with a proposed payment rate of around $5,838.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment requesting that we reassign CPT code 43497 to APC 5361 (Level 1 Laparoscopy and Related Services) with a proposed payment of around $5,798. The commenter stated that the procedure utilizes techniques that are surgical in nature and that APC 5361 would be a more appropriate APC assignment, based on clinical homogeneity and resource utilization with other services in APC 5361.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         The OPPS is a prospective payment system that provides payment for groups of services that share clinical and resource use characteristics. Based on our understanding of the service and input from our medical advisors, we do not agree that CPT code 43497 has clinical and resource homogeneity to other services in APC 5361 such that it should be assigned to APC 5361.
                    </P>
                    <P>In summary, after consideration of the public comment, we are finalizing our proposal, without modification, to assign CPT code 43497 to APC 5331 for CY 2025. The final CY 2025 payment rate for the code can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the SI meanings for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">46. Magnetic Resonance Exam Safety Procedures, CPT Codes 76014 Through 76019 (APCs 5521, 5523, 5731, 5733, and 5742)</HD>
                    <P>For CY 2025, the AMA CPT Editorial Panel created six codes to report magnetic resonance (MR) examination safety procedures, effective January 1, 2025. The new codes did not have a predecessor code or a one-to-one match to an existing code. When determining the proposed status indicators and APC assignments for CY 2025, we reviewed the clinical and resource characteristics of the procedures, considered input from our medical advisors, and reviewed existing APC classifications to identify similar and closely related procedures. The codes, their long descriptors, and their proposed CY 2025 OPPS status indicators and APC assignments are listed in Table 96.</P>
                    <P>We note that CPT codes 76014, 76015, 76016, 76017, 76018, and 76019 were listed as placeholder codes 7XX00, 7XX01, 7XX02, 7XX03, 7XX04, and 7XX05 respectively, in OPPS Addendum B and Addendum O that were released with the CY 2025 OPPS/ASC proposed rule. Because we had not received the final CPT code numbers from AMA for the new codes that would be effective January 1, 2025, in time for the publication of the proposed rule, we listed the new CPT codes with their respective placeholder codes in OPPS Addendum B and Addendum O.</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94103"/>
                        <GID>ER27NO24.120</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <P>
                        <E T="03">Comment:</E>
                         Some commenters disagreed with the proposed assignments for the five separately payable codes and provided 
                        <PRTPAGE P="94104"/>
                        recommendations for APC reassignments. They stated that the proposed APC assignments for the new codes would be insufficient to cover the cost of furnishing the procedures and would impact beneficiary access. Commenters detailed that the proposed APC assignments for CPT codes 76017, 76018, and 76019 did not reflect the facility costs associated with these procedures, including additional staff time, MR room time and clinical resources for planning, preparation, and patient positioning.
                    </P>
                    <P>The commenters requested that CMS reassign CPT codes 76014 (placeholder code 7XX00) and 76016 (placeholder code 7XX05) to APC 5611(Level 1 Therapeutic Radiation Treatment Preparation) with a proposed payment rate of $89.12. Commenters requested that CMS reassign CPT codes 76017 (placeholder code 7XX03) and 76019 (placeholder code 7XX05) to APC 5612 (Level 2 Therapeutic Radiation Treatment Preparation; proposed payment rate of around $370). Commenters shared that CPT codes 76017 (placeholder code 7XX03) and 76019 (placeholder code 7XX05) require additional staff time and clinical resources for planning, preparation, and positioning which warrants reassignment to APC 5612.</P>
                    <P>One commenter requested that CMS reassign CPT code 76018 (placeholder code 7XX04) to APC 5612 (Level 2 Therapeutic Radiation Treatment Preparation; proposed payment rate of around $370), Another commenter requested a reassignment of CPT code 76018 to APC 5742 (Level 2 Electronic Analysis of Devices; proposed payment rate of around $92). The commenter stated that CPT code 76018 involves interrogation and programming of an implanted device to protect the device and patient against interactions with the MRI scanner and would therefore fit well within APC 5612.</P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their feedback and recommendations. In determining the appropriate APC placement for new codes, we rely on input from a variety of sources, including, but not limited to, review of the resource costs and clinical similarity of the service to existing procedures; input from CMS medical advisors; and information from interested specialty societies. We evaluated the recommendations, modeled the suggestions, analyzed the cost results of the suggested APC reassignments, and received additional input from our medical advisors. Because we believe that the services assigned to the Therapeutic Radiation Treatment Preparation APC family have higher degrees of technicality, require higher levels of trained professional staff, and therefore have additional facility costs beyond those described by the CPT codes 76014 through 76019, we disagree with the commenter requests to assign these CPT codes to APCs 5611 and 5612. And while we recognize that there is not currently a one-to-one match to crosswalk to the new codes, we based the proposed APC assignments for CPT codes 76014, 76016, and 76019 on crosswalks to CPT codes that have similar service and resource elements, as well as required staff, to the new codes.
                    </P>
                    <P>Specifically, we continue to believe that:</P>
                    <P>• CPT code 76014 is similar to the service described by CPT code 0521T (Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing), which is assigned to APC 5731.</P>
                    <P>• CPT code 76016 is similar to the service described by CPT code 77091 (Trabecular bone score (tbs), structural condition of the bone microarchitecture; technical calculation only), which is assigned to APC 5521.</P>
                    <P>• CPT code 76019 is similar to CPT code 29520 (Strapping; hip), which is assigned to APC 5733.</P>
                    <P>
                        After consideration of the public comments, our review of CPT code 76017 identified procedures in APC 5523 (Level 3 Imaging without Contrast) that we believe better align with the clinical characteristics and resources required for CPT code 76017, including CPT code 73718 (Magnetic resonance (
                        <E T="03">e.g.,</E>
                         proton) imaging, lower extremity other than joint; without contrast material(s)). After further input from CMS medical advisors, we believe that it may be appropriate to assign CPT code 76017 to APC 5523.
                    </P>
                    <P>Additionally, we believe that we have identified additional procedures in APC 5742 that share similar resource and clinical characteristics with CPT code 76018. Specifically, we believe that CPT code 76018 shares resource and clinical similarities to the service described by CPT code 29125 (Application of short arm splint (forearm to hand); static). Based on our assessment, we believe it appropriate to assign CPT code 76018 to APC 5742, based on shared resource and clinical characteristics.</P>
                    <P>In summary, we believe that the below assignment of the new codes in Table 97 are the most appropriate, in terms of clinical and resource homogeneity. We note that we review our claims data on an annual basis to establish the OPPS payment rates and we will reevaluate the status indicator and APC assignments annually.</P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal with modification for CPT codes 76014 through 76019. Table 97 shows the finalized status indicators and APC assignments for all of the procedure codes. The final CY 2025 payment rates for these codes can be found in Addendum B to this final rule with comment period. We also refer readers to Addendum D1 of this final rule with comment period for the SI meanings for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94105"/>
                        <GID>ER27NO24.121</GID>
                    </GPH>
                    <PRTPAGE P="94106"/>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <HD SOURCE="HD3">47. MindMotion GO Neurorehabilitative Remote Therapy Service, CPT Code 0733T (APC 1505)</HD>
                    <P>
                        Effective July 1, 2022, the AMA established CPT code 0733T (Remote real-time, motion capture-based neurorehabilitative therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days) to describe the procedure associated with the use of MindMotion GO, which provides remote real-time, motion capture-based neurorehabilitative therapy. In the CY 2025 OPPS/ASC proposed rule, CMS proposed to continue to assign CPT code 0733T to APC 5741 (Level 1 Electronic Analysis of Devices) with a proposed payment rate of $36.90, due to its similarity to CPT code 98976 (Remote therapeutic monitoring (
                        <E T="03">e.g.,</E>
                         therapy adherence, therapy response); device(s) supply with scheduled (
                        <E T="03">e.g.,</E>
                         daily) recording(s) and/or programmed alert(s) transmission to monitor respiratory system, each 30 days).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment from the manufacturer of MindMotion GO requesting that CMS reassign CPT code 0733T to APC 1510 (New Technology—Level 10 ($801-$900)). The commenter stated that the resource costs of this service are $849 and that the MindMotion GO technology will not be commercially available until early 2025, so there is currently no claims data available to assign this service to a clinical APC. The commenter also believed that CPT code 0733T was not clinically homogeneous with APC 5741 as the procedures in the APC are for monitoring services, while CPT code 0733T also describes a device used primarily for treatment of neurological conditions.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input. We agree with the commenter that the current assignment of APC 5741 would result in too low of a payment for CPT code 0733T. After further review, we believe this procedure is similar to the procedure described by CPT code 0693T (Comprehensive full body computer-based markerless 3d kinematic and kinetic motion analysis and report), which describes technology for DARI Motion. CPT code 0693T is currently assigned to APC 1505 (New Technology—Level 5 ($301—$400)). Therefore, we are reassigning CPT code 0733T to APC 1505 until we are able to obtain claims data for this procedure.
                    </P>
                    <P>After consideration of the public comment we received, we are finalizing our proposal with modification to reassign CPT code 0733T to APC 1505 (New Technology—Level 5 ($301-$400)). Table 98 shows the finalized status indicator and APC assignment for the procedure code. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="148">
                        <GID>ER27NO24.122</GID>
                    </GPH>
                    <HD SOURCE="HD3">48. Musculoskeletal Procedures (APCs 5111 Through 5116)</HD>
                    <P>Prior to the CY 2016 OPPS, payment for musculoskeletal procedures was primarily divided according to anatomy and the type of musculoskeletal procedure. As part of the CY 2016 reorganization to better structure the OPPS payments to utilize prospective payment packages, we consolidated these individual APCs so that they became a general Musculoskeletal APC series (80 FR 70397 and 70398).</P>
                    <P>In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59300), we continued to apply a six-level structure for the Musculoskeletal APCs because doing so provided an appropriate distinction for resource costs at each level and provided clinical homogeneity. However, we indicated that we would continue to review the structure of these APCs to determine whether additional granularity would be necessary. In the CY 2019 OPPS proposed rule (83 FR 37096), we recognized that commenters had previously expressed concerns regarding the granularity of the current APC levels and, therefore, requested comment on the establishment of additional levels. Specifically, we solicited comments on the creation of a new APC level between the current Level 5 and Level 6 within the Musculoskeletal APC series. While some commenters suggested APC reconfigurations and requested changes to APC assignments, many commenters requested that we maintain the current six-level structure and continue to monitor the claims data as they become available. Therefore, in the CY 2019 OPPS/ASC final rule with comment period, we maintained the six-level APC structure for the Musculoskeletal Procedures APCs (83 FR 58920 and 58921).</P>
                    <P>For CY 2025, based on the claims data available for the CY 2024 OPPS/ASC proposed rule, we continued to believe that the six-level APC structure for the Musculoskeletal Procedures APC series is appropriate, and we proposed to maintain it for the CY 2025 OPPS update.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters supported the assignment of HCPCS code 0737T (Xenograft implantation into the articular surface) to APC 5115 (Level 5 Musculoskeletal Procedures) and recommended that we finalize the assignment in the CY 2025 OPPS.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' support of our proposal. We agree and are finalizing the proposed assignment of HCPCS code 0737T (Xenograft implantation into the articular surface) to APC 5115 (Level 5 Musculoskeletal Procedures). We refer 
                        <PRTPAGE P="94107"/>
                        readers to section III.E.67 of this final rule with comment period for a detailed discussion of this issue.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A commenter supported the continued assignment of HCPCS code C9781 (Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (
                        <E T="03">e.g.,</E>
                         balloon), includes debridement (
                        <E T="03">e.g.,</E>
                         limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed) to APC 5115 (Level 5 Musculoskeletal Procedures).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's support of our proposal. We agree and are finalizing the proposed assignment of HCPCS code C9781 (Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (
                        <E T="03">e.g.,</E>
                         balloon), includes debridement (
                        <E T="03">e.g.,</E>
                         limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed) to APC 5115 (Level 5 Musculoskeletal Procedures). We refer readers to section III.E.11. of this final rule with comment period for a detailed discussion of this issue.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A few commenters recommended that CMS consider the creation of additional musculoskeletal APC levels. Commenters noted that additional APCs should be considered with the goal of reducing payment gaps and volatility, while aligning cost and clinical homogeneity in the APCs. One commenter recommended that an additional APC level be considered between the current levels 4 and 5 with costs ranging from $7,000 to $12,000. Another commenter requested that we create an additional Musculoskeletal APC level from codes currently in APC 5116 (Level 6 Musculoskeletal Procedures) with geometric mean costs above $22,000, while moving codes with geomean costs above $14,000 in the current level 5 APC to the level 6 APC.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' recommendations. We also appreciate the goal of developing APC levels that properly group procedures by clinical and resource similarity. At this time, we believe the six-level structure for the Musculoskeletal APCs that we proposed continues to provide an appropriate distinction between the resource costs at each level and clinical homogeneity and are therefore finalizing that six-level structure for the Musculoskeletal Procedures APC series in the CY 2025 OPPS. However, we will take these comments into consideration for future rulemaking and continue to monitor the claims data as they are available.
                    </P>
                    <P>
                        After consideration of the public comments, we are finalizing our proposal to maintain the six-level Musculoskeletal Procedures APC structure. We are also finalizing the assignment of HCPCS code 0737T (Xenograft implantation into the articular surface) to APC 5115 and HCPCS code C9781 (Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (
                        <E T="03">e.g.,</E>
                         balloon), includes debridement (
                        <E T="03">e.g.,</E>
                         limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed) to APC 5115 for the CY 2025 OPPS.
                    </P>
                    <HD SOURCE="HD3">49. Noncontact Near-Infrared (NIR) Spectroscopy, CPT 0640T (APC 5732)</HD>
                    <P>
                        Effective CY 2024, there are three codes that describe the service related to NIR spectroscopy: CPT codes 0640T (Noncontact near-infrared spectroscopy (
                        <E T="03">e.g.,</E>
                         for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; first anatomic site, 0859T (Noncontact near-infrared spectroscopy (
                        <E T="03">e.g.,</E>
                         for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; each additional anatomic site (list separately in addition to code for primary procedure)), and 0860T (Noncontact near-infrared spectroscopy (
                        <E T="03">e.g.,</E>
                         for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), for screening for peripheral arterial disease, including provocative maneuvers, image acquisition, interpretation, and report, one or both lower extremities). Only CPT code 0640T is separately paid under the OPPS. For CY 2025, CMS proposed to assign CPT code 0640T to APC 5732 (Level 2 Minor Procedures) and status indicator “S” with a $39 payment rate.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment regarding the proposed APC assignment for CPT code 0640T. The commenter requested that we reassign 0640T to APC 5722 (Level 2 Imaging without contrast) with a proposed payment rate of approximately $310 for CY 2025 based on a crosswalk to CPT code 0598T (Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (
                        <E T="03">e.g.,</E>
                         lower extremity)). The commenter explained that CPT code 0598T is an appropriate crosswalk code because it yields diagnostic images without contrast, is newer, and utilizes a Category III CPT code.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input. First, we note that prior to the AMA's CPT Editorial Panel descriptor revision for CPT code 0640T, the technical service associated with NIR spectroscopy was described by CPT code 0641T, which was assigned to APC 5732 for CY 2023, prior to being deleted for CY 2024. Under the OPPS, the predecessor code for CPT code 0640T is CPT code 0641T. We note for CY 2025, OPPS payment rates are proposed based on available CY 2023 claims data. Based on our analysis of the claims data for this final rule with comment period, we found a geometric mean cost of about $16 for predecessor CPT code 0641T, based on 32 single frequency claims (out of 445 total claims). In contrast, we found a geometric mean cost of approximately $170 for CPT code 0598T based on 1109 single frequency claims (out of 2531 total claims). Based on the data, the resource cost associated with noncontact real-time fluorescence imaging (CPT code 0598T), is significantly higher compared to noncontact near-infrared (NIR) spectroscopy (CPT code 0640T/0641T). We disagree that the resource cost for NIR spectroscopy is similar to noncontact real-time fluorescence imaging. Therefore, we do not agree that both technologies should be placed in the same APC. We believe that the code describing NIR spectroscopy, specifically, CPT code 0640T, is appropriately placed in APC 5732.
                    </P>
                    <P>In consideration of the public comment we received, we are finalizing our proposal without modification for CPT code 0640T. Specifically, for CY 2025, we are finalizing our proposal to assign CPT code 0640T to APC 5732. The final CY 2025 OPPS payment rate for all the codes payable under the OPPS can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the SI meanings for all codes reported under the OPPS. Addendum D1 is available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">50. Percutaneous Coronary Revascularization Services by Intracoronary Antiproliferative Drug Delivery, CPT Codes 0913T and 0914T (APC 5192)</HD>
                    <P>
                        For the July 2024 update, the AMA's CPT Editorial Panel established two Category III codes to describe percutaneous coronary revascularization services by intracoronary antiproliferative drug delivery, performed for occlusive disease of the coronary vessels (major coronary arteries, coronary artery branches) using 
                        <PRTPAGE P="94108"/>
                        drug-delivery balloon (
                        <E T="03">e.g.,</E>
                         drug-coated, drug-eluting) for intracoronary antiproliferative drug delivery:
                    </P>
                    <P>
                        • CPT code 0913T (placeholder code XX23T) (Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (
                        <E T="03">e.g.,</E>
                         drug-coated, drug-eluting), including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch)); and,
                    </P>
                    <P>
                        • CPT code 0914T (placeholder code XX40T) (Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (
                        <E T="03">e.g.,</E>
                         drug-coated, drug-eluting) performed on a separate target lesion from the target lesion treated with balloon angioplasty, coronary stent placement or coronary atherectomy, including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch (List separately in addition to code for percutaneous coronary stent or atherectomy intervention)).
                    </P>
                    <P>In the CY 2025 OPPS/ASC proposed rule, we proposed to assign CPT code 0913T (placeholder code XX23T) to APC 5192 (Level 2 Endovascular Procedures; geometric mean cost of $5,771.29) based on clinical and resource similarity to other Percutaneous Coronary Intervention (PCI) procedures, including CPT code 92920 (Percutaneous transluminal coronary angioplasty; single major coronary artery or branch). Additionally, as an add-on code, we proposed to assign CPT code 0914T to status indicator “N.”</P>
                    <P>
                        We note that a transitional device pass-through application was submitted for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter for CY 2025 to request separate payment for the device under the OPPS, in addition to the surgical CPT codes. We direct readers to section IV.A (Pass-Through Payment for Devices) of this final rule with comment period for a more detailed discussion of the transitional device pass-through applications and the status of the CY 2025 device pass-through application for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter.
                    </P>
                    <P>
                        We also note that a presenter provided information to the Panel on the description of the service and the cost of the Agent
                        <E T="51">TM</E>
                         device and procedure at the August 28, 2024, HOP Panel Meeting. At the conclusion of the presentation, the presenter asked the Panel to request that CMS reassign CPT code 0913T from APC 5192 to APC 5193 (Level 3 Endovascular Procedures). Based on the information presented at the HOP Panel meeting, the HOP Panel recommended reassigning CPT 0913T to APC 5193.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received several comments from interested parties, including the manufacturer, a trade association, and several practitioners. One commenter reiterated information shared during the 2024 HOP Panel. Commenters stated that coronary drug-delivery by drug-coated balloon (DCB) is a clinically similar procedure to a drug-eluting stent (DES) implant, which is reported with HCPCS code C9600 (Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch) and is assigned to APC 5193 (Level 3 Endovascular Procedures). The manufacturer also provided a cost analysis of one facility's Medicare outpatient claims for coronary DCB. Their provided cost analysis included eleven claims and indicated that the geometric mean cost of those eleven claims was $18,935.69.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their comments. After consideration of the public comments, we continue to believe that CPT code 0913T is appropriately assigned to APC 5192. We note that the long descriptor for CPT code 0913T describes a service similar to other codes in APC 5192. After review of the service and input from our CMS medical officers, we believe that CPT code 92920 (Percutaneous transluminal coronary angioplasty; single major coronary artery or branch) which is assigned to APC 5192 is a good crosswalk code for CPT code 0913T because it is clinically similar.
                    </P>
                    <P>In summary, we are finalizing our proposal to assign CPT code 0913T to status indicator “J1,” and APC 5192. The final CY 2025 payment rate for CPT code 0913T can be found in Addendum B to this final rule with comment period. We also refer readers to Addendum D1 of this final rule with comment period for the SI meanings for all codes reported under the OPPS. Addendums B and D1 are available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">51. Potential Two-Times Rule Violations (APCs 5302, 5415, 5092, and 5114)</HD>
                    <P>We received comments on the APC assignments we proposed in the CY 2025 OPPS/ASC proposed rule, which commenters believe result in 2-times rule violations.</P>
                    <HD SOURCE="HD3">Endoscopic Esophageal Procedures</HD>
                    <P>CPT code 43254 (Esophagogastroduodenoscopy, flexible, transoral; with endoscopic mucosal resection) with a geometric mean cost of around $2,632; CPT code 43270 (Esophagogastroduodenoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)) with a geometric mean cost of around $2,985; and CPT code 43275 (Endoscopic retrograde cholangiopancreatography (ERCP); with removal of foreign body(s) or stent(s) from biliary/pancreatic duct(s)) with a geometric mean cost of around $2,886 describe endoscopic procedures that are performed on the esophagus. For the CY 2025 OPPS/ASC proposed rule, we proposed to assign all 3 procedures to APC 5302 (Level 2 Upper GI Procedures), which had a proposed a payment rate of around $1,884.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter requested that we reassign CPT codes 43254, 43270, and 43275 to APC 5303 (Level 3 Upper GI Procedures) with a proposed payment rate of around $3,648, due to the geometric mean costs of these codes being more than 2 times that of CPT code 0653T (Esophagogastroduodenoscopy, flexible, transnasal; with biopsy, single or multiple). CPT code 0653T has a geometric mean cost of around $1,212.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's request. We did not identify a 2-times rule violation for APC 5302. Since the release of the CY 2025 OPPS proposed rule, we have updated our 2-times analysis of claims from CY 2023 that are used to set rates for CY 2025. Our updated claims data found CPT code 0653T has fewer than 100 claims and does not meet the significance threshold for the two times rule evaluation, and therefore is not considered the lowest cost significant procedure for APC 5302.
                    </P>
                    <HD SOURCE="HD3">Vaginal Hysterectomy Procedures</HD>
                    <P>
                        CPT code 58260 (Vaginal hysterectomy, for uterus 250 g or less) with a geometric mean cost of around $6,083 and CPT code 58262 (Vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s), and/or ovary(s)) with a geometric mean cost of around $6,753 describe vaginal hysterectomy procedures. For the CY 2025 OPPS/ASC proposed rule, we proposed to assign both procedures to APC 5415 (Level 5 Gynecologic Procedures) with a 
                        <PRTPAGE P="94109"/>
                        proposed payment rate of around $4,902.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         A commenter requested that we reassign CPT codes 58260 and 58262 to APC 5416 (Level 6 Gynecologic Procedures) with a proposed payment rate of around $7,312, citing the geometric mean cost of CPT code 57550 (Excision of cervical stump, vaginal approach) which is around $1,879.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's request. We did not identify a 2-times rule violations for APC 5415. Our updated claims data found CPT code 57550 has fewer than 100 claims and does not meet the significance threshold for the 2-times rule evaluation, and therefore is not considered the lowest cost significant procedure for APC 5415.
                    </P>
                    <HD SOURCE="HD3">Mastectomy Procedures</HD>
                    <P>CPT code 19303 (Mastectomy, simple, complete) with a geometric mean cost of around $7,236 and CPT code 19307 (Mastectomy, modified radical, including axillary lymph nodes, with or without pectoralis minor muscle, but excluding pectoralis major muscle) with a geometric mean cost of around $7,412 describe mastectomy procedures. For the CY 2025 OPPS/ASC proposed rule, we proposed to assign both procedures to APC 5092 (Level 2 Breast/Lymphatic Surgery and Related Procedures) with a proposed payment rate of around $6,473.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Another commenter requested that we reassign CPT code 19303 and 19307 to APC 5093 (Level 3 Breast/Lymphatic Surgery and Related Procedures) with a proposed payment rate of around $9,417, citing the geometric mean cost of CPT code 38555 (Excision of cystic hygroma, axillary or cervical; with deep neurovascular dissection) which is around $3,475.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's request. We did not identify a 2-times rule violations for APC 5092. Our updated claims data found CPT code 38555 has fewer than 100 claims and does not meet the significance threshold for the two times rule evaluation and therefore is not considered the lowest cost significant procedure for APC 5092.
                    </P>
                    <HD SOURCE="HD3">Arthrodesis Procedure</HD>
                    <P>CPT code 28740 (Arthrodesis, midtarsal or tarsometatarsal, single joint), which has a geometric mean cost of around $11,058, describes an arthrodesis procedure performed in the foot. For the CY 2025 OPPS/ASC proposed rule, we proposed to assign this procedure to APC 5114 (Level 4 Musculoskeletal Procedures) with a proposed payment rate of around $7,090.</P>
                    <P>
                        <E T="03">Comment:</E>
                         A commenter requested that CPT code 28740 be reassigned to APC 5115 (Level 5 Musculoskeletal Procedures) with a proposed payment rate of around $12,755, citing the geometric mean cost of CPT code 27385 which is around $5,616.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's request. Our updated claims data did not identify a 2-times rule violation for APC 5115. We also found that the geometric mean cost for CPT code 28740 is $11,074. This is less than two times the updated cost of the suggested code CPT code 27385, which is $5,616.
                    </P>
                    <P>In summary, after consideration of these public comments, we are finalizing our proposal without modification to assign CPT codes 43254, 43270, and 43275 to APC 5302 (Level 2 Upper GI Procedures); CPT codes 58260 and 58262 to APC 5415 (Level 5 Gynecologic Procedures); CPT codes 19303 and 19307 to APC 5092 (Level 2 Breast/Lymphatic Surgery and Related Procedures); and CPT code 28740 to APC 5114 (Level 4 Musculoskeletal Procedures). We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">52. Prostate Laser Enucleation Procedure, CPT Code 52649 (APC 5375)</HD>
                    <P>Prostate laser enucleation procedure utilizes laser to remove the prostate tissue to treat benign prostatic hyperplasia. The procedure is described by CPT code 52649 (Laser enucleation of the prostate with morcellation, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, internal urethrotomy and transurethral resection of prostate are included if performed)).</P>
                    <P>For CY 2025, the OPPS payment rates are proposed based on available CY 2023 claims data. For the CY 2025 proposed rule, based on our analysis of claims data, we found a total of 7,494 single frequency claims and a geometric mean cost of approximately $6,812 for CPT code 52649. For CY 2025, we proposed to continue to assign CPT code 52649 to Level 5 Urology and Related Services (APC 5375) with a proposed payment rate of approximately $5,057.</P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter disagreed with the proposed APC assignment to APC 5375 (Level 5 Urology and Related Services) and requested the reassignment of CPT code 52649 to APC 5376 (Level 6 Urology and Related Services). The commenter argued that CPT code 52649 shared more clinical and resource similarities with CPT code 50562 (Renal endoscopy through established nephrostomy or pyelostomy, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service; with resection of tumor) and CPT code 55873 (Cryosurgical ablation of the prostate (includes ultrasonic guidance and monitoring)), which are currently assigned to APC 5376. Moreover, the commenter argued that there is more work involved in CPT code 52649 than CPT code 52601 (Transurethral electrosurgical resection of prostate, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included)) which is currently assigned to APC 5375 (Level 5 Urology and Related Services).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         The CY 2025 OPPS payment rates were proposed based on available CY 2023 claims data. We analyzed the claims data for this final rule, and based on our review, we found a geometric mean cost of approximately $6,812 for CPT code 52649 based on 7,494 single claims (out of 7,564 total claims), is consistent with the geometric mean cost of about $5,145 for APC 5375, rather than the geometric mean cost of approximately $9,356 for APC 5376. Based on the claims data, we believe that CPT code 52649 fits more appropriately in APC 5375, rather than in APC 5376, based on resource cost and clinical similarity to CPT code 52601 in APC 5375. We note that we review, on an annual basis, the APC assignments for all services and items paid under the OPPS based on our analysis of the latest claims data.
                    </P>
                    <P>We also disagree that CPT code 52649 is sufficiently clinically similar to CPT code 50562 because the latter code involves a surgical treatment of the kidney rather than the prostate. Furthermore, we disagreed that CPT code 52649 shares resource similarity with CPT code 55873, as cryosurgical ablation requires many more resources than the prostate laser enucleation procedure.</P>
                    <P>
                        In summary, after consideration of the public comment, we are finalizing our proposal, without modification, to assign CPT code 52649 to APC 5375 for CY 2025. Please refer to Table 99 below for the final OPPS APC and status indicator assignment for HCPCS code 52649 for CY 2025. The final CY 2025 payment rate for the code can be found in Addendum B to this final rule with comment period. In addition, we refer 
                        <PRTPAGE P="94110"/>
                        readers to Addendum D1 of this final rule with comment period for the SI meanings for all codes reported under the OPPS. Both Addendum B and D1 are available via the internet on the CMS website.
                    </P>
                    <GPH SPAN="3" DEEP="197">
                        <GID>ER27NO24.123</GID>
                    </GPH>
                    <HD SOURCE="HD3">53. Remote Uroflowmetry Service, CPT Code 0812T (APC 5721)</HD>
                    <P>
                        Remote uroflowmetry is a service that allows patients to measure urine output while remotely monitored by health professionals. This service aids in the diagnosis and management of lower urinary tract issues, such as benign prostatic hyperplasia. It is described by CPT code 0812T (Remote multi-day complex uroflowmetry (
                        <E T="03">e.g.,</E>
                         calibrated electronic equipment); device supply with automated report generation, up to 10 days) which became effective January 1, 2024. For CY 2025, we proposed to assign CPT code 0812T to APC 5741 (Level 1 Electronic Analysis of Devices).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter disagreed with our proposed APC assignment of APC 5741 (Level 1 Electronic Analysis of Devices), citing higher equipment and labor cost associated with the CPT code 0812T than services assigned to APC 5741. The commenter requested CPT code 0812T be reassigned to APC 5722 (Level 2 Diagnostic Tests and Related Services), citing resource similarity to CPT code 51741(Complex uroflowmetry (
                        <E T="03">e.g.,</E>
                         calibrated electronic equipment)).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's recommendation regarding the APC assignment for CPT code 0812T. However, we disagree with the commenter that CPT code 51741 shares similar resource requirements with CPT code 0812T, although both CPT codes describe the uroflowmetry service. CPT code 51741 is a more complex procedure than CPT code 0812T, which is why we proposed to assign CPT code 51741 to APC 5722 (Level 2 Diagnostic Tests and Related Services)). However, we also believe CPT code 0812T shares more resource similarity with CPT code 51703 (Insertion of temporary indwelling bladder catheter; complicated (
                        <E T="03">e.g.,</E>
                         altered anatomy, fractured catheter/balloon)) than CPT code 51741. Therefore, for CY 2025, we are reassigning CPT code 0812T to APC 5721 (Level 1 Diagnostic Tests and Related Services).
                    </P>
                    <P>After consideration of the public comment we received, we are finalizing our proposal with modification and reassigning CPT code 0812T to APC 5721 (Level 1 Diagnostic Tests and Related Services). Please refer to Table 100 below for the final OPPS APC and status indicator assignment for CPT code 0821T for CY 2025. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="134">
                        <GID>ER27NO24.124</GID>
                    </GPH>
                    <PRTPAGE P="94111"/>
                    <HD SOURCE="HD3">54. Skin Cell Suspension Autograft (SCSA) Procedures, CPT Codes 15011 Through 15018 (APCs 5051, 5054, and 1567)</HD>
                    <P>The RECELL System is a device used for skin cell suspension autograft (SCSA) procedures. Skin cell suspension autograft procedures treat acute thermal burn injuries by adhering skin cell solutions to the wound site without use of fixation. There are three steps to perform a SCSA procedure: (1) skin harvesting, (2) SCSA preparation (utilizing the RECELL System), and (3) SCSA application to the wound bed.</P>
                    <P>The RECELL System is on transitional pass-through (TPT) effective January 1, 2022, to December 31, 2024. While on TPT, each time the RECELL device is used, providers must bill device code HCPCS C1832 (Autograft suspension, including cell processing and application, and all system components) and either CPT code 15110 (Epidermal autograft, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children) or CPT code 15115 (Epidermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children),as provided in the January 2022 OPPS Change Request 12552 (Transmittal R11150CP).</P>
                    <P>While HCPCS code C1832 describes the RECELL System that prepares the SCSA, CPT codes 15110 and 15115 describe the autograft procedure, which includes both the skin harvesting and SCSA application components of the service. For CY 2024, CPT codes 15510 and 15115 were assigned to APC 5054 (Level 4 Skin Procedures), with a payment rate of approximately $1,800. HCPCS code C1832 can also be billed with CPT codes 15100 (Split-thickness autograft, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children (except 15050)) or 15120 (Split-thickness autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children (except 15050)), so long as it is billed with one of the two preceding codes (CPT codes 15110 or 15115).</P>
                    <P>In September 2023, AMA's CPT Editorial Panel created eight new Category 1 CPT codes to describe SCSA procedures, effective January 1, 2025. The eight new codes are provided in Table 101.</P>
                    <GPH SPAN="3" DEEP="430">
                        <GID>ER27NO24.125</GID>
                    </GPH>
                    <PRTPAGE P="94112"/>
                    <P>In creating these eight new CPT codes, the harvesting, preparation, and application components of the service are each split into separate codes. The harvesting of the skin is described by CPT codes 15011 and 15012, the preparation of the SCSA is described by CPT codes 15013 and 15014, and the application of the SCSA is described by CPT codes 15015 through 15018. While the RECELL System is on TPT, it is sufficient to bill the device code HCPCS C1832 and only one procedure code (either CPT code 15110 or CPT 15115) to describe all three components of the service. However, with the creation of the eight new CPT codes, at least three CPT codes will need to be billed each time the RECELL System is used for a SCSA procedure: CPT code 15011 with or without CPT code 15012 for the skin harvesting, CPT code 15013 with or without CPT code 15014 for the SCSA preparation, and CPT code 15015 with or without CPT code 15016 or CPT code 15017 with or without CPT code 15018 for the SCSA application.</P>
                    <P>For CY 2025, we proposed to assign the eight new CPT codes to various clinical APCs and status indicators provided in Table 102.</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94113"/>
                        <GID>ER27NO24.126</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <P>
                        <E T="03">Comment:</E>
                         We received two comments requesting that we finalize our proposal to assign 15011, 15015, and 15017 to 
                        <PRTPAGE P="94114"/>
                        APC 5054 (Level 4 Skin Procedures) for CY 2025.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their support.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received two comments, including one comment from the manufacturer of the RECELL System, requesting that we reassign CPT code 15013 from APC 5051 (Level 1 Skin Procedures) to APC 1575 (New Technology—Level 38 ($10,001-$15,000) with a payment rate of $12,500.50 for CY 2025. The commenters expressed concern that the proposed APC assignment for CPT code 15013 to APC 5051 does not accurately reflect the hospital-reported costs associated with the RECELL System. The commenters requested that we consider the hospital costs reported with device code C1832 during the TPT period when finalizing the APC assignment for CPT 15013. The comments estimated a combined total cost of $10,188.96 for CPT code 15013 by adding the purported mean cost for device code C1832 ($7,220) with supply and operating room time costs of approximately $2,900. Based on these estimates, the commenters believe assigning CPT code 15013 to APC 1575 with a payment rate of $12,500.50 would sufficiently pay for the preparation step of the SCSA procedure.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their input. Under the OPPS, once pass-through status ends for a device, the cost of the device is packaged into its associated procedure. For the RECELL System, once TPT expires on December 31, 2024, the associated procedure will be CPT code 15013. We agree with the commenters that we need to use the claims data available while the RECELL System is on TPT to determine the appropriate APC placement for CPT code 15013.
                    </P>
                    <P>However, given the restructuring of how SCSA procedures utilizing the RECELL System will be billed effective January 1, 2025, we also believe we need to consider the costs of the skin harvesting and application steps of the procedure, which are currently billed by only one procedure code (either CPT Code 15110 or CPT code 15115), paid at approximately $1,800, to determine the appropriate payment for the RECELL System and SCSA application step. In other words, we believe that the sum of the payment rates for the new codes describing the three steps of the SCSA procedure should approximate the cost of the RECELL System on TPT and CPT codes 15110 or 15115. Based on our review of the claims data for device code C1832 during the TPT period, as well as the payment rates for CPT codes 15110 and 15115, we believe assigning CPT code 15013 to APC 1567 (New Technology—Level 30 ($6001-$6500)) with a $6,250.50 payment rate would be appropriate for CY 2025, considering that it will be billed with additional procedure codes that describe the other steps of the SCSA procedure. Rather than assigning CPT code 15013 to APC 5051, as proposed, which has a payment rate of approximately $200 for CY 2025, we believe assigning CPT code 15013 to APC 1567 with a payment rate of $6,250.50 will more appropriately pay for the preparation part of the service, which uses the device. When the full service is performed, meaning that the harvesting, preparation, and application steps are performed, the total cost of the service for CY 2025 will be approximately $10,000, an amount that we believe is appropriate based on the data we have collected while the device has had transitional pass-through status.</P>
                    <P>In consideration of the public comments received, we are finalizing our proposal with modification. For CY 2025, we are finalizing the APC assignments for CPT codes 15011, 15015, and 15017 to APC 5054 (Level 4 Skin Procedures) as proposed. However, we are not finalizing our proposal to assign CPT code 15013 to APC 5051 (Level 1 Skin Procedures) as proposed. For CY 2025, we are assigning CPT code 15013 to APC 1567 ((New Technology—Level 30 ($6001-$6500)).</P>
                    <P>The final 2025 payment rates for the codes can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">55. Surgical Pathology Examination, CPT Code 88309 (APC 5674)</HD>
                    <P>CPT code 88309 describes a level VI examination of a surgical pathology specimen performed by the physician, typically a pathologist. The examination includes accessioning the specimen into the lab, which involves formally receiving the specimen, examining gross and microscopic features of the specimen, and reporting findings.</P>
                    <P>In the CY 2025 OPPS/ASC proposed rule, we proposed to reassign CPT code 88309 from APC 5674 (Level 4 Pathology) to APC 5673 (Level 3 Pathology) with a proposed payment rate of $356.00.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Three commenters asked CMS to maintain the assignment of CPT code 88309 in APC 5674.
                    </P>
                    <P>One commenter recommended that CMS maintain the current assignment of CPT 88309 (Level VI—Surgical pathology, gross and microscopic examination) in APC 5674, (Level 4 Pathology), rather than assigning the code to APC 5673, (Level 3 Pathology), to promote resource and clinical cohesion.</P>
                    <P>Two commenters stated that the proposed reassignment is based on claims data that do not reflect the actual costs of performing the test. They stated that the CY 2025 geometric mean cost for this code is over 25% lower than the geometric mean cost for the prior calendar years and that the complexity of specimens and technical work associated with these services requires the maintenance of the code in APC 5674. Therefore, to ensure resource cohesion within the clinical APCs, the commenters asked CMS to maintain the assignment of CPT code 88309 to APC 5674 for CY 2025 and to not finalize an APC reassignment that would result in a greater than 56% reduction in the payment rate for this important service for Medicare beneficiaries.</P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their input. We acknowledge a significant drop in the geometric mean cost for CPT code 88309, which is almost 25% lower than the geometric mean cost in previous years.
                    </P>
                    <P>For this final rule with comment period, we once again reviewed the available CY 2023 claims data and observed a wide variation in claims used for ratesetting purposes for CY 2025. We note that the claims included in ratesetting for this code reflect a wide range of estimated costs and providers furnishing this service along with their associated clinical patterns. We believe these claims are an accurate reflection of those changing costs. However, we are sympathetic to commenters' concerns regarding the 25% reduction in the proposed payment rate for CPT code 88309 from CY 2024 to CY 2025. Therefore, we will use our equitable adjustment authority under section 1833(t)(2)(E) of the Act to continue to assign CPT code 88309 to APC 5674 for CY 2025.</P>
                    <P>In summary, after consideration of the public comments that we received, we are finalizing our proposal with modification to assign CPT code 88309 to APC 5674. However, we will continue to monitor the claims data as they are updated and available.</P>
                    <P>
                        We refer readers to Addendum B to this final rule with comment period for the final CY 2025 OPPS payment rate for this code. Addendum B is available via the internet on the CMS website.
                        <PRTPAGE P="94115"/>
                    </P>
                    <HD SOURCE="HD3">56. Therapeutic Ultrafiltration, CPT 0692T (APC 5242)</HD>
                    <P>In the CY 2025 OPPS/ASC proposed rule, we proposed to continue to assign CPT code 0692T (Therapeutic ultrafiltration), which became effective January 1, 2022, to APC 5241 (Level 1 Blood Product Exchange and Related Services) with a proposed payment rate of $431.37.</P>
                    <P>Therapeutic ultrafiltration reported with CPT code 0692T, is an apheresis procedure for fluid-overloaded heart failure patients through which plasma water and sodium are removed from the blood using the Aquadex SmartFlow System.</P>
                    <P>We received several comments requesting CMS reassign CPT code 0692T from APC 5241 (Level 1 Blood Product Exchange and Related Services) to APC 5242 (Level 2 Blood Product Exchange and Related Services).</P>
                    <P>
                        <E T="03">Comment:</E>
                         Several commenters claimed that the payment rate for APC 5241 is inadequate for CPT code 0692T and that APC 5242 better aligns with the resource costs and clinical aspects of the service. According to the commenters, the resources required, and risks associated with ultrafiltration are the same as plasmapheresis, which is assigned to APC 5242. Ultrafiltration (
                        <E T="03">e.g.,</E>
                         apheresis) is the extracorporeal removal of isotonic plasma water (water and salt/electrolytes) and is very similar to plasmapheresis according to the commenters, which involves the extracorporeal removal, return, or exchange of blood plasma or components and is assigned to APC 5242. Commenters suggested that reassigning the ultrafiltration therapy code 0692T to APC 5242 would align OPPS payment with the cost of providing the service.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their input. We have limited claims data (9 total claims) for CPT code 0692T available for CY 2025 ratesetting. However, based on the code's clinical similarity and expected resource cost similarity to CPT code 36514 (Therapeutic apheresis; for plasma pheresis), which we have assigned to APC 5242 (Level 2 Blood Product Exchange and Related Services) for CY 2025, we believe that we should reassign CPT code 0692T to APC 5242.
                    </P>
                    <P>In summary, after consideration of the public comments that we received, we are finalizing our proposal with modification, and assigning CPT code 0692T to APC 5242 for CY 2025. The CY 2025 final payment rate for this code can be found in Addendum B of this final rule with comment period.</P>
                    <HD SOURCE="HD3">57. Thyroid Ablation, CPT Codes 60660 and 60661 (APC 5072)</HD>
                    <P>The AMA established CPT codes 60660 (Ablation of 1 or more thyroid nodule(s), one lobe or the isthmus, percutaneous, including imaging guidance, radiofrequency) and 60661 (Ablation of 1 or more thyroid nodule(s), additional lobe, percutaneous, with imaging guidance, radiofrequency (List separately in addition to code for primary service), effective January 1, 2025. These codes were previously described by the placeholder codes 6XX01 and 6XX02. In the CY 2025 OPPS/ASC proposed rule, CMS crosswalked CPT code 60660 to CPT code 0673T (Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance) and proposed to assign it to APC 5072 (Level 2 Excision/Biopsy/Incision and Drainage) for CY 2025. CMS also proposed to assign CPT code 60661 to status indicator “N” (packaged), as it is an add-on code.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received two comments requesting reassignment for CPT codes 60660 and 60661. One comment requested we reassign CPT code 60660 to APC 5073 (Level 3 Excision/Biopsy/Incision and Drainage), due to its clinical similarity and resource homogeneity with the other procedures in APC 5073. A second comment requested we reassign both 60660 and 60661 to APC 5164 (Level 4 ENT Procedures), due to their similarity to CPT code 30140 (Submucous resection inferior turbinate, partial or complete, any method).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their suggestions. After further clinical review, we continue to believe that CPT code 0673T is the appropriate crosswalk for CPT code 60660 and that CPT code 30140 would not be the correct clinically comparable code. CPT code 0673T has a geometric mean cost of around $1,578 and is assigned to APC 5072, which has a payment rate of around $1,620. We believe that 0673T is appropriately placed in APC 5072, and therefore, CPT code 60660 is appropriately assigned to APC 5072 and should not be reassigned to APC 5073 at this time. Additionally, because CPT code 60661 is an add-on code, we believe that the current status indicator assignment of “N” is correct.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal without modification to assign CPT code 60660 to APC 5072 (Level 2 Excision/Biopsy/Incision and Drainage) and 60661 to status indicator “N” for CY 2025. Table 103 shows the finalized status indicator and APC assignment for the procedure code. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="216">
                        <PRTPAGE P="94116"/>
                        <GID>ER27NO24.128</GID>
                    </GPH>
                    <HD SOURCE="HD3">58. Thyroid Removal, CPT Code 60240 (APC 5361)</HD>
                    <P>In the CY 2025 OPPS/ASC proposed rule, CPT code 60240 (Thyroidectomy, total or complete), which describes thyroid removal, was proposed to be assigned to APC 5361 (Level 1 Laparoscopy and Related Services) with a proposed geometric mean cost of $7,150.89 and proposed APC payment rate of $5,798.13.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment requesting that we reassign CPT code 60240 to APC 5362 (Level 2 Laparoscopy and Related Services), which had a proposed payment rate of $10,378.45. The commenter argued that keeping CPT code 60240 in APC 5361 would be a 2 times rule violation because CPT code 60240 has a geometric mean cost that is greater than 2 times the geometric mean value of CPT code 60281(Excision of thyroglossal duct cyst or sinus; recurrent), which had a proposed geometric mean cost of around $3,462 and is also in APC 5361.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input. Our review found that APC 5361 was not in violation of the 2 times rule. Because CPT code 60821 has only 2 claims for CY 2025, it does not meet the significance threshold for the 2 times rule evaluation. Additionally, the updated geometric mean cost for CPT code 60240 of $7,022.82 is closer to the payment rate of APC 5361 ($5,834.36) compared to APC 5362 ($10,411.39).
                    </P>
                    <P>After consideration of the public comment we received, we are finalizing our proposal without modification to assign CPT code 60240 to 5361 (Level 1 Laparoscopy and Related Services) for CY 2025. Table 104 shows the finalized status indicator and APC assignment for the procedure code. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="081">
                        <GID>ER27NO24.129</GID>
                    </GPH>
                    <HD SOURCE="HD3">59. Trabecular Bypass Procedures, CPT Codes 66989, 66991, 0660T, 0661T, and 0671T (APCs 5492 and 5493)</HD>
                    <P>
                        Trabecular bypass procedures are used for the treatment of glaucoma and may be performed along with cataract surgery or as a stand-alone procedure. Another glaucoma treatment involves the implantation of a device that releases a drug into the eye. For the CY 2025 OPPS final rule, we proposed to assign CPT code 66989 (Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (
                        <E T="03">e.g.,</E>
                         irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (
                        <E T="03">e.g.,</E>
                         iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; with insertion of intraocular (
                        <E T="03">e.g.,</E>
                         trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more) with a geometric mean cost around $5,440; CPT code 66991 (Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (
                        <E T="03">e.g.,</E>
                         irrigation and aspiration or phacoemulsification); with insertion of intraocular (
                        <E T="03">e.g.,</E>
                         trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more) with a geometric mean cost around $4,990; and CPT code 0671T (Insertion of anterior segment aqueous drainage device into the trabecular meshwork, without external 
                        <PRTPAGE P="94117"/>
                        reservoir, and without concomitant cataract removal, one or more) with a geometric mean cost around $5,527 to APC 5493 (Level 3 Intraocular Procedures) with a payment rate around $5,160.
                    </P>
                    <P>Also, for the CY 2025 OPPS final rule, we proposed to assign CPT code 0660T (Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach) with no claims data for CY 2025, and CPT code 0661T (Removal and reimplantation of anterior segment intraocular nonbiodegradable drug-eluting implant) with no claims data for CY 2025 to APC 5492 (Level 2 Intraocular Procedures) with a payment rate of around $4,023.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Multiple commenters supported our proposal to assign CPT codes 66989, 66991, and 0671T to APC 5493 (Level 3 Intraocular Procedures) with a payment rate around $5,160. The commenters also supported our proposal to assign CPT codes 0660T and 0661T to APC 5492 (Level 2 Intraocular Procedures) with a payment rate of around $4,023.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' support for our proposals.
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal without modification for CPT codes 66989, 66991, 0660T, 0661T, 0671T to assign these procedures to APC 5493 (Level 3 Intraocular Procedures). We also are implementing our proposal without modification for CPT codes 0660T and 0661T to assign these procedures to APC 5492 (Level 2 Intraocular Procedures). Table 105 shows the finalized status indicator and APC assignment for all of the procedure codes. We refer readers to Addendum B of this final rule for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="623">
                        <PRTPAGE P="94118"/>
                        <GID>ER27NO24.130</GID>
                    </GPH>
                    <PRTPAGE P="94119"/>
                    <HD SOURCE="HD3">60. Transcutaneous Magnetic Peripheral Nerve Stimulation CPT Codes 0766T and 0767T (APC 5722)</HD>
                    <P>Transcutaneous Magnetic Peripheral Nerve Stimulation is intended to stimulate peripheral nerves for relief of chronic intractable pain, post‐traumatic pain, post‐surgical pain and/or for relief of chronic painful diabetic peripheral neuropathy in the lower extremities for patients 18 and older. CPT code 0766T (Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve) became effective January 1, 2023. For CY 2024, CPT code 0766T has been assigned to APC 5721 (Level 1 Diagnostic Tests and Related Services) with the status indicator “Q1” (STV-Packaged Codes). There are no claims available for CPT codes 0766T in CY 2023. For CY 2025, we proposed to continue assigning CPT codes 0766T to APC 5721.</P>
                    <P>CPT code 0767T (Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (list separately in addition to code for primary procedure)) became effective January 1, 2023. CPT code 0767T is an add-on code and we proposed to assign status indicator “N” (packaged) for this code.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters disagreed with the proposed assignment of APC 5721 (Level 1 Diagnostic Tests and Related Services) and the status indicator “Q1” for CPT code 0766T, claiming that CPT code 0766T is not clinically similar nor uses comparable resources to other services in APC 5721. The commenters stated that the HOP Panel recommended that 0766T be reassigned to APC 5431 (Level 1 Nerve Procedures) with a status indicator “S” (Significant Procedures, Not Discounted when Multiple. Paid under OPPS; separate APC payment). Additionally, commenters disagreed with the status indicator of “N” for CPT code 0767T and requested the 0767T be reassigned status indicator “S” and assigned to APC 5431 (Level 1 Nerve Procedures).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank commenters for their input. We disagree that CPT code 0766T is comparable clinically and in resource costs to the services assigned to APC 5431. However, after further evaluation, we believe CPT code 0766T is more comparable clinically and from a resource cost perspective to CPT code 90867 (Therapeutic repetitive transcranial magnetic stimulation (tms) treatment; initial, including cortical mapping, motor threshold determination, delivery and management), which is assigned to APC 5722 (Level 2 Diagnostic Tests and Related Services), because these services share similar magnetic stimulation and nerve localization processes. Additionally, we believe that patients may receive this service as a primary standalone service. Therefore, for CY 2025, we are finalizing the reassignment of CPT code 0766T to APC 5722 (Level 2 Diagnostic Tests and Related Services) and its status indicator to “S” (Significant Procedures, Not Discounted when Multiple. Paid under OPPS; separate APC payment).
                    </P>
                    <P>We note that CPT code 0767T is an add-on code. Add-on codes are always performed in addition to the primary service or procedure and must never be reported as a stand-alone code. As specified under regulation 42 CFR 419.2(b)(18), add-on codes are generally packaged under the OPPS, and payment for the codes are bundled with the primary codes. Consequently, CPT code 0767T is not paid separately under the OPPS, but instead, its payment is packaged into payment for the primary code.</P>
                    <P>After consideration of the public comments we received, we are finalizing reassigned status indicator and APC assignments for CPT codes 0766T and finalizing as proposed the status indicator assignment for 0767T. Please refer to Table 106 below for the final OPPS APC and status indicator assignment for CPT codes 0766T and 0767T for CY 2025. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="264">
                        <PRTPAGE P="94120"/>
                        <GID>ER27NO24.131</GID>
                    </GPH>
                    <HD SOURCE="HD3">61. Transurethral Ultrasound Ablation (TULSA) Procedure, HCPCS Code C9734 and CPT Code 55882 (APC 5377)</HD>
                    <P>The TULSA procedure is a minimally invasive procedure that, under MRI guidance, delivers precise doses of therapeutic ultrasound to treat prostate cancer. HCPCS code C9734 (Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic resonance (mr) guidance) became effective April 1, 2013.</P>
                    <P>For CY 2025, the OPPS payment rates are proposed based on available CY 2023 claims data. For CY 2025, based on our analysis of claims data, we found a total of 89 single frequency claims and an estimated geometric mean cost of $10,056 for HCPCS code C9734. For CY 2025, we proposed to continue to assign HCPCS code C9734 to APC 5115 (Level 5 Musculoskeletal Procedures) with a proposed payment rate of approximately $12,756.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters pointed out that the AMA CPT created a new code, CPT code 5X008, to describe the TULSA procedure represented by HCPCS code C9734. CPT code 5X008 (Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation; with insertion of transurethral ultrasound transducer for delivery of thermal ultrasound, including suprapubic tube placement and placement of an endorectal cooling device, when performed) becomes effective January 1, 2025.
                    </P>
                    <P>Commenters also recommended that the TULSA procedure be reassigned to the Urology and Related Services APC series, which is more clinically consistent with other urology related procedures. Furthermore, commenters stated TULSA is more similar clinically and in terms of resources to the procedures in APC 5377 (Level 7 Urology and Related Services) than procedures in APC 5376 (Level 6 Urology and Related Services). Commenters referenced the use of a MRI technology, specialized staffing, and the longer procedural time that increases the resources needed to perform the TULSA procedure relative to other prostate ablation procedures in Level 6 Urology and Related Services (APC 5376). Commenters stated that HCPCS code C9734's geometric mean cost aligns more appropriately with APC 5377 (Level 7 Urology and Related Services) with a proposed APC geometric mean cost of $13,217.</P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for pointing out that CPT code 5X008 (55882) will become effective January 1, 2025. We note that we will replace HCPCS code C9734 with CPT code 5X008 (55882) effective January 1, 2025, as well as assign the underlying claims associated with C9734 to CPT code 5X008 (55882).
                    </P>
                    <P>We agree with the commenters that the TULSA procedure, described by HCPCS code C9734 (CPT code 55882) should be reassigned to the Urology and Related Services APC series to be consistent with other urological related procedures. We also believe that the TULSA procedure is clinically similar to CPT code 55880 (Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (hifu), including ultrasound guidance) or CPT code 55873 (Cryosurgical ablation of the prostate (includes ultrasonic guidance and monitoring)) which are assigned to APC 5376. However, we acknowledge that the TULSA procedure requires greater resources from MRI equipment and MRI technologists, and requires a longer procedure time than CPT codes 55880 and 55873. Therefore, for CY 2025, we are reassigning CPT code 5X008 (55882) to APC 5377 (Level 7 Urology and Related Services). We note that we will continue to evaluate and monitor the cost of CPT code 5X008 (55882) for future rulemaking.</P>
                    <P>After consideration of the public comments we received, we are finalizing our policy to assign CPT code 5X008 (55882) to APC 5377 (Level 7 Urology and Related Services). Please refer to Table 107 below for the final OPPS APC and status indicator assignment for CPT code 5X008 (55882) for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="227">
                        <PRTPAGE P="94121"/>
                        <GID>ER27NO24.132</GID>
                    </GPH>
                    <HD SOURCE="HD3">62. Unfold AI Service, CPT Code 0898T (APC 5724)</HD>
                    <P>Unfold AI is an algorithm-based test that analyzes multiple clinical data inputs and multi-modal images to create a newly computed 3D visualization of the precise location and dimensions of clinically significant prostate cancer. The generated output assists physicians in identifying the cancer margins for treatment. The Unfold AI service is represented by CPT code 0898T (Noninvasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report) which became effective July 1, 2024. As this is a new code in 2024, we have no claims data for CPT code 0898T. For CY 2025, we proposed to assign CPT Code 0898T to APC 5724 (Level 4 Diagnostic Tests and Related Services).</P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters supported our proposal to assign CPT code 0898T to Level 4 Diagnostic Tests and Related Services (APC 5724).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their support on our proposal to assign CPT code 0898T to Level 4 Diagnostic Tests and Related Services (APC 5724).
                    </P>
                    <P>After consideration of the public comments we received, we are finalizing our proposal without modification for CPT code 0898T. Please refer to Table 108 below for the final OPPS APC and status indicator assignment for HCPCS code 0898T for CY 2025. The final CY 2025 payment rates can be found in Addendum B to this final rule with comment period via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="183">
                        <GID>ER27NO24.133</GID>
                    </GPH>
                    <HD SOURCE="HD3">63. Ureteroscopy, HCPCS Code C9761 (APC 5376)</HD>
                    <P>The ureteroscopy procedure addresses kidney stones and may apply catheterization to vacuum aspirate the fragmented kidney stones. HCPCS code C9761 (Cystourethroscopy, with ureteroscopy and/or, with lithotripsy, and ureteral catheterization for steerable vacuum aspiration of the kidney, collecting system, ureter, bladder, and urethra if applicable (must use a steerable ureteral catheter) became effective October 1, 2020.</P>
                    <P>
                        For CY 2025, the OPPS payment rates are proposed based on available CY 
                        <PRTPAGE P="94122"/>
                        2023 claims data. For the CY 2025 OPPS/ASC proposed rule, we found a total of 95 single frequency claims and a geometric mean cost of approximately $9,718 for HCPCS code C9761. For CY 2025, we proposed to continue to assign HCPCS code C9761 to APC 5376 (Level 6 Urology and Related Services) with a proposed payment rate of approximately $9,208.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter requested CMS provide coding guidance if HCPCS code C9761 should be reported when the ureteroscopy procedure utilizes the flexible ureteroscopy (fURS) with the flexible and navigable suction (FANS) sheath.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         This comment is out of scope of this OPPS/ASC final rule with comment period. We note that if hospitals have questions about appropriate coding that they cannot resolve on their own, the appropriate first step would be to review the HCPCS codes or consult a Medicare Administrative Contractor (MAC).
                    </P>
                    <HD SOURCE="HD3">64. V-LAP System Left Atrial Pressure Monitoring Procedure, CPT Code 0933T (APC 5191)</HD>
                    <P>On January 1, 2025, CPT code 0933T (Transcatheter implantation of wireless left atrial pressure sensor for long-term left atrial pressure monitoring, including sensor calibration and deployment, right heart catheterization, transseptal puncture, imaging guidance, and radiological supervision and interpretation) will become effective to report the implantation and remote monitoring of the V-LAP System. The system is used to measure and monitor left atrial pressure in patients with advanced congestive heart failure (CHF).</P>
                    <P>The V-LAP system was designated as a Category A IDE clinical study (NCT06147336) on January 30, 2024. Since devices in Category A IDE studies are not covered by Medicare during the study, the payment for CPT code 0933T while in the Category A IDE study will reflect only the cost of the service that is performed each time it is reported on a claim. For CY 2025, we proposed to assign CPT code 0933T to APC 5191 (Level 1 Endovascular Procedures) and status indicator of “J1” (Hospital Part B Services Paid Through a Comprehensive APC) with a proposed payment of around $3,210.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment from the manufacturer requesting that we reassign CPT code 0933T from APC 5191 (Level 1 Endovascular Procedures) to APC 1532 (New Technology—Level 32 ($7001-$7500)), as it more accurately reflects the costs of this procedure.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's input. The commenter asserts that the current APC assignment of 5191 (Level 1 Endovascular Procedures) does not adequately reflect the complex nature and resource demands of the V-LAP procedure even though the procedure is described as a standard minimally invasive catheterization. We are unclear what procedural steps makes this procedure more complex than the other procedures assigned to APC 5191. Based on our understanding of the service and input from our medical advisors, we do not agree and believe that CPT code 93451 (Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed) is an appropriate crosswalk code while the V-LAP
                        <E T="51">TM</E>
                         procedure is in a Category A IDE trial. Once the service receives appropriate FDA approval outside of the Category A IDE study (
                        <E T="03">e.g.,</E>
                         PMA approval or 510(k)), we will work to assign CPT code 0933T to an APC that is more reflective of the cost of the service, beyond routine care items and services.
                    </P>
                    <P>We remind the readers that for Category A IDE studies, Medicare only provides payment for routine care items and services furnished in the FDA-approved Category A study. We refer readers to the Medicare Benefit Policy Manual, See 20.1—Medicare Requirements for Coverage of Items and Services in FDA-approved Category A and B IDE Studies.</P>
                    <P>After consideration of the public comment we received, we are finalizing our proposal without modification to assign CPT code 0933T to APC 5191. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">65. Vagal Nerve Neurostimulator System, CPT Codes 0908T Through 0912T</HD>
                    <P>The CPT Editorial Panel created 5 new Category III CPT codes, effective January 1, 2025, which describe the implantation, replacement, removal, interrogation, and programming of the integrated vagus nerve stimulation device used for the treatment of patients who have rheumatoid arthritis (RA) and are not responsive to pharmacological therapy. The patient is placed under general anesthesia (for about 60-90 minutes) while the neurosurgeon dissects the tissue on the left side of the neck to access the cervical vagus nerve within the carotid sheath. The rechargeable integrated neurostimulator is then placed directly on the cervical vagus nerve. The implant is charged weekly with an external charger. A rheumatologist is responsible for prescribing and making changes to the stimulation therapy via an app. See Table 109 for the CPT codes, their long descriptors, and the proposed payment assignments.</P>
                    <GPH SPAN="3" DEEP="359">
                        <PRTPAGE P="94123"/>
                        <GID>ER27NO24.134</GID>
                    </GPH>
                    <P>For CY 2025, we proposed to assign 0908T and 0909T to APC 5462 (Level 2 Neurostimulator and Related Procedures) and status indicator “J1” (Hospital Part B Services Paid Through a Comprehensive APC; Paid under OPPS.) based on their similarity to CPT code 0587T (Percutaneous implantation or replacement of integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve) and because CPT 0587T also describes an integrated system.</P>
                    <P>We proposed to assign 0910T to APC 5461 (Level 1 Neurostimulator and Related Procedures) and status indicator “J1” based on its similarity to CPT code 0588T (Revision or removal of percutaneously placed integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve) as both codes describe the removal of an integrated neurostimulation system.</P>
                    <P>
                        We also proposed to assign CPT codes 0911T to APC 5733 (Level 3 Minor Procedures) and status indicator “Q1” (STV-Packaged Codes; Paid Under OPPS) using CPT code 95981(Electronic analysis of implanted neurostimulator pulse generator system (
                        <E T="03">e.g.,</E>
                         rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming) as a crosswalk code and 0912T to APC 5742 (Level 2 Electronic Analysis of Devices) and status indicator of “S” (Procedure or Service, Not Discounted When Multiple; Paid under OPPS; separate APC payment.) using CPT code 0589T (Electronic analysis with simple programming of implanted integrated neurostimulation system for bladder dysfunction (
                        <E T="03">e.g.,</E>
                         electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters) as a crosswalk code.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received several comments from stakeholders requesting that CPT codes XX32T (0908T) and XX33T (0909T) be reassigned from APC 5462 (Level 2 Neurostimulator and Related Procedures) to APC 5465 (Level 5 Neurostimulator and Related Procedures) because the proposed APC assignments do not reflect the costs of the device and procedure or consider the clinical intensity and risk of the procedure. Commenters provided CPT code 64568 (Open implantation of cranial nerve (
                        <E T="03">e.g.,</E>
                         vagus nerve) neurostimulator electrode array and pulse generator) as an appropriate comparator code, noting that the integrated devices do not require the creation of an additional subcutaneous pocket. While there are some differences in the two surgical procedures described by CPT codes XX32T (0908T) and XX33T (0909T) compared to CPT code 64568, the commenter asserted that 
                        <PRTPAGE P="94124"/>
                        inserting the integrated system is a complex procedure to perform and is similar in cost, resources, and required skill.
                    </P>
                    <P>Another commenter requested that we reassign XX34T (0910T) from APC 5461 (Level 1 Neurostimulator and Related Procedures) to APC 5463 (Level 3 Neurostimulator and Related Procedures) stating that CPT code 61888 (Revision or removal of cranial neurostimulator pulse generator or receiver) is an appropriate comparator code.</P>
                    <P>Commenters noted that the vagal nerve neurostimulation system is a novel treatment for rheumatoid arthritis patients who have exhausted other pharmacological options to manage their disease. They stated that biological therapies are expensive and may cost over $50,000/per year, while this neurostimulation system is expected to have a shelf life of 10 years. They asserted that APC reassignments of XX32T (0908T), XX33T (0909T), and XX34T (0910T) would support CMS' commitment to promoting new innovative treatment options and expanding access for beneficiaries with chronic conditions.</P>
                    <P>In addition to the comments requesting APC reassignments, the manufacturer stated they were expecting FDA approval, specifically Premarket Approval (PMA), in the 2nd quarter of 2025 with an expected statement “for the treatment of adult patients with moderately to severely active RA who have had an inadequate response, loss of response or intolerance to one (1) or more biological or targeted synthetic DMARDs (disease-modifying antirheumatic drugs)”. They acknowledged that, in the past, CMS has assigned non-FDA approved technologies a status indicator of “E1” and addressed the APC assignments once FDA approval is received. The manufacturer asserted the lack of payment assignments (APCs and status indicators) would significantly hinder commercialization of their neurostimulation system.</P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for all their valuable input. Because this vagal nerve neurostimulation system has not yet received FDA approval, we believe that we should reassign CPT codes 0908T, 0909T, 0910T, 0911T, and 0912T to status indicator “E1” to indicate that the code is not payable by Medicare when submitted on outpatient claims (any outpatient bill type). When we are notified by stakeholders that the FDA has approved this neurostimulation system, we will reassess the status indicator and APC assignments for these codes based on the comments we have received, in a future quarterly update and/or rulemaking cycle.
                    </P>
                    <P>In summary, after consideration of the public comments received, we are finalizing our proposal, with modification, to assign status indicator “E1” to CPT codes 0909T through 0912T. The final status indicator assignment for the codes is listed in Table 110. We refer readers to Addendum D1 of this final rule with comment period for the complete list of the OPPS payment status indicators and their definitions for CY 2025. Addendum D1 is available via the internet on the CMS website.</P>
                    <GPH SPAN="3" DEEP="345">
                        <GID>ER27NO24.135</GID>
                    </GPH>
                    <PRTPAGE P="94125"/>
                    <HD SOURCE="HD3">
                        66. VisONE® Synchronized Diaphragmatic Stimulation
                        <E T="51">TM</E>
                         (SDS®) System CPT Codes 0674T Through 0685T
                    </HD>
                    <P>
                        The VisONE® Synchronized Diaphragmatic Stimulation
                        <E T="51">TM</E>
                         (SDS®) System is a technology being studied to treat select patients with chronic heart failure by delivering electrical stimulation to the diaphragm to modulate intrathoracic pressure pulses on the cardiovascular system. The SDS® System is comprised of an implantable pulse generator (IPG), sensing and therapy lead electrodes, a laparoscopic implant tool to place the leads, and an external programmer and telemetry wand.
                    </P>
                    <P>There are 12 Category III CPT codes that may describe the various procedures related to the procedures involving the SDS® System: CPT codes 0674T-0685T. For CY 2025, as the SDS® System did not have FDA approval at the time of the proposed rule, we proposed to assign CPT codes 0674T-0685T to status indicator “E1” to indicate that the services are not paid by Medicare when submitted on outpatient claims (any outpatient bill type). Please refer to Table 111 for the full list of CPT codes and the proposed status indicators for CY 2025.</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94126"/>
                        <GID>ER27NO24.136</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter, specifically, the manufacturer of the SDS® System, requested clinical APC assignments for 9 of the 12 CPT codes 
                        <PRTPAGE P="94127"/>
                        describing the various procedures involving the SDS® System. The commenter requested assignments to packaged status indicator “N” for the remaining three add-on CPT codes for which they did not request a clinical APC assignment.
                    </P>
                    <P>Specifically, the commenter requested that, for CY 2025, CMS assign:</P>
                    <P>• CPT code 0674T to APC 5465 (Level 5 Neurostimulator and Related Procedures) with SI “J1” based on a crosswalk to CPT code 63685.</P>
                    <P>• CPT code 0675T to APC 5463 (Level 3 Neurostimulator and Related Procedures) with SI “J1” based on a crosswalk to CPT code 43647.</P>
                    <P>• CPT codes 0677T and 0679T to APC 5362 (Level 2 Laparoscopy and Related Services) with SI “J1” based on a crosswalk to CPT code 43648.</P>
                    <P>• CPT code 0680T to APC 5464 (Level 4 Neurostimulator and Related Procedures) with SI “J1” based on a crosswalk to CPT code 64590.</P>
                    <P>• CPT code 0681T and 0682T to APC 5461 (Level 1 Neurostimulator and Related Procedures) with SI “J1” based on a crosswalk to CPT code 64595.</P>
                    <P>• CPT code 0683T and 0685T to APC 5741 (Level 1 Electronic Analysis of Devices) with SI “Q1” based on crosswalks to CPT codes 93281 and 93288, respectively.</P>
                    <P>• SI “N” to CPT codes 0676T, 0678T, and 0684T.</P>
                    <P>The commenter also provided additional information regarding the FDA approval status of the SDS® System. Per the commenter, on July 26, 2024, the SDS® System received FDA approval for the Investigational Device Exemption (IDE) regarding the RECOVER-HF trial, which was anticipated to begin in late 2024. The request for Medicare coverage of the RECOVER-HF trial was pending when the comment was submitted. The commenter requested that CMS make the 12 codes payable effective January 1, 2025, in anticipation of Medicare's approval of their Category B IDE trial application.</P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their input and agree with the suggested CPT crosswalk codes provided by the commenter.
                    </P>
                    <P>We note that the RECOVER-HF trial was approved for Medicare coverage on September 23, 2024. Because the Category B IDE trial meets the CMS standards for coverage, and appears on the CMS approved IDE list on the CMS website, we are not finalizing our proposal to assign the 12 codes that describe the various procedures associated with the SDS® System to status indicator “E1.” In light of the recent Category B IDE study approval for the RECOVER-HF clinical trial, and based on our review of the comment received, more specifically the crosswalk codes recommended by the commenter, we are finalizing the following clinical APC and status indicator assignments:</P>
                    <BILCOD>BILLING CODE 4120-01-P</BILCOD>
                    <GPH SPAN="3" DEEP="640">
                        <PRTPAGE P="94128"/>
                        <GID>ER27NO24.137</GID>
                    </GPH>
                    <GPH SPAN="3" DEEP="256">
                        <PRTPAGE P="94129"/>
                        <GID>ER27NO24.138</GID>
                    </GPH>
                    <BILCOD>BILLING CODE 4120-01-C</BILCOD>
                    <P>The final CY 2025 payment rate for the codes can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 to this final rule with comment period for the complete list of the OPPS payment status indicators and their definitions for CY 2025. Addendum D1 is available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">67. Xenograft Implantation Into the Articular Surface, CPT Code 0737T (APC 5115)</HD>
                    <P>
                        For the July 1, 2022, update, the AMA CPT Editorial Panel established CPT code 0737T (Xenograft implantation into the articular surface) to describe xenograft implantation for use in cartilage and osteochondral defects in joints. Since July 1, 2022, CPT code 0737T has been assigned to status indicator “E1” (Not paid by Medicare when submitted on outpatient claims (any outpatient bill type)) to indicate that the code was not payable under the OPPS. In the OPPS Quarterly Change Request (Transmittal 12816, CR 13784) dated August 29, 2024, we noted that the device associated with this code (Agili-C
                        <E T="51">TM</E>
                        ) had become available, and therefore we reassigned CPT code 0737T to status indicator “J1” (Hospital Part B Services Paid Through a Comprehensive APC; Paid under OPPS) and APC 5115 (Level 5 Musculoskeletal Procedures) effective July 1, 2024. For CY 2025, we proposed to continue to assign CPT code 0737T to APC 5115 with a proposed payment assignment of around $12,755.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received a couple of comments expressing support for assigning CPT code 0737T to APC 5115 and status indicator “J1”. Commenters noted that the reimbursement was consistent with the costs associated with the procedure and would ensure equitable patient access, even allowing some beneficiaries to possibly avoid more costly knee replacement procedures. They requested that we maintain the APC and status indicator assignments for several years to gather claims data as they anticipate the patient volume will be limited due to the patient selection criteria.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their input. Under the OPPS, we review our claims data on an annual basis to determine payment rates and will continue to monitor the claims data and the appropriateness of the APC assignment for CPT code 0737T to APC 5115.
                    </P>
                    <P>In summary, we are finalizing our proposal, without modification, to assign CPT code 0737T to APC 5115 for CY 2025. The final CY 2025 payment rate for the code can be found in Addendum B to this final rule with comment period. In addition, we refer readers to Addendum D1 of this final rule with comment period for the SI meanings for all codes reported under the OPPS. Addenda B and D1 are available via the internet on the CMS website.</P>
                    <HD SOURCE="HD3">68. OPPS Payment for Software as a Service</HD>
                    <P>New clinical software, which includes clinical decision support software, clinical risk modeling, and computer aided detection (CAD), is becoming increasingly available to providers. These technologies often perform data analysis of diagnostic images from patients. While many of these technologies are new, we note that clinical software, particularly CAD, has been used to aid or augment clinical decision making for decades. These technologies rely on complex algorithms or statistical predictive modeling to aid in the diagnosis or treatment of a patient's condition. We refer to these algorithm-driven services that assist practitioners in making clinical assessments, and that providers pay for either on a subscription or per-use basis, as Software as a Service (SaaS).</P>
                    <P>
                        We note the proliferation of SaaS procedures approved by the FDA and their subsequent assignment of CPT codes by the AMA has led the agency to seek a workable SaaS payment strategy. We are seeking a strategy that would provide equitable payment for these new technologies while also preserving the integrity of the OPPS payment bundles, an essential component of a prospective payment system. We are seeking a payment strategy that aligns with our agency's mission to improve quality, health, reduce cost, and strengthen the health care system. We note that the manufacturer-supplied cost data of 
                        <PRTPAGE P="94130"/>
                        these SaaS services is often high and the true return in investment for these services is still unknown. Moreover, many SaaS services often do not share clinical and resource similarity to existing medical services. Thus, it generally has been challenging to compare a new SaaS service to existing medical services for the purpose of determining a fair payment rate for these new services.
                    </P>
                    <P>
                        Although some have recently received separate payment for these SaaS procedures under the OPPS, we recognize that certain clinical decision support software, including machine learning or “AI,” has been available for many years. In the past ten years, clinical decision support software has been commonly used alongside electronic medical records by medical practitioners. Nonetheless, the number of FDA approved or cleared “machine learning” or “AI” clinical software programs has rapidly increased in the past few years. We note that the FDA has approved many SaaS procedures for similar functions: there are at least six software products that purport to detect findings in Computed Tomography (CT) studies of the chest.
                        <SU>29</SU>
                        <FTREF/>
                         Additionally, we note some clinical software developers are now using alternative licensing that charges per use rather than using the traditional annual subscription or bulk use subscription. As a result of these variables and potentially others, there is significant price variation within the SaaS procedure space.
                    </P>
                    <FTNT>
                        <P>
                            <SU>29</SU>
                             
                            <E T="03">https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices</E>
                        </P>
                    </FTNT>
                    <P>We recognize that, as described in the CY 2023 OPPS/ASC final rule with comment period (87 FR 72027), SaaS procedures are a heterogenous group of services, which presents challenges when it comes to adopting payment policy for SaaS procedures as a whole. In the CY 2023 OPPS/ASC final rule, we solicited public comment on a payment approach that would broadly apply to SaaS procedures and have received some valuable feedback. Some of the feedback includes incorporating AI taxonomy across agencies and interested parties, or not to establish a single policy that would apply to all SaaS-type technology but instead separately evaluate each new technology to determine the appropriate HCPCS coding, including whether or not a potential CPT code can be used to support payment for the separate and distinct service under the OPPS.</P>
                    <P>For CY 2025, we are continuing to work to formulate a workable SaaS payment policy that would enhance our ability to provide equitable payment for SaaS procedures while responsibly managing cost and protecting the Medicare trust fund. Specifically, we are working to address the following:</P>
                    <P>• Identifying a payment strategy that is applicable across the settings of care (physician offices, for example);</P>
                    <P>• Identifying the fair costs associated for SaaS services;</P>
                    <P>• Distinguishing services that should be paid separately versus services that should be packaged under a prospective payment system; and</P>
                    <P>• Identifying a payment strategy for SaaS services that are part of other medical devices versus those that are distinct services.</P>
                    <P>We did not make any proposals on OPPS payment for SaaS for CY 2025 but received a number of comments on the topic.</P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters suggested CMS formulate a SaaS payment policy that would incentivize adoption of new AI and ensure access and provide stability for its adoption of SaaS technologies. Commenters stated that CMS payment decisions have not uniformly and consistently ensured appropriate levels of payment. Some commenters recommended that we adopt the term “Algorithm-based healthcare services” (ABHS), which include SaaS procedures. ABHS includes these services regardless of whether they are delivered by a third party, or a health care professional using the AI software through the cloud, the web, a workstation, or embedded in imaging acquisition hardware. Commenters also recommended that ABHS codes be initially assigned to New Technology APCs for at least 5 years based on manufacture-supply cost data, until sufficient claims data are available. Some commenters also recommend that we codify the 2023 packaging exemption for SaaS add-on codes policy.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' valuable input on a SaaS payment policy approach, and we will consider their input for any future SaaS payment policy. We note that the suggestion for any new SaaS services to remain in the initial New Technology APC assignment for at least 5 years is in contrast to our current Transitional Pass-Through policy of three years for device or drugs. Moreover, we would need to examine the feasibility of payment determination based on manufacture-supplied cost data, which has historically not been comparable when the claims data become available.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter requested CMS clarify that SaaS codes created by the AMA CPT are to be vendor neutral, and that these codes do not represent any single vendor's services. The commenter stated the focus on a single commercial platform for a code is not accurate, confuses the applicability, and limits adoption of other tools for which the code was intended. The commenter recommended removing the current language that these codes are “associated with” a specific service, which may result in an increase in claims, therefore allowing for a more accurate understanding of actual costs associated with these services.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for the valuable input. We recognize that the proliferation of SaaS procedures has created a need for the agency to continue to update our payment approach. We are continuing to work to improve SaaS payment policy in future rulemakings to enhance our ability to provide equitable payment for SaaS procedures while responsibly managing cost and protecting the Medicare trust fund.
                    </P>
                    <HD SOURCE="HD3">69. APC and Status Indicator Review Process</HD>
                    <P>Each year, CMS receives a high volume of requests from stakeholders and other interested parties to make certain OPPS payment policy changes, including many requesting changes to the APC and status indicator assignments of new or revised codes. Current APC groupings, APC assignments, and status indicators are reflected in the various addenda to the proposed and final OPPS payment rules. In addition, comments within the scope of the proposed rule, are summarized and responded to in the annual OPPS final rule with comment period.</P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment requesting that CMS outline a process that describes the criteria used to determine which stakeholder requests regarding APC assignments are included in the OPPS proposed rule. The commenter suggested that all APC assignment requests, including APC structure requests, be included in the OPPS proposed rule and that we should follow a process similar to the IPPS, which includes an annual deadline, and requests discussed in the following year's proposed rule.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the feedback and will consider this comment for future rulemaking. As a reminder, codes are updated and changed throughout the year. CPT and Level II HCPCS code changes that affect the OPPS are published through the annual rulemaking cycle and through the OPPS quarterly update Change Requests (CRs). Generally, these code changes are effective January 1, April 1, July 1, or 
                        <PRTPAGE P="94131"/>
                        October 1. CPT code changes are released by the AMA (via their website) while Level II HCPCS code changes are released to the public via the CMS HCPCS website. CMS recognizes the release of new CPT and Level II HCPCS codes outside of the formal rulemaking process via OPPS quarterly update CRs. Based on our review, we assign the new codes to interim status indicators (SIs) and APCs. These interim assignments are finalized in the OPPS/ASC final rules. This quarterly process offers hospitals access to codes that more accurately describe the items or services furnished and provides payment for these items or services in a timelier manner than if we waited for the annual rulemaking process. We solicit public comments on the new CPT and Level II HCPCS codes, status indicators, and APC assignments through our annual rulemaking process.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         We received one comment requesting information about our process for assigning status indicator “E1” to CPT or HCPCS codes that are not FDA approved. The commenter asserts that the delay in timing (from FDA approval to APC and SI assignment) affects beneficiary access to new technologies and services and impacts how other payers will pay for the services.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the feedback. We believe for items and services that are not FDA approved, it is appropriate to assign the codes to status indicator “E1” to indicate that they are not payable by Medicare when submitted on outpatient claims (any outpatient bill type) because the services are either not covered by any Medicare outpatient benefit category, statutorily excluded by Medicare, or not reasonable and necessary. We rely on stakeholders to notify us upon FDA approval of their device and/or service and we work to ensure a timely transition and assign the applicable codes to APCs that reflect clinical and resource similarity to the new codes. We accept information regarding the device and/or service that the stakeholder can provide to us to assist us in our review. We remind readers that OPPS payment policies are updated quarterly through a sub-regulatory process.
                    </P>
                    <HD SOURCE="HD1">IV. OPPS Payment for Devices</HD>
                    <HD SOURCE="HD2">A. Pass-Through Payment for Devices</HD>
                    <HD SOURCE="HD3">1. Beginning Eligibility Date for Device Pass-Through Status and Quarterly Expiration of Device Pass-Through Payments</HD>
                    <HD SOURCE="HD3">a. Background</HD>
                    <P>The intent of transitional device pass-through payment, as implemented at § 419.66, is to facilitate access for beneficiaries to the advantages of new and truly innovative devices by allowing for adequate payment for these new devices while the necessary cost data is collected to incorporate the costs for these devices into the procedure APC rate (66 FR 55861). Under section 1833(t)(6)(B)(iii) of the Act, the period for which a device category eligible for transitional pass-through payments under the OPPS can be in effect is at least 2 years but not more than 3 years. Prior to CY 2017, our regulation at § 419.66(g) provided that this pass-through payment eligibility period began on the date CMS established a particular transitional pass-through category of devices, and we based the pass-through status expiration date for a device category on the date on which pass-through payment was effective for the category. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79654), in accordance with section 1833(t)(6)(B)(iii)(II) of the Act, we amended § 419.66(g) to provide that the pass-through eligibility period for a device category begins on the first date on which pass-through payment is made under the OPPS for any medical device described by such category.</P>
                    <P>In addition, prior to CY 2017, our policy was to propose and finalize the dates for expiration of pass-through status for device categories as part of the OPPS annual update. This means that device pass-through status would expire at the end of a calendar year when at least 2 years of pass-through payments had been made, regardless of the quarter in which the device was approved. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79655), we changed our policy to allow for quarterly expiration of pass-through payment status for devices, beginning with pass-through devices approved in CY 2017 and subsequent calendar years, to afford a pass-through payment period that is as close to a full 3 years as possible for all pass-through payment devices. We also have an established policy to package the costs of the devices that are no longer eligible for pass-through payments into the costs of the procedures with which the devices are reported in the claims data used to set the payment rates (67 FR 66763).</P>
                    <P>
                        We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79648 through 79661) for a full discussion of the current device pass-through payment policy.
                        <SU>30</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>30</SU>
                             To apply for OPPS transitional device pass-through status, applicants complete an application that is subject to the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501 
                            <E T="03">et seq.</E>
                            ). This information collection (CMS-10052) is currently approved under OMB control number 0938-0857 and has an expiration date of November 30, 2025.
                        </P>
                    </FTNT>
                    <P>In the CY 2023 OPPS/ASC final rule with comment period, we finalized our policy to publicly post online OPPS device pass-through applications received on or after March 1, 2023, beginning with the issuance of the CY 2025 proposed rule and for each OPPS rulemaking thereafter. We refer readers to the CY 2023 OPPS/ASC final rule with comment period (87 FR 71934 through 71938) for a full discussion of the policy to publicly post OPPS device pass-through applications.</P>
                    <HD SOURCE="HD3">b. Expiration of Transitional Pass-Through Payments for Certain Devices</HD>
                    <P>As stated earlier, section 1833(t)(6)(B)(iii) of the Act requires that, under the OPPS, a category of devices be eligible for transitional pass-through payments for at least 2 years, but not more than 3 years. Currently, there are 13 device categories eligible for pass-through payment. These devices are listed in Table 112 of this final rule where we detail the expiration dates of pass-through payment status for each of the 13 devices currently receiving device pass-through payment.</P>
                    <GPH SPAN="3" DEEP="612">
                        <PRTPAGE P="94132"/>
                        <GID>ER27NO24.139</GID>
                    </GPH>
                    <PRTPAGE P="94133"/>
                    <P>
                        As discussed in section IV.A.2. New Device Pass-Through Applications for CY 2024 of the CY 2024 OPPS/ASC final rule with comment period, we approved HCPCS code C1601 (Endoscope, single-use (
                        <E T="03">i.e.</E>
                         disposable), pulmonary, imaging/illumination device (insertable)), as a new device category for pass-through status under the OPPS, with an effective date of January 1, 2024. For the full discussion of the criteria used to evaluate device pass-through applications, refer to the CY 2024 OPPS/ASC final rule with comment period, which was published in the 
                        <E T="04">Federal Register</E>
                         on November 22, 2023 (88 FR 81729 through 81743). We note that HCPCS code C1601 was established for a bronchoscope that can only be used for a single procedure and cannot be reprocessed. As such, HCPCS code C1601 only describes devices that cannot be reprocessed.
                    </P>
                    <P>
                        In addition, as discussed in section IV.A.2 (New Device Pass-Through Applications for CY 2023) of the CY 2023 OPPS/ASC final rule with comment period, we approved HCPCS code C1747 (Endoscope, single-use (
                        <E T="03">i.e.</E>
                         disposable), urinary tract, imaging/illumination device (insertable)), as a new device category for pass-through status under the OPPS, with an effective date of January 1, 2023. For the full discussion on the criteria used to evaluate device pass-through applications, refer to the CY 2023 OPPS/ASC final rule with comment period, which was published in the 
                        <E T="04">Federal Register</E>
                         on November 23, 2022 (87 FR 71929 through 71934). We note that HCPCS code C1747 was established for a ureteroscope that can only be used for a single procedure and cannot be reprocessed. As such, HCPCS code C1747 only describes devices that cannot be reprocessed.
                    </P>
                    <HD SOURCE="HD3">2. New Device Pass-Through Applications for CY 2025</HD>
                    <HD SOURCE="HD3">a. Background</HD>
                    <P>Section 1833(t)(6) of the Act provides for pass-through payments for devices, and section 1833(t)(6)(B) of the Act requires CMS to use categories in determining the eligibility of devices for pass-through payments. As part of implementing the statute through regulations, we have continued to believe that it is important for hospitals to receive pass-through payments for devices that offer substantial clinical improvement in the treatment of Medicare beneficiaries to facilitate access by beneficiaries to the advantages of the new technology. Conversely, we have noted that the need for additional payments for devices that offer little or no clinical improvement over previously existing devices is less apparent. In such cases, these devices can still be used by hospitals, and hospitals will be paid for them through appropriate APC payment. Moreover, a goal is to target pass-through payments for those devices where cost considerations are most likely to interfere with patient access (66 FR 55852; 67 FR 66782; and 70 FR 68629).</P>
                    <P>As specified in regulations at § 419.66(b)(1) through (3), to be eligible for transitional pass-through payment under the OPPS, a device must meet the following criteria:</P>
                    <P>• If required by FDA, the device must have received FDA approval or clearance and FDA marketing authorization (except for a device that has received an FDA investigational device exemption (IDE) and has been classified as a Category B device by FDA), or meet another appropriate FDA exemption; and the pass-through payment application must be submitted within 3 years from the date of the initial FDA marketing authorization, if required, unless there is a documented, verifiable delay in U.S. market availability after FDA marketing authorization is granted, in which case CMS will consider the pass-through payment application if it is submitted within 3 years from the date of market availability;</P>
                    <P>• The device is determined to be reasonable and necessary for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body part, as required by section 1862(a)(1)(A) of the Act; and</P>
                    <P>• The device is an integral part of the service furnished, is used for one patient only, comes in contact with human tissue, and is surgically implanted or inserted (either permanently or temporarily), or applied in or on a wound or other skin lesion.</P>
                    <P>In addition, according to § 419.66(b)(4), a device is not eligible to be considered for device pass-through payment if it is any of the following: (1) equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15-1); or (2) a material or supply furnished incident to a service (for example, a suture, customized surgical kit, or clip, other than a radiological site marker).</P>
                    <P>Separately, we use the following criteria, as set forth under § 419.66(c), to determine whether a new category of pass-through payment devices should be established. The device to be included in the new category must—</P>
                    <P>• Not be appropriately described by an existing category or by any category previously in effect established for transitional pass-through payments, and was not being paid for as an outpatient service as of December 31, 1996;</P>
                    <P>• Have an average cost that is not “insignificant” relative to the payment amount for the procedure or service with which the device is associated as determined under § 419.66(d) by demonstrating: (1) the estimated average reasonable cost of devices in the category exceeds 25 percent of the applicable APC payment amount for the service related to the category of devices; (2) the estimated average reasonable cost of the devices in the category exceeds the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent; and (3) the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device exceeds 10 percent of the APC payment amount for the related service (with the exception of brachytherapy and temperature-monitored cryoablation, which are exempt from the cost requirements as specified at § 419.66(c)(3) and (e)); and</P>
                    <P>• Demonstrate a substantial clinical improvement, that is, substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment, or, for devices for which pass-through payment status will begin on or after January 1, 2020, as an alternative pathway to demonstrating substantial clinical improvement, a device is part of the FDA's Breakthrough Devices Program and has received marketing authorization for the indication covered by the Breakthrough Device designation.</P>
                    <P>
                        Beginning in CY 2016, we changed our device pass-through evaluation and determination process. Device pass-through applications are still submitted to CMS through the quarterly subregulatory process, but the applications are subject to notice and comment rulemaking in the next applicable OPPS annual rulemaking cycle. Under this process, all applications that are preliminarily approved upon quarterly review will automatically be included in the next applicable OPPS annual rulemaking cycle, while submitters of applications that are not approved upon quarterly review will have the option of being 
                        <PRTPAGE P="94134"/>
                        included in the next applicable OPPS annual rulemaking cycle or withdrawing their application from consideration. Under this notice-and-comment process, applicants may submit new evidence, such as clinical trial results published in a peer-reviewed journal or other materials, for consideration during the public comment process for the proposed rule. This process allows those applications that we are able to determine meet all of the criteria for device pass-through payment under the quarterly review process to receive timely pass-through payment status, while still allowing for a transparent, public review process for all applications (80 FR 70417 through 70418).
                    </P>
                    <P>In the CY 2020 annual rulemaking process, we finalized an alternative pathway for devices that are granted a Breakthrough Device designation (84 FR 61295) and receive FDA marketing authorization for the indication covered by the Breakthrough Device designation. Under this alternative pathway, devices that are granted an FDA Breakthrough Device designation are not evaluated in terms of the current substantial clinical improvement criterion at § 419.66(c)(2) for the purposes of determining device pass-through payment status, but do need to meet the other requirements for pass-through payment status in our regulation at § 419.66. Devices that are part of the Breakthrough Devices Program, have received FDA marketing authorization for the indication covered by the Breakthrough Devices designation, and meet the other criteria in the regulation can be approved through the quarterly process and announced through that process (81 FR 79655). Proposals regarding these devices and whether pass-through payment status should continue to apply are included in the next applicable OPPS rulemaking cycle. This process promotes timely pass-through payment status for innovative devices, while also recognizing that such devices may not have a sufficient evidence base to demonstrate substantial clinical improvement at the time of FDA marketing authorization.</P>
                    <P>
                        More details on the requirements for device pass-through payment applications are included on the CMS website in the application form itself at: 
                        <E T="03">https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/passthrough_payment.html</E>
                        , in the “Downloads” section. In addition, CMS is amenable to meeting with applicants or potential applicants to facilitate information sharing to support the evaluation of an OPPS device pass-through payment application or discuss general application criteria, including the substantial clinical improvement criterion.
                    </P>
                    <HD SOURCE="HD3">b. Applications Received for Device Pass-Through Status for CY 2025</HD>
                    <P>
                        We received 14 complete applications by the March 1, 2024, quarterly deadline, which was the last quarterly deadline for applications to be received in time to be included in this final rule. Of the complete applications, we received two applications in the second quarter of 2023, two application in the third quarter of 2023, three applications in the fourth quarter of 2023, and seven applications in the first quarter of 2024. Three of the applications were approved for device pass-through payment during the quarterly review process: The DETOUR
                        <E T="51">TM</E>
                         System, which was preliminarily approved upon quarterly review under the alternative pathway effective January 1, 2024, and the AVEIR
                        <E T="51">TM</E>
                         DR Dual Chamber Leadless Pacemaker System and the EndoSound Vision System
                        <E T="51">TM</E>
                         (EVS
                        <E T="51">TM</E>
                        ) which both were preliminarily approved upon quarterly review under the alternative pathway effective July 1, 2024. As previously stated, all applications that are preliminarily approved upon quarterly review will automatically be included in the next applicable OPPS annual rulemaking cycle. Therefore, the DETOUR
                        <E T="51">TM</E>
                         System, the AVEIR
                        <E T="51">TM</E>
                         DR Dual Chamber Leadless Pacemaker System, and the EndoSound Vision System
                        <E T="51">TM</E>
                         (EVS
                        <E T="51">TM</E>
                        ) are discussed in the following section IV.2.b.1.
                    </P>
                    <P>
                        We note that the quarterly application process and requirements have not changed because of the addition of rulemaking review. Detailed instructions on submission of a quarterly device pass-through payment application are included on the CMS website at: 
                        <E T="03">https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/catapp.pdf</E>
                        .
                    </P>
                    <P>Discussions of the applications we received by the March 1, 2024, deadline are included below. We did not include the description and discussion of new device category for transitional pass-through payment status applications which were included in the proposed rule that were withdrawn for consideration for the upcoming calendar year. We also do not summarize or respond to public comments received regarding these withdrawn or ineligible applications.</P>
                    <HD SOURCE="HD3">(1) Alternative Pathway Device Pass-Through Applications</HD>
                    <P>We received 10 device pass-through applications by the March 2024 quarterly application deadline for devices that have received Breakthrough Device designation from FDA and FDA marketing authorization for the indication for which they have a Breakthrough Device designation, and therefore were eligible to apply under the alternative pathway.</P>
                    <HD SOURCE="HD3">
                        (a) AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter
                    </HD>
                    <P>
                        Boston Scientific Corporation submitted an application for a new device category for transitional pass-through payment status for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter for CY 2025. Per the applicant, the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is a device/drug combination product consisting of a semi-compliant intracoronary balloon catheter with a paclitaxel/acetyl tributyl citrate drug coating on the balloon component. The applicant asserted that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter delivers paclitaxel, an antiproliferative drug, directly to the arterial tissue which inhibits the proliferation of neointimal smooth muscle cells without introducing an additional stent layer, thereby reducing the rate of restenosis. According to the applicant, the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is intended for use in adult patients, after appropriate vessel preparation, undergoing percutaneous coronary intervention (PCI) in coronary arteries 2.0 mm to 4.0 mm in diameter and lesions up to 26 mm in length for the purpose of improving myocardial perfusion when treating in-stent restenosis (ISR) and the management of atherosclerotic coronary artery disease.
                    </P>
                    <P>
                        Please refer to the online application posting for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter, available at 
                        <E T="03">https://mearis.cms.gov/public/publications/device-ptp/DEP2402295H2TU</E>
                        , for additional detail describing this device and the disease treated by the device.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Many commenters expressed their support for the approval of transitional pass-through payment for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter. The commenters, including the applicant, emphasized their positive views on the device's transformational nature as a treatment for ISR, the device's ability to demonstrate clinical improvement relative to other available treatments, and the device's safety profile. In addition, many commenters expressed their concerns that without 
                        <PRTPAGE P="94135"/>
                        adequate reimbursement many medical facilities may not adopt widespread use of the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' input and support for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter application for transitional pass-through payment. We have taken these comments into consideration in our final determination for pass-through status for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter.
                    </P>
                    <P>
                        As stated previously, to be eligible for transitional pass-through payment under the OPPS, a device must meet the criteria at § 419.66(b)(1) through (4). With respect to the newness criterion at § 419.66(b)(1), the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter received FDA Breakthrough Device designation effective January 22, 2021, as a combination product indicated for percutaneous transluminal coronary angioplasty (PTCA) in coronary arteries 2.0 mm to 4.0 mm in diameter to treat ISR, up to 26 mm in length, for the purpose of improving myocardial perfusion. FDA approved the premarket approval application (PMA) for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter on February 29, 2024, as indicated for use after appropriate vessel preparation in adult patients undergoing PCI in coronary arteries 2.0 mm to 4.0 mm in diameter and lesions up to 26 mm in length for the purpose of improving myocardial perfusion when treating ISR. We noted that while the indication for the FDA Breakthrough Device designation and the indication for the FDA premarket approval vary slightly, we stated that we believe that FDA premarket approval indication is the indication covered by the Breakthrough Device designation. We received the application for a new device category for transitional pass-through payment status for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter on February 29, 2024, which is within 3 years of the date of the initial FDA marketing authorization.
                    </P>
                    <P>
                        We invited public comment on whether the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to the newness criterion at § 419.66(b)(1), the applicant reiterated that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter received FDA premarket approval on February 29, 2024, for use after appropriate vessel preparation in adult patients undergoing PCI in coronary arteries 2.0 mm to 4.0 mm in diameter and lesions up to 26 mm in length for the purpose of improving myocardial perfusion when treating ISR. In addition, a few other commenters expressed their belief that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and commenters' input. The AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter received FDA Breakthrough Device designation effective January 22, 2021. We received the application for a new device category for transitional pass-through payment status for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter on February 29, 2024, which is within 3 years of February 29, 2024, the date of FDA premarket approval application. Based on our review of the application, we have determined that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        With respect to the eligibility criterion at § 419.66(b)(3), the device must be an integral part of the service furnished, used for one patient only, come in contact with human tissue, and be surgically inserted or implanted, or applied in or on a wound or other skin lesion. The applicant did not explicitly indicate whether the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is integral to the service provided. The applicant stated that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is used for one patient only, comes in contact with human tissue, and is surgically implanted or inserted as required by § 419.66(b)(3).
                    </P>
                    <P>
                        We invited public comment on whether the AGENT
                        <SU>TM</SU>
                         Paclitaxel-Coated Balloon Catheter meets the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant and another commenter asserted that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets all the requirements of § 419.66(b)(3). The applicant submitted a comment clarifying that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is integral to the service provided and meets the eligibility criterion at § 419.66(b)(3) because the service cannot be furnished without the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter. Specifically, the applicant commented that that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is a device/drug combination product consisting of a semi-compliant intracoronary balloon catheter with a drug coating consisting of paclitaxel/acetyl tributyl citrate on the balloon component. In addition, the applicant provided that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is inserted transiently in a coronary artery suffering from ISR and transfers a long-dwelling, therapeutic dose of paclitaxel to the vessel wall of the artery to prevent ISR reoccurrence. The applicant reiterated that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is used for one patient only, comes in contact with human tissue, and is surgically implanted or inserted.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and commenter's clarification, and we agree that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is integral to the service furnished. We agree with the applicant and commenter that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is used for one patient only, comes in contact with human tissue, and is surgically implanted or inserted, or applied in or on a wound or other skin lesion. After consideration of the public comments received and our review of the application, we have determined that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        With respect to the exclusion criterion at § 419.66(b)(4), a device is not eligible to be considered for device pass-through payment if it is any of the following: (1) equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15-1); or (2) a material or supply furnished incident to a service (for example, a suture, customized surgical kit, or clip, other than a radiological site marker). The applicant did not indicate whether the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered, or if the AGENT
                        <SU>TM</SU>
                         Paclitaxel-Coated Balloon Catheter is a supply or material furnished incident to a service.
                    </P>
                    <P>
                        We invited public comment on whether the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the exclusion criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant and commenter submitted a comment clarifying that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the eligibility criterion at § 419.66(b)(4) because it is not equipment, an instrument, apparatus, implement or any type of item for which depreciation and financing expenses are recovered, and because it is the primary therapeutic intervention and is not a supply or material furnished incident to a service.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and commenter's clarification. We agree with the 
                        <PRTPAGE P="94136"/>
                        applicant and commenter that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is not equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets, or a material or supply furnished incident to a service. After consideration of the public comments received and our review of the application, we have determined that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the eligibility criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        In addition to the criteria at § 419.66(b)(1) through (4), the criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. According to the applicant, no previous or existing device categories for pass-through payment appropriately describe the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter. Per the applicant, while device category C2623 (Catheter, transluminal angioplasty, drug-coated, non-laser) describes related or similar products to the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter, the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is not appropriately described by C2623 because the devices in this category differ from the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter in both size and indicated use, and therefore, the device is not appropriately described by C2623. The applicant further claimed that the devices described by C2623 are approved for use in the femoral or popliteal arteries in vessels with a diameter of at least 4.0 mm, whereas the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is indicated for use in coronary arteries that are between 2.0 mm to 4.0 mm in diameter. In addition, the applicant also noted that the length of the lesions (up to 180 mm) treated with devices in this device category greatly exceeds the maximum lesion size of 26 mm for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter. Moreover, the applicant asserted that the devices described by C2623 are used to treat peripheral arterial disease and are contraindicated for use in coronary arteries. Per the applicant, the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is used in conjunction with transluminal PCIs which are described by different procedure codes than the percutaneous transluminal angioplasty services used for the devices in C2623. Lastly, the applicant stated that an analysis of claims found that the devices described by C2623 are typically reported with femoral or popliteal revascularization procedures (HCPCS codes from 37224 to 37227).
                    </P>
                    <P>
                        We noted that, based on the description the applicant provided, the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is a device/drug combination product consisting of a semi-compliant intracoronary balloon catheter with a paclitaxel/acetyl tributyl citrate drug coating on the balloon component and thus could be appropriately described by C2623. Specifically, we stated that we believe that C2623 may appropriately describe the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter because it is a non-laser, drug-coated catheter used for transluminal angioplasty procedures. In this context, we noted that we believe the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter may be similar to the devices described by C2623, and therefore, the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter may also be appropriately described by C2623.
                    </P>
                    <P>
                        In addition, while we acknowledged that when C2623 was established as a device category code effective April 1, 2015, the procedure codes with which C2623 could be reported (HCPCS code 37224 and HCPCS code 37226) were limited to use in the femoral or popliteal arteries. However, based on the subsequent changes that were made to the procedure codes with which C2623 could be reported, we did not agree that C2623 is limited to use with femoral or popliteal revascularization procedures. First, we noted that effective August 25, 2017, while C2623 was in device pass-through payment status, CMS added two procedure codes with which C2623 could be reported that were for procedures other than femoral popliteal revascularization procedures. Specifically, based on the FDA approval of a new indication for an existing device (a drug-coated balloon catheter for use with dialysis circuit procedures for the treatment of patients with dysfunctional arteriovenous fistulae),
                        <SU>31</SU>
                        <FTREF/>
                         CMS added two procedure codes, HCPCS codes 36902 and 36903 (transluminal balloon angioplasty procedures in peripheral dialysis segments),
                        <SU>32</SU>
                        <FTREF/>
                         with which C2623 could be reported effective August 25, 2017. The devices used with these two added HCPCS codes, 36902 and 36903, which are also described by C2623, are drug-coated balloon catheters used for dialysis circuit procedures in the upper extremities. We stated that we believe the inclusion of these additional reportable procedure codes illustrates that devices that may be described by C2623 were neither intended to be restricted to the treatment of vascular lesions of a specified dimension nor anatomically limited to femoral or popliteal revascularization procedures and is inconsistent with the applicant's assertion that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is not appropriately described by C2623 because the category is only applicable for devices used in femoral or popliteal arteries with a diameter of at least 4.0 mm, and not smaller coronary arteries.
                    </P>
                    <FTNT>
                        <P>
                            <SU>31</SU>
                             Centers for Medicare &amp; Medicaid Services (2017). Pub 100-04 Medicare Claims Processing (Transmittal 3941) in CMS Manual System. Accessed at 
                            <E T="03">https://www.cms.gov/regulations-and-guidance/guidance/transmittals/2017downloads/r3941cp.pdf.</E>
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>32</SU>
                             HCPCS code 36902 (Introduction of needle(s) and/or catheter(s), dialysis circuit, with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava, fluoroscopic guidance, radiological supervision and interpretation and image documentation and report; with transluminal balloon angioplasty, peripheral dialysis segment, including all imaging and radiological supervision and interpretation necessary to perform the angioplasty) and HCPCS code 36903 (Introduction of needle(s) and/or catheter(s), dialysis circuit, with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava, fluoroscopic guidance, radiological supervision and interpretation and image documentation and report; with transcatheter placement of intravascular stent(s) peripheral dialysis segment, including all imaging and radiological supervision and interpretation necessary to perform the stenting, and all angioplasty within the peripheral dialysis segment).
                        </P>
                    </FTNT>
                    <P>
                        Further, beginning January 1, 2018, upon the expiration of device pass-through payment status for C2623, CMS packaged the payment for the costs of each of the devices described by C2623 into the payment for the costs related to the procedure with which each device is reported in the hospital claims data (FR 82 59321 through 59323). We further noted that upon becoming packaged for payment, C2623 effectively became reportable with other transluminal angioplasty procedure codes, including procedure codes for percutaneous coronary transluminal angioplasty services. Finally, we noted that while, per the applicant, the devices described by C2623 are typically reported with femoral or popliteal revascularization procedures, other procedure codes, including procedure codes for other percutaneous transluminal angioplasty services and 
                        <PRTPAGE P="94137"/>
                        other related coronary procedure codes can and have been performed with devices described by C2623. As such, we stated that we believe the procedures with which the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is utilized could be reported with C2623.
                    </P>
                    <P>
                        In this context, based on the description the applicant provided, we stated that we believe the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter may be similar to the devices described by C2623, and therefore, the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter may also be appropriately described by C2623.
                    </P>
                    <P>
                        We invited public comment on whether the AGENT
                        <SU>TM</SU>
                         Paclitaxel-Coated Balloon Catheter meets the device category criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         In response to our concerns that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter may be appropriately described by C2623, the applicant and many commenters asserted that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is not described by C2623 because the device is not used to perform transluminal angioplasties. Specifically, these commenters explained that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is used to effectively deliver its drug to a lesion after the vessel wall has been prepared, typically through an angioplasty. They also asserted that C2623 is used to describe drug-coated balloons indicated for use in the peripheral vasculature which are capable of both angioplasty and drug-delivery; however, according to the commenters, the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is used solely for drug-delivery and cannot be used for performing an angioplasty. In addition, the applicant commented that peripheral drug-coated balloon catheters, like those described by C2623, are primarily used for treating typically diffused atherosclerotic/restenotic lesions in the comparatively elastic femoral or popliteal arteries, whereas coronary drug-coated balloons are used for treatment of substantially smaller, stented (and therefore, relatively inelastic) coronary segments, with largely focal lesions. Similarly, many commenters underlined the differences between the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter and peripheral drug-coated balloon catheters, including design, size, deployment location and time length, clinical indication, and procedural complexity.
                    </P>
                    <P>
                        The applicant and a few commenters noted that CMS has historically included specific anatomy in several device categories, including those differentiating coronary and non-coronary devices. The applicant offered the following as examples of device categories that are specific to a particular type of intervention: C1759 (Catheter, intracardiac echocardiography), C1761 (Catheter, transluminal intravascular lithotripsy, coronary), and C1888 (Catheter, ablation, non-cardiac, endovascular). A few commenters highlighted device categories that are more granular in description than C2623, such as C1714 (Catheter, transluminal atherectomy, directional), C1724 (Catheter, transluminal atherectomy, rotational), C1732 (Catheter, electrophysiology, diagnostic/ablation, 3D or vector mapping), and C1733 (Catheter, electrophysiology, diagnostic/ablation, other than 3D or vector mapping, other than cool-tip), and suggested that CMS similarly acknowledge the differences between the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter and those devices in device category C2623.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and commenters' input. We note that while the FDA Breakthrough Device designation for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter stated a proposed indication for PTCA in coronary arteries 2.0 mm to 4.0 mm in diameter to treat ISR, up to 26 mm in length, for the purpose of improving myocardial perfusion, the FDA PMA for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter on February 29, 2024, stated the combination drug/device is indicated for use after appropriate vessel preparation in adult patients undergoing PCI in coronary arteries 2.0 mm to 4.0 mm in diameter and lesions up to 26 mm in length for the purpose of improving myocardial perfusion when treating ISR, removing the PTCA indication. This appears to be consistent with the applicant's and commenters' assertions that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is not utilized in the treatment of PTCA. After consideration of the public comments received, we agree that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is not indicated for use in transluminal angioplasty; rather, it is intended for improving myocardial perfusion when treating in-stent restenosis after appropriate vessel preparation. Further, we agree that C2623 describes drug-coated balloons which are capable of angioplasty, while the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter appears to be used solely for drug-delivery and cannot be used for performing an angioplasty, including PCTAs. As such, we do not believe that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is described by C2623.
                    </P>
                    <P>We acknowledge that CMS has included specific anatomic language in the descriptors of previous device category codes when such language was necessary based on the unique circumstances surrounding the establishment of a particular device category code. We note that CMS does not establish pass-through device categories for the purposes of describing specific devices, but rather, device categories which are intended to encompass all devices that can be appropriately described by a category. As such, all device categories, regardless of the language utilized in the descriptors, are established in such a way that no medical device is described by more than one category in accordance with section 1833(t)(6)(B)(ii)(II) of the Act.</P>
                    <P>
                        After consideration of the public comments received and our review of the application, we agree there is no existing category or category previously in effect that appropriately describes the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter. Based on this information, we have determined that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the eligibility criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines either of the following: (i) that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment; or (ii) for devices for which pass-through status will begin on or after January 1, 2020, as an alternative to the substantial clinical improvement criterion, the device is part of the FDA's Breakthrough Devices Program and has received FDA marketing authorization for the indication covered by the Breakthrough Device designation. The AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter has a Breakthrough Device designation and marketing authorization from FDA for the indication covered by the Breakthrough Device designation (as explained in the discussion of the newness criterion), and therefore, is not evaluated for substantial clinical improvement.
                    </P>
                    <P>
                        We invited public comment on whether the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the device category criterion at § 419.66(c)(2)(ii).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant and one commenter confirmed that the 
                        <PRTPAGE P="94138"/>
                        AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter has received both Breakthrough Device designation and marketing authorization from FDA, meeting the device category criterion at § 419.66(c)(2).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and commenter's input. The AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter has a Breakthrough Device designation effective January 22, 2021, and marketing authorization from FDA effective February 29, 2024, for the indication covered by the Breakthrough Device designation. Therefore, the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the criterion at 419.66(c)(2)(ii) and is not evaluated for substantial clinical improvement at § 419.66(c)(2)(i). Based on our review of the application, we have determined that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the device category criterion at § 419.66(c)(2).
                    </P>
                    <P>
                        The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. The applicant stated that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter would be reported with the HCPCS codes as shown in Table 113.
                    </P>
                    <GPH SPAN="3" DEEP="238">
                        <GID>ER27NO24.140</GID>
                    </GPH>
                    <P>
                        To meet the cost criterion for device pass-through payment status, a device must pass all three tests of the cost criterion for at least one APC. As we explained in the CY 2005 OPPS final rule (69 FR 65775), we generally use the lowest APC payment rate applicable for use with the nominated device when we assess whether a device meets the cost significance criterion, thus increasing the probability the device will pass the cost significance test. Beginning in CY 2017, we calculate the device offset amount at the HCPCS/CPT code level instead of the APC level (81 FR 79657). We noted that the applicant utilized the CY 2024 payment rates for the three tests of the cost criterion. For our calculations, we used APC 5192, which had a CY 2024 payment rate of $5,445.84 at the time the application was received. HCPCS code 92920 in APC 5192 had a device offset amount of $1,662.61 at the time the application was received. According to the applicant, the cost of the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is $5,500.00.
                    </P>
                    <P>
                        Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The average reasonable cost of $5,500.00 for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is 101.00 percent of the applicable APC payment amount for the service related to the category of devices of $5,445.84 (($5,500.00/$5,445.84) × 100 = 101.00 percent). Therefore, we stated that we believe the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the first cost significance requirement.
                    </P>
                    <P>
                        The second cost significance requirement, at § 419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $5,500.00 for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter is 330.81 percent of the cost of the device-related portion of the APC payment amount for the related service of $1,662.61 (($5,500.00/$1,662.61) × 100 = 330.81 percent). Therefore, we stated that we believe the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the second cost significance requirement.
                    </P>
                    <P>
                        The third cost significance requirement, at § 419.66(d)(3), provides that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $5,500.00 for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter and the portion of the APC payment amount for the device of $1,662.61 is 70.46 percent of the APC payment amount for the related service of $5,445.84 ((($5,500.00 − 
                        <PRTPAGE P="94139"/>
                        $1,662.61)/$ 5,445.84) × 100 = 70.46 percent). Therefore, we stated that we believe the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the third cost significance requirement.
                    </P>
                    <P>
                        We invited public comment on whether the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the device pass-through payment criteria discussed in this section, including the cost criterion for device pass-through payment status.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to cost significance criteria, the applicant and a commenter reiterated that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets all three of the cost significance criteria.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and commenter's input. After consideration of the public comments received and our findings from the first, second, and third cost significance tests, we agree that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the cost significance criteria specified at § 419.66(d).
                    </P>
                    <P>
                        After consideration of the public comments received and our review of the device pass-through application, we have determined that the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter meets the requirements for device pass-through status described at § 419.66. We are finalizing approval for device pass-through payment status for the AGENT
                        <E T="51">TM</E>
                         Paclitaxel-Coated Balloon Catheter effective January 1, 2025 under the alternative pathway for devices that have an FDA Breakthrough Device designation and have received FDA marketing authorization for the indication covered by the Breakthrough Device designation.
                    </P>
                    <HD SOURCE="HD3">
                        (b) Aveir
                        <E T="51">TM</E>
                         DR Dual Chamber Leadless Pacemaker System
                    </HD>
                    <P>
                        Abbott Laboratories submitted an application for a new device category for transitional pass-through payment status for the Aveir
                        <E T="51">TM</E>
                         DR Dual Chamber Leadless Pacemaker System (Aveir
                        <E T="51">TM</E>
                         DR System) for CY 2025. Per the applicant, the Aveir
                        <E T="51">TM</E>
                         DR System is comprised of two leadless pacemakers, one atrial and one ventricular with each containing a generator and electrodes, that provide dual-chamber pacing therapy after being placed within the heart's myocardium through a minimally invasive catheter-based procedure. According to the applicant, the Aveir
                        <E T="51">TM</E>
                         DR System is without the need for traditional wire electrodes and can provide beat-to-beat communication and synchrony between the two pacemakers for the treatment of arrhythmia/bradycardia. Per the applicant, patients with indication for dual-chamber pacing would benefit from a dual-chamber leadless pacemaker system that provides atrial and ventricular bradycardia therapy, while eliminating the complications associated with conventional pacing systems.
                    </P>
                    <P>
                        Please refer to the online application posting for the Aveir
                        <E T="51">TM</E>
                         DR System, available at 
                        <E T="03">https://mearis.cmsgov/public/publications/device-ptp/DEP230831B8DX0</E>
                        , for additional detail describing the device and the disease treated by the device.
                    </P>
                    <P>
                        As stated previously, to be eligible for transitional pass-through payment under the OPPS, a device must meet the criteria at § 419.66(b)(1) through (4). With respect to the newness criterion at § 419.66(b)(1), the Aveir
                        <E T="51">TM</E>
                         DR System received FDA Breakthrough Device designation effective March 27, 2020, as a pacemaker implantation indicated in one or more of the following permanent conditions: syncope, presyncope, fatigue, disorientation due to arrhythmia/bradycardia, or any combination of these symptoms. FDA approved the premarket approval application (PMA) for the Aveir
                        <E T="51">TM</E>
                         DR System on June 29, 2023, for the indication covered by the Breakthrough Device designation. We received the application for a new device category for transitional pass-through payment status for the Aveir
                        <E T="51">TM</E>
                         DR System on March 23, 2023, which is within 3 years of the date of the initial FDA marketing authorization.
                    </P>
                    <P>
                        We invited public comment on whether the Aveir
                        <E T="51">TM</E>
                         DR System meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        We did not receive public comments regarding whether the Aveir
                        <E T="51">TM</E>
                         DR System meets the newness criterion at § 419.66(b)(1). The Aveir
                        <E T="51">TM</E>
                         DR System received FDA Breakthrough Device designation effective March 27, 2020. We received the application for a new device category for transitional pass-through payment status for the Aveir
                        <E T="51">TM</E>
                         DR System on March 23, 2023, which is within 3 years of June 29, 2023, the date of FDA PMA. Based on our review of the application, we have determined that the Aveir
                        <E T="51">TM</E>
                         DR System meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        With respect to the eligibility criteria at § 419.66(b)(3), the device must be an integral part of the service furnished, used for one patient only, come in contact with human tissue and be surgically inserted or implanted, or applied in or on a wound or other skin lesion. As noted in the proposed rule, the applicant did not indicate whether the Aveir
                        <E T="51">TM</E>
                         DR System is integral to the service furnished. The applicant also did not explicitly state that the Aveir
                        <E T="51">TM</E>
                         DR System is single-use; however, the applicant did state that one Aveir
                        <E T="51">TM</E>
                         DR System is required per patient per procedure. While the applicant did not explicitly state whether the Aveir
                        <E T="51">TM</E>
                         DR System comes in contact with human tissue or is surgically inserted or implanted, the applicant noted that the two Aveir
                        <E T="51">TM</E>
                         Delivery Catheters are inserted into the peripheral vasculature and the cardiovascular system to deliver and implant the Aveir
                        <E T="51">TM</E>
                         AR Atrial Leadless Pacemaker and the Aveir
                        <E T="51">TM</E>
                         VR Ventricular Leadless Pacemaker into the right atrium and right ventricle of the heart, respectively.
                    </P>
                    <P>
                        We invited public comment on whether the Aveir
                        <E T="51">TM</E>
                         DR System meets the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment confirming that the Aveir
                        <E T="51">TM</E>
                         DR System is an integral part of the service provided, is used for one patient only, comes in contact with human tissue, and is surgically inserted or implanted using two delivery catheters that are inserted into the peripheral vasculature and cardiovascular system to deliver and implant the Aveir
                        <E T="51">TM</E>
                         AR Atrial Leadless Pacemaker and the Aveir
                        <E T="51">TM</E>
                         VR Ventricular Leadless Pacemaker into the right atrium and right ventricle of the heart, respectively. The applicant also stated that therefore, it believes the Aveir
                        <E T="51">TM</E>
                         DR System meets the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. We agree with the applicant that the Aveir
                        <E T="51">TM</E>
                         DR System is an integral part of the service furnished, is used for one patient only, comes in contact with human tissue, and is surgically implanted or inserted, or applied in or on a wound or other skin lesion. After consideration of the public comment received and our review of the application, we have determined that the Aveir
                        <E T="51">TM</E>
                         DR System meets the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        With respect to the exclusion criterion at § 419.66(b)(4), a device is not eligible to be considered for device pass-through payment if it is any of the following: (1) equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15-1); or (2) a material or supply furnished incident to a service (for example, a suture, customized surgical kit, or clip, other than a radiological site marker). The applicant did not indicate whether the Aveir
                        <E T="51">TM</E>
                         DR System is equipment, an instrument, apparatus, implement, or item of this type for which depreciating and financing expenses are recovered, 
                        <PRTPAGE P="94140"/>
                        or if the Aveir
                        <E T="51">TM</E>
                         DR System is a supply or material furnished incident to a service.
                    </P>
                    <P>
                        We invited public comment on whether the Aveir
                        <E T="51">TM</E>
                         DR System meets the exclusion criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant confirmed that the Aveir
                        <E T="51">TM</E>
                         DR System is not an instrument, apparatus, implement, or similar item for which depreciation and financing expenses are recovered. The applicant also stated that the Aveir
                        <E T="51">TM</E>
                         DR System is not a supply or material furnished incident to a service, and therefore, meets the eligibility criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. With respect to the eligibility criterion at § 419.66(b)(4), we agree with the applicant that the Aveir
                        <E T="51">TM</E>
                         DR System is not equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets, or a material or supply furnished incident to a service. After consideration of the public comment received and our review of the application, we have determined that the Aveir
                        <E T="51">TM</E>
                         DR System meets the eligibility criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        In addition to the criteria at § 419.66(b)(1) through (4), the criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. The applicant asserted that the Aveir
                        <E T="51">TM</E>
                         DR System is the only dual-chamber leadless pacemaker authorized by FDA and indicated for implantation in patients with one or more of the following permanent conditions: syncope, presyncope, fatigue, disorientation due to arrhythmia/bradycardia, or any combination of those conditions. Per the applicant, the Aveir
                        <E T="51">TM</E>
                         DR System is a modular dual-chamber leadless pacemaker system with bidirectional implant-to-implant communication that can accommodate all pacing indications. According to the applicant, no previous or existing device categories for pass-through payment appropriately describe the Aveir
                        <E T="51">TM</E>
                         DR System. The applicant stated that device categories C1785 (Pacemaker, dual-chamber, rate-responsive (implantable)) and C1889 (Insertable/implantable device, not otherwise classified) do not appropriately describe the Aveir
                        <E T="51">TM</E>
                         DR System because the Aveir
                        <E T="51">TM</E>
                         DR System received Breakthrough Device designation from FDA and has specific functionality and capabilities that are new to the market. The applicant also asserted that the Aveir
                        <E T="51">TM</E>
                         DR system is modular, such that a single device can be implanted in a heart chamber initially, and the second pacemaker added to the other heart chamber in the future should the clinical need arise; and therefore, it is not appropriately described by either C1785 or C1889.
                    </P>
                    <P>
                        We did not identify an existing pass-through payment category that describes the Aveir
                        <E T="51">TM</E>
                         DR System. We invited public comment on whether the Aveir
                        <E T="51">TM</E>
                         DR System meets the device category criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant agreed with CMS's assessment that there are no existing pass-through payment categories that describe the Aveir
                        <E T="51">TM</E>
                         DR System.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. After consideration of the public comment received and our review of the application, we continue to believe that there is no existing category or category previously in effect that appropriately describes the Aveir
                        <E T="51">TM</E>
                         DR System. Therefore, we have determined that the Aveir
                        <E T="51">TM</E>
                         DR System meets the device category eligibility criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines either of the following: (i) that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment; or (ii) for devices for which pass-through status will begin on or after January 1, 2020, as an alternative to the substantial clinical improvement criterion, the device is part of the FDA's Breakthrough Devices Program and has received FDA marketing authorization for the indication covered by the Breakthrough Device designation. The Aveir
                        <E T="51">TM</E>
                         DR System has a Breakthrough Device designation and marketing authorization from FDA for the indication covered by the Breakthrough Device designation (as explained in more detail in the discussion of the newness criterion), and therefore, is not evaluated for substantial clinical improvement.
                    </P>
                    <P>
                        We invited public comment on whether the Aveir
                        <E T="51">TM</E>
                         DR System meets the device category criterion at § 419.66(c)(2)(ii).
                    </P>
                    <P>
                        We did not receive public comment regarding whether the Aveir
                        <E T="51">TM</E>
                         DR System meets the device category criterion at § 419.66(c)(2)(ii). However, the Aveir
                        <E T="51">TM</E>
                         DR System has a Breakthrough Device designation effective March 27, 2020, and a marketing authorization from FDA effective June 29, 2023, for the indication covered by the Breakthrough Device designation. Therefore, the Aveir
                        <E T="51">TM</E>
                         DR System meets the criterion at § 419.66(c)(2)(ii) and is not evaluated for substantial clinical improvement at § 419.66(c)(2)(i). Based on our review of the application, we have determined that the Aveir
                        <E T="51">TM</E>
                         DR System meets the device category criterion at § 419.66(c)(2).
                    </P>
                    <P>
                        The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. The applicant stated that the Aveir
                        <E T="51">TM</E>
                         DR System would be reported with HCPCS codes as shown in Table 114.
                    </P>
                    <GPH SPAN="3" DEEP="247">
                        <PRTPAGE P="94141"/>
                        <GID>ER27NO24.141</GID>
                    </GPH>
                    <P>
                        To meet the cost criterion for device pass-through payment status, a device must pass all three tests of the cost criterion for at least one APC. As we explained in the CY 2005 OPPS final rule (69 FR 65775), we generally use the lowest APC payment rate applicable for use with the nominated device when we assess whether a device meets the cost significance criterion, thus increasing the probability the device will pass the cost significance test. Beginning in CY 2017, we calculate the device offset amount at the HCPCS/CPT code level instead of the APC level (81 FR 79657). We noted that the applicant used the CY 2023 payment rates for the three tests of the cost criterion. For our calculations, we used APC 5224, which had a CY 2023 payment rate of $18,672.01 at the time the application was received. We used the CY 2023 APC level device offset amount of $11,739.09 for APC 5224, as HCPCS codes 0795T and 0801T provided by the applicant were not included in Addendum P to the CY 2023 OPPS/ASC final rule with comment period and no CY 2023 HCPCS/CPT code level device offset amount was available at the time the application was received.
                        <SU>33</SU>
                        <FTREF/>
                         According to the applicant, the cost of the Aveir
                        <E T="51">TM</E>
                         DR System is $24,000.00.
                    </P>
                    <FTNT>
                        <P>
                            <SU>33</SU>
                             We noted that the applicant originally utilized APC 5231 (Level 1 ICD and Similar Procedures) for the three tests of the cost criteria in the application. However, the applicant provided supplemental information indicating that, HCPCS codes 0795T and 0801T were assigned to APC 5224 (Level 4 Pacemaker and Similar Procedures) in the corrected Addendum B to the CY 2024 OPPS/ASC final rule with comment period and they believed that APC 5224 is currently the appropriate APC for the purposes of performing the cost significance calculations. We agreed with the applicant and selected APC 5224 for our calculation, which we believe is a more appropriate APC to use based on the assignment of HCPCS codes 0795T and 0801T to APC 5224 and the clinical similarity to other pacemaker insertion codes in APC 5224.
                        </P>
                    </FTNT>
                    <P>
                        Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The average reasonable cost of $24,000.00 for the Aveir
                        <E T="51">TM</E>
                         DR System is 128.54 percent of the applicable APC payment amount for the service related to the category of devices of $18,672.01 (($24,000.00/$18,672.01) × 100 = 128.54 percent). Therefore, we stated that we believe the Aveir
                        <E T="51">TM</E>
                         DR System meets the first cost significance requirement.
                    </P>
                    <P>
                        The second cost significance requirement, at § 419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $24,000.00 for the Aveir
                        <E T="51">TM</E>
                         DR System is 204.45 percent of the cost of the device-related portion of the APC payment amount for the related service of $11,739.09 (($24,000.00/$11,739.09) × 100 = 204.45 percent). Therefore, we stated that we believe the Aveir
                        <E T="51">TM</E>
                         DR System meets the second cost significance requirement.
                    </P>
                    <P>
                        The third cost significance requirement, at § 419.66(d)(3), provides that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $24,000.00 for the Aveir
                        <E T="51">TM</E>
                         DR System and the portion of the APC payment amount for the device of $11,739.09 is 65.66 percent of the APC payment amount for the related service of $18,672.01 ((($24,000.00−$11,739.09)/$ 18,672.01) × 100 = 65.66 percent). Therefore, we stated that we believe the Aveir
                        <E T="51">TM</E>
                         DR System meets the third cost significance requirement.
                    </P>
                    <P>
                        We invited public comment on whether the Aveir
                        <E T="51">TM</E>
                         DR System meets the device pass-through payment criteria discussed in this section, including the cost criterion for device pass-through payment status.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to cost significance criteria, the applicant reiterated that the Aveir
                        <E T="51">TM</E>
                         DR System meets all three of the cost significance criteria.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. After consideration of the public comment we received and our findings from the first, second, and third cost significance tests, we agree that the Aveir
                        <E T="51">TM</E>
                         DR System meets the cost significance criteria specified at § 419.66(d).
                        <PRTPAGE P="94142"/>
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment requesting that CMS revise the proposed device offset for HCPCS code 0795T (Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (
                        <E T="03">e.g.,</E>
                         fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (
                        <E T="03">e.g.,</E>
                         interrogation or programming), when performed; complete system (
                        <E T="03">i.e.,</E>
                         right atrial and right ventricular pacemaker components)) used to report dual-chamber leadless pacemaker procedures.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input regarding the device offset amount associated with HCPCS code 0795T. We note that we have addressed this comment in Section IV.B of this final rule with comment period.
                    </P>
                    <P>
                        As discussed, the Aveir
                        <E T="51">TM</E>
                         DR System pass-through application was preliminarily approved for transitional pass-through payment under the alternative pathway effective July 1, 2024. After consideration of the public comment we received and our review of the device pass-through application, we have determined that the Aveir
                        <E T="51">TM</E>
                         DR System meets the requirements for device pass-through status described at § 419.66 and we are finalizing approval for device pass-through payment status for the Aveir
                        <E T="51">TM</E>
                         DR System under the alternative pathway for devices that have an FDA Breakthrough Device designation and have received FDA marketing authorization for the indication covered by the Breakthrough Device designation.
                    </P>
                    <HD SOURCE="HD3">
                        (c) The DETOUR
                        <E T="51">TM</E>
                         System
                    </HD>
                    <P>
                        Endologix, LLC submitted an application for a new device category for transitional pass-through payment status for the DETOUR
                        <E T="51">TM</E>
                         System for CY 2025. According to the applicant, the DETOUR
                        <E T="51">TM</E>
                         System is an implantable component, used to create a femoropopliteal bypass routed through the femoral vein. The DETOUR
                        <E T="51">TM</E>
                         System is comprised of two main components: (1) the TORUS
                        <E T="51">TM</E>
                         Stent Graft System, which is comprised of the TORUS
                        <E T="51">TM</E>
                         Stent Graft and the TORUS
                        <E T="51">TM</E>
                         Stent Graft Delivery System, and (2) the ENDOCROSS
                        <E T="51">TM</E>
                         Device. Per the applicant, the DETOUR
                        <E T="51">TM</E>
                         System is used to treat patients with advanced peripheral vascular disease, specifically those with long complex femoropopliteal artery stenoses and occlusions resulting in lifestyle limiting claudication or severe lower limb threatening ischemia. According to the applicant, the DETOUR
                        <E T="51">TM</E>
                         System can restore arterial blood flow to the lower limb around the blocked femoral artery and allows for venous blood flow around the conduit for normal venous return, to reduce signs and symptoms of lower limb ischemia and prevent amputation.
                    </P>
                    <P>
                        Please refer to the online application posting for the DETOUR
                        <E T="51">TM</E>
                         System, available at 
                        <E T="03">https://mearis.cms.gov/public/publications/device-ptp/DEP23090164QL2</E>
                        , for additional detail describing the device and the disease treated by the device.
                    </P>
                    <P>
                        As stated previously, to be eligible for transitional pass-through payment under the OPPS, a device must meet the criteria at § 419.66(b)(1) through (4). With respect to the newness criterion at § 419.66(b)(1), the DETOUR
                        <E T="51">TM</E>
                         System received FDA Breakthrough Device designation effective September 2, 2020, under the name the PQ Bypass System, as a device intended for percutaneous revascularization of symptomatic femoropopliteal lesions 200mm to 460mm with a chronic total occlusion 100mm to 425mm, and/or moderate-to-severe calcification, and/or in-stent-restenosis in patients with severe peripheral arterial disease. FDA approved the premarket approval application (PMA) for the DETOUR
                        <E T="51">TM</E>
                         System on June 7, 2023, indicated for use for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis &gt;70 percent who may be considered suboptimal candidates for surgical or alternative endovascular treatments. The DETOUR
                        <E T="51">TM</E>
                         System, or any of its components, is not for use in the coronary and cerebral vasculature. We noted that while the indication for the FDA Breakthrough Device designation and the indication for the FDA premarket approval vary slightly, we stated we believe that FDA premarket approval indication is the indication covered by the Breakthrough Device designation. We received the application for a new device category for transitional pass-through payment status for the DETOUR
                        <E T="51">TM</E>
                         System on September 1, 2023, which is within 3 years of the date of the initial FDA marketing authorization.
                    </P>
                    <P>
                        We invited public comment on whether the DETOUR
                        <E T="51">TM</E>
                         System meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        We did not receive public comments regarding whether the DETOUR
                        <E T="51">TM</E>
                         System meets the newness criterion at § 419.66(b)(1). The DETOUR
                        <E T="51">TM</E>
                         System received FDA Breakthrough Device designation effective September 2, 2020. We received the application for a new device category for transitional pass-through payment status for the DETOURÔ System on September 1, 2023, which is within 3 years of June 7, 2023, the date of FDA PMA. Based on our review of the application, we have determined that the DETOUR
                        <E T="51">TM</E>
                         System meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        With respect to the eligibility criteria at § 419.66(b)(3), the device must be an integral part of the service furnished, used for one patient only, come in contact with human tissue, and be surgically inserted or implanted, or applied in or on a wound or other skin lesion. Per the applicant, the DETOUR
                        <E T="51">TM</E>
                         System is integral to the service provided and is used for one patient only. While the applicant did not indicate whether the DETOUR
                        <E T="51">TM</E>
                         System comes in contact with human tissue, the applicant did specify that both components of the DETOUR
                        <E T="51">TM</E>
                         System, the TORUS
                        <E T="51">TM</E>
                         Stent Graft System and the ENDOCROSS
                        <E T="51">TM</E>
                         Device, are inserted or implanted during the percutaneous transmural femoropopliteal bypass procedure, as required by § 419.66(b)(3).
                    </P>
                    <P>
                        We invited public comments on whether the DETOUR
                        <E T="51">TM</E>
                         System meets the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        We did not receive public comments regarding whether the DETOUR
                        <E T="51">TM</E>
                         System meets the eligibility requirements of § 419.66(b)(3). As noted in the proposed rule, the applicant did not indicate that the DETOUR
                        <E T="51">TM</E>
                         System comes in contact with human tissue. However, because both components of the DETOUR
                        <E T="51">TM</E>
                         System, the TORUS
                        <E T="51">TM</E>
                         Stent Graft System and the ENDOCROSS
                        <E T="51">TM</E>
                         Device, are inserted or implanted during the percutaneous transmural femoralpopliteal bypass procedure, we believe that the DETOUR
                        <E T="51">TM</E>
                         System comes into contact with human tissue. After consideration of the information in the application, we have determined that the DETOUR
                        <E T="51">TM</E>
                         System meets the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        With respect to the exclusion criterion at § 419.66(b)(4), a device is not eligible to be considered for device pass-through payment if it is any of the following: (1) equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15-1); or (2) a material or supply furnished incident to a service (for example, a suture, customized surgical kit, or clip, other than a radiological site marker). The applicant asserted that the DETOUR
                        <E T="51">TM</E>
                         System meets the device eligibility 
                        <PRTPAGE P="94143"/>
                        requirements because it is not an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered, and it is not a supply or material furnished incident to a service.
                    </P>
                    <P>
                        We invited public comment on whether the DETOUR
                        <E T="51">TM</E>
                         System meets the exclusion criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        We did not receive public comments regarding whether the DETOUR
                        <E T="51">TM</E>
                         System meets the eligibility requirements of § 419.66(b)(4). Based on our review of the application, we agree with the applicant that the DETOUR
                        <E T="51">TM</E>
                         System is not equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets, or a material or supply furnished incident to a service. Therefore, we have determined that the DETOUR
                        <E T="51">TM</E>
                         System meets the eligibility criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        In addition to the criteria at § 419.66(b)(1) through (4), the criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. The applicant described that the DETOUR
                        <E T="51">TM</E>
                         System is a minimally invasive, single-use device with an implantable component, used to create a femoropopliteal bypass routed through the femoral vein. The applicant provided a list of existing and previous device categories for pass-through payment for other stents and explained why they do not believe any of the categories describe the DETOUR
                        <E T="51">TM</E>
                         System. In summary, the applicant asserted that the referenced device categories do not adequately describe the DETOUR
                        <E T="51">TM</E>
                         System because, in contrast to the DETOUR
                        <E T="51">TM</E>
                         System, the referenced device categories do not have: (1) a crossing device with long needle for transmural access, (2) a crossing device with high pressure needle delivery for heavily calcified and atherosclerotic arteries, (3) a high radial strength transmural stent graft capable of self-support and sustaining blood flow through conduit bridging artery to vein and back to artery, (4) a percutaneous stent graft delivery catheter, (5) a covered stent graft to allow for arterial blood flow within the conduit as venous blood flows around it in the vein, or (6) a permanent implant to maintain arterial and venous blood flow. The reasons the applicant asserted for why the DETOUR
                        <E T="51">TM</E>
                         System is not adequately described by each of the device categories are shown in Table 115.
                    </P>
                    <GPH SPAN="3" DEEP="379">
                        <GID>ER27NO24.142</GID>
                    </GPH>
                    <PRTPAGE P="94144"/>
                    <P>
                        We did not identify an existing pass-through payment category that describes the DETOUR
                        <E T="51">TM</E>
                         System.
                    </P>
                    <P>
                        We invited public comment on whether the DETOUR
                        <E T="51">TM</E>
                         System meets the device category criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        We did not receive any comments regarding whether the DETOUR
                        <E T="51">TM</E>
                         System meets the eligibility requirements at § 419.66(c)(1). Based on our review of the application, we continue to believe there is no existing category or category previously in effect that appropriately describes the DETOUR
                        <E T="51">TM</E>
                         System. Therefore, we have determined that the DETOUR
                        <E T="51">TM</E>
                         System meets the device category eligibility criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines either of the following: (i) that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment; or (ii) for devices for which pass-through status will begin on or after January 1, 2020, as an alternative to the substantial clinical improvement criterion, the device is part of the FDA's Breakthrough Devices Program and has received FDA marketing authorization for the indication covered by the Breakthrough Device designation. The DETOUR
                        <E T="51">TM</E>
                         System has a Breakthrough Device designation and marketing authorization from FDA for the indication covered by the Breakthrough Device designation (as explained in more detail in the discussion of the newness criterion), and therefore, is not evaluated for substantial clinical improvement.
                    </P>
                    <P>
                        We invited public comment on whether the DETOUR
                        <E T="51">TM</E>
                         System meets the device category criterion at § 419.66(c)(2).
                    </P>
                    <P>
                        We did not receive public comment regarding whether the DETOUR
                        <E T="51">TM</E>
                         System meets the device category criterion at § 419.66(c)(2). However, the DETOUR
                        <E T="51">TM</E>
                         System has a Breakthrough Device designation effective September 2, 2020, and marketing authorization from FDA effective June 7, 2023, for the indication covered by the Breakthrough Device. Therefore, the DETOUR
                        <E T="51">TM</E>
                         System meets the criterion at § 419.66(c)(2)(ii) and is not evaluated for substantial clinical improvement at § 419.66(c)(2)(i). Based on our review of the application, we have determined that the DETOUR
                        <E T="51">TM</E>
                         System meets the device category criterion at § 419.66(c)(2).
                    </P>
                    <P>
                        The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. The applicant stated that the DETOUR
                        <E T="51">TM</E>
                         System would be reported with the HCPCS code as shown in Table 116.
                    </P>
                    <GPH SPAN="3" DEEP="130">
                        <GID>ER27NO24.143</GID>
                    </GPH>
                    <P>
                        To meet the cost criterion for device pass-through payment status, a device must pass all three tests of the cost criterion for at least one APC. As we explained in the CY 2005 OPPS final rule (69 FR 65775), we generally use the lowest APC payment rate applicable for use with the nominated device when we assess whether a device meets the cost significance criterion, thus increasing the probability the device will pass the cost significance test. Beginning in CY 2017, we calculate the device offset amount at the HCPCS/CPT code level instead of the APC level (81 FR 79657). We noted that the applicant used the CY 2023 payment rates for the three tests of the cost criterion. For our calculations, like the applicant, we used APC 5193, which had a CY 2023 payment rate of $10,615.31 at the time the application was received. HCPCS code 0505T in APC 5193 had a CY 2023 device offset amount of $5,229.10 at the time the application was received. According to the applicant, the cost of the DETOUR
                        <E T="51">TM</E>
                         System is $25,000.00.
                    </P>
                    <P>
                        Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The average reasonable cost of $25,000.00 for the DETOUR
                        <E T="51">TM</E>
                         System is 235.51 percent of the applicable APC payment amount for the service related to the category of devices of $10,615.31 (($25,000.00/$10,615.31) × 100 = 235.51 percent). Therefore, we stated that we believe the DETOUR
                        <E T="51">TM</E>
                         System meets the first cost significance requirement.
                    </P>
                    <P>
                        The second cost significance requirement, at § 419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $25,000.00 for the DETOUR
                        <E T="51">TM</E>
                         System is 478.09 percent of the cost of the device-related portion of the APC payment amount for the related service of $5,229.10 (($25,000.00/$5,229.10) × 100 = 478.09 percent). Therefore, we stated that we believe the DETOUR
                        <E T="51">TM</E>
                         System meets the second cost significance requirement.
                    </P>
                    <P>
                        The third cost significance requirement, at § 419.66(d)(3), provides that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related 
                        <PRTPAGE P="94145"/>
                        service. The difference between the estimated average reasonable cost of $25,000.00 for the DETOUR
                        <E T="51">TM</E>
                         System and the portion of the APC payment amount for the device of $5,229.10 is 186.25 percent of the APC payment amount for the related service of $10,615.31 ((($25,000.00−$5,229.10)/$10,615.31) × 100 = 186.25 percent). Therefore, we stated that we believe the DETOUR
                        <E T="51">TM</E>
                         System meets the third cost significance requirement.
                    </P>
                    <P>
                        We invited public comment on whether the DETOUR
                        <E T="51">TM</E>
                         System meets the device pass-through payment criteria discussed in this section, including the cost criterion for device pass-through payment status.
                    </P>
                    <P>We did not receive any comments regarding whether the DETOURÔ System meets the cost significance criteria as described at § 419.66(d). Based on our findings from the first, second, and third cost significance tests, we have determined that the DETOURÔ System meets the cost significance criteria specified at § 419,66(d).</P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant commented that the device offset amount assigned to HCPCS code 0505T should remain at $0.00 to align with the precedent set for similarly situated devices and ensure that hospitals continue to receive full and fair reimbursement for C1604.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input regarding the device offset amount associated with HCPCS code 0505T. We note that we have addressed this comment in section IV.B of this final rule with comment period.
                    </P>
                    <P>
                        As discussed, the DETOUR
                        <E T="51">TM</E>
                         System pass-through application was preliminarily approved for transitional pass-through payment under the alternative pathway effective January 1, 2024. After our review of the device pass-through application, we have determined that the DETOURÔ System meets the requirements for device pass-through status described at § 419.66 and we are finalizing approval for device pass-through payment status for the DETOURÔ System under the alternative pathway for devices that have an FDA Breakthrough Device designation and have received FDA marketing authorization for the indication covered by the Breakthrough Device designation.
                    </P>
                    <HD SOURCE="HD3">
                        (d) EndoSound Vision System
                        <E T="51">TM</E>
                         (EVS
                        <E T="51">TM</E>
                        )
                    </HD>
                    <P>
                        EndoSound, Inc. submitted an application for a new device category for transitional pass-through payment status for the EVS
                        <E T="51">TM</E>
                         for CY 2025. The applicant is only seeking a new device category for transitional pass-through payment status for the Ultrasound Disposable Kit—Diagnostic/Therapeutic (UDK-T) component (hereinafter referred to as “UDK-T”) of the EVS
                        <E T="51">TM</E>
                        . According to the applicant, the EVS
                        <E T="51">TM</E>
                         is an ultrasound system designed to externally attach to an upper gastrointestinal (GI) endoscope (gastroscope/upper (EGD) endoscope). Per the applicant, the EVS
                        <E T="51">TM</E>
                         is a device that, once attached to an EGD endoscope, temporarily converts the EGD endoscope to a fully capable endoscopic ultrasound (EUS) endoscope. The applicant asserted that the EVS
                        <E T="51">TM</E>
                         can be coupled with an upper GI endoscope device to enable real-time ultrasound imaging, ultrasound guided needle aspiration, and other EUS guided procedures within the upper GI tract and surrounding organs. According to the applicant, the EVS
                        <E T="51">TM</E>
                         consists of: (1) the EVS Scanner, a beamformer/scanner that performs ultrasound signal processing; (2) the Ultrasound Transducer Module (UTM), a reusable transducer assembly that converts the electrical signals from the scanner into ultrasound energy; (3) the Transducer Extension Cable (TEC), a cable/connector to interface the UTM to the EVS Scanner; and (4) the UDK-T, a disposable mounting kit with an operator control mechanism used to externally affix the EVS
                        <E T="51">TM</E>
                         to a standard EGD endoscope and to provide needle and transducer angulation while maintaining the native gastroscope controls.
                    </P>
                    <P>
                        Please refer to the online application posting for the EVS
                        <E T="51">TM</E>
                        , available at 
                        <E T="03">https://mearis.cms.gov/public/publications/device-ptp/DEP240228GJT0X</E>
                        , for additional detail describing this device and the disease treated by the device.
                    </P>
                    <P>
                        As stated previously, to be eligible for transitional pass-through payment under the OPPS, a device must meet the criteria at § 419.66(b)(1) through (4). With respect to the newness criterion at § 419.66(b)(1), the EVS
                        <E T="51">TM</E>
                        , which includes the UDK-T, received FDA Breakthrough Device designation effective July 29, 2021, as a device intended to provide optical visualization of, ultrasonic visualization of, and therapeutic access to, the upper GI tract including but not restricted to the organs, tissues, and subsystems: esophagus, stomach, duodenum, and underlying areas. FDA granted the applicant 510(k) clearance for the EVS
                        <E T="51">TM</E>
                         on December 27, 2023, indicated for use such that when affixed to an endoscope, is intended to provide ultrasonic visualization of, and ultrasound guided therapeutic access to the upper GI tract including but not restricted to the organs, tissues, and subsystems: esophagus, stomach, duodenum, and underlying areas. The EVS
                        <E T="51">TM</E>
                        , mounted on an endoscope, is introduced orally when indications consistent with the requirement for a GI procedure are met. The EVS
                        <E T="51">TM</E>
                         is a prescription-only device to be used by a qualified physician. The clinical environments where the system can be used include clinics, hospitals, and ambulatory surgery centers. We noted that while the indication for the FDA Breakthrough Device designation and the indication for the FDA 510(k) clearance vary slightly, we stated we believe that the FDA 510(k) clearance indication is the one covered by the Breakthrough Device designation. We received the application for a new device category for transitional pass-through payment status for the EVS
                        <E T="51">TM</E>
                         on February 28, 2024, which is within 3 years of the date of the initial FDA marketing authorization.
                    </P>
                    <P>
                        We invited public comment on whether the EVS
                        <E T="51">TM</E>
                        , inclusive of the UDK-T component, meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to the newness criterion at § 419.66(b)(1), the applicant clarified that the EVS
                        <E T="51">TM</E>
                         received FDA market authorization for 510(k) clearance. The applicant asserted that, according to FDA guidance,
                        <SU>34</SU>
                        <FTREF/>
                         510(k) clearance is permissible for pre-determined Breakthrough Device designation and stated there were no changes specific to device components, mechanism of use, or indications of use for either the Breakthrough Device designation or the 510(k) clearance. The applicant stated the 510(k) clearance occurred within 3 years of the submission of the pass-through application such that the EVS
                        <E T="51">TM</E>
                         meets the newness criterion at 42 CFR 419.66(b)(1).
                    </P>
                    <FTNT>
                        <P>
                            <SU>34</SU>
                             See Breakthrough Devices Program, Guidance for Industry and Food and Drug Administration Staff Document issued on September 15, 2023. 
                            <E T="03">https://www.fda.gov/media/162413/download</E>
                            .
                        </P>
                    </FTNT>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's input. The EVS
                        <E T="51">TM</E>
                         received Breakthrough Device designation effective July 29, 2021. We received the application for a new device category for transitional pass-through payment status for the EVS
                        <E T="51">TM</E>
                         on February 28, 2024, which is within 3 years of December 27, 2023, the date of FDA 510(k) clearance. Based on our review of the application, we have determined that the EVS
                        <E T="51">TM</E>
                         meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        With respect to the eligibility criterion at § 419.66(b)(3), the device must be an integral part of the service furnished, used for one patient only, come in 
                        <PRTPAGE P="94146"/>
                        contact with human tissue, and be surgically inserted or implanted, or applied in or on a wound or other skin lesion. The applicant did not indicate whether the UDK-T component of the EVS
                        <E T="51">TM</E>
                         is integral to the service furnished; however, the applicant did indicate that the UDK-T is single-use, comes in contact with human tissue, and is inserted as part of an endoscopy procedure. We preliminarily approved the EVS
                        <E T="51">TM</E>
                         HCPCS code C1606 (Adapter, single-use (
                        <E T="03">i.e.,</E>
                         disposable), for attaching ultrasound system to upper gastrointestinal endoscope) upon quarterly review under the alternative pathway with an effective date of July 1, 2024. We noted that C1606 was established for an adapter for attaching an ultrasound system to an upper GI endoscope that can only be used for a single procedure and cannot be reprocessed. As such, C1606 only describes devices that cannot be reprocessed.
                    </P>
                    <P>
                        We invited public comment on whether the UDK-T component of the EVS
                        <E T="51">TM</E>
                         meets the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment reiterating that the EVS
                        <E T="51">TM</E>
                         is used for one patient, comes into contact with human tissue, and is surgically implanted or inserted. The applicant clarified that the C1606 device component (
                        <E T="03">i.e.,</E>
                         the UDK-T component) of the EVS
                        <E T="51">TM</E>
                         meets the § 419.66(b)(3) criteria and is integral to the function and operation of the EVS
                        <E T="51">TM</E>
                        . The applicant further commented that C1606 was established for an adapter for attaching an ultrasound system to an upper GI endoscope that can only be used for a single procedure and cannot be reprocessed. The applicant asserted that the C1606 device component of the EVS
                        <E T="51">TM</E>
                         meets the eligibility criterion at 42 CFR 419.66(b)(3).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's clarification. We agree with the applicant that the UDK-T component of the EVS
                        <E T="51">TM</E>
                         is integral to the function and operation of the EVS
                        <E T="51">TM</E>
                         and that the device is used for one patient only, comes into contact with human tissue, and is surgically implanted or inserted. After consideration of the applicant's comments and our review of the application we have determined that the UDK-T component of the EVS
                        <E T="51">TM</E>
                         meets the eligibility requirement at § 419.66(b)(3).
                    </P>
                    <P>With respect to the exclusion criterion at § 419.66(b)(4), a device is not eligible to be considered for device pass-through payment if it is any of the following: (1) equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15-1); or (2) a material or supply furnished incident to a service (for example, a suture, customized surgical kit, or clip, other than a radiological site marker). The applicant claimed that the UDK-T meets the device eligibility requirements because it is not equipment or an item for which depreciation and financing expenses are recovered. In addition, the applicant asserted that the UDK-T is not a supply or material.</P>
                    <P>
                        We invited public comment on whether the UDK-T component of the EVS
                        <E T="51">TM</E>
                         meets the exclusion criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment reiterating that the UDK-T component of the EVS
                        <E T="51">TM</E>
                         is not equipment or an item for which depreciation and financing expenses are recovered and is not a supply or material.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. We agree with the applicant that the UDK-T component of the EVS
                        <E T="51">TM</E>
                         is not equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets, or a material or supply furnished incident to a service. After consideration of the applicant comments we received and our review of the application, we have determined that the UDK-T component of the EVS
                        <E T="51">TM</E>
                         meets the eligibility criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        In addition to the criteria at § 419.66(b)(1) through (4), the criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. According to the applicant, the EVS
                        <E T="51">TM</E>
                         is an ultrasound system designed to externally attach to an upper GI endoscope (gastroscope/upper (EGD) endoscope). According to the applicant, no previous or existing device categories for pass-through payment appropriately describe the UDK-T. Per the applicant, device category C1748 (Endoscope, single-use (
                        <E T="03">i.e.,</E>
                         disposable), Upper GI, imaging/illumination device (insertable)) does not appropriately describe the EVS
                        <E T="51">TM</E>
                        , inclusive of the UDK-T, because: (1) the EVS
                        <E T="51">TM</E>
                        , inclusive of the UDK-T, enables an endoscope that a hospital has to have added functionalities such as the ability to perform an EUS procedure, but is not an endoscope like the devices in C1748; (2) the EVS
                        <E T="51">TM</E>
                        , inclusive of the UDK-T, when used with an endoscope allows EUS procedures to be done without an elevator, unlike the other devices described in C1748; and (3) the EVS
                        <E T="51">TM</E>
                        , inclusive of the UDK-T, and the devices described in C1748 are used in different procedures. The applicant explained that CMS indicated that C1748 should always be billed with a HCPCS code in the ranges of 43260-43265 and 43274-43278, but there is no overlap between those HCPCS codes billed with C1748 and the HCPCS codes the applicant stated that the EVS
                        <E T="51">TM</E>
                         would be reported with as shown in Table 48 of the CY 2025 OPPS/ASC proposed rule.
                    </P>
                    <P>
                        We did not identify an existing pass-through payment category that describes the UDK-T component of the EVS
                        <E T="51">TM</E>
                        .
                    </P>
                    <P>
                        We invited public comment on whether the UDK-T component of the EVS
                        <E T="51">TM</E>
                         meets the device category criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant agreed with CMS' assessment that there are no existing pass-through payment categories that describe the UDK-T component of the EVS
                        <E T="51">TM</E>
                        . The applicant further asserted that there is no other product similar in how the EVS
                        <E T="51">TM</E>
                         assembles, operates, and functions and that, therefore, the device meets the criteria in 42 CFR 419.66(c)(1).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. After consideration of the comment and our review of the application, we continue to believe that there is no existing category or category previously in effect that appropriately describes the UDK-T component of the EVS
                        <E T="51">TM</E>
                        . Therefore, we have determined that the UDK-T component of the EVS
                        <E T="51">TM</E>
                         meets the device category eligibility criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines either of the following: (i) that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment; or (ii) for devices for which pass-through status will begin on or after January 1, 2020, as an alternative to the substantial clinical improvement criterion, the device is part of the FDA's Breakthrough Devices Program and has received FDA marketing authorization for the indication covered by the Breakthrough 
                        <PRTPAGE P="94147"/>
                        Device designation. The EVS
                        <E T="51">TM</E>
                        , inclusive of the UDK-T, has a Breakthrough Device designation and marketing authorization from FDA for the indication covered by the Breakthrough Device designation (as explained in more detail in the discussion of the newness criterion) and therefore is not evaluated for substantial clinical improvement.
                    </P>
                    <P>
                        We invited public comment on whether the EVS
                        <E T="51">TM</E>
                        , inclusive of the UDK-T component, meets the device category criterion at § 419.66(c)(2)(ii).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant reiterated that the EVS
                        <E T="51">TM</E>
                         and its components were granted Breakthrough Device designation and received FDA marketing authorization for the indication covered by the Breakthrough Device designation, and therefore, meets the criteria at 42 CFR 419.66(c)(2)(ii).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's comment. The EVS
                        <E T="51">TM</E>
                         and its components have a Breakthrough Device designation effective July 29, 2021, and marketing authorization from FDA effective December 27, 2023, for the indication covered by the Breakthrough designation. Therefore, the EVS
                        <E T="51">TM</E>
                         meets the criterion at § 419.66(c)(2)(ii) and is not evaluated for substantial clinical improvement at § 419.66(c)(2)(i). Based on our review of the application and the applicant's comments, we have determined that the EVS
                        <E T="51">TM</E>
                         meets the device category criterion at § 419.66(c)(2).
                    </P>
                    <P>
                        The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. The applicant stated that the EVS
                        <E T="51">TM</E>
                         would be reported with HCPCS codes as shown in Table 117.
                    </P>
                    <GPH SPAN="3" DEEP="409">
                        <GID>ER27NO24.144</GID>
                    </GPH>
                    <P>
                        To meet the cost criterion for device pass-through payment status, a device must pass all three tests of the cost criterion for at least one APC. As we explained in the CY 2005 OPPS final rule (69 FR 65775), we generally use the lowest APC payment rate applicable for use with the nominated device when we assess whether a device meets the cost significance criterion, thus increasing the probability the device will pass the cost significance test. Beginning in CY 2017, we calculate the device offset amount at the HCPCS/CPT code level instead of the APC level (81 FR 79657). We noted that the applicant used the CY 2024 payment rates for the three tests of the cost criterion. For our calculations, 
                        <PRTPAGE P="94148"/>
                        we used APC 5302, which had a CY 2024 payment rate of $1,812.99 at the time the application was received. HCPCS code 43232 in APC 5302 had a CY 2024 device offset amount of $14.50 at the time the application was received.
                        <SU>35</SU>
                        <FTREF/>
                         According to the applicant, the cost of the disposable, single-use UDK-T component of the EVS
                        <E T="51">TM</E>
                         is $500.00.
                    </P>
                    <FTNT>
                        <P>
                            <SU>35</SU>
                             We noted that the applicant selected the APC payment rate of $1,814.88 and the APC level device offset amount of $178.95 for APC 5302. However, the values selected are inconsistent with the APC payment rate and the APC level device offset amount found in CY 2024 OPPS APC Offset File, which were corrected as described in the CY 2024 OPPS/ASC final rule with comment period correction (89 FR 9002). The HCPCS/CPT code level device offset amounts for the HCPCS/CPT codes provided by the applicant are available in the corrected Addendum P to the CY 2024 OPPS/ASC final rule with comment period. For our calculation, we selected the APC payment rate of $1,812.99 and the HCPCS/CPT code level device offset amount of $14.50 related to HCPCS 43232 in APC 5302 found in the corrected Addendum P, which are the accurate values for these codes. Based on our initial assessment in the proposed rule, using the APC payment rate of $1,812.99 and the device offset amount of $14.50 would result in the EVS
                            <E T="51">TM</E>
                             meeting the cost significance requirement.
                        </P>
                    </FTNT>
                    <P>
                        Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The average reasonable cost of $500.00 for the UDK-T is 27.59 percent of the applicable APC payment amount for the service related to the category of devices of $1,812.99 (($500.00/$1,812.99) × 100 = 27.59 percent). Therefore, we stated that we believe the UDK-T component of the EVS
                        <E T="51">TM</E>
                         meets the first cost significance requirement.
                    </P>
                    <P>
                        The second cost significance requirement, at § 419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $500.00 for the UDK-T is 3,448.28 percent of the cost of the device-related portion of the APC payment amount for the related service of $14.50 (($500.00/$14.50) × 100 = 3,448.28 percent). Therefore, we stated that we believe the UDK-T component of the EVS
                        <E T="51">TM</E>
                         meets the second cost significance requirement.
                    </P>
                    <P>
                        The third cost significance requirement, at § 419.66(d)(3), provides that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $500.00 for the UDK-T and the portion of the APC payment amount for the device of $14.50 is 26.78 percent of the APC payment amount for the related service of $1,812.99 ((($500.00 − $14.50)/$1,812.99) × 100 = 26.78 percent). Therefore, we stated that we believe the UDK-T component of the EVS
                        <E T="51">TM</E>
                         meets the third cost significance requirement.
                    </P>
                    <P>
                        We invited public comment on whether the UDK-T component of the EVS
                        <E T="51">TM</E>
                         meets the device pass-through payment criteria discussed in this section, including the cost criterion for device pass-through payment status.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to the cost criterion, the applicant agreed that the UDK-T component of the EVS
                        <E T="51">TM</E>
                         meets all three of the cost criterion outlined in 42 CFR 419.66(c)(3) and (d)(1) through (3).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. After consideration of the comment we received and our findings from the first, second, and third cost significance tests, we agree that the UDK-T component of the EVS
                        <E T="51">TM</E>
                         meets the cost significance criteria specified at § 419.66(d).
                    </P>
                    <P>
                        As discussed, the UDK-T component of the EVS
                        <E T="51">TM</E>
                         pass-through application was preliminarily approved for transitional pass-through payment under the alternative pathway effective July 1, 2024. After considering the applicant comment received and our review of the device pass-through application, we have determined that the UDK-T component of EVS
                        <E T="51">TM</E>
                         meets the requirements for device pass-through status described at § 419.66. We are finalizing approval for device pass-through payment status for the UDK-T component of the EVS
                        <E T="51">TM</E>
                         under the alternative pathway for devices that have an FDA Breakthrough Device designation and have received FDA marketing authorization for the indication covered by the Breakthrough Device designation.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant commented that HCPCS codes 43240 and 43253 should be added to the list of procedures that can be reported with C1606. The applicant stated that in Table 48 of the CY 2025 OPPS/ASC proposed rule, there are 6 primary HCPCS procedures codes reported with the nominated device, including HCPCS codes 43231, 43232, 43237, 43238, 43242, and 43259. The applicant stated that in the July 2024 ASC code pairs file,
                        <SU>36</SU>
                        <FTREF/>
                         dated June 14, 2024, 8 primary HCPCS procedures codes were listed with HCPCS code C1606, which included the HCPCS codes listed included those listed in proposed rule, with the addition of HCPCS codes 43240 and 43253. The applicant agreed with the preliminary approval of pass-through status for the nominated device and requested that it should be made clear that the 8 procedures codes on the July 2024 ASC code pairs file for C1606 are the procedures that can be reported with C1606.
                    </P>
                    <FTNT>
                        <P>
                            <SU>36</SU>
                             July 2024 ASC code pairs file: 
                            <E T="03">https://www.cms.gov/license/ama?file=/files/zip/july-2024-asc-codepairs.zip.</E>
                        </P>
                    </FTNT>
                    <P>
                        <E T="03">Response:</E>
                         We thank the applicant for the comment. We will evaluate this request and add HCPCS codes 43240 and 43253 to the list of procedures that can be reported with C1606 if appropriate.
                    </P>
                    <HD SOURCE="HD3">
                        (e) iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System
                    </HD>
                    <P>
                        SI-BONE submitted an application for a new device category for transitional pass-through payment status for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System for CY 2025. According to the applicant, the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System consists of iFuse Granite
                        <E T="51">TM</E>
                         implants of various lengths and diameters and associated instruments sets. The titanium (Ti-6Al-4V ELI) iFuse Granite
                        <E T="51">TM</E>
                         implant consists of a porous fusion sleeve with threaded length attached to a solid post that has connection and implant placement features of a typical pedicle fixation screw. The iFuse Granite
                        <E T="51">TM</E>
                         implant is intended to provide sacropelvic fusion of the sacroiliac joint (when placed in the sacral-alar-iliac (SAI) trajectory) and fixation to the pelvis when used in conjunction with commercially available pedicle screw fixation systems as a foundational element for segmental spinal fusion only when performing both a lumbar and a sacroiliac joint (SIJ) fusion procedure in the same operative session. The applicant asserted that joint fusion occurs as a result of the device's porous surface and interstices and fixation occurs through the device's helical threaded design and traditional posterior fixation rod connection.
                    </P>
                    <P>
                        Per the applicant, the device can be placed into the pelvis in two trajectories: the SAI trajectory (
                        <E T="03">i.e.,</E>
                         into the sacrum, across the SIJ and into the ilium), or directly into the ilium. The applicant explained that the iFuse Granite
                        <E T="51">TM</E>
                         implant is typically placed in the SAI trajectory, bilaterally, and 
                        <PRTPAGE P="94149"/>
                        oftentimes stacked to achieve two points of fusion and fixation/stabilization across each SIJ. According to the applicant, the iFuse Granite
                        <E T="51">TM</E>
                         implant may also be used in a single, but bilateral, configuration, where only two implants may be required when replacing traditional pedicle screws in either a SAI trajectory or iliac trajectory. The applicant asserted that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is always used in addition to lumbar fusion instrumentation when used to perform lumbar and SIJ fusion at the same time.
                    </P>
                    <P>
                        Please refer to the online application posting for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System, available at 
                        <E T="03">https://mearis.cms.gov/public/publications/device-ptp/DEP240220LPFNM,</E>
                         for additional detail describing the device and the disease treated by the device.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         One commenter strongly encouraged CMS to consider the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System as having met all requirements for transitional pass-through payment status for CY 2025 and noting that that the device has Breakthrough Device designation for lumbar spinal deformity indications and was granted with New Technology Add-on Payment status effective in FY 2023 (87 FR 48780).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' input and support for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System application for transitional pass-through payment. We have taken these comments into consideration in our final determination for pass-through status for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System.
                    </P>
                    <P>
                        As stated previously, to be eligible for transitional pass-through payment under the OPPS, a device must meet the criteria at § 419.66(b)(1) through (4). With respect to the newness criterion at § 419.66(b)(1), the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System received FDA Breakthrough Device designation effective November 23, 2021, as a treatment of the acute and chronic instabilities or deformities of the thoracic, lumbar, and sacral spine, including: (1) degenerative disc disease (DDD), as defined by back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies; (2) severe spondylolisthesis (Grades 3 and 4) of the L5-S1 vertebra; (3) skeletally mature patients receiving fusions by autogenous bone graft having implants attached to the lumbar and sacral spine (L3 to sacrum) with removal of the implants after the attainment of a solid fusion; (4) spondylolisthesis; (5) trauma (
                        <E T="03">i.e.,</E>
                         fracture or dislocation); (6) spinal stenosis; (7) deformities or curvatures (
                        <E T="03">i.e.,</E>
                         scoliosis, kyphosis, and/or lordosis); (8) spinal tumor; and (9) pseudarthrosis, and/or failed previous fusion. Subsequently, FDA also granted the applicant 510(k) clearance for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System on May 26, 2022, and December 22, 2022, for the indication covered by the Breakthrough Device designation with one additional indication for use: SIJ dysfunction that is a direct result of SIJ disruption and degenerative sacroiliitis, including conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. We noted that the 510(k) clearance dated December 22, 2022, expanded the previously cleared indication of the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System to include general compatibility with certain compatible pedicle screw systems, whereas the indications under the May 26, 2022, 510(k) clearance only addressed compatibility of the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System with the SeaSpine Mariner Pedicle Screw System. Each 510(k) clearance, the May 26, 2022, and the December 22, 2022, are covered by the November 23, 2021, Breakthrough Device designation for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System. We received the application for a new device category for transitional pass-through payment status for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System on February 20, 2024, which is within 3 years of the dates of the May 26, 2022, and December 22, 2022, FDA marketing authorizations for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System.
                    </P>
                    <P>
                        We invited public comment on whether the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to the newness criterion at § 419.66(b)(1), the applicant reiterated that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System received FDA marketing authorization on May 26, 2022. The applicant requested that CMS begin the newness period for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System using the FDA Breakthrough Device designation of November 23, 2021, and the earlier market availability date of May 26, 2022, for the 510(k) marketing authorization.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. We agree with the applicant that the market availability date for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System should be May 26, 2022, rather than December 22, 2022, because that is when the device became commercially available. We received the application for a new device category for transitional pass-through payment status for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System on February 20, 2024, which is within 3 years of May 26, 2022, the date of 510(k) clearance. After consideration of the public comments received and our review of the application, we have determined that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        With respect to the eligibility criterion at § 419.66(b)(3), the device must be an integral part of the service furnished, used for one patient only, come in contact with human tissue, and be surgically inserted or implanted, or applied in or on a wound or other skin lesion. The applicant did not indicate if the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is integral to the service furnished. The applicant provided that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is single-use, permanently implanted, and surgically inserted into the patient. However, we noted that we do not have sufficient information to determine if the associated instruments sets included in the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meet the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        We invited public comment on whether the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment clarifying that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System, including the associated instrument sets included in the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System, meet the eligibility criterion at § 419.66(b)(3). Specifically, the applicant stated that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System technology, including the associated instrument sets is integral to the service furnished, is single-use, permanently implanted, and surgically inserted into the patient, aligning fully with § 419.66(b)(3).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the applicant for the additional information. We agree with the applicant that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System, including the associated instrument sets, is an integral part of the service furnished, used for one patient only, comes in contact with human tissue, and is surgically implanted or inserted, or applied in or on a wound or other skin lesion. After consideration of the public comments received and our review of the application, we have determined that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        With respect to the exclusion criterion at § 419.66(b)(4), a device is not eligible to be considered for device pass-through 
                        <PRTPAGE P="94150"/>
                        payment if it is any of the following: (1) equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15-1); or (2) a material or supply furnished incident to a service (for example, a suture, customized surgical kit, or clip, other than a radiological site marker). The applicant did not indicate whether the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered, or if the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is a supply or material furnished incident to a service.
                    </P>
                    <P>
                        We invited public comment on whether the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the exclusion criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment clarifying that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is not a material or supply furnished incident to a service and meets the eligibility criterion at § 419.66(b)(4) because neither the implant nor its associated instrument sets are a material or supply furnished incident to a service, and that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System operates like a vast majority of spine and orthopedic hardware typically used in surgery of this type. The applicant also confirmed that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is not equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. We agree with the applicant that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System, including the associated instruments, is not equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets, or a material or supply such as a suture or clip furnished incident to a service. After consideration of the public comments received and our review of the application, we have determined that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the eligibility criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        In addition to the criteria at § 419.66(b)(1) through (4), the criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. According to the applicant, no previous or existing device categories for pass-through payment appropriately describe the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System. Per the applicant, the device category C1821 (Interspinous process distraction device) does not appropriately describe the iFuse Bedrock Granite
                        <SU>TM</SU>
                         Implant System because the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is used to fixate and fuse, while the devices described in C1821 are interspinous spacers which, after implantation, are opened or expanded to distract the neural foramina and decompress the nerves. The applicant asserted that device category C1713 (Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)) also does not appropriately describe the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System because the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System allows for simultaneous fusion of the SIJ and fixation of the pelvis by connecting via the Tulip Connector to the base of the stabilizing rods within the lumbosacral spinal construct, while C1713 includes implantable pins and/or screws that are used to oppose soft tissue-to-bone, tendon-to-bone, or bone-to-bone. Per the applicant, the device category C1889 (Implantable/insertable device, not otherwise classified) also does not appropriately describe the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System because it does not describe any specific device category, and therefore does not uniquely describe the device category proposed for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System.
                    </P>
                    <P>
                        We noted that, according to the applicant, the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is intended to provide sacropelvic fusion of the sacroiliac joint (when placed in the SAI trajectory) and fixation to the pelvis when used in conjunction with commercially available pedicle screw fixation systems as a foundational element for segmental spinal fusion only when performing both a lumbar and SIJ fusion procedure in the same operative session. The applicant asserted that joint fusion occurs as a result of the device's porous surface and interstices and fixation occurs through the device's helical threaded design and traditional posterior fixation rod connection. We stated that we believe that the device category C1713 may appropriately describe the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System and questioned whether a transfixing device utilizing the Tulip Connector is sufficiently distinguishable from traditional implantable pins or screws that it is meant to replace. In this context, based on the description the applicant provided, we stated that we believe the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System may be similar to the devices described by C1713, and therefore, the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System may also be appropriately described by C1713.
                    </P>
                    <P>
                        In addition, we stated that we believe the device category C1889 may appropriately describe the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System because C1889 may be used to describe any implantable/insertable device that is not otherwise described by a more specific device category and is, therefore, sufficiently broad to include implantable devices that allow for simultaneous fusion of the SIJ and fixation of the pelvis. We noted that in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79562), CMS created C1889 with the specific intent to recognize devices furnished during a device intensive procedure that are not described by a specific Level II HCPCS Category C-code. In this context, we stated that we believe the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System may be appropriately described by either C1713 or C1889.
                    </P>
                    <P>
                        We invited public comment on whether the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the device category criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         In response to our concerns that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System may be appropriately described by the device pass-through category C1713, the applicant and a few other commenters asserted that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is not described by C1713. Specifically, the applicant relied upon the C1713 descriptor and supporting guidance: C1713: Anchor for opposing bone-to-bone or soft tissue-to-bone—Implantable pins and/or screws that are used to oppose soft tissue-to-bone, tendon-to-bone, or bone-to-bone. Screws oppose tissues via drilling as follows: soft tissue-to-bone, tendon-to-bone, or bone to-bone fixation. Pins are inserted or drilled into bone, principally with the intent to facilitate stabilization or oppose bone-to-bone. This may include orthopedic plates with accompanying washers and nuts. This category also applies to synthetic bone substitutes that may be used to fill bony void or gaps (
                        <E T="03">i.e.,</E>
                         bone substitute implanted into a bony defect created from trauma or surgery). The applicant and commenters clarified that, unlike 
                        <PRTPAGE P="94151"/>
                        devices described by C1713, the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System's intended use is not to anchor bone to bone, or soft tissue, tendons, or ligaments to bone, but to promote simultaneous pelvic stabilization and fusion across the SI joint space, via a unique and proprietary Tulip Connector that attaches to the spinal fusion construct. The applicant and another commenter further provided that the typical use scenarios for reporting C1713 include orthopedic procedures involving bone sutures, anchors, small plastic polyether ether ketone (PEEK) screws for bone-to-bone or bone-to-tendon/tissue connections, often in anatomic areas outside of the spine (including the extremities, shoulders, knees and small bones). Furthermore, the applicant and commenter noted that C1713 is used to report procedures that are mostly non-fusion applications with the intent to restore motion or function to anatomy(ies) and that C1713 can also include bone void filler or bone substitute materials (
                        <E T="03">e.g.,</E>
                         demineralized bone matrix, Subchondroplasty, etc.).
                    </P>
                    <P>
                        The applicant and commenters specified that other implanted devices in this category restore motion while the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System immobilizes; and that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is intended to traverse an articulating joint space and fuse two bones via bridging the joint to immobilize it so bony fusion may occur.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant and commenters' clarifications and the additional information. We agree that the ability to simultaneously fuse the SIJ and fixate the pelvis to the spinal fusion construct distinguishes the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System from other implant devices described by C1713 that anchor bone-to-bone, or soft tissue-to-bone, tendons-to-bone, or ligaments-to-bone. We also agree that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is distinguishable from other implant devices described by C1713 because it secures bone to a metal rod via the Tulip Connector, and that typical C1713 implants do not include joint fusion technologies, and are not specific to anatomic areas, nor do they function similarly to the iFuse Bedrock Granite
                        <E T="51">TM</E>
                        .
                    </P>
                    <P>
                        After consideration of the public comments we received and our review of the application, we agree that existing device category C1713 does not appropriately describe the iFuse Bedrock Granite
                        <E T="51">TM</E>
                        .
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         In response to our concerns that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System may be appropriately described by C1889, the applicant and a few commenters noted that C1889 is not, and has not been, a device pass-through category code, and that it is not included in the complete list of device pass-through category codes.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' input. We agree that C1889 is not a device pass-through category code, and therefore, agree that it is not relevant to our determination at § 419.66(c)(1).
                    </P>
                    <P>
                        After consideration of the public comments received and our review of the application, we agree there is no existing category or category previously in effect that appropriately describes the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System. Based on this information, we have determined that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the eligibility criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        The second criterion for establishing a device category at § 419.66(c)(2) provides that CMS determines either of the following: (i) that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment; or (ii) for devices for which pass-through status will begin on or after January 1, 2020, as an alternative to the substantial clinical improvement criterion, the device is part of the FDA's Breakthrough Devices Program and has received FDA marketing authorization for the indication covered by the Breakthrough Device designation. The iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System has a Breakthrough Device designation and marketing authorization from FDA for the indication covered by the Breakthrough Device designation (as explained in the discussion of the newness criterion) and therefore is not evaluated for substantial clinical improvement.
                    </P>
                    <P>
                        We invited public comment on whether the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the device category criterion at § 419.66(c)(2)(ii).
                    </P>
                    <P>
                        We did not receive any public comment regarding whether the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the device category criterion at § 419.66(c)(2)(ii). The iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System has a Breakthrough Device designation effective November 23, 2021, and marketing authorization from FDA effective May 26, 2022, for the indication covered by the Breakthrough Device designation. Based on our review of the application, we have determined that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the device category criterion at § 419.66(c)(2)(ii) and is not evaluated for substantial clinical improvement at § 419.636(c)(2)(i).
                    </P>
                    <P>
                        The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. The applicant stated that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System would be reported with HCPCS codes shown in Table 118.
                    </P>
                    <GPH SPAN="3" DEEP="191">
                        <PRTPAGE P="94152"/>
                        <GID>ER27NO24.145</GID>
                    </GPH>
                    <P>
                        According to the applicant, the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is only used when both a SIJ fusion procedure and a lumbar fusion procedure are performed in the same operative session. The applicant stated that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is not utilized when only a SIJ fusion procedure is performed (HCPCS code 27279) or when only a lumbar fusion procedure is performed (HCPCS code 22612, 22630, or 22633). Rather, per the applicant, the appropriate coding of the procedure where the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is used should include the HCPCS code for SIJ fusion (HCPCS code 27279) 
                        <E T="03">and</E>
                         a HCPCS code for lumbar fusion (HCPCS code 22612, 22630, or 22633). Per the applicant, the selection of the primary lumbar fusion HCPCS code (HCPCS code 22612, 22630, or 22633) is dependent on the procedure performed.
                    </P>
                    <P>
                        To meet the cost criterion for device pass-through payment status, a device must pass all three tests of the cost criterion for at least one APC. As we explained in the CY 2005 OPPS final rule (69 FR 65775), we generally use the lowest APC payment rate applicable for use with the nominated device when we assess whether a device meets the cost significance criterion, thus increasing the probability the device will pass the cost significance test. Beginning in CY 2017, we calculate the device offset amount at the HCPCS/CPT code level instead of the APC level (81 FR 79657). We noted that the applicant utilized the CY 2024 payment rates for the three tests of the cost criterion. For our calculations, we used APC 5116, which had a CY 2024 payment rate of $17,756.28 at the time the application was received. The applicant stated the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System device should be reported with the SIJ fusion procedure HCPCS code 27279 along with one of the three lumbar fusion procedures (HCPCS code 22612, 22630 or 22633). While the applicant utilized HCPCS code 22612 for the device offset amount for test two of the cost criterion, we stated that we believe that HCPCS code 27279 is the appropriate HCPCS code for the offset and subsequent calculation. Specifically, we understood that code 27279 is always reported when the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is used along with only one of the three specified lumbar fusion codes and that the SIJ fusion procedure described by code 27279 is always performed when the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         is used along with just one of three possible lumbar procedures, depending on the specific surgical approach used. Therefore, we stated that we believe that neither HCPCS codes 22612, 22630, nor 22633 is appropriate to use for the cost criterion calculation. As such, we used HCPCS code 27279, the code that should always be reported with the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System, for our calculations. HCPCS code 27279 in APC 5116 had a CY 2024 device offset amount of $12,264.26 at the time the application was received. According to the applicant, the cost of the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is $11,689.00.
                    </P>
                    <P>
                        Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The average reasonable cost of $11,689.00 for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is 65.83 percent of the applicable APC payment amount for the service related to the category of devices of $17,756.28 (($11,689.00/$17,756.28) × 100 = 65.83 percent). Therefore, we stated that we believe the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the first cost significance requirement.
                    </P>
                    <P>
                        The second cost significance requirement, at § 419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $11,689.00 for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is 95.31 percent of the cost of the device-related portion of the APC payment amount for the related service of $12,264.26 (($11,689.00/$12,264.26) × 100 = 95.31 percent). Therefore, we stated that we believe the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System does not meet the second cost significance requirement.
                    </P>
                    <P>
                        The third cost significance requirement, at § 419.66(d)(3), provides that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $11,689.00 for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System and the portion of the APC payment amount for the device of $12,264.26 is negative 3.24 percent of the APC payment amount for the related service of $17,756.28 ((($11,689.00−$12,264.26)/$17,756.28) × 100 =−3.24 percent). Therefore, we stated that we believe the iFuse Bedrock 
                        <PRTPAGE P="94153"/>
                        Granite
                        <E T="51">TM</E>
                         Implant System does not meet the third cost significance requirement.
                    </P>
                    <P>
                        We invited public comment on whether the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the device pass-through payment criteria discussed in this section, including the cost criterion for device pass-through payment status.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         In response to our proposal to utilize HCPCS code 27279 for evaluation of cost criteria for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System, the applicant and another commenter asserted that the most appropriate HCPCS code to evaluate the criterion for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is HCPCS code 22612. The applicant and another commenter provided several reasons: (1) The intended indication and use of the nominated device in the hospital outpatient and ASC setting will be in support of the lumbar spinal construct for lumbar fusion cases; (2) The typical patient for the nominated device has severe lumbar spinal pathology, such as scoliosis or kyphosis of the lumbar spine, as the primary diagnosis, whereas sacroiliac joint disease or dysfunction is not the primary diagnosis or procedure indication for these patients; and (3) As evidence of the consensus on this type of pelvic fixation to support lumbar patients, numerous commercial payers across the U.S. agree and have published medical coverage policies stating that SI joint fusion at the bottom of a long construct is covered for treatment of lumbar disease or dysfunction.
                        <SU>37</SU>
                        <FTREF/>
                         The applicant claimed that in the outpatient setting, the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System would always be used in conjunction with one of three spinal fusion procedures and would always be considered as a secondary procedure. The applicant stated that of the four relevant HCPCS codes in its application (HCPCS codes 22612, 22630, 22633, and 27279), the threshold for HCPCS code 22612 is the most appropriate for evaluating the cost criterion for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System. The applicant provided the following reasons: (1) HCPCS code 22612 is the only lumbar spinal fusion procedure payable by Medicare in both hospital outpatient and ASC settings; (2) HCPCS code 22612 has a lower device offset, consistent with CMS' policies; and (3) HCPCS code 22612 is the primary code in spinal fusion procedures in which the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         will always be used as an adjunctive technology, when connected to compatible posterior spinal rods, to improve the potential outcome of the lumbar fusion case. Finally, the applicant argued that HCPCS code 22612 would also be appropriate from a primary assignment rank perspective, stating that since the nominated device will have multiple J1 HCPCS codes, it would be appropriate to determine which HCPCS code has the highest primary assignment ranking. The applicant referenced Addendum J of the CY 2024 final rule and the CY 2025 proposed rule stating that HCPCS code 22612 has a higher ranking for primary assignment purposes than HCPCS code 27279. The applicant claimed that it would be consistent with CMS' policy on assignment of primary procedures to select the cost threshold for HCPCS code 22612, as opposed to HCPCS code 27279, to assess the cost criterion for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System.
                    </P>
                    <FTNT>
                        <P>
                            <SU>37</SU>
                             Anthem CG-SURG-111: “Open sacroiliac joint fusion procedures are considered medically necessar y. . . 
                            <E T="03">during multisegment spinal constructs (for example, correction of deformity in scoliosis or kyphosis surgery) extending to the ilium.</E>
                            ” Ref: 
                            <E T="03">https://www.anthem.com/dam/medpolicies/abcbs/active/guidelines/gl_pw_e001136.html</E>
                             (accessed August 24, 2024).
                        </P>
                    </FTNT>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for the additional information. Based on the updated information provided in the comments, we agree HCPCS code 22612 is an appropriate procedure code for the evaluation of the cost criterion for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System. As such, we have updated our calculations accordingly for the second and third cost significance requirements, at § 419.66(d)(2) and (3), respectively as below.
                    </P>
                    <P>
                        The second cost significance requirement, at § 419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The average reasonable cost of $11,689 for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System is 136.75 percent of the cost of the device-related portion of the APC payment amount for the related service of $8,547.88 (($11,689.00/$8,547.88) × 100 = 136.75 percent). Therefore, we agree that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the second cost significant requirement.
                    </P>
                    <P>
                        The third cost significance requirement, at § 419.66(d)(3), provides that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $11,689.00 for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System and the portion of the APC payment amount for the device of $8,547.88 is 17.70 percent of the APC payment amount for the related service of $17,756.28 ((($11,689.00−$8,547.88)/$17,756.28) × 100 = 17.70 percent). Therefore, we agree that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the third cost significance requirement.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant and another commenter stated that they believe it is appropriate for CMS to use the lowest APC payment rate applicable for use with the nominated device regarding the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System, stating that this is consistent with increasing probability that the device will pass the cost significance test. The applicant and another commenter asserted that CMS should likewise use the offset amount that gives the nominated device the best opportunity to pass the test, arguing that HCPCS code 22612 is the most appropriate code for assessing the cost threshold in this context.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters for their input. As we explained in the CY 2005 OPPS/ASC final rule with comment period (69 FR 65775), we generally use the lowest APC payment rate applicable for use with the nominated device when we assess whether a device meets the cost significance criterion. We note that in both the original evaluation of cost in the proposed rule as well as in the re-evaluation in this final rule, we followed this procedure by selecting the lowest, and in this case only, APC payment rate applicable for APC 5116 of $17,756. While we note that since 2017, we calculate the device offset amount at the HCPCS/CPT® code level instead of the APC level (89 FR 79657), we disagree that we are bound by the same policy to select the HCPCS code with the lowest offset amount. We believe that doing so would potentially conflict with our stated policy of selecting the lowest APC payment rate, which is intended to increase the probability the device will pass the cost significance test. We do, however, agree to use HCPCS code 22612 and its device offset amount for the evaluation of the cost criterion for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System, based on the updated information we received in the comments.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant requested that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System be approved for the transitional pass-through status and the 
                        <PRTPAGE P="94154"/>
                        device offset amount should be set to $0. The applicant asserted that the costs of the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System are not included as part of the device-related portion of the APC 5116 payment supporting hospitals performing a primary lumbar fusion procedure. The applicant stated that hospital outpatient departments and ASCs do not typically support combination lumbar fusion with SI joint fusion procedures performed in the same operative session, and claims data reveals an extremely low volume of these codes being reported together each year in the HOPD setting relative to other code pairings. In addition, the applicant stated that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System cannot be used as a stand-alone device; rather, it will only be used in conjunction with one of three lumbar spinal fusion procedures. The applicant referred to the CY 2024 and CY 2025 Addendum J files and stated that all three HCPCS codes describing lumbar fusion which are eligible for payment in the hospital outpatient setting (HCPCS 22612, 22630, and 22633) are all ranked higher for primary assignment purposes than HCPCS code 27279. The applicant therefore argued that the device costs of the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System have not been appropriately included in the device offset of any of the fusion procedures. The applicant further stated that, since the costs of the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System are purely additive for hospitals currently performing lumbar spinal fusion procedures (HCPCS codes 22612, 22630, or 22633) mapping to Comprehensive APC 5116, the applicant requested that CMS set the device offset to $0 when granting transitional pass-through status for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System for CY 2025.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         After further review, we are persuaded by commenters that the iFuse Bedrock Granite
                        <SU>TM</SU>
                         Implant System cannot be used as a stand-alone device and that it is only used in conjunction with the existing device costs for the lumbar spinal fusion procedures. Therefore, we agree that the device is not included in the existing APC payment amount for these procedures and a device offset amount under 42 CFR 419.66(h) would not be appropriate at this time. For CY 2025, for the procedures we described that are performed with this new transitional pass-through device category, we are accepting the commenter's recommendation to apply a $0 offset for the iFuse Bedrock Granite
                        <SU>TM</SU>
                         Implant System. We refer the reader to Addendum B of this CY 2025 OPPS/ASC final rule with comment period for APC payment rates.
                    </P>
                    <P>
                        After consideration of the public comments we received and our findings from the first, second, and third cost significance tests, we agree that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         meets the cost significance criteria specified at § 419.66(d).
                    </P>
                    <P>
                        After consideration of the public comments we received and our review of the device pass-through application, we have determined that the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System meets the criteria for device pass-through status described at § 419.66. We are finalizing approval for device pass-through payment status for the iFuse Bedrock Granite
                        <E T="51">TM</E>
                         Implant System effective January 1, 2025, under the alternative pathway for devices that have an FDA Breakthrough Device Designation and have received FDA marketing authorization for the indication covered by the Breakthrough Device designation.
                    </P>
                    <HD SOURCE="HD3">(f) Paradise® Ultrasound Renal Denervation (RDN) System</HD>
                    <P>ReCor Medical, Inc. submitted an application for a new device category for transitional pass-through payment status for the Paradise® Ultrasound RDN System for CY 2025. Per the applicant, the Paradise® Ultrasound RDN System is a catheter-based system that delivers ultrasound energy in the location of sympathetic nerves surrounding the renal arteries. The applicant explained that the Paradise® Ultrasound RDN System is indicated to reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. According to the applicant, the Paradise® Catheter, when used with the other Paradise® Ultrasound RDN System components, provides complete 360-degree energy delivery and targeted ablation depth with each energy emission with the goal of disrupting the nerves and consequently achieving a reduction in systemic arterial blood pressure. The applicant asserted that the Paradise® Catheter protects the artery walls using a cooling system during periods of ultrasound energy emission (also called sonications).</P>
                    <P>
                        Per the applicant's instructions for use, the Paradise® Ultrasound RDN System includes the following components: (1) Paradise® Generator, which circulates coolant fluid and electrical energy to the Paradise® Catheter via the Paradise® Cable and Paradise® Cartridge; (2) Paradise® Catheter, which connects with the Paradise® Generator and has a distal balloon (available in six different diameters that correspond to varying artery diameter ranges) that is pressurized using coolant fluid; (3) Paradise® Cartridge, which controls the fluid flow into and out of the Paradise® Catheter when used in conjunction with the Paradise® Generator; (4) Paradise® Connection Cable, which transfers electrical energy from the Paradise® Generator to the Paradise® Catheter; (5) Paradise® Remote, included with the Paradise® Generator for optional use; and (6) Paradise® Cart, an optional wheeled cart to which the Paradise® Generator can be mounted to stabilize the Paradise® Generator during a procedure and to transport the Paradise® Generator from one location to another. Per the applicant, additional items required for the procedure include: (1) a bag of coolant fluid for inflation and cooling of balloon; (2) a 0.014 inch guidewire to track the Paradise® Catheter into position for delivery of ultrasound energy; (3) a push/pull style hemostasis valve; (4) a 6 French (Fr) or larger guide sheath; and (5) a 7 Fr or larger guide catheter. According to the applicant, the Paradise® Catheter, Paradise® Cartridge, and Paradise® Connection Cable are single-patient, one-time use components of the system. According to the applicant, key steps for operating the Paradise® Ultrasound RDN System include: (1) gaining access to the femoral artery using standard interventional techniques and placing a 7 Fr (or larger) guide catheter; (2) advancing the 7 Fr guide catheter into the left or right renal artery under fluoroscopic guidance; (3) performing an angiogram to verify the patency of the left or right renal artery; (4) measuring the distal, mid, and proximal artery diameters and selecting the appropriate Paradise® Catheter balloon size; (5) preparing and attaching the Paradise® Cartridge, Paradise® Connection Cable, and sterile water supply, and connecting the Paradise® Cartridge extension tubing to the Paradise® Catheter; (6) preparing and flushing the Paradise® Catheter; removing access devices from the lumen of the guide catheter and inserting a 0.014 inch guidewire; (7) verifying the balloon on the Paradise® Catheter is deflated; (8) tracking the Paradise® Catheter over the guidewire and gently inserting the Paradise® Catheter into the push/pull style hemostasis valve and guide catheter; (9) advancing and positioning the Paradise® Catheter in desired locations within the renal arteries; (10) inflating the balloon via 
                        <PRTPAGE P="94155"/>
                        the Paradise® Generator; (11) verifying the position of the balloon and catheter transducer via fluoroscopy and contrast injection; (12) performing denervation of the left and/or right renal artery by delivery of ultrasound energy; (13) verifying balloon deflation via fluoroscopy before moving to the next location; (14) withdrawing the Paradise® Catheter back into the guide catheter prior to moving the device into an alternate artery or accessory vessel, continuing to another position and exchanging the balloon catheter, as needed; (15) removing the Paradise® Catheter, ensuring that Paradise® Catheter balloon is in a deflated state prior to removal, by slowly withdrawing the Paradise® Catheter through the guide catheter, until completely withdrawn, and removing the guidewire and guide catheter; and (16) closing the wound per standard of practice.
                    </P>
                    <P>
                        Please refer to the online application posting for the Paradise® RDN System, available at 
                        <E T="03">https://mearis.cms.gov/public/publications/device-ptp/DEP231128137E1,</E>
                         for additional detail describing the device and the disease treated by the device.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Many commenters expressed their support for the approval of the Paradise® Ultrasound RDN System for transitional pass-through payment. In addition, many commenters shared their positive experiences with the Paradise® Ultrasound RDN System.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' input and support for the Paradise® Ultrasound RDN System application for transitional pass-through payment. We have taken these comments into consideration in our final determination for pass-through status for the Paradise® Ultrasound RDN System.
                    </P>
                    <P>As stated previously, to be eligible for transitional pass-through payment under the OPPS, a device must meet the criteria at § 419.66(b)(1) through (4). With respect to the newness criterion at § 419.66(b)(1), the Paradise® Ultrasound RDN System received FDA Breakthrough Device designation effective December 4, 2020, as a device with the indicated use to reduce blood pressure in adult (≥22 years of age) patients with uncontrolled hypertension, who may be inadequately responsive to, or who are intolerant to anti-hypertensive medications. FDA approved the premarket approval application (PMA) for the Paradise® Ultrasound RDN System on November 7, 2023, for the indicated use to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. We noted that while the indication for the FDA Breakthrough Device designation and the indication for the FDA premarket approval vary slightly, we believed that FDA premarket approval indication is the one covered by the Breakthrough Device designation. We received the application for a new device category for transitional pass-through payment status for the Paradise® Ultrasound RDN System on November 28, 2023, which is within 3 years of the date of the initial FDA marketing authorization.</P>
                    <P>We invited public comment on whether the Paradise® Ultrasound RDN System meets the newness criterion at § 419.66(b)(1).</P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to the newness criterion at § 419.66(b)(1), the applicant reiterated that the Paradise® Ultrasound RDN System received Breakthrough Device designation and later FDA approval on November 7, 2023, and CMS received the application for a new device category for transitional pass-through payment status on November 28, 2023, which is within 3 years of FDA approval. A few commenters stated the Paradise® Ultrasound RDN System meets the newness criterion, with one commenter specifically noting that the Paradise® Ultrasound RDN System meets the newness criterion based on its FDA Breakthrough Device designation.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' input. We agree with the applicant and commenters that the Paradise® Ultrasound RDN System meets the device eligibility requirements of § 419.66(b)(1); however, while we agree that the Paradise® Ultrasound RDN System meets the eligibility criterion specified at § 419.66(b)(1), we note that a device's uniqueness or FDA designation does not alone qualify a device for transitional pass-through payment. Specifically, when we adopted the alternative pathway for device pass-through payments under the OPPS, we stated that applications for devices that have received FDA marketing authorization and are part of the FDA Breakthrough Devices Program would not be evaluated in terms of the current substantial clinical improvement criterion at § 419.66(c)(2) for purposes of determining device pass-through payment status, but would continue to need to meet the other requirements for pass-through payment status in our regulations at § 419.66(c)(1) (84 FR 61295).
                    </P>
                    <P>The Paradise® Ultrasound RDN System received Breakthrough Device designation on December 4, 2020. We received the application for a new device category for transitional pass-through payment status for the Paradise® Ultrasound RDN System on November 28, 2023, which is within 3 years of November 7, 2023, the date of FDA PMA. Based on our review of the application, we have determined that the Paradise® Ultrasound RDN System meets the newness criterion at § 419.66(b)(1).</P>
                    <P>With respect to the eligibility criteria at § 419.66(b)(3), the device must be an integral part of the service furnished, be used for one patient only, come in contact with human tissue, and be surgically inserted or implanted, or applied in or on a wound or other skin lesion. The applicant did not explicitly state whether the Paradise® Ultrasound RDN System is integral to the service furnished. With respect to whether the Paradise® Ultrasound RDN System is used for one patient only, the applicant asserted that the Paradise® Catheter, Paradise® Cartridge, and Paradise® Connection Cable are single-patient use. However, the Paradise® Generator, Paradise® Remote, and Paradise® Cart are reusable and are capital equipment. While the applicant did not explicitly state whether the Paradise® Ultrasound RDN System comes into contact with human tissue, the applicant provided that the Paradise® Catheter is placed within the renal artery. According to the applicant, the Paradise® Ultrasound RDN System is an implantable device. We noted that the Paradise® Generator, Paradise® Remote, and Paradise® Cart are reusable, do not come in contact with the patient's tissue, are not surgically implanted or inserted, or applied in or on a wound or other skin lesion, as required by § 419.66(b)(3).</P>
                    <P>We invited public comment on whether the Paradise® Ultrasound RDN System meets the eligibility criterion at § 419.66(b)(3).</P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment clarifying that the Paradise® Ultrasound RDN System is an integral part of the service furnished and meets the eligibility criterion at § 419.66(b)(3) because the Paradise® Ultrasound RDN System performs the ablations via ultrasound which produce the therapeutic effect to reduce blood pressure. The applicant also clarified that the Paradise® Ultrasound RDN System comes into contact with human tissue and meets the eligibility criterion at § 419.66(b)(3) because the Paradise® Ultrasound RDN System's ablation catheter comes in contact with human tissue and is surgically inserted into the body and removed at the end of the procedure. Finally, the applicant reiterated that the Paradise® Connector 
                        <PRTPAGE P="94156"/>
                        Cable, Paradise® Cartridge, and Paradise® Catheter components of the Paradise® Ultrasound RDN System are single-use only and the Paradise® Catheter is surgically inserted into the body and removed at the end of the procedure.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. We agree with the applicant that the Paradise® Ultrasound RDN System is an integral part of the service furnished, and is surgically implanted or inserted, or applied in or on a wound or other skin lesion. In addition, we agree that the Paradise® Connector Cable, Paradise® Cartridge, and Paradise® Catheter components of the Paradise® Ultrasound RDN System are used for one patient only and come in contact with human tissue. We continue our discussion and final determination of the criterion at § 419.66(b)(3) in our response below.
                    </P>
                    <P>With respect to the exclusion criterion at § 419.66(b)(4), a device is not eligible to be considered for device pass-through payment if it is any of the following: (1) equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15-1); or (2) a material or supply furnished incident to a service (for example, a suture, customized surgical kit, or clip, other than a radiological site marker). While the applicant did not explicitly state whether the Paradise® Ultrasound RDN System, or select components, is equipment, an instrument, apparatus, implement, or item for which depreciation and financing expenses are recovered, per the applicant, the Paradise® Catheter, Paradise® Cartridge, and Paradise® Connection Cable are single-use only. The applicant further explained that the Paradise® Generator, Paradise® Cart, and Paradise® Remote are capital equipment; as such, they are excluded from device pass-through payment eligibility under § 419.66(b)(4). The applicant did not explicitly state whether the Paradise® Ultrasound RDN System is a supply or material furnished incident to a service.</P>
                    <P>The applicant requested pass-through payment for the Paradise® Ultrasound RDN System, but we questioned whether only the Paradise® Catheter component of the Paradise® Ultrasound RDN System, as opposed to the whole system, is eligible for pass-through payments under § 419.66(b)(3) or at § 419.66(b)(4). We stated that we do not believe the Paradise® Generator, Paradise® Cable, Paradise® Cartridge, Paradise® Connection Cable, Paradise® Remote, or Paradise® Cart meet the eligibility requirements under § 419.66(b)(3) or at § 419.66(b)(4), and, as such, are not eligible for pass-through payments.</P>
                    <P>We invited public comment on whether the Paradise® Ultrasound RDN System meets the exclusion criterion at § 419.66(b)(4).</P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment clarifying that the Paradise® Cartridge and Paradise® Connector Cable meet the eligibility criterion at § 419.66(b)(4) because they are critical parts of a single piece of equipment, they are not sold without the Paradise® Catheter, and because these two components are not separable from the Paradise® Catheter component. With regard to our question as to whether only the Paradise® Catheter component of the Paradise® Ultrasound RDN System is eligible for pass-through payments under § 419.66(b)(3) or at § 419.66(b)(4), the applicant stated that the Paradise® Cartridge and Paradise® Connector Cable are eligible for pass-through payment because the procedure cannot be performed without all three components, 
                        <E T="03">i.e.,</E>
                         the Paradise® Catheter, the Paradise® Cartridge, and the Paradise® Connector Cable. The applicant further stated that while the Paradise® Connector Cable and Paradise® Cartridge are not inserted into the body, the Paradise® Catheter that is inserted into the body will not function without them. Therefore, the applicant asserted that the Paradise® Connector Cable and Paradise® Cartridge should also be eligible for transitional pass-through status along with the Paradise® Catheter. The applicant also confirmed that the Paradise® Generator, Paradise® Remote, and Paradise® Cart components of the Paradise® Ultrasound RDN System are capital equipment and are not eligible for pass-through payment. With regard to our question about whether the Paradise® Ultrasound RDN System is a supply or material furnished incident to a service, the applicant submitted a comment clarifying that the Paradise® Ultrasound RDN System is not a supply or material furnished incident to a service because the purpose of the procedure is to use the Paradise® Ultrasound RDN System to treat the patient with renal denervation; therefore, it is integral and essential and it is not a supply that is used incident to or for the purpose of doing another procedure.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the applicant for the clarification and agree with the applicant that the Paradise® Catheter, Paradise® Cartridge, and Paradise® Connection Cable components of the Paradise® Ultrasound RDN System meet the eligibility requirements under § 419.66(b)(3) and (4) because the Paradise® Connector Cable and Paradise® Cartridge are required parts of a single piece of equipment, they are not sold without the Paradise® Catheter, they are single-use and they are not separable. We also agree with the applicant that the Paradise® Generator, Paradise® Remote, or Paradise® Cart are capital equipment and do not meet the eligibility requirements under § 419.66(b)(3) or (4). Finally, we agree with the applicant that the Paradise® Ultrasound RDN System is not a material or supply furnished incident to a service. After consideration of the public comments we received and our review of the application, we have determined that the applicable components of the Paradise® Ultrasound RDN System meet the eligibility criteria at § 419.66(b)(3) and (4).
                    </P>
                    <P>
                        In addition to the criteria at § 419.66(b)(1) through (4), the criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. Per the applicant, the Paradise® Ultrasound RDN System is a catheter-based system that delivers ultrasound energy in the location of sympathetic nerves surrounding the renal arteries. According to the applicant, no previous or existing device categories for pass-through payment have encompassed the Paradise® Ultrasound RDN System. Per the applicant, device categories C1753 (Catheter, intravascular ultrasound) and C1888 (Catheter, ablation, noncardiac, endovascular (implantable)) do not appropriately describe the Paradise® Ultrasound RDN System. The applicant asserted that C1753 does not appropriately describe the Paradise® Ultrasound RDN System because the Paradise® Ultrasound RDN System is used to treat a disease and denervates renal nerves, whereas C1753 was created to describe ultrasound catheter devices that are not used to treat a disease and are used for imaging of the vessel. According to the applicant, C1888 does not appropriately describe the Paradise® Ultrasound RDN System because the Paradise® Ultrasound RDN System is intended to denervate renal nerves by using ultrasound energy that does not otherwise affect the blood vessel tissue, whereas C1888 was 
                        <PRTPAGE P="94157"/>
                        created to describe devices that use radiofrequency or laser technologies to occlude or obliterate blood vessels.
                        <SU>38</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>38</SU>
                             The applicant referenced the Medicare Claims Processing Manual, Chapter 4 to support these assertions.
                        </P>
                    </FTNT>
                    <P>We did not identify an existing pass-through payment category that describes the Paradise® Ultrasound RDN System. We invited public comment on whether the Paradise® Ultrasound RDN System meets the device category criterion at § 419.66(c)(1).</P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant and a few other commenters agreed with CMS' assessment that there are no existing pass-through payment categories that describe the Paradise® Ultrasound RDN System.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' input. After consideration of the public comments we received and our review of the application, we continue to believe that there is no existing category or category previously in effect that appropriately describes the Paradise® Ultrasound RDN System. Therefore, we have determined that the Paradise® Ultrasound RDN System meets the device category eligibility criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        We noted that the applicant indicated the Paradise® Ultrasound RDN System is the only device authorized by FDA with an indication for renal denervation using ultrasound energy to achieve reductions in blood pressure. However, we noted that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter (Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System) device, for which we also received an application for transitional pass-through payments for CY 2025 as discussed in the proposed rule (89 FR 59312 through 59315) and this final rule with comment, is also authorized by FDA with an indication for renal denervation using a radiofrequency modality to achieve reductions in blood pressure. Accordingly, we noted that while the Paradise® Ultrasound RDN System device may have a different modality (
                        <E T="03">i.e.,</E>
                         ultrasound compared to radiofrequency) than that of the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter device, the Paradise® Ultrasound RDN System device may have a similar mechanism of action to that of the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter device. We questioned whether the device descriptions provided in the respective applications support establishing two modality specific pass-through payment device categories or a single device category that would encompass both RDN device modalities. We address this question in section (i) in detail immediately following the full discussion of all other applicable eligibility criteria for both the Paradise® Ultrasound RDN System and the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applications.
                    </P>
                    <P>
                        For the summary of public comments received and our final decision on the question of whether the device descriptions provided in the respective applications support establishing two modality-specific pass-through payment device categories or a single device category that would encompass both RDN device modalities, please see section (i) immediately following the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System application determination.
                    </P>
                    <P>The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines either of the following: (i) that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment; or (ii) for devices for which pass-through status will begin on or after January 1, 2020, as an alternative to the substantial clinical improvement criterion, the device is part of the FDA's Breakthrough Devices Program and has received FDA marketing authorization for the indication covered by the Breakthrough Device designation. As previously stated, the Paradise® Ultrasound RDN System has Breakthrough Device designation and marketing authorization from FDA for the indication covered by the Breakthrough Device designation (as explained in more detail in the discussion of the newness criterion) and therefore is not evaluated for substantial clinical improvement.</P>
                    <P>We invited public comment on whether the Paradise® Ultrasound RDN System meets the device category criterion at § 419.66(c)(2)(ii).</P>
                    <P>
                        <E T="03">Comment:</E>
                         A few commenters stated that the Paradise® Ultrasound RDN System meets the eligibility criterion at § 419.66(c)(2)(ii), with one commenter asserting that the Paradise® Ultrasound RDN System meets the clinical improvement criterion based on its FDA Breakthrough Device designation.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenter's input. We agree with the commenters that the Paradise® Ultrasound RDN System has a Breakthrough Device designation effective December 4, 2020, and marketing authorization from FDA effective November 7, 2023, for the indication covered by the Breakthrough Device designation and therefore, meets the criterion at § 419.66(c)(2)(ii) and is not evaluated for substantial clinical improvement at § 419.66(c)(2)(i). Based on our review of the application and consideration of the public comments we received, we have determined that the Paradise® Ultrasound RDN System meets the device category criterion at § 419.66(c)(2).
                    </P>
                    <P>The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. The applicant stated that the Paradise® Ultrasound RDN System would be reported with HCPCS codes shown in Table 119.</P>
                    <GPH SPAN="3" DEEP="306">
                        <PRTPAGE P="94158"/>
                        <GID>ER27NO24.146</GID>
                    </GPH>
                    <P>
                        To meet the cost criterion for device pass-through payment status, a device must pass all three tests of the cost criterion for at least one APC. As we explained in the CY 2005 OPPS final rule (69 FR 65775), we generally use the lowest APC payment rate applicable for use with the nominated device when we assess whether a device meets the cost significance criterion, thus increasing the probability the device will pass the cost significance test. Beginning in CY 2017, we calculate the device offset amount at the HCPCS/CPT code level instead of the APC level (81 FR 79657). We noted that the applicant used the CY 2023 payment rates for the three tests of the cost criterion. For our calculations, we used APC 5192, which had a CY 2023 payment rate of $5,215.40 at the time the application was received. We used the CY 2023 APC level device offset amount of $1,491.08 for APC 5192, since HCPCS codes 0338T and 0339T were not included in Addendum P to the CY 2023 OPPS/ASC final rule with comment period and no CY 2023 HCPCS/CPT code level device offset amount was available at the time the application was received.
                        <SU>39</SU>
                        <FTREF/>
                         According to the applicant, the operating cost 
                        <SU>40</SU>
                        <FTREF/>
                         of the Paradise® Ultrasound RDN System is $23,000.00.
                    </P>
                    <FTNT>
                        <P>
                            <SU>39</SU>
                             The applicant stated as neither HCPCS code 0338T nor 0339T had a device offset amount listed in Addendum P to the CY 2023 OPPS/ASC final rule with comment period, it selected a device offset amount of $0.00. However, for our calculation, we selected the CY 2023 APC level device offset amount of $1,491.08 for APC 5192 found in CY 2023 NFRM OPPS APC Offset File, as no CY 2023 HCPCS/CPT code level device offset amount was available at the time the application was received. Based on our initial assessment for the proposed rule, using the device offset amount of $1,491.08 would result in the Paradise® Ultrasound RDN System meeting the cost significance requirement.
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>40</SU>
                             According to the applicant, the current total cost of the Paradise® Ultrasound RDN System device is $23,235.00. For the cost criteria estimates, the applicant submitted an operating cost of $23,000.00 for the Paradise® Ultrasound RDN System device. Per the applicant, the individual component costs are as follows: Paradise® Remote (capital equipment) is $5.00; Paradise® Cart (capital equipment) is $5.00; Paradise® Generator (capital equipment) is $225.00; Paradise® RDN Catheter Kit (one time use) is $22,000.00; Paradise RDN Cable (one time use) is $250.00; and the Paradise® RDN Cartridge (one time use) is $750.00.
                        </P>
                    </FTNT>
                    <P>Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The average reasonable cost of $23,000.00 for the Paradise® Ultrasound RDN System is 441.00 percent of the applicable APC payment amount for the service related to the category of devices of $5,215.40 (($23,000.00/$5,215.40) × 100 = 441.00 percent). Therefore, we stated that we believe the Paradise® Ultrasound RDN System meets the first cost significance requirement.</P>
                    <P>The second cost significance requirement, at § 419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $23,000.00 for the Paradise® Ultrasound RDN System is 1,542.51 percent of the cost of the device-related portion of the APC payment amount for the related service of $1,491.08 (($23,000.00/$1,491.08) × 100 = 1,542.51 percent). Therefore, we stated that we believe the Paradise® Ultrasound RDN System meets the second cost significance requirement.</P>
                    <P>
                        The third cost significance requirement, at § 419.66(d)(3), provides that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $23,000.00 for the Paradise® Ultrasound 
                        <PRTPAGE P="94159"/>
                        RDN System and the portion of the APC payment amount for the device of $1,491.08 is 412.41 percent of the APC payment amount for the related service of $5,215.40 ((($23,000.00−$1,491.08)/$5,215.40) × 100 = 412.41 percent). Therefore, we stated that we believe the Paradise® Ultrasound RDN System meets the third cost significance requirement.
                    </P>
                    <P>We invited public comment on whether the Paradise® Ultrasound RDN System meets the device pass-through payment criteria discussed in this section, including the cost criterion for device pass-through payment status.</P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to cost significance criteria, the applicant and a few other commenters reiterated that the Paradise® Ultrasound RDN System meets all three of the cost significance criteria. The applicant further clarified that the Paradise® Ultrasound RDN System meets the cost criteria regardless of whether the Paradise® Cartridge and Paradise® Connection Cable are deemed eligible for pass-through or excluded from the calculation. The applicant stated that the Paradise® Cartridge and Paradise® Connection Cable should be included when evaluating the cost criteria because they are both single-use items that are required for the Paradise® Ultrasound RDN System to function as intended and are essential to complete each patient treatment.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and commenters' input. We agree with the applicant that the Paradise® Catheter, Paradise® Cartridge, and Paradise® Connection Cable are single-use components that are required for the Paradise® Ultrasound RDN System to function as intended and are essential to complete each patient treatment and should be included when evaluating the cost criteria. After consideration of the public comments we received and our findings from the first, second, and third cost significance tests, we agree that the Paradise® Catheter, Paradise® Cartridge, and Paradise® Connection Cable components of the Paradise® Ultrasound RDN System meet the cost significance criteria specified at § 419.66(d).
                    </P>
                    <P>After consideration of the public comments we received and our review of the device pass-through application, we have determined that the Paradise® Catheter, Paradise® Cartridge, and Paradise® Connection Cable components of the Paradise® Ultrasound RDN System meet the requirements for device pass-through status described at § 419.66. Therefore, effective beginning January 1, 2025, we are finalizing approval for device pass-through payment status for the applicable components of the Paradise® Ultrasound RDN System under the alternative pathway for devices that have an FDA Breakthrough Device designation and have received FDA marketing authorization for the indication covered by the Breakthrough Device designation.</P>
                    <HD SOURCE="HD3">(g) Precision GI</HD>
                    <P>Limaca Medical submitted an application for a new device category for transitional pass-through payment status for Precision GI for CY 2025. According to the applicant, Precision GI is a motorized, battery operated, single-use, fully disposable endoscopic ultrasound-guided (EUS) fine needle biopsy device used to obtain biopsies of tissue for definitive diagnosis of pancreatic cancer and other life-threatening gastrointestinal (GI) abnormalities. Per the applicant, Precision GI is untethered and battery operated with an internally powered and controlled motor, featuring a long flexible shaft transferring the proximal force of the motor through the inserted endoscope to the needle circumferential cutting tip. The device is controlled by a physician, who inserts the device into the patient's GI tract via the ultrasound endoscope. Upon reaching the designated biopsy site, the physician operates the device's motorized mechanism that automatically rotates the needle (which is included in the device's package) to cut and extract tissue. The biopsy site is accessed through the instrument channel of an ultrasound imaging endoscope that detects the device's echogenic needle tip.</P>
                    <P>
                        Please refer to the online application posting for Precision GI, available at 
                        <E T="03">https://mearis.cms.gov/public/publications/device-ptp/DEP23113023REE,</E>
                         for additional detail describing the device and the disease treated by the device.
                    </P>
                    <P>As stated previously, to be eligible for transitional pass-through payment under the OPPS, a device must meet the criteria at § 419.66(b)(1) through (4). With respect to the newness criterion at § 419.66(b)(1), Precision GI received FDA Breakthrough Device designation effective March 24, 2022, as a device used with an ultrasound endoscope for fine needle biopsy of submucosal lesions, mediastinal masses, lymph nodes, and intraperitoneal masses within or adjacent to the GI tract. FDA granted the applicant 510(k) clearance for Precision GI on August 28, 2023, for the indication covered by the Breakthrough Device designation. We received the application for a new device category for transitional pass-through payment status for Precision GI on November 30, 2023, which is within 3 years of the date of the initial FDA marketing authorization.</P>
                    <P>We invited public comment on whether Precision GI meets the newness criterion at § 419.66(b)(1).</P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to the newness criterion at § 419.66(b)(1), the applicant and one commenter agreed with CMS' assessment and the applicant noted that CMS raised no concerns about Precision-GI meeting the criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and the commenter's input. We received the application for a new device category for transitional pass-through payment status for Precision GI on November 30, 2023, which is within 3 years of August 28, 2023, the date of FDA 510(k) clearance. Based on our review of the application and public comments received, we have determined that Precision GI meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>With respect to the eligibility criteria at § 419.66(b)(3), the device must be an integral part of the service furnished, used for one patient only, come in contact with human tissue, and be surgically inserted or implanted, or applied in or on a wound or other skin lesion. The applicant did not indicate whether Precision GI is an integral part of the service furnished. The applicant stated that the device is intended for single use. While the applicant did not explicitly state whether Precision GI comes in contact with human tissue and is surgically inserted or implanted, the applicant noted that Precision GI is used to sample targeted submucosal lesions, mediastinal masses, lymph nodes, and intraperitoneal masses within or adjacent to the GI tract and this is achieved by a physician who inserts Precision GI into the patient's GI tract using an ultrasound endoscope. However, we noted that, while the needle (which is a component of the device and is included in the device's package) does come into contact with human tissue and is surgically inserted, the motorized mechanism of the Precision GI device itself may not come in contact with human tissue and may not be surgically implanted or inserted (either permanently or temporarily), or applied in or on a wound or other skin lesion, as required at § 419.66(b)(3).</P>
                    <P>We invited public comment on whether Precision GI meets the eligibility criterion at § 419.66(b)(3).</P>
                    <P>
                        <E T="03">Comment:</E>
                         In response to our concern about whether Precision GI is integral to the service furnished and meets the eligibility criterion at § 419.66(b)(3), the 
                        <PRTPAGE P="94160"/>
                        applicant clarified that Precision GI is an integral part of the service furnished because the Precision GI device is an endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) medical device and is the essential device that physicians must use to enable the procedures for the services the applicant identified. The applicant clarified that physicians use Precision GI for procedures that are reported using the following HCPCS codes: 43238 (Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures), and 43242 (Esophagogastroduodenoscopy, flexible, transoral with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus stomach and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis)) and Precision GI is clearly integral to performing both of these services, given that these procedures are intended to extract suspected cancerous tissue and that Precision GI is the essential device used to obtain and remove the tissue. A commenter stated that based on the Precision GI application, they believe Precision GI would be integral to the procedures with which it is associated. The applicant reiterated that Precision GI is a single-use device and clarified that it is used for one patient only.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and the commenter's input. Based on the information provided in the comments we agree with the applicant and commenter that Precision GI is an essential device that physicians must use to enable the procedures for the services the applicant identified and, as such, Precision GI is an integral part of the service furnished. After consideration of the public comments received and our review of the application, we have determined that Precision GI is integral to the service furnished and is used for one patient only. We have taken this information into consideration in making our final determination of whether Precision GI meets the requirements of § 419.66(b)(3).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         In response to our concerns about whether Precision GI comes in contact with human tissue and meets the eligibility criterion at § 419.66(b)(3), the applicant and a commenter submitted comments clarifying that Precision GI comes in contact with human tissue when the device enters the patient and extracts suspected tumor tissue from the body. The applicant and commenter explained that after the Precision GI device is advanced through the mouth via the working channel of the upper GI endoscope to the section of the gastric wall located closest to the mass or tumor as identified by endoscopic ultrasound, the rotating needle component of Precision GI goes through the gastric wall to acquire tissue from the tumor. The applicant clarified that Precision GI operates as a single unit, which includes the needle and emphasized that Precision GI is not provided in separate components, does not require assembly, and does not require any additional supplies or materials to operate. As such, the applicant and the commenter asserted that Precision GI comes into contact with human tissue as required.
                    </P>
                    <P>In response to our concerns about whether Precision GI is surgically inserted or implanted the applicant and another commenter clarified that Precision GI is surgically inserted when Precision GI is inserted through a natural orifice (the mouth) to access the biopsy site, and therefore it meets the eligibility criterion at § 419.66(b)(3). Specifically, the applicant clarified that the surgical path to the tumor is created by the endoscope which is passed through the mouth (natural orifice) where Precision GI is then used to access the site and to extract tissue in or adjacent to the GI tract, meeting the requirements of § 419.66(b)(3).</P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and the commenter's input. Based on the clarifying information provided in the comments, we agree with the applicant that Precision GI comes in contact with human tissue and is surgically implanted or inserted as required by § 419.66(b)(3). Specifically, we relied upon the clarification that Precision GI functions collectively as a single unit with no separate components and the device enters the patient via an endoscope to extract human tissue from the body, and as such, we believe that Precision GI comes into contact with human tissue. In addition, we agree with the applicant and commenter that Precision GI is surgically inserted when it is advanced through a natural orifice (
                        <E T="03">i.e.,</E>
                         the mouth) via an endoscope to create a surgical path to the tumor. After consideration of the public comments received and our review of the application, we have determined that Precision GI comes in contact with human tissue and is surgically inserted in accordance with the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>We agree with the applicant and commenter that Precision GI is an integral part of the service furnished, used for one patient only, comes in contact with human tissue, and is surgically implanted or inserted, or applied in or on a wound or other skin lesion. After consideration of the public comments received and our review of the application, we have determined that Precision GI meets the eligibility criterion at § 419.66(b)(3).</P>
                    <P>With respect to the exclusion criterion at § 419.66(b)(4), a device is not eligible to be considered for device pass-through payment if it is any of the following: (1) equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15-1); or (2) a material or supply furnished incident to a service (for example, a suture, customized surgical kit, or clip, other than a radiological site marker). The applicant indicated that Precision GI is not equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets; the applicant noted that Precision GI is a motorized, single-use, fully disposable EUS fine needle biopsy device that functions with no related capital component. The applicant stated that Precision GI is not a material or supply furnished incident to a service. However, based on the applicant's description of Precision GI as a biopsy device, we questioned whether Precision GI may be considered a supply or material furnished incident to a service and excluded from device pass-through payment eligibility under § 419.66(b)(4).</P>
                    <P>
                        Specifically, in the CY 2001 OPPS interim final rule with comment period (65 FR 67804 through 67805), we explained how we interpreted § 419.43(e)(4)(iv). We stated that we consider a device to be surgically implanted or inserted if it is introduced into the human body through a surgically created incision. We also stated that we do not consider an item used to cut or otherwise create a surgical opening to be a device that is surgically implanted or inserted. We consider items used to create incisions, such as scalpels, electrocautery units, biopsy apparatuses, or other commonly used operating room instruments, to be supplies or capital equipment not eligible for transitional pass-through payments. We stated that we believe the function of these items is different and distinct from that of devices that are 
                        <PRTPAGE P="94161"/>
                        used for surgical implantation or insertion. Finally, we stated that, generally, we would expect that surgical implantation or insertion of a device occurs after the surgeon uses certain primary tools, supplies, or instruments to create the surgical path or site for implanting the device. Further, in the CY 2006 OPPS final rule with comment period (70 FR 68629 through 68630), we adopted as final our interpretation that the surgical insertion or implantation criterion can be met by devices that are surgically inserted or implanted via a natural or surgically created orifice, as well as those devices that are inserted or implanted via a surgically created incision. We reiterated that we maintain all of the other criteria in § 419.66 of the regulations, namely, that we do not consider an item used to cut or otherwise create a surgical opening to be a device that is surgically implanted or inserted. We reiterated this interpretation in the CY 2024 OPPS final rule (88 FR 81543, 81743).
                    </P>
                    <P>We noted that Precision GI, is inserted into the patient's GI tract via the ultrasound endoscope to reach the designated biopsy site where the device's motorized mechanism is then used for cutting and extraction of tissue endoscopically from within or adjacent to the patient's GI tract. However, we questioned whether Precision GI, which is described as a biopsy device, may be considered a supply or material furnished incident to a service consistent with our previous interpretation of § 419.43(e)(4)(iv) and therefore excluded from device pass-through payment eligibility under § 419.66(b)(4).</P>
                    <P>We welcomed additional evidence regarding whether Precision GI should be considered a material or supply incident to a service based on our previous interpretation of § 419.43(e)(4)(iv) as it has been applied to biopsy devices and we invited public comments on whether Precision GI meets the exclusion criterion at § 419.66(b)(4).</P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment stating that there is agreement that Precision GI is not equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. We agree with the applicant that Precision GI is not equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets. We have taken this information into consideration in making our final determination of whether Precision GI meets the requirements of § 419.66(b)(4).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment clarifying that Precision GI is not a material or supply incident to a service and meets the eligibility criterion at § 419.66(b)(4) because Precision GI does not create incisions and is not used to create a surgical opening, rather Precision GI is used to capture and extract a diagnostically relevant portion of the tumor. The applicant stated that Precision GI's cutting function does not make the device a commodity supply and that Precision GI should not be placed in the same category as simple cutting or basic commodity tools (
                        <E T="03">e.g.,</E>
                         such as scalpel, biopsy forceps, simple exchangeable needles, etc.).
                    </P>
                    <P>
                        Additionally, the applicant stated that Precision GI is not a generic biopsy device as defined by CMS for pass-through devices, referencing section 60.4.3, Chapter 4 of the Medicare Claims Processing Manual. In support, the applicant compared Precision GI to devices described by C1782 (Morcellator), which like Precision GI are also used for tissue removal. The applicant explained that because C1782 devices are used for laparoscopic tissue removal, per the CMS guidance in the Medicare Claims Processing Manual, they are not considered generic biopsy devices.
                        <SU>41</SU>
                        <FTREF/>
                         Thus, the applicant asserted its belief that, similar to C1782 devices, Precision GI is not a generic biopsy device because it is used for tissue removal. Furthermore, the applicant noted that C1782 would not appropriately describe Precision GI because C1782 is specific to laparoscopic removal of tissue, whereas Precision GI is endoscopically inserted to remove tissue within or adjacent to the GI tract.
                    </P>
                    <FTNT>
                        <P>
                            <SU>41</SU>
                             According to the Medicare Claims Processing Manual (60.4.3), the device pass-through category C1782 (Morcellator) is specific to devices used for cutting, coring, and extracting tissue in laparoscopic procedures. These are distinct from biopsy devices because morcellators are used for the laparoscopic removal of tissue.
                        </P>
                    </FTNT>
                    <P>The applicant asserted that CMS previously created a pass-through device category C1830 (Powered bone marrow biopsy needle), effective October 1, 2011, and that the device in this category functions similarly to Precision GI in complexity of operation and is not a biopsy needle as the applicant stated CMS defines this term. The applicant further commented that suggesting that Precision GI is a supply ignores the complexity of the device compared to commonly used endoscopic biopsy forceps and interchangeable commodity operating instruments.</P>
                    <P>One commenter stated that, per the application, Precision GI is a single, disposable, mechanized unit that would be integral to the procedures with which it is associated and for this reason, it should not be categorized with scalpels, needles, and other commonly used operating room instruments as a supply furnished incident to a service and should not be excluded from device pass-through eligibility under § 419.66(b)(4).</P>
                    <P>The applicant asserted that the FDA Breakthrough Designation implicitly recognizes the innovative nature of Precision GI and that it would be unlikely to have received this designation if it were deemed a supply. The applicant also asserted that Precision GI obtains tumor tissue in a superior method compared to today's non-motorized EUS-FNB devices, providing consistently higher quality core tumor tissue for the anatomic pathologist to more confidently diagnose.</P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and commenter's input and the additional information. We agree with the applicant that Precision GI is not a supply or material furnished incident to a service because the device does not appear to be an item used to cut or otherwise create a surgical opening, rather it is inserted through a natural orifice (
                        <E T="03">i.e.,</E>
                         the mouth) via an endoscope to create a surgical path to reach the designated biopsy site where the device's motorized mechanism is used for cutting and extraction of tissue endoscopically from within or adjacent to the patient's GI tract.
                    </P>
                    <P>We also agree with the applicant that similar to devices described by C1782 and C1830, Precision GI appears to be distinct from biopsy devices as defined by section 60.4.3, Chapter 4 of the Medicare Claims Processing Manual.</P>
                    <P>
                        In response to the applicant's comment that FDA Breakthrough Designation implicitly recognizes the innovative nature of Precision GI and that it would be unlikely to have received this designation if it were deemed a supply, we note that a device's FDA designation does not alone qualify a device for transitional device pass-through payment; the criteria FDA utilizes to grant medical device approvals differ from the criteria CMS has established to evaluate device eligibility for OPPS device pass-through payments. As such, CMS must evaluate all information submitted for each device pass-through application for each applicable criterion as it applies to the nominated device. In response to the 
                        <PRTPAGE P="94162"/>
                        applicant's comment that Precision GI obtains tumor tissue in a superior method compared to today's non-motorized EUS-FNB devices, providing consistently higher quality core tumor tissue for the anatomic pathologist to more confidently diagnose, we note that § 419.66(b)(4) does not require that a device is superior to other available devices.
                    </P>
                    <P>Based on the additional information provided in the comments, we agree with the applicant and commenter that Precision GI is not equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets, or a material or supply furnished incident to a service. After consideration of the public comments received and our review of the application, we have determined that Precision GI meets the eligibility criterion at § 419.66(b)(4).</P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to our concerns about the eligibility criterion at § 419.66(b)(3), the applicant sought to distinguish Precision GI from the CytoCore device, which was denied pass-through status in CY 2024 (88 FR 81744). The applicant stated that Precision GI differs from CytoCore in two ways: unlike the CytoCore device, Precision GI does not have a separate needle component and Precision GI comes into contact with human tissue. Specifically, the applicant commented that the needle attached to the CytoCore is a separate needle, and not part of the CytoCore device and the needle is the only portion of the device that comes in contact with human tissue, whereas Precision GI's needle is an integral part of the Precision GI device that works in conjunction with Precision GI's long flexible shaft fully driven by its control system and motor, to transfer the proximal driving force of the motor to the highly specialized circumferential cutting and capturing tip to access the tumor tissue and perform the biopsy. The applicant further clarified that the Precision GI's needle is not only an integrated part of the device, but it is also a specifically and uniquely designed cannula with circumferential internal sharpening to enable superior tumor tissue capture when driven by Precision GI as a motor and microchip control program. The applicant stated that Precision GI enables the physician to accomplish motorized, automated, and synchronized axial advancement and rotational cutting and extraction of tissue at the target tissue site. Finally, the applicant noted that the needle used with Precision GI cannot be swapped out for other generic needles.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input and agree that because Precision GI does not have separate components, functions collectively as a single device, and is surgically inserted when it is advanced through a natural orifice (
                        <E T="03">i.e.,</E>
                         the mouth) via an endoscope, creating a surgical path to the tumor, the device comes into contact with human tissue and is surgically inserted as required by § 419.66(b)(3).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         With regard to our discussion about the eligibility criterion specified at § 419.66(b)(4), a commenter stated that the Precision GI transitional pass-through payment application raises an important policy question about the definition of a biopsy apparatus. According to the commenter, items used to create incisions, such as biopsy apparatuses, or other commonly used operating room instruments, that CMS classified as supplies in in the CY 2006 OPPS final rule (70 FR, 68629 through 68630) 
                        <SU>42</SU>
                        <FTREF/>
                         are substantially different from the targeted mechanical core biopsies of today. The commenter explained that technological advances in incision devices began in the late 2010s with various alterations to needle shapes and have continued to improve and progress to the current, mechanical, EUS-guided devices, which do not merely create incisions and should not be classified along with biopsy forceps or even aspiration needles. Therefore, the commenter requested that CMS consider the definition of a supply and consider re-classification of mechanical tissue extraction apparatuses such as Precision GI into a new category of devices outside of the existing definition. The commenter stated their belief that this would enable CMS to determine the benefits and costs of single-use devices and future innovations in this space and determine their role in therapeutic decision-making and associated improvements in patient outcomes.
                    </P>
                    <FTNT>
                        <P>
                            <SU>42</SU>
                             Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2006 Payment Rates, 70 FR 68516 (November 10, 2005).
                        </P>
                    </FTNT>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenter for their feedback. We will continue to consider issues related to the definition of a biopsy apparatus as it relates to the criterion at § 419.66(b)(4).
                    </P>
                    <P>In addition to the criteria at § 419.66(b)(1) through (4), the criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. The applicant asserted that Precision GI is authorized by FDA with an indication to sample targeted submucosal lesions, mediastinal masses, lymph nodes, and intraperitoneal masses within or adjacent to the GI tract. Per the applicant, the device category C1830 (Powered bone marrow biopsy needle) does not appropriately describe Precision GI because Precision GI is not targeting bone marrow and instead is targeting sub‐mucosal and extramural GI lesions. According to the applicant, the device category C1782 (Morcellator) also does not appropriately describe Precision GI because that device category, per Medicare Claims Processing Manual, Ch. 4, section 60.4.3, is only for laparoscopic procedures. The applicant added that Precision GI cuts and extracts tissue endoscopically, not laparoscopically.</P>
                    <P>We did not identify an existing pass-through payment category that describes Precision GI. We invited public comment on whether Precision GI meets the device category criterion at § 419.66(c)(1).</P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to the device category criterion at § 419.66(c)(1), the applicant agreed with our assessment that there are no existing pass-through payment categories that describe Precision GI.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. After consideration of the public comments received and our review of the application, we continue to believe there is no existing category or category previously in effect that appropriately describes Precision GI. Therefore, we have determined that Precision GI meets the device category eligibility criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines either of the following: (i) that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment; or (ii) for devices for which pass-through status will begin on or after January 1, 2020, as an alternative to the substantial clinical improvement criterion, the device is part of the FDA's Breakthrough Devices Program and has received FDA marketing authorization for the indication covered by the Breakthrough Device designation. Precision GI has a Breakthrough Device designation and marketing authorization from FDA for 
                        <PRTPAGE P="94163"/>
                        the indication covered by the Breakthrough Device designation (as explained in more detail in the discussion of the newness criterion) and therefore is not evaluated for substantial clinical improvement.
                    </P>
                    <P>We invited public comment on whether Precision GI meets the device category criterion at § 419.66(c)(2)(ii).</P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to the device category criterion at § 410.66(c)(2)(ii), the applicant reiterated that Precision GI received FDA Breakthrough Device designation and marketing authorization for the same indication. The applicant agreed with CMS that Precision GI meets the device category criterion at § 410.66(c)(2)(ii), and therefore, is not evaluated for substantial clinical improvement.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. FDA granted Precision GI Breakthrough Device designation effective March 24, 2022, and a marketing authorization effective August 28, 2023, for the indication covered by the Breakthrough Device designation. Therefore, Precision GI meets the criterion at § 419.66(c)(2)(ii) and is not evaluated for substantial clinical improvement at § 419.66(c)(2)(i). After consideration of public comments received and our review of the application, we have determined that Precision GI meets the device category criterion at § 419.66(c)(2).
                    </P>
                    <P>The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. The applicant stated that Precision GI would be reported with HCPCS codes as shown in Table 120.</P>
                    <GPH SPAN="3" DEEP="167">
                        <GID>ER27NO24.147</GID>
                    </GPH>
                    <P>
                        To meet the cost criterion for device pass-through payment status, a device must pass all three tests of the cost criterion for at least one APC. As we explained in the CY 2005 OPPS final rule (69 FR 65775), we generally use the lowest APC payment rate applicable for use with the nominated device when we assess whether a device meets the cost significance criterion, thus increasing the probability the device will pass the cost significance test. Beginning in CY 2017, we calculate the device offset amount at the HCPCS/CPT code level instead of the APC level (81 FR 79657). We noted that the applicant utilized the CY 2024 payment rates for the three tests of the cost criterion. For our calculations, we used APC 5302, which had a CY 2024 payment rate of $1,812.99 at the time the application was received. HCPCS code 43242 in APC 5302 had a CY 2024 device offset amount of $23.75 at the time the application was received.
                        <SU>43</SU>
                        <FTREF/>
                         According to the applicant, the cost of Precision GI is $1,400.00.
                    </P>
                    <FTNT>
                        <P>
                            <SU>43</SU>
                             We noted that the applicant selected the APC payment rate of $1,814.88 and the APC level device offset amount of $178.95 for APC 5302. However, the values selected are inconsistent with the APC payment rate and the APC level device offset amount found in CY 2024 OPPS APC Offset File, which were corrected as described in the CY 2024 OPPS/ASC final rule with comment period correction (89 FR 9002). The HCPCS/CPT code level device offset amounts for the HCPCS/CPT codes provided by the applicant are available in the corrected Addendum P to the CY 2024 OPPS/ASC final rule with comment period. For our calculation, we selected the APC payment rate of $1,812.99 and the HCPCS/CPT code level device offset amount of $23.75 related to HCPCS 43242 in APC 5302 found in the corrected Addendum P, which are the accurate values for these codes. Based on our initial assessment for the proposed rule, using the APC payment rate of $1,812.99 and the device offset amount of $23.75 would result in Precision GI meeting the cost significance requirement.
                        </P>
                    </FTNT>
                    <P>Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The average reasonable cost of $1,400.00 for Precision GI is 77.22 percent of the applicable APC payment amount for the service related to the category of devices of $1,812.99 (($1,400.00/$1,812.99) × 100 = 77.22 percent). Therefore, we stated that we believe Precision GI meets the first cost significance requirement.</P>
                    <P>The second cost significance requirement, at § 419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount. The estimated average reasonable cost of $1,400.00 for Precision GI is 5894.74 percent of the cost of the device-related portion of the APC payment amount for the related service of $23.75 (($1,400.00/$23.75) × 100 = 5894.74 percent). Therefore, we stated that we believe Precision GI meets the second cost significance requirement.</P>
                    <P>
                        The third cost significance requirement, at § 419.66(d)(3), provides that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of 
                        <PRTPAGE P="94164"/>
                        $1,400.00 for Precision GI and the portion of the APC payment amount for the device of $23.75 is 75.91 percent of the APC payment amount for the related service of $1,812.99 ((($1,400−$23.75)/$1,812.99) × 100 = 75.91 percent). Therefore, we stated that we believe Precision GI meets the third cost significance requirement.
                    </P>
                    <P>We invited public comment on whether Precision GI meets the device pass-through payment criteria discussed in this section, including the cost criterion for device pass-through payment status.</P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to cost significance criteria, the applicant stated that they agree with CMS that Precision GI satisfies the cost criteria.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. After consideration of the public comment received and our findings from the first, second, and third cost significance tests, we have determined that Precision GI meets the cost significance criteria specified at § 419.66(d).
                    </P>
                    <P>After consideration of the public comments received, and our review of the device pass-through application, we have determined that Precision GI meets the requirements for device pass-through status described at § 419.66, and we are finalizing approval for device pass-through payment status for Precision GI effective January 1, 2025, under the alternative pathway for devices that have an FDA Breakthrough Device designation and have received FDA marketing authorization for the indication covered by the Breakthrough Device designation.</P>
                    <HD SOURCE="HD3">
                        (h) Symplicity Spyral
                        <E T="51">TM</E>
                         Renal Denervation (RDN) System
                    </HD>
                    <P>
                        Medtronic submitted an application for a new device category for transitional pass-through payment status for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System for CY 2025. The applicant is seeking a new device category for transitional pass-through payment status only for the Symplicity Spyral
                        <E T="51">TM</E>
                         Multi-Electrode RDN Catheter (hereinafter Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter) component of the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System. According to the applicant, the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System consists of the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter and the Symplicity G3
                        <E T="51">TM</E>
                         generator; however, the applicant requested device pass-through status for the catheter component of the system only. The applicant further explained that the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. Per the applicant, the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter, when used with the Symplicity G3
                        <E T="51">TM</E>
                         generator, delivers radiofrequency (RF) energy through the wall of the renal artery to disrupt the surrounding renal nerves with the aim of modulating or suppressing sympathetic nerve hyperactivity. According to the applicant, the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is a single-use catheter used to deliver multiple ablations in both kidneys, in the renal main, accessory, and branch arteries, based on a patient's artery anatomy and size.
                    </P>
                    <P>
                        Per the applicant, the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is designed to be used with the Symplicity G3
                        <E T="51">TM</E>
                         generator and includes the following components: (1) four gold radiopaque electrodes at the spiral (helical) distal end that are deployed into a spiral (helical) shape by partially retracting the guidewire proximal to the spiral section of the catheter; (2) self-expanding electrode array assembly which radially spaces the four gold electrodes for quadratic ablation; (3) rapid exchange port; (4) straightening tool intended to facilitate safe insertion of the guidewire into the catheter; (5) cable connector attached to the catheter handle that connects the catheter to the generator; (6) catheter handle; and (7) femoral marker. Per the applicant, additional components of the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System include the: (1) Symplicity G3
                        <E T="51">TM</E>
                         generator, which is only compatible with the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter, which includes a remote control, power cable, and output for the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter; (2) Symplicity G3
                        <E T="51">TM</E>
                         generator cart, an optional mobile cart; and (3) foot switch, an optional component. Per the applicant, additional items required for the procedure include: (1) a 0.36 mm (0.014 in) guidewire, preferably without hydrophilic coating; (2) a dispersive electrode; (3) a sterile bag to cover the remote control if used in the sterile field; (4) a 6 French (Fr) guide-catheter; (5) an introducer sheath; (6) a stopcock sidearm; (7) a Tuohy-Borst adapter; and (8) other standard items used to aid percutaneous transluminal catheterization in renal arteries.
                    </P>
                    <P>
                        According to information submitted by the applicant, key steps for operating the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter include: (1) connecting the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter to the Symplicity G3
                        <E T="51">TM</E>
                         generator; (2) inserting the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter through a small femoral incision and guiding it to the renal artery via the abdominal aorta; (3) advancing the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter until the distal electrode is located in the desired position within the renal artery; (4) retracting the guidewire, allowing the self-expanding catheter to expand and fit the renal arterial vessel walls; (5) delivering the treatment of RF energy to ablate the renal nerves through the activation of the catheter electrodes, which is controlled using the generator; (6) if treating another vessel, repositioning the guide catheter within the next vessel and repeating the procedure for positioning the catheter and delivering treatments; (7) upon completion of all treatments, straightening the distal end by advancing the guidewire and withdrawing both the guidewire and the straightened catheter from the guide catheter; (8) retracting the guide catheter from the sheath and removing the introducer sheath from the artery; (9) using standard of care procedures to achieve hemostasis at the puncture site; and (10) disposing of the devices.
                    </P>
                    <P>
                        Please refer to the online application posting for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System, available at 
                        <E T="03">https://mearis.cms.gov/public/publications/device-ptp/DEP231130WPU4J,</E>
                         for additional detail describing the device and the disease treated by the device.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Many commenters expressed their support for the approval of the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System for transitional pass-through payment.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' input and support for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System application for transitional pass-through payment. We have taken these comments into consideration in our final determination for pass-through status for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System.
                    </P>
                    <P>
                        As stated previously, to be eligible for transitional pass-through payment under the OPPS, a device must meet the criteria at § 419.66(b)(1) through (4). With respect to the newness criterion at § 419.66(b)(1), the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System received FDA Breakthrough Device designation effective March 27, 2020, as a device with the following indicated use: the Symplicity Spyral
                        <E T="51">TM</E>
                         multi-electrode renal denervation catheter and the Symplicity G3
                        <E T="51">TM</E>
                         RF Generator are indicated for the reduction of blood pressure in patients with uncontrolled hypertension despite the use of anti-hypertensive medications or in patients who may have documented intolerance to anti-hypertensive medications. FDA approved the premarket approval application (PMA) for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System on November 17, 2023, for the indicated use to reduce blood pressure as an adjunctive treatment in patients with hypertension 
                        <PRTPAGE P="94165"/>
                        in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. We received the application for a new device category for transitional pass-through payment status for the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter on November 30, 2023, which is within 3 years of the date of the initial FDA marketing authorization.
                    </P>
                    <P>
                        We invited public comment on whether the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to the newness criterion at § 419.66(b)(1), the applicant reiterated that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter received FDA marketing authorization on November 17, 2023, and the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System was granted Breakthrough Device designation effective March 27, 2020. A few other commenters also stated that they believed the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System meets the newness criterion.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and commenters' input. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System received FDA Breakthrough Device designation on March 27, 2020. We received the application for a new device category for transitional pass-through payment status for the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter on November 30, 2023, which is within 3 years of November 17, 2023, the date of FDA PMA. After consideration of the public comments received and our review of the application, we have determined that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the newness criterion at § 419.66(b)(1).
                    </P>
                    <P>
                        With respect to the eligibility criteria at § 419.66(b)(3), the device must be an integral part of the service furnished, used for one patient only, come in contact with human tissue, and be surgically inserted or implanted, or applied in or on a wound or other skin lesion. The applicant did not indicate whether the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is integral to the service furnished. Per the applicant, the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is intended for single-patient use only. While the applicant did not explicitly state whether the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter comes into contact with human tissue, the applicant asserted that the Symplicity
                        <E T="51">TM</E>
                         Catheter ablates renal nerve tissue by positioning the catheter within the renal artery, which expands and fits the renal arterial vessel walls. While the applicant did not explicitly state if the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is surgically inserted or implanted, per the device description, the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is inserted through a small femoral incision, after which it is inserted into the renal arterial vessel.
                    </P>
                    <P>
                        We invited public comment on whether the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment stating that the Symplicity Spyral
                        <E T="51">TM</E>
                         catheter meets all eligibility criteria as laid out at § 419.66(b)(3). The applicant clarified that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is required to ablate the renal sympathetic nerves in this procedure, is integral to the service furnished, and meets the eligibility criterion at § 419.66(b)(3). The applicant further clarified that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter comes into contact with human tissue because it is inserted through the skin and into the arterial system, and is then introduced into the renal artery.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's input. We agree with the applicant that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is an integral part of the service furnished, used for one patient only, comes in contact with human tissue, and is surgically implanted or inserted, or applied in or on a wound or other skin lesion because the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is a single-use catheter and is inserted through a small femoral incision, after which it is inserted into the renal arterial vessel. After consideration of the public comments we received and our review of the application, we have determined that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the eligibility criterion at § 419.66(b)(3).
                    </P>
                    <P>
                        With respect to the exclusion criterion at § 419.66(b)(4), a device is not eligible to be considered for device pass-through payment if it is any of the following: (1) equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15-1); or (2) a material or supply furnished incident to a service (for example, a suture, customized surgical kit, or clip, other than a radiological site marker). The applicant did not state whether the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered, or whether the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is a supply or material furnished incident to a service.
                    </P>
                    <P>
                        We invited public comment on whether the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the exclusion criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment confirming that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the eligibility criterion at § 419.66(b)(4) because it is not equipment, an instrument, apparatus, implement, or item for which depreciation and financing expenses are recovered as defined in Chapter 1 of the Medicare Provider Reimbursement Manual. The applicant clarified that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is not a supply or material furnished incident to a service. The applicant commented that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is used with the Symplicity G3
                        <E T="51">TM</E>
                         generator, which may be considered depreciating equipment as defined at § 419.66(b)(4); however, the applicant noted that it is only seeking pass-through status for the single-use Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We thank the applicant for the clarification and agree with the applicant that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is not equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets, or a material or supply furnished incident to a service. After consideration of the public comments we received and our review of the application, we have determined that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the eligibility criterion at § 419.66(b)(4).
                    </P>
                    <P>
                        In addition to the criteria at § 419.66(b)(1) through (4), the criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. According to the applicant, the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is a single-use catheter used to deliver multiple ablations in both kidneys, in the renal main, accessory, and branch arteries, based on a patient's artery anatomy and size. According to the applicant, no previous or existing device categories for pass-through payment appropriately describe the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter. The applicant asserted that two categories, C1886 (Catheter, extravascular tissue ablation, any modality (insertable)) and C1888 (Catheter, ablation, noncardiac, endovascular (implantable)), do not appropriately describe the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter. Per the applicant, C1886 does not appropriately describe the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter because the Symplicity Spyral
                        <E T="51">TM</E>
                          
                        <PRTPAGE P="94166"/>
                        Catheter ablates renal nerve tissue via an endovascular approach by positioning the catheter within the renal artery and C1886 was created to describe devices that ablate extravascular tissue (via an extravascular approach).
                        <SU>44</SU>
                        <FTREF/>
                         According to the applicant, C1888 does not appropriately describe the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter because the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter does not ablate or otherwise affect the blood vessel tissue and C1888 was created to describe devices designed to occlude or obliterate blood vessels.
                        <SU>45</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>44</SU>
                             The applicant referenced CY 2013 OPPS FR (77 FR 68352) and Transmittal 2386, Change Request 7672 (Jan 13, 2012) to support these assertions.
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>45</SU>
                             The applicant referenced the Medicare Claims Processing Manual, Chapter 4, section 60.4.3 to support these assertions.
                        </P>
                    </FTNT>
                    <P>
                        We did not identify an existing pass-through payment category that describes the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter. We invited public comment on whether the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the device category criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant and a few other commenters agreed with CMS' assessment that there are no existing pass-through payment categories that describe the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the commenters' input. After consideration of the public comments we received and our review of the application, we continue to believe that there is no existing category or category previously in effect that appropriately describes the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter. Therefore, we have determined that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the device category eligibility criterion at § 419.66(c)(1).
                    </P>
                    <P>
                        We noted that the applicant indicated the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is not the only device authorized by FDA with an indication for renal denervation to achieve reductions in blood pressure. Paradise® Ultrasound RDN System, for which we also received an application for transitional pass-through payments for CY 2025 as discussed in more detail in the proposed rule (89 FR 59304 through 59307) and this final rule with comment, is also authorized by FDA with an indication for renal denervation using ultrasound energy to achieve reductions in blood pressure. Per the applicant, the Paradise® Ultrasound RDN System would also be described by the applicant's proposed pass-through payment category: Ablation catheter, renal nerve, via endovascular approach, any modality. Accordingly, we noted that while the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter device may have a different modality (
                        <E T="03">i.e.,</E>
                         radiofrequency compared to ultrasound), the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter device may have a similar mechanism of action to that of the Paradise® Ultrasound RDN System device. We questioned whether the device descriptions provided in the respective applications support establishing two modality specific pass-through payment device categories or a single device category that would encompass both RDN device modalities. We address this question in section (i) in detail immediately following the full discussion of all other applicable eligibility criteria for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System application.
                    </P>
                    <P>
                        For the summary of public comments received and our final decision on the question of whether the device descriptions provided in the respective applications support establishing two modality-specific pass-through payment device categories or a single device category that would encompass both RDN device modalities, please see section (i) immediately following the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System application determination.
                    </P>
                    <P>
                        The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines either of the following: (i) that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment; or (ii) for devices for which pass-through status will begin on or after January 1, 2020, as an alternative to the substantial clinical improvement criterion, the device is part of the FDA's Breakthrough Devices Program and has received FDA marketing authorization for the indication covered by the Breakthrough Device designation. As previously stated, the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter has Breakthrough Device designation and marketing authorization from FDA for the indication covered by the Breakthrough Device designation (as explained in more detail in the discussion of the newness criterion) and therefore is not evaluated for substantial clinical improvement.
                    </P>
                    <P>
                        We invited public comment on whether the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the device category criterion at § 419.66(c)(2)(ii).
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant submitted a comment confirming that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the eligibility criterion at § 419.66(c)(2)(ii) because as an FDA Breakthrough Device, it meets the device category criterion as described at § 419.66(c)(2)(ii). A few commenters also stated that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the eligibility criterion at § 419.66(c)(2)(ii).
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and commenters' input. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System has a Breakthrough Device designation, as stated by the applicant, effective March 27, 2020, and marketing authorization from FDA effective November 17, 2023, for the indication covered by the Breakthrough Device designation and therefore, meets the criterion at § 419.66(c)(2)(ii) and is not evaluated for substantial clinical improvement at § 419.66(c)(2)(i). Based on our review of the application and consideration of the public comments we received, we have determined that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the eligibility criterion at § 419.66(c)(2).
                    </P>
                    <P>
                        The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. The applicant stated that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter would be reported with HCPCS codes shown in Table 121.
                    </P>
                    <GPH SPAN="3" DEEP="247">
                        <PRTPAGE P="94167"/>
                        <GID>ER27NO24.148</GID>
                    </GPH>
                    <P>
                        To meet the cost criterion for device pass-through payment status, a device must pass all three tests of the cost criterion for at least one APC. As we explained in the CY 2005 OPPS final rule (69 FR 65775), we generally use the lowest APC payment rate applicable for use with the nominated device when we assess whether a device meets the cost significance criterion, thus increasing the probability the device will pass the cost significance test. Beginning in CY 2017, we calculate the device offset amount at the HCPCS/CPT code level instead of the APC level (81 FR 79657). We noted that the applicant used the CY 2024 payment rates for the three tests of the cost criterion. For our calculations, we used APC 5192, which had a CY 2024 payment rate of $5,445.84 at the time the application was received. HCPCS code 0339T in APC 5192 had a CY 2024 device offset amount of $3,362.26 at the time the application was received.
                        <SU>46</SU>
                        <FTREF/>
                         According to the applicant, the cost of the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is $16,000.00.
                    </P>
                    <FTNT>
                        <P>
                            <SU>46</SU>
                             We noted that the applicant selected the APC payment rate of $5,451.51 and the HCPCS/CPT code level device offset amount of $3,365.76 for HCPCS 0339T in APC 5192. However, the values selected are inconsistent with the APC payment rate and the device offset amount found in the corrected Addendum P to the CY 2024 OPPS/ASC final rule with comment period. For our calculation, we selected the APC payment rate of $5,445.84 and the HCPCS/CPT code level device offset amount of $3,362.26 for HCPCS 0339T in APC 5192 found in the corrected Addendum P, which are the accurate values for these codes. Based on our initial assessment for the proposed rule, using the APC payment rate of $5,445.84 and the HCPCS/CPT code level device offset amount of $3,362.26 would result in the Symplicity Spyral
                            <E T="51">TM</E>
                             Catheter meeting the cost significance requirement.
                        </P>
                    </FTNT>
                    <P>
                        Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The average reasonable cost of $16,000.00 for the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is 293.80 percent of the applicable APC payment amount for the service related to the category of devices of $5,445.84 (($16,000.00/$5,445.84) × 100 = 293.80 percent). Therefore, we stated that we believe the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the first cost significance requirement.
                    </P>
                    <P>
                        The second cost significance requirement, at § 419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $16,000.00 for the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter is 475.87 percent of the cost of the device-related portion of the APC payment amount for the related service of $3,362.26 (($16,000.00/$3,362.26) × 100 = 475.87 percent). Therefore, we stated that we believe the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the second cost significance requirement.
                    </P>
                    <P>
                        The third cost significance requirement at § 419.66(d)(3), provides that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $16,000.00 for the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter and the portion of the APC payment amount for the device of $3,362.26 is 232.06 percent of the APC payment amount for the related service of $5,445.84 ((($16,000.00−$3,362.26)/$5,445.84) × 100 = 232.06 percent). Therefore, we stated that we believe the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the third cost significance requirement.
                    </P>
                    <P>
                        We invited public comment on whether the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the device pass-through payment criteria discussed in this section, including the cost criterion for device pass-through payment status.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         With respect to cost significance criteria, the applicant and a few other commenters reiterated that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets all three of the cost significance criteria.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the applicant's and commenters' input. After consideration of the public comments we received and our findings from the first, second, and third cost significance tests, we agree that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter meets the cost significance criteria specified at § 419.66(d).
                    </P>
                    <P>
                        After consideration of the public comments we received and our review of the device pass-through application, we have determined that the Symplicity 
                        <PRTPAGE P="94168"/>
                        Spyral
                        <E T="51">TM</E>
                         Catheter meets the requirements for device pass-through status described at § 419.66. Therefore, effective beginning January 1, 2025, we are finalizing approval for device pass-through payment status for the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter under the alternative pathway for devices that have an FDA Breakthrough Device designation and have received FDA marketing authorization for the indication covered by the Breakthrough Device designation.
                    </P>
                    <P>
                        (i) Paradise® Ultrasound RDN System and the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System Device Category Code Establishment
                    </P>
                    <P>
                        As previously discussed, we received two applications for transitional device pass-through status for RDN devices: the Paradise® Ultrasound RDN System and the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System (Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter). Per the applicants, both are RDN devices that use an endovascular approach to enter the renal arteries and ablate renal sympathetic nerves to achieve reductions in blood pressure. We questioned whether the information provided for each nominated device supported establishing two modality-specific device pass-through payment device categories or establishing a single device category that would encompass both RDN devices.
                    </P>
                    <P>
                        We noted that the Paradise® Ultrasound RDN System and the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System are both authorized by FDA for the indicated use to reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. In addition, based on the information provided in the respective applications, we stated that it appears that both devices use the same procedure (renal sympathetic denervation, also called renal sympathetic nerve ablation) with the same underlying mechanism of action (thermal ablation), treat the same disease (hypertension) in the same patient population (patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure), and aim to achieve the same therapeutic outcome (to reduce blood pressure). We noted that in addition to having the same indicated use, per the applicants, both devices may be used with the same HCPCS procedure codes: 0338T 
                        <SU>47</SU>
                        <FTREF/>
                         or 0339T.
                        <SU>48</SU>
                        <FTREF/>
                    </P>
                    <FTNT>
                        <P>
                            <SU>47</SU>
                             HCPCS procedure code 0338T (Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral).
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>48</SU>
                             HCPCS procedure code 0339T (Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral).
                        </P>
                    </FTNT>
                    <P>
                        We noted several differences in procedural technique with use of the Paradise® Ultrasound RDN System device compared to the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System device. Per the applicants, the Paradise® Ultrasound RDN System delivers ablation while positioned in the main renal arteries only, whereas the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System may deliver ablation while positioned in the main renal, accessory, and branch arteries and therefore may require advancing the catheter beyond the main renal arteries. According to the applicants, the Paradise® Ultrasound RDN System procedural technique requires the measurement of the main renal artery diameter to select an appropriate size cooling balloon catheter, whereas the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System does not require a cooling balloon catheter nor this measurement. Similarly, per the applicants, the Paradise® Catheter's cooling balloon catheter requires additional procedural techniques to ensure the balloon is appropriately inflated and deflated during the procedure, but the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter does not require this.
                    </P>
                    <P>
                        The two applicants proposed different device category descriptions. Based on the information submitted, we acknowledged that the device category proposed by the applicant for the Paradise® Ultrasound RDN System would not appropriately describe the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System, but that the device category proposed by the applicant for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System would appropriately describe the Paradise® Ultrasound RDN System. Specifically, the applicant for the Paradise® Ultrasound RDN System proposed the following device category: 
                        <E T="03">Catheter, intravascular renal denervation, ultrasound, with balloon cooling</E>
                        ,
                        <SU>49</SU>
                        <FTREF/>
                         while the applicant for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System proposed the following device category: 
                        <E T="03">Ablation catheter, renal nerve, via endovascular approach, any modality.</E>
                         The device category descriptor the applicant proposed for the Paradise® Ultrasound RDN System specifies the device's treatment or procedure (catheter renal denervation), the ablation modality (
                        <E T="03">i.e.,</E>
                         ultrasound), and an attribute of the catheter (
                        <E T="03">i.e.,</E>
                         the cooling balloon). We noted that while the device category descriptor the applicant proposed for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System device also specifies the device's treatment or procedure (catheter ablation of the renal nerves), it does not specify an ablation modality or any additional attributes of the catheter; rather, the proposed device category for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System more broadly describes any ablation modality (
                        <E T="03">e.g.,</E>
                         radiofrequency or ultrasound).
                    </P>
                    <FTNT>
                        <P>
                            <SU>49</SU>
                             The Paradise® Ultrasound RDN System device category does not explicitly describe using an endovascular approach; however, it does describe renal nerve ablation via a catheter. We stated that we believe the device category describes the intravascular sonication (ultrasound treatment) delivered by the catheter. We noted that the proposed device description does not preclude an endovascular approach, and that, per the applicant, the Paradise® Ultrasound RDN system is a catheter-based endovascular based system.
                        </P>
                    </FTNT>
                    <P>
                        The applicant for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System asserted that the use of a common thermal mechanism of action in both systems supported the establishment of a single device category irrespective of modality. However, we noted the applicant of the Paradise® Ultrasound RDN System stated a separate device category associated with ultrasound denervation is supported by possible differences in clinical efficacy between RDN devices using ultrasound and those using radiofrequency ablation. However, we noted that we did not evaluate the validity or generalizability of these claims, nor was it clear if the two different ablation modalities (
                        <E T="03">i.e.,</E>
                         ultrasound and radiofrequency) would render different clinical results in larger studies or in the long term.
                        <E T="51">50 51</E>
                        <FTREF/>
                         We further noted that we discussed these claims solely for the purpose of 
                        <PRTPAGE P="94169"/>
                        determining whether the information provided supports establishing two modality-specific pass-through payment device categories or establishing a single device category that may encompass both RDN devices.
                    </P>
                    <FTNT>
                        <P>
                            <SU>50</SU>
                             Fengler, K., Rommel, K.-P., Kriese, W., Blazek, S., Besler, C., von Roeder, M., Desch, S., Thiele, H., &amp; Lurz, P. (2023, February 13). Research Correspondence: 6- and 12-Month Follow-Up From a Randomized Clinical Trial of Ultrasound vs Radiofrequency Renal Denervation (RADIOSOUND-HTN). 
                            <E T="03">JACC: Cardiovascular Interventions, 16</E>
                            (3),: 367-369. 
                            <E T="03">https://doi.org/10.1016/j.jcin.2022.10.058</E>
                        </P>
                        <P>
                            <SU>51</SU>
                             Fengler, K., Rommel, K.-P., Blazek, S., Besler, C., Hartung, P., von Roeder, M., Petzold, M., Winkler, S., Höllriegel, R., Desch, S., Thiele, H., &amp; Lurz, P. (2019). A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN). 
                            <E T="03">Circulation: 139</E>
                            (5), 590-600. 
                            <E T="03">https://doi.org/10.1161/CIRCULATIONAHA.118.037654</E>
                            .
                        </P>
                    </FTNT>
                    <P>
                        In seeking comment, we noted that in accordance with section 1833(t)(6)(B)(ii)(II) of the Act, new categories must be established in such a way that no medical device is described by more than one category. We further noted that CMS does not establish pass-through device categories for the purposes of describing specific devices, but rather, device categories which are intended to encompass all devices that can be appropriately described by a category. However, there are instances where CMS has defined specific ablation modalities (
                        <E T="03">e.g.,</E>
                         high intensity ultrasound, microwave, and cryoablation) in HCPCS codes for use with the OPPS. In addition, we noted the existence of several modality-specific tissue ablation procedure codes in the Current Procedural Terminology (CPT®) 2024. However, there are examples where CMS has established device categories with additional granularity to differentiate similar devices with special characteristics (
                        <E T="03">e.g.,</E>
                         implantable neurostimulators). Further, there are examples where CMS has created HCPCS codes specifying the modality of ablation (
                        <E T="03">e.g.,</E>
                         ultrasound, microwave). Finally, we noted that the intent of transitional device pass-through payment, as implemented at § 419.66, is to facilitate access for beneficiaries to the advantages of new and truly innovative devices by allowing for adequate payment for these new devices while the necessary cost data is collected to incorporate the costs for these devices into the procedure APC rate (66 FR 55861). We questioned whether two modality-specific device category codes may facilitate the collection of more accurate data for incorporating the costs of these two devices into the procedure APC rate as well as foster the tracking of efficacy data for these two ablation modalities.
                    </P>
                    <P>
                        As such, we invited public comment on whether the device descriptions provided in the Paradise® Ultrasound RDN System and the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applications support establishing two modality-specific pass-through payment device categories or a single device category that would encompass both RDN device modalities.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters, including the Paradise® Ultrasound RDN System applicant, overwhelmingly supported establishing two pass-through payment device categories. However, some commenters suggested that the device category codes be specific to the physical device characteristics while other commenters suggested the device category codes be specific to modality. Specifically, the applicant for the Paradise® Ultrasound RDN System and many other commenters stated that two device categories are more appropriate for many reasons such as documented procedural differences between the two treatment modalities, differences in the prices between the two technologies, CMS's previous creation of separate and distinct device categories for similar technologies, CMS's recent creation of different ICD-10-PCS codes for radiofrequency and ultrasound renal denervation modalities in the FY 2025 IPPS final rule, and to facilitate the tracking of each device's efficacy data.
                    </P>
                    <P>
                        We received a few comments, including from the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant, who suggested that CMS establish a single device category that would encompass both RDN device modalities. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant and a few other commenters supported the establishment of an energy modality-agnostic RDN device pass-through payment device category for several reasons. Specifically, the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant emphasized the similarities between the two devices and procedures, opinions from the physician community, existing policy and coding standards, and potential future consequences of this determination. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant also disagreed with many of the reasons for separate pass-through payment device categories provided by the Paradise® Ultrasound RDN System applicant that were outlined in the proposed rule.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         We appreciate the feedback provided by the applicants and the commenters on this topic. We have taken the points raised into consideration in our final decision.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         Commenters, including the Paradise® Ultrasound RDN System applicant noted many procedural differences between the two treatment modalities. For example, the radiofrequency system (
                        <E T="03">i.e.,</E>
                         Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System) requires ablation of the main renal artery and branches of the main renal artery, whereas the Paradise® Ultrasound RDN System normally requires ablation of only the main renal artery, leading to significantly fewer ablations 
                        <E T="51">52 53</E>
                        <FTREF/>
                         and the Paradise® Ultrasound RDN System requires the estimation of the size of the patient's renal artery to ensure the correct balloon size is utilized, which may require additional equipment or procedural steps at the discretion of the operator compared to the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System procedure, where this is not required. In addition, the applicant and many commenters noted that the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System procedure takes longer than the overall procedure for the Paradise® Ultrasound RDN System, and the Paradise® Ultrasound RDN System applicant specified this difference in procedure time as approximately 30 percent.
                        <E T="51">54 55 56 57 58</E>
                        <FTREF/>
                         Many other commenters also indicated additional potential procedural differences between the two devices, including variation in the number of catheters used, pre- and post-procedure scheduling and workflow protocols, complexity of the procedure, depth of ablation, specialized training requirements, patient selection and management issues, and recovery time.
                    </P>
                    <FTNT>
                        <P>
                            <SU>52</SU>
                             Fengler, et al. (2019). A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN). 
                            <E T="03">Circulation, 139</E>
                            (5), 590-600. 
                            <E T="03">https://doi.org/10.1161/CIRCULATIONAHA.118.037654</E>
                            .
                        </P>
                        <P>
                            <SU>53</SU>
                             Fengler, et al. (2023). Research Correspondence: 6- and 12-Month Follow-Up From a Randomized Clinical Trial of Ultrasound vs Radiofrequency Renal Denervation (RADIOSOUND-HTN). 
                            <E T="03">JACC: Cardiovascular Interventions, 16</E>
                            (3): 367—369. 
                            <E T="03">https://doi.org/10.1016/j.jcin.2022.10.058</E>
                            .
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>54</SU>
                             Fengler, et al. (2019).
                        </P>
                        <P>
                            <SU>55</SU>
                             Fengler, et al. (2023).
                        </P>
                        <P>
                            <SU>56</SU>
                             Symplicity Spyral renal denervation system Instructions for Use. Medtronic.
                        </P>
                        <P>
                            <SU>57</SU>
                             Azizi, M., Schmieder, R.E., Mahfoud, F., Weber, M.A., Daemen, J., Davies, J., Basile, J., Kirtane, A.J., Wang, Y., Lobo, M.D., Saxena, M., Feyz, L., Rader, F., Lurz, P., Sayer, J., Sapoval, M., Levy, T., Sanghvi, K., Abraham, J., Sharp, A.S.P., Fisher, N.D.L., Bloch, M.., Reeve-Stoffer, H., Coleman, L., Mullin, C., &amp; Mauri, Laura on behalf of the RADIANCE-HTM Investigators (2018). Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. 
                            <E T="03">Lancet, 391</E>
                            (10137), P2335-P2345. 
                            <E T="03">https://doi.org/10.1016/S0140-6736(18)31082-1</E>
                            .
                        </P>
                        <P>
                            <SU>58</SU>
                             Azizi, M., Sanghvi, K., Saxena, M., Gosse, P., Reilly, J.P., Levy, T., Rump, L.C., Persu, A., Basile, J., Bloch, M.J., Daemen, J., Lobo, M.D., Mahfoud, F., Schmieder, R.E., Sharp, A.S.P., Weber, M.A., Sapoval, M., Fong, P., Pathak, A., Lantelme, P., Hsi, D., Bangalore, S., Witkowski, A., Weil, J., Kably, B., Barman, N.C., Reeve-Stoffer, H., Coleman, L., McClure, C.K., Kirtane, A.J. on behalf of the RADIANCE-HTN Investigators (2021). Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCEHTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet, 397(10293), P2476-P2486. 
                            <E T="03">https://doi.org/10.1016/S0140-6736(21)00788-1</E>
                            .
                        </P>
                    </FTNT>
                    <P>
                        With respect to procedural and device similarities, the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant and another commenter reiterated that both devices share the same intended use, for the same patient population, with identical 
                        <PRTPAGE P="94170"/>
                        or nearly identical FDA-approved indications, and are deployed similarly, on the same anatomy. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant further stated that the two devices have the same mechanism of action (thermal ablation of renal sympathetic nerves using heat energy), a similar form factor and product composition (single use endovascular catheters, connected to a generator, and delivered over a wire to the renal arteries, with distal ends containing heat energy emitting implements which ablate nerve tissue), and that the RDN procedure performed with either technology is fundamentally the same. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant also asserted that even though there may be small differences in the placement of each device along the renal arterial vasculature, they believe these small differences can be expected for devices that are inherently similar but not identical in form factor, size, and deliverability. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant asserted that the RDN procedure performed by both devices is also fundamentally the same, as both include catheter-based femoral access and closure, intraprocedural imaging, physician wire skills and expertise, and the ablation targeting of the sympathetic renal nerves to achieve the identical therapeutic goal of reducing blood pressure.
                    </P>
                    <P>
                        The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant reiterated that the Paradise® Catheter's cooling balloon requires specific procedural techniques to ensure the balloon is appropriately inflated and deflated during the procedure, noting that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter does not have this requirement. The applicant stated that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter does not require a cooling balloon as the non-occlusive spiral design of the radiofrequency catheter allows for continued collateral blood flow to cool the artery wall during ablation. Further, while use of the Paradise® Catheter's cooling balloon does require some different considerations when compared to the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter, particularly related to vessel size, the cooling balloon itself is not providing the therapeutic effect (
                        <E T="03">i.e.</E>
                         ablation of the nerves); rather, the balloon is preventing vessel damage from heat energy. The applicant stated this distinction makes it similar to many medical devices which provide the same treatment but require slightly different considerations based on manufacturer-specific equipment differences, and while the energy modality has driven some differences in the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter and the Paradise® Catheter designs, the overall procedure is substantially similar between the two technologies.
                    </P>
                    <P>
                        With respect to the differences in procedural technique described in the proposed rule that the Paradise® Ultrasound RDN System only ablates in the main renal arteries, while the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System typically involves ablation in the main renal arteries, accessories, and branches, the applicant stated that according to the Paradise® Ultrasound RDN System instructions for use (IFU),
                        <SU>59</SU>
                        <FTREF/>
                         the Paradise® Ultrasound RDN System is recommended for treatment of branches and accessory arteries, provided they are of appropriate size to accommodate the balloon and meet specific spacing requirements. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant explained that the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System IFU 
                        <SU>60</SU>
                        <FTREF/>
                         do not specify or require that distal branches be treated (only a size range for vessel diameters is specified). Furthermore, per the applicant, a thorough treatment strategy typically including distal branches is recommended for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System. The applicant noted that this recommendation is based on available knowledge of renal sympathetic nerve anatomy, to increase the likelihood of thorough and complete denervation up to the size limitations of the device, given that the current procedure and technology do not yet have an intraprocedural way to validate successful denervation. Additionally, the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant noted that several studies, including a sub-analysis of the Paradise® Ultrasound RDN System applicant's RADIANCE-HTN SOLO 
                        <SU>61</SU>
                        <FTREF/>
                         study, point to the importance of thorough ablation, including appropriate branch and accessory renal arteries, to achieving optimal nerve ablation and blood pressure reduction with RDN.
                        <E T="51">62 63</E>
                        <FTREF/>
                         Further, the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant stated that proceduralists with both devices seek to denervate to the greatest extent possible up to the limitations of the RDN technology used, and there are many considerations in how proceduralists may determine where to denervate, and with how many energy emissions, based on clinical experience and patient anatomical considerations.
                    </P>
                    <FTNT>
                        <P>
                            <SU>59</SU>
                             ReCor Paradise Ultrasound RDN Instructions for Use. 
                            <E T="03">https://mearis.cms.gov/public/publications/device-ptp/DEP231128137E1</E>
                             (accessed July 26, 2024).
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>60</SU>
                             Symplicity Spyral Indications for Use. Available at: 
                            <E T="03">https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220026D.pdf</E>
                            . Accessed Sept 2024.
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>61</SU>
                             Saxena, M., Schmieder, R.E., Kirtane, A.J., Mahfoud, F., Daemen, J., Basile, J., Lurz, P., Gosse, P., Sanghvi, K., Fisher, N.D.L., Rump, L.C., Pathak, A., Blakenstjn, P.J., Mathur, A., Wang, Y., Weber, M.A., Sharp, A.S.P., Bloch, M.J., Barman, N.C., Claude, L., Song, Y., Aziz, M. &amp; Lobo, M.D. (2022). Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. 
                            <E T="03">Journal of Human Hypertension, 36</E>
                            (7), 629-639. 
                            <E T="03">https://doi.org/10.1038/s41371-021-00547-y</E>
                            .
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>62</SU>
                             Sato, Y., Kawakami, R., Jinnouchi, H., Sakamoto, A., Cornelissen, A., Mori, M., Kawai, K., Guo, L., Coleman, L., Nash, S., Claude, L., Barman, N.C., Romero, M., Kolodgie, F.D., Virmani, R., &amp; Finn, A.V. (2001). Comprehensive Assessment of Human Accessory Renal Artery Periarterial Renal Sympathetic Nerve Distribution. 
                            <E T="03">JACC: Cardiovascular Interventions, 14</E>
                            (3), 304-15. 
                            <E T="03">https://doi.org/10.1016/j.jcin.2020.09.043</E>
                            .
                        </P>
                        <P>
                            <SU>63</SU>
                             Struthoff, H., Lauder, L, Hohl, M., Hermens, A., Rami Tzafriri, A., Edelman, E.R., Kunz, M., Böhm, M., Tschernig, T., &amp; Mahfoud, F. (2023). Histological examination of renal nerve distribution, density, and function in humans. 
                            <E T="03">EuroIntervention, 19</E>
                            (7), 612-620. 
                            <E T="03">https://doi.org/10.4244/eij-d-23-00264</E>
                            .
                        </P>
                    </FTNT>
                    <P>
                        The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant disagreed with some assertions provided in the Paradise application and discussed in some of the comments supporting the creation of two device category codes. Primarily, the applicant asserted that the differences in intraprocedural metrics cited in the proposed rule noted are not accurate comparisons. For example, the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant stated that the average procedure times from respective pooled analyses suggest that the total procedure time is 85 minutes for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System 
                        <SU>64</SU>
                        <FTREF/>
                         and 78 minutes for the Paradise® Ultrasound RDN but the total procedure times attributed to using either device are variable across studies, and, due to differing trial procedural requirements and physician experience, it is difficult to compare procedure times across studies. In addition, the applicant further stated other intraprocedural metrics, such as total ablation time and ablation time per cycle, are not necessarily reflective of additional resources involved in the procedures. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant noted that in the proposed rule CMS stated that the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter required more ablations per patient at 46.9, compared to 5.4 ablations for the Paradise® Ultrasound RDN System. However, the applicant stated that as a quadripolar device, each of the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter's four electrodes may be activated independently for focal treatments, causing the difference in the number of ablations. The applicant clarified that the SPYRAL HTN-OFF MED 
                        <PRTPAGE P="94171"/>
                        randomized controlled trial 
                        <SU>65</SU>
                        <FTREF/>
                         counted ablations from each of the four electrodes of the Symplicity Spyral
                        <E T="51">TM</E>
                         Catheter as a separate ablation, although most ablation cycles would have counted the four ablations simultaneously as a single ablation. The applicant indicated that given this design difference, it is misleading to draw comparisons between those two data points for each system. The applicant also clarified that regarding ablation depth, cadaveric studies found that &gt;90 percent of the renal nerves lie within 6.39 mm of the arterial lumen.
                        <SU>66</SU>
                        <FTREF/>
                         While the applicant stated that it cannot independently confirm the 1-6 mm ablation depth cited for the Paradise® Ultrasound RDN System, a histological study of radiofrequency RDN in porcine models using the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System found a comparable mean lesion depth of 6.26 mm (+/- 1.62) in the main renal segment.
                        <SU>67</SU>
                        <FTREF/>
                         The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant also stated that regardless of modality, ablation depth is not uniform and occurs asymmetrically as a result of heating different tissue types surrounding the renal artery (given the presence of other organs surrounding the renal artery, and anatomical variability between patients, this heat energy is variably dissipated). Therefore, the applicant asserted that ablation depth, by itself, is an incomplete two-dimensional measure of a three-dimensional phenomenon.
                    </P>
                    <FTNT>
                        <P>
                            <SU>64</SU>
                             Podium presentation. Mahfoud. Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter. Transvascular Cardiotherapuetics Conference. October 2023.
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>65</SU>
                             Böhm, M., Kario, K., Kandzari, D.E., Mahfoud, F., Weber, M.A., Schmieder, R.E., Tsioufis, K., Pocock, S., Konstantinidis, D., Choi, J.W., East, C., Lee, D.P., Ma, A., Ewen, S., Cohen, D.L., Wilensky, R., Devireddy, C.M., Lea, J., Schmid, A., Weil, J., Agdirlioglu, T., Reedus, D., Jefferson, B.K., Reyes, D., D'Souza, R., Sharp, A.S.P., Sharif, F., Fahy, M., DeBruin, V., Cohen, S.A., Brar, S., &amp; Townsend, R.R. on behalf of the SPYRAL HTN-OFF MED Pivotal Investigators (2020). Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. 
                            <E T="03">Lancet, 395</E>
                            (10234), 1444-1451. 
                            <E T="03">https://doi.org/10.1016/s0140-6736(20)30554-7</E>
                            .
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>66</SU>
                             Sakakura, K., Ladich, E., Cheng, Q., Otsuka, F., Yahagi, K., Fowler, D.R., Kolodgie, F.D., Virmani, R., &amp; Joner, M. (2014). Anatomic assessment of sympathetic peri-arterial renal nerves in man. 
                            <E T="03">Journal of American College of Cardiology, 64</E>
                            (7), 635-43. 
                            <E T="03">https://doi.org/10.1016/j.jacc.2014.03.059</E>
                            .
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>67</SU>
                             Wolf, M., Hubbard, B., Sakaoka, A., Rousselle, S., Tellez, A., Jiang, X., Kario, K., Hohl, M., Böhm, M., &amp; Mahfoud, F. (2018). Procedural and anatomical predictors of renal denervation efficacy using two radiofrequency renal denervation catheters in a porcine model. 
                            <E T="03">Journal of Hypertension, 36</E>
                            (12), 2453-2459. 
                            <E T="03">https://doi.org/10.1097/hjh.0000000000001840</E>
                            .
                        </P>
                    </FTNT>
                    <P>
                        <E T="03">Response:</E>
                         We thank the commenters and the applicants for the information. We agree with commenters that the Paradise® Ultrasound RDN System and the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System have the same underlying thermal mechanism of action, have the same intended use for the same patient population, and have identical FDA-approved primary indications. However, we continue to believe that, while there are similarities, the devices are not identical and warrant separate device categories. We note that commenters, including the applicants, addressed potential clinical impacts, efficacy, and outcomes in the comments. While we have included some of those details in our discussion for the purposes of illustrating the procedural comparison of the two devices and determining whether the information provided supports establishing two modality-specific pass-through payment device categories or establishing a single device category that may encompass both RDN devices, we note that we did not evaluate the validity or generalizability of these claims, nor was it is clear if the two different ablation modalities (
                        <E T="03">i.e.,</E>
                         ultrasound and radiofrequency) would render different clinical results in larger studies or in the long term. In regard to comments on the differences in clinical trial data between the Paradise® Ultrasound RDN System and the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System, we are not evaluating any evidence submitted in relation to the devices' clinical outcomes or the comparison of clinical outcomes to other similar devices because both devices meet the requirements at § 419.66(c)(2)(ii) and are not required to prove substantial clinical improvement for pass-through payment, as discussed in this final rule.
                    </P>
                    <P>With regard to the procedural differences we noted in the proposed rule, we agree with commenters that there are some procedural differences between the two RDN technologies and that the long-term impact of these differences on patient outcomes is unknown. We appreciate that differences between the two treatment modalities may result in different resource requirements such as operating room time, more anesthetic, and more contrast medium. We also agree with the many commenters who stated the Paradise® Ultrasound RDN System may require additional equipment or procedural steps to determine the estimation of the size of the patient's renal artery to ensure the correct balloon size is utilized.</P>
                    <P>
                        With regards to comments stating the cooling balloon itself is not providing the therapeutic effect (
                        <E T="03">i.e.</E>
                         ablation of the nerves); rather, the balloon is preventing vessel damage from heat energy, we appreciate that the cooling balloon does not constitute a difference in mechanism of action. However, we believe the different considerations of resources due to the differences of the cooling balloon may be considered a significant difference in modalities that could reasonably suggest a need for separate device codes.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The Paradise® Ultrasound RDN System applicant and many commenters stated that the difference in price between the two technologies also warrants two device categories. The Paradise® Ultrasound RDN System applicant and many other commenters stated that while the transitional pass-through payment calculation is based on hospital charges, having only one device category could lead to undercharging for one technology and overcharging for the other. The Paradise® Ultrasound RDN System applicant and many other commenters further stated that having two distinct device categories would allow hospitals to set charges that accurately reflect the cost of each procedure, thereby enabling CMS to more accurately calculate the costs of each procedure. The applicant and a few commenters further stated two distinct device categories would provide additional flexibility for CMS to more fully evaluate both modalities over the pass-through period to determine the most appropriate APC assignment when transitional pass-through payment expires.
                    </P>
                    <P>
                        The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant commented that it appreciates CMS' intent to facilitate access for beneficiaries to innovative technologies by allowing for adequate payment while cost data is collected for APC assignments, and that the payment calculation methodology for transitional device pass-through provides for adequate payments based on charges on individual hospital claims adjusted to costs during the 3-year eligibility period, regardless of device category assignment. The applicant further commented that when the pass-through period expires and CMS packages the procedures into an APC, payment will be calculated at the level of the CPT code, which both RDN technologies share. The applicant claimed that the RDN device costs for both technologies will be packaged into the payment for the same CPT code, whether these costs are similar or not. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant therefore questioned the utility of using separate device categories for cost tracking. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant also opined that tracking efficacy data for the two devices is beyond the fundamental purpose of establishing device categories and should not be a primary consideration. The applicant stated that both manufacturers are engaged in post-
                        <PRTPAGE P="94172"/>
                        market research to continue building the body of evidence for RDN specific to each technology, and the research will continue independent of the establishment of pass-through device categories. The applicant urged CMS to prioritize and maintain an OPPS policy-based rationale in establishing new device categories, with focus on the payment-driven mechanisms and purposes of the device category codes.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         In response to comments on the difference in price between the two technologies and whether that difference warrants two device categories, we note that while price difference considerations are generally outside the scope of the traditional pass-through payment program, we agree with commenters that two distinct device categories will provide an easier mechanism for hospitals to set charges that reflect the price differences between the two device categories which will enable CMS to more accurately calculate the costs of each procedure for future rulemaking.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The Paradise® Ultrasound RDN System applicant and many commenters asserted that CMS has previously created separate and distinct device categories for similar technologies. The applicant suggested the most notable of these are the neurostimulators, where CMS created categories to differentiate rechargeable, non-rechargeable, high-frequency, and closed feedback loop neurostimulators for the treatment of chronic pain.
                        <SU>68</SU>
                        <FTREF/>
                         The Paradise® Ultrasound RDN System applicant stated that other neurostimulator categories have also been created for phrenic nerve stimulation, paired stimulation, and carotid sinus baroreceptor stimulation. Further, the applicant stated that there are also currently five device categories 
                        <SU>69</SU>
                        <FTREF/>
                         that are all electrophysiology catheters. The applicant stated that they believe that these device categories appropriately capture the characteristics among these groups of technologies to allow for the most accurate reporting of device costs. The Paradise® Ultrasound RDN System applicant opined that the situation with respect to the Paradise® Ultrasound RDN System and the Symplicity
                        <E T="51">TM</E>
                         Spryal RDN System is similar to the examples presented, and therefore, it is appropriate to have two device categories to differentiate tracking of ultrasound and radiofrequency renal denervation. Several other commenters also referenced device categories that were differentiated due to their unique characteristics, including examples related to cardiology, neurostimulators, catheters, and ablation modalities (
                        <E T="03">i.e.,</E>
                         high-intensity ultrasound, microwave, and cryoablation), to support their position that the Paradise® Ultrasound RDN System and the Symplicity
                        <E T="51">TM</E>
                         Spryal RDN System should be classified within two different pass-through payment device categories.
                    </P>
                    <FTNT>
                        <P>
                            <SU>68</SU>
                             HCPCS codes C1826 (Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system), C1827 (Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller), C1821 (Interspinous process distraction device (implantable)), C1822 (Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system), C1823 (Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads), C1767 (Generator, neurostimulator (implantable), non-rechargeable), C1820 (Generator, neurostimulator (implantable), with rechargeable battery and charging system), and C1825 (Generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor stimulation lead(s).
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>69</SU>
                             HCPCS codes C1730 (Catheter, electrophysiology, diagnostic, other than 3D mapping (19 or fewer electrodes)), C1731 Catheter, electrophysiology, diagnostic, other than 3D mapping (20 or more electrodes)), C1732 (Catheter, electrophysiology, diagnostic/ablation, 3D or vector mapping), C1733 (Catheter, electrophysiology, diagnostic/ablation, other than 3D or vector mapping, other than cool-tip), and C2630 (Catheter, electrophysiology, diagnostic/ablation, other than 3D or vector mapping, cool-tip).
                        </P>
                    </FTNT>
                    <P>Further, the Paradise® Ultrasound RDN System applicant and many commenters noted that CMS recently created different ICD-10-PCS codes that differentiate between radiofrequency and ultrasound renal denervation modalities for the new technology add-on payments confirmed in the IPPS final rule for FY 2025. The applicant and several commenters opined that it is important to be consistent across inpatient and outpatient settings as the same rationale for separation and independent tracking of costs applies in both instances. A few commenters stated that the use of separate ICD-10-PCS codes for the two devices reflect their unique contributions to the treatment of hypertension.</P>
                    <P>
                        The applicant for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System argued that pass-through device categories are not established for the purpose of describing specific devices; rather, device categories are intended to encompass all devices that can be appropriately described by a category (89 FR 59316). The applicant acknowledged that, as stated in the proposed rule, CMS has established energy-specific device categories in the past; however, the applicant asserted that the establishment of device categories requires a nuanced approach, balancing appropriate granularity without becoming manufacturer- or device-specific. The applicant asserted that CMS must assess each situation on a case-by-case basis, in the context of the procedure and device in question, the existing code set, and established policy. The applicant asserted its belief that a single device category for the two RDN technologies is consistent with the considerations put forth by CMS in the proposed rule and consistent with past precedent, whereas the creation of two categories may conflict with these policy standards. Another commenter stated a preference for a simple single code to be used on claims when performing RDN, regardless of which device is chosen.
                    </P>
                    <P>
                        With regard to broader device category definitions, the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant asserted that RDN ablation catheters in the future may come with several combinations of modalities and cooling mechanisms, noting that there are other RDN devices currently in development, such as a radiofrequency RDN catheter with balloon cooling under study by Metavention, with an approved Investigational Device Exemption (IDE) in the United States. The applicant stated the belief that other manufacturers may eventually gain FDA authorization with various device structures and features employing either ultrasound or radiofrequency RDN, and thus believed that the specific category description proposed by the Paradise® Ultrasound RDN System applicant would establish a framework in which different iterations of RDN technology could be considered new by virtue of their brand-specific characteristics. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant asserted that, in contrast, a broader device category definition for RDN technologies currently eligible for pass-through would provide flexibility for future RDN devices to be evaluated on their own merits and that, if those devices meet the newness and other criteria for pass-through payment status, a broad category code for RDN can be easily adapted to reflect the distinguishing characteristic that merits such recognition.
                    </P>
                    <P>
                        The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant noted that the RDN procedure used with either device is currently reported using the same energy modality-agnostic Category III CPT® codes. This applicant further opined that the broader physician community views RDN as fundamentally a single procedure with multiple technologies 
                        <PRTPAGE P="94173"/>
                        available in the same class.
                        <E T="51">70 71 72 73</E>
                        <FTREF/>
                         Specifically, the applicant commented that in a Society for Cardiovascular Angiography &amp; Interventions (SCAI) expert consensus statement published in August 2023, the operator training and experience recommended for the RDN procedure is the same, regardless of which technology is used, with the only device-specific training noted in the statement being operator familiarity with the functionality of each technology's generator and knowledge regarding balloon sizing with ultrasound RDN,
                        <SU>74</SU>
                        <FTREF/>
                         while the European Society of Cardiology/European Society of Hypertension (ESC/ESH) Guidelines refer only to RDN as a class and do not distinguish between radiofrequency and ultrasound technologies.
                        <E T="51">75 76</E>
                        <FTREF/>
                         A commenter stated that from a physician work perspective, the two systems are similar in time and technique. The applicant further asserted that this issue was addressed at the September 2023 American Medical Association CPT® Editorial Panel meeting, where a request for a CPT® code for an energy modality-specific ultrasound RDN procedure was ultimately rejected by the Panel.
                    </P>
                    <FTNT>
                        <P>
                            <SU>70</SU>
                             Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M.L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E.A.E., Azizi, M., Benetos, A., Borghi, C., Hitij, J.B., Cifkova, R., Coca, A., Cornelissen, V., Cruickshank, J.K., Cunha, P.G., Danser, A.H.J., Pinho, R.M., Delles, C., Dominiczak, A.F., Dorobantu, M., Doumas, M., Fernández-Alfonso, M.S., Halimi, J.M., Járai, Z., Jelaković, B., Jordan, J., Kuznetsova, T., Laurent, S., Lovic, D., Lurbe, E., Mahfoud, F., Manolis, A., Miglinas, M., Narkiewicz, K., Niiranen, T., Palatini, P., Parati, G., Pathak, A., Persu, A., Polonia, J., Redon, J., Sarafidis, P., Schmieder, R., Spronck, B., Stabouli, S., Stergiou, G., Taddei, S., Thomopoulos, C., Tomaszewski, M., Van de Borne, P., Wanner, C., Weber, T., Williams, B., Zhang, Z.Y., &amp; Kjeldsen, SE (2023). 2023 ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension. 
                            <E T="03">Journal of Hypertension, 41</E>
                            (12), 1874-2071. 
                            <E T="03">https://doi.org/10.1097/HJH.0000000000003480</E>
                            .
                        </P>
                        <P>
                            <SU>71</SU>
                             Barbato, E., Azizi, M., Schmieder, R.E., Lauder, L., Böhm, M., Brouwers, S., Bruno, R.M., Dudek, D., Kahan, T., Kandzari, D.E., Lüscher, T.F., Parati, G., Pathak, A., Ribichini, F.L., Schlaich, M.P., Sharp, A.S.P., Sudano, I., Volpe, M., Tsioufis, C., Wijns, W., &amp; Mahfoud, F. (2023). Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). 
                            <E T="03">European Heart Journal, 44</E>
                            (15), 1313-1330. 
                            <E T="03">https://doi.org/10.1093/eurheartj/ehad054</E>
                            .
                        </P>
                        <P>
                            <SU>72</SU>
                             Swaminathan, R.V., East, C.A., Feldman, D.N., Fisher, N.D., Garasic, J.M., Giri, J.S., Kandzari, D.E., Kirtane, A.J., Klein, A., Kobayashi, T., Koenig, G., Li, J., Secemsky, E., Townsend, R.R., &amp; Aronow, H.D. (2023). SCAI Position Statement on Renal Denervation for Hypertension: Patient Selection, Operator Competence, Training and Techniques, and Organizational Recommendations. 
                            <E T="03">Journal of the Society for Cardiovascular Angiography &amp; Interventions, 2</E>
                            (6), 101121. 
                            <E T="03">https://doi.org/10.1016/j.jscai.2023.101121</E>
                            .
                        </P>
                        <P>
                            <SU>73</SU>
                             Kandzari DE, Townsend RR, Bakris G, Basile, J., Bloch, M.J., Cohen, D.L., East, C., Ferdinand, K.C., Fisher, N., Kirtane, A., Lee, D.P., Puckrein, G., Rader, F., Vassalotti, J.A., Weber, M.A., Willis, K., &amp; Secemsky, E. (2021). Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. 
                            <E T="03">Catheterization &amp; Cardiovascular Interventions, 98</E>
                            (3), 416-426. 
                            <E T="03">https://doi.org/10.1002/ccd.29884</E>
                            .
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>74</SU>
                             Swaminathan, R.V., East, C.A., Feldman, D.N., Fisher, N.D., Garasic, J.M., Giri, J.S., Kandzari, D.E., Kirtane, A.J., Klein, A., Kobayashi, T., Koenig, G., Li, J., Secemsky, E., Townsend, R.R., &amp; Aronow, H.D. (2023). SCAI Position Statement on Renal Denervation for Hypertension: Patient Selection, Operator Competence, Training and Techniques, and Organizational Recommendations. 
                            <E T="03">Journal of the Society for Cardiovascular Angiography &amp; Interventions, 2</E>
                            (6), 101121. 
                            <E T="03">https://doi.org/10.1016/j.jscai.2023.101121</E>
                            .
                        </P>
                    </FTNT>
                    <FTNT>
                        <P>
                            <SU>75</SU>
                             Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M.L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E.A.E., Azizi, M., Benetos, A., Borghi, C., Hitij, J.B., Cifkova, R., Coca, A., Cornelissen, V., Cruickshank, J.K., Cunha, P.G., Danser, A.H.J., Pinho, R.M., Delles, C., Dominiczak, A.F., Dorobantu, M., Doumas, M., Fernández-Alfonso, M.S., Halimi, J.M., Járai, Z., Jelaković, B., Jordan, J., Kuznetsova, T., Laurent, S., Lovic, D., Lurbe, E., Mahfoud, F., Manolis, A., Miglinas, M., Narkiewicz, K., Niiranen, T., Palatini, P., Parati, G., Pathak, A., Persu, A., Polonia, J., Redon, J., Sarafidis, P., Schmieder, R., Spronck, B., Stabouli, S., Stergiou, G., Taddei, S., Thomopoulos, C., Tomaszewski, M., Van de Borne, P., Wanner, C., Weber, T., Williams, B., Zhang, Z.Y., &amp; Kjeldsen, SE (2023). 2023 ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension. 
                            <E T="03">Journal of Hypertension, 41</E>
                            (12), 1874-2071. 
                            <E T="03">https://doi.org/10.1097/HJH.0000000000003480</E>
                            .
                        </P>
                        <P>
                            <SU>76</SU>
                             Barbato, E., Azizi, M., Schmieder, R.E., Lauder, L., Böhm, M., Brouwers, S., Bruno, R.M., Dudek, D., Kahan, T., Kandzari, D.E., Lüscher, T.F., Parati, G., Pathak, A., Ribichini, F.L., Schlaich, M.P., Sharp, A.S.P., Sudano, I., Volpe, M., Tsioufis, C., Wijns, W., &amp; Mahfoud, F. (2023). Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). 
                            <E T="03">European Heart Journal, 44</E>
                            (15), 1313-1330. 
                            <E T="03">https://doi.org/10.1093/eurheartj/ehad054</E>
                            .
                        </P>
                    </FTNT>
                    <P>
                        <E T="03">Response:</E>
                         As commenters stated, we have established precedent for creating both broad and distinct device categories for similar technologies. In fact, there have been many scenarios is which we have established distinct device categories to differentiate between various neurostimulators, electrophysiology catheters, and ablation modalities to ensure that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect due as required by § 419.66(c)(1). We agree with the Symplicity
                        <E T="51">TM</E>
                         Spryal RDN System applicant that the establishment of device categories requires a nuanced approach, and that CMS must assess each situation on a case-by-case basis in accordance with established policy. We believe that we have followed not only our established policy, but our precedent in our evaluation of the device category code determination for the two nominated RDN devices. We agree with commenters that this situation with respect to the Paradise® Ultrasound RDN System and the Symplicity
                        <E T="51">TM</E>
                         Spryal RDN System is similar to the examples presented.
                    </P>
                    <P>
                        The Symplicity
                        <E T="51">TM</E>
                         Spryal RDN System applicant noted that manufacturers may gain FDA authorization for other RDN devices with various device characteristics employing either ultrasound or radiofrequency RDN and establishing device category codes that are device characteristic specific, like the code descriptor proposed by the Paradise® Ultrasound RDN System applicant. This, according to the Symplicity
                        <E T="51">TM</E>
                         Spryal RDN System applicant, would establish a framework in which different iterations of RDN technology could be considered new by virtue of their brand-specific characteristics. We acknowledge that concern and agree that the device category codes established for the nominated devices should not typically be differentiated by the specific device characteristics, rather, consistent with the options in the proposed rule, we believe that in this instance the device pass-through payment device categories should be modality-specific.
                    </P>
                    <P>
                        With respect to a comment on the September 2023 AMA CPT® Editorial Panel meeting, where the Symplicity
                        <E T="51">TM</E>
                         Spryal RDN System applicant stated that a request for a CPT® code specific to an energy modality ultrasound RDN procedure was ultimately rejected, as of the date this final rule with comment period is issued, we are not aware of any decision made by the AMA CPT® Editorial Panel regarding this issue.
                    </P>
                    <P>
                        <E T="03">Comment:</E>
                         The Paradise® Ultrasound RDN System applicant and many commenters also stated creating two categories may facilitate tracking modality-specific efficacy data and shared their belief that having the ability to identify and track which RDN device modality Medicare patients receive via claims data may be beneficial for CMS in the future.
                    </P>
                    <P>
                        The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant stated that tracking efficacy data for the two devices is beyond the fundamental purpose of establishing device categories and should not be a primary consideration.
                    </P>
                    <P>
                        <E T="03">Response:</E>
                         In response to comments on tracking of long-term efficacy data for the nominated devices, while we note that collecting long-term efficacy data is always a priority of CMS and other interested parties, we agree with the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant that we do not believe the tracking of long-term efficacy is a fundamental purpose of establishing 
                        <PRTPAGE P="94174"/>
                        device category codes, as such, we did not consider this topic in our final decision.
                    </P>
                    <P>We thank the commenters for their feedback and took into account all of the points raised in our final decision.</P>
                    <P>
                        <E T="03">Comment:</E>
                         The applicant for the Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System, Medtronic, submitted another application for its device, PulseSelect
                        <E T="51">TM</E>
                        , for transitional pass-through payment during CY 2025. The proposed rule stated that PulseSelect
                        <E T="51">TM</E>
                         is used to achieve catheter ablation to treat atrial fibrillation, and thus, could be appropriately described by C1733. The Symplicity Spyral
                        <E T="51">TM</E>
                         RDN System applicant stated that the PulseSelect
                        <E T="51">TM</E>
                         application involved the interpretation of an existing device categ